ARO_id,DNA Sequence,Gene Family,Resistance Mechanism,Drug Class,Mega id,type,MEGARes_header,Source_header,label
,TTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACATGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6755,Drugs,MEG_6755|Drugs|betalactams|Class_A_betalactamases|TEM,gb|AY130284|+|0-785|ARO:3000941|TEM-75 [Klebsiella pneumoniae] ,0
,atgagtattcaacattttcgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttaagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggtccttccggctggctggtttattgctgataaatctggagccagtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6668,Drugs,MEG_6668|Drugs|betalactams|Class_A_betalactamases|TEM,1188444896|WP_085562398.1|NG_054684|1|1|blaTEM-226|blaTEM|class_A_beta-lactamase_TEM-226 NG_054684:1-861,0
,atgaaaatcgtaaaaaggatattattagtattgttaagtttattttttacagttgtgtattcaaatgctcaaactgacaacttaactttgaaaattgagaatgttttaaaggcaaaaaatgccagaataggagtagcaatattcaacagcaatgagaaggatactttgaagattaataacgacttccatttcccgatgcaaagcgttatgaaatttccgattgctttagccgttttgtctgagatagataaagggaatctttcttttgaacaaaaaatagagattacccctcaagaccttttgcctaaaatgtggagtccgattaaagaggaattccctaatggaacaactttgacgattgaacaaatactaaattatacagtatcagagagcgacaatattggttgtgatattttgctaaaattaatcggaggaactgattctgttcaaaaattcttgaatgctaatcatttcactgatatttcaatcaaagcaaacgaagaacaaatgcacaaggattggaatacccaatatcaaaattgggcaaccccaacagcgatgaacaaactgttaatagatacttataataataagaaccaattactttctaaaaaaagttatgattttatttggaaaattatgagagaaacaacaacaggaagtaaccgattaaaaggacaattaccaaagaatacaattgttgctcataaaacagggacttccggaataaataatggaattgcagcagccactaatgatgttggggtaattactttaccgaatggacaattaatttttataagcgtatttgttgcagagtccaaagaaacttcggaaattaatgaaaagattatttcagacattgcaaaaataacgtgggattactatttgaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7654,Drugs,MEG_7654|Drugs|betalactams|Class_A_betalactamases|VEB,1028110886|WP_063865155.1|NG_050323|1|1|blaVEB-15|blaVEB|class_A_extended-spectrum_beta-lactamase_VEB-15 NG_050323:1-900,0
,atgacgacatctacgggcgacgaccgtatcgaccagcttcagcaggccatcaccaagagccggcgctaccagacggtggccccggccaccgtgcggcgcctggcccgggccgccctggtcgcctcgcggggggacgtgccggacgcggtgaagcgcacgaagcgcgggctgcacgagatctacggcgcctttctgccccccagtgcgcctaactacacagcgttgctgcggcacctcgactccgcagtggaggccggtgacgacgaggcggtcgttcgttgggacagacgcgcgatgtcggtgcacatgtccacccgagagcgcgtgccgcacctcgacgagttctaccgggagatcttccgtcacgtgccacggccgaacacgttgcgtgacctggcgtgtggcctcaacccgctggccgtgccctggatgggcctgtccgacgagaccgtctacgtcgcctccgacatcgacgcccgcctgatggacttcgtgggcgctgccctgacgaggctgggggtggcgcaccgtacgagcgtggtcgacctccttgaggcccgccttgacgagccggccgacgtcacgctattgctgaagacgctcccctgtctggagactcagcaacgaggctccggctgggaagtgattgacattgtcaactcgccgattatcgtggtaaccttcccgaccaagtctctcggtcagcgatcgaaggggatgtttcagaactattcacagagttttgagtcccaggctagcgaacgatcgtgccgcattcagcgactggagatcggcaacgagctgatttacgttattcacaaatag,beta-lactamase,antibiotic target alteration,Aminoglycosides,MEG_3172,Drugs,MEG_3172|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|GRM,1028094245|WP_063851283.1|NG_047907|1|1|grm|grm|Grm_family_16S_rRNA_(guanine(1405)-N(7))-methyltransferase NG_047907:101-925,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaataccccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatcgcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttagaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcatttggttataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgcccctgcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_614,Drugs,MEG_614|Drugs|betalactams|Class_C_betalactamases|ADC,1028102022|WP_063857799.1|NG_048653|1|1|blaADC-38|blaADC|class_C_beta-lactamase_ADC-38 NG_048653:1-1152,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgtccactacgtgaaaggcgagatcaccaaggtaatcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_798,Drugs,MEG_798|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,487415002|WP_001682441.1|NG_052146|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052146:101-892,2
,atgatcatgtcgaaaaaattaaaatgtctgacgctgtttacagccatcttttttgcgattcccatggccgcttgtcaaagttttagtcaacaaaagcaacagctttcgacacagaaaaatgaacagcaacagatttcaagcttatttcagagtgcccaaaccagtggtgttttggtgatttatgatggcaagaaaattcaaagctatggcaatgatatacatcgcgcagatcagcgctatattcctgcctcaacctttaaaatgctaaacgccttgattggtatacaacatcataagaccacaccagatgaagtgtttaaatgggatggcaaaaagcgggcattcagcagttgggaaaaagatttaaccttagctgaagcgatgcaggcatcggcggtacctgtgtatcaagagttggcaagacgtattggcttggagttaatgacccgtgaagtgaagcgtgtgggttatggcaataaaaatattgggacacaagttgataatttctggttagttggcccattaaaaatcacccccgtagaagaagttcgctttgcctatgcgttggcaaaacagaaattgccatttgaccagccaacacagcaacaagtcaaagcgatgttattggtggatcagattcagggaactaaaatctatgcaaaaagtggttggggcatggatgttagcccgcaagtgggatggtggacaggctggattgaacagccaaatggtaagatcacagccttctcactgaatatgcaaatgagccagcctgagcatgcagatgcacgtaaagcgattgtgtatcaagccttgcaacagttgggattgttagcccattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4592,Drugs,MEG_4592|Drugs|betalactams|Class_D_betalactamases|OXA,555499079|WP_023271137.1|NG_062221|1|1|blaOXA-672|blaOXA-286_like|OXA-286_family_class_D_beta-lactamase_OXA-672 NG_062221:101-943,0
,GTGAGTGAAATAATTCAAGATTTATCACTTGAAGATGTTTTAGGTGATCGCTTTGGAAGATATAGTAAATATATTATTCAAGAGCGTGCATTGCCAGATGTTCGTGATGGTTTAAAACCAGTACAACGTCGTATTTTATATGCAATGTATTCAAGTGGTAATACACACGATAAAAATTTCCGTAAAAGTGCGAAAACAGTCGGTGATGTTATTGGTCAATATCATCCACATGGAGACTCCTCAGTGTACGAAGCAATGGTCCGTTTAAGTCAAGACTGGAAGTTACGACATGTCTTAATAGAAATGCATGGTAATAATGGTAGTATCGATAATGATCCGCCAGCGGCAATGCGTTACACTGAAGCTAAGTTAAGCTTACTAGCTGAAGAGTTATTACGTGATATTAATAAAGAGACAGTTTCTTTCATTCCAAACTATGATGATACGACACTCGAACCAATGGTATTGCCATCAAGATTTCCTAACTTACTAGTGAATGGTTCTACAGGTATATCTGCAGGTTACGCGACAGATATACCACCACATAATTTAGCTGAAGTGATTCAAGCAACACTTAAATATATTGATAATCCGGATATTACAGTCAATCAATTAATGAAATATATTAAAGGTCCTGATTTTCCAACTGGTGGTATTATTCAAGGTATTGATGGTATTAAAAAAGCTTATGAATCAGGTAAAGGTAGAATTATAGTTCGTTCTAAAGTTGAAGAAGAAACTTTACGCAATGGACGTAAACAGTTAATTATTACTGAAATTCCATATGAAGTGAACAAAAGTAGCTTAGTAAAACGTATCGATGAATTACGTGCTGACAAAAAAGTCGATGGTATCGTTGAAGTACGTGATGAAACTGATAGAACTGGTTTACGAATAGCAATTGAATTGAAAAAAGATGTGAACAGTGAATCAATCAAAAATTATCTTTATAAAAACTCTGATTTACAGATTTCATATAATTTCAACATGGTCGCTATTAGTGATGGTCGTCCAAAATTGATGGGTATTCGTCAAATTATAGATAGTTATTTGAATCACCAAATTGAGGTTGTTGCAAATAGAACGAAGTTTGAATTAGATAATGCAGAAAAACGTATGCATATCGTTGAAGGTTTGATTAAAGCGTTGTCAATTTTAGATAAAGTAATCGAATTGATTCGTAGCTCTAAAAACAAGCGTGACGCTAAAGAAAACCTTATCGAAGTATACGAGTTCACAGAAGAACAGGCTGAAGCAATTGTAATGTTACAGTTATATCGTTTAACAAATACTGACATAGTTGCGCTTGAAGGTGAACATAAAGAACTTGAAGCATTAATCAAACAATTACGTCATATTCTTGATAACCATGATGCATTATTGAATGTCATAAAAGAAGAATTGAATGAAATTAAAAAGAAATTCAAATCTGAACGACTGTCTTTAATTGAAGCAGAAATTGAAGAAATTAAAATTGACAAAGAAGTTATGGTGCCTAGTGAAGAAGTTATTTTAAGTATGACACGTCATGGATATATTAAACGTACTTCTATTCGTAGCTTTAATGCTAGCGGTGTTGAAGATATTGGTTTAAAAGATGGTGACAGTTTACTTAAACATCAAGAAGTAAATACGCAAGATACCGTACTAGTATTTACAAATAAAGGTCGTTATCTATTTATACCGGTTCATAAATTAGCAGATATTCGTTGGAAAGAATTGGGACAACATGTATCACAAATAGTTCCTATCGAAGAAGATGAAGTGGTTATTAATGTCTTTAATGAAAAGGACTTTAATACAGATGCATTTTATGTTTTTGCGACTCAAAATGGCATGATTAAGAAAAGTACAGTGCCTCTATTTAAAACAACGCGTTTTAATAAACCTTTAATTGCTACTAAAGTTAAAGAAAATGATGATTTGATTAGTGTTATGCGCTTTGAAAAAGATCAATTAATTACCGTCATTACTAATAAAGGTATGTCATTAACGTATAATACAAGTGAACTATCAGATACCGGATTAAGGGCAGCTGGTGTTAAATCAATAAATCTTAAAGCTGAAGATTTCGTTGTTATGACAGAAGGTGTTTCTGAAAATGATACTATATTGATGGCCACACAACGCGGCTCGTTAAAACGTATTAGTTTTAAAATCTTACAAGTTGCTAAAAGAGCACAACGTGGAATAACTTTATTAAAAGAATTAAAGAAAAATCCACATCGTATTGTAGCTGCACATGTAGTGACAGGTGAACATAGTCAATATACATTATATTCAAAATCAAATGAAGAACATGGTTTAATTAATGATATTCATAAATCTGAACAATATACAAATGGCTCATTCATTGTAGATACAGATGATTTTGGTGAAGTAATAGACATGTATATTAGCTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5359,Drugs,MEG_5359|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|941146344|gb|CP007676.1|1358389-1360791 gi|941142962|gb|CP007672.1|1356603-1359005 gi|941139768|gb|CP007657.1|1370321-1372723 gi|828461663|gb|CP007674.1|1353469-1355871 gi|828444881|gb|CP007670.1|1368972-1371374 gi|827440804|gb|CP011526.1|1356370-1358772 gi|777226173|emb|LN831049.1|2098228-2095826 gi|640834542|gb|CP007690.1|1388113-1390515 gi|610395799|gb|CP007539.1|1410356-1412758 gi|374362062|gb|CP003033.1|1297859-1300261,3
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaagtataccgttctttatccgcattagacggagcagtattattagtttctgcaaaggatggcatacaggcacagacccgtatactgtttcatgcactacagataatgaagattccgacaatttttttcatcaataaaattgaccaagaggggattgatttgccaatggtatatcgggaaatgaaagcaaagctttcttcggaaattatagtgaagcaaaaggttgggcagcatccccatataaatgtaacggacaatgacgatatggaacagtgggatgcggtaattatgggaaacgatgaactattagagaaatatatgtcagggaaaccgtttaaaatgtcagaactggaacaggaagaaaacaggagattccaaaacggaacgttatttcccgtttatcacggaagcgctaaaaacaatctggggattcggcagcttatagaagtaattgccagtaaattttattcatcaacgcctgaaggtcaatctgaactatgcgggcgggtttttaagattgaatattcaaagaaaaggcggcgttttgtttatgtgcgtatatatagcggaacattgcatttgagggatgttattagaatatctgaaaaagagaaaataaaaatcacagagatgtgtgttccgacaaacggtgaattatattcatccgatacagcctgctctggtgatattgtaattttaccaaatgatgttttgcagctaaacagtattttggggaacgaaatactgttgccgcagagaaaatttattgaaaatcctctccctatgctccaaacaacgattgcagtaaagaaatctgaacagcgggaaatattgcttggggcacttacagaaatttcagatggcgaccctcttttaaaatattatgtggatactacaacgcatgagattatactttcttttttggggaatgtgcagatggaagtcatttgtgccatccttgaggaaaaatatcatgtggaggcagaaataaaagagcctactgttatatatatggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaatcaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttgtttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7152,Drugs,MEG_7152|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,695263665|WP_032490535.1|NG_048256|1|1|tet(O)|tet(O)|tetracycline_resistance_ribosomal_protection_protein_Tet(O) NG_048256:1-1920,4
,atgagtgagtggcgacgacagcaagtctgtgcacctattcccatgcctgcgagcatggcaaccagtctggaaggataccaatgggcgcctatcacaattggtgaatccggcagcaatgtttatcgactttatgggaaaccaaaagctcctgatttgtttttgaagcgaggtaagtacgacgttgctgatgatgtgaccgatgaaatggtcaggctacgctggcttgccgaacgtatccctgtgccaaccgtcgtcaactttgttcgcaccctcgacgaagcgtggttgctgacaacggcaatgcctggcaggacggtctacgaagagctggaggcgaatcccgatgcttgccttgccatcgcagacgcgctagctgatttcttgcgccgcctgcatgagatcccaacgattgaatgccctttcaacagcaatcacatctacagacttgctcttgcgcgcaaacgcatcgaagcgggcatggtcgaggtcgatgactttgatgacgaacggaaaggctgggcggctgagcaggtatgggatgcgatgcataatcttcttccgttcacgcccgatcctgtcacaacgcacggagattctgctctcgagaatctcttcgttcgcgaaggcaaggtgactggttgcattgatgttggaagatcaggcgttgcagatcgataccaggacatagccatactctggaaccgtctaggtgagtttggctctttgccccaggaacgattcgtggagcaatatggcatcgctgatgtagatcgacggaagctgtcatttcacttgatgctggatgagctgttttga,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1031,Drugs,MEG_1031|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,499193545|WP_010891085.1|NG_047445|1|1|aph(3')-Id|aph(3')-Id|aminoglycoside_O-phosphotransferase_APH(3')-Id NG_047445:101-916,2
,atgcaatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgttagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgctgagttttattcatgccaacctcaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaattagaaaccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagatagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_514,Drugs,MEG_514|Drugs|betalactams|Class_C_betalactamases|ADC,1625655383|WP_136512060.1|NG_064715|1|1|blaADC-192|blaADC|class_C_beta-lactamase_ADC-192 NG_064715:1-1152,0
,atgcgcttcattcacgcactattactggcagcgatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcgaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccggagatgagcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacggggcccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3086,Drugs,MEG_3086|Drugs|betalactams|Class_A_betalactamases|GES,1511261580|WP_123002100.1|NG_062356|1|1|blaGES-40|blaGES|class_A_beta-lactamase_GES-40 NG_062356:1-864,0
,atgcgccactctctttttgccccgatcctcctgctcgccctgttcgccctgcccgcctgggcgcatgaggcgacggtaaaccaggtcaaagccgctgagcgccagctcgaggccagagtaggctacgcggagctggatttagccagcggacggctgctggcaagctatcgccccgacgagcgtttcccgatgatgagcacctttaaagtgccgctctgcgcggcggtactggcgcgcgtggatgccggagaggagaagctcgatcgccgcgtccgctaccgtcagcaggatctggttgaatactccccggtgaccgaaaagcacctcgccgacggcatgacggtagccgagctgtgcgctgcggcaatcacccttagcgataacaccgccgctaatctgctgctggcgagcgtcggcggcacgcaggggttgaccgccttcctgcgccgcagcggagaccagacttcgcgcctcgaccgctgggagaccgagcttaacgaggccctgcccggcgacgcgcgtgataccaccacgccgcaggcgatggccaaaaccttgcacaatctgctcaccggcagcgtgctttccgccgcatcgcgacagcagctgcgcagctggatggttgacgataaggttgccggcccgctgctgcgctcgacgctgccgcacggctggtttatcgctgacaaaaccggcgcgggcaaccgcgggtcgcgcggtattatcgccgccctcggcccggacgggcagcccgcgcgtatcgtaattatttatttaaccggcaccgaggcctcaatggatgagcggaaccggcagattgccgagattggtgagacgctggttaagcactggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6953,Drugs,MEG_6953|Drugs|betalactams|Class_A_betalactamases|TER,1028110869|WP_063865145.1|NG_050309|1|1|blaTER-1|blaTER|class_A_beta-lactamase_TER-1 NG_050309:101-955,0
,ATGCGTTATGTTCGCCTGTGCCTTATCTCCCTGATTGCCGCCCTGCCACTGGCGGTATTCGCCAGCCCTCAGCCGCTTGAGCAGATTAAAATCAGCGAAAGTCAGCTGGCGGGCCGGGTGGGCTATGTTGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCAGTGAGCGCTTTCCGCTGATGAGCACCTTTAAAGTGCTGCTCTGCGGCGCGGTGCTGGCCCGGGTGGATGCCGGCGACGAACAGCTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCCGTCAGCGAAAAACACCTTGCCGACGGGATGACCGTTGGCGAACTCTGCGCCGCCGCCATCACCATGAGCGACAACAGCGCCGGCAATCTGCTGTTGAAGAGCGTCGGCGGCCCCGCGGGATTGACCGCTTTTCTGCGCCAGATCGGTGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTCAATGAGGCGCTTCCCGGCGACGTGCGCGACACCACCACCCCGGCCAGCATGGCCACCACCCTGCGCAAGTTGCTAACCACCCCCTCTCTGAGCGCCCGTTCGCAGCAGCAGCTGCTGCAGTGGATGGTGGACGACCGGGTGGCCGGCCCGTTGATCCGCGCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAAACCGGGGCCGGTGAGCGGGGCTCACGCGGCATTGTCGCCCTGCTCGGCCCAGACGGCAAAGCGGAGCGTATCGTGGTGATCTATCTACGGGATACCGCGGCGACCATGGCCGAACGTAACCAGCAGATCGCCGGGATAGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4240,Drugs,MEG_4240|Drugs|betalactams|Class_A_betalactamases|OKP,(Bla)OKP-B-6:AY850171:1-861:861,0
,GTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTTACTGGCGAATGCGTCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGCACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_359,Drugs,MEG_359|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|940516916|dbj|LC091210.1|5147-5701 gi|940516911|dbj|LC091209.1|3811-4365 gi|765098769|dbj|LC031883.1|5968-6522 gi|13094933|gb|AF318077.1|517-1071,2
,gtggaacgtcaaaataacaatgaaaaccagtatggaagaaaccgcagaaaagacaaaagaagaaaattgtttttttacagagcagcatgtgccatgctcggtctgctcatagtctctgtaatttttggagctgtgtattttctgagagagagtaaagatcccgctcttccatccaaagaaaatacaaagacaagcaaggactattcatttctggccgacgttcagagtgaggatgagtctccagtttcggagccagccatatccaaccgggcgaatacgattgacctgaacatcatagcagcaaatgccattgtggtgaataaagacaccgatgcggtattgtatcaaaaaaacggcacggacagaattgcgccggccagtacagccaaaatgattacagcgttgactgtgcttgaatattgttctccggaggaggagatgagggtaggtgcagagattgaaatgatccatagtgattcgtcaaccgcatggcttatgaaaggcgataccctgactgtcaggcagctcctgattgcccttatgcttccgtccggcaatgatgcagcctatacccttgcagtcaataccggaaagacgattgcgggtgataacagcctgtccaatcagcaggccattaaaatattcatggataaggtgaacgagaaggccagggagcttggcgttacagactcgaattttgtggttccggatgggtatgacgccgagggacagtataccacggcctatgatcttgccatcattgcaaaggcatgtttggagaatcccattatttcagaaattgtggcaagcaatacgtcgtatgaaaaatggccgaacggcagggaggtcacttacaacaattccaatgagcttcttgatccgaacagtccctattaccgtccggaggtgatcggtctgaaaaccgggaccagcagccttggcggcgcctgtgtcgtctccgcagcagtgattgacggagaaacctatatctgcgtagccatgggctctacgaaagaaagcaggtttcaggacagcgttgatattttagataaaatcaaagcccagtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7602,Drugs,MEG_7602|Drugs|Glycopeptides|VanD-type_accessory_protein|VANYD,1391852846|WP_109545033.1|NG_048525|1|1|vanY-D|vanY-D|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D NG_048525:101-1168,5
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTACAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1953,Drugs,MEG_1953|Drugs|betalactams|Class_C_betalactamases|CMY,gi|2959383|emb|Y16782.1|1-1143,0
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacactctacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcaaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattacggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggtaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4431,Drugs,MEG_4431|Drugs|betalactams|Class_D_betalactamases|OXA,1509794585|WP_122630894.1|NG_062314|1|1|blaOXA-692|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-692 NG_062314:14-838,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGGATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6480,Drugs,MEG_6480|Drugs|betalactams|Class_A_betalactamases|SHV,gi|74058436|gb|DQ166781.1|1-861 gi|940656576|gb|CP012883.1|5133963-5133105 gi|728797461|emb|LN515533.1|9-867 gi|160948460|emb|AM176558.2|3-861,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACTCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAACTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTACAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1949,Drugs,MEG_1949|Drugs|betalactams|Class_C_betalactamases|CMY,gb|Y16785|+|0-1143|ARO:3002023|CMY-12 [Proteus mirabilis] ,0
,atgagtgatcaccccgggccgggggccgtcacgccggagctgttcggcgtgggcggcgactggctggccgtcaccgcgggcgaatcgggcgcctccgtctttcgcgccgcggacgccacccggtacgccaagtgcgtgcccgccgcggacccggccggtcttgaggcggaacgcgaccggatcgcctggctgagcgggcagggcgtaccgggcccccgcgtcctcgactggtacgccggtgacgcgggcgcctgcctggtcacccgtgccgtccccggcgtacccgctgatcgggtgggcgccgatgaccttcgcactgcctggggggccgtcgcggacgcggtccgtcggctgcacgaggtacccgtggcctcgtgtccgttccgccgggggctggactccgtggtcgacgccgcccgtgacgtggtggcccgtggcgcggtgcatccggagttcctgccggtggagcagcggctcgctcccccggcggagctgctggcccggctcaccggggagctcgcccgtcggcgcgatcaggaggccgccgacacggtcgtctgccacggtgatctctgcctgcccaacatcgtcctccatccggagaccctggaggtgtcgggcttcatcgacctgggacggctcggggcggccgaccgccacgccgacctggcgctgctgctggccaacgcgcgcgagacctgggtggacgaggagcgggcgcggttcgccgacgcggcgttcgccgagcgctacggcatcgccccggacccggaacggctgcgcttctacctccatctcgatccgctcacctggggctag,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1032,Drugs,MEG_1032|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,1028081343|WP_063840677.1|NG_047410|1|1|aph(3'')-Ia|aph(3'')-Ia|aminoglycoside_O-phosphotransferase_APH(3'')-Ia NG_047410:101-919,2
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAGCTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCACAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGCAGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2377,Drugs,MEG_2377|Drugs|betalactams|Class_A_betalactamases|CTX,gi|16304825|emb|AJ416345.1|132-1007 gi|825088700|gb|KP975077.1|39408-38535 gi|516560780|gb|JX515588.1|200604-199731 gi|299483205|gb|HM569735.1|1115-1988 gi|130918109|gb|EF441350.1|132-1005 gi|695200454|ref|NG_036140.1|5317-6190 gi|695208190|ref|NG_035493.1|6336-7209 gi|695200140|ref|NG_035386.1|1-874 gi|71273537|emb|AM040708.1|5582-6455,0
,atgaaaaactactttaacagccctttcaaaggggaacttctttctgagcaagtgaaaaatccaaatatcagagtaggccggtatagctattactctggctactatcacgggcactcatttgatgaatgcgcgcgatacttgcttccagatcgtgatgacgttgataaattgatcattggcagcttttgttctataggaagcggggcttccttcatcatggctggcaatcaggggcatcggcatgactgggcatcatccttccccttcttctatatgcaaggggagcctgctttctcaagcgcactcgacgccttccaaagagcaggtgataccgtcattggcaatgatgtctggataggctcggaggcaatgattatgcctggcatcaaaattggagacggtgccgtgataggtagtcgctcgttggtgacaaaagatgtagagccttatgccatcatcgggggaaatcccgcaaagcaaattaagaagcgcttctccgatgaggaaatctcattgctcatggagatggagtggtggaactggccactagataaaattaagacagcaatgcctctgctgtgctcgtcaaatatttttggtctgcataagtattggcgcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1596,Drugs,MEG_1596|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1104448620|WP_071766400.1|NG_052093|1|1|catB8|catB8|type_B-3_chloramphenicol_O-acetyltransferase_CatB8 NG_052093:101-733,6
,CTGCTAACACAAGTACGTTTCCAAATACCATATGGCAAAAATATAGCACTCGTAGGTGCAAATGGTGTAGGTAAGACAACTTTACTTGAAGCTATTTACCACCAAATAGAGGGAATTGATTGTTCTCCTAAAGTGCAAATGGCATACTATCGTCAACTTGCTTATGAAGACATGCGTGACGTTTCATTATTGCAATATTTAATGGATGAAACGGATTCATCAGAATCATTCAGTAGAGCTATTTTAAATAACTTGGGTTTAAATGAAGCACTTGAGCGTTCTTGTAATGTTTTGAGTGGTGGGGAAAGAACGAAATTATCGTTAGCAGTATTATTTTCAACGAAAGCGAATATGTTAATTTTGGATGAACCAACTAATTTTTTAGATATTAAAACATTAGAAGCATTAGAAATGTTTATGAATAAATATCCTGGAATCATTTTGTTTACATCACATGATACAAGGTTTGTTAAACATGTATCAGATAAAAAATGGGAATTAACAGGACAATCTATTCATGATATAACTTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_4068,Drugs,MEG_4068|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|MSRA,gi|153050|gb|M81802.1|STAMSRB|94-624,7
,atgattgatttggacgtagaaatatatcagcatttgaatgaacagataaaaataaataaactctgctatttgtcatcaggtgatgatagcgatacttttttatgtaatgaacaatatgttgtgaaagttccaaaacgagattctgttagatttgctcagaaacgagagtttgaattgtatcggtttttagaaaattgtaatttatcttatcagacccctgcggtagtatatcaaagtgaccgatttaatattatgaaatatattaaaggggaacgtattacttatgagcagtatcataagttgagtgaaaaggaaaaggatgcccttgcatatgatgaagctacgtttttgaaagagttacattctatagagattgattgttctgtcagtttgttttcagatgctctggtgaataagaaagataagtttttgcaagataaaaaattacttataagtattttggaaaaggagcagctgttgactgatgagatgttggaacatatcgaaacaatatatgaaaacatatcaagcaatgctgttatatttaactatatcccttgtttggtacataatgatttcagtgcaaataacttgatttttagaaataatagactgtttggagttattgattttggcgattttaatgtaggtgacccggataatgattttttatgcttgctggattgtagtacagatgatttcgggaaagaatttggcaggaaggtattaaaatactatcagcataaggcgccggaagtagcagaaagaaaagcagagcttaatgatgtgtattggtcgatagaccaaatcatttatggttatgaaagaaaagatagggaaatgttgattaagggtgtttctgaattgctacagacacaagcagagatgtttatattttag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_1008,Drugs,MEG_1008|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH2-DPRIME,949621775|WP_057038954.1|NG_047402|1|1|aph(2'')-IIa|aph(2'')-IIa|aminoglycoside_O-phosphotransferase_APH(2'')-IIa NG_047402:1-900,2
,gtgcgcgcggatcgcggaggtgctcgacgcggcgccgcccggcgagatcaaggccagcccaccgtcgagggggacgccgagatcctcgggcggatcgtccgtgaaccggacgtcgccgcgtggtggtcgccgccgaaggactacgggcgaatgctcgcggtgctcgccgggggcgaggtcgtcggcgcgatccggttccacgaggagaccgatcccgagttccggcatgccgggatcgacgtcttcctggcggcgcggcaccacggcaagggcctcggcaccgacgccgtgcgcacgctggcccgccggctcgtgcgcgaacgcggccaccaccggctcgtcatcgacccggcggcggcgaacgaggccgcgatccgcagctacgtcaaggtcgggttcaggccggtgggggtcctgcgcgcgtactggcgcgaccaccgtacggggcggtgggaggacgggttgctgatggacctgctcgcccgggagctgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_263,Drugs,MEG_263|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,496358368|WP_009067544.1|NG_052139|1|1|aac(6')_Strep|aac(6')_Strep|aminoglycoside_6'-N-acetyltransferase NG_052139:101-598,2
,ATGACTCGACATAATGAAATTATTAAATGTGCAGAAAAATATCAATTACACATCCAACCTCAAACAATCTCATTGAATGAATCGGGACTTGATTTTCAAGTTGCATTTGGAAAAGATAAACATGGAGTAGAATGGGTTTTGAGACTACCAAGAAGACCTGACGTTTATAAACGAACAAAACCCGAAAAACAAACGGTAGACTTCTTACAGAAGAATGTTTCATTTGAAATACCGAAGTGGAAAGTACATGCAAAAGACCTTATTGCTTACCCAAAACTTACAGGTAAACCCGCAGCCACAATAGATCCAGAAATACAAAATTATGTATGGGAAATTGAACACAAACCATTACCAGAAAACTTTATTAACACATTAGCTGAAACACTCGTAGATTTACACAACATACCAGAAGAAAACATTAACGTTCAGCATATAAATATCAAAACCATACAAGAAATAAAAAATGACTTTCAAAGAAGAATGAATAAAGTTAAAGAAACTTATGGCGTATCAGATGAATTATGGAACAGATGGAAACAATGGTTAGAAAACGACGAACTATGGCCTCGACATGCGACCATGATACATGGGGACTTACATCCAGGACATATAATGGTAGATAACCAAGCAAACGTCACAGGTCTCATAGACTGGACTGAAGCAACCCACTCCGACCCATCAATGGACTTTATAGGACACCATCGTGTATTCGACGACGAAGGATTAGAGCAACTTATAACAGCATACGGTAAAGCTGGAGGTGAAATATGGCCACGAATGAAAGAGCATATAATAGAACTCAATGCAGTATTCCCAATGTTTATCGCTGAGTTTGCTATGGAATCAGGAGAATCGGCGTATGAAACGATGGCATTGAAAGAGTTAGGTATGAAAGAGTAG,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4038,Drugs,MEG_4038|Drugs|MLS|Macrolide_phosphotransferases|MPHC,(MLS)MphC:AF167161:5665-6564:900,7
,atgcgtatccgtcccacccgtcgtcttctcctcggcgcggtcgcgccgctcgccctcgttccgctggtggcctgcggtcaggcgtcgggctccgagagcggccagcagcccggcctcggcggttgcgggacgagcgcacacggctcggcggacgcccacgagaaggagttccgggcgctggagaagaagttcgacgcccaccctggcgtctacgccatcgacacccgcgacggccaggagatcacccaccgggccgacgagcgcttcgcctacggctcgaccttcaaggccctccaggcgggcgcgatccttgcgcaagttctccgagacgggcgcgaagtccggcggggcgccgaggccgacggcatggacaaggtggtccactacgggcaggacgcgatcctgcccaactcaccggtgaccgagaagcacgtcgcggacggcatgtccctgcgcgagctgtgcgacgccgtcgtggcctacagcgacaacaccgcggccaacctgctcttcgaccagctcggcggccgaaggggctcaacgcgggtcctcaagcagctcggcgaccacaccacgagcatggaccgctacgagcaggagctgggctcggccgtccccggcgacccccgggacaccagcacgccgcgcgcgttcgccgaggacctgcgcgccttcgccgtcgaggacggcgagaaggccgccctcgcgcccaacgaccgcgagcagctgaacgactggatgagcgggagcaggaccggcgacgcgctgatccgggccggtgtgccgaaggactggaaggtggaggacaagagcggccaggtcaagtacggcacccggaacgacatcgccgtcgtccgcccgcccggccgcgcgccgatcgtcgtctcggtgatgagccacggcgacacccaggacgccgagccgcacgacgagctggtggccgaggccggcctcgtcgtcgccgacggtctgaagtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1292,Drugs,MEG_1292|Drugs|betalactams|Class_A_betalactamases|BLAL,1040476735|WP_065102178.1|NG_050939|1|1|blaL|blaL|BlaL_family_class_A_beta-lactamase NG_050939:101-1078,0
,atggaaaaatacaacaattggaaacgaaaattttatgcaatatgggcagggcaagcagtatcattaatcactagtgccatcctgcaaatggcgattattttttaccttacagaaaaaacaggatctgcgatggtcttgtctatggcttcattagtaggttttttaccctatgcgattttgggacctgccattggtgtgctagtggatcgtcatgataggaagaagataatgattggtgccgatttaattatcgcagcagctggtgcagtgcttgctattgttgcattctgtatggagctacctgtctggatgattatgatagtattgtttatccgtagcattggaacagcttttcataccccagcactcaatgcggttacaccacttttagtaccagaagaacagctaacgaaatgcgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcagttgcagcactcttatactccgtttgggatttaaatgctattattgccatcgacgtattgggtgctgtgattgcatctattacggtagcaattgtacgtatacctaagctgggtaatcaagtgcaaagtttagaaccaaatttcataagggagatgaaagaaggagttgtggttctgagacaaaacaaaggattgtttgccttattactcttaggaacactatatacttttgtttatatgccaatcaatgcactatttcctttaataagcatggaacactttaatggaacgcctgtgcatatttctattacggaaatttcctttgcatttgggatgctagcaggaggcttattattaggaagattagggggcttcgaaaagcatgtattactaataacaagttcattttttataatggggaccagtttagccgtttcgggaatacttcctccaaatggatttgtaatattcgtagtttgctgtgcaataatggggctttcggtgccattttatagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttgatcggaagtatcatgtcacttgctatgccaattgggttaattctttctgtttcttttgctgataaaatcggtgtaaatcattggtttttactatcaggtattttaattattggcattgctatagtttgccaaatgataactgaggttagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3806,Drugs,MEG_3806|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028096836|WP_063853554.1|NG_047959|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047959:93-1310,7
,ATCTTGATCATCATTCCTTTCGCAGTACGCTTCGTTGCTGGAATGAGGGTCTGGTATGGCTATGAACCCATTTATCAAATTTTACGTCTTTTTGCTGACTATTGGCTTCTTTGCTTAGCCATCGGGGCCTTACTGATTTGGGTGAGCACAACGATTTATTATATGAGTAAAGCTATCAGTTATTTGAATGAAACGATCCAAGCCACAAACCAACTGATTGCCGAACCCACGAAGCGAATCGTTCTTTCCAGCAATATGATTGATGTGCAAGAAGAAATGAACCAGTTGCGAGAGAAAAACTTACAGGATCAACGAGCCGCCAAAGAAGCGGAACAACGAAAAAATGATTTGATCGTCTATCTCGCACATGATTTACGAACGCCTTTGACCAGTGTGATCGGCTATTTGACGCTTTTAGAAGAGGAACCACAGCTTTCTACCGAACTACGCGCACGCTATACGAAGATCGCCTTGCAAAAAGCCCAACGGCTGGAACTATTGATCAGCGAATTTTTCGAAATCACCCGCTTTAATCTTACAACGATCGCCTTGCAAACTGAAACCACGGATCTGAGCTTGATGCTGGAACAATTGACGTTTGAATTTTTGCCGCTGTTAGAAGAAAAAAACCTCCATTGGCAACTTCAGCTACAGAAAAAAGTCTTTGCGACCGTTGATACGGAGAAAATGGAACGCGTTTTTGATAACTTGATCCGCAATGCCATCAATTATAGCTATCCTAACTCCCCTTTGCGATTAGCCATCAGCGAGTCTGATGATATCCTGATTCGTTTGACCAATCAAGGAAAAACGATCCCAGCTGAAAAGATCGGCTTGATTTTTGAGCCTTTCTACCGCATGGATGCTTCCCGAGCAACAGCGACGGGTGGGACGGGTCTTGGTTTGCCGATCGCCAAAGAAATCGTTGAAGCATTAGGTGGAAAGATTTGGGCGGAAAGCCGTGATGAAACCATCGTCTTTTCGATTCGCCTACCGAAGGCAGCAATGGAAAAAAATGAACAGCTGTCAAAGCCCCATCCATCTGAACCAACCGCTTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7500,Drugs,MEG_7500|Drugs|Glycopeptides|VanC-type_regulator|VANSC,(Gly)VanSc3:AY033764:4604-5662:1059,5
,ATGAAAAAAATTGCCGTTTTATTTGGAGGGAATTCTCCAGAATACTCAGTGTCACTAGCCTCAGCAGCAAGTGTGATCCAAGCTATTGACCCGCTGAAATATGAAGTAATGACCATTGGCATCGCGCCAACAATGGATTGGTATTTGTATCAAGGAAACCTCGCGAATGTTCGCAATGATACTTGGCTAGAAGATCACAAAAACTGTCACCAGCTGACTTTTTCTAGCCAAGGATTTATATTAGGAGAAAAACGAATCGTCCCTGATGTCCTCTTTCCAGTCTTGCATGGGAAGTATGGCGAGGATGGCTGTATTCAAGGACTGCTTGAACTAATGAACCTGCCTTATGTTGGTTGCCATGTCGCTGCCTCCGCATTATGTATGAACAAATGGCTCTTGCATCAACTTGCTGATACCATGGGAATCGCTAGTGCTCCCACTTTGCTTTTATCCCGCTATGAAAACGATCCTGCCACAATCGATCGTTTTATTCAAGACCATGGATTCCCGATCTTTATCAAGCCGAATGAAGCCGGTTCTTCAAAAGGGATCACAAAAGTAACTGACAAAACAGCGCTCCAATCTGCATTAACGACTGCTTTTGCTTACGGTTCTACTGTGTTGATCCAAAAGGCGATAGCGGGTATTGAAATTGGCTGCGGCATCTTAGGAAATGAGCAATTGACGATTGGTGCTTGTGATGCGATTTCTCTTGTCGACGGTTTTTTTGATTTTGAAGAGAAATACCAATTAATCAGCGCCACGATCACTGTCCCAGCACCATTGCCTCTCGCGCTTGAATCACAGATCAAGGAGCAGGCACAGCTGCTTTATCGAAACTTGGGGTTGACGGGTCTGGCTCGAATCGATTTTTTCGTCACCAATCAAGGAGCGATCTATTTAAACGAAATCAACACCATGCCGGGATTTACCGGGCACTCCCGCTACCCAGCTATGATGGCGGAAGTCGGGTTATCCTACGAAATATTAGTAGAGCAATTGATTGCACTGGCAGAGGAGGACAAACGATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7370,Drugs,MEG_7370|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,gi|67479934|gb|DQ022190.1|205-1236 gi|58045581|gb|AY870596.1|4-430 gi|58045583|gb|AY870597.1|1-402 gi|58045587|gb|AY870599.1|1-387,5
,atgaaaaaaattgccgttttatttggagggaattctccagaatactcagtgtcactagcctcagcagcaagtgtgatccaagctattgacccgctgaaatatgaagtaatgaccatcggcatcgcaccaacaatggattggtattggtatcaaggaaacctcgcgaatgttcgcaatgatacttggctagaagatcacaaaaactgtcaccagctgactttttctagccaaggatttatattaggagaaaaacgaatcgtccctgatgtcctctttccagtcttgcatgggaagtatggcgaggatggctgtatccaaggactgcttgaactaatgaacctgccttatgttggttgccatgtcgctgcctccgcattatgtatgaacaaatggctcttgcatcaacttgctgataccatgggaatcgctagtgctcccactttgcttttatcccgctatgaaaacgatcctgccacaatcgatcgttttattcaagaccatggattcccgatctttatcaagccgaatgaagccggttcttcaaaagggatcacaaaagtaactgacaaaacagcgctccaatctgcattaacgactgcttttgcttacggttctactgtgttgatccaaaaggcgatagcgggtattgaaattggctgcggcatcttaggaaatgagcaattgacgattggtgcttgtgatgcgatttctcttgtcgacggtttttttgattttgaagagaaataccaattaatcagcgccacgatcactgtcccagcaccattgcctctcgcgcttgaatcacagatcaaggagcaggcacagctgctttatcgaaacttggggttgacgggtctggctcgaatcgattttttcgtcaccaatcaaggagcgatttatttaaacgaaatcaacaccatgccgggatttactgggcactcccgctacccagctatgatggcggaagtcgggttatcctacgaaatattagtagagcaattgattgcactggcagaggaggacaaacgatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7361,Drugs,MEG_7361|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,748755610|WP_040013725.1|NG_048356|1|1|vanC1|vanC1|D-alanine--D-serine_ligase_VanC1 NG_048356:31-1062,5
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagttaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgatgaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgcgcgggaggaacagcagcgggttcaagacgcctccctgttcccagtctatcatggcagcgccaaaaatggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggggcgccgccctatgcggcagcgttttcaaggttgagtacaccgattgcggccagcggcgtgtctatctacggttatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatcagggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggaccaaacccggctccctcgtaaaaggtggcgcgaggaccccctccccatgctgcggacgacgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgttgcgaagtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaaccctccgtcatttatatggagcggccgctcaaagcagccagccccaccatccatatcgaggtgccgcccaacccgttttgggcatccataggactgtctgttacaccactctcgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcggggacgcagctgctggaaccttatctctccttcatcctctatgcgccccaggaatacctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggcccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcggagcgtatgccttacagagctgaaaggatatcaggccgctgtcggtcagccggtcatccagccccgccgtccaaacagccgcctggacaaggtgcgccatatgtttcagaaggtaatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7221,Drugs,MEG_7221|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100290|WP_063856425.1|NG_048301|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048301:101-2020,4
,ATGCGCCCTCTCCTCTTCAGTGCCCTTCTCCTGCTTTCCGGGCATACCCAGGCCAGCGAATGGAACGACAGCCAGGCCGTGGACAAGCTATTCGGCGCGGCCGGGGTGAAAGGCACCTTCGTCCTCTACGATGTGCAGCGGCAGCGCTATGTTGGCCATGACCGGGAGCGCGCGGAAACCCGCTTCGTTCCCGCTTCCACCTACAAGGTGGCGAACAGCCTGATCGGCTTATCCACAGGGGCGGTTAGATCCGCCGACGAGGTTCTTCCCTATGGCGGCAAGCCCCAGCGCTTCAAGGCCTGGGAGCACGACATGAGCCTGCGCGAGGCGATCAAGGCATCGAACGTACCGGTCTACCAGGAACTGGCGCGGCGCATCGGCCTGGAGCGGATGCGCGCCAATGTCTCGCGCCTGGGTTACGGCAACGCGGAAATCGGCCAGGTTGTGGATAACTTCTGGTTGGTGGGACCGCTGAAGATCAGCGCGATGGAACAGACCCACTTTCTGCTCCGACTGGCGCAGGGAGAATTGCCATTCCCCGCCCCGGTGCAGTCCACCGTGCGCGCCATGACCCTGCTGGAAAGCGGCCCGGGCTGGGAGCTGCACGGCAAGACCGGCTGGTGCTTCGACTGCACGCCGGAACTCGGCTGGTGGGTGGGCTGGGTGAAGCGCAACGAGCGGCTCTACGGCTTCGCCCTGAACATCGACATGCCCGGCGGCGAGGCCGACATCGGCAAGCGCGTCGAACTGGGCAAGGCCAGTCTCAAGGCTCTCGGGATACTGCCCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5272,Drugs,MEG_5272|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-494_1_AY597430,0
,atgacaaaaaagaaattgcccgttcgttttacgggtcagcactttactattgataaagtgctaataaaagatgcaataagacaagcaaatataagtaatcaggatacggttttagatattggggcaggcaaggggtttcttactgttcatttattaaaaattgccaacaatgttgttgctattgaaaacgacacagctttggttgaacatttacgaaaattattttctgatgcccgaaatgttcaagttgtcggttgtgattttaggaattttgcagttccgaaatttcctttcaaagtggtgtcaaatattccttatggcattacttccgatattttcaaaatcctgatgtttgagaatcttgaaaattttctgggaggttccattgtccttcagttcgaacctacacaaaagttattttcaaggaagctttacaatccatataccgttttctgtcatactttttttgatttgaaacttgtctatgaggtaggtcctgaaagtttcttgccaccgccaactgtaaaatcagccctgttaaacattaaaagaaaacacttattttttgattttaagattaaagccaaatacttagcatttatttcctgtctgttagagaaacctgatttatctgtaaaaacagctttaaagtcgattttcaggaaaagtcaggtcaggacaatttcggaaaaattcggtttaaaccttaatgctcaaattgtttgtttgtctccaagtcaatggttaaactgttttttggaaatgctggaagttgtccctgaaaaatttcatccttcgtag,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2830,Drugs,MEG_2830|Drugs|MLS|23S_rRNA_methyltransferases|ERMF,1028086399|WP_063844773.1|NG_047826|1|1|erm(F)|erm(F)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(F) NG_047826:101-901,7
,atgtccgctagatgcctgcccgcgctgacgctgccgctggcccttgcggcttgcgccccgccgatccagacgcccgatccactgcccccgcgcgaaatcgtcacgccgcagcaatgggcgcagcaatgcaccgactgggacgaatgggacaaacccgccccgccctaccgcatccacggatcgacctattacgtgggcacttgcggcatcgccgcgatcctcgtcgcgggcgacggcggccatatcctgatcgatagcgggaccgaggcgggcgcggatgtggtgctcgacaacgtcggcaagctcggcttccgtcccaacgagatcgccagcctgctgcacagccacgaacatttcgaccacaccggtgggcacgcgctggtcaggcgggaaagcggcgcccatgtcgttgcctcgccgcaggccgcgccggtcctgcgtaccggcgaagacgaccccgccgatccccagcacggcctgcacgatgcgatggagccggtgccggtcgatgtcatcgtgcgcgacggtgaaaccgtgcgcagcgaaagcgcgacgcttaccgcgatcgcgaccccggggcacacgccgggggcgttgagctgggcatggcaatcctgcgatgaggcaggtgattgcctttcgatagtctatgccgattcgctttcgccgatcagccgcaaaggctatcgcttcggcgaccaccccgagtacctcgagggcttccgtgccggcctcgaaaagctccgtgcggtcgattgcgacatcctgctcaccccgcatccctcggccagcgacatggtgacacgcgccgctgcgggatcgatggtcgggggcatgagctgcgtggactatgccgatgcggtcgaagcgcggctcgacgcgcggctggtggaggaagcgggtgactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_2703,Drugs,MEG_2703|Drugs|betalactams|Class_B_betalactamases|EFM,1509794513|WP_122630822.1|NG_062204|1|1|blaEFM-1|blaEFM|subclass_B3_metallo-beta-lactamase_EFM-1 NG_062204:1-909,0
,GTGTCATTAATTGTGTTTGATTATGGTAAAAGAACTTATATAATGGGAATATTAAATGTAACTCCAGATAGTTTTTCTGATGGAGGAGATTTTAATAACTTGGACATAGCAATACAACATGCAAAAGATATGGTTGACCAAGGTGCAGATATAATAGACCTAGGAGGAGAGTCTACACGCCCAGGTCATAGCTATGTAGACTCAGACGAAGAGCTAAGAAGAGTAATCCCTGTAATAAAAAAACTTAAACAGGAATTGGATATACCAATATCAATAGACACTTATAAGGCAGATGTTGCAGAAGAAGCATTAAAATTAGGTGTCACTATGGTAAATGATGTTTGGGGTCTTAGAAAAGATAAAAATATGGCTTCTGTAATAGGAAAATATGATGCAGAAGTGTGTATAATGCATAATCAAGATGGGACAAACTATGACAAAGATATAATGGAGTCAATAAAAGACTTTTTTAAGGTAAGTATAGAAATGGCAATGAGTTGTGGTGTAAAAAAAGAAAAAATAGTACTTGACCCAGGTGTAGGATTTGGCAAGGATTTTGAACAAAATATTGAAGTATTGAGAAGATTAAATGAATTAAAAGATTTAGGGTATCCTATTTTGCTTGGGACATCCAGAAAATCAGTAATAGGAAAAGTACTTCCAGTTGAGCCTAAAAAAAGATTAGAAGGTACAATAGCTACTACTGTTCTTGGTATAAGAGATGGCGTAGATATAGTTAGAGTACATGATGTTTATGAAAATTTAATGGCAGCTAGAATGACTGATGCAATATATAGAAAGTAG,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2963,Drugs,MEG_2963|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|953830676|gb|CP013196.1|3132565-3133368 gi|777202877|emb|LN831030.1|1462866-1463669 gi|760237048|gb|CP010905.1|1664847-1665650 gi|733567460|emb|LN614756.1|1685497-1686300 gi|115249003|emb|AM180355.1|1680199-1681002,8
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagacagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5508,Drugs,MEG_5508|Drugs|betalactams|Class_C_betalactamases|PDC,1035157541|WP_064511506.1|NG_050829|1|1|blaPDC-156|blaPDC|class_C_beta-lactamase_PDC-156 NG_050829:1-1194,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAGATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTATTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1402,Drugs,MEG_1402|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_21_JGQH01000014,0
,atgaaaaaatcgttatctgcaacactgatttccgctctgctggcgttttccgccccggggttttctgccgctgataatgtcgcggcggtggtggacagcaccattaaaccgctgatggcacagcaggatattcccgggatggcggttgccgtctccgtaaagggtaagccctattatttcaattatggttttgccgatattcaggcaaaacagccggtcactgaaaatacactatttgagctcggatctgtaagtaaaactttcacaggtgtgctgggtgcggtttctgtggcgaaaaaagagatggcgctgaatgatccggcggcaaaataccagccggagctggctctgccgcagtggaaggggatcacattgctggatctggctacctataccgcaggcggactgccgttacaggtgccggatgcggtaaaaagccgtgcggatctgctgaatttctatcagcagtggcagccgtcccggaaaccgggcgatatgcgtctgtatgcaaacagcagtatcggcctgtttggtgctctgaccgcaaacgcggcggggatgccgtatgagcagttgctgactgcacggatcctggcaccgctggggttatctcacacctttattactgtgccggaaagtgcgcaaagccagtatgcgtacggttataaaaacaaaaaaccggtccgcgtgtcgccgggacagcttgatgcggaatcttacggcgtgaaatccgcctcaaaagatatgctgcgctgggcggaaatgaatatggagccgtcacgggccggtaatgcggatctggaaatggcaatgtatctcgcccagacccgctactataaaaccgccgcgattaaccaggggctgggctgggaaatgtatgactggccgcagcagaaagatatgatcattaacggtgtgaccaacgaggtcgcattgcagccgcatccggtaacagacaaccaggttcagccgtataaccgtgcttcctgggtgcataaaacgggcgcagcaactggtttcggcgcctatgtcgcctttattccggaaaaacaggtggcgattgtgattctggcgaataaaaactacccgaataccgaaagagtcaaagctgcacaggctattttgagtgcgctggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2586,Drugs,MEG_2586|Drugs|betalactams|Class_C_betalactamases|DHA,1028104928|WP_063860114.1|NG_049070|1|1|blaDHA-24|blaDHA|class_C_beta-lactamase_DHA-24 NG_049070:1-1140,0
,ATGCTTTTATATAAAATGTGTGACAATCAAAATTATGGGGTTACTTACATGAAGTTTTTATTGGCATTTTCGCTTTTAATACCATCCGTGGTTTTTGCAAGTAGTTCAAAGTTTCAGCAAGTTGAACAAGACGTTAAGGCAATTGAAGTTTCTCTTTCTGCTCGTATAGGTGTTTCCGTTCTTGATACTCAAAATGGAGAATATTGGGATTACAATGGCAATCAGCGCTTCCCGTTAACAAGTACTTTTAAAACAATAGCTTGCGCTAAATTACTATATGATGCTGAGCAAGGAAAAGTTAATCCCAATAGTACAGTCGAGATTAAGAAAGCAGATCTTGTGACCTATTCCCCTGTAATAGAAAAGCAAGTAGGGCAGGCAATCACACTCGATGATGCGTGCTTCGCAACTATGACTACAAGTGATAATACTGCGGCAAATATCATCCTAAGTGCTGTAGGTGGCCCCAAAGGCGTTACTGATTTTTTAAGACAAATTGGGGACAAAGAGACTCGTCTAGACCGTATTGAGCCTGATTTAAATGAAGGTAAGCTCGGTGATTTGAGGGATACGACAACTCCTAAGGCAATAGCCAGTACTTTGAATAAATTTTTATTTGGTTCCGCGCTATCTGAAATGAACCAGAAAAAATTAGAGTCTTGGATGGTGAACAATCAAGTCACTGGTAATTTACTACGTTCAGTATTGCCGGCGGGATGGAACATTGCGGATCGCTCAGGTGCTGGCGGATTTGGTGCTCGGAGTATTACAGCAGTTGTGTGGAGTGAGCATCAAGCCCCAATTATTGTGAGCATCTATCTAGCTCAAACACAGGCTTCAATGGCAGAGCGAAATGATGCGATTGTTAAAATTGGTCATTCAATTTTTGACGTTTATACATCACAGTCGCGCTGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1540,Drugs,MEG_1540|Drugs|betalactams|Class_A_betalactamases|CARB,AAA25740.1 M69058.1:98-1012,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6247,Drugs,MEG_6247|Drugs|betalactams|Class_A_betalactamases|SHV,(Bla)SHV-31:GU064396:1-861:861,0
,atggatgaacgagcgcaggcggcactggacgcgctgctttccgcgaagaatctgcgggacgtatgtcccgagacggtgcggcgcgtgtttatggagcttttgccgcgatacagaaaaccgaaggacgcggagaaggcggcgcgcacgcatctgcaccagatcaccggcgcgttcatgacggcggacgcgcaggaaaaggcgcgggcattgcttgcgcgctggaacgagggcgacgaatcggcgctcgctgccgcgctgtccctgcacgcgtccacgcgcgagcgcctgccgggcgcggatgaatggatgcggcgcgtttcgccgtttctgggcgcggacgcgcgcgtgctcgatctggcctgcgggctgaacccgatcctactgggctccatgggcgtgacgaacgcgctgggcatggacattcatctgggctgcgtgcgacttgtgaacgaaacggcgcgggcgcgcggctggcatacgcgcgcgcgagcctgcgacctgctgagcgagattcccgcggaggaagccgacgcggcgcttctgatgaagctcctgcccgtgctggaagcccagaaaaccggccgcgccgccgagctgctcgcaagcctccgcgcccccaggctggtcgtgaccttccccacccgcaccctcggcggccgcggcgtgggcatggaaaagcactatgccgactggttcgagcgcatcctccccgataccctctccgtccgcgaccgatttacggtgtcggacgagctggtgtatctggtggagcggacgtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_6071,Drugs,MEG_6071|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|RMTF,557680565|WP_023434793.1|NG_051537|1|1|rmtF2|rmtF|16S_rRNA_(guanine(1405)-N(7))-methyltransferase_RmtF2 NG_051537:101-880,2
,ATGAATAAAAAAATGGATATTACTGTTTTTGGATGTGAGTCAGACGAAATGGAGGTTTTTCAAAAGATTTCTTATGAGCTTGGTGTTACAGCTACACTCATAAAAGATTCTATATCAGAAAGCAATGCTGGATTAGCTGATGGATGCTGCTGCGTAAGCGTAAGCCATAAAGCGGAGCTGTCAGAACCGATTCTTCTTGCACTAAAAAATGCAGGGGTAAAGTATATCAGTACCCGGAGCATTGGCTTTAACCATATTGATATACAGGCGGCCGGGTTGCTGGGTATGGTTGTTGGCACGGTAGAATACTCGCCGGGAAGTGTGGCCGATTATACCGTCATGCTGATGCTTATGCTGATGCGCGGCACAAAGTCGATTCTGCGTGAAACCCAGAGGCAGAATTATTGCCTGAATGACCTGCGCGGAAAAGAACTGCGGGATATGACCGTCGGTGTGTTAGGAACTGGGCGAATCGGACAGGCAGTCATGGAACGCCTGAAGGGATTCGGCTGTAAGGTATTGGCGTATGACCGAAATCAAAAAGCAGGAACGGACTATGTTTCGTTTCATGAACTGCTGAAAAAAAGTGATATTGTTACACTGCATATTCCGTTGGCAGAAGATACCCGCCATATGATTGGATGTGAAGAGCTGGAAATGATGAAGCAGGAGGCGCTTCTGATCAATACAGGACGGGGCGCTTTAGTGGATACCGCAGCATTGGTAGAAGCATTAAAAGGACAGAAAATCGGCGGTGCCGCCCTGGATGTTTTAGAGGGCGAAGAAGGTATCTTTTACCATGACTGCACTCAAAGAACGATAGAGCATCCTTTCCTGTCTGTCCTGCAGGGAATGCCGAATGTCATTGTTACGCCGCACACAGCCTATCATACGGATCGGGTACTGGTCGATACCGTGAGCAATACCATCCGAAATTGTCTGAATTTTGAAAGGAGTCTTGGAAATGTATAAGCTTAAAATTGCAGTCCTGTTTGGAGGCTGCTCAGAGGAACATGATGTTTCAGTGAAATCTGCGATGGAGGTTGCAGCAAATATAAACAAGGAAAAATACCAGCCGTTTTATATTGGAATCACAAAATCCGGCGCATGGAAACTATGCGATAAGCCCTGCCGGGACTGGGAAAACTATGCGGGATACCCGGCTGTGATTTCTCCGGACAGAAGGACCCATGGCCTGCTGATACAAAAGGATGGCGGATATGAGAGCCAGCCTGTAGACGTGGTGCTTCCGATGATTCATGGAAAATTTGGCGAGGACGGAACCATACAGGGTCTGCTTGAGCTGTCCGGCATTCCTTATGTGGGATGCGACATTCAAAGTTCTGTAACCTGTATGGATAAGTCGCTCGCTTATATGGTTGTGAAAAATGCGGGAATTGAGGTACCTGGGTTTCGAGTTCTACAAAAGGGGGACAGCCTGAAAGCAGAGACACTCTCGTACCCGGTCTTTGTAAAACCTGCCCGTTCCGGCTCCTCTTTTGGCGTGAATAAGGTATGCCGGGCAGAGGAACTGCAGGCAGCGGTCACAGAGGCGGGCAAGTATGACTGCAAAATATTGGTTGAGGAGGCCGTTTCCGGGAGTGAGGTAGGCTGTGCCATACTGGGAAATGAAAATGCTCTCATGGCTGGCGAGGTGGATCAGATTGAGCTGAGACACGGTTTTTTTAAGATTCATCAGGAAGCACAGCCGGAGAAAGGTTCTGAAAATGCAGTTATCAGAGTTCCAGCTGTCTTACCGGATGAGGTAAGAGAACGGATTCAGAAAACAGCAATGAAGATTTACCGGATACTTGGCTGCCGAGGATTGGCTCGTATTGATCTGTTTTTGCGGGAGGACGGCTGCATTGTGCTGAATGAAGTGAATACCATGCCGGGTTTTACTTCCTACAGCCGTTATCCCCGCATGATGACAGCAGCCGGTTTTACGCTTACTGAAATACTGGATCGCTTGATTGAACTTTCACTTAGGAGGTAACTGCCATGAAAAAGAACTTTGCCTTTTTAGATGAAATGATTCCCGGAATCCGATGGGATGCTAAATATGCCACATGGGACAATTTCACCGGGAAACCGGTAGACGGATACATGGTAAACCGTGTTATGGGAACGAAGGAGCTGGGAGTTGCTTTGCGTAAGGCTCAGAAGATGGCGGAGAAACTGGGATATGGTTTGCTCTTATGGGACGGCTATCGCCCCCAGTGCGCAGTGGATTGTTTTCTGAATTGGACTTCCCAACCGGAAGACAATCTGACGAAAAAGCGTTACTATCCAAATATCAAAAGGAATGAGATGGTTGCGAAGGGGTATGTGGCCTCAAAATCCAGCCACAGCCGTGGAAGTACGGTTGACCTTACAATTTTTCATTTGAATAGCGGTATGCTTGTTCCTATGGGTGGAGATTTTGACTATATGGATGAACGGTCACACCATACCGCAAGCGGTCTGAGCGAAGAAGAATCAAAAAACCGGCAGTGTTTGCGTTATATCATGGAGAGCAGCGGATTTGAAGCCTATCGTTATGAATGGTGGCATTACGTCTTGGTGGACGAGCCATACCCGGATACATATTTTGATTTTTGGATGGCCTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7431,Drugs,MEG_7431|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,VanHDX_5_AY489045,5
,atgaaaaagataaaaattgttccacttattttaatagttgtagttgtcgggtttggtatatatttttatgcttcaaaagataaagaaattaataatactattgatgcaattgaagataaaaatttcaaacaagtttataaagatagcagttatatttctaaaagcgataatggtgaagtagaaatgactgaacgtccgataaaaatatataatagtttaggcgttaaagatataaacattcaggatcgtaaaataaaaaaagtatctaaaaataaaaaacgagtagatgctcaatataaaattaaaacaaactacggtaacattgatcgcaacgttcaatttaattttgttaaagaagatggtatgtggaagttagattgggatcatagcgtcattattccaggaatgcagaaagaccaaagcatacatattgaaaatttaaaatcagaacgtggtaaaattttagaccgaaacaatgtggaattggccaatacaggaacagcatatgagataggcatcgttccaaagaatgtatctaaaaaagattataaagcaatcgctaaagaactaagtatttctgaagactatatcaaacaacaaatggatcaaaattgggtacaagatgataccttcgttccacttaaaaccgttaaaaaaatggatgaatatttaagagatttcgcaaaaaaatttcatcttacaactaatgaaacagaaagtcgtaactatcctctaggaaaagcgacttcacatctattaggttatgttggtcccattaactctgaagaattaaaacaaaaagaatataaaggctataaagatgatgcagttattggtaaaaagggactcgaaaaactttacgataaaaagctccaacatgaagatggctatcgtgtcacaatcgttgacgataatagcaatacaatcgcacatacattaatagagaaaaagaaaaaagatggcaaagatattcaactaactattgatgctaaagttcaaaagagtatttataacaacatgaaaaatgattatggctcaggtactgctatccaccctcaaacaggtgaattattagcacttgtaagcacaccttcatatgacgtctatccatttatgtatggcatgagtaacgaagaatataataaattaaccgaagataaaaaagaacctctgctcaacaagttccagattacaacttcaccaggttcaactcaaaaaatattaacagcaatgattgggttaaataacaaaacattagacgataaaacaagttataaaatcgatggtaaaggttggcaaaaagataaatcttggggtggttacaacgttacaagatatgaagtggtaaatggtaatatcgacttaaaacaagcaatagaatcatcagataacattttctttgctagagtagcactcgaattaggcagtaagaaatttgaaaaaggcatgaaaaaactaggtgttggtgaagatataccaagtgattatccattttataatgctcaaatttcaaacaaaaatttagataatgaaatattattagctgattcaggttacggacaaggtgaaatactgattaacccagtacagatcctttcaatctatagcgcattagaaaataatggcaatattaacgcacctcacttattaaaagacacgaaaaacaaagtttggaagaaaaatattatttccaaagaaaatatcaatctattaactgatggtatgcaacaagtcgtaaataaaacacataaagaagatatttatagatcttatgcaaacttaattggcaaatccggtactgcagaactcaaaatgaaacaaggagaaactggcagacaaattgggtggtttatatcatatgataaagataatccaaacatgatgatggctattaatgttaaagatgtacaagataaaggaatggctagctacaatgccaaaatctcaggtaaagtgtatgatgagctatatgagaacggtaataaaaaatacgatatagatgaataa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3772,Drugs,MEG_3772|Drugs|betalactams|Penicillin_binding_protein|MECA,446643960|WP_000721306.1|NG_047939|1|1|mecA|mecA|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA NG_047939:101-2107,0
,AAGGAATCCCATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGAAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACTTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCGATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTTCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGTAATCTGACGCTGGGTAAAGCATTGGGTGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_2371,Drugs,MEG_2371|Drugs|betalactams|Class_A_betalactamases|CTX,gi|124365351|gb|EF219142.1|1-889,0
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaagcagtatcattaatcactagtgccatcttgcaaatggcgattattttttaccttacagaaaaaactggatctgcgatggtcttgtctatggcttcactagtaggttttttaccctatgcggtctttggacctgcaattggtgtgctagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctggttcggtgcttactattgttgcattctatatggagctacctgtctggatgattatgatagtattgtttatccgtagcattggaacagcttttcataccccggctctcaatgcggttacgccacttttagtaccagaagaacagcttacgaaatgtgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcggttgcagcactcttatactccgtttgggaactaaatgctattattgccatcgacgtattgggtgctgtgattgcatctattacggtagcaattgtacgtattcctaagctgggtgatcgcgtgcaaagtttggaaccaaatttcataagagagatgcaagaaggaatggcggtactacggcaaaataaaggattgtttgctttattactcgttggaacattatatatgtttgtttatatgccaattaatgcactattccctttaataagcatggattactttaatggaacacctgtgcatatttctattacggaaatttcctttgcatctggaatgttgatagggggtctattattagggttatttgggaatttccaaaagcgaatcttattaataacggcatccatttttatgatggggataagcttaaccatttcaggattacttccccaaagtggatttgtcatttttgtagtctgctgtgcaataatggggctttctgttccgttttacagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttaactggaagtatcatgtctcttgctatgccaattggattaattctttctggactctttgctgatagaatcggtgtaaatcattggtttttactatcaggtattttaattatttgcattgcaatagtttgcccaatgataaatgagattagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3816,Drugs,MEG_3816|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028097016|WP_063853713.1|NG_047976|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047976:101-1318,7
,atgcaacaaaaaaataagtatataagaattcaagagttcttgaagcagaataaatttcctaattatagaatgaaacaaattacaaatgctatattcccagggagaataaataatttcaacgaaataacggttcttcctaaatcactaagagatatgttaattgaggagtttggagaatcgattttaaatattgttcctttaaaagcacaacaatctacacaagtttcaaaagtcttatttggaatttcaggagacgaaaaaatagaaacggtaaatatgaaatataaagctggttgggagtcattttgtatatcatcgcagtgcggttgtaattttggttgtaaattttgtgcaactggagatataggtttaaaacgtaacttaacttcagatgaaattactgaccagattttgtactttcacttacaagggcattcaattgacagtatttcttttatgggaatgggagaagcattagcgaatgtacaagtttttgatgctttaaatgtacttacagatcctgcgttgtttgctttaagtccgcgtaggttatctatatccactataggaattattccaaacattaaaaaattgactcaaaactatccgcaggtcaacctgacattttcattacattctccttttaatgaacagcgaagtgagttaatgccaattaatgaacgctacccattatcagatgtgatggatacattagatgagcatatacgagtaacctcaagaaaagtttatattgcttatattatgttgcacggagttaatgattctattgaacatgcgaaagaagtcgtaaaccttttaagaggtagatataggagtgggaacttgtatcatgtgaacatcattagatataacccgactgttagttcacggatgcggtttgaagaagcaaatgagaaatgtcttgtcaacttttataaaaaattaaagtcagcaggaattaaagttaccattagaagtcaatttggcattgatatagacgctgcttgcggtcaattgtatggaaactatcaaaaaaccaatagccagtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Multi-drug_resistance,MEG_1683,Drugs,MEG_1683|Drugs|Multi-drug_resistance|MDR_23S_ribosomal_RNA_methyltransferase|CFRB,488278773|WP_002349981.1|NG_050395|1|1|cfr(B)|cfr(B)|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(B) NG_050395:101-1150,1
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaggcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagcactggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_235,Drugs,MEG_235|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502235|WP_071846385.1|NG_052520|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052520:101-655,2
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAATACGCCGTTTCTTTAGCTTCAGCAACTAGCGCACTCGAAGCACTCCAATCATCTCCCTATGACTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACATAAACAGAAAATACAGCCGCTATTTGAAGGAAACGGCTTTTGGCTAAGTGAAGAGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATATGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAGCTGCCTTATGTAGGTTGCGGGGTGGCAGGTTCTGCCTTATGTATGAACAAATGGCTGCTGCATCAAGCTGCAGCAGCCATTGGCGTACAAAGTGCTCCTACGATTCTCTTGACAAATCAAGCCAACCAGCAAGAACAAATCGAAGCTTTTATCCAGACCCATGGCTTTCCAGTTTTCTTTAAGCCTAATGAAGCGGGCTCCTCAAAAGGGATCACTAAAGTCACCTGCGTTGAAGAAATCGCTTCTGCCTTAAAAGAAGCCTTCACTTATTGTTCCGCAGTGCTCCTACAAAAAAATATTGCCGGTGTTGAGATCGGTTGCGGTATTTTGGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCCATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGCTGATCAGCGCCAAAATCACCGTCCCTGCGCCATTGCCTGAAACGATTGAAACCAAGGTCAAAGAACAAGCTCAGCTGCTCTATCGTAGTCTTGGTCTTAAAGGTCTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGCTTATCCTATCAAGAACTACTACAAAAACTGCTTGTCTTAGCAAAGGAGGAAGTCAAATGAATCCCTATCTACAGTTAGTTAGCAAAGAATTTCCGTTAGAAAAAAACCAAGAACCCCCTCATTTAGTCCTTGCTGCCTTCAGCGAAGACGAGGTTTACTTGCAGCCAGAAGCAGCCAAACAATGGGAACGGCTCGTCAAAGCTTTAAAGCTTGAAAACGAGATCTGCTTATTAGATGGCTACCGAACCGAAAAGCAGCAACGGTATTTATGGGAATATTCCTTGAAAGAAAATGGGCTAGCCTATACGAAACAATTTGTGGCGTTGCCCGGTTGCAGTGAACATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAGGGCAGCCAGGATGATTTGATCTGCCCACGATTTCGTGACAGCGCAGCCGCTGATTTATTTACCCAGGAAATGATGAACTATGGGTTTATTTTACGCTATCCCGCAGACAAACAGGAAATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTGCCTCATAGTCAAATCATCGCCAGTCAACAGTGGACCTTGGAAGAATACCATCAATACCTTGAACAAACTGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7382,Drugs,MEG_7382|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC2XY_4_EU151758,5
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgagctggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagaactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaacccgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtggatctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6666,Drugs,MEG_6666|Drugs|betalactams|Class_A_betalactamases|TEM,1028110623|WP_063864901.1|NG_050245|1|1|blaTEM-212|blaTEM|class_A_beta-lactamase_TEM-212 NG_050245:1-861,0
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCACAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGACATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCGCCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1369,Drugs,MEG_1369|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_97_FMOK01000003,0
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaatgaaacccagagtgagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaaacagataaaaaaattaatctgtatggtaatgctctaagccgtgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttatcgcttgggaaaaagacatgacactaggagaagccatgaagctttccgcagtcccagtctatcaagaacttgcaagacgtattggtcttgatctcatgcaaaaagaagtagaacgtattgatttcggtaatactgaaattggacagcaggttgataatttctggttggtagggccattaaaggttacgcctattcaagaggtagagtttgtttctcaattggcgcatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgcttcttttagaagagagtaatggctacaaaatttttggaaagactggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcgcttttgcattaaatatggaaatgcggtcagaaatgccggcatctatacgtaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4524,Drugs,MEG_4524|Drugs|betalactams|Class_D_betalactamases|OXA,736682273|WP_034688190.1|NG_064770|1|1|blaOXA-812|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-812 NG_064770:1-822,0
,atgcgaacgctcctcgcccgcgtcgtcgtgctgctcctcgtgccctggtccgccgcgcggggggaacccgagaccgacctcggcgaccgcgtccgggcgcgcccgctctcggcccacgcctggctgatccggtcggtgagcgcgctcgagggcttcggcgacgtcgagtcgaacgcggtgctggtgacgggggcgacggagtccgtgctcgtcgacacccccgccacggacgagcagaccgcgcccgtgctcgcctgggcggagaagacgctgcgccgaccggtgcgccacctgatcgtcacccactggcacgccgaccggatgggcgggatcggcgccgcgcgggcgcgccaggtcgcgacctacgccttcggcaggacccgcgcgctggcgcggcagaaggggctcgtggttccggagcacgagctcggacccgcagagcggctcacgctcgcgggcctatctctggcgacctggtatcccggccacgggcacaccgcggacaacatcgtcgtgtggctgcccgaggacggggtgctcgtcgcgggatgcttcgtgaaggacgcagcggcggggacgctcggcaacgtacgggaggccgaccccgtccagtgggcgaccggggtggccgccctgcggcggcgctacccgggggctcgtatcgtcgtcccgggccacggcgcggccggaggctccgagctgctcgcccgaacgacggcgctgctcgaggcgcacggcagtcggggagttccggcctcaggccggtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_734,Drugs,MEG_734|Drugs|betalactams|Class_B_betalactamases|ANA,752809742|WP_041449074.1|NG_057424|1|1|blaANA-1|blaANA|subclass_B1_metallo-beta-lactamase_ANA-1 NG_057424:101-868,0
,GATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTTCGACGAGTGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGATCGCAAGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGGCTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCCGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATCGGTGCTTCCCTTATCAAACATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6898,Drugs,MEG_6898|Drugs|betalactams|Class_A_betalactamases|TEM,gi|2648042|emb|X97254.1|1-1011,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatccagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_908,Drugs,MEG_908|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1693892905|WP_140423282.1|NG_065409|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_065409:101-889,2
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6478,Drugs,MEG_6478|Drugs|betalactams|Class_A_betalactamases|SHV,gi|695223691|ref|NG_040871.1|1-861,0
,ATGAACGAGAAAAATATAAAACACAGTCAAAACTTTATTACTTCAAAACATAATATAGATAAAATAATGACAAATATAAGATTAAATGAACATGATAATATCTTTGAAATCGGCTCAGGAAAAGGCCATTTTACCCTTGAATTAGTACAGAGGTGTAATTTCGTAACTGCCATTGAAATAGACCATAAATTATGCAAAACTACAGAAAATAAACTTGTTGATCACGATAATTTCCAAGTTTTAAACAAGGATATATTGCAGTTTAAATTTCCTAAAAACCAATCCTATAAAATATTTGGTAATATACCTTATAACATAAGTACAGATATAATACGCAAAATTGTTTTTGATAGTATAGCTGATGAGATTTATTTAATCGTGGAATACGGGTTTGCTAAAAGATTATTAAATACAAAACGCTCATTGGCATTACTTTTAATGGCAGAAGTTGATATTTCTATATTAAGTATGGTTCCAAGAGAATATTTTCATCCTAAACCTAAAGTGAATAGCTCACTTATCAGATTAAATAGAAAAAAATCAAGAATATCACACAAAGATAAACAGAAGTATAATTATTTCGTTATGAAATGGGTTAACAAAGAATACAAGAAAATATTTACAAAAAATCAATTTAACAATTCCTTAAAACATGCAGGAATTGACGATTTAAACAATATTAGCTTTGAACAATTCTTATCTCTTTTCAATAGCTATAAATTATTTAATAAGTAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2818,Drugs,MEG_2818|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,(MLS)ErmC:M19652:988-1722:735,7
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6691,Drugs,MEG_6691|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-1D:AF188200:215-1075:861,0
,atggttaaaaaatcactgcgtcagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggaagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgtggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgacttggttaactataatccgattgcggaaaagcacgtcgatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgatttctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcgtaatctgacgctgggtaaagcattgggtgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggatagaaccggcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccaacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2213,Drugs,MEG_2213|Drugs|betalactams|Class_A_betalactamases|CTX,1331531444|WP_102607454.1|NG_056169|1|1|blaCTX-M-146|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-146 NG_056169:101-976,0
,CCCAGATCATAATGGTAAAAAGTGAACTGGGCTATAAACTAACTCTATAAAATACCTAATTGTTCTAAACTTTTATAAGTAATCTCTTTTCGAACAGAGCTAGGTATTCCTTTTTTCATTTCTAAGTTAAGGGAGAACGCTACAATATTTCCTTGAGGCTGAACAACCCATCCAGTTAACCAGCCTACTTGTGGGTCTACATCCCATCCCCAACCACTTTTTGCGTATATTTTATTTCCATTCTTTTCTTCTATGAATAACATGGATTGCACTTCATCTTGGACTTTTAGGCTAAATGGAAGCGTTTTATTAGCTAGCTTGTAAGCAAACTGTGCCTCTTGCTGAGGAGTAATTTTTAAAGGACCCACCAGCCAAAAATTATCGACTTGGGTACCGATATCTGCATTGCCATAACCAACACGCTTCACTTCCTTAGACATGAGTTCAAGTCCAATACGACGAGCTAAATCTTGATAAACCGGAATAGCGGAAGCTTTCATAGCATCACCTAGGGTCATGTCCTTTTCCCATTCTGGGAACAGCCTTTTTTGCCCGTCCCACTTAAATATTTCTGTGGTGGTTGCCTTATGGTGCTCAAGGCCGATCAAAGCATTAAGCATTTTGAAGGTCGAAGCAGGTACATACTCGGTCGAAGCACGAGCAAGATCATTACCATAGCTTTGTTGAGTTTGACCTTGATGGATAACTAAAACACCCGTAGTGTGTGCTTCGTTAAATAAATTTTTAATTTTCTCTGCTTTGTCATCAGATTTTGAAGCACTGTGATTTGGATTAGCAGTCACTATATAAGGTGAGCAGGCTGAAATAAAAATAGCGCTTGTTATAAGTAAGAGTGCTTTAATGTTCATAAGACTTATAAAATTGAATTTGAAGTTTAGCTAATTAATGTAACTTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5234,Drugs,MEG_5234|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389157|gb|KF986261.1|1-917,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggagccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5557,Drugs,MEG_5557|Drugs|betalactams|Class_C_betalactamases|PDC,1028110209|WP_063864579.1|NG_049904|1|1|blaPDC-32|blaPDC|class_C_beta-lactamase_PDC-32 NG_049904:1-1194,0
,TGGCAGATAGTAAATTTTATAGATTTAAATCAACATCTATAACTGTATAATTCGTTTTCTCAACTCATTACAACACTCCGTTAGTAATGAAGCTCATTCTATACAATGACAGTTAATAGGTAAAGTTATGTCAAACAAAGTAAATTTTAAAACGGCTTCATTTTTGTTTAGTGTTTGTTTAGCTTTGTCGGCATTTAATGCTCATGCTAACAAAAGTGATGCTGCGGCAAAACAAATAAAAAAATTAGAGGAAGACTTTGATGGGAGGATTGGCGTCTTTGCAATAGATACAGGATCGGGTAATACATTTGGGTATAGATCAGATGAGCGGTTCCCTTTATGCAGTTCATTTAAAGGTTTTTTGGCGGCTGCTGTTTTAGAGAGGGTGCAACAAAAAAAACTAGATATCAACCAAAAGGTTAAATATGAGAGTAGGGATCTAGAATATCATTCACCTATTACAACAAAATATAAAGGCTCAGGTATGACATTAGGTGATATGGCTTCTGCTGCATTGCAATATAGCGACAATGGGGCAACAAATATAATTATGGAACGATTTCTTGGCGGTCCTGAGGGGATGACTAAATTTATGCGTTCTATTGGAGATAATGAGTTTAGGTTAGATCGCTGGGAACTGGAACTTAACACTGCAATCCCAGGAGATAAACGTGACACTTCAACGCCAAAAGCTGTTGCAAATAGTTTGAATAAACTAGCTTTGGGGAATGTTCTCAATGCTAAAGTGAAAGCGATTTATCAAAATTGGTTAAAAGGTAATACAACTGGTGATGCTCGAATTCGTGCTAGTGTTCCTGCTGATTGGGTTGTAGGTGACAAAACTGGGAGCTGTGGGGCTATAGGTACTGCGAATGATTATGCCGTCATTTGGCCTAAAAATAGAGCACCATTAATTGTCTCTATATATACAACACGAAAATCGAAAGATGATAAGCACAGTGATAAAACTATTGCGGAAGCATCACGTATTGCAATTCAGGCAATTGATTAATATTGTCTTATAAATACCAAAAATTTCACGTCTCTTGTTTAAAGAGGCGTGCTTTAATATTTTCTTAGAGTCCAATACATGAGAGTTTTAATTTCGTTTTTTTTCCTTATTTTTTCTATTAGCGTTAGAGCTGACTGTGGCCTTGAAAGAGAAAACGGTGTGGTTATTGATAACATTAATATGTTGCAATGGCAAGCTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_1319,Drugs,MEG_1319|Drugs|betalactams|Class_A_betalactamases|BLASME,gi|472863|emb|Z28968.1|1-1211 gi|510203|emb|Z30237.1|222-1,0
,ATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGATACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACCGACGGGGAGTCAGGCAACTATGGATGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6683,Drugs,MEG_6683|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-1:JQ735917:1-861:861,0
,atggaattgcccaatattatgcacccggtcgcgaagctgagcaccgcattagccgctgcattgatgctgagcgggtgcatgcccggtgaaatccgcccgacgattggccagcaaatggaaactggcgaccaacggtttggcgatctggttttccgccagctcgcaccgaatgtctggcagcacacttcctatctcgacatgccgggtttcggggcagtcgcttccaacggtttgatcgtcagggatggcggccgcgtgctggtggtcgataccgcctggaccgatgaccagaccgcccagatcctcaactggatcaagcaggagatcaacctgccggtcgcgctggcggtggtgactcacgcgcatcaggacaagatgggcggtatggacgcgctgcatgcggcggggattgcgacttatgccaatgcgttgtcgaaccagcttgccccgcaagaggggatggttgcggcgcaacacagcctgactttcgccgccaatggctgggtcgaaccagcaaccgcgcccaactttggcccgctcaaggtattttaccccggccccggccacaccagtgacaatatcaccgttgggatcgacggcaccgacatcgcttttggtggctgcctgatcaaggacagcaaggccaagtcgctcggcaatctcggtgatgccgacactgagcactacgccgcgtcagcgcgcgcgtttggtgcggcgttccccaaggccagcatgatcgtgctgagccattccgcccccgatagccgcgccgcaatcactcatacggcccgcatggccgacaagctgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4139,Drugs,MEG_4139|Drugs|betalactams|Class_B_betalactamases|NDM,1393270468|WP_109791213.1|NG_057612|1|1|blaNDM-22|blaNDM|subclass_B1_metallo-beta-lactamase_NDM-22 NG_057612:1-813,0
,ATGACTCTGGCATTAGTTGGCGAAAAAATTGACAGAAACCGCTTCACCGGTGAGAAAGTTGAAAATAGTACATTTTTTAACTGCGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGCCAGTTCTATGATCGCGAAAGTCAGAAAGGGTGCAATTTTAGTCGCGCAATGCTGAAAGATGCCATTTTCAAAAGCTGTGATTTATCAATGGCAGATTTCCGCAACGTCAGCGCATTGGGCATTGAAATTCGCCACTGTCGCGCACAAGGCGCAGATTTTCGCGGTGCAAGCTTTATGAATATGATCACCACGCGCACCTGGTTTTGCAGCGCATATATCACTAATACCAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTATGGGAAAACCGCTGGATGGGGACTCAGGTACTGGGTGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCCGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTAGGTGACTTAGATATTCGGGGTGTTGATTTACAAGGCGTTAAGTTAGACAACTACCAGGCATCGTTGCTCATGGAGCGACTTGGCATCGCTGTGATTGGTTAG,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6000,Drugs,MEG_6000|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,qnrB10_1_DQ631414 ,3
,GAGGTATTATGAAATACACTATTATTGATATTAAAGATTCAGAAACGTACATTACTCAAGCTGCAGAAATATTATTTGATGTATTTTCAGAAATAAGCCCAGAATCATGGCCAACACTCCAAAAAGCAAAAGAAGATGTTATTGAATGTATAGAAGGTGAAAACATTTGCATTGGCATTATAATAAATAAAGAATTAATTGGATGGATTGGATTAAGAGAAATGTATAAAAAAACATGGGAATTACATCCTATGGTTATCAAGAAAACACATCATAATATGGGATTTGGAAAAATACTAATTAATGAAATAGAAAAAAAAGCAAGAGAAAGAAATTTAGAAGGTATTGTACTTGGAACAGATGATGAAACATATAGAACTTCATTATCAATGATTGAATTAAATAATGAAAATATTTTGCAAGAAATAAAGAATATTAGAAATTTAGAAAATCATCCTTATGAATTTTATAAAAAATGTGGATATTGTATTATTGGTGTAATTCCAAACGCAAATGGGAAGAATAAGCCAGATATATTAATGTGGAAAAATATTATGGAAGAAAATTGCGGCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_342,Drugs,MEG_342|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|208436664|gb|EU886977.1|536-1110,2
,gtgagcgacctggagctgcgcggcgagcgggtcctgctccgctccaccacccccgccgacaccgccttgctcgaccggatcgtccgcgagccggaggtggcgctgtggtggccgccgccccaggggtacgcgcgcatgctcgccgtcgtcgtggacggcgaggtgatcggcgccatccagttcagcgaggagaccgacccggagttccgccacgccggcatcgacctcttcctgtcggcccggtggcaggggcagggcctgggacccgacgcggtacgcaccctggcccgctggctgatcgccgagcgcggccaccaccgcctggtcatcgacccggccgccgccaacgcgcacgccatccgcagctaccgcaaggtcggcttcgccccggtcgggatcatgcgcgcctactggcgcaaccaccgcaccggggaatgggaggacggcctgctgatggacctgctggcgggcgaactgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_252,Drugs,MEG_252|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,557415130|WP_023417224.1|NG_052413|1|1|aacA-STR-13|aacA-STR-13|aminoglycoside_6'-N-acetyltransferase NG_052413:101-583,2
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCAGCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6625,Drugs,MEG_6625|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|18693100|emb|AJ319822.1|1779-2594,8
,atgattaagaaaagaatagcaatcatttttggaggaaattcaacggaatacgaggtgtccttgcagtcggcatctgccgtttttgagaatatcaacactaaaaagtttgacattgttcctattggaattaccagaaatggcgactggtatcattacacaggcaaaaaagaaaagattgcaaataatacttggtttgaggataacgaaaacctgtattctgttgcggtatcgcaaaaccgttctgtaaaaggctttatagaatttaaggaagaaaaattctacatcatcaaggttgacttgatatttcctgtattgcacggcaagaacggcgaggacggtactttgcagggattatttgaattagcaggaatacctgttgttgggtgtgatacactctcgtctgctctttgtatggacaaagataaggcacataaacttgttagccttgcgggtatctctgttccaaaatcagtaacttttaaattctctggcaaaaaggcagccttgaaaaaaattgaaaaggagttaagctatccattatttgtgaagcctgtccgtgcaggctcgtcatttggaataacaaaagtaactaaacagcaggaacttgaaaacgctatacaattagcgtttgaacacgatgcggaagtcattgttgaagaaaccataaacggctttgaggttggttgtgcggtacttggtatagatgaactgattgtcggcagagttgatgaaatcgaactgtcaagcggcttttttgattatacagagaaatatacacttaaatcttcaaagatatatatgcctgcaaggattgatgccgaagcagaaaaacggatacaagaaacggctgtaaccatatataaagctctgggctgttcgggtttttccagagtggatatgttttatacaccgtctggcgaaattgtatttaatgaggtaaacacaataccaggctttacctcgcacagtcgctatccaaatatgatgaaaggcattggtctatcgttcgcccaaatgttggataagctgataggtctgtatgtggaatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7393,Drugs,MEG_7393|Drugs|Glycopeptides|VanG-type_resistance_protein|VANG,1028100561|WP_063856696.1|NG_048370|1|1|vanG2|vanG2|D-alanine--D-serine_ligase_VanG2 NG_048370:101-1150,5
,ATGGACACAACGCAGGTCACATTGATACACAAAATTCTAGCTGCGGCAGATGAGCGAAATCTGCCGCTCTGGATCGGTGGGGGCTGGGCGATCGATGCACGGCTAGGGCGTGTAACCCGCAAGCACGATGATATTGATCTGACGTTTCCCGGCGAGAGGCGCGGCGAGCTCGAGGCAATAGTTGAAATGCTCGGCGGGCGCGTCATGGAGGAGTTGGACTATGGATTCTTAGCGGAGATCGGGGATGAGTTACTTGACTGCGAACCTGCTTGGTGGGCAGACGAAGCGTATGAAATCGCGGAGGCTCCGCAGGGCTCGTGCCCAGAGGCGGCTGAGGGCGTCATCGCCGGGCGGCCAGTCCGTTGTAACAGCTGGGAGGCGATCATCTGGGATTACTTTTACTATGCCGATGAAGTACCACCAGTGGACTGGCCTACAAAGCACATAGAGTCCTACAGGCTCGCATGCACCTCACTCGGGGCGGAAAAGGTTGAGGTCTTGCGTGCCGCTTTCAGGTCGCGATATGCGGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_752,Drugs,MEG_752|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,gi|114421723|emb|AJ487033.2|107-640,2
,atggcaatccgaatcttcgcgatacttttctccattttttctcttgccactttcgcgcatgcgcaagaaggcacgctagaacgttctgactggaggaagtttttcagcgaatttcaagccaaaggcacgatagttgtggcagacgaacgccaagcggatcgtgccatgttggtttttgatcctgtgcgatcgaagaaacgctactcgcctgcatcgacattcaagatacctcatacactttttgcacttgatgcaggcgctgttcgtgatgagttccagatttttcgatgggacggcgttaacaggggctttgcaggccacaatcaagaccaagatttgcgatcagcaatgcggaattctactgtttgggtgtatgagctatttgcaaaggaaattggtgatgacaaagctcggcgctatttgaagaaaatcgactatggcaaccccgatccttcgacaagtaatggcgattactggatagaaggcagccttgcaatctcggcgcaggagcaaattgcatttctcaggaagctctatcgtaacgagctgccctttcgggtagaacatcagcgcttggtcaaggatctcatgattgtggaagccggtcgcaactggatactgcgtgcaaagacgggctgggaaggccgtatgggttggtgggtaggatgggttgagtggccgactggctccgtattcttcgcactgaatattgatacgccaaacagaatggatgatcttttcaagagggaggcaatcgtgcgggcaatccttcgctctattgaagcgttaccgcccaacccggcagtcaactcggacgctgcgcgataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4727,Drugs,MEG_4727|Drugs|betalactams|Class_D_betalactamases|OXA,1509794547|WP_122630856.1|NG_062269|1|1|blaOXA-737|blaOXA-2_like|OXA-2_family_class_D_beta-lactamase_OXA-737 NG_062269:1-828,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggatagaaccggcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2199,Drugs,MEG_2199|Drugs|betalactams|Class_A_betalactamases|CTX,1209144250|WP_088245212.1|NG_055269|1|1|blaCTX-M-203|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-203 NG_055269:1-876,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccgagaaattaaaaaactggtagatcaaaactttaaacctttattagataaatatgatgtgccgggtatggccgtgggcgttattcagaataataaaaaatatgaaacgtattatggtcttcaatctgttcaagataaaaaagccgtaagtagcagtaccatttttgaactaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaacttgctacttatacgagtggcaaccttggcttacagtttccagatgaagtccaaacagatcagcaagttttaacttttttcaaagactggaagcctaaaaactcaatcggtgaatatcgacaatattcaaatccaagcattggtttatttggaaaagttgttgcattgtctatgaataaacctttcgaccaactcttagaaaaaacaatttttccagatcttggcttaaaacatagctatgtaaatgtaccgaagacccagatgcaaaactatgcttttggctataatcaagaaaatcagccaattcgtgttaaccctggtccgctagatgctccagcatatggggttaaatcgaccctacctgatatgctgagtttcattaatgccaacctcaacccacagaaatatccgaaagatattcaacgtgcaattaatgaaacacatcaaggtttctatcaagtcggcaccatgtatcaagcattaggttgggaagaattttcttatccagcgcctttacaaactttattagacagtaattcagaacaaattgtgatgaagcctaataaagtgactgctatttcaaaagaaccttcagttaagatgttccacaaaactggctcaaccaatggtttcggaacatatgtcgtgttcattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaagcagcgtatgcagtattaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_541,Drugs,MEG_541|Drugs|betalactams|Class_C_betalactamases|ADC,503973278|WP_014207272.1|NG_064704|1|1|blaADC-149|blaADC|class_C_beta-lactamase_ADC-149 NG_064704:101-1252,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggctacggcaatgcggacgtctcgggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaagctggtgaaccggcaattgccggtcaaggccgccgcctatgagctggccgacaacctcttcgaggcgggccaggccgatggctggcgcctgtatggcaagaccggcaccggttcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccggcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4725,Drugs,MEG_4725|Drugs|betalactams|Class_D_betalactamases|OXA,935729370|WP_054517040.1|NG_064734|1|1|blaOXA-114l|blaOXA-114_like|class_D_beta-lactamase_OXA-114l NG_064734:1-828,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGAGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGAAAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTGACGATGAGGCCCAGGATATTGGGCCTCCTTTCTTTCTCTTTTTTTCCGTTGTTCATCACA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1996,Drugs,MEG_1996|Drugs|betalactams|Class_C_betalactamases|CMY,gi|72199369|gb|DQ139328.1|161-1369,0
,gtgaccggcagcgcggccacgatccgcccggccacggcggccgatgcggccgcgtgggcgcagctgcgtctgggcctgtggcccgatgccgatgatccgctggagacgctggtggcggcgctggccgaggacgcaggtgcggttttcctggcgtgtgcagcgggtggccaggcgatcggcttcgccgaagtgcgcctgcgccatgactacgtgaacggcaccgattcctcgccggtgggcttcctggagggctggtacgtgcagccgcagtggcaaggccgcggcgtgggccgcgccctgctggcggcggtgcgggcgtggacgcgcgatgcgggctgccgcgaactggcttcggatagtcgcgtggaggacgtgcaggctcacgccgcgcatcgggcctgcggcttcgaagaaaccgaacgggtggtctatttccgcatgccgctggagccatcggcgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_247,Drugs,MEG_247|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,923078096|WP_053461075.1|NG_052203|1|1|aac(6')-Iak|aac(6')-Iak|aminoglycoside_N-acetyltransferase_AAC(6')-Iak NG_052203:101-562,2
,ATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTAAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6866,Drugs,MEG_6866|Drugs|betalactams|Class_A_betalactamases|TEM,gi|1045658|gb|U37195.1|ECU37195|1-950,0
,atgaaaaaattaatcatcgccatcgtgattgtaatcatcgctgttggttcaggcgtattcttttatgcatctaaagataagaaaataaacgaaacaattgatgccattgaagataaaaacgttaagcaagtctttaaaaatagtacttaccaatctaaaaacgataatggtgaagtagaaatgacagaccgccctattaagatttatgacagtctcggcgtcaaagatatcaacattaaagatcgtgatatcaaaaaggtttcgaaaaacaaaaaacaagtcacagcaaagtatgaacttcaaacgaattacggcaaaattaatcgtgacgttaaattaaactttattaaagaagataaagattggaaattggattggaatcaaaatgccattattccaggcatgaagaaaaatcaatccatcaatattgaaccattgaaatcagaacgaggtaagattttagacaggaacaatgtagagttagccactacaggaacaacacatgaagttggtattgttcctaataatgtttccacaagtgattacaaagcaatcgctgaaaagttagacctttcagaatcgtatattaaacagcaaacagaacaggattgggttaaagatgatacattcgtccctctcaagactgttcaagatatgaatcaagatttaaagaattttgttgaaaagtatcatctcacatcacaggaaacagaaagtcgacagtatccgcttgaagaagcaacaacgcacttacttggatatgttggccctattaattcagaagaattgaagcaaaaagcatttaaaggttataaaaaggatgccatcgttggtaaaaaaggtatcgaaaaactatacgataaagaccttcaaaataaagacggataccgtgtcacaataattgatgataataataaagttattgatacattaatagagaaaaagaaaatagacggcaaagatattaaattaaccattgatgctagagtccaaaaaagtatttataacaacatgaaagatgactacggttcggggactgctattcatccacaaactggtgaactcttagcacttgtcagcacgccatcttatgatgtttatccatttatgaatggaatgagcgatgaagattataagaaattaactgaagatgataaagagccactccttaataagttccaaattacgacatcaccaggttcgactcaaaaaatattaacagccatgattggcttaaacaataagacattagacggcaaaacaagttataaaattaatggaaaaggttggcaaaaagataaatcttggggtgactacaacgttacaagatacgaagttgtgaatgccgatatcgacttaaaacaagctattgaatcatcagataatatcttctttgcgagagttgcacttgaattaggcagcaaaaaattcgaagaaggaatgaaacgccttggtgttggtgaagatatcccgagtgattatccattctacaatgcacaaatttcaaataagaacttagataatgaaatattgttagctgactcaggttatggccaaggtgaaatattaatcaatcctgttcaaattctttcaatatacagcgcattagagaacaaaggtaatgtgaatgcaccacatgtactcaaagatacgaaaaataaagtctggaagaagaacatcatttcccaggaaaatattaaattgttaacagacggtatgcaacaagtcgtgaacaaaacacatagagaagatatttatagatcatatgccaacttagttggtaaatcaggtacagctgaactcaagatgaaacaaggtgagacaggacaacaaataggttggttcatttcatatgataaagataatccaaatataatgatggctattaatgtgaaagatgtacaagataaaggcatggcaagttacaatgccaaaatatctggaaaagtgtatgacgatttatatgataacggtaagaaaacgtatcgtattgataaataa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3768,Drugs,MEG_3768|Drugs|betalactams|Penicillin_binding_protein|MECA,872669217|WP_048540464.1|NG_047949|1|1|mecA1|mecA1|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA1 NG_047949:101-2101,0
,ATGGAAAGAAAAGGGATTTTCATTAAGGTTTTTTCCTATACGATCATTGTCCTGCTACTGCTTGTCGGTGTAACAGCAACACTGTTTGCACAGCAATTTGTGTCTTATTTCAGAGTGATGGAATTACAGCAAACAGTAAAATCCTATCAGCCATTGGTGGAACTGATTCAGAATAGCGATAGGCTTGATATTCAAGAGGTGGCAGGGCTGTTTCACTACAATAACCAATCCTTTGAGTTTTATATTGAAGATAAAGAGGGAAGCGTACTCTATGCCACACCAAATGCCAATACATCAAATAGTTTTAGACCCGACTTTCTTTATGTGGTACATAGAGATGATAATATTTCGATTGTTGCTCAAAGCAAGGCAGGTGTGGGATTGCTTTATCAAGGGCTGACAATTCGGGGAATTGTTATGATTGCGATAATGGTTGTATTCAGCCTTTTATGCGCGTATATCTTTGCGCGGCAAATGACAACGCCGATCAAAGCCTTAGCGGACAGTGCGAATAAAATGGCAAACCTGAAAGATGTACCGCCGCCGCTGGAGCGAAAGGATGAGCTTGGCGCACTGGCTCATGATATGCATTCCATGTATGTCAGGCTGAAAGAAACCATCGCAAGGCTGGAGGATGAAATCGCAAGGGAACATGAGTTGGAGGAAACACAGCGATATTTCTTTGCGGCAGCTTCTCATGAGCTAAAAACGCCCATCGCGGCTACAAGCGTTCTGTTGGAGGGAATGCTTGAAAATATCGGTGACTACAAAGATCATTCTAAGTATCTGCGCGAATGCATCAAAATGATGGATAGGCAGGGCAAAATCATTTCCGAAATACTGGAGCTTGTCAGCCTGAATGATGGGAGAATCGTACCCATAGCTGAACCGTTGGACATAGGGCGCACGGTTGCCGAGTTGCTGCCCGATTTTCAAACCTTGGCAGAGGCAAACAACCAGCGGTTCGTCACAGATATTCCAGCCGGGCAAATTGTCCTGTCCGATCCGAGGCTGCTCCAAAAGGCACTATCCAATGTCATATTGAATGCAGTTCAGAACACGCCGCAGGGAGGCGAGGTACGGATATGGAGTGAGCCTGGTGCTGAAAAATGCCGCCTTTTTGTTTTGAACATGGGCGTTCACATTGATGATACTGCGCTTCCAAGGCTGTTCACCCCATTCTATCGCATTGATCAGGCGCGAAGCAGAAAAAGTGGGCGAAGCGGTTTAGGACTTGCCATCGTACAAAAAACGCTGGATGCCATGAGCCTCCAGTATGCGCTGGAAAACACCTCGGATGGCGTTTTGTTCTGGCTGGATTTACCGCTCACATCAACATTGTA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7493,Drugs,MEG_7493|Drugs|Glycopeptides|VanB-type_regulator|VANSB,(Gly)VanS-B:AY655721:731-2074:1344,5
,ATGTTACGCAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGGTGGCTCAAGTATGGGCATCATTCGCACATGTAGGCTCGGCCCTGACCAAGTCAAATCCATGCGGGCTGCTCTTGATCTTTTCGGTCGTGAGTTCGGAGACGTAGCCACCTACTCCCAACATCAGCCGGACTCCGATTACCTCGGGAACTTGCTCCGTAGTAAGACATTCATCGCGCTTGCTGCCTTCGACCAAGAAGCGGTTGTTGGCGCTCTCGCGGCTTACGTTCTGCCCAGGTTTGAGCAGCCGCGTAGTGAGATCTATATCTATGATCTCGCAGTCTCCGGCGAGCACCGGAGGCAGGGCATTGCCACCGCGCTCATCAATCTCCTCAAGCATGAGGCCAACGCGCTTGGTGCTTATGTGATCTACGTGCAAGCAGATTACGGTGACGATCCCGCAGTGGCTCTCTATACAAAGTTGGGCATACGGGAAGAAGTGATGCACTTTGATATCGACCCAAGTACCGCCACCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_67,Drugs,MEG_67|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,aac(3)-Ia_1_X15852 ,2
,atgcgatttaaaaaaatttcttgcttacttttaccttctctttttattcttaatacctcaatttatgcaggtaatacctctaaagatcaagaaattaaacaactggtagatcaaaactttaaacccttattagaaaaatataatgtgccgggtatggcggtaggtgttattcaaaataataaaaaatatgaaatgtattatggtttgcagtccgttcaagataaaaaagtcgtaaacagcaataccatttttgagctaggttctgtcagtaaattatttactgcaaccgcaggtgcctatgccaaaaataaaggaaaaatctcttttgaagacacaccaagtaaatactggaaagaactcaaaaatacgccaattgatcaagttaacctacttcaacttgccacctataccagtggtaaccttgcccttcaatttccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggcaacctaaaaacccaattggtgaatatagacaatattcaaacccaagtattggcctatttggaaaaattgtaggcctatcgatgaatcagccttttagtcagttcctagaaaagacaatttttccagaccttggcttaaaacatagctatgtcaatgtgcctaaaacccaaatacaaaactatgcatttggctacaacccagaaaatcagccgattcgcgttaaccccggtccactcgatgctccagcatacggtgttaaatctaccttgcctgacatgctaagttttattcatgccaacctgaacccacagaaatatccggcagatattcaaagcgcaattaatgaaactcacaaaggtttctatcaagtaggtaccatgtatcaagcgcttggttgggaagagttttcttatcctgcaaccttacaaactttattagacagtaattcagaacaaattgtgatgaaacctaataaagtgagtgctatttcaaaagaaccttcagttaagatgttccataaaacaggttcaaccaacggttttggaacctatgtcgtatttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagaacgtattaaggctgcttatgctgttttgaatgcgataaaaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_530,Drugs,MEG_530|Drugs|betalactams|Class_C_betalactamases|ADC,1058243583|WP_068981615.1|NG_051447|1|1|blaADC-83|blaADC|class_C_beta-lactamase_ADC-83 NG_051447:1-1152,0
,GGGATCNACTTTGGGAGNGAGTTCAAAATTGATCCTTTTTTTATAACAGGAATTCCCTATAGTGAGTCGTATTAAATTCGAGCTCGGTACCCGGGGATCCTTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACAACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTGGATCCCCGGGTACCGAGCTCGAATTTAATACGACTCACTATAGGGAATTCCTGTTATAAAAAAAGGATCAATTTTGAACTCT,beta-lactamase,antibiotic inactivation,betalactams,MEG_6909,Drugs,MEG_6909|Drugs|betalactams|Class_A_betalactamases|TEM,gi|358009200|gb|JN227084.1|1-1391 gi|358009200|gb|JN227084.1|100-19 gi|358009200|gb|JN227084.1|1390-1309 gi|961666360|gb|KT185451.1|87734-87690 gi|961666360|gb|KT185451.1|4506-4477 gi|961666360|gb|KT185451.1|86442-86413 gi|975048878|gb|CP013962.1|163827-163856 gi|973715451|gb|CP013836.1|133859-133830 gi|973705327|gb|CP013832.1|72159-72130 gi|943457735|gb|KT818627.1|21845-21816 gi|943457735|gb|KT818627.1|81788-81817 gi|943457735|gb|KT818627.1|143379-143408 gi|970338578|gb|KT725789.1|68997-68968 gi|970338460|gb|KT725788.1|68997-68968 gi|961494526|gb|KT282968.1|27451-27422 gi|959190550|gb|CP013325.1|33445-33416,0
,atgaacatcaacgatgccctcacctccatcctggcctcaaaaaaataccgcgccctttgcccggataccgttcggcgcatcctgaccgaggaatgggggcggcataaatcccccaaacaggccgtagaggctgcacgcacccggctgcatggaatttgcggggcatatgtcaccccggaatcgctcaaggccgctgccgccgcgctttctgcgggcgatgtaaaaaaggcattgtcgctgcatgtctccaccaaggagagactggccgagctggataccctgtacgattttatcttttcagccgaaactccccgccgcgtgctggatatcgcctgcggtcttaaccccttggcgctatacgagcgcggggttgcatccgtgtggggctgtgatgtccaccagggattgggggatgtaatcaccccctttgctagggaaaaagattgggattttacctttgccctgcaggatgtgctgtgtgcgccgcccgccgaaaccggggatctggcgctgatattcaagttactgcccctattggagcgggagcaggccggttctgccatggcacttttacaatccatcaataccccgcgcatggctgtcagttttcccacacgtagtttaggcgggcgtggaaaaggcatggaggcgaactacgccgcatggttcgagggcggcttgcccaccgagtttgagattgaggataaaaagaccatcggaacagaacttatatatttgataaaaaagaatggataa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_6063,Drugs,MEG_6063|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|RMTB,852041985|WP_048266647.1|NG_051535|1|1|rmtB3|rmtB|16S_rRNA_(guanine(1405)-N(7))-methyltransferase_RmtB3 NG_051535:1-756,2
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6674,Drugs,MEG_6674|Drugs|betalactams|Class_A_betalactamases|TEM,445949205|WP_000027060.1|NG_050218|1|1|blaTEM-181|blaTEM|class_A_beta-lactamase_TEM-181 NG_050218:101-961,0
,ATGACTATACCTGACGCAAATGCAATCTATCATAACTCAGCCATCAAAGAGGTTGTCTTTATCAAGAACGTGATCAAAAGTCCCAATATTGAAATTGGGGACTACACCTATTATGATGACCCAGTAAATCCCACCGATTTTGAGAAACACGTTACCCATCACTATGAATTTCTAGGCGACAAATTAATCATCGGTAAATTTTGTTCTCTCGCCAGTGGCATTGAATTTATCATGAACGGTGCCAACCACGTAATGAAAGGTATTTCGACTTATCCATTTAATATATTAGGTGGCGATTGGCAACAATACACTCCTGAACTGACTGATTTGCCGTTGAAAGGTGATACTGTAGTCGGAAATGACGTGTGGTTTGGGCAAAATGTGACCGTCCTACCAGGCGTAAAAATAGGTGACGGTGCCATTATCGGAGCAAATAGTGTTGTAACAAAAGACGTCGCTCCATATACAATTGTCGGTGGCAATCCAATTCAACTCATCGGACCAAGATTTGAACCGGAAGTTATTCAAGCATTAGAAAATCTGGCATGGTGGAATAAAGATATTGAATGGATAACTGCTAATGTTCCTAAACTAATGCAAACAACACCCACACTTGAATTGATAAACAGTTTAATGGAAAAATAA,streptogramin inactivation enzyme,antibiotic inactivation,MLS,MEG_7632,Drugs,MEG_7632|Drugs|MLS|Streptogramin_A_O-acetyltransferase|VATE,gi|695199387|ref|NG_035215.1|271-915,7
,ATCTTATAAGTCTTATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAAACTGATAAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGAACGGGCAAAAAAGGCTGTTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGGCTTGAACTCATGTCTAATGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTACTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCAGTTCACTTTTTACCATTTTGATCTGGGCCATTGCCTATTTTCAAAACTGATAATCTATCCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5240,Drugs,MEG_5240|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389169|gb|KJ135345.1|1-917,0
,atgaatattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctaatgaaaaagcagagaaaattaaaaatttatttaacaaagcacacactacgggtgtcttagttatccagcaagggcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccatagggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4528,Drugs,MEG_4528|Drugs|betalactams|Class_D_betalactamases|OXA,1559613007|WP_128268272.1|NG_063877|1|1|blaOXA-773|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-773 NG_063877:24-848,0
,atgaaaaaatcgttatctgcaacactgatttccgctctgctggcgttttccgccccggggttttctgccgctgataatgtcgcggcggtggtggacagcaccattaaaccgctgatggcacagcaggatattcccgggatggcggttgccgtctccgtaaagggtaagccctattatttcaattatggttttgccgatattcaggcaaaacagccggtcactgaaaatacactatttgagctcggatctgtaagtaaaactttcacaggtgtgctgggtgcggtttctgtggcgaaaaaagagatggcgctgaatgatccggcggcaaaataccagccggagctggctctgccgcagtggaaggggatcacattgctggatctggctacctataccgcaggcggactgccgttacaggtgccggatgcggtaaaaagccgtgcggatctgctgaatttctatcagcagtggcagccgtcccggaaaccgggcgatatgcgtctgtatgcaaacagcagtatcggcctgtttggtgctctgaccgcaaacgcggcggggatgccgtatgagcagttgctgactgcacggatcctggcaccgctggggttatctcacacctttattactgtgccggaaagtgcgcaaagccattatgcgtacggttataaaaacaaaaaaccggtccgcgtgtcgccgggacagcttgatgcggaatcttacggcgtgaaatccgcctcaaaagatatgctgcgctgggcggaaatgaatatggagccgtcacgggccggtaatgcggatctggaaatggcaatgtatctcgcccagacccgctactataaaaccgccgcgattaaccaggggctgggctgggaaatgtatgactggccgcagcagaaagatatgatcattaacggtgtgaccaacgaggtcgcattgcagccgcatccggtaacagacaaccaggttcagccgtataaccgtgcttcctgggtgcataaaacgggcgcaacaactggtttcggcgcctatgtcgcctttattccggaaaaacaggtggcgattgtgattctggcgaataaaaactacccgaataccgaaagagtcaaagctgcacaggctattttgagtgcactggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2588,Drugs,MEG_2588|Drugs|betalactams|Class_C_betalactamases|DHA,1391852883|WP_109545068.1|NG_057482|1|1|blaDHA-26|blaDHA|class_C_beta-lactamase_DHA-26 NG_057482:1-1140,0
,ATGACAGACACGACGTTGCCGCCTGACGACTCGCTCGACCGGATCGAACCGGTTGACATCCAGCAGGAGATGCAGCGCAGCTACATCGACTATGCGATGAGCGTGATCGTCGGCCGCGCGCTGCCGGAGGTGCGCGACGGGCTCAAGCCCGTGCATCGCCGGGTGCTCTATGCAATGTTCGATTCCGGCTTCCGCCCGGACCGCAGCCACGCCAAGTCGGCCCGGTCGGTTGCCGAGACCATGGGCAACTACCACCCGCACGGCGACGCGTCGATCTACGACACCCTGGTGCGCATGGCCCAGCCCTGGTCGCTGCGCTACCCGCTGGTGGACGGCCAGGGCAACTTCGGCTCGCCAGGCAATGACCCACCGGCGGCGATGAGGTACACCGAAGCCCGGCTGACCCCGTTGGCGATGGAGATGCTGAGGGAAATCGACGAGGAGACAGTCGATTTCATCCCTAACTACGACGGCCGGGTGCAAGAGCCGACGGTGCTACCCAGCCGGTTCCCCAACCTGCTGGCCAACGGGTCAGGCGGCATCGCGGTCGGCATGGCAACCAATATCCCGCCGCACAACCTGCGTGAGCTGGCCGACGCGGTGTTCTGGGCGCTGGAGAATCACGACGCCGACGAAGAGGAGACCCTGGCCGCGGTCATGGGGCGGGTTAAAGGCCCGGACTTCCCGACCGCCGGACTGATCGTCGGATCCCAGGGCACCGCTGATGCCTACAAAACTGGCCGCGGCTCCATTCGAATGCGCGGAGTTGTTGAGGTAGAAGAGGATTCCCGCGGTCGTACCTCGCTGGTGATCACCGAGTTGCCGTATCAGGTCAACCACGACAACTTCATCACTTCGATCGCCGAACAGGTCCGAGACGGCAAGCTGGCCGGCATTTCCAACATTGAGGACCAGTCTAGCGATCGGGTCGGTTTACGCATCGTCATCGAGATCAAGCGCGATGCGGTGGCCAAGGTGGTGATCAATAACCTTTACAAGCACACCCAGCTGCAGACCAGCTTTGGCGCCAACATGCTAGCGATCGTCGACGGGGTGCCGCGCACGCTGCGGCTGGACCAGCTGATCCGCTATTACGTTGACCACCAACTCGACGTCATTGTGCGGCGCACCACCTACCGGCTGCGCAAGGCAAACGAGCGAGCCCACATTCTGCGCGGCCTGGTTAAAGCGCTCGACGCGCTGGACGAGGTCATTGCACTGATCCGGGCGTCGGAGACCGTCGATATCGCCCGGGCCGGACTGATCGAGCTGCTCGACATCGACGAGATCCAGGCCCAGGCAATCCTGGACATGCAGTTGCGGCGCCTGGCCGCACTGGAACGCCAGCGCATCATCGACGACCTGGCCAAAATCGAGGCCGAGATCGCCGATCTGGAAGACATCCTGGCAAAACCCGAGCGGCAGCGTGGGATCGTGCGCGACGAACTCGCCGAAATCGTGGACAGGCACGGCGACGACCGGCGTACCCGGATCATCGCGGCCGACGGAGACGTCAGCGACGAGGATTTGATCGCCCGCGAGGACGTCGTTGTCACTATCACCGAAACGGGATACGCCAAGCGCACCAAGACCGATCTGTATCGCAGCCAGAAACGCGGCGGCAAGGGCGTGCAGGGTGCGGGGTTGAAGCAGGACGACATCGTCGCGCACTTCTTCGTGTGCTCCACCCACGATTTGATCCTGTTCTTCACCACCCAGGGACGGGTTTATCGGGCCAAGGCCTACGACTTGCCCGAGGCCTCCCGGACGGCGCGCGGGCAGCACGTGGCCAACCTGTTAGCCTTCCAGCCCGAGGAACGCATCGCCCAGGTCATCCAGATTCGCGGCTACACCGACGCCCCGTACCTGGTGCTGGCCACTCGCAACGGGCTGGTGAAAAAGTCCAAGCTGACCGACTTCGACTCCAATCGCTCGGGCGGAATCGTGGCGGTCAACCTGCGCGACAACGACGAGCTGGTCGGTGCGGTGCTGTGTTCGGCCGACGACGACCTGCTGCTGGTCTCGGCCAACGGGCAGTCCATCAGGTTCTCGGCGACCGACGAGGCGCTGCGGCCAATGGGTCGTGCCACCTCGGGTGTGCAGGGCATGCGGTTCAATATCGACGACCGGCTGCTGTCGCTGAACGTCGTGCGTGAAGGCACCTATCTGCTGGTGGCGACGTCAGGGGGCTATGCGAAACGTACCGCGATCGAGGAATACCCGGTACAGGGCCGCGGCGGTAAAGGTGTGCTGACGGTCATGTACGACCGCCGGCGCGGCAGGTTGGTTGGGGCGTTGATTGTCGACGACGACAGCGAGCTGTATGCCGTCACTTCCGGCGGTGGCGTGATCCGCACCGCGGCACGCCAGGTTCGCAAGGCGGGACGGCAGACCAAGGGTGTTCGGTTGATGAATCTGGGCGAGGGCGACACACTGTTGGCCATCGCGCGCAACGCCGAAGAAAGTGGCGACGATAATGCCGTGGACGCCAACGGCGCAGACCAGACGGGCAATTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3237,Drugs,MEG_3237|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|984994143|gb|CP010340.1|7302-9818 gi|984989958|gb|CP010339.1|7302-9818 gi|984985728|gb|CP010338.1|7302-9818 gi|984972452|gb|CP010335.1|8658-11174 gi|918453982|gb|CP012090.1|8660-11176 gi|755917060|gb|CP007299.1|8660-11176 gi|702068662|emb|HG813240.1|8660-11176 gi|686571222|gb|CP009426.1|8660-11176 gi|669122404|gb|CP008983.1|4082183-4084699 gi|669114883|gb|CP008981.1|4082182-4084698,3
,ATGATGAAAAAATCGTTATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACATTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGCTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGTACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1940,Drugs,MEG_1940|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KM087844|+|0-1146|ARO:3002128|CMY-117 [Citrobacter freundii] ,0
,GTTAGAAAAGGAAAAGTATGAGCAAGTTATCTGTATTCTTTATATTTTTGTTTTGCAGCATTGCTACCGCAGCAGAGTCTTTGCCAGATTTAAAAATTGAAAAGCTTGATGAAGGCGTTTATGTTCATACTTCGTTTGAAGAAGTTAACGGGTGGGGCGTTGTTCCTAAACATGGTTTGGTGGTTCTTGTAAATGCTGAGGCTTACCTAATTGACACTCCATTTACGGCTAAAGATACTGAAAAGTTAGTCACTTGGTTTGTGGAGCGTGGCTATAAAATAAAAGGCAGCATTTCCTCTCATTTTCATAGCGACAGCACGGGCGGAATAGAGTGGCTTAATTCTCGATCTATCCCCACGTATGCATCTGAATTAACAAATGAACTGCTTAAAAAAGACGGTAAGGTTCAAGCCACAAATTCATTTAGCGGAGTTAACTATTGGCTAGTTAAAAATAAAATTGAAGTTTTTTATCCAGGCCCGGGACACACTCCAGATAACGTAGTGGTTTGGTTGCCTGAAAGGAAAATATTATTCGGTGGTTGTTTTATTAAACCGTACGGTTTAGGCAATTTGGGTGACGCAAATATAGAAGCTTGGCCAAAGTCCGCCAAATTATTAAAGTCCAAATATGGTAAGGCAAAACTGGTTGTTCCAAGTCACAGTGAAGTTGGAGACGCATCACTCTTGAAACTTACATTAGAGCAGGCGGTTAAAGGGTTAAACGAAAGTAAAAAACCATCAAAACCAAGCAACTAAATTTCTAACAAGTCGTTGCAGCACGCCTACGTGGCTGGACAGTTTGTAAGTTGCGCTTTTGTGGTTTGCTTCGCAAAGTATTCCACAACGCGCAACTTACAAACTGCCGCTGAACTTAGCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3394,Drugs,MEG_3394|Drugs|betalactams|Class_B_betalactamases|IMP,gi|4210822|emb|AJ223604.1|1468-2346 gi|1435171|emb|X98393.1|1146-2024 gi|537705843|dbj|AB472901.2|1169-1197,0
,ATGAGGGAAGCGGTGATCGCCGAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCACACAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACGTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAGTTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATTGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAGAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCGCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_916,Drugs,MEG_916|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,(AGly)AadA1:M95287:3320-4111:792;(AGly)AadA1b:JN596991:1364-2155:792,2
,ATGAAGAAAATACCCAATATGAATGAAGTAACTGAAAAAAAGCCGCTTACTGAGTTTACAGAAAAAGCTTATCTTGATTATTCAATGTATGTCATTTTGGACAGAGCATTACCGAGCATCGCAGATGGACTTAAGCCTGTCCAACGCAGAATTGTTTATGCTATGTCTGAGTTGGGTTTGAAAGCAACAGCAAAATATAAAAAATCAGCGCGTACAGTAGGGGATGTTCTTGGTAAATTCCATCCTCATGGTGATAGTGCATGCTATGAAGCTATGGTATTAATGGCACAACCTTTCTCGTATCGTTATCCTTTTGTTGATGGACAAGGAAATTGGGGATCCCCGGATGATCCCAAATCATTTGCTGCAATGAGATATACAGAAGCAAGATTATCTCATTATGCTGATGTGTTACTTGGAGAACTGCTACAAGGAACCGTAGATTGGGTAGATAATTTTGATGGTACTTTGCAAGAGCCAGCTCTTTTACCAGCACGTTTGCCTAATATTTTATTGAATGGTGCAACAGGTATAGCTGTTGGTATGGCTTCAGATATTCTTCCGCACAATTTGACTGAAGTTGCTAATGCGTGTATTCATCTGCTGGATAACCCCCAAGCCGATATTAAGACTATATGTGAATATATTAAAGGCCCTGATTTTCCAACAGAAGCAGAAATCATTAGCCCAAGTGAAACAATTAGAGCTATGTACGAGTCTGGTAATGGCTCAATTAAAATGCGAGCAATTTATACTCAAGAAAAACAAAATATCGTCATAACCGCTTTGCCTTATCAAGTATCCGGAGCTAGGGTAATGGAGCAAATTGCGTTGCAGATGCAACAGAAAAAATTACCGATGGTTGAGGATTTACGTGATGAATCAGATCACGAGCATCCAACACGGTTGGTTATTATCCCTCGTTCTAATCGAGTAGATATAGAAAGTTTAATGTCGCATTTATTTGCTACCACGGATTTGGAGCGTAGCTATCGAGTTAATTTTAATATGATTGGGCTTGATGGCAAGCCAAGGGTTAAAGGACTGTTAGCAATCTTGACTGAATGGTTGGAATTTAGGCTTGCCACAGTAAAAAGACGTCTTCAATTCAGATTGGAAAAGGTACTGGAGCGTATTCATATTCTTGAAGGATTGCTTATCGCCTATCTTAATATAGATGAAGTCATTGCAATCATCAGAGAACATGAGCAACCAAAACAAGGATTAATTTCGCGCTTTAACTTAACCGAAAGACAGGCTGAAGCAATTTTGGAAATGAAACTGCGGCATTTAGCCAAATTGGAAGAGATTAAATTGCGTGGTGAACTGGACGAGCTGTCTGATGAACGTGATACTTTACAAAAAACGCTGGCTAGTCATTTTCTCTTAAAAGAACTGGTAAAAGAAGAGATAACGAAAGATCGAGATGAGTTTGGTGACCCACGCCGTTCACCCATTATTACAAGGGAGGACTCTCAGGCATTAAAAGAAGAGGATATTTTGCCTAATGAGCCTATTACGGTTGTATTGTCTAAAAATGGATGGGTCAGAGCGGCCAAGGGGCATGATGTCGATGGTAAGGAACTCAGCTATAAAGCTGGAGATGAATTCAAAGCCCAAACGCTAGCTCGTACTAATCAGCAAGTTTTATTTTTTGATGGAGAGGGAAAGGTCTATTCGCTTCCAGGACATGTATTGCCATCAGCACGTGGTCAAGGCGAGCCTTTGACCGGAAAATTAAACCCTGCTGAAGGAGTATTGTTTGAAGCAATTGTTGGCGGAGAGCCTGAGCAAAAGGTGTTATTGGCTACTGATTCCGGGTATGGATTTATCGCCAAAATTGAAGATTTATATGTAAAAAATCGTAATGGAAAGGCATGCATCAAATTAAGTGAAAAAAGTCATATATTGCCGCCAAGGCTAATACCAAATCGAGAGCAATTATTTGTTGCTTGTGCAACGAATGTAGGGCGTTTATTGATTTTTTCTCTTGAGGAGTTGCCCGAATTATCTCGAGGAAAAGGGAATAAATTGATCAGTATCCCTGCCGCTAAAGCGGTCTCACGAGAAGAGTATATAGTTGATATACAAGTTTTAACAACAAATGATTCACTGACAGTTCATGCCGGTAAGCGGCATTTTACTCTGAAAGGTGAGGATTTGACTCACTATAAGGGTGAACGGGGCAGGAGAGGAAACCGGTTGCCAAGAGGTTTACAAAATGTTTCTCAATTACATGTTACTCAATCTGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5347,Drugs,MEG_5347|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|53752796|emb|CR628337.1|3321661-3319406,3
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAAGGCGGCTGGGCGTCCCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAACTGGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2404,Drugs,MEG_2404|Drugs|betalactams|Class_A_betalactamases|CTX,gi|56554766|gb|AY847145.1|82-962,0
,atggccgtccgcaagtccctgtccttcgcggcgctgaccgcctgcctgcttgtcgccatgccgctgtccgccgcacccaagaagaaggctcccgccaagaaggctgaggatgtgccggtcctgccgacacagttacccccggcgccccgatatctggtgccgcaatcggccctgacctcggtccgcaatccaaaggaaatcgaggaggagacgggcgggcgcatgggcattgcgctggtcgaccgcgacggcgcactcatccttggcttcaatcgcgacgatcgctttgccatgtgctcgaccttcaaggcgccgcttgccgccgccgtgctgatcggcgcggagggcggcaaatttggtctggatggagagatccctttcaccaaggacgatattctcgattacgcgcctgtagtgaagaagaacaggaagcgcggacgcatgtcgatggccgagttggcgcaggccgcagtcgaagtgagcgacaacagcgccgccaacctgctgctgccgatgctgggcggtccggaagggctgactgccttcatgcgtgcccatggcgacaagattacccggctcgatcgcaacgaaccggcccttaacgagaatatcgagggtgatgggcgcgatacgaccagtcccgccgccatggccgggctgatgagccggctgctgttccgggacatgcaggcggccgacgctgacaggctgcgcggctggctcaatgccagcaccaccggtgacaagcggatcaaggcgggcctgcccgaaggctggacctcgggcagcaagaccggcagttgcggcacggcctataatgacgtcgcgctggtaaaggcgccgagcggcgaggaatatatattggcgatctatctcgatcgcccgaccgtcgaccagaaggcagcagaggccgcgatcgccgaagcggcccattcggcgctcgaatttgtcagcaaggcgaagaagagcggactggactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1309,Drugs,MEG_1309|Drugs|betalactams|Class_A_betalactamases|BLASGM,494982315|WP_007708339.1|NG_049987|1|1|blaSGM-5|blaSGM|class_A_beta-lactamase_SGM-5 NG_049987:101-1081,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgctcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgacagcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcctagcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcttggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5591,Drugs,MEG_5591|Drugs|betalactams|Class_C_betalactamases|PDC,1201190438|WP_087587958.1|NG_054974|1|1|blaPDC-188|blaPDC|class_C_beta-lactamase_PDC-188 NG_054974:1-1194,0
,ATGACTCTGGCATTAGTTGGCGAAAAAATTGACAGAAATCGCTTCACTGGTGAGAAAGTTGAAAATAGTACATTTTTTAACTGCGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGCCAGTTCTATGATCGCGAAAGTCAGAAAGGATGCAATTTTAGTCGCGCAATGCTGAGAGATGCCATTTTCAAAAGCTGTGATTTATCAATGGCAGATTTCCGCAACGTCAGCGCATTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGTGCAAGCTTTATGAATATGATCACCACGCGCACCTGGTTTTGCAGCGCATATATCACTAATACCAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTATGGGAAAACCGCTGGATGGGGACTCAGGTACTGGGTGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTAGGTGACTTAGATACTCGGGGTGTTGATTTACAAGGCGTTAAGTTAGACAACTACCAGGCATCGTTGCTCATGGAGCGGCTTGGCATCGCGGTAATTGGTTA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6003,Drugs,MEG_6003|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,qnrB46_1_JQ349154 ,3
,ATGCCTACGCAGATCACCGCCCTCGCCGTCACCAAGGCATACCAGGGCCAGGTCGTGCTCGACTCGGTCACCTGCTCGCTCACCGAGGGTGAGCGCACCGGGATCATCGGGGAGAACGGTTCCGGCAAGACCACGCTGCTGCGCCTGCTCGCCGGACCGGAGCAGCCCGACAGCGGCGAGATCGTCCTCCACGCCACCGGCGGCGTGGGCTACTTCGCCCAGGACGGCGAACTGCCGCCGCACGTCACCGTCGCGCAGGTCGTCGACCACGCCCTCGGCGAACTGCGCGCCGTCGAAGCCCGTCTGCGCGATCTCGAAGCGCGGATGGCCGACGGTGACACCTCGTCCCTGGCCGAGTACGGCGACCTGCTCACCGTCTTCGAGCTGCGTGGCGGCTACGAGGCCGACGCCCGCCTGGAGCGCGCCCTGCACGGGCTCGGCCTCGGCCACCTGCCCCGGGACCGTGTGGTCGGCGGGCTGTCCGGCGGCGAACAGGCACGGCTGCGGCTCGCCTGCGTCCTCGCGTCCGGCCCCGAGGTGCTGCTGCTGGACGAACCCACCAACCACCTCGACGCCTCCGCGCTCACCTGGCTGGAGACGTATCTGAGCACCCGGCGCGGCACCACGGTGGCGGTCTCCCACGACCGGGCCTTCCTGGAACACGTCACCACCACCTTGCTGGAGGTGGACGCCGACCGCCGCCAGGTCTTCCGCTACGGCAACGGCTACGCCGGCTACCTCGCCGAGAAGGCGGCGGCCCGGCAGCGCTGGGCGCAGGCGTACGACGAGTGGCGGGCCGAGACCGACCGGCTGCGGGAGACGGCGGCCACCACCGCCCGCCGGGTCGCCCCCGGCCGGGCGATGACCGACCGCAACAAGATGGCGTACGGGCGGGCCGCCGGGCGCGTCCAGCAGTCCGTGGCGAGCCGGGTGCGCAACGCGGAGGAACGGCTGCGCCGGCTCCTCGCCGACCCGGTGCCGGCCCCGCCCGAACCGTTGCGGTTCACCGCGGCACCACGGCCGGCCGGAGACCCGCAAGGCGCCGTGCTCGACGCCGCCGCCATCACCGTCACCGGCCGCCTCGCCGCCACCGACCTCACCGTCACGGCGGGGGAACGGGTGCTGATCACCGGGGCCAACGGCGCGGGCAAGACCACGTTGCTGCGGGTGCTCGCCGGTGAACTGGCCCCCGACGGCGGACGCGTGTCCCGGCGCGGCCGGATCGGCTACCTGTCCCAGGAGCCGCCCCCCGGCCGCCCCGGCGAGACGCTGCTCGCGGCGTTCGCCCGCGGCCGGGCCGGTACCGCCGAGGAACACGCCGAACGGCTGCTCGCCCTCGGCCTGTTCACCGCCGACCGGTTCGACACCCCGGTCACCCGGCTCTCCACCGGTCAGCGGCAGCGCCTCGCCCTGGCCCGGCTGGTCACCGCGCCCGCCGACGTCCTGCTGCTGGACGAGCCGACCAACCACCTCTCCCCGGCCCTGGTCGAGGAGTTGGAGGAGGCCCTGGCCGGGTTCCCGGGCGCGCTGGTGGTGGTCAGCCACGACCGCAGGCTGCGGGAACGCTGGCGCGGCAGCCGGGTGGAGCTGGCGGACAGCGGTACCGCCGCACTGCGGATGTGA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_7256,Drugs,MEG_7256|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|TLRC,(MLS)TlrC:NC_016113:803268-384890:1623,7
,atgaacatgaatggacctgtaaaaatttctcgaagtgaacgatttcaaacctgccaagaaattgctgcgagattgcatgaagtgtacaaagaaaaaattctggccattggggtgtatggttctatttctcgtgggacagacggcccttattcggatatcgagatgttttgtgtactagaagaaacaggggaagaaatagaatttagctacgaatggtcagcgggaccttggaaggcggaagtgaatgtgtgcagtgcagatgttttgctgaacactgcgtctactgtcgaggatgattggccgctgacacatggcccattcttttctccgctgagtctgtacgatccgaagggctttttggaaacgctcaaaaaagcagcggaatcaccgtcgcaggaagagttcacagagaatatcaacggtattctcgtaggggaaatgtacgagtttattggcaagttgcgaaacgtaaatctagacggcccacatacctatctgccttacttggctatggagtttgcccaatatggtgcgatgttgatcgggctgcataaccgaaagctctactcgacaggggccaaggttttgccagaagcgctggaattgccgcatcgcccggctggatacgatcaggtagccagattggtaatggcgggggatctgactgatccagcaaaaatcgttaccgcttgcgaagcattctgggatggtctccaagagtgggctgcacaacatcactatgtgattcattcagagcgaattcctttttaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_977,Drugs,MEG_977|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT4-PRIME,1199612229|WP_087346196.1|NG_063817|1|1|ant(4')-Ic|ant(4')-Ic|aminoglycoside_O-nucleotidyltransferase_ANT(4')-Ic NG_063817:1-771,2
,ATGCAAAAAAGACTTATACATTTATCCATTATCTTCTTTCTGCTATGTCCTGCCCTGGTAGTTGCGCAGAACAGTCCTCTTGAAACTCAACTCAAGAAAGCCATAGAAGGGAAAAAAGCCGAAATAGGAATTGCAGTCATTATCGACGGGCAAGATACGATAACAGTCAATAATGATATTCATTATCCCATGATGAGTGTTTTCAAATTTCATCAGGCATTGGCATTGGCCGATTACATGCATCATCAAAAGCAACCTTTGGAAACCCGGTTATTGATTAAAAAGTCGGATTTAAAGCCGGACACCTATAGTCCGCTTCGAGAAACATACCCACAGGGAGGAATCGAAATGAGCATTGCCGATCTACTGAAATATACGCTTCAGCAAAGTGACAATAATGCCTGCGATATTCTTTTTAATTATCAAGGTGGTCCGGATGCCGTGAATAAGTATCTTCATTCATTGGGAATTCGTGAATGTGCTGTCATCCATACAGAAAACGATATGCATAAGAATCTGGAGTTCTGTTACCAAAACTGGACTACTCCATTAGCAGCCGCCAAATTACTGGAAATATTTCGCAATGAAAACCTTTTTGACAAAGAATACAAGAATTTCATTTATCAAACAATGGTGGAATGTCAGACAGGACAAGACCGCCTGATTGCTCCACTGCTCGATAAAAAAGTAACAATGGGGCATAAAACCGGAACAGGCGACCGTAATGCGAAAGGACAACAGATCGGTTGCAATGACATCGGGTTTATTCTTCTTCCCGACGGACATGCCTATAGTATAGCCGTCTTCGTGAAAGATTCCGAAGCAGATAACAGAGAAAACAGTGAGATTATCGCAGAAATTTCGCGCATCGTTTACGAATACGTAACGCAACAGATAGATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1651,Drugs,MEG_1651|Drugs|betalactams|Class_A_betalactamases|CEPA,gi|307075858|emb|FR688023.1|1-903 gi|437319|gb|L13472.1|BNRCEPA|436-1338,0
,atgaacattaaagcactcttatttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4494,Drugs,MEG_4494|Drugs|betalactams|Class_D_betalactamases|OXA,1559612996|WP_128268261.1|NG_063866|1|1|blaOXA-762|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-762 NG_063866:25-849,0
,ATGAAAAAATTTATACTTCCTATATTCAGCATTTCTATTCTAGTTTCTCTCAGTGCATGTTCATCTATTAAAACTAAATCTGAAGATAATTTTCATATTTCTTCTCAGCAACATGAAAAAGCTATTAAAAGCTATTTTGATGAAGCTCAAACACAGGGTGTAATTATTATTAAAGAGGGTAAAAATCTTAGCACCTATGGTAATGCTCTTGCACGAGCAAATAAAGAATATGTCCCTGCATCAACATTTAAGATGCTAAATGCTTTAATCGGGCTAGAAAATCATAAAGCAACAACAAATGAGATTTTCAAATGGGATGGTAAAAAAAGAACTTATCCTATGTGGGAGAAAGATATGACTTTAGGTGAGGCAATGGCATTGTCAGCAGTTCCAGTATATCAAGAGCTTGCAAGACGGACTGGCCTAGAGCTAATGCAGAAAGAAGTAAAGCGGGTTAATTTTGGAAATACAAATATTGGAACACAGGTCGATAATTTTTGGTTAGTTGGCCCCCTTAAAATTACACCAGTACAAGAAGTTAATTTTGCCGATGACCTTGCACATAACCGATTACCTTTTAAATTAGAAACTCAAGAAGAAGTTAAAAAAATGCTTCTAATTAAAGAAGTAAATGGTAGTAAGATTTATGCAAAAAGTGGATGGGGAATGGATGTTACTCCACAGGTAGGTTGGTTGACTGGTTGGGTGGAGCAAGCTAATGGAAAAAAAATCCCCTTTTCGCTCAACTTAGAAATGAAAGAAGGAATGTCTGGTTCTATTCGTAATGAAATTACTTATAAGTCGCTAGAAAATCTTGGAATCATTTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4888,Drugs,MEG_4888|Drugs|betalactams|Class_D_betalactamases|OXA,gb|EF534256|+|0-827|ARO:3001705|OXA-72 [Acinetobacter baumannii] ,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggttttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaaaaatacttaattgtatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4394,Drugs,MEG_4394|Drugs|betalactams|Class_D_betalactamases|OXA,1391852921|WP_109545106.1|NG_057540|1|1|blaOXA-606|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-606 NG_057540:1-774,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccgaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_910,Drugs,MEG_910|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502099|WP_071846251.1|NG_052277|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052277:101-889,2
,atgcgccatgcgacaatcctcaacctgtgcggcctcgccgcttccaccctgttcttcgcgacaacatcggccttcgccacggaggcgccggcggagcgcctgaaggctctggtggacgccgccgtgcaaccggtcatgaaggccaatgatatcccgggactggccgtcgccatcactctcaagggcgaaccgcattacttcagttatggggtggcctcgaaggaggacgcccgcaaggtgacccccgagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctacgccctggcccaggacaagatgcgcctcgacgaccgcgccagccggcactggcccgccctgcagggcagccgcttcgacggtatcagcctgctcgacctcggcacctacagcgctggcggcctgccgctacagttccccgatgcggtgcagaaggatccggcgcagatccgcgactactaccgccagtggcaaccgacctacgccccgggcagccaccgccagtactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccattcgagcgcagcatggaacggcagctgttcccggcgctcggcctggagcacacctttatccgggtgcccgccgcgcagcaggggctgtacgcccagggctacggcaaggacgaccgcccgctgcgggtcggacccggtccgctggacgccgaggcctacgggctgaagtccagcgctgcggacctgctgcgcttcgtcgaggccaacctgcaccccgagcgcctggagaagccctgggcgcaggccctcgacgccacccatcgcggctactacaaggtgggcgacatgacccagggcctgggctgggaagcctacgactggccgatcgacctgaagcgcctgcaggcgggcaactcggcgccgatggcgctgcaggcgcacaaggtcgccaggttgccggcgccgcaagccctggacggccagcgcctgctgaacaagaccggctccaccaacggtttcggcgcctacctggcgttcatcccgggacgcgacgtcggcctggtgatcctggccaatcgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggaacagcaggccaaggtaccgctggtgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5432,Drugs,MEG_5432|Drugs|betalactams|Class_C_betalactamases|PDC,501021662|WP_012074328.1|NG_049905|1|1|blaPDC-33|blaPDC_var|class_C_beta-lactamase_PDC-33 NG_049905:101-1294,0
,atggatagttcgccgctcgtcaggcctgttgaaactaccgattcggccagttggctaagcatgcgctgtgagctgtggccagatggcacatgtcaagagcaccagtcagagatcgcagaatttctgtccggaaaagtcgcccggcctgctgctgtcctcattgctgtagcacccgacggagaagcactagggtttgccgagctttcgatccgcccgtatgcggaggagtgctactccggcaacgttgcgttcttggagggttggtacgttgtgccaagtgcgcggcgtcagggcgtaggtgtagctctggtaaaagccgccgagcattgggctcgtggtcgcggatgcaccgaattcgcctccgacactcgacttaccaacagcgcaagcacctcggcgcacctggcggctggattcacggatgttgatcaagtacgctgcttccggaaaccgttgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_201,Drugs,MEG_201|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502167|WP_071846318.1|NG_052392|1|1|aac(6')-Il|aac(6')-Il|aminoglycoside_N-acetyltransferase_AAC(6')-Il NG_052392:101-559,2
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGGATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6492,Drugs,MEG_6492|Drugs|betalactams|Class_A_betalactamases|SHV,gi|83596179|gb|DQ296194.1|1-861,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgccggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5496,Drugs,MEG_5496|Drugs|betalactams|Class_C_betalactamases|PDC,1509794542|WP_122630851.1|NG_062264|1|1|blaPDC-313|blaPDC|class_C_beta-lactamase_PDC-313 NG_062264:1-1194,0
,CCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAACGGTTTGTAATAGCGGAAACGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_2390,Drugs,MEG_2390|Drugs|betalactams|Class_A_betalactamases|CTX,gi|300392842|gb|HM470254.1|1602-2492 gi|19526203|gb|AY080894.1|1-891,0
,ATGAGCGAATCCCTCGATCTGAGCCTGGAAGGGGTCGAACGCCGGTCGTTGGCCGAGTTCACCGAGCAGGCCTATCTGAACTATTCCATGTACGTGATCATGGACCGCGCCCTGCCGCATATCGGCGACGGCCTGAAACCGGTGCAGCGACGCATCGTCTACGCCATGAGCGAACTGGGGCTGGATGCCGATTCCAAGCACAAGAAGTCGGCGCGCACCGTCGGCGACGTGCTCGGCAAGTTCCACCCGCACGGCGACTCGGCCTGCTACGAGGCCATGGTGCTGATGGCGCAGCCGTTCTCCTATCGCTATCCGCTGGTGGACGGCCAGGGCAACTGGGGGGCTCCGGACGATCCCAAGTCCTTCGCCGCCATGCGTTATACCGAGGCGCGCCTGTCGCGCTATTCCGAGGTGCTGCTCAGCGAACTGGGCCAGGGTACCGTGGACTGGGTACCGAACTTCGACGGCACCCTCGACGAGCCGGCCGTGCTGCCGGCCCGCCTGCCCAACCTGCTGCTCAACGGCACCACCGGCATCGCGGTGGGCATGGCCACCGACGTGCCGCCGCACAACCTGCGGGAAGTCGCGTCGGCCTGCGTGCGCCTGCTCGACCAGCCGGGCGCGACGGTCGCCGAATTGTGCGAACACGTGCCGGGCCCGGACTTCCCCACCGAAGCCGAGATCATCACCCCGCGCGCCGACCTGCAGAAGGTCTACGAGACCGGCCGCGGTTCGGTGCGCATGCGCGCGGTGTACCGCTTCGAGGACGGCGATATCGTCATCCACGCCCTGCCGCACCAGGTGTCCGGTTCCAAGGTGCTGGAACAGATCGCCGGGCAGATGCAGGCCAAGAAGCTGCCGATGGTGGCCGACCTGCGCGACGAGTCGGACCACGAGAACCCGACCCGCATCGTCATCATCCCGCGTTCGAACCGGGTCGATGTCGAAGAGCTGATGACCCATCTGTTCGCCACCACCGACCTGGAGACCAGCTACCGGGTCAACCTGAACATCATCGGCCTCGACGGCAAGCCGGCAGTCAAGGACCTGCGCCAGTTGCTCTCGGAGTGGCTGCAGTTCCGCATCGGCACCGTGCGTCGACGCCTGCAGTTCCGCCTGGACAAGGTCGAGCGCCGCCTGCATCTGCTGGATGGCTTGCTGATCGCCTTCCTCAACCTCGACGAGGTGATCCACATCATCCGCACCGAGGACCAGCCCAAGGCGGTGCTGATGGAGCGCTTCGAACTCAGCGAGGTGCAGGCCGACTACATCCTCGACACCCGCCTGCGCCAGTTGGCACGCCTGGAAGAGATGAAGATCCGCGGCGAGCAGGAAGAGTTGCTGAAGGAGCAGAAGCGCCTGCAGACCCTGCTCGGCAGCGAGGCCAAGCTGAAGAAGCTGGTGCGCGAGGAGCTGATCAAGGACGCCGAGACCTACGGCGACGACCGCCGTTCGCCGATCGTCGCCCGCGCCGAGGCCCGCGCGCTGTCGGAAACCGAGCTGATGCCCACCGAACCGGTGACCGTGGTGCTCTCGGAAAAAGGCTGGGTGCGTTGCGCCAAGGGCCACGACATCGACGCCGCCGGCCTCTCCTACAAGGCCGGCGACGGCTTCAAGGCCGCCGCGCCGGGACGCTCGAACCAGTATGCGGTGTTCATCGACTCCACCGGGCGCAGCTACTCGCTGCCGGCCCACAGCCTGCCGTCCGCGCGAGGCCAGGGCGAGCCACTCAGCGGCCGGCTGACGCCGCCGCCGGGGGCCAGCTTCGAATGCGTGCTGCTGCCGGACGACGATGCGCTGTTCGTGATCGCTTCCGACGCCGGCTATGGTTTCGTGGTCAAGGGCGAGGACCTGCAGGCCAAGAACAAGGCCGGCAAGGCCCTGCTCAGCCTGCCCAACGGCTCCGCCGTGGTGGCGCCGCGCCCGGTGCGCGATGTGGAGCAGGATTGGCTGGCGGCCGTGACGACCGAGGGCCGTCTGCTATTGTTCAAGGTCTCCGACCTGCCGCAGCTCGGCAAGGGCAAGGGCAACAAGATCATCGGCATCCCCGGCGAACGCGTGGCCAGCCGCGAGGAATACCTCACCGACCTGGCTGTTCTGCCAGCCGGGGCGACGTTGGTCCTGCAGGCCGGAAAGCGTACCCTGTCGCTCAAGGGCGACGACCTGGAACACTACAAGGGGGAGCGAGGCCGGCGAGGCAACAAGCTGCCGCGCGGTTTCCAGCGCGTCGACAGCCTGCTGGTGGATATTCCGCCACAGGATTGA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5325,Drugs,MEG_5325|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gb|AB003428.1|+|151-2416|ARO:3003702|Pseudomonas aeruginosa gyrA and parC conferring resistance to fluoroquinolone [Pseudomonas aeruginosa] ,3
,ACTTCAATTCAATTTTATAAGTCTTATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGTGCTTCAAAATCTGATGACAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCATCAAGGTCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGAACGGGCAAAAAAGGCTGTTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTGATGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCAGTTCACTTTTTACCATTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5248,Drugs,MEG_5248|Drugs|betalactams|Class_D_betalactamases|OXA,gi|751813263|gb|KM979380.1|1-885,0
,ATGGCACGACACGTTTGGCAGGCAGGACGGTTTGAAATCGGTTTGGACAAACCGAAAATCATGGGCATCGTGAATCTCACACCCGATTCTTTTTCCGACGGCGGCGTGTATTCGCAAAACGCCCAAACAGCCTTGGCACATGCCGAACAGCTTCTAAAAGAAGGCGCAGACATTCTCGACATCGGCGGCGAATCGACGCGGTCGGGTGCGGATTATGTTTCGCCTGAAGAAGAATGGGCGCGGGTTGAGCCTGTTTTGGCGGAAGTGGCGGGGTGGGGCGTTCCCATCAGTTTGGACACGCGCCGCACGGTGATTATGGAAAAAGCGTTGGCACTCGGCGGCATCGATATTATTAATGATGTGGCGGCGTTGAATGACGAGGGCGCGGTCGAATTGCTGGCGCGTCAGGCGGACACGGGCATTTGCCTGATGCACATGCAGGGTTTGCCCAAAACCATGCAGATTAATCCGAAATATCAAGATGTTGTCGGTGAAGTAGCGCGGTATTTGAAAGCGCGCTCAGCGGAATGTATCGCGGCAGGCATCGCACCGCAACGCATCATACTCGACCCCGGCTTCGGCTCCGGCTTCGGCAAACCCTTGCAACACAATATCGCGCTGATGCGGCATTTGCCCGAATTGATGGCGGAAACAGGTTTTCCGCTGCTCATCGGCGTATCGCGCAAAAGCACGATAGGCGAGCTGACCGGCGAGGCAAATGCGGCGGAACGCGTACACGGCAGCGTGGCGGCAGCGTTGGCTTCCGTAGCGCGCGGCGCGCAAATCGTGCGGGTGCATGATGTGAAGGCGACAGCGGATGCGTTGAAGGTGTGGGAAGCGTTGGGCATCAATCTGTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2953,Drugs,MEG_2953|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|744797373|gb|CP006869.1|1821639-1822496 gi|730579451|gb|CP009422.1|340596-339739 gi|325199235|gb|CP002420.1|561697-562554 gi|66731897|gb|AE002098.2|1769557-1768700 gi|45023|emb|X68063.1|29-886 gi|45021|emb|X68062.1|697-1554 gi|57339164|gb|AY722007.1|14-871 gi|57339134|gb|AY721992.1|19-876,8
,ATGTTCAAACTTTTGAGTAAGTTATTGGTCTATTTGACCGCGTCTATCATGGCTATTGCGAGTCCGCTCGCTTTTTCCGTAGATTCTAGCGGTGAGTATCCGACAGTCAGCGAAATTCCGGTCGGGGAGGTCCGGCTTTACCAGATTGCCGATGGTGTTTGGTCGCATATCGCAACGCAGTCGTTTGATGGCGCAGTCTACCCGTCCAATGGTCTCATTGTCCGTGATGGTGATGAGTTGCTTTTGATTGATACAGCGTGGGGTGCGAAAAACACAGCGGCACTTCTCGCGGAGATTGAGAAGCAAATTGGACTTCCTGTAACGCGTGCAGTCTCCACGCACTTTCATGACGACCGCGTCGGCGGCGTTGATGTCCTTCGGGCGGCTGGGGTGGCAACGTACGCATCACCGTCGACACGCCGGCTAGCCGAGGTAGAGGGGAACGAGATTCCCACGCACTCTCTAGAAGGACTCTCATCGAGCGGGGACGCAGTGCGCTTCGGTCCAGTAGAACTCTTCTATCCTGGTGCTGCGCATTCGACCGACAACTTAGTTGTGTACGTCCCGTCTGCGAGTGTGCTCTATGGTGGTTGTGCGATTTATGAGTTGTCAAGCACGTCTGCGGGGAACGTGGCCGATGCCGATCTGGCTGAATGGCCCACCTCCATTGAGCGGATTCAACAACACTACCCGGAAGCACAGTTCGTCATTCCGGGGCACGGCCTGCCGGGCGGTCTAGACTTGCTCAAGCACACAACGAATGTTGTAAAAGCGCACACAAATCGCTCAGTCGTTGAGTAGCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_7763,Drugs,MEG_7763|Drugs|betalactams|Class_B_betalactamases|VIM,gi|253684194|gb|GQ242167.1|1-803,0
,atggcagaaaaaataattgttgttgatgatgaaaaagaaatcgcggagttagtcacgacgtttctaaggaatgaaggcttccaagtagaacctttttatgatggaacgagcgctttggcctatcttgaaaaagaaacggtcgacgtggcggttttagatgtgatgctgccggatatcgacggcttccagctgttgcagcaaattcgtaagacccactttttcccagtactgatgctcacggcaaaaggggaagacttggataaaatcaccggtctaagccttggggcagatgattatgtgaccaagcccttcaatcctttagaagtcgttgctcgggtcaaaacgcagctgcggcgataccagcgttacaaccagtcagcgaatccccagaagattgaagaatacgaaaaggaaggcttactgttgaaaatcaatagccaccaatgttttctttatggcaaagaggttttcttgacccccatcgaatttaaaatcttgctttacttatttgaacaccaaggatcggtcgttgcctcggaaaccctttttgaagcagtttggaaagaaaagtatttagacaacaataacacagtgatggcacatatcgcccgtttgcgggaaaaactgaacgaacaaccccgcaaaccgaaattaatcaaaaccgtatggggggtcggctatatcattgaaaaatag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7471,Drugs,MEG_7471|Drugs|Glycopeptides|VanC-type_regulator|VANRC,491370941|WP_005228837.1|NG_048408|1|1|vanR-C|vanR-C|VanC-type_vancomycin_resistance_DNA-binding_response_regulator_VanR NG_048408:101-796,5
,atgtttttttttaaaaaaagtgcacgtacatttatttttttgctctgtcttccattgaactcatttgcctctcaggaaagtaatggtgttgagcaaatgagggaattggaaacttcttttggggggcggataggtgtttatattttaaacacaaaaaatgggaaagaattttcctacagacaagatgagagatttcctttatgtagttcatttaaggcgttcctcgctgcatccgtattaaaaagaactcaggataaatctgtttctcttgatgatatgatggaatattctggacgtgttatggaaaagcattctcctgtatcagaaaaataccgcgaaacaggagcaagcgtgcagactttggccaaggcagcaattcagtatagtgacaatggagcttctaatctattaatggaaagatacataggaggtcctgagggtttgactgcatttatgcggtcaacgggagacactgacttcaggcttgatcgttgggaattagaattaaactcagctattccaggcgatgaacgtgatacttccactccaaaagcagtggctatgagccttaataatattgcttttggttcagtactcgatgctaaaaataaatccttgctacaggattggcttaaaggcaacactactggtaatgcgcgaattagagctgctgttccagataagtgggttgttggcgataaaacaggcacctgtggtttttatggtacagccaatgatattgctattttatggccagatgccaattcacctgcagttatggctgtctacacaacacgtcctaatcaaaacgacaaacatgacgaaacagttataaaaaatgctgcaaaaatagctataaatgcagtgtatggaagtactaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3057,Drugs,MEG_3057|Drugs|betalactams|Class_A_betalactamases|FRI,1625655389|WP_136512066.1|NG_064722|1|1|blaFRI-7|blaFRI|carbapenem-hydrolyzing_class_A_beta-lactamase_FRI-7 NG_064722:101-985,0
,atgacgttgtttcctcttcgttggttttgtgccggtgctcttctcatcaccctgagcaccgcctgcacccgctccacgccggccgcgacggtggagcggaacatccccgtgaaggcgcagtcccagggtccggacgaatacgtgctggcggatgacgtgagcgtgcggaagctcgcgcctggcgtgtggctgcacatcacggtggtgacgttggagccattcggccgcgtctccaccaacgggctcatcatcgaggacggtgaaacgtccttgctggtcgacacgggctgggatgcacggcagggcgcgctactgctcgactgggcccgggacacgcttcggcgtccggtccgcgcggcggtggtgacgcacttccatgaagatcgcctcggtggtgttccggcgctcgccccgcatggcatccccgtccatggcttggaggagacggcacggattgccacgtccctgggcctgccaggccccacggagaccttcgccaagacgagcacggtggactccctggagctcttcttcccgggggcgggccacgcgaaggacaacatcgtcgtgtggcaccgggacagcggcgtgctgttcggcggctgcttcgtgaaggacggcgcctcgacgaacctgggcaacgtggcggacgcggacgtagcggcctggcccgcgagcctgtcgcggacgcggcagcggtttccggaggcgcgcgtggtggtcccgggtcacggacagcccggtgggccggagctgctgggccacacggaagcgctgctccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4108,Drugs,MEG_4108|Drugs|betalactams|Class_B_betalactamases|MYX,499869831|WP_011550565.1|NG_057453|1|1|blaMYX-1|blaMYX|subclass_B1_metallo-beta-lactamase_MYX-1 NG_057453:101-886,0
,ATGAGCGACCTTGCGAGAGAAATTACACCGGTCAACATTGAGGAAGAGCTGAAGAGCTCCTATCTGGATTATGCGATGTCGGTCATTGTTGGCCGTGCGCTGCCAGATGTCCGAGATGGCCTGAAGCCGGTACACCGTCGCGTACTTTACGCCATGAACGTACTAGGCAATGACTGGAACAAAGCCTATAAAAAATCTGCCCGTGTCGTTGGTGACGTAATCGGTAAATACCATCCCCATGGTGACTCGGCGGTCTATGACACGATCGTCCGCATGGCGCAGCCATTCTCGCTGCGTTATATGCTGGTAGACGGTCAGGGTAACTTCGGTTCTATCGACGGCGACTCTGCGGCGGCAATGCGTTATACGGAAATCCGTCTGGCGAAAATTGCCCATGAACTGATGGCCGATCTCGAAAAAGAGACGGTCGATTTCGTTGATAACTATGACGGCACGGAAAAAATTCCGGACGTCATGCCAACCAAAATTCCTAACCTGCTGGTGAACGGTTCTTCCGGTATCGCCGTAGGTATGGCAACCAACATCCCGCCGCACAACCTGACGGAAGTCATCAACGGTTGTCTGGCGTATATTGATGATGAAGACATCAGCATTGAAGGGCTGATGGAACACATCCCGGGGCCGGACTTCCCGACGGCGGCAATCATTAACGGTCGTCGCGGTATTGAAGAAGCTTACCGTACCGGTCGCGGCAAGGTGTATATCCGCGCTCGCGCAGAAGTGGAAGTTGACGCCAAAACCGGTCGTGAAACCATTATCGTCCACGAAATTCCGTATCAGGTAAACAAAGCGCGCCTGATCGAGAAGATTGCGGAACTGGTAAAAGAAAAACGCGTGGAAGGCATCAGCGCGCTGCGTGACGAGTCTGACAAAGACGGTATGCGCATCGTGATTGAAGTGAAACGCGATGCGGTCGGTGAAGTTGTGCTCAACAACCTCTACTCCCAGACCCAGTTGCAGGTTTCTTTCGGTATCAACATGGTGGCATTGCACCATGGTCAGCCGAAGATCATGAACCTGAAAGACATCATCGCGGCGTTTGTTCGTCACCGCCGTGAAGTGGTGACCCGTCGTACTATTTTCGAACTGCGTAAAGCTCGCGATCGTGCTCATATCCTTGAAGCATTAGCCGTGGCGCTGGCGAACATCGACCCGATCATCGAACTGATCCGTCATGCGCCGACGCCTGCAGAAGCGAAAACTGCGCTGGTTGCTAATCCGTGGCAGCTGGGCAACGTTGCCGCGATGCTCGAACGTGCTGGCGACGATGCTGCGCGTCCGGAATGGCTGGAGCCAGAGTTCGGCGTGCGTGATGGTCTGTACTACCTGACCGAACAGCAAGCTCAGGCGATTCTGGATCTGCGTTTGCAGAAACTGACCGGTCTTGAGCACGAAAAACTGCTCGACGAATACAAAGAGCTGCTGGATCAGATCGCGGAACTGTTGCGTATTCTTGGTAGCGCCGATCGTCTGATGGAAGTGATCCGTGAAGAGCTGGAGCTGGTTCGTGAACAGTTCGGTGACAAACGTCGTACTGAAATCACCGCCAACAGCGCAGACATCAACCTGGAAGATCTGATCACCCAGGAAGATGTGGTCGTGACGCTCTCTCACCAGGGCTACGTTAAGTATCAGCCGCTTTCTGAATACGAAGCGCAGCGTCGTGGCGGGAAAGGTAAATCTGCCGCACGTATTAAAGAAGAAGACTTTATCGACCGACTGCTGGTGGCGAACACTCACGACCATATTCTGTGCTTCTCCAGCCGTGGTCGCGTCTATTCGATGAAAGTTTATCAGTTGCCGGAAGCCACTCGTGGCGCGCGCGGTCGTCCGATCGTCAACCTGCTGCCGCTGGAGCAGGACGAACGTATCACTGCGATCCTGCCAGTGACCGAGTTTGAAGAAGGCGTGAAAGTCTTCATGGCGACCGCTAACGGTACCGTGAAGAAAACTGTCCTCACCGAGTTCAACCGTCTGCGTACCGCCGGTAAAGTGGCGATCAAACTGGTTGACGGCGATGAGCTGATCGGCGTTGACCTGACCAGCGGCGAAGACGAAGTAATGCTGTTCTCCGCTGAAGGTAAAGTGGTGCGCTTTAAAGAGTCTTCTGTCCGTGCGATGGGCTGCAACACCACCGGTGTTCGCGGTATTCGCTTAGGTGAAGGCGATAAAGTCGTCTCTCTGATCGTGCCTCGTGGCGATGGCGCAATCCTCACCGCAACGCAAAACGGTTACGGTAAACGTACCGCAGTGGCGGAATACCCAACCAAGTCGCGTGCGACGAAAGGGGTTATCTCCATCAAGGTTACCGAACGTAACGGTTTAGTTGTTGGCGCGGTACAGGTAGATGACTGCGACCAGATCATGATGATCACCGATGCCGGTACGCTGGTACGTACTCGCGTTTCGGAAATCAGCATCGTGGGCCGTAACACCCAGGGCGTGATCCTCATCCGTACTGCGGAAGATGAAAACGTAGTGGGTCTGCAACGTGTTGCTGAACCGGTTGACGAGGAAGATCTGGATACCATCGACGGCAGTGCCGCGGAAGGGGACGATGAAATCGCTCCGGAAGTGGACGTTGACGACGAGCCAGAAGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3187,Drugs,MEG_3187|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|U00096.3|-|2336792-2339420|ARO:3003294|Escherichia coli gyrA conferring resistance to fluoroquinolones [Escherichia coli str. K-12 substr. MG1655] ,3
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaataccccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagtgctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgaagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggtccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaacctcaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaccggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctggatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_606,Drugs,MEG_606|Drugs|betalactams|Class_C_betalactamases|ADC,489203076|WP_003112187.1|NG_064714|1|1|blaADC-191|blaADC|class_C_beta-lactamase_ADC-191 NG_064714:1-1152,0
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGGTGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACAAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6881,Drugs,MEG_6881|Drugs|betalactams|Class_A_betalactamases|TEM,gi|16798371|gb|AF427128.1|AF427128|1-1103,0
,atgattatcacagaatttgatcgcgaggatcgaagtttaaaatctcaattagctgatcttttgcggctaacttggccagaagaatatggggagacagctgttcaagaagcagaccagctgatggaagctgacagaatcgcagtcgcagcgatagagggagacgaattactcggctttgctggagcgattcctcaatatcagcaaacaggttgggaattacacccattagtagtagaaagtgctaagaggaagaatcaaataggcactcggttgcttcattatgtagaaagagaagtcgtattcagaggcggaatcacgctttatttaggtacagatgatctggaacatgaaacgtctttaggttctggggatctattcgaagagacattcaaaaaaatacaagaaattgaaaatttgaaaaaacatccttatgaattttacaagaaacttggatataccatcgtcggtgtcatccctgacgcaaatggctgggaccgacctgacatctggatggcaaaacgcttagtcgaacgaccacataacacttaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_170,Drugs,MEG_170|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,736861087|WP_034860925.1|NG_052291|1|1|aac(6')_Entco|aac(6')_Entco|aminoglycoside_6'-N-acetyltransferase NG_052291:101-649,2
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAGCCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCGGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTCGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAGTCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCAGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATTTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATATATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGGAAACTCATTCCGTTTTTGTTTATCGCCTTAGACGGCAAAAGCGCTG,beta-lactamase,antibiotic inactivation,betalactams,MEG_2369,Drugs,MEG_2369|Drugs|betalactams|Class_A_betalactamases|CTX,gi|121495528|emb|AM411407.1|1-941,0
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGACATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCGCCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCAAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1365,Drugs,MEG_1365|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_105_FQJS01000007,0
,GCCACCCTGCCACTGGTGGTATACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGCTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTGTCGACGGGATGACGATCGGCGAACTCTGTGCCGCCGCCATCACCCTGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGCACTGAATGAGGCGCTTCCCGGCGACGCGCGCGACACCACCACCCCGGCCAGCATGGCCGCCACGCTGCGCAAACTACTGACCGCGCAGCATCTGAGCGCCCGTTCGCAACAGCAACTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGCCGGGCTGGTTTATCGCCGACAAAACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAACCGGAGCGCATTGTGGTGATCTATCTGCGGGATACCCCGGCGAGTATGGCCGAGCGTAATCAACATATCGCCGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3578,Drugs,MEG_3578|Drugs|betalactams|Class_A_betalactamases|LEN,gi|46309185|emb|AJ635405.1|1-789,0
,atgcgatttaaaaaaatttcttacttacttttaccttctctttttatttttaatacctcaatttatgcgggcaatagttctaaagaccaagaaattaaacaattggtagatcaaaattttaaacccttattagaaaaatataatgtgccgggcatggcggtaggtgttattcaaaacaataaaaaatatgaaacgtattatggtctacaatccgttcaagataaaaaagctgtaaatagcaataccatttttgagctaggttctgtcagtaaattatttactgcgacggcaggtgcttatgcaaaaaatacaggaaaaatttcttttgatgatacgccgggcaaatactggaaagagttaaaaaacaccccaattgatcaggtcaatttacttcaacttgccacctatacaagtggtaacctcgccttgcaattcccagatgaagtacaaacagatcaacaggttttaactttttttaaagattggaaacctaaaaacccaatcggtgaatatagacaatattcaaacccaagtatcggtctatttggggaaatagttggtttatcaatgaagcagccttttagtcaggtcttggaaaaaacgatttttccggaccttggcttaaaacatagctatgtcaatgtgcctaaaactcagatgcaaaactatgcatttggttataaccaagaaaatcagccaattcgagttaaccctggcccactcgatgccccagcatacggcgtcaaatcgaccctacccgacatgctgagctttattcatgccaacctgaatccacagaaatatccggcaaatattcaatgtgcaattaatgagacacatcaaggtcgctatcaagtaaatagcatgtatcaggcactcggttgggaagagtttgcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtcatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccacaaaactggttcaacaaatggtttcggaacctatgccgtatttatacctaaagaaaatattggtttagtcatgttaaccaataaacgcattccaaatgaagaacgcattaaagcagcttatgctgtgctaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_524,Drugs,MEG_524|Drugs|betalactams|Class_C_betalactamases|ADC,491024400|WP_004886093.1|NG_064686|1|1|blaADC-130|blaADC|class_C_beta-lactamase_ADC-130 NG_064686:101-1252,0
,ATGTCGATACGAATTCTACTTGTCGAGGATGATGATCATATCTGTAATACAGTAAGGGGGTTTCTGGCTGAGGCAGGATATCAGGTGGATGCCTGCACAGATGGAAATGAGGCATACACCAAGTTTTACGAAAACACCTATCAACTGGTTATTCTTGATATTATGCTGCCCGGTATGAACGGGCATGAACTTTTGCGTGAATTTCGTGCGAAAAATGATACTCCCATTCTGATGATGACAGCCCTGTCGGATGACGAAAACCAAATCCGGGCGTTTGATGCAGAGGCAGACGACTATGTAACAAAGCCATTCAAGATGCAGATTTTACTAAAGCGGGTGGAAGCCCTGTTACGGCGCAGCGGTGCGCTGGCAAAGGAAATCCGTGTCGGCAGGCTGACACTTCTGCCGGAGGATTTCACGGTACTTTGTGACGGTACAGAGCTGCCCCTGACACGAAAAGAATTTGAAATCCTTTTGCTGCTGGTGCAGAACAAAGGCAGAACCTTAACGCATGAAATCATTTTGTCACGTATATGGGGATATGACTTTGAGGGTGATGGCAGCACAGTCCACACTCATATCAAAAATTTGCGGGCCAAGCTGCCGGAAAATATCATCAAAACCATTCGCGGTGTAGGATACCGATTGGAGGAATCATTATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7469,Drugs,MEG_7469|Drugs|Glycopeptides|VanB-type_regulator|VANRB,gi|695199646|ref|NG_035288.1|24047-24709,5
,atgaaaacatttgccgcatatgtaattatcgcgtgtctttcgagtacggcattagctggttcaattacagaaaatacgtcttggaacaaagagttctctgccgaagccgtcaatggtgtcttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaatgacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaagcaatgggaaagagacttgaccttaagaggggcaatacaagtttcagctgttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcctatggcaaccagaatatcagtggtggcattgacaaattctgtttggaaggccagcttagaatttccgcagttaatcaagtggagtttctagagtctctatatttaaataaattgtcagcatctaaagaaaaccagctaatagtaaaagaggctttggtaacggaggcggcacctgaatatctagtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttgggtgggttgagaaggagacagaggtttactttttcgcctttaacatggatatagacaacgaaagtaagttgccgctaagaaaatccattcccaccaaaatcatggaaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4675,Drugs,MEG_4675|Drugs|betalactams|Class_D_betalactamases|OXA,1625655409|WP_136512086.1|NG_064752|1|1|blaOXA-794|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-794 NG_064752:1-801,0
,CTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGTATTCATGTTGTTGTTATTTCGTCTCTTTCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTCCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2429,Drugs,MEG_2429|Drugs|betalactams|Class_A_betalactamases|CTX,gi|81238144|gb|DQ256091.1|1-993 gi|291061254|gb|GU477621.1|145-1136 gi|378406451|gb|JN420336.1|243635-243690,0
,atgcgttcgttcgccatatcgactgtgttggggatgtcctcactgttagcgtcgtcaatcattgccgccccgacttttgcctcaacagcggtgaagaaggagtggcaagaaacccgtagttgggatgccatttttactcagcaccaagttgaaccgcaacaagctaaactgcaaaaaactaagctccaacaaacctcgggcgtggtagcactatggaacgaaaacaagcaacagggatataccaacaatcttaaacgtgccaatcaaggttttttacctgcatcgacctttaaaatccctaacagtctgattgcgctagatctcggtgtggtgaaggatgaacatcaagtgtttaagtgggatggtaaaagccgtgatattgccacttggaatcgtgaccacaacttgattaccgggatgaagtattcggttgtgccagtctatcaagagtttgcccgccaaattggtgaggcgcgaatgtcgaagatgatcgcctctttcgattatggtaatgagactatctcgggtaacttagatagcttttggcttgatggtggtattcggatatcggctactgagcaaattgatttcctgcgccggctttatcacaacaaggtacacgcttcagagcgcagtcaacgcatcgttaagcaagccatgctcaccgaggcgaattctgactatattatccgcgcaaaaaccggttatgcggtcagagctgagccaagcattggctggtgggttggttgggtagagctcgatgataatgtgtggttttttgcaatgaatatggatatccccgacgctgcaggtttgccattgcgtcaagccattactaaggaagtattaaaactggaacacgtaattccttag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4621,Drugs,MEG_4621|Drugs|betalactams|Class_D_betalactamases|OXA,1201190420|WP_087587940.1|NG_054954|1|1|blaOXA-549|blaOXA-548_like|OXA-548_family_class_D_beta-lactamase_OXA-549 NG_054954:1-873,0
,GTGAGCAGTTCGGACGAGCAGCCGCGCCCGCGTCGCCGCAACCAGGATCGGCAGCACCCCAACCAGAACCGGCCGGTGCTGGGCCGTACCGAGCGGGACCGCAACCGGCGCCAGTTCGGGCAGAACTTCCTCCGCGACCGCAAGACCATCGCGCGCATCGCCGAGACAGCCGAGCTGCGGCCCGATCTGCCGGTGCTGGAAGCCGGCCCCGTCGAAGGGCTGCTCACCAGGGAACTCGCCGACCGCGCGCGTCAGGTGACGTCGTACGAGATCGACCCCCGGCTGGCGAAGTCGTTGCGGGAGAAGCTTTCCGGCCACCCGAACATCGAAGTCGTCAACGCCGACTTCCTCACCGCCGAACCGCCGCCCGAGCCGTTCGCCTTCGTCGGCGCGATCCCCTACGGCATCACCTCGGCGATCGTGGACTGGTGCCTGGAGGCGCCGACGATCGAGACGGCGACGATGGTCACGCAGCTGGAGTTCGCCCGGAAGCGGACCGGCGATTACGGCCGCTGGAGCCGCCTCACGGTGATGACCTGGCCGCTGTTCGAGTGGGAGTTCGTCGAGAAGGTCGACTCGGCGATCATGCGGCTGCGCAGGCGCGCCGAACCGCTGCTGGAAGGCGCGGCGCTCGAACGCTACGAGTCGATGGTCGAGCTGTGCTTCACCGGCGTCGGCGGCAACATCCAGGCGTCGCTTCTGCGCAAGTACCCGAGGCGCCGCGTCGAGGCGGCGTTCGACCACGCGGGGGTCGGGGGCGGCGCCGTGGTCGCCTACGTCCGGCCGGAGCAGTGGCTCCGGCTGTTCGAGCGGCTGGATCAGAAGAACGAACCGAGGGGTGGGCAGCCCCAGCGGGGCAGGCGAACCGGCGGACGGGACCACGGGGACCGGCGAACCGGCGGGCAGGATCGCGGCGATCGGCGAACCGGCGGCCGCGACCACAGGGACCGGCAAGCCAGCGGCCACGGCGATCGTCGCAGCAGCGGACGCAATCGCGACGACGGACGAACCGGCGAGCGCGAGCAGGGGGACCAAGGCGGGCGGCGGGGGCCGTCCGGGGGTGGACGGACCGGCGGACGTCCAGGGCGACGCGGCGGACCCGGGCAGCGGTAG,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2826,Drugs,MEG_2826|Drugs|MLS|23S_rRNA_methyltransferases|ERME,(MLS)ErmE:M11200:284-1396:1146,7
,atgcgtcaatatcgattcgcccttctgccattgttagccgccctggcgctccccggttgggcgcatgaagccacggtgacgacggttaaacaagccgaaagccagctgcagggccgggtcggctacgccgaactggatttagcttccggccaactgctgtccggctatcgcgctggcgaacgcttcccgatgatgagcacctttaaagtgctgctctgcggcgcagtcttgtcgcgcgtcgataccggtgaagaacagctcgatcgccgtatccattaccggcagcaggatctggtggaatactcgccggtgacggagaagcatcttgccgatgggctcaccgtgggcgaactgtgcgcggccgccattaccctgagcgataatacggcggcaaacctgctgttgaccactatcggcggcccgcaggggctgaccacgttcctgcgccacagcggcgaccagacttcgcgactcgaccggtgggaaacggaactcaatgaagcgcggccgggcgatgtgcgtgatacgacgactccggaagcgatggccaggacactgcgaaatctgttgaccggccgcgtgctttcccccgcctcgcagcagcagttgcaacgctggatggtagaggacaaagttgcggggccgctgttgcgctctgcgctgccggcgggctggtttattgccgataagaccggagccggcaatcgcggctcgcgcggaatcatcgccgctctcggtccggacggtaaagccgcgcgcatcgtggtgatttatttaaccgcaaccccggcctcaatggatgagcgcaataaacagattgcggccatcggtgaaacgctggtcaggcactggtccaaagacgataaaagaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4372,Drugs,MEG_4372|Drugs|betalactams|Class_A_betalactamases|ORN,1028105954|WP_063860935.1|NG_049390|1|1|blaORN-5|blaORN|class_A_beta-lactamase_ORN-5 NG_049390:101-976,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4652,Drugs,MEG_4652|Drugs|betalactams|Class_D_betalactamases|OXA,488871003|WP_002783228.1|NG_049489|1|1|blaOXA-193|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-193 NG_049489:101-874,0
,TCACATCGAGTCGCCGCTCGCCCAAGAGCCGAACTTCGGGGACGCTGCTGTACCACGCATGATGAGAATCACGCAGGGCACGTAGAGTGCTGCGGCGCAGAGCCAGAGGAAGCCGTCGGCGTTGATGTAAGTGAGCGCGAAGATCGTTGTGAAAGCGACCGGTCCGAAGATCGATGTGATGCTGTTGATCCTGGCGAGCACACCCTGGAGGCGCCCTTGGTGCTGTTCATCGACGCGCTGGGAGAGAAGGGTTTGCAGAGCGGGGAGGCCGATGCCACCGATCCCGAGTGCCGCCAAGATAGGCGCCATGGAAAATGCGTCAGTGACAATCGCCAGGCCTACGAGACCCAAGGCGTCGGTAACACACCCGATGATGACTGTTTTTGCCTCACCGATCCACTCCACGATGCGGCCAGTAAGGAGGGCCTGCACGAGAACCTGTACGATCCCGAAAACGGACAGGGAGATTCCAACTTCGACGGGACTCCAGTCGAGGCGGTGTTCAGTAAACAGCACCCAGGTCGCACCTGGAGCCTGCCCAATGAATTGAACAAGGCCGAATGCGACTAATAGGAAGGTAATCCCAGGCACCGCGCTGAGGCCGGGGCGACCACGATGCTGAGCGAGCGACGCAGAGCGCGCAGGGGAATCAGGACGGGTCTCGCGTAACAGGATAAAGGTGAGTGCCAGATTGCTCGCTGAGAGAAGAGCAGCGAGCAAAAACGGCAGATGTGGCGAGATGGCACCGAACAGTCCACCCATGGCTGGCCCCGCGATCATTCCGCCGCCATAGCAGGCACTGAGTAAACCGAAACGCTTGGCGCGCTGGTGGGGTGGCGTGATGTCGGCGATCACGGTGGCGGTGACCGCATTGGTCGCTCCGGTTATCCCAGCCACTGCGCGGGCGATATAGAACACCGACAGAGCGGACGTCGTGGCGAGCACGAGATAGTCCACGGTCGCACCGGCCAGGGAAACAAGCAGCACCCGGCGGCGGCCGAATCGGTCCGACAGCGTTCCCAGTACGGGGGCAAAGATGAACTGCATTACCGCGTAGAGCGCGATCAGCACTCCGACGTTCAGCGGAACCGCATCAGCGGTGACCCCTGCCTCGTGTAGCAGTGCGGGAAGAATCGGCATCACCAGGCCCATGCCGGCGGCGTCGAGGCTAGCCGTGATGAGGACCGTGGCCAACGAGCCACGAGCGGAAGTGAGAAATGACACCTTATCAACGATAAAGTTATCGATGATAAAGTGCAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6975,Drugs,MEG_6975|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET33,gi|89513168|gb|DQ390458.1|31989-33248,4
,atgcttcaactgaaaatgatagaactcttcaaggaaggttgtcatgaggatgcacgaataatcgcgacattgatgttcggctcatttgctatcggagagggtgacgagttctctgatatcgaattcgcagtgttcatccaggatgaccattttgaaaatttcgatcagcgctcgtggcttaatgccgtaagtccggttgctgcttactttccggacgacttcggccaccacaccgcactttttgaaaacggcattcgcggtgaattccatttcatgcgaaaatcggacataccggtcatttccacttggcaaggctatgggtggtttccctcgcttgaggcggctgttttgttggaccgatcaggagagttgtcaaggtatgcaagcgctctcgtgggcgatcccccgatacgtgaaggcgcgccgctggtggaagggcttgtgttgaacctcatcagcctgatgctctttggggccaatcttttaaatcggggagagtacgctcgcgcctgggccttgctcagcaaagcccatgaaaacttactcaagttgatccgccttgacgaaagggcaacagaccactggccgacaccgtcacgcgcgttggaaaaggatatctcggcggactcgtataatcgctacctggcatgcacatccagtgcagagccgagagcactatgtgtagcctatcgtgaaacctggaagtggagtctcgaattgtacaagagtgttgcagaacctctgaacatcccgcttccgagaactgtaattatgcaggcaaaaaggttgctcaatgagtctgcgacgccgcacaacaagtaa,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3614,Drugs,MEG_3614|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUF,1105502133|WP_071846285.1|NG_052332|1|1|linH2|lnu(F)|lincosamide_nucleotidyltransferase_Lnu(F) NG_052332:101-922,7
,GTGCTGCCTAAAACAAAGTTAGACATCATGAGGGAAGCGGTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGTTGGTTACTGTGGCCGTAAAGCTTGATGAAACGACGCGGCGAGCATTGCTCAATGACCTTATGGAGGCTTCGGCTTTCCCTGGCGAGAGCGAGACGCTCCGCGCTATAGAAGTCACCCTTGTCGTGCATGACGACATCATCCCGTGGCGTTATCCGGCTAAGCGCGAGCTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCATGATCGACATTGATCTAGCTATCCTGCTTACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCGGCAGCGGAGGAATTCTTTGACCCGGTTCCTGAACAGGATCTATTCGAGGCGCTGAGGGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCCGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAATAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATAAAACGCCTACCTGCCCAGTATCAGCCCGTCTTACTTGAAGCTAAGCAAGCTTATCTGGGACAAAAAGAAGATCACTTGGCCTCACGCGCAGATCACTTGGAAGAATTTATTCGCTTTGTGAAAGGCGAGATCATCAAGTCAGTTGGTAAATGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_975,Drugs,MEG_975|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,aadA2_1_NC_010870 ,2
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagtgagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcacttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_810,Drugs,MEG_810|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,695263570|WP_032490440.1|NG_052250|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052250:101-892,2
,ATGCGTTATTTTCGCCTGTGTATTATCTCCCTGTTAATGCGTTATTTTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCAGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGGACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGGATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6413,Drugs,MEG_6413|Drugs|betalactams|Class_A_betalactamases|SHV,gi|14532426|gb|AY036620.1|53-978 gi|14532426|gb|AY036620.1|89-124 gi|959190351|gb|CP013324.1|103683-103718 gi|828982914|gb|CP011656.1|56532-56567 gi|828965798|gb|CP011640.1|21109-21144 gi|828958653|gb|CP011632.1|57041-57076 gi|828952302|gb|CP011622.1|131229-131194 gi|828945263|gb|CP011614.1|45611-45646 gi|828939458|gb|CP011609.1|21460-21495 gi|828933472|gb|CP011599.1|56057-56092 gi|562889814|gb|KF585141.1|48-83,0
,TCGGCCCTCACTCAAGGATGTATTGTGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGTGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6423,Drugs,MEG_6423|Drugs|betalactams|Class_A_betalactamases|SHV,gi|160948452|emb|AM176554.2|1-891,0
,atggaggaacgggagatggagatgacgaagggcagctggatggtggccatggcgatcctgggcatcgccgcgtgcgcgcccgcgccggcgccgcaggccgcgaccacgcgggcggtcgaggtggcggggacgccggtgatcgcgccggcgagggcggacacgctgggcgacgacatcgtgatccggcacctggcggggcggatctggctgcacgtgacgctctcccccgacgcgaaccgcatcccctccaacggcctgctggtggacgagggcgacggcgtgctcctgatcgacaccgcgtgggacgacgagcagaccggccgcctggccgagtggagcctgcgccgcctgggcaagcccatccgccgctccatctccacgcacttccacgacgaccggctgggcggcatcgacacgctgcgggcgctcggcatcgacgcccgcgcgctggacctgacagtgtcgaaggcgcgggagaaggggaaggcgtcgctgcccgccatctacatgacggtggcgcagcgcgcgcggatggacccggcggggttcgaggtcttccatcccggcccgggccactcgcccgacaacatcgtcgtctggttcccggcggagggcgtgctcttcggcggctgcttcgtgaagggcgccgaatcgcgcgacctgggcaacctctccgacgccgacgtgggccgctggcccgcctccgtcgccgccgtcctcgaccgctatccccgcgcctccatcgtcatccccggccacggcgcccccggcgggctgaacctgctgtcgcacactaccgcgctcctcgccgcgccggcgcacaacggtggcggctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_6555,Drugs,MEG_6555|Drugs|betalactams|Class_B_betalactamases|SPN,1509794521|WP_122630830.1|NG_062234|1|1|blaSPN79-1|blaSPN79|subclass_B1_metallo-beta-lactamase_SPN79-1 NG_062234:1-837,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatctacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctatttcagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4699,Drugs,MEG_4699|Drugs|betalactams|Class_D_betalactamases|OXA,1058244060|WP_068981640.1|NG_051475|1|1|blaOXA-525|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-525 NG_051475:1-825,0
,ATGAAGCGCAATATCCTGGCAGTGGTTATCCCTGCCCTGCTGGTAGCCGGTGCAGCAAACGCTGCAGAAATCTATAACAAAAACGGCAACAAACTGGATCTTTACGGCAAAGTTACTGCTGAACACGATTTCGTGACATCAGGCGACAACACCAGCAATGGTGATGCGACTTACGCTCAGCTGGGCTTCAAAGGCGAAACTCAGATTAACGATCAGCTGACCGGTTATGGTCAGTGGGAATACCGTGCGTATGCGACCAGCGCTGAATCTGAGCAGGGCGCTAACAACTCTAACCGTACCCGTCTGGCCTTTGCTGGTCTGAAAATTGCGGACGCGGGCTCCATCGATTACGGCCGTAATTACGGTATCGTATACGATGTTGAATCCTACACCGATATGGCACCGTCTTACTCCGGTATGACCTGGGCTAACTATTCTGATAACTTCATGACCGGCCGTACCACTGGTGTTCTGACTTACCGTAACACCGGCTTCTTCGGCCTGGCTGACGGTCTGAACTTTGGTATCCAGTATCAGGGTAAAAACGACCGTGATAACGTTGCTACTTCTAACGGCGATGGCGTTGGTTACTCACTGGGTTACGATTTTGGCGAAGGCTTCAGCCTGATTGGTGCGTACAGCAACTCTAACCGTACTCTTCAGCAGAAACTGGATGATAAAGGCGATCGCGCTGAAGCATGGGCAGTTGGTGCCAAGTACGATGCTAACAACCTGTACCTGGCGACCGTGTATGCTGAGACTCGCAACATGACTCGCGAAGCTGATAACACCTTTGCGAACAAAACTCAGAACTTTGAAGCGATCGCTCAGTACCAGTTCGATTTCGGTCTGCGTCCGTCCCTGTCTTACGTACAGTCTAAAGGTAAAAACCTGACTGCTCGTGGCACCTTCGATGGCGGCGATGCTGACCTGCAGAAATATGTTGAAGTTGGTGCTTACTACTACTTCAACAAAAACTTCAACGTATACGTTGACTACCAGATCAACCTGATCGATAACGACGCTTACGCTCGTAACGTGGGTATCGTTAACGGTCGTGACGACCAGGTTGCACTGGCTGCGACCTACCAGTTCTAA,General Bacterial Porin (GBP),reduced permeability to antibiotic,Multi-drug_resistance,MEG_4287,Drugs,MEG_4287|Drugs|Multi-drug_resistance|MDR_mutant_porin_proteins|OMPF,gi|323575285|emb|FN543093.2|1634198-1633101,1
,ATGAAAAAAATTGCCGTTTTATTTGGAGGGAATTCTCCAGAATACTCAGTGTCACTAGCCTCAGCAGCAAGTGTGATCCAAGCTATTGACCCGCTGAAATATGAAGTAATGACCATTGGCATCGCGCCAACAATGGATTGGTATTTGTATCAAGGAAACCTCGCGAATGTTCGCAATGATACTTGGCTAGAAGATCACAAAAACTGTCACCAGCTGACTTTTTCTAGCCAAGGATTTATATTAGGAGAAAAACGAATCGTCCCTGATGTCCTCTTTCCAGTCTTGCATGGGAAGTATGGCGAGGATGGCTGTATTCAAGGACTGCTTGAACTAATGAACCTGCCTTATGTTGGTTGCCATGTCGCTGCCTCCGCATTATGTATGAACAAATGGCTCTTGCATCAACTTGCTGATACCATGGGAATCGCTAGTGCTCCCACTTTGCTTTTATCCCGCTATGAAAACGATCCTGCCACAATCGATCGTTTTATTCAAGACCATGGATTCCCGATCTTTATCAAGCCGAATGAAGCCGGTTCTTCAAAAGGGATCACAAAAGTAACTGACAAAACAGCGCTCCAATCTGCATTAACGACTGCTTTTGCTTACGGTTCTACTGTGTTGATCCAAAAGGCGATAGCGGGTATTGAAATTGGCTGCGGCATCTTAGGAAATGAGCAATTGACGATTGGTGCTTGTGATGCGATTTCTCTTGTCGACGGTTTTTTTGATTTTGAAGAGAAATACCAATTAATCAGCGCCACGATCACTGTCCCAGCACCATTGCCTCTCGCGCTTGAATCACAGATCAAGGAGCAGGCACAGCTGCTTTATCGAAACTTGGGGTTGACGGGTCTGGCTCGAATCGATTTTTTCGTCACCAATCAAGGAGCGATCTATTTAAACGAAATCAACACCATGCCGGGATTTACCGGGCACTCCCGCTACCCAGCTATGATGGCGGAAGTCGGGTTATCCTACGAAATATTAGTAGAGCAATTGATTGCACTGGCAGAGGAGGACAAACGATGAACACATTACAATTGATCAATAAAAACCATCCATTGAAAAAAAATCAAGAGCCCCCGCACTTAGTGCTAGCTCCTTTTAGCGATCACGATGTTTACCTGCAGCCAGAAGTGGCAAAACAATGGGAACGACTCGTACGAGCAACCGGACTAGAAAAGGACATTCGTCTGGTAGATGGGTATCGTACGGAAAAAGAACAGCGACGCTTGTGGGAGTATTCTCTAAAAGAAAACGGGTTAGCTTATACCAAACAATTCGTTGCTTTGCCAGGTTGCAGTGAACATCAAATCGGTCTGGCCATTGATGTAGGACTAAAGAAACAAGAAGATGATGATCTTATCTGCCCTCATTTTCGAGATAGTGCTGCTGCTGATTTATTTATGCAGCAGATGATGAATTATGGCTTTATTCTACGCTATCCGGAAGATAAACAAGAGATCACCGGTATCAGTTATGAACCTTGGCATTTTCGTTATGTCGGGCTTCCCCATAGCCAAGTCATCACTGCCCAAAAATGGACTCTGGAAGAATACCATGATTACTTGGCTCAGACAGTGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7374,Drugs,MEG_7374|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC1XY_2_DQ022190,5
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGACCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCCCGCAGCACCTCGCAGGCGTGCCGGGCGATA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6468,Drugs,MEG_6468|Drugs|betalactams|Class_A_betalactamases|SHV,gi|562889820|gb|KF585144.1|48-967,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctactggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgatgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctagcaagcggggtgcgcgcgggattgtcgacctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggataccccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6191,Drugs,MEG_6191|Drugs|betalactams|Class_A_betalactamases|SHV,1252412304|WP_096807447.1|NG_055588|1|1|blaSHV-200|blaSHV|class_A_beta-lactamase_SHV-200 NG_055588:1-861,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaaccttaacccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcgtatgcagttttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_559,Drugs,MEG_559|Drugs|betalactams|Class_C_betalactamases|ADC,516427395|WP_017816757.1|NG_064675|1|1|blaADC-116|blaADC|class_C_beta-lactamase_ADC-116 NG_064675:101-1252,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaataccccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagtgctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatccagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggtgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactagcggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgtattaaggcagcgtatgcagttttaaatgcaataaaaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_613,Drugs,MEG_613|Drugs|betalactams|Class_C_betalactamases|ADC,1058243680|WP_068981622.1|NG_051455|1|1|blaADC-91|blaADC|class_C_beta-lactamase_ADC-91 NG_051455:1-1152,0
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcggatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccggagatgagcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacgggggccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3097,Drugs,MEG_3097|Drugs|betalactams|Class_A_betalactamases|GES,1509794518|WP_122630827.1|NG_062216|1|1|blaGES-39|blaGES|class_A_beta-lactamase_GES-39 NG_062216:1-864,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcaccgcgctgtggccctccagctcgcctgaagatcaccgcgcggaaatgcgcgagatactggcttcaccgcaccactccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgtcgagggcgcccgccgccagggctgggccgcgcgcttaatcgcacaggtgcaggagtgggcgaagcagcaggggtgcagcgagctggcgtcggataccgacatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggagcgggtggtgttttaccgcaaaacgctggtctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_154,Drugs,MEG_154|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,742400403|WP_038879528.1|NG_052292|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052292:101-541,2
,ATGGCGCAGCACACAATAGATCAAACACAAGTAATCCACACTAAGCCCAGCGCTTTATCATATAAAGAGAAGACGCTGGTGATGGGAATTTTAAACGTAACGCCTGACTCTTTCTCGGACGGCGGAAAATATGACAGCTTGGACAAGGCGCTGCTGCACGCGAAAGAGATGATCGATGATGGTGCCCATATCATTGATATTGGAGGGGAATCGACAAGGCCTGGCGCTGAGTGCGTATCTGAGGATGAGGAGATGTCCAGAGTCATTCCGGTGATTGAGCGGATTACGAAAGAGCTTGGTGTTCCTATTTCTGTAGACACGTACAAGGCTTCTGTCGCAGATGAAGCAGTGAAAGCCGGTGCATCCATTATCAATGATATTTGGGGAGCCAAACATGATCCGAAGATGGCTTCCGTTGCAGCTGAACATAATGTTCCAATTGTACTCATGCATAACCGCCCTGAAAGAAACTACAATGACTTATTGCCGGATATGCTGTCGGACTTAATGGAGAGTGTAAAAATTGCTGTTGAGGCCGGAGTAGACGAGAAGAACATTATTCTTGATCCTGGTATCGGTTTCGCGAAAACCTATCACGATAACTTGGCAGTGATGAACAAACTAGAGATTTTCAGCGGATTGGGATATCCGGTTCTTCTGGCAACCTCCCGAAAAAGATTCATCGGACGTGTTCTGGATCTTCCGCCTGAGGAGCGGGCTGAGGGCACAGGCGCGACTGTGTGTCTCGGCATTCAAAAAGGCTGTGACATTGTCAGGGTCCATGATGTAAAGCAAATTGCCAGAATGGCGAAAATGATGGACGCGATGCTGAATAAGGGAGGGGTGCACCATGGATAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2967,Drugs,MEG_2967|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|983204966|gb|CP014166.1|85736-86593 gi|807072327|gb|CP011115.1|85736-86593 gi|758179040|gb|CP010014.1|3934420-3935277 gi|749183975|gb|CP010314.1|85737-86594 gi|728887195|gb|CP010053.1|85736-86593 gi|728882887|gb|CP010052.1|85737-86594 gi|724425628|emb|LN680001.1|85736-86593 gi|723796434|emb|LN649259.1|85736-86593 gi|649013680|gb|CP008698.1|85737-86594 gi|649009321|gb|CP007800.1|85737-86594,8
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5638,Drugs,MEG_5638|Drugs|betalactams|Class_C_betalactamases|PDC,730255999|WP_033957064.1|NG_049943|1|1|blaPDC-68|blaPDC|class_C_beta-lactamase_PDC-68 NG_049943:1-1194,0
,atggccgccatggccgccgtggctgccgtactgctcggcgtgtttgcattcgcgcacgcgcaggatcagccggccttgtggactcaaccgcagcagcccgttcgcatcattggcaacgcctggtacgtcggcacgcgcgggctgagcgccattctcatcacgtcgcccaccggcgccgtgctcatcgacggagcgatgcgtgaatcggcggacgatatcgccaagaacatcacgagcctcggtgtacggctcgaggacgtcaagctgatcgtcaattcgcatgcgcacaacgatcatgctggcgggatcgcggaacttcagcggcgtacgggcgccacggtggccgcgctgccctggagcgcggaggcgctgcgaagcggacggaagcatcagggcgatccgcagttcgacacacaaacgcctcctcccgatcgtgtccccaaggtcaaaacgattcgggatggcgaggcgcttcatgccggtggcgtgacgatcacggcgcacaagaccggcggccacacgccaggcagcacgtcatggacgtggcgctcgtgcgaggagaaccggtgcgtcgacatcgtgtatgccgacagcatcactgccgtctcggcggatggattccgcttcaccgacaacaagacgtatccgcaggcgatcgacgacttcaacaagggctacgcgttcctgcgatcggcgagttgcgacatcctggtgacaccgcaccccgaagcctcggacttctgggggcggatcgccaaacgtgacgccggagagcgcgatgcgctgatcgatcgctcgcagtgcgcgcgctatgccgatcgtgccgacgcgcaactccagaaacgcctcgcgacggagcgcgcgaaatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3171,Drugs,MEG_3171|Drugs|betalactams|Class_B_betalactamases|GRD,1509794525|WP_122630834.1|NG_062238|1|1|blaGRD33-1|blaGRD33|subclass_B3_metallo-beta-lactamase_GRD33-1 NG_062238:1-870,0
,atgcgcgataccagatttccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccacctcggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5703,Drugs,MEG_5703|Drugs|betalactams|Class_C_betalactamases|PDC,1035157528|WP_064511493.1|NG_050815|1|1|blaPDC-142|blaPDC|class_C_beta-lactamase_PDC-142 NG_050815:1-1194,0
,atgaccgcgacaacaaatccgccggacgcgatgcttgtgccgccacaactgcaagctctcgtcgcgggctacagctggaaccgcgatgcgctcggctgttccgatgcgcaggttttcatgctgcaaggcgaaggcttgccccggctcttcatcaaggtcgaagccgttagcccttacggtgagttgcccgatgaggcggtgcggcttcgctggctgtcctcccgtgatatgccctgccccgatgttctcttcgagggcgcccatgctggccgcttctggctgttgatgagcggggttcctggtgaagatcttgcctcggccggttcgttgtccatcgaaacgcgtatccggatttttgccggggcgctgcgccagttgcatgcgcttgatcccgcgacctgtccgttcgatcaccggcttgacgggcgcattgaagcggcgcgggcccgcatgcaggccgggctggtggacgagacggatttcgacgacgatatgctgggaaagacgacatctgaccttttcagccggctggcggccgaaaagccgatggttggagatgtggttgttacccacggcgatgcctgcctgccgaatttcatggccgataaaggcatcttcaccggctatatcgactgcggccggcttggtcttgccgatcgctaccaggatattgggctggcgtgccgcagcattgcggataatttcggtgacgaaagggtgaagctttttctggattgctacggcctgatgcaggccgatccggcaaagctggcttattaccggctgctcgacgagtttttctga,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1021,Drugs,MEG_1021|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,1201190413|WP_087587933.1|NG_054945|1|1|aph(3')-II-therm|aph(3')-II-therm|APH(3')-II_family_aminoglycoside_O-phosphotransferase NG_054945:1-804,2
,atgaaactgctgctctacccgttattgctgttccttgtcattccagcctttgcccaggcggactttgaacatgccatttcagatcttgaggcgcacaatcaagccaagatcggagtggccctagttagtgaaaatggcaacctgattcaagggtatcgtgcgaatgaaaggttcgcgatgtgctcaactttcaagttgccgttggccgctcttgttctgagtcgcattgacgctggggaagagaatcctgagcgcaagcttcattacgattccgcgttccttgaagagtacgccccagccgcaaaacggtatgtggcaactggatatatgactgtaactgaggcaattcaatccgccctccaactcagcgacaatgccgcagctaacctgctgttaaaagaggttggcggcccacctttattgacaaagtatttccgtagcctgggtgataaagtaagtcgccttgatcgtattgaaccgactttgaacaccaatacgcccggcgatgaaagagatgcaacaacgcccatgtccatggcacagactgtgtcaaagctgatttttggagacacgttgacatataaatccaaggggcagctaaggcgattactcatcggcaatcagaccggggacaaaaccattcgagctggcttgcctgattcatgggtaacgggtgacaagacaggctcgtgtgcgaatggcggccgtaacgatgtggcgttttttataaccactgccggaaaaaaatatgttctttctgtatataccaatgcacctgaattgcaaggcgaggaaagggcgttattaattgcttctgtagcaaagttagcacgtcaatatgttgttcactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1219,Drugs,MEG_1219|Drugs|betalactams|Class_A_betalactamases|BEL,1040941096|WP_065158950.1|NG_050978|1|1|blaBEL-4|blaBEL|class_A_extended-spectrum_beta-lactamase_BEL-4 NG_050978:1-852,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgctatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3474,Drugs,MEG_3474|Drugs|betalactams|Class_A_betalactamases|KPC,1311416408|WP_101140102.1|NG_056170|1|1|blaKPC-33|blaKPC|inhibitor-resistant_carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-33 NG_056170:101-982,0
,ATGACCAACTATTTTGAAAGTCCATTTAAAGGCAAACTGCTGGCCGACCAGGTAAAGAACCCGAACATCAAAGTCGGACGGTATAGCTATTATTCCGGCTATTACCATGGCCATTCGTTTGACGAGTGCGCTCGCTTTCTCTTGCCAGATCGCGATGACATCGACCAACTGATCGTTGGTAGCTTCTGTTCCATCGGCACGGGCGCCTCCTTCATCATGGCCGGAAATCAGGGGCACCGTTATGACTGGGCGTCTTCTTTTCCCTTCTTCTACATGAAAGAGGAGCCAGCATTCTCGGGCGCACTTGATGCATTCCAAAAAGCCGGTGACACAGTCATCGGAAGTGATGTCTGGATAGGCTCTGAGGCCATGATCATGCCCGGCATCAACGTCGGTCATGGCGCTGTGATTGGAAGCCGCGCTTTGGTCACGAAAGATGTGGAGCCGTACACTATCGTTGGCGGAAATCCCGCCAAACCGATCAAGAAACGCTTCTCCGACGAGGAGATCGCCATGCTTTTGAAAATGAATTGGTGGGATTGGCCAACTGAAAAAATTGAGGAAGCAATGCCTTTGCTATGCTCATCCAACATCGTTGGGCTGCATCGATACTGGCAAGGCTTTGCCGTCTAA,chloramphenicol acetyltransferase (CAT),antibiotic inactivation,Phenicol,MEG_1549,Drugs,MEG_1549|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CAT,gb|AJ878850|+|1196-1829|ARO:3003110|catB10 [Pseudomonas aeruginosa] ,6
,atgttcaaaatcacgctctgcgccttattaattaccgcctcttgctccacatttgctgcccctcaacaaatcaacgatattgtgcatcgcacaattaccccgcttatagagcaacaaaagatccccggtatggcggtggcggtaatttatcagggtaaaccttattactttacctggggctatgcggacatcgccaaaaagcagcccgtcacacagcaaacgttgtttgagttaggctcggtcagcaaaacatttacgggcgtacttggtggcgacgctattgcacgaggggaaatcaagttaagcgatcccgcgacaaaatactggcctgaacttaccgctaaacaatggaatgggatcacactattacatcttgcgacctacaccgctggcggcctgccattgcaggtgccggatgaggtgaaatcctcaagcgacttgctgcgcttctatcaaaactggcaacctgcatggactccaggaacacaacgtctgtatgccaacaccagtattgggttgttcggtgcactggcggtgaaaccatccggtttgagctttgaacaggcaatgcaaactcgtgtcttccagccactcaaactcaaccatacgtggattaatgtaccgcccgcagaagaaaagaattacgcctggggatatcgcgaaggtaaggcagtgcatgtttcgccaggggcgttagatgctgaagcttatggtgtgaagtcgaccattgaagatatggcccgctgggtgcaaagcaatttaaaaccccttgatatcactgagaaaacgcttcaacaagggatacaactggcacaatctcgctactggcaaaccggcgatatgtatcagggcctgggctgggaaatgcaggactggccggtaaatcctgacatcatcattaacggcagtgacaataaaattgcactggcagcacgccccgtaaaagcgattacgcccccaactcctgcagtgcgcgcatcatgggtacataaaacgggagcgaccggcggatttggtagctatgtcgcgtttattccagaaaaagagctgggtatcgtgatgctggctaacaaaaactatcccaatccagcgagagtcactgccgcctggcagattctcaacgctctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1284,Drugs,MEG_1284|Drugs|betalactams|Class_C_betalactamases|BLAEC,1028083606|WP_063842627.1|NG_047495|1|1|blaEC|blaEC|BlaEC_family_class_C_beta-lactamase NG_047495:101-1234,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggttttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaaagttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4395,Drugs,MEG_4395|Drugs|betalactams|Class_D_betalactamases|OXA,928888754|WP_053921012.1|NG_057507|1|1|blaOXA-603|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-603 NG_057507:1-762,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6216,Drugs,MEG_6216|Drugs|betalactams|Class_A_betalactamases|SHV,1028110263|WP_063864633.1|NG_050022|1|1|blaSHV-148|blaSHV|class_A_extended-spectrum_beta-lactamase_SHV-148 NG_050022:1-861,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggtcagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacatcttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcgacgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggataccccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6232,Drugs,MEG_6232|Drugs|betalactams|Class_A_betalactamases|SHV,1028110297|WP_063864667.1|NG_050057|1|1|blaSHV-191|blaSHV|class_A_beta-lactamase_SHV-191 NG_050057:1-861,0
,atgagagattttattgtatttatatggtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattataatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttcaaagagctaaacaagccttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagctataaaacgctctcaagtacctgtttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgatactttttggctagataattctttacaaatttctgcaaaaaatcaagctgatttactttttaaactttcgcaaaattctttacctttttctaaaaaaaatcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattattaaataagtatttagctaatttttccaacaataataggattaaaagcttttactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4588,Drugs,MEG_4588|Drugs|betalactams|Class_D_betalactamases|OXA,1391852931|WP_109545116.1|NG_057553|1|1|blaOXA-621|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-621 NG_057553:1-774,0
,ATGGACACGTCAAAAGCGATCGAGGTCCCGGAACACCTGGCGGCGTCGTACAGCAGGGGATTCGGCGAGGAAGGGAGGGCCTGGATCGCTGCGCTGCCGACTCTCGCCGCGGCATTCCTGGACAGGTGGGAACTGCGGCGCGATGGTGCGGCCCGGGCAGGGGAAGCCTCGCTGGTACTGCCGGTGTTACGCCAGGACGGTACCCGCGCGGTCCTCAAGCTCCAGATGCCCCGGGAAGAGACCACTGCGGCCCTCATCGGCCTGTGCACATGGAACGGTGCCGGCACGGTACGGCTGCTCGACCACGATCCCCACAGCAGCACCATGCTCCTGGAGCGGCTGGACAGCGCCCGCACCTTGGCCTCACTCGAGGACGACGACGTCGCGATGGGAATCCTCGCCGAACTGCTGGCGCGGCTCGTCAGCGTCCCCGCCCCCCGGGAACTGCGCCGCCTCAAAGACATCGCCGCCGACATGCTGGAGCGGGTACCGCGCGCGGTCACGGCCCTGGCCGACCCGGCCGACCGGCAGTTGTTGCGTGGCTGGGCGGCGGCCGTCGCCGAACTGATCGAGGAACCCGGCGACCAGATGCTGCACTGGGACCTGCACTACGACAACGTGCTGGCCGCGGAGCGTGAGCCGTGGCTCGCCATCGACCCCGAACCGCTCGCAGGGGACCCCGGTTTCGACCTGTGGCCGGCCCTGGACAGCCGGTGGGACGACATCGTCGCCACGGGCGACACCCGGCGTGTGGTGCGGCGCCGGTTCGACCTGCTCACCGGGGTCCTCGGTCTGGACCGCGGGCGTGCGGCCGGCTGGACGCTGGGGCGGCTGCTGCAGAACGAGCTGTGGGACATCGAGGGCGGTGGCTCCGCCCTCGCCCCGTCCTCGGTCGCGATGGCGGAGGCGCTCCAGAACCGTTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1089,Drugs,MEG_1089|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH6,(AGly)Aph9-Ib:U70376:3618-4541:996,2
,ATGGATATGAATAAAAACACTAAAATAAAAAACAAAAATTTCAACATTAAAGACTCACAGAATTTTTTGCATAATACTAAATTAGTCGAAGATTTGCTTTTTAAAAGCAATATAACTAAGGAGGATTTTGTTGTTGAGATTGGGCCTGGAAAAGGCATAATAACCAAGGCATTAAGCAAAATCTGCAAAGCCGTTACTGCTATTGAGTTCGATAGTGTATTGGCTGATAAGTTGACCCATGAATTTAAAAGTTCAAATGTGTCTATTATTGAAGCCGATTTTTTAAAATACAATTTACCAGACCATAATTATAAAGTTTTTTCAAACATTCCATTTAACATAACGGCAAGTATTTTAAATAAATTGTTAGATAGTGAGAACCCACCCTTAGATACTTTTTTAATTATGCAATATGAACCTTTTTTAAAGTATGCGGGTGCACCATCTTACAAGGAGTCTTATAAATCTTTATTATATAAACCATTTTTCAAAACTAACATATTGCATAGCTTTAGCAAATTTGATTTTAAGCCAGCTCCAAACGCAAACATTATTTTGGGCCAATTTTCTTATAAAGACTTTACAGATATAAACCTTGAAGACAGGCATGCTTGGAAAGATTTTTTAGCCTTTGTCTTTTTAGAAAAGGGAGTTACATTTAAAGAAAAAACAAAACGAATTTTTAGTTATAAGCAACAAAAAATAATTTTAAAAGAAAGCCGAATTAATGATGATTCAAATATAAGTAATTGGAGTTATGAATTTTGGCTAAAAATGTTTAAACTCTATAATTCGAACATGGTAAGCAAGGATAAAAAAGTTTTAGTTAACAATTCGTATAAAAGAATGTTAGAACATGAGTCTAGTTTAGAAAAGATTCATAGAAATAGAAAGCAAAATAACAGAAAATAG,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2781,Drugs,MEG_2781|Drugs|MLS|23S_rRNA_methyltransferases|ERM42,gi|312836915|dbj|AB601890.1|4808-5719,7
,atgatcatcagtgaatttgatcgtagaaatatcggtttgaaggatcagctagctgaccttttgcgattgacttggccgaaggattacggtgaacaaccaatgaaagaagtcgagcaactgctggcgacggatcgaatcgctgtctcagcggtggaacaagatcgtttggttggttttatcggtgcgactccgcagtatggaatgactggttgggaaattcaccctctagtagtagaaacttcttatcgaaagcagtatatcggtagccgcttagttgcttatgtggagaaagaaatcgcctctaaaggtggtgtgatggtttatttaggaacagatgatacggatggggacacgagtcttagtcatacggatctttttgatcatccgttagataaactgaaatcaatcgaaactttcaacaagcatccttatacattttatgaaaaaatgggctatcaagtcgttggagcgattcctgatgcaaatgggatcaatcaaccagatatcattctggcaaaacgacttggagaaataaatcaatga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_89,Drugs,MEG_89|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,498430382|WP_010736157.1|NG_052162|1|1|aacA-ENT4|aacA-ENT4|aminoglycoside_6'-N-acetyltransferase NG_052162:101-643,2
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgttattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggcacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgtccactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_843,Drugs,MEG_843|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502081|WP_071846233.1|NG_052245|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052245:101-892,2
,ATGATGTCTAGATTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAGCTGCTTAATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAGCTAGGTGTAGAGCAGCCTACATTGTATTGGCATGTAAAAAATAAGCGGGCTTTGCTCGACGCCTTAGCCATTGAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGATTTTTTACGTAATAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGCGATGGAGCAAAAGTACATTTAGGTACACGGCCTACAGAAAAACAGTATGAAACTCTCGAAAATCAATTAGCCTTTTTATGCCAACAAGGTTTTTCACTAGAGAATGCATTATATGCACTCAGCGCTGTGGGGCATTTTACTTTAGGTTGCGTATTGGAAGATCAAGAGCATCAAGTCGCTAAAGAAGAAAGGGAAACACCTACTACTGATAGTATGCCGCCATTATTACGACAAGCTATCGAATTATTTGATCACCAAGGTGCAGAGCCAGCCTTCTTATTCGGCCTTGAATTGATCATATGCGGATTAGAAAAACAACTTAAATGTGAAAGTGGGTCTTAA,tetR,antibiotic efflux,Tetracyclines,MEG_7196,Drugs,MEG_7196|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_regulator|TETRM,gb|AL513383|+|179218-179845|ARO:3003479|tetR [Salmonella enterica subsp. enterica serovar Typhi str. CT18] ,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcgccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcacgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5551,Drugs,MEG_5551|Drugs|betalactams|Class_C_betalactamases|PDC,1393270441|WP_109791186.1|NG_057584|1|1|blaPDC-252|blaPDC|class_C_beta-lactamase_PDC-252 NG_057584:1-1194,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaacctttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgataagcctggtaaatattggaaagaactaaaaaatacaccgattgaccaaattaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcggccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagactcaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaaagggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacagactttattagacagtaattcagaacaaattgtgatgaagcctaataaagtgaccgctatttcaaaagaaccttcagttaagatgttccacaaaactggctcaaccaatggttttggaacttatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcagttttaaatgcaataaaggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_590,Drugs,MEG_590|Drugs|betalactams|Class_C_betalactamases|ADC,1209144265|WP_088245227.1|NG_055287|1|1|blaADC-157|blaADC|class_C_beta-lactamase_ADC-157 NG_055287:1-1152,0
,atgacttttaatattattaatttagaaacttgggatagaaaagaatatttcaatcattattttaatcaacaaacaacttatagtgttactaaagaattagatattaccttgttaaaaagtatgataaagaataaaggatatgaactgtatcctgctttgattcatgcaattgtaagtgttataaatcgaaataaagtatttagaacagggattaatagtgaggggaatttgggttattgggataaattagaacctttatatacagtctttaataaagaaactgaaaatttttctaatatttggacagaatcaaatgctagttttactcttttttataatagttataagaatgatttaattaaatataaagataaaaatgaaatgtttcctaaaaagccgatacctgaaaacacagttcctatctcgatgattccttggattgattttagttcatttaatttaaatattggtaataatagtagatttttattgccaattattacaataggtaaattttatagtaaggatgataagatctatttaccatttccattgcaagtccatcatgcagtatgtgatggttaccatgtttcattatttatgaatgaatttcaaaatataattcgataa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1573,Drugs,MEG_1573|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,1028084242|WP_063843210.1|NG_047571|1|1|catA8|catA8|type_A-8_chloramphenicol_O-acetyltransferase NG_047571:90-719,6
,ATGGATATTATTGATAAAGTTTTTCAGCAAGAGGATTTCTCACGCCAGGATTTGAGTGACAGCCGTTTTCGCCGCTGCCGCTTTTATCAGTGTGACTTCAGCCACTGCCAGCTAAGGGATGCCAGTTTCGAGGATTGCAGTTTCATTGAAAGCGGCGCCGTCGAAGGGTGCCACTTCAGCTATGCCGATCTGCGCGATGCCAGTTTCAAGGCCTGCCGCCTGTCTTTGGCTAATTTCAGCGGTGCCAACTGCTTTGGCATAGAGTTCAGGGAGTGCGATCTCAAGGGCGCCAATTTTTCCCGGGCCCGTTTTTACAATCAAATCAGCCATAAGATGTACTTCTGCTCGGCTTATATCTCAGGCTGCAACCTGGCCTATGCCAATTTGAGCGGCCAATGCCTGGAAAAGTGCGAGCTGTTTGAAAACAACTGGAGCAATGCCAACCTCAGCGGCGCTTCCTTGATGGACTCCGACCTCAGTCGCGGCACCTTCTCCCGCGACTGCTGGCAACAGGTAAACCTGCGAGGCTGTGACCTGACCTTTGCCGATCTGGATGGGCTCGATCCCAGACGGGTCAACCTCGAAGGCGTCAAGATCTGTGCCTGGCAGCAGGAGCAACTGCTGGAACCCTTGGGAGTCATAGTGCTGCCGGATTAG,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_5877,Drugs,MEG_5877|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRA,qnrA8_1_KY554783 ,3
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgttagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattaaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcgatcaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagactcaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcagggtcactatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaatgttacaaactttactagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacgtatgtggtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcgtatacagttttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_599,Drugs,MEG_599|Drugs|betalactams|Class_C_betalactamases|ADC,1315549097|WP_101244937.1|NG_056108|1|1|blaADC-166|blaADC|class_C_beta-lactamase_ADC-166 NG_056108:1-1152,0
,atggacacaacgcaggtcacattgatacacaaaattctagctgcggcagatgagcgaaatctgccgctctggaccggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatagttgaaatgctcggcgggcgcgtcatggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccagtggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_736,Drugs,MEG_736|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1105502191|WP_071846341.1|NG_052437|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052437:101-634,2
,TTCACATCGGCTTCACAGAGCCTCATATTGCGCACACCTTGCGGGATTAGGCTGGGAGCACTGCCAGGCACCCAGGCAGCACATTCGACTTATGACGAGAGGAGTAGACCCGATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTACTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCGGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGCCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCGTTTGCCCCCTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGTGTCAACCCTGGCATGCTGGCGGACGAGGCCTATGGCATCAAGACCAGCTCGGCGGATCTGCTGCGTTTTGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACCAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGAGCCTCGAAGCCAATCCGACGGCGGCGCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTACCCCATCGAGGCGCGCATCAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGAAAGAAAGAGGGCGGTACATTCGGTGAATGTGCCGCCCTTTTTCT,beta-lactamase,antibiotic inactivation,betalactams,MEG_1995,Drugs,MEG_1995|Drugs|betalactams|Class_C_betalactamases|CMY,gi|695214120|ref|NG_036738.1|6455-7759 gi|13591818|gb|AF357599.1|142-1446,0
,GGCATCCAAGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGAAAAGGATAAGTATGAAAAAATTATTTGTTTTATGTGTATTCTTCTTCTGCAACATTGCAGTTGCAGAAGAATCTTTGCCTGATTTAAAAATTGAGAAGCTTGAAGAAGGCGTTTATGTTCATACTTCGTTTGAAGAAGTTAAAGGTTGGAGTGTGGTCACTAAACACGGTTTGGTGGTTCTTGTGAAAAATGACGCCTATCTGATTGATACTCCAATTACTGCTAAAGATACTGAAAAATTAGTCAATTGGTTTGTTGAGCGGGGCTATAAAATCAAAGGCAGTATTTCCACACATTTCCATGGTGACAGTACGGCTGGAATAGAGTGGCTTAATTCTCAATCTATCCCCACATATGCTTCTGAATTAACAAATGAACTTCTTAAAAAAGACAATAAGGTACAAGCTAAACACTCTTTTTATGGGGTTAGTTATTCACTAATAAAAAACAAAATTGAAGTTTTTTATCCAGGCCCAGGGCACACTCAAGATAACGTAGTGGTTTGGTTACCTGAAAAGAAAATTTTATTCGGTGGTTGCTTTGTTAAACCGGACGGTCTTGGCTATTTGGGGGACGCAAATTTAGAAGCTTGGCCAAAGTCCGCTAAAATATTAATGTCTAAATATGGTAAAGCAAAACTAGTTGTGTCGAGTCATAGTGATATTGGAGATGTATCACTCTTGAAACGTACATGGGAGCAGGCTGTTAAAGGGCTGAATGAAAGTAAAAAATCATCACAGCCAAGCGACTAAATTTCTAACAAGGCGCTTCAGCACCGCGCACTTCGTGCGCTCGACAGTTCGTAAGCCGCTTTTTTGTGGTTTTGCTACGCAAAAGGTTTCCACAAAAAATCAACTTACAAACTGCGGCTGAGCTTAACGTTAGAAGGCCCAGGCTATGCAGTACTCCATTCGCTCGGTTCGTGTTTCGGATACATCTGATTGGTTACGCCTTCGCAACCTCCTGTGGGAAGGGGATGACCACGAAACCGAGATCGCCCAGTTTTTCGCCGGAGCCCTGGCCGAGCCCAACGAAGTGCTGGTAGCCCATGAAGATGCGGGGGCCGTTGTTGGGCATGTCGAGTTATCCATCCGCGAGGATGTCGCAGGGCTGGAAGGCATCAGAGCGGGCTATATCGAAGGCCTGTACATCGAGCAGGCCCATCGCTCGTCCAGCGTCGCGACGCAGTTACTACAGCACTCCGAGCAATGGGCCCAAAGTCAGGGATGCCGGGCGTTTGCATCGGATCGAGAGGATCGCCTGATCATCCATAAGTGGTTTTCTGTGGGTCCGCTTTCTAACCCTTCATTCCAGCGGACCGCCTTCGGCGGCCGCTGAATTGGAACGTTAGATGCACTAAGCACATAATTGCTCACAGCCAAACTATCAGGTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_3393,Drugs,MEG_3393|Drugs|betalactams|Class_B_betalactamases|IMP,gi|403309640|gb|JQ002629.1|1-1495 gi|226426103|gb|EU855788.1|275470-275370 gi|226426103|gb|EU855788.1|139851-139925 gi|226426103|gb|EU855788.1|139920-139967 gi|226426103|gb|EU855788.1|269337-269290 gi|226425792|gb|EU855787.1|253232-253332 gi|226425792|gb|EU855787.1|139851-139925 gi|226425792|gb|EU855787.1|139920-139967 gi|226425792|gb|EU855787.1|259365-259412 gi|365269063|gb|JN624388.2|3938-3985 gi|239702135|emb|FN397627.1|1662-1708 gi|209943874|gb|FJ267650.1|954-991,0
,atgacaaaaaagaaattgccccttcgttttacgggtcagcactttactattgataaagtgctaataaaagatgcaataagacaagcaaatataagtaatcaggatacggttttagatattggggcaggcaaggggtttcttactgttcatttattaaaaattgccaacaatgttgttgctattgaaaacgacacagctttggttgaacatttacgaaaattattttctgatgcccgaaatgttcaagttgtcggttgtgattttaggaattttgcagttccgaaatttcctttcaaagtggtgtcaaatattccttatggcattacttccgatattttcaaaatcctgatgtttgagaatcttgaaaattttctgggaggttccattgtccttcagttcgaacctacacaaaagttattttcaaggaagctttacaatccatataccgttttctatcatactttttttgatttgaaacttgtctatgaggtaggtcctgaaagtttcttgccaccgccaactgtaaaatcagccctgttaaacattaaaagaaaacacttattttttgattttaagattaaagccaaatacttagcatttatttcctgtctgttagagaaacctgatttatctgtaaaaacagctttaaagtcgattttcaggaaaagtcaggtcaggacaatttcggaaaaattcggtttaaaccttaatgctcaaattgtttgtttgtctccaagtcaatggttaaactgttttttggaaatgctggaagttgtccctgaaaaatttcatccttcgtag,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2828,Drugs,MEG_2828|Drugs|MLS|23S_rRNA_methyltransferases|ERMF,1028086397|WP_063844771.1|NG_047823|1|1|erm(F)|erm(F)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(F) NG_047823:101-901,7
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGTCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGGAAACTCATTCCGTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2428,Drugs,MEG_2428|Drugs|betalactams|Class_A_betalactamases|CTX,gi|78057321|gb|DQ223685.1|1-909,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaagaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcgactacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggaatctctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2184,Drugs,MEG_2184|Drugs|betalactams|Class_A_betalactamases|CTX,1028104608|WP_063859924.1|NG_048905|1|1|blaCTX-M-110|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-110 NG_048905:1-879,0
,gtgatcgacagtgtgcccacgatccgccaggccacgccggccgatgtggccgcgtgggcgcagttgcgtctcggcctgtggcccgatgccgatgatccgctggaggaactggcggagtcgctggccgatgccgaaggcgcggtattccttgcctgtctggccggtggcgaagcggtggggttcgccgaagtgcgcctgcgccacgactacgtgaatggcaccgagtcttcgccggtcggcttcctggaaggctggtacgtgcagccgcagtggcagggccacgccgtgggccgcgctctgctggcggcagtgcaggcgtggacgcgcacggccggctgcagcgagctggcgtctgacagtcgcgtggaagacgtacaggcgcatgccgcgcatcgtgcgtgtggtttcgaggaaaccgagcgcgtggtgtatttccgcatggtgttggacgccgagctgccccggtag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_260,Drugs,MEG_260|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,896541468|WP_049443010.1|NG_052189|1|1|aac(6')_Steno|aac(6')_Steno|aminoglycoside_6'-N-acetyltransferase NG_052189:101-568,2
,atgaaaaaatcgttatctgcaacactgatttccgctctgctggcgttttccgccccggggttttctgccgctgataatgtcgcggcggtggtggacagcaccattaaaccgctgatggcacagcaggatattcccgggatggcggttgccgtctccgtaaagggtaagccctattatttcaattatggttttgccgatattcaggcaaaacagccggtcactgaaaatacactatttgagctcggatctgtaagtaaaactttcacaggtgtgctgggtgcggtttctgtggcgaaaaaagagatggcgctgaatgatccggcggcaaaataccagccggagctggctctgccgcagtggaaggggatcacattgctggatctggctacctataccgcaggcggactgccgttacaggtgccggatgcggtaaaaagccgtgcggatctgctgaatttctatcagcagtggcagccgtcccggaaaccgggcgatatgcgtctgtatgcaaacagcagtatcggcctgtttggtgctctgaccgcaaacgcggcggggatgccgtatgagcagttgctgactgcacggatcctggcaccgctggggttatctcacacctttattactgtgccggaaagtgcgcaaagccagtatgcgtacggttataaaaacaaaaaaccggtccgcgtgtcgccgggacagcttgatgcggaatcttacggcgtgaaatccgactcaaaagatatgctgcgctgggcggaaatgaatatggagccgtcacgggccggtaatgcggatctggaaatggcaatgtatctcgcccagacccgctactataaaaccgccgcgattaaccaggggctgggctgggaaatgtatgactggccgcagcagaaagatatgatcattaacggtgtgaccaacgaggtcgcattgcagccgcatccggtaacagacaaccaggttcagccgtataaccgtgcttcctgggtgcataaaacgggcgcaacaactggtttcggcgcctatgtcgcctttattccggaaaaacaggtggcgattgtgattctggcgaataaaaactacccgaataccgaaagagtcaaagctgcacaggctattttgagtgcactggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2584,Drugs,MEG_2584|Drugs|betalactams|Class_C_betalactamases|DHA,1149331619|WP_077767294.1|NG_052903|1|1|blaDHA-25|blaDHA|class_C_beta-lactamase_DHA-25 NG_052903:1-1140,0
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGCTGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCGTAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6880,Drugs,MEG_6880|Drugs|betalactams|Class_A_betalactamases|TEM,gi|16798369|gb|AF427127.1|AF427127|1-1103,0
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6901,Drugs,MEG_6901|Drugs|betalactams|Class_A_betalactamases|TEM,gi|29650763|gb|AY243512.1|1-1069,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactactaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaaacacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctacggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaccccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4439,Drugs,MEG_4439|Drugs|betalactams|Class_D_betalactamases|OXA,1509794601|WP_122630910.1|NG_062330|1|1|blaOXA-718|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-718 NG_062330:12-836,0
,ATGAGATCAGAAAAAGAAATGATGGATTTAGTACTTTCTTTAGCAGAACAGGATGAACGTATTCGAATTGTGACCCTTGAGGGGTCACGCGCAAATATTAATATACCTAAAGATGAATTTCAGGATTATGATATTACATATTTTGTAAGTGATATAGAACCGTTTATATCTAATGATGACTGGCTTAATCAATTTGGGAATATAATAATGATGCAAAAGCCGGAGGATATGGAATTATTCCCACCTGAAGAAAAGGGATTTTCCTATCTTATGCTATTTGATGATTACAATAAAATTGATCTTACCTTATTGCCCTTGGAAGAGTTAGATAATTACCTAAAGGGCGATAAATTAATAAAGGTTCTAATTGATAAAGATTGTAGAATTAAAAGGGACATAGTTCCGACTGATATAGATTATCATGTAAGAAAGCCAAGCGCAAGGGAGTATGATGATTGCTGCAATGAATTTTGGAATGTAACACCTTATGTTATTAAAGGATTGTGCCGTAAGGAAATTTTATTTGCTATTGATCATTTTAATCAGATTGTTCGCCATGAGCTGCTGAGAATGATATCATGGAAGGTCGGCATCGAAACAGGCTTTAAATTAAGTGTAGGCAAGAACTATAAGTTTATTGAAAGGTATATATCCGAGGATTTGTGGGAGAAACTTTTGTCCACCTACCGGATGGATTCCTATGAAAACATATGGGAAGCATTATTTCTATGCCATCAATTGTTCAGGGCGGTATCCGGTGAGGTGGCGGAAAGGCTTCATTATGCCTATCCGGAGTATGATAGGAATATAACAAAATATACCAGGGACATGTATAAAAAATACACTGGTAAAACCGGCTGCCTGGATAGCACATATGCCGCTGATATAGAAGAGAGGCGGGAACAGTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_994,Drugs,MEG_994|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,(AGly)Ant6-Ia:AF330699:22-930:909,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccgcggcccactcgatgccgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaaaaaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_572,Drugs,MEG_572|Drugs|betalactams|Class_C_betalactamases|ADC,691101865|WP_032027415.1|NG_056162|1|1|blaADC-172|blaADC|class_C_beta-lactamase_ADC-172 NG_056162:101-1255,0
,atggctctggcactcgttggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagctttatgaatatgatcaccacgcgcacctggttttgtagcgcatatatcacgaataccaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagctggacaactaccaggcgtcgttgctcatggagcggcttggcatcgcggtgattggttag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5892,Drugs,MEG_5892|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,487657649|WP_001749994.1|NG_050523|1|1|qnrB6|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB6 NG_050523:37-681,3
,TTTTGTTTGGAGAGTTTGATCCTGGCTCAGGACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGGAAAGGTCTCTTCGGAGATACTCGAGTGGCGAACGGGTGAGTAACACGTGGGTGATCTGCCCTGCACTTCGGGATAAGCCTGGGAAACTGGGTCTAATACCGGATAGGACCACGGGATGCATGTCTTGTGGTGGAAAGCGCTTTAGCGGTGTGGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGGGGTGACGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGTGTCCGGCCACACTGGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCGACGCCGCGTGGGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCACCATCGACGAAGGTCCGGGTTCTCTCGGATTGACGGTAGGTGGAGAAGAAGCACCGGCCAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCGAGCGTTGTCCGGAATTACTGGGCGTAAAGAGCTCGTAGGTGGTTTGTCGCGTTGTTCGTGAAATCTCACGGCTTAACTGTGAGCGTGCGGGCGATACGGGCAGACTAGAGTACTGCAGGGGAGACTGGAATTCCTGGTGTAGCGGTGGAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGGTCTCTGGGCAGTAACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGTACTAGGTGTGGGTTTCCTTCCTTGGGATCCGTGCCGTAGCTAACGCATTAAGTACCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGGTTTGACATGCACAGGACGCGTCTAGAGATAGGCGTTCCCTTGTGGCCTGTGTGCAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCTCATGTTGCCAGCACGTAATGGTGGGGACTCGTGAGAGACTGCCGGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGTCCAGGGCTTCACACATGCTACAATGGCCGGTACAAAGGGCTGCGATGCCGCGAGGTTAAGCGAATCCTTAAAAGCCGGTCTCAGTTCGGATCGGGGTCTGCAACTCGACCCCGTGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCAACGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCATGAAAGTCGGTAACACCCGAAGCCAGTGGCCTAACCCTCGGGAGGGAGCTGTCGAAGGTGGGATCGGCGATTGGGACGAAGTCGTAACAAGGTAGCCGTACCGGAAGGTGCGGCTGGATCACCTCCTTTCT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_3,Drugs,MEG_3|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|AL123456.3|+|1471846-1473382|ARO:3003481|Mycobacterium tuberculosis 16S rRNA mutation conferring resistance to amikacin [Mycobacterium tuberculosis H37Rv] ,2
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGGCATATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1442,Drugs,MEG_1442|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_98_LTEF01000041,0
,atgaaaatcatgcctgtaaccgagccgttattggccgactggctgcaattaagacgattactctggcctgatcatgaagacgcgcatttactggaaatgcggcagttactcgaacaaccacagaccctgcaattattaagctataacgatcagcagcaagcaattgccatgctggaagcctcgattcgttatgaatatgtaaatggcacacaaacttcaccggtggcttttctggaaggtatttatgtgttgccagagtgtcgacgtttaggtgttgctagcacgttggtacagcaggtagaacactgggccaagcagtttgcatgtaccgaatttgcttcagatgctgcgctggataatacgatcagtcatgccatgcatcgcgcgctgggctttcaggaaaccgagcgtgtggtttattttaagaaaaacatcagttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_110,Drugs,MEG_110|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,696294757|WP_032870384.1|NG_052458|1|1|aacA-ACI5|aacA-ACI5|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052458:101-541,2
,atggaaagcacgttgcgccggacatacccgcaccacacttggcacctcgtgaacgaaggagactcgggcgccttcgtctaccgcctcaccggacacgggcccgagctctacgcgaagatcgccccccgcacccccgagaactccgccttccacctcgacggcgaggccgaccgcctcgactggctcgcccgccatggcatctcggtcccccgtgtcgtcgagcgcggtgccgacgacaccaccgcctggctcgtcaccgaggccgtgcccggcgccgcggcctccgaggagtggcccgaggacgagcgggcggccgttgtcgacgcgatcgccgaaatggcccgcaccctccatgaactccccgtgtccgagtgccccttcgaccgccgcctcgacgtcaccgtcggcgaggcccggcacaacgtccgcgagggcctggtcgacctcgacgacctccaggaggagcgcgccggctggaccggcgaccaactcctggccgaactcgaccgtacccggcccgagaaggaggacctggtcgtctgccatggcgacctgtgccccaacaacgtgctgctcgaccccgagacccaccggatcaccgggctgatcgacgtcggccgcctcggcgtcgccgaccgccacgccgacctcgccctcgccgcccgcgaactggcgatcgacgaggacccgtggttcggccccgcatacgccgaacggttcctcgaacggtacggggcccaccacgtcgaccaggagaagatggccttctaccagctgctcgacgagttcttctag,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1035,Drugs,MEG_1035|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,1028082921|WP_063842178.1|NG_047453|1|1|aph(3')-Vb|aph(3')-Vb|aminoglycoside_O-phosphotransferase_APH(3')-Vb NG_047453:101-895,2
,gtgatcgacagcgcgcccacgatccgccaggccacgccggccgatgcggccgcgtgggcgcagttgcgtctcggcctgtggactgatgccgatgatccgctggaggaactgacgcagtcgctggcagatgccgagggtgctgtgtttttggcctgtgcggcggatggcgaggcggttggtttcgctgaagtgcgcctgcgccatgactacgtgaacggcaccgagtcttcgccggtggggttcctggagggctggtacgtgcagccgcagtggcaaggtcgcggcgtcggccgcgccctgctgacggcggtgcaggcgtggacgcgcgatgcgggctgccgcgaactggcctcggacagtcgcgtggaagacgtgcaggctcacgccgcgcatcgggcctgcggcttcgaagagaccgaacgggtcgtctatttccgcatgccgctggagccatcggcgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_257,Drugs,MEG_257|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,640522596|WP_024956926.1|NG_052348|1|1|aac(6')-Iz|aac(6')-Iz|aminoglycoside_N-acetyltransferase_AAC(6')-Iz NG_052348:101-562,2
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggcatacctagctctgttcgaaaagagattacttataaaagcttagaactattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4687,Drugs,MEG_4687|Drugs|betalactams|Class_D_betalactamases|OXA,1509794544|WP_122630853.1|NG_062266|1|1|blaOXA-734|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-734 NG_062266:1-825,0
,ATGAGCGATAAAATACTTATTGTGGATGATGAACATGAAATTGCCGATTTGGTTGAATTATACTTAAAAAACGAGAATTATACGGTTTTCAAATACTATACCGCCAAAGAAGCATTGGAATGTATAGACAAGTCTGAGATTGACCTTGCCATATTGGACATCATGCTTCCCGGCACAAGCGGCCTTACTATCTGTCAAAAAATAAGGGACAAGCACACCTATCCGATTATCATGCTGACCGGGAAAGATACAGAGGTAGATAAAATTACAGGGTTAACAATCGGCGCGGATGATTATATAACGAAGCCCTTTCGCCCACTGGAGTTAATTGCTCGGGTAAAGGCCCAGTTGCGCCGATACAAAAAATTCAGTGGAGTAAAGGAGCAGAACGAAAATGTTATCGTCCACTCCGGCCTTGTCATTAATGTTAACACCCATGAGTGTTATCTGAACGAGAAGCAGTTATCCCTTACTCCCACCGAGTTTTCAATACTGCGAATCCTCTGTGAAAACAAGGGGAATGTGGTTAGCTCCGAGCTGCTATTTCATGAGATATGGGGCGACGAATATTTCAGCAAGAGCAACAACACCATCACCGTGCATATCCGGCATTTGCGCGAAAAAATGAACGACACCATTGATAATCCGAAATATATAAAAACGGTATGGGGGGTTGGCTATAAAATTGAAAAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7451,Drugs,MEG_7451|Drugs|Glycopeptides|VanA-type_regulator|VANRA,(Gly)VanR-Pt2:AY926880:718-1413:696,5
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAGATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6883,Drugs,MEG_6883|Drugs|betalactams|Class_A_betalactamases|TEM,gi|16798375|gb|AF427130.1|AF427130|1-1103,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCACCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1879,Drugs,MEG_1879|Drugs|betalactams|Class_C_betalactamases|CMY,gb|FJ437066|+|0-1134|ARO:3002055|CMY-44 [Escherichia coli] ,0
,atgcgttatgttcgcctgtgtgttatctccctgttagccaccctgccactggcggtagacgccggtccacagccgcttgagcagattaaacaaagcgaaagccagctgtcgggccgcgtggggatggtggaaatggatctggccagcggccgcacgctggccgcctggcgcgccgatgaacgctttcccatggtgagcacctttaaagtgctgctgtgcggcgcggtgctggcgcgggtggatgcaggggtcgaacaactggatcggcggatccactaccgccagcaggatctggtggactactccccggtcagcgaaaaacaccttaccgacgggatgacgatcggcgaactctgcgccgccgccatcaccctgagcgataacagcgctggcaatctgctgctggccaccgtcggcggccccgcgggattaactgcctttctgcgccagatcggtgacaacgtcacccgtcttgaccgctgggaaacggcgctgaatgaggcgcttcccggcgacgcgcgcgacaccaccaccccggccagcatggccgccacgctgcgcaaactactgaccgcgcagcatctgagcgcccgttcgcaacagcaactcctgcagtggatggtggacgatcgggttgccggcccgctgatccgcgccgtgctgccgccgggctggtttatcgccgacaaaaccggggctggcgaacggggtgcgcgcggcattgtcgccctgctcggcccggacggcaaaccggagcgcattgtggtgatctatctgcgggataccccggcgagtatggccgagcgtaatcaacatatcgccgggatcggcgcagcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3541,Drugs,MEG_3541|Drugs|betalactams|Class_A_betalactamases|LEN,817653623|WP_046619698.1|NG_050778|1|1|blaLEN-7|blaLEN|class_A_beta-lactamase_LEN-7 NG_050778:101-961,0
,ATGAACAAAAATATAAAATATTCTCAAAACTTTTTAACGAGTGAAAAAGTACTCAACCAAATAATAAAACAATTGAATTTAAAAGAAACCGATACCGTTTACGAAATTGGAACAGGTAAAGGGCATTTAACGACGAAACTGGCTAAAATAAGTAAACAGGTAACGTCTATTGAATTAGACAGTCATCTATTCAACTTATCGTCAGAAAAATTAAAACTGAACATTCGTGTCACTTTAATTCACCAAGATATTCTACAGTTTCAATTCCCTAACAAACAGAGGTATAAAATTGTTGGGAGTATTCCTTACCATTTAAGCACACAAATTATTAAAAAAGTGGTTTTTGAAAGCCATGCGTCTGACATCTATCTGATTGTTGAAGAAGGATTCTACAAGCGTACCTTGGATATTCACCGAACACTAGGGTTGCTCTTGCACACTCAAGTCTCGATTCAGCAATTGCTTAAGCTGCCAGCGGAATGCTTTCATCCTAAACCAAAAGTAAACAGTGTCTTAATAAAACTTACCCGCCATACCACAGATGTTCCAGATAAATATTGGAAGCTATATACGTACTTTGTTTCAAAATGGGTCAATCGAGAATATCGTCAACTGTTTACTAAAAATCAGTTTCATCAAGCAATGAAACACGCCAAAGTAAACAATTTAAGTACCGTTACTTATGAGCAAGTATTGTCTATTTTTAATAGTTATCTATTATTTAACGGGAGGAAATAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2804,Drugs,MEG_2804|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,gi|938507137|gb|KP842560.1|20891-21628 gi|409183623|gb|JQ663598.1|26630-25893 gi|388535180|gb|CP003585.1|47170-46433 gi|383850702|gb|JN899593.1|211-948 gi|383850692|gb|JN899591.1|273-1010 gi|383850677|gb|JN899588.1|273-1010 gi|373218503|gb|JN607214.1|242-979 gi|323463200|gb|CP002478.1|1849667-1848930 gi|319739722|gb|HQ115078.1|34525-33788 gi|260177113|gb|GQ900487.1|40580-39843,7
,TATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6902,Drugs,MEG_6902|Drugs|betalactams|Class_A_betalactamases|TEM,gi|296951|emb|X65252.1|175-1044,0
,GGCGGCGTGCTTAACACATGCAAGTCGAACGGAAAGGCCCTTTCGGGGGTACTCGAGTGGCGAACGGGTGAGTAACACGTGGGTGATCTGCCCTGCACTTTGGGATAAGCCTGGGAAACTGGGTCTAATACCGAATACACCCTGCTGGTCGCATGGCCTGGTAGGGGAAAGCTTTTGCGGTGTGGGATGGGCCCGCGGCCTATCAGCTTGTTGGTGGGGTGATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGTGACCGGCCACACTGGGACTGAGATACGGCCCAGACTNCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCACAGACGAAGCGCAAGTGACGGTATGTGCAGAAGAAGGACCGGCCAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTCCGAGCGTTGTCCGGAATTACTGGGCGTAAAGAGCTCGTAGGTGGTTTGTCGCGTTGTTCGTGAAAACTCACAGCTTAACTGTGGGCGTGCGGGCGATACGGGCAGACTAGAGTACTGCAGGGGAGACTGGAATTCCTGGTGTAGCGGTGGAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGGTCTCTGGGCAGTAACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGNCGTAAACGGTGGGTACTAGGTGTGGGTTTCCTTCCTTGGGATCCGTGCCGTAGCTAACGCATTAAGTANCCCGCCTGGGGAGTACGGNCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGNCCGCACAAGCGGCGGAGCATGTGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGGTTTGACATGCACAGGACGCCGGCAGAGATGTCGGTTCCCTTGTGGCCTGTGTGCAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCTCATGTTGCCAGCACGTTATGGTGGGGACTCGTGAGAGACTGCCGGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGTCCAGGGCTTCACACATGCTACAATGGCCGGTACAAAGGGCTGCGATGCCGTGAGGTGGAGCGAATCCTTTCAAAGCCGGTCTCAGTTCGGATCGGGGTCTGCAACTCGACCCCGTGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCAACGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCATGAAAGTCGGTAACACCCGAAGCCGGTGGCCTAACCCTTGTGGAGGGAGCCGTCGAAGGTGGGATCGGCGATTGGGACGAAGTCGTAACAAGGTAGCCG,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_12,Drugs,MEG_12|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|X52922.1|+|0-1454|ARO:3003540|Mycolicibacterium smegmatis 16S rRNA mutation in the rrsB gene conferring resistance to hygromycin B [Mycolicibacterium smegmatis] ,2
,ATGACAATGCGAATAAATACAGACAAACAAATGAATTTACTTAGTGATAAGAACGTTGCAATAATTGGTGGTGGACCCGTTGGACTGACTATGGCAAAATTATTACAGCAAAACGGCATAGACGTTTCAGTTTACGAAAGAGACAACGACCGAGAGGCAAGAATTTTTGGTGGAACCCTTGACCTACACAAAGGTTCAGGTCAGGAAGCAATGAAAAAAGCGGGATTGTTACAAACTTATTATGACTTAGCCTTACCAATGGGTGTAAATATTGCTGATGAAAAAGGCAATATTTTATCCACAAAAAATGTAAAGCCCGAAAATCGATTTGACAATCCTGAAATAAACAGAAATGACTTAAGGGCTATCTTGTTGAATAGTTTAGAAAACGACACGGTTATTTGGGATAGAAAACTTGTTATGCTTGAACCTGGTAAGAAGAAGTGGACACTAACTTTTGAGAATAAACCGAGTGAAACAGCAGATTTGGTTATTCTTGCCAATGGCGGGATGTCCAAGGTAAGAAAATTTGTTACCGACACGGAAGTTGAAGAAACAGGTACTTTCAATATACAAGCCGATATTCATCAACCAGAGATAAACTGTCCTGGATTTTTTCAGCTATGCAATGGAAACCGGCTAATGGCATCTCACCAAGGTAATTTATTATTTGCTAACCCCAATAATAATGGTGCATTGCATTTTGGAATAAGTTTTAAAACACCTGATGAATGGAAAAACCAAACGCAGGTAGATTTTCAAAACAGAAATAGTGTCGTTGATTTTCTTCTGAAAAAATTTTCCGATTGGGACGAACGCTACAAAGAATTGATTCATGCGACGTTGTCATTTGTAGGATTGGCTACACGGATATTTCCTTTAGAAAAGCCTTGGAAAAGCAAGCGCCCATTACCCATAACAATGATTGGGGATGCCGCACATTTGATGCCGCCTTTTGCAGGGCAGGGAGTAAATAGTGGGTTGGTGGATGCCTTGATATTGTCTGATAATCTAGCCGATGGAAAATTTAATAGCATTGAAGAGGCTGTTAAAAATTATGAACAGCAAATGTTTATCTATGGCAAAGAAGCACAAGAAGAATCAACTCAAAACGAAATTGAAATGTTTAAACCCGACTTTACGTTTCAGCAATTGTTAAATGTATAA,tetracycline inactivation enzyme,antibiotic inactivation,Tetracyclines,MEG_7243,Drugs,MEG_7243|Drugs|Tetracyclines|Tetracycline_inactivation_enzymes|TETX,gi|291192074|gb|GU014535.1|6304-7470,4
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1419,Drugs,MEG_1419|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_57_NZ_JURP01000126,0
,atgtttctttgcaaaaaaacaagcattatgtcttttctgctctgcctttcttttatttcatttaactcgcttgccactcaggaaaataatagtgttgctaaaatgaaggaactggagactgctttcggtggtcggataggtgtttatcttttaaatacagggaatgggaaagagttttcctacagacaggatgagagatttcctttgtgcagttcatttaaggtgtttctcgctgcatcggtgttaaaaagaatccagagcaaatctatttctcttgatgattcggtggagtatgtcggtcgtgttatggaaaaacattctcctgtatcagaaaaatatcgtgaaaagggagcaagcgtgcagactttggctatggcagcaattcagtatagtgacaatggagcttctaacctgttaatggaaagatacatcggaggtcctgaaggtttaactgcatttatgcggtcgacgggagatactgacttcaggcttgatcgctgggaattagaattaaactcagctattccaggcgataaacgtgacacatccactccgaaagcagtagcaatgagccttaaaaatattgcatttggttcgatacttaatgctaaaaataaagccttactgcaggattggcttaaaggcaacactactggtaatgcgcgagtcagagcagctgttccagataaatgggttgttggcgataaaacaggtacctgtggtttctatggtacagctaatgatgttgctattttatggccagacaacaattcacctgctgttatcgctgtgtatacaacgcgtcctaatcaaaacgacaagcatgatgaaacagtaattaaaaatgccgcaaaaatagctatagattcggtatatggaagttataaatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3053,Drugs,MEG_3053|Drugs|betalactams|Class_A_betalactamases|FRI,1391852888|WP_109545073.1|NG_057488|1|1|blaFRI-5|blaFRI|carbapenem-hydrolyzing_class_A_beta-lactamase_FRI-5 NG_057488:1-891,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAACTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1893,Drugs,MEG_1893|Drugs|betalactams|Class_C_betalactamases|CMY,gb|HQ322613|+|0-1146|ARO:3002067|CMY-56 [Klebsiella pneumoniae] ,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1399,Drugs,MEG_1399|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_94_LYRW01000005,0
,atgaccactaccattagcttcgtcacgctgcgcctcatgaccgagcacgaccttccgatgctccatgactggctaaatcggcctcacatcgttgagtggtggggcggagaagaaacacgtccaacacttgctgaagtgctggagcaatacctaccaagtgccctggcgaaagagtccgtcactccctacatcgcaatgctggatgaagaaccgattgggtacgctcagtcgtacattgcactcggaagcggtggcggatggtgggaagacgaaaccgatccaggagtacgcggaatagaccagtctctggcgaatccatcgcagctgggcaagggcttgggaaccaagctcgttcgcgcgctcgttgagatgctgtttaaagaccctgaggtaaccaagatccaaacggacccgtcgccgaacaacttacgcgcaatccggtgctacgagaaggcgggttttgtggcgcaaagaaccataaacaccccagatggaccggccgtatacatggttcaaacacgtcaggcgttcgagcaggcgcgcagtgttgtctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_127,Drugs,MEG_127|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,939369456|WP_054914207.1|NG_052210|1|1|aac(6')-31|aac(6')-31|aminoglycoside_N-acetyltransferase_AAC(6')-31 NG_052210:101-655,2
,atggcgctgcgcaaatccctctcgctcgcggcgctgacggcctgtctggtcgtggccttgccgttgtcggccgcgcccaagaagaaggcgccggccaagaaggtggaagaggtgccgaccctgccgacattgttgccgccggcaccacgctatctggtgccgcaatccgcgctcacctccgtccgcaatcccaaggagatcgaggaggagaccggcgggcgcatgggcatcgcgctggtcgatcgcgagggtgcgctgatcctgggtttcaaccgcgatgatcgctttgccatgtgctcgaccttcaaggcgccgctggccgccgccgtgctgatcggcgcgcagggcggcaagttcgggctggagggggagatccccttcaccaaggacgatattctcgattacgcgccggtcgtgaagaagaacaagaagcgtggccgcatgtcgatggccgaactggccgcggcggccgtggaggtcagcgacaacagtgccgccaacctgttgctgccgatgctgggcgggccggaggggctgacctccttcatccgcgcccatggcgacaagatcacgcggctcgatcgcatcgagccggacctcaacgagaatattgcgggcgatccgcgcgacacgaccagcccggcggcgatggccgggctgatggggcggctgttgttccgcgacatggcagcggccgatgccgacaggctgcgcggctggctgaatgccagcaccaccggcgacaaaaggatcaaggctggtctgcccgaaggctggacctcgggcagcaagaccggcagctgcggtaccgcctataatgacgtcgcgctggtgaagtcgccggcgggcgaggaatatatattggccatctatctcgaccggccgaccgtggacgacaagaaggccgaggcggcgatcgccgaagccgcccattcggcgctggagttcgtcagcaaggcgcagaagagcgggctgaactag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1310,Drugs,MEG_1310|Drugs|betalactams|Class_A_betalactamases|BLASGM,498022977|WP_010337133.1|NG_050614|1|1|blaSGM-7|blaSGM|class_A_beta-lactamase_SGM-7 NG_050614:101-1081,0
,ATGCTAAATTTAACCGTTTGTCAGCCACAGTCAAATCCAACAGACTACTGAGGTCTGACGGGCCCGGACACTCCCTTGAACCGCTATTACGGAAGAAAACTGATGAAGACAAAATCCCTTTGCTGTGCCCTGCTGCTCAGCACCTCCTGCTCTGTTCTCGCCGCGCCGATGTCAGAGAAACAGCTGTCTGACGTGGTGGAACGTACCGTTACCCCCCTGATGAAAGCGCAAGCCATTCCGGGCATGGCGGTAGCGGTGATTTATCAGGGTCAGCCGCACTACTTTACCTTCGGAAAGGCCGATGTTGCGGCGAACAAACCTGTCACCCCGCAAACCCTGTTTGAGCTGGGCTCTATAAGTAAAACCTTCACCGGCGTATTAGGTGGCGATGCGATTGCGCGCGGAGAAATATCGCTGGGCGACCCCGTGACAAAGTACTGGCCCGAGCTAACAGGCAAGCAGTGGCAGGGTATTCGCATGTTGGATCTGGCGACCTACACCGCGGGTGGCCTGCCGCTACAGGTGCCGGATGAGGTCACGGATAACGCCTCCCTGCTGCGTTTCTATCAACACTGGCAACCGCAGTGGAAACCAGGCGCAACGCGTCTTTATGCGAACGCCAGCATCGGGCTTTTTGGCGCCCTCGCGGTTAAACCCTCCGGCATGAGCTTTGAACAGGCCATGACGAAGCGGGTCTTCAAGCCACTCAAACTGGACCATACATGGATTAACGTTCCGAAAGAAGAAGAGGCGCATTACGCCTGGGGATACCGTGATGGTAAAGCAATCCACGTTTCACCGGGAATGCTGGATGCCGAAGCGTATGGTGTCAAAACCAACATCCAGGATATGGCGAGCTGGCTGAAGGCCAACATGAACCCTGACGCCCTTCCGGATTCAACGTTGAAACAGGGTATTGCCCTGGCACAGTCTCGCTACTGGCGCGTGGGTGCCATGTATCAGGGTCTGGGCTGGGAGATGCTCAACTGGCCGGTAGAAGCCAAAACCGTCGTGGAGGGCAGCGATAACAAGGTGGCTCTTGCACCGTTACCGGTGGCAGAAGTGAACCCTCCAGCTCCGCCAGTAAAAGCATCATGGGTACATAAAACAGGCTCGACGGGTGGATTCGGCAGCTATGTCGCATTTATTCCTGAAAAGGAACTCGGCATTGTTATGCTGGCGAACAAGAGCTACCCGAACCCGGCGCGCGTGGAAGCGGCATACCGTATTCTGAGCGCTCTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_488,Drugs,MEG_488|Drugs|betalactams|Class_C_betalactamases|ACT,gi|591542910|gb|KJ207206.1|650-1897,0
,atgatcgtcaactgcgaccacgacaacctcgacgcctggctggcgctacgcgcggcgctgtggcccacttgtccgttggaagagcaccgcgcggagatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgccacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttacaccgtcgaacgcgcccgccgccagggctgggcggcgcgtttgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgacatcgccaatctgtactcccagcgcctgcatgcggcgctgggctttgccgaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_97,Drugs,MEG_97|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,505192038|WP_015379140.1|NG_052263|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052263:101-541,2
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1861,Drugs,MEG_1861|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AY743434|+|46-1198|ARO:3002029|CMY-18 [Escherichia coli] ,0
,atgagaaattttattgtatttataatgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattataatacaagtgggacttttatagtttttgatggaaaaaattatgcaagtaatgattttaaaagagctaaaaaagctttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgttctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgataccttttggctagataattctttacaaatttctgcaaaaaatcaagctgatttactttttaaactttcgcaaaattctttacctttttctaaaaaaaatcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgttaaaacaggttttaatgatagtataaatttagcttggattgttggatttgtaaagactaaaaataaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagagaagaattgctagaaaaatatctagcaatcataacaaattag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4573,Drugs,MEG_4573|Drugs|betalactams|Class_D_betalactamases|OXA,1391852925|WP_109545110.1|NG_057545|1|1|blaOXA-616|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-616 NG_057545:1-750,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATGGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1962,Drugs,MEG_1962|Drugs|betalactams|Class_C_betalactamases|CMY,gi|388564831|gb|JQ733572.1|1028-2255,0
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAGATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTATTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1362,Drugs,MEG_1362|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_26_JBJP01000007,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_575,Drugs,MEG_575|Drugs|betalactams|Class_C_betalactamases|ADC,447133971|WP_001211227.1|NG_055786|1|1|blaADC-158|blaADC|class_C_beta-lactamase_ADC-158 NG_055786:1-1152,0
,AATTCAATCTTATAAGTCTTATGAACATTAAAACACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGTACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGTACCATAAGGCAACCACCACAGAAGTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAGTTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCCAAAAGTCCAAGATGAAGTGCAATCCATGTTATTCATAGAAGAAAAGAACGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGAAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCAGTTCACTTTTTACCATTATGATCTGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5230,Drugs,MEG_5230|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389149|gb|KF986257.1|1-888,0
,atggacagaaaaagattgacacagcgtttcccgttcctgcttccaatgagacgggcgcagagaaaaatgtgcttttatgcgggaatgagatttgacggctgtcgctatgcgcagacgataggggaaaaatcgctttcccatttgctctttgaaacggattgcgcattatacaaccacaataccggatttgacatgatataccaggaaaacaaggtgttcaacttaaagctggcagcaaagaccttaaacggcttattgataagaccgggggaaaccttttctttctggtggctggtacgccatgcggacaaagataccccctataaagacggccttacggtgaccaatggtaaactcaccaccatgtcgggcggcggtatgtgccagatgatcaatttactattttggatgttcctgcatacgccattgacaattatccagcgcagaggtcacgaagtaaaggagtttccagagccaaacagtgacgagattaaaggggtggatgcaaccatttcagagggctggattgatttaaaagtgcgaaacgataccgactgcacctaccaaatatgggtgaccttagatgatgagaaaatcatcggtcaggtgtccgccgacaaagagccccaagcattatacaaaattacaaatggcagtatccagtatgtccgtgaaagtggcgggatttatgaatatgcccaggttaaacggatgcaagttgccttaggtaccggggaaataatagattgcaagctgctttatacaaacaaatgcaaaatctgttatcccctcccggaaagtgtggatattcaggaggagaaccaatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7539,Drugs,MEG_7539|Drugs|Glycopeptides|VanB-type_accessory_protein|VANWB,1028100630|WP_063856765.1|NG_048473|1|1|vanW-B|vanW-B|glycopeptide_resistance_accessory_protein_VanW-B NG_048473:101-928,5
,ATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTATTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCAGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGCCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCATTTGCCCAGTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGGGTCAACCCTGGCATGCTGGCGGACGAGGCCTACGGCATCAAGACCAGCTCGGCGGATCTGCTCGCCTTCGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACAAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGATCCTCGAAGCCAATCCGACGGCGGCTCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTATCCCATCCCGGCCAGGGTGAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1951,Drugs,MEG_1951|Drugs|betalactams|Class_C_betalactamases|CMY,AAZ03413.1 DQ094251.1:1-1149,0
,ATGAAAATTATTAATATTGGAGTTTTAGCTCATGTTGATGCAGGAAAAACTACCTTAACAGAAAGCTTATTATATAACAGTGGAGCGATTACAGAATTAGGAAGCGTGGACAAAGGTACAACGAGGACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACAGGAATAACCTCTTTTCAGTGGGAAAATACGAAGGTGAACATCATAGACACGCCAGGACATATGGATTTCTTAGCAGAAGTATATCGTTCATTATCAGTTTTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATGGCGTACAAGCACAAACTCGTATATTGTTTCATGCACTTAGGAAAATGGGGATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCCGAAATTGTAATCAAACAGAAGGTAGAACTGTATCCTAATATGTGTGTGACGAACTTTACCGAATCTGAACAATGGGATACGGTAATAGAGGGAAATGATGACCTTTTAGAGAAATATATGTCCGGTAAATCATTAGAAGCATTGGAACTCGAACAAGAGGAAAGCATAAGATTTCATAATTGTTCCCTGTTCCCTGTTTATCACGGAAGTGCAAAAAACAATATAGGGATTGATAACCTTATAGAAGTGATTACGAATAAATTTTATTCATCAACACATCGAGGTCCGTCTGAACTTTGCGGAAATGTTTTCAAAATTGAATATACAAAAAAAAGACAACGTCTTGCATATATACGCCTTTATAGTGGAGTACTACATTTACGAGATTCGGTTAGAGTATCAGAAAAAGAAAAAATAAAAGTTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAGATTGATAGAGCTTATTCTGGAGAAATTGTTATTTTGCAAAATGAGTTTTTGAAGTTAAATAGTGTTCTTGGAGATACAAAACTATTGCCACAGAGAAAAAGAATTGAAAATCCGCATCCTCTACTACAAATAACTGTTGAACCGAGTAAACCTGAACAGAGAGAAATGTTGCTTGATGCCCTTTTGGAAATCTCAGATAGTGATCCGCTTCTACGATATTACGTGGATTCTACGACACATGAAATTATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGATTAGTGCACTGTTGCAAGAAAAGTATCATGTGGAGATAGAACTAAAAGAGCCTACAGTCATTTATATGGAGAGACCGTTAAAAAATGCAGAATATACCATTCACATCGAAGTGCCGCCAAATCCTTTCTGGGCTTCCATTGGTTTATCTGTATCACCGCTTCCGTTGGGAAGTGGAATGCAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCATTTCAAAATGCAGTTATGGAAGGGATACGCTATGGTTGCGAACAAGGATTATATGGTTGGAATGTGACGGAATGTAAAATCTGTTTTAAGTATGGCTTATACTATAGCCCTGTTAGTACCCCAGCAGATTTTCGGATGCTTGCTCCTATTGTATTGGAACAAGTCTTAAAAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAATTTATGCGCCACAGGAATATCTTTCACGAGCATACAACGATGCTCCTAAATATTGTGCGAACATCGTAGACACTCAATTGAAAAATAATGAGGTCATTCTTAGTGGAGAAATCCCTGCTCGGTGTATTCAAGAATATCGTAGTGATTTAACTTTCTTTACAAATGGACGTAGTGTTTGTTTAACAGAGTTAAAAGGGTACCATGTTACTACCGGTGAACCTGTTTGCCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7134,Drugs,MEG_7134|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,(Tet)TetM:U08812:1981-3900:1920,4
,TTGTATAGAGTAAAAATAGCCATCCTGTTTGGGGGCTGCTCAGAGGAACATGATGTGTCGGTAAAATCAGCGAAAGAGATTGCCAACAACATTAACACAGAAAAATATGAGCCAATATACATTGGAATAACCCGATCCGGCGTTTGGAAAATGTGCGAAAAGCCATGCATGGATTGGGACAACGAAAACTGCCGTTCGGCAGTGCTTTCTCCGGACAAAAGAATGCACGGGCTGCTTGTCATGCGGGATAAGGGATATCAAATACAGCGTATAGATGCGGCATTTTCGGTTTTGCACGGCAAATCGGGCGAAGACGGCGCCATACAAGGTTTATTTGAATTGTCCGGCATCCCCTATGTAGGCTGTGATATTCAAAGCTCGGCGGTGTGTATGGACAAATCGCTGGCATACATCATTGCGAAAAACGATGGCATAGCTACTCCCGAATTTTGGGTTATTAATAAAGACGATAGGCCGGCGGCAGCTGCGTTTACCTATCCTGTTTTTGTTAAGCCGGCGCGTTCAGGCTCATCCTATGGCGTGAAAAAAGTCAATGGCGCGGACGAATTGGACGCCGCAATTGAATCGGCAAGACAATATGACAGCAAAATCTTAATTGAGCAGGCTGTTTTGGGCTGTGAGGTCGGTTGTGCCGTATTGGGAAACAGTTCCGAGTTGATTGTTGGCGAGGTGGACCAAATCAGGCTGCAGCACGGTATCTTTCGTATTCATCAGGAAGCCGAGCCGGAAAAAGGCTCTGAAAACGCAGTTATAACCATTCCCGCAGACCTGTCGGCAGAGGAGCGAGGACGGATACGGGATACGGCAAAAAAAATATATAAGGCGCTCGGCTGTAGAGGTCTTGCCCGTGTTGATATGTTTTTACAAGATAACGGCCGCATTGTACTTAACGAAGTCAATACCCTGCCCGGTTTCACGTCATACAGCCGTTATCCCCGTATGATGGTCGCTGCAGGTATAACGCTTCCCGAACTGATTGACCGCCTGATCGTATTAGCGTTAAAGGGGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7343,Drugs,MEG_7343|Drugs|Glycopeptides|VanA-type_resistance_protein|VANA,gi|50082942|gb|AY648698.1|1-1032 gi|66731642|gb|DQ018711.1|4129-5160,5
,atgaaacattcttcgctgcggcgttcgttattattagccggtattaccctccccttggtcagttttgcactaccagcttgggcaaatgcgctaccggcttcagtagataaacaattagccgagcttgaacgaaatgccaatggccgtttaggtgtcgcgatgattaataccggcaatggcaccaaaattttgtatcgcgcagctcaacgtttcccattctgtagtacttttaagtttatgctggccgctgctgtattagatcaaagccagtctcagccgaatttactcaataagcatataaattaccatgagagtgatttgttatcttatgcccccatcacgcgtaaaaatcttgcgcatggcatgaccgtctccgaattatgtgctgccaccattcaatatagtgataacactgccgcaaatttattaattaaagagttgggtggtttagcggctgttaatcagttcgctcgcagtattggcgatcagatgttcagattagaccgctgggagcctgatttaaataccgcgcgacctaatgacccacgtgataccaccactcctgcggctatggcagcgagtatgaataaattggtgttgggtgatgcattgcgccctgcccaacgaagtcaactcgctgtatggctgaaaggaaataccactggggatgccacaattcgtgcgggtgcccctactgactggattgtgggtgacaaaacgggtagtggcgattacggaaccaccaatgatattgcggtactttggccgactaaaggcgcgccgattgttttagtcgtgtatttcacgcaacgcgaaaaagacgcgaagccacgccgcgacgtattggcctctgtgaccaaaataattttgtcgcagatatcctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1239,Drugs,MEG_1239|Drugs|betalactams|Class_A_betalactamases|BLAA,491307788|WP_005165780.1|NG_047488|1|1|blaA_Yent|blaA_Yent|class_A_beta-lactamase_BlaA NG_047488:101-985,0
,TATCATTGCAGCAAAGATGAAATCAATGATTTATCAAAAATGATTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGTTTCATTCTGGCGACGTCCGTATTTGCCTTTCGGAAGCATAAAATCGGACGCGTTGTGGCTCGCTTCAGGTAAAATATTGACTATTCATGTTGTTGTTATTTCGTCTCTTCCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCTGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGGAAACTCATTCCGTTTTTGTTTATCGCCTTAGACGGCAAAAGTGCTGTCGCCCACCTGCGCTTGCGCATACCAGGCCATAAGCTCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_2425,Drugs,MEG_2425|Drugs|betalactams|Class_A_betalactamases|CTX,gi|695228197|ref|NG_041750.1|1-1254 gi|529205529|gb|KC788405.1|41529-41384,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATCGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTGACGATGAGGCCCAGGATATTGGGCCTCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_1975,Drugs,MEG_1975|Drugs|betalactams|Class_C_betalactamases|CMY,gi|442540408|gb|JX514368.1|272-1448,0
,ATGAAAAAGATAAAAATTGTTCCACTTATTTTAATAGTTGTAGTTGTCGGGTTTGGTATATATTTTTATGCTTCAAAAGATAAAGAAATTAATAATACTATTGATGCAATTGAAGATAAAAATTTCAAACAAGTTTATAAAGATAGCAGTTATATTTCTAAAAGCGATAATGGTGAAGTAGAAATGACTGAACGTCCGATAAAAATATATAATAGTTTAGGCGTTAAAGATATAAACATTCAGGATCGTAAAATAAAAAAAGTATCTAAAAATAAAAAACGAGTAGATGCTCAATATAAAATTAAAACAAACTACGGTAACATTGATCGCAACGTTCAATTTAATTTTGTTAAAGAAGATGGTATGTGGAAGTTAGATTGGGATCATAGCGTCATTATTCCAGGAATGCAGAAAGACCAAAGCATACATATTGAAAATTTAAAATCAGAACGTGGTAAAATTTTAGACCGAAACAATGTGGAATTGGCCAATACAGGAACAGCATATGAGATAGGCATCGTTCCAAAGAATGTATCTAAAAAAGATTATAAAGCAATCGCTAAAGAACTAAGTATTTCTGAAGACTATATCAAACAACAAATGGATCAAAATTGGGTACAAGATGATACCTTCGTTCCACTTAAAACCGTTAAAAAAATGGATGAATATTTAAGTGATTTCGCAAAAAAATTTCATCTTACAACTAATGAAACAGAAAGTCGTAACTATCCTCTAGGAAAAGCGACTTCACATCTATTAGGTTATGTTGGTCCCATTAACTCTGAAGAATTAAAACAAAAAGAATATAAAGGCTATAAAGATGATGCAGTTATTGGTAAAAAGGGACTCGAAAAACTTTACGATAAAAAGCTCCAACATGAAGATGGCTATCGTGTCACAATCGTTGACGATAATAGCAATACAATCGCACATACATTAATAGAGAAAAAGAAAAAAGATGGCAAAGATATTCAACTAACTATTGATGCTAAAGTTCAAAAGAGTATTTATAACAACATGAAAAATGATTATGGCTCAGGTACTGCTATCCACCCTCAAACAGGTGAATTATTAGCACTTGTAAGCACACCTTCATATGACGTCTATCCATTTATGTATGGCATGAGTAACGAAGAATATAATAAATTAACCGAAGATAAAAAAGAACCTCTGCTCAACAAGTTCCAGATTACAACTTCACCAGGTTCAACTCAAAAAATATTAACAGCAATGATTGGGTTAAATAACAAAACATTAGACGATAAAACAAGTTATAAAATCGATGGTAAAGGTTGGCAAAAAGATAAATCTTGGGGTGGTTACAACGTTACAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCAGATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAAGATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTACGGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCACCTCACTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCAACAAGTCGTAAATAAAACACATAAAGAAGATATTTATAGATCTTATGCAAACTTAATTGGCAAATCCGGTACTGCAGAACTCAAAATGAAACAAGGAGAAACTGGCAGACAAATTGGGTGGTTTATATCATATGATAAAGATAATCCAAACATGATGATGGCTATTAATGTTAAAGATGTACAAGATAAAGGAATGGCTAGCTACAATGCCAAAATCTCAGGTAAAGTGTATGATGAGCTATATGAGAACGGTAATAAAAAATACGATATAGATGAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3777,Drugs,MEG_3777|Drugs|betalactams|Penicillin_binding_protein|MECA,(Bla)MECA:AB221124:91-2097:2007,0
,ttgcaaattcgactaatggatgaagcttctttgagcatgtgggttgggcttcgaagtcagctatggccagaccatagctatgaagatcatattctggatagccaacacattttatcttgtcccgataaatatgtttcattcctggcaataaataaccagagtcaggcaatagcgtttgccgatgccgcggttcgccatgattatgtgaatggttgtgaaagcagtccggtggtttatcttgaagggatttttgttattccggagcagagaggccatggcgttgccaaactactggttgcagccgtacaggattggggagtggcgaaaggttgcaccgagatggcaagcgatgcggctttagataaccatatatcctatcaaatgcatcaggctttaggctttgaagaaaccgaacgcgtggtatttttcagaaaaagaatagctggttaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_271,Drugs,MEG_271|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1102724733|WP_071593229.1|NG_047295|1|1|aac(6')-If|aac(6')-If|aminoglycoside_N-acetyltransferase_AAC(6')-If NG_047295:101-550,2
,atggcaatccgattcttcaccatactgctatccaccttctttcttacctcattcgtgtatgcgcaagaacatgtggtaatccgttcggactggaaaaagttcttcagcgacctccaggccgaaggtgcaatcgttattgcagacgaacgtcaagcgaagcatactttatcggtttttgatcaagagcgagcggcaaagcgttactcgccagcttcaaccttcaagataccccacacactttttgcacttgatgcagacgccgttcgtgatgagttccaggtttttcgatgggacggcgttaaccgaagctttgcaggtcacaatcaaaaccaagatttgcgatcagcgatgcgaaattctacggtttgggtttatgagctgtttgcaaaagatatcggagaggacaaagcaagacgttatttaaagcaaattgattatggcaacgtcgatccttcgacaatcaagggcgattactggatagatggaaatcttaaaatctcagcgcacgaacagattttgtttctcagaaaactctatcgaaatcagttaccatttaaggtggagcaccagcgcttggtgaaagatctcatgattacggaagccgggcgcagttggatactacgcgcaaagaccggctgggaaggcaggtttggctggtgggtagggtggattgaatggccaacaggccccgtattctttgcgctgaatattgatacgccaaacagaacggacgatcttttcaaaagagaggccatcgcacgggcaatccttcgttctattgacgcattgccacccaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4732,Drugs,MEG_4732|Drugs|betalactams|Class_D_betalactamases|OXA,1509879090|WP_122634438.1|NG_062354|1|1|blaOXA-779|blaOXA-46_like|OXA-46_family_oxacillin-hydrolyzing_class_D_beta-lactamase_OXA-779 NG_062354:1-801,0
,atgatgaaaaaatccctttgctgcgccctgctgctcggcatctcttgctctgctctcgccacgccagtgtcagaaaaacagctggcggaggtggtagcgaatacggttaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaaccgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccggcgttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagcatcggtctttttggtgcgctggcggtcaaaccttctggcatgccctatgagcaagccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgtgccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggtatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaacgttgctgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcgagggcagcgacagtaaggtggcgctggcgccgttgcccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggctctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaatacaaactatccgaacccggcacgcgttgaggcggcataccatatcctcgaggcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_422,Drugs,MEG_422|Drugs|betalactams|Class_C_betalactamases|ACT,779829263|WP_045340466.1|NG_050707|1|1|blaACT-44|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-44 NG_050707:1-1146,0
,AATTTTAATTATTTCTCCATAAAAATTATGAAAAAAAGTATTCAGCTTTTGATGATGTCAATGTTTTTAAGCCCATTGATCAATGCCCAGGTTAAAGATTTTGTAATTGAGCCGCCTGTTAAACCCAACCTGTATCTTTATAAAAGTTTCGGAGTTTTCGGGGGTAAAGAATATTCTGCCAATGCTGTATATCTTACCACTAAGAAAGGAGTTGTCTTATTTGATGTCCCATGGCAAAAGGAACAATATCAAACCCTTATGGACACCATACAAAAGCGTCATCACCTTCCTGTAATTGCTGTATTTGCCACCCACTCTCATGATGACAGAGCGGGTGATCTAAGCTTTTACAATCAAAAAGGAATTAAAACATATGCGACCGCCAAGACCAATGAACTGTTGAAAAAAGACGGAAAAGCAACCTCAACCGAAATTATAAAAACAGGAAAACCTTACAAAATTGGTGGTGAAGAATTTATGGTAGACTTTCTTGGAGAAGGACATACAGTTGATAATGTTGTTGTATGGTTCCCCAAATATAAAGTACTGGACGGAGGATGTCTTGTAAAAAGCAGGACAGCCACTGACCTGGGATATACCGGTGAAGCAAATGTAAAACAATGGCCGGAAACCATGCGAAAACTAAAAACGAAATATGCTCAGGCCACTCTGGTAATCCCGGGACACGACGAATGGAAAGGCGGTGGCCATGTACAGCATTCTCTGGATCTTCTGGATAAGAATAAAAAGCCGGAATAATGTACCACATTAAAATGGTTCGGAAAAAATCGAAAGATTTTATAAAGCCTATTATTTATACTTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3425,Drugs,MEG_3425|Drugs|betalactams|Class_B_betalactamases|IND,gi|300510841|gb|HM245380.1|1-823,0
,atgcgcaccctgaacatcggcattctggcccacgtcgacgcgggtaagaccagcctgaccgaacggctcctgttcgaccacggcgccgtcgaccggctcggcagcgtcgacgccggcgacacccgtacggtcgacggcggtatcgagcgccgccgcggcatcaccatccgctccgccgtcgccgccttcaccgtcggcgacacgcgcgtcaacctgatcgacaccccgggacactccgacttcgtcgcggaggtcgagcgggccctggaagtgctcgacggggcggtgctgctgctgtccgccgtcgagggcgtccaggcgcggacccgcgtcctgatgcgcgcgctgcggcggctgcggctgcccacgatcgtgttcgtcaacaagatcgaccgggccggcgcgcgcaccgacggcctcctcggtgacgtccggcgcctgctgacgccgcacgtcgcgccgctgaccgaggtggcggacgccggtaccccgcgcgcccgggtcacccgccgcccgccggacgggcggaccgcggaggccctcgccgaggtcgacacggaggtcctggccgcgctggtcgacggccccgagccgaccggggaggacgtggcccgcgccctcgccgcccgtaccgccgacggctcgttccacccgctgtaccacggctccgcgctcggcggacagggcgtcgcggagctggtcgagggcctgctcggcctgatcccggccgccacgccgggcacgtccggcggcacgtccggcggcacggaaccgcgcggcacggtcttcgccgtgcgccccggacccgccggcgagcgcaccgcgtacctcaggctgtacggcggcgaggtgcacccgcgccggcggctcaccttcctgcggcgcgagtccgacgggcggaccaccgaggtctccggccgggtgacccgcctcgacgtcgtcggcggcgacgccacgctcaccgccgggaacatcgccgcgctcaccgttcccgggggcctgcgcgtcggcgaccggctcggcggaccgaccgaccgtgcaccgcagttcgcgccaccgaccctgcagacgctggtccgggcccggcacccggagcaggcggcgccgctgcgctccgccctgctggcgctggccgaccaggacccgctgctgcacgcccgaccggcggcgtccggcgccaccgccctgctcctgtacggcgaggtccagatggaggtgctcgcggcgacactggccgaggacttcgggatcgaggcggagttcacgccgggccgcgtccggttcctggagcgtccggcgggcaccgacgaggccgcggaggagatgccgtggctcgaccgcacccggtacttcgcgacgatcgggctgcgcgtcgaaccgggtccgcgcggctccggcggggccttcgggtacgagacggagctcggcgcgctcccccgggccttccaccaggccgtcgaggagaccgtccacgacacgctgcggaccgggctcaccggtgcggcggtcaccgactaccgggtcacgctgatccgctccggcttcagctcgccgctcagcacggccgccgacttccgcgggctgacaccgctcgtgctgcgccgtgccctcgcccgcgcggggaccgtgctccacgagccgtaccaggccttcgaggcggaggtcccggcggacacgctggccgccgtgacggccctgctggcctcgctgggcgcggacttcaccggaacgacggggggcgacccggcctggatcgtcaccggcgagctgccggcccggcgggtgcgggaggccgagctgcggctgccggggctgacgcacggggaggcggtctggtcctcccgcccttgcgaggaccgaccgctgaaggccggaaactctgggcctggcacgggagttggcgggcattcgggtgagtag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_4378,Drugs,MEG_4378|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|OTRA,1028097903|WP_063854498.1|NG_048027|1|1|otr(A)|otr(A)|tetracycline_resistance_ribosomal_protection_protein_Otr(A) NG_048027:101-2020,4
,TTGATTTATAAAAATTACAACTGTAATATCGGAGGGTTTATTTTGAAAAGGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1409,Drugs,MEG_1409|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_79_KU607584,0
,atgaaattatggttcagtactttaaaactgaaaaaggctgcagcagtgttgcttttctcttgcgtcgcgcttgcaggatgcgctaacaatcaaacgaatgcctcgcaacctgccgagaagaatgaaaagacggagatgaaagatgattttgcaaaacttgaggaacaatttgatgcaaaactcgggatctttgcattggatacaggtacaaaccggacggtagcgtatcggccggatgagcgttttgcttttgcttcgacgattaaggctttaactgtaggcgtgcttttgcaacagaaatcaatagaagatctgaaccagagaataacatatacacgtgatgatcttgtaaactacaacccgattacggaaaagcacgttgatacgggaatgacgctcaaagagcttgcggatgcttcgcttcgatatagtgacaatgcggcacagaatctcattcttaaacaaattggcggacctgaaagtttgaaaaaggaactgaggaagattggtgatgaggttacaaatcccgaacgattcgaaccagagttaaatgaagtgaatccgggtgaaactcaggataccagtacagcaagagcacttgtcacaagccttcgagcctttgctcttgaagataaacttccaagtgaaaaacgcgagcttttaatcgattggatgaaacgaaataccactggagacgccttaatccgtgccggtgtgccggacggttgggaagtggctgataaaactggagcggcatcatatggaacccggaatgacattgccatcatttggccgccaaaaggagatcctgtcgttcttgcagtattatccagcagggataaaaaggacgccaagtatgatgataaacttattgcagaggcaacaaaggtggtaatgaaagccttaaacatgaacggcaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1294,Drugs,MEG_1294|Drugs|betalactams|Class_A_betalactamases|BLAP,564754507|WP_023857755.1|NG_051161|1|1|blaP|blaP|class_A_beta-lactamase_BlaP NG_051161:101-1024,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacagtccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcggctacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2185,Drugs,MEG_2185|Drugs|betalactams|Class_A_betalactamases|CTX,1149331617|WP_077767292.1|NG_052901|1|1|blaCTX-M-195|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-195 NG_052901:1-876,0
,atggaccggaacacggaactccacggcgaccgggtagcgctgcgaaccgttgtggacgccgacaccgacacgctccaccgcatcgttcgcgaaccggaggtcgcggcatggtggagcacgccggaggacttcgacggcatgctcgtgatcgtcctcgacagcgaggtcgtcggcgccgtccaatacgaggaggaggacgaccccgactaccggcacgcgagcatcgacctcttcctctccgcgcgccaccacggccgcggtatcggagccgagaccgtccgcacgctggcccggtggctgatcgaggtacgcggccaccaccgcctcaccatcgacccggccgccgccaacaccaccgcgatccgcagctacacccgcgtcggcttcaagccggtcggcgtactgcgcgcctacgaacgcgatccgctgactggcacctggcgcgacggcctcctgatggacctcctcgccggcgaactcacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_195,Drugs,MEG_195|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,558873518|WP_023529211.1|NG_052445|1|1|aac(6')_Strep|aac(6')_Strep|aminoglycoside_6'-N-acetyltransferase NG_052445:101-586,2
,atgcgttctaccctgctcgccttcgccctggccgtcgctcttccggccgcccacgccagcgccgccgaggcaccgctgccacaactgcgggcctataccgtggatgcgtcctggctgcagccgatagcgccgctgcaggttgccgaccacacctggcagatcggcaccgaggacctgaccgcgctgctggtgcagaccgccgagggcgcagtactgctggatggcggcatgccacagatggccggtcacctgctggacaacatgaagctgcgcggcgtggccccgcaggacctgcgattgatcctgctcagccatgcgcatgccgaccacgccggcccggtcgccgagctcaagcgtcgcaccggcgcgcatgtggcggccaatgcagaaacggcggtgctgctggcgcgcggcggcagcaacgacctgcactttggcgacggcatcacctatccgccggccagcgccgaccgcatcatcatggatggcgaagtggtcacggtgggcggcatcgcgttcaccgcgcacttcatgccagggcacaccccgggcagcaccgcctggacctggaccgacacccgcgatggcaagccggtgcgcatcgcctacgccgacagcctcagcgcaccgggttaccagctgaagggcaatccccgttatccgcgcctgatcgaggactacaagcgcagcttcgcaacggtgcgggcgctgccctgcgatctgctgctcaccccgcatccgggcgccagcaactggaactacgccgccggcagcaaggccagcaccgaggcactgacctgcaacgcctacgcggatgcggccgagaagaagttcgacgcgcagctggccaaggaaacggccggggcccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3523,Drugs,MEG_3523|Drugs|betalactams|Class_B_betalactamases|L1,1028083728|WP_063842696.1|NG_047514|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047514:1-873,0
,atgaatagaataaaagtcgcaatcatcttcggcggttgctcggaggaacatgatgtgtcggtaaaatccgcaatagaaattgctgcgaacattgatacggaaaaattcgatccgcactacatcggaattacaaaaaacggtgtatggaagctatgcaagaagccatgtacggaatgggaagccgacagtctccccgccatactctccccggataggaaaacgcatgggctgcttgtcatgaaagaaagcgaatacgaaacacggcgtattgatgtggctttcccggttttgcatggcaaatgcggggaggatggtgcgatacaggggctgtttgtattgtctggtatcccctatgtgggctgtgatattcaaagctccgcagcttgcatggacaaatcactggcctacattcttacaaaaaatgcgggcatcgccgttcccgaatttcaaattattgataaaggtgacaagccggaggcgggtgcgcttacctaccctgtctttgtgaagccggcacggtcaggttcgtcctttggcgtaaccaaagtaaacggtacggaagaacttaacgctgcgatagaagcggcaggacaatatgatggaaaaatcttaattgagcaagcgatttcggtctgtgaggtcgggtgtgcggtcatggggaacgaggatgatttgattgtcggcgaagtggatcaaatccggctgagccacggtatcttccgcatccatcaggaaaacgagccggaaaaaggctcagaaaatgcgatgattacagttcccgcagacattccggtcgaggaacgaaatcgggtgcaggaaacggcaaagaaagtatatcgggtgcttggatgcagagggcttgcccgtgttgatctttttttgcaggaggatggcggcatcgttctaaatgaggtcaataccatgcccggttttacatcgtacagccgctacccacgtatggtggccgccgcaggaatcacgcttcctgcactgattgacagcctgattacattggcgttaaagaggtga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7348,Drugs,MEG_7348|Drugs|Glycopeptides|VanB-type_resistance_protein|VANB,1028100458|WP_063856593.1|NG_048339|1|1|vanB|vanB|D-alanine--(R)-lactate_ligase_VanB NG_048339:101-1129,5
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcaccaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4645,Drugs,MEG_4645|Drugs|betalactams|Class_D_betalactamases|OXA,1391852907|WP_109545092.1|NG_057526|1|1|blaOXA-587|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-587 NG_057526:1-774,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgtatcgaacacgcttgtgaggccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacactgtttttgcgctctattggcgacgaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacaccgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1507,Drugs,MEG_1507|Drugs|betalactams|Class_A_betalactamases|CARB,686266368|WP_031847165.1|NG_048749|1|1|blaCARB-46|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-46 NG_048749:101-952,0
,atgaatcgctatatcacaatcgccctcttaattaccttcctagatgcaacaggaatgggcttaatcatgcctgtattaccaacacttttagaagagttctctgtcaaagagtctatcgccactcattatggttttatcctcgcaatctatgcgctgatgcaagttatttttgcaccaatattaggacaactctcggataaatttggcagaaaaccggtcttgattctctcattaataggcgctgtttgtgattacaccctactctcattttctagcgccttatggatgctctatctagggagaatgattgccggcatttctgctgcaacaggagccgtagcagcatcaatggtcgcagatcacacaaaaaaagcagagagaactaaatggtttggaaagttaggcgcagcttttggggcgggactcattgccggacccgctattggtggatttatcggacaatattctgcacatttcccctttatcattgccgcaattttaaatgccattgctcttatcatggtcattatcctcttccctaaagagcaatcacgcccaaaagaaatcgagcaagatcaatctaaaattcatgaaaaaaccaccatcaatgccccgctaattcatattctcaaacccgttttgctacttctcatgctgttttttacagtacaactcatcggacaaatccctgcatcaacttgggttctatttactgagtaccgttttgagtggaatacctttaacattggtttatcccttgcagggctagggttaatgcatattatctttcaggcttttgtcgcaggatatatcgcatctcgctggaaaaatgaaaccgtatttattctcggatttatactagatgcgagcgcattcttattactggcctttatctctcaagtttggctggtaattcctacattgatcttattagcaggaggaggcatcgccttaccggcattacaaggattaatctctataaagacagcagatgaacatcaaggaaagatacaaggtatcatggttagcctcactaatattaccggaataattggaccgcccatttttgcattttcctttgcaaaaacggttacaaactgggatggcacactttggctaatcggtgctgtactctatagcattttattaggtctctattttctctatcaaaagatacgcgcctataaacaacttaagtctcaaactgcttaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6966,Drugs,MEG_6966|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET31,665836803|WP_031204920.1|NG_048123|1|1|tet(31)|tet(31)|tetracycline_efflux_MFS_transporter_Tet(31) NG_048123:101-1312,4
,atggctgacgtgatcgttctcaacggtggttccagctcggggaagtccgggatcgtccggtgtctgcaggcggtcttgcctgatccgtggctggctctcgggaccgacacgctggttgacgcgatgcccgcgtccatgcaggcctctgatgcggggatcgagttcgctccggacggagaggtgatcgtcggaccggagttccggacgctggaagcggcatggatcgagggggtcgccgcgatggcccgtgcgggcgcccgggtcatcgtcgacgaggtcttcctcggcggagcggactcgcagcagcggtggcagaaggctttgcgcgacctgcgggtgctgtgggtcggcgtccgctgtgacggtgccgttgccgcaggccgtgagatcgcacgaggcgatcgggtcatcgggatggccgcgtcgcaggcggatgtggtccaccggggcgtggtctatgacctcgaggtcgacaccacacatgccgagtcgatggagtgtgcacgggccatcgccacacatgtcaggtga,antibiotic molecule,antibiotic inactivation,Phenicol,MEG_2113,Drugs,MEG_2113|Drugs|Phenicol|Chloramphenicol_phosphotransferase|CPT,499291057|WP_010982315.1|NG_051909|1|1|cpt|cpt|chloramphenicol_phosphotransferase_CPT NG_051909:101-631,6
,ATGTGCGGGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGCTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6905,Drugs,MEG_6905|Drugs|betalactams|Class_A_betalactamases|TEM,gi|313586334|gb|HQ529916.1|1-1020,0
,atgggcatcattcgcacatgtaggctcggccctgaccaagtcaaatccatgagggctgctcttgatcttttcggtcgtgagttcggagacgtagccacctactcccaacatcagccggactccgattacctcgggaacttgctccgtagtaagacattcatcgcgcttgctgccttcgaccaagaagcggttgttggcgctctcgcggcttacgttctgccaaagtttgagcaggcgcgtattgagatctatatctatgatctcgcagtctccggcgagcaccggaggcaaggcattgccaccgcgctcatcaatctcctcaagcatgaggccaacgcgcttggtgcttatgtgatctacgtgcaagcagattacggtgacgatcccgcagtggctctctatacaaagttgggcatacgggaagaagtgatgcactttgatatcgacccaagtaccgccacctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_26,Drugs,MEG_26|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,695269179|WP_032491356.1|NG_047233|1|1|aac(3)-I|aac(3)-I|AAC(3)-I_family_aminoglycoside_3-N-acetyltransferase NG_047233:101-565,2
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATGGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1985,Drugs,MEG_1985|Drugs|betalactams|Class_C_betalactamases|CMY,gi|591542892|gb|KJ207205.1|1040-2267,0
,TTGGCCAGGTTGAAGGTCGGCATCGTATTCGGGGGCTCTTCCGAAGAACACGCCGTTTCCGTCAAGTCCGCCCAGGAGGTCGCACGCAACCTCGACACCGAGAAGTACCAGCCGTTCTTCGTGGGGATCACGAAGGACGGCGCCTGGAGACTCTGCGACGGGCCAGGCCAGGACTGGGAGAACGGCGACTGCCGTCCGGTCGTGCTGTCACCGGACCGGAGCGTGCACGGGCTGCTCGTCCTGGAGCAGGGGCAGTACCGGTCGGTCCGCCTGGACGTCGTCCTTCCCGTCCTGCACGGCACCCTCGGTGAGGACGGTGCGACGCAGGGGCTGCTGGAGCTCTCCGGCATTCCGTACGTGGGCTGCGACGTCCAGAGCTCCGCCCTGTGCATGGACAAATCCCTTGCGTACGTCGTCGCCAGGAGCGCGGGGATCGCCACGCCGGATTTCTGGACCGTGACAGGAGACGAGACCATCGATCCCGGCCGGCTCACGTATCCCGTCTTCGTGAAGCCGGCCCGTTCGGGGTCGTCCTTCGGCGTCAGCAAGGTGTGCCGCCCGGAAGACCTGGCGACCGCGGTGGAGTCCGCCCGGCGGTACGACACGAAGGTGCTGATCGAAGCGGCCGTCGTCGGCAGCGAGGTCGGCTGCGCCATCCTGGGGAACGACCCCGACCTGATCGTGGGCGAGGTGGACCGCATCGCGCTCTCCCACGGATTCTTCCGGATCCACCAGGAGGAGCAGCCCGAGAACGGCTCGGAGAACTCGACGCCGGTCGTTCCCGCCGACATCCCGACGGAGAAGCGGTCGCTCGTCCAGGAGACCGCGAAGGCCGTGTACCGAGCCCTGGGATGCCGGGGGCTGTCCCGCGTGGACATGTTCCTCAAGGAGGACGGGGAAGTCGTCCTCAACGAGGTCAACACCCTGCCCGGCATGACCTCGTACAGCCGTTATCCGAGGATGATGGCGGCCGCGGGGCTGCCACTGTCCGAGGTGATCGACCGGACGCTGTCCCTGGCGTTGACGGGGAAGCTCCGATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7340,Drugs,MEG_7340|Drugs|Glycopeptides|VanA-type_resistance_protein|VANA,gi|24427162|emb|AL939117.1|54367-55407,5
,ATGAACAAAAATATAAAATATTCTCAAAACTTTTTAACGAGTGAAAAAGTACTCAACCAAATAATAAAACAATTGAATTTAAAAGAAACCGATACCGTTTACGAAATTGGAACAGGTAAAGGGCATTTAACGACGAAACTGGCTAAAATAAGTAAACAGGTAACGTCTATTGAATTAGACAGTCATCTATTCAACTTATCGTCAGAAAAATTAAAACTGAACATTCGTGTCACTTTAATTCACCAAGATATTCTACAGTTTCAATTCCCTAACAAACAGAGGTATAAAATTGTTGGGAGTATTCCTTACCATTTAAGCACACAAATTATTAAAAAAGTGGTTTTTGAAAGCCATGCGTCTGACATCTATCTGATTGTTGAAGAAGGATTCTACAAGCGTACCTTGGATATTCACCGAACACTAGGGTTGCTCTTGCACACTCAAGTCTCGATTCAGCAATTGCTTAAGCTGCCAGCGGAATGCTTTCATCCTAAACCAAAAGTAAACAGTGTCTTAATAAAACTTACCCGCCATACCACAGATGTTCCAGATAAATATTGGAAGCTATATACGTACTTTGTTTCAAAATGGGTCAATCGAGAATATCGTCAACTGTTTACTAAAAATCAGTTTCATCAAGCAATGAAACACGCCAAAGTAAACAATTTAAGTACCATTACTTATGAGCAAGTATTGTCTATTTTTAATAGTTATCTATTATTTAACGGGAGGAAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2807,Drugs,MEG_2807|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,erm(B)_22_X52632 ,7
,atgaagaaattatttgttttatgtgtgtttttgttttgtagcattactgccgcaggagagtctttgcccgatttaaaaattgaaaagcttgaagaaggtgtttatgttcatacatcgtttgaagaagttaatggttggggcgttttttctaaacacggtttggttattcttgtgaatactgacgcctatctgattgacactccattcacggctaaagatactgaaaagttagtcacctggtttgtggagcgcggctataaaatcaaaggtagcatttcctcacatttccatagcgacagcacgggtggaatagagtggcttaattctcaatcaattcccacgtatgcatctgaattaacaaatgaccttcttaaacaaaacggtaaggtacaagctaaaaactcatttagcggagttagttattggttagttaaaaataaaattgaagttttctatcccggccccgggcacactcaagataacgtagtggtttggttgcctgaaaagaaaattttatttggtgggtgctttgttaaaccgtacggtcttggaaatctcgatgacgcaaatgttgtagcatggccacattctgctgaaatattaatgtctaggtatggtaatgcaaaactggttgttccaagccatagtgacatcggagatgcgtcgctcttgaagcttacatgggagcaggctgttaaagggctaaaagaaagtaaaaaaccatcggagccaagtaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3329,Drugs,MEG_3329|Drugs|betalactams|Class_B_betalactamases|IMP,1028105506|WP_063860618.1|NG_049219|1|1|blaIMP-58|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-58 NG_049219:1-741,0
,ATGCGTTATATTCGCCTGTTGTTTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGTCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6450,Drugs,MEG_6450|Drugs|betalactams|Class_A_betalactamases|SHV,gi|30908725|gb|AY273807.1|1-861,0
,atgacgaaaatgaaccgcctggcggccgcgctgatcgccgcactgatcttgccgaccgcgcaggccgcgcagcagcaggatatcgacgccgttattcagccgctgatgaaaaaatatggcgtaccgggcatggcgatcgccgtgtcggtcgacggcaaacagcagatttacccgtatggcgtcgcctcgaagcagaccggcaaaccgatcaccgaggagacgctgttcgaagtgggctcgctgagcaaaaccttcaccgcgacgctggcggtctatgcgcagcagcagggcaagctgtcgttcaacgatccggccagccgctacctgcccgagctgcgcggcagcgccttcgacggcgtcagcctgctgaatctggcgacgcatacctccggcctgccgctgttcgtgccggacgacgtcaccaacaacgcccaactgatggcctactaccgggcctggcagccgaaacacccggcgggcagctaccgggtctattccaacctcggcatcggcatgctgggcatgatcgccgccaagagcctcgaccagccgtttatccaggcgatggaacaggggatgctgccggcgctgggcatgagccacacctacgttcaggtgccggcggtgcagatggccaactatgcgcagggttacagcaaggacgataagccggtgcgggtcaaccccggcccgctggacgccgaatcttacggcatcaagtccaacgctcgcgatctgattcgctatctggacgccaacctgcagcaggtgaaggtggcgcagccgtggcgcgacgcgctggccgcgacgcacgtcgggtattacaaggcgggcgcgttcacgcaggatctgatgtgggagaactacccgtatccggtgaaactgtcgcgtttgattgaaggcaacaacgccgggatgatcatgaacggcacgccggccaccgccatcacgccgccgcagccggaattgcgcgccggttggtataacaaaaccggctccaccggcggtttctccacctacgcggtatttatcccggcgaagaatatcgccgtggtgatgctggccaacaagtggttcccgaacgacgatcgcgttgaagcggcttaccacatcatccaggcgctggagaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_6566,Drugs,MEG_6566|Drugs|betalactams|Class_C_betalactamases|SRT,1028083976|WP_063842944.1|NG_047548|1|1|blaSRT|blaSRT|SRT/SST_family_class_C_beta-lactamase NG_047548:1-1137,0
,atgcagtactccattcgctcggttcgtgtttcggatacatctgattggttacgccttcgcaatctcctgtgggaaggggatgaccacgaaaccgagatcgcccagtttttcgccggagccctggccgagcccaacgaagtgctggtagcccatgatgatgcgggggccgttgttgggcatgtcgagttatccatccgcgaggatgtcgcagggctggaaggcatcagagcgggctatatcgaaggcctgtacatcgaggaggcccatcgctcgtccagcgtcgcgacgcagttactacggcactccgagcaatgggcccaaagtcagggatgccgggcgtttgcatcggatcgagaggatcgcctgatcatccataagcggttttctgtgagtccgctttctaacccttcattccagcggaccgccttcggcggccgctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_179,Drugs,MEG_179|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,917771860|WP_052285801.1|NG_047319|1|1|aacA34|aacA34|aminoglycoside_6'-N-acetyltransferase_AacA34 NG_047319:101-541,2
,ATGAAAAAAATTGCCGTTTTATTTGGAGGGAATTCTCCAGAATACTCAGTGTCACTAACCTCAGCAGCAAGTGTGATCCAAGCTATTGACCCGCTGAAATATGAAGTAATGACCATTGGCATCGCACCAACAATGGATTGGTATTGGTATCAAGGAAACCTCGCGAATGTTCGCAATGATACTTGGCTAGAAGATCACAAAAACTGTCACCAGCTGACTTTTTCTAGCCAAGGATTTATATTAGGAGAAAAACGAATCGTCCCTGATGTCCTCTTTCCAGTCTTGCATGGGAAGTATGGCGAGGATGGCTGTATCCAAGGACTGCTTGAACTAATGAACCTGCCTTATGTTGGTTGCCATGTCGCTGCCTCCGCATTATGTATGAACAAATGGCTCTTGCATCAACTTGCTGATACCATGGGAATCGCTAGTGCTCCCACTTTGCTTTTATCCCGCTATGAAAACGATCCTGCCACAATCGATCGTTTTATTCAAGACCATGGATTCCCGATCTTTATCAAGCCGAATGAAGCCGGTTCTTCAAAAGGGATCACAAAAGTAACTGACAAAACAGCGCTCCAATCTGCATTAACGACTGCTTTTGCTTACGGTTCTACTGTGTTGATCCAAAAGGCGATAGCGGGTATTGAAATTGGCTGCGGCATCTTAGGAAATGAGCAATTGACGATTGGTGCTTGTGATGCGATTTCTCTTGTCGACGGTTTTTTTGATTTTGAAGAGAAATACCAATTAATCAGCGCCACGATCACTGTCCCAGCACCATTGCCTCTCGCGCTTGAATCACAGATCAAGGAGCAGGCACAGCTGCTTTATCGAAACTTGGGATTGACGGGTCTGGCTCGAATCGATTTTTTCGTCACCAATCAAGGAGCGATTTATTTAAACGAAATCAACACCATGCCGGGATTTACTGGGCACTCCCGCTACCCAGCTATGATGGCGGAAGTCGGGTTATCCTACGAAATATTAGTAGAGAAATTGATTGCACTGGCAGAGGAGGACAAACGATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7363,Drugs,MEG_7363|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,(Gly)VanC1:EU151769:31-1062:1032,5
,ATGTCCCGCCTTCTCTTATCCGGCCTGCTCGGCGCAGGCCTGCTGTTCTCGCTGCCGGCCAGCGCCGCCACCGGCTGCTTTCTCTATGCCGACGGCAACGGCCAGACCCTCTCCAGCGAAGGGGATTGTTCAAGCCAGCTGCCACCCGCGTCCACCTTCAAGATCCCGCTGGCGCTGATGGGCTACGACAGCGGCTTTCTGGTGGATGAAGAACACCCGGCACTGCCCTTCAAACCCGGTTACGACGACTGGCTGCCCGCCTGGCGGGAGACCACCACTCCGCGCCGCTGGGAAACCTACTCGGTGGTCTGGTTCTCCCAGCAGATCACCGAATGGCTGGGGATGGAGCGCTTCCAGCAGTACGTCGACCGTTTTGACTACGGCAACCGGGATCTCTCCGGCAATCCTGGCAAGCACGACGGCCTGACCCAGGCCTGGCTCAGTTCCAGCCTTGCCATCAGTCCACAGGAGCAGGCCCGCTTCCTCGGCAAGATGGTGAGCGGCAAGCTGCCGGTGTCGGCGCAAACCCTGCAGTACACCGCCAACATCCTCAAGGTGAGCGAGATCGACGGCTGGCAGATCCACGGCAAGACCGGCATGGGCTACCCGAAGAAGCTGGATGGCAGCCTCAACCGGGAGCAGCAGATCGGCTGGTTCGTCGGCTGGGCCAGCAAGCCGGGCAAACAGCTCATCTTCGTCCATACCGTGGTGCAGAAACCCGGCAAACAGTTCGCCTCGCTCAAGGCCAAGGAAGAGGTGCTGGCCGCCCTGCCGGCCAAACTGAAAACCCTGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5218,Drugs,MEG_5218|Drugs|betalactams|Class_D_betalactamases|OXA,gi|333448873|gb|HQ586946.1|1-795,0
,atgcaatttaacaaaatttcttgcttacttttatcccctctttttatttttaatacctcaatttatgcagggaatacaccaaaagagcaagaaattaagaaactggttgatcaaaattttaaaccgttattagaaaaatatgatgtgcctgggatggctgttggcatcatccaaaataataaaaagtatgaaacgtattatggtctacaatccgttcaagataaaaaagccgtaaatagcagtaccatttttgagctcggttcagttagtaaattatttactgctacagctggtggatatgccaaaacaaaaggaacaatttcttttaaagacacacccggaaaatattggaaagaattaaaaaacacaccgattgaccaagttaacttacttcaacttgctacttatacaagtggcaaccttggcttacagtttccagatgaagtccaaacagatcagcaagttttaacttttttcaaagactggaagcctaaaaactcaatcggtgaatatcgacaatattcaaatccaagcattggtttatttggaaaagttgttgctttgtctatgaataaaccttttgaccaagtcttagaaaaaaccatttttccagatcttggcttaaaacatagctatgtaaatgtgcctaaaactcaaatgcaaaactatgcatttggctataaccaagaaaatcagccgattcgagttaaccccggcccgctagatgcacctgcgtacggcgttaaatcgaccttacctgatatgctgagtttcgttaatgccaacctcaacccacaaaaatatccggcagatattcaacacgcaattaatgaaacacataaaggtttctaccaagtaggtacgatgtatcaagcattaggttgggaagagttctcttatccagcaccgttacagactttattagacagtaattcagaacaaatcgtgatgaagcctaataaagtgacagctatttcaaatgaaccttcagttaagatgttccacaaaactggttcaaccaacggttttggaacctatgtcgtgtttattccaaaagaaaatattggtttagtcatgttaaccaataaacgtattcccaatgaagaacgcattaaagcagcgtatgcagtgttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_516,Drugs,MEG_516|Drugs|betalactams|Class_C_betalactamases|ADC,491449431|WP_005307218.1|NG_064690|1|1|blaADC-134|blaADC|class_C_beta-lactamase_ADC-134 NG_064690:101-1252,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtgggttggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4480,Drugs,MEG_4480|Drugs|betalactams|Class_D_betalactamases|OXA,1509794591|WP_122630900.1|NG_062320|1|1|blaOXA-698|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-698 NG_062320:27-851,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacctgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5594,Drugs,MEG_5594|Drugs|betalactams|Class_C_betalactamases|PDC,1393270440|WP_109791185.1|NG_057583|1|1|blaPDC-251|blaPDC|class_C_beta-lactamase_PDC-251 NG_057583:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacctacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5524,Drugs,MEG_5524|Drugs|betalactams|Class_C_betalactamases|PDC,1001067679|WP_061199990.1|NG_054970|1|1|blaPDC-184|blaPDC|class_C_beta-lactamase_PDC-184 NG_054970:1-1194,0
,AAAAATGATTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGTATTCATGTTGTTGTTATTTCGTCTCTTACAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGACGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2394,Drugs,MEG_2394|Drugs|betalactams|Class_A_betalactamases|CTX,gi|337729566|gb|JF966749.1|1-1033,0
,ATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAATCGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6940,Drugs,MEG_6940|Drugs|betalactams|Class_A_betalactamases|TEM,gi|695211221|ref|NG_036036.1|1-1080 gi|479327147|gb|KC354802.1|11753-11985,0
,ATGAATAGAGTAAAAGTTGCAATCCTGTTTGGGGGTTGCTCGGAGGAGCATGACGTTTCGGTTAAATCTGCAAGAGAGATTGCCGCTAACATTGACAACGAAAAATACGAGCCGTTATACATTGGAATTACGAAATTCGGTGTTTGGAAAATGTGCGAAAAACCGTGCGCGGAATGGGAAAACAGCAATTGCTATTCAGCCGTACTCTCGCCGGATAAAAAAATGCACGGTTTGCTTGTTAAAAAGAACCATGAATATGAAATCCACCACGTTGATGTAGCATTTTCGGTTTTGCACGGCAAGTCGGGTGAAGATGGATCAATACAAGGTCTGTTTGAATTGTCCGGTATCCCCTATGTGGGCTGCGATATTCAAAGCTCCGCGATTTGTATGGACAAATCGCTGACATACACAATTGCGAAAAACGCTGGCATAGCTACTCCTGATTTTTGGGTTATTAATAAAGACGATAAGCCGGCGATAGATGCGTTTACCTATCCTGTTTTTGTTAAGCCGGCGCGTTCAGGCTCATCTTATGGCGTGAAAAAAGTCAATGGCGCAGACGAATTGGACGCCGCAATTGAATCGGCAAGACAATATGACAGCAAAATCTTAATTGAGCAGGCTGTTTTGGGCTGTGAGGTCGGTTGTGCCGTATTGGGAAACAGTTCCGAGTTGATTGTTGGCGAGGTGGACCAAATCAGGCTGCAGCACGGTATCTTTCGTATTCATCAGGAAGCCGAGCCGGAAAAAGGCTCTGAAAACGCAGTTATAACCATTCCCGCAGACCTGTCGGTAGAGGTGCGAGGACGGATACAGGAAACGGCAAAAAAAATATATAAGGCGCTCGGTTGTAGAGGTCTTTCCCGTGTTGATATGTTTTTACAAGATAACGGCAGCATTGTACTTAACGAAGTCAATACCCTGCCTGGTTTCACGTCATACAGCCGTTATCCCCGTATGATGGTCGCTGCAGGTATAACGCTTCCCGAACTGATTGACCGCCTGATCGTATTAGCATTAAAGGGATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7342,Drugs,MEG_7342|Drugs|Glycopeptides|VanA-type_resistance_protein|VANA,gi|50082936|gb|AY648035.1|1-1032 gi|66731632|gb|DQ018710.1|6070-7101,5
,TGTTATCTCCCTGTTAGCCACCCTGCCACTGGCGGTAGACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGCTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTACCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGCACTGAATGAGGCGCTTCCCGGCGACGCGCGCGACACCACCACCCCGGCCAGCATGGCCGCCACGCTGCGCAAACTACTGACCGCGCAGCATCTGAGCGCCCGTTCGCAACAGCAACTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGCCGGGCTGGTTTATCGCCGACAAAACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAACCGGAGCGCATTGTGGTGATCTATCTGCGGGATACCCCGGCGAGTATGGCCGAGCGTAATCAACAAATCGCCGGGATCGGCGCGGCGCTGAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3565,Drugs,MEG_3565|Drugs|betalactams|Class_A_betalactamases|LEN,gb|AY130287|+|0-822|ARO:3002472|LEN-4 [Klebsiella pneumoniae] ,0
,atgagcaagttatctgtattctttatatttttgttttgcagcattgctaccgcagcagagtctttgccagatttaaaaattgaaaagcttgatgaaggcgtttatgttcatacttcgtttgaagaagttaacgggtggggcgttgttcctaaacatggtttggtggttcttgtaaatgctgaggcttatctaattgacactccatttacggctaaagatactgaaaagttagtcacttggtttgtggagcgtggctataaaataaaaggcagtatttcctctcattttcatagcgacagcacgggcggaatagagtggcttaattctcgatctatccccacgtatgcatctgaattaacaaatgaactgcttaaaaaagacggtaaggttcaagccacaaattcatttagcggagttaactattggctagttaaaaataaaattgaagttttttatccaggcccgggacacactccagataacgtagtggtttggctgcctgaaaggaaaatattattcggtggttgttttattaaaccgtacggtttaggcaatttgggtgacgcaaatatagaagcttggccaaagtccgccagattattaaagtccaaatatggtaaggcaaaactggttgttccaagtcacagtgaagttggagacgcatcactcttgaaacttacattagagcaggcggttaaaggattaaacgaaagtaaaaaaccatcaaaaccaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3332,Drugs,MEG_3332|Drugs|betalactams|Class_B_betalactamases|IMP,1463920497|WP_116786839.1|NG_061626|1|1|blaIMP-79|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-79 NG_061626:1-741,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgtgtcgaacacgcttgtgaggctgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgatctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcaaaaccgggcgataagcgagacaccacaacgcctaacgccatggtaaacaccctacataccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacaccgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1509,Drugs,MEG_1509|Drugs|betalactams|Class_A_betalactamases|CARB,647428388|WP_025788060.1|NG_048744|1|1|blaCARB-41|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-41 NG_048744:1-852,0
,ATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGCTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTTGGCATTGAAATTCGCCACTGTCGTGCGCAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACTCGCACCTGGTTTTGCAGCGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAATGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTTTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGCGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGTTGCTCATGGAACGTCTTGGCATCGCGATTATTGGCTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5993,Drugs,MEG_5993|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gi|161579479|gb|EU273756.1|37-681 gi|161579477|gb|EU273755.1|37-681,3
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcataattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtccgtctgaactttgcggaaatgttttcaaaattgaatatacaaaaaaaagacaacgtcttgcatatatacgcctttatagtggagtactacatttacgagattcggttagagtatcagaaaaagaaaaaataaaagttacagaaatgtatacttcaataaatggtgaattatgtaagattgatagagcttattctggagaaattgttattttgcaaaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtctatctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcgaatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcgatgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtaggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7103,Drugs,MEG_7103|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,568064907|WP_024052575.1|NG_048249|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048249:1-1920,4
,ATGGGTCTCGGCCTCATCATGCCCGTCCTTCCGACGCTTCTGCGTGAGCTTGTGCCAGCAGAGCAGGTCGCTGGACACTATGGTGCCTTGCTGTCGCTCTATGCATTGATGCAGGTCGTCTTCGCGCCCATGCTTGGACAGCTTTCGGATTCTTACGGTCGGCGTCCGGTACTTCTGGCTTCTCTTGCAGGAGCCGCAGTCGATTACACGATTATGGCATCAGCGCCGGTCTTATGGGTGCTCTATATCGGCCGACTCGTGTCCGGCGTCACGGGCGCAACCGGAGCTGTAGCAGCCTCAACCATTGCCGATTCGACGGGGGAAGGTTCTCGCGCACGCTGGTTCGGCTACATGGGGGCCTGTTATGGGGCGGGCATGATTGCCGGGCCAGCACTTGGTGGCATGCTCGGTGGTATCTCTGCTCATGCCCCGTTTATCGCCGCCGCCCTTCTCAACGGGTTCGCGTTCCTGCTTGCCTGCATTTTCCTCAAGGAGACTCATCACAGCCATGGCGGGACCGGAAAGCCGGTTCGCATCAAACCATTCGTTCTGTTACGGCTGGATGATGCATTGCGCGGGCTAGGTGCGCTTTTCGCAGTTTTCTTCATTATTCAACTGATCGGCCAAGTGCCTGCAGCCCTATGGGTCATATATGGCGAGGACCGTTTTCAGTGGAACACCGCGACCGTTGGTTTGTCGCTCGCGGCGTTTGGGGCAACACATGCGATCTTCCAAGCGTTTGTTACCGGCCCGCTTTCAAGCCGGCTTGGAGAGCGGCGCACGCTGCTGTTTGGCATGGCTGCGGATGCGACTGGCTTCGTTCTTCTGGCTTTTGCCACGCAGGGATGGATGGTGTTCCCGATTCTGTTGCTGCTTGCCGCCGGGGGTGTTGGCATGCCGGCCTTGCAGGCAATGCTCTCAAACAATGTCAGCAGTAACAAGCAAGGGGCTTTGCAAGGAACGCTAACGAGCCTCACCAATCTAAGCTCTATCGCAGGACCGCTTGGCTTCACAGCACTCTATTCTGCCACCGCCGGGGCATGGAACGGTTGGGTTTGGATTGTCGGCGCGATCCTCTATTTAATATGTCTGCCAATACTACGCAGACCATTCGCAACTTCATTGTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7081,Drugs,MEG_7081|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETG,gi|828977575|gb|CP011649.1|65355-64228 gi|828916727|gb|CP011583.1|58511-59638 gi|828911534|gb|CP011580.1|65355-64228 gi|828895865|gb|CP011571.1|44953-46080 gi|700676355|gb|KM234279.1|32679-33806 gi|777182157|emb|LN829403.1|65997-67124 gi|761589803|dbj|AP014651.1|321502-320375 gi|761589803|dbj|AP014651.1|5297573-5298700 gi|704485843|gb|KJ186153.1|32673-33800 gi|704485786|gb|KJ186152.1|32679-33806 gi|674252391|gb|CP008739.2|6816903-6818030,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggggctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5605,Drugs,MEG_5605|Drugs|betalactams|Class_C_betalactamases|PDC,1028110195|WP_063864565.1|NG_049875|1|1|blaPDC-108|blaPDC|class_C_beta-lactamase_PDC-108 NG_049875:1-1194,0
,atgaaaaagataaaaattgttccacttattttaatagttgtagttgtcgggtttggtatatatttttatgcttccaaagataaagaaattaataatactattgatgcaattgaagataaaaatttcaaacaagtttataaagatagcagttatatttctaaaagcgataatggtgaagtagaaatgactgaacgtccgataaaaatatataatagtttaggcgttaaagatataaacattcaggatcgtaaaataaaaaaagtatctaaaaataaaaaacgagtagatgctcaatataaaattaaaacaaactacggtaacattgatcgcaacgttcaatttaattttgttaaagaagatggtatgtggaagttagattgggatcatagcgtcattattccaggaatgcagaaagaccaaagcatacatattgaaaatttaaaatcagaacgtggtaaaattttagaccgaaacaatgtggaattggccaatacaggaacagcatatgagataggcatcgttccaaagaatgtatctaaaaaagattataaagcaatcgctaaagaactaagtatttctgaagactatatcaaacaacaaatggatcaaaattgggtacaagatgataccttcgttccacttaaaaccgttaaaaaaatggatgaatatttaagtgatttcgcaaaaaaatttcatcttacaactaatgaaacagaaagtcgtaactatcctctaggaaaagcgacttcacatctattaggttatgttggtcccattaactctgaagaattaaaacaaaaagaatataaaggctataaagatgatgcagttattggtaaaaagggactcgaaaaactttacgataaaaagctccaacatgaagatggctatcgtgtcacaatcgttgacgataatagcaatacaatcgcacatacattaatagagaaaaagaaaaaagatggcaaagatattcaactaactattgatgctaaagttcaaaagagtatttataacaacatgaaaaatgattatggctcaggtactgctatccaccctcaaacaggtgaattattagcacttgtaagcacaccttcatatgacgtctatccatttatgtatggcatgagtaacgaagaatataataaattaaccgaagataaaaaagaacctctgctcaacaagttccagattacaacttcaccaggttcaactcaaaaaatattaacagcaatgattgggttaaataacaaaacattagacgataaaacaagttataaaatcgatggtaaaggttggcaaaaagataaatcttggggtggttacaacgttacaagaaatgaagtggtaaatggtaatatcgacttaaaacaagcaatagaatcatcagataacattttctttgctagagtagcactcgaattaggcagtaagaaatttgaaaaaggcatgaaaaaactaggtgttggtgaagatataccaagtgattatccattttataatgctcaaatttcaaacaaaaatttagataatgaaatattattagctgattcaggttacggacaaggtgaaatactgattaacccagtacagatcctttcaatctatagcgcattagaaaataatggcaatattaacgcacctcacttattaaaagacacgaaaaacaaagtttggaagaaaaatattatttccaaagaaaatatcaatctattaactgatggtatgcaacaagtcgtaaataaaacacataaagaagatatttatagatcttatgcaaacttaattggcaaatccggtactgcagaactcaaaatgaaacaaggagaaactggcagacaaattgggtggtttatatcatatgataaagataatccaaacatgatgatggctattaatgttaaagatgtacaagataaaggaatggctagctacaatgccaaaatctcaggtaaagtgtatgatgagctatatgagaacggtaataaaaaatacgatatagatgaataa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3776,Drugs,MEG_3776|Drugs|betalactams|Penicillin_binding_protein|MECA,1028095789|WP_063852677.1|NG_047947|1|1|mecA-ceftar|mecA-ceftar|ceftaroline-resistant_PBP2a_family_peptidoglycan_transpeptidase_MecA NG_047947:1-2007,0
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5698,Drugs,MEG_5698|Drugs|betalactams|Class_C_betalactamases|PDC,730339926|WP_033990638.1|NG_049877|1|1|blaPDC-11|blaPDC|class_C_beta-lactamase_PDC-11 NG_049877:1-1194,0
,atgtccgccacgctccacgacaccgcagcggatcgtcggaaggccacccgccgcgaatggatcggcctggccgtggtcgccctgccgtgcctggtctacgccatggacctcacggtgctgaacctggcgctgccggtgctcagccgtgaactgcagccctccagcgcccagcttctctggatcctggacatctacggcttcttcgtcgccggcttcctgatcaccatgggcacgctgggcgaccgcatcggccggcgccggctgttgttgatcggcgcggcgttcttcgcattcgcctcggtgttcgcggcgctggccgataccgccgcgctgttgatcgcggcgcgcgccttgctcggcctggccggcgccaccatcgcgccgtccaccatggcgctggtccgcaacatgttccacgacccgcgccagcgccagttcgccatcggcgtgtggatcgccgcgttttcgctgggcagcgcgatcggtccgctggtcggcggcgtgttgctggagttcttccactggggcgccgtgttctggctcaacgtgccggtgatgctgctgacgctggcgctcggccctcgcttcctgcccgagtatcgtgatccggacgcggggcacctggacctggccagcgtgctgctgtcgctggcggcggtgctgctgacgatctacgggctcaagcagttggccgagcatggagcgggcctcgcctcgatggctgcgctgctggccgggctggcggtcggggcgctgttcctgcgccgccagggccacatcgcctacccgctgctggacctgcggctgttcgcgcacgcgccgttccgcgcggcgctggcggcgtatgcgctggccgcgctggccatgttcggcgtctacatcttcatgacgcagtacctgcagctcgtgctggggctgtcgccgctgcaggccgggctggccacgctgccctggtccctgtgcttcgtcatcggttcgctgttgtcgccgcagctcgcggcgcgctggccggcggcgcgcatcctcgtcgtgggcctgtcggcagcggcgttcggcttcgccgtgctggggctggggcagggcctgtggtggctggtgccggccacgatcgtcatgggcctgggcctggcgccggtgttcaccatcggcaacgagatcatcatcaccagcgcgccgtccgagcgcgcgggcgcggcctcggccttgtcggagacggtgtccgaattcagcggcgcgctgggcatcgcgctgttcggcagcgtcggcctggtggtctaccggcaggcgctgaccagcgcggcgctgcccggcctgccggccgatgcgctgcaggcggccggtgcctcgctcgggggcgccgtgcacctggccgacaccctgccggcgtggcagggcgcggccttgctggcggccgcacgcgcgggcttcaccgatgcgctgcaggccacggcctgggccggcgcggtgctggtgctggtggccgctgggctggtggcgcgcctgctgcgcaagcgcccagcgctcgcatctggttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Fluoroquinolones,MEG_5863,Drugs,MEG_5863|Drugs|Fluoroquinolones|Quinolone_active_efflux|QEPA,1039291348|WP_064768701.1|NG_062230|1|1|qepA7|qepA|fluoroquinolone_efflux_MFS_transporter_QepA7 NG_062230:101-1636,3
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_867,Drugs,MEG_867|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502171|WP_071846322.1|NG_052405|1|1|aadA8|aadA8|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA8 NG_052405:101-892,2
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGTCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATTACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTCCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1967,Drugs,MEG_1967|Drugs|betalactams|Class_C_betalactamases|CMY,gi|388564855|gb|JQ733578.1|1008-2235,0
,ATGTCCCGCCTGCTTCTCTCCAGCCTGCTGGCCACCGGTCTGCTCGCAGCCCTGCCTGCCTCCGCCGCCAGCGGCTGCTTTCTCTATGCTGACGGCAACGGCCAGACTCTCTCCAGCGAAGGGGACTGCTCCAGCCAGCTACCGCCCGCCTCCACCTTCAAGATCCCGCTGGCGCTGATGGGCTATGACAGCGGCTTTCTGGTAGATGAAGAGCATCCGGCACTGCCCTTCAAACCGGGTTACGACGACTGGCTGCCCGCCTGGCGCGAAACCACTACCCCGCGCCGCTGGGAAACCTACTCGGTGGTCTGGTTCTCCCAGCAGATCACCGAATGGCTGGGGATGGAGCGTTTCCAGCAGTATGTCGACCGCTTCGACTACGGCAACCGGGATCTCTCCGGCAATCCGGGCAAGCATGACGGTCTGACTCAGGCCTGGCTCAGCTCCAGCCTCGCCATCAGCCCGGAGGAGCAGGCCCGCTTCCTCGGCAAAATGGTGAGCGGCAAGCTGCCTGTTTCGGCGCAGACCCTGCAGTACACTGCCAATATCCTCAAGGTGAGCGAGATCGACGGCTGGCAGATCCACGGCAAGACCGGCATGGGCTACCCGAAGAAGCTGGATGGCAGCCTCAACCGCGATCAGCAGATCGGCTGGTTCGTCGGCTGGGCCAGCAAACCGGGCAAGCAGCTGATCTTCGTCCATACCGTGGTGCAAAAGCCCGGCAAGCAGTTCGCCTCCCTCAAAGCGAAAGAAGAGGTGCTGGCCGCCCTGCCGGCCAAACTGAAAACCCTGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5204,Drugs,MEG_5204|Drugs|betalactams|Class_D_betalactamases|OXA,gi|117558854|gb|CP000462.1|4713960-4714754 gi|1072324|emb|X80276.1|1-795,0
,atgaagcacatccgcctcgcctgcgtcgcggccggactggtcgcggccgcatcctccgtcagcgccatcggcgccgactggaacgcgccgcaggaaccgttcgccctgttcggcaacagctactacgtcggcccgcacggcgtggcctcggtcttgatcacgtcgaatcagggtcacatcctgatcgacggcggcagcgacaaatcgccgccgcagatcgccgcgcgcatccgccagctcggcttcaagccggaagacatccgcttcatcctggtctcgcacgagcacatcgaccatgcgggcggtgtcgccgagctgcagcgcctgtcgaacgccgaggtgctggccggcgccgccgcggtgccggtgctgcatagcggcgaggccggtcgcaacgatccgcaatacggcggcctgccgaagatggcgccggtggcgcgggtgcgcgcggtgcgcgacggcgaggtggtcaaactcgggccgctggcggtgacgatgcacgccacgccgggccatacgcagggtggcgccagctggacctggcaatcaaacgaaggcggacgcacggccaacatggtgtatgccgacagcctgacggcgttcggatccgggggctttcgctacagcggcgatgcgcgctatccgagcgcgcgcgccgacgtcgagcgatcgatcgcgaaggtcgccgcgctgccgtgcgacatcctggtgtcggcgcatccggaagtgagcgagctgtggacccggtacgagcggcgcgcggcgcaaggcaacgccgcgttcatcgacgccggcgcctgcaaggcctatgccgtcaaggcccgcgtgaagctgcaggaacaactggccagggaaacggccaagccatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4062,Drugs,MEG_4062|Drugs|betalactams|Class_B_betalactamases|MSI,1104448622|WP_071766402.1|NG_049323|1|1|blaMSI-1|blaMSI-1_fam|subclass_B3_metallo-beta-lactamase_MSI-1 NG_049323:101-970,0
,TTGATTTATAGAAATTACAACTGTAATATTGGAGGGTATATTTTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1411,Drugs,MEG_1411|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_138_CP003979,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatccccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1831,Drugs,MEG_1831|Drugs|betalactams|Class_C_betalactamases|CMY,1201190429|WP_087587949.1|NG_054964|1|1|blaCMY-153|blaCMY|class_C_beta-lactamase_CMY-153 NG_054964:1-1146,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccagggcaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5548,Drugs,MEG_5548|Drugs|betalactams|Class_C_betalactamases|PDC,1034011142|WP_064484006.1|NG_050797|1|1|blaPDC-141|blaPDC|class_C_beta-lactamase_PDC-141 NG_050797:1-1194,0
,atgcgttttaccctgctcgccttcgccctggccgtcgcgcttccggccgcccacgccagcgccgccgaggcaccgctgccacaactgcgggcctataccgtggatgcgtcctggctgcagccgatggcgccgctgcaggttgccgaccacacctggcagatcggcaccgaggacctgaccgcgctgctggtgcagaccgccgagggcgcagtactgctggatggcggcatgccacagatggccggtcacctgctggacaacatgaaactgcgcggcgtggccccgcaggacctgcgattgatcctgctcagccatgcgcatgccgaccacgccggcccggtcgccgagctcaagcgtcgcaccggcgcgcatgtggcggccaatgcagaaacggcggtgctgctggcgcgcggcggcagcaacgacctgcactttggcgacggcatcgcctatccgccggccagcgccgaccgcatcatcatggatggcgaagtggtcacggtgggcggcatcgcattcaccgcgcacttcatgccggggcacaccccgggcagcaccgcctggacctggaccgacacccgcgatgggaagccggtgcgcatcgcctacgccgacagcctgagtgcaccgggttaccagctgaagggcaatccccgttatccgcgcctgatcgaggactacaagcgcagcttcgcaacggtacgggcgctgccctgcgatctgctgctcaccccgcatccgggcgccagcaactggaactatgccgccggcagcaaggccagcgccgaggcactgacctgcaatgcctacgcggatgcggccgagaagaagttcgacgcgcagttggccagggaaacggccgggacccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3528,Drugs,MEG_3528|Drugs|betalactams|Class_B_betalactamases|L1,1028083724|WP_063842692.1|NG_047510|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047510:1-873,0
,TCCAATCGGCTTTTTCTTCAGCATACTTTTTGAAACACTACCAAATTTTAAAGTTGTATATCATGAAATTATTAAAAATATTGAGTTTAGTTTGCTTAAGCATAAGTATTGGGGCTTGTGCTGAGCATAGTATGAGTCGAGCAAAAACAAGTACAATTCCACAAGTGAATAACTCAATCATCGATCAGAATGTTCAAGCGCTTTTTAATGAAATCTCAGCTGATGCTGTGTTTGTCACATATGATGGTCAAAATATTAAAAAATATGGCACGCATTTAGACCGAGCAAAAACAGCTTATATTCCTGCATCTACATTTAAAATTGCCAATGCACTAATTGGTTTAGAAAATCATAAAGCAACATCTACAGAAATATTTAAGTGGGATGGAAAGCCACGTTTTTTTAAAGCATGGGACAAAGATTTTACTTTGGGCGAAGCCATGCAAGCATCTACAGTGCCTGTATATCAAGAATTGGCACGTCGTATTGGTCCAAGCTTAATGCAAAGTGAATTGCAACGTATTGGTTATGGCAATATGCAAATGGGCACGGAAGTTGATCAATTTTGGTTGAAAGGGCCTTTGACAATTACACCTATACAAGAAGTAAAGTTTGTGTATGATTTAGCCCAAGGGCAATTGCCTTTTAAACCTGAAGTTCAGCAACAAGTGAAAGAGATGTTGTATGTAGAGCGCAGAGGGGAGAATCGTCTATATGCTAAAAGTGGCTGGGGAATGGCTGTAGACCCGCAAGTGGGTTGGTATGTGGGTTTTGTTGAAAAGGCAGATGGGCAAGTGGTGGCATTTGCTTTAAATATGCAAATGAAAGCTGGTGATGATATTGCTCTACGTAAACAATTGTCTTTAGATGTGCTAGATAAGTTGGGTGTTTTTCATTATTTATAAGAATTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5259,Drugs,MEG_5259|Drugs|betalactams|Class_D_betalactamases|OXA,gi|94960154|gb|DQ519090.1|1-911 gi|300244960|gb|GU911349.1|6390-6476 gi|300244960|gb|GU911349.1|2423-2379 gi|971493847|gb|CP010351.1|395920-395964 gi|827342761|gb|KR055667.1|3539-3495 gi|442769248|gb|JX101647.1|56497-56541 gi|544205277|gb|KF208466.1|2584-2540 gi|522376232|gb|CP003848.1|48892-48848 gi|441494717|gb|JX968506.1|589-633 gi|695226605|ref|NG_041543.1|2470-2426 gi|695226596|ref|NG_041542.1|4614-4570,0
,atgcgcttcattcacgcactattcctggcagggatcgctcactctgcatctgcgtcggaaaacttaaccttcaggaccgatcttgagaagctagagcgcgagaaagcagctgagatcggtgttgcgatcgtcgatccccaaggacagatcgtcgcgggccaccgaatcgagcagcgttttgcaatgtgctctacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcgtacgggcgggacatgatcgtcaaatggtctcctgccgcggagcggtttctcgcatcgggacatatgacggttctcgaggcagcgcaagcggcggtgcagctcagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccggagatgggcgacaacacacctggcgacctcagagatacaaccacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgcccacctcgacccacacaattgagaggtggctgatcggaaaccaaacgggagacgcgacattacgagcgggttttcctaaagattgggttattggagagaaaaccggcacctgcgccaacgggggccggaacgacattgggttttttaaagcccaggacagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgaacaacgtgacgaattagttgcctctgtcggtcaagttattacgcaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3100,Drugs,MEG_3100|Drugs|betalactams|Class_A_betalactamases|GES,1062509491|WP_069280709.1|NG_051512|1|1|blaGES-32|blaGES|class_A_beta-lactamase_GES-32 NG_051512:1-864,0
,TTGAATACATACGAACAAATTAATAAAGTGAAAAAAATACTTCGGAAACATTTAAAAAATAACCTTATTGGTACTTACATGTTTGGATCAGGAGTTGAGAGTGGACTAAAACCAAATAGTGATCTTGACTTTTTAGTCGTCGTATCTGAACCATTGACAGATCAAAGTAAAGAAATACTTATACAAAAAATTAGACCTATTTCAAAAAAAATAGGAGATAAAAGCAACTTACGATATATTGAATTAACAATTATTATTCAGCAAGAAATGGTACCGTGGAATCATCCTCCCAAACAAGAATTTATTTATGGAGAATGGTTACAAGAGCTTTATGAACAAGGATACATTCCTCAGAAGGAATTAAATTCAGATTTAACCATAATGCTTTACCAAGCAAAACGAAAAAATAAAAGAATATACGGAAATTATGACTTAGAGGAATTACTACCTGATATTCCATTTTCTGATGTGAGAAGAGCCATTATGGATTCGTCAGAGGAATTAATAGATAATTATCAGGATGATGAAACCAACTCTATATTAACTTTATGCCGTATGATTTTAACTATGGACACGGGTAAAATCATACCAAAAGATATTGCGGGAAATGCAGTGGCTGAATCTTCTCCATTAGAACATAGGGAGAGAATTTTGTTAGCAGTTCGTAGTTATCTTGGAGAGAATATTGAATGGACTAATGAAAATGTAAATTTAACTATAAACTATTTAAATAACAGATTAAAAAAATTATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1007,Drugs,MEG_1007|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT9,gi|814617358|gb|KM009065.1|5135-4383 gi|469521017|gb|KC747117.1|291-1043 gi|410110450|gb|JX964749.1|8154-7402 gi|385137449|gb|JQ776640.1|4223-4975 gi|319919358|gb|HQ122651.1|2232-2984 gi|262478123|gb|GU126429.1|1367-2119 gi|237871515|gb|FJ946915.1|2743-3495 gi|219718108|gb|FJ410919.1|3268-4020 gi|219718104|gb|FJ410918.1|3511-4263 gi|219718101|gb|FJ410917.1|1840-2592,2
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTATCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAACAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1441,Drugs,MEG_1441|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_130_AHKZ01000073,0
,ATGAATAGTTCGACAAAGATCGCATTGGTAATTACGTTACTCGATGCCATGGGGATTGGCCTTATCATGCCAGTCTTGCCAACGTTATTACGTGAATTTATTGCTTCGGAAGATATCGCTAACCACTTTGGCGTATTGCTTGCACTTTATGCGTTAATGCAGGTTATCTTTGCTCCTTGGCTTGGAAAAATGTCTGACCGATTTGGTCGGCGCCCAGTGCTGTTGTTGTCATTAATAGGCGCATCGCTGGATTACTTATTGCTGGCTTTTTCAAGTGCGCTTTGGATGCTGTATTTAGGCCGTTTGCTTTCAGGGATCACAGGAGCTACTGGGGCTGTCGCGGCATCGGTCATTGCCGATACCACCTCAGCTTCTCAACGCGTGAAGTGGTTCGGTTGGTTAGGGGCAAGTTTTGGGCTTGGTTTAATAGCGGGGCCTATTATTGGTGGTTTTGCAGGAGAGATTTCACCGCATAGTCCCTTTTTTATCGCTGCGTTGCTAAATATTGTCACTTTCCTTGTGGTTATGTTTTGGTTCCGTGAAACCAAAAATACACGTGATAATACAGATACCGAAGTAGGGGTTGAGACGCAATCGAATTCGGTATACATCACTTTATTTAAAACGATGCCCATTTTGTTGATTATTTATTTTTCAGCGCAATTGATAGGCCAAATTCCCGCAACGGTGTGGGTGCTATTTACCGAAAATCGTTTTGGATGGAATAGCATGATGGTTGGCTTTTCATTAGCGGGTCTTGGTCTTTTACACTCAGTATTCCAAGCCTTTGTGGCAGGAAGAATAGCCACTAAATGGGGCGAAAAAACGGCAGTACTGCTCGAATTTATTGCAGATAGTAGTGCATTTGCCTTTTTAGCGTTTATATCTGAAGGTTGGTTAGATTTCCCTGTTTTAATTTTATTGGCTGGTGGTGGGATCGCTTTACCTGCATTACAGGGAGTGATGTCTATCCAAACAAAGAGTCATGAGCAAGGTGCTTTACAGGGATTATTGGTGAGCCTTACCAATGCAACCGGTGTTATTGGCCCATTACTGTTTACTGTTATTTATAATCATTCACTACCAATTTGGGATGGCTGGATTTGGATTATTGGTTTAGCGTTTTACTGTATTATTATCCTGCTATCGATGACCTTCATGTTAACCCCTCAAGCTCAGGGGAGTAAACAGGAGACAAGTGCTTAG,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7051,Drugs,MEG_7051|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,gi|536186947|dbj|AB848355.1|3191-4396 gi|154845|gb|J01830.1|TRN10TETR|1608-2813 gi|14485027|gb|AF362081.1|AF362081|2339-3544 gi|8919959|emb|AJ277653.1|4551-5756 gi|5327029|emb|AJ247373.1|4486-5691 gi|43700|emb|V00611.1|61-1266,4
,ATGAGGGTAGCGGTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTAGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCGCGCGCAGATCAGTTGGAAGAATTTGTCCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_956,Drugs,MEG_956|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|51011757|emb|AJ809407.1|107-898,2
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatgctggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcaccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcaccttcttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2920,Drugs,MEG_2920|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,1028086746|WP_063845119.1|NG_047873|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047873:67-1281,6
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacctacctcgacgtgcccgaggcggcgttggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcatacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5474,Drugs,MEG_5474|Drugs|betalactams|Class_C_betalactamases|PDC,1343491220|WP_104009836.1|NG_056393|1|1|blaPDC-238|blaPDC|class_C_beta-lactamase_PDC-238 NG_056393:1-1194,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCATTCTCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGAGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGGCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGTGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCAATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCTGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAAACTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1895,Drugs,MEG_1895|Drugs|betalactams|Class_C_betalactamases|CMY,gb|HQ650104|+|63-1209|ARO:3002076|CMY-63 [Citrobacter freundii] ,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactactaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatacagatatcggtacccaagtcgataatttttggctgatgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagagaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4441,Drugs,MEG_4441|Drugs|betalactams|Class_D_betalactamases|OXA,1509794593|WP_122630902.1|NG_062322|1|1|blaOXA-700|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-700 NG_062322:13-837,0
,ATGAATATTATAAATTTAGGAATTCTTGCTCACATTGATGCAGGAAAAACTTCCGTAACCGAGAATCTGCTGTTTGCCAGTGGAGCAACGGAAAAGTGCGGCCGTGTGGATAATGGTGACACCATAACGGACTCTATGGATATAGAGAAACGTAGAGGAATTACTGTCCGGGCTTCTACGACATCTATTATCTGGAATGGAGTGAAATGCAATATCATTGACACTCCGGGACACATGGATTTTATTGCGGAAGTGGAGCGGACATTCAAAATGCTTGATGGAGCAGTCCTCATCTTATCCGCAAAGGAAGGCATACAAGCGCAGACAAAGTTGCTGTTCAGTACTTTACAAAAGCTGCAAATCCCGACAATTATATTTATCAATAAGATTGACCGTGCCGGTGTGAATTTGGAGCGTTTGTATATGGATATAAAAACAAATCTGTCGCAAGATGTCCTGTTTATGCAAACTGTTGTCGATGGATCGGTTTATCCGGTTTGCTCCCAAACATATATAAAGGAAGAATACAAAGAATTTGTATGCAACCATGACGACGATATATTAGAACGATATTTGGCGGATAGCGAAATTTCACCGGCTGATTATTGGAATACGATAATCGCTCTTGTGGCAAAAGCCAAAGTCTATCCGGTGCTACATGGATCAGCAATGTTCAATATCGGTATCAATGAGTTGTTGGACGCCATTACTTCTTTTATACTTCCTCCGGCATCAGTCTCAAACAGACTTTCAGCTTATCTCTATAAGATAGAGCATGACCCCAAAGGGCATAAAAGAAGTTTTCTTAAAATAATTGACGGAAGTCTGAGACTTCGAGACGTTGTAAGAATCAACGATTCGGAAAAATTCATCAAGATTAAAAATCTAAAGACTATTTATCAGGGCAGAGAGATAAATGTTGATGAAGTGGGTGCCAATGATATCGCGATTGTAGAAGATATAGAAGATTTTCGAATCGGAGATTATTTAGGTGCTAAACCTTGTTTGATTCAAGGATTATCTCATCAGCATCCCGCTCTCAAATGCTCCGTCCGGCCAAATAAGCCCGAAGAGAGAAGCAAGGTGATATCCGCTCTGAATACATTGTGGATTGAAGACCCGTCTTTGTCCTTTTCCATAAACTCATATAGTGATGAATTGGAAATCTCGTTATATGGTTTGACCCAAAAGGAAATCATACAGACATTGCTGGAAGAACGATTTTCCGTAAAGGTCCATTTTGATGAGATCAAGACTATCTACAAAGAACGACCTATAAAAAAGGTCAATAAGATTATTCAGATCGAAGTACCACCCAACCCTTACTGGGCCACAATAGGGCTGACTCTTGAACCCTTACCGTTAGGGGCAGGGTTGCAAATCGAAAGTGACATCTCCTATGGTTATCTGAACCATTCTTTTCAAAATGCCGTTTTTGAAGGGATTCGTATGTCTTGCCAATCTGGTTTACATGGATGGGAAGTGACAGATCTGAAAGTAACTTTTACTCAAGCCGAGTATTATAGCCCGGTAAGTACACCTGCTGATTTCAGACAGCTGACCCCTTATGTCTTCAGGCTGGCTTTGCAACAGTCAGGTGTGGACATTCTCGAACCGATGCTCTGTTTTGAGTTGCAGATACCCCAAGTAGCGAGTTCCAAAGCTATTACAGATTTGCAAAAAATGATGTCTGAGATTGAAGACATCAGTTGTAATAATGAGTGGTGTCATATTAAAGGGAAAGTTCCATTAAATACAAGTAAAGACTATGCCTCAGAAGTAAGTTCGTACACTAAGGGCTTAGGCATTTTTATGGTTAAGCCATGTGGGTATCAAATAACAAAAGACGGTTATTCTGATAATATCCGCATGAACGAAAAAGATAAACTTTTATTCATGTTCCAAAAATCAATGTCATTAAAATAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7183,Drugs,MEG_7183|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETQ,gi|499664|gb|L33696.1|PVOTETQ|825-2750,4
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagccgtcgggcagcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6204,Drugs,MEG_6204|Drugs|betalactams|Class_A_betalactamases|SHV,1028110267|WP_063864637.1|NG_050026|1|1|blaSHV-151|blaSHV|class_A_beta-lactamase_SHV-151 NG_050026:1-861,0
,ATGGTCAAGCCAAACGAGCAATTAGTATTGGTTAGCTACATGTATCACTACACTTCCACACCCAACCTATCAACGTCGTCGTCTACAACGGCTCTTTAGGGAAATCTTATCTTGAGGTGGGCTTCCCGCTTAGATGCTTTCAGCGGTTATCCCATCCGAACATAGCTACTCGGCAATGCCACTGGCGTGACAACCGAAACACCAGAGGTTCGTCCACTCTGGTCCTCTCGTACTAGGAGCAGATCCTCTCAAATTTCCAACGCCCACGGTAGATAGGGACCGAACTGTCTCACGACGTTCTAAACCCAGCTCGCGTACCTCTTTAAATGGCGAACAGCCATACCCTTGGGACCTGCTTCAGCCCCAGGATGAGATGAGCCGACATCGAGGTGCCAAACACCGCCGTCGATATGAACTCTTGGGCGGTATCAGCCTGTTATCCCCAGAGTACCTTTTATCCGTTGAGCGATGGCCCTTCCATACAGAACCACCGGATCACTAAGACCTACTTTCGTACCTGCTCGACTTGTGGGTCTCGCAGTTAAGCGCGCTTTTGCCTTTATACTCTTTGAACGATTTCCGACCGTTCTGAGCGCACCTTCGTACTCCTCCGTTACTCTTTAGGAGGAGACCGCCCCAGTCAAACTACCCACCATACATTGTCCTTGGATTTGTTGATCCTAAGTTAGAACCCCAACATAACCAGGGTGGTATTTCAAGGTTGGCTCCACAAATACTGGCGTATCTGCTTCAAAGCCTCCCACCTATCCTACACAAGTTAGGTCAAAGTTCAATGTAAAGCTGTAGTAAAGGTTCACGGGGTCTTTCCGTCTAGCCGCGGGTACACAGCATCTTCACTGCGATTTCGATTTCACTGAGTCTCTGCTGGAGACAGCGCTGCCATCATTATGCCATTCGTGCAGGTCGGAACTTACCCGACAAGGAATTTCGCTACCTTAGGACCGTTATAGTTACGGCCGCCGTTTACTGGGGCTTCGATCAAGAGCTTCGCTTACGCTAACCCCATCAATTAACCTTCCAGCACCGGGCAGGCATCACACCCTATACGTCCACTTTCGTGTTTGCAGAGTGCTGTGTTTTTAATAAACAGTTGCAGCAGCCTGGTATCTGCGACTGCCAACAGCTCAAAGAGCAAGTCTTATCACCATCGGCAGCGTACCTTCTCCCGAAGTTACGGTACCATTTTGCCTAGTTCCTTCAGCAGAGTTCTCTCAAGCGCCTTGGTATTCTCTACCTGACCACCTGTGTCGGTTTCGGGTACGATTCGTTTATGACTATCGCTTAGAAGCTTTTCCTGGAAGCAGGGTATTTGCCACTTTGCCAGTAAACTGGCTTGCTATCAGATCTCATTAATAACCGAGCGGATTTGCCTACTCAGTCTAACTACATCCTTCCACCTGGACAACCATCGCCAGGCTGGCATAACCTTCTCCGTCCCTCCATCGCATCATAAACAAGTATCGGAATATTAACCGATTTCCCATCGACTACGCCTTTCGGCCTCGCCTTAGGGGTCGACTCACCCAGCCCCGATTAACGTTGGACTGGAACCCTTGGTCTTCCGGCGAACGGGCTTTTCACCCGTTTTGTCGTTACTCACGTCAGCATTCGCTCTTGTGATACCTCCAGCACACCTTACAGTGCACCTTCACAGGCTTACACAACGCTCCCCTACCACTTAATTGAAACAATTAAATCCGCAGCTTCGGCTCCTAGTTTGAGCCCCGTTACATCTTCCGCGCAGGCCGACTCGACTAGTGAGCTATTACGCTTTCTTTAAAGGGTGGCTGCTTCTAAGCCAACCTCCTAGCTGTCTGTGCCTTCCCACATCGTTTCCCACTTAACTAGGAATTTGGGGCCTTAGCTGGCGGTCTGGGTTGTTTCCCTCTTGACGACGGACGTTAGCACCCGCCGTCTGTCTCCCGGATATTACTCATCGGTATTCGGAGTTTGCATCGGTTTGGTAAGTCGGTGTGACCCCCTAGCCGAAACAGTGCTCTACCCCCAATGGTATTCGTCCGAGGCGCTACCTAAATAGCTTTCGGGGAGAACCAGCTATCACCGAGTTTGATTAGCCTTTCACCCCTATCCACAAGTCATCCCCTGGCTTTTCAACGACAGTGGGTTCGGTCCTCCGGTGCCTGTTACGGCACTTTCAACCTGCTCATGGATAGATCACTCGGTTTCGGGTCTATACCCTGCAACTCATTCGCCCTATTAAGACTCGGTTTCCCTACGGCTCCCCTATTCGGTTAACCTTGCTACAGAATATAAGTCGCTGACCCATTATACAAAAGGTACGCCGTCACCCGACCACTTAATCGTTCTGATTGTCAAATTGTGATTTGACACGATTCATCAAGAAAGTTCTCATACGACCATTATTTTTTATGGTTCGCTCTCGTTTTCTTGCCACTTGTTCATTAATGTAGGCTTCACAATAAACAATACGCCATGTTCTTGCTCTGGTTGAGTAAGTTGTGCCATTATTATGGTCATCAATTCTTTGTTTTAAACTGGTGGTAAAACCAACATAAAACTCATCATGATTATCCACGTTTTGTATGACATAGACGTAGTAAAAATTCATTGTTATCCTCAAAACGATTAAGTGGTCGGGCTCCGACTGCTTGTATGCACACGGTTTCAGGTTCTATTTCACTCCCCTAACAGGGGTTCTTTTCGCCTTTCCCTCACGGTACTGGTTCACTATCGGTCAGTCAGGAGTATTTAGCCTTGGAGGATGGTCCCCCCATCTTCAGACAGAATTTCTCGTGTTCCGCCCTACTTAATATGTCGCTTAAACAGTTTCGCATACAGGACTATCACCTACTATGGTTGGCTTTCCCACGCCATTTTGCTACTGTAAAATTGATCGGCTCCTCCGTGTTCGCTCGCCGCTACTTACGGAATCTCATTTGATGTCTTTTCCTCGGGGTACTGAGATGTTTCACTTCTCCCGGTTTGCCTTACACAGTAAACTGTGTAATAACCAACTTATGTTGGTTGGGTTTCCCCATTCAGAAATCGCCGGGTCACAGGATATTGCCACCTCACCGACGCTTATCGCAGGCTATCACGTCTTTCATCGCCTCTGACTGCCAAGGCATCCACCATGTGCACTTCATTACTTGA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3978,Drugs,MEG_3978|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|CP002005.1|-|317713-320869|ARO:3004138|Moraxella catarrhalis 23S rRNA with mutation conferring resistance to macrolide antibiotics [Moraxella catarrhalis BBH18] ,7
,ttgtctgatttcattcagttagaatatctacaagaaaaattacagcaacttttagcggaatcattatttgcaatctatctttatggttcagctgttgatggtggcttagggccagaaagtgaccttgatgttctggtcgtggttactcaaccattaacatctgctttacgcgagcagcttgcacgagaattactaaaaatttcacagcctgttggggaattacaaagaccattagaagttactattttattaaaagatgagattcagtctggaaattatcctttaagttatgaaatgcagtttggtgaatggctacgtgaagaacttaaagaaggtggaacattaagttcgcagaaagacccagatattagtatattgcttagaaaagcgagatctcatcatacagttttatttggtccagctctaaaccaatgggcacctgaaatttctgatcaagaactatggcaagcaatgtctgatacttatcccgaaattgtagctcattgggatgaggatgcagatgaaagaaaccagattttagctttatgccggatctattttagtttagtcatgaaggatattgcttcaaaaggcaatgcagctcgatgggttatgcctcagcttcctcctgagcagaaattcgtattgcagcggcttatacaggaatatagaggggaaatcggcaagcaaaattggcaagaggaacattatgctttgcagcctattgttaattttctgagttcaaaaattgaagagcagtttgagcagaaaagaaatttgatcacataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_914,Drugs,MEG_914|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,447201812|WP_001279068.1|NG_054652|1|1|ant(3'')-IIa|ant(3'')-IIa|aminoglycoside_nucleotidyltransferase_ANT(3'')-IIa NG_054652:101-889,2
,atgttcatgccgcctgtttttcctgctcattggcacgtttcgcaacctgttctcattgcggacaccttttccagcctcgtttggaaagtttcattgccagacgggactcctgcaatcgtcaagggattgaaacctatagaagacattgctgatgaactgcgcggggccgactatctggtatggcgcaatgggaggggagcagtccggttgctcggtcgtgagaacaatctgatgttgctcgaatatgccggggagcgaatgctctctcacatcgttgccgagcacggcgactaccaggcgaccgaaattgcagcggaactgatggcgaagctgtatgccgcatctgaggaacccctgccttctgcccttctcccgatccgggatcgctttgcagctttgtttcagcgggcgcgcgatgatcaaaacgcaggttgtcaaactgactacgtccacgcggcgattatagccgatcaaatgatgagcaatgcctcggaactgcgtgggctatatggcgatctgcatcatgaaaacatcatgttctccagtcgcggctggctggtgatagatcccgtcggtctggtcggtgaagtgggctttggcgccgccaatatgttctacgatccggctgacagagacgacctttgtctcgatcctagacgcattgcacagatggcggacgcattctctcgtgcgctggacgtcgatccgcgtcgcctgctcgaccaggcgtacgcttatgggtgcctttccgcagcttggaacgcggatggagaagaggagcaacgcgatctagctatcgcggccgcgatcaagcaggtgcgacagacgtcatactag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_1087,Drugs,MEG_1087|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH6,499474577|WP_011161217.1|NG_047467|1|1|aph(6)-Id|aph(6)-Id|aminoglycoside_O-phosphotransferase_APH(6)-Id NG_047467:101-937,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcttggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacctgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5597,Drugs,MEG_5597|Drugs|betalactams|Class_C_betalactamases|PDC,1035157544|WP_064511509.1|NG_050832|1|1|blaPDC-159|blaPDC|class_C_beta-lactamase_PDC-159 NG_050832:1-1194,0
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAATACACCGTTTCTTTAGCTTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGACTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACAGAAACAGAAAATACAGCCGCTATTCGAAGGAAACGGCTTTTGGTTAAGTGAAGAGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGAATGTTTGAATTGATGAAGCTACCTTATGTAGGCTGCGGGGTGGCAGGTTCTGCCTTATGTATGAACAAATGGTTGCTGCATCAAGCTGCAGCAGCCATTGGCGTACAAAGTGCTCCTACGATTCTCTTGACAAATCACGCCAACCAGCAAGAACAAATCGAAGCTTTTATCCAGACCCATGGCTTTCCAGTTTTCTTTAAGCCTAATGAAGCGGGTTCCTCAAAAGGGATCACTAAAGTCACCTGCGTTGAAGAAATCGCTTCTGCCTTAAAAGAAGCCTTTACTTATTGTTCCGCAGTGCTCCTACAAAAAAATATTGCCGGTGTTGAGATCGGTTGCGGTATTTTGGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCCATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGCTGATCAGCGCCAAAATCACCGTCCCTGCGCCATTGCCTGAAACGATTGAAACTAAGGTCAAAGAACAAGCTCAGCTGCTCTATCGTAGTCTTGGACTTAAAGGTCTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGGTTATCCTATCAAGAACTACTACAAAAACTACTTGTCTTAGCAAAGGAGGAAGTCAAATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7366,Drugs,MEG_7366|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,(Gly)VanC3:AY033764:26-1078:1053,5
,atgaaaaaaaaccttggttatctgacggctatgacggttgctctgtgtttcggcgctcaggcgcagcttaatccggcacagccgttgtccagtgcgccgccctattcgctttttgaacagtgggcgcagccggtcgcgccatttcagatgttcccgcatgtttattacgtgggcacccgcaacctatcgtccgtgctgctgagcacgccggaaggactgattctgatcgacgccgcgctggacgccagcgctccggcaataagagcgcacatagaggctttgggttttaacatcaaggatctgcgctatatcctcaatagtcacgcgcgtctcgatcaggcgggtggcattgcgcgtctgcaagtctggagcggggcaaaagttgtcgccagcgctgccaatgcccaacagttggcgcttggcggcaaacaggattttgctctgggagatgcgctgagcttcccgccggtgaaggtcgatattatcgtcggggagggggacagcattaccttgggcgacctgaaattaacggcattgatgacgccaggccatttgccgggggccacctcgtggctgaccacgctacatcagggagggcaaagttaccgactggtctatgctgatagcctggcaacgccggactactatctgatcgacaacaaaaactaccccagtctggtgcaggatatccgtggcagttttgctcggttggctcagcagcaggcggatatttttatcgtcaataagggaacgcgcttcgatctggataataaaatgcaacgcctgcaggctggcgatctggatgcgtttgtcgatcgtcaggggttgcagcaatatgtgcaacagtcacaacagacatttgaggcgcagttaaaacagcaacaaagtaaaatgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_6556,Drugs,MEG_6556|Drugs|betalactams|Class_B_betalactamases|SPR,501095925|WP_012145975.1|NG_052102|1|1|blaSPR-1|blaSPR|putative_metallo-beta-lactamase_SPR-1 NG_052102:101-997,0
,TTGTCCAAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATTATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGGTGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAACTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATTATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4320,Drugs,MEG_4320|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_5_KT862783 ,1
,ATGACGGATTCAATCCAATCATCTATCACCCCTGTCAATATCGAAGAAGAACTTAAATCTTCCTACCTTGACTACGCGATGTCGGTTATCGTTGGGCGTGCATTACCTGACGTTCGAGATGGTTTAAAACCTGTTCACCGCCGCGTACTATTCTCAATGGATCGCGAAGGCAATACCGCCAATAAAAAATACGTAAAATCAGCGCGTGTTGTGGGTGATGTAATCGGTAAATATCACCCGCATGGTGACTCAGCCGTGTACGATACAATCGTTCGTATGGCACAACCCTTCTCACTTCGCTATATGTTGGTTGATGGGCAAGGTAACTTTGGTTCAATTGACGGCGATGCACCTGCTGCAATGCGTTATACCGAAGTGCGTATGCAAAAAATTACGCAAGCATTGCTCACGGATTTGGATAAAGAAACCGTCAATTTCTCGCCAAACTATGATGGCGAATTAATGATTCCAGATGTATTGCCGACTCGTATTCCAGCACTTTTAGCAAATGGTTCTTCTGGTATTGCGGTGGGGATGGCAACTAACATTCCCCCTCACAACTTAAACGAAGTATTAAATGGTTGTTTGGCTTATATTGACAACAATGAAATTACCATTGATGAATTAATGCAACATATTCCGGGCCCAGACTTTCCAACCGCTGCATTAATTAATGGTCGTAAAGGGATTGAAGAAGCCTATCGCACTGGTCGTGGTAAAGTGTATGTTCGTGCTCGTGCAACCGTAGAAACCAACGAAAAAGGACGCGAGCAAATTATCGTGTCTGAATTGCCATACCAAGTAAATAAAGCAAAATTAGTCGAGAAAATCGCCGAATTAATTCGCGAGAAAAAAATCGAAGGTATCAGCAATATTACTGACCTTTCAAATAAAGAAGGGATCCGTATTGAAATTGATATTAAACGTGATGCAGTGGGGGAAGTGGTATTAAACCATCTTTACTCACTCACTCAAATGCAAGTGACCTTTGGTATCAATATGGTGGCATTGGATCACGGTCAGCCACGTTTATTTAATCTTAAAGAAATTATTGAAGCCTTTGTTTTACACCGCCGTGAAGTCGTTACACGTCGTTCTATCTTTGAGCTTCGCAAAGCACGTGAACGTACGCATATTTTGGAAGGTTTAGCGGTTGCTCGTTCTAATATCGATGAAATGATTGCGATCATTCGTAACTCTAAAAACCGTGAGGAAGCGGCAACAGCAATCAGTTCACGCTCTTGGACGTTACATAGCGATATTATTAATCTTCTTGATGCTTCTGCTCGTCCTGATGAGTTAGAAGAAAATCTTGGTATTCAAGGCGAACAATATTACTTATCGCCAGCGCAAGTAAACGCAATTCTAGAACTTCGTTTACACCGTTTAACGGGCATTGCGTTTGAAGAAGTTATAAAAGAATATGAAGAATTATTAGTTAAAATTGCGGATCTTCTTCATATTTTAAGTAGCGCAGAACGTTTAATGGAAGTAATTCGTGAAGAATTGGAAGAAGTAAAAGCACAATTTGGTGATGATCGTTTAACTGAAATTACCGCTGCTTCTGGCGATATTGATTTAGAAGATTTAATCGCACAAGAAGACGTGGTTGTGACGCTTTCTCACGAAGGTTATGTGAAATACCAACCACTGACTGACTATGAAGCACAACGCCGTGGCGGTAAAGGCAAATCTGCAACGAAGATGAAAGAAGAAGATTTCATCGAAAAATTACTGGTAGCAAATACTCACGATACCATCCTCTGCTTCTCTAGCCGTGGTCGTTTATATTGGTTGAAAGTATATCAACTTCCGCAAGCGAGCCGTGGCGCACGCGGGCGTCCAATTGTGAATATTCTTCCGTTACAAGAAAACGAACGTATTACTGCAATCTTGCCAGTTTCTGCTTACGAAGAAGATAAATTCGTAGTCATGGCAACTGCTGGCGGTATTGTGAAGAAAATCGCCTTAACCGAATTTAGCCGTCCACGTTCAAACGGTATCATCGCATTGAATTTACGTGACGAAGATGAATTAATCGGCGTGGATATTACTAATGGCAGCAACGAAATTATGTTGTTCTCATCGCAAGGTCGCGTGGTGCGTTTTGCTGAAAATGCCGTGCGTGCAATGGGGCGTTTAGCAACAGGTGTTCGCGGTATCAAACTGGCTTTAACAAACGATATTTCTGACGATGAAAGTGCGGTAGAAATTGAAGATATTTCTGATGACAACGCTGAAGCATCATTAGACTTAAATATCGATAAAGTGGTTTCTCTCGTTGTGCCAAAAGGTGAAGGGGCAATTTTAACCGCAACACAAAACGGCTACGGAAAACGCACACAATTAAGTGAATACCCAACTAAATCACGTAATACAAAAGGTGTGATTTCGATTAAAGTGAGTGAACGCAATGGTAAAGTCGTTGCCGCAACTCAAGTAGAAGAAACAGACCAAATTATGTTGATCACTGATGCAGGAACGCTTGTTCGCACACGCGTAAGCGAAGTGAGCATTGTAGGGCGTAACACGCAAGGTGTCCGTTTAATTCGTACCGCAGATGATGAACACGTAGTAAGTTTAGAGCGTGTTTGTGATGCGGATGAAGAAGATTCTTTGGAAGAAAGTAGTTCTGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3203,Drugs,MEG_3203|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|301168602|emb|FQ312006.1|1476045-1473403,3
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATTGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTAGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1926,Drugs,MEG_1926|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KF526115|+|0-1146|ARO:3002114|CMY-102 [Escherichia coli] ,0
,ATGACGAACCCCGCACCTCTCGGTCGCCGCGAACGGAAGAAGGCCGCGACCCGCAAGGCGATCTCCGACGTCGCGACGGCCATGTTCCTGGAACGCGGCTTCGATGAGGTGAGCATCCGCGAGGTCGCCGATGCCGCAGATGTCTCCCCCACGACCGTGTTCGCGCACTTCCCTCAGAAGGAGGCGCTGGTGTTCGACGAAGACGACGAGCAGCGCGACCGCCTGGTGGCCGCCGTCCGCGAGCGCCCGTCGGGGAGCACGATCAACCGCGCCATCCACGACTTCTACGCCTCAGAGCTCCGCGCGAACGTCGACGAGCACGGAGACGAGATCACTCGCACCTTCATGCGCTTCCTGAACGAGACACCGGCGCTGCGCGACTACGCGGCGAAGATGTGGCTCCGACACGAAGACGCCCTCTCCGACGCGATCGCCGACGAACTGGGACTCGATACACCCACCCCGGAGATCCGGGTCTACTCGCGGTTCATCCTGCAGATGCAGCTGCTCGTCAACGAGAACGACGACCCCTTCGGGACGCTCGAAGCAGGGTTCGTGATCCTCGAGAACGGCTGGGCGCCGGTCGAAGCCGGCCTCAGCGGATCCGCCAGCTAG,tetR,antibiotic target alteration,Tetracyclines,MEG_7190,Drugs,MEG_7190|Drugs|Tetracyclines|Tetracycline_transcriptional_repressor|TETR,gi|187763215|gb|EU523697.1|615-1,4
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCTTTCTCCACGTTTGCCGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCAATTCCGGGCATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACTCAACAAACGCTGTTTGAACTCGGTTCGGTCAGTAAAACGTTCAACGGTGTGCTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGCAGTACTGGCCTGAACTGACGGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCATTACTACACTTTTATCAAAACTGGCAGCCGCAATGGGCCTCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGCGCCCTGGCGGTGAAACCTTCAGGCATGAGCTACGAAGAGGCGATGACCAAACGCGTCCTGCACCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGCCAACTTGATGCCGAAGCCTACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGAATCGAGCTTGCGCAGTCACGTTACTGGCGTATTGGCGATATGTACCAGGGCCTGGGTTGGGAGATGCTGAACTGGCCGGTGAAGGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTAGCACTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTTGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAGAGCTACCCAAACCCTGTTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1924,Drugs,MEG_1924|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KF526113|+|0-1146|ARO:3002112|CMY-100 [Citrobacter freundii] ,0
,GTGGCACAGCCAGAATTATTTCATGATTTACCGTTAGAAGAAGTAATCGGCGACCGTTTCGGACGCTACAGTAAATACATTATTCAAGACAGGGCGCTGCCCGACGCTCGTGACGGTTTAAAGCCGGTGCAGCGGAGAATTTTATACGCCATGCACGCGGACGGAAATACATTCGATAAAAATTTCCGTAAAGCGGCGAAAACGGTCGGAAACGTTATCGGTAATTATCATCCGCACGGTGACAGCTCTGTTTATGAAGCGATGGTGCGGATGAGCCAGGATTGGAAAGTGCGGAATGTGCTGATTGAGATGCACGGCAACAATGGAAGCATTGACGGTGATCCGCCGGCTGCCATGCGTTATACGGAAGCGAGATTATCTTCTATCGCGTCAGAGCTTTTGCGTGACATCGATAAAAATACGGTTGAATTCGTTCCGAACTTTGATGACACTAGTAAAGAACCGGTTGTTTTGCCCGCCATGTTCCCTAACTTGCTTGTCAACGGATCAACCGGGATTTCAGCGGGCTATGCGACTGATATTCCCCCTCATCATCTGGGTGAGGTCATTGATGCCGTCATTAAACGGATTGAATCTCCGGATTGCACCGTCGATGACTTGATGCAGGTGATTAAAGGGCCTGACTTTCCGACAGGAGGCATTATTCAAGGAGTCGACGGCATTCGGAAGGCTTATGAAACCGGGAAAGGCAAAATTATTATCCGCGGCAAGGCTGAAGTGGAATCCGTAAGAGGTGGACGGGAGCAGATCGTCATTACAGAAATTCCGTTTGAAGTAAACAAAGCCAATCTCGTAAAGAAAATGGACGAATACCGCATAGACAAAAAAGTCGAAGGCATTTCTGAAGTCCGGGATGAAACTGACCGCACGGGGCTTCGGGTCGTCGTTGAGTTAAAGAAAGAAGCCGATGCAAAAGGCATTTTGAATTTCTTATATAAAAACACTGATCTGCAGACAACTTATAACTTTAATATGGTCGCCATACATAACCGCCGGCCGATGCTGATGAGTCTTACGGCCATCCTGGATGCGTATATTTCCCATCAGAAGGAAGTGGTGACAAACCGCTCCGTCTTTGAATTGCAAAAAGCAAAAGAGCGGCACCACATCGTTGAAGGACTGATGAAGGCACTGTCTGTGTTAGATGAGGTCATAGCCGTCATCCGGGCAAGCAGCGACAAGAAAGATGCGAAACAAAACGTAATGTCTAAATTCACATTTACGGAGCCGCAGGCCGAAGCGATCGTATCCTTGCAGCTGTATCGTCTGACAAACACGGATATTACGGCGCTAAAAGAGGAAGCGGAAGAGCTCAGCAAGAAAATTCAGGAGCTCGAAGCCATTTTAAGTCATGATAAAAAGCTGTTAAAAGTCATTACAAGCAGCCTGAAAAAATTGAAAAAGACCTATGCTGACAGCAGACGGTCTGTCATTGAAGAAAAGATTGAGGAAATTAAAATCAATCTTGAAGTCATGGTTGCCTCTGAGGACGTATATGTGACAGTCACAAAAGACGGCTATGTAAAACGAACAAGTCAGCGGTCATTTGCCGCTTCTAACGGCCAGGATTTCGGTATGAAGGATACTGACAGGCTGATTCACCAATTTGAAATGAATACAACGGATGTTCTCCTGCTCTTTACCAATAAGGGAAGCTATGTTTATTGTCCGGTTCACCAGCTTCCCGATATCAGGTGGAAAGACATGGGGCAGCACGTAACGAACATCATCACGATTGACCGTGATGAAACCATCGTGAAAGCTATACCGGTAAAAGAATTTGATCCATCTTCATATTTATTGTTTATGACGAAAAACGGCATGGTGAAAAGAACTGAAATGACGCATTACAAAGCGCAGCGTTACTCGAAAGCGCTTGTTGCCCTTAACCTTAAAGGGGACGACGAGCTGATTGATGTTCATGTCACAGACGGCGGCAGCCAGCTGTTTATCGCCACCCGTCTCGGGTACGGTTTATGGTTCGGTGAAGATGAAGTAAATGTAGTCGGTGCCCGTGCGGCCGGCGTAAAGGGCATAAATGTAAAAGACGGTGATACCGTCGTATCAGGACAAATCCTGCATGAGACAGATTCGCTTGTCCTTGTCACACAGCGGGGAGCAATCAAGCGGATGAACCTATCTGAATTCGAAAAAACATCCAGGGCGAAGCGCGGTGTCATCATGCTGCGTGAGCTTAAAAAGAACCCGCATCGCGCAGTCGGCGTATTCGCGTGCGCTTTAGCCGACATGATCGCTGCGGAAACAGAAAAAGGCGAGAGAATCGAAATCGCCGTGAAGTCCTTGCGGGCGAATGACCGATACAGCAACGGCTCCTTCTTTACCGATGAAGATGAGACAGGGCCGGTAACAGACGTATGGCGTATCCCCGCGTCTGATGTTTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3210,Drugs,MEG_3210|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|556017688|gb|CP006845.1|1840935-1843358 gi|154350369|gb|CP000560.1|1845574-1847997,3
,atgacagtcgccctcgacgaagtatctgaactaaagaatttgctttcacccttgttggatgaatgcacttttgaagaagttgagtatggtcagtcagatgctcgagtgattcgagttctatttcctgatcgcaataccgcgtatctaaagtacgcctccggatcttctgctcaagaaattcttcaagagcatcagcgcactagatggctcagaacacgagctctcgtaccggaagtgatctcatatgtctcgacttcaactgtcaccatcctgttgacaaaagcattgattggccacaatgccgctgacgccgcacatgcagatccagctattgttgttgcagagatggcacgagcgttacgcgacctccattcgatctcgcctgacgattgcccattcgacgaaaggctccacctgcgactgaagctggcttcgggccgtttggaagccgggttagttgatgaggaggactttgatcacgcaaggcaaggcatgctggcgcgggatgtttacgagcaactttttttacaaatgcctggagcggagcagctggtagtcacacatggcgacgcctgtcccgagaacttcatcttccaaggtaatgccttcgtcggcttcatagactgcggtcgggtcgggcttgccgataagtatcaagacctggcgcttgcatcgagaaacattgacgcggtatttggaccagaactcactaaccagttctttatcgagtatggagagccaaatccgaacatagctaagattgagtactaccggatcttggatgagttcttctaa,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1020,Drugs,MEG_1020|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,730672929|WP_034067921.1|NG_052510|1|1|aph(3')-XV|aph(3')-XV|aminoglycoside_O-phosphotransferase_APH(3')-XV NG_052510:101-895,2
,ATGAATAACATCGGCATTACTGTTTATGGATGTGAGCAGGATGAGGCAGATGCATTCTGTGCCCTTTCGCCGCGTTTTGGCGTTATGCCCTCGATAATTAACGCCAACGTGTCGGAATCCAACGCCAAATCCGCGCCTTTCAATCAATGTATCAGCGTGGGACATAAATCAGAGGTGTCCGCGTCTATTCTTCTTGCGCTGAAGAGAGCCGGTGTGAAATATATCTCCACCCGAAGCATCGGCTGCAATCATATAGATACAACTGCCGCTAAGAGAATGGGCATCACTGTCGGCAATGTGGCGTATTCGCCGGATAGCGTTGCCGATTATACCATGATGCTGATGCTTATGGCAGTACGCAACGCTAAATCTATTGTCCGCTCTGTGGAAAAACATGATTTCAGGTTGGACAGTGTCCGTGGCAAGGTACTGAGCGACATGACAGTCGGCGTGGTGGGAACGGGCCATATAGGCAAAGCAGTTATTGAGCGGTTGCGGGGATTTGGATGTAAAGTGCTGGCTTATAGTCGCAGCCAAAGTATAGAGGCAAACTATGTTCCGTTTGATGAGTTGTTGCAAAATAGCGATATCGTTACGCTTCATGTGCCGCTCAATGCGGATACGCGCCATATCATCAGCCACGAACAAATACAGAGAATGAAGCAAGGCGCGTTTATTATCAATACTGGCCGCGGTCCACTTGTATATACCAATGAGCTGGTCAAAGCATTAGAAAACGGAAAACTGGGCGGTGCCGCATTGGATGTATTGGAAGGAGAGGAAGAGTTTTTCTACTCTGATTGCTCACAAAAACCAATTGATAATCAATTTTTACTGAAACTTCAAAGAATGCCGAACGTGATAATCACGCCGCATACGGCTTTTTATACCGAACAGGCGTTGCGTGATACCGTTGAAAAAACCAATATAAACTGTTTGGATTTTGAAAGGAGCCAGGAGCATGAATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7403,Drugs,MEG_7403|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,(Gly)VanH-Pt2:AY926880:2771-3739:969,5
,atgaatgaaaaaatcttagtggttgatgatgaaaaagagttagccgatttggttgaagtctatctgaaaaacgatggatacaccgtttataaattttataatggcacggatgcgttaaagtgtatcgagtccacccctctggatttagccatattggatattatgctcccggatattgatggctttcaaatttgccagaaaatccgggagaaattttattttcctgtgatcatgctaacggcaaaagttgaagatggggataaaatcatggggctctccatcgcagatgactatattaccaagcccttcaatccgctggaagtagttgccagagtgaaagcgcagttaaggcagtatatgaggtacagacagccccacttcaaacaggaggatgaacgcagcgaatacgatataagaggaatgacaatcagtaagaacagccacaaatgtatcttgttcgggaaagaacttcaactaacgccaacagagttttctattctctggtatctgtgtgaaaaccaggggaaggttgtttcaacggaggaactatttgaagcggtatggggcgaaaaatacatggataacaataatactgttatggcccatattggacgtctcagagaaaaaatgaaggaacgggcaaagaaccctaaatttataaaaactgtgtggggagtgggatataccattgaaaaatag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7477,Drugs,MEG_7477|Drugs|Glycopeptides|VanD-type_regulator|VANRD,1028100587|WP_063856722.1|NG_048416|1|1|vanR-D|vanR-D|VanD-type_vancomycin_resistance_DNA-binding_response_regulator_VanR NG_048416:1-699,5
,ATGAGGACTGAAAAAGAAATTTTAAATTTAGTTTCTGAATTTGCTTATCAACGAAGCAATGTAAAAATTATTGCTCTCGAGGGTTCAAGAACTAATGAAAATATAAAAAAAGATAAGTTTCAAGATTATGATTTTGCTTTTTTCGTATCAGATATTGAGTGTTTCACACATGAAGAAAGTTGGTTAAGTTTATTTGGAGAATTATTGTTTATACAGAAACCAGAAGATATGGAATTATTCCCACCTGATTTAGATTATGGTTACAGTTATATAATGTATTTTAAAGATGGCATAAAAATGGATATTACATTAATTAATTTAAAAGATTTAAATCGTTATTTTAGTGATTCTGATGGTCTTGTAAAAATTTTAGTTGATAAAGATAATTTAGTAATTCAAGAAATTGTTCCAGATGACTCAAATTATTGGTTAAAAAAACCAACAGAACGAGAATTTTATGATTGCTGTAATGAGTTTTGGAGTGTCTCAACGTATGTAGCAAAGGGTGTTTTTAGAAGAGAAATATTATTTGCTTTAGATCATTTCAATAATATTTTACGTCCTGAATTATTAAGAATGATTTCTTGGTATATTGGCTTTAATAGGGGTTTTGATTTTAGTTTAGGAAAGAATTATAAGTTTATAAACAAATATTTAACTGATAAAGAATTCAATATGTTTTTAGCTACTTTTGAGATGAATGGATATAGAAAGACATACCAATCTTTTAAGCTTTGTTGTGAATTATTTAAATATTATTCAAATAAAGTAAGTTGTTTAGGAAATTATAACTATCCAAATTACGAAAAAAATATTGAGAATTTTATTCGTAATAATTATGAGAATTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_995,Drugs,MEG_995|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,(AGly)Str:X92946:18908-18060:849,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtacccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5603,Drugs,MEG_5603|Drugs|betalactams|Class_C_betalactamases|PDC,1343491221|WP_104009837.1|NG_056394|1|1|blaPDC-239|blaPDC|class_C_beta-lactamase_PDC-239 NG_056394:1-1194,0
,atgtccgccacgctccacgacaccgcagcggatcgtcggaaggccacccgccgcgaatggatcggcctggccgtggtcgccctgccgtgcctggtctacgccatggacctcacggtgctgaacctggcgctgccggtgctcagccgtgaactgcagccctccagcgcccagcttctctggatcctggacatctacggcttcttcgtcgccggcttcctgatcaccatgggcacgctgggcgaccgcatcggccggcgccggctgttgttgatcggcgcggcgttcttcgcattcgcctcggtgctcgcggcgctggccgataccgccgcgctgttgatcgcggcgcgcgccttgctcggcctggccggcgccaccatcgcgccgtccaccatggcgctgatccgcaacatgttccacgacccgcgccagcgccagttcgccatcggcgtgtggatcgccgcgttttcgctgggcagcgcgatcggtccgctggtcggcggcgtgttgctggagttcttccactggggcgccgtgttctggctcaacgtgccggtgatgctgctgacgctggcgctcggccctcgcttcctgcccgagtatcgtgatccggacgcggggcacctggacctggccagcgtgctgctgtcgctggcggcggtgctgctgacgatctacgggctcaagcagttggccgagcatggagcgggcctcgcctcgatggctgcgctgctggccgggctggcggtcggggcgctgttcctgcgccgccagggccacatcgcctacccgctgctggacctgcggctgttcgcgcacgcgccgttccgcgcggcgctggcggcgtatgcgctggccgcgctggccatgttcggcgtctacatcttcatgacgcagtacctgcagctcgtgctggggctgtcgccgctgcaggccgggctggccacgctgccctggtccctgtgcttcgtcatcggttcgctgttgtcgccgcagctcgcggcgcgctggccggcggcgcgcatcctcgtcgtgggcctgtcggcagcggcgttcggcttcgccgtgctggggctggggctggggcagggcctgtggtggctggtgccggccacgatcgtcatgggcctgggcctggcgccggtgttcaccatcggcaacgagatcatcatcaccagcgcgccgtccgagcgcgcgggcgcggcctcggccttgtcggagacggtgtccgaattcagcggcgcgctgggcatcgcgctgttcggcagcgtcggcctggtggtctaccggcaggcgctgaccagcgcggcgctgcccggcctgccggccgatgcgctgcaggcggccggtgcctcgctcgggggcgccgtgcacctggccgacaccctgccggcgtggcagggcgcggccttgctggcggccgcacgcgcgggcttcaccgatgcgctgcaggccacggcctgggccggcgcggtgctggtgctggtggccgctgggctggtggcgcgcctgctgcgcaagcgcccagcgctcgcatctggttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Fluoroquinolones,MEG_5860,Drugs,MEG_5860|Drugs|Fluoroquinolones|Quinolone_active_efflux|QEPA,1392506017|WP_109638756.1|NG_062251|1|1|qepA8|qepA|fluoroquinolone_efflux_MFS_transporter_QepA8 NG_062251:101-1642,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgatgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtggtcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5657,Drugs,MEG_5657|Drugs|betalactams|Class_C_betalactamases|PDC,759359981|WP_043089496.1|NG_049935|1|1|blaPDC-60|blaPDC|class_C_beta-lactamase_PDC-60 NG_049935:1-1194,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6434,Drugs,MEG_6434|Drugs|betalactams|Class_A_betalactamases|SHV,gi|256033059|gb|GQ380692.1|1-861,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATACAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1380,Drugs,MEG_1380|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_90_FKVU01000010,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggatagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgtatcgaacacgcttgtgaagccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacactgtttttgcgctctattggcgacaaagcaacgcgacttgaccgattggagccccgtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacaccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1512,Drugs,MEG_1512|Drugs|betalactams|Class_A_betalactamases|CARB,757494676|WP_042764055.1|NG_048747|1|1|blaCARB-44|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-44 NG_048747:101-952,0
,atggaactgcgtggagccgaggtcgtactgcggccggtcgccgccggcgacgaggaagtcctcgacaggatcgtccgggagcccgaggtcgccgcatggtggtcgccgccggacgacttccagcgcatgctcgccgtcgtcctccagggcgaagtcatcggagcgatccagtaccaggaggagaccgaccccgagttccggcacgccggactcgacgtcttcctgaccgcccgccaccacggaaaaggactcggcaccgacgccgtacggaccctcgcccgctggctggtgcacgaccgcggccaccaccgcctgaccatcgaccccgccgcggccaacaccgcggcgatccgcagctaccgcaaggtcggcttcaagcccgtcggaatcatgcggtcctactggcgcgaccaccggacgggcacctggcaggacggactgctcatggacctgctcgccgaggaactgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_191,Drugs,MEG_191|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,763027631|WP_043911783.1|NG_052429|1|1|aac(6')_Strep|aac(6')_Strep|aminoglycoside_6'-N-acetyltransferase NG_052429:101-574,2
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcgggtatctccgagccagccatgatcgacgttgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagctgcggaggaactctttgatcccgttcctgaacaggatctattcgaggcactgaatgaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgctcacgttgtcccgcatttggtacaccgaagtaaccggcaaaatcgtgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaggaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_807,Drugs,MEG_807|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502118|WP_071846270.1|NG_052311|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052311:101-892,2
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatagctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4393,Drugs,MEG_4393|Drugs|betalactams|Class_D_betalactamases|OXA,1391852914|WP_109545099.1|NG_057533|1|1|blaOXA-610|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-610 NG_057533:1-774,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCGTTCTCCACGTTTGCCGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACTCAACAAACGCTGTTTGAACTCGGATCGGTCAGTAAAACGTTCAACGGCGTGCTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGCATTACTGGCCTGAACTGACTGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCGTTACTACGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGTGCCCTGGCGGTCAAACCCTCAGGCATGAGCTACGAAGAGGCGATGACCAAACGCGTCCTGCGCCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGCCAACTTGATGCCGAAGCCTACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGCATCGAGCTTGCGCAGTCACGTTACTGGCGTATTGGCGATATGTACCAGGGCCTGGGCTGGGAGATGCTGAACTGGCCGGTGAAGGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTGGCACTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCGTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAGAGCTACCCAAACCCTGTTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1932,Drugs,MEG_1932|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KJ207203|+|5-1151|ARO:3002095|CMY-82 [Citrobacter freundii] ,0
,ATGAAAAAGATAAAAATTGTTCCACTTATTTTAATAGTTGTAGTTGTCGGGTTTGGTATATATTTTTATGCTTCAAAAGATAAAGAAATTAATAATACTATTGATGCAATTGAAGATAAAAATTTCAAACAAGTTTATAAAGATAGCAGTTATATTTCTAAAAGCGATAATGGTGAAGTAGAAATGACTGAACGTCCGATAAAAATATATAAAAGTTTAGGCGTTAAAGATATAAACATTCAGGATCGTAAAATAAAAAAAGTATCTAAAAATAAAAAACGAGTAGATGCTCAATATAAAATTAAAACAAACTACGGTAACATTGATCGCAACGTTCAATTTAATTTTGTTAAAGAAGATGGTATGTGGAAGTTAGATTGGGATCATAGCGTCATTATTCCAGGAATGCAGAAAGACCAAAGCATACATATTGAAAATTTAAAATCAGAACGTGGTAAAATTTTAGACCGAAACAATGTGGAATTGGCCAATACAGGAACAGCATATGAGATAGGCATCGTTCCAAAGAATGTATCTAAAAAAGATTATAAAGCAATCGCTAAAGAACTAAGTATTTCTGAAGACTATATCAAACAACAAATGGATCAAAATTGGGTACAAGATGATACCTTCGTTCCACTTAAAACCGTTAAAAAAATGGATGAAGATTTAAGTGATTTCGCAAAAAAATTTCATCTTACAACTAATGAAACAGAAAGTCGTAACTATCCTCTAGAAAAAGCGACTTCACATCTATTAGGTTATGTTGGTCCCATTAACTCTGAAGAATTAAAACAAAAAGAATATAAAGGCTATAAAGATGATGCAGTTATTGGTAAAAAGGGACTCGAAAAACTTTACGATAAAAAGCTCCAACATGAAGATGGCTATCGTGTCACAATCGTTGACGATAATAGCAATACAATCGCACATACATTAATAGAGAAAAAGAAAAAAGATGGCAAAGATATTCAACTAACTATTGATGCTAAAGTTCAAAAGAGTATTTATAACAACATGAAAAATGATTATGGCTCAGGTACTGCTATCCACCCTCAAACAGGTGAATTATTAGCACTTGTAAGCACACCTTCATATGACGTCTATCCATTTATGTATGGCATGAGTAACGAAGAATATAATAAATTAACCGAAGATAAAAAAGAACCTCTGCTCAACAAGTTCCAGATTACAACTTCACCAGGTTCAACTCAAAAAATATTAACAGCAATGATTGGGTTAAATAACAAAACATTAGACGATAAAACAAGTTATAAAATCGATGGTAAAGGTTGGCAAAAAGATAAATCTTGGGGTGGTTACAACGTTACAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCAGATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAAGATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTACGGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCACCTCACTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCAACAAGTCGTAAATAAAACACATAAAGAAGATATTTATAGATCTTATGCAAACTTAATTGGCAAATCCGGTACTGCAGAACTCAAAATGAAACAAGGAGAAACTGGCAGACAAATTGGGTGGTTTATATCATATGATAAAGATAATCCAAACATGATGATGGCTATTAATGTTAAAGATGTACAAGATAAAGGAATGGCTAGCTACAATGCCAAAATCTCAGGTAAAGTGTATGATGAGCTATATGAGAACGGTAATAAAAAATACGATATAGATGAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3794,Drugs,MEG_3794|Drugs|betalactams|Penicillin_binding_protein|MECA,mecA_4_AB546266,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacagcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggcttatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5449,Drugs,MEG_5449|Drugs|betalactams|Class_C_betalactamases|PDC,657908293|WP_029610673.1|NG_049876|1|1|blaPDC-109|blaPDC|class_C_beta-lactamase_PDC-109 NG_049876:1-1194,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAAACTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1944,Drugs,MEG_1944|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KP862820.1|+|0-1146|ARO:3003652|CMY-132 [Escherichia coli] ,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6689,Drugs,MEG_6689|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-135:JQ060998:1-861:861,0
,ATGGCAATCCGAATCTTCGCGATACTTTCCTCCATTTTTTCTCTTGCCACTTTCGCGCATGCGCAAGAAGGCACGCTAGAACGTTCTGACTGGAGGAAGTTTTTCAGCGAATTTCAAGCCAAAGGCACGATAGTTGTGGCAGACGAACGCCAAGCGGATCGTGCCATGTTGGTTTTTGATCCTGTGCGATCGAAGAAACGCTACTCGCCTGCATCGACATTCAAGATACCTCATACACTTTTTGCACTTGATGCAGGCGCTGTTCGTGATGAGTTCCAGATTTTTCGATGGGACGGCGTTAACAGGGGCTTTGCAGGCCACAATCAAGACCAAGATTTGCGATCAGCAATGCGGAATTCTACTGTTTGGGTGTATGAGCTATTTGCAAAGGAAATTGGTGATGACAAAGCTCGGCGCTATTTGAAGAAAATCGACTATGGCAACGCCGATCCTTCGACAAGTAATGGCGATTACTGGATAGAAGGCAGCCTTGCAATCTCGGCGCAGGAGCAAATTGCATTTCTCAGGAAGCTCTATCGTAACGAGCTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGATCTCATGATTGTGGAAGCCGGTCGCAACTGGATACTGCGTGCAAAGACGGGCTGGGAAGGCCGTATGGGTTGGTGGGTAGGATGGGTTGAGTGGCCGACTGGCTCCGTATTCTTCGCACTGAATATTGATACGCCAAACAGAATGGATGATCTTTTCAAGAGGGAGGCAATCGTGCGGGCAATCCTTCGCTCTATTGAAGCGTTACCGCCCAACCCGGCAGTCAACTCGGACGCTGCGCGATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5224,Drugs,MEG_5224|Drugs|betalactams|Class_D_betalactamases|OXA,gi|42563726|gb|AY444814.1|3988-4815,0
,atgacctataaatcaaccgtattacttttgttcttgattacggctttcttttcctgtaagtcacaacaaccgaccttaacttacagtagcgaggacttaaaaatcatcccgctctccaaaaacagcttcgtccatatctcttacctatcgaccggagactttggaaaagtggcctgtaacggacttatctacataaaccaaggccaggccgttgttttcgatacgcccaccgacaacgaaacttccgaagagctcatccattggataaccgaaactaaaaaacaacagatcaaggccgtggtcatcaaccactttcacgacgactgccttggcgggatcgaggcctttcacgaactaagcattccctcttacgctagcaatacgaccatagaacttgctaaaaaagaaggaaacccggttccacaaattggttttgacaccaccaacgaactgaccattgggaagcaaaaaataatcaaccgtcattttggcgaggcccataccaaagacaacattgtaagttacatccctagcgagcacctcctttttggcggatgcgcccttaaatcgctcaatgccgccaaaggatacctaggcgatgcgaacaccaacgaatggggcaacaccatcaaaaagataaaagcagcctatcccgaccttaaaacggccattcccggacacggggaatacggaggctcagaattactggattataccatttccctttttagcacgaaacaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7860,Drugs,MEG_7860|Drugs|betalactams|Class_B_betalactamases|ZOG,503758107|WP_013992183.1|NG_057434|1|1|blaZOG-1|blaZOG|subclass_B1_metallo-beta-lactamase_ZOG-1 NG_057434:101-844,0
,ATGAAAAAGAACTTTGCCTTTTTAGATGAAATGATTCCCGGAATCCGATGGGATGCTAAATATGCCACATGGGACAATTTCACCGGGAAACCGGTAGACGGATACATGGTAAACCGTGTTATGGGAACGAAGGAGCTGGGAGTTGCTTTGCGTAAGGCTCACAAGATGGCGGAGAAACTGGGATATGGTTTGCTCTTATGGGACGGCTATCGCCCCCAGTGCGCAGTGGATTGTTTTCTGAATTGGGCTTCCCAACCGGAAGACAATCTGACGAAAAAGCGTTACTATCCAAATATCAAAAGGAACGAGATGATCACGAAAGGGTATGTGGCTTCACAATCCAGCCACAGCCGTGGAAGTACGGTTGACCTTACAATTTTTCATTTGAATAGTGGTATGCTTGTTCCTATGGGTGGGGATTTCGACTTTATGGATGAACGGTCACACCATGCCGCAAGCGGTCTGAGCGAAGAGGAATCAAAAAACCGGCAGTGCTTGCGTTATATCATGGAGAGCAGCGGATTTGAAGCCTATCGTTATGAATGGTGGCATTACGTCTTGGCGGACGAGCCATACCCGGATACATATTTTGATTTTTGTATCGCCTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7569,Drugs,MEG_7569|Drugs|Glycopeptides|VanD-type_resistance_protein|VANXD,gi|5759260|gb|AF175293.1|AF175293|5116-5724,5
,atgcgcaacagaggattcggtcgtcgcgaactgctggtagcgatggcaatgctggtttccgtgacggggtgtgcacggcatgcgagcggggcccgtccggcatcgacaaccttgccggccggagcggatctggcggatcgcttcgccgagctggagcgcagatacgatgcccggcttggggtgtatgtgcccgccaccggcaccaccgccgcgatcgaataccgcgccgatgagcggttcgcattctgctccacgttcaaggcgccgctcgtggcggcggtgctgcaccaaaacccgctcacgcatctggacaaactgatcacctacaccagtgacgacattcggtcgatctccccggtggcccaacaacacgttcagaccgggatgacgatcgggcagctttgcgatgcggcgatacgctatagcgacggcaccgccgccaacctgttgctggccgatcttggcggtcccgggggcggcaccgcggcatttaccggctacctccgcagcttgggtgacaccgtgagccggttggacgccgaggaaccggagttgaaccgcgatccgcccggggacgaacgggataccacaacaccgcacgccatcgccctggtgttgcagcagcttgttctcggcaacgcgttgccgcccgacaagcgggcactgctcaccgattggatggcgcgcaacaccaccggagccaagcggatccgagcgggctttcccgccgattggaaggtgatcgacaagaccgggaccggtgactacggacgagcaaacgacatcgcggtcgtgtggtcaccgaccggcgtgccctacgtggtggccgtcatgtccgatcgtgccggcggcgggtatgacgccgagccccgtgaggcgctgctcgccgaggcggcgacgtgcgttgccggtgtgcttgcatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1242,Drugs,MEG_1242|Drugs|betalactams|Class_A_betalactamases|BLAA,489505800|WP_003410677.1|NG_047489|1|1|blaA_Mtub|blaA_Mtub|class_A_beta-lactamase_BlaA NG_047489:101-1024,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataggaccggcagcggcggctacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2179,Drugs,MEG_2179|Drugs|betalactams|Class_A_betalactamases|CTX,1331531442|WP_102607452.1|NG_056166|1|1|blaCTX-M-192|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-192 NG_056166:1-876,0
,ATGAAAAACATCGGCATTACCATCTATGGATGTGAGCAGGATGAGGCTGATGTGTTCAAGGAACTTTCGCCGCGCTTTGGCGTTATACCTGCCATTACAAGCTCTGCCGTATCAGAAACCAACGTAATGTTAGCCCCTGGAAATCAATGTATCAGCGTGGGGCACAAATCTGAGATTTCCGAATCCATTCTTCTTGCGTTGAAGGAATCCGGCGTCAAATATATCTCTACTCGAAGTATTGGTTACAATCACATAGACATGAAGGCCGCGGAAAGTATGGGTATTGCTGTCGGGAACGTGGCATATTCACCGGATAGCGTTGCCGATTATACATTGATGCTGATGCTCATGGCAGTACGCAACGCGAAATCTATTGTGCGCTCTGTGGAAAAACATGATTTCAAGCTGGACAGCGTCCGTGGCAAGGTACTGCGCGACATGACAGTCGGCGTGCTGGGAACCGGTCATATAGGCAAGAGGGTTATTGAGCGACTGCGGGGATTTGGATGTCATGTGCTGGCGTATGGTCACAACAAAGAGGCGGCGGCAAATTATGTGTCCCTCAATGAATTGCTGCAAAAAAGCGACATTCTTACCATTCACGTACCGCTTAGCGCGGACACATACCATATGATCGGTCGCGAACAGATTAAAGCAATGAAACAGGGCGCGTTTCTTATCAATACAGCGCGAGGCGGGCTTATAGATACCGATGTGCTGGTTAAAGCATTGGAAAACGGAAAACTGGGCGGCGCCGCATTGGATGTATTGGAGGGAGAGGAAGGACTTTTCTACTTTGATTGCACACAAAAACCAATTGATAATCAATTTTTACTGAAACTTCAAAGGATGCCGAACGTGATAATCACGCCGCATACGGCTTACTATACCGAACAGGCGTTGCGTGATACCGTTGAAAATACAATCAAGAACTGTCTGGAATTTGAGAGGAGAGAGACACTTGTATAGAGTAAAAATAGCCATCCTGTTTGGGGGCTGCTCAGAGGAACATGATGTGTCGGTAAAATCAGCGAAAGAGATTGCCAACAACATTAACACAGAAAAATATGAGCCAATATACATTGGAATAACCCGATCCGGCGTTTGGAAAATGTGCGAAAAGCCATGCATGGATTGGGACAACGAAAACTGCCGTTCGGCAGTGCTTTCTCCGGACAAAAGAATGCACGGGCTGCTTGTCATGCGGGATAAGGGATATCAAATACAGCGTATAGATGCGGCATTTTCGGTTTTGCACGGCAAATCGGGCGAAGACGGCGCCATACAAGGTTTATTTGAATTGTCCGGCATCCCCTATGTAGGCTGTGATATTCAAAGCTCGGCGGTGTGTATGGACAAATCGCTGGCATACATCATTGCGAAAAACGATGGCATAGCTACTCCCGAATTTTGGGTTATTAATAAAGACGATAGGCCGGCGGCAGCTGCGTTTACCTATCCTGTTTTTGTTAAGCCGGCGCGTTCAGGCTCATCCTATGGCGTGAAAAAAGTCAATGGCGCGGACGAATTGGACGCCGCAATTGAATCGGCAAGACAATATGACAGCAAAATCTTAATTGAGCAGGCTGTTTTGGGCTGTGAGGTCGGTTGTGCCGTATTGGGAAACAGTTCCGAGTTGATTGTTGGCGAGGTGGACCAAATCAGGCTGCAGCACGGTATCTTTCGTATTCATCAGGAAGCCGAGCCGGAAAAAGGCTCTGAAAACGCAGTTATAACCATTCCCGCAGACCTGTCGGCAGAGGAGCGAGGACGGATACGGGATACGGCAAAAAAAATATATAAGGCGCTCGGCTGTAGAGGTCTTGCCCGTGTTGATATGTTTTTACAAGATAACGGCCGCATTGTACTTAACGAAGTCAATACCCTGCCCGGTTTCACGTCATACAGCCGTTATCCCCGTATGATGGTCGCTGCAGGTATAACGCTTCCCGAACTGATTGACCGCCTGATCGTATTAGCGTTAAAGGGGTGATAAGCATGGAAAAGGGATTTGTTTTTTTAGATGAAATATTGCACGGTGTTCGCTGGGACGCCAAATATGCCACATGGGACAATTTCACAGGGAAACCAGTAGACGGATATGAGGTCAATCGCATAGTGGGAACACATGCCTTAGCCCTTGCGCTGCTGAAGGCGCAGAAGCAAGCGGCGGCTCTTGGGTACGGTTTGCTGTTATGGGACGGGTATCGGCCCAAACGTGCGGTAGATTGCTTCCTGCGTTGGTCCGAACAACCGGAAGACAACCTCACAAAAGAAAGATACTATCCGAATATCGAGCGAACCGAGATGGTTTCAAAAGGATACGTGGCTTCAAAATCAAGCCATAGCCGCGGAAGCGCAATTGATCTTACGCTTTATCGATTAGACACGGGTGAGCTTGTACCAATGGGGAGCGGATTTGATTTTATGGATGAGCGTTCACACCATGCGGCAAAAGGGATTGCAAGCATGGAAGCGCAAAATCGCAGACGTTTGCGTTCCATCATGGAAAACAGTGGGTTTGAACCATATAGCTTCGAATGGTGGCACTATGTATTAAGAAACGAAACCATACCCCAATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7408,Drugs,MEG_7408|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,VanHAX_PA_1_DQ018711,5
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaaaggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5589,Drugs,MEG_5589|Drugs|betalactams|Class_C_betalactamases|PDC,959882895|WP_058157026.1|NG_057602|1|1|blaPDC-271|blaPDC|class_C_beta-lactamase_PDC-271 NG_057602:1-1194,0
,atgaacattaaagcactcttacttataacaagcactatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcacttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaaatatttaagtgggacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggtgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagttatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcctaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagatgacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4437,Drugs,MEG_4437|Drugs|betalactams|Class_D_betalactamases|OXA,1559612978|WP_128268243.1|NG_063848|1|1|blaOXA-744|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-744 NG_063848:40-864,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGTCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGACGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCTCGTAGCACCTCGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAGAGATGCCGGTCGGTAATGATGGTGGTGAACCGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6414,Drugs,MEG_6414|Drugs|betalactams|Class_A_betalactamases|SHV,gi|15721850|gb|AY037778.1|92-1067,0
,atgaagaaaaagattgatattactgtttttggatgtgagccggacgaagcgacagttttccgtaaactgtcccatgaatttggtgttacggtctcactcgtaagagaagcagtatcggaggacaatgcaaaagtagccgatggatgccagtgtgtcagcataagccataaagcggagctgtcggagcctctccttctcgcgttgaaagacgccggagtgaaatatatctgcacccggagcatcggttataaccatattgatatacaggcggccggtcaaatgggaatgaccatcggcacagtagcctactcgccggggagcgtcgccgactatgccattatgctgatgcttatgctgatgcgtggaacaaaatccgtaatacacagaactgaaaaacaggattattgcctgaatagccttcgcgggaaggaattgcgggatatgacggttggcgtattaggggcgggacggatcggacaggctgttatggaacgcttgaaaggattcggctgtacggtgctggcatatgaccgtaatcataaagccggagcagattatgtttcattttgtgagctgctgcaaagaagcgacatcattacgcttcatgttccgctggcagaagatactttccatatgattgggcgcgagcaattagaaatgatgaagaaagaggcgcttcttatcaatacggcgcggggcgctttagtggacaccggggcattggtagaggcactggcagatgggaaaattggaggcgccgctttagatgtactggaaggcgaagaagggtttttttattatgactgcacgtacaaggcggtagaacatccctttttatcgaccctacaaaggatgccaaatgtaattgttacgccgcatactgcctaccatacggaacgggtgttggttgacaccgtgagcaatacgattcggaattgtctgaactttgaaaggagtcttggaaatgtatag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7419,Drugs,MEG_7419|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,1028100570|WP_063856705.1|NG_048385|1|1|vanH-D|vanH-D|D-lactate_dehydrogenase_VanH-D NG_048385:101-1072,5
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGATAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTACAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1837,Drugs,MEG_1837|Drugs|betalactams|Class_C_betalactamases|CMY,(Bla)CMY-14:EU600193:1702-2847:1146,0
,ATGAAAATAGGATTTACTTTTTTAGATGAAATATTACACGGTGTTCGTTGGGACGCTAAATATGCCACATGGGACAATTTCACCGGAAAGCCGGTTGACGGATATGAAGTAAATCGCATTGTAGGAACATACGAGTTGGCCGACGCGCTTTTGAAGGTAAAAGAACTGGCTGCTACTCAAGGGTACGGATTGCTTCTATGGGACGGTTACCGTCCCCAACGCGCTGTAAACTGTTTTTTGCAATGGGCTGCACAGCCGGAAGATGACCTGACAAAGGAAAGATATTATCCCAATATTGACCGAACCGAGATGGTTTCAAAAGGATACGTGGCTTCAAAATCAAGCCATAGCCGCGGAAGTGCAATTGATCTTACGCTTTATCGATTAGACACGGGTGAGCTGGTACCAATGGGGAGCGGATTTGATTTTATGGATGAACGCTCTCATCATGCGGCAAAAGGAATTTCAGGCAATGAAGCGCAAAATCGCAGACGTTTGCGTTCCATCATGGAAGACAGTGGGTTTGAAGCATATAGCTTCGAATGGTGGCACTATGTATTAAGAAACGAACCATACCCCAACAGCTATTTTGATTTCCCCGTTAAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7553,Drugs,MEG_7553|Drugs|Glycopeptides|VanA-type_resistance_protein|VANXA,(Gly)VanX-Pt:DQ018710:7107-7715:609,5
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggcctatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcaacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5556,Drugs,MEG_5556|Drugs|betalactams|Class_C_betalactamases|PDC,1028110207|WP_063864577.1|NG_049899|1|1|blaPDC-26|blaPDC|class_C_beta-lactamase_PDC-26 NG_049899:1-1194,0
,ATGAAAAAAAGTATTCAGCTTTTGATGATGTCAATGTTTTTTAGCCCATTGATCAATGCCCAGGTTAAAGATTTTGTAATTGAGCCGCCTGTTAAACCCAACCTGTATCTTTATAAAAGTTTCGGAGTTTTCGGAGGTAAAGAATATTCTGCCAATGCTGTATATCTTACCACTAAGAAAGGAGTTGTCTTATTTGATGTACCATGGCAAAAGGAACAATATCAAACCCTTATGGACACCATACAAAAGCGTCATCACCTTCCTGTAATTGCTGTATTTGCCACCCACTCTCATGATGACAGAGCGGGCGATCTAAGCTTTTACAATCAAAAAGGAATTAAAACATATGCGACCGCCAAGACCAATGAACTGTTGAAAAAAGACGGAAAAGCAACCTCAACCGAAATTATAAAAACAGGAAAACCTTACAAAATTGGTGGTGAAGAATTTATGGTAGACTTTCTTGGAGAAGGACATACAGTTGATAATGTTGTCGTATGGTTTCCCAAATATAAAGTATTGGACGGAGGATGTCTTGTAAAAAGCAGGACAGCCACTGACCTGGGATATACCGGTGAAGCAAATGTAAAACAATGGCCGGAAACCATGCGAAAACTAAAAACGAAATATGCTCAGGCCACTCTGGTAATCCCGGGACACGACGAATGGAAAGGCGGTGGCCATGTACAGCATACTCTGGATCTTCTGGATAAGAATAAAAAGCCGGAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3403,Drugs,MEG_3403|Drugs|betalactams|Class_B_betalactamases|IND,(Bla)IND-2:EF394439:1-732:732,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagtctcattctccacgtttgccgccgccaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaactctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaatctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatcagcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttacagataaagccgcattactgcgtttttatcaaaactggcagccgcaatgggctccgggcgctaagcgtctttacgctaactccagcattggtctgtttggtgcgctggcggtgaaaccctcaggtatgagctacgaagaggcaatcaccagacgcgtcctgcagccattaaaactggcgcatacctggattacagttccgcaaagcgaacaaaaagattatgcctggggctatcgcgaagggaagcctgtacacgtttctccgggacaacttgatgccgaagcctatggcgtgaaatccaacgttaccgatatggcacgctgggttcaggtcaacatggacgccagccgcgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggatgggagatgctgaactggccgctgaaagctgattcgatcatcaacggtagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggatccactggaggatttggcagctacgtagccttcattccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1832,Drugs,MEG_1832|Drugs|betalactams|Class_C_betalactamases|CMY,1102724728|WP_071593224.1|NG_052048|1|1|blaCMY-144|blaCMY|class_C_beta-lactamase_CMY-144 NG_052048:101-1246,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAAAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACACATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGATGGTGTTTCAAAAGACTGTAAGGTGGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1344,Drugs,MEG_1344|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_121_AIWM01000014,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTACACATACTAAAGAGTTAAATAATTTAGAAAAAAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTACAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAAGTTGCTGATAAAAGTGGTCAAGCAATAACATTTGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1333,Drugs,MEG_1333|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_41_AENR01000015,0
,GTGATGATGGCACTGGTCATCATTTTTTTAGATGCTATGGGGATTGGCATAATTATGCCTGTCTTGCCGGCGTTATTACGGGAGTTTGTTGGAAAGGCTAATGTTGCAGAGAACTACGGTGTTTTATTGGCGCTGTATGCAATGATGCAAGTGATTTTTGCCCCTCTTCTCGGCCGCTGGTCAGATCGCATAGGTCGTCGCCCTGTATTGTTACTTTCACTTTTAGGTGCAACACTGGACTACGCATTAATGGCAACAGCCAGCGTAGTGTGGGTGTTGTATTTGGGACGCTTAATTGCTGGTATTACCGGTGCGACTGGAGCTGTTGCAGCCTCAACAATTGCCGATGTCACACCTGAGGAATCCAGGACACATTGGTTTGGTATGATGGGTGCCTGTTTTGGTGGCGGTATGATTGCTGGACCAGTCATTGGTGGTTTTGCCGGTCAACTTTCGGTACAGGCACCGTTTATGTTCGCTGCTGCTATTAACGGGCTGGCATTTCTGGTCTCCCTATTCATTTTACATGAGACCCATAATGCTAATCAGGTTAGTGACGAGTTAAAGAATGAAACAATCAATGAAACCACATCCTCCATACGCGAGATGATCTCCCCATTATCGGGATTGTTAGTTGTCTTTTTCATCATTCAATTGATTGGCCAAATCCCCGCAACATTATGGGTTTTATTCGGAGAAGAGCGCTTCGCATGGGATGGCGTAATGGTCGGTGTTTCATTGGCTGTGTTCGGGCTGACACACGCACTGTTTCAAGGACTTGCTGCTGGTTTTATCGCTAAACATTTGGGAGAACGGAAAGCTATAGCGGTTGGCATTTTGGCTGACGGTTGTGGCCTATTTTTATTGGCGGTCTTTACACAAAGCTGGATGGTTTGCCCGGTTTTGCTGTTACTAGCTTGTGGTGGCATCACACTTCCCGCCTTGCAGGGAATTATATCTGTTCGTGTCGGTCAGGTAGCACAGGGACAATTACAAGGGGTGCTGACCAGTTTGACCCACCTGACAGCTGTAATCGGTCCACTTGTTTTTGCATTTTTGTATAGTGCAACCCGCGAAACGTGGAATGGATGGGTATGGATAATTGGCTGCGGATTATATGTAGTTGCATTGATTATACTGAGGTTTTTCCATCCAGGTAGGGTAATCCACCCGATAAATAAGAGCGATGTACAGCA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7074,Drugs,MEG_7074|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETE,gi|12053583|emb|Y19116.1|1-1196 gi|327195566|gb|HQ399593.1|1-273 gi|296044842|gb|HM041202.1|195-1 gi|296044846|gb|HM041204.1|189-1,4
,ATGAAAATTATTAATATAGGAATATTAGCACATGTTGATGCAGGTAAAACAACTGTTACAGAAGGTTTATTATATAAAAGTGGGGCGATTAATAAAATTGGAAGAGTTGATAATGCTACAACGACAACGGATTCGATGGAACTTGAAAGAGATAGGGGAATAACTATACGGGCGTCTACAGTTTCATTTAATTACAATGATACAAAGGTAAATATCATAGATACACCTGGGCACATGGATTTCATAGCCGAAGTTGAGCGAACTCTGAAAGTGTTAGATGGAGCTATTTTAGTAATTTCAGCAAAAGAAGGAATTCAAGTCCAAACTAAAGTGATTTTTAATACTTTAGTGAAATTAAATATACCAACACTTATATTTGTGAATAAAATAGATCGAAAGGGAGTATGTTTGGATGAGATATACACTCAAATACAGGAGAAATTAACTTCTAATCTTGCAATAATGCAATCAGTTAAAATAAAAGATAAAGGTGATTTTGAATTGACAAATGTAAGGGATGATAAAGTAATTCAAAGTCAAATAATAGAGAAGTTACTGGATATAAATGATTATCTAGCAGAAAAATATATAAATGGCGATGTCATTGCAGAAAAAGAATATAATGATGTATTTTTGGATGAGATTAATAACTGCAATCTTTATCCTGTATTTCATGGTTCGGCTTTAAAAAATATTGGAATTGACGAGCTATTATTTGCCATTACTAAATATCTTCCTACCAAGAGCTATAATACTGAAGACCTTTTATCAGCGTATGTTTATAAGATTGATAGGGATGAAAAATCTAGAAAGATGACTTTCTTAAGAGTATTCAGTGGGAATATAAGGACACGTCAAGATGTTTATATAAATGGCACAGAAGAAACTTTCAAGATAAAAAGTCTGGAATCAGTTATGAATGGTGAAATTGTGAAGGTAGATCAGGTTAATAGTGGGGATATTGCTATTATTTCTAATGCTAATTCTCTGAAGATAGGTGATTATATTGGTAAGAAATATGACGGGATTTTAGATATAAAGATAGCCCAACCGGCATTGAGAGCATCAATTAAACCTTGTGATTTAAGCAAAAGAAGCAAACTGATAGAAGCACTATTTGAATTAACTGAAGAAGACCCATTTCTCGATTGTGAAATTAACGGAGATACTGGAGAAATCATATTGAAGCTATTTGGAAATATTCAAATGGAAGTAATAGAATCACTACTTAAAAGCCGATACAAAATAGATGCTAGATTTTGTGAATTGAAAACAATATATAAAGAACGACCTAAGAGAAACTCTAAAGCAGTAATCCATATAGAGGTTCCACCAAATCCTTATTGGGCATCTATTGGACTGTCAATAGAACCACTACCAATAGGGTCAGGATTATTATATAAGACAGAGGTGTCCTATGGATATTTAAATAATTCATTTCAAAATGCAGTAAAAGATGCTGTAGAGAAGGCTTGTAAAGAAGGGCTTTATGGATGGGAAGTTACAGACTTAAAGGTAACTTTTGACTACGGATTATACTATAGCCCGGTAAGTACCCCCTCTGACTTTAGGAATTTAACACCATATGTATTTTGGGAAGCTCTTCGAAAAGCAGGAACTGAAATATTAGAACCTTATTTAAAATATACAGTTCAAGTTCCAAATGATTTCTGCGGAAGGGTTATGAGTGATCTTAGAAAGATGAGGGCTTCTATTGAAGATATAATAGCCAAGGGAGAGGAGACAACTTTAAGTGGAAAGATACCTGTTGATACATCGAAGTCCTATCAGTCAGAATTACTTTCTTATTCAAATGGAAAGGGTATATTTATTACTGAGCCTTATGGGTATGATATATATAATGATAAGCCTATAATTAATGATATTGGGAACGACAATAATGATAGCAACAAGGAAGGGTTAAGATATTTATTTCAAAAACAGGATGAAAATTGA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7203,Drugs,MEG_7203|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETT,gi|56155266|gb|AY660530.1|48-2003 gi|239829480|gb|FJ950716.1|1-114,4
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTTTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1340,Drugs,MEG_1340|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_61_NZ_JVAT01000021,0
,ATGAAAAAATCCCTGATTGCCCTGACTTTGGCAGCCCTTCCTGTTGCGGCAACGGCCGATGTCACCCTGTACGGCGCCATCAAAGCCGGCGTACAAACTTACCGTTCTGTAGAACATACAAAAGGCAAGGTAAGTAAAGTGGAAACCGGCAGCGAAATCGCCGACTTCGGTTCAAAAATCGGCTTCAAAGGCCAAGAAGACCTCGGCAACGGCCTGAAGGCCGTTTGGCAGTTGGAACAAGGTGCCTCCGTCGCCGGCACTAACACCGGCTGGGGCAACAAACAATCCTTCGTCGGCTTGAAGGGCGGCTTCGGTACCATCCGCGCCGGTAGCCTGAACAGCCCCCTGAAAAACACCGGCGCCAACGTCAATGCTTGGGAATCCGGCAAATTTACCGGCAATGTGCTGGAAATCAGCGGAATGGCCCAACGGGAACACCGCTACCTGTCCGTACGCTACGATTCTCCCGAATTTGCCGGCTTCAGCGGCAGCGTACAATACGCACCTAAAGACAATTCAGGCTCAAACGGCGAATCTTACCACGTTGGTTTGAACTACCGAAACAACGGCTTCTTCGCACAATACGCCGGCTTGTTCCAAAGATACGGCGAAGGCACTAAAAAAATCGAATACGAACATCAAGTTTATAGTATCCCCAGCCTGTTTGTTGAAAAACTGCAAGTTCACCGTTTGGTAGGCGGTTACGACAATAATGCCCTGTACGTTTCCGTAGCCGCGCAACAACAAGATGCCAAATTGTATGGAGCAAGGAGGGCTAATTCGCACAACTCTCAAACCGAAGTTGCCGCTACCGCGGCATACCGTTTCGGCAATGTAACGCCCCGCGTTTCTTACGCCCACGGCTTCAAAGGCACTGTTGATAGTGCAGACCACGACAATACTTATGACCAAGTGGTTGTCGGTGCGGAATACGACTTCTCCAAACGCACTTCTGCCTTGGTTTCTGCCGGCTGGTTGCAAGAAGGCAAAGGCGCAGACAAAATCGTATCGACTGCCAGCGCCGTCGTTCTGCGCCACAAATTCTAA,General Bacterial Porin (GBP),reduced permeability to antibiotic,Multi-drug_resistance,MEG_5808,Drugs,MEG_5808|Drugs|Multi-drug_resistance|MDR_mutant_porin_proteins|POR,gb|U75641|+|19-1066|ARO:3000464|Neisseria gonorrhoeae mutant porin PIB (por) with reduced permeability to antibiotic [Neisseria gonorrhoeae] ,1
,ATGTTCAAACTTTTGAGTAAGTTATTGGTCTATTTGACCGCGTCTATCATGGCTATTGCGAGTCCGCTCGCTTTTTCCGTAGATTCTAGCGGTGAGTATCCGACAGTCAGCGAAATTCCGGTCGGGGAGGTCCGGCTTTACCAGATTGCCGATGGTGTTTGGTCGCATATCGCAACGCAGTCGTTTGATGGCGCAGTCTACCCGTCCAATGGTCTCATTGTCCGTGATGGTGATGAGTTGCTTTTGATTGATACAGCGTGGGGTGCGAAAAACACAGCGGCACTTCTCGCGGAGATTGAGAAGCAAATTGGACTTCCTGTAACGCGTGCAGTCTCCACGCACTTTCATGACGACCGCGTCGGCGGCGTTGATGTCCTTCGGGCGGCTGGGGTGGCAACGTACGCATCACCGTCGACACGCCGGCTAACCGAGGTAGAGGGGAACGAGATTCCCACGCACTCTCTAGAAGGACTCTCATCGAGCGGGGACGCAGTGCGCTTCGGTCCAGTAGAACTCTTCTATCCTGGTGCTGCGCATTCGACCGACAACTTAGTTGTGTACGTCCCGTCTGCGAGTGTGCTCTATGGTGGTTGTGCGATTTATGAGTTGTCACGCACGTCTGCGGGGAACGTGGCCGATGCCGATCTGGCTGAATGGCCCACCTCCATTGAGCGGATTCAACAACACTACCCGGAAGCACAGTTCGTCATTCCGGGGCACGGCCTGCCGGGCGGTCTAGACTTGCTCAAGCACACAACGAATGTTGTAAAAGCGCACACAAATCGCTCAGTCGTTGAGTAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_7721,Drugs,MEG_7721|Drugs|betalactams|Class_B_betalactamases|VIM,(Bla)VIM-14:EF055455:1-801:801,0
,atgacttttaatattattaatttggaaacttgggatagaaaagaatattttaatcattatttcaatcaacaaacaacttacagtgttactaaagaatttgatatcactttacttaaaagtatgataaaaaataaaggatatgaactgtatcctgctttgatttatacaattgtaaatattataaatcaaaataaagtatttagaacaggaattaatagtagtggaaatttgggattttgggataaattaaaccctttatatacatgtttaataaacgaaactgaaaaatttctaaacatttggatagaatcaaatgttagttttagttctttttataatagttataagagtgacttacttgaatataaagatacaaatgaaatgtttcctaaaaaaccaatacctgaaaacacaggtcctatttcgatgattccttggattgattttagttcatttaatttaaatattggtaataatagtagattcctattgccaattattacaataggtaaattttatagtaagaataataagatctatttaccagtctcattgcaagttcatcatgcggtatgtgatggttaccatgtttcattatttatgagtgaatttcaaaatatagttgatagtgtaaatgaatgggatttaaatctaaaataa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1574,Drugs,MEG_1574|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,1028084241|WP_063843209.1|NG_047570|1|1|catA8|catA8|type_A-8_chloramphenicol_O-acetyltransferase NG_047570:101-760,6
,ATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGGGTGGCATTGATTAACACAGCGGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTCGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAGTCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2438,Drugs,MEG_2438|Drugs|betalactams|Class_A_betalactamases|CTX,blaCTX-M-206_1_KJ802520,0
,ATTACGGAACTGATTTCATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACTCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCACCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTGACGATGAGGCCCAGGATATTGGGCCTCCTTTCTTTCTCTTTTTTTCCTGTTGTCATCTACACTTAACAAAAATACAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_1979,Drugs,MEG_1979|Drugs|betalactams|Class_C_betalactamases|CMY,gi|537366551|gb|KF305673.1|1-1243,0
,atgtcagagactttgcaattagaacaattaacggcatctttacagcagcttctgggtgaggcactgtttggtatttatctatatggttcagctgttgatggtggtttaggtccagaaagtgatttggatcttttggttgtcataactcaagcattgacacttcagcaacgaaaacaactggcagaaaccttattacaaatttcgcatccgattggtgctgtacaacgtgcacttgaagtcactatcgtacacaaagatcatattctttcgggaagttatccactcagctacgaactacagtttggggaatggttacgggatgagttaaaccaaggtgttatacttagcgaacatgcagacccagatctaagcattctgctgaagaaagcacagatgcatcatcttactttgttagggccaagtttttcacagtggtcagttgagattcctgtacagcaactctggcaggcgatggcagatacctatccatcaattgtggcacattgggatgaggatgctgatgagcgtaatcagattttggccttatgccgtatctattttagtttggtgacgaatgagattgcacctaaagatcaggctgcgcaatgggtgattgctcagttacaaccgcaacatcagcctgttttgcagcgcatgagtcaagaatataaaggtcagattgcaaagcaaaattggcaggatgagtatcaggctttacagcccattgttgatttcctgagttcaagaattgatgaacaatttaagaagaagagtagcctgaacaaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_835,Drugs,MEG_835|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,491143196|WP_005001597.1|NG_054653|1|1|ant(3'')-IIc|ant(3'')-IIc|aminoglycoside_nucleotidyltransferase_ANT(3'')-IIc NG_054653:101-889,2
,ATGAAAAAATTATTTGTTTTATGTGTATTCTTCCTTTGCAACATTGCTGCTGCAGATGATTCTTTGCCTGATTTAAAAATTGAGAAGCTTGAAAAAGGCGTTTATGTTCATACTTCGTTTGAAGAAGTTAAAGGTTGGGGTGTAGTCACAAAACACGGTTTAGTGGTTCTTGTAAAGAATGATGCTTATCTGATAGATACTCCAATTACCGCTAAAGATACTGAAAAATTAGTTAATTGGTTTATTGAGCACGGCTATAGAATCAAAGGCAGTATTTCCACACATTTCCATGGCGACAGTACGGCTGGAATAGAGTGGCTTAATTCTCAATCTATCTCCACGTATGCCTCTGAATTAACAAATGAACTTCTAAAAAAAGACAATAAGGTGCAAGCTACAAATTCTTTTAGTGGAGTTAGTTATTCACTTATCAAAAACAAAATTGAAGTTTTCTATCCAGGTCCAGGACACACTCAAGATAACGTAGTGGTTTGGTTACCTGAAAAGAAAATTTTATTCGGTGGTTGCTTTGTTAAACCGGACGGTCTTGGAAATTTAGGGGATGCAAATTTAGAAGCTTGGCCAAAGTCCGCTAAAATATTAATGTCTAAATATGGTAAAGCAAAACTGGTTGTTTCAAGTCATAGTGAAATTGGAAACGCATCACTCTTGCAGCGCACATGGGAGCAGGCTGTTAAAGGGTTAAATGAAAGTAAAAAACCGTTACAGCCAAGTAGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3340,Drugs,MEG_3340|Drugs|betalactams|Class_B_betalactamases|IMP,(Bla)IMP-18:AB587676:1366-2106:741,0
,GGATCCCGAGTTCTGGCCCGACGCCCTCAAGGGGGAGGCCGCATATCTGCACAAGCTCGCGGTGCGACGGACACATGCGGGCCGGGGTGTCAGCTCCGCGCTGATCGAGGCTTGCCGCCATGCCGCGCGAACGCAGGGGTGCGCCAAGCTGCGGCTCGACTGCCACCCGAACCTGCGTGGCCTATACGAGCGGCTCGGATTCACCCACGTCGAGGCAATGGTTGAAATGCTCGGCGGGCGCGTCACGGAGGAGTTGGACTATGGATTCTTAGCGGAGATCGGGGATGAGTTACTTGACTGCGAACCTGCTTGGTGGGCAGACGAAGCGTATGAAATCGCGGAGGCTCCGCAGGGCTCGTGCCCAGAGGCGGCTGAGGGCGTCATCGCCGGGCGGCCAGTCCGTTGTAACAGCTGGGAGGCGATCATCTGGGATTACTTTTACTATGCCGATGAAGTACCACCAATGGACTGGCCTACAAAGCACATAGAGTCCTACAGGCTCGCATGCACCTCACTCGGGGCGGAAAAGGTTGAGGTCTTGCGTGCCGCTTTCAGGTCGCGATATGCGGCCTAACAATTCGTCCAAGCCGACGCCGCTTCGCGGCGCGGCTTAACTCAGGTGTTAGCCTTATTTGAATACTTCACACTCTGATATAAGATGTAAGCCAATCAAAATGATGAGGTTATTACATGAAGCTTTTACTGGTATTTTCGCTTTTAATACCGTCTATGGTGTTTGCAAATAGTTCAAAGTTTCAACAGGTTGAACAAGATGCTAAGGTAATTGAAGCATCTCTTTCTGCGCATATAGGGATTTCTGTTCTTGATACTCAAACTGGAGAGTATTGGGATTACAATGGCAATCAGCGTTTTCCTTTGACAAGTACTTTTAAAACAATAGCTTGTGCTAAATTATTATATGATGCTGAGCAAGGGGAAATAAACCCTAAGAGTACAATTGAGATCAAAAAAGCAGATCTTGTGACCTATTCTCCCGTAATAGAAAAGCAAGTAGGACAAGCAATAACGCTCGATGATGCGTGTTTTGCAACTATGACGACAAGTGATAATGCAGCAGCAAATATCATCCTAAATGCCCTAGGAGGTCCTGAAAGCGTGACGGATTTTCTAAGACAAATCGGAGATAAAGAAACCCGTCTAGACCGTATTGAACCTGAATTAAATGAAGGCAAGCTTGGTGATTTGAGGGATACGACAACTCCTAATGCAATAGTGAATACTTTAAATGAATTATTATTTGGTTCCACATTGTCTCAAGATGGCCAGAAAAAATTAGAGTATTGGATGGTGAATAATCAAGTCACTGGTAATTTATTGCGGTCAGTATTGCCAGAGGGATGGAATATTGCGGATCGTTCAGGTGCTGGCGGATTTGGTGCTCGGAGTATTACAGCCGTTGTTTGGAGTGAAGCTCAATCCCCAATCATAGTTAGTATCTATCTAGCGCAAACAGAGGCTTCAATAGCAGATCGAAATGATGCAATTGTTAAAATTGGTCGTTCAATTTTTGAAGTTTATTCATCACAATCGCGTTGATAAGGCTAACAAAGCATTTAAGAGGGACAGCCAACGCGTGGCACTTTTATTATGCGTTGGTTTTTGTGGTTACGGTGTTATGCGGTAAGTTGGTAGTAGCGTTGGCTGCCCCTTAATGCGGCGTTAGATGCACTAAGCACATAATTGCTCACAGCCAAACTATCAGGTCAAGTCTGCTTTTATTATTTTTAAGCGTGCATAATAAGCCCTACACAAATTGGGAGATATATCATGAAAGGCTGGCTTTTTCTTGTTATCGCAATAGTTGGCGAAGTAATCGCAACATCCGCATTAAAATCTAGCGAGGGCTTTACTAAGCTT,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1544,Drugs,MEG_1544|Drugs|betalactams|Class_A_betalactamases|CARB,gi|695198358|ref|NG_034961.1|1-1878 gi|62719421|gb|AY913771.1|1496-2556 gi|815968487|gb|CP011317.1|3717410-3717622 gi|815968487|gb|CP011317.1|3715763-3715964 gi|815968487|gb|CP011317.1|3715155-3715260 gi|815968487|gb|CP011317.1|3713637-3713738 gi|408362959|gb|JX448550.1|11231-11019 gi|408362959|gb|JX448550.1|12880-12677 gi|88911226|gb|DQ393781.1|2781-2962 gi|81345567|gb|DQ266447.1|2355-2417 gi|330885916|gb|HQ880250.1|2329-2357,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6431,Drugs,MEG_6431|Drugs|betalactams|Class_A_betalactamases|SHV,gi|2113854|emb|X98098.1|74-934,0
,ATGTCCAAGTATAAAAAAATGAAACAGCTCATAGCGGATATGCGCTTACCTGAGTATCGTTATAAGCAACTGCTTGATGCTGTGTTCCTACAAGGAATTATGCGTTTTGAAGATATGAAGTTGCTTCCAAAAACGCTGCGCGAAAAGTTGGTGGAGCAGTTTGGTGAAACTGTTGTGGAGATCAAGGCGATCCATCATGAGAAATCAATGCAAACTGACAAGGTGCTGTTTGAACTGTCGGACGGAAACCGTGTGGAAACGGTGGGTCTGTTTTATAAAGAGGGCTGGAACTCCTTTTGCATTTCATCTCAAAGCGGTTGCGGCTTCGGTTGTAAGTTTTGCGCAACAGGGACTTTGGGATTACGCAGAAACTTGACTGTGGATGAAATTACCGACCAAATCCTATATTTTATGCAACAAGGATGCAGTATCAACAGTATCTCTTTTATGGGAATGGGAGAGCCGTTCGCTAATCCACAAGTTTTTGAAGCCCTGCATGATCTGACCGCCCCGGAACTGTTCGGGCTGTCCCAGCGACGCATCACCATTTCGACTATCGGTATCGTGCCGGGTATTCAAAAATTGACAAGAGAATATCCGCAAGTCAATCTGGCCTATTCCCTCCACGCACCTACTGACCGTCTGAGGGAAACGCTCATGCCAATAACTAAAACATACCCCCTTGGTCAGGTACTGGATACATTAGATCAGCACATTCGGCAAACAAATCGCAAGGTGTTTTTGGCATACATCATGCTAAAGGATGTCAATGACAGCGACAGACACGCAGAGCAACTTACCAAGTTGTTATTCAAACACAAAAAGTATTTGCCACTATACCATTTAGATTTAATCCCATACAATCAAACGACAGTTACGGAAACTATGGTGCCCTCAAGCCACACACGAATAAAGGCCTTTTGCCGTATCATTCATAATGCAGGAATTAGCGTCAATATCCGAACGCAATTTGGCTCCGATATTAACGCTGCTTGTGGCCAGTTGGCGGGGGCCTACCGTGACGATCAAAAACAAGGAGAGAGAACAATGTCCGCTATACAAGAACAGTCTTTTGAATGGCTCTTGTGTCCTGTGTGCAAGAGCAAAACACGACTTAAAATCCGAAAGGACACGATACTTGACAATTTCCCACTCTTTTGTCCCAAATGCAAAAGTGAAATGCTTATCTGTGTCAAACAATTTCATATATCTATTATCAAAGAGCCAGACGCACAGACGCAGAGCCGATAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_1680,Drugs,MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR,cfr(C)_2_CANB01000378 ,7
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcagccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4682,Drugs,MEG_4682|Drugs|betalactams|Class_D_betalactamases|OXA,1509794612|WP_122630921.1|NG_062341|1|1|blaOXA-713|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-713 NG_062341:15-839,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgagctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacagttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1793,Drugs,MEG_1793|Drugs|betalactams|Class_C_betalactamases|CMY,1209144251|WP_088245213.1|NG_055270|1|1|blaCMY-154|blaCMY|class_C_beta-lactamase_CMY-154 NG_055270:1-1146,0
,TTGATTCATAGAAATTACAACTGTAATATTGGAGGGTATATTTTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAAAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCACAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAACAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1407,Drugs,MEG_1407|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_133_AIDT01000014,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAATACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGTAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGATGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6411,Drugs,MEG_6411|Drugs|betalactams|Class_A_betalactamases|SHV,gi|125658591|gb|EF373974.1|1-861,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgattttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_779,Drugs,MEG_779|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502217|WP_071846367.1|NG_052494|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052494:101-892,2
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTAGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_6895,Drugs,MEG_6895|Drugs|betalactams|Class_A_betalactamases|TEM,gi|25900616|emb|AJ437107.1|1-1091 gi|961666360|gb|KT185451.1|87734-87690 gi|530347473|gb|CP006657.1|114767-114811,0
,TTGTAAGTGTTTAAGGGCGCATGGTGGATGCCTTGGCACTGGGAGCCGATGAAGGACGTAGGAGGCTGCGATAAGCCTCGGGGAGCTGTCAACCGAGCGTTGATCCGAGGATGTCCGAATGGGGAAACCCGGCACGAGTGATGTCGTGTCACCAGGCGCTGAATATATAGGCGTCTGGGGGGAACGCGGGGAAGTGAAACATCTCAGTACCCGTAGGAAGAGAAAACAAAATGTGATTCCGTGAGTAGTGGCGAGCGAAAGCGGAGGATGGCTAAACCGTATGCATGTGATACCGGGTAGGGGTTGTGTGTGCGGGGTTGTGGGACCTATCTTTCCGGCTCTACCTGGCTGGAGGGCAGTGAGAAAATGTTGTGGTTAGCGGAAATGGCTTGGGATGGCCTGCCGTAGACGGTGAGAGCCCGGTACGTGAAAACCCGACGTCTGTCTTGATGGTGTTCCCGAGTAGCAGCGGGCCCGTGGAATCTGCTGTGAATCTGCCGGGACCACCCGGTAAGCCTGAATACTTCCCAGTGACCGATAGCGGATTAGTACCGTGAGGGAATGGTGAAAAGTACCCCGGGAGGGGAGTGAAAGAGTACCTGAAACCGTGCGCTTACAATCCGTCAGAGCCCTCGACGTGTCGTGGGGTGATGGCGTGCCTTTTGAAGAATGAGCCTGCGAGTCAGGGACATGTCGCGAGGTTAACCCGGGTGGGGTAGCCGCAGCGAAAGCGAGTCTGAATAGGGCGTATCCACGCAACAGTGTGTGGTGTAGTGGTGTGTTCTGGACCCGAAGCGGAGTGATCTACCCATGGCCAGGGTGAAGCGCGGGTAAGACCGCGTGGAGGCCCGAACCCACTTAGGTTGAAGACTGAGGGGATGAGCTGTGGGTAGGGGTGAAAGGCCAATCAAACTCCGTGATAGCTGGTTCTCCCCGAAATGCATTTAGGTGCAGCGTTGCGTGTTTCTTGCCGGAGGTAGAGCTACTGGATGGCCGATGGGCCCCACAGGGTTACTGACGTCAGCCAAACTCCGAATGCCGGTAAGTCCAAGAGTGCGGCAGTGAGACGGCGGGGGATAAGCTCCGTGCGTCGAGAGGGAAACAGCCCAGATCGCCGGCTAAGGCCCCTAAGCGTGTGCTAAGTGGAAAAGGATGTGCAGTCGCGAAGACAACCAGGAGGTTGGCTTAGAAGCAGCCACCCTTGAAAGAGTGCGTAATAGCTCACTGGTCAAGTGATTGTGCGCCGATAATGTAGCGGGGCTCAAGCACACCGCCGAAGCCGCGGCAACGACCTTGTGTCGTTGGGTAGGGGAGCGTCCTGCATCCGGTGAAGCCGCCGAGTGATCGAGTGGTGGAGGGTGTGGGAGTGAGAATGCAGGCATGAGTAGCGATTAGGCAAGTGAGAACCTTGCCCGCCGAAAGACCAAGGGTTCCTGGGCCAGGCCAGTCCGCCCAGGGTGAGTCGGGACCTAAGGCGAGGCCGACAGGCGTAGTCGATGGACAACGGGTTGATATTCCCGTACCCGTGTATGTGCGTCCATGATGAATCAGCGGTACTAACCATCCAAAACCACCGTGACTGCACCTTTCGGGGTGTGGCGTTGGTGGGGCTGCATGGGACCTTCGTTGGTAGTAGTCAAGCGATGGGGTGACGCAGGAAGGTAGCCGTACCGGTCAGTGGTAATACCGGGGTAAGCCTGTAGGGAGTCAGATAGGTAAATCCGTCTGGCATATATCCTGAGAGGTGATGCATAGCCGAGTGAGGCGAATTCGGTGATCCTATGCTGCCGAGAAAAGCCTCTAGCGAGGACATACACGGCCCGTACCCCAAACCAACACAGGTGGTCAGGTAGAGAATACTAAGGCGTACGAGTGAACTATGGTTAAGGAACTCGGCAAAATGCCCCCGTAACTTCGGGAGAAGGGGGACCCACATGGCGTGTAAGCCTTTACGGCCCAAGCGTGAGTGGGTGGCACAAACCAGTGAGAAGCGACTGTTTACTAAAAACACAGGTCCGTGCGAAGTCGCAAGACGATGTATACGGACTGACGCCTGCCCGGTGCTGGAAGGTTAAGAGGACCCGTTAACCCTTCGGGGTGAAGCGGAGAATTTAAGCCCCAGTAAACGGCGGTGGTAACTATAACCATCCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCTGCACGAATGGCGTAACGACTTCTCAACTGTCTCAACCATAGACTCGGCGAAATTGCACTACGAGTAAAGATGCTCGTTACGCGCGGCAGGACGAAAAGACCCCGGGACCTTCACTACAACTTGGTATTGGTGCTCGATACGGTTTGTGTAGGATAGGTGGGAGACTGTGAAGCTCACACGCCAGTGTGGGTGGAGTCGTTGTTGAAATACCACTCTGATCGTATTGGGCCTCTAACCTCGGACCGTATATCCGGTTCAGGGACAGTGCCTGGTGGGTAGTTTAACTGGGGCGGTTGCCTCCTAAAATGTAACGGAGGCGCCCAAAGGTTCCCTCAACCTGGACGGCAATCAGGTGTTGAGTGTAAGTGCACAAGGGAGCTTGACTGCGAGACGGACATGTCGAGCAGGGACGAAAGTCGGGACTAGTGATCCGGCACCTCTGAGTGGAAGGGGTGTCGCTCAACGGATAAAAGGTACCCCGGGGATAACAGGCTGATCTTCCCCAAGAGTCCATATCGACGGGATGGTTTGGCACCTCGATGTCGGCTCGTCGCATCCTGGGGCTGGAGCAGGTCCCAAGGGTTGGGCTGTTCGCCCATTAAAGCGGCACGCGAGCTGGGTTTAGAACGTCGTGAGACAGTTCGGTCTCTATCCGCCGCGCGCGTCAGAAGCTTGAGGAAACCTGTCCCTAGTACGAGAGGACCGGGACGGACGAACCTCTGGTATACCAGTTGTCCCACCAGGGGCACGGCTGGATAGCCACGTTCGGACAGGATAACCGCTGAAAGCATCTAAGCGGGAAACCTCTTCCAAGACCAGGCTTCTCACCCTCTAGGAGGGATAAGGCCCCCCGCAGACCACGGGATTGATAGACCAGACCTGGAAGCCTAGTAATAGGTGCAGGGAACTGGCACTAACCGGCCGAAAACTTACAACACCCCATAATCGTTGTAAGAAGAAAACATTGACGCACC,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3975,Drugs,MEG_3975|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|AB011184.1|+|0-3162|ARO:3004169|Mycolicibacterium smegmatis 23S rRNA with mutation conferring resistance to clarithromycin [Mycolicibacterium smegmatis] ,7
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactatagtccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2205,Drugs,MEG_2205|Drugs|betalactams|Class_A_betalactamases|CTX,1408841629|WP_111672902.1|NG_060560|1|1|blaCTX-M-220|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-220 NG_060560:1-876,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagctggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1830,Drugs,MEG_1830|Drugs|betalactams|Class_C_betalactamases|CMY,1028104401|WP_063859784.1|NG_048800|1|1|blaCMY-130|blaCMY|class_C_beta-lactamase_CMY-130 NG_048800:1-1146,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACTCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAACTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTACAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1835,Drugs,MEG_1835|Drugs|betalactams|Class_C_betalactamases|CMY,(Bla)CMY-12:FR716828:847-1992:1146,0
,ATGCGTTATGTTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTCACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAATGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6466,Drugs,MEG_6466|Drugs|betalactams|Class_A_betalactamases|SHV,gi|50513038|gb|AY677211.1|1-861,0
,atgcgcgataccagatttccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccacctcggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5705,Drugs,MEG_5705|Drugs|betalactams|Class_C_betalactamases|PDC,1035157546|WP_064511511.1|NG_050834|1|1|blaPDC-161|blaPDC|class_C_beta-lactamase_PDC-161 NG_050834:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagcccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5611,Drugs,MEG_5611|Drugs|betalactams|Class_C_betalactamases|PDC,1343491218|WP_104009834.1|NG_056391|1|1|blaPDC-236|blaPDC|class_C_beta-lactamase_PDC-236 NG_056391:1-1182,0
,atggttaataaactttcagcatataaaacttatttattattttcagctattacagcaatgtgtttttcactagtagctacagttatgatagtgtatcacattgaaacggtgcatttaaatccacttcagcttatacttgttggaactactttagaagtagcatgctttatatttgaaattcctacaggaatagttgcagatgtgtacagtcgtaaactatctattgttattggtgtagttttaacaggagtgggatttattttagaaggttctatttctagtttcgttttcgtacttgtagcacagattgtatggggattaggttctacttttattagtggatctgttgaagcttggattgcggaagaagagaaagataaagatttggataaaatttatataaagggagcacaagcaggacagataggatcggttattggaatagtactaagcactgtaatagctaatttatctgtaagactacctattatagttagtggagtcttatttataattcttgcattatttttatggttatatatgccagaaaataattttaaatcatctgctccagaggatttaaatacttttaaaaagatgggatatacctttaaatctggtcttaaatttataaaaaataaacctataattataattttgctttcagtaactttattttatggattatccagtgaaggttatgatagactttctaatatgcattttttacaagatactatgcttcctaaacttggaaaccttaaaccagtgacttggttcggaatttttggaattgcaggaatgatattgagtgctatagtaatgcattttatggaaaagaagcttaaggatgatgataagaataaaaatggaaagctgttattatgtataaatatattttatatatcatttatgttcatatttgctattacaaaaagatttaacttaatgctaatagcttatttagcgacaagtacctttagaactataaatgaacctatatttagtgcatggcttaatggacatatagatgacaaggccagatctactgtactttctataaatggacaaataaattccttaggtcaaattttaggtggaccaattataggaatcatagctacaaatatttcagtgagtatgggtatagcatgtacttcgttattagtaacaccggtattagtgttatatattgttgctatgataatggataaaaaggtggttgatagagttggaggtattgattatgaagaaaataattaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7014,Drugs,MEG_7014|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,493486205|WP_006440994.1|NG_048316|1|1|tetA(P)|tetA(P)|tetracycline_efflux_MFS_transporter_TetA(P) NG_048316:1-1263,4
,atgcgatttaaaaaaatttcttatctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatgggcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgataagcctggtaaatattggaaagaactaaaaaatacaccgattgaccaagttaatttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcaacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccggcagatattcaacgtgcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttctgttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_525,Drugs,MEG_525|Drugs|betalactams|Class_C_betalactamases|ADC,491273066|WP_005131186.1|NG_064682|1|1|blaADC-125|blaADC|class_C_beta-lactamase_ADC-125 NG_064682:101-1252,0
,ATGACAGACACGACGTTGCCGCCTGACGACTCGCTCGACCGGATCGAACCGGTTGACATCGAGCAGGAGATGCAGCGCAGCTACATCGACTATGCGATGAGCGTGATCGTCGGCCGCGCGCTGCCGGAGGTGCGCGACGGGCTCAAGCCCGTGCATCGCCGGGTGCTCTATGCAATGTTCGATTCCGGCTTCCGCCCGGACCGCAGCCACGCCAAGTCGGCCCGGTCGGTTGCCGAGACCATGGGCAACTACCACCCGCACGGCGACGCGTCGATCTACGACAGCCTGGTGCGCATGGCCCAGCCCTGGTCGCTGCGCTACCCGCTGGTGGACGGCCAGGGCAACTTCGGCTCGCCAGGCAATGACCCACCGGCGGCGATGAGGTACACCGAAGCCCGGCTGACCCCGTTGGCGATGGAGATGCTGAGGGAAATCGACGAGGAGACAGTCGATTTCATCCCTAACTACGACGGCCGGGTGCAAGAGCCGACGGTGCTACCCAGCCGGTTCCCCAACCTGCTGGCCAACGGGTCAGGCGGCATCGCGGTCGGCATGGCAACCAATATCCCGCCGCACAACCTGCGTGAGCTGGCCGACGCGGTGTTCTGGGCGCTGGAGAATCACGACGCCGACGAAGAGGAGACCCTGGCCGCGGTCATGGGGCGGGTTAAAGGCCCGGACTTCCCGACCGCCGGACTGATCGTCGGATCCCAGGGCACCGCTGATGCCTACAAAACTGGCCGCGGCTCCATTCGAATGCGCGGAGTTGTTGAGGTAGAAGAGGATTCCCGCGGTCGTACCTCGCTGGTGATCACCGAGTTGCCGTATCAGGTCAACCACGACAACTTCATCACTTCGATCGCCGAACAGGTCCGAGACGGCAAGCTGGCCGGCATTTCCAACATTGAGGACCAGTCTAGCGATCGGGTCGGTTTACGCATCGTCATCGAGATCAAGCGCGATGCGGTGGCCAAGGTGGTGATCAATAACCTTTACAAGCACACCCAGCTGCAGACCAGCTTTGGCGCCAACATGCTAGCGATCGTCGACGGGGTGCCGCGCACGCTGCGGCTGGACCAGCTGATCCGCTATTACGTTGACCACCAACTCGACGTCATTGTGCGGCGCACCACCTACCGGCTGCGCAAGGCAAACGAGCGAGCCCACATTCTGCGCGGCCTGGTTAAAGCGCTCGACGCGCTGGACGAGGTCATTGCACTGATCCGGGCGTCGGAGACCGTCGATATCGCCCGGGCCGGACTGATCGAGCTGCTCGACATCGACGAGATCCAGGCCCAGGCAATCCTGGACATGCAGTTGCGGCGCCTGGCCGCACTGGAACGCCAGCGCATCATCGACGACCTGGCCAAAATCGAGGCCGAGATCGCCGATCTGGAAGACATCCTGGCAAAACCCGAGCGGCAGCGTGGGATCGTGCGCGACGAACTCGCCGAAATCGTGGACAGGCACGGCGACGACCGGCGTACCCGGATCATCGCGGCCGACGGAGACGTCAGCGACGAGGATTTGATCGCCCGCGAGGACGTCGTTGTCACTATCACCGAAACGGGATACGCCAAGCGCACCAAGACCGATCTGTATCGCAGCCAGAAACGCGGCGGCAAGGGCGTGCAGGGTGCGGGGTTGAAGCAGGACGACATCGTCGCGCACTTCTTCGTGTGCTCCACCCACGATTTGATCCTGTTCTTCACCACCCAGGGACGGGTTTATCGGGCCAAGGCCTACGACTTGCCCGAGGCCTCCCGGACGGCGCGCGGGCAGCACGTGGCCAACCTGTTAGCCTTCCAGCCCGAGGAACGCATCGCCCAGGTCATCCAGATTCGCGGCTACACCGACGCCCCGTACCTGGTGCTGGCCACTCGCAACGGGCTGGTGAAAAAGTCCAAGCTGACCGACTTCGACTCCAATCGCTCGGGCGGAATCGTGGCGGTCAACCTGCGCGACAACGACGAGCTGGTCGGTGCGGTGCTGTGTTCGGCCGGCGACGACCTGCTGCTGGTCTCGGCCAACGGGCAGTCCATCAGGTTCTCGGCGACCGACGAGGCGCTGCGGCCAATGGGTCGTGCCACCTCGGGTGTGCAGGGCATGCGGTTCAATATCGACGACCGGCTGCTGTCGCTGAACGTCGTGCGTGAAGGCACCTATCTGCTGGTGGCGACGTCAGGGGGCTATGCGAAACGTACCGCGATCGAGGAATACCCGGTACAGGGCCGCGGCGGTAAAGGTGTGCTGACGGTCATGTACGACCGCCGGCGCGGCAGGTTGGTTGGGGCGTTGATTGTCGACGACGACAGCGAGCTGTATGCCGTCACTTCCGGCGGTGGCGTGATCCGCACCGCGGCACGCCAGGTTCGCAAGGCGGGACGGCAGACCAAGGGTGTTCGGTTGATGAATCTGGGCGAGGGCGACACACTGTTGGCCATCGCGCGCAACGCCGAAGAAAGTGGCGACGATAATGCCGTGGACGCCAACGGCGCAGACCAGACGGGCAATTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3180,Drugs,MEG_3180|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|AL123456|+|7301-9818|ARO:3003295|Mycobacterium tuberculosis gyrA conferring resistance to fluoroquinolones [Mycobacterium tuberculosis H37Rv] ,3
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagccttgctgcttatggctcccttcgacatcctcgcctcgctggcgatggatatttatcttccagtcgttccggcgatgccgggcgtcctgaacacgactccatccataatccaactcacgttgagcctctacatggtgatgctcggtgtgggccaagtgatctttgggccactctccgatcgcgtcgggcgacggccgatcctgcttgtaggcgcaacggctttcgttgctgcgtctctgggagcggcttgttcttcaactgcattagcctttgttgcgtttcgtctggttcaggctgttggagcatcggccatgctggtggccaccttcgcgaccgtgcgcgacgtatatgccaatcgtcccgaaggtgccgtcatctacggccttttcagttcgatgctggcgttcgtgcctgcgctcggccctatagccggtgcgctgatcggcgagttttggggatggcaggcgatcttcatcacactggctgcactggcttcgctcgcactcttaaacgccagtttcaggtggcatgaaacccgaccgttggatcaggccagaacgcaacgatctgttttgccgatcttcgcgagtccggccttttgggtttacacggtcggatttagtgccggcatgggcacattcttcgttttcttctcgacagccccccgtgttctcataggccaagccggctattccgagatcggatttagcttggccttcgcgactgtcgcgctggtcatggtcacgacaacccgcttcgcaaagtccttcgttgccaaatggggtatcgcgggatgcgtagcgcgcgggatggcgttgctcgtttccggcgcgatcctgttggggatcggccaacttttcggatcgccgtcatttttcagcttcatcctgccgatgtgggttgtcgcggtcggcattgtcttcacggtgtccgttaccgccaacggcgcacttgcgcagttcgacgacatcgctggatcagcggttgcgttctacttctgcatccaaagcctgatagtcagtatcgtcgggacattggcggtgacgctgttaaacggcgatacagcgtggcccgtgatttgttacgccacggcaatggcagtgctggtgtcgttggggctggcgctccttcgatcccgtgatgctgccaccgagaagtcgccagtcgtctag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2912,Drugs,MEG_2912|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,446136270|WP_000214125.1|NG_047875|1|1|floR2|floR2|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR2 NG_047875:101-1315,6
,ATGACTCACCACCGGAAGCGTCTCGACCGCACGTCCGTGTTGCTCGGGGCCCGGCAGGTGCTCGACGAGACTGGGCTCGATGGCTTCACCACTCGCGCGCTGGCGGCTCACTTACAGGTACAGCAGCCCGGCCTCTACTGGCACTTCCGCACGAAGGCCGAACTCCTCGCAGCGCTGGCGAGCGACGTGCTTGACCGAGAGCATCACGCTTCCTTCCCCGAGTCCGACGAGAAATGGGACGCATTTCTCTTGCGAAACGCAAGAAGTTTCCGCCACGCACTACACGCGGTCCGTGACGGTGCGCGTCTCCACGCTGAGCACCACCGCAGACCATCCGGCGACGACACCGACGAAGGAGCTGAGGCTTCCGGTCAGCAAGTCGGGCTTCTCGTGTCTCAGGGATTCGATGAACAGACAGCCATCAGCATGCTCATCGCGGTCAGCCGATACACCGTCGGTGTCGTACTGGAGGAGCAAACCGCAGAGGTCGGCAATGCGAGCGTTCCTGAACGCGACCGGGAATTCGATTTCGGCCTGACAGCACTGATCGACGGATTCTCTCACTCCCGCACAGCGTCATTGACCTCGAGCGAATCGTGA,tetR,antibiotic target alteration,Tetracyclines,MEG_7191,Drugs,MEG_7191|Drugs|Tetracyclines|Tetracycline_transcriptional_repressor|TETR,gi|295986902|gb|HM002748.1|669-70 gi|4583389|gb|AF121000.1|AF121000|13133-13732 gi|29164981|gb|AY219860.1|1081-724 gi|29164976|gb|AY219695.1|910-553 gi|29164967|gb|AY219692.1|589-232 gi|29242917|gb|AY222825.1|3566-3209 gi|29242897|gb|AY222819.1|907-550 gi|29164940|gb|AY219684.1|3540-3250,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacggccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5522,Drugs,MEG_5522|Drugs|betalactams|Class_C_betalactamases|PDC,1035157535|WP_064511500.1|NG_050822|1|1|blaPDC-149|blaPDC|class_C_beta-lactamase_PDC-149 NG_050822:1-1194,0
,ATGAGGGTAGCGGTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGTTGGTTACTGTGGCCGTAAAGCTTGATGAAACGACGCGGCGAGCATTGCTCAATGACCTTATGGAGGCTTCGGCTTTCCCTGGCGAGAGCGAGACGCTCCGCGCTATAGAAGTCACCCTTGTCGTGCATGACGACATCATCCCGTGGCGTTATCCGGCTAAGCGCGAGCTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCATGATCGACATTGATCTAGCTATCCTGCTTACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCGGCAGCGGAGGAATTCTTTGACCCGGTTCCTGAACAGGATCTATTCGAGGCGCTGAGGGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCCGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGTAGTAACCGGAAAGATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCGCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGACGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_922,Drugs,MEG_922|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,(AGly)AadA8:AF326210:1-792:792,2
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtcggcatgttcttttaataccgtacaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaacagaggaaatctatggcaatgatcttaaaagatcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttgtttcctgattgggaaaaggacatgactctaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaagaatgtgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacggaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaacctcaaggaaaaattgtagcgttctcactcaatttagaaatgaaaaaaggcatacctagttctattcgaaaagaaattgcttataagggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4562,Drugs,MEG_4562|Drugs|betalactams|Class_D_betalactamases|OXA,691064087|WP_032007272.1|NG_049784|1|1|blaOXA-506|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-506 NG_049784:1-822,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacagttctccgggacaacttgacgccggagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1818,Drugs,MEG_1818|Drugs|betalactams|Class_C_betalactamases|CMY,1393270470|WP_109791215.1|NG_057614|1|1|blaCMY-160|blaCMY|class_C_beta-lactamase_CMY-160 NG_057614:1-1146,0
,GTGGCTGCCCAGAGGAAGGCCCAAGACGAATATGGCGCTGCGTCCATCACTATTCTTGAAGGGCTGGAGGCCGTTCGCAAACGTCCCGGTATGTACGTCGGGTCAACTGGTGAGCGTGGTCTCCACCATCTGATATGGGAAGTGGTGGACAACTCAGTAGATGAGGCGATGGCCGGTTATGCTACGCAAGTTGATGTGCGGTTATTCGACGACGGTAGTGTCGAGGTCGCCGATAACGGTCGTGGTATTCCGGTGGCAGTGCATGCTACGGGGGTACCGACTGTTGACGTAGTTATGACCCAATTACATGCCGGCGGTAAATTCGGTGGTAAAGATAGCGGTTATAACGTCAGTGGTGGTTTGCATGGGGTAGGTGTGTCGGTGGTTAACGCATTGTCCACCAGGGTCGAGGTCGACATCAAACGTGACGGCTATGAATGGTCACAGTTTTACGACAAGGCTGTGCCGGGCATTCTTAAGCAAGGCGAAGCTACTGAGGCGACGGGAACGACGATTAGATTTTGGGCAGATCCTGACATTTTCGAAACCACAAAGTATGACTTTGGGACGGTGGCGCGCCGAATTCAAGAAGTGGCTTTCTTGAACAAGGGTTTGACGATCAATCTTGTTGACGAACGGGTGAAGCAGGACGAAGTTGTCGACGATGTCGTCAGCGATACAGCCGAGGCTCCTGTGGCTATGACCGTTGAAGAAAAGTCAACGGAGTCGAGTGCGCCGCACAAGGTTAGACACCGTACGTTCCACTACCCCGGAGGCCTGGTGGACTTCGTCAAGCACATCAACCGGACTAAGACTCCTATTCAACAGAGCATTATCGATTTTGATGGCAAAGGTGCCGGTCACGAGGTTGAAGTTGCGATGCAGTGGAACGGCGGCTATTCGGAATCAGTGCATACCTTTGCGAACACGATTAACACCCATGAAGGCGGCACCCACGAAGAAGGTTTCCGTAGCGCTTTGACATCAGTGGTGAACAAGTACGCTAAGGATAAAAAACTACTCAAAGACAAGGATCCCAACCTAACTGGCGACGATATCCGTGAAGGTCTGGCGGCGGTTATCTCGGTTAAGGTCAGTGAACCACAGTTTGAGGGTCAGACCAAAACAAAGCTGGGGAACACCGAAGTTAAGTCATTCGTGCAGAGGGTCTGTAATGAGCAACTTATTCACTGGTTTGAAGCCAATCCAGTAGATGCGAAAGCGGTTGTGAATAAGGCGATATCGTCGGCACAAGCCCGAATAGCTGCACGTAAAGCACGAGAGTTAGTGCGTCGAAAAAGTGCCACCGATCTTGGTGGACTTCCTGGAAAACTTGCCGATTGCCGCTCTACTGATCCTCGAAGTTCTGAACTGTATGTAGTGGAAGGTGATTCGGCTGGTGGTTCAGCAAAGAGTGGCCGTGATTCGATGTTTCAGGCAATCCTTCCGTTACGTGGCAAGATCATAAATGTTGAAAAGGCACGTATTGACCGAGTGCTAAAGAACACCGAAGTTCAAGCAATTATTACGGCATTGGGTACTGGAATCCATGATGAATTCGATATCTCCAGGCTGCGTTATCACAAAATTGTTTTGATGGCCGACGCTGACGTTGACGGCCAACATATCTCGACGCTGTTGTTGACTTTGTTATTTCGGTTCATGCGACCACTCATCGAGCATGGGTACGTGTTTTTAGCGCAGCCGCCACTTTACAAATTGAAGTGGCAACGTATGGATCCGGAATTTGCTTACTCCGATAGCGAGCGCGACGGCTTATTAGAGACCGGGCTTAAGCTTGGCAAGAAAATCAACAAAGAGGATGGTATCCAACGTTATAAAGGTTTAGGTGAAATGGATGCCAAGGAGTTGTGGGAAACCACCATGGACCCGTCGGTGCGAGTTTTGCGTCAAGTAACACTGGATGACGCGGCGGCTGCTGACGAGTTATTCTCTATTCTGATGGGTGAGGACGTCGATGCACGCCGTAGCTTTATCACCCGTAATGCCAAGGATGTTCGTTTCCTGGATGTCTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3239,Drugs,MEG_3239|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRB,gb|AL450380|+|5228-7265|ARO:3003304|Mycobacterium leprae gyrB conferring resistance to fluoroquinolone [Mycobacterium leprae TN] ,3
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgacctttaaaatgcttaatgctttgatcggccttgagcattataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattccccgaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4457,Drugs,MEG_4457|Drugs|betalactams|Class_D_betalactamases|OXA,1559612980|WP_128268245.1|NG_063850|1|1|blaOXA-746|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-746 NG_063850:24-848,0
,ATGAAGAAAATACCCAATATGAATGAAGTAACTGAAAAAAAACCGCTTACTGAGTTTACAGAAAAAGCTTATCTTGATTATTCAATGTATGTCATTTTGGACAGAGCATTACCGAGCATCGCAGATGGACTTAAGCCTGTTCAACGCAGAATTGTTTATGCTATGTCTGAGTTGGGTCTGAAAGCAACAGCAAAATATAAAAAATCAGCGCGTACAGTAGGGGATGTTCTTGGTAAATTCCATCCTCATGGTGATAGTGCATGCTATGAAGCTATGGTTTTAATGGCTCAACCTTTTTCATATCGCTATCCATTTGTTGATGGACAAGGAAATTGGGGATCCCCGGATGATCCCAAATCATTTGCTGCAATGAGGTATACAGAAGCAAGATTATCTCTTTATGCTGATGTGTTACTCGGAGAACTGCTACAAGGAACCGTGGATTGGGTAGATAATTTTGATGGTACTTTGCAAGAGCCCGCTCTTTTACCCGCTCGTTTGCCTAATATTTTATTGAATGGTGCAACAGGTATAGCTGTTGGTATGGCTTCAGATATTCTTCCGCACAATTTGACTGAAGTTGCTAATGCGTGTATTCATCTGCTGGATAACCCCCAAGCCGATATTAAGACTATTTGTGAATATATTAAAGGTCCTGATTTTCCAACAGAAGCAGAAATCATTAGCCCTAGTGAAACAATTAGAGCTATGTACGAGTCCGGTAATGGCTCAATTAAAATGCGAGCAATTTATGCTCAAGAAAAACAAAATATTGTCATAACAGCTTTACCTTATCAAGTATCCGGAGCCAGGGTAATGGAGCAAATCGCGTTGCAGATGCAACAGAAAAAATTACCGATGGTTGAGGATTTACGTGATGAATCAGATCACGAGCATCCAACACGGTTGGTTATTATCCCCCGCTCTAATCGAGTAGATATAGAAAGTTTAATGTCGCATTTATTTGCTACCACGGATTTGGAGCGTAGCTATCGAGTTAATTTTAATATGATTGGTCTTGATGGCAAGCCACGAGTTAAAGGACTGTTAGCAATCTTGACTGAATGGTTGGAATTTAGGCTTACCACAGTAAAAAGACGTCTTCAATTCAGATTGGAAAAGGTACTGGAGCGTATTCATATTCTTGAAGGACTGCTTATTGCCTATCTTAATATAGATGAAGTCATTGCAATCATCAGAGAACATGAGCAACCAAAACAAGGATTAATTTCACGCTTTAATTTAACCGAACGACAAGCTGAAGCAATATTGGAAATGAAACTGCGGCATTTAGCCAAATTGGAAGAGATTAAATTGCGTGGTGAACTGGATGAGCTGTCTGATGAACGTGATACTTTACAAAAAACGCTGGCTAGTCATTCTCTCTTAAAAGAACTGGTAAAAGAAGAGATAACGAAAGATCGAGATGAATTTGGTGACCCACGCCGTTCACCCATTATTACAAGGGAAGACTCTCAGGCATTAAAAGAAGAGGATATTTTGCCTAATGAACCTATCACGGTTGTATTGTCTAAAAATGGATGGGTCAGAGCGGCCAAGGGGCATGATGTCGATGGTAAGGAACTCAGCTATAAAGCTGGAGATGAATTCAAAGCCCAAACGCTAGCTCGTACTAATCAGCAAGTTTTATTTTTTGATGGAGAGGGAAAGGTCTATTCGCTTCCAGGACATGCATTGCCATCGGCACGTGGCCAAGGCGAGCCTTTGACTGGTAAATTAAACCCTGCTGAAGGAGTATTGTTTGAAGCAATTGTTGGCGGAGAGCCTGAGCAAAAGGTGTTATTGGCTACCGATTCCGGGTATGGATTTATCGCCAAAATTGAAGATTTATATGTAAAAAATCGTAATGGAAAGGCATGCATCAAATTAAGTGAAAACAGTCATATATTGCCGCCAAGGCTAATACCAAATCGAGAGCAATTATTTGTTGCTTGTGCGACTAATGTAGGGCGTTTACTGATTTTTTCTCTTGAGGAGTTGCCCGAATTATCTCGAGGAAAAGGGAATAAATTGATCAGTATCCCTGTTGCTAAAGCGGTCTCACGAGAAGAGTATATAGTTGATATGCAAGTTTTAACAACGAATGATTCGCTGACGGTTCATGCCGGTAAGCGGCATTTTACTCTGAAAGGTGAGGATTTGACTCACTATAAGGGTGAAAGGGGCAGGAGAGGAAACCGGTTGCCAAGAGGCTTACAAAATGTTTCTCAATTGCATGTTACTCAATCTGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5337,Drugs,MEG_5337|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|225791049|gb|CP000675.2|3550879-3548624 gi|984671414|emb|LT009690.1|1401817-1401844,3
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAAAAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1372,Drugs,MEG_1372|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_19_JBMK01000007,0
,atgacgaaaatgaaccgcctggcggcagcgctgatcgccgcactgatcttgccgaccgctcaggccgcgcagcagcaggatatcgacgccgttattcagccgctgatgaaaaaatatggcgtaccgggcatggcgatcgccgtgtcggtcgacggcaaacagcagatttacccatatggcgtcgcctcgaagcagaccggcaaaccgatcaccgaggagacgctgttcgaagtgggctcgctgagcaaaaccttcaccgcgacgctggcggtctatgcgcagcagcagggcaagctgtcgttcaacgatccggccagccgctacctgcccgagctgcgcggcagcgccttcgacggcgtcagcctgctgaatctggcgacgcatacctccggcctgccgctgttcgtgccggacgacgtcaccaacaacgcccaactgatggcctactaccgggcctggcagccgaaacacccggcgggcagctaccgcgtctattccaacctcggcatcggcatgctgggcatgatcgccgccaagagcctcgaccagccgtttatccaggcgatggaacaggggatgctgccggcgctgggcatgagccacacctacgttcaggtgccggcggcgcagatggctaactatgcgcagggttacagcaaggacgataagccggtgcgggtcaatcccggcccgctggacgccgaatcttacggcatcaaatccaacgctcgcgatctgattcgctatctggacgccaacctgcaacaggtgaaggtggcgcagccgtggcgcgacgcgctggccgcgacgcacgtcggttattacaaggcgggcgcgttcacgcaggatctgatgtgggagaactacccgtatccggtgaaactgtcgcgtttgattgaaggcaacaacgcagggatgatcccggccaccgccatcacgccgccgcagccggaattgcgcgccggctggtataacaaaaccggctccaccggcggcttctccacctacgcggtatttatcccggcgaaaaatatcgccgtggtgatgctggccaacaagtggttcccgaacgacgatcgcgtcgaggcggcttaccacatcgtccaggcgctggagaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_6568,Drugs,MEG_6568|Drugs|betalactams|Class_C_betalactamases|SRT,1028081082|WP_063840465.1|NG_047384|1|1|blaSRT|blaSRT|SRT/SST_family_class_C_beta-lactamase NG_047384:1-1125,0
,atggctctggcactcgttggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgataatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagttttatgaatatgatcactactcgcacctggttttgtagtgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggggacttagatattcggggcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggagcgacttggcatcgcggtgattggttag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5917,Drugs,MEG_5917|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,696366843|WP_032941855.1|NG_050478|1|1|qnrB18|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB18 NG_050478:37-681,3
,atggttaaaaaatcactgcaccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2192,Drugs,MEG_2192|Drugs|betalactams|Class_A_betalactamases|CTX,1149331616|WP_077767291.1|NG_052900|1|1|blaCTX-M-194|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-194 NG_052900:1-876,0
,ATGGGTGAATTTTTCCCTGCACAAGTTTTCGAGCAGCTGTCCCACGCTCGCGCGGTGATCGAGCGCCATCTGGCTGCGACACTGGACACAATCCACCTGTTCGGATCTGCGATCGATGGAGGGCTGAAGCCGGACAGCGACATAGACTTGCTCGTGACCGTCAGCGCCGCACCTAACGATTCGCTCCGGCAGGCGCTAATGCTCGATTTGCTGAAAGTCTCATCACCGCCAGGCGATGGCGGAACATGGCGACCGCTGGAGCTAACTGTTGTCGCTCGAAGCGAAGTAGTGCCTTGGCGCTATCCGGCGCGGCGTGAGCTTCAGTTCGGTGAGTGGCTCCGCCACGACATCCTTTCCGGAACGTTCGAGCCTGCCGTTCTGGATCACGATCTTGCGATTTTGCTGACCAAGGCGAGGCAACACAGCCTTGCGCTTCTAGGCCCATCCGCAGCCACGTCTTTCGAGCCGGTGCCGAAGGAGCATTTCTCCAAGGCGCTTTTCGACACTATTGCCCAGTGGAATGCAGAGTCGGATTGGAAGGGTGACGAGCGGAACGTCGTTCTTGCTCTTGCTCGCATTTGGTACAGCGCTTCAACTGGTCTCATTGCTCCTAAGGACGTTGCTGCCGCATGGGTATCGGAGCGTTTGCCTGCCGAGCATCGGCCCCTCATCTGCAAGGCACGCGCGGCGTACCTGGGTAGCGAGGACGACGACCTAGCAATGCGCGTCGAAGAGACGGCCGCGTTCGTTCGATATGCCAAAGCAACGATTGAGAGAATCTTGCGTTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_953,Drugs,MEG_953|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|24209721|gb|AY139598.1|618-1406,2
,ATGAAAAAATTAATCATCGCCATCGTGATTGTAATCATCGCTGTTGGTTCAGGCGTATTCTTTTATGCATCTAAAGATAAGAAAATAAACGAAACAATTGATGCCATTGAAGATAAAAACGTTAAGCAAGTCTTTAAAAATAGTACTTACCAATCTAAAAACGATAATGGTGAAGTAGAAATGACAGACCGCCCTATTAAGATTTATGACAGTCTCGGCGTCAAAGATATCAACATTAAAGATCGTGATATCAAAAAGGTTTCGAAAAACAAAAAGCAAGTCACAGCAAAGTATGAACTGCAAACGAATTACGGCAAAATTAATCGTGACGTTAAATTAAACTTTATTAAAGAAGATAAAGATTGGAAATTGGATTGGAATCAAAGTGTCATTATTCCAGGCATGAAGAAAAATCAATCCATCAATATTGAACCATTGAAATCAGAACGTGGTAAGATTTTAGACCGAAACAATGTAGAGTTAGCCACTACAGGAACAGCACATGAAGTTGGTATTGTTCCTAATAATGTTTCCACAAGTGATTACAAAGCAATCGCTGAAAAGTTAGACCTTTCAGAATCGTATATTAAACAACAAACAGAACAGGATTGGGTTAAAGATGATACATTCGTCCCTCTCAAGACTGTTCAAGATATGAATCAAGATTTAAAGAATTTTGTTGAAAAGTATCATCTCACATCACAGGAAACAGAAAGTCGAGAGTATCCGTTTGAAGAAGCAACAACGCACTTACTTGGATACGTTGGCCCTATTAATTCAGAAGAATTGAAGCAAAAAGCATTTAAAGGTTATAAAAAGGATGCCATCGTTGGTAAAAAAGGTATCGAAAAACTATACGATAAAGAACTTCAAAATAAAGACGGATACCGTGTCACAATTATTGATGATCAAAATAAAGTGATAGATACATTAATCGAGAAAAAGAAAAAAGACGGTAAAGATATTAAATTAACCATTGATGCTAGAGTCCAAAAAAGTATTTATAACAACATGAAAGATGACTACGGTTCGGGGACTGCTATTCATCCAAAAACTGGTGAACTCTTAGCACTTGTCAGCACGCCATCTTATGATATTTATCCATTTATGAATGGAATGAACGATGAAGATTATAAGAAATTAACTGAAGATGATAAAGAGCCACTCCTTAATAAGTTCCAAATTACGACATCACCGGGTTCGACTCAAAAAATATTAACAGCCATGATTGGCTTAAACAATAAGACATTAGACGGCAAAACAAGTTATAAAATTAATGGAAAAGGTTGGCAAAAAGATAAATCTTGGGGTGGCTACAACGTTACAAGATATGAGGTCGTGAATGGCGATATTGACTTAAAACAAGCTATTGAATCATCAGATAATATCTTCTTTGCGAGAGTTGCACTTGAATTAGGCAGCAAAAAATTCGAAGAAGGAATGAAACGCCTTGGTGTTGGTAAAGATATCCCGAGTGATTATCCATTCTACAATGCACAAATTTCAAATAAGAACTTAGATAATGAAATATTGTTAGCTGACTCAGGTTATGGCCAAGGTGAAATATTAATCAATCCTGTTCAAATTCTTTCAATATACAGCGCATTAGAGAACAAAGGTAATGTGAATGCACCACATGTACTGAAAGATACGAAAAATAAAGTCTGGAAGAAGAACATCATTTCCCAGGAAAATATTAAGTTGTTAACAGACGGTATGCAACAAGTCGTTAACAAAACACATAGAGAAGATATTTATAGATCATATGCCAACTTAGTTGGTAAATCAGGTACAGCTGAACTCAAGATGAAACAAGGTGAGACAGGACAACAAATAGGTTGGTTCATTTCATATGATAAAAATAATCCAAATATGATGATGGCTATTAATGTGAAAGATGTACAAGATAAAGGCATGGCAAGTTACAATGCCAAAATATCTGGAAAAGTGTATGACGATTTATATGATAACGGTAAGAAAACGTATCGTATTGATAAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3792,Drugs,MEG_3792|Drugs|betalactams|Penicillin_binding_protein|MECA,mecA1_4_AB547236,0
,atgaaaaactactttaacagccctttcaaaggggaacttctttctgagcaagtgaaaaatccaaatatcagagtaggccggtatagctattactctggctactatcacgggcactcatttgatgaatgcgcgcgatacttgtttccagatcgtgatgacgttgataaattgatcattggcagcttttgttctataggaagcggggcttccttcatcatggctggcaatcaggggcatcggcatgactgggcatcatccttccccttcttctatatgcaagaggagcctgctttctcaagagcactcgacgccttccaaagagcaggtgataccgtcattggcaatgatgtctggataggctcggaggcaatgattatgcctggcatcaaaattggagacggtgccgtgataggtagtcgctcgttggtgacaaaagatgtagagccttatgccatcatcgggggaaatcccgcaaagcaaattaagaagcgcttctccgatgaggaaatctcattgctcatggagatggagtggtggaactggccactagataaaattaagacagcaatgcctctgctgtgctcgtcaaatatttttggtctgcataagtattggcgcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1605,Drugs,MEG_1605|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,498321738|WP_010635894.1|NG_052738|1|1|catB8|catB8|type_B-3_chloramphenicol_O-acetyltransferase_CatB8 NG_052738:101-733,6
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCCGCCCGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2954,Drugs,MEG_2954|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|806639039|gb|KM972598.1|3988-4827 gi|806639024|gb|KM972596.1|3992-4831 gi|213054530|gb|CP001182.1|315605-316444 gi|974751547|gb|KU130294.1|233473-234001 gi|982189197|gb|CP013993.1|5430539-5431065,8
,ATGAGCGACCTTGCGAGAGAAATTACACCGGTCAACATTGAGGAAGAGCTGAAGAGCTCCTATCTGGATTATGCGATGTCGGTCATTGTTGGCCGTGCGCTGCCGGATGTCCGAGATGGCCTGAAGCCGGTACACCGTCGCGTACTTTACGCCATGAACGTATTGGGCAATGACTGGAACAAAGCCTATAAAAAATCTGCCCGTGTCGTTGGTGACGTAATCGGTAAATACCATCCCCACGGCGATTCCGCAGTGTATGACACCATCGTTCGTATGGCGCAGCCATTCTCGCTGCGTTACATGCTGGTGGATGGTCAGGGTAACTTCGGTTCTATTGACGGCGACTCCGCGGCGGCAATGCGTTATACGGAGATCCGTCTGGCGAAAATCGCCCACGAACTGATGGCCGATCTCGAAAAAGAGACGGTGGATTTCGTGGATAACTATGACGGTACGGAAAAAATTCCGGACGTCATGCCGACCAAAATTCCGAATCTGCTGGTGAACGGTTCTTCCGGTATCGCAGTAGGTATGGCGACGAATATCCCGCCGCACAACCTGACGGAAGTGATTAACGGCTGCCTGGCGTATATCGACAACGAAGACATCAGCATTGAAGGGCTGATGGAACATATTCCGGGTCCGGACTTCCCGACCGCCGCGATCATCAACGGTCGTCGTGGTATCGAAGAAGCCTACCGTACCGGTCGTGGCAAAGTGTACATTCGCGCCCGCGCGGAAGTTGAAGCTGACGCGAAAACGGGCCGTGAAACCATCATCGTCCATGAAATTCCCTATCAGGTGAACAAAGCGCGCCTGATCGAGAAAATCGCCGAGCTGGTGAAAGATAAACGCGTGGAAGGCATCAGCGCGCTGCGTGACGAATCCGACAAAGACGGGATGCGCATCGTGATTGAAGTAAAACGCGATGCGGTGGGCGAGGTGGTGCTTAATAATCTCTACTCCCAGACCCAGCTACAGGTTTCCTTCGGTATTAACATGGTGGCGCTGCATCACGGCCAGCCGAAGATCATGAACCTGAAAGATATCATTTCAGCGTTCGTGCGCCACCGCCGTGAAGTGGTGACGCGTCGGACTATTTTTGAACTGCGTAAAGCCCGTGACCGCGCGCATATCCTTGAAGCTCTGGCGATTGCGCTGGCCAACATCGACCCGATTATCGAACTGATTCGCCGCGCGCCAACGCCGGCAGAAGCAAAAGCGGCGCTGATTTCGCGTCCGTGGGATCTGGGCAACGTTGCTGCGATGCTGGAGCGCGCCGGTGATGACGCCGCGCGCCCGGAATGGCTGGAGCCAGAATTTGGCGTGCGTGACGGTCAGTACTACCTGACTGAGCAGCAGGCGCAGGCGATTCTGGATCTGCGTTTGCAGAAACTGACCGGCCTGGAGCATGAAAAACTGCTCGACGAATACAAAGAGTTGCTGGAGCAGATTGCTGAACTGCTGCACATTCTGGGCAGCGCCGATCGCCTGATGGAAGTGATCCGTGAAGAGATGGAGTTAATTCGCGATCAGTTCGGCGATGAGCGTCGTACCGAAATCACCGCCAACAGCGCCGATATTAATATCGAAGATCTGATTAGCCAGGAAGATGTTGTCGTGACGCTGTCTCACCAGGGTTACGTCAAGTATCAACCGCTGACGGATTACGAAGCGCAACGTCGTGGTGGGAAAGGTAAATCTGCCGCGCGTATTAAAGAAGAAGACTTTATCGACCGCCTGCTGGTGGCCAACACCCATGACACCATCCTCTGCTTCTCCAGCCGGGGCCGTCTGTACTGGATGAAGGTCTATCAGTTGCCGGAAGCCAGTCGTGGCGCGCGCGGTCGTCCGATCGTCAATCTACTGCCGCTGGAAGCCAACGAACGTATCACCGCGATTCTGCCGGTTCGTGAGTACGAAGAAGGCGTCAACGTCTTTATGGCGACCGCCAGCGGTACCGTGAAGAAAACGGCGCTGACCGAATTCAGCCGTCCGCGTTCCGCCGGTATTATCGCGGTAAACCTCAACGACGGCGACGAGCTGATTGGCGTTGACCTGACTTCTGGTTCTGACGAAGTCATGCTGTTCTCGGCCGCGGGTAAAGTGGTGCGCTTCAAAGAAGACGCCGTCCGTGCGATGGGGCGTACCGCGACCGGTGTGCGCGGTATTAAGCTGGCGGGAGACGATAAAGTCGTCTCTCTGATCATCCCACGCGGCGAAGGCGCTATTCTGACCGTAACGCAAAACGGCTACGGGAAGCGTACCGCAGCGGACGAGTACCCGACCAAGTCTCGTGCGACGCAGGGCGTTATCTCTATCAAAGTGACCGAGCGCAACGGTTCCGTTGTCGGTGCGGTACAGGTAGACGATTGCGACCAGATCATGATGATCACGGATGCCGGTACTCTGGTGCGTACCCGTGTGTCCGAGATCAGCGTAGTGGGACGTAATACCCAGGGCGTTATCCTTATCCGCACGGCGGAAGATGAAAACGTGGTGGGTCTGCAACGCGTTGCTGAACCGGTAGATGACGAAGAACTCGACGCTATCGACGGCAGCGTGGCGGAAGGGGATGAGGATATCGCCCCGGAAGCGGAAAGCGATGACGACGTTGCGGATGACGCTGACGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3220,Drugs,MEG_3220|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|807109228|gb|CP011259.1|4159751-4157115 gi|563346448|gb|CP006876.1|2327360-2324724 gi|197211055|gb|CP001138.1|2327829-2325193,3
,atggagaaaaaaatcactggatataccaccgttgatatatcccaatggcatcgtaaagaacattttgaggcatttcagtcagttgctcaatgtacctataaccagaccgttcagctggatattacggcctttttaaagaccgtaaagaaaaataagcacaagttttatccggcctttattcacattcttgcccgcctgatgaatgctcatccggaattacgtatggcaatgaaagacggtgagctggtgatatgggatagtgttcacccttgttacaccgttttccatgagcaaactgaaacgttttcatcgctctggagtgaataccacgacgatttccggcagtttctacacatatattcgcaagatgtggcgtgttacggtgaaaacctggcctatttccctaaagggtttattgagaatatgtttttcgtctcagccaatccctgggtgagtttcaccagttttgatttaaacgtggccaatatggacaacttcttcgcccccgttttcaccatgggcaaatattatacgcaaggcgacaaggtgctgatgccgctggcgattcaggttcatcatgccgtttgtgatggcttccatgtcggcagaatgcttaatgaattacaacagtactgcgatgagtggcagggcggggcgtaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1578,Drugs,MEG_1578|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,493329079|WP_006286297.1|NG_047587|1|1|catA1|catA1|type_A-1_chloramphenicol_O-acetyltransferase NG_047587:101-760,6
,atgttggaagaaaagcgagtttcctttcgcccgatgaatgaggatgatttagtactaatgttaaaatggctgacagatgaccgtgttcttgaattttacgacggtagagataaaaagcatacacagaaaacgattcgtgagcattatacagagcaatgggcggatgagatttatcgagtcatcattgcatatgatacaattcccatcggttacgcacaaatatatagaattcagggggaacttttcgacgaatataattaccatgagacggaagaaaagatttatgcgatggaccaatttatcggtgagccggaatattggaatatgggaatcggtgcagaatattgcagagtagtatgccaatatctacgaacggaaatggatgccgatgcggtgattcttgacccacgaaaaaataatccacgagcggtacgagcatatcagaaggcgggatttgaaattattaaggagcttcccgaacatgagctacacgaagggaagaaggaagattgtgtgttgatggaatggagagcgtaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_212,Drugs,MEG_212|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,949621776|WP_057038955.1|NG_052222|1|1|aac(6')-Im|aac(6')-Im|aminoglycoside_N-acetyltransferase_AAC(6')-Im NG_052222:101-637,2
,atggaaataggatttacttttttagatgaaatagtacacggtgttcgttgggacgctaaatatgccacttgggataatttcaccggaaaaccggttgacggttatgaagtaaatcgcattgtagggacatacgagttggctgaatcgcttttgaaggcaaaagaactggctgctacccaagggtacggattgcttctatgggacggttaccgtcctaatcgtgctgtaaactgttttatgcaatgggctgcacagccggaaaataacctgacaaaggaaagttattatcccaatattgaccgaactgagatgatttcaaaaggatacgtggcttcaaaatcaagccatagccgcggcagtgccattgatcttacgctttatcgattagacacgggtgagcttgtaccaatggggagccgatttgattttatggatgaacgctctcatcatgcggcaaatggaatatcatgcaatgaagcgcaaaatcgcagacgtttgcgctccatcatggaaaacagtgggtttgaagcatatagcctcgaatggtggcactatgtattaagagacgaaccataccccaatagctattttgatttccccgttaaataa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7547,Drugs,MEG_7547|Drugs|Glycopeptides|VanA-type_resistance_protein|VANXA,446324493|WP_000402348.1|NG_048476|1|1|vanX-A|vanX-A|D-Ala-D-Ala_dipeptidase_VanX-A NG_048476:101-709,5
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgctcggcgctgtggcccacctgtccgttggaagagcaccgcgcggagatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttacaccgtcgaatgcgcccgccgccagggctgggccacgcgtttgatcgcgcaggtacaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgacatcgccaacctggactcccaacgcctgcatgcggcgctgggctttgccgaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_166,Drugs,MEG_166|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,852261252|WP_048325528.1|NG_052187|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052187:101-541,2
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGCACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACATTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTATCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1912,Drugs,MEG_1912|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JQ733579|+|1027-2173|ARO:3002097|CMY-84 [Citrobacter freundii] ,0
,gtgagcgacctggagctgcgcggcgagcgggtcctgctccgctccaccacccccgccgacaccgccgcgctcgaccggatcgtccgcgagccggaggtggcgctgtggtggccgccgcccgaggggtacgaacggatgctcgccgtcgtcgtggacggcgaggtgatcggcgcgatccagttcagcgaggagaccgacccggagttccgccacgccggcatcgacctcttcctgtcggcccggtggcacgggcagggcctgggccccgacgccgtccgcaccctggcccgctggctgatcgccgagcgcggccaccaccgcctggtcatcgacccggccgccgccaacacgtacgccgtccgcagctaccgcaaggtcggcttcgccccggtcgggatcatgcgcgcctactggcgcaaccaccgcaccggggagtgggaggacggcctgctcatggacctgctggcggccgaactgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_251,Drugs,MEG_251|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,490048320|WP_003950682.1|NG_052138|1|1|aacA-STR-13|aacA-STR-13|aminoglycoside_6'-N-acetyltransferase NG_052138:101-583,2
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTCGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCACGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCTTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGAGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGACATTCTAGGAAATGAAAAACTCCTGCCTCATAAAACACGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCGCAGAGATTGCTGATACAGACCCTCTTTTGCATTTTGACATTGATACTGTTACACATGAGATTATGTTATCTTTTTTGGGAAAAGTACAGTTAGAAGTTATTTGTTCGCTATTAGAAGAAAAATATCATGTGGGCGTGGCTATGAAAGAGCCTTCGGTTATTTATCTGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAGGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTAATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7167,Drugs,MEG_7167|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/W/32/O)_1_EF065523 ,4
,atgttaaaagttattagtagtttattggtctacatgaccgcgtctgtcatggctgtcgcaagtccgttagcccattccggggagccgagtggtgagtatccgacagtcaacgaaattccggtcggagaggtccgactttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcggtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgaaaagcaaattggacttcccgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggcagaggggaacgagattcccacgcattctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagagatcttctatcctggtgctgcgcattcgaccgacaatctggttgtatacgtcccgtcagcgaacgtgctatacggtggttgtgccgttcatgagttgtcaagcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccgttgagcggattcaaaaacactacccggaagcagaggtcgtcattcccgggcacggtctaccgggcggtctagacttgctccagcacacagcgaacgttgtcaaagcacacaaaaatcgctcagtcgccgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7697,Drugs,MEG_7697|Drugs|betalactams|Class_B_betalactamases|VIM,1408841641|WP_111672914.1|NG_060572|1|1|blaVIM-57|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-57 NG_060572:1-801,0
,atgagaaaatctacgacacttttgatcggtttcctcaccactgccgctattatcccgaataatggcgcgctggctgcgagcaaggcgaatgatggcgacttgcgccgtattgtcgatgaaacggtgcgcccgctcatggccgagcagaaaatccccggcatggccgtcgctataaccatcgacggcaatagccacttcttcggttatggtgtggcatcgaaagaaagcgggcaaaaagtcactgaacacacgattttcgagatcggttcggtcagcaagaccttcactgcaatgcttggcggttacgggctggcgacaggcgcgttctcactgtccgatcccgcgaccaaatgggctcctgaactggcaggcagcagcttcgacaagatcaccatgcttgatcttgggacctacacgccgggcggattgcccctccagtttcccgatgctgtcaccgatgacagttcgatgctggcatatttcaagaactggaaacccgattacccggcagggacgcagcgtcgctattcgaatcccagcatcggcctgttcggctatctggcggcacgaagcatggacaagccgttcgacgttttgatggagcaaaagcttctgcctgcattcggcctgaagaacaccttcatcaatgtgccggaaagccagatgaagaactacgcctacggctattccaaagccaacaagccgatccgggtatcgggcggggcgctggatgcacaagcctatggcatcaagaccaccgcgcttgatcttgcccgcttcgtcgaactgaacatcgacagctcatctctggagcctgatttccagaaagccgtcgccgcaacgcataccggttactaccatgtcggagcgaacaatcagggacttggctgggagttctacaactatccgactgcgctcaagacacttcttgccggcaattcgtcggacatggcgctgaagtcgcacaaaatcgagaaattcgatacacctcgccaaccgtcagctgatgtgtggctcaacaagacaggctcaaccaacggctttggcgcttatgcggcctttattcctgcgaagaagaccggaattgttctgcttgccaaccggaattatccgatcgatgagcgcgtaaaggctgcctatcggatattgcaggcgctcgacaacaagcaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4224,Drugs,MEG_4224|Drugs|betalactams|Class_C_betalactamases|OCH,1028083762|WP_063842730.1|NG_047527|1|1|blaOCH|blaOCH|OCH_family_class_C_extended-spectrum_beta-lactamase NG_047527:101-1273,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgaggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3478,Drugs,MEG_3478|Drugs|betalactams|Class_A_betalactamases|KPC,1028105599|WP_063860711.1|NG_049254|1|1|blaKPC-21|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-21 NG_049254:1-882,0
,atgactcaacataatgaaattattaaaattgcagaaaaacatcaattacacatcaaacctcaaacaatatcattgaatgaatcagggctagatttccaagttgcatttggagaagatgaacacggaatagagtgggttttaagactaccaagaagacctgacgtttataaacgaacaaaacccgaaaaacaaatggtagacttcttacaaaaaaatgtttcgtttgaagtaccgaattggaaagtacatacaaaagaccttattgcttatccaaaacttacaggcaaacccgcagccacaatagatccagaaatacaaaattacgtatgggaaattgaacacaaaccagtaacaaaaaattttattaacacattagctgaaacactcgtagatttacacaacataccagaggaaaatattaccgcacaccatataaatatcaaaactatacaagaaataaaaaatgattttcaaagaagaatgaataaagttagagaaacttatggcgtggcagatggattatggaacagatggaaacaatggttagaaaacgacgaactgtggcctcgacgtgcaaccatgatacatggagacttacatccaggacatataatggtagataaccaagcaaatgtcacaggactcatagactggactgaagcaacctattccgatccatcaatggactttatgggataccatcgtgtattcgacgacgaaggcttagagcaactcataacagcatacgataaagctggaggagaaacatggccacgaatgaaagagcatataatagaactcaatgcagtattcccaatgtttatcgctgagtttgctatggaatcaggagaaccagcgtatgaaaaaatggcattgcaagagttaggtatgaaagagtag,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4034,Drugs,MEG_4034|Drugs|MLS|Macrolide_phosphotransferases|MPHC,1028097434|WP_063854131.1|NG_047992|1|1|mph(C)|mph(C)|Mph(C)_family_macrolide_2'-phosphotransferase NG_047992:101-1000,7
,atgaacgagaaaaatataaaacacagtcaaaactttattacttcaaaacataatatagataaaataatgacaaatataagattaaatgaacatgataatatctttgaaatcggctcaggaaaaggccattttacccttgaattagtaaagaggtgtaatttcgtaactgccattgaaatagaccataaattatgcaaaactacagaaaataaacttgttgatcacgataatttccaagttttaaacaaggatatattgcagtttaaatttcctaaaaaccaatcctataaaatatttggtaatataccttataacataagtacggatataatacgcaaaattgtttttgatagtatagctgatgagatttatttaatcgtggaatacgggtttgctaaaagattattaaatacaaaacgctcattggcattatttttaatggcagaagttgatatttctatattaagtatggttccaagagaatattttcatcctaaacctaaagtgaatagctcacttatcagattaaatagaaaaaaatcaagaatatcacacaaagataaacagaagtataattatttcgttatgaaatgggttaacaaagaatacaagaaaatatttacaaaaaatcaatttaacaattccttaaaacatgcaggaattgacgatttaaacaatattagctttgaacaattcttatctcttttcaatagctataaattatttaataagtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2811,Drugs,MEG_2811|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,695262051|WP_032489010.1|NG_047811|1|1|erm(C)|erm(C)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(C) NG_047811:58-792,7
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatggccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagcactggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_236,Drugs,MEG_236|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502149|WP_071846301.1|NG_052361|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052361:101-655,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagctgtaaatagcaataccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccctggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgttgtgctggatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_540,Drugs,MEG_540|Drugs|betalactams|Class_C_betalactamases|ADC,490850798|WP_004712857.1|NG_064677|1|1|blaADC-119|blaADC|class_C_beta-lactamase_ADC-119 NG_064677:101-1252,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacagtccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgtgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcggctacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2186,Drugs,MEG_2186|Drugs|betalactams|Class_A_betalactamases|CTX,1509794553|WP_122630862.1|NG_062275|1|1|blaCTX-M-223|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-223 NG_062275:1-876,0
,ATGAAAAAAATATTTTTGCTTTTTGGTCTTTTTTGCTCTTTTGCTTTGGCAAATGAAAATTTAAAAGATCTTTTTAAAGATTATAATGAAAGTGGAGTTTTTATAGCTTATGATGGTAAAAATTATTATAGCAATGACTTTAAAAAAGCAAACAAACGCATTTTACCTGCCTCTACTTTTAAAATTTTCAATGCCTTAATCGCACTTAATGAAGGTGTTGTGAAAGATACTAATGAAATTTTTTATCATTACAAAGGTGAAAAAGTATTTTTACCATCTTGGAAAAATAATGCAAACTTAGCTTTAGCTATGCAAAGATCACAACTACCTGCTTATAAAGAACTAGCTAGAAAAATAGGCTTAGAAAAAATGCAAAAAAACTTAAATAAACTTAATTATGGCAACCAAAAAATAAGTAAAATAGATGAGTTTTGGATAGATGATTCTTTACAAATTAGTCTTAAAGAACAAGCTACTTTACTTTTTAAGCTTGCCAATTTAACACTAGATTACCCTAAACATATACAAGAAGAAGTGATTAATATCATCAAGTTAAAAGAAAATGATCATTATGAACTTTTTGCAAAAACAGGTTGGGGTCTTAGACAATATGGACAAATCGTAGGTTTTATAAAAAGTAAAAAAAGTGACAAAATTTACGCTTTTGCTTTAAATATGAATATAAGTGATTTTAACAAGCTTTATCTAAGAGAAGAAATAGTACAACTGTATCTAGATCAATTATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5273,Drugs,MEG_5273|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-493_1_KU739135,0
,atgtcgatacgaattctacttgtcgaggatgatgatcatatctgtaatacagtaagggcgtttctggctgaggcaggatatcaggtggatgcctgcacagatggaaatgaggcatacaccaagttttacgaaaacacttatcaactggttattcttgatattatgctgcccggtatgaacgggcatgaacttttgcgtgaatttcgtgcgaaaaatgatactcccattctgatgatgacagccctgtcggatgacgaaaaccaaatccgggcgtttgatgcagaggcagacgactatgtaacaaagccattcaagatgcagattttactaaagcgggtggaagccctgctgcggcgcagcggtgcgctggcaaaggaaatccgtgtcggcaggctgacacttctgccggaggatttcacggtactttgtgacggtacagagctgcccctgacacgaaaagaatttgaaatccttttgctgctggtgcagaacaaaggcagaaccttaacgcatgaaatcattttgtcacgtatatggggatatgactttgagggtgatggcagcacagtccacactcatatcaaaaatttgcgggccaagctgccggaaaatatcatcaaaaccattcgcggtgtaggataccgattggaggaatcattataa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7460,Drugs,MEG_7460|Drugs|Glycopeptides|VanB-type_regulator|VANRB,1028100584|WP_063856719.1|NG_048410|1|1|vanR-B|vanR-B|VanB-type_vancomycin_resistance_response_regulator_transcription_factor_VanR NG_048410:101-763,5
,ATGGCTGAATTACCTCAATCAAGAATTAATGAACGAAATATAACCAGTGAAATGCGTGAATCATTCTTAGACTATGCTATGAGTGTTATCGTTTCTCGTGCATTACCTGATGTTAGAGACGGATTAAAGCCAGTACATCGTCGTATTCTTTATGGTTTAAATGAACAAGGTATGACGCCCGATAAACCTTATAAGAAATCTGCACGTATAGTCGGGGATGTCATGGGTAAATATCACCCTCATGGTGATTCTTCAATTTATGAAGCAATGGTAAGAATGGCCCAAGACTTTAGTTATCGTTATCCACTTGTAGATGGTCAAGGTAACTTTGGCTCTATGGATGGTGACGGTGCAGCCGCAATGCGTTATACCGAAGCACGTATGACTAAAATAACATTAGAACTTTTACGTGATATCAACAAAGACACAATTGATTTTATTGACAACTATGATGGTAATGAAAGAGAGCCGTCAGTCTTACCTGCACGTTTCCCTAACTTACTAGTAAATGGTGCGGCAGGAATTGCCGTAGGTATGGCTACAAATATTCCTCCCCACAATTTAACTGAAGTTATTGATGGTGTGCTCAGTTTAAGTAAGAATCCAGACATCACAATTAATGAGCTGATGGAAGACATCCAAGGTCCTGATTTTCCTACAGCCGGTTTAGTACTAGGAAAAAGTGGTATTCGTCGAGCTTATGAAACAGGTCGTGGGTCAATTCAAATGCGTTCTCGTGCTGAAATAGAAGAACGTGGTGGTGGCCGTCAACGTATTGTCGTAACGGAAATACCTTTCCAAGTCAATAAAGCGCGTATGATTGAAAAAATCGCAGAGTTAGTTAGAGATAAGAAAATCGACGGTATTACAGATTTACGTGATGAAACAAGTTTGCGTACAGGTGTAAGAGTAGTTATTGATGTACGTAAAGATGCAAATGCGAGTGTTATTTTAAATAATTTATATAAACAAACGCCATTACAAACATCATTTGGTGTAAATATGATTGCTTTAGTGAATGGTAGACCTAAACTAATCAATTTAAAAGAAGCACTTATTCATTACTTAGAACACCAAAAAACAGTGGTTAGACGACGTACTGAATATAATCTTAAAAAAGCAAGAGACCGTGCACATATTCTAGAAGGTTTACGAATAGCACTAGATCATATTGATGAAATTATCACAACAATTCGTGAATCGGACACTGATAAAATTGCGATGGCAAGTTTACAAGAGCGTTTTAAACTTACTGAACGTCAAGCTCAAGCAATTTTAGATATGCGTTTAAGACGTTTAACTGGATTAGAAAGAGATAAAATAGAATCTGAGTATAATGAACTTCTAGAATATATTAAAGAGTTAGAAGAGATTTTAGCTGATGAAGAAGTACTATTACAATTAGTTCGTGATGAATTGACTGAAATTAAAGAACGTTTCGGCGATGAACGTCGCACTGAAATTCAATTAGGTGGTCTAGAAGATCTTGAAGATGAAGACTTAATCCCTGAAGAACAAATTGTTATTACATTAAGTCATAATAACTATATTAAACGTTTACCAGTATCTACATATCGTTCTCAAAATCGTGGTGGTCGTGGCATACAAGGTATGAACACGTTGGATGAGGACTTCGTTAGTCAATTGGTAACAATGAGTACACATGATCATGTTCTGTTCTTTACGAATAAAGGTCGTGTATATAAACTCAAAGGTTATGAAGTTCCTGAGTTGTCACGTCAATCCAAAGGCATACCTATTATTAATGCGATTGAACTCGAAAATGACGAAACAATAAGTACGATGATTGCAGTTAAAGACCTTGAAAGTGAAGAAGATTATCTCGTATTTGCGACAAAACAAGGTATCGTTAAACGTTCATCATTAAGTAACTTCTCCCGTATTAACAAAAACGGTAAAATTGCAATTAACTTTAAAGAAGATGATGAATTAATTGCAGTACGTCTAACAACAGGTAATGAAGATATTCTTATTGGAACTGCACATGCATCATTAATTAGATTCTCTGAATCTACATTACGCCCATTAGGCCGTACAGCAGCAGGTGTGAAAGGTATTTCTCTACGTGAAGGGGATACTGTCGTAGGTCTTGATGTTGCAGATTCAGAAAGTGAAGATGAAGTATTAGTAGTTACTGAAAATGGTTACGGTAAACGTACACCTGTTAGCGAATATCGTTTATCAAATCGTGGTGGTAAAGGAATCAAAACTGCGACAATTACCGAGCGTAATGGTAACATCGTTTGTATCACAACTGTAACCGGTGAAGAGGATTTAATGGTTGTAACTAACGCTGGTGTTATTATTCGTCTTGACGTTCATGATATTTCTCAAAATGGACGTGCAGCACAAGGTGTACGCCTTATGAAACTCGGAGATGGTCAATTTGTTTCTACTGTTGCTAAAGTAAACGAAGAAGACGATAATGAGGAAAATGCAGATGAAGCGCAACAATCTACTACTACTGAAACAGCAGATGTAGAAGAGGTAGTCGATGATCAGACACCAGGCAATGCGATTCATACAGAAGGTGATGCAGAAATGGAATCTGTAGAGTCTCCTGAAAATGATGATCGTATTGATATTAGACAAGATTTTATGGATAGAGTGAATGAAGATATCGAGAGTGCTTCAGATAATGAAGAAGATAGTGATGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3199,Drugs,MEG_3199|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|27316888|gb|AE015929.1|6916-9597,3
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1385,Drugs,MEG_1385|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_48_CFPA01000022,0
,ATGCCGCCTGTTTTTCCTGCTCATTGGCACGTTTCGCAACCTGTTCTCATTGCGGACACCTTTTCCAGCCTCGTTTGGAAAGTTTCATTGCCAGACGGGACTCCTGCAATCGTCAAGGGATTGAAACCTATAAAAGACATTGCTGATGAACTGCGCGGGGCCGACTATCTGGTATGGCGCAATGGGAGGGGAGCAGTCCGGTTGCTCGGTCGTGAGAACAATCTGATGTTGCTCGAATATGCCGGGGAGCGAATGCTCTCTCACATCGTTGCCGAGCACGGCGACTACCAGGCGACCGAAATTGCAGCGGAACTAATGGCGAAGCTGTATGCCGCATCTGAGGAACCCCTGCCTTCTGCCCTTCTCCCGATCCGGGATCGCTTTGCAGCTTTGTTTCAGCGGGCGCGCGATGATCAAAACGCAGGTTGTCAAACTGACTACGTCCACGCGGCGATTATAGCCGATCAAATGATGAGCAATGCCTCGGAACTGCGTGGGCTACATGGCGATCTGCATCATGAAAACATCATGTTCTCCAGTCGCGGCTGGCTGGTGATAGATCCCGTCGGTCTGGTCGGTGAAGTGGGCTTTGGCGCCGCCAATATGTTCTACGATCCGGCTGACAGAGACGACCTTTGTCTCGATCCTAGACGCATTGCACAGATGGCGGACGCATTCTCTCGTGCGCTGGACGTCGATCCGCGTCGCCTGCTCGACCAGGCGTACGCTTATGGGTGCCTTTCCGCAGCTTGGAACGCGGATGGAGAAGAGGAGCAACGCGATCTAGCTATCGCGGCCGCGATCAAGCAGGTGCGACAGACGTCATACTAG,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1097,Drugs,MEG_1097|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH6,aph(6)-Id_4_CP000971 ,2
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgtcgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2146,Drugs,MEG_2146|Drugs|betalactams|Class_A_betalactamases|CTX,1044690744|WP_065419569.1|NG_051165|1|1|blaCTX-M-186|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-186 NG_051165:1-876,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACGACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1870,Drugs,MEG_1870|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EF622224|+|0-1146|ARO:3002042|CMY-31 [Klebsiella pneumoniae] ,0
,ATGAGCGTATCGGAAATCCGACCGATTGCCATTGAGGACGAACTCAAGCATTCATATTTAGATTACGCGATGAGTGTAATTGTATCTCGTGCATTGCCGGATGTGAGAGACGGTCTTAAACCTGTTCACCGTCGTGTGCTTTATGCCATGCACGAATTGGGCAATGACTATAACAAAGCCTACAAGAAATCTGCTCGTGTCGTTGGGGACGTAATCGGTAAATATCACCCGCATGGTGACTTAGCTGTTTATGAAACCATTGTTCGTATGGCTCAAGACTTTAGCTTACGTTATTTATTGGTTGATGGTCAGGGTAACTTCGGTTCGATCGATGGTGATAGCGCTGCGGCAATGCGTTATACCGAAGTCCGTATGACTAAGCTGGCACATGAGCTTCTTGCAGATTTAGAAAAAGACACAGTTGACTGGGAAGATAACTACGACGGTTCGGAACGTATCCCTGAAGTACTTCCGACACGTGTTCCAAACTTATTAATTAACGGTGCTGCTGGTATTGCTGTAGGTATGGCAACTAACATGGCACCACACAACATGACAGAAGTTGTGAATGCTTGTTTGGCTTATGCTGACAATCCGAATATCTCGATTGAAGGATTGATGGAATACATTACTGGTCCTGACTTCCCTACAGGCGGTATTATTTACGGTAAATCAGGTATTGTTGATGCCTACCGTACCGGTAAAGGTCGTTTACACATTCGTGGTAAATACCATTTCGAAGAAGATGAAAAGACAGGTCGTACAACCATCGTCTTTACTGAAATTCCATATCAAGTAAACAAAGCAAGAGTTATTGAACGTATTGCCGAGTTAGTAAAAGAGAAAAAGCTTGAAGGTATTTCAGAACTTCGTGATGAGTCTGATAAAGAAGGTATGCGTATTGCAATTGACTTGAAACGCGGTGAAAACGCAGAAGTCGTTGTAAATAACTTATTCTTAAATACCCAGCTTGAAAACTCATTCAGCATCAACATGGTTTGTCTAGACAATGGACAACCAAAATTGATGAATCTAAAAGATATTATTGCGGCATTTATTCGTCACCGCCAAGAAGTTGTGACACGCCGTACCATGTTCGAATTACGTAAAGCACGTGAACGTGGTCATATCTTGGAAGGCTTGACAGTTGCCTTAGCCAATATTGATGAAATTATTGAAACCATCAAAACTTCTGCAAACCCTGCTGAAGCGCGTGAGCGTTTACTTGCGGGTGAGTGGGCAGGTGGTGGCGTTGTTGCACTACTTGAAAAAGCTGGTGCAATTTCTGTTCGCCCAGATGAAATTGAAGGTGAAGATCCAAATCGTCCATTTGGTTTAAGTGATTCAATTTATCGTCTGTCACCAACACAAGTAGGCGCAATTTTAGAATTACGTTTACACCGTTTAACTGGTCTTGAACAAGACAAGTTACATGCGGAATATACTGAAATTTTAGGTCAAATTGCTGAACTTACTGCAATTTTAAATGACTTTAACTTGTTAATGGGTGTTATTCGCGAAGAGTTGGCACAAGTTTTACAACAATATGGCGATGCACGTCGTACCGAAATTGTTGAATCTCGTGTGGATTTCTGCCGTGAAGATTTAATTCCTGAAGAGCAAGTGGTATTAACGGTTTCGCAAACGGGTTATGCAAAAACTCAACCTCTTTCAGACTATCAGGCACAGCGCCGTGGTGGACGTGGTAAGTCTGCAACCTCAATGAAAGATGATGACTTTATTCAACATCTGATTGTGGCATCGAACCATGCGACCGTACTTTGCTTTACCAATGTGGGTAAAGTGTACCGTCTGAAAGTATTTGAAGTTCCTCAAGCATCACGTGGGGCAAAAGGCCGTCCAATCGTGAACTTGTTACCTCTAGATGCAACAGAAACCGTAACCGCAATCTTGCCGTTAACCGAGTTCCCGGAAAACCACTATGTGTTTATGGCGACAGCTTCTGGTACGGTTAAGCGTGTTGAGTTAGAGCAATTTGCAAACATTCGTTCAAATGGTCTACGTGCTATTGAACTTAATGAAGAAGATACTTTAATTGGTGTTGCGATTACTGATGGTAATCAGCAAATCATGTTGTTCTCTAACGAAGGTAAGGCAATTCGTTTTGCTGAAACTGACGTACGTGCAATGGGTCGTACAGCGAAAGGTGTACGCGGTATGCGCGTGAGTTTTGCAAGCAGCACCTTAAGTGAAGAAGATGCAGATGTTGAAAATGATGATTCAGATGATAATGATGATTCAACAGATTCAAGTCTAGTAAGTCGCATCGTATCGCTTGTTGTTGTACCTGAGACAGGCGAAGTACTGTGTGCGAGTGCCAACGGTTATGGTAAACGTACTCCAGTAAATGACTTCCCGACCAAGAAACGTGGTGGTAAGGGTGTTATTGCGATCAAGACAAGTGAACGTAACGGTGAGCTAGTTGGTGCAGTTTCTATTGATGAAACCAAAGAGTTATTATTAATTTCTGATGGTGGTACGCTTGTTCGTACGCGTGCTGCAGAAGTTGCAATGACAGGCCGTAATGCTCAAGGTGTTCGTCTGATCCGTTTAAGCGAAGAAGAAACGCTCGTTGGCGTAGTTTCAATTGAAGCTGTAGAAGACGAAGAAGAACTTCTTGAAGGTGAAGTAGATACGACTGAAACTGATAGCGAAGAAGCTGTATCTAATAATGAAGATACTTCTGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3228,Drugs,MEG_3228|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|939559781|gb|CP012952.1|1020345-1023059 gi|787858845|gb|CP008706.1|968423-971137 gi|213985689|gb|CP001172.1|926712-929426,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccagggcaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcagaccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5549,Drugs,MEG_5549|Drugs|betalactams|Class_C_betalactamases|PDC,1034011045|WP_064483995.1|NG_050786|1|1|blaPDC-130|blaPDC|class_C_beta-lactamase_PDC-130 NG_050786:1-1194,0
,GTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_349,Drugs,MEG_349|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|401668653|gb|JX131372.1|840-1397,2
,ATGGCAAACCAAAAAATCCGTATCCGCCTGAAAGCTTATGATTACGCCCTGATTGACCGTTCTGCACAAGAAATCGTTGAAACTGCAAAACGTACCGGTGCTGTTGTAAAAGGCCCGATTCCTTTGCCGACCAAAATCGAGCGTTTCAACATTTTGCGTTCTCCGCACGTGAACAAAACTTCCCGTGAACAATTGGAAATCCGCACCCATTTGCGCCTGATGGACATCGTGGATTGGACCGATAAAACTACCGATGCGCTGATGAAGCTGGATTTGCCGGCCGGTGTTGATGTAGAAATTAAAGTCCAATAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_6143,Drugs,MEG_6143|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|RPSJ,gb|AE004969.1|-|1807358-1807670|ARO:3003930|rpsJ [Neisseria gonorrhoeae FA 1090] ,4
,atggatagttcgccgctcgtcaggcctgttgaaactaccgattcggccagttggctaagcatgcgctgtgagctgtggccagatggcacatgtcaagagcaccagtcagagatcgcagaatttctgtccggaaaagtcacccggcctgctgctgtcctcattgctgtagcacccgacggagaagcactagggtttgccgagctttcgatccgcccgtatgcggaggagtgctactccggcaacgttgcgttcttggagggttggtacgttgtgccaagtgcgcggcgtcagggcgtaggtgtagctctggtaaaagccgccgagcattgggctcgtggtcgcggatgcaccgaattcgcctccgacactcaacttaccaacagcgcaagcacctcggcgcacctggcggctggattcacggaggttgctcaagtacgctgcttccggaaaccgttgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_199,Drugs,MEG_199|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1028080942|WP_063840325.1|NG_047305|1|1|aac(6')-Il|aac(6')-Il|aminoglycoside_N-acetyltransferase_AAC(6')-Il NG_047305:101-559,2
,TTTTAATGATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAGATTCTCTACCGTGCCGATGAACGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAAGAAGAGCGACCTGGTTAACTACAATCCCATTGCGGAGAAACACGTTAACGGCACGATGACGCTGGCTGAGCTTGGCGCAGCGGCGCTGCAGTATAGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGTCCCGATAAAGTGACGGCGTTTGCTCGCTCGTTGGGTGATGAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATACCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAAGCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTCTGCCGAAATCATGGGTAGTGGGCGATAAAACCGGCAGCGGAGATTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGAAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGCCGTCGGGATATTCTGGCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGATGCAATAAATGGAGCGAGGTATCGCTCCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2426,Drugs,MEG_2426|Drugs|betalactams|Class_A_betalactamases|CTX,gi|697655994|dbj|AB976587.2|4452-5361 gi|695934953|gb|CP007636.1|141150-142059 gi|668347677|dbj|AB976589.1|97-1006 gi|668347674|dbj|AB976588.1|1244-2153 gi|668347663|dbj|AB976586.1|1755-2664 gi|569555425|gb|CP004000.1|131642-132551 gi|695224103|ref|NG_041018.1|570-1479 gi|526482529|gb|KC879156.1|6091-7000 gi|695214733|ref|NG_036899.1|43228-42319 gi|288872174|dbj|AB543701.1|1813-2722,0
,ATGGAAAAATACAACAATTGGAAACTTAAGTTTTATACAATATGGGCAGGGCAAGCAGTATCATTAATCACTAGTGCCATCCTGCAAATGGCGATTATTTTTTACCTTACAGAAAAAACTGGATCTGCGATGGTCTTGTCTATGGCTTCACTAGTAGGTTTTTTACCCTATGCGGTCTTTGGACCTGCAATTGGTGTGCTAGTGGATCGTCATGATAGGAAGAAGATAATGATTGGTGCTGATTTAATTATCGCAGCAGCTGGTGCAGTGCTTGCTATTGTTGCATTCTATATGGAGCTACCTGTCTGGATGGTTATGATAGTATTGTTTATCCGTAGCATTGGAACAGCTTTTCATACCCCAGCACTCAATTCGGTTACACCACTTTTAGTACCAGAAGAGCAGCTAACGAAATGCGCAGGCTATAGTCAGTCTTTGCAGTCTATAAGCTATATTGTTAGTCCGGCAGTTGCAGCACTCTTATACTCCGTTTGGGATTTAAATGCTATTATTGCCATCGACGTATTGGGTGCTGTGATTGCATCTATTACGGTAGCAATTGTACGTATACCTAAGCTGGGTAATCAAGTGCAAAGTTTGGAACCAAATTTCATAAGAGAAATGAAAGAAGGAATTGTCGTTCTGAGACAAAACAAAGGATTGTTTGCCTTATTACTCTTAGGAACACTATATACTTTTGTTTATATGCCAATTAATGCACTATTTCCTTTAATAAGCATGGAATACTTTAATGGAACACCTGTGCATATTTCTATTACGGAAATTTCCTTTGCCTTTGGAATGCTAGCAGGAGGCTTATTGTTAGGAAGATTAGGGAGCTTCGAAAAGCGTGTATTACTAATAACTAGTTCATTTTTTATAATGGGGGCCAGTTTAGCCGTTTCGGGAATACTTCCTCCAAATGGATTTGTAATATTTGTAGTTTGCTGTGCAATAATGGGGCTTTCGGTGCCATTTTATAGCGGTGTGCAAACAGCTCTTTTTCAGGAGAAAATTAAGCCTGAATATTTAGGACGTGTATTTTCTTTGACCGGAAGTATCATGTCACTTGCTATGCCAATTGGATTAATTCTTTCTGGATTCTTTGCTGATAGAATTGGTGTAAATCATTGGTTTTTACTATCAGGTATTTTAATTATTGGCATTGCTATAGTTTGCCCAATGATAACAGAGGTTAGAAAATTAGATTTAAAATAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3824,Drugs,MEG_3824|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,gi|568818634|gb|KF648874.1|66509-65292,7
,atgaaaaaaatatttttgctttttggtcttttttgctcttttgctttggcaaatgaaaatttaaaagatctttttaaagattataatgaaagtggagtttttatagcttatgatggtaaaaattattatagcaatgactttaaaaaagcaaacaaacgcattttacctgcctctacttttaaaattttcaatgccttaatcgcacttaatgaaggtgttgtgaaagatactaatgaaattttttatcattacaaaggtgaaaaagtatttttaccatcttggaaaaataatgcaaacttagctttagctatgcaaagatcacaactacctgcttataaagaactagctagaaaaataggcttagaaaaaatgcaaaaaaacttaaataaacttaattatggcaaccaaaaaataagtaaaatagatgagttttggatagatgattctttacaaattagtcttaaagaacaagctactttactttttaagcttgccaatttaacactagactaccctaaacatatacaagaagaagtgattaatatcatcaagttaaaagaaaatgatcattatgaactttttgcaaaaacaggttggggtcttagacaatatggacaaatcgtaggttttataaaaagtaaaaaaagtgacaaaatttacgcttttgctttaaatatgaatataagtgattttaacaagctttatctaagagaagaaatagtacaactgtatctagatcaattataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4663,Drugs,MEG_4663|Drugs|betalactams|Class_D_betalactamases|OXA,501874739|WP_012662081.1|NG_049772|1|1|blaOXA-493|blaOXA-493_like|class_D_beta-lactamase_OXA-493 NG_049772:101-847,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCGTTCTCCACGTTTGCCGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACTCAACAAACGCTGTTTGAACTCGGATCGGTCAGTAAAACGTTCAACGGCGTGCTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGCATTACTGGCCTGAACTGACTGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCGTTACTACGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGCGCCCTGGCGGTGAACCCCTCAGGCATGAGCTACGAAGAGGCGATGACCAAACGCGTCCTGCGCCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGGCAACTTGATGCCGAAGCCTACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGCATCGAGCTTGCGCAGTCACGTTACTGGCGTATTGGCGATATGTACCAGGGCCTGGGCTGGGAGATGCTGAACTGGCCGGTGAAGGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTGGCCCTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAGAGCTACCCAAACCCTGTTCGCGTCGAAGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1916,Drugs,MEG_1916|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JX440351|+|1026-2172|ARO:3002096|CMY-83 [Citrobacter braakii] ,0
,atgcgccatgcgacaatcctcaacctgtgcggcctcgccgcttccaccctgttcttcgcgacaacatcggccttcgccacggaggcgccggcggagcgcctgaaggctctggtggacgccgccgtgcaaccggtcatgaaggccaatgatatcccgggactggccgtcgccatcactctcaagggcgaaccgcattacttcagttatggggtggcctcgaaggaggacgcccgcaaggtgacccccgagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctacgccctggcccaggacaagatgcgcctcgacgaccgcgccagccggcactggcccgccctgcagggcagccgcttcgacggtatcagcctgctcgacctcggcacctacaccgctggcggcctgccgctacagttccccgatgcggtgcagaaggatccggcgcagatccgcgactattaccgccagtggcaaccgacctacgccccgggcagccaccgccagtactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccattcgagcgcagcatggaacggcagctgttcccggcgctcggcctggagcacacctttatccgggtgcccgccgcgcagcaggggctgtacgcccagggctacggcaaggacgaccacccgctgcgggtcggacccggtccgctggacgccgaggcctacgggctgaagtccagcgctgcggacctgctgcgcttcgtcgaggccaacctgcaccccgagcgcctggagaagccctgggcgcaggccctcgacgccacccatcgcggctactacaaggtgggcgacatgacccagggcctgggctgggaagcctacgattggccgatcgacctgaggcgcctgcaggcgggcaactcggcgccgatggcgctgcaggcgcacaaggtcgccaggttgccggcgccgcaagccctggacggccagcgcctgctgaacaagaccggctccaccaacggtttcggcgcctacctggcgttcatcccgggacgcgacgtcggcctggtgatcctggccaatcgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggaacagcaggccaaggtaccactggtgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5430,Drugs,MEG_5430|Drugs|betalactams|Class_C_betalactamases|PDC,1034011133|WP_064484005.1|NG_050796|1|1|blaPDC-140|blaPDC_var|class_C_beta-lactamase_PDC-140 NG_050796:1-1194,0
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_2433,Drugs,MEG_2433|Drugs|betalactams|Class_A_betalactamases|CTX,gi|953271687|gb|KT175891.1|137-1015 gi|930714478|gb|KR093975.1|153-1031 gi|930714476|gb|KR093974.1|183-1061 gi|923480230|gb|KP902666.1|203-1081 gi|800908771|gb|KP125893.1|130342-129464 gi|762041701|gb|KJ201887.1|9169-8291 gi|668347631|dbj|AB976577.1|1932-2810 gi|668347606|dbj|AB976571.1|1232-2110 gi|668347594|dbj|AB976568.1|1325-2203 gi|578355140|gb|KF914891.1|43942-43064,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1337,Drugs,MEG_1337|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_20_JBVX01000014,0
,gtgaatacatcctattcacaatcgaatttacgacacaaccaaattttaatttggctttgcattttatctttttttagcgtattaaatgaaatggttttgaacgtctcattacctgatattgcaaatgattttaataaaccacctgcgagtacaaactgggtgaacacagcctttatgttaaccttttccattggaacagctgtatatggaaagctatctgatcaattaggcatcaaaaggttactcctatttggaattataataaattgtttcgggtcggtaattgggtttgttggccattctttcttttccttacttattatggctcgttttattcaaggggctggtgcagctgcatttccagcactcgtaatggttgtagttgcgcgctatattccaaaggaaaataggggtaaagcatttggtcttattggatcgatagtagccatgggagaaggagtcggtccagcgattgttggaatgatagcccattatattcattggtcctatcttctactcattcctatgataacaattatcactgttccgtttcttatgaaattattaaagaaagaagtaaggataaaaggtcattttgatatcaaaggaattatactaatgtctgtaggcattgtattttttatgttgtttacaacatcatatagcatttcttttcttatcgttagcgtgctgtcattcctgatatttgtaaaacatatcaggaaagtaacagatccttttgttgatcccggattagggaaaaatatactttttatgattggagttctttgtgggggaattatatttggaacagtagcagggtttgtctctatggttccttatatgatgaaagatgttcaccagctaagtactgccgaaatcggaagtgtaattattttccctggaacaatgagtgtcattattttcggctacattggtgggatacttgttgatagaagaggtcctttatacgtgttaaacatcggagttacatttctttctgttagctttttaactgctttctttcttttagaaacaacatcatggttcatgacaattataatcgtatttgttttaggtgggctttcgttcaccaaaacagttataccaacaattgtttcaagtagcttgaaacagcaggaagctggtgctggaatgagtttgcttaactttaccagctttttatcagagggaacaggtattgcaattgtaggtggtttattatccatacccttacttgatcaaaggttgttacctatgggagttgatcagtcaacttatctgtatagtaatttgttattacttttttcaggaatcattgtcattagtgggctggttaccgtgaatgtatataaacattctcaacgggatttctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7093,Drugs,MEG_7093|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETL,501174780|WP_012218461.1|NG_048207|1|1|tet(L)|tet(L)|tetracycline_efflux_MFS_transporter_Tet(L) NG_048207:101-1477,4
,AAGACTTTCAGTCGATCCGGAAAACAGCAAATTTTAATTATTTCTCCATAAAAATTATGAAAAAAAGTATTCAGCTTTTGATGATGTCAATGTTTTTAAGCCCATTGATCAATGCCCAGGTTAAAGATTTTGTAATTGAGCCGCCTGTTAAACCCAACCTGTATCTTTATAAAAGTTTCGGAGTTTTCGGGGGTAAAGAATATTCTGCCAATGCTGTATATCTTACCACTAAGAAAGGAGTTGTCTTATTTGATGTCCCATGGCAAAAGGAACAATATCAAACCCTTATGGACACCATACAAAAGCGTCATCACCTTCCTGTAATTGCTGTATTTGCCACCCACTCTCATGATGACAGAGCGGGTGATCTAAGCTTTTACAATCAAAAAGGAATTAAAACATATGCGACCGCCAAGACCAATGAACTGTTGAAAAAAGACGGAAAAGCAACCTCAACCGAAATTATAAAAACAGGAAAACCTTACAAAATTGGTGGTGAAGAATTTATGGTAGACTTTCTTGGAGAAGGACATACAGTTGATAATGTTGTTGTATGGTTCCCCAAATATAAAGTACTGGACGGAGGATGTCTTGTAAAAAGCAGGACAGCCACTGACCTGGGATATACCGGTGAAGCAAATGTAAAACAATGGCCGGAAACCATGCGAAAACTAAAAACGAAATATGCTCATGCCACTCTGGTAATCCCGGGACACGACGAATGGAAAGGCGGTGGCCATGTACAGCATACTCTGGATCTTCTGGATAAGAATAAAAAGCCGGAATAATGTAACACATTAAAATGGTTCGGAAAAAATCGAAAGATTTTATAAAGCCTATTATTTATACTTAAAAAATCCCGAATTTTCATTCGGGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3424,Drugs,MEG_3424|Drugs|betalactams|Class_B_betalactamases|IND,gi|300510839|gb|HM245379.1|1-877,0
,atgcatacgcggaaggcaataacggaggcaattcgaaaactcggagtccaaaccggtgacctgttgatggtgcatgcctcacttaaagcgattggtccggtcgaaggaggagcggagacggtcgttgccgcgttacgctccgcggttgggccgactggcactgtgatgggatacgcgtcgtgggaccgatcaccctacgaggagactctgaatggcgctcggttggatgacaaagcccgccgtacctggccgccgttcgatcccgcaacggccgggacttaccgtgggttcggcctgctgaatcaatttctggttcaagcccccggcgcgcggcgcagcgcgcaccccgatgcatcgatggtcgcggttggtccgctagctgaaacgctgacggagcctcacgaactcggtcacgccttgggggaagggtcgcccgtcgagcggttcgtccgccttggcgggaaggtcctgctgttgggtgcgccgctaaactccgttaccgcattgcactacgccgaggcggttgcggatatccccaacaaacgatgggtgacgtatgagatgccgatgcttggaagaaacggtgaagtcgcctggaaaacggcatcagaatacgattcaaacggcattctcgattgctttgctatcgaaggaaagccggatgcggtcgaaactatagcaaatgcttacgtgaagctcggtcgccatcgagaaggtgtcgtgggctttgctcagtgctacctgttcgacgcgcaggacatcgtgacgttcggcgtcacctatcttgagaagcacttcggagccactccgatcgtgccagcacacgaagccgcccagcgctcttgcgagccttccggttag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_20,Drugs,MEG_20|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,504873195|WP_015060297.1|NG_047248|1|1|aac(3)-IIa|aac(3)-IIa|aminoglycoside_N-acetyltransferase_AAC(3)-IIa NG_047248:101-961,2
,GAGCGGTTTAGGCTGGACCGGCAGTTAAAATTGGGGCTTGAGCGGTAAACGAGTGAGGGAATTTCAGGTAAGATACTTCGGATGAGGAGCAAAAAGGTGGTTTATACTTCCTATACCCACTTCACATCGGCTTCACAGAGCCTCATATTGCGCACACCTTGCGGGAATAGGCTGGGAGCACTGCCAGGCACCCAGGCAGCACATTCGACTTATGACAAGAGGAGTAGACCCGATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTATTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCAGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGTCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCATTTGCCCAGTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGGGTCAACCCTGGCATGCTGGCGGACGAGGCCTACGGCATCAAGACCAGCTCGGCGGATCTGCTCGCCTTCGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACAAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGATCCTCGAAGCCAATCCGACGGCGGCTCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGAGCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTATCCCATCCCGGCCAGGGTGAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGACAGAAAGAGGGCGGTACATTCGGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4025,Drugs,MEG_4025|Drugs|betalactams|Class_C_betalactamases|MOX,gi|695200064|ref|NG_035368.1|1-1407 gi|573013567|dbj|AP013064.1|27485-27603 gi|573013567|dbj|AP013064.1|29740-29858 gi|695214120|ref|NG_036738.1|6267-6384 gi|695214108|ref|NG_036737.1|5356-5473 gi|695197690|ref|NG_034779.1|51-168 gi|13591818|gb|AF357599.1|1-71 gi|14318308|gb|AF381618.1|1-71 gi|13591814|gb|AF357597.1|1-71,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcacgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcggatggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcatcgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6194,Drugs,MEG_6194|Drugs|betalactams|Class_A_betalactamases|SHV,1509794529|WP_122630838.1|NG_062244|1|1|blaSHV-201|blaSHV|class_A_beta-lactamase_SHV-201 NG_062244:1-861,0
,ATGAAGAAATTATTTGTTTTATGTGTATGCTTCTTTTGTAGCATTACTGCCGCAGGAGCGGCTTTACCTGATTTAAAAATCGAGAAGCTTGAAGAAGGTGTTTTTGTTCATACATCGTTCGAAGAGGTTAACGGTTGGGGGGTTGTTACTAAACACGGTTTAGTGGTGCTTGTAAACACAGACGCCTATCTAATTGACACTCCATTTACTGCTACAGACACTGAAAAATTAGTCAATTGGTTTGTGGAGCGCGGCTATGAAATCAAAGGCACTATTTCATCACATTTCCATAGCGACAGCACAGGAGGAATAGAGTGGCTTAATTCTCAATCTATTCCCACGTATGCATCTGAATTAACAAATGAACTTTTGAAAAAATCCGGTAAGGTACAAGCTAAATATTCATTTAGCGAAGTTAGCTATTGGCTAGTTAAAAATAAAATTGAAGTTTTCTACCCTGGCCCAGGTCACACTCAAGATAACCTAGTGGTTTGGTTGCCTGAAAGTAAAATTTTATTCGGTGGTTGCTTTATTAAACCTCACGGTCTTGGCAATTTAGGTGACGCAAATTTAGAAGCTTGGCCAAAGTCCGCCAAAATATTAATGTCTAAATATGGCAAAGCAAAGCTTGTTGTTTCAAGTCATAGTGAAAAAGGGGACGCATCACTAATGAAACGTACATGGGAACAAGCCCTTAAAGGGCTTAAAGAAAGTAAAAAAACATCATCACCAAGTAACTAAATTTCTAACAAGTCGTTGCAGCACCGCGCACTTCGTGCGCTGGACAGTTTTTAAGTCGCGGCTTTATGGTTTTGCTGCGCAAAAGTATTCCATAAAACCACAACTTAAAAACTGCCGCTGAACTCGGCGTTAGGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_3391,Drugs,MEG_3391|Drugs|betalactams|Class_B_betalactamases|IMP,gi|354549225|gb|JN091097.1|261-1136 gi|281021955|gb|GU207399.1|66-941 gi|219664352|gb|FJ172676.1|869-1744 gi|164663647|emb|AM931299.1|32-907 gi|72416444|emb|AJ628135.2|2228-3103 gi|33086392|emb|AJ550807.1|2243-3118 gi|401668650|gb|JX131371.1|724-1597 gi|219664342|gb|FJ172674.1|168-1041,0
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGCTGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCGTAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAGATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6884,Drugs,MEG_6884|Drugs|betalactams|Class_A_betalactamases|TEM,gi|20198332|gb|AF347054.1|1-1082,0
,atgaaaaactactttaacagccctttcaaaggggaacttctttctgagcaagtgaaaaatccaaatatcagagtaggccggtatagctattactctggctactatcacgggcactcatttgatgaatgcgcgcgatacttgtttccagatcgtgatgacgttgataaattgatcattggcagcttttgttctataggaagcggggcttccttcatcatggctggcaatcaggggcatcggcatgactgggcatcatccttccccttcttctatatgcaagaggagcctgctttctcaagagcactcgacgccttccaaagagcaggtgataccgtcattggcaatgatgtctggataggctcggaggcaatgattatgcctggcatcaaaattggagacggtgccgtgataggtagtcgctcgttggtgacaaaagatgtagagccttattccatcatcgggggaaatcccgcaaagcaaattaagaagcgcttctccgatgaggaaatctcattgttcatggagatggagtggtggaactggccactagataaaattaagacagcaatgcctctgctgtgctcgtcaaatatttttggtctgcataagtattggcgcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1606,Drugs,MEG_1606|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,543134908|WP_021018581.1|NG_060511|1|1|catB8|catB8|type_B-3_chloramphenicol_O-acetyltransferase_CatB8 NG_060511:101-733,6
,atgcgccgcgtggtgggcaagcgggtcctggagttctccgaagccgagttcgaccagctccggagtcagtacgacgaggtggtgctcgacgtcggcaccggcgacggcaagcacccgtacaaggtcgcccgccagcacccgaaccagctcgtcgtcgcactggacgccgacaagaccaggatggagcggatgtcggcgaaggcggcggccaagccggcgaagggcggcctgcccaacctgctctacctgtgggcgaccgcggagaagctgccgccgctgaccggcgtgggcgagctgcacgtcctcatgccctggggcagcctgctgcgcggcatcctcggctcctcgccggagatgctgcgggggctggccgcggtctgccggccggacgccgccttcctcgtggcgctgaacctgcacgcgtggcggcccccggtgcccgaggtgggcgagcaccccgaacccaccccggagaccgtggacgagggactggccgcccgctacgcgcaggccggctggcagctcaccgactgccggtacctggccgcggaggaggtggcggccctggagacctcctggacccgccggctgaactcctcccgggaccggttcgacgtgctcgccctcaccggcaagatcaacccgtga,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_3442,Drugs,MEG_3442|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|KAMB,1028223006|WP_063964001.1|NG_050562|1|1|kamB|kamB|16S_rRNA_(adenine(1408)-N(1))-methyltransferase_KamB NG_050562:101-748,2
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttgggtagtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4505,Drugs,MEG_4505|Drugs|betalactams|Class_D_betalactamases|OXA,1188444900|WP_085562402.1|NG_054692|1|1|blaOXA-545|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-545 NG_054692:1-825,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAAAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACACATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGATGGTGTTTCAAAAGACTGTAAGGTGGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTATTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1449,Drugs,MEG_1449|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_15_JAZQ01000018,0
,ttgaactattcaatatgcgatatagctgaatcaaatgaattaatccttgaagcagcaaagatgcttaagaaaagctttcttgatgctggaaatgaatcatggggagatattaaaaatgctattgaagaagttgaagaatgtatagaacatccaaatatatgcttgggaatatgtctggatgataaactgattggatggaccggattaaggccgatgtacgataagacctgggaacttcatcccatggttataaaaactgaatatcaaggcaagggttttgggaaagtactactaagagaactagagacgagagcgaagagtaggggaattatcggaatagctcttggaactgatgacgaatatcagaaaactagtttgtctatgattgatataaacgaacgaaatatcttcgatgaaatcgggaatataaagaacgttaataatcatccatatgagttttataagaaatgtggttatatgatcgttggaataatccctaatgctaatggaaaaagaaaaccagatatatggatgtggcagatattagctaggaagaacagcccaacaatcgcttcaacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_266,Drugs,MEG_266|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1063842728|WP_069453146.1|NG_047307|1|1|aac(6')-Ip|aac(6')-Ip|aminoglycoside_6'-N-acetyltransferase_AAC(6')-Ip NG_047307:101-682,2
,ATGGATATTATTGATAAAGTTTTTCAGCAAGAGGATTTCTCACGCCAGGATTTGAGCGACAGCCGTTTTCGCCGCTGCCGCTTTTATCAGTGTGACTTCAGCCATTGCCAGCTAAGGGATGCCAGTTTCGAGGATTGCAGTTTCATTGAAAGCGGCGCCGTCGAAGGGTGCCACTTCAGCTATGCCGATCTGCGCGATGCCAGTTTCAAGGCCTGCCGCCTGTCTTTGGCCAATTTCAGCGGTGCCAACTGCTTTGGCATAGAGTTCAGGGAGTGCGATCTCAAGGGTGCCAATTTTTCCCGGGCCCGTTTTTACAATCAAATCAGCCATAAGATGTACTTCTGCTCGGCTTATATCTCAGGCTGCAACCTGGCCTATGCCAATTTGAGCGGCCAATGCCTGGAAAAGTGCGAGCTGTTTGAAAACAACTGGAGCAATGCCAACCTCAGCGGCGCTTCCTTGATGGGCTCCGACCTCAGCCGCGGCACCTTCTCCCGCGACTGCTGGCAACAGGTAAACCTGCGGGGCTGTGACCTGACCTTTGCCGATCTGGATGGGCTCGACCCCAGACGGGTCAACCTCGAAGGGGTCAAGATCTGTGCCTGGCAGCAGGAGCAACTGCTGGAACCCTTGGGAGTAATAGTGCTGCCGGATTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5876,Drugs,MEG_5876|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRA,gi|695213299|ref|NG_036595.1|3354-4010 gi|695213288|ref|NG_036594.1|3354-4010 gi|90289592|gb|DQ435306.1|1-657 gi|160213053|gb|EU247883.1|1-578,3
,atgacaatgcgaatagatacagacaaacaaatgaatttacttagtgataagaacgttgcaataattggtggtggacccgttggactgactatggcaaaattattacagcaaaacggcatagacgtttcagtttacgaaagagacaacgaccgagaggcaagaatttttggtggaacccttgacctacacaaaggttcaggtcaggaagcaatgaaaaaagcgggattgttacaaacttattatgacttagccttaccaatgggtgtaaatattgctgatgaaaaaggcaatattttatccacaaaaaatgtaaagcccgaaaatcgatttgacaatcctgaaataaacagaaatgacttaagggctatcttgttgaatagtttagaaaacgacacggttatttgggatagaaaacttgttatgcttgaacctggtaagaagaagtggacactaacttttgagaataaaccgagtgaaacagcagatttggttattcttgccaatggcgggatgtccaaggtaagaaaatttgttaccgacacggaagttgaagaaacaggtactttcaatatacaagccgatattcatcaaccagagataaactgtcctggattttttcagctatgcaatggaaaccggctaatggcatctcaccaaggtaatttattatttgctaaccccaataataatggtgcattgcattttggaataagttttaaaacacctgatgaatggaaaaaccaaacgcaggtagattttcaaaacagaaatagtgtcgttgattttcttctgaaagaattttccgattgggacgaacgctacaaagaattgattcatacgacgttgtcatttgtaggattggctacacggatatttcctttagaaaagccttggaaaagcaagcgcccattacccataacaatgattggggatgccgcacatttgatgccgccttttgcagggcagggagtaaatagtgggttggtggatgccttgatattgtctgataatctagccgatggaaaatttaatagcattgaagaggctgttaaaaattatgaacagcaaatgtttatctatggcaaagaagcacaagaagaatcaactcaaaacgaaattgaaatgtttaaacccgactttacgtttcagcaattgttaaatgtataa,tetracycline inactivation enzyme,antibiotic inactivation,Tetracyclines,MEG_7238,Drugs,MEG_7238|Drugs|Tetracyclines|Tetracycline_inactivation_enzymes|TETX,495926503|WP_008651082.1|NG_048305|1|1|tet(X)|tet(X)|tetracycline-inactivating_monooxygenase_Tet(X) NG_048305:101-1267,4
,ATGAATCCCTATCTACAGTTAGTTAGCAAAGAGTTTCCATTAGAAAAAAAACAAGAGCCGCCCCACCTAGTCCTTGCTGCTTTTAGTGAAGAAGAAGTTTACTTGCAGCCTGAAGCAGCCAAACAATGGGAACGCCTCGTCAAAGCCTTAAAACTTGAAAACGAGATCTGCTTATTAGACGGCTATCGAACCGAAAAGCAGCAACGGTATTTATGGGAATATTCCTTAAAAGAAAATGGATTAGCCTATACGAAACAATTTGTGGCGTTGCCCGGCTGTAGCGACCATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAGGGCAGCCAGAATGATTTGATCTGTCCACGTTTTCGTGACAGCGCAGCCGCTGATTTATTTACCCAGGAAATGATGAACTACGGATTTATTTTACGCTACCCCGCAGACAAACAAGAAATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTTTGCCTCATAGTCAAATCATGGCCAATCAACAGTGGACCTTGGAAGAATACCATCAGTATCTTGAACAGACCACGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7585,Drugs,MEG_7585|Drugs|Glycopeptides|VanC-type_resistance_protein|VANXYC,gi|161779845|gb|EU151752.1|1078-1650,5
,atgaaaaagataaaaattgttccacttattttaatagttgtagttgtcgggtttggtatatatttttatgcttccaaagataaagaaattaataatactattgatgcaattgaagataaaaatttcaaacaagtttataaagatagcagttatatttctaaaagcgataatggtgaagtagaaatgactgaacgtccgataaaaatatataatagtttaggcgttaaagatataaacattcaggatcgtaaaataaaaaaagtatctaaaaataaaaaacgagtagatgctcaatataaaattaaaacaaactacggtaacattgatcgcaacgttcaatttaattttgttaaagaagatggtatgtggaagttagattgggatcatagcgtcattattccaggaatgcagaaagaccaaagcatacatattgaaaatttaaaatcagaacgtggtaaaattttagaccgaaacaatgtggaattggccaatacaggaacagcatatgagataggcatcgttccaaagaatgtatctaaaaaagattataaagcaatcgctaaagaactaagtatttctgaagactatatcaaacaacaaatggatcaaaattgggtacaagatgataccttcgttccacttaaaaccgttaaaaaaatggatgaatatttaagtgatttcgcaaaaaaatttcatcttacaactaatgaaacagaaagtcgtaactatcctctaggaaaagcgacttcacatctattaggttatgttggtcccattaactctgaagaattaaaacaaaaagaatataaaggctataaagatgatgcagttattggtaaaaagggactcgaaaaactttacgataaaaagctccaacatgaagatggctatcgtgtcacaatcgttgacgataatagcaatacaatcgcacatacattaatagagaaaaagaaaaaagatggcaaagatattcaactaactattgatgctaaagttcaaaagagtatttataacaacatgaaaaatgattatggctcaggtactgctatccaccctcaaacaggtgaattattagcacttgtaagcacaccttcatatgacgtctatccatttatgtatggcatgagtaacgaagaatataataaattaaccgaagataaaaaagaacctctgctcaacaagttccagattacaacttcaccaggttcaactcaaaaaatattaacagcaatgattgggttaaataacaaaacattagacgataaaacaagttataaaatcgatggtaaaggttggcaaaaagataaatcttggggtggttacaacgttacaagaaataaagtggtaaatggtaatatcgacttaaaacaagcaatagaatcatcagataacattttctttgctagagtagcactcgaattaggcagtaagaaatttgaaaaaggcatgaaaaaactaggtgttggtgaagatataccaagtgattatccattttataatgctcaaatttcaaacaaaaatttagataatgaaatattattagctgattcaggttacggacaaggtgaaatactgattaacccagtacagatcctttcaatctatagcgcattagaaaataatggcaatattaacgcacctcacttattaaaagacacgaaaaacaaagtttggaagaaaaatattatttccaaagaaaatatcaatctattaactgatggtatgcaacaagtcgtaaataaaacacataaagaagatatttatagatcttatgcaaacttaattggcaaatccggtactgcagaactcaaaatgaaacaaggagaaactggcagacaaattgggtggtttatatcatatgataaagataatccaaacatgatgatggctattaatgttaaagatgtacaagataaaggaatggctagctacaatgccaaaatctcaggtaaagtgtatgatgagctatatgagaacggtaataaaaaatacgatatagatgaataa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3775,Drugs,MEG_3775|Drugs|betalactams|Penicillin_binding_protein|MECA,1028095795|WP_063852683.1|NG_047948|1|1|mecA-ceftar|mecA-ceftar|ceftaroline-resistant_PBP2a_family_peptidoglycan_transpeptidase_MecA NG_047948:1-2007,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactaccagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_770,Drugs,MEG_770|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502195|WP_071846345.1|NG_052442|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052442:101-892,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacctacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5525,Drugs,MEG_5525|Drugs|betalactams|Class_C_betalactamases|PDC,1201190450|WP_087587970.1|NG_054990|1|1|blaPDC-205|blaPDC|class_C_beta-lactamase_PDC-205 NG_054990:1-1194,0
,atgataatcagtgaatttgaccgtaataatctagtattgaaagatcagctttctgatttactgagactgacatggccggaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacggatcgcggtagcagcagttgaccaagatgagttagtaggatttattggtgcaatccctcaatacggtatcacaggttgggaattgcatccattagtcgtagaaagctcccgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagaggaggaataacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaaacggacctgtatgagcatacatttgataaagtggcttccatccagaaccttcgtgaacatccgtatgagttctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaaatggctgggacaaaccggatatttggatggcaaaaacgattattcctcgaccagattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_144,Drugs,MEG_144|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,488302933|WP_002373947.1|NG_052285|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052285:101-649,2
,GCCACCCTGCCACTGGCGGTAGACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGCTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTGTCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGCACTGAATGAGGCGCTTCCCGGCGACGCGCGCGACACCACCACCCCGGCCAGCATGGCCGCCACGCTGCGCAAACTACTGACCGCGCAGCATCTGAGCGCCCGTTCGCAACAGCAACTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGGCGGGCTGGTTTATCGCCGACAAAACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAACCGGAGCGCATTGTGGTGATCTATCTGCGGGATACCCCGGCGAGTATGGCCGAGCGTAATCAACATATCGCCGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3553,Drugs,MEG_3553|Drugs|betalactams|Class_A_betalactamases|LEN,gb|AJ635417|+|0-789|ARO:3002461|LEN-11 [Klebsiella pneumoniae] ,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgataggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtattggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcaacaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatatctagctctgttcgaaaagagattacttatagaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4475,Drugs,MEG_4475|Drugs|betalactams|Class_D_betalactamases|OXA,1509794577|WP_122630886.1|NG_062306|1|1|blaOXA-684|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-684 NG_062306:30-854,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctacccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgactttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_831,Drugs,MEG_831|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502206|WP_071846356.1|NG_052476|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052476:101-889,2
,atgaatattatgcctgtatctgaatccctgatggcagattggttaggattgagaaaactgctctggcctgatcatgacgaggcacatttacaggaaatgcagcggctacttcaacagacacaaagcttacagctactcgcatattcagatactcaacaagcgattgccatgctagaagcatcgattcgatatgaatatgtaaatggcacgcaaacttcaccagttgcatttcttgaagggatttatgtccttcctgattatcgacgttcaggcatcgcaacacgtctggttcaacaagtagaagcgtgggcaaaaccgtttggatgtactgaatttgcctctgatgcagccctcgacaatcgtattagccatgcgatgcatcaggcgcttggttttcatgaaactgaacgtgtggtttatttcaagaaacacattggctga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_118,Drugs,MEG_118|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491411993|WP_005269797.1|NG_052527|1|1|aacA-ACI3|aacA-ACI3|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052527:101-541,2
,ATGCGCCCTCTCCTCTTCAGTGCCCTTCTCCTGCTTTCCGGGCATACCCAGGCCAGCGAATGGAACGACAGCCAGGCCGTGGACAAGCTATTCGGCGCGGCCGGGGTGAAAGGCACCTTCGTCCTCTACGATGTGCAGCGGCAGTGCTATGTCGGCCATGACCGGGAGCGCGCGGAAACCCGCTTCGTTCCCGCTTCCACCTACAAGGTGGCGAACAGCCTGATCGGCTTATCCACAGGGGCGGTTAGATCCGCCGACGAGGTTCTTCCCTATGGCGGCAAGCCACAGCGCTTCAAGGCCTGGGAGCACGACATGAGCCTGCGCGAGGCGATCAAGGCATCGAACGTACCGGTCTACCAGGAACTGGCGCGGCGCATCGGCCTGGAGCGGATGCGCGCCAATGTCTCGCGCCTGGGTTACGGCAACGCGGAAATCGGCCAGGTTGTGGATAACTTCTGGTTGGTGGGACCGCTGAAGATCAGCGCGATGGAACAGACCCGCTTTCTGCTCCGACTGGCGCAGGGAGAATTGCCATTCCCCGCCCCGGTGCAGTCCACCGTGCGCGCCATGACCCTGCTGGAAAGCGGCCCGGGCTGGGAGCTGCACGGCAAGACAGGCTGGTGCTTCGACTGCACGCCGGAACTCGGCTGGTGGGTGGGCTGGGTGAAGCGCAACGAGCGGCTCTACGGCTTCGCCCTGAACATCGACATGCCCGGCGGCGAGGCCGACATCGGCAAGCGCGTCGAACTGGGCAAGGCCAGTCTCAAGGCTCTCGGGATACTGCCCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5266,Drugs,MEG_5266|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-486_1_AY597426,0
,ATGGAAAGAAAAGGGATTTTCATTAAGGTTTTTTCCTATACGATCATTGTCCTGCTACTGCTTGTCGGTGTAACAGCAACACTGTTTGCACAGCAATTTGTGTCTTATTTCAGAGTGATGGAATTACAGCAAACAGTAAAATCCTATCAGCCATTGGTGGAACTGATTCAGAATAGCGATAGGCTTGATATTCAAGAGGTGGCAGGGCTGTTTCACTACAATAACCAATCCTTTGAGTTTTATATTGAAGATAAAGAGGGAAGCGTACTCTATGCCACACCAAATGCCAATACATCAAATAGTTTTAGACCCGACTTTCTTTATGTGGTACATAGAGATGATAATATTTCGATTGTTGCTCAAAGCAAGGCAGGTGTGGGATTGCTTTATCAAGGGCTGACAATTCGGGGAATTGTTATGATTGCGATAATGGTTGTATTCAGCCTTTTATGCGCGTATATCTTTGCGCGGCAAATGACAACGCCGATCAAAGCCTTAGCGGACAGTGCGAATAAAATGGCAAACCTGAAAGATGTACCGCCGCCGCTGGAGCGAAAGGATGAGCTTGGCGCACTGGCTCATGATATGCATTCCATGTATGTCAGGCTGAAAGAAACCATCGCAAGGCTGGAGGATGAAATCGCAAGGGAACATGAGTTGGAGGAAACACAGCGATATTTCTTTGCGGCAGCTTCTCATGAGCTAAAAACGCCCATCGCGGCTACAAGCGTTCTGTTGGAGGGAATGCTTGAAAATATCGGTGACTACAAAGATCATTCTAAGTATCTGCGCGAATGCATCAAAATGATGGATAGGCAGGGCAAAATCATTTCCGAAATACTGGAGCTTGTCAGCCTGAATGATGGGAGAATCGTACCCATAGCTGAACCGTTGGACATAGGGCGCACGGTTGCCGAGTTGCTGCCCGATTTTCAAACCTTGGCAGAGGCAAACAACCAGCGGTTCGTCACAGATATTCCAGCCGGGCAAATTGTCCTGTCCGATCCGAGGCTGCTCCAAAAGGCACTATCCAATGTCATATTGAATGCAGTTCAGAACACGCCGCAGGGAGGCGAGGTACGGATATGGAGTGAGCCTGGTGCTGAAAAATGCCGCCTTTTTGTTTTGAACATGGGCGTTCACATTGATGATACTGCGCTTCCAAGGCTGTTCACCCCATTCTATCGCATTGATCAGGCGCGAAGCAGAAAAAGTGGGCGAAGCGGTTTAGGACTTGCCATCGTACAAAAAACGCTGGATGCCATGAGCCTCCAGTATGCGCTGGAAAACACCTCGGATGGCGTTTTGTTCTGGCTGGATTTACCGCTCACATCAACATTGTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7496,Drugs,MEG_7496|Drugs|Glycopeptides|VanB-type_regulator|VANSB,gi|941949718|gb|CP013009.1|131299-129956 gi|577698893|gb|KF823968.1|976-2319 gi|378937014|gb|CP003351.1|2844531-2843188 gi|229463101|gb|FJ767776.1|976-2319 gi|80973263|gb|AY655721.2|731-2074 gi|80973252|gb|AY655720.2|731-2074 gi|80973242|gb|AY655718.2|731-2074 gi|11878534|gb|AF310956.2|AF310956|1133-2476 gi|33336058|gb|AF550668.1|2242-3579,5
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTATACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1868,Drugs,MEG_1868|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EF415650|+|0-1146|ARO:3002035|CMY-24 [Escherichia coli] ,0
,GTGCGCAGCTCTGCCATCATTGCCCTGCTGATCGTGGGTCTTGACGCCATGGGTCTCGGCCTCATCATGCCCGTCCTTCCGACGCTTCTGCGTGAGCTTGTGCCAGCAGAGCAGGTCGCTGGACACTATGGTGCCTTGCTGTCGCTCTATGCATTGATGCAGGTCGTCTTCGCGCCCATGCTTGGACAGCTTTCGGATTCTTACGGTCGGCGTCCGGTACTTCTGGCTTCTCTTGCAGGAGCCGCAGTCGATTACACGATTATGGCATCAGCGCCGGTCTTATGGGTGCTCTATATCGGCCGACTCGTGTCCGGCGTCACGGGCGCAACCGGAGCTGTAGCAGCCTCAACCATTGCCGATTCGACGGGGGAAGGTTCTCGCGCACGCTGGTTCGGCTACATGGGGGCCTGTTATGGGGCGGGCATGATTGCCGGGCCAGCACTTGGTGGCATGCTCGGTGGTATCTCTGCTCATGCCCCGTTTATCGCCGCCGCCCTTCTCAACGGGTTCGCGTTCCTGCTTGCCTGCATTTTCCTCAAGGAGACTCATCACAGCCATGGCGGGACCGGAAAGCCGGTTCGCATCAAACCATTCGTTCTGTTACGGCTGGATGATGCATTGCGCGGGCTAGGTGCGCTTTTCGCAGTTTTCTTCATTATTCAACTGATCGGCCAAGTGCCTGCAGCCCTATGGGTCATATATGGCGAGGACCGTTTTCAGTGGAACACCGCGACCGTTGGTTTGTCGCTCGCGGCGTTTGGGGCAACACATGCGATCTTCCAAGCGTTTGTTACCGGCCCGCTTTCAAGCCGGCTTGGAGAGCGGCGCACGCTGCTGTTTGGCATGGCTGCGGATGGCACTGGCTTCGTTCTTCTGGCTTTTGCCACGCAGGGATGGATGGTGTTCCCGATTCTGTTGCTGCTTGCCGCCGGGGGTGTTGGCATGCCGGCCTTGCAGGCAATGCTCTCAAACAATGTCAGCAGTAACAAGCAAGGGGCTTTGCAAGGAACGCTAACGAGCCTCACCAATCTAAGCTCTATCGCAGGACCGCTTGGCTTCACAGCACTCTATTCTGCCACCGCCGGGGCATGGAACGGTTGGGTTTGGATTGTCGGCGCGATCCTCTATTTAATATGTCTGCCAATACTACGCAGACCATTCGCAACTTCATTGGTGATTTAG,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7080,Drugs,MEG_7080|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETG,gi|695196871|ref|NG_034552.1|495-1676,4
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcactaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgagcttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4391,Drugs,MEG_4391|Drugs|betalactams|Class_D_betalactamases|OXA,765035154|WP_044600959.1|NG_057508|1|1|blaOXA-594|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-594 NG_057508:1-774,0
,atgtataaaaaagtccttgtcgttgcaacagctactctatttttatctgcctgctcttctaacacggtaaaacaacatcaaatacattctatttccgccaataaaaaatcagaagaaattaaatctctgtttgatcaggcacagaccacaggagttttagtggttaagcgtgggcaaaccgaagaaatttatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatgctaaatgctttaattggacttgaacatcataaagcaacgacaactgaaatatttaaatgggatgggcaaaagcgtttatttcctgattgggaaaaggatatgactctaggcgatgctatgaaagcttctgctattccagtttatcaagaactagcgcgaagaattggacttgatcttatgtctaaagaggtaaaacgtattggtttcggtaatgctgatattggttcaaaagtagataatttttggcttgtcggtccacttaaaattacacctgagcaagaaacccaatttgcttataaattagctaataaaactcttccatttagtaaaaatgtacaagaacaagtccaatcaatggtgtttatagaagaaaaaaatggacgtaaaatttatgctaaaagtggttggggatgggatgttgaaccacaagttggctggttaaccggctgggtcgttcaaccacaaggagaaattgtggcattctcactcaatttagaaatgaaaaaaggaattcctagttctattcgaaaagaaattgcttataaaggattagaacaactcggtgttttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4733,Drugs,MEG_4733|Drugs|betalactams|Class_D_betalactamases|OXA,1625655419|WP_136512096.1|NG_064763|1|1|blaOXA-805|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-805 NG_064763:1-822,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgtgtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4716,Drugs,MEG_4716|Drugs|betalactams|Class_D_betalactamases|OXA,1509794587|WP_122630896.1|NG_062316|1|1|blaOXA-694|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-694 NG_062316:28-852,0
,atgcgtgtattagccttatcgactgtgtttttggtggcatcgattatcggaatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgtgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcagttgtgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgctttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccacggagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagccagcgtattgtcaaacaagccatgctgaccgaagccaatggtgactatattattcgggctaaaactggatactcgactagaatcgaacctaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggaaaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4607,Drugs,MEG_4607|Drugs|betalactams|Class_D_betalactamases|OXA,1028109715|WP_063864118.1|NG_049783|1|1|blaOXA-505|blaOXA-48_like|OXA-48_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-505 NG_049783:1-798,0
,atgaatgttgaatattctaaaataaagaaagcagtacctattttattattcttatttgtattcagtttggttatagacaactcattcaaattgatttctgtagccattgctgatgacttaaacatttcagtaacgacagtaagttggcaagcgacattagccggtttagtaattggtattggcgctgtagtatacgcttcattatctgatgccattagtatacgcacactatttatttatggcgtgatattaatcattatcggatcaattattggttacattttccaacatcaattcgcattacttttagttggacgtattattcaaactgcaggtttagctgctgcagagacattatatgtgatatatgttgcaaagtatctttctaaagaggaccagaagacttaccttggcttaagtacgagcagttattccttgtcattagttatcggtacattatcaggtggatttatttctacgtatttacactggacaaatatgtttttaattgcattaatcgtagtatttacgttgccattcctatttaaattattaccaaaagaaaataatacaaataaagctcatttagattttgttggcttaattctagtggcaactatcgctacaacagttatgctgtttattacgaactttaattggttatatatgattggtgccttaattgcgattatcgtttttgcgctatatattaaaaatgcgcaacgtccattagtaaacaaatcatttttccaaaataaacgttatgcttcatttttatttatagtatttgtaatgtatgccatccaattgggttatatttttacgttcccattcataatggaacaaatttatcatcttcagctagacacaacatcactgctattagtaccgggttatattgtagcagtcatcgttggtgcactaagtggtaaaatcggcgaatatcttaattcaaaacaagcgattatcacagcaattattttaatcgcactgagcttgattttacctgcatttgcagtaggtaatcacatttcaatcttcgtcatttctatgatattctttgcaggtagctttgctttaatgtatgcacctttacttaacgaagccattaaaacaatagatcttaatatgacaggtgtggctattggtttttataatttaattattaatgtggcggtatctgtaggtattgcgattgctgcggctttaatcgattttaaagcattaaatttcccaggcaatgatgcattaagttcacatttcggtattattttaattattttaggtttaatgagtattgtcggattagttttattcgtcatcttaaatcgttggacacaatctgaaaaataa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6981,Drugs,MEG_6981|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET38,447023037|WP_001100293.1|NG_055983|1|1|tet(38)|tet(38)|tetracycline_efflux_MFS_transporter_Tet(38) NG_055983:101-1453,4
,CTGTTCGGTTCGTAAACTGTAATGCAAGTAGCGTATGCGCTCACGCAACTGGTCCAGAACCTTGACCGAACGCAGCGGTGGTAACGGCGCAGTGGCGGTTTTCATGGCTTGTTATGACTGTTTTTTTGTACAGTCTATGCCTCGGGCATCCAAGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGGCATCACAAAGTACAGCATCGTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAACCCTTCCATCGAGGACGTCCACGGGCTGGCGCCTTGGCCGCCCCTCATGTCAAACGTTAGACATCATGAGGGTAGCGGTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_333,Drugs,MEG_333|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gb|Y11946.1|+|0-980|ARO:3002578|AAC(6')-Ib7 [Salmonella enterica subsp. enterica serovar Corvallis] ,2
,CACTAATACCTCTGGACATCATTGCTTGCAAAGCAGGAACGGCTACTCCACCAAGGGCAAACAATGGTAACAACGCAAAAGGCACCCATTCTTCAACAGCAATAGATAAAAGAAGTAAACCAATTGCATCGCAAGCTATTCCACATAACAACGTATTTTTCTCTCCAAACCTCTTTACCATAGGGGCGATAGCAAAAGCCTGTGCAATAGAATGGCATATTCCATAACTAGCAAGGGAAACACCTGCAATAAATATACTCCAGCCATAACGATCCTGCCCATAGATAACCCATAAAGTTGCGGGGACTTGTGAAACCAATGTGATAATTAAAAAGATACCAAGCAATGGAGCCATATTAGGTTGAGTGATCAAATAGGATAATTTCTTTAATATTGATTGCTCCTGAACCTTCTCAGTCATTTTATTGCTGTGTTTTGATTCTTTTAATAAGACTGCTGTCATTATTAAATTAATCCCATTCATAAAAGCAGCAGCAAAGAACGGTGCATGTAAGTTCCATTCACCCAAAACTCCACCTATTACCGGACCCGCTATAAACCCAATACCAAAGACAGCTCCAAGGAGACCAAACCTTTTTGCACGCTCATGGGCTGGAGTAATATCTGAAACATAAGCTGTTGCAACAGCCATGTTGGCACCTGTAATTCCCGCAAAAATACGACCAATATATAGCCACAATAGAGAAGGAG,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6989,Drugs,MEG_6989|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET39,gi|924867386|gb|KT346360.1|2120-2830 gi|187384667|gb|EU495991.1|1-711 gi|187384663|gb|EU495989.1|711-1 gi|695211247|ref|NG_036045.1|1730-1020 gi|77745205|gb|DQ195075.1|675-2,4
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTAGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1838,Drugs,MEG_1838|Drugs|betalactams|Class_C_betalactamases|CMY,(Bla)CMY-2:AM779746:1-1149:1149,0
,ATGAACTTCTTTACGTCTCCATTTTCTGGGATTCCCTTAGATCAGCAAGTAACAAATCCGAACATTATTGTGGGAAAACACAGTTATTATTCTGGTTATTATCACGGGCACAGTTTCGATGATTGTGTGCGATATTTACATCCAGAAAGAGATGACGTTGATAAGTTAGTCATAGGGAGTTTTTGTTCTATAGGCTCTGGTGCTGTATTTATGATGGCCGGTAATCAAGGGCATCGCAGTGATTGGATAAGTACATTCCCATTTTTCTATCAGGATAATGATAATTTTGCAGATGCACGCGATGGTTTTACGCGTTCAGGAGACACAATTATTGGTCATGATGTGTGGATTGGCACTGAGGCTATGATAATGCCTGGGGTTAAAATTGGACATGGAGCGATAATCGCCAGTCGTTCAGTAGTGACTAAGGATGTTGCACCTTATGAAGTGGTCGGTTCAAATCCTGCTAAACATATCAAGTTTAGATTTTCTGATGTGGAAATAGCGATGTTACTTGAAATGGCATGGTGGAATTGGCCAGAATCGTGGTTGAAAGAGAGTATGCAGTCTCTGTGTTCATCAGACATTGAAGGGCTTTATCTCTATTGGCAGTCAAAAGCACGCACATAA,chloramphenicol acetyltransferase (CAT),antibiotic inactivation,Phenicol,MEG_1621,Drugs,MEG_1621|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB,(Phe)CatB5:AAWG01000020:33604-34233:630,6
,GTGAGCTTGCCCAGGCGCCTGATATTCGCGGCCCTGCTGCTCGCCGCCCCGGCGGCCGCGCAGCAGGAAGCGCCGCGCCAGTCGCTGCTCCCGCCGCCGCCCCGCTATATGGTGAGCGAATCCGCCATGAAGTCGGTCCGCAATCCCAAGGAGATAGAGACGGAAAGCGGCGGCCGGCTGGGCGTGGCGCTGGTCGACGGCAAGGGCGCGCTGATCCTTGGTTTCAACCGGGACGAGCGTTTCGCCATGTGCTCGACCTTCAAGGCGCCGCTCGCCGCCGCCGTGCTGGCGGGCGCGGAAGGCGGCAAGTTCGGGCTGGAGGGGCAGATCAGCTTCGCCAAGGCCGATCTGCTGGACTATGCCCCGGTCGTCAGGAAGAATGTGAAGCGCGGCCGCATGTCGATGGAGGAACTCGCCGCCGCCGCCGTGGAGGTCAGCGACAACAGCGCGGCCAACCTGCTGCTGCCGATGGTCGGCGGGCCGGAGGGCCTGACCCGCTTCATCCGCGCCCATGGCGACATGGTGACGCGGCTCGACCGCAATGAGCCGTCTCTCAACGAGAATGCGGAGGGCGACGAGCGCGACACCACCAGCCCCGCCGCCATGGCCGGCCTGATGGGCCGCCTGATCTTCCGCGACCTCGCTCCGGAAAGCGCCGGAAAGCTGCGCGGCTGGCTCAATGCCAGCACCACCGGCGCCAACCGGATCAAGGCGGGCCTGCCCAAGGGCTGGATCTCCGGCAGCAAGACGGGAAGCTGCGGCACCGCCTATAATGACGTGGCGCTGGTGAAGGCCCCGTCGGGCGAGGAATATATCCTGGCCATCTATCTCGACCGCCCGACGGTCGACGCCAAGGCCGCCGAAGCCGCCATAGCCGAAACCGCCCGCGCCGCGCTGGATTTCGTGGATAAGGCGCAGAAGACCGGGCTGGAATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1312,Drugs,MEG_1312|Drugs|betalactams|Class_A_betalactamases|BLASGM,blaSGM-2_1_AP010803 ,0
,atgcgtcaatatcgattcgcccttctcccattgttagccgccctggcgctccccggttgggcgcatcaagctacggtgacaacggttaaacaagccgaaagccagcttcagggccgggtcggctacgccgaactggatttagcttccgggcaactgctggccggctatcgttctgacgaacggttcccgatgatgagcacttttaaagttctgctctgcggcgcagtcttgtcgcgtgtcgatgccggtgaagaacagctcgatcgccgtatccattaccggcagcaggatctggtggaatattcgccggtgacggaaaagcatcttaccgatgggctcaccgtgggcgaactgtgcgctgccgccattaccctgagcgataatacggcggcaaacctgctgttgaccactctcggcggcccgcaggggctgaccagcttcctgcgccacagcggcgaccagacgtcgcggcttgaccgttgggaaacggaactcaatgaagcgcggccgggcgacgtgcgagataccacgactccgcaagcgatggccaggacactgcgaaatctgttgaccggtcgcgtgctttccagcgcctcgcagcagcagttgcaacgctggatggtagaggacaaagttgcggggccgctgttgcgatcggtgctgccggcgggctggtttattgccgataagaccggagccggcaatcgcggctcgcgcgggatcatcgcggctctcggtccggacggtaaagctgcgcgcatcgtggtgatttatttgaccgggccccccgccacaatggatgaacgcaataaacagattgcggccatcggcgcaacgctggtcacgcactggtccgcagacgagaacagaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_5788,Drugs,MEG_5788|Drugs|betalactams|Class_A_betalactamases|PLA,695773245|WP_032696109.1|NG_049971|1|1|blaPLA-3|blaPLA|class_A_beta-lactamase_PLA-3 NG_049971:101-976,0
,GGATGTATGTGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATGGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATATATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCTCGTAGCACCTCGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAAAGATGCCGGTCGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6449,Drugs,MEG_6449|Drugs|betalactams|Class_A_betalactamases|SHV,gi|291621298|dbj|AB551737.1|1-972,0
,atgtcgaaaaaattaaaatgtctgacgctttttacagccatcttttttgcaattcctatggctgcttgtcaaagtttaagccaacaaaagcaacagctcacgacagaaaaaaatgatcagcagcagatctcaagtttattccagagcgctcaaaccagtggtgttttggtgatttatgacggcaagaaaattcaaagctatggcaatgcgcttgatcgtgcagagcagcgttatattcccgcctcaacctttaaaatgttgaatgctttgatcgggatacaacatcataagactgcaccaaatgaagtgtttaaatgggatggaaaaaagcgagcatttagtagctgggaaaaagatttaaccttagctgaagcgatgcaggcatcggcggtacccgtttatcaagagttggcaagacggattggtttagaactgatgacccgtgaagtgaagcgtgtaggttatggtaataaaaatattgggacgcaagtggataatttctggttagttggtcccttaaaaatcactcccgtagaggaagttcgctttgcctatgcattagcaaaacagaaattaccctttgatcagccgacacagcaacaagtcaaagcgatgttattggtggatcagatccaggataccaaaatctatgccaaaagcggttggggaatggatgtcagcccgcaagtgggttggtggacggggtggattgaacagccaaatggtaaggtcattgcattctcattgaatatgcaaatgagccagcctgaacatgcagatgcacgtaaagcgattgtgtatcaagccttgcaacagttgggattgttagccacttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4737,Drugs,MEG_4737|Drugs|betalactams|Class_D_betalactamases|OXA,514971824|WP_016660101.1|NG_062218|1|1|blaOXA-671|blaOXA-286_like|OXA-286_family_class_D_beta-lactamase_OXA-671 NG_062218:101-937,0
,TTGAAAAATAGAAATCCTTTGATCCGAAAGCTCTTGACCCAATACTTCGTCACCACTGGAATCTTGCTGGCATTCCTTGTAATGATTCCATTAGTCATTCGCTTTATTGCCGGAACCCGGACTTGGTATGGAACGGAACCTATCTACTATATCTTACGTTTTTTTGCGGATCGCTGGTTGTTTTGTGTTGCGATAGGCGCTTTACTGATATGGTTTGGTACCACCATTTACTATATGACCAAAGCCATCGGTTATTTGAATGAAACGATCCAAGCCACGACTCAACTGATAGAAGAACCAACCAAACGCATCACTTTGTCGAGCCATCTGGTTGATGTTCAAGAGGAAATGAATCAACTGCGGGAGAAAAGTCTGCAAGATCAACGTGCCGCTAAAGAAGCGGAACAGCGGAAAAATGATTTGATCGTTTATCTCGCCCATGATTTGCGGACGCCTCTGACAAGTGTCATAGGTTATCTGACTCTTCTAAAAGAAGAACCACAATTATCCAATGCGATGCGGAATCGTTACACGGAGATTGCTTTACAAAAAGCCCAACGGCTGGAACTATTGATCAGTGAATTCTTCGAGATCACACGCTTCAATTTGACCACGATCGTTTTGCAGACAGAAACGACTGATTTAAGTTTAATGCTTGAACAGCTGACCTTTGAGTTTTTACCTCTCTTGGAAGAAAAGAATCTAAATTGGCAACTCAACTTACAAAAAAATGTTCTTGCAACAGTAGACACCGAAAAAATAGCTCGTGTCTTTGATAATCTCATTCGCAATGCCATCAACTACAGCTATCCAGATTCGCCTTTACTTCTTGAATTGGTCGAATCAGACAGTATCCACATTCGTCTGACGAATCGTGGAAAAACAATTCCAGAAGAGATGATCGGACGTCTCTTTGAACCTTTCTATCGCATGGATTCTTCCCGAGCTACAGCCACAGGCGGAACTGGTCTTGGTCTTCCGATTGCAAAAGAGATTCTGTTAGCATCTGGCGGGGATATCTCGGCAGAAAGCAAAGACGAAACCATCATTTTCAACGTTCGCTTGCCAAAACCTGCCAACAGCTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7499,Drugs,MEG_7499|Drugs|Glycopeptides|VanC-type_regulator|VANSC,(Gly)VanS-C:DQ022190:4672-5757:1086,5
,atgaacattaaagcactcttacttataacaagcactatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcacttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaaatatttaagtgggacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggtgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcatattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattacgcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4436,Drugs,MEG_4436|Drugs|betalactams|Class_D_betalactamases|OXA,1058244112|WP_068981644.1|NG_051479|1|1|blaOXA-529|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-529 NG_051479:1-825,0
,TTGTCCAAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAAAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGGTGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4309,Drugs,MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_11_KX620934 ,1
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgacgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgtggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2147,Drugs,MEG_2147|Drugs|betalactams|Class_A_betalactamases|CTX,1625655388|WP_136512065.1|NG_064721|1|1|blaCTX-M-226|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-226 NG_064721:1-876,0
,atgaatattaaacctgcatcagaagcttcactcaaagattggttagaattaagaaataaattgtggagtgattctgaatcttctcatttacaagagatgcatcaattattaaccgaaaaatatgccctacaattattggcctattccgatcaccaagctattgcgatgttagaagcctcaattcggtttgaatatgtgaatgggactgagacttctcctgtgggttttttggaaggtatttacgtacttcctgaacagcgtcgctcgggcgttgcaaccatgcttattcgacaggccgaagtgtgggcaaaacaattttcttgcactgaatttgcatctgatgctgcattggacaatgtaattagtcatgctatgcatcgttcattaggttttcaagaaactgaaaaagtcgtttattttagtaaaaaaatagattaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_115,Drugs,MEG_115|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,496226869|WP_008940904.1|NG_052523|1|1|aacA-ACI1|aacA-ACI1|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052523:101-538,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcgggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5499,Drugs,MEG_5499|Drugs|betalactams|Class_C_betalactamases|PDC,1393270446|WP_109791191.1|NG_057589|1|1|blaPDC-257|blaPDC|class_C_beta-lactamase_PDC-257 NG_057589:1-1194,0
,ATGAAAATTATTAATATTGGAGTTTTAGCTCATGTTGATGCAGGAAAAACTACCTTAACAGAAAGCTTATTATATAACAGTGGAGCGATTACAGAATTAGGAAGCGTGGACAAAGGTACAACGAGGACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACAGGAATAACCTCTTTTCAGTGGGAAAATACGAAGGTGAACATCATAGACACGCCAGGACATATGGATTTCTTAGCAGAAGTATATCGTTCATTATCAGTTTTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATGGCGTACAAGCACAAACTCGTATATTATTTCATGCACTTAGGAAAATGGGGATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCCGAAATTGTAATCAAACAGAAGGTAGAACTGTATCCTAATATGTGTGTGACGAACTTTACCGAATCTGAACAATGGGATACGGTAATAGAGGGAAACGATGACCTTTTAGAGAAATATATGTCCGGTAAATCATTAGAAGCATTGGAACTCGAACAAGAGGAAAGCATAAGATTTCAGAATTGTTCTCTGTTCCCTCTTTATCATGGAAGTGCAAAAAGTAATATAGGGATTGATAACCTTATAGAAGTGATTACGAATAAATTTTATTCATCAACACATCGAGGTCAGTCTGAACTTTGCGGAAAAGTTTTCAAAATTGAGTATTCGGAAAAAAGACAGCGTCTTGCATATATACGTCTTTATAGTGGCGTACTGCATTTGCGAGATTCGGTTAGAATATCGGAAAAGGAAAAAATAAAAATTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAAATCGATAAGGCTTATTCCGGGGAAATTGTTATTTTGCAGAATGAGTTTTTGAAGTTAAATAGTGTTCTTGGAGATACAAAGCTATTGCCACAGAGAGAGAGAATTGAAAATCCCCTCCCTCTGCTGCAAACGACTGTTGAACCGAGCAAACCTCAACAAAGGGAAATGTTACTTGATGCACTTTTAGAAATCTCCGACAGTGACCCGCTTCTGCGATATTATGTGGATTCTGCGACACATGAAATCATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGACTTGTGCTCTGCTGCAAGAAAAGTATCATGTGGAGATAGAAATAAAAGAGCCTACAGTCATTTATATGGAAAGACCGTTAAAAAAAGCAGAGTATACCATTCACATCGAAGTTCCACCGAATCCTTTCTGGGCTTCCATTGGTCTATCTGTAGCACAGCTTCCATTAGGGAGCGGAGTACAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCGTTTCAAAATGCAGTTATGGAGGGGATACGCTATGGCTGTGAACAAGGATTGTATGGTTGGAATGTGACGGACTGTAAAATCTGTTTTAAGTATGGCTTATACTATAGCCCTGTTAGTACCCCAGCAGATTTTCGGATGCTTGCTCCTATTGTATTGGAACAAGTCTTAAAAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAATTTATGCGCCACAGGAATATCTTTCACGAGCATACAACGATGCTCCTAAATATTGTGCGAACATCGTAGACACTCAATTGAAAAATAATGAGGTCATTCTTAGTGGAGAAATCCCTGCTCGGTGTATTCAAGAATATCGTAGTGATTTAACTTTCTTTACAAATGGACGTAGTGTTTGTTTAACAGAGTTAAAAGGGTACCATGTTACTACCGGTGAACCTGTTTGCCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7137,Drugs,MEG_7137|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|321157445|emb|FR671418.1|17031-18950 gi|220673408|emb|FM211187.1|1278602-1280521,4
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4708,Drugs,MEG_4708|Drugs|betalactams|Class_D_betalactamases|OXA,1559612973|WP_128268238.1|NG_063842|1|1|blaOXA-738|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-738 NG_063842:50-874,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccggaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcactgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5472,Drugs,MEG_5472|Drugs|betalactams|Class_C_betalactamases|PDC,959903632|WP_058169253.1|NG_054667|1|1|blaPDC-80|blaPDC|class_C_beta-lactamase_PDC-80 NG_054667:1-1194,0
,atggctaaattactaataacgagcgtagtaagcttttgttttatatttctattgttagtattttttaagtacatattaaaacgctattttaattatagtttaaattataaagtttggtatctaacagtgcttgctggattaataccttttatcccaattaaattctcttttataaaatttaataatgtgaataatcaagcgcccacagttgaaagtaagtcacacgacttgaaccataacataaataccaccaaacctattcaagagttcacaacagatatccataagtttaattgggattcaattgataatatctgcacagttgtttggatagttttagttattattttaagttttaaatttttgaaatccttattatatcttaaatatttaaagaaacagtcactttatctaaacgaaaatgaaaaaaataaagtagatacgatacttttcaaccatcaatataaaaaaaatattgtgattcgaaaagcagagactattcaatctccaataactttttggtatgggaaatatattattttgattcctagttcatattttaaaagtgtaattgataaaagactaaaatatataatactgcatgaatatgctcatgctaaaaatagagatactttacatttaattatctttaatatcttctctattgttatgagttacaatccattaatacatattgtaaaaagaaagataattcatgacaatgaagtagaagctgatagatttgttcttaataatattaacaaaaatgaatttaaaacttatgcggaatctattatggactccgtattaaatattccattttttaataaaaatatattaagccattcatttaatggtaaaaagtcattactcaaaagaagattaattaatataaaagaagccaatttgaaaaaacagtctaaattaattccaatttttatttgtatttttacttttttgctcatagtaattcaaagccagtttttgatggggcaatccataactgattataattataaaaagcccttacagaacgatcaccaaattttagatgaaagtaaaaattttggttcaaatagtggatctttcgtcatgtacagcatgaagaaagacaaatactatatttataatgaaaaagaaagtagaaaaagatattctcctgattcaacttataaaatttatttagcgatgtttggacttgaccgtcatatcataagtgataaaaattcacgtatgtcatggaatcataaacattatcctttcgagtcttggaataaggaacaagatttaaatacagcaatgcaaaattcagttaattggtacttcgaacgtattagtaatcaaataccaaagaactatactgcggctcaactcaagcaattaaattatggtaatgaaaatttgggaagttataaaaactattggatggaagatagtttgaaaatatctaatcttgaacaagtaatagtttttaaaaatatgatggaacaaaataaccattttagtaaaaaagcaaagaatcaattatcttcttcattattgattaagaaaaatgaaaagtatgaactgtatgggaaaacaggtacaggtatagtaaacgggaagtataataatgggtggtttgtaggttacgtaattacaaatcatgataagtattattttgctacacatttatcagatggaaacccgtctgggaaaaatgctgaattaatcagtgaaaaaatattaaaagaaatgggtgttttaaatggccaataa,beta-lactamase,antibiotic target alteration,betalactams,MEG_1299,Drugs,MEG_1299|Drugs|betalactams|Penicillin_binding_protein_regulator|BLAR,447019136|WP_001096392.1|NG_051774|1|1|blaR1|blaR1|beta-lactam_sensor/signal_transducer_BlaR1 NG_051774:101-1858,0
,atggaaaaaagcaactatcattccaatgcggatcatcacaaacggcatatgaaacaatccgtggaaaagcgggcttttctatgtgcgttcattatttcgttcacagtctgcacgctgtttttggggtggagactggcttccgtattggaggcaacacagataccgcccatccctgcaactcatacaggcagcagcactgacgtagtggagaatttggaggaaaacgctcttgccaccgccaaagaacagggagatgaacaggaatggagcctgattttagtgaacaggcagaaccccatccccgcacagtacgatgtggagcttgagcaactatcaaatggtgagcggatagatattcggatttctccctatcttcaagatttgtttgatgccgcaagaactgatggagtttacccgattgtcgcatccggataccgaacaacagaaaaacagcaagaaattatggatgaaaaaattgccgaatataaggcgaaaggctacacctctgcacaggctaaagcggaagcagaaacttgggtggccgtgccgggaacgagcgagcatcagcttggtcttgctgtggatatcaatgcggacggaattcattcaacaggcaacgaggtttatagatggctggatgaaaacagctatcgttttggttttattcgtcgctacccaccagacaagacagagataaccggtgtgagcaacgagccgtggcattaccgatatgttggcatcgaagctgccacagagatgtacaaccaaggggtttgccttgaggaatatttaaaaccagaaaaatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7598,Drugs,MEG_7598|Drugs|Glycopeptides|VanD-type_accessory_protein|VANYB,488346685|WP_002416070.1|NG_048519|1|1|vanY-B|vanY-B|D-Ala-D-Ala_carboxypeptidase_VanY-B NG_048519:101-907,5
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgttagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccacttgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaaggtctctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcacctttacaaactttattagacagtaattcagaacaaattgtgatgaagcctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_538,Drugs,MEG_538|Drugs|betalactams|Class_C_betalactamases|ADC,491265137|WP_005123276.1|NG_064680|1|1|blaADC-122|blaADC|class_C_beta-lactamase_ADC-122 NG_064680:101-1252,0
,atgatcgtcaactgcgaccacgacaaccttgatgcctggctggctctgcgctcggcgctgtggcccacctgcccgcgggaagaacaccgcgcggaaatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctgggcggcgctttcgttggctttgccgaggtcgcgctgcgctacgattatgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgtcgaacgcgcccgccgccagggttgggcggcgcgcctgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgacatcgctaatctggattcccaacgcctgcatgcggcgctgggctttgccgaaacggagcgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_151,Drugs,MEG_151|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,896201646|WP_049208356.1|NG_052194|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052194:101-541,2
,atgagtaattaccgatttaaatctaaaataaaaagcagtgtattgatcattctgagtagtgtggcattttcaggttgtgtttctaatgccaatttgcatgatccagcgtcatcacaaagaacaagtgaaatcccgttgttgtttaattatgcgcaaactcaagccgtctttgtgacttatgatggaactcaatttaaacgttatgggaatgatttaaatagagccaagactgcctatattccagcctctacttttaaaatgttgaatgccttaattggtttgcaacatgcgaaagcgacgaatacagaagtatttaagtggaatggagaaaaaagatcttttcctgcatgggaaaaagatatgaccttggcacaagcaatgcaggcttcagccgtacctgtatatcaggagttggcacgacgtattggcttggatttgatgagtaaagaagtcaagcgtgttggttttggcaatacacaaattggtcaacaggtagataatttctggctagtcggcccattgaaaattaccccagagcaagaagctaaatttgcttatcaattggcaaagaaaacattgccttttgatgatgctgtacagcaacaagttaaagatatgctctatgtcgaaagacggggtgattccaagctttatgccaaaagtggatggggaatggatgtggagccacaagtgggttggtatacgggatgggtggaacagccgaatggtcagatcaccgcttttgctttaaatatgcacatgcagacaggggatgatcctgctgaacgcaagcaactgacattaagtatcttggataaattaggcttattcttttatttgagataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4590,Drugs,MEG_4590|Drugs|betalactams|Class_D_betalactamases|OXA,736604034|WP_034612711.1|NG_062224|1|1|blaOXA-668|blaOXA-274_like|OXA-274_family_class_D_beta-lactamase_OXA-668 NG_062224:101-946,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5467,Drugs,MEG_5467|Drugs|betalactams|Class_C_betalactamases|PDC,565829475|WP_023913271.1|NG_049955|1|1|blaPDC-98|blaPDC|class_C_beta-lactamase_PDC-98 NG_049955:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacggggcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagcccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5569,Drugs,MEG_5569|Drugs|betalactams|Class_C_betalactamases|PDC,1209144258|WP_088245220.1|NG_055278|1|1|blaPDC-215|blaPDC|class_C_beta-lactamase_PDC-215 NG_055278:1-1194,0
,ATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6950,Drugs,MEG_6950|Drugs|betalactams|Class_A_betalactamases|TEM,gi|981191958|emb|LN999997.1|2513287-2512427 gi|975048878|gb|CP013962.1|4121685-4120825 gi|973715451|gb|CP013836.1|137763-138623 gi|973705327|gb|CP013832.1|76064-76924 gi|971339514|gb|CP006662.2|50825-51685 gi|943457735|gb|KT818627.1|33069-33929 gi|970338578|gb|KT725789.1|75462-76322 gi|970338460|gb|KT725788.1|80722-81582 gi|962148759|gb|KT002541.1|3910-4770 gi|961666360|gb|KT185451.1|17735-16875,0
,ATACATCTTGTTTATGCTAATGCCAATTTCATTCACCACGAGAATAGCCATATGCAACAACGGCGTGCGTTCGCGCTACTGACGCTGGGTAGCCTGCTGTTAGCCCCTTGTACTTATGCCAGCGGGGAGGCTCCGTTGACCGCCGCTGTGGACGGCATTATCCAGCCGATGCTCAAGGCGTATCGGATCCCGGGGATGGCGGTCGCCGTACTGAAAGATGGCAAAGCCCACTATTTCAACTATGGGGTTGCCAACCGGGAGAGTGGCCAGCGCGTCAGCGAGCAGACCCTGTTCGAGATTGGCTCGGTCAGCAAGACCCTGACTGCGACCCTCGGTGCCTATGCCGCGGTCAAGGGGGGCTTTGAGCTGGATGACAAGGTGAGCCAGCACGCCCCCTGGCTCAAAGGTTCCGCCTTGGATGGTGTGACCATGGCCGAGCTTGCCACCTACAGTGCGGGTGGTTTGCCGCTGCAGTTCCCCGATGAGGTGGATTCGAATGACAAGATGCGCACTTACTATCGGAGCTGGTCACCGGTTTATCCGGCGGGGACCCATCGCCAGTATTCCAACCCCAGCATCGGCCTGTTTGGTCACCTGGCCGCAAATAGTCTGGGCCAGCCATTTGAGCAACTGATGAGCCAGACCCTGCTGCCCAAGCTGGGTTTGCACCACACCTATATCCAGGTACCGGAGTCGGCTATGGTGAACTATGCCTACGGCTATTCGAAGGAAGATAAGCCCGTCCGGGTCACTCCGGGCGTGCTGGCAGCCGAGGCTTACGGGATCAAGACCGGCTCGGCGGATCTGCTGAAGTTTGCCGAGGCAAACATGGGGTATCAGGGAGATGCCGCGGTAAAAAGCGCGATCGCGCTCACCCACACCGGTTTCTACTCGGTGGGAGACATGACCCAGGGACTGGGCTGGGAGAGTTACGCCTATCCGGTGACCGAGCAGACATTGCTGGCGGGTAACGCACCGGCGGTGAGCTTCCAGGCCAATCCGGTTACGCGCTTTGCGGTGCCCAAGGCGATGGGCGAGCAGCGGCTCTATAACAAGACGGGCTCGACTGGCGGCTTTGGCGCCTATGTGGCGTTCGTGCCCGCCAGAGGGATCGCCATCGTCATGCTGGCCAATCGCAACTATCCCATCGAGGCCAGGGTGAAGGCGGCTCACGCCATCCTGAGTCAGTTGGCCGAGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3043,Drugs,MEG_3043|Drugs|betalactams|Class_C_betalactamases|FOX,gi|14626421|gb|AY034848.1|1-1200,0
,TCATAGAATTAATTTCCTCCCGTTAAATAATAGATAACTATTAAAAATAGACAATACTTGCTCATAAGTAATGGTACTTAAATTGTTTACTTTGGCGTGTTTCATTGCTTGATGAAACTGATTTTTAGTAAACAGTTGACGATATTCTCGATTGACCCATTTTGAAACAAAGTACGTATATAGCTTCCAATATTTATCTGGAACATCTGTGGTATGGCGGGTAAGTTTTATTAAGACACTGTTTACTTTTGGTTTAGGATGAAAGCATTCCGCTGGCAGCTTAAGCAATTGCTGAATCGAGACTTGAGTGTGCAAGAGCAACCCTAGTGTTCGGTGAATATCCAAGGTACGCTTGTAGAATCCTTCTTCAACAATCAGATAGATGTCAGACGCACGGCTTTCAAAAACCACTTTTTTAATAATTTGTGTGCTTAAATTGTAAGGAATACTCCCAACAATTTTATACCTCTGTTTGTTAGGGAATTGAAACTGTAGAATATCTTGGTGAATTAAAGTGACACGAGTATTCAGTTTTAATTTTTCTGACGATAAGTTGAATAGATGACTGTCTAATTCAATAGACGTTACCTGTTTACTTATTTTAGCCAGTTTCGTCGTTAAATGCCCTTTACCTGTTCCAATTTCGTAAACGGTATCGGTTTCTTTTAAATTCAATTGTTTTATTATTTGGTTGAGTACTTTTTCACTCGTTAAAAAGTTTTGAGAATATTTTATATTTTTGTTCAT,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2799,Drugs,MEG_2799|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,gb|AF242872.1|-|2131-2878|ARO:3000375|ErmB [Enterococcus faecium] Partial,7
,TTATTAGCTGGTATTACCCTGCCCTTAGTTAATTTTTCGCTACCTACCTGGGCTGCTGGGATCCCGGGATCATTAGACAAGCAATTGGCAGCACTTGAGCACAGTGCTAACGGTCGTTTAGGCATTGCGATGATTAATACCGGCAATGGCACCAAAATTCTGTATCGCGGAGCTCGACGTTTCCCATTCTGTAGTACTTTTAAGTTTATGTTAGCCGCTGCTGTATTGGGTCAAAGCCAATCTCAGCCGAATTTGCTCAATAAGCATATCAATTACCATGAGAGTGATTTGTTATCTTATGCCCCCATCACGCGTAAAAATCTGGCGCATGGTATGACAGTTTCTGAATTATGTGCGGCTACCATTCAATATAGCGATAACACGGCCGCGAATTTATTACTTAAAGAGTTGGGTGGTTTAGCGGCTGTTAATCAGTTTGCTCGCAGTATTGGCGATCAGATGTTCAGGTTAGACCGCTGGGAACCGGATTTAAACACCGCATTACCTAATGACCCACGTGATACCACCACTCCTGCGGCTATGGCAGCTAGTATAAATAAATTGGTATTGGGTGATGCATTGCACCCTGCCCAACGAAGCCAACTCACGGCATGGCTGAAAGGAAACACCACCGGGGATGCCACGATTCGCGCGGGTGCCCCTACTGACTGGATTGTGGGTGACAAAACAGGTAGTGGCGATTACGGAACCACCAATGATATTGCGGTACTTTGGCCGACGAAAGGTGCACCGATTGTTTTAGTGGTGTATTTCACGCAACGTGAAAAAGATGCAAACCCCGTTCCCGATGTATTGGCCCTTTGCCAACCAAAATATTTTGGCCGCAAATTTTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1249,Drugs,MEG_1249|Drugs|betalactams|Class_A_betalactamases|BLAA,gi|90018739|gb|DQ424965.1|1-855,0
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctgagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcaaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccggagatgggcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacgctacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacgggggccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3098,Drugs,MEG_3098|Drugs|betalactams|Class_A_betalactamases|GES,1028105368|WP_063860517.1|NG_049135|1|1|blaGES-31|blaGES|class_A_beta-lactamase_GES-31 NG_049135:1-864,0
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgttgaaaaagcagagaaaattaaaaatttatttaacgaagtacactctacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4434,Drugs,MEG_4434|Drugs|betalactams|Class_D_betalactamases|OXA,1559612977|WP_128268242.1|NG_063847|1|1|blaOXA-743|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-743 NG_063847:19-843,0
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaagcagtatcattaatcactagtgccatcttgcaaatggcgattattttttaccttacagaaaaaactggatccgcgatggtcttgtctatggcttcactattaggttttttaccctatgcggtctttggacctgcaattggtgtgctagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctggttcggtgcttactattgttgcattctatatggagctacctgtctggatggttatgatagtattgtttatccgtagcattggaacagcttttcacaccccggctctcaatgcggttacgccacttttagtaccagaagaacagcttacgaaatgtgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcggttgcagcactcttatactccgtttgggaactaaatgctattattgccatcgatgtattgggtgctgtgattgcatctattacggtagcaattgtacgtatacctaagctgggtaatcaagtgcaaagtttagaaccaaatttcataagagagatgaaagaaggagttgtggttctgagacaaaacaaaggattgtttgccttattactcttaggaacactatatacttttgtttatatgccaatcaatgcactatttcctttaataagcatggaacactttaatggaacgcctgtgcatatttctattacggaaatttcctttgcatttgggatgctagcaggaggcttattattaggaagattagggggcttcgaaaagcatgtattactaataacaagttcattttttataatggggaccagtttagccgtttcgggaatacttcctccaaatggatttgtaatattcgtagtttgctgtgcaataatggggctttcggtgccattttatagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttgaccggaagtatcatgtcacttgctatgccaattgggttaattctttctgcactctttgctgatagaatcggtgtaaatcattggtttttactatcaggtattttaattatttgcattgcaatagtttgcccaatgataaatgagattagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3811,Drugs,MEG_3811|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,504449202|WP_014636304.1|NG_047975|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047975:1-1218,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaaggtgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccattcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5546,Drugs,MEG_5546|Drugs|betalactams|Class_C_betalactamases|PDC,730460451|WP_034020787.1|NG_049942|1|1|blaPDC-67|blaPDC|class_C_beta-lactamase_PDC-67 NG_049942:1-1194,0
,atgcttcagcagaaaatgatcgaacgcttcaaggaagcttgccatgaggatgcacgaataatcgcggcgctgatgttcggctcatttgctatcggagagggtgacgagttctctgatatcgaatttgcagtgttcatccaggatgatcattttgaaaatttcgatcagcgctcgtggcttaatgctgtaagtccggttgcagcttactttccggatgacttcggccaccacaccgcgctttttgaaaacggcattcgcggtgaattccatttcatgcgaaaatcggacataccggtcatttccacttggcaaggctacgggtggtttccctcgcttgaggaggctgttttgttggaccgatcaggagagttgtcaaggtacgcgagtgctctcgtgggcagtcccccgaaacgtgaaggcgcgccgctggtggaaggacttgtattgaacctcatcagcctgatgctctttggggcaaatcttttaaatcggggagagtatgctcgcgcctgggctttgctcagcaaagcacatgaaaacttactcaagttggttcgcctccatgaaggggcaacagaccactggccgacaccttcacgcgcgctcgaaaaggatgtctcggaggactcgtataatcgctacctggcatgcacaggcagcgcggaaccaaaagcactatgtgtagcctatcatgaaacgtggaagtggagtctcgaattgttcaggagtgtggctggacctctgaatatcgagcttccgagaattgtaattgcgcagacaaaaaggttgctaaatgaatctgcgacgccgcacaataaaatgttaacctctgaggaagaattgtga,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3616,Drugs,MEG_3616|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUF,1080153684|WP_070342364.1|NG_051889|1|1|lnu(F)|lnu(F)|lincosamide_nucleotidyltransferase_Lnu(F) NG_051889:101-946,7
,ttgaaaaatagaaataaaaccagtcatgaagatgactatttactttttaaaaacagattgtccgttaaaatactgcttatgatggtatattccattctgattattgcgggtgtttatctgtttatcttaaaagataattttgcaaatgtcgtggtagccattttagacagctttatctatcatgatcgggatgaggcggtggctgtttatctgagaacctttaaggcgtctgagatatggcttttcctgatagcggttatgggcgtgttttttatgatcttccgccgttatctggacagtatttcaaaatattttaaggagatcaaccgggggatcgatactttggtgaatgaggatgccaacgatattgggctgcctccggagttggcttcgaccgaaagaaaaatcaattccatacggcataccctgacgaaacggaaaacggacgctgagcttgcagagcaaaggaaaaacgatcttgtcatgtatctggcccatgacctgaagaccccgcttccatcggtcataggatatttgaacctgttaagggatgagaatcagatttccgaggaacttagggaaaaatatttgtccatatcattggataaggctgagcgtctggaagaactgattaatgagttttttgaaattacgaggtttaatctttcaaacatcacgcttgtgtacagcaaaatcaatctgacgatgatgctggaacagctggggtatgagtttaagccgatgctggccgggaaaaatctgaaatgtgaatttgatgttcagccagacatgatgctgtcctgcgatgccaacaagctgcagcgggtcttcgataatgtgctgagaaatgccgtcagctactgctatgagaataccaccattcgggtgaaagccaggcagaccgaagaccatgtactcatcaaaatcataaacgaaggggatacgattcctggggagagattggaaagaatctttgagcagttttaccgcctggatgtatctcgaagctcaagtaccggcggggccggtctggggcttgccattgcaaaagagattgtggaactgcaccatggacagatcactgcccacagcgaaaatggtatcaccagttttgaggttacattgcccgtcgtaggaaaatcgtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7505,Drugs,MEG_7505|Drugs|Glycopeptides|VanD-type_regulator|VANSD,1028100595|WP_063856730.1|NG_048426|1|1|vanS-D|vanS-D|VanD-type_vancomycin_resistance_histidine_kinase_VanS NG_048426:101-1246,5
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCCAGATCGGCGCGAGGGCACCCGCTGGCGACATTCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6636,Drugs,MEG_6636|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|88853289|emb|AM183225.1|10491-11309,8
,atgcgtcaatatcgattcgcccttctgccattgttagccgccctggcgctccccggttgggcgcatgaagccacggtgacgacggttaaacaagccgaaagccagctgcagggccgggtcggctacgccgaactggatttagcttccggccaactgctgtccggctatcgcgctggcgaacgcttcccgatgatgagcacctttaaagtgctgctctgcggcgcagtcttgtcgcgcgtcgataccggtgaagaacagctcgatcgccgtatccattaccggcagcaggatctggtggaatactcgccggtgacggagaagcatcttgccgatgggctcaccgtgggcgaactgtgcgcggccgccattaccctgagcgataatacggcggcaaacctgctgttgaccactctcggcggcccgcaggggctgaccacgttcctgcgccacagcggcgaccagacttcgcgactcgaccggtgggaaacggaactcaatgaagcgcggccgggcgatgtgcgtgatacgacgactccggaagcgatggccaggatactgcgaaatctgttgaccggccgcgtgctttcccctgcctcgcagcagcagttgcaacgctggatggtagaggacaaagttgcggggccgctgttgcgctcagcgctgccggcgggctggtttattgccgataagaccggagccggcaaccgcggctcgcgcggaatcatcgccgctctcggtccggacggtaaagccgcgcgcatcgtggtgatttatttaaccgcaaccccggcctcaatggatgagcgcaataaacagattgcggccatcggtgaaacgctggtcaggcactggtccaaagacgataaaagaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4374,Drugs,MEG_4374|Drugs|betalactams|Class_A_betalactamases|ORN,1028105955|WP_063860936.1|NG_049391|1|1|blaORN-6|blaORN|class_A_beta-lactamase_ORN-6 NG_049391:101-976,0
,atgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctcgggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1798,Drugs,MEG_1798|Drugs|betalactams|Class_C_betalactamases|CMY,1028104359|WP_063859750.1|NG_048792|1|1|blaCMY-121|blaCMY|class_C_beta-lactamase_CMY-121 NG_048792:1-1143,0
,atgaaaaactactttaacagccctttcaaaggggaacttctttctgagcaagtgaaaaatccaaatatcagagtaggccggtatagctattactctggctactatcacgggcactcatttgatgaatgcgcgcgatacttgtttccagatcgtgatgacgttgataaattgatcattggcagcttttgttctataggaagcggggcttccttcatcatggctggcaatcaggggcatcggcatgactgggcatcatccttccccttcttctatatgcaagaggagcctgctttctcaagagcactcgacgccttccaaagagcaggtgataccgtcattggcaatgatgtctggataggctcggaggcaatgattatgcctggcatcaaaattggagacggtgccgtgataggtagtcgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaatgcccatgctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctcacaattcaatcaagccgatgccgcttcgcggcacggcttatttcaggcgttaggcatcacaaagtacagcatcgtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,chloramphenicol acetyltransferase (CAT),antibiotic inactivation,Phenicol,MEG_1607,Drugs,MEG_1607|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1102724732|WP_071593228.1|NG_052052|1|2|catB8|catB8|bifunctional_type_B-3_chloramphenicol_O-acetyltransferase_CatB8/aminoglycoside_N-acetyltransferase_AAC(6')-Ib NG_052052:90-1349,6
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacccgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5507,Drugs,MEG_5507|Drugs|betalactams|Class_C_betalactamases|PDC,1201190448|WP_087587968.1|NG_054988|1|1|blaPDC-203|blaPDC|class_C_beta-lactamase_PDC-203 NG_054988:1-1194,0
,atgagccatattcaacgggaaacgtcttgctcgaggccgcgattaaattccaacatggatgctgatttatatgggtataaatgggctcgcgataatgtcgggcaatcaggtgcgacaatcgatcgattgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggatgacggaatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccccgggaaaacagcattccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagtgttcctgcgccggttgcattcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgtctcgtccaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataagcttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgagttttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttactttgatgctcgatgagtttttctaa,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1024,Drugs,MEG_1024|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,499193550|WP_010891090.1|NG_047435|1|1|aph(3')-Ia|aph(3')-Ia|aminoglycoside_O-phosphotransferase_APH(3')-Ia NG_047435:101-916,2
,atgaaccatatgaatatgaaacacagacgcagaaaacgcagacgtaaccaatcttttttgttcacaggaattttactcttagttgtagtatctgcaagcgccaatttatggtacggttttggcaatgcggcaaaaaaagacagtgttattgaagaaatgccatttaccattacacaggacggaatgcaggcaaaggaagaaataaagaaaacggtactggaaacttcctatggcggcaaacagcaggtagcggaagaaaatcacggcaatacacaaaatgcagggacagacgaagcgtggaatttaatgcttgtcaacagagataatgcgattccagacaattacaaagtaaatctggcaagtaaaggcggggagcgtgtaaatcaccgtatctatgaacctcttatggaaatgcttaatgcggcaagggaagaaaactggggcgaattgccgatggtagtatctggctatcggacgcaggaaaaacagcagagcctttatgatgaaaagattgcaaagttcaaaaaagaggggtattcagacagtgaagccgtaaggcaggcagaacaatgggttgcagtgccaggtcacagtgagcatcagctcggttttgcagtggatattaacggggcaacttatgatgtttatctatggttgcaggaaaacagctataaatacacggctttatcttcagatacccggcagaaaacggatattaccgggactgctgaagaagtatggcattaccgttatgttggagtggaagcggcaactgaaatgtatgaaaatggattatgtcttgaggaatatcttgagaaaaagcaatcagaaaactaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7613,Drugs,MEG_7613|Drugs|Glycopeptides|VanG-type_accessory_protein|VANYG,1028100759|WP_063856894.1|NG_048527|1|1|vanY-G|vanY-G|D-Ala-D-Ala_carboxypeptidase_VanY-G NG_048527:101-937,5
,ATGAAATTTTTTAAAATCAATCCAAACACCGATTTTAATTTGCTTTGTTCTTTCATAAACCCTCATAAAATGGGACAAAAGATCATGAGTGAAAAAACAAAAATTCATTTTATTTTTATCAAAGATATTTCTACTCCTGCGGCAAATATTTTAAAACAAGATGCTTTAAGAGTAGGAGCTGAACTTATTACTCATAAAGAAGTAATTACTGCAAAAATCACTCATTCAAATGCGCTTTTAATGGCAAGTAAAGAGCAAATTCAAAAGCTTGTTGTCAAAGAAAAACTTCAAGATTTTGGACTTAAAAATTTGGCTCTTTTTTTGCAAAAAGATTTTTTAAAACCGAAAAAAGCCGAGCTTATGGCAGTGATTAATGTCAATGAAGACAGTTTTAATGCAAAAAGTCGTGTGAGTGAAGAAGACTTTGAAAAAAGGCTTAATGACTTTCTTGCTTTAAAGCCTGAATATATCGATATAGGTGCGGTAAGCTCAAGACCTGGGAGTGAGTATTGTGGCAAGGAAGAGGAATTTAAAAGACTGAAAAAAGTACTTGACTTAATTTATGAGAAAAATTATTACGAACAAGCAATTTTTAGTTTAGATAGTTTTGATGAATATTGTCTAGAATATGCTTTAAATAAGGGTTTTAAACTCATTAATGATATTACAAGTTTAAGAAATCTTAATCTAGCCAAACTTGCAAGTAAATATGGGGCAAAATATTGCTTAATGCACATGCAAAACAATCCAAATAACATGCAAGATAATCCTTTTTATGAAGATTTGCTTGATGAGATGACTTTGTTTTTTAAAGAAAAACTTGAGCTTTTAGAAAGTTTTGGAGTAAAAGAAAGTATTTTAGATGTAGGTATTGGTTTTGGAAAGAGTGCGGGGCATAATATGATTTTAATCAAACACTTAGAACATTTTTTGCAATTTAATAAACCTTTACTTATAGGTGCGAGTCGTAAAAGTGTGATTAATGCGTATTTTCAAAGCGAGATTAAAGATCGTTTAGCGGGAACTTTATATTTGCATTTAAAGGCTTTTGAAAATGGTGCTAGTATTATAAGAGTGCATGATTTATATGAGCATAAACAACTTTTTGCTTTAGCGCAGGCAATGGATAATATAGGAGTTTAG,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2960,Drugs,MEG_2960|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|938159898|gb|CP012696.1|545611-546753 gi|780862670|gb|CP003871.3|543985-545127 gi|756103065|gb|CP010301.1|548585-549727 gi|756089737|gb|CP010072.1|586335-587477 gi|690551456|gb|CP006729.2|583098-584240 gi|690545238|gb|CP006709.2|583100-584242 gi|690532631|gb|CP006708.2|544545-545687 gi|690532129|gb|CP006707.2|583099-584241 gi|589078008|gb|CP006689.1|544185-545327 gi|589076343|gb|CP006688.1|544182-545324,8
,gtggacgagaaggaactgatcgagcgcgccggcggccccgtcacccgcggccggctcgtgcgcgacctcgaggcactcggcgtcggcgccggcgacaccgtcatggtgcacacccgcatgtcggcgatcggctacgtcgtgggcggcccgcagaccgtgatcgacgcgctccgcgacgccgtcggcgccgacggcaccctcatggcctactgcggctggaacgacgccccgccctacgacctcgccgagtggccccccgcgtggcgggaggccgcacgcgccgagtggcccgcctacgacccgctgctcagcgaggccgaccggggcaacggccgggtccccgaggccctgcgccaccagcccggcgcggtccgcagccggcaccccgacgcgagcttcgtcgcggtcgggccggccgcccacccgctcatggacgaccacccctgggacgacccgcacggaccggacagcccgctcgcccggctcgccggggccggcggacgggtactgctgctcggcgccccgctggacaccctgacgctgctgcaccacgcggaggcactggccgaggcccccggcaagcggttcgtcgcgtacgagcagcccgtgaccgtcggcgggcgacgggtctggcggcgcttccgcgacgtcgacaccgagaccgaggcgttcccctacgggcgggtggtgcccgagggggtctggccgttcaccgtcatcgcccaggacatgctcgccgccgggatcggccggaccggccgggtcgccgccgccccctgccacctcttcgaggccgccgacgtggtccgcttcggcgtcgagtggatcgagagccggatggggggcgcggccggcggcgcgtga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_34,Drugs,MEG_34|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,665542538|WP_031136588.1|NG_047258|1|1|aac(3)-VIII|aac(3)-VIII|aminoglycoside_N-acetyltransferase_AAC(3)-VIII NG_047258:101-964,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctgaccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5630,Drugs,MEG_5630|Drugs|betalactams|Class_C_betalactamases|PDC,489229219|WP_003137570.1|NG_049906|1|1|blaPDC-34|blaPDC|class_C_beta-lactamase_PDC-34 NG_049906:1-1194,0
,ttgaaaaaaatacttttactttttagtcttttttactcttttgctttggcaaatgataaattaaaagatttttttaaagactacaatacaagcggagtttttataacttttgatggaaaacattatgcaagtaataattttaaaagagctaaagaacctttttctcctgcttcgacttttaaaatttttaatgctttaattgcgcttgataatggtgtagttaaagatacaaaggaaattttttatcattataagggtgaaaaagtatttttgccctcttggaaacaagatgctagtttaagatcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcctatggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatataaatttagcttggattgttggattcgtaaagactaaaaacaaaattttatcttttgccttaaatgttgatataaagaacattaaaaatcttaaaataagagaagaattgctagaaaaatatatttattctttaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4631,Drugs,MEG_4631|Drugs|betalactams|Class_D_betalactamases|OXA,1391852897|WP_109545082.1|NG_057499|1|1|blaOXA-633|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-633 NG_057499:1-747,0
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgccgccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5691,Drugs,MEG_5691|Drugs|betalactams|Class_C_betalactamases|PDC,553759835|WP_023092413.1|NG_049909|1|1|blaPDC-37|blaPDC|class_C_beta-lactamase_PDC-37 NG_049909:1-1194,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGAGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6481,Drugs,MEG_6481|Drugs|betalactams|Class_A_betalactamases|SHV,gi|742679781|gb|CP006738.1|2729064-2729924 gi|549815675|gb|CP006648.1|1717001-1716141 gi|695220748|ref|NG_039545.1|77-937,0
,ATGAGGGAAGCGGTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGTTGGTTACTGTGGCCGTAAAGCTTGATGAAACGACGCGGCGAGCATTGCTCAATGATCTTATGGAGGCTTCGGCTTTCCCTGGCGAGAGCGAGACGCTCCGCGCTATAGAAGTCACCCTTGTCGTGCATGACGACATCATCCCGTGGCGTTATCCGGCTAAGCGCGAGCTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCATGATCGACATTGATCTAGCTATCCTGCTTACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCGGCAGCGGAGGAATTCTTTGACCCGGTTCCTGAACAGGATCTATTCGAGGCGCTGAGGGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCCGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAATAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATAAAACGCCTACCTGCCCAGTATCAGCCCGTCTTACTTGAAGCTAAGCAAGCTTATCTGGGACAAAAAGAAGATCACTTGGCCTCACGCGCAGATCACTTGGAAGAATTTATTCGCTTTGTGAAAGGCGAGATCATCAAGTCAGTTGGTAAATGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_970,Drugs,MEG_970|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|984348768|gb|KT425375.1|1012-1803 gi|975900838|gb|CP014005.1|53050-53841 gi|971497742|gb|CP012903.1|35736-36527 gi|971497538|gb|CP012902.1|59147-58356 gi|970338578|gb|KT725789.1|87007-86216 gi|970338460|gb|KT725788.1|92267-91476 gi|963885563|gb|KT355691.1|1056-1847 gi|963329770|gb|KT316808.1|970-1761 gi|958108507|emb|LN824138.1|5339-6130 gi|948288870|gb|KR259318.1|1054-1845,2
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaataaaacccagagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaagcagataaaaaaattaatctgtatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttaccgcttgggaaaaagacatgacactaggagaagccatgaagctttccgcagtcccagtctatcaggaacttgcgcgacgtatcggtcttgatctcatgcaaaaagaagtaaaacgtattggtttcggtaatgctgaaattggacagcaggttgataatttctggttggtagggccattaaaggttacgcctattcaagaggtagagtttgtttctcaattggcgcatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgcttcttttagaagagagtaatggctacaaaatttttggaaagactggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcgcttttgcactaaatatggaaatgcggtcaggaatgcctgcatctatacgtaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4721,Drugs,MEG_4721|Drugs|betalactams|Class_D_betalactamases|OXA,1625655420|WP_136512097.1|NG_064764|1|1|blaOXA-806|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-806 NG_064764:1-822,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCAAGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATGGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGTTACTGGGGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1850,Drugs,MEG_1850|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AB872957.1|+|0-1146|ARO:3002071|CMY-110 [Escherichia coli] ,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctatcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccgcggcccactcgatgccgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_563,Drugs,MEG_563|Drugs|betalactams|Class_C_betalactamases|ADC,691165248|WP_032071188.1|NG_056164|1|1|blaADC-173|blaADC|class_C_beta-lactamase_ADC-173 NG_056164:101-1255,0
,atgttcaaaacgacgctctgcgccttattaattaccgcctcttgctccacatttgctgccccccaaaaaatcaacgatattgtgcatcgcacaattaccccgcttatagagcaacaaaagatccccggtatggcggtggcggtaatttatcagggtaaaccttattactttacctggggctatgcggacatcgccaaaaagcagcccgtcacacagcaaacgttgtttgagttaggttcggtcagcaaaacatttacgggcgtgcttggtggcgacgctattgctcgaggggaaatcaagttaagcgatcccgcaacaaaatactggcctgaacttaccgctaaacagtggaatgggatcacactattacatctcgcaacctacactgctggcggcctgccattgcaggtgccggatgaagtgaaatcctcaagcgacttgctgcgcttctatcaaaactggcagcctgcatgggctccaggaacacaacgtctgtatgccaactccagtatcggtttgttcggcgcactggctgtgaagccgtctggtttgagttttgagcaggcgatgcaaactcgtgtcttccagccactcaaactcaaccatacatggattaatgtaccgcccgcagaagaaaagaattacgcctggggatatcgcgaaggtaaggcagtgcatgtttcgccaggggcgttagatgctgaagcttatggtgtgaagtcgaccattgaagatatggcccgctgggtgcaaatcaatttaaaaccccttgatatcaatgagaaaacgcttcaacaagggatacaagtggcacaatctcgctactggcaaaccggcgatatgtatcagggtctgggctgggaaatgctggactggccggtaaatcctgacatcatcgttaacggcagtgacaataaaattgcactggcagcacgccccgtaaaagcgattacgcccccaactcctgcagtacgcgcatcatgggtacataaaacaggggcgaccggcggatttggtagctatgtcgcgtttattccagaaaaagagctgggtatcgtgatgctggctaacaaaaactatcccaatccagcgagagtcgccgccgcctggcagattctcaacgctctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1276,Drugs,MEG_1276|Drugs|betalactams|Class_C_betalactamases|BLAEC,485860783|WP_001460207.1|NG_047496|1|1|blaEC|blaEC|BlaEC_family_class_C_beta-lactamase NG_047496:1-1134,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCTTTCTCCACGTTTGCCGCCGCCAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACGCAACAAACGCTGTTTGAACTCGGATCGGTCAGTAAAACGTTCAACGGCGTGCTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGCATTACTGGCCTGAACTGACTGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCGTTACTACGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGCGCCCTGGCGGTGAAACCCTCAGGCATGAGCTACGAAGAGGCGATGACCAAACGCGTCCTGCACCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGCCAACTTGATGCCGAAGCATACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGCATCGAGCTTGCGCAGTCACGTTACTGGCGTATTGGCGATATGTACCAGGGCCTGGGTTGGGAGATGCTGAACTGGCCGGTGAAAGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTGGCACTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAGAGCTACCCAAACCCTGTTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1925,Drugs,MEG_1925|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KF526114|+|0-1146|ARO:3002113|CMY-101 [Escherichia coli] ,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccgccccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5655,Drugs,MEG_5655|Drugs|betalactams|Class_C_betalactamases|PDC,1201190434|WP_087587954.1|NG_054969|1|1|blaPDC-183|blaPDC|class_C_beta-lactamase_PDC-183 NG_054969:1-1194,0
,ATGAAAATAATCAATATTGGAATTCTCGCCCATGTAGACGCAGGAAAAACAACATTGACGGAAAGCCTGCTGTACACCAGTGGAGCGATTGCGGAACAAGGAAACGTGGATAAAGGAACTACAAGAACAGACACTATGATTTTGGAACGGCAGCGCGGAATTACCATTCAGACAGCGGTTACTTCTTTTTGCTGGAATGATTATAAAATCAATATCGTGGACACTCCCGGTCATATGGATTTTTTAACCGAAGCATACCGCTCTTTATCTGTCCTTGACGGAGCTGTTTTAGTCATTTCGGCAAAAGACGGCGTACAGGCACAAACCCGTATATTATTCCATGCGCTTCAGAAAATGGACATTCCGACAATTATCTTTATAAATAAGATAGACCAAAATGGGATCGACCTGCGGCGTGTTTACCAAAGCATTAAAGATAAACTTACCAGTGATATGATTGTCATGCAGGAGGTTTCCCTGTCGCCAAAGATAACCATGACCGATATTTCTGATTTGGACAAATGGGATATGATTATTTCCGGAAGCGATGAACTATTAGAACGATATGTTGCAGAGGATTCTTTGGATATACAGGAATTACAATATGAAAAGTGCAAAAGAACCAGATGCTGCTCTTTGTTTCCTGTTTATCATGGGAGTGCAAAAGACAATTTAGGAACAGAAAAACTGATTGAAGCGATTACAGAAACTTTCATTACAGAAACAGACGATATTCAGTCTGAATTATGTGGATATGTTTTTAAGGTTGAGTATACAGAGCGGAAAAAACGGCTTTCTTATTTACGCCTGTATCATGGGACGCTCCATTTACGGGATACCCTGCTGCTGTCAAAAAAGGAAAAAATAAAGATTACAGAAATGTGTATTCCGTCAAATGGTGAAATCGTCCCGGTTGACCATGCCTGTCCGGGAGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGACATTCTGGGAAATGAAAAACTCCTGCCTCACAAAACACGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCACAGAGATTGCTGATACAGACCCTCTTTTGCATTTTGACATTGATACTGTTACACATGAGATTATATTATCTTTTTTGGGAAAAGTACAGTTAGAAGTTATTTGTTCGCTATTAGAAGAAAAATATCATGTGGGCGTGGCTATGAAAGAGCCTTCGGTTATTTATCTGGAAAGACCGCAAAAAAAAGCGAGCTACACGATTCATATTGAAGTGCCGCCGAATCCGTTTTGGGCATCTATTGGTTTGACTGTAACACCGCTTCCTGTTGGAAGCGGAACACAATATAAAAGCGAGGTATCTCTCGGCTATTTAAACCAAAGTTTTCAAAATGCCGTCATGGAGGGTGTGCGTTATGGAATGGAGCAGGGCTTATATGGCTGGGGAGTGACAGACTGCCAAATTTGTTTTGATTATGGAGTTTATTACAGCCCGGTCAGCACCCCCGCTGATTTTCGTTTTCTTGCGCCTGTCGTGTTGGAGCAGGCATTGAAAAAAGCAGGAACACAACTGTTGGAACCATACCTTTCCTTTACCCTTTTTGCACCGCAGGAATATCTTTCACGGGCTTATAATGACGCACCAAAGTATTGCGCAATCATTGAATCAACCAGACTTGAAAAAGATGAAGTTATTTTTAAGGGGGAAATCCCTGCCCGTTGTATTGGTGAATATAGAAATGATTTGAATTTTTATACAAATGGAAGAAGTGTCTGCATTACAGAATTAAAAGGGTATCAGGAAACTTCCGGCGAGCCTGTGTTTCAGCCACGCCGCCCGAACAGCCGTTTAGACAAGATCCGGCATATGTTTCAGAAGATAATGTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_6970,Drugs,MEG_6970|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TET32,(Tet)Tet-32:DQ647324:181-2100:1920,4
,ATGAGTTATCTATTTTTGTCGTGTACAGAGGAGCTAATCATGCGATTTAAAAAAATTTCTTGTCTACTTTTATCCCCGCTTTTTATTTTTAGTACCTCAATTTATGCGGGCAATACACCAAAAGACCAAGAAATTAAAAAACTGGTAGATCAAAACTTTAAACCGTTATTAGAAAAATATGATGTGCCAGGTATGGCTGTGGGTGTTATTCAAAATAATAAAAAGTATGAAATGTATTATGGTCTTCAATCTGTTCAAGATAAAAAAGCCGTAAATCGCAGTACCATTTTTGAGCTAGGTTCTGTCAGTAAATTATTTACCGCGACAGCAGGTGGATATGCAAAAAATAAAGGAAAAATCTCTTTTGACGATACGCCTGGTAAATATTGGAAAGAACTAAAAAACACACCGATTGACCAAGTTAACTTACTTCAACTCGCGACGTATACAAGTGGTAACCTTGCCTTGCAGTTTCCAGATGAAGTACAAACAGACCAACAAGTTTTAACTTTTTTCAAAGACTGGCAACCTAAAAACCCAATCGGTGAATACAGACAATATTCAAATCCAAGTATTGGCCTATTTGGAAAGGTTGTGGCTTTGTCTATGAATAAACCTTTCGACCAAGTCTTAGAAAAAACAATTTTTCCGGCCCTTGGCTTAAAACATAGCTATGTAAATGTACCTAAGACCCAGATGCAAAACTATGCATTTGGTTATAACCAAGAAAATCAGCCGATTCGAGTTAACCCCGGCCCACTCGATGCCCCTGCATATGGCGTCAAATCGACACTACCCGACATGTTGAGTTTTATTCATGCCAACCTTAACCCACAGAAATATCCGGCTGATATTCAACGGGCAATTAATGAAACACATCAAGGGTTCTATCAAGTAAATACCATGTATCAGGCACTCGGTTGGGAAGAGTTTTCTTATCCGGCAACGTTACAAACTTTATTAGACAGTAATTCAGAACAGATTGTGATGAAACCTAATAAAGTGACTGCTATTTCAAAGGAACCTTCAGTTAAGATGTACCATAAAACTGGCTCAACCAACGGTTTCGGAACATATGTAGTGTTTATTCCTAAAGAAAATATTGGCTTAGTCATGTTAACCAATAAACGTATTCCAAATGAAGAGCGCATTAAGGCAGCTTATGCTGTGCTGGATGCAATAAAGAAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_629,Drugs,MEG_629|Drugs|betalactams|Class_C_betalactamases|ADC,(Bla)beta-lactamase_class-C:NC_010410:1184557-1185747:1191,0
,atgcgatttaaaaaaaattcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtattattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgacaagcctggtaaatattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtagtgtttatacctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_521,Drugs,MEG_521|Drugs|betalactams|Class_C_betalactamases|ADC,1058243749|WP_068981629.1|NG_051462|1|1|blaADC-98|blaADC|class_C_beta-lactamase_ADC-98 NG_051462:1-1152,0
,atgagtaacgcagtacccgccgagatttcggtacagctatcactggctctcaacgccatcgagcgtcatctggaatcaacgttgctggccgtgcatttgtacggctctgcactggacggtggcctgaagccatacagtgatattgatttgctggttactgtggctgcacagctcgatgagactgtccgacaagccctggtcgtagatctcttggaaatttctgcctcccctggccaaagtgaggctctccgcgccttggaagttaccatcgtcgtgcatggtgatgttgtcccttggcgttatccggccagacgggaactgcaattcggggagtggcagcgtaaggacattcttgcgggcatcttcgagcccgccacaaccgatgttgatctggctattctgctaactaaagtaaggcagcatagccttgcattggcaggttcggccgcagaggatttctttaacccagttccggaaggcgatctattcaaggcattgagcgacactctgaaactatggaattcgcagccggattgggaaggcgatgagcggaatgtagtgcttaccttgtctcgcatttggtacagcgcagcaaccggcaagatcgcaccgaaggatatcgttgccaactgggcaattgagcgtctgccagatcaacataagcccgtactgcttgaagcccggcaggcttatcttggacaaggagaagattgcttggcctcacgcgcggatcagttggcggcgttcgttcacttcgtgaaacatgaagccactaaattgcttggtgccctgccagtgatgtctaacaattcattcaagccgaacccgcttcgcgggtcggcttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_816,Drugs,MEG_816|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1028081032|WP_063840415.1|NG_047332|1|1|aadA11|aadA11|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA11 NG_047332:101-946,2
,ATGACTAAAAAAGCTCTTTTCTTTGCCATTGGTACGATGTTTTTGTCGGCATGTTCTTTTAATACCGTACAACAACATCAAATACAGTCAATTTCTACCAATAAAAACTCAGAGAAAATTAAATCATTGTTTGATCAAGCACAAACTGAAGGTGTTTTAGTTATAAAACGTGGGCAAACAGAGGAAATCTATGGCAATGATCTTAAAAGATCATCAACCGAATATGTTCCCGCCTCTACCTTTAAAATGTTAAATGCTTTGATAGGACTTGAGCATCATAAAGCAACACCAACTGAAGTGTTTAAATGGTATGGGCAAAAGCGTTTATTTCCCGATTGGGAAAAAGACATGACCTTAGGTGATGCTATGAAAGCTTCTGCTATTCCAGTTTATCAGGAACTAGCTCGACGAATTGGCCTTGATCTTATGTCTAAAGAGGTAAAACGCATTGGTTTCGGTAATGCTGATATTGGTTCAAAAGTAGATGATTTTTGGCTTGTTGGTCCACTTAAAATTACACCTCAACAAGAAGTACGGTTTGCTTACAAATTAGCCAACAAAACTCTTCCCTTTAGCAAAAATGTACAAGAACAAGTTCAATCTATGGTGTTCATTGAAGAAAAAAATGGACGAAAAATTTATGCCAAAAGTGGTTGGGGATGGGATGTTGACCCTCAAGTGGGTTGGTTTACAGGCTGGGTAGTTCAACCTCAGGGAGAAATTATAGCTTTCTCACTTAATTTAGAAATGAAGAAAGGCATACCTAGTTCTATTCGAAAAGAAATTGCTTATAAAGGATTAGAGCAGCTAGGTATTTTATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5276,Drugs,MEG_5276|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-272_1_LSAL01000001,0
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCCGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2382,Drugs,MEG_2382|Drugs|betalactams|Class_A_betalactamases|CTX,gi|20145491|emb|AJ310929.1|244-1119,0
,atgccccgtatgctgttgtccagtctgcttgctgctggcctcttctgtgcactgcctgccagcgccgcttctggctgcatgctgtttgccgacggcaccggcaaacccgtcagcacccagggggactgtgccgcccagttgaccccggcctccaccttcaagatcccgctggcactgatgggctatgacagcggcttcctggtggatgaacaactgcctgccctgccgttcaaggccggtgatcctgatttcctgccggagtggaaacagaccaccaccccgagcagctggatgcaattctcggtcatctggtactcgcagcgcctcaccgagtggctgggagaggctcgcttccagcactacgtggacagcttcgactacggcaaccgggatctcgaaggcaacccgggcaagcacgacggtctgacccaggcctggctcagcgccagcctcgccatcagcccccaggagcaagcccgcttccttggcaagatggtgagcggcaagctgccggtctccgcccagaccctgcgccataccgccaacctgatgcgtcagcccgacatcgacggttggcagatccacggcaagaccggcatgggttaccccaagctgctggatggcagcttggacagggagcagcagatcggctggttcgtcggctgggccagcaaacaggacaagacgctcatcttcgtccacaccgtcatccagacgccgggcaagcagttcgcttccctcagggccagggaggaggtgttcgccgccctgccggcccggttgaagacactctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4600,Drugs,MEG_4600|Drugs|betalactams|Class_D_betalactamases|OXA,1028109712|WP_063864115.1|NG_049782|1|1|blaOXA-504|blaOXA-PR|class_D_beta-lactamase_OXA-504 NG_049782:1-795,0
,atgagtaacgcagtacccgccgagatttcggtacagctatcactggctctcaacgccatcgagcgtcatctggaatcaacgttgctggccgtgcatttgtacggctctgcactggacggtggcctgaagccatacagtgatattgatttgctggttactgtggctgcacggctcgatgagactgtccgacaagccctggtcgtagatctcttggaaatttctgcctcccctggccaaagtgaagctctccgcgccttggaagttaccatcgtcgtgcatggtgatgttgtcccttggcgttatccggccagacgggaactgcaattcggggagtggcagcgtaaggacattcttgcgggcatcttcgagcccgccacaaccgatgttgatctggctattctgctaactaaagtaaggcagcatagccttgcattggcaggttcggccgcagaggatttctttaacccagttccggaaggcgatctattcaaggcattgagcgacactctgaaactatggaattcgcagccggattgggaaggcgatgagcggaatgtagtgcttaccttgtctcgcatttggtacagcgcagcaaccggcaggatcgcaccgaaggatatcgttgccaactgggcaatggagcgtctgccagatcaacataagcccgtactgcttgaagcccggcaggcttatcttggacaaggagaagattgcttggcctcacgcgcggatcagttggcggcgttcgttcacttcgtgaaacatgaagccactaaattgcttagtgccatgccagtgatgtctaacaattcattcaagccgacgccgcttcgcggcgcggcttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_818,Drugs,MEG_818|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502145|WP_071846297.1|NG_052355|1|1|aadA6|aadA6|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA6 NG_052355:101-946,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactacagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagtctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgttgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5660,Drugs,MEG_5660|Drugs|betalactams|Class_C_betalactamases|PDC,1188444891|WP_085562393.1|NG_054679|1|1|blaPDC-177|blaPDC|class_C_beta-lactamase_PDC-177 NG_054679:1-1194,0
,ATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGCTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTTGGCATTGAAATTCGCCACTGTCGTGCGCAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACTCGCACCTGGTTTTGCAGCGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGCTGGAAAAATGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTTTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGCTGCTCATGGAACGTCTTGGCATCGCGATTATTGGCTAG,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6005,Drugs,MEG_6005|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,qnrB76_1_KM985469 ,3
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccgctgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3472,Drugs,MEG_3472|Drugs|betalactams|Class_A_betalactamases|KPC,1625655393|WP_136512070.1|NG_064727|1|1|blaKPC-42|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-42 NG_064727:1-882,0
,GTGAATACATCCTATTCACAATCGAATTTACGACACAACCAAATTTTAATTTGGCTTTGCATTTTATCTTTTTTTAGCGTATTAAATGAAATGGTTTTGAACGTCTCATTACCTGATATTGCAAATGATTTTAATAAACCACCTGCGAGTACAAACTGGGTGAACACAGCCTTTATGTTAACCTTTTCCATTGGAACAGCTGTATATGGAAAGCTATCTGATCAATTAGGCATCAAAAGGTTACTCCTATTTGGAATTATAATAAATTGTTTCGGGTCGGTAATTGGGTTTGTTGGCCATTCTTTCTTTTCCTTACTTATTATGGCTCGTTTTATTCAAGGGGCTGGTGCAGCTGCATTTCCAGCACTCGTAATGGTTGTAGTTGCGCGCTATATTCCAAAGGAAAATAGGGGTAAAGCATTTGGTCTTATTGGATCGATAGTAGCCATGGGAGAAGGAGTCGGTCCAGCGATTGGTGGAATGATAGCCCATTATATTCATTGGTCCTATCTTCTACTCATTCCTATCATAACAATTATCACTGTTCCGTTTCTTATGAAATTATTAAAGAAAGAAGTAAGGATAAAAGGTCATTTTGGATCTAAAGGAATTATACTAATGTCTGTAGGCATTGTATTTTTTATGTTGTTTACAACATCATATAGCATTTCTTTTCTTATCGTTAGCGTGCTGTCATTCCTGATATTTGTAAAACATATCAGGAAAGTAACAGATCCTTTTGTTGATCCCGGATTAGGGAAAAATATACCTTTTATGATTGGAGTTCTTTGTGGGGGAATTATATTTGGAACAGTAGCAGGGTTTGTCTCTATGGTTCCTTATATGATGAAAGATGTTCACCAGCTAAGTACTGCCGAAATCGGAAGTGTAATTATTTTCCCTGGAACAATGAGTGTCATTATTTTCGGCTACATTGGTGGGATACTTGTTGATAGAAGAGTGCCTTTATATGCGTTAAACATCGGAGTTACATTTCTTTCTGTTAGCTTTTTAACTGCTTCCTTTCTTTTAGAAACAACATCATGGTTCATGACAATTATTATCGTATTTGTTTTAGGTGGGCTTTCGTTCACCAAAACAGTTATATCAACAATTGTTTCAAGTAGCTTGAAACAGCAGGAAGCTGGTGCTGGAATGAGTTTGCTTAACTTTACCAGCCTTTTATCAGAGGGAACAGGTATTGCAATTGTAGGTGGTTTATTATCCATACCCTTACTTGATCCACGGTTGTTACCTATGGAAGTTGATCAGTCAACTTATCTGTATAGTAATTTGTTATTACTTTTTTCAGGAATCATTGTCATTAGTTGGCTGGTTACCTTGAATCTATATAAACATTCTCAAAGGGATTTCTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7100,Drugs,MEG_7100|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETL,gi|695196392|ref|NG_034404.1|168-1544,4
,atggaacaatatacaattaaatttaaccaaatcaatcataaattgacagatttacgatcacttaacatcgatcatctttatgcttaccaatttgaaaaaatagcacttattgggggtaatggtactggcaaaaccacattactaaatatgattgctcaaaaaacaaaaccagaacctggaacagttgaaacgaatggcgaaattcaatattttgaacagcttaacatggatgtggaaaatgattttaacacgttagacggtagtttaatgagtgaactccatatacctatgcatacaaccgacagtatgagtggtggtgaaaaagcaaaatataaattagctaatgtcatatcaaattatagtccgatattacttttagatgaacctacaaatcacttggataaaattggtaaagattatctgaataatattttaaaatattactatggtactttaattatagtaagtcacgatagagcacttatagaccaaattgctgacacaatttgggatatacaagaagatggcacaataagagtgtttaaaggtaattacacacagtatcaaaatcaatatgaacaagaacagttagaacaacaacgtaaatatgaacagtatataagtgaaaaacaaagattgtcccaagccagtaaagctaaacgaaatcaagcgcaacaaatggcacaagcatcatcaaaacaaaaaaataaaagtatagcaccagatcgtttaagtgcatcaaaacaaaaaggcacggttgagaaggctgctcaaaaacaagctaagcatattgaaaaaagaatggaacatttggaagaagttgaaaaaccacaaagttatcatgaattcaattttccacaaaataaaatttatgatatccataataattatccaatcattgcacaaaatctaacattggttaaaggaagtcaaaaactgctaacacaagtacgattccaaataccatatggcaaaaatatagcgctcgtaggtgcaaatggtgtaggtaagacaactttacttgaagctatttaccaccaaatagagggaattgattgttctcctaaagtgcaaatggcatactatcgtcaacttgcttatgaagacatgcgtgacgtttcattattgcaatatttaatggatgaaacggattcatcagaatcattcagtagagctattttaaataacttgggtttaaatgaagcacttgagcgttcttgtaatgttttgagtggtggggaaagaacgaaattatcgttagcagtattattttcaacgaaagcgaatacgttaattttggatgaaccaactaattttttagatattaaaacattagaagcattagaaatgtttatgaataaatatcctggaatcattttgtttacatcacatgatacaaggtttgttaaacatgtatcagataaaaaatgggaattaacaggacaatctattcatgatataacttaa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_4065,Drugs,MEG_4065|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|MSRA,1028097644|WP_063854341.1|NG_048002|1|1|msr(A)|msr(A)|ABC-F_type_ribosomal_protection_protein_Msr(A) NG_048002:101-1567,7
,atgcaacaaagatgtgcgttcgcgctactgacgctggttagcctgctgctagccccttgtacttatgccagcggggaggccccgctgaccgccactgtggacggcattatccagccgatgctcaaggagtatcggatcccggggatggcggtcgccgtactgaaagatggcaaggcccactatttcaactatggggttgccaaccgcgagagtggccagcgcgtcagcgagcagaccctgttcgagattggctcggtcagcaagaccctgaccgcgaccctcggtgcctatgccgcggtcaaggggggctttgtgctggatgacaatgtgagccagcacgccccttggctcaaaggttccgccttggatggtgtgaccatggccgagcttgccacctacagtgcgggtggtttgccgctgcagttccccgatgaggtagattcgaatgacaagatgcgcacttactatcggagctggtcaccggtttatccggcggggacccatcgccagtattccaaccccagcataggcctgtttggtcacctggccgcaaatagtctgggccagccatttgagcaactgatgagccagaccctgctgcccaagctgggtttgcaccacacctatattcaggtgccggagtcggccatagcgaactatgcctacggctattcgaaggaagataagcccgtccgggtcactccgggcgtgctggcggccgaggcttacgggatcaagaccggctcggcggatctgctgaagtttgccgaggcaaacatggggtatcagggagatgccgcggtaaaaagcgcgatcgcgctgacccacaccggtttctactcggtgggagacatgactcagggactgggctgggagagttacgcctatccggtgaccgagcagacattgctggcgggcaattcaccagcggtgagcttccaggccaatccggttacgcgctttgcggtgcccaaagcgatgggcgagcagcggctctataacaagacgggctcgactggcggctttggcgcctatgtggcgttcgtgcccgccagagggatcgccatcgtcatgctggccaatcgcaactatcccatcgaggctagggtgaaggcggctcacgccatcctgagtcagttggccgagtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3029,Drugs,MEG_3029|Drugs|betalactams|Class_C_betalactamases|FOX,1391852881|WP_109545066.1|NG_057480|1|1|blaFOX-16|blaFOX|cephalosporin-hydrolyzing_class_C_beta-lactamase_FOX-16 NG_057480:1-1149,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaattgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgcatcgaacacgcttgtgaagccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacactgtttttgcgctctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcgaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacataccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaagactggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacaccgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1493,Drugs,MEG_1493|Drugs|betalactams|Class_A_betalactamases|CARB,659007663|WP_029839920.1|NG_048731|1|1|blaCARB-28|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-28 NG_048731:1-852,0
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAGAGTTTATTGTATACCAGTGGTGCAATTGCAGAACCAGGGAGCGTAGATAAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGTGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGAGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGACATTCTAGGAAATGAAAAACTCCTGCCTCATAAAACACGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCGCAGAGATTGCTGATACAGACCCTCTTTTGCATTTTGACATTGATACTGTTACACATGAGATTATGTTATCTTTTTTGGGAAAAGTACAGTTAGAAGTTATTTGTTCGTTATTAGAAGAAAAATATCATGTGGGCGTGGCTATGAAAGAGCCTTCGGTTATTTATCTGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAGGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTAATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7177,Drugs,MEG_7177|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/W/32/O)_5_JQ740053 ,4
,ATGCAGGATAAAAATTTAGTGAATGTCAATCTGACAAAGGAGATGAAGGCAAGTTTTATCGACTACGCCATGAGTGTTATCGTAGCGCGAGCTCTTCCTGATGTTCGAGATGGCTTAAAACCTGTTCACCGTCGCATTCTCTACGGAATGAATGAATTGGGTGTGACCCCAGACAAACCCCATAAAAAATCTGCTCGTATTACAGGGGATGTCATGGGTAAATACCACCCACACGGGGATTCCTCTATTTATGAAGCCATGGTCCGTATGGCTCAATGGTGGAGCTACCGTTACATGCTTGTAGATGGTCATGGGAATTTTGGTTCCATGGATGGAGATAGTGCTGCCGCTCAACGTTATACCGAGGCACGTATGAGCAAGATTGCTCTGGAAATGCTTCGTGATATCAACAAAAATACAGTTGATTTCGTTGATAACTATGATGCCAATGAACGGGAACCCTTGGTCTTGCCAGCGCGTTTTCCAAACCTTTTGGTTAATGGAGCAACTGGTATCGCGGTTGGGATGGCAACCAATATTCCACCTCATAATCTGGGTGAAACCATTGATGCAGTGAAGTTGGTCATGGATAATCCTGAAGTGACTACCAAGGACTTGATGGAAGTCTTGCCTGGACCAGATTTTCCAACTGGTGCTCTTGTCATGGGGAAATCAGGTATCCATAAGGCTTATGAAACAGGTAAAGGTTCGATTGTCCTACGTTCTCGTACAGAGATTGAAACGACTAAGACTGGTCGTGAGCGTATCGTTGTAACAGAATTTCCTTACATGGTCAATAAAACCAAGGTGCATGAGCATATTGTTCGCTTGGTTCAGGAAAAACGCATTGAGGGTATCACAGCAGTACGTGATGAGTCAAACCGTGAAGGTGTTCGATTTGTTATTGAAGTCAAGCGCGACGCCTCAGCCAATGTTATTCTCAATAACCTCTTCAAAATGACCCAAATGCAAACCAATTTTGGTTTCAATATGCTCGCTATCCAAAATGGTATACCGAAAATTTTGTCTCTTCGTCAGATTTTGGATGCTTATATTGAGCACCAAAAAGAAGTGGTTGTTCGTCGTACACGTTTTGATAAGGAAAAAGCGGAAGCGCGCGCTCATATCTTAGAAGGTCTCTTGATTGCGCTAGACCATATCGACGAAGTGATTCGTATCATCCGTGCTAGTGAAACGGATGCGGAAGCTCAAGCTGAGTTGATGAGCAAGTTTAAGCTTTCTGAACGTCAAAGTCAAGCTATCCTTGATATGCGTCTTCGTCGTTTGACAGGTTTGGAACGCGATAAGATTCAATCTGAGTATGATGACCTCTTGGCTCTGATTGCGGATTTAGCAGATATTCTTGCTAAGCCTGAACGTGTTTCTCAAATTATCAAAGACGAATTGGATGAAGTTAAACGTAAATTTTCTGATAAACGCCGTACAGAGTTGATGGTTGGACAGGTCTTGAGTCTCGAGGATGAGGACTTGATTGAAGAATCGGATGTCTTGATTACCCTTTCTAACAGAGGCTACATTAAGCGTTTGGATCAGGACGAGTTCACTGCTCAAAAACGTGGGGGTCGTGGTGTCCAAGGAACGGGAGTGAAAGATGATGACTTTGTTCGTGAGTTAGTGTCAACTAGTACCCATGATCATCTGCTCTTCTTCACAAACAAGGGACGTGTCTATCGTCTTAAAGGTTATGAAATTCCTGAGTATGGTCGGACTGCCAAAGGGCTACCAGTAGTCAATCTCTTGAAATTGGATGAAGACGAAAGTATTCAGACGGTTATCAATGTTGAGTCTGATCGCAGTGATGATGCTTATCTCTTCTTTACAACCCGTCACGGTATTGTGAAGAGAACCAGTGTTAAGGAGTTTGCCAATATTCGTCAAAATGGTCTCAAAGCGCTGAATTTAAAGGATGAAGATGAGTTAATCAATGTCTTGTTGGCAGAAGGAGATATGGATATTATCATTGGTACCAAGTTTGGTTATGCAGTTCGCTTTAATCAATCAGCCGTTCGTGGTATGAGCCGTATCGCCACTGGTGTGAAAGGTGTTAACCTTCGTGAAGGAGACACAGTTGTTGGTGCCAGCTTGATTACTGATCAAGATGAGGTTCTTATTATCACAGAAAAAGGATATGGTAAGCGTACAGTCGCTACTGAATACCCAACAAAAGGTCGTGGTGGTAAGGGAATGCAGACAGCTAAAATTACCGAAAAAAATGGCTTGCTGGCCGGTCTTATGACTGTTCAAGGGGATGAGGATTTGATGATTATCACTGATACAGGTGTCATGATTCGAACCAATCTTGCCAATATTTCACAAACAGGACGTGCAACTATGGGAGTTAAAGTAATGCGCCTGGATCAAGATGCTCAGATAGTGACTTTCACAACGGTTGCGGTGGCAGAAAAAGAAGAAGTTGGGACAGAAAACGAAACAGAAGGTGAAGCATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3198,Drugs,MEG_3198|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|25307955|gb|AE007317.1|1097931-1095463,3
,atgaacataaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgtagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4680,Drugs,MEG_4680|Drugs|betalactams|Class_D_betalactamases|OXA,1433308462|WP_114225343.1|NG_063843|1|1|blaOXA-739|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-739 NG_063843:1-825,0
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttgggcggtacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgtttccggaccgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcatggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctgaggcaatggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaatgcccattctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1614,Drugs,MEG_1614|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,695270125|WP_032492194.1|NG_047612|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_047612:101-733,6
,gtgaccaacagcaacgattccgtcacactgcgcctcatgattgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_239,Drugs,MEG_239|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502097|WP_071846249.1|NG_052274|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052274:101-655,2
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTTGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6588,Drugs,MEG_6588|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|154757953|emb|AM746675.2|2311-3150 gi|974751547|gb|KU130294.1|233473-234001 gi|982189197|gb|CP013993.1|5430539-5431065,8
,atgttacgcagcagggcagtcgccctcgacgaagtatctgaactaaagaatttgctttcacccttgttggatgaatgcacttttgaagaagttgagtatggtcagtcagatgctcgagtgattcgagttctatttcctgatcgcaataccgcgtatctaaagtacgcctccggatcttctgctcaagaaattcttcaagagcatcagcgcactagatggctcagaacacgagctctcgtaccggaagtgatctcatatgtctcgacttcaactgtcaccatcctgttgacaaaagcattgattggccacaatgccgctgacgccgcagatgcagatccagttattgttgttgcagagatggcacgagcgttacgcgacctccattcgatctcgcctgacgattgcccattcgacgaaaggctccacctgcgactgaagctggcttcgggccgtttggaagccgggttagttgatgaggaggactttgatcacgcaaggcaaggcatgctggcgcgggatgtttacgagcaactttttatacaaatgcctggagcggagcagctggtagtcacacatggcgacgcctgtcccgagaacttcatcttccaaggtaatgccttcgtcggcttcatagactgcggtcgggtcgggcttgccgataagtatcaagacctggcgcttgcatcgagaaacattgacgcggtatttggaccagaactcactaaccagttcttcatcgagtatggagagccaaatccgaacatagctaagattgagtactaccggatcttggatgagttcttctaa,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1042,Drugs,MEG_1042|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,695270510|WP_032492579.1|NG_052270|1|1|aph(3')-XV|aph(3')-XV|aminoglycoside_O-phosphotransferase_APH(3')-XV NG_052270:63-869,2
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggggtggcattgattaacacagcggataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgactgctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaatgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2152,Drugs,MEG_2152|Drugs|betalactams|Class_A_betalactamases|CTX,1028104773|WP_063860019.1|NG_048962|1|1|blaCTX-M-177|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-177 NG_048962:1-876,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGGCATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATTGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1355,Drugs,MEG_1355|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_120_NZ_ALWG01000005,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAAAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCGCTTTAAAAGAACTTATTGAGGCTTCAATGAAGTACAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAATTTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAAGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1424,Drugs,MEG_1424|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_137_GQ915265,0
,atgaaatctaacaatgcgctcatcgtcatcctcggcaccgtcaccctagatgctgtaggcataggcttggttatgccggtactgccgggcctcttgcgggatatcgtccattccgacagcatcgccagtcactatggcgtgctgctagcgctatatgcgttgatgcaatttctatgcgcacccgttctcggagcactgtccgaccgctttggccgccgcccagtcctgctcgcttcgctacttggagccactatcgactacgcgatcatggcgaccacacccgtcctgtggatcctctacgccggacgcatcgtggccggcatcaccggcgccacaggtgcggttgctggcgcctatatcgccgacatcaccgatggggaagatcgggctcgccacttcgggctcatgagcgcttgtttcggcgtgggtatggtggcaggccccgtggccgggggactgttgggcgccatctccttgcatgcaccattccttgcggcggcggtgctcaacggcctcaacctactactgggctgcttcctaatgcaggagtcgcataagggagagcgtcgaccgatgtccttgagagccttcaacccagtcagctccttccggtgggcgcggggcatgactatcgtcgccgcacttatgactgtcttctttatcatgcaactcgtaggacaggtgccggcagcgctctgggtcattttcggcgaggaccgctttcgctggagcgcgacgatgatcggcctgtcgcttgcggtattcggaatcttgcaaaccctcgctcaagccttcgtcactggtcccgccaccaaacgtttcggcgagaagcaggccattatcgccggcatggcggccgacgcgctgggctacgtcttgctggcgttcgcgacgcgaggctggatggccttccccattatgattcttctcgcttccggcggcatcgggatgcccgcgttgcaggccatgctgtccaggcaggtagatgacgaccatcagggacagcttcaaggatcgctcgcggctcttaccagcctaacttcgatcattggaccgctgatcttcacggcgatttatgccgcctcggcgagcacatggaacgggttggcatggattgtaggcgccgccctataccttgtctgcctccccgcgttgcgtcgcggtgcatggagccgggccacctcgacctga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7056,Drugs,MEG_7056|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETC,1028099799|WP_063856071.1|NG_048178|1|1|tet(C)|tet(C)|tetracycline_efflux_MFS_transporter_Tet(C) NG_048178:101-1291,4
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttggtgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagggcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccggtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_895,Drugs,MEG_895|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,695263581|WP_032490451.1|NG_052314|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052314:101-892,2
,ATGTTCAAACTTTTGAGTAAGTTATTGGTCTATTTGACCGCGTCTATCATGGCTATTGCGAGTCCGCTCGCTTTTTCCGTAGATTCTAGCGGTGAGTATCCGACAGTCAGCGAAATTCCGGTCGGGGAGGTCCGGCTTTACCAGATTGCCGATGGTGTTTGGTCGCATATCGCAACGCGGTCGTTTGATGGCGCAGTCTACCCGTCCAATGGTCTCATTGTCCGTGATGGTGATGAGTTGCTTTTGATTGATACAGCGTGGGGTGCGAAAAACACAGCGGCACTTCTCGCGGAGATTGAGAAGCAAATTGGACTTCCTGTAACGCGTGCAGTCTCCACGCACTTTCATGACGACCGCGTCGGCGGCGTTGATGTCCTTCGGGCGGCTGGGGTGGCAACGTACGCATCACCGTCGACACGCCGGCTAGCCGAGGTAGAGGGGAGCGAGATTCCCACGCACTCTCTAGAAGGACTCTCATCGAGCGGGGACGCAGTGCGCTTCGGTCCAGTAGAACTCTTCTATCCTGGTGCTGCGCATTCGACCGACAACTTAGTTGTGTACGTCCCGTCTGCGAGTGTGCTCTATGGTGGTTGTGCGATTTATGAGTTGTCACGCACGTCTGCGGGGAACGTGGCCGATGCCGATCTGGCTGAATGGCCCACCTCCATTGAGCGGATTCAACAACACTACCCGGAAGCACAGTTCGTCATTCCGGGGCACGGCCTGCCGGGCGGTCTAGACTTGCTCAAGCACACAACGAATGTTGTAAAAGCGCACACAAATCGCTCAGTCGTTGAGTAGCAGGCAGATGCGGCATAACATGAAGTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_7767,Drugs,MEG_7767|Drugs|betalactams|Class_B_betalactamases|VIM,gi|925170830|gb|KR337993.1|115-942 gi|825088620|gb|KP975076.1|26784-25957 gi|222446218|emb|FM994936.1|972-1799 gi|145321079|gb|EF522838.1|1057-1884 gi|26892103|gb|AY165025.1|1-828,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcttggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtkccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5596,Drugs,MEG_5596|Drugs|betalactams|Class_C_betalactamases|PDC,1393270454|WP_109791199.1|NG_057597|1|1|blaPDC-265|blaPDC|class_C_beta-lactamase_PDC-265 NG_057597:1-1173,0
,atgactaaaaaagctcttttctttgccattagtacgatgtttttgtcggcatgttcttttaataccgtacaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaacagaggaaatctatggcaatgatcttaaaagatcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgcattgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttgtttcctgattgggaaaaggacatgactctaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaagaatgtgcaagaagaagttcaatctatgctgttcatagaagaaaaaaatggacggaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaacctcaaggagaaattgtagcgttctcactcaatttagaaatgaaaaaaggcatacctagttctattcgaaaagaaattgcttataagggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4551,Drugs,MEG_4551|Drugs|betalactams|Class_D_betalactamases|OXA,949717113|WP_057061999.1|NG_064779|1|1|blaOXA-821|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-821 NG_064779:1-822,0
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCCCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAACTGGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2405,Drugs,MEG_2405|Drugs|betalactams|Class_A_betalactamases|CTX,gi|56554768|gb|AY847146.1|83-963,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgtccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_801,Drugs,MEG_801|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,695270511|WP_032492580.1|NG_052271|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052271:101-892,2
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggagatgggatgtagacccacaagtaggctggttaackggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4691,Drugs,MEG_4691|Drugs|betalactams|Class_D_betalactamases|OXA,1509794597|WP_122630906.1|NG_062326|1|1|blaOXA-704|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-704 NG_062326:17-841,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGCTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATCGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1920,Drugs,MEG_1920|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JX514369|+|296-1442|ARO:3002108|CMY-95 [Escherichia coli] ,0
,atgcgcgataccggattcccctgcctgtgcggcatcgccgcctccacactgctgttcgccgccacctcggccattgccggcgaggccccggcggatcgcctgaagacactggtcgacgccgccgtacaaccggtgatgaaggccaatgatattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcttcgaaagaggacggtcgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagcctgcactggccggcgctgcaaggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaagaccaggcacagatccgcgactactaccgccagtggcagccgacctacacgccgggcagccagcgcctctactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggatcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaagccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggcgggcaactcgacgccgatggcgctgcaaccgcacaggatcgccagactgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccaggcagcgacctgggcctggtgatcctggccaaccgcaattatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5708,Drugs,MEG_5708|Drugs|betalactams|Class_C_betalactamases|PDC,730281025|WP_033969586.1|NG_049938|1|1|blaPDC-63|blaPDC|class_C_beta-lactamase_PDC-63 NG_049938:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgatgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaaggccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctaccactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5446,Drugs,MEG_5446|Drugs|betalactams|Class_C_betalactamases|PDC,1343491228|WP_104009844.1|NG_056403|1|1|blaPDC-248|blaPDC|class_C_beta-lactamase_PDC-248 NG_056403:1-1194,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttgtttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatgcaaaaatacttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4397,Drugs,MEG_4397|Drugs|betalactams|Class_D_betalactamases|OXA,1440786791|WP_114699279.1|NG_061407|1|1|blaOXA-660|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-660 NG_061407:1-720,0
,AATAACGAAGAGTTTGATCCTGGCTTAGAACTAACGCTGGCAGTGCGTCTTAAGCATGCAAGTCAAACGGGATGTAGCAATACATTCAGTGGCGAACGGGTGAGTAACGCGTGGATGATCTACCTATGAGATGGGGATAACTATTAGAAATAGTAGCTAATACCGAATAAGGTCAGTTAATTTGTTAATTGATGAAAGGAAGCCTTTAAACGTTCGCTTGTAGATGAGTCTGCGTCTTATTAGCTAGTTGGTAGGGTAAATGCCTACCAAGGCAATGATAAGTAACCGGCCTGAGAGGGTGAACGGTCACACTGGAACTGAGATACGGTCCAGNCTCCTACGGGAGGCAGCAGCTAAGAATCTTCCGCAATGGGCGAAAGCCTGACGGAGCGACACTGCGTGAATGAAGAAGGTCGAAAGATTGTAAAATTCTTTTATAAATGAGGAATAAGCTTTGTAGGAAATGACAAAGTGATGACGTTAATTTATGAATAAGCCCCGGCTAATTACGTGCCAGNAGCCGCGGTAATACGTAAGGGNNNAGCGTTGTTCGGGATTATTGGGCGTAAAGGGTGAGTAGGCGGATATATAAGTCTATGCATAAAATACCACAGCTCAACTGTGGACCTATGTTGGAAACTATATGTCTAGAGTCTGATAGAGGAAGTTAGAATTTCTGGTGTAAGGGTGGAATCTGTTGATATCAGAAAGAATACCGGAGGCGAAGGCGAACTTCTGGGTCAAGACTGACGCTGAGTCACGAAAGCGTAGGGAGCAAACAGGATTAGATACCCTGGTAGTCTACGCTGTAAACGATGCACACTTGGTGTTAACTAAAAGTTAGTACCGAAGCTAACGTGTTAAGTGTGCAGCCTGGGGAGTATGCTCGCAAGAGNGAAACTCAAAGGNATTNANNNGNGCCNGCACAAGNNGTGGAGCATGTGGTTTNNNNNNANNNTACGCGAGGAACCTTACCAGGGCTTGACATATATAGGATATAGTTAGAGATAATTATTCCCCGTTTGGGGTCTATATACAGGTGCTGCATGGTTGTCGTCAGCTCGTGCTGTGAGGTGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTTATCTGTTACCAGCATGTAATGGTGGGGACTCAGATAAGACTGCCGGTGATAAGTCGGAGGAAGGTGAGGATGACGTCAAATCATCATGGCCCTTATGTCCTGGGCTACACACGTGCTACAATGGCCTGTACAAAGCGAAGCGAAACAGTGATGTGAAGCAAAACGCATAAAGCAGGTCTCAGTCCGGATTGAAGTCTGAAACTCGACTTCATGAAGTTGGAATCGCTAGTAATCGTATATCAGAATGATACGGTGAATACGTTCTCGGGCNTTGTACACACCGCCCGTCACACCACCCGAGTTGAGGATACCCGAAGCTATTATTCTAACCCGTAAGGGAGGAAGGTATTTAAGGTATGTTTAGCA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_10,Drugs,MEG_10|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|NR_044732.2|+|0-1477|ARO:3003504|Borreliella burgdorferi 16S rRNA mutation conferring resistance to gentamicin [Borreliella burgdorferi] ,2
,atgaatattataaatttaggaattcttgctcacattgatgcaggaaaaacttccgtaaccgagaatctgctgtttgccagtggagcaacggaaaagtgcggccgtgtggataatggtgacaccataacagactctatggatatagagaaacgtagaggaattactgtccgggcttctacgacatctattatctggaacggggtgaaatgcaatatcattgacactccgggacacatggattttattgcggaagtggagcggacattcaaaatgcttgatggagcagtcctcatcttatccgcaaaggaaggcatacaagcgcagacaaagttgctgttcaatactttacagaagctgcaaatcccgacaattatatttatcaataagattgaccgtgccggtgtgaatttggagcgtttgtatctggatataaaaacaaatctgtcgcaagatgtcctgtgtatgcaaactgttgtcgatggatcggtttatccagtttgctcccaaacatatataaaggaagaatacaaagaatttgtatgcgaccatgacgacaacatattggaacgatatttggcggatagcgaaattccaccgactgattattggaatacgataatcgctcttgtggcaaaagccaaagtctatccggtgctacatggatcagcaatgttcaatatcggcatcaatgagttgatggacgccatcacttcttttatacttcctccggcatcagtctcagacagactttcagcttatctctataagatagagcatgaccccaaaggacataaaagaagttttctaaaaataattgacggaagtctgagacttagagacgttgtaagaatcaacgattcggaaaaatccatcaagattaaaaatctgaaaactatttatcagggcagagagataaatgttgatgaagtgggtgccaatgatatcgcgattgtagaggatatggaagattttcgaatcggagattatttaggtgctgagccttgtttgattcaaggattatctcatcagcatcccgctctcaaatcctccgtccggccagacaagcccgaagagaggagcaaggttatatccgctctgaatacattgtggattgaagacccgtctttgtccttttccataaactcatatagcgatgaattggaaatctcgttatatggtttgacccaaaaggaaatcatacagacattgctggaagaacgattttccgtaaaggtccattttgatgagatcaagactatctacaaagaacgacctataaaaaaggtcaataagattattcagatcgaagtaccacccaacccttactgggccacaatagggctgactcttgaacccttaccgttaggggcagggttgcaaatcgaaagtgacatctcctatggttatctgaaccattcttttcaaaatgccgtttttgaaggaatccgtatgtcttgccaatcaggattacatggatgggaagtgacagatctgaaagtgacttttactcaagccgaatattatagcccggtaagtacacctgctgatttcaggcagctgaccccttatgtcttcaggctggctttgcaacagtcaggtgtggacattctcgaaccgatgctatattttgagttgcagataccccaggaggcaagttccaaagctattacagatttgcaaaaaatgatgtctgagattgaagacatcagttgcaataatgagtggtgtcatattaaagggaaagttccattaaatacaagtaaagactatgcctcagaagtaagttcgtacactaagggcttaggcatttttatggttaagccatgtgggtatcaaataacaaaagacggttattctgataatatccgcatgaacgaaaaagataaacttttattcatgttccaaaaatcaatgtcattaaaataa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7178,Drugs,MEG_7178|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETQ,1028100274|WP_063856409.1|NG_048272|1|1|tet(Q)|tet(Q)|tetracycline_resistance_ribosomal_protection_protein_Tet(Q) NG_048272:101-2026,4
,atgcaaccaaaaagtatcattttatttttctatggttacattttatttttccgccgacaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttgtttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4599,Drugs,MEG_4599|Drugs|betalactams|Class_D_betalactamases|OXA,1440786788|WP_114699276.1|NG_061400|1|1|blaOXA-659|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-659 NG_061400:1-828,0
,ATGACCAGCCTTGCGCATCATGCGACAGAAAACCGCTCTGTAGCCGAATTTACTGAACAGGCTTACTTGAATTATGCCATGTACGTCATTATGGACCGTGCATTACCGCATATCAGTGATGGCTTAAAGCCCGTACAGCGCCGTATTGTCTATGCCATGAGCGAGCTAGGCTTAAAAAGCAGTGGCAAGCCAAAAAAATCAGCGCGTACAGTGGGTGATGTACTTGGTAAATACCACCCACATGGTGACTCGGCATGTTATGAAGCCATGGTACTCATGGCTCAGCCATTTAGTTACCGCTATCCTTTAATCGAAGGTCAGGGGAACTGGGGCTCACCTGATGATCCTAAGTCTTTTGCTGCGATGCGTTATACCGAAGCAAAACTCTCGGCTTATAGTGAATTATTGCTGAGCGAATTAGGTCAGGGCACTAGCGAATGGCAAGATAACTTTGATGGTTCTTTAAAAGAACCGATCACTTTACCTGCGCGTGTACCTAATATTCTTCTTAATGGTACGACAGGTATTGCTGTTGGGATGGCAACTGATATCCCGCCACATAATTTGCGTGAAGTTGTAAAAGGCACAATTGCTTTAATCCGTAATCCGCAAACCTCGGACGAAAAATTAGCTGAATATATTCCGGCTCCGGATTTACCAACCAAAGCTGAAATTATTACCCCGCCAGAAGAATTACTCAAAATCCAGACCACTGGTCGTGGTAGTTATCGTATGCGAGCGGTATATACCATTGAGAAAAATGAAATTGTAATTACTGAGCTGCCATATCAAGTCTCTGGTTCTAAGGTAATTACTCAAATTGCTGACCAGATGCAGGCTAAAAAGCTGCCATTAGTTGTCGACGTGCGTGATGAATCGGATCATGAAAACCCGACACGACTCGTGATTGTACTGCGCTCTAACCGTATTGATGCGGAAGCAGTGATGAGCCACTTATTTGCGACCACCGATTTAGAATCAAGCTATCGTGTCAATTTGAACATGATTGGCGAAGATGGCCGTCCTCAGGTGAAATCAATTCGTCGTATTTTGCTTGAATGGATCGAGATCCGTAAAAAAACGGTAACTCGTCGTTTGCAGTACCATTTAAACCGTATTGAAAAGCGCCTGCATATTTTGGCAGGTCTTTTAATTGCTTATCTCGATATTGATACAGTCATTCGTATTATTCGTGAAGAAGACCAGCCTAAGCCAGTCTTGATGGAACACTTTAATATTGATGAGATACAGGCCGAGGCGATTTTAGAGCTTAAATTACGTCATTTGGCAAAGCTTGAAGAGATGGAAATCCGTCATGAACAAGATGAACTTTCTGCGAAAGCTGCCATTATTCGTGAACAACTCGAAAATCCTGAATCTTTAAAAAACCTAATTATCAGTGAATTAAAAGAAGATGCGAAAAAGTTCGGTGATGAGCGCCGTTCTCCAATTGTTGCACGTGCTGAAGCAGTTCAAATTAAAGAACAGGATTTAATGCCAGCTGAAACGGTAACGGTGGTTTTGTCTGAAGCAGGCTGGGTTCGTGCGGCAAAAGGTGCGGATGTGGATGCCGAAAATCTCAACTACCGTGCTGGGGACCAATATTTAAGTCATGCTGTCGGGAAAACCAATCAGCGAGTTTACTTCCTTGATGAAACAGGGCGCAGCTATGCCTTGCCAATTAGTAACTTACCTTCAGCGAGAGGCTTGGGGGATCCATTAAGTTCTAAATTATCACCAGCAAGTGGCGTATCGTTTATTCAGGTTTATTTAGATGATGATGAGTCTGAATTGATTGCTGCAAGTTCGGCAGGTTATGGTTTTAAAACGCAAACCAAGCAATTAGATACCAATGCGAAAGCCGGTAAGACATTCTTAACGGTTCCGGATAAGGCAAAGGCTTTACCACTCATTTCTGCCCAAAACATGACGCATTTGGCTGTACTGAGCTCAGCAGGGCGTTTGTTAATTTTAGATTTGGCAGAACTACCAAATTTAAATAAAGGTAAAGGTAATAAGTTGATACAACTTGAAGGCAAAGAGCAAATTTTATCCATGACAACCCTGAACTTAGATGAAATAATTCAGGTGGTTGCAGGTCAACAACATCTCAAATTAAAAGGTGATGATCTACAAAAATACATGGGTAAACGTGCTTCGAAAGGTCAGCTCTTACCACGTGGATATCAAAAAGCAAATAAACTGTTGATTCAGAGATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5352,Drugs,MEG_5352|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|751410783|gb|CP010781.1|239136-241355 gi|213985689|gb|CP001172.1|3539471-3537252,3
,atgcgatttaaaaaaatttcttgcttacttttacctcctctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccgagaaattaaaaaactggtagatcaaaactttaaacctttattagataaatatgatgtgccgggtatggccgtgggcgttattcagaataataaaaaatatgaaacgtattatggtcttcaatctgttcaagataaaaaagccgtaagtagcagtaccatttttgaactaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatttcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcaacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaactcaatcggtgaatatagacaatattcaaatccaagcattggtttatttggaaaagttgtggcattgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccagatcttggcttaaaacatagctatgtaaatgttcctaaaactcagatgcaaaactatgcttttggctataaccaagaaaatcagccaattcgtgttaaccctggtccgctagatgctccagcatatggggttaaatcgacgctacccgatatgcttaagtttattaatgccaacctcaacacacagaaatatccgaaagatattcaacgtgcaattaatgaaacacatcagggtttctatcaagtcggcaccatgtatcaggcacttggttgggaagaattttcttatccagcgcctttacaaactttattagacagtaattcagaacaaattgtgatgaagcctaataaagtgactgccatttcaaaagaaccttcagttaagatgttccacaaaactggttcaaccaatggtttcggaacttatgtcgtgttcattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgccgtgttaaatggaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_528,Drugs,MEG_528|Drugs|betalactams|Class_C_betalactamases|ADC,515955985|WP_017386568.1|NG_064705|1|1|blaADC-150|blaADC|class_C_beta-lactamase_ADC-150 NG_064705:1-1152,0
,atgagggactcagtgaccgccgaaatttcgacgcaactatccaaggtgcttagtgttatcgagcaccatctggaaccgacgttgcttgccgtacatttgtacggctccgcagtggatggcggcctgaagccatacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgctgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_850,Drugs,MEG_850|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502119|WP_071846271.1|NG_052312|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052312:101-892,2
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGTGAAATTGTTATCCTTCCCAGCGACAGCGTGAGGTTAAACGATGTATTAGGGGACCCAACCCGGCTCCCTCGTAAAAGGTGGCGTGAGGACCCCCTCCCCATGCTGCGGACGTCGATTGCGCCGAAAACGGCAGCGCAAAGAGAACGGCTGCTGGACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGCTGCGAGGTGGATTCCATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTTGTTTCCGCTTTGCTGTCGGAAAAATACAAGCTTGAAACAGTGGTAAAGGAACCCACCGTCATTTATATAGAGCGGCCGCTCAAAGCAGCCAGCCACACCATCCATATCGAGGTGCCGCCCAACCCGTTTTGGGCATCCATCGGACTGTCTGTTACACCACTCCCGCTTGGCTCCGGTGTACAATACGAGAGCCGGGTTTCGCTGGGATACTTGAACCAGAGTTTTCAAAACGCTGTCAGGGATGGTATCCGTTACGGGCTGGAGCAGGGCTTGTTCGGCTGGAACGTAACGGACTGTAAGATTTGCTTTGAATACGGGCTTTATTACAGTCCGGTCAGCACGCCGGCGGACTTCCGCTCATTGGCCCCGATTGTATTGGAACAGGCATTGAAGGAATCAGGGACGCAACTGCTGGAACCTTATCTCTCCTTCACCCTCTATGCGCCCCGGGAATATCTTTCCAGGGCTTATCATGATGCACCGAAATACTGTGCCACCATCGAAACGGTCCAGGTAAAAAAGGATGAAGTTGTCTTTACTGGCGAGATTCCCGCCCGCTGTATACAGGCATACCGTACTGATCTGGCCTTTTACACCAACGGGCAGAGCGTATGCCTTACAGAACTGAAAGGGTATCAGGCCGCTGTCGGCAAGCCAGTCATCCAGCCCCGCCGTCCAAACAACCGCCTGGACAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7170,Drugs,MEG_7170|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/W)_4_AM889121 ,4
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcacaattgttgtgcacgacgacatcattccgaggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgtcgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_788,Drugs,MEG_788|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1102724712|WP_071593208.1|NG_052032|1|1|aadA1bt|aadA1bt|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1bt NG_052032:101-892,2
,ATGACAAAGTTGCAGCCGAATACAGTGATCCGTGCCGCCCTGGACCTGTTGAACGAGGTCGGCGTAGACGGTCTGACGACACGCAAACTGGCGGAACGGTTGGGGGTTCAGCAGCCGGCGCTTTACTGGCACTTCAGGAACAAGCGGGCGCTGCTCGACGCACTGGCCGAAGCCATGCTGGCGGAGAATCATACGCATTCGGTGCCGAGAGCCGACGACGACTGGCGCTCATTTCTGATCGGGAATGCCCGCAGCTTCAGGCAGGCGCTGCTCGCCTACCGCGATGGCGCGCGCATCCATGCCGGCACGCGACCGGGCGCACCGCAGATGGAAACGGCCGACGCGCAGCTTCGCTTCCTCTGCGAGGCGGGTTTTTCGGCCGGGGACGCCGTCAATGCGCTGATGACAATCAGCTACTTCACTGTTGGGGCCGTGCTTGAGGAGCAGGCCGGCGACAGCGATGCCGGCGAGCGCGGCGGCACCGTTGAACAGGCTCCGCTCTCGCCGCTGTTGCGGGCCGCGATAGACGCCTTCGACGAAGCCGGTCCGGACGCAGCGTTCGAGCAGGGACTCGCGGTGATTGTCGATGGATTGGCGAAAAGGAGGCTCGTTGTCAGGAACGTTGAAGGACCGAGAAAGGGTGACGATTGA,tetR,antibiotic target alteration,Tetracyclines,MEG_7185,Drugs,MEG_7185|Drugs|Tetracyclines|Tetracycline_transcriptional_repressor|TETR,(Tet)TetR:HF545434:53576-54226:651,4
,atgatgaaaaaatccctttgctgcgccctgctgctcggcatctcttgctctgctctcgccacgccagtgtcagaaaaacagctggcggaggtggtagcgaatacggttaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaaccgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccggcgttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagcatcggtctttttggtgcgctggcggtcaaaccttctggcatgccctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgtgccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggtatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaacgttgctgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcgagggcagcgacagtaaggtagcgctggcgccgttgcccgtggtagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggctctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaatacaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgaggcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_423,Drugs,MEG_423|Drugs|betalactams|Class_C_betalactamases|ACT,704515306|WP_033487869.1|NG_061415|1|1|blaACT-56|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-56 NG_061415:1-1146,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccaactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5455,Drugs,MEG_5455|Drugs|betalactams|Class_C_betalactamases|PDC,1201190431|WP_087587951.1|NG_054966|1|1|blaPDC-180|blaPDC|class_C_beta-lactamase_PDC-180 NG_054966:1-1194,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgagcaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttggagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_877,Drugs,MEG_877|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502158|WP_071846309.1|NG_052376|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052376:101-892,2
,TTGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATTTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGTCTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACACCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGAGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6471,Drugs,MEG_6471|Drugs|betalactams|Class_A_betalactamases|SHV,gi|695208304|ref|NG_035517.1|1-870,0
,atggctctggcactcgttggcgtaaaaattgacagaaaccgtttcaccggtgagaaaattgaaaatggtacattttttaattgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagctttatgaatatgatcaccacgcgcacctggttttgtagcgcatatatcacgaataccaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcgaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagctggacaactaccaggcgtcgttgctcatggagcggcttggcatcgcggtgattggttag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5894,Drugs,MEG_5894|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111766|WP_063865978.1|NG_050487|1|1|qnrB26|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB26 NG_050487:37-681,3
,atggaattgcccaatattatgcacccggtcgcgaagctgagcaccgcattagccgctgcattgatgctgagcgggtgcatgcccggtgaaatccgcccgacgattggccagcaaatggaaactggcgaccaacggtttggcgatctggttttccgccagctcgcaccgaatgtctggcagcacacttcctatctcgacatgccgggtttcggggcagtcgcttccaacggtttgatcgtcagggatggcggccgcgtgctgttggtcgataccgcctggaccgatgaccagaccgcccagatcctcaactggatcaagcaggagatcaacctgccggtcgcgctggcggtggtgactcacgcgcatcaggacaagatgggcggtatggacgcgctgcatgcggcggggattgcgacttatgccaatgcgttgtcgaaccagcttgccccgcaagaggggatggttgcggcgcaacacagcctgactttcgccgccaatggctgggtcgaaccagcaaccgcgcccaactttggcccgctcaaggtattttaccccggccccggccacaccagtgacaatatcaccgttgggatcgacggcaccgacatcgcttttggtggctgcctgatcaaggacagcaaggccaagtcgctcggcaatctcggtgatgccgacactgagcactacgccgcgtcagcgcgcgcgtttggtgcggcgttccccaaggccagcatgatcgtgatgagccattccgcccccgatagccgcgccgcaatcactcatacggcccgcatggccgacaagctgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4141,Drugs,MEG_4141|Drugs|betalactams|Class_B_betalactamases|NDM,1408841640|WP_111672913.1|NG_060571|1|1|blaNDM-24|blaNDM|subclass_B1_metallo-beta-lactamase_NDM-24 NG_060571:1-813,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaaccgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggagcgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_829,Drugs,MEG_829|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502231|WP_071846381.1|NG_052515|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052515:101-889,2
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgccgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagcttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3466,Drugs,MEG_3466|Drugs|betalactams|Class_A_betalactamases|KPC,1463920490|WP_116786832.1|NG_061612|1|1|blaKPC-37|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-37 NG_061612:1-882,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcttggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5595,Drugs,MEG_5595|Drugs|betalactams|Class_C_betalactamases|PDC,489223901|WP_003132320.1|NG_049889|1|1|blaPDC-19a|blaPDC|class_C_beta-lactamase_PDC-19a NG_049889:1-1194,0
,GGAGCTCGCGCGCCTGCAGGTCGACACTAGTGGATCCCATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAGAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAAGAATTCAAAAAGCTTCTCGAGAGTACGTTTAGAGCGGCCGCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6941,Drugs,MEG_6941|Drugs|betalactams|Class_A_betalactamases|TEM,gi|695211426|ref|NG_036075.1|1-941,0
,ATGGAAAAATACAACAATTGGAAACGAAAATTTTATGCAATATGGGCAGGGCAGGCGGTATCTTTAATCACTAGTGCCATCCTGCAAATGGCGATAATTTTTTACCTTACAGAAAAAACAGGATCTGCGATGGTCTTGTCTATGGCTTCACTATTAGGGTTTTTACCCTATGCGGTCTTTGGACCAGCCATTGGTGTATTAGTGGATCGTCATGATAGGAAGAAGATAATGATTGGTGCTGATTTAATTATAGCAGTAGCTGGAGCAGTGCTCGCTATTGTTGCATTGTTTACGGAGTTATCTGTATGGATGGTTATGGTAGTATTGTTTATCCGTAGCATTGGAACGGCTTTTCATTCTCCGGCTCTCAATGCGGTTACGCCGCTTTTAGTACCAGAAGAACAGCTTACGAAATGTGCAGGTTATAGTCAGTCTTTGCAGTCGATAAGCTATATTATTAGTCCGGCGGCCGCAGCATTGTTATACTCCGTTTGGAAACTAAATGCAATTATTGCTATCGATGTATTGGGCGCTGTGATTGCATCTATTACGGTAGCAATTGTAAGTATTCCTAAGCTGGGCGATCAAGTGCAAAGTTTGAAACCAAATTTCTTAAGAGAAATGAAAGAAGGAATTGTCGCATTGAGACAAAACAAAGGCTTATTTGCCTTATTACTCTTAGGAACGCTATATACGTTTGTGTATATGCCAATTAATGCACTATTTCCTTTAATTAGCATGGAATACTTTAATGGAACACCTGTGCATATTTCCATTACCGAAATCGCTTTTGCATCTGGAATGCTAGTAGGCGGTCTACTATTAGGAAGGTTGAGGAACTTTGAAAAGCGTGTATTACTAATAACAGGTTCATTCTTTATAATGGGAGCCAGTTTAGCAGTTTCAGGATTACTTCCTCCAAGTGGATTTGTTATATTTGTAGCTTGCTGTGCAGTAATGGGGCTTTCTGTGCCATTTTATAGCGGTGTGCAAACAGCTCTTTTTCAGGAGAAGATTAAGCCTGAATATTTAGGACGTGTATTTTCTTTGACCGGAAGTATTATGTCATTTGCTATGCCAATTGGATTAATTCTTTCTGGATTCTATGCTGATAGAATTGGTGTAAATCATTGGTTTTTACTATCAGGTATTTTAATTATTGGCATTGCTATAGTTTGCCCAATGATAACAGAGGTTAGAAAATTAGATTTAAAATAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3826,Drugs,MEG_3826|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,mef(A)_4_HG423652,7
,atgcttcaactgaaaatgatagaactcttcaaggaaggttgtcatgaggatgcacgaataatcgcgacattgatgttcggctcatttgctatcggagagggtgacgagttctctgatatcgaattcgcagtgttcatccaggatgaccattttgaaaatttcgatcagcgctcgtggcttaatgccgtaagtccggttgctgcttactttccggacgacttcggccaccacaccgcactttttgaaaacggcattcgcggtgaattccatttcatgcgaaaatcggacataccggtcatttccacttggcaaggctatgggtggtttccctcgcttgaggcggctgttttgttggaccgatcaggagagttgtcaaggtatgcaagcgctctcgtgggcgatcccccgatacgtgaaggcgcgccgctggtggaagggcttgtgttgaacctcatcagcctgatgctctttggggccaatcttttaaatcggggagagtacgctcgcgcctgggccttgctcagcaaagcccatgaaaacttactcaagttgatccgccttgacgaaagggcaacagaccactggccgacaccgtcacgcgcgttggaaaaggatatctcggcggactcgtataatcgctacctggcatgcacatccagtgcagagccgagagcactatgtgtagcctatcgtgaaacctggaagtggagtctcgaattgtacaagagtgttgcagaacctctgaacatcccgcttccgagaactgtaattacgcaggcaaaaaggttgctcaatgagtctgcgacgccgcacaacaagtaa,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3613,Drugs,MEG_3613|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUF,1080153687|WP_070342367.1|NG_051892|1|1|lnu(F)|lnu(F)|lincosamide_nucleotidyltransferase_Lnu(F) NG_051892:101-922,7
,ATGCACCACTCAACACCCTTAATTACCACGATCGTCGGAGGCCTTGTTCTCGCCTTCCTCTTGGGCTCCTTGGCTCACCGCCTGCGCTCATCACCACTGGTGGGGTACCTTGCCGCAGGGGTGCTGGCCGGGCCATTTACGCCAGGTTTCGTTGCTGATACCTCATTAGCACCAGAACTGGCTGAAATTGGTGTTATCTTGTTGATGTTTGGTGTCGGACTTCACTTCTCACTTAAAGACCTCCTCGCAGTAAAAGCCATCGCCATACCCGGTGCTGTGGCACAAATTGCCGTTGCCACCTTACTCGGAATGGGACTGTCTCATTTATTAGGCTGGGATTTGATGACAGGTTTTGTCTTCGGTCTTTGTCTATCAACAGCAAGTACCGTGGTATTACTACGAGCTCTAGAAGAACGGCAACTCATAGATAGCCAGCGGGGGCAAATTGCTATCGGTCGGTCGATTGTCGAAGATTTGGCGATGGTACTCACATTGGTGCTATTACCAGCCTTTGCCGGCGTGATGGGTAACGAAACCACCAGTCTCAGCCAGTTATTCACTGAACTAGCAATAACCATCGGTAAAGTCATTGCCTTCATTACGCTGATGATTGTTGTCGGTCGTCGTTTGGTCCCCTGGATACTGGCTAAAACCGCCAGTACCGGTTCCCGTGAGCTATTTACCTTGGCAGTGCTGGTATTAGCGCTTGGTATTGCTTACGGCGCTGTAGGGCTGTTCGACGTATCCTTTGCTCTCGGTGCATTCTTCGCAGGAATGGTATTGAATGAATCAGAGCTCAGCCACCGTGCGGCGCAAGATACCTTACCGCTACGTGATGCATTTGCCGTACTGTTCTTCGTTTCAGTTGGGATGTTGTTCGACCCAATGATTTTGCTACGTGAACCATTAGCTGTACTGGCTTCACTAGCTATCATTATCTTCGGCAAATCAGCAGCAGCGTTTATATTAGTGCGGATGTTTGGTCACTCAAACGTGTACAGCACTCACCATTTCTGTCCCTGGCGCAAATCGGTGAATTTGCCCTTTATTCTCGCCGGGCTTGGAATTTCTCTCGGTTTAATGTCTGAGCATGGCCGTAATCTGGTGCTGGCGGGCGCAATTTTATCAATTATGCTCAACCCGCTACTGTTTACATTATTAGATCGCTATTTGGCTAAAAACGAGACGATGGAAGATCTGATTCTGGAAGAGGCAGTCGAAGAGGAAAAGCAGATACCCGGTAGATTTGTGCAATCATGCACTGTTAGTCGGTTATGGTCGGGTGGGAGTTTATTAGGTGCAAAACTGCACGCGGAAGGTATTCCATTAGTGGTCATTGAGAACTCTCGACCAAGAGTTGAGGCGCTACGTGAACAAGGCATTAATGCGGTATTAGGCAATGCTGCAAGTGCAGATATTATGTCGCTGGCTCGTTTGGATTGTGCCCTGGTTATTATACTGACCATACCGAATGGCTACGAAGCTGGGGAAATTGTCGCCTCCGCCAGAATTAAACGGCCAGACCTTGAGATAATTGCTCGCGCGCATTATGACGACGAAGTGGTTTATATCTCGGTACGTGGCGCGAACCAGGTTGTGATGGGCGAACGTGAAATTGCCAACAGTATGCTTAATATGTTGAAGATAGAAACGCTGACCGAAGAAGACAAACGCCCGCTTTGCCCAATTTAA,subunit of efflux pump conferring antibiotic resistance,antibiotic efflux,Multi-drug_resistance,MEG_6084,Drugs,MEG_6084|Drugs|Multi-drug_resistance|Multi-drug_MFS_efflux_pumps|ROSB,gi|1197638|gb|U46859.1|YEU46859|24057-22366,1
,atgcgccatgcgacaatcctcaacctgtgcggcctcgccgcttccaccctgttcttcgcgacaacatcggccttcgccacggcggcgccggcggagcgcctgaaggctctggtggacgccgccgtgcaaccggtcatgaaggccaatgatatcccgggactggccgtcgccatcactctcaagggcgaaccgcattacttcagttatggggtggcctcgaaggaggacgcccgcaaggtgacccccgagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctacgccctggcccaggacaagatgcgcctcgacgaccgcgccagccggcactggcccgccctgcagggcagccgcttcgacggtatcagcctgctcgacctcggcacctacagcgctggcggcctgccgctacagttccccgatgcggtgcagaaggatccggcgcagatccgcgactactaccgccagtggcaaccgacctacgccccgggcagccaccgccagtactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccattcgagcgcagcatggaacggcagctgttcccggcgctcggcctggagcacacctttatccgggtgcccgccgcgcagcaggggctgtacgcccagggctacggcaaggacgaccgcccgctgcgggtcggacccggtccgctggacgccgaggcctacgggctgaagtccagcgctgcggacctgctgcgcttcgtcgaggccaacctgcaccccgagcgcctggagaagccctgggcgcaggccctcgacgccacccatcgcggctactacaaggtgggcgacatgacccagggcctgggttgggaagcctacgattggccgatcgacctgaagcgcctgcaggcgggcaactcggcgccgatggcgctacaggcgcacaaggtcgccaggttgccggcgccgcaagccctggacggccagcgcctgctgaacaagaccggctccaccaacggtttcggcgcctacctggcgttcatcccgggacgcgacgtcggcctggtgatcctggccaatcgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggaacagcaggccaaggtaccgctggtgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5622,Drugs,MEG_5622|Drugs|betalactams|Class_C_betalactamases|PDC,730360176|WP_033998317.1|NG_049937|1|1|blaPDC-62|blaPDC_var|class_C_beta-lactamase_PDC-62 NG_049937:1-1194,0
,ATGACGCCATTACTGTATAAAAAAACAGGTACAAATATGGCACTGGCACTCGTTAGCGAAAAAATTGACAGAAACCGCTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTTGGCATTGAAATTCGCCACTGTCGTGCGCAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACTCGCACCTGGTTTTGTAGTGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGCTGGAAAAGTGTGAGCTGTGGGAAAACCGTTGGATGGGTACCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGTTGCTCATGGAACGTCTTGGCATCGCGATTATTGGCTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5995,Drugs,MEG_5995|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gi|619533401|emb|HE820727.2|551-1231,3
,atgaagcatatttttttggtctttctgattctttgctcaaattttgctctcgctgaggacaaagctatttcggctattttttccacagaaggtgttgatgggaccatcattttgaagtcgttgcgaggagataagacaatcacgcacaatgatgcacgcgcttctcgccgattcgcgtcagcctcgactttcaagatattcaacacgctgattgcagttcaagaaaacgtggtgagtttgtcgggtactgcattccgatgggatggaaaaacgcatgacttccccgactggaaccgtgaccaaacacttgaaagcgcattcaaagtttcttgtgtgtggtgctatcaggaaatcgccaagcaagtgggggaagaaacttatcgacgctatcttgcgcttgcaaggtatggtgctctgagcaacgtggcagacagtacaaccttttggcttgatggcagctttacggtcagcgccgtcgagcaagtggctctgttgaaaaaaatctatctgcgagaacttccgtttcgcgatgacgcctacgacgctttaaagcgggtgatgctggcagagcagactgacagctacaagctttacgcaaagactggctgggcaggaagaatgaaccctcaaattgggtggtacgttggatatgttgaaacatccgatgatgtatggttttttgccatcaatttgaccttgaggtcagaaactgacttaggtttgcgccagcaaataacaaaggctgtgcttagggctgaacgcattattccctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4513,Drugs,MEG_4513|Drugs|betalactams|Class_D_betalactamases|OXA,1391852887|WP_109545072.1|NG_057486|1|1|blaOXA-641|blaOXA-372_like|OXA-372_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-641 NG_057486:1-774,0
,ttgcactttatcatcgataactttatcttagataaagtgactgctcgctactctcatctgactgctcgctactctcatcgtggaatcctgacagccgtgctcatcacggcgaccctcgatgctgcagggctgggcctcgtgatgccgatcttgcctacccttctcgaccaggtcggtgcccccgacgacatgatcccactgcacgtcggactactgacagcgctctatgcgatcatgcagtttctttgcgccccgatccttggccgactctctgaccgtttcggacgccgccgcgtgcttgtcgcctccctcgcaggcgcgacgatcgactacctcgtgctcgcactgacggacacgctgtgggtcttttacctcgcccgcgcggttgcaggcattaccggcgccacgaacgccgtcaccgcgacggtgatcgccgacattactccgccggatcagcgcgcaaaacgctacgggtggctcggcgcatgctacggcggtggcatgatcgcgggtcccgccattggcggtcttttcggcggggtctcaccgcatctgccattcctcgtcgccgccgcgctcgccggaatcaccctcgtactcagcgcgagtcttctgcgtgagacgcggccaccgggcagcaacggctcgcacgcacagcaacccggtacggcgaagcgaaccgcagtgccggggatgcttatccttctcgcagtcttcggcatcgtgcagttcatcggccaagcaccaggctccacctgggtgctcttcacgcagcagcgcctcgactggaaccccgtcgaagtcggcgtttcgctatccatcttcggaatggtgcaagtattcgtgcaggcggcactgaccggacgcatcgtgtcccggatcggcgagacccgggcgatcctcgtcggtatcgccgcagacgccattgggctcatcggccttgccctcatcgccagcacatgggcgatgctaccgatcctcgcagcgctcggactcggcagcatcacgttgcccgcactgcagacgctgctctcgagacgcgcgcccgagcagcagcagggacgcctgcagggaacacttgcaagcctgaacagcctcacctcgatcatcggcccggtcaccttcaccggcattttcgcactcacccgaacgaatgcagacggcaccctctggatctgcgccgcagcgctctacgttctctgcgccctcctgatgatccgtgagacatgcgcctcacggcgatctcgataa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7247,Drugs,MEG_7247|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETZ,1031994772|WP_064190967.1|NG_048311|1|1|tet(Z)|tet(Z)|tetracycline_efflux_MFS_transporter_Tet(Z) NG_048311:101-1351,4
,ATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAATTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6910,Drugs,MEG_6910|Drugs|betalactams|Class_A_betalactamases|TEM,gi|379056275|dbj|AB700703.1|1-1022,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgacgagaccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5435,Drugs,MEG_5435|Drugs|betalactams|Class_C_betalactamases|PDC,1408841626|WP_111672899.1|NG_060557|1|1|blaPDC-288|blaPDC|class_C_beta-lactamase_PDC-288 NG_060557:1-1194,0
,ATGAATAAACCCGCTGTCATCGCGCTGGTGATTACACTGCTGGACGCGATGGGAATTGGTCTGATCATGCCGGTATTACCGTCACTGCTGCGGGAATATCTCCCGGAAGCGGATGTGGCAAACCATTACGGCATTCTGCTGGCGCTGTATGCGGTGATGCAGGTCTGTTTTGCTCCGCTGCTGGGCAGATGGTCAGATAAGCTGGGGCGCAGACCGGTGCTGCTGTTATCCCTGGCGGGTGCCGCGTTTGATTACACACTGCTGGCACTGTCCAATGTGCTGTGGATGTTGTATCTCGGGCGGATTATCTCCGGGATCACTGGTGCCACCGGCGCGGTTGCGGCTTCGGTAGTGGCGGACAGCACGGCGGTCAGCGAGCGTACCGCCTGGTTCGGCCGTCTCGGTGCGGCCTTTGGTGCCGGGCTGATTGCCGGGCCGGCTATCGGCGGACTGGCGGGGGATATCTCACCGCATCTGCCGTTTGTCATTGCGGCAATACTGAATGCCTGCACCTTTCTGATGGTCTTTTTTATCTTTAAACCGGCGGTACAGACAGAAGAAAAACCGGCGGACGAGAAACAAGAAAGCGCAGGTATCAGCTTTATCACACTGCTTAAACCTCTGGCGCTGTTGCTGTTTGTCTTTTTTACCGCGCAGCTTATCGGGCAGATCCCGGCCACTGTCTGGGTATTGTTTACGGAGAGCCGCTTTGCCTGGGACAGCGCGGCGGTCGGTTTTTCACTGGCGGGACTCGGGGCGATGCATGCACTGTTTCAGGCGGTGGTTGCCGGGGCGCTGGCAAAACGGCTGAGTGAGAAAACCATTATTTTCGCCGGATTTATTGCCGATGCCACCGCGTTTTTACTGATGTCTGCTATCACTTCCGGATGGATGGTGTATCCGGTCCTGATCCTGCTGGCAGGCGGCGGAATTGCACTGCCTGCATTGCAGGGCATTATCTCTGCCGGGGCATCGGCGGCAAATCAGGGAAAACTACAGGGTGTGCTGGTCAGCCTGACCAATCTGACCGGCGTGGCGGGCCCGCTGCTGTTTGCTTTTATTTTCAGTCAGACACAGCAGAGTGCGGACGGTACGGTGTGGCTGATTGGCACGGCACTGTACGGTCTGCTGCTGGCAATCTGTCTGCTGATCAGAAAACCGGCACCGGTGGCGGCCACCTGCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7069,Drugs,MEG_7069|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETD,gi|49073|emb|X65876.1|1521-2705,4
,atgcgatttattctgtgtctattgttaatggtatccagtctcacttatgcagctcaggggccgtcaaagctcaaaattgtgcaactctccgatattgtctaccagcatacctcactatcagatggtgacgcttatggcgttatggctgcaaacggcttaattgttatcgtgggcaagcaagcctatttgattgacaccccatggacggaagcggataccaacacattaattcaatgggttaccgttaaaggcttaaccataggtggggtcatagtcacccattttcatcaagactccagtggcgggcttgcagtattaaataaactaaaaataaatacctatgcgacgacactgacaaatcaattgttaaaagccaataaccgtgaaccggcaagcaatgaaatcacttctgagacctttgatctagtcccaggagtgatccaagcttattacccaggtgcgggtcatacccaagataatcttgttgtctggttagcgaaatctaatttactctttggcggttgtttagtgcagagttttaacaatagaaaactgctcaacatcgaagatgcttcaattaaagattggccgaaatcattgcaaaatgtcatggttaaatacccaaacatagatatggttatcccagggcatggccaaataggggacgtgagtttgttagagctaacccaacagcttgccagaaaagccttgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_6187,Drugs,MEG_6187|Drugs|betalactams|Class_B_betalactamases|SHN,499816841|WP_011497575.1|NG_059313|1|1|blaSHN-1|blaSHN|subclass_B1_metallo-beta-lactamase_SHN-1 NG_059313:101-814,0
,atgagtaacgcagtacccgccgagatttcggtacagctatcactggctctcaacgccatcgagcgtcatctggaatcaacgttgctggccgtgcatttgtacggctctgcactggacggtggcctgaagccatacagtgatattgatttgctggttactgtggctgcacggctcgatgagactgtccgacaagccctggtcgtagatctcttggaaatttctgcctcccctggccaaagtgaagctctccgcgccttggaagttaccatcgtcgtgcatggtgatgttgtcccttggcgttatccggccagacgggaactgcaattcggggagtggcagcgtaaggacattcttgcgggcatcttcgagcccgccacaaccgatgttgatctggctattctgctaactaaagtaaggcagcatagccttgcattggcaggttcggccgcagaggatttctttaacccagttccggaaggcgatctattcaaggcattgagcgacactctgaaactatggaattcgcagccggattgggaaggcgatgagcggaatgtagtgcttaccttgtctcgcatttggtacagcgcagcaaccggcaagatcgcaccgaaggatatcgttgccactggggcaatggagcgtctgccagatcaacataagcccgtactgcttgaagcccggcaggcttatcttggacaaggagaagattgcttggcctcacgcgcggatcagttggcggcgttcgttcacttcgtgaaacatgaagccactaaattgcttagtgccatgccagtgatgtctaacaattcattcaagccgacgccgcttcgcggcgcggcttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_817,Drugs,MEG_817|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502212|WP_071846362.1|NG_052483|1|1|aadA6|aadA6|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA6 NG_052483:101-946,2
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaattatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4653,Drugs,MEG_4653|Drugs|betalactams|Class_D_betalactamases|OXA,1391852911|WP_109545096.1|NG_057530|1|1|blaOXA-589|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-589 NG_057530:1-774,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggctgcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5450,Drugs,MEG_5450|Drugs|betalactams|Class_C_betalactamases|PDC,1408841636|WP_111672909.1|NG_060567|1|1|blaPDC-302|blaPDC|class_C_beta-lactamase_PDC-302 NG_060567:1-1194,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcaccgcgctgtggccgtccggctcgcctgaagatcaccgcgcggaaatgcgcgagatactggcttcaccgcaccacaccgcgtttatggcgcggaggctggacggcactttcgttgcctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgccgaacgcgcccgccgccagggctgggccgcgcgcctgatcgcgcaggtgcaggagtgggcgaagcaacagggatgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggagcgagtagtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_158,Drugs,MEG_158|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,983555919|WP_060706838.1|NG_052209|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052209:101-541,2
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGGTGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAATCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCTCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTCCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1964,Drugs,MEG_1964|Drugs|betalactams|Class_C_betalactamases|CMY,gi|388564843|gb|JQ733575.1|1028-2255,0
,ttgaaaaatagaaagaaaacaaaatatgaagatgactatttgcttttcaaaaacagattatccatcaaaatgcttctcatgatggtgtgctcccttctgattatagcgggtgtttatctgtttatcttaaaaggaaattttgcaaatgccgtagtttccattttagaacattttgtttaccatgaccgcgatgaggccgcagtggtttatttgaaaacctttaagagatatgaattttggcttttcctgttggcgattttgggcgtgttttttgtgatttttcgtatgtttgtgggcaatgtttcaaaatactttaaggagatcaaccgtggcattgattccctggtacatgaagatgccgaggatattgcccttccggcagaactggcttcaacggaaagaaagatcaattccatacggcataccctggcgaaaagaaagacggacgccgagcttgcggagcaacggaaaaatgaccttgttatgtacctggcccatgacttaaaaacgccgctttcatcggtgatcggatatttgaccctgttaagggatgaaggccagatttccgatgaactccgggaacggtatttatccatatcactggataaggcagaacgccttgaagatctgattaacgaattttttgagatcacacggttcaacctttcccatattacacttgtatacggcaaaatcaatctgacaagaatgctcgaacagttggcatacgagtttaagccgatgctggccgggaaaaacctgaagctggaatttgaaatacagccggatatttctatttcgtgtgatgcaaataaaatgcagcgtgtatttgataacctgctgcgaaacgctgtcagctattgtaatgcagatacaagcattaagataactgcggagcagatggaagatcatgtgatcattaaagtcataaacgagggaaatacaattccgcaggaacgattagaaagaatatttgagcagttctaccgcctggatgtatcaagaagctccgcaacgggcggggccggcctgggactcgccattgcaaaggagattgttgaacttcatcatgggcagattaccgcccacagtgcggacggcctcacctgctttgaggtgtcattgccgctcgtaggaaaatcgtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7504,Drugs,MEG_7504|Drugs|Glycopeptides|VanD-type_regulator|VANSD,1028100609|WP_063856744.1|NG_048444|1|1|vanS-D|vanS-D|VanD-type_vancomycin_resistance_histidine_kinase_VanS NG_048444:101-1246,5
,ATGCCGCACCCGGCTCCCGGACCCGGCGATCCCGAGGACCCGAGGCTGGCGGAGGTCGTCGACGCGGTCCGGTCCAGCAGGCGCTACCAGAGCGTCGCGCCCGAAACCGTGCGCCGGCTGGCCACGAGCGCCCTGGTGGCCAGCCGCGGCGACCTCGCGGAGGCGGTCAAGCGCACCAAGCGCGGGCTGCACGAGATCTTCGGCGCCTACCTGCCCAGCCCGCCCAAGTACGACGCCCTCCTCCGCCAGCTCAGGGGGGCGGTCGACGCGGCGACGACGAGGCCGTGCGGGCACCCTGCACCGCGCCATGTCCACGCACGCCTCCACCCGCGAGCGCTGCCCATCCTCGACGAGTTCTACCGCGAGGTCTTCGCCCGGTGCGCCGACCCGGCCAGCGTGCGTGACCTGGCCTGCGGGATGAACCCGCTCGCCGCGCCGTGGATGCCCGGCTCGGACGCGTTCACCTACCACGCGTCCGACATCGACACCCGGCTCATGGAGTTCCTCGACGCCGCCCTGGAGACGCTCGGGGTCGCGCACGACGTCCGGGTGCGCGACCTGATGACCGGGGTCGGCGAGGTCGAGACCGACGTGACGCTGCTGCTCAAGACCGTGCCCTGCATCGAGGCGCAGGGGAGGGGGCAGGGCTGGGACCTCATCGACGCGATCCGCTCGCCGCTGGTCGTGGTGAGTTTCCCGACGAAGTCCCTCGGCCAGCGTTCCAAGGGGATGTTCAACACCTACTCGGCGAATTTCGACGCCTGGCTGGAGAACCGGCCGCACGACGTCGAGCAGCTCGAATTCAGGAACGAACTGGTCTATTTCGTGCGGAAGAACGCGTGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_3450,Drugs,MEG_3450|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|KGMB,kgmB_1_S60108 ,2
,atgaaatctagaaaacataatattacaaaaggattatttatagtttacataattattttaacatggataatactatttaagttgcaatttgatatctcatcccttgaaaccatgaatcttagaagcataaacttagtaccttttgctgggtcacttataattaataatagagtagatatatcagagattatattaaatgtggctatatttgtaccatttgggatatatgtgtgtatgctaaaagaagaatggagctttataaaaaaagttatacctatttttataactagtttggcatttgaaacacttcaatatatatttgcactaggtgcaagtgatataacggatttgataggaaacacactaggaggaatcataggaatagctgtttttatgctattatcgaaaatatttaagaataataccataaaaattatcaatgtattggcattgattgtgacaattattgttgtattatttttaggattagttatttttgcaaacttatag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7615,Drugs,MEG_7615|Drugs|Glycopeptides|VanA-type_accessory_protein|VANZA,497574828|WP_009889012.1|NG_061614|1|1|vanZ1|vanZ1|glycopeptide_resistance_protein_VanZ1 NG_061614:101-610,5
,gtggaactgaacggtgagaaagtgctgctgcggcccgtgctcgacagcgatgtgaagaagctcgacaagatcgtcagagaacccgaggtggccgcttggtggtcgacccccgatgactacgaggagatgctcgccatcaccctcgacggcgaggtcatcggggcagtgcagtacgaggaggaggaagaccccgagttccgccacgcgggcatcgacatcttcctcacggcgagtcggcacggcctcggcctcggcacggacaccgtccgcaccgtggcacgttggctgatcgacgagcggggacaccaccggatcaccatcgacccggcggtggcgaacgcgggcgcgatccgcagctacagcaaggtgggcttcaagccggtcggcgtcatgcggtcatacgcccgtgaccacacgagcggcgtgtggcaggacgccctgctgatggacctgctggccgaagagctggtctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_264,Drugs,MEG_264|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,943909695|WP_055545096.1|NG_052084|1|1|aac(6')-sk|aac(6')-sk|aminoglycoside_6'-N-acetyltransferase NG_052084:101-574,2
,TTGTCCGAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGATTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGATGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAACTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATTATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4321,Drugs,MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_6_KT862784 ,1
,atgatgaaaaaatccctttgctgcgccctgctgctcggcatctcttgctctgctctcgccacgccagtgtcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaaccgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccgccgttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagcatcggtctttttggtgcgctggcggtcaaaccttctggcatgccctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgtgccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggtatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaacgttgctgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcgagggcagcgacagtaaggtagcactggcgccgttgcccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggctctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaatacaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgaggcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_425,Drugs,MEG_425|Drugs|betalactams|Class_C_betalactamases|ACT,779797391|WP_045328874.1|NG_050703|1|1|blaACT-40|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-40 NG_050703:1-1146,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagtttcccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5478,Drugs,MEG_5478|Drugs|betalactams|Class_C_betalactamases|PDC,1001044756|WP_061190338.1|NG_056104|1|1|blaPDC-226|blaPDC|class_C_beta-lactamase_PDC-226 NG_056104:1-1194,0
,atgataatcagtgaatttgaccgtaataatccagtattgaaagatcagctttctgatttactgagactgacttggccggaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacgaatcgcggtagcagcggtagaccaagatgagttagtaggatttattggtgcaatccctcaatacggtatcacaggttgggaattgcatccattagttgtagaaagctcccgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagaggaggaatcacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaaacggacctgtatgagcatacatatgataaagtggcttccatccagaaccttcgtgaacatccgtatgaattctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaaatggctgggacaaaccggatatttggatggcaaaaacgattattcctcgaccagattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_143,Drugs,MEG_143|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,498419823|WP_010727362.1|NG_052159|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052159:101-649,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacctacctcgacgtgcccgaggcggcgctggcgcagtgcgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5675,Drugs,MEG_5675|Drugs|betalactams|Class_C_betalactamases|PDC,1408841613|WP_111672886.1|NG_060541|1|1|blaPDC-296|blaPDC|class_C_beta-lactamase_PDC-296 NG_060541:1-1194,0
,atgatgatgactaaatccctttgctgcgccctgctgctcagcacctcctgctcggtattggctatcccgatgtcagaaaaacagctggctgaggtggtggaacggaccgttacgccgctgatgaaagcgcaggccattccgggtatggcggtggcggtgatttatgagggtcagccgcactacttcaccttcggtaaagccgatgttgcggcgaacaaacctgtcactccacaaaccttgttcgaactgggttctataagtaaaaccttcaccggcgtactcggtggcgatgccattgttcgcggtgaaatatcgctgggcgatccggtgacaaaatactggcctgagctaacaggcaagcagtggcaggggatccgcatgctggatctggcaacctataccgcaggaggtttgccgttacaggtaccggatgaggtcacggataacgcctctctgttgcgcttttatcaaaactggcagccgcagtggaagccgggcaccacgcgtctttacgccaatgccagcatcggtctttttggcgcgctggcggtcaaaccttccggcatgagctatgagcaggccataacgacgcgggtctttaagccgctcaagctggaccatacgtggattaacgttccgaaagcggaagaggcgcattacgcctggggataccgcgacggtaaagcggtacacgtttcgccaggaatgctggacgctgaagcctatggcgtaaaaaccaacgtgcaggatatggcaagctgggtgatggtcaacatgaagccggactcccttcaggataattcactcaggaaaggccttaccctggcgcagtctcgctactggcgcgtgggggccatgtatcaggggttaggctgggaaatgcttaactggccggtcgatgccaaaaccgtggttgaaggtagcgacaataaggtggcactggcaccgctgcctgcgagagaagtgaaaccaccggtgcccccggtcaacgcatcctgggtccataaaacaggctctaccggcgggtttggcagctacgtggcatttattcctgaaaagcagctcggtattgtgatgctggcaaataaaagctatccgaacccggcacgcgttgaggcggcataccgtattttgagcgcgctgtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_444,Drugs,MEG_444|Drugs|betalactams|Class_C_betalactamases|ACT,1028101940|WP_063857778.1|NG_048621|1|1|blaACT-34|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-34 NG_048621:1-1146,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatgcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagtacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3480,Drugs,MEG_3480|Drugs|betalactams|Class_A_betalactamases|KPC,1114603965|WP_072081992.1|NG_052581|1|1|blaKPC-28|blaKPC|inhibitor-resistant_class_A_extended-spectrum_beta-lactamase_KPC-28 NG_052581:1-876,0
,atgcaacgccgtcattttttacaaaaaaccttattggcactacctattattttttctggcaatttattaactggatgtaaaacgaatttgtctgatgattatttgcccgatgacaagataacaaacaatccaaatttattacaaaataaattaaaagagatattgccaatttgggaaaataaatttaatgccaaaattggtatgacgattattgctgacaatggtgaactatccagtcatcgtggtaatgaatattttcctgttaatagtaccattaaagcctttattgcaagtcatatattattacttgtagataaagaaaaattggatttaaacgaaaaaatcatcattaaagaaagcgatttgatagaatattctcctgtctgtaaaaaatactttgatgagaataaaccaatttctattagtgaattgtgcgaagctaccataacactgagtgataatggttctgctaatatcttgttggataaaattgggggtttgactgcattcaatcaatttttgaaagagattggggcggatatggtgctggcaaataatgaacctttattaaatcgctcacattatggtgaaaccagtgataccgcaaaaccaattccttacacaaaaagcctaaaagcactgattgtaggcaatatcctatccaatcaaagcaaagaacagttgataacttggcttatcaacgataaagttgctgataatttattgagaaaatatttaccaaaaaattggcgaattggcgacaaaacaggcacaggtagtgaatcaaaaaatatcattgctgtgatttggaatgaaaataataaaccttattttatcagcctatttatcacccagccccatgatggtaaatcccttggttttaaaaatcaaaaagatgaaataatggcacaaattggtaaagaaatttatccatttttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1474,Drugs,MEG_1474|Drugs|betalactams|Class_A_betalactamases|BRO,489761603|WP_003665544.1|NG_054940|1|1|blaBRO-2|blaBRO|class_A_beta-lactamase_BRO-2 NG_054940:101-1042,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAATTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1892,Drugs,MEG_1892|Drugs|betalactams|Class_C_betalactamases|CMY,gb|HQ285243|+|0-1146|ARO:3002068|CMY-57 [Escherichia coli] ,0
,ttgaaaaagttaatatttttaattgcaattgctttagttttaagtgcatgtaattcaaacagttcacatgccaaagagttaaatgatttagaaaaaaaatataatgctcatattggtgtttatgctttaaatactaaaagtggtaaggaagtaaaatttaattcagataagagatttgcctatgcttcgacttcaaaagcgataaatagtgctattttgttagaacaagtaccttataataagttaaataaaaaagtacatattaacaaagatgatatagttgcttattctcctattttagaaaaatatgtaggaaaagatatcactttaaaagaacttattgaggcttcaatgacatatagtgataatacagcaaacaataaaattataaaagaaatcggtggaatcaaaaaagttaaacaacgtctaaaagaactaggagataaagtaacaaatccagttagatatgagatagaattaaattactattcaccaaagagcaaaaaagatacttcaacgcctgctgctttcggcaagactttaaataaacttatcgcaaatggaaaattaagcaaaaaaaataaaaatttcttacttgatttaatgtttaataataaaaacggagacactttaattaaagatggtgttccaaaagactataaggttgctgataaaagtggtcaagcaataacatatgcttctagaaatgatgttgcttttgtttatcctaagggccaatctgaacctattgttttagtcatttttacgaataaagacaataaaagtgataagccaaatgataagttgataagtgaaaccgccaagagtgtaatgaaggaattttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1320,Drugs,MEG_1320|Drugs|betalactams|Class_A_betalactamases|BLAZ,446655929|WP_000733275.1|NG_055994|1|1|blaZ|blaZ|penicillin-hydrolyzing_class_A_beta-lactamase_BlaZ NG_055994:101-946,0
,TCTTTACTCGCCTTTATCGGCCCTCACTCAAGGATGTATTGTGGTTATGCGTTATTTTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCAGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGACGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGGATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCTCGTAGCACCTCGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAAAGATGCCGGTCGGTAAAAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6428,Drugs,MEG_6428|Drugs|betalactams|Class_A_betalactamases|SHV,gi|206813968|gb|FJ194944.1|1-1007,0
,atgcgcgataccagatttccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccacctcggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5704,Drugs,MEG_5704|Drugs|betalactams|Class_C_betalactamases|PDC,896243332|WP_049239252.1|NG_055488|1|1|blaPDC-124|blaPDC|class_C_beta-lactamase_PDC-124 NG_055488:1-1194,0
,ATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6946,Drugs,MEG_6946|Drugs|betalactams|Class_A_betalactamases|TEM,gi|765365306|dbj|AB751206.1|1-861 gi|391883318|gb|JQ269336.1|17026-17886 gi|330687083|gb|JF776874.1|17026-17886 gi|2612977|gb|AF027199.1|AF027199|215-1075,0
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagttaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgatgaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgcgcgggaggaacagcagcgggttcaagacgcctccctgttcccagtctatcatggcagcgccaaaaatggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggggcgccgccctatgcggcagcgttttcaaggttgagtacaccgattgcggccagcggcgtgtctatctacggttatacagcggaacgctgcgcctgcgggatacggtggccctgggcgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatcagggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggaccaaacccggctccctcgtaaaaggtggcgcgaggaccccctccccatgctgcggacgacgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgttgcgaagtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaaccctccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccataggactgtctgttacaccactctcgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcggggacgcagctgctggaaccttatctctccttcatcctctatgcgccccaggaatacctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggcccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcggagcgtatgccttacagagctgaaaggatatcaggccgctgtcggtcagccggtcatccagccccgccgtccaaacagccgcctggacaaggtgcgccatatgtttcagaaggtaatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7222,Drugs,MEG_7222|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100289|WP_063856424.1|NG_048298|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048298:101-2020,4
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaagcagtatcattaatcactagtgccatcctgcaaatggcgattattttttaccttacagaaaaaactggatctgcgatggtcttgtctttggcttcactagtaggttttttaccctatgcggtctttggacctgcaattggtgtgctagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctagttcagtgcttactattgttgcactctatatggagctacctgtctggatggttatgatagtattgtttatccgtagcattggaacagcttttcataacccagcactcaattcggttacaccacttttagtaccagaagagcagctaacgaaatgcgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcacttgcagcactcttatactccgtttgggatttaaatgctattattgccatcgacgtattgggtgctgtgattgcatctattacggtagcaattgtacgtatacctaagctgggtaatccagtgcaaagtttggaaccaaatttcataagagagatgagagaaggaattgtggttctgagacaaaacaaaggattgtttgccttattactcttaggaacactatatacttttgtttatatgcctatcaatgcactgtttcctttgataagcatggaacactttaatggaacacctgtgcatatttctattacggaaatttcctttgcatttggaatgctagcaggaggcttattgttaggaagattagggagcttcgaaaagcgtgtattactaataactagttcattttttataatgggagccagtttagccgtttcgggaatacttcctccaaatggatttgtaatatttgtagtttgctgtgcaataatggggctttcggtgccattttatagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttgaccggaagtatcatgtcacttgctatgccaattgggttaattctttctggattctttgctgaaagaatcggtgtaaatgattggtttttactatcaggtgttttaattattggcattgccatagcttgccccatgataactgaggttagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3808,Drugs,MEG_3808|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028096862|WP_063853574.1|NG_047962|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047962:1-1218,7
,atgatcatcagtgaatttgatcgtagaaatatcggtttgaaggatcagctagctgaccttttgcgattgacttggccgaaggattacggtgaacaaccaatgaaagaagtcgagcaactgctggcgatggatcgaatcgctgtctcagcggtggaacaagatcgtttggttggttttatcggtgcgattccgcagtatggaatgactggttgggaaattcaccctctagtagtagaaacttcttatcgaaagcagtatatcggtagccgcttagttgcttatgtggagaaagaaatcgcttctaaaggtggtgtgatggtttatttaggaacagatgatacggatggggacacgagtcttagtcatacggatctttttgatcatccgttagataaactgaaatcaatcgaaactttcaacaagcatccttatacattttatgaaaaaatgggctatcaagtcgttggagcgattcctgatgcaaatgggctcaatcaaccagatatcattctggcaaaacgacttggagaaataaatcaatga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_91,Drugs,MEG_91|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,558689798|WP_023519215.1|NG_052446|1|1|aacA-ENT4|aacA-ENT4|aminoglycoside_6'-N-acetyltransferase NG_052446:101-643,2
,TATCGCGTGTCTTTCGAGTACGGCATTAGCTGGTTCAATTACAGAAAATACGTCTTGGAACAAAGAGTTCTCTGCCGAAGCCGTCAATGGTGTCTTCGTGCTTTGTAAAAGTAGCAGTAAATCCTGCGCTACCAATGACTTAGCTCGTGCATCAAAGGAATATCTTCCAGCATCAACATTTAAGATCCCCAGCGCAATTATCGGCCTAGAAACTGGTGTCATAAAGAATGAGCATCAGGTTTTCAAATGGGACGGAAAGCCAAGAGCCATGAAGCAATGGGAAAGAGACTTGACCTTAAGAGGGGCAATACAAGTTTCAGCTGTTCCCGTATTTCAACAAATCGCCAGAGAAGTTGGCGAAGTAAGAATGCAGAAATACCTTAAAAAATTTTCCTATGGCAACCAGAATATCAGTGGTGGCATTGACAAATTCTGGTTGGAAGGCCAGCTTAGAATTTCCGCAGTTAATCAAGTGGAGTTTCTAGAGTCTCTATATTTAAATAAATTGTCAGCATCTAAAGAAAACCAGCTAATAGTAAAAGAGGCTTTGGTAACGGAGGCGGCACCTGAATATCTAGTGCATTCAAAAACTGGTTTTTCTGGTGTGGGAACTGAGTCAAATCCTGGTGTCGCATGGTGGGTTGGGTGGGTTGAGAAGGAGACAGAGGTTTACTTTTTCGCCTTTAACATGGATATAGACAACGAAAGTAAGTTGCCGCTAAGAAAATCCATTCCCACCAAAATCATGGAAAGTGAGGGCATCATTGGTGGCTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4765,Drugs,MEG_4765|Drugs|betalactams|Class_D_betalactamases|OXA,gb|AF060206|+|0-774|ARO:3001412|OXA-17 [Pseudomonas aeruginosa] ,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactatgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4479,Drugs,MEG_4479|Drugs|betalactams|Class_D_betalactamases|OXA,1509794604|WP_122630913.1|NG_062333|1|1|blaOXA-721|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-721 NG_062333:12-836,0
,atgcgcgataccagatttccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgcttgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgacgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5700,Drugs,MEG_5700|Drugs|betalactams|Class_C_betalactamases|PDC,1034011119|WP_064484004.1|NG_050795|1|1|blaPDC-139|blaPDC|class_C_beta-lactamase_PDC-139 NG_050795:1-1194,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCATTCTCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTCTCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTTGCCAGAACTGACAGGCAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACAGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTACTCCTGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAACGTTACCGATATGGCCCGTTGGATTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGTGACAGCAAAGTGGCATTGGCAGCGCTTCCCACCGTTGAGGTAAACCCGCCCGCCCCGGCAGTGAAAGCCTCATGGGTGCATAAAACGGGTTCCACTGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTACAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1883,Drugs,MEG_1883|Drugs|betalactams|Class_C_betalactamases|CMY,gb|GQ351345|+|0-1146|ARO:3002086|CMY-73 [Citrobacter freundii] ,0
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgcctttatagtggcgtactgcatttgcgagatccggttagaatatcggaaaaggaaaaaataaaagttacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattctggagaaattgttattttgcaaaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtctatctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7125,Drugs,MEG_7125|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028099858|WP_063856112.1|NG_048219|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048219:101-2020,4
,GAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAAACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6922,Drugs,MEG_6922|Drugs|betalactams|Class_A_betalactamases|TEM,gi|48527203|gb|AY628199.1|1-1064,0
,atgatcgtcaactgcgaccacgacaaccttgatgcctggctggcgctgcgctcggcgctgtggcccacctgcccgcgggaagaacaccgcgcagaaatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattatgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccatcgaacgcgcccgccgccagggctgggcggcgcgcctgatcgcgcaggtgcaggagtgggccaagcagcaggggtgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgcagaaacggaacgggtggtgttttaccgaaaaacgcttggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_148,Drugs,MEG_148|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,727189478|WP_033651281.1|NG_052178|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052178:101-541,2
,GGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTACTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGTCCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6483,Drugs,MEG_6483|Drugs|betalactams|Class_A_betalactamases|SHV,gi|74422850|gb|DQ174304.1|1-865,0
,atgtccgccacgctccacgacaccgcagcggatcgtcggaaggccacccgccgcgaatggatcggcctggccgtggtcgccctgccgtgcctggtctacgccatggacctcacggtgctgaacctggcgctgccggtgctcagccgtgaactgcagccctccagcgcccagcttctctggatcctggacatctacggcttcttcgtcgccggcttcctgatcaccatgggcacgctgggcgaccgcatcggccggcgccggctgttgttgatcggcgcggcgttcttcgcattcgcctcggtgctcgcggcgctggccgataccgccgcgctgttgatcgcggcgcgcgccttgctcggcctggccggcgccaccatcgcgccgtccaccatggcgctggtccgcaacatgttccacgacccgcgccagcgccagttcgccatcggcgtgtggatcgccgcgttttcgctgggcagcgcgatcggtccgctggtcggcggcgtgttgctggagttcttccactggggcgccgtgttctggctcaacgtgccggtgatgctgctgacgctggcgctcggccctcgcttcctgcccgagtatcgtgatccggacgcggggcacctggacctggccagcgtgctgctgtcgctggcggcggtgctgctgacgatctacgggctcaagcagttggccgagcatggagcgggcctcgcctcgatggctgcgctgctggccgggctggcggtcggggcgctgttcctgcgccgccagggccacatcgcctacccgctgctggacctgcggctgttcgcgcacgcgccgttccgcgcggcgctggcggcgtatgcgctggccgcgctggccatgttcggcgtctacatcttcatgacgcagtacctgcagctcgtgctggggctgtcgccgctgcaggccgggctggccacgctgccctggtccctgtgcttcgtcatcggttcgctgttgtcgccgcagctcgcggcgcgctggccggcggcgcgcatcctcgtcgtgggcctgtcggcagcggcgttcggcttcgccgtgctggggctggggcagggcctgtggtggctggtgccggccacgatcgtcatgggcctgggcctggcgccggtgttcaccatcggcaacgagatcatcatcaccagcgcgccgtccgagcgcgcgggcgcggcctcggccttgtcggagacggtgtccgaattcagcggcgcgctgggcatcgcgctgttcggcagcgtcggcctggtggtctaccggcaggcgctgaccggcctgccggccgatgcgctgcaggcggccggtgcctcgctcgggggcgccgtgcacctggccgacaccctgccggcgtggcagggcgcggccttgctggcggccgcacgcgcgggcttcaccgatgcgctgcaggccacggcctgggccggcgcggtgctggtgctggtggccgctgggctggtggcgcgcctgctgcgcaagcgcccagcgctcgcatctggttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Fluoroquinolones,MEG_5862,Drugs,MEG_5862|Drugs|Fluoroquinolones|Quinolone_active_efflux|QEPA,1426566883|WP_113334341.1|NG_062254|1|1|qepA10|qepA|fluoroquinolone_efflux_MFS_transporter_QepA10 NG_062254:101-1621,3
,TTGCAGAGTTGCTTGAAAGTTGTTACGATTCAAATTCAATCATGAGATAGTCAGCAGATGAGCACTTCCAAGAACGCAGACAAGTAAGCCGCAGCAACCTTCATTTTTCGGTTGTTGCGGCGTTCTCATGAATCCTTTTGCTCTACGGGAGCGCCGCCAAATCCTTTGTTCAAGGAGATGGTTTCGTGAGCTCAAAAAACTTTAGTTGGCGGTACTCCCTTGCCGCCACGGTGTTGTTGTTATCACCGTTCGATTTATTGGCATCACTCGGCATGGACATGTACTTGCCAGCAGTGCCGTTTATGCCAAACGCGCTTGGTACGACAGCGAGCACAATTCAGCTTACGCTGACAACGTACTTGGTCATGATTGGTGCCGGTCAGCTCTTGTTTGGACCGCTATCGGACCGACTGGGGCGCCGCCCCGTTCTACTGGGAGGTGGCCTCGCCTACGTTGTGGCGTCAATGGGCCTCGCTCTTACGTCATCGGCTGAAGTCTTTCTGGGGCTTCGGATTCTTCAGGCTTGTGGTGCCTCGGCGTGCCTTGTTTCCACATTTGCAACAGTACGTGACATTTACGCAGGTCGCGAGGAAAGTAATGTCATTTACGGCATACTCGGATCCATGCTGGCCATGGTCCCGGCGGTAGGCCCATTGCTCGGAGCGCTCGTCGACATGTGGCTTGGGTGGCGGGCTATCTTTGCGTTTCTAGGTTTGGGCATGATCGCTGCATCTGCAGCAGCGTGGCGATTCTGGCCTGAAACCCGGGTGCAACGAGTTGCGGGCTTGCAATGGTCGCAGCTGCTACTCCCCGTTAAGTGCCTGAACTTCTGGTTGTACACGTTGTGTTACGCCGCTGGAATGGGTAGCTTCTTCGTCTTTTTCTCCATTGCGCCCGGACTAATGATGGGCAGGCAAGGTGTGTCTCAGCTTGGCTTCAGCCTGCTGTTCGCCACAGTGGCAATTGCCATGGTGTTTACGGCTCGTTTTATGGGGCGTGTGATACCCAAGTGGGGCAGCCCAAGTGTCTTGCGAATGGGAATGGGATGCCTGATAGCTGGAGCAGTATTGCTTGCCATCACCGAAATATGGGCTTTGCAGTCCGTGTTAGGCTTTATTGCTCCAATGTGGCTAGTGGGTATTGGTGTCGCCACAGCGGTATCTGTGGCGCCCAATGGCGCTCTTCGAGGATTCGACCATGTTGCTGGAACGGTCACGGCAGTCTACTTCTGCTTGGGCGGTGTACTGCTAGGAAGCATCGGAACGTTGATCATTTCGCTGTTGCCGCGCAACACGGCTTGGCCGGTTGTCGTGTACTGTTTGACCCTTGCAACAGTCGTGCTCGGTCTGTCTTGTGTTTCCCGAGTGAAGGGCTCTCGCGGCCAGGGGGAGCATGATGTGGTCGCGCTACAAAGTGCGGAAAGTACATCAAATCCCAATCGTTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1771,Drugs,MEG_1771|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,gi|937637492|gb|KT334335.1|95895-94451 gi|917657445|gb|KR827684.1|43816-45260 gi|909636816|emb|LN850165.1|97737-99181 gi|909636430|emb|LN850162.1|2424-3868 gi|828971497|gb|CP011644.1|28053-29497 gi|754341646|gb|CP010575.1|10635-12079 gi|743008998|gb|CP010362.1|64155-62711 gi|742999823|gb|CP010396.1|6628-5184 gi|660582341|gb|CP008800.1|54959-56403 gi|587656709|gb|KF921569.1|3087-4531,6
,atgaaaaaatcgttatctgcaacactgatttccgccctgctggcgttttccgccccggggttttctgccgctgataatgtcgcggctgtggtggacagcaccattaaaccgctgatggcacagcaggacattcccgggatggcggttgccgtctctgtaaagggcaagccctattatttcaattacggttttgccgatgttcaggcaaaacaaccggtcactgaaaatacactatttgagctcggatctgtaagtaaaactttcacaggtgtgctgggtgcggtttctgtggcgaaaaaagagatggcgctgaatgatccggcggcaaaataccagccggagctggctctgccgcagtggaaggggatcacattgctggatctggctacctataccgcaggcggactgccgttacaggtgccggatgcggtaaaaagccgtgcggatctgctgaatttctatcagcagtggcagccgtcccggaaaccgggcgatatgcgtctgtatgcaaacagcagtatcggcctgtttggtgctctgaccgccaacgcggcggggatgccgtatgagcagttgctgaccgcgcggatcctggcaccgctgggattatctcacacctttattaccgtgccggaaagcgcgcaaagtcagtatgcgtacggttataaaaacaaaaaaccggtccgcgtgtcaccgggacagcttgatgcggaatcttacggtgtgaaatccgcctcaaaagatatgctgcgctgggcggaaatgaatatggagccgtcacgggccggtaatgcggatctggaaatggcaatgtatctcgcccagacccgttactataaaaccgccgcgattaatcaggggctgggctgggaaatgtatgactggccgcagcagaaagatatgatcattaacggcgtgaccaacgaggtcgcattgcagccgcacccggtaacagacaaccaggttcagccgtataaccgtgcttcctgggtgcataaaacgggggcaacaacgggtttcggcgcctatgtggcctttattccggaaaaacaggtagcgattgtgattctggcgaataaaaactacccgaataccgaaagagtcaaagccgcacaggctattttgagtgcactggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2591,Drugs,MEG_2591|Drugs|betalactams|Class_C_betalactamases|DHA,692181423|WP_032097955.1|NG_049072|1|1|blaDHA-4|blaDHA|class_C_beta-lactamase_DHA-4 NG_049072:101-1240,0
,ATGAGGGAAGCGGTGATCGCCGAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCACACAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAGAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCGCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_963,Drugs,MEG_963|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|944374642|gb|KT692980.1|679-1470 gi|941350200|gb|KT345946.1|27861-28652 gi|939537623|gb|KR610435.1|635-1426 gi|930190865|emb|LN555650.1|260489-259698 gi|930189590|emb|HG530658.1|196197-195406 gi|925216761|gb|KR028103.1|642-1433 gi|825088700|gb|KP975077.1|104895-104104 gi|821392896|gb|KP873171.1|18696-17905 gi|768032361|gb|KM975294.1|2539-3330 gi|752292861|emb|LN794247.1|62181-61390,2
,atgttttttaatcagaaatatttttttcaagcaagcttcattacgatggttatcggttttggtatgaatttaaatgcaagtgaagtcagtcaaaatgagcaaaatattgaaaaagttgttacccaatcatttaagccacttatggatgagtatggtgtagctggtatggctataggcgtaatttacaacggtaaaagttatgaaaaatattatggtgtccgatctaaagatacaaatgaaagcgtaaatagtcagacactttttgagttaggttctttaagtaaaacttttactgctatttcaggaacatatgccaataatcaaggtaaaatatcgttcaacgatcatcctagtaaatacgtccctgctttaaaaaattcagaaattgataaggtaaatttattagagttattaacttatacaagtggcaatttaccattacaattcccagataatatcaaaactgataagcaaatattagagtatttcaaaaattggaaagtaaagaatcctcctggtacttatcgtgaatactcaaatccaagtataggactttttgggtatctaactgcaaaatcgatgaatgttcctttctcttcattattagagaagactgtttttcctcaacttaatttgaaacatacatacgtcaatgttccagaagcacaaaaaacgaactatgcttttggttatgatgaaaataataagccaattcgagttaatcctggtccattgtcggatgaagcatatggcgttaaatcaacactcccagatatgcttaagtttgtaaattcgaatcttaatgtagatacaaatagccctgctatgaaaaaagctatactggatacacacaaaggatattttaaagtttctgatagcggtatgacacaagcacttggatgggaaatgttttcttatcccactacttctgaaattctacaggctagtaattcaaaacaaatcttattgggctcaaatcctgttgtaaaagaattatcgcaaccaaaatctaaagtttttcataaaacaggttcgactaatggctttggggcgtatgttttatttattccagaagaaggatttggattggttatgttaatgaataaaaagataccaaatgtagatcgtattaaggctgcatataatgtttttgagacattgaaagataattaa,rRNA with mutation conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_3664,Drugs,MEG_3664|Drugs|betalactams|Class_C_betalactamases|MCA,953339420|WP_057991970.1|NG_055474|1|1|blaMCA|blaMCA|class_C_beta-lactamase NG_055474:101-1273,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacatcttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgagtcgccggaccgttgatccgctccgtgctgccggcggactggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcatcgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6225,Drugs,MEG_6225|Drugs|betalactams|Class_A_betalactamases|SHV,1509794556|WP_122630865.1|NG_062280|1|1|blaSHV-208|blaSHV|class_A_beta-lactamase_SHV-208 NG_062280:1-861,0
,ATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGTCGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6889,Drugs,MEG_6889|Drugs|betalactams|Class_A_betalactamases|TEM,gi|21541782|gb|AF516719.1|1-1080 gi|961666360|gb|KT185451.1|87740-87690,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggctcggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagtacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3482,Drugs,MEG_3482|Drugs|betalactams|Class_A_betalactamases|KPC,1444647619|WP_115470049.1|NG_064726|1|1|blaKPC-40|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-40 NG_064726:101-988,0
,atgtcacttaatgtaaaaccaagtagaatagccatcttgtttagctcttgtttagtttcaatatcatttttctcacaggccaatacaaagggcatcgatgagattaaagaccttgaaacagatttcaatggtagaattggtgtctacgctttagacactggctcaggcaaatcattttcatacaaagcaaatgaacgatttccattatgtagttctttcaaaggttttttagctgctgctgtattaaaaggctctcaagataatcaactaaatcttaatcagatcgtgaattataatacaagaagtttagagttccattcacccatcacaactaaatataaagataatggaatgtcattaggtgatatggctgctgcagctttacaatatagcgacaatggtgctactaatattatccttgaacgatatatcggtggtcctgagggtatgactaaattcatgcggtcgattggagataaagattttagactcgatcgttgggagttagatctaaacacagctattcctggcgatgaacgtgacacatctacacctgcagcagtagctaagagcctgaaaacccttgcactgggtaacatactcaatgagcgtgaaaaggaaacctatcagacatggttaaagggtaacacaaccggtgcagcgcgtattcgtgctagcgtaccaagcgattgggtagttggcgataaaactggtagttgcggtgcatacggtacggcaaatgattatgcggtagtctggccaaagaaccgagctcctcttataatttctgtatacactacaaaaaacgaaaaagaagccatgcatgaggataaagtaatcgcagaagcttcaagaatcgcaattgataaccttaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3298,Drugs,MEG_3298|Drugs|betalactams|Class_A_betalactamases|IMI,1142971251|WP_077064887.1|NG_052863|1|1|blaIMI-14|blaIMI|carbapenem-hydrolyzing_class_A_beta-lactamase_IMI-14 NG_052863:1-879,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaaggatgacaagtacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3470,Drugs,MEG_3470|Drugs|betalactams|Class_A_betalactamases|KPC,1252412296|WP_096807439.1|NG_055580|1|1|blaKPC-29|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-29 NG_055580:1-891,0
,atgaaaaaaatttatattagtgttctagttcttttactaactattattataataacttggttattcagagatgacgatattgagaaaacaattaatgctattgaaaagggagactataacaaaatatataaaaatagttcagaaacatctaaacttgcatttggagaagaagaaattatagataggaataaaaaaattcacaaagatttaggtgtcaataacttaaaaattactaatcataaaactaaaaaaactggaaaagataaaaagcaagttgacgttaaatataacatgtatacaaaatatggaactatacgccgtaattcacaattaaactttatttatgaagataagcattggaaattagattgggaccagggagtaataatacctggattgaaaaatagacaaaaaattaatatagaaacattaaaatcagaacgaggcaaaataatagatagaaatggtatagaattagctaaaactggaaatgcatacgaaatcggtattgttcctaataaaacacccgaaaataaatatagcgatattgctcgtgacttacaaattgatacaacagctataaccaataaagttaatcaaaaatgggtacagccagattcatttgtaccaattaaaaaggtaaataaaaaagacgaatctatagacaaattaattaaatcatacaatttacaaataaatactataaaaagccgtgtttatccgttgaataaagcaacagcacatcttttaggttatgtaggtcccattaattccgaagagttacaaagtaaacaatttaaaaactatagcaaaaatactgttattggaaaaaagggcttagaacgcctctatgataaacaattgcaaaatactgatggttttagagtatccattgcaaatacttacgaaaataaacctttagacacattattagagaaaaaagctaagaacggcaaagatctttacttaactatagatacaagagtacaagaaagtatttataaaaatatgaaaaatgactatgggtccggtacagcattacaaccgaaaactggagaaattttagctttggtaagtaccccatcgtatgatatttacccattcatgaatggaataagcaatcatgattaccataaattaagtaacaataaaaaagagccttttctcaacaaatttcaaatcactacatcaccaggttcaactcaaaaaatattaacatctattatagctttaaaagaaaataaactaaacaacaatactaattttgatatttatggtaaaggttggcaaaaagatgaatcatggggagattataatataacaagatttaaagtagtagacggtaagatagatttaaagcaagcaatagaatcatcagataacatattttttgcacgtattgcattagctttaggagctaaaaaatttgagaaaggtatgaaagatttaggagttggtgaaaatatcccgagtgattaccccttttataaagcacaaatttcaaatagtaatttaaataatgacatattgctagcagattcaggatatggccaaggtgagatactagtaaatcctatacaaattttgtcaatctacagtgctttagaaaataacggaaatatacaaaaccctcatgttttacgtgaaacaaagtctcaaatttggaaaaagtctattatatctaaaaaagacataggtatattaactaatggtatggaacgcgtagtgactaaaacacatagagatgatatttacaaaaactatgcccgaattataggtaaatctggaacagcagaattaaaaatgaaaaaaggtgaaaccggaagacaaataggttggtttgtttcatatgataaaaataatcccaatatgctaatggcgattaatattaaagacgttcaaaataaagggatggccagctataatgctgcgatatctggaaaagtttatgatgatttatatgatcacggaaatactaaatttgacatagataagtaa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3798,Drugs,MEG_3798|Drugs|betalactams|Penicillin_binding_protein|MECC,1073565725|WP_069996660.1|NG_063822|1|1|mecC3|mecC3|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC3 NG_063822:101-2098,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATTCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACAATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCGCAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6693,Drugs,MEG_6693|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-21:AF466526:1346-2206:861,0
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcaacggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_842,Drugs,MEG_842|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502121|WP_071846273.1|NG_052316|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052316:64-855,2
,atgttcaaacttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgatagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7713,Drugs,MEG_7713|Drugs|betalactams|Class_B_betalactamases|VIM,1028110983|WP_063865195.1|NG_050373|1|1|blaVIM-45|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-45 NG_050373:1-801,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATACCCAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACATCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1377,Drugs,MEG_1377|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_114_NC_013379,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgctcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggttcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaagcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5434,Drugs,MEG_5434|Drugs|betalactams|Class_C_betalactamases|PDC,685986033|WP_031692400.1|NG_055479|1|1|blaPDC-115|blaPDC|class_C_beta-lactamase_PDC-115 NG_055479:1-1194,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1420,Drugs,MEG_1420|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_59_NZ_JVBT01000063,0
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgcttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatgctggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcaccttcttcctcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2916,Drugs,MEG_2916|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,1028086663|WP_063845037.1|NG_047864|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047864:101-1315,6
,ATGTCGAATACCTATGACTCCTCAAGTATCAAAGTATTAAAAGGGCTGGACGCGGTGCGTAAACGCCCGGGAATGTACATTGGTGATACCGATGACGGAACCGGTTTACACCACATGGTCTTCGAGGTTGTTGACAACGCTATCGACGAAGCCCTCGCCGGTTACTGTAAAGACATCATTGTGACCATTCACAATGATAATTCAGTCTCCGTACAGGATGACGGTCGCGGTATCCCGACCGGGATCCATGAAGAAGAAGGCGTCTCCGCCGCAGAAGTTATCATGACTGTTCTGCACGCCGGCGGGAAGTTCGATGATAACTCCTATAAAGTCTCAGGCGGCCTGCACGGCGTCGGGGTCTCTGTTGTTAACGCCCTGTCTGAAAAACTGGAACTGGTTATCCGCCGTGACGGCAAAGTTCACGAGCAGATTTACCGCCACGGTGAACCGCAGGATCGCCTGACTGTTGTCGGCGAAACCGATAAAACCGGGACACGCGTGCGTTTCTGGCCGAGCATGGACACCTTCAAAGGCGAGACTGAATTCCAGTACGACATTCTGGCAAAACGCCTGCGCGAACTCTCCTTCCTGAACTCCGGTGTATCGATCCGTCTGATCGATAAACGCGACGGCAAAGAAGATCACTTTCACTACGAAGGCGGTATCAAAGCATTCGTGGAATATTTAAGCCGCGCCAAAACTTCGATTCATAACAACGTTTTCTATTTCTCCACTGAGAAAGACGATATCGGCGTGGAAATCTCCATGCAGTGGAATGACTCCTTCCAGGAAAACGTATACTGCTTCACCAACAACATTCCGCAGCGCGACGGTGGTGCTCACCTCGCCGGTTTCCGCGCCGCCATGACCCGTACCCTCAACAGCTATATTGAGAAAGAAGGGCTGAATAAAAAATCCAAAGTCAGCACCACCGGGGACGATGCCCGTGAAGGACTGGTGGCGGTCATTTCCGTCAAAGTGCCGGATCCGAAATTCTCCTCCCAGACTAAAGACAAGCTGGTCTCTTCCGAAGTGAAAACGGCGGTTGAAACCCTGATGAACGAAAAGCTGTCTGAATATCTGGATGAAAACCCGAACGACACCAAAATCATTGTCGGCAAAATTATTGATGCCGCACGCGCCCGTGAAGCTGCACGCCGTGCCCGTGAAATGACCCGCCGTAAAGGCGCGCTGGATTTAGCCGGTCTGCCGGGTAAACTGGCGGATTGTCAGGAACGCGACCCGGCCTTCTCCGAACTGTACTTAGTGGAAGGGGACTCTGCGGGCGGCTCTGCAAAACAGGGGCGTAACCGTAAGAACCAGGCTATCCTGCCGCTGAAAGGTAAAATCCTGAACGTTGAGAAGGCGCGTTTTGATAAAATGCTGGCTTCTCAGGAAGTTGCCACCCTGATCACCGCACTCGGCTGCGGTATCGGCCGCGACGAATACAACCCGGACAAACTGCGCTATCACAGCATCATCATCATGACCGATGCCGACGTCGATGGTTCACACATCCGTACCCTGTTACTGACTTTCTTCTACCGTCAGATGCCGGAAATCATTGAGCGCGGTTATGTGTATATCGCACAGCCGCCGCTGTATAAAGTGAAAAAAGGCAAGCAGGAACAGTATATTAAAGATGACGAAGCGATGGAGCAGTATCAGGTCTCTATCGCACTGGATGGCGCGGCACTGTATGTAAACGAAAATGCAGCTCCGATTCAGGGCGAACATCTGGAAAAACTGCTGCACGAATACAACGGCGCACACAAAATTATCCGCCGTTTAGAGCGTCTCTATCCGCTGGCACTGTTAAACAGCCTGGTCTACCAGCCGAAACTGGAAGAATCCGCGCTGCTGAACAAAACCGAGGTGGAAGCCTGGGCACAGAGCCTGACAGAGCGCCTGACCCGTCATGAAGAGCACGGCAGCACCTACAGCTACCGTATTGCGGAAAACAAAGAGCGCCAGCTGTTTGAGCCGGTACTGACTATCCGTACCCACGGTGTGGATACTGACTACAATCTGGATTTCGATTTTGTTCACGGCAGCGAATATGCCCGTATCTCCAAACTGGGTGAGCTTATCCGTGGTCTGATTGAAGAAGGTGCTTATGTTGTCCGTGGTGAACGCCGTCAGAACGTCAGCAACTTTGAGCAGGCACTGGACTGGCTGATGAAAGAATCACGCCGTGGTCTGGCTGTACAGCGCTATAAAGGGCTGGGTGAAATGAACCCGGAACAGCTGTGGGAAACCACAATGAACCCGGAAACCCGCCGTATGTTGCAGGTCACGGTAAAAGATGCGATTGCAACGGATCAGTTATTCACCACACTGATGGGTGATGATGTTGAACCGCGCCGTGCCTTTATCGAAGAGAATGCCCTGAAAGCGGCAAACATCGACGTATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3242,Drugs,MEG_3242|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRB,gb|CP004345.1|-|545199-547614|ARO:3003306|Morganella morganii gyrB conferring resistance to fluoroquinolone [Morganella morganii subsp. morganii KT] ,3
,atgaatattataaatttaggaattcttgctcacattgatgcaggaaaaacttccgtaaccgagaatctgctgtttgccagtggagcaacggaaaagtgcggccgtgtggataatggtgacaccataacagactctatggatatagagaaacgtagaggaattactgttcgggcttctacgacatctattatctggaatggagtgaaatgcaatatcattgacactccgggacacatggattttattgcggaagtggagcggacattcaaaatgcttgatggagcagtcctcatcttatccgcaaaggaaggcatacaagcgcaaacaaagttgctgttcaatactttacaaaaactgcaaatcccgacaattatatttatcaataaaattgaccgtgacggtgtgaatttagagcgtttgtatctggatataaaaacaaatctgtctcaagatgtcctgtttatgcaaactgttgtcgatggattggtttatccgatttgctcccaaacatatataaaggaagaatacaaagaatttgtatgcaaccatgacgacaatatattagaacgatatttggcggatagcgaaatttcaccggctgattattggaatacgataatcgatcttgtggcaaaagccaaagtctatccggtactacatggatcagcaatgttcaatatcggtatcaatgagttgttggacgccatctcttcttttatacttcctccagaatcagtctcaaacagactttcagcttatctctataagatagagcatgaccccaaaggacataaaagaagttttctaaaaataattgacggaagtctgagacttcgagacattgtaagaatcaacgattcggaaaaattcatcaagattaaaaatctaaagactatttatcagggcagaaagataaatgttgatgaagtgggggccaatgatatcgcgattgtagaagatatggaagattttcgaatcggagattatttaggtactaaaccttgtttgattcaagggttatctcatcagcatcccgctctcaaatcctccgtccggccagacaggtccgaagagagaagcaaggtgatatccgctctgaatacattgtggattgaagacccgtctttgtccttttccataaactcatatagtgatgaattggaaatctcgttatatggtttgacacaaaaggaaatcatacagacattgctggaagaacgattttccgtaaaggtccattttgatgagatcaagactatctacaaagaacgacctgtaaaaaaggtcaataagattattcagatcgaagtgccacccaacccttactgggccacaatagggctgacgcttgaacccttgccgttagggacagggttgcaaatcgaaagtgacatctcctatggttatctgaaccattcttttcaaaatgccgtttttgaagggattcgtatgtcttgccaatctggtttacatggatgggaagtgactgatctgaaagtaacttttactcaagccgagtattatagcccggtaagtacacctgctgatttcagacagctgaccccttatgtcttcaggctggccttgcaacagtcaggtgtggacattctcgaaccgatgctctattttgagttgcagataccccaagcggcaagttccaaagctattacagatttgcaaaaaatgatgtctgagattgaagacatcagttgcaataatgagtggtgtcatattaaagggaaagttccatacaatacaagtaaagactacgcctcagaagtaagttcatacactaagggcttaggcgtttttatggtcaagccatgcgggtatcaaataacaaaaggcgattattctgataatatccgcatgaacgaaaaagataaaattttattcatgttccaaaaatccaatgtcatcaaaataatggagcggtcaggaaatttctataaggcaatacagtag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7179,Drugs,MEG_7179|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETQ,1028100273|WP_063856408.1|NG_048271|1|1|tet(Q)|tet(Q)|tetracycline_resistance_ribosomal_protection_protein_Tet(Q) NG_048271:101-2065,4
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCTTTCTCCACGTTTGCCGCCGCCAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCAATTCCGGGCATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACTCAACAAACGCTGTTTGAACTCGGATCGGTCAGTAAAACGTTCAACGGCGTGCTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGCATTACTGGCCTGAACTGACTGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCGTTACTACGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGCGCCCTGGCGGTGAAACCCTCAGGCATGAGCTACGAAGAGGCGATGACCAAACGCGTCCTGCACCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGCCAACTTGATGCCGAAGCCTACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGCATCGAGCTTGCGCAGTCACGTTACTGGCGTGTTGGCGATATGTACCAGGGCCTGGGCTGGGAGATGCTGAACTGGCCGGTGAAAGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTGGCACTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAATAAGAGCTACCCAAACCCTGTTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAACGGACAAGGAGGCCCTGGATATTGGGCTTCCTTTCTTTCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAATCCAGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1969,Drugs,MEG_1969|Drugs|betalactams|Class_C_betalactamases|CMY,gi|407731510|gb|JX440349.1|1027-2255,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGCCCCTGCGCTCTATCCCGATATTGCTGACGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6594,Drugs,MEG_6594|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|375155456|gb|JN790946.1|3874-4713,8
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5469,Drugs,MEG_5469|Drugs|betalactams|Class_C_betalactamases|PDC,1276739991|WP_099982812.1|NG_055780|1|1|blaPDC-173|blaPDC|class_C_beta-lactamase_PDC-173 NG_055780:1-1170,0
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcactgcaaccgcacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5697,Drugs,MEG_5697|Drugs|betalactams|Class_C_betalactamases|PDC,553752829|WP_023085632.1|NG_055485|1|1|blaPDC-121|blaPDC|class_C_beta-lactamase_PDC-121 NG_055485:1-1194,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgtctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_578,Drugs,MEG_578|Drugs|betalactams|Class_C_betalactamases|ADC,1270501573|WP_099156045.1|NG_055657|1|1|blaADC-153|blaADC|class_C_beta-lactamase_ADC-153 NG_055657:1-1152,0
,ATGGACACAACGCAGGTCACATTGATACACAAAATTCTAGCTGCGGCAGATGAGCGAAATCTGCCGCTCTGGATCGGTGGGGGCTGGGCGATCGATGCACGGCTAGGGCGTGTAACACGCAAGCACGATGATATTGATCTGACGTTTCCCGGCGAGAGGCGCGGCGAGCTCGAGGCAATAGTTGAAATGCTCGGCGGGCGCGTCATGGAGGAGTTGGACTATGGATTCTTAGCGGAGATCGGGGATGAGTTACTTGACTGCGAACCTGCTTGGTGGGCAGACGAAGCGTATGAAATCGCGGAGGCTCCGCAGGGCTCGTGCCCAGAGGCGGCTGAAGGCGTCATCGCCCGGCGGCCAGTCCGTTGTAACAGCTGGGAGGCGATCATCTGGGATTACTTTTACTATGCCGATGAAGTACCACCAGTGGACTGGCCTACAAAGCACATAGAGTCCTACAGGCTCGCATGCACCTCACTCGGGGCGGAAAAGGTTGAGGTCTTGCGTGCCGCTTTCAGGTCGCGATATGCGGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_756,Drugs,MEG_756|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,gi|66269634|gb|AY920928.1|6009-6542,2
,ATGAAAATTATTAATATTGGAGTTTTAGCTCATGTTGATGCAGGAAAAACTACCTTAACAGAAAGCTTATTATATAACAGTGGAGCGATTACAGAATTAGGAAGCGTGGACAAAGGTACAACGAGGACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACAGGAATAACCTCTTTTCAGTGGGAAAATACGAAGGTGAACATCATAGACACGCCAGGACATATGGATTTCTTAGCAGAAGTATATCGTTCATTATCAGTTTTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATGGCGTACAAGCACAAACTCGTATATTATTTCATGCACTTAGGAAAATGGGGATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCCGAAATTGTAATCAAACAGAAGGTAGAACTGTATCCTAATGTGTGTGTGACGAACTTTACCGAATCTGAACAATGGGATACGGTAATAGAGGGAAACGATGACCTTTTAGAGAAATATATGTCCGGTAAATCATTAGAAGCATTGGAACTCGAACAAGAGGAAAGCATAAGATTTCAGAATTGTTCTCTGTTCCCTCTTTATCATGGAAGTGCAAAAAGTAATATAGGGATTGATAACCTTATAGAAGTTATTACTAATAAATTTTATTCATCAACACATCGAGGTCCGTCTGAACTTTGCGGAAATGTTTTCAAAATTGAATATACAAAAAAAAGACAACGTCTTGCATATATACGCCTTTATAGTGGAGTACTACATTTACGAGATTCGGTTAGAGTATCAGAAAAAGAAAAAATAAAAGTTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAGATTGATAGAGCTTATTCTGGAGAAATTGTTATTTTGCAAAATGAGTTTTTGAAGTTAAATAGTGTTCTTGGAGATACAAAACTATTGCCACAGAGAAAAAAGATTGAAAATCCGCACCCTCTACTACAAACAACTGTTGAACCGAGTAAACCTGAACAGAGAGAAATGTTGCTTGATGCCCTTTTGGAAATCTCAGATAGTGATCCGCTTCTACGATATTACGTGGATTCTACGACACATGAAATTATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGATTAGTGCACTGTTGCAAGAAAAGTATCATGTGGAGATAGAACTAAAAGAGCCTACAGTCATTTATATGGAGAGACCGTTAAAAAATGCAGAATATACCATTCACATCGAAGTGCCGCCAAATCCTTTCTGGGCTTCCATTGGTTTATCTGTATCACCGCTTCCGTTGGGAAGTGGAATGCAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCATTTCAAAATGCAGTTATGGAAGGGATACGCTATGGTTGTGAACAAGGATTGTATGGTTGGAATGTGACGGACTGTAAAATCTGTTTTAAGTATGGCTTATACTATAGCCCTGTTAGTACCCCAGCAGATTTTCGGATGCTTGCTCCTATTGTATTGGAACAAGTCTTAAAAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAATTTATGCGCCACAGGAATATCTTTCACGAGCATACAACGATGCTCCTAAATATTGTGCGAACATCGTAGACACTCAATTGAAAAATAATGAGGTCATTCTTAGTGGAGAAATCCCTGCTCGGTGTATTCAAGAATATCGTAGTGATTTAACTTTCTTTACAAATGGACGTAGTGTTTGTTTAACAGAGTTAAAAGGGTACCATGTTACTACCGGTGAACCTGTTTGCCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7142,Drugs,MEG_7142|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|760459614|gb|KM516885.1|12123-14042 gi|724425628|emb|LN680001.1|1892461-1890542 gi|723796434|emb|LN649259.1|1487222-1489141 gi|723796434|emb|LN649259.1|3260897-3258978 gi|426308955|gb|JQ679011.1|13242-11323 gi|377684511|gb|JN846700.1|325-2244 gi|377684509|gb|JN846699.1|325-2244 gi|340708491|gb|JF830611.2|623-2542 gi|334279325|dbj|AP012053.1|1649285-1647366 gi|215269142|emb|X92947.2|214-2133 gi|198385243|gb|EU918661.1|1-1920,4
,atgaaaaaaattgccgttttatttggagggaattctccagaatactcagtgtcactagcctcagcagcaagtgtgatccaagctattgacccgctgaaatatgaagtaatgaccattggcatcgcaccaacaatggattggtattggtatcaaggaaacctcgcgaatgttcgcaatgatacttggctagaagatcacaaaaactgtcaccagctgactttttctagccaaggatttatattaggagaaaaacgaatcgtccctgatgtcctctttccagtcttgcatgggaagtatggcgaggatggctgtatccaaggactgcttgaactaatgaacctgccttatgttggttgccatgtcgctgccaccgcattatgtatgaacaaatggctcttgcatcaacttgctgataccatgggaatcgctagtgctcccactttgcttttatcccgctatgaaaacgatcctgccacaatcgatcgttttattcaagaccatggattcccgatctttatcaagccgaatgaagccggttcttcaaaagggatcacaaaagtaactgacaaaacagcgctccaatctgcattaacgactgcttttgcttacggttctactgtgttgatccaaaaggcgatagcgggtattgaaattggctgcggcatcttaggaaatgagcaattgacgattggtgcttgtgatgcgatttctcttgtcgacggtttttttgattttgaagagaaataccaattaatcagcgccacgatcactgtcccagcaccattgcctctcgcgcttgaatcacagatcaaggagcaggcacagctgctttatcgaaacttggggttgacgggtctggctcgaatcgattttttcgtcaccaatcaaggagcgatttatttaaacgaaatcaacaccatgccgggatttactgggcactcccgctacccagctatgatggcggaagtcgggttatcctacgaaatattagtagagcaattgattgcactggcagaggaggacaaacgatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7362,Drugs,MEG_7362|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,1028100551|WP_063856686.1|NG_048354|1|1|vanC1|vanC1|D-alanine--D-serine_ligase_VanC1 NG_048354:31-1062,5
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1345,Drugs,MEG_1345|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_123_NC_013653,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgccacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5531,Drugs,MEG_5531|Drugs|betalactams|Class_C_betalactamases|PDC,1408841614|WP_111672887.1|NG_060542|1|1|blaPDC-297|blaPDC|class_C_beta-lactamase_PDC-297 NG_060542:1-1194,0
,GCCCTCACTTCAAGGATGTATTGCGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCGCCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATATATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6456,Drugs,MEG_6456|Drugs|betalactams|Class_A_betalactamases|SHV,gi|372864060|gb|JQ029959.1|1-890 gi|544280853|gb|KF211414.1|1123-2011,0
,ATGATGAAGCGCAAAATCCTGGCAGCGGTGATCCCTGCCCTGCTGGCTGCTGCAACCGCAAACGCAGCAGAAATTTATAATAAAGATGGTAATAAGCTGGATCTGTACGGTAAAGCCGTGGGTCGTCACGTATGGACAACGACCGGCGATAGTAAAAATGCCGACCAGACTTATGCCCAGATTGGTTTTAAAGGGGAAACGCAGATTAACACCGATCTGACCGGTTTCGGTCAGTGGGAATACCGTACTAAAGCAGACCGCGCTGAAGGCGAACAGCAGAACTCGAATCTGGTCCGTCTGGCTTTCGCGGGTTTGAAATACGCGGAAGTGGGTTCAATCGATTATGGTCGTAACTACGGTATCGTTTATGATGTTGAATCCTATACCGATATGGCCCCCTACTTCTCCGGCGAAACCTGGGGCGGCGCCTATACTGATAACTACATGACCAGCCGTGCTGGCGGTTTGTTGACCTACCGTAACTCTGACTTCTTTGGTCTGGTGGACGGTCTCTCTTTCGGTATCCAGTATCAGGGTAAAAATCAGGACAACCACAGCATTAACTCTCAGAATGGCGATGGCGTAGGTTACACCATGGCATATGAGTTCGACGGCTTTGGCGTCACCGCAGCGTACAGCAACAGCAAGCGTACTAACGATCAGCAGGATCGCGATGGTAATGGCGATCGCGCAGAATCGTGGGCCGTTGGCGCGAAATATGATGCAAACAACGTCTACCTGGCTGCCGTATATGCTGAAACCCGCAATATGAGCATTGTTGAAAATACGGTTACCGATACCGTGGAAATGGCAAACAAAACGCAGAACCTGGAAGTGGTCGCTCAGTACCAGTTTGACTTCGGCCTGCGTCCGGCAATCTCGTATGTGCAGAGTAAAGGTAAGCAGTTGAACGGCGCCGGCGGCTCGGCCGATCTGGCGAAATATATTCAGGCGGGCGCGACTTACTACTTCAACAAAAACATGAACGTATGGGTTGACTACCGTTTCAACCTGCTGGACGAAAACGACTACAGCTCCAGCTACGTTGGCACCGACGATCAGGCGGCTGTCGGTATTACTTACCAGTTCTGA,General Bacterial Porin (GBP),reduced permeability to antibiotic,Multi-drug_resistance,MEG_4288,Drugs,MEG_4288|Drugs|Multi-drug_resistance|MDR_mutant_porin_proteins|OMPF,gi|981191958|emb|LN999997.1|4323854-4324945 gi|973795115|gb|AE006468.2|1090875-1089784 gi|949877344|gb|CP012930.1|1091644-1090553 gi|949872475|gb|CP012924.1|1091525-1090434 gi|928084184|gb|CP012681.1|1091116-1090025 gi|821161554|gb|CP011428.1|1089131-1088040 gi|808186398|gb|CP007523.1|1822333-1821242 gi|777177758|emb|LN829401.1|1881416-1882507 gi|764057510|gb|CP007235.1|1821670-1820579 gi|674281104|gb|CP009102.1|1017102-1016011,1
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAACTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1856,Drugs,MEG_1856|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AJ555823|+|0-1146|ARO:3002026|CMY-15 [Proteus mirabilis] ,0
,GTGACAAGCTACTAAGTGCGATCGGTGGATGCCTAGGCACCAAGAGCCGATGAAGGACGTTGTAACCTGCGATAAGCCCTGGGGAGCTGGTAAACGAGCTTTGATCCGGGGATGTCCGAATGGGGAAACCTCGAAGGTGACCAGTTTAGCTACTGGCGACCGCCGCCTGAATGTATAGGGCGGTTGGAGGGAACGTGGGGAAGTGAAACATCTTAGTACCCACAGGAAGAGRAAACAACCGTGAWTCCGTGAATATTGGCGAGCGAAAGCGGAAGAGGCCAAACCGGAGTGTGTGATAGCCGGCAGGTGTTGCATGTGCGGGGTTGTGGGAAGCGTTTTGACTGAACTGCCGTGAGGTCGGAGAGTGATAAAGGATTGATGAAGCAGAAGCGTCTGGGAAGGCGCGGCATAGATGGTGATACCCCTGTATGCGTAAGTTGATCTCTCTCTTAATGTTTTCCCAAGTAGTACGGAACCCCTGAAATYCCGTACGAATCTGGCGGACCACCCGTTAAGCCTAAATACBCCTTGGTGACCGATMGCGGACAAGTACCCGTGAGGGAAAGGGTGAAAATGTACCCCCGGGAGGGGAGTGAAATAGTMCCTGAAACCGATCGCATACAATCCGTCGGAGCCTGCCCTTGTGGTGGGTGACGGCGTGCCTTTTGRAAGAATGAGCCTGCGAGTTAGTGGTGTGTGGCGAGGTTAACCCGTGTGGGGAAGCCGTAGCGAAAGCGAGTCCGAATAGGGCGTTTGAGTCGCATGCTCTAGACCCGAAGCGGTGTGATCTATCCATGGCCAGGGTGAAGCGACGGTAAGACGTCGTGGAGGCCCGAACCCACCAGGGTTGCAAACCTGGGGGATGAGCTGTGGATAGGGGTGAAAGGCCAATCAAACACCGTGATAGCTGGTTCTCCCCGAAATGCATTTAGGTGCAGCGTCATGTGTTTCTTGTCGGAGGTAGAGCACTGGATGGTCTAGGGGGCTTACCAGCTTACCGAAATCAGCCAAACTCCGAATGCCGACAAGTGAGAGCATGGCAGTGAGACGGCGGGGGATAAGCTTCGTCGTCGAGAGGGAAACAGCCCAGATCATCAGCTAAGGCCCCTAAGTGGTGACTAAGTGGAAAAGGACGTGGAGTTGCGGAGACAACCAGGAGGTTGGCTTGGAAGCAGCCATCCTTGAAAGAGTGCGTAATAGCTCACTGGTCAAGTGATTCTGCACCGACAATTTAGCGGGGCTCAAGTCATCCGCCGAAGCTGTGGCATCTACGCGTGTATCCGGCATCCTTTGGGGTGTCCAGGTGCGTGGATGGGTAGGGGAGCGTTGTGTGTGCGTTGAAGCGGCGGGGTGACCCGGTCGTGGAGTGCACGCAAGTGAGAATGCAGGCATGAGTAGCGTATGACGGGTGAGAAACCCGTCCGCCGAATATCCAAGGGTTCCAGGGTCAAGCTAATCTGCCCTGGGTGAGTCGGGTCCTAAGGCGAGGCCGACAGGCGTAGTCGATGGACAACGGGTTGATATTCCCGTACCGGCGCGAGAACGATCCTGCCGAGGTGAGTGATGCTAAGCATGCAAGGCGGTCGTGGGGGCTTCGGTTCCCTGATCGTTGAGTCTGTAACCCGATCTTGTAGTAGGCAAGCTGCGGAGGGACGCAGGAAGGTAGTCTGGCACCGTATTGGTTTGCGGTGTTAAGCCTGTAGGGTGTCTGGCCAGGTAAATCCGGTCGGACGTGTGCCTGAGAGGTGATGAGTGGTGCCACTTTTGTGGTACGTATCCGGATGATCCTATGCTGCCTAGAAAATCTTCGTGAGCGAGTTCTCGAGCTGCCCGTACCCCAAACCGACACTGGTGGATAGGTAGAGAATACCAAGGCGATCGAGATAATCATGGTGAAGGAACTCGGCAAAATCCTCCCGTAACTTCGGAATAAGGGAGACTGGAGGCGTGACGGCAGTTTACTTGTCGGTGCGTCGATAGTCGCAGAGAATAGGCCCAAGCGACTGCTTACTAAAAGCACAGGTCCGTGCTAAGTCGAAAGACGATGTATACGGACTGACTCCTGCCCGGTGCTCKGAAGGTTAAGGGGACGTGTTAGCACTTTTGTGCGAGGCACTGAACTTAAGCCCCAGTAAACGGCGGTGGTAACTATAACCATCCTAAGGKAGCGAAATTCCTTGTCGGGKAAGTTCCGRCCTGSACGAATGGAGTAACGACTTGGGCGCTGTCTCCACCATGAACTCGGCGAAATTGCATTACGAGTAAAGATGCTCGTTACGCGCACAGGGACGGAAAGVNCCCGGGACCTTTACTATAGTTTGGTATTGGTGATCGGTACGACTTGTGTAGGATAGGTGGGAGACTTTGAAGCGGTCACGCTAGTGATTGTGGAGTCATTGTTGAAATACCACTCTGGTCGTTCTGGTTATCTAACCTAGGTCCGTGATCCGGATCAGGGACAGTGCCTGATGGGTAGTTTGACTGGGGCGGTCGCCTCCMAAAAGGTAACGGAGGCGCCCAAAGGTTCCCTCAGCCTGGTTGGTAATCAGGTGTTGAGTGTAAGTGCACAAGGGAGCTTGACTGTGAGACAGACATGTCGAGCAGGGACGAAAGTCGGGACTAGTGATCYTCTGGTGGATTGTGGAATCGCCAGAACTCAACGGATAAAAGGTACCCCGGGGATAACAGGCTGATCTTTCCCGAGCGCTCACAGCGACGGAATGGNTTGGCACCTCGATGTCGGCTCGTCGCATCCTGGGGCTGGAGTCGGTCCCAAGGGTTGGGCTGTTCGCCCATTAAAGCGGCACGCGARGCTGGGGKTAAGAACGTCGTGAGACAGTTCCGGKCCCTATACCGCTGCSCGTMGKATCTTGAGAGGGCTGTCCTTAGTACGCAAGGACCGGGACGGACCAACCTCTGGTGTGCCAGTTGTTCCACCAGGAGCATGGCTGGTTGGCTACGTTGGGGAGTGATAACCGCTGAAAGCATCTAAGTGGGAAGCACGCTTCAAGATGAGGGTTCCTGCACAGTTAATGTGGTAAGGCCCCCGGTAGACCACCGGGTGATAGGTCGGATGTGGAAGCATGGTGACATGTGGAGCTGACCGATACTAAGTGGCCGAGGGCTTGTCCCACA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3994,Drugs,MEG_3994|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|Y10819.1|+|1849-4984|ARO:3004161|Propionibacteria 23S rRNA with mutation conferring resistance to macrolide antibiotics [Propionibacterium freudenreichii] ,7
,ATGATGAAAAAATCCCTTACAGGCGTACTGCTGCTGGGCGCCTCATTTTCGACTTTTGCCGCGCCGCAAACGGCGGAGCAGCTTCGCGAACTGGTCAATCAGACCATCACGCCGTTAATGAAAGAACAGGCGATACCGGGCATGGCGGTGGCGGTGATCTATCACGGCAAACCCTATTATTTCACCTGGGGCCAGGCCGATGTTGCCGGGCAGCGTCCGGTGACGCGACAGACGTTGTTTGAGCTGGGCTCTGTTAGTAAGACTTTCACCGGCGTGCTGGGCGGCGATGCGGTGGCGCGCGGTGAAATTAAGCTCAGCGATCCGGCGCAGAAGTACTGGCCGCAGCTCACCGGCCAGCAGTGGCAGGGGATCTCGCTGCTGCATCTCGCCACCTATACCGCAGGCGGTCTGCCGCTGCAGGTTCCGGACGAGGTGACGGATGAAGCGGCATTACTGCGTTACTATCAGAACTGGCAACCGCAGTGGGCGCCGGGTAGTAAACGGCTGTACGCCAATGCCAGCATTGGCCTGTTCGGCGCGCTGGCGGTGAAACCTTCCGGCATGAGCTTTGAACAGGCGATGAGCCAGCGGGTTTTGCAGCCGTTAAAACTGAGCCACACCTGGATTAACGTACCGCCCGCCCAGAGCAAGGACTACGCCTGGGGTTATCGTGACGGTAAAGCGGTACATGTTTCGCCGGGGCAGCTGGACGCTGAGGCTTACGGCGTGAAGTCGAGCATTGAGGATATGGCGCACTGGGTGCTGGCGAATATGAACAGCGAAGCGGTGCAGGATAAAAATCTGCGGCAGGGGATCCAGCTGGCGCAGTCGCGCTATTGGCGGGCTGGGGAGATGTATCAGGGGCTCGGCTGGGAGATGCTGAACTGGCCGGTGCCGGCCGAGGTAGTAATTAACGGCAGCGATAATAAGGTAGCGCTTGCCGCGACGCCGGTAACGGCGGTCAATCCGCCCGCGCCGTCGGTGAAAGCCTCCTGGGTACATAAAACCGGCTCCACCGGCGGATTCGGCAGCTACGTGGCTTTTATCCCGCAACAGGATCTCGGTATCGTGATGCTGGCGAATAAAAGCTACCCCAACCCGGAGCGGGTGAAGGCTGCGTATCATATTCTTGAGGCGCTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1834,Drugs,MEG_1834|Drugs|betalactams|Class_C_betalactamases|CMY,(Bla)AmpC:AF211348:233-1378:1146,0
,atgatcgtcacagagtttgaccgggaagatccggcgttaaaagtccaattagctgatttgttagagcagacttggccagaagcttatggcggacaaggtgccaaggaagtggatcaactattgcaaaaagaccgcatcgccattgtggctttggcggacgatgagttgatcggttttgtgggggcgattcctcaatatgataaaaccggttgggaattgcatcctttagtggtgcgagacagtcatcgccggcagcgaattggcgctcgtttaatgacctttgtggaagatgaaatcgcctctcgtgggggcttagtggtttatttaggtgccgatgacgaccaccaacaaacgagtttgagccagttggatgggtttcaagatcctttacaagcactcaaagaaatcaaaaatcttaatcatcatccctttgagttttatgaaaaacaagggtatcaagtggtggggatgattccagatgccagtgggtggcaaaagccagatattttaatggccaagcgtgtggccgagtacccagacgaattgaaacaacctgaaaaatga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_152,Drugs,MEG_152|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,498447238|WP_010752789.1|NG_052163|1|1|aac(6')_Entco|aac(6')_Entco|aminoglycoside_6'-N-acetyltransferase NG_052163:101-664,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5571,Drugs,MEG_5571|Drugs|betalactams|Class_C_betalactamases|PDC,496670839|WP_009313329.1|NG_049882|1|1|blaPDC-12|blaPDC|class_C_beta-lactamase_PDC-12 NG_049882:1-1194,0
,ATGAAGAAGATAAAAATTGTTCCACTTATTTTAATAGTTGTAGTTGTCGGGTTTGGTATATATTTGTATGCTTCAAAAGATAAAGAAATTAATAAAACTATTGATGCAATTGAAGATAAAAATTTCAAACAAGTTTATAAAGATAGCAGTTATATTTCTAAAAGCGATAATGGCGAAGTAGAAATGACTGAACGTCCGATAAAAATATATAAAAGTTTAGGCGTTAAAGATATAAACATTCAGGACCGCAAAATAAAAAAAATATCTAAAAATAAAAAAAGAGTAGATGCTCAATATAAAATTAAAACAAACTACGGTAACATTGATCGCAACGTTCAATTTAATTTTGTTAAAGAAGATGGCATGTGGAAATTAGATTGGGATCATAGCGTCATTATTCCAGGAATGCAGAAAGACCAAAGCATACATATTGAAAATTTAAAATCAGAACGTGGTAAAATTTTAGACCGAAACAATGTGGAATTGGCCAATACAGGAACAGCATATGAGATAGGCATCGTTCCAAAGAGTGTATTTAAAAAAGATTATAAAGCAATCGCTAAAGAACTAAGTATTTCTGAAGACTATATCAAACAACAAATGGATCAAAATTGGGTACAAGATGATACCTTCGTTCCACTTAAAACCGTTAAAAAAATGGATGAAGATTTAAGTGATTTCGCAAAAAAATTTCATCTTACAACTAACGAAACAGAAAGTCGTAACTATCCTCTAGAAGAAGCGACTTCACATCTATTAGGTTATGTTGGTCCCATTAACTCTGAAGAATTAAAACAAAAAGAATATAAAGGTTATAAAGATGATGCAGTTGTTGGTAAAAAGGGACTCGAAAAACTTTACGATAAAAAGCTCCAACATGAAGATGGCTATCGTGTCACAATCTTTGACGATAATAGCAATACAATCGCACATACATTAATAGAGAAAAAGAAAAAAGATGGCAAAGATATTCAACTAACTATTGATGCTAAAGTTCAAAAGAGTATTTATAACAACATGAAAAATGATTATGGCTCAGGTACTGCTATTCACCCTCAAACAGGTGAATTGTTAGCACTTGTAAGCACACCTTCATATGACGTGTACCCATTTATGTATGGCATGAGTAACGAAGAATATAATAAATTAACCGAAGATAAAAAAGAACCACTGCTCAACAAGTTCCAGATTACAACTTCACCAGGTTCAACTCAAAAAATATTAACAGCAATGATTGGGTTAAATAACAAAACATTAGACGATAAAACAAGTTATAAAATCGATGGTAAAGGTTGGCAAAAAGATAAATCTTGGGGTGGTTACAACGTTACAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCAGATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAGTTTGAAAAAGCCATGAAAAAACTAGGTGTTGGTGAAGATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTACGGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAACAATGGCAATATCAATGCACCTCACTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCAACAAGTCGTAAATAAAACACATAAAGAAGATATTTATAGACCTTACGCAAACTTAATTGGCAAATCCGGTACTGCAGAACTCAAAATGAAACAAGGAGAAACTGGGAGACAAATTGGGTGGTTTATATCATATGATAAAGATAATCCAAACATGATGATGGCTATTAATGTTAAAGATGTACAAGATAAAGGAATGGCTAGCTACAATGCCAAAATCTCAGGTAAAGTGTATGATGAGCTATATGAGAACGGTAATAAAAAATACGATATAGATAAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3789,Drugs,MEG_3789|Drugs|betalactams|Penicillin_binding_protein|MECA,mecA_5_AB546267,0
,ATGATGAAAAAATCGTTATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATGGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGTTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATTACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1942,Drugs,MEG_1942|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KM087846|+|0-1146|ARO:3002125|CMY-114 [Citrobacter freundii] ,0
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAAGTATACCGTTCTTTATCCGTATTAGACGGAGCAGTATTATTAGTTTCTGCAAAGGATGGCATACAGGCACAGACCCGTATACTGTTTCATGCACTACAGATAATGAAGATTCCGACAATTTTTTTCATCAATAAAATTGACCAAGAGGGGATTGATTTGCCAATGGTATATCGGGAAATGAAAGCAAAGCTTTCTTCGGAAATTATAGTGAAGCAAAAGGTTGGGCAGCATCCCCATATAAATGTAACGGACAATGACGATATGGAACAGTGGGATGCGGTAATTATGGGAAACGATGAACTATTAGAGAAATATATGTCAGGGAAACCGTTTAAAATGTCAGAACTGGAACAGGAAGAAAACAGGAGATTCCAAAACGGAACGTTATTTCCCGTTTATCACGGAAGCGCTAAAAACAATCTGGGGATTCGGCAGCTTATAGAAGTAATTGCCAGTAAATTTTATTCATCAACGCCTGAAGGTCAATCTGAACTATGCGGGCAGGTTTTTAAGATTGAATATTCAGAGAAAAGGCGGCGTTTTGTTTATGTGCGTATATATAGCGGAACATTGCATTTGAGGGATGTTATTAGAATATCTGAAAAAGAGAAAATAAAAATCACAGAGATGTGTATTCCGTCAAATGGTGAAATCGTCCCGGCTGACCATGCCTGTCCGGGAGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGATATCCTGGGAAATGAAAAACTCCTGCCTCACAAAACACGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCGCAGAGATTGCTGATACAGACCCTCTTTTGCATTTTGACATTGATACTGTTACCCATGAGATTATGTTATCTTTTTTGGGGAATGTGCAGATGGAAGTCATTTGTGCCATCCTTGAGGAAAAATATCATGTGGAGGCAGAAATAAAAGAGCCTACTGTTATATATATGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAGGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTTGTTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7164,Drugs,MEG_7164|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/32/O)_4_AIOQ01000025 ,4
,ATGACTCTGGCATTAGTTGGCGAAAAAATTGACAGAAATCGCTTCACCGGTGAGAAAGTTGAAAATAGTACATTTTTTAACTGCGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGCCAGTTCTATGATCGCGAAAGTCAGAAAGGATGCAATTTTAGTCGCGCAATGCTGAGAGATGCCATTTTCAAAAGCTGTGATTTATCAATGGCAGATTTCCGCAACGTCAGCGCATTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGTGCAAGCTTTATGAATATGATCACCACGCGCACCTGGTTTTGCAGCGCATATATCACTAATACCAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTATGGGAAAACCGCTGGATGGGGACTCAGGTACTGGGTGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTAGGTGACTTAGATATTCGGGGTGTTGATTTACAAGGCGTTAAGTTAGACAACTACCAGGCATCGTTGCTCATGGAGCGGCTTGGCATCGCGGTAATTGGTTA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6002,Drugs,MEG_6002|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,qnrB47_1_JQ349155 ,3
,atgagcacgagcaacggtttcgtcacactgcgcctcatgaccgagcaagacctcccgatgctctatgaatggctaaatcggcctcatatcgtcgagtggtggggtggagaagaagaacgcccaacactcgctgacgtgcagaaacagtacctgccaagcgctctagcgcaagagtccgtcactccctacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgtagcgctcggaagcggcgacgggtggtgggaagacgaaaccgatccaggagtacgcggaatagaccagtcattggcaaatccctcgcaactggacaagggcctgggaaccaagctagttcgcgcgctggttgaactgcttttcaatgatcctgaggtaaccaagattcaaacggacccgtcaccgagcaacatgcgcgcgattcgatgctacgagaaggcggggtttgaaaggcaagaaaccatagccaccccagatgggccagctgtgtacatggttcaaacccgtcaggcattcgagcgggcgcgcagtgatgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_131,Drugs,MEG_131|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502087|WP_071846239.1|NG_052254|1|1|aac(6')-set_A|aac(6')-set_A|aminoglycoside_6'-N-acetyltransferase NG_052254:101-655,2
,ATGAATCCCTATCTACAGTTAGTTAGCAAAGAATTTCCGTTAGAAAAAAACCAAGAACCCCCTCATTTAGTCCTTGCTGCCTTCAGCGAAGACGAGGTTTACTTGCAGCCAGAAGCAGCCAAACAATGGGAACGGCTCGTCAAAGCCTTAAAGCTTGAAAACGAGATCTGCTTGTTAGATGGCTACCGAACCGAAAAGCAGCAACGGTATTTATGGGAATATTCCTTGAAAGAAAATGGGCTAGCCTATACGAAACAATTTGTGGCGTTGCCCGGTTGCAGTGAACATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAGGGCAGCCAGGATGATTTGATCTGCCCACGATTTCGTGACAGCGCAGCCGCTGATTTATTTACCCAGGAAATGATGAACTATGGGTTTATTTTACGCTATCCCGCAGACAAACAGGAAATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTGCCTCATAGTCAAATCATCGCCAGTCAACAGTGGACCTTGGAAGAATACCATCAATACCTTGAACAAACTGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7578,Drugs,MEG_7578|Drugs|Glycopeptides|VanC-type_resistance_protein|VANXYC,(Gly)VanXYc2/3:EU151760:1078-1650:573,5
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagagctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgattggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5529,Drugs,MEG_5529|Drugs|betalactams|Class_C_betalactamases|PDC,730314934|WP_033982123.1|NG_049884|1|1|blaPDC-14|blaPDC|class_C_beta-lactamase_PDC-14 NG_049884:1-1194,0
,atgttaaaaaaaatgcgaaaaaatgcgattattctttctttttcgctctgccttccttttgcttcatctaactcatttgcaaatcaggaaaggaatggcctggctcaaattaaggaactggaaactgtttttggagggcggataggtgtttatcttttaaatacagaaaatgggaaagagttttcctacaggcaaaatgagagatttcctttatgcagttcatttaaggtgttcttagctgcatccgtattaaaaaaaactcaggataaatctttttctcttaatgatacggtagagtattccggtcgtgttatggagaagcattctcctgtatcagaaaaatacctagaaacgggtgcaagcgttcagactttggctatggcagcaattcagtacagtgataatggagcgtctaatctattaatggaaagatacgtcggaggtcctgaaggtttgactgcatttatgcgatcaacgggagacacggagttcaggcttgatcgctgggagttagaattaaactcagctattccaggcgataaacgtgatacttcaactccgaaagcagtagcaatgagcctaaaaaatattgcatttggttctgtacttgatgctaaaaataaagccttactgcaggattggcttcaaggaaacacgactggcaatgcgcgagtcagagccgcagttcctgataaatgggttgttggcgataaaacaggcacctgtggtttctatggtacagctaatgatgttgctattttatggcctgattccaattcacctgctgttatcgctgtgtatacaacgcgtactaatcaaaacgataaacatgatgaaacaataattaaaaatgctgcaaaaattgctataaatgcagtgtatggaagttataaatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3052,Drugs,MEG_3052|Drugs|betalactams|Class_A_betalactamases|FRI,1693892931|WP_140423308.1|NG_065423|1|1|blaFRI-8|blaFRI|carbapenem-hydrolyzing_class_A_beta-lactamase_FRI-8 NG_065423:101-997,0
,TTAAATTATGAAAAAAAGAATTCAGTTCTTTATGGTTTCAATGATGCTAAGTCCATTATTCAGTGCCCAGGTAAAAGATTTTGTCATCGAACCACCGATTAAAAAGAATTTACATATTTACAAAACTTTTGGTGTATTCGGAGGTAAAGAATATTCTGCCAATTCAGTATATCTTGTTACCCAAAAAGGAGTTGTCTTATTTGATGTTCCGTGGGAAAAGGTACAGTACCAAAGCCTGATGGATACCATCCAAAAACGCCACAATTTACCCGTAATAGCGGTGTTTGCCACTCACTCCCATGATGACCGTGCCGGAGATCTGAGCTTTTTTAACAACAAAGGAATTAAAACCTACGCTACTGCCAAAACCAATGAGTTCCTGAAAAAAGACGGAAAAGCAACATCCACAGAGATCATTAAGACCGGAAAACCTTATCGCATAGGAGGTGAGGAATTTGTGGTTGATTTTCTTGGAGAAGGGCATACTGCTGATAATGTAGTGGTATGGTTTCCCAAATATAACGTCCTGGATGGCGGATGCCTTGTAAAAAGTAAAGCTGCAACCGATCTTGGATATATTAAGGAAGCCAATGTAGAGCAATGGCCCAAGACCATCAATAAACTGAAATCCAAATATTCAAAAGCAAGCCTGGTTATTCCCGGACATGATGAATGGAAAGGTGGAGGCCATATAGAGCATACTCTTGAACTTCTTAACAAAAAATAAATTTTTCAGCCCCGGCATTCGCCGGGGCTGAAAATTTAAATGATCAATGGATGTCTATCGTGCTAAAAGACCGGATACAACTTCAATCTCTTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_3427,Drugs,MEG_3427|Drugs|betalactams|Class_B_betalactamases|IND,gi|300863226|gb|HM367709.1|1-820,0
,atgaatttaatagatttttctcattctcctgtttcattattgcctcctattgttgctctgacattggcgattctgactcgacgtgtattagtttctcttggtgtaggtatcgcgcttggtgcggttctacttaacagctggtcaattggtggtactgcaagctatgtaggtactcaagtgtcttctgtcttcattgaagatggtggaattaacacttggaacatgagcattgttggtttcctaattctattaggcatgacaacggctctattgacactttctggcggtactcgcgcattcgctgaatgggcacagtctcgtgtgaaaagtaaacgcggctctaaacttcttgcagcctttttaggcgtattcatttttgtcgacgattactttaatagtcttgctgtaggtgcgatttcacgcccagtaacggatcgcttctatgtatctcgtgcgaaactggcttacatcctagattcaaccgctgcacctatgtgtgtcatcatgcctgcttctagttggggtgcttacatcatcactatcatcggcggtattttagtatcacacggtattactgagtattcagcgcttggggcgtatgtgcgtcttatcccaatgaacttctacgctgtatttgcgctgttaatggtgtttgcagtagcgtggtttggtctggatatcggtaagatgcgcgagcatgaaattgcagcgtctcaaggtcgtggttttgacaaagacaaagagaacgacactcaagaagcgcatgagcttaacgaagagttggacattcgtgagagcgaaaaaggtaaagtctctgacttaatcctaccgattgttacgcttatcatcgcgacaattgcttcgatgatgtacaccggtggtcaagcgttggctgctgacggtaaagagtttgcattgttaggtgcattcgagaataccgatgtgggtacgtctctgatttacggtagcttgcttggtttggccgttgctctgtttactgttctaaaacaaggtctaccactgactgagattactcgtacactgtggattggtgctaaatcgatgtttggtgcgattcttatccttgtgtttgcgtggacaatcggttctgttatcggtgacatgaagacgggttcgtacctatcgactatggctcaaggtaacattaatccgcattggttacctgtaatcctgttcttgttgtcgggtctaatggcgttctcaaccggtacttcatggggtacattcggtatcatgttaccaatcgccggtgatatggcgggtgcaactgacatcgcactaatgcttcctatgctaagtgcagttttggccggtgcagtattcggtgaccactgttcaccaatctcggacacgactattttgtcttcgacaggtgctcgttgtaatcacatcgaccacgtatcgactcagttgccttatgcgctgtcagttgctttggtttcatgtgtcggctttattgcacttggtatgacaacgtcaatcgcgttctctttcattgcagcatcgattacatttgttatcgtctgtgctgttctatcatggttgtcgaaatcgaaaatagaatcatgtcagagcgcttaa,ATP-binding cassette (ABC) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6977,Drugs,MEG_6977|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET35,491622861|WP_005480402.1|NG_063830|1|1|tet(35)|tet(35)|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35) NG_063830:101-1702,4
,TTGTCCGAAGCCACCTTTGCAATTGCTAGTACTTACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAATTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGAATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGATTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGATGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATGGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4323,Drugs,MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_13_KX620939 ,1
,atgcgatttaacaaaatttcctgcttacttttaccccctctttttatttttaatacctcaatttatgcgggtaattcaccaaaagagcaagaaattaaaaaactggttgatcaaaactttaaaccattattagaaaaatatgatgtgcccggaatggctgttggcgtcattcaaaataataaaaactatgaaatgtattatggtctacaatccgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgttagtaaattatttaccgctacagcaggtggatatgccaaaacaaaaggaacaatttcttttaaagacacacctggaaaatattggaaagaattaaaaaacacaccgattgaccaaattaatttacttcaacttgctacttatacaagtggcaaccttggcttacagtttccagatgaagtccaaacagatcagcaagttttaacttttttcaaagactggaagcctaaaaactcaatcggtgaatatcgacaatattcaaatccaagcattggtttatttggaaaagttgttgctttgtctatgaataaacctttcgaccaagtcttagaaaaaactatttttccagatcttggcttaaaacatagctatgtaaatgtgcctaaaactcaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccgctagatgcacctgcgtacggtgttaaatcgaccttacctgatatgctgagtttcgttaaggccaatctaaatccacaaaaatatccggcagatattcaacacgcgattaatgaaacacataaaggtttctatcaagtaggtactatgtatcaagcattgggttgggaagaattctcttatccagcacctttacaaactttattagacagtaattcagaacaaatcgtgatgaagcctaataaagtgactgccctttcaaaagaaccttcagtcaagatttaccacaaaactggttcaactaacggctttggaacatatgttgtctttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattcccaatgaagaacgcattaaagcagcgtatgcagtattgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_623,Drugs,MEG_623|Drugs|betalactams|Class_C_betalactamases|ADC,507066709|WP_016137488.1|NG_064692|1|1|blaADC-136|blaADC|class_C_beta-lactamase_ADC-136 NG_064692:101-1252,0
,atgaactttaataaaattgatttagacaattggaagagaaaagagatatttaatcattatttgaaccaacaaacgacttttagtataaccacagaaattgatattagtgttttataccgaaacataaaacaagaaggatataaattttaccgtgcatttattttcttagtgacaagggtgataaactcaaatacagcttttagaactggttacaatagcgacggagagttaggttattgggataagttagagccactttatacaatttttgatggtgtatctaaaacattctctggtatttggactcctgtaaagaatgacttcaaagagttttatgatttatacctttctgatgtagagaaatataatggttcggggaaattgtttcccaaaacacctatacctgaaaatgctttttctctttctattattccatggacttcatttactgggtttaacttaaatatcaataataatagtaattaccttctacccattattacagcaggaaaattcattaataaaggtaattcaatatatttaccgctatctttacaggtacatcattctgtttgtgatggttatcatgcaggattgtttatgaactctattcaggaattgtcagataggcctaatgactggcttttataa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1564,Drugs,MEG_1564|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,501374837|WP_012406403.1|NG_047580|1|1|catA9|catA9|type_A-9_chloramphenicol_O-acetyltransferase NG_047580:101-751,6
,ATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6914,Drugs,MEG_6914|Drugs|betalactams|Class_A_betalactamases|TEM,gi|403398703|gb|JX469833.1|62898-61824 gi|356472769|gb|HQ659758.1|7728-8802 gi|157277474|tpe|BN000925.1|6713-5639 gi|114703507|emb|AM261760.1|6713-5639 gi|109389586|gb|DQ388534.1|23927-25001 gi|53794349|gb|AY741093.1|50588-49514 gi|3859493|gb|AF080442.1|3728-4802 gi|21998650|emb|X54606.1|1-1075 gi|8117219|dbj|AB043582.1|7744-6670 gi|8117212|dbj|AB043581.1|7744-6670,0
,atgataatcagtgaatttgaccgtaataatccagtattgaaagaccagctttctgatttactgagactgacttggccggaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacgaatcgcggtagcagcggtagatcaagatgagttagtaggatttattggtgcaatccctcaatacggtatcacaggttgggaattgcatccattagttgtagaaagctctcgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagaggaggaataacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaaacggacctgtatgagcatacgtttgataaagtggcttccatccagaaccttcgtgaacatccgtatgagttctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaaatggttgggacaaaccggatatttggatggcaaaaacgattattcctcgaccagattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_139,Drugs,MEG_139|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,488222781|WP_002293989.1|NG_052140|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052140:101-649,2
,atgaaaagcaaagtcagtgcgctgttaatgatgatagttcttgcgggccatgcgcaggccgcgcccgttgcgccgccggatgcggtcgttaagccattgatggcgcgctaccagatcccgggcatggcggtggcggtgtcggttaacggcgaaacgcatttctggcattacggcgtggcgtcaaaagcgacgcgcaagccggtggatgaaaacacgcttttcgaaatcggctcgctcagtaaaacctttaccgcgacgctcgcaagcaaggcgcagcaagacggcaagctggatttcagcgcgcccgccagccagtatcttcctgcactgaaaggcagcgcgttcgaccacgtgacgctgctgaatctcgccacgcacaccgcgggaacgccgctctttgtgcccgatgcggtgaaaaacaccccacagctgatggactggtatcgcgcctggcagcctgaaaagccggtcggcacagagcgcgtttactcgaatcttgggatagggctgctcgggatgattaccgcgaaggcgctcgataagccgttcagcgaggcgatggagcaggggctgctcagggatttcggcatgacgcacacctttattaacgtgccggatgccgcgatgggcgactacgcccagggttataacaaagacgacaaaccggtgcgggtgacgcccggcccgcttgacgccgaatcgtatgggctgaaatccggcagcgcggatctgctgcgttatctgcaaatccagcttggcgagcaggaggtcgcgccaggctggcgtcaggcgattaacgccacgcacaacggctactaccgcagcggtgagttcacgcagggattgatgtgggaatattatccgtggccgtcaccactctcgcgccttgttgaaggcaacagcagccagcgcatcatgaaagggcttgcgaccaccgcgatcgttccgccgcagcctgcgccgcaggccgcgtggtataacaaaaccggctcgaccaacggcttttccacatacgcagtgtttatccctgagaagcgtatcgcgctgattatgctcgccaacaagtggttccctaatgacgaccgcgtgaaagcggcgtatgcgattattcaggagcttgataagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2135,Drugs,MEG_2135|Drugs|betalactams|Class_C_betalactamases|CSA,490519461|WP_004384957.1|NG_062211|1|1|blaCSA-2|blaCSA|class_C_beta-lactamase_CSA-2 NG_062211:101-1228,0
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGGCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2410,Drugs,MEG_2410|Drugs|betalactams|Class_A_betalactamases|CTX,gi|668347719|dbj|AB976600.1|1214-2089 gi|283466726|emb|FN594520.1|7075-6200 gi|282192949|gb|GU226842.1|1-876 gi|221149286|gb|EU418918.1|64-939 gi|197215894|gb|EU921824.1|553-1428,0
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggagagtttattgtataccagtggtgcaattgcagaaccagggagcgtagataaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaagtataccgttctttatccgtattagacggagcagtattattagtttctgcaaaggatggcatacaggcacagacccgtatactgtttcatgcactacagacaatgaagattccgacaatttttttcatcaataaaattgaccaagaggggattgatttgccaatggtatatcaagaaatgaaagcaaagctttcttcggaaattatagtgaagcaaaaggttgggcagcatccccatataaatgtaacggacaatgacgatatggaacagtgggatgcggtaattatgggaaacgatgaactattagagaaatatatgtcagggaaaccgtttaaaatgtcagaactggaacaggaagaaaacaggagattccaaaacggaacgttatttcccgtttatcacggaagtgctaaaaacaatctggggattcggcagcttatagaagtgattgccagtaagttttattcatcaacgcctgaaggtcaatctgaactatgcgggcaggtttttaagattgaatattcagagaaaaggcggcgttttgtttatgtgcgtatatatagcggaacattgcatttgagggatgttattaaaatatctgaaaaagagaaaataaaaatcacagagatgtgtgttccgacaaacggtgaattatattcatccgatacagcctgctctggtgatattgtaattttaccaaatgatgttttgcagctaaacagtattttggggaacgaaatgctgttgccgcagagaaaatttattgaaaatcctctccctatgctccaaacaacgattgcagtaaagaaatctgaacagcgggaaatattgcttggggcacttacagaaatttcagatggcgaccctcttttaaaatattatgtggatactacaacgcatgagattatactttcttttttggggaatgtgcagatggaagtcatttgtgccatccttgaggaaaaatatcatgtggaggcagaaataaaagagcctactgttatatatatggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaatcaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7159,Drugs,MEG_7159|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,504449189|WP_014636291.1|NG_048267|1|1|tet(O)|tet(O)|tetracycline_resistance_ribosomal_protection_protein_Tet(O) NG_048267:62-1981,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagctccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5485,Drugs,MEG_5485|Drugs|betalactams|Class_C_betalactamases|PDC,1201190440|WP_087587960.1|NG_054977|1|1|blaPDC-191|blaPDC|class_C_beta-lactamase_PDC-191 NG_054977:1-1194,0
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttaagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgacgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccagtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggtaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6663,Drugs,MEG_6663|Drugs|betalactams|Class_A_betalactamases|TEM,1132963066|WP_075985686.1|NG_052651|1|1|blaTEM-225|blaTEM|class_A_beta-lactamase_TEM-225 NG_052651:1-861,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6692,Drugs,MEG_6692|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-20:EU527189:4132-4992:861,0
,ATGAAGAAGAATCAAGGAATCGAGCAATTTCGGGTGATTTTGGCGATGATGGTGGTGGCGATCCACTGTCTGCCTCTTCATCACTTATGGCCTGACGGTGATACCCTGATCACGTTGACGCTCTTCAGAATTGCCGTTCCCTTCTTTTTTATGATCAGCGGATATTACGTGTTCAGCGACTTAGCCACCCAAAACAGCTATCCTGCCAGACATCGTGTCTGGCAGTTTATTAAAAAGCAGCTGCAAGTCTACCTCATAGCCACACTGCTCTTTTTGCCGCTTGCTTGGTACAGCGGCATGCTAGGGTTGAACATGCCACTAGGCACTTTTATTCAAACTTTGCTGGTCAATGGCATCCTTTATCATCTATGGTATTTTCCTGCGATCATTACCGGCAGTCTATTAGTGATGGGCCTCTTGACACGTCTTTCTTTCAAGCAGGTGTTTTTCACTGCTGTCGGCTTGTATGTGGTTGGTTTAGGTGGGGACAGTTGGTCTGGCCTGGCTGCCCAAACACCCATCACGCCACTCTATTCACGGATTTTTCAACTATTGGATGGAACTCGCAACGGCATTTTCTTTGCTCCTTTGTTTTTGATCTTAGGGGTACTAGCCAGAAGATTTGCCAAGAAACCAGCTTCTCCCCATCGCTATAGTTATCTGCTGATCAGTCTGATTTGCTTGCTTTTGGAAAGTTACCTTTTGCATCACTTTACCACGCCGAAACATGACAGCATGTATATTTTTTTGCCCTTCGTCCTGTTGTTTTTATTTCCGATCATCCAGCAATGGCAAGCACCCATAATCTGGAAACAAGCGGGTCGACTGTCCCTTTGGCTCTATTTGCTCCATCCTTATACCATTGCAGTGACCCATTTTCTTAGTCAAAAACTGCCCTTGCTGCAAAACAATCTGATCAATTTCTTCGTGGTCTTAGGACTGACCATTGGGGTGGTGCATGGTCTCTTTGCTTTGCAAAAGCTGTTCCCGTTTCCGAAAAAAACGCCGCCCCACTTGCAGCGAGCAACCAAAGAATTTTCCGCCCCCGCTTTGTTGCACAACCTGCAGGAAATCAAGCGATTGATCCCAGCAACAACTAAAGTGATGGCGGTGGTTAAAGCGGATGCTTATGGTTGTGATGCGAAGACGGTCGCCAGTACCCTAGAAAGAGCCGGCGTCGATTTCTTTGCCGTTGCTACCCTTGAAGAAGCCATTGAATTACGGCGAGCTGGCATCAAAAGTCGCTTACTGATTTTAGGGTACACTTCTGCCCAACGTGCCAAAGAGCTGAAACATTATTCCTTGATTCAAACCATCGTTAGTGAGGCCCATGGGCATGCTTTAGCCCAAACAAGCATTCCGATCGAATGCCATTTAGCGGTAGATACTGGTATGCACCGCTTAGGCGTTGCACCTGATCTTGAGACAGTTACTGGACTTTACGCCTTGCCATCTCTCAAGATCACACGCATTTTTTCCCATCTAGGCTCTTCAGATCAGCTGGATACGGCAAGTATCTTGCGGACACAAGCCCAAATCACTTGTTTTGATGATCTGTTGGCTGGCTTATCCGCTAGAAATATCGCCTATGGACTGACACATCTGCAAAGCAGCTACGGAATATTGAATTACCCAGAGAAACACTATGATTATGTACGTCCAGGTATTCTTCTAACTGGTTCATTGAGCGTCCCGAACGAACCAACGAAGCAGAAGATAAACGTACAACCAATTTTGACACTCAAAGCCTTACTGGTAGACAAAAAAACAGTTGCCGCTGGTGAAGCGATCGGCTATGGATTAGGCACTGTTTTTGATCGACCAGCCACGATTGGGATCGTTAGCATCGGCTACTGCGACGGGGTTCCACGTGCCCTATCAAACCAAGGGTTCCAACTTTCTTATCAGGGTGCTTTACTCCCGCAGATTGGGTTGGTTTGTATGGATATGCTCTTGATCGATTTAACGGACTATCCAGAACTGGCGGTCGAAAGTTCGCTCGAAGTAATCAGCGATTGGACGACTACCGCTTATCAAGCACAAACCATTACCAATGAATTGATCAGCCGCCTAGGTTCCCGCATCACCTCTAGTTCAAAGTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7527,Drugs,MEG_7527|Drugs|Glycopeptides|VanC-type_resistance_protein|VANTC,(Gly)VanTc3:AY033764:1644-3746:2103,5
,atgaaaatcgtaaaaaggatattattagtattgttaagtttattttttacaattgagtattcaaatgctcaaactgacaacttaactttgaaaattgagaatgttttaaaggcaaaaaatgccagaataggagtagcaatattcaacagcaatgagaaggatactttgaagattaataacgacttccatttcccgatgcaaagcgttatgaaatttccgattgctttagccgttttgtctgagatagataaagggaatctttcttttgaacaaaaaatagagattacccctcaagaccttttgcctaaaacgtggagtccgattaaagaggaattccctaatggaacaactttgacgattgaacaaatactaaattatacagtatcagagagcgacaatattggttgtgatattttgctaaaattaatcggaggaactgattctgttcaaaaattcttgaatgctaatcatttcactgatatttcaatcaaagcaaacgaagaacaaatgcacaaggattggaatacccaatatcaaaattgggcaaccccaacagcgatgaacaaactgttaatagatacttataataataagaaccaattactttctaaaaaaagttatgattttatttggaaaattatgagagaaacaacaacaggaagtaaccgattaaaaggacaattaccaaagaatacaattgttgctcataaaacagggacttccggaataaataatggaattacagcagccactaatgatgttggggtaattactttaccgaatggacaattaatttttataagcgtatttgttgcagagtccaaagaaacttcggaaattaatgaaaagattatttcagacattgcaaaaataacgtggaattactatttgaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7644,Drugs,MEG_7644|Drugs|betalactams|Class_A_betalactamases|VEB,763233433|WP_044103626.1|NG_063895|1|1|blaVEB-21|blaVEB|class_A_extended-spectrum_beta-lactamase_VEB-21 NG_063895:1-900,0
,atggttaaaaaatcactgcgtcagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggaagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgtggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgacttggttaactataatccgattgcggaaaagcacgtcgatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgatttctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcgtaatctgacgctgggtaaagcattgggtgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaatccgtcaccaacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2212,Drugs,MEG_2212|Drugs|betalactams|Class_A_betalactamases|CTX,1073722254|WP_070064534.1|NG_051737|1|1|blaCTX-M-138|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-138 NG_051737:1-876,0
,TGTGTGTAAGTAAGTGTTTAAGGGCGCATGGTGGATGCCTTGGCATCGAGAGCCGATGAAGGACGTGGGAGGCTGCGATATGCCTCGGGGAGCTGTCAACCGAGCATTGATCCGAGGATTTCCGAATGGGGAAACCCAGCACGAGTGATGTCGTGTTACCCGTATCTGAATATATAGGGTGCGGGAGGTAACGCGGGGAAGTGAAACATCTCAGTACCCGTAGGAGAAGAAAACAATTGTGATTCCGTCAGTAGTGGCGAGCGAACGCGGAACAGGCTAAACCGCATGCATGGACAACCGGGTAGGGGTTGTGTGTGCGGGGTTGTGGGATTGATATGTCTCAGCTCTACCTGGCTGAGGGGTAGTCAGAAAGTGTCGTGGTTAGCGGAAGTGGCCTGGGACGGCCCGCCGTAGACGGTGAGAGCCCGGTACGCGAAAACCCGGCACCTGCCTTATATCAACACCCGAGTAGCAGCGGGCCCGTGGAATCTGCTGTGAATCTGCCGGGACCACCCGGTAAGCCTAAATACTTCTCGATGACCGATAGCGGATTAGTACCGTGAGGGAATGGTGAAAAGTACCCCGGGAGGGGAGTGAAATAGTACCTGAAACCGTGTGCCTACAATCCGTCAGAGCCTCCTCGTGGGGTGATGGCGTGCCTTTTGAAGAATGAGCCTGCGAGTCAGGGACACGTCGCGAGGTTAACCCGTGCGGGGTAGCCGCAGCGAAAGCGAGTCTGAATAGGGCGCATCCCCTTTGGGGTGTAGTGGCGTGTTCTGGACCCGAAGCGGAGTGATCTACCCATGGCCAGGGTGAAGCGCGGGTAAGACCGCGTGGAGGCCCGAACCCACTTAGGTTGAAGACTGAGGGGATGAGCTGTGGGTAGGGGTGAAAGGCCAATCAAACTCCGTGATAGCTGGTTCTCCCCGAAATGCATTTAGGTGCAGCGTTGCGTGGTTCACCACGGAGGTAGAGCTACTGGATGGCCGATGGGCCCTACTAGGTTACTGACGTCAGCCAAACTCCGAATGCCGTGGTGTAAAGCGTGGCAGTGAGACGGCGGGGGATAAGCTCCGTACGTCGAAAGGGAAACAGCCCAGATCGCCGGCTAAGGCCCCTAAGCGTGTGCTAAGTGGAAAAGGATGTGTAGTCGCAGAGACAACCAGGAGGTTGGCTTAGAAGCAGCCACCCTTGAAAGAGTGCGTAATAGCTCACTGGTCAAGTGATTATGCGCCGATAATGTAGCGGGGCTCAAGCACACCGCCGAAGCCGCGGCACATTCATCTTTACGGTGGATGTGGGTAGGGGAGCGTCCCCCATTCAGCGAAGCCTCCGGGTGACCGGTGGTGGAGGGTGGGGGAGTGAGAATGCAGGCATGAGTAGCGATAAGGCAAGTGAGAACCTTGCCCGCCGTAAGACCAAGGGTTCCTGGGCCAGGCCAGTCCGCCCAGGGTGAGTCGGGACCTAAGGCGAGGCCGACAGGCGTAGTCGATGGACAACGGGTTGATATTCCCGTACCCGTGTATGGGCGTCCCTGATGAATCAGCGGTACTAACCACCCAAAACCGGATCGACCATTCCCCTTCGGGGGCGTGGCGATTCGGGGCTGCGTGGGACCTTCGCTGGTAGTAGTCAAGCAATGGGGTGACGCAGGAAGGCAGCCGTACCAGTCAGTGGTAATACTGGGGCAAGCCCGTAGGGAGAGCGATAGGCAAATCCGTCGCTCACTAATCCTGAGAGGTGATGCATAGCCGGTTGAGGCGAATTCGGTGATCCTCTGCTGCCAAGAAAAGCCTCTAGCGAGCACATACACGGCCCGTACCCCAAACCAACACAGGTGGTCAGGTAGAGAATACCAAGGCGTACGAGATAACTATGGTTAAGGAACTCGGCAAAATGCCCCCGTAACTTCGGGAGAAGGGGGGCCGGAATACCGTGAACACCCTTGCGGTGGGAGCGGGATTCGGCCGCAGAAACCAGTGGGTAGCGACTGTTTACTAAAAACACAGGTCCGTGCGAAGTCGCAAGACGATGTATACGGACTGACGCCTGCCCGGTGCTGGAAGGTTAAGAGGACCCGTTAACCCGTAAGGGTGAAGCGGAGAATTTAAGCCCCAGTAAACGGCGGTGGTAACTATAACCATCCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCTGCACGAATGGCGTAACGACTTCCCAACTGTCTCAACCATAGACTCGGCGAAATTGCACTACGAGTAAAGATGCTCGTTACGCGCGGCAGGACGAAAAGACCCCGGGACCTTCACTACAACTTGGTATTGGTGTTCGGTACGGTTTGTGTAGGATAGGTGGGAGACTTTGAAGCACAGACGCCAGTTTGTGTGGAGTCGTTGTTGAAATACCACTCTGATCGTATTGGACACCTAACGTCGAACCCTTATCGGGTTCACGGACAGTGCCTGGCGGGTAGTTTAACTGGGGCGGTTGCCTCCTAAAATGTAACGGAGGCGCCCAAAGGTTCCCTCAACCTGGACGGCAATCAGGTGGCGAGTGTAAGTGCACAAGGGAGCTTGACTGCGAGACTTACAAGTCAAGCAGGGACGAAAGTCGGGACTAGTGATCCGGCACCCCCGAGTGGAAGGGGTGTCGCTCAACGGATAAAAGGTACCCCGGGGATAACAGGCTGATCTTCCCCAAGAGTCCATATCGACGGGATGGTTTGGCACCTCGATGTCGGCTCGTCGCATCCTGGGGCTGGAGCAGGTCCCAAGGGTTGGGCTGTTCGCCCATTAAAGCGGCACGCGAGCTGGGTTTAGAACGTCGTGAGACAGTTCGGTCTCTATCCGCCGCGCGCGTCAGAAACTTGAGGAAACCTGTCCCTAGTACGAGAGGACCGGGACGGACGAACCTCTGGTATACCAGTTGTCCCACCAGGGGCACGGCTGGATAGCCACGTTCGGACAGGATAACCGCTGAAAGCATCTAAGCGGGAAACCTTCTCCAAGATCAGGTTTCTCACCCTTTTAGAGGGATAAGGCCCCCCGCAGACCACGGGATTGATAGGCCAGACCTGGAAGCTCAGTAATGAGTGCAGGGAACTGGCACTAACCGGCCGAAAAC,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3984,Drugs,MEG_3984|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NG_041979.1|+|0-3112|ARO:3004164|Mycobacterium avium 23S rRNA with mutation conferring resistance to clarithromycin [Mycobacterium avium] ,7
,ATGAAAGACGATTTCGTCTTCGTAGACGAGGTTGTGCCCGGAATCCGCTGGGATGCCAAATACGCCACCTGGGACAACTTCACCGGCAAACCGGTGGACGGATATCTGGTGAACCGCGTCGTCGGCACGCGGGCTTTCTGCGCGGCGTTGGAAAAGGCGCGGGAGAAAGCCGAGTCTCTCGGCTTCGGCCTGCTCCTTTGGGACGTCTACCGTCCGCAGCGCGCCGTGGACTGCTTCATGCGCTGGGCGGAACAGCCCGAAGACGGCCGCAAGAAGCTCAGGCACTACCCGAACATCGACCGGCCCCAGATGTTCGAAAAGGGCTACGTGGCCACCAAGTCGGGCCACAGCCGGGGCAGCACGGTGGACCTGACGCTGTACCACTTGGACACCGGTGAACTCGCCGACATGGGTGGCGACCACGACGTGATGGACGTCGTTTCACACCACGGCGCGGCGGGAATCACGCCGGAACAGGAGAAGAACCGTGAACACCTCTGCTCCATCATGGTGGACAGCGGGTTCGGCTCCTATGAGTTCGAGTGGTGGCATTACAACCTGAAGAACGAACCTTATCCGGACACCTATTTCGACTTTCCCATCGCGGGCTCGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7549,Drugs,MEG_7549|Drugs|Glycopeptides|VanA-type_resistance_protein|VANXA,(Gly)VanX-Ac1:DQ246438:2221-2835:615,5
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTTAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTGATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1342,Drugs,MEG_1342|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_103_FQSJ01000009,0
,ttgaaaaaaatacttttactttttagtcttttttactcttttgctttggcaaatgataaattaaaagatttttttaaagactacaatacaagcggagtttttataacttttgatggaaaacattatgcaagtaataattttaaaagagctaaagaacctttttctcctgcttcgacttttaaaatttttaatgctttaattgcgcttgataatggtgtagttaaagatacaaaggaaattttttatcattataagggtgaaaaagtatttttgccctcttggaaacaagatgctggtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcctatggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgatggtataaatttggcttggattgttggatttatagagagtaaaaacaaaattttatcttttgccttaaatgttgatataaagaacattaaaaatcttaaaataagagaagaattgctagaaaaatatatttattctttaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4635,Drugs,MEG_4635|Drugs|betalactams|Class_D_betalactamases|OXA,1391852896|WP_109545081.1|NG_057498|1|1|blaOXA-627|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-627 NG_057498:1-747,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcgcggcgctgtggccatccagctcgcctgaagatcaccgcgcggaaatgcgcgagatactggcttcaccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcatcggctttgccgaagtggcgctacgctacgattacgtcaacggctgcgagtcatcgccggtggcgtttctggaagggatctataccgtcgaacgcgcccgccgccagggctgggccacgcgattgatcgcacaggtgcaggaatgggccaagcagcaaggctgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgccgcgctgggctttgccgaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_164,Drugs,MEG_164|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,518282883|WP_019453091.1|NG_052284|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052284:101-541,2
,atgaatagcatcttttccctgtcccgccgtaaatacttactggccgccgccggactgaccatcgccgcgctatttccgccatccgtggtgctggccgaacaaccagcaacgctggcggctcagctcagcgcactggaggcatcggccaatggccgtctcggtgtggcgctgattgacagcggatcttcacgccagctgagttatcgcggggaagagcgtttcgccatggccagtacgtttaaagcgcttgccgccgccgccgtgctgcaacgcagtgttgaacagcccgcactgctgaataaacgcattatttatcaacagagcgaactgatcacttactcgccggtaaccgaaaagcatctgcaacagggcatgaccgtcgcggaactctgtgctgcggcagttgaactcagtgataacacggcggggaatattctgctgcgggaaataggggggccgcaagggattacccaactggcacgccgtttaggtgataatcagacgcgtcttgaccgccgggaacccgcgttaaacagcgcgattccgggtgatgtacgtgatacttcaacacctctggcgatggccgggaatttaaatcagctggcgctgggcaaggcgttaccctccgctcagcaacagctgctgattcagtggctaaagcagagcaaaaccggggcgcagagcattcgtgccggggtgccgcaaggctggcaagtgggtgataaaaccggggcgggaggctacggcacgactaacgatctggcaatcctctggccaccacagggtaaaccgctggtgctggccgtctatttcacccagcataatccgcaggctgaggcacgccgcgatgtgctggccagcgccaccaggctggtactggcggcgtgggaaaaacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3640,Drugs,MEG_3640|Drugs|betalactams|Class_A_betalactamases|LRG,1028105801|WP_063860827.1|NG_049283|1|1|blaLRG-1|blaLRG|class_A_extended-spectrum_beta-lactamase_LRG-1 NG_049283:101-1000,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTACACATGCCAAAAAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGATGGTGTTTCAAAAGACTGTAAGGTGGCTGATAAAAGTGGCCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1445,Drugs,MEG_1445|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_131_GQ900485,0
,atgacttttaatattatcaaattagaaaattgggatagaaaagaatattttgaacactattttaaccagcaaactacgtatagcattactaaagaaattgatattactttgtttaaagatatgagtaaaaagaaaggatatgaaatttatccttctttgatttatgcaattatggaagttgtaaataaaaataaagtgtttagaacaggaattaatagtgagaataaattaggttattgggataagttaaatcctttgtatacagtttttaataagcaaactgaaaaatttactaacatttggactgaatctgataacaacttcacttctttttataataattataaaaatgacttgcttgaatataaagataaagaagaaatgtttcctaaaaaaccgatacctgaaaacaccctaccgatttcaatgattccttggattgattttagttcatttaatttaaacattggtaacaatagcaactttttattgcctattattacgataggtaaattttatagtgagaataataaaatttatataccagttgccttgcagcttcatcatgctgtatgtgatggttaccatgcttcattatttataaatgaatttcaagatataattaagaaggtagatgattggatttag,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1569,Drugs,MEG_1569|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,695261507|WP_032488466.1|NG_047567|1|1|catA7|catA7|type_A-7_chloramphenicol_O-acetyltransferase NG_047567:88-735,6
,ATGCCCTCCCACGATCATCCTGTCACCTTGCGGCTTATGACGGAGCAAGACCTGCCTATGCTCCATGAATGGCTGAATCGGCCGCACATAGTCGAGTGGTGGGGCGGTGAAGAGCAACGTCCGACACTGGCGGATGTACTGGAACACTACAGGCCCAGAATCTTGGCGCACGAGTCGGTCACTCCATACATCGCCATGCTGGGCGAAGAACCAATCGGATATGCGCAGTCGTACGTCGCGCTCGGAAGCGGCGATGGATGGTGGGAAGAGGAAACCGACCCAGGAGTACGAGGAATCGATCAGTCGTTGGCGAATCCTACGCAGTTGAACATGGGCCTGGGAACAGAGCTTGTGCGAGCGCTGGTTGATCGGTTGTTCTCCGACCCAACGGTGACAAAGATCCAGACTGATCCGGCCCCAAACAATCGCCGCGCGATCCGCTGCTACGAGAAGGCGGGCTTTGTGCAGGAGAGAGTCATCACGACACCCGACGGGCAGGCCGTCTACATGACCCAATCTAGGCAAGCCTACGAGCGTGCGCGCGGTGCTGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_272,Drugs,MEG_272|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,(AGly)Aac:AJ628983:1985-2539:555,2
,atgaagctatcaaaattatacatcctcactgtgctcatagggtttggattaagcggtgtcgcctgccagcatatccatactccagtctcgttcaatcaaattgaaaacgatcaaacaaagcagatcgcttccttgtttgagaatgttcaaacaacaggcgttctgattacctttgatggacaggcgtataaagcatacggtaatgatctgaatcgtgccagaactgcgtatatcccagcatctactttcaaaatattaaatgctttgattggcattgaacatgataaaacttcaccaaatgaagtatttaagtgggatggtcagaagcgtgcttttgaaagttgggaaaaagatctgactttagctgaagccatgcaagcttctgctgtacctgtttatcaagcgcttgcccagagaatcggattggatttgatggcaaaggaagtcaaaagagtcggcttcggtaatacacgcatcggaacacaagttgataacttctggctcattggacctttaaagatcacgccaatcgaagaagcacaatttgcttacaggcttgcaaaacgggaactaccgtttacccaagacactcaaaagcaagtgattgatatgctgctggtggatgaaatacggggaactaaagtttacgccaaaagtggttggggaatggatattaccccacaagtaggatggtggactggatggattgaagatccgaacggaaaagtgatcgctttttctctcaatatggaaatgaatcaacctgcgcatgcagctgcacgtaaagaaattgtttatcaggcacttacgcaattgaaattattgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4514,Drugs,MEG_4514|Drugs|betalactams|Class_D_betalactamases|OXA,1343491237|WP_104009853.1|NG_056415|1|1|blaOXA-575|blaOXA-214_like|OXA-214_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-575 NG_056415:1-828,0
,atgatgaaaaaaaccctttgctgcgccgtgctgctcggcatctcttgctctgccctcgccgcgccagtatccgaacaacagctggcggaggtggtcgcgaagacggttacgccgctgatgaaagcccagtctattcccggtatggcggtggccgttatttatcagggtaaaccgcactattacacgtttggcaaggccgatatcgcagccaacaaaccggttacccctcagaccctgttcgagctgggctctataagtaaaaccttcaccggcgttttaggtggggatgcccttgctcgcggtgaaatttcgctggacgatccggtgatcaaatactggcctgagctgacgggcaagcagtggcaagggattcgcatgctggatctcgcgacctacaccgctggcggtctgccgctacaggtgcccgatgaggtgacggatgacgcctccctgctgcgcttctatcaacactggcagccacagtggaagccaggcacaacgcgcctttatgccaacgccagcatcggcctgtttggtgcgctggcggttaagccttccggcatgcgctacgagcaggcgatgaccgagcgagtcttcaaaccgctggcgctgcatcacacctggattaacgtgccgaaagcggaagaggcgcattacgcctggggctatcgtgacggcaaagcggtacacgtttcgccggggatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccagagaacgttgctgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcggttcaatgtaccagggcctgggctgggagatgctcaactggcccgtggaggcaaaaacggtggttgatggcagcgacagtaaggtggcgctggccgccttgcctgcggtcgaaataaatcctccggctccgcctgtaaaagcctcctgggtgcacaaaaccggctcgacgggcgggttcggcagctacgtggcctttattcctgaaaagcagatcggcatcgtaatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgacgcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_419,Drugs,MEG_419|Drugs|betalactams|Class_C_betalactamases|ACT,1425138846|WP_112792421.1|NG_061401|1|1|blaACT-59|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-59 NG_061401:1-1146,0
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcgccaggatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_225,Drugs,MEG_225|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1102724736|WP_071593232.1|NG_052063|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052063:101-655,2
,GTGAAAGAACAAGACGCTGCCGACTGGCTAGCGCTGCGGAATCTTCTTTGGCTCGCGGATGATCACGCCTCGGAGATTGAGCAGTACTTCTCTGGTGGACTTGAGGAGCCTGTAGAAGTGCTCATCGCACGTGATGCTACCGGCGCGGCTGTTGGGCATGTCGAACTCTCGATAAGACATGACTTGGAAGAACTCCAAGGAATCAAGACCGGCTACATCGAAGGCCTTTATGTGGCCCCAAGCCATCGATCAACAGACCTTGTGAAGCGTTTCTTGCGTGAGTCCGAGAAGTGGGCCCTAGAACAAGGGTGCAGCGCATTTGCCTCAGACAGAAGTGATCGGGTCATCACGCACCGCAAGTTCGCAGGCAGCGCCGTCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_274,Drugs,MEG_274|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,(AGly)AacA29b:AY139599:768-1148:381,2
,TTGTCAACACGGTGCAAATCAAACACACTGATTGCGTCTGACGGGCCCGGACACCTTTTTGCTTTTAATTACGGAACTGATTTCATGATGAAAAAATCGTTATGCTCCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAACCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGGAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACTGTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAAAAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCTTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACGACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1978,Drugs,MEG_1978|Drugs|betalactams|Class_C_betalactamases|CMY,gi|496632|emb|X78117.1|58-1287,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacgataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcgactacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagcaccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2182,Drugs,MEG_2182|Drugs|betalactams|Class_A_betalactamases|CTX,1559612970|WP_128268235.1|NG_063838|1|1|blaCTX-M-215|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-215 NG_063838:1-876,0
,atgcgtaaaaaaatgcagaacacattgaagctgttatccgtgattacctgtctggcagcaactgtccaaggtgctctggctgctaatatcgatgagagcaaaattaaagacaccgttgatgacctgatccagccgctgatgcagaagaataatattcccggtatgtcggtcgcagtgaccgtcaacggtaaaaactacatttataactatgggttagcggcaaaacagcctcagcagccggttacggaaaatacgttatttgaagtgggttcgctgagtaaaacgtttgctgccaccttggcgtcctatgcgcaggtgagcggtaagctgtctttggatcaaagcgttagccattacgttccagagttgcgtggcagcagctttgaccacgttagcgtactcaatgtgggcacgcatacctcaggcctacagctatttatgccggaagatattaaaaataccacacagctgatggcttatctaaaagcatggaaacctgccgatgcggctggaacccatcgcgtttattccaatatcggtactggtttgctagggatgattgcggcgaaaagtctgggtgtgagctatgaagatgcgattgagaaaaccctccttcctcagttaggcatgcatcacagctacttgaaggttccggctgaccagatggaaaactatgcgtggggctacaacaagaaagatgagccagtgcacgggaatatggagattttgggtaacgaagcttatggtatcaaaaccacctccagcgacttgttacgctacgtgcaagccaatatggggcagttaaagcttgatgctaatgccaagatgcaacaggctctgacagccacccacaccggctatttcaaatcgggtgagattactcaggatctgatgtgggagcagctgccatatccggtttctctgccgaatttgctcaccggtaacgatatggcgatgacgaaaagcgtggctacgccgattgttccgccgttaccgccacaggaaaatgtgtggattaataagaccggatcaactaacggcttcggtgcctatattgcgtttgttcctgctaagaagatggggatcgtgatgctggctaacaaaaactactcaatcgatcagcgagtgacggtggcgtataaaatcctgagctcattggaagggaataagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_387,Drugs,MEG_387|Drugs|betalactams|Class_C_betalactamases|ACC,1028101860|WP_063857708.1|NG_048594|1|1|blaACC-4|blaACC|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACC-4 NG_048594:1-1173,0
,atgcaatttaaaaaaatttcttacttacttttaccttctctttttatttttaatacctcaatttatgcgggcaatacttctaaagaccaagaaattaaacaattgatagatcaaaattttaaacccttattagaaaaatataatgtgccgggtatggcggtaggtgttattcaaaacaataaaaaatatgaaacgtattatggtctacaatccgttcaagataaaaaagctgtaaatagcaataccatttttgagctaggttctgtcagtaaattatttactgcgacggcaggtgcttatgcaaaaaatacaggaaaaatctcttttaatgatacgccgggcaaatactggaaagagttaaaaaacaccccaattgatcaggtcaatttacttcaacttgccacctatacaagtggtaacctcgctttgcaattcccagatgaagtacaaacagatcaacaggttttaactttttttaaagattggaaacctaaaaacccaatcggtgaatatagacaatattcaaacccaagtattggcctatttggggaaatagttggtttatcaatgaagcagccttttagtcaggtcttggaaaaaacgatttttccggaccttggcttaaaacatagctatgtcaatgtgcctaaaactcagatgcaaaactatgcatttggctataaccaagaaaatcagccaattcgagttaaccctggcccactcgatgccccagcatacggcgtcaaatcgaccctacccgacatgctgagctttattcatgccaacctgaacccacagaaatatccggcaaatattcaacgtgcaattaatgagacacatcaaggtcgctatcaagtaaatagcatgtatcaggcactcggttgggaagagtttgcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccacaaaactggttcaacaaatggtttcggaacctatgccgtatttatacctaaagaaaatattggtttagtcatgttaaccaataaacgcattccaaatgaagaacgcattaaagcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_506,Drugs,MEG_506|Drugs|betalactams|Class_C_betalactamases|ADC,746188675|WP_039246976.1|NG_064703|1|1|blaADC-148|blaADC|class_C_beta-lactamase_ADC-148 NG_064703:101-1252,0
,atgagggaagcgatgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_768,Drugs,MEG_768|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,817656445|WP_046622360.1|NG_052536|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052536:101-892,2
,CGGAAGATAACCGATGATGACAAAATCCCTAAGCTGTGCCCTGCTGCTCAGCGTCGCCAGCGCTGCATTCGCCGCACCGATGTCCGAAAAACAGCTGGCTGAGGTGGTGGAACGTACCGTTACGCCGCTGATGAACGCGCAGGCCATTCCGGGTATGGCGGTGGCGGTAATTTATCAGGGTCAGCCACACTACTTTACCTTCGGTAAAGCCGATGTTGCGGCGAACAAACCCGTCACCCCGCAAACCCTGTTTGAGCTGGGCTCTATAAGTAAAACCTTCACCGGCGTACTGGGCGGCGATGCCATTGCCCGGGGTGAAATAGCGCTGGGCGATCCGGTAGCAAAATACTGGCCTGAGCTCACGGGCAAGCAGTGGCAGGGCATTCGCATGCTGGATCTGGCAACCTATACCGCAGGCGGTCTGCCGTTACAGGTGCCGGATGAGGTCACGGATACCGCCTCTCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCGGGCACCACGCGTCTTTACGCTAACGCCAGCATCGGTCTTTTTGGTGCGCTGGCGGTCAAACCTTCCGGCATGAGCTATGAGCAGGCCATGACGACGCGGGTCTTTAAACCCCTCAAGCTGGACCATACCTGGATTAACGTCCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGATACCGTGAGGGTAAAGCGGTCCACGTTTCGCCAGGGATGCTGGACGCGGAAGCCTATGGCGTAAAAACTAACGTGAAGGATATGGCGAGCTGGCTGATAGCCAACATGAAGCCGGATTCTCTTCACGCTCCCTCACTCAAGCAAGGCATTGCTCTGGCGCAGTCTCGCTACTGGCGCGTGGGTGCTATGTATCAGGGGTTAGGCTGGGAGATGCTCAACTGGCCGGTCGATGCCAAAACCGTCGTCGGAGGCAGTGATAACAAGGTGGCGCTGGCACCATTGCCCGTGGCAGAAGTGAATCCACCCGCGCCGCCGGTCAAAGCCTCCTGGGTCCATAAAACAGGCTCGACGGGCGGGTTTGGCAGCTACGTGGCATTTATTCCTGAAAAGCAGCTCGGCATTGTGATGCTGGCGAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCGTATCCTCGACGCGCTGCAGTAAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3972,Drugs,MEG_3972|Drugs|betalactams|Class_C_betalactamases|MIR,gi|53854917|gb|AY743435.1|1-1160 gi|666667509|gb|KJ949090.1|1-1146,0
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttggtcgggacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgtttccggaccgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcatggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctgaggcaatggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaatgcccatgctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1616,Drugs,MEG_1616|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1028084260|WP_063843228.1|NG_047611|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_047611:101-733,6
,atgagaaaaagtgtgggcattactgtttttggatgcgaacaggatgaggcaaatgctttccgcgctttatcgccggattttcatattatccctacgctgattagcgatgcgatatcggcagacaacgcaaaattggccgctggcaatcaatgcgttagcgtaggccataagtccgaggtttccgaggcgacaattcttgcgctgagaaaggtcggggtaaaatacatttctacccgcagcatcggctgcgatcacattgatacgactgccgccgagagaatgggaatctcggttggcacggttgcgtattcgccggacagcgttgcggattatgctttgatgctgatgctgatggccatacggggtgcaaaacccaccatgcacgccgtggcgcaacaagatttcagattggatcgtatccgggggaaagaactgggggatatgactgtgggagttattggaaccggccatatcgggcaagcggtcgtcaaaaggctgcggggatttggatgccatgtgctggcctatgataacagccgaaaaatggatgcagattatgtccagcttgatgagcttctaaaaaacagcgatattgttacgctccatgtgccgctttgtgcggatacccgccatctgatcggtcagaagcaaattggagagatgaagcaaggcgcatttttaatcaacaccgggcgcggagcgcttgtcgataccggggcgctggtggaggcgttggaaagcggaaagctgggtggtgcggcactggatgtgttggagggcgaggatcagtttgtttataccgattgctcgcagaaagtgcttgaccatccctttttgtcgcagcttttaaggatgccgaatgtgatcatcacaccccatacggcgtactacactgagcgtgtgctgcaggatactacagaaaaaacaatcaggaattgtctcaattttgaaaggagtttacagcatgaatag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7415,Drugs,MEG_7415|Drugs|Glycopeptides|VanB-type_resistance_protein|VANHB,488313489|WP_002382874.1|NG_048377|1|1|vanH-B|vanH-B|D-lactate_dehydrogenase_VanH-B NG_048377:101-1072,5
,atgagggaagtggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggctaatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_848,Drugs,MEG_848|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,695270417|WP_032492486.1|NG_047328|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_047328:101-892,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccatactgctgttcgccaccaccccggccattgccgacgaggccccggcagatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttctccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcctgaagcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgatatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5682,Drugs,MEG_5682|Drugs|betalactams|Class_C_betalactamases|PDC,759376626|WP_043104614.1|NG_049939|1|1|blaPDC-64|blaPDC|class_C_beta-lactamase_PDC-64 NG_049939:1-1194,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6947,Drugs,MEG_6947|Drugs|betalactams|Class_A_betalactamases|TEM,gi|82468436|gb|DQ269440.1|1-861 gi|3281931|emb|Y17584.1|1-858,0
,ATGTCGGGACTGCTGCTGGCCGTGTTCCTCGCGGCCCTGGACCAGACGGTCATCGCCACCGCGATGCGCACCATCGCGGACGACCTCCACGGCCAGACCGAGCAGGCATGGGCGACGACGGGCTACCTCATCGCCTCCGTCCTGGCGATGCCGTTCTACGGCAAGCTGTCCGACATCTACGGGCGCAAGCCCATGTACCTGATCTCCATCGTGGTGTTCATCGGCGGCTCGGTGCTGTGCGGCACGGCCGGCTCGATGTGGGAGCTGGCCCTCTTCCGGGCCGTCCAGGGACTGGGCGGCGGCGGGCTGATGTCCCTGCCCACCGCGGTGGTCGCCGACCTCGCCCCGGTGCGCGAGCGCGGCCGCTACTTCGCCTTCCTCCAGATGGCGTGGGTGGTCGCCAGCGTCGCGGGCCCGCTGGCGGGCGGCTTCTTCGCGGAGGCGGGCCAGGTCTTCGGCATCGACGGCTGGCGCTGGGTGTTCCTGCTCAACGTACCGCTGGGCCTGCTGGCCCTGGTCACCGTGCGCAAGGCCCTGAACCTGCCGCACGAACGGCGCGAGCACCGCATGGACGTACTGGGCGCGGCGGCGCTGGCGCTGTTCCTGGTGCCCCTGCTGATCGTCGCCGAACAGGGCCGGACCTGGGGCTGGGGCTCGCCGGCCGCCCTCGCCCTCTTCGCGCTCGGCGCGGCCGGGCTGGCGGTCTTCATCCCCGTCGAGCTGCGGCGCGGCGACGAGGCCATCCTGCCGCTGGGGCTCTTCCGGCGCGGCAGCATCGCGCTGTGCTCCGCGGTCAACTTCACCATCGGCGTCGGCATCTTCGGCACGGTCACCACCCTGCCGCTGTTCCTCCAGATGGTGCAGGGGCGGACCCCGACCCAGGCCGGACTGGTGGTCATCCCGTTCATGCTGGGCACCATCGCCTCGCAGATGGTCTCCGGCAAGCTCATCGCGTCCTCGGGCCGGTTCAAGAAACTGGCGATCGTGGGCCTGGGCTCGATGGCCGGGGCGCTGCTGGCCATGGCCACCACCGGCGCGACGACCCCGATGTGGGGCATCGTCCTGATCGTCCTCTGGCTCGGCGTCGGCATCGGCCTGTCCCAGACCGTCATCACCTCGCCCATGCAGAACTCGGCCCCCAAGAGCCAGCTCGGCGTGGCGAACGGCGCCTCCGGCCTGTGCCGGCAGATCGGCGGCTCCACCGGCATCGCGGTTCTGTTCTCCGTGATGTTCGCGGTGGCGCTCGGCCGCCTCGCCGACCTGCTGCACACCCCGCGCTACGAGCGCCTCCTGACGGACCCGGCGATCACCGGCGACCCCGCCAACCACCGCTTCCTTGACATGGCCGAGTCCGGGCAGGGCGCGGGGATCAACCTTGACGACACGTCCCTGCTGAACGGCATCGACGCCCGGCTGATGCAGCCGGTGACGGATTCCTTCGCCCACGGCTTCCACATCATGTTCCTCGCCGGCGGCGTGGTGCTGCTGGCCGGGTTCGTCATGACCTGGTTCCTGCGCGAACTCCAGGAGGAGACCGCGCCGGAGGAGGAGCGGCCGGCCGAGAGCGGCGCCGGGGCGAAGAACGGGCCGCTGCCCGCGTCGGACGCCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_4382,Drugs,MEG_4382|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|OTRB,gi|3617953|gb|AF079900.1|AF079900|121-1731 gi|3108176|gb|AF061335.1|AF061335|1-1611,4
,ATGATAGGGAAACTTATAATGATGAATCGCTATATCACAATCGCCCTCTTAATTACCTTCCTAGATGCAACAGGAATGGGCTTAATCATGCCTGTATTACCAACACTTTTAGAAGAGTTCTCTGTCAAAGAGTCTATCGCCACTCATTATGGTTTTATCCTCGCAATCTATGCGCTGATGCAAGTTATTTTTGCACCAATATTAGGACAACTCTCGGATAAATTTGGCAGAAAACCGGTCTTGATTCTCTCATTAATAGGCGCTGTTTGTGATTACACCCTACTCTCATTTTCTAGCGCCTTATGGATGCTCTATCTAGGGAGAATGATTGCCGGCATTTCTGCTGCAACAGGAGCCGTAGCAGCATCAATGGTCGCAGATCACACAAAAAAAGCAGAGAGAACTAAATGGTTTGGAAAGTTAGGCGCAGCTTTTGGGGCGGGACTCATTGCCGGACCCGCTATTGGTGGATTTATCGGACAATATTCTGCACATTTCCCCTTTATCATTGCCGCAATTTTAAATGCCATTGCTCTTATCATGGTCATTATCCTCTTCCCTAAAGAGCAATCACGCCCAAAAGAAATCGAGCAAGATCAATCTAAAATTCATGAAAAAACCACCATCAATGCCCCGCTAATTCATATTCTCAAACCCGTTTTGCTACTTCTCATGCTGTTTTTTACAGTACAACTCATCGGACAAATCCCTGCATCAACTTGGGTTCTATTTACTGAGTACCGTTTTGAGTGGAATACCTTTAACATTGGTTTATCCCTTGCAGGGCTAGGGTTAATGCATATTATCTTTCAGGCTTTTGTCGCAGGATATATCGCATCTCGCTGGAAAAATGAAACCGTATTTATTCTCGGATTTATACTAGATGCGAGCGCATTCTTATTACTGGCCTTTATCTCTCAAGTTTGGCTCGTAATTCCTACATTGATCTTATTAGCAGGAGGAGGCATCGCCTTACCGGCATTACAAGGATTAATCTCTATAAAGACAGCAGATGAACATCAAGGAAAGATACAAGGTATCATGGTTAGCCTCACTAATATTACCGGAATAATTGGACCGCCCATTTTTGCATTTTCCTTTGCAAAAACGGTTACAAACTGGGATGGCACACTTTGGCTAATCGGTGCTGTACTCTATAGCATTTTATTAGGTCTCTATTTTCTCTATCAAAAGATACGCGCCTATAAACAACTTAAGTCTCAAACTGCTTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6968,Drugs,MEG_6968|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET31,gi|915642179|gb|CP012365.1|755197-753965 gi|256260251|gb|GQ283908.1|4089-5321,4
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATACTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1431,Drugs,MEG_1431|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_83_FGWO01000019,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccaacgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5579,Drugs,MEG_5579|Drugs|betalactams|Class_C_betalactamases|PDC,730619314|WP_034054438.1|NG_049927|1|1|blaPDC-53|blaPDC|class_C_beta-lactamase_PDC-53 NG_049927:1-1194,0
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagttaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgatgaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgcgcgggaggaacagcagcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaatggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggggcgccgccctatgcggcagcgttttcaaggttgagtacaccgattgcggccagcggcgtgtctatctacggttatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatcagggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggaccaaacccggctccctcgtaaaaggtggcgcgaggaccccctccccatgctgcggacgacgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgttgcgaagtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccatcggactgtctgttacaccactcccgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcagggacgcaactgctggaaccttatctctccttcaccctctatgcgccccgggaatatctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggtccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcagagcgtatgccttacagaactgaaagggtatcaggccgctgtcggcaagccagtcatccagccccgccgtccaaacagccgcctggacaaggtgcgctatatgtttcagaagataatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7223,Drugs,MEG_7223|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,914626309|WP_050618045.1|NG_048303|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048303:1-1920,4
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAATACACCGTTTCTTTAGCTTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGACTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACAGAAACAGAAAATACAGCCGCTATTCGAAGGAAACGGCTTTTGGCTAAGTGAAGAGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAGCTGCCTTATGTAGGCTGCGGGGTGGCAAGTTCTGCCTTATGTATGAACAAATGGCTGCTGCATCAAGCTGCAGCAGCCATTGGCGTACAAAGTGCTCCTACGATTCTCTTGACAAATCAAGCCAACCAGCAAGAACAAATCGAAGCTTTTATCCAGACCCATGGCTTTCCAGTTTTCTTTAAGCCTAATGAAGCGGGCTCCTCAAAAGGGATCACTAAAGTCACCTGCGTTGAAGAAATCGCTTCTGCCTTAAAAGAAGCCTTTACTTATTGTTCCGCAGTGCTCCTACAAAAAAATATTGTCGGTGTTGAGATCGGTTGCGGTATTTTGGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCCATTTCATTAGAAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGCTGATCAGCGCCAAAATCACCGTCCCTGCGCCATTGCCTGAAACGATTGAAACCAAGGTCAAAGAACAAGCTCAGCTGCTCTATCGTAGTCTTGGTCTTAAAGGTCTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGCTTATCCTATCAAGAACTACTACAAAAACTGCTTATCTTAGCAAAGGAGGAAGTCAAATGAATCCCTATCTACAGTTAGTTAGCAAAGAATTTCCGTTAGAAAAAAACCAAGAACCCCCTCATTTAGTCCTTGCTGCCTTCAGCGAAGACGAGGTTTACTTGCAGCCAGAAGCAGCCAAACAATGGAAACGGCTCGTCAAAGCCTTAAAGCTTGAAAACGAGATCTGCTTGTTAGATGGCTACCGAACCGAAAAGCAGCAACGGTATTTATGGGAATATTCCTTGAAAGAAAATGGGCTAGCCTATACGAAACAATTTGTGGCGTTGCCCGGTTGCAGTGAACATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAGGGCAGCCAGGATGATTTGATCTGCCCACGATTTCGTGACAGCGCAGCCGCCGATTTATTTACCCAGGAAATGATGAACTATGGGTTTATTTTACGCTATCCCGCAGACAAACAGGAGATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTGCCTCATAGTCAAATCATCGCCAGTCAACAGTGGACCTTGGAAGAATACCATCAATACCTTGAACAAACTGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7378,Drugs,MEG_7378|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC2XY_3_EU151757,5
,atgcgttatgttcgcctgtgtgttatctccctgttagccaacctgccactggcggtagacgccggtccacagccgcttgagcagattaaacaaagcgaaagccagctgtcgggccgcgtggggatggtggaaatggatctggccagcggccgcacgctggccgcctggcgcgccgatgaacgctttcccatggtgagcacctttaaagtgctgctgtgcggcgcggtgctggcgcgggtggatgccgggctcgaacaactggatcggcggatccactaccgccagcaggatctggtggactactccccggtcagcgaaaaacaccttgtcgacgggatgacgatcggcgaactctgcgccgccgccatcaccctgagcgataacagcgctggcaatctgctgctggccaccgtcggcggccccgcgggattaactgcctttctgcgccagatcggtgacaacgtcacccgtcttgaccgctgggaaacggcactgaatgaggcgcttcccggcgacgcgcgcgacaccaccaccccggccagcatggccgccacgctgcgcaaactactgaccgcgcagcatctgagcccccgttcgcaacagcaactcctgcagtggatggtggacgatcgggttgccggcccgctgatccgcgccgtgctgccggcgggctggtttatcgccgacaagaccggggctggcgaacggggtgcgcgcggcattgtcgccctgctcggcccggacggcaaaccggagcgcattgtggtgatctatctgcgggataccccggcgagtatggccgagcgtaatcaacatatcgccgggatcggcgcagcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3540,Drugs,MEG_3540|Drugs|betalactams|Class_A_betalactamases|LEN,501535802|WP_012541790.1|NG_060510|1|1|blaLEN-28|blaLEN|class_A_beta-lactamase_LEN-28 NG_060510:101-961,0
,atgataaaaagttcgtggcgtaaaattgcaatgctagccgccgccgttccgctgctgctggcgagcggcgcactgtgggccagtaccgatgctatccatcagaagctgacagatctcgagaagcgttcaggcggcaggttgggcgtggcgctaatcaacacggcagataattctcaaatcttatatcgcggcgacgagcgttttgccatgtgcagcaccagtaaagtgatggccgccgccgcggtattaaaacagagcgaaagcaataaagaggtggtaaataaaaggctggagattaacgcagccgatttggtggtctggagtccgattaccgaaaaacatctccagagcggaatgacgctggctgagctaagcgcggcgacgctgcaatatagcgacaatacggcgatgaatctgatcatcggctaccttggcgggccggaaaaagtcaccgccttcgcccgcagtatcggcgatgccacctttcgtctcgatcgtacggagcccacgctgaataccgccatcccgggcgatgagcgtgataccagcacgccgctggcgatggctgaaagcctgcgcaagctgacgcttggcgatgcgctgggcgaacagcaacgcgcccagttagtcacctggctgaaaggcaataccaccggcgggcaaagcattcgcgcgggcctgcctgaaagctgggtggtcggcgataaaaccggtgccggagattacggcaccaccaatgatattgcggttatctggccggaaaatcacgctccgctggtattagtcacctactttacccagccgcagcaggatgcgaaaaaccgcaaagaggtgttagccgcagcggcaaaaatcgtgaccgaagggctttag,beta-lactamase,antibiotic inactivation,betalactams,MEG_5281,Drugs,MEG_5281|Drugs|betalactams|Class_A_betalactamases|OXY,1028110178|WP_063864548.1|NG_049849|1|1|blaOXY-2-12|blaOXY-2|class_A_extended-spectrum_beta-lactamase_OXY-2-12 NG_049849:1-873,0
,ATGACTAAAACAAAAATTATGGGCATATTAAACGTCACACCTGATTCATTCTCAGATGGTGGAAAATTTAATAATGTTGAATCAGCTATAAATAGAGTGAAAGCCATGATAGATGAAGGTGCTGACATTATAGATGTTGGAGGTGTTTCAACGAGACCCGGTCATGAAATGGTTTCATTAGAAGAAGAGATGAACAGAGTATTACCTGTTGTTGAAGCTATTGTCGGTTTTGATGTAAAAATTTCAGTCGATACATTTCGAAGTGAGGTTGCTGAAGCATGTTTAAAATTAGGCGTTGATATGATTAATGATCAATGGGCGGGTCTGTATGATCATCGTATGTTCCAAATTGTAGCTAAATATGACGCGGAAATTATTTTAATGCATAATGGAAATGGTAATCGTGATGAACCGGTTGTCGAAGAAATGTTAACATCTTTGTTAGCACAAGCACATCAAGCTAAAATAGCTGGTATACCTTCAAATAAAATTTGGCTAGATCCAGGTATAGGTTTCGCTAAAACTAGAAATGAAGAAGCCGAAGTTATGGCAAGACTGGATGAACTTGTTGCAACAGAATATCCAGTTTTATTAGCGACAAGCCGGAAACGTTTCACTAAAGAGATGATGGGTTATGATACAACACCGGTTGAAAGAGATGAAGTAACTGCAGCTACGACTGCATATGGTATTATGAAAGGCGTTAGAGCAGTACGCGTTCATAATGTCGAGTTGAATGCTAAATTAGCTAAAGGTATAGATTTTTTAAAGGAGAATGAAAATGCAAGACACAATCTTTCTTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2962,Drugs,MEG_2962|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|941146344|gb|CP007676.1|516912-517715 gi|941142962|gb|CP007672.1|541645-542448 gi|941139768|gb|CP007657.1|542121-542924 gi|899756207|gb|CP012119.1|1376783-1375980 gi|899750970|gb|CP012120.1|396378-395575 gi|828461663|gb|CP007674.1|525195-525998 gi|828444881|gb|CP007670.1|554935-555738 gi|827440804|gb|CP011526.1|497861-498664 gi|777225872|emb|LN831048.1|36428-37231 gi|743649775|gb|CP010300.1|551994-552797,8
,GTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCATCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6614,Drugs,MEG_6614|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|943457735|gb|KT818627.1|96560-97396 gi|943457735|gb|KT818627.1|158153-158989 gi|950836029|gb|KT897470.1|1833-2669 gi|829596799|gb|KR351290.1|89181-88345 gi|746616805|gb|KJ187752.1|78174-79010 gi|742994109|gb|CP010391.1|46165-45329 gi|667713574|gb|CP006801.1|42395-41559 gi|662716651|gb|CP008824.1|205800-206636 gi|660573358|gb|CP008790.1|157279-158115 gi|640855459|gb|CP007732.1|158132-158968 gi|619739382|gb|CP007558.1|158121-158957,8
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactactaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatcctttgatcggccttgagcaccatagggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4440,Drugs,MEG_4440|Drugs|betalactams|Class_D_betalactamases|OXA,1625655413|WP_136512090.1|NG_064757|1|1|blaOXA-799|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-799 NG_064757:1-825,0
,gtgaccaacagcaacgattccgtcgcactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttgtagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_240,Drugs,MEG_240|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502057|WP_071846209.1|NG_052182|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052182:101-655,2
,ATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2408,Drugs,MEG_2408|Drugs|betalactams|Class_A_betalactamases|CTX,gi|649725590|gb|KJ802489.1|1-876 gi|384406792|gb|JQ343850.1|1079-1954,0
,atgcgttttaccctgctcgccttcgccctggccgtcgctcttccggccgtccacgccagcgccgccgaggcaccgctgccacaactgcgggcctataccgtggatgcgtcccggctgcagccgatggcgccgctgcaggttgccgaccacacctggcagatcggcaccgaggacctgaccgcgctgctggtgcagaccgccgagggcgcagtactgctggatggcggcatgccacagatggccggtcacctgctggacaacatgaagctgcgcggcgtggccccgcaggacctgcgattgatcctgctcagccatgcgcatgccgaccacgccggcacggtcgccgagctcaagcgtcgcaccggcgcgcatgtggcggccaatgcagaaacggcggtgctgctggcgcgcggcggcagcaacgacctgcactttggcgacggcatcacctatccgccggccagcgccgaccgcatcatcatggatggcgaagtggtcacggtgggcggcatcgcattcaccgcgcacttcatgccggggcacaccccgggcagcaccgcctggacttggaccgacacccgcgatgggaagccggtgcgcatcgcctacgccgacagcctgagtgcaccgggttaccagctgaagggcaatccccgttatccgcgcttgatcgaggactacaagcgcagcttcgcaacggtacgggcgctgccctgcgatctgctgctcaccccgcatccgggcgccagcaactggaactatgccgccggcagcaaggccagcgccgaggcactgacctgcaacgcctacgcggatgcggccgagaagaagttcgacgcgcagttggccagggaaacggccgggacccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3529,Drugs,MEG_3529|Drugs|betalactams|Class_B_betalactamases|L1,1028083723|WP_063842691.1|NG_047509|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047509:1-873,0
,ATGAAAAAGATAAAAATTGTTCCACTTATTTTAATAGTTGTAGTTGTCGGGTTTGGTATATATTTTTATGCTTCAAAAGATAAAGAAATTAATAATACTATTGATGCAATTGAAGATAAAAATTTCAAACAAGTTTATAAAGATAGCAGTTATATTTCTAAAAGCGATAATGGTGAAGTAGAAATGACTGAACGTCCGATAAAAATATATAATAGTTTAGGCGTTAAAGATATAAACATTCAGGATCGTAAAATAAAAAAAGTATCTAAAAATAAAAAACGAGTAGATGCTCAATATAAAATTAAAACAAACTACGGTAACATTGATCGCAACGTTCAATTTAATTTTGTTAAAGAAGATGGTATGTGGAAGTTAGATTGGGATCATAGCGTCATTATTCCAGGAATGCAGAAAGACCAAAGCATACATATTGAAAATTTAAAATCAGAACGTGGTAAAATTTTAGACCGAAACAATGTGGAATTGGCCAATACAGGAACAGCATATGAGATAGGCATCGTTCCAAAGAATGTATCTAAAAAAGATTATAAAGCAATCGCTAAAGAACTAAGTATTTCTGAAGACTATATCAAACAACAAATGGATCAAAATTGGGTACAAGATGATACCTTCGTTCCACTTAAAACCGTTAAAAAAATGGATGAATATTTAAGTGATTTCGCAAAAAAATTTCATCTTACAACTAATGAAACAGAAAGTCGTAACTATCCTCTAGAAAAAGCGACTTCACATCTATTAGGTTATGTTGGTCCCATTAACTCTGAAGAATTAAAACAAAAAGAATATAAAGGCTATAAAGATGATGCAGTTATTGGTAAAAAGGGACTCGAAAAACTTTACGATAAAAAGCTCCAACATGAAGATGGCTATCGTGTCACAATCGTTGACGATAATAGCAATACAATCGCACATACATTAATAGAGAAAAAGAAAAAAGATGGCAAAGATATTCAACTAACTATTGATGCTAAAGTTCAAAAGAGTATTTATAACAACATGAAAAATGATTATGGCTCAGGTACTGCTATCCACCCTCAAACAGGTGAATTATTAGCACTTGTAAGCACACCTTCATATGACGTCTATCCATTTATGTATGGCATGAGTAACGAAGAATATAATAAATTAACCGAAGATAAAAAAGAACCTCTGCTCAACAAGTTCCAGATTACAACTTCACCAGGTTCAACTCAAAAAATATTAACAGCAATGATTGGGTTAAATAACAAAACATTAGACGATAAAACAAGTTATAAAATCGATGGTAAAGGTTGGCAAAAAGATAAATCTTGGGGTGGTTACAACGTTACAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCAGATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAAGATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTACGGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCACCTCACTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCAACAAGTCGTAAATAAAACACATAAAGAAGATATTTATAGATCTTATGCAAACTTAATTGGCAAATCCGGTACTGCAGAACTCAAAATGAAACAAGGAGAAACAGGCAGACAAATTGGGTGGTTTATATCATATGATAAAGATAATCCAAACATGATGATGGCTATTAATGTTAAAGATGTACAAGATAAAGGAATGGCTAGCTACAATGCCAAAATCTCAGGTAAAGTGTATGATGAGCTATATGAGAACGGTAATAAAAAATACGATATAGATGAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3787,Drugs,MEG_3787|Drugs|betalactams|Penicillin_binding_protein|MECA,mecA_9_AB505630,0
,TATCGCGTGTCTTTCGAGTACGGCATTAGCTGGTTCAATTACAGAAAATACGTCTTGGAACAAAGAGTTCTCTGCCGAAGCCGTCAATGGTGTCTTCGTGCTTTGTAAAAGTAGCAGTAAATCCTGCGCTACCAATGACTTAGCTCGTGCATCAAAGGAATATCTTCCAGCATCAACATTTAAGATCCCCAACGCAATTATCGGCCTAGAAACTGGTGTCATAAAGAATGAGCATCAGGTTTTCAAATGGGACGGAAAGCCAAGAGCCATGAAGCAATGGGAAAGAGACTTGACCTTAAGAGGGGCAATACAAGTTTCAGCTGTTCCCGTATTTCAACAAATCGCCAGAGAAGTTGGCGAAGTAAGAATGCAGAAATACCTTAAAAAATTTTCCTATGGCAACCAGAATATCAGTGGTGGCATTGACAAATTCTGGTTGGAAGACCAGCTTAGAATTTCCGCAGTTAATCAAGTGGAGTTTCTAGAGTCTCTATATTTAAATAAATTGTCAGCATCTAAAGAAAACCAGCTAATAGTAAAAGAGGCTTTGGTAACGGAGGCGGCACCTGAATATCTAGTGCATTCAAAAACTGGTTTTTCTGGTGTGGGAACTGAGTCAAATCCTGGTGTCGCATGGTGGGTTGGGTGGGTTGAGAAGGAGACAGAGGTTTACTTTTTCGCCTTTAACATGGATATAGACAACGAAAGTAAGTTGCCGCTAAGAAAATCCATTCCCACCAAAATCATGGAAAGTGAGGGCATCATTGGTGGCTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5154,Drugs,MEG_5154|Drugs|betalactams|Class_D_betalactamases|OXA,gb|L38523|+|0-774|ARO:3001409|OXA-14 [Pseudomonas aeruginosa] ,0
,atgataatcagtgaatttgaccgtaataatccagtattgaaagatcagctttctgatttactgagactgacttggccggaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacggatcgcggtagcagcggttgaccaagatgagttagtaggatttattggtgcaatccctcaatacggtatcacaggttgggaattgcatccattagttgtagaaagctcccgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagaggaggaatcacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaaacggacctgtatgagcatacgtttgataaagtggcctccatccagaaccttcgtgaacatccctatgagttctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaagtggttgggacaaaccggatatttggatggcaaaaacgattattcctcgaccagattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_87,Drugs,MEG_87|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,488222361|WP_002293569.1|NG_052275|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052275:101-649,2
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCGGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6251,Drugs,MEG_6251|Drugs|betalactams|Class_A_betalactamases|SHV,(Bla)SHV2A-kp:X62115:1281-2141:861,0
,ATGGAATTGCCCAATATTATTCAACAATTTATTGGAAACAGCGTTTTAGAGCCAAATAAAATTGGTCAGTCGCCATCGGATGTTTATTCTTTTAATCGAAATAATGAAACTTTTTTTCTTAAGCGATCTAGCACTTTATATACAGAGACCACATACAGTGTCTCTCGCGAAGCGAAAATGTTGAGTTGGCTCTCTGAGAAATTAAAGGTGCCTGAACTCATCATGACTTTTCAGGATGAGCAGTTTGAATTAATGATCACTAAAGCGATCAATGCAAAACCAATTTCAGCGCTTTTTTTAACAGACCAAGAATTGCTTGCTATCTATAAGGAGGCACTCAATCTGTTAAATTCAGTTGCTATTATTGATTGTCCATTTATTTCAAACATTGATCATCGGTTAAAAGAGTCAAAATTTTTTATTGATAACCAACTCCTTGACGATATAGATCAAGATGATTTTGACGCTGAATTATGGGGAGACCATAGAACTTACCTAAGTCTATGGAATGAGTTAACTGAGACTCGTGTTGAAGAAAGATTGGTTTTTTCTCATGGCGATATCACGGATAGTAATATTTTTATAGATAAATTCAATGAAATTTACTTTTTAGATCTTGGCCGTGCTGGGTTAGCTGATGAATTTGTAGATATATCCTTTGTTGAACGTTGCCTAAGAGAGGATGCCTCGGAGGAAACTGCTAAAATATTTTTAAAGCATTTAAAAAATGATAGACCTGACAAAAGGAATTATTTTTTAAAACTTGATGAATTGAATTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1069,Drugs,MEG_1069|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-PRIME,gb|KC170992.1|+|8362-9142|ARO:3003687|APH(3')-VI [Pseudomonas aeruginosa] ,2
,ATGAAAGTTAAAGTACTGTCCCTCCTGGTACCAGCACTGCTGGTAGCGGGCGCAGCAAATGCGGCTGAAATCTACAACAAAGACGGCAACAAATTAGACCTGTACGGTAAAATCGACGGTCTGCACTACTTCTCTTCCGACGACAGCGTCGACGGCGACCAGACCTACATGCGTATCGGCGTGAAAGGCGAAACCCAGATCAACGACCAGCTGACCGGTTACGGCCAGTGGGAATACAACGTTCAGGCGAACAACACTGAAAGCTCCAGCGACCAGGCGTGGACTCGTCTGGCCTTCGCGGGTCTGAAATTCGGCGACGCGGGTTCTTTCGACTACGGTCGTAACTACGGCGTTGTTTACGACGTAACTTCCTGGACCGACGTTCTGCCGGAATTCGGTGGCGACACCTACGGTTCCGACAACTTCCTGCAGTCCCGTGCTAACGGCGTTGCCACCTACCGTAACTCTGACTTCTTCGGTCTGGTTGACGGCCTGAACTTTGCTCTGCAGTACCAGGGTAAAAACGGCAGCGTGAGCGGCGAAGATCAGACCAACAACGGTCGCGGCTTCCAGAAACAGAACGGCGAAGGCTTCGGCACCTCCGTGACTTATGAGATCTGGGACGGCATCAGCGCTGGTTTCGCGTACTCCAGCTCTAAACGTACCGATGAGCAGAACAACTCTACTTATTTTTCTAAGTCCTATCAGCGTACATACGGTGTTCTGGGTGAAGGCGATCACGCTGAAACCTATACCGGTGGTCTGAAATATGACGCCAACAACATTTACCTGGCGACTCAGTACACCCAGACCTACAACGCAACTCGCACTGGCGACATCGGTTTTGCTAACAAAGCGCAGAACTTCGAAGTGGTTGCTCAGTACCAGTTCGACTTCGGTCTGCGTCCGTCCGTGGCTTACCTGCAGTCTAAAGGTAAAGACATGGGCCGTTACGGCGACCAGGACATCCTGAAATATGTTGACCTGGGTGCGACCTACTACTTCAACAAAAACATGTCCACCTACGTTGATTACAAAATCAACCTGCTGGACGACAACAAGTTCACTAAAGATGCAAGCATCTCTACTGACAACGTTGTGGCTCTGGGCCTGGTTTACCAGTTCTAA,General Bacterial Porin (GBP),reduced permeability to antibiotic,betalactams,MEG_4281,Drugs,MEG_4281|Drugs|betalactams|Mutant_porin_proteins|OMP36,gi|13384120|gb|AF336097.1|1-1128,0
,AACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGGTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAGGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_340,Drugs,MEG_340|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|18958399|gb|AF355189.1|1891-2439,2
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaatgaaacccagagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaaacagataaaaaaattaatctgtatggtaatgctctaagccgtgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttatcgcttgggaaaaagacatgacactaggagaagccatgaagctttccgcagtcccagtctatcaagaacttgcaagacgtattggtcttgatctcatgcaaaaagaagtagaacgtattgatttcggtaatactgaaattggacagcaggttgataatttctggttggtagggccattaaaggttacgcctattcaagaggtagagtttgtttctcaattggcgcatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgcttcttttagaagagagtaatggctacaaaatttttggaaagactggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcgcttttgcattaaatatggaaatgcggtcagaaatgccggcatctatacgtaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4519,Drugs,MEG_4519|Drugs|betalactams|Class_D_betalactamases|OXA,651319547|WP_026444036.1|NG_064774|1|1|blaOXA-816|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-816 NG_064774:1-822,0
,atgaaaacaataatgcttctggtgctgtgcagcagccttatgctgatggcttgtacctcacctacgacatctttatctacaccatcacagcatgtccagacccaacaggcacaagtaatcgcggaattatttaatcaagctcagactcaaggggttttagtcattcagcatggcgctaaggtacaaagctatggcaatgacttaagccgtgcagataccgaatatgtgcccgcctccacttttaaaatgctgaatgccttgattggattacaacatcacaaagccaacatagaggaagtgtttaaatgggatggcaagaaacgtagctttccggcctgggaaaaggacatgaccttgggcgaagctatgcaggcctctgctgtacctgtctatcaggagctggcacgccgtattggtctggagctcatgcaacaggaagtgcgacggatcaaatttggtaatcaaaagattgggcaacaagtcgataacttctggttagtgggccccttaaaaatcactcctaaacaggaggccgattttgtcgctcgcctggctcaacagcaattggcttttgatcctctggttcagcaacaagtgaaacagatgttactcttgcaacaaagacagggttatcgtctctatgccaaatctggctggggaatggatcttgaaccacaagtcggctggttgacaggctggattgaaactccagacgctgaaatcgtggcattctcactgaatatgcagatgtataattcgacgaatccggcaattcgcctagaaattttacaacaggcgctggctgaattagggctttatccaaaagcatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4414,Drugs,MEG_4414|Drugs|betalactams|Class_D_betalactamases|OXA,1271558630|WP_099337823.1|NG_055785|1|1|blaOXA-568|blaOXA|class_D_beta-lactamase_OXA-568 NG_055785:101-931,0
,atgccaatggagcaagctttgttcgttaggattgcgcgtgcacttgccgcatcgctcattaccctttccgctgtcgcttttgcgcaagagccgaaggtggatatccccgccgatcaacaggcttttgtcgatatctgcaagccatgggacgaatgggacaaacctgccccacccttcgagatttaccgcgacacctattatgtcgggacctgcggcatcgccgcgattcttatcaccgatgaggagggccatatcctgatcgacagcgggaccgaggcaggcgcggatgtggtcatggccaatgtggcggcgctgggctttgaccttaaagatgtgcgctatcttttgtatagccacgaacacttcgaccacgtcggcggcatggcaaagcttcaacgcgcaaccggcgcactggtggtcgcttcaaaagccgcagagcccgtgctgacatcaggcgaagattcgctggcggacccgcagcacgggatgcacgaaccgttcgaaggggttgccgtaggacggatcatggccgcaggagacatcctagagctgggcggcaccaccattcgtgcgatcgaaacacccggccacacccctggcgcgatgagctggtggtggcaggaatgcaaggaacgctgcgagaatatcgtctacgccgacagcctttctcccatcagccgcgatgactaccgatttggcgatcaccccgaatatgtcgccgcataccgcgccggactggtcgcattggggcgtgaggactgcaccgttttgctgaccccgcacccttcgcacagccgcatgatccgccggatgcaagagggtgatctgatcgaaaacaggcaagggacgcggccatgtgcccgctatgcagggcaaaagctgctcgaccttgaaacgcgactttccaatgaaacgctatccgaagaagatcgggcccaatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_2708,Drugs,MEG_2708|Drugs|betalactams|Class_B_betalactamases|ELM,1175305388|WP_081853183.1|NG_062206|1|1|blaELM-1|blaELM|subclass_B3_metallo-beta-lactamase_ELM-1 NG_062206:1-942,0
,atgaaaaaattatttgttttatgtgtattcttcttctgcaacattgcagttgcagaagaatctttgcctgatttaaaaattgagaagcttgaagaaggcgtttatgttcatacttcgtttgaagaagttaaaggttggagtgtggtcactaaacacggtttggtggttcttgtgaaaaatgacgcctatctgattgatactccagttactgctaaagatactgaaaaattagtcaattggtttgttgagcggggctataaaatcaaaggcagtatttccacacatttccatggtgacagtacggctggaatagagtggcttaattctcaatctatccccacatatgcttctgaattaacaaatgaacttcttaaaaaagacaataaggtacaagctaaacactcttttaatggggttagttattcactaattaaaaacaaaattgaagttttttatccaggcccagggcacactcaagataacgtagtggtttggttacctgaaaagaaaattttattcggtggttgctttgttaaaccggacggtcttggctatttgggggacgcaaatttagaagcttggccaaagtccgctaaaatattaatgtctaaatatggtaaagcaaaactagttgtgtcgagtcatagtgatattggagatgtatcactcttgaaacgtacatgggagcaggctgttaaagggctgaatgaaagtaaaaaatcatcacagccaagcgactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3314,Drugs,MEG_3314|Drugs|betalactams|Class_B_betalactamases|IMP,1028105503|WP_063860615.1|NG_049216|1|1|blaIMP-54|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-54 NG_049216:1-741,0
,ATGATAAAAAGTTCGTGGCGTAAAATTGCAATGCTAGCCGCCGTTCCGCTGCTGCTGGCGAGCGGCGCACTGTGGGCCAGTACCGATGCTATCCATCAGAAGCTGACAGATCTCGAGAAGCGTTCAGGCGGCAGGTTGGGCGTGGCGCTAATCAACACGGCAGATAATTCTCAAATCTTATATCGCGGCGACGAGCGTTTTGCCATGTGCAGCACCAGTAAAGTGATGGCCGCCGCCGCGGTATTAAAACAGAGCGAAAGCAATAAAGAGGTGGTAAATAAAAGGCTGGAGATTAACGCAGCCGATTTGGTGGTCTGGAGTCCGATTACCGAAAAACATCTCCAGAGCGGAATGACGCTGGCTGAGCTAAGCGCGGCGACGCTGCAATATAGCGACAATACGGCGATGAATCTGATCATCGGCTACCTTGGCGGGCCGGAAAAAGTCACCGCCTTCGCCCGCAGTATCGGCGATGCCACCTTTCGTCTCGATCGTACGGAGCCCACGCTGAATACCGCCATCCCGGGCGATGAGCGTGATACCAGCACGCCGCTGGCGATGGCTGAAAGCCTACGCAAGCTGACGCTTGGCGATGCGCTGGGCGAACAGCAACGCGCCCAGTTAGTCACCTGGCTGAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCGGGCCTGCCTGAAAGCTGGGTGGTCGGCGATAAAACCGGCGCCGGAGATTACGGCACCACCAATGATATTGCGGTTATCTGGCCGGAAGATCACGCTCCGCTGGTATTAGTCACCTACTTTACCCAGCCGCAGCAGGATGCGAAAAACCGCAAAGAGGTGTTAGCCGCAGCGGCAAAAATCGTGACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5286,Drugs,MEG_5286|Drugs|betalactams|Class_A_betalactamases|OXY,(Bla)OXY2-5:AY077487.2|:180-1049:870,0
,atgaaaaaaatcgccattatttttggaggcaattcaccggaatacaccgtttctttagcttcagcaactagcgcaatcgaagcactccaatcatctccctatgactacgacctctctttgatcgggatcgccccagatgctatggattggtacttgtatacaggagaactggaaaacatccgacaagacacgtggttgttggatacgaaacataaacagaaaatccagccgctattcgaaggaaacggcttttggctaagtgaagagcagcaaacgttggtacctgatgttttatttcccattatgcatggcaaatatggggaagatggcagtatccaaggattgtttgaattgatgaagctgccttatgtaggttgcggggtggcaggttctgccttatgtatgaacaaatggctgctgcatcaagctgcagcagccattggcgtacaaagtgctcctacgattctcttgacaaatcaagccaaccagcaagaacaaatcgaagcttttatccagacccatggcttcccagttttctttaagcctaatgaagcgggctcctcaaaagggatcactaaagtcacctgcgttgaagaaatcgcttctgccttaaaagaagcctttacttattgttccgcagtgctcctacaaaaaaatattgccggtgttgagatcggttgcggtattttgggcaacgactctttgactgtcggtgcttgtgacgccatttcattagtagacggctttttcgattttgaagaaaagtaccagctgatcagcgccaaaatcaccgtccctgcgccattgcctgaaacgattgaaaccaaggtcaaagaacaagctcagctgctctatcgtagtcttggtcttaaaggtcttgctcgcatcgacttttttgtcacggatcaaggagaactatacttgaatgaaatcaatactatgccgggctttacgagtcactcccgctatcctgccatgatggcagcggtcggcttatcctatcaagaactactacaaaaactgcttgtcttagcaaaggaggaagtcaaatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7358,Drugs,MEG_7358|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,1028100535|WP_063856670.1|NG_048350|1|1|vanC2/3|vanC2/3|D-alanine--D-serine_ligase_VanC2/3 NG_048350:29-1081,5
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagtcaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgataaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgtgcgggaggaacagcggcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgccgccctatgcggcagcgttttcaaggtggagtatacagattgcggccagcggcgtgtctatctacggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggacccaacccggctccctcgtaaaaggtggcgtgaggaccccctccccatgctgcggacgtcgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgctgcgaggtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccataggactgtctgttacaccactctcgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcagggacgcaactgctggaaccttatctctccttcaccctctatgcgccccgggaatatctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggtccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcagagcgtatgccttacagaactgaaaggatatcaggccgctgtcggcaagccggtcatccagccccgccgtccaaacagccgcctggacaaggtgcgccatatgtttcagaaggtaatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7214,Drugs,MEG_7214|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100282|WP_063856417.1|NG_048289|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048289:101-2020,4
,ATGAAAACAGTATTTATCCTTATCTCCATGCTTTTCCCTGTCGCAGTTATGGCACAGAAAAGCGTAAAAATATCCGATGATATCAGTATCACCCAACTCTCGGACAAAGTGTACACTTATGTATCCCTCGCCGAAATCGAAGGATGGGGTATGGTACCTTCCAACGGAATGATTGTTATCAACAACCATCAGGCAGCGTTGCTGGACACACCGATCAATGACGCACAAACGGAAACGCTGGTCAACTGGGTAGCGGACTCTTTGCATGCCAAAGTCACCACGTTTATCCCGAACCACTGGCACGGCGATTGTATTGGCGGACTGGGTTACCTGCAAAAGAAAGGTGTCCAATCATACGCAAACCAGATGACGATAGACCTCGCCAAGGAAAAAGGATTGCCCGTACCGGAACATGGATTCACCGATTCACTGACCGTCAGCTTGGACGGCATGCCTCTCCAATGTTATTATTTAGGAGGCGGACATGCGACCGACAATATCGTGGTTTGGCTGCCGACAGAGAATATCCTTTTTGGCGGATGTATGCTTAAAGACAACCAGGCGACAAGCATCGGCAACATCTCGGACGCGGACGTGACGGCATGGCCGAAAACTCTCGATAAGGTAAAAGCCAAGTTCCCCTCGGCCCGCTACGTCGTGCCCGGACATGGCGACTATGGCGGAACCGAACTGATAGAGCATACCAAGCAGATCGTGAACCAATATATAGAAAGCACCTCAAAGCCATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1675,Drugs,MEG_1675|Drugs|betalactams|Class_B_betalactamases|CFIA,(Bla)cfiA6:AB087231:1-750:750;(Bla)CfiA16:FM200792:1845-2594:750;(Bla)cfi6A1:FM200792,0
,AAATTGAAGAGTTTGATCATGGCTCAGATTGAACGCTGGCGGCAGGCCTAACACATGCAAGTCGAACGGTAACAGGAAGAAGCTTGCTTCTTTGCTGACGAGTGGCGGACGGGTGAGTAATGTCTGGGAAACTGCCTGATGGAGGGGGATAACTACTGGAAACGGTAGCTAATACCGCATAACGTCGCAAGACCAAAGAGGGGGACCTTCGGGCCTCTTGCCATCGGATGTGCCCAGATGGGATTAGCTAGTAGGTGGGGTAACGGCTCACCTAGGCGACGATCCCTAGCTGGTCTGAGAGGATGACCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCCATGCCGCGTGTATGAAGAAGGCCTTCGGGTTGTAAAGTACTTTCAGCGGGGAGGAAGGGAGTAAAGTTAATACCTTTGCTCATTGACGTTACCCGCAGAAGAAGCACCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAGGGTGCAAGCGTTAATCGGAATTACTGGGCGTAAAGCGCACGCAGGCGGTTTGTTAAGTCAGATGTGAAATCCCCGGGCTCAACCTGGGAACTGCATCTGATACTGGCAAGCTTGAGTCTCGTAGAGGGGGGTAGAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGTCGACTTGGAGGTTGTGCCCTTGAGGCGTGGCTTCCGGAGCTAACGCGTTAAGTCGACCGCCTGGGGAGTACGGCCGCAAGGTTAAAACTCAAATGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGATGCAACGCGAAGAACCTTACCTGGTCTTGACATCCACAGAACTTTCCAGAGATGGATTGGTGCCTTCGGGAACTGTGAGACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTTGTGAAATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATCTTTTGTTGCCAGCGGTCCGGCCGGGAACTCAAAGGAGACTGCCAGTGATAAACTGGAGGAAGGTGGGGATGACGTCAAGTCATCATGGCCCTTACGACCAGGGCTACACACGTGCTACAATGGCGCATACAAAGAGAAGCGACCTCGCGAGAGCAAGCGGACCTCATAAAGTGCGTCGTAGTCCGGATTGGAGTCTGCAACTCGACTCCATGAAGTCGGAATCGCTAGTAATCGTGGATCAGAATGCCACGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGGGAGTGGGTTGCAAAAGAAGTAGGTAGCTTAACCTTCGGGAGGGCGCTTACCACTTTGTGATTCATGACTGGGGTGAAGTCGTAACAAGGTAACCGTAGGGGAACCTGCGGTTGGATCACCTCCTTA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_6147,Drugs,MEG_6147|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|RRSH,gb|U00096|+|223771-225312|ARO:3003372|Escherichia coli 16S rRNA mutation in the rrsH gene conferring resistance to spectinomycin [Escherichia coli K-12] ,2
,atgaacaaagtaaatataaaagatagtcaaaattttattacttcaaaatatcacatagaaaaaataatgaattgcataagtttagatgaaaaagataacatctttgaaataggtgcagggaaaggtcattttactgctgaattggtaaagagatgtaattttgttacggcgatagaaattgattctaaattatgtgaggtaactcgtaataagctcttaaattatcctaactatcaaatagtaaatgatgatatactgaaatttacatttcctagccacaatccatataaaatatttggcagcataccttacaacataagcacaaatataattcgaaaaattgtttttgaaagttcagccacaataagttatttaatagtggaatatggttttgctaaaaggttattagatacaaacagatcactagcattgctgttaatggcagaggtagatatttctatattagcaaaaattcctaggtattatttccatccaaaacctaaagtggatagcgcattaattgtattaaaaagaaagccagcaaaaatggcatttaaagagagaaaaaaatatgaaacttttgtaatgaaatgggttaacaaagagtatgaaaaactgtttacaaaaaatcaatttaataaagctttaaaacatgcgagaatatatgatataaacaatattagtttcgaacaatttgtatcgctatttaatagttataaaatatttaacggctaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2834,Drugs,MEG_2834|Drugs|MLS|23S_rRNA_methyltransferases|ERMG,504199925|WP_014387027.1|NG_047827|1|1|erm(G)|erm(G)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(G) NG_047827:101-835,7
,TCTCTCGAGCTATCAGGCTAGAGATTTTACCGCCAAATCGAACCTTATTAGAGCGGTTTAGGCTGGACCGGCAGTTAAAATTGGGGCTTGAGCGGTAAACGAGTGAGGGAATTTCAGGTAAGATACTTCGGATGAGGAGCAAAAAGGTGGTTTATACTTCCTATACCCGGGGGGGCAAGTCATGGATAACCCATTGAAACTGGGCTATTTGAACGCCGACTTCACATCGGCTTCACAGAGCCTCATATTGCGCACACCTTGCGGGATTAGGCTGGGAGCACTGCCAGGCACCCAGGCAGCACATTCGACTTATGACGAGAGGAGTAGACCCGATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTACTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCGGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGCCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCGTTTGCCCCCTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGTGTCAACCCTGGCATGCTGGCGGACGAGGCCTATGGCATCAAGACCAGCTCGGCGGATCTGCTGCGTTTTGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACCAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGATCCTCGAAGCCAATCCGACGGCGGCGCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTACCCCAACGAGGCGCGCATCAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGAAAGAAAGAGGGCGGTACATTCGGTGAATGTGCCGCCCTTTTTCTGGTGCTGGGGGAATACCCCCGCTAGTCGTACTGCT,beta-lactamase,antibiotic inactivation,betalactams,MEG_1991,Drugs,MEG_1991|Drugs|betalactams|Class_C_betalactamases|CMY,gi|695197690|ref|NG_034779.1|1-1560 gi|573013567|dbj|AP013064.1|27435-27602 gi|573013567|dbj|AP013064.1|29690-29857 gi|573013567|dbj|AP013064.1|29858-29976 gi|146150962|gb|EF382672.1|102351-102518 gi|695199441|ref|NG_035225.1|331-498 gi|695200064|ref|NG_035368.1|1-118,0
,atgaggctgcacgggaatcaagtggtgctgcgtgcggtgaccgggagcgacatcgggaccctcgacaggatcgtgcgggaaccggaggtcgcggcgtggtggtcgccccccgaggactaccggggcatgctggccgtcgtcttcgagggtgaggtcgtcggcgcggtccagttccacgaggagaccgatcccgagttccgccacgccggcatcgacatcttcctgacggcacggcagcacgggaagggactcggcaccgacacggtgcgcacgctggcccgttggctggtggaggaacgcggccaccaccggctgaccatcgaccccgccgcggccaacaccgcggcgatccgctgctatgccggggtcggcttcaaacccgtggggatcatgcgggcctacgcccgcgaccaccgcacgggcacctggcaggacggtctgctgatggacctgctcgcggccgagctgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_134,Drugs,MEG_134|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,664569945|WP_031084431.1|NG_052342|1|1|aacA-STR-7|aacA-STR-7|aminoglycoside_6'-N-acetyltransferase NG_052342:101-574,2
,atggtcacgggtgcgtgggtgagtacagtgagggaaaacaggaactggtctgagtttgatgtgtgtaagcacccctccctgcacgctgatgctgcagccttgctgatgaacaccttccaggctaaaggcattacatcctggcctaatattgaatctgcgcgccagacgcttgatgagtgcattgcagttccaaacctgtgtctgggcatgctcattgatggcaagttagccgggtgggtgggtctacggccaatgtatgacaagacctgggagctgcaccctttggttgttgcacctgcgcagcaagggcagggcgtcggtaaagcactgctgcaaactctggagcaacgagccaaagcacaggggttgatcggtattgtcctggggacggacgacgagctgtttgaaaccagcctgtcacaaacggacctcaacggcagcaatgtacttgctgaattgaagcggttatccaacagggcccgtcatccgttcgaattctaccaaaagtgcggctacagcgttatcggggcggttcccaacgccaatggcaagaacaaacccgatatcatgatgtggaaagatctgagtgcggatggagtatag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_203,Drugs,MEG_203|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,916601194|WP_051208285.1|NG_052294|1|1|aac(6')_Ia_fam|aac(6')_Ia_fam|AAC(6')-Ia_family_aminoglycoside_6'-N-acetyltransferase NG_052294:101-703,2
,TTGGGATACAGTCCTGTATTCGGGAAGCGCATCAAGGAGGCGGTCACCATCACGAAGCGACTCACCCGGCAGCAGAGCCGGCAGGTCACCCGCGAGCAGATCCTCCGGTCGGCGGCCGCCCTCTTCGCGGGCCAGGGCGTCAGCGGAACCTCGGTGGAGCAGATCGTCGAGTCCGCCGGATACACCCGCGGCGCCTTCTACGGCAACTTCGAGGGCAAGCACGAGCTCGTCCTCGCCCTGCTGGAGCAGCGGACCCAGCACGAGCTCGAAGAGATCCAGGCGATGAGCCGCGAGGCGGCCACCTTCGAGGAGATGCTGGACCACCTGCGCTCCTGGCACCGACGGCGCGACGAGAACCTCGCCAGCTGGCTCGCGCTGCGCACCGAACTCTGGCTCTACGGACTGCGCGACCCGGAGCTGCTGCCCCTGTTGGCGGACCGCGAGCGCCGCTCGCGGGACGCGATCGCCCAGTCGCTGGAGCAGGGCTTCGCCGCACGCGGGGTGACCACCCCGGCGCCCGTGGAGCTCCTGGCACTGATCGTCCACGCGCTGGACGACGGACTGTCCATCCAGCGCGTGCTCTTCCCCTCCGACAGCGGCACGGACTCCGTCGTGGACGTGGTGGAGCTCCTCATGAAGTCCTGGACCGCACTCGCCCGCAGCACCGCACCCGCACCCGCGGCCGAACCCGCCGCCGAACCCCCGACCGAGAAGCTGGAGAAGAACCCATGA,tetR,antibiotic target alteration,Tetracyclines,MEG_7192,Drugs,MEG_7192|Drugs|Tetracyclines|Tetracycline_transcriptional_repressor|TETR,gi|388890562|gb|JQ768046.1|7033-7764,4
,GGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGTGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6486,Drugs,MEG_6486|Drugs|betalactams|Class_A_betalactamases|SHV,gi|74422856|gb|DQ174307.1|1-865,0
,atgataatcagtgaatttgaccgtaataatccagtattgaaagatcagctttctgatttactgagactgacttggccggaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacgaatcgcggtagcagcggtagaccaagatgagttagtaggatttattggtgcaatccctcaatacggtatcacaggttgggaattgcatccattagttgtagaaagctcccgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagaggaggaatcacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaaacggacctgtatgagcatacatttgataaagtggcttccatccagaaccttcgtgaacatccgtatgaattctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaaatggctgggacaaaccggatatttggatggcaaaaacgattattcctcgacaagattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_83,Drugs,MEG_83|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,514902502|WP_016628216.1|NG_052290|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052290:101-649,2
,ATGGAATTAATATTAAAAGCAAAAGACATTAGTGTGGAATTCAAAGGACACGATGTTTTAGATATAAATGAATTAGAAGTATATGATTATGACCGTATTGGTTTAGTAGGAGCAAATGGTGCAGGAAAAAGCACTTTATTCAAGGTACTTTTAGGAGAATTAATTCCCCCAGGATGTAAAATGAATCATCTGGGTGAACTTGCCTATATTCCCCAGTTGGACGAAGTAACTCTGCAGGAGGAAAAAGATTTTGCGCTTGTAGGCAAGCTAGGTGTTGAGCAATTAAATATACAGACCATGAGCGGTGGTGAAGAAACAAGGCTTAAAATAGCACAGGCCTTATCGGCACAGGTTCATGGTATTTTAGCGGATGAACCTACGAGCCATTTAGACCGTGAAGGAATTGATTTTCTAATAGGACAGCTAAAATATTTTACAGGTGCACTGTTAGTTATTAGCCATGACCGCTATTTTCTTGATGAAATAGTAGATAAAATATGGGAACTGAAAGATGGCAAAATCACTGAGTATTGGGGAAACTATTCTGATTATCTTCGTCAGAAAGAGGAAGAACGTAAGAGACAAGCTGCAGAATACGAACAATTTATTGCGGAACGTGCTCGATTGGAAAGGGCTGCGGAGGAAAAGCGAAAACAGGCTCGTAAAATAGAACAGAAGGCAAAAGGTTCTTCAAAGAAAAAAAGTACTGAAGGCGGAGGGCGTTTAGCTCATCAAAAATCAATAGGAAGTAAGGAAAAAAAGATGCATAATGCCGCTAAATCCCTAGAGAACAGGATTGCGGCATTAGGAAAAGTAGAAGCTCCGGAAGGCATTCGCAGAATTCGTTTCAGGCAAAGTAAAGCATTGGAGCTCCATAATCCATACCCTATAGTCGGTGCGGAAATTAATAAAGTATTTGGGGATAAGGCACTGTTTGAAAATGCATCTTTTCAAATTCCGCTAGGAGCAAAAGTGGCATTAACGGGTGGTAATGGAACCGGAAAAACAACTTTAATCCAAATGATCTTAAACCATGAAGAAGGAATTTCTATTTCACCTAAGGCAAAAATAGGTTACTTTGCACAGAATGGTTACAAGTACAACAGTAATCAGAATGTTATGGAGTTTATGCAGAAGGATTGTGATTACAATATATCAGAAATTCGTTCTGTGCTAGCATCTATGGGGTTCAAACAGAACGATATTGGAAAAAGCTTATCTGTTTTAAGCGGTGGAGAAATTATAAAATTGTTGCTTGCTAAAATGCTCATGGGTAGATATAACATCCTAATAATGGATGAACCCAGTAACTTCCTTGACATACCAAGTTTAGAGGCTTTGGAAATACTAATGAAGGAGTACACCGGAACTATCGTGTTTATCACCCACGATAAACGATTACTCGAAAATGTAGCTGATGTAGTTTATGAAATTAGAGATAAGAAAATTAAGCTGAAACATTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_4074,Drugs,MEG_4074|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|MSRD,gi|301800973|emb|FQ312029.1|887331-888794 gi|50902420|gb|CP000003.1|1167421-1165958 gi|50261575|gb|AY657002.1|4608-6071 gi|40218525|gb|AY445042.1|10960-12423 gi|18478326|gb|AF227521.1|4607-6070 gi|10119923|gb|AF227520.1|AF227520|4591-6054,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactactgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacctacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctgggtgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5624,Drugs,MEG_5624|Drugs|betalactams|Class_C_betalactamases|PDC,1040941174|WP_065159028.1|NG_050981|1|1|blaPDC-169|blaPDC|class_C_beta-lactamase_PDC-169 NG_050981:1-1194,0
,atgcgtaaaaaaatgcagaacacattgaagctgttatccgtgattacctgtctggcagcaactgcccaaggtgctctggctgctaatatcgatgagagcaaaattaaagacaccgttgatgacctgatccagccgctgatgcagaagaataatattcccggtatgtcggtcgcagtgaccgtcaacggtaaaaactacatttacaactatgggttagcggcaaaacagcctcagcagccggttacggaaaatacgttatttgaagtgggttcgctgagtaaaacgtttgccgccaccttggcgtcctatgcgcaggtgagcggtaagctgtctttggatcaaagcgttagccattacgttccagagttgcgcggcagcagctttgaccacgttagcgtactcaatgtgggcacgcatacctcaggcctacagctatttatgccggaagatattaaaaataccacacagctgatggcttatctaaaagcatggaaacctgccgatgcggctggaacccatcgcgtttattccaatatcggtactggtttgctagggatgattgcggcgaaaagtctgggtgtgagctatgaagatgcgattgagaaaaccctccttcctcagttaggcatgcatcacagctacttgaaggttccggctgaccagatggaaaactatgcgtggggctacaacaagaaagatgagccagtgcacgtgaatatggagattttgggtaacgaagcttatggtatcaaaaccacttccagcgacttgttacgctacgtgcaagccaatatggggcagttaaagcttgatgctaatgccaagatgcaacaggctctgacagccacccacaccggctatttcaagtcgggtgagattactcagggtctgatgtgggagcagctgccatatccggtttctctgccgaatttgctcaccggtaacgatatggcgatgacgaaaagcgtggctacgccgattgttccgccgttaccgccacaggaaaatgtgtggattaataagaccggatcaactaacggcttcggtgcctatattgcgtttgttcctgctaagaagatggggatcgtgatgctggctaacaaaaactactcaatcgatcagcgagtgacggtggcgtataaaatcctgagctcattggaagggaataagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_382,Drugs,MEG_382|Drugs|betalactams|Class_C_betalactamases|ACC,1028101850|WP_063857698.1|NG_048591|1|1|blaACC-1c|blaACC|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACC-1c NG_048591:1-1173,0
,atggcactggcactcgttggcgaaaaaattgacagaaaccgcttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacatgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggtggattttcgcaatgccagtgcgcttggcattgaaattcgccactgtcgtgcgcaaggcgcagatttccgcggcgcaagctttatgaatatgatcactactcgcacctggttttgcagcgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaaatgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctttccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcggtgattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5904,Drugs,MEG_5904|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111748|WP_063865960.1|NG_050485|1|1|qnrB24|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB24 NG_050485:37-681,3
,GTGACCGATCTTACTCGACTACCAGAACATGATGTGTCGACCGGTATTGAACCAGTCAGTATCATTGAAGAAATGCAGTGCTCTTATCTAGATTATGCGATGAGCGTAATTGTGTCGCGCGCACTGCCTGATGTCCGTGATGGGCTTAAGCCTGTCCATCGGCGCATTCTTCATGCGATGAATGAAATGGGACTTTTGTTCAATAAGCCTTATCGTAAGTCAGCGGGTGTTGTTGGTGAAGTGATGGGAAAGTTTCATCCTCATGGTGATGCTTCAATTTATGATGCCTTGGTGCGTATGGCACAGGATTTTTCTTTACGAAATCCTCTGATTGATGGACAGGGAAATTTTGGCTCTGTTGACGGTGATCCACCCGCAGCGATGCGTTACACGGAATGTCGTTTAGAAAAAGTTGCAGAAGAACTTTTAGCTGATATTGATAAAGATACTGTTGATTTTCAAGATAATTATGATGGGCGTGAGCATGAACCTATAGTTTTGCCTGCACGTTTCCCTAACCTGTTAGTAAATGGATCGGGTGGTATTGCTGTAGGTATGGCAACCAATATTCCTCCACATAATCTAGGTGAGGTTATTGATGGATGTGTTGCTTTGATCGATAATCCTAACATAACTATAGATGAGATGTTAGCAATTATTCCGGGGCCTGATTTTCCTACAGGTGGTATTATTCTTGGCCATTCTGGTGTCCGTTCTGCTTATGAAACAGGGCGTGGTTCAATTATTATGCGTGCTAAGGTTGAGATCGAGGAAATTCGCAATCAGCGGCAGGCAATTATCGTAAGCGAAATACCTTATCAAGTTAATAAAGCAACAATGGTTGAGAAGATGGCCGAATTGGTGCGTGATAAACGTATCGAAGGAATCTCCGATTTGCGTGATGAATCTGATCGTGATGGGTATCGAGTTGTCATTGAGCTAAAAAGAGAAGCTGTTGCAGACGTTGTTTTGAATCAGCTTTATCGTTATACACCGTTGCAAGCCTCATTTGGTTGCAATATGGTTGCGTTGAATGGAGGAAAGCCTGAACAAATGACGTTGCTTGACATGCTTCGTGCATTTGTTTCCTTCCGCGAAGAAGTGGTAAGCCGGCGCACAAAATATCTTTTGCGTAAAGCACGTGAGCGTGCGCATGTTTTAGTTGGTCTTGCTATCGCTGTTGCTAATATTGATGAGATTATAGAATTAATTCGCAAAGCTCATGATCCACAGACAGCGCGTACACAGTTAATGGAACGGCGTTGGCCGGCTTCTGAGGTAGCAGCTTTGATTAAGCTTATAGATGATCCTCGTCATATTATTCATGAGGATAATACGTACAATTTGTCTGAAGAACAAGCGCGTGCTATTTTAGAATTGCGTTTGCAAAGATTAACAGCGCTTGGTCGTAATGAAATTGCTGATGAACTCAATGCAATTGGAGAAGATATTGCTGACTATCTTGGTATTTTAGCATCACGCTCACGGATCATGGACATTGTTAAAAGTGAGCTCAGCGCTTTGCGTGAAACATTTGCAACACCACGGCGTACTGTATTTGGTTTTGGTAGTGCCGAGATGGACTGCGAAGATCTGATTGTTCCAGAAGATATGGTGGTGACAGTGAGCCATAGTGGCTATATTAAGCGTGTGCCTCTAAATACATACCGTGCGCAGCGTCGTGGTGGTAAGGGACGTTCTGGTATGGCAACAAAGGATCAGGATTTTGTTACTCGCTTATTCGTGGCCAATACACATACACCAGTTCTTTTCTTTTCATCACGTGGGATTGTTTATAAAGAGAAGGTTTGGCGTTTACCTGTTGGTACGCCGCAATCACGCGGTAGAGCTTTAATTAATATGTTGCCTTTGCAACAAGGCGAGCGCATTACAACAATTATGCCATTGCCGGAGGATGAGGCAAGTTGGGGTAAACTGGATATTATGTTTGCAACAACGCGTGGAACTGTGCGCCGTAATAAATTATCAGACTTTATTCAAGTTAATCGCAATGGTAAAATAGCAATGAAACTTGATGAAGAGGGAGATGAGATCCTTTCTGTAGAGACCTGTACAGAACATGATGACGTTGTTCTTATTACAGCAAACGGGCAGTGTATTCGTTTTCCAGTTACTGATATTCGTGTATTTTCTGGTCGTAATTCGATGGGGGTACGCGGTATCAATATGGTTGAGGGTGATAAGGTCATTTCAATGACTATTTTAGAGCATGTTGAAGCGACATCAGTCGAACGTTCTGCTTATATTAAACGTGCAATCAATGAGCGTCGTGTTGCAGGTTCAGATGATGAAGATATTTTAACTGTTGATGAAGATGGAGAGGAAACTGAGGTTGAATTAACAGATGAACGTTATGCAGAACTTAGCGCTCATGAGCAAATGCTTTTAACAGTTAGTGAATTTGGTTATGGAAAACGCTCTTCTTCTTATGATTTCCGTATTTCAGGACGCGGTGGAAAAGGGATACGCGCAACTGATCTATCAAAGGCGGCTGAAATTGGTAAGTTAGTAGCAGCCTTTCCAGTAGGAGAACGAGATCAAATTATGTTAGTTTCGGATGGAGGACAGCTTATTCGTGTTCCCGTCAACTGTATTCGTATAGCGGGTCGTTCAACTAAAGGGGTCACAGTCTTTAATACAGCAAAAGGTGAAAAAGTTGTATCGGTTGAGCGTATTTCTGAATCTGAAAATGATACTAATCAGTTAGATATTGAAAGTGAGGAACATTCCGGAACAGTTAGCATGAGTGAAGAGAAAAAACTCTGA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3179,Drugs,MEG_3179|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|AF469609|+|566-3353|ARO:3003297|Bartonella bacilliformis gyrA conferring resistance to fluoroquinolones [Bartonella bacilliformis] ,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5489,Drugs,MEG_5489|Drugs|betalactams|Class_C_betalactamases|PDC,1201190430|WP_087587950.1|NG_054965|1|1|blaPDC-179|blaPDC|class_C_beta-lactamase_PDC-179 NG_054965:1-1194,0
,atgaatattatgccgatatctgaatcacaattatcagattggctagcattaagaagtttgctctggcctgatcatgacgatgcgcatttattggaaatgcgtcagctacttaaacaaactgatactttacaattattggcttataccgacacccaacaagcaattggcatgttggaagcttcgattcgatatgaatatgtgaatggtacacaaacctcacccgtggcttttcttgaagggatttatgtattacctgaatatcgacgttcaggtatcgcgactcagttggttcagttcgtagaggaatgggcgaaacaatttgcatgtactgagttcgcttcagatgcagcgctggacaatcatattagccatgcaatgcatcgagcactcggttttcatgaaactgaacgtgtggtgtattttaagaaaaatatcggctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_81,Drugs,MEG_81|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491344301|WP_005202238.1|NG_052529|1|1|aacA-ACI6|aacA-ACI6|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052529:101-541,2
,TTCACATCGGCTTCACAGAGCCTCATATTGCGCACACCTTGCGGGAATAGGCTGGGAGCACTGCCAGGCACCCAGGCAGCACATTCGACTTATGACAAGAGGAGTAGACCCGATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTATTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCAGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGTCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCATTTGCCCAGTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGGGTCAACCCTGGCATGCTGGCGGACGAGGCCTACGGCATCAAGACCAGCTCGGCGGATCTGCTCGCCTTCGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACAAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGATCCTCGAAGCCAATCCGACGGCGGCTCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTATCCCATCCCGGCCAGGGTGAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1981,Drugs,MEG_1981|Drugs|betalactams|Class_C_betalactamases|CMY,gi|573013567|dbj|AP013064.1|29985-31245 gi|146150962|gb|EF382672.1|102521-103781 gi|695199441|ref|NG_035225.1|501-1761 gi|58430781|dbj|AB201268.1|1-1149,0
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACATGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6893,Drugs,MEG_6893|Drugs|betalactams|Class_A_betalactamases|TEM,gi|237846382|gb|FJ919776.1|1-1069,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgcgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_904,Drugs,MEG_904|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502092|WP_071846244.1|NG_064656|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_064656:101-889,2
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcaacaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatatctagctctgttcgaaaagagattacttatagaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4715,Drugs,MEG_4715|Drugs|betalactams|Class_D_betalactamases|OXA,1625655414|WP_136512091.1|NG_064758|1|1|blaOXA-800|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-800 NG_064758:1-825,0
,atgcgtaaaaaaatgcagaacaccttgaagctgttatccgtgattacctgtctggcagcaactgcccaaggcgctatggctgccaatatcgatgagagcaaaattaaagacaccgtcgatagcctgatccagccgctgatgcagaagaataatattcccggtatgtcggtcgcagtgaccatcagaggtaggaactatatttataactacgggttagcggcaaaacagcctcagcagcccgtgacgaaaaatacattgtttgaagtgggctctctgagtaaaacgtttgctgccactttggcttcctatgcgcaggcgagcggtaagctgtctttggagcaaagcgtgagccactacgttccagaactgcgcggcagcagctttgaccacgttagcgtactcaatgtgggtacgcatacctcaggtctacagctgtttatgccggaagatatcaagaacaccacacagctgatgacttatctaaaagcatggaaacctgctgatgcggctggaacccatcgcgtttattccaatatcggtaccggtttgctagggatgattgcggcgaaaagtctgggtgtgagctatgaagatgcgattgagcaaaccatccttcctctattaggcatgaatcaaacctacctgaaggttccggctgaccagatggaaaactatgcgtggggctacaacaagaaagatgagccagtgcacgtcaatatggagattttgggtaacgaagcttatggcatcaaaactacctccagcgacttgttgcattacgtgcaagccaatatggggcagttaaagcttgatggtaatgccaagatccaacatgcactgacagccacccacaccggctatttcaaatcgggtgagattactcaggatctgatgtgggagcagctgccatatccagtttctctgccgaatttgctcactggtaacgatatggcgatgacgaaaagcgtggctacgccgattgttcccccgttaccgccacaggaaaatgtgtggattaataagaccggatcaactaacggcttcggtgcctatattgcgtttgttcctgctaagaagatggggatcgtgatgctggctaacaaaaactactcaatcgatcagcgagtgacggtggcgtataaaatcctgagctcgttggaagggaataagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_385,Drugs,MEG_385|Drugs|betalactams|Class_C_betalactamases|ACC,1270501813|WP_099156055.1|NG_055669|1|1|blaACC-7|blaACC|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACC-7 NG_055669:1-1173,0
,atgagaaaaagtgtgggcattactgtttttggatgcgaacaggatgaggcaaatgctttccgcgctttatcgccggattttcatattatccctacgctgattagcgatgcgatatcggcagacaacgcaaaattggccgctggcaatcaatgcgttagcgtaggccataagtccgaggtttccgaggcgacaattcttgcgctgagaaaggtcggggtaaaatacatttctacccgcagcatcggctgcgatcacattgatacgactgccgccgagagaatgggaatctcggttggcacggttgcgtattcgccggacagcgttgcggattatgctttgatgctgatgctgatggccatacggggtgcaaaacccaccatgcacgccgtggcgcaacaagatttcagattggatcgtatccgggggaaagaactgggggatatgactgtgggagttattggaaccggccatatcgggcaagcggtcgtcaaaaggctgcggggatttggatgccatgtgctggcctatgataacagccgaaaaatggatgcagattatgtccagcttgatgagcttctaaaaaacagcgatattgttacgctccatgtgccgctttgtgcggatacccgccatctgatcggtcagaagcaaattggagagatgaagcaaggcgcatttttaatcaacaccgcgcgcggagcgcttgtcgataccggggcgctggtggaggcgttggaaagcggaaagctgggtggtgcggcactggatgtgttggagggcgaggatcagtttgtttataccgattgctcgcagaaagtgcttgaccatccctttttgtcgcagcttttaaggatgccgaatgtgatcatcacaccccatacggcgtactacactgagcgtgtgctgcaggatactacagaaaaaacaatcaggaattgtctcaattttgaaaggagtttacagcatgaatag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7414,Drugs,MEG_7414|Drugs|Glycopeptides|VanB-type_resistance_protein|VANHB,488246060|WP_002317268.1|NG_048378|1|1|vanH-B|vanH-B|D-lactate_dehydrogenase_VanH-B NG_048378:101-1072,5
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaataccccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagtgctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatccagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagctaaccccggcccactcgatgccccagcatacggtgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgtattaaggcagcgtatgcagttttaaatgcaataaaaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_612,Drugs,MEG_612|Drugs|betalactams|Class_C_betalactamases|ADC,1028102029|WP_063857806.1|NG_048664|1|1|blaADC-53|blaADC|class_C_extended-spectrum_beta-lactamase_ADC-53 NG_048664:1-1152,0
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAGCTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCACAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTAGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2375,Drugs,MEG_2375|Drugs|betalactams|Class_A_betalactamases|CTX,gi|161367439|gb|EU274579.1|1-876 gi|909636667|emb|LN850164.1|120961-121834 gi|805300500|gb|KP025948.1|33151-32278 gi|751373027|gb|KM580532.1|34173-35046 gi|514058406|gb|JX981514.1|30331-31204 gi|512493214|gb|KC577200.1|879-6 gi|479327067|gb|KC354801.1|26361-25488 gi|695214643|ref|NG_036860.1|1470-2343 gi|695214629|ref|NG_036857.1|513-1386 gi|86161573|gb|DQ359215.1|1-874,0
,ATGACCAGCCTTGCGCATCATGCGACAGAAAACCGCTCTGTAGCCGAATTTACTGAACAGGCTTATTTGAATTATGCCATGTACGTCATTATGGACCGTGCATTGCCGCATATCAGTGATGGCTTAAAGCCCGTACAGCGCCGTATTGTCTATGCTATGAGCGAGCTAGGCTTAAAAAGCAGTGGCAAGCCAAAAAAATCAGCGCGTACAGTGGGTGATGTACTTGGTAAATACCACCCACATGGTGACTCGGCATGTTATGAAGCCATGGTACTCATGGCTCAGCCATTTAGTTACCGCTATCCTTTAATCGAAGGTCAGGGGAACTGGGGCTCACCTGATGATCCTAAGTCTTTTGCTGCGATGCGTTATACCGAAGCCAAACTCTCGGCTTATAGTGAATTATTGCTGAGCGAATTAGGTCAGGGCACTAGCGAATGGCAAGATAACTTTGATGGTTCTTTAAAAGAACCGATCACTTTACCTGCACGTGTACCTAATATTCTTCTTAATGGTACGACGGGTATTGCTGTCGGGATGGCAACTGATATCCCGCCACATAATTTGCGTGAAGTTGTAAAAGGCACAATTGCTTTAATCCGTAATCCGCAAACCTCGGATGAAAAATTAGCTGAATATATTCCGGCTCCGGATTTACCAACCAAAGCTGAAATTATTACCCCGCCAGAAGAATTACTCAAAATCCAGACCACTGGTCGTGGTAGTTACCGTATGCGAGCGGTATATACCATTGAGAAAAATGAAATTGTAATTACTGAGCTGCCATATCAAGTCTCTGGTTCTAAGGTAATTACTCAAATTGCTGACCAGATGCAGGCGAAAAAGCTGCCATTAGTCGTTGATGTGCGTGATGAATCGGATCATGAAAACCCGACACGACTCGTGATTGTACTTCGCTCTAACCGTATTGATGCGGAAGCAGTGATGAGCCACTTATTTGCGACCACCGATTTAGAATCAAGCTATCGTGTCAATTTAAACATGATTGGCGAAGATGGCCGTCCTCAGGTGAAATCAATTCGTCGTATTTTGCTTGAATGGATCGAGATCCGTAAAAAAACGGTAACTCGTCGTTTACAGTACCATTTAAACCGTATTGAAAAGCGCCTGCATATTTTGGCAGGTCTTTTAATTGCTTATCTCGATATTGATACAGTTATTCGTATTATTCGTGAAGAAGACCAGCCTAAGCCAGTCTTGATGGAACACTTCAATATTGATGAGATACAGGCCGAAGCGATTTTAGAGCTTAAATTACGTCATTTGGCAAAGCTTGAAGAGATGGAAATTCGTCATGAACAAGATGAGCTTTCCGCAAAAGCTGCCATTATTCGTGAACAACTCGAAAATCCTGAATCTTTAAAAAACCTGATTATCAGTGAATTAAAAGAAGATGCGAAAAAGTTCGGTGATGAGCGCCGTTCTCCAATTGTTGCACGTGCTGAAGCGGTTCAAATTAAAGAACAGGATTTAATGCCAGCTGAAACGGTAACAGTCGTTTTGTCTGAAGCAGGCTGGGTTCGTGCGGCAAAAGGTGCGGATGTGGATGCTGAAAATCTGAACTACCGTGCTGGGGACCAATATTTAAGTCATGCTGTCGGGAAAACCAATCAGCGAGTTTACTTCCTTGATGAAACAGGGCGCAGCTATGCCTTGCCAATTAGTAACTTACCTTCAGCAAGAGGCTTGGGGGATCCATTAAGTTCTAAATTATCACCAGCAAGTGGCGTATCGTTTATTCAGGTTTATTTAGATGATGATGAGTCTGAGTTGATTGCTGCAAGTTCGGCAGGTTATGGTTTTAAAACGCAAACCAAGCAATTAGATACCAATGCGAAAGCCGGTAAGACATTCTTAACGGTTCCGGATAAGGCAAAGGCTTTACCACTCATTTCTGCCCAAAACATGACGCATTTGGCTGTACTGAGCTCAGCAGGGCGTTTGTTAATTTTAGATTTGGCAGAGCTACCAAATTTAAATAAAGGTAAAGGTAATAAGTTGATACAACTTGAAGGAAAAGAGCAAATTTTATCCATGACAACCCTGAACTTAGATGAAATAATTCAGGTGGTTGCAGGTCAACAACATCTCAAATTAAAAGGTGATGATCTACAAAAATACATGGGTAAACGTGCTTCGAAAGGTCAGCTCTTACCACGTGGATATCAAAAAGCAAATAAACTGTTGATTCAGAGATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5335,Drugs,MEG_5335|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|169150821|emb|CU468230.2|203454-205673,3
,atggttaaaaaatcattacgccagtttgcgctgttggccgcgacggtctttccgctgctggcaagcagcgtatcgctacaggcacaaacgctaagcgtagagcagaaacttgcggctttagagcagcgttcagggggacggcttggggtcgcgttgatagatactgcggatggttcgcaaattctctatcgtggcgatgagcgtttcgcgatgtgtagtaccagcaaagtgatggccgctgccgcggtgctaaagcaaagtgaaagtcagcacgatcttttaaatcagcgcattgagatcaaaaagggtgacctgactaactataacccgattgcggaaaaacatgtcggtgggtcgatgtcgttgtctgagctcagcgccgcggccttgcagtacagcgataacgtggcgatgaataagcttatcgctcaactgggtggcccgcagggggttaccgcgtttgcccgtaagattggggatgagacgtttcgtctcgatcgcacggaaccgacgctgaacactgcaattcccggcgatccacgcgataccacatcaccacgggctatggcacaaacgctgcgcaacctgacgctgggaaaagcgcttggtgacgctcaaagggcgcagttggtgacctggatgaaagggaatacgactggaacggccagtattcaggctggactaccggcttcgtgggtggtgggcgataaaaccggcagcggtggttacggcaccaccaacgacattgcggtgatttggccgaaagatcgtgcaccattggttttggttacctacttcacgcagcctcagcctgaggcggaaagccgtcgtgatgtattagcctcggcggcgaaaatcgtcactgagggattatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3456,Drugs,MEG_3456|Drugs|betalactams|Class_A_betalactamases|KLUC,695273557|WP_032495491.1|NG_062209|1|1|blaKLUC-3|blaKLUC|class_A_extended-spectrum_beta-lactamase_KLUC-3 NG_062209:1-876,0
,atgcgccatgcgacaatcctcaacctgtgcggcctcgccgcttccaccctgttcttcgcgacaacatcggccttcgccacggaggcgccggcggagcgcctgaaggctctggtggacgccgccgtgcaaccggtcatgaaggccaatgatatcccgggactggccgtcgccatcactctcaagggcgaaccgcattacttcagttatggggtggcctcgaaggaggacgcccgcaaggtgacccccgagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctacgccctggcccaggacaagatgcgcctcgacgaccgcgccagccggcactggcccgccctgcagggcagccgcttcgacggtatcagcctgctcgacctcggcacctacagcgctggcggcctgccgctacagttccccgatgcggtgcagaaggatccggcgcagatccgcgactattaccgccagtggcaaccgacctacgccccgggcagccaccgccagtactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccattcgagcgcagcatggaacggcagctgttcccggcgctcggcctggagcacacctttatccgggtgcccgccgcgcagcaggggctgtacgcccagggctacggcaaggacgaccgcccgctgcgggtcggacccggtccgctggacgccgaggcctacgggctgaagtccagcgctgcggacctgctgcgcttcgtcgaggccaacctgcaccccgagcgcctggagaagccctgggcgcaggccctcgacgccacccatcgcggctactacaaggtgggcgacatgacccagggcctgggctgggaagcctacgattggccgatcgacctgaggcgcctgcaggcgggcaactcggcgccgatggcgctgcaggcgcacaaggtcgccaggttgccggcgccgcaagccctggacggccagcgcctgctgaacaagaccggctccaccaacggtttcggcgcttacctggcgttcatcccgggacgcgacgtcggcctggtgatcctggccaatcgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggaacagcaggccaaggtaccgctggtgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5433,Drugs,MEG_5433|Drugs|betalactams|Class_C_betalactamases|PDC,1028110212|WP_063864582.1|NG_049915|1|1|blaPDC-42|blaPDC_var|class_C_beta-lactamase_PDC-42 NG_049915:1-1194,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCATTCTCCACGTTTGCCGCCGCCAAAACAGAACCACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAATCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTAAAGTTCCGCAAAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGTATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1910,Drugs,MEG_1910|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JQ733577|+|1026-2172|ARO:3002093|CMY-80 [Citrobacter freundii] ,0
,ATGAACAAAAAAAATATAAAAGATAGTCAAAACTTTATTACTTCAAAGCATCATATAAATGAAATTTTGAGAAATGTACATTTAAATACAAATGATAATATTATTGAGATTGGTTCAGGGAAAGGTCATTTCACGTTTGAATTAGCTAAAAGGTGTAATTATGTAACCGCCATTGAAATAGATCCTAAATTATGTAGGATAACTAAAAACAAACTTATTGAATATGAGAACTTCCAGGTTATCAATAAAGATATTTTACAATTTAAGTTTCCTAAAAATAAGTCATATAAGATATATGGAAATATACCCTACAATATAAGTACAGATATAATTCGAAAAATTGTTTTTGAAAGCACAGCTACAGAAAGTTATTTAATAGTGGAATATGGATTTGCTAAAAGGTTGCTAAATACAAATCGTTCACTAGCACTATTTTTAATGACAGAAGTTGATATATCCATATTAAGTAAAATCCCTAGAGAATACTTTCATCCAAAACCTAGAGTTAATAGCTCGTTAATTGTATTAAAAAGACACCCTTCAAAAATATCACTCAAAGATAGAAAACAATATGAAAATTTTGTTATGAAATGGGTTAACAAAGAATACATAAAACTATTTTCCAAAAACCAATTTTATCAAGCCTTAAAATATGCAAGAATTGACGATTTAAACAATATTAGCTTTGAACAATTCTTGTCTCTTTTCAATAGCTATAAATTATTTAATAGATAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2848,Drugs,MEG_2848|Drugs|MLS|23S_rRNA_methyltransferases|ERMT,gi|968578997|gb|CP013689.1|1399687-1400421 gi|961575529|gb|CP013627.1|3256-3990 gi|760459632|gb|KM576795.1|1-735 gi|663089991|gb|KJ778678.1|1981-1247 gi|695224142|ref|NG_041022.1|12078-11344 gi|695224112|ref|NG_041020.1|10006-9272 gi|448100274|gb|EU192194.2|15-749 gi|344221780|gb|JF308631.1|126-860 gi|344221775|gb|JF308630.1|126-860 gi|344221769|gb|JF308629.1|126-860,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccatactgctgttcgccaccaccccggccattgccgacgaggccccggcagatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggcttggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttctccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaagcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcggtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5683,Drugs,MEG_5683|Drugs|betalactams|Class_C_betalactamases|PDC,730324621|WP_033985393.1|NG_049920|1|1|blaPDC-47|blaPDC|class_C_beta-lactamase_PDC-47 NG_049920:1-1194,0
,ATGAAAGTTAAAGTACTGTCCCTCCTGGTACCAGCACTGCTGGTAGCGGGCGCAGCAAATGCGGCTGAAATTTATAACAAAGACGGCAACAAATTAGACCTGTACGGTAAAATCGACGGTCTGCACTACTTCTCTTCCGACGACAGCGTCTACGGCGACCAGACCTACATGCGTATCGGCGTGAAAGGCGAAACCCAGATCAACGACCAGCTGACCGGTTACGGCCAGTGGGAATACAACGTTCAGGCGAACAACACTGAAAGCTCCAGCGACCAGGCGTGGACTCGTCTGGCCTTCGCGGGTCTGAAATTCGGCGACGCGGGTTCTTTCGACTACGGTCGTAACTACGGCGTTGTTTACGACGTAACTTCCTGGACCGACGTTCTGCCGGAATTCGATGGCGACACCTACGGTTCCGACAACTTCCTGCAGTCCCGTGCTAACGGTGTTGCCACCTACCGTAACTCTGACTTCTTCGGTCTGGTTGACGGCCTGAACTTTGCTCTGCAGTACCAGGGTAAAAACGGCAGCGTGAGCGGCGAAGATCAGACCAACAACGGTCGCGGCTTCCAGAAACAGAACGGCGAAGGCTTCGGCACCTCCGTGACTTATGAGATCTGGGACGGCATCAGCGCTGGTTTCGCGTACTCCAGCTCTAAACGTACCGATGAGCAGAACAACTCTACTTACTTTTCTAAGTCCTATCGTCGTACATACGGTGTTCTGGGTGAAGGCGATCACGCTGAAACCTATACCGGTGGTCTGAAATATGACGCCAACAACATTTACCTGGCGACTCAGTACACCCAGACCTACAACGCAACTCGCACTGGCGACATCGGTTTTGCTAACAAAGCGCAGAACTTCGAAGTGGTTGCTCAGTACCAGTTCGACTTCGGTCTGCGTCCGTCCGTGGCTTACCTGCAGTCTAAAGGTAAAGACATGGGCCGTTACGGCGACCAGGACATCCTGAAATATGTTGACCTGGGTGCGACCTACTACTTCAACAAAAACATGTCCACCTACGTTGATTACAAAATCAACCTGCTGGACGACAACAAGTTCACTAAAGATGCAAGCATCTCTACTGACAACGTTGTGGCTCTGGGCCTGGTTTACCAGTTCTAA,General Bacterial Porin (GBP),reduced permeability to antibiotic,betalactams,MEG_4282,Drugs,MEG_4282|Drugs|betalactams|Mutant_porin_proteins|OMP36,gi|13384122|gb|AF336098.1|1-1128,0
,TTGGCTATAAAATTGAAAAATAAGAATAAAAAAACCGATTATTCCAAACTAAAACGAAAACTCTACCAGTATATCGTTGTGATTGTTATGGCAGCAGTTGTATTCGTGTTGTTTTTGCGTTTATTTATCAAGGGGACACTTGGGGAGTGGATCGTACGTTTTTTGGAAAACAGTTATCACTTAGAGCGTCAGGACGCGATGAAAATATATCAGTATACTATACGGAACAATATAGAAATCTTTATTTATGTGGCGATTGCCATTAGTATTCTTATTCTATGCCGCGTCATGCTTTCAAAATTTGCAAAATACTTTGACGAGATAAATACCGGCATTGATATACTTATTCAGAACGAAGATAAACAAATTGAGCTTTCTGCGGAAATGGAGTTCATGGAACAGAAGCTCAACACATTAAAACGGACTCTGGAAAAGCGAGAGCAGGATGCAAAGCTGGCCGAACAAAGAAAAAATGACGTTGTTATGTACTTGGCGCACGATATTAAAACGCCCCTTACATCCGTTATCGGTTATCTGAGCCTGCTTGACGAGGCGCCAGACATGCCGGTAGAGCAAAAGGCAAAGTATGTGCATATCACGTTGGACAAAGCGTATCGCCTCGAACAGCTAATCGACGAGTTTTTTGAGATTACACGGTATAACCTCCAAACGATTACGCTCACGAAAAAGCACATAGACCTATACTATATGCTGGTGCAGATGACCGATGAATTTTATCCCCAGCTTGCCGCGAATGGAAAACAGGCGGTTATCCATGCTTCCGAGGATTTGACCGTATCCGGCGACCCCGATAAGCTGGCGAGGGTCTTTAACAACATTTTGAAAAACGCCGCTGCATACAGCGAGGACAACAGCGTCATTGACATTACGGCGGGCCTCTCCGGGGATGTGGTGTCCATCGTTTTCAAGAACGCCGGAAGCATCCCCAAAGATAAGCTCGCTGCCATATTTGAAAAGTTTTACAGGCTGGACGATGCCCGTTCTTCCGATACGGGCGGCGCGGGACTTGGATTGGCGATTGCAAAAGAAATCATTGTTCAGCATGGCGGGCAGATTTACGCGGAAAGCAATGATAACTACACGACGTTCACGGTAGAGCTTCCGGCCTTGCCAGACTTGGTTGATAAAAGGAGTTCCTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7488,Drugs,MEG_7488|Drugs|Glycopeptides|VanA-type_regulator|VANSA,(Gly)VanS-Pt2:DQ018710:3721-4881:1161,5
,ATGAATAAATCAATTATTATTATACTGCTGATCACCGTATTAGATGCCATTGGTATCGGGCTTATCATGCCAGTACTCCCTACTCTATTAAATGAATTTGTCAGTGAAAATTCACTGGCAACCCATTACGGTGTGCTATTAGCGCTCTATGCTACCATGCAGGTTATTTTTGCTCCTATTCTAGGACGACTGTCTGATAAATACGGCAGAAAACCCATCTTGCTGTTTTCCCTTTTAGGCGCGGCACTCGACTATCTTTTAATGGCATTCTCAACCACACTTTGGATGCTCTATATTGGGCGCATCATTGCGGGGATCACAGGCGCAACAGGTGCCGTATGTGCATCAGCGATGAGTGATGTGACTCCCGCTAAAAATCGAACTCGCTATTTTGGTTTCTTAGGTGGTGCTTTTGGTGTTGGCCTTATTATCGGCCCAATGCTAGGGGGATTATTAGGTGATATCAGTGCTCATATGCCATTTATTTTTGCCGCTATTTCACACTCGATATTATTAATACTCTCTTTGCTCTTTTTCCGAGAAACACAAAAAAGAGAAGCGCTTGTTGCCAATAGGACACCTGAAAACCAAACTGCCTCAAATACAGTCACTGTTTTTTTTAAGAAAAGCCTCTACTTTTGGTTAGCAACCTATTTTATTATCCAGCTTATCGGGCAAATTCCTGCCACCATCTGGGTGCTGTTTACACAATATCGTTTTGATTGGAACACAACTTCTATCGGTATGTCTTTGGGGGTTCTGGGTGTATTACATATTTTCTTTCAGGCGATTGTCGCTGGGAAATTGGCACAAAAATGGGGCGAAAAAACCACCATTATGATCAGTATGTCTATTGATATGATGGGCTGTTTATTATTAGCGTGGATAGGCCACGTTTGGGTCATCTTACCAGCATTAATTTGCTTAGCGGCAGGAGGTATGGGGCAACCCGCATTACAAGGTTATTTATCAAAATCTGTCGATGATAATGCGCAAGGGAAATTACAAGGTACTCTGGTGAGCCTAACCAATATTACCGGGATCATTGGTCCCCTTTTATTTGCCTTTATTTATAGTTATAGCGTCGCTTATTGGGATGGTCTGTTATGGCTGATGGGGGCAATACTTTATGCTATGTTGCTTATTACCGCTTATTTTCACCAAAGAAAAACCACACCTAAAGCTGTTATTTCAACCCCTTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7083,Drugs,MEG_7083|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETH,gi|4138314|emb|Y16103.1|1140-2342 gi|356596244|gb|CP003022.1|336102-336144,4
,ATGATGACTCAGAGCATTGGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAGATTCTCTACCGTGCCGATGAACGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAAGAAGAGCGACCTGGTTAACTACAATCCCATTGCGGAGAAACACGTTAACGGCACGATGACGCTGGCTGAGCTTGGCGCAGCGGCGCTGCAGTATAGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGTCCCGATAAAGTGACGGCGTTTGCTCGCTCGTTGGGTGATGAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATACCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAAGCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTCTGCCGAAATCATGGGTAGTGGGCGATAAAACCGGCAGCGGAGATTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGAAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGCCGTCGGGATATTCTGGCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGATGCAATAAAATCACGAATTCTGGATCCGATACGTAACGCGTCTGCAGCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2391,Drugs,MEG_2391|Drugs|betalactams|Class_A_betalactamases|CTX,gi|303297116|gb|HM776707.1|1-925,0
,atgaatagttcgacaaagatcgcattggtaattacgttattcgatgccatggggattggccttatcatgccagtcttgccaacgttattacgtgaatttattgcttcggaagatatcgctaaccactttggcgtattgcttgcactttatgcgttaatgcaggttatctttgctccttggcttggaaaaatgtctgaccgatttggtcggcgcccagtgctgttgttgtcattaataggcgcatcgctggattacttattgctggctttttcaagtgcgctttggatgctgtatttaggccgtttgctttcagggatcacaggagctactggggctgtcgcggcatcggtcattgccgataccacctcagcttctcaacgcgtgaagtggttcggttggttaggggcaagttttgggcttggtttaatagcggggcctattattggtggttttgcaggagagatttcaccgcatagtcccttttttatcgctgcgttgctaaatattgtcactttccttgtggttatgttttggttccgtgaaaccaaaaatacacgtgataatacagataccgaagtaggggttgagacgcaatcgaattcggtatacatcactttatttaaaacgatgcccattttgttgattatttatttttcagcgcaattgataggccaaattcccacaacggtgtgggtgctatttaccgaaaatcgttttggatggaatagcatgatggttggcttttcattagcgggtcttggtcttttacactcagtattccaagcctttgtggcaggaagaatagccactaaatggggcgaaaaaacggcagtactgctcggatttattgcagatagtagtgcatttgcctttttagcgtttatatctgaaggttggttagttttccctgttttaattttattggctggtggtgggatcgctttacctgcattacagggagtgatgtctatccaaacaaagagtcatcagcaaggtgctttacagggattattggtgagccttaccaatgcaaccggtgttattggcccattactgtttgctgttatttataatcattcactaccaatttgggatggctggatttggattattggtttagcgttttactgtattattatcctgctatcgatgaccttcatgttaacccctcaagctcaggggagtaaacaggagacaagtgcttag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7044,Drugs,MEG_7044|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,1028223007|WP_063964002.1|NG_048170|1|1|tet(B)|tet(B)|tetracycline_efflux_MFS_transporter_Tet(B) NG_048170:101-1306,4
,atggacacaacgcaggtcacattgatacacaaaattctagctgcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatccgacgtttcccggcgagaggcgcggcgagctcgaggcaatagttgaaatgctcggcgggcgcgtcatggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccagtggactggcctacaaagcacatagagtcgtacaggctcgcatgcacctcactcggggcggaaaaggttgagatcttgcgtgctgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_737,Drugs,MEG_737|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1105502086|WP_071846238.1|NG_052251|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052251:101-634,2
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccatttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcggcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccattgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgacccggcgcgctggatccagtattcggtggtctggtattcacagctgatcgccaaggcgctgggacaggaccgcttccagcgctacgccagcgcattcggctacggcaatgcggacgtctcgggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaggctggtgaaccgggagttgccggtcaaggccgccgcctatgagctggccgacaacttgttcgaggtgggccaggccgatggctggcgcctgtatggcaagaccggcaccggttcgcccggcggcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcacgccacccggcccaatgccggcctgcgcgcccgcgacgagctgatgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4535,Drugs,MEG_4535|Drugs|betalactams|Class_D_betalactamases|OXA,1625655402|WP_136512079.1|NG_064742|1|1|blaOXA-114u|blaOXA-114_like|class_D_beta-lactamase_OXA-114u NG_064742:1-828,0
,ATGCGTTATGTTCGCCTGTGTGTTATCTCCCTGTTAGCCAACCTGCCACTAGCGGTATACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGGTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTACCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCATGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTGACCGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGCACTGAATGAGGCGCTTCCCGGCGACATGCGCGACACCACTACCCCGGCCAGCATGGCCGCCACGCTGCGTAAACTACTGACTGCGCAGCATCTGAGCGCCCGTTCACAGCAGCAGCTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGGCGGGCTGGTTTATCGCCGACAAGACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAAGCGGAGCGCATTGTGGTGATTTATATGCGGGATACGCCGGCGACCATCGCCGAGCGTAACCAGCAGATCGCCGCTATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3577,Drugs,MEG_3577|Drugs|betalactams|Class_A_betalactamases|LEN,gi|372995327|gb|JQ067123.1|1-861,0
,CTGGCCGTTCTAAACCTGCTATCCAAGGTCAGCGCACATTGACCGGGTTGGCATCTAACAATTCATTCAAGCCGACGCCGCTTCGCGGCACGGCTTAACTCAGGCGTTGGGCATTAAGGAAAAGTTAATGGCAATCCGAATCTTCGCGATACTTTTCTCCATTTTTTCTCTTGCCACTTTCGCGCATGCGCAAGAAGGCACGCTAGAACGTTCTGACTGGAGGAAGTTTTTCAGCGAATTTCAAGCCAAAGGCACGATAGTTGTGGCAGACGAACGCCAAGCGGATCGTGCCATGTTGGTTTTTGATCCTGTGCGATCGAAGAAACGCTACTCGCCTGCATCGACATTCAAGATACCTCATACACTTTTTGCACTTGATGCAGGCGCTGTTCGTGATGAGTTCCAGATTTTTCGATGGGACGGCGTTAACAGGGGCTTTGCAGGCCACAATCAAGACCAAGATTTGCGATCAGCAATGCGGAATTCTACTGTTTGGGTGTATGAGCTATTTGCAAAGGAAATTGGTGATGACAAAGCTCGGCGCTATTTGAAGAAAATCGACTATGGCAACGCCGGTCCTTCGACAAGTAATGGCGATTACTGGATAGAAGGCAGCCTTGCAATCTCGGCGCAGGAGCAAATTGCATTTCTCAGGAAGCTCTATCGTAACGAGCTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGATCTCATGATTGTGGAAGCCGGTCGCAACTGGATACTGCGTGCAAAGACGGGCTGGGAAGGCCGTATGGGTTGGTGGGTAGGATGGGTTGAGTGGCCGACTGGCTCCGTATTCTTCGCACTGAATATTGATACGCCAAACAGAATGGATGATCTTTTCAAGAGGGAGGCAATCGTGCGGGCAATCCTTCGCTCTATTGAAGCGTTACCGCCCAACCCGGCAGTCAACTCGGACGCTGCGCGATAAAACCGCGCAGCGCCGGTTACTTCAACGTTAGATGCACTAAGCACATAATTGCTCACAGCCAAACTATCAGGTCAAGTCTGCTTTTATTATTTTTAAGCGTGCATAATAAGCCCTACACAAATTGGGAGATATATCATGAAAGGCTGGCTTTTTCTTGTTATCGCAATAGTTGGCGAAGTAATCGCAACATCCGCATTAAAATCTAGCGAGGGCTTTACTAAGCTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5208,Drugs,MEG_5208|Drugs|betalactams|Class_D_betalactamases|OXA,gi|1488048|gb|U63835.1|PAU63835|1-1180 gi|828945263|gb|CP011614.1|36371-36570,0
,atgactcgacataatgaaattattaaaattgcagaaaaacatcaattgcacatcaaacctcaaacaatatcattgaatgaatcagggctagatttccaagttgcgtttggagaagatgaacacggaatagaatgggttttaagactaccaagaagacctgacgtttataaacgaacaaaacccgaaaaacaaatggtagacttcttacaaaaaaatgtttcgtttgaagtaccgaattggaaagtacatacaaaagaccttattgcttatccaaaacttacaggcaaacccgcagccacaatagatccagaaatacaaaattacgtatgggaaattgaacacaaaccagtaacaaaaaattttattaacacattagctgaaacactcgtagatttacacaacataccagaggaaaatattaccgcacagcatataaatatcaaaactatacaagaaataaaaaaagattttcaaagaagaatgaataaagttaatgaaacttatggcgtggcagacggattatggaacagatggaaacaatggttagaaaacgacgaactgtggcctcgacgtgcaaccatgatacatggagacttacatccaggacatataatggtagataaccaagcaaatgtcacaggactcatagactggactgaagcaacctactccgatccatcaatggactttatgggataccatcgtgtattcgacgacgaaggcttagagcaacttataacagcatacggtaaagctggaggagaaacatggccacgaatgaaagagcatataatagaactcaatgcagtattccccatgtttatcgctgagtttgctatggaatcaggagaaccagcgtatgaaaaaatggcattgcaagagttaggtatgaaagagtag,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4036,Drugs,MEG_4036|Drugs|MLS|Macrolide_phosphotransferases|MPHC,1028097453|WP_063854150.1|NG_047994|1|1|mph(C)|mph(C)|Mph(C)_family_macrolide_2'-phosphotransferase NG_047994:1-900,7
,atgagaaatgaggaagtcattagtatgtggcaacggatgaaatggggtctgtgtgtgctggcactcagcggttctgcgatggccgcaccgctgacggcgcaatacgtgtcggctatcgcgacgcaggaagaacagcgtcttcatgcccggattggcattgcggtacttgatacggcgaccaacagtatcacccattatcggggagaagaacggttcccgttaaacagtacgcacaagccgctgttatgcgcagcgttattacgcgaagtcgacaggaaggcgctggcgctttctgcttcaacgcagtttgaaccctcgcagctggtggagtattcgccgattactgaaaaacatgtggcgccagacgccatgaactgggcgcaattgtgcagcgcggcggtaagctacagcgataacacggccgccaatctcatcgccaggaagctcaacgggccgcaggccgtcacgcagtttttgcgtgattcgggggatacgataacccgcctcgatcgctatgagcccgaactgaacagcgccattcccggtgatgaacgcgactccacgacgcctgtcgcgatagcgaagacgctcaatacgctactgctggggaatgtgttgcagccatcctcaagagagcagcttatgcaatggatgcgggacgacaaagtggctgacggtctgctgcgttcggtcttgccggacggctggaaaatcgcggataaaaccggggcgggcgacaacggttcgcgttctattgtcagcgttgtctggccgacatcacaaaaacctttgctcgtggttatctatattacacaaactccggcgacaatggcgcagcgtgacgccgcgattgtccgcatcggggagtcgctgttttcaacactcgcagtctatgattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1724,Drugs,MEG_1724|Drugs|betalactams|Class_A_betalactamases|CKO,1028105809|WP_063860834.1|NG_049291|1|1|blaMAL-2|blaCKO|MAL/CKO_family_class_A_beta-lactamase_MAL-2 NG_049291:3-902,0
,atgactctggcgttagttggcgaaaaaattgacagaaacaggttcaccggtgaaaaagtcgaaaatagcacatttttcaactgtgatttttcgggtgccgacctttgcggtactgaatttattggctgccagttttatgatcgagaaagccagaaagggtgtaattttagtcgcgctaacctgaaggatgccattttcaaaagttgtgatctctccatggcggatttcagaaatatcaatgcgctgggaatcgaaattcgccactgccgggcacaagggtcagattttcgcggcgcaagctttatgaatatgatcaccacccgcacctggttttgtagcgcttatatcaccaataccaacttaagctacgccaacttttctaaagtcgtactggaaaagtgcgagctgtgggagaaccgctggatgggtactcaggtgctgggcgcaacgttcagtggatcagacctctctggcggcgagttttcatccttcgactggcgagcagcaaacgtaacgcactgtgatttgaccaattcggaactgggcgatttagatatccgggtagttgatttgcaaggcgtcaaactggacagctaccaggcatcgttgctcctggaacgtcttggtatcgctgtcatgggttaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5901,Drugs,MEG_5901|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1391852847|WP_109545034.1|NG_050483|1|1|qnrB22|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB22 NG_050483:4-648,3
,atgaaaaaacggattaccccattttcccgatttgcatcaaaaggccttttcgcctgtagcgcaggcatgttgctggtgacggtggcacatgccgccaatacggcagcagcgccagccggtgtggatgccatggtccaaaccgtgatgcaggcacaccagattccgggcatggccattgccatcatccagccaggcaagacctcttatcacaattatggtgtcgcctcccgcgaaaccggccagccggtccgggaaaccactctgtttgaaatcggctccctttccaaaccgtttactgcactggtcgcccagcgggccgaaaccgaaggccggattgacctgtctgcaccggccagccgctacgttgccgccctgcgaggcagtgcattcgaccggatcaccctcaggcagctcggtacttatagcgcaggcggattaccgctccagtttcctgacaatgtcaccaccccggcagacatgctggcttattaccagcattggcaacctgtccatccggcaggtaccacccggctgtattccaatccgagcattggcctgatggggctggctgccagtcaggcaaccggagagtcctttgccggcctgctcgggacaacggtgctgcaacctctcggcatgaactcgacctatctgcaagtgcccccggaggcccgttcacgttatgccatgggttataccgccgccgggaaaccggtcagggtcagccccggtccgctggatgaggaaacctacggcatcaagtccacaaccgcagacatggccggatttttactggcgcatatggaccctgcgcgcagcaaagatgcattgcggtcggcattacagcaacgtgcaccggtttattgcgccggacagacccggcaaggactgggctgggaaagttatcaagactggaaaaacctagacgtgctgctggcgggaaattcaaatcaaatggtgtttgaaccgcagccggtaaaagcctgtcctgccggcaccatgaatgagcccgatgtgtgggtcaacaagaccggttctactgcgggattcggcgcttatgccgtattcctgcctgcccgacagaccggcattgtcatcctggccaaccgtaattacccgattacagaccgtatccggctcgctcacgggattttgaccgcattgcactag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3583,Drugs,MEG_3583|Drugs|betalactams|Class_A_betalactamases|LHK,1349894762|WP_104531865.1|NG_056483|1|1|blaLHK-2|blaLHK|class_C_beta-lactamase_LHK-2 NG_056483:1-1170,0
,GGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACCCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCACCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6484,Drugs,MEG_6484|Drugs|betalactams|Class_A_betalactamases|SHV,gi|74422852|gb|DQ174305.1|1-865,0
,ATGCCTTTTGCCCTCTACATGCTTGCCCTGGCGGTCTTCGTCATGGGCACTTCAGAATTCATGCTCGCGGGATTGCTCCCCGCGATCGCGACCGAACTTGACGTCTCGGTCGGCACTGCGGGCCTGCTGACCTCCGCATTCGCAGTCGGTATGGTCGTCGGCGCGCCAGTGATCGCGGCATTCGCTCGCCGTTGGCCACCGCGGCTCACATTGATCGTTTGCCTTCTCGTGTTCGCGGGAAGCCACGTCATCGGAGCGATGACACCAGTGTTCTCTCTCCTGCTCATCACCCGGGTGCTCAGCGCTCTCGCAAACGCAGGATTCCTCGCCGTAGCACTGAGCACGGCCACTACCCTCGTGCCAGCGAACCAGAAGGGGCGTGCACTGTCGATCCTGCTCTCCGGCACGACGATCGCAACCGTCGTGGGCGTCCCCGCCGGGGCACTGCTCGGCACAGCGCTGGGCTGGCGAACGACGTTCTGGGCGATCGCCATCCTCTGTATTCCCGCGGCCGTTGGAGTCATTCGTGGCGTCACGAACAATGTTGGTCGGAGCGAGACTAGCGCGACCTCACCAAGGCTCCGTGTCGAGCTCAGCCAGTTGGCGACGCCGCGGCTCATCCTGGCCATGGCACTCGGAGCGCTGATCAACGGAGGGACCTTTGCGGCATTCACCTTCCTGGCACCCATCGTGACCGAGACCGCGGGCTTGGCCGAAGCGTGGGTGTCCGTCGCGCTGGTGATGTTCGGCATCGGATCGTTCCTTGGCGTCACGATCGCAGGACGACTATCAGATCAACGACCTGGCCTCGTGCTCGCAGTCGGCGGACCGCTATTGCTGACAGGCTGGATCGTGTTGGCAGTGGTCGCATCTCATCCCGTTGCGCTTATCGTCCTCGTCCTCGTTCAGGGATTCCTGTCGTTCGGCGTCGGCAGTACTCTGATCACGCGTGTGCTGTATGCAGCATCGGGTGCGCCAACGATGGGCGGTTCGTACGCAACCGCAGCATTGAATATCGGAGCTGCAGCGGGGCCCGTGCTTGGTGCGCTCGGGCTCGCGACCGGGCTGGGGCTGCTCGCGCCGGTTTGGGTCGCTTCGGTGCTGACAGCGATCGCTCTCGTCATCATGCTTCTCACCAGACGCGCGCTTACGAAGACCGCGGCGGAGGCCAATTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1784,Drugs,MEG_1784|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMX,(Phe)Cmr:U85507:3518-4693:1172,6
,atgacaaaatcattatctgcaacactgatttccgccctgctggcgttttccgccccggggttttccgccgctgacaatgtcgcggcggtggtggacagcaccattaaaccgctgatggcacagcaggatattcccgggatggcggttgccgtctctgtaaagggcaagccctattatttcaattacggttttgccgatgttcaggcaaaacagccggtcactgaaaatacactatttgagctcggatctgtaagtaaaactttcacaggtgtgctgggtgcggtttctgtggcgaaaaaagagatgacgctgaatgatccggcggcaaaataccagccggagctggctctgccgcagtggaaggggatcacgctgctggatctggccacctataccgcaggcgggctgccgttacaggtgccggacgcggtgaaaaaccgtgcggatctgctgaatttctatcagcagtggcagccgtcatggcaaccgggcgatatgcgtctgtatgcaaacagcagtatcggcctgtttggtgctctgaccgccaacgcagcggggatgccgtatgagcagttgctgactgcgcggatcctggcaccgctgggattatctcacacctttattaccgtgccggaaagcgcgcaaagccagtatgcatacggttataaaaacaaaaagccggttcgcgtgtcaccgggacagcttgatgcggaatcttacggcgtgaaatccgcttcaaaagatatgctgcgctgggcggaaatgaatatggagccgtcacggaccggtaatgcggatctggaaatggcaatgtatcttgcacagacccgctactataaaaccgtcgcgattaatcaggggctgggctgggaaatgtatgactggccgcagcagaaagatatgatcattaacggcgtgaccaacgaggtcgcattgcagccgcacccggtaacagacaaccaggttcagccgtataaccgtgcttcctgggtgcataaaacgggggcaacaactggtttcggcgcctatgtggcctttattccggaaaaacaggtggcgattgtgattctggcgaataaaaactacccgaataccgaaagagtcaaagccgcacaggctattttgagtgcactggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2590,Drugs,MEG_2590|Drugs|betalactams|Class_C_betalactamases|DHA,1559612971|WP_128268236.1|NG_063839|1|1|blaDHA-28|blaDHA|class_C_beta-lactamase_DHA-28 NG_063839:1-1140,0
,AACGAGTGAGGGAATTTCAGGTAAGATACTTCGGATGAGGAGCAAAAAGGTGGTTTATACTTCCTATACCCCCAGCCGCCGGGCAAGGGGGGGCAAGTCATGGATAACCCATTGAAACTGGGCTATTTGAACGCCGACTTCACATCGGCTTCACAGAGCCTCATATTGCGCACACCTTGCGGGATTAGGCTGGGAGCACTGCCAGGCACCCAGGCAGCACATTCGACTTATGACGAGAGGAGTAGACCCGATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTACTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCGGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGCCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCGTTTGCCCCCTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGTGTCAACCCTGGCATGCTGGCGGACGAGGCCTATGGCATCAAGACCAGCTCGGCGGATCTGCTGCGTTTTGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACCAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGATCCTCGAAGCCAATCCGACGGCGGCGCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTACCCCATCGAGGCGCGCATCAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGAAAGAAAGAGGGCGGTACATTCGGTGAATGTGCCGCCCTTTTTCTGGTGCTGGGGGAATACCCCCGCTAGTCGTACT,beta-lactamase,antibiotic inactivation,betalactams,MEG_1993,Drugs,MEG_1993|Drugs|betalactams|Class_C_betalactamases|CMY,gi|695214108|ref|NG_036737.1|5403-6877 gi|13591814|gb|AF357597.1|1-1475 gi|302371353|gb|AF373217.2|1-1171 gi|573013567|dbj|AP013064.1|27532-27602 gi|573013567|dbj|AP013064.1|29787-29857 gi|573013567|dbj|AP013064.1|29906-29976 gi|146150962|gb|EF382672.1|102448-102518 gi|695199441|ref|NG_035225.1|428-498 gi|695200064|ref|NG_035368.1|48-118,0
,atgaacgagaaaaatataaaacacagtcaaaactttattacttcaaaacataatatagataaaataatgacaaatataagattaaatgaacatgataatatctttgaaatcggctcaggaaaaggggattttacccttgaattagtacagaggtgtaatttcgtaactgccattgaaatagaccataaattatgcaaaactacagaaaataaacttgttgatcacgataatttccaagttttaaacaaggatatattgcagtttaaatttcctaaaaaccaatcctataaaatatttggtaatataccttataacataagtacggatataatacgcaaaattgtttttgatagtatagctgatgagatttatttaatcgtggaatacgggtttgctaaaagattattaaatacaaaacgctcattggcattatttttaatggcagaagttgatatttctatattaagtatggttccaagagaatattttcatcctaaacctaaagtgaatagctcacttatcagattaaatagaaaaaaatcaagaatatcacacaaagataaacagaagtataattatttcgttatgaaatgggttaacaaagaatacaagaaaatatttacaaaaaatcaatttaacaattccttaaaacatgcaggaattgacgatttaaacaatattagctttgaacaattcttatctcttttcaatagctataaattatttaataagtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2816,Drugs,MEG_2816|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,499596187|WP_011276921.1|NG_055985|1|1|erm(C)|erm(C)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(C) NG_055985:101-835,7
,atgaaaatcatgcctgtaaccgagcctttcctggccgattggctggaattaagacgattactctggccagatcatgaagacgcgcatttactggaaatgcggcagctactcgaacaaacacagaccctgcaattattaagctataacgatcagcagcaagcaattgcgatgctggaagcctcgattcgatatgaatatgtgaatggcacgcaaagctcaccggtggcttttctggaaggtatttatgtgttgccagaatatcgacgttcaggtgttgctagcgcgttggtacagcaggcagaagactgggccaagcagtttgcatgtaccgaatttgcttcggacgctgcgctggataatacgatcagtcatgccatgcatcgcgcgctgggctttcaggaaaccgagcgtgtggtttactttaagaaaaacatcagttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_112,Drugs,MEG_112|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,696298948|WP_032874497.1|NG_052457|1|1|aacA-ACI5|aacA-ACI5|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052457:101-541,2
,ATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCAAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGTTGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_347,Drugs,MEG_347|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|38154309|gb|AY162283.2|443-961 gi|14133992|gb|AF369871.1|1492-2010,2
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggagagtttattgtataccagtggtgcaattgcagaaccagggagcgtagataaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaagtataccgttctttatccgtattagacggagcagtattattagtttctgcaaaggatggcatacaggcacagacccgtatactgtttcatgcactacagacaatgaagattccgacaatttttttcatcaataaaattgaccaagaggggattgatttgccaatggtatatcaagaaatgaaagcaaagctttcttcggaaattatagtgaagcaaaaggttgggcagcatccccatataaatgtaacggacaatgacgatatggaacagtgggatgcggtaattatgggaaacgatgaactattagagaaatatatgtcagggaaaccgtttaaaatgtcagaactggaacaggaagaaaacaggagattccaaaacggaacgttatttcccgtttatcacggaagtgctaaaaacaatctggggattcggcagcttatagaagtgattgccagtaagttttattcatcaacgcctgaaggtcaatctgaactatgcgggcaggtttttaagattgaatattcagagaaaaggcggcgttttgtttatgtgcgtatatatagcggaacattgcatttgagggatgttattaaaatatctgaaaaagagaaaataaaaatcacagagatgtgtgttccgacaaacggtgaattatattcatccgatacagcctgctctggtgatattgtaattttaccaaatgatgttttgcagctaaacagtattttggggaacgaaatgctgttgccgcagagaaaatttattgaaaatcctctccctatgctccaaacaacgattgcagtaaagaaatctgaacagcgggaaatattgcttggggcacttacagaaatttcagatggcgaccctcttttaaaatattatgtggatactacaacgcatgagattatactttcttttttggggaatgtgcagatggaagtcatttgtgccatccttgaggaaaaatatcatgtggaggcagaaacaaaagagtctactgttatatatatggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaatcaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7158,Drugs,MEG_7158|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,502377330|WP_012775603.1|NG_048266|1|1|tet(O)|tet(O)|tetracycline_resistance_ribosomal_protection_protein_Tet(O) NG_048266:101-2020,4
,atgactaaaaaagctcttttctttgccattggtacgatgtttttatcggcatgttcttttaatacggtagaacagcatcaaatacagtcaatttctaccaataaaaactcaaagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacatgggcaaacagaggaagtctatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatggtaaatgctttgattggacttgagcatcataaagcaacgccaactgaagtgtttaaatgggatgggcaaaagcgtttatttcccgattgggaaaaagacatgacattaggcgatgcgatgaaagcttctgctattccagtttatcgggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagataatttttggcttgttggcccacttaaaattacacctcaacaagaagtacagtttgcttataaattagcccacaaaactcttccctttagcaaaaatgtacaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacgaaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggtttacaggctgggtagttcaaccacaaggagaaattgtagcgttctcactcaatttagaaatgaagaaaggcatacctagttctattcgaaaagaaattgcttataagggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4554,Drugs,MEG_4554|Drugs|betalactams|Class_D_betalactamases|OXA,1509794614|WP_122630923.1|NG_062346|1|1|blaOXA-777|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-777 NG_062346:1-822,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggttcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccatctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5558,Drugs,MEG_5558|Drugs|betalactams|Class_C_betalactamases|PDC,553768633|WP_023100808.1|NG_049908|1|1|blaPDC-36|blaPDC|class_C_beta-lactamase_PDC-36 NG_049908:1-1194,0
,ATGAAAAAACATCTTGTTGTAATTGCATTTTGTGTGCTTTTTGCTTCTGCTTCTGCTTTTGCGGCTAAAGGTACGGATTCGCTTAAAAGCAGTATTGAAAAATATCTTAAAGATAAAAAAGCTAAAGTGGGTGTTGCCGTTTTGGGAATTGAAGATAATTTTAAATTGAACGTTAACGAAAAGCATCACTATCCTATGCAGAGCACTTATAAGTTCCATCTTGCATTGGCTGTGCTCGATAAACTTGATAAGGAGAATATTTCCATTGACAAGAAGCTTTTTGTAAAAAAATCGGAGCTTCTGCCGAATACTTGGAGTCCGCTAAGAGATAAATATCCCGATGGAAATGTGGATTTATCCATAAGCGAAATTCTGAAAGCTACCGTTTCGCGTAGCGATAATAACGGTTGTGATATTCTCTTCAGATTTGTTGGTGGAACAAATAAAGTCCACAATTTTATTAGCAAGCTTGGCGTTAAGAATATTTCTATCAAAGCTACAGAAGAAGAAATGCACAAGGCATGGAATGTACAATATACCAATTGGACAACTCCCGACGCTACCGTTCAGCTCTTAAAGAAGTTCTACAAAAATGAAATACTCTCAAAAAATAGTTACGACTATTTGCTTAATACTATGATTGAAACTACTACCGGACCGAAACGACTCAAAGGACTTTTGCCCGATGGAACTGTTGTTGCTCATAAAACCGGAAGCTCCGATACTAACGATAAAGGCATTACTGCTGCCACAAATGATATCGGTATTATTACTCTGCCGAACGGTAAACACTTTGCCATTGCTGTTTATGTGTCGGATTCAAGCGAAAAGAGCGATGTTAACGAAAAGATTATTGCCGAAATTTGCAAAAGCGTTTGGGATTATCTAGTTAAGGATGGGAAATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_7251,Drugs,MEG_7251|Drugs|betalactams|Class_A_betalactamases|TLA,(Bla)TLA-1:GU441460:3220-4125:906,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6408,Drugs,MEG_6408|Drugs|betalactams|Class_A_betalactamases|SHV,gi|124053902|gb|EF035557.1|1-861,0
,atgaccactaccattagcttcgtcacgctgcgcctcatgaccgagcacgaccttccgatgctccatgactggctaaatcggcctcacatcgttgagtggtggggcggagaagaaacacgtccaacacttgctgaagtgctggagcaatacctaccaagcgccctggcgaaagagtccgtcactccctacatcgcaatgctggatgaagaaccgattgggtacgctcagtcgtacattgcactcggaagcggtgacggatggtgggaagacgaaaccgatccaggagtacgcggaatagaccagtctctggcgaatccatcgcagctgggcaagggcttgggaaccaagctcgtttgcgcgctcgttgagatgctgttcaaagacgctgaggtaaccaagatccaaacggacccgtcgccgaacaacttacgcgcaatccggtgctacgagaaggcgggttttgtggcgcaaagaaccataaacaccccagatggaccggccgtatacatggttcaaacacgtcaggcgttcgagcaggcgcgcagtgctgtctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_126,Drugs,MEG_126|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,764588668|WP_044424439.1|NG_047265|1|1|aac(6')-31|aac(6')-31|aminoglycoside_N-acetyltransferase_AAC(6')-31 NG_047265:101-655,2
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1349,Drugs,MEG_1349|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_40_NZ_AZBT01000050,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgtatcgaacacgcttgtgaggccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgatctattggtgacaaagcaacgcgacttgaccgattggaaccccgtttgaacgaagcaaaaccgggcgacaagcgagataccacaacgcctaacgccatggtaaacaccctacactccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattcgctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1508,Drugs,MEG_1508|Drugs|betalactams|Class_A_betalactamases|CARB,646415024|WP_025525762.1|NG_048740|1|1|blaCARB-36|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-36 NG_048740:1-852,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacacctggtaaatattgggaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatatcgacaatattcaaacccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcgatcaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtagctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaaagggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcgtatgcagttttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_544,Drugs,MEG_544|Drugs|betalactams|Class_C_betalactamases|ADC,727731285|WP_033851992.1|NG_055787|1|1|blaADC-159|blaADC|class_C_beta-lactamase_ADC-159 NG_055787:1-1152,0
,CTAAGTTATTTTATTGAACATATATCTTACTTTATCTATCCGACTATTTAGACGACGGGTCTGGCAAACAGGTTCGCCAGTGGTAACCTGATATCCTTTTAGCTCTGCTAAACAAACACTAAGCCCATTTGTAAAAAAAGTTAAATCATTGCGATAATCTTGAATACATCGAGCAGGAATTTCTCCAATAATAATGACCTCATTATTTTTCAGTTGAGTATTTACGATATTTGCACAATATTTGGGAGCATCGTTATATGCCCGTGAAAGATATTCCTGTGGTGCATAAACTTTAAAACTAAGATATGGCTCTAACAATTCTGTTCCAGCTTTTCTAAAGGCTTGCTCCAGTACAATAGGAGTAAGCATCCGAAAATCTGCTGGAGTACTAACAGGGCTATAGTATAAACCGTACTTAAAACAGATTTTACAATCCGTCACATTCCAACCATATAATCCTTGTTCGCAACCATAGCGTATCCCTTCCATAACTGCATTTTGAAATGATTGATTTAAGTATCCAAGAGAAACCGAGCTCTCATACTGCATTCCACTTCCCAACGGAAGCGGTGATACAGATAAACCAATGGAAGCCCAGAAAGGATTTGGCGGCACTTCGATGTGAATGGTATATTCTGCATTTTTTAACGGTCTCTCCATATAAATGACTGTAGGCTCTTTTAGTTCTATCTCCACATGATACTTTTCTTGCAACAGTGCACTAATCACTTCCATTTGTACTTTCCCTAAGAAAGAAAGTATAATTTCATGTGTCGTAGAATCCACGTAATATCGTAGAAGCGGATCACTATCTGAGATTTCCAAAAGGGCATCAAGCAACATTTCTCTCTGTTCAGGTTTACTCGGTTCAACAGTTGTTTGTAGTAGAGGGTGCGGATTTTCAATCTTTTTTCTCTGTGGCAATAGTTTTGTATCTCCAAGAACACTATTTAACTTCAAAAACTCATTTTGCAAAATAACAATTTCTCCAGAATAAGCTCTATCAATCTTACATAATTCACCATTTATTGAAGTATACATTTCTGTAACTTTTATTTTTTCTTTTTCTGATACTCTAACCGAATCTCGTAAATGTAGTACTCCACTATAAAGGCGTATATATGCAAGACGTTGTCTTTTTTTTGTATATTCAATTTTGAAAACATTTCCGCAAAGTTCAGACGGACCTCGATGTGTTGATGAATAAAATTTATTAGTAATAACTTCTATAAGGTTATCAATCCCTATATTACTTTTTGCACTTCCATGATAAAGAGGGAACAGAGAACAATTCTGAAATCTTATGCTTTCCTCTTGTTCGAGTTCCAATGCTTCTAATGATTTACCGGACATATATTTCTCTAAAAGGTCATCGTTTCCCTCTATTACCGTATCCCATTGTTCAGATTCGGTAAAGTTCGTCACACACATATTAGGATACAGTTCTACCTTCTGTTTGATTACAATTTCGGCAGAAAGTTTCTCTTTAATATCCTGATAAACCGTTGATAAATCAATTCCATTTTGGTCAATCTTATTGATAAAAAAGATTGTGGGAATCCCCATTTTCCTAAGTGCATGAAATAATATACGAGTTTGTGCTTGTACGCCATCTTTTGCAGAAATCAGTAGAATTGCCCCATCTAAAACTGATAATGAACGATATACTTCTGCTAAGAAATCCATATGTCCTGGCGTGTCTATGATGTTCACCTTCGTATTTTCCCACTGAAAAGAGGTTATTCCTGTCTGAATTGTAATTCCTCTCTGACGTTCTAAAAGCGTATTATCCGTCCTCGTTGTACCTTTGTCCACGCTTCCTAATTCTGTAATCGCTCCACTGTTATATAATAAGCTTTCTGTTAAGGTAGTTTTTCCTGCATCAACATGAGCTAAAACTCCAATATTAATAATTTTCAT,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7146,Drugs,MEG_7146|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|985632614|gb|CP012480.1|997947-996028 gi|974161314|gb|CP012018.1|455470-457389 gi|974158397|gb|CP012015.1|455557-457476 gi|974152716|gb|CP012012.1|455763-457682 gi|827385634|gb|CP007686.1|1140317-1142236 gi|675299197|gb|KM015350.1|2229-310 gi|606215985|emb|HG939456.1|932467-930548 gi|554590848|gb|CP006838.1|441732-443651 gi|488461440|emb|HF930766.1|4147-6066 gi|329312723|gb|CP002643.1|427033-428952,4
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttagacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaactttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4656,Drugs,MEG_4656|Drugs|betalactams|Class_D_betalactamases|OXA,1391852913|WP_109545098.1|NG_057532|1|1|blaOXA-599|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-599 NG_057532:1-774,0
,ATGTTTATAAAATTCAATAAAGTTTCTTTTTCTTATGATAGTTCTGATAATATATTAAATGATGTTTCTTTTCATATAGATAATTCATGCACTGCAATAGTAGGTGAAAATGGATGCGGTAAAACCACGCTAGCTAAACTTATAACAGGTATATTAAAGCCTAATTCAGGAAGCATAGAATATTCAAATAAAAATATTATAACTGCTTACTGCGATCAGGAATGTATCAACTTACCTGATAATGCTGAAAATTTATTTTATGATGATAGTTCATACTCAGGATATTTAACTTCTATATTTAAAATAGATTATAATTATTTATATAGATTTGATACTCTTAGTTTCGGAGAGAGAAAAAGACTACAAATAGCTTCTGCTTTATACTCTAATCCTGATATATTGGTATTAGATGAGCCTACGAATCATATTGATATAGAATGCAAAGATATACTTATTAATGTAATAAAAAGACTCGATTGTATAGTTATAATTATAAGCCATGATATTGATTTTCTTGATGAGTTAGTAGAAAAATGTATATTTATAAGAAATGGAAATTGCAAGATAAGAATAGGTAATTACACTCAATGCAGAGGATATGAAAAAGACGAAGAAGATTATAATTTTAGTTTATATGAGGAAAGCAGGAAGAAAGCTAAAATATTAGAAAATAGATACAAAAAACTACAAAATGAATCGGATGCTAAAAAAAGCAAATGCGGAAGTAAAAGACATATAGATAAAAAAGATCATGATGCTAAGGGAAAAATAGACGCAGCAAGACTTGCAGGTAAAGATTCAAGACTTGCAACTAAGGCTAAGCAGGCCAAAAGTTTATACAATAATACAGTAATGGAAATGGAATCTCTTTATACTAAGAAAAGAGAAGTTATGGATATGGAGTTTATTGGAGAAAGGTATAAAGGAAAATTTTTATTTTATCTTGAGGCAGGAGAAACAAAAATAAATAGTATAGTTCTAAGACATCCCGAACTTATAGTGAAAAAAGACAGCAGAATAGGTATTGAAGGTGTAAACGGGGCAGGTAAAACCAGTTTATTAAATTATATAATTGAAACAATGTATGATAATTCTATAGATAAAGAAAAGATAATATATATTCCTCAGGATATAGATAGAGAAAGTTGGAATAATACTTTTAATAATATAAAGGCATTGGATCATGAATCATTAGGTTTTTTAATGAGTTTTGTAAATAGACTAGGAAGCAATGCTAAATCTGTGATTAATTCATTGAATCATAGTCCGGGTGAGATGCGTAAAATAATGCTTGGAATGGCGGTTATAAAAAAGCCTTATATTATAATGTTAGATGAGCCTACGAATCATCTGGATATAGACTCAATAGAGCGTTTAGAGGAGGCTTTAATTTCTTTTAATTGTGCTTTGATTATAGTAAGTCATAATAGAAATTTTATTAAAAATGCAGTAAATACTTTATGGAGTATAAAAATAGAATATAATTACAGTATTTTAGATATTAAAAACACTATATAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_7327,Drugs,MEG_7327|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|TVAA,gb|LT970863.1|+|0-1518|ARO:3004730|tva(A) [Brachyspira hyodysenteriae] ,1
,ATGAAACTCTTTGCCCAGGGTACTTCACTGGACCTTAGCCATCCTCACGTAATGGGGATCCTCAACGTCACGCCTGATTCCTTTTCGGATGGTGGCACGCATAACTCGCTGATAGATGCGGTGAAACATGCGAATCTGATGATCAACGCTGGCGCGACGATCATTGACGTTGGTGGCGAGTCCACGCGGCCAGGGGCGGCGGAAGTTAGCGTTGAAGAAGAGTTGCAACGTGTTATTCCTGTGGTTGAGGCAATTGCTCAACGCTTCGAAGTCTGGATCTCGGTCGATACATCCAAACCAGAAGTCATCCGTGAGTCAGCGAAAGTTGGCGCTCACATTATTAACGATATCCGCTCCCTTTCCGAACCTGGCGCTCTGGAGGCGGCTGCAGAAACCGGTTTACCGGTTTGTCTGATGCATATGCAGGGAAATCCAAAAACCATGCAGGAAGCCCCGAAGTATGACGATGTCTTTGCAGAAGTGAATCGCTACTTTATTGAGCAAATAGCACGTTGCGAGCAGGCGGGTATCGCAAAAGAGAAATTGTTGCTCGACCCCGGATTCGGTTTCGGTAAAAATCTCTCCCATAACTATTCATTACTGGCGCGCCTGGCTGAATTTCACCATTTCAACCTGCCGCTGTTGGTGGGTATGTCACGAAAATCGATGATTGGGCAGCTGCTGAACGTGGGGCCGTCCGAGCGCCTGAGCGGTAGTCTGGCCTGTGCGGTCATTGCCGCAATGCAAGGCGCGCACATTATTCGTGTTCATGACGTCAAAGAAACCGTAGAAGCGATGCGAGTGGTGGAAGCTACTCTGTCTGCAAAGGAAAACAAACGCTATGAGTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2959,Drugs,MEG_2959|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|937297913|gb|CP012802.1|3939786-3938938 gi|734586714|gb|CP010304.1|4085721-4084873 gi|675820603|emb|LM997165.1|335747-334899 gi|667689599|gb|CP008957.1|4155036-4154188 gi|666001753|gb|CP008805.1|4120986-4120138 gi|386794017|gb|CP001925.1|3994669-3993821 gi|374356928|gb|CP003109.1|3864577-3863729 gi|290760697|gb|CP001846.1|3956094-3955246 gi|254590536|gb|CP001368.1|4125217-4124369 gi|209758267|gb|EU894885.1|46-894,8
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATGGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGTTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAACGACCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTACACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGCAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1987,Drugs,MEG_1987|Drugs|betalactams|Class_C_betalactamases|CMY,gi|620596490|dbj|AB931163.1|811-2038 gi|388564827|gb|JQ733571.1|1028-2255,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttctcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgagggcgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_907,Drugs,MEG_907|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502229|WP_071846379.1|NG_052513|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052513:101-889,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5520,Drugs,MEG_5520|Drugs|betalactams|Class_C_betalactamases|PDC,510945383|WP_016263090.1|NG_049892|1|1|blaPDC-20|blaPDC|class_C_beta-lactamase_PDC-20 NG_049892:1-1194,0
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttgggcggtacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgtttccggaccgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcatggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctgaggcaatggtcatgcccggagtcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaatgcccatgctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1598,Drugs,MEG_1598|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1028084257|WP_063843225.1|NG_047608|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_047608:86-718,6
,atgattaggaataaatcttatgcagggcttgattattttaggattatagctgcattacttataattgcaattcatacatctccattattatcatatagtaaaatggctgactttgtgttaactagtataattgctcgtattgctgtgccattcttttttatgctatcaggcttttttctaatttcaacatataattataattgtaataaactgaaatcttttctaaaaaatgtattatttatttacgggatagctattgtaatttatattcccttaaatatttacactggatatttttccatgaataatttagtgcccaatattattaaggacattgtatttgatgggactttatatcatttatggtatctacctgcatcaattattggtgcaagtattgcatactttcttgtaaaaaaactaggtttaaagtactcattagtaatcactattgttatttatgtaattggtatgtttggtgatagttattatggttttttagaaaaaataccactattaaagaatttatatgggtatatttttgaagtatcagattatacacgaaatggtatattttttgcacctgtatttttcatacttggtggaataatatctaataaatctaattatatgtcaactaaaaatagcttgattggatttcttatatcattcttacttatgttatgtgagggaatgtttttacataaactaggggtacagcgtcatgatagcatgtatattatgttattgccatgtatgtatttcttatttacagccttaacatttttgaaaggttctcgagctaggttattgcgaacatcatcattaattatttatattatacatcctatgatgattgttgttattcgtatgttttctaaaatattcggaatacaaactgtcttggttgacaatagccttattcattatatagtggtaagtatagcatcttttatagcttctataattattatattgattcttaaacctctaaaaaaagacttgaaaggagaacataaggtaaataccaatagagcttggattgaaattgatttaaataatttggaacataatgtaaagatgatacaaaaagctatgccagaagattgtgaattgatggcagttgtaaaagctaatgcctatggtcatagtgcttttgaagtagcgacttgtgcaaaccaaataggtgtaaaagcatttgcagtagcaacaatagatgaggggattgatttacgtcgatatggaatactaggagaaatattgattcttggatatactaacccaataagggcaaaggaacttcataaatacaatcttacacagagtgttattgaccttaatcatgctatctctttaaacaaacagaaatacaacataaaatcacacattaaaattgatacaggtatgcacagactgggttttgatgttaatgatgtgaggtcaattttaaaggcatttaaattaaaatacttagatatatgtggaatatttacacacttgtgtgtttcagatagtctgaaagatgaagatgtagactttacaaataaacaaattgaatgtttttataagttaattgattttctgttaaaaaaaggtataaaaattcctaaagtacatattcaaagtagttatggtttttttaattatcccaatcttaagtgtaattatgtaagaattggaattgcattatacgggatattaagttctccaaatgatacgactaaattgcaacttgatttacgacctgttttatccttaaaatcacaagtaattcttattagaaaaatacaaaaagatgatagttttggatatggaagagtttttattgcaagcagagatagcgtaattgctatattatctattggctatgccgatggtatacctagaaatttatcctgtggaaaaagttacgtaataataaatggttgtagagcagcaatagtgggtcgaatttgcatggaccaacttgctgttgatattacagatatacctaatgtagaagttggtaatacggcaataataataggaagagataatttagctgaattatctgcttctgaagttgcaaataactcatgtagtatatcgaatgaattattgagcagagtaggaagaaggttaaatgttataaagaagtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7525,Drugs,MEG_7525|Drugs|Glycopeptides|VanC-type_resistance_protein|VANTC,1102724726|WP_071593222.1|NG_052046|1|1|vanT-Cd|vanT-Cd|membrane-bound_serine_racemase_VanT-Cd NG_052046:101-2239,5
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagctgtaaatagcaataccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatacaaaactatgcttttggctataaccaaaaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgctgagttttattcatgccaatctgaacccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaagcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_539,Drugs,MEG_539|Drugs|betalactams|Class_C_betalactamases|ADC,1440786784|WP_114699272.1|NG_061396|1|1|blaADC-180|blaADC|class_C_beta-lactamase_ADC-180 NG_061396:1-1152,0
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5694,Drugs,MEG_5694|Drugs|betalactams|Class_C_betalactamases|PDC,550049059|WP_022580963.1|NG_049910|1|1|blaPDC-38|blaPDC|class_C_beta-lactamase_PDC-38 NG_049910:1-1194,0
,atgatgaaaaaatccctttgctgcgccctgctgctgggcctctcttgctctgctctcgccgcgccagtatcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaatcgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccggcgttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacaggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagcatcggtctttttggcgcgctggcggtcaaaccttctggcatgccctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggaatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaaggttgccgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcgaaggcagcgacagtaaggtagcgctggcgccattacccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggttctaccggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgaggcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_432,Drugs,MEG_432|Drugs|betalactams|Class_C_betalactamases|ACT,556463459|WP_023315250.1|NG_050702|1|1|blaACT-16|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-16 NG_050702:1-1146,0
,atgagcaagttatctgtattctttatatttttgttttgcagcattgctaccgcagcagagtctttgccagatttaaaaattgaaaagcttgatgaaggcgtttatgttcatacttcgtttgaagaagttaacgggtggggcgttgttcctaaacatggtttggtggttcttgtaaatgctgaggcttacctaattgacactccatttacggctaaagatactgaaaagttagtcacttggtttgtggagcgtggctataaaataaaaggcagcatttcctctcattttcatagcgacagcacgggcggaatagagtggcttaattctcgatctatccccacgtatgcatctgaattaacaaatgaactgcttaaaaaagacggtaaggttcaagccacaaattcatttagcggagttaactattggctagttaaaaataaaattgaagttttttatccaggcccgggacacactccagataacgtagtggtttggttgcctaaaaggaaaatattattcggtggttgttttattaaaccgtacggtttaggcaatttgggtgacgcaaatatagaagcttggccaaagtccgccaaattattaaagtccaaatatggtaaggcaaaactggttgttccaagtcacagtgaagttggagacgcatcactcttgaaacttacattagagcaggcggttaaagggttaaacgaaagtaaaaaaccatcaaaaccaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3331,Drugs,MEG_3331|Drugs|betalactams|Class_B_betalactamases|IMP,1040476845|WP_065102288.1|NG_050945|1|1|blaIMP-60|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-60 NG_050945:1-741,0
,atgcgcgataccagattcccctgcctgttcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5685,Drugs,MEG_5685|Drugs|betalactams|Class_C_betalactamases|PDC,1201190443|WP_087587963.1|NG_054983|1|1|blaPDC-198|blaPDC|class_C_beta-lactamase_PDC-198 NG_054983:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcacagcctgggccagccgttcaaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5456,Drugs,MEG_5456|Drugs|betalactams|Class_C_betalactamases|PDC,1121409587|WP_073669325.1|NG_060555|1|1|blaPDC-285|blaPDC|class_C_beta-lactamase_PDC-285 NG_060555:1-1194,0
,atggctctggcactcgttggcgaaaaaattaacagaaaccgcttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgcttggcattgaaatttgccactgtcgtgcgcaaggcgcagattttcgcggcgcaagttttatgaatatgatcactactcgcacctggttttgcagtgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgttggatgggggcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggcgcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5889,Drugs,MEG_5889|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1051486255|WP_065908739.1|NG_057450|1|1|qnrB91|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB91 NG_057450:101-745,3
,gtgcaatacgaatggcgaaaagccgagctcatcggtcagcttctcaaccttggggttacccccggcggtgtgctgctggtccacagctccttccgtagcgtccggcccctcgaagatgggccacttggactgatcgaggccctgcgtgctgcgctgggtccgggagggacgctcgtcatgccctcgtggtcaggtctggacgacgagccgttcgatcctgccacgtcgcccgttacaccggaccttggagttgtctctgacacattctggcgcctgccaaatgtaaagcgcagcgcccatccatttgcctttgcggcagcggggccacaggcagagcagatcatctctgatccattgcccctgccacctcactcgcctgcaagcccggtcgcccgtgtccatgaactcgatgggcaggtacttctcctcggcgtgggacacgatgccaacacgacgctgcatcttgccgagttgatggcaaaggttccctatggggtgccgagacactgcaccattcttcaggatggcaagttggtacgcgtcgattatctcgagaatgaccactgctgtgagcgctttgccttggcggacaggtggctcaaggagaagagccttcagaaggaaggtccagtcggtcatgcctttgctcggttgatccgctcccgcgacattgtggcgacagccctgggtcaactgggccgagatccgttgatcttcctgcatccgccagagggcgggatgcgaagaatgcgatgccgctcgccagtcgattggctgagctcatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_32,Drugs,MEG_32|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,1028080885|WP_063840268.1|NG_047254|1|1|aac(3)-IVa|aac(3)-IVa|aminoglycoside_N-acetyltransferase_AAC(3)-IVa NG_047254:101-886,2
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCCGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCACACCATCACCCCGTTGATGCAGAAGCAGGCTATTCCGGGGATGGCCGTTGCAGTTATCTACCAGGGTAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGTGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAGCCACAATGGACTCCGAGCACTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGTATGAGCTACGAAGAGGCGATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAAAAAACACTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGTTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTACATAAAACGGGATCCACTGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGCCCGCGTCGATGCAGCCTGGCGTATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1922,Drugs,MEG_1922|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KF150216|+|0-1146|ARO:3002116|CMY-104 [Citrobacter sp. OTESBL0707] ,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaatggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgtatagaacacgcttgtgaagccgccatgttgatgagtgacaactccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgatctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaacgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagttgaaaatctggatgcaagacaacaaagtatcggattcgctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatttggaaagacaactacaagccggtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1514,Drugs,MEG_1514|Drugs|betalactams|Class_A_betalactamases|CARB,491640763|WP_005498292.1|NG_048734|1|1|blaCARB-30|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-30 NG_048734:1-852,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaatctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2180,Drugs,MEG_2180|Drugs|betalactams|Class_A_betalactamases|CTX,1440786796|WP_114699284.1|NG_061413|1|1|blaCTX-M-221|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-221 NG_061413:1-876,0
,atgaaaacatttgccgcatatgtaattatcgcgtgtctttcgagtacggcattagctggttcaattacagaaaatacgtcttggaacaaagagttctctgccgaagccgtcaatggtgtcttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaatgacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaagcaatgggaaagagacttgaccttaagaggggcaatacaagtttcagctgttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcctatggcaaccagaatatcagtggtggcattgacaaattctggttggaagaccagcttagaatttccgcagttaatcaagtggagtttctagagtctctatatttaaataaattgtcagcatctaaagaaaaccagctaatagtaaaagaggctttggtaacggaggcggcacctgaatatctagtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttgggtgggttgagaaggagacagaggtttactttttcgcctttaacatggatatagacaacgaaagtaagttgccgctaagaaaatccattcccaccaaaatcatggaaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4673,Drugs,MEG_4673|Drugs|betalactams|Class_D_betalactamases|OXA,1029192944|WP_064056056.1|NG_050656|1|1|blaOXA-14|blaOXA-10_like|OXA-10_family_oxacillin-hydrolyzing_class_D_extended-spectrum_beta-lactamase_OXA-14 NG_050656:101-901,0
,CGGACTACGACCATTACCCCTGATAATGCTTCATAATATTAGAAAAAGGAGAAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCTTTTTGCCTTCCTGTTTTTGCTCACCCAAAAACGCTGGTGAAAGTAAAAGATGCTGAAAATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAAAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAGTGACGTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6872,Drugs,MEG_6872|Drugs|betalactams|Class_A_betalactamases|TEM,gi|134154076|gb|EF468463.1|9-927,0
,TTGAATTGAAGAGTTTGATCATGGCTCAGATTGAACGCTGGCGGCAGGCTTAACACATGCAAGTCGAACGGTAGCAGGAAGAAAGCTTGCTTTCTTTGCTGACGAGTGGCGGACGGGTGAGTAATGCTTGGGAATCTGGCTTATGGAGGGGGATAACTGTGGGAAACTGCAGCTAATACCGCGTATTCTCTGAGGAGGAAAGGGTGGGACCTTAGGGCCACCTGCCATAAGATGAGCCCAAGTGGGATTAGGTAGTTGGTGGGGTAAAGGCCTACCAAGCCTGCGATCTCTAGCTGGTCTGAAAGGATGACCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCGCAATGGGGGGAACCCTGACGCAGCCATGCCGCGTGAATGAAGAAGGCCTTCGGGTTGTAAAGTTCTTTCGGTAATGAGGAAGGGATGTTGTTAAATAGATAGCATCATTGACGTTAATTACAGAAGAAGCACCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAGGGTGCGAGCGTTAATCGGAATAACTGGGCGTAAAGGGCACGCAGGCGGACTTTTAAGTGAGATGTGAAATCCCCGAGCTTAACTTGGGAACTGCATTTCAGACTGGGAGTCTAGAGTACTTTAGGGAGGGGTAGAATTCCACGTGTAGCGGTGAAATGCGTAGAGATGTGGAGGAATACCGAAGGCGAAGGCAGCCCCTTGGGAATGTACTGACGCTCATGTGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCTGTAAACGCTGTCGATTTGGGGATTGGGCTATATGCTTGGTGCCCGAAGCTAACGTGATAAATCGACCGCCTGGGGAGTACGGCCGCAAGGTTAAAACTCAAATGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGATGCAACGCGAAGAACCTTACCTACTCTTGACATCCTAAGAAGAGCTCAGAGATGAGCTTGTGCCTTCGGGAACTTAGAGACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTTGTGAAATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATCCTTTGTTGCCAGCGATTCGGTCGGGAACTCAAAGGAGACTGCCAGTGACAAACTGGAGGAAGGTGGGGATGACGTCAAGTCATCATGGCCCTTACGAGTAGGGCTACACACGTGCTACAATGGTGCATACAGAGGGCAGCGAGAGTGCGAGCTTGAGCGAATCTCAGAAAGTGCATCTAAGTCCGGATTGGAGTCTGCAACTCGACTCCATGAAGTCGGAATCGCTAGTAATCGCAAATCAGAATGTTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCCGTACACCATGGGAGTGGGTTGTACCAGAAGTAGATAGCTTAACCTTCGGGAGGGCGTTTACCACGGTATGATTCATGACTGGGGTGAAGTCGTAACAAGGTAACCGTAGGGGAACCTGCGGTTGGATCACCTCCTTACCTAAAA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_6,Drugs,MEG_6|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|NC_002663.1|+|341427-342977|ARO:3003493|Pasteurella multocida 16S rRNA mutation conferring resistance to spectinomycin [Pasteurella multocida 36950] ,2
,atgggcatcattcgcacatgtaggctcggccctgaccaagtcaaatccatgcgggctgctcttgatcttttcggtcgtgagttcggagacgtagccacctactcccaacatcagccggactccgattacctcgggaacttgctccgtagtaagacattcatcgcgctcgctgccttcgaccaagaagcggttgttggcgctctcgcggcttacgttctgcccaagtttgagcaggcgcgtagtgagatctatatctatgatctcgcagtctccggcgagcaccggcggcagggcattgccaccgcgctcatcaatctcctcaagcatgaggccaacgcgcttggtgcttatgtgatctacgtgcaagcagattacggtgacgatcccgcagtggctctctatacaaagttgggcatacgggaagacgtgatgcactttgatatcgacccaagtaccgccacctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_28,Drugs,MEG_28|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,1028080875|WP_063840258.1|NG_047238|1|1|aac(3)-I|aac(3)-I|AAC(3)-I_family_aminoglycoside_3-N-acetyltransferase NG_047238:101-565,2
,ATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGCTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTACGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTTGGCATTGAAATTCGCCACTGTCGTGCGCAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACTCGCACCTGGTTTTGTAGTGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGCTGGAAAAGTGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGTTGCTCATGGAACGTCTTGGCATCGCGGTGATTGGTTA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6004,Drugs,MEG_6004|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,qnrB45_1_JQ349152 ,3
,atgaaaaaatttatacttcctatcttcagcatttctactctactttctctcagtgcatgctcaactattcaaaataaatttgaaaaaacttctgatatttctgatcagcaacatgaaaaagccattaaaagctattttgatgaagctcaaacacaaggtgtaatcattattaaagagggaaagaatattagaatctatggtaataacctggtacgagcacatacagaatatgtccctgcgtcaacatttaagatgctaaatgccttaattggattagaaaatcataaagctacaacaactgagattttcaaatgggatggtaaaaaaagatcttatcctatatgggaaaaagatatgactttaggtgatgccatggcactttcagcagttcctgtatatcaagaacttgcaagacggactggcttagatctaatgcaaaaagaagttaaacgggttggttttggtaatatgaacatcgggacacaagttaataacttctggttagttggccccctcaagattacaccaatacaagaggctaattttgtcgatgatcttgcgaataatcgattaccctttaaattagaaactcaagaagaagtaaaaaaaatgcttctgattaaagaagtcaatggtagtaaaatttatgcgaaaagtggatggggaatggatgtgacccctcaagtaggttggttaacaggttgggtagaaaaatctaatggcgaaaaagttcccttttctctaaacctagaaatgaagcaaggaatgtctggttctattcgtaatgaaattacttataaatcattagaaaatttagggattatataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4406,Drugs,MEG_4406|Drugs|betalactams|Class_D_betalactamases|OXA,1693892941|WP_140423318.1|NG_065436|1|1|blaOXA-825|blaOXA-143_like|OXA-143_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-825 NG_065436:1-828,0
,GTGAATACATCCTATTCACAATCGAATTTACGACACAACCAAATTTTAATTTGGCTTTGCATTTTATCTTTTTTTAGCGTATTAAATGAAATGGTTTTGAACGTCTCATTACCTGATATTGCAAATGATTTTAATAAACCACCTGCGAGTACAAACTGGGTGAACACAGCCTTTATGTTAACCTTTTCCATTGGAACAGCTGTATATGGAAAGCTATCTGATCAATTAGGCATCAAAAGGTTACTCCTATTTGGAATTATAATAAATTGTTTCGGGTCGGTAATTGGGTTTGTTGGCCATTCTTTCTTTTCCTTACTTATTATGGCTCGTTTTATTCAAGGGGCTGGTGCAGCTGCATTTCCAGCACTCGTAATGGTTGTAGTTGCGCGCTATATTCCAAAGGAAAATAGGGGTAAAGCATTTGGTCTTATTGGATCGATAGTAGCCATGGGAGAAGGAGTCGGTCCAGCGATTGGTGGAATGATAGCCCATTATATTCATTGGTCCTATCTTCTACTCATTCCTATGATAACAATTATCACTGTTCCGTTTCTTATGAAATTATTAAAGAAAGAAGTAAGGATAAAAGGTCATTTTGATATCAAAGGAATTATACTAATGTCTGTAGGCATTGTATTTTTTATGTTGTTTACAACATCATATAGCATTTCTTTTCTTATCGTTAGCGTGCTGTCATTCCTGATATTTGTAAAACATATCAGGAAAGTAACAGATCCTTTTGTTGATCCCGGATTAGGGAAAAATATACCTTTTATGATTGGAGTTCTTTGTGGGGGAATTATATTTGGAACAGTAGCAGGGTTTGTCTCTATGGTTCCTTATATGATGAAAGATGTTCACCAGCTAAGTACTGCCGAAATCGGAAGTGTAATTATTTTCCCTGGAACAATGAGTGTCATTATTTTCGGCTACATTGGTGGGATACTTGTTGATAGAAGAGGTCCTTTATACGTGTTAAACATCGGAGTTACATTTCTTTCTGTTAGCTTTTTAACTGCTTCCTTTCTTTTAGAAACAACATCATGGTTCATGACAATTATAATCGTATTTGTTTTAGGTGGGCTTTCGTTCACCAAAACAGTTATATCAACAATTGTTTCAAGTAGCTTGAAACAGCAGGAAGCTGGTGCTGGAATGAGTTTGCTTAACTTTACCAGCTTTTTATCAGAGGGAACAGGTATTGCAATTGTAGGTGGTTTATTATCCATACCCTTACTTGATCAAAGGTTATTACCTATGGAAGTTGATCAGTCAACTTATCTGTATAGTAATTTGTTATTACTTTTTTCAGGAATCATTGTCATTAGTTGGCTGGTTACCTTGAATGTATATAAACATTCTCAAAGGGATTTCTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7101,Drugs,MEG_7101|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETL,gi|695196836|ref|NG_034536.1|189-1565,4
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcaggggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttgaagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagggaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_880,Drugs,MEG_880|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502080|WP_071846232.1|NG_052244|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052244:101-892,2
,atggacagtgactatacacagctccagacaaaaatattaataaggacagcggttgtgctattcggggcgtttgctctgatttccgcatctcttagtttattaagcgggcatttttcaagggctgttgtggggattttggaaatattctataaagattatgaaaaggctttggtggtatacacctatgtgtttcgggacaataaagaatggtttgtgatgatagctgcatttgtcgtttctaattgtattacgatgtatctgaaaggcttcacaaagtattttaatgaaataaacagaggtattaatgccttgaaagaggaaagttcagaagatgttgtattatcttctgagcttgcggcgactgaaaaaacaatcaatacaattaagcatacccttgaacagcagaaaactgcggcgctggttgcagagcaaaggaagaacgaccttgtagtgtatcttgctcatgatttaaagactccgcttacatctgtgattggatatttgacattgcttagggacgagaagcaaatttcagatgaattaagggaaaagtatatatgtatttcactggaaaaagcagaacgattggaaaatctgatcaatgaattttttgagattacacgttttaatctttccaacataatacttgaatatagtgtggtaaatttaactcgtatgttggagcagttggtttttgaattcaatccaatgcttgcggaaaaaaaattaaattgtgttcttaagacgatgccgaataaaatgatacgctgcgacgccaataaaatgcagagggtattcgataatttattgagaaatgcagtgaattatagttttgagaatacagagatttctattacagtcacacaaaatgaaaatatggttcatattaaatttgtaaatcatggaaatacaattccaaaagagaaactggaacgtatttttgaacagttttatcgtctggatacttccagaagcacagggaatggcggcgcaggcttagggcttgctattgcaagggaaatcgtaatgctgcatggagggacaataaccgcccgcagtgaagatgaaaggattgaatttgaagtgacgattctttcatcgtag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7512,Drugs,MEG_7512|Drugs|Glycopeptides|VanG-type_regulator|VANSG,1028100597|WP_063856732.1|NG_048428|1|1|vanS-G|vanS-G|VanG-type_vancomycin_resistance_histidine_kinase_VanS NG_048428:101-1204,5
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGTCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAAAACGCAGAGCGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2386,Drugs,MEG_2386|Drugs|betalactams|Class_A_betalactamases|CTX,gi|237511596|gb|FJ907380.1|1-876,0
,AGGACGTAAAATATTATTGAAATGATCTAAAGCAAATAATATTTCTCTTCTAAAAACACCCTTTGCTACATATGTTGAAACACTCCAAAATTCATTGCAACAATCATGAAATTCTCGTTCTGTTGGCTTTTTTAACCAATAATTTGAATCATCTGGAACAATTTCTTTAGTTACTAAATTATCCTTATCAACTAAAATTTTTACAAGACCATCAGAATCATTAAAATAACGATTTAAATCTTTCAAATTAATTAGCGTAATGTCCATTTTTATACCATCTTTAAAATACATTATATAACTATATCCATAATCTAAATCAGGAGGAAATAATTCCATATCTTCTGGTTTCTGTATAAACAATAATTCTCCAAATAGACTTAACCAGCTTTCTTCACTGGTAAAATAATCAACATCTGATACGAAAAAAGTAAAATCATAATCTTGAAATTTATCTTTTTTTATATTTTTATTAGTTCTTGAACCCTCGAGAGTAATAATTTTTATATTACTTTGTTGATAAGCAAATTCAGAAACTAAACTTAGAATTTCATTTTCAGTTCTCAT,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_999,Drugs,MEG_999|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,gi|695220799|ref|NG_039568.1|12853-13416 gi|196158933|emb|AM932524.1|10852-11415 gi|190350257|emb|AM931300.1|14583-14020 gi|124012095|emb|AM410096.1|8647-8084 gi|121490884|emb|AM296544.1|8647-8084 gi|50980339|gb|AY592978.1|51-422,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtaccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgatcaagttaacttacttcaactcgcgacgtatacaagtggcaacctcgctttacaatttccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccacttgatgccccagcatacggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaccccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtcggcaccatgtatcaggcacttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagagactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaccggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_592,Drugs,MEG_592|Drugs|betalactams|Class_C_betalactamases|ADC,1559612967|WP_128268232.1|NG_063834|1|1|blaADC-183|blaADC|class_C_beta-lactamase_ADC-183 NG_063834:1-1152,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcacgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccaaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5493,Drugs,MEG_5493|Drugs|betalactams|Class_C_betalactamases|PDC,1509794538|WP_122630847.1|NG_062260|1|1|blaPDC-309|blaPDC|class_C_beta-lactamase_PDC-309 NG_062260:1-1194,0
,ATGAAAATAATCAATATTGGAATTCTTGCCCATGTAGACGCTGGAAAGACGACCTTGACGGAGAGCCTGCTATATGCCAGCGGAGCCATTTCAGAACCGGGGAGCGTCGAAAAAGGGACAACGAGGACGGACACCATGTTTTTGGAGCGGCAGCGTGGGATTACCATTCAAGCGGCAGTCACTTCCTTCCAGTGGCACAGATGTAAAGTTAACATTGTGGATACGCCCGGCCACATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATGAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGCGCGGGAGGAACAGCAGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAATGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGGGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTTGAGTACACCGATTGCGGCCAGCGGCGTGTCTATCTACGGTTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCAGGGTGAAATTGTTATCCTTCCCAGCGACAGCGTGAGGTTAAACGATGTATTAGGGGACCAAACCCGGCTCCCTCGTAAAAGGTGGCGCGAGGACCCCCTCCCCATGCTGCGGACGACGATTGCGCCGAAAACGGCAGCGCAAAGAGAACGGCTGCTGGACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGTTGCGAAGTGGATTCCATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTTGTTTCCGCTTTGCTGTCGGAAAAATACAAGCTTGAAACAGTGGTAAAGGAACCCACCGTCATTTATATGGAGCGACCGCTCAAAGCAGCCAGCCACACCATCCATATCGAGGTGCCGCCCAACCCGTTTTGGGCATCCATCGGACTGTCTGTTACACCACTCCCGCTTGGCTCCGGTGTACAATACGAGAGCCGGGTTTCGCTGGGATACTTGAACCAGAGTTTTCAAAACGCTGTCAGGGATGGTATCCGTTACGGGCTGGAGCAGGGCTTGTTCGGCTGGAACGTAACGGACTGTAAGATTTGCTTTGAATACGGGCTTTATTACAGTCCGGTCAGCACGCCGGCGGACTTCCGCTCATTGGCCCCGATTGTATTGGAACAGGCATTGAAGGAATCAGGGACGCAACTGCTGGAACCTTATCTCTCCTTCACCCTCTATGCGCCCCGGGAATATCTTTCCAGGGCTTATCATGATGCACCGAAATACTGTGCCACCATCGAAACGGTCCAGGTAAAAAAGGATGAAGTTGTCTTTACTGGCGAGATTCCCGCCCGCTGTATACAGGCATACCGTACTGATCTGGCCTTTTACACCAACGGGCAGAGCGTATGCCTTACAGAACTGAAAGGGTATCAGGCCGCTGTCGGCAAGCCAGTCATCCAGCCCCGCCGTCCAAACAGCCGCCTGGACAAGGTGCGCTATATGTTTCAGAAGATAATGTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7230,Drugs,MEG_7230|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,gi|260161304|emb|FN396364.1|3373-5292 gi|296182618|gb|CP002010.1|1457082-1457216,4
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAAAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGATGGTGTTTCAAAAGACTGTAAGGTGGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1373,Drugs,MEG_1373|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_110_AJCZ01000013,0
,ATGATGAAAAAATCGTTATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGGCAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCTCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1935,Drugs,MEG_1935|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KM087836|+|0-1146|ARO:3002124|CMY-113 [Citrobacter freundii] ,0
,atgtattacagcctccttatttcagcatttctcttatccatatccgcttgcggaggaaaaagtgaaaaattacaggaacatcttgttgctgagcaaacctccacttttactgaaaaagaggtctattcatcggataaactcattatcaaacaagtcagtccccatacttatgttcacgtttcctttctggacaccgacaccttcggaaaagtagcctgcaacgggatgatcgtcatcagtgatggagaagctgtcgtattcgacaccccaagtacctcaaatgagaccagtgaacttctttcatttttggaagaggagaagctacaggtcaacgctgtagtagcgacacattttcacttggattgcctgggtggacttgaagcatttcacgccaggaacattccgtcatatgcctttaaaaacaccctatctttagcatctcagcatgacttcccacaaccccaaaagggcttttctgacgagctgaccttaaaagtaggcactaaagcagtctttgttcactattttggggaaggacatacccaagacaatgtaattggatacttccctgatgaccaagtgctgtttggcgggtgtctcatcaaagctaatggtgctggaaaaggtaacctcgaagatgccaatgtcgaggcttggccggtcaccgtgaacaaaatcagtaccgcttatccaaaccttcggctagtcattccaggacatggcaattggggcgacaaaaccttactgcattacaccgaaaccctcttcaaatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_2699,Drugs,MEG_2699|Drugs|betalactams|Class_B_betalactamases|ECV,505079325|WP_015266427.1|NG_059320|1|1|blaECV-1|blaECV|subclass_B1_metallo-beta-lactamase_ECV-1 NG_059320:101-874,0
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtctgcatgttcttttaatacggtagaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcgttgtttgatcaagcacaaactacaggtgttttagttataaaacgtgggcaaacagaggaagtctatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttatttcccgattgggaaaaagatatgacattaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaaaaatatgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacggaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaaccacaaggagaaattatagctttctcacttaatttagaaatgaaaaaaggcatacctagctctattcgaaaagaaattgcttataagggattggaacaactcggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4568,Drugs,MEG_4568|Drugs|betalactams|Class_D_betalactamases|OXA,488049989|WP_002121386.1|NG_049778|1|1|blaOXA-500|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-500 NG_049778:1-822,0
,ATGAATACGCAACCGCACGCTTCCCATACCGATTCCAACACGCTGATGCTCGGCCGATACGCCGAACGCGCCTATCTCGAATACGCCATGAGCGTGGTCAAAGGCCGCGCGCTGCCTGAAGTTTCAGACGGCCAAAAGCCCGTGCAGCGGCGCATTTTGTTTGCCATGCGCGATATGGGTTTGACGGCGGGGGCGAAGCCGGTGAAATCGGCGCGCGTGGTCGGCGAGATTTTGGGTAAATACCATCCGCACGGCGACAGTTCCGCCTATGAGGCGATGGTGCGCATGGCTCAGGATTTTACCTTGCGCTACCCCTTAATCGACGGCATCGGCAACTTCGGTTCGCGCGACGGCGACGGGGCGGCGGCGATGCGTTACACCGAAGCGCGGCTGACGCCGATTGCGGAATTGCTGTTGTCCGAAATCAATCAGGGGACGGTGGATTTTATGCCGAACTACGACGGCGCGTTTGACGAGCCGCTGCACCTTCCCGCCCGCTTGCCTATGGTGTTGCTCAACGGCGCGTCGGGCATCGCGGTGGGTATGGCGACCGAGATTCCGTCGCACAATTTGAACGAAGTCACGCAGGCGGCGATTGCACTGTTGAAGAAACCGACGCTGGAAACCGCCGACCTGATGCAATATATTCCTGCTCCCGATTTTGCCGGCGGCGGTCAAATCATCACGCCGGCGGACGAATTGCGCCGTATTTACGAAACCGGCAAGGGCAGCGTGCGCGTGCGTGCGCGTTATGAAATCGAGAAATTGGCGCGCGGACAGTGGCGCGTCATCGTAACCGAACTGCCGCCGAACGCCAACTCCGCCAAAATCCTTGCCGAAATCGAAGAGCAAACCAACCCGAAACCGAAAGCGGGTAAAAAGCAGCTCAACCAAGACCGGCTCAATACCAAAAAGCTGATGCTGGATTTAATCGACCGCGTGCGCGACGAGTCCGACGGCGAACATCCCGTGCGCCTTGTATTTGAACCGAAATCCAGCCGCATCGATACCGATACCTTCATCAACACGCTGATGGCGCAAACTTCGCTGGAAGGCAATGTGTCCATGAACTTGGTGATGATGGGTTTGGACAACCGCCCCGCGCAGAAAAACCTGAAAACGATTTTGCAGGAATGGCTGGATTTCCGCGTCGTTACCGTAACACGCCGTCTGAAATTCCGTTTAAACCAAGTGGAAAAACGGCTGCACATCCTCGAAGGCCGTCTGAAAGTCTTTCTGCACATCGACGAAGTGATTAAAGTCATCCGCGAATCGGACGACCCGAAAGCCGATTTGATGGCGGTGTTCGGGCTGACCGAAATCCAAGCCGAAGACATTTTGGAAATCCGCCTGCGTCAGCTGGCGCGTTTGGAAGGTTTCAAACTCGAAAAAGAATTGAACGAATTGCGCGAAGAACAAGGCCGTCTGAATATCTTTTTGGGCGACGAAAACGAAAAACGCAAGCTGATTATCAAAGAGATGCAGGCGGACATGAAGCAGTTCGGCGACGCGCGCCGCACGCTGGTGGAAGAGGCCGGACGCGCCGTGCTGACACAAACCGCCGCCGACGAACCCATCACGCTGATTTTGTCGGAAAAAGGCTGGATACGCAGCCGTGCCGGACATAATCTCGATTTGAGCCAAACCGCGTTCAAAGAAGGCGACCGCCTCAAACAAACCCTTGAAGGCCGCACTGTTTTACCCGTCGTCATCCTCGATTCATCGGGCAGAACCTACTCGATCGATGCCGCCGAAATCCCCGGCGGACGCGGCGACGGCGTACCGGTTTCCTCCTTAATCGAGTTGCAAAACGGCGCGAAACCCGTCGCGATGTTGACAGGATTGCCGGAACAACATTATTTATTATCAAGCAGCGGCGGCTACGGCTTTATCGCCAAGCTGGGCGATATGGTCGGACGCGTGAAAGCGGGCAAAGTGGTGATGACCGCAGACAGCGGCGAAACCGTCCTGCCGCCGGTTGCCGTCTATGCCTCCTCGTTCATCAACCCCGACTGCAAAATCATTGCAGCCACCAGTCAAAACCGCGCCCTCGCCTTCCCCATCGGCGAATTGAAAATTATGGCGAAAGGCAAAGGACTGCAAATCATCGGATTAAACGCCGGCGAATCGATGACGCATACCGCCGTTTCTTCCGAGCCGGAAATCCTGATTGAAAGCGAAGGCAGGCGCGGCGCGGCGCACAAAGACCGCCTCCCCGTCGCCCTGATTGAGGCAAAACGCGGCAAAAAAGGCAGACTGTTGCCCATATCGGGCAGCCTGAAACAGCTTTCTTCCCCCAAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5326,Drugs,MEG_5326|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gb|AE004969.1|+|1210523-1212827|ARO:3003929|Neisseria gonorrhoeae parC conferring resistance to fluoroquinolone [Neisseria gonorrhoeae FA 1090] ,3
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATATAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1429,Drugs,MEG_1429|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_87_NZ_LRNC01000042,0
,ACGATGAGACATCGCGTTAAGCGGATGATGCTAATGACAACGGCCTGTATTTCGCTGTTGCTGGGGAGTGCGCCGCTGTATGCGCAGGCGAACGACGTTCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGGGGGCGGTTGGGAGTGGCGCTGATTGACACCGCCGATAACGCACAGACGCTCTACCGCGCCGACGAGCGCTTTGCCATGTGCAGCACCAGTAAGGTGATGGCAGCCGCGGCGGTGCTCAAGCAAAGTGAAACGCAAAAGAACGTGTTGAGTCAGAAGGTTGAGATTAAATCCTCGGACCTGATTAACTACAATCCCATCGCTGAAAAACACGTCAACGGCACGATGACGCTGGCGGAATTGAGCGCCGCGGCGTTGCAGTACAGCGATAATACGGCCATGAACAAGCTGATTGCCCATCTTGGGGGGCCGGATAAAGTGACGGCGTTTGCCCGTGCGATTGGGGATGACACCTTCCGGCTCGATCGTACTGAGCCGACGCTCAACACCGCGATCCCCGGCGACCCGCGCGATACCACCACGCCATTAGCGATGGCGCAGACGCTTCGCCATCTGACGTTGGGCAGTGCCTTAGGTGAAACTCAGCGTGCGCAACTGGTAACGTGGCTGAAAGGCAACACCACCGGTGCTGCCAGCATTCAGGCTGGGCTACCCACATCGTGGGTTGTCGGGGATAAAACCGGCAGCGGTGATTATGGTACGACGAATGACATCGCCGTCATCTGGCCGGAAGGGCGTGCGCCGCTTATTCTGGTCACTTACTTCACCCAACCGGAGCAGAAGGCAGAAAATCGTCGTGACGTGCTCGCGGCTGCCGCGAAAATCGTCACCGACGGTTATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2380,Drugs,MEG_2380|Drugs|betalactams|Class_A_betalactamases|CTX,gi|189304726|gb|EU660216.1|46-921 gi|60359799|dbj|AB205197.1|1-876,0
,atgatgaaactccgccacgccgcgaccggcgccctgctggccgcgcttgccacctttgcccatgccgagcgcacgatctgcacgatcgttgccgatgccgccaccggcaaggttgttctgcacgaaggccagtgcgccgaacgcgtcacgcctgcgtccaccttcaagctggcgctggcggtcatgggctacgaccacggtttcctgagggacgagcacacccccatcgagcacatgaaggctggcgaccccgattggggtggcgaggcctggcaccagcccatcgaccccacgctgtggctcaagtactccgtggtctggtattcgcagcgcatcacgcatgcgatgggtgcgcagacgctgcatgcgtatctgcgcaaattcgactacggcaacatggacgcgagcggcgatccggggaagaacaacggcctggaccgctcgtggatcacctcgtcgctgaagatctcgccggaggagcaggtgggcttcatgcgcaagatcgtcaaccgccagttgccggtgtctgcgcatacgtatgagatggtggaccgtacggtgcagacctggccggtgccgggtggctgggctgtgcagggcaaaacgggcactgctgggccgggccccggcaatacgtcgcccgatggcacgtgggatcaggcacacgcttatggctggtttgtcggctgggcgaagaagggcacgggtgacgacagtcggacctacgtgtttgcgaacctgatccaggacgacaagcttgagccgacatcggggggcttgcgctcgcgcgatgcgctgctggcgcgcctgccggaagtgctggcccttgcgagccactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4596,Drugs,MEG_4596|Drugs|betalactams|Class_D_betalactamases|OXA,1039445484|WP_064808581.1|NG_056183|1|1|blaOXA-574|blaOXA-22_like|OXA-22_family_class_D_beta-lactamase_OXA-574 NG_056183:1-840,0
,ttgagcaataaaattcttgttgtagacgatgaacatgatattgctgatttggttgagctatacttgaaaaacgagaattatacggttttcaaatactataccgctaaagaagcgttggattgtatagacaagaccgagcttgaccttgccatattggacatcatgcttcccggtgcaagtggcctttctatctgccaaaaaataagggacaagtatacctatcccattatcatgctgaccgcgaaagattcggagatagataaaattacagggctaaccatcggcgcagacgattatataacgaagccctttcgcccgctggagttaattgcacgggttaaggcacagttgcgccgatacaaaaaatacagtggagtaacggagcagaacgaaaatattatcgtccactccggccttgtcattaatataaacacgcatgagtgttttctgaatgagaagccgttatccctcactcccaccgagttttcaatcctgcgcatcctctgtgaaaacaaggggaatgtggttagctccgagcagatatttcatgagatatggggagaagaatatttcaacaagagcaacaacaccatcacggtgcatatccggcatctgcgcgaaaaaatgaacgccaccattgataatccgaaatatataaaaacggtatggggggttggctataaaattgaaaaataa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7449,Drugs,MEG_7449|Drugs|Glycopeptides|VanA-type_regulator|VANRA,1028100581|WP_063856716.1|NG_048402|1|1|vanR-A|vanR-A|VanA-type_vancomycin_resistance_DNA-binding_response_regulator_VanR NG_048402:25-720,5
,atgatcatcagtgaatttgatcgtgataatttagttttaagagaccagcttgcggatcttttgaggctaacttggcccgatgaatacggcaaagagccgatgaaagaggtagagcaattgctgacaccggagcgtattgcggtatcagcaattgaaggagatgagttgcttggctttgttggagcgattccccaatatggcaaaactggttgggagttacatcctttagtggtcgcaagctcacatcgtaaacagcaaattggtactcgcttagttacttatttagaaaaagaagttgcttcacgtggtggaatcgttatctatttggggactgatgacaccgagggacaaactagtctgagtgaagtcgatttatttgatcaaacatttgagaaattaaaagaaataaagaataaaaatcatcacccttacagcttttatgaaaagttaggttatcaaatcgtcggagtaataccagatgccaatggatggtaccaacctgacatttggatggctaaacgtattgtaaaaaaaatcaaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_145,Drugs,MEG_145|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,498444835|WP_010750427.1|NG_052164|1|1|aac(6')_Entco|aac(6')_Entco|aminoglycoside_6'-N-acetyltransferase NG_052164:101-643,2
,atgtcactgtatcgccgtctaattctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3463,Drugs,MEG_3463|Drugs|betalactams|Class_A_betalactamases|KPC,1028105528|WP_063860640.1|NG_049251|1|1|blaKPC-18|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-18 NG_049251:1-882,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattacggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2156,Drugs,MEG_2156|Drugs|betalactams|Class_A_betalactamases|CTX,1149331615|WP_077767290.1|NG_052899|1|1|blaCTX-M-193|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-193 NG_052899:1-876,0
,ATGACCACCACACGCCCCGCGTGGGCCTATACGCTGCCGGCAGCACTGCTGCTGATGGCTCCTTTCGACATCCTCGCTTCACTGGCGATGGATATTTATCTCCCTGTCGTTCCAGCGATGCCCGGCATCCTGAACACGACGCCCGCTATGATCCAACTCACGTTGAGCCTCTATATGGTGATGCTCGGCGTGGGCCAAGTGATTTTTGGTCCGCTCTCAGACAGAATCGGGCGACGGCCAATTCTACTTGCGGGCGCAACGGCTTTCGTCATTGCGTCTCTGGGAGCAGCTTGGTCTTCAACTGCACCGGCCTTTGTCGCTTTCCGTCTACTTCAAGCAGTGGGCGCGTCGGCCATGCTGGTGGCGACGTTCGCGACGGTTCGCGACGTTTATGCCAACCGTCCTGAGGGTGTCGTCATCTACGGCCTTTTCAGTTCGATGCTGGCGTTCGTGCCTGCGCTCGGCCCTATCGCCGGAGCATTGATCGGCGAGTTCTTGGGATGGCAGGCGATATTCATTACTTTGGCTATACTGGCGATGCTCGCACTCCTAAATGCGGGTTTCAGGTGGCACGAAACCCGCCCTCTGGATCAAGTCAAGACGCGCCGATCTGTCTTGCCGATCTTCGCGAGTCCGGCTTTTTGGGTTTACACTGTCGGCTTTAGCGCCGGTATGGGCACCTTCTTCGTCTTCTTCTCGACGGCTCCCCGTGTGCTCATAGGCCAAGCGGAATATTCCGAGATCGGATTCAGCTTTGCCTTCGCCACTGTCGCGCTTGTAATGATCGTGACAACCCGTTTCGCGAAGTCCTTTGTCGTCAGATGGGGCATCGCAGGATGCGTGGCGCGTGGGATGGCGTTGCTTGTTTGCGGAGCGGTCCTGTTGGGGATCGGCGAACTTTACGGCTCGCCGTCATTCCTCACCTTCATCCTACCGATGTGGGTTGTCGCGGTCGGTATTGTCTTCACGGTGTCCGTTACCGCGAACGGCGCTTTGGCAGAGTTCGACGACATCGCGGGATCAGCGGTCGCGTTCTACTTCTGCATCCAAAGCCTGATAGTCAGTATCGTCGGGACATTGGCGGTGACGCTGTTAAACGGCGATACAGCGTGGCCCGTGATTTGTTACGCCACGGCAATGGCAGTGCTGGTGTCGTTGGGGCTGGCGCTCCTTCGATCCCGTGATGCTGCCACCGAGAAGTCGCCAGTCGTCTAG,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2931,Drugs,MEG_2931|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,gi|6625533|emb|AJ251806.1|34-1248 gi|4063850|gb|AF071555.1|AF071555|4445-5659,6
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgatctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5447,Drugs,MEG_5447|Drugs|betalactams|Class_C_betalactamases|PDC,1209144255|WP_088245217.1|NG_055274|1|1|blaPDC-212|blaPDC|class_C_beta-lactamase_PDC-212 NG_055274:1-1194,0
,TTGTCCGAAGCCACCTTTGCAATTGCTAGTACTTACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGATGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4314,Drugs,MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_10_KT601170 ,1
,gtgaccggcagcgcggccacgacccgcccggccacggcggccgatgcggttgcgtgggcgcagctgcgtctgggcctgtggcccgatgccgatgatccgctggagacgctggtggcggcgctggccgaggacgcaggtgcggttttcctggcgtgtgcagcgggtggccaggcgatcggcttcgccgaagtgcgcctgcgccatgactacgtgaacggcaccgattcctcgccggtgggcttcctggagggctggtacgtgcagccgcagtggcaaggccgcggcgtgggccgcgccctgctggcggcggtgcgggcatggacgcgcgacgcgggctgccgcgaactggcttcggacagtcgcgtggaagacgtgcaggctcacgccgcgcatcgggcctgcggcttcgaagagaccgaacgggtggtctatttccgcatgccactggagccatcggcgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_245,Drugs,MEG_245|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491560784|WP_005418370.1|NG_052391|1|1|aac(6')-Iak|aac(6')-Iak|aminoglycoside_N-acetyltransferase_AAC(6')-Iak NG_052391:101-562,2
,atgctgaaaacaaaaatcacgtcgtctatccttgtaggtgcctgtttactgattggttgttcgaatggcaatgagcaaccggtttccaacgaacctgaacctgaagagtctgtcgagacgggagaggcggtttttaaagcgttagaagaagagtacgctgcccgccttggcgtatttgctttagacaccgggacaggacaaaccgtttcctaccgctccgatgaacgcttcacctatgcgtctgcccataaaccacttgccgttgccgttctgcttcaacaaaaatcaatcgaagagttggaacaattgattacgtactcggccgatgatttagtaaactacaatccaattaccgaaaaccacgttgagacaggcatgacactaagagagttaagcgatgcttcgattcgttatagcgataacacggctgcaaacttcattttcgatgaaattggagggccagagggctttaaagaaggacttcgagcgattggagacacggtaaccgaacctgaacgaatcgaacctgagctcaatcatgttgaacctggagagatccaagatacgagtacaccagaggcgttggccaaaagcttgcaagaatttgctttaggagaggcgctgccagctgacaaacaggaactgttaatcgattggctaataggaaacacgactggagatgctttaatacgtgctggggtgccggaaggttgggaagttggcgacaaaacaggcgcaggttcctatgggactcgaaatgatattgccattctttggccacctgaaaaagagcccattattttagccgtcctatcgagcaaagacgaaaaggatgccgaatatgatgatgaactgatcgcgaaagcgacagaggaagtgatcaatctcctcgcccaaacagaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1207,Drugs,MEG_1207|Drugs|betalactams|Class_A_betalactamases|BCL,1049330895|WP_065825670.1|NG_051318|1|1|blaBCL-1|blaBCL|class_A_beta-lactamase_BCL-1 NG_051318:101-1006,0
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaaaatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagaccatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_861,Drugs,MEG_861|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1080153692|WP_070342372.1|NG_051906|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_051906:101-892,2
,ATGACGCCATTACTGTATAAAAAAACAGGCATAGATATGACTCTGGCATTAGTTGGCGAAAAAATTGACAGAAATCGCTTCACTGGTGAGAAAGTTGAAAATAGTACATTTTTTAACTGCGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGCCAGTTCTATGATCGCGAAAGTCAGAAAGGATGCAATTTTAGTCGCGCAATGCTGAGAGATGCCATTTTCAAAAGCTGTGATTTATCAATGGCAGATTTCCGCAACGTCAGCGCATTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGTGCAAGCTTTATGAATATGATCACCACGCGCACCTGGTTTTGCAGCGCATATATCACTAATACCAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTATGGGAAAACCGCTGGATGGGGACTCAGGTACTGGGTGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTAGGTGACTTAGATACTCGGGGTGTTGATTTACAAGGCGTTAAGTTAGACAACTACCAGGCATCGTTGCTCATGGAGCGGCTTGGCATCGCGGTAATTGGTTA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_5922,Drugs,MEG_5922|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,(Flq)QnrB46:JQ349154:1-680:680,3
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaagggtgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_866,Drugs,MEG_866|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1080153677|WP_070342357.1|NG_051848|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_051848:101-892,2
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6241,Drugs,MEG_6241|Drugs|betalactams|Class_A_betalactamases|SHV,(Bla)SHV-1:AF148850:6-866:861,0
,gtggctttgagaacggaacaagaaatgatgagcatgctgatcgatttcgccaggaaggatgatcgaatccgcttggtaaccttggaagggtcacgcacgaacaaaaatatacccgctgatccattccaagattatgatatttcgtattttgtaacagaaatggattctttcaaggaaagtgatcaatggctcgatgtttttgggaatcgaatcatgatgcaaaaaccggaagatatggagctttttccgtctgagttagggaattggttttcctatctcatgctatttgaggatggaaataaagtggatctgacgctgattccgatagacgagacagagcagtattttgcagatagcgacggtctggttgagattttgcttgataaagacgagcttatcaaacacgaggtgctcccttccgatcgccaatattggacccggaagccaagtgccagagagtttgatgactgctgcaatgaattttggatggtctctacttatgttgtcaaaggtttggcgagaaaagaaattctgtttgcgattgaccatctcaacgaaattgcccgaccgaatttgctccgaatgatggcttggcaaatcggatgcgagaaagggtttacccttagtgtcgggaaaaattacaaatttattgatcaccatctcccaaaagaagattgggaatccttactatccagttatcgcgaaaatagctacgcagacatgtgggaatcgttattcacttgctatgagctatttcgaaagtactccaaagcggtggcagaaaatctcgaatatccgtatccagattacgaagaagccattaccaagtacgcggaacatatctaccattcgtggaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_991,Drugs,MEG_991|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,1199609820|WP_087343787.1|NG_063818|1|1|ant(6)-Ic|ant(6)-Ic|aminoglycoside_nucleotidyltransferase_ANT(6)-Ic NG_063818:1-861,2
,ATGGCTAAAAAAATAGTAATACCTAAAGATAACAATATAATATCTTTTCCGTTAGAAGAGGCTATGCCAGAGAATTATTTACCTTACGCAGTAGAAGTATCCAAGGAAAGAGCACTGCCAGATGTCAGAGATGGATTAAAACCAGTACAAAGAAGAATAGTTTATGGTTCATATATGTTAAAAGCCTTTCCAGATAAGCCTTATTACAAATCTGCTAGAATAGTAGGTGATATATTAGGTAAATATCACCCTCATGGAGACTCTTCTGTTTATGATGCAATGGTAATATTAGCTCAAGATTTTACCACAAGAATGCCACTTATAGATGGACATGGAAACTGGGGAAGTCAAGATGGAGATAGTGCAGCAGCTATGCGTTATACAGAAGCAAGACTTACACCTATTGCCATGGAAATGATAAGAGACATAGATAAAGATGTAGTAAATATGGTAGATAACTATTCAAATTCAGAAAAAGAACCAGAAGTATTGCCAGCAAAGTATCCAAATATCCTTGTAAATGGTGCCTTTGGAATAGCAGTAGGGCTAGCCACTAATATACCACCTCATAATTTAGTAGAAGTTATAGATGGAACTTTAGCTTACATAGATAAAAATGAAATAACTACTAAAGAGTTATTAAATTACATAAAGGGACCAGATCTTCCAACAGGAGGAGTTATAATAGGTAAAAAATCCATGTTATCTGCATATGAAACAGGAGAGGGAAGAGTAACATTAAGAGCTAAGACAACCATAGAAAAATTGGAAAATGGAAGGTTATCTATTGTAATTACAGAATTTCCTTTTAGAAAAAACAAGGCAAAACTTCTTCAATTCATATCAGAAATGACTGCAGACAAAAAACATTCTAAAGCTTTAGAAAATATCACGGATATAAGAGATGAATCTGATAGAAATGGAATAAGAGCAGTAATAGAATTTAAAAAAATAGCTACTGAAGATATAGTAGAAAAAACTTTAAAATATTTATATAAAAAGACAGACCTTCAGAGTAATATATCTTTTAATATGGTAGCATTGGCAGATGGTAAACCTAAAACTTTAGGACTAAAGTCCATGTTAAAATACTATGTGGAGCATCAAAAAGAAGTGATTACCAGAAGAACAAAAAGAGAATTAGAAATAGCAGAAAAAAGATTCCATATAGTAGAAGGATTTATAAAAGCTATAGGAATAATGGACGAAATAATAAAAACTATAAGAGAATCAAAATCTAAAAAAAATGCTAGGGAAAATTTAATTGAAAAGTTTTCTTTTACAGATATTCAAGCAGAGGCTATACTAGAACTTATGTTATATAAACTTACAGGCCTTGAAGTAGTAGCTTTTGAAAAGGAATATAAAGAATTAGAAAAGTTAATAAATAAGCTTACAAAAATATTAAAAAGTGAAAAGGAACTTCTAAAAGTTATAAAGAAAGAATTAATTGAAGTTAAAGAAACTTATAATGACAAAAGAAGAACAGCAATAATAGAAGATGATGAAAAAGCAAAAATAGATGTGGAAGAAATAATAGTGGAAGAAGATGTAGTATTAACTTTATCTAATGAAGGCTTTACAAAGAGAATAGCTCTTAAATCCTATAATAGATCTAGTGCTAATGTAGAAGATATAGAGTATAGGGAAGGGGACTTTAATAGGTTTCTAATTCAGTGTAATACAAAAGATACATTATGTTTAGTAACAAAAGAGGGAAATATGTATCAAATAAAAGTTATAAATATACCAGAATTTAAGTGGAAAGAAAAAGGTGTTAAGCTAGATGAAATAATTAAAACTATAGATTTATCTGAAACTATAATAGAAGCCTTTTCAATAGAAGACTTTACGGCTCAAAAGGATATGTTATTTATAACAGATAGTGGATATATTAAGAAAACTACATTAGATAAATTTAATACAAATTATACAAAAATAATGGCTTTAAAGCTTAAAAAAGGAGAATCCCTTGTTAAGTCTGATTTAGTAGATCGAACTAGAGAAGAAAAATTTTTCAATATAAAAACACAGAAGGGATTAAGCTTTAATATAGAGGAGCCTAGCTTAGAGCCAGTAGATAGAAATATAATAGGATACAAATTATTTGATATTTTACCTAACGATAGTATAAAAAAGGTAGACTTTTGTGATAACTATGAATATAAGAGTTTTTATGTAAATATATCTAAAGAGGGATTAATAACTATATCAGATTTGAAGGATAATAAATCACATATAAGTTTATTTACGGATTCTTCTAAAACTCTAGTTTTATTTGATGATGAGGGTAAAGCCTATTACATACCGGCATTTATGCTTCAAAGCATAAAAGAAGAGGGTGTAAATATTTCAGCCTTTACTGGGGATAAAATAAGTTTGCTAAATGCAATATCCACCTTTAGATTTGAAGAAGATATTAGTATCTATTTTTCATCAGAAAAAGGATTAATAAAAAGAACTTTATTGGGTGAACTAAAGATAGAGGGTAATTCAACTCAAGTTTATAAATTTAAACATAAGGATGATAAATTAGTAAGTATACTTATAAAGGAACATGAAGAACAAAAAAATATACTGATAATAACAGAAAAAGCAATGGTAATAAGATTTAAAAGTGAGGCTGTAAATCCTATGGGGAAAATGGCATCAGGAGTTACAGGTATAAGTTTGAAAGATTTAGATAAAGTAATTTTAGCCTTAATAATAGATGAAAATGATACAAGAAAAATAAAAATAAAAACAAAGGCAAAGGATAAAGGAACTATAGAAATAAATAAAATAAAAGTTCAAAATAGAGCAGGTATAGGAAATAGCTTGATGCCTCTTTTGTTAAATGATTTTGTAGAGGTAGTAGAATTTAAAAAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5339,Drugs,MEG_5339|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|226840737|gb|CP001581.1|3145179-3142309,3
,ACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGAGCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6877,Drugs,MEG_6877|Drugs|betalactams|Class_A_betalactamases|TEM,gi|15485218|emb|AJ308558.1|1-1042,0
,ttgcccaggcgcctgatattcgcggccctgctgctcgccgccccggcggccgcgcagcaggaagcgccgcgccagtcgctgctcccgccgccgccccgctatatggtgagcgaatccgccatgaagtcggtccgcaatcccaaggagatagagacggaaagcggcggccggctgggcgtggcgctggtcgacggcaagggcgcgctgatccttggtttcaaccgggacgagcgtttcgccatgtgctcgaccttcaaggcgccgctcgccgccgccgtgctggcgggcgcggaaggcggcaagttcgggctggaggggcagatcagcttcgccaaggccgatctgctggactatgccccggtcgtcaggaagaatgtgaagcgcggccgcatgtcgatggaggaactcgccgccgccgccgtggaggtcagcgacaacagcgcggccaacctgctgctgccgatggtcggcgggccggagggcctgacccgcttcatccgcgcccatggcgacatggtgacgcggctcgaccgcaatgagccgtctctcaacgagaatgcggagggcgacgagcgcgacaccaccagccccgccgccatggccggcctgatgggccgcctgatcttccgcgacctcgctccggaaagcgccggaaagctgcgcggctggctcaatgccagcaccaccggcgccaaccggatcaaggcgggcctgcccaagggctggatctccggcagcaagacgggaagctgcggcaccgcctataatgacgtggcgctggtgaaggccccgtcgggcgaggaatatatcctggccatctatctcgaccgcccgacggtcgacgccaaggccgccgaagccgccatagccgaaaccgcccgcgccgcgctggatttcgtggataaggcgcagaagaccgggctggaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1306,Drugs,MEG_1306|Drugs|betalactams|Class_A_betalactamases|BLASGM,752738827|WP_041385949.1|NG_049984|1|1|blaSGM-2|blaSGM|class_A_beta-lactamase_SGM-2 NG_049984:101-1030,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggtgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4405,Drugs,MEG_4405|Drugs|betalactams|Class_D_betalactamases|OXA,919247097|WP_052788483.1|NG_057510|1|1|blaOXA-611|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-611 NG_057510:1-774,0
,ATCTTATAAGTCTTATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGTCTACTAATCCAAATCACAGTGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACTACAGAAGTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGAACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAATGAAGTGAAACGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGAAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCAGTTCACTTTTTACCATTTGATCTGGGCCATTGCCTATTTTCAAAACTGATAATCTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5246,Drugs,MEG_5246|Drugs|betalactams|Class_D_betalactamases|OXA,gi|751813259|gb|KM979378.1|1-912,0
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtcggcatgttcttttaataccgtacaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaatagaggaagtctatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaaacgtttatttcctgattgggaaaaggacatgactctaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaaaaatgtgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacgaaaaatttatgccaaaagtggttggggatggaatgtggagcctcaagtgggctggttaacaggctgggtcgttcaacctcaaggagaaattatagcgttctcacttaatttagaaatgaaaaaaggcatacctagttctattcgaaaagaaattgcttataaaggattggaacaactaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4565,Drugs,MEG_4565|Drugs|betalactams|Class_D_betalactamases|OXA,1625655417|WP_136512094.1|NG_064761|1|1|blaOXA-803|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-803 NG_064761:1-822,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaataccccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtgttattcataataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagtgctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatccagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggtgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgtattaaggcagcgtatgcagttttaaatgcaataaaaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_615,Drugs,MEG_615|Drugs|betalactams|Class_C_betalactamases|ADC,1058243691|WP_068981623.1|NG_051456|1|1|blaADC-92|blaADC|class_C_beta-lactamase_ADC-92 NG_051456:1-1152,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattacgcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4714,Drugs,MEG_4714|Drugs|betalactams|Class_D_betalactamases|OXA,1509794608|WP_122630917.1|NG_062337|1|1|blaOXA-709|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-709 NG_062337:12-836,0
,atgactctggcgttagttggcgaaaaaattgacagaaacagattcactggtgcgaaagttgaaaatagcacatttttcaactgtgatttttcgggcgccgacctcagcggcactgagtttattggctgccagttctatgatcgagaaagccagaaagggtgtaattttagtcgcgctatcctgaaagatgccattttcaaaagttgtgatctctccatggcggatttcaggaatgtgagcgcgctgggaatcgaaattcgccactgccgcgcacaaggttcagattttcgcggcgcaagctttatgaatatgattaccacacgcacctggttttgtagcgcctatatcaccaataccaacttaagctacgccaacttttcaaaagtcgtactggaaaagtgcgagctgtgggaaaaccgttggatgggtactcaggtactgggggcgacgttcagtggttcggatctttccggcggtgagttttcgtcgttcgactggcgggccgcaaactttacgcactgtgatttgaccaattcagaactgggcgatctcgatgtccggggtgttgatttgcaaggcgtcaaactggacagctaccaggcatcgttgatcctggaacgtcttggtatcgctgtcatgggttaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5899,Drugs,MEG_5899|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1391852845|WP_109545032.1|NG_050471|1|1|qnrB11|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB11 NG_050471:4-648,3
,AACACACTGATTGCGTCTGACGGGCCCGGACACCTTTTTGCTTTTAATTACGGAACTGATTTCATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCATTCTCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGAGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGGCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGTGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCAATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCTGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAAACTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTGACGATGAGGCCCAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1957,Drugs,MEG_1957|Drugs|betalactams|Class_C_betalactamases|CMY,gi|356457901|gb|HQ650104.1|1-1226,0
,ATAAAATTGAGTGTTGCTCTGTGGATAACTTGCAGAGTTTATTAAGTATCATTGCAGCAAAGATGAAATCAATGATTTATCAAAAATGATTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGTATTCATGTTGTTGTTATTTCGTCTCTTTCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGGAAACTCATTCCGTTTTTGTTTATCGCCTTAGACGGCAAAAGTGCTGTCGCCCACCTGCGCT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2427,Drugs,MEG_2427|Drugs|betalactams|Class_A_betalactamases|CTX,gi|768457552|gb|KJ125070.2|25570-26763 gi|756420160|gb|KP198616.1|25558-26751 gi|449331660|gb|KC160505.1|534-1727 gi|375313996|gb|JN790864.1|1-1194,0
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgctccttgtaccctgtttatcatggaagcgcaaaaagcaacatagggattgagcagcttatagaagtgataacgaataaattttattcatcaacatacagaaagaagtctgaactttgcggaaatgtcttcaaaattgaatattcggaagaaagacaacgtcttgcatatgtacgcctttatggcggaatcctgcatttgcgggattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaattgataaggcttattccggggaaattgttattttgcaaaatgagtttttgaagctaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatccgctccctctgctgcaaacaactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaagggatacgctatggttgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7124,Drugs,MEG_7124|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100186|WP_063856399.1|NG_048240|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048240:101-2020,4
,TTAGAAAAGGAAAAGTATGAGCAAGTTATCTGTATTCTTTATATTTTTGTTTTGCAGCATTGCTACCGCAGCAGAGTCTTTGCCAGATTTAAAAATTGAAAAGCTTGATGAAGGCGTTTATGTTCATACTTCGTTTGAAGAAGTTAACGGGTGGGGCGTTTTTCCTAAACATGGTTTGGTGGTTCTTGTAAATGCTGAGGCTTACCTAATTGACACTCCATTTACGGCTAAAGATACTGAAAAGTTAGTCACTTGGTTTGTGGAGCGTGGCTATAAAATAAAAGGCAGCATTTCCTCTCATTTTCATAGCGACAGCACGGGCGGAATAGAGTGGCTTAATTCTCGATCTATCCCCACGTATGCATCTGAATTAACAAATGAACTGCTTAAAAAAGACGGTAAGGTTCAAGCCACAAATTCATTTAGCGGAGTTAACTATTGGCTAGTTAAAAATAAAATTGAAGTTTTTTATCCAGGCCCGGGACACACTCCAGATAACGTAGTGGTTTGGTTGCCTGAAAGGAAAATATTATTCGGTGGTTGTTTTATTAAACCGTACGGTTTAGGCAATTTGGGTGACGCAAATATAGAAGCTTGGCCAAAGTCCGCCAAATTATTAAAGTCCAAATATGGTAAGGCAAAACTGGTTGTTCCAAGTCACAGTGAAGTTGGAGACGCATCACTCTTGAAACTTACATTAGAGCAGGCGGTTAAAGGGTTAAACGAAAGTAAAAAACCATCAAAACCAAGCAACTAAATTTCTAACAAGTCGTTGCAGCACGCCACTACGTGGCTGGACAGTTTGTAAGTTGCGCTTTTGTGGTTTGCTTCGCAAAGTATTCCACAACGCGCAACTTACAAACTGCCGCTGAACTTAGCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3397,Drugs,MEG_3397|Drugs|betalactams|Class_B_betalactamases|IMP,gi|772402180|gb|KP177455.1|428-1307 gi|575771412|dbj|AB901046.1|81-960 gi|575771406|dbj|AB901044.1|53-932 gi|575771387|dbj|AB901039.1|56-935 gi|575771377|dbj|AB901037.1|48-927 gi|82754992|gb|DQ288156.1|979-1858 gi|695208228|ref|NG_035500.1|1-880 gi|537705843|dbj|AB472901.2|1170-1197,0
,gtgaacgatattgatcgagaagagccctgcgcagccgctgccgtgcccgagagcatggcggctcacgtgatgggatacaaatgggcgcgtgataaggttggtcagtccggctgcgcggtctatcggctgcatagcaagtcaggcggctccgacttgtttctgaagcacggcaaagatgcttttgccgacgacgtgactgatgaaatggtgagattgcgttggctggcggggcacatttctgtgccctccgttgtaagcttcgttcgcacgcccaatcaggcatggctcctgacaacagcaatacatggaaaaacggcatatcaagtgctgaaatcggatttcggagcccgtctcgttgttgttgacgcattggcggcgttcatgcgccgactgcatgcgatcccagtgagcgaatgctccttcaacagtgaccacgcatgcaggcttgcccgagcgcgggagcgtatcgaggcgggggttgttgatgtcgatgacttcgataaggagcgcgaagggtggacggccgaacaggtttgggaggcgatgcatcgcctcctaccgctcgcgccggacccagtcgtgacgcacggcgatttttcactcgataatctacttatcgtcgaaggtaaggtagtcggctgcatcgacgttgggcgggctggtattgctgatcgataccaagaccttgccgtgttatggaactgtcttgaggagttcgaaccttcgcttcaggagaggcttgttgcgcaatatggcattgccgatccggataggcgcaagctgcaatttcatctcctgctggacgaacttttctaa,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1043,Drugs,MEG_1043|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,499519170|WP_011205810.1|NG_059324|1|1|aph(3')-Ib|aph(3')-Ib|aminoglycoside_O-phosphotransferase_APH(3')-Ib NG_059324:101-916,2
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcagccttgagcaccataaggcaaccaccacagaagtatttaaatgggatggggaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatataggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4476,Drugs,MEG_4476|Drugs|betalactams|Class_D_betalactamases|OXA,1028108231|WP_063862927.1|NG_049717|1|1|blaOXA-430|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-430 NG_049717:14-838,0
,ATGAAAAACATCGGCATTACCGTTTATGGATGCGAGCAGGATGAGGCAGATGCATTCCGTGCCCTTTCGCCGCGCTTTGGCATTATGCCCACGATAATTAACGCCGCCGTGTCAGAAGCCAACGCCATATCAGCCCCCTGCAATCAATGTATCAGCGTGGGACACAAATCCGAGGTTTCCGCGTCTATTCTTCTTGCGCTGAAGAGAGCCGGCGTGAAATATATCTCTACCCGAAGCATCGGCTGCAATCATATAGATACAACTGCCGCTAAGAGAATGGGCATCGCTGTCGGCAATGTGGCGTATTCGCCGGATAGCGTTGCCGATTATACCATGATGCTGATGCTTATGGCAGTACGCAACGCCAAATCTATTGTGCGCTCTGTGGAAAAACATGATTTCAGGCTGGACAGTGTCCGTGGCAAGGTACTGCGCGACATGACAGTCGGCGTGGTGGGAACCGGCCATATAGGCAAAGCGGTTATTGAGCGGCTGCGGGGATTTGGATGTCATGTGCTGGCTTATGATCGCAGCCAAAAAATAGAGGCAAACTATGTTCCGTTTGATGCGTTGTTGCAAAATAGCGATATCGTTACGCTTCATGTGCCGCTCAATGCGGATACGCGCCATATCATCGGCCACGAACAAATAAAGAGAATGAAGCAAGGCGCGTTTATTATCAATACTGGGCGCGGTCCACTTGTAGATACCGATGCGCTGGTTAAAGCATTAGAAAACGGAAAACTGGGCGGTGCCGCATTGGATGTATTGGAGGGAGAGGAAGAGTTTTTCTACTCTGATTGCTCACAAAAACCAATTGATAATCAATTTTTACTGAAACTTCAAAGAATGCCGAACGTGATAATCACGCCGCATACGGCTTACTATACCGAACAGGCGTTGCGTGATACCGTTGAAAAAACAATTAAAAACTGTTTGGATTTTGAAAGGAGCCAGGAGCATGAATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7402,Drugs,MEG_7402|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,(Gly)VanH-Pt:DQ018710:5109-6077:969,5
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgctcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5620,Drugs,MEG_5620|Drugs|betalactams|Class_C_betalactamases|PDC,730704555|WP_034075190.1|NG_049900|1|1|blaPDC-28|blaPDC|class_C_beta-lactamase_PDC-28 NG_049900:1-1194,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggaaagatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaagacgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_778,Drugs,MEG_778|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502172|WP_071846323.1|NG_052406|1|1|aadA8|aadA8|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA8 NG_052406:101-892,2
,atgagggaagcggtgaccgccgaaatttcgactcaactatcagaggtgcttagcgtcatcgagcgccatctggagtcgacgttgctggccgtgcatttgtacggctccgcagtggatggcggcttgaagccatacagcgatattgatttgctggttactgtgaccgtaaggcttaatgaagcaacacggcaagctttgctcaatgaccttttggaggcttcggctttccctggcgagagcgagactctccgcgctatagaagtcaccattgtcgtgcacgacgacatcatcccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgtaatgacattcttgcgggtatctccgagccagccatgatcgacgttgatctggctatcttgcttacaaaagcaagagaacatagcgttgccttggtaggtccagctgcggaggaactctttgatcccgttcctgaacaggatctattcgaggcactgaatgaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgctcacgttgtcccgcatttggtacaccgaagtaaccggcaaaatcgtgccgaaggatgtcgctgccgactgggcaatggagcgcctacctgcccagcatcagcccgtcttacttgaagctagacaggcttatcttggacaaaaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcacttcgtgaaaggcgagatcactaaggtagtcggcaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_783,Drugs,MEG_783|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,695273445|WP_032495379.1|NG_047331|1|1|aadA11|aadA11|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA11 NG_047331:1-792,2
,ATGAAAATTGGAAGGTTTGTGATTGAGGGCAATGCGGCTATCATGGGGATTTTAAATGTGACTCCAGATTCTTTTTCAGATGGGGGGTCTTACACTACTGTGCAAAAAGCATTAGATCACGTTGAGCAAATGATTGCTGATGGTGCTAAAATCATCGACGTTGGTGGAGAATCAACACGTCCAGGTTGCCAATTTGTAAGCGCTACCGATGAAATTGACAGGGTGGTTCCTGTGATCAAGGCCATCAAAGAAAACTATGATATTCTAATCAGCATTGATACCTATAAAACCGAAACAGCTAGAGCAGCTTTAGAGGCGGGTGCCGATATTCTCAATGATGTTTGGGCAGGTTTGTACGACGGTCAAATGTTTGCCTTAGCAGCCGAGTACGATGCGCCTATCATCTTGATGCATAACCAAGACGAAGAAGTTTATCAAGAGGTAACACAAGACGTTTGTGATTTTCTAGGCAATAGAGCACAAGCAGCTCTTGATGCTGGCGTGCCAAAAAACAATATTTGGATTGATCCAGGATTTGGATTTGCCAAATCTGTTCAACAGAATACGGAGTTATTAAAAGGATTGGACCGCGTCTGTCAGTTGGGCTATCCTGTCTTGTTTGGTATTTCGAGAAAGCGTGTCGTAGATGCCTTGTTAGGCGGCAATACCAAAGCTAAAGAGCGAGACGGAGCGACAGCAGCCTTGTCTGCTTATGCCCTTGGAAAAGGCTGTCAGATTGTACGCGTACACGATGTCAAGGCTAATCAAGACATTGTGGCTGTGTTGAGCCAGTTGATGTGA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2934,Drugs,MEG_2934|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gb|AE009949|+|878481-879282|ARO:3003387|Streptococcus pyogenes folP with mutation conferring resistance to sulfonamides [Streptococcus pyogenes MGAS8232] ,8
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacatcgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtagctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgcttaagtttattcatgccaatctgaacccacagaaatatccgacagatattcaacgtgcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaaccagcggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcagttttaaatgcaataaaggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_549,Drugs,MEG_549|Drugs|betalactams|Class_C_betalactamases|ADC,447133977|WP_001211233.1|NG_054691|1|1|blaADC-152|blaADC|class_C_beta-lactamase_ADC-152 NG_054691:1-1152,0
,ATGACGCCATTACTGTATAAAAAAACAGGTACAAATATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGTTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTAAGTGGTACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCAATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGTGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACACGCACCTGGTTTTGCAGCGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGCTGGAAAAGTGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTACGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGTTGCTCATGGAACGTCTTGGCATCGCGGTCATTGGTTA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_5970,Drugs,MEG_5970|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gb|JQ349153|+|0-680|ARO:3002759|QnrB44 [Escherichia coli] ,3
,GTGCCGGCCGGTGAACCGGCACCGGCCACCCGGCCGGAGCCGGAGTCGGCCATCCTGCCGGAGCCGGCCGCGGCCGTGCCGTCGCCGCCGCCGGAGTCACCCGCCGTGCAGAAGGTGATCGCCCGGCTCACCGCCGCGGCCAAGTACCGTGACGTGCACCCGGAGACCGTCGCCGACCTGGTCCGGCGGGAGGGTCGGGCCACCGGGGACGCCGCCGAGCTGGAACGGCGGGTCCGGGCCCGGCTGCACAAGGTCGCCGCCCTGCACCTGCTCACCGCCCGGCCGGCGGCGCTGCGCAAGGCGCTGGACCGGGCCGACCTCGACGACCCGCAGTCCCGGCGGGACTGGTGCCGGCAGGTGCTGGCCGGGCACTTCTCCACCGCCGAACGCCTGCCCGACCTGGACACCTTCTACCCGACCCTGTTCGGGCTGGTGCCGCCGCCGGAGACGGTGGCCGACATCGCGTGCGCGCTGAACCCGTTCACCGTGCCCTGGCTGCGGGAGGTGAGCGACGCCCGCTACGTCGGCTACGACTTCAACGCGACGTTCGTGGAGCTGGGCAACGCGTTCCTCGCCCGGACCCATCCGGAGTGCGAGATCCGGCACGAGGAGGTGCTCACCGACGGCCACCGGGTGAGCGCTGACCTGGGGTTGCTGCTCAAGACGTACCACTGCATGGAGGGACGCCGGCCCGGCGCCGGGCTGGCGCTGGTCGACCGGCTGGCGTGCCGGCACGTGGTGGTGTCGTTCCCCACCCGGGCCATGAACGGCCGGGCGGCGGTCTTCGTGCCCCGTCACGTGGAGGAGCTGGCCGAGCTGGCCCGCGACCGGGGATGGAGCTGGTCGCGGGCCACTCTGGCGTCCGAGGACCTGGTGGCGATCCACAAGGAGTGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_3174,Drugs,MEG_3174|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|GRM,grmO_1_AY524043 ,2
,atgaataagttaaaaatcgccatcatcttcggaggctgttctgaagaacatcctgtctccgttaaatcagctcaagaggtcgccgacaatctggatcttgaaaagtatgaacccttctatatcgggattacgaaaagtggggtttggaagctttgtcaccgccctgaggcaaattgggaaaagggtagctgcctgccggcgatcctgtcaccggacagaagcgtgcagggattgctggttctggagcatggacattacaaaaccatccctttggatatggtgtttcccgttctgcatggcaaattcggtgaggatggtgcgatgcagggtttgctggagctttccggcatcccttatgcaggctgcgatgttccaagttccgccctgtgtatggacaaagccctggcctatatcgttgcgggaagcgcaggaattgcgacgccaaatttccggacggtcacagcggaggaggatatcgatgccgatgggcttgcttatcccgtttttgtcaaaccggcccgttcgggttcatcctttggcgtcactaaagtatgccgcaaagaagacttgctgagtgcggtggccagcgccagagagtatgacacgaaggtgttgattgaagaagctgtcgccggcagtgaggtaggatgcgcgatatttggaaatgatccggatttggtggcaggggaggtggatcagatttgcctgtcccatggttttttcaaaatccatcaggaggatgagccggaaaagggttccgaaaactcaaagctgatcgttccctccgacattccggcggaggcgcgcctgcaggttcaggagacggccaaagccatctaccgcgccttgggatgcagggggctggcccgggtggatatgttcctgaaggaagatggagaagtcatcctgaacgaggtgaataccttgcccggcatgacctcctacagccgttttccgaaaatggtggcggctgcagggctgccctttgccgaagtgctcgaccggattatctcattggccttgaaaggaaaaagatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7439,Drugs,MEG_7439|Drugs|Glycopeptides|VanI-type_resistance_protein|VANI,517010483|WP_018211347.1|NG_050603|1|1|vanI|vanI|D-alanine--(R)-lactate_ligase_VanI NG_050603:101-1138,5
,atgatgaaaaaatccctaagctgcgccctgctgctcagcgttgcctgctctgcttttgccgcgccgatgtcagaaaaacagctggctgacgtcgtggaacgtaccgttacgcccctgatgaaggcgcaggccatacccggaatggccgtggccgtcatttatcagggccagccacactattttactttcggtaaagcagacgtcgcggcgaataagcccgtcacgccgcaaaccttatttgaactgggctccgtcagtaaaaccttcactggcgtgctgggtggcgatgccattgcccgcaaagagatttcgctggccgacccggtcacgaaatattggcctgaattgacgggcaagcagtggcaaggcattcgcctgctcgacctggcaacctatacggcaggcggattgccgttgcaggtaccggatgatgttaccgataacgcctctctgctgcgtttctaccagtcctggcagccaaagtgggccccgggtaccacgcgtctgtacgccaacaccagcatcggcctgtttggctcactggccgttaaaccgtccggcatgcgcttcgagcaggccatggcggagcgggtctttaagcccctgaaactcaaccatacgtggataaacgttccacacgctgaagagccgcactacgcatggggttatcgtgagggaaaagcggtccacgtttcgcctggtatgctggatgcagaagcctatggtgtgaaatctaacgtcaaagatatggcgagctgggtgatggccaatatggcacctgagacactcccgcagtccactctgcagcagggtattgcgctggcgcagtctcgctactggcgcgtgggtgccatgtatcaagggttaggctgggagatgctcaactggccggtcgatgccaaaaccgtggtggatggcagcgacaataaggtcgcactggcgccgttgccggtcgcagaagtgaatcctccggctccgccagtaaaagcctcctgggtgcataaaacgggctctacgggtgggtttggcagctacgtggcgtttattcctgaaaagcagatcggtattgtgatgctcgcaaataaaagctatccgaacccggtacgggtggaaacggcttaccgtatcctcgacgcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1750,Drugs,MEG_1750|Drugs|betalactams|Class_C_betalactamases|CMH,502860294|WP_013095270.1|NG_061416|1|1|blaCMH-4|blaCMH|class_C_beta-lactamase_CMH-4 NG_061416:1-1146,0
,ATGATGAAAAAATCGTTATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGTTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGACCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTACACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGCAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGTGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCTAACCCGGTCCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1882,Drugs,MEG_1882|Drugs|betalactams|Class_C_betalactamases|CMY,gb|FN645444|+|0-1146|ARO:3002061|CMY-50 [Escherichia coli] ,0
,ATGAAATCTAACAATGCGCTCATCGTCATCCTCGGCACCGTCACCCTGGATGCTGTAGGCATAGGCTTGGTTATGCCGGTACTGCCGGGCCTCTTGCGGGATATCGTCCATTCCGACAGCATCGCCAGTCACTATGGCGTGCTGCTAGCGCTATATGCGTTGATGCAATTTCTATGCGCACCCGTTCTCGGAGCACTGTCCGACCGCTTTGGCCGCCGCCCAGTCCTGCTCGCTTCGCTACTTGGAGCCACTATCGACTACGCGATCATGGCGACCACACCCGTCCTGTGGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGGCCTGTCGCTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAACGTTTCGGCGAGAAGCAGGCCATTATCGCCGGCATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTCCCCATTATGATTCTTCTCGCTTCCGGCGGCATCGGGATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGATCGCTCGCGGCTCTTACCAGCCTAACTTCGATCATTGGACCGCTGATCGTCACGGCGATTTATGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATGGATTGTAGGCGCCGCCCTATACCTTGTCTGCCTCCCCGCGTTGCGTCGGGCCACCTCGACCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7065,Drugs,MEG_7065|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETC,gi|295311792|gb|GU987054.1|833-2008 gi|190887131|gb|EU751613.1|1-1176 gi|17342620|gb|AY046276.1|42760-43935 gi|961454902|gb|KT991388.1|1293-134 gi|961454902|gb|KT991388.1|6978-7007 gi|954665409|gb|KT072898.1|4416-5575 gi|933685907|gb|KR827392.1|16075-14916 gi|825088250|gb|KP975074.1|124202-125361 gi|823682865|emb|LN831184.1|226875-228034 gi|808740283|gb|CP011301.1|4026739-4025580 gi|764145230|gb|KM604642.1|2836-3995,4
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacgaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3473,Drugs,MEG_3473|Drugs|betalactams|Class_A_betalactamases|KPC,1625655394|WP_136512071.1|NG_064728|1|1|blaKPC-43|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-43 NG_064728:1-882,0
,atgctcgcccgtcgccgattcctgcagttcagtggtgctgccgttgcttcctcgctgcttgccccggcgttggcgcgagctgtttccccatcgtccggcatatccgccgcgaacgccgccattgccggcgccgccgatttcgccgcgctggagaaagccagtggtggccgtctgggcgtcaccgtgctgaacaccggtaacggccgtcgcatcggcggacatcgtcaggacgagcgcttcccgatgtgcagcacgttcaagtcgatgctggttgcccatgtgctgagccttgccgatgcaggccgcgtttcgctcgacacacgtgtgcccatcgccgaaaaggatctgctgtcctacgccccggtggcgcgccgccatgtgggcaaggacctgacggtgcgcgacctgtgccggggcacgctgaccaccagcgacaacacggcggccaacctgctgctggaggtggtgggcgggccgtcggcgctgactgcattcctgcgcgggcagggcgacagcgttacccgcaatgaccgcaacgagccggacgtgaatctgttcgcgaagggagacccgcgcgataccaccagcccggccgcgatggccaccagcttggcccgcttcgcggtgggcaatggcctgcagccggcatcgcgccagcagttcactgattggctcatcgacaaccagaccggcgatgcctgcctgcgcgccgggctggccaagcgctggcgggtgggggacaagaccggcagcaacggtgatgacacgcgcaacgacattgccgtgctgtggccgcatgcgggcggcgcagcgtgggtggtcaccgcctatctgcagggcgcgtcggtcgatgacgatcagcgcgcagcggtgcttgcacgggtgggggcgctggccgacgcgatgatcggatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3532,Drugs,MEG_3532|Drugs|betalactams|Class_B_betalactamases|L1,1028083732|WP_063842700.1|NG_047518|1|1|blaL2|blaL2|L2_family_class_A_beta-lactamase NG_047518:101-1015,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaaaaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4448,Drugs,MEG_4448|Drugs|betalactams|Class_D_betalactamases|OXA,1509794610|WP_122630919.1|NG_062339|1|1|blaOXA-711|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-711 NG_062339:22-846,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattcaagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggattggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4471,Drugs,MEG_4471|Drugs|betalactams|Class_D_betalactamases|OXA,1532001207|WP_125052736.1|NG_065444|1|1|blaOXA-834|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-834 NG_065444:101-925,0
,ATGAAAATAATCAATATTGGAATTCTTGCCCATGTAGACGCTGGAAAGACGACCTTGACGGAGAGCCTGCTATATGCCAGCGGAGCCATTTCAGAACCGGGGAGCGTCGAAAAAGGGACAACGAGGACGGACACCATGTTTTTGGAGCGGCAGCGTGGGATTACCATTCAAGCGGCAGTCACTTCCTTCCAGTGGCACAGATGTAAAGTTAACATTGTGGATACGCCCGGCCACATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGAGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGACATTCTAGGAAATGAAAAACTCCTGCCTCATAAAACACGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCGCAGAGATTGCTGATACAGACCCTCTTTTGCATTTTGACATTGATACTGTTACACATGAGATTATGTTATCTTTTTTGGGAAAAGTACAGTTAGAAGTTATTTGTTCGCTATTAGAAGAAAAATATCATGTGGGCGTGGCTATGAAAGAGCCTTCGGTTATTTATCTGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAAGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGACATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTAATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7234,Drugs,MEG_7234|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,tet(W/32/O)_4_AM710605 ,4
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtactttccaagcgttttagcgcaagagtccgtcactccatacattgcaatggtgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggtgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_238,Drugs,MEG_238|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502232|WP_071846382.1|NG_052517|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052517:93-647,2
,ATGCCGAATTTCGTATGCGGTCGGTTTGAACTCGATCTGACGCAGCCACGCATCATGGCCATCATCAACGTGACCGATGATTCATTCTCGGGTGATGGCTTGAGAGGAAATCTGGACGGGGCCTTGAATAAGGCGGAGCGTGCCCTGGCCGAAGGGGCGGATATCCTCGATCTCGGCGCGGAGTCCACCCGTCCGGGCAGTGATCCGGTACCCGAGCAGCAGGAGATCGACCGGCTGGTACCGCTTATCGAGGCCTTGCAGGGCTGCGGTGTGCCGCTATCGGTGGATACGCTGAAGCCTTCGGTGATGCGCGCCGCGCTTGCGGCAGGTGCGGACCTGATCAACGACGTCAACGGATTCCGGGCGGAAGGCGCGGTCGAGGCTGTCGCGGCCGGCACAGCGGGGCTCTGCGTGATGCACATGCAGGGCGAACCGCGGACGATGCAGCAGGCGCCCCAGTACGCCAATGTCGTCGATGAGGTCGGCGCCTTTCTGGTTCGGCGAACGGAAGTGCTCCTGCGGGCAGGAGTCCGCCGCGAGCGGGTGTTGCTGGATCCCGGATTCGGTTTCGGCAAGAGCACCGAGCACAACCTGGCCCTGGTTCGCGGACTCGGGGCGCTGCGTGATCTCGGCTACCCGTTGTTGGTGGGTTTGTCGCGCAAGAGTCTGTTGGGCGCGATTACCGGCAAGCCGGTGGAGGCGCGTGGTCCGGCCAGTGTGGCTGCGGCGCTGATGGCGGTTCAGTACGGTGCCGCGATCGTTCGTGTGCACGATGTGGCGCCGACCCGCGATGCACTCGCGGTGTGGCAAGCAATGTCATAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2936,Drugs,MEG_2936|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|119668705|emb|AM406670.1|1517394-1518215 gi|862570604|emb|HG917972.2|4917158-4917131 gi|442581001|gb|CP003899.1|4811703-4811676 gi|183173361|gb|CP000854.1|5210475-5210448 gi|118568029|gb|CP000325.1|1006418-1006445,8
,ATGGCTTGTTATGACTGTTTTTTTGTACAGTCTATGCCTCGGGCATCCAAGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGGCCGCATGGACACAACGCAGGTCACATTGATACACAAAATTCTAGCTGCGGCAGATGAGCGAAATCTGCCGCTCTGGATCGGTGGGGGCTGGGCGATCGATGCACGGCTAGGGCGTGTAACACGCAAGCACGATGATATTGATCTGACGTTTCCCGGCGAGAGGCGCGGCGAGCTCGAGGCAATAGTTGAAATGCTCGGCGGGCGCGTCATGGAGGAGTTGGACTATGGATTCTTAGCGGAGATCGGGGATGAGTTACTTGACTGCGAACCTGCTTGGTGGGCAGACGAAGCGTATGAAATCGCGGAGGCTCCGCAGGGCTCGTGCCCAGAGGCGGCTGAGGGCGTCATCGCCGGGCGGCCAGTCCGTTGTAACAGCTGGGAGGCGATCATCTGGGATTACTTTTACTATGCCGATGAAGTACCACCAGTGGACTGGCCTACAAAGCACATAGAGTCCTACAGGCTCGCATGCACCTCACTCGGGGCGGAAAAGGTTGAGGTCTTGCGTGCCGCTTTCAGGTCGCGATATGCGGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_757,Drugs,MEG_757|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,gi|973585379|gb|KP054476.2|32591-33271 gi|973585379|gb|KP054476.2|28124-28265 gi|973585379|gb|KP054476.2|51695-51836 gi|959190351|gb|CP013324.1|126758-126078 gi|957647579|dbj|AP017302.1|414271-413591 gi|957647579|dbj|AP017302.1|2607581-2607722 gi|828952302|gb|CP011622.1|98143-98823 gi|821346305|dbj|LC054840.1|1119-1799 gi|787862679|gb|CP008707.1|37652-36972 gi|723217920|gb|KM382179.1|3-683 gi|662716992|gb|CP008825.1|138416-139096 gi|662716651|gb|CP008824.1|204619-205299 gi|662716651|gb|CP008824.1|269504-269647 gi|662716651|gb|CP008824.1|54725-54865 gi|662716651|gb|CP008824.1|212958-213076 gi|659224586|gb|KJ668712.1|10-690,2
,atggaaacctacaatcatacatatcggcaccacaacttttcacataaagacttaagtgatctcaccttcaccgcttgcacattcattcgctgcgactttcgacgtgctaacttgcgtgatacgacattcgtcaactgcaagttcattgaacagggtgatatcgaaggctgccactttgatgtcgcagatcttcgtgatgcaagtttccaacaatgccaacttgcgatggcaaacttcagtaatgccaattgctacggtatagagttccgtgcgtgtgatttaaaaggtgccaacttttcccgaacaaactttgcccatcaagtgagtaatcgtatgtacttttgctcagcatttatttctggatgtaatctttcctatgccaatatggagagggtttgtttagaaaaatgtgagttgtttgaaaatcgctggataggaacgaacctagcgggtgcatcactgaaagagtcagacttaagtcgaggtgttttttccgaagatgtctgggggcaatttagcctacagggtgccaatttatgccacgccgaactcgacggtttagatccccgcaaagtcgatacatcaggtatcaaaattgcagcctggcagcaagaactgattctcgaagcactgggtattgttgtttatcctgactaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_6018,Drugs,MEG_6018|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRS,1031871489|WP_064186845.1|NG_059275|1|1|qnrS13|qnrS|quinolone_resistance_pentapeptide_repeat_protein_QnrS13 NG_059275:101-757,3
,ATGTTCTCTCGCTGGTCGAAGACTTTCGCGTCCGCCCTCACGGCCTGCGCCGTTGCGATGAGCACCACCACCGCCCACGCCGAGCTGGTCGTGCGTAATGACCTCAAGCGCGCGTTCGACGACGCGGGTGTCTCGGGCACCTTTGTACTGATGGACATCGGCGCCGACCGCACCTATGTCGTCGATCCGGCGCGCGCCGCGCGGCGCATCCATCCGGCATCGACGTTCAAGATTCCGAACAGCCTGATCGCCTTCGACACCGGGGCCGTGCGCGACGATCAGGAAGTGCTGCCTTACGGCGGCAAGCCGCAGCCTTACCAGCAGTGGGAGCACGACATGGCGTTGCCCGAGGCGATCCGCCTGTCGGCCGTGCCGATATACCAGGAGGTGGCACGGCGTGTCGGCCTTGAACGCATGCAGGCTTATGTGGACGCTTTTGAGTACGGCAATCGCCAGCTCGGCAGCGTGATCGATCAATTCTGGCTGCGTGGCCCGCTGGAGATTTCCGCATTCGAAGAAGCGCGCTTCACCAGCCGCATGGCGCTCAAGCAGTTGCCGGTGAAGCCGCGCACGTGGGACATGGTCCAGCGCATGCTGTTGATCGAGCAGCAGGGCGATGCCGCGCTGTATGCCAAGACCGGCGTCGCCACCGAATACCAGCCGGAGATCGGTTGGTGGGTCGGCTGGGTGGAGCGTGCCGGCCACGTGTATGCCTTTGCTCTGAACATCGACATGCCGCGCGAGGGCGATATGGCCAAGCGAGTCCCGCTGGGCAAGCAGTTGATGCAGGCGCTGGCGGTGTGGCCGGCACCGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5213,Drugs,MEG_5213|Drugs|betalactams|Class_D_betalactamases|OXA,gi|240867064|gb|CP001645.1|664045-664860 gi|187727712|gb|CP001069.1|220251-221066 gi|50236434|gb|AY664506.1|1-816,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagcccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5570,Drugs,MEG_5570|Drugs|betalactams|Class_C_betalactamases|PDC,489200938|WP_003110141.1|NG_049902|1|1|blaPDC-30|blaPDC|class_C_beta-lactamase_PDC-30 NG_049902:1-1194,0
,ATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATTGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_353,Drugs,MEG_353|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|700659332|gb|KJ541071.1|37250-36732 gi|700659309|gb|KJ541070.1|14876-14358 gi|700659271|gb|KJ541069.1|33363-32845 gi|700659241|gb|KJ541068.1|24984-24466 gi|166034465|gb|EU358785.1|122-640,2
,atggtgacggtgttcggcattctgaatctcaccgaggactccttcttcgatgagagccggcggctagaccccgccggcgctgtcaccgcggcgatcgaaatgctgcgagtcggatcagacgtcgtggatgtcggaccggccgccagccatccggacgcgaggcctgtatcgccggccgatgagatcagacgtattgcaccgctcttagacgccctgtccgatcagatgcaccgtgtttcaatcgacagcttccaaccggaaacccagcgctatgcgctcaagcgcggcgtgggctacctgaacgatatccaaggatttcctgaccctgcgctctatcccgatattgctgaggcggactgcaggctggtggttatgcactcagcgcagcgggatggcatcgccacccgcaccggtcaccttcgacccaaagacgcgctagacgagattgtgcggttcttcgaggagcgggtttccgccttgcgacggagcggggtcgctgccgaccggctcatcctcgatccggggatgggatttttcatgagccccgcaccggaaacatcgctgcacgtgctgtcgaaccttcaaaagctgaagtcggcgttggggcttccgctattggtctcggtgtcgcggaaatccttcttgggcgccaccgttggccttcctgtaaaggatctgggtccagcgagccttgcggcggaacttcacgcgatcggcaatggcgctgactacgtccgcacccacgcgcctggagatctgcgaagcgcaatcaccttctcggaaaccctcgcgaaatttcgcagtcgcgacgccagagaccgagggttagatcatgcctag,beta-lactamase,antibiotic target replacement,Sulfonamides,MEG_6579,Drugs,MEG_6579|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,1028098535|WP_063855037.1|NG_048084|1|1|sul1|sul1|sulfonamide-resistant_dihydropteroate_synthase_Sul1 NG_048084:101-940,8
,atgagggaagtggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgcccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_849,Drugs,MEG_849|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502098|WP_071846250.1|NG_052276|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052276:101-892,2
,atggaactgcgtgggaacgaggtcgtgctgcgcacgacggcagaaggggattccgaagtcctcgacaggatcctgagagagccggaagtcgcggcgtggtggccgcccctggacgactacgagggcatgctggccgtcgttttcgggggtgaagtcatcggagctgtcacgttcgacgaggagaccgaccccgagttccgccgtgccggcatcgacatcttcctgacagcgagccatcacgggaaggggctcggcgccgacaccgtgcgcacgctggcccggtggctgcttcaggagcgcggccatcaccggctgaccatcgatcccgccgcggccaacaccgcggcgatccgcagctacagcagggccgggttcaaacccgtagggatcatgcgggcgtactggcgcgaccggcgcaccggcacgtggcaggacgggctgttgatggacctgctggcggatgagctgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_192,Drugs,MEG_192|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,817129630|WP_046502149.1|NG_052464|1|1|aac(6')_Strep|aac(6')_Strep|aminoglycoside_6'-N-acetyltransferase NG_052464:101-574,2
,ATGAGAAAAAGTATGGGCATTACTGTTTTTGGATGCGAACAGGATGAGGCAAATGCTTTCCGCGCTTTATCGCCAGATTTTCATATTATCCCTACGCTGATTAGCGATGCGATATCGGCAGACAACGCAAAATTGGCCGCTGGCAATCAATGCGTTAGCGAAGGCCATAAGTCCGAGGTTTCCGAGGCGACAATTCTTGCGCTGAGAAAGGTCGGGGTAAAATACATTTCTACCCGCAGCATCGGCTGCGATCACATTGATACGACTGCCGCCGAGAGAATGGGAATCTCGGTTGGCACGGTTGCGTATTCGCCGGACAGCGTTGCGGATTATGCTTTGATGCTGATGCTGATGGCCATACGGGGTGCAAAACCCACCATGCACGCCGTGGCGCAACAAGATTTCAGATTGGATCGTATCCGGGGGAAAGAACTGGGGGATATGACTGTGCGAGTTATTGGAACCGGCCATATCGGGCAAGCGGTCGTCAAAAGGCTGCGGGGATTTGGATGCCATGTGCTGGCCTATGATAACAGCCGAAAAATGGATGCAGATTATGTCCAGCTTGATGAGCTTCTAAAAAACAGCGGTATTGTTACGCTCCATGTGCCGCTTTGTGCGGATACCCGCCATCTGATCGGTCAGAAGCAAATTGGAGAGATGAAGCAAGGCGCATTTTTAATCAACACCGGGCGCGGAGCGCTTGTCGATACCGGGGCGCTGGTGGAGGCGTTGGAAAGCGGAAAGCTGGGTGGTGCGGCACTGGATGTGTTGGAGGGCGAGGATCAGTTTGTTTATACCGATTGCTCGCAGAAAGTGCTTGACCATCCCTTTTTGTCGCAGCTTTTAAGGATGCCGAATGTGATCATCACACCCCATACGGCGTACTACACTGAGCGTGTGCTGCAGGATACTACAGAAAAAACAATCAGGAATTGTCTCAATTTTGAAAGGAGTTTACAGCATGAATAGAATAAAAGTCGCAATCATCTTCGGCGGTTGCTCGGAGGAACATGATGTGTCGGTAAAATCCGCAATAGAAATTGCTGCGAACATTAATACTGAAAAATTCGATCCGCACTACATCGGAATTACAAAAAACGGCGTATGGAAGCTATGCAAGAAGCCATGTACGGAATGGGAAGCCGACAGTCTCCCCGCCATACTCTCCCCGGATAGGAAAACGCATGGGCTGCTTGTCATGAAAGAAAGCGAATACGAAACACGGCGTATTGATGTGGCTTTCCCGGTTTTGCATGGCAAATGCGGGGAGGATGGTGCGATACAGGGTCTGTTTGAATTGTCTGGTATCCCCTATGTAGGCTGCGATATTCAAAGCTCCGCAGCTTGCATGGACAAATCACTGGCCTACATTCTTACAAAAAATGCGGGCATCGCCGTTCCCGAATTTCAAATGATTGATAAAGGTGACAAGCCGGAGGCGGGTGCGCTTACCTACCCTGTCTTTGTGAAGCCGGCACGGTCAGGTTCGTCCTTTGGCGTAACCAAAGTAAACGGTACGGAAGAACTTAACGCTGCGATAGAAGCGGCAGGACAATATGATGGAAAAATCTTAATTGAGCAAGCGATTTCGGGCTGTGAGGTCGGGTGTGCGGTCATGGGGAACGAGGATGATTTGATTGTCGGCGAAGTGGATCAAATCCGGCTGAGCCACGGTATCTTCCGCATCCATCAGGAAAACGAGCCGGAAAAAGGCTCAGAAAATGCGATGATTACAGTTCCCGCAGACATTCCGGTCGAGGAACGAAATCGGGTGCAGGAAACGGCAAAGAAAGTATATCGGGTGCTTGGATGCAGAGGGCTTGCCCGTGTTGATCTTTTTTTGCAGGAGGATGGCGGCATCGTTCTAAATGAGGTCAATACCCTGCCTGGTTTTACATCGTACAGCCGCTACCCACGTATGGTGGCCGCCGCAGGAATCACGCTTCCTGCACTGATTGACAGCCTGATTACATTGGCGTTAAAGAGGTGACCCGTATGGAAAATGGTTTTTTGTTTTTAGATGAAATGTTGCATTGCGTCCGTTGGGATGCCAAGTACGCCACATGGGATAACTTCACAGGAAAACCGGTGGATGGGTATGAGGTGAATCGCATCATCGGCACAAAGGCCGTGGCGTTTGCTCTGCGCGAGGCACAAATCCATGCGGCACGCCTTGGCTATGGCTTGCTTTTATGGGATGGATATCGGCCAAAATCTGCGGTGGACTGTTTCCTGCGTTGGGCGGCGCAGCCGGAGGACAACCTCACAAAAGAAAAATATTACCCCAATATTGAGCGAGCCGAGTTGATTACAAAGGGCTATGTGGCCTCACAATCCAGCCATAGCCGTGGAAGCACAATTGATCTTACGCTCTACCACTTGGATACAGGGGAACTTGTTTCAATGGGAAGCAACTTCGATTTTATGGACGAACGGTCGCACCATACAGCAAAAGGGATAGGGAATGCAGAGGCACAAAATCGAAGATGCTTGCGTAAAATCATGGAAAGCAGCGGATTTCAGTCCTATCGCTTTGAATGGTGGCACTATAAGTTGATTGATGAGCCATACCCCGATACCTATTTTAATTTTGCCGTTTCATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7417,Drugs,MEG_7417|Drugs|Glycopeptides|VanB-type_resistance_protein|VANHB,VanHBX_1_AF192329,5
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccacccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5577,Drugs,MEG_5577|Drugs|betalactams|Class_C_betalactamases|PDC,1028110205|WP_063864575.1|NG_049894|1|1|blaPDC-21b|blaPDC|class_C_beta-lactamase_PDC-21b NG_049894:1-1194,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacgacggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2149,Drugs,MEG_2149|Drugs|betalactams|Class_A_betalactamases|CTX,1391852877|WP_109545062.1|NG_057476|1|1|blaCTX-M-210|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-210 NG_057476:1-876,0
,ATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGTTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATTCCAGTGCGCTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACCACGCGCACCTGGTTTTGTAGCGCATATATCACGAATACCAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCGAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGCTGGACAACTACCAGGCGTCGTTGCTCATGGAGCGGCTTGGCATCGCGGTGATTGGTTAG,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6009,Drugs,MEG_6009|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,qnrB17_2_AM919398 ,3
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACATTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGATAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGTACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1909,Drugs,MEG_1909|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JQ733576|+|1027-2173|ARO:3002092|CMY-79 [Citrobacter freundii] ,0
,ATGAGCGATAAAATACTTGTTGTGGACGATGAACATGAAATTGCCGATTTGGTTGAGCTATACTTGAAAAACGAGAATTATACGGTTTTCAAATACTATACCGCCAAAGAAGCGTTGGAATGTATAGACAAGACCGATCTTGACCTTGCCATATTGGACATCATGCTTCCCGGCGCAAGCGGCCTCGCTATCTGCCAAAAAATAAGGGACAAGCACACCTATCCAATTATCACGCTGACCGCGAAAGATACGGAGGTAGATAAAATTACAGGGCTAACAATCGGCGCGGACGATTATATAACGAAGCCCTTTCGCCCGCTGGAGTTAATTGCGCGGGTCAAGGCGCAGTTGCGCCGATACAAAAAATACAATGGAGTAACGGAGCAGAACGAAAATGTTATCGTCCACTCCGGCCTTGTCATTAATATAAACACGCATGAGTGTTTTCTGAACGAGAAGCAGTTATCCCTCACTCCCACCGAGTTTTCAATCCTGCGCATCCTCTGTGAAAACAAGGGGAATGTGGTTAGCTCCGAGCAGTTATTTCATGAGATATGGGGCGACGAATATTTCAGCAAGAGCAACAACACCATCACCGTGCATATCCGGCATCTGCGCGAAAAAATGAACGACACCATTGATAATCCGAAGTATATAAAAACGGTATGGGGGGTTGGCTATAAAATTGAAAAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7450,Drugs,MEG_7450|Drugs|Glycopeptides|VanA-type_regulator|VANRA,(Gly)VanR-Pt:DQ018711:1-696:696,5
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacagttctccgggacaacttgacgccgcagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1817,Drugs,MEG_1817|Drugs|betalactams|Class_C_betalactamases|CMY,1149331614|WP_077767289.1|NG_052898|1|1|blaCMY-147|blaCMY|class_C_beta-lactamase_CMY-147 NG_052898:1-1146,0
,atgaatgtcattataaaagctgtagttactgcctcgacgctactgatggtatcttttagttcattcgaaacctcagcgcaatccccactgttaaaagggcaaattgaatccatagtcattggaaaaaaagccactgtaggcgttgcagtgtgggggcctgacgatctggaacctttactgattaatccttttgaaaaattcccaatgcaaagtgtatttaaattgcatttagctatgttggtactgcatcaggttgatcagggaaagttggatttaaatcagaccgttatcgtaaacagggctaaggttttacagaatacctgggctccgataatgaaagcgtatcagggagacgagtttagtgttccagtgcagcaactgctgcaatactcggtctcgcacagcgataacgtggcctgtgatttgttatttgaactggttggtggaccagctgctttgcatgactatatccagtctatgggtataaaggagaccgctgtggtcgcaaatgaagcgcagatgcacgccgatgatcaggtgcagtatcaaaactggacctcgatgaaaggtgctgcagagatcctgaaaaagtttgagcaaaaaacacagctgtctgaaacctcgcaggctttgttatggaagtggatggtcgaaaccaccacaggaccagagcggttaaaaggtttgttaccagctggtactgtggtcgcacataaaactggtacttcgggtatcaaagccggaaaaactgcggccactaatgatttaggtatcattctgttgcctgatggacggcccttgctggttgctgtttttgtgaaagactcagccgagtcaagccgaaccaatgaagctatcattgcgcaggttgctcagactgcgtatcaatttgaattgaaaaagctttctgccctaagcccaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_5762,Drugs,MEG_5762|Drugs|betalactams|Class_A_betalactamases|PER,1028110224|WP_063864594.1|NG_049964|1|1|blaPER-5|blaPER|class_A_extended-spectrum_beta-lactamase_PER-5 NG_049964:1-927,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcggctacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagcgccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2178,Drugs,MEG_2178|Drugs|betalactams|Class_A_betalactamases|CTX,1149331618|WP_077767293.1|NG_052902|1|1|blaCTX-M-196|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-196 NG_052902:1-876,0
,GGCGAGGCCCCGGCGGATCGCCTGAAGGCACTGGTCGACGCCGCCGTACAACCGGTGATGAAGGCCAATGACATTCCGGGCCTGGCCGTAGCCATCAGCCTGAAAGGAGAACCGCATTACTTCAGCTATGGGCTGGCCTCGAAAGAGGACGGCCGCCGGGTGACGCCGGAGACCCTGTTCGAGATCGGCTCGGTGAGCAAGACCTTCACCGCCACCCTCGCCGGCTATGCCCTGGCCCAGGACAAGATGCGCCTCGACGACCGCGCCAGCCAGCACTGGCCGGCACTGCAGGGCAGCCGCTTCGACGGCATCAGCCTGCTCGACCTCGCGACCTATACCGCCGGCGGCTTGCCGCTGCAGTTCCCCGACTCGGTGCAGAAGGACCAGGCACAGATCCGCGACTACTACCGCCAGTGGCAGCCGACCTATGCGCCGGGCAGCCAGCGCCTCTATTCCAACCCGAGCATCGGCCTGTTCGGCTATCTCGCCGCGCGCAGCCTGGGCCAGCCGTTCGAACGACTCATGGAGCAGCAAGTGTTCCCGGCACTGGGCCTCGAACAGACCCACCTCGACGTGCCCGAGGCGGCGCTGGCGCAGTACGCCCAGGGCTACGGCAAGGACGACCGCCCGCTACGGGTCGGTCCCCGCCCGCTGGATGCCGAAGGCTACGGGGTGAAGACCAGCGCGGCCGACCTGCTGCGCTTCGTCGATGCCAACCTGCATCCGGAGCGCCTGGACAGGCCCTGGGCGCAGGCGCTCGATGCCACCCATCGCGGTTACTACAAGGTCGGCGACATGACCCAGGGCCTGGGCTGGGAAGCCTACGACTGGCCGATCTCCCTGAAGCGCCTGCAGGCCGGCAACTCGACGCCGATGGCGCTGCAACCGCACAGGATCGCCAGGCTGCCCGCGCCACAGGCGCTGGAGGGCCAGCGCCTGCTGAACAAGACCGGTTCCACCAACGGCTTCGGCGCCTACGTGGCGTTCGTCCCGGGCCGCGACCTGGGACTGGTGATCCTGGCCAACCGCAACTATCCCAATGCCGAGCGGGTGAAGATCGCCTACGCCATCCTCAGCGGCCTGGAGCAGCAGGGCAAGGTGCCGCTGAAGCGCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5725,Drugs,MEG_5725|Drugs|betalactams|Class_C_betalactamases|PDC,gb|KR057743.1|+|0-1116|ARO:3004337|PDC-74 [Pseudomonas aeruginosa] ,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagctgtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2164,Drugs,MEG_2164|Drugs|betalactams|Class_A_betalactamases|CTX,1028104728|WP_063859974.1|NG_048952|1|1|blaCTX-M-167|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-167 NG_048952:1-876,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcccggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacatcttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctagcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggataccccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6200,Drugs,MEG_6200|Drugs|betalactams|Class_A_betalactamases|SHV,1028110268|WP_063864638.1|NG_050027|1|1|blaSHV-152|blaSHV|class_A_beta-lactamase_SHV-152 NG_050027:1-861,0
,atgaatagttcgacaaagatcgcattggtaattacgttactcgatgccatggggattggccttatcatgccagtcttgccaacgttattacgtgaatttattgcttcggaagatatcgctaaccacttaggcgtattgcttgcactttatgcgttaatgcaggttatctttgctccttggcttggaaaaatgtctgaccgatttggtcggcgcccagtgctgttgttgtcattaataggcgcatcgctggattacttattgctggctttttcaagtgcgctttggatgctgtatttaggccgtttgctttcagggatcacaggagctactggggctgtcgcggcatcggtcattgccgataccacctcagcttctcaacgcgtgaagtggttcggttggttaggggcaagttttgggcttggtttaatagcggggcctattattggtggttttgcaggagagatttcaccgcatagtcccttttttatcgctgcgttgctaaatattgtcactttccttgtggttatgttttggttccgtgaaaccaaaaatacacgtgataatacagataccgaagtaggggttgagacgcaatcgaattcggtatacatcactttatttaaaacgatgcccattttgttgattatttatttttcagcgcaattgataggccaaattcccgcaacggtgtgggtgctatttaccgaaaatcgttttggatggaatagcatgatggttggcttttcattagcgggtcttggtcttttacactcagtattccaagcctttgtggcaggaagaatagccactaaatggggcgaaaaaacggcagtactgctcggatttattgcagatagtagtgcatttgcctttttagcgtttatatctgaaggttggttagttttccctgttttaattttattggctggtggtgggatcgctttacctgcattacagggagtgatgtctatccaaacaaagagtcatcagcaaggtgctttacagggattattggtgagccttaacaatgcaaccggtgttattggcccattactgtttgctgttatttataatcattcactaccaatttgggatggctggatttggattattggtttagcgttttactgtattattatcctgctatcgatgaccttcatgttaacccctcaagctcaggggagtaaacaggagacaagtgcttag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7038,Drugs,MEG_7038|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,504199713|WP_014386815.1|NG_048165|1|1|tet(B)|tet(B)|tetracycline_efflux_MFS_transporter_Tet(B) NG_048165:1-1206,4
,TCGGAATTCAGCAAAGATGAAATCAATGATTTATCAAAAATGATTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGGACTATTCATGTTGTTGTTATTTCGTATCTTCCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCTGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGGAAACTCATTCCGTTTTTGTTTATCGCCTTAGACGGCAAAAGTGCTGTCGCCCACCTGCGCTTGCGCATACCAGGCCATAAGCTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_2423,Drugs,MEG_2423|Drugs|betalactams|Class_A_betalactamases|CTX,gi|695214521|ref|NG_036820.1|1-1174,0
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaagcagtatcattaatcactagtgccatcttgcaaatggcgattattttttaccttacagaaaaaactggatccgcgatggtcttgtctatggcttcactattaggttttttaccctatgcggtctttggaccttcaattggtgtgctagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctggttcggtgcttactattgttgcattctatatggagctacctgtctggatggttatgatagtattgtttatccgtagcattggaacagcttttcacaccccggctctcaatgcggttacgccacttttagtaccagaagaacagcttacgaaatgtgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcggttgcagcactcttatactccgtttgggaactaaatgctattattgccatcgatgtattgggtgctgtgattgcatctattacggtagcaattgtacgtattcctaagctgggtgatcgcgtgcaaagtttggacccaaatttcataagagaaatgaaagaaggaatggctgtactacggcaaaataaaggattatttgctttattactcgttggaacattatatatgtttgtttatatgccaattaatgcactattccctttaattagcatggattactttaatggaacacctgtgcatatttctattacggaaatttcctttgcatctggaatgttgatagggggtctattattagggttatttgggaattaccaaaagcgaatcttattaataacggcatccatttttatgatggggataagcttaaccatttcaggattacttccccaaagtggatttttcatttttgtagtctgctgtgcaataatggggctttctgttccgttttacagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttaactggaagtatcatgtctcttgctatgccaattggattaattctttctgcactctttgctgatagaatcggtgtaaatcattggtttttactatcaggtattttaattatttgcattgcaatagtttgcccaatgataaatgagattagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3815,Drugs,MEG_3815|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028096935|WP_063853632.1|NG_047967|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047967:45-1262,7
,atggacacaacgcaggtcacattgatacacaaaattctagctgcggtagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatagttgaaatgctcggcgggcgcgtcatggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccagtggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_743,Drugs,MEG_743|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1105502166|WP_071846317.1|NG_052387|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052387:81-614,2
,GTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGTCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6900,Drugs,MEG_6900|Drugs|betalactams|Class_A_betalactamases|TEM,gi|284468331|gb|GU550123.1|1-1087,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacactcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccgggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtggcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_827,Drugs,MEG_827|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,499662212|WP_011342946.1|NG_052436|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052436:101-889,2
,atgcctgatttcattcagttagaatatctacaagaaaaattacagcaacttttagcggaatcattatttgcaatctatctttatggttcagctgttgatggtggcttagggccagaaagtgaccttgatgttctggtcgtggttactcaaccattaacatctgctttacgcgagcagcttgcacaagaattactaaaaatttcacagcctgttggggaattacaaagaccattagaagttactattttattaaaagatgagattcaggctggaaattatcctttaagttatgaaatgcagtttggtgaatggctacgtgaagaacttaaagaaggtggaacattaagttcgcagaaagacccagatattagtatattgcttagaaaagcgagatttcatcatacagttttatttggtccagctttggaccaatgggcacctgaaatttctgatcaagaactatggcaagcaatgtctgatacttatcccgaaattgtagctcattgggatgaggatgcagatgaaagaaaccagattttagctttatgccggatctattttagtttagtcatgaaggatattgcttcaaaagacaatgcagctcgatgggttatgcctcagcttcctcctgagcagaaattcgtattgcagcggcttatacaggaatatagaggggaaataggcaaacaaaattggcaagaggaacattatgctttgcagcctattgttaattttctgagttcaaaaattgaagagcagtttgagcagaaaagaaatttgatcacataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_899,Drugs,MEG_899|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,447035368|WP_001112624.1|NG_054648|1|1|ant(3'')-IIa|ant(3'')-IIa|aminoglycoside_nucleotidyltransferase_ANT(3'')-IIa NG_054648:101-889,2
,ATGGCTGAATTACCTCAATCAAGAATAAATGAACGAAATATTACCAGTGAAATGCGTGAATCATTTTTAGATTATGCGATGAGTGTTATCGTTGCTCGTGCATTGCCAGATGTTCGTGACGGTTTAAAACCAGTACATCGTCGTATACTATATGGATTAAATGAACAAGGTATGACACCGGATAAATCATATAAAAAATCAGCACGTATCGTTGGTGACGTAATGGGTAAATATCACCCTCATGGTGACTTATCTATTTATGAAGCAATGGTACGTATGGCTCAAGATTTCAGTTATCGTTATCCGCTTGTTGATGGCCAAGGTAACTTTGGTTCAATGGATGGAGATGGCGCAGCAGCAATGCGTTATACTGAAGCGCGTATGACTAAAATCACACTTGAACTGTTACGTGATATTAATAAAGATACAATAGATTTTATCGATAACTATGATGGTAATGAAAGAGAGCCGTCAGTCTTACCTGCTCGATTCCCTAACTTGTTAGCCAATGGAGCATCAGGTATAGCGGTAGGTATGGCAACGAATATTCCACCACATAACTTAACAGAATTAATCAATGGTGTACTTAGCTTAAGTAAGAACCCTGATATTTCAATTGCTGAGTTAATGGAGGATATTGAAGGTCCTGATTTCCCAACTGCTGGACTTATTTTAGGTAAGAGTGGTATTAGACGTGCATATGAAACAGGTCGTGGTTCAATTCAAATGCGTTCTCGTGCAGTTATTGAAGAACGTGGAGGCGGACGTCAACGTATTGTTGTCACTGAAATTCCTTTCCAAGTGAATAAGGCTCGTATGATTGAAAAAATTGCAGAGCTCGTTCGTGACAAGAAAATTGACGGTATCACTGATTTACGTGATGAAACAAGTTTACGTACTGGTGTGCGTGTCGTTATTGATGTGCGTAAGGATGCAAATGCTAGTGTCATTTTAAATAACTTATACAAACAAACACCTCTTCAAACATCATTTGGTGTGAATATGATTGCACTTGTAAATGGTAGACCGAAGCTTATTAATTTAAAAGAAGCGTTGGTACATTATTTAGAGCATCAAAAGACAGTTGTTAGAAGACGTACGCAATACAACTTACGTAAAGCTAAAGATCGTGCCCACATTTTAGAAGGATTACGTATCGCACTTGACCATATCGATGAAATTATTTCAACGATTCGTGAGTCAGATACAGATAAAGTTGCAATGGAAAGCTTGCAACAACGCTTCAAACTTTCTGAAAAACAAGCTCAAGCTATTTTAGACATGCGTTTAAGACGTCTAACAGGTTTAGAGAGAGACAAAATTGAAGCTGAATATAATGAGTTATTAAATTATATTAGTGAATTAGAAACAATCTTAGCTGATGAAGAAGTATTACTACAATTAGTTAGAGATGAATTAACAGAAATTCGAGATCGTTTCGGTGATGATCGTCGTACTGAAATCCAATTAGGTGGATTTGAAGATTTAGAAGATGAAGATCTCATTCCAGAAGAACAAATTGTAATTACACTAAGCCATAATAACTACATTAAACGTTTGCCGGTATCTACATATCGTGCTCAAAACCGTGGTGGTCGTGGTGTTCAAGGTATGAATACATTGGAAGAAGATTTTGTCAGTCAATTGGTAACTTTAAGTACACATGACCATGTATTGTTCTTTACTAACAAAGGTCGTGTATACAAACTTAAAGGTTATGAAGTGCCTGAGTTATCAAGACAGTCTAAAGGTATTCCTGTAGTGAATGCTATTGAACTTGAAAATGATGAAGTCATTAGTACAATGATTGCTGTTAAAGACCTTGAAAGTGAAGACAACTTCTTAGTGTTTGCAACTAAACGTGGTGTCGTTAAACGTTCAGCATTAAGTAACTTCTCAAGAATAAATAGAAATGGTAAGATTGCGATTTCGTTCAGAGAAGATGATGAGTTAATTGCAGTTCGCTTAACAAGTGGTCAAGAAGATATCTTGATTGGTACATCACATGCATCATTAATTCGATTCCCTGAATCAACATTACGTCCTTTAGGCCGTACAGCAACGGGTGTGAAAGGTATTACACTTCGTGAAGGTGACGAAGTTGTAGGGCTTGATGTAGCTCATGCAAACAGTGTTGATGAAGTATTAGTAGTTACTGAAAATGGTTATGGTAAACGTACGCCAGTTAATGACTATCGTTTATCAAATCGTGGTGGTAAAGGTATTAAAACAGCTACGATTACTGAGCGTAATGGTAATGTTGTATGTATCACTACAGTAACTGGTGAAGAAGATTTAATGATTGTTACTAATGCAGGTGTCATTATTCGACTAGATGTTGCAGATATTTCTCAAAATGGTCGTGCAGCACAAGGTGTTCGCTTAATTCGCTTAGGTGATGATCAATTTGTTTCAACGGTTGCTAAAGTAAAAGAAGATGCAGAAGATGAAACGAATGAAGATGAGCAATCTACTTCAACTGTATCTGAAGATGGTACTGAACAACAACGTGAAGCGGTTGTAAATGATGAAACACCAGGAAATGCAATTCATACTGAAGTGATTGATTCAGAAGAAAATGATGAAGATGGACGTATTGAAGTAAGACAAGATTTCATGGATCGTGTTGAAGAAGATATACAACAATCATCAGATGAAGATGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3233,Drugs,MEG_3233|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|974697948|dbj|AP017320.1|7002-9671 gi|760495145|gb|CP010944.1|2675556-2678225 gi|760491253|gb|CP010943.1|2679692-2682361 gi|748807120|gb|CP010526.1|7005-9674 gi|408436493|emb|HE579073.1|7005-9674 gi|408434508|emb|HE579071.1|7005-9674 gi|408432519|emb|HE579069.1|7005-9674 gi|408430526|emb|HE579067.1|7005-9674 gi|408428537|emb|HE579065.1|7005-9674 gi|408426549|emb|HE579063.1|7005-9674,3
,atgagtaacgcagtacccgccgagatttcggtacagctatcactggctctcaacgccatcgagcgtcatctggaatcaacgttgctggccgtgcatttgtacggctctgcactggacggtggcctgaagccatacagtgatattgatttgctggttactgtggctgcacggctcgatgagactgtccgacaagccctggtcgtagatctcttggaaatttctgcctcccctggccaaagtgaagctctccgcgccttggaagttaccatcgtcgtgcatggtgatgttgtcccttggcgttatccggccagacgggaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_820,Drugs,MEG_820|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,763190381|WP_044067522.1|NG_052539|1|1|aadA6|aadA6|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA6 NG_052539:101-892,2
,atgtccgccacgctccacgacaccgcagcggatcgtcggaaggccacccgccgcgaatggatcggcctggccgtggtcgccctgccgtgcctggtctacgccatggacctcacggtgctgaacctggcgctgccggtgctcagccgtgaactgcagccctccagcgcccagcttctctggatcctggacatctacggcttcttcgtcgccggcttcctgatcaccatgggcacgctgggcgaccgcatcggccggcgccggctgttgttgatcggcgcggcgttcttcgcattcgcctcggtgctcgcggcgctggccgataccgccgcgctgttgatcgcggcgcgcgccttgctcggcctggccggcgccaccatcgcgccgtccaccatggcgctgatccgcaacatgttccacgacccgcgccagcgccagttcgccatcggcgtgtggatcgccgcgttttcgctgggcagcgcgatcggtccgctggtcggcggcgtgttgctggagttcttccactggggcgccgtgttctggctcaacgtgccggtgatgctgctgacgctggcgctcggccctcgcttcctgcccgagtatcgtgatccggacgcggggcacctggacctggccagcgtgctgctgtcgctggcggcggtgctgctgacgatctacgggctcaagcagttggccgagcatggagcgggcctcgcctcgatggctgcgctgctggccgggctggcggtcggggcgctgttcctgcgccgccagggccacatcgcctacccgctgctggacctgcggctgttcgcgcacgcgccgttccgcgcggcgctggcggcgtatgcgctggccgcgctggccatgttcggcgtctacatcttcatgacgcagtacctgcagctcgtgctggggctgtcgccgctgcaggccgggctggccacgctgccctggtccctgtgcttcgtcatcggttcgctgttgtcgccgcagctcgcggcgcgctggccggcggcgcgcatcctcgtcgtgggcctgtcggcagcggcgttcggcttcgccgtgctggggctggggcagggcctgtggtggctggtgccggccacgatcgtcatgggcctgggcctggcgccggtgttcaccatcggcaacgagatcatcatcaccagcgcgccgtccgagcgcgcgggcgcggcctcggccttgtcggagacggtgtccgaattcagcggcgcgctgggcatcgcgctgttcggcagcgtcggcctggtggtctaccggcaggcgctgaccagcgcggcgctgcccggcctgccggccgatgcgctgcaggcggccggtgcctcgctcgggggcgccgtgcacctggccgacaccctgccggcgtggcagggcgcggccttgctggcggccgcacgcgcgggcttcaccgatgcgctgcaggccacggcctgggccggcgcggtgctggtgctggtggccgctgggctggtggcgcgcctgctgcgcaagcgcccagcgctcgcatctggttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Fluoroquinolones,MEG_5859,Drugs,MEG_5859|Drugs|Fluoroquinolones|Quinolone_active_efflux|QEPA,1253080148|WP_096941464.1|NG_062246|1|1|qepA6|qepA|fluoroquinolone_efflux_MFS_transporter_QepA6 NG_062246:101-1636,3
,AGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6951,Drugs,MEG_6951|Drugs|betalactams|Class_A_betalactamases|TEM,gi|981191958|emb|LN999997.1|2513296-2512427 gi|975048878|gb|CP013962.1|4121694-4120825 gi|973715451|gb|CP013836.1|137754-138623 gi|973705327|gb|CP013832.1|76055-76924 gi|971339514|gb|CP006662.2|50816-51685 gi|943457735|gb|KT818627.1|33060-33929 gi|970338578|gb|KT725789.1|75453-76322 gi|970338460|gb|KT725788.1|80713-81582 gi|962148759|gb|KT002541.1|3901-4770 gi|961666360|gb|KT185451.1|17744-16875,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcacgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggctacggcaatgcggacgtctccggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaaggtggtgaaccggcaattgccggtcaaggccgccgcctatgagctggcggacaacctcttcgaggtgggccaggccgatggctggcgcctgtatggcaagaccggcaccgggtcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccggcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4541,Drugs,MEG_4541|Drugs|betalactams|Class_D_betalactamases|OXA,1625655401|WP_136512078.1|NG_064741|1|1|blaOXA-114t|blaOXA-114_like|class_D_beta-lactamase_OXA-114t NG_064741:1-828,0
,ATCCATGGAGAGTTTGATCCTGGCTCAGGACGAACGCTGGCGGCATGCTTAACACATGCAAGTCGAACGAGCAAAGCAATTTGTGTAGTGGCGAACGGGTGCGTAACGCGTAAGAACCTACCTATCGGAGGGGGATAACATTGGGAAACTGTTGCTAATACCCCATACAGCTGAGGAGTGAAAGGTGAAAAACCGCCGATAGAGGGGCTTGCGTCTGATTAGCTAGTTGGTGGGGGTAACGGCCTCCCAAGGCCACGAGCAGTAGCTGGTCTGAGAGGATGATCAGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGAGGAATTTTTCGCAATGGGCGCAAGCGACGGAGCAATGCCGCGTGCAGGAAGAAGGCCTGTGGGTCGTAAACTGCTTTTCTCAGAGAAGAAGTTCTGACGGTATCTGAGGAATAAGCACCGGCTAACTCTGTGCCAGCAGCCGCGGTAATACAGAGGGTGCAAGCGTTGTCCGCAATGATTGGGCGTAAAGCGTCTGTAGGTGGCTCGTAAAGTCTAATGTCAAATACCAGGGCTCAACCTTGGACCGGCATTGGAGTACTCACGAGCTTGAGTACGGTAGGGGCAGAGGGAATTCCATGTGGAGCGGTGAAATGCGTAGAGATATGGAGGAACACCAGTGGCGAAGGCGCTCTGCTGGGCCGAAACTGACACTGAGAGACGAAAGCTGGGGGAGCGAATAGGATTAGATACCCTAGTAGTCCCAGCCGTAAACTATGGAGACTAAGTGCTGCCGCAAGCAGTGCTGTAGCTAACGCGTTAAGTCTCCCGCCTGGGGAGTATGCTCGCAAGAGTGAAACTCAAAGGAATTGACGGGACCGCACAAGCGGTGGATTATGTGGATTAATTCGATACAACGCGAAGAACCTTACCAGGGTTTGACATGTCAAGAACCTCTCAGAAATGGGAGGGTGCCCTAACGGACTTGAACACAGGTGGTGCATGGCTGTCGTCAGCTCGTGCTGTGAAGTGTATAGTTAAGTCTCATAACGAGCGCAACCCTCGTCTTTAGTTGCCATTTGGTTCTCTAAAGAGACTGCCAGTGTAAGCTGGAGGAAGGTGAGGATGACGTCAAGTCAGCATGCCCCTTACATCCTGGGCTTCACACGTAATACAATGGTTGGGACAATCAGAAGCGACTCGTGAGAGCTAGCGGCTCTGTTAAACCCAACCTCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGAAGCCGGAATCGCTAGTAATCGCCAGTCAGCTATATGGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGAAGCTGGTTCTGCTCCAAGTCGTTACCCTAACCTTCGGGAGGGGGGCGCCTAAAGCAGGGCTAGTGACTAGGGTGAAGTCGTAACAAGGTAGGGCTACTGGAAGGTGGCCCTGGCTCACCTCCTTC,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_8,Drugs,MEG_8|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|NC_005353.1|+|38549-40023|ARO:3003978|Chlamydomonas reinhardtii 16S rRNA mutation in the rrnS gene conferring resistance to streptomycin [Chlamydomonas reinhardtii] ,2
,atgagactgtcccgccgcctcgttttgctgtcttgcctgctattgccgcaggcaggcttttccgcagccatgcctgccaatcttgccgaccagaaaatagccaggctggagcgcgtttttggcggccagatcggggtgtatgcgctggataccggctcaggcgccgccgtgagttaccgcgcggatgagcgcttcccgctgtgcagctcgttcaagggttttctggccgcctccgcgctggcgcatagccagagcaaaccgggctttctggatcaaatcctccattacggcaaggaagagctgatagcctggtcccccatctcggagaagcaccagtccagcggcatgacggtagccggcctgtgcgcggccactgtgcagtacagcgataatgcagccgccaatgtcttgatgaagcagctggatggcccggccggcctgacggccttcatgcgcgccatcggcgacagcaccttccgccttgaccgctgggagccggagttgaacacggccatacccggcgacgcgcgcgatacctccaccccgcgcgccgtggcggaaagcctgcaaaaactgacccttggcacggcactggcggcgcatcagcgccagcagctggtggattggctcaaagggaacactaccggcaaccagcgcattcgcgccgccgtgccggccggctggttggtgggcgacaaaaccggcacttgcggcgtgtacggcacggccaatgattacgcggtgatctggcccactggccgcgcgcccatcgtgatggcggtttatacccgcgcgtccaagaaagacatcaagcacagcgatgccgtcattgccgatgcggccaaggccgcgctggaagcgctaggggtgatgacgcggtaa,antibiotic molecule,antibiotic inactivation,betalactams,MEG_1272,Drugs,MEG_1272|Drugs|betalactams|Class_A_betalactamases|BLACRP,759944943|WP_043629745.1|NG_054657|1|1|blaCRP-1|blaCRP|carbapenem-hydrolyzing_class_A_beta-lactamase_CRP-1 NG_054657:101-982,0
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatgctggcgttcgtgcctgcgctcggccctatcgccggagtattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcacctacttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggccccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2924,Drugs,MEG_2924|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,500434783|WP_011931116.1|NG_047874|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047874:101-1315,6
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaatggacgaacgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgagaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacgcgtatcgaacacgcttgtgaagccgccatgttgatgagcgacaacaccgccgcaaacttagtgctaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgctctgttggcgacaaagcaacgcgacttgaccgattggagccccgtttgaacgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctaccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatttggaaagacaactacaagccggtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcgctacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1513,Drugs,MEG_1513|Drugs|betalactams|Class_A_betalactamases|CARB,659003653|WP_029837067.1|NG_048736|1|1|blaCARB-32|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-32 NG_048736:1-852,0
,ATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGGGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6926,Drugs,MEG_6926|Drugs|betalactams|Class_A_betalactamases|TEM,gi|5650760|gb|AF062386.1|AF062386|1-862,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatctaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4709,Drugs,MEG_4709|Drugs|betalactams|Class_D_betalactamases|OXA,1559612985|WP_128268250.1|NG_063855|1|1|blaOXA-751|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-751 NG_063855:14-838,0
,atgcgttttattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacatcttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgctcgagtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcatcgtggtgatttatctgcgggataccccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6238,Drugs,MEG_6238|Drugs|betalactams|Class_A_betalactamases|SHV,1509794554|WP_122630863.1|NG_062276|1|1|blaSHV-205|blaSHV|class_A_beta-lactamase_SHV-205 NG_062276:1-861,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctgttccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggattggatgtaaacctacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaataaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4701,Drugs,MEG_4701|Drugs|betalactams|Class_D_betalactamases|OXA,1693892945|WP_140423322.1|NG_065440|1|1|blaOXA-829|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-829 NG_065440:1-825,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaaaaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4706,Drugs,MEG_4706|Drugs|betalactams|Class_D_betalactamases|OXA,1559612994|WP_128268259.1|NG_063864|1|1|blaOXA-760|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-760 NG_063864:30-854,0
,ATGACGCCATTACTGTATAAAAAAACAAGTACAAATATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGCTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTTGGCATTGAAATTCGCCACTGTCGTGCGCAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACTCGCACCTGGTTTTGCAGCGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAATGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTTTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGCGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGTTGCTCATGGAACGTCTTGGCATCGCGATTATTGGCTAG,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_5919,Drugs,MEG_5919|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,(Flq)QnrB13:EU273756:37-681:645,3
,ATGAATAGTTCGACAAAGATCGCATTGGTAATTACGTTACTCGATGCCATGGGGATTGGCCTTATCATGCCAGTCTTGCCAACGTTATTACGTGAATTTATTGCTTCGGAAGATATCGCTAACCACTTTGGCGTATTGCTTGCACTTTATGCGTTAATGCAGGTTATCTTTGCTCCTTGGCTTGGAAAAATGTCTGACCGATTTGGTCGGCGCCCAGTGCTGTTGTTGTCATTAATAGGCGCATCGCTGGATTACTTATTGCTGGCTTTTTCAAGTGCGCTTTGGATGCTGTATTTAGGCCGTTTGCTTTCAGGGATCACAGGAGCTACTGGGGCTGTCGCGGCATCGGTCATTGCCGATACCACCTCAGCTTCTCAACGCGTGAAGTGGTTCGGTTGGTTAGGGGCAAGTTTTGGGCTTGGTTTAATAGCGGGGCCTATTATTGGTGGTTTTGCAGGAGAGATTTCACCGCATAGTCCCTTTTTTATCGCTGCGTTGCTAAATATTGTCGCTTTCCTTGTGGTTATGTTTTGGTTCCGTGAAACCAAAAATACACGTGATAATACAGATACCGAAGTAGGGGTTGAGACGCAATCGAATTCGGTATACATCACTTTATTTAAAACGATGCCCATTTTGTTGATTATTTATTTTTCAGCGCAATTGATAGGCCAAATTCCCGCAACGGTGTGGGTGCTATTTACCGAAAATCGTTTTGGATGGAATAGCATGATGGTTGGCTTTTCATTAGCGGGTCTTGGTCTTTTACACTCAGTATTCCAAGCCTTTGTGGCAGGAAGAATAGCCACTAAATGGGGCGAAAAAACGGCAGTACTGCTCGGATTTATTGCAGATAGTAGTGCATTTGCCTTTTTAGCGTTTATATCTGAAGGTTGGTTAGTTTTCCCTGTTTTAATTTTATTGGCTGGTGGTGGGATCGCTTTACCTGCATTACAGGGAGTGATGTCTATCCAAACAAAGAGTCATCAGCAAGGTGCTTTACAGGGATTATTGGTGAGCCTTACCAATGCAACCGGTGTTATTGGCCCATTACTGTTTGCTGTTATTTATAATCATTCACTACCAATTTGGGATGGCTGGATTTGGATTATTGGTTTAGCGTTTTACTGTATTATTATCCTGCTATCGATGACCTTCATGTTAACCCCTCAAGCTCAGGGGAGTAAACAGGAGACAAGTGCTTAG,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7052,Drugs,MEG_7052|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,gi|981191958|emb|LN999997.1|2497385-2498590 gi|971520763|gb|CP008715.1|92038-93243 gi|953946047|emb|LN908249.1|1550466-1549261 gi|949881887|gb|CP012931.1|25030-26235 gi|917657445|gb|KR827684.1|38452-37247 gi|909636483|emb|LN850163.1|118331-117126 gi|857118485|gb|CP011223.1|1683038-1684243 gi|834763093|gb|CP006636.1|352526-351321 gi|828386350|gb|CP006635.1|154867-153662 gi|825091926|gb|KP789020.1|135877-134672,4
,ATGAGGGAAGCGGTGATCGCCGAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCACACAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGGCAGGCTTATCTTGGACAAGAAGATCGCTTGGCCTCGCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_968,Drugs,MEG_968|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|975003027|gb|CP010829.1|4112979-4112191 gi|943457735|gb|KT818627.1|74232-73444 gi|943457735|gb|KT818627.1|135823-135035 gi|963329722|gb|KT316807.1|1252-2040 gi|963329696|gb|KT316806.1|1264-2052 gi|959195734|gb|CP013326.1|60115-59327 gi|959190351|gb|CP013324.1|109569-108781 gi|953271705|gb|KT175897.1|1251-2039 gi|953271701|gb|KT175896.1|1241-2029 gi|952545745|dbj|LC095818.1|2073-2861 gi|948288901|gb|KR259326.1|2016-2804,2
,atggccgtattgctctcgggggttcccgttctcgccgccctcgacgtttccaccacgcagaagttctggatcgaggtcctcggcttcaccgaggaattcctcaccgaggatttcggcggcgtcagccgcgacggggtcgagttgttcatctgctccgtcgaggaccaggtcgttcccgacaacacgcaggcgtggctgcgggtccgcgacatcgacgccctgcacgccgagtggtccgcgcgtgtctcctcggactacgccgacgccagtcaccctgccatgaccgcgatcagggaggtgccctgggggcgggagttcgggctgcgcgaccccgccggaaacctggtgcacttcagcgagttgagcgaggcggccgaaacgacccggacggttcgttga,beta-lactamase,antibiotic inactivation,Glycopeptides,MEG_7844,Drugs,MEG_7844|Drugs|Glycopeptides|Bleomycin_resistance_protein|ZBMA,1028100806|WP_063856941.1|NG_048567|1|1|zbmA|zbmA|zorbamycin_binding_protein_ZbmA NG_048567:101-499,5
,TTGTTATTGTTATTCTTAATATACTTAGGTTATGACTACGTTAATGAAGCACTGTTTTCTCAGGAAAAAGTCGAATTTCAAAATTATGATCAAAATCCCAAAGAACATTTAGAAAATAGTGGGACTTCTGAAAATACCCAAGAGAAAACAATTACAGAAGAACAGGTTTATCAAGGAAATCTGCTATTAATCAATAGTAAATATCCTGTTCGCCAAGAAAGTGTGAAGTCAGATATCGTGAATTTATCTAAACATGACGAATTAATAAATGGATACGGGTTGCTTGATAGTAATATTTATATGTCAAAAGAAATAGCACAAAAATTTTCAGAGATGGTCAATGATGCTGTAAAGGGTGGCGTTAGTCATTTTATTATTAATAGTGGCTATCGAGACTTTGATGAGCAAAGTGTGCTTTACCAAGAAATGGGGGCTGAGTATGCCTTACCAGCAGGTTATAGTGAGCATAATTCAGGTTTATCACTAGATGTAGGATCAAGCTTGACGAAAATGGAACGAGCCCCTGAAGGAAAGTGGATAGAAGAAAATGCTTGGAAATACGGGTTCATTTTACGTTATCCAGAGGACAAAACAGAGTTAACAGGAATTCAATATGAACCATGGCATATTCGCTATGTTGGTTTACCACATAGTGCGATTATGAAAGAAAAGAATTTCGTTCTCGAGGAATATATGGATTACCTAAAAGAAGAAAAAACCATTTCTGTTAGTGTAAATGGGGAAAAATATGAGATCTTTTATTATCCTGTTACTAAAAATACCACCATTCATGTGCCGACTAATCTTCGTTATGAGATATCAGGAAACAATATAGACGGTGTAATTGTGACAGTGTTTCCCGGATCAACACATACTAATTCAAGGAGGTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7597,Drugs,MEG_7597|Drugs|Glycopeptides|VanA-type_accessory_protein|VANYA,gi|975002886|gb|CP013996.1|5097-5987 gi|925192758|gb|CP012594.1|31666-30776 gi|830872341|gb|KR349520.1|11068-11958 gi|816206772|gb|KR047792.1|11067-11957 gi|695226492|ref|NG_041525.1|11337-12227 gi|359465430|dbj|AB611033.1|11358-10468 gi|695224489|ref|NG_041086.1|3134-2244 gi|304325020|gb|GQ484956.1|31045-31935 gi|304324978|gb|GQ484955.1|29957-30847 gi|304324937|gb|GQ484954.1|25282-26172,5
,atgagccacggcatcccgtgcgccccgagttcaagaatggagacccagatggtttcgaagatggcgatggccgcaatcctgctgctggccggcccgactgcagctgccgaggtcactcccaccacgcccatcgtgtgctcgatgtgcgaaggctggaacaggccgcagaagcctttcaagatctacggcaacacctggtacgtcggaaccaacgacctgtcggcgctgctggtcaccagccccaacggccatgtcctgctcgacggcgcgctgccgcagtcggcgccgctgatcgaagcgaacatccaggcgctcggcttcaagctgaaggacgtgaagctgatcctcaactcgcacgagcacttcgatcacgcaggcggcataccggccctgcagcgcgccagtggtgcgaccgtggcggcgagcatccgcggggccaaggtgctgcgcgcgggaaccgtgggcaaggacgatccgcagttcgacccggtcaagccgttcttcctggcgaagctcgagaaggtgcgtgaagtggccgatggcgagacgctgactgccggcgacctgagaatcacggcgcactacacgccgggccatacgccgggcggtaccagctggacctggacctcgtgcgagaacggccgctgcctgaacatggtgtacgcggacagcctcacgccggtgtcgagcgagggctttcggttcagcggcggcaacggcgcccccgacatctccagcgccttccaggccaccatcgacaaggtcgcggccctgaagtgcgacgtgatggtgtcgaaccatccgggcttctcgcaggtcatggagaagctggctgcgcgcacggatgcgaacaacaccttcatcgatccgaccggctgccggaagtatgcggcggccgcctcgaagcggctggcgaaccggctggccacggaggcgaagcagaaggccgccaggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_718,Drugs,MEG_718|Drugs|betalactams|Class_B_betalactamases|ALG,1509794523|WP_122630832.1|NG_062236|1|1|blaALG6-1|blaALG6|subclass_B3_metallo-beta-lactamase_ALG6-1 NG_062236:1-957,0
,atgttcaaacttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgtggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7710,Drugs,MEG_7710|Drugs|betalactams|Class_B_betalactamases|VIM,1028110988|WP_063865200.1|NG_050379|1|1|blaVIM-51|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-51 NG_050379:1-801,0
,atgaaattattaaaaatattgagtttagtttgcttaagcataagtattggggcttgtgctgagcatagtatgagtcgagcaaaaacaagtacattcccacaagtgaataactcaatcatcgatcagaatgttcaagcgctttttaatgaaatctcagctgatgctgtgtttgtcacatatgatggtcaaaatattaaaaaatatggcacgcatttagaccgagcaaaaacagcttatattcctgcatctacatttaaaattgccaatgcactaattggtttagaaaatcataaagcaacatctacagaaatatttaagtgggatggaaagccacgtttttttaaagaatgggacaaagattttactttgggcgaagccatgcaagcatctacagtgcctgtatatcaagaattggcacgtcgtattggtccaagcttaatgcaaagtgaattgcaacgtattggttatggcaatatgcaaataggcacggaagttgatcaattttggttgaaagggcctttgacaattacacctatacaagaagtaaagtttgtgtatgatttagcccaagggcaattgccttttaaacctgaagttcagcaacaagtgaaagagatgttgtatgtagagcgcagaggggagaatagtctatatgctaaaagtggctggggaatggctgtagacccgcaagtgggttggtatgtgggttttgttgaaaaggcagatgggcaagtggtggcatttgctttaaatatgcaaatgaaagctggtgatgatagtgctctacgtaaacaattgtctttagatgtgctagataagttgggtgtttttcattatttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4428,Drugs,MEG_4428|Drugs|betalactams|Class_D_betalactamases|OXA,1028109781|WP_063864184.1|NG_049789|1|1|blaOXA-512|blaOXA-58_like|OXA-58_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-512 NG_049789:1-843,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgtcaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_589,Drugs,MEG_589|Drugs|betalactams|Class_C_betalactamases|ADC,1625655378|WP_136512055.1|NG_064672|1|1|blaADC-113|blaADC|class_C_beta-lactamase_ADC-113 NG_064672:1-1152,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcggatggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacatcttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgagtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcatcgtggtgatttatctgcgggataccccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6195,Drugs,MEG_6195|Drugs|betalactams|Class_A_betalactamases|SHV,1509794558|WP_122630867.1|NG_062284|1|1|blaSHV-212|blaSHV|class_A_beta-lactamase_SHV-212 NG_062284:1-861,0
,ATATGGTCAAGTCATTGGTCTGATTAGTGCTGCTCAGCTGAACAGGTATTTCTTCCCTGCTTACACTTGCAGTCTATCAACGTCGTAGTCTCCAACGAAACTCATAGGGAAAGTTAATCTTGAAGGAGGCTTCCCACTTAGATGCTTTCAGCGGTTATCCCGTCCGCACATAGCTACTCTGCGATGCTCTTGGCAGAACAACAGATACACCAGCGGTGCGTTCATTCCGGTCCTCTCGTACTAAGAATGACTCTTCTCAACTTTCCAACGCCCACAACGGATAGGGACCAAACTGTCTCACGACGTTCTGAACCCAGCTCGCGTACCGCTTTAATTGGCGAACAGCCAAACCCTTGGGACCTGCTCCAGCCCCAGGATGCGATGAGCCGACATCGAGGTGCCAAACCTCCCCGTCGATATGAACTCTTGGGGGAGATAAGCCTGTTATCCCCGGAGTACCTTTTGTCCGTTTAGCGATGGCCCTTCCACTCGGGACCACCGGATCACTAAAACCTACTTTCGTACCTGCTCGAGATGTCTCTCTCGCAGTCAAGCCACCTTATGCCTTTATACTCTACTACCGATTTCTATTCGGTTTGAGGTGACCTTTGCACGCCTCCGTTACTCTTTAGGAGGCGACCGCCCCAGTCAAACTACCCGCCTGACAATGTCCGACTGCCGGATAACGGCTAATCGTTAGAATCCCATTTTGCGAAGGATGGTATTTCAACGATGGCTCCATGAAAGCTGGCGCTCCCACTTCAAAGCCTCCCATCTATCCTACACATCACAAAACAAAACTCAATGTCAAGTTATAGTAAAGGTTCACGGGGTCTTTCCGTCCTGTTGCGGGTAATCAGCATCTTCACTGATAATTCAATTTCACCGAGTTCTTCCCCGAGACAGTGCCCGGATCGTTACACCATTCGTGCAGGTCGGAACTTACCCGACAAGGAATTTCGCTACCTTAGGACCGTCATAGTTACGGCCGCCGTTTACTGGGGCTTCAATTCGAAGCTTCGCTTACGCTAACCTCTCCTTTTAACCTTCCAGCACTGGGCAGGTGTCAATCCCTATACATCCATTTACATGTTTGCAGAGATCTGTGTTTTTGTTAAACAGTCGGCCAGGCCTTTTCACTGCGACTCTCCTCTCAATATTGCTACCAAGATTCAAGCGTCTCTTTTTCCGAAGTTACAAGACTAATTTGCAGAGTTCCTTAGGGAAGATTATCTCGAGCGCCTTAGAATACTCATCTCACCCACCTGTGTCGGTTTGCGGTACGATTATGACATGCCTAACCTTAGAAATTATTTCTCGACAGCCTAGCTCATGCAACTTCCTGAACCCGAAAGCCCAGTCACTATCCAGCCTCAACCTTAAAGAAGCAAGCATTTGACTCACCTCAAGTCTAAACTGTTTGACGTTATCTACCAATCTAACGCGTACATAAACAATCTGTGTCATTCCATCGAAACATATCATAGTACAGGAATATTTACCTGTTTCCCATCGACTACGCTTTTCAGCCTCATCTTAGGGGTCGACTAACCCTAGGCAGATTAGCTTTACCTAGGAAACCTTGGGTTTGCGGCGAACGGGTTTCTCACCCGTTTTCTCGTTACTCATGCCTGCATCCTCACTTCTTATACCTCCAGCCCACCTCACGATGAACCTTCGACGGCTTAAAGAACGCTCTCCTACCAATTATAGATTAACTCTATAATTCCCTAGCTTCGGTACTATGTTTGAGCCCCGTTACATTTTCGGCGCAAGAACACTCGACCAGTGAGCTGTTACGCACTCTTTAAAGGAATGGCTGCTTCTAAGCCAACCTCCTGGCTGTTTAAGTATTCTCACATCCTTTCCCACTTAACATAGATTTTGGGACCTTAGCTGAGGATCTGGGCTGTTTCCCTTTTGACAATGACGCTTATCCGCCGCTGTCTAACTGCCATGTTCTTAACTTACGGTATTCGGAGTTTAGTTGGGTTTGGTACTCGGTTAGGAGCCCTAGTCCATTTAGTGCTCTACCCCCGCAAGTAAACACATAACGCTGCCCCTAAAGACATTTCGGAGAGAACCAGCTATCTCCAAGTTTGATTAGCCTTTCACTCCTACCCACAAGTCATCCAAAGCCTTTTCACGGCCACTGGTTCGCACCTCCATTCGATGTTACTCGAGTTTCGCGCTGCTCATAGGTAGATCACTTGGCTTCGGGTCGTATAGCATGCAACTAATTTCGCCCTATTAAGGCTCGCTTTCACTACGACTACAAGGCTATTACCTCTTAATCTTGCTACATACTATAAGTCGCAGGCTCATTCTACAAAAGGCACGCCATCAGGCCATCTACTATTGCTAGCAGGGTACCCTCTGACTACTTGTAAGCTTAAGGTTTCAGGTTCTATTTAATAACCCTCAACGGGAGACTTTTCACCTTTCCCTCACGGTACTCTACACTATTGGTCACTGGTTAGTATTTTGCCTTGGATAGTGGTCTACCCAGATTCAAACAGGGTTTCACGTGCCCCGCCCTACTCAGGAACGATAAAACCTTGTCTATATGATTTCGTGTACAGGACTATCACCCACTATGGTCTGCTTTTCCAAAACAGTTCCACTATCATATAAAGCAAAGTCGATGCATGCAAGTACATCGCTTACCGCCCTACAACACCATAATAACAACGCCTTGCAGCTTGACATTATTAAGGTTTAGGCTCTTCCCCTTTCGCTCGCCACTACTTAGGGAATCTCAATTTTGATTACTCTTCCTCCAGGTACTTAGATGTTTCAGTTCCCTGGGTGTCGCCTCATACACCTATGGATTCAGTGTATGATATAGAAGGTTTACTTCTATAGGTTTTCCCATTCGGTGATCTACGGATCATAGAATATTTGCTTCTCCCCGTAGCTTATCGCAGCTTGTCACGACCTTCATCGCCTTCCAGTGCCTAGGCATCCACCTTAAGCCCTTACTTACTTGACCATAT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3991,Drugs,MEG_3991|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NZ_CP015910.2|-|2512812-2515808|ARO:3004133|Brachyspira hyodysenteriae 23S rRNA with mutation conferring resistance to tylosin [Brachyspira hyodysenteriae ATCC 27164] ,7
,atgacttttaatattatcaaattagaaaattgggatagaaaagaatattttgaacactattttaaccagcaaactacgtatagcattactaaagaaattgatattactttgtttaaagatatgataaaaaagaaaggatatgaaatttatccttctttgatttatgcaattatggaagttgtaaataaaaataaagtgtttagaacaggaattaatagtgagaataaattaggctattgggataagttaaatcctttgtatacagtttttaataagcaaactgaaaaatttactaacatttggactgaatctgataacaacttcacttctttttataataattataaaaatgacttgtttgaatataaagataaagaagaaatgtttcctaaaaaagcgatacctgaaaacaccataccgatttcaatgattccttggattgattttagttcatttaatttaaacattggtaacaatagcagctttttattgcctattattacgataggtaaattttatagtgagaataataaaatttatataccagttgccttacagcttcatcatgctgtatgtgatggttaccatgcttcattatttataaatgaatttcaagatataattaataaggtagatgattggatttag,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1571,Drugs,MEG_1571|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,499193572|WP_010891112.1|NG_047575|1|1|catA7|catA7|type_A-7_chloramphenicol_O-acetyltransferase NG_047575:101-748,6
,AGAGATTGAACATAAGAGTTTGATCCTGGCTCAGATTGAACGCTGGCGGCATGCTTTACACATGCAAGTCGGACGGCAGCACAGGGAAGCTTGCTTCTCGGGTGGCGAGTGGCGAACGGGTGAGTAACATATCGGAACGTACCGGGTAGCGGGGGATAACTGATCGAAAGATCAGCTAATACCGCATACGTCTTGAGAGGGAAAGCAGGGGACCTTCGGGCCTTGCGCTATCCGAGCGGCCGATATCTGATTAGCTGGTTGGCGGGGTAAAGGCCCACCAAGGCGACGATCAGTAGCGGGTCTGAGAGGATGATCCGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGGACAATGGGCGCAAGCCTGATCCAGCCATGCCGCGTGTCTGAAGAAGGCCTTCGGGTTGTAAAGGACTTTTGTCAGGGAAGAAAAGGCCGTTGCCAATATCGGCGGCCGATGACGGTACCTGAAGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCGAGCGTTAATCGGAATTACTGGGCGTAAAGCGGGCGCAGACGGTTACTTAAGCAGGATGTGAAATCCCCGGGCTCAACCCGGGAACTGCGTTCTGAACTGGGTGACTCGAGTGTGTCAGAGGGAGGTGGAATTCCACGTGTAGCAGTGAAATGCGTAGAGATGTGGAGGAATACCGATGGCGAAGGCAGCCTCCTGGGATAACACTGACGTTCATGTCCGAAAGCGTGGGTAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCCTAAACGATGTCAATTAGCTGTTGGGCAACTTGATTGCTTGGTAGCGTAGCTAACGCGTGAAATTGACCGCCTGGGGAGTACGGTCGCAAGATTAAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGATGATGTGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGTTTTGACATGTGCGGAATCCTCCGGAGACGGAGGAGTGCCTTCGGGAGCCGTAACACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCATTAGTTGCCATCATTCGGTTGGGCACTCTAATGAGACTGCCGGTGACAAGCCGGAGGAAGGTGGGGATGACGTCAAGTCCTCATGGCCCTTATGACCAGGGCTTCACACGTCATACAATGGTCGGTACAGAGGGTAGCCAAGCCGCGAGGCGGAGCCAATCTCACAAAACCGATCGTAGTCCGGATTGCACTCTGCAACTCGAGTGCATGAAGTCGGAATCGCTAGTAATCGCAGGTCAGCATACTGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTGGGGGATACCAGAAGTAGGTAGGGTAACCGCAAGGAGTCCGCTTACCACGGTATGCTTCATGACTGGGGTGAAGTCGTAACAAGGTAGCCGTAGGGGAACCTGCGGCTGGATCACCTCCTTTCTA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_4,Drugs,MEG_4|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|CP020418|+|383737-385288|ARO:3003495|Neisseria gonorrhoeae 16S rRNA mutation conferring resistance to spectinomycin [Neisseria gonorrhoeae] ,2
,atgcgtatccgtcccacccgtcgtcttctcctcggcgcggtcgcgccgctcgccctcgttccgctggtggcctgcggtcaggcgtcgggctccgagagcgcgggcagcagcccggcctcggcggtgcggacgagcgcacacggctcggcggacgcccacgagaaggaattccgggcgctggagaagaagttcgacgccaccctgggcgtctacgccatcgacaccgccgacggccaggagatcacccaccgggccgacgagcgcttcgcctacggctcgaccttcaaggccctccaggcgggcgcgatcctgcgcaagttctccgagacgggcgcgaagtccggcgggggcgccgaggccgacggcatggacaaggtggtccactacgggcaggacgcgatcctgcccaactcgccggtgaccgagaagcacgtcgcggacggcatgtccctgcgcgagctgtgcgacgccgtcgtccgctacagcgacaacaccgcggccaacctgctcttcgaccagctcggcggcccgaaggggctcaacgcggtcctcaagcagctcggcgaccacaccacgagcatggaccgctacgagcaggagctgggctcggccgtccccggcgacccccgggacaccagcacgccgcgcgcgttcgccgaggacctgcgcgccttcgccgtcgaggacggcgagaaggccgccctcgcgcccaacgaccgcgagcagctgaacgactggatgagcgggaacgccaccggcgacgcgctgatccgggccggtgtgccgaaggactggaaggtggcggacaagagcggccaggtcaagtacggcacccggaacgacatcgccgtcgtccgcccgcccggccgcgcgccgatcgtcgtctcggtgatgagccacggcgacacccaggacgccgagccgcacgacgagctggtggccgaggccgcctccgtcgtcgccgacggtctgaagtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1290,Drugs,MEG_1290|Drugs|betalactams|Class_A_betalactamases|BLAL,664349848|WP_030877515.1|NG_050596|1|1|blaL|blaL|BlaL_family_class_A_beta-lactamase NG_050596:101-1078,0
,atcagaaaactgaaggaacctccattgaatcgaactaatattttttttggtgaatcgcattctgactggttgcctgtcagaggcggagaatctggtgattttgtttttcgacgtggtgacgggcatgccttcgcgaaaatcgcacctgcttcccgccgcggtgagctcgctggagagcgtgaccgcctcatttggctcaaaggtcgaggtgtggcttgccccgaggtcatcaactggcaggaggaacaggagggtgcatgcttggtgataacggcaattccgggagtaccggcggctgatctgtctggagcggatttgctcaaagcgtggccgtcaatggggcagcaacttggcgctgttcacagcctatcggttgatcaatgtccgtttgagcgcaggctgtcgcgaatgttcggacgcgccgttgatgtggtgtcccgcaatgccgtcaatcccgacttcttaccggacgaggacaagagtacgccgcagctcgatcttttggctcgtgtcgaacgagagctaccggtgcggctcgaccaagagcgcaccgatatggttgtttgccatggtgatccctgcatgccgaacttcatggtggaccctaaaactcttcaatgcacgggtctgatcgaccttgggcggctcggaacagcagatcgctatgccgatttggcactcatgattgctaacgccgaagagaactgggcagcgccagatgaagcagagcgcgccttcgctgtcctattcaatgtattggggatcgaagcccccgaccgcgaacgccttgccttctatctgcgattggaccctctgacttggggttga,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1019,Drugs,MEG_1019|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,1391852856|WP_109545041.1|NG_056002|1|1|aph(3'')-Ib|aph(3'')-Ib|aminoglycoside_O-phosphotransferase_APH(3'')-Ib NG_056002:101-928,2
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattaccgaaaaacacgtcaacggcacaatgacgctggcagagctgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcacagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgcaggtgataagaccggcagcggcgactacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2176,Drugs,MEG_2176|Drugs|betalactams|Class_A_betalactamases|CTX,1391852884|WP_109545069.1|NG_057483|1|1|blaCTX-M-214|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-214 NG_057483:1-876,0
,ATGGAGAAAATAATAGACATAACTGTTTTTGGCTGCGAGCCAGACGAAATGGAGGTTTTTCAAAAGATTACTTATGAGCTTGGCGTTACAGCCACACTCATAAAAGATTCTATATCAGAAAGCAATGCTAAATTAGCAGATGGATGCCGGTGTGTAAGCGTAAGCCATAAAGCGGAGCTATCAGAACCGATTCTTCTTGCACTAAAAAATGCAGGGGTAAAGTATATCAGTACCCGGAGCATTGGCTTTAACCATATTGATATACAGGCGGCCGGGTTGCTGGGTATGGTTGTTGGCACAGTAGAATACTCGCCGGGAAGTGTGGCCGATTATACCGTCATGCTGATGCTTATGCTGATGCGCGGCACAAAGTCGATTCTGCGTGAAACCCAGAGGCAGAATTATTGCCTGAATGACCTGCGCGGAAAAGAACTGCGGGATATGACCGTCGGTGTGTTAGGAACTGGGCGAATCGGACAGGCAGTCATGGAACGCCTGAAGGGATTCGGCTGTAAGGTATTGGCGTATGACCGAAATCAAAAAGCAGGAGCGGACTATGTTTCGTTTCATGAACTGCTGAAAAAAAGTGACATTGTTACACTGCATATTCCGTTGGCAGAAGATACCCGCCATATGATTGGATGTGAAGAGCTGGAAATGATGAAGCAGGAGGCGCTTCTGATCAATACAGGACGGGGCGCTTTAGTGGATACCGCAGCATTGGTAGAAGCATTAAAAGGACAGAAAATCGGCGGCGCCGCACTGGATGTTTTAGAGGGCGAAGAAGGTATCTTTTACCATGACTGCACTCAAAGAACGATAGAACATCCTTTCTTGTCTGTCCTGCAGGGAATGCCGAATGTCATTGTTACGCCGCACACGGCCTATCACACGGAGCGGGTGTTGGTTGACACGGTTAGAAATACCATTAGAAATTGTTTGAATTTTGAAAGGAGTCTGGGAAATGTTTAAGATTAAAGTTGCAGTTCTGTTTGGGGGCTGTTCAGAGGAACATAATGTTTCGATAAAATCTGCGATGGAGATTGCCGCAAACATAGATACAAAAAAATATCAGCCTTATTATATTGGAATCACAAAATCCGGCGTTTGGAAGATGTGTGAAAAACCTTGTTTGGGGTGGGAACAATATGCGGGGGATCCGGTTGTTTTTTCGCCGGACAGAAGTACGCATGGTCTGCTGATACAAAAAGACACTGGGTATGAAATCCAGCCTGTAGATGTGGTATTTCCGATGATTCATGGCAAGTTTGGCGAAGATGGATCCATACAAGGCTTGCTTGAATTGTCAGGCATTCCGTATGTGGGATGCGATATTCAAAGCTCCGTGATCTGCATGGATAAGGCGCTTGCATATACCGTTGTGAAAAATGCGGGTATCGCTGTGCCTGGGTTCCGGATCCTTCAGGAGGGGGATCGCCTGGAAACGGAGGATTTAGTATATCCCGTCTTTGTAAAGCCTGCCCGTTCTGGCTCATCCTTTGGCGTAAACAAGGTATGCAAGGCAGAAGAACTGCAGGCAGCAATCAGAGAAGCAAGAAAATATGATAGCAAGATTTTGATTGAAGAGGCCGTTACCGGGAGTGAGGTAGGCTGCGCCATACTGGGAAACGAAAATGATCTCATGGCTGGCGAGGTGGATCAGATTGAGCTGAGACACGGCTTTTTTAAGATTCATCAGGAAGCACAGCCGGAGAAGGGATCTGAAAATGCAGTTATCAGAGTTCCAGCCGCCTTACCGGATGAGGTAAGAGAACGGATTCGGAAAACAGCAATGAAGATTTACCGGATACTTGGCTGCCGAGGATTGGCCCGTATTGATCTGTTTTTGCGGGAGGACGGCTGCATTGTGCTGAATGAAGTGAATACCATGCCGGGTTTTACTTCCTACAGCCGTTATCCCCGCATGATGACAGCAGCCGGTTTTACGCTTTCTGAAATACTGGATCGCTTGATTGAATTTTCACTTAGGAGGTAACTGTTATGAAAAAGAACTTTGCCTTTTTAGATGAAATGATTCCCGGGATCCGATGGGATGCCAAATATGCCACATGGGACAATTTCACCGGGAAACCGGTAGACGGATACATGGTAAACCGTGTTATGGGAACGAAGGAGTTGGGAGTTGCTTTGCGTAAGGCTCAGAAGATGGCGGAGAAACTGGGATATGGTTTGCTCTTATGGGACGGCTATCGCCCCCAGTGCGCAGTGAATTGTTTTCTGAATTGGGCTTCCCAACCGGAAGACAATCTGACGAAAAAGCGTTACTATCCAAATATCAAAAGGAACGAGATGGTCACCAAAGGGTATGTGGCTTCCCAGTCCAGCCACAGCCGCGGAAGTGCAGTTGACCTTACGATTTTCCGTTTGGATACGGGGATGCTTGTGCCAATGGGCGGAGATTTCGACTTCATGGATGTGCGGTCACATCATGCCGCAAGCGGTCTGAGCGAAGAGGAATCAAAAAACCGGCAGTGCTTGCGTTATATCATGGAAAGCAGCGGATTTGAAGCCTATCGCTATGAATGGTGGCATTACGTCTTGGCGGACGAGCCATACCCGGATACATACTTTGATTTTTGCATTGCCTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7435,Drugs,MEG_7435|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,VanHDX_2_EU999036,5
,atgacgaaactccgccacgccaccaccggcgccttccttgccgccctggccaccttcgcccatgccgaacaccctgtctgcacgctcgttgccgacgcggccacgggcaaggtcgtcctgcaggagggcaagtgcaacgagcgcgtgacgccggcgtccaccttcaagctggcgctggccgtcatgggctacgacgccggcttcctgaaagacccgcacacgccggtcgaacacttcaggcgcggcgaccccgactggggcggccggccgtggcgccagcctgtcgacccgacgctgtggctcaagtattcggtggtctggtattcccagcgcatcacccacgcgatgggcgcgcagatgttcgcctcgtacgtgcgcaagctcgactacggcaacatggatgtgagcggcgacccgggcaagaacaacggcctggatcgctcgtggatcacctcgtcgctgaagatctcgcccgaggagcaggtcggctttctgcgccggctcgtcaaccggcagttgcccgtgtcggcgcagacgtacgagatggtcgaccgcaccgtgcagacgtggcaggtgcccggcggctgggccgtgcagggcaagacgggcacggcgggcccggcgccgggcaatacctcggccgacggcacgtgggatcaggcccacgcttatggctggtttgtcggctgggcgaagaaaggaggccggacctacgtgtttgcgaacctgatccaggacgacaagatcgagcccacctcgggcggcatccgctcgcgcgacgcgatgctggcgcgcctgccgcaggtgctggctgccgccaagccctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4549,Drugs,MEG_4549|Drugs|betalactams|Class_D_betalactamases|OXA,771608095|WP_045219048.1|NG_049729|1|1|blaOXA-443|blaOXA-22_like|OXA-22_family_class_D_beta-lactamase_OXA-443 NG_049729:1-828,0
,CCCGAGTTCAAGGACAAGGTCGCCACCCCGGCCTTCCAGGAGTACTACAGCGGCGCCATCGGCCTGTCCGAGCTGCGGACCCGCCTGGAACGCGACGGCAACCTGGTGCTCGCCCGCTACCAGCGCTGACGTAAATCCCTTTGCGCGCGACGCGGGCACCTGCCTAGCGTGCCGTCCATGGCAGCGAACAACGCGATCACGAACTCCGGTCTCGGCCGGGGCTGTGCGCACTCCGTACGGATGCGCCGTGGCCCCGGAGCCCTGACCGGCCCGGGGAGCCACACCGCCCGCTGATCGCGCGCGCGGACCGCTGTCTCCTCCCTTCTCTCTCCTGTCTTCCGGTCAGGGCCTTCGGCTGCCCTTCTCCCTCTCCACGGAAGACAAGGACCGCAGGCCATGGCCCGCCCCAGTCGCGTATCCCGCGCGCTCTCGCAGAACTTCCTCGCCGACCGCGCCGCCGCCGGACAGCTCGCCCGGCTCGCCGCGCCCCACGGCCTCCCCGTCCCGCTGCTGCTCGAAGTCGGCGCGGGCAAAGGCGCGTTGACCGAGCTGCTCGCCCCGCGCTGTCGCAGTCTCCTCGCCTACGAGATCGACCCACGGCTCGTCCCCGTCCTGCGCTCGCGCTTCGCGGACGCCCCGCACGTCCGCGTCCTCGGCGAGGACTTCCTGCGCGCCAGGGCGCCGCGCACCCCGTTCTCCGTCGCCGGGAACGTCCCCTTCTCCCGTACCGCCGCCGTCGTCGCGTGGTGTCTGCGGGCCCCGCACCTCACCGACGCCACCCTGCTCACCCAGCTGGAGTACGCCCGCAGACGCACCGGCGACTACGGCAGCTGGACGCGGCTGACCGTGCTGACTTGGCCCCGCCACGAGTGGCGGCTCGCCGGGCGGGTCGGGCGCCGCAGCTTCCGTCCCGTGCCCCGGGTGGACGCGGGGATCGTCCGTATCGAGCGGCGTCGCACCCCGCTGCTCGCGCCCGGTGCCGACGCCGGCTGGCGGGAGCTGGTCGACCTCGGCTTCTCCGGGGCCGGCGGCTCCCTGCACGCCTCGCTGCGGCGGGCCCGCCCGAGACGGCGGGTGGACGCGGCGTTCCGCGCGGCGGGGCTCGACCGGGACGTCCTGGTGGGGGAGGTGCCGCCGTGGACGTGGCTGAGGCTGCACGAGGTGCTGGGCTCGTGAATCCGGATCACAGAGCAGCCGGCGTCATGAATTCAGGTTGCACGAGACGTATCGTCTCGCCTATGGTCGAGCCCATGACCACTCCCGCACACATCGCCATGTTCTCCGTCGCCGCCCACGGGCA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2853,Drugs,MEG_2853|Drugs|MLS|23S_rRNA_methyltransferases|ERMV,erm(V)_1_U59450 ,7
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgcgaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgatgcattattggaaaagtatatcgcaggagaaccaatcagccaggaaaaacttgcgcgggaggaacagcggcgggttcaagaagcctccctgtttccggtctatcatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacaggactgttccaaccgattggggaacaggggagcgccaccctatgcggcagcgttttcaaggttgagtacaccgattgcggccagcggcgtgtctatctgcggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggcgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggatcaaacccggctccctcgtaaaaggtggcgcgaggcccccctccccatgctgcggacgacgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgctgcgaagtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggtcgtttccgctttgctgtcggaaaaatacaagattgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatctatcggactgtctgttacaccactcccgcttggctccggcgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccagtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcggggacgcagctgctggaaccttatctctccttcaccctctatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7207,Drugs,MEG_7207|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,933770025|WP_054336482.1|NG_048285|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048285:1-1920,4
,atgaccgtagtcacgaccgccgatacctcccaactgtacgcacttgcagcccgacatgggctcaagctccatggcccgctgactgtcaatgagcttgggctcgactataggatcgtgatcgccaccgtcgacgatggacgtcggtgggtgctgcgcatcccgcgccgagccgaggtaagcgcgaaggtcgaaccagaggcgcgggtgctggcaatgctcaagaatcgcctgccgttcgcggtgccggactggcgcgtggccaacgccgagctcgttgcctatcccatgctcgaagactcgactgcgatggtcatccagcctggttcgtccacgcccgactgggtcgtgccgcaggactcggaggtcttcgcggagagcttcgcgaccgcgctcgccgccctgcatgccgtccccatttccgccgccgtggatgcggggatgctcatccgtacaccgacgcaggcccgtcagatggtggccgactacgttgaccgcgtccgacgcgagttcgtggtgaacgacaagcgcctccaccggtggcagcgctggctcgacgacgattcgtcgtggccagatttctccgtggtggtgcatggcgatctctacgtgggccatgtgctcatcgacaacacggagcgcgtcagcgggatgatcgactggagcgaggcccgcgttgatgaccctgccatcgacatggccgcgcaccttatggtctttggtaaagaggggctcgcgaagctcctcctcacgtatgaaacggccggtggccgggtgtggccgcggctcgcccaccacatcgcggagcgccttgcgttcggggcggtcacctacgcactcttcgccctcgactcgggtaacgaagagtacctcgctgcggcgaaggcgcagctcgccgcagcggaatga,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4028,Drugs,MEG_4028|Drugs|MLS|Macrolide_phosphotransferases|MPHA,1028097169|WP_063853866.1|NG_047987|1|1|mph(A)|mph(A)|Mph(A)_family_macrolide_2'-phosphotransferase NG_047987:101-1006,7
,atggaaaaaaacagaaaaaaacaaatcgtagttttgagtatagctttagtttgcattttcatcttggtattttcattgttccataaatcagcgacaaaagatagcgcaaatcctcctttaacaaatgttttgactgatagcatttctcaaattgtctcagcttgtcctggcgaaattggtgtggcggttattgttaataacagagatacggttaaggccaataataagagtgtttatcctatgatgagtgtgtttaaggttcatcaggcattagctctttgtaatgactttgacaataaaggaatttcacttgataccttagtaaatataaatagggataaacttgacccaaagacttggagtcctatgctgaaagattattcagggccagtcatatcattgacagtgagagatttgctgcgttatactcttactcagagtgacaacaatgcaagcaaccttatgtttaaggatatggttaatgtcgctcaaacagatagttttatagccacactcattcctcgttcaagttttcagatagcttatacggaagaggaaatgtcggctgaccataacaaggcttactctaactatacatctcctcttggtgctgcaatgttgatgaatcggttggttactgaaggtcttatcgatgatgagaaacaaagtttcattaagaatacgttaaaagaatgcaaaacaggtgtagataggatagcagctccacttcttgataaagaaggggttgttatagcgcataagacaggttcaggttatgttaatgaaaatggtgttcttgcagctcacaatgatgttgcctatatatgtctgcctaataatatcagttataccttagcggtatttgttaaggatttcaagggaaatgaatcacaagcgtcacaatatgttgcgcatatatcagctgtagtatattctttattaatgcaaacttcagtaaaatcttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1687,Drugs,MEG_1687|Drugs|betalactams|Class_A_betalactamases|CFX,1028084273|WP_063843241.1|NG_047638|1|1|cfxA_gen|cfxA_gen|CfxA_family_class_A_broad-spectrum_beta-lactamase NG_047638:1-966,0
,gtgaaacccaacagacccctgatcgtaattctgagcactgtcgcgctcgacgctgtcggcatcggcctgattatgccggtgctgccgggcctcctgcgcgatctggttcactcgaacgacgtcaccgcccactatggcattctgctggcgctgtatgcgttggtgcaatttgcctgcgcacctgtgctgggcgcgctgtcggatcgtttcgggcggcggccaatcttgctcgtctcgctggccggcgccactgtcgactacgccatcatggcgacagcgcctttcctttgggttctctatatcgggcggatcgtggccggcatcaccggggcgactggggcggtagccggcgcttatattgccgatatcactgatggcgatgagcgcgcgcggcacttcggcttcatgagcgcctgtttcgggttcgggatggtcgcgggacctgtgctcggtgggctgatgggcggtttctccccccacgctccgttcttcgccgcggcagccttgaacggcctcaatttcctgacgggctgtttccttttgccggagtcgcacaaaggcgaacgccggccgttacgccgggaggctctcaacccgctcgcttcgttccggtgggcccggggcatgaccgtcgtcgccgccctgatggcggtcttcttcatcatgcaacttgtcggacaggtgccggccgcgctttgggtcattttcggcgaggatcgctttcactgggacgcgaccacgatcggcatttcgcttgccgcatttggcattctgcattcactcgcccaggcaatgatcaccggccctgtagccgcccggctcggcgaaaggcgggcactcatgctcggaatgattgccgacggcacaggctacatcctgcttgccttcgcgacacggggatggatggcgttcccgatcatggtcctgcttgcttcgggtggcatcggaatgccggcgctgcaagcaatgttgtccaggcaggtggatgaggaacgtcaggggcagctgcaaggctcactggcggcgctcaccagcctgacctcgatcgtcggacccctcctcttcacggcgatctatgcggcttctataacaacgtggaacgggtgggcatggattgcaggcgctgccctctacttgctctgcctgccggcgctgcgtcgcgggctttggagcggcgcagggcaacgagccgatcgctga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7019,Drugs,MEG_7019|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,1028099571|WP_063855982.1|NG_048155|1|1|tet(A)|tet(A)|tetracycline_efflux_MFS_transporter_Tet(A) NG_048155:101-1300,4
,ATGACCGACGCAACCATCCGCCACGACCACAAATTCGCCCTCGAAACCCTGCCCGTCAGCCTTGAAGACGAAATGCGCAAAAGCTATCTCGACTACGCCATGAGCGTCATTGTCGGGCGCGCGCTGCCGGACGTTCGCGACGGCCTAAAGCCGGTGCACCGGCGCGTACTGTACGCGATGCACGAGCTGAAAAATAACTGGAATGCCGCCTACAAAAAATCGGCGCGCATCGTCGGCGACGTCATCGGTAAATACCACCCCCACGGCGATTTCGCAGTTTACGGCACCATCGTCCGTATGGCGCAAAATTTCGCTATGCGTTATGTGCTGATAGACGGACAGGGCAACTTCGGATCGGTGGACGGGCTTGCCGCCGCAGCCATGCGCTATACCGAAATCCGCATGGCGAAAATCTCACATGAAATGCTGGCAGACATTGAGGAAGAAACCGTTAATTTCGGCCCGAACTACGACGGTAGCGAACACGAGCCGCTTGTACTGCCGACCCGTTTCCCCACACTGCTCGTCAACGGCTCGTCCGGTATCGCCGTCGGTATGGCGACCAACATCCCGCCGCACAACCTCACCGACACCATCAACGCCTGTCTGCGTCTTTTGGACGAACCCAAAACCGAAATCGACGAACTGATCGACATTATCCAAGCCCCCGACTTCCCGACCGGGGCAACCATCTACGGCTTGGGCGGCGTGCGCGAAGGCTATAAAACAGGCCGCGGCCGCGTCGTTATGCGCGGTAAGACCCATATCGAACCCATAGGCAAAAACGGCGAACGCGAAGCCATCGTTATCGACGAAATCCCCTATCAGGTCAACAAAGCCAAGTTGGTCGAGAAAATCGGCGATTTGGTTCGGGAAAAAACGCTGGAAGGCATTTCCGAGCTCCGCGACGAATCCGACAAATCCGGGATGCGCGTCGTTATCGAGCTGAAACGCAACGAAAATGCCGAAGTCGTCTTAAACCAACTCTACAAACTGACTCCGCTGCAAGACAGTTTCGGCATCAATATGGTTGTTTTGGTCGACGGACAACCGCGCCTGTTAAACCTGAAACAGATTCTCTCCGAATTCCTGCGCCACCGCCGCGAAGTCGTTACCCGACGTACGCTTTTCCGGCTGAAGAAGGCACGCCATGAAGGGCATATCGCCGAAGGCAAAGCCGTCGCACTGTCCAATATCGATGAAATCATCAAGCTCATCAAAGAATCGCCCAACGCGGCCGAGGCCAAAGAAAAACTGCTTGCGCGCCCTTGGCGCAGCAGCCTCGTTGAAGAAATGCTGACGCGTTCCGGTCTGGATTTGGAAATGATGCGTCCGGAAGGATTGGCTGCAAACATTGGTCTGAAAAAACAAGGTTATTACCTGAGCGAGATTCAGGCAGATGCTATTTTACGCATGAGCCTGCGAAACCTGACCGGCCTCGATCAGAAAGAAATTATCGAAAGCTACAAAAACCTGATGGGTAAAATCATCGACTTTGTGGATATCCTCTCCAAACCCGAACGCATTACCCAAATCATCCGTGACGAACTGGAAGAAATCAAAACCAACTATGGCGACGAACGCCGCAGCGAAATCAACCCGTTCGGCGGCGACATTGCCGATGAAGACCTGATTCCGCAACGCGAAATGGTCGTGACCCTGACCCACGGCGGCTATATAAAAACCCAGCCGACCACCGACTATCAGGCTCAGCGTCGCGGCGGGCGCGGCAAACAGGCGGCTGCCACCAAAGACGAAGACTTTATCGAAACCCTGTTTGTTGCCAACACGCATGACTATTTGATGTGTTTTACCAACCTCGGCAAGTGCCACTGGATTAAGGTTTACAAACTGCCCGAAGGCGGACGCAACAGCCGCGGCCGTCCGATTAACAACGTCATCCAGCTGGAAGAAGGCGAAAAAGTCAGCGCGATTCTGGCAGTACGCGAGTTTCCCGAAGACCAATACGTCTTCTTCGCCACCGCGCAGGGAATGGTGAAAAAAGTCCAACTTTCCGCCTTTAAAAACGTCCGCGCCCAAGGCATTAAAGCCATCGCACTCAAAGAAGGCGACTACCTCGTCGGCGCTGCGCAAACAGGCGGTGCGGACGACATTATGTTGTTCTCCAACTTGGGCAAAGCCATCCGCTTCAACGAATACTGGGAAAAATCCGGCAACGACGAAGCGGAAGATGCCGACATCGAAACCGAGATTTCAGACGACCTCGAAGACGAAACCGCCGACAACGAAAACACCCTGCCAAGCGGCAAAAACGGCGTGCGTCCGTCCGGTCGCGGCAGCGGCGGTTTGCGCGGTATGCGCCTGCCTGCCGACGGCAAAATCGTCAGCCTGATTACCTTCGCCCCTGAAACCGAAGAAAGCGGTTTGCAAGTTTTAACCGCCACCGCCAACGGATACGGAAAACGCACCCCGATTGCCGATTACAGCCGCAAAAACAAAGGCGGGCAAGGCAGTATTGCCATTAACACCGGCGAGCGCAACGGCGATTTGGTCGCCGCAACCTTGGTCGGCGAAACCGACGATTTGATGCTGATTACCAGCGGCGGCGTGCTTATCCGTACCAAAGTCGAACAAATCCGCGAAACCGGCCGCGCCGCAGCAGGCGTGAAACTGATTAACTTGGACGAAGGCGAAACCTTGGTATCGCTGGAACGTGTTGCCGAAGACGAATCCGAACTCTCCGGCGCTTCTGTAATTTCCAATGTAACCGAACCGGAAGCCGAGAACTGA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3194,Drugs,MEG_3194|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|193932879|gb|CP001050.1|1051396-1054146,3
,atgaccaccacacgccccgcgtgggtctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatactggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcaccttcttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtggattgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2911,Drugs,MEG_2911|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,1028086691|WP_063845065.1|NG_047867|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047867:101-1315,6
,atgaattatcaaattgtgaatattgcggaatgcagcaattaccagttagaagcagcaaatatactaacagaagcgttcaatgatcttggtaacaattcatggccagatatgacgagtgcaacaaaagaagtaaaagaatgtattgagagtccaaacctttgtttcggtctgctaataaataactccttagttggctggataggcttaaggccaatgtacaaggaaacctgggaattgcatccattggttatcagaccagattatcaaaataaaggtattggcaagatcctgcttaaggaattagaaaacagagctagagagcaaggtattattggaatcgctttaggaacagatgatgaatactatagaacaagtctctctttaataactataacagaagataatatatttgattcaataaaaaatattaaaaatattaataaacatccatatgagttttatcagaagaatggttattatattgttggaataattccaaatgccaatggtaaaaacaaaccagatatttggatgtggaaaagtttaatcaaagagtaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_121,Drugs,MEG_121|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,970308038|WP_058677876.1|NG_052217|1|1|aac(6')-Ia|aac(6')-Ia|aminoglycoside_6'-N-acetyltransferase_AAC(6')-Ia NG_052217:101-658,2
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTACAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAACAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTATTCCAAAAGACTATAAAGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1404,Drugs,MEG_1404|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_62_NZ_JVOH01000023,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTTGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6604,Drugs,MEG_6604|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|695212668|ref|NG_036469.1|1925-1086,8
,ATGAGGGAAGCGGTGATCGCCGAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCACACAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACGTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAGTTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATTGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAGAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGTCCTCGCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_950,Drugs,MEG_950|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|18650777|emb|AJ310480.1|2065-2856 gi|8546572|emb|AJ243491.1|2002-2793,2
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATAGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6891,Drugs,MEG_6891|Drugs|betalactams|Class_A_betalactamases|TEM,gi|223006550|emb|AM941159.1|1-1092,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgagacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagggagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_812,Drugs,MEG_812|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502123|WP_071846275.1|NG_052320|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052320:101-892,2
,gtgatcgacagcgcgcccatgatccgccaggccacgccggccgatgcggccgcatgggcgcggttgcgtctcggcctgtggactgatgccgatgatccgctggaggagctgacgcagtcgctggcagatgccgaaggtgctgtgttcttggcctgtgccgcggatggcgagacggttggtttcgctgaagtgcgcctgcgccatgactacgtgaacggtaccgagtcttcgccggtggggttcctggagggctggtacgtgcagccgcagtggcaaggcagcggcgtcggccgcgccctgctggcggcggtgcaggcgtggacgcgcgatgcgggctgccgcgaactggcttcggacagtcgcgtggaggacgtgcaggctcacgccgcgcatcgggcctgcggcttcgaagagaccgaacgggtcgtctatttccgcatgccgctggagccatcggcgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_259,Drugs,MEG_259|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,501457566|WP_012481011.1|NG_052343|1|1|aac(6')-Iz|aac(6')-Iz|aminoglycoside_N-acetyltransferase_AAC(6')-Iz NG_052343:1-462,2
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCTAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACATTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1945,Drugs,MEG_1945|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KP981366.1|+|0-1146|ARO:3004778|CMY-135 [Citrobacter freundii] ,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatatccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgtatcgaacacgcttgtgaggccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacgttgtttttgcgatctattggcgacaacgcaacgcgacttgaccgattggagccccgtttaaacgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgctatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcagctgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1499,Drugs,MEG_1499|Drugs|betalactams|Class_A_betalactamases|CARB,647460046|WP_025794721.1|NG_048746|1|1|blaCARB-43|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-43 NG_048746:1-852,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcatcgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagtttcccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5550,Drugs,MEG_5550|Drugs|betalactams|Class_C_betalactamases|PDC,1304472400|WP_100931732.1|NG_056056|1|1|blaPDC-222|blaPDC|class_C_beta-lactamase_PDC-222 NG_056056:1-1194,0
,atgaaaaaatttatacttcctatcttcagcatttctattctactttctctcagtgcatgctcatctattcaaaataaatttgaatatacttctgatatttctgatcagcagcatggaaaagccattaaaagctattttgatgaagctcagacacaaggtgtaatcattattaaagagggaaagaatattagtacctatggtaataacctggcacgagcacatacagaatatgtccctgcatcaacatttaagatgctaaatgccttaattggattagaaaatcataaagctacaacaactgagattttcaaatgggatggtaaaaaaagatcttatcctatgtgggaaaaagatatgactttaggtgatgccatggcactttcagcagttcctgtatatcaagaacttgcaagacggactggtttagacctaatgcaaaaagaagtcaaacgggttggttttggtaatatgaacattggaacacaagttgataacttctggttggttggcccgcttaaaattacaccaatacaagaggttaattttgccgacgatctcgctaataatcgattaccctttaaattagaaactcaagaagaagtaaaaaaaatgcttctgattaaagaagtcaatggtagtaaaatttatgcgaaaagcggatggggaatggatgtaacccctcaggtaggttggttaacaggttgggtagaaaaatctaatggcgaaaaagttcccttttctctaaacctagaaatgaagcaaggaatgtctggttctattcgtaatgaaattacttataagtcattagaaaatttagggattatatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4407,Drugs,MEG_4407|Drugs|betalactams|Class_D_betalactamases|OXA,1391852886|WP_109545071.1|NG_057485|1|1|blaOXA-649|blaOXA-143_like|OXA-143_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-649 NG_057485:1-828,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacggttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1797,Drugs,MEG_1797|Drugs|betalactams|Class_C_betalactamases|CMY,446899257|WP_000976513.1|NG_048825|1|1|blaCMY-30|blaCMY|class_C_extended-spectrum_beta-lactamase_CMY-30 NG_048825:101-1246,0
,GATGTGTCATAGTATTCGTCGTTAGAAAACAATTATTATGACATTATTTCAATGAGTTATCTATTTTTGTCGTGTACAGAGCTCTTTTTTATTTTCTATTGATCTGGTGTTTAAAATGAATAAATATTTTACTTGCTATGTGGTTGCTTCTCTTTTTCTTTCTGGTTGTACGGTTCAGCATAATTTAATAAATGAAACCCCGAGTCAGATTGTTCAAGGACATAATCAGGTGATTCATCAATACTTTGATGAAAAAAACACCTCAGGTGTGCTGGTTATTCAAACAGATAAAAAAATTAATCTATATGGTAATGCTCTAAGCCGCGCAAATACAGAATATGTGCCAGCCTCTACATTTAAAATGTTGAATGCCCTGATCGGATTGGAGAACCAGAAAACGGATATTAATGAAATATTTAAATGGAAGGGCGAGAAAAGGTCATTTACCGCTTGGGAAAAAGACATGACACTAGGAGAAGCCATGAAGCTTTCTGCAGTCCCAGTCTATCAGGAACTTGCGCGACGTATCGGTCTTGATCTCATGCAAAAAGAAGTAAAACGTATTGGTTTCGGTAATGCTGAAATTGGACAGCAGGTTGATAATTTCTGGTTGGTAGGACCATTAAAGGTTACGCCTATTCAAGAGGTAGAGTTTGTTTCCCAATTAGCACATACACAGCTTCCATTTAGTGAAAAAGTGCAGGCTAATGTAAAAAATATGCTTCTTTTAGAAGAGAGTAATGGCTACAAAATTTTTGGAAAGACTGGTTGGGCAATGGATATAAAACCACAAGTGGGCTGGTTGACCGGCTGGGTTGAGCAGCCAGATGGAAAAATTGTCGCTTTTGCATTAAAAATGGAAATGCGGTCAGAAATGCCGGCATCTATACGTAATGAATTATTGATGAAATCATTAAAACAGCTGAATATTATTTAAGAGCTTGACAGAAACTCTAATTTTATAAAAAGCCCATTTGAGATAAATGGGCCTTTTATAATCTGACTAATAATGAAACCTGTTAATTTTTCTAGTTTAAAATTTTACAGTGCTTTTAGTTGTTG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5225,Drugs,MEG_5225|Drugs|betalactams|Class_D_betalactamases|OXA,gi|56684452|gb|AY762325.1|1-1062 gi|939559781|gb|CP012952.1|1232386-1232467 gi|939559781|gb|CP012952.1|2561141-2561222 gi|939559781|gb|CP012952.1|2743155-2743074 gi|939559781|gb|CP012952.1|1035980-1036060 gi|939559781|gb|CP012952.1|1312277-1312197 gi|939559781|gb|CP012952.1|1549317-1549237 gi|939559781|gb|CP012952.1|1673965-1673885 gi|939559781|gb|CP012952.1|1976686-1976766 gi|939559781|gb|CP012952.1|2359896-2359816 gi|939559781|gb|CP012952.1|3581430-3581510 gi|939559781|gb|CP012952.1|3705318-3705238 gi|939559781|gb|CP012952.1|3838592-3838512 gi|939559781|gb|CP012952.1|3855125-3855045 gi|693578048|dbj|AP014649.1|718278-718359 gi|693578048|dbj|AP014649.1|477947-477867 gi|693578048|dbj|AP014649.1|2686880-2686960 gi|693578048|dbj|AP014649.1|2905183-2905103 gi|693578048|dbj|AP014649.1|3755940-3755860 gi|984881271|gb|CP014215.1|432616-432696 gi|984881271|gb|CP014215.1|2332338-2332258 gi|984881271|gb|CP014215.1|2825934-2826014 gi|984881271|gb|CP014215.1|3326705-3326785 gi|984686374|gb|HQ700358.2|8155-8235 gi|974022331|gb|CP013924.1|914680-914600 gi|974022331|gb|CP013924.1|1418214-1418294 gi|974022331|gb|CP013924.1|3335874-3335794 gi|884906331|gb|CP012008.1|45430-45350 gi|884902522|gb|CP012006.1|3691827-3691747 gi|827403829|gb|CP010779.1|3022167-3022087 gi|730910803|gb|KM977710.1|29944-30024,0
,atgagatcagaaaaagaaatgatggatttagtactttctttagcagaacaggatgaacgtattcgaattgtgacccttgaggggtcacgcgcaaatattaatatacctaaagatgaatttcaggattatgatattacatattttgtaagtgatatagaaccgtttatatctaatgatgactggcttaatcaatttgggaatataataatgatgcaaaagccggaggatatggaattattcccacctgaagaaaagggattttcctatcttatgctatttgatgattacaataaaattgatcttaccttattgcccttggaagagttagataattacctaaagggcgataaattaataaaggttctaattgataaagattgtagaattaaaagggacatagttccgactgatatagattatcatgtaagaaagccaagcgcaagggagtatgatgattgctgcaatgaattttggaatgtaacaccttatgttattaaaggattgtgccgtaaggaaattttatttgctattgatcattttaatcagattgttcgccatgagctgctgagaatgatatctaggaaggtcggcatcgaaacaggctttaaattaagtgtaggcaagaactataagtttattgaaaggtatatatccgaggatttgtgggagaaacttttgtccacctaccggatggattcctatgaaaacatatgggaagcattatttctatgccatcaattgttcagggcggtatccggtgaggtggcggaaaggcttcattatgcctatccggagtatgataggaatataacaaaatataccagggacatgtataaaaaatacactggtaaaaccggctgcctggatagcacatatgccgctgatatagaagagaggcgggaacagtga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_986,Drugs,MEG_986|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,695269602|WP_032491779.1|NG_047394|1|1|ant(6)-Ia|ant(6)-Ia|aminoglycoside_nucleotidyltransferase_ANT(6)-Ia NG_047394:101-1009,2
,TTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGCTTCACTCACACGAATTGAATGTTCAGGGGATTAGGATGATGAGAAAAAGCGTAAGGCGGGCGATGTTAATGACGACAGCCTGTGTTTCGCTGCTGTTGGCCAGTGTGCCGCTGTGTGCCCAGGCGAACGATGTTCAACAAAAGCTCGCGGCGCTGGAGAAAAGCAGCGGGGGACGACTGGGTGTGGCGTTGATTAACACCGCCGATAACACGCAGACGCTCTACCGCGCCGACGAGCGTTTTGCCATGTGCAGCACCAGTAAAGTGATGGCGGTAGCGGCGGTGCTTAAGCAAAGTGAAACGCAAAAGGGCTTGTTGAGTCAGCGGGTTGAAATTAAGCCCTCAGACTTGATTAACTACAACCCCATTGCGGAAAAACACGTCAATGGCACGATGACATTCGGGGAGTTGAGCGCGGCGGCGCTACAGTACAGCGATAATACTGCCATGAATAAGCTGATTGCCCATCTCGGGGGGCCGGATAAAGTGACGGCATTTGCCCGTACGATTGGCGATGACACGTTCCGGCTCGATCGTACCGAGCCGACGCTCAACACCGCGATCCCCGGCGACCCGCGCGATACCACCACGCCGTTAGCGATGGCGCAGGCTCTGCGCAATCTGACGTTGGGCAATGCCCTGGGTGACACTCAGCGTGCGCAGCTGGTGATGTGGCTGAAAGGCAACACCACCGGCGCTGCCAGCATTCAGGCAGGGCTACCCACATCGTGGGTTGTCGGGGATAAAACCGGCAGCGGCGGTTATGGTACGACGAATGATATCGCGGTTATTTGGCCGGAAGGTCGCGCGCCGCTCGTTCTGGTGACTTACTTCACCCAGTCGGAGCCGAAGGCAGAGAGCCGTCGTGACGTGCTCGCTGCTGCCGCCAGAATTGTCACCGACGGTTATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2409,Drugs,MEG_2409|Drugs|betalactams|Class_A_betalactamases|CTX,gi|657224404|gb|KF056330.2|145961-146976 gi|37789822|gb|AF518567.2|2181-3196,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcgaccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggctacggcaatgcggacgtctcgggcgagcccggcaagcataacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaagctggtgaatcggcaattgccggtcaaggccgccgcctatgagcttgccgaaaacctcttcgaggcgggccaggccgatggctggcgcctgtatggcaagaccggcaccgggtcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccggcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4536,Drugs,MEG_4536|Drugs|betalactams|Class_D_betalactamases|OXA,1625655405|WP_136512082.1|NG_064745|1|1|blaOXA-114x|blaOXA-114_like|class_D_beta-lactamase_OXA-114x NG_064745:1-828,0
,atgaaaaaacggattaccccattttcccgctttgcatcaaaaggccttttcgcctgtagcacaggcatgttgctggtgacggtggcacatgctgccaatacagcagcagccggcatggatgccatgatacaaaccgtgatgcaggcacaccagattccgggcatggccattgccatcatccagtcaggcaagaccacttatcacaattatggtgtcgcctcccgcgaaaccggccagccggtccgggaaaccaccctgtttgaaatcggctccctttccaaaccgtttactgcactgatcgcccagcgggctgaaaccgaaggccggattgacctgtctgcaccggccagccgctacgttaccgccctgcggggcagtgcattcgaccggatcaccctcaggcagctcggtacttatagcgcaggcggattaccgctccagtttcctgacaatgtcaccaccccggcagatgtgctggcttattaccggcattggcaacctgtccatccggcaggcaccacccggctgtattccaatccgagcattggcctgatggggctggctgccagcctggcaaccggagagtcctttgccggcctgctcgggacaacggtgctgcaacccctcggcatgaactcgacctatctgcaaatgcccccggaggcccgttcacgttatgccatgggttataccgccgccgggaaaccggtcagggtcaaccccggtccgctggatgaggaaacctacggcgtcaagtccacaaccgcagacatggccggatttttattggcgcatatggaccctgcacgcagcaaaggtgcattgcggtcggcattacagcaaacacgtgtaccggtttattgcgccggacagacccggcaaggactgggctgggaaagttatcaagactggaaaaacctcgacgtgctgctggcgggaaattcaaatcaaatggtgtttgagccgcagccggtgaaagcctgtcctgccggcaccatgaatgagcccgatgtgtgggtcaacaagaccggttctactgcgggattcggcgcttatgccgtattcctgcctgcccgacaaaccggcattgtcatcctggccaaccgtaattacccgattgcagaccgtatccggctcgctcacggaattttgaccgcattgcactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3585,Drugs,MEG_3585|Drugs|betalactams|Class_A_betalactamases|LHK,1175118064|WP_081666691.1|NG_056482|1|1|blaLHK-1|blaLHK|class_C_beta-lactamase_LHK-1 NG_056482:1-1167,0
,ATGACTCTGGCATTAGTTAGCGAAAAAATTGACAGAAACCGCTTCACCGGGGAAAAAGTTGAAAACAGTACTTTTTTTAACTGTGATTTTTCAGGGGCCGATCTTAGCGGCACTGAATTTATCGGCTGTCAGTTTTATGATCGTGAAAGCCAGAAAGGGTGTAATTTTAGTCGCGCAATGCTGAAAGATGCCATTTTTAAAAGTTGCGATTTATCCATGGCGGATTTTCGCAACGCCAGTGCCCTGGGAATTGAAATTCGCCACTGCCGCGCGCAGGGTTCAGATTTTCGCGGCGCGAGTTTTATGAACATGATCACCACGCGGACCTGGTTTTGCAGCGCATACATCACGAATACCAATCTAAGCTACGCCAACTTTTCGAAGGTTGTCCTGGAAAAGTGCGAGCTGTGGGAAAACCGCTGGATGGGAACTCAGGTAGCGGGTGCAACGTTCAGTGGATCAGATCTCTCGGGCGGTGAATTTTCAGCGTTCGACTGGCGGGCCGCAAACTTCACGCACTGTGATTTGACCAATTCAGAACTGGGTGATTTAGATATTCGGGGTGTAGATTTACAAGGCGTCAAATTGGATAGCTATCAGGCAGCGTTGCTGATGGAGCGGCTTGGCATCGCGGTGATTGGCTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5997,Drugs,MEG_5997|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gi|695224415|ref|NG_041069.1|1-645,3
,AGGAGATGGTTTCGTGCGCTCAAAAAATTTTAGTTGGCGGTACTCCCTTGCCGCCACGGTGTTGTTGTTATCACCGTTCGATTTATTGGCATCACTCGGCATGGACATGTACTTGCCGGCAGTGCCGTTTATGCCAAACGCGCTTGGTACGACAGCGAGCACAATTCAGCTTACGCTGACAACGTACTTGGTCATGATTGGTGCCGGTCAGCTCTTGTTTGGACCGCTATCGGACCGACTGGGGCGCCGCCCCGTTCTACTGGGAGGTGGCCTCGCCTACGTTGTGGCGTCAATGGGCCTCGCTCTTACGTCATCGGCTGAAGTCTTTCTGGGGCTTCGGATTCTTCAGGCTTGTGGTGCCTCGGCGTGCCTTGTTTCCACGTTTGCAACAGTACGTGACATTTACGCAGGTCGCGAGGAAAGTAATGTCATTTACGGCATACTCGGATCCATGCTGGCCATGGTCCCGGCGGTAGGCCCATTGCTCGGAGCGCTCGTCGACATGTGGCTTGGGTGGCGGGCTATCTTTGCGTTTCTAGGTTTGGGCATGATCGCTGCATCTGCAGCAGCGTGGCGATTCTGGCCTGAAACCCGGGTGCAACGAGTTGCGGGCTTGCAATGGTCGCAGCTGCTACTCCCCGTTAAGTGCCTGAACTTCTGGTTGTACACGTTGTGTTACGCCGCTGGAATGGGTAGCTTCTTCGTCTTTTTCTCCATTGCGCCCGGACTAATGATGGGCAGGCAAGGTGTGTCTCAGCTTGGCTTCAGCCTGCTGTTCGCCACAGTGGCAATTGCCATGGTGTTTACAGCTCGTTTTATGGGGCGTGTAATACCCAAGTGGGGCAGCCCAAGCGTCTTGCGAATGGGAATGGGATGCCTGATAGCTGGAGCAGTATTGCTTGCCATCACCGAAATATGGGCTTCGCAGTCCGTGTTAGGCTTTATTTCTCCAATGTGGCTAGTGGGTATTGGTGTCGCCACAGCGGTATCTGTGGCGCCCAATGGCGCTCTTCGAGGATTCGACCATGTTGCTGGAACGGTCACGGCAGTCTACTTCTGCTTGGGCGGTGTACTGCTAGGAAGCATCGGAACGTTGATCATTTCGCTGTTGCCGCGCAACACGGCTTGGCCGGTTGTCGTGTACTGTTTGACCCTTGCAACAGTCGTGCTCGGTCTGTCTTGTGTTTCCCGAGCGGAGGGCTCTCGCGGCCAGGGGGAGCATGATGTGGTCGCGCTACAAAGTGCGGAAAGTACGTCAAATCCCAATCGTTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1769,Drugs,MEG_1769|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,gi|765098769|dbj|LC031883.1|7518-8790 gi|364524682|gb|JN108884.1|915-2187 gi|335335057|gb|HQ634775.2|4055-5327 gi|330885969|gb|HQ880268.1|917-2189 gi|330885964|gb|HQ880266.1|923-2195 gi|330885950|gb|HQ880261.1|922-2194 gi|308826678|emb|FQ482074.1|78423-77151 gi|225217195|gb|FJ716798.1|889-2161 gi|27462652|gb|AF458080.1|1492-2764 gi|63147351|dbj|AB212941.1|949-2221,6
,atgaatattatgccgatatctgaatcacaattatcagattggctacagctaagaagcttgctttggcctgatcatgaagatgcgcatttagtggaaatgcgtcagttacttacacgaacagatactttgcagttattggcatattcagaaatgcaacagccgattgcaatgttagaagcatcaattcgacatgaatatgtgaacggtacgcaaacttcacctgtggcatttctggaagggatttatgtcctgcctgaacatcgacgttcaggtattgccactcaattgattcaacaagtagaacaatgggcaaaacaatatgcatgtactgaatttgcttcagatgcagcaattgataataccatcagtcatgcaatgcatcaggccttaggttttcatgaaactgaacgcgtggtttatttcaagaaaaatatcagttag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_77,Drugs,MEG_77|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491287000|WP_005145021.1|NG_052399|1|1|aacA-ACI7|aacA-ACI7|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052399:101-541,2
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaatgaaacccagagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaagcagataaaaaaattaatctgtatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttaccggttgggaaaaagacatgacactaggagaagccatgaagctttccgcagtcccagtctatcaggaacttgcgcgacgtatcggtcttgatctcatgcaaaaagaagtaaaacgtattggtttcggtaatgctgaaattggacagcaggttgataatttctggttggtagggccattaaaggttacgcctattcaagaggtagagtttgtttctcaattggcgcatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgcttcttttagaagagagtaatggctacaaaatttttggaaagaccggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcacttttgcattaaatatggaaatgcggtcagaaatgcctgcatctatacgtaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4522,Drugs,MEG_4522|Drugs|betalactams|Class_D_betalactamases|OXA,491547999|WP_005405613.1|NG_064772|1|1|blaOXA-814|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-814 NG_064772:1-822,0
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggcatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgcgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcagttgtgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgctttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccactgagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagccagcgtattgtcaaacaagccatgctgaccgaagccaatagcgactatattattcgggctaaaacgggatactcgactagaatcgaacctaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggaaaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4620,Drugs,MEG_4620|Drugs|betalactams|Class_D_betalactamases|OXA,1226997327|WP_094009804.1|NG_055476|1|1|blaOXA-515|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-515 NG_055476:1-798,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5537,Drugs,MEG_5537|Drugs|betalactams|Class_C_betalactamases|PDC,489213196|WP_003121934.1|NG_049901|1|1|blaPDC-3|blaPDC|class_C_extended-spectrum_beta-lactamase_PDC-3 NG_049901:101-1294,0
,atgatttataacattattaacattgctgattctgaaaagaacaaggaagacgctgcgcaaattctatattctgcatttcgcggaaagggaaaagatgcttggcctacattagattcagctcgtgaagaaatagcagagtgcatagcaagtcctaatatttgcttaggcataaccttagatgatcgcttagtagggtggggcggacttcgtcccatgtatgaaaccacatgggaattgcatcccttagtaatagatcctgattatcaaggtaatggattaggaaaactgctcctatcaaagattgagagcactgcaaccacaaatagaataattggaataatgcttggaacagatgatgagacattgagtacaagtctttcaatgactgatatagatgagtctaatattttccaagagataaaaaatataattaatataaagaatcatccatttgaattttataaaaaatgcgggtacatcattgttgggatagtacctaacgcaaatgggtatagaaaacctgacatttggatgtggaagaatctagaaaagaaaagtggctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_175,Drugs,MEG_175|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502226|WP_071846376.1|NG_052508|1|1|aacA43|aacA43|AAC(6')-Ia_family_aminoglycoside_6'-N-acetyltransferase_AacA43 NG_052508:101-664,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaacctttattagataaatatgatgtgccgggtatggccgtgggtgttattcagaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctcggttcagttagtaaattatttaccgctacagcaggtggatatgccaaaacaaaaggaacaatttcttttaaagacacaaccggaaaatattggaaagaattaaaaaacacaccaattgaccaagttaacttacttcaacttgctacttatacgagtggcaaccttggcttacagtttccagatgaagtccaaacagatcagcaagttttaacttttttcaaagactggaagcctaaaaactcaatcggtgaatatcgacaatattcaaatccaagcattggtttatttggaaaagttgttgcattgtctatgaataaacctttcgaccaactcttagaaaaaacaatttttccagatcttggcttaaaacatagctatgtaaatgtaccgaagacccagatgcaaaactatgcttttggctataatcaagaaaatcagccaattcgtgttaaccctggtccgttagatgcacctgcgtacggcgtcaaatcgacactacccgatatgcttaagtttattaatgccaacctcaacccacagaaatatccgaaagatattcaacgtgcaattaatgaaacacatcagggtttctatcaagtcggcaccatgtatcaggcacttggttgggaagaattttcttatccagcgcctttacaaactttattagacagtaattcagaacaaattgtgatgaagcctaataaagtgactgccatttcaaaagaaccttcagttaagatgttccacaaaactggttcaaccaatggtttcggaacttatgtcgtgtttattcctaaagaaaatattggcttagtcatgttgaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcggtgttaaatgcaataaaaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_534,Drugs,MEG_534|Drugs|betalactams|Class_C_betalactamases|ADC,1058243616|WP_068981618.1|NG_051450|1|1|blaADC-86|blaADC|class_C_beta-lactamase_ADC-86 NG_051450:1-1152,0
,atgaaaatcgtaaaaaggatattattagtattgttaagtttattttttacagttgagtattcaaatgctcaaactgacaacttaactttgaaaattgagaatgttttaaaggcaaaaaatgccagaataggagtagcaatattcaacagcaatgagaaggatactttgaagattaataacgacttccatttcccgatgcaaagcgttatgaaatttccgattgctttagccgttttgtctgagatagataaagggaatctttcttttgaacaaaaaatagagattacccctcaagaccttttgcctaaaacgtggagtccgattaaagaggaattccctaatggaacaactttgacgattgaacaaatactaaattatacagtatcagagagcgacaatattggttgtgatattttgctaaaattaatcggaggaactgattctgttcaaaaattcttgaatgctaatcatttcactgatatttcaatcaaagcaaacgaagaacaaatgcacaaggattggaatacccaatatcaaaattgggcaaccccaacagcgatgaacaaactgttaatagatacttataataataagaaccaattactttctaaaaaaagttatgattttatttggaaaattatgagagaaacaacagcaggaagtaaccgattaaaaggacaattaccaaagaatacaattgttgctcataaaacagggacttccggaataaataatggaattgcagcagccactaatgatgttggggtaattactttaccgaatggacaattaatttttataagcgtatttgttgcagagtccaaagaaacttcggaaattaatgaaaagattatttcagacattgcaaaaataacgtggaattactatttgaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7650,Drugs,MEG_7650|Drugs|betalactams|Class_A_betalactamases|VEB,1028110881|WP_063865152.1|NG_050320|1|1|blaVEB-12|blaVEB|class_A_extended-spectrum_beta-lactamase_VEB-12 NG_050320:1-900,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5516,Drugs,MEG_5516|Drugs|betalactams|Class_C_betalactamases|PDC,1343491226|WP_104009842.1|NG_056401|1|1|blaPDC-246|blaPDC|class_C_beta-lactamase_PDC-246 NG_056401:1-1194,0
,ttgaaaaatagaaataaaaccagtcatgaagatgactatttactttttaaaaacagattgtccgttaaaatattgcttatgatggtatattccattctaattattgcgggtgtttatctgtttatcttaaaagataattttgcaaatgtcgtggtagccattttagacagctttatctatcatgatcgggatgaggcggtggctgtttatctgagaacctttaaggcgtatgagatatggcttttcctgatagcggttatgggcgtgttttttatgatcttccgccgttatctggacagtatttcaaaatattttaaggagatcaaccgggggatcgatactttggtgaatgaggatgccaacgatattgggctgcctccggagttggcttcgaccgaaagaaaaatcaattccatacggcataccctgacgaaacggaaaacggacgctgagcttgcagagcaaaggaaaaacgatcttgtcatgtatctggtccatgacctgaagaccccgctttcatcggtcataggatatttgaacctgttaagggatgagaatcagatttccgaggaactcagggaaaaatatttgtccatatcattggataaggctgagcgtctggaagaactgatcaatgagttttttgaaattacgaggtttaatctttcaaacatcacgcttgtgtacagcaaaatcaatctgacgatgatgctggaacagctggggcacgagtttaagccgatgctggctgggaaaaatctgatatgtgaatttgatgttcagccggacatgatgctgtcctgtgatgccaacaagctgcagcgggtgttcgataatgtgctgagaaatgccgtcagttactgctatgagaataccaccattcgggtgaaagccaggcagaccgaagaccatgtactcatccaaatcataaacgaaggggatacgattcctggggagagattggaaagaatctttgagcagttttaccgcctggatgtatctcgaagctcaagtaccggcggggccggtctggggcttgccattgcaaaagagattgtggaactgcaccatggacagatcactgcccgcagcgaaaatggtatcaccagttttgaggttgcattgcccgtcgtaggaaaatcgtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7506,Drugs,MEG_7506|Drugs|Glycopeptides|VanD-type_regulator|VANSD,655082055|WP_028530133.1|NG_048445|1|1|vanS-D|vanS-D|VanD-type_vancomycin_resistance_histidine_kinase_VanS NG_048445:101-1246,5
,atgcgttcgttcgccatatcgactgtgttggtgatgtcctcactgttagcgtcgtcaatcattgccgccccgacttttgcctcaacagcggtgaagaaggagtggcaagaaacccgcagttgggatgccatttttactcagcaccaagttgaaccgcaacaagctaagcaacaacaagctaaaccgcaaaaaactaagtcccaacaaacctcgggcgtggtagcactatggaacgaaaacaagcaacagggatataccaacaatcttaaacgtgccaatcaaggttttttacctgcatcgacctttaaaatccctaacagtttgattgcgcttgatctcggtgtggtgaaggatgaacatcaagtgtttaagtgggatggtaaaagccgtgatattgccacttggaatcgtgaccacaacttgattaccgggatgaagtattcggtggtgccagtctatcaagagtttgcccgccaaattggtgaggcgcgaatgtcgaagatgatcgcctctttcgattatggtaatgaggatatctcgggtaacttagatagcttttggcttgatggtggtattcggatatcggccactgagcaaatcgatttcctgcgccgactttattacaacaaaatacacgcttcagagcgcagtcaacgcatcgttaagcaagccatgctcaccgaggcgaattctgattatattatccgcgcaaaaaccggttatgcggtcagagctgagccaagcattggctggtgggttggttggatagaactcgatgataatgtgtggttttttgcaatgaatatggatatccctgatgccgcaggtttgccattgcgccaagccattactaaagaagtattaaaactggaacacgtaattccttag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4623,Drugs,MEG_4623|Drugs|betalactams|Class_D_betalactamases|OXA,1201190424|WP_087587944.1|NG_054958|1|1|blaOXA-553|blaOXA-548_like|OXA-548_family_class_D_beta-lactamase_OXA-553 NG_054958:1-888,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6496,Drugs,MEG_6496|Drugs|betalactams|Class_A_betalactamases|SHV,gi|970339223|gb|CP013711.1|4593419-4592559 gi|562889804|gb|KF585136.1|48-908 gi|259089732|gb|GQ463148.1|3276-4136 gi|259089723|gb|GQ463147.1|3276-4136 gi|150953431|gb|CP000647.1|1785004-1784144 gi|85003006|gb|DQ166779.3|1-861,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgtcggtcggtgaactctgcgctgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6208,Drugs,MEG_6208|Drugs|betalactams|Class_A_betalactamases|SHV,1509794568|WP_122630877.1|NG_062297|1|1|blaSHV-225|blaSHV|class_A_beta-lactamase_SHV-225 NG_062297:1-861,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCTTTCTCCACGTTTGCCGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCAATTCCGGGTATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACGCAACAAACGCTGTTTGAACTCGGATCGGTCAGTAAAACGTTCAACGGTGTGCTGGGCGGCGATGCTATAGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGCAGTACTGGCCTGAACTGACTGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCGTTACTACGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGCGCCCTGGCAGTGAAACCCTCAGGCATGAGCTACGAAGAGGCGATGTCCAAACGCGTCCTGCACCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGCCAACTTGATGCCGAAGCATACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGCATCGAGCTTGCGCAGTCACGTTACTGGCGTATTGGCGATATGTACCAGGGCCTGGGCTGGGAGATGCTGAACTGGCCGGTGAAGGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTGGCACTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAGAGCTACCCAAACCCTGTTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1915,Drugs,MEG_1915|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JX440350|+|1026-2172|ARO:3002083|CMY-70 [Citrobacter braakii] ,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacagcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgaagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggcttatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5448,Drugs,MEG_5448|Drugs|betalactams|Class_C_betalactamases|PDC,1035157550|WP_064511515.1|NG_050838|1|1|blaPDC-165|blaPDC|class_C_beta-lactamase_PDC-165 NG_050838:1-1194,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacggcgccgccaatctgctactggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgtaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggataccccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6221,Drugs,MEG_6221|Drugs|betalactams|Class_A_betalactamases|SHV,1114603966|WP_072081993.1|NG_052582|1|1|blaSHV-197|blaSHV|class_A_beta-lactamase_SHV-197 NG_052582:1-861,0
,ttgattattacagaatttgatcgagaagatgtggtcatgcgggatcagttggcggacctgttgaaaaaaacttggccggaggaatatagggaggaatcgcagatcaacgccttgttagcagaagaacgtttggcagtcgcggcgctggaagaggacatgttgattggctttatcggcgcaattccacaatacgatcatacgggatgggagctgcatccgttagtcgttggagatgcctatcgtcgacgaaaaatcggtatgcgtttggtggatttcttagaaaaagaagttgcttctcatggtggtatcaccatgtatctggggacagatgatgaaaatcatgccacttcattgagtgagctggatttgtatcaagatacgtttcaagccctcagtcaaatcaaaaatttaaaaaatcatccctttgaattttatgaaaaacaaggctatcagattgtgggtgttattccagatgccaatggctggaacaaaccagatattttaatggcaaaacgaattgccgaaccggaaaatgaaaattctccctcataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_269,Drugs,MEG_269|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,873897426|WP_048603867.1|NG_052188|1|1|aac(6')_Entco|aac(6')_Entco|aminoglycoside_6'-N-acetyltransferase NG_052188:101-652,2
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtgacaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4389,Drugs,MEG_4389|Drugs|betalactams|Class_D_betalactamases|OXA,1391852906|WP_109545091.1|NG_057525|1|1|blaOXA-577|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-577 NG_057525:1-774,0
,atgaaaaaattatttgttttatgtgtattcttcctttgcaacattgctgctgcagatgattctttgcctgatttaaaaattgagaagcttgaaaaaggcgtttatgttcatacttcgtttgaagaagttaaaggttggggtgtattcacaaaacacggtttagtggttcttgtaaagaatgatgcttatctgatagatactccaattaccgctaaagatactgaaaaattagttaattggtttattgagcacggctatagaatcaaaggcagtatttccacacatttccatggcgacagtacggctggaatagagtggcttaattctcaatctatctccacgtatgcctctgaattaacaaatgaacttctaaaaaaagacaataaggtgcaagctacaaattcttttagtggagttagttattcacttatcaaaaacaaaattgaagttttctatccaggtccaggacacactcaagataacgtagtggtttggttacctgaaaagaaaattttattcggtggttgctttgttaaaccggacggtcttggaaatttaggggatgcaaatttagaagcttggccaaagtccgctaaaatattaatgtctaaatatggtaaagcaaaactggttgtttcaagtcatagtgaaattggaaacgcatcactcttgcagcgcacatgggagcaggctgttaaagggttaaatgaaagtaaaaaaccgttacagccaagtagctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3320,Drugs,MEG_3320|Drugs|betalactams|Class_B_betalactamases|IMP,1028105498|WP_063860610.1|NG_049211|1|1|blaIMP-49|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-49 NG_049211:1-741,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAATCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCTCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1917,Drugs,MEG_1917|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JX440352|+|1027-2173|ARO:3002085|CMY-72 [Citrobacter freundii] ,0
,gtgagcgacctggagctgcggggcgaacgggtcctgctgcgctccaccgtccccgccgacacccccgtcctcgacgcgatcgtccgcgaacccgaggtcgcccggtggtggccgccgcccgaggcgtacgccgccatgctcgccgtcgtcgtggacggcgaggtgatcggcgcgatccagttcagcgaggagagcgacccggagttccgccacgccggcatcgacctcttcctgtcggcccggtggcacgggcagggcctgggccccgacgccgtacgcaccctggcccgctggctgatcgccgagcgcggccaccaccgcctggtcatcgacccggccgccgccaacacgcacgccatccgcagctaccgcaaggtcggcttcgccccggtcgggatcatgcgcgcctactggcgcaaccaccgcaccggcgcgtgggaggacggcctgctcatggacctgctggcggccgaactgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_255,Drugs,MEG_255|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,835346782|WP_047467383.1|NG_052425|1|1|aacA-STR-13|aacA-STR-13|aminoglycoside_6'-N-acetyltransferase NG_052425:101-583,2
,atgaataaaaaaataaaactaatttttattttaattttttcaataaatttatttgcaaatgatgtggaacttgaaaatttatttaaaaaataccaagttgaaggaactttagtattagagtctttaaatacaaaaaaagtagatatttataatgaaaagagagcaaatacatcattttctcctgcttcaacatttaaaataccaaatactttgatagctttaaatgaaggtgttgtaaacaaagattctataatagtttgggataaaaaagtaagagaatttgatgcttggaataaagaccaaactttacaatcagctttcaaaagttcttgtgtttggtgttataaagagttcgcttcaaaaattggagttgaaaaatataaaaagtatctaaaagagcttaattatggaaataaaacaataggcaaagatgtaactgatttttggttggatgagagtttgagaattacagcttttgaagaaataagatttttaaaacaattacaagcaaacaatttagcttttaaacaagaagatataaatcttttaaaagagttgatgattgatgaaaaaagcgaaaattatgtagttagagcaaaaacaggttgggaaggaaaatatggttggtatgttggttatgttgaaacaaaaaatgatgtttggttttttgctttaaatatcgacacaaaaacaaaagaagatttagcaaaaagaaaagctttaactttagaagctttaaaaacaaaaggtattatagattga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4720,Drugs,MEG_4720|Drugs|betalactams|Class_D_betalactamases|OXA,822608710|WP_046991607.1|NG_049748|1|1|blaOXA-464|blaOXA|class_D_beta-lactamase_OXA-464 NG_049748:101-862,0
,TCGGCCCTCACTCAAGGATGTATTGTGGTTATGCGTTATTTTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGTAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAGGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGGATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6416,Drugs,MEG_6416|Drugs|betalactams|Class_A_betalactamases|SHV,gi|160948434|emb|AM176547.2|1-891,0
,atgaaaaagataaaaattgttccacttattttaatagttgtagttgtcgggtttggtatatatttttatgcttccaaagataaagaaattaataatactattgatgcaattgaagataaaaatttcaaacaagtttataaagatagcagttatatttctaaaagcgataatggtgaagtagaaatgactgaacgtccgataaaaatatataatagtttaggcgttaaagatataaacattcaggatcgtaaaataaaaaaagtatctaaaaataaaaaacgagtagatgctcaatataaaattaaaacaaactacggtaacattgatcgcaacgttcaatttaattttgttaaagaagatggtatgtggaagttagattgggatcatagcgtcattattccaggaatgcagaaagaccaaagcatacatattgaaaatttaaaatcagaacgtggtaaaattttagaccgaaacaatgtggaattggccaatacaggaacagcatatgagataggcatcgttccaaagaatgtatctaaaaaagattataaagcaatcgctaaagaactaagtatttctgaagactatatcaaacaacaaatggatcaaaattgggtacaagatgataccttcgttccacttaaaaccgttaaaaaaatggatgaatatttaagtgatttcgcaaaaaaatttcatcttacaactaatgaaacaaaaagtcgtaactatcctctaggaaaagcgacttcacatctattaggttatgttggtcccattaactctgaagaattaaaacaaaaagaatataaaggctataaagatgatgcagttattggtaaaaagggactcgaaaaactttacgataaaaagctccaacatgaagatggctatcgtgtcacaatcgttgacgataatagcaatacaatcgcacatacattaatagagaaaaagaaaaaagatggcaaagatattcaactaactattgatgctaaagttcaaaagagtatttataacaacatgaaaaatgattatggctcaggtactgctatccaccctcaaacaggtgaattattagcacttgtaagcacaccttcatatgacgtctatccatttatgtatggcatgagtaacgaagaatataataaattaaccgaagataaaaaagaacctctgctcaacaagttccagattacaacttcaccaggttcaactcaaaaaatattaacagcaatgattgggttaaataacaaaacattagacgataaaacaagttataaaatcgatggtaaaggttggcaaaaagataaatcttggggtggttacaacgttacaagaaataaagtggtaaatggtaatatcgacttaaaacaagcaatagaatcatcagataacattttctttgctagagtagcactcgaattaggcagtaagaaatttgaaaaaggcatgaaaaaactaggtgttggtgaagatataccaagtgattatccattttataatgctcaaatttcaaacaaaaatttagataatgaaatattattagctgattcaggttacggacaaggtgaaatactgattaacccagtacagatcctttcaatctatagcgcattagaaaataatggcaatattaacgcacctcacttattaaaagacacgaaaaacaaagtttggaagaaaaatattatttccaaagaaaatatcaatctattaactgatggtatgcaacaagtcgtaaataaaacacataaagaagatatttatagatcttatgcaaacttaattggcaaatccggtactgcagaactcaaaatgaaacaaggagaaactggcagacaaattgggtggtttatatcatatgataaagataatccaaacatgatgatggctattaatgttaaagatgtacaagataaaggaatggctagctacaatgccaaaatctcaggtaaagtgtatgatgagctatatgagaacggtaataaaaaatacgatatagatgaataa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3774,Drugs,MEG_3774|Drugs|betalactams|Penicillin_binding_protein|MECA,1028095782|WP_063852670.1|NG_047946|1|1|mecA-ceftar|mecA-ceftar|ceftaroline-resistant_PBP2a_family_peptidoglycan_transpeptidase_MecA NG_047946:1-2007,0
,atgtgctgcatggaactgcacggagagaaagtcgtccttcgtccggtggaggacagcgagacggagacgctcgaccgcatcgtcagggagcccgaggtcgcggcgtggtggtcgcccccgaacggctacgagaacaccttcgccgtcttcctcgacgacgagatcatcggtgccgtgcagttcaccgaggagagcgaccccgagtaccggcacgccgggatcgacgtcttcctcaccgcccgccgcaccggcgccggactcggcaccgacaccgtccgcaccctcgcccgctggctcctcgacgaccgcgggcaccaccgcctcaccatcgaccccgcggcggagaacgcaccggcgatcgccagctaccggaaggtcgggttccagccggtcggcgtgctgcgcaggtactggcgcgaccaccagacgggcgagtggcgggacgggctgctcatggatctgctcgccgacgaactcacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_209,Drugs,MEG_209|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,657307400|WP_029391459.1|NG_052157|1|1|aacA-STR-10|aacA-STR-10|aminoglycoside_6'-N-acetyltransferase NG_052157:101-583,2
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatgctggcgttcgtgcctgcgctcggccctatcgccggagtattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcacctacttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2925,Drugs,MEG_2925|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,446136267|WP_000214122.1|NG_047877|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047877:1-1215,6
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttactgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatgtttccggctcttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgctgagttttattcatgccaacctcaacccacagaaatatccgaaagatattcaacttgcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaatctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaaccagcggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_588,Drugs,MEG_588|Drugs|betalactams|Class_C_betalactamases|ADC,1058243500|WP_068981608.1|NG_051440|1|1|blaADC-101|blaADC|class_C_beta-lactamase_ADC-101 NG_051440:1-1152,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttactcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctgaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttcacccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4469,Drugs,MEG_4469|Drugs|betalactams|Class_D_betalactamases|OXA,1188444913|WP_085562415.1|NG_054705|1|1|blaOXA-561|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-561 NG_054705:1-825,0
,ATGCTAAATTTAACCGTTTGTCAGGCACAGTCAAATCCAACAGACTACGCCTGTCTGACGGGCCCGGACATCCCCTTGACTCGCTATTACGGAAGATTACTGATGATGAAAAAATCTCTTTGCTGCGCCCTGCTGCTCGGCATCTCTTGCTCTGCTCTCGCCGCGCCAGTGTCAGAAAAACAGCTGGCGGAGGTGGTCGCGAATACGATTACCCCGCTGATGAAAGCCCAGTCGATTCCAGGCATGGCGGTGGCCGTTATTTATCAGGGTAAACCGCACTATTATACGTTTGGCAAAGCCGATATCGCGGCTAATAAACCCGTTACGCCTCAGACTCTGTTCGAGCTGGGCTCTATAAGTAAAACCTTCACCGGGGTTTTAGGTGGGGATGCCATTGCTCGCGGTGAAATTTCGCTGGACGATCCGGTGACCAGATACTGGCCACAGCTGACGGGCAAGCAGTGGCAGGGGATTCGTATGCTGGATCTCGCAACCTACACCGCTGGCGGCCTGCCGCTACAGGTACCGGATGAGGTCACGGATAATGCCGCCCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCTGGCACAACGCGTCTTTACGCCAACGCCAGTATCGGTCTTTTTGGCGCGCTGGCGGTCAAACCTTCCGGCATGGGCTATGAGCAGGCCATGACGACGCGGGTCCTTAAGCCGCTCAAGCTGGACCATACCTGGATTAACGTTCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGCTATCGTGACGGTAAAGCGGTGCGCGTTTCGCCGGGAATGCTGGATGCACAAGCCTATGGCGTGAAAACCAACGTGCAGGATATGGCGAACTGGGTCATGGCAAACATGGCGCCGGAGAAGGTTGCTGATGCCTCACTTAAGCAGGGCATCGCGCTGGCGCAGTCGCGCTACTGGCGTATCGGGTCAATGTATCAGGGTCTGGGCTGGGAGATGCTCAACTGGCCCGTGGAGGCCAACACGGTGATCGAGGGCAGCGACAGTAAGGTGGCGCTGGCACCGCTGCCCGTGGCAGAAGTGAATCCACCGGCTCCCCCGGTCAAAGCGTCCTGGGTCCATAAAACGGGCTCTACTGGCGGGTTTGGCAGCTACGTGGCCTTTATTCCTGAAAAGCAGATCGGTATTGTGATGCTCGCGAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCATATCCTCGACGCGCTACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_494,Drugs,MEG_494|Drugs|betalactams|Class_C_betalactamases|ACT,gi|595583485|gb|KF992028.1|660-1907,0
,atggcgcccgattacgcacgcacagacgcggtcgcacccgcaagtgtgaaggagaccttcgcgtacctctcggcgctgcccaacgcgctggacagacgctggtgggcgggtctgctgctcatccaggcgctcatcgtcgccgtgtacaccacgcagtcgaacctgttcgggcgcagcgtcgacccgctcaccggaggcgaggtgccgctactgggcaccggcacccgcgcctttgtgtggactgttggactggcgttggcctgcatgctcgtcgagatgttcctgcgcgccctcggtaactacgtggtgggcctcaaggtcgcccgcgcgtccatcgacttgcgccgtcgctgcctcgacgcgatcctgcgcgcacctgtgccgcgggtgatggagctcggcaccggcaacgtgatcacacgcatgaccaaggacatcgacgacgtcgtccaaaccatcaccgccatcggctcgcgcgtgctcaccaccgtgttcgtctttccgatcacgtttatcgggcttttgcttatcgacgtccgcttcgccttgatcctgcttttgatctgcatctgcacgtacccgttcgcccgcgcggtggtccgcgccatcccggatgcctccaacgcggtgagcgtggcggaggcgcgtcgcaacgcggtgctgctggataccgtccggggcctgcccacgctgcgcgccttcgacttggagcgctgggcgttggcacggatgcggcggacctcgtggggcgcggtggaggcggagatggaccgtgtgcactggttcatccggctcacaggcatcggccaggtcgctttcgccgcgtgggtgctgctcacgcttggcgtcggcgcgtggctcgcgtcggccggagttgtcacccgggcggcgcaacgtgctggaagacctctctgtcacgctcgaggcggaacaaccaccgcgctggtgggcacttcgggcgccggcaagtccacgctcgccgcgctcattgcggggctggtggagcccacagctgggagcatccgggtaggggccgtggaaacctcgcaggtcagcgacacgtggaccgccaagaacgtcaccctgctcacccaggacgtccacctgttcgccggcaccctgcgcgaggacctctcgatggccgcacaggatgcgaccgacgcggacctgctgcgggcgctggcaagtgtcgggctcgaccctgaaggcacccagttcgcgcgcctgttcccgaaggggctggacaccgccgtcggcgcaggcgcggaggacatacccccggaggtggagcagcagctcgcgctcgcacgcgtggcgctgtcgggcccgaaggtgctcatcctggacgaggccacagcggaagccggcagcgacgccacgaacgcgctggaggacgccgccgcgcggatcaccgcagacaccacggcactggtggtggcgcaccgcctagaccaggcggcggccgcggaccggatcctggtcatggacgccgggcgcatcatcgaggacggcacccacaccgaactcgtcgccgccgacgggagatacgcgcaactgttcgctgcgtggagtggcggcggtcactaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7022,Drugs,MEG_7022|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,499429506|WP_011116970.1|NG_048317|1|1|tetAB_B|tetAB_B|tetracycline_efflux_ABC_transporter_TetAB_subunit_B NG_048317:101-1687,4
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccaccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5696,Drugs,MEG_5696|Drugs|betalactams|Class_C_betalactamases|PDC,1028110219|WP_063864589.1|NG_049956|1|1|blaPDC-99|blaPDC|class_C_beta-lactamase_PDC-99 NG_049956:1-1194,0
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAGTACGCCGTTTCTTTAGCCTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGATTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTATTTGTACACAGGAGAACTGGAAAACATCCGACAAGACACGTGGCTGTTGGATACGAAACATAAACAGAAAATCCAGCCGCTTTTTGAAGGAAACGGCTTTTGGCTAAGTGAAGAGCAACAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAACTACCTTATGTAGGCTGCGGTGTGGCGGCCTCCGCATTATGTATGAACAAATGGTTATTGCATCAAGCAGCAGAAGCGATTGGCGTACAAAGCGCTCCTACGATTCTCTTGACAAATCAAGACAACCAGCAAAGACAAATCGAAGCCTTTATCCAGACCCATGACTTTCCGGTTTTCTTTAAGCCTAATGAAGCTGGCTCCTCAAAAGGGATCACAAAAGTGACTTGTGTCGAAGAAATTGCTCCTGCCTTGAAGGAAGCCTTCGCTTATTGTTCAGCAGTGCTCTTACAAAAAAATATAGCTGGCGTTGAGATTGGTTGCGGTATCTTAGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCTATTTCATTAGTAGAAGGCTTTTTCGATTTTGAAGAAAAGTACCAGTTGATTAGCGCCAAGATCACCGTTCCTGCACCATTGCCTGAAACGATTGAAACCAAGGTCAAAGAACAAGCTCAGCTGCTCTATCACAGTCTTGGTCTTAAAGGACTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACTAGTCACTCCCGCTATCCTGCCATGATGGCAGCAATCGGCTTATCCTATCAAGAACTACTACAAAAACTGCTTGTCTTAGCAAAGGAGGAAGGCAAATGAATCCCTATCTACAGTTAGTTAGCAAAGAGTTTCCATTAGAAAAAAACCAAGAGCCGCCCCACCTCGTCCTTGCTGCTTTTAGTGAAGAAGAAGTTTACTTGCAGCCTGAAGCAGCCAAACAATGGGAACGCCTCGTCAAAGCCTTAAAACTTGAAAACGAGATCTGCTTATTAGACGGCTATCGAACCGAAAAGCAGCAACGGCATTTATGGGAATATTCCTTAAAAGAAAATGGATTAGCCTATACGAAACAATTTGTGGCGTTGCCCGACTGCAGCGAGCATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAAGGCCAGCAAGGTGATTTGATCTGCCCACGGTTTCGTGACAGCGTAGCGGCGGATTTATTTACACAGGAAATGATGAACTACGGATTTATTTTACGCTATCCCGCAGACAAACAGGAGATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTGCCTCATAGTCAAATCATCGCCAGTCAACAGTGGACATTGGAAGAATACTATCAATACCTTGAACAAACCGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7371,Drugs,MEG_7371|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC4XY_2_EU151753,5
,ATGGAGAAAATAATAGACATAACTGTTTTTGGCTGCGAGCCAGACGAAATGGAGGTTTTTCAAAAGATTTCTTATGAGCTTGGTGTTACAGCCACACTCATAAAAGATTCTATATCAGAAAGCAATGCTGGATTAGCTAATGGATGCCGGTGTGTAAGCGTAAGCCATAAAGCGGAGCTATCAGAACCGATTCTTCTTGCGCTAAAAAATGCAGGGGTAAAATATATCAGTACCCGGAGCATTGGTTTTAACCATATTGATATACAGGCGGCTGGGTTACTGGGTATGGTTGTTGGCACAGTAGAATACTCGCCGGGAAGTGTGGCCGATTATACCGTCATGCTGATGCTTATGCTGATGCGTGGCACAAAGTCGATTCTGCGTGAAACCCAGAGGCAGAATTATTGCCTGAATGACCTGCGCGGAAAAGAACTGCGGGATATGACCGTGGGTGTGTTAGGAACTGGGCGAATCGGACAGGCAGTCATGGAGCGCCTGGAGGGATTCGGTTGTAAGGTATTGGCGTATGACCGAAATCAAAAAGCAGGAGCAGACTATGTTTCGTTTCATGAACTGCTGAAAAAAAGTGACATTGTTACACTGCATATCCCGTTGGCGGAGGATACCCGCCATATGATTGGCTATGAAGAGCTGGAAATGATGAAGGAAGAGGCGCTTCTGATCAATACAGGGCGGGGCGCTTTAGTGGATACCGCAGCATTGGTAGAAGCATTAAAAGGACAGAAAATCGGCGGCGCCCTGGATGTTTTGGAAGGCGAAGAAGGTATCTTTTACCATGACTGCACCCAAAGAAGAATAGAACATCCTTTCCTGTCGGTCCTGCAGGGAATGCCGAATGTCATTGTTACGCCGCACACAGCCTATCATACGGAACGGGTGTTGGTTGACACGGTCAGAAATACTATTAGAAATTGTTTGAATTTTGAAAGGAGTCTGGGAAATGTTTAGAATTAAAGTTGCAGTTCTGTTTGGGGGCTGTTCAGAGGAACATAATGTTTCGATAAAATCTGCGATGGAGATTGCCGCAAACATAGATACAAAAAAATATCAGCCTTATTATATTGGAATCACAAAATCCGGCGTTTGGAAAATGTGTGAAAAACCTTGTTTGGAGTGGGAACAATATGCGGGGGATCCGGTTGTTTTTTCGCCGGACAGAAGTACGCATGGTCTGCTGATACAAAAAGACAAAGGGTATGAAATCCAGCCTGTGGATGTGGTGTTTCCGATGATTCATGGCAAGTTTGGGGAGGATGGCTCCATACAAGGCTTGCTTGAATTGTCAGGCATTCCGTATGTGGGATGCGATATTCAAAGCTCCGTGATCTGCATGGATAAGGCGCTTGCATATACCGTTGTGAAAAATGCGGGTATCACTGTGCCTGGGTTCCGGATCCTTCAGGAGGGGGATCGCCTGGAAACGGAGGATTTCGTATATCCCGTTTTTGTAAAGCCTGCCCGTTCCGGCTCATCCTTTGGCGTAAACAAGGTATGCAAGGCAGAAGAACTGCAGGCAGCAATCGAAGAAGCAAGAAAATATGACAGCAAGATTTTGATTGAAGAGGCCGTTACCGGGAGTGAGGTAGGCTGCGCCATACTGGGAAACGGAAATGATCTCATGGCTGGCGAGGTGGATCAGATTGAGCTGAGACACGGCTTTTTTAAGATTCATCAGGAAGCACAGCCGGAGAAGGGATCTGAAAATGCAGTCATCCGAGTTCCAGCCGCCTTACCGGATGAGGTAAGAGAACAGATTCAGGAAACGGCAATGAAGATTTACCGGATACTTGGCTGCAGAGGATTGGCCCGCATTGACCTGTTTTTGCGGGAGGACGGTTGCATTGTGCTGAATGAAGTGAATACCATGCCAGGTTTTACTTCCTACAGCCGCTATCCCCGCATGATGACAGCAGCCGGTTTTACGCTTTCTGAAATACTGGATCGCTTGATTGAACTTTCACTTAGGAGGTAACTGTCATGAAAAAGAACTTTGCCTTTTTAGATGAAATGATTCCCGGGATCCGATGGGATGCCAAATATGCCACCTGGGACAATTTCACCGGGAAACCGGTAGACGGATACATGGTAAACCGTGTTATGGGAACGAAGGAGCTGGGAGTTGCTTTGCGTAAGGCTCAGAAGATGGCGGAGAAGCTAGGATATGGTTTGCTCTTATGGGACGGCTATCGCCCCCAGTGCGCAGTGAATTGTTTTCTGAATTGGGCTTCCCAACCGGAAGACAATCTGACGAAAAAGCGTTACTATCCAAATATCAAAAGGAATGAGATGGTTGCGAAGGGGTATGTGGCCTCACAATCCAGCCACAGCCGTGGAAGTACGGTTGACCTTACAATTTTTCATTTGAATAGCGGTATGCTTGTTCCTATGGGTGGAGATTTTGACTTTATGGATGAACGGTCACACCATGCCGCAAGCGGTCTGAGCGAAGAAGAATCAAAAAACCGGCAGTGCTTGCGTTATATCATGGAGAGTAGCGGATTTGAAGCCTATCGTTATGAATGGTGGCATTACGTCTTGGCGGACGAGCCATACCCGGATACATATTTTGATTTTTGCATTGCCTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7437,Drugs,MEG_7437|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,VanHDX_1_AF130997,5
,ATGCGTCAATATCGATTCGCCCTTCTCCCATTGTTAGCCGCCCTGGCGCTCCCCGGTTGGGCGCATCAAGCTACGGTGACGACGGTTAAACAAGCCGAAAGCCAGCTTCAGGGTCGGGTCGGCTACGCCGAACTGGATTTAGCTTCCGGGCAACTGCTGGCCGGCTATCGTTCTGACGAACGGTTCCCGATGATGAGCACTTTTAAAGTTCTGCTCTGCGGCGCAGTCTTGTCGCGTGTCGATGCTGGTGAAGAACAGCTCGATCGCCGTATCCATTACCGGCAGCAGGATCTGGTGGAATATTCGCCGGTGACGGAAAAGCATCTTACCGATGGGCTCACCGTGGGCGAACTGTGTGCTGCCGCCATTACCCTGAGCGATAATACGGCGGCAAACCTGCTGTTGACCACTCTCGGCGGCCCGCAGGGGCTGACCAGCTTCCTGCGCCACAGCGGCGACCAGACTTCGCGGCTTGACCGTTGGGAAACGGAACTCAATGAAGCGCGGCCGGGCGACGTGCGAGATACCACGACTCCGCAAGCGATGGCCAGGACACTGCGAAATCTGCTGACCGGTCGCGTGCTTTCCAGCGCCTCGCAGCAGCAGTTGCAACGCTGGATGGTAGAGGACAAAGTTGCGGGGCCGCTGTTGCGATCGGTGCTGCCGGCGGGCTGGTTTATTGCCGATAAGACCGGAGCCGGCAATCGCGGCTCGCGCGGGATCATCGCGGCTCTCGGTCCGGACGGTAAAGCTGCGCGCATCGTGGTGATTTATTTGACCGGGACCCCCGCCACAATGGATGAACGCAATAAACAGATTGCGGCCATCGGCGCAACGCTGATCACGCACTGGTCCGCAGACGAGAACAGACCCTAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1297,Drugs,MEG_1297|Drugs|betalactams|Class_B_betalactamases|BLAPLA,blaPLA-5A_1_DQ249871 ,0
,TTGAAAAAATTAATAATTTTAATCATGTTAGCATTGATATTAAGTGCTTGTAATACTAAGCATTCAACTAATAATGATATTGAAAAACTCGAAAAAAAATATGGTGCTAACATAGGTATGTATGCGCTTAACACTCAAAACAGTGAAGCATTATCATTTAATGAAAATAAACGTTTTGCTTATGCTTCCACATTAAAAGCTATAAGTAGTGCCATGCTACTTGAGCAAACACCTTACAACAAATTAGATAAAAAAATTCACATCAACAAAGATGATATCGTTCCATATTCACCAGTGTTAGAGAAATATATCGGCAAAGAGATAACTATTAAAAAACTTATAGAAGCTACCATGTTATTTAGCGATAACACTGCTAACAATAAAATTATCGATGAATTAGGAGGGTATGAGCATGTAAAAAATAGACTGACAGATTTAGGAGATACAACTACACATCCATCTAGAAAAGAACCCGACTTAAATTTTTATTCGCCAAAGGATAAACGAGATACAACTACTCCAATGGCCTATGGTAAATCTTTAAATAAACTTATAGTTGATGGAAATCTTAGTAAAGCGAACAAAGATTTATTGCTTGACTTAATGTTGAAAAATAAAAGTGGCGATACATTAATTAAGGATGGCGCACCTTCAAACTTTAAAGTTATGGATAAGAGTGGTCAGGCACTAACATACGGTTCAAGAAACGATGTTGCACTTGTTTATCCAGATGGACAAGATAAACCTATCATTTTAGTTATATTTACAAATAAAGATAAAAAGGATGGTAAACCTAATGATAAAATAGTAAGTGAAGTCGCCGAAATTGTATTAAAAAATATGAGTAAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1322,Drugs,MEG_1322|Drugs|betalactams|Class_A_betalactamases|BLAZ,gi|413915517|emb|HE993884.1|11937-11086,0
,atgaaaaactactttaacagccctttcaaaggggaacttctttctgagcaagtgaaaaatccaaatatcagagtaggccggtatagctattactctggctactatcacgggcactcatttgatgaatgcgcgcgatacttgcttccagatcgtgatgacgttgataaattgatcattggcagcttttgttctataggaagcggggcttccttcatcatggctggcaatcaggggcatcggcatgactgggcatcatccttccccttcttctatatgcaagaggagcctgctttctcaagagcactcgacgccttccaaagagcaggtgataccgtcattggcaatgatgtctggataggctcggaggcaatgattatgcctggcatcaaaattggagacggtgccgtgataggtagtcgcccgttggtgacaaaagatgtagagccttatgccatcatcgggggaaatcccgcaaagcaaattaagaagcgcttctccgatgaggaaatctcattgctcatggagatggagtggtggaactggccactagataaaattaagacagcaatgcctctgctgtgctcgtcaaatatttttggtctgcataagtattggcgcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1594,Drugs,MEG_1594|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1105502132|WP_071846284.1|NG_052331|1|1|catB8|catB8|type_B-3_chloramphenicol_O-acetyltransferase_CatB8 NG_052331:101-733,6
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCACAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGAGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTACCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAAGGGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGTTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1927,Drugs,MEG_1927|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KF526116|+|0-1146|ARO:3002115|CMY-103 [Citrobacter freundii] ,0
,AAGAAGTTACTAATGACAAAAAAGAAATTGCCCCTTCGTTTTACGGGTCAGCACTTTACTATTGATAAAGTGCTAATAAAAGATGCAATAAGACAAGCAAATATAAGTAATCAGGATACGGTTTTAGATATTGGGGCAGGCAAGGGGTTTCTTACTGTTCATTTATTAAAAATTGCCAACAATGTTGTTGCTATTGAAAACGACACAGCTTTGGTTGAACATTTACGAAAATTATTTTCTGATGCCCGAAATGTTCAAGTTGTCGGTTGTGATTTTAGGAATTTTGCAGTTCCGAAATTTCCTTTCAAAGTGGTGTCAAATATTCCTTATGGCATTACTTCCGATATTTTCAAAATCCTGATGTTTGAGAATCTTGAAAATTTTCTGGGAGGTTCCATTGTCCTTCAGTTCGAACCTACACAAAAGTTATTTTCAAGGAAGCTTTACAATCCATATACCGTTTTCTATCATACTTTTTTTGATTTGAAACTTGTCTATGAGGTAGGTCCTGAAAGTTTCTTGCCACCGCCAACTGTAAAATCAGCCCTGTTAAACATTAAAAGAAAACACTTATTTTTTGATTTTAAGATTAAAGCCAAATACTTAGCATTTATTTCCTGTCTGTTAGAGAAACCTGATTTATCTGTAAAAACAGCTTTAAAGTCGATTTTCAGGAAAAGTCAGGTCAGGACAATTTCGGAAAAATTCGGTTTAAACCTTAATGCTCAAATTGTTTGTTTGTCTCCAAGTCAATGGTTAAACTGTTTTTTGGAAATGCTGGAAGTTGTCCCTGAAAAATTTCATCCTTCGTAG,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2832,Drugs,MEG_2832|Drugs|MLS|23S_rRNA_methyltransferases|ERMF,gi|143942|gb|M62487.1|BNRERMFU|259-1071,7
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTGATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTACTGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1338,Drugs,MEG_1338|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_65_CSEV01000005,0
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgaacaacttacgcgcagtccggtgctacgagaaggcgggttttgtggcgcaaagaaccataaacaccccagatggaccggccgtatacatggttcaaacacgtcaggcgttcgagcgagcgcgcagtgctgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_223,Drugs,MEG_223|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502110|WP_071846262.1|NG_052303|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052303:101-655,2
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCAAATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTACAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1374,Drugs,MEG_1374|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_100_LTMH01000008,0
,ATGACCAACAGCACCGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_351,Drugs,MEG_351|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|459978576|dbj|AB777501.1|2292-2846 gi|974751547|gb|KU130294.1|207921-207368 gi|762041897|gb|KM589497.1|3859-4412 gi|723217933|gb|KM382183.1|734-1287 gi|697287983|dbj|AB715422.2|26596-27149 gi|672858205|gb|KF998105.1|4296-4849 gi|648296171|dbj|AB917040.2|102-655 gi|636632020|gb|KJ623741.1|734-1287 gi|636631997|gb|KJ575542.1|682-1235 gi|636631830|gb|KJ543560.1|681-1234,2
,TCCCAGCAAGTCCTAACTTTAATTACTACCTTAAAAATTATGAAAAAAAGCATTCAATTTTTTATTGTTTCCATGTTGTTGAGCCCTTTTGCCAATTCACAGGTAAAAGATTTTGTAATTGAGCCACCTATTAAATCCAATCTATATATTTACAAGACTTTTGGAGTATTCGGAGGTAAAGAATATTCTGCCAATGCAGCCTATCTTAAGACTAAAAAAGGTGTAATTCTGTTTGATGTACCCTGGGAAAAAGTACAGTATCAAAGCCTGATGGATACCATCAAAAAACGTCATAACTTACCGGTAATTGCCGTATTTGCTACGCATTCCCATGATGACCGTGCAGGAGACTTAAGCTTTTTCAATAATAAAGGCATTAAGACGTATGCTACCCTGAAAACCAATGAGTTTCTGAAGAAAGATGGAAAAGCAACATCCACAGAGATCATCCAAACCGGAAAACCTTATCACATTGGCGGAGAAGAATTTGTGGTCGATTTTCTTGGTGAAGGACATACTGCTGATAATGTAGTGGTATGGTTTCCAAAATATAATGTTTTGGATGGCGGATGTCTTGTAAAAAGTAATTCTGCTACTGACTTAGGATACATTAAAGAAGCCAATGTAGAACAATGGCCCAAGACGATGAATAAATTAAAAACCAAATATTCAAAAGCCACATTAATTATTCCCGGGCATGATGAATGGAAAGGGGGTGGACATGTTGAACACACTTTAGAGCTTTTGAACAAAAAATAACTCTGGTTTTTCCTGCCAATAAAAAATCCCGAATGAACAGTCATCCGGGATTTGTATTTTATAAAGGATTGATTTAATTTAATCCAATAC,beta-lactamase,antibiotic inactivation,betalactams,MEG_3421,Drugs,MEG_3421|Drugs|betalactams|Class_B_betalactamases|IND,gi|270266459|gb|GU186044.1|1-849,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgctttcaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgttaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4387,Drugs,MEG_4387|Drugs|betalactams|Class_D_betalactamases|OXA,488913604|WP_002824679.1|NG_057513|1|1|blaOXA-595|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-595 NG_057513:1-774,0
,ATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTATTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCAGCGTCAGCGAGCAGACCCTGTTCGATATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGTCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCATTTGCCCAGTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGGGTCAACCCTGGCATGCTGGCGGACGAGGCCTACGGCATCAAGACCAGCTCGGCGGATCTGCTCGCCTTCGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACAAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGATCCTCGAAGCCAATCCGACGGCGGCTCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTATCCCATCCCGGCCAGGGTGAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1842,Drugs,MEG_1842|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AB061794|+|6017-7166|ARO:3002020|CMY-9 [Escherichia coli] ,0
,atgaacattaaagccctcttccttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttgggtggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4510,Drugs,MEG_4510|Drugs|betalactams|Class_D_betalactamases|OXA,1028106551|WP_063861475.1|NG_049490|1|1|blaOXA-194|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-194 NG_049490:1-825,0
,ATGAAAATTATTAATATTGGAGTTTTAGCTCATGTTGATGCGGGAAAAACTACCTTAACAGAAAGCTTATTATATAACAGTGGAGCGATTACAGAATTAGGAAGCGTGGACAAAGGTACAACGAGGACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACAGGAATAACCTCTTTTCAGTGGGAAAATACGAAGGTGAACATCATAGACACGCCAGGACATATGGATTTCTTAGCAGAAGTATATCGTTCATTATCAGTTTTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATGGCGTACAAGCACAAACTCGTATATTATTTCATGCACTTAGGAAAATGGGGATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCCGAAATTGTAATCAAACAGAAGGTAGAACTGTATCCTAATATGTGTGTGACGAACTTTACCGAATCTGAACAATGGGATACGGTAATAGAGGGAAACGATGACCTTTTAGAGAAATATATGTCCGGTAAATCATTAGAAGCATTGGAACTCGAACAAGAGGAAAGCATAAGATTTCATAATTGTTCCCTGTTCCCTGTTTATCACGGAAGTGCAAAAAACAATATAGGGATTGATAACCTTATAGAAGTGATTACGAATAAATTTTATTCATCAACACATCGAGGTCAGTCTGAACTTTGCGGAAAAGTTTTCAAAATTGAGTATTCGGAAAAAAGACAGCGTCTTGCATATATACGTCTTTATAGTGGCGTACTGCATTTGCGAGATTCGGTTAGAATATCGGAAAAGGAAAAAATAAAAATTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAAATCGATAAGGCTTATTCCGGGGAAATTGTTATTTTGCAGAATGAGTTTTTGAAGTTAAATAGTGTTCTTGGAGATACAAAGCTATTGCCACAGAGAGAGAGAATTGAAAATCCCCTCCCTCTGCTGCAAACGACTGTTGAACCGAGCAAACCTCAACAAAGGGAAATGTTACTTGATGCACTTTTAGAAATCTCCGACAGTGACCCGCTTCTGCGATATTATGTGGATTCTGCGACACATGAAATCATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGACTTGTGCTCTGCTGCAAGAAAAGTATCATGTGGAGATAGAAATAAAAGAGCCTACAGTCATTTATATGGAAAGACCGTTAAAAAAAGCAGAGTATACCATTCACATCGAAGTTCCACCGAATCCTTTCTGGGCTTCCATTGGTTTATCTGTATCACCGCTTCCGTTGGGAAGTGGAATGCAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCATTTCAAAATGCAGTTATGGAAGGGATACGCTATGGCTGTGAACAAGGATTGTATGGTTGGAATGTGACGGACTGTAAAATCTGTTTTAAGTATGGCTTATACTATAGCCCTGTTAGTACCCCAGCAGATTTTCGGATGCTTGCTCCTATTGTATTGGAACAAGTCTTAAAAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAATTTATGCGCCACAGGAATATCTTTCACGAGCATACACCGATGCTCCTAAATATTGTGCGAACATCGTAGACACTCAATTGAAAAATAATGAGGTCATTCTTAGTGGAGAAATCCCTGCTCGGTGTATTCAAGAATATCGTAGTGATTTAACTTTCTTTACAAATGGACGTAGTGTTTGTTTAACAGAGTTAAAAGGGTACCATGTTACTACCGGTGAACCTGTTTGCCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7143,Drugs,MEG_7143|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|909837468|gb|CP003357.2|1835472-1837391 gi|556027507|gb|CP006844.1|1758283-1760202 gi|183217285|gb|EU351020.1|23041-21122 gi|259906609|gb|FJ711160.1|5910-3991 gi|225726369|gb|CP000921.1|1797283-1799202 gi|169636207|dbj|AB426620.1|14972-16891 gi|975709|emb|X90939.1|2098-4017,4
,ATGCGTTATGTTCGCCTGTGTGTTATCTCCCTGTTAGCCACCCTGCCACTGGCGGTAGACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCAGGGGTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTGTCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTTTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGCACTGAATGAGGCGCTTCCCGGCGACGCGCGCGACACCACCACCCCGGCCAGCATGGCCGCCACGCTGCGCAAACTACTGACCGCGCAGCATCTGAGCGCCCGTTCGCAACAGCAACTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGCCGGGCTGGTTTATCGCCGACAAAACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAACCGGAGCGCATTGTGGTGATCTATCTGCGGGATACCCCGGCGAGTATGGCCGAGCGTAATCAACATATCGCCGGGATCGGCGCAGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTACCGTGCGTTAGCCGGCCCGCAGCACCTCGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGACAGATGCCGATCGGTAATAATAATGGTGAACCGGGTCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3574,Drugs,MEG_3574|Drugs|betalactams|Class_A_betalactamases|LEN,gi|15721854|gb|AY037780.1|89-1065,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatcgcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttagaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcatttggttataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgcccctgcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtagttcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctggatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_582,Drugs,MEG_582|Drugs|betalactams|Class_C_betalactamases|ADC,447133952|WP_001211208.1|NG_061391|1|1|blaADC-175|blaADC|class_C_beta-lactamase_ADC-175 NG_061391:1-1152,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGTGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6593,Drugs,MEG_6593|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|325301795|gb|JF262178.1|326-1165,8
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatactggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccgttatgggcaccttcttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2918,Drugs,MEG_2918|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,487467289|WP_001694495.1|NG_047863|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047863:67-1281,6
,ATGAATGAAAAAATCTTAGTGGTTGATGATGAAAAAGAATTGGCCGACTTAGTTGAAGTATATCTGAAAAACGATGGATATACCGTTTATAAATTTTATAATGGCAAGGATGCACTAAAGTGTATTGAATCCGTGGAACTGGATTTAGCCATATTGGATATCATGCTTCCGGATGTAGACGGGTTTCAGATCTGCCAGAAAATCCGGGAAAAGTTTTACTTCCCTGTTATCATGCTGACAGCAAAAGTGGAGGACGGGGATAAAATCATGGGACTGTCTGTGGCAGATGATTATATTACGAAGCCGTTTAACCCGTTGGAAGTGGTTGCGAGGGTAAAGGCGCAGCTAAGGCAGTACATGCGGTACAAGCAGCCCAGCTTAAAGCAAGAGGCTGAATGCACAGAATACGATATCAGAGGGATGACAATTAGCAAGAGCAGCCATAAGTGTATCTTGTTTGGAAAGGAGATTCAGCTGACGCCAACGGAATTTTCGATTCTTTGGTATCTGTGCGAGCGTCAGGGGACGGTTGTTTCTACGGAGGAATTATTTGAAGCAGTATGGGGGGAACGGTATTTTGACAGCAATAATACCGTGATGGCGCATATCGGACGTCTCCGGGAAAAAATGAAGGAACCGTCAAGAAATCCGAAATTTATAAAAACCGTGTGGGGAGTGGGATATACCATTGAAAAATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7478,Drugs,MEG_7478|Drugs|Glycopeptides|VanD-type_regulator|VANRD,gi|40021670|gb|AY489045.1|1-699 gi|484574986|gb|CP005586.1|3026140-3026112,5
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacatcgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtagctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagctaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgcttaagtttattcatgccaatctgaacccacagaaatatccgacagatattcaacgtgcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaaccagcggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcagttttaaatgcaataaaggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_547,Drugs,MEG_547|Drugs|betalactams|Class_C_betalactamases|ADC,1331531448|WP_102607458.1|NG_056175|1|1|blaADC-170|blaADC|class_C_beta-lactamase_ADC-170 NG_056175:1-1152,0
,atggaattgcccaatattatgcacccggtcgcgaagctgagcaccgcattagccgctgcattgatgctgagcgggtgcatgcccggtgaaatccgcccgacgattggccagcaaatggaaactggcgaccaacggtttggcgatctggttttccgccagctcgcaccgaatgtctggcagcacacttcctatctcgacatgccgggtttcggggcagtcgcttccaacggtttgatcgtcagggatggcggccgcgtgctggtggtcgataccgcctggaccgatgaccagaccgcccagatcctcaactggatcaagcaggagatcaacctgccggtcgcgctggcggtggtgactcacgcgcatcaggacaagatgggcggtatggacgcgctgcatgcggcggggattgcgacttatgccaatgcgttgtcgaaccagcttgccccgcaagaggggatggttgcggcgcaacacagcctgactttcgccgccaatggctgggtcgaaccagcaaccgcgcccaactttggcccgctcaaggtattttaccccggccccggccacaccagtgacaatatcaccgttgggatcgacggcaccgacatcgcttttggtggctgcctgatcaaggacagcaaggccaagtcgctcggcaatctcggtgatgccgacactgagcactacgccgcgtcagcgcgcgcgtttggtgcggcgttccccaaggccagcatgatcgtgatgagccattccgcccccgatagccgcgccgcaatcactcatacggcccacatggccgacaagctgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4137,Drugs,MEG_4137|Drugs|betalactams|Class_B_betalactamases|NDM,1028105834|WP_063860859.1|NG_049333|1|1|blaNDM-16|blaNDM|subclass_B1_metallo-beta-lactamase_NDM-16 NG_049333:1-813,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgccgccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatcaccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5636,Drugs,MEG_5636|Drugs|betalactams|Class_C_betalactamases|PDC,730690110|WP_034071670.1|NG_049896|1|1|blaPDC-23|blaPDC|class_C_beta-lactamase_PDC-23 NG_049896:1-1194,0
,ATGAGCGTATCGGAAATCCGACCGATTGCCATTGAGGACGAACTCAAGCATTCATATTTAGATTACGCGATGAGTGTAATTGTATCTCGTGCATTGCCGGATGTGAGAGACGGTCTTAAACCTGTTCACCGTCGTGTGCTTTATGCCATGCACGAATTGGGCAATGACTATAACAAAGCCTACAAGAAATCTGCTCGTGTCGTTGGGGACGTAATCGGTAAATATCACCCGCATGGTGACTTAGCTGTTTATGAAACCATTGTTCGTATGGCTCAAGACTTTAGCTTACGTTATTTATTGGTTGATGGTCAGGGTAACTTCGGTTCGATCGATGGTGATAGCGCTGCGGCAATGCGTTATACCGAAGTCCGTATGACTAAGCTGGCACATGAGCTTCTTGCAGATTTAGAAAAAGACACAGTTGACTGGGAAGATAACTACGACGGTTCGGAACGTATCCCTGAAGTACTTCCGACACGTGTTCCAAACTTGTTAATTAACGGTGCTGCTGGTATTGCTGTAGGTATGGCAACTAACATGGCACCACACAACATGACAGAAGTTGTGAATGCTTGTTTGGCTTATGCTGACAATCCGAATATCTCGATTGAAGGATTGATGGAATACATTACCGGCCCTGACTTCCCTACAGGCGGTATTATTTACGGTAAATCAGGTATTGTTGATGCCTACCGTACCGGTAAAGGTCGTTTACACATTCGTGGTAAATACCATTTCGAAGAAGATGAAAAGACAGGTCGTACAACCATCGTCTTTACTGAAATTCCATATCAAGTAAACAAAGCAAGAGTTATTGAACGTATTGCCGAGTTAGTAAAAGAGAAAAAGCTTGAAGGTATTTCAGAACTTCGTGATGAGTCTGATAAAGAAGGTATGCGTATTGCAATTGACTTGAAACGCGGTGAAAACGCAGAAGTCGTTGTAAATAACTTATTCTTAAATACCCAGCTTGAAAACTCATTCAGCATCAACATGGTTTGTCTAGACAATGGACAACCAAAATTGATGAATCTAAAAGATATTATTGCGGCATTTATTCGTCACCGCCAAGAAGTTGTGACACGCCGTACCATGTTCGAATTACGTAAAGCACGTGAACGTGGGCATATCTTGGAAGGCTTGACAGTTGCTTTAGCCAATATTGATGAAATTATTGAAACCATCAAAACTTCTGCAAACCCTGCTGAAGCGCGTGAGCGTTTACTTGCGGGTGAGTGGGCAGGTGGTGGCGTTGTTGCACTACTTGAAAAAGCTGGTGCAATTTCTGTTCGCCCAGATGAAATTGAAGGTGAAGATCCAAATCGTCCATTTGGTTTAAGTGATTCAATTTATCGTCTGTCACCAACACAAGTAGGCGCAATTTTAGAATTACGTTTACACCGTTTAACTGGTCTTGAACAAGACAAGTTACATGCGGAATATACTGAAATTTTAGGTCAAATTGCTGAACTTACTGCAATTTTAAATGACTTTAACTTGTTAATGGGTGTTATTCGCGAAGAGTTGGCACAAGTTTTACAACAATATGGTGATGCACGTCGTACCGAAATTGTTGAATCTCGTGTGGATTTCTGCCGTGAAGATTTGATTCCTGAAGAGCAAGTGGTATTAACTGTTTCACAAACGGGTTATGCAAAAACTCAACCACTTTCAGACTATCAGGCACAGCGCCGTGGTGGACGTGGTAAGTCTGCGACTTCAATGAAAGATGATGACTTTATTCAACATCTGATTGTGGCATCGAACCATGCGACCGTACTTTGCTTTACCAACGTGGGTAAAGTGTACCGTCTGAAAGTTTTTGAAGTTCCTCAAGCATCACGTGGGGCAAAAGGCCGTCCAATCGTGAATTTGTTACCACTAGATGCAACAGAAACCGTAACCGCAATCTTGCCGTTAACCGAGTTCCCGGAAAACCACTATGTGTTTATGGCGACAGCTTCTGGTACGGTTAAGCGTGTTGAGTTAGAACAATTTGCAAACATTCGTTCAAATGGTCTACGTGCTATTGAACTTAATGAAGAAGATACCTTAATTGGTGTTGCGATTACTGATGGTAATCAGCAAATCATGTTGTTCTCTAACGAAGGTAAAGCAATTCGTTTTGCTGAAACTGACGTACGTGCAATGGGTCGTACAGCGAAAGGTGTACGTGGTATGCGTGTAAGCTTTGCAAGCAGCACCTTAAGTGAAGAAGATGCAGATGTTGAAAATGATGATTCAGATGATAATGATGATTCAGCAGATTCAAGTCTAGTAAGTCGCATCGTATCGCTTGTTGTTGTACCTGAGACAGGCGAAGTACTGTGCGCGAGTGCCAACGGTTATGGTAAACGTACTCCAGTAAATGACTTCCCGACCAAGAAACGTGGTGGTAAGGGTGTTATTGCGATCAAGACAAGTGAACGTAACGGTGAGCTAGTTGGTGCAGTTTCTATTGATGAAACCAAAGAGTTATTATTAATTTCTGATGGTGGTACGCTTGTTCGTACGCGTGCTGCAGAAGTTGCAATGACAGGCCGTAATGCTCAAGGTGTTCGTCTGATCCGTTTAAGCGAAGAAGAAACGCTCGTTGGCGTAGTTTCAATTGAAGCTGTAGAAGACGAAGAAGAACTTCTTGAAGGTGAAGTAGATACGACTGAAACTGATAGCGAAGAAGCTGTATCTAATAATGAAGATACTTCTGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3232,Drugs,MEG_3232|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|974022331|gb|CP013924.1|885887-888601 gi|827403829|gb|CP010779.1|890123-892837 gi|803657307|gb|CP007535.2|1233897-1236611 gi|615556143|gb|CP007577.1|370218-367504 gi|586958174|gb|CP006963.1|3175129-3172415 gi|546200742|dbj|AP013357.1|908721-911435 gi|522344435|gb|CP003849.1|3000680-2997966 gi|522324570|gb|CP003846.1|3093306-3090592 gi|407899266|gb|CP003856.1|3298078-3295364 gi|385876581|gb|CP003500.1|884596-887310,3
,atgtcacttaatgtaaaaccaagtagaatagccatcttgtttagctcttgtttagtttcaatatcatttttctcacaggccaatacaaagggcatcgatgagattaagaaccttgaaacagatttcaatggtagaattggtgtctacgctttagacactggctcaggtaaatcattttcatacaaagcaaatgaacgatttccattatgtagttctttcaaaggttttttagctgctgctgtattaaaaggctctcaagataatcaactaaatcttaatcagatcgtgaattacaatacaagaagtttagagttccattcacccatcacaactaaatataaagataatggaatgtcattaggtgatatggctgctgccgctttacaatatagcgacaatggtgctactaatattattcttgaacgatatatcggtggtcctgagggtatgactaaattcatgcggtcgattggagataaagattttagactcgatcgttgggagttagatctaaacacagctattcctggcgatgaacgtgacacatctacacctgcagcagtagctaagagcctgaaaacccttgctctgggtaacatacttaatgagcgtgaaaaggaaacctatcagacatggttaaagggtaacacaaccggtgcagcacgtattcgtgctagcgtaccaagcgattgggtagttggcgataaaactggtagttgcggagcatacggtacggcaaatgattatgcggtagtctggccaaagaaccgagctcctcttataatttctgtatacactacaaaaaacgaaaaagaagccaagcatgacgataaagtaatcgcagaagcttcaagaatcgcaattgataaccttaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3306,Drugs,MEG_3306|Drugs|betalactams|Class_A_betalactamases|IMI,1031994775|WP_064190970.1|NG_050720|1|1|blaIMI-12|blaIMI|carbapenem-hydrolyzing_class_A_beta-lactamase_IMI-12 NG_050720:1-879,0
,GTGAATACGTCTTATTCACAGTCAACTTTACGGCACAATCAAGTTTTGATTTGGCTTTGTGTTCTATCATTTTTCAGCGTATTAAATGAAATGGTTCTGAACGTCTCATTACCTGATATTGCCAACGAGTTTAATAAACTGCCAGCAAGTGCAAACTGGGTGAATACAGCCTTTATGTTAACCTTCTCCATTGGAACAGCTCTATATGGAAAGCTATCAGACCAGCTGGGCATCAAAAATCTGCTTCTATTTGGGATTATGGTAAATGGCTTAGGGTCGATCATTGGATTTGTTGGACACTCTTTCTTTCCTATTCTCATTCTAGCCCGATTTATTCAAGGAATTGGTGCAGCCGCATTCCCAGCTCTTGTGATGGTTGTCGTTGCGCGCTATATTCCAAAAGAGAACAGGGGGAAAGCATTTGGCCTGATCGGGTCCCTGGTAGCAATGGGAGAAGGTGTTGGGCCAGCTATTGGCGGAATGGTTGCTCATTATATCCATTGGTCGTATTTGCTGCTTATTCCAACTGCAACAATTATCACCGTTCCATTCCTTATAAAATTGTTGAAAAAGGAAGAGAGAATAAGAGGACACATTGATATGGCAGGGATTATATTGATGTCTGCAGGTATCGTATTTTTTATGCTGTTTACAACATCTTATAGATTTTCTTTTCTGATCATCAGTATCCTTGCTTTCTTCATATTTGTGCAACACATTAGGAAAGCTCAGGACCCTTTTGTTGACCCTGAATTAGGGAAAAACGTCTTTTTTGTGATTGGAACCCTTTGCGGAGGACTAATATTTGGTACAGTAGCAGGATTTGTCTCTATGGTTCCTTACATGATGAAAGATGTTCACCATTTAAGTACTGCAGCAATTGGAAGCGGCATTATTTTCCCCGGAACAATGAGTGTCATCATCTTTGGTTACATTGGGGGATTGCTTGTTGATCGGAAAGGTTCCTTGTATGTACTAACTATTGGAAGTGCATTGCTTTCTTCCGGCTTTTTAATCGCTGCCTTTTTTATAGATGCAGCACCATGGATCATGACAATTATAGTAATTTTTGTTTTTGGGGGGCTATCTTTCACAAAAACAGTTATATCTACAGTTGTGTCTAGCAGTTTGAAAGAAAAGGAAGCGGGCGCTGGAATGAGTTTGCTTAATTTCACGAGCTTTTTATCAGAGGGAACGGGTATTGCGATTGTAGGCGGTTTATTATCTATCGGCTTCCTAGATCATAGGCTGCTGCCTATTGACGTTGATCACTCTACCTATTTGTATAGCAATATGCTCATACTTTTTGCAGGAATCATTGTTATTTGTTGGCTAGTAATCTTGAATGTATATAAACGTTCGCGGAGACATGGCTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7102,Drugs,MEG_7102|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETL,gi|983204966|gb|CP014166.1|4029732-4028356 gi|846133629|gb|CP011882.1|927825-926449 gi|807072327|gb|CP011115.1|4189084-4187708 gi|749183975|gb|CP010314.1|4168553-4167177 gi|728887195|gb|CP010053.1|4188818-4187442 gi|728882887|gb|CP010052.1|4189070-4187694 gi|724425628|emb|LN680001.1|4207066-4205690 gi|723796434|emb|LN649259.1|4225103-4223727 gi|670919138|gb|CP005997.1|4032729-4031353 gi|655529211|gb|CP007409.1|4014291-4012915,4
,atgaaaacagtatttatccttatctccatgcttttccctgtcgcagttatggcacagaaaagcgtaaaaatatctgatgatatcagtatcacccaactctcggataaagtgtacacttatgtatccctcgccgaaatcgaaggatggggcatggtaccttccaacggaataattgttatcaacaaccatcgggcagcgttgctggacacaccgatcaatgacgcacaaacggaaacactggtcaactgggtgacagactctttgcatgccaaagtcaccacgtttatcccgaaccactggcacggcgattgtattggcggactgggttacctgcaaaagaaaggtgtccaatcatacgcaaaccagatgacgatagacttcgctaaggaaaaaggattgcccataccggaacatggattcaccgattcactgaccgtcagtctggacggcatgcctctccaatgttattatttaggaggcggacatgcgaccgacaatatcgtggtttggctgccgacagagaatatcctttttggcggatgtatgcttaaagacaaccaggcgacaagcatcggcaacatctcggacgcggacgtgacggcatggccgaaaactctcgataaggtaaaagccaagttcccctcggcccgctacgtcgtgcccggacatggcgactatggcggaaccgaactgatagagcataccaagcagatcgtgaaccaatatatagaaagcacttcaaagccatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1665,Drugs,MEG_1665|Drugs|betalactams|Class_B_betalactamases|CFIA,1188444887|WP_085562389.1|NG_054674|1|1|cfiA17|cfiA|subclass_B1_metallo-beta-lactamase_CfiA17 NG_054674:1-750,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcaccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5574,Drugs,MEG_5574|Drugs|betalactams|Class_C_betalactamases|PDC,1028110202|WP_063864572.1|NG_049888|1|1|blaPDC-18|blaPDC|class_C_beta-lactamase_PDC-18 NG_049888:1-1194,0
,TTGGCTATAAAATTGAAAAATAAGAATAAAAAAACCGATTATTCCAAACTAAAACGAAAACTCTACCAGTATATCGTTGTGATTGTTATGGCAGCAGTTGTATTCGTGTTGTTTTTGCGTTTATTTATCAAGGGGACACTTGGGGAGTGGATCGTACGTTTTTTGGAAAACAGTTATCACTTAGATCGCCTGGACGCGATGAAATTATATCAATATTCCATACGGAACAATATAGATATCTTTATTTATGTGGCGATTGTCATTAGTATTCTTATTCTATGTCGCGTCATGCTTTCAAAATTCGCAAAATACTTTGACGAGATAAATACCGGCATTGATGTACTTATTCAGAACGAAGATAAACAAATTGAGCTTTCTGCGGAAATGGATGTTATGGAACAAAAGCTCAACACATTAAAACGGACTCTGGAAAAGCGAGAGCAGGATGCAAAGCTGGCCGAACAAAGAAAAAATGACGTTGTTATGTACTTGGCGCACGATATTAAAACGCCCCTTACATCCATTATCGGTTATTTGAGCCTGCTTGACGAGGCTCCAGACATGCCGGTAGATCAAAAGGCAAAGTATGTGCATATCACGTTGGACAAAGCGTATCGACTCGAACAGCTAATCGACGAGTTTTTTGAGATTACACGGTATAACCTACAAACGATAACGCTAACAAAAACGCACATAGACCTATACTATATGCTGGTGCAGATGACCGATGAATTTTATCCTCAGCTTTCCGCACATGGAAAACAGGCGGTTATTCACGCCCCCGAGGATCTGACCGTGTCCGGCGACCCTGATAAACTCGCGAGAGTCTTTAACAACATTTTGGAAAACGCCGCTGCATACAGCGAGGACAACAGCGTCATTGACATTACGGCGGGCCTCTCCGGGGATGTGGTGTCCATCGTTTTCAAGAACGCCGGAAGCATCCCCAAAGATAAGCTCGCTGCCATATTTGAAAAGTTTTACAGGCTGGACGATGCTCGTTCTTCCGATACGGGCGGCGCGGGACTTGGATTGGCGATTGCAAAAGAAATCATTGTTCAGCATGGCGGGCAGATTTACGCGGAAAGCAATGATAACTACACTACGTTCACGGTAGAGCTTCCGGCCTTGCCAGACTTGGTTGATAAAAGGAGTTCCTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7487,Drugs,MEG_7487|Drugs|Glycopeptides|VanA-type_regulator|VANSA,(Gly)VanS-Pt:AY926880:1391-2551:1461,5
,atgcgggataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggtagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgatgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctgaatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5713,Drugs,MEG_5713|Drugs|betalactams|Class_C_betalactamases|PDC,1509794573|WP_122630882.1|NG_062302|1|1|blaPDC-315|blaPDC|class_C_beta-lactamase_PDC-315 NG_062302:1-1194,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCCCTTTCTCCACGTTTGCCGCAGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAAAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGTGGCCTGGCACATTCTTGAAAAGCTGCAATAACTAACGATGAGGCCCAGGATATTGGGCCTCCTTTCTTTCTCTTTTTTTCCTGTTGTCATCTACACTTAACAAAAATACAGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1984,Drugs,MEG_1984|Drugs|betalactams|Class_C_betalactamases|CMY,gi|591542868|gb|KJ207204.1|580-1808,0
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaataaaacccagagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaagcagataaaaaaattaatctgtatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttaccggttgggaaaaagacatgacactaggagaagccatgaagctttccgcagtcccagtctatcaggaacttgcgcgacgtatcggtcttgatctcatgcaaaaagaagtaaaacgtattggtttcggtaatgctgaaattggacagcaggttgataatttctggttggtagggccattaaaggttacgcctattcaagaggtagagtttgtttctcaattggcgcatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgcttcttttagaagagagtaatggctacaaaatttttggaaagaccggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcacttttgcattaaatatggaaatgcggtcagaaatgcctgcatctatacgtaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4518,Drugs,MEG_4518|Drugs|betalactams|Class_D_betalactamases|OXA,1625655421|WP_136512098.1|NG_064765|1|1|blaOXA-807|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-807 NG_064765:1-822,0
,atgaacaaaaaaaatataaaagacagtcaaaactttattacttcgaaacgtaatgtagataaaataatgacaaatataagcttaaatgaacatgataatatctttgaaattggctcaggaaaagggcattttacccttgaattagtacaaaggtgtaatttcgtaactgctattgaaatagaccataaattatgcaagactacagaaaataaacttgttaatcacgataattttcaagttttaaacaaggatatattgcagtttaaatttcctaaaaaccaatcctataaaatatttggtaatataccttacaacataagtacggatataatacgcaaagttgtttttgaaagtatagctgatgagatttatttaatcgtggaatacgggtttgctaaaaggttattgaatacaaagcgctcattggcgttacttttaatggcagaagttgatatttctatattaagtatggttccaagagaatattttcatcctaaacctaaagtgaatagcgcgcttatcagattaaagagaaaaaaatcaagaatatcgtacaaagataaacagaagtataattatttcgttatgaaatgggttaacaaagaatacaagaaaatatttacaaagaatcaatttaacaaatccttaaaacatgcgggaattgacgatttaaacaatattagctttgagcaattcttgtctcttttcaatagctataaattatttaataagtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2809,Drugs,MEG_2809|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,695270347|WP_032492416.1|NG_047817|1|1|erm(C)|erm(C)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(C) NG_047817:101-835,7
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGATGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1341,Drugs,MEG_1341|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_37_JIFD01000012,0
,ATGTTCTCTCGCTGGTCGAAGACTTTCGCGTTTGCCGTGGTGGCCTGCACGCTCGCAATAAGCACCGCCACCGCTCATGCCGAGCTGGTCGTGCGCAATGACCTCAAGCGCGTGTTCGACGACGCCGGCGTCTCCGGCACCTTCGTGCTGATGGACATCACCGCCGACCGTACCTATGTCGTCGATCCGGCGCGTGCCGCGCGGCGCATCCATCCGGCTTCGACGTTCAAGATTCCGAACAGCCTGATCGCCTTCGACACCGGGGCCGTGCGCGACGATCAGGAAGTGCTGCCCTACGGCGGCAAGCCGCAGCCTTACGAGCAGTGGGAGCACGACATGGCGTTACCCGAGGCGATTCGCCTGTCGGCCGTGCCGATCTATCAGGAAGTCGCGCGCCGCGTTGGCTTCGAGCGCATGCAGGCTTATGTCGATGCGTTCGACTACGGCAATCGCCAGCTCGGCAGCGCGATCGACCAGTTCTGGCTGCGTGGCCCGCTGGAGATTTCCGCTTTCGAAGAAGCACGCTTCACCAGCCGCATGGCGCTCAAGCAGTTGCCGGTGAAGCCGCGCACGTGGGACATGGTCCAGCGCATGCTGTTGATCGAGCAGCAGGGCGATGCCGCGCTGTATGCCAAGACCGGCGTCGCCACCGAATACCAGCCGGAGATCGGTTGGTGGGTCGGCTGGGTGGAGCGTGCGGGGCATGTCTATGCATTCGCGCTGAACATCGACATGCCGCGCGAGGGCGATATGGCCAAGCGCATTCCGCTGGGCAAGCAGTTGATGCGGGCGCTCGAGGTGTGGCCGGCACCGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5242,Drugs,MEG_5242|Drugs|betalactams|Class_D_betalactamases|OXA,gi|636668380|gb|KJ692398.1|1938-1123 gi|50236430|gb|AY664504.1|1-816,0
,atggctctggcgctcgtgggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgaaaatagtacattttttttatgtgatttttcaggagccgacctgagcggcactgagtttatcggctgtcaattctatgatcgtgaaagccagaaaggctgcaattttagtcgtgcgatgttaaaggatgccatttttaaaagctgcgatttatccatggcggattttcgcaatgcaagcgccctgggtattgagatttctcattgtagggctcagggtgcagattttcgcggcgcaagctttatgaacatgattaccacgcgcacttggttctgcagcgcgtatatcacgaatacgaatctgtcttatgccaatttttcgaaagtcgtgttggagaagtgtgagttatgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcaactttcgactggcgagcagcaaactttacacattgcgatctcacaaattcggagttgggtgacttagatattcgtcgggttgatttacaaggcgttaagttggacaactaccaggcttcgttgctcatggagcgacttggcatcgcgataattggttga,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5895,Drugs,MEG_5895|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111810|WP_063866022.1|NG_050493|1|1|qnrB31|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB31 NG_050493:37-681,3
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1454,Drugs,MEG_1454|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_128_GQ900471,0
,gtgaccaacagcaacgattccgtcacactgcgccacatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggacggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccatatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_215,Drugs,MEG_215|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502063|WP_071846215.1|NG_052213|1|1|aac(6')-Ib-cr|aac(6')-Ib-cr|fluoroquinolone-acetylating_aminoglycoside_6'-N-acetyltransferase_AAC(6')-Ib-cr NG_052213:101-655,2
,TGGAAACCTACAATCATACATATCGGCACCGCAACTTTTCACATAAAGACTTAAGTGATCTCACCTTCACCGCTTGCACATTCATTCGCAGCGACTTTCGACGTGCTAACTTGCGTGATACGACATTCGTCAACTGCAAGTTCATTGAACAGGGTGATATCGAAGGCTGCCACTTTGATGTCGCAGATCTTCGTGATGCAAGTTTCCAACAATGCCAACTTGCGATGGCAAACTTCAGTAATGCCAATTGCTACGGTATAGAGTTCCGTGCGTGTGATTTAAAAGGTGCCAACTTTTCCCGAACAAACTTTGCCCATCAAGTGAGTAATCGTATGTACTTTTGCTCAGCATTTATTTCTGGATGTAATCTTTCCTATGCCAATATGGAGAGGGTTTGTTTAGAAAAATGTGAGTTGTTTGAAAATCGCTGGATAGGAACGAACCTAGCGGGTGCATCACTGAAAGAGTCAGACTTAAGTCGAGGTGTTTTTTCCGAAGATGTCTGGGGGCAATTTAGCCTACAGGGTGCCAATTTATGCCACGCCGAACTCGACGGTTTAGATCCCCGCAAAGTCGATACATCAGGTATCAAAATTGCAGCCTGGCAGCAAGAACTGATTCTCGAAGCACTGGGTATTGTTGTTTATCCTGACTAA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6019,Drugs,MEG_6019|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRS,(Flq)QnrS3:EU077611:1-657:657,3
,GTGGCAAAGCAAAAGTTCAAAATCACCAACTGGCCCACCTACAATAAAGCCCTCATCAACCGTGGCTCCATAACTTTCTGGCTGGATGATGAAGCTATTCAGGCCTGGTATGAGTCAGCAACACCTTCTTCACGAGGCAGACCTCAGCGCTATTCTGACCTTGCCATCACGACTGTGCTGGTCATTAAACGCGTATTCAGGCTGACCCTGCGCGCTGCGCAGGGCTTTATTGATTCCATTTTTTCTCTGATGAACGTTCCGCTACGCTGCCCGGATTACAGCTGTGTCAGCAGGCGGGCAAAGTCGGTTAACGTCAGTTTCAAAACGTTCACCCGGGGTGAAATCGCGCATCTGGTGATTGATTCCACCGGGCTGAAGGTCTTTGGTGAAGGCGAGTGGAAAGTCAAAAAGCATGGCCAGGAACGCCGTCGTATATGGCGAAAGTTGCATCTGGCAGTTGACAGCAACACACATGAAATCATCTGTGCAGACCTGTCGCTGAACAATGTGACGGACTCAGAAGCCTTCCCGGGTCTTATCCGGCAGACTCACAGAAAAATCAGGGCAGCATCGGCAGACGGCGCTTACGACACCCGGCTCTGTCACGATGAACTGCGGCGTAAGAAAATCAGCGCGCTTATCCCACCCCGAAAAGGTGCGGGTTACTGGCCCGGTGAATATGCAGACCGTAACCGTGCAGTGGCTAATCAGCGAATGACCGGGAGTAATGTGCGGTGGAAATGGACAACAGATTACAACCGTCGCTCGATAGCGGAAACGGCGATGTACCGGGTAAAACAGCTGTTCGGGGGTTCACTGACGCTGCGTGACTACGATGGTCAGGTTGCGGAGGCTATGGCCCTGGTACGAGCGCTGAACAAAATGACGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2430,Drugs,MEG_2430|Drugs|betalactams|Class_A_betalactamases|CTX,gi|90019040|gb|DQ303459.3|3175-4063 gi|908301814|gb|CP012165.1|2401724-2401398 gi|908276372|gb|CP010376.2|2363798-2363472 gi|908266278|gb|CP012170.1|86929-87255 gi|828977725|gb|CP011650.1|1898170-1897844 gi|828945832|gb|CP011618.1|579945-579619 gi|828945832|gb|CP011618.1|4494210-4493884 gi|828945622|gb|CP011617.1|71779-72105 gi|828933802|gb|CP011601.1|275235-274909 gi|828927642|gb|CP011597.1|560219-559893 gi|828927436|gb|CP011596.1|70452-70778,0
,GTGAGAAGTGAACCAGAAATGATGAATATGCTTGTAAAGTTTGCTATGAACGATAAAAGAATACGATTGGTCACGATGGAAGGATCACGTACAAACTTCAATGTTCCTCCTGATTCATTTCAAGATTATGATATTTCTTACTTTGTAACAGATATGGATTCTTTCAAGGAAAGTGATCAATGGCTGAACGTGTTTGGGGATAGGCTTATGATGCAAAAACCCGAGGATATGGAGCTTTTTCCATCAGAACTAGGTAACTGGTTTTCATATATCATTCTTTTTGAGGATGGAAACAAATTAGATCTGACACTGATCCCTATAAACGAGGTAGAGGATTATTTTACGAATAGCGATGGTTTAGTTGAGGTTCTGCTCGACAAGGATGTGCTGATCCAAGAGGAAGTGATCGCAAACGATCATCAATATTGGATTAAAAAGCCCACTGCAAGGGAATTTGATGATTGCTGTAATGAATTTTGGATGGTTTCAACTTATATCGTAAAAGGATTGGCGAGAAAAGAAATCCTGTTTGCTATTGACCATTTGAACGAGATTGCACGACCTAATTTGTTGCGAATGATGGCTTGGAAGATTGGATCAGAGCAAGGGTACACCTTTAGTGTAGGAAAAAACTATAAATTTATAAATCAGTATCTTCCTAATGAAGATTGGAAAAGCCTACTATCGACTTACTCAGAGAACGGCTATCAAGAAATGTGGCAGTCTTTACTTACTTGTTATTCATTGTTTAGAACATACGCTAAGGCTGTGGCAAGCAGTTTGAAATATGAGTATCCAGAATACGATGAAGCCATTACTAGGTACACTGTAAATATTTATAATTCATTGAATTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_992,Drugs,MEG_992|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,(AGly)AadE-Pp:HE577054:1299623-1300477:855,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgataagcctggtaaatattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaagttgttgctttgtctatgaataaacctttcaaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatatacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaatcctggtccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctcaatccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcgtatgcagttttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_553,Drugs,MEG_553|Drugs|betalactams|Class_C_betalactamases|ADC,1058243528|WP_068981610.1|NG_051442|1|1|blaADC-103|blaADC|class_C_beta-lactamase_ADC-103 NG_051442:1-1152,0
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatgctggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcacctacttcgtcttcttctcgacggctccccgtgtgctcttaggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2921,Drugs,MEG_2921|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,501556594|WP_012561099.1|NG_047876|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047876:101-1315,6
,ATGAAAAAGATAAAAATTGTTCCACTTATTTTAATAGTTGTAGTTGTCGGGTTTGGTATATATTTTTATGCTTCAAAAGATAAAGAAATTAATAATACTATTGATGCAATTGGAGATAAAAATTTCAAACAAGTTTATAAAGATAGCAGTTATATTTCTAAAAGCGATAATGGTGAAGTAGAAATGACTGAACGTCCGATAAAAATATATAATAGTTTAGGCGTTAAAGATATAAACATTCAGGATCGTAAAATAAAAAAAGTATCTAAAAATAAAAAACGAGTAGATGCTCAATATAAAATTAAAACAAACTACGGTAACATTGATCGCAACGTTCAATTTAATTTTGTTAAAGAAGATGGTATGTGGAAGTTAGATTGGGATCATAGCGTCATTATTCCAGGAATGCAGAAAGACCAAAGCATACATATTGAAAATTTAAAATCAGAACGTGGTAAAATTTTAGACCGAAACAATGTGGAATTGGCCAATACAGGAACAGCATATGAGATAGGCATCGTTCCAAAGAATGTATCTAAAAAAGATTATAAAGCCATCGCTAAAGAACTAAGTATTTCTGAAGACTATATCAAACAACAAATGGATCAAAATTGGGTACAAGATGATACCTTCGTTCCACTTAAAACCGTTAAAAAAATGGATGAATATTTAAGTGATTTCGCAAAAAAATTTCATCTTACAACTAATGAAACAGAAAGTCGTAACTATCCTCTAGAAAAAGCGACTTCACATCTATTAGGTTATGTTGGTCCCATTAACTCTGAAGAATTAAAACAAAAAGAATATAAAGGCTATAAAGATGATGCAGTTATTGGTAAAAAGGGACTCGAAAAACTTTACGATAAAAAGCTCCAACATGAAGATGGCTATCGTGTCACAATCGTTGACGATAATAGCAATACAATCGCACATACATTAATAGAGAAAAAGAAAAAAGATGGCAAAGATATTCAACTAACTATTGATGCTAAAGTTCAAAAGAGTATTTATAACAACATGAAAAATGATTATGGCTCAGGTACTGCTATCCACCCTCAAACAGGTGAATTATTAGCACTTGTAAGCACACCTTCATATGACGTCTATCCATTTATGTATGGCATGAGTAACGAAGAATATAATAAATTAACCGAAGATAAAAAAGAACCTCTGCTCAACAAGTTCCAGATTACAACTTCACCAGGTTCAACTCAAAAAATATTAACAGCAATGATTGGGTTAAATAACAAAACATTAGACGATAAAACAAGTTATAAAATCGATGGTAAAGGTTGGCAAAAAGATAAATCTTGGGGTGGTTACAACGTTACAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCAGATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAAGATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTACGGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCACCTCACTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCAACAAGTCGTTAATAAAACACATAAAGAAGATATTTATAGATCTTATGCCAACTTAATTGGCAAATCCGGTACTGCCGAACTCAAAATGAAACAAGGAGAAACTGGCCGACCAATTGGGTGGTTTATATCATATGATAAAGATAATCCCCACCTGATGATGGCTATTAATGTTAAAGATGTTCCAGATAAAGGAATGGCTAGCTACAATGCCAAAATCTCAGGTAAAGTGTATGATGAGCTATATGAGAACGGTAATAAAAAATACGATATAGATGAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3788,Drugs,MEG_3788|Drugs|betalactams|Penicillin_binding_protein|MECA,mecA_3_Y13095,0
,atgaaaacatttgccgcatatgtaattatcgcgtgtctttcgagtacggcattagctggttcaattacagaaaatacgtcttggaacaaagagttctctgccgaagccgtcaatggtgtcttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaatgacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaagcaatgggaaagagacttgaccttaagaggggcaatacaagtttcagctgttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcctatggcaaccagaatatcagtggtggcattgacaaattggaaggccagcttagaatttccgcagttaatcaagtggagtttctagagtctctatatttaaataaattgtcagcatctaaagaaaaccagctaatagtaaaagaggctttggtaacggaggcggcacctgaatatctagtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttgggtgggttgagaaggagacagaggtttactttttcgcctttaacatggatatagacaacgaaagtaagttgccgctaagaaaatccattcccaccaaaatcatggaaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4421,Drugs,MEG_4421|Drugs|betalactams|Class_D_betalactamases|OXA,1625655410|WP_136512087.1|NG_064753|1|1|blaOXA-795|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-795 NG_064753:1-795,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcagcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5511,Drugs,MEG_5511|Drugs|betalactams|Class_C_betalactamases|PDC,1201190435|WP_087587955.1|NG_054971|1|1|blaPDC-185|blaPDC|class_C_beta-lactamase_PDC-185 NG_054971:1-1194,0
,atggccgcctcggccgccgtatcgctcgtcgtgttcctgttcgtgttcgtgtttacgttcgcgcacgcgcaggatcagccggcctcgtgggctcagccgcagaagcccgttcgcatcttcggcaacacttggtacgtaggcacgcgcgggctgagcgccattctcatcacgtcgcccaccggcgccgtgctcatcgacggagcggtgcgtgaagcggcgtccgatatcgccagcaacatcacgtcgcttggcgtacggctcgaggacatcaaactgatcgtcaattcgcatgcgcacaacgatcacgccggcgcgattgcggaactacagcggcggacgggcgccacggtggccgcgctgccgtggagcgcggaggcgctgcgaagcggacggaagcatcagggcgatccgcagttcgaatcaccaacgtcacctcccgaccgcgtcgccaacgtcaagacgatccaggatggcgaggtgctgcgtgccggaggcgtggaggtcacggcgcacaagaccgccggccatacgccgggcggcacgacatggacgtggcgctcgtgcgaggagaacaggtgcgtcgacatcgtgtatgccgacagcctgaccgccgtttcggccgatgggttccgcttcaccgacaacaaaacgtatccgcaggcgatcgacgatttcaacaaaggctacgcgttcctgcgatccgcgagctgcgacatcctggtgacgccgcatccggaagcctcggacttctggggccgcatcgccaagcgcgacgccggagagcgcgatgcgctgatcgatcgctcgcagtgcgcgcgttatgccgatcgcgccgatgcgcagttgcagaaacgcctggcgacggagcgcgcggagcgcccgaaatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_719,Drugs,MEG_719|Drugs|betalactams|Class_B_betalactamases|ALG,1509794524|WP_122630833.1|NG_062237|1|1|blaALG11-1|blaALG11|subclass_B3_metallo-beta-lactamase_ALG11-1 NG_062237:1-888,0
,ATGGCAAATAACTTCCAGTGCGGGCGCTTTGAGTTCGATCTCGAGCGCCCGCTTGTCATGGGCATCGTCAACGTCACGCCCGACTCGTTTTCCGATGGCGGCGAGCACGCCGATACCGACAGCGCGATCGCCCACGCGCGCCAATTGATCGACGAAGGGGCCCATATCCTGGACCTGGGCGGCGAATCGACGCGGCCGGGCGCGCAGCCGGTCAGCGCGGCCGACGAGCTGGCGCGCATCCTGCCGCTGATCGAAGGGCTGCGCGACTGCGGCGTGCCGTTGTCGATCGACACCTTCAAGCCCGAGGTCATGCGCGCCGTGCTTGACGCCGGCGCCGACATGATCAACGACATCTACGGTTTCCGGCAGCCCGGCGCCATCGACGCGGTGGCGCGCTCGCGCTGCGGCCTGTGCGTCATGCACATGAAGGGCGAGCCGCGCACCATGCAGGAGGCGCCCGAGTACGCCGACCTGATGGGCGAAATCGGGGTCTTCCTGGGCGCGCGCGCCCAGCGGCTGCGCGCCGCGTGGGTCGACCCCCGGCGCATCGTGCTGGACCCGGGCTTCGGGTTCGGCAAGACCATGGATCAGAATTATCAGTTGCTGCGCCGCCTGGCCAGCTTGCGCGTCTCCAGCTACCCCCTGCTGGTGGGCGTCTCGCGCAAATCCATGATAGGCGCGGCCACCGGCAAGCCGGTGGGCGACCGCCTGGCCGGCAGCGTTGCCGCCGCGCTGGCATGCGTGGCGCGCGGCGCCGCCATCGTGCGTGTGCACGATGTCGCCGCGACCGTGGATGCGCTAAAAGTGTGGCAGGCGGCCGAACAAGGAGCAGTCCCTACATGA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2965,Drugs,MEG_2965|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|973420427|gb|CP010966.1|1110748-1109906 gi|973416827|gb|CP010965.1|2947944-2948786 gi|937412521|gb|CP011401.1|2941237-2942079 gi|937409066|gb|CP011400.1|826129-825287 gi|937404317|gb|CP011448.1|1109694-1108852 gi|937400854|gb|CP011447.1|1109703-1108861 gi|937393878|gb|CP011446.1|1108655-1107813 gi|937390412|gb|CP011445.1|1108651-1107809 gi|937386949|gb|CP011444.1|1108637-1107795 gi|937383491|gb|CP011443.1|2945859-2946701,8
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGGCCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6607,Drugs,MEG_6607|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|695223897|ref|NG_040952.1|6926-7765 gi|695220981|ref|NG_039598.1|6926-7765,8
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcgaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccggagttgggcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaaatcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacggggcccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3095,Drugs,MEG_3095|Drugs|betalactams|Class_A_betalactamases|GES,1407696516|WP_111273848.1|NG_060520|1|1|blaGES-35|blaGES|class_A_beta-lactamase_GES-35 NG_060520:1-864,0
,atgagcaagttatctgtattctttatatttttgttttgcagcattgctaccgcagcagagtctttgccagatttaaaaattgaaaagcttgatgaaggcgtttatgttcatacttcgtttgaagaagttaacgggtggggctttgttcctaaacatggtttggtggttcttgtaaatgctgaggcttacctaattgacactccatttacggctaaagatactgaaaagttagtcacttggtttgtggagcgtggctataaaataaaaggcagcatttcctctcattttcatagcgacagcacgggcggaatagagtggcttaattctcgatctatccccacgtatgcatctgaattaacaaatgaactgcttaaaaaagacggtaaggttcaagccacaaattcatttagcggagttaactattggctagttaaaaataaaattgaagttttttatccaggcccgggacacactccagataacgtagtggtttggttgcctgaaaggaaaatattattcggtggttgttttattaaaccgtacggtttaggcaatttgggtgacgcaaatatagaagcttggccaaagtccgccaaattattaaagtccaaatatggtaaggcaaaactggttgttccaagtcacagtgaagttggagacgcatcactcttgaaacttacattagagcaggcggttaaagggttaaacgaaagtaaaaaaccatcaaaaccaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3336,Drugs,MEG_3336|Drugs|betalactams|Class_B_betalactamases|IMP,1188444889|WP_085562391.1|NG_054676|1|1|blaIMP-66|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-66 NG_054676:1-741,0
,ATGGCTGAATTACCTCAATCAAGAATAAATGAACGAAATATTACCAGTGAAATGCGTGAATCATTTTTAGATTATGCGATGAGTGTTATCGTTGCTCGTGCATTGCCAGATGTTCGTGACGGTTTAAAACCAGTACATCGTCGTATACTATATGGATTAAATGAACAAGGTATGACACCGGATAAATCATATAAAAAATCAGCACGTATCGTTGGTGACGTAATGGGTAAATATCACCCTCATGGTGACTCATCTATTTATGAAGCAATGGTACGTATGGCTCAAGATTTCAGTTATCGTTATCCGCTTGTTGATGGCCAAGGTAACTTTGGTTCAATGGATGGAGATGGCGCAGCAGCAATGCGTTATACTGAAGCGCGTATGACTAAAATCACACTTGAACTGTTACGTGATATTAATAAAGATACAATAGATTTTATCGATAACTATGATGGTAATGAAAGAGAGCCGTCAGTCTTACCTGCTCGATTCCCTAACTTATTAGCCAATGGTGCATCAGGTATCGCGGTAGGTATGGCAACGAATATTCCACCACATAACTTAACAGAATTAATCAATGGTGTACTTAGCTTAAGTAAGAACCCTGATATTTCAATTGCTGAGTTAATGGAGGATATTGAAGGTCCTGATTTCCCAACTGCTGGACTTATTTTAGGTAAGAGTGGTATTAGACGTGCATATGAAACAGGTCGTGGTTCAATTCAAATGCGTTCTCGTGCAGTTATTGAAGAACGTGGAGGCGGACGTCAACGTATTGTTGTCACTGAAATTCCTTTCCAAGTGAATAAGGCTCGTATGATTGAAAAAATTGCAGAGCTCGTTCGTGACAAGAAAATTGACGGTATCACTGATTTACGTGATGAAACAAGTTTACGTACTGGTGTGCGTGTCGTTATTGATGTGCGTAAGGATGCAAATGCTAGTGTCATTTTAAATAACTTATACAAACAAACACCTCTTCAAACATCATTTGGTGTGAATATGATTGCACTTGTAAATGGTAGACCGAAGCTTATTAATTTAAAAGAAGCGTTGGTACATTATTTAGAGCATCAAAAGACAGTTGTTAGAAGACGTACGCAATACAACTTACGTAAAGCTAAAGATCGTGCCCACATTTTAGAAGGATTACGTATCGCACTTGACCATATCGATGAAATTATTTCAACGATTCGTGAGTCAGATACAGATAAAGTTGCAATGGAAAGCTTGCAACAACGCTTCAAACTTTCTGAAAAACAAGCTCAAGCTATTTTAGACATGCGTTTAAGACGTCTAACAGGTTTAGAGAGAGACAAAATTGAAGCTGAATATAATGAGTTATTAAATTATATTAGTGAATTAGAAGCAATCTTAGCTGATGAAGAAGTGTTATTACAGTTAGTTAGAGATGAATTGACTGAAATTAGAGATCGTTTCGGTGATGATCGTCGTACAGAAATTCAATTAGGTGGATTTGAAAACTTAGAGGACGAAGACTTAATTCCAGAAGAACAAATAGTAATTACACTAAGCCATAATAACTACATTAAACGTTTGCCGGTATCTACATATCGTGCTCAAAACCGTGGTGGTCGTGGTGTTCAAGGTATGAATACATTGGAAGAAGATTTTGTCAGTCAATTGGTAACTTTAAGTACACATGACCATGTATTGTTCTTTACTAACAAAGGTCGTGTATACAAACTTAAAGGTTACGAAGTGCCTGAGTTATCAAGACAGTCTAAAGGTATTCCTGTAGTGAATGCTATTGAACTTGAAAATGATGAAGTCATTAGTACAATGATTGCTGTTAAAGACCTTGAAAGTGAAGACAACTTCTTAGTGTTTGCAACTAAACGTGGTGTCGTTAAACGTTCAGCATTAAGTAACTTCTCAAGAATAAATAGAAATGGTAAGATTGCGATTTCGTTCAGAGAAGATGATGAGTTAATTGCAGTTCGCTTAACAAGTGGTCAAGAAGATATCTTGATTGGTACATCACATGCATCATTAATTCGATTCCCTGAATCAACATTACGTCCTTTAGGCCGTACAGCAACGGGTGTGAAAGGTATTACACTTCGTGAAGGTGACGAAGTTGTAGGGCTTGATGTAGCTCATGCAAACAGTGTTGATGAAGTATTAGTAGTTACTGAAAATGGTTATGGTAAACGTACGCCAGTTAATGACTATCGCTTATCAAATCGTGGTGGTAAAGGTATTAAAACAGCTACGATTACTGAGCGTAATGGTAATGTTGTATGTATCACTACAGTAACTGGTGAAGAAGATTTAATGATTGTTACTAATGCAGGTGTCATTATTCGACTAGATGTTGCAGATATTTCTCAAAATGGTCGTGCAGCACAAGGTGTTCGCTTAATTCGCTTAGGTGATGATCAATTTGTTTCAACGGTTGCTAAAGTAAAAGAAGATGCAGAAGATGAAACGAATGAAGATGAGCAATCTACTTCAACTGTATCTGAAGATGGTACTGAACAACAACGTGAAGCGGTTGTAAATGATGAAACACCAGGAAATGCAATTCATACTGAAGTGATTGATTCAGAAGAAAATGATGAAGATGGACGTATTGAAGTAAGACAAGATTTCATGGATCGTGTTGAAGAAGATATACAACAATCATCAGATGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3230,Drugs,MEG_3230|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|941146344|gb|CP007676.1|7032-9695 gi|941142962|gb|CP007672.1|7032-9695 gi|941139768|gb|CP007657.1|7032-9695 gi|899756207|gb|CP012119.1|1918651-1915988 gi|828461663|gb|CP007674.1|7032-9695 gi|828444881|gb|CP007670.1|7032-9695 gi|640834542|gb|CP007690.1|7032-9695 gi|610395799|gb|CP007539.1|6489-9152 gi|160367075|gb|CP000730.1|7032-9695 gi|150373012|dbj|AP009351.1|7012-9675,3
,ATGAAAATAATGTTAGAGGGACTTCATATAAAACATTATGTTCAAGATCGTTTATTGTTGAACATAAATCATCTAAAGATTTATCAGAATGATCGTATTGGTTTAGTTGGCAAAAATGGAAATGGAAAAACAACGTTACTTCACATATTATATAAAAAAATTGTGCCTGAAGAAGGTATTGTAAAACAATTTTCACATTGTGAACTTATTCCCCAATTGAAGCTCATAGAATCAACTAAAAGTGGTGGTGAAGTAACACGAAACTATATTCGGCAAGCGCTTGATAAAAATCCAGAACTGCTATTAGCAGATGAACCAACAACTAACTTAGATAATAACTATATAGAAAAATTAGAACAGGATTTAAAAAATTGGCATGGAGCATTTATTATAGTTTCACATGATCGCGCTTTTTTAGATAACTTGTGTACTACTATATGGGAAATTGAAGAGGGGAGAATAACTGAATATAAGGGGAATTATAGTAAATATGTTGAACAAAAAGAATTAGAAAGACACCGAGAAGACTTAGAATATGAAAAATATGAAAAAGAAAAGAAACGATTGGAAAAAGCTATAAATATAAAAGAACAGAAAGCTCAACGAGCAACTAAAAAACCAAAAAACTTAAGTTCATCTGAGGGCAGAATAAAAGGAACAAAGCCATACTTTGCAGGTAAACAGAAGAAGTTACGAAAAACTGTAAAGTCTCTAGAAACCAGACTAGAAAAACTTGAAAGTGTCGAAAAGAGAAACGAACTTCCTCCACTTAAAATGGATTTAGTGAATTTAGAAAGTGTAAAAAATAGAACTATAATACGTGGTGAAGATGTCTCGGGCACAATTGAAGGACGAGTATTGTGGAAAGCAAAAAGTTTTAGTATTCGCGGAGGAGACAAGATGGCAATTATCGGATCTAATGGTACAGGAAAGACAACGTTTATAAAAAAAATTGTTCATGGGAATCCTGGTATTTCATTATCGCCATCTGTCAAAATCGGTTATTTTAGTCAAAAAATAGATACATTAGAATTAGATAAGAGTATTTTAGAAAATGTTCAATCTTCTTCACAACAAAATGAAACTCTTATTCGAACTATTCTAGCTAGAATGCATTTTTTTAGAGATGATGTTTATAAACCAATAAATGTCTTAAGTGGTGGAGAGCGAGTTAAAGTAGCACTAACTAAAGTATTCTTAAGTGAAGTTAATACATTAGTACTAGATGAACCAACAAACTTTCTTGATATGGAAGCTATAGAGGCGTTTGAATCTTTGTTAAAGGAATATAATGGCAGTATAATCTTTGTATCTCACGATCGTAAATTTATCGAAAAAGTAGCCACTCGAATAATGACAATTGATAATAAAGAAATAAAAATATTTGATGGCACATATGAACAATTTAAACAAGCTGAAAAGCCGACAAGGAATATTAAAGAAGATAAAAAACTTTTACTTGAGACAAAAATTACAGAAGTACTCAGTCGATTGAGTATTGAACCTTCGGAAGAATTAGAACAAGAGTTTCAAAACTTAATAAATGAAAAAAGAAATTTGGATAAATAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_7684,Drugs,MEG_7684|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA,gi|641688293|emb|HG799495.1|70853-70880 gi|321156851|emb|FR671404.1|6271-6244,1
,GGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCTCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6918,Drugs,MEG_6918|Drugs|betalactams|Class_A_betalactamases|TEM,gi|4557167|gb|AF104442.1|1-1054,0
,atgcgatttaaaaaaatttcttgtttacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggttttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggtccactcgatgccccagcatatggcgtcaaatcaacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaaagggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacgtatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgttgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_621,Drugs,MEG_621|Drugs|betalactams|Class_C_betalactamases|ADC,1625655386|WP_136512063.1|NG_064719|1|1|blaADC-66|blaADC|class_C_beta-lactamase_ADC-66 NG_064719:1-1152,0
,ATGAAGAAGTGGGGTTTTTTATTGTTATTTTTATTGTGCTTAGGTTTTGCCTTCATTAATAAAGCACTGTTTTTTCAGGATAAAGTAGAGATTCAAAAATATGATCAAAATCACAAAGATAATATAGATAACATAGAGAATATAGGGACCCCCTTAAGTATCCAAAAGAATGAGATTGTAAAAGAACAGATCTATCAAGGAAATCTGCTCTTAATCAACAGTAAATATCCTATTCGCCAAGAGAGTGTGAAATCGGATATCGTAAATTTATCTAAACATAATGAATTGATAAATGGATACGGGTTGCTTAATACGAATATTTATCTGTCAAAAGGAATTGCACAAAAGTTTTCAGAGATGATCAATGATGCTGTAAAGGAAGGGGTTAGTCAATTTTTTATTAATAGTGGCTATCGTGACTTTGATGAGCAAAGTGTTCTTTACCAAGAAATGGGGGCTGATTATGCCTTGCCAGCAGGTTATAGTGAACATAATTCAGGCTTATCACTTGATGTAGGATCAAGCTTAACGAAAATGGAGCGAGCACCTGAAGGAAAGTGGCTGAAAGAAAATGCCTGGAAATACGGCTTTATATTACGCTATCCAAAGGATAAAACTGATGTTACTGGAATTCAATATGAACCATGGCATATCCGTTATGTTGGTTTCCCTCACAGCGCGATTATGAAAGAAAAGAATTTCGCTCTAGAAGAATATATGGATTTTTTGAAGGAACAGAAGTCCATTACGACTACAATAGACCACCAAGTCTATAAAATCTTTTACTATCCTATCTCCCAAAATACAACGATCCCTGTGCCTGCGAATGGCCAGTATGAAATTTCAGGCAACAATATGGATGGCGTGATTGTGACAGTGTATTCTGGTAAGCGAGACTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7595,Drugs,MEG_7595|Drugs|Glycopeptides|VanA-type_accessory_protein|VANYA,(Gly)VanY-Pt2:DQ018711:6234-7133:900,5
,atgatcgtcaactgcgaccacgacaaccttgatgcctggctggcgctgcgctcggcgctgtggcccacctgcctgcgggaagaacaccgcgcagaaatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattatgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgtcgaacgcgcccgccgccagggctgggcggcgcgtttgatcgcgcaggtgcaggagtgggccaagcagcaggggtgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgcagaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_150,Drugs,MEG_150|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,727182101|WP_033644545.1|NG_052450|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052450:101-541,2
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacatcttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcagaattgactgcctttttgcgccagatcgacgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6227,Drugs,MEG_6227|Drugs|betalactams|Class_A_betalactamases|SHV,1509794562|WP_122630871.1|NG_062288|1|1|blaSHV-216|blaSHV|class_A_beta-lactamase_SHV-216 NG_062288:1-861,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatcgcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttagaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcatttggttataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgcccctgcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtacttcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctggatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_580,Drugs,MEG_580|Drugs|betalactams|Class_C_betalactamases|ADC,1625655382|WP_136512059.1|NG_064713|1|1|blaADC-190|blaADC|class_C_beta-lactamase_ADC-190 NG_064713:1-1152,0
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAACCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGAGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTAAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6618,Drugs,MEG_6618|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,Sul|sul2_3_HQ840942|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,8
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTATCGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1897,Drugs,MEG_1897|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JF460794|+|0-1146|ARO:3002073|CMY-60 [Escherichia coli] ,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggctcactcgatgccccagcatatagcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_571,Drugs,MEG_571|Drugs|betalactams|Class_C_betalactamases|ADC,1625655380|WP_136512057.1|NG_064711|1|1|blaADC-188|blaADC|class_C_beta-lactamase_ADC-188 NG_064711:1-1152,0
,ATGAGTGAACTGACTCATGATGGTGTAGAGCGCCAACCGCTCCACTTATTTACGGAAAATGCCTATCTCAATTACTCAATGTACGTGATTATGGATCGTGCATTGCCTTTTATTGGCGATGGGTTAAAACCAGTACAGCGTCGTATCGTCTATGCGATGTCTGAATTAGGTTTAAACAGCAGTGCTAAATTTAAAAAATCAGCACGAACAGTGGGGGATGTATTAGGTAAATATCATCCCCACGGTGATAGCGCCTGTTATGAAGCCATGGTATTGATGGCGCAACCCTTCTCTTATCGTTATCCATTAATTGATGGGCAAGGTAACTGGGGGGCTCCGGATGATCCTAAATCTTTCGCAGCTATGCGTTATACCGAGTCTCGCTTATCTAAATATTCACAGATCCTGCTAAGCGAATTGGGACATGGTACTGTTGATTGGATCCCCAATTTTGATGGCACCCTGCAAGAGCCAAAAATGTTGCCTGCTCGTTTACCTAATATTTTATTAAATGGGACAACGGGGATTGCTGTCGGTATGGCAACGGATATTCCGCCACATAATGCGCGGGAAATCGGCCAAGCATTAACCATGCTATTAGATAATCCTGATGCTGGGTTATCTGATGTTATGCAATATGTACAAGGACCTGATTATCCAACAGAAGCGGAAGTGATCACCGCTCCTGAGGATATCAAAAAGATTTATAAAACAGGACGTGGTTCTATTAGAATGCGTGCTGTTTGGCAAAAAGAAGAGGGTTGTGCGGTGATAACAGCTCTCCCTCATCAAGTCTCTGGTGCTAAGGTACTTGAACAAATTGCTGCATTAATGCGAGCGAAAAAATTGCCTTTAGTTGATGATTTACGTGATGAGTCAGATCATGAAAATCCTACTCGATTGGTAATTGTTCCTCGTAGTAATCGTGTCGATTTAGAACAAGTCATGTATTACTTATTTGTAAATACAGACTTAGAGAAAAGTTATCGCGTTAACCTCAATATGATTGGGTTAGATAACCGTCCTGCTGTGAAAGGGCTATTAACCATTTTAAATGAGTGGTTAGTTTATCGCCGTCAAACCGTAACCAATCGTTTAAACCATCGCTTAGAAAAAGTATTACGCCGTTTAGAAATTCTAAAAGGTTTATTAATCGCTTATCTCAATATTGATGAAGTGATTGAGATCATCCGTTATGAAGATGAGCCAAAAGCCGAATTAATGCGTCGTTTTGCATTATCAGATATTCAAGCAGAAGCGATTTTAGAGTTACGTTTACGTCACTTAGCTAAGCTTGAAGAGATAAAACTGCAAGCTGAAAGTGATGAACTGGAAAAAGAGCGCGACAGTATTGAAAAACTGTTAAATTCTCCTCGCCGTCTCAATACGTTATTGAAAAAAGAGATAGAGGCAGACGCTAAAGAGTTTGGTGATGAACGACGTTCTCCTATTCGACCTCAAGAAGAGGCGAAAGTGGTTAATGAACAAGATATGTTGCCATCAGAGCCTGTGACTATTGTGCTTTCTGAAATGGGATGGGTGCGTAGTGCGAAAGGGCACGAAATTGATCCTAGTACCATGAGTTATCGTGCCGGAGACAGTTATCATAGTGCGGTACGGGGTATGAGCAACCAGCCAGTATTGTTCCTTGATTCAACGGGTAGAAGCTATAGTTTAAGTCCCAATGACATGCCATCAGGCCGTAGCCAAGGTGAGCCTTTAACCGGTAAATTGACCTTCCCACCTGACGCCAGCGTAAAATATATGTTAGCGGGAGCCGCTAAACAGGAGTATTTACTGGCAACGAAAGAGGGTTATGGCTCCGTACTCAGTTATGAAGAAATGGAGACAAAAAATAAAACCGGTAAAGGGTTGTTAACGGTTTCAGATGAAACAGAATTGCTAGCGCCTTTCTTAGTCGATGCAGAAAAGAAAAACAATCAACATTGGTTAGTTATTATCACCGATAAAACACGTATTCTGGCGATATCTGCAGAACATCTAAATGAGATGAATAAGAAAGGTCGAGGCACTCGCTTAGTTACATTAGGCAAAGAGCAAAGTGATGTTATCGAACAAATCGTGTTAATAGCAAAAAATGAAGCCCTCACTTTTACTGTTGATGGTCAACAACAAACATTAAAAGCAGAAGAGATTAGCTATTTTAGTGGTGATGTTGGCGATGAGCCTATCCCATTAAAACATCTTCACCCTGAAGCGGTTACCGTGATCATGTCCGAAAAAGGGCTTATCCGTTGCCAAAAAGGCCATAACATTGATGCGAAATCAGTGGGCTTTAAGACAGGGGATGATTATTTTGATGCAGTTGAAGGGATGAGCAATCAAGCGGTACATCTGATTGATACCACGGGTCAAAGTTATACTGTTGATGTTGACGCATTACCATCAGGCCGTAGTAAAGGTGATGATTTAACAGGACGATTAAAAGTCCAAAAAGGGGCTCAATTACGTCATGTAGTGATGGGGGAAAGTAGCGATAAGATCTTAATGGCATCCGACGCTGGTTATGGGTTTATCTGTAGTATTGATGACTTAACCTCTAAAAATAGAGCTGGTAAATCATTATTAACATTACCTGAAAATGCATTACCATTACCACCTCAACGCTTAAATGATGAATTGAGTGATTTGATCATGATCATTACTCAGGGTGGGCGAATGCTGATTTTTGAAGCCTCTGAGTTGCCAACTATGGTAAAAGGAAAAGGTAACCAAATGGTTTCTATTCCTGCTTCACAGGCTGCAAGTGGTGAAGATAAAGTCGCTTGGTTACGGGTATTACCAGAAAATGCCAGTGTTACATTGCATTTTGGTAAACGTAAACTCACGATGTCGATGAATGAATTACAGACATTTAAAGCCAAACGTGGTCGTCGTGGAACATCGCTCCCTCGTGGTGCACAAAGTATCGATCATATAGATATCGAAACTCATTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5346,Drugs,MEG_5346|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|529186758|gb|CP004022.1|2698902-2695945,3
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACATTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGGCAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCTCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTCCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1958,Drugs,MEG_1958|Drugs|betalactams|Class_C_betalactamases|CMY,gi|374414413|gb|JN714478.1|1035-2262,0
,atgcgcctctgcctgactcccctcgccctggctgccacgctcgtctttgatgtcgctgccgccgacgcaccgctgccgcagctccgggcctacaccgtcgacgcttcgtggctgcagccgatggcaccgctgcagattgccgaccacacctggcagatcggcaccgaggacctgacggcactgctggtgcagaccaccgagggcgcagtgctattggatggcggcatgccgcagatggccggtcacctgctggacaacatgaaggcacgcgaggtggcaccacaggatctacggctgatcctgctcagccatgcgcatgccgaccacgccgggccggtggcggaactcaagcgccgcaccggtgcccaggtggtcgcgaacgccgaaacggccgtgctgctaccgcgcggcggcagcaacgacctgcacttcggtgatgacatcacctacccgccggccagtgccgaccgcatcatcatggatggtgagagggtgacggtaggcggcatggcattcaccgcgcacttcatgccagggcacacccccggcagcaccgcctggacctggaccgatacccgcgatggcaagcccgtgcgcatcgcctacgccgacagcctgagtgcgccgggctaccagctgcagtacaacgcacgctatccccgcctggtcgaggactaccggcgcagcttcacgacggtgcgcggcctgccctgcgacctgctgccgaccccgcatccgggcgccagccgctggaactatgccgccggtgccgaggccggggccaacgtcctgacctgcaaggcctacgcggatgcggccgagaaggcattcgacgcgcagttggccaaggaaacgaccggggcccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3520,Drugs,MEG_3520|Drugs|betalactams|Class_B_betalactamases|L1,1028083726|WP_063842694.1|NG_047512|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047512:1-870,0
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1360,Drugs,MEG_1360|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_23_JBND01000015,0
,TTGAAAAATAGAGATAAAACCAGTCATGAAGATGACTATTTACTTTTTAAAAACAGACTGTCCCTTAAAATACTGCTGATAATGGCATGCTCCATTCTAATTATAGCGGCAGTGTATCTATTCGTTTTAAAAGATAATTTTGCAAATGTGGTGGTAGCCATTTTAGATAGCTTTATCTATCATGATCGGGATGAGGCGGTGGCTGTTTATCTGAGAACCTTTAAGGCGTATGAGATATGGCTTTTTCTGATAGCGGTTATGGGTGTGTTTTTTATGATCTTTCGCCGTTATCTGGACAGTATCTCAAAGTATTTTAAGGAGATCAACCGGGGGATTGATACCCTGGTGCATGAAGATACCAATGATATCGCCCTGCCTCCGGAACTGGCTTCGACCGAAAGAAAAATCAATTCCATACGGCATACACTGACGAAACGGAAAACGGACGCCGAGCTTGCGGAACAGCGGAAAAACGACCTTGTTATGTACCTGGCTCATGACTTGAAGACTCCGCTTTCATCGGTTATAGGGTATTTAAACCTGTTAAGGGATGAGAATCAAATCTCCGAGGAACTCCGGGAAAAATATCTGTCCATTTCACTGGATAAAGCTGAACGTCTGGAAGAGCTGATCAATGAGTTTTTTGAAATTACGAGGTTTAATCTTTCAAACATCACGCTTGTGTACAGCAAAATCAATCTGACGATGATGCTGGAACAGCTGGGGCACGAGTTTAAGCCGATGTTGGCCGGGAAAAATCTCAAATGTGAATTTGATGTTCAGCCGGACATGATGCTGTCCTGTGATGCCAACAAACTGCAGAGAGTGTTCGATAATGTGCTGAGAAATGCCGTCAGCTACTGTTATGAGAATACTACCATTCAGGTGAATGCCAGGCAGGCGGAAGACTATGTGCTCATCCAAGTCATAAACGAAGGGGATACGATTCCCGGGGAGAGATTGGAAAGAATCTTTGAGCAGTTTTACCGCCTGGATGTGTCACAAAGCTCAAGCACCGGCGGAGCCGGTCTGGGACTTGCGATTGCAAGGGAGATTGTGGAACTGCACCATGGACAGATCACTGCCCGCAGCGAAAACGGTATCACCAGTTTTGAGGTTACATTGCCCACCGTAGGAAAATCGTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7509,Drugs,MEG_7509|Drugs|Glycopeptides|VanD-type_regulator|VANSD,gi|40021670|gb|AY489045.1|689-1834,5
,atgggcatcattcgcacatgtaggctcggccctgaccaagtcaaatccatgcgggctgctcttgatcttttcggtcgtgagttcggagacgtagccacctactcccaacatcagccggactccgattacctcgggaacttgctccgtagtaagacattcatcgcgcttgctgccttcgaccaagaagcggttgttggcgctctcgcggcttacgttctgcccaagtttgagcagccgcgtagtgagatctatatctatgatctcgcagtctccggcgagcaccggaggcagggcattgccaccgcgctcatcaatctcctcaagcatgaggccaacgcgcttggtgcttatgtgatctacgtgcaagcagattacggtgacgatcccgcagtggctctctatacaaagttgggcatacgggaagaagtgatgcactttgatatcgacccaagtaccgccacctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_29,Drugs,MEG_29|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,549637587|WP_022542381.1|NG_047232|1|1|aac(3)-I|aac(3)-I|AAC(3)-I_family_aminoglycoside_3-N-acetyltransferase NG_047232:101-565,2
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcgacggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcatcgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6207,Drugs,MEG_6207|Drugs|betalactams|Class_A_betalactamases|SHV,1509794557|WP_122630866.1|NG_062281|1|1|blaSHV-209|blaSHV|class_A_beta-lactamase_SHV-209 NG_062281:1-861,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcacggcactgtggccctccagctcgcctgaagagcaccgcgcggaaatgcgcgagatactggcttcgccgcaccacaccgcgtttatggcgcggggactggacggcgctttcgttggctttgccgaggtggcgctgcgctacgattacgtcaacggctgcgaatcgtcaccggtggcgtttctggaagggatttataccgtcgaacgcgcccgccgccagggctgggccgcgcgcttgatcgcgcaggtgcaggagtgggcgaagcagcaggggtgcagcgagctggcgtcggataccgacatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggaacgggtggtgttttaccgtaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_160,Drugs,MEG_160|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,896189014|WP_049198488.1|NG_052195|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052195:101-541,2
,atgaacgaaaatattttgattgtggatgatgaaaaagaaatagcagatttaattgaagtatatttaaaaaatgaaggttttacagtatacaagttttatacaggtaaggaagctctagaatgtattgaatctaaaaatttggatatggctattttagatattatgcttcctgatattgatggatttcatatttgccagaaaattcgagaaaaatactattatcctatcattatgttaacagctaaaattgaagatatagacaagataatgggtttaaccataggtgctgatgattatataacaaagccatttaaccctttggaagttgttgcaagagtaaagacacaattaagaagatatatgcgatataataattcttatgaacaacagtcgataattgttaatgagtatgatattaaaggattgattatcaataaagaaacacataaatgtagtttatttgggaaagaagtagcattaacaccgattgaattttctattctttggtatttatgtgaacatcaaggaaaagtggttccttctgaagaattgtttgaagctgtatggggagaaaaatatcttgataataataacacagttatggctcatatagggcgattacgtgaaaaaattcatgaaccttctaaaaacccgaaatttataaaaactgtatggggagtaggttatacaattgaaaagtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7470,Drugs,MEG_7470|Drugs|Glycopeptides|VanC-type_regulator|VANRC,489531669|WP_003436401.1|NG_061618|1|1|vanR-Cd|vanR-Cd|VanG-Cd-type_vancomycin_resistance_DNA-binding_response_regulator_VanS NG_061618:101-802,5
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtcggcatgttcttttaataccgtacaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaacagaggaaatctatggcaatgatcttaaaagatcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttgtttcctgattgggaaaaggacatgactctaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaaaaagcccagtttgcttatgaactagcccataaaactcttccttttagcaagaatgtgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacggaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaacctcaaggaaaaattgtagcgttctcactcaatttagaaatgaaaaaaggcatacctagttctattcgaaaagaaattgcttataagggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4560,Drugs,MEG_4560|Drugs|betalactams|Class_D_betalactamases|OXA,1058244029|WP_068981637.1|NG_051472|1|1|blaOXA-522|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-522 NG_051472:1-822,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcgggtatctccgagccagccatgatcgacgttgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagctgcggaggaactctttgatcccgttcctgaacaggatctattcgaggcactgaatgaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgctcacgttgtcccgcatttggtacaccgaagtaaccggcaaaatcgtgccgaaggatgtcgctgccgactgggcaatggagcgcctacctgcccagcatcagcccgtcttacttgaagctagacaggcttatcttggacaaaaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcacttcgtgaaaggcgagatcactaaggtagtcggcaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_777,Drugs,MEG_777|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502115|WP_071846267.1|NG_052308|1|1|aadA11|aadA11|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA11 NG_052308:101-892,2
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTTCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGTCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2225,Drugs,MEG_2225|Drugs|betalactams|Class_A_betalactamases|CTX,(Bla)CTX-M-62:GU125669:1-876:876,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgttagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattaaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaagtttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttaagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgagtgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_537,Drugs,MEG_537|Drugs|betalactams|Class_C_betalactamases|ADC,490877489|WP_004739487.1|NG_050717|1|1|blaADC-32|blaADC|class_C_extended-spectrum_beta-lactamase_ADC-32 NG_050717:101-1252,0
,TTAGAAAGGAGTAAGTATGAAAAAACTATTTGTTTTATGTATATTTTTGTTTTGTAGCATTACTGCCGCAGGAGCGTCTTTGCCTGATTTAAAAATTGAGAAGCTTGAAGAGGGTGTTTATGTTCATACATCGTTTGAAGAAGTTAACGGCTGGGGTGTTGTTTCTAAACACGGTTTGGTGGTTCTTGTAAATACTGACGCCTATCTGATTGACACTCCATTTACTGCTAAAGATACTGAAAAGTTAGTCAATTGGTTTGTGGAGCGCGGCTATAAAATCAAAGGCAGTATTTCCTCACATTTCCATAGCGACAGCACGGGTGGAATAGAGTGGCTTAATTCTCAATCTATTCCCACGTATGCATCTGTATTAACAAATGAACTTCTCAAAAAAGACGGTAAGGTGCAAGCTAAAAACTCATTTAGCGGAGTTAGCTATTGGCTAGTTAAAAATAAAATTGAAGTTTTTTATCCAGGCCCAGGGCACACTCAAGATAACGTAGTGGTTTGGCTACCTAAAAATAAAATCTTATTTGGTGGTTGTTTTGTTAAACCATATGGTCTTGGTAATCTAGATGACGCAAATGTTGAAGCATGGCCACATTCGGCTGAAAAATTAATATCTAAGTATGGTAATGCAAAACTGGTTGTTCCAAGCCATAGTGACATAGGAGATGCGTCGCTCTTGAAGCTTACGTGGGAACAGGCGGTAAAAGGGCTTAATGAAAGCAAAAAAAGTAACACTGTTCATTAACCAAATTTCTAACAAGTCGCTGAAGCATCGCACCTTCGGTGCTGGACAGTTTTTAAGTCGCGCTTTTGTGGTTTTGCTACGCAAAAGGTTTCCACAAAATCACAACTTAAAAACTGCCGCTTAGCTCGGCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3395,Drugs,MEG_3395|Drugs|betalactams|Class_B_betalactamases|IMP,gi|575771398|dbj|AB901042.1|637-1521 gi|346644638|dbj|AB625454.1|81-965 gi|17026025|dbj|AB074436.1|1-885,0
,ATGATGCAAGAAAAAAAGCAAACTTATGATGAAAATCAAATACAAGTATTAGAAGGTCTTGAAGCTGTTAGAAAAAGACCTGGAATGTATATTGGAAGTACTAGTTCTAGGGGGCTTCATCATTTAGTGTATGAGATAGTTGATAATAGCATAGATGAGGCATTGGCAGGATATTGCGATAAAATAAATGTAATTATACATAAAGATAATTCTATAACAGTTACGGATAATGGTAGAGGAATGCCTGTTGGAATGCACCATAAAATGAAGAAACCAACTGTAGAAGTTATAATGACTATACTACATGCAGGAGGGAAATTTGGTGGTGGAGGATACAAAGTTTCCGGCGGACTTCATGGAGTTGGAGCATCAGTTGTAAATGCTTTATCTGAAATCTGTGAAGTTGAAGTAAAAAGAGAAAGCCATATATGGAGACAGGTATTTAAAAGAGGAAAAGTAGCAAGCGGACTTGACATAATAGGTGATAGTGAGGAGCACGGAACAAAAATTCACTTTAAACCAGATGCAGAAATATTTGATGAAATAGAATATGATTATGATACATTGGCTCAAAGGCTTAGAGAATTGGCATTTTTAAACAAGGGTATAAAAATAAGGTTAGAAGATGAGAGAGATGATAAAGAAGAAATATTTCACTATGAAGGTGGAATAAAGTCCTTTGTAACTTATCTTAATAGAAATAAACAACCAATTCATAAAGAGCCTATATACGTAGAAGGCAAAAAAGATGACTACTCTGTAGAAATTGCTATTCAATACAATGATGGGTATACTGAAAATATTTTTGCTTTTGCTAATAACATAGATACAGTAGAAGGTGGAACTCATTTAGCTGGATTTAAGTCAGCACTTACTAGAGTATTTAATGATTATGCAAAAAAATTTGGTATATTAAAAGAAAATGATAAGAACCTATCAGGAGAAGATATAAGGGAAGGCCTTACTGCAGTTATATCTGTAAAACTTGTAGACCCTCAATTTGAAGGCCAGACGAAAACAAAACTAGGAAATAGTGAAGTGCGTGGTATAGTTGACAGCATAATGGGAGAGTCCTTAAATAATTTTTTACAGGAAAATCCTCAAGTAGCAAAGATGATACTTGATAAATCACTTATGGCATCACGTGCTAGAGAAGCGGCAAGAAAAGCAAGAGAGCTTACAAGACGTAAATCTATACTTGAAAATACTTCTCTTCCAGGAAAATTAGCAGATTGTTCATCTAAAGATCCTTCTGAATGTGAAATATATTTAGTCGAGGGTGATTCTGCAGGTGGATCTGCAAAACAAGGTAGAAATAGAAAATTTCAAGCTATACTTCCGCTACGTGGTAAAATAATGAATGTTGAGAAACAAAGGCTTGACAAAATACTTGGCTATGAAGAAATAAGAGCTATGATAACGGCATTTGGAGCAGGTATAGGAAAAGACTTTGATGTAAATAAAATAAGATACAATAAAATAATAATAATGACAGATGCAGATGTAGATGGTGCGCACATAAGAACATTATTACTTACTTTTTTCTTCAGATATATGAAGGAACTTGTTGAAAAATGTCACGTTTATATAGCTCAACCACCTTTATATAGAGTAGCTAAAGGGAAGAAGGAATACTACGCATATTCAGATGATGAATTAGATGTATTGCTTACTGAAATAGGTGGGAAAGACAGTAATGTAGATATACAAAGATATAAAGGACTTGGAGAAATGGATTCAGAGCAACTTTGGGATACTACAATGAATCCTGAAACAAGGACTCTTATTCAAGTAAATGTAGAGGACACTATGGCTGCTGATGAAATCTTTACTATACTTATGGGTGACAAGGTAGAACCTCGTAGAAATTTTATACAAGAAAATGCTAAAAAAGTTGTAAACTTAGATATATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3241,Drugs,MEG_3241|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRB,gb|CP001666.1|+|4516-6430|ARO:3004562|Clostridioides difficile gyrB conferring resistance to fluoroquinolone [Clostridium ljungdahlii DSM 13528] ,3
,ATGAAAATTATTAATATTGGAGTTTTAGCTCATGTTGATGCAGGAAAAACTACCTTAACAGAAAGCTTATTATATAACAGTGGAGCGATTACAGAATTAGGAAGCGTGGACAAAGGTACAACGAGGACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACAGGAATAACCTCTTTTCAGTGGGAAAATACGAAGGTGAACATCATAGACACGCCAGGACATATGGATTTCTTAGCAGAAGTATATCGTTCATTATCAGTTTTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATTTCGTACAAGCACAAACTCGTATATTATTTCATGCACTTAGGAAAATGGGGATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCCGAAATTGTAATCAAACAGAAGGTAGAACTGTATCCTAATATGTGTGTGACGAACTTTACCGAATCTGAACAATGGGATACGGTAATAGAGGGAAACGATGACCTTTTAGAGAAATATATGTCCGGTAAATCATTAGAAGCATTGGAACTCGAACAAGAGGAAAGCATAAGATTTCAGAATTGTTCTCTGTTCCCTCTTTATCATGGAAGTGCAAAAAGTAATATAGGGATTGATAACCTTATAGAAGTTATTACTAATAAATTTTATTCATCAACACATCGAGGTCCGTCTGAACTTTGCGGAAATGTTTTCAAAATTGAATATACAAAAAAAAGACAACGTCTTGCATATATACGCCTTTATAGTGGAGTACTACATTTACGAGATTCGGTTAGAGTATCAGAAAAAGAAAAAATAAAAGTTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAGATTGATAGAGCTTATTCTGGAGAAATTGTTATTTTGCAAAATGAGTTTTTGAAGTTAAATAGTGTTCTTGGAGATACAAAACTATTGCCACAGAGAAAAAAGATTGAAAATCCGCACCCTCTACTACAAACAACTGTTGAACCGAGTAAACCTGAACAGAGAGAAATGTTGCTTGATGCCCTTTTGGAAATCTCAGATAGTGATCCGCTTCTACGATATTACGTGGATTCTACGACACATGAAATTATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGATTAGTGCACTGTTGCAAGAAAAGTATCATGTGGAGATAGAACTAAAAGAGCCTACAGTCATTTATATGGAGAGACCGTTAAAAAATGCAGAATATACCATTCACATCGAAGTGCCGCCAAATCCTTTCTGGGCTTCCATTGGTTTATCTGTATCACCGCTTCCGTTGGGAAGTGGAATGCAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCATTTCAAAATGCAGTTATGGAAGGGATACGCTATGGTTGCGAACAAGGATTATATGGTTGGAATGTGACGGATTGTAAAATCTGTTTTAAGTACGGTTTATACTATAGCCCTGTTAGTACTCCAGCAGATTTTCGGATGCTTACTCCTATTGTACTGGAGCAAGCCTTTAGAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAGTTTATGCACCACAGGAATATCTTTCACGGGCATATAACGATGCTCCCAAATATTGTGCAAATATCGTAAATACTCAACTGAAAAATAATGAGGTCATTATTATTGGAGAAATTCCTGCTCGATGTATTCAAGATTATCGCAATGATTTAACTTTTTTTACAAATGGGCTTAGTGTTTGTTTAGCAGAGCTAAAAGGATATCAGGTTACCACTGGCGAACCTGTTTGCCAGACCCGTCGTCTAAATAGTCGGATAGATAAAGTAAGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7136,Drugs,MEG_7136|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|153114|gb|M21136.1|STATETM|458-2377,4
,TATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGATCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6316,Drugs,MEG_6316|Drugs|betalactams|Class_A_betalactamases|SHV,gb|AY590467|+|0-729|ARO:3001110|SHV-53 [Klebsiella pneumoniae] ,0
,ATGGGTGAATTCTTTCCTGCACAAATTTCCGAGCAGCTATCCCACGCTCGCGGGGTGATCGAGCGCCATCTGGCTGCAACGCTGGACACAATCCACCTGTTCGGATCTGCGCTCGATGGAGGGTTGAAGCCGGACAGCGACATCGACTTGCTCGTGACCGTCAGCGCCGCACCTAACGATTCGCTCCGGCAGGCACTAATGCTCGACCTGCTAAAAGTCTCATCACCGCCAGGCGATGGCGGACCATGGCGACCGCTGGAGGTGACTGTTGTCGCTCGAAGCGAAGTAGTGCCCTGGCGCTATCCGGCGATACGTGAGCTTCAGTTCGGTGAGTGGCTCCGCCACGACATCCTCTCCGGAACGTTCGAGCCTTCCGTTCTGGATCACGATCTTGCGATTTTGCTGACCAAGGCGAGGCAACACAGCCTTGCTCTGCTAGGTCCATCCGCAGTCACGTTCTTCGAGCCGGTGCCGAACGAGCATTTTTCCAAGGCGCTTTTCGACACGATTGCCCAGTGGAATTCAGAGTCGGATTGGAAGGGTGACGAGCGGAACGTCGTTCTTGCTCTTGCTCGCATTTGGTACAGTGCTTCAACGGGTCTCATTGCTCCTAAGGACGTTGCTGCCGCATGGGTATCGGAGCGTTTGCCTGCCGAGCATCGGCCCATCATTTGCAAGGCACGCGCGGCGTACCTGGGTAGCGAGGACGACGACCTAGCAATGCGCGTCGAAGAGACGGCTGCGTTCGTTCGATATGCCAAAGCAACGATTGAGAGAATCTTGCGTTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_920,Drugs,MEG_920|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,(AGly)AadA4:AY138986:1-798:789,2
,AGGAGACACCGATGAACATCAACGATGCCCTCACCTCCATCCTGGCCTCAAAAAAATACCGCGCCCTTTGCCCGGATACCGTGCGGCGCATCCTGACTGAGGAATGGGGGCGGCATAAATCCCCCAAACAGACCGTAGAGGCTGCACGCACCCGGCTGCATGGAATTTGCGGGGCATATGTCACCCCGGAATCGCTCAAGGCTGCTGCCGCCGCGCTTTCTGCGGGCGATGTAAAAAAGGCATTGTCGCTGCATGCCTCCACCAAGGAGCGACTGGCCGAGCTGGATACCCTGTACGATTTTATCTTTTCAGCCGAAACTCCCCGCCGCGTGCTGGATATCGCCTGCGGTCTTAACCCCTTGGCGCTATACGAGCGCGGCATTGCATCCGTGTGGGGCTGTGATATCCACCAGGGATTGGGGGATGTCATCACCCCCTTTGCTAGGGAAAAAGATTGGGATTTTACCTTTGCCCTGCAGGATGTGCTGTGTGCGCCGCCCGCCGAAGCCGGCGACCTGGCGCTGATTTTTAAGCTTTTGCCCCTGCTGGAGCGGGAGCAGGCCGGTTCTGCCATGGCACTTTTACAATCCCTCAATACCCCGCGCATGGCTGTCAGCTTTCCCACGCGTAGTTTAGGCGGGCGTGGAAAAGGCATGGAGGCGAACTACGCCGCATGGTTCGAGGGCGGCTTGCCCGCCGAGTTTGAGATTGAGGATAAAAAGACCATCGGAACAGAACTTATATACTTGATAAAAAAGAATGGATAAGCCAATCAGAAGGCAAATCATCTAAAAAAGAGGAACGAAAAATATTTTTCGTTCCTC,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_6065,Drugs,MEG_6065|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|RMTB,gi|970338578|gb|KT725789.1|76481-77304 gi|970338578|gb|KT725789.1|77308-77277 gi|970338460|gb|KT725788.1|81741-82564 gi|970338460|gb|KT725788.1|82568-82537 gi|962148759|gb|KT002541.1|4929-5752 gi|962148759|gb|KT002541.1|5756-5725 gi|961666360|gb|KT185451.1|16716-15893 gi|961666360|gb|KT185451.1|15889-15920 gi|961494526|gb|KT282968.1|32453-33276 gi|961494526|gb|KT282968.1|33280-33249 gi|954665559|gb|KT879914.1|12008-12831 gi|954665559|gb|KT879914.1|12835-12804 gi|873464120|gb|KR259134.1|969-1792 gi|873464120|gb|KR259134.1|1796-1765 gi|873464057|gb|KR259131.1|2832-3655 gi|873464057|gb|KR259131.1|3659-3628 gi|873464024|gb|KR259130.1|2585-3408 gi|873464024|gb|KR259130.1|3412-3381 gi|817046807|gb|KP893385.1|83747-84570 gi|817046807|gb|KP893385.1|84574-84543,2
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggctacggcaatgcggacgtctcgggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaaggtggtgaaccggcaattgccggtcaaggccgccgcctatgagctggcggacaacctcttcgaggtgggccaggccgatggctggcgcctgtatggcaagaccggcaccgggtcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggctcgcaaggatggccgccaactggtgtacgcccgcctgctgcaggacgagcgcgccacccagcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4543,Drugs,MEG_4543|Drugs|betalactams|Class_D_betalactamases|OXA,651247775|WP_026382828.1|NG_064731|1|1|blaOXA-114i|blaOXA-114_like|class_D_beta-lactamase_OXA-114i NG_064731:1-828,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtaatgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_874,Drugs,MEG_874|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502122|WP_071846274.1|NG_052319|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052319:101-892,2
,ATGGCTCTGGCACTCGTTGGCGAAAAAATTAACAGAAACCGCTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTTGGCATTGAAATTCGCCACTGTCGTGCGCAAGGCGCAGATTTTCGCGGCGCAAGTTTTATGAATATGATCACTACTCGCACCTGGTTTTGCAGTGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTGTGGGAAAACCGTTGGATGGGGGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGCGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGTTGCTCATGGAACGTCTTGGCATCGCGATTATTGGCTAG,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_5920,Drugs,MEG_5920|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,(Flq)QnrB2:DQ351242:1-645:645,3
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGGAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1865,Drugs,MEG_1865|Drugs|betalactams|Class_C_betalactamases|CMY,gb|DQ463751|+|75-1221|ARO:3002034|CMY-23 [Salmonella enterica subsp. enterica serovar Senftenberg] ,0
,ATGAGCGACCTTGCGAGAGAAATTACACCGGTCAACATTGAGGAGGAGCTGAAGAGCTCCTATCTGGATTATGCGATGTCGGTCATTGTTGGCCGTGCGCTGCCGGATGTCCGAGATGGCCTGAAGCCGGTACACCGTCGCGTACTTTACGCCATGAACGTATTGGGCAATGACTGGAACAAAGCCTATAAAAAATCTGCCCGTGTCGTTGGTGACGTAATCGGTAAATACCATCCCCACGGCGATTCCGCAGTGTATGACACCATCGTTCGTATGGCGCAGCCATTCTCGCTGCGTTACATGCTGGTGGATGGTCAGGGTAACTTCGGTTCTATTGACGGCGACTCCGCGGCGGCAATGCGTTATACGGAGATCCGTCTGGCGAAAATCGCCCACGAACTGATGGCCGATCTCGAAAAAGAGACGGTGGATTTCGTGGATAACTATGACGGTACGGAAAAAATTCCGGACGTCATGCCGACCAAAATTCCGAATCTGCTGGTGAACGGTTCTTCCGGTATCGCAGTAGGTATGGCGACGAATATCCCGCCGCACAACCTGACGGAAGTGATTAACGGCTGCCTGGCGTATATCGACAACGAAGACATCAGCATTGAAGGGCTGATGGAACATATTCCGGGGCCGGACTTCCCGACCGCCGCGATCATCAACGGTCGTCGTGGTATCGAAGAAGCCTACCGCACCGGTCGTGGCAAAGTGTACATTCGCGCCCGCGCGGAAGTTGAAGCTGACGCCAAAACGGGCCGTGAAACCATCATCGTCCATGAAATTCCCTATCAGGTGAACAAAGCGCGCCTGATCGAGAAAATCGCCGAGCTGGTGAAAGATAAACGCGTGGAAGGCATCAGCGCGCTGCGTGACGAATCCGACAAAGACGGGATGCGCATCGTGATTGAAGTGAAACGCGATGCGGTGGGCGAGGTGGTGCTTAATAATCTCTACTCCCAGACCCAGCTACAGGTTTCCTTCGGTATTAACATGGTGGCGCTGCATCACGGCCAGCCGAAGATCATGAACCTGAAAGATATCATTTCAGCGTTCGTGCGCCACCGCCGTGAAGTGGTGACGCGTCGGACTATTTTTGAACTGCGTAAAGCCCGTGACCGTGCGCATATCCTTGAAGCTCTGGCGATTGCGCTGGCCAACATCGACCCGATTATCGAACTGATTCGCCGCGCGCCAACGCCGGCGGAAGCAAAAGCGGCGCTGATTTCGCGTCCGTGGGATCTGGGCAACGTTGCTGCGATGCTGGAGCGCGCTGGTGATGACGCCGCGCGTCCGGAATGGCTGGAGCCAGAATTTGGCGTGCGTGACGGTCAGTACTACCTGACTGAACAGCAGGCGCAGGCGATTCTGGATCTGCGTTTGCAGAAACTGACCGGCCTGGAGCATGAAAAACTGCTCGACGAATACAAAGAGCTGCTGGAGCAGATTGCTGAATTGCTGCACATTCTGGGCAGCGCCGATCGCCTGATGGAAGTGATCCGCGAAGAGATGGAGTTAATTCGCGATCAGTTCGGCGATGAGCGTCGTACCGAAATCACCGCCAACAGCGCCGATATTAATATCGAAGATCTGATTAGCCAGGAAGATGTTGTCGTGACGCTGTCTCACCAGGGTTACGTCAAATATCAACCGCTGACAGATTACGAAGCGCAACGTCGTGGTGGGAAAGGTAAATCTGCCGCGCGTATTAAAGAAGAAGACTTTATCGACCGCCTGCTGGTGGCTAACACCCATGACACCATCCTCTGCTTCTCCAGCCGGGGCCGTCTGTACTGGATGAAGGTCTATCAGCTGCCGGAAGCCAGCCGCGGCGCGCGCGGTCGTCCGATCGTCAACCTGCTGCCGCTGGAAGCCAACGAACGTATCACCGCGATTCTGCCGGTTCGTGAGTATGAAGAAGGCGTCAACGTCTTTATGGCGACCGCCAGCGGTACCGTGAAGAAAACGGCGCTGACCGAATTCAGCCGTCCGCGTTCCGCCGGTATTATCGCGGTGAACCTCAACGACGGCGACGAGCTGATTGGCGTTGACCTGACTTCTGGTTCTGACGAAGTCATGCTGTTCTCGGCCGCGGGTAAAGTGGTGCGCTTCAAAGAAGACGCCGTCCGTGCGATGGGGCGTACCGCGACCGGTGTGCGCGGTATTAAGCTGGCGGGAGACGATAAAGTCGTCTCTCTGATCATCCCACGCGGCGAAGGCGCTATTCTGACCGTAACGCAAAACGGCTACGGGAAGCGTACCGCAGCGGACGAGTACCCGACCAAGTCTCGTGCGACGCAGGGCGTTATCTCTATCAAAGTGACCGAGCGCAACGGTTCCGTTGTCGGTGCGGTACAGGTAGACGATTGCGACCAGATCATGATGATCACGGATGCCGGTACTCTGGTGCGTACCCGTGTGTCCGAGATCAGCGTAGTGGGACGTAATACCCAGGGCGTTATCCTTATCCGCACGGCGGAAGATGAAAACGTGGTGGGTCTGCAACGCGTTGCTGAACCGGTAGATGACGAAGAACTCGACGCTATCGACGGCAGCGTGGCGGAAGGGGATGAGGATATCGCCCCGGAAGCGGAAAGCGATGACGACGTTGCGGATGACGCTGACGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3234,Drugs,MEG_3234|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|981191958|emb|LN999997.1|3006363-3008999 gi|973795115|gb|AE006468.2|2376346-2373710 gi|821161554|gb|CP011428.1|2444280-2441644 gi|808186398|gb|CP007523.1|3108514-3105878 gi|777177758|emb|LN829401.1|509442-512078 gi|764057510|gb|CP007235.1|3148307-3145671 gi|669110799|gb|CP007804.2|2318514-2315878 gi|661245796|dbj|AP014565.1|2542881-2540245 gi|618631222|gb|CP007581.1|2443861-2441225 gi|548933035|emb|HG326213.1|2366948-2364312,3
,ATGACTATACCTGACGCAAATGCAATCTATCCTAACTCAGCCATCATAGAGGTTGTCTTTATCAAGAACGTGATCAAAAGTCCCAATATTGAAATTGGGGACTACACCTATTATGATGACCCAGTAAATCCCACCGATTTTGAGAAACACGTTACCCATCACTATGAATTTCTAGGCGACAAATTAATCATCGGTAAATTTTGTTCTATCGCCAGTGGCATTGAATTTATCATGAACGGTGCCAACCACGTAATGAAAGGTATTTCGACTTATCCATTTAATATTTTAGGTGGCGATTGGCAACAATACACTCCTGAACTGACTGATTTGCCGTTGAAAGGTGATACTGTAGTCGGAAATGACGTGTGGTTTGGGCAAAATGTGACCGTCCTACCAGGCGTAAAAATAGGTGACGGTGCCATTATCGGAGCAAATAGTGTTGTAACAAAAGACGTCGCTCCATATACAATTGTCGGTGGCAATCCAATTCAACTCATCGGACCAAGATTTGAACCGGAAGTTATTCAAGCATTAGAAAATCTGGCATGGTGGAATAAAGATATTGAATGGATAACTGCTAATGTTCCTAAACTAATGCAAACAACACCCACACTTGAATTGATAAACAGTTTAATGGAAAAATAA,streptogramin inactivation enzyme,antibiotic inactivation,MLS,MEG_7630,Drugs,MEG_7630|Drugs|MLS|Streptogramin_A_O-acetyltransferase|VATE,gi|15266481|gb|AY043212.1|1-645,7
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgacgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcataattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtccgtctgaactttgcggaaatgttttcaaaattgaatatacaaaaaaaagacaacgtcttgcatatatacgcctttatagtggagtactacatttacgagattcggttagagtatcagaaaaagaaaaaataaaagttacagaaatgtatacttcaataaatggtgaattatgtaagattgatagagcttattctggagaaattgttattttgcaaaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaagggatacgctatggttgcgaacaaggattatatggttggaatgtgacggattgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7121,Drugs,MEG_7121|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100187|WP_063856400.1|NG_048241|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048241:101-2020,4
,atgaatagttcgacaaagatcgcattggtaattacgttactcgatgccatggggattggccttatcatgccagtcttgccaacgttattacgtgaatttattgcttcggaagatatcgctaaccactttggcgtattgcttgcactttatgcgttaatgcagggtatctttgctccttggcttggaaaaatgtctgaccgatttggtcggcgcccagtgctgttgttgtcattaataggcgcatcgctggattacttattgctggctttttcaagtgcgctttggatgctgtatttaggccgtttgctttcagggatcacaggagctactggggctgtcgcggcatcggtcattgccgataccacctcagcttctcaacgcgtgaagtggttcggttggttaggggcaagttttgggcttggtttaatagcggggcctattattggtggttttgcaggagagatttcaccgcatagtcccttttttatcgctgcgttgctaaatattgtcgctttccttgtggttatgttttggttccgtgaaaccaaaaatacacgtgataatacagataccgaagtaggggttgagacgcaatcgaattcggtatacatcactttatttaaaacgatgcccattttgttgattatttatttttcagcgcaattgataggccaaattcccgcaacggtgtgggtgctatttaccgaaaatcgttttggatggaatagcatgatggttggcttttcattagcgggtcttggtcttttacactcagtattccaagcctttgtggcaggaagaatagccactaaatggggcgaaaaaacggcagtactgctcggatttattgcagatagtagtgcatttgcctttttagcgtttatatctgaaggttggttagttttccctgttttaattttattggctggtggtgggatcgctttacctgcattacagggagtgatgtctatccaaacaaagagtcatcagcaaggtgctttacagggattatttgtgagccttaccaatgcaaccggtgttattggcccattactgtttgctgttatttataatcactcactaccaatttgggatggctggatttggattattggtttagcgttttactgtattattatcctgctatcgatgaccttcatgttaacccctcaagctcaggggagtaaacaggagacaagtgcttag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7039,Drugs,MEG_7039|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,695263263|WP_032490133.1|NG_048162|1|1|tet(B)|tet(B)|tetracycline_efflux_MFS_transporter_Tet(B) NG_048162:101-1306,4
,TGCTCTGTGGATAACTTGCAGAGTTTATTAAGTATCATTGCAGCAAAGATGAAATCAATGATTTATCAAAAATGATTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGGACTATTCATGTTGTTGTTATTTCGTATCTTCCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2431,Drugs,MEG_2431|Drugs|betalactams|Class_A_betalactamases|CTX,gi|918463128|gb|KP987217.1|5569-6671 gi|818476716|gb|KJ866866.1|84525-83423 gi|668347635|dbj|AB976578.1|1036-2138 gi|668347614|dbj|AB976573.1|2355-3457 gi|256576431|gb|GQ456159.1|24-1126 gi|110630022|gb|DQ810789.1|1-1103 gi|971338783|gb|CP006659.2|2745049-2744871 gi|958102843|emb|LN824133.1|127585-127763 gi|958102843|emb|LN824133.1|1153905-1154083 gi|958102843|emb|LN824133.1|3347218-3347040 gi|828906158|gb|CP011578.1|655965-656143 gi|828906158|gb|CP011578.1|849677-849499,0
,atgaaaacatttgccgcatatgtaattactgcgtgtctttcaagtacggcattagctagttcaattacagaaaatacgtcttggaacaaagagttctctgccgaagccgtcaatggtgttttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaataacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaaacaatgggaaagagacttgagcttaagaggggcaatacaagtttcagcggttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcatatggcagccagaatatcagtggtggcattgacaaattctggttggaggatcagctaagaatttccgcagttaatcaagtggagtttctagagtctctatttttaaataaattgtcagcatcaaaagaaaatcagctaatagtaaaagaggctttggtaacggaggctgcgcctgaatatcttgtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttggttgggttgagaagggaacagaggtttactttttcgcctttaacatggatatagacaacgaaaataagttgccgctaagaaaatccattcccaccaaaatcatggcaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4416,Drugs,MEG_4416|Drugs|betalactams|Class_D_betalactamases|OXA,1509794546|WP_122630855.1|NG_062268|1|1|blaOXA-736|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-736 NG_062268:1-801,0
,atgaaaattattaatattggagttttagctcatgttgatgcgggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaatgttttcaaaattgaatatacaaaaaaaagacaacgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacgactgttgaaccgagcaaacctcaacaaagggaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccattagggagcggagtgcagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7132,Drugs,MEG_7132|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,446614400|WP_000691746.1|NG_048232|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048232:1-1920,4
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggatcgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6219,Drugs,MEG_6219|Drugs|betalactams|Class_A_betalactamases|SHV,1226997338|WP_094009815.1|NG_055503|1|1|blaSHV-199|blaSHV|class_A_beta-lactamase_SHV-199 NG_055503:1-861,0
,atgactctggcgttggttggcgaaaaaattgacagaaacaggttcaccggtgtgaaagttgaaaatagcacgtttttcaactgtgatttttcgggtaccgaccttagcggcactgaatttattggctgccagttttatgatcgagagagccagaaagggtgtaattttagtcgcgctatcctgaaagatgccattttcaaaagctgtgatttatccatggcggatttcagaaatgccagcgcgctgggaatcgagattcgccactgccgcgcgcaaggttcggattttcgcggtgccagttttatgaatatgatcaccacccgcacctggttttgcagcgcttatatcaccaatacaaacttaagctacgccaacttttcgaaagtcgtactggaaaagtgcgagctgtgggaaaaccgttggatgggtactcaggtactgggggcgacgttcagtggttcagatctttccggcggcgagttttcgtcgttcgactggcgggccgcgaactttacgcactgtgacctgaccaactcggagctgggtgatttagacgtccgtggggtggatttacaaggcgttaaactggacagctaccaggcgtctttgatcctggagcgtcttggcatcgctgtcattggttaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5903,Drugs,MEG_5903|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,493735121|WP_006684339.1|NG_050501|1|1|qnrB39|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB39 NG_050501:101-745,3
,atgataaaaagttcgtggcgtaaaattgcaatgctagccgccgccgttccgctgctgctggcgagcggcgcactgtgggccagtaccgatgctatccatcagaagctgacagatctcgagaagcgttcaggcggcaggttgggcgtggcgctaatcaacacggcagataattctcaaatcttatatcgcggcgacgagcgttttgccatgtgcagcaccagtaaagtgatggccgccgccgcggtattaaaacagagcgaaagcaataaagaggtggtaaataaaaggctggagattaacgcagccgatttggtggtctggagtccgattaccgaaaaacatctccagagcggaatgacgctggctgagctaagcgcggcgacgctgcaatatagcgacaatacggcgatgaatctgatcatcggctaccttggcgggccggaaaaagtcaccgccttcgcccgcagtatcggcgatgccacctttcgtctcgatcgtacggagcccaataccgccatcccgggcgatgagcgtgataccagcacgccgctggcgatggctgaaagcctgcgcaagctgacgcttggcgatgcgctgggcgaacagcaacgcgcccagttagtcacctggctgaaaggcaataccaccggcgggcaaagcattcgcgcgggcctgcctgaaagctgggtggtcggcgataaaaccggcgccggagattacggcaccaccaatgatattgcggttatctggccggaagatcacgctccgctgatattagtcacctactttacccagccgcagcaggatgcgaaaaaccgcaaagaggtgttagccgcagcggcaaaaatcgtgaccgaagggctttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_5280,Drugs,MEG_5280|Drugs|betalactams|Class_A_betalactamases|OXY,1028110180|WP_063864550.1|NG_049851|1|1|blaOXY-2-15|blaOXY-2|class_A_extended-spectrum_beta-lactamase_OXY-2-15 NG_049851:1-867,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggttcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgtccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcagccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5678,Drugs,MEG_5678|Drugs|betalactams|Class_C_betalactamases|PDC,1035157543|WP_064511508.1|NG_050831|1|1|blaPDC-158|blaPDC|class_C_beta-lactamase_PDC-158 NG_050831:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtgcgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctgggcgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5539,Drugs,MEG_5539|Drugs|betalactams|Class_C_betalactamases|PDC,1201190449|WP_087587969.1|NG_054989|1|1|blaPDC-204|blaPDC|class_C_beta-lactamase_PDC-204 NG_054989:1-1194,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttaaatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4649,Drugs,MEG_4649|Drugs|betalactams|Class_D_betalactamases|OXA,1391852903|WP_109545088.1|NG_057522|1|1|blaOXA-584|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-584 NG_057522:1-774,0
,atgcgatttaaaaaaatttcttacttacttttaccttctctttttatttttaatacctcaatttatgcgggcaatacttctaaagaccaagaaattaaacaattggtagatcaaaattttaagcccttattagaaaaatataatgtgccgggtatggcggtaggtgttattcaaaacaataaaaaatatgaaacgtattatggtctacaatccgttcaagataaaaaagctgtaaatagcaataccatttttgagctaggttctgtcagtaaattatttactgcgacggcaggtgcttatgcaaaaaatacagggaaaatttcttttgatgatacgccgggcaaatactggaaagagttaaaaaacaccccaattgatcaggtcaatttacttcaacttgccacctatacaagtggtaacctcgctttgcaattcccagatgaagtacaaacagatcaacaggttttaactttttttaaagattggaaacctaaaaacccaatcggtgaatatagacaatattcaaacccaagtattggcctatttggggtaatagttggtttatcaatgaagcagccttttagtcaggtcttggaaaaaacgatttttccggaccttggcttaaaacatagctatgtcaatgtgcctaaaactcagatgcaaaactatgcatttggttataaccaagaaaatcagccaattcgagttaaccctggcccactcgatgccccagcatacggcgtcaaatcgaccctacccgacatgctgagctttattcatgccaacctgaacccacagaaatatccggcaaatattcaacgtgcaattaatgagacacatcaaggtcgctatcaagtaaatagcatgtatcaggcactcggttgggaagagtttgcttatccagcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccacaaaactggttcaacaaatggtttcggaacctatgtcgtatttattcctaaagacaatattggtttagtcatgttaaccaataaacgcattccaaatgaagaacgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_523,Drugs,MEG_523|Drugs|betalactams|Class_C_betalactamases|ADC,490845638|WP_004707701.1|NG_064687|1|1|blaADC-131|blaADC|class_C_beta-lactamase_ADC-131 NG_064687:101-1252,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcaaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5459,Drugs,MEG_5459|Drugs|betalactams|Class_C_betalactamases|PDC,1035157533|WP_064511498.1|NG_050820|1|1|blaPDC-147|blaPDC|class_C_beta-lactamase_PDC-147 NG_050820:1-1194,0
,TGTTGTTGTTATTTCGTATCTTCCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAACGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGGAAACTCATTCCGTTTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2400,Drugs,MEG_2400|Drugs|betalactams|Class_A_betalactamases|CTX,gi|530776686|emb|HG423149.1|1-950,0
,ATGTCTGCATACGGACACGGCCGTCACGAACATGGCCAAAATTTTCTCACCGACCACAAGATCATCAACTCCATCATCGACCTTGTAAAACAAACCTCCGGCCCCATCATTGAGATCGGACCAGGAAGCGGTGCCCTCACTCACCCGATGGCCTACTTGGGGAGGGCAATAACGGCAGTTGAAGTGGACGCAAAACTAGCTGCCAAACTCACACAAGAAACCTCCTCGGCGGCGGTCGAAGTGGTCCATGATGATTTCCTTAACTTCCGTTTACCCGCCACTCCCTGCGTCATTGTGGGAAATATTCCCTTTCATCTCACCACTGCCATTCTTCGAAAGTTGCTGCATGCGCCGGCATGGACTGACGCTGTACTCCTCATGCAGTGGGAAGTCGCTCGCCGCCGGGCTGGGGTAGGCGCAAGCACGATGATGACGGCTCAGTGGTCCCCATGGTTCACATTTCACCTGGGTTCCCGGGTACCAAGGTCTGCTTTCCGGCCACAGCCAAACGTTGACGGGGGGATCTTAGTGATCCGCCGGGTGGGTGACCCGAAGATTCCGATAGAGCAGCGCAAAGCCTTTCAGGCGATGGTGCACACCGTTTTCACTGCCCGGGGACGCGGGATAAGGGAAATTCTCCGAAGGGCAGGGTTGTTTTCATCACGTTCAGAAACACAATCATGGTTGCACTCGCGAGGAATCGACCCTGCGACCCTACCTCCCAGATTGCACACCAGCGACTGGATCGATCTCTTCCAGGTGACTGGTTCCTCTTCACCGCACCATCGACCAATTTCACCATCGGGAAGTAGTCAACGACCTCCTCAACGGAAAAACCGAAGCCGGCGGCGTTAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2860,Drugs,MEG_2860|Drugs|MLS|23S_rRNA_methyltransferases|ERMX,gi|927041813|gb|CP012649.1|2201510-2202364 gi|89513168|gb|DQ390458.1|27639-28493 gi|37993850|gb|AY255627.1|3668-4522 gi|37993850|gb|AY255627.1|3582-3654,7
,atgccccactttcgtctggcccttatcccattacttaccgcattttgtctgcccgcgtttgcccacccgacaacgctgaataaagtcaaagaagcagaaagccagctcaccgcacgcgtcggttatgccgagctggatctcaccagcggcgagattctggaaagctatcgcctgcaagagcgttttcctatgatgagtacatttaaggttttactctgcggcgcggtgctcgcacgcgttgacgcaggaaaagagcggctggatcgtcgcatcccattcagccggcgtgatctggtcgaatactcgccggttacagaaaaacacctgaccgatggcatgaccgtcggcgaattatgcgatgccgccatcaccatgagcgataacacggcggcgaatctactgcttacggccatcggcggtccgcaaggattaaccgcgtttctgcgcacaaccggcgatcgggtgacccgactcgaccgctgggaacccgaattgaacgaagcgctacccggcgataaacgcgatacgacgacacctgaaaatatggcgcaaacgttgcgccaactgctcaccggaaaaatcttgacgacgacatcacagcagcaactcacccactggatggtgacggataaagtcgcggggccactgttgcgctcggtacttccggcaggctggtttatagccgataaaacaggtgccggggcacgcggttctcgcgggatcgtcgcggcgttagggccggacggtaagccttcccgtatcgtggtgatttacatcaccgaaagccaggcaacaatggcggagcgaaacagacagattgcggggattggggcgacgctgatccaacactgggatgagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3136,Drugs,MEG_3136|Drugs|betalactams|Class_A_betalactamases|GIL,1028105372|WP_063860521.1|NG_049142|1|1|blaGIL-1|blaGIL|class_A_broad-spectrum_beta-lactamase_GIL-1 NG_049142:101-961,0
,TTGAAAATTATTTTATTATATGGCGGACGCAGTGCAGAGCATGATGTATCGCTTCTATCCGCTTTTTCAGTAGTCAATGCTGTATATTATAATTACTACCAAGTACAATTAGTAATGATCACGAGAGATGGCCAGTGGCTAAAAGGCTCTTTATTGACTGAAGCCCCTACATCCAAAGAAGTGTTGAATCTGACGGATTCGGCTTACCAAGGGACGCCGATCCAACCTGGTGAGATCAAGGAAGAGGATGCGATTGTTTTTCCGCTGCTCCACGGACCAAATGGAGAAGATGGAACGATCCAAGGTTTTCTAGAGACCATCGGCATGCCTTATGTAGGCGCAGGGGTTTTAACTAGTGCCTGTGGCATGGATAAGATTATGACCAAATATATCTTGCAGGCGGCGGGGATTCCGCAAGTTCCTTATGTACCCGTTCTTAAAAACTATTGGAAAGAAAATCCTAAAAAAGTATTTGAACAATGTGAAGGCAGTCTTTTGTATCCAATGTTTATCAAACCTGCCAATATGGGTTCAAGTGTTGGGATCACAAAAGCTGAAAATCGGGAAGAATTGCAAAATGCACTTCAAGAAGCCTACCGTTATGATACACGAGCGATCGTAGAACAAGGGATCGAAGCTCGCGAAATCGAAGTCGCTGTTCTTGGAAATGAAGATGTGCGTACAACAATGCCCGGCGAGATCGTTAAAGATGTAGCTTTTTATGATTACAATTCGAAGTATCTTGACAATAAGATTGAGATGCAGATCCCAGCTCAAATTCCTGAGGAGACACAAGCGAAAGCGCAAGAGTTTGCCAAAAAAGCTTATACGATGCTTGGAGGAAGCGGCCTCAGCCGCTGCGACTTTTTCTTGACGAACAAAAACGAATTATTCCTGAATGAATTGAACACGATGCCTGGTTTTACCGAGTTTAGTATGTACCCGCTGTTGTGGGAAAAAACCGGTCTGCCATATGGTGATTTGATTGAGGAATTGATTCAATTAGGAGTCAACCGTTTTAAACAGCGTCAAGCCTTTTTAACCGATGTCGAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7333,Drugs,MEG_7333|Drugs|Glycopeptides|VanA-type_resistance_protein|VAN,gb|AY168442.1|+|53-1109|ARO:3003970|D-Ala-D-Ala ligase [Enterococcus gallinarum] ,5
,ATGCAGCTAAGACGTGGCAAAGCAACGGATTGGCATGCGATGGTTCAGGAAAGCTTAGATAGTTTTGCAAGCCCGCATTTTTTGCCGATTGATATAAAACCTATTGATAAAATAGTTATTGAAGGTTTGATAGCTGAGCCTTCTAATTGGTCGATAATTGCTAGACATACAAAATATAAATATCGGAATTTGCTGAAGCAAGAAAGTCAAAATGATGAGTTAACGAACCATTTACGAGAGACTTTTAAGGAATCTGCAGACGAATTAAAAAAAGAATTGGATACGTGGCTTTTGGGGTTGGATGTGACAGAGAAGTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7204,Drugs,MEG_7204|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_regulator|TETU,gb|U01917.1|+|412-730|ARO:3004650|tetU [Enterococcus faecium] ,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcagaccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5598,Drugs,MEG_5598|Drugs|betalactams|Class_C_betalactamases|PDC,1035157532|WP_064511497.1|NG_050819|1|1|blaPDC-146|blaPDC|class_C_beta-lactamase_PDC-146 NG_050819:1-1194,0
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAGAGTTTATTGTATACCAGTGGTGCAATTGCAGAACCAGGGAGCGTAGATAAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAAGTATACCGTTCTTTATCCGTATTAGACGGAGCAGTATTATTAGTTTCTGCAAAGGATGGCATACAGGCACAGACCCGTATACTGTTTCATGCACTACAGACAATGAAGATTCCGACAATTTTTTTCATCAATAAAATTGACCAAGAGGGGATTGATTTGCCAATGGTATATCGAGAAATGAAAGCAAAGCTTTCTTCGGAAATTATAGTGAAGCAAAAGGTTGGGCAGCATCCCCATATAAATGTAACAGACAATGACGATATGGAACAGTGGGATACGGTAATTATGGGAAACGATGAACTATTAGAGAAATATATGTCAGGGAAACCGTTTAAAATGTCAGAACTGGAACAGGAAGAAAACAGGAGATTCCAAAACGGAACGTTATTTCCCGTTTATCACGGAAGCGCTAAAAACAATCTGGGGATTCGGCAGCTTATAGAAGTGATTGCCAGTAAATTTTATTCATCAACGCCTGAAGGTCAATCTGAACTATGCGGGCAGGTTTTTAAGATTGAATATTCAGAGAAAAGGCGGCGTTTTGTTTATGTGCGTATATATAGCGGAACATTGCATTTGAGGGATGTTATTAGAATATCTGAAAAAGAGAAAATAAAAATCACAGAGATGTGTGTTCCGACAAACGGTGAATTATATTCATCCGATACAGCCTGCTCTGGTGATATTGTAATTTTACCAAATGATGTTTTGCAGCTAAACAGTATTTTGGGGAACGAAATACTGTTGCCGCAGAGAAAATTTATTGAAAATCCTCTCCCTATGCTCCAAACAACGATTGCAGTAAAGAAATCTGAACAGCGGGAAATATTGCTTGGGGCACTTACAGAAATTTCAGATGGCGACCCTCTTTTAAAATATTATGTGGATACTACAACGCATGAGATTATACTTTCTTTTTTGGGGAATGTGCAGATGGAAGTCATTTGTGCCATCCTTGAGGAAAAATATCATGTGGAGGCAGAAATAAAAGAGCCTACTGTTATATATATGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAGGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTTATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7161,Drugs,MEG_7161|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,gi|153116|gb|M20925.1|STATETOSM|183-2102,4
,TTGTCAAAATAGAGGGAGTCACGGATAGTCCGGACAGCTAATCACTATCAAGGAATCTGAAATGATTAAAACTTCGTGGCGTAAAAGCGCCCTGATTGCCGCCGCCCTGCCTTTATTGCTCTGTAGCAGTTCATTATGGGCCAATGCTATTCAGCAGAAGCTGGCCGATTTGGAAAAAAGTACCGGCGGGCGACTGGGCGTCGCGCTGATTGACACCACAGATAACTCTCAAATTCTATATCGCGGTGACGAGCGTTTTGCTATGTGCAGTACCGGTAAAGTGATGGCTGCCGCCGCGGTGTTAAAACAGAGCGAAAGCAATAAAGATGTGGTGAATAAAAGGCTGGAGATTAAAGCATCGGATCTGGTGGTCTGGAGCCCGGTGACTGAAAAACATCTGCAGAGCGGAATGACGTTGGCGGAATTAAGCGCCGCCGCGCTGCAATATAGCGACAATACCGCGATGAATAAGATGATTGGTTATCTTGGCGGACCGGAAAAAGTGACCGCCTTCGCCCGCAGTATCGGCGATGTCACTTTTCGTCTCGATCGTACGGAGCCTGCACTAAACACCGCGATCCCGGGTGACGAACGCGATACCACCACGCCGCTGGCGATGGCCGAAAGCCTGCACAAGCTGACGCTGGGTAATGCGCTGGGTGAACAACAGCGCGCACAGTTAGTGACATGGTTGAAAGGCAACACCACCGGCGGGCAGAGTATTCGTGCGGGGCTGCCTGCAAGCTGGGTCGTGGGAGATAAAACCGGAGCTGGTGATTACGGCACCACCAATGATATCGCCGTTATCTGGCCGGAAAATCATGCTCCGCTGGTATTAGTCACTTATTTCACCCAACCGCTGCAGGATGCGAAAAGCCGCAAAGATGTGCTAGCCGCAGCGGCAAAAATCGTGACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5313,Drugs,MEG_5313|Drugs|betalactams|Class_A_betalactamases|OXY,gi|23345325|gb|AF491278.1|123-1050,0
,ATGCAAAAAAGACTTATACATTTATCCATTATCTTCTTTCTGCTATGTCCTGCCCTGGTAGTTGCGCAGAACAGTCCTCTTGAAACTCAACTCAAGAAAGCCATAGAAGGGAAAAAAGCCGAAATAGGAATTGCAGTCATTATCGACGGGCAAGATACGATAACAGTCAATAATGATATTCATTATCCCATGATGAGTGTTTTCAAATTTCATCAGGCATTGGCATTGGCCGATTACATGCATCATCAAAAGCAACCTTTGAAAACCCGGTTATTGATTAAAAAGTCGGATTTAAAGCCGGACACCTATAGTCCGCTTCGAGAAACATACCCACAGGGAGGAATCGAAATGAGCATTGCCGATCTACTGAAATATACGCTTCAGCAAAGTGACAATAATGCCTGCGATATTCTTTTTAATTATCAAGGTGGTCCGGATGCCGTGAATAAGTATCTTCATTCATTGGGAATTCGTGAATGTGCTGTCATCCATACAGAAAACGATATGCATGAGAATCTGGAGTTCTGTTACCAAAACTGGACTACTCCATTAGCAGCCGCCAAATTACTGGAAATATTTCGCAATGAAAACCTTTTTGACAAAGAATACAAGAATTTCATTTATCAAACAATGGTGGAATGTCAGACAGGACAAGACCGCCTGATTGCTCCACTGCTCGATAAAAAAGTAACAATGGGGCATAAAACCGGAACAGGCGACCGTAATGCGAAAGGACAACAGATCGGTTGCAATGACATCGGGTTTATTCTTCTTCCCGACGGACATGTCTATAGTATAGCCGTCTTCGTGAAAGATTCCGAAGCAGATAACAGAGAAAACAGTGAGATTATCGCAGAAATTTCGCGCATCGTTTACGAATACGTAACGCAACAGATAGATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1648,Drugs,MEG_1648|Drugs|betalactams|Class_A_betalactamases|CEPA,(Bla)CEPA-85:U05887:556-1458:903;(Bla)CEPA-29:FR688019:1-903:903,0
,ATGAGCGACAGCAATCAACCGGGCCTGTTCGACGGTGGCGCCACCGATCCCCACGAAGCCATCACCCTGGGCCGCTATGCCGAGCAGGCCTACCTGGACTACGCCGTGTCCGTGGTGCGCGGCCGCGCCCTGCCCGATGTGGGCGACGGCCAGAAACCGGTGCAGCGCCGCATCCTGTACGCGATGCAGGCCATGGGGCTGGCGGCAGGCGCCAAGCCGGTGAAGTCGGCGCGCGTGGTCGGCGACGTGCTGGGCAAGTACCACCCGCACGGCGACCAGGCCGCCTATGACGCCATGGTCCGGATGGCGCAGGACTTCTCGCTGCGCTATCCCCTGATCGACGGCCATGGCAACTTCGGCTCGCGCGACGGCGACAACGCGGCGGCCATGCGTTATACCGAAGCGCGCCTGACGCCGTTCTCCAAGCTGCTGCTCGACGAGCTGGAGGAGGGCACGGTCGACTTCGTGCCGAACTACGACGGCAGCCAGCAGGAGCCGGCCATGCTGCCGGCGCGCCTGCCCGTGATGCTGCTCAACGGCGCCTCGGGCATCGCCGTGGGCATGGCCACCGAGATTCCCTCGCACAACCTGCGCGAGGTGGCGCAGGCCTGCGTGGCGCTGATCCGCAATCCCAAGCTGCCGCAGGAAGAGCTGCTGGCGCTGGTGCCGGGCCCGGATTTCGCCGGGGGCGGCCAGATCATCACCCCGGCGGCCGATATCGCGCAGATCTACGCCACCGGGCGCGGCTCGCTGAAGGCGCGCGCGCGCTGGCAGTTCGAGGAAATGGCGCGCGGGCAGTGGCAGCTGGTGGTGACCGAGCTGCCGCCGGGCACCTCGGGCCAGAAGGTGCTGGAAGAGATCGAGGAAATCACCAATCCGAAGGTGCGCGCGGGCAAGAAGAGCCTTTCGGCCGAGCAGCAGCAGGCCAAGGCGGTCATGCTCAGCCTGCTCGACGCGGTGCGCGACGAGTCCGGCAAGGACGCGGCGGTGCGGCTGGTGTTCGAGCCCAAGACCTCGCGCGTCGATCGCGACGAATTCGTCAACACCTTGCTGGCGCAGACCAGCATGGAAAGCAACGTGCCGGTCAACGTGGTGTGCATCGGCACCGATGGCCGGCCGCGCCAGAAGAGCCTGCGCGACGTGCTGGAAGAGTGGGTGGCGTTTCGCACCGATACGGTGGTGCGCCGCACGCGCCATCGCCTGGACAAGGTGCTCGACCGCATCCATGTGCTGGAAGGGCGCATGGTGGTCTACCTCAATGTCGACGAGGTCATCCAGACCATTCGCGAGGCCGAGGAGCCGCGCGCCGCGCTGATGGCGCGTTTCGGGCTGACCGAGCGCCAGGCCGAGGACATCCTGGAAATGCGCCTGCGCCAGCTGGCGCGCCTGGAAGGCATCAAGATCGAACAGGAACTGGCCGGCAAGCGCGAAGAACAGCTGCGCCTGCAGGACCTGCTGGACAACCCGGGCTCGCTCAAGCGCCTGCTCATCAAGGAAATCGAGGGCGACGCCAAGCAGTACGGCGACGACCGCCGCACCCTGATCGAAACCGCCGAGCGCGCGGTGCTCGAGACCAAGGTGGTCGACGAGCCCGTCACGGTGATCGTGTCGCAGAAAGGCTGGCTGCGCGCCCGCCAGGGCCACGGCCATGATGCCGGGCAATTCAGCTTCAAGCAGGGCGACGACCTGTACGGCGCCTTCGAGTGCCGCACCACCGATACCCTGATCGCGGTGGGCGACAACGGCCGCGTCTATTCGGTGGCCGTATCCGGCCTGCCGTCGGCGCGTGGCGATGGCCAGCCGGTCACCACCATGATCGATCTCGAGGCCGGCACGCGCATCGTGCACACCATCGCGGCGGCGCCCGACAGCCGCTGGTTGTTGGCCACGCGGCGCGGCTTCGGTTTTGCCGCCCGGCTCAGCGACATGAGCAGCCGCCAGCGCGCTGGCAAGCAGTTCATCACCCTGGAGAAGGGCGATGAGCTGTTGCGGCCGGTTCCGCTGTTCGAGGGGGCGACCCAGCTGGCGCTGCTGTCGGCCAAGGGCAAGTTCCTGGTGTTCGACCTGGACGAGGTCAAGAGCCTGTCGGGCGGCGGGCGCGGCACCATCCTGATGGGGCTGGACACCGCCGACAAGCTGGACCAGACCGTGCCGATCGGCGCGGCCGGCCTGCGCGCCGCCGGCATCTACCGCAACAAGCAGACCGAGGACATCCTGGCCGGCGCCGCGCTCGCGCCGTACGTCGGCAAGCGCGCCCGCAAGGGCCGGCAACTGAACGTGCGTCCCAGGCAGCCGGTGCTGTCGCCGGTGTTCTGA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5360,Drugs,MEG_5360|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|973420427|gb|CP010966.1|1315475-1317790 gi|973416827|gb|CP010965.1|2742169-2739854 gi|937412521|gb|CP011401.1|2734411-2732096 gi|937409066|gb|CP011400.1|1030858-1033173 gi|937404317|gb|CP011448.1|1315474-1317789 gi|937400854|gb|CP011447.1|1315484-1317799 gi|937393878|gb|CP011446.1|1314428-1316743 gi|937390412|gb|CP011445.1|1313376-1315691 gi|937386949|gb|CP011444.1|1314411-1316726 gi|937383491|gb|CP011443.1|2741134-2738819,3
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6942,Drugs,MEG_6942|Drugs|betalactams|Class_A_betalactamases|TEM,gi|695212971|ref|NG_036530.1|1-1123 gi|981191958|emb|LN999997.1|2513495-2513298 gi|975048878|gb|CP013962.1|4121893-4121696 gi|973715451|gb|CP013836.1|137555-137752 gi|973705327|gb|CP013832.1|75856-76053 gi|971339514|gb|CP006662.2|50617-50814 gi|943457735|gb|KT818627.1|32861-33058 gi|970338578|gb|KT725789.1|75254-75451 gi|970338460|gb|KT725788.1|80514-80711 gi|962148759|gb|KT002541.1|3702-3899,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaaacttctgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4485,Drugs,MEG_4485|Drugs|betalactams|Class_D_betalactamases|OXA,1509794603|WP_122630912.1|NG_062332|1|1|blaOXA-720|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-720 NG_062332:20-844,0
,ATGAAAACAGTATTTATCCTTATCTCCATGCTTTTCCCTGTCGCAGTTATGGCACAGAAAAGCGTAAAAATATCCGATGACATCAGTATCACCCAACTCTCGGACAAAGTGTACACTTATGTATCCCTCGCCGAAATCGAAGGATGGGGTATGGTACCTTCCAACGGGATGATTGTTATCAACAACCACCAGGCAGCGTTGCTGGACACACCGATCAATGACGCACAAACGGAAATGCTGGTCAACTGGGTGACAGACTCTTTGCATGCCAAAGTCACCACGTTTATCCCGAACCACTGGCACGGCGATTGTATTGGCGGACTGGGTTACCTGCAAAGGAAAGGTGTCCAATCATACGCGAACCAGATGACGATAGACCTCGCCAAGGAAAAAGGGTTGCCCGTACCGGAACATGGATTCACCGATTCACTGACCGTCAGCTTGGACGGCATGCCTCTCCAATGCTATTATTTAGGAGGCGGGCATGCGACCGACAATATCGTGGTTTGGCTGCCGACAGAGAATATCCTTTTTGGCGGATGTATGCTTAAAGACAACCAGGCGACAAGCATCGGCAACATCTCGGACGCAGACGTGACGGCATGGCCGAAAACTCTCGATAAGGTAAAAGCCAAGTTCCCCTCGGCCCGCTACGTCGTGCCCGGACATGGCGACTATGGCGGAACCGAACTGATAGAGCATACCAAGCAGATCGTGAACCAATATATAGAAAGCACCTCAAAGCCATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1669,Drugs,MEG_1669|Drugs|betalactams|Class_B_betalactamases|CFIA,(Bla)cfiA13:FM200787:3-752:750,0
,ATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTTGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6925,Drugs,MEG_6925|Drugs|betalactams|Class_A_betalactamases|TEM,gi|494595013|gb|KC865667.1|1-1111,0
,ATGTTGAAAAGTTCGTGGCGTAAAACCGCCCTGATGGCCGCCGCCGCCGTTCCGCTGCTGCTGGCGAGCGGTTCATTATGGGCCAGTGCCGATGCTATCCAGCAAAAGCTGGCTGATTTAGAAAAACGTTCCGGCGGTCGGCTGGGCGTAGCGCTGATTAACACGGCAGATGATTCGCAAACCCTCTATCGCGGCGATGAACGTTTTGCCATGTGCAGCACCGGTAAAGTGATGGCCGCCGCCGCGGTGTTAAAACAGAGCGAAAGCAATCCAGAGGTGGTGAATAAAAGGCTGGAGATTAAAAAATCGGATTTAGTGGTCTGGAGCCCGATCACCGAAAAACATCTGCAAAGCGGAATGACCCTGGCGGAACTCAGCGCGGCGGCGCTGCAGTACAGCGACAATACCGCGATGAATAAGATGATTAGCTACCTTGGCGGACCGGAAAAGGTGACCGCATTCGCCCAGAGTATCGGGGATGTCACTTTTCGTCTCGATCGTACGGAGCCGGCGCTGAACAGCGCGATTCCCGGCGATAAGCGCGATACCACCACCCCGTTGGCGATGGCCGAAAGCCTGCGCAAGCTGACGCTGGGCAATGCGCTGGGCGAACAGCAGCGCGCCCAGTTAGTAACGTGGCTAAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCAGGCCTGCCCGCAAGCTGGGTGGTCGGGGATAAAACCGGCGGCGGAGATTACGGCACCACCAACGATATCGCGGTGATCTGGCCGGAAAATCATGCCCCGCTGGTGCTGGTGACCTATTTTACCCAGCCGCAGCAGGATGCGAAAAGCCGCAAAGAGGTGTTAGCCGCGGCGGCAAAAATCGTCACCGAAGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5284,Drugs,MEG_5284|Drugs|betalactams|Class_A_betalactamases|OXY,(Bla)OXY1-5:AY077483:181-1056:876,0
,atgactctggcgttagttggcgaaaaaattgacagaaacaggttcaccggtgaaaaagttgaaaatagcacatttttcaactgtgatttttcgggtgccgaccttagcggcactgaatttattggctgccagttttatgatcgagaaagtcagaaaggatgtaattttagtcgcgctaacctgaaagatgccattttcaaaagttgtgatctctccatggctgatttcaggaatatcaatgcgctgggaatcgaaattcgccactgccgggcacaagggtcagattttcgcggcgcaagttttatgaatatgatcaccacccgcacctggttttgtagcgcctatatcaccaataccaacttaagctacgccaacttttcaaaagtcgtactggaaaagtgcgagctgtgggaaaaccgctggatgggtactcaggtgctgggcgcaacgttcagtggatcagacctctctggcggcgagttttcatccttcgactggcgagcagcaaacgttacgcactgtgatttgaccaattcggaactgggcgatttagatatccgcggggttgatttgcaaggcgtcaaactggacagctaccaggcatcgttgctcctggaacgtcttggtatcgctgtcatgggttaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5902,Drugs,MEG_5902|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,516512552|WP_017900990.1|NG_050502|1|1|qnrB4|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB4 NG_050502:4-648,3
,ATGAGCAACGCAGTGCCCGCCGAGATTTCGGTACAGCTATCACAGGCACTCAACGTCATCGAGCATCATCTGGGATCGACGTTGCTGGCCGTGCATTTGTACGGCTCTGCACTCGACGGTGGCCTGAAGCCATGCAGTGATATTGATTTGCTGGTTACTGTGACTGCACAGCTCGATGAGACTGTGCGGCAGGCTCTGTTCGTAGATTTCCTGGAAGTTTCCGCTTCTCCCGGCCAAAGTGAAGCTCTCCGTGCCTTGGAAGTTACCATCGTCGTGTACGGCGATGTTGTTCCTTGGCGTTATCCAGCCAGACGGGAACTGCAATTCGGGGAGTGGCAGCGCAAGGACATTCTTGCGGGCATCTTCGAGCCCGCGACAACCGATGTTGATCTGGCTATTCTGCTAACTAAAGCAAGGCAACACAGCCTTGCCTTGGCAGGTTCGGCCGCGGAAGATTTCTTCAACCCAGTCCCGGAAAGCGATCTATTCAAAGCACTGGCCGACACCTTGAAACTATGGAACTCACAACCGGATTGGGCAGGCGACGAGCGGAATGTAGTGCTTACCTTGTCTCGCATTTGGTACAGCGCAGCAACCGGCAAGATCGCGCCGAAGGATGTAGCTGCCAACTGGGTAATGGAACGCCTGCCCGTCCAACATCAGCCCGTGCTGCTTGAAGCCCAGCAGGCTTACCTTGGACAAGGGATGGATTGCTTGGCCTCACGCGCTGATCAGTTGACTGCGTTCATTTACTTTGTGAAGCACGAAGCCGCCAGTCTGCTCGGCTCCACGCCAATGATGTCTAAAACAAAGTTA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_955,Drugs,MEG_955|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|406507747|gb|JX128136.1|469-1284 gi|388837265|gb|JQ837993.1|709-1524 gi|52858431|gb|AY740681.1|715-1530,2
,ttgaaaaaatacttttactttttagtctttttttactcttttgctttggcaaatgataaattaaaagatttttttaaagactacaatacaagcggagtttttataacttttgatggaaaacattatgcaagtaataattttaaaagagctaaagaacctttttctcctgcttcgacttttaaaatttttaatgctttaattgcgcttgataatggtgtagttaaagatacaaaggaaattttttatcattataagggtgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcctatggaaatacaaaaatttcaaaaatcgataccttttggctggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgatggtataaatttggcttggattgttggatttatagagagtaaaaacaaaattttatcttttgccttaaatgttgatataaagaacattaaaaatcttaaaataagagaagaattgctagaaaaatatatttattctttaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4639,Drugs,MEG_4639|Drugs|betalactams|Class_D_betalactamases|OXA,1391852899|WP_109545084.1|NG_057502|1|1|blaOXA-634|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-634 NG_057502:1-747,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgattgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagcgggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_832,Drugs,MEG_832|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,983327881|WP_060512885.1|NG_052475|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052475:101-889,2
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCGCTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1440,Drugs,MEG_1440|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_81_FGJZ01000020,0
,TTGTCAAAATAGCGGGAGTCGCAGATAATCCGCTGCGACTTATCACTCTCAAGGAATCAGAAATGATAAAAAGTTCGTGGCGTAAAATTGCAATGCTAGCCGCCGCCGTTCCGCTGCTGCTGGCGAGCGGCGCACTGTGGGCCAGTACCGATGCTATCCATCAGAAGCTGACAGATCTCGAGAAGCGTTCAGGCGGCAGGTTGGGCGTGGCGCTAATCAACACGGCAGATAATTCTCAAATCTTATATCGCGGCGACGAGCGTTTTGCCATGTGCAGCACCAGTAAAGTGATGGCCGCCGCCGCGGTATTAAAACAGAGCGAAAGCAATAAAGAGGTGGTAAATAAAAGGCTGGAGATTAACGCAGCCGATTTGGTGGTCTGGAGTCCGATTACCGAAAAACATCTCCAGAGCGGAATGACGCTGGCTGAGCTAAGCGCGGCGACGCTGCAATATAGCGACAATACGGCGATGAATCTGATCATCGGCTACCTTGGCGGGCCGGAAAAAGTCACCGCCTTCGCCCGCAGTATCGGCGATGCCACCTTTCGTCTCGATCGTACGGAGCCCACGCTGAATACCGCCATCCCGGGCGATGAGCGTGATACCAGCACGCCGCTGGCGATGGCTGAAAGCCTGCGCAAGCTGACGCTTGGCGATGCGCTGGGCGAACAGCAACGCGCCCAGTTAGTCACCTGGCTGAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCGGGCCTGCCTGAAAGCTGGGTGGTCGGCGATAAAACCGGTGCCGGAGATTACGGCACCACCAATGATATTGCGGTTATCTGGCCGGAAAATCACGCTCCGCTGGTATTAGTCACCTACTTTACCCAGCCGCAGCAGGATGCGAAAAACCGCAAAGAGGTGTTAGCCGCAGCGACAAAAATCGTGACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5315,Drugs,MEG_5315|Drugs|betalactams|Class_A_betalactamases|OXY,gi|257136311|gb|FJ785626.1|70-1004,0
,ATGGAGGAAATAAAATTGAAAATTATTAATATCGGTATCTTAGCACATGTTGATGCAGGAAAAACTACTTTGACAGAAAGCTTACTATACAGTAGCGGAGCGATTACAGAATTAGGAAGCGTGGACAAAGGTACAACGAGGACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACAGGAATAACCTCTTTTCAGTGGGAAAATACGAAGGTGAACATCATAGACACGCCAGGACATATGGATTTCTTAGCAGAAGTATATCGTTCATTATCAGTTTTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATGGCGTACAAGCACAAACTCGTATATTGTTTCATGCACTTAGGAAAATAGGTATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCGGAAATTGTAATCAAACAGAAGGTAGAACTGTATCCTAATATGTGTGTGACGAACTTTACCGAATCTGAACAATGGGATACGGTAATAGAGGGAAACGATGACCTTTTAGAGAAATATATGTCCGGTAAATCATTAGAAGCATTGGAACTCGAACAAGAGGAAAGCATAAGATTTCAGAATTGTTCTCTGTTCCCTCTTTATCATGGAAGTGCAAAAAGTAATATAGGGATTGATAACCTTATAGAAGTTATTACTAATAAATTTTATTCATCAACACATCGAGGTCCGTCTGAACTTTGCGGAAATGTTTTCAAAATTGAATATACAAAAAAAAGACAACGTCTTGCATATATACGCCTTTATAGTGGAGTACTACATTTACGAGATTCGGTTAGAGTATCAGAAAAAGAAAAAATAAAAGTTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAGATTGATAGAGCTTATTCTGGAGAAATTGTTATTTTGCAAAATGAGTTTTTGAAGTTAAATAGTGTTCTTGGAGATACAAAACTATTGCCACAGAGAAAAAAGATTGAAAATCCGCACCCTCTACTACAAACAACTGTTGAACCGAGTAAACCTGAACAGAGAGAAATGTTGCTTGATGCCCTTTTGGAAATCTCAGATAGTGATCCGCTTCTACGATATTACGTGGATTCTACGACACATGAAATTATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGATTAGTGCACTGTTGCAAGAAAAGTATCATGTGGAGATAGAACTAAAAGAGCCTACAGTCATTTATATGGAGAGACCGTTAAAAAATGCAGAATATACCATTCACATCGAAGTGCCGCCAAATCCTTTCTGGGCTTCCATTGGTTTATCTGTATCACCGCTTCCGTTGGGAAGTGGAATGCAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCATTTCAAAATGCAGTTATGGAAGGGATACGCTATGGCTGTGAACAAGGATTGTATGGTTGGAATGTGACGGACTGTAAAATCTGTTTTAAGTATGGCTTATACTATAGCCCTGTTAGTACCCCAGCAGATTTTCGGATGCTTGCTCCTATTGTATTGGAACAAGTCTTAAAAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAATTTATGCGCCACAGGAATATCTTTCACGAGCATACAACGATGCTCCTAAATATTGTGCGAACATCGTAGACACTCAATTGAAAAATAATGAGGTCATTCTTAGTGGAGAAATCCCTGATCGGTGTATTCAAGAATATCGTAGTGATTTAACTTTCTTTACAAATGGACGTAGTGTTTGTTTAACAGAGTTAAAAGGGTACCATGTTACTACCGGTGAACCTGTTTGCCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7148,Drugs,MEG_7148|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,tet(S/M)_1_HM367711 ,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5588,Drugs,MEG_5588|Drugs|betalactams|Class_C_betalactamases|PDC,1034011009|WP_064483991.1|NG_050782|1|1|blaPDC-126|blaPDC|class_C_beta-lactamase_PDC-126 NG_050782:1-1194,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggttgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4453,Drugs,MEG_4453|Drugs|betalactams|Class_D_betalactamases|OXA,1559612988|WP_128268253.1|NG_063858|1|1|blaOXA-754|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-754 NG_063858:30-854,0
,atgaatagaataaaagtcgcaatcatcttcggcggttgctcggaggaacatgatgtgtcggtaaaatccgcaatagaaattgctgcgaacattgatacggaaaaattcgatccgcactacatcggaattacaaaaaacggtgtatggaagctatgcaagaagccatgtacggaatgggaagccgacagtctccccgccatactctccccggataggaaaacgcatgggctgcttgtcatgaaagaaagcgaatacgaaacacggcgtattgatgtggctttcccggttttgcatggcaaatgcggggaggatggtgcgatacaggggctgtttgtattgtctggtatcccctatgtgggctgtgatattcaaagctccgcagtttgcatggacaaatcactggcctacattcttacaaaaaatgcgggcatcgccgttcccgaatttcaaatgattgataaaggtgacaagccggaggcgggtgcgcttacctaccctgtctttgtgaagccggcacggtcaggttcgtcctttggcgtaaccaaagtaaacggtacggaagaacttaacgctgcgatagaagcggcaggacaatatgatggaaaaatcttaattgagcaagcgatttcgggctgtgaggtcgggtgtgcggtcatggggaacgaggatgatttgattgtcggcgaagtggatcaaatccggctgagccacggtatcttccgcatccatcaggaaaacgagccggaaaaaggctcagaaaatgcgatgattacagttcccgcagacattccggtcgaggaacgaaatcgggtgcaggaaacggcaaagaaagtatatcgggtgcttggatgcagagggcttgcccgtgttgatctttttttgcaggaggatggcggcatcgttctaaatgaggtcaataccctgcccggttttacatcgtacagccgctacccacgtatggtggccgccgcaggaatcacgcttcctgcactgattgacagcctgattacattggcgttaaagaggtga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7350,Drugs,MEG_7350|Drugs|Glycopeptides|VanB-type_resistance_protein|VANB,757732571|WP_042958124.1|NG_048334|1|1|vanB|vanB|D-alanine--(R)-lactate_ligase_VanB NG_048334:1-1029,5
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAACCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1389,Drugs,MEG_1389|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_115_FN433596,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGAACAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1452,Drugs,MEG_1452|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_126_NC_013374,0
,atgatgaaaaaatccctttgctgcgccctgctgctcggcatctcttgctctgctctcgccacgccagtgtcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaaccgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccgccgttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagcatcggtctttttggtgcgctggcggtcaaaccttctggcatgccctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccataccaggattaacgtgccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggtatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaacgttgctgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcgagggcagcgacagtaaggtagcactggcgccgttgcccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggctctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaatacaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgaggcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_424,Drugs,MEG_424|Drugs|betalactams|Class_C_betalactamases|ACT,749204511|WP_040117106.1|NG_050705|1|1|blaACT-42|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-42 NG_050705:1-1146,0
,TAATTTGCCGGTGAGCGTGGCGTTGGGCGTCAAGGAAAACTTAATGGCAATCCGAATCTTTGCAATACTTTTCTCCACTTTTGTTTTTGGCACGTTCGCGCATGCACAAGAAGGCATGCGCGAACGTTCTGACTGGCGGAAGTTTTTCAGCGAATTTCAAGCCAAAGGCACGATAGTTGTGGCAGACGAACGCCAAACAGATCGTGTCATATTGGTTTTTGATCAGGTGCGGTCAGAGAAACGCTACTCGCCGGCCTCGACATTCAAGATTCCACATACACTTTTTGCACTTGACGCAGGCGCTGCACGTGATGAGTTTCAAGTTTTCCGATGGGACGGCATCAAAAGAAGCTTTGCAGCTCACAACCAAGACCAAGACTTGCGATCAGCAATGCGGAATTCTACTGTCTGGATTTATGAGCTATTTGCAAAAGAGATCGGTGAAGACAAGGCTCGACGCTATTTGAAGCAAATCGACTATGGCAACGCCGATCCTTCGACAAGTAATGGCGATTACTGGATAGATGGCAATCTTGCTATCGCGGCACAAGAACAGATTGCATTTCTCAGGAAGCTCTATCATAACGAGTTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGACCTCATGATTGTGGAAGCCGGTCGCAACTGGATACTGCGCGCAAAGACGGGCTGGGAAGGCCGCATTGGTTGGTGGGTAGGATGGGTTGAGTGGCCGACTGGCCCCGTATTCTTCGCACTGAATATTGATACGCCAAACAGGATGGATGACCTTTTCAAAAGGGAGGCAATAGTGCGGGCAATCCTTCGCTCTATCGAAGCGTTGCCGCCCAACCCGGCAGTCAACTCGGACGCAGCGCGATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5250,Drugs,MEG_5250|Drugs|betalactams|Class_D_betalactamases|OXA,gi|784887|gb|L07945.1|PSEBLAOXA3|18-888,0
,gtgcgctcaaaaaactttagttggcggtactcccttgccgccacggtgttgttgttatcaccgttcgatttattggcatcactcggcatggacatgtacttgccagcagtgccgtttatgccaaacgcgcttggtacgacagcgagcacaattcagcttacgctgacaacgtacttggtcatgattggtgccggtcagctcttgtttggaccgctatcggaccgactggggcgccgccccgttctactgggaggtggcctcgcctacgttgtggcgtcaatgggcctcgctcttacgtcatcggctgaagtctttctggggcttcggattcttcaggcttgtggtgcctcggcgtgccttgtttccacatttgcaacagtacgtgacatttacgcaggtcgcgaggaaagtaatgtcatttacggcatactcggatccatgctggccatggtcccggcggtaggcccattgctcggagcgctcgtcgacatgtggcttgggtggcgggctatctttgcgtttctaggtttgggcatgatcgctgcatctgcagcagcgtggcgattctggcctgaaacccgggtgcaacgagttgcgggcttgcaatggtcgcagctgctactccccgttaagtgcctgaacttctggttgtacacgttgtgttacgccgctggagtgggtagcttcttcgtctttttctccattgcgcccggactaatgatgggcaggcaaggtgtgtctcagcttggcttcagcctgctgttcgccacagtggcaattgccatggtgtttacggctcgttttatggggcgcgtgatacccaagtggggcagcccaagtgtcttgcgaatgggaatgggatgcctgatagctggagcagtattgcttgccatcaccgaaatatgggcttcgcagtccgtgttaggctttattgctccaatgtggctagtgggtattggtgtcgccacagcggtatctgtgtcgcccaatggcgctcttcgaggattcgaccatgttgctggaacggtcacggcagtctacttctgcttgggcggtgtactgctaggaagcatcggaacgttgatcatttcgctgttgccgcgcaacacggcttggccggttgtcgtgtactgtttgacccttgcaacagtcgtgctcggtctgtcttgtgtttcccgagtgaagggctctcgcggccagggggagcatgatgtggtcgcgctacaaagtgcggaaagtacatcaaatcccaatcgttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1756,Drugs,MEG_1756|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,1105502045|WP_071846197.1|NG_052155|1|1|cmlA|cmlA|CmlA_family_chloramphenicol_efflux_MFS_transporter NG_052155:101-1360,6
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacaaggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtcccattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_828,Drugs,MEG_828|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1080153682|WP_070342362.1|NG_051886|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_051886:101-889,2
,ATGATTGGACTGACCTTGCTTGGTTGTCAAAATTTTCACGCCCCAACTCAAAGCGCCGTGTCAAAAAAACACGATCAAACCGAGATCGCTTCTTTATTCCAACATGCTCAAACTGTTGGCGTATTTGTTACATATGATGGGCAAACACTTCAAGCATATGGCAATGCGTTGAGTCGATCGAATACGGCTTATATTCCAGCCTCAACCTTCAAGATGTTAAATGCTCTGATTGGGATACAGCATCACAAAACTTCACCAAACGAAGTGTTTAAATGGGATGGCAAAAAGCGTGCTTTTGCGAGCTGGGAAAAAGATTTAACTTTAGCCGAGGCGATGCAGGCATCAGCAGTGCCTGTTTATCAGGAATTGGCTCGGCGTATCGGGTTAGAGTTGATGGCGAACGAAGTAAAACGCGTTGGCTTTGGCAATGCCGAGATCGGAACGCAAGTCGATGATTTTTGGTTGGTTGGCCCGCTTAAGATTACCCCAATTGAAGAGGTTAAATTTGCTTATGCTTTGGCAAATAAGCAGCTTGAATTTGACCAATCTGTGCAAAAACAAGTGAAACAGATGGTCTTCGTTGATGAAGTTCATGGAACTAAGATTTATGCCAAAAGTGGTTGGGGGATGGATGTAACACCGCAAGTGGGTTGGTGGACGGGCTGGATTGAACAACCGAATGGACAGGTGATTGCATTTTCTTTAAATCTGGAAATAAATAAGCCTGAGCACGGTGATGCGCGTAAAGCGATTGTTTATCAAGCATTACAACAATTGAAATTGTTACAGAAGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5270,Drugs,MEG_5270|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-289_1_APRM01000005,0
,TTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAAC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6754,Drugs,MEG_6754|Drugs|betalactams|Class_A_betalactamases|TEM,gb|AY130282|+|0-764|ARO:3000980|TEM-117 [Escherichia coli] ,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacatcttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcggattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccaggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6228,Drugs,MEG_6228|Drugs|betalactams|Class_A_betalactamases|SHV,1509794565|WP_122630874.1|NG_062291|1|1|blaSHV-219|blaSHV|class_A_beta-lactamase_SHV-219 NG_062291:1-861,0
,atggacacaacgcaggtcacattgatacacaaaattctagctgcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatggttgaaatgctcggcgggcgcgtcacggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccaatggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_742,Drugs,MEG_742|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1105502161|WP_071846312.1|NG_052382|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052382:101-634,2
,ATGAATCTGAATATAAGAGGACATTTAATGAAGAACTTTCTCACCAAGAAAATGTACGCAACTAGAGCTTTATTTTTTGCTGTAGGTGTTACGGCTTTGAATGTTTCCCCTATTGTTATTTCTACTACTCATGCAGCGACAGAACAAAAAATGGATAATTTATCGACTACACTTTCATTAATTTTTGCAGATAAACCCATAGAAGCTTCTTTATTTAGCCCTCAATTTTTAGGACAAGTTCCCATCACACAAATTCAAAAAATCGTTGATGATTTAAAAGTCTCTTTAGGTGCTCTTAAAAATATTAATGTTTCAAATGGCTCTGGGACTATTGATTTCGAAAAGGGAGAATTACCCGTTTCAATTAGCTTAAATGAGCAAGAACAAATTAGTACTCTTTGGTTTAGTGCGCCTCATTTTAAGACAATAAGCCTAGACGAAATGGTTAAAGGTCTACATGAAAATGCGATCGGTAAAACTTCTCTTTTAGTTATTGTAGATAACAAGCCTGTGGTTGTAGAAAATGATAAAACCCCTATGGCTGTCGGTTCGACTTTTAAGTTACTAGTTTTAAAAGCTTATGAAGATGCGATAAAAAAAGGCGAATTAAAAAGAGAAACTATTGTTTCTTTAAAAGAAAAGAATCGCTCGTTGCCAACAGGAGTTTTACAAAACTTGCCTGCTGGTACACCTATAAATCTCGAACTTCTTGCGCAGTTAATGATACAAATTAGCGATAATACAGCAACAGATAGCTTGATAGATGTATTAAAGAAACCTCGTATAGAAGCGTTGTCACCTAGAAATTCTCCTCTGCTGACGACACGAGAGCTATTTCAACTGATTGATTCAAGTAATGAAAAGCTCAGAAATAAGTTTAAAACAGGAACAAAGTCGGCTCGTCTGGAAGCACTCTCTGAGCTAGACAAACTGCCACTACCAAGTGTGAGTAGCATTGGAAAATCGGCTACTTGGCAAGATGCTGAATGGTATATGTCAGCCCATGAGATTTGTCCTCTTCTTGAAAGTGTTCAAGATGCTCCGGCTCTGAACAGTTCTTTAAATCCACTTTTTAAAAATTTAAATTGGCAAAAGATTGGTTTCAAAGGTGGTTCCGAATACGGCGTCATCAACTTTTCTGTAATTGGAAAAACTCAAAAAGGTCATAACGTGTGTGCCGTATTTACCGCAAATGGAAATGAGCCACAACCCGAATCAAAACTAGCAATATTATTTACAGGCATACTTCAAGCTGTTGATTCTATGAGTCATTAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1247,Drugs,MEG_1247|Drugs|betalactams|Class_A_betalactamases|BLAA,(Bla)BlaA2:NC_010410:2507740-2509014:1275,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAGATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1455,Drugs,MEG_1455|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_93_FKQA01000038,0
,ATGACTATACCTGACGCAAATGCAGTCTATCCTAACCTCATCCTCATAGAGCTAGACTTTATCAAGAACGTGATCAAAAGTCCCAATATTGAAATTGGGGACTACACCTATTATGATGACCCAGTAAATCCCACCGATTTTGAGAAACACGTTACCCATCACTATGAATTTCTAGGCGACAAATTAATCATCGGTAAATTTTGTTCTATCGCCAGTGGCATTGAATTTATCATGAACGGTGCCAACCACGTAATGAAAGGTATTTCGACTTATCCATTTAATATTTTAGGTGGCGATTGGCAACAATACACTCCTGAACTGACTGATTTGCCGTTGAAAGGTGATACTGTAGTCGGAAATGACGTGTGGTTTGGGCAAAATGTGACCGTCCTACCAGGCGTAAAAATAGGTGACGGTGCCATTATCGGAGCAAATAGTGTTGTAACAAAAGACGTCGCTCCATATACAATTGTCGGTGGCAATCCAATTCAACTCATCGGACCAAGATTTGAACCGGAAGTTATTCAAGCATTAGAAAATCTGGCATGGTGGAATAAAGATATTGAATGGATAACTGCTAATGTTCCTAAACTAATGCAAACAACACCCACACTTGAATTGATAAACAGTTTAATGGAAAAATAA,streptogramin inactivation enzyme,antibiotic inactivation,MLS,MEG_7631,Drugs,MEG_7631|Drugs|MLS|Streptogramin_A_O-acetyltransferase|VATE,gi|15266484|gb|AY043213.1|1-645,7
,atgaccgcgaacgaaaacaccgtaaccctgcgcctgatgactgagcacgacctccccatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_130,Drugs,MEG_130|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1102724704|WP_071593200.1|NG_052024|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052024:101-655,2
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgataggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatggggtgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4450,Drugs,MEG_4450|Drugs|betalactams|Class_D_betalactamases|OXA,1559613002|WP_128268267.1|NG_063872|1|1|blaOXA-768|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-768 NG_063872:13-837,0
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGGGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6931,Drugs,MEG_6931|Drugs|betalactams|Class_A_betalactamases|TEM,gi|6176545|gb|AF190694.1|AF190694|1-1103 gi|961666360|gb|KT185451.1|87734-87690,0
,ATGTCACTGTATCGCCGTCTAGTTCTGCTGTCTTGTCTCTCATGGCCGCTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTCGAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACTGTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCTGCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTACGGCAAAAATGCGCTGGTTCCGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATGACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTGTTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGATACCACGTTCCGTCTGGACCGCTGGGAGCTGGAGCTGGAGCTGAACTCCGCCATCCCAGGCGATGCGCGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCTGCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGCAACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACCTGCGGAGTGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCTATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGCACAGCGAGGCCGTCATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGGGCGTCAACGGGCAGTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3511,Drugs,MEG_3511|Drugs|betalactams|Class_A_betalactamases|KPC,blaKPC-25_1_KU216748,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgttgcgcaccgcgctgtggccgtccggctcgcctgaagagcaccgcgcggaaatgcgcgagatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcactttcgttgcctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcttttttggaaggaatttataccgccgaacgcgctcgccgccagggctgggccgcacgcctgatcgcgcaggtgcaggagtgggcgaagcagcaggggtgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggagcgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_168,Drugs,MEG_168|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,727193031|WP_033654785.1|NG_052345|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052345:101-541,2
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctggcaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_805,Drugs,MEG_805|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502068|WP_071846220.1|NG_052230|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052230:101-892,2
,GCACGAATGAGGGCCGACAGGAAGCAAAGCTGAAAGGAATCAAATTTGGCCGCAGGCGTACCGTGGACAGGAACGTCGTGCTGACGCTTCATCAGAAGGGCACTGGTGCAACGGAAATTGCTCATCAGCTCAGTATTGCCCGCTCCACGGTTTATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACGGACTGTTGCAAAGTTAGCGAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_6875,Drugs,MEG_6875|Drugs|betalactams|Class_A_betalactamases|TEM,gi|149167|gb|M88143.1|KPNBETALAC|1-1268,0
,atgagccatattcaacgggaaacgtcttgctcgaggccgcgattaaattccaacctggatgctgatttatatgggtataaatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggcatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgctccccgggaaaacagcattccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagcgttcctgcgccggttgcattcgattcctgttagtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataagcttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcgtgccatcctatggaactgcctcggtgaattttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctga,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1026,Drugs,MEG_1026|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,501454377|WP_012477822.1|NG_047439|1|1|aph(3')-Ia|aph(3')-Ia|aminoglycoside_O-phosphotransferase_APH(3')-Ia NG_047439:101-916,2
,atgaaaaaaattgccgttttatttggagggaattctccagaatactcagtgtcactaacctcagcagaaagtgtgatccaagctattaacccgctgaaatatgaagtaatgaccattggcatcgcaccaacaatggattggtattggtatcaaggaaacctcgcgaatgttcgcaatgatacttggctagaagatcacaaaaactgtcaccagctgactttttctagccaaggatttatattaggagaaaaacgaatcgtccctgatgtcctctttccagtcttgcatgggaagtatggcgaggatggctgtatccaaggactgcttgaactaatgaacctgccttatgttggttgccatgtcgctgcctccgcattatgtatgaacaaatggctcttgcatcaacttgctgataccatgggaatcgctagtgctcccactttgcttttatcccgctatgaaaacgatcctgccacaatcgatcgttttattcaagaccatggattcccgatctttatcaagccgaatgaagccggttcttcaaaagggatcacaaaagtaactgacaaaacagcgctccaatctgcattaacgactgcttttgcttacggttctactgtgttgatccaaaaggcgatagcgggtattgaaattggctgcggcatcttaggaaatgagcaattgacgattggtgcttgtgatgcgatttctcttgtcgacggtttttttgattttgaagagaaataccaattaatcagcgccacgatcactgtcccagcaccattgcctctcgcgcttgaatcacagatcaaggagcaggcacagctgctttatcgaaacttgggattgacgggtctggctcgaatcgattttttcgtcaccaatcaaggagcgatttatttaaacgaaatcaacaccatgccgggatttactgggcactcccgctacccagctatgatggcggaagtcgggttatcctacgaaatattagtagagcaattgattgcactggcagaggaggacaaacgatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7360,Drugs,MEG_7360|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,1028100553|WP_063856688.1|NG_048357|1|1|vanC1|vanC1|D-alanine--D-serine_ligase_VanC1 NG_048357:31-1062,5
,ATGACGCAAATTTTAATAGTAGAAGATGAACAAAACTTAGCAAGATTTCTTGAATTGGAACTCACACATGAAAATTACAATGTGGACACAGAGTATGATGGACAAGACGGTTTAGATAAAGCGCTTAGCCATTACTATGATTTAATCATATTAGATTTAATGTTGCCGTCAATTAATGGCTTAGAAATTTGTCGCAAAATTAGACAACAACAATCTACACCTATCATTATAATTACAGCGAAAAGTGATACGTATGACAAAGTTGCTGGGCTTGATTACGGTGCAGACGATTATATAGTTAAGCCATTTGATATTGAAGAACTTTTAGCAAGAATTCGTGCGATTTTACGTCGTCAGCCACAAAAAGATATTATCGATGTCAATGGTATTACAATTGATAAGAATGCTTTTAAAGTGACGGTAAATGGCGCAGAAATTGAATTAACAAAAACAGAGTATGATTTACTATATCTTCTAGCTGAAAATAAAAACCATGTTATGCAACGGGAACAAATTTTAAATCATGTATGGGGTTATAATAGTGAAGTAGAAACAAATGTCGTAGATGTTTATATAAGATATTTAAGAAACAAGTTAAAACCATACGATCGTGACAAAATGATTGAAACAGTTCGTGGCGTTGGGTATGTGATACGATGA,protein of two-component regulatory system modulating antibiotic efflux,antibiotic efflux,Multi-drug_resistance,MEG_1116,Drugs,MEG_1116|Drugs|Multi-drug_resistance|MDR_regulator|ARLR,gi|82655308|emb|AJ938182.1|1389401-1388742,1
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGAGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6410,Drugs,MEG_6410|Drugs|betalactams|Class_A_betalactamases|SHV,gi|124053922|gb|EF035567.1|1-861,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcacgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacctacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcactgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5495,Drugs,MEG_5495|Drugs|betalactams|Class_C_betalactamases|PDC,730547383|WP_034043639.1|NG_049922|1|1|blaPDC-49|blaPDC|class_C_beta-lactamase_PDC-49 NG_049922:1-1194,0
,atgcgaatagatacagacaaacaaatgaatttacttagtgataagaacgttgcaataattggtggtggacccgttggactgactatggcaaaattattacagcaaaacggcatagacgtttcagtttacgaaagagacaacgaccgagaggcaagaatttttggtggaacccttgacctacacaaaggttcaggtcaggaagcaatgaaaaaagcgggattgttacaaacttattatgacttagccttaccaatgggtgtaaatattgctgatgaaaaaggcaatattttatccacaaaaaatgtaaagcccgaaaatcgatttgacaatcctgaaataaacagaaatgacttaagggctatcttgttgaatagtttagaaaacgacacggttatttgggatagaaaacttgttatgcttgaacctggtaagaagaagtggacactaacttttgagaataaaccgagtgaaacagcagatttggttattcttgccaatggtggaatgtcgaaaataaggagctttgttaccgacacgcaagttgaagaaaccggtactttcaacatccaagctgatattcttcaaccggaaataaactgtcccggattttttcagctatgcaacggcaaccgattaatggcgggacatcagggcattttattgtttgccaatcccaataataatggtgcattgtatttaggaattagttttaaaacgcccgatgaatggaaaaataaaattcccttagattttcaggacagaaacagcgttgccgattttttattgaaaagattttccaaatggagtgaagtttacaaacaattaatacgttcggtatcaacatttcaatgcttgcccacaaggaaatttcctttgaacaatgattggaaaagtaaccgtccattacccataacaatgattggcgatgctgctcatttgatgtcgccttttgcaggacagggtgtaaatacgggattattggatgctttgatattgtctgaaaaccttacaaacggagaatttacaagtattgaaaatgccatcgaaaactacgaacaacaaatgtttgtttatgcaaaagatacgcaggacgaatcgacagaaaacgaaaccgaaatgtttagtcccaatttttcgtttcaaaaattattgaatctataa,tetracycline inactivation enzyme,antibiotic inactivation,Tetracyclines,MEG_7239,Drugs,MEG_7239|Drugs|Tetracyclines|Tetracycline_inactivation_enzymes|TETX,504873815|WP_015060917.1|NG_048307|1|1|tet(X)|tet(X)|tetracycline-inactivating_monooxygenase_Tet(X) NG_048307:101-1261,4
,atggttaaaaaatctaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2215,Drugs,MEG_2215|Drugs|betalactams|Class_A_betalactamases|CTX,1391852878|WP_109545063.1|NG_057477|1|1|blaCTX-M-211|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-211 NG_057477:1-885,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctgggtgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5488,Drugs,MEG_5488|Drugs|betalactams|Class_C_betalactamases|PDC,935281132|WP_054379352.1|NG_050980|1|1|blaPDC-168|blaPDC|class_C_beta-lactamase_PDC-168 NG_050980:1-1194,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACATGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGAAGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1889,Drugs,MEG_1889|Drugs|betalactams|Class_C_betalactamases|CMY,gb|HM544040|+|0-1146|ARO:3002066|CMY-55 [Escherichia coli] ,0
,ATGACCAGCCTTGCGCATCATGCGACAGAAAACCGCTCTGTAGCCGAATTTACTGAACAGGCTTACTTGAATTATGCCATGTACGTCATTATGGACCGTGCATTGCCGCATATCAGTGATGGCTTAAAGCCCGTACAGCGCCGTATTGTCTATGCCATGAGCGAGCTAGGCTTAAAAAGCAGTGGCAAGCCAAAAAAATCAGCGCGTACAGTGGGTGATGTACTTGGTAAATACCACCCACATGGTGACTTGGCATGTTATGAAGCCATGGTACTCATGGCTCAGCCATTTAGTTATCGTTATCCGCTAATTGAAGGACAGGGGAACTGGGGTTCACCAGATGATCCTAAATCTTTTGCTGCGATGCGTTATACCGAAGCCAAACTCTCGGCTTATAGTGAATTATTGCTGAGCGAATTAGGCCAGGGCACTAGCGAATGGCAAGATAACTTTGATGGTTCTTTAAAAGAACCGATCACTTTACCTGCACGTGTACCTAATATTCTTCTTAATGGTACGACAGGTATTGCTGTCGGGATGGCAACTGATATCCCGCCACATAATTTGCGTGAAGTTGTAAAAGGCACAATTGCTTTAATCCGTAATCCGCAAACCTCGGACGAAAAATTAGCTGAATATATTCCGGCTCCGGATTTACCAACCAAAGCTGAAATTATTACCCCGCCAGAAGAATTACTCAAAATCCAGACCACTGGTCGTGGTAGTTACCGTATGCGAGCGGTATATACCATTGAGAAAAATGAAATCGTAATTACTGAGCTGCCATATCAAGTCTCTGGTTCTAAGGTAATTACTCAAATTGCTGACCAGATGCAGGCTAAAAAGCTGCCATTAGTCGTCGACGTGCGTGATGAATCGGATCATGAAAACCCGACACGACTCGTGATTGTACTGCGCTCTAACCGTATTGATGCGGAAGCAGTGATGAGTCACTTATTTGCGACCACTGATTTAGAATCAAGCTATCGTGTCAATTTAAACATGATTGGCGAAGATGGCCGTCCTCAGGTGAAATCAATTCGTCGTATTTTGCTTGAATGGATCGAGATCCGTAAAAAAACGGTAACTCGTCGTTTACAGTACCATTTAAACCGTATTGAAAAGCGCCTGCATATTTTGGCAGGTCTTTTAATTGCTTATCTCGATATTGATACAGTCATTCGTATTATTCGTGAAGAAGACCAGCCTAAGCCAGTCTTAATGGAACACTTCAATATTGATGAGATACAGGCCGAAGCGATTTTAGAGCTTAAATTACGTCATTTGGCAAAGCTTGAAGAGATGGAAATCCGTCATGAACAAGATGAACTTTCTGCGAAAGCTGCCATTATTCGTGAACAACTCGAAAATCCTGAATCTTTAAAAAATTTGATTATTGGCGAATTAAAAGAAGATGCGAAAAAGTTCGGTGATGAGCGCCGTTCTCCAATTGTTGCACGTGCTGAAGCGGTTCAAATTAAAGAACAGGATTTAATGCCAGCTGAAACGGTAACGGTGGTTTTGTCTGAAGCAGGCTGGGTTCGTGCGGCAAAAGGTGCGGATGTGGATGCTGAAAATCTGAACTACCGTGCTGGGGACCAATATTTAAGTCATGCTGTCGGGAAAACCAATCAGCGAGTTTACTTCCTTGATGAAACAGGGCGCAGCTATGCCTTGCCGATTAGTAACTTACCTTCAGCGAGAGGCTTGGGGGATCCATTAAGTTCTAAATTATCACCAGCAAGTGGCGTATCGTTTATTCAGGTTTATTTAGATGATGATGAGTCTGAATTGATTGCTGCAAGTTCGGCAGGTTATGGTTTTAAAACGCAAACCAAGCAATTAGATACCAATGCGAAAGCCGGTAAGACATTCTTAACGGTTCCGGATAAGGCAAAGGCTTTACCACTCATTTCTGCCCAAAACATGACGCATTTGGCTGTACTGAGCTCAGCAGGGCGTTTGTTAATTTTAGATTTGGCAGAGCTACCAAATTTAAATAAAGGTAAAGGTAATAAGTTGATACAACTTGAAGGCAAAGAGCAAATTTTATCCATGACAACCCTGAACTTAGATGAAATAATTCAGGTGGTTGCAGGTCAACAACATCTCAAATTAAAAGGTGATGATCTACAAAAATACATGGGTAAACGTGCTTCGAAAGGTCAGCTCTTACCACGTGGATATCAAAAAGCAAATAAACTGTTGATTCAGAGATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5350,Drugs,MEG_5350|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|602249473|gb|KC118540.6|41596-43815 gi|213054530|gb|CP001182.1|250701-252920,3
,ATGCTGTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6474,Drugs,MEG_6474|Drugs|betalactams|Class_A_betalactamases|SHV,gi|695211016|ref|NG_035987.1|1-861 gi|846281090|gb|KP294351.1|15265-16119 gi|846280946|gb|KP294350.1|15266-16120 gi|800908535|gb|KM406490.1|73379-74233 gi|723258375|gb|CP009883.1|264247-265101 gi|723243622|gb|CP009869.1|124331-123477 gi|678126431|gb|KJ541681.1|27819-26965 gi|662716651|gb|CP008824.1|264934-264080 gi|640855459|gb|CP007732.1|217266-216412 gi|619739382|gb|CP007558.1|217255-216401,0
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcgaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccggagatgagcgacaacacacctggcgacctcagaaatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacgggggccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3094,Drugs,MEG_3094|Drugs|betalactams|Class_A_betalactamases|GES,1028105364|WP_063860513.1|NG_049131|1|1|blaGES-28|blaGES|class_A_beta-lactamase_GES-28 NG_049131:1-864,0
,ATGAACAAAAATATAAAATATTCTCAAAACTTTTTAACGAGTGAAAAAGTACTCAACCAAATAATAAAACAATTGAATTTAAAAGAAACCGATACCGTTTACGAAATTGGAACAGGTAAAGGGCATTTAACGACGAAACTGGCTAAAATAAGTAAACAGGTAACGTCTATTGAATTAGACAGTCATCTATTCAACTTATCGTCAGAAAAATTAAAACTGAATACTCGTGTCACTTTAATTCACCAAGATATTCTACAGTTTCAATTCCCTAACAAACAGAGGTATAAAATTGTTGGGAATATTCCTTACCATTTAAGCACACAAATTATTAAAAAAGTGGTTTTTGAAAGCCATGCGTCTGACATCTATCTGATTGTTGAAGAAGGATTCTACAAGCGTACCTTGGATATTCACCGAACACTAGGGTTGCTCTTGCACACTCAAGTCTCGATTCAGCAATTGCTTAAGCTGCCAGCGGAATGCTTTCATCCTAAACCAAAAGTAAACAGTGTCTTAATAAAACTTACCCGCCATACCACAGATGTTCCAGATAAATATTGGAAGCTATATACGTACTTTGTTTCAAAATGGGTCAATCGAGAATATCGTCAACTGTTTACTAAAAATCAGTTTCATCAAGCAATGAAACACGCCAAAGTAAACAATTTAAGTACCGTTACTTATGAGCAAGTATTGTCTATTTTTAATAGTTATCTATTATTTAACGGGAGGAAATAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2805,Drugs,MEG_2805|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,gi|970338797|gb|KT962975.1|2951-3688 gi|920768663|gb|CP011419.1|1940585-1939848 gi|749389159|gb|KJ645709.1|25732-24995 gi|663450304|gb|KC876752.1|5178-5915 gi|663450289|gb|KC876751.1|5181-5918 gi|663450275|gb|KC876750.1|4592-5329 gi|663450246|gb|KC876748.1|4592-5329 gi|510787448|gb|KC575115.1|8506-9243 gi|459385823|gb|CP003922.1|716338-715601 gi|383850662|gb|JN899585.1|275-1012,7
,gtgatcgacagcgcgcccacgatccgccaggccacgccggccgatgcggccgcgtgggcgcagttgcgtctcggcctgtggcctgatgccgatgatccgctggaggaactgacgcagtcgctggcagatgccgaaggtgctgtgttcttggcctgtgaggcggatggcgaggcggttggtttcgctgaagtgcgcctgcgccatgactacgtgaacggcaccgagtcttcgccggtggggttcctggagggctggtacgtgcagccgcagtggcaaggccgcggcgtcggccgcgccctgctggcggcggtgcaggcgtggacgcgcgatgcgggctgccgcgaactggcttcggacagtcgcgtggaagacgtgcaggctcacgccgcgcatcgggcctgcggcttcgaagagaccgaacgggtcgtctattttcgcatgcagctggaaccatcggcgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_258,Drugs,MEG_258|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,896538090|WP_049440615.1|NG_054659|1|1|aac(6')-Iz|aac(6')-Iz|aminoglycoside_N-acetyltransferase_AAC(6')-Iz NG_054659:101-562,2
,atgactaaaaaagctcttttctttgctattagtaccatatttttgtcagcatgttctttcaatacagtacaacagcaccaaatacacgctatttctactcataaaaattcagaagaaattaaatcactgtttgatcaggcacagaccacgggagttttagtgattaagcgtgggcaaaccgaagaaatttatggcaataatcttaaaagagcatcaaccgaatatgttcccgcctctacatttaaaatgctaaatgctttaattggacttgaacatcataaagcaacgacaactgaaatgttcaaatgggatggacaaaagcgtttatttcctgattgggaaaaggatatgactctgggtgaggccatgaaagcttctgctattcctgtctatcaagaactagcgcgaagaattggccttgatcttatgtccaaagaggtcaagcgtattggtttcggtaatgctgatattggttcaaaagtagataatttttggcttgtcggtccccttaaaattacacctcagcaagaaacccagtttgcttatgaattagcccataaaactcttccctttagcaaaaatgtacaagaacaagttcaatctatggtgttcgtagaagaaaaaaacggacgtaaaatttacgctaaaagcggttggggatgggatgttgaaccacaagttggctggttaacaggctgggtcgttcaaccacaaggagaaattgtagcgttctcactcaatttagaaatgaaaaaaggaacacctagttctattcgaaaagaaattgcttataaaggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4570,Drugs,MEG_4570|Drugs|betalactams|Class_D_betalactamases|OXA,691140431|WP_032053762.1|NG_064777|1|1|blaOXA-819|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-819 NG_064777:1-822,0
,ATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCCGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGTTTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAACAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTCCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1862,Drugs,MEG_1862|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AY960293|+|0-1143|ARO:3002031|CMY-20 [Escherichia coli] ,0
,atgggcatcattcgcacatgtaggctcggccctgaccaagtcaaatccatgagggctgctcttgatcttttcggtcgtgagttcggaggcgtagccacctactcccaacatcagccggactccgattacctcgggaacttgctccgtagtaagacattcatcgcgcttgctgccttcgaccaagaagcggttgttggcgctctcgcggcttacgttctgccaaagtttgagcaggcgcgtagtgagatctatatctatgatctcgcagtctccggcgagcaccggaggcaaggcattgccaccgcgctcatcaatctcctcaagcatgaggccaacgcgcttggtgcttatgtgatctacgtgcaagcagattacggtgacgatcccgcagtggctctctatacaaagttgggcatacgggaagaagtgatgcactttgatatcgacccaagtaccgccacctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_27,Drugs,MEG_27|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,1028080876|WP_063840259.1|NG_047239|1|1|aac(3)-I|aac(3)-I|AAC(3)-I_family_aminoglycoside_3-N-acetyltransferase NG_047239:101-565,2
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGATACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_6879,Drugs,MEG_6879|Drugs|betalactams|Class_A_betalactamases|TEM,gi|166157193|emb|AM183304.1|1-1091 gi|943457735|gb|KT818627.1|75115-74889 gi|943457735|gb|KT818627.1|136706-136480 gi|959195734|gb|CP013326.1|60998-60772 gi|959190351|gb|CP013324.1|110452-110226 gi|910286593|gb|CP012163.1|68956-69182 gi|902611595|gb|CP011978.1|70729-70955 gi|828971542|gb|CP011645.1|70767-70993 gi|828965729|gb|CP011639.1|9292-9066 gi|828952302|gb|CP011622.1|124460-124686 gi|828952208|gb|CP011621.1|60998-60772,0
,TCTCCCTGTTAGCCACCCTGCCACTGGCGGTATACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCGGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGCTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTACCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACTGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3546,Drugs,MEG_3546|Drugs|betalactams|Class_A_betalactamases|LEN,(Bla)LEN-14:AY265889:1-861:861,0
,GTGGGGCTTTGTAGGTATGGGGCTCATAATTGCTGCCTTTTTGCTCGCCCGATCCCCATCGTGGAAGTCGCTGCGGAGGCCGACGCCATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGTTGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6591,Drugs,MEG_6591|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|226426103|gb|EU855788.1|148975-149901 gi|226425792|gb|EU855787.1|148975-149901 gi|973585379|gb|KP054476.2|28624-28651,8
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAATACACCGTTTCTTTAGCTTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGACTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACAGAAACAGAAAATACAGCCGCTATTCGAAGGAAACGGCTTTTGGTTAAGTGAAGAGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAGCTACCTTATGTAGGCTGCGGGGTGGCAGGTTCTGCCTTATGTATGAACAAATGGTTGCTGCATCAAGCTGCAGCAGCCATTGGCGTACAAAGTGCTCCTACGATTCTCTTGACAAATCACGCCAACCAGCAAGAACAAATCGAAGCTTTTATCCAGACCCATGGCTTTCCAGTTTTCTTTAAGCCTAATGAAGCGGGTTCCTCAAAAGGGATCACTAAAGTCACCTGCGTTGAAGAAATCGCTTCTGCCTTAAAAGAAGCCTTTACTTATTGTTCCGCAGTGCTCCTACAAAAAAATATTGCCGGTGTTGAGATCGGTTGCGGTATTTTGGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCCATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGCTGATCAGCGCCAAAATCACCGTCCCTGCGCCATTGCCTGAAACGATTGAAACTAAGGTCAAAGAACAAGCTCAGCTGCTCTATCGTAGTCTTGGACTTAAAGGTCTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGGTTATCCTATCAAGAACTACTACAAAAACTACTTGTCTTAGCAAAGGAGGAAGTCAAATGAATCCCTATCTACAGTTAGTTAGCAAAGAATTTCCGTTAGAAAAAAACCAAGAGCCGCCTCATTTAGTCCTTGCTGCCTTCAGTGAAGACGAGGTTTACTTGCAACCAGAAGCAGCCAAACAATGGAAACGGCTAGTCAAAGCTTTAAAGCTTGAAGACGAGATCTGCTTATTAGATGGCTACCGAACCGAAAAGCAGCAACGGTATTTATGGGAATATTCCTTGAAAGAAAATGGGCTAGCCTATACGAAACAATTTGTGGCATTGCCCGGGTGCAGTGAACATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAAGGCAGCCAGGATGATTTGATCTGCCCACGATTTCGTGACAGCGCAGCCGCTGATTTATTTACCCAGGAAATGATGAACTATGGGTTTATTTTACGCTATCCCGCGGACAAACAGGAAATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTGCCCCATAGTCAAATCATCGCCAGCCAACAGTGGACCTTGGAAGAATACCATCAATACCTTGAACAAACGGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7380,Drugs,MEG_7380|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC3XY_2_EU151759,5
,GTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGATGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAATACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGTAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6458,Drugs,MEG_6458|Drugs|betalactams|Class_A_betalactamases|SHV,gi|393716100|dbj|AB733453.1|1-849,0
,ATGAAGTTTTTATTGGCATTTTCGCTTTTAATACCATCCGTGGTTTTTGCAAGTAGTTCAAAGTTTCAGCAAGTTGAACAAGACGTTAAGGCAATTGAAGTTTCTCTTTCTGCTCGTATAGGTGTTTCCGTTCTTGATACTCAAAATGGAGAATATTGGGATTACAATGGCAATCAGCGCTTCCCGTTAACAAGTACTTTTAAAACAATAGCTTGCGCTAAATTACTATATGATGCTGAGCAAGGAAAAGTTAATCCCAATAGTACAGTCGAGATTAAGAAAGCAGATCTTGTGACCTATTCCCCTGTAATAGAAAAGCAAGTAGGGCAGGCAATCACACTCGATGATGCGTGCTTCGCAACTATGACTACAAGTGATAATACTGCGGCAAATATCATCCTAAGTGCTGTAGGTGGCCCCAAAGGCGTTACTGATTTTTTAAGACAAATTGGGGACAAAGAGACTCGTCTAGACCGTATTGAGCCTGATTTAAATGAAGGTAAGCTCGGTGATTTGAGGGATACGACAACTCCTAAGGCAATAGCCAGTACTTTGAATAAATTTTTATTTGGTTCCGCGCTATCTGAAATGAACCAGAAAAAATTAGAGTCTTGGATGGTGAACAATCAAGTCACTGGTAATTTACTACGTTCAGTATTGCCGGCGGGATGGAACATTGCGGATCGCTCAGGTGCTGGCGGATTTGGTGCTCGGAGTATTACAGCAGTTGTGTGGAGTGAGCATCAAGCCCCAATTATTGTGAGCATCTATCTAGCTCAAACACAGGCTTCAATGGCAGAGCGAAATGATGCGATTGTTAAAATTGGTCATTCAATTTTTGACGTTTATACATCACAGTCGCGCTGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1519,Drugs,MEG_1519|Drugs|betalactams|Class_A_betalactamases|CARB,(Bla)CARB-2:HQ157204:747-1613:867;(Bla)CARB-8:GQ866976:1345-2211:867,0
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5686,Drugs,MEG_5686|Drugs|betalactams|Class_C_betalactamases|PDC,1393270449|WP_109791194.1|NG_057592|1|1|blaPDC-260|blaPDC|class_C_beta-lactamase_PDC-260 NG_057592:1-1194,0
,ATGAAAATAATCAATATTGGAATTCTTGCCCATGTAGACGCTGGAAAGACGACCTTGACGGAGAGCCTGCTATATGCCAGCGGAGCCATTTCAGAACCGGGGAGCGTCGAAAAAGGGACAACGAGGACGGACACCATGTTTTTGGAGCGGCAGCGTGGGATTACCATTCAAGCGGCAGTCACTTCCTTCCAGTGGCACAGATGTAAAGTTAACATTGTGGATACGCCCGGCCATATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGAGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGACATTCTAGGAAATGAAAAACTCCTGCCTCATAAAACACGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCGCAGAGATTGCTGATACAGACCCTCTTTTGCATTTTGACATTGATACTGTTACACATGAGATTATGTTATCTTTTTTGGGAAAAGTACAGTTAGAAGTTATTTGTTCGCTATTAGAAGAAAAATATCATGTGGGCGTGGCTATGAAAGAGCCTTCGGTTATTTATCTGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAGGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTAATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7237,Drugs,MEG_7237|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,tet(W/32/O)_1_AM710601 ,4
,ATGATGCAACGCCGTCATTTTTTACAAAAAACCTTATTGGCACTACCTATTATTTTTTCTGGCAATTTATTAACTGGATGTAAAACGAATTTATCTGATGATTATTTGCCCGATGATAAGATAACAAACAATCCAAATTTATTACAAAATAAATTAAAAGAGATATTGCCAATTTGGGAAAATAAATTTAATGCCAAAATTGGTATGACGATTATTGCTGACAATGGTGAACTATCCAGTCATCGTGGTAATGAATATTTTCCTGTTAATAGTACCATTAAAGCCTTTATTGCAAGTCATATATTATTACTTGTAGATAAAGAAAAATTGGATTTAAACGAAAAAATCATCATTAAAGAAAGCGATTTGATAGAATATTCTCCTGTCTGTAAAAAATACTTTGATGAGAATAAACCAATTTCTATTAGTGAATTGTGCGAAGCTACCATAACACTGAGTGATAATGGTTCTGCTAATATCTTGTTGGATAAAATTGGGGGTTTGACTGCATTCAATCAATTTTTGAAAGAGATTGGGGCGGATATGGTGCTGGCAAATAATGAGCCTTTATTAAATCGCTCACATTATGGTGAAACCAGTGATACCGCAAAACCAATTCCTTACACAAAAAGCCTAAAAGCACTGATTGTAGGCAATATCCTATCCAATCAAAGCAAAGAACAGTTGATAACTTGGCTTATCAATGATAAAGTTGCTGATAATTTATTGAGAAAATATTTACCAAAAAATTGGCGAATTGGCGACAAAACAGGCACAGGTAGTGAATCAAAAAATATCATTGCTGTGATTTGGAATGAAAATAATAAACCTTATTTTATCAGCCTATTTATCACCCAGCCCCATGATGGTAAATCCCTTGATTTTAAAAATCAAAAAGATGAAATAATGGCACAAATTGGTAAAGAAATTTATCCATTTTTATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1475,Drugs,MEG_1475|Drugs|betalactams|Class_A_betalactamases|BRO,gb|Z54180.1|+|83-1028|ARO:3004761|BRO-1 [Moraxella catarrhalis] ,0
,CATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAGCATTCACCTTCCGGCCGCCCGCTAGCGGACCCTGGTCAGGTTCCGCGAAGGTGGGCGCAGACATGCTGGGCTCGTCAGGATCAAACTGCACTATGAGGCGGCGGTTCATACCGCGCCAGGGGAGCGA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6615,Drugs,MEG_6615|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|970698242|gb|KT988020.1|22634-23601 gi|970698221|gb|KT988019.1|7446-8413 gi|970698093|gb|KT988018.1|115120-116087 gi|982189197|gb|CP013993.1|5424787-5425754 gi|982189197|gb|CP013993.1|5430539-5431065 gi|974751143|gb|KU238092.1|13029-12062 gi|975048878|gb|CP013962.1|2821896-2822863 gi|974255378|gb|CP008857.1|6671282-6672249 gi|974022331|gb|CP013924.1|2757406-2756439 gi|974022331|gb|CP013924.1|1441529-1442393 gi|973715451|gb|CP013836.1|106323-105356 gi|973715451|gb|CP013836.1|118429-119396 gi|973585379|gb|KP054476.2|53137-54104 gi|973585379|gb|KP054476.2|33768-34632,8
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcagcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_906,Drugs,MEG_906|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502150|WP_071846302.1|NG_052362|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052362:101-889,2
,atgcttcagcagaaaatgatcgaacgcttcaaggaagcttgccatgaggatgcacgaataatcgcggcgctgatgttcggctcatttgctatcggagagggtgacgagttctctgatatcgaatttgcagtgttcatccagaatgatcattttgaaaatttcgatcagcgctcgtggcttaatgctgtaagtccggttgcagcttactttccggatgacttcggccaccacaccgcgctttttgaaaacggcattcgcggtgaattccatttcatgcgaaaatcggacataccggtcatttccacttggcaaggctacgggtggtttccctcgcttgaggaggctgttttgttggaccgatcaggagagttgtcaaggtacgcgagtgctctcgtgggcagtcccccgaaacgtgaaggcgcgccgctggtggaaggacttgtattgaacctcatcagcctgatgctctttggggcaaatcttttaaatcggggagagtatgctcgcgcctgggctttgctcagcaaagcacatgaaaacttactcaagttggttcgcctccatgaaggggcaacagaccactggccgacaccttcacgcgcgctcgaaaaggatgtctcggaggactcgtataatcgctacctggcatgcacaggcagcgcggaaccaaaagcactatgtgtagcctatcatgaaacgtggaagtggagtctcgaattgttcaggagtgtggctggacctctgaatatcgagcttccgagaattgtaattgcgcagacaaaaaggttgctaaatgaatctgcgacgccgcacaacaagtaa,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3615,Drugs,MEG_3615|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUF,1080153680|WP_070342360.1|NG_051883|1|1|lnu(F)|lnu(F)|lincosamide_nucleotidyltransferase_Lnu(F) NG_051883:101-922,7
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacagataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctatggaaattataatcaaacagaaagtagagctgcaccctaatatgtgtgtgatgagctgtacggaacctgagcaatgggatgtggtaatagaaggaaatgatgaccttttagagaaatatatgtccggtaaatcattagaagcattagaactcgaacaagaggaaatcagaagatttcagaattgctccttgtaccctgtttatcatggaagcgcaaaaagcaacatagggattgagcagcttatagaagtgataacgaataaattttattcatcaacatacagaaagaagtctgaactttgcggaaatgtcttcaaaattgaatattcggaagaaagacaacgtcttgcatatgtacgcctttatggcggaatcctgcatttgcgggattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaattgataaggcttattccggggaaattgttattttgcaaaatgagtttttgaagctaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatccgctccctctgctgcaaacaactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctacaatattatgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaagggatacgctatggttgcgaacaaggattatatggttggaatgtgacggattgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7118,Drugs,MEG_7118|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,486295952|WP_001574275.1|NG_048233|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048233:1-1920,4
,AGGAGTATTGATGTTTCAAATTCGCAGCTTTCTGGTTGGTATCAGTGCATTCGTCATGGCCGTACTTGGATCAGCAGCATATTCCGCACAGCCTGGCGGTGAATATCCGACAGTAGATGACATACCGGTAGGGGAAGTTCGGCTGTACAAGATTGGCGATGGCGTTTGGTCGCATATCGCAACTCAGAAACTCGGTGACACGGTGTACTCGTCTAATGGACTTATCGTCCGCGATGCTGATGAGTTGCTTCTTATTGATACAGCGTGGGGGGCGAAGAACACGGTAGCCCTTCTCGCGGAGATTGAAAAGCAAATTGGACTTCCAGTAACGCGCTCAATTTCTACGCACTTCCATGACGATCGAGTCGGTGGAGTTGATGTCCTCCGGGCGGCTGGAGTGGCAACGTACACCTCACCCTTGACACGCCAGCTGGCCGAAGCGGCGGGAAACGAGGTGCCTGCGCACTCTCTAAAAGCGCTCTCCTCTAGTGGAGATGTGGTGCGCTTCGGTCCCGTAGAGGTTTTCTATCCTGGTGCTGCGCATTCGGGCGACAATCTTGTGGTATACGTGCCGGCCGTGCGCGTACTGTTTGGTGGCTGTGCAGTTCATGAGGCGTCACGCGAATCCGCGGGTAATGTTGCCGATGCCAATTTGGCAGAATGGCCTGCTACCATTAAACGAATTCAACAGCGGTATCCGGAAGCAGAGGTCGTCATCCCCGGCCACGGTCTACCGGGCGGTCTGGAATTGCTCCAACACACAACTAACGTTGTCAAAACGCACAAAGTACGCCCGGTGGCCGAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_7761,Drugs,MEG_7761|Drugs|betalactams|Class_B_betalactamases|VIM,gi|156104616|emb|AM778842.1|13155-12348 gi|30014071|emb|AJ536835.1|140-947,0
,atgtccaagtataaaaaaatgaaacagctcatagcggatatgcgcttacctgagtatcgttataagcaactgcttgatgctgtgttcctacaaggaattatgcgttttgaagatatgaagttgcttccaaaaacgctgcgcgaaaagttggtggagcagtttggtgaaactgttgtggagatcaaggcgatccatcatgagaaatcaatgcaaactgacaaggtgctgtttgaactgtcggacggaaaccgtgtggaaacggtgggcctgttttataaagagggctggaactccttttgcatttcatctcaaagcggttgcggcttcggttgtaagttttgcgcaacagggactttgggattacgcagaaacttgactgtggatgaaattaccgaccaaatcctatattttatgcaacaaggatgcagtatcaacagtatctcttttatgggaatgggagagccgttcgctaatccacaagtttttgaagccctgcatgatctgaccgccccggaactgttcgggctgtccaagcgacgcatcaccatttcgactatcggtatcgtgccgggtattcaaaaattgacaagagaatatccgcaagtcaatctggcctattccctccacgcacctactgaccgtctgagggaaacgctcatgccaataactaaaacatacccccttggtcaggtactggatacattagatcagcacattcggcaaacaaatcgcaaggtgtttttggcatacatcatgctaaaggatgtcaatgacagcgacagacacgcagagcaacttaccaagttgttattcaaacacaaaaagtatttgccactataccatttagatttaatcccatacaatcaaacgacagttacggaaactatggtgccctcaagccacacacgaataaaggccttttgccgtatcattcataatgcaggaattagcatcaatatccgaacgcaatttggctccgatattaacgctgcttgtggccagttggcgggggcctaccgtgacgatcaaaaacaaggagagagaacaatgtccgctagagatgtaaagagttttggtgaagaggtttgtgagtatggcttttataaccagggtgcaatgagaagcactaacagcagctag,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_1679,Drugs,MEG_1679|Drugs|MLS|23S_rRNA_methyltransferases|CFR,1409027051|WP_111690898.1|NG_060579|1|1|cfr(C)|cfr(C)|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C) NG_060579:101-1240,7
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6949,Drugs,MEG_6949|Drugs|betalactams|Class_A_betalactamases|TEM,gi|951285167|emb|LN869922.1|874845-873985 gi|926539378|gb|CP012632.1|36531-35671 gi|909636816|emb|LN850165.1|94108-93248 gi|704486155|gb|KM083064.1|113268-112408 gi|566129968|gb|KF705206.1|12464-11604 gi|566129838|gb|KF705205.1|18294-17434 gi|695216944|ref|NG_037753.1|1556-696 gi|353233769|emb|HE603110.1|36101-36961 gi|695224810|ref|NG_041152.1|5229-6089 gi|254967221|gb|GQ343176.1|902-42,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgagggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagctccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5559,Drugs,MEG_5559|Drugs|betalactams|Class_C_betalactamases|PDC,1509794539|WP_122630848.1|NG_062261|1|1|blaPDC-310|blaPDC|class_C_beta-lactamase_PDC-310 NG_062261:1-1194,0
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCGATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2224,Drugs,MEG_2224|Drugs|betalactams|Class_A_betalactamases|CTX,(Bla)CTX-M-61:GU125683:1-876:876,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaaatgggatgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtacaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4711,Drugs,MEG_4711|Drugs|betalactams|Class_D_betalactamases|OXA,1559613003|WP_128268268.1|NG_063873|1|1|blaOXA-769|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-769 NG_063873:19-843,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCCCTTTCTCCACGTTTGCCGCAGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAAAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGTGGCCTGGCACATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1933,Drugs,MEG_1933|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KJ207204|+|579-1725|ARO:3002099|CMY-86 [Citrobacter freundii] ,0
,atggttaaaaaatcattacgccagtttgcgctgttggccgcgacggtttttccgctgctggcaggcagcgtatcgctacaggcacaaacgctaagcgtagagcagaaacttgcggctttagagcagcgttcagggggacggcttggggtcgcgttgatagatactgcggatggttcgcaaattctctatcgtggcgatgagcgtttcgcgatgtgtagtaccagcaaagtgatggccgctgccgcggtgctaaagcaaagtgaaagtcagcacgatcttttaaatcagcgcattgagatcaaaaagggtgacctgactaactataacccgattgcggaaaaacatgtcggtaggtcgatgtcgttgtctgagctcagcgccgcggccttgcagtacagcgataacgtggcgatgaataagcttatcgctcaactgggtggcccgcagggggttaccgcgtttgcccgtaagattggggatgagacgtttcgtctcgatcgcacggaaccgacgctgaacactgcaattcccggcgatccacgcgataccacatcaccacgggctatggcacaaacgctgcgcaacctgacgctgggaaaagcgcttggtgacgctcaaagggcgcagttggtgacctggatgaaagggaatacgactggaacggccagtattcaggctggactaccggcttcgtgggtggtgggcgataaaaccggcagcggtgattacggcaccaccaacgacattgcggtgatttggccgaaagatcgtgcaccattggttttggttacctacttcacgcagcctcagcctgaggcggaaagccgtcgtgatgtattagcctcggcggcgaaaatcgtcactgagggattatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3457,Drugs,MEG_3457|Drugs|betalactams|Class_A_betalactamases|KLUC,695269806|WP_032491875.1|NG_049242|1|1|blaKLUC-2|blaKLUC|class_A_extended-spectrum_beta-lactamase_KLUC-2 NG_049242:101-976,0
,CTAAGTTCTTAAGGGCACATGGTGAATGCCTTGGCACTAGAAGCCGAAGAAGGACGTAGGAGGCTGCGATAAGCCTCGGGGAGCTGCCAACCGAGCTTTGATCCGAGGATGTCCGAATGGGGAAACCCAGCACGAGTGATGTCGTGTTACCCACTGCTGAATATATAGGCTTTGGGAGGAAACGCGGGGAAGTGAAACATCTCAGTACCCGTAGGAAGAGAAAACAACCGTGATTCCGTGAGTAGTGGCGAGCGAAAGCGGAAGATGGCTAAACCGCATGCATGTGATACCTGGTAGGGGTTGTGTGTGCGGGGTTGTGGGAGTTGTACTTGCCGGTTCTACCAGGCCGGCGGACAGTAAAAAAGTGTCGTGATTAGCGGAAGTGGTCTGGGACGGCCCGCCGCAGACGGTGAGAGTCCGGTACGCGAAAATCCGACACCTGTCTCGTACTTCATCCCGAGTAGCAGCGGGCTCGTGGAATCTGCTGTGAATCTGCCGGGACCACCCGGTAAGCCTAAATACTCTCTAGTGACCGATAGCGGATTAGTACCGTGAGGGAATGGTGAAAAGTACCCCGGGAGGGGAGTGAAATAGTACCTGAAACCATGTGCCTACAATCCGTCAAAGCCTCCTTGTGGGGTGATGGCGTGCCTTTTGAAGAATGAGCCTGCGAGTCAGGGACACGTCGCGAGGTTAACCCGTGAGGGGTAGCCGTAGCGAAAGCGAGTCTGAATAGGGCGCCCATAGTGGCGTGTTCTGGACCCGAAGCGGAGTGATCTACCCATGGCCAGGGTGAAGCGGCGGTAAGACGCCGTGGAGGCCCGAACCCACTTAGGTTGAAGACTGAGGGGATGAGCTGTGGGTAGGGGTGAAAGGCCAATCAAACTCCGTGATAGCTGGTTCTCCCCGAAATGCATTTAGGTGCAGCGTCGCGTGTTTCTTATTGGAGGTAGAGCTACTGGATGGCCGATGGGCCCTACTAGGTTACTGACGTCAGCCAAACTCCGAATGCCAATAAGTTAGAGCGCGGCAGTGAGACGGCGGGGGAGAAGCTCCGTACGTCGAGAGGGAAACAGCCCAGATCGCCGGCTAAGGCCCCTAAGCGTGTACTAAGTGGAAAAGGATGTGCAGTCGCAAAGACAACCAGGAGGTTGGCTTAGAAGCAGCCACCCTTGAAAGAGTGCGTAATAGCTCACTGGTCAAGTGATTGTGCGCCGACAATGTAGCGGGGCTCAAGTACACCGCCGAAGCCGCGGCATTCATGCAATACATTCCCTTCGGGGCAGTGGCATGGATGGGTAGGGGAGCGTCCTGCACCCAGCGAAGCTGCGGAGTAATCCAGCAGTGGAGGGTGCGGGAGTGAGAATGCAGGCATGAGTAGCGACAGGCAAGTGAGAAACTTGCCCGCCGAATGACCAAGGGTTCCTGGGCCAGGCTAGTCCTCCCAGGGTAAGTCGGGACCTAAGGCGAGGCCGACAGGCGTAGTCGATGGACAACGGGTTGATATTCCCGTACCCGTGTGTGCGCGCCCATGATGAATCATCGGTACTAACCACCCAAAAGGTTCTAGATCAATCTCTTCGGAGTGCGACGTGAACCCGCTGCGTGGGACCTTCGGTGGTAGTAGTCAAGCGATGGGGTGACGCAGGAAGGTAGCTGTACCGGTTAGTGGTTATACCGGAGCAAGCCCGTAGGGCGACGTCTAGGTAAATCCGGATGTCATTAAGCCTGAGAGGTGACGCATAGCCGATTGAGGCGAATTCAGTGATCCTATGCTGCCAAGAAAAGCCTCTAGTGAGTTCACACACGGCCCGTACCCCAAACCAACACAGGTGGTCAGGTAGAGAATACTAAGGCGTACGAGATAACTATGGTTAAGGAACTCGGCAAAATACCCCCGTAACTTCGGGAGAAGGGGGACCTCGCTTGGTGACCGGACTTGCTCCGTGAGCTGAACGAGGTCGCAGAGACCAGTGAGAAGCGACTGTTTACTAAAAACACAGGTCCGTGCGAAGTCGCAAGACGATGTATACGGACTGACGCCTGCCCGGTGCTGGAAGGTTAAGAGGACCCGTTAACCCTTGGGTGAAGCGGAGAATTTAAGCCCCAGTAAACGGCGGTGGTAACTATAACCATCCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCTGCACGAATGGCGTAACGACTTCTCAACTGTCTCAACCATAGACTCGGCGAAATTGCACTACGAGTAAAGATGCTCGTTACGCGCGGCAGGACGAAAAGACCCCGGGACCTTCACTATAGCTTGGTATTGGCGTTTGGTTCGGTTTGTGTAGGATAGGTGGGAGACTGTGAAGCAGGCACGCCAGTGTTTGTGGAGTCATCGTTGAAATACCACTCTGATCGTATTGAACCTCTAACCTCGGACCGTATATCCGGTCCAGGGACAGTGCCTGGTGGGTAGTTTAACTGGGGCGGTTGCCTCCCAAAATGTAACGGAGGCGCCCAAAGGTTCCCTCAACCTGGACGGCAATCAGGTGTTGAGTGCAAGTGCACAAGGGAGCTTGACTGCGAGACTTACAAGTCGAGCAGGGACGAAAGTCGGGACTAGTGATCCGGCATCTCTGAGTGGAAGGGATGTCGCTCAACGGATAAAAGGTACCCCGGGGATAACAGGCTGATCTTCCCCAAGAGTCCATATCGACGGGATGGTTTGGCACCTCGATGTCGGCTCGTCGCATCCTGGGGCTGGAGCAGGTCCCAAGGGTTGGGCTGTTCGCCCATTAAAGCGGCACGCGAGCTGGGTTTAGAACGTCGTGAGACAGTTCGGTCTCTATCCGCCGCGCGCGTCAGAAACTTGAGGAAACCTGTCCCTAGTACGAGAGGACCGGGACGGACGAACCTCTGGTGTACCAGTTGTTCCACCAGGAGCACGGCTGGATAGCTACGTTCGGACAGGATAACCGCTGAAAGCATCTAAGCGGGAAACCTATTCCAAGACCAGGTTTCTTACCCTTTTAGAGGGATAAGGTCACCCACAGACTATGGGTTCAATAGGCCAGACCTGTAAGCGTAGTAATACGTTCAGGGAACTGGCACTAATCGACCGAAAACTTACTAAT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3980,Drugs,MEG_3980|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|GU143889.1|+|0-3113|ARO:3004165|Mycobacteroides chelonae 23S rRNA with mutation conferring resistance to clarithromycin [Mycobacteroides chelonae] ,7
,ATGACGCCATTACTGTATAAAAAAACAGGTACAAATATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGCTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTTGGCATTGAAATTCGCCACTGTCGTGCGCAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACTCGCACCTGGTTTTGCAGCGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAATGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTTGCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGCTGCTCATGGAACGTCTTGGCATCGCGGTAATTGGTTA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_5968,Drugs,MEG_5968|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gb|JQ349151|+|0-680|ARO:3002758|QnrB43 [Escherichia coli] ,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctgaacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5534,Drugs,MEG_5534|Drugs|betalactams|Class_C_betalactamases|PDC,685979280|WP_031687354.1|NG_055481|1|1|blaPDC-117|blaPDC|class_C_beta-lactamase_PDC-117 NG_055481:1-1194,0
,atgaatatacaaattttgaacctagcagaatgtaccgaatttcaagagagtgcagcaagagtcctattagatggatttagagaggttggcaagattgcatgggctacctatgaagaagctatggtcgaagtacaggaatgtactgagattcctaatatagcaatatgtgctgtcgataataataaagtcgttggttgggttggaattcgtccaatgtacgattacgtttgggaactacatccaatgatagtaaccaagaaataccaaaaaaaaggaatagggaccaaactacttaaggaaattgaacagattgcgaaagagaaaggtttactaggactggctcttggaactgatgatgaaactgatagtacaagtctatcgaaatgcgatttttcccgagataatatattgatcgagatagcgaatatcaaatcatctatgtcgcacccctatgcgttctatgaaaagaacggatactttattgtaggagtgattccgaatgcgaatggaaaaagaaaaccagacatttggatgtggaaagaacttgaaagctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_74,Drugs,MEG_74|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1102724706|WP_071593202.1|NG_052026|1|1|aacA49|aacA49|AAC(6')-Ia_family_aminoglycoside_6'-N-acetyltransferase_AacA49 NG_052026:52-606,2
,ATGAGGGAAGCGGTGATCGCGAAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCACACAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGGCAGGCTTATCTTGGACAAGAAGATCGCTTGGCCTCGCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_951,Drugs,MEG_951|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|19698424|gb|AF479774.1|7975-8763 gi|155010|gb|M55547.1|TRNTAAB|1466-2254,2
,atgaacattaaaacactcttacttataacaagcgctatctttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcatcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttacttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4681,Drugs,MEG_4681|Drugs|betalactams|Class_D_betalactamases|OXA,515028634|WP_016685888.1|NG_062343|1|1|blaOXA-715|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-715 NG_062343:14-838,0
,atgaatagaataaaagtcgcaatcatcttcggcggttgctcggaggaacatgatgtgtcggtaaaatccgcaatagaaattgctgcgaacattgatacggaaaaattcgatccgcactacatcggaattacaaaaaacggtgtatggaagctatgcaagaagccatgtacggaatgggaagccgacagtctccccgccatactctcccyggataggaaaacgcatgggctgcttgtcatgaaagaaagcgaatacgaaacacggcgtattgatgtggctttcccggttttgcatggcaaatgcggggaggatggtgcgatacaggggctgtttgtattgtctggtatcccctatgtgggctgtgatattcaaagctccgcagcttgcatggacaaatcactggcctacattcttacaaaaaatgcgggcatcgccgttcccgaatttcaaattattgataaaggtgacaagccggaggcgggtgcgcttacctaccctgtctttgtgaagccggcacggtcaggttcgtcctttggcgtaaccaaagtaaacggtacggaagaacttaacgctgcgatagaagcggcaggacaatatgatggaaaaatcttaattgagcaagcgatttcgggctgtgaggtcgggtgtgcggtcatggggaacgaggatgatttgattgtcggcgaagtggatcaaatccggctgagccacggtatcttccgcatccatcaggaaaacgagccggaaaaaggctcagaaaatgcgatgattacagttcccgcagacattccggtcgaggaacgaaatcgggtgcaggaaacggcaaagaaagtatatcgggtgcttggatgcagagggcttgcccgtgttgatctttttttgcaggaggatggcggcatcgttctaaatgaggtcaataccatgcccggttttacatcgtacagccgctacccacgtatggtggccgccgcaggaatcacgcttcctgcactgattgacagcctgattacattggcgttaaagaggtga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7351,Drugs,MEG_7351|Drugs|Glycopeptides|VanB-type_resistance_protein|VANB,1028100455|WP_063856590.1|NG_048338|1|1|vanB|vanB|D-alanine--(R)-lactate_ligase_VanB NG_048338:1-1029,5
,CCCGCATTACCGGCCCGTGACGGCTCCATATTCATTTCCGCCCAGCGCAGCATATCTTTTGAGGCGGATTTCACGCCGTAAGATTCCGCATCAAGCTGTCCCGGCGACACGCGGACCGGTTTTTTGTTTTTATAACCGTACGCATACTGGCTTTGCGCACTTTCCGGCACAGTAATAAAGGTGTGAGATAACCCCAGCGGTGCCAGGATCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_2612,Drugs,MEG_2612|Drugs|betalactams|Class_C_betalactamases|DHA,gi|944204231|gb|KR733543.1|2853-3063 gi|823683259|emb|LN831185.1|84631-84421 gi|746616805|gb|KJ187752.1|36297-36507 gi|746616518|gb|KF856624.1|43384-43594 gi|695227729|ref|NG_041672.1|7809-8019 gi|532025274|gb|KC999035.1|20157-20367 gi|485460042|dbj|AB759690.1|34730-34940 gi|429345463|gb|JX988621.1|49758-49968 gi|335355361|gb|JF922606.1|2937-3147 gi|323700877|gb|HQ451074.1|12301-12511,0
,ATGAAAAACATCGGCATTACCGTTTATGGATGCGAGCAGGATGAGGCAGATGCATTCCGTGCCCTTTCGCCGCGCTTTGGCATTATGCCCACGATAATTAACGCCGCCGTGTCAGAAGCCAACGCCATATCAGCCCCCTGCAATCAATGTATCAGCGTGGGACACAAATCCGAGGTTTCCGCGTCTATTCTTCTTGCGCTGAAGAGAGCCGGCGTGAAATATATCTCTACCCGAAGCATCGGCTGCAATCATATAGATACAACTGCCGCTAAGAGAATGGGCATCGCTGTCGGCAATGTGGCGTATTCGCCGGATAGCGTTGCCGATTATACCATGATGCTGATGCTTATGGCAGTACGCAACGCCAAATCTATTGTGCGCTCTGTGGAAAAACATGATTTCAGGCTGGACAGTGTCCGTGGCAAGGTACTGCGCGACATGACAGTCGGCGTGGTGGGAACCGGCCATATAGGCAAAGCGGTTATTGAGCGGCTGCGGGGATTTGGATGTCATGTGCTGGCTTATGATCGCAGCCAAAAAATAGAGGCAAACTATGTTCCGTTTGATGCGTTGTTGCAAAATAGCGATATCGTTACGCTTCATGTGCCGCTCAATGCGGATACGCGCCATATCATCGGCCACGAACAAATAAAGAGAATGAAGCAAGGCGCGTTTATTATCAATACTGGGCGCGGTCCACTTGTAGATACCGATGCGCTGGTTAAAGCATTAGAAAACGGAAAACTGGGCGGTGCCGCATTGGATGTATTGGAGGGAGAGGAAGAGTTTTTCTACTCTGATTGCTCACAAAAACCAATTGATAATCAATTTTTACTGAAACTTCAAAGAATGCCGAACGTGATAATCACGCCGCATACGGCTTACTATACCGAACAGGCGTTGCGTGATACCGTTGAAAAAACAATTAAAAACTGTTTGGATTTTGAAAGGAGCCAGGAGCATGAATAGAGTAAAAGTTGCAATCCTGTTTGGGGGTTGCTCGGAGGAGCATGACGTTTCGGTTAAATCTGCAAGAGAGATTGCCGCTAACATTGACAACGAAAAATACGAGCCGTTATACATTGGAATTACGAAATTCGGTGTTTGGAAAATGTGCGAAAAACCGTGCGCGGAATGGGAAAACAGCAATTGCTATTCAGCCGTACTCTCGCCGGATAAAAAAATGCACGGTTTGCTTGTTAAAAAGAACCATGAATATGAAATCCACCACGTTGATGTAGCATTTTCGGTTTTGCACGGCAAGTCGGGTGAAGATGGATCAATACAAGGTCTGTTTGAATTGTCCGGTATCCCCTATGTGGGCTGCGATATTCAAAGCTCCGCGATTTGTATGGACAAATCGCTGACATACACAATTGCGAAAAACGCTGGCATAGCTACTCCTGATTTTTGGGTTATTAATAAAGACGATAAGCCGGCGATAGATGCGTTTACCTATCCTGTTTTTGTTAAGCCGGCGCGTTCAGGCTCATCTTATGGCGTGAAAAAAGTCAATGGCGCAGACGAATTGGACGCCGCAATTGAATCGGCAAGACAATATGACAGCAAAATCTTAATTGAGCAGGCTGTTTTGGGCTGTGAGGTCGGTTGTGCCGTATTGGGAAACAGTTCCGAGTTGATTGTTGGCGAGGTGGACCAAATCAGGCTGCAGCACGGTATCTTTCGTATTCATCAGGAAGCCGAGCCGGAAAAAGGCTCTGAAAACGCAGTTATAACCATTCCCGCAGACCTGTCGGTAGAGGTGCGAGGACGGATACAGGAAACGGCAAAAAAAATATATAAGGCGCTCGGTTGTAGAGGTCTTTCCCGTGTTGATATGTTTTTACAAGATAACGGCAGCATTGTACTTAACGAAGTCAATACCCTGCCTGGTTTCACGTCATACAGCCGTTATCCCCGTATGATGGTCGCTGCAGGTATAACGCTTCCCGAACTGATTGACCGCCTGATCGTATTAGCATTAAAGGGATGATAAGAATGAAAATAGGATTTACTTTTTTAGATGAAATATTACACGGTGTTCGTTGGGACGCTAAATATGCCACATGGGACAATTTCACCGGAAAGCCGGTTGACGGATATGAAGTAAATCGCATTGTAGGAACATACGAGTTGGCCGACGCGCTTTTGAAGGTAAAAGAACTGGCTGCTACTCAAGGGTACGGATTGCTTCTATGGGACGGTTACCGTCCCCAACGCGCTGTAAACTGTTTTTTGCAATGGGCTGCACAGCCGGAAGATGACCTGACAAAGGAAAGATATTATCCCAATATTGACCGAACCGAGATGGTTTCAAAAGGATACGTGGCTTCAAAATCAAGCCATAGCCGCGGAAGTGCAATTGATCTTACGCTTTATCGATTAGACACGGGTGAGCTGGTACCAATGGGGAGCGGATTTGATTTTATGGATGAACGCTCTCATCATGCGGCAAAAGGAATTTCAGGCAATGAAGCGCAAAATCGCAGACGTTTGCGTTCCATCATGGAAGACAGTGGGTTTGAAGCATATAGCTTCGAATGGTGGCACTATGTATTAAGAAACGAACCATACCCCAACAGCTATTTTGATTTCCCCGTTAAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7409,Drugs,MEG_7409|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,VanHAX_PT_1_DQ018710,5
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggcagcgtaggcatggtagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccagccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctagcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcggattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6198,Drugs,MEG_6198|Drugs|betalactams|Class_A_betalactamases|SHV,1028110279|WP_063864649.1|NG_050038|1|1|blaSHV-162|blaSHV|class_A_beta-lactamase_SHV-162 NG_050038:1-861,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatactctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4385,Drugs,MEG_4385|Drugs|betalactams|Class_D_betalactamases|OXA,1391852910|WP_109545095.1|NG_057529|1|1|blaOXA-588|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-588 NG_057529:1-774,0
,ATGCGCCCTCTCCTCTTCAGTGCCCTTCTCCTGCTTTCCGGGCATACCCAGGCCAGCGAATGGAACGACAGCCAGGCCGTGGACAAGCTATTCGGCGCGGCCGGGGTGAAAGGCACCTTCGTCCTCTACGATGTGCAGCGGCAGCGCTATGTCGGCCATGACCGGGAGCGCGCGGAAACCCGCTTCGTTCCCGCTTCCACCTACAAGGTGGCGAACAGCCTGATCGGCTTATCCACAGGGGCGGTTAGATCCGCCGACGAGGTTCTTCCCTATGGCGGCAAGCCCCAGCGCTTCAAGGCCTGGGAGCACGACATGAGCCTGCGCGACGCGATCAAGGCATCGAACGTACCGGTCTACCAGGAACTGGCGCGGCGCATCGGCCTGGAGCGGATGCGCGCCAATGTCTCGCGCCTGGGTTACGGCAACGCGGAAATCGGCCAGGTTGTGGATAACTTCTGGTTGGTGGGACCGCTGAAGATCAGCGCGATGGAACAGACCCGCTTTCTGCTCCGACTGGCGCAGGGAGAATTGCCATTCCCCGCCCCGGTGCAGTCCACCGTGCGCGCCATGACCCTGCTGGAAAGCGGCCCGGGCTGGGAGCTGCACGGCAAGACCGGCTGGTGCTTCGACTGCACGCCGGAACTCGGCTGGTGGGTGGGCTGGGTGAAGCGCAACGAGCGGCTCTACGGCTTCGCCCTGAACATCGACATGCCCGGCGGCGAGGCCGACATCGGCAAGCGCGTCGAACTGGGCAAGGCCAGTCTCAAGGCTCTCGGGATACTGCCCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5262,Drugs,MEG_5262|Drugs|betalactams|Class_D_betalactamases|OXA,gi|974298776|gb|CP008864.1|5482818-5483606 gi|926451317|emb|LN871187.1|6219306-6220094 gi|745838743|gb|CP007399.1|2474938-2475726 gi|589338112|gb|CP006985.1|6465670-6466458 gi|589332184|gb|CP006984.1|6450687-6451475 gi|589326231|gb|CP006983.1|6468621-6469409 gi|589320215|gb|CP006982.1|6532730-6533518 gi|589314341|gb|CP006981.1|6409530-6410318 gi|589308385|gb|CP006980.1|6484966-6485754 gi|566561164|gb|CP006937.1|6491686-6492474,0
,ATGAACAAAAATATAAAATATTCTCAAAACTTTTTAACGAGTGAAAAAGTACTCAACCAAATAATAAAACAATTGAATTTAAAAGAAACCGATACCGTTTACGAAATTGGAACAGGTAAAGGGCATTTAACGACGAAACTGGCTAAAATAAGTAAACAGGTAACGTCTATTGAATTAGACAGTCATCTATTCAACTTATCGTCAGAAAAATTAAAACTGAATACTCGTGTCACTTTAATTCACCAAGATATTCTACAGTTTCAATTCCCTAACAAACAGAGGTATAAAATTGTTGGGAGTATTCCTTACCATTTAAGCACACAAATTATTAAAAAAGTGGTTTTTGAAAGCCGTGCGTCTGACATCTATCTGATTGTTGAAGAAGGATTCTACAAGCGTACCTTGGATATTCACCGAACACTAGGGTTGCTCTTGCACACTCAAGTCTCGATTAAGCAATTGCTTAAGCTGCCAGCTGAATGCTTTCATCCTAAACCAAAAGTAAACAGTGCCTTAATAAAACTTACCCGCCATACCACAGATGTTCCAGATAAATATTGGAAACTATATACGTACTTTGTTTCAAAATGGGTCAATCGAGAATATCGTCAACTGTTTACTAAAAATCAGTTTCATCAAGCAATGAAATACGCCAAAGTAAACGATTTAAGTACCGTTACTTATGAGCAAGTATTGTCTATTTTTAATAGTTATCTATTATTTAACGGGAGGAAATAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2802,Drugs,MEG_2802|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,gi|777202877|emb|LN831030.1|2100371-2099634 gi|777202877|emb|LN831030.1|2102778-2102041 gi|760237048|gb|CP010905.1|2302352-2301615 gi|760237048|gb|CP010905.1|2304759-2304022 gi|733567460|emb|LN614756.1|2277429-2276692 gi|115249003|emb|AM180355.1|2317704-2316967 gi|115249003|emb|AM180355.1|2320111-2319374 gi|669664083|ref|NG_034211.1|4433-5170 gi|669664083|ref|NG_034211.1|6840-7577 gi|15986372|emb|AJ294530.1|399-1136 gi|745811785|gb|CP007593.1|960658-961393,7
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacattacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttcacccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4490,Drugs,MEG_4490|Drugs|betalactams|Class_D_betalactamases|OXA,1509794605|WP_122630914.1|NG_062334|1|1|blaOXA-722|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-722 NG_062334:13-837,0
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1359,Drugs,MEG_1359|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_25_JBKK01000017,0
,ATGACTGAGCACGACCTCTCGATGCTCCATGAGTGGCTGAACCGGCCACACATAGTTGAATGGTGGGGCGGTGAGGACGAACGTCCAACACTGGACGAGGTATATGAACACTACCTGCCAAGAGTTCTGGCGCAGGAATCGGTCACCCCGTACATCGCCATGCTCGGCAACGAACCGATTGGCTACGCGCAGTCGTACGTAGCGCTCGGTAGCGGTGACGGATGGTGGGAAGAGGAAACTGACCCAGGGGTGCGAGGAATCGATCAGTCGCTGGCCAACCCAACGAAACTGAACAAAGGCCTCGGAACGAAGCTTGTACGCGCGCTGGCTGATCTGCTGTTCTCAGATGCGTCAGTGACAAAGATCCAGACCGACCCGGCTCCGGGTAACCATAGAGCTATTCGTTGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_348,Drugs,MEG_348|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|383216584|gb|JQ407409.1|2163-2681 gi|383216582|gb|JQ407408.1|1-519,2
,ATGAGCGACATTGCCAGAGAAATCACACCAGTTAATATCGAAGAAGAGCTGAAAAGCTCATATTTGGATTATGCGATGTCCGTTATTGTAGGACGCGCATTACCCGATGTTCGAGACGGACTGAAGCCAGTACACCGCCGAGTGCTATTTGCGATGAATGTACTGGGAAACGATTGGAATAAACCTTATAAAAAATCAGCCCGTGTTGTTGGGGATGTAATCGGTAAATATCACCCGCACGGTGACAGTGCTGTCTATGAAACGATTGTTCGTTTAGCACAGCCTTTTTCTATGCGCTACATGTTGGTTGACGGTCAGGGTAACTTCGGGTCAGTTGATGGTGACTCCGCGGCGGCTATGCGTTATACCGAAGTTCGTATGGCGAAGATCGCCCATGAACTGCTGGCGGATTTGGAAAAAGAGACGGTCGACTTTGTTCCTAACTATGATGGAACAGAAAATATACCGGCTGTTATGCCAACCCGTATTCCAAACTTGTTAGTTAATGGCTCTTCAGGTATTGCCGTTGGGATGGCAACGAATATCCCTCCGCATAACCTCGGTGAAGTTATCGACGGTTGTCTTGCCTATGTTGATAATGAAGACATCACCATAGAAGAATTAATGGAATATATTACCGGGCCTGATTTTCCGACTGCTGCGATTATTAATGGTCGCAGAGGAATATTAGATGCTTATCGTACAGGGCGTGGAAAGATTTATATCCGTGCTCAGGCTGATATTGAAACTGATGAGAAAACAGGTCGCGAAACCATTATCGTGACAGAAATTCCTTATCAGGTGAATAAAGCCCGTTTAATTGAAAAAATTGCGGAGCTTGTAAAAGATAAACGTATTGAAGGTATCAGCGGATTACGTGACGAGTCTGATAAAGACGGTATGCGTATTGTTGTTGAGATCAAACGTGATGCAGTCGGTGAAGTAGTATTAAATCACCTCTTTTCACAAACTCAAATGCAAGTCTCTTTTGGTATTAATATGGTTGCGCTTCATCAAGGCCAACCAAAATTATTGAACCTAAAAGAAATTATCGCAGCCTTTATTCGCCATCGTCGTGAAGTGGTGACTCGTCGTACCATTTTTGAATTACGTAAAGCACGTGATCGTGCTCATATCTTAGAAGCACTTGCGGTCGCTTTGGCCAATATCGATCCTGTGATTGAATTAATTCGTCAAGCACCAACCCCAGCAGAAGCGAAAGCGGCATTAATTGCCCAACCTTGGGATCTCGGTAGCGTGTCTACGATGTTAGAGCGTGCTGGTGATAGCAATGTTGCTCGCCCTGAGTGGTTAGAGCCACAATTTGGTGTGCATGACGGTAAATACTATCTAACAGAACAACAAGCACAAGCCATTTTAGATTTGCGGTTGCAGAAACTGACCGGACTTGAGCATGAAAAACTGCTAGATGAATATCGTGAATTACTGCTACAAATTGCTGAGTTATTGCATATTTTGAGAAGCCCTGAGCGTTTAATGGACGTTATTCGTGAAGAGCTAACAGCAATTAAAACACAATATAACGATCCTCGTCGTACTGAAATCACTGAAAATACCGCTGATATTAATATCGAAGATCTGATTAATGAAGAAAATGTGGTTGTGACACTATCTCACCAAGGTTACGTTAAATATCAGCCATTGACTGATTATGAAGCGCAACGTCGTGGAGGAAAAGGTAAGTCAGCCGCAAGGATCAAAGAAGAAGACTTTATCGATCGCCTACTGGTGGCTAATACACACGATACTATTTTGTGTTTCTCAAGTCGTGGTCGCCTGTACTGGATGAAAGTTTATCAGTTACCAGAAGCGAGCCGCGGTGCTCGTGGTCGCCCAATTATCAATTTGTTACCTCTAGAACAAGATGAGCGGATCACCGCTATTCTTCCAGTAAGAGAGTATGAAGAAGGTAAATTTGTCTTTATGGCAACGGCGAGCGGTACGGTTAAAAAGACACCATTACAAGACTTCAGTCGTCCTCGTAGTGCCGGTATTATCGCGGTTAATTTAAATGATGGCGATGAGCTTATCGGTGTTGATTTAACCGACGGTAGTAATGAAGCTATGCTGTTCTCAGCAGATGGTAAAGTGGTTCGTTTCGCAGAAGAGTGTGTTCGTCCAATGGGTCGTACTGCGACAGGTGTTCGTGGTATGAAACTGGTTGATGATGATAAAGTGGTTTCACTGATCATTCCTCGTGGCGAAGGTGATATCTTAACAGTGACTGAAAACGGTTATGGTAAACGTACCGTTCAAAGTGAATACCCAACCAAAAACCGTGCAACACAAGGCGTTATCTCGATTAAAGTGAGTGAGCGTAATGGTAAAGTGGTAGGCGCTATTCAAGTTGAAGAAACTGACCAGATTATGATGATCACCAATGCCGGAACGTTAGTGCGTACCCGAGTATCAGAAGTCAGCATTGTGGGACGTAATACACAAGGTGTTACCTTGATCCGTACTACAGAAGACGAGCTAGTCGTTGGCTTACAACGTGTTGAAGATGAAGATGATGCGTTAGATGATGATGAAGTTGATGAAATGATCAGCGACAATATCTCTGATGTTCCAGAGTCTGAACCAACAGATGATGCGGATAGTGAAGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3208,Drugs,MEG_3208|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|529186758|gb|CP004022.1|1979719-1977086,3
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGATAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1857,Drugs,MEG_1857|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AJ555825|+|0-1146|ARO:3002025|CMY-14 [Proteus mirabilis] ,0
,atgagggaagcggtgaccgccgaaatttcgactcaactatcagaggtgcttagcgtcatcgagcgccatctggagtcgacgttgctggccgtgcatttgtacggctctgcactggacggtggcctgaagccatacagtgatattgatttgctggttactgtggctgcacagctcgatgagactgtccgacaagccctggtcgtagatctcttggaaatttctgcctcccctggccaaagtgaggctctccgcgccttggaagttaccatcgtcgtgcatggtgatgttgtcccttggcgttatccggccagacgggaactgcaattcggggagtggcagcgtaaggacattcttgcgggcatcttcgagcccgccacaaccgatgttgatctggctattctgctaactaaagtaaggcagcatagccttgcattggcaggttcggccgcagaggatttctttaacccagttccggaaggcgatctattcaaggcattgagcgacactctgaaactatggaattcgcagccggattgggaaggcgatgagcggaatgtagtgcttaccttgtctcgcatttggtacagcgcagcaaccggcaagatcgcaccgaaggatatcgttgccaactgggcaattgagcgtctgccagatcaacataagcccgtactgcttgaagcccggcaggcttatcttggacaaggagaagattgcttggcctcacgcgcggatcagttggcggcgttcgttcacttcgtgaaacatgaagccactaaattgcttggtgccatgccagtgatgtctaacaattcattcaagccgaacccgcttcgcgggtcggcttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_882,Drugs,MEG_882|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502113|WP_071846265.1|NG_052306|1|1|ant(3'')-Ia|ant(3'')-Ia|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA NG_052306:101-946,2
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAAGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1393,Drugs,MEG_1393|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_69_NZ_CUHB01000033,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcttgaagcaatacagcgatattgatttgttgcttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_780,Drugs,MEG_780|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502220|WP_071846370.1|NG_052497|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052497:101-892,2
,ATGACGAATTATTTTGAGAGTCCCTTCAAAGGGAAGCTTCTGACTGAGCAGGTGAAGAATCCGAACATCAAGGTAGGGCGGTATAGCTACTATTCCGGCTATTACCATGGGCACTCGTTTGATGATTGTGCTCGCTACCTTCTACCGGACCGTGATGACGTTGATCAGCTGATTATCGGCAGCTTCTGCTCCATCGGATCAGGCGCAGCTTTTATTATGGCTGGGAATCAAGGCCACCGATATGATTGGGTCTCTTCTTTCCCTTTCTTCTACATGAACGAGGAGCCCGCGTTTGCAAAATCAGTCGATGCATTCCAGCGGGCTGGCGACACAGTTATAGGAAGTGATGTGTGGATCGGTTCGGAGGCCATGATCATGCCCGGGATCAAGATCGGGCATGGAGCGGTGATAGGTAGCCGCGCTTTGGTTGCCAAAGACGTGGAACCCTACACCATAGTGGGGGGAAACCCTGCAAAGTCGATTAGGAAGCGCTTTTCTGAAGAAGAAATTTCTATGCTTTTAGATATGGCTTGGTGGGATTGGCCGCTGGAACAAATCAAGGAAGCAATGCCTTTTCTTTGTTCGTCTGGCATTGCCAGCCTGTATCGTCGCTGGCAAGGCACAAGCGCCTAA,chloramphenicol acetyltransferase (CAT),antibiotic inactivation,Phenicol,MEG_1626,Drugs,MEG_1626|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB,gi|24209732|gb|AY139601.1|555-1187,6
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagttaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgatgaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgcgcgggaggaacagcagcgggttcaagacgcctccctgttcccagtctatcatggcagcgccaaaaatggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggggcgccgccctatgcggcagcgttttcaaggttgagtacaccgattgcggccagcggcgtgtctatctacggttatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatcagggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggaccaaacccggctccctcgtaaaaggtggcgcgaggaccccctccccatgctgcggacgacgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgttgcgaagtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaaccctccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccataggactgtctgttacaccactctcgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaangtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcggggacgcagctgctggaaccttatctctccttcatcctctatgcgccccaggaatacctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggcccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcggagcgtatgccttacagagctgaaaggatatcaggccgctgtcggtcagccggtcatccagccccgccgtccaaacagccgcctggacaaggtgcgccatatgtttcagaaggtaatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7220,Drugs,MEG_7220|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100281|WP_063856416.1|NG_048287|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048287:1-1920,4
,ATGCGTTATGTTCGCCTGTGCCTTATCTCCCTGATTGCCGCCCTGCCACTGGCGGTATTCGCCAGCCCTCAGCCGCTTGAGCAGATTAAAATCAGCGAAAGTCAGCTGGCGGGCCGGGTGGGCTATGTTGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCAGTGAGCGCTTTCCGCTGATGAGCACCTTTAAAGTGCTGCTCTGCGGCGCGGTGCTGGCCCGGGTGGATGCCGGCGACGAACAGCTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTGCCGACGGGATGACCGTTGGCGAACTCTGCGCCGCCGCCATCACCATGAGCGACAACACCGCCGGCAATCTGCTGTTGAAGATCGTCGGCGGCCCCGCGGGATTGACCGCTTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGAACTCAATGAGGCGCTTCCCGGCGACGTGCGCGACACCACCACCCCGGCCAGCATGGCCACCACCCTGCGCAAGCTTCTAACCACCCCCTCTCTGAGCGCCCGTTCGCAGCAGCAGCTGCTGCAGTGGATGGTTGACGACCGGGTGGCCGGCCCGTTGATCCGCGCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAAACCGGGGCCGGTGAGCGGGGCTCACGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAAGCGGAGCGTATCGTGGTGATCTATCTGCGTGATACCCCGGCGACCATGGTCGAGCGTAACCAGCAGATCGCCGGGATAGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4239,Drugs,MEG_4239|Drugs|betalactams|Class_A_betalactamases|OKP,(Bla)OKP-B-5:AY512506:68-928:861,0
,ATGAATAGAGTAAAAGTTGCAATCCTGTTTGGGGGTTGCTCCGAGGAGCATGACGTGTCGGTTAAATCTGCAAGAGAGATTGCCGCTAACATTGACAACGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCCGGTGTTTGGAAAATGTGCGAAAAACCGTGCGCGGAATGGGAAAACAGCAATTGCTATTCAGCCGTACTCTCGCCGGATAAAAAAATGCACGGTTTGCTTGTTAAAAAGAACCATGAATATGAAATCCACCACGTTGATGTAGCATTTTCGGGGATGCACAGCAAGTCAGGTGAAGATGGATCCATACAAGGTCTGTTTGAATTGTCCGGTATCCCTTATGTGGGCTGCGATATTCAAAGCTCCGCGATTTGTATGGACAAATCGCTTACATACACAATTGCGAAAAACGCTGGCATAGCTATTCCTGAATTTTGGGTTATTAATAAAGACGATAAGCCGGCGGCAGATACGTTTACCTATCCTGTTTTTGTTAAGCCGGCGCGTTCAGGCTCATCTTATGGCGTGAAAAAAGTCAATGTCGCAGACGAATTGGACGCCGCAATTGAATCGGCAAGACAATATGACAGCAAAATCTTAATTGAGCAGGCTGTTTTGGGCTGTGAGGTCGGTTGTGCCGTATTGGGAAACAGTTCCGAGTTGATTGTTGGCGAGGTGGACCAAATCAGGCTGCAGCACGGTATCTTTCGTATTCATCAGGAAGCCGAGCCGGAAAAAGGCTCAGAAAACGCAGTTATAACCATTCCCGCAGACCTGTCAGCAGAGGAGCGAGGACGGATACAGGAAACGGCAAAAAAAATATATAAGGCGCTCGGTTGCAGAGGTCTTTCCCGTGTTGATATGTTTTTACAAGATAACGGCCGCATTGTACTTAACGAAGTCAATACCCTGCCTGGTTTCACGTCGTACAGCCGTTATCCCCGTATGATGGCCGCTGCAGGTATAACGCTCCCCGAACTGATTGACCGCCTGATCGTATTCGCGTTACAGGGGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7341,Drugs,MEG_7341|Drugs|Glycopeptides|VanA-type_resistance_protein|VANA,gi|257412320|gb|AY926880.2|3732-4763,5
,GTGCGTACCCTGACCACCTTCGGCCTTGCCCTGCTGCTGGCCCAACCCGCCATGGCCGCCCAGGCCGTCCTGCCGCAACTGCAGCCCTACACCGCCCCGGCCGCCTGGCTGACCCCGGTGGCACCGCTGCGTATCGCCGACAACACCTGGCACATCGGCACCGCCAGCATCACCGCGCTGCTGGTGAAGACGCCGGAAGGCGCCGTGCTGCTGGACGGCGGCATGCCCCAGGTGGCCGACCACCTGCTGGCCAACATGCGCGAGCTGGGTGTGGCGCCGGGCGACCTCAAGCTGATCCTGCACAGCCACGCCCACATCGATCACGTCGGCCCGCTGGCCGCCATCAAGAAGGCCACCGGCGCGCAACTGGTGAGCAACGCCGAATCGGCCGTGCTGCTGCAGCGCGGCGACAGCCAGGACATCCACTTCGGCGACGACATGGTCTTCGCCCCGGTGCAGGTGGACCGCCTGGTGCAGGACGGCGAAACCGTGGAGCTGGGCGGCATGACCTTCACCGCCCACTTCACCCCCGGGCACACCCCCGGCAGCCTGAGCTGGACCTGGACCGACCGTCGCGACGGCAAGCCCCTGCGCATCGCCTACAGCGACAGCTTGAGCGCCCCCGGATACAGCCTGTGGATGAACCCGCGCTTCTCGAAGATCGCCGAGGCCTTCCGCAGCGGCTTCGCCGCCGTCCGCGCCCTGCCCTGCGACCTGCTGATCACCCCCCACGCCGAGGCCAGCGGCTGGGACTACACCAACGCCGAACACCCCAACCCGTCGCCCATGAGCTGCAAGGCCTACGCCGACAAGGCCGAGGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_5807,Drugs,MEG_5807|Drugs|betalactams|Class_B_betalactamases|POM,gi|302139992|gb|GU002295.1|97-917,0
,ATGGAAGAAAATAACAAAATACTCCCTATTGAAATAGCGGAAGAAATGAAAAAATCGTATATTGATTATTCAATGAGTGTTATAGCTGGACGTGCTCTTCCTGATGTTAGAGATGGTTTAAAGCCAGTTCATAGAAGAATATTATATTCAATGAGTGAGTTAAATTTAACTCCAGATAAACCATACAGGAAGTCAGCTCGTATTGTTGGGGACGTTTTAGGTAAGTACCATCCTCATGGAGATACTGCTGTTTATTATGCTATGGTAAGAATGGCACAAGATTTTTCAACTAGAGCACTTTTAGTAGATGGTCATGGTAACTTTGGTTCTGTTGATGGGGATTCACCAGCTGCTATGCGTTATACAGAAGCTAAAATGAGTAAATTATCATTAGAACTACTGAGAGATATTGAAAAGGAAACTGTAGACTTTAAACCAAACTTTGATGAGTCGTTAAAAGAGCCTTCAGTATTGCCAGCTAGATATCCTAATTTATTAGTAAATGGCTCAAATGGTATAGCTGTTGGTATGGCAACTTCAATACCTCCACATAATTTAGCAGAAGTAATTGATGCAACTGTATATTTGATAGATAATCCAGAGTGTAGTGTAGATGATTTAATAAAATTTGTTCAAGGACCAGATTTCCCTACAGCTGCAATTATAATGGGAAAAGAAAGTATAGCAGAAGCATACAGAACTGGAAGAGGAAAAGTTAAAGTTAGGTCTAGAGCTTTTATAGAAGAGCTACCAAAAGGAAAACAGCAAATAATAGTTACAGAAATACCTTATCAAGTAAATAAGGCTAAACTGGTTGAAAGAATAGCAGAGTTAGTTAAAGAAAAGAGAATAGAAGGTATATCAGACCTAAGAGACGAAAGTAATAGAAATGGTATGAGAATTGTTATAGAATTAAAGAGGGATGCTAATGCTAATATAGTATTAAATAATTTGTATAAACATTCTCAAATGGAAGATACTTTTAGTATAATAATGCTTGCACTTGTAGATGGTCAGCCAAGAGTTTTAAATCTTAAACAAATATTATATCATTATATTAAACATCAAGAAGATGTTGTTACAAGAAGAACTAAATTTGAACTAAATAAAGCTGAAGCAAGAGCACATATTTTAGAAGGATTAAAGATTGCTTTAGATAATATAGATGCTGTTATAAGCTTGATAAGAGCTTCAAAGACTGGGCAAGAAGCTAAGCTAGGTTTAATAGAAAAATTCAAATTAACTGAAATCCAAGCACAAGCTATATTAGATATGAGACTTCAAAGACTTACAGGTTTAGAAAGAGATAAGATAGAAGCTGAATATGAAGATTTAATCAAGAAGATAAATAGATTAAAAGAGATTTTAGCTGATGAAAGATTACTTTTAAATGTAATAAAGGATGAAATTACAATAATAAAAGAAAATTACTCTGATGAGAGAAGAACAGAAATAAGACATGCTGAAGGCGAAATAGATATGAGAGATCTTATAAGTGATGAAGAAATAGCAATAACTCTTACTCACTTTGGATATATAAAAAGGCTTCCATCTGATACTTATAAGAGTCAAAAAAGGGGTGGAAGAGGTATTTCAGCACTTACAACTAGAGAAGAAGATTTTGTAAGGCACTTGGTAACTACAACTACTCATAGTAGACTATTATTCTTTACAAATAAAGGTAGAGTATTTAAATTAAATGCATATGAAATACCAGAAGGTAAGAGACAGGCTAAAGGTACTGCTATAGTGAATTTACTTCAATTGTCAGCAGATGAGAAAATTGCTACTCTAATACCTATTGATGGTAATGATGAAAATGAATATTTATTACTTGCAACGAAAAAAGGTATTGTTAAAAAGACTAAGAGAGAAGAGTTCAAAAATATAAATAAATCTGGTCTTATTGCAATAGGTTTAAGAGATGATGATGAGCTTATTGGAGTAGAACTTACAGATGGAAAACAAGAAGTACTTTTAGTAACTAAAGAAGGTATGTCTATAAGATTTGATGAAAATGATATAAGATATATGGGTAGAACAGCAATGGGTGTAAAAGGTATAACTTTAAGTAAAGAAGATTTTGTTGTGTCTATGAACCTTTGTAGTAAAGGTACAGATGTGTTAGTTGTAAGTAAGAATGGTTTTGGAAAGAGAACAAATATAGAAGAGTATAGAAGTCAAATAAGAGCTGGTAAAGGAATTAAAACTTATAATATATCTGAAAAAACTGGTACAATTGTAGGTGCAGATATGGTCAACGAAGATGATGAGATAATGATTATAAATTCTGATGGAGTTCTTATTAGAATAAGAGTCAATGAAATATCACTGTTTGGAAGAGTTACAAGTGGTGTTAAATTAATGAAGACGAATGATGAAGTCAATGTAGTTTCGATTGCCAAAATAAATATTGAAGAAGAATAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3219,Drugs,MEG_3219|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|777202877|emb|LN831030.1|9003-6577 gi|760237048|gb|CP010905.1|6066-8492 gi|733567460|emb|LN614756.1|6066-8492 gi|115249003|emb|AM180355.1|6066-8492,3
,ATGAGCAATATTAATTACGAAGGCATCGAGCAGATGCCACTTCGCACCTTTACAGAAAAGGCTTACCTTAATTATTCAATGTACGTCATCATGGATCGTGCATTGCCTTTTATTGGCGATGGCTTAAAGCCTGTTCAACGTCGTATTGTCTATGCGATGTCTGAACTGGGTTTAAATGCCGCGGCAAAATTTAAAAAGTCCGCGCGTACCGTCGGTGATGTGTTAGGTAAATTCCATCCACATGGTGACTCTGCTTGTTATGAAGCCATGGTATTAATGGCTCAGCCTTTTTCTTATCGTTATCCTTTGGTAGATGGGCAAGGAAACTGGGGGGCGCCAGATGATCCTAAATCATTTGCGGCAATGCGTTATACAGAATCTCGCCTGTCCAAAATCTCTGAAATTTTATTATCTGAATTAGGCCAAGGCACTGTTGATTTCCAACCGAACTTTGATGGTACCTTAGAAGAACCTCAATATTTGCCTGCACGTTTGCCTCATATTCTGTTAAACGGCACCACCGGGATTGCCGTCGGGATGGCAACCGATATTCCACCACATAATATTAATGAAGTGGCGGATGCCGCTGTTATGCTATTAGATAATCCAAAAGCAGGATTAGATGATGTACTCAATATCATTCAAGGCCCGGATTTCCCAACTGAAGCGGAAATTATTTCACCAAAAGATGATATTCGCAAAATGTATGAAACCGGTCGTGGTTCTATCAAAATGCGTGCAACATGGCATAAAGAAGACGGTGAAATCATCATTAGTGCACTTCCTCATCAATCTTCACCATCAAAAATCATTGCGCAAATTGCTGAACAAATGACAGCAAAAAAATTGCCAATGGTGGAAGATATTCGTGATGAAGCAGATTATGAAAACCCTGTACGTATCGTGCTTGTGCCACGTTCAAATCGTGTTGATACGGATGCCTTAATGGCGCATTTATTTGCGACGACTGATCTCGAAAAAAGCTATCGTGTAAATATGAATATGATCGGACTTGATCATAAACCAGCCGTAAAAGGCCTACTTCAAGTTCTTATCGAATGGCTGACATTCCGTCGTACTACCGTGACACGTCGTTTACAACATCGTTTAGATAAAGTACTCGCTCGTTTGCACATTTTAGATGGTTTGATGATTGCCTTCCTCAATATTGACGAAGTGATTGAGATTATTCGTACTGAAGATGAACCAAAACAAGTTTTAATGGCTCGCTTTAACTTAAGTGATGAACAGGCAGAAGCCATTTTAAACTTACGTTTACGCCATTTGGCCAAATTAGAAGAACATCAATTACAAGCTGAAAAAGATAAACTCGAAGAAGAGCGGTCAAATTTAGAGTTAATTTTAGGATCTGAACGTCGCTTAAATACCTTGATCAAAAAAGAAATTCAAGAAGATGCGAAAAAATACGCCAGCCCTAGAATGTCTCAATTAGTTGAACGTGAAGAAGCGAAAGCCATTTCTGAAAGTGAAATGACTCCGGCTGAACCCGTTACCGTTATCTTATCTGAAATGGGCTGGGTACGCTGTGCAAAAGGTCATGACATTGATCCGGAAGGATTAAGCTATAAAGCAGGCGATAAATATCTGGCTCACGCTTGCGGTAAAAGTAATCAGCCTGTAATCTTTATTGACAGCACGGGGCGTAGCTATGCTTTAGATCCATTAAGCTTGCCTTCTGCGCGTTCACAAGGTGAACCACTCACCGGTAAACTGACATTACCGGCCGGTGCGACCATTGAACAGGTTATTATGGAACCTGAAAAACAAGAATTATTGATGGCATCAGATGCAGGATATGGTTTTATTTGCAAATTTGAAGATTTAATTGCGCGTAATAAAGCAGGAAAAGCCTTGATTTCTTTGCCAGAAAATGCGAAAGTCTTGAAACCTGAGACACTTTCCGAGTCGACCTCACTTCTTGTGTCCCTCACTTCAGCGGGTCGAATGCTGATTTTTCCGGTACGGGATTTACCGGCATTATCAAAAGGGAAAGGCAACAAAATCATCAGTATTCCAGCAGCGAATGCAAAAGCGCGGTCAGAATTATTAGTGAAATTGTTCTTAATTTCAGAGCAAGCTAGCCTTGAGTTCCATTCCGGTAAACGAAAAATCACATTAAAACCGGAAGATCTGCAAAAATTCCGAGCGGAACGCGGCAGAAAAGGCTCCCAATTACCACGTGGATTACATAGCAATGTTGATATTGTGGTAGTTGAACCCGAACACAACTCATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3251,Drugs,MEG_3251|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRC,gb|NC_015964.1|+|1905162-1907418|ARO:3003925|Haemophilus parainfluenzae parC conferring resistance to fluoroquinolones [Haemophilus parainfluenzae] ,3
,ATGACAAAAAAGAAATTGCCCGTTCGTTTTACGGGTCAGCACTTTACTATTGATAAAGTGCTAATAAAAGATGCAATAAGACAAGCAAATATAAGTAATCAGGATACGGTTTTAGATATTGGGGCAGGCAAGGGGTTTCTTACTGTTCATTTATTAAAAATCGCCAACAATGTTGTTGCTATTGAAAACGACACAGCTTTGGTTGAACATTTACGAAAATTATTTTCTGATGCCCGAAATGTTCAAGTTGTCGGTTGTGATTTTAGGAATTTTGCAGTTCCGAAATTTCCTTTCAAAGTGGTGTCAAATATTCCTTATGGCATTACTTCCGATATTTTCAAAATCCTGATGTTTGAGAGTCTTGGAAATTTTCTGGGAGGTTCCATTGTCCTTCAGTTAGAACCTACACAAAAGTTATTTTCGAGGAAGCTTTACAATCCATATACCGTTTTCTATCATACTTTTTTTGATTTGAAACTTGTCTATGAGGTAGGTCCTGAAAGTTTCTTTCCACCGCCAACTGTCAAATCAGCCCTGTTAAACATTAAAAGAAAACAGTTATTTTTTGATTTTAAGTTTAAAGCCAAATACTTAGCATTTATTTCCTGTCTGTTAGAGAAACCTGATTTATCTGTAAAAACAGCTTTAAAGTCGATTTTCAGGAAAAGTCAGGTCAGGTCAATTTCGGAAAAATTCGGTTTAAACCTTAATGCTCAAATTGTTTGTTTGTCTCCAAGTCAATGGGTAAACTGTTTTTTGGAAATGCTGGAAGTTGTCCCTGAAAAATTTCATCCTTCGTAG,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2833,Drugs,MEG_2833|Drugs|MLS|23S_rRNA_methyltransferases|ERMF,gi|859808409|gb|KP265722.1|13238-14038 gi|356668588|gb|JN086160.1|580-1380 gi|324316725|gb|CP002530.1|2982575-2983375,7
,atgatgaaaaaattcctttgctgcgccctgctgctcagcacatcctgctctgtactcgccgcgccgatgtcggaaaaacagctggctgacgtggtagaacgcaacgttacgcccctgatgaaagcgcagggtattccaggcatggcggtggccgtgatttatcagggccagccacactactttacctttggaaaggccgatatcgcggcgaacaaatccgtcaccccgcaaaccctgttcgagctgggctctataagtaaaaccttcaccggcgtgctggggggcgatgctattgcccgcggcgaaatttcgctgggcgatccggtaaccaaatattggcctgatctgaccggcaagcagtggcaagggattcgcatgctggatctggcaacctacaccgccggtggcctgcctttacaggtgcccgatgaggtcacagataacgcatccctgctgcgcttctatcaaaactggcagcctcagtggaagccgggcacaacgcgtctttacgccaactccagcatcggtctttttggcgcgctggcggtcaaaccttccggcatgaactatgagcaggccatgacgacgcgggtctttaagccgctcaagctggatcatacctggattaacgttccgaaagcggaggagacgcattacgcctggggatatcgtgacggtaaagcggtccacgtttcaccgggcatgctggacgcagaggcatatggcgtgaaaaccaacgtgcaggatatggcgagctgggtgatggccaatatggcccctgacgcgctgcaggatacgtccctgaagcaaggcattacgctggcgcagtctcgctactggcgcgtgggtgccatgtatcaggggttaggttgggagatgcttaactggccggtcgatgccaaaaccgtcgtcggaggcagtgataacaaggtggcgctggcaccgttgcctgcgagagaagtgagtccacccgttcccccggttaaggcctcatgggtgcacaaaacgggctccaccggcgggtttggcagctacgtggcctttattcctgaaaagcagctcggcattgtgatgctggcgaataaaagctatccgaacccggcgcgagttgaggcggcataccgtatcctcgacgcgctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_439,Drugs,MEG_439|Drugs|betalactams|Class_C_betalactamases|ACT,772581133|WP_045261282.1|NG_050712|1|1|blaACT-49|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-49 NG_050712:1-1146,0
,atgacgaaaataaatcgcttggcgacagcattgttcgccgcactgatcctgccggcaggccatgccgccgataaagccgacattgacgccattattcagccgctgatgcagaaatatgccgttccaggcatggcaattgcggtatcggtagaggggaaacagcagttttatcactatggcgtggcgtccaggcagaccggcaaaccaatcaccaaccagacgctgtttgaaattggttcattgagcaaaaccttcactgcgaccttggccacctacgcggtcagtgaaggcaaaatgtcgtttgccgatccggccagtcgatatttgccggcgttgcgcggcagcgcctttgaccatgtcaccttgttgaatctggcgacccacacctccggtttgccgctgtttgtcccggacgacgtgaccaacgacgcgcagttgatggcctattaccgacaatggcagccgccgcatgcggtgggcagctaccgcgtttattccaacctgggcatcggtatgctggggatgattaccgccaagagcctgaaccagcctttcactcaggcgatggaaaaacagctgctgccggctctggggatgaatcacacttatattaaggtgccggccgaagaaatggcgaattacgcccagggttacaataaaaaagaccaaccggtgcgcgtcacgccggggccattggatgccgaagcctacggcatcaaatccaacgcccaggatctgatccgctacctcgacgccaacatgcaggtggtcaaggtcggggatccgtggcgcaaggcgctggcggccacccataccggttattaccgtaccggggtgtttactcaggatctgatgtgggaaagctatgcgtatccagagaagttggcgacgctgacggaaggcaacaatgccgggatgatcatgaacggggcgccggccacggcgataacgccgccgaagcaggatcagggcgcggcctggtacaacaaaaccggttcaaccggcggcttctccacttatgcggtatttatcccttcgcaaaaaattgcggtggtgatgctggccaataaatggttcccgaacgatgaccgggttgcagccacttaccgtattgttcaggcgctggacaaacgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1270,Drugs,MEG_1270|Drugs|betalactams|Class_C_betalactamases|BLAC,1028081083|WP_063840466.1|NG_047385|1|1|bla-C|bla-C|class_C_beta-lactamase NG_047385:101-1237,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagttatgggctggcgtcgaaagaggacggtcgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcaaggcagccgcttcgacggcatcagcctgctcgacctcgcgacctacaccgccggcggcttgccgctgaagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgagcggatcatggagcagcgcctgttcccggccctgggcctcgaacagactcacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctccgggtcggccccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgactggaccggcagtgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatcgccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacagggtcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctggcgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5554,Drugs,MEG_5554|Drugs|betalactams|Class_C_betalactamases|PDC,1408841618|WP_111672891.1|NG_060547|1|1|blaPDC-277|blaPDC|class_C_beta-lactamase_PDC-277 NG_060547:1-1194,0
,atgaaaatcgtaaaaaggatattattagtattgttaagtttattttttacaattgcgtattcaaatgctcaaactgacaacttaactttgaaaattgagaatgttttaaaggcaaaaaatgccagaataggagtagcaatattcaacagcaatgagaaggatactttgaagattaataacgacttccatttcccgatgcaaagcgttatgaaatttccgattgctttagccgttttgtctgagatagataaagggaatctttcttttgaacaaaaaatagagattacccctcaagaccttttgcctaaaatgtggagtccgattaaagaggaattccctaatggaacaactttgacgattgaacaaatactaaattatacagtatcagagagcgacaatattggttgtgatattttgctaaaattaatcggaggaactgattctgttcaaaaattcttgaatgctaatcatttcactgatatttcaatcaaagcaaacgaagaacaaatgcacaaggattggaatacccaatatcaaaattgggcaaccccaacagcgatgaacaaactgttaatagatacttataataataagaaccaattactttctaaaaaaagttatgattttatttggaaaattatgagagaaacaacaacaggaagtaaccgattaaaaggacaattaccaaagaatacaattgttgctcataaaacagggacttccggaataaataatggaattgcagcagccactaatgatgttggggtaattactttaccgaatggacaattaatttttataagcgtatttgttgcagagtccaaagaaacttcggaaattaatgaaaagattatttcagacattgcaaaaataacgtgggattactatttgaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7646,Drugs,MEG_7646|Drugs|betalactams|Class_A_betalactamases|VEB,1049330903|WP_065825678.1|NG_051319|1|1|blaVEB-18|blaVEB|class_A_extended-spectrum_beta-lactamase_VEB-18 NG_051319:101-1000,0
,atgaaaacatttaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_105,Drugs,MEG_105|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,503015906|WP_013250882.1|NG_047288|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_047288:101-655,2
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgtgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcagttttgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgctttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccacggagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagccagcgtattgtcaaacaagccatgctgaccgaagccaatggtgactatattattcgggctaaaactggatactcgactagaatcgaacctaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggaaaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4617,Drugs,MEG_4617|Drugs|betalactams|Class_D_betalactamases|OXA,1226997331|WP_094009808.1|NG_055490|1|1|blaOXA-519|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-519 NG_055490:1-798,0
,GACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGGAAAGGCCCTTCGGGGTACTCGAGTGGCGAACGGGTGAGTAACACGTGGGTGATCTGCCCTGCACTCTGGGATAAGCCTGGGAAACTGGGTCTAATACCGGATAGGACCACACACTTCATGGTGAGTGGTGCAAAGCTTTTGCGGTGTGGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGGGGTAATGGCCCACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGTGACCGGCCACACTGGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGTAGGGACGAAGCGAAAGTGACGGTACCTACAGAAGAAGGACCGGCCAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTCCGAGCGTTGTCCGGAATTACTGGGCGTAAAGAGCTCGTAGGTGGTTTGTCGCGTTGTTCGTGAAAACTCACAGCTTAACTGTGGGCGTGCGGGCGATACGGGCAGACTAGAGTACTGCAGGGGAGACTGGAATTCCTGGTGTAGCGGTGGAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGGTCTCTGGGCAGTAACTGACGCTGAGGAGCGAAAGCGTGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGTACTAGGTGTGGGTTTCCTTCCTTGGGATCCGTGCCGTAGCTAACGCATTAAGTACCCCGCCTGGGGAGTACGGTCGCAAGACTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGGTTTGACATGCGCAGGACGTATCTAGAGATAGGTATTCCCTTGTGGCCTGCGTGCAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCCTATGTTGCCAGCGGGTAATGCCGGGGACTCGTAGGAGACTGCCGGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGTCCAGGGCTTCACACATGCTACAATGGCCAGTACAGAGGGCTGCGAAGCCGCAAGGTGGAGCGAATCCCTTAAAGCTGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCAACGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCATGAAAGTCGGTAACACCCGAAGCCAGTGGCCTAACCTTTTGGAGGGAGCTGTCGAAGGTGGGATCGGCGATTGGGACGAAG,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_11,Drugs,MEG_11|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|NR_114659.1|+|1-1441|ARO:3003515|Mycobacteroides chelonae 16S rRNA mutation conferring resistance to kanamycin A [Mycobacterium] ,2
,atgcgttttaccctgctcgccttcgccctggccgtcgcgcttccggccgcccacgccagcgccgccgaggcaccgctgccacaactgcgggcctataccgtggatgcgtcctggctgcagccgatggcgccgctgcaggttgccgaccacacctggcagatcggcaccgaggacctgaccgcgctgctggtgcagaccgccgagggcgcagtactgctggatggcggcatgccacagatggccggtcacctgctggacaacatgaaactgcgcggcgtggccccgcaggacctgcgattgatcctgctcagccatgcgcatgccgaccacgccggcccggtcgccgagctcaagcgtcgcaccggcgcgcatgtggcggccaatgcagaaacggcggtgctgctggcgcgcggcggcagcaacgacctgcactttggcgacggcatcacctatccgccggccagcgccgaccgcatcatcatggatggcgaagtggtcacggtgggcggcatcgcattcaccgcgcacttcatgccggggcacaccccgggcagcaccgcctggacctggaccgacacccgcgatgggaagccggtgcgcatcgcctacgccgacagcctgagtgcaccgggttaccagctgaagggcaatccccgttatccgcgcctgatcgaggactacaagcgcagcttcgcaacggtacgggcgctgccctgcgatctgctgctcaccccgcatccgggcgccagcaactggaactatgccgccggcagcaaggccagcgccgaggcactgacctgcaacgcctacgcggatgcggccgagaagaagttcgacgcgcagttggccagggaaacggccgggacccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3526,Drugs,MEG_3526|Drugs|betalactams|Class_B_betalactamases|L1,696392814|WP_032966056.1|NG_047501|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047501:100-972,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaagaagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgttggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5586,Drugs,MEG_5586|Drugs|betalactams|Class_C_betalactamases|PDC,1408841619|WP_111672892.1|NG_060549|1|1|blaPDC-279|blaPDC|class_C_beta-lactamase_PDC-279 NG_060549:1-1194,0
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaagtataccgttctttatccgtattagacggagcagtattattagtttctgcaaaggatggcatacaggcacagacccgtatactgtttcatgcactacagataatgaagattccgacaatttttttcatcaataaaattgaccaagaggggattgatttgccaatggtatatcgggaaatgaaagcaaagctttcttcggaaattatagtgaagcaaaaggttgggcagcatccccatataaatgtaacggacaatgacgatatggaacagtgggatgcggtaattatgggaaacgatgaactattagagaaatatatgtcagggaaaccgtttaaaatgtcagaactggaacaggaagaaaacaggagattccaaaacggaacgttatttcccgtttatcacggaagcgctaaaaacaatctggggattcggcagcttatagaagtaattgccagtaaattttattcatcaacgcctgaaggtcaatctgaactatgcgggcaggtttttaagattgaatattcagagaaaaggcggcgttttgtttatgtgcgtatatatagcggaacattgcatttgagggatgttattagaatatctgaaaaagagaaaataaaaatcacagagatgtatgttccgacaaacggtgaattatattcatccgatacagcctgctctggtgatattgtaattttaccaaatgatgttttgcagctaaacagtattttggggaacgaaatactgttgccgcagagaaaatttattgaaaatcctctccctatgatccaaacaacgattgcagtaaagaaatctgaacagcgggaaatattgcttggggcacttacagaaatttcagattgcgaccctcttttaaaatattatgtggatactacaacgcatgagattatactttcttttttggggaatgtgcagatggaagtcatttgtgccatccttgaggaaaaatatcatgtggaggcagaaataaaagagcctactgttatatatatggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaatcaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7153,Drugs,MEG_7153|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,499500588|WP_011187228.1|NG_048260|1|1|tet(O)|tet(O)|tetracycline_resistance_ribosomal_protection_protein_Tet(O) NG_048260:1-1920,4
,ATGAAAATAATCAATATTGGAATTCTTGCCCATGTAGACGCTGGAAAGACGACCTTGACGGAGAGCCTGCTATATGCCAGCGGAGCCATTTCAGAACCGGGGAGCGTCGAAAAAGGGACAACGAGGACGGACACCATGTTTTTGGAGCGGCAGCGTGGGATTACCATTCAAGCGGCAGTCACTTCCTTCCAGTGGCACAGATGTAAAGTTAACATTGTGGATACGCCCGGCCACATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATGAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGCGCGGGAGGAACAGCAGCGGGTTCAAGACGCCTCCCTGTTCCCAGTCTATCATGGCAGCGCCAAAAATGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGGGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTTGAGTACACCGATTGCGGCCAGCGGCGTGTCTATCTACGGTTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCAGGGTGAAATTGTTATCCTTCCCAGCGACAGCGTGAGGTTAAACGATGTATTAGGGGACCAAACCCGGCTCCCTCGTAAAAGGTGGCGCGAGGACCCCCTCCCCATGCTGCGGACGACGATTGCGCCGAAAACGGCAGCGCAAAGAGAACGGCTGCTGGACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGTTGCGAAGTGGATTCCATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTTGTTTCCGCTTTGCTGTCGGAAAAATACAAGCTTGAAACAGTGGTAAAGGAACCCTCCGTCATTTATATGGAGCGGCCGCTCAAAGCAGCCAGCCACACCATCCATATCGAGGTGCCGCCCAACCCGTTTTGGGCATCCATAGGACTGTCTGTTACACCACTCTCGCTTGGCTCCGGTGTACAATACGAGAGCCGGGTTTCGCTGGGATACTTGAACCAGAGTTTTCAAAACGCTGTCAGGGATGGTATCCGTTACGGGCTGGAGCAGGGCTTGTTCGGCTGGAACGTAACGGACTGTAAGATTTGCTTTGAATACGGGCTTTATTACAGTCCGGTCAGCACGCCGGCGGACTTCCGCTCATTGGCCCCGATTGTATTGGAACAGGCATTGAAGGAATCGGGGACGCAGCTGCTGGAACCTTATCTCTCCTTCATCCTCTATGCGCCCCAGGAATACCTTTCCAGGGCTTATCATGATGCACCGAAATACTGTGCCACCATCGAAACGGCCCAGGTAAAAAAGGATGAAGTTGTTTTTACTGGCGAGATTCCCGCCCGCTGTATACAGGCATACCGTACTGATCTGGCCTTTTACACCAACGGGCGGAGCGTATGCCTTACAGAGCTGAAAGGATATCAGGCCGCTGTCGGTCAGCCGGTCATCCAGCCCCGCCGTCCAAACAGCCGCCTGGACAAGGTGCGCCATATGTTTCAGAAGGTAATGTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7233,Drugs,MEG_7233|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,gi|94016154|emb|AJ427421.2|1477-3396,4
,atgatgaaaaaatccctttgctgcgccctgctgctcggcatctcttgctctgctctcgccacgccagtgtcagaaaaacagctggcggaggtggttgcgaatacggttaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaaccgcactattacacgtttggcaaggccgatatcgcggcgaataaatccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccggcgttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagcatcggtctttttggtgcgctggcggtcaaaccttctggcatgccctatgagcaagccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgtgccgaaagcggaagaggcgcattacgcctggggctatcgtgatggtaaagcggtgcgtgtttcgccgggtatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaacgttgctgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcgagggcagtgacagtaaggtagcgctggcgccgttgcccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggctctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaatacaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgaggcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_427,Drugs,MEG_427|Drugs|betalactams|Class_C_betalactamases|ACT,836568411|WP_047726486.1|NG_064665|1|1|blaACT-65|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-65 NG_064665:1-1146,0
,atgcgcctctgcctgactcccctcgccctggctgccacgctcgtcttcgatgtcgctgccgccgacgcaccgctgccgcagctccgggcctacaccgtcgacgcttcgtggctgcagccgatggcaccgctgcagattgccgaccacacctggcagatcggcaccgaggacctgacggcactgctggtgcgaaccaccgggggcgcagtgctattggatggcggcatgccgcagatggccggtcacctgctggacaacatgaaggcacgcggggtggcaccacaggatctacggctgatcctgctcagccatgcgcatgccgaccacgccgggccggtggcggaactcaagcgccgcaccggtgcccaggtggtcgcgaacgccgaaacggccgtgctgctgccgcgcggcagcagcaacgacctgcacttcggtgatgacatcacctacccgccggccagtgccgaccgcatcatcatggatggtgagagggtgacggtaggcggcatggcattcaccgcgcacttcatgccagggcacacccccggcagcaccgcctggacctggaccgatacccgcgatggcaagcccgtgcgcatcgcctacgccgacagcctgagtgcgccgggctaccagctgcagtacaacgcacgctatccccgcctggtcgaggactaccggcgcagcttcacaacggtgcgcggcctgccctgcgacctgctgctgaccccgcatccgggcgccagccgctggaactatgccgccggtgccgaggccggggccaacgtcctgacctgcaaggcctacgcggatgcggccgagaaggcattcgacgcgcagttggccaagggaacgaccggggcccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3517,Drugs,MEG_3517|Drugs|betalactams|Class_B_betalactamases|L1,1028083725|WP_063842693.1|NG_047511|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047511:1-870,0
,ATGAGCGTATCGGAAATCCGACCGATTGCCATTGAGGACGAACTCAAGCATTCATATTTAGATTACGCGATGAGTGTAATTGTATCTCGTGCATTGCCGGATGTGAGAGACGGTCTTAAACCTGTTCACCGTCGTGTGCTTTATGCCATGCACGAATTGGGCAATGACTATAACAAAGCCTACAAGAAATCTGCTCGTGTCGTTGGGGACGTAATCGGTAAATATCACCCGCATGGTGACTTAGCTGTTTATGAAACCATTGTTCGTATGGCTCAAGACTTTAGCTTACGTTATTTATTGGTTGATGGTCAGGGTAACTTCGGTTCGATCGATGGTGATAGCGCTGCGGCAATGCGTTATACCGAAGTCCGTATGACTAAGCTGGCACATGAGCTTCTTGCAGATTTAGAAAAAGACACAGTTGACTGGGAAGATAACTACGACGGTTCGGAACGTATCCCTGAAGTACTTCCGACACGTGTTCCAAACTTGTTAATTAACGGTGCTGCGGGTATTGCTGTAGGTATGGCAACTAACATGGCACCACACAACATGACAGAAGTTGTGAATGCTTGTTTGGCTTATGCTGACAATCCGAATATCTCGATTGAAGGATTGATGGAATACATTACTGGTCCTGACTTCCCTACAGGCGGTATTATTTACGGTAAATCAGGTATTGTTGATGCCTACCGTACCGGTAAAGGTCGTTTACACATACGTGGTAAATACCATTTCGAAGAAGATGAAAAGACAGGTCGTACAACCATCGTCTTTACTGAAATTCCATATCAGGTAAACAAAGCAAGAGTTATTGAACGTATTGCCGAGTTAGTAAAAGAGAAAAAGCTTGAAGGTATTTCAGAACTTCGTGATGAGTCTGATAAAGAAGGTATGCGTATTGCAATTGACTTGAAACGCGGTGAAAACGCAGAAGTCGTTGTAAATAACTTATTCTTAAATACCCAGCTTGAAAACTCATTCAGCATCAACATGGTTTGTCTAGACAATGGACAACCAAAATTGATGAATCTAAAAGATATTATTGCGGCATTTATTCGTCACCGCCAAGAAGTTGTGACACGCCGTACCATGTTCGAATTACGTAAAGCACGTGAACGTGGTCATATCTTGGAAGGCTTGACAGTTGCCTTAGCCAATATTGATGAAATTATTGAAACCATCAAAACTTCTGCAAACCCTGCTGAAGCGCGTGAGCGTTTACTTGCGGGTGAGTGGGCAGGTGGTGGCGTTGTTGCACTACTTGAAAAAGCTGGTGCAATTTCTGTTCGCCCAGATGAAATTGAAGGTGAAGATCCAAATCGTCCATTTGGTTTAAGTGATTCAATTTATCGTCTGTCACCAACACAAGTAGGCGCAATTTTAGAATTACGTTTACACCGTTTAACTGGTCTTGAACAAGACAAGTTACATGCGGAATATACTGAAATTTTAGGTCAAATTGCTGAACTTACTGCAATTTTAAATGACTTCAACTTGTTAATGGGTGTTATTCGCGAAGAGTTGGCACAAGTTTTACAACAATATGGTGATGCACGTCGTACCGAAATTGTTGAATCTCGTGTGGATTTCTGCCGTGAAGATTTAATTCCTGAAGAGCAAGTGGTATTAACTGTTTCACAAACAGGTTATGCAAAAACTCAACCACTTTCAGACTATCAGGCACAGCGCCGTGGTGGACGTGGTAAGTCTGCAACCTCTATGAAAGATGATGACTTTATTCAACATCTGATTGTGGCATCGAACCACGCGACCGTACTTTGCTTTACCAACGTGGGTAAAGTGTACCGTTTGAAAGTATTTGAGGTTCCTCAAGCATCACGTGGGGCAAAAGGCCGTCCAATCGTGAACTTGTTACCTCTAGATGCAACAGAAACCGTAACTGCAATCTTGCCATTAACCGAGTTCCCGGAAAACCACTATGTGTTTATGGCGACAGCTTCTGGTACGGTTAAGCGTGTTGAGTTAGAACAATTTGCAAACATTCGTTCAAATGGTCTACGTGCTATTGAACTTAATGAAGAAGATACCTTAATTGGTGTTGCGATTACTGATGGTAATCAGCAAATCATGTTGTTCTCTAACGAAGGTAAAGCAATTCGTTTTGCTGAAACTGACGTACGTGCAATGGGTCGTACAGCGAAAGGTGTACGTGGTATGCGTGTAAGCTTTGCAAGCAGCACCTTAAGTGAAGAAGATGCAGATGTTGAAAATGATGATTCAGATGATAATGATGATTCAGCAGATTCAAGTCTAGTAAGTCGCATCGTATCGCTTGTTGTTGTACCTGAGACAGGCGAAGTACTGTGCGCGAGTGCCAACGGTTATGGTAAACGTACTCCAGTAAATGACTTCCCGACCAAGAAACGTGGTGGTAAGGGTGTTATTGCGATCAAGACAAGTGAACGTAACGGTGAGCTAGTTGGTGCAGTTTCTATTGATGAAACCAAAGAGTTATTATTAATTTCTGATGGTGGTACGCTTGTTCGTACGCGTGCTGCAGAAGTTGCAATGACAGGCCGTAATGCTCAAGGTGTTCGTCTGATCCGTTTAAGCGAAGAAGAAACGCTTGTTGGCGTAGTTTCAATTGAAGCTGTAGAAGACGAAGAAGAACTTCTTGAAGGTGAAGTAGATACGACTGAAACTGATAGCGAAGAAGCTGTATCTAATAATGAAGATACTTCTGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3215,Drugs,MEG_3215|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|602249473|gb|KC118540.6|117170-114456 gi|213054530|gb|CP001182.1|3132795-3130081,3
,atgtccgttaagttcctcgtccccatcgctttcgctttgtcgggctgcgcagtcctgcctccaccgatccagacgccggagcctctgcctccggccgaagaggtccagcctgaacaatgggcggctacctgcgagccttgggatgattgggacaaacccgccccgccctatcgtatcttcggttcgacctattatgtcggcacctgcggcatttccgcgatcctcatagcaggcgacgatggacacatcctgatcgacagcgggaccgaggaaggcgccgaggtcgtcatggacaacatccagaagctgggcttccggctcaacgagatcgcgagcatcctccacagccacgaacatttcgaccatgtcggcggtctggccaaacttcgcgccgcgaccggggcgcatatcgtttcatcggcggaagcagcgaaggtgctctcgacgggagaggaccatccggaggacccgcagttcggggtccatgagccgatggagccggtgcaggtcgatgtcatcgtcgaagacggagacacggtacgcacagagaccgctacggtcacggcacatgcgacgcccggccacagtccgggcgcactcagttggacctgggtgagttgcagcctgccgggcgaaccgccagcctgcagcaggatcgcctatgtcgacagtctgtcggccgtttcttccgatgactatcgctttaccgaccaccccgaggtcgtggccgcattccgcaccagcatagacaaggtacggtccctgccctgcgatatcctcctcactccgcatccctcttccagccaattgatcgagcggttgcgcaccgggacgcttggcgcaccgggcaaatgtgccacctatgcggcgcaactcggcgataagctcgacgaacggcttgcgaaagaaaacccgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2871,Drugs,MEG_2871|Drugs|betalactams|Class_B_betalactamases|EVM,1509794514|WP_122630823.1|NG_062205|1|1|blaEVM-1|blaEVM|subclass_B3_metallo-beta-lactamase_EVM-1 NG_062205:1-918,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCCTCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCATTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACTGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAACCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAACGTTACCGATATGGCACGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCGGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1836,Drugs,MEG_1836|Drugs|betalactams|Class_C_betalactamases|CMY,(Bla)CMY-13:AY339625:3641-4786:1146,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCACTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGTTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6441,Drugs,MEG_6441|Drugs|betalactams|Class_A_betalactamases|SHV,gi|257043791|gb|GQ407137.1|1-861,0
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAATTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGACATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCGCCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1358,Drugs,MEG_1358|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_45_CP010941,0
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattataatacaagcgggacttttatggtttttgatggaaaaaattatgcaagtaatgattttaaaagagctaaaaaagctttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgttctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgataccttttggctagataattctttacaaatttctgcaaaaaatcaagttgatttactttttaaactttcgcaaaattctttacctttttctaaaaaaattcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattattaaataagtatttagctaattttttcaacaataataggattaaaagcttttactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4574,Drugs,MEG_4574|Drugs|betalactams|Class_D_betalactamases|OXA,1391852928|WP_109545113.1|NG_057549|1|1|blaOXA-618|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-618 NG_057549:1-774,0
,ATGGCAAAGCAACAAGATCAAGTAGATAAGATTCGTGAAAACTTAGACAATTCAACTGTCAAAAGTATTTCATTAGCAAATGAACTTGAGCGTTCATTCATGGAATATGCTATGTCAGTTATTGTTGCTCGTGCTTTACCTGATGCTAGAGATGGACTTAAACCAGTTCATCGTCGTGTTCTTTATGGTGCTTATATTGGTGGCATGCACCATGATCGTCCTTTTAAAAAGTCTGCGAGGATTGTTGGTGATGTAATGAGTAAATTCCACCCTCATGGTGATATGGCAATATATGACACCATGTCAAGAATGGCTCAAGACTTTTCATTAAGATACCTTTTAATTGATGGTCATGGTAATTTTGGTTCTATAGATGGTGATAGACCTGCTGCACAACGTTATACAGAAGCAAGATTATCTAAACTTGCAGCAGAACTTTTAAAAGATATTGATAAAGATACAGTTGACTTTATTGCTAATTATGATGGTGAGGAAAAAGAACCAACTGTTCTACCAGCAGCTTTCCCTAACTTACTTGCAAATGGTTCTAGTGGGATTGCAGTTGGAATGTCAACATCTATTCCTTCCCATAATCTCTCTGAATTAATTGCGGGTTTAATCATGTTAATTGATAATCCTCAATGCACTTTTCAAGAATTATTAACTGTAATTAAAGGACCTGATTTTCCAACAGGAGCTAACATTATCTACACAAAAGGAATTGAAAGCTACTTTGAAACAGGTAAAGGCAATGTAGTAATTCGTTCTAAAGTTGAGATAGAACAATTGCAAACAAGAAGTGCATTAGTTGTAACTGAAATTCCTTACATGGTTAACAAAACTACCTTAATTGAAAAGATTGTAGAACTTGTTAAAGCTGAAGAGATTTCAGGAATTGCTGATATCCGTGATGAATCCTCTCGAGAAGGAATAAGGTTAGTGATTGAAGTAAAACGCGACACTGTACCTGAAGTTTTATTAAATCAACTTTTTAAATCAACAAGATTACAAGTACGCTTCCCTGTTAATATGCTTGCTTTAGTTAAAGGAGCTCCTGTACTTCTCAACATGAAACAAGCTTTGGAAGTATATCTTGATCATCAAATTGATGTTCTTGTTAGAAAAACAAAGTTTGTGCTTAATAAACAACAAGAACGTTATCACATTTTAAGCGGACTTTTAATTGCTGCTTTAAATATTGATGAGGTTGTTGCAATTATTAAAAAATCAGCAAATAACCAGGAAGCAATTAATACATTAAATACAAAGTTTAAGCTTGATGAAATTCAAGCTAAAGCAGTTCTTGACATGCGTTTAAGGAGCTTAAGCGTACTTGAAGTTAACAAACTTCAAACTGAACAAAAAGAGTTAAAAGATTCAATTGAATTTTGTAAGAAAGTGTTAGCTGATCAAAAATTACAGCTAAAAATAATCAAAGAGGAATTGCAAAAAATCAATGATCAGTTTGGTGATGAAAGAAGAAGTGAAATTCTCTATGATATCTCTGAGGAAATTGATGATGAATCATTGATAAAAGTTGAGAATGTAGTGATAACTATGTCTACAAATGGTTATCTAAAAAGGATTGGAGTTGATGCTTATAATCTTCAACATCGTGGTGGAGTTGGGGTTAAAGGGCTAACTACTTATGTTGATGATAGTATTAGTCAATTATTGGTCTGTTCAACTCACTCTGACTTATTATTTTTTACTGATAAGGGTAAGGTTTATAGAATTAGAGCTCATCAAATTCCCTATGGTTTTAGAACAAATAAAGGTATTCCCGCTGTTAACTTAATCAAAATTGAAAAGGATGAAAGAATTTGTTCATTGTTATCTGTTAATAACTATGATGATGGTTATTTCTTTTTCTGTACTAAAAATGGAATTGTTAAAAGAACGAGCTTGAATGAATTCATCAACATCTTAAGTAATGGTAAGCGGGCTATATCTTTTGATGATAATGACACTTTGTATTCAGTAATTAAAACCCACGGAAATGATGAGATTTTTATTGGTTCTACCAATGGATTTGTTGTTCGCTTCCATGAAAATCAACTCAGAGTTCTTTCAAGAACAGCAAGAGGTGTATTTGGTATCAGTTTAAATAAAGGAGAATTTGTTAATGGACTATCAACTTCAAGCAACGGTAGCTTACTTTTATCAGTCGGTCAAAATGGAATAGGTAAATTAACGAGCATAGATAAATATAGACTCACAAAACGTAATGCTAAGGGAGTTAAAACTCTAAGGGTTACTGATAGAACAGGCCCTGTTGTTACAACAACCACTGTTTTTGGTAATGAGGATCTTTTAATGATTTCCTCTGCTGGTAAAATTGTGCGTACCAGTTTACAAGAACTTTCAGAACAAGGTAAAAACACTTCTGGTGTTAAGTTAATTAGATTAAAAGATAATGAACGTTTAGAAAGAGTAACTATCTTTAAAGAAGAGTTAGAAGACAAAGAAATGCAACTAGAAGATGTTGGATCCAAACAAATTACGCAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3185,Drugs,MEG_3185|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|L43967.2|+|4811-7322|ARO:3004631|Mycoplasma Genitalium GyrA mutation confers resistance to fluoroquinolones [Mycoplasma genitalium G37] ,3
,atgagtattcaacattttcgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcagtcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6680,Drugs,MEG_6680|Drugs|betalactams|Class_A_betalactamases|TEM,1393270465|WP_109791210.1|NG_057609|1|1|blaTEM-234|blaTEM|class_A_beta-lactamase_TEM-234 NG_057609:1-861,0
,atgaggctgcacgggaatcaagtggtgctgcgcgcggtgaccgagagcgacatcgggacccttgacaggatcgtgcgggaaccggaggtcgcggcgtggtggtcgccccccgaggactacgggggcatgctggccgtcgtcttcgagggtgaggtcgtcggcgcggtccagttccacgaggagaccgatcccgagttccgccacgccggcatcgacatcttcctgacggcacggcagcacgggaagggactcggcaccgacacggtgcgcacgctggcccgttggctggtggaggaacgcggccaccaccggctgaccatcgaccccgccgcggccaacaccgcggcgatccgctgctacgccggggtcggcttcaaacccgtgggaatcatgcgggcctacgcccgcgaccaccgcacgggcacctggcaggacggtctgctgatggacctgctcgcggccgagctgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_133,Drugs,MEG_133|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,926302680|WP_053638058.1|NG_052206|1|1|aacA-STR-7|aacA-STR-7|aminoglycoside_6'-N-acetyltransferase NG_052206:101-574,2
,gtgagcgacctggagctgcgcggcgagcgggtcctgctccgctccaccacccccgccgacaccgccgcgctcgaccggatcgtccgcgagccggaggtcgcgctgtggtggccgccgcccgaggggtacgcgcggatgctcgccgtcgtcgtggacggcgaggtgatcggcgcgatccagttcagcgaggagaccgacccggagttccgccacgccggcatcgacctcttcctgtcggcccggtggcacgggcagggcctgggccccgacgccgtccgcaccctggcccgctggctgatcgccgagcgcggccaccaccgcctggtcatcgacccggccgccgccaacacgtacgccgtgcgcagctaccgcaaggtcggcttcgccccggtcgggatcatgcgcgcctactggcgcgaccaccgcaccggggagtgggaggacggcctgctcatggacctgctggcggccgaactgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_250,Drugs,MEG_250|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,517723415|WP_018893623.1|NG_052532|1|1|aacA-STR-13|aacA-STR-13|aminoglycoside_6'-N-acetyltransferase NG_052532:101-583,2
,AACACACTGATTGCGTCTGACGGGCCCGGACACCCTTTTGCTTTTAATTACGGAACTGATTTCATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACGATGAGGCCCAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1955,Drugs,MEG_1955|Drugs|betalactams|Class_C_betalactamases|CMY,gi|336318752|gb|JF780936.1|1-1226,0
,atggataaacttccaaatttcatatttgaaaactatagtgacttaaaaattgaacgagatactgagggttggtctccggctgaggtatatagtgttacaaccaagaaaaaaaggtggtttctaaaaagaagtcatacgagatacaataaaactacatataatgtaagaagagagaaagaaattattgaatgggcctatccaaagtttagagtaccacaaataatacattatgaagaagcaaaagaatataattcattactaatgaatcacattggcggctctagccttgaaatgcttggtccatcaattactttagagaaatatatcgattactatgtacaatccttaaaattaatgcagtccattaacatcgaaaactgtccatacaataattgtataaagaatagaataatcgaattagaatatttattagagaatgatctagcagatattaattcaaataactgggaagaagatacgcgtgagcatttcagaaacggtaaagacttatttaattatatagtaaataataagccaaatgaagacttagttttctcacatggagatatgacaaactctaacatatttattgaaaacgaagaagttggatttatagatctcggtcgatgtggattagctgataagtgggttgatattgcattttgtgttagagatataagagaaataagtaatgaaaataaatggataaagatgttatttgataaattagaaatagtacccaattgggataaaatgagatactacattttgttagatgagctgttctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1059,Drugs,MEG_1059|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-PRIME,490312881|WP_004206941.1|NG_051908|1|1|aphA16|aphA16|APH(3')_family_aminoglycoside_O-phosphotransferase_AphA16 NG_051908:101-889,2
,atgcgttctaccctgctcgccttcgccctggccgtcgctcttccgtccgcccacgccagcgccgccgaggcaccgctgccacaactgcgggcctataccgtggatgcgtcctggctgcagccgatggcgccgctgcaggttgccgaccacacctggcagatcggcaccgaggacctgaccgcgctgctggtgcagaccgccgagggcgcagtactgctggatggcggcatgccacagatggccggtcacctgctggacaacatgaagctgcgcggcgtggccccgcaggacctgcgattgatcctgctcagccatgcgcatgccgaccacgccggcccggtcgccgagctcaagcgtcgcaccggcgcgcatgtggcggccaatgcagaaacggcggtgctgctggcgcgcggcggcagcaacgacctgcactttggcgacggcatcacctatccgccggccagcgccgaccgcatcatcatggacggcgaagtggtcacggtgggcggcatcgcattcaccgcgcacttcatgccggggcacaccccgggcagcaccgcctggacctggaccgacacccgcgatgggaagccggtgcgcatcgcctacgccgacagcctgagtgcaccgggttaccagctgaagggcaatccccgttatccgcgcctgatcgaggactacaagcgcagcttcgcaacggtacgggcgctgccctgcgatctgctgctcaccccgcatccgggcgccagcaactggaactacgccgtcggcagcaaggccagcgccgaggcactgacctgcaacgcctacgcggatgcggccgagaagaagttcgacgcgcagctggccaaggaaacggccggggcccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3524,Drugs,MEG_3524|Drugs|betalactams|Class_B_betalactamases|L1,1028083721|WP_063842689.1|NG_047506|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047506:1-873,0
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAATGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAACTGGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2403,Drugs,MEG_2403|Drugs|betalactams|Class_A_betalactamases|CTX,gi|56554764|gb|AY847144.1|82-962,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATACTAAAGAGTTAAATAATTTAGAAAAAAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTACAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAAGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1423,Drugs,MEG_1423|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_132_AHVO01000010,0
,ATGAGCGATATGGCAGAGCGCCTTGCGCTACATGAATTTACGGAAAACGCCTACTTAAACTACTCCATGTACGTGATCATGGATCGTGCGTTGCCGTTTATTGGCGACGGCCTGAAGCCGGTACAGCGCCGCATCGTCTATGCGATGTCAGAGCTGGGGCTGAACGCCAGCGCTAAATTTAAAAAATCCGCCCGTACCGTCGGTGACGTACTGGGTAAGTATCATCCGCACGGCGACAGCGCCTGCTATGAAGCCATGGTGCTGATGGCGCAGCCGTTCTCTTACCGTTACCCGCTGGTCGATGGCCAGGGAAACTGGGGCGCGCCGGATGATCCGAAGTCATTCGCGGCAATGCGTTATACCGAATCTCGCCTGTCCAAATATGCCGAGCTGCTGTTAAGCGAACTCGGCCAGGGGACGGCGGACTGGGTGCCAAACTTCGACGGCACGATGCAGGAACCGAAAATGTTACCGGCGCGTCTGCCGAACATCCTGCTGAACGGCACCACCGGTATTGCGGTGGGGATGGCAACAGATATCCCGCCGCACAACCTGCGCGAAGTGGCGAAAGCGGCGATTACGCTGATTGAGCAGCCGAAAACGACGCTGGATCAGTTGCTGGATATCGTCCAGGGGCCGGATTACCCGACCGAAGCGGAGATCATTACCCCACGTGCGGAAATTCGTAAAATTTACGAAAACGGGCGGGGCTCCGTGCGTATGCGCGCGGTATGGACCAAAGAAGACGGCGCCGTGGTAATTTCCGCGCTGCCGCATCAGGTCTCTGGCGCGAAAGTGCTGGAACAGATTGCTGCGCAGATGCGTAATAAAAAACTGCCGATGGTGGACGATCTGCGCGATGAATCAGATCACGAAAACCCGACGCGTTTAGTGATTGTCCCGCGCTCCAACCGTGTGGATATGGAGCAGGTGATGAACCATCTGTTCGCCACCACCGATCTGGAAAAAAGCTACCGTATTAACCTGAACATGATCGGTCTGGATGGTCGTCCGGCGGTGAAAAACCTGCTGGAGATCCTCACCGAGTGGTTGGCGTTCCGTCGCGACACGGTACGCCGTCGTCTGAACTATCGTCTGGAGAAAGTGCTTAAGCGCCTGCATATTCTCGAAGGTTTGCTGGTGGCGTTTCTCAACATCGACGAAGTGATTGAGATTATCCGTAACGAGGATGAGCCAAAACCCGCGCTGATGTCGCGTTTCGGCATCAGCGAAACCCAGGCGGAAGCGATTCTCGAACTGAAACTGCGCCATCTCGCCAAACTGGAAGAGATGAAAATTCGCGGCGAGCAGGACGAGCTGGAAAAAGAGCGTGACCAGTTGCAGGGCATTCTCGCGTCCGAACGCAAAATGAATACCTTGCTGAAAAAAGAACTACAGGCGGACGCCGATGCCTATGGCGACGATCGCCGTTCTCCGCTGCGTGAGCGCGAAGAAGCTAAAGCGATGAGCGAACACGACATGCTGCCGTCCGAACCGGTGACTATCGTGCTGTCGCAGATGGGCTGGGTGCGCAGCGCCAAAGGTCATGATATTGATGCGCCGGGGCTTAACTATAAAGCGGGCGACAGCTTTAAAGCCGCGGTGAAAGGTAAGAGCAATCAACCGGTGGTGTTTATTGATACCACCGGGCGCAGCTATGCTATTGATCCCATTACGCTTCCGTCGGCGCGTGGGCAGGGCGAGCCGCTGACCGGCAAACTCACGCTGCCGCCGGGGGCGACCGTGGAGCATATGCTGATGGAAGGCGATGACCAGAAACTGCTGATGGCGTCGGATGCGGGCTACGGCTTCGTTTGTACGTTTAACGATCTGGTTGCCCGTAACCGTGCCGGTAAAGCGTTGATTACACTGCCGGAAAATGCGCACGTCATGCCGCCGCTGGTGATTGAAGACGAGCACGATATGCTGCTGGCGATTACCCAGGCCGGACGGATGTTGATGTTCCCGGTAGACTCTCTGCCGCAGCTGTCGAAAGGCAAAGGGAATAAGATCATTAATATCCCCTCTGCGGAAGCGGCGAAAGGCGATGATGGACTGGCGCACCTGTACGTGCTGCCGCCACAAAGCACTCTGACTATCCATGTCGGGAAGCGCAAAATCAAACTGCGCCCTGAAGAGTTACAGAAGGTGGTCGGCGAACGCGGACGCCGTGGCACATTAATGCGCGGCCTGCAGCGTATCGATCGCATTGAGATTGATTCACCGCATCGCGTAAGTCATGGCGACAGCGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5353,Drugs,MEG_5353|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|807109228|gb|CP011259.1|294232-291974 gi|563346448|gb|CP006876.1|3226439-3224181 gi|197211055|gb|CP001138.1|3260817-3258559,3
,atgaataaatcgctcatcattttcggcatcgtcaacataacctcggacagtttctccgatggaggccggtatctggcgccagacgcagccattgcgcaggcgcgtaagctgatggccgagggggcagatgtgatcgacctcggtccggcatccagcaaccccgacgccgcgcctgtttcgtccgacacagaaatcgagcgtatcgcgccggtgctggacgcgctcaaggcagatggcattcccgtctcgctcgacagttatcaacccgcgacgcaagcctatgccttgtcgcgtggtgtggcctatctcaatgatattcgcggttttccagacgctgcgttctatccgcaattggcgaaatcatctgccaaactcgtcgttatgcattcggtgcaagacgggcaggcagatcggcgcgaggcacccgctggcgacatcatggatcacattgcggcgttctttgacgcgcgcatcgcggcgctgacgggtgccggtatcaaacgcaaccgccttgtccttgatcccggcatggggttttttctgggggctgctcccgaaacctcgctctcggtgctggcgcggttcgatgaattgcggctgcgcttcgatttgccggtgcttctgtctgtttcgcgcaaatcctttctgcgcgcgctcacaggccgtggtccgggggatgtcggggccgcgacactcgctgcagagcttgccgccgccgcaggtggagctgacttcatccgcacacacgagccgcgccccttgcgcgacgggctggcggtattggcggcgctaaaagaaactgcaagaattcgttaa,beta-lactamase,antibiotic target replacement,Sulfonamides,MEG_6582,Drugs,MEG_6582|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,446966009|WP_001043265.1|NG_048118|1|1|sul2|sul2|sulfonamide-resistant_dihydropteroate_synthase_Sul2 NG_048118:101-916,8
,ATGAACATTAAAGCACTCTTACTTATAACAAACGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTCTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGACAACCACCACAGAAGTATTTAAGTGGGACGGGCAAAAAAGGCTATGCCCAGAATGGGAAAAGGACATGACCCTAGGCGACGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCCAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGAAATATTGTAGCATTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5182,Drugs,MEG_5182|Drugs|betalactams|Class_D_betalactamases|OXA,ABX45060.1 EU255290.1:1-825,0
,ttgcaaattcgactaatggatgaagcttctttgagcatgtgggttgggcttcgaagtcagctatggccagaccatagctatgaaaatcatattctggatggccaacacattttatcttgtcccgataaatatgtttcattcctggcactaaataaccagagtcaggcaatagcgtttgccgatgccgcggttcgccatgattatgtgaatggttgtgaaagcagtccggtggtttatcttgaagggatttttgttattcctgagcagagaggccatggcgttgccaaactactggttgcagccgtacaggattggggagtggcgaaaggttgcaccgagatggcaagcgatgcgtctttagataaccatatatcctatcaaatgcatcaggctttaggctttgaagaaaccgaacgcgtggtatttttcagaaaaagaatagctggttaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_270,Drugs,MEG_270|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,851962760|WP_048233550.1|NG_052054|1|1|aac(6')-If|aac(6')-If|aminoglycoside_N-acetyltransferase_AAC(6')-If NG_052054:101-550,2
,atgatcatgtcgaaaaaattaacatgtctggccctgtttacagccatcttttttgcgattcccatggccgcttgtcaaagttttagtcaacaaaagcaacagctttcgacacagaaaaatgaacagcaacagatttcaagcttatttcagagtgcccaaaccagtggtgttttggtgatttatgatggcaagaaaattcaaagctatggcaatgatcttgatcgtgcagaacagcgctatattcctgcctcaacctttaaaatgttaaacgccttgatcggcatacagcatcataagaccacaccagatgaagtgtttaaatgggatggtaaaaagcgggcattcagcagttgggaaaaagatttaaccttggctgaagccatgcaggcatcggcggtacctgtctatcaggaattggcacgacgtattggcttagaactgatgacccgtgaagtgaagcgtgtaggttatggcaataaaaatatcgggacgcaagttgatactttctggttggttggcccattaaaaatcacccccgtagaagaagttcgctttgcctatgcattggcaaaacagaagctgccatttgaccagccaacgcagcaacaagtcaaagcgatgttattggtggatcagattcagggaactaaaatctatgccaaaagtggttggggcatggatgttagccctcaagtggggtggttgacaggctggattgaacagccaaacggtaagatcactgccttctcgctcaatatgcaaatgagtcagcctgaacatgcagatgcacgcaaagtgattgtgtatcaagccttgcaacagttgggattgttagcccattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4594,Drugs,MEG_4594|Drugs|betalactams|Class_D_betalactamases|OXA,507091682|WP_016162389.1|NG_062214|1|1|blaOXA-673|blaOXA-286_like|OXA-286_family_class_D_beta-lactamase_OXA-673 NG_062214:101-943,0
,ATGGGGGTTCTAAACGTCACGGACGACTCTTTCTCGGACGGCGGGTGTTATCTCGATCTCGACGATGCGGTGAAGCACGGTCTGGCGATGGCAGCCGCAGGTGCGGGCATCGTCGACGTCGGTGGTGAGTCGAGCCGGCCCGGTGCCACTCGGGTTGACCCGGCGGTGGAGACGTCTCGTGTCATACCCGTCGTCAAAGAGCTTGCAGCACAAGGCATCACCGTCAGCATCGATACCATGCGCGCGGATGTCGCTCGGGCGGCGTTGCAGAACGGTGCCCAGATGGTCAACGACGTGTCGGGTGGGCGGGCCGATCCGGCGATGGGGCCGCTGTTGGCCGAGGCCGATGTGCCGTGGGTGTTGATGCACTGGCGGGCGGTATCGGCCGATACCCCGCATGTGCCTGTGCGCTACGGCAACGTGGTGGCCGAGGTCCGTGCCGACCTGCTGGCCAGCGTCGCCGACGCGGTGGCCGCAGGCGTCGACCCGGCAAGGCTGGTGCTCGATCCCGGGCTTGGATTCGCCAAGACGGCGCAACATAATTGGGCGATCTTGCATGCCCTTCCGGAACTGGTCGCGACCGGAATCCCAGTGCTGGTGGGTGCTTCGCGCAAGCGCTTCCTCGGTGCGTTGTTGGCCGGGCCCGACGGCGTGATGCGGCCAACCGATGGGCGTGACACCGCGACGGCGGTGATTTCCGCGCTGGCCGCACTGCACGGGGCCTGGGGTGTGCGGGTGCATGATGTGCGGGCCTCGGTCGATGCCATCAAGGTGGTCGAAGCGTGGATGGGAGCGGAAAGGATAGAACGCGATGGCTGA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2970,Drugs,MEG_2970|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|984994143|gb|CP010340.1|4064308-4063490 gi|984989958|gb|CP010339.1|4037434-4036616 gi|984985728|gb|CP010338.1|4055014-4054196 gi|984981517|gb|CP010337.1|4039875-4039057 gi|984976917|gb|CP010336.1|4045889-4045071 gi|984972452|gb|CP010335.1|4057576-4056758 gi|984967653|gb|CP010334.1|4028670-4027852 gi|984963331|gb|CP010333.1|4027755-4026937 gi|984959134|gb|CP010332.1|3983950-3983132 gi|984954355|gb|CP010331.1|4006020-4005202,8
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGGTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1872,Drugs,MEG_1872|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EF685372|+|0-1143|ARO:3002041|CMY-30 [Escherichia coli] ,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtattattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgataagcctggtaaatattggaaagaactaaaaaatacaccgattgaccaagttaatttacttcaactcgcgacgtatacaagtggcaacctcgctttacaatttccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaagaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcatttggttataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcaacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaaagggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatatagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgagtgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_601,Drugs,MEG_601|Drugs|betalactams|Class_C_betalactamases|ADC,974662282|WP_059247009.1|NG_064707|1|1|blaADC-184|blaADC|class_C_beta-lactamase_ADC-184 NG_064707:1-1152,0
,ATGAAACATGATTTTGTCTTTGTAGACGAGTTTGTATCAGGAATACGCTGGGACGCTAAATACGCCACATGGGATAATTTTATCGGCAAACCGGTGGACGGATATGCAGCCAATCGAATTGTCGGTACGAGAGCTTTGTGCTTAAGTCTGGAAAAAGCACGAGAAAAAGCCTCATCCTTTGGCTTTGGCTTGCTTCTTTGGGATGGTTATCGCCCTCAAAGTGCCGTAGATTGTTTTCTGCGCTGGTCAAAACAGCCGGAAGACGGCCGGACGAAACTGAAACACTATCCTAATATTGACCGATCCGAGATAGTAGCAAAAGGATATGTGGCCGCTAAGTCGGGTCACAGCCGGGGCAGCGCAATTGACTTAACACTTTATCATTTAGCTTCCGGAATACTTGTGCCAATGGGCGGCGGCTTTGATTTAATGGATTCGGTCTCACATCATGGAGCAAAAGGAATCACACAAGCCGAAGCAAGAAACCGTCAATACCTTTGTTCTATCATGGAGGCCAGCGGTTTTGTTTCCTACGATTGCGAATGGTGGCATTACACACTGAAACACGAACCATATCCAAATACTTATTTTGATTTTCTCATCGCCTAGTTGAGCCGGAAAACTGTGAGGTGCTTGTTTACAATGGAAATGACGGTACAGAAAATCGTCGCCGCGTGCGGCGGAAAATTACTCTGCGGGAACCCGGATACGCTGGTGACCTCGGTGGTGACCGACAGCAGGGAGGTGGCCGGCGGTTCCCTGTTTGTCCCCCTCAAAGGAGAAAAGACGGACGCCCACACCTTTCTGCACGCCGCATTCGCCTCGGGCGCGGCCACGGTGTTGACCCAGGAGCATACGCAGACGGAGGCGGAAGAAGCCTGGATCGCGGTGGATTCGACTCAGCCGGCGCTCCAGAACATTGCCGCCGCCTATCGACAGAGATTTCCCATCCCTGTCGTTGGGATCACGGGGAGCGTCGGGAAGACGACGACGAAAGAAATGGTTGCTCTGGCACTCGCCGCAAGATACAAGGTGATGAAGACGAGGGGAAACCATAACAGCCAGATCGGACTGCCTCTGATGATGTTCGAGTTTTCCGGGGAACATGAAGCGGCGGTGGTGGAGATGGGGATCAGCGATTTCGGCGAAATGGCTTGCCTGGCTCGGGTCGCCGAGCCGAAGTACGCCGTTATGACCAACATCGGTATTACCCACATCGGCCAGCTCAAAACCCAGGAGAACATCCTGGGGGAGAAGCTGCACATCACCGATCGGTTCACACAGGGTTCTGTTCTGTTTTTAAACGGGGATGACCCCATGCTCGCCGGCCTCCGCGGAAAGACAACCTATGAGACCGTCTTTTACGGCAGGGCGCCCTGGTGCGATTTCCGCGCGGAGGGGATTACGGTTCAAAAGGAAACCACCACTTTCCGCTGCCTTGCTCCGGGGAGAGAGTGTGTCGATGTGAACCTGCCGGTACTTGGTATGCACCATGTTCTGGATGCCCTCGCCGGTCTTGCCGTGGCGGAGCGGCTGGGCGTACCCCTGGACCGGGCCGTCACCGCCCTTGGGGATTACCGCCCCCTGACCATGCGCCAGCAGATTTACCATGTCAATGAGGTTACCGTCATCGACGATTCCTACAACTCCAGTCCCGACGCGGCCAAAAGCAGCCTGAGCGTCCTTGCGGGGTTCCGGACCGGCCGCAGAGTAGCCGTGCTGGCGGATATGCTCGAACTGGGGGAGTATTCCCGGCAGGCGCATTTTGAAGTCGGTGTCTGCGCCGCGGAAAAGGGAGTCGATATTTTACTCACCGTCGGTCCGGAGGCGAAAGCCGTGGCCGAGGGCGCGCGCTCCGTCCGGTCCGGGATCGACTGCCGCGTTTTGGACAATAACGATCAGGCCGCAGCGGAGTTGAAATCCTTTCTGTCTTCCGGCGACGCGGTTCTGGTCAAAGGCTCCCGCGGCATGCATACGGACGAGATCGTCCGTGCCCTGCTTTAGCTTCCCACATCTCTGAAACTGATTTCAAGTTTCTGAACATGCTGAGAAACAGAACTGGCAGTGCTCCGGAGAATACCATCGGCAACGCAGCAGGGCAACCAGGACAGTTCGTCCAGACAAAATGGAGTGTAATTTTCTTGATGTTAAAAGTAGATAAAATAAGTGAAGAAATCTATTATTCCTTTATTTCTCAAGCAGATTTAGGCAATTTTATGCAGTATCCTTCCTGGGCCAAGGTCAAAACCGAGTGGACCAGCGATTTATTGGGGTGGTTTACCCCGGATAAGAAATTGGTAGGGTGTGGTTTAGTTTTATACCGGAAAATGCCCTGCCTTAACCGGTACCTGGCTTATTGTCCCCGCGGCCCGATTATTGACTGGCAGAGCTCCAACCTCAAGGAATGGTTTGAACCATTTCTTGCTTATTTGAAGAGCAAGCACGTTTTCAGTGTCAAAATCGACCCTCCGGTAGTACAGGCAAAATGGTCTACTCCTATAATTAAGAAGTTTTTAGAGCAAGCTCGAGAACAGGGCAGCTCCGGTAAAGTTTTGCGTGATTTGCCACCTGATGAGGACTACGCAACGGCCCAACAGGTGCAGCAGCAATTACGGCAAATCGGTTGGCAGAAGCAGGGAGGTGATACGGGTTTCGCCGCGACCCAACCCGAATATGTTTACCGCCTGCCCTTAAAGGGGCGCAGCTTGACTGAGATCTTCGCCTGTTTTCATACCAACTGGAGGCGCAACGTTAAAAAGGCTGAGCGGTTAGGCGTCAAGGTCCGAGTCGGGACAGAACAGGATTTACCGGCTTTCTACGAGCTGCTGAAGGTAACTTCAGAACGGGATCAATTCAAGGTGCGTACTTTCTCCTACTTTTCCAACCTGTACCGGTCATTAAAGGCTGAAACAGCCGACCGTATTAATCTTTATCTGGCGGAAGACGAAGAGGAATTATTGGCTGCAACCTTAGCTGTCCATTCCAACTTCCACTCATGGTATCTTTACGGGGCCAGCAGCAATGTGAAACGGGAGAAGGTCCCTAATCATGCTATCCAGTGGCGTATGATTCAAGATGCTTATCAGCTTAAGGCCCACACCTATGATTTTCGAGGCATTAGCCCTACCCTGGATGAATCTGACCACCTGTTTGGGTTGTTGCGATTTAAATTGGGCTTTGGAGGTGAGGCCTGTGAAATGATCAGTGCTTGGGACTACCCCCTGCAGCCTTTATTACACCGGGCTTTCCAGCTGTATTTAAAACGGCGGTAGGGTGGTGAAACCATATTCCTGAAAAGGGGTCTCAGACATGAAACGAAAAAGAATGACTCAGATTTTTCCATTCATATTGCCGTTGCGCAGGACACAAAGAAAATTATTCTTCTATGCTAAGATGTACTTTGACCGGAACCACTATGCAAAAGCAAAGGCTTCGGAGTTTTTGCCTTTTTGCATTTATGAAACCAAGTCGAAGCTTCTCAATGAGAATACAGGCTTTGATATGAAATATCAGGAAAACAAGGTGTTTAATCTGCGTCTTGCCGCGGAGACTATTAATGGCTTGGTCATACGCCCTGGTGAAACATTTTCATTTTGGCAGCGTGTGAGATATGCCGAGAAAAAAGAGCGGTATAAGGACGGTTTGTGCGTGGTGAATGGCAAATTGGTCACGGTCCCGGGAGGCGGTTCGTGTCATCTCAGCAATTTGCTGTTCTGGTTGTTTCTGCATACACCCCTCACTATTGCAGAACGGCATCCTCATCAGCTTAAGGATTTTCCTTCTCCTGATGAGGATGAACCGGATGGTGTGGACGCTACGGTCAGTGAAGGGTGGCTGGATTTAAAAGTCAAAAACAATACCAATCTTACCTTCCAAATTGAAATATCCATCAATAGGCCTAACTTATACGGCCGTATTTTTGTGGATCAGGACAAAGGGTATTGTTACGAGGTCATTAATCGGGATAAGAGCTTTTTCAAAAAAGACGGGAAAATCTTTGAGCAAGTTTCTGTTTGTCGGCAGGTGCTGGACAGCAAATCCCAACAGGTTGTTTCCGAAAGCCTGCTTTATACGGATGTATTTGAAATCGGGTATTCGCTTCCGGAAGGAACGGTTATCCAAGAAGAAAGGTAGTGATTCTCCACAGTGAGATACTGTTGAAAATACTATTATAAATTGCTTGAAATTTGAAAGGAGAAAGCAGCATGGATAAGTTGAAAATCGCAATTATCTTCGGAGGCTGTTCCGAAGAACATCTCATCTCCGTTAAATCTGCGCAAGAGGTCGCCAAAAACCTTGATCTCGAAAAGTATGAACCCTTCTATATCGGGATTACAAAAGATGGTGTTTGGAAGCTTTGTCACTGTCCTGAGGCCAATTGGGAAAAGGGCAGTTGCCGTCCGGCTATACTGTCACCGGACAGAAGTGTACACGGATTGCTTGTTCTGGTCAAGGACAATACAAAACGATTCGATTGGATATGGTGTTTCCCGTTCTGCATGGTAAACTTGGCGAGGATGGTGCGATGCAAGGTTTGTTGGAGCTTTCCGGCATCCCCTATGTAGGCTGCGATGTGCAAAGTTCTGCTCTGTGTATGGACAAATCCCTTGCTTATATCGTCGCTGGAAAGGCGGGAATTGGGACGCCAAATTTCCGGACTGTCACGGCAAAGGAGACTATTGATGCCGACGGACTTTCTTATCCCGTTTTTGTCAAGCCGGCCCGTTCGGGTTCATCCTTCGGCGTCAGTAAGGTATGCCGAAAAGAAGAATTGCGGAGCGCGGTGGAAACCGCAAGACAATATGACTCGAAGGTGTTGATTGAAGAGGCTGTCGCCGGCAGCGAGGTAGGATGTGCCATATTAGGGAACGATCCGGAGTTGATGGCAGGCGAGGTAGATCAAATTTCTCTGTCCCATGGTTTTTTCAGAATCCATCAGGAGAATGAGCCTGAAAAGGGTTCCGAAAACTCAACATTCATCGTTCCCGCCGGCATTTCGGCAGAGGCGCGCTTGTTCGTTCAGGAGACAGCAAAAGCCGTCTATCGCGCCTTGGGGTGCAGGGGACTTGCGCGGGTGGATATGTTTCTGAAGGAAGATGGAAAAGTAATCCTTAACGAGGTTAATACGTTGCCCGGTATGACCTCATATAGCCGTTATCCGAGAATGGTGGCGGCCGCAGGGTTGACCTTTGCCGAAGTGATCGACCGGATTGTGGCATTGACATTGCAAGGAAAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7563,Drugs,MEG_7563|Drugs|Glycopeptides|VanB-type_resistance_protein|VANXB,vanXmurFvanKWI_1_NZAGAF01000127,5
,atgaaaaaagttgtatttcctatattgagtatctttactttattttctctgaatgcgtgttcatcggttcagacagcatccgaaagtactatttcagcttacaatcaacagagtaaagaaactataaaaaaatattttgatgatgctcaaacacaaggtgtaattgttattaaagataataatcatcttgcgatatatggtaataatttaacacgagcacatacacaatatgttccagcatcaacttttaaaatgttgaacgctttaattggattagaaaataataaagtaaccacggatgaactgtttaagtgggatggtaataaaaaagctttcccaatttgggaaaaagatatgaacttagatgaggcgatgaaattatcagcagttcctgtatatcaagaacttgcaaaacgtattggtatagatttaatgcagaaagaagtaaaacgggttaattttggtaatgctaatattggaactaaagttgataatttttggttagttggccctttgaagattacacctattcaagaagttaaatttgctgatgatcttgcacataacaaattacctttcaaaattgaaactcaagaaacagttaaaaatatgcttctaattaaagaaattaatggaagtaaaatttatgcaaaaagtggttggggaatggatgttacacctcaagtgggttggttaactggttgggtagaacagcctacagggaagataatttcattttcattaaatttagaaatgaaaaataatatgacaggttctattcgcaatgaaattacatataaagcattagagaatcttggtatcatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4667,Drugs,MEG_4667|Drugs|betalactams|Class_D_betalactamases|OXA,1391852863|WP_109545048.1|NG_057454|1|1|blaOXA-542|blaOXA-542_like|carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-542 NG_057454:1-828,0
,GATGAGGCCCCGGCGGATCGCCTGAAGGCACTGGTCGACGCCGCCGTACAACCGGTGATGAAGGCCAATGACATTCCGGGCCTGGCCGTAGCCATCAGCCTGAAAGGAGAACCGCATTACTTCAGCTATGGGCTGGCCTCGAAAGAGGACGGCCGCCGGGTGACGCCGGAGACCCTGTTCGAGATCGGCTCGGTGAGCAAGACCTTCACCGCCACCCTCGCCGGCTATGCCCTGGCCCAGGACAAGATGCGCCTCGACGACCGCGCCAGCCAGCACTGGCCGGCACTGCAGGGCAGCCGCTTCGACGGCATCAGCCTGCTCGACCTCGCGACCTATACCGCCGGCGGCTTGCCGCTGCAGTTCCCCGACTCGGTGCAGAAGGACCAGGCACAGATCCGCGACTACTACCGCCAGTGGCAGCCGACCTACGCGCCGGGCAGCCAGCGCCTCTATTCCAACCCGAGCATCGGCCTGTTCGGCTATCTCGCCGCGCGCAGCCTGGGCCAGCCGTTCGAACGGCTCATGGAGCAGCAATTGTTCCCGGCACTGGGCCTCGAACAGACCCACCTCGACGTGCCCGAGGCGGCGCTGGCGCAGTACGCCCAGGGCTACGGCAAGGACGACCGCCCGCTACGGGTCGGTCCCGGCCCGCTGGATGCCAAAGGCTACGGGGTGAAGACCAGCGCCGCCGACCTGCTGCGCTTCGTCGATGCCAACCTGCATCCGGAGCGCCTGGACAGGCCCTGGGCGCAGGCGCTCGATGCCACTCATCGCGGTTACTACAAGGTCGGCGACATGACCCAGGGCCTGGGCTGGGAAGCCTACGACTGGCCGATCTCCCTGAAGCGCCTGCAGGCCGGCAACTCGACGCCGATGGCGCTGCAACCACACAGGATCGCCAGGCTGCCCGCGCCACAGGCGCTGGAGGGCCAGCGCCTGCTGAACAAGACCGGCTCCACCAACGGCTTCGGCGCCTACGTGGCGTTCATTCCGGGCCGCGACCTGGGCCTGGTGATCCTGGCCAACCGCAACTATCCCAATGCCGAGCGGGTGAAGATCGCCTACGCCATCCTCAGCGGCCTGGAGCAGCAGGCCAAGGTGCCGCTGAAGCGCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5737,Drugs,MEG_5737|Drugs|betalactams|Class_C_betalactamases|PDC,gb|KR057755.1|+|0-1116|ARO:3004349|PDC-86 [Pseudomonas aeruginosa] ,0
,atgagtgaaaaagtgcccgccgagatttcggtgcaactatcacaagcactcaacgtcatcgggcgccacttggagtcgacgttgctggccgtgtatttgtacggctccgcactggatggcggattgaaaccgtacagtgatattgatttgctggtggctgtagctgcaccgcacaatgatgccgtgcggcaagccctgctcgtcgatctcttggaggtttcagcttcccctggccaaaacaaggtactccgcgccttggaagtgaccatcgtcgtgcacagtgacatcgtaccttggcgttatccggccaggcgggaactgcagttcggagagtggcagcgcaaagacatccttgcgggcatcttcgagcccgccacaacagattctgacttggcgattctgctaacaaaggcaaagcaacatagcatcgtcttggcaggttcagcagcgaaggatctcttcagctcagtcccagaaagcgatctattcaaggcactggccgatactctgaagctatggaactcgccgccagattgggcgggtgatgagcggaatgtagtgcttactttgtctcgtatctggtacaccgcagcaaccggcaagatcgcgccaaaggatgtcgctgccacttgggcaatggcacgcttgccagctcaacatcagcccatcctgttgaatgccaagcgggcttatcttgggcaagaagaggattacttgcccgctcgtgcggatcaggtggcggcgctcattaaattcgtgaagtatgaagcagttaaactgcttggtgccagccaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_824,Drugs,MEG_824|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502175|WP_071846326.1|NG_052410|1|1|aadA7|aadA7|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA7 NG_052410:101-898,2
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccagctgcggaggaactctttgatcccgttcctgaacaggatctattcgaggtactgaatgaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgctcacgttgtcccgcatttggtacaccgaagtaaccggcaaaatcgtgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_841,Drugs,MEG_841|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502173|WP_071846324.1|NG_052407|1|1|aadA8|aadA8|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA8 NG_052407:101-892,2
,ATGAGTAAAAATATGAAACAAGTTATAGAAATAGCTAAAAAACATAATCTTATTCTAAAGGAAGAAACAATGCAGTTTAATGAATCCGGACTTGATTTTCAAGTTGTATATGCTCTAGATGAAAGTGGAGTAGATTGGGTTCTTAGATTGCCTAGGCGTGAAGATGTTATGCCTAGAACAAAGGTAGAAAAACAAGCATTAGATTTGGTTAATCAGTATGTTAAATATTTCCAGGCGCCAAACTGGATTATATACACAGATGAGCTAATAGCATACAAGAAGTTAGATGGTGTGCCAGCAGGAACCATTGATCATAATATCGGAAATTATGTTTGGGAGATAGATATTAACAACGTTCCACCATCATTTCACATGTCTCTTGGAAGAGTGTTAGCAGAGCTTCATAGCATACCTAGTGATAAAGCTGCAGAATTTGGACTAATAGTGCAAACCCCTGAAGAAGCGAGAAAATCAATGAAGCAACGTATGAATGATATAAAAACAAAATTCGGTGTAGGTGAGAAATTATGGAATAGATGGCAGTCGTGGGTTAATGATGATGAAATGTGGCCAAAGAAAACTGGACTGATTCATGGAGATGTTCATGCCGGACATACCATGATTGATGAAGAGGCTAATGTGACTGGATTGATCGACTGGACTGAAGCTAAGGTAACAGATATTTCAAATGACTTTGTTTTCAACTACAAGGCTTTTGGAGAAGAAGGATTAGAAGATCTGATAATTGCTTATAAAGAAGCTGGGGGTTATTACTGGCCTAAAATGAAAGAGCATATTATTGAACTGGTCGCTGCATATCCGGTTTCAATTGCTGAGTTTGCAATAGTATCTGGTGTTGAAGAATATGTTCAAATGGCGAAAAAGGCATTGGAAATAGACGATGTTTAA,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4051,Drugs,MEG_4051|Drugs|MLS|Macrolide_phosphotransferases|MPHN,mph(N)_1_KF648874,7
,ATGCGCCCCCTCCTCTTCAGTGCCCTTCTCCTGCTTTCCGGGCATACCCAGGCCAGCGAATGGAATGACAGCCAGGCCGTGGACAAGCTATTCGGCGCGGCCGGGGTGAAAGGCACCTTCGTCCTCTACGATGTGCAGCGGCAGCGCTATGTCGGCCATGACCGGGAGCGCGCGGAAACCCGCTTCGTTCCCGCTTCCACCTACAAGGTGGCGAACAGCCTGATCGGCTTATCCACAGGGGCGGTTAGATCCGCCGACGAGGTTCTTCCCTATGGCGGCAAGCCCCAGCGCTTCAAGGCCTGGGAGCACGACATGAGCCTGCGCGAGGCGATCAAGGCATCGAACGTACCGGTCTACCAGGAACTGGCGCGGCGCATCGGCCTGGAGCGGATGCGCGCCAATGTCTCGCGCCTGGGTTACGGCAACGCGGAAATCGGCCAGGTTGTGGATAACTTCTGGTTGGTGGGACCGCTGAAGATCAGCGCGATGGAACAGACCCACTTTCTGCTCCGACTGGCGCAGGGAGAATTGCCATTCCCCGCCCCGGTGCAGTCCACCGTGCGCGCCATGACCCTGCTGGAAAGCGGCCCGGGCTGGGAGCTGCACGGCAAGACCGGCTGGTGCTTCGACTGCACGCCGGAACTCGGCTGGTGGGTGGGCTGGGTGAAGCGCAACGAGCGGCTCTACGGCTTCGCCCTGAACATCGACATGCCCGGCGGCGAGGCCGACATCGGCAAGCGCGTCGAACTGGGCAAGGCCAGTCTCAAGGCTCTCGGGATACTGCCCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4752,Drugs,MEG_4752|Drugs|betalactams|Class_D_betalactamases|OXA,(Bla)OXA-50:AM117128:1-789:789,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACGCTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1438,Drugs,MEG_1438|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_75_LNTF01000008,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttgtttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4396,Drugs,MEG_4396|Drugs|betalactams|Class_D_betalactamases|OXA,488978855|WP_002889704.1|NG_057511|1|1|blaOXA-591|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-591 NG_057511:1-774,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6282,Drugs,MEG_6282|Drugs|betalactams|Class_A_betalactamases|SHV,gb|AJ920369|+|23-860|ARO:3001071|SHV-12 [Escherichia coli] ,0
,atgaaaaatttacagttgggcctcatcgccctcattacaaccttcggttccgcatgtaccacaataaacccctccgtagaaacagctaaaaatcaccaacaacaaagcgcgcagcagcagatccaacaagccttcaatcaactccaaaccacgggggtgattgtcattaaggataaacatggcttgcacagctacggcaatgacttgagccgtgctcagacaccctatgtaccggcctctacctttaaaatgctgaatgccttaatcggactagaacatggtaaagcaaccagcaccgaggtgtttaaatgggatggtcaaaagcgcagcttccctgcttgggaaaaagacatgactttaggccaagccatgcaagcatctgccgttcccgtttatcaggagcttgcacggcgcattggcctagacctgatgcaaaaagaagtgcagcgcattggatatggcaatcaacagattggcaccgttgtcgataatttttggttagtcggtccactgcaaattacgcctattcaagaagtcctttttgtggagaaactagccaatacaaaactcgcttttaagcccgacgtgcaacatgcagtacaagacatgctgctgattgaacaaaaaccgaattataaactctatgcaaaatcaggctggggcatggacctagaaccgcaagtaggctggtggacaggctgggtcgaaacagcaacaggtgcaaaagtgtattttgctttgaatatgcagatgaaaacgggaatttcagccagcgtgcgtgagcaactggtcaaacaaagcctgacagcactggggataatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4412,Drugs,MEG_4412|Drugs|betalactams|Class_D_betalactamases|OXA,1693892940|WP_140423317.1|NG_065435|1|1|blaOXA-650|blaOXA-211_like|OXA-211_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-650 NG_065435:1-825,0
,ttgaaaaaaatacttttactttttagtcttttttactcttttgctttggcaaatgataaattaaaagatttttttaaagactacaatacaagcggagtttttataacttttgatggaaaacattatgcaagtaataattttaaaagagctaaagaacctttttctcctgcttcgacttttaaaatttttaatgctttaattgcgcttgataatggtgtagttaaagatacaaaggaaattttttatcattataagggtgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcctatggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgatggtataaatttggcttggattgttggatttatagagagtaaaacaaaatttttatcttttgccttaaatgttgatataaagaacattaaaaatcttaaaataagagaagaattgctagaaaaatatatttattctttaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4633,Drugs,MEG_4633|Drugs|betalactams|Class_D_betalactamases|OXA,949616509|WP_057036510.1|NG_057501|1|1|blaOXA-629|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-629 NG_057501:1-747,0
,ATGATGACTAAATCCCTTTGCTGCGCCCTGCTGCTCAGCACCTCCTGCTCGGTATTGGCTGCACCGATGTCAGAAAAACAGCTGGCTGAGGTGGTGGAACGGACCGTTACGCCGCTGATGAAAGCGCAGGCCATTCCGGGTATGGCGGTGGCGGTGATTTATCAGGGCCAGCCGCACTACTTTACCTTCGGTAAAGCCGATGTTGCGGCGAACAAACCTGTCACCCCACAAACCTTGTTCGAACTGGGTTCTATAAGTAAAACCTTTACCGGCGTACTGGGTGGCGATGCCATTGCTCGGGGTGAAATATCGCTGGGCGATCCGGTGACAAAATACTGGCCTGAGCTGACGGGCAAGCAGTGGCAGGGGATCCGCATGCTGGATCTGGCAACCTATACCGCAGGCGGTCTGCCGTTACAGGTACCGGATGAGGTCGCGGATAACGCCTCTCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCGGGTACCACGCGTCTTTACGCCAATACCAGCATCGGCCTTTTTGGCGCGCTGGCGGTCAAACCTTCCGGCATGAGCTATGAACAGGCCATAACGACGCGGGTCTTTAAGCCGCTCAAGCTGGACCATACGTGGATTAACGTTCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGATACCGCGACGGTAAAGCGGTACACGTTTCGCCAGGCATGCTGGACGCTGAAGCCTATGGCGTAAAAACCAACGTGCAGGATATGGCAAGCTGGGTGATGGTCAACATGAAGCCGGACTCCCTTCAGGATAATTCACTCAGGCAAGGCATTGCCCTGGCGCAGTCTCGCTACTGGCGCGTAGGGGCCATGTATCAGGGGTTAGGCTGGGAAATGCTTAACTGGCCGGTCGATGCCAAAACCGTGGTTGAAGGTAGCGACAATAAGGTGGCACTGGCACCGCTGCCCGCAAGAGAAGTGAATCCTCCGGCGCCTCCGGTCAACGCGTCCTGGGTCCATAAAACAGGCTCTACCGGCGGGTTTGGCAGCTACGTGGCCTTTATTCCTGAAAAGCAGCTCGGCATTGTGATGCTGGCGAATAAAAGCTATCCCAACCCAGCACGCGTTGAGGCGGCTTACCGTATTTTGAGCGCGCTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_445,Drugs,MEG_445|Drugs|betalactams|Class_C_betalactamases|ACT,(Bla)ACT-4:AJ311172:12-1157:1146,0
,ATGAAATTATTAAAAATATTGAGTTTAGTTTGCTTAAGCATAAGTATTGGGGCTTGTGCTGAGCATAGTATGAGTCGAGCAAAAACAAGTACAATTCCACAAGTGAATAACTCAATCATCGATCAGAATGTTCAAGCGCTTTTTAATGAAATCTCAGCTGATGCTGTGTTTGTCACATATGATGGTCAAAATATTAAAAAATATGGCACGCATTTAGACCGAGCAAAAACAGCTTATATTCCTGCATCTACATTTAAAATTGCCAATGCACTAATTGGTTTAGAAAATCATAAAGCAACATCTACAGAAATATTTAAGTGGGATGGAAAGCCACGTTTTTTTAAAGCATGGGACAAAGATTTTACTTTGGGCGAAGCCATGCAAGCATCTACAGTGCCTGTATATCAAGAATTGGCACGTCGTATTGGTCCAAGCTTAATGCAAAGTGAATTGCAACGTATTGGTTATGGCAATATGCAAATAGGCACGGAAGTTGATCAATTTTGGTTAAAAGGGCCTTTGACAATTACACCTATACAAGAAGTAAAGTTTGTGTATGATTTAGCCCAAGGGCAATTGCCTTTTAAACCTGAAGTTCAGCAACAAGTGAAAGAGATGTTGTATGTAGAGCGCAGAGGGGAGAATCGTCTATATGCTAAAAGTGGCTGGGGAATGGCTGTAGACCCGCAAGTGGGTTGGTATGTGGGTTTTGTTGAAAAGGCAGATGGGCAAGTGGTGGCATTTGCTTTAAATATGCAAATGAAAGCTGGTGATGATATTGCTCTACGTAAACAATTGTCTTTAGATGTGCTAGATAAGTTGGGTGTTTTTCATTATTTATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5209,Drugs,MEG_5209|Drugs|betalactams|Class_D_betalactamases|OXA,gi|156938936|gb|EU107364.1|1-843,0
,gtgaaacccaacagacccctgatcgtaattctgagcactgtcgcgctcgacgctgtcggcatcggcctgattatgccggtgctgccgggcctcctgcgcgatctggttcactcgaacgacgtcaccgcccactatggcattctgctggcgctgtatgcgttgatgcaatttgcctgcgcacctgtgctgggcgcgctgtcggatcgtttcgggcggcggccggtcttgctcgtctcgctggccggcgctgctgtcgactacgccatcatggcgacggcgcctttcctttgggttctctatatcgggcggatcgtggccggcatcaccggggcgactggggcggtagccggcgcttatattgccgatatcactgatggcgatgagcgcgcgcggcacttcggcttcatgagcgcctgtttcgggttcgggatggtcgcgggacctgtgctcggtgggctgatgggcggtttctccccccacggtccgttcttcgccgcggcagccttgaacggcctcaatttcctgacgggctgtttccttttgccggagtcgcacaaaggcgaacgccgtccgttacgcgggagctctcacccgctcgcttcgttccggtgggcccggggcatgaccgtcgtcgccgccctgatggcggtcttcttcatcatgcaacttgtcggacaggtgccggccgcgctttgggtcattttcggcgaggatcgctttcactgggacgcgaccacgatcggcatttcgcttgccgcatttggcattctgcattcactcgcccaggcaatgatcaccggccctgtagccgcccggctcggcgaaaggcgggcactcatgctcggaatgattgccgacggcacaggctacatcctgcttgccttcgcgacacggggatggatggcgttcccgatcatggtcctgcttgcttcgggtggcatcggaatgccggcgctgcaagcaattttgtccaggcaggtggatgaggaacgtcaggggcagctgcaaggctcactggcggcgctcaccagcctgacctcgatcgtcggacccctcctcttcacggcgatctatgcggcttctataacaacgtggaacgggtgggcatggattgcaggcgctgccctctacttgctctgcctgccggcgctgcgtcgcgggctttggagaaattcttcaaattcccgttgcacatag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7017,Drugs,MEG_7017|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,1028099442|WP_063855886.1|NG_048150|1|1|tet(A)|tet(A)|tetracycline_efflux_MFS_transporter_Tet(A) NG_048150:101-1297,4
,atgaatatagttgaaaatgaaatatgtataagaactttaatagatgatgattttcctttgatgttaaaatggttaactgatgaaagagtattagaattttatggtggtagagataaaaaatatacattagaatcattaaaaaaacattatacagagccttgggaagatgaagtttttagagtaattattgaatataacaatgttcctattggatatggacaaatatataaaatgtatgatgagttatatactgattatcattatccaaaaactgatgagatagtctatggtatggatcaatttataggagagccaaattattggagtaaaggaattggtacaagatatattaaattgatttttgaatttttgaaaaaagaaagaaatgctaatgcagttattttagaccctcataaaaataatccaagagcaataagggcataccaaaaatctggttttagaattattgaagatttgccagaacatgaattacacgagggcaaaaaagaagattgttatttaatggaatatagatatgatgatattgccacaaatgttaaggcaatgaaatatttaattgagcattactttgataatttcaaagtagatagtattgaaataatcggtagtggttatgatagtgtggcatatttagttaataatgaatacatttttaaaacaaaatttagtactaataagaaaaaaggttatgcaaaagaaaaagcaatatataattttttaaatacaaatttagaaactaatgtaaaaattcctaatattgaatattcgtatattagtgatgaattatctatactaggttataaagaaattaaaggaacttttttaacaccagaaatttattctactatgtcagaagaagaacaaaatttgttaaaacgagatattgccagttttttaagacaaatgcacggtttagattatacagatattagtgaatgtactattgataataaacaaaatgtattagaagagtatatattgttgcgtgaaactatttataatgatttaactgatatagaaaaagattatatagaaagttttatggaaagactaaatgcaacaacagtttttgagggtaaaaagtgtttatgccataatgattttagttgtaatcatctattgttagatggcaataatagattaactggaataattgattttggagattctggaattatagatgaatattgtgattttatatacttacttgaagatagtgaagaagaaataggaacaaattttggagaagatatattaagaatgtatggaaatatagatattgagaaagcaaaagaatatcaagatatagttgaagaatattatcctattgaaactattgtttatggaattaaaaatattaaacaggaatttatcgaaaatggtagaaaagaaatttataaaaggacttataaagattga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_75,Drugs,MEG_75|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,695264030|WP_032490744.1|NG_047212|1|2|aac(6')-Ie|aac(6')-Ie|bifunctional_aminoglycoside_N-acetyltransferase_AAC(6')-Ie/aminoglycoside_O-phosphotransferase_APH(2'')-Ia NG_047212:101-1540,2
,TTTACTACCTTAAAAATTATGAAAAAAAGCATTCAATTTTTTATTGTTTCCATGTTGTTGAGCCCTTTTGCCAATGCACAGGTAAAAGATTTTGTAATTGAGCCACCTATTAAATCCAATCTATATATTTACAAGACTTTTGGAGTATTCGGAGGTAAAGAATATTCTGCCAATGCAGCCTATCTTAAGACTAAAAAAGGTGTAATTCTGTTTGATGTACCCTGGGAAAAAGTACAGTATCAAAGCCTGATGGATACCATCAAAAAACGTCATAACTTACCGGTAATTGCCGTATTTGCTACGCATTCCCATGATGACCGTGCAGGAGACTTAAGCTTTTTCAATAATAAAGGCATTAAGAAGTATGCTACCCTGAAAACCAATGAGTTTCTGAAGAAAGATGGAAAAGCAACATCCACAGAGATCATCCAAACCGGAAAACCTTATCACATTGGCGGAGAAGAATTTGTGGTCGATTTTCTTGGTGAAGGACATACTGCTGATAATGTAGTGGTATGGTTTCCAAAATATAATGTTTTGGATGGCGGATGTCTTGTAAAAAGTAATTCTGCTACTGACTTAGGATACATTAAAGAAGCCAATGTAGAACAATGGCCCAAGACGATGAATAAATTAAAAACCAAATATTCAAAAGCCACATTAATTATTCCCGGGCATGATGAATGGAAAGGGGGTGGACATGTTGAACACACTTTAGAGCTTTTGAACAAAAAATAACTCTGGTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3423,Drugs,MEG_3423|Drugs|betalactams|Class_B_betalactamases|IND,gi|281021928|gb|GU206353.1|1-746,0
,CAATAAGTTACTAAGGGCTTATGGTGGATGCCTTGGCACTAATAGGCGATGAAGGACGTGTTAACCTGCGATAAGCTTCGGGTAGGTGGTAAGAACCTCAGATCCGGAGATTTCCGAATGGAGCAATCCGGTAGTTGGAAACAGCTATCATTAATTGATGAATAAATAGTCAATTAAAGCAATACGTGGTGAAGTGAAACATCTCAGTAGCCACAGGAAAAGAAAACGAATGTGATTCCGTGTGTAGTGGCGAGCGAAAGCGGAACAGGCCAAACTTATCATTAGATAGGGGTTGTAGGGCTTGCAATGTGGACTTGAAAACGATAGAAGAAGCTGTTGGAAAGCAGCGCGCAAAAGGGTGATAGCCCCGTATTTGAAATTGTTTTCATACCTAGCGAGATCCCTGAGTAGCTCGGAAAACGTTATTTTGAGTGAATCTGCCCAGACCATTGGGTAAGCCTAAATACTAATTAGTGACCGATAGCGAAACAGTACCGTGAGGGAAAGGTGAAAAGAACCCAGAGATGGGAGTGAAATAGATTCTGAAACCATATGCCTACAACGTGTCAGAGCACATTAATGTGTGATGGCGTGCGTTTTGAAGTATGAGCCGGCGAGTTATGATAGCAAGCGTTAGTTAACCAGGAGATGGGGAGCTGTAGCGAAAGCGAGTTTTAAAAGAGCGTTTGTTTGTTATTATAGACCCGAAACGGGTTGAGCTAGTCATGAGCAGGTTGAAGGTTGAGTAACATCAACTGGAGGACCGAACCGACTCTCGTTGAAACGATAGCGGATGACTTGTGATTAGGGGTGAAATTCCAATCGAAATCCGTGATAGCTGGTTCTCGTCGAAATAGCTTTAAGGCTAGCGTGAGATCACAAATAAGTGGAGGTAAAGCTACTGAATGTATGATGGCGCCACCTAGGCGTACTGAATACAATTAAACTCTGAATGCCATTTATTTTATTCTCGCAGTCAGACAGTGGGGGATAAGCTTCATTGTCAAGAGGGGAAGAGCCCAGATCATTAAATAAGGTCCCCAAAATATACTAAGTGGAAAAGGATGTGAAAGTGCTAAAACAGCAAGGATGTTGGCTTAGAAGCAGCCATCGTTTAAAGAGTGCGTAACAGCTCACTTGTCGAGTGTTTTTGCGCCGAAGATGTAACGGGGCTAAGTATATTACCGAATTTATGGATAAGATTTATATCTTGTGGTAGACGAGCGTTGTATTGGAGTTGAAGTCAAAGCGTGAGCATTGGTGGATCCAATACAAGTGAGAATGCCGGCATGAGTAACGCTTGGGAGTGAGAATCTCCCAAACCGATTGACTAAGGTTTCCTGGACCAGGGTCGTCCTTCCAGGGTTAGTCTGGACCTAAGCTGAGGCTGAAAAGCGTAGGCGATGGACAACAGGTTAATATTCCTGTACTTACAGTTAGACTGATGGAGTGACAAAGAAGGTTTTCCACCCCCATAATTGGATTTGGGGATAAATCATAAGGTGGTACAATAGGCAAATCCGTTGTGCATAACATTGAGTGATGATGTCGAGTGAATGAGTGATCAAGTAGCGAAGGTGGTATTAATCATGCTTTCAAGAAAAGCTTCTAGGGTTAATCTAGCTGTAACCAGTACCGAGAACGAACACACGTAGTCAAGGAGAGGATCCTAAGGTTAGCGAGTGAACTATAGCCAAGGAACTCTGCAAATTAACCCCGTAAGTTAGCGAGAAGGGGTGCTTATGTAAAAGTAAGCCGCAGTGAAGAACGAGGGGGGACTGTTTAACTAAAACACAACTCTATGCCAAACCGTAAGGTGATGTATATGGGGTGACACCTGCCCAGTGCTGGAAGGTTAAAGAAGGAGGTTAGCGCAAGCGAAGCTTTTAACTGAAGCCCCAGTGAACGGCGGCCGTAACTATAACGGTCCTAAGGTAGCGAAATTCCTAGTCGGGTAAATTCCGTCCCGCTTGAATGGTGTAACCATCTCTTGACTGTCTCGGCTATAGACTCGGTGAAATCCAGGTACGGGTGAAGACACCCGTTAGGCGCAACGGGACGGAAAGACCCCGTGAAGCTTTACTGTAGCTTAATATTGATCAGGACATTATCATGTAGAGAATAGGTAGGAGCAATCGATGCAAGTTCGCTAGGACTTGTTGATGCGAAAGGTGGAATACTACCCTTGGTTGTGTGCTGTTCTAATTGGTAACTGTTATCCAGTTTCAAGACAGTGTTAGGTGGGCAGTTTGACTGGGGCGGTCGCCTCCTAAAAGGTAACGGAGGCGTACAAAGGTACCTTCAGTACGGTTGGAAATCGTATGTAGAGTGTAATGGTGTAAGGGTGCTTGACTGTGAGACATACAGGTCGAACAGGTGAGAAATCAGGTCATAGTGATCCGGTGGTCCAGTATGGAATGGCCATCGCTCAACGGATAAAAGCTACTCCGGGGATAACAGGCTGATACTGCCCAAGAGTTCATATCGACGGCAGTGTTTGGCACCTCGATGTCGACTCATCTCATCCTCGAGCTGAAGCAGGTTCGAAGGGTTCGGCTGTTCGCCGATTAAAGAGATACGTGAGTTGGGTTCAAACCGTCGTGAGACAGGTTGGTCCCTATCTATTGTGCCCGTAGGAAGATTGAAGAGTGTTGCTTCTAGTACGAGAGGACCGAAGCGAGGACACCTCTTATGCTCCAGTTGTAGCGCCAGCTGCACCGCTGGGTAGTAACGTGTCTATTAGATAAACGCTGAAAGCATCTAAGTGTGAAACTATCTCAAAGATTAATCTTCCCATTTCGCAAGAAAGTAAGAGCCGTCAAAGACGATGACGTTGATAGGTTACAGGTGTAAGCATAGTGATATGTTGAGCTGAGTAATACTAATTGCTCGAGGACTTATTGGA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3989,Drugs,MEG_3989|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NR_077056.1|+|0-2905|ARO:3004179|Mycoplasma pneumoniae 23S rRNA mutation conferring resistance to erythromycin [Mycoplasma pneumoniae] ,7
,TGCCTTATCTCCCTGATTGCCGCCCTGCCACTGGCGGTATTCGCCAGCCCTCAGCCGCTTGAGCAGATTAAAATCAGCGAAAGTCAGCTGGCGGGCCGGGTGGGCTATGTTGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCAGTGAGCGCTTTCCGCTGATGAGCACCTTTAAAGTGCTGCTCTGCGGCGCGGTGCTGGCCCGGGTGGATGCCGGCGACGAACAGCTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTGCCGACGGGATGACCGTTGGCGAACTCTGCGCCGCCGCCATCACCATGAGCGACAACAGCGCCGGCAATCTGCTGTTGAAGAGCGTCGGCGGCCCTGCGGGATTGACCGCTTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGAACTCAATGAGGCGCTTCCCGGCGACGTGCGCGACACCACCACCCCGGCCAGCATGGCCACCACCCTGCGCAAGTTGCTAACCACCCCCTCTCTGAGCGCCCGTTCGCAGCAGCTGCTGCTGCAGTGGATGGTTGACGACCGGGTGGCCGGCCCGTTGATCCGCGCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAAACCGGGGCCGGTGAGCGGGGCTCACGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAAGCGGAGCGTATCGTGGTGATCTATCTACGGGATACCGCGGCGACCATGGCCGAACGTAACCAGCAGATCGCCGGGATAGGCGCGGCGCTG,beta-lactamase,antibiotic inactivation,betalactams,MEG_4274,Drugs,MEG_4274|Drugs|betalactams|Class_A_betalactamases|OKP,gi|119434091|gb|DQ995288.1|3-824,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccggctgtcgggcagcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctctttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6233,Drugs,MEG_6233|Drugs|betalactams|Class_A_betalactamases|SHV,1028110264|WP_063864634.1|NG_050023|1|1|blaSHV-149|blaSHV|class_A_beta-lactamase_SHV-149 NG_050023:1-861,0
,ATGAAAGTTAAAGTACTGTCCCTCCTGGTACCAGCACTGCAGGTAGCGGGCGCAGCATATGCGGCTGAAATTTATAACAAAGACGGCAACAAATTAGACCTGTACGGTAAAATCGACGGTCTGCACTACTTCTCTTCCGACGACAGCGTCGACGGCGACCAGACCTACATGCGTATCGGCGTGAAAGGCGAAACCCAGATCAACGACCAGCTGACCGGTTACGGCCAGTGGGAATACAACGTTCAGGCGAACAACACTGAAAGCTCCAGCGACCAGGCATGGACTCGTCTGGCCTTCGCGGGTCTGAAATTCGGCGACGCGGGTTCTTTCGACTACGGTCGTAACTACGGCGTTGTTTACGACGTAACTTCCTGGACCGACGTTCTGCCGGAATTCGGTGGCGACACCTACGGTTCCGACAACTTCCTGCAGTCCCGTGCTAACGGTGTTGCCACCTACCGTAACTCTGACTTCTTCGGTCTGGTTGACGGCCTGAACTTTGCTCTGCAGTACCAGGGTAAAAACGGCAGCGTAAGCGGCGAAGATCAGACCAACAACGGTCGCGGCTACCAGAAACAGAACGGCGAAGGCTTCGGCACCTCCGTGACTTATGATATCTGGGACGGCATCAGCGCTGGTTTCGCGTACTCCAGCTCTAAACGTACCGATGAGCAGAACAGCGTTAACACTCGTTATACTGACTCCAACGGTGTTTCCCGTCGCGTACTGGGTGAAGGCGATCACGCTGAAACCTACACCGGTGGTCTGAAATACGACGCCAACAACATCTACCTGGCGACTCAGTACACCCAGACCTACAACGCAACCCGCACCGGTATCATCGGTTTTGCTAACAAAGCGCAGAACTTCGAAGTAGTTGCTCAGTACCAGTTCGACTTCGGTCTGCGTCCGTCCGTGGCTTACCTGCAGTCTAAAGGTAAAGACATGGGCCGTTACGGCGACCAGGACATCCTGAAATATGTTGACCTGGGTGCGACTTACTACTTCAACAAAAACGTGTCCACGTACGTTGATTACAAAATCAACCTGCTGGACGACAACTGTTTCACTAAAGATGCAAGCATCTCTACTGACAACGTTGTGGCTCTGGGCCTGGTTTACCAGTTCTAA,General Bacterial Porin (GBP),reduced permeability to antibiotic,betalactams,MEG_4280,Drugs,MEG_4280|Drugs|betalactams|Mutant_porin_proteins|OMP36,gi|13384118|gb|AF336096.1|1-1131,0
,atgaatattatgccgatatctgaatcacaattgtcagattggctagcattaagatgcttactttggcctgatcatgaagatgtgcatttacaggaaatgcgccaactgatcacacaggcacattgcttacaattattggcttataccgacacccaacaagcaattgccatgttggaagcttcaattcggtatgaatatgtgaatggcacacaaacatcgcctgtggcttttttggaagggatttatgtattgcctgaatatcgtcgttcaggtatcgcaacggggttggttcaacaagtagaaatttgggcgaaacagtttgcatgtacagagtttgcctcggatgcagcgttggataatcagatcagccacgccatgcatcaagcactcggttttcatgaaactgaacgtgtggtgtattttaagaaaaatatcggctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_82,Drugs,MEG_82|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502064|WP_071846216.1|NG_052216|1|1|aacA-ACI2|aacA-ACI2|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052216:101-541,2
,TTTCCCTAACATGAATTTGTAATGAAAAAATTTATACTTCCTATATTCAGCATTTCTATTCTAGTTTCTCTCAGTGCATGTTCATCTATTAAAACTAAATCTGAAGATAATTTTCATATTTCTTCTCAGCAACATGAAAAAGCTATTAAAAGCTATTTTGATGAAGCTCAAACACAGGGTGTAATTATTATTAAAGAGGGTAAAAATCTTAGCACCTATGGTAATGCTCTTGCACGAGCAAATAAAGAATATGTCCCTGCATCAACATTTAAGATGCTAAATGCTTTAATCGGGCTAGAAAATCATAAAGCAACAACAAATGAGATTTTCAAATGGGATGGTAAAAAAAGAACTTATCCTATGTGGGAGAAAGATATGACTTTAGGTGAGGCAATGGCATTGTCAGCAGTTCCAGTATATCAAGAGCTTGCAAGACGGACTGGCCTAGAGCTAATGCAGAAAGAAGTAAAGCGGGTTAATTTTGGAAATACAAATATTGGAACACAGGTCGATAATTTTTGGTTAGTTGGCCCCCTTAAAATTACACCAGTACAAGAAGTTAATTTTGCCGATGACCTTGCACATAACCGATTACCTTTTAAATTAGAAACTCAAGAAGAAGTTAAAAAAATGCTTCTAATTAAAGAAGTAAATGGTAGTAAGATTTATGCAAAAAGTGGATGGGGAATGGGTGTTACTCCACAGGTAGGTTGGTTGACTGGTTGGGTGGAGCAAGCTAATGGAAAAAAAATCCCCTTTTCGCTCAACTTAGAAATGAAAGAAGGAATGACTGGTTCTATTCGTAATGAAATTACTTATAAGTCGCTAGAAAATCTTGGAATCATTTAATAATTTCTAAAATTAACATAATACCGCCTTATGCGAAATGCTTGAAATTTTCTTATAAGCATCAATAGTTTAGTCAAAGCCGTTCTAGAGTTCAGCGCACTAGAACGGCTTTTTCATGATTATTCACGTTCCACGCATATTATTTGAGTAATGTTTCACAACTTTGATTAGTAC,beta-lactamase,antibiotic inactivation,betalactams,MEG_5203,Drugs,MEG_5203|Drugs|betalactams|Class_D_betalactamases|OXA,gi|11493693|gb|AF201827.1|AF201827|1-1023,0
,GAAAGGGCCTCGTGATACACTATATTTATAGGTTAATGTCATGATAATAACTGGTTTCTTAGACGTCAGGTGGCACCTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTAAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTTGAAATGTAAGGCCTTTGATAAGACAAAAGGCTGCCTCATGCAACTTTGCAAGCATGTGCCGTCTCGATATGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6912,Drugs,MEG_6912|Drugs|betalactams|Class_A_betalactamases|TEM,gi|3851587|gb|AF093512.1|AF093512|1-1167,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactaggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcaccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5527,Drugs,MEG_5527|Drugs|betalactams|Class_C_betalactamases|PDC,1147955307|WP_077248206.1|NG_052891|1|1|blaPDC-175|blaPDC|class_C_beta-lactamase_PDC-175 NG_052891:1-1194,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctttaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatcaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaaagttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4658,Drugs,MEG_4658|Drugs|betalactams|Class_D_betalactamases|OXA,1391852920|WP_109545105.1|NG_057539|1|1|blaOXA-602|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-602 NG_057539:1-762,0
,atgattatcagtgagtttgatcgtgagaatattgtcttgcgagatcagcttgcagatcttttaagattgacttggcctgatgagtatggaacagagccgatgaaagaagtcgaacagttgatggctccagaacggattgctgtatcggcgattgaaggggaggaattggttggttttgttgaagcgatccctcaatatggcaaaacagggtgggagttacatcctttggtagtagcaagcacacatcgcaaacaacaaatcgggacacgattggtttcctacctggaaaaagaagtcgcttcatatggtggcctggtcatctatctagggacagatgatgttgaaggacaaacaaatttagttgaaacggatttatttgaagatacctttgcaaagttacaagaaatcaaaaatatcaatcatcatccctatacattttatgagaaacttggctatcagatcatcggtgtgatcccagatgcgaatgggtggaaccagcctgatatttggttagcaaaacgagtggccaaacgagagccaacggaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_172,Drugs,MEG_172|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,498431401|WP_010737153.1|NG_052281|1|1|aacA-ENT2|aacA-ENT2|aminoglycoside_6'-N-acetyltransferase NG_052281:101-649,2
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccacttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagtcaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgataaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgtgcgggaggaacagcggcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgccgccctatgcggcagcgttttcaaggtggagtatacagattgcggccagcggcgtgtctatctacggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggacccaacccggctccctcgtaaaaggtggcgtgaggaccccctccccatgctgcggacgtcgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgcttcgaggtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccatcggactgtctgttacaccactcccgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcagggacgcaactgctggaaccttatctctccttcaccctctatgcgccccgggaatatctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggtccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggcctcttacaccaacgggcagagcgtatgccttacagaactgaaagggtatcaggccgctgtcggcaagccagtcatccagccccgccgtccaaacagccgcctggacaaggtgcgctatatgtttcagaagataatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7210,Drugs,MEG_7210|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,918672380|WP_052543100.1|NG_048302|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048302:101-2020,4
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagcgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcatcgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6190,Drugs,MEG_6190|Drugs|betalactams|Class_A_betalactamases|SHV,1344403573|WP_104159136.1|NG_062296|1|1|blaSHV-224|blaSHV|class_A_beta-lactamase_SHV-224 NG_062296:1-861,0
,ATGAGTGAAGAAATTAAAGAAAACATTCAAGACGTCAATCTGACCAGCGAAATGAAAGAATCTTTCATTGACTACGCAATGAGTGTTATCGTAGCCCGCGCGTTACCTGACGTTCGTGACGGTTTAAAACCTGTTCATCGCCGAATCTTATATGGAATGAACGAATTAGGGGTAACCCCTGATAAACCACACAAAAAATCAGCCCGGATTGTTGGGGATGTTATGGGTAAATATCACCCCCATGGGGACAGTGCGATTTACGAATCAATGGTGCGGATGGCACAACCTTTTAGTTATCGGGCTATGTTAGTTGACGGCCACGGAAACTTCGGTTCCGTCGATGGTGACGGCGCTGCCGCTATGCGTTATACCGAAGCACGTATGAGTAAAATTGCTTTAGAAATGCTACGAGATATTAACAAAAATACAGTCGATTTCCAAGGAAACTATGATGATTCAGAACAAGAACCAGTAGTTTTACCTGCTCGTTTTCCAAACTTACTAGTTAACGGAACAACGGGGATTGCGGTGGGGATGGCAACAAATATTCCACCACACAATTTAAGTGAAGTGATTGATGCAACAAGTTTATTGATGGACAATCCTGATGTAACGACGAATGAATTGATGGAAGTGTTACCTGGACCAGATTTTCCAACAGGCGGTTTAGTGATGGGGAAATCAGGGATTCGCCGAGCATATGAAACAGGGAAAGGTTCGATTACTGTTCGTGCAAAAGTTGAATTGACTGAAATGCCGAATGGAAAAGAACGTATTTTAGTAACTGAATTGCCTTATATGGTGAATAAAGCCAAATTAATCGAACGAATTTCTGAATTACACAGAGATAAACGAATTGAAGGAATTACTGATTTGCGGGATGAATCTTCTCGTGAAGGCATGCGGATTGTCATCGATGTTCGTCGAGATGTGAGTGCCTCTGTTGTGTTAAACAACTTGTACAAAATGACTGCCTTACAAACATCTTTTGGTTTTAACATGTTAGCCATCGAAAAAGGCGTACCGAAAATTTTAAGCTTGAAACGTATTTTAGAAAACTACGTCGAGCACCAAAAAGAAGTCATTACTCGCCGGACGATTTTTGACAAAAACAAAGCAGAAGCACGGGCGCATATTTTAGAAGGTCTACGAATTGCCTTAGATCATATCGATGAAATCATTGCCATTATCCGTGGGTCACAATCAGATGACGAAGCAAAAGCAACGTTAATTGAACGCTTTGAATTTTCAGATCGTCAAGCGCAAGCGATTTTAGATATGCGTTTACGCCGTTTAACAGGCTTAGAACGCGACAAAATTGAAAATGAATATCAAGAGCTATTGAAATTCATTGCGGACTTAGAGGACATTTTAGCCCGCCCAGAACGCGTCATTGAAATCATTAAAACAGAGTTAAATGACGTTCGCACAAAATTTGGTGATGCACGACGCACAGAATTATTAGTAGGTGAAGTCCTAAGTCTTGAAGATGAAGATTTAATCGAAGAAGAAGAAGTCGTGATTACATTAACCAATAACGGCTACATTAAGCGGATGGCAAACTCCGAATTCCGGGCGCAACGCCGCGGCGGACGTGGTGTCCAAGGCATGGGCGTTCATGATGATGATTTCGTGAAAAACCTAGTTTCTTGTTCAACACATGACACGTTATTATTCTTTACGAACACTGGGAAAGTTTACCGAGCAAAAGGTTACGAAATCCCTGAATACGGTAGAACAGCAAAAGGAATTCCAGTGATTAACTTACTGGGAATTGATTCTGCAGAAAAAATTCAAGCGATTATTTCTGTTGAGGGCAAAGCGGAAGCAGGTAAATACTTGTTCTTCACAACCTTAAAAGGAACCGTCAAACGGACAGCCGTAACAGCCTTTTCTAATATCCGTAGTAATGGATTAATCGCCATTAGCTTAAAAGAAGATGATGAGTTAGTTAACGTAGTAACGACTAATGGCAATCAGAAGATGATTATCGGAACACATGCAGGATACTCTGTCACATTTGATGAAAATACTGTACGTGATATGGGCCGGACAGCATCAGGTGTTCGTGGAATCCGTCTCCGCGAAAATGATTATGTGGTCGGCGCAGCGATTCTGGATGAAAATAAAGAAGTCCTAGTCATTACTGAAAATGGTTATGGTAAGCGTACAAAAGCCTCTGAATATCCAGTTAAAGGACGTGGCGGTAAAGGGATTAAGACAGCAAATATCACTGAGAAAAATGGTCCATTAGCTGGTTTAACCACGGTCAATGGTGATGAAGATATCTTATTGATTACGAACAAAGGCGTCATTATCCGCTTTAACGTTGATTCTGTTTCTCAAACAGGACGCGCAACATTAGGGGTTCGTTTAATGAGAATGGAAGATGGTGCCAAAGTGGTAACAATGGCTGTTGTAGAACCAGAAGAAGTGGAAGAAGAAATCGTTGAAGTTGTAGAAACAACAGAAAACGAAACAACATCAGAAACAGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3200,Drugs,MEG_3200|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|29350190|gb|AE016830.1|6674-9175 gi|15982566|dbj|AB059405.1|2836-5337,3
,ttgaaaaatagaagtccattgatccgcaagctcttgacccaatactttatcaccacgggcatcttgatggcgatcttgatcatcattcctttcgcagtacgcttcgttgctggaatgagggtctggtatggctatgaacccatttatcaaattttacgtctttttgctgactattggcttctttgcttagccatcggggccttactgatttgggtgagcacaacgatttattatatgagtaaagctatcagttatttgaatgaaacgatccaagccacaaaccaactgattgccgaacccacgaagcgaatcgttctttccagcaatatgattgatgtgcaagaagaaatgaaccagttgcgggagaaaaacttacaggatcaacgagccgccaaagaagcggaacaacgaaaaaatgatttgatcgtctatctcgcacatgatttacgaacgcctttgaccagtgtgatcggctatttgacgcttttagaagaggaaccgcagctttctaccgaactacgcgcacgctatacgaagatcgccttgcaaaaagcccaacggctggaactattgatcagcgaatttttcgaaatcacccgctttaatcttacaacgatcgccctgcaaactgaaaccacggatctgagcttgatgctggaacaattgacgtttgaatttttgccgctgttagaagaaaaaaacctccattggcaacttcagctacagaaaaaagtctttgcgaccgttgatacggagaaaatggaacgcgtttttgataacttgatccgcaatgccatcaattatagctatcctaactcccctttgcgattagccatcagcgagtctgatgatatcctgattcgtttgaccaatcaaggaaaaacgatcccagctgaaaagatcgtcttgatttttgagcctttctaccgcatggatgcttcccgagcaacagcgacgggtgggacgggtcttggtttgccgatcgccaaagaaatcgttgaagcattaggtggaaagatttgggcggaaagccgtgatgaaaccatcgtcttttcgattcgcctaccgaaggcagcaatggaaaaaaatgaacagctgtcaaagccccatccatctgaaccaaccgcttaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7497,Drugs,MEG_7497|Drugs|Glycopeptides|VanC-type_regulator|VANSC,736869479|WP_034869172.1|NG_051722|1|1|vanS-C|vanS-C|VanC-type_vancomycin_resistance_histidine_kinase_VanS NG_051722:101-1231,5
,TCAGCCGGGCGACAAGTGCAAGGCCAAGGCGTCCAGCGGGCTGGAGGTGCCTCCGGCAGCGACTTTCAGCACATGCGTGTAGATCATCGTCGTGCTCACGTCCGAATGCCCCAACAACTCTTGCACCGTTCGGATGTCTGTGCCTGCTTGCAGCAAGTGGGTGGCGAATGAGTGGCGCAGGGTGTGGACAGATACGTGTTTGGCAATGCCAGCCTGAACTACCGCTTTTTTTAGTTGCCGGTTCAGTCTTTCCTCAAACAAGTGGTGGCGGCGCTCAACGCCGGTTTGTGGGTCCACAGACAGCTTGGCCGATGGAAACACCCAGAACCAGGCCCAGCTCTCGCCCGCCCTGGGGTACTTGCGCTCCAGTGCATGAGGCAGATACACGCCTCCGCGCCCCGTGGCACGGTCCTGCCCCCACACAGCGCGGACCTGAATCAGCTGCGCCCGCAACCGAGGTACGAGCGCCCTGGGCAGCATCACCACGCGGTCCTTGTCGCCCTTGCCGCTGCGCACAATGATCGCGTGGCGGTCGAAATCCACATCCTTGACCCGCAGGCCCAGCGCTTCGCGCAGGCGCAACCCACTGCCGTAAAGCAGGGCGGCCAACAGCGCTTCGGTGCCCGCCATGTGCGAAAGCAACGTCTGAACCTCCTGCACCGTCAGCACCACCGGAATCCGCTTGCGTTCTGGCGGCCGACCAATCTGCTGCATCCACGGCAATTCCATGCCCAGCACCTGCCGATACAAGAACAACAGCGCGTTGAGCGCCTGCCGGTGGGTGGCCGGCGCCACTTGCTTCTCGGTGGCGAGCATGGTCAGAAAACCCTCGACTTCAGCTTGCCCCATTTCGCGCGGATGTCGAAACCCACCATGGCTGCGGGCCGTCCACAACACAAATGCCTTGGCCCAGTAGACATAAGCTTTCTCGGTCTGTAGGCTGTAATGCAGGTAGCGAACCCGTTCGCGCACCTGATCGAGCAGCTTGATGGATCGGGGAGGGAACCAGTCAGGTTTGTCATTTCTGTTATACCTGTTCATGCATCCGGTATGATGCTTTACAGAATTGATTTCAAACACTTTTTTTGGGTGCCGTGCGACATTGTTTAACGACCACGGTTGTGGGTATCCGGTGTTTGGTCAGATAAACCATAAGTTAGCCACCAAGAAGGTGCCATGAAAACATTTGCCGCATATGTAATTATCGCGTGTCTTTCGAGTACGGCATTAGCTGGTTCAATTACAGAAAATACGTCTTGGAACAAAGAGTTCTCTGCCGAAGCCGTCAATGGTGTCTTCGTGCTTTGTAAAAGTAGCAGTAAATCCTGCGCTACCAATGACTTAGCTCGTGCATCAAAGGAATATCTTCCAGTATCAACATTTAAGATCCCCAGCGCAATTATCGGCCTAGAAACTGGTGTCATAAAGAATGAGCATCAGGTTTTCAAATGGGACGGAAAGCCAAGAGCCATGAAGCAATGGGAAAGAGACTTGACCTTAAGAGGGGCAATACAAGTTTCAGCTGTTCCCGTATTTCAACAAATCGCCAGAGAAGTTGGCGAAGTAAGAATGCAGAAATACCTTAAAAAATTTTCCTATGGCAACCAGAATATCAGTGGTGACATTGACAAATTCTGGTTGGAAGGCCAGCTTAGAATTTCCGCAGTTAATCAAGTGGAGTTTCTAGAGTCTCTATATTTAAATAAATTGTCAGCATCTAAAGAAAACCAGCTAATAGTAAAAGAGGCTTTGGTAACGGAGGCGGCACCTGAATATCTAGTGCATTCAAAAACTGGTTTTTCTGGTGTGGGAACTGAGTCAAATCCTGGTGTCGCATGGTGGGTTGGGTGGGTTGAGAAGGAGACAGAGGTTTACTTTTTCGCCTTTAACATGGATATAGACAACGAAAGTAAGTTGCCGCTAAGAAAATCCATTCCCACCAAAATCATGGAAAGTGAGGGCATCATTGGTGGCTAACAAGTCGCTCAAGGTCGCTCCCTGCGGTCGCTGGACAGTCCCAGTCGGCGCATGCTTCGCATTTTATGCGCCGCCTGTGCCTGCCCCTTAGCTCCAACGTTAGGCATCACAAAGTACAGCATCGTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGTTGCCTAACCCTTCCATCGAGGGGGACGTCCAAGGGCTGGCGCCCTTGGCCGCCCCTCATGTCAAACGTTGAGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_5148,Drugs,MEG_5148|Drugs|betalactams|Class_D_betalactamases|OXA,gb|KT736121.1|+|0-2721|ARO:3001555|OXA-368 [Aeromonas sobria] ,0
,atgtctgatttcattcagttagaatatctacaagaaaaattacagcaacttttagcgaaatcattatttgcaatctatctttatggttcagctgttgatggtggtttaggaccagaaagtgaccttgatgttatggtcgtggttactcaaccattaacatctgctttacgcgagcagcttgcacaagaattactaaaaatttcacagcctgttggagaattacaaagaccattagaagttactattttattaaaagatgagattcagtctggaaattatcctttaagttatgaaatgcagtttggtgaatggctacgtgaagaacttaaagaaggtggaacattaaattcgcagaaagacccagatattagtatattgcttagaaaagcgagatttcatcatacagttttatttggtccagctttagaccaatgggcacctgaaatttctgatcaagaactatggcaagcaatgtctgatacttatcccgaaattgtagcgcattgggatgaagatgcagatgaaagaaaccagattttagctttatgccggatctattttagtttagtcatgaaggatattgcttcaaaagacaatgcagcacgatgggttatgtctcagcttcctcctgaacagaaattcgtattgcagcggcttatacaggaatatagaggggaaatcagcaagcaaaattggcaagaggaacattatgctttgcagcctattgttaattttctgagttcaaaaattgaagagcagtttgagcagaaaagaaatttaatcacataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_912,Drugs,MEG_912|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,447201817|WP_001279073.1|NG_054647|1|1|ant(3'')-IIa|ant(3'')-IIa|aminoglycoside_nucleotidyltransferase_ANT(3'')-IIa NG_054647:101-889,2
,TTGTCCAAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGATATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGATGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4305,Drugs,MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_20_ALMZ01000078 ,1
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggcaacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5530,Drugs,MEG_5530|Drugs|betalactams|Class_C_betalactamases|PDC,1201190451|WP_087587971.1|NG_054991|1|1|blaPDC-206|blaPDC|class_C_beta-lactamase_PDC-206 NG_054991:1-1194,0
,atgatgaaaaaatcgatatgctgcgcactgctgctgacagcctctttctccacgtttgctgccgcaaaaacagaacaacaaattgccgatatcgttaaccgcaccatcacaccactgatgcaggagcaggctattccgggtatggccgtggcgattatctacgaggggaaaccttattactttacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgacgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcggggtatcagcctgctgcacttagccacctatacagcgggtggcctgccgctgcagatccccgatgacgttacggataaagccgaattactgcgcttttatcaaaactggcaaccacaatggactccgggcgctaagcgtctttacgctaactccagcattggtctgtttggtgcgctggtggtaaaacattcaggtatgagctacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcaaagcgaacaaaaaaattatgcctggggctatcgcgaagggaagcctgtacacgtttctccggggcaacttgacgccgaagcctatggcgtgaaatccagcgttatcgatatggcccgctgggttcaggccaacatggacgccagcctcgttcaggagaaaacgctccagcagggcattgagcttgcgcagtctcgctactggcgtattggtgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgccagcacctgccgtgaaagcctcatgggtgcataaaacaggatccacaggcggatttggcagctacgttgccttcgttccagaaaaaaaccttggcatcgtaatgttggcaaacaaaagctaccccaacccggctcgcgtcgaggcggcctggcgcattcttgaaaaactgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1786,Drugs,MEG_1786|Drugs|betalactams|Class_C_betalactamases|CMY,1371724125|WP_106672612.1|NG_060513|1|1|blaCMY-150|blaCMY|class_C_beta-lactamase_CMY-150 NG_060513:101-1246,0
,ATGCGCTTCATTCACGCACTATTACTGGCAGGGATCGCTCACTCTGCATATGCGTCGGAAAAATTAACCTTCAAGACCGATCTTGAGAAGCTAGAGCGCGAAAAAGCAGCTCAGATCGGTGTTGCGATCGTCGATCCCCAAGGAGAGATCGTCGCGGGCCACCGAATGGCGCAGCGTTTTGCAATGTGCTCAACGTTCAAGTTTCCGCTAGCCGCGCTGGTCTTTGAAAGAATTGACTCAGGCACCGAGCGGGGGGATCGAAAACTTTCATATGGGCCGGACATGATCGTCGAATGGTCTCCTGCCACGGAGCGGTTTCTAGCATCGGGACACATGACGGTTCTCGAGGCAGCGCAAGCTGCGGTGCAGCTTAGCGACAATGGGGCTACTAACCTCTTACTGAGAGAAATTGGCGGACCTGCTGCAATGACGCAGTATTTTCGTAAAATTGGCGACTCTGTGAGTCGGCTAGACCGGAAAGAGCCGGAGATGAGCGACAACACACCTGGCGACCTCAGAGATACAACTACGCCTATTGCTATGGCACGTACTGTGGCTAAAGTCCTCTATGGCGGCGCACTGACGTCCACCTCGACCCACACCATTGAGAGGTGGCTGATCGGAAACCAAACGGGAGACGCGACACTACGAGCGGGTTTTCCTAAAGATTGGGTTGTTGGAGAGAAAACTGGTACCTGCGCCAACGGGGGCCGGAACGACATTGGTTTTTTTAAAGCCCAGGAGAGAGATTACGCTGTAGCGGTGTATACAACGGCCCCGAAACTATCGGCCGTAGAACGTGACGAATTAGTTGCCTCTGTCGGTCAAGTTATTACACAACTCATCCTGAGCACGGACAAATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3103,Drugs,MEG_3103|Drugs|betalactams|Class_A_betalactamases|GES,(Bla)GES-5:DQ236171:112-975:864,0
,AGGACCGCAGGCCATGGCCCGCCCCAGTCGCGTATCCCGCGCGCTCTCGCAGAACTTCCTCGCCGACCGCGCCGCCGCCGGACAGCTCGCCCGGCTCGCCGCGCCCCACGGCCTCCCCGTCCCGCTGCTGCTCGAAGTCGGCGCGGGCAAAGGCGCGTTGACCGAGCTGCTCGCCCCGCGCTGTCGCAGTCTCCTCGCCTACGAGATCGACCCACGGCTCGTCCCCGTCCTGCGCTCGCGCTTCGCGGACGCCCCGCACGTCCGCGTCCTCGGCGAGGACTTCCTGCGCGCCAGGGCGCCGCGCACCCCGTTCTCCGTCGCCGGGAACGTCCCCTTCTCCCGTACCGCCGCCGTCGTCGCGTGGTGTCTGCGGGCCCCGCACCTCACCGACGCCACCCTGCTCACCCAGCTGGAGTACGCCCGCAGACGCACCGGCGACTACGGCAGCTGGACGCGGCTGACCGTGCTGACTTGGCCCCGCCACGAGTGGCGGCTCGCCGGGCGGGTCGGGCGCCGCAGCTTCCGTCCCGTGCCCCGGGTGGACGCGGGGATCGTCCGTATCGAGCGGCGTCGCACCCCGCTGCTCGCGCCCGGTGCCGACGCCGGCTGGCGGGAGCTGGTCGACCTCGGCTTCTCCGGGGCCGGCGGCTCCCTGCACGCCTCGCTGCGGCGGGCCCGCCCGAGACGGCGGGTGGACGCGGCGTTCCGCGCGGCGGGGCTCGACCGGGACGTCCTGGTGGGGGAGGTGCCGCCGTGGACGTGGCTGAGGCTGCACGAGGTGCTGGGCTCGTGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2852,Drugs,MEG_2852|Drugs|MLS|23S_rRNA_methyltransferases|ERMV,gi|1927193|gb|U59450.1|SVU59450|384-1176,7
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcccctttatccacgtttgccgccgccaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggctattgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcaccaataaccacccagtcacgcagcaaactctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaataccggccagaactgacaggcaaacagtggcagggtatcagcctgctgcacttagccacctacacggcaggcggcctgccgctgcagatccccgatgacgttacggataaagccgcattactgcgtttttatcaaaactggcagccgcaatgggccccgggcgctaagcgtctttacgctaactccagcattggtctttttggcgcgctggcggtgaacccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacagttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaaggctgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagtgttattgatatggcccgctgggttcaggtcaacatggacgccagccgcgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggatgggagatgctgaactggccgctgaaagctgattcgatcatcaacggtagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggatccactggaggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1789,Drugs,MEG_1789|Drugs|betalactams|Class_C_betalactamases|CMY,1028104382|WP_063859770.1|NG_048796|1|1|blaCMY-127|blaCMY|class_C_beta-lactamase_CMY-127 NG_048796:1-1146,0
,atgagaaaaagtgtgggcattactgtttttggatgcgaacaggatgaggcaaatgctttccgcgctttatcgccggattttcatattatccctacgctgattagcgatgcgatatcggcagacaacgcaaaattggccgctggcaatcaatgcgttagcgtaagccataagtccgaggtttccgaggcgacaattcttgcgctgagaaaggtcggggtaaaatacatttctacccgcagcatcggctgcgatcacattgatacgactgccgccgagagaatgggaatctcggttggcacggttgcgtattcgccggacagcgttgcggattatgctttgatgctgatgctgatggccatacggggtgcaaaacccaccatgcacgccgtggcgcaacaagatttcagattggatcgtatccgggggaaagaactgggggatatgactgtgggagttattggaaccggccatatcgggcaagcggtcgtcaaaaggctgcggggatttggatgccatgtgctggcctatgataacagccgaaaaatggatgcagattatgtccagcttgatgagcttctaaaaaacagcgatattgttacgctccatgtgccgctttgtgcggatacccgccatctgatcggtcagaagcaaattggagagatgaagcaaggcgcatttttaatcaacaccgggcgcggagcgcttgtcgataccggggcgctggtggaggcgttggaaagcggaaagctgggtggtgcggcactggatgtgttggagggcgaggatcagtttgtttataccgattgctcgcagaaagtgcttgaccatccctttttgtcgcagcttttaaggatgccgaatgtgatcatcacaccccatacggcgtactacactgagcgtgtgctgcaggatactacagaaaaaacaatcaggaattgtctcaattttgaaaggagtttacagcatgaatag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7413,Drugs,MEG_7413|Drugs|Glycopeptides|VanB-type_resistance_protein|VANHB,1028100566|WP_063856701.1|NG_048379|1|1|vanH-B|vanH-B|D-lactate_dehydrogenase_VanH-B NG_048379:101-1072,5
,CCGTTTCCGCTATTACAAACCGTCGGTGACGATTTTAGCCGCCGACGCTAATACATCGCGACGGCTTTCTGCCTTAGGTTGAGGCTGGGTGAAGTAAGTGACCAGAATCAGCGGCGCACGATCTTTTGGCCAGATCACCGCGATATCGTTGGTGGTGCCATAGCCACCGCTGCCGGTTTTATCCCCCACAACCCAGGAAGCAGGCAGTCCAGCCTGAATGCTCGCTGCACCGGTGGTATTGCCTTTCATCCATGTCACCAGCTGCGCCCGTTGGCTGTCGCCCAATGCTTTACCCAGCGTCAGATTCCGCAGAGTTTGCGCCATTGCCCGAGGTGAAGTGGTATCACGCGGATCGCCCGGAATGGCGGTGTTTAACGTCGGCTCGGTACGGTCGAGACGGAACGTTTCGTCTCCCAGCTGTCGGGCGAACGCGGTGACGCTAGCCGGGCCGCCAACGTGAGCAATCAGCTTATTCATCGCCACGTTATCGCTGTACTGTAGCGCGGCCGCGCTAAGCTCAGCCAGTGACATCGTCCCATTGACGTGCTTTTCCGCAATCGGACTATAGTTAACAAGGTCAGATTTTTTGATCTCAACTCGCTGATTTAACAGATTCGGTTCGCTTTCACTTTTCTTCAGCACCGCGGCCGCGGCCATCACTTTACTGGTGCTGCACATCGCAAAGCGCTCATCAGCACGATAAAGTATTTGCGAATTATCTGCTGTGTTAATCAATGCCACACCCAGTCTGCCTCCCGACTGCCGCTCTAATTCGGCAAGTTTTTGCTGTACGTCCGCCGTTTGCGCATACAGCGGCACACTTCCTAACAACAGCGTGACGGTTGCCGTCGCCATCAGCGTGAACTGGCGCAGTGATTTTTTAACCATGGGATTCCTTATTCTGGAAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_2419,Drugs,MEG_2419|Drugs|betalactams|Class_A_betalactamases|CTX,gi|695209447|ref|NG_035830.1|1-908,0
,ATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGATAGGTTAATGACATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGGTGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTAAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAGATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6868,Drugs,MEG_6868|Drugs|betalactams|Class_A_betalactamases|TEM,gi|114386381|gb|DQ834728.1|1-1066,0
,atgaatcgattgaaaatcgccattatcttcggaggttgttctgaagaacattccgtttccgttaaatctgcccaagaggtcgctaaaaaccttgatctcgaaaagtatgagccctactatatcggaattacgcaaaatggtgtctggaagctttgtcacttccctgaagcaaattgggaaaatagttgttgtcttccggctatgctggcaccggacagtggggtacacggcttgattgttttggagcagggaaaatacaagatgatacctttggatatggtgtttcctgttctgcatggcaaatttggcgaggatggtgccatacaaggtttgttggagctttcctgcatcccatatgtaggctgcgatatccaaagttctgctctgtctatggacaaatcccttgcttatatcgtcgccggaaacgcgagaattgcgaccccgaatttctggacgtttacggagaacgaggatatggaccccgaccggtttatttaccccgtttttgttaagccggcccgttcggggtcatcttttggggttactaaggtatgccgagaagaagaattgctaagtgcggtggaaatcgccagacagtatgattcgaaggtgctgattgaagaggctgtcgtcggtagtgaggtaggatgtgcgatatttggggacgatccggatttgactgcaggagaagtagatcaaatttcactatcgcatggtttttttagaatccatcaggagagtgagcctgaaaacggttccgaaaactcaacaatcatcgttcccgctgatatttcgacggagatgcgcttgcatatccaggagacggctaaagccatctatcgtgctttgggatgcaggggactggcgcgagtggatatgtttctgaaggaagatggggaagtaattctaaacgaggtaaatacgttgcctggaatgacctcgtacagccgttttccgagaatgatggcagccgcagggctaacttttgccgaagtgatcgaccgaatcgttgcattaaccttggaagggaaaagacgatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7440,Drugs,MEG_7440|Drugs|Glycopeptides|VanI-type_resistance_protein|VANI,752548558|WP_041219811.1|NG_050587|1|1|vanI|vanI|D-alanine--(R)-lactate_ligase_VanI NG_050587:101-1141,5
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgataactcactaaaaataagcgctaaagaacaagcaattttgctttttaaactttcacaaaattctttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4655,Drugs,MEG_4655|Drugs|betalactams|Class_D_betalactamases|OXA,919235677|WP_052781249.1|NG_057519|1|1|blaOXA-583|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-583 NG_057519:1-774,0
,atgaatattaaacctgcatcagaagcttcactcaaagattggttagaattaagaaataaattgtggagtgattctgaatcttctcatttacaagagatgcgtcaattattaaccgaaaaatatgccctacaattattagcctattctgagcaccaagctattgcgatgttagaagcctcaattcggtttgaatatgtgaatgggactgagacttctcctgtgggttttttggaaggtatttacgtacttcctgaacagcgtcgctcgggcgttgcaaccatgcttattcgacaggccgaagtgtgggcaaaacaattttcttgcactgaatttgcatctgatgcggcattggacaatgtaattagtcatgctatgcatcgttcattaggttttcaagaaactgaaaaagtcgtttattttagtaaaaaaatagattaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_117,Drugs,MEG_117|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,515965189|WP_017395772.1|NG_052255|1|1|aacA-ACI1|aacA-ACI1|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052255:101-538,2
,atgcgcaataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcacgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcactgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5426,Drugs,MEG_5426|Drugs|betalactams|Class_C_betalactamases|PDC,730561829|WP_034048369.1|NG_049924|1|1|blaPDC-50|blaPDC|class_C_beta-lactamase_PDC-50 NG_049924:1-1194,0
,TTGAAGGAGGAACTCTTGATGGCTGAATTACCTCAATCAAGAATAAATGAACGAAATATTACCAGTGAAATGCGTGAATCATTTTTAGATTATGCGATGAGTGTTATCGTTGCTCGTGCATTGCCAGATGTTCGTGACGGTTTAAAACCAGTACATCGTCGTATACTATATGGATTAAATGAACAAGGTATGACACCGGATAAATCATATAAAAAATCAGCACGTATCGTTGGTGACGTAATGGGTAAATATCACCCTCATGGTGACTCATCTATTTATGAAGCAATGGTACGTATGGCTCAAGATTTCAGTTATCGTTATCCGCTTGTTGATGGCCAAGGTAACTTTGGTTCAATGGATGGAGATGGCGCAGCAGCAATGCGTTATACTGAAGCGCGTATGACTAAAATCACACTTGAACTGTTACGTGATATTAATAAAGATACAATAGATTTTATCGATAACTATGATGGTAATGAAAGAGAGCCGTCAGTCTTACCTGCTCGATTCCCTAACTTATTAGCCAATGGTGCATCAGGTATCGCGGTAGGTATGGCAACGAATATTCCACCACATAACTTAACAGAATTAATCAATGGTGTACTTAGCTTAAGTAAGAACCCTGATATTTCAATTGCTGAGTTAATGGAGGATATTGAAGGTCCTGATTTCCCAACTGCTGGACTTATTTTAGGTAAGAGTGGTATTAGACGTGCATATGAAACAGGTCGTGGTTCAATTCAAATGCGTTCTCGTGCAGTTATTGAAGAACGTGGAGGCGGACGTCAACGTATTGTTGTCACTGAAATTCCTTTCCAAGTGAATAAGGCTCGTATGATTGAAAAAATTGCAGAGCTCGTTCGTGACAAGAAAATTGACGGTATCACTGATTTACGTGATGAAACAAGTTTACGTACTGGTGTGCGTGTCGTTATTGATGTGCGTAAGGATGCAAATGCTAGTGTCATTTTAAATAACTTATACAAACAAACACCTCTTCAAACATCATTTGGTGTGAATATGATTGCACTTGTAAATGGTAGACCGAAGCTTATTAATTTAAAAGAAGCGTTGGTACATTATTTAGAGCATCAAAAGACAGTTGTTAGAAGACGTACGCAATACAACTTACGTAAAGCTAAAGATCGTGCCCACATTTTAGAAGGATTACGTATCGCACTTGACCATATCGATGAAATTATTTCAACGATTCGTGAGTCAGATACAGATAAAGTTGCAATGGAAAGCTTGCAACAACGCTTCAAACTTTCTGAAAAACAAGCTCAAGCTATTTTAGACATGCGTTTAAGACGTCTAACAGGTTTAGAGAGAGACAAAATTGAAGCTGAATATAATGAGTTATTAAATTATATTAGTGAATTAGAAGCAATCTTAGCTGATGAAGAAGTGTTATTACAGTTAGTTAGAGATGAATTGACTGAAATTAGAGATCGTTTCGGTGATGATCGTCGTACAGAAATTCAATTAGGTGGATTTGAAAACTTAGAGGACGAAGACTTAATTCCAGAAGAACAAATAGTAATTACACTAAGCCATAATAACTACATTAAACGTTTGCCGGTATCTACATATCGTGCTCAAAACCGTGGTGGTCGTGGTGTTCAAGGTATGAATACATTGGAAGAAGATTTTGTCAGTCAATTGGTAACTTTAAGTACACATGACCATGTATTGTTCTTTACTAACAAAGGTCGTGTATACAAACTTAAAGGTTACGAAGTGCCTGAGTTATCAAGACAGTCTAAAGGTATTCCTGTAGTGAATGCTATTGAACTTGAAAATGATGAAGTCATTAGTACAATGATTGCTGTTAAAGACCTTGAAAGTGAAGACAACTTCTTAGTGTTTGCAACTAAACGTGGTGTCGTTAAACGTTCAGCATTAAGTAACTTCTCAAGAATAAATAGAAATGGTAAGATTGCGATTTCGTTCAGAGAAGATGATGAGTTAATTGCAGTTCGCTTAACAAGTGGTCAAGAAGATATCTTGATTGGTACATCACATGCATCATTAATTCGATTCCCTGAATCAACATTACGTCCTTTAGGCCGTACAGCAACGGGTGTGAAAGGTATTACACTTCGTGAAGGTGACGAAGTTGTAGGGCTTGATGTAGCTCATGCAAACAGTGTTGATGAAGTATTAGTAGTTACTGAAAATGGTTATGGTAAACGTACGCCAGTTAATGACTATCGCTTATCAAATCGTGGTGGTAAAGGTATTAAAACAGCTACGATTACTGAGCGTAATGGTAATGTTGTATGTATCACTACAGTAACTGGTGAAGAAGATTTAATGATTGTTACTAATGCAGGTGTCATTATTCGACTAGATGTTGCAGATATTTCTCAAAATGGTCGTGCAGCACAAGGTGTTCGCTTAATTCGCTTAGGTGATGATCAATTTGTTTCAACGGTTGCTAAAGTAAAAGAAGATGCAGAAGATGAAACGAATGAAGATGAGCAATCTACTTCAACTGTATCTGAAGATGGTACTGAACAACAACGTGAAGCGGTTGTAAATGATGAAACACCAGGAAATGCAATTCATACTGAAGTGATTGATTCAGAAGAAAATGATGAAGATGGACGTATTGAAGTAAGACAAGATTTCATGGATCGTGTTGAAGAAGATATACAACAATCATCAGATGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3229,Drugs,MEG_3229|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|941146344|gb|CP007676.1|7014-9695 gi|941142962|gb|CP007672.1|7014-9695 gi|941139768|gb|CP007657.1|7014-9695 gi|899756207|gb|CP012119.1|1918669-1915988 gi|828461663|gb|CP007674.1|7014-9695 gi|828444881|gb|CP007670.1|7014-9695 gi|640834542|gb|CP007690.1|7014-9695 gi|610395799|gb|CP007539.1|6471-9152 gi|160367075|gb|CP000730.1|7014-9695 gi|150373012|dbj|AP009351.1|6994-9675,3
,atgaccgcgaacgaaaacaccgtaaccctgcgcctgatgactgagcacgacctccccatgctccatgaatggctgaaccggccacacatagttgaatggtggggcggtgaggaagaacgtccaacactggacgaggtatatgaccactacctgccaacagttctggcgcaggaatcagtcaccccgtacatcgccatgctaggcaacgaaccgattggctacgcgcagtcgtatgtcgcgcttggcagcggtgacgggtggtgggaagaggaaaccgacccaggcgtgcgaggaatcgatcagtcgctggccaacccaacgaaactgaacaaaggcctcgggaccaagcttgtacgcgcgctggctgatctgctgttctcagatgcgtcagtgacaaagatccagaccgacccggctccgggtaaccatagagctatccgttgctacgagaaggcaggctttttgcaggaaaaggtcatcaccacacctgacgggccggctgtctacatggttcagtcaaggcaaacatacgagcgtgcgcgcggtgctgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_129,Drugs,MEG_129|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502108|WP_071846260.1|NG_052301|1|1|aac(6')-set_A|aac(6')-set_A|aminoglycoside_6'-N-acetyltransferase NG_052301:101-655,2
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATCGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATATAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1434,Drugs,MEG_1434|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_36_JITV01000006,0
,GCAGCAAAGATGAAATCAATGATTTATCAAAAATGATTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGTTTTACTTTTTGTGCTGACTGTGAATACTTCAGCCACACGGATTCAATTTTCAGGAGTTTGAGACGATGAGACATCGCGTTAAGCGGATGATGCTAATGACAACGGCCTGTATTTCGCTGTTGCTGGGGAGTGCGCCGCTGTATGCGCAGGCGAACGACGTTCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGGGGGCGGTTGGGAGTGGCGCTGATTGACACCGCCGATAACGCACAGACGCTCTACCGCGCCGACGAGCGCTTTGCCATGTGCAGCACCAGTAAGGTGATGGCAGCCGCGGCGGTGCTCAAGCAAAGTGAAACGCAAAAGAACGTGTTGAGTCAGAAGGTTGAGATTAAATCCTCGGACCTGATTAACTACAATCCCATCGCTGAAAAACACGTCAACGGCACGATGACGCTGGCGGAATTGAGCGCCGCGGCGTTGCAGTACAGCGATAATACGGCCATGAACAAGCTGATTGCCCATCTTGGGGGGCCGGATAAAGTGACGGCGTTTGCCCGTGCGATTGGGGATGACACCTTCCGGCTCGATCGTACTGAGCCGACGCTCAACACCGCGATCCCCGGCGACCCGCGCGATACCACCACGCCATTAGCGATGGCGCAGACGCTTCGCCATCTGACGTTGGGCAGTGCCTTAGGTGAAACTCAGCGTGCGCAACTGGTAACGTGGCTGAAAGGCAACACCACCGGTGCTGCCAGCATTCAGGCTGGGCTACCCACATCGTGGGTTGTCGGGGATAAAACCGGCAGCGGTGATTATGGTACGACGAATGACATCGCCGTCATCTGGCCGGAAGGGCGTGCGCCGCTTATTCTGGTCACTTACTTCACCCAACCGGAGCAGAAGGCAGAAAGTCGTCGTGACGTGCTCGCGGCTGCCGCGAAAATCGTCACCGACGGTTATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2412,Drugs,MEG_2412|Drugs|betalactams|Class_A_betalactamases|CTX,gi|67462182|gb|AY750914.2|1-1079,0
,atgttcaaacttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgcggggaacgtggccaatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7706,Drugs,MEG_7706|Drugs|betalactams|Class_B_betalactamases|VIM,1028110979|WP_063865191.1|NG_050369|1|1|blaVIM-41|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-41 NG_050369:1-801,0
,atgcgcctctgcctgactcccctcgccctggctgccacgctcgtctttgatgtcgccgccgccgacgcaccgctgccgcagctccgggcctacaccgtcaacgcttcgtggctgcagccgatggcaccgctgcaaattgccgaccacacctggcaaatcggcaccgaggacctgaccgcactgctggtgcaaaccaccgagggcgcagtgctattggatggcggcatgccgcaaatggccggtcacctgctggacaacatgaaggcacgcggggtggcaccacaggatctacggctgatcctgctcagccatgcgcatgccgaccatgccgggccggtggcggaactgaagcgccgcaccggtgccacggtggtcgcgaacgccgaaacggccgtgctgcttgcgcgcggcggcagcaacgacctgcacttcggtgatgacatcacctacccgccggccagtgccgaccgcaccatcatggatggtgaaagggtgacggtaggcggcatggcattcaccgcgcacttcatgcctgggcacacccccggcagcaccgcctggacctggaccgatagccgcgatggcaagcccgtgcgcatcgcctacgccgacagcctgagtgcgccgggctaccagctgcagcacaacgcacgctatccccgactggtcgaggactactggcgcagcttcacgacggtgcgcggcctgccctgcgacctgctgctgaccccgcatccgggcgccagccgctggaactatgccgccggtgccgaggccggggccaacgtcctgacctgcaaggcctacgcggatgcggccgagaaggcgttcgacgcgcagttggccaaggaagcggccggggcccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3519,Drugs,MEG_3519|Drugs|betalactams|Class_B_betalactamases|L1,1028083730|WP_063842698.1|NG_047516|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047516:1-870,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggcttatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgccgccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatcaccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5587,Drugs,MEG_5587|Drugs|betalactams|Class_C_betalactamases|PDC,730393645|WP_034005655.1|NG_049933|1|1|blaPDC-59|blaPDC|class_C_beta-lactamase_PDC-59 NG_049933:1-1194,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttattcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4462,Drugs,MEG_4462|Drugs|betalactams|Class_D_betalactamases|OXA,1509794584|WP_122630893.1|NG_062313|1|1|blaOXA-691|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-691 NG_062313:14-838,0
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttctctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttacttgatgcacttttagaaatctccgacagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaagggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcagatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7128,Drugs,MEG_7128|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,912687134|WP_050232631.1|NG_048246|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048246:101-2020,4
,atgaactttcaagcactcttacttataacaagcgctatttttatttcagcctactcaccttatatagtgactgctaatccaaattacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgataggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtattggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcaacaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatatctagctctgttcgaaaagagattacttatagaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4719,Drugs,MEG_4719|Drugs|betalactams|Class_D_betalactamases|OXA,1509794590|WP_122630899.1|NG_062319|1|1|blaOXA-697|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-697 NG_062319:37-861,0
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_864,Drugs,MEG_864|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1028081059|WP_063840442.1|NG_047354|1|1|aadA3|aadA3|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA3 NG_047354:16-807,2
,atgaaaactttacaatttggattcatcgccctcattacaaccttcagttccgcatgtaccacaataagcccctccgtagaaacagctaaaaaccaacagcaacaaagtgcgcagcagcagatccaacaggccttcgatcaactccaaaccactggggtgattgtcattaaggataagcacggcttacacagctacggcaatgacttgagccgtgctcagacaccctatgtacccgcctctacctttaaaatgctgaatgccttaatcggactagaacatggtaaagcaaccagcactgaggtgtttaaatgggatggtcaaaagcgcagcttccctgcttgggaaaaagatatgactttagggcaagccatgcaagcatctgccgttcccgtttatcaggagctagcacggcgcattggtctagacctaatgcaaaaagaagtacagcgcattcgatatggcaatcaacagattggcaccgttgtcgataatttttggttagtcggcccactgcaaattacgcctgttcaagaagtcctttttgtagagaagctggccaatacccaactcgcttttaagcccgacgtgcaacatgcagtacaagacctgctgctgattgaacaaaaaccgaattataaactttatgcaaaatcaggctggggcatggacctagaaccgcaagtcggctggtggacaggctgggtcgaaacagcaacaggtgaaaaagtgtattttgctttgaatatgcatatgaaaacaggaatttcagccagcgtgcgtgagcaactggtcaaacaaagtctgacagcactggggataatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4678,Drugs,MEG_4678|Drugs|betalactams|Class_D_betalactamases|OXA,1440786786|WP_114699274.1|NG_061398|1|1|blaOXA-662|blaOXA-211_like|OXA-211_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-662 NG_061398:1-825,0
,atgaaaataatgttagagggacttcatataaaacattatgttcaagatcgtttattgttgaacataaatcatctaaagatttatcagaatgatcgtattggtttagttggcaaaaatggaaatggaaaaacaacgttacttcacatattatataaaaaaattgtgcctgaagaaggtattgtaaaacaattttcacattgtgaacttattccccaattgaagctcatagaatcaactaaaagtggtggtgaagtaacacgaaactatattcggcaagcgcttgataaaaatccagaactgctattagcagatgaaccaacaactaacttagataataactatatagaaaaattagaacaggatttaaaaaattggcatggagcatttattatagtttcacatgatcgcgcttttttagataacttgtgtactactatatgggaaattgaagaggggagaataactgaatataaggggaattatagtaaatatgttgaacaaaaagaattagaaagacaccgagaagacttagaatatgaaaaatatgaaaaagaaaagaaacgattggaaaaagctataaatataaaagaacagaaagctcaacgagcaactaaaaaaccaaaaaacttaagttcatctgagggcagaataaaaggaacaaagccatactttgcaggtaaacagaagaagttacgaaaaactgtaaagtctctagaaaccagactagaaaaacttgaaagtgtcgaaaagagaaacgaacttcctccacttaaaatggatttagtgaatttagaaagtgtaaaaaatagaactataatacgtggtgaagatgtctcgggcacaattgaaggacgagtattgtggaaagcaaaaagttttagtattcgcggaggagacaagatggcaattatcggatctaatggtacaggaaagacaacgtttataaaaaaaattgttcatgggaatcctggtatttcattatcgccatctgtcaaaatcggttattttagtcaaaaaatagatacattagaattagataagagtattttagaaaatgttcaatcttcttcacaacaaaatgaaactcttattcgaactattctagctagaatgcatttttttagagatgatgtttataaaccaataaatgtcttaagtggtggagagcgagttaaagtagcactaactaaagtattcttaagtgaagttaatacattagtactagatgaaccaacaaactttcttgatatggaagctatagaggcgtttgaatctttgttaaaggaatataatggcagtataatctttgtatctcacgatcgtaaatttatcgaaaaagtagccactcgaataatgacaattgataataaagaaataaaaatatttgatggcacatatgaacaatttaaacaagctgaaaagccgacaaggaatattaaagaagataaaaaacttttacttgagacaaaaattacagaagtactcagtcgattgagtattgaaccttcggaagaattagaacaagagtttcaaaacttaataaatgaaaaaagaaatttagataaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_7676,Drugs,MEG_7676|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA,1028100802|WP_063856937.1|NG_048554|1|1|vga(A)|vga(A)|ABC-F_type_ribosomal_protection_protein_Vga(A) NG_048554:101-1669,1
,AGAGTTTGATCCTGGCTCAGGACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGGAAAGGCCCTGCTTTTGTGGGGTGCTCGAGTGGCGAACGGGTGAGTAACACGTGAGTAACCTGCCCTTGACTTTGGGATAACTTCAGGAAACTGGGGCTAATACCGGATAGGAGCTCCTGCTGCATGGTGGGGGTTGGAAAGTTTCGGCGGTTGGGGATGGACTCGCGGCTTATCAGCTTGTTGGTGGGGTAGTGGCTTACCAAGGCTTTGACGGGTAGCCGGCCTGAGAGGGTGACCGGCCACATTGGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGGAAGCCTGATGCAGCAACGCCGCGTGCGGGATGACGGCCTTCGGGTTGTAAACCGCTTTCGCCTGTGACGAAGCGTGAGTGACGGTAATGGGTAAAGAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTGATACGTAGGGTGCGAGCGTTGTCCGGATTTATTGGGCGTAAAGGGCTCGTAGGTGGTTGATCGCGTCGGAAGTGTAATCTTGGGGCTTAACCCTGAGCGTGCTTTCGATACGGGTTGACTTGAGGAAGGTAGGGGAGAATGGAATTCCTGGTGGAGCGGTGGAATGCGCAGATATCAGGAGGAACACCAGTGGCGAAGGCGGTTCTCTGGGCCTTTCCTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGCTTAGATACCCTGGTAGTCCACGCTGTAAACGGTGGGTACTAGGTGTGGGGTCCATTCCACGGGTTCCGTGCCGTAGCTAACGCTTTAAGTACCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGCCCCGCACAAGCGGCGGAGCATGCGGATTAATTCGATGCAACGCGTAGAACCTTACCTGGGTTTGACATGGATCGGGAGTGCTCAGAGATGGGTGTGCCTCTTTTGGGGTCGGTTCACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTTCACTGTTGCCAGCACGTTATGGTGGGGACTCAGTGGAGACCGCCGGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGTCCAGGGCTTCACGCATGCTACAATGGCTGGTACAGAGAGTGGCGAGCCTGTGAGGGTGAGCGAATCTCGGAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCTCATGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCAACGCTGCGGTGAATACGTTCCCGGGGCTTGTACACACCGCCCGTCAAGTCATGAAAGTTGGTAACACCCGAAGCCGGTGGCCTAACCGTTGTGGGGGAGCCGTCGAAGGTGGGACTGGTGATTAGGACTAAGTCGTAACAAGGTAACC,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Tetracyclines,MEG_6964,Drugs,MEG_6964|Drugs|Tetracyclines|Tetracycline-resistant_16S_ribosomal_subunit_protein|TET16S,gb|NR_040847.1|+|0-1486|ARO:3003499|Cutibacterium acnes 16S rRNA mutation conferring resistance to tetracycline [Cutibacterium acnes] ,4
,ATGATGAAAAAATCGTTATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACAAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCATACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACATTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCACTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTATCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1938,Drugs,MEG_1938|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KM087839|+|0-1146|ARO:3002126|CMY-115 [Citrobacter freundii] ,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCCCTTTCTCCACGTTTGCCGCAGCCAAAACAGAACAACAGATTGCCGATACCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGGCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGGTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAAACTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1903,Drugs,MEG_1903|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JQ711184|+|1026-2172|ARO:3002084|CMY-71 [Citrobacter freundii] ,0
,atgagaaacacagtgcccgccgagatttcggtacagttatcacaggcactcaacgtcatcgagcatcctctgggatcgacgttgctggccatgcatttgtatggctctgcactcgacggtggcctgaagccatacagtgacattgatttgctggttactgtgaccgcacggctcgatgagagtgtgcggcaagctctgttcgtcgatctcttgggggcttccgttttccctggtcaaagcagagttctccgcgccttggaagttaccattgtcgtgcacagtgacatcgttccttggcgctatccggccagacgggaactgcaattcggggagtggcagcgcaaagacattcttgcgggcatcttcgagcctgcgacaaccgatgttgatctagccattctgctaacaaaagcaaggcaacatagccttgccttggccggttcggctgcggaagatttcttcaacccagtcccggaaagcgatctgttcaaggcactggccgacaccctgaaactatggaactcacagccggattggataggtgacgagcggaatgtagtgcttactttgtctcgtatttggtacagcgcagcaaccggcaagatcgcaccgaaggatgttgccgccaactgggtaatggagcgtttgccagttcaacatcagcccgtgctgcttgaagcccggcaggcttatcttggacaaggagaagattgcttggcttcgctcacggatcagttagaggcgtttgttcacttcgtgaagcatgaagccactaaactgcttggtgccacgccaatgatgtctaattcaggcgttatgcgctcacgtccttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_760,Drugs,MEG_760|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502109|WP_071846261.1|NG_052302|1|1|aadA10|aadA10|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA10 NG_052302:101-934,2
,ATGGCTGCACAATCGTTATGCTGCGCGTTGCTGCTGACAGCCTCTTTCTCTACGTTTGCCGCCGCAAAAACAGAACAACAGATTGCCGATATCGTAAACCGTACCATCACACCGCTGATGCAAGAACAGGCTATTCCGGGTATGGCCGTAGCAATTATCTACCAGGGAAAACCCTATTACTTTACCTGGGGGAAAGCCGATATCGCCAATGACCGCCCCGTCACCCGGCAAACGCTGTTTGAGCTTGGATCGGTAAGTAAGACGTTTAACGGTGTGCTGGGCGGCGATGCTATCGCCCGTGGTGAAATTAAGCTCAGCGATCCGGTCACCCAATACTGGCCCGAATTAACTGGCAAACAATGGCAGGGTATCAGCCTGCTGCACCTGGCCACCTATACGGCGGGTGGTCTGCCGCTTCAGGTACCTGACGACGTTACAGATAAAGCGGCATTACTGCGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGTGCTAAACGCCTGTATGCTAACTCCAGTATTGGTCTGTTTGGCGCACTGGCGGTGAAACCTTCAGGAATGGGCTATGAAGAGGCGATGACCAAACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCACAGAGCGAACAAAAGGATTATGCCTGGGGTTATCGCGAAGGGAAGCCCGTACACGTATCTCCGGGCCAGCTTGATGCCGAAGCCTACGGGGTGAAATCCAGCCTTGTCGATATGACTCGTTGGATTCAGGCCAACATGGACGCCAGCCAGGTGCAGGAGAAAACGCTCCGACAGGGAATTGAAATTGCGCAGGCTCGTTACTGGCATATTGGCGATATGTACCAGGGATTAGGTTGGGAGATGCTGAACTGGCCGGTGAATGCCGACTCGATAATCAACGGTAGCGACAGTAAAGTCGCACTAGCGGCGCTTCCCGCCGTTGAGGTCAATCCGCCCGCCCCTGCAGTGAAAGCCTCATGGGTGCACAAAACCGGCTCCACTGGCGGATTTGGCAGCTACGTTGCGTTCGTTCCGGAAAAAAATCTCGGCATCGTGATGCTGGCAAACAAAAGCTACCCAAACCCTGCTCGCGTCGAGGCCGCCTGGCGCATCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1921,Drugs,MEG_1921|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KC603538|+|0-1131|ARO:3002111|CMY-98 [Citrobacter freundii] ,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTAGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1899,Drugs,MEG_1899|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JF460796|+|0-1146|ARO:3002075|CMY-62 [Escherichia coli] ,0
,TTACTGATCTATATCAAATTGAGTTTTTCCATTATCATACAAATCATCATAAACTTTTCCAGATATAGTAGCATTATAGCTGGCCATCCCTTTATTTTGAACGTCTTTAACATTAATCGCCATTAACATATTAGGATTATTTTTATTATATGAAACAAACCAACCTATTTGTCTTCCAGTTTCCCCTTGATTCATTTTTAATTCTGCTGTGCCAGATTTACCAATAATTCGGGCATAATTTTTGTATATATCATCCCTATGTGTTTTATTAACTACACGTTCCATACCATTAGTTAATATATCTATGTCTTTTTTAGGTATAATATCTTTTTTCCATATTTGAGATTTTGTTTTACGTAAAACATGAGGATTTTGTATATTTCCGTTATTTTCTAAAGCACTGTATATTGATAAAATTTGTATAGGGTTTACTAGTATCTCGCCTTGGCCATATCCTGAATCTGCTAATAATATTTCATTTTTTAAATTACTATTTGAGATTTGTGCTTTATAAAAGGGATAATCACTCGGGATATTTTCACCGATTCCCAAATCTTGCATACCTTGCTCAAATTTTTTGGCTCCTAATGCTAATGCAATGCGGGCAAAAAATATGTTGTCTGATGATTCTATTGCTTGCTTTAAATCGATATTGCCGTCTACTACTTTAAATCTTGTGATATTATAATTACCCCATGATGCATCTTTTTGCCAACCCTTACCATAAATATCAAAATTAGTATTTTTGTCTAGTTTATTTTCTTTTAAGGCTATAATAGATGTTAATATTTTTTGGGTTGAACCTGGTGATGTAGTGATTTGAAATTTGTTGAGCAAAGGCTCTTTTTTATTGTTAGTTAATTTACGGTAGTCATTATTGCTTAATCCATTCATGAATGGATAAACATCGTACGATGGGGTACTTACCAAAGCTAAAATTTCTCCAGTTTTTGGTTGTAATGCTGTACCAGATCCATCGTCATTTTTCATATGTTTATAAATACTTTCTTGTACTCTAGCATCTATAGTTAAATGAAGATCTTTTCCGTTTTCAGCCTTTTTCTCCAATAATGTGTCTAAAGGTTTATTGTCATAAGTATTTGCAATGGATACCTTAAAACCATCAGTGTTTTGCAATTGTTTATCATAGAGGCGTTCTAAGCCTTTTTTTCCAATAACAGTATTTTTGCTATAGTTTCTAAATTGCTTACTTTTTAACTCGTCAGAATTAATTGGACCCACATAACCTAAAAGGTGTACTGTTGCTTCGTTCAATGGATAAACACGGCTTTTTATAGTGTTTATTTGTAAATTGTATGATTTAATTAATTTGTCTATATATTCATCTTGTTTATTTATCTTTTTAATTGGTACAAATGAATCTGGCTGAACCCATTTTTGATTAACTTTATTGGTTATAGCTTTTGTATCAATTTGTAAGTCACGAGCAATATCATCATATTTTTCTTTGGGTGTTTTGTTAGGGACAATACCGATTTCATATGTATTTCCAGTTTTAGCTAATTCTATACCATTTCTATCTTTTATTTTGCCTCGCTCTGATTTTAATGTTTCTATATTAATTTTCTGTCCATTTTTCAAACCAGGTACTATTACGTCTGGTCTCCAATCTAATTTCCAATGCTTATCTTCATAAATAAAGTTTAATTGTGTATTACGTCGTATAGTTCCATATTTTGTATATATGTTATATTTAACATCAACTTGCTTTTTATCTTTTCCAGTTTTTTTAATTTCATGATTAGTAATTTTTAAGTTATTGACACTTAAATCTTTGTAAATTTTTTTATTCCTATCTACAATTTCTTCTTCTCCATATGCCAGTTTAGATTTTTCTGAACTATTTTTATATACTTCGTTATAGTTTCCTTTTTCAATAGAACTAATTGTTTTCTCAATATCGTCATCTTTGAATAACCAAGTTATTATAATCATAATTAGTAAAAGAACTAGCACACTAATATAAATTTTTTTCAT,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_5402,Drugs,MEG_5402|Drugs|betalactams|Penicillin_binding_protein|PBP2,gi|333033673|emb|FR823292.1|1741-3738,0
,atgacgataaccatttcacgccgccaggccatggccggcgctcttcttgccattcccgcggtttctgcgctgacggccggcaccagccgcgccgccggtgagaaccttgcgcaacggcttgccgcattagaggcacgccacggcgggcgcatcggcgttgcaatacataatctttcgacaggcgcgcggctcggtcacaacacggacgagcgtttcctgatgtgcagcaccttcaaggcgctgctggcgggccatatcctcgtccgggtggaccgcggcgaggagacgctggaccgacgcatcgtcgtgaaggaagcggatctcgtggattggtcgccggtggtggaaaagcgcatcggcggggatgtcatctctattgccgaactctgcgaggcgaccatcacgctcagcgacaatgccgccgccaacctgctgctcgccgcatcgggcgggcctaaggccgtcacggcgtttctgcgtggcctcggcgatgaagtgacgcgtctcgaccgtacggagccgacgctcaactaccacgagacgccgggcgatgagcgtgacacgacgacgccgagcgccatggtggagacgctgcgcaggctgctcttcacggacgttctgtcggcgcgttcgaaggcgcagcttgccgcctggctgataatgaacaagacgggcgacacgcggctgcgcgctggcttcccggcagactggatgaccggcgacaagaccggcaccaacggcgacaaggccggaaacgccaacgatgtcgcggtcgcctggtcgccggatcgcggtgcagtcattgttgccgccttctgcgaaatccccggcatttccggtgacgagcgcaatgccgttattgccgaaatcgggcgcatcgcggcagaggtctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3169,Drugs,MEG_3169|Drugs|betalactams|Class_A_betalactamases|GPC,1391852889|WP_109545074.1|NG_057489|1|1|blaGPC-1|blaGPC|carbapenem-hydrolyzing_class_A_beta-lactamase_GPC-1 NG_057489:1-894,0
,atgaatagttcgacaaagatcgcattggtaattacgttactcgatgccatggggattggccttatcatgccagtcttgccaacgttattacgtgaatttattgcttcggaagatatcgctaaccactttggcgtattgcttgcactttatgcgttaatgcaggttatctttgctccttggcttggaaaaatgtctgaccgatttggtcggcgcccagtgctgttgttgtcattaataggcgcatcgctggattacttattgctggctttttcaagtgcgctttggatgctgtatttaggccgtttgctttcagggatcacaggagctactggggctgtcgcggcatcggtcattgccgataccacctcagcttctcaacgcgtgaagtggttcggttggttaggggcaagttttgggcttggtttaatagcggggcctattattggtggttttgcaggagagatttcaccgcatagtcccttttttatcgctgcgttgctaaatattgtcactttccttgtggttatgttttggttccgtgaaaccaaaaatacacgtgataatacagataccgaagtaggggttgagacgcaatcgaattcggtatacatcactttatttaaaacgatgcccattttgttgattatttatttttcagcgcaattgataggccaaattcccgcaacggtgtgggtgctatttaccgaaaatcgttttggatggaatagcatgatggttggcttttcattagcgggtcttggtcttttacactcagtattccaagcctttgtggcaggaagaatagccactaaatggggcgaaaaaacggcagtactgctcggatttattgcagatagtagtgcatttgcctttttagcgtttatatctgaaggttggttagttttccctgttttaattttattggctggtggtgggatcgctttacctgcattacagggagtgatgtctatccaaacaaagagtcatcagcaaggtgctttacagggattattggtgagccttaccaatgcaaccggtgttattggcccattactgtttgctgttatttataatcattcactaccaatttgggatggctggatttggattattggtttagcgttttactgtattattatcctgctatcgatgaccttcatgttaacccctcaagctcaggggagtaaacaggagacaagtgcttag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7042,Drugs,MEG_7042|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,447011816|WP_001089072.1|NG_048161|1|1|tet(B)|tet(B)|tetracycline_efflux_MFS_transporter_Tet(B) NG_048161:101-1306,4
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCGATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1396,Drugs,MEG_1396|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_92_FKWG01000001,0
,ATTTTATAAGTCTTATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGTGCTTCAAGATCTGATGACAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCATCAAGGTCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGAACGGGCAAAAAAGGCTGTTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAATGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGAAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCAGTTCACTTTTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5247,Drugs,MEG_5247|Drugs|betalactams|Class_D_betalactamases|OXA,gi|751813261|gb|KM979379.1|1-867,0
,atgaaaaaaaatataaaatattctcaaaactttttaacgaatgaaaaggtactcaaccaaataataaaacaattgaatttaaaagaaaccgataccgtttacgaaattggaacaggtaaagggcatttaacgacgaaactggctaaaataagtaaacaggtaacgtctattgaattagacagtcatctattcaacttatcttcagaaaaattaaaactgaacattcgtgtcactttaattcaccaagatattctacagtttcaattccctaacaaacagaggtataaaattgttgggagtattccttaccatttaagcacacaaattattaaaaaagtggtttttgaaagccatgcgtctgacatctatctgattgttgaagaaggattctacaagcgtaccttggatattcaccgttcactagggttgctcttgcacactcaagtctcgattcagcaattgcttaagctgccagcggaatgctttcatcctaaaccaaaagtaaacagtgtcttaataaaacttacccgccataccacagatgttccagataaatattggaagctatatacgtactttgtttcaaaatgggtcaatcgagaatatcgtcaactgtttactaaaaatcagtttcatcaagcaatgaaacacgccaaagtaaacaatttaagtaccgttacttatgagcaagtattgtctatttttaatagttatctattatttaacgggaggaaataa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2788,Drugs,MEG_2788|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,1028086175|WP_063844614.1|NG_047795|1|1|erm(B)|erm(B)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B) NG_047795:101-838,7
,atgatgaaaaaatcgatatgctgcgcgctgctgctgacagcctctttctccacgtttgctgccgcaaaaacagaacaacaaattgccgatatcgttaaccgcaccatcacaccactgatgcaggagcaggctattccgggcatggccgtggcaattatctacgaggggaaaccttattactttacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgacgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcggggtatcagcctgctgcacttagccacctatacagcgggtggcctgccgctgcagatccccgatgacgttacggagaaagccgcattactgcgcttttatcaaaactggcaaccacaatggactccgggcgctaagcgtctttacgctaactccagcattggtctgtttggtgcgctggtggtgaaaccttcaggtatgagctacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcaaagcgaacaaaaaaattatgcctggggctatcgcgaagggaagcctgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttatcgatatggcccgctgggttcaggccaacatggacgccagccacgttcaggagaaaacgctccagcagggcattgagcttgcgcagtctcgctactggcgtattggtgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgccagcacctgccgtgaaagcctcatgggtgcataaaacaggatccacaggcggatttggcagctacgttgccttcgttccagaaaaaaaccttggcatcgtaatgttggcaaacaaaagctaccccaacccggctcgcgtagaggcggcctggcgcattcttgaaaaactgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1803,Drugs,MEG_1803|Drugs|betalactams|Class_C_betalactamases|CMY,1028104598|WP_063859918.1|NG_048894|1|1|blaCMY-97|blaCMY|class_C_beta-lactamase_CMY-97 NG_048894:1-1146,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcacggcactgtggccctccagctcgcctgaagagcaccgcgcggaaatgcgcgagatactggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttctggaagggatttataccgtcgaacgcgcccgccgccagggctgggccgcgcgcttgatcgcgcaggtgcaggagtgggcgaagcagcaggggtgcagcgagctggcgtcggataccgacatcgccaatcttgactcccagcgcctgcatgcggcgctgggctttgccgaaacggagcgggtggtgttttaccgcaaaacgctgagctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_161,Drugs,MEG_161|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,896287250|WP_049270433.1|NG_052190|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052190:101-541,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcagtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccattgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5453,Drugs,MEG_5453|Drugs|betalactams|Class_C_betalactamases|PDC,730607094|WP_034051361.1|NG_049921|1|1|blaPDC-48|blaPDC|class_C_beta-lactamase_PDC-48 NG_049921:1-1194,0
,TTCAAATATGTATCCGCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACATGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6894,Drugs,MEG_6894|Drugs|betalactams|Class_A_betalactamases|TEM,gi|237846382|gb|FJ919776.1|139-1069,0
,atggcaatccgaatcttcgcgatacttttctccattttttctcttgccactttcgcgcatgcgcaagaaggcacgctagcacgttctgactggaggaagtttttcagcgaatttcaagccaaaggcacgatagttgtggcagacgaacgccaagcggatcgtgccatgttggtttttgatcctgtgcgatcgaagaaacgctactcgcctgcatcgacattcaagatacctcatacactttttgcacttgatgcaggcgctgttcgtgatgagttccagatttttcgatgggacggcgttaacaggggctttgcaggccacaatcaagaccaagatttgcgatcagcaatgcggaattctactgtttgggtgtatgagctatttgcaaaggaaattggtgatgacaaagctcggcgctatttgaagaaaatcgactatggcaacgccgatccttcgacaagtaatggcgattactggatagaaggcagccttgcaatctcggcgcaggagcaaattgcatttctcaggaagctctatcgtaacgagctgccctttcgggtagaacatcagcgcttggtcaaggatctcatgattgtggaagccggtcgcaactggatactgcgtgcaaagacgggctgggaaggccgtatgggttggtgggtaggatgggttgagtggccgactggctccgtattcttcgcactgaatattgatacgccaaacagaatggatgatcttttcaagagggaggcaatcgtgcgggcaatccttcgctctattgaagcgttaccgcccaacccggcagtcaactcggacgctgcgcgataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4730,Drugs,MEG_4730|Drugs|betalactams|Class_D_betalactamases|OXA,1105502051|WP_071846203.1|NG_052174|1|1|blaOXA-540|blaOXA-2_like|OXA-2_family_class_D_beta-lactamase_OXA-540 NG_052174:101-928,0
,atgtttaagattaaagttgcagttctgtttgggggctgttcagaggaacataatgtttcgataaaatctgcgatggagattgccgcaaacatagatacaaaaaaatatcagccttattatattggaatcacaaaatccggcgtttggaagatgtgtgaaaaaccttgtttggggtgggaacaatatgcgggggatccggttgttttttcgccggacagaagtacgcatggtctgctgatacaaaaagacactgggtatgaaatccagcctgtagatgtggtatttccgatgattcatggcaagtttggcgaagatggatccatacaaggcttgcttgaattgtcaggcattccgtatgtgggatgcgatattcaaagctccgtgatctgcatggataaggcgcttgcatataccgttgtgaaaaatgcgggtatcgctgtgcctgggttccggatccttcaggagggggatcgcctggaaacggaggatttagtatatcccgtctttgtaaagcctgcccgttctggctcatcctttggcgtaaacaaggtatgcaaggcagaagaactgcaggcagcaatcagagaagcaagaaaatatgatagcaagattttgattgaagaggccgttaccgggagtgaggtaggctgcgccatactgggaaacgaaaatgatctcatggctggcgaggtggatcagattgagctgagacacggcttttttaagattcatcaggaagcacagccggagaagggatctgaaaatgcagttatcagagttccagccgccttaccggatgaggtaagagaacggattcggaaaacagcaatgaagatttaccggatacttggctgccgaggattggcccgtattgatctgtttttgcgggaggacggctgcattgtgctgaatgaagtgaataccatgccgggttttacttcctacagccgttatccccgcatgatgacagcagccggttttacgctttctgaaatactggatcgcttgattgaattttcacttaggaggtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7384,Drugs,MEG_7384|Drugs|Glycopeptides|VanD-type_resistance_protein|VAND,1028100554|WP_063856689.1|NG_048358|1|1|vanD|vanD|D-alanine--(R)-lactate_ligase_VanD NG_048358:101-1132,5
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_773,Drugs,MEG_773|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,851889999|WP_048207712.1|NG_052537|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052537:101-892,2
,atgagcaactctatacacaccggaatctcaagacagctttcacaggcacgcgatgtaattaaacgccatttggcatcaacgctgaaagccatacacttgtatggttctgcaattgatggtggcctcaaaccatatagcgacattgatctgctggttaccgtggatgcacgcttggatgaagctaccagacgctccctgatgctcgatttcttgaatatctcggcaccaccatgcgaaagctcaatactccggccgctagaggtaactgttgttgcatgcaacgaagtagtgccttggcgttatccggcacgacgagaactgcagttcggggagtggctgccggaggatattcttgaaggtgtcttcgagccagccgccttggacgccgaccttgcaattctaataacgaaagctaggcaacacagcatcgctttagtaggtccagtggctcaaaaagtcttcatgccggtgccagagcatgactttctccaggtgctttccgatacccttaagctgtggaatactcatgaggattgggaaaatgaggagcggaacatcgtactcacgttagctcggatctggtatagcactgaaactggaggaatcgtccccaaggatgtggccgccgaatgggttttagagcgcttgccagctgagcataagccaatactggttgaggcgcggcaagcctatcttgggctttgcaaggatagtcttgctttgcgtgcagatgagacttcggcgttcattggctatgcaaagtctgcggtcgctgatttgctcgaaaagcgaaaatctcaaacttcgcatatttgcgatggcgccaagaacgtctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_764,Drugs,MEG_764|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502194|WP_071846344.1|NG_052441|1|1|aadA9|aadA9|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA9 NG_052441:101-937,2
,GGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCGCAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6919,Drugs,MEG_6919|Drugs|betalactams|Class_A_betalactamases|TEM,gi|46370392|gb|AY589493.1|1-1027 gi|943457735|gb|KT818627.1|75073-74889 gi|943457735|gb|KT818627.1|136664-136480 gi|959195734|gb|CP013326.1|60956-60772 gi|959190351|gb|CP013324.1|110410-110226 gi|910286593|gb|CP012163.1|68998-69182 gi|902611595|gb|CP011978.1|70771-70955 gi|828971542|gb|CP011645.1|70809-70993 gi|828965729|gb|CP011639.1|9250-9066 gi|828952302|gb|CP011622.1|124502-124686 gi|828952208|gb|CP011621.1|60956-60772,0
,ATGAAAAATAATAATGTAACAGAAAAAGATTTATTTTATATTTTAGATTTATTTGAACACATGAAAGTAACTTATTGGTTAGATGGTGGCTGGGGGGTAGATGTATTAACTGGAAAACAACAAAGAGAACACAGAGATATAGATATAGATTTTGACGCTCAACACACTCAAAAAGTTATACAAAAATTAGAAGATATCGGATACAAAATAGAAGTTGATTGGATGCCTTCACGTATGGAACTTAAGCATGAAGAATATGGGTATTTAGATATTCATCCTATAAATCTAAATGATGATGGATCAATTACCCAAGCAAACCCAGAAGGTGGTAATTATGTTTTCCAAAATGACTGGTTTTCAGAAACTAATTACAAAGGTCGAAAAATACCATGTATTTCAAAAGAAGCTCAACTTCTTTTTCATTCTGGTTATGATTTAACAGAAAAAGACCATTTTGATATAAAAAATTTAAAATCAATAACATAA,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3608,Drugs,MEG_3608|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUA,gi|391225694|gb|JQ861958.1|2562-2077 gi|158526956|gb|EU185047.1|716-231 gi|114425695|emb|AM399080.1|2150-1665 gi|86439166|emb|AM184102.1|2433-1948,7
,ATGAACAAAAATATAAAATATTCTCAAAACTTTTTAACGAGTGAAAAGGTACTCAACCAAATAATAAAACAATTGAATTTAAAAGAAACCGATACCGTTTACGAAATTGGAACAGGTAAAGGGCATTTAACGACGAAACTGGCTAAAATAAGTAAACAGGTAACGTCTATTGAATTAGACAGTCATCTATTCAACTTATCGTCAGAAAAATTAAAACTGAACATTCGTGTCACTTTAATTCACCAAGATATTCTACAGTTTCAATTCCCTAACAAACAGAGGTATAAAATTGTTGGGAATATTCCTTACCATTTAAGCACACAAATTATTAAAAAAGTGGTTTTTGAAAGCCATGCGTCTGACATCTATCTGATTGTTGAAGAAGGATTCTACAAGCGTACCTTGGATATTCACCGAACACTAGGGTTGCTCTTGCACACTCAAGTCTCGATTCAGCAATTGCTTAAGCTGCCAGCGGAATGCTTTCATCCTAAACCAAAAGTAAACAGTGTCTTAATAAAACTTACCCGCCATACCACAGATGTTCCAGATAAATATTGGAAGCTATATACGTACTTTGTTTCAAAATGGGTCAATCGAGAATATCGTCAACTGTTTACTAAAAATCAGTTTCATCAAGCAATGAAACACGCCAAAGTAAACAATTTAAGTACCGTTACTTATGAGCAAGTATTGTCTATTTTTAATAGTTATCTATTATTTAACGGGAGGAAATAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2797,Drugs,MEG_2797|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,1066|unknown_id|unknown_name|MLS|23S_rRNA_methyltransferases|ERMB,7
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGAGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAACAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1869,Drugs,MEG_1869|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EF561644|+|0-1146|ARO:3002039|CMY-28 [Escherichia coli] ,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaacgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagtacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3465,Drugs,MEG_3465|Drugs|betalactams|Class_A_betalactamases|KPC,1440786779|WP_114699267.1|NG_061389|1|1|blaKPC-36|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-36 NG_061389:1-882,0
,GTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTTACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_360,Drugs,MEG_360|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|954629879|gb|CP013215.1|130748-131302 gi|944545016|gb|KR868995.1|335-889 gi|944545013|gb|KR868994.1|334-888 gi|806639053|gb|KM972600.1|1221-1775 gi|806639006|gb|KM972594.1|1194-1748 gi|806638978|gb|KM972589.1|1194-1748 gi|925170830|gb|KR337993.1|2007-2561 gi|925170817|gb|KR337990.1|1043-1597 gi|918039404|gb|KR259332.1|1702-2256 gi|914244709|gb|KR184824.1|537-1091,2
,GTGAGGGCATCATTGGTGGCTAAAACAAAGTTAAACATCATGAGGGAAGCGGTGATCGCCGAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCACACAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCGCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_915,Drugs,MEG_915|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,(AGly)AadA1-pm:JQ690540:7968-8798:831,2
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtgtcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6659,Drugs,MEG_6659|Drugs|betalactams|Class_A_betalactamases|TEM,1172316146|WP_080699425.1|NG_056416|1|1|blaTEM-229|blaTEM|class_A_beta-lactamase_TEM-229 NG_056416:1-861,0
,ATGACCACCACACGCCCCGCGTGGGCCTATACGCTGCCGGCAGCACTGCTGCTGATGGCTCCTTTCGACATCCTCGCTTCACTGGCGATGGATATTTATCTCCCTGTCGTTCCAGCGATGCCCGGCATCCTGAACACGACGCCCGCTATGATCCAACTCACGTTGAGCCTCTATATGGTGATGCTCGGCGTGGGCCAGGTGATTTTTGGTCCGCTCTCAGACAGAATCGGGCGACGGCCAATTCTACTTGCGGGCGCAACGGCTTTCGTCATTGCGTCTCTGGGAGCAGCTTGGTCTTCAACTGCACCGGCCTTTGTCGCTTTCCGTCTACTTCAAGCAGTGGGCGCGTCGGCCATGCTGGTGGCGACGTTCGCGACGGTTCGCGACGTTTATGCCAACCGTCCTGAGGGTGTCGTCATCTACGGCCTTTTCAGTTCGATGCTGGCGTTCGTGCCTGCGCTCGGCCCTATCGCCGGAGCATTGATCGGCGAGTTCTTGGGATGGCAGGCGATATTCATTACTTTGGCTATACTGGCGATGCTCGCACTCCTAAATGCGGGTTTCAGGTGGCACGAAACCCGCCCTCTGGATCAAGTCAAGACGCGCCGATCTGTCTTGCCGATCTTCGCGAGTCCGGCTTTTTGGGTTTACACTGTCGGCTTTAGCGCCGGTATGGGCACCTACTTCGTCTTCTTCTCGACGGCTACCCGTGTGCTCATAGGCCAAGCGGAATATTCCGAGATCGGATTCAGCTTTGCCTTCGCCACTGTCGCGCTTGTAATGATCGTGACAACCCGTTTCGCGAAGTCCTTTGTCGCCAGATGGGGCATCGCAGGATGCGTGGCGCGTGGGATGGCGTTGCTTGTTTGCGGAGCGGTCCTGTTGGGGATCGGCGAACTTTACGGCTCGCCGTCATTCCTCACCTTCATCCTACCGATGTGGGTTGTCGCGGTCGGTATTGTCTTCACGGTGTCCGTTACCGCGAACGGCGCTTTGGCAGAGTTCGACGACATCGCGGGATCAGCGGTCGCGTTCTACTTCTGCGTTCAAAGCCTGATAGTCAGCATTGTCGGGACATTGGCGGTGGCACTTTTAAACGGTGACACAGCGTGGCCCGTGATCTGTTACGCCACGGCGATGGCGGTACTGGTTTCGTTGGGGCTGGTGCTCCTTCGGCTCCGTGGGGCTGCCACCGAGAAGTCGCCAGTCGTCTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2927,Drugs,MEG_2927|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,(Phe)FloR:AKLJ01000508:383-1597:1215,6
,atggaaaaatatataaactggaaacttaagttttatactatatgggcagggcaggcggtatctttaatcactagtgccatcctgcaaatggcgataattttttaccttacagaaaaaacaggatctgcgatggttttgtctatggcttcactagtagggtttttaccctatgcggtctttggaccagccattggtgtattagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatagcagcagctggagcagtgctcgctattgttgcattgtatacggagttatctgtatggatggttatggtagtattgtttatccgtagcattggaacggcatttcattctccggctctcaatgcggttacgccgcttttagtaccagaagaacagcttacgaaatgtgcaggttatagtcagtctttgcagtcgataagttatattattagtccggcggctgcagcattgttatactccgtttggaaattaaatgcaattattgctatcgatgtattgggtgctgtgattgcatctattacggtagcaattgtaagtattcctaagctgggcgatcaagtgcaaagtttgaaaccgaatttcttaagagaaatgaaagaaggaattgtcgcattgagacaaaacaaaggcatatttgccttattactcttaggaacgctatatacgtttgtgtatatgccaattaatgcactgtttcctttaattagcatggaatactttaatggaaaacctgtgcatatttcaattaccgaaatcgcttttgcatctggaatgctagtaggcggtctaatattaggaaggttgggtaattttgaaaagcgtgtattactaataactggttcattctttataatgggggccagtttagtcgtttcaggattacttcctccaagtggatttgttatatttgtagcttgctgtgcagtaatggggctttcggtgccattttatagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttgactggaagtattatgtcatttgctatgccaattggattaattctttctgggttctttgctgatagaatcggtgtgaatcattggtttttactatcaggtattttaattattggcattgctatagtttgccccatgataacagaggttagaaaattagattttaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3821,Drugs,MEG_3821|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028096901|WP_063853602.1|NG_047964|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047964:1-1218,7
,atgaatattaaaccagcatcagaagcttcactcaaagattggttaaaactaagaataaagctttggaatgatcttgaagaatcacatttgcaagagatgcatcagttattggctgaaaagcatgcattacaattattagtctattcggatgatcacgcggttgcgatgctagaagcatctattcggtatgaatatgtaaacgggacagagacttctcccgtggcatttctagaaggcatttatgtacttccagaatatcgtcgcttaggtgtagcaactttacttgttcgtcaggttgaggcgtgggcaaaacaattttcttgtactgagtttgcatctgatgcggcattggacaatgtcattagtcatgcaatgcatcgtgcattgggttttcaagaaactgaaagagttgtttattttagtaaaaaaatagattaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_76,Drugs,MEG_76|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,490808240|WP_004670361.1|NG_052394|1|1|aacA-ACI4|aacA-ACI4|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052394:101-538,2
,atgcaacaggggttattttacttcggctggttattacttttaacgcaattaagtgcttgccacatgaacatggcgcagatgtctgatccatccgtacaaaaggtggtttcgaaggcaatatttgaacgctcagaagagattaaggcattattcaacgctgcaaatacatcagccgtttttatgacttatgacggtcagcagtttcattattatggtaatgctttggcccgtgctaagaatgcctatattccagcttcaacatttaaaatgttaaatgcattgattgctcttcagcatcataaagtaactacttccgaagtgtttgaatggaagggtgaaaagcgttcattttctgcgtgggaaaaagacatgaacttggcgcaagccatgcaagcttcagcagttccagtgtatcaagagcttgctagacgtattgggttagagttgatgcagaaagaagtttctcgacttggttttggcaatcaaaaaattggtcaacaggtggataatttttggctggttggccctttaaaagtaaccccagaacaagaagtaaaatttgtttatcaactggcaacagagcaattactttttgatgtaaaagtacaaaaacaggtcaaagaaatgctttatattgagcgtcgtggtgatacaaaactatatgcaaaaagtggttggggaatggatgtaaagccccaagtggggtggtacacagggtgggttgaacaacccaatggacagatcaccgcttttgttttaaatttggaaatgcatgatggcgatgatgtaggcgaacgtaagcagcttactttggatgtgttagataagttaggattattcttttatttacactag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4598,Drugs,MEG_4598|Drugs|betalactams|Class_D_betalactamases|OXA,1224670996|WP_092689909.1|NG_062232|1|1|blaOXA-666|blaOXA|carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-666 NG_062232:101-955,0
,atgatgactcagagcattcgccgctcaatgttaacggtgatggcgacgctacccctgctatttagcagcgcaacgctgcatgcgcaggcgaacagcgtgcaacagcagctggaagccctggagaaaagttcgggaggtcggcttggcgttgcgctgattaacaccgccgataattcgcagattctctaccgtgccgatgaacgttttgcgatgtgcagtaccagtaaggtgatggcggccgcggcggtgcttaaacagagcgagagcgataagcacctgctaaatcagcgcgttgaaatcaagaagagcgacctggttaactacaatcccattgcggagaaacacgttaacggcacgatgacgctggctgagcttggcgcagcggcgctgcagtatagcgacaatactgccatgaataagctgattgcccatctgggtggtcccgataaagtgacggcgtttgctcgctcgttgggtgatgagaccttccgtctggacagaaccgagcccacgctcaataccgccattccaggcgacccgcgtgataccaccacgccgctcgcgatggcgcagaccctgaaaaatctgacgctgggtaaagcgctggcggaaactcagcgggcacagttggtgacgtggcttaagggcaatactaccggtagcgcgagcattcgggcgggtctgccgaaatcatgggtagtgggcgataaaaccggcatcggagattatggcaccaccaacgatatcgcggttatctggccggaaaaccacgcaccgctggttctggtgacctactttacccaaccggagcagaaggcggaaagccgtcgggatattctggctgcggcggcgaaaatcgtaacccacggtttctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_2169,Drugs,MEG_2169|Drugs|betalactams|Class_A_betalactamases|CTX,1226997336|WP_094009813.1|NG_055501|1|1|blaCTX-M-200|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-200 NG_055501:1-876,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6498,Drugs,MEG_6498|Drugs|betalactams|Class_A_betalactamases|SHV,gi|979522909|gb|CP014008.1|2497261-2496401 gi|257043755|gb|GQ407119.1|1-861,0
,GTGACCGCCGAAATTTCGACGCAACTATCCAAGGTGCTTAGTGTTATCGAGCACCATCTGGAACCGACGTTGCTTGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGTGATATTGATTTGCTGGTTACTGTGACCGCAAGGCTTGATGACACAACGCGGCGAGCTTTGTTCAACGATCTTTTGGAGGTTTCGGCTTTCCCAGGCGAGAGTGAGATTCTCCGCGCTATAGAAGTCACCATTGTCGTGCACGAAGACATTATGCCGTGGCGTTATCCAGCCAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCACGATCGACATCGATCTGGCTATCTTGCTAACGAAAGCGAGAGAACATAGCGTGGCTTTGGTAGGTCCGGCGGCGGAGGAACTCTTTGATCCAGTTCCTGAACAAGATCTAATCAAGGCGCTGAATGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCCGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGCAACTGGTAAAATCGCGCCGAAGGATGTCGCTGCCAACTGGGCAATGGAACATCTACCTGCCCAGCATCAGTCTGTCTTGCTTGAAGCTAGACAGGCTTATCTTGGGCAAGAGGAAGATCGCTCGGTCTTGCGCGCAGATAAGTTGGAAGAATTTATTCACTTCATGAAAAGCGAGATCACCAAGGTGCTCGGCAATGATGTCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_957,Drugs,MEG_957|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|667671718|gb|KF468749.1|1547-2332 gi|667671714|gb|KF468748.1|1535-2320 gi|667671697|gb|KF468743.1|2165-2950 gi|551485251|gb|KF525328.1|398-1183 gi|402748691|gb|JX195556.1|111-896 gi|383216584|gb|JQ407409.1|2763-3548 gi|359743183|gb|JN106164.1|22643-23428 gi|355336852|gb|JN118546.1|748-1533 gi|351214313|gb|HQ170513.2|3185-3970 gi|300391784|gb|HM175875.1|715-1500,2
,ATGAGGGAAGCGGTGATCGCCGAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGTGGCCTGAAGCCACACAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCCCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_954,Drugs,MEG_954|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|308052966|gb|GU060319.1|975-1766,2
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAGATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTATTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1361,Drugs,MEG_1361|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_18_JBQW01000016,0
,TCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTATTAGGAAGTGTGCCGCTGCATGCGCAAACGGTGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGAAGGCTGGGTGTGGCATTGATTAACACGGCGGATAATTCGCAAATACTTTATCGTGCTGATGAGCGTTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTAAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTCGAGATCAAAAAATCTGACCTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTCAGCGCGGCCGCGCTACAGTACAGCGATAATGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGATGACACGTTCCGTCTCGACCGCACCGAGCCGACGTTAAACACCGCCATTCCTGGCGATCCGCGTGATACCACTTCACCTCGGGCGATGGCGCAAACGCTGCGTAATCTGACGCTGGGTAAAGCGTTGGGCGACAGCCAACGGGCGCAGCTGGTGACGTGGATGAAAGGCAATACTACCGGTGCCGCGAGTATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGTACCACCAACGATATCGCGGTGATTTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGGAAACGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_2374,Drugs,MEG_2374|Drugs|betalactams|Class_A_betalactamases|CTX,gi|157812671|gb|EU177100.1|1-893,0
,ATGAAAAATTTCTTCGAAAGTCCTTTTAAAGGAAAAATAATCAAAGACCACATAACTAATCCCAATATAATTTCGGGTAAATATTCTTATTATTCCGGTTATTATCACGGTCATTCATTTGATGATTGTGCTCGTTATCTGTTTCCGGACAGGAATGATGTCGATAAACTAATTATCGGTTCTTACTGCTCAATAGGGAGTGGTGCAAGTTTCATAATGGCAGGTAATCAAGGTCATAAATATGATTGGATTTCCAGTTTTCCATTTTTTTATATGTCTGAATTTGATGTTTTCAGTAAAAGCCAAGATGGATTTCAAAAAGCAGGAGATACAGTTGTTGGGAATGATGTTTGGATTGGTAGTGAAGCTATGATAATGCCAGGAGTTCAGATAGGAGATGGAGCTGTTATTGGCAGTCGTGCTTTGGTTACAAAAGATGTTGAACCTTATTCAATTGTAGGGGGAAATCCAGCCAAATTGATAAAAAAGAGATTTAGTGATGATGACATCCAAAAATTGCAGGAAATGAAATGGTGGGAATGGGATGAAGAAACCCTTTTTGAAGCAATGCCAATTCTTTGTTCAAATAAAATCGATTTGTTGTACAAGTTTTTTAGAAAAATGAAATGA,chloramphenicol acetyltransferase (CAT),antibiotic inactivation,Phenicol,MEG_1628,Drugs,MEG_1628|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB,gi|343916463|gb|JF268689.1|5207-5836 gi|343916452|gb|JF268688.1|6609-7238,6
,ATGGCAGAAGAAACTGCTCGGTTTCCAAAAGTCGATATTAGCCACGAAATGAGAGAATCGTTCATTAGCTATGCGATGAGCGTTATCGTCAGTCGGGCTTTGCCTGACGTTCGCGATGGTTTGAAGCCTGTACACAGGCGTATTTTGTATGCCATGCACGATATGGGCCTTACTCCTGACAAGCCGTTCCGTAAATCGGCAAACGTTGTCGGGGAAGTAATGGCGAACTACCATCCGCATGGTGACTCTTCCATCTATGAAGCGATGGTACGTATGGCCCAAGATTTTAACATGCGCTACATGCTGGTTGAAGGGCAAGGGAACTTCGGTTCTGTAGACGGCGACCCGGCAGCGGCGATGCGTTATACGGAGTCGCGTTTTTCCAAGCTCGCGCTGGAGCTTTTGCGCGATATTGATAAAGAAACGGTCGATTTCATTCCTAACTACGACGGACGCAAAGAAGAGCCGGTTGTATTGCCTTCTCGTTTCCCGAACCTGCTTTTGAATGGTGCATCAGGGATTGCTGTAGGTATGGCTACCAATATTCCGCCACATAACTTGACGGAAGTTGTTGATGGTGTCATTGCCATGATCGACAATCCTGATATTACGATTCAAGATTTGATGAAAATCATCAAGGGACCTGACTTCCCTACAGCGGGGGAGATTCTCGGTTACAGTGGTATTCGCCGTGCCTATGAAACAGGCCGTGGTTCCATTATTATGCGCGCCAAAACCCAGATTGAAGAGGATGGGAAAGGCAAACCACGCATCATCGTAACAGAGATCCCTTATCAGGTAAACAAGGCTAGACTCGTGGAAAAAATCGCGGAGCTAGTGCGCGAGAAAAAAATCGAAGGCATTACCGACCTTCGTGATGAGTCTGACCGCAAAGGTATGCGTATTGTCATGGAATTGCGCCGTGACGTCATTCCAAAGGTTGTATTGAACAATCTATTTAAGCATACCCAAATGCAGTCTACATTTGGTGTGAATATGCTGGCACTCGTTGATAGTCGTCCGCGTGTATTGAATCTGCGTGACATGCTCTATTACTATTTGGAGCACCAACGTGTCATTATCCGCAGAAGGACCGAATACGATCTCAAGCAAGCAGAAGCCCGTGCGCACATCTTGGAAGGCTTGCGTATTGCATTGGATCATATTGACGAGATTATCAGCTTGATTCGTTCTTCTCAAACCACGGAAGAAGCTCGCACAGGACTCATGGAGAATTACTCCTTGTCCTACGAGCAGGCACAGGCGATTCTCGATATGCGTCTGCAACGCCTGACTGGTTTGGAACGAGAAAAAATCGAGAACGAATACCAGGAGCTCATGGTAAAAATCGCAGAACTGCGTGCTATTCTTGCAGACGAAGCTAAAATCTACGCGATCATCCGCGATGAGCTGGGTGAGATCAAAGAGAAGTTTGGCGATGAAAGACGCACAGAAATTACTTTCGATGAGAATCATATCGAAGATGCTGATTTGATCCCAGAGGAAGATGTCGTAATCACCCTGACGCATGACGGTTATATCAAGCGTCTGCCTGTTTCGACCTACCGTTCGCAAAAACGTGGTGGACGTGGCGTGCAGGGATTGGGAACCAAGGATGACGATTTTGTCGAGCATCTGTACATTACCAACTCGCATGATTACATCATGTTCTTTACGAGCAAAGGGAAGGTGTATCGCCTAAAAGGATTTGAGATTCCTGACCTGAGCCGGACAGCAAAAGGTACCCCAATCATCAATCTCATTCAGATTGAAAAAGGGGAGCGGGTTAGTGCGGTAATCCCTGTGAAAGAGTTTGATCAAGAACATTACCTGTTCTTTGCGACCAAGAAGGGGATTATTAAGAAAACTACGCTGGAGTCCTATGAAAACATTCGCAAAGGCGGGCTAATTGCGGTTAACCTGCGCGAAGATGATGAGTTGATTGGTGTTCGTCTGACGGATGGCCAACAACAAATCATTATGGGTACTCATAAAGGTATGTCCGTCCGTTTCAATGAGGGAGACGTACGCACGATGGGACGTAACGCCACCGGTGTGAAGGGGATTACCCTTGACGACGATGATGATGTCATCGATATGGACGTTATCAAGCCAAATGCAGAAGTGCTCATTGTAACGGCGAATGGTTACGGAAAACGGACTCCTGTCGATGAATACCGCATTCAATCTCGTGGCGGTAAAGGAATTAAGACACACAATGTAACGGATCGTAGCGGTCCGGTCGTCGGTCTGAAAGTCGTTGAGCCTGAAGAAGATCTGATGATTATTACCACTTCCGGTATCATCATTCGTACAGAAATGAAAGGTATTTCTGTGATGGGGCGCTACACGCAAGGTGTGAAACTGATCCGTTTGTCTGAAAATGAGCAAGTGGGATCAGTCGCCAAATGTCCTCCGACTGAGGAAGAGGATATGACGGATGAAGATGCAGAAGAGGGAATCGAAGATCTGCAAGACGGAGAGACTGTCGAAGCAACCGAGCCTATCGAACCTACCGAACCGACAGAGGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3195,Drugs,MEG_3195|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|226092535|dbj|AP008955.1|17306-19840,3
,TGTTAGCGGTAATTTAACCAGATAGGAGTACAGACATATGAAAATCGTAAAAAGGATATTATTAGTATTGTTAAGTTTATTTTTTACAGTTGTGTATTCAAATGCTCAAACTGACAACTTAACTTTGAAAATTGAGAATGTTTTAAAGGCAAAAAATGCCAGAATAGGAGTAGCAATATTCAACAGCAATGAGAAGGATACTTTTAAGATTAATAACGACTTCCATTTCCCGATGCAAAGCGTTATGAAATTTCCGATTGCTTTAGCCGTTTTGTCTGAGATAGATAAAGGGAATCTTTCTTTTGAACAAAAAATAGAGATTACCCCTCAAGACCTTTTGCCTAAAACGTGGAGTCCGATTAAAGAGGAATTCCCTAATGGAACAACTTTGACGATTGAACAAATACTAAATTATACAGTATCAGAGAGCGACAATATTGGTTGTGATATTTTGCTAAAATTAATCGGAGGAACTGATTCTGTTCAAAAATTCTTGAATGCTAATCATTTCACTGATATTTCAATCAAAGCAAACGAAGAACAAATGCACAAGGATTGGAATACCCAATATCAAAATTGGGCAACCCCAACAGCGATGAACAAACTGTTAATAGATACTTATAATAATAAGAACCAATTACTTTCTAAAAAAAGTTATGATTTTATTTGGAAAATTATGAGAGAAACAACAACAGGAAGTAACCGATTAAAAGGACAATTACCAAAGAATACAATTGTTGCTCATAAAACAGGGACTTCCGGAATAAATAATGGAATTGCAGCAGCCACTAATGATGTTGGGGTAATTACTTTACCGAATGGACAATTAATTTTTATAAGCGTATTTGTTGCAGAGTCCAAAGAAACTTCGGAAATTAATGAAAAGATTATTTCAGACATTGCAAAAATAACGTGGAATTACTATTTGAATAAATAAAAGGGTATAGGAAGTATAAACCACCTTTTTGCTCCTGGCTCTGTTGCAAAGATTGGCGGCAGTCAGAGGTAGGCTGTCGCTCTGCGCCGATCAGGCGGCTGCTGCGAAATGGTGGTTGAGCATGCCCAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_7667,Drugs,MEG_7667|Drugs|betalactams|Class_A_betalactamases|VEB,gi|44894130|gb|AY536519.1|1-1066 gi|530347473|gb|CP006657.1|152699-153763 gi|530347473|gb|CP006657.1|67625-67717 gi|695214579|ref|NG_036847.1|6046-4982 gi|695224365|ref|NG_041064.1|4703-4611 gi|260677483|gb|GQ388247.1|26590-26498 gi|169147133|emb|CU459141.1|3648664-3648756 gi|169147133|emb|CU459141.1|3652547-3652580 gi|85813394|emb|CT025832.1|54107-54015 gi|85813394|emb|CT025832.1|50224-50191,0
,atggatattattgataaagtttttcagcaagaggatttctcatgccaggatttgagtgacagccgttttcgccgctgccgcttttatcagtgtgacttcagccactgtcagctgcaggatgccagtttcgaggattgcagtttcattgaaagcggcgccgttgaagggtgtcacttcagctatgccgatctgcgcgatgccagtttcaaggcctgccgtctgtctttggccaacttcagcggtgccaactgctttggcatagagttcagggagtgcgatctcaagggcgccaacttttcccgggcccgcttctacaatcaagtcagccataagatgtacttctgctcggcttatatctcaggttgcaacctggcctataccaacttgagtggccaatgcctggaaaaatgcgagctgtttgaaaacaactggagcaatgccaatctcagcggcgcttccttgatgggctcagatctcagccgcggcaccttctcccgcgactgttggcaacaggtcaatctgcggggctgtgacctgacctttgccgatctggatgggctcgaccccagacgggtcaacctcgaaggagtcaagatctgtgcctggcaacaggagcaactgctggaacccttgggagtaatagtgctgccggattag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5868,Drugs,MEG_5868|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRA,1394338112|WP_109997726.1|NG_059280|1|1|qnrA9|qnrA|quinolone_resistance_pentapeptide_repeat_protein_QnrA9 NG_059280:101-757,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatgacgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5471,Drugs,MEG_5471|Drugs|betalactams|Class_C_betalactamases|PDC,1393270460|WP_109791205.1|NG_057604|1|1|blaPDC-273|blaPDC|class_C_beta-lactamase_PDC-273 NG_057604:1-1194,0
,gtgatcgccagcgcgcccacgatccgccaggccacgccggccgatgcggccgcatgggcgcagttgcgtctcgtcctgtggcctgatgccgatgatccgctggaggaactgacgcagtcgctggcagatgccgaaggtgctgtgttcttggcctgtgccgcggatggcgagacggttggtttcgctgaagtgcgcctgcgccatgactacgtgaacggtaccgagtcttcgccggtggggttcctggagggctggtacgtgcagccgcagtggcaaggccgcggcgtcggccgcgccctgctggcggcggtgcaggcgtggacgcgcgatgcgggctgccgcgaactggcttcggacagtcgcgtggaagacgtgcaggctcaccccgcgcatcgggcctgcggcttcgaagagaccgaacgggtcgtctatttccgcatgccgctggagccatcggcgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_261,Drugs,MEG_261|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491556564|WP_005414154.1|NG_052390|1|1|aac(6')-Iz|aac(6')-Iz|aminoglycoside_N-acetyltransferase_AAC(6')-Iz NG_052390:101-562,2
,ATGTTACGCAGCAGGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGCTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGAACTGCGAAGCGCAATCGCCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6620,Drugs,MEG_6620|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|117580241|dbj|AB281183.1|28-879 gi|117580238|dbj|AB281182.1|835-1686 gi|761589803|dbj|AP014651.1|324887-324361 gi|761589803|dbj|AP014651.1|5294188-5294714 gi|672940377|gb|AY963803.6|23638-24164 gi|666688170|gb|KJ463833.1|24848-25374,8
,ATGAACCGCACTGTGATGATGGCACTGGTCATCATTTTTTTAGATGCCATAGGGATTGGCATAATTATGCCTGTCTTACCGGCGTTATTACGGGAGTTTGTTGGAAAGGCTAATGTTGCGGAGAACTACGGTGTTTTATTGGCGCTGTATGCAATGATGCAAGTGATTTTTGCCCCTCTTCTCGGCCGCTGGTCAGATCGCATAGGTCGTCGCCCTGTATTATTACTTTCACTTTTAGGTGCAACACTGGACTACGCATTAATGGCAACAGCCAGCGTAGTGTGGGTGTTGTATCTGGGACGCTTAATTGCTGGTATTACCGGTGCGACTGGAGCTGTTGCAGCCTCAACAATTGCCGATGTCACACCTGAGGAATCCAGGACACATTGGTTTGGTATGATGGGTGCCTGTTTTGGTGGCGGTATGATTGCTGGACCAGTCATTGGTGGTTTTGCAGGTCAACTTTCGGTACAGGCACCGTTTATGTTCGCTGCTGCCATTAACGGGCTGGCATTTCTGGTCTCCCTATTCATTTTACATGAGACCCATAATGCTAATCAGGTTAGTGACGAGATAAAGAATGAAACAATCAATGAAACCACATCCTCCATACGCGAGATGATCTCCCCATTATCGGGATTGCTAGTTGTCTTTTTCATCATTCAATTGATTGGCCAAATCCCTGCAACATTATGGGTTTTATTCGGAGAAGAGCGCTTCGCATGGGATGGCGTAATGGTCGGTGTTTCATTGGCTGTGTTTGGGCTTACACACGCTCTGTTTCAAGGACTTGCTGCTGGTTTTATCGCTAAACATTTGGGAGAACAGAGAGCTATCGTGGTTGGCATCTTGGCTGATGGCTGTGGCCTACTTTTATTGGCAGTCATTACGCAAAGCTGGATGGTTTGGCCAGTTGTGCTGTTACTCGCTTGTGGTGGCATAACTCTTCCCGCTTTGCAGGGAATTATATCTGTTCGTGTCGGTCAGGTAGCACAGGGACAATTGCAAGGGTTGCTGACCAGTTTGACACACCTCACGGGTGTAATCGGTCCACTTATTTTTGCATTTTTGTATAGTGCAACCCACGAATCTTGGAATGGTTGGGTGTGGATAGTTGGATGCGGATTGTATGTAGTTGCACTGACTATACTGAGGTTTTTCTATCCCGGCAGGGCAGTCCACCCGAAAAATCAGAGCAATTCACAGCCATTTCTTTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7072,Drugs,MEG_7072|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETE,(Tet)TetE:DQ366299:36-1253:1218,4
,ATTTCATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCGTTCTCCACGTTTGCCGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACTCAACAAACGCTGTTTGAACTCGGATCGGTCAGTAAAACGTTCAACGGCGTGCTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGCATTACTGGCCTGAACTGACTGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCGTTACTACGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGTGCCCTGGCGGTCAAACCCTCAGGCATGAGCTACGAAGAGGCGATGACCAAACGCGTCCTGCGCCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGCCAACTTGATGCCGAAGCCTACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGCATCGAGCTTGCGCAGTCACGTTACTGGCGTATTGGCGATATGTACCAGGGCCTGGGCTGGGAGATGCTGAACTGGCCGGTGAAGGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTGGCACTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCGTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAGAGCTACCCAAACCCTGTTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAACGGACAAGGAGGCCCTGGATATTGGGCTTCCTTTCTTTCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAATCCAGCAAGGAAAATCCCATGCGCATTCTGCCCGTCGTTGCTGCAGTTACGGCTGCATTTCTGGTTGTCGCTTGCAGCACCCCAACACCCCCGAAAGGTGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_1983,Drugs,MEG_1983|Drugs|betalactams|Class_C_betalactamases|CMY,gi|591542849|gb|KJ207203.1|1-1327,0
,ttgaactattcaatatgcgatatagctgaatcaaatgaattaatccttgaagcagcaaagatgcttaagaaaagctttcttgatgctggaaatgaatcatggggagatattaaaaatgctattgaagaagttgaagaatgtatagaacatccaaatatatgcttgggaatatgtctggatgataaactgattggatggaccggattaaggccgatgtacgataagacctgggaacttcatcccatggttataaaaactgaatatcaaggcaagggttttgggaaagtactactaagagaactagagacgagagcgaagagtaggggaattatcggaatagctcttggaactgatgacgaatatcagaaaactagtttgtctatgattgatataaacgaacgaaatatcttcgatgaaatcgggaatataaagaacgttaataatcatccatatgagttttataagaaatgtggttatatgatcgttggaataatccctaatgctaatggaaaaagaaaaccagatatatggatgtggaaagatattagctag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_265,Drugs,MEG_265|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,447032388|WP_001109644.1|NG_052380|1|1|aacA16|aac(6')_Ia_fam|AAC(6')-Ia_family_aminoglycoside_6'-N-acetyltransferase_AacA16 NG_052380:101-652,2
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggggtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaagcttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcgtttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagaccgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_847,Drugs,MEG_847|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,970287743|WP_058664416.1|NG_052344|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052344:101-892,2
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggggtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6673,Drugs,MEG_6673|Drugs|betalactams|Class_A_betalactamases|TEM,1509794532|WP_122630841.1|NG_062250|1|1|blaTEM-237|blaTEM|class_A_beta-lactamase_TEM-237 NG_062250:101-961,0
,atggacacaacgcaggtcacattgatacaccaaattctaccttcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatggttgaaatgctcggcgggcgcgtcacggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccaatggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_744,Drugs,MEG_744|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1105502162|WP_071846313.1|NG_052383|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052383:58-591,2
,atggaaagaaaagggattttcattaaggttttttcctatacgatcattgtcctgctactgcttgtcggtgtaacagcaacactgtttgcacagcaatttgtgtcttatttcagagtgatggaattacagcaaacagtaaaatcctatcagccattggtggaactgattcagaatagcgataggcttgatattcaagaggtggcagggctgtttcactacaataaccaatcctttgagttttatattgaagataaagagggaagcgtactctatgccacaccaaatgccaatacatcaaatagttttagacccgactttctttatgtggtacatagagatgataatatttcgattgttgctcaaagcaaggcaggtgtgggattgctttatcaagggctgacaattcggggaattgttatgattgcgataatggttgtattcagccttttatgcgcgtatatctttgcgcggcaaatgacaacgccgatcaaagccttagcggacagtgcgaataaaatggcaaacctgaaagatgtaccgccgccgctggagcgaaaggatgagcttggcgcactggctcatgatatgcattccatgtatgtcaggctgaaagaaaccatcgcaaggctggaggatgaaatcgcaagggaacatgagttggaggaaacacagcgatatttctttgcggcagcttctcatgagctaaaaacgcccatcgcggctacaagcgttctgttggagggaatgcttgaaaatatcggtgactacaaagatcattctaagtatctgcgcgaatgcatcaaaatgatggataggcagggcaaaatcatttccgaaatactggagcttgtcagcctgaatgatgggagaatcgtacccatagctgaaccgttggacatagggcgcacggttgccgagttgctgcccgattttcaaaccttggcagaggcaaacaaccagcggttcgtcacagatattccagccgggcaaattgtcctgtccgatccgaggctgctccaaaaggcgctatccaatgtcatattgaatgcagttcagaacacgccgcagggaggcgaggtacggatatggagtgagcctggtgctgaaaaatgccgcctttttgttttgaacatgggcgttcacattgatgatactgcgcttccaaggctgttcaccccattctatcgcattgatcaggcgcgaagcggtttaggacttgccatcgtacaaaaaacgctggatgccatgagcctccagtatgcgctggaaaacacctcggatggcgttttgttctggctggatttaccgctcacatcaacactataa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7491,Drugs,MEG_7491|Drugs|Glycopeptides|VanB-type_regulator|VANSB,1028100602|WP_063856737.1|NG_048434|1|1|vanS-B-Delta|vanS-B|VanB-type_vancomycin_resistance_histidine_kinase_VanS-B-Delta NG_048434:77-1402,5
,ATGCGTTTTATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6246,Drugs,MEG_6246|Drugs|betalactams|Class_A_betalactamases|SHV,(Bla)SHV-28:EU441172:57-917:861,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacatacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcgactacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2177,Drugs,MEG_2177|Drugs|betalactams|Class_A_betalactamases|CTX,1028104729|WP_063859975.1|NG_048953|1|1|blaCTX-M-168|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-168 NG_048953:1-876,0
,TTAAAATTCCTTCATTACACTCTTGGCGGTTTCACTTATCAACTTATCATTTGGCTTATCACTTTTATTGTCTTTATTCGTAAAAATGACTAAAACAATAGGTTCAGATTGGCCCTTAGGATAAACAAAAGCAACATCATTTCTAGAAGCATATGTTATTGCTTGACCACTTTTATCAGCAACCTTATAGTCTTTTGGAACACCATCTTTAATTAAAGTGTCTCCGTTTTTATTATTAAACATTAAATCAAGTAAGAAATTTTTATTTTTTTTGCTTAATTTTCCATTTGCGATAAGTTTATTTAAAGTCTTGCCGAAAGCAGCAGGCGTTGAAGTATCTTTTTTGCTCTTTGGTGAATAGTAATTTAATTCTATCTCATATCTAACTGGATTTGTTACTTTATCTCCTAGTTCTTTTAGACGTTGTTTAACTTTTTTGATTCCACCGATTTCTTTTATAATTTTATTGTTTGCTGTATTATCACTATATGTCATTGAAGCCTCAATAAGTTCTTTTAAAGTGATATCTTTTCCTACATATTTTTCTAAAATAGGAGAATAAGCAACTATATCATCTTTGTTAATATGTACTTTTTTATTTAACTTATTATAAGGTACTTGTTCTAACAAAATAGCACTATTTATCGCTTTTGAAGTCGAAGCATAGGCAAATCTCTTATCTGAATTAAATTTTACTTCCTTACCACTTTTAGTATCTAAAGCATAAACACCAATATGAGCATTATATTTTTTTTCTAAATCATTTAACTCTTTGGCATGTGAACTGTTTGAATTACATGCACTTAAAACTAAAGCAATTACAATTAAAAATATTAACTTTTTCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1328,Drugs,MEG_1328|Drugs|betalactams|Class_A_betalactamases|BLAZ,gi|90960963|dbj|AB255366.1|7716-8561 gi|13774139|dbj|AP003139.1|7945-8790,0
,atgatgaaacagaattttatttttttagacgaagtgctgcctggtattcgttgggatgccaaatatgccacatgggataattttacaggcaaaccggtggacggatatgaggtaaaccgtattgtaggaaccaaagagctgggagctgctttacgcaaagctcaaaaacttgccatgaaacagggatatgggctgctcttatgggatggttatcgccctcagcgtgccgtggattgttttctgcattgggcgtcactaccggagaataatctaacgaaaaaccggtattaccctaatataaagcggaatgaaatggtgacaaagggatatgtggcctcacagtccagccatagccgcggaggcgcagttgatctcacgattttttatttagataccggtatgcttgttcctatgggcggagattttgattttatggatgaacggtcccatcatgctgcaagcggactgacggaggaagaatccagaaaccgggaatgtctgcgccatatcatgggaaggagcggctttgaagcctattgtaacgaatggtggcattatgtcctggcagatgaaccatacccaaatacatatttcaatttttgcattgcatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7566,Drugs,MEG_7566|Drugs|Glycopeptides|VanD-type_resistance_protein|VANXD,1028100640|WP_063856775.1|NG_048490|1|1|vanX-D|vanX-D|D-Ala-D-Ala_dipeptidase_VanX-D NG_048490:101-712,5
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgatgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtggtcctggccaaccgcaactatcccattgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5445,Drugs,MEG_5445|Drugs|betalactams|Class_C_betalactamases|PDC,1035157548|WP_064511513.1|NG_050836|1|1|blaPDC-163|blaPDC|class_C_beta-lactamase_PDC-163 NG_050836:1-1194,0
,atggcctacagcgaaccagtacgaacaacggccccgacgcggccgaccgtccggcagatcagcgccgccgagcacctggcgttcgtgcgggcgcagcgctcggtcagcttcctgcagacccctgcctgggggcgcgtcaagacagagtggcgcagcgagtccctgggctggttcgacggcgggcggctggtcggtgccgggctcgtcctgcaccggccggtgccacggctcgagcgcttcacgctggcctatctgcccgagggaccggtcatcgactggaccggcgacatcgacgcgtggctcgatccgctggccgcgtatctcaaggcacgcggtgcgttcgcgatacggctcggtccgccggtgtgcacggacgtgtggagcgcggacgagatcaaggagggcatcgccgatccgggcacgcggcggctcaccggactgcccactcggtggaccgacccggtcggcgcccacgtgacggaccggctcagggacgccggctggctgccgcagagcccggaggacggcttcggggtcggacatccgcagttcaagtacgaggtcccactggccggaagaaccgaggacgacctgctcaagggcatgaaccagctctggcggcgcaacatacgcaaggcggccaaggagggcgtcgaggtgacgctcggggatgccacgcccgggtatgccgcagcaggggaggcggcggtcgcggacgacgtgaaggcgttccacgacctctacgtccacaccgccgagcgggaccgcttcacgccccgtccactgcgctacttcgcgaccatgttcgccgtgctcggcgccgaggaccccgagcggatcaagctctatctggcccgtcaccggggcgacctggtcgccgccaccgtcatggtccgggtcggcacccacgcggtgtacgcctacggcgcctcgtccaccgggaagcgcgaagtgcgtggctccaacgcctgccagtgggcgatgatccgcgacgcgctcgccgccgactgcgacgtctacgacctgcgcggcatcactccgaccctcgacgcggacgacccgcacgtcggactgatcaagttcaaggtcggcaccggcggtcgggccgtgcgatatgtgggcgagtgggacctgccgctgcggccgctggtgtaccggaccttcgacctctatatgaagcgacgtggtcgatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7443,Drugs,MEG_7443|Drugs|Glycopeptides|VanK-type_resistance_protein|VANK,499339400|WP_011029108.1|NG_055982|1|1|vanK-Sc|vanK-Sc|peptidoglycan_bridge_formation_peptidyltransferase_VanK-Sc NG_055982:101-1294,5
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaagtataccgttctttatccgtattagacggagcagtattattagtttctgcaaaggatggcatacaggcacagacccgtatactgtttcatgcactacagataatgaagattccgacaatttttttcatcaataaaattgaccaagaggggattgatttgccaatggtatatcgggaaatgaaagcaaagctttcttcggaaattatagtgaagcaaaaggttgggcagcatccccatatgaatgtaacggacaatgacgatatggaacagtgggatgcggtaattatgggagacgatgaactattagagaaatatatgtcagggaaaccgtttaaaatgtcagaactggaacaggaagaaaacaggagattccaaaacggaacgttatttcccgtttatcacggaagcgctaaaaacaatctggggattcggcagcttatagaagtaattgccagtaaattttattcatcaacgcctgaaggtcaatctgaactatgcgggcaggtttttaagattgaatattcagagaaaaggcggcgttttgtttatgtgcgtatatatagcggaacattgcatttgagggatgttattagaatatctgaaaaagagaaaataaaaatcacagagatgtgtgttccgacaaacggtgaattatattcatccgatacagcctgctctggtgatattgtaattttaccaaatgatgttttgcagctaaacagtattttggggaacgaaatactgttgccgcagagaaaatttattgaaaatcctctccctatgctccaaacaacgattgcagtaaagaaatctgaacagcgggaaatattgcttggggcacttacagaaatttcagatggcgaccctcttttaaaatattatgtggatactacaacgcatgagattatactttcttttttggggaatgtgcagatggaagtcatttgtgccatccttgaggaaaaatatcatgtggaggcagaaataaaagagcctactgttatatatatggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaatcaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7156,Drugs,MEG_7156|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,1028100271|WP_063856406.1|NG_048265|1|1|tet(O)|tet(O)|tetracycline_resistance_ribosomal_protection_protein_Tet(O) NG_048265:101-2020,4
,atgggtgaatttttccctgcacaagttttcaaacagctgtcccacgctcgcgcggtggtcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggatagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgtgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_901,Drugs,MEG_901|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,446425719|WP_000503574.1|NG_047358|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_047358:101-889,2
,GTTAAGCAATAATGACTACCGTAAATTAACTAACAATAAAAAAGAGCCTTTGCTCAACAAATTTCAAATCACTACATCACCAGGTTCAACCCAAAAAATATTAACATCTATTATAGCCTTAAAAGAAAATAAACTAGACAAAAATACTAATTTTGATATTTATGGTAAGGGTTGGCAAAAAGATGCATCATGGGGGAATTATAATATCACAAGATTTAAAGTAGTAAACGGCAATATCGATTTAAAGCAAGCAATAGA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_5403,Drugs,MEG_5403|Drugs|betalactams|Penicillin_binding_protein|PBP2,gi|478686599|gb|KC601653.1|258-1,0
,ATGAATCCCTATCTACAGTTAGTTAGCAAAGAGTTTCCATTAGAAAAAAACCAAGAGCCGCCCCACCTCGTCCTTGCTGCTTTTAGTGAAGAAGAAGTTTACTTGCAGCCTGAAGCAGCCAAACAATGGGAACGCCTCGTCAAAGCCTTAAAACTTGAAAACGAGATCTGCTTATTAGACGGCTATCGAACCGAAAAGCAGCAACGGCATTTATGGGAATATTCCTTAAAAGAAAATGGATTAGCCTATACGAAACAATTTGTGGCGTTGCCCGACTGCAGCGAGCATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAAGGCCAGCAAGGTGATTTGATCTGCCCACGGTTTCGTGACAGCGTAGCGGCGGATTTATTTACACAGGAAATGATGAACTACGGATTTATTTTACGCTATCCCGCAGACAAACAGGAGATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTGCCTCATAGTCAAATCATCGCCAGTCAACAGTGGACATTGGAAGAATACTATCAATACCTTGAACAAACCGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7580,Drugs,MEG_7580|Drugs|Glycopeptides|VanC-type_resistance_protein|VANXYC,(Gly)VanXYc4:EU151753:1078-1650:573,5
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1406,Drugs,MEG_1406|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_35_JIVZ01000012,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttctccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaagcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5567,Drugs,MEG_5567|Drugs|betalactams|Class_C_betalactamases|PDC,1028110217|WP_063864587.1|NG_049952|1|1|blaPDC-95|blaPDC|class_C_beta-lactamase_PDC-95 NG_049952:1-1194,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaacgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactagcggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_550,Drugs,MEG_550|Drugs|betalactams|Class_C_betalactamases|ADC,447133953|WP_001211209.1|NG_064696|1|1|blaADC-140|blaADC|class_C_beta-lactamase_ADC-140 NG_064696:101-1252,0
,ATGGAAAAAAACAGAAAAAAACAAATCGTAGTTTTGAGTATAGCTTTAGTTTGCATTTTCATCTTGGTATTTTCATTGTTCCATAAATCAGCGACAAAAGATAGCGCAAATCCTCCTTTAACAAATGTTTTGACTGATAGCATTTCTCAAATTGTCTCAGCTTGTCCTGGCGAAATTGGTGTGGCGGTTATTGTTAATAACAGAGATACGGTTAAGGTCAATAATAAGAGTGTTTATCCTATGATGAGTGTGTTTAAGGTTCATCAGGCATTAGCTCTTTGTAATGACTTTGACAATAAAGGAATTTCACTTGATACCTTAGTAAATATAAATAGGGATAAACTTGACCCAAAGACTTGGAGTCCTATGCTGAAAGATTATTCAGGGCCAGTCATATCATTGACAGTGAGAGATTTGCTGCGTTATACTCTTACTCAGAGTGACAACAATGCAAGCAACCTTATGTTTAAGGATATGGTTAATGTCGCTCAAACAGATAGTTTTATAGCCACACTCATTCCTCGTTCAAGTTTTCAGATAGCTTATACGGAAGAGGAAATGTCGGCTGACCATAACAAGGCTTACTCTAACTATACATCTCCTCTTGGTGCTGCAATGTTGATGAATCGTTTGTTTACTGAAGGTCTTATCGATGATGAGAAACAAAGTTTCATTAAGAATACGTTAAAAGAATGCAAAACAGGTGTAGATAGGATAGCAGCTCCACTTCTTGATAAAGAAGGGGTTGTTATAGCGCATAAGACAGGTTCAGGTTGTGTTAATGAAAATGGTGTTCTTGCAGCTCACAATGATGTTGCCTATATATGTCTGCCTAATAATATCAGTTATACCTTAGCGGTATTTGTTAAGGATTTCAAGGGAAATGAATCACAAGCGTCACAATATGTTGCGCATATATCAGCTGTAGTATATTCTTTATTAATGCAAACTTCAGTAAAATCTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1694,Drugs,MEG_1694|Drugs|betalactams|Class_A_betalactamases|CFX,gb|AY769934|+|27-993|ARO:3003096|CfxA5 [Parabacteroides distasonis] ,0
,atgaaaaaattatttgttttatgtgtctttgtcttttgtagtattactgtcgcaggtgagactttgcctaatttgagagttgaaaagcttgaagaaggtgtttatgttcatacatcgtatgaagaagttaaaggttggggtgttgttactaaacacggtttggtggttctcataggcgctgacgcctatctgattgatactccatttactgctaaagatactgaaaagttagtcaattggtttgtggagcgcggctataaaataaaaggcactgtttcctcacatttccatagcgacagtacggggggaatagagtggcttaactctcagtctatccccacgtatgcgtctgaattaacgaatgaacttctgaaaaaagacggtaaggttcaagccaaaaactcatttgacggggttagttattggctggcgaaagataaaatagaagtgttttatcctggccctggccacactcaagacaacgtagtagtttggctgcctgaaaaggaaatattatttggcggttgctttgttaagcctcacggccttggtaatttgggtgacgcaaatttagaggcttggccagagtccgccaaaatattgatggaaaaatatggtaaagcaaagctggttgtttcaggtcatagcgaaaccggagactcgacacacttgaagcgtacctgggagcaggctgttaaaggacttaaagaaagtaaaaagacattgcagccaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3324,Drugs,MEG_3324|Drugs|betalactams|Class_B_betalactamases|IMP,1209144252|WP_088245214.1|NG_055271|1|1|blaIMP-67|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-67 NG_055271:1-741,0
,ATGATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAGATTCTCTACCGTGCCGATGAACGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAAGAAGAGCGACCTGGTTAACTACAATCCCATTGCGGAGAAACACGTTAACGGCACGATGACGCTGGCTGAGCTTGGCGCAGCGGCGCTGCAGTATAGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGTCCCGATAAAGTGACGGCGTTTGCTCGCTCGTTGGGTGATGAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATACCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAAGCGCTGGCGGAAACTCAGCGGGAACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTCTGCCGAAATCATGGGTAGTGGGCGATAAAACCGGCAGCGGAGATTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGAAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGCCGTCGGGATATTCTGGCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGATGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2399,Drugs,MEG_2399|Drugs|betalactams|Class_A_betalactamases|CTX,gi|508128869|gb|KC964871.1|1-884,0
,GTGCCCAGCCGATACGGCAGCCGGCAGGAACTCGGTCAGAATTTTCTCGTCGACCCCGACATCATCAAGCTGATACGCCGAGCCGCCGAACGAACGGAAGGTCCCATCGTTGATCTGGGCGCCGGAGACGGCGCCCTGACGCTGCCCTTGAGTCGATTGGGCCGCCCTGTCACCGCGGTTGAGCTCGATCCCCGCCGGGTCAAACGGCTTTCGGCGCGTGCCCCGGAAAACGTCAAGGTCGTCGGCGAGGACATTCTGCGCTTTCGGCTTCCGACCGTTCCGCACACCGTCGTGGGGAACATCCCCTTCCATGTCACGACGGCCACGATGCGCCGGATCCTCGTGGCTCCCGCATGGGTGTCGGCCGTCCTCGTGGTGCAGTGGGAAGTGGCGCGCCGCCGGGCCGGCATCGGCGGCTGCTCGCTGGTCACGGCGGAGTCCTGGCCGTGGTTCGACTTCTCGGTGCTCAAGCGGGTGCCGAGGTTCGCCTTCCGGCCCGCGCCCTCCGTGGACGGCGGGATCCTCGTCATCGAGCGGCGGCCCGAGCCACTGGTGCGGGAGCGCAGGGAGTACCAGGACTTCGTCAGACAGGTCTTCACCGGGCGCGGTCACGGGCTGCGGGAGATCCTCCAACGCATCGGGCGGGTCCAGGACAGCGACCTGTCCGCGTGGTTCAGGGCACATGGAGTCTCGCCGCAGGCGCTGCCGAAGGACCTCACCGCCGAGCAGTGGGCGTCGCTCTGGGGCATGGCGCGTGGCGGCCGGTCCGTGCCGCGGACGCGGCGACCCCGGGGCCTGCCGCCCCGCACGTCCCGCGGGCCGCGGCGCAACAGCGGCTGA,ATP-binding cassette (ABC) antibiotic efflux pump,antibiotic target alteration,MLS,MEG_2849,Drugs,MEG_2849|Drugs|MLS|23S_rRNA_methyltransferases|ERMU,(MLS)LmrB:X79146:27840-28679:840,7
,GCTGTATGCGTTGGTGCAATTTCTATGCGCACCCGTTCTCGGAGCACTGTCCGACCGCTTTGGCCGCCGCCCAGTCCTGCTCGCTTCGCTACTTGGAGCCACTATCGACTACGCGATCATGGCGACCACACCCGTCCTGTGGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7064,Drugs,MEG_7064|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETC,gi|27543325|gb|AY171578.1|1-567 gi|961454907|gb|KT991389.1|3654-3683 gi|961454902|gb|KT991388.1|6978-7007,4
,ATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGAAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACTTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCGATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACGGCGATAACGTGGCGATGAATAAGCTGATTTCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGTCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGTAATCTGACGCTGGGTAAAGCATTGGGTGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2223,Drugs,MEG_2223|Drugs|betalactams|Class_A_betalactamases|CTX,(Bla)CTX-M-58:HQ734707:1-876:876,0
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgattgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataagacaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcagtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4508,Drugs,MEG_4508|Drugs|betalactams|Class_D_betalactamases|OXA,1509794579|WP_122630888.1|NG_062308|1|1|blaOXA-686|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-686 NG_062308:14-838,0
,ATGCGTTATTTTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCAGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGCCAAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGGATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCTCGTAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6488,Drugs,MEG_6488|Drugs|betalactams|Class_A_betalactamases|SHV,gi|7595230|gb|AF132290.1|AF132290|88-983 gi|14532426|gb|AY036620.1|53-88,0
,atgaaaaaaataactttatttttacttttcttaaatttaaagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4641,Drugs,MEG_4641|Drugs|betalactams|Class_D_betalactamases|OXA,1391852917|WP_109545102.1|NG_057536|1|1|blaOXA-607|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-607 NG_057536:1-759,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_6461,Drugs,MEG_6461|Drugs|betalactams|Class_A_betalactamases|SHV,gi|43935|emb|X55640.1|112-980 gi|846281090|gb|KP294351.1|15259-16126 gi|846280946|gb|KP294350.1|15260-16127 gi|800908535|gb|KM406490.1|73373-74240 gi|723258375|gb|CP009883.1|264241-265108 gi|723243622|gb|CP009869.1|124337-123470 gi|678126431|gb|KJ541681.1|27825-26958 gi|662716651|gb|CP008824.1|264940-264073 gi|640855459|gb|CP007732.1|217272-216405 gi|619739382|gb|CP007558.1|217261-216394,0
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaggcagtttctttaatcactagtgctatcctgcaaatggcgattattttttaccttacagaaagaacaggatctgcgatggtcttgtctatggcttcactagtaggttttttaccctatgctgtctttggacctgccataggtgtattagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctggggcagtgctggctattgttgcattgtatatggagttacctgtctggatggttatggtagtattgtttatccgcagcgttggaacagcttttcataccccagcactcaatgcagttacgccacttttagtaccagaagagcagcttacgaaatgcgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcagttgcagcactcttatactccgtttgggatttaaatgctattattgccatcgacgtattgggtgctgtgattgcatctattacggtagcaattgtacgtatacctaagctgggtgatcgagtgcaaagtttggaaccaaatttcataagagaaatgaaagaaggaattgtcgttctgagacaaaacaaaggattgtttgccttattactcttaggaacactatatacttttgtttatatgccaattaatgcactatttcctttaataagcatggattactttaatggaacacctgtgcatatttctattacggaaatttcctttgcatctggaatgttagcaggaggcttattgttaggaagattagggagcttcgaaaaacgtgtattactaataacaagttcattttttatcatgggggccagtttagccgtttcgggaatacttcctccaaatggatttgtaatatttgtagtttgctgtgcaataatggggctttcggtgccattttatagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttgaccggaagtatcatgtcacttgctatgccaattgggttaattctatctgggttctttgctgatagaatcggtgtaaatcattggtttttactatcaggtattttaattattggcattgctatagcttgccccatgataactgaggttagaaaattagatttaaaacaaaattcatag,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3819,Drugs,MEG_3819|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028097001|WP_063853698.1|NG_047973|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047973:1-1227,7
,CTCCTGTAACCAAGCCAATTGCTACATGCGCTCTTCATCAACAATCTCCTGAAACTCCTCGTCCCAGACATCGCAGATTCGCTTGAGAACAGCAATGTGGAAGATGTAAGTCTTTGAAATCAGCGCATCCCGGGCCGCGCAGACATGTTGGCGGATCTCCTCCCAGAGTGGCTATTGGTGGCGTGTCTCAAGGGTTGGCTGAGGGTGTGGCTAGATTTGTTGATCGNCTCAAACGCGGTGCTCCTTCTGTATTCGATGCTCGTCGCCTCGGCGGCGGGTGTGTTCTTGCTTGGCTCGTAAACCCCCGCCTCGGTCGTGCCGCCGGCTTCGGCAGATTTCGGCGAGAGCTTTTCTACCTTCCTCGCAGCCCTTCATTCGGCAACAGCCTGTGCAACCATTGACAACTGCATGTTGAGACGTCCAGAAACGGTAGCCACACAACATTCGAGCAATCTTCATCATCGCGTGCGTCAAGAGCTGCTGAATCGCTACACGCTACTGCTGCGAAGAGCACGTCGGCCCGGGATCGATTCCGGCTGCGGTGACTCCTTGGTCTCGCCCCGTGGCGCCTCCAATGCTTCCGAAGTGGCTATTGGCATCACGGATCGTCGCTGCGGAAGCTGCGCATAGAAACAGTCGTCGTCTCACGCCGAAGACATCGCGATCGTCGCCAGCCCGGTGAGCTGTGCCTCAAACGCGAAAGTGCCCCTTCTCGTATCCGATGTCGCGCCTCGGCGGCGGGTGTGTTCTTGCTTGGCTCGTAAACCCCCGCTGGGTCGTGCGCAGGACTCGGAGGTCTTCGCGGAGAGCTCCCTCGCCTAATCTGGTCGGGGTTGATAA,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4041,Drugs,MEG_4041|Drugs|MLS|Macrolide_phosphotransferases|MPHD,mph(D)_1_AB048591,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcagcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5658,Drugs,MEG_5658|Drugs|betalactams|Class_C_betalactamases|PDC,1001048721|WP_061193431.1|NG_060543|1|1|blaPDC-298|blaPDC|class_C_beta-lactamase_PDC-298 NG_060543:1-1194,0
,ATGACTCAACATAATGAAATTATTAAAATTGCAGAAAAACATCAATTACACATCAAACCTCAAACAATATCATTGAATGAATCAGGGCTAGATTTCAAAGTTGCATTTGGAGAAGATGAACACGGAATAGAATGGGTTTTAAGACTACCAAGAAGATCTGACGTTTATAAACGAACAAAACCCGAAAAACAAATGGTAGACTTCTTACAAAAAAATGTTTCGTTTGAAGTACCAAATTGGAAAGTACATACAAAAGATCTTATTGCTTATCCAAAACTTACAGGCAAACCCGCAGCCACAATAGATCCAGAAATACAAAATTATGTATGGGAAATTGAACACAAACCAGTAACAAAAAATTTTATTAACACATTAGCTGAAACACTCGTAGATTTACACAACATACCAGAGGAAAATATTACCGCACAGCATATAAATATCAAAACTATACAAGAAATAAAAAAAGATTTTCAAAGAAGAATGAATAAAGTTAAAGAAACTTATGGCGTGGCAGACGGATTATGGAACAGATGGAAACAATGGTTAGAAAACGACGAACTGTGGCCTCGACGTGCAACCATGATACATGGAGACTTACATCCAGGACATATAATGGTAGATAACCAAGCAAATGTCACAGGACTCATAGACTGGACTGAAGCAACCTACTCCGATCCGTCAATGGACTTTATGGGATACCATCGTGTATTCGACGACGAAGGCTTAGAGCAACTCATAACAGCATATGGTAAAGCTGGAGGAGAAACATGGCCACGAATGAAAGAGCATATAATAGAACTCAACGCAGTTTTCCCAATGTTTATCGCTGAGTTTGCTATGGAATCAGGAGAACCGGCGTATGAAAAAATGGCATTGCAAGAGTTAGGTATGAAAGAGTAG,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4040,Drugs,MEG_4040|Drugs|MLS|Macrolide_phosphotransferases|MPHC,mph(C)_5_AM180067,7
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4504,Drugs,MEG_4504|Drugs|betalactams|Class_D_betalactamases|OXA,1559613008|WP_128268273.1|NG_063878|1|1|blaOXA-774|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-774 NG_063878:23-847,0
,ATGAAAATAATTAACTTAGGCATTCCGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGTGAAATTGTTATCCTTCCCAGCGACAGCGTGAGGTTAAACGATGTATTAGGGGACCCAACCCGGCTCCCTCGTAAAAGGCGGCGTGAGGACCCCCTCCCCATGCTGCGGACGTCGATTGCGCCGAAAACGGCAGCGCAAAGAGAACGGCTGCTGGACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGCTGCGAGGTGGATTCCATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTTGTTTCCGCTTTGCTGTCGGAAAAATACAAGCTTGAAACAGTGGTAAAGGAACCCACCGTCATTTATATGGAGCGGCCGCTCAAAGCAGCCAGCCACACCATCCATATCGAGGTGCCGCCCAACCCGTTTTGGGCATCCATCGGACTGTCTGTTACACCACTCCCGCTTGGCTCCGGTGTACAATACGAGAGCCGGGTTTCGCTGGGATACTTGAACCAGAGTTTTCAAAACGCTGTCAGGGATGGTATCCGTTACGGGCTGGAGCAGGGCTTGTTCGGCTGGAACGTAACGGACTGTAAGATTTGCTTTGAATACGGGCTTTATTACAGTCCGGTCAGCACGCCGGCGGACTTCCGCTCATTGGCCCCGATTGTATTGGAACAGGCATTGAAGGAATCAGGGACGCAACTGCTGGAACCTTATCTCTCCTTCACCCTCTATGCGCCCCGGGAATATCTTTCCAGGGCTTATCATGATGCACCGAAATACTGTGCCACCATCGAAACGGTCCAGGTAAAAAAGGATGAAGTTGTCTTTACTGGCGAGATTCCCGCCCGCTGTATACAGGCATACCGTACTGATCTGGCCTTTTACACCAACGGGCAGAGCGTATGCCTTACAGAACTGAAAGGGTATCAGGCCGCTGTCGGCAAGCCAGTCATCCAGCCCCGCCGTCCAAACAACCGCCTGGACAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7163,Drugs,MEG_7163|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/W)_5_AM889122 ,4
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaaataaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctagtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4497,Drugs,MEG_4497|Drugs|betalactams|Class_D_betalactamases|OXA,1058244018|WP_068981636.1|NG_051471|1|1|blaOXA-511|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-511 NG_051471:1-825,0
,atgcaacaacgacaatccttcctgtggggggccgtggccaccctgatgtgggccggtctggcccatgcaggtgagacttcaccggtcgatcccctgcgccccgtggtggatgccagcatccagccgctgctcaaggagcacaggatcccgggcatggcggtggccgtgctcaaggatggcaaggcccactatttcaactacggtgtggccgatcgggagcgcgcggtcggtgtcagcgagcagaccctgttcgagataggctccgtgagcaagcccctgaccgcgaccctaggagcctatgcggtggtcaagggagcgatgcaactggatgacaaggcgagccggcacgccccctggctcaagggatccgcctttgacagcatcaccatgggggagctggctacctacagcgcgggcggcttgccgctgcaattccccgaggaggtggattcgctcgagaagatgcaggcctactaccgccagtggaccccagcctactcgccgggttcccatcgccagtactctaaccccagcatagggctgttcggccacctggcggcgagcagcctgaagcagccgtttgcccagttgatggagcagacgctcctgccggggcttggcctgcaccacacctatgtcaatgtgccgaagcaggccatggcgagttatgcctatggctattcgaaagaggacaagcccatcagggtcagccccggcatgctggcggacgaggcctacggcatcaagaccagctcggcggatctgctgcgctttgtgaaggccaacatcagcggggttgatgacaaggcgttgcagcaggccatctccctgacccacaaagggcactactcggtaggcgggatgacccagggactgggttgggagcgttacgcctatcccgtcagcgagcagacattgctggcgggcaattcggccaaggtgatcctcgaagccaatccgacggcggcgccccgggagtcggggagccagatgctcttcaacaagaccggctcgaccagcggcttcggcgcctatgtggccttcgtgccggccaaagggatcggcatcgtcatgctggccaaccgcaactatcctatcccggccagggtgaaagcggcccacgccatcctgacgcaactggccaggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4015,Drugs,MEG_4015|Drugs|betalactams|Class_C_betalactamases|MOX,1028105819|WP_063860844.1|NG_049313|1|1|blaMOX-11|blaMOX|CMY-1/MOX_family_class_C_beta-lactamase_MOX-11 NG_049313:1-1149,0
,atgaataataaaaaaattgcagttatatttggtggaaactcaacagaatatgatgtatcattacaatcagcttttgcagtacttgagaatttgaatacggaaaaatatgatattctaccaattggaattacaagggagggtaattggtatcattatattggagattataataatatccagaataacacttggtttgaaagggatactgatataattccagttattgtttcgcagaaccgtgtcaaaaatggtattattgaatttttaatttctgatgctgtttctcagaatcatattccaaatagtgctattgaatcatgtgaaaatgatattaaatacactaaacttgattttgtatttcctgtattgcatggaaaaaatggagaagatggaacagtgcaggggttatttgaattggcaggtatacaggttattggatgtggtactctttcttcagcattatgtatggacaaagacaaatcacataaacttgttcattcagaaggtattaaagtaccaaaatcaatattactaaaatactcagataaatttaatgtggctgaactgtcaaaagacttaacttatccattatttataaaacctgtgcgtgcaggttcatcatttggtattagtaaaatttataaaaaagaagagttacaagtagcagtagacttggcttttgaacatgataatgaagtaataattgaggaaaatattgatggttttgaggtagggtgtgcagttttaggaaacaatgacttacttgttggaagagtagatgaaatagaattgtcaaaaggattttttgattatacagaaaaatatacattgaaaagttcaaaaattcatatgccagctagaattgatttggattgtgagaaaagaatacaagagacagcaaaaattatttatagaactcttggatgttctggatttgctagagtagatatgtttttaactccatctggtgaaattatttttaatgaagtcaatacaattcctggctttacttctcatagtcgttatccaaatatgatgaaaggtattggactgtcttttgaagaaatattggacaagataattgaggtgtacataaaatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7392,Drugs,MEG_7392|Drugs|Glycopeptides|VanG-type_resistance_protein|VANG,500187919|WP_011861276.1|NG_061616|1|1|vanG-Cd|vanG-Cd|D-alanine--D-serine_ligase_VanG-Cd NG_061616:101-1201,5
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtggtcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5500,Drugs,MEG_5500|Drugs|betalactams|Class_C_betalactamases|PDC,644501353|WP_025325152.1|NG_054981|1|1|blaPDC-195|blaPDC|class_C_beta-lactamase_PDC-195 NG_054981:1-1194,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggaagactgggggtggcattgattaacacagcggataattcgcaaatactttatcgtgctgatgagcgcttcgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgagtctgttaaatcagcgagttgagatcaaaaaatctgacctggttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggcaggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaatgatatcgcggtgatttggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattggcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2150,Drugs,MEG_2150|Drugs|betalactams|Class_A_betalactamases|CTX,1028104730|WP_063859976.1|NG_048954|1|1|blaCTX-M-169|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-169 NG_048954:101-976,0
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGGCAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1841,Drugs,MEG_1841|Drugs|betalactams|Class_C_betalactamases|CMY,(Bla)CMY-65:JN714479:1041-2186:1146,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacatcttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgtgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6226,Drugs,MEG_6226|Drugs|betalactams|Class_A_betalactamases|SHV,1509794570|WP_122630879.1|NG_062299|1|1|blaSHV-227|blaSHV|class_A_beta-lactamase_SHV-227 NG_062299:1-861,0
,atggctaaaatgagaatatcaccggaattgaaaaaactgatcgaaaaataccgctgcgtaaaagatacggaaggaatgtctcctgctaaggtatataagctggtgggagaaaatgaaaacctatatttaaaaatgacggacagccggtataaagggaccacctatgatgtggaacgggaaaaggacatgatgctatggctggaaggaaagctgcctgttccaaaggtcctgcactttgaacggcatgatggctggagcaatctgctcatgagtgaggccgatggcgtcctttgctcggaagagtatgaagatgaacaaagccctgaaaagattatcgagctgtatgcggagtgcatcaggctctttcactccatcgacatatcggattgtccctatacgaatagcttagacagccgcttagccgaattggattacttactgaataacgatctggccgatgtggattgcgaaaactgggaagaagacactccatttaaagatccgcgcgagctgtatgattttttaaagacggaaaagcccgaagaggaacttgtcttttcccacggcgacctgggagacagcaacatctttgtgaaagatggcaaagtaagtggctttattgatcttgggagaagcggcagggcggacaagtggtatgacattgccttctgcatccggtcgatcagggaggatatcggggaagaacagtatgtcgagctattttttgacttactggggatcaagcctgattgggagaaaataaaatattatattttactggatgaattgttttag,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1040,Drugs,MEG_1040|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,1028082228|WP_063841495.1|NG_047419|1|1|aph(3')-IIIa|aph(3')-IIIa|aminoglycoside_O-phosphotransferase_APH(3')-IIIa NG_047419:101-895,2
,ACTATTAAAAATAGACAATACTTGCTCATAAGTAATGGTACTTAAATTGTTTACTTTGGCGTGTTTCATTGCTTGATGAAACTGATTTTTAGTAAACAGTTGACGATATTCTCGATTGACCCATTTTGAAACAAAGTACGTATATAGCTTCCAATATTTATCTGGAACATCTGTGGTATGGCGGGTAAGTTTTATTAAGACACTGTTTACTTTTGGTTTAGGATGAAAGCATTCCGCTGGCAGCTTAAGCAATTGCTGAATCGAGACTTGAGTGTGCAAGAGCAACCCTAGTGTTCGGTGAATATCCAAGGTACGCTTGTAGAATCCTTCTTCAACAATCAGATAGATGTCAGACGCACGGCTTTCAAAAACCACTTTTTTAATAATTTGTGTGCTTAAATGGTAAGGAATATTCCCAACAATTTTATACCTCTGTTTGTTAGGGAATTGAAACTGTAGAATATCTTGGTGAATTAAAGTGACACGAGTATTCAGTTTTAATTTTTCTGACGATAAGTTGAATAGATGACTGTCTAATTCAATAGACGTTACCTGTTTACTTATTTTAGCCAGTTTCGTCGTTAAATGCCCTTTACCTGTTCCAATTTCGTAAACGGTATCGGTTTCTTTTAAATTCAATTGTTTTATTATTTGGTTGAGTACTTTTTCACTCGTTAAAAAGTTTTGAGAATATTTTATATTTTTGTTCAT,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2803,Drugs,MEG_2803|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,gi|874011340|gb|CP012045.1|1118501-1119211 gi|745811785|gb|CP007593.1|967037-966327 gi|703570643|gb|CP009612.1|1079619-1080329 gi|698841295|emb|LK020698.1|24093-24803 gi|698841065|emb|LK020692.1|27752-27042 gi|698840909|emb|LK020687.1|14138-14848 gi|649571968|emb|HG799503.1|4837-4127 gi|641688100|emb|HG799491.1|44245-44955 gi|556027507|gb|CP006844.1|1748341-1747631 gi|537629960|gb|CP003858.1|645192-644482,7
,ATGTTCAAACTTTTGAGTAAGTTATTGGTCTATTTGACCGCGTCTATCATGGCTATTGCGAGTCCGCTCGCTTTTTCCGTAGATTCTAGCGGTGAGTATCCGACAGTCAGCGAAATTCCGGTCGGGGAGGTCCGGCTTTACCAGATTGCCGATGGTGTTTGGTCGCATATCGCAACGCAGTCGTTTGATGGCGCAGTCTACCCGTCCAATGGTCTCATTGTCCGTGATGGTGATGAGTTGCTTTTGATTGATACAGCGTGGGGTGCGAAAAACACAGCGGCACTTCTCGCGGAGATTGAGAAGCAAATTGGACTTCCTGTAACGCGTGCAGTCTCCACGCACTTTCATGACGACCGCGTCGGCGGCGTTGATGTCCTTCGGGCGGCTGGGGTGGCAACGTACGCATCACCGTCGACACGCCGGCTAGCCGAGGTAGAGGGGAACGAGATTCCCACGCACTCTCTAGAAGGACTCTCATCGAGCGGGGACGCAGTGCGCTTCGGTCCAGTAGAACTCTTCTATCCTGGTGCTGCGCATTCGACCGACAACTTAGTTGTGTACGTCCCGTCTGCGAGTGTGCTCTATGGTGGTTGTGCGATTTATGAGTTGTCACGCACGTCTGCGGGGAACGTGGCCGATGCCGATCTGGCTGAATGGCCCACCTCCATTGAGCGGATTCAACAACACTACCCGGAAGCACAGTTCGTCATTCCGGGGCACGGCCTGCCGGGCGGTCTAGACTTGCTCAAGCACACAACGAATGTTGTAAAAGCGGGCTCTGTTGCAAAGATTGGCGGCAGTCAGAGGTAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_7769,Drugs,MEG_7769|Drugs|betalactams|Class_B_betalactamases|VIM,blaVIM-48_1_KY362199,0
,ATGACACAGTTCGCCAAGGAAACGCTGCCGATCAGCCTCGAGGAGGAAATGCGCCACTCCTACCTGGATTACGCCATGAGCGTGATCGTGGGGCGGGCGCTGCCCGATGCGCGCGACGGCCTGAAGCCGGTGCACCGCCGGGTGCTGTACGCGATGCACGAGCTTTCCAACGACTGGAACCGCGCCTACAAGAAGTCGGCGCGTATCGTCGGCGACGTCATCGGTAAGTACCACCCGCATGGCGACTCGGCGGTGTACGACACCATCGTGCGCATGGCGCAGGATTTCTCGCTGCGCTACATGCTGGTCGACGGCCAGGGCAACTTCGGCTCGGTCGACGGCGACAACGCCGCGGCGATGCGTTACACCGAAATCCGCATGGCGCGCATCGGTCACGAACTGCTGGCCGACATCGACAAGGAAACGGTGGATTTCGGGCCGAACTACGACGGCTCGGAAAAAGAGCCGCTGATCCTGCCGGCCCGCATCCCCAATCTGCTGATCAACGGTTCCTCCGGTATCGCGGTCGGCATGGCGACCAACATCCCGCCGCACAACCTGGGCGAAGTGGTCGATGCCTGTCTCAAGCTGCTCGAAGATCCGGAAACCGACCTCGAAGCGCTGATCGAAATCGTCAAGGCGCCCGACTTCCCCACCGCGGGTCTGATCTACGGCCTGCACGGCGTGCACGAAGGCTATCGCACCGGCCGCGGCCGGGTGGTGATGCGCGCCCGCACCCATATCGAGCCGATCGGCAAGAACAGCGACCGCGAAGCCATCATCGTCGACGAGCTGCCCTACCAGGTGAACAAGCGCACCCTGCTGGAGCGCATCGCCGAGCTGGTCAACGAAAAGAAGGTCGAGGGCATCAGCGAGATCCGCGACGAGTCGGACAAGTCCGGCATGCGCGTGGTGATCGAACTGAAGCGCAACGAAATGCCCGAGGTGGTGCTCAACAACCTGTACAAGCACACCCAGCTGCAGGACACCTTCGGCATGAACATGGTGGCGCTGGTGGACGGCAAGCCCCGCCTGCTCAACCTCAAGCAGATGCTGGTGTGCTTCCTCGAGCACCGCCGCGAGGTCGTCACCCGCCGCACCATCTTCGAACTGAAGAAGGCGCGCGACCGCGGCCACATCCTCGAAGGCCTGGCGGTGGCGCTGTCCAACGTGGACGAGATCATCGCCCTGATCAAGGCCGCGCCGACGCCGGCGGATGCCAAGCGCGGCCTGATGGAACGCACGTGGCGCTCGCCGCTGGTGGAAGAAATGCTGTCGCGCGCGCTCGCCGACAGCTACCGCCCGGAAGGGCTGGACCCCGAGTTCGGCTTCTCGGCCCAGGGTTACAAGCTGTCCGACGCCCAGGCCCAGGCCATCCTGGAACTGCGCCTGCAGCGCCTGACCGGCCTCGAACAGGACAAGATCGTCGGCGAGTACCGCGAGGTGATGGATCTCATCACCGACCTGCTCGACATCCTGGCCCGTCCCGAGCGCATCACCGCGATCATCGTCGAGGAGCTGACCGCGATCCGCAACCAGTTCGGCGACCCGCGCCGTTCCGAGATCGTGCTCAGCACCGCCGAGATCAACATCGAGGACCTGATCACGCCGGAAGACATGGTGGTGACGCTGTCGCACACCGGTTACTTCAAGCGCCAGCCGCTCGCCGACTACCGCGCCCAGCGTCGCGGCGGCCGCGGCAAGCAGGCCACCTCGATGAAGGACGAGGACTTCATCGACCACCTCTTCGTCGCCAATACCCACGACACCGTGCTGTGCTTCTCCAGCCGCGGCCGCGCCTACTGGCTGAAGGTGTACGAGGTGCCCGAAGGCACCCGCAACTCGCGCGGCAAGCCGATCGTGAACCTGTTCCCGTTGATCGAGGGCGAGAAGATCACCGCGGTGCTGCCGGTGCAGACCTTCGATGAAGAGCATTTCGTGTTCATGGCGACTTCGGAAGGCACGGTCAAGAAGACTGCGCTCACCGCTTTCGCCAACCCGCGCAAGGCCGGCATCATCGCGGTCAACCTCGATGACGGCGACCACCTGATCGGCGTCGCGATCACCGACGGTGAGTGCGACGTGATGCTGTTCTCCGACGCCGGCAAGGCCGTGCGCTTTGCCGAGAGCGACGTGCGCCCGATGGGCCGCGAAGCGCGCGGCGTGCGCGGCATGACGCTGGAAGACGGCCAGCGCGTGATCGCGATGCTGGTCGCCAAGGGCGAAACCCAGTCGGTGTTGACGGCTACCGAAAACGGTTATGGCAAGCGCACCCCGGTGGCGGAATACACCCGCCACGGCCGCGGCACCAAGGGCATGATCGCGATCCAGACCTCGGACCGCAACGGCAAGCTGGTCGGCGCGGTGCTGGTCGATCCGACCGACGAGGTGATGCTGATCTCCACCGGTGCGGTGCTGATCCGCACCAAGGTGCAGGACATCCGCGAGCTTGGCCGCGCCACCCAGGGCGTGACGCTGATCAACCTCGATGAGGGCACGTACCTGGCCGGGATCGAGAAGGTGGCCGAGTCCGGCGCCGAGGCGGACGAACTGGTGGAAGGTGGCGAAGAGGGCGCCGCGGACGGCGAGGATGCCGGCGCGCCGGGCGCCGCGGGTGAAGGAGAACAGGAATGA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3188,Drugs,MEG_3188|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|119668705|emb|AM406670.1|1146520-1149153,3
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcactgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgataaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgtgcgggaggaacagcggcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgccgccctatgcggcagcgttttcaaggtggagtatacagattgcggccagcggcgtgtctatctacggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggagaaattgttattttagctgatgatactttgaaactgaacgacattctaggaaatgaaaaactcctgcctcataaaacacggattgataatcccatgccattacttcggacaacggtagagccgcaaaagccggagcaaagggaagccctgttaaatgccctcgcagagattgctgatacagaccctcttttgcattttgacattgatactgttacacatgagattatgttatcttttttgggaaaagtacagttagaagttatttgttcgctattagaagaaaaatatcatgtgggcgtggctatgaaagagccttcggttatttatctggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgcccaacccgttttgggcatccatcggactgtctgttacaccactcccgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaactaatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7209,Drugs,MEG_7209|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100284|WP_063856419.1|NG_048292|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048292:29-1948,4
,GTTTCGATCTTACCTGTGAAAGAACAAGACGCTGCCGACTGGCTAGCGCTGCGGAATCTTCTTTGGCTCGCGGATGATCACGCCTCGGAGATTGAGCAGTACTTCTCTGGTGGATTTGAGGAGCCTGCAGAAGTGCTCATCGCCCGTGATGCTACCGGCGCGGCTGTTGGGCATGTCGAACTCTCGATAAGACATGACTTGGAAGAACTCCAAGGAATCAAGACCGGCTACATCGAAGGCCTTTATGTGGCCCCAAGCCATCGATCAACAGACCTTGTGAGGCGTTTCTTGCGTGAGTCCGAGAAGTGGGCCCTAGAACAAGGGTGCAGCGCATTTGCCTCAGACAGAAGTGATCGGGTCATCACGCACCGCAAGTTCGCAGGCAGCGCCGTCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_312,Drugs,MEG_312|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gb|EU118148|+|2006-2402|ARO:3002584|AAC(6')-29b [Pseudomonas aeruginosa] ,2
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgcatcgaacacgcttgtgaggccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaataaaattggtggtcctaaagcggtcacgctgtttttgcgatctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1505,Drugs,MEG_1505|Drugs|betalactams|Class_A_betalactamases|CARB,646402466|WP_025521699.1|NG_048739|1|1|blaCARB-35|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-35 NG_048739:1-852,0
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaagcagtatcattaatcactagtgccatcttgcaaatggcgattattttttaccttacagaaaaaactggatccgcgatggtcttgtctatggcttcactattaggttttttaccctatgcggtctttggacctgcaattggtgtgctagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctggttcggtgcttactattgttgcattctatatggagctacctgtctggatggttatgatagtattgtttatccgtagcattggaacagcttttcacaccccggctctcaatgcggttacgccacttttagtaccagaagaacagcttacgaaatgtgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcggttgcagcactcttatactccgtttgggaactaaatgctattattgccatcgatgtattgggtgctgtgattgcatctattacggtagcaattgtacgtattcctaagctgggtgatcgcgtgcaaagtttggacccaaatttcataagagaaatgcaagaaggaatggctgtactacggcaaaataaaggattatttgctttattactcgttggaacattatatatgtttgtttatatgccaattaatgcactattccctttaattagcatggattactttaatggaacacctgtgcatatttctattacggaaatttcctttgcatctggaatgttgatagggggtctattattagggttatttgggaattaccaaaagcgaatcttattaataacggcatccatttttatgatggggataagcttaaccatttcaggattacttccccaaagtggatttttcatttttgtagtctgctgtgcaataatggggctttctgttccgttttacagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttaactggaagtattatgtctcttgctatgccaattggattaattctttctgcactctttgctgatagaatcggtgtaaatcattggtttttactatcaggtattttaattatttgcattgcaatagttttcccaatgataaatgagattagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3812,Drugs,MEG_3812|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028096886|WP_063853591.1|NG_047963|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047963:101-1318,7
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccattcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggataccccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6206,Drugs,MEG_6206|Drugs|betalactams|Class_A_betalactamases|SHV,1509794561|WP_122630870.1|NG_062287|1|1|blaSHV-215|blaSHV|class_A_beta-lactamase_SHV-215 NG_062287:1-861,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaaaggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2148,Drugs,MEG_2148|Drugs|betalactams|Class_A_betalactamases|CTX,1035157525|WP_064511490.1|NG_050812|1|1|blaCTX-M-183|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-183 NG_050812:1-876,0
,atgaatattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaagaccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggctttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattacgcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccctttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggcatacctagctctgttcgaaaagagattacttataaaagcttagaactattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4532,Drugs,MEG_4532|Drugs|betalactams|Class_D_betalactamases|OXA,1509794606|WP_122630915.1|NG_062335|1|1|blaOXA-723|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-723 NG_062335:18-842,0
,atgcaacaacgacaatccatcctgtggggcgctctggccaccctgatgtgggccggcctggctcatgccggtgacaaggcggcgaccgatcccctgcgccccgtggtggatgccagcatccggccgctgctcaaggagcacaggatcccgggcatggcggtggccgtgctcaaggatggcaaggcccactatttcaactacggtgtggccgatcgggagcgcgcggtcggtgtcagcgagcagaccctgttcgagataggctccgtgagcaagaccctgaccgcgacgctgggggcctacgccgtggtgcaggggggcttcgagctcgatgacaaggcgagtctgttcgccccctggctcaagggatccgcctttgacaacatcaccatgggggagctggctacctacagcgcaggcggcttgccgctgcaattccccgaggaggtggattcgctcgagaagatgcaggcctactaccgccagtggaccccagcctactcgccgggttcccatcgccagtacgccaaccccagcatcgggctctttggctatctggcggcgagcagcatgaagcagccgttcgatcgcctgatggagcagacgatcctgccggggcttggcctgtaccatacctacctcaatgtgcccgagcaggccatggggcactacgcctacggctactcgaaggaggacaagcccatccgcgtcactcccggcatgctggcggacgaggcctacggcatcaagaccagctcggcggatctgctgcgctttgtgaaggcgaacatcagcggggtggataatgcggccatgcagcaggccatcgacctgactcaccagggccagtatgcggtgggggagatgacccagggactgggctgggagcgttacgcctatcccgtcagcgagcagacgctgctggcgggcaactccccggcgatgatttataatacgaacccggcggcgcccgcgcccgctgcggcagggcaccctgtgctcttcaacaagaccggctcgaccaacggcttcggggcctatgtggccttcgtgccggccaaagggatcggcgtcgtcatgctggccaatcgcaactaccccaacgaggcgcgcatcaaggcggctcacgccatcctgacgaaactggccaggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4013,Drugs,MEG_4013|Drugs|betalactams|Class_C_betalactamases|MOX,759433136|WP_043155783.1|NG_049314|1|1|blaMOX-12|blaMOX|CMY-1/MOX_family_class_C_beta-lactamase_MOX-12 NG_049314:101-1252,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1398,Drugs,MEG_1398|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_70_NZ_CUEK01000047,0
,ATGGAAAAAAACAGAAAAAAACAAATCGTAGTTTTGAGTATAGCTTTAGTTTGCATTTTCATCTTGGTATTTTCATTGTTCCATAAATCAGCGACAAAAGATAGCGCAAATCCTCCTTTAACAAATGTTTTGACTGATAGCATTTCTCAAATTGTCTCAGCTTGTCCTGGCGAAATTGGTGTGGCGGTTATTGTTAATAACAGAGATACGGTTAAGGTCAATAATAAGAGTGTTTATCCTATGATGAGTGTGTTTAAGGTTCATCAGGCATTAGCTCTTTGTAATGACTTTGACAATAAAGGAATTTCACTTGATACCTTAGTAAATATAAATAGGGATAAACTTGACCCAAAGACTTGGAGTCCTATGCTGAAAGATTATTCAGGGCCAGTCATATCATTGACAGTGAGAGATTTGCTGCGTTATACTCTTACTCAGAGTGACAACAATGCAAGCAACCTTATGTTTAAGGATATGGTTAATGTCGCTCAAACAGATAGTTTTATAGCCACACTCATTCCTCGTTCAAGTTTTCAGATAGCTTATACGGAAGAGGAAATGTCGGCTGACCATAACAAGGCTTACTCTAACTATACATCTCCTCTTGGTGCTGCAATGTTGATGAATCGTTTGTTTACTGAAGGTCTTATCGATGATGAGAAACAAAGTTTCATTAAGAATACGTTAAAAGAATGCAAAACAGGTGTAGATAGGATAGCAGCTCCACTTCTTGATAAAGAAGGGGTTGTTATAGCGCATAAGACAGGTTCAGGTTATGTTAATGAAAATGGTGTTCTTGCAGCTCACAATGATGTTGCCTATATATGTCTGCCTAATAATATCAGTTATACCTTAGCGGTATTTGTTAAGGATTTCAAGGGAAATAAATCACAAGCGTCACAATATGTTGCGCATATATCAGCTGTAGTATATTCTTTATTAATGCAAACTTCAGTAAAATCTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1696,Drugs,MEG_1696|Drugs|betalactams|Class_A_betalactamases|CFX,gb|U38243|+|149-1115|ARO:3003001|CfxA [Bacteroides vulgatus] ,0
,atgacatccagcattagtttcgtcaagctgcgcctcatgaccgagcaagaccttccgatgctccatgagtggctaaaccggcctcacatcgttgagtggtggggcggagaagaagcacgtccaacacttgctgaagtgcaggagcaatacctgccaagcgccttggcgagagagtccgtcactccctacatcgcaatgctggatgaagaaccgattgggtacgctcagtcgtacgttgcactcggaagcggtggcggatggtgggaagacgaaacggatccaggagtacgcggaattgaccagtccctggcaaatccatcgcagctgggaaaggggctaggaaccaagcttgttcgcgcgctcgttgagatgctgttcaaagacgctaaggtaaccaatatccaaacggacccgtcgccgaacaacttgcgcgcaatccggtgctacgagaaggcggggtttgtgacgcaaagaaccataaccaccccagacgggccggctgtgtacatggttcaaacacgtcaggcgttcgagcaggcgcgcagtgctgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_122,Drugs,MEG_122|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,916842019|WP_051449075.1|NG_052107|1|1|aacA8|aacA8|aminoglycoside_6'-N-acetyltransferase_AacA8 NG_052107:101-655,2
,ATGAGCGATATGGCAGAGCGCCTTGCGCTACATGAATTTACGGAAAACGCCTACTTAAACTACTCCATGTACGTGATCATGGACCGTGCGTTGCCGTTTATTGGTGATGGTCTGAAACCTGTTCAGCGCCGCATTGTGTATGCGATGTCTGAACTGGGCCTGAATGCCAGCGCCAAATTTAAAAAATCGGCCCGTACCGTCGGTGACGTACTGGGTAAATACCATCCGCACGGCGATAGCGCCTGTTATGAAGCGATGGTCCTGATGGCGCAACCGTTCTCTTACCGTTATCCGCTGGTTGATGGTCAGGGGAACTGGGGCGCGCCGGACGATCCGAAATCGTTCGCGGCAATGCGTTACACCGAATCCCGGTTGTCGAAATATTCCGAGCTGCTATTGAGCGAGCTGGGGCAGGGGACGGCTGACTGGGTGCCAAACTTCGACGGCACTTTGCAGGAGCCGAAAATGCTACCTGCCCGTCTGCCAAACATTTTGCTTAACGGCACCACCGGTATTGCCGTCGGCATGGCGACCGATATTCCACCGCATAACCTGCGTGAAGTGGCTCAGGCGGCAATCGCATTAATCGACCAGCCGAAAACCACGCTCGATCAGCTGCTGGATATCGTGCAGGGGCCGGATTATCCGACTGAAGCGGAAATTATCACTTCGCGCGCCGAGATCCGTAAAATCTACGAGAACGGACGTGGTTCAGTGCGTATGCGCGCGGTGTGGAAGAAAGAAGATGGCGCGGTGGTTATCAGCGCATTGCCGCATCAGGTTTCAGGTGCGCGCGTACTGGAGCAAATTGCTGCGCAAATGCGCAACAAAAAGCTGCCGATGGTTGACGATCTGCGCGATGAATCTGACCACGAGAACCCGACCCGCCTGGTGATTGTGCCGCGTTCCAACCGCGTGGATATGGATCAGGTGATGAACCACCTCTTCGCTACCACCGATCTGGAAAAGAGCTATCGTATTAACCTTAATATGATCGGTCTGGATGGTCGTCCGGCGGTGAAAAACCTGCTGGAAATCCTCTCCGAATGGCTGGTGTTCCGCCGCGATACCGTGCGCCGCCGACTGAACTATCGTCTGGAGAAAGTCCTCAAGCGCCTGCATATCCTCGAAGGTTTGCTGGTGGCGTTTCTCAATATCGACGAAGTGATTGAGATCATTCGTAATGAAGATGAACCGAAACCGGCGCTGATGTCGCGGTTTGGCCTTACGGAAACCCAGGCGGAAGCGATCCTCGAACTGAAACTGCGTCATCTTGCCAAACTGGAAGAGATGAAGATTCGCGGTGAGCAGAGTGAACTGGAAAAAGAGCGCGACCAGTTGCAGGGCATTTTGGCTTCCGAGCGTAAAATGAATAACCTGCTGAAGAAAGAACTGCAGGCAGACGCGCAAGCCTACGGTGACGATCGTCGTTCGCCGTTGCAGGAACGCGAAGAAGCGAAAGCGATGAGCGAGCACGACATGCTGCCGTCTGAACCTGTCACCATTGTGCTGTCGCAGATGGGCTGGGTACGCAGCGCTAAAGGCCATGATATCGACGCGCCGGGCCTGAATTATAAAGCGGGTGATAGCTTCAAAGCGGCGGTGAAAGGTAAGAGCAACCAACCGGTAGTGTTTGTTGATTCCACCGGTCGTAGCTATGCCATTGACCCGATTACGCTGCCGTCGGCGCGTGGTCAGGGCGAGCCGCTCACCGGCAAATTAACGTTGCCGCCTGGGGCGACCGTTGACCATATGCTGATGGAAAGCGACGATCAGAAACTGCTGATGGCTTCCGATGCGGGTTACGGTTTCGTCTGCACCTTTAACGATCTGGTGGCGCGTAACCGTGCAGGTAAGGCTTTGATCACCTTACCGGAAAATGCCCATGTTATGCCGCCGGTGGTGATTGAAGATGCTTCCGATATGCTGCTGGCAATCACTCAGGCAGGCCGTATGTTGATGTTCCCGGTAAGTGATCTGCCGCAGCTGTCGAAGGGCAAAGGCAACAAGATTATCAACATTCCATCGGCAGAAGCCGCGCGTGGAGAAGATGGTCTGGCGCAATTGTACGTTCTGCCGCCGCAAAGCACGCTGACCATTCATGTTGGGAAACGCAAAATTAAACTGCGCCCGGAAGAGTTACAGAAAGTCACTGGCGAACGTGGACGCCGCGGTACGTTGATGCGCGGTTTGCAGCGTATCGATCGTGTTGAGATCGACTCTCCTCGCCGTGCCAGCAGCGGTGATAGCGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5333,Drugs,MEG_5333|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gb|U00096.3|-|3163714-3165973|ARO:3003308|Escherichia coli parC conferring resistance to fluoroquinolone [Escherichia coli str. K-12 substr. MG1655] ,3
,atgagtaacgcagtacccgccgagatttcggtacagctatcactggctctcaacgccatcgagcgtcatctggaatcaacgttgctggccgtgcatttgtacggctctgcactggacggtggcctgaagccatacagtgatattgatttgctggttactgtgaccgtaaggcttaatgaagcaacacggcaagctttgctcaatgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_815,Drugs,MEG_815|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502112|WP_071846264.1|NG_052305|1|1|ant(3'')-Ia|ant(3'')-Ia|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA NG_052305:101-892,2
,atggttaaaaaatcattacgccagtttgcgctgttggccgcgacggtttttccgctgctggcaggcagcgtatcgctacaggcacaaacgctaagcgtagagcagaaacttgcggctttagagcagcgttcagggggacggcttggggtcgcgttgatagatactgcggatggttcgcaaattctctatcgtggcgatgagcgtttcgcgatgtgtagtaccagcaaagtgatggccgctgccgcggtgctaaagcaaagtgaaagtcagcacgatcttttaaatcagcgcattgagatcaaaaagggtgacctgactaactataacccgattgcggaaaaacatgtcggtgggtcgatgtcgttgtctgagctcagcgccgcggccttgcagtacagcgataacgtggcgatgaataagcttatcgctcaactgggtggcccgcagggggttaccgcgtttgcccgtaagattggggatgagacgtttcgtctcgatcgcacggaaccgacgctgaacactgcaattcccggcgatccacgcgataccacatcaccacgggctatggcacaaacgctgcgcaacctgacgctgggaaaagcgcttggtgacgctcaaagggcgcagttggtgacctggatgaaagggaatacgactggaacggccagtattcaggctggactaccggcttcgtgggtggtgggtgataaaaccggcagcggtgattacggcaccaccaacgacattgcggtgatttggccgaaagatcgtgcaccattggttttggttacctacttcacgcagcctcagcctgaggcggaaagccgtcgtgatgtattagcctcggcggcgaaaatcgtcactgagggattatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3458,Drugs,MEG_3458|Drugs|betalactams|Class_A_betalactamases|KLUC,1001733947|WP_061284984.1|NG_049241|1|1|blaKLUC-1|blaKLUC|class_A_extended-spectrum_beta-lactamase_KLUC-1 NG_049241:101-976,0
,atgagtattcaacattttcgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaaactggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacatgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6669,Drugs,MEG_6669|Drugs|betalactams|Class_A_betalactamases|TEM,1343491238|WP_104009854.1|NG_056417|1|1|blaTEM-230|blaTEM|class_A_beta-lactamase_TEM-230 NG_056417:1-861,0
,AACACAGGCATAGATATGACTCTGGCATTAGTTGGCGAAAAAATTGACAGAAATCGCTTCACTGGTGAGAAAGTTGAAAATAGTACATTTTTTAACTGCGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGCCAGTTCTATGATCGCGAAAGTCAGAAAGGATGCAATTTTAGTCGCGCAATGCTGAGAGATGCCATTTTCAAAAGCTGTGATTTATCAATGGCAGATTTCCGCAACGTCAGCGCATTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGTGCAAGCTTTATGAATATGATCACCACGCGCACCTGGTTTTGCAGCGCATATATCACTAATACCAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTATGGGAAAACCGCTGGATGGGGACTCAGGTACTGGGTACGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTAGGTGACTTAGATATTCGGGGTGTTGATTTACAAGGCGTTAAGTTAGACAACTACCAGGCATCGTTGCTCATGGAGCGGCTTGGCATCGCTGTGATTGGTTAG,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_5958,Drugs,MEG_5958|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gb|JN166689|+|0-660|ARO:3002755|QnrB40 [Citrobacter braakii] ,3
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTTGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1855,Drugs,MEG_1855|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AJ011293|+|0-1146|ARO:3002017|CMY-6 [Escherichia coli] ,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttacttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4460,Drugs,MEG_4460|Drugs|betalactams|Class_D_betalactamases|OXA,1509794594|WP_122630903.1|NG_062323|1|1|blaOXA-701|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-701 NG_062323:18-842,0
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6892,Drugs,MEG_6892|Drugs|betalactams|Class_A_betalactamases|TEM,gi|22725666|gb|AF535127.1|1-1069 gi|8117219|dbj|AB043582.1|3802-4116 gi|8117212|dbj|AB043581.1|3802-4116 gi|8117205|dbj|AB043580.1|3802-4116,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgctcggcgctgtggccctccagctcgcctgaagcgcaccgcgcggaaatgcgcgaaatattggcttcgccacaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttctggaagggatttataccgtcgaacgcgcccgccgccagggctgggccgcgcgcttgatcgcgcaggtgcaagagtgggcgaaacaacaggggtgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_167,Drugs,MEG_167|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,727165197|WP_033636082.1|NG_052451|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052451:101-541,2
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgtgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcagttgtgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgatttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccacggagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagccagcgtattgtcaaacaagccatgctgaccgaagccaatggtgactatattattcgggctaaaactggatactcgactagaatcgaacctaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggaaaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4611,Drugs,MEG_4611|Drugs|betalactams|Class_D_betalactamases|OXA,1226997334|WP_094009811.1|NG_055499|1|1|blaOXA-566|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-566 NG_055499:1-798,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatcacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5637,Drugs,MEG_5637|Drugs|betalactams|Class_C_betalactamases|PDC,1408841624|WP_111672897.1|NG_060554|1|1|blaPDC-284|blaPDC|class_C_beta-lactamase_PDC-284 NG_060554:1-1194,0
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4683,Drugs,MEG_4683|Drugs|betalactams|Class_D_betalactamases|OXA,1509794611|WP_122630920.1|NG_062340|1|1|blaOXA-712|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-712 NG_062340:29-853,0
,ATGAAAAAAATAACTTTATTTTTGCTTTTCTTAAATTTAGTGTTTGGGCAAGATAAGATATTAAATAATTGGTTTAAAGAGTATAATACAAGCGGCACTTTTGTTTTTTATGATGGAAAAACTTGGGCGAGTAACGACTTTTCAAGGGCTATGGAGACTTTCTCTCCCGCTTCCACTTTTAAAATTTTTAATGCTCTAATTGCACTTGATAGTGGTGTGATAAAAACTAAAAAAGAAATTTTTTATCACTATAGAGGTGAAAAAGTATTTTTATCTTCTTGGGCGCAAGATATGAATTTAAGTTCAGCTATAAAATATTCTAATGTTCTTGCTTTTAAAGAAGTGGCAAGAAGAATTGGTATCAAAACTATGCAAGAATATTTAAACAAGCTTCATTATGGTAATGCTAAAATTTCCAAGATCGATACTTTTTGGCTTGACAACTCACTAAAAATAAGCGCTAAAGAACAAGCAATTTTGCTTTTTAGACTTTCACAAAATAGCTTACCTTTTTCTCAAGAAGCAATGAATAGTGTTAAGGAAATGATTTATTTAAAAAATATGGAAAATTTAGAGCTTTTTGGAAAAACAGGTTTTAATGATGAGCAAAAAATTGCTTGGATTGTAGGTTTTGTGTATTTAAAAGATGAAAATAAATATAAGGCTTTCGCGCTAAATTTAGATATTGATAAATTTGAAGATTTATATAAAAGAGAAAAAATTTTAGAAAAATATTTAGATGAACTTGTAAAAAAAGTTAAAAATGATGGCTAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5264,Drugs,MEG_5264|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-193_1_CP013032,0
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcactgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgataaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgtgcgggaggaacagcggcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgccgccctatgcggcagcgttttcaaggtggagtatacagattgcggccagcggcgtgtctatctacggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggagaaattgttattttagctgatgatactttgaaactgaacgacattctaggaaatgaaaaactcctgcctcataaaacacggattgataatcccatgccattacttcggacaacggtagagccgcaaaagccggagcaaagggaagccctgttaaatgccctcgcagagattgctgatacagaccctcttttgcattttgacattgatactgttacacatgagattatgttatcttttttgggaaaagtacagttagaagttatttgttcgctattagaagaaaaatatcatgtgggcgtggctatgaaagagccttcggttatttatctggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgcccaacccgttttgggcatccatcggactgtctgttacaccactcccgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttctcaaaacgctgtcagggatggtatccgttacgggctggagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaactaatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttaccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7208,Drugs,MEG_7208|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100285|WP_063856420.1|NG_048293|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048293:1-1920,4
,atggaaaaatacaacaattggaaatttaagttttatactatatgggcagggcaggcggtatctttaatcactagtgccatcctgcaaatggcgataattttttaccttacagaaaaaacaggatctgcgatggttttgtctatggcttcactagtagggtttttaccctatgcggtctttggaccagccattggtgtattagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatagcagcagctggagcagtgctcgctattgttgcattgtatacggagttatctgtatggatggttatggtagtattgtttatccgtagcattggaacggcttttcattctccggctctcaatgcggttacgccgcttttagtaccagaagaacagcttacgaaatgtgcaggttatagtcagtctttgcagtcgataagttatattattagtccggctgctgcggcattgttatactccgtttggaaattaaatgcaattattgctatcgatatattgggtgctatgattgcatctattacggtagcaattgtaagtattcctaagctgggcgatcaagtgcaaagtttgaaaccaaatttcttaagagaaatgaaagaaggaattgtcgcattgagacaaaacaaaggcttatttgccttattactcttaggaacgctatatacgtttgtgtatatgccaattaatgcactatttcctttaattagcatggaatattttaatggaacacctgtgcatatttccattaccgaaatcgcttttgcatctggaatgctagtaggcggtctactattaggaaggttggggaactttgaaaagcgtgtattgctaataacaggttcattctttataatgggagccagtttagccgtttcaggattacttccgccaagtggatttgttatatttgtagcttgctgtgcagtaatggggctttcggtgccattttatagcggtgtgcaaacagctctttttcaggagaagattaagcctgaatatttaggacgtgtattttctttgaccggaagtattatgtcatttgcaatgccaattggattaattctttctggattctttgctgatagaattggtgtaaatcattggtttttactatcaggtattttaattattggcattgctatagtttgcccgatgataacagaggttagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3820,Drugs,MEG_3820|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028096845|WP_063853563.1|NG_047960|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047960:1-1218,7
,atgacaatccgaatctttgcaatatttttctccactcttatttttgccactttcgcgcatgcacaagaaggcacgctagaacgttctgactggaagaagttcttcgacgattaccaagccaaaggcacgatagttgtggcagacgaacgtcaagcagatcgcatcctatcggtttttgatcaagcacgggcgacaaaacgttactcgcctgcatcaacattcaagattccacacacactttttgcacttgatgtaggtgctgttcgtgatgagttccaggttttccgatgggacggtattaaacgaagctttgcaggacacaatcaagaccaaaacttgcgatcagctatgcgaaactctacggtctgggtttatgagctatttgcaagagagatcggtgaggaaaaagccaaacgctatttaaagcaaataggttatggcaacgccgacccttcgacaagcaaaggcgattattggatagatggcactctagaaatttctgcgtacgaacagatttcgtttctcagaaaactctatcgaaatgaattgccatttcgggtagagcatcagcgcttggtcaaagatctcatgattacggaagccgggcgcaactggattctgcgcgcaaagactggctgggaaggtaggtttggctggtgggtgggatgggttgagtggcctaccggcgccgtattcttcgcattgaatatcgatacgccaaacagaatggatgatcttttcaaaagagaggcaatcgtgcgggcaatcctccactctatcgacgcgttgccgcccaactag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4533,Drugs,MEG_4533|Drugs|betalactams|Class_D_betalactamases|OXA,1119781282|WP_072678505.1|NG_061615|1|1|blaOXA-732|blaOXA|class_D_beta-lactamase_OXA-732 NG_061615:101-901,0
,atgttcaaacttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgttgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcactcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacgctacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7711,Drugs,MEG_7711|Drugs|betalactams|Class_B_betalactamases|VIM,1625655432|WP_136512109.1|NG_064786|1|1|blaVIM-66|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-66 NG_064786:1-801,0
,GGTTAAGCGACTAAGCGTACACGGTGGATGCCCTGGCAGTCAGAGGCGATGAAGGACGTGCTAATCTGCGATAAGCGTCGGTAAGGTGATATGAACCGTTATAACCGGCGATTTCCGAATGGGGAAACCCAGTGTGTTTCGACACACTATCATTAACTGAATCCATAGGTTAATGAGGCGAACCGGGGGAACTGAAACATCTAAGTACCCCGAGGAAAAGAAATCAACCGAGATTCCCCCAGTAGCGGCGAGCGAACGGGGAGGAGCCCAGAGCCTGAATCAGTGTGTGTGTTAGTGGAAGCGTCTGGAAAGGCGCGCGATACAGGGTGACAGCCCCGTACACAAAAATGCACATGCTGTGAGCTCGATGAGTAGGGCGGGACACGTGGTATCCTGTCTGAATATGGGGGGACCATCCTCCAAGGCTAAATACTCCTGACTGACCGATAGTGAACCAGTACCGTGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGTGAAAAAGAACCTGAAACCGTGTACGTACAAGCAGTGGGAGCATGCTTAGGCGTGTGACTGCGTACCTTTTGTATAATGGGTCAGCGACTTATATTCTGTAGCAAGGTTAACCGAATAGGGGAGCCGAAGGGAAACCGAGTCTTAACTGGGCGTTAAGTTGCAGGGTATAGACCCGAAACCCGGTGATCTAGCCATGGGCAGGTTGAAGGTTGGGTAACACTAACTGGAGGACCGAACCGACTAATGTTGAAAAATTAGCGGATGACTTGTGGCTGGGGGTGAAAGGCCAATCAAACCGGGAGATAGCTGGTTCTCCCCGAAAGCTATTTAGGTAGCGCCTCGTGAACTCATCTCCGGGGGTAGAGCACTGTTTCGGCAAGGGGGTCATCCCGACTTACCAACCCGATGCAAACTGCGAATACCGGAGAATGTTATCACGGGAGACACACGGCGGGTGCTAACGTCCGTCGNGAAGAGGGAAACAACCCAGACCGCCAGCTAAGGTCCCAAAGTCATGGTTAAGTGGGAAACGATGTGGGAAGGCCCAGACAGCCAGGATGTTGGCTTAGAAGCAGCCATCATTTAAAGAAAGCGTAATAGCTCACTGGTCGAGTCGGCCTGCGCGGAAGATGTAACGGGGCTAAACCATGCACCGAAGCTGCGGCAGCGACGCTTATGCGTTGTTGGGTAGGGGAGCGTTCTGTAAGCCTGTGAAGGTGTACTGTGAGGTATGCTGGAGGTATCAGAAGTGCGAATGCTGACATAAGTAACGATAAAGCGGGTGAAAAGCCCGCTCGCCGGAAGACCAAGGGTTCCTGTCCAACGTTAATCGGGGCAGGGTGAGTCGACCCCTAAGGCGAGGCCGAAAGGCGTAGTCGATGGGAAACAGGTTAATATTCCTGTACTTGGTGTTACTGCGAAGGGGGGACGGAGAAGGCTATGTTGGCCGGGCGACGGTTGTCCCGGTTTAAGCGTGTAGGCTGGTTTTCCAGGCAAATCCGGAAAATCAAGGCTGAGGCGTGATGACGAGGCACTACGGTGCTGAAGCAACAAATGCCCTGCTTCCAGGAAAAGCCTCTAAGCATCAGGTAACATCAAATCGTACCCCAAACCGACACAGGTGGTCAGGTAGAGAATACCAAGGCGCTTGAGAGAACTCGGGTGAAGGAACTAGGCAAAATGGTGCCGTAACTTCGGGAGAAGGCACGCTGATATGTAGGTGAAGCGACTTGCTCGTGGAGCTGAAATCAGTCGAAGATACCAGCTGGCTGCAACTGTTTATTAAAAACACAGCACTGTGCAAACACGAAAGTGGACGTATACGGTGTGACGCCTGCCCGGTGCCGGAAGGTTAATTGATGGGGTTAGCGCAAGCGAAGCTCTTGATCGAAGCCCCGGTAAACGGCGGCCGTAACTATAACGGTCCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCTGCACGAATGGCGTAATGATGGCCAGGCTGTCTCCACCCGAGACTCAGTGAAATTGAACTCGCTGTGAAGATGCAGTGTACCCGCGGCAAGACGGAAAGACCCCGTGAACCTTTACTATAGCTTGACACTGAACATTGAGCCTTGATGTGTAGGATAGGTGGGAGGCTTTGAAGTGTGGACGCCAGTCTGCATGGAGCCGACCTTGAAATACCACCCTTTAATGTTTGATGTTCTAACGTTGACCCGTAATCCGGGTTGCGGACAGTGTCTGGTGGGTAGTTTGACTGGGGCGGTCTCCTCCTAAAGAGTAACGGAGGAGCACGAAGGTTGGCTAATCCTGGTCGGACATCAGGAGGTTAGTGCAATGGCATAAGCCAGCTTGACTGCGAGCGTGACGGCGCGAGCAGGTGCGAAAGCAGGTCATAGTGATCCGGTGGTTCTGAATGGAAGGGCCATCGCTCAACGGATAAAAGGTACTCCGGGGATAACAGGCTGATACCGCCCAAGAGTTCATATCGACGGCGGTGTTTGGCACCTCGATGTCGGCTCATCACATCCTGGGGCTGAAGTAGGTCCCAAGGGTATGGCTGTTCGCCATTTAAAGTGGTACGCGAGCTGGGTTTAGAACGTCGTGAGACAGTTCGGTCCCTATCTGCCGTGGGCGCTGGAGAACTGAGGGGGGCTGCTCCTAGTACGAGAGGACCGGAGTGGACGCATCACTGGTGTTCGGGTTGTCATGCCAATGGCACTGCCCGGTAGCTAAATGCGGAAGAGATAAGTGCTGAAAGCATCTAAGCACGAAACTTGCCCCGAGATGAGTTCTCCCTGACTCCTTGAGGGTCCTGAAGGAACGTTGAAGACGACGACGTTGATAGGCCGGGTGTGTAAGCGCAGCGATGCGTTGAGCTAACCGGTACTAATGAACCGTGAGGCTTAACCTT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3977,Drugs,MEG_3977|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|AE014075.1|+|237159-240063|ARO:3004149|Escherichia coli 23S rRNA with mutation conferring resistance to clindamycin [Escherichia coli CFT073] ,7
,gtgcgctcaaaaaactttagttggcggtactcccttgccgccacggtgttgttgttatcaccgttcgatttattggcatcactcggcatggacatgtacttgccagcagtgccgtttatgccaaacgcgcttggtacgacagcgagcacaattcagcttacgctgacaacgtacttggtcatgattggtgccggtcagctcttgtttggaccgctatcggaccgactggggcgccgccccgttctactgggaggtggcctcgcctacgttgtggcgtcaatgggcctcgctcttacgtcatcggctgaagtctttctggggcttcggattcttcaggcttgtggtgcctcggcgtgccttgtttccacatttgcaacagtacgtgacatttacgcaggtcgcgaggaaagtaatgtcatttacggcatactcggatccatgctggccatggtcccggcggtaggcccattgctcggagcgctcgtcgacatgtggcttgggtggcgggctatctttgcgtttctacgtttgggcatgatcgctgcatctgcagcagcgtggcgattctggcctgaaacccgggtgcaacgagttgcgggcttgcaatggtcgcagctgctactccccgttaagtgcctgaacttctggttgtacacgttgtgttacgccgctggaatgggtagcttcttcgtctttttctccattgcgcccggactaatgatgggcaggcaaggtgtgtctcagcttggcttcagcctgctgttcgccacagtggcaattgccatggtgtttacggctcgttttatggggcgtgtgatacccaagtggggcagcccaagtgtcttgcgaatgggaatgggatgcctgatagctggagcagtattgcttgccatcaccgaaatatgggcttcgcagtccgtgttaggctttattgctccaatgtggctagtgggtattggtgtcgccacagcggtatctgtgtcgcccaatggcgctcttcgaggattcgaccatgttgctggaacggtcacggcagtctacttctgcttgggcggtgtactgctaggaagcatcggaacgttgatcatttcgctgttgccgcgcaacacggcttggccggttgtcgtgtactgtttgacccttgcaacagtcgtgctcggtctgtcttgtgtttcccgagtgaagggctctcgcggccagggggagcatgatgtggtcgcgctacaaagtgcggaaagtacatcaaatcccaatcgttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1755,Drugs,MEG_1755|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,695263026|WP_032489896.1|NG_047653|1|1|cmlA5|cmlA5|chloramphenicol_efflux_MFS_transporter_CmlA5 NG_047653:101-1360,6
,AGCAGGGCAGTCGCCCTAAAACAAAGTTAGCCATATTATGGAGCCTCATGCTTTTATATAAAATGTGTGACAATCAAAATTATGGGGTTACTTACATGAAGTTTTTATTGGCATTTTCGCTTTTAATACCATCCGTGGTTTTTGCAAGTAGTTCAAAGTTTCAGCAAGTTGAACAAGACGTTAAGGCAATTGAAGTTTCTCTTTCTGCTCGTATAGGTGTTTCCGTTCTTGATACTCAAAATGGAGAATATTGGGATTACAATGGCAATCAGCGCTTCCCGTTAACAAGTACTTTTAAAACAATAGCTTGCGCTAAATTACTATATGATGCTGAGCAAGGAAAAGTTAATCCCAATAGTACAGTCGAGATTAAGAAAGCAGATCTTGTGACCTATTCCCCTGTAATAGAAAAGCAAGTAGGGCAGGCAATCACACTCGATGATGCGTGCTTCGCAACTATGACTACAAGTGATAATACTGCGGCAAATATCATCCTAAGTGCTGTAGGTGGCCCCAAAGGCGTTACTGATTTTTTAAGACAAATTGGGGACAAAGAGACTCGTCTAGACCGTATTGAGCCTGATTTAAATGAAGGTAAGCTCGGTGATTTGAGGGATACGACAACTCCTAAGGCAATAGCCAGCACGTTAAATCAATTATTATTTGGTTCCACATTATCTGAAGCTAGTCAGAAAAAATTAGAGTCTTGGATGGTGAACAATCAAGTTACGGGTAATTTATTGAGGTCAGTATTGCCAGTGAAGTGGAGTATTGCTGATCGCTCAGGAGCAGGTGGATTTGGTGCTAGGAGTATTACAGCGATTGTGTGGAGTGAAGAAAAAAAAACGATTATCGTAAGTATTTATCTAGCTCAAACCGAGGCTTCAATGGCAGAACGAAATGATGCGATAGTTAAAATTGGTCGTTCAATTTTTGAAGTTTATACATCACAGTCGCGCTGATAAGG,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1520,Drugs,MEG_1520|Drugs|betalactams|Class_A_betalactamases|CARB,(Bla)CARB-6:AF030945:1-867:867,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAGATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTATTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1351,Drugs,MEG_1351|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_27_JDGZ01000043,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggggtggcattgattaacacagcggataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgtggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagacgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaatgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2153,Drugs,MEG_2153|Drugs|betalactams|Class_A_betalactamases|CTX,1391852879|WP_109545064.1|NG_057478|1|1|blaCTX-M-212|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-212 NG_057478:1-876,0
,CTAAGTTATTTTATTGAACATATATCGTACTTTATCTATCCGACTATTTGGACGACGGGGCTGGCAAACAGGTTCACCGGTAGTAACATGGTACCCTTTTAACTCTGTTAAACAAACACTACGTCCATTTGTAAAGAAAGTTAAATCACTACGATATTCTTGAATACACCGAGCAGGGATTTCTCCACTAAGAATGACCTCATTATTTTTCAATTGAGTGTCTACGATGTTCGCACAATATTTAGGAGCATCGTTGTATGCTCGTGAAAGATATTCCTGTGGCGCATAAATTTTAAAACTAAGATATGGCTCTAACAATTCTGTTCCAGCTTTTTTTAAGACTTGTTCCAATACAATAGGAGCAAGCATCCGAAAATCTGCTGGGGTACTAACAGGGCTATAGTATAAGCCATACTTAAAACAGATTTTACAGTCCGTCACATTCCAACCATACAATCCTTGTTCACAGCCATAGCGTATCCCCTCCATAACTGCATTTTGAAACGATTGATTTAAGTATCCAAGAGAAACCGAGCTCTCATACTGCATTCCACTTCCCAACGGAAGCGGTGATACAGATAAACCAATGGAAGCCCAGAAAGGATTTGGCGGCACTTCGATGTGAATGGTATATTCTGCATTTTTTAACGGTCTCTCCATATAAATGACTGTAGGCTCTTTTAGTTCTATCTCCACATGATACTTTTCTTGCAACAGTGCACTAATCACTTCCATTTGTACTTTCCCTAAGAAAGAAAGTATAATTTCATGTGTCGTAGAATCCACGTAATATCGTAGAAGCGGATCACTATCTGAGATTTCCAAAAGGGCATCAAGCAACATTTCTCTCTGTTCAGGTTTACTCGGTTCAACAGTTGTTTGTAGTAGAGGGTGCGGATTTTCAATCTTTTTTCTCTGTGGCAATAGTTTTGTATCTCCAAGAACACTATTTAACTTCAAAAACTCATTTTGCAAAATAACAATTTCTCCAGAATAAGCTCTATCAATCTTACATAATTCACCATTTATTGAAGTATACATTTCTGTAACTTTTATTTTTTCTTTTTCTGATACTCTAACCGAATCTCGTAAATGTAGTACTCCACTATAAAGGCGTATATATGCAAGACGTTGTCTTTTTTTTGTATATTCAATTTTGAAAACATTTCCGCAAAGTTCAGACGGACCTCGATGTGTTGATGAATAAAATTTATTAGTAATAACTTCTATAAGGTTATCAATCCCTATATTACTTTTTGCACTTCCATGATAAAGAGGGAACAGAGAACAATTCTGAAATCTTATGCTTTCCTCTTGTTCGAGTTCCAATGCTTCTAATGATTTACCGGACATATATTTCTCTAAAAGGTCATCGTTTCCCTCTATTACCGTATCCCATTGTTCAGATTCGGTAAAGTTCGTCACACACATATTAGGATACAGTTCTACCTTCTGTTTGATTACAATTTCGGCAGAAAGTTTCTCTTTAATATCCTGATAAACCGTTGATAAATCAATTCCATTTTGGTCAATCTTATTGATAAAAAAGATTGTGGGAATCCCCATTTTCCTAAGTGCATGAAATAATATACGAGTTTGTGCTTGTACGCCATCTTTTGCAGAAATCAGTAGAATTGCCCCATCTAAAACTGATAATGAACGATATACTTCTGCTAAGAAATCCATATGTCCTGGCGTGTCTATGATGTTCACCTTCGTATTTTCCCACTGAAAAGAGGTTATTCCTGTCTGAATTGTAATTCCTCTCTGACGTTCTAAAAGCGTATTATCCGTCCTCGTTGTACCTTTGTCCACGCTTCCTAATTCTGTAATCGCTCCACTGTTATATAATAAGCTTTCTGTTAAGGTAGTTTTTCCTGCATCAACATGAGCTAAAACTCCAATATTAATAATTTTCAT,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7145,Drugs,MEG_7145|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|974999704|gb|CP013994.1|1048959-1050878 gi|961586173|gb|CP013621.1|983024-984943 gi|961572904|gb|CP013619.1|966863-968782 gi|961570270|gb|CP013616.1|939354-941273 gi|955670971|gb|CP013202.1|619120-621039 gi|827409863|gb|CP010867.1|595588-597507 gi|507581572|emb|HF952104.1|595380-597299 gi|442768434|gb|JX120102.1|17332-15413 gi|404438823|gb|CP003808.1|980074-981993 gi|283469229|emb|AM990992.1|1001761-1003680,4
,atgtttttttttaaaaaaagcgcaagtacatttattttttttctctgtcttccattgaactcattcgcctctcaggaaagtaatagtattgagcaaatgagggaattggaagcttcttttggggggcggataggtgtttatattttaaacacaaaaaatgggaaagaattttcctacagacaagatgagagatttcctttatgtagttcatttaaggcattcctcgctgcatccgtattaaaaaaaactcaggataaatctgtttctcttgatgatatgatggaatattctggacgtgttatggaaaagcattctcctgtgtcagaaaaataccgcaaaacaggagcaagcgtgcggactttggcgaaggcagcaattcagtacagtgacaatggagcttctaatctattaatggaaagatacataggaggtcctgagggtttgactgcatttatgcggtcaacgggagacactgacttcaggcttgatcgttgggaattagaattaaactcagctattccaggcgatgaacgagatacttcaactccaaaagcagtggcaatgagccttaaaaatattgcttttggttcagtactcgatgctaaaaataaatcattgctgcaggaatggcttaaaggcaacactactggtaatgcgcgaattagagctgcggttccagataagtgggatgtcggcgataaaacaggcacctgtggtttttatggtacagccaatgatgttgctattttatggccagacgctaattcacctgcagttatggctgtctacacaacacgtcctaatcaaaacgacaaacatgacgaagcagtaattaaagattctgcaaaaatagctataaatgcagtgtatggaagttataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3055,Drugs,MEG_3055|Drugs|betalactams|Class_A_betalactamases|FRI,1206531106|WP_087907639.1|NG_055010|1|1|blaFRI-2|blaFRI|carbapenem-hydrolyzing_class_A_beta-lactamase_FRI-2 NG_055010:1-885,0
,atgaaaaaaatcatcttgtttttatggattttaaattttgcctttggacaagataaaatattagaagatttttttaaagattataatacaagtgggatttttataatctttgatggaaaaaattatgcaagtaatgattttcaaagagcaaaacaaaccttttctcctgcttcaacttttaaaatttttaatgctttaattgcgcttgataatggtgtagttaaagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgtcctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattagcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgataccttttggctggataattctttgcaaatttctgcaaaaaatcaagctgatttactttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaacttcttctttttaaagaaaataaaatacaaaaaatttatgccaaaacaggttttaatgataatataaatttagcttggattgttggattcgtaaagactaaaaacaaaattttatcttttgctttaaatgttgatataaagcacgttaaaaatattaaaataagagaagaattgctagaaaaatatctagcaatcataacaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4665,Drugs,MEG_4665|Drugs|betalactams|Class_D_betalactamases|OXA,1391852893|WP_109545078.1|NG_057495|1|1|blaOXA-635|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-635 NG_057495:1-750,0
,atgagggaagcggtgaccgccgaaatttcgactcaactatcagaggtgcttagcgtcatcgagcgccatctggagtcgacgttgctggccgtgcatttgtacggctccgcagtggatggcggcttgaagccatacagcgatattgatttgctggttactgtgaccgtaaggcttaatgaagcaacacggcaagctttgctcaatgaccttttggaggcttcggctttccctggcgagagcgagactctccgcgctatagaaatcaccattgtcgtgcacgacgacatcatcccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggaaagatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_782,Drugs,MEG_782|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502170|WP_071846321.1|NG_052404|1|1|aadA22|aadA22|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA22 NG_052404:101-892,2
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttctctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacgactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctgcgatattatgtggattctgcgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctgctgcaagaaaagtatcatgtggagatagaaataaaagagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagttccaccgaatcctttctgggcttccattggtctatctgtagcacagcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7129,Drugs,MEG_7129|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,446614397|WP_000691743.1|NG_048230|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048230:101-2020,4
,ATGATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAGATTCTCTACGTGGCCGATGAGCGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAGAGCAAGCGACCTGGTTAACTACAATCCGATTGCGGAGAAACACGTTAACGGCACGATGACGCTGGCTCAGCTTGGCGCCGGCGCCCTGCAGTATAGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGGCCCGATAAAGTGACGGCGTTTGCTCGCTCATTGGGTGATGAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATAGCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGCAAAGCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTCTGCCGAAATCATGGGGAGTGGGCGATAAAACCGGCAGCGGAGATTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGAAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGCCGTCGGGATGTTCTGGCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGATGCAATAAATGGAGCGAGGTATCGCTCCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2226,Drugs,MEG_2226|Drugs|betalactams|Class_A_betalactamases|CTX,(Bla)CTX-M-7:AJ005045:1-876:976,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgatatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2200,Drugs,MEG_2200|Drugs|betalactams|Class_A_betalactamases|CTX,1391852876|WP_109545061.1|NG_057475|1|1|blaCTX-M-209|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-209 NG_057475:1-876,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCGTTCTCCACGTTTGCCGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACTCAACAAACGCTGTTTGAACTCGGATCGGTCAGTAAAACGTTCAACGGCGTGCTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGCATTACTGGCCTGAACTGACTGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCGTTACTACGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGCGCCCTGGCGGTGAACCCCTCAGGCATGAGCTACGAAGAGGCGATGACCAAACGCGTCCTGCGCCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGGCAACTTGATGCCGAAGCCTACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGCATCGAGCTTGCGCAGTCACGTTACTGGCGTATTGGCGATATGTACCAGGGCCTGGGCTGGGAGATGCTGAACTGGCCGGTGAAGGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTGGCCCTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAGAGCTACCCAAACCCTGTTCGCGTCGAAGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAACGGACAAGGAGGCCCTGGATATTGGGCTTCCTTTCTTTCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAATCCAGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1971,Drugs,MEG_1971|Drugs|betalactams|Class_C_betalactamases|CMY,gi|407731518|gb|JX440351.1|1027-2255,0
,ATGATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAGATTCTCTACCTGGCCGATGAGCGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAAGGCGAGCGACCTGGTTAACTACAATCCCATTGCGGAGAAACACGTTAACGGCACGATGACGCTGGCTGAGCTTGGCGCAGGCGCCCTGCAGTATAGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGGCCCGATAAAGTGACGGCGTTTGCCCGCTCGTTGGGTGATGAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATAGCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAAGCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTCTGCCGAAATGTTGGGTAGTGGGCGATAAAACCGGCAGCGGAGATTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGAAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGCCGTCGGGATGTTCTGGCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGATGCAATAAATGGAGCGAGGTATCGCTCCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2416,Drugs,MEG_2416|Drugs|betalactams|Class_A_betalactamases|CTX,gi|695198362|ref|NG_034962.1|1-905,0
,TAAATATTTTCTTACATTCTTGGCACAATATATTTTTCCATGATCTCTACGATTTCAATTTTTCAGCATGTTAGAGTGGTATTTAAGGTCACCAATATCATGAAGTTTAAAATGAAAGGTTTATTTTGTGTCATCCTCAGTAGTTTGGCATTTTCAGGTTGTGTTTATGATTCAAAATTACAACGCCCAGTCATATCAGAGCGAGTAACTGAGATTCCTTTATTATTTAATCAAGCACAGACTCAAGCTGTGTTTGTTACTTATGATGGGATTCATCTAAAAAGTTATGGTAATGATCTAAGCCGAGCAAAGACTGAATATATTCCTGCATCTACATTTAAGATGTTGAATGCTTTAATTGGCTTGCAAAATGCAAAAGCAACCAATACTGAAGTATTTCATTGGAATGGTGAAAAGCGCGCTTTTTCAGCATGGGAAAAAGATATGACTTTGGCAGAAGCGATGCAGGCTTCAGCTGTTCCTGTATATCAAGAGCTTGCTCGACGTATTGGCTTGGAATTGATGCGTGAAGAAGTGAAGCGTGTAGGTTTTGGCAATGCGGAGATTGGTCAGCAAGTCGATAATTTTTGGTTGGTGGGTCCTTTAAAAATCTCCCCTGAACAAGAAGTTCAATTTGCCTATCAACTGGCAATGAAGCAATTGCCTTTTGATTCAAATGTACAGCAACAAGTCAAAGATATGCTTTATATCGAGAGACGTGGTGACAGTAAACTGTATGCTAAAAGTGGTTGGGGAATGGATGTTGAACCTCAAGTGGGTTGGTATACGGGATGGGTTGAACAACCCAATGGCAAGGTGACTGCATTTGCGTTAAATATGAACATGCAAGCAGGTAATGATCCAGCTGAACGTAAACAATTAACCTTAAGTATTTTGGACAAATTGGGTCTATTTTTTTATTTAAGATAAATGCATGAGTTAAAAAAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5219,Drugs,MEG_5219|Drugs|betalactams|Class_D_betalactamases|OXA,gi|392295711|gb|JQ422053.1|1-948,0
,atgactaaaaaagctcttttctttgccattggtacgatgtttttatcggcgtgttcttttgataccgtagaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattcaatcattgtttgatcaagcacaaactacaggtattttaattataaaacgtggccaaacagaggaagtctatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgatcggacttgagcatcataaagcaacaccaactgaagtatttaaatgggatgggcaaaagcgtttatttcccgattgggaaaaagacatgacattaggcgatgctatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggtcttgatcttatgtctaaagaggtgaagcgtattggtttcggtaatgctgatattggttcaaaaatagataatttttggcttgttggcccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccctttagcaaaaatgtgcaagaacaagttcaatctctgttgttcatagaagaaaaaaatggacgaaaaatttatgctaaaagtggttggggatgggatgtggaaccacaagttggttggtttacaggctgggtggttcaaccacaaggagaaattgtagcgttcgcacttaatttagaaatgaaaaaaggaatacctagttctattcgaaaagaaattgcttataaaggattagaacaattaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4557,Drugs,MEG_4557|Drugs|betalactams|Class_D_betalactamases|OXA,1196807648|WP_086264536.1|NG_065442|1|1|blaOXA-832|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-832 NG_065442:1-822,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgtcctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5475,Drugs,MEG_5475|Drugs|betalactams|Class_C_betalactamases|PDC,730387143|WP_034003797.1|NG_049928|1|1|blaPDC-54|blaPDC|class_C_beta-lactamase_PDC-54 NG_049928:1-1194,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACATTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1430,Drugs,MEG_1430|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_77_FGNH01000009,0
,ATGACTGATATCACGCTGCCACCAGGTGACGGTTCTATACAGCGGGTTGAGCCGGTCGACATTCAGCAGGAAATGCAGCGCAGCTATATTGATTACGCGATGAGTGTGATTGTGGGCCGGGCGTTGCCTGAAGTCCGCGATGGTCTCAAACCGGTACATCGTCGGGTCTTGTACGCGATGTTAGACTCCGGTTTCCGCCCGGACCGTAGCCACGCTAAGTCAGCACGGTCAGTCGCTGAGACGATGGGCAATTACCATCCGCACGGCGACGCATCGATTTATGACACGTTAGTGCGCATGGCGCAGCCGTGGTCGCTGCGGTATCCCTTGGTTGATGGGCAAGGCAATTTCGGTTCGCCGGGTAATGACCCACCGGCAGCGATGCGTTATTGTGTGTCAGGAAATTCCTTGGTGAGGTTGCTATTTGGGAAATCAATACGAATCGGTGATATCGTTACTGGAGCTCAGTTCAATTCGGACAATCCGATCGACTTGAAGGTTCTTGATCGGCATGGTAATCCGGTTGTAGCCGATTATTTATTCCATTCAGGAGAGCACCAAACCTATACAGTGCGCACCACTGAAGGCTATGAGATCACCGGGACGTCGAACCATCCCTTGTTGTGTTTAGTGAATGTCGGCGGTATACCCACCTTGTTGTGGAAGCTGATTGGAGAAATTCGATCAGGAGACTACGTTGTTTTACAGCGGATCCCACCAGTGGAATTTGGTCCGGCGGACTGGTATTCTACGATGGAAGCATTGTTATTCGGAGCCTTTATTAGTGGGGGCTTCGTTTTTCAGGACCATGCTGGATTTAACAGCCTTGACCGTGACTATTTCACCATGGTTGTTAATGCTTATGATACGGTTGTGGGTGGCCTGCGTTGCATATCTTCTCGAATCACCGTATCGGGGTCGACGCTACTCGAACTTGATGTTTATAACCTCATCGAGTTTAAGAAGACAAGACTTAGCGGTTTATGCGGGCAACGGTCTGCGGACAAGTTGGTACCTGACTGGTTGTGGCACTCACCTTCCACCGTCAAACGAGCATTCCTTCAGGCATTGTTTGAAGGTGAAGGATTTTCTTCGATATTGTCGCGAAATATAATTGAGATTTCCTACTCGACACTTAGTGAGCGACTGGCCGCCGACGTCCAGCAGATGCTGCTTGAATTCGGAGTCGTGTCTGAGCGCTATTGCCATACTGTCAATGAGTACAAGGTTGTCATAGCTAACCGCGCTCAAGTAGAAATGTTTTTCACCCAAGTCGGTTTCGGTGTTACTAAACAAGCTAAGCTTATCCGGGACGTGGTATCTATGTCTCCATGCGTTGGCATGGATATCAACTGCGTACCAGGTTTGGCCACTTTCATTCGTAAGCATTGTGATAACCGCTGGGTCGAGGAAGACTCATTTAATCAGCATAATGTTGATTGCGTCCAACATTGGCACCATCATAGCGCGGAAATCGTCGGCCACATCGCCGATCCCGATATTCGTGCCATCGTGACTGACCTTACTGATGGCCGGTTCTACTACGCGCGCGTCGCGTCCGTGACTGATACCGGTATTCAACCTGTGTTCAGTCTACATGTGGACACCGAGGATCATTCGTTTTTGACTAATGGATTCATCAGCCATAACACCGAGGCTCGGCTTACTCCATTGGCGATGGAAATGTTGCGCGAGATCGACGAGGAGACAGTTGATTTCATATCTAACTACGATGGCCGGGTGCAGGAACCGATGGTGTTGCCTAGCCGTTTTCCCAACCTGTTGGCTAATGGTTCTGGCGGTATCGCGGTCGGCATGGCTACCAATATCCCGCCGCACAACCTGTATGAGCTCGCCGACGCTGTGTTTTGGTGCCTAGAGAACCATGACGCTGACGAAGAGACGATGCTGGTCGCTGTTATGGAACGGGTCAAAGGTCCTGATTTCCCTACCGCCGGGTTGATTGTCGGTTCGCAAGGCATTGCCGATGCTTACAAGACTGGCCGTGGTTCCATTCGGATACGCGGAGTTGTTGAGGTTGAAGAAGATTCACGCGGAAGGACGTCATTGGTCATCACTGAGCTACCGTATCAGGTCAACCACGACAACTTCATCACTTCTATCGCTGAGCAAGTCCGCACTGGCCGGCTAGCCGGCATCTCCAATGTAGAAGACCAAGGCAGCGACCGGGTTGGTGTACGTATCGTCATCGAGATCAAGCGTGACGCGGTGGCCAAAGTGGTGCTCAATAACCTGTACAAGCATACTCAGCTGCAAACTAGTTTCGGAGCCAACATGTTGTCAATCGTTGACGGCGTGCCGCGCACTTTGCGGTTGGATCAGATGATTTGTTATTATGTCGAACATCAACTGGACGTCATTGTCCGGCGCACTACCTACCGATTGCGTAAAGCCAACGAGCGGGCTCATATTTTGCGTGGATTGGTCAAAGCGCTCGATGCGTTAGATGAGGTTATTACGTTGATTCGGGCATCGCAGACCGTGGATATTGCTCGTGTTGGGGTGGTCGAGTTACTCGATATCGACGACATTCAGGCTCAAGCTATCCTGGACATGCAGCTGCGGCGTTTGGCGGCTTTGGAGCGTCAACGCATTATTGATGATCTCGCTAAGATTGAGGTCGAGATCGCTGATCTGGGAGATATTCTGGCTAAGCCGGAGCGTCGGCGTGGTATCATTCGTAATGAACTGACTGAGATCGCAGAGAAGTACGGTGATGACCGTCGTACTCGGATAATAGCGGTTGATGGTGATGTCAACGACGAGGATTTGATTGCTCGTGAAGAGGTCGTTGTCACGATAACTGAAACTGGATATGCTAAACGTACTAAAACTGACCTGTATCGCAGCCAGAAACGCGGCGGGAAAGGTGTTCAAGGCGCCGGTTTGAAGCAGGACGACATCGTCCGGCATTTCTTCGTGTGTTCAACTCACGATTGGATCCTGTTTTTCACCACCCAAGGCCGCGTATACCGGGCCAAGGCCTATGAATTGCCAGAGGCTTCTCGAACGGCACGCGGGCAACACGTGGCCAATTTGCTTGCATTCCAGCCTGAAGAGCGCATCGCTCAGGTAATTCAGATCCGTAGCTATGAAGACGCTCCATACTTGGTCCTTGCCACGCGCGCCGGTCTGGTTAAGAAGTCAAAGTTGACCGATTTTGACTCTAATCGTTCGGGTGGGATCGTGGCAATTAATTTACGTGACAACGATGAGTTGGTCGGTGCAGTGTTGTGCGCGGCCGACGGCGACTTGCTTCTGGTATCGGCTAACGGCCAGTCTATCCGGTTCTCAGCGACTGACGAGGCCTTGCGTCCGATGGGGCGGGCTACCTCTGGTGTGCAGGGCATGCGGTTTAACGCCGATGATCGACTGTTGTCGTTGAATGTGGTTCGCGAAGATACTTACCTGCTTGTCGCAACGTCTGGGGGTTACGCTAAACGCACCTCGATTGAGGAGTACCCGATGCAGGGCCGTGGCGGAAAGGGTGTTCTAACGGTCATGTACGATCGTCGGCGCGGTAGCTTGGTTGGGGCCATCGTGGTTGATGAAGACAGCGAGTTGTACGCGATCACCTCAGGGGGTGGGGTAATTCGTACAACGGCACGCCAGGTTCGCCAGGCAGGACGCCAGACCAAGGGTGTTCGGTTGATGAACTTAGGTGAGGGCGACACGCTGTTAGCCATCGCACGTAATGCCGAAGAAAGCGCCGACGGCGGTGTCGGTTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3181,Drugs,MEG_3181|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|AL450380|+|7317-11067|ARO:3003298|Mycobaterium leprae gyrA conferring resistance to fluoroquinolones [Mycobacterium leprae TN] ,3
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagcctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaaacaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_905,Drugs,MEG_905|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502040|WP_071846192.1|NG_052148|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052148:101-889,2
,atgatgaaactccgccacgccgcgaccggcgccctgctggccgcgcttgccacctttgcccatgccgagcgcacgatctgcacgatcgttgccgatgccgccaccggcaaggttgttctgcacgaaggccagtgcgccgaacgtgtcacgcctgcatctaccttcaagctggcgctggccgtgatgggctacgaccacggtttcctgaaggacgagcacgcccccatcgagcacatgaaggctggcgaccccgattggggtggcgaggcctggcaccagcccatcgaccccacgctgtggctcaagtactccgtggtctggtattcgcagcgcatcacgcatgcgatgggtgcgcagacgctgcatgcgtatctgcgcaaattcgactacggcaacatggacgcgagcggcgacccggggaagaacaacggtctggaccgctcgtggatcacctcgtcgctgaagatctcgccggaggagcaggtgggcttcatgcgcaagatcgtcaaccgccagttgccagtgtctgcgcatacgtatgagatggtcgagcgcgcggtgcagacctggccggtgccgggtggctggactgtgcagggcaaaacgggcactgctgggccgggccccggcaatacgtcgcccgatggcacgtgggatcaggcacacgcttatggctggtttgtcggctgggcgaagaagggcacgggtgacgacagtcggacctacgtgtttgcgaacctgatccaggacgacaagcttgagccgacatcggggggcttgcgctcgcgcgatgcgctgctggcgcgcctgccggaagtgctggcccttgcgagtcactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4597,Drugs,MEG_4597|Drugs|betalactams|Class_D_betalactamases|OXA,1331531451|WP_102607461.1|NG_056178|1|1|blaOXA-569|blaOXA-22_like|OXA-22_family_class_D_beta-lactamase_OXA-569 NG_056178:1-840,0
,GTGATCGCCGAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCACACAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCCCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_972,Drugs,MEG_972|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|984881271|gb|CP014215.1|2293487-2292708 gi|984881271|gb|CP014215.1|2306251-2305472 gi|974751547|gb|KU130294.1|205895-205116 gi|974022331|gb|CP013924.1|1440246-1441025 gi|973715451|gb|CP013836.1|109155-108376 gi|969995259|gb|KT317079.1|2327-3106 gi|969995242|gb|KT317078.1|4213-4992 gi|969995220|gb|KT317076.1|5188-5967 gi|969995200|gb|KT317075.1|7074-7853 gi|969972869|gb|KT354506.1|6179-6958 gi|953773532|gb|CP013224.1|40663-39884,2
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGATGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6609,Drugs,MEG_6609|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|765526698|gb|KF743818.1|15871-15032 gi|478439656|gb|CP003376.1|17497-16658 gi|409723607|gb|CP003505.2|15871-15032 gi|89211889|gb|DQ352176.1|2394-1555 gi|31746361|emb|AJ564903.1|15871-15032,8
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGAGCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6610,Drugs,MEG_6610|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|817614502|gb|KF483599.2|47041-47880 gi|730910660|gb|KM921776.1|20926-21765 gi|602249473|gb|KC118540.6|67243-68082 gi|484355510|gb|FJ172370.5|47759-48598 gi|325301724|gb|JF262165.1|2493-3332 gi|169147133|emb|CU459141.1|3651456-3650617 gi|85813394|emb|CT025832.1|51315-52154,8
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgtgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcagttgtgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgctttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccacggagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagccagcgtattgtcaaacaagccatgctgaccgaagccaatggtgactatattattcgggctaaaactggatactcgactagacctaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggaaaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4614,Drugs,MEG_4614|Drugs|betalactams|Class_D_betalactamases|OXA,1625655408|WP_136512085.1|NG_064751|1|1|blaOXA-793|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-793 NG_064751:1-792,0
,atgatgaaaaaatccctttgctgcgccctgctgctgggcctctcttgctctgctctcgccgcgccagtatcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaaccgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccggcgttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagcatcggtctttttggtgcgctggcggtcaaaccttccggcatgccctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggaacgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggaaaaggttgccgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcgaaggcagcgacagtaaggtagcgctggcgccgttacccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggttctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcaaggcgcttcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_431,Drugs,MEG_431|Drugs|betalactams|Class_C_betalactamases|ACT,695626088|WP_032608349.1|NG_050708|1|1|blaACT-45|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-45 NG_050708:1-1146,0
,ATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAATGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6890,Drugs,MEG_6890|Drugs|betalactams|Class_A_betalactamases|TEM,gi|21541784|gb|AF516720.1|1-1080 gi|961666360|gb|KT185451.1|87740-87690,0
,atgactctggcattagttggcgaaaaaattgacagaaatcgcttcactggtgagaaagttgaaaatagtacattttttaactgcgatttttcaggtgccgacctgagcggcactgaatttatcggctgccagttctatgatcgcgaaagtcagaaaggatgcaattttagtcgcgcaatgctgagagatgccattttcaaaagctgtgatttatcaatggcagatttccgcaacgtcagcgcattgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggtgcaagctttatgaatatgatcaccacgcgcacctggttttgcagcgcatatatcactaataccaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctatgggaaaaccgctggatggggactcaggtactgggtgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttaggtgacttagatactcggggtgttgatttacaaggcgttaagttagacaactaccaggcatcgttgctcatggagcggcttggcatcgcggtaattggttaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5898,Drugs,MEG_5898|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111913|WP_063866119.1|NG_050509|1|1|qnrB46|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB46 NG_050509:37-681,3
,atggcagaagcaaagaaggtttcgttccgattgatgaatgataaagatgaccttagatttatgttgaaatggttaaccgatgaaagggttcttgaattttacgacggcaggggcagcaagtttactgcggagacgattcgtgaaaaatacacggaagaagaggatgatttctaccggatgattattgagtatgattcggttccgattggttatgcacagatgtacagagtacagggtgaattgttcgaagaatacgattatcctgagacggaagagaagatatttgcgatggatcagttcatcggtgagccggagtattggaacaagggaatcggtacggaatattgcaaagcggcatgcagatatttggcggaagaattgggtgcagatgcagtgattcttgatccgcacaagagcaatccgcgtgcaatccgggcgtatgagaaggctggatttaaggttctgagggaccttcccgcacatgaattgcatgaggggaagtgggaagattgcgtgttgatggaatggcgagtgtga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_202,Drugs,MEG_202|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1104448888|WP_071766620.1|NG_052119|1|1|aacA10|aacA10|AAC(6')-I_family_aminoglycoside_6'-N-acetyltransferase NG_052119:101-637,2
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaagtataccgttctttatccgtattagacggagcagtattattagtttctgcaaaggatggcatacaggcacagacccgtatactgtttcatgcactacagataatgaagattccgacaatttttttcatcaataaaattgaccaagaggggattgatttgccaatggtatatcgggaaatgaaagcaaagctttcttcggaaattatagtgaagcaaaaggttgggcagcatccccatataaatgtaacggacaatgacgatatggaacagtgggatgcggtaattatgggaaacgatgaactattagagaaatatatgtcagggaaaccgtttaaaatgtcagaactggaacaggaagaaaacaggagattccaaaacggaacgttatttcccgtttatcacggaagcgctaaaaacaatctggggattcggcagcttatagaagtaattgccagtaaattttattcatcaacgcctgaaggtcaatctgaactatgcgggcaggtttttaagattgaatattcagagaaaaggcggcgttttgtttatgtgcgtatatatagcggaacattgcatttgagggatgttattagaatatctgaaaaagagaaaataaaaatcacagagatgtgtgttccgacaaacggtgaattatattcatccgatacagcctgctctggtgatattgtaattttaccaaatgatgttttgcagctaaacagtattttggggaacgaaatactgttgccgcagagaaaatttattgaaaatcctctccctatgctccaaacaacgattgcagtaaagaaatctgaacagcgggaaatattgcttggggcacttacagaaatttcagatggcgaccctcttttaaaatattatgtggatactacaacgcatgagattatactttcttttttggggaatttgcagatggaagtcatttgtgccatccttgaggaaaaatatcatgtggaggcagaaataaaagagcctactgttatatatatggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaatcaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7154,Drugs,MEG_7154|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,501919555|WP_012669445.1|NG_048264|1|1|tet(O)|tet(O)|tetracycline_resistance_ribosomal_protection_protein_Tet(O) NG_048264:101-2020,4
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcataattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtccgtctgaactttgcggaaatgttttcaaaattgaatatacaaaaaaaagacaacgtcttgcatatatacgcctttatagtggagtactacatttacgagattcggttagagtatcagaaaaagaaaaaataaaagttacagaaatgtatacttcaataaatggtgaattatgtaagattgatagagcttattctggagaaattgttattttgcaaaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaagggatacgctatggttgcgaacaaggattatatggttggaatgtgacggattgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7104,Drugs,MEG_7104|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,446614381|WP_000691727.1|NG_048250|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048250:101-2020,4
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctattcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4488,Drugs,MEG_4488|Drugs|betalactams|Class_D_betalactamases|OXA,1559612984|WP_128268249.1|NG_063854|1|1|blaOXA-750|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-750 NG_063854:15-839,0
,ATGTTAAAACAAAAAGAATTAATTGCAAACGTTAAGAATCTTACTGAGTCAGATGAACGAATTACAGCTTGTATGATGTATGGATCGTTTACCAAAGGAGAAGGTGACCAATACTCTGATATAGAGTTCTATATATTTTTGAAAGATAGTATAACCTCGAACTTTGATTCATCCAACTGGTTGTTTGACGTAGCTCCGTACTTGATGCTTTATAAAAATGAGTACGGAACAGAGGTAGTTATTTTTGATAATCTTATACGTGGGGAATTTCATTTCCTTTCTGAAAAAGATATGAACATAATCCCCTCGTTTAAAGATTCAGGTTATATTCCTGATACGAAGGCTATGCTTATTTACGATGAAACAGGGCAATTAGAAAATTATTTATCAGAGATAAGTGGTGCAAGACCAAATAGACTTACTGAAGAAAATGCTAATTTTTTGTTGTGTAATTTCTCTAATCTATGGTTGATGGGAATCAACGTTCTAAAAAGAGGAGAATATGCTCGTTCATTAGAACTCTTATCACAACTTCAAAAAAATACACTACAACTTATACGTATGGCAGAAAAAAATGCTGATAATTGGCTAAACATGAGTAAAAACCTTGAAAAAGAAATTAGCCTTGAAAATTATAAAAAATTTGCAAAGACCACTGCTCGATTAGATAAGGTAGAATTATTTGAAGCCTATAAAAATTCTTTGCTATTAGTTATGGATTTGCAAAGTCACCTTATTGAACAATACAACTTAAAAGTTACACATGACATTTTAGAAAGATTGTTGAATTACATTAGTGAATAG,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_3648,Drugs,MEG_3648|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|LSAE,gb|AF408195.1|+|9446-10250|ARO:3003206|lsaE [Enterococcus faecalis] ,1
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaagcagtatcattaatcactagtgccatcctgcaaatggcgattattttttaccttacagagaaaacaggatctgcgatggtcttgtctatggcttcactagtaggttttttaccctatgcggtctttggacctgcgattggtgtgctagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctggggcagtgcttgctattgttgcattgtatatggagctacctgtctggatagttatgatagtattgtttatccgtagcattggaacagcttttcataccccagcactcaatgcggttacgccacttttagtaccagaagaacagctgacgaaatgcgcaggctatagtcagtctttgcagtctataagctatattgttagtccagcagttgcagcactcctatactccgtttgggatttaaatgctattattgccatcgatgtgttgggtgctgtgattgcatctattacggtagcaattgtacgtattcctaagctgggtgatcaagtgcaaagtttggaaccaaatttcataagagaaatgaaagaaggaattgtcgttatgagacaaaacaaaggattgtttgccttattactcttaggaacactatatacttttgtttatatgccaattaatgcactatatcctttaatcagcatggaatattttaatggaacaccgatgcatatttctattaccgaaattgcttttgcctctggcatgctggcaggcggcttgatattaggaagattgggaagttacgaaaagcgtgtacctttaataacaggttcattttttatgatgggagctagtttagccattgcaggattacttcctccaagtggatttatcatatttgtagtctgctgtgcaataatggggctttcagttccattttacagcggtgtacaaacagcactatttcagcaaaaaatcaagcctgaatatttagggcgtgtattttccttcaccggtagtatcatgtcacttgcaatgccactagggttaatcctttccgggttctttgctgatagaattggtataaaccattggtttttaatatcaggtattttaatcatcggtattgctatagtttgcccgatgatgactgaggttagaaaattagatttaaaacaaaattcatag,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3809,Drugs,MEG_3809|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028096941|WP_063853638.1|NG_047968|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047968:46-1272,7
,atgactctggcgttagttggcgaaaaaattgacagaaacagattcactggtgcgaaagttgaaaatagcacatttttcaactgtgatttttcgggtgccgacctcagcggtactgagtttattggctgccagttctatgatcgagagagccagaaagggtgtaattttagtcgcgctatcctgaaagatgccattttcaaaagttgtgatctctccatggcgggtttcaggaatgtgagcgcgctgggaatcgaaattcgccactgccgcgcacaaggttcagattttcgcggcgcaagctttatgaatatgattaccacacgcacctggttttgtagcgcctatatcaccaataccaacttaagctacgccaacttttcaaaagtcgtactggaaaagtgcgagctgtgggaaaaccgttggatgggtactcaggtactgggggcgacgttcagtggttcagatctttccggcggtgagttttcgtcgttcgactggcgggccgcaaactttacgcactgtgatttgaccaattcagaactgggcgatctcgatgtccggggtgttgatttgcaaggcgtcaaactggacagctaccaggcatcgttgatcctggaacgtcttggcatcgctgtcattggttaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5900,Drugs,MEG_5900|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1315549095|WP_101244935.1|NG_050496|1|1|qnrB34|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB34 NG_050496:39-683,3
,GTGGCAAAATCAGAACGTTATCTCGACCTTCCTTTAGAAGAAGTCATCGGCGACCGTTTTAGCCGCTACAGCAAATACATTATCCAGGAACGGGCATTGCCTGATGCCAGAGACGGACTAAAGCCTGTGCAACGCCGTATTTTGTATGCAATGTACAATGAAGGCAATACGGCCGATAAACCGTATCGAAAGGCAGCCAAAACGGTTGGAAACGTCATCGGCAATTACCATCCCCATGGCGACAGTTCCGTGTATGAAGCAATGGTCCGCATGAGCCAAGAATGGAAAGTGCGTGAACAATTAATCGACATGCACGGCAACAACGGTTCAGTGGATGGCGATCCACCGGCGGCCATGCGTTATACGGAAGCGCGGCTATCGGCGATTAGTGCAGAGTTGATGCGTGATTTAGATAAAGGCACAGTCGACTACATCCCGAACTTTGATGATTCAATTGAAGAGCCCGTCGTCTTGCCGGCGATGTTTCCAAATTTGCTTGTGAATGGTTCAACAGGTATTTCGGCTGGTTACGCGACAGACATACCGCCTCATCACTTGCCAGAGATCATTGACGGCATTACGTTGTTGATGCAAAAGCCACATACAAGCCTTGATGAATTGTTAGAAATTATTAAAGGCCCTGACTTCCCTACTGGCGGAATTGTCCAAGGCTCAAACGGCATCCGCCAAGCTTATGAAACAGGGAAAGGCAAAATCGTCGTTCGGGGCCGGACAGCGATTGAAGAAACGCGTGGCGGCCGCAAGCAAATCGTCATTACGGAAATTCCTTACGAAGTAGTAAAGGCGAGCTTAGTTAAAAAAATGGATGAAATCCGATTTGACAAAAAAGTGGACGGTATTGCCGAAGTCCGCGACGATACAGACCGTACCGGGATGCGCATTGTCGTTGAACTGAAAAAGGAAGCTGATCCAGAAGCGATTCTCCATTACCTGTTTAAAAATACCGATTTGCAAGTGACGTACCACTTTAATATGGTGGCGATACACAATAAAACACCTAAGTTAATGGGGCTGCTCGACTTGATGCAAGCGTACATCGACCATCAAAAGCAAGTGTTTACGCGACGCTCCCAATTCGAGCTTAAAAAAGCCGTTGACCGCGCCCACATTGTCGAAGGTCTTATGAAAGCCGTTTCCATTTTGGATGAAGTCATTGCTGTGATCCGTGCTTCAAAAGATAAGAAAGACGCAAAAGCCAATTTGCAAAGCCAGTTTGGCTTTACTGAACCACAAGCAGAAGCAATTGTCACACTCCAACTTTACCGTCTGACCAATACCGACATTACGACGCTTCAAAAAGAAGCAGAGGAGCTTGAAAAGCAAATTGCCGAATTAAAAGCGATTTTGGCCAGCGAAAAGAAACTCATTTCCGTCATTAAAAAGGAATTAAACCAAATTAAAAAGACATTTGCTTCTCCGCGCCGAACCGAAATTCGAGCGGAAATTGAAGAAATCAAAATCAACATGGACATGTTGATTGCCTCGGAAGACGTGCGCGTGACGATCACAAAGGCAGGCTACGTCAAACGGACAAGCCTGCGCTCCTACTCAGCCTCTAGCCAGGATGGGCCAGGAATGAAAGAAGGAGACCGTCTCTTATTATCCCAAGAAGCCAATACAACTGATGTGGTGCTATTGTTTACCAAACGGGGGAGTTACTTGTACGTGCCTGTCCACTCGCTGCCAGACATCCGTTGGAAAGACGACGGCCAACATGTTGCCAACCTCGTTGCGATTGATGCCGATGATGAAATTATTGCTGCGCAAATCATTCGCGAGTTTGCTGAGACGAAGTATTTGCTCTTTATGACGCGAGCAGGAATGGCCAAACGGTCAACGTTAAACTTATACCAAGCCCAACGTTATTCCAAACCACTGATGGCCTTAAAGCTAAAAGAAGGGGACGAAGTCGTTCGCGTGCTTTTGACAGACGGCCAGCAAGAACTGTTCGTAGCCACTGCTTTTGGGTATGGCCTTTGGTTTTCGGAAGAAGATGTTTCTTTAGTCGGCCAACGTGCCGCTGGTGTAAAGGGAATCAATTTAAAAGAAGGCGATTACTGCATTGGCGCCGAAGCATTTGGTCTTGAAGATTCTGTTGAATTTCTCGTTGCCACACACCGTGGAGCGGTCAAGAAAATGGCCATTACTGAATTTGAAAAGTCAAGCCGCGCCAAACGAGGCGTGTTAATGCTAAGGGAATTAAAAAACAACCCTCATCGATTAGTTGGGCTCAAGCGGGTCCGCTCTCAAGATGAAACGTTTGCTATCGAAACGGCAAAAGGAGACATGATTGCCATCTCGCCAAGGGACTATCGCCGTGCTGATCGCTATTCCAACGGCTCCTATGCTTTTGACCAACACGAAAGCGGCGACGCGCTTACGTTAGTACGTGTGATTCAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5349,Drugs,MEG_5349|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|56908016|dbj|AP006627.1|2101292-2098869,3
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttgggcggtacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgtttccggaccgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcatggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctgaggcaatggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggaatggtggaattggtcactggagaagatcaaagcggcaatgcccatgctgtgctcgtctaatattggtggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1612,Drugs,MEG_1612|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1105502200|WP_071846350.1|NG_052455|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_052455:101-733,6
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctatggaaattataatcaaacagaaagtagagctgcaccctaatatgtgtgtgatgagctgtacggaacctgagcaatgggatgtggtaatagaaggaaatgatgaccttttagagaaatatatgtccggtaaatcattagaagcattagaactcgaacaagaggaaatcagaagatttcagaattgctccttgtaccctgtttatcatggaagcgcaaaaagcaacatagggattgagcagcttatagaagtgataacgaataaattttattcatcaacatacagaaagaagtctgaactttgcggaaatgtcttcaaaattgaatattcggaagaaagacaacgtcttgcatatgtacgcctttatggcggaatcctgcatttgcgggattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaattgataaggcttattccggggaaattgttattttgcaaaatgagtttttgaagctaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatccgctccctctgctgcaaacaactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctacaatattatgtggattctacgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctattgcaagaaaagtatcatgtggaggtaaaaataaaaaagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagtgccaccgaatcccttctgggcttccattggtctttctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaagggatacgatatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagttttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcaccacaagaatatctttcacgagcatataacgatgctcccaaatattgtgcaaatatcgtaaatactcaactgaaaaataatgaggtcattcttagtggagaaattcctgctcggtgtattcaagaatatcgtaatgatttaactttctttacaaatggacgtagcgtttgtttaacagagttaaaagggtactatgttactactggtgaatctgtttgtcagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7119,Drugs,MEG_7119|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100171|WP_063856394.1|NG_048231|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048231:21-1940,4
,atgatgaaaaaatccctaagctgtgcactgttgctcagcgttgcctgctctgcctttgccgcgccaatgtcagaaaaacagctggctaacgtcgtggaacgtaacgttacgcccctgatgaaagcgcaggccatacccggtatggccgtggctgtcatttatcagggtcagccgcactattttacttttggtaaagcagacgtcgcagcgaataagcctgtcacaccgcaaaccttatttgagctgggctccgtcagcaaaactttcaccggggtgctgggtggcgataccattgcccgcaaagagatctcgctggccgacccggtcacgaaatattggcctgaattgacgggcaagcagtggcagggcattcgcctgctcgatctggcaacttataccgctggtggattgccgttgcaggtaccggatgctgtcaccgataacgcctctctgctgcgtttctaccagtcctggcagccaaagtgggccccgggtactacgcgtctgtacgccaacaccagcatcggtttgtttggctcactgacggttaaaccttccggcatgcgctttgaggaggccatgacggagcgggtctttaagcccctgaaactcaatcatacgtggataaacattccacacgctgaggagccgcattacgcatggggttatcgtgagggtaaagcggtccacgtttcgccgggtatgctggatgcagaagcctatggcgtgaaatctaatgtcaaagatatggcgagctgggtgatggccaatatggcaccggagacaatccagcagccctctctgaagcagggtattgcgctggcgcagtctcgctactggcgcgtgggtgccatgtatcaagggttaggctgggagatgctcaactggccggtcgacgccaaaaccgtggtggatggcagcgacaataaggttgcactggcgccgttaccggcagcagaagtgaatcctccggctccgcctgtgaaagcctcatgggtgcataaaacgggctctacgggggggtttggcagctacgtggcgtttattcctgaaaagcagatcggtattgtgatgctcgcgaataaaagctatccgaacccgctacgggtggaaacggcttaccgtatcctcgacacgctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1751,Drugs,MEG_1751|Drugs|betalactams|Class_C_betalactamases|CMH,822027863|WP_046887417.1|NG_061417|1|1|blaCMH-5|blaCMH|class_C_beta-lactamase_CMH-5 NG_061417:1-1146,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6840,Drugs,MEG_6840|Drugs|betalactams|Class_A_betalactamases|TEM,gb|L19940|+|197-1006|ARO:3000896|TEM-26 [Klebsiella pneumoniae] ,0
,atgtctaaaatcgaaataaaaaatctgacattcggctacgacagccaaggcacattattatttgaacaagcaaatctaaattttgacacacaatggaaactaggacttatcggacgaaacggtcgaggaaagacaactttactgaatattctacaaaacaaactaccttatcaagggcaagtaatccatcagcaagaatttgcctatttcccgcaacagacaaaagataaagaacgtttaacctattacgtgttaaatgatattacggattttgagatatgggaaatcgaaagagagctccaattgatgcaaacagatcctgaaatcttatggagagaattcagcacactatcggggggagagaagacaaaagtcctactggcacttttatttgtggatgacactcatttcccgttaatcgatgaaccaacgaatcatttggatatctctggtagaaaacaagtagcggcttatttgaaaaagaaaaaacaaggcttcatcgtggtcagccatgaccggggatttatcgatgaagtagtggaccatgttttagcaatcgaaaaaagtcaactggaactttatcaagggaatttctctatctatgaagaacagaaaaaacttcgtgatgaatttgaaatggctcaaaatgaaaaattgaaaaaagaagtcagtaggctaaagaaaacagcagctgaaaaagccgaatggtctcgttcccgagaaggagataaaacaaagaaacaagtcggattcatcgatactgaatctagacgagtgaataaaggagcagtgggtgctgatgctgcacggacgatgaaacgatccaaagcaatcgtgaatcggatggagacccagatcagcgagaaagaaaaactattaaaagatatcgaatatatcgattctttgacgatgaatagccaagcgtctcaccataagcgacttttaagcgtagaagatcttcaattagggtatgaaaatctgttattcgagccaattcattttacaatcgagcctcatcagcgggtggcgatttcaggtcctaacggtgcaggaaagtcatccattatccattatcttctgggggcattcaacggcaaggttataggagaaaaataccagccaaaacatctgagcattagttatgcaagccaaaattatgaagacaatcgaggaacgttggcggaatttgcagagaaaaaccaagtagactaccaagcatttttgaacaacctccgaaagcttgggatggaaagagatgtttttcataacaagatcgagcagatgagtatgggccaacggaaaaaagtggaattggctaaatctttatcacagccagctgaactatatacatgggatgaaccattgaattatttggatgtcttcaatcaagaacaattagaacaactgatcttgaacgtgaaacctgccatgttactagtggaacatgatcaaaccttcctggataaagtatctactgagattatttctcttgagagaatctaa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_2693,Drugs,MEG_2693|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|EATAV|RequiresSNPConfirmation,488224967|WP_002296175.1|NG_047762|1|1|eat(A)|eat(A)|ABC-F_type_ribosomal_protection_protein_Eat(A) NG_047762:101-1603,1
,atgacgaatctctcacgacgcagtgtgttgatcggatccctggcagtgatggcggccgccggtgtgcgtatgccgacggcttccgccgctcccgtcgacgaccggatcgccgatctcgaacgacggaacaacgcatccatcggcatctatgccgtcgacctcgattcgaaccgtacggtcgcgcaccgcgccgacgactcgttcgcgatgtgctcgacgttcaaggcctacctcgcggcccggatcctgcggggcgccgagcgcggcgagttgtcgctggacgatcgtgtcttcgtggatcccgcggcgctgctgagcaactcgccgatcaccgagacacacgcaggcggcgagatgacgctggccgagttgtgccaggcggcactgcagcgcagcgacaacgccgcggccaacctgttgctcaagcagatcggcgggccggccgagatcaccgcgttcgcgcggtcgatcggcgaccagcgcacacgcctggaccgctgggagaccgaactgaactcggcggtgcccggcgatccgcgtgacaccagcaccccggccgcgctggccggtggtttccgcgccgtgctgaccggcgacgtgctggccccgccgcagcgtcaattgctcgacgagtggatgcgggccaacgagacctccagcctgcgtgcgggtttgccggacggctggaccagtgccgacaagaccggcagcggcgactacggatccaccaacgatgtgggtatcgcctacggcccgcaggggcagcgcatcctgctggcgttgatggtgcggacgcgcggcgacgatccgaacgcggacgggttccggcccctcatcggggaactcaccgcgctggtgctgcccgaactcggcgtgcactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1304,Drugs,MEG_1304|Drugs|betalactams|Class_A_betalactamases|BLAS,500047791|WP_011728509.1|NG_047542|1|1|blaS|blaS|class_A_beta-lactamase NG_047542:101-982,0
,atgcgcctctgcctgactcccctcgccctggctgccacgctcgtcttcgatgtcgctgccgccgacgcaccgctgccgcagctccgggcctacaccgtcgacgcttcgtggctgcagccgatggcaccgctgcagattgccgaccacacctggcagatcggcaccgaggacctgacggcactgctggtgcggaccaccgagggcgcagtgctattggatggcggcatgccgcagatggccggtcacctgctggacaacatgaaggcacgcggggtggcaccacaggatctacggctgatcctgctcagccatgcgcatgccgaccacgccgggccggtggcggaactcaagcgccgcaccggtgcccaggtggtcgcgaacgccgaaacggccgtgctgctgccgcgcggcggcagcaacgacctgcacttcggtgatgacatcacctacccgccggccagtgccgaccgcatcatcatggatggtgagagggtgacggtaggcggcatggcattcaccgcgcacttcatgccagggcacacccccggcagcaccgcctggacctggaccgatacccgcgatggcaagcccgtgcgcatcgcctacgccgacagcctgagtgcgccgggctaccagctgcagtacaacgcacgctatccccgcctggtcgaggactaccggcgcagcttcacaacggtgcgcggcctgccctgcgacctgctgctgaccccgcatccgggcgccagccgctggaactatgccgccggtgccgaggccggggccaacgtcctgacctgcaaggcctacgcggatgcggccgagaaggcattcgacgcgcagttggccaaggaaacgaccggggcccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3518,Drugs,MEG_3518|Drugs|betalactams|Class_B_betalactamases|L1,1028083729|WP_063842697.1|NG_047515|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047515:1-870,0
,atgtcccgccttctgttatccggcctgctcggcgcaggcctgctgttctcgctgccggccagcgccgccaccggctgttttctctatgccgacggcaacggccagaccctctccagcgaaggggattgttcaagccagctgccacccgcgtccaccttcaagatcccgctggcgctgatgggctacgacagtggctttctggtggacgaagagcacccggcactgcctttcaagccgggttacgacgactggctgcccgcctggcgggaaaccaccaccccgcgccgctgggaaacctactcggtggtctggttctcccagcagatcaccgaatggctggggatggagcgcttccagcagtacgtcgaccgttttgactacggcaaccgggatctctccggcaatcctggcaagcacgacggtctgacccaggcctggctcagtgccagccttgccatcagtccacaggagcaggcccgcttcctcggcaagatggtgagcggcaagctgccggtgtcggcgcaaaccctgcagtacaccgccaacatcctcaaggtgagcgagatcgacggctggcagatccacggcaagaccggcatgggctacccgaagaagctggatggcagcctcaaccgcgatcagcagatcggctggttcgtcggctgggccagcaagccgggcaagcagctcatcttcgtccataccgtggtgcagaaacccggcaagcagttcgcctcgctcaaggccaaggaagaggtgctggccgccctgccggccaaactgaaaaccctgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4734,Drugs,MEG_4734|Drugs|betalactams|Class_D_betalactamases|OXA,1311480306|WP_101150415.1|NG_062247|1|1|blaOXA-726|blaOXA-12_like|OXA-12_family_class_D_beta-lactamase_OXA-726 NG_062247:101-895,0
,atgaaccattctccgttgcgccgttcgctacttgccgcggccgttttcgcgccgctgatcggcgcatgtgcgccgctgatcggcaactcgaacggcgtcgccgccgccgagcggcaattgagcgaactcgagtcgtcgttcggcggccgcctcggcttcgtcgcgctcgacacggcgacgggcgcgcgcatcgcgcatcgcgccgacgagcgcttcccgttctgcagcacgttcaagacgatgctgtcggccgcgatcctcgcgcgcagcgcgggtgacgccacgttgctgcagcgacggatcccgtatgcgaagcgcgacctcgtcagctattcgccggtcaccgaaaagcacgtcggcgacgggatgaccgtcgccgaactttgcgcggcagcgctccagtacagcgacaacaccgcggcgaacctgctgatcgcgctgctcggcggtccgcaggccgtcaccgcgtatgcgcgctcgatcggcgacacgacgttccgcctcgaccgccgggagaccgagctgaacaccgcgattcccggcgacgagcgcgatacgacgacgcccgccgcgatggcggcgagcttgcgccgcctgctcgtcggcgatgcgctcggcgcagcgcagcgcgcgcaactcgatacgtggatgctcggcaacacgacaggcgccgcgcggatccgcgcgggcgtgccggccgactggcgcgtcgccgacaagacgggcacgggcgactacgggacggggaacgacattggcgtcgcgtatccgccgaaccgcgcgccgatcgtgatcgtcatctacacgacgatgcgcgacaagaatgcgcaagcgcgcaacgacgtgctcgcgtcggcggcgcggatcgccgcgcggacattcggctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5753,Drugs,MEG_5753|Drugs|betalactams|Class_A_betalactamases|PENI,497794633|WP_010108817.1|NG_048034|1|1|penI_Bp|penI_Bp|PenI_family_class_A_extended-spectrum_beta-lactamase NG_048034:101-988,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAATACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCAGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6446,Drugs,MEG_6446|Drugs|betalactams|Class_A_betalactamases|SHV,gi|262477944|gb|GU064395.1|1-861,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGCCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1913,Drugs,MEG_1913|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JX049132|+|0-1146|ARO:3002082|CMY-69 [Escherichia coli] ,0
,atgttcaagcatctgattttattcgcatcgctggccgcgccgctaacccaggccgtcgccgccgatccgctcgccgtcgccgccgacaagctggccaaactggaacgcgactttggcggcagcatcggcgtctacgccatcgacaccggctccggcgccaccgtggccaaccgccccaacgaacgctttcccatgtgcagctctttcaaaggctttctggcggcgggagtgctggcgcaaagtcaagacaaacccggcctgctggacaaacgcatccgctacagcaaggcggctctgcctaattggtccccgattaccaccaaacaccaagcaagcggcatgaccgtggccgagctcaacgccgcctccgtgcaatacagcgacaacggcgcggccaacctgctgctcaaggaaatcaacggccccgccgcgctgaccgccttcatgcgctccatcggcgacgccagcttccgcctggatcgtcgggagccggaactgaactccgccatccccggcgacccgcgcgacacctccacccccaaagcggtggcggaaagcgcgcaaaaactggcgctgggcaaggcgctgccggaaccgcaacgccaacagctggcggactggctgaagggcaacaccaccggcaacgccagaatccgcgccgcggtgccggccggctgggaagtgggagacaaaaccggcacttgcggcgtctacggcaccgccaacgacttcgcggtgatctggccgcccaagcgcgcgcccatcgtgctggcggtctacaccaagcacgccaagaaagaagccaagcacagcgacgaagtgatcgccgccgcggcgcgggcggcgctggaagcctttaacgtgaagaaataa,antibiotic molecule,antibiotic inactivation,betalactams,MEG_2131,Drugs,MEG_2131|Drugs|betalactams|Class_A_betalactamases|CRH,759906063|WP_043592266.1|NG_054656|1|1|blaCRH-1|blaCRH|carbapenem-hydrolyzing_class_A_beta-lactamase_CRH-1 NG_054656:101-973,0
,atgaatagttcgacaaagatcgcattggtaattacgttactcgatgccatggggattggccttatcatgccagtcttgccaacgttattacgtgaatttattgcttcggaagatatcgctaaccactttggcgtattgcttgcactttatgcgttaatgcaggttatctttgctccttggcttggaaaaatgtctgaccgatttggtcggcgcccagtgctgttgttgtcattaataggcgcatcgctggattacttattgctggctttttcaagtgcgctttggatgctgtatttaggccgtttgctttcagggatcacaggagctactggggctgtcgcggcatcggtcattgccgataccacctcagcttctcaacgcgtgaagtggttcggttggttaggggcaagttttgggcttggtttaatagcggggcctattattggtggttttgcaggagagatttcaccgcatagtcccttttttatcgctgcgttgctaaatattgtcactttccttgtggttatgttttggttccgtgaaaccaaaaatacacgtgataatacagataccgaagtaggggttgagacgcaatcgaattcggtatacatcactttatttaaaacgatgcccattttgttgattatttatttttcagcgcaattgataggccaaattcccgcaacggtgtgggtgctatttaccgaaaatcgttttggatggaatagcatgatggttggcttttcattagcgggtcttggtcttttacactcagtattccaagcctttgtggcaggaagaatagccactaaatggggcgaaaaaacggcagtactgctcggatttattgcagatagtagtgcatttgcctttttagcgtttatatctgaaggttggttagttttccctgttttaattttattggctggtggtgggatcgctttacctgcattacagggagtgatgtctatccaaacaaagagtcatcagcaaggtgctttacagggattattggtgagccttaacaatgcaaccggtgttattggcccattactgtttgctgttatttataatcattcactaccaatttgggatggctggatttggattattggtttagcgttttactgtattattatcctgctatcgatgaccttcatgttaacccctcaagctcaggggagtaaacaggagacaagtgcttag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7041,Drugs,MEG_7041|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,498132411|WP_010446567.1|NG_048167|1|1|tet(B)|tet(B)|tetracycline_efflux_MFS_transporter_Tet(B) NG_048167:1-1206,4
,GGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATAAGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACGATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6920,Drugs,MEG_6920|Drugs|betalactams|Class_A_betalactamases|TEM,gi|46370394|gb|AY589494.1|1-1054,0
,ATGATGAAATTGAAAAAGATAGCCATAATATTCGGAGGTCAATCTTCGGAATATGAAGTCTCACTTAAATCAACAGTAAGTGTACTAGAAACTCTATCAACTTGTAATTTTGAAATTATAAAAATAGGAATTGATTTAGGCGGAAAGTGGTATCTCACCACAAGCAACAACAAAGATATTGAATATGATGTTTGGCAAACTGATCCTTCATTACAAGAAATAATCCCATGTTTCAATAATCGAGGCTTTTATAACAAAACTACAAATAAATATTTCAGACCAGATGTACTCTTTCCAATTCTTCATGGGGGGACTGGAGAAGATGGAACCCTCCAAGGTGTATTTGAATTAATGAATATTCCTTACGTTGGATGTGGGGTGACGCCTTCGGCTATTTGTATGGACAAATACTTATTGCATGAGTTTGCTCAGAGTGTGGGTGTAAAAAGTGCCCCTACGCTCATAATTCGCACTAGAAACTGCAAAGATGAAATTGACAAGTTCATAGAAAAAAATGACTTCCCTATTTTTGTAAAGCCTAACGAAGCGGGCTCATCAAAAGGAATAAACAAAGTAAATGAGCCAGATAAGCTAGAGGATGCTTTAACAGAAGCGTTTAAGTATAGTAAAAGTGTTATCATTCAGAAAGCTATAATTGGAAGAGAAATTGGCTGTGCTGTCTTAGGTAATGAAAAACTCCTAGTAGGAGAATGTGATGAAGTTTCCCTTAATAGCGATTTTTTTGATTATACCGAGAAATACCAAATGATCTCAGCAAAGGTAAATATACCTGCTTCTATATCTGTAGAATTTTCTAATGAAATGAAGAAACAAGCTCAGCTGTTATATAGGTTACTAGGCTGTTCAGGACTAGCACGAATTGATTTCTTCTTATCAGATAATAACGAAATACTATTAAACGAAATTAATACTTTGCCTGGTTTTACTGAGCATTCCAGATATCCCAAAATGATGGAAGCTGTAGGTGTTACCTATAAAGAGATTATCACGAAGTTAATCAATTTAGCGGAGGAAAAATATTATGGATAACGATTACAAGTATTATTTACAATTAGTCAATAAGCAATATCCTTGGCAGATAAACAATGGTTCTAAAAAAATGGTAAGGGTGCCTTATACAGATAAAGAAATTTATTTAGATGCAGTTGTTGTTGAACATTTGATTCAGTTGATCGAAACTATTCAATTACAAGAGAAAATAGAAATAGTTGATGGTTACCGTACGATAGACGAACAAAAAGAATTATGGGAATTTTCTTTAAAAGATAGAGGGAAACGATATACTCATGATTATGTTGCCTATCCTGGGTGTAGTGAGCATCATACTGGACTTGCATTAGATATTGGTCTTAAAAAAACAGCACATGATATCATAGCACCAAAATTTAATGGAGAAGAGGCAAAAAAATTTTTAGAGCATATGAAAGATTACGGATTTATTTTAAGGTACCCTCCAAACAAAAAAAAGGTAACAGGGATTGCGTATGAACCGTGGCATTTTAGGTATGTTGGAGTTCCTCACAGCCAAATCATTACTCAGCAAGCTTGGACGCTGGAAGAATATATCGCTTTTTTACACACAGTAGGAGAAAAAGTTTCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7445,Drugs,MEG_7445|Drugs|Glycopeptides|VanL-type_resistance_protein|VANL,VanLXY_1_EU250284,5
,atgaacacaagggaaacaattgcggcggacctttcacggctgggtgtccaatccggcgctctcgtcatggttcacgcatcgctgaaggcgatcggccccgtcgatggaggcgcagcatcgatagtgtctgccctgctcgatgccgtcggccccactggaagcttgatgggatacgcctcgtgggaccggtcgccttacgaagaaacgctcaatggcgcacggatggatgcggaactgcgccaccgatggccgccgttcgatccagccatatcaggcacgtatcgcggcttcggcctgctcaaccggttcctcctccagacacccggcgcccggcgcagcgcgcacccggatgcctcgatggtcgcggtagggcctctggccggcactctgacgcggcctcacgaacttgggcaggctttcggacctggatcgccgctggagcgtttcgtcgagcgtgccggaaaggttctgttgctcggagccccgctcgattccgttaccgtcctgcactacgccgaggccattgcccgcatcccgaacaagcgacgcgtgagctacgaaatgccgatccgcagcgaggacggcggagtgagatggaaacgcgccgaggatttcgactccaacggcattctcgattgtttcgctatcgaaggagagccggacgccgtcgagacaattaccaatgcctatgtggagctgcgacgccatcgggagggcttggtcggtcaggcgcactgctacttgttcgaagcgcgggatatcgtttcgttcggtgtcgactatcttcaacggcactttggctcgccctga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_36,Drugs,MEG_36|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,502019214|WP_012695485.1|NG_047231|1|1|aac(3)-II|aac(3)-II|AAC(3)-II_family_aminoglycoside_N-acetyltransferase NG_047231:101-910,2
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacgcgtatcgaacacgcttgtgaggccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgatctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacaccgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagatcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1492,Drugs,MEG_1492|Drugs|betalactams|Class_A_betalactamases|CARB,757503230|WP_042771632.1|NG_048728|1|1|blaCARB-25|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-25 NG_048728:1-852,0
,atgcgcgataccggattcccctgcctgtgcggcatcgccgcctccacactgctgttcgccgccacctcggccattgccggcgaggccccggcggatcgcctgaagacactggtcgacgccgccgtacaaccggtgatgaaggccaatgatattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcttcgaaagaggacggtcgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagcctgcactggccggcgctgcaaggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaagaccaggcacagatccgcgactactaccgccagtggcagccgacctacacgccgggcagccagcgcctctactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggatcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccctctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaagccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggcgggcaactcgacgccgatggcgctgcaaccgcacaggatcgccagactgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccaggccgcgacctgggcctggtgatcctggccaaccgcaattatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5710,Drugs,MEG_5710|Drugs|betalactams|Class_C_betalactamases|PDC,730300910|WP_033977759.1|NG_049941|1|1|blaPDC-66|blaPDC|class_C_beta-lactamase_PDC-66 NG_049941:1-1194,0
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgcctgcggtagcaagggaatggcaagaaaacaaaagttggaatgttcactttactgaacataaatcacagggcgtagttgtgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacatttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcggttgtgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgctttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccattgagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagtcagcgcatcgtgaaacaagccatgctgaccgaagccaatggcgactatattattcgggctaaaactggatactcgactagaatcgaacctaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggaaaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4619,Drugs,MEG_4619|Drugs|betalactams|Class_D_betalactamases|OXA,1188444901|WP_085562403.1|NG_054693|1|1|blaOXA-547|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-547 NG_054693:19-816,0
,atgttcatgccgcctgtttttcctgctcattggcacgtttcgcaacctgttctcattgcggacaccttttccagcctcgtttggaaagtttcattgccagacgggactcctgcaatcgtcaagggattgaaacctatagaagacattgctgatgaactgcgcggggccgactatctggtatggcgcaatgggaggggagcagtccggttgctcggtcgtgagaacaatctgatgttgctcgaatatgccggggagcgaatgctctctcacatcgttgccgagcacggcgactaccaggcgaccgaaattgcagcggaactaatggcgaagctgtatgccgcatctgaggaacccctgccttctgcccttctcccgatccgggatcgctttgcagctttgtttcagcgggcgcgcgatgatcaaaacgcaggttgtcaaactgactacgtccacgcggcgattatagccgatcaaatgatgagcaatgcctcggaactgcgtgggctacatggcgatctgcatcatgaaaacatcatgttctccagtcgcggctggctggtgatagatcccgtcggtctggtcggtgaagtgggctttggcgccgccaatatgttctacgatccggctgacagagacgacctttgtctcgatcctagacgcattgcacagatggcggacgcattctctcgtgcgctggacgtcgatccgcgtcgcctgctcgaccaggcgtacgcttatgggtgcctttccgcagcttggaacgcggatggagaagaggagcaacgcgatctagctatcgcggccgcgatcaagcaggtgcgacagacgtcatactag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_1086,Drugs,MEG_1086|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH6,446403113|WP_000480968.1|NG_047464|1|1|aph(6)-Id|aph(6)-Id|aminoglycoside_O-phosphotransferase_APH(6)-Id NG_047464:101-937,2
,atgcaacaacgacaatccttcctgtggggggccgtggccaccctgatgtgggccggtctggcccatgcaggtgagacttcaccggtcgatcccctgcgccccgtggtggatgccagcatccagccgctgctcaaggagcacaggatcccgggcatggcggtggccgtgctcaaggatggcaaggcccactatttcaactacggtgtggccgatcgggagcgcgcggtcggtgtcagcgagcagaccctgttcgagataggctccgtgagcaagcccctgaccgcgaccctaggagcctatgcggtggtcaagggagcgatgcaactggatgacaaggcgagccggcacgccccctggctcaagggatccgcctttgacagcatcaccatgggggagctggctacctacagcgcgggcggcttgccgctgcaattccccgaggaggtggattcgctcgagaagatgcaggcctactaccgccagtggaccccagcctactcgccgggttcccatcgccagtactctaaccccagcatagggctgttcggccacctggcggcgagcagcctgaagcagccgtttgcccagttgatggagcagacgctcctgccggggcttggcctgcaccacacctatgtcaatgtgccgaagcaggccatggcgagttatgcctatggctattcgaaagaggacaagcccatcagggtcagccccggcatgctggcggacgaggcctacggcatcaagaccagctcggcggatctgctgcgctttgtgaaggccaacatcagcggggttgatgacaaggcgttgcagcaggccatctccctgacccacaaagggcactactcggtaggcgggatgacccagggactgggttgggagagttacgcctatcccgtcagcgagcagatattgctggcgggcaattcggccaaggtgatcctcgaagccaatccgacggcggcgccccgggagtcggggagccagatgctcttcaacaagaccggctcgaccagcggcttcggcgcctatgtggccttcgtgccggccaaagggatcggcatcgtcatgctggccaaccgcaactatcctatcccggccagggtgaaagcggcccacgccatcctgacgcaactggccaggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4014,Drugs,MEG_4014|Drugs|betalactams|Class_C_betalactamases|MOX,1028105818|WP_063860843.1|NG_049312|1|1|blaMOX-10|blaMOX|CMY-1/MOX_family_class_C_beta-lactamase_MOX-10 NG_049312:1-1149,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaaggactatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaataaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4643,Drugs,MEG_4643|Drugs|betalactams|Class_D_betalactamases|OXA,1053179495|WP_065980086.1|NG_063885|1|1|blaOXA-784|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-784 NG_063885:1-774,0
,atgaagtttttattggcattttcgcttttaataccatccgtggtttttgcaagtagttcaaagtttcagcaagttgaacaagacgttaaggcaattgaagtttctctttctgctcgtataggtgtttccgttcttgatactcaaaatggagaatattgggattacaatggcaatcagcgcttcccgttaacaagtacttttaaaacaatagcttgcgctaaattactatatgatgctgagcaaggaaaagttaatcccaatagtacagtcgagattaagaaagcagatcttgtgacctattcccctgtaatagaaaagcaagtagggcaggcaatcacactcgatgatgcgtgcttcgcaactatgactacaagtgataatactgcggcaaatatcatcctaagtgctgtaggtggccccaaaggcgttactgattttttaagacaaattggggacaaagagactcgtctagaccgtattgagcctgatttaaatgaaggtaagctcggtgatttgagggatacgacaactcctaaggcaatagccagtactttgaataaacttttatttggttccgcgctatctgaaatgaaccagaaaaaattagagtcttggatggtgaacaatcaagtcactggtaatttactacgttcagtattgccggcgggatggaacattgcggatcgctcaggtgctggcggatttggtgctcggagtattacagcagttgtgtggagtgagcatcaagccccaattattgtgagcatctatctagctcaaacacaggcttcaatggcagagcgaaatgatgcgattgttaaaattggtcattcaatttttgacgtttatacatcacagtcgcgctga,chloramphenicol acetyltransferase (CAT),antibiotic inactivation,betalactams,MEG_5810,Drugs,MEG_5810|Drugs|betalactams|Class_A_betalactamases|PSE,1028103685|WP_063859105.1|NG_048733|1|1|blaCARB-3|blaPSE|PSE_family_carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-3 NG_048733:101-967,0
,CGTTGATGTCACTGTATCGCCGTCTAGTTCTGCTGTCTTGTCTCTCATGGCCGCTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTCGAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACTGTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCTGCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTACGGCAAAAATGCGCTGGTTCCGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATGACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTGTTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGATACCACGTTCCGTCTGGACCGCTGGGAGCTGGAGCTGAACTCCGCCATCCCAGGCGATGCGCGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCTGCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGCAACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACCTGCGGAGTGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCTATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGCACAGCGAGGCCGTCATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGGGCGTCAACGGGCAGTAAGGCTCTGAAAATCATCTATTGGCCCACCACC,beta-lactamase,antibiotic inactivation,betalactams,MEG_3508,Drugs,MEG_3508|Drugs|betalactams|Class_A_betalactamases|KPC,gi|873464424|gb|KR014106.1|9895-10812 gi|962148899|gb|KU176944.1|36848-37765 gi|961666360|gb|KT185451.1|86335-85418 gi|966624506|gb|CP012000.1|12165-13082 gi|966624404|gb|CP011999.1|28777-27860 gi|959190550|gb|CP013325.1|38362-37445 gi|941349957|gb|KP726894.1|3977-3060 gi|918463219|gb|KP987218.1|19745-18828 gi|918462945|gb|KP987215.1|6227-7144 gi|817046807|gb|KP893385.1|125827-124910,0
,ATGATGAATCGTTATGCTGCAGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1898,Drugs,MEG_1898|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JF460795|+|0-1143|ARO:3002074|CMY-61 [Escherichia coli] ,0
,ATGACATGGAGAACGACCAGAACACTTTTACAGCCTCAAAAGCTGGAGTTCAATGAGTTTGAGATTCTTAATCCCGTAGTTGAGGGCGCCCGAATTGTCGGCATTGGCGAGGGTGCTCACTTTGTCGCGGAGTTCTCACTGGCTAGAGCTAGTCTTATTCGCTATTTTGTCGAGAGGCATGATTTTAATGCGATTGGTTTGGAATGTGGGGCGATTCAGGCATCCCGGCTATCTGAATGGCTCAACTCAACAGCCGGTGCTCATGAACTTGAGCGATTTTCGGATACCCTGACCTTTTCTTTGTATGGCTCAGTGCTGATTTGGGTTAAATCATATCTACGGGAATCAGGAAGAAAACTGCAGTTAGTCGGAATCGATTTACCCAACACCTTGAATCCAAGGGACGACCTAGCGCAATTGGCCGAAATTATCCAGGTCATCGACCACCTCATGAAACCCCACGTTGATGCGCTGACTCAGTTGTTGACGTCCATTGATGGCCAGTCGGCGGTTATTTCATCGGCAAAATGGGGGGAGTTGGAAACGGCTCAGCAGGAGAAAGCTATCTCAGGGGTAACCAGATTGAAGCTCCGTTTGGCGTCGCTTGCCCCTGTCCTGAAAAATCACGTCAACAGCGATTTTTTCCGAAAAGCCTCTGATCGAATAGAGTCGATAGAGTATACGTTGGAAACCTTGCGTGTAATGAAAGCTTTCTTCGATGGTACCTCTCTTGAGGGAGATACTTCCGTACGTGACTCGTATATGGCGGGCGTGGTGGATGGAATGGTTCGAGCGAATCCGGATGTAAGGATAATTCTGCTGGCGCACAACAATCATTTACAAAAAACTCCAGTTTCCTTTTCAGGCGAGCTTACGGCTGTTCCCATGGGACAGCATCTCGCAGAGAGGGAGGAGGGGGATTACCGTGCGATTGCATTCACCCATCTTGGACTCACCGTGCCGGAAATGCATTTCCCATCGCCCGACAGTCCTCTTGGATTCTCTGTTGTGACCACGCCTGCCGATGCAATCCGTGAGGATAGTGTGGAACAGTATGTCATCGATGCCTGTGGTAAGGAGGATTCATGCCTGACATTGACAGATGACCCCATGGAAGCAAAGCGAATGCGGTCCCAAAGCGCCTCTGTAGAAACGAATTTGAGCGAGGCATTTGATGCCATCGTCTGCGTTCCCAGCGCCGGCAAGGACAGCCTGGTTGCCCTATAG,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_2750,Drugs,MEG_2750|Drugs|MLS|Macrolide_esterases|EREA,gi|21263078|gb|AF512546.1|716-1942 gi|954629879|gb|CP013215.1|280834-280647 gi|948288909|gb|KR259328.1|932-1119 gi|908266278|gb|CP012170.1|140874-141061 gi|659224503|gb|KJ668707.1|918-1105,7
,TTGTCAAAAGCGCGGGAGTCGCGGATAATCCGGGCAGCTCATCACTATCAAGGAGTCTGAGATGTTGAAAAGTTCGTGGCGTAAAACCGCCCTGATGGCCGCCGCCGTTCCGCTGCTGCTGGCGAGCGGTTCATTATGGGCCAGTGCCGATGCTATCCAGCAAAAGCTGGCTGATTTAGAAAAACGTTCCGGCGGTCGGCTGGGCGTAGCGCTGATTAACACGGCAGATGATTCGCAAACCCTCTATCGCGGCGATGAACGTTTTGCCATGTGCAGCACCGGTAAAGTGATGGCCGCCGCCGCGGTGTTAAAACAGAGCGAAAGCAATCCAGAGGTGGTGAATAAAAGGCTGGAGATTAAAAAATCGGATTTAGTGGTCTGGAGCCCGATCACCGAAAAACATCTGCAAAGCGGAATGACCCTGGCGGAACTCAGCGCGGCGGCGCTGCAGTACAGCGACAATACCGCGATGAATAAGATGATTAGCTACCTTGGCGGACCGGAAAAGGTGACCGCATTCGCCCAGAGTATCGGGGATGTCACTTTTCGTCTCGATCGTACGGAGCCGGCGCTGAACAGCGCGATTCCCGGCGATAAGCGCGATACCACCACCCCGTTGGCGATGGCCGAAAGCCTGCGCAAGCTGACGCTGGGCAATGCGCTGGGCGAACAGCAGCGCGCCCAGTTAGTGACGTGGCTAAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCAGGCCTGCCCGCAAGCTGGGTGGTCGGGGATAAAACCGGCGCCGGAGATTACGGCACCACCAACGATATCGCGGTGATCTGGCCGGAAAATCATGCCCCGCTGGTGCTGGTGACCTATTTTACCCAGCCGCAGCAGGATGCGAAAAGCCGCAAAGAGGTGTTAGCCGCGGCGGCAAAAATCGTCACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5310,Drugs,MEG_5310|Drugs|betalactams|Class_A_betalactamases|OXY,gi|18844707|gb|AY077483.1|122-1055,0
,ATGAACAAAAAAAATATAAAAGATAGTCAAAACTTTATTACTTCAAAGCATCATATAAATGAAATTTTGAGAAATGTACATTTAAATACAAATGATAATATTATTGAGATTGGTTCAGGGAAAGGTCATTTCACGCTTGAATTAGCTAAAAGGTGTAATTATGTAACCGCCATTGAAATAGATCCTAAATTATGTAGGATAACTAAAAACAAACTTATTGAATATGAGAACTTCCAGGTTATCAATAAAGATATTTTACAATTTAAGTTTCCTAAAAATAAGTCATATAAGATATATGGAAATATACCCTACAATATAAGTACAGATATAATTCGAAAAATTGTTTTTGAAAGCACAGCTACAGAAAGTTATTTAATAGTGGAATATGGATTTGCTAAAAGGTTGCTAAATACAAATCGTTCACTAGCACTATTTTTAATGACAGAAGTTGATATATCCATATTAAGTAAAATCCCTAGAGAATACTTTCATCCAAAACCTAGAGTTAATAGCTCGTTAATTGTATTAAAAAGACACCCTTCAAAAATATCACTCAAAGATAGAAAACAATATGAAAATTTTGTTATGAAATGGGTTAACAAAGAATACAGAAAACTATTTTCCAAAAACCAATTTTATCAAGCCTTAAAATATGCAAGAATTGACGATTTAAACAATATTAGCTTTGAACAATTCTTGTCTCTTTTCAATAGCTATAAATTATTTAATAGATAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2846,Drugs,MEG_2846|Drugs|MLS|23S_rRNA_methyltransferases|ERMT,gi|11527992|gb|AF310974.1|934-1668,7
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAAAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAAAGATTTGCCTATGCTTCAACTTCAAAAGCAATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTCAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTACAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAAGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1335,Drugs,MEG_1335|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_72_NZ_CUHG01000035,0
,GTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGTTGGTTACTGTGGCCGTAAAGCTTGATGAAACGACGCGGCGAGCATTGCTCAATGATCTTATGGAGGCTTCGGCTTTCCCTGGCGAGAGCGAGACGCTCCGCGCTATAGAAGTCACCCTTGTCGTGCATGACGACATCATCCCGTGGCGTTATCCGGCTAAGCGCGAGCTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCATGATCGACATTGATCTAGCTATCCTGCTTACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCGGCAGCGGAGGAATTCTTTGACCCGGTTCCTGAACAGGATCTATTCGAGGCGCTGAGGGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCCGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAATAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATAAAACGCCTACCTGCCCAGTATCAGCCCGTCTTACTTGAAGCTAAGCAAGCTTATCTGGGACAAAAAGAAGATCACTTGGCCTCACGCGCAGATCACTTGGAAGAATTTATTCGCTTTGTGAAAGGCGAGATCATCAAGTCAGTTGGTAAATGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_971,Drugs,MEG_971|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|984348768|gb|KT425375.1|1024-1803 gi|975900838|gb|CP014005.1|53062-53841 gi|971497742|gb|CP012903.1|35748-36527 gi|971497538|gb|CP012902.1|59135-58356 gi|970338578|gb|KT725789.1|86995-86216 gi|970338460|gb|KT725788.1|92255-91476 gi|963885563|gb|KT355691.1|1068-1847 gi|963329770|gb|KT316808.1|982-1761 gi|958108507|emb|LN824138.1|5351-6130 gi|948288870|gb|KR259318.1|1066-1845,2
,atgaatgtcattataaaagctgtagttactgcctcgacgctactgatggtatcttttagttcattcgaaacctctgcacaatccccactgttaaaagagcaaattgaatccatagtcattggaaaaaaagccactgtaggcgttgcagtgtgggggcctgacgatctggaacctttactgattaatccttttgaaaaattcccaatgcaaagtgtatttaaattgcatttagctatgttggtactgcatcaggttgatcagggaaagttggatttaaatcagaccgttatcgtaaacagggctaaggttttacagaatacctggtcgcccatgatggaagagcatccgggcgatgaatttactgttgctgtgcagcagttgttgcaatattcggtgtcgcatagtgacaacgtggcttgtgatttgttattcgaactggttggagggcctgcagccttagatgcctacatccgttctataggagtgaaagagacggctgtggtcgcaaatgaagcgcagatgcacgccgatgatcaggtgcagtatcaaaactggacctcgatgaagggggccgcagagatcctgaaaaagtttgagcaaaaaacacagctgtctgaaacctcgcaggctttgttatggaagtggatggtcgaaaccaccacaggaccagagcggttaaaaggtttgttaccagcaggtactgtggtcgcacataaaactggtacttcgggtgtcagagccgggaaaactgcggccactaatgatttaggtatcattctgttgcctgatggacggcccttgctggttgctgtttttgtgaaagactcagccgagtcaagccgaaccaatgaagctatcattgcgcaggttgctcaggctgcgtatcaatttgaattgaaaaagctttctgccctaagcccaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_5760,Drugs,MEG_5760|Drugs|betalactams|Class_A_betalactamases|PER,1252954843|WP_096865225.1|NG_059335|1|1|blaPER-12|blaPER|class_A_extended-spectrum_beta-lactamase_PER-12 NG_059335:101-1027,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgcagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgcatcgaacacgcttgtgaagccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgatctattggcgacaaagcaacgcgacttgaccgattggaacccggtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcagctgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1496,Drugs,MEG_1496|Drugs|betalactams|Class_A_betalactamases|CARB,835944962|WP_047706904.1|NG_048748|1|1|blaCARB-45|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-45 NG_048748:101-952,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaagggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5519,Drugs,MEG_5519|Drugs|betalactams|Class_C_betalactamases|PDC,1509794536|WP_122630845.1|NG_062258|1|1|blaPDC-307|blaPDC|class_C_beta-lactamase_PDC-307 NG_062258:1-1194,0
,atgagtattcaacattttcgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgctgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctagcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6681,Drugs,MEG_6681|Drugs|betalactams|Class_A_betalactamases|TEM,1028110718|WP_063864996.1|NG_050286|1|1|blaTEM-77|blaTEM|inhibitor-resistant_class_A_broad-spectrum_beta-lactamase_TEM-77 NG_050286:101-961,0
,atgatcgtcaactgcgaccacgacaacctcgacgcctggctggcgctgcgctcggcgctgtggcccacctgcccgttggaagagcaccgcgcggagatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgctctgcgccacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgccgaacgcgcccgccgccagggctgggcggcccgcctgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgatatcgccaatctggactcccaacgcctgcatgcggcgctgggctttgcagaaacggaacgggtggtgttttaccgaaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_102,Drugs,MEG_102|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,727172415|WP_033639326.1|NG_052346|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052346:101-541,2
,ATGGTTGAAGGAGAAAAACTCATTCCTATTAACATAGAAGACCAGATGAAGACAGCCTACATTGACTATTCAATGTCAGTGATTGTCTCAAGAGCTTTGCCCGATGTACGCGATGGGCTGAAGCCTGTACATCGTCGTGTACTCTTTGGAATGCACGAGCTTGGCGTACGTAGCAACACCGCTCATAAGAAATCAGCCCGTATCGTAGGGGAAGTACTCGGTAAGTACCATCCACACGGCGATTCTTCCGTATATGACACAATGGTACGTATGGCACAATGGTGGAACATGCGCTATATGCTTGTAGATGGGCAAGGTAACTTTGGTTCTATCGATGGAGACTCTCCTGCAGCTATGCGTTATACCGAGGCGAGAATGAGAAAAATGGCCGAGGATATGCTGATAGATATCGACAAAGAAACAGTAGATCACAGCCTGAACTTTGACGATACCCTACTCGAACCTACTGTATTGCCTACCCGCATCCCTAACCTACTGGTGAATGGGTCTTCGGGTATTGCTGTAGGTATGGCTACCAATATGCCACCTCATAATCTTGCTGAAGTAGTTGATGGTATAATTGCTTATCTTGGCAATCAAGATATTACCATCGATGAACTTATGGAATATATCAAGGCTCCTGACTTCCCTACAGGTGGAATCATCTATGGCTATGATGGAGTAAGAGAAGCCTTCAAGACTGGACGTGGACGTGTAGTAATCCGCGCCAAGGCTCATTTTGAAGAAGTTAATGGTCGTGACTGTATTGTCGTAACTGAAGTTCCCTATCAAGTGAACCCAGAGACGATGCGTGAACAGACTTCGAACCTTGTCAAAGAAGGCAAACTCGAAGGCCTAGCCGATATCGTAGATCAAACAGGTAAAGGAGGAATGCGCATCGTATATGAACTCAAAAAAGATGCTATTCCCAACGTAGTGCTGAATAACCTCTTCAAACACACAGCATTACAATCCTCCTTCAGTGTCAATAATATTGCCTTGGTCAATGGACGCCCTCAGCAACTGAACCTCAAGGACTTAATATATCACTTTGTAGAACATCGCCACGATGTAGTATACAGACGTACTGAGTATGAGCTCAAAAAAGCCAAAGAACGTATCCATATCTTGGAAGGGTTCATGAAGGTGATGGCCACAGAAGACACTATGGGGAAAGCTATTGAAATCATCCGTTTTCATGACAAGCCCAAAGAGGATTTGATGACCGAGTTCGAGCTTACCGAAATACAAGCTGAAGCTATCTTAGCCTTACAGCTACGTCGTATCAATAAGCTATTAATCCTTCAAACCAAAGAAGAATATGAGCAATTATTAGCACAAATTATTGATTTGGAAGATATCCTTGCTCGCAAAGAACGCCGTACCGAGATTATCAAAGAAGAACTCTTGGAAATAAAATCCAAATATGGAGACGAACGTCGTTCTGTCATAGAATATGCAGGGGGTGATATCTCCATTGAGGATATTATCCCTGATGATCAAGTGGTTATTACCATTTCCAACGCAGGTTACATAAAGCGTACTTCTGTCAATGAATACAAAACCCAAGCACGTGGTGGTGTAGGACAAAAAGCCTCTGCTACTCGTGATAAGGACTTCATAGAGCATCTGTTCATAGGTACCAACCACCAGTATATGCTGTTCTTTACAGAGAAAGGTAAGTGTTTTTGGCTCAGGGTGTATGAGATTCCTGAAGGAGGTAAAAATACCAAAGGACGCGCCATACAGAACCTTATCAATATCGAACCCGATGACCTTGTTAAGGCAGTCATCTGTACCCATGACCTCAAGGAAAAAGACTATACCAATAGTCACTATGTCATCATGGCTACTAAAAAAGGGATTATTAAGAAAACCAGCTTAGAACAATATTCACGTCCACGCCAGAATGGTATCGTTGCCATCACTATCAAAGAAGATGATGAGCTATTAGAAGCACGTCTTACCTCTGGCAACAGCCAAATCATGCTAGCTGTCAAGTCTGGAAAGGCTATTCGCTTCCCAGAGGACAAGGTGAGAGCTGTAGGGCGTAGTGGCTCTGGAGTACGAGGTATCTCTTTGGATAGTGACAAAGATGAGGTAATCGGAATGATTGCCATAGAAAATCCTCTGGAAGAAACCGTATTGGTAGTTTCCGAGAATGGTTATGGTAAGCGTACCTTTATCGATGAACCAGAGACAGGAGAAGCAGTATATCGTATTACCAACCGTGGAGGAAAAGGAGTCAAGACTATTTCTATCACAGAGAAAACAGGTAATCTGGTAGCAATCAAGTCAGTTTTGGAAGAAGACGATCTGATGATTATCAATAAGTCGGGTATGGCTATTCGCCTCCCTGTAAGTGGACTCCGTGTGATGGGACGTGCTACCCAAGGAGTACGCCTTATCAATATCAAAGGAAATGACTCTATTGCCGCAGTAGCAAAGGTTATGAAAGAAGATGAGGATGAAAATACTACCGAAGAGATAGAAAACCCAACAGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3176,Drugs,MEG_3176|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|ACLQ01000019.1|+|24238-26749|ARO:3003931|Capnocytophaga gingivalis gyrA conferring resistance to fluoroquinolones [Capnocytophaga gingivalis ATCC 33624] ,3
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaataccccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagtgctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggtccactcgatgccccagcatacggcgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaacctcaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_609,Drugs,MEG_609|Drugs|betalactams|Class_C_betalactamases|ADC,1058243731|WP_068981627.1|NG_051460|1|1|blaADC-96|blaADC|class_C_beta-lactamase_ADC-96 NG_051460:1-1167,0
,atgaaaaagatccgccttattataatctctttactggctggaatgtgtactccagcattatctacaccagtcaatgttactgatacaatacaaagcacagaagaccatatcaaaggtcgggttggttttactgaaatagactttttatccgggaaggttctgagtagtcatcgccgtgaagaacgttttcctatgatgagcacattcaaagttttgttatgtggagcaatattagtacgtgttgataaagggcttgaacaacttgaacgccgaattacctataataagcatgacctggacgactattctccactaaccagtcagcacattgcagatggaatgacggtttctgagttatgcaatgctgccattaccaccagtgataacactgctgcaaatttattgctatcaactattggcgggccggagggattaactcattttctgcgtagcactggtgatagttatacaaggcttgatcgacacgaacccagccttaatgaggcgaagcctggcgatgagcgtgataccaccactccggcagcgatggctcaaacgctacaaaaattgttaaacgaaagtgtacttacagaaaaatctcgaaaaaaattaataagctggatgcaggaagataaagtcggcgggcctctgttccgctctgtactgccagctggctggatgatagcggataaaacaggagcaggtgatcacggatctcggggcatcgttgcactgttgggccccggaggcaagccatctcgtatagtagtcctgtatattacaaatactcattcatctatgaatgaactcaacgagcatattgcagggatcggagattcagtaattaagaactggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3535,Drugs,MEG_3535|Drugs|betalactams|Class_A_betalactamases|LAP,501454150|WP_012477595.1|NG_049264|1|1|blaLAP-2|blaLAP|class_A_beta-lactamase_LAP-2 NG_049264:1-858,0
,atgataatcagtgaacttgaccgtaataatccagtattgaaagatcagctttctgatttactgagactgacttggccggaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacgaatcgcggtagcagcggtagaccaagatgagttagtaggatttattggtgcaatccctcaatacggtatcacaggttgggaattgcatccattagttgtagaaagctcccgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagaggaggaatcacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaaacggacctgtatgagcatacatttgataaagtggcttccatccagaaccttcgtgaacatccgtatgaattctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaaatggctgggacaaaccggatatttggatggcaaaaacgattattcctcgaccagattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_138,Drugs,MEG_138|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,488268538|WP_002339746.1|NG_052261|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052261:101-649,2
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaatgaaaccccgagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaaacagataaaaaaattaatctatatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttaccgcttgggaaaaagacatgacactaggagaagccatgaagctttctgcagtcccagtctatcaggaacttgcgcgacgtatcggtcttgatctcatgcaaaaagaagtaaaacgtattggtttcggtaatgctgaaattggacagcaggttgataatttctggttggtaggaccattaaaggttacgcctattcaagaggtagagtttgtttcccaattagcacatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgcttcttttagaagagagtaatggctacaaaatttttggaaagactggttgggcaatgggtataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcgcttttgcattaaatatggaaatgcggtcagaaatgccggcatctatacgtaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4525,Drugs,MEG_4525|Drugs|betalactams|Class_D_betalactamases|OXA,1408841634|WP_111672907.1|NG_060565|1|1|blaOXA-657|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-657 NG_060565:1-822,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGAGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGTTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1956,Drugs,MEG_1956|Drugs|betalactams|Class_C_betalactamases|CMY,gi|347364914|gb|HM046998.2|1040-2267,0
,ATGAAAAAAAGCATCCGTTTTTTTATTGTTTCGATATTGTTGAGCCCTTTTGCAAGTGCGCAGGTAAAAGATTTTGTAATAGAACCACCCATCAAAAATAACCTGCATATTTATAAAACTTTTGGAGTATTTGGTGGTAAAGAATATTCTGCAAATTCAATGTATCTGGTTACTAAAAAAGGAGTTGTTCTCTTTGATGTTCCATGGGAAAAAGTACAGTACCAAAGCCTCATGGATACCATTAAAAAACGTCATAATTTACCGGTTGTAGCGGTATTTGCCACACACTCCCATGATGACCGCGCCGGTGACCTTAGCTTTTTCAATAATAAAGGGATTAAAACATATGCAACTGCCAAAACCAACGAGTTCCTGAAAAAAGACGGAAAAGCAACATCCACAGAAATCATCAAAATCGGAAAACCGTACCGCATTGGCGGAGAAGAATTTGTGGTAGATTTTCTTGGTGAAGGGCATACTGCTGATAATGTAGTGGTATGGTTCCCTAAATACAATGTATTGGATGGTGGCTGTCTTGTAAAAAGTAATTCAGCTACTGATTTAGGATATATTAAGGAAGCCAATGTAGAACAGTGGCCCAAAACTATAAATAAATTAAAAGCCAAATATTCTAAAGCAACATTAATTATTCCGGGACATGATGAATGGAAAGGCGGTGGACATGTTGAACACACTTTAGAACTTCTGAATAAAAAATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3402,Drugs,MEG_3402|Drugs|betalactams|Class_B_betalactamases|IND,(Bla)IND-1:EF394436:1-720:720,0
,atgcgtcaatatcgattcgcccttctgccattgttagccgccctggcgctccccggttgggcgcatgaagccacggtgacgacggttaaacaagccgaaagccagctgcagggccgggtcggctacgccgaactggatttagcttccggccaactgctgtccggctattgcgctggcgaacgcttcccgatgatgagcacctttaaagtgctgctctgcggcgcagtcttgtcgcgcgtcgataccggtgaagaacagctcgatcgccgtatccattaccggcagcaggatctggtggaatactcgccggtgacggagaagcatcttgccgatgggctcaccgtgggcgaactgtgcgcggccgccattaccctgagcgataatacggcggcaaacctgctgttgaccactctcggcggcccgcaggggctgaccacgttcctgcgccacagcggcgaccagacttcgcgactcgaccggtgggaaacggaactcaatgaagcgcggccgggcgatgtgcgtgatacgacgactccggaagcgatggccaggacactgcgaaatctgttgaccggccgcgtgctttcccccgcctcgcagcagcagttgcaacgctggatggtagaggacaaagttgcggggccgctgttgcgctcagcgctgccggcgggctggtttattgccgataagaccggagccggcaaccgcggctcgcgcggaatcatcgccgctctcggtccggacggtaaagccgcgcgcatcgtggtgatttatttaaccgcaaccccggcctcaatggatgagcgcaataaacagattgcggccatcggtgaaacgctggtcaggcactggtccaaagacgataaaagaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4375,Drugs,MEG_4375|Drugs|betalactams|Class_A_betalactamases|ORN,1028105952|WP_063860933.1|NG_049388|1|1|blaORN-3|blaORN|class_A_beta-lactamase_ORN-3 NG_049388:101-976,0
,atgatcgtccgccgcctcggccccggcgacatcgccgcagtgcgcgcgctgaacgcggtctatggcgccgccttcgacgaccccgaaacctatcgcgccgaccgtcccgacgacgcatggctggcgcgccagcttggccgcgagggggtgatcgtgctggtcgccgaactggacggcaacatcgtcggcggcctcaccgcctatgagctaccgaagcttgaggcggcgcgcagcgaaatctatctctatgacctcgcggtcgatgccgcgcaccgccgctgcggtatcgccaccgcgctgatcggggagcttcaacatatcgccgccgaaaccggcgcctgggcggtgttcgtccaggccgaccatggcgacgaccccgcggttgcgttatacaccgggctcggcgcgcgcgaggatgtgatgcatttcgacctgcccccgcgaccgcgcggcgcatag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_40,Drugs,MEG_40|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,499860203|WP_011540937.1|NG_048573|1|1|aac(3)-Ii|aac(3)-I|aminoglycoside_N-acetyltransferase_AAC(3)-Ii NG_048573:101-559,2
,GTGACACAAATATTCCCTTTCCTGTTGCCGGTCAGGGTAATGCAGCGGAAAATGTGTTTTTATGCCGGGATGCGGTTTGATGGCCGCCGCTACGCGGAAACCATTGACGGGAAGCAGCTTCCTTATAAGCTCTTTGAAGCGGGCTGCGCGTTATACAACGGCAATACCGGCTTTGATATGGCGTATCAGGAAAACAAGGTGTTTAACCTGAAGCTGGCGGCAAAGACACTGAACGGCCTTTTGATAAGACCGGGCGAAACCTTTTCCTTTTGGCGTCTTGTACGCCATGCGGACAAGCATATTCCCTATAAAGACGGTCTTACGGTGACAAATGGCAAACTCACTACCGCGCCGGGCGGCGGCTTGTGTCAAATGAGCAATCTGCTGTTTTGGATGTTTCTGCACACGCCGCTGACGGTCACCGAGCGGAGCGGCCACGAGGTCAAGGAGTTTCCCGAACCAAACAGTGACGAGATCAAAGGGGTGGACGCAACAATCTCCGAGGGATGGATTGACTTAAAGGCGCGAAACGGTACCGATTGCACATATCAAATTTCAGTGGCGTTCGATGATGAAAACATCATAGGGACGGTGTTCGTGGACAAGCGGCCCCAAGTGCTGTACAGAGTTGCAAACGGCGGCATTGAGTATTCCCGCGAAAGCGGCGGGATTTATGAATCCGTCAAGGTTGAGAGAGCGGAAATTGACTCGGACACCGGCGAAATAACAGGACAAAAGCCGCTTTACACTAACAAATGTAAAATCTGCTATCCCCTGCCGGAGAACGTGGAAATCAAGGAGGCGAAAAAAGTTTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7537,Drugs,MEG_7537|Drugs|Glycopeptides|VanA-type_accessory_protein|VANWA,(Gly)VanZ-Pa:DQ018711:2047-2862:816,5
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6442,Drugs,MEG_6442|Drugs|betalactams|Class_A_betalactamases|SHV,gi|257043795|gb|GQ407139.1|1-861,0
,ATGAGCAATCCGCAATACCCGACCCGACTGCCTTGCGGCAGTCGGGTTCTTGATTTGGCCCGCCCACATGTCATGGGCATCCTCAATGTCACCCCCGATTCCTTTTCCGACGGCGGCCGTTACGACCGGCTGGACGATGCCCTGCGGCATGCCGAGCGCATGGTGCTGGAAGGCGCAACGCTCATCGACGTCGGCGGCGAGTCGACCCGTCCCGGTGCGCGCAGCGTTTCTCCGACGGAGGAGCTGGAGCGGGTCGCTCCGGTAGTCGAACGCATCGCCCGCGAACTGGACGTCGTGATTTCGGTGGATACCTCCACGCCTGCGGTCATGCGCGAAACTGCGCGTCTCGGAGCGGGTCTGATCAACGACGTCCGTTCGCTGCAGCGCGACGGTGCGTTGGATGCTGCGGTGGATAGCGGCCTGGCGGTCTGCCTCATGCACATGCGTGGAGAACCGCAGACCATGCAGGATGCGCCTGCCTACCAGGATGTGGTGGCGGAAGTCGGCGCGTTCCTGCAGGAGCGTGTGGATGCCTGCGTGGCGGCCGGAATCGACCGCGAGCGGCTGTTGCTGGATCCGGGTTTCGGTTTTGCCAAGACACTGGAGCACAACCTGGTGCTGTTCAGGCATCTGCAGGCGCTCCATGGTCTGGGCCTGCCGTTGTTGGTCGGCGTTTCGCGCAAGAGCATGATCGGCAAGGTACTGGGGCGGGAGGTGGACGAACGCCTCTACGGCAGTCTCGCGCTGGCGGCCCTGGCGCTGGCCAAGGGCGCACGGATAATTCGAGTGCATGACGTGGCGGCGACCGTCGACGTGATGCGAATGATCTCCGCCGTTGAAATGGCGGATTGA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2958,Drugs,MEG_2958|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|926451317|emb|LN871187.1|5347833-5346982 gi|553895034|gb|CP006832.1|5335767-5334916 gi|553886202|gb|CP006831.1|5336852-5336001 gi|543879514|gb|CP006705.1|5115352-5114501 gi|110227054|gb|AE004091.2|5335772-5334921,8
,atggaattgcccaatattatgcacccggtcgcgaagctgagcaccgcattagccgctgcattgatgctgagcgggtgcatgcccggtgaaatccgcccgacgattggccagcaaatggaaactggcgaccaacggtttggcgatctggttttccgccagctcgcaccgaatgtctggcagcacacttcctatctcgacatgccgggtttcggggcagtcgcttccaacggtttgatcgtcagggatggcggccgcgtgctggtggtcgataccgcctggaccgatgaccagaccgcccagatcctcaactggatcaagcaggagatcaacctgccggtcgcgctggcggtggtgactcacgcgcatcaggacaagatgggcggtatgaacgcgctgcatgcggcggggattgcgacttatgccaatgcgttgtcgaaccagcttgccccgcaagaggggctggttgcggcgcaacacagcctgactttcgccgccaatggctgggtcgaaccagcaaccgcgcccaactttggcccgctcaaggtattttaccccggccccggccacaccagtgacaatatcaccgttgggatcgacggcaccgacatcgcttttggtggctgcctgatcaaggacagcaaggccaagtcgctcggcaatctcggtgatgccgacactgagcactacgccgcgtcagtgcgcgcgtttggtgcggcgttccccaaggccagcatgatcgtgatgagccattccgcccccgatagccgcgccgcaatcactcatacggcccgcatggccgacaagctgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4136,Drugs,MEG_4136|Drugs|betalactams|Class_B_betalactamases|NDM,1226997333|WP_094009810.1|NG_055498|1|1|blaNDM-19|blaNDM|subclass_B1_metallo-beta-lactamase_NDM-19 NG_055498:1-813,0
,ATGCATACGCGGAAGGCAATAACGGAGGCGCTTCAAAAACTCGGAGTCCAAACCGGTGACCTCTTGATGGTGCATGCCTCACTTAAAGCGATTGGTCCGGTCGAAGGAGGAGCGGAGACGGTCGTTGCCGCGTTACGCTCCGCGGTTGGGCCGACTGGCACTGTGATGGGATACGCGTCGTGGGACCGATCACCCTACGAGGAGACTCTGAATGGCGCTCGGCTGGATGACGAAGCCCGCCGTACCTGGCTGCCGTTCGATCCCGCAACAGCCGGGACTTACCGTGGGTTCGGCCTGCTGAATCAATTTCTGGTTCAAGCCCCCGGCGCGCGGCGCAGCGCGCACCCCGATGCATCGATGGTCGCGGTTGGTCCGCTGGCTGAAACGCTGACGGAGCCTCACGAACTCGGTCACGCCTTGGGGGAAGGATCGCCCGTCGAGCGGTTCGTTCGCCTTGGCGGGAAGGCCCTGCTGTTGGGTGCGCCGCTAAACTCCGTTACCGCATTGCACTACGCCGAGGCGGTTGCCGATATCCCCAACAAACGGTGGGTGACGTATGAGATGCCGATGCTTGGAAGAGACGGTGAAGTCGCCTGGAAAACGGCATCGGATTACGATTCAAACGGCATTCTCGATTGCTTTGCTATCGAAGGAAAGCCGGATGCGGTTGAAACTATAGCAAATGCTTACGTGAAGCTCGGTCGCCATCGAGAAGGTGTCGTGGGCTTTGCTCAGTGCTACCTGTTCGACGCGCAGGACATCGTGACGTTCGGCGTCACCTATCTTGAGAAGCATTTCGGAACCACTCCGATCGTGCCTCCGCACGAGGCCGTCGAGCGCTCTTGCGAGCCTTCAGGTTAG,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_64,Drugs,MEG_64|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,gi|975048878|gb|CP013962.1|318833-319693 gi|971493847|gb|CP010351.1|285748-286608 gi|943457735|gb|KT818627.1|82130-82990 gi|943457735|gb|KT818627.1|143721-144581 gi|928083869|gb|CP012682.1|23040-22180 gi|926473560|gb|CP012626.1|106956-106096 gi|909636483|emb|LN850163.1|64828-65688 gi|834762928|gb|CP006642.1|54938-54078 gi|825089575|gb|KP899804.1|15903-15043 gi|821436432|gb|EU418931.1|7932-8792 gi|808175404|emb|LN833432.1|39539-40399,2
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGTCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATTACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1911,Drugs,MEG_1911|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JQ733578|+|1007-2153|ARO:3002094|CMY-81 [Citrobacter freundii] ,0
,ATTTCAGTGCCTAATGCTTTAAGTTAAGATGTATGCCAATCAATATTATGGGGTCACATACATGAAGTCTTTGTTGGTATTTGCGCTTTTAATGCCATCTGTAGTTTTTGCAAGCAGTTCAAAATTTCAATCAGTTGAACAAGAAATTAAGGGAATTGAGTCTTCACTCTCTGCTCGTATAGGAGTTGCCATTTTGGATACTCAAAATGGCGAAAGCTGGGATTATAATGGTGATCAACGATTTCCATTAACAAGTACTTTCAAAACAATAGCTTGTGCTAAGTTGCTGTATGATGCAGAGCATGGGAAAGTTAATCTCAATAGTACAGTTGAGGTTAAGAAAGCAGATCTTGTTACGTATTCGCCTGTATTAGAAAAGCAAGTAGGTAAACCAATAACGCTCTCTGATGCATGCTTTGCTACTATGACAACAAGCGACAATACAGCAGCCAATATTGTTATAAATGCTGTGGGTGATCCTAAAAGCATTACTGATTTTCTGAGACAAATTGGTGACAAAGAAACTCGTCTAGATCGTGTCGAGCCTGAGCTCAATGAAGGTAAACTCGGTGATTTGAGGGATACGACAACGCCTAATGCAATAACCAGCACGTTAAATCAATTATTATTTGGTTCCACATTATCTGAAGCTAGTCAGAAAAAATTAGAGTCTTGGATGGTGAACAATCAAGTTACGGGTAATTTATTGAGGTCAGTATTGCCAGTGACGTGGAGTATTGCTGATCGCTCAGGGGCAGGTGGATTTGGTGCTAGGAGTATTACAGCGATTGTGTGGAGTGAAGAAAAAAAACCGATTATCGTAAGTATTTATCTAGCTCAAACCGAGGCTTCAATGGCAGAACGAAATGATGCGATAGTTAAGATTGGTCGTTCAATTTTTGAAGTTTATACATCACAGTCGCGTTGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1543,Drugs,MEG_1543|Drugs|betalactams|Class_A_betalactamases|CARB,gi|42567123|gb|AY248038.1|2012-2939,0
,TTGTCAAAATAGCGGGAGTCGCAGATAGTCCGCTGCGACTTATCACTCTCAAGGAATCAGAAATGATAAAAAGTTCGTGGCGTAAAATTGCAATGCTAGCCGCCGCCGTTCCGCTGCTGCTGGCGAGCAGCGCACTGTGGGCCAGTACCGATGCTATCCATCAGAAGCTGACAGATCTCGAGAAGCGTTCAGGCGGCAGGTTGGGCGTGGCGCTAATCAACACGGCAGATAATTCTCAAATCTTATATCGCGGCGACGAGCGTTTTGCCATGTGCAGCACCAGTAAAGTGATGGCCGCCGCCGCGGTATTAAAACAGAGCGAAAGCAATAAAGAGGTGGTAAATAAAAGGCTGGAGATTAACGCAGCCGATTTGGTGGTCTGGAGTCCGATTACCGAAAAACATCTCCAGAGCGGAATGACGCTGGCTGAGCTAAGCGCGGCGACGCTGCAATATAGCGACAATACGGCGATGAATCTGATCATCGGCTACCTTGGCGGGCCGGAAAAAGTCACCGCCTTCGCCCGCAGTATCGGCGATGCCACCTTTCGTCTCGATCGTACGGAGCCCACGCTGAATACCGCCATCCCGGGCGATGAGCGTGATACCAGCACGCCGCTGGCGATGGCTGAAAGCCTACGCAAGCTGACGCTTGGCGATGCGCTGGGCGAACAGCAACGCGCCCAGTTAGTCACCTGGCTGAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCGGGCCTGCCTGAAAGCTGGGTGGTCGGCGATAAAACCGGCGCCGGAGATTACGGCACCACCAATGATATTGCGGTTATCTGGCCGGAAGATCACGCTCCGCTGGTATTAGTCACCTACTTTACCCAGCCGCAGCAGGATGCGAAAAACCGCAAAGAGGTGTTAGCCGCAGCGGCAAAAATCGTGACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5316,Drugs,MEG_5316|Drugs|betalactams|Class_A_betalactamases|OXY,gi|32130554|gb|AY077485.2|122-1056,0
,atgaaaacatttgccgcatatgtaattatcgcgtgtctttcgagtacggcattagctggttcaattacagaaaatacgtcttggaacaaagagttctctgccgaagccgtcaatggtgtcttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaatgacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaagcaatgggaaagagacttgaccttaagaggggcaatacaagtttcagctgttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcctatggcaaccagaatatcagtggtggcattgacaaattcgggttggaaggccagcttagaatttccgcagttaatcaagtggagtttctagagtctctatatttaaataaattgtcagcatctaaagaaaaccagctaatagtaaaagaggctttggtaacggaggcggcacctgaatatctagtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttgggtgggttgagaaggagacagaggtttactttttcgcctttaacatggatatagacaacgaaagtaagttgccgctaagaaaatccattcccaccaaaatcatggaaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4419,Drugs,MEG_4419|Drugs|betalactams|Class_D_betalactamases|OXA,1040941160|WP_065159014.1|NG_050979|1|1|blaOXA-520|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-520 NG_050979:1-801,0
,atgaatattatgccgatatctgaatcacaattatcagattggctagcattaagaagcttactctggcctgatcatgacgatgcgcatttattggaaatgcatcagctacttaaacaaacagatactttacaattattggcttataccgatagccaacaagcaattgcaatgttagaagcatcgattcggcatgaatatgtgaatggtacgcaaacctcacccgttgcttttcttgaagggatttatgtattacctgaatatcgacgttcaggtatcgcgacccagttagttcagtacgtagaggagtgggcgaaacaatttgcatgtactgagttcgcttcagatgcagcgattgacaatacgattagccatgcaatgcatcgagcactgggttttcacgaaactgaacgtgtggtgtattttaagaaaaatatcggctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_79,Drugs,MEG_79|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491326234|WP_005184197.1|NG_052401|1|1|aacA-ACI6|aacA-ACI6|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052401:101-541,2
,atggacgagagggaactgatcgagcgcgccgacggccccgtcacccgctgccgcctcgtgcgcgacctgaaggaactgggcgtcggccccggcgacaccgtcatggtgcacacccgcatgtccgccgtcggatacgtcgtcggcggcacacagacgctgatcggggcgctcctcaacgccgtcggcgacaccggcacgctcatggcgtactgcggctggaacgacgccccgccctacgacctcgccgactggccgccggagtggcgggacgcggcacgggccgcgtggcccgcgtacgacacgcggttcagcgaggccgaccacggcgtcggccgggtccccgaggcgctgcgccactggccgggcgccgtgcgcagccggcaccccgacgccagcttcgtcgccgtcgggcccgccgcccatcggctgatggacgaccacccgtgggacgacccgcacggcccggacagcccgctcggtcggctcacccgggacggcggccgggtgctgctcctcggcgcgccgctggacgcgctgacgctgctacaccacgcggaggcgctggccgaggcgcccggcaagcggtatgtggagtacgagcagcccatcacggtcgacgggcgccgggtgtggcggcgcttccgggatgtcgacacgcagacggaggcgttcccgtacgggagggtggtgcccgagggcgtatggccgttcacggtcatggccgaggagatgctggccgccgggatcgggcgcaccgggcgcgtgggcgccgctccgagccatctcttcgaggccccggacgtggtccggttcggtgtcgagtggatcgagagcaggctcggggaggcggccgacggctcctga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_23,Drugs,MEG_23|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,1028080888|WP_063840271.1|NG_047260|1|1|aac(3)-VIII|aac(3)-VIII|aminoglycoside_N-acetyltransferase_AAC(3)-VIII NG_047260:101-964,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccgacggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5602,Drugs,MEG_5602|Drugs|betalactams|Class_C_betalactamases|PDC,1393270459|WP_109791204.1|NG_057603|1|1|blaPDC-272|blaPDC|class_C_beta-lactamase_PDC-272 NG_057603:1-1194,0
,atgatcatcagtgaatttgatcgtagaaatattggtttgaaggatcagctagctgaccttttgcgattgacttggccgaaggattacggcgaacaaccaatgaaagaagtcgagcaactactagcgacggatcgaatcgccgtctcagcggttgaacaagatcgtttggttggttttatcggtgcgattccgcaatatggaatgactggttgggaaattcaccctctagtagtagaaacttcttatcgaaagcagtatgtcggtagccgcttagttgactatttggagaaagaaatcacctctaaaggtggtgtgacggtttacttaggaacagatgatatggatggagacacaagtcttagtcatacagatctttttgatcatccattagataaactgaaatcaatcgaaaccatcaacaagcatccttatacattttatgaaaaaatgggttatcaagtcgttggagtgattcctgatgcaaatgggatcaatcaaccagatatcattctggcaaaacggcttggagaaatgaatcaatga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_92,Drugs,MEG_92|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,736683039|WP_034688908.1|NG_052177|1|1|aacA-ENT4|aacA-ENT4|aminoglycoside_6'-N-acetyltransferase NG_052177:101-643,2
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGAACAGCCAACGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAACAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_6448,Drugs,MEG_6448|Drugs|betalactams|Class_A_betalactamases|SHV,gi|28912444|gb|AY210887.1|112-980,0
,ATGCTGCCTACAATGTCCGCCATGACCTACAGCGAACCAGCGCGATCAGAGGCAAGTCGCTCCCGATCGCTGGCGTCCGCGCCCTCCTCGGCCGACGAGGCAAGGGGAATCACGATTTATGGCTGCGGTCAGGACGAGGCCGTCCTCTTCAAGGAGATGGCGCCTCGCTTCGGCATAATGCCGACCATCGCGGAAGCGCCGGTATCCGAAGCCACTATCGAATTGGCGTCAGGTAACCGATGCATCAGTGTCGGTCATAAGACTCCGATCTCGAACTCCATTCTCCTCGCGCTCCGTGAGGCGGGTGTGGAGTACATCTCCACGAGGAGCATCGGGTTCAATCACATCGACGTGAAATACGCCGAGAGCATCGGCATCACCGTCGGTAACGTCGCCTACTCGCCGGACAGCGTCGCGGACTTCACGCTGATGCTGATGCTGATGGTGATACGCGACGCCAAATCCATCATCCGCCGCACGGAAGTCCATGACTACCGGCTGAACGCCGTACGCGGGAAAGAACTGCGCGACCTGACCGTCGGGGTGGTCGGAACAGGGCGCATCGGTGTCGCGGTCATGGACAGGTTGAAGGGCTTCGGCTGCCGGGTGCTGGCCTATGACACGATCCCCAACGCCTCCGCCGATTACGTCCCCCTCGACGATTTGCTGCAGCAGAGCGATATCGTGACACTTCACGTGCCACTCAACACGGACACGTATCACCTCCTCGATCGTCGGAACATCGAGGAGATGAAGGGTGGCGCGTACATCATCAACACCGGGCGCGGTCCACTCATCGAAACCGAGGCCCTCATCTCGGCCCTGGAAAGCGGAAACCTCGGCGGAGCGGCGCTGGACGTCCTCGAAGGAGAGGAAGGGATCTTCTACGCCGACTGCCGGGACAAGGCAATCGACGGCAACAAGCCGTTGCTGCGGCTGCAGGAGCTGTCGAACGTGATCATCAGTCCGCATACCGCCTATTACACGGACCACGCTCTGAGCGACACTGTTGAAAACTCCATCATCAATTGCCTCGAATTCGAAAGCGGGAAGTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7404,Drugs,MEG_7404|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,(Gly)VanH:DQ246438:124-1179:1056;(Gly)VanH-Ac1:DQ246438:124-1179:1056,5
,atggaattgcccaatattatgcacccggtcgcgaagctgagcaccgcattagccgctgcattgatgctgagcgggtgcatgcccggtgaaatccgcccgacgattggccagcaaatggaaactggcgaccaacggtttggcgaccaacggtttggcgatctggttttccgccagctcgcaccgaatgtctggcagcacacttcctatctcgacatgccgggtttcggggcagtcgcttccaacggtttgatcgtcagggatggcggccgcgtgctggtggtcgataccgcctggaccgatgaccagaccgcccagatcctcaactggatcaagcaggagatcaacctgccggtcgcgctggcggtggtgactcacgcgcatcaggacaagatgggcggtatggacgcgctgcatgcggcggggattgcgacttatgccaatgcgttgtcgaaccagcttgccccgcaagaggggatggttgcggcgcaacacagcctgactttcgccgccaatggctgggtcgaaccagcaaccgcgcccaactttggcccgctcaaggtattttaccccggccccggccacaccagtgacaatatcaccgttgggatcgacggcaccgacatcgcttttggtggctgcctgatcaaggacagcaaggccaagtcgctcggcaatctcggtgatgccgacactgagcactacgccgcgtcagcgcgcgcgtttggtgcggcgttccccaaggccagcatgatcgtgatgagccattccgcccccgatagccgcgccgcaatcactcatacggcccgcatggccgacaagctgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4133,Drugs,MEG_4133|Drugs|betalactams|Class_B_betalactamases|NDM,1142971254|WP_077064890.1|NG_052866|1|1|blaNDM-18|blaNDM|subclass_B1_metallo-beta-lactamase_NDM-18 NG_052866:1-828,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagcgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagtacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3479,Drugs,MEG_3479|Drugs|betalactams|Class_A_betalactamases|KPC,1408841638|WP_111672911.1|NG_060569|1|1|blaKPC-23|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-23 NG_060569:1-882,0
,ATGAGCGATATGGCAGAGCGCCTTGCGCTACATGAATTTACGGAAAACGCCTACTTAAACTACTCCATGTACGTGATCATGGACCGTGCGTTGCCGTTTATTGGTGATGGTCTGAAACCTGTTCAGCGCCGCATTGTGTATGCGATGTCTGAACTGGGCCTGAATGCCAGCGCCAAATTTAAAAAATCGGCCCGTACCGTCGGTGACGTACTGGGTAAATACCATCCGCACGGCGATAGCGCCTGTTATGAAGCGATGGTCCTGATGGCGCAGCCGTTCTCTTACCGTTATCCGCTGGTTGATGGTCAGGGGAACTGGGGCGCGCCGGACGATCCGAAATCGTTCGCGGCAATGCGTTACACCGAATCCCGGTTGTCGAAATATTCCGAGCTGCTATTGAGCGAGCTGGGGCAGGGGACGGCTGACTGGGTACCAAACTTCGACGGCACTTTGCAGGAGCCGAAAATGCTACCTGCCCGTCTGCCAAACATTTTGCTTAACGGCACCACCGGTATTGCCGTCGGCATGGCGACCGATATTCCACCACATAACCTGCGTGAAGTGGCTCAGGCGGCAATCGCATTAATCGACCAGCCGAAAACCACGCTCGATCAGCTGCTGGATATCGTGCAGGGGCCGGATTATCCGACTGAAGCGGAAATTATCACTTCGCGCGCCGAGATCCGTAAAATCTACGAGAACGGACGTGGTTCAGTGCGTATGCGCGCGGTGTGGAAGAAAGAAGATGGCGCGGTGGTTATCAGCGCATTGCCGCATCAGGTTTCAGGTGCGCGCGTACTGGAGCAAATTGCTGCGCAAATGCGCAACAAAAAGCTGCCGATGGTTGACGATCTGCGCGATGAATCTGACCACGAGAACCCGACCCGTCTGGTGATTGTGCCGCGTTCCAACCGCGTGGATATGGATCAGGTGATGAACCACCTCTTCGCTACCACCGATCTGGAAAAGAGCTATCGTATTAACCTTAATATGATCGGTCTGGATGGTCGTCCGGCGGTGAAAAACCTGCTGGAAATCCTCTCCGAATGGCTGGTGTTCCGCCGCGATACCGTGCGCCGCCGACTGAACTATCGTCTGGAGAAAGTCCTCAAGCGCCTGCATATCCTCGAAGGTTTGCTGGTGGCGTTTCTCAATATCGACGAATTGATTGAGATCATTCGTAATGAAGATGAACCGAAACCGGCGCTGATGTCGCGGTTTGGCCTTACGGAAACCCAGGCGGAAGCGATCCTCGAACTGAAACTGCGTCATCTTGCCAAACTGGAAGAGATGAAGATTCGCTGTGAGCAGAGTGAGCTGGAAAAAGAGCGCGACCAGTTGCAGGGCATTTTGGCTTCCGAGCGTAAAATGAATAACCTGCTGAAGAAAGAACTGCAGGCAGACGCGCAAGCCTACGGTGACGATCGTCGTTCGCCGTTGCAGGAACGCGAAGAAGCGAAAGCGATGAGCGAGCACGACATGCTGCCGTCTGAACCTGTCACCATTGTGCTGTCGCAGATGGGCTGGGTACGCAGCGCTAAAGGCCATGATATCGACGCGCCGGGCCTGAATTATAAAGCGGGTGATAGTTTCAAAGCGGCGGTGAAAGGTAAGAGCAACCAACCGGTAGTGTTTGTTGATTCCACCGGTCGTAGCTATGCCATCGACCCGATTACGCTGCCGTCGGCGCGTGGTCAGGGCGAACCGCTCACCGGCAAATTAACGTTGCCGCCTGGGGCGACCGTTGACCATATACTGATGGAAAGCGACGATCAGAAACTGCTGATGGCTTCCGATGCGGGTTACGGTTTCGTCTGCACCTTTAACGATCTGGTGGCGCGTAACCGTGCAGGTAAGGCTTTGATAACCTTACCGGAAAATGCCCATGTTATGCCGCCGGTGGTGATTGAAGATGCTTCCGACATGCTGCTGGCAATCACTCAGGCAGGCCGTATGTTGATGTTCCCGGTAAGTGATCTGCCGCAGCTGTCGAAGGGCAAAGGCAACAAGATTATCAACATTCCATCGGCAGAAGCCGCGCGTGGCGAGGATGGTCTGGCGCAACTGTACGTTCTGCCGTCGCAAAGCACGCTGACCATTCATGTTGGGAAACGCAAAATTAAACTGCGTCCGGAAGAGCTACAGAAAGTCACTGGCGAACGTGGACGCCGCGGTACGTTGATGCGCGGTTTGCAGCGTATCGATCGTGTTGAGATCGACTCTCCTCGCCGTGCCAGCAGCGGTGATAGCGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5348,Drugs,MEG_5348|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|558570689|gb|CP006736.1|2931686-2933944 gi|81239530|gb|CP000034.1|2980057-2982315,3
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccggcaccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_228,Drugs,MEG_228|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1028080900|WP_063840283.1|NG_047286|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_047286:52-606,2
,atgatgacaaaatccctaagctgtgccctgctgctcagcgtcgccagttctgcattcgccgcaccgatgtccgaaaaacagctggctgaggtggtggaacgtaccgttacgccgctgatgaacgcgcaggccattccgggtatggcggtggcggtaatttatcagggtcagccacactactttaccttcggtaaagccgatgttgcggcgaacaaacccgtcaccccgcaaaccctgtttgagctgggctctataagtaaaaccttcaccggcgtactgggcggcgatgccattgcccggggtgaaatagcgctgggcgatccggtagcaaaatactggcctgagctcacgggcaagcagtggcagggcattcgcatgctggatctggcaacctataccgcaggcggtctgccgttacaggtgccggatgaggtcacggataccgcctctctgctgcgcttttatcaaaactggcagccgcagtggaagccgggcaccacgcgtctttacgctaacgccagcatcggtctttttggtgcgctggcggtcaaaccttccggcatgagctatgagcaggccatgacgacgcgggtctttaaacccctcaagctggaccatacctggattaacgtcccgaaagcggaagaggcgcattacgcctggggataccgtgagggtaaagcggtccacgtttcgccagggatgctggacgcggaagcctatggcgtaaaaactaacgtgaaggatatggcgagctggctgatagccaacatgaagccggattctcttcaggctccctcactcaagcaaggcattgctctggcgcagtctcgctactggtgcgtgggggctatgtatcaggggttgggctgggagatgctcaactggccggtcgatgccaaaaccgtcgtcggaggcagtgataacaaggtggcgctggcaccattgcccgtggcagaagtgaatccacccgcgccgccggtcaaggcctcctgggtccataaaacaggctcgacgggcgggtttggcagctacgtggcatttattcctgaaaagcagctcggcattgtgatgctggcgaataaaagctatccgaacccggcacgcgttgaggcggcataccgtatcctcgacgcgctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3954,Drugs,MEG_3954|Drugs|betalactams|Class_C_betalactamases|MIR,779866371|WP_045354584.1|NG_050721|1|1|blaMIR-19|blaMIR|cephalosporin-hydrolyzing_class_C_beta-lactamase_MIR-19 NG_050721:1-1146,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1321,Drugs,MEG_1321|Drugs|betalactams|Class_A_betalactamases|BLAZ,(Bla)BlaZ:AB245469:2235-3080:861,0
,ATGAAAAAATTAATCATCGCCATCGTGATAGTAATCATCGCTGTTGGTTCAGGCGTATTCTTTTATGCATCTAAAGATAAGAAAATAAACGAAACAATTGATGCCATTGAAGATAAAAACGTTAAGCAAGTCTTCAAAAATAGTACTTACCAATCTAAAAACGATAATGGTGAAGTAGAAATGACAGACCGTCCTATTAAGATTTATGACAGTCTCGGCGTCAAAGATATCAACATTAAAGATCGTGATATCAAAAAGGTTTCAAAAGACAAAAAGCAAGTCACAGCAAAATATGAACTTCAAACGAATTACGGCAAAATTAATCGCGACGTTAAATTAAACTTTATTAAAGAAGATAAAGATTGGAAATTGGATTGGAATCAAAGTGTCATTATTCCAGGCATGAAGAAAAATCAATCTATCAATATTGAACCATTGAAATCAGAACGAGGTAAGATTTTAGACCGAAACAATGTAGAGTTAGCCACTACAGGAACAGCACATGAAGTTGGCATTGTTCCTAATAATGTTTCGTCAAATGATTATAAAGCAATCGCTGAAAAATTAGACCTTTCAGAATCGTACATTAAACAACAAACAGAACAGGACTGGGTTAAAGATGATACATTCGTCCCTCTTAAGACTGTTCAAAATATGAATCAAGATACAAAGAATTTTGTTGAGAAGTATCATCTCACAACACAAGAAACAGAAAGTCGACAGTATCCGCTTGAAGAAGCAACAACGCACTTGCTTGGTTATGTTGGCCCTATTAACTCAGAAGAATTAAAGCAAAAAGCATTTAAAGGTTATAAAAAAGATGCCATCGTCGGTAAAAAAGGGATCGAAAAACTTTACGATAAAGAACTTCAAAATAAAGACGGGTATCGTGTCACAATTATTGATGATAATAATAAAGTGATAGATACATTGATTAAGAAAAAGAAAAAAGATGGCAAAGATATTAAATTAACCATTGATGCCAGAGTTCAAAAAAGTATTTATAACAACATGAAAGATGACTACGGTTCAGGGACTGCTATTCATCCACAAACAGGCGAATTGTTAGCACTTGTCAGCACGCCATCTTATGATGTTTATCCATTTATGAACGGTATGAGCGATGAAGATTATAAGAAATTAACAGAAGATGATAAAGAGCCACTTCTTAATAAGTTCCAAATCACGACATCACCAGGTTCTACTCAAAAAATATTAACAGCTATGATTGGCTTAAATAATAAGACGTTAGACGACAAAACAAGTTATAAAATTAACGGAAAAGGCTGGCAAAAAGATAAATCTTGGGGTGATTACAACGTCACAAGATATGAAGTTGTTAATGGTGATATCGACTTAAAACAAGCTATTGAATCATCGGATAATATCTTCTTTGCGAGAGTTGCACTTGAATTAGGAAGTAAAAAATTCGAAGAAGGTATGAAACGTCTAGGTGTTGGTGAAGATATCCCGAGTGATTATCCATTCTATAATGCACAAATTTCAAATAAGAACTTAGATAATGAAATATTGTTAGCTGACTCAGGTTATGGCCAAGGTGAAATATTGATTAATCCAGTTCAAATTCTTTCAATATACAGTGCATTAGAGAATAAAGGTAATGTGAATGCACCACATGTACTGAAAGATACGAAAAATAAAGTCTGGAAGAAGAATATCATTTCCCAGGAAAATATTAAATTGTTAACAGACGGTATGCAACAAGTCGTCAACAAAACACATAGAGAAGATATTTATAGATCATATGCCAACTTAGTTGGTAAATCAGGTACAGCTGAACTCAAGATGAAACAAGGTGAGACAGGACAACAAATAGGCTGGTTCATTTCATATGATAAAGATAATCCAAATATGATGATGGCTATTAATGTGAAAGATGTTCAAGATAAAGGTATGGCAAGTTACAATGCCAAAATATCAGGAAAAGTGTATGACGATTTATATGATAACGGCAAGAAAACGTATCGTATTGATAAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3790,Drugs,MEG_3790|Drugs|betalactams|Penicillin_binding_protein|MECA,mecA1_1_AB547235,0
,ATGAGCGATATGGCAGAGCGCCTTGCGCTACATGAATTTACGGAAAACGCCTACTTAAACTACTCCATGTACGTGATCATGGATCGTGCGTTGCCGTTTATTGGCGACGGCCTGAAGCCGGTACAGCGCCGCATCGTCTATGCGATGTCAGAGCTGGGGCTGAACGCCACCGCTAAATTTAAAAAATCCGCCCGTACCGTTGGTGACGTACTGGGTAAGTATCACCCGCATGGCGACAGCGCCTGCTATGAAGCCATGGTGCTGATGGCGCAGCCGTTCTCTTACCGTTACCCGCTGGTCGATGGCCAGGGGAACTGGGGCGCGCCGGATGATCCGAAGTCATTCGCGGCGATGCGTTATACCGAATCCCGCCTGTCCAAATACGCCGAGCTGCTGTTAAGCGAACTCGGTCAGGGGACGGCGGACTGGGTGCCAAACTTCGACGGCACCATGCAGGAACCGAAAATGTTACCGGCGCGTCTGCCGAACATCCTGCTGAACGGCACCACCGGTATTGCGGTGGGCATGGCAACAGATATCCCGCCGCACAACCTGCGCGAAGTGGCGAAAGCGGCGATTACGCTGATTGAGCAGCCGAAAACGACGCTGGATCAGTTGCTGGATATCGTTCAGGGGCCGGATTACCCGACCGAAGCGGAGATCATTACCCCACGTGCGGAAATTCGTAAAATTTACGAAAACGGGCGGGGCTCCGTGCGTATGCGCGCGGTATGGACCAAAGAAGACGGCGCTGTGGTAATTTCCGCGCTGCCGCATCAGGTCTCTGGCGCGAAAGTGCTGGAGCAGATTGCTGCGCAGATGCGTAATAAAAAACTGCCGATGGTGGACGATCTGCGCGATGAATCGGATCACGAAAACCCGACGCGTTTAGTGATTGTGCCACGCTCCAACCGTGTGGATATGGAACAGGTGATGAACCATCTGTTCGCCACCACCGATCTGGAAAAAAGCTACCGTATTAACCTGAACATGATCGGTCTGGATGGTCGTCCGGCGGTGAAAAACCTGCTGGAGATCCTCACCGAGTGGCTGGCGTTCCGCCGCGACACGGTGCGCCGTCGTCTGAACTATCGTCTGGAGAAAGTGCTTAAGCGCCTGCATATCCTCGAAGGTTTGCTGGTGGCGTTTCTCAACATCGACGAAGTGATTGAGATTATCCGTAGCGAAGACGAGCCAAAACCCGCGCTGATGTCGCGTTTCGGCATCAGCGAAACCCAGGCGGAAGCGATTCTCGAACTGAAACTGCGCCATCTCGCCAAACTGGAAGAGATGAAAATTCGCGGCGAGCAGGACGAGCTGGAAAAAGAGAGGGACCAGTTGCAGGGCATTCTCGCGTCCGAACGCAAAATGAATACCTTGCTGAAAAAAGAACTACAGGCGGACGCCGATGCCTATGGCGACGATCGCCGTTCTCCGCTGCGTGAGCGCGAAGAAGCTAAAGCGATGAGCGAACACGATATGCTGCCGTCCGAACCGGTGACTATCGTGCTGTCGCAGATGGGCTGGGTGCGCAGCGCCAAAGGTCATGATATTGATGCGCCGGGGCTTAACTATAAAGCGGGCGACAGCTTTAAAGCCGCGGTGAAAGGTAAGAGCAATCAACCGGTGGTGTTTATTGATACCACCGGGCGCAGCTATGCTATTGATCCCATTACGCTTCCGTCGGCGCGTGGGCAGGGCGAGCCGCTGACCGGCAAACTCACGCTGCCGCCGGGGGCGACCGTAGAGCATATGCTGATGGAAGGCGATGACCAGAAACTGCTGATGGCGTCGGATGCGGGCTACGGCTTCGTTTGTACGTTTAACGATCTGGTTGCCCGTAACCGTGCCGGTAAGACATTGATTACACTGCCGGAAAATGCGCACGTCATGCCGCCGCTGGTGATTGAAGACGAGCACGATATGCTGCTGGCGATTACCCAGGCCGGACGGATGTTGATGTTCCCGGTAGACTCTCTGCCGCAGCTGTCGAAAGGCAAAGGGAATAAGATCATTAATATCCCCTCTGCAGAAGCGGCGAAAGGCGATGATGGACTGGCGCACCTGTACGTGCTGCCGCCACAAAGCACTCTGACTATCCATGTCGGGAAGCGCAAAATCAAACTGCGCCCTGAAGAGTTACAAAAGGTGGTCGGTGAACGCGGACGCCGTGGCACATTAATGCGCGGCCTGCAGCGTATCGATCGCATTGAGATTGATTCGCCGCATCGCGTAAGTCATGGCGACAGCGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5361,Drugs,MEG_5361|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|973795115|gb|AE006468.2|3339212-3336954 gi|808186398|gb|CP007523.1|4023443-4021185 gi|777181114|emb|LN829402.1|678255-680513 gi|764057510|gb|CP007235.1|4110891-4108633 gi|674281104|gb|CP009102.1|3275107-3272849 gi|669110799|gb|CP007804.2|3250748-3248490 gi|661245796|dbj|AP014565.1|3471173-3468915 gi|618631222|gb|CP007581.1|3372468-3370210 gi|545006446|emb|HF937208.1|3372464-3370206 gi|523821078|gb|CP006602.1|4592941-4590683,3
,ATGCGCCCTCTCCTCTTCAGCGCCCTTCTCCTGCTCTCCGGGCATGCCCAGGCCAGCGAATGGAACGACAGCCGGGCCGTGGACAAGCTATTCGGAGCGGCCGGTGTGAAAGGCACCTTCGTCCTTTACGATGTGCAGCGGCAGCGCTATGTCGGCCATGACCGGGAGCGCGCGGAAACCCGCTTCGTTCCCGCTTCCACCTACAAGGTGGCGAACAGCCTGATCGGCTTATCCACAGGGGCGGTTAGATCCGCCGACGAGGTTCTTCCCTATGGCGGCAAACCCCAGCGCTTCAAGGCCTGGGAGCACGACATGAGCCTGCGCGACGCGATCAAGGCATCGAACGTACCGGTCTACCAGGAACTGGCGCGGCGCATCGGCCTGGAGCGGATGCGCGCCAATGTCTCGCGCCTGGGTTACGGCAACGCGGAAATCGGCCAGGTTGTGGATAACTTCTGGTTGGTGGGACCGCTGAAGATCAGCGCGATGGAGCAGACCCGCTTTCTGCTCCGACTGGCGCAGGGAGAATTGCCATTCCCCGCCCCGGTGCAGTCCACCGTGCGCGCCATGACCCTGCTGGAAAGCGGCCCGGGCTGGGAGCTGCACGGCAAGACCGGCTGGTGCTTCGACTGCACGCCGGAACTCGGCTGGTGGGTGGGCTGGGTGAAGCGCAACGAGCGGCTCTACGGCTTCGCCCTGAACATCGACATGCCCGGCGGCGAGGCCGACATCGGCAAGCGCGTCGAACTGGGCAAGGCCAGTCTCAAGGCTCTCGGGATACTGCCCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5179,Drugs,MEG_5179|Drugs|betalactams|Class_D_betalactamases|OXA,AAQ76279.1 AY306132.1:1-789,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1427,Drugs,MEG_1427|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_134_NZ_AJGE01000047,0
,AGGATGTATTGTGGTTATGCGTATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAATTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGTAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAGGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGGATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6417,Drugs,MEG_6417|Drugs|betalactams|Class_A_betalactamases|SHV,gi|160948436|emb|AM176548.2|1-874,0
,atgaattttacccggattgacctgaatacctggaatcgcagggaacactttgccttctatcgtcagcagattaaatgcggattcagcctgaccaccaaactcgatattaccgctttgcgtaccgcactggcggagacaggttataagttttatccgctgatgatttacctgatctcccgggctgttaatcagtttccggagttccggatggcactgaaagacaatgaacttatttactgggaccagtcagacccggtctttactgtctttcataaagaaaccgaaacattctctgcactgtcctgccgttattttccggatctcagtgagtttatggcaggttataatgcggtaacggcagaatatcagcatgataccagattgtttccgcagggaaatttaccggagaatcacctgaatatatcatcattaccgtgggtgagttttgacggatttaacctgaacatcaccggaaatgatgattattttgccccggtttttacgatggcaaagtttcagcaggaaggtgaccgcgtattattacctgtttctgtacaggttcatcatgcagtctgtgatggctttcatgcagcacggtttattaatacacttcagctgatgtgtgataacatactgaaataa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1567,Drugs,MEG_1567|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,695268618|WP_032490795.1|NG_047595|1|1|catA2|catA2|type_A-2_chloramphenicol_O-acetyltransferase_CatII NG_047595:101-742,6
,ATGAAAAAGATAAAAATTGTTCCACTTATTTTAATAGTTGTAGTTGTCGGGTTTGGTATATATTTTTATGCTTCAAAAGATAAAGAAATTAATAAAACTATTGATGCAATTGAAGATAAAAATTTCAAACAAGTTTATAAAGATAGCAGTTATATTTCCAAAAGCGATAATGGTGAAGTAGAAATGACTGAACGTCCGATAAAAATATATAAAAGTTTAGGCGTTAAAGATATAAACATTCAAGAACGCAAAATAAAAAAAATATCTAAAAATAAAAAACGAGTAGATGCTCAATATAAAATTAAAACAAACTACGGTAACATTGATCGCAACGTTCAATTTAATTTTGTTAAAGAAGATGGCATGTGGAAGTTAGATTGGGATCATAGCGTCATTATTCCAGGAATGCAGAAAGACCAAAGCATACATATTGAAAATTTAAAATCAGAACGTGGTAAAATTTTAGACCGAAACAATGTGGAATTGGCCAATACAGGAACAGCATATGAGATAGGCATCGTTCCAAAGAATGTATCTAAAAAAGATTATAAAGCAATCGCTAAAGAACTAAGTATTTCTGAAGACTATATTAAACAACAAATGGATCAAAATTGGGTACAAGATGATACCTTCGTTCCACTTAAAACCGTTAAAAAAATGGATGAAGATTTAAGTGATTTCGCAAAAAAATTTCATCTTACAACTAATGAAACAGAAAGTCGTAACTATCCTCTAGAAGAAGCGACTTCACATCTATTAGGTTATGTTGGTCCCATTAACTCTGAAGAATTAAAACAAAAAGAATATAAAGGTTATAAAGATGATGCAGTTGTTGGTAAAAAGGGACTCGAAAAACTTTACGATAAAAAGCTCCAACATGAAGATGGCTATCGTGTCACAATCGTTGACGATAATAGCAATACAATCGCACATACATTAATAGAGAAAAAGAAAAAAGATGGCAAAGATATTCAACTAACTATTGATGCTAAAGTTCAAAAGAGTATTTATAACAACATGAAAAATGATTATGGCTCAGGTACTGCTATCCACCCTCAAACAGGTGAATTGTTAGCACTTGTAAGCACACCTTCATATGACGTGTATCCATTTATGTATGGTATGAGTAACGAAGAATATAATAAATTAACCGAAGATAAAAAAGAACCTCTGCTCAACAAGTTCCAGATTACAACTTCACCAGGTTCAACTCAAAAAATATTAACAGCAATGATTGGGTTAAATAACAAAACATTAGACGATAAAACAAGTTATAAAATCGATGGTAAAGGTTGGCAAAAAGATAAATCTTGGGGTGGTTACAACGTTACAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCAGATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAAGATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTACGGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCACCTCACTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGCATGCAACAAGTCGTAAATAAAACACATAAAAAAGATATTTATAGACCTTACGCAAACTTAATTGGCAAATCCGGTACTGCAGAACTCAAAATGAAACAAGGAGAAACTGGCAGACAAATTGGGTGGTTTATATCATATGATAAAGATAATCCAAACATGATGATGGCTATTAATGTTAAAGATGTACAAGATAAAGGAATGGCTAGCTACAATGCCAAAATCTCAGGTAAAGTGTATGATGAGCTATATGAGAACGGTAATAAAAAATACGATATAGATGAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3793,Drugs,MEG_3793|Drugs|betalactams|Penicillin_binding_protein|MECA,mecA_7_HE861945,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGAGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1854,Drugs,MEG_1854|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AJ011291|+|0-1146|ARO:3002018|CMY-7 [Escherichia coli] ,0
,CTGTTTTCGTTCATTCAAGTTCATAAGGGAATGGCAATGAAACTCTTCGCTCAGGGCTCAACGCTCGAACTTTCTCATCCGCATGTCATGGGGATCCTGAATGTCACGCCGGATTCTTTTTCCGATGGTGGCCAGCACAACACGCTGACAGAGGCGGTAAAACACGCCAATGCGATGATTAACGCTGGTGCGACCATCATTGACGTAGGCGGAGAATCGACGCGCCCTGGCGCGGCGGAAGTGAGTGTGGAAGAAGAGCTTTCCCGCGTGGTGCCGGTGGTGGAAGCGCTGGCGCAGCGTTTTGAGGTCTGGGTGTCGGTCGATACGTCTAAACCAGAAGTGATCCGCGAGTCGGCGCGGGTCGGCGCGCATATCATCAACGATATTCGCTCGCTGACGGAGCCTGGTGCGCTTGAGGCGGCGGCAGAGACCGGTTTGCCGGTGTGTCTGATGCATATGCAGGGCCAGCCGAAAACGATGCAGCAGGCGCCGCACTATGAAGATGTTTTTGCCGACGTCACGCGTTTTTTTGAGCAACAGATCGCCCGCTGCGAAGCGGCAGGCATTACAAAAGAAAAAATCATACTCGACCCGGGATTCGGTTTCGGTAAAAATCTGACCCACAATTACCAGCTTCTCGCCCGGCTTTCAGAATTCCAGCGTTTCGAAATGCCTTTGCTGGTGGGAATGTCGCGTAAGTCGATGATTGGACAACTACTTAATGTCGGGCCCGATCAGCGTCTGCCCGGAAGCCTTGCCTGCGCGGTGATGGCGGCCATGCAGGGGGCGCAGATTATTCGGGTTCATGACGTCAAAGAAACCGTCGAAGCGATGCGCGTGGTGGAAGCAACTCTTTCAGCGAAGGATAAAAAATGTTATGAGTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2944,Drugs,MEG_2944|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|323575285|emb|FN543093.2|449844-450728,8
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacaacaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1821,Drugs,MEG_1821|Drugs|betalactams|Class_C_betalactamases|CMY,1040476795|WP_065102238.1|NG_050943|1|1|blaCMY-140|blaCMY|class_C_beta-lactamase_CMY-140 NG_050943:1-1146,0
,atgtctgcatacggacacggccgtcacgagcatggccaaaattttctcaccaaccacaagatcatcaactccatcatcgaccttgtgaaacaaacctccggccccatcattgagatcggaccaggaagcggtgccctcactcacccgatggcccacttggggagggcgataacggcagttgaagtggacgcaaaactagctgccaaaatcacacaagaaacctcctcggcggcggtcgaagtggtccatgatgatttccttaacttccggttacccgccactccctgcgtcattgtgggaaacattccctttcacctcaccactgccattcttcgaaagttgctgcatgcgccagcatggactgacgctgtactcctcatgcagtgggaagtcgctcgccgccgggccggggtaggcgcaagcacgatgatgacggctcagtggtccccatggttcacatttcacctgggttctcgggtaccaaggtctgctttccggccacagccaaacgttgacggggggatcttagtgatccgccgggtgggtgacccgaagattccgatagagcagcgcaaagcctttcaggcgatggtgcacaccgttttcactgcccggggacgcgggataggggaaattctccgaagggcagggttgttttcatcacgttcagaaacacaatcatggttgcgctcgcgaggaatcgaccccgcgaccctacctcccagattgcacaccaacgactggatcgatctcttccaggtgactggttcctctctacctcaccatcgacccatttcaccatcgggaagtagtcaacgacctcctcaacggaaaaaccgaagccggcggcgttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2857,Drugs,MEG_2857|Drugs|MLS|23S_rRNA_methyltransferases|ERMX,499430016|WP_011117480.1|NG_047853|1|1|erm(X)|erm(X)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(X) NG_047853:101-955,7
,atgaagatcgtcaccgcccttggcgccctggcgctgctcgccgcgcccgcctccgccgccgaccgtcagaagaccccggcgcaggagcccgcgccgaccggcaatctcgacaatctcatgcccgccgcgccgcgctatctggtgccgcaatcggcgctggagcaggtccgcaatcccaaggagattgaggaggagacgggcggccgcctgggcgtcgcgctggtcgaccggcagggcgcgctgctcttgggcttcaaccgtgacgagcggttcgccatgtgctcgaccttcaaggcgccgctggccgccgccgtgctgaccggcgcggatggcggcaagttcgggctggaagggaccatccccttcggcaaggaggatgtgctcgattacgcgccggtggtgaagaagaacctcaagcgcggccgcatgtcgatggaggaactggcgcgcgcggcggtggaggtcagcgacaatagcgccgccaatctgctgctgccgatgctgggcgggccggaagggctgaccgccttcatgcgcgtccatggcgatgacgtcacccggctcgaccgcactgaacccgcgctcaacgaaaatgcggaaggcgacccgcgcgacacgaccacgcccgccgccatggcgggcctgatggcgcgcctcttcttccgcgacctgaaggcggagagcgccgaccgcctgcgcgcctggttcaacgccagcagcaccggcgacaagcgcatcaaggccggcctgccagaaggctggacctcgggcagcaagaccggcagctgcggcaccgcctataatgacgtggcgctggtcaagtcccccaccggcgaggaatatatcctcgccatctatctcgaccgcccaaccatcgacgcgaagaaagccgaagccgcgatcgccgaagccgcccgcgccgcgctgaacttcgtggggcaagcgcgcaagagcggcctggaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1308,Drugs,MEG_1308|Drugs|betalactams|Class_A_betalactamases|BLASGM,497507277|WP_009821475.1|NG_049983|1|1|blaSGM-1|blaSGM|class_A_extended-spectrum_beta-lactamase_SGM-1 NG_049983:101-1066,0
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaggcagtttctttaatcactagtgctatcctgcaaatggcgattattttttaccttacagaaaaaacaggatctgcgatggtcttgtctatggcttcactagtaggttttttaccctatgctgtctttggacctgccataggtgtattagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctggggcagtgctggctattgttgcattgtatatggagttacctgtctggatggttatggtagtattgtttatccgcagcgttggaacagcttttcataccccagcactcaatgcagttacgccacttttagtaccagaagaacagctaacgaaatgcgcaggctatagtcagtctttgcagtctataagctatattgttagtccagcggttgcagcattgttatattctgtttgggaattaaatgctattattgccatcgacgtattgggtgctgtgattgcatctattacggtagcaattgtacgtatacctaagctgggtgatcgagtgcaaagtttggaaccaaatttcataagagaaatgaaagaaggaattgtcgttctgagacaaaacaaaggattgtttgccttattactcttaggaacactatatacttttgtttatatgccaattaatgcactatttcctttaataagcatggaatactttaatggaacacctgtgcatatttctattacggaaatttcctttgcatctggcatgttagcaggaggcttattgttaggaagattagggagcttcgaaaagcgtgtattactaataactggttcattctttataatgggggccagtttagccgtttcaggattacttcctacaagtggatttgtaatatttgtagcttgctgtgcagtaatggggctttcggtgccattttatagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttgaccggaagtataaagtcacttgctatgccaattggattaattctttctgggttctttgctgatagaatcggtgtaaatcattggtttttactatcaggtattttaattattggcattgctatagtttgccccatgataactgaggttagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3818,Drugs,MEG_3818|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028096992|WP_063853689.1|NG_047972|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047972:101-1318,7
,ATGAGCGACCTTGCGAGAGAAATTACACCGGTCAACATTGAGGAAGAGCTGAAGAGCTCCTATCTGGATTATGCGATGTCGGTCATTGTTGGCCGTGCGCTGCCAGATGTCCGAGATGGCCTGAAGCCGGTACACCGTCGCGTACTTTACGCCATGAACGTACTAGGCAATGACTGGAACAAAGCCTATAAAAAATCTGCCCGTGTCGTTGGTGACGTAATCGGTAAATACCATCCCCATGGTGACTCGGCGGTTTATGACACGATCGTCCGTATGGCGCAGCCATTCTCGCTGCGTTACATGCTGGTAGACGGTCAGGGTAACTTCGGTTCCATCGACGGCGACTCTGCGGCGGCAATGCGTTATACGGAAATCCGTCTGGCGAAAATTGCCCATGAACTGATGGCCGATCTCGAAAAAGAGACGGTCGATTTCGTTGATAACTATGACGGCACGGAAAAAATTCCCGACGTCATGCCAACCAAAATTCCTAACCTGCTGGTGAACGGTTCTTCCGGTATCGCCGTAGGTATGGCAACCAACATCCCGCCGCACAACCTGACGGAAGTCATCAACGGTTGTCTGGTGTATATCGATGATGAAGACATCAGCATTGAAGGGCTGATGGAACACATCCCGGGGCCGGACTTCCCGACGGCGGCAATCATTAACGGTCGTCGCGGTATTGAAGAAGCTTACCGTACCGGTCGCGGCAAGGTATATATCCGCGCCCGTGCTGAAATGGAAGTTGACGCCAAAACCGGACGTGAAACCATTATCGTCCACGAAATTCCGTATCAGGTAAACAAAGCGCGCCTGATCGAGAAGATTGCGGAACTGGTAAAAGAAAAACGCGTGGAAGGCATCAGCGCGCTGCGTGACGAGTCTGACAAAGACGGTATGCGCATCGTGATTGAAGTGAAACGCGATGCGGTCGGTGAAGTTGTGCTCAACAACCTCTACTCCCAGACCCAGTTGCAGGTTTCTTTCGGTATCAACATGGTGGCATTGCACCATGGTCAGCCAAAGATCATGAACCTGAAAGACATCATCGCGGCGTTTGTTCGTCACCGCCGTGAAGTGGTGACCCGTCGTACTATTTTCGAACTGCGTAAAGCTCGCGATCGTGCTCATATCCTTGAAGCATTAGCCGTGGCGCTGGCGAACATCGACCCGATCATCGAACTGATCCGTCATGCGCCGACGCCTGCAGAAGCGAAAACTGCGCTGGTTGCTAATCCGTGGCAGCTGGGCAACGTTGCCGCGATGCTCGAACGTGCTGGCGACGATGCTGCGCGTCCGGAATGGCTGGAGCCAGAGTTCGGCGTGCGTGATGGTCTGTACTACCTGACCGAACAGCAAGCTCAGGCGATTCTGGATCTGCGTTTGCAGAAACTGACCGGCCTTGAGCACGAAAAACTGCTCGACGAATACAAAGAGCTGCTGGATCAGATCGCGGAACTGTTGCGTATTCTTGGTAGCGCCGATCGTCTGATGGAAGTGATCCGTGAAGAGCTGGAGCTGGTTCGTGAACAGTTCGGTGACAAACGTCGTACTGAAATCACCGCCAACAGCGCAGACATCAACCTGGAAGATCTGATCACCCAGGAAGATGTGGTCGTGACGCTCTCTCACCAGGGCTACGTTAAATATCAGCCGCTTTCTGAATACGAAGCGCAGCGTCGTGGTGGGAAAGGTAAATCTGCCGCACGTATTAAAGAAGAAGACTTTATCGACCGACTGCTGGTGGCGAACACGCACGACCATATTCTGTGCTTCTCCAGCCGTGGTCGCGTCTATTCGATGAAAGTTTACCAGTTGCCGGAGGCCACTCGTGGCGCGCGCGGTCGTCCGATCGTCAACCTACTGCCGCTGGAGCAGGACGAACGTATCACCGCGATCCTGCCGGTGACCGAGTTTGAAGAAGGCGTGAAAGTCTTCATGGCGACCGCTAACGGTACTGTGAAGAAAACCGTCCTCACCGAATTCAACCGTCTGCGTACCGCCGGTAAAGTGGCGATCAAACTGGTTGAAGGCGATGAGTTGATCGGCGTTGACCTGACCAGTGGCGAAGATGAAGTAATGCTGTTCTCCGCCGAAGGTAAAGTGGTGCGCTTTAAAGAGTCTTCTGTCCGTGCGATGGGCTGCAATACCACTGGTGTGCGCGGTATTCGCTTAGGCGAAGGCGATAAAGTCGTCTCTCTGATCGTGCCTCGTGGCGATGGCGCAATCCTCACCGCAACGCAAAACGGTTATGGTAAGCGTACCGCAGTGGCGGAATACCCAACCAAGTCGCGTGCGACGAAAGGGGTTATCTCCATCAAGGTTACCGAACGTAACGGTTTAGTTGTTGGCGCGGTACAGGTAGATGACTGCGACCAGATCATGATGATCACCGATGCCGGTACGCTGGTACGTACTCGCGTTTCAGAAATCAGCATCGTGGGCCGTAACACCCAAGGCGTGATCCTCATCCGTACTGCGGAAGATGAAAACGTAGTGGGTCTGCAACGTGTTGCTGAACCGGTTGACGAGGAAGATCTGGATACCATCGACGGCAGTGCCGCGGAAGGGGACGATGAAATCGCTCCGGAAGTGGACGTTGACGACGAGCCAGAAGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3212,Drugs,MEG_3212|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|558570689|gb|CP006736.1|2179279-2176652 gi|81239530|gb|CP000034.1|2222984-2220357,3
,atgttcaaacttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcgccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaatgcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7712,Drugs,MEG_7712|Drugs|betalactams|Class_B_betalactamases|VIM,1028110982|WP_063865194.1|NG_050372|1|1|blaVIM-44|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-44 NG_050372:1-801,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagccttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_560,Drugs,MEG_560|Drugs|betalactams|Class_C_betalactamases|ADC,691120398|WP_032039838.1|NG_064695|1|1|blaADC-139|blaADC|class_C_beta-lactamase_ADC-139 NG_064695:101-1252,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacctacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5468,Drugs,MEG_5468|Drugs|betalactams|Class_C_betalactamases|PDC,1408841622|WP_111672895.1|NG_060552|1|1|blaPDC-282|blaPDC|class_C_beta-lactamase_PDC-282 NG_060552:1-1194,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTTCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAAAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGATGGTGTTTCAAAAGACTGTAAGGTGGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1357,Drugs,MEG_1357|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_13_KF471116,0
,ATGAATGAAAAAATCTTAGTGGTTGATGATGAAAAAGAATTGGCCGATTTAGTTGAAGTATATCTGAAAAACGATGGATATACCGTTTATAAATTTTATAATGGCAAGGATGCACTAAAGTGTATTGAATCCGTGGAACTGGATTTAGCCATATTGGATATCATGCTTCCGGATGTAGACGGGTTTCAGATCTGCCAGAAAATCCGGGAAAAGTTTTACTTCCCTGTTATCATGCTGACGGCAAAAGTGGAGGACGGGGATAAAATCATGGGACTGTCCGTGGCGGATGATTATATTACGAAGCCGTTTAACCCGCTGGAACTGGTTGCGAGGGTAAAGGCGCAGCTAAGGCAGTACATGCGGTACAAGCAGCCCGGCATAAAGCAGGAGGCTGAACGCACGGAATACGATATCCGGGGAATGACAATCAGCAAGAGCAGCCATAAGTGTATCCTGTTTGGAAAGGAAATTCAGCTGACGCCAACAGAGTTTTCCATCCTTTGGTATCTGTGCGAGCGTCAGGGTACGGTTGTTTCTACGGAGGAATTATTTGAGGCAGTATGGGGTGAACGGTTTTTTGACAGCAATAATACTGTGATGGCGCATATCGGGCGGCTTCGGGAGAAAATGAAGGAACCGTCAAGAAATCCGAAATTTATAAAAACTGTGTGGGGAGTGGGATATACCATTGAAAAATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7479,Drugs,MEG_7479|Drugs|Glycopeptides|VanD-type_regulator|VANRD,gi|5759260|gb|AF175293.1|AF175293|71-769,5
,atgaggaaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgtccactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_767,Drugs,MEG_767|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502199|WP_071846349.1|NG_052454|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052454:101-892,2
,atgatgacaaaaaccctttgctgcgccctgctgctcagcacctcctgctcagtattggccgcaccgctgtcagaaaaacagctggctgaagtggtggagcgcaccgttacgcccctgatgaaagcgcaggctattccgggtatggcggtggcggtgatttatcagggccagccgcactactttaccttcggtaaagccgatgttgcaaagaacaaaccggttaccccacaaaccctgttcgagctgggctctataagtaaaaccttcaccggcgtactgggtggcgatgccgttgctcgcggtgaaatatcgctgggcgaccccgtgacaaagtactggcccgcgctgacaggcaagcagtggcaggggatccgcatgctggatctggccacctataccgcgggaggtctgccgctacaggtaccggatgaggtcacggatagcgcctctctgctgcgcttttatcaaaactggcagccgcagtggaagccgggcacaacgcgtctttacgccaacgccagcatcggtctttttggcgcgctggcggtgaagccttccggcatgagctatgagcaggccataacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggataccgtgacggtaaagcggtgcacgtttcgccgggaatgctcgatgcggaagcttatggcgtgaaaaccaacgtgcaggatatggcaagctgggtgatggtcaacatgaagccggaaacccttcaggatacgtcactcaggcaaggcattaccctggcgcagtctcgctactggcgcgtgggggccatgtaccagggattaggctgggaaatgcttaactggccggtggatgccaaaaccgtggttgacggcagcgacaataaggtggcgctggcgccgctgcctgcgagcgaagtcaatccgcccgcgccgccggttaaggcatcctgggtccacaaaacgggttcaaccggcgggtttggcagctacgcggcatttattccggagaaaagtctcggtatcgtgatgctggcgaataaaagctacccgaacccggcacgcgttgaggcggcataccgtatcctcgacgcattgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_440,Drugs,MEG_440|Drugs|betalactams|Class_C_betalactamases|ACT,779806134|WP_045331469.1|NG_050711|1|1|blaACT-48|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-48 NG_050711:1-1146,0
,atgaaaattgataatgtaacagaaaaggatttattttatattttagacttttttgaaaagatggaagtaacctattggttagatggaggttggggcgtagatgtattaactggaaaacagcaaagagaacacagagatatagatatagattttgacgctcaacacactcaaaaagttatacagaagttaaaagatataggatacaaaatagaagttgattggatgccttcacgtatggaacttaaacataaagaatatggatatttagatattcatcccataaatctaaatgatgatggttcaattactcaagcaaaccccgaaggtggcaattacgtttttcaaaatgaatggttctcagaaactaattataaaggccgaaaaataccatgtatttcaaaagaagctcaacttctttttcattctggttatgacttaacagaaaaagaccattttgatataaaaaatttaaaatcaataacttaa,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3605,Drugs,MEG_3605|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUA,695268929|WP_032491106.1|NG_047914|1|1|lnu(A)|lnu(A)|lincosamide_nucleotidyltransferase_Lnu(A) NG_047914:101-586,7
,atgcgtcaatatcgattcgcccttctcccattgttagccgccctggcgctccccggttgggcgcatcaagctacggtgacgacggttaaacaagccgaaagccagcttcagggtcgggtcggctacgccgaactggatttagcttccgggcaactgctggccggctatcgttctgacgaacggttcccgatgatgagcacttttaaagttctgctctgcggcgcagtcttgtcgcgtgtcgatgctggtgaagaacagctcgatcgccgtatccattaccggcagcaggatctggtggaatattcgccggtgacggaaaagcatcttaccgatgggctcaccgtgggcgaactgtgcgctgccgccattaccctgagcgataatacggcggcaaacctgctgttgaccactctcggcggcccgcaggggctgaccagcttcctgcgccacagcggcgaccagacttcgcggcttgaccgttgggaaacggaactcaatgaagcgcggccgggcgacgtgcgagataccacgactccgcaagcgatggccaggacactgcgaaatctgttgaccggcagcgtgctttccagcgcctcgcagcagcagttgcaacgctggatggtagaggacaaagttgcggggccgctgttgcgatcggtgctgccggcaggctggtttattgccgataagaccggagccggcaatcgcggctcgcgcgggatcatcgcggctctcggtccggacggtaaagctgcgcgcatcgtggtgatttatttgaccgggacccccgccacaatggatgaacgcaataaacagattgcggccatcggcgcaacgctgatcaggcactggtccgcagacgagaacagaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_5791,Drugs,MEG_5791|Drugs|betalactams|Class_A_betalactamases|PLA,1028110228|WP_063864598.1|NG_049972|1|1|blaPLA-6|blaPLA|class_A_beta-lactamase_PLA-6 NG_049972:101-976,0
,atgcgttttaccctgctcgccttcgccctggccgtcgctcttccggccgtccacgccagcgccgccgaggcaccgctgccacaactgcgggcctataccgtggatgcgtcctggctgcagccgatggcgccgctgcaggttgccgaccacacctggcagatcggcaccgaggacctgaccgcgctgctggtgcagaccgccgagggcgcagtactgctggatggcggcatgccacagatggccggtcacctgctggacaacatgaagctgcgcggcgtggccccgcaggacctgcgattgatcctgctcagccatgcgcatgccgaccacgccggcccggtcgccgagctcaagcgtcgcaccggcgcgcatgtggcggccaatgcagaaacggcggtgctgctggcgcgcggcggcagcaacgacctgcactttggcgacggcatcacctatccgccggccagcgccgaccgcatcatcatggacggcgaagtggtcacggtgggcggcatcgcattcaccgcgcacttcatgccggggcacaccccgggcagcaccgcctggacctggaccgacacccgcgatgggaagccggtgcgcatcgcctacgccgacagcctgagtgcaccgggttaccagctgaagggcaatccccgttatccgcgcttgatcgaggactacaagcgcagcttcgcaacggtacgggcgctgccctgcgatctgctgctcaccccgcatccgggcgccagcaactggaactacgccgtcggcagcaaggccagcgccgaggcactgacctgcaacgcctacgcggatgcggccgagaagaagttcgacgcgcagctggccaaggaaacggccggggcccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3530,Drugs,MEG_3530|Drugs|betalactams|Class_B_betalactamases|L1,1028083701|WP_063842669.1|NG_047502|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047502:1-873,0
,ATGATGAGAAAAAGCGTAAGGCGGGCGATATTAATGACGACAGCCTGTGTTTCGCTGCTGTTGGCCAGTGTGCCGCTGTATGCCCACGCGAACGATGTTCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGGGGACGACTGGGTGTGGCGTTGATTAACACCGCCGATAACACGCAGACGCTCTACCGCGCCGACGAGCGTTTTGCTATGTGCAGCACCAGTAAAGTGATGGCGGCGGCGGCGGTGCTTAAGCAAAGTGAAACGCAAAAGGACTTACTGAGTCAGCGGGTTGAAATTAAGTCCTCAGACTTGATTAACTACAACCCAATCGCTGAAAAGCACGTCAATGGCACGATGACACTCGGGGAGCTGAGCGCGGCGGCGCTGCAGTACAGCGATAATACTGCCATGAATAAGCTGATTGCCCATCTCGGGGGGCCGGGTAAAGTGACGGCATTTGCTCGTGCGATTGGCGATGACACTTTCCGGCTCGATCGTACCGAGCCGACGCTCAACACCGCGATCCCCGGCGACCCGCGCGATACCACCACGCCGTTAGCGATGGCGCAGGCTCTGCGCAATCTGACGTTGGGCAATGCCCTGGGTGACACTCAGCGTGCGCAGCTGGTGATGTGGCTGAAAGGCAACACCACCGGCGCTGCCAGCATTCAGGCAGGGCTACCCACATCGTGGGTTGTCGGGGATAAAACCGGCAGCGGCGATTATGGTACGACGAATGATATCGCGGTTATTTGGCCGGAAGGTCGCGCGCCGCTCGTTCTGGTGACTTACTTCACCCAGTCGGAGCCGAAGGCAGAGAGCCGTCGTGACGTGCTCGCTGCTGCCGCCAGAATTGTCACCGACGGTTATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2407,Drugs,MEG_2407|Drugs|betalactams|Class_A_betalactamases|CTX,gi|620597417|gb|KJ461948.1|1-876,0
,atgaaaaaattatttgttttatgtgtattcttcctttgcaacattgctgctgcagatgattctttgcctgatttaaaaattgagaagcttgaaaaaggcgtttatgttcatacttcgtttgaagaagttaaaggttggggtgtattcgcaaaacacggtttagtggttcttgtaaagaatgatgcttatctgatagatactccaattaccgctaaagatactgaaaaattagttaattggtttattgagcacggctatagaatcaaaggcagtatttccacacatttccatggcgacagtacggctggaatagagtggcttaattctcaatctatctccacgtatgcctctgaattaacaaatgaacttctaaaaaaagacaataaggtgcaagctacaaattcttttagtggagttagttattcacttatcaaaaacaaaattgaagttttctatccaggtccaggacacactcaagataacgtagtggtttggttacctgaaaagaaaattttattcggtggttgctttgttaaaccggacggtcttggaaatttaggggatgcaaatttagaagcttggccaaagtccgctaaaatattaatgtctaaatatggtaaagcaaaactggttgttccaagtcatagtgaaattggaaacgcatcactcttgcagcgcacatgggagcaggctgttaaagggttaaatgaaagtaaaaaaccgttacagccaagtagctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3321,Drugs,MEG_3321|Drugs|betalactams|Class_B_betalactamases|IMP,1393270463|WP_109791208.1|NG_057607|1|1|blaIMP-75|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-75 NG_057607:1-741,0
,GGATGTATTGTGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCATGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCCCGCAGCACCTCGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAGAGAATGCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6493,Drugs,MEG_6493|Drugs|betalactams|Class_A_betalactamases|SHV,gi|84105058|gb|DQ322460.1|1-965,0
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAATACACCGTTTCTTTAGCCTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGATTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACATACACAGAAAATCCAGCCACTTTTTGAAGGAAACGGCTTTTGGATAAGTGAAGCGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGTAAATACGGGGAAGATGGCAGTATCCAAGGAATGTTTGAATTGATGAAGCTGCCTTATGTAGGCTGTGGGGTGGCAGCCTCTGCCTTATGTATGAACAAATGGTTATTGCATCAAGCAGCAGCAGCGATTGGCGTACAAAGCGCTCCTACGATTCTCTTGACAAATCAAGCCAACCAGCAAAGACAAATCGAAGCCTTTATCCAGACCCATGGCTTTCCAGTTTTCTTTAAGCCTAATGAAGCGGGCTCCTCAAAAGGGATCACAAAAGTAACTTGTGTTGAAGAAATCGCTCCTGCCTTGAAGGAAGCCTTCGCTTATTGTTCCGCAGTGCTCTTACAAAAAAATATCGCTGGCGTTGAGATTGGTTGCGGTATCTTAGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCTATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGTTGATCAGCGCCAAAATCACCGTTCCTGCGCCATTGCCTGAAACGATTGAAACCAAAGTCAAAGAACAAGCTCAGCTGCTCTATCACAGTCTTGGTCTTAAAGGACTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGCTTATCCTATCAAGAATTACTACAAAAACTGCTTGTCTTAGCAAAGGAGGAAGGCAAATGAATCCCTATCTACAGTTAGTTAGCAAAGAGTTTCCATTAGAAAAAAAACAAGAGCCGCCCCACCTAGTCCTTGCTGCTTTTAGTGAAGAAGAAGTTTACTTGCAGCCTGAAGCAGCCAAACAATGGGAACGCCTCGTCAAAGCCTTAAAACTTGAAAACGAGATCTGCTTATTAGACGGCTATCGAACCGAAAAGCAGCAACGGTATTTATGGGAATATTCCTTAAAAGAAAATGGATTAGCCTATACGAAACAATTTGTGGCGTTGCCCGGCTGTAGCGACCATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAGGGCAGCCAGAATGATTTGATCTGTCCACGTTTTCGTGACAGCGCAGCCGCTGATTTATTTACCCAGGAAATGATGAACTACGGATTTATTTTACGCTACCCCGCAGACAAACAAGAAATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTTTGCCTCATAGTCAAATCATGGCCAATCAACAGTGGACCTTGGAAGAATACCATCAGTATCTTGAACAGACCACGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7377,Drugs,MEG_7377|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC4XY_1_EU151752,5
,atgaattttacccggattgacctgaatacctggaatcgcagggaacattttgccctttatcgtcagcagattaaatgcggattcagcctgaccaccaaactcgatattaccgctttgcgtactgcactggcgaaaaccggttataagttttatccgctgatgatttacctgatctcccgggctgttaatcagtttccggagttccggatggcaatgaaagataatgaactgatttactgggaacagtcagacccggtctttactgtctttcataaagaaaccgaaacattctccgcactgtcctgccgttattttccggatctcagtgagtttatggcgggttataacgcggtaacagcagaatatcagcatgataccaggttgtttccgcagggaaatttaccggagaatcacctgaatatatcatcgttaccctgggtgagttttgacggatttaatctgaatatcaccggaaatgatgattatttttccccggtttttacaatggcaaagtttcagcaggaaggtgaccgcgtactattacctgtttctgtacaggttcatcatgcagtctgtgatggttttcatgcagcaaggtttatcaatacacttcagctgatgtgtgataacatactgaaataa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1568,Drugs,MEG_1568|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,446934683|WP_001011939.1|NG_047596|1|1|catA2|catA2|type_A-2_chloramphenicol_O-acetyltransferase_CatII NG_047596:101-742,6
,CAGTTTTTGCGGCCGCCCAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACGTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAGTTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATTGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAGAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCGCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_965,Drugs,MEG_965|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|953357758|gb|KT290957.1|3027-3701 gi|953357739|gb|KT290954.1|3027-3701 gi|953357733|gb|KT290953.1|3027-3701 gi|425862464|gb|JX566710.1|3027-3701 gi|317017986|gb|GU390399.1|2988-3662 gi|42516777|emb|AJ620678.1|3665-4339 gi|953357751|gb|KT290956.1|2419-3082 gi|953357745|gb|KT290955.1|1935-2598 gi|617018635|gb|KJ420611.1|2446-3109 gi|957761167|gb|KT440883.1|4196-4853,2
,ATGAAAAAATTATTTGTTTTATGTGTATTCTTCTTCTGCAACATTGCAGTTGCAGAAGAATCTTTGCCTGATTTAAAAATTGAGAAGCTTGAAGAAGGCGTTTATGTTCATACTTCGTTTGAAGAAGTTAAAGGTTGGAGTGTGGTCACTAAACACGGTTTGGTGGTTCTTGTGAAAAATGACGCCTATCTGATTGATACTCCAATTACTGCTAAAGATACTGAAAAATTAGTCAATTGGTTTGTTGAGCGGGGCTATAAAATCAAAGGCAGTATTTCCACACATTTCCATGGTGACAGTACGGCTGGAATAGAGTGGCTTAATTCTCAATCTATCCCCACATATGCTTCTGAATTAACAAATGAACTTCTTAAAAAAGACAATAAGGTACAAGCTAAACACTCTTTTAATGGGGTTAGTTATTCACTAATTAAAAACAAAATTGAAGTTTTTTATCCAGGCCCAGGGCACACTCAAGATAACGTAGTGGTTTGGTTACCTGAAAAGAAAATTTTATTCGGTGGTTGCTTTGTTAAACCGGACGGTCTTGGCTATTTGGGGGACGCAAATTTAGAAGCTTGGCCAAAGTCCGCTAAAATATTAATGTCTAAATATGGTAAAGCAAAACTAGTTGTGTCGAGTCATAGTGATATTGGAGATGTATCACTCTTGAAACGTACATGGGAGCAGGCTGTTAAAGGGCTGAATGAAAGTAAAAAATCATCACAGCCAAGCGACTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3339,Drugs,MEG_3339|Drugs|betalactams|Class_B_betalactamases|IMP,(Bla)IMP-1:HM036079:114-854:741,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCTTTCTCCACGTTTGCCGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCAATTCCGGGTATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACGCAACAAACGCTGTTTGAACTCGGATCGGTCAGTAAAACGTTCAACGGTGTGCTGGGCGGCGATGCTATAGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGCAGTACTGGCCTGAACTGACTGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCGTTACTACGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGCGCCCTGGCAGTGAAACCCTCAGGCATGAGCTACGAAGAGGCGATGTCCAAACGCGTCCTGCACCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGCCAACTTGATGCCGAAGCATACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGCATCGAGCTTGCGCAGTCACGTTACTGGCGTATTGGCGATATGTACCAGGGCCTGGGCTGGGAGATGCTGAACTGGCCGGTGAAGGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTGGCACTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAGAGCTACCCAAACCCTGTTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAACGGACAAGGAGGCCCTGGATATTGGGCTTCCTTTCTTTCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAATCCAGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1970,Drugs,MEG_1970|Drugs|betalactams|Class_C_betalactamases|CMY,gi|407731514|gb|JX440350.1|1027-2255,0
,TTATCCTTATCTCCATGCTTTTCCCTGTCGCAGTTATGGCACAGAAAAGCGTAAAAATATCCGATGACATCAGTATCACCCAACTCTCGGACAAAGTGTACACTTATGTATCCCTCGCCGAAATCGAAGGATGGGGTATGGTACCTTCCAACGGGATGATTGTTATCAACAACCACCAGGCAGCGTTGCTGGACACACCGATCAATGACGCACAAACGGAAATGCTGGTCAACTGGGTGACAGACTCTTTGCATGCCAAAGTCACCACGTTTATCCCGAACCACTGGCACGGCGATTGTATTGGCGGACTGGGTTACCTGCAAAGGAAAGGTGTCCAATCATACGCGAACCAGATGACGATAGACCTCGCCAAGGAAAAAGGGTTGCCCGTACCGGAACATGGATTCACCGATTCACTGACCGTCAGCTTGGACGGCATGCCTCTCCAATGCTATTATTTAGGAGGCGGGCATGCGACCGACAATATCGTGGTTTGGCTGCCGACAGAGAATATCCTTTTTGGCGGATGTATGCTTAAAGACAACCAGGCGACAAGCATCGGCAACATCTCGGACGCAGACGTGACGGCATGGCCGAAAACTCTCGATAAGGTAAAAGCCAAGTTCCCCTCGGCCCGCTACGTCGTGCCCGGACATGGCGACTATGGCGGAACCGAACTGATAGAGCATACCAAGCAGATCGTGAACCAATATATAGAAAGCACCTCAAAGCCATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1668,Drugs,MEG_1668|Drugs|betalactams|Class_B_betalactamases|CFIA,(Bla)cfiA12:FM200786:1-737:737,0
,atgataaaaagttcgtggcgtaaaattgcaatgctagccgccgccgttccgctgctgctggcgagcggcgcactgtgggccagtaccgatgctatccatcagaagctgacagatctcgagaagcgttcaggcggcaggttgggcgtggcgctaatcaacacggcagataattctcaaatcttatatcgcggcgacgagcgttttgccatgtgcagcaccagtaaagtgatggccgccgccgcggtattaaaacagagcgaaagcaataaagaggtggtaaataaaaggctggagattaacgcagccgatttggtggtctggagcccgattaccgaaaaacatctccagagcggaatgacgctggctgagctaagcgcggcgacgctgcaatatagcgacaatacggcgatgaatctgatcatcggctaccttggcgggccggaaaaagtcaccgccttcgcccgcagtatcggcgatgccacctttcgtctcgatcgtacggagcccacgctgaataccgccatcccgggcgatgagcgtgataccagcacgccgctggcgatggctgaaagcctgcgcaagctgacgcttggcgatgcgctgggcgaacagcaacgcgcccagttagtcacctggctgaaaggcaataccaccggcgggcaaagcattcgcgcgggcctgcctgaaagctgggtggtcggcgataaaaccggctccggagattacggcaccaccaatgatattgcggttatctggccggaagatcacgctccgctggtattagtcacctactttacccagccgcagcaggatgcgaaaaaccgcaaagaggtgttagccgcagcggcaaaaatcgtgaccgaagggctttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_5278,Drugs,MEG_5278|Drugs|betalactams|Class_A_betalactamases|OXY,1028083784|WP_063842752.1|NG_047529|1|1|blaOXY-2-14|blaOXY-2|class_A_extended-spectrum_beta-lactamase_OXY-2-14 NG_047529:95-967,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcgcggcgctgtggccatccagttcgcctgaagagcaccgcgcggagatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgaggggtggacggcgctttcatcggctttgccgaagtggcgctgcgctacgattacgtcaacggctgcgagtcgtcgccggtggcgtttctggaaggtatctatgccgtcgaacgcgcccgccgccagggctgggccacgcgattgatcgcacaggtgcaggaatgggccaagcagcaaggctgcagcgagctggcatcggataccgatatcgccaatctggactcccagcgcctgcatgccgcgctgggctttgccgaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_165,Drugs,MEG_165|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,822042381|WP_046897272.1|NG_052467|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052467:101-541,2
,atgaaaacatttgccgcatatgtaattactgcgtgtctttcaagtacggcattagctagttcaattacagaaaatacgtcttggaacaaagagttctctgccgaagccgtcaatggtgttttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaataacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaaacaatgggaaagagacttgagcttaagaggggcaatacaagtttcagcggttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcatatggcaaccagaatatcagtggtggcattgacaaattctggttggaggatcagctaagaatttccgcagttaatcaagtggagtttctagagtctctatttttaaataaattgtcagcatcaaaagaaaatcagctaatagtaaaaaaggctttggtaacggaggctgcgcctgaatatcttgtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttggttgggttgagaagggaacagaggtttactttttcgcctttaacatggatatagacaacgaaaataagttgccgctaagaaaatccattcccaccaaaatcatggcaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4415,Drugs,MEG_4415|Drugs|betalactams|Class_D_betalactamases|OXA,1509794549|WP_122630858.1|NG_062271|1|1|blaOXA-676|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-676 NG_062271:1-801,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaccggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5490,Drugs,MEG_5490|Drugs|betalactams|Class_C_betalactamases|PDC,1147955308|WP_077248207.1|NG_052892|1|1|blaPDC-176|blaPDC|class_C_beta-lactamase_PDC-176 NG_052892:1-1194,0
,atgagtgaaaaagtgcccgccgagatttcggtgcaactatcacaagcactcaacgtcatcgggcgccacttggagtcgacgttgctggccgtgcatttgtacggctccgcactggatggcggattgaaaccgtacagtgatattgatttgctggtgactgtagctgcaccgctcaatgatgccgtgcggcaagccctgctcgtcgatctcttgnaggtttcagcttcccctggccaaaacaaggcactccgcgccttggaagtgaccatcgtcgtgcacagtgacatcgtaccttggcgttatccggccaggcgggaactgcagttcggagagtggcagcgcaaagacatccttgcgggcatcttcgagcccgccacaaccgattctgacttggcgattctgctaacaaaggcaaagcaacatagcgtcgtcttggcaggttcagcagcgaaggatctcttcagctcagtcccagaaagcgatctattcaaggcactggccgatactctgaagctatggaactcgccgccagattgggcgggcgatgagcggaatgtagtgcttactttgtctcgtatctggtacaccgcagcaaccggcaagatcgcgccaaaggatgttgctgccacttgggcaatggcacgcttgccagctcaacatcagcccatcctgttgaatgccaagcgggcttatcttgggcaagaagaagattatttgcccgctcgtgcggatcaggtggcggcgctcattaaattcgtgaagtatgaagcagttaaactgcttggtgccagccaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_821,Drugs,MEG_821|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1080153676|WP_070342356.1|NG_051845|1|1|aadA7|aadA7|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA7 NG_051845:90-887,2
,ATGTCACTGTATCGCCGTCTAGTTCTGCTGTCTTGTCTCTCATGGCCGCTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTCGAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACTGTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCTGCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGGCACACCCATCCGTTACGGCAAAAACGCGCTGGTTCCGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATGACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTGTTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGATACCACGTTCCGTCTGGACTGCTGGGAGCTGGAGCTGAACTCCGCTATCCCAGGCGATGCGCGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCTGCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGCAACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACCTGCGGAGTGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCTATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGTACAGCGAGGCCGTCATCGCCGCTGCGGCTGGACTCGCGCTCGAGGGATTGGGCGTCAACGGGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3485,Drugs,MEG_3485|Drugs|betalactams|Class_A_betalactamases|KPC,(Bla)KPC-13:HQ342890:1-882:882,0
,GTGAAACCCAACAGACCCCTGATCGTAATTCTGAGCACTGTCGCGCTCGACGCTGTCGGCATCGGCCTGATTATGCCGGTGCTGCCGGGCCTCCTGCGCGATCTGGTTCACTCGAACGACGTCACCGCCCACTATGGCATTCTGCTGGCGCTGTATGCGTTGATGCAATTTGCCTGCGCACCTGTGCTGGGCGCGCTGTCGGATCGTTTCGGGCGGCGGCCGGTCTTGCTCGTCTCGCTGGCCGGCGCTGCTGTCGACTACGCCATCATGGCGACGGCGCCTTTCCTTTGGGTTCTCTATATCGGGCGGATCGTGGCCGGCATCACCGGGGCGACTGGGGCGGTAGCCGGCGCTTATATTGCCGATATCACTGATGGCGATGAGCGCGCGCGGCACTTCGGCTTCATGAGCGCCTGTTTCGGGTTCGGGATGGTCGCGGGACCTGTGCTCGGTGGGCTGATGGGCGGTTTCTCCCCCCACGGTCCGTTCTTCGCCGCGGCAGCCTTGAACGGCCTCAATTTCCTGACGGGCTGTTTCCTTTTGCCGGAGTCGCACAAAGGCGAACGCCGGCCGTTACGCCGGGAGGCTCTCAACCCGCTCGCTTCGTTCCGGTGGGCCCGGGGCATGACCGTCGTCGCCGCCCTGATGGCGGTCTTCTTCATCATGCAACTTGTCGGACAGGTGCCGGCCGCGCTTTGGGTCATTTTCGGCGAGGATCGCTTTCACTGGGACGCGACCACGATCGGCATTTCGCTTGCCGCATTTGGCATTCTGCATTCACTCGCCCAGGCAATGATCACCGGCCCTGTAGCCGCCCGGCTCGGCGAAAGGCGGGCACTCATGCTCGGAATGATTGCCGACGGCACAGGCTACATCCTGCTTGCCTTCGCGACACGGGGATGGATGGCGTTCCCGATCATGGTCCTGCTTGCTTCGGGTGGCATCGGAATGCCGGCGCTGCAAGCAATTTTGTCCAGGCAGGTGGATGAGGAACGTCAGGGGCAGCTGCAAGGCTCACTGGCGGCGCTCACCAGCCTGACCTCGATCGTCGGACCCCTCCTCTTCACGGCGATCTATGCGGCTTCTATAACAACGTGGAACGGGTGGGCATGGATTGCAGGCGCTGCCCTCTACTTGCTCTGCCTGCCGGCGCTGCGTCGCGGGCTTTGGAGCGGCGCAGGGCAACGAGCCGATCGCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7026,Drugs,MEG_7026|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,gi|14547129|emb|AJ313332.1|990-2189,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagcgagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5646,Drugs,MEG_5646|Drugs|betalactams|Class_C_betalactamases|PDC,1035157549|WP_064511514.1|NG_050837|1|1|blaPDC-164|blaPDC|class_C_beta-lactamase_PDC-164 NG_050837:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggtcggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5521,Drugs,MEG_5521|Drugs|betalactams|Class_C_betalactamases|PDC,1201190446|WP_087587966.1|NG_054986|1|1|blaPDC-201|blaPDC|class_C_beta-lactamase_PDC-201 NG_054986:1-1194,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACTCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1858,Drugs,MEG_1858|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AJ781421|+|0-1146|ARO:3002027|CMY-16 [Proteus mirabilis] ,0
,atgaaaaaaatatttttgctttttggtcttttttgctcttttgctttggcaaatgaaaatttaaaagatctttttaaagattataatgaaagtggagtttttatagcttatgatggtaaaaattattatagcaatgactttaaaaaagcaaacaaacgcattttacctgcctctacttttaaaattttcaatgccttaatcgcacttaatgaagatgttgtgaaagatactaatgaaattttttatcattacaaaggtgaaaaagtatttttaccatcttggaaaaataatgcaaacttagctttagctatgcaaagatcacaactacctgcttataaagaactagctagaaaaataggcttagaaaaaatgcaaaaaaacttaaataaacttaattatggcaaccaaaaaataagtaaaatagatgagttttggatagatgattctttacaaattagtcttaaagaacaagctactttactttttaagcttgccaatttaacactagattaccctaaacatatacaagaagaagtgattaatatcatcaagttaaaagaaaatgatcattatgaactttttgcaaaaacaggttggggtcttagacaatatggacaaatcgtaggttttataaaaagtaaaaaaagtgacaaaatttacgcttttgctttaaatatgaatataagtgattttaacaagctttatctaagagaagaaatagtacaactgtatctagatcaattataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4662,Drugs,MEG_4662|Drugs|betalactams|Class_D_betalactamases|OXA,1028109813|WP_063864216.1|NG_049792|1|1|blaOXA-518|blaOXA-493_like|OXA-493_family_class_D_beta-lactamase_OXA-518 NG_049792:1-747,0
,ATGTATATTGAACAGCATTCTCGCTATCAAAATAAAGCTAATAACATCCAATTAAGATATGATGATAAGCAGTTTCATACAACGGTTATCAAAGATGTTCTATTATGGATTGAACATAATTTAGATCAGTCTTTACTGCTTGATGATGTGGCGAATAAAGCGGGTTATACCAAGTGGTATTTTCAGCGGCTGTTCAAAAAAGTAACAGGGGTCACACTGGCTAGCTATATTCGTGCTCGTCGTTTGACGAAAGCGGCTGTTGAGTTGAGGTTGACGAAAAAAACTATCCTTGAGATCGCATTAAAATATCAATTTGATTCCCAACAATCTTTTACACGTCGATTTAAGTACATTTTTAAGGTTACACCAAGTTATTATCGGCGTAATAAATTATGGGAATTGGAGGCAATGCACTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7070,Drugs,MEG_7070|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETD,gi|953946047|emb|LN908249.1|1548467-1548051 gi|951285167|emb|LN869922.1|884081-883665 gi|949881887|gb|CP012931.1|27029-27445 gi|917657445|gb|KR827684.1|36453-36037 gi|909636483|emb|LN850163.1|116332-115916 gi|857118485|gb|CP011223.1|1685037-1685453 gi|834763093|gb|CP006636.1|350527-350111 gi|828386350|gb|CP006635.1|152868-152452 gi|825091926|gb|KP789020.1|133878-133462 gi|808208366|gb|CP009232.1|107604-108020,4
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATTGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGTTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1959,Drugs,MEG_1959|Drugs|betalactams|Class_C_betalactamases|CMY,gi|374414421|gb|JN714480.1|1040-2267,0
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgccgccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagaccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5690,Drugs,MEG_5690|Drugs|betalactams|Class_C_betalactamases|PDC,1028110193|WP_063864563.1|NG_049873|1|1|blaPDC-106|blaPDC|class_C_beta-lactamase_PDC-106 NG_049873:1-1194,0
,ATGCGTTTTGATATCGATGAGATGATTTCTCCTGAAATGCTTGACCGCCTTGCAGAAGTCGCAATAAAAGTAGGGCTCAATTTACAAGAAGGACAGGATCTTGTTTTGACTGCTCCAGTTAAAGCTTTACCTTTGGTTCGGCGGATAACTTATTATGCTTATAAGGCTGGTGCTGGTGTTATTACACCACTTTTTGGTGATGAAGCATTATCACTTATCCGTTTTGAAAATGCTCATTCTGCTAGTTTTGATTGTGCACCTTCTTGGCTTTATGAAGGAATGGCAAAAGCTTTTGAAAATGGAGCTGCACGTTTGGCGATTGTTGGTGATGATCCGTTGTTGTTTTCCAATCAAGATTTGGATAAAATTTCACGTTTGAATAAAGCTACTTCGATGGCTTATCAGCCAGCTCTTAACAAAATATCGAATTTTACGATTAATTGGTCGATTATCGCTTATCCAACTCCGGAATGGGCTATCGCAATGTTTTCTGATTTGCCTCTTGATAAAGCAGTTCAGAAATTAGCAGAAGCTATTTTTTCTGCTTCACGTGTGACACAAGATAATGCTGTATATGAATGGCATGCACACAATGCTAATTTAAAGCAACGTTCATCTTGGCTTAATGAACAACGTTTTGCTGCTTTGCATTTTATAGGTCCAGGAACCAATTTAACGGTTGGTTTAGCAGATGAACATGAATGGCATGGAGGTACCTCGATAGCTCAAAATGGTGTTGTCTGTAACCCTAACATTCCAACTGAAGAAGTATTTACGACTCCTCATGCTTATAAAGTTGATGGTTTTGTTCGTTCAACAAAGCCACTTTCCTATCAAGGAACGCTCATTGATAATATTGAAGTGCGTTTTGAAGAAGGGCGTATTATCAATGCGTCTGCTTCAAAGGGACAGGAAGTTTTGCAACGGGTTTTACAAAGTGATGAGGGGGCTAGTCGATTGGGTGAAGTTGCTCTTGTTCCTCATTCTTCACCTATTTCTAAGAGTGGTTTACTTTTTTATAATACATTGTTTGATGAAAATGCTGCATGTCATATCGCTTTAGGACAATGTTATTCTAAATGCTTTTTAAATGGAGCGGCATTAACTGCAGAAGATATTGCAATGCGTGGTGGGAATAAGAGTATTATTCATATTGACTGGATGATTGGATCAAATGAAATTAACATAGACGGTATTATGCAAGATGGTGCAAAAATTCCTGTATTTCGTCGGGGTGAGTGGGTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_727,Drugs,MEG_727|Drugs|betalactams|Class_C_betalactamases|AMPC,gb|FN645454.1|+|210004-211252|ARO:3004614|ampS [Bartonella clarridgeiae 73] ,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcaacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2160,Drugs,MEG_2160|Drugs|betalactams|Class_A_betalactamases|CTX,1028104738|WP_063859984.1|NG_048956|1|1|blaCTX-M-170|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-170 NG_048956:1-876,0
,ATGAAAAAAGGATTTACTTTTTTAGATGAAATATTACACGGTGTTCGTTGGGACGCTAAATATGCTACATGGGACAATTTCACCGGAAAGCCGGTTGACGGATATGAAGTAAATCGCATTGCAGGAACATACGAGTTGGCCGACGCGCTTTTGAAGGTAAAAGAACTGGCTGCTGCTCAAGGGTACGGATTGCTTCTATGGGACGGTTACCGTCCCCAACGCGCTGTAAATTGTTTTGTGCAATGGGCTGCACAGCCGGAAGATGGCCTGACAAAGGAAAGATATTATCCCAATATTGACCGAACCGAGATGGTTTCAAAAGGATACGTGGCTTCAAAATCAAGCCATAGCCGCGGAAGTGCGATTGATCTTACGCTTTATCGATTAGACACGGGTGAGCTTGTACCAATGGGGAGCGGGTTTGATTTTATGGATGAACGCTCTCATCATGCGGCAAAAGGAATTTCAGGCAATGAAGCGCAAAATCGCAGATGTTTGCGTTCCATCATGGAAAACAGCGGGTTTGAAGCATATAGCTTCGAATGGTGGCACTATGTATTAAGAAACGAACCATACCCCAATAGCTATTTTGATTTCCCCGTCAAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7554,Drugs,MEG_7554|Drugs|Glycopeptides|VanA-type_resistance_protein|VANXA,(Gly)VanX-Pt2:AY926880:4769-5377:609,5
,atgaaaaacacaatacatatcaacttcgctatttttttaataattgcaaatattatctacagcagcgccagtgcatcaacagatatctctactgttgcatctccattatttgaaggaactgaaggttgttttttactttacgatgtatccacaaacgctgaaattgctcaattcaataaagcaaagtgtgcaacgcaaatggcaccagattcaactttcaagatcgcattatcacttatggcatttgatgcggaaataatagatcagaaaaccatattcaaatgggataaaacccccaaaggaatggagatctggaacagcaatcatacaccaaagacgtggatgcaattttctgttgtttgggtttcgcaagaaataacccaaaaaattggattaaataaaatcaagaattatctcaaagattttgattatggaaatcaagacttctctggagataaagaaagaaacaacggattaacagaagcatggctcgaaagtagcttaaaaatttcaccagaagaacaaattcaattcctgcgtaaaattattaatcacaatctcccagttaaaaactcagccatagaaaacaccatagagaacatgtatctacaagatctggataatagtacaaaactgtatgggaaaactggtgcaggattcacagcaaatagaaccttacaaaacggatggtttgaagggtttattataagcaaatcaggacataaatatgtttttgtgtccgcacttacaggaaacttggggtcgaatttaacatcaagcataaaagccaagaaaaatgcgatcaccattctaaacacactaaatttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4409,Drugs,MEG_4409|Drugs|betalactams|Class_D_betalactamases|OXA,1402729792|WP_110612827.1|NG_064754|1|1|blaOXA-796|blaOXA-1_like|OXA-1_family_class_D_beta-lactamase_OXA-796 NG_064754:101-931,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccagggcaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacggaccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5482,Drugs,MEG_5482|Drugs|betalactams|Class_C_betalactamases|PDC,1343491227|WP_104009843.1|NG_056402|1|1|blaPDC-247|blaPDC|class_C_beta-lactamase_PDC-247 NG_056402:1-1194,0
,ATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGTCTGCTAATCCAAATCACAGTGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACTACAGAAGTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGAACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAATGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTAGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAAACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGCTTAGAACAATTAGGTATTTTATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5210,Drugs,MEG_5210|Drugs|betalactams|Class_D_betalactamases|OXA,gi|160623381|gb|EU255288.1|1-825,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgagggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5560,Drugs,MEG_5560|Drugs|betalactams|Class_C_betalactamases|PDC,1509794541|WP_122630850.1|NG_062263|1|1|blaPDC-312|blaPDC|class_C_beta-lactamase_PDC-312 NG_062263:1-1194,0
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAACCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGAGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTNTGCGCGCGCTCACAGNCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTAAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6619,Drugs,MEG_6619|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,946|DQ464881.1|DQ464881|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,8
,TTGTTTAGTTTATATAAAAAATTTAAAGGTTTGTTTTATAGCGTTTTATTTTGGCTTTGTATTCTTTCATTTTTTAGTGTATTAAATGAAATGGTTTTAAATGTTTCTTTACCTGATATTGCAAATCATTTTAATACTACTCCTGGAATTACAAACTGGGTAAACACTGCATATATGTTAACTTTTTCGATAGGAACAGCAGTATATGGAAAATTATCTGATTATATAAATATAAAAAAATTGTTAATTATTGGTATTAGTTTGAGCTGTCTTGGTTCATTGATTGCTTTTATTGGTCACAATCACTTTTTTATTTTGATTTTTGGTAGGTTAGTACAAGGAGTAGGATCTGCTGCATTCCCTTCACTGATTATGGTGGTTGTAGCTAGAAATATTACAAGAAAAAAACAAGGCAAAGCCTTTGGTTTTATAGGATCAATTGTAGCTTTAGGTGAAGGGTTAGGTCCTTCAATAGGGGGAATAATAGCACATTATATTCATTGGTCTTACCTACTTATACTTCCTATGATTACAATAGTAACTATACCTTTTCTTATTAAAGTAATGGTACCTGGTAAATCAACAAAAAATACATTAGATATCGTAGGTATTGTTTTAATGTCTATAAGTATTATATGTTTTATGTTATTTACGACAAATTATAATTGGACTTTTTTAATACTCTTCACAATCTTTTTTGTGATTTTTATTAAACATATTTCAAGAGTTTCTAACCCTTTTATTAATCCTAAACTAGGGAAAAACATTCCGTTTATGCTTGGTTTGTTTTCTGGTTGGGCTAATATTTTCTATAGTAGCTGGTTTTATATCAATGGTGCCTTATATGATGAAAACTATTTATCATGTAAATGTAGCGACAATAGGTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7091,Drugs,MEG_7091|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETK,gi|408684196|gb|JX893516.1|956-1843 gi|51493750|gb|AY672108.1|9124-8237 gi|1045523|gb|U36910.1|SAU36910|1932-2819 gi|151679|gb|J01764.1|PT1CG|956-1843,4
,ATGAAAAGTGATTTTGTCTTTGTGGACGAGTTGGTATCAGGAATACGTTGGGATGCTAAATACGCCACCTGGGATAATTTTACCGGCAAACCGGTGGACGGCTATGCAGCCAATCGAATTGTCGGTACGAGAGCGTTGTGCGCGGCCTTGGAAAAAGCACGGGAAAACGCCGCATCCTTGGGCTTTGGCTTGCTTCTTTGGGATGGTTACCGCCCTCAATGCGCCGTAGATTGCTTTCTGCGCTGGTCTAAACAGCCGGAAGATGGCCGGACGAAACAGAAACACTATCCGAATATTGACCGATCCGAGATCATCGAAAAAGGATATGTGGCTGCCAAGTCGGGCCACAGCCGGGGCAGCGCCATTGATTTAACCCTTTATCATTTAGCTTCCGGAACACTTGTGCCCATGGGCGGTGATTTTGATTTGATGGATTCAGTCTCACATCATGGCGCACATGGAATCAGCCAAGCCGAAGCGAGAAACCGTCAATATCTTTGTTCGATCATGGAGGCCAGCGGTTTTGTTTCCTACGCTTGCGAGTGGTGGCATTACAGCCTGAAACACGAACCTTATCCCAACACTTACTTTGATTTTCTCATCGCCTAGCTGAGCCGGAGCTCAGCGTGCGGCGGCATCTGGGAATGCCGGCGGAAGTGAGCATAAGACCTGGCGGAATACATACAGTGTAAAACATGCTGTTCCGCTAGTGCAAAACCGGAAATAGCAATCTTGACGACGAGAGCTGTGAGGTGCTTTTTGCAATGGAAATGACAGTACGCGAAATCGTTGCCGCCTGCGGCGGAAAATTACTCTGCGGGGACCCGGATACGATGGTGACCTCGGTGGTGACCGACAGCCGGAAAGTGACCGACGGTTCCCTGTTTGTCCCCCTCAAAGGCGAAAAGGCGGACGCCCACACCTTTCTGCACGCCGCATTCGCCTCGGGTGCAGCCGCGGCACTGACCCAGGAGCATATGCGGATGGAGGCGGAAGAAGCCTGGATCGCGGTGGATTCGACTCAGCTGGCGCTCCAGCAGATTGCCGCCGCCTATCGGCAGAGATTTTCCATCCCTGTCGTCGGGATCACAGGGAGCGCCGGGAAGACGACGACGAAAGAAATGACCGCACTGGCACTTTCCGCAGGATACAAGGTGATGAAGACGGGAGGAAACCATAACAGCCAGATCGGACTGCCCCTGATGATGTTTCAGTTTTCCTGGGAACACGAAGCGGCGGTGGTGGAGATGGGGATAAGCGATTTCGGCGAAATGGCGCGCCTGGCTCAGGTCGCCGAGCCGAAGTACGCCGTCATGACCAACCTCGGCATTACTCACATCGGCCAGCTCAAAACCCAGGGGAACATCCTGCGGGAGAAGCTGCACATCACCGACCGGTTCACTCAGGGTTCCGTTCTGTTTTTAAACGGGGACGATCCGATGCTGGCCGGACTCCGCGGCAAGACAGGGTATGAGACCGTTTTTTATGGCAGGTTGCCTTGGTGTGATTTTCGCGCGGAGGGGATTACGGTTCAAGAGGAAACCACCGCTTTCCGCTGCCTTGCTCCGGGGAGCGAGAGCGTGGAGGTGACCCTGCCGGTACTGGGAATGCACCATGTTCTGGATGCCCTGGCCGCTCTGGCCGTGGCGGAGCGGCTGGGCGTGCCTCTGAAACGGGCCGCCGCCGCACTCAGGGATTACCGCCCCCTGGCCATGCGCCAGCAGATTTACCATGTCAATGAGGTTGCCGTCATTGATGATTCCTACAACTCCAGTCCCGGCGCGGCCAAAAGCAGCCTGAGTGTTCTTGCGGGGTTCCGGGCCGGCCGCAGAGTAGCCGTGCTGGCGGATATGCTGGAACTGGGGGAGTATTCCCGGCAGGCGCATTTTGAAGTCGGCGTCTGCGCTGCGGAAAACGGAGTGGATATTTTACTCACCGTCGGTCAGGAGGCGAAAGCCGTGGCCGAGGGTGCCCGCTCCGTCCGGGCCGGGATCGACTGCCGCGTTTTGGACAATAACTATCAGGCCGCTGAGGAGTTGAAATCCTTTCTGTCTCCCGGTGACGCAGTTCTGGTCAAAGGCTCCCGCGGCATGCATACGGAGGAGATCGTCCGCGCCCTGCTTTAGCTTCCCGTTAACCGGGCTTTCCAGCTGTACTTAAAACGGCGGTAGGGTGGTGAAACCATATTCCTGAAAGGGGTCTCGACATGAAAAGAAAAAGATTGACTCAGTTATTCCCATTCCTGCTGCCGGTCCGCAGGATACAACGGAAATTATGCTTCTATACCAAGATGTACCTTGACCGGAACCACTATGCCAAAGCAAAGGCTCCAGAGTTTTTGCCTTTTTGCATTTATGAAACCAAGTCGAAGCTTCTCAATGAAAATACCGGCATGGATATAAAATACCAGGAGAACAAGGTGTTTAATCTGCGCCTTGCTGCGGAGCCCGTCAATGGCCTATTGATCCGCCCTGGCGAAACATTTTCATTTTGGCAGCGGGTGAGATATGCCGAGAAAAATGAGCGGTATAAGGACGGTCTATGCGTGGTCAATGACGAATTGGTTACGGTTCCGGGAGGCGGTTTGTGTCATCTCAGCAATTTGCTGTTTTGGCTCTTTCTGCATACTCCCCTCACGATTGTCGAACGGCATGCTCATGAGATTAAAGATTTTCCTTCTCCCGATGAGGATGAACCGGATGGTGTGGACGCGACAATCCACGAAGGGTGGTTGGATTTAAAGGTCAAAAACGATACCAATCTTACCTTCCAAATTGAACTATCCATTGATGGGCCTTACATCTATGGCCGTATTTTTATGGATCAGGCTAAAGGGTATAGTTACGAGGTTGTTAATCGTGATAAGCGCTTTCTCCAAAAAGAGGGAAAAATATTTGAGCGGGTTTCCGTTTGCCGGCAGGTGATCGACAACAAATCCAAGCAAGTTATTTCCGAAAATATGCTTTATACGGATGTATTTGAAATCGGGTATCCGCTTCCGGAAGGAACTGCTATCGCAGAGGAAAAGGAAATTTGAAAGGAGAAAGCTTATGAGTAAGTTGAAAATCGCAATTATCTTCGGAGGCTGTTCCGAAGAACATCCCGTCTCCGTTAAATCTGCTGGGGAGGTGGCCAAAAACCTGGATCTCGAAAAGTATGAACCCTTCTATATCGGGATTACGAAAGATGGGGTTTGGCAGCTTTGTCACTACCCTGAGGCCAATTGGGAAAAGGGCAGTTGCCGTCCGGCTATCCTGTCACCGGACAGAAGCGTCCAGGGATTGCTTGTTCTGGAGCAGGGGCAATACCAAAGGATCCCCTTGGATCTGGTGTTTCCCGTTCTGCATGGCAAATTTGGCGAGGATGGCGCGATACAGGGTTTGTTGGAGCTTTCCGGCATCCCCTATGTGGGCTGCGATATCCCGAGTTCGGCTCTGTGCATGGACAAATCCCTGGCTTATATCGTCGCTGGAAAGGCAGGAATTGCCACGCCAAAGTTCCGGACGGTCACTGCGAAGGAGACTATTGACGCCGAACGGCTTGCTTATCCCGTTTATGTCAAGCCGGCCCGTTCGGGTTCATCCTTCGGCGTCACTAAGGTATGCCGCCAAGAAGAATTGCTGAGTGCGGTGGAAATCGCCAGACAGTATGACTCGAAGGTGCTGATTGAAGAGGCTGTCGTCGGCAGCGAGGTAGGCTGTGCGATATTTGGAAACGATCTGGATTTGATGGCCGGTGAGGTCGATCAGATCTGTCTGTCTCATGGCTTTTTCAGAATCCATCAGGAGAATGAGCCGGAAAAGGGTTCCGAAAACTCAACACTAATCGTTCCCGCCGACATTTCCCCAGAGGCGCGCTCGCGGGTTCAGGAGACGGCAAAAGCCATCTATCGCGCTTTGGGCTGCAGGGGACTGGCGCGGGTGGATATGTTTCTGAAAGAAGATGGAACAGTAATCCTCAACGAGGTGAATACTTTGCCCGGCATGACCTCATACAGCCGTTTTCCGAGAATGATGGCGGCCGCAGGCTTGCCCTTTGCCGAAGTGATCGACCGGCTTGTCTCGTTGGCCTTTTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7571,Drugs,MEG_7571|Drugs|Glycopeptides|VanM-type_resistance_protein|VANXM,vanXmurFvanWI_1_CP001336,5
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtgaatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacacggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_885,Drugs,MEG_885|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502190|WP_071846340.1|NG_052435|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052435:101-892,2
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaagcagtatcattaatcactagtgccatcttgcaaatggcgattattttttaccttacagaaaaaactggatccgcgatggtcttgtctatggcttcactattaggttttttaccctatgcggtctttggacctgcaattggtgtgttagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctggttcggtgcttactattgttgcattctatatggagctacctgtctggatggttatgatagtattgtttatccgtagcattggaacagcttttcacaccccggctctcaatgcggttacgccacttttagtaccagaagaacagcttacgaaatgtgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcggttgcagcactcttatactccgtttgggaactaaatgctattattgccatcgatgtattgggtgctgtgattgcaactattacggtagcaattgtacgtattcctaagctgggtgatcgcgtgcaaagtttggacccaaatttcataagagaaatgaaagaaggaatggctgtactacggcaaaataaaggattatttgctttattactcgttggaacattatatatgtttgtttatatgccaattaatgcactattccctttaattagcatggattactttaatggaacacctgtgcatatttctattacggaaatttcctttgcatctggaatgttgatagggggtctattattagggttatttgggaattaccaaaagcgaatcttattaataacggcatccatttttatgatggggataagcttaaccatttcaggattacttccccaaagtggatttttcatttttgtagtctgctgtgcaataatggggctttctgttccgttttacagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttaactggaagtatcatgtctcttgctatgccaattggattaattctttctgcactctttgctgatagaatcggtgtaaatcattggtttttactatcaggtattttaattatttgcattgcaatagtttgcccaatgataaatgagattagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3813,Drugs,MEG_3813|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028096928|WP_063853625.1|NG_047966|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047966:45-1262,7
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagctccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacagttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1827,Drugs,MEG_1827|Drugs|betalactams|Class_C_betalactamases|CMY,1046308072|WP_065644637.1|NG_051215|1|1|blaCMY-141|blaCMY|class_C_beta-lactamase_CMY-141 NG_051215:1-1146,0
,atgcgtaaaaaaatgcagaacacattgaagctgttatccgtgattacctgtctggcagcaactgcccaaggtgctctggctgctaatatcgatgagagcaaaattaaagacaccgttgatgacctgatccagccgctgatgcagaagaataatatccccggtatgtcggtcgcagtgaccgtcaacggtaaaaactacatttataactatgggttagcggcaaaacagcctcagcagtcggttacggaaaatacgttatttgaagtgggttcgctgagtaaaacgtttgctgccaccttggcgtcctatgcgcaggtgagcggtaagctgtctttggatcaaagcgttagccattacgttccagagttgcgtggcagcagctttgaccacgttagcgtactcaatgtgggcacgcatacctcaggcctacagctatttatgccggaagatattaaaaataccacacagctgatggcttatctaaaagcatggaaacctgccgatgcggctggaacccatcgcgtttattccaatatcggtactggtttgctagggatgattgcggcgaaaagtctgggtgtgagctatgaagatgcgattgagaaaaccctccttcctcagttaggcatgcatcacagctacttgaaggttccggctgaccagatggaaaactatgcgtggggctacaacaagaaagatgagccagtgcacgtgaatatggagattttgggtaacgaagcttatggtatcaaaaccacctccagcgacttgttacgctacgtgcaagccaatatggggcagttaaagcttgatgctaatgccaagatgcaacaggctctgacagccacccacaccggctatttcaagtcgggtgagattactcaggatctgatgtgggagcagctgccatatccggtttctctgccgaatttgctcaccggtaacgatatggcgatgacgaaaagcgtggctacgccgattgttcccccgttaccgccacaggaaaatgtgtggattaataagaccggatcaactaacggcttcggtgcctatattgcgtttgttcctgctaagaagatggggatcgtgatgctggctaacaaaaactactcaatcgatcagcgagtgacggtggcgtataaaatcctgagctcattggaagggaataagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_386,Drugs,MEG_386|Drugs|betalactams|Class_C_betalactamases|ACC,496091043|WP_008815550.1|NG_048592|1|1|blaACC-1d|blaACC|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACC-1d NG_048592:1-1173,0
,ATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAGATTCTCTACCGTGCCGATGAACGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAAGAAGAGCGACCTGGTTAACTACAATCCCATTGCGGAGAAACACGTTAACGGCACGATGACGCTGGCTGAGCTTGGCGCAGCGGCGCTGCAGTATAGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGTCCCGATAAAGTGACGGCGTTTGCTCGCTCGTTGGGTGATGAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATACCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAAGCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTCTGCCGAAATCATGGGTAGTGGGCGATAAAACCGGCAGCGGAGGTTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGAAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGCCGTCGGGATATTCTGGCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2217,Drugs,MEG_2217|Drugs|betalactams|Class_A_betalactamases|CTX,(Bla)CTX-M-131:JN969893:1-873:873,0
,atgagccatattcaacgggaaacgtcttgctcgaggccgcgattaaattccaacctggatgctgatttatatgggtataaatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggcatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgctccccgggaaaacagcattccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagcgttcctgcgccggttgcattcgattcctgttagtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataagcttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgaattttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctga,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1027,Drugs,MEG_1027|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,445940466|WP_000018321.1|NG_056047|1|1|aph(3')-Ia|aph(3')-Ia|aminoglycoside_O-phosphotransferase_APH(3')-Ia NG_056047:101-916,2
,CCTCACTCAAGGATGTATTGTGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCAGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6424,Drugs,MEG_6424|Drugs|betalactams|Class_A_betalactamases|SHV,gi|160948456|emb|AM176556.2|1-886,0
,gtgaccaactgcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgggtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggacggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccatatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_244,Drugs,MEG_244|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1028080937|WP_063840320.1|NG_047292|1|1|aac(6')-Ib-cr6|aac(6')-Ib-cr|fluoroquinolone-acetylating_aminoglycoside_6'-N-acetyltransferase_AAC(6')-Ib-cr6 NG_047292:101-655,2
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3481,Drugs,MEG_3481|Drugs|betalactams|Class_A_betalactamases|KPC,1693892934|WP_140423311.1|NG_065427|1|1|blaKPC-44|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-44 NG_065427:1-927,0
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagataagttgggtgcacgagtgggttacatcgagctggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttaagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaacccgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggaggcagtgagcgtggatctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6658,Drugs,MEG_6658|Drugs|betalactams|Class_A_betalactamases|TEM,1028110628|WP_063864906.1|NG_050252|1|1|blaTEM-22|blaTEM|class_A_extended-spectrum_beta-lactamase_TEM-22 NG_050252:101-961,0
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatacctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6661,Drugs,MEG_6661|Drugs|betalactams|Class_A_betalactamases|TEM,1343491239|WP_104009855.1|NG_056418|1|1|blaTEM-231|blaTEM|class_A_beta-lactamase_TEM-231 NG_056418:1-861,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgctcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgacagcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcaacaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcttggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5625,Drugs,MEG_5625|Drugs|betalactams|Class_C_betalactamases|PDC,1034011099|WP_064484002.1|NG_050793|1|1|blaPDC-137|blaPDC|class_C_beta-lactamase_PDC-137 NG_050793:1-1194,0
,atgaagaagctcacggccgcgctgtgtgcgctggcgtttttcgcaacgggcgcgcaggcgcagacggtcaaggatttcattgcggcggtcaccaagaaatggaccacgccgttcgagccgttccagctgatcgacaacatctattatgtcggcaccgacggcatcgccgtctacgtcatcaagacctcgcaaggcctgatcctgatggacacggcgcttccacagtctaccggcatgatcaaggacaacatcacgaagctcggcctgaaggtcgccgacatcaagatcatcctcaacacgcacgcgcatttcgatcacaccggcggcttcgccgaggtcaagaaggagaccggcgcgcagctcatcgccggcgagcgcgacaagccgctgctcgaaggcggctactatcccggcgacgagaagaacgaggatctcgccttccccgcggtcaaggtcgatcgcaccgtgaaggaaggcgataaggtcacgcttggtgagaccacgctgacggcgcacgccactcccggccactcgccgggctgcacgagctgggagatgaccgtcaaggacggcggccaggaccgccaggtgctgttcttctgcagcggcacggtggcgctaaaccggctggtcggccagccaacccacgccggcatcgtcgacgactatcgcgcgacctatgccaaggtgaaggcgatgaagatcgacgtcctgctcggaccgcatcccgaagtctacggcatgcaggccaagcgcgcggcaatgaaggacggcgcaccgaacccgttcgtcaagcccggcgagctcgcgacctacgcgaccagcctgtcggaggacttcgacaagcagctcgccaagcagacagcggcgctagagaagaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1234,Drugs,MEG_1234|Drugs|betalactams|Class_B_betalactamases|BJP1,505722318|WP_015684602.1|NG_055769|1|1|blaBJP|blaBJP|BJP_family_subclass_B3_metallo-beta-lactamase NG_055769:101-985,0
,gtgcgctcaaaaaattttagttggcggtactcccttgccgccacggtgttgttgttatcaccgttcgatttattggcatcactcggcatggacatgtacttgccggcagtgccgtttatgccaaacgcgcttggtacgacagcgagcacaattcagcttacgctgacaacgtacttggtcatgattggtgccggtcagctcttgtttggaccgctatcggaccgactggggcgccgccccgttctactgggaggtggcctcgcctacgttgtggcgtcaatgggcctcgctcttacgtcatcggctgaagtctttctggggcttcggattcttcaggcttgtggtgcctcggcgtgccttgtttccacgtttgcaacagtacgtgacatttacgcaggtcgcgaggaaagtaatgtcatttacggcatactcggatccatgctggccatggtcccggcggtaggcccattgctcggagcgctcgtcgacatgtggcttgggtggcgggctatctttgcgtttctaggtttgggcatgatcgctgcatctgcagcagcgtggcgattctggcctgaaacccgggtgcaacgagttgcgggcttgcaatggtcgcagctgctactccccgttaagtgcctgaacttctggttgtacacgttgtgttacgccgctggaatgggtagcttcttcgtctttttctccattgcgcccggactaatgatgggcaggcaaggtgtgtctcagcttggcttcagcctgctgttcgccacagtggcaattgccatggtgtttacagctcgttttatggggcgtgtaatacccaagtggggcagcccaagcgtcttgcgaatgggaatgggatgcctgatagctggagcagtattgcttgccatcaccgaaatatgggcttcgcagtccgtgttaggctttatttctccaatgtggctagtgggtattggtgtcgccacagcggtatctgtggcgcccaatggcgctcttcgaggattcgaccatgttgctggaacggtcacggcagtctacttctgcttgggcggtgtactgctaggaagcatcggaacgttgatcatttcgctgttgccgcgcaacacggcttggccggttgtcgtgtactgtttgacccttgcaacagtcgtgctcggtctgtcttgtgtttcccgagcggagggctctcgcggccagggggagcatgatgtggtcgcgctacaaagtgcggaaagtacgtcaaatcccaatcgttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1761,Drugs,MEG_1761|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,447179520|WP_001256776.1|NG_047647|1|1|cmlA1|cmlA1|chloramphenicol_efflux_MFS_transporter_CmlA1 NG_047647:101-1360,6
,atgaaaatcgtaaaaaggatattattagtattgttaagtttattttttacaattgtgtattcaaatgctcaaactgacaacttaactttgaaaattgagaatgttttaaaggcaaaaaatgccagaataggagtagcaatattcaacagcaatgagaaggatactttgaagattaataacgacttccatttcccgatgcaaagcgttatgaaatttccgattgctttagccgttttgtctgagatagataaagggaatctttcttttgaacaaaaaatagagattacccctcaagaccttttgcctaaaacgtggagtccgattaaagaggaattccctaatggaacaactttgacgattgaacaaatactaaattatacagtatcagagagcgacaatattggttgtgatattttgctaaaattaatcggaggaactgattctgttcaaaaattcttgaatgctaatcatttcactgatatttcaatcaaagcaaacgaagaacaaatgcacaaggattggaatacccaatatcaaaattgggcaaccccaacagcgatgaacaaactgttaatagatacttataataataagaaccaattactttctaaaaaaagttatgattttatttggaaaattatgagagaaacaacaacaggaagtaaccgattaaaaggacaattaccaaagaatacaattgttgctcataaaacagggacttccggaataaataatggaattgcagcagccactaatgatgttggggtaattactttaccgaatggacaattaatttttataagcgtatttgttgcagagtccaaagaaacttcggaaattaatgaaaagattatttcagacattgcaaaaataacgtgggattactatttgaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7648,Drugs,MEG_7648|Drugs|betalactams|Class_A_betalactamases|VEB,1226997335|WP_094009812.1|NG_055500|1|1|blaVEB-19|blaVEB|class_A_extended-spectrum_beta-lactamase_VEB-19 NG_055500:1-900,0
,atcatgatgtcgaaaaaattaaaatgtctggccttttttacagccatcttttttgcaattcccatgactgcttgtcaaagttttagccaacaaaagcaacagctctcgacacaaaaaaatgagcagcagcagatctcaagtttattccagagtgcccaaaccagtggtgttttggtgatttatgatggtaagaaaattcaaagctatggcaatgacgtacatcgtgcagaacagcgctatattcctgcctcaacctttaaaatgttaaacgccttgatcggaatacagcatcataagaccacaccagatgaagtgtttaaatgggacggcaaaaagcgggcatttagcagttgggaaaaagatttaaccttagctgaggcgatgcaggcatcggcggtacctgtctatcaagaattggcaagacgtattggcttggaactgatgagccgtgaagtaaagcgtgtgggttatggtaataaaaatatcgggacacaagtcgataatttctggttagttggccccttaaaaatcactcccgtagaagaagttcgctttgcctatgcgctggcaaaacagaaactgccctttgaccagccaacgcagcaacaagtcaaagcgatgttattggtggatcagattcagggtaccaaaatctatgccaaaagtggttggggaatggatgtcagcccgcaagtgggatggtggacaggctggattgaacagccaaatggcaagatcactgcattttcactcaatatgcaaatgagccagcctgagcatgcagatgcacgtaaggcgattgtgtatcaagccttgcaggagttgggattgttagcccattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4640,Drugs,MEG_4640|Drugs|betalactams|Class_D_betalactamases|OXA,1174040756|WP_081406929.1|NG_062226|1|1|blaOXA-674|blaOXA-286_like|OXA-286_family_class_D_beta-lactamase_OXA-674 NG_062226:101-943,0
,atgatcatgtcgaaaaaattaacatgtctggccctgtttacagccatcttttttgcgattcccatggccgcttgtcaaagttttagtcaacaaaagcaacagctttcgacacagaaaaatgaacagcaacagatttcaagcttatttcagagtgcccaaaccagtggtgttttggtgatttatgatggcaagaaaattcaaagctatggcaatgatcttgatcgtgcagaacagcgctatattcctgcctcaacctttaaaatgctaaatgccttgattggtatacaacatcataagaccacaccagatgaagtgtttaaatgggatggcaaaaagcgggcattcagcagttgggaaaaagatttaaccttagctgaagcgatgcaggcatcggcggtacctgtgtatcaggaactagcaagacgtattggcttggagttaatgacccgtgaagtgaagcgtgtgggttatggcaataaaaatattgggacacaagttgataatttctggttagttggcccattaaaaatcacccccgtagaagaagttcgctttgcctatgcgttggcaaaacagaaattgccatttgaccagccaacacagcaacaagtcaaagcgatgttattggtggatcagattcagggaactaaaatctatgcaaaaagtggttggggcatggatgttagcccgcaagtgggatggtggacaggctggattgaacagccaaatggtaagatcacagccttctcactgaatatgcaaatgagccagcctgagcatgcagatgcacgtaaagcgattgtgtatcaagccttgcaacagttgggattgttagcccattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4593,Drugs,MEG_4593|Drugs|betalactams|Class_D_betalactamases|OXA,490795061|WP_004657207.1|NG_049584|1|1|blaOXA-286|blaOXA-286_like|class_D_beta-lactamase_OXA-286 NG_049584:101-943,0
,atgaaccgcactgtgatgatggcactggtcatcatttttttagatgccatagggattggcataattatgcctgtcttaccggcgttattacgggagtttgttggaaaggctaatgttgcggagaactacggtgttttattggcgctgtatgcaatgatgcaagtgatttttgcccctcttctcggccgctggtcagatcgcataggtcgtcgccctgtattattactttcacttttaggtgcaacactggactacgcattaatggcaacagccagcgtagtgtgggtgttgtatctgggacgcttaattgctggtattaccggtgcgactgtagctgttgcagcctcaacaattgccgatgtcacacctgaggaatccaggacacattggtttggtatgatgagtgcctgttttggtggcggtatgattgctggaccagtcattggtggttttgcaggtcaactttcggtacaggcaccgtttatgttcgctgctgccattaacgggctggcatttctggtctccctattcattttacatgagacccataatgctaatcaggttagtgacgagataaagaatgaaacaatcaatgaaaccacatcctccatacgcgagatgatctccccattatcgggattgctagttgtctttttcatcattcaattgattggccaaatccctgcaacattatgggttttattcggagaagagcgcttcgcatgggatggcgtaatggtcggtgtttcattggctgtgtttgggcttacacacgctctgtttcaaggacttgctgctggttttatcgctaaacatttgggagaacagagagctatcgtggttggcatcttggctgatggctgtggcctacttttattggcagtcattacgcaaagctggatggtttggccagttgtgctgttactcgcttgtggtggcataactcttcccgctttgcagggaattatatctgttcgtgtcggtcaggtagcacagggacaattgcaagggttgctgaccagtttgacacacctcacgggtgtaatcggtccacttatttttgcatttttgtatagtgcaacccacgaatcttggaatggttgggtgtggatagttggatgcggattgtatgtagttgcactgactatactgaggtttttctatcccggcagggcagtccacccgaaaaatcagagcaattcacagccatttctttaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7071,Drugs,MEG_7071|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETE,695263298|WP_032490168.1|NG_048187|1|1|tet(E)|tet(E)|tetracycline_efflux_MFS_transporter_Tet(E) NG_048187:101-1318,4
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattgtaatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttaaaagagctaaacaagccttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagctataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgataccttttggctcgataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcgcaaaattctttacctttttccaaaaaaagtcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagagaagaattgctagaaaaatatctagcaatcataacaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4582,Drugs,MEG_4582|Drugs|betalactams|Class_D_betalactamases|OXA,766599280|WP_044779552.1|NG_057544|1|1|blaOXA-638|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-638 NG_057544:1-750,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagccgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3467,Drugs,MEG_3467|Drugs|betalactams|Class_A_betalactamases|KPC,1407696520|WP_111273852.1|NG_060524|1|1|blaKPC-35|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-35 NG_060524:1-882,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAARCAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTARCAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGGCATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATTGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGAYAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1325,Drugs,MEG_1325|Drugs|betalactams|Class_A_betalactamases|BLAZ,gi|695200788|ref|NG_036179.1|6-851,0
,atgtctgcatacggacacggccgtcacgagcatggccaaaattttttcaccaaccacaagatcatcaagtccatcatcgaccttgtgaaacaaacctccggccccatcattgagatcggaccaggaagcggtgccctcactcacccgatggcccacttggggagggcgataacggcagttgaagtggacgcaaaactagctgccaaaatcacacaagaaacctcctcggcggcggtcgaagtggtccatgatgatttccttaacttccggttacccgccactccctgcgtcattgtgggaaacattccctttcacctcaccactgccattcttcgaaagttgctgcatgcgccagcatggactgacgctgtactcctcatgcagtgggaagtcgctcgccgccgggccggggtaggcgcaagcacgatgatgacggctcagtggtccccatggttcacatttcacctgggttctcgggtaccaaggtctgctttccggccacagccaaacgttgacggggggatcttagtgatccgccgggtgggtgacccgaagattccgatagagcagcgcaaagcctttcaggcgatggtgcacaccgttttcactgcccggggacgcgggataggggaaattctccgaagggcagggttgttttcatcacgttcagaaacacaatcatggttgcgctcgcgaggaatcgaccccgcgaccctacctcccagattgcacaccaacgactggatcgatctcttccaggtgactggttcctctctacctcaccatcgacccatttcaccatcgggaagtagtcaacgacctcctcaacggaaaaaccgaagccggcggcgttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2858,Drugs,MEG_2858|Drugs|MLS|23S_rRNA_methyltransferases|ERMX,1028086515|WP_063844889.1|NG_047850|1|1|erm(X)|erm(X)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(X) NG_047850:101-955,7
,TTGAATCGAACTAATATTTTTTTTGGTGAATCGCATTCTGACTGGTTGCCTGTCAGAGGCGGAGAATCTGGTGATTTTGTTTTTCGACGTGGTGACGGGCATGCCTTCGCGAAAATCGCACCTGCTTCCCGCCGCGGTGAGCTCGCTGGAGAGCGTGACCGCCTCATTTGGCTCAAAGGTCGAGGTGTGGCTTGCCCCGAGGTGATCAACTGGCAGGAGGAACAGGAGGGTGCATGCTTGGTGATAACGGCAATTCCGGGAGTACCGGCGGCTGATCTGTCTGGAGCGGATTTGCTCAAAGCGTGGCCGTCAATGGGGCAGCAACTTGGCGCTGTTCACAGCCTATCGGTTGATCAATGTCCGTTTGAGCGCAGGCTGTCGCGAATGTTCGGACGCGCCGTTGATGTGGTGTCCCGCAATGCCGTCAATCCCGACTTCTTACCGGACGAGGACAAGAGTACGCCGCAGCTCGATCTTTTGGCTCGTGTCGAACGAGAGCTACCGGTGCGGCTCGACCAAGAGCGCACCGATATGGTTGTTTGCCATGGTGATCCCTGCATGCCGAACTTCATGGTGGACCCTAAAACTCTTCAATGCACGGGTCTGATCGACCTTGGGCGGCTCGGAACAGCAGATCGCTATGCCGATTTGGCACTCATGATTGCTAACGCCGAAGAGAACTGGGCAGCGCCAGATGAAGCAGAGCGCGCCTTCGCTGTCCTATTCAATGTATTGGGGATCGAAGCCCCCGACCGCGAACGCCTTGCCTTCTATCTGCGATTGGACCCTCTGACTTGGGGTTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1045,Drugs,MEG_1045|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,(AGly)StrA:AB366441:22458-23261:804,2
,AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGACGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6937,Drugs,MEG_6937|Drugs|betalactams|Class_A_betalactamases|TEM,gi|695200248|ref|NG_035413.1|1-973,0
,GGCATCCAAGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTATGCCGCACTCACCCCCATGGAGTTTTGATGTTCAAACTTTTGAGTAAGTTATTGGTCTATTTGACCGCGTCTATCATGGCTATTGCGAGTCCGCTCGCTTTTTCCGTAGATTCTAGCGGTGAGTATCCGACAGTCAGCGAAATTCCGGTCGGGGAGGTCCGGCTTTACCAGATTGCCGATGGTGTTTGGTCGCATATCGCAACGCAGTCGTTTGATGGCGCAGTCTACCCGTCCAATGGTCTCATTGTCCGTGATGGTGATGAGTTGCTTTTGATTGATACAGCGTGGGGTGCGAAAAACACAGCGGCACTTCTCGCGGAGATTGAGAAGCAAATTGGACTTCCTGTAACGCGTGCAGTCTCCACGCACTTTCATGACGACCGCGTCGGCGGCGTTGATGTCCTTCGGGCGGCTGGGGTGGCAACGTACGCATCACCGTCGACACGCCGGCTAGCCGAGGTAGAGGGGAGCGAGATTCCCACGCACTCTCTAGAAGGACTCTCATCGAGCGGGGACGCAGTGCGCTTCGGTCCAGTAGAACTCTTCTATCCTGGTGCTGCGCATTCGACCGACAACTTAGTTGTGTACGTCCCGTCTGCGAGTGTGCTCTATGGTGGTTGTGCGATTTATGAGTTGTCACGCACGTCTGCGGGGAACGTGGCCGATGCCGATCTGGCTGAATGGCCCACCTCCATTGAGCGGATTCAACAACACTACCCGGAAGCACAGTTCGTCATTCCGGGGCACGGCCTGCCGGGCGGTCTAGACTTGCTCAAGCACACAACGAATGTTGTAAAAGCGCACACAAATCGCTCAGTCGTTGAGTAGCAGGCAGATGCGGCATAACA,beta-lactamase,antibiotic inactivation,betalactams,MEG_7765,Drugs,MEG_7765|Drugs|betalactams|Class_B_betalactamases|VIM,gi|54887317|gb|AY605049.2|1-948 gi|51571647|emb|AJ628983.2|954-1901,0
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGCGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGTGAAATTGTTATCCTTCCCAGCGACAGCGTGAGGTTAAACGATGTATTAGGGGACCCAACCCGGCTCCCTCGTAAAAGGTGGCGTGAGGACCCCCTCCCCATGCTGCGGACGTCGATTGCGCCGAAAACGGCAGCGCAAAGAGCACGGCTGCTGGACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGCTGCGAGGTGGATTCCATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTTGTTTCCGCTTTGCTGTCGGAAAAATACAAGCTTGAAACAGTGGTAAAGGAACCCACCGTCATTTATATGGAGCGGCCGCTCAAAGCAGCCAGCCACACCATCCATATCGAGGTGCCGCCCAACCCGTTTTGGGCATCCATCGGACTGTCTGTTACACCACTCCCGCCTGGCTCCGGTGTACAATACGAGAGCCGGGTTTCGCTGGGATACTTGAACCAGAGTTTTCAAAACGCTGTCAGGGATGGTATCCGTTACGGGCTGGAGCAGGGCTTGTTCGGCTGGAACGTAACGGACTGTAAGATTTGCTTTGAATACGGGCTTTATTACAGTCCGGTCAGCACGCCGGCGGACTTCCGCTCATTGGCCCCGATTGTATTGGAACAGGCATTGAAGGAATCAGGGACGCAACTGCTGGAACCTTATCTCTCCTTCACCCTCTATGCGCCCCGGGAATATCTTTCCAGGGCTTATCATGATGCACCGAAATACTGTGCCACCATCGAAACGGTCCAGGTAAAAAAGGATGAAGTTGTCTTTACTGGCGAGATTCCCGCCCGCTGTATACAGGCATACCGTACTGATCTGGCCTTTTACACCAACGGGCAGAGCGTATGCCTTACAGAACTGAAAGGGTATCAGGCCGCTGTCGGCAAGCCAGTCATCCAGCCCCGCCGTCCAAACAACCGCCTGGACAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7169,Drugs,MEG_7169|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/W)_3_AM889120 ,4
,atgaacaaaaatataaaatattctcaaaactttttaacgagtgaaaaagtactcaaccaaataataaaacaattgaatttaaaagaaaccgataccgtttacgaaattggaacaggtaaagggcatttaacgacgaaactggctaaaataagtaaacaggtaacgtctattgaattagacagtcatctattcaacttatcgtcagaaaaattaaaactgaatactcgtgtcactttaattcaccaagatattctacagtttcaattccctaacaaacagaggtataaaattgttgggagtattccttaccatttaagcacacaaattattaaaaaagtggtttttgaaagccatgcgtctgacatctatctgattgttgaagaaggattctacaagcgtaccttggatattcaccgaacactagggttgctcttgcacactcaagtctcgattcagcaattgcttaagctgccagcggaatgctttcatcctaaaccaaaagtaaacagtgtcttaataaaacttacccgccataccacagatgttccagataaatattggaagctatatacgtactttgtttcaaaatgggtcaatcgagaatatcgtcaactgtttactaaaaatcagtttcatcaagcaatgaaacacgccaaagtaaacaatttaagtaccgttacttatgagcaagtattgtctatttttaatagttatctattatttaacgggaggaaataa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2794,Drugs,MEG_2794|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,488221018|WP_002292226.1|NG_047794|1|1|erm(B)|erm(B)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B) NG_047794:101-838,7
,ATGACGCCATTACTGTATAAAAAAACAGGCATAGATATGACTCTGGCATTAGTTGGCGAAAAAATTGACAGAAATCGCTTCACCGGTGAGAAAGTTGAAAATAGTACATTTTTTAACTGCGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGCCAGTTCTATGATCGCGAAAGTCAGAAAGGATGCAATTTTAGTCGCGCAATGCTGAGAGATGCCATTTTCAAAAGCTGTGATTTATCAATGGCAGATTTCCGCAACGTCAGCGCATTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGTGCAAGCTTTATGAATATGATCACCACGCGCACCTGGTTTTGCAGCGCATATATCACTAATACCAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTATGGGAAAACCGCTGGATGGGGACTCAGGTACTGGGTGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTAGGTGACTTAGATATTCGGGGTGTTGATTTACAAGGCGTTAAGTTAGACAACTACCAGGCATCGTTGCTCATGGAGCGGCTTGGCATCGCGGTAATTGGTTA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_5923,Drugs,MEG_5923|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,(Flq)QnrB47:JQ349155:1-680:680,3
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaaaatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_862,Drugs,MEG_862|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,499541312|WP_011222095.1|NG_052324|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052324:101-892,2
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtgacaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaaaagttaaaaatgatggctagtgagtatttcgtaaaatgcaaaaatacttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4388,Drugs,MEG_4388|Drugs|betalactams|Class_D_betalactamases|OXA,1391852923|WP_109545108.1|NG_057542|1|1|blaOXA-605|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-605 NG_057542:1-807,0
,atgacgtggagaacgaccagaacacttttacagcctcaaaatctggacttcaatgagtttgagattcttacttccgtaattgagggcgcccgaattgtcggcattggcgagggcgctcattttgtcgcggagttttcactggctagagcaagtcttatccgctatttggtcgaaaggcatgattttaatgcgattggtttggaatgtggggcgattcaggcatcccggttatctgaatggctcaactcaacagccggtgctcatgaacttgagcgattttcggataccctgaccttttctgtgtatggctcagtgctgatctggctgaaatcatatctccgcgaatcaggaagaaaactgcagttagtcggaatcgacttacccaacaccctgaacccaagggacgacctagcgcaattggccgaaattatccagctcatcgatcacctcatgaaaccgcacgttgatatgctgactcacttgttggcgtccattgatggccagtcggcggttatttcatcggcaaaatggggggagctagaaacggctcggcaggagaaagctatctcaggggtaaccagattgaagctccgcttggcgtcgcttgcccctgtactgaaaaaacacgtcaacagcgatttgttccgaaaagcctctgatcgaatagaatcgatagagtatacgttggaaaccttgcgtataatgaaaactttcttcgatggtacctctcttgagggagatacttccgtacgtgactcgtatatggcgggcgtagtagatggaatggttcgagcgaatccggatgtgaagataattctgctggcgcacaacaatcatttacaaaaaaccccagtctccttttcaggcgagcttacggctgttcccatggggcagcacctcgcagagagggtgaattaccgtgcgattgcattcacccatcttggacccaccgtgccggaaatgcatttcccatcgcccgacagtcctcttggattctctgttgtgaccacgcctgccgatgcaatccgtgaggatagtatggaacagtatgtcatcgacgcctgtggtacggagaattcatgtctgacattgacagatgcccccatggaagcaaagcgaatgcggtctcaaagcgcctctgtaaaaacgaaattgagcgaggcatttgatgccatcgtctgtgttccaagcgccggcaaggacagcctagttgccctatag,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_2744,Drugs,MEG_2744|Drugs|MLS|Macrolide_esterases|EREA,692128548|WP_032084014.1|NG_047767|1|1|ere(A)|ere(A)|EreA_family_erythromycin_esterase NG_047767:101-1321,7
,ATGAATAAAAAAATGGATATTACTGTTTTTGGATGTGAGTCAGACGAAATGGAGGTTTTTCAAAAGATTTCTTATGAGCTTGGTGTTACAGCTACACTCATAAAAGATTCTATATCAGAAAGCAATGCTGGATTAGCTGATGGATGCTGCTGCGTAAGCGTAAGCCATAAAGCGGAGCTGTCAGAACCGATTCTTCTTGCACTAAAAAATGCAGGGGTAAAGTATATCAGTACCCGGAGCATTGGCTTTAACCATATTGATATACAGGCGGCCGGGTTGCTGGGTATGGTTGTTGGCACGGTAGAATACTCGCCGGGAAGTGTGGCCGATTATACCGTCATGCTGATGCTTATGCTGATGCGCGGCACAAAGTCGATTCTGCGTGAAACCCAGAGGCAGAATTATTGCCTGAATGACCTGCGCGGAAAAGAACTGCGGGATATGACCGTCGGTGTGTTAGGAACTGGGCGAATCGGACAGGCAGTCATGGAACGCCTGAAGGGATTCGGCTGTAAGGTATTGGCGTATGACCGAAATCAAAAAGCAGGAACGGACTATGTTTCGTTTCATGAACTGCTGAAAAAAAGTGATATTGTTACACTGCATATTCCGTTGGCAGAAGATACCCGCCATATGATTGGATGTGAAGAGCTGGAAATGATGAAGCAGGAGGCGCTTCTGATCAATACAGGACGGGGCGCTTTAGTGGATACCGCAGCATTGGTAGAAGCATTAAAAGGACAGAAAATCGGCGGTGCCGCCCTGGATGTTTTAGAGGGCGAAGAAGGTATCTTTTACCATGACTGCACTCAAAGAACGATAGAGCATCCTTTCCTGTCTGTCCTGCAGGGAATGCCGAATGTCATTGTTACGCCGCACACAGCCTATCATACGGATCGGGTACTGGTCGATACCGTGAGCAATACCATCCGAAATTGTCTGAATTTTGAAAGGAGTCTTGGAAATGTATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7427,Drugs,MEG_7427|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,gi|40021670|gb|AY489045.1|3046-4017 gi|54114872|dbj|AB183866.1|1-79,5
,atgtctgatttcattcagttagaatatctacaagaaaaattacagcaacttttagcggaatcattatttgcaatctatctttatggttcagctgttgatggtggcttagggccagaaagtgaccttgatgttctggtcgtggttactcaaccattaacatctgctttacgcgagcagcttgcacaagaattactaaaaatttcacagcctgttggagaattacaaagaccattagaagttactattttattaaaagacgagattcagtctggaaattatcctttaagttatgaaatgcagtttggtgaatggctacgtgaagaacttaaagaaggtggaacattaagttcgcagaaagacccagatattagtatattgcttagaaaagcgagatttcatcatgcagttttatttggtccagctttagaccaatgggcacctgaaatttctgatcaagaactatggcaagcaatgtctgatacttatcccgaaattgtagctcattgggatgaggatgcagatgaaagaaaccagattttagctttatgccggatctattttagtttagtcatgaaggatattgcttcaaaaggcaatgcagctcgatgggttatgcctcagcttcctcctgagcagaaattcgtattgcagcggcttatacaggaatatagaggggaaatcggtaaacaaaattggcaagaggaacattatgctttgcagcctattgttaattttctgagttcaaaaattgaagagcagtttgagcagaaaagaaatttgatcacataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_913,Drugs,MEG_913|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,447201806|WP_001279062.1|NG_054646|1|1|ant(3'')-IIa|ant(3'')-IIa|aminoglycoside_nucleotidyltransferase_ANT(3'')-IIa NG_054646:1-789,2
,ATGAGAAACTTTGCAATTTTATTTTTTTTACTGATCACTTTCAGCTGGAAAGCACAGGTTGTTAAAGAACCGGAAAATACAAATGAAGAATGGTCCCGATCATATGAGCCATTCAGAATTGCGGGTAACTTATACTATGTAGGAACTTACGATCTGGCTTCTTATTTAATAGTTACCGATAAAGGAAATATTCTCATTAATACAGGATTGGCAGGTTCTCTTCCTATGATAAAAGAGAATATTAAAAAACTGGGATTCAATTATAAAGACATTAAAATTCTGCTTTTAACCCAGGCGCATTATGATCATACAGGTGCATTAAAAGATTTGCAAACAGAAACAGGTGCGAAATTTTATGCAGACAGTGCTGATGCTGATGTATTGAAAACGGGCGGTAAATCCGATTATGAAATGGGGAAATACGGGGCAACCTTTAAGCCGATTAAGCCTGATATCCTGTTGAAAGATCAGGATAAAATAAAACTGGGGAATACAACCTTAACTTTACTTCATCATCCGGGGCACACAAAAGGTTCATGCAGTTTTATATTTGAAACAAAGGATGAAAACAGAAATTACAAAGTGCTGATAGCCAATATGCCATCGGTTATAGTTGACCGTAAGTTTTCCGAAATAAAAGATTACCCTAATATTCAGGCCGATTATGCTTATACATTTAAAGCCATGAAAAAACTGGATTTTGATCTTTGGGTCGCTTCACATGCAAGTCAGTTTGATTTACATACAAAACATAAAGAGGGAGACCCTTATAACCCACAGGTATTTATGGATAAGGCCAATTATTTTGCATTCCTCAATAGCCTGGAAACAGATTATCTGGAAAAAATTAAAAACGACTCACAAAAGAAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3150,Drugs,MEG_3150|Drugs|betalactams|Class_B_betalactamases|GOB,(Bla)GOB-17:AY899332:1-873:873,0
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAACCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGAGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6637,Drugs,MEG_6637|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|952556149|emb|LN879484.1|11950-11135 gi|690385522|gb|KM023773.1|15734-14919 gi|394343076|gb|CP003683.1|2037047-2036232 gi|695220958|ref|NG_039594.1|7577-6762 gi|145848882|emb|AM412236.1|98642-99457,8
,atgagtattcaacattttcgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatggtgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgagatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6671,Drugs,MEG_6671|Drugs|betalactams|Class_A_betalactamases|TEM,1132963065|WP_075985685.1|NG_052650|1|1|blaTEM-36|blaTEM|inhibitor-resistant_class_A_broad-spectrum_beta-lactamase_TEM-36 NG_052650:1-861,0
,atgcgatttaaaaaaatttcttgtctacttttctccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcgatcaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtagctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaaagggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccgacacctttacaaactttattagacagtaattcagaacaaattgtgatgaagcctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgtattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_617,Drugs,MEG_617|Drugs|betalactams|Class_C_betalactamases|ADC,690996864|WP_031965243.1|NG_048661|1|1|blaADC-50|blaADC|class_C_extended-spectrum_beta-lactamase_ADC-50 NG_048661:1-1152,0
,atgaaatttaacactattaatcgtgatacatgggatcgaaaagaatattttgaacactatttacagcagcagacaacattcagtctgacgaatgaaattaatataactatacttatgaagaacttaaagaaaaagcattataagttatatcctgcgtttatttttatggtgacaaaaatcgtgaacgcccatagagaatttagaataaattttaactcagaaggaaatttaggttactggacggagatttgcccactctataccatttttgataacaaatcacacacattttctggcatctggtcaccaaacttaactattttttctgagtttcattctaaatatgaaaatgatgcagaaagatacaatggcacgaggagattatttccaaaaaaaccaataccagataacactattccgatttctatgattccttggagttcttttacagcatttaatctaaatataaataatggcggagattttctcttacccataataactggagggaagtattcacaagtaaatgatgaattattcctgcctgtctctatccaaatgcatcatgctatttgtgatggctaccatgcaagtgtttttatcaatgacttacaaaaacttgctgatgaaagtgaagactggatttaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1560,Drugs,MEG_1560|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,737219152|WP_035203840.1|NG_060532|1|1|catA10|catA10|type_A-10_chloramphenicol_O-acetyltransferase NG_060532:101-748,6
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATAACGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1391,Drugs,MEG_1391|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_34_JJAO01000008,0
,ATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGTAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGGATGGTAAAAAAAGGTTATTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCCATGAAAGCTTCCGCTATTCCAGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAGCTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGGTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAGTTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAACAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAAACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGCTTAGAACAATTAGGTATTTTATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_4756,Drugs,MEG_4756|Drugs|betalactams|Class_D_betalactamases|OXA,(Bla)OXA-82:GQ352402:8775-9599:825,0
,ATGGGCATCATTCGCACATGTAGGCTCGGCCCTGACCAAGTCCAATCCATGCGGGCTGCTCTTGATCTTTTCGGTCGTGAGTTCGGAGACGTAGCCACCTACTCCCAACATCAGCCGGACTCCGATTACCTCGGGAACTTGCTCCGTAGTAGGACATTCATCGCGCTTGCTGCCTTCGAGCAAGAAGCGGTTGTTGGCGCTCTCGCGGCTTACGTTCTGCCCAAGTTTGAGCAGGCGCGTAGTGAGATCTATATCTATGATCTCGCAGTCTCCGGCGAGCACCGCCGGCAGGGCATTGCCACCGCGCTCATCAATCTCCTCAAGCATGAGGCCAACGCGCTTGGTGCTTACGTGATCTACGTGCAAGCGGATTACGGTGACGATCCCGCAGTGGCTCTCTATACAAAGTTGGGCATACGGGAAGACGTGATGCACTTTGATATCGACCCAAGTTCCGCCACCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_63,Drugs,MEG_63|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,gi|295984001|gb|HM021184.1|2023-2487 gi|19919175|gb|AF347074.1|2576-3040 gi|13094933|gb|AF318077.1|2035-2499,2
,GGGAGCGCCACCTAACAATTCATTAGGCATCACAAAGTACAGCATCGTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGTTGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_346,Drugs,MEG_346|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|37653301|emb|AJ584652.2|2313-2913 gi|984881271|gb|CP014215.1|2294860-2294282 gi|984881271|gb|CP014215.1|2307624-2307046 gi|982900370|gb|KT736121.1|2077-2655 gi|974022331|gb|CP013924.1|1438873-1439451 gi|969995259|gb|KT317079.1|954-1532 gi|969995242|gb|KT317078.1|2840-3418 gi|969995220|gb|KT317076.1|3815-4393 gi|969995200|gb|KT317075.1|5701-6279 gi|969972869|gb|KT354506.1|4806-5384 gi|961377543|gb|KT326691.1|2060-2638,2
,ATGGCTGACGACGAGAAGCCCGACGAGCAGAACCAGGCCGACCGTCAAGGATTGGTGACCGGCCGTCACGTCGGAATCCAGCCGGTCGAGATTCGTGACGAGATCCAGAACGCGTACCTCGACTACGCGATGAGCGTCATCGTCGGGCGTGCCCTGCCCGATGTGCGCGACGGCCTCAAACCGGTACACCGTCGGGTCATCTACGCGATGTACGACGGCGGTTACCGCCCCGACCGTGGCTGGAATAAGTGTTCCCGCGTCGTCGGTGACGTCATGGGTAAGTACCACCCTCACGGCGACTCGGCCATTTACGACACCTTGGTGCGTCTGGCTCAGCCATGGGCTATGCGATACAAGCTTGTCCAGGGTCAGGGTAACTTCGGGTCCCAGGGCAACGATGGTGCGGCTGCCATGCGATATACCGAGTGCAAGATGGCGCCGCTGGCCATGGAGATGGTGCGCGACATCGACCAGGACACTGTCGATTTCCAGCCCAATTATGACAACAAGGAGACCGAACCGGTCGTCTTGCCGTCGAGGTTCCCCAACCTGCTTGTCAATGGTTCTTCAGGTATCGCGGTGGGCATGGCCACCAACATCCCGACCCATAATCTGCGCGAGGTCAACGAGGCCGTGCAGTGGTCTTTGGCTCATCCCAATGCTTCCCACGAGGAACTGCTCGAGGCGTGCATGGAGCGCATTAAGGGTCCGGATTTCCCCGGCGGCGCCCTCATCGTGGGTCGGCAGGGCATCGAGGACGCCTACCGCACCGGCCGCGGTTCGGTGACGATGCGTGCCGTCATCGACATGGAAGAGGACAAGAAGGGACGCCAGTGCCTGGTCGTCACCGAGTTGCCTTATATGTGCAACCCGGACAACCTCGCCACCAAGATCGCCGACCTGGTGAACTCCGGTCGCATCAACGGTATCGCCGACATCCGTGACGACTCCTCAGCCCGTACTGGTCAGCGTTTAGTCATCGTCCTCAAGCGTGACGCTCAGCCGCGTGTCGTCATGAACAACCTGTACAAGCACACGGCTTTGCAGGACACCTTCGGCTGCAACATGCTGGCTCTGGTGGACAACGTGCCGCGCACTTTGCGTCTGGACCAATTCATCAGCTACTGGATTGACCACCAGATGGAGGTCATCCGCAGGCGTACCGAGTACCGCCTGGCTCAGGCCGAAAAAGACGCCCATATCCAGCGGGCTCTCGTTAAAGCCCTCGATATGCTCGACGAGGTCATCGCGCTCATCCGTCGCTCCCCGAACACTGAGGCCGCCAGCACCGGCCTACAGGAACTGCTCGATATCGACGAGATTCAGGCTCGCGCCATCCTCGATATGCAGTTGCGTCGTCTGGCTGCCCTGGAGCGTCAAAAGATCATCGACCGACTTGAGGAACTCGAGCGCCTCATCGCTGATTACAAAGCAATTCTGGCTAGCGAGGACCGCCAGCGCGAGATCATCTCTACCGAGCTTGCCGAGATCGTCGATAAGTACGGTGACGAGCGTCGCACCCGCATTATCGCCGCCGATGGGGACTTTTCTGAGGAAGACTTCATCCCCGACGATGACGTCGTCGTCACCATTACCCGGGGCGGCTACGCCAAGCGCACCCGCACTGACCTGTACCGGGTCCAGAAACGCGGTGGCAAGGGTGTTCGCGGCGCCAGCCTGCGCACTGACGATGAGGTGGCACAGCTATTCACTACCACGAACCACCAGTGGATCCTCTTCTTCACGAATATGGGTCGGGTCTATCGCACCAAGGTATGGCAGCTGCCGGAGGCTGGTCGTGACGCCAGGGGGGGTCACGTCGCTGGGTTGCTGAGCTTCCTGCCTGACGAGAAGATCGCCCAAGTCATGACCCTACGGTCCTACGACGACGCCGAGTACCTCCTCCTGGCCACTCGCAAGGGTATGGTCAAGAAGACGGCGCTCAAGGCTTATGACTCGTCTCGTCAGGCCGGCGTTATTGCCGTTAATTTCCGTACCGAGGACGATGAGCTTATCGGCGCCGAGCAGTGCTCCGCCGCTGACGACGTGCTGCTTATCAGCCGTAAGGGGCAGGCGATCCGGTTCTCTGCCGGCGACGACCAGTTGCGCCCGATGGGGCGTGCGACTTCGGGCGTTACCGGCATGAAGTTCCGTGGTGATGACGAGTTGCTGTCAATGTCGATTATTCACTCCGACATGCCTGAGGATGATCGGTTCGTTTTCACAGCAACCGGTGGCGGCTACGCCAAGCGCACTGCTGTGTCGGAGTACCGTCAGCAGAGGCGTGGGGGAGTCGGCATCAAAGCGATGGCCCTCAGTGAGGAGCGCGGCTCCCTGGTTGGTGGCCTGGTGGTCAGCGAGGCTGACGAAATCATCGCGATTAAGACGTCAGGTCAGATCACCCGATCGGCCGTGTCTGAGGTGCCCGCCAAGGGACGCTCCACGATGGGGGTGAAGTTCGTCTCCGTACGCGGTGACGACGCTGTCTCAATCATCGCTGTCAACCCCGAACATACCGTCGAGGAGGAAGTCGCTGACGAATCGGTGGAAACTGTTGAAGGCGATGCCACGAAGGCCCAATCGGGAGATGTGGTTCGGCGAAGCGATACTGTGGATGACGACCGTGCCGTCGATACGGCGGGAAACGACATGAAGCCGGAGGACAACGGTGAGTGA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3182,Drugs,MEG_3182|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|CP003084.1|+|1004589-1007265|ARO:3003974|Cutibacterium acnes gyrA conferring resistance to fluoroquinolones [Cutibacterium acnes subsp. defendens ATCC 11828] ,3
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcatgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctctcttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4486,Drugs,MEG_4486|Drugs|betalactams|Class_D_betalactamases|OXA,1559612982|WP_128268247.1|NG_063852|1|1|blaOXA-748|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-748 NG_063852:41-865,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACATGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGGCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGTGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCAATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCTGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1867,Drugs,MEG_1867|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EF394371|+|0-1146|ARO:3002046|CMY-35 [Citrobacter freundii] ,0
,atgaaaattattaatattggagttttagctcatgttgacgcaggaaaaactactttgacagaaagcttactatatactagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactccaacaagaggaaagcataagatttcataattgttccctgttccctgtttattacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtccgtctgaactttgcggaaatgttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacgactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctgcgatattatgtggattctgcgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctgctgcaagaaaagtatcatgtggagatagaaataaaagagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagttccaccgaatcctttctgggcttccattggtctatctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7117,Drugs,MEG_7117|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100199|WP_063856401.1|NG_048245|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048245:101-2020,4
,ATGAAAAAAATAATTACGCTGATAATTGGTATAATATTTATAACTTTTAGTTTTGCTACTACAAAAATAGATACCCAAGTTACCAATGATATTCAAAATATAGAAAAAAAACATGGTGGTAAAATTGGTGTATATACTATAAATCGAAATGACTGGAGTAATTTTGCAGTCAATGCTAGCTTCTACTTTCCAATATGTAGTACTTATAAATTTCTTGTAGTTGGTGCAATACTTAAACAAAGTATGACTGATAATAAACTACTTAATCAAAAAATCAAAATCTCAAAAAATCAAATTGTTGAGTATTCCCCTATTACAAGAAGGCATATTAATCAAATAATGACTGTGAAACAACTTTGCCAAGCATCTATGCAAGGGGATAATACTGCGACAAATATCCTAATTGAAAAACTAGGTGGTTTGAAAAATCTCAATAAGTTTATCTTATCGCTTGCAGATCATGCGACAAAAGTCGCTAATTTAGAGCCTAAAGTCAATCATGTCAGCCTAACGACAAACGAAAATAAGACCACTCCCAAGATTATGGCAAGAGATATTAATAAACTTGCTTTTAGCGATGATATACTTGATAAAAAACATCGCTTAATGTTTAAACAATGGCTAATAGCGAGTAATACTAGCAACAATCGTATAGCTGCTGAGGTGCCTGATGAGTGGGAAGTTGGTGATAAAACTGGAACTTGTCAATATGGTACAACAAATGATGTTGCTATTATTTGGCCTGATGATAATAGAGCTGTTATTATGGCAATTTTTTATACCCAATCGCAAAAAAATGCTAAACCAAACAGTAAAATTGTTAGAGAGGTAACTAAAATACTGCTAAACAGACTACAATTAAACAATACTACGAAAAATGCCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1245,Drugs,MEG_1245|Drugs|betalactams|Class_A_betalactamases|BLAA,(Bla)BlaA:CP003048:1-885:885,0
,ATGAATATTATAAATTTAGGAATTCTTGCTCACATTGATGCAGGAAAAACTTCCGTAACCGAGAATCTGCTGTTTGCCAGTGGAGCAACGGAAAAGTGCGGCTGTGTGGATAATGGTGACACCATAACGGACTCTATGGATATAGAGAAACGTAGAGGAATTACTGTTCGGGCTTCTACGACATCTATTATCTGGAATGGTGTGAAATGCAATATCATTGACACTCCGGGACACATGGATTTTATTGCGGAAGTGGAGCGGACATTCAAAATGCTTGATGGAGCAGTCCTCATCTTATCCGCAAAGGAAGGCATACAAGCGCAGACAAAGTTGCTGTTCAATACTTTACAGAAGCTGCAAATCCCGACAATTATATTTATCAATAAGATTGACCGAGCCGGTGTGAATTTGGAGCGTTTGTATCTGGATATAAAAGCAAATCTGTCTCAAGATGTCCTGTTTATGCAAAATGTTGTCGATGGATCGGTTTATCCGGTTTGCTCCCAAACATATATAAAGGAAGAATACAAAGAATTTGTATGCAACCATGACGACAATATATTAGAACGATATTTGGCGGATAGCGAAATTTCACCGGCTGATTATTGGAATACGATAATCGCTCTTGTGGCAAAAGCCAAAGTCTATCCGGTGCTACATGGATCAGCAATGTTCAATATCGGTATCAATGAGTTGTTGGACGCCATCACTTCTTTTATACTTCCTCCGGCATCGGTCTCAAACAGACTTTCATCTTATCTTTATAAGATAGAGCATGACCCCAAAGGACATAAAAGAAGTTTTCTAAAAATAATTGACGGAAGTCTGAGACTTCGAGACGTTGTAAGAATCAACGATTCGGAAAAATTCATCAAGATTAAAAATCTAAAAACTATCAATCAGGGCAGAGAGATAAATGTTGATGAAGTGGGCGCCAATGATATCGCGATTGTAGAGGATATGGATGATTTTCGAATCGGAAATTATTTAGGTGCTGAACCTTGTTTGATTCAAGGATTATCGCATCAGCATCCCGCTCTCAAATCCTCCGTCCGGCCAGACAGGCCCGAAGAGAGAAGCAAGGTGATATCCGCTCTGAATACATTGTGGATTGAAGACCCGTCTTTGTCCTTTTCCATAAACTCATATAGTGATGAATTGGAAATCTCGTTATATGGTTTAACCCAAAAGGAAATCATACAGACATTGCTGGAAGAACGATTTTCCGTAAAGGTCCATTTTGATGAGATCAAGACTATATACAAAGAACGACCTGTAAAAAAGGTCAATAAGATTATTCAGATCGAAGTGCCGCCCAACCCTTATTGGGCCACAATAGGGCTGACTCTTGAACCCTTACCGTTAGGGACAGGGTTGCAAATCGAAAGTGACATCTCCTATGGTTATCTGAACCATTCTTTTCAAAATGCCGTTTTTGAAGGGATTCGTATGTCTTGCCAATCCGGGTTACATGGATGGGAAGTGACTGATCTGAAAGTAACTTTTACTCAAGCCGAGTATTATAGCCCGGTAAGTACACCTGCTGATTTCAGACAGCTGACCCCTTATGTCTTCAGGCTGGCCTTGCAACAGTCAGGTGTGGACATTCTCGAACCGATGCTCTATTTTGAGTTGCAGATACCCCAAGCGGCAAGTTCCAAAGCTATTACAGATTTGCAAAAAATGATGTCTGAGATTGAAGACATCAGTTGCAATAATGAGTGGTGTCATATTAAAGGGAAAGTTCCATTAAATACAAGTAAAGACTATGCATCAGAAGTAAGTTCATACACTAAGGGCTTAGGCATTTTTATGGTTAAGCCATGCGGGTATCAAATAACAAAAGGCGGTTATTCTGATAATATCCGCATGAACGAAAAAGATAAACTTTTATTCATGTTCCAAAAATCAATGTCATCAAAATAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7184,Drugs,MEG_7184|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETQ,gi|686511930|gb|CP006828.1|2131472-2133397 gi|807867|emb|X58717.1|586-2511,4
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcaacactacccgacatgttgagttttattcatgccaacctcaatccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacaaattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacgtatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcagttttaaatgcaataaaggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_586,Drugs,MEG_586|Drugs|betalactams|Class_C_betalactamases|ADC,1058243740|WP_068981628.1|NG_051461|1|1|blaADC-97|blaADC|class_C_beta-lactamase_ADC-97 NG_051461:1-1152,0
,atgaagacaaaatccctttgctgtgccctgctgctcagcacctcctgctctgttctcgccgcgccgatgtcagagaaacagctgtctgacgtggtggaacgtaccgttacccccctgatgaaagcgcaagccattccgggcatggcggtagcggtgatttatcagggtcagccgcactactttaccttcggaaaggccgatgttgcggcgaacaaacctgtcaccccgcaaaccctgtttgaactgggctctataagtaaaaccttcaccggcgtattaggtggcgatgcgattgcgcgcggagaaatatcgctgggcgaccccgtgacaaagtactggcccgagctaacaggcaagcagtggcagggtattcgcatgttggatctggcgacctacaccgcgggtggcctgccgctacaggtgccggatgaggtcacggataacgcctccctgctgcgtttctatcaacactggcaaccgcagtggaaaccaggcgcaacgcgtctttatgcgaacgccagcatcgggctttttggcgccctcgcggttaaaccctccggtatgagctttgaacaggccatgacgaagcgggtcttcaagccactcaaactggaccatacatggattaacgttccgaaagaagaagaggcgcattacgcctggggataccgtgatggtaaagcggtccacgtttcaccgggaatgctggatgccgaagcgtatggtgtcaaaaccaacgtccaggatatatcgagctgggtgaaggccaacatgaaccctgccgcccttccggattcaacgctgaaacagggtattgccctggcacagtctcgctactggcgcgtgggtgccatgtatcagggtctgggctgggagatgctcaactggccggtagaagccaaaaccgtcgtggagggcagcgataacaaggtggctcttgcaccgttaccggtggcagaagtgaaccctccagctccgccagtaaaagcatcatgggtacataaaacaggctcgacgggtggattcggcagctatgtcgcatttattcctgagaaggaactcggcattgttatgctggcgaacaagagctacccgaacccggcgcgcgtggaagcggcataccgtattctgagcgctctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_417,Drugs,MEG_417|Drugs|betalactams|Class_C_betalactamases|ACT,504695109|WP_014882211.1|NG_050715|1|1|blaACT-52|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-52 NG_050715:1-1146,0
,gtgaccaacagcaccgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggacggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccatatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_241,Drugs,MEG_241|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1040987693|WP_065187000.1|NG_052463|1|1|aac(6')-Ib-cr4|aac(6')-Ib-cr|fluoroquinolone-acetylating_aminoglycoside_6'-N-acetyltransferase_AAC(6')-Ib-cr4 NG_052463:101-655,2
,ATGATGAAGCGCAATATTCTGGCAGTGATCGTCCCTGCTCTGTTAGTAGCAGGTACTGCAAACGCTGCAGAAATCTATAACAAAGATGGCAACAAAGTAGATCTGTACGGTAAAGCTGTTGGTCTGCATTATTTTTCCAAGGGTAACGGTGAAAACAGTTACGGTGGCAATGGCGACATGACCTATGCCCGTCTTGGTTTTAAAGGGGAAACTCAAATCAATTCCGATCTGACCGGTTATGGTCAGTGGGAATATAACTTCCAGGGTAACAACTCTGAAGGCGCTGACGCTCAAACTGGTAACAAAACGCGTCTGGCATTCGCGGGTCTTAAATACGCTGACGTTGGTTCTTTCGATTACGGCCGTAACTACGGTGTGGTTTATGATGCACTGGGTTACACCGATATGCTGCCAGAATTTGGTGGTGATACTGCATACAGCGATGACTTCTTCGTTGGTCGTGTTGGCGGCGTTGCTACCTATCGTAACTCCAACTTCTTTGGTCTGGTTGATGGCCTGAACTTCGCTGTTCAGTACCTGGGTAAAAACGAGCGTGACACTGCACGCCGTTCTAACGGCGACGGTGTTGGCGGTTCTATCAGCTACGAATACGAAGGCTTTGGTATCGTTGGTGCTTATGGTGCAGCTGACCGTACCAACCTGCAAGAAGCTCAACCTCTTGGCAACGGTAAAAAAGCTGAACAGTGGGCTACTGGTCTGAAGTACGACGCGAACAACATCTACCTGGCAGCGAACTACGGTGAAACCCGTAACGCTACGCCGATCACTAATAAATTTACAAACACCAGCGGCTTCGCCAACAAAACGCAAGACGTTCTGTTAGTTGCGCAATACCAGTTCGATTTCGGTCTGCGTCCGTCCATCGCTTACACCAAATCTAAAGCGAAAGACGTAGAAGGTATCGGTGATGTTGATCTGGTGAACTACTTTGAAGTGGGCGCAACCTACTACTTCAACAAAAACATGTCCACCTATGTTGACTACATCATCAACCAGATCGATTCTGACAACAAACTGGGCGTAGGTTCAGACGACACCGTTGCTGTGGGTATCGTTTACCAGTTCTAA,General Bacterial Porin (GBP),reduced permeability to antibiotic,betalactams,MEG_4289,Drugs,MEG_4289|Drugs|betalactams|Mutant_porin_proteins|OMPFB,gb|U00096.3|-|985893-986982|ARO:3003390|Pseudomonas aeruginosa ompF with mutation [Escherichia coli str. K-12 substr. MG1655] ,0
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAATACACCGTTTCTTTAGCCTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGACTATGACCTCTCTTTGATCGGGATCACCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACATAAACAGAAAATACAGCCGCTATTCGAAGGAAACGGCTTTTGGCTAAGTGAAGAGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAGCTGCCTTATGTAGGCTGCGGGGTGGCAGGTTCTGCCTTATGTATGAACAAATGGCTGCTGCATCAAGCTGCAGCAGCCATTGGCGTACAAAGTGCTCCTACGATTCTCTTGACAAATCAAGCCAACCAGCAAGAACAAATCGAAGCTTTTATCCAGACCCATGGCTTTCCAGTTTTCTTTAAGCCTAATGAAGCGGGCTCCTCAAAAGGGATCACTAAAGTCACCTGCGTTGAAGAAATCGCTTCTGCCTTAAAAGAAGCCTTTACTTATTGTTCCGCAGTGCTCCTACAAAAAAATATTGTCGGTGTTGAGATCGGTTGCGGTATTTTGGGCAACGACTCTTTGACTGTCGGTGCTTGTGACACCATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGCTGATCAGCGCCAAAATCACCGTCCCTGCGCCATTGCCTGAAACGATTGAAACCAAGGTCAAAGAACAAGCTCAGCTGCTCTATCGTAGTCTTGGTCTTAAAGGTCTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGCTTATCCTATCAAGAACTACTACAAAAACTGCTTGTCTTAGCAAAGGAGGAAGTCAAATGAATCCCTATCTACAGTTAGTTAGCAAAGAATTTCCGTTAGAAAAAAACCAAGAACCCCCTCATTTAGTCCTTGCTGCCTTCAGCGAAGACGAGGTTTACTTGCAGCCAGAAGCAGCCAAACAATGGGAACGGCTCGTCAAAGCCTTAAAGCTTGAAAACGAGATCTGCTTGTTAGATGGCTACCGAACCGAAAAGCAGCAACGGTATTTATGGGAATATTCCTTGAAAGAAAATGGGCTAGCCTATACGAAACAATTTGTGGCGTTGCCCGGTTGCAGTGAACATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAGGGCAGCCAGGATGATTTGATCTGCCCACGATTTCGTGACAGCGCAGCCGCTGATTTATTTACCCAGGAAATGATGAACTATGGGTTTATTTTACGCTATCCCGCAGACAAACAGGAAATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTGCCTCATAGTCAAATCATCGCCAGTCAACAGTGGACCTTGGAAGAATACCATCAATACCTTGAACAAACTGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7376,Drugs,MEG_7376|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC2XY_1_EU151754,5
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4712,Drugs,MEG_4712|Drugs|betalactams|Class_D_betalactamases|OXA,1559613004|WP_128268269.1|NG_063874|1|1|blaOXA-770|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-770 NG_063874:34-858,0
,ATGAAAATTATTAATATTGGAGTTTTAGCTCATGTTGATGCAGGAAAAACTACCTTAACAGAAAGCTTATTATATAACAGTGGAGCGATTACAGAATTAGGAAGCGTGGACAAAGGTACAACGAGGACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACAGGAATAACCTCTTTTCAGTGGGAAAATACGAAGGTGAACATCATAGACACGCCAGGACATATGGATTTCTTAGCAGAAGTATATCGTTCATTATCAGTTTTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATGGCGTACAAGCACAAACTCGTATATTATTTCATGCACTTAGGAAAATGGGGATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCCGAAATTGTAATCAAACAGAAGGTAGAACTGTATCCTAATGTGTGTGTGACGAACTTTACCGAATCTGAACAATGGGATACGGTAATAGAGGGAAACGATGACCTTTTAGAGAAATATATGTCCGGTAAATCATTAGAAGCATTGGAACTCGAACAAGAGGAAAGCATAAGATTTCAGAATTGTTCTCTGTTCCCTCTTTATCATGGAAGTGCAAAAAGTAATATAGGGATTGATAACCTTATAGAAGTTATTACTAATAAATTTTATTCATCAACACATCGAGGTCCGTCTGAACTTTGCGGAAATGTTTTCAAAATTGAATATACAAAAAAAAGACAACGTCTTGCATATATACGCCTTTATAGTGGAGTACTACATTTACGAGATTCGGTTAGAGTATCAGAAAAGGAAAAAATAAAAGTTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAGATTGATAGAGCTTATTCTGGAGAAATTGTTATTTTGCAAAATGAGTTTTTGAAGTTAAATAGTGTTCTTGGAGATACAAAACTATTGCCACAGAGAAAAAAGATTGAAAATCCGCACCCTCTACTACAAACAACTGTTGAACCGAGTAAACCTGAACAGAGAGAAATGTTGCTTGATGCCCTTTTGGAAATCTCAGATAGTGATCCGCTTCTACGATATTACGTGGATTCTACGACACATGAAATTATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGATTAGTGCACTGTTGCAAGAAAAGTATCATGTGGAGATAGAAATAACAGAGCCTACAGTCATTTATATGGAGAGACCGTTAAAAAATGCAGAATATACCATTCACATCGAAGTGCCGCCAAATCCTTTCTGGGCTTCCATTGGTCTATCTGTATCACCGCTTCCGTTGGGAAGTGGAATGCAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCATTTCAAAATGCAGTTATGGAAGGGATACGCTATGGTTGTGAACAAGGATTGTATGGTTGGAATGTGACGGACTGTAAAATCTGTTTTAAGTATGGCTTATACTATAGCCCTGTTAGTACCCCAGCAGATTTTCGGATGCTTGCTCCTATTGTATTGGAACAAGTCTTAAAAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAATTTATGCGCCACAGGAATATCTTTCACGAGCATACAACGATGCTCCTAAATATTGTGCGAACATCGTAGACACTCAATTGAAAAATAATGAGGTCATTCTTAGTGGAGAAATCCCTGCTCGGTGTATTCAAGAATATCGTAGTGATTTAACTTTCTTTACAAATGGACGTAGTGTTTGTTTAACAGAGTTAAAAGGGTACCATGTTACTACCGGTGAACCTGTTTGCCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7141,Drugs,MEG_7141|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|569556619|gb|KF861545.1|2622-4541 gi|291587249|gb|GU593054.1|8413-6494 gi|259045723|gb|GQ420676.1|345-2264 gi|23262700|gb|AY047229.1|1450-3369 gi|47061|emb|X56353.1|223-2142 gi|1277145|gb|U50983.1|CVU50983|205-2124,4
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactactaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatacagatatcggtacccaagtcgataatttttggctgatgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaagtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4442,Drugs,MEG_4442|Drugs|betalactams|Class_D_betalactamases|OXA,1559612992|WP_128268257.1|NG_063862|1|1|blaOXA-758|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-758 NG_063862:44-868,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAGATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTATTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1384,Drugs,MEG_1384|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_14_JBAG01000015,0
,ATGATGAAAAAATCGTTATGCTCCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAACCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGGAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACTGTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAAAAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCTTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACGACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTGACGATGAGGCCCAGGATATTGGGCCTCCTTTCTTTCTCTTTTTTTCCTGTTGTCATCTACACTTAACAAAAATACAGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1977,Drugs,MEG_1977|Drugs|betalactams|Class_C_betalactamases|CMY,gi|496632|emb|X78117.1|142-1370,0
,atgagcaagttatctgtattctttatatttttgttttgcagcattgctaccgcagcagagtctttgccagatttaaaaattgaaaagcttgatgaaggcgtttatgttcatacttcgtttgaagaagttaacgggtggggcgttgctcctaaacatggtttggtggttcttgtaaatgctgaggcttacctaattgacactccatttacggctaaagatactgaaaagttagtcacttggtttgtggagcgtggctataaaataaaaggcagcatttcctctcattttcatagcgacagcacgggcggaatagagtggcttaattctcgatctatccccacgtatgcatctgaattaacaaatgaactgcttaaaaaagacggtaaggttcaagccacaaattcatttagcggagttaactattggctagttaaaaataaaattgaagttttttatccaggcccgggacacactccagataacgtagtggtttggttgcctgaaaggaaaatattattcggtggttgttttattaaaccgtacggtttaggcaatttgggtgacgcaaatatagaagcttggccaaagtccgccaaattattaaagtccaaatatggtaaggcaaaactggttgttccaagtcacagtgaagttggagacgcatcactcttgaaacttacattagagcaggcggttaaagggttaaacgaaagtaaaaaaccatcaaaaccaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3330,Drugs,MEG_3330|Drugs|betalactams|Class_B_betalactamases|IMP,1440786792|WP_114699280.1|NG_061409|1|1|blaIMP-76|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-76 NG_061409:1-741,0
,atgaaaaatttacagttgggactcatcgtcctcattacaaccttcggttccgcatgtacaacaataagcccctccgtagaaacagctaaaaaccaacagcaacaaagtgcgcagcagcagatccaacaagccttcgatcaactccaaaccacaggggtgattgtcataaaggataagcatggcttacacagctacggcaatgacttgagccgtgctcagacaccctatgtacccgcctctacctttaaaatgctgaatgccttaatcggactagaatatggtaaagcaaccagcaccgaggtatttaaatgggatggtcaaaagcgcagcttccctgcttgggaaaaagacatgactttagggcaagccatgcaagcatctgccgttcccgtttatcaggagctagcacggcgcattggcctagacctgatgaaaaaagaagtacagcgcattggatatggcaatcaacagattggcaccgttgtcgataatttttggttagtcggtccactgcaaattacgcctgttcaagaaatcctttttgtagagaagctggccaatacacaactcgcttttaaacccgatgtacaacatgcagtacaagacatgctgctgattgaacaaaaaccgaattataaactctacgccaaatctggttggggcatggacctagaaccgcaagtgggctggtggacaggctgggtcgaaacagcaacaggtgaaaaagtgtattttgctttgaatatgcatatgaaaacagggatttcagccagcgagcgtgagcaactggtcaaacaaagtctgacagcactgggaataatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4411,Drugs,MEG_4411|Drugs|betalactams|Class_D_betalactamases|OXA,1693892935|WP_140423312.1|NG_065429|1|1|blaOXA-643|blaOXA-211_like|OXA-211_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-643 NG_065429:1-825,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6445,Drugs,MEG_6445|Drugs|betalactams|Class_A_betalactamases|SHV,gi|262477942|gb|GU064394.1|1-861,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAATCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCTCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1972,Drugs,MEG_1972|Drugs|betalactams|Class_C_betalactamases|CMY,gi|407731522|gb|JX440352.1|1028-2255,0
,ATGCTGCGCAGACTCTCCCTGGCGGCCGCCGTGGCCGCTGCTACCGGTGTCGCCTGGGCCGCCCAGCCGACCCCGCTGCCGACCAAGACCGACCTGATCAGCGTCTACAAGGAAGCCGTCGACAACAACGCCGACCTCGCCGCCGCCCAGGCCGACTACCTGGCGCGCAAGGAAGTGGTGCCCCAGGCCCGCGCCGGCCTGCTGCCGCAACTCGGCGCCGGCGCCCGCGTCGGAGACACCCGGATCGCATTCGACGAGCGTCCGGCGACCGTCAAGCGCAACAGCCAGGTCGTCCAGGCCACCCTCAGCCAGCCGTTGTTCCGCGCCGACCGCTGGTTCCAGTGGCAGGCCGCCAAGGAAACCAGCGACCAGGCCCGGCTGGAATTCTCCGCGACCCAGCAGGACCTGATCCTGCGCAGCGCCGAGACCTACTTCACGGTGCTCCGCGCCCAGGACAACCTGGCCACCAGCAAGGCCGAGGAAGCCGCCTTCAAGCGCCAGCTGGACCAGGCCAACGAGCGCTTCGACGTGGGCCTTTCCGACAAGACCGACGTGCTCGAGGCCCAGGCCAGCTACGACACCGCCCGCGCCAACCGGTTGATCGCCGAACAGCGCGTGGACGATGCCTTCCAGGCCCTGGTGACCCTGACCAACCGCGACTACAGCGCCATCGAGGGCATGCGCCACACCCTGCCGGTGGTGCCGCCGGCGCCGAACGACGCCAAGGCCTGGGTCGACACCGCGGTGCAGCAGAACCTGCGCCTGCTGGCCAGCAACTACGCGGTCAACGCCGCCGAGGAAACCCTCCGCCAGCGCAAGGCCGGGCACCTGCCGACCCTCGATGCCGTGGCCCAGTACCAGAAGGGCGACAACGACGCCCTCGGCTTCGCCAACAGCGCCGCCAATCCGCTGGTGCACTATGGCAAGTATGTCGACGAGCGCAGCATTGGCCTGGAACTGAACATCCCGATCTACAGCGGCGGCCTGACCTCCTCCCAGGTCCGCGAGTCCTACCAGCGCCTCAACCAGAGCGAGCAATCCCGCGAAGGCCAGCGCCGCCAGGTGGTGCAGGATACCCGCAACCTGCACCGCGCGGTGAATACCGACGTCGAGCAGGTCCAGGCGCGGCGCCAGGCGATCATCTCCAACCAGAGTTCGCTGGAAGCCACCGAGATCGGCTACCAGGTCGGCACCCGCAACATCGTCGACGTGCTCAACGCCCAGCGCCAGCTGTACGCCGCCGTGCGCGACTACAACAACAGCCGCTACGACTACATCCTCGATACCCTGCGCCTGAAGCAGGCGGCCGGCACCCTCAGCCCGGCCGACCTGGAGGCGCTCAGCGCCTACCTGAAGCAGGACTACGATCCGGACAAGGACTTCCTCCCGCCGGACCTGGCCAAGGCCGCCGCCGAGCAGTTACAGAGCAAGCCGCGCCAGCAGTACTAG,subunit of efflux pump conferring antibiotic resistance,antibiotic efflux,Multi-drug_resistance,MEG_4294,Drugs,MEG_4294|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_pumps|OPMH,gb|AE004091.2|+|5584100-5585549|ARO:3003682|OpmH [Pseudomonas aeruginosa PAO1] ,1
,atgaaaaatttacagttgggcctcatcgccctcattacaaccttcggttccgcatgtaccacaataagcccctccgtagaaacagctaaaaaccaacagcaacaaagtgcgcagcagcagatccaacaggccttcgatcaactccaaaccactggggtgattgtcattaaggataagcatggcttacgcagctacggcaatgacttgagccgtgctcagacagcctatgtacccgcctctacctttaaaatgctgaatgccttaatcggactagaacatggtaaagcaaccagcactgaggtgtttaaatgggatggtcaaaagcgtagtttccctgcctgggaaaaagacatgactttagggcaagccatgcaagcatctgctgttcccgtttatcaggagcttgcacggcgcattggtctagacctgatgcaaaaagaagtacagcgcattggatatggcaatcaacggattggcaccgttgtcgataatttttggttagtcggtccactgcaaattacgcctgttcaagaagtcctttttgtagagaagctggccaatacacaactcgcttttgagccagatgtgcaacataccgtacaagacatgttgctgattgaacaaaaaccgaattataaactctatgccaaatctggttggggcatggacctagaaccgcaagtgggctggtggacaggctgggtcgaaacagcaacaggtgaaaaagtgtattttgctttgaatatgcagatgaaaacaggaatttcagccagcgtgcgtgagcaactggtcaaacaaagtctaacagcactggggataatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4413,Drugs,MEG_4413|Drugs|betalactams|Class_D_betalactamases|OXA,1693892937|WP_140423314.1|NG_065431|1|1|blaOXA-645|blaOXA-211_like|OXA-211_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-645 NG_065431:1-825,0
,CTGATACGATCTAGCCGCACGAGCGGCTGATGTCCCGTTAGAAACCGGACACTTGGGTTCCGGTGGCGGCTAACTCTTGGCATGTACGTACTTTCCGTGGAGAAACCTACATTGAGAAACAAATTTGCGGCCGGAATAGGCGTCGTGCTTGTATGTGTCGTTGCCTCGTTTATTCCAACCCCAGTATTCGCCCTAGACACCACGAAGCTGATCCAAGCCGTCCAGTCGGAAGAGAGCGCCTTGCATGCCCGAGTCGGCATGACCGTGTTTGACTCAAACACTGGAACGACTTGGAACTATCGGGGCGATGAGCGGTTTCCATTGAACAGTACGCACAAGACGTTTTCCTGTGCAGCTTTGCTCGCGAAGGTCGATGGGAAGTCCCTCTCTCTGGGCCAATCCGTATCGATCAGCAAGGAAATGCTGGTCACCTATTCGCCGATTACGGAAAAGTCGCTGTCACCCGAAACCGTTACCTTCGGCAAGATTTGTCAGGCAGCGGTGAGCTATAGCGATAACACAGCCGCAAACGTCGTCTTTGATGCCATTGGAGGAGCAACCGGATTCAACGCATACATGCGGTCTATCGGCGATGAAGAAACCCAGCTTGATCGCAAAGAACCCGAGTTGAACGAAGGTACGCCGGGCGATGTGCGTGACACCACCACTCCCAACGCCATGGTCAATAGTCTTAGGAAGATACTTCTTGGCGACGCGTTGTCAGCATCATCCCGATCCCAGCTGACGCAATGGATGCTGGACGATCAGGTTGCTGGTGCGCTCCTGCGTGCCTCACTGCCATCCGATTGGAAGATCGCCGACAAGACCGGCGCGGGGGGTTACGGCTCACGCTCGATCGTCGCAGTAATCTGGCCGCCATCGAAGCAGCCACTGGTGGTTGGCATCTATATCACGCAAACCAAAGCATCCATGCAGGCCAGCAATCAGGCGATTGCAAGGATAGGAGTGGTGCTGAAGGATACGGTCGCTCCTTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_708,Drugs,MEG_708|Drugs|betalactams|Class_A_betalactamases|AER,gi|2992468|gb|U14748.1|AHU14748|244-1239,0
,atgctaagaaataacattccggatcaacacctcattgcgcttttgaaagtctattatggaattgatattcatactgtacaactcatcgtgggtggtgctgatatgaatgcctttggatataaagcggattcagaatccaattcttatttcgtaaagctgaaatacggccatcatgatgaaattaatttatcaatcattcgcctcttgcatgattctggaataaaagaaattatttttcctatctacacacgtgatacaaaattatttcagcaaatagatcattttaaaataatagtgtatccatttattaatgcgcccaatggcttcactcaaaatttaacagaaaaacagtggcaccagcttggaaaagtattaagacaaattcatgaaacttctgttcccaccgctattcagcaacgattaaggaaagaaacttattcgcctaaatggcgtgaaatggttagatctttttataacaaaattggatttgatgattcagatgatcaaattactactgacttcaaaactttttttaatcaaaatatcgattcaattcatcgattagtcgattcttcagaagaactatctaaaaaaattcaacccgatttagataaatatgtactgtgtcattctgatgtacatgcgggcaatgtattggtcgttaatgaggaatctatttacattattgattgggatgagcccatgttagcgccaaaagagtgtgatttgatgttcattggcggtggcattggtaatgtatggaataaacaccatgaaatcaattatttttatgaaggttatggtaaaacaaacgttgataaaataattttatcttattacagacatgaacgaattgtcgaagatatagctgtatatggacaagacttactttcacgtgatcaaaacgacgagtccagacttgaaagttttaaacattttaaatcgatgtttactccaaatgatgttgttgaaatagctttttcttcggattaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1099,Drugs,MEG_1099|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH9,499534615|WP_011215574.1|NG_051696|1|1|aph(9)-Ia|aph(9)-Ia|aminoglycoside_O-phosphotransferase_APH(9)-Ia NG_051696:101-1093,2
,atgaaaatcgtaaaaaggatattattagtattgttaagtttattttttacaattgtgtattcaaatgctcaaactgacaacttaactttgaaaattgagaatgttttaaaggaaaaaaatgccagaataggagtagcaatattcaacagcaatgagaaggatactttgaagattaataacgacttccatttcccgatgcaaagcgttatgaaatttccgattgctttagccgttttgtctgagatagataaagggaatctttcttttgaacaaaaaatagagattacccctcaagaccttttgcctaaaacgtggagtccgattaaagaggaattccctaatggaacaactttgacgattgaacaaatactaaattatacagtatcagagagcgacaatattggttgtgatattttgctaaaattaatcggaggaactgattctgttcaaaaattcttgaatgctaatcatttcactgatatttcaatcaaagcaaacgaagaacaaatgcacaaggattggaatacccaatatcaaaattgggcaaccccaacagcgatgaacaaactgttaatagatacttataataataagaaccaattactttctaaaaaaagttatgattttatttggaaaattatgagagaaacaacaacaggaagtaaccgattaaaaggacaattaccaaagaatacaattgttgctcataaaacagggacttccggaataaataatggaattgcagcagccactaatgatgttggggtaattactttaccgaatggacaattaatttttataagcgtatttgttgcagagtccaaagaaacttcggaaattaatgaaaagattatttcagacattgcaaaaataacgtggaattactatttgaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7647,Drugs,MEG_7647|Drugs|betalactams|Class_A_betalactamases|VEB,1028110880|WP_063865151.1|NG_050319|1|1|blaVEB-11|blaVEB|class_A_extended-spectrum_beta-lactamase_VEB-11 NG_050319:1-900,0
,ATGGCAATCCGAATCTTCGCAATACTTTTCTCCACTTTTGTTTTTGGCACGTTCGCGCATGCACAAGAAGGCATGCGCGAACGTTCTGACTGGCGGAAGTTTTTCAGCGAATTTCAAGCCAAAGGCACGATAGTTGTGGCAGACGAACGCCAAACAGATCGTGTCATATTGGTTTTTGATCAGGTGCGGTCAGAGAAACGCTACTCGCCGGCCTCGACATTCAAGATTCCACATACACTTTTTGCACTTGACGCAGGCGCTGCACGTGATGAGTTTCAAGTTTTTCGATGGGACGGCATCAAAAGAAGCTTTGCAGCTCACAACCAAGACCAAGACTTGCGATCAGCAATGCGGAATTCTACTGTCTGGATTTATGAGCTATTTGCAAAAGAGATCGGTGAAGACAAGGCTCGACGCTATTTGAAGCAAATCGACTATGGCAACGCCGATCCTTCGACAAGTAATGGCGATTACTGGATAGATGGCAATCTTGCTATCGCGGCACAAGAACAGATTGCATTTCTCAGGAAGCTCTATCATAACGAGTTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGACCTCATGATTGTGGAAGCCGGTCGCAACTGGATACTGCGCGCAAAGACGGGCTGGGAAGGCCGCATGGGTTGGTGGGTAGGATGGGTTGAGTGGCCGACTGGCCCCGTATTCTTCGCACTGAATATTGATACGCCAAACAGGATGGATGACCTTTTCAAAAGGGAGGCAATAGTGCGGGCAATCCTTCGCTCTATCGAAGCGTTGCCGCCCAACCCGGCAGTCAACTCGGACGCAGCGCGATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4749,Drugs,MEG_4749|Drugs|betalactams|Class_D_betalactamases|OXA,(Bla)OXA-21:DQ522237:3974-4801:825,0
,atgagatcagaaaaagaaatgatggatttagtactttctttagcagaacaggatgaacgtattcgaattgtgacccttgaggggtcacgcgcaaatattaatatacctaaagatgaatttcaggattatgatattacatattttgtaagtgatatagaaccgtttatatctaatgatgactggcttaatcaatttgggaatattataatgatgcaaaaaccggaggatatggaactattcccggctgaagagaaaggctactcctatataatactttttgatgattataataaaatagaccttaccttattgcccctggaagagttgggaaactacctgaatgacgataaattgataaagattattctggataaggatggaaggattcagcaagctgtagttccgaccgacatggattatcatataagaaaacccagtgcccgggaatacgatgactgctgcaatgaattctggaacaccactacctatgtggttaagggactgtgccgtaaggaaattttatttgctattgatcattttaatcagattgttcgccatgagctgctgagaatgatatcatggaaggtcggcatcgaaacaggctttaaattaagtgtaggcaagaactataagtttattgaaaggtatatatccgaggatttgtgggagaaacttttgtccacctaccggatggattcctatgaaaacatatgggaagcattatttctatgccatcaattgttcagggcggtatccggtgaggtggcggaaaggcttcattatgcctatccggagtatgataggaatataacaaaatataccagggacatgtataaaaaatacactggtaaaaccggctgcctggatagcacatatgccgctgatatagaagagaggcgggaacagtga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_987,Drugs,MEG_987|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,447178608|WP_001255864.1|NG_047395|1|1|ant(6)-Ia|ant(6)-Ia|aminoglycoside_nucleotidyltransferase_ANT(6)-Ia NG_047395:101-1009,2
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6426,Drugs,MEG_6426|Drugs|betalactams|Class_A_betalactamases|SHV,gi|18656795|gb|AF462396.1|1-861,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcttggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccaaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5441,Drugs,MEG_5441|Drugs|betalactams|Class_C_betalactamases|PDC,959944869|WP_058198950.1|NG_050726|1|1|blaPDC-86|blaPDC|class_C_beta-lactamase_PDC-86 NG_050726:101-1294,0
,atgagtgaaaaagtgcccgccgagatttcggtgcaactatcacaagcactcaacgtcatcgggcgccacttggagtcgacgttgctggccgtgcatttgtacggctccgcactggatggcggattgaaaccgtacagtgatattgatttgctggtggctgtagctgcaccgctcaatgatgccgtgcggcaagccctgctcgtcgatctcttggaggtttcagcttcccctggccaaaacaaggcactccgcgccttggaagtgaccatcgtcgtgcacagtgacatcgtaccttggcgttatccggccaggcgggaactgcagttcggagagtggcagcgcaaagacatccttgcgggcatcttcgagcccgccacaaccgattctgacttggcgattctgctaacaaaggcaaagcaacatagcatcgtcttggcaggttcagcagcgaaggatctcttcagctcagtcccagaaagcgatctattcaaggcactggccgatactctgaagctatggaactcgccgccagattgggcgggcgatgagcggaatgtagtgcttactttgtctcgtatctggtacaccgcagcaaccggcaagatcgcgccaaaggatgttgctgccacttgggcaatggcacgcttgccagctcaacatcagcccatcctgttgaatgccaagcgggcttatcttgggcaagaagaagattatttgcccgctcgtgcggatcaggtggcggcgctcattaaattcgtgaagtatgaagcagttaaactgcttggtgccagccaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_823,Drugs,MEG_823|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,498493509|WP_010794258.1|NG_047365|1|1|aadA7|aadA7|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA7 NG_047365:101-898,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5540,Drugs,MEG_5540|Drugs|betalactams|Class_C_betalactamases|PDC,1509794540|WP_122630849.1|NG_062262|1|1|blaPDC-311|blaPDC|class_C_beta-lactamase_PDC-311 NG_062262:1-1194,0
,atggctctggcactcgttggcgaaaaaattgacagaaaccgcttcaccggtgagaaaattgaaaatagtacatttttttactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgcttggcattgaaattcgccactgtcgtgcgcaaggcgcagatttccgcggcgcaagctttatgaatatgatcactactcgcacctggttttgcagcgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggggacttagatattcggggcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5910,Drugs,MEG_5910|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111736|WP_063865948.1|NG_050484|1|1|qnrB23|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB23 NG_050484:37-681,3
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAGCTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6611,Drugs,MEG_6611|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|87295500|gb|DQ125241.2|3549-4388 gi|974751547|gb|KU130294.1|233473-234001 gi|982189197|gb|CP013993.1|5430539-5431065,8
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccacttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5503,Drugs,MEG_5503|Drugs|betalactams|Class_C_betalactamases|PDC,1201190433|WP_087587953.1|NG_054968|1|1|blaPDC-182|blaPDC|class_C_beta-lactamase_PDC-182 NG_054968:1-1194,0
,TTGGCTATAAAATTGAAAAATAAAAATAAGAATAAAAAAACCGATTATTCCAAACTAAAACGAAAACTCTACCAGTATATCGTTGTGATTGTTATGGCAGCAGCTGTATTCGTGTTGTTTTTGCGTTTATTTATCAAGGGGACACTTGGGGAGTGGATCGTACGTTTTTTGGAAAACAGTTATCACTTAGAGCGTCAGGACGCGATGATAATATATCAGTATACTATACGGAACAATATAGAAATTTTTATTTATGTGGCGATTGCCATTAGTATTCTTATTCTATGCCGCGTCATGCTTTCAAAATTTGCGAAATACTTTGACGAGATAAATACCGGCATTGATATACTTATTCAGAACGAAGATAAACAAATTGAGCTTTCTGCGGAAATGGAGTTCATGGAACAGAAGCTCAACACATTAAAACGGACTCTGGAAAAGCGAGAGCAGGATGCAAAGCTTGCAGAACAAAGAAAAAATGACGTTGTTATGTACTTGGCGCACGATATTAAAACGCCCCTTACATCCGTTATCGGTTATCTGAGCCTGCTTGACGAGGCGCCAGACATGCCGGTAGAGCAAAAGGCAAAGTATGTGCATATCACGTTGGACAAAGCGTATCGCCTCGAACAGCTAATCGATGAGTTTTTTGAGATTACGCGGTATAACCTCCAAACGATTACGCTCACGAAAAAGCACATAGACCTATACTATATGCTGGTGCAGATGGCCGATGAATTTTATCCGCAGCTTGCCGCGAATGGAAAACAGGCGGTTATCCATGCTTCCGAGGATTTGACCGTAACCGGCGACTCCGATAAGCTGGCGAGGGTCTTTAACAACATTTTGAAAAACGCCGCTGCATACAGCGAGGACAACAGCGTCATTGACATTACGGCGGGCCTCTCCGGGGATGTGGTGTCCATCGTTTTCAAGAACGCAGGAAGCATCCCCAAAGATAAGCTCGCTGCCATATTTGAAAAGTTTTACAGGCTGGACGATGCCCGTTCTTCCGATACGGGCGGCGCGGGACTTGGATTGGCGATTGCAAAAGGAATCATTGTTCAGCATGGCGGGCAGATTTACGCGGAAAGCAATGATAACTACACGACGTTTACGGTAGAGCTTCCGGCCTTGCCAGACTTGGTTGATAAAAGGAGTTCCTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7489,Drugs,MEG_7489|Drugs|Glycopeptides|VanA-type_regulator|VANSA,gi|66731642|gb|DQ018711.1|674-1840,5
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcataattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtccgtctgaactttgcggaaatgttttcaaaattgaatatacaaaaaaaagacaacgtcttgcatatatacgcctttatagtggagtactacatttacgagattcggttagagtatcagaaaaagaaaaaataaaagttacagaaatgtatacttcaataaatggtgaattatgtaagattgatagagcttattctggagaaattgttattttgcaaaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgcggccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaagggatacgctatggttgcgaacaaggattatatggttggaatgtgacggattgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7105,Drugs,MEG_7105|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,499429550|WP_011117014.1|NG_048225|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048225:101-2020,4
,atgaaaaaatcgttatctgcaacactgatttccgctctgctggcgttttccgccccggggttttctgccgctgataatgtcgcggcggtggtggacagcaccattaaaccgctgatggcacagcaggatattcccgggatggcggttgccgtctccgtaaagggtaagccctattatttcaattatggttttgccgatattcaggcaaaacagccggtcactgaaaatacactatttgagctcggatctgtaagtaaaactttcacaggtgtgctgggtgcggtttctgtggcgaaaaaagagatggcgctgaatgatccggcggcaaaataccagccggagctggctctgccgcagtggaaggggatcacattgctggatctggctacctataccgcaggcggactgccgttacaggtgccggatgcggtaaaaagccgtgcggatctgctgaatttctatcagcagtggcagccgtcctggaaaccgggcgatatgcgtctgtatgcaaacagcagtatcggcctgtttggtgctctgaccgcaaacgcggcggggatgccgtatgagcagttgctgactgcacggatcctggcaccgctggggttatctcacacctttattactgtgccggaaagtgcgcaaagccagtatgcgtacggttataaaaacaaaaaaccggtccgcgtgtcgccgggacagcttgatgcggaatcttacggcgtgaaatccgcctcaaaagatatgctgcgctgggcggaaatgaatatggagccgtcacgggccggtaatgcggatctggaaatggcaatgtatctcgcccagacccgctactataaaaccgccgcgattaaccaggggctgggctgggaaatgtatgactggccgcagcagaaagatatgatcattaacggtgtgaccaacgaggtcgcattgcagccgcatccggtaacagacaaccaggttcagccgtataaccgtgcttcctgggtgcataaaacgggcgcaacaactggtttcggcgcctatgtcgcctttattccggaaaaacaggtggcgattgtgattctggcgaataaaaactacccgaataccgaaagagtcaaagctgcacaggctattttgagtgcactggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2589,Drugs,MEG_2589|Drugs|betalactams|Class_C_betalactamases|DHA,1391852882|WP_109545067.1|NG_057481|1|1|blaDHA-27|blaDHA|class_C_beta-lactamase_DHA-27 NG_057481:1-1140,0
,TTGAATCGAACTAATATTTTTTTTGGTGAATCGCATTCTGACTGGTTGCCTGTCAGAGGCGGAGAATCTGGTGATTTTGTTTTTCGACGTGGTGACGGGCATGCCTTCGCGAAAATCGCACCTGCTTCCCGCCGCGGTGAGCTCGCTGGAGAGCGTGACCGCCTCATTTGGCTCAAAGGTCGAGGTGTGGCTTGCCCCGAGGTCATCAACTGGCAGGAGGAACAGGAGGGTGCATGCTTGGTGATAACGGCAATTCCGGGAGTACCGGCGGCTGATCTGTCTGGAGCGGATTTGCTCAAAGCGTGGCCGTCAATGGGGCAGCAACTTGGCGCTGTTCACAGCCTATCGGTTGATCAATGTCCGTTTGAGCGCAGGCTGTCGCGAATGTTCGGACGCGCCGTTGATGTGGTGTCCCGCAATGCCGTCAATCCCGACTTCTTACCGGACGAGGACAAGAGTACGCCGCTGCACGATCTTTTGGCTCGTGTCGAACGAGAGCTACCGGTGCGGCTCGACCAAGAGCGCACCGATATGGTTGTTTGCCATGGTGATCCCTGCATGCCGAACTTCATGGTGGACCCTAAAACTCTTCAATGCACGGGTCTGATCGACCTTGGGCGGCTCGGAACAGCAGATCGCTATGCCGATTTGGCACTCATGATTGCTAACGCCGAAGAGAACTGGGCAGCGCCAGATGAAGCAGAGCGCGCCTTCGCTGTCCTATTCAATGTATTGGGGATCGAAGCCCCCGACCGCGAACGCCTTGCCTTCTATCTGCGATTGGACCCTCTGACTTGGGGTTGA,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1055,Drugs,MEG_1055|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,gi|846281253|gb|KP272131.1|3856-3053 gi|846281244|gb|KP272130.1|3858-3055 gi|402294554|gb|JX181780.1|5336-6139 gi|402294540|gb|JX181779.1|8456-9259 gi|402294528|gb|JX181778.1|253-1056 gi|380863171|gb|JQ282797.1|381-1184 gi|145315385|gb|EF467360.1|63-866 gi|145315375|gb|EF467359.1|63-866 gi|145315364|gb|EF467358.1|63-866 gi|120573441|gb|EF189157.1|63-866,2
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggattgtgggaagaagataccgatccaggagtacgcggaatagaccagtttatggcgaatgcatcacaactgggcaaaggcttgggaaccaagttggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_234,Drugs,MEG_234|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1693892789|WP_140423191.1|NG_065404|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_065404:101-655,2
,atgaaaaactactttaacagccctttcaaaggggaacttctttctgagcaagtgaaaaatccaaatatcagagtaggccggtatagctattactctggctactatcacgggcactcatttgatgaatgcgcgcgatacttgcttccagatcgtgatgacgttgataaattgatcattggcagcttttgttctataggaagcggggcttccttcatcatggctggcaatcaggggcatcggcatgactgggcatcatccttccccttcttctatatgcaagaggagcctgctttctcaagagcactcgacgccttccaaagagcaggtgataccgtcattggcaatgatgtctggataggctcggaggcaatgattatgcctggcatcaaaattggagacggtgccgtgataggtagtcgctcgttggtgacaaaagatgtagagccttatgccatcatcgggggaaatcccgcaaagcatattaagaagcgcttctccgatgaggaaatctcattgctcatggagatggagtggtggaactggccactagataaaattaagacagcaatgcctctgctgtgctcgtcaaatatttttggtctgcataagtattggcgcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1595,Drugs,MEG_1595|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1028084264|WP_063843232.1|NG_047620|1|1|catB8|catB8|type_B-3_chloramphenicol_O-acetyltransferase_CatB8 NG_047620:101-733,6
,gtgagcgacctggagctgcgcggcgagcgggtcctgctgcgctccaccgtccccgccgacacccccgtcctcgacgcgatcgtccgcgagcttgaggtcgccttgtggtggccgccgcccgaggactacgccgccatgctcgccgtcgtcgtggacggcgaggtgatcggcgcgatccagttcagcgaggagaccgacccggagttccgccacgccggcatcgacctcttcctgtcgacccggtggcgcgggcagggcctgggccccgacgccgtccgcaccctggcccgctggctgatcgccgagcgcggccaccaccgtctggtcatcgacccggccgccgccaacacggccgccatccgcagctaccgcaaggtcggcttcgccccggtcggcatcatgcgcgcctactggcgcaaccaccgcaccggcgcgtgggaggacggcctgctgatggacctgctggcggccgaactgagctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_253,Drugs,MEG_253|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502202|WP_071846352.1|NG_052459|1|1|aacA-STR-13|aacA-STR-13|aminoglycoside_6'-N-acetyltransferase NG_052459:101-583,2
,atgagaaacacagtgcccgccgagatttcggtacagttatcacaggcactcaacgtcatcgagcatcatctgggatcgacgttgctggccatgcatttgtatggctctgcactcgacggtggcctgaagccatacagtgacattgatttgctggttactgtgaccgcacggctcgatgagagtgtgcggcaagctctgttcgtcgatctcttgggggtttccgttttccctggtcaaagcagagttctccgcgccttggaagttaccattgtcgtgcacagtgacatcgttccttggcgctatccggccagacgggaactgcaattcggggagtggcagcgcaaagacattcttgcgggcatcttcgagcctgcgacaaccgatgttgatctagccattctgctaacaaaagcaaggcaacatagccttgccttggccggttcggctgcggaagatttcttcaacccagtcccggaaagcgatctgttcaaggcactggccgacaccctgaaactatggaactcacagccggattggataggtgacgagcggaatgtagtgcttactttgtctcgtatttggtacagcgcagcaaccggcaagatcgcgccgaaggatgttgccgccaactgggtaatggagcgcttgccagttcaacatcagcccgtgctgcttgaagcccggcaggcttatcttggacaaggagaagattgcttggcttcgctcacggatcagttagaggcgtttgttcacttcgtgaagcatgaagccactaaactgcttggtgccacgccaatgatgtctaattcaggcgctatgcgctcacgtccttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_759,Drugs,MEG_759|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502176|WP_071846327.1|NG_052411|1|1|aadA10|aadA10|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA10 NG_052411:101-934,2
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaatttaaatgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacatttaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagtacacgtatcgaacacgcttgtgaggccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacactgtttttgcgctctattggcgacaaagcaacgcgacttgaccgattggagccccgtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatttggaaagacaactacaagccggtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1515,Drugs,MEG_1515|Drugs|betalactams|Class_A_betalactamases|CARB,645071864|WP_025442943.1|NG_048726|1|1|blaCARB-23|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-23 NG_048726:101-958,0
,atgaaaattaataatgtaacagaaaaggatttattttatattttagacttatttgaaaaaatggaagtaacttattggttagatggaggttggggtgtagatgtattaactggaaaacaacaaagagaacacagagatatagatatagattttgacgcccaacacactcaaaaagttatacaaaaattagaagatataggatataaaatagaagttgattggatgccttcacgcatggaacttaaacataaaaaatatggatatttagatattcatcccataaatttaaatgatgatggttccattactcaagcaaatccagaaggtggcaattacgtttttcaaaatgaatggttttcagaaactaattataaaggtcgaaaaataccatgtatttcaaaagaagctcagcttctttttcattctggttatgacttaacagaaaaagaccattttgatataaaaaatttaaaatcaataacataa,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3603,Drugs,MEG_3603|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUA,446623302|WP_000700648.1|NG_047915|1|1|lnu(A)|lnu(A)|lincosamide_nucleotidyltransferase_Lnu(A) NG_047915:101-586,7
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtcggcatgttcttttaataccgtacaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaacagaggaaatctatggcaatgatcttaaaagatcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttgtttcctgattgggaaaaggacatgactctaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagtacggtttgcttataaattagccaacaaaactcttccctttagcaaaaatgtacaagaacaagttcaatctatggtgttcattgaagaaaaaaatggacgaaaaatttatgccaaaagtggttggggatgggatgttgacccagaagttggttggtttacaggctgggtagttcaacctcagggagaaattatagctttctcacttaatttagaaatgaagaaaggcatacctagttctattcgaaaagaaattgcttataagggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4563,Drugs,MEG_4563|Drugs|betalactams|Class_D_betalactamases|OXA,1625655418|WP_136512095.1|NG_064762|1|1|blaOXA-804|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-804 NG_064762:1-822,0
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcacatgcgtcggaaaaattaaccttcaagaccgatcttgagaggctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcgaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccggagatgagcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggcaaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacgggggccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3087,Drugs,MEG_3087|Drugs|betalactams|Class_A_betalactamases|GES,1028105361|WP_063860510.1|NG_049128|1|1|blaGES-25|blaGES|class_A_beta-lactamase_GES-25 NG_049128:1-864,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcacttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtattggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4482,Drugs,MEG_4482|Drugs|betalactams|Class_D_betalactamases|OXA,953976195|WP_058061931.1|NG_049774|1|1|blaOXA-497|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-497 NG_049774:101-925,0
,atgaaaatactgttagagggacttcatataaaacattatgttcaagatcgtttattgttgaacataaatcgcctaaagatttatcagaatgatcgtattggtttaattggtaaaaatggaagtggaaaaacaacgttacttcacatattatataaaaaaattgtgcctgaagaaggtattgtaaaacaattttcacattgtgaacttattcctcaattgaagctcatagaatcaactaaaagtggtggtgaagtaacacgaaactatattcggcaagcgcttgataaaaatccagaactgctattagcagatgaaccaacaactaacttagataataactatatagaaaaattagaacaggatttaaaaaattggcatggagcatttattatagtttcacatgatcgcgcttttttagataacttatgtactactatatgggaaattgacgaggggagaataactgaatataaggggaattatagtaactatgttgaacaaaaagaattagaaagacatcgagaagaattagaatatgaaaaatatgaaaaagaaaagaaacgattggaaaaagctataaatataaaagaacagaaagctcaacgagcaactaaaaaaccgaaaaacttaagttcatctgaaggcaaaataaaaggaacaaagccatactttgcaagtaagcaaaagaagttacgaaaaactgtaaaatctctagaaaccagactagaaaaacttgaaagggtcgaaaagagaaacgaacttcctccacttaaaatggatttagtgaacttagaaagtgtaaaaaatagaactataatacgtggtgaagatgtctcgggtacaattgaaggacgggtattgtggaaagcaaaaagttttagtattcgcggaggagacaagatggcaattatcggatctaatggtacaggaaagacaacgtttattaaaaaaattgtgcatggaaatcctggtatttcattatcgccatctgtcaaaatcggttattttagccaaaaaatagatacattagaattagataagagcattttagaaaatgttcaatcttcttcacaacaaaatgaaactcttattcgaactattctagctagaatgcatttttttagagatgatgtttataaaccaataagtgtcttaagtggtggagagcgagttaaagtagcactaactaaagtattcttaagtgaagttaatacgttggtactagatgaaccaacaaactttcttgatatggaagctatagaggcgtttgaatctttgttaaaggaatataatggcagtataatttttgtatctcacgatcgtaaatttatcgaaaaagtagccactcgaataatgacaattgataataaagaaataaaaatatttgatggcacatatgaacaatttaaacaagctgaaaagccaacaaggaatattaaagaagataaaaaacttttacttgagacaaaaattacagaagtactcagtcgattgagtattgaaccttcggaagaattagaacaagagtttcaaaacttaataaatgaaaaaagaaatttggataaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_7678,Drugs,MEG_7678|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA,501574685|WP_012579073.1|NG_048556|1|1|vga(A)|vga(A)|ABC-F_type_ribosomal_protection_protein_Vga(A) NG_048556:101-1669,1
,atgaaaaagaatacattattaaaattaggggtatgtgttagtttgctaggaacaattcaatttgttagcacaatttcttctgtgaaagcggaacaaaagctagagcaaaaagtaataaagaatgagacaggaactatttcaatttctcagttaaacaaaaatgtatgggttcatactgagctaggctattttaatggagtagcagttccttcgagtggtctagttcttactacttctaaagggttagtacttgtcgattcttcttgggatgataagttaacgaaggaactaatagagatggtagaaaagaaatttaagaagcgcgtaacggatgttattattacacatgcgcatgctgatcgaattggcggaataaaaacgttgaaagaaagaggcattaaagcgcatagtacagcattaactgcggaactagcaaagaaaaatggatatgaagagccacttggagacttacaaacaattacgaatatgaagtttggaaatataaaagtagaaacgttctatccagggaaagggcatacagaagataatattgtcgtatggttaccgcaatacaacattttagctggaggctgtttagtgaaatctgcggaagctaaagatttagggaatgttgctgatgcatatgtaaatgaatggtccacatcgattgagaatgtgttgaagcgatatggaaatatgaacttagtagtgcctggtcatggagaagtaggggacagaggattatttttacatacattggatttgttgaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1202,Drugs,MEG_1202|Drugs|betalactams|Class_B_betalactamases|BCII,501218310|WP_012261328.1|NG_047224|1|1|BcII|BcII|BcII_family_subclass_B1_metallo-beta-lactamase NG_047224:101-874,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5650,Drugs,MEG_5650|Drugs|betalactams|Class_C_betalactamases|PDC,1393270444|WP_109791189.1|NG_057587|1|1|blaPDC-255|blaPDC|class_C_beta-lactamase_PDC-255 NG_057587:1-1194,0
,atggaaatcaaaaagttaagccgtgctaatattaacttatggatagcgctaagagagcagctatggccgcatcatcctgaaaataaaactgatggggaaaatattattctgtctgatgggttggcttcatttattgctatagataaccttggtcaaggcattggtttcgctgatgcatccatacggaacgattatgtgaatggttgtattcatagccctgttgccttccttgagggcatttttattgtcccaccctctcggcgtagtggtgttgccaaacagttagttgatgctgtgcaagcatgggggttagaaaaggggtgccaggaactggcatctgataccgcattggataatgttttatcacaacaagtccatgaagctttgggatttaaggaaactgagagggtcgtttactaccgcaaagcctcacttagctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_189,Drugs,MEG_189|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,914221899|WP_050537864.1|NG_052201|1|1|aac(6')_Yersi|aac(6')_Yersi|aminoglycoside_6'-N-acetyltransferase NG_052201:101-541,2
,atgaaaagcaaagtcagtgcgctgttaatgatgatagttctcgcgggccatgcgcaggccgcgcccgttgcgccaccggatgcggtcgttaagccgttgatggcgcgttaccagatcccgggcatggcggtggcggtgtcggtcaatggcgaaacgcatttctggcactacggcgtggcgtcaaaagcgacgcgcaagccggtggatgaaaaaacgcttttcgaaatcggctcgctcagtaaaacctttaccgcgacgctcgcaagcgcggcgcagcaagagggcaaactggatttcagcgcgcccgccagccagtatcttcctgcactgaaaggcagcgcgttcgaccacgtgacgctgctgaaccttgccacgcacacctcgggaacgccgctgtttgtgccggatgcggtgaaaaacaccgcgcagctgatggcctggtatcgcgcctggcaacctgaaaagccggtcggcaccgagcgcgtatactcgaatctcgggatcgggctgctcgggatgattaccgcgaaggcgctcgataaaccgttcagcgaggcgatggagcaggggctgctcagggatttcggcatgacgcacacctttatcaacgtgccggatgccgcgatggacgactacgcccagggctataacaaagacgacaaaccggtgcgggtgacgcccggcccgctggatgctgaatcctatgggctgaaatccggcagcgccgacctgctgcgttatctgcaaatccagcttggcgagcaggaggtggcccctcgctggcgtcaggcgattaacgccacgcacaacggctactaccgcagcggtgagttcacacagggaatgatgtgggaatattatccgtggccatcgccgctctcgcgccttgttgaaggcaacagcagccagcgcatcatgaaagggctcgcggccaccgctattgtgccgccgcagcccgcaccagaggccgcgtggtataacaaaaccggttcgaccaacgggttttcctcttacgcggtgtttatccctgaaaagcgtatcgcgctgattatgctcgccaacaagtggttcccgaatgacgaccgcgtgaaggcggcgtatgcgattattcagcagcttgataagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1733,Drugs,MEG_1733|Drugs|betalactams|Class_C_betalactamases|CMA,1358818350|WP_105620838.1|NG_062212|1|1|blaCMA-2|blaCMA|class_C_beta-lactamase_CMA-2 NG_062212:101-1228,0
,ATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2384,Drugs,MEG_2384|Drugs|betalactams|Class_A_betalactamases|CTX,gi|225579719|gb|FJ815279.1|4-879 gi|225579691|gb|FJ815265.1|1-876,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1988,Drugs,MEG_1988|Drugs|betalactams|Class_C_betalactamases|CMY,gi|629511207|gb|KJ496347.1|160-1305 gi|326328196|gb|HQ267531.1|1-1146,0
,ATGAGGACTGAAAAAGAAATTTTAAATTTAGTTTCTGAATTTGCTTATCAACGAAGCAATGTAAAAATTATTGCTCTCGAGGGTTCAAGAACTAATGAAAATATAAAAAAAGATAAGTTTCAAGATTATGATTTTGCTTTTTTCGTATCAGATATTGAGTATTTCACACATGAAGAAAGTTGGTTAAGTTTATTTGGAGAATTATTGTTTATACAGAAACCAGAAGATATGGAATTATTCCCACCTGATTTAGATTATGGTTACAGTTATATAATGTATTTTAAAGATGGCATAAAAATGGATATTACATTAATTAATTTAAAAGATTTAAATCGTTATTTTAGTGATTCTGATGGTCTTGTAAAAATTTTAGTTGATAAAGATAATTTAGTAACTCAAGAAATTGTTCCAGATGACTCAAATTATTGGTTAAAAAAACCAACAGAACGAGAATTTTATGATTGCTGTAATGAGTTTTGGAGTGTCTCAACGTATGTAGCAAAGGGTGTTTTTAGAAGAGAAATATTATTTGCTTTAGATCATTTCAATAATATTTTACGTCCTGAATTATTAAGAATGATTTCTTGGTATATTGGCTTTAATAGGGGTTTTGATTTTAGTTTAGGAAAGAATTATAAGTTTATAAACAAATATTTAACTGATAAAGAATTCAATATGCTTTTAGCTACTTTTGAGATGAATGGATATAGAAAGACATACCAATCTTTTAAGCTTTGTTGTGAATTATTTAAATATTATTCAAATAAAGTAAGTTGTTTAGGAAATTATAACTATCCAAATTACGAAAAAAATATTGAGAATTTTATTCGTAATAATTATGAGAATTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1001,Drugs,MEG_1001|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,gi|961575513|gb|CP013623.1|1013-1861 gi|283471934|emb|AM990994.1|185-1033 gi|255914602|emb|FN435330.1|1-849 gi|46643|emb|X06627.1|1-774 gi|46643|emb|X06627.1|4323-4397 gi|222121420|dbj|AP009489.1|653-1 gi|222121420|dbj|AP009489.1|4398-4203 gi|919235037|gb|KR778883.1|1-432,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcaccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagttatgggctggcgtcgaaagaggacggtcgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcaaggcagccgcttcgacggcatcagcctgctcgacctcgcgacctacaccgccggcggcttgccgcttcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgagcggatcatggagcagcgcctgttcccggccctgggcctcgaacagactcacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctccgggtcggccccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgactggaccggcagtgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatcgccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacagggtcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctggcgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5590,Drugs,MEG_5590|Drugs|betalactams|Class_C_betalactamases|PDC,640475059|WP_024915536.1|NG_054975|1|1|blaPDC-189|blaPDC|class_C_beta-lactamase_PDC-189 NG_054975:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcaacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5514,Drugs,MEG_5514|Drugs|betalactams|Class_C_betalactamases|PDC,1092775147|WP_070698497.1|NG_060548|1|1|blaPDC-278|blaPDC|class_C_beta-lactamase_PDC-278 NG_060548:1-1194,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcacggcgctgtggcccacttgtccgttggaagagcaccgcgcggagatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttacaccgtcgaatgcgcccgccgccagggctgggccacgcgtttgatcgcgcaggtacaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgacatcgccaacctggactcccaacgcctgcatgcggcgctgggctttgccgaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_162,Drugs,MEG_162|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,727159600|WP_033632034.1|NG_052347|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052347:101-541,2
,ATGGAGAAAATAATAGACATAACTGTTTTTGGCTGCGAGCCAGACGAAATGGAGGTTTTTCAAAAGATTTCTTATGAGCTTGGCGTTACGGCCACACTCATAAAAGATTCTATATCAGAAAGCAATGCTGGATTAGCTAATGGATGCCGGTGTGTAAGCGTAAGCCATAAAGCGGAGCTATCAGAACCGATTCTTCTTGCACTAAAAAATGCAGGGGTAAAATATATCAGTACCCGGAGCATTGGCTTTAACCATATTGATATACAGGCGGCTGGGTTACTGGGTATGGTTGTTGGTACAGTAGAATACTCGCCGGGAAGTGTGGCCGATTATACCGTCATGCTGATGCTTATGCTGATGCGCGGCACAAAGTCGATTCTGCGTGAAACCCAGAGGCAGAATTATTGCCTGAATGACCTGCGCGGAAAAGAACTGCGGGATATGACCGTGGGTGTGTTAGGAACTGGACGAATCGGACAGGCAGTCATGGAACGTCTGGAGGGATTCGGCTGTAAGGTATTGGCGTATGACCGAAATCAAAAAGCAGGAGCGGACTATGTTTCGTTTCATGAGCTGCTGAAAAAAAGTGACATTGTTACACTGCATATCCCGTTGGCGGAGGATACCCGCCATATGATTGGCTATGAAGAGCTGGAAATGATGAAGCAGGAGGCGCTTCTGATCAATACAGGGCGGGGCGCTTTAGTGGATACCGCAGCATTGGTAGAAGCATTAAAAGGACAGAAAATCGGCGGCGCCGCCCTGGATGTTTTAGAGGGCGAAGAAGGTATCTTTTATCATGACTGCACCCAAAGAAGGATAGAACATCCTTTCCTGTCGGTCCTGCAGGGAATGCCGAATGTCATTGTTACGCCGCACACAGCCTATCACACGGAACGGGTGTTGGTTGACACGGTCAGAAATACTATTAGAAATTGTTTGAACTTTGAAAGGAGTCTGGGAAATGTTTAGAATTAAAGTTGCAGTTCTGTTTGGGGGCTGTTCAGAGGAACATAATGTTTCGATAAAATCTGCGATGGAGATTGCCGCAAACATAGATACAAAAAAGTATCAGCCTTATTATATTGGAATCACAAAATCCGGCGTTTGGAAAATGTGTGAAAAACCTTGTTTGGAGTGGGAACAATATGCGGGGGATCCGGTTGTTTTTTCACCGGACAGAAGTACGCATGGTCTGCTGATACAAAAAGACACTGGGTATGAAATCCAGCCTGTGGATGTGGGATTACCGATGATTCATGGCAAGTTTGGCGAGGATGGCTCCATACAAGGCTTGCTTGAATTGTCAGGCATTCCGTATGTGGGATGCGATATTCAAAGCTCCGTGACCTGCATGGATAAGGCGCTTGCATATACCGTTGTGAAAAATGCGGGTATCGCTGTGCCTGGGTTCCGGATCCTTCAGGAGGGGGATCGCCTGGAAACAGAGGATTTCGTATATCCCGTTTTTGTAAAGCCTGCCCGTTCCGGCTCATCCTTTGGCGTAAACAAGGTATGCAAGGCAGAAGAACTGCAGGCAGCAATCGAAGATGCAAGAAAATATGACAGCAAGATTTTGATTGAAGAGGCCGTTACCGGGAGTGAGGTAGGCTGCGCCATACTGGGAAACGGAAATGATCTCATGGCTGGCGAGGTGGATCAGATTGAGCTGAGACACGGCTTTTTTAAGATTCATCAGGAAGCACAGCCGGAGAAAGGATCTGAAAATGCAGTCATCCGAGTTCCAGCCGCCTTACCGGATGAGGTAATAGAACGGATTCAGAAAACAGCAATGAAGATTTACCGGATACTTGGCTGCAGAGGATTGGCCCGCATTGACCTGTTTTTGCGGGAGGACGGCTGCATTGTGTTGAATGAAGTGAATACCATGCCGGGTTTTACTTCCTACAGCCGTTATCCCCGCATGATGACAGCAGCCGGTTTTACGCTTACTGAAATACTGGATCGCTTGATTGAACTTTCACTTAGGAGGTAACTGCTATGAAAAAGAACTTTGCCTTTTTAGATGAAATGATTCCCGGAATCCGATGGGATGCTAAATATGCCACATGGGACAATTTCACCGGGAAACCGGTAGACGGATACATGGTAAACCGTGTTATGGGAACGAAGGAGCTGGGAGTTGCTTTGCGTAAGGCTCACAAGATGGCGGAGAAACTGGGATATGGTTTGCTCTTATGGGACGGCTATCGCCCCCAGTGCGCAGTGGATTGTTTTCTGAATTGGGCTTCCCAACCGGAAGACAATCTGACGAAAAAGCGTTACTATCCAAATATCAAAAGGAACGAGATGATCACGAAAGGGTATGTGGCTTCACAATCCAGCCACAGCCGTGGAAGTACGGTTGACCTTACAATTTTTCATTTGAATAGTGGTATGCTTGTTCCTATGGGTGGGGATTTCGACTTTATGGATGAACGGTCACACCATGCCGCAAGCGGTCTGAGCGAAGAGGAATCAAAAAACCGGCAGTGCTTGCGTTATATCATGGAGAGCAGCGGATTTGAAGCCTATCGTTATGAATGGTGGCATTACGTCTTGGCGGACGAGCCATACCCGGATACATATTTTGATTTTTGTATCGCCTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7436,Drugs,MEG_7436|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,VanHDX_3_AF175293,5
,ATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGATCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6463,Drugs,MEG_6463|Drugs|betalactams|Class_A_betalactamases|SHV,gi|46562013|gb|AY590467.1|2-729,0
,TCACTTCTCCGCCAGCGCCTCCAGGGCCATGCGGGCGACTGTCTCGTCGATATCGGCCGGGTCGCCGTCATCCCTGAACCACACTGCCGACAGCGCAGTGCTGGCCGCGATCCAGCGCAGCAGGCGTGTGCGTTCCAGTTCGGACAGCGCACAGACCTGCTCAAGGCGGATCGCAAACCGCTCGGGCCGCGTCGCAACGTGGATGCCCGGACCACAGAGGTCCGGGTTGCTGAACATCGTCGTGTAATCGAACGCACGGTCCCCCAGCAGTCGCTTCGGGTCGATCGCCAACCAGCCGCGCGGGCCGAAATCCAGCACATTGTCATGATGCAGGTCGCCGTGCAGCGGGCGGATCTCCTGTTCGTCATGCAGCAGCCCCTCCGCCAGTGATCTGCACTGTTCCAGCAGTGGCGGCAGGACAGCCCTTGGCTGCAGCAGGTCGGCGAACCATGTTCGCAGGCAGACCAGTTCCGCTGGCGGCGCGCTCCGTGGCCGGTGCAGCCGCTGCAGGACCTGGCACAGGATCGCGGTGCAGGCGTCATCGTCGCCCTCGATCGAGCGTTGCCGCAGCGAGTCACCGCGGGCACGCTCGATCAGGATCGCAGGCCCCTCGTGGGCCAGCAGGCGGGCGGCGCCATCGCCGTTCCACCAGCGTAGCAGGCGATGACTGTTCTGCTCCTCGGTCTCGCTGCTGATCTTCAGCATCGCTGGCTCGCCCGCAGCGGTCAGCACCGGCCAGAGCCGGGCGTGGGGCGTACGGAGGGCCGGGCCATCACGCCGCAATCGCCAGCGGCTCAGGTAGGGTTCGCTCAT,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1077,Drugs,MEG_1077|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-PRIME,gi|190010013|emb|AM743169.1|2377498-2378310,2
,ATGCGCTTCATTCACGCACTATTACTGGCAGGGATCGCTCACTCTGCATATGCGTCGGAAAAATTAACCTTCAAGACCGATCTTGAGAAGCTAGAGCGCGAAAAAGCAGCTCAGATCGGTGTTGCGATCGTCGATCCCCAAGGAGAGATCGTCGCGGGCCACCGAATGGCGCAGCGTTTTGCAATGTGCTCAACGTTCAAGTTTCCGCTAGCCGCGCTGGTCTTTGAAAGAATTGACTCAGGCACCGAGCGGGGGGATCGAAAACTTTCATATGGGCCGGACATGATCGTCAAATGGTCTCCTGCCACGGAGCGGTTTCTAGCATCGGGACACATGACGGTTCTCGAGGCAGCGCAAGCTGCGGTGCAGCTTAGCGACAATGGGGCTACTAACCTCTTACTGAGAGAAATTGGCGGACCTGCTGCAATGACGCAGTATTTTCGTAAAATTGGCGACTCTGTGAGTCGGCTAGACCGGAAAGAGCCGGAGATGGGCGACAACACACCTGGCGACCTCAGAGATACAACTACGCCTATTGCTATGGCACGTACTGTGGCTAAAGTCCTCTATGGCGGCGCACTGACGTCCACCTCGACCCACACCATTGAGAGGTGGCTGATCGGAAACCAAACGGGAGACGCGACACTACGAGCGGGTTTTCCTAAAGATTGGGTTGTTGGAGAGAAAACTGGTACCTGCGCCAACGGGGGCCGGAACGACATTGGTTTTTTTAAAGCCCAGGAGAGAGATTACGCTGTAGCGGTGTATACAACGGCCCCGAAACTATCGGCCGTAGAACGTGACGAATTAGTTGCCTCTGTCGGTCAAGTTATTACACAACTCATCCTGAGCACGGACAAATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3130,Drugs,MEG_3130|Drugs|betalactams|Class_A_betalactamases|GES,gi|316994923|gb|HM453325.1|2632-3495,0
,atggcaatccgaatcttcgcgatacttttctccattttttctcttgccactttcgcgcatgcgcaagaaggcacgctagaacgttctgactggaggaagtttttcagcgaatttcaagccaaaggcacgatagttgtggcagacgaacgccaagcggatcgtgccatgttggtttttgatcctgtgcgatcgaagaaacgctactcgcctgcatcgacattcaagatacctcatacactttttgcacttgatgcaggcgctgttcgtgatgagttccagatttttcgatgggacggcgttaacaggggctttgcaggccacaatcaagaccaagatttgcgatcagcaatgcggaattctactgtttgggtgtatgagctatttgcaaaggaaattggtgatgacaaagctcggcgctatttgaagaaaatcgactatggcaacgccgatgatccttcgacaagtaatggcgattactggatagaaggcagccttgcaatctcggcgcaggagcaaattgcatttctcaggaagctctatcgtaacgagctgccctttcgggtagaacatcagcgcttggtcaaggatctcatgattgtggaagccggtcgcaactggatactgcgtgcaaagacgggctgggaaggccgtatgggttggtgggtaggatgggttgagtggccgactggctccgtattcttcgcactgaatattgatacgccaaacagaatggatgatcttttcaagagggaggcaatcgtgcgggcaatccttcgctctattgaagcgttaccgcccaacccggcagtcaactcggacgctgcgcgataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4729,Drugs,MEG_4729|Drugs|betalactams|Class_D_betalactamases|OXA,1102724737|WP_071593233.1|NG_052064|1|1|blaOXA-539|blaOXA-2_like|OXA-2_family_class_D_extended-spectrum_beta-lactamase_OXA-539 NG_052064:1-831,0
,ATGGCTATCGGACGTGATCGCATTGTCGATGAGGCCCTGCGGCTCCTGAACGAGGTGGGAATAGACAAGCTGTCCACCCGCAAGCTCGCGGAACGGCTGGGCGTCCAGCAGCCGGCGCTCTACTGGCACTTCCGCAACAAGGCGGAATTGCTCGACGCCATCAATTCCGAAATGCTGCTGCGTTATCACTGCGATCGCCTGCCCAAACCCGGCCAGGATTGGATTACGTTCACGCTGGCCAATGCCCGCAGCATTCGCAAGACCTTGCTCACCGTGCGCGATGGCGCGCGGCTAACCGCAGGTACACGGCCTTCCGTCGCCGAGTTTGCCGATGTGGAAAGCGTCTTGCAGCTCTATGTCGAGACGGGATTTTCCGCAGAGGAGGCATTTGGGATCGCCATTTGCATCACGCGCTATGTGGTCGGCTATGTGCTCGAAGAACAGGGAGAGCGCGAACGGGATCGGATGGATCAACACTCGCCCAATACCGACATCATGGCAGAACTCGCACAGTTCCCCCTGCTTGCAAAAGCTCTTGAAAGCTTCCCCACGGTTGGAACGGTCAACACCGAAGCCGTGTTCGAGAGTGGGCTAAGTTACCTGCTGGCCGGTATGAAGGAGAAGCTGCGGGAGAAACAGTCTAGATAG,tetR,antibiotic target alteration,Tetracyclines,MEG_7188,Drugs,MEG_7188|Drugs|Tetracyclines|Tetracycline_transcriptional_repressor|TETR,gi|159140696|gb|AE007870.2|1328236-1327589 gi|3860030|gb|AF090987.1|AF090987|1041-394,4
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTTATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6460,Drugs,MEG_6460|Drugs|betalactams|Class_A_betalactamases|SHV,gi|41584435|gb|AY502004.1|1-861 gi|40950643|gb|AY509128.1|1-859,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgaggacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaaatgggatggggaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4704,Drugs,MEG_4704|Drugs|betalactams|Class_D_betalactamases|OXA,1559613010|WP_128268275.1|NG_063880|1|1|blaOXA-776|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-776 NG_063880:16-840,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttgaaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_562,Drugs,MEG_562|Drugs|betalactams|Class_C_betalactamases|ADC,1440786782|WP_114699270.1|NG_061394|1|1|blaADC-178|blaADC|class_C_beta-lactamase_ADC-178 NG_061394:1-1152,0
,atgaagtactctttaaatccaatccgtcccgaagaatcacacgattggctgcgccttcgagatctgctttgggaagctgatgaccatgcgatagaaattgcgagattctttactggcgagctagaggaaacggttgaagtactgatcgcacgcgacctcgaaggacgtgcggtagggcacgttgagctttccatccgtgaagacatagatggtctgaatggcgtcaagaccggatacatcgaggggttgtacgttgatgtattgcatcgctcaagcggtctggtcaggcagtttctgagagcatcggaacaatgggcaaaagatcaaggctgtagcgcattcgcatctgatcggcaagaccgagtaatcatccacaggcggttctccggtggctccgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_73,Drugs,MEG_73|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1028080949|WP_063840332.1|NG_047320|1|1|aacA37|aacA37|aminoglycoside_6'-N-acetyltransferase_AacA37 NG_047320:81-482,2
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattacttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4392,Drugs,MEG_4392|Drugs|betalactams|Class_D_betalactamases|OXA,1391852904|WP_109545089.1|NG_057523|1|1|blaOXA-585|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-585 NG_057523:1-774,0
,ATGACGCCATTACTGTACAAAAAAACAGGTACAAATATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGTTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTAAGTGGTACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCAATGCTAAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACACGCACCTGGTTTTGCAGCGCATATATCACTAACTCAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGCTGGAAAAGTGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGTTGCTCATGGAACGTCTTGGCATCGCGATTATTGGCTAG,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_5921,Drugs,MEG_5921|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,(Flq)QnrB32:JN173054:37-681:645,3
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6425,Drugs,MEG_6425|Drugs|betalactams|Class_A_betalactamases|SHV,gi|18656791|gb|AF462394.1|1-861,0
,atggttaaaaaatcactgcgtcagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggaagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgtggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgacttggttaactataatccgattgcggaaaagcacgtcgatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgatttctcacgttggcggcccggctagcatcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcgtaatctgacgctgggtaaagcattgggtgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccaacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2211,Drugs,MEG_2211|Drugs|betalactams|Class_A_betalactamases|CTX,1463920487|WP_116786829.1|NG_061609|1|1|blaCTX-M-222|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-222 NG_061609:1-876,0
,ATGAAAAAAATCGCCTTAATTTTTGGTGGTACTTCAGCAGAATATGAAGTATCCCTCAAATCAGCAGCTAGTGTTTTGTCTGTATTAGAAAATCTAAATGTTGAAATTTACAGAATTGGCATAGCTTCGAACGGAAAATGGTATTTAACCTTTAGTGATAATGAAACTATTGCAAATGACTTATGGTTACAAGATAAAAAATTAAATGAGATCACTCCCTCCTTCGATGGGAGAGGGTTTTATGACCAAGCAGAAAAAGTATATTTTAAACCAGATGTCTTATTTCCGATGCTACACGGTGGCACTGGAGAAAATGGTACATTACAAGGAGTTTTTGAATGTATGCAAATTCCTTATGTTGGTTGCGGCGTTGCCTCCTCTGCCATTTGTATGAATAAATATCTATTACATCAGTTTGCAAAAAGTGTCGGAGTGATGAGTACGCCTACACAGCTGATCTCATCGACGGACGAACAACAAGTAATCAAAAATTTTACTGAGTTGTACGGTTTTCCTATATTTATCAAACCAAATGAAGCTGGTTCTTCAAAGGGAATCAGCAAAGTTCATACCGAAGCAGAGTTAACTAAAGCGCTGACCGAAGCGTTCCAATTCAGTCAGACAGTCATTTTACAAAAAGCTGTTTCTGGAGTAGAGATCGGTTGCGCCATCCTAGGAAATGATCAATTGCTTGTTGGGGAATGTGATGAAGTATCCTTAGCGACCGACTTTTTTGATTATACGGAAAAATATCAAATGACTACAGCAAAGTTGACCGTTCCAGCAAAAATTCCAGTGGCAACTAGTAGAGAAATCAAGCGTCAAGCACAATTACTGTATCAATTACTTGGATGTCAGGGCTTAGCTCGCATTGATTTTTTTCTAACAGAAGCAGGTGAAATTCTCTTAAATGAAATCAATACAATGCCAGGCTTTACCAATCATTCTAGATTTCCAGCCATGATGGCAGCTACGGGTATCACTTATCAGGAGCTTATTTCAACATTAATTACTTTAGCGGAGGATAAATAGCATGCATAATTTTTATTTACAGCTTGTAAACCAACAACACCCTTGGAAATCATTTAATCATTCGCCACAGCTTGTTCAAGCGACCTATGCGGAAGAAAAGATTTTAATAGATTCCAAGGTTAACCATCAATTCAATCAGTTACTTGAAACACTACAATTAACTGATCGCATCATGATCGTTGATGGTCATCGAACGGTTGCTGAGCAAAAACATTTGTGGAACTATTCTTTAAACGCACATGGGGTGAATTATACAAAAAGTTATGTAGCATCTCCTGGCTGTAGTGAACATCATACGGGACTAGCAATTGATCTCGGTCTACGAAAGACAGAACATGATCTCATTGCGCCACGCTTCGAGGGACCAGAAGCCGAACTGTTTTTACAACATATGAAAGATTATGGATTTATTTTACGCTATCCTAAAAATAAGCAAAAAATTACAGGAATTGCTTATGAGCCTTGGCATTTTCGCTATGTAGGTACCCCTCATAGTCAAATCATCATGGACCACGGATGGACCTTAGAAGAGTATATTGAATTTTTAAAACATCAAATTGAGGCGGTCTCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7447,Drugs,MEG_7447|Drugs|Glycopeptides|VanN-type_resistance_protein|VANN,VanNXY_1_JF802084,5
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCACCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6592,Drugs,MEG_6592|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|270267857|gb|GU187357.1|6-845 gi|157139467|gb|EU117158.1|2360-3199 gi|118511772|emb|AJ311891.3|4927-5766 gi|71273546|emb|AM040709.1|2463-3302,8
,atgatgaaaaaatctctttgctgcgccctgctgctcggcatctcttgctctgctctcgccgcgccagtgtcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgaaagcccagtcgattccaggcatggcggtggccgttatttatcagggtaaaccgcactattacacgtttggcaaagccgatatcgcggccagcaaacccgttacgcctcagactctgttcgagctgggttctataagtaaaaccttcaccggggttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcaggggattcgtatgctggatctcgcaacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataatgccgccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagtatcggtctttttggcgcgctggcggtcaaaccttccggcatgggctatgagcgggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggaatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaaggttgctgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtgatcgagggcagcgacagtaaggtggcgctggcaccgcttcccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggctctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgacgcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_438,Drugs,MEG_438|Drugs|betalactams|Class_C_betalactamases|ACT,1016945748|WP_063147148.1|NG_064667|1|1|blaACT-67|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-67 NG_064667:1-1146,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACTCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCACCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1923,Drugs,MEG_1923|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KF305673|+|17-1163|ARO:3002070|CMY-99 [Proteus mirabilis] ,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgctcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccagaacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggactaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcttggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5618,Drugs,MEG_5618|Drugs|betalactams|Class_C_betalactamases|PDC,1408841620|WP_111672893.1|NG_060550|1|1|blaPDC-280|blaPDC|class_C_beta-lactamase_PDC-280 NG_060550:1-1194,0
,ATGAAAATTATTAATATTGGAGTTTTAGCTCATGTTGATGCGGGAAAAACTACCTTAACAGAAAGCTTATTATATAACAGTGGAGCGATTACAGAATTAGGAAGCGTGGACAGAGGTACAACGAAAACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACGGCGATAACCTCTTTTCAGTGGAAAAATACTAAGGTGAACATCATAGACACGCCAGGACATATGGATTTTTTAGCAGAAGTATATCGTTCATTATCAGTATTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATGGCGTACAAGCACAAACTCGTATATTGTTTCATGCACTTAGGAAAATAGGTATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCGGAAATTGTAATCAAACAGAAGGTAGAACTGCATCCTAATATGCGTGTAATGAACTTTACCGAATCTGAACAATGGGATATGGTAATAGAAGGAAATGATTACCTTTTGGAGAAATATACGTCTGGGAAATTATTGGAAGCATTAGAACTCGAACAAGAGGAAAGCATAAGATTTCATAATTGTTCCCTGTTCCCTGTTTATCACGGAAGTGCAAAAAACAATATAGGGATTGATAACCTTATAGAAGTGATTACGAATAAATTTTATTCATCAACACATCGAGGTCAGTCTGAACTTTGCGGAAAAGTTTTCAAAATTGAGTATTCGGAAAAAAGACAGCGTCTTGCATATATACGTCTTTATAGTGGCGTACTGCATTTGCGAGATCCGGTTAGAATATCGGAAAAGGAAAAAATAAAAATTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAAATCGATAAGGCTTATTCCGGGGAAATTGTTATTTTGCAGAATGAGTTTTTGAAGTTAAATAGTGTTCTTGGAGATACAAAGCTATTGCCACAGAGAGAGAGAATTGAAAATCCCCTCCCTCTGCTGCAAACGACTGTTGAACCGAGCAAACCTCAACAAAGGGAAATGTTACTTGATGCACTTTTAGAAATCTCCGACAGTGACCCGCTTCTGCGATATTATGTGGATTCTGCGACACATGAAATCATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGACTTGTGCTCTGCTGCAAGAAAAGTATCATGTGGAGATAGAAATAAAAGAGCCTACAGTCATTTATATGGAAAGACCGTTAAAAAAAGCAGAGTATACCATTCACATCGAAGTTCCACCGAATCCTTTCTGGGCTTCCATTGGTCTATCTGTAGCACCGCTTCCATTAGGGAGCGGAGTACAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCGTTTCAAAATGCAGTTATGGAGGGGATACGCTATGGCTGTGAACAAGGATTGTATGGTTGGAATGTGACGGACTGTAAAATCTGTTTTAAGTATGGCTTATACTATAGCCCTGTTAGTACCCCAGCAGATTTTCGGATGCTTGCTCCTATTGTATTGGAACAAGTCTTAAAAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAATTTATGCGCCACAGGAATATCTTTCACGAGCATACAACGATGCTCCTAAATATTGTGCGAACATCGTAGACACTCAATTGAAAAATAATGAGGTCATTCTTAGTGGAGAAATCCCTGCTCGGTGTATTCAAGAATATCGTAGTGATTTAACTTTCTTTACAAATGGACGTAGTGTTTGTTTAACAGAGTTAAAAGGGTACCATGTTACTACCGGTGAACCTGTTTGCCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7139,Drugs,MEG_7139|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|377684519|gb|JN846704.1|200-2119 gi|168478963|emb|AM889142.2|1618-3537 gi|48189|emb|X04388.1|131-2050,4
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcaggtttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_229,Drugs,MEG_229|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1028080898|WP_063840281.1|NG_047284|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_047284:101-655,2
,CATGGCTTGTTATGACTGTTTTTTTGTACAGTCTATGCCTCGGGCATCCAAGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGAAAAGGGAAAGTATGAAGAAATTATTTGTTTTATGCATTTTTTTGTTTTTAAGTATTACTGCCTCAGGTGAGGTTTTGCCTGATTTGAAAATTGAGAAGCTTGAAGAGGGTGTTTATCTTCATACATCTTTTGAAGAGGTTAGCGGTTGGGGTGTTGTTACTAAACATGGTTTGGTAGTTCTTGTAAATAATGACGCCTATCTAATTGACACTCCATTTACAAATAAAGATACTGAAAAATTAGTTGCTTGGTTTGTAGGGCGCGGCTTTACAATAAAGGGAAGTGTTTCCTCACATTTTCATAGCGACAGTACGGGTGGAATAGAGTGGCTTAATTCTCAATCTATTCCCACGTATGCATCTGAGTTAACAAATGAACTTCTGAAAAAGAACGGTAAGGTGCAAGCTACAAATTCATTTAGCGGGGTTAGTTATTGGCTAGTTAAAAATAAAATTGAAATTTTTTATCCCGGCCCAGGACATACTCAAGATAACGTAGTGGTTTGGCTACCTGAAAACAAAATTTTATTCGGTGGTTGTTTTGTTAAACCGGACGGTCTTGGTAATTTGGATGACGCAAATTTAAAAGCTTGGCCAAAGTCCGCAAAAATATTAATGTCTAAATATGGTAAAGCAAAGTTAGTTGTTTCAGGTCATAGTGAAATTGGGAACGCATCACTCTTGAAACTTACTTGGGAGCAGGCTGTTAAAGGGCTAAAAGAAAGTAAAAAACCATTACTGCCAAGTAACTAATTTTCTAACAAGTCGTTGCAGCACCGTTCCTTCGCTCCACTGGACAGTTTTTAAGTCGCGGTTTTATGGTTTGTGCGCAAAAGTATTTCATAAAACCACAACTTAAAAACTGCCGCTGAACTCGGCGTTAGGCATCACAAAGTACAGCATCGTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTCGATGCTCT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3390,Drugs,MEG_3390|Drugs|betalactams|Class_B_betalactamases|IMP,gi|25278055|emb|AJ420864.1|1-1110,0
,atgcgaaaaaatctcaaagttgctctgctatgtagttcgttatgcttaagtttaggcttggttgcttgtcacagcttaaattcagagctgcagattgcagaacagcaaaagcaacaacaaaaaatttctaagctatttgtgaatgccaaaacagaaggcgtatttgtcacttatgacggtcaaaagatacatgaatatgggaatgccttaaatcgggctcaaacctcttatatccctgcatctacttttaaaatgctcaatgctttgattggcatccaacaccataaaacgacaccaaatgaagtttttaaatggaatggagaaaagcgtagatttaagagctgggaaaaagatttgactttaactgaagcgatccaagcatccgctgttcctatttatcaagaattagccagacgaataggtttagatatgatggcatctgaagttaaaagaataggctttggaaattcagatataggcaatcaggtcgataatttttggttggttggcccattaaaaattacacctattcaagaagtcagatttgcctacgcgttggcaaatgagcaattggcgtttgacattcctgttcagcagcaagttaagcaaatgttattggtggatcaggtgaatgggacaaaagtttatgcgaaaagtggttggggaatggatgttgagccacaagtgggatggtggacaggatgggtagagcagcctgatggtaaaataactgcattttctctaaatatggagatgaataaaactgaacatgtggaggctcggaaaacgattgtttatgaggcattgcagcagttaggtttaattcagcattag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4604,Drugs,MEG_4604|Drugs|betalactams|Class_D_betalactamases|OXA,1440786785|WP_114699273.1|NG_061397|1|1|blaOXA-661|blaOXA-266_fam|OXA-266_family_class_D_beta-lactamase_OXA-661 NG_061397:1-834,0
,atgttcatgccgcctgtttttcctgctcattggcacgtttcgcaacctgttctcattgcggacaccttttccagcctcgtttggaaagtttcattgccagacgggactcctgcaatcgtcaagggattgaaacctatagaagacattgctgatgaactgcgcggggccgactatctggtatggcgcaatgggaggggagcagtccggttgctcggtcgtgagaacaatctgatgttgctcgaatatgccggggagcgaatgctctctcacatcgttgccgagcacggcgactaccaggcgaccgaaattgcagcggaactaatggcgaagctgtatgccgcatctgaggaacccctgccttctgcccttctcccgatccgggatcgctttgcagctttgtttcagcgggcgcgcgatgatcaaaacgcaggttgtcaaactgactacgtccacgcggcgattatagccgatcaaatgatgagcaatgcctcggaactgcgtgggctacatggcgatctgcatcatgaaaacatcatgttctccagtcgcggctggctggtgatagatcccgtcggtctggtcggtgaagtgggctttggcgccgccaatatgttctacgatccggctgacagagacgacctttgtctcgatcctagacgcattgcacagatggcggacgcattctctcgtgcgctggacgtcgatccgcgtcgcctgctcgaccaggcgtacgctaatgggtgcctttccgcagcttggaacgcggatggagaagaggagcaacgcgatctagctatcgcggccgcgatcaagcaggtgcgacagacgtcatactag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_1085,Drugs,MEG_1085|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH6,1028083028|WP_063842184.1|NG_047469|1|1|aph(6)-Id|aph(6)-Id|aminoglycoside_O-phosphotransferase_APH(6)-Id NG_047469:101-937,2
,atgcgttcgttcgccatatcgactgtgttggtgatgtcctcactgttagcgtcgtcaatcattgccgccccgacttttgcctcaacagcggtgaagaaggagtggcaagaaacccgtagttgggatgccatttttactcagcaccaagttgaaccgcaacaagctaaactgcaaaaaactaagctccaacaaacctcgggcgtggtagcactatggaacgaaaacaagcaacagggatataccaacaatcttaaacgtgccaatcaaggttttttacctgcatcgacctttaaaatccctaacagtttgattgcgctagatctcggtgtggtgaaggatgaacatcaagtgtttaagtgggatggtaaaagccgtgatattgtcacttggaatcgtgaccacagcttgattaccgggatgaagtattcggtggtgccagtctatcaagagtttgcccgccaaattggtgaggcgcgaatgtcgaagatgatcgcctctttcgattatggtaatgaggatatctcgggtaacttagatagcttttggcttgatggcggtattcggatatcggccactgagcaaatcgatttcctgcgccgactttattacaacaaaatacacgcttcagagcgcagtcaacgcatcgttaagcaagccatgctcaccgaggcgaattctgattatattatccgcgcaaaaaccggttatgcggtcagagctgagccaagcattggctggtgggtgggttgggtagaactcgatgataatgtgtggttttttgcaatgaatatggacatcccagatgccgcaggtttgccattgcgccaagccattactaaggaagtattaaaactggaacacgtaattccttag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4625,Drugs,MEG_4625|Drugs|betalactams|Class_D_betalactamases|OXA,1201190421|WP_087587941.1|NG_054955|1|1|blaOXA-550|blaOXA-548_like|OXA-548_family_class_D_beta-lactamase_OXA-550 NG_054955:1-873,0
,gtgaccaacagcaccgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaagccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcagcttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_243,Drugs,MEG_243|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502139|WP_071846291.1|NG_052349|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052349:101-655,2
,AAATGAATATAGTTGAAAATGAAATATGTATAAGAACTTTAATAGATGATGATTTTCCTTTGATGTTAAAATGGTTAACTGATGAAAGAGTATTAGAATTTTATGGTGGTAGAGATAAAAAATATACATTAGAATCATTAAAAAAACATTATACAGAGCCTTGGGAAGATGAAGTTTTTAGAGTAATTATTGAATATAACAATGTTCCTATTGGATATGGACAAATATATAAAATGTATGATGAGTTATATACTGATTATCATTATCCAAAAACTGATGAGATAGTCTATGGTATGGATCAATTTATAGGAGAGCCAAATTATTGGAGTAAAGGAATTGGTACAAGATATATTAAATTGATTTTTGAATTTTTGAAAAAAGAAAGAAATGCTAATGCAGTTATTTTAGACCCTCATAAAAATAATCCAAGAGCAATAAGGGCATACCAAAAATCTGGTTTTAGAATTATTGAAGATTTGCCAGAACATGAATTACACGAGGGCAAAAAAGAAGATTGTTATTTAATGGAATATAGATATGATGATAATGCCACAAATGTTAAGGCAATGAAATATTTAATTGAGCATTACTTTGATAATTTCAAAGTAGATAGTATTGAAATAATCGGTAGTGGTTATGATAGTGTGGCATATTTAGTTAATAATGAATACATTTTTAAAACAAAATTTAGTACTAATAAGAAAAAAGGTTATGCAAAAGAAAAAGCAATATATAATTTTTTAAATACAAATTTAGAAACTAATGTAAAAATTCCTAATATTGAATATTCGTATATTAGTGATGAATTATCTATACTAGGTTATAAAGAAATTAAAGGAACTTTTTTAACACCAGAAATTTATTCTACTATGTCAGAAGAAGAACAAAATTTGTTAAAACGAGATATTGCCAGTTTTTTAAGACAAATGCACGGTTTAGATTATACAGATATTAGTGAATGTACTATTGATAATAAACAAAATGTATTAGAAGAGTATATATTGTTGCGTGAAACTATTTATAATGATTTAACTGATATAGAAAAAGATTATATAGAAAGTTTTATGGAAAGACTAAATGCAACAACAGTTTTTGAGGGTAAAAAGTGTTTATGCCATAATGATTTTAGTTGTAATCATCTATTGTTAGATGGCAATAATAGATTAACTGGAATAATTGATTTTGGAGATTCTGGAATTATAGATGAATATTGTGATTTTATATACTTACTTGAAGATAGTGAAGAAGAAATAGGAACAAATTTTGGAGAAGATATATTAAGAATGTATGGAAATATAGATATTGAGAAAGCAAAAGAATATCAAGATATAGTTGAAGAATATTATCCTATTGAAACTATTGTTTATGGAATTAAAAATATTAAACAGGAATTTATCGAAAATGGTAGAAAAGAAATTTATAAAAGGACTTATAAAGATTGATTA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_364,Drugs,MEG_364|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|974700633|dbj|AP017321.1|1564-3008 gi|937637449|gb|KT601170.1|53746-52302 gi|908234448|gb|CP010309.1|342357-340913 gi|841330217|emb|LN866849.1|1591030-1592474 gi|822490352|gb|CP003939.1|1724078-1722634 gi|807232188|gb|CP011116.1|1632283-1630839 gi|756766642|gb|KJ922127.1|19641-18197 gi|748807120|gb|CP010526.1|59775-61219 gi|675304693|gb|CP007500.1|19567-18123 gi|663450275|gb|KC876750.1|2011-3455,2
,ATGAAGTTTTTATTGGCATTTTCGCTTTTAATACCATCCGTGGTTTTTGCAAGTAGTTCAAAGTTTCAGCAAGTTGAACAAGACGTTAAGGCAATTGAAGTTTCTCTTTCTGCTCGTATAGGTGTTTCCGTTCTTGATACTCAAAATGGAGAATATTGGGATTACAATGGCAATCAGCGCTTCCCGTTAACAAGTACTTTTAAAACAATAGCTTGCGCTAAATTACTATATGATGCTGAGCAAGGAAAAGTTAATCCCAATAGTACAGTCGAGATTAAGAAAGCAGATCTTGTGACCTATTCCCCTGTAATAGAAAAGCAAGTAGGGCAGGCAATCACACTCGATGATGCGTGCTTCGCAACTATGACTACAAGTGATAATACTGCGGCAAATATCATCCTAAGTGCTGTAGGTGGCCCCAAAGGCGTTACTGATTTTTTAAGACAAATTGGGGACAAAGAGACTCGTCTAGACCGTATTGAGCCTGATTTAAATGAAGGTAAGCTCGGTGATTTGAGGGATACGACAACTCCTAAGGCAATAGCCAGTACTTTGAATAAATTTTTATTTGGTTCCGCGCTATCTGAAATGAACCAGAAAAAATTAGAGTCTTGGATGGTGAACAATCAAGTCACTGGTAATTTACTACGTTCAGTATTGCCGGCGGGATGGAACATTGCGGATCGCTCAGGTGCTGGCGGATTTGGTGCTCGGAGTATTACAGCAGTTGTGTGGAGTGAGCATCAAGCCCCAATTATTGTGAGCATCTATCTAGCTCAAACACAGGCTTCAATGGCAGAGCGAAATGATGCGATTGTTAAAATTGGTCATTCAATTTTTGACGTTTATACATCACAGTCGCGCTGATAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1547,Drugs,MEG_1547|Drugs|betalactams|Class_A_betalactamases|CARB,gi|829496271|gb|KP420006.1|1359-2228 gi|815968487|gb|CP011317.1|5587392-5588261 gi|800908878|gb|KP345882.1|99012-98143 gi|777182157|emb|LN829403.1|70646-71515 gi|766547679|gb|KP116299.1|40819-41688 gi|742994109|gb|CP010391.1|50752-49883 gi|704485843|gb|KJ186153.1|37322-38191 gi|686483924|gb|KM111262.1|167-1036 gi|675294670|dbj|AB985401.1|1023-1892 gi|660573358|gb|CP008790.1|139113-139982,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5640,Drugs,MEG_5640|Drugs|betalactams|Class_C_betalactamases|PDC,489183985|WP_003093423.1|NG_049907|1|1|blaPDC-35|blaPDC|class_C_beta-lactamase_PDC-35 NG_049907:1-1194,0
,AAGGAAAAGTTAATGGCAATCCGAATCTTCGCGATACTTTTCTCCATTTTTTCTCTTGCCACTTTCGCGCATGCGCAAGAAGGCACGCTAGAACGTTCTGACTGGAGGAAGTTTTTCAGCGAATTTCAAGCCAAAGGCACGATAGTTGTGGCAGACGAACGCCAAGCGGATCGTGCCATGTTGGTTTTTGATCCTGTGCGATCGAAGAAACGCTACTCGCCTGCATCGACATTCAAGATACCTCATACACTTTTTGCACTTGATGCAGGCGCTGTTCGTGATGAGTTCCAGATTTTTCGATGGGACGGCGTTAACAGGGGCTTTGCAGGCCACAATCAAGACCAAGATTTGCGATCAGCAATGCGGAATTCTACTGTTTGGGTGTATGAGCTATTTGCAAAGGAAATTGGTGATGACAAAGCTCGGCGCTATTTGAAGAAAATCGACTATGGCAACGCCGATCCTTCGACAAGTAATGGCGATTACTGGATAGAAAGCAGCCTTGCAATCTCGGCGCAGGAGCAAATTGCATTTCTCAGGAAGCTCTATCGTAACGAGCTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGATCTCATGATTGTGGAAGCCGGTCGCAACTGGATACTGCGTGCAAAGACGGGCTGGGAAGGCCGTATGGGTTGGTGGGTAGGATGGGTTGAGTGGCCGACTGGCTCCGTATTCTTCGCACTGAATATTGATACGCCAAACAGAATGGATGATCTTTTCAAGAGGGAGGCAATCGTGCGGGCAATCCTTCGCTCTATTGAAGCGTTACCGCCCAACCCGGCAGTCAACTCGGACGCTGCGCGATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5207,Drugs,MEG_5207|Drugs|betalactams|Class_D_betalactamases|OXA,gi|146261808|gb|EF552405.1|1-840,0
,ATGGACACAACGCAGGTCGCATTGATACTCCAATTTCTAGCTGCGGCAGATGAGCGAAATCTGCCGCTCTGGATCGGTGGGGGCTGGGCGATCGATGCACGGCTAGGGCGTGTAACACGCAAGCACGATGATATTGATCTGACGTTTCCCGGCGAGAGGCGCGGCGAGCTCGAGGCAATAGTTGAAATGCTCGGCGGGCGCGTCACGGAGGAGTTGGACTATGGATTCTTAGCGGAGATCGGGGATGAGTTACTTGACTGCGAACCTGCTTGGTGGGCAGACGAAGCGTATGAAATCGCGGAGGCTCCGCAGGGCTCGTGCCCAGAGGCGGCTGAGGGTGTCATCGCCGGGCGGCCAGTCCGTTGTAACAGCTGGGAGGCGATCATCTGGGATTACTTTTACTATGCCGATGAAGTACCACCAGTCGACTGGCCTACAAAGCACATAGAGTCCTACAGGCTCGCATGCACCTCACTCGGGGCGGAAAAGGTTGAGGTCTTGCGTGCCGCTTTCAGGTCGCGATATGCGGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_755,Drugs,MEG_755|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,gi|425862449|gb|JX566708.1|1168-1701 gi|370318299|gb|JF414726.1|1160-1693 gi|317018024|gb|GU390404.1|1112-1645 gi|317018018|gb|GU390403.1|1142-1675 gi|317018003|gb|GU390401.1|1132-1665 gi|24209725|gb|AY139599.1|107-640 gi|26655445|gb|AF364344.1|126-659,2
,TTGTATCTTATGTCTAACATTCAAAACATGTCCCTGGAGGACATCATGGGAGAGCGCTTTGGTCGCTACTCCAAGTACATTATTCAAGACCGGGCTTTGCCAGATATTCGTGATGGGTTGAAGCCGGTTCAGCGCCGTATTCTTTATTCTATGAATAAGGATAGCAATACTTTTGACAAGAGCTACCGTAAGTCGGCCAAGTCAGTCGGGAACATCATGGGGAATTTCCACCCACACGGGGATTCTTCTATCTATGATGCCATGGTTCGTATGTCACAGAACTGGAAAAATCGTGAGATTCTAGTTGAAATGCACGGTAATAACGGTTCTATGGACGGAGATCCTCCTGCGGCTATGCGTTATACTGAGGCACGTTTGTCTGAAATTGCAGGCTACCTTCTTCAGGATATCGAGAAAAAGACAGTTCCTTTTGCATGGAACTTTGACGATACGGAGAAAGAACCAACGGTCTTGCCAGCAGCCTTTCCAAACCTCTTGGTCAATGGTTCGACTGGGATTTCGGCTGGTTATGCCACAGACATTCCTCCCCATAATTTAGCTGAGGTCATAGATGCTGCAGTTTACATGATTGACCACCCAACTGCAAAGATTGATAAACTCATGGAATTCTTGCCTGGACCAGACTTCCCTACAGGGGCTATTATTCAGGGTCGTGATGAAATCAAGAAAGCTTATGAGACTGGGAAAGGGCGCGTGGTTGTTCGTTCCAAGACTGAAATTGAAAAGCTAAAAGGTGGTAAGGAACAAATCGTTATTACTGAGATTCCTTATGAAATCAATAAGGCCAATCTAGTCAAGAAAATCGATGATGTTCGTGTTAATAACAAGGTAGCTGGGATTGCTGAGGTTCGTGATGAGTCTGACCGTGATGGTCTTCGTATCGCTATCGAACTTAAGAAAGACGCTAATACTGAGCTTGTTCTCAACTACTTATTTAAGTACACCGACCTACAAATCAACTACAACTTTAATATGGTGGCGATTGACAATTTCACACCTCGTCAGGTTGGGATTGTTCCAATCCTGTCTAGCTACATCGCTCACCGTCGAGAAGTGATTTTGGCGCGTTCACGCTTTGACAAAGAAAAGGCTGAGAAACGTCTCCATATCGTCGAAGGTTTGATTCGTGTGATTTCGATTTTGGATGAAGTCATTGCTCTTATCCGTGCTTCTGAGAATAAGGCGGACGCCAAGGAAAACCTCAAAGTTAGCTATGATTTTACGGAAGAACAGGCTGAGGCTATCGTAACTTTGCAACTGTACCGTTTGACCAATACCGATGTGGTTGTCTTGCAGGAAGAAGAAGCAGAGCTTCGTGAGAAGATTGCTATGCTGGCGGCTATTATCGGTGATGAAAGGACTATGTACAATCTCATGAAGAAAGAACTTCGTGAGGTCAAGAAGAAATTTGCAACTCCTCGTTTGAGTTCTTTAGAAGACACTGCGAAAGCAATTGAGATTGATACAGCTAGTCTTATCGCTGAGGAAGATACCTACGTCAGCGTGACCAAGGCAGGTTACATCAAGCGTACCAGTCCACGTTCCTTTGCGGCTTCCACCTTGGAAGAAATTGGCAAGCGTGATGATGACCGTTTGATTTTTGTTCAATCTGCCAAGACAACCCAGCACCTCTTGATGTTCACAAGTCTTGGAAATGTCATCTACAGACCAATCCATGAGTTGGCAGATATTCGTTGGAAGGACATCGGAGAGCATCTGAGCCAAACCATCACAAACTTTGAAACGAATGAAGAAATCCTTTATGTGGAAGTACTGGATCAGTTTGACGATGCGACAACCTACTTTGCAGTGACTCGCCTTGGTCAAATCAAACGGGTAGAGCGAAAAGAATTCACTCCATGGCGGACCTATAGATCTAAGTCTGTCAAGTATGCTAAGCTCAAAGACGATACAGATCAGATTGTAGCAGTGGCTCCGATTAAACTAGATGATGTTGTCTTGGTTAGTCAAAATGGTTATGCCCTGCGTTTCAATATCGAAGAGGTTCCGGTTGTCGGTGCTAAGGCAGCAGGTGTCAAGGCTATGAATTTGAAAGAAGATGATGTCCTCCAATCTGGCTTTATCTGTAATACTTCGTCCTTCTACCTCTTGACCCAGCGTGGAAGCTTGAAACGTGTTTCCATTGAGGAAATTCTAGCAACCAGCCGTGCCAAACGAGGATTACAAGTCTTGCGTGAGTTGAAAAACAAACCGCATCGTGTCTTCTTGGCAGGAGCAGTTGCAGAGCAAGGATTTGTTGGCGATTTCTTCAGTACGGAAGTGGATGTGAACGACCAAACTCTGCTTGTCCAATCCAATAAAGGAACAATCTATGAAAGCCGATTGCAAGACTTGAACTTGTCAGAACGCACTAGCAATGGAAGCTTCATTTCTGACACGATTTCAGATGAAGAAGTTTTTGACGCTTATCTTCAGGAAGTAGTTACTGAAGATAAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5356,Drugs,MEG_5356|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|909837468|gb|CP003357.2|1328560-1326080 gi|556027507|gb|CP006844.1|1248487-1246007 gi|298237097|gb|CP001993.1|1511745-1509265 gi|225726369|gb|CP000921.1|1289966-1287486,3
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATGATACAGCAAACAATAAAATTATAAAAGAGATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTATTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1347,Drugs,MEG_1347|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_74_CZWI01000159,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgccgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5542,Drugs,MEG_5542|Drugs|betalactams|Class_C_betalactamases|PDC,730509500|WP_034032599.1|NG_049917|1|1|blaPDC-44|blaPDC|class_C_beta-lactamase_PDC-44 NG_049917:1-1194,0
,atgaacgagaaaaatataaaacacagtcaaaactttattacttcaaaacataatatagataaaataatgacaaatataagattaaatgaacatgataatatctttgaaatcggctcaggaaaaggccattttacccttgaattagtacagaggtgtaatttcgtaactgccattgaaatagaccataaattatgcaaaactacagaaaataaacttgttgatcacgataatttccaagttttaaacaaggatatattgcagtttaaatttcctaaaaaccaatcctataaaatatttggtaatatacgttataacataagtacagatataatacgcaaaattgtttttgatagtatagctgatgagatttatttaatcgtggaatacgggtttgctaaaagattattaaatacaaaacgctcattggcattacttttaatggcagaagttgatatttctatattaagtatggttccaagagaatattttcatcctaaacctaaagtgaatagctcacttatcagattaaatagaaaaaaatcaagaatatcacacaaagataaacagaagtataattatttcgttatgaaatgggttaacaaagaatacaagaaaatatttacaaaaaatcaatttaacaattccttaaaacatgcaggaattgacgatttaaacaatattagctttgaacaattcttatctcttttcaatagctataaattatttaataagtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2812,Drugs,MEG_2812|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,695262050|WP_032489009.1|NG_047810|1|1|erm(C)|erm(C)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(C) NG_047810:101-835,7
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagttgtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggatcgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4403,Drugs,MEG_4403|Drugs|betalactams|Class_D_betalactamases|OXA,488926694|WP_002837769.1|NG_057514|1|1|blaOXA-579|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-579 NG_057514:1-774,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACCCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6476,Drugs,MEG_6476|Drugs|betalactams|Class_A_betalactamases|SHV,gi|695220746|ref|NG_039544.1|77-937,0
,ATGCGTTATTTTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCAGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGCGCGCGTTATCCGGCTCGTAGCACCTCGCAGGCTGCCGGGCGATATGACTGGCGGCGGCATCGGAGAGAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_6470,Drugs,MEG_6470|Drugs|betalactams|Class_A_betalactamases|SHV,gi|684933|gb|U20270.1|ECU20270|125-1065,0
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagtcaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgataaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgtgcgggaggaacagcggcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgccgccctatgcggcagcgttttcaaggtggagtatacagattgcggccagcggcgtgtctatctacggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggacccaacccggctccctcgtaaaaggtggcgtgaggaccccctccccatgctgcggacgtcgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgctgcgaggtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccatcggactgtctgttacaccactcccgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcagggacgcaactgctggaaccttatctctccttcaccctctatgcgccccgggaatatctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggtccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcagagcgtatgccttacagaactgaaagggtatcaggccgctgtcggcaagccagtcatccagccccgccgtccaaacagccgcctggacaaggtgcgctatatgtttcagaagataatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7217,Drugs,MEG_7217|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,446614375|WP_000691721.1|NG_048291|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048291:101-2020,4
,ATGGAAAAGGGATTTGTTTTTTTAGATGAAATATTGCACGGTGTTCGCTGGGACGCCAAATATGCCACATGGGACAATTTCACAGGGAAACCAGTAGACGGATATGAGGTCAATCGCATAGTGGGAACACATGCCTTAGCCCTTGCGCTGCTGAAGGCGCAGAAGCAAGCGGCGGCTCTTGGGTACGGTTTGCTGTTATGGGACGGGTATCGGCCCAAACGTGCGGTAGATTGCTTCCTGCGTTGGTCCGAACAACCGGAAGACAACCTCACAAAAGAAAGATACTATCCGAATATCGAGCGAACCGAGATGGTTTCAAAAGGATACGTGGCTTCAAAATCAAGCCATAGCCGCGGAAGCGCAATTGATCTTACGCTTTATCGATTAGACACGGGTGAGCTTGTACCAATGGGGAGCGGATTTGATTTTATGGATGAGCGTTCACACCATGCGGCAAAAGGGATTGCAAGCATGGAAGCGCAAAATCGCAGACGTTTGCGTTCCATCATGGAAAACAGTGGGTTTGAACCATATAGCTTCGAATGGTGGCACTATGTATTAAGAAACGAAACCATACCCCAATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7557,Drugs,MEG_7557|Drugs|Glycopeptides|VanA-type_resistance_protein|VANXA,gi|66731642|gb|DQ018711.1|5166-5750,5
,ATGTCATTTACGGCATACTCGGATCCATGCTGGCCATGGTCCCGCGGTAGGCCCATTGCTCGGAGCGCTCGTCGACATGTGGCTTGGGTGGCGGGCTATCTTTGCGTTTCTAGGTTTGGGCATGATCGCTGCATCTGCAGGCGTGGCAGCTTCTGGCCTGAAACCCGGGTGCAACGAGTTGCGGGCTTGCAATGGTCGCAGCTGCTACTCCCCGTTAAGTGCCTGAACTTCTGGTTGTACACGTTGTGTTACGCCGCTGGAATGGGTAGCTTCTTCGTCTTTTTCTCCATTGCGCCCGGACTAATGATGGGCAGGCCAAGGTGTGTCTCAGCTTGGCTTCAGCCTGCTGTTCGCCACAGTGCAATTGCCATGGTGTTTACGGCTCGTTTTATGGGGAGTGTGATACCCAAGTGGGGCAGCCCAAGTGTCTTGCGAATGGGAATGGGATGCCTGATAGCTGGAGCAGTATTGCTTGCCATCACCGAAATATGGGCTTTGCACCGTGTTAGGCTTTATTGCTCCAATGTGGCTAGTGGTATTGGTGTCGCCACAGCGGTATCTGTGCCAATGGCGCTCTTCGAGGATTCGACCATGTTGCTGGAACGGTCACGGCAGTCTACTTCTGCTTGGGCGTGTACTGCTAGGAAGCATCGGAACGTTGATCATTTCGCTGTTGCCGCGCAACGGCTTGGGCCTTGTCGTGTAACTGTTTGGACCCTTGCAACAGTCGTGCTCGGTCTGTCTTGTGTTTCCCGAGTGAAGGGCTCTCGCGGCCAGGGGGAGCATGATGCTGGTCGCGCTACAAATGTCGGAAAGTACATCAAATCCCAATCGTTGAGAGAATGTGGCAAGCTATCGCCCAACAAATGCTGCAGCCGACCCAAAACGTACGCGTTTCGGCTCGGCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1773,Drugs,MEG_1773|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,cml_1_M22614 ,6
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgctgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgtggggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6677,Drugs,MEG_6677|Drugs|betalactams|Class_A_betalactamases|TEM,983454382|WP_060615518.1|NG_050212|1|1|blaTEM-169|blaTEM|class_A_extended-spectrum_beta-lactamase_TEM-169 NG_050212:1-861,0
,ATGTTACGCAGCAGGGTGACGGTGTTCGGCATTCTGAATCCCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGCTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGAACTGCGAAGCGCAATCGCCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6623,Drugs,MEG_6623|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|15983740|gb|AY047357.1|63-914,8
,atgaatattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaagaccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctcttccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4531,Drugs,MEG_4531|Drugs|betalactams|Class_D_betalactamases|OXA,1028109805|WP_063864208.1|NG_049791|1|1|blaOXA-516|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-516 NG_049791:1-825,0
,CTAAGCTGTGCCCTGCTGCTCAGCGTCACCAGCGCTGCATTCGCCGCACCGATGTCCGAAACACAGCTGGCTGAGGTGGTGGAACGTACCGTTACGCCGCTGATGAACGCGCAGGCCATTCCGGGTATGGCGGTGGCGGTAATTTATCAGGGTCAGCCACACTACTTTACCTTCGGTAAAGCCGATGTTGCGGCGAACAAACCCGTCACCCCGCAAACCCTGTTTGAGCTGGGCTCTATAAGTAAAACCTTCACCGGCGTACTGGGCGGCGATGCCATTGCCCGGGGTGAAATAGCGCTGGGCGATCCGGTAGCAAAATACTGGCCTGAGCTCACGGGCAAGCAGTGGCAGAGCATTCGCATGCTGGATCTGGCAACCTATACCGCAGGCGGTCTGCCGTTACAGGTGCCGGATGAGGTCACGGATACCGCCTCTCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCGGGTACCACGCGTCTTTACGCTAACGCCAGCATCGGTCTTTTTGGTGCGCTGGCGGTCAAACCTTCCGGCATGAGCTATGAGCAGGCCATGACGACGCGGGTCTTTAAACCCCTCAAGCTGGACCATACCTGGATTAACGTCCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGATACCGTGAGGGTAAAGCGGTCCACGTTTCGCCAGGGATGCTGGACGCGGAAGCCTATGGCGTAAAAACTAACGTGAAGGATATGGCGAGCTGGGTGATAGCCAACATGAAGCCGGATTCTCTTCAGGCTCCCTCACTCAAGCAAGGCATTGCTCTGGCGCAGTCTCGCTACTGGCGCGTGGGGGCTATGTATCAGGGGTTAGGCTGGGAGATGCTCAACTGGCCGGTCGATGCCAAAACCGTCGTCGGAGGCAGTGATAACAAGGTGGCGCTGGCACCATTGCCCGTGGCAGAAGTGAATCCACCCGCGCCTCCGGTCAAGGCCTCCTGGGTCCATAAAACAGGCTCGACGGGCGGGTTTGGCAGCTACGTGGCATTTATTCCTGAAAAGCAGCTCGGCATTGTGATGCTCGCGAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3955,Drugs,MEG_3955|Drugs|betalactams|Class_C_betalactamases|MIR,(Bla)MIR-4:EF587233:1-1101:1101,0
,GTTTCGATCTTACCTGTGAAAGAACAAGACGCTGCCGACTGGCTAGCGCTGCGGAATCTTCTTTGGCTCGCGGATGATCACGCCTCGGAGATTGAGCAGTACTTCTCTGGTGGACTTGAGGGGCTTGTAGAAGTGCTCATCGCCCGTGATGCTACCGGCGCGGCTGTTGGGCATGTCGAACTCTCGATAAGACATGACTTGGAAGAACTCCAAGGAATCAAGACCGGCTACATCGAAGGCCTTTATGTGGCCCCAAGCCATCGATCAACAGACCTTGTGAGGCGTTTCTTGCGTGAGTCCGAGAAGTGGGCCCTAGAACAAGGGTGCAGCGCATTTGCCTCAGACAGAAGTGATCGGGTCATCACGCACCGCAAGTTCGCAGGCAGCGCCGTCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_298,Drugs,MEG_298|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gb|AF263519.1|+|1402-1798|ARO:3002583|AAC(6')-29a [Pseudomonas aeruginosa] ,2
,atgatcgtcaactgcgaccacgacaaccttgatgcctggctggcgctgcgctcggcgctgtggcccacctgcccgcgggaagaacaccgcgcagaaatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattatgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgtcgaacgcgcccgccgccagggctgggcggcgcgtttgatcgcgcaggtgcaggagtgggccaagcagcaggggtgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgcagaaacggaacgggtggtgttttaccgaaaaacgcttggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_103,Drugs,MEG_103|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,823104339|WP_047026538.1|NG_052468|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052468:101-541,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_570,Drugs,MEG_570|Drugs|betalactams|Class_C_betalactamases|ADC,1532001247|WP_125052776.1|NG_064673|1|1|blaADC-114|blaADC|class_C_beta-lactamase_ADC-114 NG_064673:31-1185,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_774,Drugs,MEG_774|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502196|WP_071846346.1|NG_052443|1|1|aadA3|aadA3|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA3 NG_052443:101-892,2
,ttgaaaaaaatacttttactttttagtcttttttactcttttgctttggcaaatgataaattaaaagatttttttaaagactacaatacaagcggagtttttataacttttgatggaaaacattatgcaagtaatgattttaaaagagctaaagaacctttttctcctgcttcgacttttaaaatttttaatgctttaattgcgcttgataacggtgtagttaaagatacaaaggaaattttttatcattataagggtgaaaaagtatttttgccttcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcctatggaaatgcaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgatggtgtaaatttggcttggattgtcggatttatagagagtaaaaacaaaattttatcttttgccttaaatgttgatataaagaatattaaaaatcttaaaataagagaagaattactagaaaaatatatttattctttaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4637,Drugs,MEG_4637|Drugs|betalactams|Class_D_betalactamases|OXA,1543523687|WP_126205827.1|NG_063886|1|1|blaOXA-785|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-785 NG_063886:1-747,0
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatgcattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_237,Drugs,MEG_237|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1028080899|WP_063840282.1|NG_047285|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_047285:52-606,2
,ATGAACGATTCTAATAAAGAAAATAAATACACCGCTGAAAGTATTAAAGTACTTGAAGGATTAGAAGCGGTACGAAAACGTCCTGGTATGTATATTGGTTCAACTCAATCAGAAGGTTTGCACCATATGATTTGAGAAATTGTTGATAACTCAATCGATGAAGCAATGGGTGGTTTTGCAACAGTTGTTAAAGTTATTATAAAAAAAGATGGAGTAATACGAGTTGAAGATGATGGACGTGGAATTCCAGTTGGAATTCATGAAAAAACTGGTTTATCAGGTGTTGAAACTGTATTAACTGTGTTGCATGCTGGAGGTAAATTTGATAATGATAGTTACAAAGTCTCTGGTGGATTACATGGTGTTGGTGCATCTGTTGTTAATGCTTTAAGTAAAAACTTTAAAGTTTGAGTTAATAAAAATTATGTTCAACATTACGTTGAATTTATTAATGGTGGACATGCTATTGAACCATTAAAAATAATTAACGACAAAGATATCAAAGAAAAAGGAACAACAATTGAGTTTATTCCTGACTTTGAAATCATGGAAGAAAATGAATGAGATGAGCTAAAAATAATGGCTCGTTTAAAACAATTAGCTTACCTTAATAAAGGTGTTAATATCGAATTTGAATCAGAAATGACTAATCGTAAAGAAAAATGACATTACGAAGGTGGTTTAAAAGAGTATATAGCTGATTTAAACGCTGAAAAAGAACCATTATTTGATGCTATTGTTTACGGTGAAGAAGAAAAAGAAGTTAAAGTTCCAGGTCACAATGATCAAACTTATAACATTAAATGTGAAGTAGCATTTCAATACAATAATTCGTACAACAATTCAACACACTCATTCTGTAATAACATTAATACTACAGAAGGTGGAACACACGAAGAAGGTTTTAAATTAGCGATTACACGTTTATTAAACAAATATGCAATCGATAAAAAGTATTTAAAAGACACTGATGATAAAATCACTAAAGAAGACGTGAGCGAAGGGTTAACAGCGATTATTTCTATTAAGCACCCTAACCCTCAATATGAAGGTCAAACAAAGAAAAAATTAGGAAATAGTGAAGTTCGTCCTTATGTTAATGAAATTACTTCTATAATTTTCGAAAAATTCTTAAATGAAAATCCAGAAGAATCAAAAAAAATTGTTGCTAAAGTTATGCAAGCCGCTGAGGCACGTCGTCGTTCTCATGAAGCGCGTGAAGCTACAAGACGAAAATCACCATTTGAATCAAATTCATTACCAGGTAAATTAGCTGATTGTTCAAATCGTGATTCAAGTGTTACAGAAATTTATATTGTCGAAGGGGATTCAGCTGGTGGATCAGCAAAAACTGGTCGTGAACGTGAATTCCAAGCAATTTTACCATTGCGTGGAAAAATTATTAATGTTGAAAAAGCAAAAATTGACAAGATTTTCGCTAATGAAGAAATTCAAAACATGATTACTGCTTTTGGAGCAGGAATAGGGCCTGAATTTAATATTGAAAAATTAAGATATTCAAAAATTATTATTATGACCGATGCCGATGTCGATGGTAGCCATATTCGAATCTTGTTATTAACATTCTTTTATCGATACATGTTACCATTGATTCAAAATGGTAATGTTTATATTGCTCAACCACCACTTTATAAAGTGAGTTATGGTAAAACAATTAAATATGCATATTCTGATCAAGAATTAGAAAAAATTAAATCAACATTGTTGAATACAAAATATAACATTCAACGTTATAAAGGGTTAGGGGAGATGAATCCTGATCAATTATGAGAAACAACAATGGATCCTAAAAATCGTCTTTTATTAAAAGTTAATATTGAAGATGCGGCAATCGCTGATAAAACATTTTCTTTATTAATGGGTGATGATGTAACACCACGAAAAGAATTTATTGAAAAAAATGCAAAATATGTAAAGAATATTGATGCTTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3240,Drugs,MEG_3240|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRB,gb|CP001184.1|+|104283-106236|ARO:3003305|Ureaplasma urealyticum gyrB conferring resistance to fluoroquinolone [Ureaplasma urealyticum serovar 10 str. ATCC 33699] ,3
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgccgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_840,Drugs,MEG_840|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502096|WP_071846248.1|NG_052273|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052273:101-892,2
,atgaacaaaaaaaatataaaagacagtcaaaactttattacttcgaaacgtaatgtagataaaataatgacaaatataagcttaaatgaacatgataatatctttgaaattggctcaggaaaagggcattttacccttgaattagtacaaaggtgtaatttcgtaactgctattgaaatagaccataaattatgcaagactacagaaaataaacttgttgatcacgataattttcaagttttaaacaaggatatattgcagtttaaatttcctaaaaaccaatcctataaaatatttggtaatataccttacaacataagtacggatataatacgcaaagttgtttttgaaagtatagctgatgagagttatttaatcgtggagtacgagtttgctaaaaggttattgaatacaaagcgctcattggcgttacttttaatggcagaagttgatatttctatattaagtatggttccaagagaatattttcatcctaaacctaaagtgaatagctcgcttatcagattaaatagaaaaaaatcaagaatatcgtacaaagataaacagaagtataattatttcgttatgaaatgggttaacaaagaatacaagaaaatatttacaaagaatcaatttaacaaatccttaaaacatgcgggaattgacgatttaaacaatattagctttgagcaattcttgtctcttttcaatagctataaattatttaataagtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2810,Drugs,MEG_2810|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,499701410|WP_011382144.1|NG_047816|1|1|erm(C)|erm(C)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(C) NG_047816:101-835,7
,atgagcaacgcagtgcccgccgagatttcggtacagctatcacaggcactcaacgtcatcgagcatcatctgggatcgacgttgctggccgtgcatttgtacggctctgcactcgacggtggcctgaagccatgcagtgatattgatttgctggttactgtgactgcacagctcgatgagactgtgcggcaggctctgttcgtagatttcctggaagtttccgcttctcccggccaaagtgaagctctccgtgccttggaagttaccatcgtcgtgtacggcgatgttgttccttggcgttatccagccagacgggaactgcaattcggggagtggcagcgcaaggacattcttgcgggcatcttcgagcccgcgacaaccgatgttgatctggctattctgctaactaaagcaaggcaacacagccttgccttggcaggttcggccgcggaagatttcttcaacccagtcccggaaagcgatctattcaaagcactggccgacaccttgaaactatggaactcacaaccggattgggcaggcgacgagcggaatgtagtgcttaccttgtctcgcatttggtacagcgcagcaaccggcaagatcgcgccgaaggatgtagctgccaactgggtaatggaacgcctgcccgtccaacatcagcccgtgctgcttgaagcccagcaggcttaccttggacaagggatggattgcttggcctcacgcgctgatcagttgactgcgttcatttactttgtgaagcacgaagccgccagtctgctcggctccacgccaatgatgtctaaaacaaagttaggcatcacaaagtacagcatcgtgaccaacagcaccgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_761,Drugs,MEG_761|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1028078994|WP_063839875.1|NG_047214|1|2|ant(3'')-I|ant(3'')-I|bifunctional_aminoglycoside_nucleotidyltransferase_ANT(3'')-Ij/aminoglycoside_N-acetyltransferase_AAC(6')-Ib NG_047214:101-1492,2
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGGAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCCGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGTGAAATTGTTATCCTTCCCAGCGACAGCGTGAGGTTAAACGATGTATTAGGGGACCCAACCCGGCTCCCTCGTAAAAGGTGGCGTGAGGACCCCCTCCCCATGCTGCGGACGTCGATTGCGCCGAAAACGGCAGCGCAAAGAGAACGGCTGCTGAACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGCTGCGAGGTGGATTCCATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTTGTTTCCGCTTTGCTGTCGGAAAAATACAAGCTTGAAACAGTGGTAAAGGAACCCACCGTCATTTATATGGAGCGGCCGCTCAAAGCAGCCAGCCGCACCATCCATATCGAGGTGCCGCCCAACCCGTTTTGGGCATCCATCGGACTGTCTGTTACACCACTCCCGCTTGGCTCCGGTGTACAATACGAGAGCCGGGTTTCGCTGGGATACTTGAACCAGAGTTTTCAAAACGCTGTCAGGGATGGTATCCGTTACGGGCTGGAGCAGGGCTTGTTCGGCTGGAACGTAACGGACTGTAAGATTTGCTTTGAATACGGGCTTTATTACAGTCCGGTCAGCACGCCGGCGGACTTCCGCTCATTGGCCCCGATTGTATTGGAACAGGCATTGAAGGAATCAGGGACGCAACTACTGGAACCTTATCTCTCCTTCACCCTCTATGCGCCCCGGGAATATCTTTCCAGGGCTTATCATGATGCACCGAAATACTGTGCCACCATCGAAACGGTCCAGGTAAAAAAGGATGAAGTTGTCTTTACTGGCGAGATTCCCGCCCGCCGTATACAGGCATACCGTACTGATCTGGCCTTTTACACCAACGGGCAGAGCGTATGCCTTACAGAACTGAAAGGGTATCAGGCCGCTGTCGGCAAGCCAGTCATCCAGCCCCGCCGTCCAAACAACCGCCTGGACAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7174,Drugs,MEG_7174|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/W)_2_AM889119 ,4
,atgttgcgttttttagaggaaagctgcgttcctatgaggcggtttgcatgtgcgttggccttcacgttgagcttgcccttagccagcgaggcggggccactgatggatacagtcggtcagttggagactgaggttggagggcgcattggtgtggtgttgcgccataccggatctgactgggccgttgagcatcgggaggatgagcgctttcccatggccagcacgttcaaggcactgctctgcggagccgttttaagccgtgttgatcgcggtgaagagagccttgatgatcttgtcacttacaaagcaaccgagctcgtctcttattctcctgtcaccaagaaccatgtggcttctggaatgagtgttggccagctgtgtgaagcgacggtcaccatgagcgataacagtgctgcaaacttgcttttgaaacgcgttgatgggccggaagggctgaccagattcttacgtgggcttggtgatcgggtgacgcgtctggaccggaatgagccagctatgaacgaagccaggcgcggagatccccgtgatactacttcgccttctgctgtgctcaagacattggacaggttgctgtttgagggtgtgttgcttccgtcttcccgcgcacagctgcagcaatggatggtggatgacaaagttgcggatgtgttgatccgaaagcatctgccgaagggctggcgcattgcagacaagagcggtgctggtcacaatggttcgcgtgggattatcagtgttatctggccggaaacgggacagccatatcttgcagcagcctatatgacgggcagtgatgcgagtattaagcagcgcaatgcggtgatcgctgagattgggaaggcgatgattgaggagattaaacagcgttga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5818,Drugs,MEG_5818|Drugs|betalactams|Class_A_betalactamases|PSV,1127299515|WP_075226241.1|NG_052626|1|1|blaPSV-1|blaPSV|penicillin-hydrolyzing_class_A_beta-lactamase_PSV-1 NG_052626:101-988,0
,ATGACTAAAACAAAAATTATGGGCATATTAAACGTCACACCTGATTCATTCTCAGATGGTGGAAAATTTAATAATGTTGAATCAGCTATAAATAGAGTGAAAGCCATGATAGATGAAGGTGCTGACATTATAGATGTTGGAGGTGTTTCAATGAGACCCGGTCATGAAATGGTTTCATTAGAAGAAGAGATGAACAGAGTATTACCTGTTGTTGAAGCTATTGTCGGTTTTGATGTAAAAATTTCAGTCGATACATTTCGAAGTGAGGTTGCTGAAGCATGTTTAAAATTAGGCGTTGATATGATTAATGATCAATGGGCGGGTCTGTATGATCATCGTATGTTCCAAATTGTAGCTAAATATGACGCGGAAATTATTTTAATGCATAATGGAAATGGTAATCGTGATGAACCGGTTGTCGAAGAAATGTTAACATCTTTGTTAGCACAAGCACATCAAGCTAAAATAGCTGGTATACCTTCAAATAAAATTTGGCTAGATCCAGGTATAGGTTTCGCTAAAACTAGAAATGAAGAAGCCGAAGTTATGGCAAGACTGGATGAACTTGTTGCAACAGAATATCCAGTTTTATTAGCGACAAGCCGGAAACGTTTCACTAAAAAGATGATGGGTTATGATACAACACCGGTTGAAAGAGATGAAGTAACTGCAGCTACGACTGCATATGGTATTATGAAAGGCGTTAGAGCAGTACGCGTTCATAATGTCGAGTTGAATGCTAAATTAGCTAAAGGTATAGATTTTTTAAAGGAGAATGAAAATGCAAGACACAATCTTTCTTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2949,Drugs,MEG_2949|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|610395799|gb|CP007539.1|567692-568495 gi|57284222|gb|CP000046.1|568249-569052,8
,atgagccatattcaacgggaaacgtcttgctcgaggccgcgattaaattccaacctggatgttgatttatatgggtatagatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggcatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccccgggaaaacagcattccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagcgttcctgcgccggttgcattcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataagcttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgagttttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctaa,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1029,Drugs,MEG_1029|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,502019139|WP_012695470.1|NG_047440|1|1|aph(3')-Ia|aph(3')-Ia|aminoglycoside_O-phosphotransferase_APH(3')-Ia NG_047440:101-916,2
,GTGAAACCCAACAGACCCCTGATCGTAATTCTGAGCACTGTCGCGCTCGACGCTGTCGGCATCGGCCTGATTATGCCGGTGCTGCCGGGCCTCCTGCGCGATCTGGTTCACTCGAACGACGTCACCGCCCACTATGGCATTCTGCTGGCGCTGTATGCGTTGATGCAATTTGCCTGCGCACCTGTGCTGGGCGCGCTGTCGGATCGTTTCGGGCGGCGGCCGGTCTTGCTCGTCTCGCTGGCCGGCGCTGCTGTCGACTACGCCATCATGGCGACGGCGCCTTTCCTTTGGGTTCTCTATATCGGGCGGATCGTGGCCGGCATCACCGGGGCGACTGGGGCGGTAGCCGGCGCTTATATTGCCGATATCACTGATGGCGATGAGCGCGCGCGGCACTTCGGCTTCATGAGCGCCTGTTTCGGGTTCGGGATGGTCGCGGGACCTGTGCTCGGTGGGCTGATGGGCGGTTTCTCCCCCCACGCTCCGTTCTTCGCCGCGGCAGCCTTGAACGGCCTCAATTTCCTGACGGGCTGTTTCCTTTTGCCGGAGTCGCACAAAGGCGAACGCCGGCCGTTACGCCGGGAGGCTCTCAACCCGCTCGCTTCGTTCCGGTGGGCCCGGGGCATGACCGTCGTCGCCGCCCTGATGGCGGTCTTCTTCATCATGCAACTTGTCGGACAGGTGCCGGCCGCGCTTTGGGTCATTTTCGGCGAGGATCGCTTTCACTGGGACGCGACCACGATCGGCATTTCGCTTGCCGCATTTGGCATTCTGCATTCACTCGCCCAGGCAATGATCACCGGCCCTGTAGCCGCCCGGCTCGGCGAAAGGCGGGCACTCATGCTCGGAATGATTGCCGACGGCACAGGCTACATCCTGCTTGCCTTCGCGACACGGGGATGGATGGCGTTCCCGATCATGGTCCTGCTTGCTTCGGGTGGCATCGGAATGCCGGCGCTGCAAGCAATGTTGTCCAGGCAGGTGGATGAGGAACGTCAGGGGCAGCTGCAAGGCTCACTGGCGGCGCTCACCAGCCTGACCTCGATCGTCGGACCCCTCCTCTTCACGGCGATCTATGCGGCTTCTATAACAACGTGGAACGGGTGGGCATGGATTGCAGGCGCTGCCCTCTACTTGCTCTGCCTGCCGGCGCTGCGTCGCGGGCTTTGGAGCGGCGCAGGGCAACGAGCCGATCGCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7032,Drugs,MEG_7032|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,gi|970698093|gb|KT988018.1|14750-15949 gi|974751143|gb|KU238092.1|6779-5580 gi|975048878|gb|CP013962.1|2246546-2247745 gi|973710347|gb|CP013833.1|73946-75145 gi|966626646|gb|CP013657.1|127298-126099 gi|959153704|gb|CP012993.1|50346-49147 gi|959147947|gb|CP012988.1|42873-44072 gi|952556149|emb|LN879484.1|75404-74205 gi|944397480|gb|CP013024.1|63015-64214 gi|933686806|gb|KT779550.1|83580-84779,4
,GGCATCCAAGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGACGGGCGTACAAAGATAATTTCCATCTCAAGGGATCACCATGCGCTTCATTCACGCTCTATTACTGGCAGGGATCGCTCACTCTGCATATGCGTCGGAAAAATTAACCTTCAAGACCGATCTTGAGAAGCTAGAGCGCGAAAAAGCAGCTCAGATCGGTGTTGCGATCGTCGATCCCCAAGGAGAGATCGTCGCGGGCCACCGAATGGCGCAGCGTTTTGCAATGTGCTCAACGTTCAAGTTTCCGCTAGCCGCGCTGGTCCTTGAAAGAATTGACTCAGGCACCGAGCGGGGGGATCGAAAACTTTCATATGGGCCGGACATGATCGTCGAATGGTCTCCTGCCACGGAGCGGTTTCTAGCATCGGGACACATGACGGTTCTCGAGGCAGCGCAAGCTGCGGTGCAGCTTAGCGACAATGGGGCTACTAACCTCTTACTGAGAGAAATTGGCGGACCTGCTGCAATGACGCAGTATTTTCGTAAAATTGGCGACTCTGTGAGTCGGCTAGACCGGAAAGAGCCGGAGATGAGCGACAACACACCTGGCGACCTCAGAGATACAACTACGCCTATTGCTATGGCACGTACTGTGGCTAAAGTCCTCTATGGCGGCGCACTGACGTCCACCTCGACCCACACCATTGAAAGGTGGCTGATCGGAAACCAAACGGGAGACGCGACACTACGAGCGGGTTTTCCTAAAGATTGGGTTGTTGGAGAGAAAACTGGTACCTGCGCCAACGGGGGCCGGAACGACATTGGTTTTTTTAAAGCCCAGGAGAGAGATTACGCTGTAGCGGTGTATACAACGGCCCCGAAACTATCGGCCGTAGAACGTGACGAATTAGTTGCCTCTGTCGGTCAAGTTATTACACAACTCATCCTGAGCACGGACAAATAGTTGACGCCCGTCTAACAATTCGTTCAAGCCGACGTTGCTTCGTGGCGGCGCTTGCGTGCTACGCTAAGCTTCGCACGCCGCTTGCCACTGCGCACCGCGGCTTAACTCAGGCGTCAGATGCACTAAGCACATAATTGCTCACAGCCAAACTATCAGGTCAAGTCTGCTCTTATTATTTTTAAGCGTGCATAATAAGCCCTACACAAATTGGGAGATATATCATGAAAGGCTGGCTTTTTCTTGTTATCGCAATAGTTGGCGAAGTAATCGCAACATCCGCATTAAAATCTAGCGAGGGCTTTACTAAGCTTGCCCCTTCCGCCGTTGTCATAATCGGTTATGGCATCGCATTTTATTTTCTTTCTCTGGTTCTGAAATCCATCCCTGTCGGTGTTGCTTATGCAGTCTGGTCGGGACTCGGCGTCGTCATAATTACAGCCATTGCCTGGTTGCTTCATGGGCAAAAGCTTGATGCGTGGGGCTTTGTAGGTATGGGCGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3131,Drugs,MEG_3131|Drugs|betalactams|Class_A_betalactamases|GES,gi|388891770|gb|JQ772478.1|1-1503 gi|695212024|ref|NG_036316.1|5026-5308,0
,atgatcatcagtgaatttgatcgtagaaatatcggtttgaaggatcagctagctgaccttttgcgattgacttggccgaaggattacggtgaacaaccaatgaaagaagtcgagcaactgctggcgacggatcgaatcgctgtctcagcggtggaacaagatcgtttggttggttttatcggtgcgattccgcagtatggaatgactggttgggaaattcaccctctagtagtagaaacttcttatcgaaagcagtatatcggtagccgcttagttgcttatgtggagaaagaaatcgcctctaaaggtggtgtgatggtttatttaggaacagatgatacggatggggacacgagtcttagtcatacggatctttttgatcatccgttggataaactgaaatcaatcgaaactttcaacaagcatccttatacattttatgaaaaaatgggctatcaagtcgttggagcgcttcctgatgcaaatggggtcaatcaaccagatatcattctggcaaaacgacttggagaaataaatcaatga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_90,Drugs,MEG_90|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,518552295|WP_019722502.1|NG_052504|1|1|aacA-ENT4|aacA-ENT4|aminoglycoside_6'-N-acetyltransferase NG_052504:101-643,2
,atgaaaaaacggattaccccattttcccgatttgcatcaaaaggccttttcgcctgtagcgcaggcatgttgctggtgacggtggcacatgccgccaatatggcagcagcaccagccggcatggatgccatggtacaaaccgtgatgcaggcacaccagattccgggcatggccattgccatcatccagccaggaaagaccacttatcacaattatggtgtcgcctcccgcgaaaccggccagccggtccgggaaaccaccctgtttgaaatcggctccctttccaaaccgtttactgcactggtcgcccagcgggctgaaaccgaaggccggattgacctgtctgcaccggccagccgctacgttaccgccctgcggggcagtgcattcgaccggatcaccctcaggcagctcggtacttatagtgcaggcggattaccgctccagtttcctgacaatgtcactaccccggcagatgtactggcttattaccgccattggcaacctgtccatccggcaggtagcacccggctgtattccaatccgagcattggcctgatggggctggctgccagtcaggcaaccggagagtcctttgccggcctgctcgggacaacggtgctgcaacccctcggcatgaactcgacctatctgcaagtgcccccggaggcccgttcacgttatgccatgggttataccgccgccgggaaaccggtcagggtcaaccccggtccgctggatgaggaaacctacggcgtcaagtccacaaccgcagacatggccggatttttactggcgcatatggaccctgcgcgcagcaaaggtgcattgcggtcggcattacagcaaacacgtgtaccggtttattgtgccggacagacccggcaaggactgggctgggaaagttatcaagactggaaaaacctcgacgtgctgctggcgggaaattcaaatcaaatggtgtttgaaccgcagccggtaaaagcctgtcttgccggcaccatgaatgagcctgatgtgtgggtcaacaagaccggttctactgcgggattcggcgcttatgccgtattcctgcctgcccgacagaccggcattgtcatcctggccaaccgtaattacccgattgcagaccgtatccggctcgctcacggaattttgaccgcattgcactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3584,Drugs,MEG_3584|Drugs|betalactams|Class_A_betalactamases|LHK,1349894763|WP_104531866.1|NG_056484|1|1|blaLHK-3|blaLHK|class_C_beta-lactamase_LHK-3 NG_056484:1-1173,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcaccgcgctgtggccctccagctcgcctgaagatcaccgcgcggaaatgcgcgagatactggcttcaccgcaccactccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgtcgagggcgcccgccgccagggctgggccgcgcgcttaatcgcacaggtgcaggagtgggcgaagcagcaggggtgcagcgagctggcgtcggataccgacatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggagcgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_153,Drugs,MEG_153|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,836571982|WP_047729810.1|NG_052471|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052471:101-541,2
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6489,Drugs,MEG_6489|Drugs|betalactams|Class_A_betalactamases|SHV,gi|77702547|gb|DQ219474.1|1-861,0
,ATGCAAAATAAAAAAATAGCAGTTATTTTTGGAGGCAATTCAACAGAGTACGAGGTGTCATTGCAATCGGCATCCGCTGTTTTTGAAAATATCAATACCAATAAATTTGACATAATTCCAATAGGAATTACAAGAAGTGGTGAATGGTATCACTATACGGGAGAAAAGGAGAAAATCCTAAACAATACTTGGTTTGAAGATAGCAAAAATCTATGCCCTGTTGTCGTTTCCCAAAATCGTTCCGTTAAAGGCTTTTTAGAAATTGCTTCAGACAAATACCGTATTATAAAAGTTGATTTGGTATTCCCCGTATTGCATGGCAAAAACGGCGAAGATGGTACTTTGCAGGGCATATTTGAATTGGCAGGAATACCTGTTGTTGGCTGCGATACACTCTCATCAGCTCTTTGTATGGATAAGGACAGGGCACATAAACTCGTTAGCCTTGCGGGTATATCTGTTCCTAAATCGGTAACATTCAAACGCTTTAACGAAGAAGCAGCGATGAAAGAGATTGAAGCGAATTTAACTTATCCGCTGTTTATTAAACCTGTTCGTGCAGGCTCTTCCTTTGGAATAACAAAAGTAATTGAAAAGCAAGAGCTTGATGCTGCCATAGAGTTGGCATTTGAACACGATACAGAAGTCATCGTTGAAGAAACAATAAACGGCTTTGAAGTCGGTTGTGCCGTACTTGGCATAGATGAGCTCATTGTTGGCAGAGTTGATGAAATCGAACTGTCAAGCGGCTTTTTTGATTATACAGAGAAATATACGCTTAAATCTTCAAAGATATATATGCCTGCAAGGATTGATGCCGAAGCAGAAAAACGGATACAAGAAGCGGCTGTAACCATATATAAAGCTCTGGGCTGTTCGGGTTTTTCCAGAGTGGATATGTTTTATACACCGTCTGGCGAAATTGTATTTAATGAGGTAAACACAATACCAGGCTTTACCTCGCACAGTCGCTATCCAAATATGATGAAAGGCATTGGTCTATCGTTCTCCCAAATGTTGGATAAGCTGATAGGTCTGTATGTGGAATGATGAAAACGATTGAGCTTGAAAAGGAAGAAATTTATTGTGGAAATTTGCTGCTCGTCAACAAAAATTATCCGCTACGAGATAACAATGTAAAGGGTTTAGTTCCTGCTGATATACGCTTTCCAAATATTCTTATGAAGCGTGATGTGGCAAATGTTTTGCAGCTTATTTTTGAAAAAATCTCGGCAGGTAACTCTATCGTTCCTGTAAGCGGTTATCGCTCATTAGAAGAACAGACAGCCATATATGACGGCTCTCTCAAAGATAATGGAGAGGATTTTACAAGAAAATATGTTGCTCTGCCCAATCATAGTGAACATCAAACAGGTCTTGCCATTGATTTAGGACTGAATAAAAAGGATATAGACTTTATCCGTCCCGATTTTCCCTATGACGGTATTTGCGATGAATTTAGGAGAGCTGCCCCAGACTATGGCTTTACCCAGCGTTATGCAAGGGATAAAGAAGAAATAACAGGGATTTCACACGAGCCGTGGCATTTTCGATATGTAGGATACCCACACTCAAAAATTATGCAGGAAAATGGTTTTTCACTTGAAGAATACACACAATTTATAAAAGCCTATCTGGAAGATAACAAATATCTTTTTGAGCAGGCTCACAGAGCTGAGATTGAAATATATTATGTTCCTGCAAAAGACGACAAAACGCTGATAAAAATACCAGAAAATTGTGTTTATCAGATTTCTGGTAATAACATAGACGGTTTTGTTGTGACCATATGGAGGAAAACAGATGACTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7397,Drugs,MEG_7397|Drugs|Glycopeptides|VanG-type_resistance_protein|VANG,VanGXY_1_AY271782,5
,gtgcgctcaaaaaattttagttggcggtactcccttgccgccacggtgttgttgttatcaccgttcgatttattggcatcactcggcatggacatgtacttgccggcagtgccgtttatgccaaacgcgcttggtacgacagcgagcacaattcagcttacgctgacaacgtacttggtcatgattggtgccggtcagctcttgtttggaccgctatcggaccgactggggcgccgccccgttctactgggaggtggcctcgcctacgttgtggcgtcaatgggcctcgctcttacgtcatcggctgaagtctttctggggcttcggattcttcaggcttgtggtgcctcggcgtgccttgtttccacgtttgcaacagtacgtgacatttacgcaggtcgcgaggaaagtaatgtcatttacggcatactcggatccatgctggccatggtcccggcggtaggcccattgctcggagcgctcgtcgacatgtggcttgggtggcgggctatctttgcgtttctaggtttgggcatgatcgctgcatctgcagcagcgtggcgattctggcctgaaacccgggtgcaacgagttgcgggcttgcaatggtcgcagctgctactccccgttaagtgcctgaacttctggttgtacacgttgtgttacgccgctggaatgggtagcttcttcgtctttttctccattgcgcccggactaatgatgggcaggcaaggtgtgtctcagcttggcttcagcctgctgttcgccacagtggcaattgccatggtgtttacagctcgttttatggggcgtgtaatacccaagtggggcaacccaagcgtcttgcgaatgggaatgggatgcctgatagctggagcagtattgcttgccatcaccgaaatatgggcttcgcagtccgtgttaggctttatttctccaatgtggctagtgggtattggtgtcgccacagcggtatctgtggcgcccaatggcgctcttcgaggattcgaccatgttgctggaacggtcacggcagtctacttctgcttgggcggtgtactgctaggaagcatcggaacgttgatcatttcgctgttgccgcgcaacacggcttggccggttgtcgtgtactgtttgacccttgcaacagtcgtgctcggtctgtcttgtgtttcccgagcggagggctctcgcggccagggggagcatgatgtggtcgcgctacaaagtgcggaaagtacgtcaaatcccaatcgttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1760,Drugs,MEG_1760|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,1105502127|WP_071846279.1|NG_052326|1|1|cmlA|cmlA|CmlA_family_chloramphenicol_efflux_MFS_transporter NG_052326:101-1360,6
,atgcaatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtgttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactagcggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_510,Drugs,MEG_510|Drugs|betalactams|Class_C_betalactamases|ADC,1119314405|WP_072292271.1|NG_064709|1|1|blaADC-186|blaADC|class_C_beta-lactamase_ADC-186 NG_064709:1-1152,0
,atgaaaagcaaagtcagtgcgctgttaatgatgatagttcttgcgggccatgcgcaggccgcgcccgttgcgccgccggatgcggtcgttaagccattgatggcgcgctaccagatcccgggcatggcggtggcggtgtcggttaacggcgaaacgcatttctggcattacggcgtggcgtcaaaagcgacccgtaagccggtggatgaaaacacgcttttcgaaatcggctcgctcagtaaaacctttaccgcgacgctcgcaagcaaggcgcagcaagacggcaaactggatttcagcgcgcccgccagccagtatcttcctgcactgaaaggcagcgcattcgataacgtgacgctgctgaacctcgccacgcacaccgcgggaacgccgctctttgtgccggatgcggtgaaaaacaccacacagctgatggactggtatcgcgcctggcagcctgaaaagccggtcggcaccgagcgcgtttactcgaatctcgggatcgggctgctcgggatgattaccgcgaaggcgctcgataagccgttcagcgaggcgatggagcaggggcttctcagggatttcggcatgacgcacacctttatcaacgtgccggaggccgcgatggacaactacgcccagggctataacaaggacgacaaaccggtgcgggtgacgcccggcccgcttgacgccgaatcgtatgggctgaaatccggcagcgcggatctgctgcgttatctgcaaatccagcttggcgagcaggaggtcgcgccaggctggcgtcaggcgattaacgccacgcacaacggctactaccgcagcggtgagttcacacaggggttgatgtgggaatactatccgtggccgtcgccgctctcgcgccttgttgaaggcaacagcagccagcgcatcatgaaagggcttgcggccaccgcgatcgttccgccgcagcctgcgccgcaggccgcgtggtataacaaaaccggctcgaccaacggcttttccacttacgcagtgtttatccctgagaagcgtatcgcgctgattatgctcgccaacaagtggttcccgaatgacgaccgtgttaaagcggcgtatacgattattcaggagcttgataagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2134,Drugs,MEG_2134|Drugs|betalactams|Class_C_betalactamases|CSA,495163963|WP_007888761.1|NG_062223|1|1|blaCSA-1|blaCSA|class_C_beta-lactamase_CSA-1 NG_062223:101-1228,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagatcctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5552,Drugs,MEG_5552|Drugs|betalactams|Class_C_betalactamases|PDC,490499611|WP_004365741.1|NG_054978|1|1|blaPDC-192|blaPDC|class_C_beta-lactamase_PDC-192 NG_054978:1-1194,0
,ATGAAAAACATCGGCATTACCATCTATGGATGTGAGCAGGATGAGGCTGATGTGTTCAAGGAACTTTCGCCGCGCTTTGGCGTTATACCTGCCATTACAAGCTCTGCCGTATCAGAAACCAACGTAATGTTAGCCCCTGGAAATCAATGTATCAGCGTGGGGCACAAATCTGAGATTTCCGAATCCATTCTTCTTGCGTTGAAGGAATCCGGCGTCAAATATATCTCTACTCGAAGTATTGGTTACAATCACATAGACATGAAGGCCGCGGAAAGTATGGGTATTGCTGTCGGGAACGTGGCATATTCACCGGATAGCGTTGCCGATTATACATTGATGCTGATGCTCATGGCAGTACGCAACGCGAAATCTATTGTGCGCTCTGTGGAAAAACATGATTTCAAGCTGGACAGCGTCCGTGGCAAGGTACTGCGCGACATGACAGTCGGCGTGCTGGGAACCGGTCATATAGGCAAGAGGGTTATTGAGCGACTGCGGGGATTTGGATGTCATGTGCTGGCGTATGGTCACAACAAAGAGGCGGCGGCAAATTATGTGTCCCTCAATGAATTGCTGCAAAAAAGCGACATTCTTACCATTCACGTACCGCTTAGCGCGGACACATACCATATGATCGGTCGCGAACAGATTAAAGCAATGAAACAGGGCGCGTTTCTTATCAATACAGCGCGAGGCGGGCTTATAGATACCGATGTGCTGGTTAAAGCATTGGAAAACGGAAAACTGGGCGGCGCCGCATTGGATGTATTGGAGGGAGAGGAAGGACTTTTCTACTTTGATTGCACACAAAAACCAATTGATAATCAATTTTTACTGAAACTTCAAAGGATGCCGAACGTGATAATCACGCCGCATACGGCTTACTATACCGAACAGGCGTTGCGTGATACCGTTGAAAATACAATCAAGAACTGTCTGGAATTTGAGAGGAGAGAGACACTTGTATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7407,Drugs,MEG_7407|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,gi|66731642|gb|DQ018711.1|3168-4136,5
,ATGGCAATCCGAATCTTCGCGATACTTTTCTCCATTTTTTCTCTAGCCACTTTCGCGCATGCGCAAGAAGGCACGCTAGAACGTTCTGACTGGAGGAAGTTTTTCAGCGAATTTCAAGCCAAAGGCACGATAGTTGTGGCAGACGAACGCCAAGCGGATCGTGCCATGTTGGTTTTTGATCCTGTGCGATCGAAGAAACGCTACTCGCCTGCATCGACATTCAAGATACCTCATACACTTTTTGCACTTGATGCAGGCGCTGTTCGTGATGAGTTCCAGATTTTTCGATGGGACGGCGTTAACAGGGGCTTTGCAGGCCACAATCAAGACCAAGATTTGCGATCAGCAATGCGGAATTCTACTGTTTGGGTGTATGAGCTATTTGCAAAGGAAATTGGTGATGACAAAGCTCGGCGCTATTTGAAGAAAATCGACTATGGCAACGCCGATCCTTCGACAAGTAATGGCGATTACTGGATAGAAGGCAGCCTTGCAATCTCGGCGCAGGAGCAAATTGCATTTCTCAGGAAGCTCTATCGTAACGAGCTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGATCTCATGATTGTGGAAGCCGGTCGCAACTGGATACTGCGTGCAAAGACGGGCTGGGAAGGCCGTATGGGTTGGTGGGTAGGATGGGTTGAGTGGCCGACTGGCTCCGTATTCTTCGCACTGAATATTGATACGCCAAACAGAATGGATGATCTTTTCAAGAGGGAGGCAATCGTGCGGGCAATCCTTCGCTCTATTGAAGCGTTACCGCCCAACCCGGCAGTCAACTCGGACGCTGCGCGATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5214,Drugs,MEG_5214|Drugs|betalactams|Class_D_betalactamases|OXA,gi|260060383|gb|GQ466184.1|2534-3361,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccattgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5538,Drugs,MEG_5538|Drugs|betalactams|Class_C_betalactamases|PDC,1034011060|WP_064483997.1|NG_050788|1|1|blaPDC-132|blaPDC|class_C_beta-lactamase_PDC-132 NG_050788:1-1194,0
,GTGGCTACTGTGCCACCTGGTGGATAGCTCGGCTCGGATGCCGACGAAGGACGTGCCAAGCTGCGATAAGCCTGAGGGAGCCGCACGGAGGCTAAGAACTCAGGATCTCCTAATGGGAATCCCTATAACAATTGCCTTGCGCAATGGGGAACGGCCGGAATTGAAGCATCTCAGTACGGCCAGGAAGAGAAATCGAATGAGACGCCGTTAGTAATGGCGAATGAACGCGGCACAGTCCAAACCGAAGCCTTCGGGCAATGTGGTGTTCGGACTGACTTTCATCGTTTGACCGTTCGTGTGAAGTCTCCTGAAACGGAGCGCGATACAGGGTGACAGCCCCGTATCACGGACCAGTACGACGTGCGTCAGCTCCAGAGTAGCGGGGGTTGGAAATCCCTCGTGAATTGTGGCAGGCATCGACTGCCAAGACTAAGTACTCTCCGAGACCGATAGTGAACAAGTAGTGTGAACGAACGCTGAAAAGCACCCCACAAAGGGGGGTGAAATAGGGCTTGAAATCAGGTGGCGATGGAGCGACGGGGCATAAAAGGCCTCTCTGGGAACGACTTGAGTGCAAACTCATGGTAGGACCTGAGAGGAGCCGATGTTCCGTCGTACGTTTTGAAAAACGAGCTAGGGAGTGTGCCTGTTTGACGAGTCTAACCGGAGTATCCGGGAAGGCGTAGGGAAACCAATATGGCCGCGGCATTGCGAGGGCCACCGTGTTCAAGCGCGGGGAGTCAAACGGGCACGACCCGAAACCCGGTGATCTACGCGTGGGCAAGGTGAAGCATGGCGAAAGCCATGTGGAGGCCTGTTAGGGTTGGTGTCTTTCAACACCCTCCCGTGACCTACGTGTAGGGGTGAAAGGCCCATCGAACCGGGCAACAGCTGGTTCCAACCGAAACATGTCGAAGCATGACCTCTGCCGAGGTAGTTCGTGGGGTAGAGCGACCGATTGGGGAGTTCAACTCCGAGAGGAGTTGTCTCCCCTGTCAAACTCCAAACCTACGGACGCCGTCGACGCAGGGAATCCGGTGTGCGGGGTAAGCCTGTGCACCGTGAGGGAGACAACCCAGAGTTAGGTTAAGGTCCCAAAGTGCGAGCTAAGTGCGATTGAAGGTGGTCTCGAGCCCTAGACAGCCGGGAGGTGAGCTTAGAAGCAGCTACCCTCTAAGAAAAGCGTAACAGCTTACCGGCCGAGGTTCGAGGCGCCCAAAATGATCGGGGCTTAAGTTCGCCACCGAGACCTAACGGCACGGGTAACACCGTGATCCAGTAGGTTGGCATTCTGTTCGGGTGGAAGCTCGGGTGAGAACTCGAGTGGACCGAGTGGAAAAGAAAATCCTGGCCATAGTAGCAGCGTTAGTCGGGTAAGAATCCCGATGGCCGAAAGAGCAAGGGTTCCTCGGCAATGCTTATCAGCCGAGGGTTAGCCGATCCTAAGGCCCGTCGTAATTCGAGCGGGTCAAAAGGGAAACTGGTTAATATTCCAGTGCCACCGTACATTGAAAGTCGACGCCTCGGAGCAGCTTGAGCCGGGCATTCGCCCGGTCGAACCGTCGAAGTTCGTGGAAGCCGTAATGGCAGGAAGCGAACGAACGTCGGAACAGGGAAACTCAAGTCAATCTGGGGCCCGTGAAAAGGCGAGTACGGTGTTCGTACCGAGATCCGACACAGGTGCTCTGGCAGAGGAAGCCAAGGCCTGTCGGGAATAACCGACGTTAGGGAATTCGGCAAGTTAGTCCCGTAAGTTCGCGATAAGGGATGCCTGCCACGCAATGAGGCAGGTCGCAGTGACTCGGAGGCTCCGACTGTCTAATAACAACATAGGTGACCGCAAATCCGCAAGGACGCGTACGGTCACTGAATCCTGCCCAGTGCGGGTATCTGAACACCCAGTACAATGGGGCGAAGGACCCGTTAACGGCGGGGGTAACTATGACCCTCTTAAGGTAGCGTAGTACCTTGCCGCTTCAGTAGCGGCTTGCATGAATGGATCAACGAGAGCCTCACTGTCCCAACGTTGGGCCCGGTGAACTGTACGTTCCAGTGCGGAGTCTGGAGACCCCCAAGGGGAAGCGAAGACCCTATAGAGCTTTACTGCAGGCTGTCGCTGGGACACGGTCGCTGATGTGCAGAGTAGGTAGGAGACGTTACACAGGTACGTGCGCTAGCACGCCACCGAGTCACACATGAAACACTACCCGTCAGTGACTGTGACCCTCACTCCGGGAGGAGGACACCGGTAGCCGGGCAGTTTGACTGGGGCGGTACGCGCTTGAAAAGATATCGAGCGCGCCCTAAGCCTATCTCAGCCGAGTCAGAGACTCGGCGAAGAGTGCAAGAGCATAAGATAGGCTGACAGTGTCCTACACAACGAGGGACGCTGACGCGAAAGCTGGTCTAGCGAACCAATTAGGCTGCTTGATGCGGCCAATTGCTGACAGAAAAGCTACCTTAGGGATAACAGAGTCGTCACTCGCAAGAGCACATATCGACCGAGTGGCTGCTACCTCGATGTCGGTTCCCTCCATCCTGCCCGTGCAGAAGCGGGCAAGGGTGAGGTTGTTCGCCTATTAAAGGAGGTCGTGAGCTGGGTTTAGACCGTCGTGAGACAGGTCGGCTGCTATCTATTGGGGGTGTTTTGGTGCTTGACAGGAACGTTCGTATAGTACGAGAGGAACTACGAACGGGTGCCACTGGTGTATCGGTTGTCCGAGAGGGCATGTGCCGAGCAGCTACGCACCACGGGGTAAGAGCTGAATGCATCTAAGCTCGAAACCCACCTGGAAAAGAAGCACCACTGAGACCGCTCGTAGAAGACGAGTTCGATAGACTTGGGGTGTACGCGTCGAGGCAACGAGACGTTTAGCCCGCGAGTACTAACAGGTCAATGCCACAC,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Phenicol,MEG_5781,Drugs,MEG_5781|Drugs|Phenicol|Phenicol-resistant_23S_rRNA_mutation|PH23S,gb|X03407.1|+|2910-5815|ARO:3004180|Halobacterium halobium 23S rRNA mutation conferring resistance to chloramphenicol [Halobacterium salinarum] ,6
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGCTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATCGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTGACGATGAGGCTCAGGATATTGAGCCTCCTTTCTTTCTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_1976,Drugs,MEG_1976|Drugs|betalactams|Class_C_betalactamases|CMY,gi|442540410|gb|JX514369.1|297-1483,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcgccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttgggggtgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4466,Drugs,MEG_4466|Drugs|betalactams|Class_D_betalactamases|OXA,1509794592|WP_122630901.1|NG_062321|1|1|blaOXA-699|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-699 NG_062321:16-840,0
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatgaaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_859,Drugs,MEG_859|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502066|WP_071846218.1|NG_052228|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052228:101-892,2
,atgaaaattattaatattggaattttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttctctgttccctctttatcatggaagtgcaaaaagtaatatagggattgataaccttatagaagttattactaataaattttattcatcaacacatcgaggtccgtctgaactttgcggaaatgttttcaaaattgaatatacaaaaaaaagacaacgtcttgcatatatacgcctttatagtggagtactacatttacgagattcggttagagtatcagaaaaagaaaaaataaaagttacagaaatgtatacttcaataaatggtgaattatgtaagattgatagagcttattctggagaaattgttattttgcaaaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaagggatacgctatggttgcgaacaaggattatatggttggaatgtgacggattgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7115,Drugs,MEG_7115|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028099861|WP_063856113.1|NG_048220|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048220:101-2020,4
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGCATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCAGCAGTCGGGAGGAAGGCTGGGTGTGGCATTGATTAACACAGCGGATAATTCGCAAATACTTTATCGTGCAGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCGATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGCACCGAGCCGACGTTAAACACAGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACGCTGCGTAATCTGACGCTGGGTAAAGCATTGGGTGACAGCCAACGGGCGCAGCTGGTGACGTGGATGAAAGGCAATACTACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGTACCACCAACGATATCGCGGTGATTTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCCCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2220,Drugs,MEG_2220|Drugs|betalactams|Class_A_betalactamases|CTX,(Bla)CTX-M-37:AY649755:18-893-876,0
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtgggttggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4688,Drugs,MEG_4688|Drugs|betalactams|Class_D_betalactamases|OXA,1509794602|WP_122630911.1|NG_062331|1|1|blaOXA-719|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-719 NG_062331:9-833,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAAAACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1394,Drugs,MEG_1394|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_113_AHVS01000008,0
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGGCGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2388,Drugs,MEG_2388|Drugs|betalactams|Class_A_betalactamases|CTX,gi|238801221|gb|FJ966096.1|1949-2824,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccaccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagtacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3468,Drugs,MEG_3468|Drugs|betalactams|Class_A_betalactamases|KPC,1559612972|WP_128268237.1|NG_063841|1|1|blaKPC-39|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-39 NG_063841:1-882,0
,GTGGAACGTCAAAATAACAATGAAAACCAGTATGGAAGGAATCGCAGAAAAGACAAAAGAAAAAAATTGTTTTTTTACAGAGCAGCATGTGCCATGCTCGGTCTGCTCATAGTCTGTGTAATTTTTGGAGCTGTGTATTTTCTCAGAGAGAGTAAAGATCCGGTTCTTCCATCCAAAGAAAATACAAAGACAGGCAAGGACTATTCATTTTTGGCCGACGGTCAGAGTGAGGATGAGTCTCCGATTTCGGAGCCAGCCATATCCAACCGGGCGAATGCGATTGACCTGAACATCATAGCAGCAAATGCCATTGTGATGAATAAAGACACCGATGCGTTATTGTATCAAAAAAACGGCACGGACAGAATTGCGCCGGCCAGTACAGCAAAGATGATTACGGCGTTGACCGTGCTTGAATATTGTTCTCCGGAGGAGGAGATGAGAGTCGGTGCAGAGATTGAAATGATCCATAGTGATTCGTCAACCGCATGGCTTATGAAAGGCGATACCCTGACTGTCAGGCAGCTCCTGATTGCCCTGATGCTTCCGTCCGGCAATGATGCAGCTTATACCCTTGCAGTCAATACCGGAAAGGTTATTGCAGGCGATAACAGCCTGTCCAATCAGCAGGCCATTCAGATATTCATGGATAAGGTAAATGAGAAGGCCAGGGCAATTGGTGTTACAGACTCGAATTTTGTGGTTCCGGATGGGTATGATGCCGAGGGGCAGTATACCACGGCCTATGATCTTGCCATCATTGCAAAGGCATGTTTGGAGGATCCCATTATTTCAGAAATTGTGGCGAGCAATACGTCGTATGAAAAATGGCCGAACGGCAGGGAGGTCACTTACAACAATTCCAATGAGCTTCTTGATCCGAACAGTCCCTATTACCGTCCGGAGGTCATCGGACTGAAAACAGGGACCAGCAGCCTTGGCGGCGCCTGTGTGGTCTCTGCGGCAGTGATTGACGGAGAAACCTATATTTGCGTAGTCATGGGCTCTACGAAAGAAAGCAGGTTTCAGGACAGCGTTGCCATTTTGGATAAAATCAAGGCCCAGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7603,Drugs,MEG_7603|Drugs|Glycopeptides|VanD-type_accessory_protein|VANYD,(Gly)VanY-D:AB242319:1958-3025:1068,5
,ATGGAGAATATTTTTAGCAAAGATTCTGATATTGAACTTGTAGATATAGAAAATTCTATAAAAAGTAGTTATTTAGACTATTCTATGAGTGTTATTATAGGTCGTGCTTTGCCTGACGCAAGAGATGGTTTAAAGCCTGTTCATAGAAGAATTTTATATGCTATGCAAAATGATGAGGCAAAAAGTAGAACAGATTTTGTCAAATCAGCCCGTATAGTGGGTGCTGTTATAGGTCGTTATCACCCACATGGAGATACAGCAGTTTATGATGCTTTGGTTAGAATGGCTCAAGATTTTTCTATGAGATATCCAAGTATTACAGGACAAGGCAACTTTGGATCTATAGATGGTGATAGTGCCGCTGCGATGCGTTATACTGAAGCAAAAATGAGTAAACTTTCTCATGAGCTTTTAAAAGATATAGATAAAGATACGGTCGATTTTGTTCCAAATTATGATGGTTCAGAAAGCGAACCTGATGTTTTACCTTCTAGGGTTCCAAATTTATTATTAAATGGTTCAAGTGGTATAGCTGTAGGTATGGCGACAAACATCCCACCTCATAGTTTAAATGAGTTGATAGATGGACTTTTATATTTGCTTGATAATAAAGATGCAAGCCTAGAAGAGATTATGCAGTTTATCAAAGGTCCAGATTTTCCAACAGGTGGAATAATTTATGGTAAAAAAGGTATTATAGAAGCTTATCGCACAGGGCGTGGTCGCGTGAAAGTGCGAGCTAAAACTCATATTGAAAAAAAGACAAATAAAGATGTTATTGTTATCGATGAGCTTCCTTATCAAACCAATAAAGCTAGGCTTATAGAGCAGATTGCAGAGCTTGTTAAAGAAAGGCAAATTGAAGGAATATCTGAAGTAAGAGATGAGAGCAATAAAGAAGGAATCCGCGTTGTTATAGAGCTTAAACGTGAGGCTATGAGTGAAATTGTTTTAAATAATCTATTTAAATCTACCACTATGGAAAGTACTTTTGGTGTGATTATGTTGGCAATTCATAATAAAGAACCTAAAATTTTCTCTTTGTTGGAACTTTTAAATCTTTTCTTAACTCATAGAAAAACAGTTATTATTAGAAGAACGATTTTTGAACTTCAAAAGGCAAGAGCAAGAGCTCATATTTTAGAAGGTCTTAAAATTGCACTTGATAATATAGATGAAGTGATTGCTTTAATTAAAAATAGTTCTGATAATAATACCGCAAGAGATTCTTTAGTAGCTAAATTTGGTCTTAGTGAGCTTCAAGCCAATGCTATTTTAGATATGAAACTTGGTCGTTTAACAGGACTTGAAAGAGAAAAAATCGAAAATGAACTTGCAGAATTAATGAAAGAAATTGCAAGACTTGAAGAAATTTTAAAAAGTGAAACCTTGCTTGAAAATTTAATTCGCGATGAATTAAAAGAAATTAGAAGTAAATTTGATGTGCCACGTATTACTCAAATTGAAGATGATTACGATGATATTGATATTGAAGATTTGATTCCTAATGAAAATATGGTTGTAACTATCACACATCGTGGTTATATTAAGCGTGTGCCTAGTAAACAATATGAAAAACAAAAACGAGGTGGAAAAGGAAAATTAGCCGTTACGACTTATGATGATGATTTTATAGAAAGTTTCTTTACGGCAAATACACATGATACGCTTATGTTTGTAACAGATCGTGGACAGCTTTATTGGCTTAAAGTTTATAAAATTCCTGAAGGCTCAAGAACGGCTAAAGGAAAAGCAGTGGTAAATCTTATCAATTTACAAGCTGAAGAAAAAATCATGGCTATTATTCCAACCACGGATTTTGATGAGAGCAAATCTTTATGTTTCTTTACTAAAAATGGTATTGTAAAGCGTACAAATTTGAGTGAATATCAAAATATCAGAAGTGTAGGAGTTAGAGCGATCAACTTGGATGAAAATGATGAGTTGGTAACTGCTATTATTGTTCAAAGAGATGAAGATGAAATTTTTGCCACTGGTGGTGAAGAAAATTTAGAAAATCAAGAAATTGAAAATTTAGATGATGAAAATCTTGAAAATGAAGAAAGTGTAAGCACACAAGGTAAAATGCTCTTTGCAGTAACCAAAAAAGGTATGTGTATCAAATTCCCACTTGCTAAAGTGCGTGAAATCGGCCGTGTAAGTCGTGGGGTGACGGCTATTAAGTTTAAAGAGAAAAATGACGAATTAGTAGGTGCAGTTGTTATAGAAAATGATGAGCAAGAAATTTTAAGCATAAGTGCAAAAGGTATAGGAAAACGCACCAATGCTGGAGAATATAGATTGCAAAGCAGAGGTGGTAAGGGTGTAATTTGTATGAAACTTACAGAAAAAACCAAAGATCTTATTAGCGTAGTTATAGTAGATGAAACTATGGATTTAATGGCTCTTACAAGTTCAGGTAAGATGATACGTGTTGATATGCAAAGCATTAGAAAAGCAGGGCGTAATACGAGTGGTGTCATTGTAGTTAATGTGGAAAATGACGAGGTGGTTAGCATCGCTAAGTGTCCTAAAGAGGAAAATGACGAGGATGAGTTAAGCGATGAAAACTTTGGTTTAGATTTGCAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3218,Drugs,MEG_3218|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|756103065|gb|CP010301.1|1001585-998994 gi|756089737|gb|CP010072.1|1039335-1036744 gi|589078008|gb|CP006689.1|960218-957627 gi|589076343|gb|CP006688.1|960219-957628 gi|589074677|gb|CP006687.1|960219-957628 gi|589073010|gb|CP006686.1|960217-957626 gi|589071344|gb|CP006685.1|960218-957627 gi|401780468|emb|HE978252.1|960222-957631 gi|284925303|gb|CP001876.1|963089-960498 gi|30407139|emb|AL111168.1|960222-957631,3
,atgaatagaataaaagtcgcaatcatcttcggcggttgctcggaggaacatgatgtgtcggtaaaatccgcaatagaaattgctgcgaacattgatacggaaaaattcgatccgcactacatcggaattacaaaaaacggtgtatggaagctatgcaagaagccatgtacggaatgggaagccgacagtctccccgccatactctccccggataggaaaacgcatgggctgcttgtcatgaaagaaagcgaatacgaaacacggcgtattgatgtggctttcccggttttgcatggcaaatgcggggaggatggtgcgatacaggggctgtttgtattgtctggtatcccctatgtgggctgtgatattcaaagctccgcagtttgcatggacaaatcactggcctacattcttacaaaaaatgcgggcatcgccgttcccgaatttcaaatgattgataaaggtgacaagccggaggcgggtgcgcttacctaccctgtctttgtgaagccggcacggtcaggttcgtcctttggcgtaaccaaagtaaacggtacggaagaacttaacgctgcgatagaagcggcaggacaatatgatggaaaaatcttaattgagcaagcgatttcgggctgtgaggtcgggtgtgcggtcatggggaacgaggatgatttgattgtcggcgaagtggatcaaatccggctgagccacggtatcttccgcatccatcaggaaaacgagccggaaaaaggctcagaaaatgcgatgattacagttcccgcagacattccggtcgaggaacgaaatcgggtgcaggaaacggcaaagaaagtatatcgggtgcttggatgcagagggcttgcccgtgttgatctttttttgcaggaggatggcggcatcgttctaaatgaggtcaataccctgcccggttttacatcgtacagccgctacccacgtatggtggccgccgcaggaatcacgcttcctgcactgattgacagcctgattacattggcgttaaagaggggataa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7349,Drugs,MEG_7349|Drugs|Glycopeptides|VanB-type_resistance_protein|VANB,1028100462|WP_063856597.1|NG_048340|1|1|vanB|vanB|D-alanine--(R)-lactate_ligase_VanB NG_048340:1-1032,5
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccgcccagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacgtcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcagtttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgattgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_844,Drugs,MEG_844|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502054|WP_071846206.1|NG_052179|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052179:101-892,2
,TTGTCAAAAGCGCGGGAGTCGCGGATAGTCCGGGCAGCTCATCACTATCAAGGAGTCTGAGATGTTGAAAAGTTCGTGGCGTAAAACCGCCCTGATGGCCGCCGCCGCCGTTCCGCTGCTGCTGGCGAGCGGTTCATTATGGGCCAGTGCCGATGCTATCCAGCAAAAGCTGGCTGATTTAGAAAAACGTTCCGGCGGTCGGCTGGGCGTAGCGCTGATTAACACGGCAGATGATTCGCAAACCCTCTATCGCGGCGATGAACGTTTTGCCATGTGCAGCACCGGTAAAGTGATGGCCGCCGCCGCGGTGTTAAAACAGAGCGAAAGCAATCCAGAGGTGGTGAATAAAAGGCTGGAGATTAAAAAATCGGATTTAGTGGTCTGGAGCCCGATCACCGAAAAACATCTGCAAAGCGGAATGACCCTGGCGGAACTCAGCGCGGCGGCGCTGCAGTACAGCGACAATACCGCGATGAATAAGATGATTAGCTACCTTGGCGGACCGGAAAAGGTGACCGCATTCGCCCAGAGTATCGGGGATGTCACTTTTCGTCTCGATCGTACGGAGCCGGCGCTGAACAGCGCGATTCCCGGCGATAAGCGCGATACCACCACCCCGTTGGCGATGGCCGAAAGCCTGCGCAAGCTGACGCTGGGCAATGCGCTGGGCGAACAGCAGCGCGCCCAGTTAGTGACGTGGCTAAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCAGGCCTGCCCGCAAGCTGGGCGGTCGGGGATAAAACCGGCGCCGGAGATTACGGCACCACCAACGATATTGCGGTGATCTGGCCGGAAAATCATGCCCCGCTGGTGCCGGTGACCTATTTTACCCAGCCGCAGCAAGATGCGAAAAGCCGCAAAAAGGTGTTAGCCGCGGCGGCAAAAATCGTCACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5319,Drugs,MEG_5319|Drugs|betalactams|Class_A_betalactamases|OXY,gi|4775479|emb|Y17715.1|86-1022,0
,atgggtaaggaaaagactcacgtttcgaggccgcgattaaattccaacatggatgctgatttatatgggtataaatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggaatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccccggcaaaacagcattccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagtgttcctgcgccggttgcattcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataagcttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgagttttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctaa,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1041,Drugs,MEG_1041|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,1028082831|WP_063842098.1|NG_047432|1|1|aph(3')-Ia|aph(3')-Ia|aminoglycoside_O-phosphotransferase_APH(3')-Ia NG_047432:101-910,2
,ATGAGGGAAGCGGTGATCGCCGAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCACATAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCGCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_958,Drugs,MEG_958|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|677283264|dbj|AB983593.1|3989-4780 gi|674252391|gb|CP008739.2|2104891-2105682 gi|575771381|dbj|AB901038.1|2713-3504 gi|575771377|dbj|AB901037.1|1584-2375 gi|549442311|gb|KF512018.1|1991-2782 gi|348031532|dbj|AP012280.1|1896671-1897462 gi|46092527|dbj|AB104852.1|2561-3352,2
,AAAGGGAGGACAATCACATGAAAATAATCAATATTGGAATTCTTGCCCATGTAGACGCTGGAAAGACGACCTTGACGGAGAGCCTGCTATATGCCAGCGGAGCCATTTCAGAACCGGGGAGCGTCGAAAAAGGGACAACGAGGACGGACACCATGTTTTTGGAGCGGCAGCGTGGGATTACCATTCAAGCGGCAGTCACTTCCTTCCAGTGGCACAGATGTAAAGTTAACATTGTGGATACGCCCGGCCACATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATGAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGCGCGGGAGGAACAGCAGCGGGTTCAAGACGCCTCCCTGTTCCCAGTCTATCATGGCAGCGCCAAAAATGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGGGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTTGAGTACACCGATTGCGGCCAGCGGCGTGTCTATCTACGGTTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGGCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCAGGGTGAAATTGTTATCCTTCCCAGCGACAGCGTGAGGTTAAACGATGTATTAGGGGACCAAACCCGGCTCCCTCGTAAAAGGTGGCGCGAGGACCCCCTCCCCATGCTGCGGACGACGATTGCGCCGAAAACGGCAGCGCAAAGAGAACGGCTGCTGGACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGTTGCGAAGTGGATTCCATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTTGTTTCCGCTTTGCTGTCGGAAAAATACAAGCTTGAAACAGTGGTAAAGGAACCCTCCGTCATTTATATGGAGCGGCCGCTCAAAGCAGCCAGCCACACCATCCATATCGAGGTGCCGCCCAACCCGTTTTGGGCATCCATAGGACTGTCTGTTACACCACTCTCGCTTGGCTCCGGTGTACAATACGAGAGCCGGGTTTCGCTGGGATACTTGAACCAGAGTTTTCAAAACGCTGTCAGGGATGGTATCCGTTACGGGCTGGAGCAGGGCTTGTTCGGCTGGAACGTAACGGACTGTAAGATTTGCTTTGAATACGGGCTTTATTACAGTCCGGTCAGCACGCCGGCGGACTTCCGCTCATTGGCCCCGATTGTATTGGAACAGGCATTGAAGGAATCGGGGACGCAGCTGCTGGAACCTTATCTCTCCTTCATCCTCTATGCGCCCCAGGAATACCTTTCCAGGGCTTATCATGATGCACCGAAATACTGTGCCACCATCGAAACGGCCCAGGTAAAAAAGGATGAAGTTGTCTTTACTGGCGAGATTCCCGCCCGCTGTATACAGGCATACCGTACTGATCTGGCCTTTTACACCAACGGGCGGAGCGTATGCCTTACAGAGCTGAAAGGATATCAGGCCGCTGTCGGTCAGCCGGTCATCCAGCCCCGCCGTCCAAACAGCCGCCTGGACAAGGTGCGCCATATGTTTCAGAAGGTAATGTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7229,Drugs,MEG_7229|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,gi|168259000|gb|EU434751.1|642-2578,4
,atgaaaaaattaacacaaatgaaaaaattaacacaaatgaaaaaatatttttctttttgtcttttggggatttttattttttgtttttctcaacaaaatttaaaaagagatatcacaaagattatacaaggcaagaatgcccttgtggcggtatctgtgatgaactcaaaagggaaaacagaagtaaatattaacggaaacaaaaaagttccgatgcttagtgtgttcaaatttcacattgcattggcagttttggatttggtggacagaggtattttggatttggaacaaaatatttttgtcaagaaatcagaacttttggagaatacttggagccccattcgtgataaatatccgaatggcaatgtgaatatccctttgagagaaatcatagaacacactgtttctcagagtgataacaatggttgtgacattctgctgaggttgattggaggagttgatactgtccagaaattcatcgagagcaagggtatcaaagattttgcgataaaatacaatgaagaagaaatgaataagaatgggaaatccatctactcaaactatacaaccgcaaacgcctccagcaggcttctgcaaaaattttataatggtgagataatttccgagtcttccagagattttctattcagaatcatgtatgagacttctactggagcagacaggctcatatccctgcttcctccagatgttatcgttgcccataaaacagggacttctggcattgtatctggaattcaggctgctaccaatgatgtgggaatcatcattttacctgatgacgaatactacaccatatctgtttttgtgataaattccaaagaaaatacatcaactaacgaaaaaataattgctgatatatcaaaaacagtgtgggattattattttcaaaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2137,Drugs,MEG_2137|Drugs|betalactams|Class_A_betalactamases|CSP,1028104601|WP_063859920.1|NG_048896|1|1|blaCSP-1|blaCSP|class_A_extended-spectrum_beta-lactamase_CSP-1 NG_048896:101-1018,0
,GGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAGAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2229,Drugs,MEG_2229|Drugs|betalactams|Class_A_betalactamases|CTX,Bla|CTX-M-107|JF274244|1-864|864|betalactams|Class_A_betalactamases|CTX,0
,atgaataaatttgcgatcaccgctttaacgatcaccgccctagatgctatggggatcggcttgatcatgcctgtattgcctacattgttacgtgaatacgtgtcggctgaaaatttagcaaatcattacggtatcctgctggcactgtatgccatcatgcaggttttttttgctcctctacttggcaaatggtctgataaattcgggcgccgaccaatattactactatctcttgcaggcgctgctgtggattacactttgcttgcattatctagctcactttggatgctatacgttgggcgattaatttctggagttactggcgcaacaggtgcggtcgccgcttctgttattgctgacaatactgcttcacaagagcgtactaagtggtttggacgcttaggggcggcttttggtgtcgggttaatctctggccctgcaattggcggctttacagggcaattctcagctcatcttccttttattattgctgccattttaaatgcgctctcttttttagttattatgttgatatttaaagataataaaatcaaaaatactgaaaaaaacaccacagaaacagcagaaaattcgcgacctttcctgcaagtgatcaagccagtcatactattgttatttatcttttttatgactcaaatgatagggcaaattccagcaacgacatgggtgttatttacggaacatcgttttcaatggggcagtatggagatcggcctatctttagcggggttaggcatcatgcatgccttgttccaagcatttgtagcgggcgcaatcgccaagaaattcaatgaaaaagtgacgattattgtgggctttgttgttgatggagcagcattcattattttgtcattattgacaaagggttggatgatttaccctacattaatcttactcgccggcggcagtattgcgctaccagccttacaggggttaatgtcagctcaagtcaatcaaactaaccaaggtaagctacaaggcgttctagtcagcttaaccaatacgacgggggtgatcggcccattattatttagctttatttttggtcaaacactggcaagttgggatggctggatatggatgattggtgcgataatgtatgttttattgattgtatttattttatctttttatagaagcaccaaaaagatagttaaaatagcgaagctaccagcgagctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7012,Drugs,MEG_7012|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET59,446954423|WP_001031679.1|NG_048313|1|1|tetA(D)|tetA(D)|Tet(D)-related_tetracycline_efflux_MFS_transporter NG_048313:101-1303,4
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattggcatccagacagccgagatcatcaactcagggggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_875,Drugs,MEG_875|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502219|WP_071846369.1|NG_052496|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052496:101-892,2
,atgttcaaaacgacgctctgcgccttattaattaccgcctcttgctccacatttgctgcccctcaacaaatcaacgatattgtgcatcgcacaattaccccgcttatagagcaacaaaagatccccggtatggcggtggcggtaatttatcagggtaaaccttattactttacctggggctatgcggacatcgccaaaaagcagcccgtcacacagcaaacgttgtttgagttaggttcggtcagcaaaacatttacgggcgtgcttggtggcgacgctattgctcgaggggaaatcaagttaagcgatcccgcaacaaaatactggcctgaacttaccgctaaacagtggaatgggatcacactattacatcttgcgacctacaccgctggcggcctgccattgcaggtgccggatgaagtgaaatcctcaagcgacttgctgcgcttctatcaaaactggcagcctgcatgggctccaggaacacaacgtctgtatgccaactccagtatcggtttgttcggcgcactggctgtgaagccgtctggtttgagttttgagcaggcgatgcaaactcgtgtcttccagccactcaaactcaaccatacgtggattaatgtacctcccccagaagaaaagaattacgcctggggatatcgcgaaggtaaggcagtgcatgtttcgccaggggcgttagatgctgaagcttatggtgtgaagtcgaccattgaagatatggcccgctgggtacgaagcaatatgaatccccgtgatatcaacgacaaaacacttcagcaagggatacaactggcacaatctcgctactggcaaaccggcgatatgtatcagggcctgggctgggaaatgctggactggccggtaaatcctgacagcatcattaacggctgtggcaataaaattgcactggcagcacaccctgtaaaagcgattacgcccccaactcctgcagtacgcgcatcatgggtacataaaacaggggcaaccggcggatttggtagctatgtcgcgtttattccagaaaaagagctgggtatagtgatgctggctaacaaaaactatcccaatccagcgagagtcgccgccgcctggcagattctcaacgctctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1283,Drugs,MEG_1283|Drugs|betalactams|Class_C_betalactamases|BLAEC,1028105063|WP_063860248.1|NG_049082|1|1|blaEC-16|blaEC|class_C_extended-spectrum_beta-lactamase_EC-16 NG_049082:101-1234,0
,ATGGGTCCGAATCCTATGAAAATGTATCCTATAGAAGGAAACAAATCAGTACAATTTATCAAACCTATTTTAGAAAAATTAGAAAATGTTGAGGTTGGAGAATACTCATATTATGATTCTAAGAATGGAGAAACTTTTGATAAGCAAATTTTATATCATTATCCAATCTTAAACGATAAGTTAAAAATAGGTAAATTTTGCTCAATAGGACCAGGTGTAACTATTATTATGAATGGAGCAAATCATAGAATGGATGGCTCAACATATCCATTTAATTTATTTGGTAATGGATGGGAGAAACATATGCCAAAATTAGATCAACTACCTATTAAGGGGGATACAATAATAGGTAATGATGTATGGATAGGAAAAGATGTTGTAATTATGCCAGGAGTAAAAATCGGGGATGGTGCAATAGTAGCTGCTAATTCTGTTGTTGTAAAAGATATAGCGCCATACATGTTAGCTGGAGGAAATCCTGCTAACGAAATAAAACAAAGATTTGATCAAGATACAATAAATCAGCTGCTTGATATAAAATGGTGGAATTGGCCAATAGACATTATTAATGAGAATATAGATAAAATTCTTGATAATAGCATCATTAGAGAAGTCATATGGAAAAAATGA,streptogramin inactivation enzyme,antibiotic inactivation,MLS,MEG_7624,Drugs,MEG_7624|Drugs|MLS|Streptogramin_A_O-acetyltransferase|VATD,(MLS)VatD:L12033:162-791:630,7
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGACATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCGCCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1364,Drugs,MEG_1364|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_33_JIXQ01000012,0
,atgttcaagcatctgattttattcgcatcgctggccgcaccgctgacccaggccgttgcggcggacccgctctccgtcgccgccgacaagctggccaaactggaacgggattttggcggcagcatcggcgtctacgccatcgacaccggctccggcgccaccgtggccaaccgtcccaacgaacgctttcccctgtgcagctctttcaaaggctttctggcggcgggagtgctggcgcaaagccaagaaaaacccggcctgctggacaaacgcatccgctacagcaagacggctctgcctaattggtccccgattaccaccaaacaccaggcaagcggcatgaccgtggccgagctcaacgccgcctccgtgcaatacagcgacaacggcgcggccaatctgctgctcaaggaaatcaacggccccgccgcgctgaccgccttcatgcgctccatcggcgacgccagcttccgcctggaccgcctggagccggaactgaactccgccgtccccggcgacccgcgcgacacctccacgcccaaagcggtggcggaaagcgcgcaaaaactggcgctgggcaaggcgctgccggaaccgcaacgccaacagctggcggactggctgaagggcaacaccaccggcaacgccagaatccgcgccgcggtgccggccggctgggaagtgggggacaaaaccggcacttgcggcgtttacggcaccgccaacgacttcgcggtgatctggccgcccaagcgcgcgcccatcgtgctggcggtctacaccaagcacgccaagaaagaagccaagcacagcgacgaagtgatcgccgccgcggcgcgggcggcgctggaagcctttaacgtgaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2130,Drugs,MEG_2130|Drugs|betalactams|Class_A_betalactamases|CRH,1391852865|WP_109545050.1|NG_057456|1|1|blaCRH-2|blaCRH|carbapenem-hydrolyzing_class_A_beta-lactamase_CRH-2 NG_057456:1-873,0
,ATGACTAAAACAAAAATTATGGGCATATTAAACGTCACACCTGATTCATTATCAGATGGTGGAAAATTTAATAATGTTGAATCAGCTATAAATAGAGTGAAAGCCATGATAGATGAAGGTGCTGACATTATAGATGTTGGAGGTGTTTCAACGAGACCCGGTCATGAAATGGTTTCATTAGAAGAAGAGATGAACAGAGTATTACCTGTTGTTGAAGCTATTGTCGGTTTTGATGTAAAAATTTCAGTCGATACATTTCGAAGTGAGGTTGCTGAAGCATGTTTAAAATTAGGCGTTGATATGATTAATGATCAATGGGCGGGTCTGTATGATCATCGTATGTTCCAAATTGTAGCTAAATATGACGCGGAAATTATTTTAATGCATAATGGAAATGGTAATCGTGATGAACCGGTTGTCGAAGAAATGTTAACATCTTTGTTAGCACAAGCACATCAAGCTAAAATAGCTGGTATACCTTCAAATAAAATTTGGCTAGATCCAGGTATAGGTTTCGCTAAAACTAGAAATGAAGAAGCCGAAGTTATGGCAAGACTGGATGAACTTGTTGCAACAGAATATCCAGTTTTATTAGCGACAAGCCGGAAACGTTTCACTAAAAAGATGATGGGTTATGATACAACACCGGTTGAAAGAGATGAAGTAACTGCAGCTACGACTGCATATGGTATTATGAAAGGCGTTAGAGCAGTACGCGTTCATAATGTCGAGTTGAATGCTAAATTAGCTAAAGGTATAGATTTTTTAAAGGAGAATGAAAATGCAAGACACAATCTTTCTTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2950,Drugs,MEG_2950|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|675300911|gb|CP007499.1|570413-571216 gi|150373012|dbj|AP009351.1|541867-542670,8
,atggacgccccgatcccgaccccggccccgatcgacctcgacacgtggccgcgccggcagcacttcgaccactaccgccggcgcgtcccgtgcacgtacgcgatgacggtggaggtggacgtcaccatcttcgccgcggccctgcgccgctcaccgcgcaagtcgtacctcgcccaggtctgggcgctcgccacggtcgtcaaccggcacgaagagttcaggatgtgcctcaccgattcgggcgacccggccgtctggccggtcgtgcaccccgccttcacggtcttcaacccggagcgcgagaccttcgcctgcgtgtgggccccctacgaccccgacttcggcaccttccacgacacggcggcccccctcctcgccgagcacagccgcgccaccgacttcttcccgcagggggacccgccccccaacaccttcgacgtgtcgagccttccgtgggcctccttcaccggcttcaccctcaacatccgcgacggctgggaccacctcgcccccatcttcaccctcggccgctacaccgaacgcgaaggccgcctcctgctccccctctccgtacagatccaccacgccgccgccgacggcttccacacagcccgcctcaccaacgacctccaaaccctgctcgccgccccgacctggctgtga,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1577,Drugs,MEG_1577|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,1028084244|WP_063843212.1|NG_047581|1|1|catA5|catA5|type_A-5_chloramphenicol_O-acetyltransferase NG_047581:101-763,6
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgaaactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_902,Drugs,MEG_902|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502135|WP_071846287.1|NG_052334|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052334:95-883,2
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6490,Drugs,MEG_6490|Drugs|betalactams|Class_A_betalactamases|SHV,gi|77702549|gb|DQ219475.1|1-861,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGACCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6596,Drugs,MEG_6596|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|68262569|emb|AM040449.1|3369-4208,8
,atgcgatttaaaaaaatttcttacttacttttaccttctctttttatttttaatacctcaatttatgcgggcaatacttctaaagaccaagaaattaaacaattgatagatcaaaattttaaacccttattagaaaaatataatgtaccgggtatggcggtaggtattattcaaaacaataaaaaatatgaaacgtattatggcctacaatccgttcaagataaaaaagctgtaaatagcaataccatttttgagctaggttctgtcagtaagttatttactgcgacggcaggtgcttatgcaaaaaatacaggaaaaatctcttttgatgatacgccgggcaaatactggaaagagctaaaaaatacaccgattaaccaagttaacttacttcaactcgcgacgtatacaagtggtaacctcgctttgcaattccccgatgaagtacaaacagatcaacaggttttaactttttttaaagattggaaacctaaaaacccaatcggtgaatatagacaatattcaaacccaagtattggcctatttggggaaatagttggtttatcaatgaagcagccttttagtcaggtcttggaaaaaacgatttttccggaccttggcttaaaacatagctatgtcaatgtgcctaaaactcagatgcaaaactatgcatttggttataaccaagaaaatcagccaattcgagttaaccctggcccactcgatgccccagcatacggcgtcaaatcgaccctacccgatatgctgagctttattcatgccaacctgaatccacagaaatatccggcaaatattcaacgggcaattaatgaaacacatcagggtcactatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaatgttacaaactttactagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacgtatgtggtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcgtatacagttttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_522,Drugs,MEG_522|Drugs|betalactams|Class_C_betalactamases|ADC,488055190|WP_002126587.1|NG_064678|1|1|blaADC-120|blaADC|class_C_beta-lactamase_ADC-120 NG_064678:101-1252,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6440,Drugs,MEG_6440|Drugs|betalactams|Class_A_betalactamases|SHV,gi|257043771|gb|GQ407127.1|1-861,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcacgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcaacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5494,Drugs,MEG_5494|Drugs|betalactams|Class_C_betalactamases|PDC,1226997329|WP_094009806.1|NG_055482|1|1|blaPDC-118|blaPDC|class_C_beta-lactamase_PDC-118 NG_055482:1-1194,0
,TATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6904,Drugs,MEG_6904|Drugs|betalactams|Class_A_betalactamases|TEM,gi|296955|emb|X65254.1|175-1044,0
,atggaaaatttagcagtaaatataacaaatctacaagtcagctttggcaaccagctagaactatctattgattctcttcgtgtctatcagcaagatcgtatagggatcataggagaaaatggtgtcggtaaatcgactttgctcaaactaatagccggtgaactttttcccgatcatgggaaaatccaaacagagatcaccttcaactacctgcctcaattaacctatctcgctgaagcaaaggacctaaatttggaattagccagtcatttccagttaagactggaagaaacttcagagcggaaatggagcggaggggaagaacgaaagatcgagttgatacgtcttctttcttcttatgaacaagggatgcttctagacgagccaacaacccatctagatagaaaaagtattgatcgactgattgaagagcttcgttattattatggtacgctggtttttgttagtcatgatcgctattttctagatgagctagcatcgaaaatctgggaagtaaaagacggagaaatccgagagttttcggggaattatagtgcctatctcactcaaaaggaattggagaaaaagactcagctacgagaagcagagtcgatcatgaaagagaaaaaacgattggaaaaatcgatccaagaaaagaaaaaacaagcggaaaagttggaaaaagtgtccagtaaaaagaaaaagcaacaaatcagaccggatcggttgtcttcctctaaacaaaaagacagtgtacaaaaagccatccaaaagaatgcgaaaacattagagagaagactccaaaaaataggagaaacaaccaagccgcagcagatgaaacaaatccgttttccagtaccaaaatctcttgaactccacagccgctatcccatcatgggacaaaatgtccaattggaaagaagtgggagaacattactggtaaatggtgattttcagttttctttaggtaaaaaaatcgcgattgtcggtgaaaatggttcaggtaagacaaccttattggaacatatccgcaaacaaggagaaggaatccttctctctccgaaagtaagctttcaagtctatcagcaaaaggattatcaaatgacatctgaagaatccgtcattcgttttgtcatgagacaaacagagttttcggaatcgcttgtccgcagtttgctgaatcacttagggtttgctcaggaaactctggcgaaaccgttgtgtacgttaagtgggggagaagcgacccgtttgatgattgctttgctttttactaagccaagtaatgtgttgctgttagatgaaccgactaatttcattgatatggcaacgatcgaagctttagagaagctgatgcaagtatatccgggaacgattttgtttacttctcatgattcttactttgtcgagcgtacggctgatgaagtttatgaaataaaagggcagaaaataaaaaaagtacttacgagaaatttttaa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_4071,Drugs,MEG_4071|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|MSRC,1028097652|WP_063854349.1|NG_048003|1|1|msr(C)|msr(C)|ABC-F_type_ribosomal_protection_protein_Msr(C) NG_048003:101-1579,7
,GGAGTTTGTTTTGGACTATTCAATATGCGATATAGCGGAATCAAATGAATTAATCCTTGAAGCAGCAAAAATACTTAGGAAAAGCTTTCTTGATGCTGGAAATGAATCATGGGTAGATATCAAAAAGGCTATTGAAGAAGTTGAGGATTGTATAGAACACCCAAATCTATGCTTGGGAATATGTCTGGATGATAAACTGATTGGCTGGACCGGATTAAGGCCGATGTACGATAAGACCTGGGAACTTCATCCCATGGTTATAAAAACTGAGTATCAATGCAGGGGTATTGGGAAAGTCTTAATAAAAGAACTAGAGAAGAGAGCGAAGGGTAGGGGAATTATCGGAATAGCTCTTGGAACTGATGATGAATATCAGAAAACTAGTTTGTCTATGATTGATATAAACGAACGAAACATCTTCGATGAAATCGGGAACATAAAGAACGTTACTAATCATCCATATGAGTTTTATAAGAAATGTGGTTATATGATCGTTGGAATAATCCCTAATGCTAATGGAAAAAGAAAACCAGATATTTGGATGTGGAAAGATATTAGCTAG,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_338,Drugs,MEG_338|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|184216053|gb|EU622037.1|203-764 gi|695198413|ref|NG_034972.1|117-678,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctattcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcgaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5452,Drugs,MEG_5452|Drugs|betalactams|Class_C_betalactamases|PDC,1028110216|WP_063864586.1|NG_049951|1|1|blaPDC-94|blaPDC|class_C_beta-lactamase_PDC-94 NG_049951:1-1194,0
,atgaacattaaagcactcttatttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctgatgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4493,Drugs,MEG_4493|Drugs|betalactams|Class_D_betalactamases|OXA,1509794596|WP_122630905.1|NG_062325|1|1|blaOXA-703|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-703 NG_062325:17-841,0
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccccgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatgtggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatactggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcaccttcttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgcttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgccgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2914,Drugs,MEG_2914|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,1028086699|WP_063845073.1|NG_047868|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047868:66-1280,6
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctggacgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgatatggacagcggcaaactcaacaaaaatgccacagcgagaatcaatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgtatcgaacacgcttgtgaagccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacactgtttttgcgctctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattcgctcatgcgctctgttctaccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatttggaaagacaactacaagccggtttacattagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1500,Drugs,MEG_1500|Drugs|betalactams|Class_A_betalactamases|CARB,647520419|WP_025816575.1|NG_048743|1|1|blaCARB-40|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-40 NG_048743:1-852,0
,atgaacaaagtaaatataaaagatagtcaaaattttattacttcaaaatatcacatagaaaaaataatgaattgcataagtttagatgaaaaagataacatctttgaaataggtgcagggaaaggtcattttactgctgaattggtaaagagatgtaattttgttacggcgatagaaattgattctaaattatgtgaggtaactcgtaataagctcttaaattatcctaactatcaaatagtaaatgatgatatactaaaatttacatttcctagccacaatccatataaaatatttggcagcataccttacaacataagcacaaatataattcgaaaaattgtttttgaaagttcagccccaataagttatttaatagtagaatatggttttgctaaaatgttattagatacaaacagatcactagcattgctgttaatggcagaggtagatatttctatattagcaaaaattcccaggtattatttccatccaaaacctaaagtggatagcgcattaattgtattaaaaagaaagccagcaaaaatggcatttaaagagagaaaaaaatatgaaacttttgtaatgaaatgggttaacaaagagtatgaaaaactgtttacaaaaaatcaatttaataaagctttaaaatatgcgagaatatatgatataaacaatattagtttcgaacaatttgtatcgctatttaatagttataaaatatttaacggctaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2835,Drugs,MEG_2835|Drugs|MLS|23S_rRNA_methyltransferases|ERMG,1028086417|WP_063844791.1|NG_047829|1|1|erm(G)|erm(G)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(G) NG_047829:101-835,7
,atgaaaaataaagctttagcaattttaattatatgtatttgccttttaatagcatataattttgtgaaaaaagatgaagttgataaaatatttgatgctattgaattaagggattcggaatatctgaatgaacatgcgacattcttatctaaaagtctttacgacaaagatcagagatataaaaggatggataagattgatgcttctcttggtattaaagaagtgaaagttagtaatgtacgactcgtgcaaaagaaaaaaaataaacgtcaatatagtgcaaatttaaattttagaactaaatatggtaatttttctagagaagggaactattcttttgaaaaggatgaaataacaaaaaattggtttttggattggtcacctgaggttataataccgggattgactgatagaaatcaaatcagtatagaaaccttggaatctttcagagggaaaatactagacagaaacgggattgatatagcgaaagacggaattcattacgaagttggaatagatattaaaaatttaaataaaaaaaataagaaaaatatttcaaaattgttatcaataagtgaatcgacactaaataaaaaattaaaacaaacatgggtaaaagaaggtgtttttgtacctttaaaatcgtacatagagttggatgatgaacttaaattgggtatccaaaaatatcatttgacggttaatcaaacaaaaggtagggtttatccattaagagaagcaacagtacatcttttagggtatgttggagaaattaatgctgaagaattaaagaataaaaagtttaaggattatgatgaacactcaatcgtaggaaaaagtggtatcgaactacaatatgataaacaattgcaaaataaagatggttataaagttgtcatgactagtgatgatgcattaaataatgatgaagatgtcttgttagaaaagaaaccaaaaaatggacaggacattatattaacaattgatagcaaagtacaaagaagtatatatagtcatttaaaagaagataatggttcaggagtagccatgaatcctaaaactggtgaattattagctttagttagttatcctgcatatgacccctatgagtttatgttcggcatttccgacgaaaactacaaaaagatagttaatgataagaaagagcccctgttaaataaatttcagacaacctcttccccaggatctactcagaaattaataacatctatcatagggttgaaaaatgggactatagacgcatcaaccaactacaacatagtaactaagggatggcagagaaatgcttcatggggaggatatgaagttacaaggtttgaggaagttaatggagatattgatttagaaaaagcgatagcacattctgataatatattttttgcaagagctaccctcgatatgggttccgaaaaatttattaagggcatgaaagctttagacattgggagaaatattccttctgattattattttcaaaaaggacaaattgcaaatccagaaagtttaaaaaacaatttaaaaaatgaaatattactagctgattcaggatatggccagggagaaatacttataagtccagtacaaatattatctatttatagtgctttaattaatgaaggtaaaatgatgaaacctaaattatttgaaacaacaaaagaagacatttggaaaaatcatattatttcaaaagatgacgtagatatattaacaagaagcatgagaaaagtagttactgggacacatagattggatgcagaaagaaattatgcacagtttgctggaaaaactggcactgcagaattgaaaacctctagagaagaggggttaggagctcaaatcggttggtttgttggatatgatcaaaataatcccaatatgatgttaggtataagtgtgaagaatgtagagaatagaggtatgtcgagttataatgcaagaaagtttgccgagataatggatgaattatatgaaaatggaaataaaaaatatgaaatagataggtga,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3795,Drugs,MEG_3795|Drugs|betalactams|Penicillin_binding_protein|MECB,1028095822|WP_063852710.1|NG_047954|1|1|mecB|mecB|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB NG_047954:101-2125,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCGCCCTGCCGCTGGTGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCGTGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGCGTGGCCGCGCGTTATCCGGCCCGCAGCACCTCGCAGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAAAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6454,Drugs,MEG_6454|Drugs|betalactams|Class_A_betalactamases|SHV,gi|338173764|gb|HQ661362.1|72-1011,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGCATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGCATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGCGTGGCCGCGCGTTATCCGGCCCGCAGCACCTCGCAGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAAAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6455,Drugs,MEG_6455|Drugs|betalactams|Class_A_betalactamases|SHV,gi|338173766|gb|HQ661363.1|72-1011,0
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGCTGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTAGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6932,Drugs,MEG_6932|Drugs|betalactams|Class_A_betalactamases|TEM,gi|6176547|gb|AF190695.1|AF190695|1-1103 gi|961666360|gb|KT185451.1|87734-87690,0
,atgttgaaaagttcgtggcgtaaaagcgccctgatggccgccgccgttccgctactgctggcgagcggttcattatgggccagtgccgatactctccagcagaagctggctgatttagaaaaacgttccggcggtcggctgggcgtggcgctgattaacacggcagatgattcgcagaccctctatcgcggcgacgaacgttttgccatgtgcagcaccggtaaagtgatggccgccgccgcggtgttaaaacagagcgaaagccatcccgatgtggtgaataaaaggctggagattaaaaaatcggatttagtggtctggagcccgattaccgaaaaacatctgcaaagcggaatgaccctggcggaactcagcgctgcggcgctgcagtatagcgacaataccgcgatgaataagattatcggttaccttggcgggccggaaaaagtcaccgcattcgcccagagcatcggtgacgttacttttcgtctcgatcggatggagccggcgctgaacagcgcgattcccggtgataagcgcgataccaccaccccattggcgatggccgaaagtctgcgtaagctgacgctgggcaatgcgctgggcgaacagcagcgcgcccagttagtgacatggctgaaaggcaataccaccggcgggcaaagcattcgtgcaggcctgcccgcaagctgggcggtcggggataaaaccggcggcggagattacggcaccaccaacgatatcgcggtgatctggccggaaaatcatgctccgctggtgctagtgacctattttacccaaccgcagcaggatgcgaaaagccgcaaagaggtgctagccgcggcggcgaaaatcgtgaccgaagggctgtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_5282,Drugs,MEG_5282|Drugs|betalactams|Class_A_betalactamases|OXY,490231781|WP_004130122.1|NG_050613|1|1|blaOXY-4-1|blaOXY-4|class_A_extended-spectrum_beta-lactamase_OXY-4-1 NG_050613:101-973,0
,ATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGTTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTAAGTGGTACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCAATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGTGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACACGCACCTGGTTTTGCAGCGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGCTGGAAAAGTGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTACGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGTTGCTCATGGAACGTCTTGGCATCGCGGTCATTGGTTA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6007,Drugs,MEG_6007|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,qnrB44_1_JQ349153 ,3
,ATGATGAAAAATACCCTGCGTAAAACAGCACTGATGGCGGCGGCTGTAGTGCCAATGCTCGCATTCAGTGCGGCGTCCTGGGCGCAAACAGCGACGAAAATGACGTCAGTTCAGCAACAGCTGACGGCGCTGGAAAAAGAAAGCGGCGGGCGTCTGGGCGTGATGCTGATTGATACGGCGGACAACTCGCAAATTGCTTATCGTGCGGATGAACGTTTTGCGATGTGCAGCACCAGTAAGTTCATGGCGGCTTCGGCGATCCTGAAAGAGAGTGAAGTTAAGAAGAATCTGCTTACTCAGCATGTTGCGCTGAAACAATCGGATCTGGTGAATTACAACCCGATTACCGAAAAGCATCTTAACGATGGCATGACGATTGGTGAGCTGGCCGCGGCGGCCTTGCAGTACAGTGATAACGCCGCCATGAATAAGCTTATCGAGCATCTCGGCGGGCCACATAAGGTCACGGATTATGCACGTACGCTGGGTGACAAAACGTTCCGTCTGGACCGCACCGAACCGACGCTGAACACCGCGATCCCGGGCGATGACCGTGATACCACGTCACCGCGTGCAATGGCCCTGAGCCTGCAACATGCCACGCTGGGCTCCGCGCTGGCTGAACCGCAGCGCGCACAACTGGTGGAATGGATGAAGGGTAACACCACCGGCGCGATGAGCATCCGCGCAGGTTTACCGGCGACCTGGGTTGTTGGCGATAAAACCGGCAGCGGCGATTACGGCACCACCAATGATATCGCGGTGATCTGGCCGGAAAATAAAGCGCCGCTGGTGCTGGTGACGTATTTCACCCAACCGGAAAAAGATGCAAAATCCCGTCGTGATGTGCTGGCAAGTGCGGCGAAGATTGTGACGCAGGGTTATTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6043,Drugs,MEG_6043|Drugs|betalactams|Class_A_betalactamases|RAHN,gi|308390286|gb|GU645205.1|966-1853 gi|295822230|gb|GU584924.1|1-655 gi|557668350|gb|KF484007.1|1-477,0
,ATGATGAAAAAATCCCTTTGCTGCGCCCTGCTGCTGGGCCTCTCTTGCTCTGCTCTCGCCGCGCCAGTATCAGAAAAACAGCTGGCGGAGGTGGTCGCGAATACGGTTACCCCGCTGATGAAAGCCCAGTCTGTTCCAGGCATGGCGGTGGCCGTTATTTATCAGGGAAAATCGCACTATTACACGTTTGGCAAGGCCGATATCGCGGCGAATAAACCCGTTACGCCTCAGACCCTGTTCGAGCTGGGTTCTATAAGTAAAACCTTCACCGGCGTTTTAGGTGGGGATGCCATTGCTCGCGGTGAAATTTCGCTGGACGATCCGGTGACCAGATACTGGCCACAGCTGACGGGCAAGCAGTGGCAGGGTATTCGTATGCTGGATCTCGCCACCTACACCGCTGGCGGCCTGCCGCTACAGGTACCGGATGAGGTCACGGATAACGCCTCCCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCTGGCACAACGCGTCTTTACGCCAACGCCAGCATCGGTCTTTTTGGTGCGCTGGCGGTCAAACCTTCTGGCATGCCCTATGAGCAGGCCATGACGACGCGGGTCCTTAAGCCGCTCAAGCTGGACCATACCTGGATTAACGTTCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGCTATCGTGACGGTAAAGCGGTGCGCGTTTCGCCGGGAATGCTGGATGCACAAGCCTATGGCGTGAAAACCAACGTGCAGGATATGGCGAACTGGGTCATGGCAAACATGGCGCCGGAGAAGGTTGCCGATGCCTCACTTAAGCAGGGCATCGCGCTGGCGCAGTCGCGCTACTGGCGTATCGGGTCAATGTATCAGGGTCTGGGCTGGGAGATGCTCAACTGGCCCGTGGAGGCCAACACGGTGGTCGAAGGCAGCGACAGTAAGGTAGCGCTGGCGCCGTTACCCGTGGCAGAAGTGAATCCACCGGCTCCCCCGGTCAAAGCGTCCTGGGTCCATAAAACGGGTTCTACCGGCGGGTTTGGCAGCTACGTGGCCTTTATTCCTGAAAAGCAGATCGGTATTGTGATGCTCGCGAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCATATCCTCGAGGCGCTACA,beta-lactamase,antibiotic inactivation,betalactams,MEG_484,Drugs,MEG_484|Drugs|betalactams|Class_C_betalactamases|ACT,gi|397174612|dbj|AB737978.1|1-1142,0
,gtggtgaaattcttgggtgccgtccccgtgctgaccgccgtggacgttccggcgaacgtctccttctgggtggacaccctcggcttcgagaaggatttcggggaccgggatttcgcgggggtccgccgcggtgacgtccggctccacatcagccggacggagcaccagatcgtcgccgacaacacctccgcctggatcgaggtcaccgaccccgacgcgctccacgaggaatgggcccgggcggtctccaccgattacgcggacacctcgggcccggccatgacgcccgtgggggagtcgcccgcgggacgggagttcgccgtccgggaccccgcggggaactgcgtccacttcaccgcgggggagtga,beta-lactamase,antibiotic inactivation,Glycopeptides,MEG_1462,Drugs,MEG_1462|Drugs|Glycopeptides|Bleomycin_resistance_protein|BLM,1114603964|WP_072081991.1|NG_052580|1|1|blmA|blmA|bleomycin_binding_protein_BLMA NG_052580:101-469,5
,atgttcaaacttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggagcgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcactcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7709,Drugs,MEG_7709|Drugs|betalactams|Class_B_betalactamases|VIM,1028110987|WP_063865199.1|NG_050378|1|1|blaVIM-50|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-50 NG_050378:1-801,0
,ATGGCAGAAACACCAAATCAACGAATAACAGAGATAAACTTAAATAAAGAAATGCGGACATCATTCCTAGACTATGCGATGAGTGTAATTGTTGCCCGTGCCCTACCTGATGTTCGTGACGGGTTAAAACCAGTTCACCGTCGTATTCTATATGCGATGAATGACTTAGGTATGACTTCTGATAAAGCCTATAAAAAATCGGCTCGTATCGTTGGTGAAGTAATTGGTAAGTATCACCCCCACGGCGATACAGCGGTTTATTTTACAATGGTTCGTATGGCGCAAGATTTTAGTTATCGTAATATGCTAGTTGATGGACATGGTAACTTTGGTTCGGTCGATGGCGATATGGCGGCAGCGATGCGTTATACAGAAGCACGTATGTCAAAAATTTCGATGGAACTACTGCGCGATATTAATAAAGACACAATTGATTACGCTGATAACTACGATGGTTCTGAACGTGAGCCAGTTATTTTACCAGCGCGTTTCCCTAACTTATTAGTCAATGGTTCGTCAGGTATCGCGGTTGGTATGGCAACAAATATTCCTACCCACCATCTTGGTGAAGTAATTGACGGCGTTTTAGCACTTAGTCACGATCCAGAAATTACTATTCGTGATTTAATGGAATATATTCCAGGCCCTGACTTCCCAACTGCTGGGATGATTATGGGACGTAGCGGAATCCGTCGCGCTTACGAAAGTGGCCGTGGTTCGATTACTGTTCGTGGTCGTGTCGATATTGAAGAAAAGAAAAATGGTAAAGAAACTATCGTTATTACCGAAATTCCTTACCAAGTGAATAAAGCACGCCTAGTTGAACGTATTGCCGAACTAGCTCGTGAGAAGAAAATCGACGGCATCACTTCCCTAAATGATGAGTCTGACCGTTCAGGAATGCGGATTGTTATTGAGGTTCGTCGTGATATTAGCGCCAGTGTTATCGTGAATAATTTATTCAAAATGACAGCACTTCAAACTACTTTTGGTATTAATATGCTTGCACTTGTCGATAACCATCCAAAAGTGCTTAATTTAAAAGAAATTCTTTATTATTATTTGGAACATCAAAAAGTAGTTATTCGTCGACGTACAGAATTTGAGCTTCGTAAAGCAGAAGCACGCGCACATATTTTAGAAGGTTTACGAATCGCTCTTGATAACATTGACGCGATTATTAAATTAATTCGTGGATCAAAAACTTCCGATGTTGCTAAAGAAGGCTTGATGACACAATTCAACCTTTCTGACAAACAAGCGCAAGCCATTCTGGACATGCGTTTGCAACGTTTAACAGGTTTAGAACGCGAAAAAATTGAAGAAGAATATCAAAACTTAGTAGCATTAATTAATGATTTAAAAGCTATTTTAGCTGATGATGAGCGTATTCTTGAAATTATTCGTGAAGAATTAGAAGAAATCAAAGTTAAATATGCGGATAAACGTCGTACAGAAATCTTGGCTGGTGATTTAGTAAGCCTTGAAGATGAAGACTTAATCCCTGAAGAAGAAGTAGCAATTACGCTAACTAAACGTGGTTATATTAAACGTTTACCACTGTCGACTTATCGTAGTCAGCGTCGAGGTGGTCGTGGTATTCAAGGTATGTCAACACATGAAGATGACTTCGTAGAACACCTAGTTGCAACGAGCACGCATGATACGTTACTATTCTTCACTAACACTGGTAAAGTTTACCGTTCGAAAGGTTATGAAGTACCTGAATACGGTCGTACCGCCAAAGGTATCCCAATAATCAACTTACTTGGAATCGAAAGCCAAGAACAAGTGAATGCCGTGATAAATCTATCCGAATTCACCGATGATAGCTACCTATTCTTCACGACGAAACATGGTGTCGTGAAGCGTACAACCCTTTCTCAATTTGCGAAAATCCGTCAAAGTGGCCTTCGTGCTGTAGAACTTCGTGAAAACGATGAACTCATTTCTGTTCAAATGACAGATGGTAGCAAAAACATGATTATCGCAACGAAACATGGTCAATCTATCTACTTCCCAGAAGAAAATATCCGTGTAATGGGCCGTACAGCTGCTGGTGTTCGTGGTATTAGACTTCGTGAAGACGATGAAGTTATCGGCATGGAAGTACTGGAGGACGATGAAAAAGTACTCGTTGTAACGGAAAAAGGTTATGGTAAACAAACGCCAGCCTCCCAATATCCGCTTCGTAATCGTGGTGGTATGGGTGTTAAAACCGTTACAATCACAGAGAAAAATGGTAACTTAGTAGCAATGAAAACTGTTACTGGTGAAGAGGACTTAATGCTAATGACAGTAAGTGGCGTATTAATTCGTTTCGAAATTGATACAGTATCACAAACTGGTCGTAGCGCAATGGGTGTTAAACTAATTCGTCTTGATGAAGATGAAAAAGTAGCCACTGTTGCAAAAGTACCAAAAGAAGAAGATGAAGTTGAGCTTGAGGAAGAAATCGACGAAACATTAATCACGCAAGTTCCTGATGAAAGTTTTGAAGATGCTCCTGGAAGCGACATAGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3214,Drugs,MEG_3214|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|584269433|emb|HG813249.1|287133-289661 gi|441472679|emb|HE999705.1|8065-10593 gi|441469547|emb|HE999704.1|8065-10593,3
,atgtttaagattaaagttgcagttctgtttgggggctgttcagaggaacataatgtttcgataaaatctgcgatggagattgccgcaaacatagatacaaaaaagtatcagccttattatattggaatcacaaaatccggcgtttggaaaatgtgtgaaaaaccttgtttggagtgggaacaatatgcgggggatccggttgttttttcgccggacagaagtacgcatggtctgctgatacaaaaagacaaagggtatgaaatccagcctgtagacgtggtattaccgatgattcatggcaagtttggcgaagatggctccatacaaggcttgcttgaattgtcaggcattccgtatgtgggatgcgatattcaaagctccgtgacctgcatggataaggcgcttgcatataccgttgtgaaaaatgcgggtatcgctgtgcctgggttccggatccttcaggagggggatcgcctggaaacggaggatttcgtatatcccgtttttgtaaagcctgcccgttccggctcctcctttggcgtaaacaaggtatgcaaggcagaagagcttcaggcagcaatcgaagaagcaagaaaatatgacagcaagattttgattgaagaggccgttaccgggagtgaggtaggctgcgccatactgggaaacggaaatgatctcatggctggcgaggtggatcagattgagctgagacacggcttttttaagattcatcaggaagcacagccggagaagggatctgaaaatgcagtcatccgagttccagccgccttaccggatgaggtaagagaacggattcagaaaacagcaatgaagatttaccggatacttggctgcagaggattggcccgcattgacctgtttttgcgggaggacggctgcattgtgctgaatgaagtgaataccatgccgggttttacttcctacagccgctatccccgcatgatgacagcagccggttttacgcttactgaaatactggatcgcttgattgaactttcacttaggaggtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7385,Drugs,MEG_7385|Drugs|Glycopeptides|VanD-type_resistance_protein|VAND,655082057|WP_028530135.1|NG_048365|1|1|vanD|vanD|D-alanine--(R)-lactate_ligase_VanD NG_048365:101-1132,5
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattgtttcatgcacttaggaaaataggtattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgcggaaattgtaatcaaacagaaggtagaactgcatcctaatatgcgtgtaatgaactttaccgaatctgaacaatgggatatggtaatagaaggaaatgattaccttttggagaaatatacgtctgggaaattattggaagcattagaactcgaacaagaggaaagcataagatttcataattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcacaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacgactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctgcgatattatgtggattctgcgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctgctgcaagaaaagtatcatgtggagatagaaataaaagagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagttccaccgaatcctttctgggcttccattggtctatctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7107,Drugs,MEG_7107|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100223|WP_063856403.1|NG_048251|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048251:101-2020,4
,atgagccatattcaacgggaaacgtcttgctcgaggccgcgattaaattccaacatggatgctgatttatatgggtataaatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggaatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccccgggaaaacagcattccmngtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagtgttcctgcgccggttgcattcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataagcttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgagttttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctaa,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1025,Drugs,MEG_1025|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,1028082881|WP_063842148.1|NG_047437|1|1|aph(3')-Ia|aph(3')-Ia|aminoglycoside_O-phosphotransferase_APH(3')-Ia NG_047437:101-916,2
,AATTCTTGAAGACGAAAGGGCCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTCTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGCTAAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAACAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTCGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAGATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6924,Drugs,MEG_6924|Drugs|betalactams|Class_A_betalactamases|TEM,gi|48734423|gb|AY628176.1|1-936,0
,atgttcaaaacgacgctctgcgccttattaattaccgcctcttgctccacatttgccgcccctcaacaaatcaacgatattgtgcatcgcacaattaccccgcttatagagcaacaaaagatccccggtatggcggtggcggtaatttatcagggtaaaccttattactttacctggggctatgcggacatcgccaaaaagcagcccgtcacacagcaaacgttgtttgagttaggttcggtcagcaaaacatttacgggcgtgcttggtggcgacgctattgcacgaggggaaatcaagttaagcgatcccgcgacaaaatactggcctgaacttaccgctaaacaatggaatgggatcacactattacatcttgcgacctacaccgctggcggcctgccattgcaggtgccggatgacgttaaatcctcaagcgacttgctgcgcttctatcaaaactggcagcctgcatgggctccaggaacacaacgtctgtatgccaactccagtatcggtttgttcggcgcactggctgtgaagccgtctggtttgagttttgagcaggcgatgcaaactcgtgtcttccagccactcaaactcaaccatacgtggattaatgtaccgcccgcagaagaaaagaattacgcctggggatatcgcgaaggtaaggcagtgcatgtttcgccaggggcgttagatgctgaagcttatggtgtgaagtcgaccattgaagatatggcccgctgggtgcaaagcaatttaaaaccccttgatatcactgagaaaacgcttcaacaagggatacaactggcacaatctcgctactggcaaaccggcgatatgtatcagggcctgggctgggaaatgctggactggccggtaaatcctgacagcatcattaacggcagtgacaataaaattgcactggcagcacgccccgtaaaagcgattacgcccccaactcctgcagtgcgcgcatcatgggtacataaaacaggggcgaccggcggatttggtagctatgtcgcgtttattccagaaaaagagctgggtatcgtgatgctggctaacaaaaactatcccaatccagcgagagtcactgccgcctggcagattctcaacgctctacagtaa,antibiotic molecule,antibiotic inactivation,betalactams,MEG_1278,Drugs,MEG_1278|Drugs|betalactams|Class_C_betalactamases|BLAEC,1028105301|WP_063860454.1|NG_049086|1|1|blaEC-8|blaEC|cephalosporin-hydrolyzing_class_C_beta-lactamase_EC-8 NG_049086:101-1234,0
,atgtctacatacggatacggccgtcacgaacatggccaaaattttctcacagaccacaagatcatcaactccatcgtcgatcttgtaaaacaaacctccggccccatcattgagatcgggccaggaagcggtgccctcactcacccgatatcccacttggggagggcaataacggcagttgaggtagacgcaaaactagctgccaaactcacaaaaaagaccgcctcggcgtcggtcgaagtggtccatgatgatttcctcaacttcccgttacccgccactccctgcgtcattgtgggaaacattccctttcacctcaccactgccattcttcgaaagttgttgcatgcgccggcatggactgacgctgtactcctcatgcagtgggaagtcgctcgccgccgggccggggtaggtgcaagcacnatgatgacggctcagtggtccccatggttcacgtttcaccttggttcccgantaccaaggtctgctttccggccacagccaaacgttgacggggggatcttagtgatccgccgggtgggtgacccgaagatcccgatagagcaacgcaaagcctttcaggcgatggtgcacaccgttttcaccgcccggggacgcgggataggggaaattctccgaagggcagggttgttttcatcacgttcagagacacaatcatggttgcgctcgcgaggaatcgaccccgcaaccctacctcccagattgcacaccagcgactggatcgatctcttccaggtgactggttcctctccaccgcgccatcggcccatttcacaatcgggaagtagtcaacgccctcctcaacggaaaaatcgaggccggcggcggtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2856,Drugs,MEG_2856|Drugs|MLS|23S_rRNA_methyltransferases|ERMX,1028086520|WP_063844894.1|NG_047851|1|1|erm(X)|erm(X)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(X) NG_047851:101-955,7
,ATGTTTGCTGGTGCAGCAAACGCAGCTGAAATGTACAACAAAGACGGCAACAAAGTAGATATCTACGGTAAAGTTGACGTTCGTCATTACTTCGCTGATGCTGATACTAAAGGCGATCATGAAAGCGGTGACGCTTCTCGTGCACGTATCGGTTTCAAAGGCGAAACTCAAATCAATAAAGATTTAACTGGTTTCGGTCGTTTTGAATACGAAGTTAAAACAAACACTACTGAAGGCGAGAACAAAGCTAAAACTCGTCTAGCATATGCTGGTCTGAAATTTGCTGACTTCGGTTCTTTAGATTACGGTCGTAACTACGGTGTAATTTATGACACCAACGCATGGACTGACGTTCTGCCTTTATGGGGTGGTGACTCCATGGCGCAAACTGACGTTTATATGACTAGCCGTACTACTGGCGTATTAACTTACCGTAACACCGATATGTTCGGTTATGTTGATGGTTTAAGCTTTGCTCTGCAATATCAAGGCAAAAATAACGAAAACACCAACAATAAACGTAAAGACAACGCTGAAGCAAATGGCGACGGTTTTGGTTTCTCTACAGCTTATAACTTAGGCTGGGGCGTAACACTGGGTGGCGGTTACTCAAGTTCTGCTCGTACTAACTGGCAAGAACATAAGAGTGATGCTACTGGTAAACGTGCTGAAGCATGGAACGTTGGTGGTAAATTCGAAGCTAACAATGTTTACTTAGCAGCAATGTACGGTGAAACCCGTAACATGAACTACTATGGTGACGGTGCAATTGCAAACAAAACTCAAAATATCGAGTTAACTGCACAGTATGACTTTGCTGATTTAGGTATCAAACCATCTTTAGGTTATGTTCAATCTAAAGGTAAAGATCTGAATAATGGTGTTGGCGGTCTGAAAGACAACAACCATGATTTAGTTAAATATATCTCTGTAGGTTCTTTCTACAAATTTAACAAAAACATGACTGCAGTTGTTGATTACAAAATCAACCTGTTAGATGAAGATGACTTCACTAAAGCTAACGGCGTTGCAACTGACAACGTAGTTGGTTTAGGTCTGACTTATCAGTTCTAA,subunit of efflux pump conferring antibiotic resistance,reduced permeability to antibiotic,betalactams,MEG_4285,Drugs,MEG_4285|Drugs|betalactams|Mutant_porin_proteins|OMPD,gi|529186758|gb|CP004022.1|960405-959332,0
,ATGCTAAATTTAACCGTTTGTCAGGCACAGTCAAATCCAACAGACTACGCCTGTCTGACGGGCCCGGACATCCCCTTGACTCGCTATTACGGAAGATGATTGATGATGAAAAAATCCTTTTGCTGCGCCCTGCTGCTCGCCATCTCTGGCTCTGCTCTCGCCGCGCCAGTGTCAGAAAAACAGCTGGCGGAGGTGGTCGCGAATACGGTTACCCCGCTGATGAAAACCCAGGCTATTCCAGGCATGGCGGTGGCCGTTATCTATCAGGGAAAACCGCACTATTACACGTTTGGCGAAGCCGATATTGCGGCCAAAAAACCTGTTACGCCACAGACCCTGTTCGAGCTGGGTTCTATAAGTAAAACCTTCACCGGCGTTTTAGGTGGGGATGCCATTGCTCGCGGTGAAATTTCCCTGGACGATCCGGTGACCAAATTCTGGCCTGAACTGACGGGCAAGCAGTGGCAGGGTATTCGTATGCTGGATCTCGCAACCTACACCGCGGGCGGCCTGCCGCTACAGGTACCGGAAGAGGTCACGGATAACGCCTCCCTGCTGCGCTTTTATCAACACTGGCAACCGCAGTGGAAGCCTGGCACAACGCGTCTTTACGCCAATGCCAGCATCGGACTTTTTGGCGCGCTGGCGGTCAAACCTTCCGGCATGCGCTATGAGCAGGCCATGACGAAGCGGGTCTTCAAGCCGCTCAGGCTGAACCATACCTGGATTAACGTTCCGAAAGCGGAAGCGGCGCATTACGCCTGGGGTTATCGTGACGGTAAAGCGGTCCACATTTCACCGGGTATGCTGGACGCAGAGGCCTATGGCGTGAAAACTAACGTGCAGGATATGGCGAACTGGGTGATGGCGAACATGGCGCCGGAGAACATTGCTGATGCCTCACTCAAGCAGGGCATCGCGCTGGCGCAGTCGCGCTACTGGCGCATCGGGTCAATGTATCAGGGCCTGGGCTGGGAAATGCTCAACTGGCCCGTGGAGGCCAAAATGGTGATCGAGGGCAGCGACAATAAGGTGGCACTGGCGCCGTTGCCCGTGGCAGAAGTGAATCCACCGGCTCCCCCGGTCAAAGCGTCCTGGGTCCATAAAACAGGCTCTACTGGCGGGTTTGGCAGCTACGTGGCATTTATTCCTGAAAAGCAGATCGGTATTGTGATGCTCGCGAATAAAAGCTATCCGAATCCGGCACGCGTTGAGGCGGCATACCATATCCTCGACGCACTACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_495,Drugs,MEG_495|Drugs|betalactams|Class_C_betalactamases|ACT,gi|595583489|gb|KF992029.1|647-1894,0
,atggtgacggtgttcggcattctgaatctcaccgaggactccttcttcgatgagagccggcggctagaccccgccggcgctgtcaccgcggcgatcgaaatgctgcgagtcggatcagacgtcgtggatgtcggaccggccgccagccatccggacgcgaggcctgtatcgccggccgatgagatcagacgtattgcgccgctcttagacgccctgtccgatcagatgcaccgtgtttcaatcgacagcttccaaccggaaacccagcgctatgcgctcaagcgcggcgtgggctacctgaacgatatccaaggatttcctgaccctgcgctctatcccgatattgctgaggcggactgcaggctggtggttatgcactcagcgcagcgggatggcatcgccacccgcaccggtcaccttcgacccgaagacgcgctcgacgagattgtgcggttcttcgaggcgcgggtttccgccttgcgacggagcggggtcgctgccgaccggctcatcctcgatccggggatgggatttttcttgagccccgcaccggaaacatcgctgcacgtgctgtcgaaccttcaaaagctgaagtcggcgttggggcttccgctattggtctcggtgtcgcggaaatccttcttgggcgccaccgttggccttcctgtaaaggatctgggtccagcgagccttgcggcggaacttcacgcgatcggcaatggcgctgactacgtccgcacccacgcgcctggagatctgcgaagcgcaatcaccatctcggaaaccctcgcgaaatttcgcagtcgcgacgccagagaccgagggttagatcatgcctag,beta-lactamase,antibiotic target replacement,Sulfonamides,MEG_6583,Drugs,MEG_6583|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,446181177|WP_000259032.1|NG_048081|1|1|sul1|sul1|sulfonamide-resistant_dihydropteroate_synthase_Sul1 NG_048081:101-940,8
,atggctctggcactcgttggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggggcaaatttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaattccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagctttatgaatatgatcaccacgcgcacctggttttgtagcgcatatatcacgaataccaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcggatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagctggacaactaccaggcgtcgttgctcatggagcggcttggcatcgcggtgattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5914,Drugs,MEG_5914|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1049330909|WP_065825684.1|NG_051320|1|1|qnrB75|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB75 NG_051320:101-745,3
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgcttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagtcaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgataaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgtgcgggaggaacagcggcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgccgccctatgcggcagcgttttcaaggtggagtatacagattgcggccagcggcgtgtctatctacggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggacccaacccggctccctcgtaaaaggtggcgtgaggaccccctccccatgctgcggacgtcgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgctgcgaggtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccatcggactgtctgttacaccactcccgcttggctccggtgtacaatacaagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcagggacgcaactgctggaaccttatctctccttcaccctctatgcgccccgggaatatctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggtccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcagagcgtatgccttacagaactgaaagggtatcaggccgctgtcggcaagccagtcatccagccccgccgtccaaacagccgcctggacaaggtgcgccatatgttcagtaagatcacttga,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7212,Drugs,MEG_7212|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,490328320|WP_004217777.1|NG_048300|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048300:101-2020,4
,TGTCTGGTATAATAAGAATATCATCAATAAAATTGAGTGTTGCTCTGTGGATAACTTGCAGAGTTTATTAAGTATCATTGCAGCAAAGATGAAATCAATGATTTATCAAAAATGATTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGTTTCATTCTGGCGACGTCCGTATTTGCCTTTCGGAAGCATAAAATCGGACGCGTTGTGGCTCGCTTCAGGTAAAATATTGACTATTCATGTTGTTGTTATTTCGTCTCTTCCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGACGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_2414,Drugs,MEG_2414|Drugs|betalactams|Class_A_betalactamases|CTX,gi|68012687|gb|DQ061159.1|1-1225 gi|529205529|gb|KC788405.1|41529-41384 gi|529205529|gb|KC788405.1|42938-42859,0
,CAGGGAGTATTTGAGTTATTAGATATTCCATATGTAGGTTGTGGTATCGGAGCTGCAGCAATTTCCATGAATAAAATAATGCTCCATCAATTTGCTGAAATAGTTGGTGTAAAAAGCACTCCTAGTATGATTATAGAAAAGGGACAAGACCTACAAAAAGTCGATGAATTTGCGAAAATACATGGATTTCCTTTATATATCAAACCGAATGAGGCAGGCTCATCAAAAGGAATTAGCAAGGTAGAACAAAAAAGTGATTTATATAAAGCAATAGACGAAGCTTCAAAATATGATAGCCGTATTTTAATTCAAAAGGAAGTGAAAGGGGTAGAAATTGGCTGTGGGATTTTAGGGAATGAACAATTGGTCGTTGGAGAATGTGATCAAATTAGTCTTGTGGATGGCTTTTTCGACTATGAAGAGAAATACAATTTAGTAACAGCAGAAATTTTGTTACCAGCTAAACTATCAATAGACAAAAAAGAAGACATCCAGATAAAAGCAAAAAAACTATACAGACTATTAGGGTGCAAAGGATTAGCGAGAATCGACTTTTTCTTAACGGATGACGGAGAAATTTTATTAAATGAGATCAACACCCTCC,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7391,Drugs,MEG_7391|Drugs|Glycopeptides|VanE-type_resistance_protein|VANE,VanE_1_AF136925,5
,ATCCTTTTGCTCTACGGGAGCGCCGCCAAATCCTTTGTTCAAGGAGATGGTTTCGTGCGCTCAAAAAACTTTAGTTGGCGGTACTCCCTTGCCGCCACGGTGTTGTTGTTATCACCGTTCGATTTATTGGCATCACTCGGCATGGACATGTACTTGCCAGCAGTGCCGTTTATGCCAAACGCGCTTGGTACGACAGCGAGCACAATTCAGCTTACGCTGACAACGTACTTGGTCATGATTGGTGCCGGTCAGCTCTTGTTTGGACCGCTATCGGACCGACTGGGGCGCCGCCCCGTTCTACTGGGAGGTGGCCTCGCCTACGTTGTGGCGTCAATGGGCCTCGCTCTTACGTCATCGGCTGAAGTCTTTCTGGGGCTTCGGATTCTTCAGGCTTGTGGTGCCTCGGCGTGCCTTGTTTCCACATTTGCAACAGTACGTGACATTTACGCAGGTCGCGAGGAAAGTAATGTCATTTACGGCATACTCGGATCCATGCTGGCCATGGTCCCGGCGGTAGGCCCATTGCTCGGAGCGCTCGTCGACATGTGGCTTGGGTGGCGGGCTATCTTTGCGTTTCTAGGTTTGGGCATGATCGCTGCATCTGCAGCAGCGTGGCGATTCTGGCCTGAAACCCGGGTGCAACGAGTTGCGGGCTTGCAATGGTCGCAGCTGCTACTCCCCGTTAAGTGCCTGAACTTCTGGTTGTACACGTTGTGTTACGCCGCTGGAATGGGTAGCTTCTTCGTCTTTTTCTCCATTGCGCCCGGACTAATGATGGGCAGGCAAGGTGTGTCTCAGCTTGGCTTCAGCCTGCTGTTCGCCACAGTGGCAATTGCCATGGTGTTTACGGCTCGTTTTATGGGGCGTGTGATACCCAAGTGGGGCAGCCCAAGTGTCTTGCGAATGGGAATGGGATGCCTGATAGCTGGAGCAGTATTGCTTGCCATCACCGAAATATGGGCTTCGCAGTCCGTGTTAGGCTTTATTGCTCCAATGTGGCTAGTGGGTATTGGTGTCGCCACAGCGGTATCTGTGTCGCCCAATGGCGCTCTTCGAGGATTCGACCATGTTGCTGGAACGGTCACGGCAGTCTACTTCTGCTTGGGCGGTGTACTGCTAGGAAGCATCGGAACGTTGATCATTTCGCTGTTGCCGCGCAACACGGCTTGGCCGGTTGTCGTGTACTGTTTGACCCTTGCAACAGTCGTGCTCGGTCTGTCTTGTGTTTCCCGAGTGAAGGGCTCTCGCGGCCAGGGGGAGCATGATGTGGTCGCGCTACAAAGTGCGGAAAGTACATCAAATCCCAATCGTTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1772,Drugs,MEG_1772|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,gi|971497538|gb|CP012902.1|79350-78037 gi|943457735|gb|KT818627.1|94711-96024 gi|943457735|gb|KT818627.1|156304-157617 gi|969995310|gb|KT317086.1|1690-3003 gi|969995276|gb|KT317085.1|13799-15112 gi|930425888|gb|KR067579.1|227-1540 gi|884906146|gb|CP012007.1|96677-97990 gi|823683259|emb|LN831185.1|66244-67557 gi|823682865|emb|LN831184.1|249956-248643 gi|822476033|dbj|LC055503.1|101761-103074 gi|778408585|gb|CP009414.2|118874-120187,6
,ATTTTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1414,Drugs,MEG_1414|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_16_JBTH01000015,0
,atgcgcgataccagattccccagcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctatggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5616,Drugs,MEG_5616|Drugs|betalactams|Class_C_betalactamases|PDC,1408841625|WP_111672898.1|NG_060556|1|1|blaPDC-287|blaPDC|class_C_beta-lactamase_PDC-287 NG_060556:1-1194,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATATAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1418,Drugs,MEG_1418|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_55_NZ_JVLY01000044,0
,ATGAAAACATTTGCCGCATATGTAATTACTGCGTGTCTTTCGAGTACGGCATTAGTTAGTTCAATTACAGAAAATACGTTTTGGAACAAAGAGTTCTCTGCCGAAGCCGTTAATGGTGTTTTCGTGCTTTGTAAAAGTAGCAGTAAATCCTGCGCTACCAATAACTTAGCTCGTGCATCAAAGGAATATCTTCCAGCATCAACATTTAAGATCCCCAACGCAATTATCGGCCTAGAAACTGGTGTCATAAAGAATGAGCATCAGGTTTTCAAATGGGACGGAAAGCCAAGAGCCATGAAACAATGGGAAAGAGACTTGAGCTTAAGAGGGGCAATACAAGTTTCAGCGGTTCCCGTATTTCAACAAATCGCCAGAGAAGTTGGCGAAGTAAGAATGCAGAAATATCTTAAAAAATTTTCGTATGGTAACCAGAATATCAGTGGTGGCATTGACAAATTCTGGTTGGAGGGTCAGCTTAGAATTTCCGCAGTTAATCAAGTGGAGTTTCTAGAGTCTCTATTTTTAAATAAATTGTCAGCATCAAAAGAAAATCAGCTAATAGTAAAAGAGGCTTTGGTAACGGAGGCTGCGCCTGAATATCTTGTGCATTCAAAAACTGGTTTTTCTGGTGTGGGAACTGAGTCAAATCCTGGTGTCGCATGGTGGGTTGGTTGGGTTGAGAAGGGAACAGAGGTTTACTTTTTCGCCTTTAACATGGATATAGACAACGAAAATAAGTTGCCGCTAAGAAAATCCATTCCCACCAAAATCATGGCAAGTGAGGGCATCATTGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5206,Drugs,MEG_5206|Drugs|betalactams|Class_D_betalactamases|OXA,gi|126952402|gb|EF437948.1|1-794,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1888,Drugs,MEG_1888|Drugs|betalactams|Class_C_betalactamases|CMY,gb|HM544039|+|0-1152|ARO:3002065|CMY-54 [Escherichia coli] ,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctgggtgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5652,Drugs,MEG_5652|Drugs|betalactams|Class_C_betalactamases|PDC,1209144260|WP_088245222.1|NG_055280|1|1|blaPDC-217|blaPDC|class_C_beta-lactamase_PDC-217 NG_055280:1-1194,0
,TTTTATAAGTCTTATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGTGCTTCAAAATCTGATGACAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCATCAAGGTCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCAGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAATGGGATGGGGAAAAAAGGCTATTCCCAGAATGGGAAAAGAACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATAGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAAACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGCTTAGAACAATTAGGTATTTTATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5103,Drugs,MEG_5103|Drugs|betalactams|Class_D_betalactamases|OXA,gb|KM979377.1|+|0-838|ARO:3003121|OXA-430 [Acinetobacter baumannii] ,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccagcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5668,Drugs,MEG_5668|Drugs|betalactams|Class_C_betalactamases|PDC,1463920495|WP_116786837.1|NG_061624|1|1|blaPDC-305|blaPDC|class_C_beta-lactamase_PDC-305 NG_061624:1-1194,0
,ATGAAGAAGTGGGGTTTTTTATTGTTATTGTGCTTAGGTTTTGTCTTCATTAATAAAGCACTGTTTTTTCAGGAAAAAGTAGAAATTCAAAATTATGATCAAAATCCCAAAGATCATTTAGATAATAGAGGGACTTCTGAAAGTACGCAAACGAAGACGATTACAAATGAACAGATTTATCAAGGAAATCTGCTATTATTCAACAGTAAATATCCTGTTCGCCAAGAAAGTGTGAAGTCAGATATCGTAAATTTATCTAAACATAACGAATTGATAAATGGGTACGGGTTGCTTGATACGAATATTTATATGTCAAAAGGAATAGCACAAAAATTTTCAGAGATGGTCAATGATGCTGTAAAGGAAGGGGTTAGTCATTTTATTATTAATAGTGGCTATCGTGACTTTGATGAGCAAAGTGTGCTTTACCAAGAAATGGGGGCTGATTATGCCTTGCCAGCAGGTTATAGTGAACATAATTCAGGCTTATCACTTGATGTAGGATCAAGCTTAACGAAAATGGAGCGAGCACCTGAAGGAAAGTGGCTGAAAGAAAATGCTTGGAAATACGGCTTTATATTACGCTATCCAAAGGATAAAACTGATGTTACTGGAATTCAATATGAACCATGGCATATCCGTTATGTTGGTTTCCCTCACAGCGCGATTATGAAAGAAAAGAATTTCGCTCTAGAAGAATATATGGATTTTTTGAAGGAACAGAAGTCCATTACGACTACAATAGACCACCAAGTCTATAAAATCTTTTACTATCCTATCTCCCAAAATACAACGATCCATGTGCCTGCGAATGGCCAGTATGAAATTTCAGGCAACAATATGGATGGCGTGATTGTGACAGTGTATTCTGGTAAGCGAGACTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7596,Drugs,MEG_7596|Drugs|Glycopeptides|VanA-type_accessory_protein|VANYA,gi|66731632|gb|DQ018710.1|8162-9046,5
,atgagggaagcggtgaccgccgaaatttcaacacaactatcagaggtgtttagcgtcatcgagcgccatctggagccgacgttgcttgccgtgcatttgtacggctccgcagtggatggcggcttgaagccatacagcgatattgatttgctggttactgtgaccgcaaggcttaatgaagcaacacggcaagctttgctcaacgaccttttggaggcttcggctttccctggcgagagcgagactctccgcgctatagaagtcacctttgtcgtgcacgacgacatcatcccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgtaatgacattcttgcgggtatctccgagccagccgcgatcgacgttgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagctgcggaggaactctttgatcccgttcctgaacaggatctattcgaggcactgaatgaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgctcacgttgtcccgcatttggtacaccgaagtaaccggaaaaatcgtgccgaaggatgtcgctgccgactgggcaatggagcgcctacctgcccagcatcagcccgtcttacttgaagctagacaggcttatcttggacaaaaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcacttcgtgaaaggcgagatcactaaggtagtcggcaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_881,Drugs,MEG_881|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,499919896|WP_011600630.1|NG_051873|1|1|aadA11|aadA11|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA11 NG_051873:101-892,2
,GTGAATGGACCAATAATAATGACTAGAGAAGAAAGAATGAAGATTGTTCATGAAATTAAGGAACGAATATTGGATAAATATGGGGATGATGTTAAGGCTATTGGTGTTTATGGCTCTCTTGGTCGTCAGACTGATGGGCCCTATTCGGATATTGAGATGATGTGTGTCATGTCAACAGAGGAAGCAGAGTTCAGCCATGAATGGACAACCGGTGAGTGGAAGGTGGAAGTGAATTTTGATAGCGAAGAGATTCTACTAGATTATGCATCTCAGGTGGAATCAGATTGGCCGCTTACACATGGTCAATTTTTCTCTATTTTGCCGATTTATGATTCAGGTGGATACTTAGAGAAAGTGTATCAAACTGCTAAATCGGTAGAAGCCCAAACGTTCCACGATGCGATTTGTGCCCTTATCGTAGAAGAGCTGTTTGAATATGCAGGCAAATGGCGTAATATTCGTGTGCAAGGACCGACAACATTTCTACCATCCTTGACTGTACAGGTAGCAATGGCAGGTGCCATGTTGATTGGTCTGCATCATCGCATCTGTTATACGACGAGCGCTTCGGTCTTAACTGAAGCAGTTAAGCAATCAGATCTTCCTTCAGGTTATGACCATCTGTGCCAGTTCGTAATGTCTGGTCAACTTTCCGACTCTGAGAAACTTCTGGAATCGCTAGAGAATTTCTGGAATGGGATTCAGGAGTGGACAGAACGACACGGATATATAGTGGATGTGTCAAAACGCATACCATTTTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_983,Drugs,MEG_983|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT4-PRIME,gb|GQ900432.1|-|26737-27499|ARO:3003905|ANT(4')-Ib [Staphylococcus aureus] ,2
,atggttaaaaaatcactgagccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2190,Drugs,MEG_2190|Drugs|betalactams|Class_A_betalactamases|CTX,1028104724|WP_063859970.1|NG_048947|1|1|blaCTX-M-162|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-162 NG_048947:1-876,0
,atggatagttcgccgctcgtcaggcctgttgaaactaccgattcggccagttggctaagcatgcgctgtgagctgtggccagatggcacatgtcaagagcaccagtcagagatcgcagaatttctgtccggaaaagtcgcccggcctgctgctgtcctcattgctgtagcacccgacggagaagcactagggtttgccgagctttcgatccgcccgtatgcggaggagtgctactccggcaacgttgcgttcttggagggttggtacgttgtgccaagtgcgcggcgtcagggcgtaggtgtagctctggtaaaagccgccgagcattgggctcgtggtcgcggatgcaccgaattcgcctccgacactcaacttaccaacagcgcaggcacctcggcgcaactggcggctggattcacggaggttgctcaggtacgctgcttccggaaaccgttgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_200,Drugs,MEG_200|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1028080941|WP_063840324.1|NG_047304|1|1|aac(6')-Il|aac(6')-Il|aminoglycoside_N-acetyltransferase_AAC(6')-Il NG_047304:101-559,2
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGGCATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATTGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTATTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1403,Drugs,MEG_1403|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_111_AJCN01000010,0
,TTTTTAGAAATTCTGTAAGCAATACTATATAGCAGTTGACAATCATACAAATTTAATATATACTCCGCAAAAATATCAAGGATTATAAATGTCTAAAAAAAATTTTATATTAATATTTATTTTTGTTATTTTAATATCTTGTAAAAATACAGAAAAAATATCAAATGAAACTACATTAATAGATAATATATTTACTAATAGCAATGCTGAAGGAACATTAGTTATATATAATTTAAATGATGATAAATATATAATTCATAATAAAGAAAGAGCTGAACAAAGATTTTATCCAGCATCAACATTTAAAATATATAATAGTTTAATAGGCTTAAATGAAAAAGCAGTTAAAGATGTAGATGAAGTATTTTATAAATATAATGGCGAAAAAGTTTTTCTTGAATCTTGGGCTAAGGACTCTAATTTAAGATATGCAATTAAAAATTCGCAAGTACCGGCATATAAAGAATTAGCAAGAAGAATAGGTCTTAAAAAGATGAAAGAGAATATAGAAAAACTAGATTTTGGTAATAAAAGTATAGGTGATAGTGTAGATACTTTTTGGCTTGAAGGACCTTTGGAAATAAGTGCGATGGAGCAAGTTAAATTATTAACTAAATTAGCTCAAAATGAATTACCGTATCCTATAGAAATACAAAAAGCTGTTTCTGATATTACTATACTAGAGCAAACTTACAATTATACGCTTCATGGAAAAACTGGATTAGCTGATTCTAAAAACATGACAACTGAGCCTATTGGTTGGTTCGTAGGCTGGCTTGAAGAAAATGATAATATATATGTCTTTGCTTTAAATATTGATAATATCAATTCAGATGACCTTGCAAAAAGGATAAATATAGTAAAAGAAAGTTTAAAAGCATTAAATTTATTAAAATAAATTATATAAAAATTAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5216,Drugs,MEG_5216|Drugs|betalactams|Class_D_betalactamases|OXA,gi|300687338|gb|CP002025.1|1473197-1472284 gi|158634575|gb|EU086830.1|1-914,0
,atgagggtagcggtgaccatcgaaatttcgaaccgactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagaggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaacttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_896,Drugs,MEG_896|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502084|WP_071846236.1|NG_052248|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052248:101-892,2
,atgtccgcgatcgacacccccgttaccttgcgcctcatgaccgagcaagatcttccgatgctccatgactggctgaaccgaccccacatattcgagtggtggggcggtgaagaggaacgcccgactcttgatgaagtgctggaacactacctgccaagagttctggcagaagagtccgtcacgccgtacatcgcaatgctgggcgaggagccgatcggctacgcccagtcttacgtcgcactcggcagcggtgatggatggtgggaagacgaaactgacccaggagtgaggggaattgaccagtctctggctaatccgacacagttgagcaagggtctgggaacaaagcttgtccgtgcgctcgttgagcggttgttcttggactccactgtgacgaagatccaaaccgacccaactccgaacaaccatcgggcgatccgttgctacgagaaggcggggtttgtacggcagaagataatcaccacgcctgatggcccagccgtctacatggttcaaacacgtcagtcattcgagaacgcgcgtagtactgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_207,Drugs,MEG_207|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,753794811|WP_041550454.1|NG_052259|1|1|aacA47|aac(6')-set_A|aminoglycoside_6'-N-acetyltransferase_AacA47 NG_052259:101-655,2
,GTGGCTGCCCAGAAAAAGAAGGCCCAAGACGAATACGGCGCTGCGTCTATCACCATTCTCGAAGGGCTGGAGGCCGTCCGCAAACGTCCCGGCATGTACATTGGCTCGACCGGTGAGCGCGGTTTACACCATCTCATTTGGGAGGTGGTCGACAACGCGGTCGACGAGGCGATGGCCGGTTATGCAACCACAGTGAACGTAGTGCTGCTTGAGGATGGCGGTGTCGAGGTCGCCGACGACGGCCGCGGCATTCCGGTCGCCACCCACGCCTCCGGCATACCGACCGTCGACGTGGTGATGACACAACTACATGCCGGCGGCAAGTTCGACTCGGACGCGTATGCGATATCTGGTGGTCTGCACGGCGTCGGCGTGTCGGTGGTTAACGCGCTATCCACCCGGCTCGAAGTCGAGATCAAGCGCGACGGGTACGAGTGGTCTCAGGTTTATGAGAAGTCGGAACCCCTGGGCCTCAAGCAAGGGGCGCCGACCAAGAAGACGGGGTCAACGGTGCGGTTCTGGGCCGACCCCGCTGTTTTCGAAACCACGGAATACGACTTCGAAACCGTCGCCCGCCGGCTGCAAGAGATGGCGTTCCTCAACAAGGGGCTGACCATCAACCTGACCGACGAGAGGGTGACCCAAGACGAGGTCGTCGACGAAGTGGTCAGCGACGTCGCCGAGGCGCCGAAGTCGGCAAGTGAACGCGCAGCCGAATCCACTGCACCGCACAAAGTTAAGAGCCGCACCTTTCACTATCCGGGTGGCCTGGTGGACTTCGTGAAACACATCAACCGCACCAAGAACGCGATTCATAGCAGCATCGTGGACTTTTCCGGCAAGGGCACCGGGCACGAGGTGGAGATCGCGATGCAATGGAACGCCGGGTATTCGGAGTCGGTGCACACCTTCGCCAACACCATCAACACCCACGAGGGCGGCACCCACGAAGAGGGCTTCCGCAGCGCGCTGACGTCGGTGGTGAACAAGTACGCCAAGGACCGCAAGCTACTGAAGGACAAGGACCCCAACCTCACCGGTGACGATATCCGGGAAGGCCTGGCCGCTGTGATCTCGGTGAAGGTCAGCGAACCGCAGTTCGAGGGCCAGACCAAGACCAAGTTGGGCAACACCGAGGTCAAATCGTTTGTGCAGAAGGTCTGTAACGAACAGCTGACCCACTGGTTTGAAGCCAACCCCACCGACGCGAAAGTCGTTGTGAACAAGGCTGTGTCCTCGGCGCAAGCCCGTATCGCGGCACGTAAGGCACGAGAGTTGGTGCGGCGTAAGAGCGCCACCGACATCGGTGGATTGCCCGGCAAGCTGGCCGATTGCCGTTCCACGGATCCGCGCAAGTCCGAACTGTATGTCGTAGAAGGTGACTCGGCCGGCGGTTCTGCAAAAAGCGGTCGCGATTCGATGTTCCAGGCGATACTTCCGCTGCGCGGCAAGATCATCAATGTGGAGAAAGCGCGCATCGACCGGGTGCTAAAGAACACCGAAGTTCAGGCGATCATCACGGCGCTGGGCACCGGGATCCACGACGAGTTCGATATCGGCAAGCTGCGCTACCACAAGATCGTGCTGATGGCCGACGCCGATGTTGACGGCCAACATATTTCCACGCTGTTGTTGACGTTGTTGTTCCGGTTCATGCGGCCGCTCATCGAGAACGGGCATGTGTTTTTGGCACAACCGCCGCTGTACAAACTCAAGTGGCAGCGCAGTGACCCGGAATTCGCATACTCCGACCGCGAGCGCGACGGTCTGCTGGAGGCGGGGCTGAAGGCCGGGAAGAAGATCAACAAGGAAGACGGCATTCAGCGGTACAAGGGTCTAGGTGAAATGGACGCTAAGGAGTTGTGGGAGACCACCATGGATCCCTCGGTTCGTGTGTTGCGTCAAGTGACGCTGGACGACGCCGCCGCCGCCGACGAGTTGTTCTCCATCCTGATGGGCGAGGACGTCGACGCGCGGCGCAGCTTTATCACCCGCAACGCCAAGGATGTTCGGTTCCTGGATGTCTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3243,Drugs,MEG_3243|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRB,gb|NC_009525.1|+|5239-7267|ARO:3003459|Mycobacterium tuberculosis gyrB mutant conferring resistance to fluoroquinolone [Mycobacterium tuberculosis H37Ra] ,3
,ATGAGCCATATTCAACGGGAAACGTCTTGCTCGAGGCCGCGATTAAATTCCAACTTGGATGCTGATTTATATGGGTATAGATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCAATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGACGGCATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCCGGGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGGTTGATGCTAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAGCTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1078,Drugs,MEG_1078|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-PRIME,gi|695210321|ref|NG_035929.1|1729-914 gi|512492521|gb|JX424614.1|31121-30308 gi|297787483|gb|GU585907.1|23579-24392,2
,atgaaaaataataatgtaacagaaaaagaattattttatattttagatttatttgaacacatgaaagtaacttattggttagatggtggctggggggtagatgtattaactgggaaaccacaaagagaacacagagatatagatatagattttgacgctcaacacactcaaaaagttatacaaaaattagaagatataggatacaaaatagaagttgattggatgccttcacgtatggaacttaagcatgaagaatatgggtatttagatattcatcctataaatctaaatgatgatggatcaattacccaagcaaacccagaaggtggtaattatgttttccaaaatgactggttttcagaaactaattacaaagatcgaaaaataccatgtatttcaaaagaagctcaacttctttttcattctggttatgatttaacagaaacagaccattttgatataaaaaatttaaaatcaataacataa,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3602,Drugs,MEG_3602|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUA,499964297|WP_011645015.1|NG_047919|1|1|lnu(A)|lnu(A)|lincosamide_nucleotidyltransferase_Lnu(A) NG_047919:101-586,7
,ATGGTTAACTTGGACGCTGAGATATATGAGCACTTAAATAAACAGATAAAAATAAATGAACTCCGTTATTTATCGTCCGGCGATGATAGTGATACTTTTTTGTGTAATGAACAATATGTTGTGAAAGTTCCTAAACGAGATTCTGTTAGAATTTCTCAGAAACGAGAGTTTGAATTGTATCGTTTTTTAGAAAACTGTAAGCTATCTTATCAAATCCCTGCGGTAGTGTATCAAAGTGACCGATTTAATATTATGAAATATATTAAAGGGGAACGTATTACTTATGAGCAGTATCATAAGTTGAGTGAAAAGGAAAAGGATGCCCTTGCATATGATGAAGCGACGTTTTTGAAAGAGTTACATTCCATAGAGATTGATTGTTCTGTCAGTTTGTTTTCAGATGCTCTGGTGAATAAGAAAGATAAGTTTTTGCAAGATAAAAAATTACTTATAAGTATTCTGGAAAAGGAGCAGCTGTTAACTGATGAGATGTTGGAACATATCGAAACAATATATGAAAACATATTAAACAATGCTGTTTTATTTAAATATACCCCTTGTTTGGTACATAATGATTTCAGTGCAAATAACATGATTTTTAGAAATAATAGACTGTTTGGAGTTATTGATTTTGGCGATTTTAATGTAGGTGACCCGGATAATGATTTTTTGTGCTTGCTGGATTGTAGTACAGATGATTTCGGGAAAGAATTTGGCAGGAAGGTATTAAAATACTATCAGCATAAGGCGCCGGAAGTAGCAGAAAGAAAAGCAGAGCTTAATGATGTATATTGGTCGATAGACCAAATTATTTATGGTTATGAAAGAAAAGATAGGGAAATGTTGATTAAGGGTGTTTCTGAATTGCTACAAACACAAGCAGAGATGTTTATATTTTAG,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1011,Drugs,MEG_1011|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH2-DPRIME,(AGly)Aph2-Ib:AF207840:272-1171:900,2
,atgtcaacaaccttaagaaaaagcaaacctgcttttcttcttggctcttttttaatgtcgatatctttgtattcatatgcgaatgaaaatggcatagatgagataaagaatcttgaaaaaaaatttaatggaaggattggtgtctacgctttagacacaggctctggcaaatcatttgcatacagagcgaatgaacgctttcctctgtgcagttcatttaaaggttttttagctgcttctgtattaaaaggttctcaagataagcaacttaactttagcgagatcgtaaattacaatacaagaagtttagaacccaattctcccatcacggcaaaatataaagagcaaggaatgccacttggagaaatggctgctgcagctttacaatatagtgacaatgctgctaccaatattattcttgaacgttatatcggtggtcctgtaggtatgactaagttcatgcggtcgatcggagatgaagaatttagactagatcgttatgaactagatcttaatacggctattccaggagatgaacgagacacatcaacacctgaagcagtgggtaaaagcttaaaaaacctcgctctgggcaatatacttaatgacagtgaaaaagaaacatatcagacatggttaaagggtaatacaacaggtgcagcgcgcattcgttctagcgtaccgcgcgaatgggtagttggcgataaaactggtacctgtggagcatacggtacggcaaatgattatgcggtagtctggccagatgacagggcaccacttatcatttccgtatacactacaaaatatgaaaaagatgccaagcatgaagaggaatttattgcagaagcttcaagaattgcgattaaaacccttaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3299,Drugs,MEG_3299|Drugs|betalactams|Class_A_betalactamases|IMI,1188444903|WP_085562405.1|NG_054695|1|1|blaIMI-5|blaIMI|carbapenem-hydrolyzing_class_A_beta-lactamase_IMI-5 NG_054695:101-979,0
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaagaaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaatattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4430,Drugs,MEG_4430|Drugs|betalactams|Class_D_betalactamases|OXA,1693892944|WP_140423321.1|NG_065439|1|1|blaOXA-828|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-828 NG_065439:1-825,0
,atgacgaaaatgaaccgcctggcggccgcgctgatcgccgcactgatcttgccgaccgcgcaggccgcgcagcagcaggatatcgacgccgttattcagccgctgatgaaaaaatatggcgtaccgggcatggcgatcgccgtgtcggtcgacggcaaacagcagtattacccgttaggcgtcgcctcgaagcagaccggcaaaccgatcaccgagcagacgctgttcgaagtgggctcgctgagcaaaacctttaccgcgacgctggcggtctatgcgcagcagcagggcaagctgtcgttcaacgatccggccagccgctacctgcccgagctgcgcggcagcgccttcgacggcgtcacggtgctgaatctggcgacgcatacctccggcctgccgctgttcgtgccggacgacgtcactaacgacgcccagctgatggcctactaccgggcctggcagccgaaacacccggcgggcagctaccgcgtttattccaacctcggcatcggcatgctgggcatgatcgccgccaagagcctcgaccagccgtttatccaggcgatggaacaggggatgctgccggcgctgggcatgagccacacctacgttcaggtgccggcggcgcagatggctaactatgcgcagggttacagcaaggacgataagccggtgcgggtcaaccccggcccgctggacgccgaatcttacggcatcaagtccaacgctcgcgatctgattcgctatctggacgccaacctgcagcaggtgaaggtggcgcagccatggcgcgacgcgctggccgcgacgcacgtcgggtattacaaggcgggcgcgttcacgcaggatctgatgtgggagaactacccgtatccagtgaaactgtcgcgtttgattgaaggcaacaacgccgggatgatcatgaacggcacgccggccaccaccatcacgccgccgcagccggaattgcgcgccggctggtataacaaaaccggctccaccggcggcttctccacctacgcggtatttatcccggcgaaaaatatcgccgtggtgatgctggccaacaagtggttcccgaacgacgatcgcgtcgaggcggcttaccacatcgtccaggcgctggagaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_6569,Drugs,MEG_6569|Drugs|betalactams|Class_C_betalactamases|SRT,1028083971|WP_063842939.1|NG_047547|1|1|blaSRT|blaSRT|SRT/SST_family_class_C_beta-lactamase NG_047547:101-1237,0
,ATGTTCATGCCGCCTGTTTTTCCTGCTCATTGGCACGTTTCGCAACCTGTTCTCATTGCGGACACCTTTTCCAGCCTCGTTTGGAAAGTTTCATTGCCAGACGGGACTCCTGCAATCGTCAAGGGATTGAAACCTATAGAAGACATTGCTGATGAACTGCGCGGGGCCGACTATCTGGTATGGCGCAATGGGAGGGGAGCAGTCCGGTTGCTCGGTCGTGAGAACAATCTGATGTTGCTCGAATATGCCGGGGAGCGAATGCTCTCTCACATCGTTGCCGAGCACGGCGACTACCAGGCGACCGAAATTGCAGCGGAACTGATGGCGAAGCTGTATGCCGCATCTGAGGAACCCCTGCCTTCTGCCCTTCTCCCGATCCGGGATCGCTTTGCAGCTTTGTTTCAGCGGGCGCGCGATGATCAAAACGCAGGTTGTCAAACTGACTACGTCCACGCGGCGATTATAGCCGATCAAATGATGAGCAATGCCTCGGAACTGCGTGGGCTACATGGCGATCTGCATCATGAAAACATCATGTTCTCCAGTCGCGGCTGGCTGGTGATAGATCCCGTCGGTCTGGTCGGTGAAGTGGGCTTTGGCGCCGCCAATATGTTCTACGATCCGGCTGACAGAGACGACCTTTGTCTCGATCCTAGACGCATTGCACAGATGGCGGACGCATTCTCTCGTGCGCTGGACGTCGATCCGCGTCGCCTGCTCGACCAGGCGTACGCTTATGGGTGCCTTTCCGCAGCTTGGAACGCGGATGGAGAAGAGGAGCAACGCGATCTAGCTATCGCGGCCGCGATCAAGCAGGTGCGACAGACGTCATACTAG,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1095,Drugs,MEG_1095|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH6,gi|575453416|gb|CP006956.1|298743-299579 gi|575450852|gb|CP006955.1|2355426-2354590 gi|481063295|gb|CP005383.1|2130235-2129399 gi|469487914|gb|CP003745.1|100549-101385 gi|9967611|emb|AJ293027.1|9782-10618 gi|9967611|emb|AJ293027.1|6278-6503 gi|7007382|emb|AJ271879.1|8271-9107 gi|695209907|ref|NG_035903.1|4633-5469,2
,atgttaaaagttattagtagtttattggtctacatgaccgcgtctgtcatggctgtcgcaagtccgttagcccattccggggagccgagtggtgagtatccgacagtcaacgaaattccggtcggagaggtccgactttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcggtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgaaaagcaaattggacttcccgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggcagaggggaacgagattcccacgcattctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagagctcttctatcctggtgctgcgcattcgaccgacaatctggttgtatacgtcccgtcagcgaaagtgctatacggtggttgtgccgttcatgagttgtcacgcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccgttgagcggattcaaaaacgctacccggaagcagaggtcgtcattcccgggcacggtctaccgggcggtctagacttgctccagcacacagcgaacgttgtcaaagcacacaaaaatcgctcagtcgccgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7698,Drugs,MEG_7698|Drugs|betalactams|Class_B_betalactamases|VIM,1625655430|WP_136512107.1|NG_064784|1|1|blaVIM-55|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-55 NG_064784:1-801,0
,atgaatgttgaatattctaaaataaagaaagcagtacctattttattattcttatttgtattcagtttggttatagacaactcatttaaattgatttctgtagccattgctgatgacttaaacatatctgtaacgacagtaagttggcaagcgacattagccggtttagtaattggtattggcgctgtagtatacgcttcattatctgatgccattagtatacgcacactatttatttatggcgtgatattaatcattatcggatcaattattggttacattttccaacatcaattcccattacttttagttggacgtattattcaaactgccggtttagctgctgcagagacattatatgtgatatatgttgcaaagtatctttctaaagaggaccagaagacttaccttggcttaagtacgagcagttattccttgtcattagttatcggtacattatcaggtggatttatttctacgtatttacactggacaaatatgtttttaattgcattaatcgtagtatttacgttgccattcctatttaaattattaccaaaagaaaataatacgaataaagctcatttagattttgttggcttaattctagtggcaactattgctacaacagtcatgctgtttattacgaactttaattggttatatatgattggtgccttaattgcgattatcgtttttgcgctatatattaaaaatgcgcaacgtccattagtaaataaatcatttttccaaaataaacgttatgcttcatttttatttatagtatttgtaatgtatgctatccaattgggttatatttttacgttcccattcataatggagcaaatttatcatctgcaactagacacaacatcactgttattagtaccgggttatatagtagcagtcattgttggtgcactaagtggtaaaatcggcgaatatctgaattcaaaacaagcgattatcacagcaattattttaatagcactgagcttgattttacctgcatttgcagtaggtaatcacatttcaatcttcgtcatttctatgatattctttgcaggtagctttgctttaatgtatgcacctttacttaacgaagccattaaaacaatagatcttaatatgacaggtgtggctattggtttttataatttaattattaatgtggcggtatctgtaggtattgcgattgctgcggctctaatcgattttaaagcattaaatttcccaggcaatgatgcattaagttcacatttcggtattattttaattattttaggtttaatgagtattgtcggattagttttattcgtcagcttaaatcgttggacacaatctgaaaaataa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6982,Drugs,MEG_6982|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET38,447023044|WP_001100300.1|NG_048134|1|1|tet(38)|tet(38)|tetracycline_efflux_MFS_transporter_Tet(38) NG_048134:101-1453,4
,TCAGCGCCGATCCGCATTCGCCGCTTGCTGCTTCGCCAGCGTCGCATCGAAAGCCTTCTCCGCCAGATCGACCTGGCGTGACAATTCGTTCGGATCGACAAAGGCGTCGGTGGCACCCGCCTGCGCCCTGGCGCGTTTTTCATCGAGCGCGAAAGCCTCGGCGTGGAAGCTCAGGAAGATATCTGCCTTCAACGCGCGGAGTTTCGCAAAGCTGGCACGGAAATCGGCGGCGGCGTTCGGATAATTTATATTATTGATAAGATTTTGGCCGGCGACACTGATACTCGATGTGAAGATCACATTCTTGCTGCCAATGCGGGTCGTCCAGCTCGTCGCGCCTTTTGTATGGCCGGGTGTCAGGATGGCGACGAGCGCGATCGGGCCGAGCGTCAGCCGGTCGCCGTCGCCGATCACACGATCGACCTTCACTGCCGGAAAGTCCGCGATATCGGTGCGGCCGATGGTGGTACCTGCTTCGAGATCGGGCTTGTCCGCAACGTTTGCGACCATTTGCGCGCCGGTCAGCCGCTTGAGTTCGGCCAGTCCACCGGCGTGATCGACATGCGAATGGTTGCTGAGCAGATATTTCACATCGGACAGTTTGAAGCCCAGTTTGCGGATGTTCGCGGCGATCAGCGGCGCGCTTTCCGGCAGAGCGCCGTCGATCAGCACATGGCCGCGCGGCCCGGCGATCAGATAGGCCGAAAGCCCGCTGGTGCCGACATAATAGAGATTGCCGGTGATGCGGAATGGCTCGCGCGGCCCGTTCCATTTCGCGCGCTGCTCGGCCGATTGGGCGAGGGCGCCGGATGGGGCTGTCATGGCGAGCGCGGATGCGAGCAGTATCAGGGGGCGCAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_6553,Drugs,MEG_6553|Drugs|betalactams|Class_B_betalactamases|SPG,gb|KP109680|+|1254-2112|ARO:3003720|SPG-1 [Sphingomonas sp. ALS-13] ,0
,ATGTCAAACTATAGTGTTGCGGAATTAAGAAACATGAAAAAAAACAGAAAAAAGCAAATCGTAGTTTTGTGTATAGCTTTAGTTTGCATCTTCATCTTGGTGTTCTCATTGTCCCATAAATCAGCTACAAAAGGTAGCGCGAATCCTCCATTAACAGATGTTTTGACTGATAGCATTTCTCAGATTGTCTCGGCTTGTCCTGGTGAAATTGGTGTGGCGGTTATTATTAATAACACAGATACGGTTAGTGTTAATAATAAAAGCATTTATCCTATGATGAGTGTATTTAAGGTTCATCAGGCATTAGCTCTTTGCAATGATTTTGACAAAAAAGGCCTTTCCCTTGATACCTTGGTAAAGATAAATAGGGAAAAACTTGATCCAAAGACATGGAGCCCTATGATGAAAGATTATTCAGCACCAGTTATATCGTTGACAGTAAGAGATCTGTTGCGCTATACTCTTTCCCAGAGCGACAATAATGCAAGCAATATCATGTTTAAGAATATGCTCAATACTGCACAAACAGACAGTTTTATAGCGAAACTCATACCACGTTCGAGTTTTCAGATAGCTTATACAGAAGAGGAAATGTCCGCTGACCATGACAAAGCTTACTCTAATTACACATCTCCTCTTGGTGCTGCAATGTTGATGAATCGTTTGTTTACAGAAAGTCTTATCAGTAATGAGAAACAAGATTTCATTAAGAATGCATTGAAAGAATGTAAAACAGGTATAGATAGGATAGTAGCTCCACTTCTTGATAAAGAAGGGGTTGTAATAGCACATAAGACAGGTTCTGGTAATGTCAATGAAAATGGTATTCTTGCAGCTCAGAATGATGTAGCCTATATATGTCTGCCTAATAAGGTCTGCTATACCTTAGCTGTATTTGTTAAGGATTTCAAGGGAAATGAATCACAAGCGTCACAATTTGTTGCGCATATATCAGCGGTAGTATATTCTTTATTAATCAATACTGCGTTAAATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1695,Drugs,MEG_1695|Drugs|betalactams|Class_A_betalactamases|CFX,gb|GQ342996|+|797-1793|ARO:3003097|CfxA6 [uncultured organism] ,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGTTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAAGCCGGCGGTGGCCGCGCGCGTTATCCGGCCCGCAGCACCTCGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAAAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6429,Drugs,MEG_6429|Drugs|betalactams|Class_A_betalactamases|SHV,gi|2113848|emb|X98102.1|74-1018,0
,ATGGCTGAAGAAGATGTACCAAGACTAAGAGAAAGACAAATAGACGAGGAAATGAAAGAATCGTTCATCGATTACGCGATGAGCGTCATTGTCAGCCGGGCGCTGCCAGACGTAAGGGATGGCATGAAGCCCGTGCATCGCCGTATTCTGTATGCCATGTTTGAGCTTGGGATGACGCCAGACAAACCATATAAAAAGTCGGCGCGGATCGTAGGCGAAGTGCTTGGAAAGTACCACCCACACGGCGATACTTCTGTATATGACGCAATGGTACGGATGGCACAAGATTTTAGTTATCGTTATATGCTCGTCAACGGGCATGGCAACTTCGGTTCCATTGATGGCGACTCTGCCGCGGCGATGCGTTATACGGAATCAAAAATGTCCAAGATTTCCATGGAACTAGTCCGGGATTTAAACAAAGATACCGTTGATTTTATCGATAACTATGACGGCACTGAGCGAGAACCGAAAGTGATGCCTTCCCGTTTTCCGAATTTACTCGTCAATGGCACGTCGGGGATTGCAGTAGGGATGGCAACCAATATCCCGCCCCATCAATTAGGTGAAGTGATTGACGGTGTACTTGCTTTAGCAAAAAATCCTGACATTAGTATTCCTGAGCTCATGGAATATATTCCAGGCCCTGATTTTCCAACAGGCGGCGAGATCCTCGGCCGCTCTGGCATACGCAAAGCCTATTCAACAGGACGAGGCTCGATTACCGTACGGGCTAAAACCGAAATTGTCGAAAACAAAGGCAAACAGTCGATTATCGTCACGGAACTGCCATACCAAGTCAATAAAGCGCGTCTGATTGAAAAAATCGCGGAACTAGTGCGTGACAAGAAAATTGATGGCATTACCGAACTGCGTGATTCCTCGGACCGCAATGGCATGAACATTGTCATCGATGTGCGTAGAGACGCAAATCCAAACGTCATTTTAAACAATTTGTTTAAACAGACAGCTTTGCAAACAAGTTTTGGCATTAATATGCTTGCTCTTGTGAATGGCCGGCCTGAAGTCTTAAACTTAAAACAGACGCTGGAACAATATTTGGCTCACCAAGTAGAAGTGATCCGCAGGCGCACTCAGTTTGACCTAAACAAAGCGGAAGCCCGCGCCCACATTTTGGAAGGCTTGCGCATTGCCCTTGACCATATTGATGAAATCATTGCCTTAATCCGTGGTTCGGATACAGCAGAAATCGCTCGAAACGGCTTAATTGAGCGATTTGAACTCAGCTATGACCAAGCACAAGCGATTCTCGATATGCGCTTGCAACGGTTAACTGGTTTGGAACGGGATAAGCTTGAACAAGAATACAAAGACGTGTTGGCGCGAATTGCTGAACTCCGTGCAATTTTGGCTAGTGACGAGAAAGTCATTGACGTCATCCAAGAAGAAATCCTTGCCATTAAAGAGAAATTTAATGACGAACGGCGGACGGTCATTTCGGCGAGCGAAGAACATTTGGAAGATGAGGATTTAATCCCACGGCAAAATATTGTTATTACTATTACCCATAACGGCTACATTAAACGCTTGCCTATTTCTACGTACCGTGCTCAAAAACGGGGCGGAAAAGGCGTACAAGGCATGGGTACGAATGATGACGACTTTGTCCAGCACTTGTTTACGACCAACACGCACCATACCGTGTTAGTCTTCACAAACAAAGGGAAAGCCTACCGCCTAAAAGGGTATGAAATCCCTGAACTAGGTCGAACAGCAAAAGGCATTCCGGCGATTAATCTGTTGCCGTTTGATCCAGGCGAAACGATCAGTACAGTCATCCCAATTGAATGCTTTGATGACGATTCGTATTTGTTTTTCGTAACAGAGCACGGCATTGCCAAACGAACAAAGTTGTCTGCATTTGCGAATATCCGTAAAGGTGGTTTGTTCGCGATCAATTTAAGAGAAGGCGATTCACTCCACGGCGTGCGTTTAACCGATGGCAACCGTGAAGTGATGATCGGGACGAAACAAGGAATGGCGATCCGTTTTCCAGAAACAGATGTCCGCCTAATGGGACGTACTGCAGGCGGCGTCAAAGGCATTACCCTATCTGAGAATGACGGTGTTGTCGGCATGGAAGTAGTGGATGAAAACCAAAGCGTGCTCGTCGTTACCGAGAAAGGCTACGGCAAACGGACGCCACTTGATGAATACCGGGTCCAAAGCCGCGGAGGAAAAGGGATTAAAACATGTAACATTACTGATAAAAACGGTCCTCTTGTCTCTTTGAAAATGGTGGCCGACGAAGACGACATTATGATTGTTACCGCCAATGGGATTATTATTCGCACCAACGTAGACGGCATTTCAACGACTGGCCGAAATACTCAAGGCGTGACGTTGATTCGTGTCAACGAAGGAGAAGAAGTAGCGACAGTCGCCCGTGTGAACATTAACGACGACGAAGTCGATGACTTAGAAGACGATGATGAGCAAGAGCAACCGACATCAGAGGAAAACGCAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3213,Drugs,MEG_3213|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|56908016|dbj|AP006627.1|6654-9146,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcaaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5526,Drugs,MEG_5526|Drugs|betalactams|Class_C_betalactamases|PDC,1408841615|WP_111672888.1|NG_060544|1|1|blaPDC-299|blaPDC|class_C_beta-lactamase_PDC-299 NG_060544:1-1194,0
,atgaatagttcgacaaagatcgcattggtaattacgttactcgatgccatggggattggccttatcatgccagtcttgccaacgttattacgtgaatttattgcttcggaagatatcgctaaccactttggcgtattgcttgcactttatgcgttaatgcaggttatctttgctccttggcttggaaaaatgtctgaccgatttggtcggcgcccagtgctgttgttgtcattaataggcgcatcgctggattacttattgctggctttttcaagtgcgctttggatgctgtatttaggccgtttgctttcagggatcacaggagctactggggctgtcgcggcatcggtcattgccgataccacctcagcttctcaacgcgtgaagtggttcggttggttaggggcaagttttgggcttggtttaatagcggggcctattattggtggttttgcaggagagatttcaccgcatagtcccttttttatcgctgcgttgctaaatattgtcactttccttgtggttatgttttggttccgtgaaaccaaaaatacacgtgataatacagataccgaagtaggggttgagacgcaatcgaattcggtatacatcactttatttaaaacgatgcccattttgttgattatttatttttcagcgcaattgataggccaaattcccgcaacggtgtgggtgctatttaccgaaaatcgttttggatggaatagcatgatggttggcttttcattagcgggtcttggtcttttacactcagtattccaagcctttgtggcaggaagaatagccactaaatggggcgaaaaaacggcagtactgctcgaatttattgcagatagtagtgcatttgcctttttagcgtttatatctgaaggttggttagatttccctgttttaattttattggctggtggtgggatcgctttacctgcattacagggagtgatgtctatccaaacaaagagtcatgagcaaggtgctttacagggattattggtgagccttaccaatgcaaccggtgttattggcccattactgtttgctgttatttataatcattcactaccaatttgggatggctggatttggattattggtttagcgttttactgtattattatcctgctatcgatgaccttcatgttaacccctcaagctcaggggagtaaacaggagacaagtgcttag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7040,Drugs,MEG_7040|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,1028099777|WP_063856070.1|NG_048172|1|1|tet(B)|tet(B)|tetracycline_efflux_MFS_transporter_Tet(B) NG_048172:101-1306,4
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcatttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2198,Drugs,MEG_2198|Drugs|betalactams|Class_A_betalactamases|CTX,1209144253|WP_088245215.1|NG_055272|1|1|blaCTX-M-202|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-202 NG_055272:1-876,0
,GTGAATTCTGAACAGTTCCTCGGTTGGCTTGAGCGAAAGAGCCAACCTGCTTCTTCCTTGGTTTTTGAAAAGCCGTTAATTATGGGTGTGCTAAATGTTACCTCTGATTCATTTTATGATGGTGGCAAGTATCTGTCTGTGGATAGAGCTTATGAGCAAGCCATACAATTAATTGCATGTGGAGCTGATCTCATTGATATTGGTGGGGAATCAACCAAACCCGGTGCTCCGCCAGTCCCTTTAGATGTTGAACTATCAAGAGTTCTTCCCATAATCAAACAACTTCGTGCGTTCACAGATGTGTGTATTTCTATTGATACAAATAAGCCAGAAGTGATGGAAGCGGCAATTAATGCTGGTGCGCATGTTATAAATGATGTTTATGCTTTAAGAAGGGATGGTGCTCTGAATGTTGCTGCACAATTAGATGTTCCTGTCTGTTTAATGCACATGAAAGGAGAGCCGCGAACCATGCAAGAAAATCCTTCTTACCCAGAAGGGATAATGAAGGAATTACAGCATTTTTTTGAAGAACGCATCGATAAATGCCAGAAAGCCGGGCTGAATAGGAATAAATTAATTCTTGACCCTGGCTTTGGTTTTGGAAAGCGCGTTCAAGATAACCTACAATTAATTTATCATCTGAACGAATTGCATTCTTTTGGATTGCCAATTCTTTTGGGCGTTTCACGCAAAAGCACAATTGGTGCCGTGTTGAATACTGAGGTTGAACAACGTTTGATTGGAAGTATTACGCTAGGGATATATGCGGCTCTTAAAGGCACTGCAATTATCAGGACACATGATGTAGATGAAACGAATCAAGCATTAACTATGATTAATGCAATTTATCAAGCTGCTAAAGAAATCAGTTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2943,Drugs,MEG_2943|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|295647398|gb|CP001828.1|3262184-3261309 gi|225791049|gb|CP000675.2|3326709-3325834,8
,atgcatgatgcagccacctccatgccgccgcaggctccctcaacctgggccgactaccttgccggctaccgctggcgagggcagggcgaaggatgttccgcggccacggtccaccgcctggaggctgcgcggcggccgaccctgttcgtcaagcaggaagtgctgtccgcacatgccgagctgcccgccgaaatcgcccgcctgcgctggctgcacggtgccggcatcgattgcccgcaggtgctgaacgaaacccagagcgacggccggcaatggctgctgatgagcgcagtgccgggggacacgctgtccgcgctggcgcagcgcggcgagctggagcccgagcgcctggtgcgcctggtggccgccgccctgcgccggctgcacgatctcgatccggctgcctgtcccttcgaccatcgcctggagcggcgtctggacaccgtgcgccagcgggtcgaggccgggctggtggacgaggcggacttcgacgacgaccatcgcggtcgcagcgccacggagctgtaccgcctgctgctcgaccggcgtccggcggtcgaagacctggtggtcgcccatggcgacgcctgcctgccaaatctgctggcggaggggcggcgcttcagcggcttcatcgattgcgggcggctcggcgtcgccgaccggcaccaggacctggccctggccgcgcgggacatcgaggccgaactcggcgcggcctgggccgaggccttcctcgtcgaatacggcggcgatatcgacggcgaacggctggcgtacttcaggctattggacgagttcttctag,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1034,Drugs,MEG_1034|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,489203925|WP_003113011.1|NG_047424|1|1|aph(3')-IIb|aph(3')-IIb|aminoglycoside_O-phosphotransferase_APH(3')-IIb NG_047424:101-907,2
,AATTGGTCGTATTTTTGCGGGAATTACAGGTGCCAACATGGCTGTTGCAACAGCTTATGTTTCAGATATTACTCCAGCCCATGAGCGTGCAAAAAGGTTTGGTCTCCTTGGAGCTGTCTTTGGTATTGGGTTTATAGCGGGTCCGGTAATAGGTGGAGTTTTGGGTGAATGGAACTTACATGCACCGTTCTTTGCTGCTGCTTTTATGAATGGGATTAATTTAATAATGACAGCAGTCTTATTAAAAGAATCAAAACACAGCAATAAAATGACTGAGAAGGTTCAGGAGCAATCAATATTAAAGAAATTATCCTATTTGATCACTCAACCTAATATGGCTCCATTGCTTGGTATCTTTTTAATTATCACATTGGTTTCACAAGTCCCCGCAACTTTATGGGTTATCTATGGGCAGGATCGTTATGGCTGGAGTATATTTATTGCAGGTGTTTCCCTTGCTAGTTATGGAATATGCCATTCTATTGCACAGGCTTTTGCTATCGCCCCTATGGTAAAGAGGTTTGGAGAGAAAAATACGTTGTTATGTGGAATAGCTTGCGATGCAATTGGTTTACTTCTTTTATCTATTGCTGTTGAAGAATGGGTGCCTTTTGCGTTGTTACCATTGTTTGCCCTTGGTGGAGTAGCCGTTCCTGCTTTGCAAGCAATGATGTCA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6988,Drugs,MEG_6988|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET39,gi|77745205|gb|DQ195075.1|1-676 gi|924867386|gb|KT346360.1|2807-2134 gi|187384667|gb|EU495991.1|688-15 gi|187384663|gb|EU495989.1|24-697 gi|695211247|ref|NG_036045.1|1043-1716 gi|187384657|gb|EU495986.1|26-697,4
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggaaggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgaaaggcaaggtaccgtaaccaccccatatggtccagccgtggtaatgggtcaaacacgccaagcattcgagcgaacacgcagtgatgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_219,Drugs,MEG_219|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1104448922|WP_071766621.1|NG_052123|1|1|aac(6')-Ib-cr3|aac(6')-Ib-cr|fluoroquinolone-acetylating_aminoglycoside_6'-N-acetyltransferase_AAC(6')-Ib-cr3 NG_052123:101-655,2
,atgaaaaaatatttttctttttgtcttttggggatttttattttttgtttttctcaacaaaatttaaaaagagatatcacaaagattatacaaggcaagaatgcccttgtggcggtatctgtgatgaactcaaaagggaaaacagaagtaaatattaacggaaacaaaaaagttccgatgcttagtgtgttcaaatttcacattgcattggcagttttggatttggtggacagaggtattttggatttggaacaaaatatttttgtcaagaaatcagaacttttggagaatacttggagccccattcgtgataaatatccgaatggcaatgtgaatatccctttgagagaaatcatagaacacactgtttctcagagtgataacaatggttgtgacattctgctgaggttgattggaggagttgatactgtccagaaattcatcgagagcaagggtatcaaagattttgcgataaaatacaatgaagaagaaatgaataagaatgggaaatccatctactcaaactatacaaccgcaaacgcctccagcaggcttctgcaaaaattttataatggtgagataatttccgagtcttccagagattttctattcagaatcatgtatgagacttctactggagcagacaggctcatatccctgcttcctccagatgttatcgttgcccataaaacagggacttctggcattgtatctggaattcaggctgctaccaatgatgtgggaatcatcattttacctgatgacgaatactacaccatatctgtttttgtgataaattccaaagaaaatacatcaactaacgaaaaaataattgctgatatatcaaaaacagtgtgggattattattttcaaaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2138,Drugs,MEG_2138|Drugs|betalactams|Class_A_betalactamases|CSP,1028110378|WP_063864748.1|NG_050141|1|1|blaSPU-1|blaCSP|CSP_family_class_A_extended-spectrum_beta-lactamase_SPU-1 NG_050141:1-882,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGCATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1400,Drugs,MEG_1400|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_39_JHTU01000073,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATACTAAAGAGTTAAATAATTTAGAAAAAAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAAATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTACAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1422,Drugs,MEG_1422|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_52_NZ_JVWM01000127,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaaagcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgcatcgaacacgcttgtgaagccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgatctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcaaaaccgggcgacaagcgagacactacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattcgctcatgcgttctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacaccgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1501,Drugs,MEG_1501|Drugs|betalactams|Class_A_betalactamases|CARB,686257849|WP_031841337.1|NG_050564|1|1|blaCARB-47|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-47 NG_050564:101-952,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggggtggcattgattaacacagcggataattcgcaaatactttatcgtgctgatgagcgcttcgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgagtctgttaaatcagcgagttgagatcaaaaaatctgacctggttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggcaggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaatgatatcgcggtgatttggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2151,Drugs,MEG_2151|Drugs|betalactams|Class_A_betalactamases|CTX,1331531445|WP_102607455.1|NG_056171|1|1|blaCTX-M-206|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-206 NG_056171:1-876,0
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGTTGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGTGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACAAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6882,Drugs,MEG_6882|Drugs|betalactams|Class_A_betalactamases|TEM,gi|16798373|gb|AF427129.1|AF427129|1-1103,0
,atggaaatagtacaagataaaataagaataagaactttgacaaatgatgattttcctttaatgctaaaatggttaactgatgatagagtattagaattttatggtggtagagataaaaaatatacattagaatcattaaaagagcattatactgaaaaatgggaagatgaagtatttagagtaattatagaatatgataatgttcctattggatatggacaagtatataaaatgtatgatgaactttattctgattatcattatccaaaaacaaatgaaatagtttatggaatggatcagtttataggagaacctgaatattggagtaaaggcattggctcaaaatatacaaaaatgatttttgagtttttaaaaaaagaaagaaatgctaatgcagttattttagaccctcataagaataatccaagagcaattaggtcatatcagaaatctggatttagaataattgaagatttgccagaacacgagttgcacgagggtaaaaaagaagattgctatttaatggaatataggtatgatgataatgttacaaatgttaaagcaatgaaatacttaatagaacattactttgaagattttaaagttgaaagtattaaggtaattggtagtggatatgatagtgtagcatatttagtaaatggagaatacatatttaaaacaaaatttagtgctaataagaaaaaaggatatgaaaaagaaaaagcaatttatgatttcttaaatcaaagattaaatactaatataaaaataccaaatgtaaaatattcatattttagtgataatatttctatattaggttataaagaaataaaaggaacttttttaacaccagaaatatattttgctttatcaaaagaaaagcaagaattattaaagcaagatattgctatgtttttaagacaaatgcacgatttagattatagtgaaataagtttgtatacgatagacaataaacaaaatgttttggaagaatatcaattactcaaagacacaatatatgatagtcttactgatattgaaaaacaatatgtagaagactttatgcaaagattacatagtacaactatatttgatggtaaaaaatgcttatgccataatgattttagttgtaatcatttattacttgatgatgaaaatagattatgtggtgtaatagattttggagattctggaattatagatgaatactgtgatttcatatatttgctagaagatagtgaagaagaaattggcgtgtcttttggagaagatatattaagattatacggaaatattgatatttcaaaagcaaaggaatatcaagatgttgtagaacaatattatccaatagaaactattgtatatggtattaaaaataatagacctgattttatagaaaaaggtagaaaagagatttatataagaactcgcaaagatgaaaaattaaggaagtga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_185,Drugs,MEG_185|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,949780442|WP_057097547.1|NG_062220|1|2|aac(6')-Ie2|aac(6')-Ie2|bifunctional_aminoglycoside_N-acetyltransferase_AAC(6')-Ie2/aminoglycoside_O-phosphotransferase_APH(2'')-If2 NG_062220:1-1455,2
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6435,Drugs,MEG_6435|Drugs|betalactams|Class_A_betalactamases|SHV,gi|256862155|gb|GQ389700.1|1-861 gi|695220758|ref|NG_039550.1|77-937,0
,atgattatcagtgagtttgatcgtgagaatattgtcttgcgagatcagcttgcagatcttttaagattgacttggcctgatgagtatggaacagagccgatgaaagaagtcgaacagttgatggctccagaacggattgctgtatcggcgattgaaggggaggaattggtcggttttgttggagcgatccctcaatatggcaaaacagggtgggagttacatcctttggtagtagcaagcgcgcatcgcaaacaacaaatcgggacacgattggtttcctatctggaaaaagaagtcgcttcatatggtggcctggtcatctatctagggacagatgatgttgaaggacaaacaaatttagttgaaacggatttatttgaagatacctttgcaaagttacaagaaatcaaaaatatcaatcatcatccctatacattttatgagaaacttggctatcagatcatcggtgtgatcccagatgcgaatgggtggaaccagcctgatatttggttagcaaaacgagtggccaaaagagagccaacggaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_171,Drugs,MEG_171|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,736694985|WP_034700626.1|NG_052337|1|1|aacA-ENT2|aacA-ENT2|aminoglycoside_6'-N-acetyltransferase NG_052337:101-649,2
,TCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATTGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6823,Drugs,MEG_6823|Drugs|betalactams|Class_A_betalactamases|TEM,gb|JX050178|+|0-852|ARO:3001058|TEM-199 [Proteus mirabilis] ,0
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattgtaatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttaaaagagctaaacaagccttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagctataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgataccttttggctcgataattctttacaaatttctgcaaaaaatcaagctgatttactttttaaactttcgcaaaattctttacctttttctaaaaaaattcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgccttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattattaaataagtatttagctaatttttccaacaataataggattaaaagcttttactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4581,Drugs,MEG_4581|Drugs|betalactams|Class_D_betalactamases|OXA,1391852890|WP_109545075.1|NG_057491|1|1|blaOXA-619|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-619 NG_057491:1-774,0
,ATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCACTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_357,Drugs,MEG_357|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|930190865|emb|LN555650.1|261077-260559 gi|930189590|emb|HG530658.1|196785-196267 gi|873463574|gb|KR106190.1|15787-15269 gi|730042884|gb|KJ571202.1|4590-5108 gi|825088700|gb|KP975077.1|106395-105877 gi|821392896|gb|KP873171.1|21051-20533 gi|768032361|gb|KM975294.1|1540-2058 gi|742797756|emb|LK054503.1|13276-13794 gi|636632016|gb|KJ579055.1|186-704 gi|635661965|gb|KJ547703.1|1034-1552,2
,ATGAAAATTATTAATATAGGTGTTTTAGCTCATGTTGATGCAGGAAAAACTACCTTAACAGAAAGCTTATTATATAACAGTGGAGCGATTACAGAATTAGGAAGCGTGGACAAAGGTACAACGAGGACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACAGGAATAACCTCTTTTCAGTGGGAAAATACGAAGGTGAACATCATAGACACGCCAGGACATATGGATTTCTTAGCAGAAGTATATCGTTCATTATCAGTTTTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATGGCGTACAAGCACAAACTCGTATATTATTTCATGCACTTAGGAAAATGGGGATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCCGAAATTGTAATCAAACAGAAGGTAGAACTGTATCCTAATATGTGTGTGACGAACTTTACCGAATCTGAACAATGGGATACGGTAATAGAGGGAAACGATGACCTTTTAGAGAAATATATGTCCGGTAAATCATTAGAAGCATTGGAACTCGAACAAGAGGAAAGCATAAGATTTCAGAATTGCTCCTTGTACCCTGTTTATCATGGAAGCGCAAAAAGCAACATAGGGATTGAGCAGCTTATAGAAGTGATAACGAATAAATTTTATTCATCAACATACAGAAAGAAGTCTGAACTTTGCGGAAATGTCTTCAAAATTGAATATTCGGAAGAAAGACAACGTCTTGCATATGTACGCCTTTATGGCGGAATCCTGCATTTGCGGGATTCGGTTAGAATATCGGAAAAGGAAAAAATAAAAATTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAAATTGATAAGGCTTATTCCGGGGAAATTGTTATTTTGCAAAATGAGTTTTTGAAGCTAAATAGTGTTCTTGGAGATACAAAGCTATTGCCACAGAGAGAGAGAATTGAAAATCCGCTCCCTCTGCTGCAAACAACTGTTGAACCGAGCAAACCTCAACAAAGGGAAATGTTACTTGATGCACTTTTAGAAATCTCCGACAGTGACCCGCTTCTACAATATTATGTGGATTCTACGACACATGAAATCATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGACTTGTGCTCTATTGCAAGAAAAGTATCATGTGGAGGTAAAAATAAAAAAGCCTACAGTCATTTATATGGAAAGACCGTTAAAAAAAGCAGAGTATACCATTCACATCGAAGTGCCACCGAATCCCTTCTGGGCTTCCATTGGTCTTTCTGTAGCACCGCTTCCATTAGGGAGCGGAGTACAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCGTTTCAAAATGCAGTTATGGAAGGGATACGATATGGCTGTGAACAAGGATTGTATGGTTGGAATGTGACGGACTGTAAAATCTGTTTTAAGTATGGCTTATACTATAGCCCTGTTAGTACCCCAGCAGATTTTCGGATGCTTGCTCCTATTGTATTGGAACAAGTTTTAAAAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAATTTATGCACCACAAGAATATCTTTCACGAGCATATAACGATGCTCCCAAATATTGTGCAAATATCGTAAATACTCAACTGAAAAATAATGAGGTCATTCTTAGTGGAGAAATTCCTGCTCGGTGTATTCAAGAATATCGTAATGATTTAACTTTCTTTACAAATGGACGTAGCGTTTGTTTAACAGAGTTAAAAGGGTACTATGTTACTACTGGTGAATCTGTTTGTCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7138,Drugs,MEG_7138|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|377684503|gb|JN846696.1|237-2156,4
,TAAAATTCTTGAAGACGAAAGGGCCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6906,Drugs,MEG_6906|Drugs|betalactams|Class_A_betalactamases|TEM,gi|3282023|emb|Y17581.1|1-936,0
,ATGTTCATGCCGCCTGTTTTTCCTGCTCATTGGCACGTTTCGCAACCTGTTCTCATTGCGGACACCTTTTCCAGCCTCGTTTGGAAAGTTTCATTGCCAGACGGGACTCCTGCAATCGTCAAGGGATTGAAACCTATAGAAGACATTGCTGATGAACTGCGCGGGGCCGACTATCTGGTATGGCGCAATGGGAGGGGAGCAGTCCGGTTGCTCGGTCGTGAGAACAATCTGATGTTGCTCGAATATGCCGGGGAGCGAATGCTCTCTCACATCGTTGCCGAGCACGGCGACTACCAGGCGACCGAAATTGCAGCGGAACTAATGGCGAAGCTGTATGCCGCATCTGAGGAACCCCTGCCTTCTGCCCTTCTCCCGATCCGGGATCGCTTTGCAGCTTTGTTTCAGCGGGCGCGCGATGATCAAAACGCAGGTTGTCAAACTGACTACGTCCACGCGGCGATTATAGCCGATCAAATGATGAGCAATGCCTCGGAACTGCGTGGGCTACATGGCGATCTGCATCATGAAAACATCATGTTCTCCAGTCGCGGCTGGCTGGTGATAGATCCCGTCGGTCTGGTCGGTGAAGTGGGCTTTGGCGCCGCCAATATGTTCTACGATCCGGCTGACAGAGACGACCTTTGTCTCGATCCCAGACGCATTGCACAGATGGCGGACGCATTCTCTCGTGCGCTGGACGTCGATCCGCGTCGCCTGCTCGACCAGGCGTACGCTTATGGGTGCCTTTCCGCAGCTTGGAACGCGGATGGAGAAGAGGAGCAACGCGATCTAGCTATCGCGGCCGCGATCAAGCAGGTGCGACAGACGTCATACTAG,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1096,Drugs,MEG_1096|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH6,gi|676254456|dbj|AP014637.1|1891020-1891856 gi|674651201|dbj|AB852526.1|52495-53331 gi|695212119|ref|NG_036333.1|16397-17233,2
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtgctggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtatttgtcaagcgttttatcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_216,Drugs,MEG_216|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502129|WP_071846281.1|NG_052328|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052328:101-655,2
,atgtcgaaaaaattaaaatgcctagcgctacttacgccattaattttgatccttccattgactgcttgtcagagtcctagccaaaaaaaacagcaagtcgtgtcattgcaaaatgagcaacagcgggtggcgaatttattccagcaggcgcaaaccacaggggttttggtcatctatgatggcaaacaaattcaaacatacggcaatgcgacacgccgtgcagatcaacgttttatcccagcctcaacctttaaaatactgaatgcactgattggtatacagcatcataaaaccacgccaaatgaagtctttaaatgggatggtcaaaaacgtgcatttagcagttgggaaaaagatttaagtttggctgaagctatgcaggcatcggctgtacctgtctatcaggagctagcacgacgcattggtctagaactcatgacccgtgaggtgaagcgtgttggctatggcaataaacatattggaacccaagtcgataatttttggttggtcgggcctttgaaaattacacctgtagaagaagttcgatttgtctatgcattggcaaagcaaaaactaccgtttgaccagtcaactcaacagcaagtgaaagacatgttattggtggatgagcatcaagggaccaagatttatgccaagagcggttggggtatggacgttaccccacaggtcggatggtggactggctggattgaacagccaaatggcaaaatcattgcattttcactgaatatgcaaatgagccagcctgcgcatgcagatgcgcgtaaagtgattgtttatcaagcattacaagagctgggattgttagccaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4735,Drugs,MEG_4735|Drugs|betalactams|Class_D_betalactamases|OXA,696303744|WP_032879257.1|NG_050611|1|1|blaOXA-307|blaOXA-286_like|OXA-286_family_class_D_beta-lactamase_OXA-307 NG_050611:101-937,0
,GTGCTCCGGGGTTTTTTCTTATCAATTCATACCAGGGATAACATCATGAAACTCTTTGCCCAGGGTACTTCACTGGACCTTAGCCATCCTCACGTAATGGGGATCCTCAACGTCACGCCTGATTCCTTTTCGGATGGTGGCACGCATAACTCGCTGATAGATGCGGTGAAACATGCGAATCTGATGATCAACGCTGGCGCGACGATCATTGACGTTGGTGGCGAGTCCACGCGGCCAGGGGCGGCGGAAGTTAGCGTTGAAGAAGAGTTGCAACGTGTTATTCCTGTGGTTGAGGCAATTGCTCAACGCTTCGAAGTCTGGATCTCGGTCGATACATCCAAACCAGAAGTCATCCGTGAGTCAGCGAAAGTTGGCGCTCACATTATTAACGATATCCGCTCCCTTTCCGAACCTGGCGCTCTGGAGGCGGCTGCAGAAACCGGTTTACCGGTTTGTCTGATGCATATGCAGGGAAATCCAAAAACCATGCAGGAAGCCCCGAAGTATGACGATGTCTTTGCAGAAGTGAATCGCTACTTTATTGAGCAAATAGCACGTTGCGAGCAGGCGGGTATCGCAAAAGAGAAATTGTTGCTCGACCCCGGATTCGGTTTCGGTAAAAATCTCTCCCATAACTATTCATTACTGGCGCGCCTGGCTGAATTTCACCATTTCAACTTGCCGCTGTTGGTGGGTATGTCACGAAAATCGATGATTGGACAGCTGCTGAACGTGGGGCCGTCCGAGCGTTTGAGCGGTAGTCTGGCCTGTGCGGTCATTGCCGCAATGCAAGGCGCGCACATCATTGGTGTTCATGACGTCAAAGAAACCGTAGAAGCGATGCGGGTGGTGGAAGCCACTCTGTCTGCAAAGGAAAACAAACGCTATGAGTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2955,Drugs,MEG_2955|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|81239530|gb|CP000034.1|3116361-3115468,8
,atgagcaagttatctgtattctttatatttttgttttgcagcattgctaccgcagcagagtctttgccagatttaaaaattgaaaagcttgatgaaggcgtttatgttcatacttcgtttgaagaagttaacgggtggggcgttgttcctaaacatggtttggtggttcttgtaaatgctgaggcttacctaattgacactccatttacggctaaagatactgaaaagttagtcacttggtttgtggagcgtggctataaaataaaaggcagcatttcctctcattttcatagcgacagcacgggcggaatagagtggcttatttctcgatctatccccacgtatgcatctgaattaacaaatgaactgcttaaaaaagacggtaaggttcaagccacaaattcatttagcggagttaactattggctagttaaaaataaaattgaagttttttatccaggcccgggacacactccagataacgtagtggtttggttgcctgaaaggaaaatattattcggtggttgttttattaaaccgtacggtttaggcaatttgggtgacgcaaatatagaagcttggccaaagtccgccaaattattaaagtccaaatatggtaaggcaaaactggttgttccaagtcacagtgaagttggagacgcatcactcttgaaacttacattagagcaggcggttaaagggttaaacgaaagtaaaaaaccatcaaaaccaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3317,Drugs,MEG_3317|Drugs|betalactams|Class_B_betalactamases|IMP,1044690745|WP_065419570.1|NG_051166|1|1|blaIMP-61|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-61 NG_051166:1-741,0
,atgctgaaaaagaattttaaaccattatttttttatttatgcttttggatgagtttggcggcgtgtcaatctcagtcttttggagggcttcagttccctaaaatagtttatcaatccgaggatttaaaggtggttcagattgcgcctgatacttttgtccatacgtcttatttagccacccagcaatggggaaaagtgccttgtaatggtatgattgtcagacatcaacgagaagcgatggtttttgatacgcccacagatgaagcctcttcggaagctttaatccattggattaaaaacgaactgaaagccgaaataaaatgggtggtgccgacgcattttcacgatgataatttgggcggattaccagcgtttcatcgggataagataatgtctattgcatattatagaactcaaaacttatctaaaaagcatcgaaaaccacagactattactaccttttcagctacagattcaacttggaatttgggaggtgcaaaaatccaaataggttattatggaaaaggacatacggaggataatatagttgtgtattttccaaaggatcaagtgttatttggtggctgtttggtaaaagaattgggggcaggtaaaggtaatttgtctgatgctttccctaaggaatggtcggcaaccattcaaaaagtgaaacacgcctatccagaagcgaaaattgtggtgcctggacatggcaaaataggggacaaagcgctattggactacacggcgcaacttttcaaaccataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4376,Drugs,MEG_4376|Drugs|betalactams|Class_B_betalactamases|ORR,1391852857|WP_109545042.1|NG_059317|1|1|blaORR-1|blaORR|subclass_B1_metallo-beta-lactamase_ORR-1 NG_059317:101-868,0
,ATGATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAGATTCTCTACCGTGCCGATGAACGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAAGAAGAGCGACCTGGTTAACTACAATCCCATTGCGGAGAAACACGTTAACGGCACGATGACGCTGGCTGAGCTTGGCGCAGCGGCGCTGCAGTATAGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGTCCCGATAAAGTGACGGCGTTTGCTCGCTCGTTGGGTGATGAGTCCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATACCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAAGCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTCTGCCGAAATCATGGGTAGTGGGCGATAAAACCGGCAGCGGAGATTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGAAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGCCGTCGGGATATTCTGGCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGATGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2392,Drugs,MEG_2392|Drugs|betalactams|Class_A_betalactamases|CTX,gi|32187778|emb|AJ567481.1|1-884,0
,atgaaaattattaatattggagttttagctcatgttgatgcgggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacagaggtacaacgaaaacggataatacgcttttagaacgtcagagaggaattacaattcagacggcgataacctcttttcagtggaaaaatactaagataaacatcatagacacgccaggacatatggattttttagcagaagtatatcgttcattatcagtattagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattgtttcatgcacttaggaaaataggtattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgcggaaattgtaatcaaacagaaggtagaactgcatcctaatatgcgtgagatgaactttaccgaatctgaacaatgggatatggtaatagaaggaaatgattaccttttggagaaatatacgtctgggaaattattggaagcattagaactcgaacaagaggaaagcataagatttcataattgttccctgttccctctttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacgactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctgcgatattatgtggattctgcgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgcactgctgcaagaaaagtatcatgtggagatagaaataaaagagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagttccaccgaatcctttctgggcttccattggtctatctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7133,Drugs,MEG_7133|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028099865|WP_063856114.1|NG_048221|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048221:1-1920,4
,GTGGAAGTCGCTGCGGAGGCCGACGCCATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACTCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6606,Drugs,MEG_6606|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|695213434|ref|NG_036607.1|16290-17156,8
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtattattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgacaagcctggtaaatattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtagtgtttatacctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_602,Drugs,MEG_602|Drugs|betalactams|Class_C_betalactamases|ADC,1058243758|WP_068981630.1|NG_051463|1|1|blaADC-99|blaADC|class_C_beta-lactamase_ADC-99 NG_051463:1-1152,0
,atgaatcttttcaggaattactataatccaatccgtaatgttatgttaattattttctttgttctaactgacttgtcgttgattgcgcaaacacaaccagaatatcctgttatcagattaaatgacgaactcgaagtacgcgaaattcttcccaatgcttttgtcattacgcataaattcccatggggggggaactcgttagttgttttgatcggagaaaaatatgcggtctttgtcgacactccatatactccagaggctaccgagaacgtactggattggataaataagcaatatggtaatcgtcaattcattgaaattaatacaggttaccatgtagataatcttggcggaaacgatgcgcttttacacagaaatataccaattatcggttccgataaaactgtatcattacttcgtgaacgtggggaagccactagacagctaacaatggggtggctggaaggcccgggaaatgaaaaattcttgaaacgacatgaaactattccctatgtaggaccatcgcagatatttcaattaacggaagggtatcattttactgtgggagatgaaccaattgaagtttttttccctggggaaacacatgctcctgataacatagtcgtgtatttcccagagcgaaaaatattatttggtggatgcatgttgcgggtaggcaatggaactggaaatagagcggatgcaaacatggatacatggaaatcatccgtggaacgattacgggatttcgattgtgttgccgtaattccaggacatggaattcgatttgatcctggcgtaattgaaaatacgatttctgttttgccatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_6557,Drugs,MEG_6557|Drugs|betalactams|Class_B_betalactamases|SPS,503020413|WP_013255389.1|NG_059316|1|1|blaSPS-1|blaSPS|subclass_B1_metallo-beta-lactamase_SPS-1 NG_059316:101-931,0
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcaaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccggagatgggcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacggggcccagaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3089,Drugs,MEG_3089|Drugs|betalactams|Class_A_betalactamases|GES,1509794517|WP_122630826.1|NG_062215|1|1|blaGES-38|blaGES|class_A_beta-lactamase_GES-38 NG_062215:1-864,0
,AACGAGTGAGGGAATTTCAGGTAAGATACTTCGGATGAGGAGCAAAAAGGTGGTTTATACTTCCTATACCCTTTATACTTCCTATACCCGGGGGGGCAAGTCATGGATAACCCATTGAAACTGGGCTATTTGAACGCCGACTTCACATCGGCTTCACAGAGCCTCATATTGCGCACACCTTGCGGGATTAGGCTGGGAGCACTGCCAGGCACCCAGGCAGCACATTCGACTTATGACGAGAGGAGTAGACCCGATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTACTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCGGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGCCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCGTTTGCCCCCTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGTGTCAACCCTGGCATGCTGGCGGACGAGGCCTATGGCATCAAGACCAGCTCGGCGGATCTGCTGCGTTTTGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACCAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGAGCCTCGAAGCCAATCCGACGGCGGCGCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTACCCCATCGAGGCGCGCATCAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGAAAGAAAGAGGGCGGTACATTCGGTGAATGTGCCGCCCTTTTTCTGGTGCTGGGGGAATACCCCCGCTAGTCGTACT,beta-lactamase,antibiotic inactivation,betalactams,MEG_1994,Drugs,MEG_1994|Drugs|betalactams|Class_C_betalactamases|CMY,gi|695214120|ref|NG_036738.1|6314-7791 gi|13591818|gb|AF357599.1|1-1478 gi|573013567|dbj|AP013064.1|27532-27602 gi|573013567|dbj|AP013064.1|29787-29857 gi|573013567|dbj|AP013064.1|29906-29976 gi|146150962|gb|EF382672.1|102448-102518 gi|695199441|ref|NG_035225.1|428-498 gi|695200064|ref|NG_035368.1|48-118,0
,atgaaaacagtatttatccttatctccatgcttttccctgtcgcagttatggcacagaaaagcgtaaaaatatccgatgatatcagtatcacccaactctcggacaaagtgtacacttatgtatccctcgccgaaatcgaaggatggggtatggtaccttccaacgggatgattgttatcaacaaccaccaggcagcgttgctggacacaccgatcaatgacgcacaaacggaaatgctggtcaactgggtgacagactctttgcatgccaaagtcaccacgtttatcccgaaccactggcacggcgattgtattggcggactgggttacctgcaaaagaaaggtgtccgatcatacgcgaaccagatgacgatagacctcgccaaggaaaaaggattgcccgtaccggaacatggattcaccgattcactgaccgtcagcttggacggcatgcctctccaatgctattatttaggaggcgggcatgcgaccgacaatatcgtggtttggctgccgacagagaatatcctttttggcggatgtatgcttaaagacaaccagacgacaagcatcggcaacatctcggacgcggacgtgacggcatggccgaaaactctcgataaggtaaaagccaagttcccctcggcccgctacgtcgtgcccggacatggtaactatggcggaaccgaactgatagagcataccaagcagatcgtgaaccaatatatagaaagcacttcaaagccatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1663,Drugs,MEG_1663|Drugs|betalactams|Class_B_betalactamases|CFIA,1188444883|WP_085562385.1|NG_054668|1|1|cfiA22|cfiA|subclass_B1_metallo-beta-lactamase_CfiA22 NG_054668:1-750,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5442,Drugs,MEG_5442|Drugs|betalactams|Class_C_betalactamases|PDC,1343491225|WP_104009841.1|NG_056399|1|1|blaPDC-244|blaPDC|class_C_beta-lactamase_PDC-244 NG_056399:1-1170,0
,atgtttaagtttattacgggtatagtcgttgcttttgttagttttaataccttgtctgcaccaatgcttaagcctcttcaatttgaagaagtcacgaccaatatttttttggttaagtcatttcgagaatttaaaaatttaaaaagtccggataacccaattattattgatgctaactcattgatttatatagatagtaaagatgcgtatctcattgatactccatggaatgctgaaaatatgcctcaattgatgacatggattgaaaacagagatttaacgcttaaaaaaacagtatttacacattttcatgaagatcaaacgggtggtttagaatatttgcaagaacatgggtttgatacttatgctacaaaattaaccaatacactgcttgttaaagataataaaaaagcggcaaatcatgagttagacgctcaggaatctgttttattggataataaaattgaggttttttatccgggaccaggacattcaaaagataactctgttgtgtggtttcctaaagaaaaagtgttattaggtggatgcctaatgcgagcgaatgaggtgaacaccattggctggacaggcgatgcagacctcgctaaatgggctcaatcagccaaaaatgtgttaataaaataccctgaaactaaattggttattcctgggcacggagatatcgggaaagggactagtgtaatttctcatactgtcaatattgctgaaagtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_721,Drugs,MEG_721|Drugs|betalactams|Class_B_betalactamases|ALI,1046203883|WP_065597326.1|NG_059328|1|1|blaALI-2|blaALI|subclass_B1_metallo-beta-lactamase_ALI-2 NG_059328:101-838,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcaaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccaaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5457,Drugs,MEG_5457|Drugs|betalactams|Class_C_betalactamases|PDC,1393270456|WP_109791201.1|NG_057599|1|1|blaPDC-267|blaPDC|class_C_beta-lactamase_PDC-267 NG_057599:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacggggcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5532,Drugs,MEG_5532|Drugs|betalactams|Class_C_betalactamases|PDC,1034011035|WP_064483994.1|NG_050785|1|1|blaPDC-129|blaPDC|class_C_beta-lactamase_PDC-129 NG_050785:1-1194,0
,ACAAAGCTTGGAGTTCGGGAAGACGTCATGCACTTCGACATTGATCCATTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGGTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAGGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_339,Drugs,MEG_339|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|18958399|gb|AF355189.1|1837-2439,2
,atggttaaaaaatcattacgccagtttgcgctgttggccgcgacggtctttccgctgctggcaagcagcgtatcgctacaggcacaaacgctaagcgtagagcagaaacttgcggctttagagcagcgttcagggggacggcttggggtcgcgctgatagatactgcggatggttcgcaaattctctatcgtggcgatgagcgtttcgcgatgtgtagtaccagcaaagtgatggccgctgccgcggtgctaaagcaaagtgaaagtcagcacgatcttttaaatcagcgcattgagatcaaaaagggtgacctgactaactataacccgattgcggaaaaacatgtcggtgggtcgatgtcgttgtctgagctcagcgccgcggccttgcagtacagcgataacgtggcgatgaataagcttatcgctcaactgggtggcccgcagggggttaccgcgtttgcccgtaagattggggatgagacgtttcgtctcgatctcacggaaccgacgctgaacactgcaattcccggcgatccacgcgataccacatcaccacgggctatggcacaaacgctgcgcaacctgacgctgggaaaagcgcttggtgacgctcaaagggcgcagttggtgacctggatgaaagggaatacgactggaacggccagtattcaggctggactaccggcttcgtgggtggtgggcgataaaaccggcagcggtgattacggcaccaccaacgacattgcggtgatttggccgaaagatcgtgcacctttggttttggttacctacttcacgcagcctcagcctgaggcggaaagccgtcgtgatgtattagcctcggcggcgaaaatcgtcactgagggattatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3454,Drugs,MEG_3454|Drugs|betalactams|Class_A_betalactamases|KLUC,695273558|WP_032495492.1|NG_062210|1|1|blaKLUC-4|blaKLUC|class_A_extended-spectrum_beta-lactamase_KLUC-4 NG_062210:1-876,0
,ATGATTGATTTAAAAAAGAATTACCAAATTATGGGGATTGTCAACACGACCCCCGACTCTTTTTCTGATGGCGGTAGCTACACAACGGTCGACGTGGCCTATCAACATGCGCTTCATCTACTAGAAGCGGGGGCCGATATTTTAGACATTGGCGGCCAATCCACACGTCCTGGCTACGAAGAAGTTTCTCCACAAGTTGAGGCAGACCGAGTATTACCATTAATAAAAAAAATACGTGAGACTTCTCTAGCGCCGATTTCTGTGGACACCTACTATCCCGAAGTAGCGGAAGCCGCGATCCAAGCTGGCGCCACAATGATTAATGACATCAAAGGATTAGACACTCCGGGGATGGCAGAAGTCCTCGCACAATATCCTGAAGTCCAAGTTGTGATTATGCATTCTAGAAAACGCCAATCGCTTTCTTTAAAAGAAGAGTTGCACCAATTTTATACAGAAAAAATTGAACAATGCCAAAAATATGGGCTTTCCTTAGAAAAAATTTGTTTCGATCCAGGGATTGGCTTTCATAAAACTGTCGCAGAAAACCTTCAACTGTTAAAAGATCCTAACGCCTTTCGCTACCAAGATTATCCGTTACTATACGGCGTTTCTCGCAAACGAACCATTGGCGCTTTAACGAACGAACCAGAACCAGCCAACCGTGATTTTGGCTCAGCCGCTGCTTCCTTGTATGCAGCACAACAAGGCGTAGAAATTTTACGTGTTCATAATGTCCAAGGCTTAAAACAAACATTTGATGTCTGGCGAGCATTGTCGGAGAAGGAGTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2942,Drugs,MEG_2942|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|29350190|gb|AE016830.1|3141537-3140746,8
,atgatgaaactccgccacgccgccacgggcgccttccttgccgcgctggccaccttcgcccatgccgaacaccctatctgcacgctcgttgccgatgcagccacgggcaaggtcgtcgtgcaggagggcaagtgcaacgagcgcgtgacgccggcgtccaccttcaagctggcgctggccgtcatgggttacgacgccggcttcctgaaagatccgcacacgccggtcgaacacttcaggcgcggcgaccccgactggggcggccagccgtggcgccagcctgtcgacccgacgctgtggctcaagtattcggtggtctggtattcccagcgcatcacccacgcgatgggcgcgcagacgttcgcctcgtacgtgcgcaagctcgactacggcaacatggatgtgagcggcgacccgggcaagaacaacggcctggaccgctcgtggatcacctcgtcgctgaagatctcgcccgaggagcaggtcggctttctgcgccggctcgtcaaccggcagttgccggtgtcggcgcagacgtacgagatggtcgaccgcatcgtgcagacgtggcaggtgccgggcggctgggccgtgcagggcaagacgggcacggcgggcccggcaccgggcaatacctcggccgacggcacgtgggatcaggcgcacgcttacggctggtttgtcggctgggcgaagaaaggaggccagacctacgtgtttgcgaacctgatccaggacgacaagatcgagcccacctcgggcggcatccgctcgcgcgatgcgatgctggcgcgcctggcgcaggtgctggctgccgccaagccctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4595,Drugs,MEG_4595|Drugs|betalactams|Class_D_betalactamases|OXA,1331531454|WP_102607464.1|NG_056181|1|1|blaOXA-572|blaOXA-22_like|OXA-22_family_class_D_beta-lactamase_OXA-572 NG_056181:1-828,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGTTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6597,Drugs,MEG_6597|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|695200407|ref|NG_036125.1|2994-3833 gi|695211628|ref|NG_036097.1|7756-8595 gi|974751547|gb|KU130294.1|233473-234001 gi|982189197|gb|CP013993.1|5430539-5431065,8
,atgaaaaagttattcctgttggttgggctgatggtttactcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacatttaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggcaggacaaagcacacgtatcgaacacgcttgtgaagccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacactgtttttgcgctctattggcgacaaagcaacgcgacttgaccgattggagccccgtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacataccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattcgctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacaccgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1498,Drugs,MEG_1498|Drugs|betalactams|Class_A_betalactamases|CARB,646509504|WP_025546314.1|NG_048735|1|1|blaCARB-31|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-31 NG_048735:1-852,0
,TCACACGAATTGAATGTTCAGGGGATTAGGATGATGAGAAAAAGCGTAAGGCGGGCGATGTTAATGACGACAGCCTGTGTTTCGCTGCTGTTGGCCAGTGTGCCGCTGTGTGCCCAGGCGAACGATGTTCAACAGAAGCTCGCGGCGCTGGAGAAAAGCAGCGGGGGACGACTGGGTGTGGCGTTGATTAACACCGCCGATAACACGCAGACGCTCTACCGCGCCGACGAGCGTTTTGCCATGTGCAGCACCAGTAAAGTGATGGCGGTAGCGGCGGTGCTTAAGCAAAGTGAAACGCAAAAGGGCTTGTTGAGTCAGCGGGTTGAAATTAAGCCCTCAGACTTGATTAACTACAACCCCATTGCGGAAAAACACGTCAATGGCACGATGACATTCGGGGAGTTGAGCGCGGCGGCGCTACAGTACAGCGATAATACTGCCATGAATAAGCTGATTGCCCATCTCGGGGGGCCGGATAAAGTGACGGCATTTGCCCGTACGATTGGCGATGACACGTTCCGGCTCGATCGTACCGAGCCGACGCTCAACACCGCGATCCCCGGCGACCCGCGCGATACCACCACGCCGTTAGCGATGGCGCAGTCTCTGCGCAATCTGACGTTGGGCAATGCCCTGGGTGACACTCAGCGTGCGCAGCTGGTGATGTGGCTGAAAGGCAACACCACCGGCGCTGCCAGCATTCAGGCAGGGCTACCCACATCGTGGGTTGTCGGGGATAAAACCGGCAGCGGCGATTATGGTACGACGAATGATATCGCGGTTATTTGGCCGGAAGGTCGCGCGCCGCTCGTTCTGGTGACTTACTTCACCCAGTCGGAGCCGAAGGCAGAGAGCCGTCGTGACGTGCTCGCTGCTGCCGCCAGAATTGTCACCGACGGTTATTAATACTCAC,beta-lactamase,antibiotic inactivation,betalactams,MEG_2389,Drugs,MEG_2389|Drugs|betalactams|Class_A_betalactamases|CTX,gi|260178851|gb|GQ870432.1|1-913,0
,TCGGCCCTCACTCAAGGAAGTATTGCGGTTATGCGTTATGTTCGCCTGTGTGTTATCTCCCTGTTAGCCAACCTGCCACTGGCGGTAGACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGCTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTGTCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGCACTGAATGAGGCGCTTCCCGGCGACGCGCGCGACACCACCACCCCGGCCAGCATGGCCGCCACGCTGCGCAAACTACTGACCGCGCAGCATCTGAGCGCCCGTTCGCAACAGCAACTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGCCGGGCTGGTTTATCGCCGACAAAACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAACCGGAGCGCATTGTGGTGATCTATCTGCGGGATACCCCGGCGAGTATGGCCGAGCGTAATCAACATATCGCCGGGATCGGCGCAGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3548,Drugs,MEG_3548|Drugs|betalactams|Class_A_betalactamases|LEN,(Bla)LEN-24:AM850914:1-861:861,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4468,Drugs,MEG_4468|Drugs|betalactams|Class_D_betalactamases|OXA,1188444907|WP_085562409.1|NG_054699|1|1|blaOXA-555|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-555 NG_054699:1-825,0
,atgagtaacgcagtacccgccgagatttcggtacagctatcactggctctcaacgccatcgagcgtcatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattactcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_814,Drugs,MEG_814|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502168|WP_071846319.1|NG_052402|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052402:101-892,2
,atgcaatttaaaaaaatttcttgcttacttttaccgcctctttttatttttagtagctcaatttatgcgggtaatacaccaaaagagcaagagatcaaaaaactggttgatcaaaattttaagcctttattagaaaaatatgatgtgcccggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtctacaatccgttcaagataaaaaagccgttaatagtagtaccatttttgagctaggctcggtcagtaaattatttaccgctacagcaggcggatatgccaaaacaaaaggaacaatctcttttgatgacacgcccggaaaatattggaaagaactaaaaaatacaccgattgatcaagtgaatttacttcaacttgcgacatataccagtggcaaccttgccttgcaatttccagatgaagtaaaaacagaacagcaagttttaacgtttttcaaagaatggaaacctaaaaacccaatcggtgaatatcgacaatattcaaatccaagcattggtttatttggaaaagttgttgctttgtctatgaataaacctttcgaccaagtcttggaaaaaaccatttttacagatcttggcttaaaacatagctatgtaaatgtgcctaaaactcaaatgcaaaactatgcatttggctatagccaagaaaatcagccgattcgcgttaatcctggtccgctcgatgcaccagcatacggcgttaaatctaccctaccagatatgctgagttttattaatgccaacctgaacccgcagaaatatccagcagatattcaacgtgcaattaatgaaacacatcaaggtttctaccaagtgggtacgatgtatcaagcactaggttgggaagagttttcttatccagcacctttacaaactttattagacagtaattcagaacaaatcgtgatgaaacctaataaagtaactgctatttcaaaagaaccttccgttaagatgttccacaaaactggatcgactaacggttttggaacatatgtcgtgttcattcctaaagaaaatattggtttagtcatgttaactaataaacgtattcccaatgaagaacgcattaaagcagcttatgctgtgttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_507,Drugs,MEG_507|Drugs|betalactams|Class_C_betalactamases|ADC,507069649|WP_016140427.1|NG_064693|1|1|blaADC-137|blaADC|class_C_beta-lactamase_ADC-137 NG_064693:101-1252,0
,atgaatccctatctacagttagttagcaaagaatttccgttagaaaaaaaccaagaaccccctcatttagtccttgctgccttcagcgaagacgaggtttacttgcagccagaagcagccaaacaatggaaacggctcgtcaaagccttaaagcttgaaaacgagatctgcttgttagatggctaccgaaccgaaaagcagcaacggtatttatgggaatattccttgaaagaaaatgggctagcctatacgaaacaatttgtggcgttgcccggttgcagtgaacatcagttaggcttagcgatcgatgttggtttaaagggcagccaggatgatttgatctgcccacgatttcgtgacagcgcagccgccgatttatttacccaggaaatgatgaactatgggtttattttacgctatcccgcagacaaacaggagattacagggattggctatgaaccatggcattttcgttatgtcggtctgcctcatagtcaaatcatcgccagtcaacagtggaccttggaagaataccatcaataccttgaacaaactgcgaggcagttcgcatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7574,Drugs,MEG_7574|Drugs|Glycopeptides|VanC-type_resistance_protein|VANXYC,491370946|WP_005228842.1|NG_048511|1|1|vanXY-c2/3|vanXY-c2/3|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C NG_048511:101-673,5
,ATGGAGAATATTTTTAGCAAAGATTCTGATATTGAACTTGTAGATATAGAAAATTCTATAAAAAGTAGTTATTTAGACTATTCTATGAGTGTTATTATAGGTCGTGCTTTGCCTGATGCAAGAGATGGTTTAAAGCCTGTTCATAGAAGAATTTTATATGCTATGCAAAATGATGAGGCAAAAAGTAGAACAGATTTTGTCAAATCAGCCCGTATAGTGGGTGCTGTTATAGGTCGTTATCACCCGCATGGAGATACAGCAGTTTATGATGCTTTAGTTAGAATGGCTCAAGATTTTTCTATGAGATATCCAAGTATTACAGGACAAGGTAACTTTGGATCTATAGATGGCGATAGTGCTGCTGCGATGCGTTATACTGAAGCAAAAATGAGTAAACTTTCTCATGAGCTTTTAAAAGATATAGATAAAGATACGGTCGATTTTGTTCCAAATTATGATGGTTCAGAAAGTGAACCTGATGTTTTACCTTCTAGGGTTCCAAATTTATTATTAAATGGTTCAAGTGGTATAGCTGTAGGTATGGCGACAAATATCCCACCTCATAGTTTAAATGAGTTGATAGATGGACTTTTATATTTGCTTGATAATAAAGATGTAAGCTTAGAAGAGATTATGCAGTTTATCAAAGGTCCAGATTTTCCAACAGGTGGAATAATTTATGGTAAAAAAGGCATTATAGAAGCTTATCGCACAGGGCGTGGTCGTGTGAAAGTGCGCGCTAAAACTCATATTGAAAAAAAGACAAATAAAGATGTTATTGTTATAGATGAGCTTCCTTATCAAACCAATAAAGCTAGGCTTATAGAGCAGATTGCAGAGCTTGTTAAAGAAAAGCAAATTGAAGGAATATCTGAAGTAAGAGATGAGAGCAATAAAGAAGGAATCCGTGTTGTTATAGAGCTTAAACGTGAGGCTATGAGTGAAATTGTTTTAAATAATCTATTTAAATCTACCACTATGGAAAGTACTTTTGGTGTGATTATGTTAGCAATTCACAATAAAGAACCTAAAATTTTCTCTTTGCTAGAACTTTTAAATCTTTTCTTAACCCATAGAAAAACAGTTATTATTAGAAGAACGATTTTTGAACTTCAAAAGGCAAGAGTAAGAGCTCATATTTTAGAAGGTCTTAAAATTGCACTTGATAATATAGATGAAGTGATTGCTTTAATTAAAAATAGTTCCGACAATAATACCGCAAGAGATTCTTTGGTAGCTAAATTTGGTCTTAGTGAACTTCAAGCGAATGCTATTTTAGATATGAAACTGGGTCGTTTAACAGGACTTGAAAGAGAAAAAATTGAAAATGAACTTGCAGAATTAATGAAAGAAATTGCAAGACTTGAAGAAATTTTAAAAAGTGAAACTTTGCTTGAAAATTTAATTCGCGATGAATTAAAAGAAATTAGAAGCAAATTTGATGTACCACGTATTACTCAAATTGAAGATGATTATGATGATATTGATATTGAAGATTTGATTCCTAATGAAAATATGGTTGTAACTATCACGCATCGTGGTTATATTAAGCGTGTGCCTAGTAAACAATATGAAAAGCAAAAACGAGGCGGAAAAGGAAAATTAGCCGTTACGACTTATGATGATGATTTTATAGAAAGTTTCTTTACGGCAAATACACATGATACGCTTATGTTTGTAACAGATCGTGGACAGCTTTATTGGCTTAAAGTTTATAAAATTCCTGAAGGCTCAAGAACGGCTAAAGGAAAAGCAGTGGTAAATCTTATCAATTTACAAGCTGAAGAAAAAATCATGGCTATTATTCCAACCACGGATTTTGACGAGAGTAAATCTTTATGTTTCTTTACTAAAAATGGTATTGTAAAGCGTACAAATTTGAGTGAATATCAAAATATCAGAAGTATTGGAGTTAGAGCGATCAACTTAAATGAAAATGATGAGTTGGTAACTGCTATTATTGTTCAAAGAGATGAAGATGAAATTTTTGCCAGTGGTGGTGAAGAAAATTTAGAAAATCAAGAAATTGAAAATTTAGATGATGAAAATCTTGAAAATGAAGAAAGTGCAAGTACACAAGGTAAAATGCTCTTTGCAGTAACCAAAAAAGGTATGTGTATCAAATTCCCGCTTGTTAAAGTGCGTGAAATCGGCCGTGTAAGTCGTGGGGTGACAGCTATTAAGTTTAAAGAGAAAAATGACGAATTAGTAGGTGCAGTTGTTATAGAAAATGATGAGCAAGAAATTTTAAGCGTAAGTGCAAAAGGTATAGGAAAACGCACCAATGCTGGAGAATATAGATTGCAAAGTAGAGGTGGTAAGGGTGTAATTTGCATGAAGCTTACAGAAAAAACTAAAGATCTTATTAGTGTAGTTATAGTAGATGAAACTATGGATTTGATGGCTCTTACAAGTTCAGGCAAGATGATACGTGTTGATATGCAAAGCATTAGAAAAGCAGGGCGTAATACGAGTGGCGTCATCGTGGTTAATGTGGAAAATGACGAGGTGGTTAGCATCGCTAAGTGTCCTAAAGAGGAAAATGATGAGGATGAGTTAAGCGATGAAAACTTTGGTTTAGATTTGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3190,Drugs,MEG_3190|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|152938384|gb|CP000768.1|685775-688363,3
,ATGAATGTTGAATATTCTAAAATAAAGAAAGCAGTACCTATTTTACTATTCTTATTTGTATTCAGTTTGGTTATAGACAACTCATTTAAATTGATTTCTGTAGCCATTGCTGATGACTTAAACATTTCTGTAACGACAGTAAGTTGGCAAGCGACATTAGCCGGTTTAGTAATTGGTATTGGCGCTGTAGTATACGCTTCATTATCTGATGCCATTAGTATACGCACACTATTTATTTATGGCGTGATATTAATCATTATCGGATCAATTATTGGTTACATTTTCCAACATCAATTCGCATTACTTTTAGTTGGACGTATTATTCAAACTGCAGGTTTAGCTGCTGCAGAGACATTATATGTGATATATGTTGCAAAGTATCTTTCTAAAGAGGACCAGAAGACTTACCTTGGCTTAAGTACGAGCAGTTATTCCTTGTCATTAGTTATCGGTACATTATCAGGTGGATTTATTTCTACGTATTTACACTGGACAAATATGTTTTTAATTGCGTTAATCGTAGTATTTACGTTGCCATTCCTATTTAAATTATTACCAAAAGAAAATAATACAAATAAAGCTCATTTAGATTTTGTTGGCTTAATTCTAGTGGCAACTATCGCTACAACAGTCATGCTGTTTATTACGAACTTTAATTGGTTATATATGATTGGTGCCTTAATTGCGATTATCGTTTTTGCGCTATATATTAAAAATGCTCAACGTCCATTAGTAAACAAATCATTTTTCCAAAATAAACGTTATGCTTCATTTTTATTTATAGTATTTGTAATGTATGCCATCCAATTGGGTTATATTTTTACGTTCCCATTCATAATGGAACAAACTTATCATCTTCAACTAGACACAACATCACTGTTATTAGTACCGGGTTATATTGTAGCAGTCATCGTTGGTGCACTAAGTGGTAAAATCGGCGAATATCTTAATTCAAAACAAGCGATTATCACAGCAATTATTTTAATCGCACTGAGCTTGATTTTACCTGCATTTGCAGTAGGTAATCACATTTCAATCTTCGTCATTTCTATGATATTCTTTGCAGGTAGCTTTGCTTTAATGTATGCACCTTTACTTAACGAAGCCATTAAAACAATAGATCTTAATATGACAGGTGTGGCTATTGGTTTTTATAATTTAATTATTAATGTGGCGGTATCTGTAGGTATTGCGATTGCTGCGGCTCTAATCGATTTTAAAGCATTAAATTTCCCAGGCAATGATGCATTAAGTTCACATTTCGGTATTATTTTAATTATTTTAGGTTTAATGAGTATTGTCGGATTAGTTTTATTCGTCATCTTAAATCGTTGGACACAATCTGAAAAATAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6985,Drugs,MEG_6985|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET38,gi|344176319|emb|FR821779.1|130976-132328,4
,atgacatggagaacgaccaaaacacttttacagcctcaaaatctggacttcaatgagtttgagattcttacttccgtaattgagggcgcccgaattgtcggcattggcgagggcgctcattttgtcgcggagttttcactggctagagcaagtcttatccgctatttggtcgaaaggcatgattttaatgcgattggtttggaatgtggggcgattcaggcatcccggttatctgaatggctcaactcaacagccggtgctcatgaacttgagcgattttcggataccctgaccttttctgtgtatggctcagtgctgatctggctgaaatcatatctccgcgaatcaggaagaaaactgcagttagtcggaatcgacttacccaacaccctgaacccaacggacgacctagcgcaattggccgaaattatccagctcatcgatcacctcatgaaaccgcacgttgatatgctgactcacttgttggcgtccattgatggccagtcggcggttatttcatcggcaaaatggggggagctagaaacggctcggcaggagaaagctatctcaggggtaaccagattgaagctccgcttggcgtcgcttgcccctgtcctgaaaaaacacgtcaacagcgatttgttccgaaaagcctctgatcgaatagagtcgatagagtatacgttggaaaccttgcgtataatgaaaactttcttcgatggtacctctcttgagggagatacttccgtacgtgactcgtatatggcgggcgtagtagatggaatggttcgagcgaatccggatgtgaagataattctgctggcgcacaacaatcatttacaaaaaaccccagtctccttttcaggcgagcttacggctgttcccatggggcagcacctcgcagagagggtgaattaccgtgcgattgcattcacccatcttggacccaccgtgccggaaatgcatttcccatcgcccgacagtcctcttggattctctgttgtgaccacgcctgccgatgcaatccgtgaggatagtatggaacagtatgtcatcgacgcctgtggtacggagaattcatgtctgacattgacagatgcccccatggaagcaaagcgaatgcggtctcaaagcgcctctgtaaaaacgaaattgagcgaggcatttgatgccatcgtctgtgttccaagcgccggcaaggacagcctagttgccctatag,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_2741,Drugs,MEG_2741|Drugs|MLS|Macrolide_esterases|EREA,1105502058|WP_071846210.1|NG_052184|1|1|ere(A)|ere(A)|EreA_family_erythromycin_esterase NG_052184:101-1321,7
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCAGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTACAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1948,Drugs,MEG_1948|Drugs|betalactams|Class_C_betalactamases|CMY,gb|Y15130|+|0-1143|ARO:3002015|CMY-4 [Proteus mirabilis] ,0
,atgagccatattcaacgggaaacatcttgctcgaggccgcgattaaattcaaatctggatgctgatctatatgggtatagatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggcatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcgtggttactcaccactgcgatccccgggaaaacagcattccaggcattagaagaataccctgattcacgtgaaaatattgttgatgctctggcagcgttcctgcgccggttgcattcgattcctctttgtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgacgagcgtaatggctgtcctgttgaacaagtctggaaagaaatgcataagcttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgaattttcaccttcattacaaaaacggctttttcataaatatggcattgataaccctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctaa,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1022,Drugs,MEG_1022|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,695270076|WP_032492145.1|NG_047438|1|1|aph(3')-Ia|aph(3')-Ia|aminoglycoside_O-phosphotransferase_APH(3')-Ia NG_047438:101-916,2
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagttagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_863,Drugs,MEG_863|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502094|WP_071846246.1|NG_052269|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052269:101-892,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaagctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5517,Drugs,MEG_5517|Drugs|betalactams|Class_C_betalactamases|PDC,959890119|WP_058161279.1|NG_054992|1|1|blaPDC-207|blaPDC|class_C_beta-lactamase_PDC-207 NG_054992:1-1194,0
,atgagcaacgcagtgcccgccgagatttcggtacagctatcacaggcactcaacgtcatcgagcatcatctgggatcgacgttgctggccgtgcatttgtacggctctgcactcgacggtggcctgaagccatgcagtgatattgatttgctggttactgtgactgcacagctcgatgagactgtgcggcaggctctgttcgtagatttcctggaagtttccgcttctcccggccaaagtgaagctctccgtgccttggaagttaccatcgtcgtgtacggcgatgttgttccttggcgttatccagccagacgggaactgcaattcggggagtggcagcgcaaggacattcttgcgggcatcttcgagcccgcgacaaccgatgttgatctggctattctgctaactaaagcaaggcaacacagccttgccttggcaggttcggccgcggaagatttcttcaactcagtcccggaaagcgatctattcaaagcactggccgacaccttgaaactatggaactcacaaccggattgggcaggcgacgagcggaatgtagtgcttactttgtctcgcatttggtacagcgcagcaaccggcaagatcgcgccgaaggatgtagctgccaactgggtaatggaacgcctgcccgtccaacatcagcccgtgctgcttgaagcccagcaggcttaccttggacaagggatggattgcttggcctcacgcgctgatcagttgactgcgttcatttactttgtgaagcacgaagccgccagtctgctcggctccacgccaatgatgtctaacagttcattcaagccgacgccgcttcgcggcgcagcttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_763,Drugs,MEG_763|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,487657632|WP_001749984.1|NG_047339|1|1|aadA16|aadA16|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA16 NG_047339:101-946,2
,atgataaaaagttcgtggcgtaaaattgcaatgctagccgccgccgttccgctgctgctggcgagcggcgcactgtgggccagtaccgatgctatccatcagaagctgacagatctcgagaagcgttcaggcggcaggttgggcgtggcgctaatcaacacggcagataattctcaaatcttatatcgcggcgacgagcgttttgccatgtgcagcaccagtaaagtgatggccgccgccgcggtattaaaacagagcgaaagcaataaagaggtggtaaataaaaggctggagattaacgcagccgatttggtggtctggagtccgattaccgaaaaacatctccagagcggaatgacgctggctgagctaagcgcggcgacgctgcaatatagcgacaatacggcgatgaatctgatcatcggctaccttggcgggccggaaaaagtcaccgccttcgcccgcagtatcggcgatgccacctttcgtctcgatcgtacggagcccacgctgaataccgccatcccgggcgatgagcgtgataccagcacgccgctggcgatggctgaaagcctgcgcaagctgacgcttggcaatgcgctgggcgaacagcaacgcgcccagttagtcacctggctgaaaggcaataccaccggcgggcaaagcattcgcgcgggcctgcctgaaagctgggtggtcggagataaaaccggcgccggagattacggcaccaccaatgatattgcggttatctggccggaagatcacgctccgctggtattagtcacctactttacccagccgcagcaggatgcgaaaaaccgcaaagaggtgttagccgcagcggcaaaaatcgtcaccgaagggctttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_5283,Drugs,MEG_5283|Drugs|betalactams|Class_A_betalactamases|OXY,490212698|WP_004111091.1|NG_049848|1|1|blaOXY-2-11|blaOXY-2|class_A_extended-spectrum_beta-lactamase_OXY-2-11 NG_049848:1-873,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5515,Drugs,MEG_5515|Drugs|betalactams|Class_C_betalactamases|PDC,730521256|WP_034035338.1|NG_056395|1|1|blaPDC-240|blaPDC|class_C_beta-lactamase_PDC-240 NG_056395:1-1194,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagatggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_909,Drugs,MEG_909|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1080153689|WP_070342369.1|NG_051894|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_051894:101-889,2
,ATGACTAAAACAAAAATTATGGGCATATTAAACGTCACACCTGATTCATTCTCAGATGGTGGAAAATTTAATAATGTTGAAACAGCTATAAATAGAGTGAAAGCCATGATAGATGAAGGTGCTGACATTATAGATGTTGGAGGTGTTTCAACGAGACCCGGTCATGAAATGGTTACATTAGAAGAAGAGCTGAACAGAGTATTACCTGTTGTTGAAGCTATTGTCGGTTTTGATGTAAAAATTTCAGTCGATACATTTCGAAGTGAGGTTGCTGAAGCATGTTTAAAATTAGGCGTTGATATGATTAATGATCAATGGGCGGGTCTGTATGATCATCGTATGTTCCAAATTGTAGCTAAATATGACGCGGAAATTATTTTAATGCATAATGGAAATGGTAATCGTGATGAACCGGTTGTCGAAGAAATGTTAACATCTTTGTTAGCACAAGCACATCAAGCTAAAATAGCTGGTATACCTTCAAATAAAATTTGGCTAGATCCAGGTATAGGTTTCGCTAAAACTAGAAATGAAGAAGCCGAAGTTATGGCAAGACTGGATGAACTTGTTGCAACAGAATATCCAGTTTTATTAGCGACAAGCCGGAAACGTTTCACTAAAGAGATGATGGGTTATGATACAACACCGGTTGAAAGAGATGAAGTAACTGCAGCTACGACTGCATATGGTATTATGAAAGGCGTTAGAGCAGTACGCGTTCATAATGTCGAGTTGAATGCTAAATTAGCTAAAGGTATAGATTTTTTAAAGGAGAATGAAAATGCAAGACACAATCTTTCTTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2968,Drugs,MEG_2968|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|984671414|emb|LT009690.1|532298-533101 gi|974697948|dbj|AP017320.1|540410-541213 gi|927048389|gb|CP010890.1|493776-494579 gi|925190036|gb|CP012593.1|546908-547711 gi|803444476|gb|CP011147.1|537166-537969 gi|595636499|gb|CP007454.1|625737-624934 gi|312828563|emb|FR714927.1|510941-511744 gi|311222926|gb|CP001844.2|543018-543821 gi|262073980|gb|CP001781.1|506426-507229 gi|156720466|dbj|AP009324.1|571107-571910,8
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacaaactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgactttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatattggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4705,Drugs,MEG_4705|Drugs|betalactams|Class_D_betalactamases|OXA,1559612993|WP_128268258.1|NG_063863|1|1|blaOXA-759|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-759 NG_063863:41-865,0
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcgaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagacggagatgagcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacgggggccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3091,Drugs,MEG_3091|Drugs|betalactams|Class_A_betalactamases|GES,1407696518|WP_111273850.1|NG_060522|1|1|blaGES-37|blaGES|class_A_beta-lactamase_GES-37 NG_060522:1-864,0
,ATGACGCAAATTTTAATAGTAGAAGATGAACAAAACTTAGCAAGATTTCTTGAATTGGAACTCACACATGAAAATTACAATGTGGACACAGAGTATGATGGACAAGACGGTTTAGATAAAGCGCTTAGCCATTACTATGATTTAATCATATTAGATTTAATGTTGCCGTCAATTAATGGCTTAGAAATTTGTCGCAAAATTAGACAACAACAATCTACACCTATCATTATAATTACAGCGAAAAGTGATACGTATGACAAAGTTGCTGGGCTTGATTACGGTGCAGACGATTATATAGTTAAGCCATTTGATATTGAAGAACTTTTAGCAAGAATACGTGCGATTTTACGTCGTCAGCCACAAAAAGATATTATCGATGTCAATGGTATTACAATTGATAAGAATGCTTTTAAAGTGACGGTAAATGGCGCAGAAATTGAATTAACAAAAACAGAGTATGATTTACTATATCTTCTTGCTGAAAATAAAAACCATGTTATGCAACGGGAACAAATTTTAAATCATGTATGGGGTTATAATAGTGAAGTAGAAACAAATGTCGTAGATGTTTATATAAGATATTTACGAAACAAATTAAAACCATACGATCGTGACAAAATGATTGAAACAGTTCGTGGCGTTGGGTATGTGATACGATGA,protein of two-component regulatory system modulating antibiotic efflux,antibiotic efflux,Multi-drug_resistance,MEG_1115,Drugs,MEG_1115|Drugs|Multi-drug_resistance|MDR_regulator|ARLR,gi|781886788|dbj|AP014653.1|1407915-1407256 gi|781883823|dbj|AP014652.1|1407915-1407256 gi|537389513|gb|CP003979.1|1395684-1395025 gi|49243355|emb|BX571857.1|1455508-1454849 gi|47118312|dbj|BA000033.2|1426954-1426295,1
,atgaaaaaaatttatattagtgtgctagttcttttactaattatgattataataacttggttattcaaagatgacgatattgagaaaacaattagttctattgcaaaaggaaactataacgaagtatataaaaatagttcagaaaaatctaaactagcatatggagaagaagaaattatagataggaataaaaaaatttacaaagatttaagtgtcaataacttaaaaattactaatcatgaaattaaaaaaactggaaaagataaaaagcaggttgatgttaaatataacatatatacaaaatatggaactatacgacgtaatacacaattaaactttatttatgaagataagcattggaaattggattggagaccagacgtaatagtacctggtttgaaaaatggacagaaaattaatatagaaacattaaaatcagagcgaggaaaaataaaagatagaaatggtatagaattagctaaaacaggcaatacatatgaaatcggtattgtccctaacaaaacacccgaagaaaaatatgatgatattgcccatgacttacaaattgataaaaaagctataatcaataaagttaatcaaaaatgggtacagccgtcttcatttgtaccaataaaaaagataaatcaaaaagatgaatctatagataaattaattaaattacacaatttacaaataaatactataaaaagccgtgtttatccattgaataaagcaacagcacatcttttaggttatgtaggtcccattaattccgaagagttacaaagtaaacaatttaaaaactatagcaaaactagtgttattggaaaaaagggattagaacgcctctatgataaacaattgcaaaacactgatggctttagaatatccatttcaaatatttatgataataaacctttggacacattattagagaaaaaagctaataatggaaaagatcttcacttaactatagatgctagagtacaagaaagtatttataaacatatgaaaaatgactatggatctggtacagcattacaaccaaaaactggagaaattttagctttggtaagtaccccatcgtatgatgtttatccattcatgaatggactaagcaataatgactaccgtaaattaactaacaataaaaaagagcctttgctcaacaaatttcaaatcactacatcaccaggttcaacccaaaaaatattcacatctattatagccttaaaagaaaataaactagacgaaaatactaattttgatatttatggtaagggttggcaaaaagatgcatcatggggggattataatatcacaagatttaaagtagtagacggcaatatcgatttaaagcaagcaatagaatcatcagataatattttttttgcccgcattgcattagcattaggggctaaaaaatttgagcaaggtatgcaagatttgggaatcggtgaaaatatcccgagtgattatcccttttataaagcacaaatctcaaatagtaatttaaaaaatgaaatattattagcagattcaggatatggccaaggcgagatactagtaaaccctatacaaattttatcaatatatagtgctttagagaataacggaaatatacaaaaccctcatgttttacgtaaaacaaaatctcaagtatggaaaaaagatattatatctaaaaaagacatagatatattaactaatggtatggaacgtgtagttaataaaacacatagggatgatatatacaaaaattatgctcgaattataggtaaatctggcacagcagaattaaaaatgaatcaaggggaaactggaagacaaataggttggtttgtttcatataataaaaataatcctaatatgttaatggcgattaatgttaaagacgttcaaaataaaggaatggccagctataatgctactatatctggaaaagtttatgatgatttgtatgataatggaaaaactcaatttgatatagatcagtaa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3797,Drugs,MEG_3797|Drugs|betalactams|Penicillin_binding_protein|MECC,1559612966|WP_128268231.1|NG_063821|1|1|mecC2|mecC2|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2 NG_063821:101-2098,0
,atggacacaacgcaggtcacattgatacacaaaattctagctgcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatagttgaaatgctcggcgggcgcgtcatggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccagtggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaagggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_739,Drugs,MEG_739|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1105502210|WP_071846360.1|NG_052480|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052480:101-634,2
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACTGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAACCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1875,Drugs,MEG_1875|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EU515249|+|0-1146|ARO:3002036|CMY-25 [Klebsiella pneumoniae] ,0
,atgaagcgaaaagagttgcacgagacgtctcgtctcgcatacggtcgtcgcatgaccactcgccccgcgcacatcgccatgttctccatcgccctgcacggccacgtgaaccccagcctggaggtcatccgcgagctcgtcgcgcgggggcaccgggtgacgtacgcgatcccgcggctcctcgcggacaaggtcgccgaggcgggcgccgaacccaagctctggaacagcacactgcccggccccgacgccgacccggaggcctgggggagcaccctcctggacaacgtggagcccttcctcgccgacgcgatccagtcgctcccgcagctcgcccaggcgtacgagggggacgagccggacctggtcctgcacgacatcgcctcctacaccgcccgcgtcctgggccgccgctgggaggtgcccgtgatctccctgtcgccctgcatggtcgcctgggaggggtacgagcaggaggtcggcgagccgatgtgggaggagccgcggaagaccgagcgcgggcaggcgtactacgcccgcttccacgcctggctggaggagaacgggatcaccgaccaccccgacccgttcatcggccgccccgaccgctccctggtgctgatccccaaggcgctccagccccacgccgaccgggtggacgagacgacgtacaccttcgtcggcgcctgccagggggaccgcaccgccgagggcgactgggcccgtcccgagggcgcggagaaggtcgtcctggtctcgctcggttcggccttcaccaagcagcccgcgttctaccgggagtgcgtccgggccttcggtgagctgcccggctggcacaccgtgctccaggtcggccggcacgtagacccggccgagctgggcgacgtaccggacaacgtggaagtccgcacgtgggtaccgcagttggcgatcctccagcaggccgacctgttcgtcacccacgcgggcgcgggcggcagccaggagggtctggccaccgccacgccgatgatcgccgtaccgcaggccgcggaccagttcggcaacgccgacatgctccagggcctcggcgtcgcccgcaccctcccgaccgaggaggccaccgcgaaggcgctgcgcaccgccgccctcgccctggtcgacgacccggaggtggcggcgcgcctgaaggagatccaggcgcggatggcccaggaggccggcacccgcgggcccgccgacctcatcgaggccgaactggccgccgcgcgcggctga,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_3944,Drugs,MEG_3944|Drugs|MLS|Macrolide_glycosyltransferases|MGT,1028097043|WP_063853740.1|NG_047982|1|1|mgt|mgt|macrolide-inactivating_glycosyltransferase NG_047982:101-1357,7
,ATGAAAGGATTAAAAGGGCTATTGGTTCTGGCTTTAGGCTTTACAGGACTACAGGTTTTTGGGCAACAGAACCCTGATATTAAAATTGAAAAATTAAAAGATAATTTATACGTCTATACAACCTATAATACCTTCAAAGGAACTAAATATGCGGCTAATGCGGTATATATGGTAACCGATAAAGGAGTAGTGGTGATAGACTCTCCATGGGGAGAAGATAAATTTAAAAGTTTTACAGACGAGATTTATAAAAAGCACGGAAAGAAAGTCATCATGAACATTGCTACACATTCTCATGACGATAGAGCCGGAGGTCTTGAATATTTTGGTAAACTAGGTGCAAAAACTTATTCTACTAAAATGACAGATTCTATTTTAGCAAAAGAGAATAAGCCAAGAGCAAAGTACACTTTTGATAATAATAAATCTTTTAAAGTAGGAAACACTGAGTTCCAGGTCTATTATCCGGGAAAAGGTCATACAGCAGATAATGTGGTGGTATGGTTCCCTAAAGACAAAGTATTAGTAGGAGGCTGCATTGTAAAAAGCGGTGATTCGAAAGACCTTGGGTTTATTGGGGAAGCTTATGTAAACGACTGGACACAGTCCATACACAACATTCAGCAGAAATTTCCCGATGTTCAGTATGTCGTTGCAGGTCATGACGACTGGAAAGATCAAACATCAATACAACATACACTGGATTTAATCAGTGAATATCAACAAAAACAAAAGGCTTCAAATTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1265,Drugs,MEG_1265|Drugs|betalactams|Class_B_betalactamases|BLAB,(Bla)B-9:AY348324:1-747:747,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagcccgcgtctgagcgtccgttcgcaacggcagctgctgcagtggatggtggacgatggggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatatatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6220,Drugs,MEG_6220|Drugs|betalactams|Class_A_betalactamases|SHV,1391019424|WP_109232473.1|NG_062292|1|1|blaSHV-220|blaSHV|class_A_beta-lactamase_SHV-220 NG_062292:1-861,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggagagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_776,Drugs,MEG_776|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1028081053|WP_063840436.1|NG_047345|1|1|aadA21|aadA21|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA21 NG_047345:101-892,2
,atgactatacctgacgcaaatgcaatttatcccaatccagccatcaaagaggttgtctttatcaagaacgtgatcaaaagtcccaatattgaaattggggactacacctattatgatgacccagtaaatcccaccgattttgagaaacacgttacccatcactatgaatttctaggcgacaaattaatcatcggtaaattctgttctatcgccagtggtattgaatttattatgaacggtgccaatcacgtaatgaaaggtatttcaacttatccatttaatattttgggtggcgattggcagaaatatactcctgaactgactgatttgccgttgaaaggtgatactgtagtcggaaatgacgtgtggtttgggcaaaatgtgaccgtcctaccaggcgtaaaaataggtgacggtgccattatcggagcaaatagtgtcgtaacaaaagacgtcgctccatatacaattgtcggtggcaatccaattcaactcatcggaccaagatttgaaccagaagttattcaagcattagaaaacctggcatggtggaataaagatgttgaatggataactgttaatgttcctaaactaatgcaaacaacgcccacagttgaattgataaacagtttaatggaaaaataa,streptogramin inactivation enzyme,antibiotic inactivation,MLS,MEG_7626,Drugs,MEG_7626|Drugs|MLS|Streptogramin_A_O-acetyltransferase|VATE,1028100794|WP_063856929.1|NG_048544|1|1|vat(E)|vat(E)|streptogramin_A_O-acetyltransferase_Vat(E) NG_048544:1-645,7
,atggcaatccgaatcttcgcgatacttttctccattttttctcttgccactttcgcgcatgcgcaagaaggcacgctagaacgttctgactggaggaagtttttcagcgaatttcaagccaaaggcacgatagttgtggcagacgaacgccaagcggatcgtgccatgttggtttttgatcctgtgcgatcgaagaaacgctactcgcctgcatcgacattcaagatacctcatacactttttgcacttgatgcaggcgctgttcgtgatgagttccagatttttcgatgggacggcgttaacaggggctttgcaggccacaatcaagaccaagatttgcgatcagcaatgcggaattctactgtttgggtgtatgagctatttgcaaaggaaattggtgatgacaaagctcggcgctatttgaagaaaatcgactatggcaacgccgatccttcgacaagtaatggcgattactggaaaggcagccttgcaatctcggcgcaggagcaaattgcatttctcaggaagctctatcgtaacgagctgccctttcgggtagaacatcagcgcttggtcaaggatctcatgattgtggaagccggtcgcaactggatactgcgtgcaaagacgggctgggaaggccgtatgggttggtgggtaggatgggttgagtggccgactggctccgtattcttcgcactgaatattgatacgccaaacagaatggatgatcttttcaagagggaggcaatcgtgcgggcaatccttcgctctattgaagcgttaccgcccaacccggcagtcaactcggacgctgcgcgataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4728,Drugs,MEG_4728|Drugs|betalactams|Class_D_betalactamases|OXA,1509794572|WP_122630881.1|NG_062301|1|1|blaOXA-681|blaOXA-2_like|OXA-2_family_class_D_beta-lactamase_OXA-681 NG_062301:1-825,0
,ATGAATAACATCGGCATTACTGTTTATGGATGTGAGCAGGATGAGGCAGATGCATTCTGTGCCCTTTCGCCGCGTTTTGGCGTTATGCCCTCGATAATTAACGCCAACGTGTCGGAATCCAACGCCAAATCCGCGCCTTTCAATCAATGTATCAGCGTGGGACATAAATCAGAGGTGTCCGCGTCTATTCTTCTTGCGCTGAAGAGAGCCGGTGTGAAATATATCTCCACCCGAAGCATCGGCTGCAATCATATAGATACAACTGCCGCTAAGAGAATGGGCATCACTGTCGGCAATGTGGCGTATTCGCCGGATAGCGTTGCCGATTATACCATGATGCTGATGCTTATGGCAGTACGCAACGCTAAATCTATTGTCCGCTCTGTGGAAAAACATGATTTCAGGTTGGACAGTGTCCGTGGCAAGGTACTGAGCGACATGACAGTCGGCGTGGTGGGAACGGGCCATATAGGCAAAGCAGTTATTGAGCGGTTGCGGGGATTTGGATGTAAAGTGCTGGCTTATAGTCGCAGCCAAAGTATAGAGGCAAACTATGTTCCGTTTGATGAGTTGTTGCAAAATAGCGATATCGTTACGCTTCATGTGCCGCTCAATGCGGATACGCGCCATATCATCAGCCACGAACAAATACAGAGAATGAAGCAAGGCGCGTTTATTATCAATACTGGCCGCGGTCCACTTGTATATACCAATGAGCTGGTCAAAGCATTAGAAAACGGAAAACTGGGCGGTGCCGCATTGGATGTATTGGAAGGAGAGGAAGAGTTTTTCTACTCTGATTGCTCACAAAAACCAATTGATAATCAATTTTTACTGAAACTTCAAAGAATGCCGAACGTGATAATCACGCCGCATACGGCTTTTTATACCGAACAGGCGTTGCGTGATACCGTTGAAAAAACCAATATAAACTGTTTGGATTTTGAAAGGAGCCAGGAGCATGAATAGAGTAAAAGTTGCAATCCTGTTTGGGGGTTGCTCCGAGGAGCATGACGTGTCGGTTAAATCTGCAAGAGAGATTGCCGCTAACATTGACAACGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCCGGTGTTTGGAAAATGTGCGAAAAACCGTGCGCGGAATGGGAAAACAGCAATTGCTATTCAGCCGTACTCTCGCCGGATAAAAAAATGCACGGTTTGCTTGTTAAAAAGAACCATGAATATGAAATCCACCACGTTGATGTAGCATTTTCGGGGATGCACAGCAAGTCAGGTGAAGATGGATCCATACAAGGTCTGTTTGAATTGTCCGGTATCCCTTATGTGGGCTGCGATATTCAAAGCTCCGCGATTTGTATGGACAAATCGCTTACATACACAATTGCGAAAAACGCTGGCATAGCTATTCCTGAATTTTGGGTTATTAATAAAGACGATAAGCCGGCGGCAGATACGTTTACCTATCCTGTTTTTGTTAAGCCGGCGCGTTCAGGCTCATCTTATGGCGTGAAAAAAGTCAATGTCGCAGACGAATTGGACGCCGCAATTGAATCGGCAAGACAATATGACAGCAAAATCTTAATTGAGCAGGCTGTTTTGGGCTGTGAGGTCGGTTGTGCCGTATTGGGAAACAGTTCCGAGTTGATTGTTGGCGAGGTGGACCAAATCAGGCTGCAGCACGGTATCTTTCGTATTCATCAGGAAGCCGAGCCGGAAAAAGGCTCAGAAAACGCAGTTATAACCATTCCCGCAGACCTGTCAGCAGAGGAGCGAGGACGGATACAGGAAACGGCAAAAAAAATATATAAGGCGCTCGGTTGCAGAGGTCTTTCCCGTGTTGATATGTTTTTACAAGATAACGGCCGCATTGTACTTAACGAAGTCAATACCCTGCCTGGTTTCACGTCGTACAGCCGTTATCCCCGTATGATGGCCGCTGCAGGTATAACGCTCCCCGAACTGATTGACCGCCTGATCGTATTCGCGTTACAGGGGTGATAAGAATGAAAAAAGGATTTACTTTTTTAGATGAAATATTACACGGTGTTCGTTGGGACGCTAAATATGCTACATGGGACAATTTCACCGGAAAGCCGGTTGACGGATATGAAGTAAATCGCATTGCAGGAACATACGAGTTGGCCGACGCGCTTTTGAAGGTAAAAGAACTGGCTGCTGCTCAAGGGTACGGATTGCTTCTATGGGACGGTTACCGTCCCCAACGCGCTGTAAATTGTTTTGTGCAATGGGCTGCACAGCCGGAAGATGGCCTGACAAAGGAAAGATATTATCCCAATATTGACCGAACCGAGATGGTTTCAAAAGGATACGTGGCTTCAAAATCAAGCCATAGCCGCGGAAGTGCGATTGATCTTACGCTTTATCGATTAGACACGGGTGAGCTTGTACCAATGGGGAGCGGGTTTGATTTTATGGATGAACGCTCTCATCATGCGGCAAAAGGAATTTCAGGCAATGAAGCGCAAAATCGCAGATGTTTGCGTTCCATCATGGAAAACAGCGGGTTTGAAGCATATAGCTTCGAATGGTGGCACTATGTATTAAGAAACGAACCATACCCCAATAGCTATTTTGATTTCCCCGTCAAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7412,Drugs,MEG_7412|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,VanHAX_PT_2_AY926880,5
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcatcgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctacgggccggtcccggcccgctggatgccgaaggctacagggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5451,Drugs,MEG_5451|Drugs|betalactams|Class_C_betalactamases|PDC,1343491224|WP_104009840.1|NG_056398|1|1|blaPDC-243|blaPDC|class_C_beta-lactamase_PDC-243 NG_056398:1-1215,0
,ATGTCCGCGAGCACCCCCCCCATAACTCTTCGCCTCATGACCGAGCGCGACCTGCCGATGCTCCATGATTGGCTCAACCGGCCGCACATCGTTGAGTGGTGGGGTGGTGACGAAGAGCGACCGACTCTTGATGAAGTGCTGGAACACTACCTGCCCAGAGCGATGGCGGAAGAGTCCGTAACACCGTACATCGCAATGCTGGGCGAGGAACCGATCGGCTATGCTCAGTCGTACGTCGCGCTCGGAAGCGGTGGTGGCTGGTGGGAAGATGAAACTGATCCAGGAGTGCGAGGAATAGACCAGTCTCTGGCTGACCCGACACAGTTGAACAAAGGCCTAGGAACAAGGCTTGTCCGCGCTCTCGTTGAACTACTGTTCTCGGACCCCACCGTGACGAAGATTCAGACCGACCCGACTCCGAACAACCATCGAGCCATACGCTGCTATGAGAAGGCAGGATTCGTGCGGGAGAAGATCATCACCACGCCTGACGGGCCGGCGGTTTACATGGTTCAAACACGACAAGCCTTCGAGAGAAAGCGCGGTGTTGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_344,Drugs,MEG_344|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|355336852|gb|JN118546.1|123-677,2
,atgataatcagtgaatttgaccgtaataatccagtattgaaagatcagctttctgatttactgagactgacttggccggaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacgaatcgcggtagcagcggtagaccaagatgagttagtaggatttattggtgcaatccctcaatacggtatcacaggttgggaattgcatccattagttgtagaaagctcccgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagaggaggaatcacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaaacggacctgtatgagcatacatttgataaagtggcttccatccagaaccttcgtgaacatccgtatgaattctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaaatggctgggacaaaccggatatttggatggcaaaaacgattattcctcgaccaaattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_84,Drugs,MEG_84|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,488218587|WP_002289795.1|NG_052371|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052371:101-649,2
,TTGTCCAAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTAAGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGGTGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAACTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATTATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4307,Drugs,MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_4_KT862777 ,1
,atggaaatcaaaaagttaagcagcactaatattaacctatggatagcgctaagagagcagctatggccgcatcatcctgaaaataaaactgatggggaaaatattattctgtctgatgagttggcttcatttattgctatagatgacgatgggctaggtattggtttcgctgatgcatccatacggaatgattatgtgaatggttgtattcatagccctgttgccttccttgaaggtatttttattgtcccatcctctcggcgtggtggcgttgccaagcagttagttgatgctgtgcaagcatgggggttagaaaaggggtgtcaggagctggcatctgataccgcattggacaatgttttgtcacaacaagtccatgaagctttgggatttaaggaaactgagagggtcgtttactaccgcaaagcatga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_186,Drugs,MEG_186|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,910928430|WP_050141558.1|NG_052200|1|1|aac(6')_Yersi|aac(6')_Yersi|aminoglycoside_6'-N-acetyltransferase NG_052200:101-532,2
,ATGTTCAAACTTTTGAGTAAGTTATTGGTCTATTTGACCGCGTCTATCATGGCTATTGCGAGTCCGCTCGCTTTTTCCGTAGATTCTAGCGGTGAGTATCCGACAGTCAGCGAAATTCCGGTCGGGGAGGTCCGGCTTTACCAGATTGCCGATGGTGTTTGGTCGCATATCGCAACGCAGTCGTTTGATGGCGCAGTCTACCCGTCCAATGGTCTCATTGTCCGTGATGGTGATGAGTTGCTTTTGATTGATACAGCGTGGGGTGCGAAAAACACAGCGGCACTTCTCGCGGAGATTGAGAAGCAAATTGGACTTCCTGTAACGCGTGCAGTCTCCACGCACTTTCATGACGACCGCGTCGGCGGCGTTGATGTCCTTCGGGCGGCTGGGGTGGCAACGTACGCATCACCGTCGACACGCCGGCTAGCCGAGGTAGAGGGGAACGAGATTCCCACGCACTCTCTAGAAGGACTCTCATCGAGCGGGGACGCAGTTCGCTTCGGTCCAGTAGAACTCTTCTATCCTGGTGCTGCGCATTCGACCGACAACTTAGTTGTGTACGTCCCGTCTGCGAGTGTGCTCTATGGTGGTTGTGCGATTTATGAGTTGTCACGCACGTCTGCGGGGAACGTGGCCGATGCCGATCTGGCTGAATGGCCCACCTCCATTGAGCGGATTCAACAACACTACCCGGAAGCACAGTTCGTCATTCCGGGGCACGGCCTGCCGGGCGGTCTAGACTTGCTCAAGCACACAACGAATGTTGTAAAAGCGCACACAAATCGCTCAGTCGTTGAGTAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_7764,Drugs,MEG_7764|Drugs|betalactams|Class_B_betalactamases|VIM,gi|30141364|emb|AJ511268.1|397-1197,0
,gtgaccggcagcgcggccacgatccgcccggccacggcggccgatgcggtcgcgtgggcgcagctgcgtctgggcctgtggcccgatgccgatgatccgctggagacgctggtggcggcgctggccgaggacgcaggtgcggttttcctggcgtgtgcagcgggtggccaggcgatcggcttcgccgaagtgcgcctgcgccatgactacgtgaacggcaccgattcctcgccggtgggcttcctggagggctggtacgtgcagccgcagtggcaaggctgcggcgtgggccgcgccctgctggcggcggtgcgggcatggacgcgcgacgcgggctgccgcgaactggcttcggacagtcgcgtggaagacgtgcaggctcacgccgcgcatcgggcctgcggcttcgaagagaccgaacgggtggtctatttccgcatgccactggagccatcggcgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_248,Drugs,MEG_248|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,896573839|WP_049468785.1|NG_052197|1|1|aac(6')-Iak|aac(6')-Iak|aminoglycoside_N-acetyltransferase_AAC(6')-Iak NG_052197:101-562,2
,atgaaaattttgattttgctgcctttacttagttgcttgggcctgacagcatgtagcctacccgtttcatctctcccatctccaagcacttcgactcaagcgattgccagcttatttgatcaggcgcaaagctctggtgttttagtgattcagcgtgatcaacaagtacaggtctatggcaatgatttaaatcgtgcaaataccgaatatgttcccgcctctacttttaaaatgctcaatgctctgattggcctgcaacatggcaaagccacaaccaatgaaatttttaaatgggatggcaagaaacgcagctttaccgcctgggaaaaagacatgactctcggccaagccatgcaagcttctgcggtaccggtctatcaagaactggcgcgtcgtattggtctggaattaatgcaacaggaagtacaacgcatccaatttggtaatcagcagattggtcaacaggtcgataacttctggttggtaggccctttgaaagttactccaaaacaggaagtccaatttgtttctgcgttggcccgagagcaactggcctttgatcctcaagtccagcaacaagtcaaagccatgttatttttacaggagcggaaagcttatcgactatatgtcaaatccggttggggcatggatgtggaaccgcaagtcggctggctcaccggctgggttgaaacaccgcaggctgaaatcgtggcattttcactcaatatgcagatgcaaaatggtatagatccggcgatccgccttgaaattttgcagcaggctttggccgaattagggctttatccaaaagatgaaggatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4427,Drugs,MEG_4427|Drugs|betalactams|Class_D_betalactamases|OXA,1693892938|WP_140423315.1|NG_065433|1|1|blaOXA-647|blaOXA-134_like|OXA-134_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-647 NG_065433:1-822,0
,TTGTCAAAAGCGCGGGAGTCGCGGATAATCCGGGCAGCTCATCACTATCAAGGAGTCTGAGATGTTGAAAAGTTCGTGGCGTAAAACCGCCCTGATGGCCGCCGCCGCCGTTCCGCTGCTGCTGGCGAGCGGTTCATTATGGGCCAGTGCCGATGCTATCCAGCAAAAGCTGGCTGATTTAGAAAAACGTTCCGGCGGTCGGCTGGGCGTAGCGCTGATTAACACGGCAGATGATTCGCAAACCCTCTATCGCGGCGATGAACGTTTTGCCATGTGCAGCACCGGTAAAGTGATGGCCGCCGCCGCGGTGTTAAAACAGAGCGAAAGCAATCCAGAGGTGGTGAATAAAAGGCTGGAGATTAAAAAATCGGATTTAGTGGTCTGGAGCCCGATCACCGAAAAACATCTGCAAAGCGGAATGACCCTGGCGGAACTCAGCGCGGCGGCGCTGCAGTACAGCGACAATACCGCGATGAATAAGATGATTAGCTACCTTGGCGGACCGGAAAAGGTGACCGCATTCGCCCAGAGTATCGGGGATGTCACTTTTCGTCTCGATCGTACGGAGCCGGCGCTGAACAGCGCGATTCCCGGCGATAAGCGCGATACCACCACCCCGTTGGCGATGGCCGAAAGCCTGCGCAAGCTGACGCTGGGCAATGCGCTGGGCGAACAGCAGCGCGCCCAGTTAGTAACGTGGCTAAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCAGGCCTGCCCGCAAGCTGGGTGGTCGGGGATAAAACCGGCGGCGGAGATTACGGCACCACCAACGATATCGCGGTGATCTGGCCGGAAAATCATGCCCCGCTGGTGCTGGTGACCTATTTTACCCAGCCGCAGCAGGATGCGAAAAGCCGCAAAGAGGTGTTAGCCGCGGCGGCAAAAATCGTCACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5311,Drugs,MEG_5311|Drugs|betalactams|Class_A_betalactamases|OXY,gi|18844713|gb|AY077486.1|120-1056 gi|219920928|emb|FM178426.1|1-825,0
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCATCGGAATACACCGTTTCTTTAGCCTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGATTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTATTTGTACACAGGAGAACTAGAAAACATCCGACAAGACACATGGTTGTTGGATACGAAACATACACAGAAAATCCAGCCACTTTTTGAAGAAAACGGCTTTTGGCTAAGTGAAGCGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAGCTTCCTTATGTAGGCTGCGGGGTGGCAGCCTCTGCCTTATGTATGAACAAATGGCTGCTGCATCAAGCTGCAGCAGCGATTGGAGTACAAAGCGCCCCTACGATTCTCTTGACAAATCAAGACAACCAACAGCAACAAATCGAAGCCTTCATCCAGACCCATGGCTTTCCAGTTTTCTTTAAGCCTAATGAAGCGGGCTCCTCAAAAGGGATCACAAAAGTAACTTGTGTTGAAGAAATCGCTCCTGCCTTGAAGGAAGCATTCGCTTATTGTTCCGCAGTGCTCTTACAAAAAAATATCGCTGGCGTTGAGATTGGTTGCGGTATCTTAGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCTATTTCATTAGTAGAAGGCTTTTTCGATTTTGAAGAAAAGTACCAATTGATTAGCGCCAAGATCACCGTTCCTGCACCATTGCCTGAAACGATTGAAACCAAGGTCAAAGAACAAGCTCAGCTGCTCTATCACAGTCTTGGTCTTAAAGGACTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACTAGTCACTCCCGCTATCCTGCCATGATGGCAGCAATCGGCTTATCCTATCAAGAACTACTACAAAAACTGCTTGTCTTAGCAAAGGAGGAAGGCAAATGAATCCCTATCTACAGTTAGTTAGCAAAGAGTTTCCATTAGAAAAAAACCAAGAGCCGCCCCACCTCGTCCTTGCTGCTTTTAGTGAAGAAGAAGTTTACTTGCAGCCTGAAGCAGCCAAACAATGGGAACGCCTCGTCAAAGCCTTAAAACTTGAAAACGAGATCTGCTTATTAGACGGCTATCGAACCGAAAAGCAGCAACGGCATTTATGGGAATATTCCTTAAAAGAAAATGGATTAGCCTATACGAAACAATTTGTGGCGTTGCCCGGCTGCAGCGAGCATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAAGGCCAGCAAGGTGATTTGATCTGCCCACGGTTTCGTGACAGCGCAGCGGCGGATTTATTTACACAGGAAATGATGAACTACGGATTTATTTTACGCTATCCCGCAGACAAACAGGAGATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTACCTCATAGTCAAATCATCGCCAGTCAACAGTGGACATTGGAAGAATACTATCAATATCTTGAACAAACCGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7372,Drugs,MEG_7372|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC4XY_3_EU151756,5
,CTGATCGCGCTCTACGCGGTAATGCAGTTCATCTTTGCCCCCGTACTGGGAACACTGTCGGACCGATTCGGCCGCCGCCGGGTGCTGCTTGTTTCCCTGGCCGGTGCGACCGTCGACTATCTCGTGCTCGCCACGACATCCGCTCTGTCGGTGTTCTATATCGCCCGTGCAGTGGCTGGGATAACCGGAGCGACCAATGCGGTCACCGCCACCGTGATCGCCGACATCACGCCACCCCACCAGCGCGCCAAGCGTTTCGGTTTACTCAGTGCCTGCTATGGCGGCGGAATGATCGCGGGGCCAGCCATGGGTGGACTGTTCGGTGCCATCTCGCCACATCTGCCGTTTTTGCTCGCTGCTCTTCTCTCAGCGAGCAATCTGGCACTCACCTTTATCCTGTTACGCGAGACCCGTCCTGATTCCCCTGCGCGCTCTGCGTCGCTCGCTCAGCATCGTGGTCGCCCCGGCCTCAGCGCGGTGCCTGGGATTACCTTCCTATTAATCGCATTCGGCCTTGTTCAATTCATTGGGCAGGCTCCAGGTGCGACCTGGGTGCTGTTTACTGAACACCGCCTCGACTGGAGTCCCGTCGAAGTTGGAATCTCCCTGTCCGTTTTCGGGATCGTACAGGTTCTCGTGCAGGCCCTCCTTACTGGCCGCATCGTGGAGTGGATCGGTGAGGCAAAAACAGTCATCATCGGGTGTATTACCGACGCCTTGGGTCTCGTAGGCCTGGCG,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6974,Drugs,MEG_6974|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET33,gi|70671867|gb|DQ077487.1|1-738,4
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcaacgcaatgacattctagcaggtatcttcgagccacccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcgcgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_789,Drugs,MEG_789|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502222|WP_071846372.1|NG_052502|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052502:101-892,2
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtctgcatgttcttttaatacggtagaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcgttgtttgatcaagcacaaactacaggtgttttagttataaaacgtgggcaaacggaggaagtctatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgaacatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcatttatttcccgattgggaaaaagacatgaccttaggcgatgctatgaaggcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaagcgtattggtttcggtaatgctgatattggttcaaaagtagataatttttggcttgttggcccacttaaaattacaccacaacaagaagcgcagtttgcttacaaattagccaataaaactcttccctttagcaaaaatgtacaagagcaagttcaatctatggtgttcatagaagaaaaaaatggacgaaaaatttatgccaaaagtggttggggatgggatgttgacccacaagttggttggtttacaggctgggtagttcaacctcagggagaaattgtagcgttctcactcaatttagaaatgaagaaaggcatacctagttctattcgaaaagaaattgcttataagggattagagcagctaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4569,Drugs,MEG_4569|Drugs|betalactams|Class_D_betalactamases|OXA,1188444915|WP_085562417.1|NG_054707|1|1|blaOXA-563|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-563 NG_054707:1-822,0
,atgcgatttaacaaaatttcttgcttacttttatcccctctttttatttttaatacctcaatttatgcagggaatacaccaaaagagcaagaaattaagaaactggttgatcaaaattttaaaccgttattagaaaaatatgatgtacccggtatggcggttggcgtcatccaaaataataaaaagtatgaaacatattatggtctacaatccgttcaagataaaaaagtcgtaaatagcagtaccatttttgagctcggttcagtcagtaaattatttaccgctacagcaggtggatatgccaaaacaaaaggaacaatttcttttaaagacacacccggaaaatattggaaagaattaaaaaacacaccgattgaccaagttaatttacttcaacttgcgacctatacaagtggcaaccttggcttacagtttccagatgaagtcaaaacagatcagcaagttttaacttttttcaaagactggaagcctaaaaactcaatcggtgaatatcgacaatattcaaatccaagcattggtttatttggaaaagttgttgctttgtctatgaataaaccttttgaccaagtcttagaaaaaaccatttttccagatcttggcttaaaacatagctatgtaaatgtgcctaaaactcaaatgcaaaactatgcatttggctataaccaagaaaatcagccgattcgagttaaccccggcccgctagatgcacctgcatacggcgttaaatcgaccttaccggatatgctgagtttcgttaatgccaatctaaatccacagaaatatccggcagatattcaacgcgcaattaatgaaacacataaaggtttctaccaagtaggcacgatgtatcaagcattaggttgggaagagttctcttatccagcaccgttacagactttattagacagtaattcagaacaaatcgtgatgaagcctaataaagtgactgctatttcaaaagaaccttcagttaagatgttccacaaaactggttcaaccaacggttttggaacctgtgttgtgtttattccaaaagaaaatattggtttagttatgttaaccaataaacgtattccgaatgaagaacgcattaaagcagcgtatgcagtattgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_625,Drugs,MEG_625|Drugs|betalactams|Class_C_betalactamases|ADC,502962208|WP_013197184.1|NG_064716|1|1|blaADC-193|blaADC|class_C_beta-lactamase_ADC-193 NG_064716:101-1252,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6438,Drugs,MEG_6438|Drugs|betalactams|Class_A_betalactamases|SHV,gi|257043749|gb|GQ407116.1|1-861,0
,gtgaatggaccaataataatgactagagaagaaagaatgaagattgttcatgaaattaaggaacgaatattggataaatatggggatgatgttaaggctattggtgtttatggctctcttggtcgtcagactgatgggccctattcggatattgagatgatgtgtgtcatgtcaacagaggaagcagagttcagccatgaatggacaaccggtgagtggaaggtggaagtgaatttttatagcgaagagattctactagattatgcatctcaggtggaatcagattggccgcttacacatggtcaatttttctctattttgccgatttatgattcaggtggatacttagagaaagtgtatcaaactgctaaatcggtagaagcccaaaagttccacgatgcgatttgtgcccttatcgtagaagagctgtttgaatatgcaggcaaatggcgtaatattcgtgtgcaaggaccgacaacatttctaccatccttgactgtacaggtagcaatggcaggtgccatgttgattggtctgcatcatcgcatctgttatacgacgagcgcttcggtcttaactgaagcagttaagcaatcagatcttccttcaggttatgaccatctgtgccagttcgtaatgtctggtcaactttccgactctgagaaacttctggaatcgctagagaatttctggaatgggattcaggagtggacagaacgacacggatatatagtggatgtgtcaaaacgcataccattttga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_980,Drugs,MEG_980|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT4-PRIME,1028081077|WP_063840460.1|NG_047374|1|1|ant(4')-Ia|ant(4')-Ia|aminoglycoside_O-nucleotidyltransferase_ANT(4')-Ia NG_047374:101-862,2
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGAACAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTCCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1451,Drugs,MEG_1451|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_50_KR230047,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggtttactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcgactacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2187,Drugs,MEG_2187|Drugs|betalactams|Class_A_betalactamases|CTX,1226997337|WP_094009814.1|NG_055502|1|1|blaCTX-M-201|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-201 NG_055502:1-876,0
,atgatcgtcaactgcgaccacgacaacctcgacgcctggctggcgctgcgctcagcgctgtggcccacttgtccgttggaagagcaccgcgcggagatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgttttcgttggctttgccgaggtcgcgctgcgccacgattacgtcaacggttgcgagtcgtcgccggtggcgtttctggaagggatctataccgtcgaacgcgcccgccgccagggctgggccacgcgattgatcgcacaggtgcaggagtgggccaagcagcaaggctgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggagcgggtggtgttttaccgtaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_99,Drugs,MEG_99|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,896176169|WP_049189080.1|NG_052193|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052193:101-541,2
,GTGAATACGTCTTATTCACAATCAAATTTACGACACAACCAAATTTTAATTTGGCTTTGCGTTCTATCTTTTTTTAGCGTATTAAATGAAATGGTTTTGAACGTCTCATTACCTGATATTGCAAATGATTTTAATAAATCACCGGCGAGTACAAGCTGGGTGAACACAGCCTTTATGTTAACCTTTTCTATTGGAACAGCTCTATATGGAAAGCTATCTGATCAGCTAGGCATTAAAAGGTTACTCCTATTTGGGATTATAATAAATTGCTTCGGATCGGTAATTGGGTTTGTTGGACATTCTTTTTTTCCCATACTTATTCTGGCTCGATTTATTCAAGGAGCTGGTGCAGCTGCATTTCCAGCACTCGTGATGGTTGTAGTTGCGCGCTATATTCCAAAGGAAAATAGGGGTAAAGCGTTTGGTCTTATTGGCTCCATAGTAGCTATGGGAGAAGGTATCGGTCCAGCTATTGGTGGAATGATAGCTCATTTTATCCATTGGTCTTATCTTCTGCTCATTCCAATGATGACAATTATCACTGTTCCGTTCCTTATTAAATTGTTGAAAAAAGAAGTAAGGATAAAAGGTCATTTTGATATTGTAGGAATTATACTAATGTCAGTGGGCATTGTATTTTTTATGCTGTTTACAACATCTTATAACATTTCTTTTCTGATCATCAGTATTCTGTCATTCCTGATATTTGTAAAACATATTAGGAAAGTAACAGAACCTTTTGTTGAACCTGCACTGGGGAAAAATATTTCTTTTATAATTGGTGTCCTTTGTGGAGGACTTATATTTGGTACAGTAGCAGGGTTTATCTATATGGTTCCTTACATGATGAAAGATGTACATCAACTAAGTACTGCTGCAATTGGCAGTGTGATTATTTTCCCTGGAACAATGAGCGTTATTATCTTCGGTTACATTGGTGGATTACTTGTTGATAGAAAAGGTCCATTGTACGTGTTAACCATTGGAGTTACATTTCTTTCCGTTAGCTTTTTAATTGCTGCCTTTTTTTTAGAAGTAACACCATGGTTACTGACAATTATATTAGTTTTTGTTTTTGGTGGGCTGTCATTCACCAAAACAGTTATATCTACAATTGTTTCAAGTAGTTTGAAACAAAAGGAAGCTGGTGCCGGAATGAGTTTGCTTAATTTTACCAGTTTTTTATCAGAGGGAATAGGTATTGCAATTGTTGGTGGTTTATTATCTGTACGCTTACTGAATCAGAAGTTGCTACCTATGGACCTTGATCAATCCACTTATTTGTATAGTAATATGCTATTCCTTTTTACAGGAGTCGTTGTTACTAGTTGGCTGATCACCTTGAATGTATATAAACGAAGACAAATTCAATTTAAAAGTTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7098,Drugs,MEG_7098|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETL,gi|307556794|gb|HM235948.1|1603-2985,4
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttgacgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1792,Drugs,MEG_1792|Drugs|betalactams|Class_C_betalactamases|CMY,1102724727|WP_071593223.1|NG_052047|1|1|blaCMY-143|blaCMY|class_C_beta-lactamase_CMY-143 NG_052047:1-1146,0
,atgaccattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatggattgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4534,Drugs,MEG_4534|Drugs|betalactams|Class_D_betalactamases|OXA,1559612998|WP_128268263.1|NG_063868|1|1|blaOXA-764|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-764 NG_063868:48-872,0
,TTGTCCAAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGATTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGATGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAACTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATTATTTCTGAACCAAACAATTCTTCTGATTATATGGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4319,Drugs,MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_16_AMBD01000029 ,1
,atgagcaagttatctgtattctttatatttttgttttgcagcattgctaccgcagcagagtctttgccagatttaaaaattgaaaagcttgatgaaggcgtttatgttcatacttcgtttgaagaagttaacgggtggggcgtttttcctaaacatggtttggtggttcttgtaaatgctgaggcttacctaattgacactccatttacggctaaagatactgaaaagttagtcacttggtttgtggagcgtggctataaaataaaaggcagcatttcctctcattttcatagcgacagcacgggcggaatagagtggcttaattctcgatctatccccacgtatgcatctgaattaacaaatgaactgcttaaaaaagacggtaaggttcaagccacaaattcatttagcggagttaactattggctagttaaaaataaaattgaagttttttatccaggcccgggacacactccagataacgtagtggtttggttgcctgaaaggaaaatattattcggtggttgttttattaaaccgtacggtttaggcaatttgggtgacgcaaatatagaagcttggccaaagtccgccaaattattaaagtccaaatatggtaaggcaaaactggttgttccagctcacagtgaagttggagacgcatcactcttgaaacttacattagagcaggcggttaaagggttaaacgaaagtaaaaaaccatcaaaaccaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3334,Drugs,MEG_3334|Drugs|betalactams|Class_B_betalactamases|IMP,1509794552|WP_122630861.1|NG_062274|1|1|blaIMP-80|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-80 NG_062274:1-741,0
,GTGCTCGCCGCGGCGAAGTACCGCAACCTGGACCCGGCGTTCGTCGAGCGCCTGGCGCAGGAGGCGGCGGAGCGATTCCGCGACCGCGGCCAAGCGGTCAAGTACGCCAAACGGAAGCTGCACCAGGCATTCGGCGCATTCGTCGCGGGCACGCCGGCGCAGGCGGTCGCCGCCTGCGTCGCGAAGATCGCCGCCGGAGCGGAGCCGAAGGAGGCGGGCCGGGAGGCGATGCGGGCACACGCCTCCTCGGCGGAACGGGTCGACTGGCTGGAGCCGTTCTACGAGCGCGTCGCCCAGTGGTGCGGCCCGGCATCCTCCGTGATCGACCTGGCCTGCGGCCTCAACCCGCTGGCCGTGCCGTGGATGGCGCTCGCTCCCGGCGCCACCTACGCCTGCTACGACGTGGACCGGACCATGGCCGAGGCGTTGCGCGCTCTGGGCACGGTTTACCCGGTCCGGGTCAACGCCGCCGCCGTCGACCTGGTCGCGGCGGTGCCGGCGGCGGGGGTCGACGTCGCGCTCGTGCTCAAGACCCTCACCACCGTGGAGCAGCAGCGCGGCGGTCGGCGCGTCGCCGAGTATCGGCGCGAGCTGACGGCAGTGCAGCACCACTCGGACGGGGCCCGCAGCCTGTCCGGGCGGCGCGGGTACGCCGACGACCCCGACGCGATCGTCCAACGGGCGGTGCACGGTACCGGATACGAGGTCGTCGACGAGGCGGCGTTCGGCACCGAGGCGCTGTACCACCTCGTGCCGTTGGCCGGTACCGCCGGACGCCCCGCTCCGGCGGAGGGCGCGGCGGAGCCGGGCGCCACCCGTCCGGTCGTCGACGTGCCGGCCACCGCGCGACCCGACGCCGATCGGGTGGACCCGACGGGG,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_2932,Drugs,MEG_2932|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|FMRO,fmrO_1_Q08325 ,2
,GTGAGTCCGGCGCCCGTGCAGGTGATGGGGGTTCTAAACGTCACGGACGACTCTTTCTCGGACGGCGGGTGTTATCTCGATCTCGACGATGCGGTGAAGCACGGTCTGGCGATGGCAGCCGCAGGTGCGGGCATCGTCGACGTCGGTGGTGAGTCGAGCCGGCCCGGTGCCACTCGGGTTGACCCGGCGGTGGAGACGTCTCGTGTCATACCCGTCGTCAAAGAGCTTGCAGCACAAGGCATCACCGTCAGCATCGATACCATGCGCGCGGATGTCGCTCGGGCGGCGTTGCAGAACGGTGCCCAGATGGTCAACGACGTGTCGGGTGGGCGGGCCGATCCGGCGATGGGGCCGCTGTTGGCCGAGGCCGATGTGCCGTGGGTGTTGATGCACTGGCGGGCGGTATCGGCCGATACCCCGCATGTGCCTGTGCGCTACGGCAACGTGGTGGCCGAGGTCCGTGCCGACCTGCTGGCCAGCGTCGCCGACGCGGTGGCCGCAGGCGTCGACCCGGCAAGGCTGGTGCTCGATCCCGGGCTTGGATTCGCCAAGACGGCGCAACATAATTGGGCGATCTTGCATGCCCTTCCGGAACTGGTCGCGACCGGAATCCCAGTGCTGGTGGGTGCTTCGCGCAAGCGCTTCCTCGGTGCGTTGTTGGCCGGGCCCGACGGCGTGATGCGGCCAACCGATGGGCGTGACACCGCGACGGCGGTGATTTCCGCGCTGGCCGCACTGCACGGGGCCTGGGGTGTGCGGGTGCATGATGTGCGGGCCTCGGTCGATGCCATCAAGGTGGTCGAAGCGTGGATGGGAGCGGAAAGGATAGAACGCGATGGCTGA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2971,Drugs,MEG_2971|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|984994143|gb|CP010340.1|4064332-4063490 gi|984989958|gb|CP010339.1|4037458-4036616 gi|984985728|gb|CP010338.1|4055038-4054196 gi|984981517|gb|CP010337.1|4039899-4039057 gi|984976917|gb|CP010336.1|4045913-4045071 gi|984972452|gb|CP010335.1|4057600-4056758 gi|984967653|gb|CP010334.1|4028694-4027852 gi|984963331|gb|CP010333.1|4027779-4026937 gi|984959134|gb|CP010332.1|3983974-3983132 gi|984954355|gb|CP010331.1|4006044-4005202,8
,atggcactggcactcgttggcgaaaaaattgacagaaaccgcttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctaaaagatgccatttttaaaagcagtgatttatccatggcggattttcgcaatgccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagttttatgaatatgatcactactcgcacctggttttgtagtgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggggacttagatattcggggcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcggtgattggttag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5905,Drugs,MEG_5905|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,696369423|WP_032944434.1|NG_050492|1|1|qnrB30|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB30 NG_050492:37-681,3
,atgatgagaaaaagcgtaaggcgggcgatgttaatgacgacagcctgtgtttcgctgctgttggccagtgtgccgctgtgtgcccaggcgaacgatgttcaacaaaagctcgcggcgctggagaaaagcagcgggggacgactgggtgtggcgttgattaacaccgccgataacacgcagacgctctaccgcgccgacgagcgttttgccatgtgcagcaccagtaaagtgatggcggcagcggcggtgcttaagcaaagtgaaacgcaaaagggcttgttgagtcagcgggttgaaattaagccctcagacttgattaactacagccccattgcggaaaaacacgtcaatggcacgatgacattcggggagttgagcgcggcggcgctacagtacagcgataatactgccatgaataagctgattgcccatctcggggggccggataaagtgacggcatttgcccgtacgattggcgatgacacgttccggctcgatcgtaccgagccgacgctcaacaccgcgatccccggcgacccgcgcgataccaccacgccgttagcgatggcgcaggctctgcgcaatctgacgttgggcaatgccctgggtgacactcagcgtgcgcagctggtgatgtggctgaaaggcaacaccaccggcgctgccagcattcaggcagggctacccacatcgtgggttgtcggggataaaaccggcagcggcggttatggtacgacgaatgatatcgcggttatttggccggaaggtcgcgcgccgctcgttctggtgacttacttcacccagtcggagccgaaggcagagagccgtcgtgacgtgctcgctgctgccgccagaattgtcaccgacggttattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2172,Drugs,MEG_2172|Drugs|betalactams|Class_A_betalactamases|CTX,1393270466|WP_109791211.1|NG_057610|1|1|blaCTX-M-217|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-217 NG_057610:1-876,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCCCTTTATCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCTGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGGCTGTACACGTTTCTCCGGGACAACTTGATGCCGAAGCCTATGGCGTGAAATCCAGTGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCAATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCTGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTAACGATGAGGCCCAGGATATTGGGCCTCCTTTCTTTCTCTTTTTTTCCTGTTGTCATCTACACTTAACAAAAATACAGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1973,Drugs,MEG_1973|Drugs|betalactams|Class_C_betalactamases|CMY,gi|407731526|gb|JX440353.1|1027-2255,0
,ATGTTTTCTCGCTGGTCGAAGACCTTCGCGTTTGGCCTCGCGGCCTGCGCCGTTGCCCTCAGCACCGCCACCGCTCATGCCGAGCTGGTGGTGCGCAATGACCTCAAGCGCGTGTTCGACGACGCCGGCGTCTCCGGCACCTTCGTGCTGATGGACATCAGCGCCGACCGCACCTATGTCGTCGATCCGGCGCGCGCCGCGCGGCACATCCATCCCGCATCGACGTTCAAGATTCCGAACAGCCTGATCGCCTTCGACACCGGGGCCGTGCGCGACGATCAGGAAGTGCTGCCCTACGGCGGCAAGCCGCAGCCTTACAAGCAGTGGGAGCACGACATGGCGTTGCCCGAGGCGATTCGCCTGTCGGCCGTGCCGATCTATCAGGAAGTCGCGCGCCGCGTTGGGTTTGAGCGCATGCAGGCCTACGTCGATGCGTTCGACTACGGCAATCGCCAACTCGGCAGCGTGATCGATCAATTCTGGCTGCGCGGCCCGCTGGAGATTTCCGCGTTCGAAGAAGCACGCTTCACCAGCCGCATGGCGCTCAAGCAGTTGCCGGTGAAGCCGCGCACGTGGGACATGGTCCACCGCATGCTGTTGATCGAGCAGCAGGGCGATGCCGCGCTGTATGCCAAGACCGGCGTCGCCACCGAATACCAGCCGCAGATCGGCTGGTGGGTCGGCTGGGTCGAGCGTGCCGGGCGCATCTATGCCTTCGCACTGAACATCGACATGCCGCGCGAAGGCGATATGGCCAAACGCATTCCGCTGGGCAAGCAATTGATGCAGGCGCTGGCGGTGTGGCCGGCGCCATGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4753,Drugs,MEG_4753|Drugs|betalactams|Class_D_betalactamases|OXA,(Bla)OXA-60:AY664505:1-816:816,0
,TCAGGTCGAGGTGGCCCGGCTCCATGCACCGCGACGCAACGCGGGGAGGCAGACAAGGTATAGGGCGGCGCCTACAATCCATGCCAACCCGTTCCATGTGCTCGCCGAGGCGGCATAAATCGCCGTGACGATCAGCGGTCCAATGATCGCAGTTAGGCTGGTAAGAGCCGCGAGCGATCCTTGAAGCTGTCCCTGATGGTCGTCATCTACCTGCCTGGACAGCATGGCCTGCAACGCGGGCATCCCGATGCCGCCGGAAGCGAGAAGAATCATAATGGGGAAGGCCATCCAGCCTCGCGTCGCGAACGCCAGCAAGACGTAGCCCAGCGCGTCGGCCGCCATGCCGGCGATAATGGCCTGCTTCTCGCCGAAACGTTTGGTAGCGGGACCAGTGACGAAGGCTTGAGCGAGGGCGTGCAAGATTCCGAATGCCGCAAGCGACAGGCCGATCATCGTCGCGTTCCAGCGAAAGCGGTCCTCGCCAAAAATGACCCAGAGCGCTGCCGGCACCTGTCCTACGAGTTGCATGATAAAGAAGACAGTCATAAGTGCGGTGACGATAGTCATGCCCCGTGCCCACCGGAAGGAGCTGACTGGGTTGAAGGCTTTCAAGGGCATCGGTCGACGCTCTCCCTTATGCGACTCCTGCAATAGGAAGCAGCCCAGTAGTAGGTTGAGGCCGTTGAGTACCGCCGCCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCCAGCCACCATACCCACGCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTCCCCATCGGTGATGTCGGCGATATAAGCGCCAGCAACCGCACCTGTGGCGCCGGTGATGCCGGCCACGATGCGTCCGGCGTAGAGGATCCAAAGGACGGGTGTGGTCGCCATGACCGCGTAGTCGATAGTGGCTCCAAGTAGCGAAGCGAGCAGGACTGGGCGGCGGCCAAAGCGGTCGGACAGTGCTCCGAGAACGGGTGCACATATAAATTGCATCAACGCATAAAGCGCTAGCAGCACGCCGTAGTGACTGGCGATGCTGTCGGAATGGACGATATCCCGCAAGAGCCCCGGCAGTATCGGCATAACCAAGCCTATGCCTACAGCATCCAGGGTGACGGTGCCGAGGATGACGAAGAGCGCATTGTTAGATTTCAT,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7063,Drugs,MEG_7063|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETC,gi|15822653|gb|AY043298.1|4007-5197 gi|961454902|gb|KT991388.1|7007-6978,4
,ATGGCTGAATTACCTCAATCAAGAATAAATGAACGAAATATTACCAGTGAAATGCGTGAATCATTTTTAGATTATGCGATGAGTGTTATCGTTGCTCGTGCATTGCCAGATGTTCGTGACGGTTTAAAACCAGTACATCGTCGTATACTATATGGATTAAATGAACAAGGTATGACACCGGATAAATCATATAAAAAATCAGCACGTATCGTTGGTGACGTAATGGGTAAATATCACCCTCATGGTGACTTATCTATTTATGAAGCAATGGTACGTATGGCTCAAGATTTCAGTTATCGTTATCCGCTTGTTGATGGCCAAGGTAACTTTGGTTCAATGGATGGAGATGGCGCAGCAGCAATGCGTTATACTGAAGCGCGTATGACTAAAATCACACTTGAACTGTTACGTGATATTAATAAAGATACAATAGATTTTATCGATAACTATGATGGTAATGAAAGAGAGCCGTCAGTCTTACCTGCTCGATTCCCTAACTTGTTAGCCAATGGAGCATCAGGTATAGCGGTAGGTATGGCAACGAATATTCCACCACATAACTTAACAGAATTAATCAATGGTGTACTTAGCTTAAGTAAGAACCCTGATATTTCAATTGCTGAGTTAATGGAGGATATTGAAGGTCCTGATTTCCCAACTGCTGGACTTATTTTAGGTAAGAGTGGTATTAGACGTGCATATGAAACAGGTCGTGGTTCAATTCAAATGCGTTCTCGTGCAGTTATTGAAGAACGTGGAGGCGGACGTCAACGTATTGTTGTCACTGAAATTCCTTTCCAAGTGAATAAGGCTCGTATGATTGAAAAAATTGCAGAGCTCGTTCGTGACAAGAAAATTGACGGTATCACTGATTTACGTGATGAAACAAGTTTACGTACTGGTGTGCGTGTCGTTATTGATGTGCGTAAGGATGCAAATGCTAGTGTCATTTTAAATAACTTATACAAACAAACACCTCTTCAAACATCATTTGGTGTGAATATGATTGCACTTGTAAATGGTAGACCGAAGCTTATTAATTTAAAAGAAGCGTTGGTACATTATTTAGAGCATCAAAAGACAGTTGTTAGAAGACGTACGCAATACAACTTACGTAAAGCTAAAGATCGTGCCCACATTTTAGAAGGATTACGTATCGCACTTGACCATATCGATGAAATTATTTCAACGATTCGTGAGTCAGATACAGATAAAGTTGCAATGAAAAGCTTGCAACAACGCTTCAAACTTTCTGAAAAACAAGCTCAAGCTATTTTAGACATGCGTTTAAGACGTCTAACAGGTTTAGAGAGAGACAAAATTGAAGCTGAATATAATGAGTTATTAAATTATATTAGTGAATTAGAAACAATCTTAGCTGATGAAGAAGTATTACTACAATTAGTTAGAGATGAATTAACAGAAATTCGAGATCGTTTCGGTGATGATCGTCGTACTGAAATCCAATTAGGTGGATTTGAAGATTTAGAAGATGAAGATCTCATTCCAGAAGAACAAATTGTAATTACACTAAGCCATAATAACTACATTAAACGTTTGCCGGTATCTACATATCGTGCTCAAAACCGTGGTGGTCGTGGTGTTCAAGGTATGAATACATTGGAAGAAGATTTTGTCAGTCAATTGGTAACTTTAAGTACACATGACCATGTATTGTTCTTTACTAACAAAGGTCGTGTATACAAACTTAAAGGTTATGAAGTGCCTGAGTTATCAAGACAGTCTAAAGGTATTCCTGTAGTGAATGCTATTGAACTTGAAAATGATGAAGTCATTAGTACAATGATTGCTGTTAAAGACCTTGAAAGTGAAGACAACTTCTTAGTGTTTGCAACTAAACGTGGTGTCGTTAAACGTTCAGCATTAAGTAACTTCTCAAGAATAAATAGAAATGGTAAGATTGCGATTTCGTTCAGAGAAGATGATGAGTTAATTGCAGTTCGCTTAACAAGTGGTCAAGAAGATATCTTGATTGGTACATCACATGCATCATTAATTCGATTCCCTGAATCAACATTACGTCCTTTAGGCCGTACAGCAACGGGTGTGAAAGGTATTACACTTCGTGAAGGTGACGAAGTTGTAGGGCTTGATGTAGCTCATGCAAACAGTGTTGATGAAGTATTAGTAGTTACTGAAAATGGTTATGGTAAACGTACGCCAGTTAATGACTATCGTTTATCAAATCGTGGTGGTAAAGGTATTAAAACAGCTACGATTACTGAGCGTAATGGTAATGTTGTATGTATCACTACAGTAACTGGTGAAGAAGATTTAATGATTGTTACTAATGCAGGTGTCATTATTCGACTAGATGTTGCAGATATTTCTCAAAATGGTCGTGCAGCACAAGGTGTTCGCTTAATTCGCTTAGGTGATGATCAATTTGTTTCAACGGTTGCTAAAGTAAAAGAAGATGCAGAAGATGAAACGAATGAAGATGAGCAATCTACTTCAACTGTATCTGAAGATGGTACTGAACAACAACGTGAAGCGGTTGTAAATGATGAAACACCAGGAAATGCAATTCATACTGAAGTGATTGATTCAGAAGAAAATGATGAAGATGGACGTATTGAAGTAAGACAAGATTTCATGGATCGTGTTGAAGAAGATATACAACAATCATCAGATGAAGATGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3191,Drugs,MEG_3191|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|156720466|dbj|AP009324.1|7005-9674 gi|47208328|dbj|BA000017.4|7005-9674,3
,atgaaatttaatttgatagatatagaggattggaatagaaagccatactttgagcattatttaaatgcggtaaggtgcacttacagtatgactgcaaatttagagataactagtttactgcgtgaaattaaacttaagggcctgaaactgtaccctacgcttatttatatcatcacaactgtagttaatcgtcacaaggagttccgcaccagttttgatcaaaacggtaagttaggatactgggatagtatgaacccaagttatactatctttcataaggataacgaaactttttcaagtatttggacagagtatgacgagaacttcccacgtttctactataattaccttgaggatatcagaaactatagcgacgttatgaatttcatgcctaaggcaggtcaacctgctaacacaattaatgtgtccagcattccttgggtgaattttaccggattcaacttgaatatatataatgatgcaacatatctaatccctatttttacattgggtaagtattttcagcaggataataaaattttattacctatgtctgtacaggtgcatcatgcggtttgcgacggttaccataccagcagattttttaatgaggcacaggaattagcctcaaattttgagacatggttaggagaaaaataa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1561,Drugs,MEG_1561|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,1028084253|WP_063843221.1|NG_047591|1|1|catA16|catA16|type_A-16_chloramphenicol_O-acetyltransferase_CatQ NG_047591:101-760,6
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattataatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttcaaagagctaaacaagccttttctcctgcttcaacttttaaaatttttaatgctttaattgcgcttgataatggtgtagttagagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagctataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgatactttttggctagataattctttacaaatttctgcaaaaaatcaagctgatttactttttaaattttcgcaaaattctttacctttttctaaaaaaattcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaaaattattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4577,Drugs,MEG_4577|Drugs|betalactams|Class_D_betalactamases|OXA,1079806831|WP_070210118.1|NG_061408|1|1|blaOXA-658|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-658 NG_061408:1-720,0
,atgcgcgataccggattcccctgcctgtgcggcatcgccgcctccacactgctgttcgccgccacctcggccattgccggcgaggccccggcggatcgcctgaagacactggtcgacgccgccgtacaaccggtgatgaaggccaatgatattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcttcgaaagaggacggtcgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggtccaggacaagatgcgcctcgacgaccgcgccagcctgcactggccggcgctgcaaggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaagaccaggcacagatccgcgactactaccgccagtggcagccgacctacacgccgggcagccagcgcctctactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggatcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaagccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggcgggcaactcgacgccgatggcgctgcaaccgcacaggatcgccagactgcccgcgccccaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccaggccgcgacctgggcctggtgatcctggccaatcgcaattatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5712,Drugs,MEG_5712|Drugs|betalactams|Class_C_betalactamases|PDC,1201190447|WP_087587967.1|NG_054987|1|1|blaPDC-202|blaPDC|class_C_beta-lactamase_PDC-202 NG_054987:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5635,Drugs,MEG_5635|Drugs|betalactams|Class_C_betalactamases|PDC,1034011017|WP_064483992.1|NG_050783|1|1|blaPDC-127|blaPDC|class_C_beta-lactamase_PDC-127 NG_050783:1-1194,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggctacggcaatgcggacgtctcgggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaagctggtgaatcggcaattgccggtcaaggccgccgcctatgagcttgccgaaaacctcttcgaggtgggccaggccgatggctggcgcctgtttggcaagaccggcaccgggtcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccggcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4726,Drugs,MEG_4726|Drugs|betalactams|Class_D_betalactamases|OXA,935530459|WP_054437016.1|NG_064732|1|1|blaOXA-114j|blaOXA-114_like|class_D_beta-lactamase_OXA-114j NG_064732:1-828,0
,gtggatatttccttcctgaagaaatctggtcgccggacgatggcggccgccgcggcgatcgcgctactgggcggctgcggcgcggacgcgggttccgagcccgccaccaccgcggcgagcacgaccgcgccgagcacggccaccgacgcggcgaccgccgagttcgccgcactggaacagcgatccggcgcgcggctgggcgtctacgcggtcgacacgaccagcggcgccgaggtcgcctaccgggcggacgagcggttcggcatggcctccaccttcaagggcctggcctgcggcgcgctgctgcgcgagcacccgctgtcgtccggctatttcgaccaggtcgtccgctactcccgcgaggaggtggtgtcctattcgccggtcaccgagacccgcgtggacaccgggatgaccgtcgccgaactgtgccacgccacgatcaccgtcagcgacaacaccgcgggcaaccagatcctgaaactgctcggcggccccgccggtttcaccgccttcctgcgctcgctcggcgacgaggtgagccggctggaccgctgggagaccgaactcaacgaggtgccgcccggcgaggaacgcgacaccaccacccccgccgccgtggcggcgaactaccgcgcgctggtgctcggtgacgtgctcgccgagcccgagcgcgcccagttgcgggactggctggtcgccaacaccaccggcgaccagcgcatccgtgcgggcgtgcccgcgggctggacggtcggcgacaagaccggcggcggcagccacggcggcaacaacgacgtggccgtggcctggaccgagaccggcgacccgatcgtcatcgccctgctctcgcaccgcaccgaccccgccgccaaggccgacaacgccctgctcgccgaggcgacccgggcggtggtcaccgccctgcgatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_2881,Drugs,MEG_2881|Drugs|betalactams|Class_A_betalactamases|FAR1,1073722251|WP_070064531.1|NG_049089|1|1|blaFAR-1|blaFAR|class_A_extended-spectrum_beta-lactamase_FAR-1 NG_049089:101-1033,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccaaggcctgggctgggaagcctacgactggccgatctccctgaggcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5580,Drugs,MEG_5580|Drugs|betalactams|Class_C_betalactamases|PDC,1028110197|WP_063864567.1|NG_049879|1|1|blaPDC-111|blaPDC|class_C_beta-lactamase_PDC-111 NG_049879:1-1194,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatcgcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttagaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcatttggttataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgcccctgcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtagttcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaaaggtttcggaacatatgtagtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctggatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_581,Drugs,MEG_581|Drugs|betalactams|Class_C_betalactamases|ADC,1625655381|WP_136512058.1|NG_064712|1|1|blaADC-189|blaADC|class_C_beta-lactamase_ADC-189 NG_064712:1-1152,0
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacacaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4690,Drugs,MEG_4690|Drugs|betalactams|Class_D_betalactamases|OXA,1509794586|WP_122630895.1|NG_062315|1|1|blaOXA-693|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-693 NG_062315:14-838,0
,atgaaaaacacaatacatatcaacttcgctatttttttaataattgcaaatattatctacagcagcgccagtgcatcaacagatatctctactgttgcatctccattatttgaaggaactgaaggttgttttttactttacgatgcatccacaaacgctgaaattgctcaattcaataaagcaaagtgtgcaacgcaaatggcaccagattcaactttcaagatcgcattatcacttatggcatttgatgcggaaataatagatcagaaaaccatattcaaatgggataaaacccccaaaggaatggagatctggaacagcaatcatacaccaaagacgtggatgcaattttctgttgtttgggtttcgcaagaaataacccaaaaaattggattaaataaaatcaagaattatctcaaagattttgattatggaaatcaagacttctctggagataaagaaagaaacaacggattaacagaagcatggctcgaaagtagcttaaaaatttcaccagaagaacaaattcaattcctgcgtaaaattattaatcacaatctcccagttaaaaactcagccatagaaaacaccatagagaacatgtatctacaagatctggataatagtacaaaactgtatgggaaaactggtgcaggattcacagcaaatagaaccttacaaaacggatggtttgaagggtttattataagcaaatcaggacataaatatttttttgtgtccgcacttacaggaaacttggggtcgaatttaacatcaagcataaaagccaagaaaaatgcgatcaccattctaaacacactaaatttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4670,Drugs,MEG_4670|Drugs|betalactams|Class_D_betalactamases|OXA,1062509493|WP_069280711.1|NG_051517|1|1|blaOXA-534|blaOXA-1_like|OXA-1_family_class_D_beta-lactamase_OXA-534 NG_051517:1-831,0
,atgaataaaaacactaaaataaaaaacaaaaatttcaacattaaagactcacagaattttttgcataatactaaattagtcgaagatttgctttttaaaagcaatataactaaggaggattttgttgttgagattgggcctggaaaaggcataataaccaaggcattaagcaaaatctgcaaagccgttactgctattgagttcgatagtgtattggctgataagttgacccatgaatttaaaagttcaaatgtgtctattattgaagccgattttttaaaatacaatttaccagaccataattataaagttttttcaaacattccatttaacataacggcaagtattttaaataaattgttagatagtgagaacccacccttagatacttttttaattatgcaatatgaaccttttttaaagtatgcgggtgcaccatcttacaaggagtcttataaatctttattatataaaccatttttcaaaactaacatattgcatagctttagcaaatttgattttaagccagctccaaacgcaaacattattttgggccaattttcttataaagactttacagatataaaccttgaagacaggcatgcttggaaagattttttagcctttgtctttttagaaaagggagttacatttaaagaaaaaacaaaacgaatttttagttataagcaacaaaaaataattttaaaagaaagccgaattaatgatgattcaaatataagtaattggagttatgaattttggctaaaaatgtttaaactctataattcgaacatggtaagcaaggataaaaaagttttagttaacaattcgtataaaagaatgttagaacatgagtctagtttagaaaagattcatagaaatagaaagcaaaataacagaaaatag,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2779,Drugs,MEG_2779|Drugs|MLS|23S_rRNA_methyltransferases|ERM42,917745009|WP_052259183.1|NG_047784|1|1|erm(42)|erm(42)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(42) NG_047784:101-1006,7
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccgtttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_786,Drugs,MEG_786|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502136|WP_071846288.1|NG_052335|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052335:101-892,2
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGAACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1873,Drugs,MEG_1873|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EU496815|+|0-1146|ARO:3002043|CMY-32 [Escherichia coli] ,0
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgtggacgccgggcaagagcacctcggtcgccgcatacactattctcagaatgacttggttgagtccccaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaagcaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6662,Drugs,MEG_6662|Drugs|betalactams|Class_A_betalactamases|TEM,1393270439|WP_109791184.1|NG_057581|1|1|blaTEM-233|blaTEM|class_A_beta-lactamase_TEM-233 NG_057581:1-861,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcaacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_561,Drugs,MEG_561|Drugs|betalactams|Class_C_betalactamases|ADC,447133958|WP_001211214.1|NG_064699|1|1|blaADC-144|blaADC|class_C_beta-lactamase_ADC-144 NG_064699:101-1252,0
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagtcaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgatgcattattggaaaagtatatcgcaggagaaccaatcagccaggaaaaacttgcgcgggaggaacagcggcgggttcaagaagcctccctgtttccggtctatcatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacaggactgttccaaccgattggggaacaggggagcgccaccctatgcggcagcgttttcaaggttgagtacaccgattgcggccagcggcgtgtctatctgcggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggcgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggatcaaacccggctccctcgtaaaaggtggcgcgaggcccccctccccatgctgcggacgacgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgctgcgaagtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggtcgtttccgctttgctgtcggaaaaatacaagattgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatctatcggactgtctgttacaccactcccgcttggctccggcgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccagtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcggggacgcagctgctggaaccttatctctccttcaccctctatgcgccccaggaatacctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggcccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcagagcgtatgccttacagagctaaaagggtatcaggccgctgtcggccagccggtcatccagccccgccgtccaaacaaccgcctggacaaggtgcgccatatgtttcagaaggtaatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7218,Drugs,MEG_7218|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100280|WP_063856415.1|NG_048286|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048286:1-1920,4
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactaagggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattgcggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4684,Drugs,MEG_4684|Drugs|betalactams|Class_D_betalactamases|OXA,1509794582|WP_122630891.1|NG_062311|1|1|blaOXA-689|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-689 NG_062311:15-839,0
,atgcaatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtgttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_515,Drugs,MEG_515|Drugs|betalactams|Class_C_betalactamases|ADC,1058243722|WP_068981626.1|NG_051459|1|1|blaADC-95|blaADC|class_C_beta-lactamase_ADC-95 NG_051459:1-1152,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacaccgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2157,Drugs,MEG_2157|Drugs|betalactams|Class_A_betalactamases|CTX,1393270469|WP_109791214.1|NG_057613|1|1|blaCTX-M-218|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-218 NG_057613:1-876,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatcagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_568,Drugs,MEG_568|Drugs|betalactams|Class_C_betalactamases|ADC,1058243485|WP_068981607.1|NG_051439|1|1|blaADC-100|blaADC|class_C_beta-lactamase_ADC-100 NG_051439:1-1158,0
,ATGGATCCTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGGTGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCTTTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6699,Drugs,MEG_6699|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-98:AF397067:1-861:861,0
,atgagatcagaaaaggaagtttatgatattgttttgaattttgcaaaaacagacaaacgcattcgcatggttactttggaaggatctagaacaaatacaaatattccgcctgatgattttcaggattttgatattactttttttgttacggatatggacagcttcacaagtgatgataaatggctagatatatttggtgaaaggttgattctgcaaaagccggaagatatggaattatttccagctgtagaaaagggattttcatatttaatgctgtttactgatgatgttaagatagatttaactttgctgccgctggaactgatagacgagtattttacatgggataaactggtaaagttactgttggataaagacaaccgtatcgtaaagccgccaataccaacggatatagactaccacttgcagaagcctactcaaagaatgtttgacgattgctgtaatgaattttggaatactacaacatatgtagtaaagggcttatgccgcaaagaaattctttttgctattgaccatatgaatgatatagtacgaaaagaattgcttcgcatgatttcctggctgattggtatcaaacagggatttcatttcagtttgggaaaaaactataaatttatgaagcaatatgtcccagaggaattgtgggaacgacttatgtccacttataatatggattcctatccccatatgtgggaatcctttgaacaatgtatggcattgttccgggaggtttcgtcagaagtggcatgccagttggattaccagtatccactatatgatgaaaaaatcagtaattatgtgattcggcaaaagaaaaaatatggcattgaagatgataacaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_988,Drugs,MEG_988|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,447178612|WP_001255868.1|NG_047378|1|1|aadE|aadE|aminoglycoside_6-adenylyltransferase_AadE NG_047378:28-894,2
,TTGTCAAAATAGCGGGAGTCGCAGATAATCCGCTGCGACTTATCACTCTCAAGGAATCAGAAATGATAAAAAGTTCGTGGCGTAAAATTGCAATGCTAGCCGCCGTTCCGCTGCTGCTGGCGAGCGGCGCACTGTGGGCCAGTACCGATGCTATCCATCAGAAGCTGACAGATCTCGAGAAGCGTTCAGGCGGCAGGTTGGGCGTGGCGCTAATCAACACGGCAGATAATTCTCAAATCTTATATCGCGGCGACGAGCGTTTTGCCATGTGCAGCACCAGTAAAGTGATGGCCGCCGCCGCGGTATTAAAACAGAGCGAAAGCAATAAAGAGGTGGTAAATAAAAGGCTGGAGATTAACGCAGCCGATTTGGTGGTCTGGAGTCCGATTACCGAAAAACATCTCCAGAGCGGAATGACGCTGGCTGAGCTAAGCGCGGCGACGCTGCAATATAGCGACAATACGGCGATGAATCTGATCATCGGCTACCTTGGCGGGCCGGAAAAAGTCACCGCCTTCGCCCGCAGTATCGGCGATGCCACCTTTCGTCTCGATCGTACGGAGCCCACGCTGAATACCGCCATCCCGGGCGATGAGCGTGATACCAGCACGCCGCTGGCGATGGCTGAAAGCCTACGCAAGCTGACGCTTGGCGATGCGCTGGGCGAACAGCAACGCGCCCAGTTAGTCACCTGGCTGAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCGGGCCTGCCTGAAAGCTGGGTGGTCGGCGATAAAACCGGCACCGGAGATTACGGCACCACCAATGATATTGCGGTTATCTGGCCGGAAGATCACGCTCCGCTGGTATTAGTCACCTACTTTACCCAGCCGCAGCAGGATGCGAAAAACCGCAAAGAGGTGTTAGCCGCAGCGGCAAAAATCGTGACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5314,Drugs,MEG_5314|Drugs|betalactams|Class_A_betalactamases|OXY,gi|257136309|gb|FJ785625.1|70-1001,0
,atgttcaaacttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagccagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgtggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7705,Drugs,MEG_7705|Drugs|betalactams|Class_B_betalactamases|VIM,1693892951|WP_140423328.1|NG_065448|1|1|blaVIM-65|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-65 NG_065448:1-801,0
,ATGACCAACTACTTTGATAGCCCCTTCAAAGGCAAGCTGCTTTCTGAGCAAGTGAAGAACCCCAATATCAAAGTTGGGCGGTACAGCTATTACTCTGGCTACTATCATGGGCACTCATTCGATGACTGCGCACGGTATCTGTTTCCGGACCGTGATGACGTTGATAAGTTGATCATCGGTAGTTTCTGCTCTATCGGGAGTGGGGCTTCCTTTATCATGGCTGGCAATCAGGGGCATCGGTACGACTGGGCATCATCTTTCCCGTTCTTTTATATGCAGGAAGAACCTGCATTCTCAAGCGCACTCGATGCCTTCCAAAAAGCAGGTAATACTGTCATTGGCAATGACGTTTGGATCGGCTCTGAGGCAATGGTCATGCCCGGAATCAAGATCGGGCACGGTGCGGTGATAGGCAGCCGCTCGTTGGTGACAAAAGATGTGGAGCCTTACGCTATCGTTGGCAGCAATCCCGCTAAGAAGATTAAGAAACGCTTCACCGATGAGGAAATTTCATTGCTTCTGGAGATGGAGTGGTGGAATTGGTCACTGGAGAAGATCAAAGCGGCAATGCCCATGCTGTGCTCGTCTAATATTGTTGGCCTGCACAAGTATTGGCTCGAGTTTGCCGTCTAA,chloramphenicol acetyltransferase (CAT),antibiotic inactivation,Phenicol,MEG_1619,Drugs,MEG_1619|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB,(Phe)CatB3:AJ009818:883-1515:633,6
,atgttaaaagttattagtagtttattggtctacatgaccgcgtctgtcatggctgtcgcaagtccgttagcccattccggggagccgagtggtgagtatccgacagtcaacgaaattccggtcggagaggtccgactttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcggtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgaaaagcaaattggacttcccgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggcagaggggagcgagattcccacgcattctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagagctcttctatcctggtgctgcgcattcgaccgacaatctggttgtatacgtcccgtcagcgaacgtgctatacggtggttgtgccgttcatgagttgtcacgcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccgttgagcggattcaaaaacactacccggaagcagaggtcgtcattcccgggcacggtctaccgggcggtctagacttgctccagcacacagcgaacgttgtcaaagcacacaaaaatcgctcagtcgccgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7702,Drugs,MEG_7702|Drugs|betalactams|Class_B_betalactamases|VIM,1142971252|WP_077064888.1|NG_052864|1|1|blaVIM-54|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-54 NG_052864:1-801,0
,atgcgcgataccggattcccctgcctgtgcggcatcgccgcctccacactgctgttcgccgccacctcggccattgccggcgaggccccggcggatcgcctgaagacactggtcgacgccgccgtacaaccggtgatgaaggccaatgatattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcttcgaaagaggacagtcgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagcctgcactggccggcgctgcaaggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaagaccaggcacagatccgcgactactaccgccagtggcagccgacctacacgccgggcagccagcgcctctactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggatcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccctctacgggtcggtcccggcccgctggatgccaaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaagccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggcgggcaactcgacgccgatggcgctgcaaccgcacaggatcgccagactgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccaggccgcgacctgggcctggtgatcctggccaaccgcaattatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5706,Drugs,MEG_5706|Drugs|betalactams|Class_C_betalactamases|PDC,1315549096|WP_101244936.1|NG_056102|1|1|blaPDC-224|blaPDC|class_C_beta-lactamase_PDC-224 NG_056102:1-1194,0
,atgactctggcattagttggcgaaaaaattgacagaaatcgcttcactggtgagaaagttgaaaatagtacattttttaactgcgatttttcaggtgccgacctgagcggcactgaatttatcggctgccagttctatgatcgcgaaagtcagaaaggatgcaattttagtcgcgcaatgctgagagatgccattttcaaaagctgtgatttatcaatggcagatttccgcaacgtcagcgcattgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggtgcaagctttatgaatatgatcaccacgcgcacctggttttgcagcgcatatatcactaataccaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctatgggaaaaccgctggatggggactcaggtactgggtacgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttaggtgacttagatattcggggtgttgatttacaaggcgttaagttagacaactaccaggcatcgttgctcatggagcggcttggcatcgctgtgattggttag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5897,Drugs,MEG_5897|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111872|WP_063866081.1|NG_050503|1|1|qnrB40|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB40 NG_050503:16-660,3
,atggaaatcaaaaagttaagcagtgctaatattaacttatggatagcgctaagagagcagctatggccgcatcatcctgaaaataaaactgatggggaaaatattattctgtctgatgggttggcttcatttattgctatagataaccttggtcaaggcattggtttcgctgatgcatccatacggaacgattatgtgaatggttgtattcatagccctgttgcctttcttgagggcatttttattgtcccatcctctcggcgtggtggtgttgccaaacagttagttgatgctgtgcaagcatgggggttagaaaaggggtgccaggaactggcatctgataccgcattggataacgttttatcacaacaagtccatgaagctttgggatttaaggaaactgagagggtcgtttactaccgcaaagcctcacttagctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_187,Drugs,MEG_187|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491012597|WP_004874306.1|NG_052265|1|1|aac(6')_Yersi|aac(6')_Yersi|aminoglycoside_6'-N-acetyltransferase NG_052265:101-541,2
,atgaaatttcaatgtcattttctctctgtccctgtggcgatactcggatgtgttggcctcatctgcacatccgcatatgccatggatacgggaatcctcgacctcgctgtaacccaagaggagaccacgcttcaggctagggtcggagtggcggtgatcgatacggattccggcctgacgtggcagcatcgtggcgacgaacgcttcccgctgaacagcacgcataaagccttttcctgcgcggccgttctggcccaggccgaccgccacaagctgaacctggagcaggcgataccgatcgagcgcacagcgctggtcacatactcacccgtgacggaaagggtgccacctggcggcacgctgaccctgcgtgagctgtgcagggccgccgtcagtatcagtgacaacacagcggccaatttggcgttggatgcaatcggcggggcacggacattcaccgcgttcatgcggtctatcggtgacgataagacacgcctggatcggcgagaacccgaactcaacgaggccacgccgggggatgcacgcgacacgacaacgccaattgcggcagcgcggagcctgcaaacactgttgctcgacggtgtcctctccgctccggctcggaacgaactgacacaatggatgctcggggatcaagttgccgatgccttgctacgcgctggcttgccgagggattggcaaattgcggacaagtcgggagcaggtggtcacggatcacgttccataatcgccgttgtctggccgcccaagcgttcagccgtcattgtggcgatctacatcacccaaaccgcagcgtctatgtcggcaagcaaccaggcggtgtccagaatcggatcagccttagcaaaggcgttgcaatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1240,Drugs,MEG_1240|Drugs|betalactams|Class_A_betalactamases|BLAA,499589388|WP_011270171.1|NG_047483|1|1|bla-A|bla-A|class_A_beta-lactamase NG_047483:101-982,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtaccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgatcaagttaacttacttcaactcgcgacgtatacaagtggcaacctcgctttacaatttccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccacttggtgccccagcatacggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaccccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtcggcaccatgtatcaggcacttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaaccgtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_594,Drugs,MEG_594|Drugs|betalactams|Class_C_betalactamases|ADC,818247024|WP_046693238.1|NG_063832|1|1|blaADC-181|blaADC|class_C_beta-lactamase_ADC-181 NG_063832:1-1152,0
,atgccttttgccctctacatgcttgccctggcggtcttcgtcatgggcacttcagaattcatgctcgcgggattgctccccgcgatcgcgaccgaacttgacgtctcggtcggcactgcgggcctgctgacctccgcattcgcagtcggtatggtcgtcggcgcgccagtgatggcggcattcgctcgccgttggccaccgcggctcacattgatcgtttgccttctcgtgttcgcgggaagccacgtcatcggagcgatgacaccagtgttctctctcctgctcatcacccgggtgctcagcgctctcgcaaacacaggattcctcgccgtagcactgagcacggccactaccctcgtgccagcgaaccagaaggggcgtgcactgtcgatcctgctctccggcacgacgatcgcaaccgtcgtgggcgtccccgccggggcactgctcggcacagcgctgggctggcgaacgacgttctgggcgatcgccatcctctgtattcccgcggccgttggagtcattcgtggcgtcacgaacaatgttggtcggagcgagactagcgcgacctcaccaaggctccgtgtcgagctcagccagttggcgacgccgcggctcatcctggccatggcactcggagcgctgatcaacggagggacctttgcggcattcaccttcctggcacccatcgtgaccgagaccgcgggcttggccgaagcgtgggtgtccgtcgcgctggtgatgttcggcatcggatcgttccttggcgtcacgatcgcaggacgactatcagatcaacgacctggcctcgtgctcgcagtcggcggaccgctattgctgacaggctggatcgtgttggcagtggtcgcatctcatcccgttgcgcttatcgtcctcgtcctcgttcagggattcctgtcgttcggcgtcggcagtactctgatcacgcgtgtgctgtatgcagcatcgggtgcgccaacgatgggcggttcgtacgcaaccgcagcattgaatatcggagctgcagcggggcccgtgcttggtgcgctcgggctcgcgaccgggctggggctgctcgcgccggtttgggtcgcttcggtgctgacagcgatcgctctcgtcatcatgcttctcaccagacgcgcgcttacgaagaccgcggcggaggccaattga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1783,Drugs,MEG_1783|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMX,499425607|WP_011113071.1|NG_047665|1|1|cmx|cmx|chloramphenicol_efflux_MFS_transporter_Cmx NG_047665:101-1276,6
,ATGCCCTCCACTGCCCCTGAAGTCACCCAGCGACTCATGGTCAAGCGCGACCTGGTAATGCTTCACGAATGGCTCAATCGCCCTCACATCGTTGAGTGGTGGGGAGGCGAAGAAGCCCGCCCGACGCTGCAAGAAGTGCAATCGCACTACCTACCTCGCGTGTTGGCCGAAGAGGCGGTCACGCCGTATATCGCGATGCTCGGGAGTGAGCCAATTGGGTACGCGCAGTCTTACGTTGCATTGGGAAGTGGCGATGGGTGGTGGGAGGATGAAACAGACCCGGGTGTGCGCGGAATAGATCAGTCGCTGGCCAATCCAGAACAACTGGGCAAGGGCCTCGGGACCAGGCTTGTTTGTACCTTGGTCAAGACACTGTTCAACGATCCATCCGTGACCAAGATTCAAACCGACCCGGCGCCAAACAACGTCCGCGCGATCCGCTGCTACGAGAAGGCTGGCTTCAGACAACAGAAGGTCATCACCACGCCGGACGGCCCGGCCGTCTACATGGTTCAAACCCGCGCCTCTTTCGAGGCAGCGCGCGGTGCTGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_341,Drugs,MEG_341|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|197111879|gb|EU912537.1|2092-2646,2
,atgactcgacataatgaaattattaaaattgcagaaaaacatcaattacacatcaaacctcaaacaatatcattgaatgaatcagggctagatttccaagttgcatttggagaagatgaacacggaatagagtgggttttaagactaccaagaagacctgacgtttataaacgaacaaaacctgaaaaacaaatggtagacttcttacaaaaaaatgtttcgtttgaagtaccgaattggaaagtacatacaaaagaccttattgcttatccaaaacttacaggcaaacccgcagccacaatagatccagaaatacaaaattacgtatgggaaattgaacacaaaccagtaacaaaaaattttattaacacattagctgaaacactcgtagatttacacaacataccaaaggaaaatattaccgcacagcatataaatatcaaaactatacaagaaataaaaaatgattttcaaagaagaatgaataaagttaaagaaacttatggcgtagcagatggattatggaacagatggaaacaatggttagaaaacgacgaactgtggcctcgacgtgcaaccatgatacatggagacttacatccaggacatataatggtagataaccaagcaaatgtcacaggactcatagactggactgaagcaacctactccgatccgtcaatggactttatgggataccatcgtgtattcgacgacgaaggattagagcaactcataacagcatacggtaaagctggaggagaaacatggccacgaatgaaagagcatataatagaactcaatgcagtattcccaatgtttatcgctgagtttgctatggaatcaggagaaccagcgtatgaaaaaatggcattgcaagagttaggtatgaaagagtag,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4035,Drugs,MEG_4035|Drugs|MLS|Macrolide_phosphotransferases|MPHC,1028097440|WP_063854137.1|NG_047993|1|1|mph(C)|mph(C)|Mph(C)_family_macrolide_2'-phosphotransferase NG_047993:1-900,7
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAATGCGGTGCAACAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCCCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAACTGGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2406,Drugs,MEG_2406|Drugs|betalactams|Class_A_betalactamases|CTX,gi|56554770|gb|AY847147.1|82-962,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagaacaacaggttttaactttttttaaagattggaaacctaaaaacccaatcggtgaatatagacaatattcaaacccaagtattggcctatttggggaaatagttggtttatcaatgaagcagccttttagtcaggtcttggaaaaaacgatttttccggaccttggcttaaaacatagctatgtcaatgtgcctaaaactcagatgcaaaactatgcatttggttataaccaagaaaatcagccaattcgagttaaccctggcccactcgatgccccagcatacggcgtcaaatcgaccctacccgacatgctgagctttattcatgccaacctgaacccacagaaatatccggcaaatattcaacgtgcaattaatgagacgcatcaaggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagtttgcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccacaaaactggctcaaccaacggtttcggaacctatgtcgtatttattcctaaagaaaatattggtttagtcatgttaaccaataaacgcattccaaatgaagaacgcattaaagcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_535,Drugs,MEG_535|Drugs|betalactams|Class_C_betalactamases|ADC,1058243629|WP_068981619.1|NG_051451|1|1|blaADC-87|blaADC|class_C_beta-lactamase_ADC-87 NG_051451:1-1152,0
,gtgagcgacctggagctgcggggcgaacgggtcctgctgcgctccaccgcccccgccgacacccccgtcctcgacgcgatcgtccgcgaacccgaggtcgcccggtggtggccgccgcccgaggcgtacgccgccatgctcgccgtcgtcgtggacggcgaggtgatcggcgcgatccagttcagcgaggagagcgacccggagttccgccacgccggcatcgacctcttcctgtcggcccggtggcacgggcagggcctgggccccgacgccgtacgcaccctggcccgctggctgatcgccgagcgcggccaccaccgcctggtcatcgacccggccgccgccaacacgcgcgccatccgcagctaccgcaaggtcggcttcgccccggtcgggatcatgcgcgcctactggcgcgaccaccgcaccggcgcgtgggaggacggactgctgatggacctgctggcggccgaactgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_254,Drugs,MEG_254|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,825324668|WP_047139664.1|NG_052469|1|1|aacA-STR-13|aacA-STR-13|aminoglycoside_6'-N-acetyltransferase NG_052469:101-583,2
,ATGATGAAAAAATCGATTTGCTGCGCGTTGCTGGTCACAGCCTCTCTGTCAACGTTTGCCGCCGACAAAACAGAACAACAGATTGCCGATATCGTAAACCGTACCATCACACCGCTGATGCAAGAACAGGCTATTCCGGGTATGCGCTTCGCAATTATCTACCAGGGAAAACCCTATTACTTTACCTGGGGGAAAGCCGATATCGCCAATGACCGCCCCGTCACCCGGCAAACGCTGTTTGAGCTTGGATCGGTAAGTAAGACGTTTAACGGTGTGCTGGGCGGCGATGCTATCGCCCGTGGTGAAATTAAGCTCAGCGATCCGGTCACCCAATACTGGCCCAAATTAACTGGCAAACAATGGCTGGGTATCAGCCTGCTGCATCTGGCCACCTATACGGCGGGTGGCCTGCCGCTTCAGGTACCTGACGACGTTACAGATAAAGCGGCATTACTGCGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAACGCCTGTATGCTAACCCAAGTATTGGTCTGTTTGGCGCACTGGCGGTGAAACCTTCAGGAATGGGCTATGAAGAGGCGATGACCAAACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCACAGAGCGAACAAAAGGATTATGCCTTGGGTTATCGCGAAGGAAGGCCCGTGCACGTATCTCCGGGCCAGCTTGATGCCGAAGCCTACGGGGTGAAATCCAGCCTTGTCGATATGACTCGCTGGATTCAGGCCAACATGGACGCCAGCCAGGTGCAGGAGAAAACGCTCCGACAGGGAATTGAAATTGCGCAGGCTCGTTACTGGCATATTGGCGATATGTACCAGGGATTAGGTTGGGAGATGGTCAACTGGCCGGTGAATGCCGACTCGATAATCAACGGTAGCGACAGTAAAGTCGCGTTAGCGGCGCTTCCCGCCGTTGAGGTCAATCCGCCCGCCCCTGCAGTGAAAGCCTCATGGGTGCACAAAACCGGCACTTCCGGCGGATTTGGCACGTACGTTGCGTTGGTTCCGGAAAAAAATCTCGTCGGCATGATGCTGGCAAACAAAAGCTACCCAAAGCCTGCTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAATTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1657,Drugs,MEG_1657|Drugs|betalactams|Class_C_betalactamases|CFE,gb|MF543129.1|-|2483-3629|ARO:3004464|CFE-2 [Citrobacter freundii] ,0
,atgtcgaaaattgaactaaaacaactatcttttgcctatgataatcaagaagtattgctttttgatcaggcaaatatcacgatggataccaattggaaattaggattgattggccgcaatggccgtgggaaaacaaccttattaagattgttacaaaaacagttggattaccaaggagagattcttcatcaagtcgatttcgtctattttccacaaacagttgcagaagaacaacagctcacttattatgtcttacaagaggtgacttcttttgaacagtgggaattagaacgagaattaacgcttttaaacgttgatcctgaagttttatggcggcccttttcttctttatcaggcggcgaaaagacgaaagttttattaggtcttctttttattgaagaaaatgcctttcctttaattgacgagccaacaaatcatttagatctagctggcagacaacaagtggctgaatatttgaagaaaaagaaacacgggtttattttagtcagccacgatcgggcatttgttgatgaagtggttgatcatattttggcgattgaaaaaagtcaattgacgctgtatcaagggaatttttctatttatgaagagcaaaaaaaattaagagatgcttttgaactagcagaaaatgaaaaaatcaaaaaagaagtcaatcgcttgaaagaaaccgctcgtaaaaaagcggaatggtcgatgaaccgtgaaggtgataagtacggcaacgctaaggaaaaagggagcggggcgatttttgatacaggagccattggtgcccgggcagcgcgcgtaatgaagcgctcgaaacacattcaacaacgcgccgaaacacaattagcagaaaaagaaaaactattaaaagatcttgagtatattgatcctttgtcaatggattatcagccaacgcatcacaaaacattattgacggtggaagagcttcgtctaggctacgagaaaaattggctatttgcgccactttctttttcaataaacgcgggagaaattgttggaataacagggaaaaatggctcaggaaaatcgagcttaattcagtatttattggataatttttctggggattcagaaggcgaagccactttggctcaccaattaaccatttcttatgtgcgccaagattatgaagacaatcaaggaactttatccgaatttgcagagaaaaatcagttagattacactcaatttttaaataacttacgaaaacttgggatggagcgtgccgttttcactaatcgaattgaacaaatgagtatggggcaacggaaaaaagtcgaagtagccaaatcattgtctcaatcagctgaactttatatttgggatgaaccccttaattacttggatgtatttaatcatcaacaattagaagcgctaatcttatctgtgaagcctgcaatgctagtgattgagcatgatgcacatttcatgaagaaaataacagataaaaaaattgtcttgaaatcataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3643,Drugs,MEG_3643|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|LSA,488329444|WP_002398829.1|NG_055640|1|1|lsa(A)|lsa(A)|ABC-F_type_ribosomal_protection_protein_Lsa(A) NG_055640:101-1597,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5541,Drugs,MEG_5541|Drugs|betalactams|Class_C_betalactamases|PDC,553758424|WP_023091031.1|NG_049911|1|1|blaPDC-39|blaPDC|class_C_beta-lactamase_PDC-39 NG_049911:1-1194,0
,atggttaaaaaatcactgcgcaagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgtggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2193,Drugs,MEG_2193|Drugs|betalactams|Class_A_betalactamases|CTX,1028104726|WP_063859972.1|NG_048949|1|1|blaCTX-M-164|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-164 NG_048949:1-876,0
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAAGTATACCGTTCTTTATCCGTATTAGACGGAGCAGTATTATTAGTTTCTGCAAAGGATGGCATACAGGCACAGACCCGTATACTGTTTCATGCACTACAGATAATGAAGATTCCGACAATTTTTTTCATCAATAAAATTGACCAAGAGGGGATTGATTTGCCAATGGTATATCGGGAAATGAAAGCAAAGCTTTCTTCGGAAATTATAGTGAAGCAAAAGGTTGGGCAGCATCCCCATATAAATGTAACGGACAATGACGATATGGAACAGTGGGATGCGGTAATTATGGGAAACGATGAACTATTAGAGAAATATATGTCAGGGAAACCGTTTAAAATGTCAGAACTGGAACAGGAAGAAAACAGGAGATTCCAAAACGGAACGTTATTTCCCGTTTATCACGGAAGCGCTAAAAACAATCTGGGGATTCGGCAGCTTATAGAAGTAATTGCCAGTAAATTTTATTCATCAACGCCTGAAGGTCAATCTGAACTATGCGGGCAGGTTTTTAAGATTGAATATTCAGAGAAAAGGCGGCGTTTTGTTTATGTGCGTATATATAGCGGAACATTGCATTTGAGGGATGTTATTAGAATATCTGAAAAAGAGAAAATAAAGATTACAGAAATGTGTATTCCGTCAAATGGTGAAATCGTCCCGGCTGACCATGCCTGTCCGGGAGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGACATTCTGGGAAATGAAAAACTCCTGCCTCACAAAACATGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCGCAGAGATTGCTGATACAGACCCTCTTTTGCATTTTGACATTGATACTGTTACACATGAGATTATGTTATCTTTTTTGGGAAAAGTACAGTTAGAAGTTATTTGTTCGCTATTAGAAGAAAAATATCATGTGGGCGTGGCTATGAAAGAGCCTTCGGTTATTTATCTGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAGGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTTATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7166,Drugs,MEG_7166|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/32/O)_3_NZ_AUJS01000017 ,4
,atgatgacaaaatccctaagctgtgccctgctgctcagcgtcgccagctctgcattcgccgcaccgatgtccgaaaaacagctggctgaggtggtggaacgtaccgttacgccgctgatgaacgcgcaggccattccgggtatggcggtggcggtaatttatcagggtcagccacactactttaccttcggtaaagccgatgttgcggcgaacaaacccgtcaccccgcaaaccctgtttgagctgggctctataagtaaaaccttcaccggcgtactgggcggcgatgccattgcccggggtgaaatagcgctgggcgatccggtagcaaaatactggcctgagctcacgggcaagcagtggcagggcattcgcatgctggatctggcaacctataccgcaggcggtctgccgttacaggtgccggatgaggtcacggataccgcctctctgctgcgcttttatcaaaactggcagccgcagtggaagccgggcaccacgcgtctttacgctaacgccagcatcggtctttttggtgcgctggcggtcaaaccttccggcatgagctatgagcaggccatgacgacgcgggtctttaaacccctcaagctggaccatacctggattaacgtcccgaaagcggaagaggcgcattacgcctggggataccgtgagggtaaagcggtccacgtttcgccagggatgctggacgcggaagcctatggcgtaaaaactaacgtgaaggatatggcgagctggctgatagccaacatgaagccggattctcttgaggctccctcactcaagcaaggcattgctctggcgcagtctcgctactggcgcgtgggggctatgtatcaggggctgggctgggagatgctcaactggccggtcgatgccaaaaccgtcgtcggaggcagtgataacaaggtggcgctggcaccattgcccgtggcagaagtgaatccacccgcgccgccggtcaaggcctcctgggtccataaaacaggctcgacgggcgggtttggcagctacgtggcatttattcctgaaaagcagctcggcattgtgatgctggcgaataaaagctatccgaacccggcacgcgttgaggcggcataccgtatcctcgacgcgctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3953,Drugs,MEG_3953|Drugs|betalactams|Class_C_betalactamases|MIR,1028105814|WP_063860839.1|NG_049302|1|1|blaMIR-18|blaMIR|cephalosporin-hydrolyzing_class_C_beta-lactamase_MIR-18 NG_049302:1-1146,0
,atgatgacaaaatccctaagctgcgcgctgctgctcagcgttgcctgctctgcttttgccgcgccgatgtcagaaaaacagctggctgacgtcgtggaacgtaccgttacgcctctgatgaaggcgcaggccatacccggaatggccgtggccgtcatttatcagggccagccacactattttactttcggtaaagcagacgttgcggcgaataagcccgtcacgccgcaaaccttatttgagctgggctccgtcagcaaaaccttcaccggcgtgctgggtggcgatgccattgcccgcaaagagatttcgctggccgacccggtcacaaaatattggcctgaattgacgggcaagcagtggcaaggcattcgcctgctagacctggcaacctataccgcaggtggattgccgttgcaggtgccggatgctgtcaccgataacgcctctctgctgcgtttctaccagtcctggcagccaaagtgggccccgggtactacgcgtctgtacgccaacaccagcatcggtttgtttggctcactggcggttaaaccttccggcatgcgctttgaggaggccatgacggagcgggtctttaagcccctgaaactcaaccatacgtggataaacgttccacacgctgaagagtcgcactacgcatggggttatcgtgagggaaaagcggtccacgtttcgcctggtatgctggatgcagaagcctatggcgtgaaatctaacgtcaaagatatggcgagctgggtgatggccaatatggcacctgagacactcccgcagtccactctgcagcagggtattgcgctggcgcagtctcgctactggcgcgtgggtgccatgtatcaagggttaggctgggagatgctcaactggccggtcgacgccaaaaccgtggtggatggcagcgataataaggtcgcactggcgccgttgccggtcgcagaagtgaatcctccggctccgccagtaaaagcctcctgggtgcataaaacgggctctacgggtgggtttggcagctacgtggcgtttattcctgaaaagcagatcggtattgtgatgctcgcaaataaaagctatccgaacccggtacgggtggaaacggcttaccgtatcctcgacgcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1752,Drugs,MEG_1752|Drugs|betalactams|Class_C_betalactamases|CMH,1028104169|WP_063859588.1|NG_048767|1|1|blaCMH-2|blaCMH|class_C_beta-lactamase_CMH-2 NG_048767:1-1146,0
,atggtgacggtgttcggcattctgaatctcaccgaggactccttcttcgatgagagccggcggctagaccccgccggcgctgtcaccgcggcgatcgaaatgctgcgagtcggatcagacgtcgtggatgtcggaccggccgccagccatccggacgcgaggcctgtatcgccggccgatgagatcagacgtattgcgccgctcttagacgccctgtccgatcagatgcaccgtgtttcaatcgacagcttccaaccggaaacccagcgctatgcgctcaagcgcggcgtgggctacctgaacgatatccaaggatttcctgaccctgcgctctatcccgatattgctgaggcggactgcaggctggtggttatgcactcagcgcagcgggatggcatcgccacccgcaccggtcaccttcgacccgaagacgcgctcgacgagattgtgcggttcttcgaggcgcgggtttccgccttgcgacggagcggggtcgctgccgaccggctcatcctcgatccggggatgggatttttcttgagccccgcaccggaaacatcgctgcacgtgctgtcgaaccttcaaaagctgaagtcggcgttggggcttccgctattggtctcggtgtcgcggaaatccttcttgggcgccaccgttggccttcctgtaaaggatctgggtccagcgagccttgcggcggaacttcacgcgatcggcaatggcgctgactacgtccgcacccacgcgcctggagatctgcgaagcgcaatcaccttctcggaaaccctcgcgaaatttcgcagtcgcgacgccagagaccagggttag,beta-lactamase,antibiotic target replacement,Sulfonamides,MEG_6580,Drugs,MEG_6580|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,1028098568|WP_063855066.1|NG_048089|1|1|sul1|sul1|sulfonamide-resistant_dihydropteroate_synthase_Sul1 NG_048089:101-928,8
,atgagtgaaaaagtgcccgccgagatttcggtgcaactatcacaagcactcaacgtcatcgggcgccacttggagtcgacgttgctggccgtgcatttgtacggctccgcactggatggcggattgaaaccgtacagtgatattgatttgctggtgactgtagctgcatcgctcaatgatgccgtgcggcaagccctgctcgtcgatctcttggaggtttcagcttcccctggccaaaacaaggcactccgcgccttggaagtgaccatcgtcgtgcacagtgacatcgtaccttggcgttatccggccaggcgggaactgcagttcggagagtggcagcgcaaagacatccttgcgggcatcttcgagcccgccacaaccgattctgacttggcgattctgctaacaaaggcaaagcaacatagcgtcgtcttggcaggttcagcagcgaaggatctcttcagctcagtcccagaaagcgatctattcaaggcactggccgatactctgaagctatggaactcgccgccagattgggcgggcgatgagcggaatgtagtgcttactttgtctcgtatctggtacaccgcagcaaccggcaagatcgcgccaaaggatgttgctgccacttgggcaatggcacgcttgccagctcaacatcagcccatcctgttgaatgccaagcgggcttatcttgggcaagaagaagattatttgcccgctcgtgcggatcaggtggcggcgctcattaaattcgtgaagtatgaagcagttaaactgcttggtgccagccaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_822,Drugs,MEG_822|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1028081073|WP_063840456.1|NG_047364|1|1|aadA7|aadA7|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA7 NG_047364:101-898,2
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgataactcactaaaaataagcgctaaagaacaagcaattttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgatggtataaatttggcttggattgttggatttatagagagtaaaaacaaaattttatcttttgccttaaatgttgatataaagaacattaaaaatcttaaaataagagaagaattgctagaaaaatatatttattctttaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4399,Drugs,MEG_4399|Drugs|betalactams|Class_D_betalactamases|OXA,1204949512|WP_087696200.1|NG_057458|1|1|blaOXA-576|blaOXA-576_like|class_D_beta-lactamase_OXA-576 NG_057458:101-847,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGATGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1381,Drugs,MEG_1381|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_28_JDYO01000009,0
,atgaaatctaacaatgcgctcatcgtcatcctcggcaccgtcaccctggatgctgtaggcataggcttggttatgccggtactgccgggcctcttgcgggatatcgtccattccgacagcatcgccagtcactatggcgtgctgctagcgctatatgcgttgatgcaatttctatgcgcacccgttctcggagcactgtccgaccgctttggccgccgcccagtcctgctcgcttcgctacttggagccactatcgactacgcgatcatggcgaccacacccgtcctgtggatcctctacgccggacgcatcgtggccggcatcaccggcgccacaggtgcggttgctggcgcctatatcgccgacatcaccgatggggaagatcgggctcgccacttcgggctcatgagcgcttgtttcggcgtgggtatggtggcaggccccgtggccgggggactgttgggcgccatctccttgcatgcaccattccttgcggcggcggtgctcaacggcctcaacctactactgggctgcttcctaatgcaggagtcgcataagggagagcgtcgaccgatgcccttgagagccttcaacccagtcagctccttccggtgggcgcggggcatgactatcgtcgccgcacttatgactgtcttctttatcatgcaactcgtaggacaggtgccggcagcgctctgggtcattttcggcgaggaccgctttcgctggagcgcgacgatgatcggcctgtcgcttgcggtattcggaatcttgcacgccctcgctcaagccttcgtcactggtcccgccaccaaacgtttcggcgagaagcaggccattatcgccggcatggcggccgacgcgctgggctacgtcttgctggcgttcgcgacgcgaggctggatggccttccccattatgattcttctcgcttccggcggcatcgggatgcccgcgttgcaggccatgctgtccaggcaggtagatgacgaccatcagggacagcttcaaggatcgctcgcggctcttaccagcctaacttcgatcattggaccgctgatcttcacggcgatttatgccgcctcggcgagcacatggaacgggttggcatggattgtaggcgccgccctataccttgtctgcctccccgcgttgcgtcgcggtgcatggagccgggccacctcgacctga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7059,Drugs,MEG_7059|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETC,446764190|WP_000841446.1|NG_048181|1|1|tet(C)|tet(C)|tetracycline_efflux_MFS_transporter_Tet(C) NG_048181:101-1291,4
,ATGACGCAAATTTTAATAGTAGAAGATGAACAAAACTTAGCAAGATTTCTTGAATTGGAACTCACACATGAAAATTACAATGTGGACACAGAGTATGATGGACAAGACGGTTTAGATAAAGCGCTTAGCCATTACTATGATTTAATCATATTAGATTTAATGTTGCCGTCAATTAATGGCTTAGAAATTTGTCGCAAAATTAGACAACAACAATCTACACCTATCATTATAATTACAGCGAAAAGTGATACGTATGACAAAGTTGCTGGGCTTGATTACGGTGCAGACGATTATATAGTTAAGCCATTTGATATTGAAGAACTTTTAGCAAGAATTCGTGCGATTTTACGTCGTCAGCCACAAAAAGATATTATCGATGTCAACGGTATTACAATTGATAAGAATGCTTTTAAAGTGACGGTAAATGGCGCAGAAATTGAATTAACAAAAACGGAGTATGATTTACTATATCTTCTAGCTGAAAATAAAAACCATGTTATGCAACGGGAACAAATTTTAAATCATGTATGGGGTTATAATAGTGAAGTAGAAACAAATGTCGTAGATGTTTATATAAGATATTTACGAAACAAATTAAAACCATACGATCGTGACAAAATGATTGAAACAGTTCGTGGCGTTGGGTATGTGATACGATGA,protein of two-component regulatory system modulating antibiotic efflux,antibiotic efflux,Multi-drug_resistance,MEG_1114,Drugs,MEG_1114|Drugs|Multi-drug_resistance|MDR_regulator|ARLR,gi|703576232|gb|CP009554.1|1461876-1461217 gi|701162461|emb|LN626917.1|989540-990199 gi|685631213|gb|CP009361.1|1414495-1413836 gi|532126991|gb|CP002388.1|1357486-1356827 gi|49240382|emb|BX571856.1|1488321-1487662,1
,TTGAAGGATCAGATCACGTATCTTCCCGACAACGCAGACCGTTCCGTGGCAAAGCAAAAGTTCAAAATCACCAACTGGCCCACCTACAATAAAGCCCTCATCAACCGTGGCTCCATAACTTTCTGGCTGGATGATGAAGCTATTCAGGCCTGGTATGAGTCAGCAACACCTTCTTCACGAGGCAGACCTCAGCGCTATTCTGACCTTGCCATCACGACTGTGCTGGTCATTAAACGCGTATTCAGGCTGACCCTGCGCGCTGCGCAGGGCTTTATTGATTCCATTTTTTCTCTGATGAACGTTCCGCTACGCTGCCCGGATTACAGCTGTGTCAGCAGGCGGGCAAAGTCGGTTAATATCAGTTTCAAAACGCCCACCCGGGGTGAAATCGCACACCTGGTAATTGATTCCACCGGGCTGAAGGTCTTCGGTGAAGGCGAGTGGAAAGTCAAAAAGCATGGCCAGGAACGCCGTCGTATATGGCGTAAGCTGCATCTGGCAGTTGACAGTAAAACACATGAAATCATCTGCGCTGACCTGTCGCTGAACAACGTTACGGACTCAGAGGCCTTCCCCGGGTTAATCCGGCAAACCCACCGGAAAATCAGGTCAGCCGCCGCCGATGGAGCTTACGATACCCGGCTCTGTCACGATGAACTGCGGCGTAAGAAAATCAGCGCGCTTATCCCGCCCCGAAAAGGTGCGGGTTACTGGCCCGGTGAATATGCAGACCGTAACCGTGCAGTGGCTAATCAGCGAATGACCGGGAGTAATGCGCGGTGGAAATGGACAACAGATTACAACCGTCGCTCGATAGCGGAAACGGCGATGTACCGGGTAAAACAGCTGTTCGGGGGTTCACTGACGCTGCGTGACTACGATGGTCAGGTTGCGGAGGCTATGGCCCTGGTACGAGCGCTGAACAAAATGACGAAAGCAGGTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2435,Drugs,MEG_2435|Drugs|betalactams|Class_A_betalactamases|CTX,gi|971520884|gb|CP008697.1|324162-323220 gi|971520884|gb|CP008697.1|496713-495771 gi|967512282|gb|KT362307.1|1109-167 gi|962148759|gb|KT002541.1|12269-13211 gi|961666360|gb|KT185451.1|26745-25803 gi|961666360|gb|KT185451.1|96539-96265 gi|961494526|gb|KT282968.1|36768-35826 gi|940516925|dbj|LC091535.1|1404-2346 gi|918462945|gb|KP987215.1|31784-30842 gi|817046807|gb|KP893385.1|73718-74660 gi|817046807|gb|KP893385.1|136031-135757 gi|831358012|emb|LN735561.1|25778-24836 gi|831357893|emb|LN735560.1|15374-14432,0
,ATGGCAGAAAAAATAATTGTTGTTGATGATGAAAAAGAAATCGCCGAGTTAGTCACGACGTTTCTAAGGAATGAAGGCTTTCAAGTGGAACCTTTTTATGATGGAACGAGTGCTTTGGCTTATCTCGAAAAAGAAACAGTCGATGTGGCAGTTTTAGATGTGATGCTGCCGGATATCGACGGCTTTCAGCTGTTACAGACCATTCGCAAAACCCACTTTTTTCCAGTACTGATGCTCACTGCCAAAGGAGAAGATCTGGATAAAATTACCGGTCTAAGTCTAGGTGCAGATGATTATGTGACTAAGCCCTTCAATCCATTAGAAGTTGTTGCTCGGGTCAAAACGCAACTACGGCGATACCAACGATACAATCAGTCAGCTGTTCCGCAGAAGATTGAAGAATACGAAAAGGAAGGCTTACTGTTGAAAATCAACAGTCACCAATGTTTTCTTTATGGCAAAGAGGTTTTCTTGACCCCCATCGAATTTAAAATCCTGCTTTACTTATTTGAACACCAAGGATCGGTCGTTGCCTCGGAAACTCTTTTTGAAGCAGTCTGGAAAGAAAAATATTTAGATAACAATAACACAGTGATGGCACATATTGCCCGTCTGCGGGAAAAGCTAAACGAACAACCCCGCAAACCGAAATTAATCAAAACTGTATGGGGGGTCGGCTATATCATTGAAAAATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7473,Drugs,MEG_7473|Drugs|Glycopeptides|VanC-type_regulator|VANRC,(Gly)VanRc4:EU151753:3848-4543:696,5
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgatgtttacgccagccggcccgagggcgtcgtcatctacggtcttttcagttcgatgctggccttcgtgcctgcgcttggcccaattgctggagcactgatcggcgagtttttcggatggcgggcgatattcgtaacgctggccgcgcttgcgttacccgcactcttgaatgccggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcaccttcttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2926,Drugs,MEG_2926|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,504199322|WP_014386424.1|NG_047865|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047865:101-1315,6
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagtttcccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5480,Drugs,MEG_5480|Drugs|betalactams|Class_C_betalactamases|PDC,1304472401|WP_100931733.1|NG_056057|1|1|blaPDC-223|blaPDC|class_C_beta-lactamase_PDC-223 NG_056057:1-1137,0
,atgcgttatgttcgcctgtgtgttatctccctgttagccaccctgccactggcggtagacgccggtccacagccgcttgagcagattaaacaaagcgaaagccagctgtcgggccgcgtggggatggtggaaatggatctggccagcggccgcacgctggcggcctggcgcgccgatgaacgctttcccatggtgagcacctttaaagtgctgctgtgcggcgcggtgctggcgcgggtggatgcaggggtcgaacaactggatcggcggatccactaccgccagcaggatctggtggactactccccggtcagcgaaaaacaccttaccgacgggatgacggtcggcgaactctgcgccgccgccatcaccctgagcgataacagtgctggcaatctgctgctggccaccgtcggcggccccgcgggattaactgcctttctgcgccagatcggtgacaacgtcacccatcttgaccgctgggaaacggcactgaatgaggcgcttcccggcgacgcacgcgacaccaccaccccggccagcatggccgccacgctgcgcaaactactgaccgcgcagcatctgagcgcccgttcgcaacagcaactcctgcagtggatggtggacgatcgggttgccggcccgctgatccgcgccgtgctgccgccgggctggtttatcgccgacaagaccggggctggcgaacggggtgcgcgcggcattgtcgccctgctcggcccggacggcaaaccggagcgcattgtggtgatctatctgcgggataccccggcgagcatggccgagcgtaatcaacatatcgccgggatcggcgcagcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3543,Drugs,MEG_3543|Drugs|betalactams|Class_A_betalactamases|LEN,507090270|WP_016160983.1|NG_050605|1|1|blaLEN-31|blaLEN|class_A_beta-lactamase_LEN-31 NG_050605:101-961,0
,atggagaaaataatagacataactgtttttggctgcgagccagacgaaatggaggtttttcaaaagatttcttatgagcttggtgttacagccacactcataaaagattctatatcagaaagcaatgctggattagctaatggatgccggtgtgtaagcgtaagccataaagcggagctatcagaaccgattcttcttgcgctaaaaaatgcaggggtaaaatatatcagtacccggagcattggttttaaccatattgatatacaggcggctgggttactgggtatggttgttggcacagtagaatactcgccgggaagtgtggccgattataccgtcatgctgatgcttatgctgatgcgtggcacaaagtcgattctgcgtgaaacccagaggcagaattattgcctgaatgacctgcgcggaaaagaactgcgggatatgaccgtgggtgtgttaggaactgggcgaatcggacaggcagtcatggagcgcctggagggattcggttgtaaggtattggcgtatgaccgaaatcaaaaagcaggagcagactatgtttcgtttcatgaactgctgaaaaaaagtgacattgttacactgcatatcccgttggcggaggatacccgccatatgattggctatgaagagctggaaatgatgaaggaagaggcgcttctgatcaatacagggcggggcgctttagtggataccgcagcattggtagaagcattaaaaggacagaaaatcggcggcgccctggatgttttggaaggcgaagaaggtatcttttaccatgactgcacccaaagaagaatagaacatcctttcctgtcggtcctgcagggaatgccgaatgtcattgttacgccgcacacagcctatcatacggaacgggtgttggttgacacggtcagaaatactattagaaattgtttgaattttgaaaggagtctgggaaatgtttag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7421,Drugs,MEG_7421|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,1028100568|WP_063856703.1|NG_048381|1|1|vanH-D|vanH-D|D-lactate_dehydrogenase_VanH-D NG_048381:101-1069,5
,atgaccatgtttaaaacaacatttcgccaaacagcagcgatcgcagtttcattaatatctctattagcatctccaatgctatgggctgacaacaataatacaattgaagagcaattaaatacgctggaaaaatatagccaaggtcgtttaggcgtggcattaatcaacaccaaagataactcacaaataacataccgtggtgaagaacgctttgcgatggcaagtacaagtaaggttatggcggttgccgccgttttaaaagcgagtgaaaaacaagccggattattagataagaatattacgattaaaaaatctgacttagttgcttacagccctattacagaaaaacatttaacaacaggaatgacactggctgaattaagtgctgctacattgcaatatagcgataatacagcaatgaataagatattagattatttaggcggtccagccaaagtcactcaatttgcacgttcaattaatgatgtcacttatcgccttgatcgtaaagagcctgaattaaatacagcaattcatggtgatcctcgtgatactacttctccaattgcgatggctaaaagtcttcaagcactgacattaggcgatgcactaggtcaatctcagcgtcaacaacttgtgacttggttaaaaggtaatacaacgggtgataacagtattaaagcgggtttaccgaaacactgggttgttggggataaaaccggtagtggtgattatggtacaactaacgatattgccgttatctggcctgaaaaccatgcgccattaattttagtcgtttatttcacacaacaagaacaagatgcaaaataccgtaaagatattattgctaaagcagctgaaattgtaacaaaagagatatctaattcacctcaaacaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3280,Drugs,MEG_3280|Drugs|betalactams|Class_A_betalactamases|HUGA,1028094250|WP_063851288.1|NG_047908|1|1|hugA|hugA|class_A_beta-lactamase NG_047908:101-1003,0
,atgcgccatgcgacaatcctcaacctgtgcggcctcgccgcttccaccctgttcttcgcgacaacatcggccttcgccacggaggcgccggcggagcgcctgaaggctctggtggacgccgccgtgcaaccggtcatgaaggccaatgatatcccgggactggccgtcgccatcactctcaagggcgaaccgcattacttcagttatggggtggcctcgaaggaggacgcccgcaaggtgacccccgagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctacgccctggcccaggacaagatgcgcctcgacgaccgcgccagccggcactggcccgccctgcagggcagccgcttcgacggtatcagcctgctcgacctcggcacctacaccgctggcggcctgccgctacagttccccgatgcggtgcagaaggatccggcgcagatccgcgactattaccgccagtggcaaccgacctacgccccgggcagccaccgccagtactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccattcgagcgcagcatggaacggcagctgttcccggcgctcggcctggagcacacctttatccgggtgcccgccgcgcagcaggggctgtacgcccagggctacggcaaggacgaccacccgctgcgggtcggacccggtccgctggacgccgaggcctacgggctgaagtccagcgctgcggacctgctgcgcttcgtcgaggccaacctgcaccccgagcgcctggagaagccctgggcgcaggccctcgacgccacccatcgcggctactacaaggtgggcgacatgacccagggcctgggctgggaagcctacgattggccgatcgacctgaagcgcctgcaggcgggcaactcggcgccgatggcgctgcaggcgcacaaggtcgccaggttgccggcgccgcaagccctggacggccagcgcctgctgaacaagaccggctccaccaacggtttcggcgcctacctggcgttcatcccgggacgcgacgtcggcctggtgatcctggccaatcgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggaacagcaggccaaggtaccgctggtgcgttga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5429,Drugs,MEG_5429|Drugs|betalactams|Class_C_betalactamases|PDC,730722906|WP_034081664.1|NG_049914|1|1|blaPDC-41|blaPDC_var|class_C_beta-lactamase_PDC-41 NG_049914:1-1194,0
,atgaacaagttatctgtattctttatgtttatgttttgtagcattactgccgcaggagagtctttgccagatttaaaaattgagaagcttgacgaaggtgtttatgttcatacttcgtttgaagaagttaacggttggggtgttgttcctaaacacggcttggtggttcttgtaaatactgaggcctatctgattgacactccatttacggcaaaagatactgaaaagttagtcacttggtttgtggagcgcggctataaaataaaaggcagtatttcctctcattttcatagcgacagcacgggcggaatagagtggcttaattctcaatctatccccacgtatgcatctgaattaacaaatgaacttcttaaaaaagacggtaaggtacaagctaaaaattcatttagcggaggtagctattggctagttaataataagattgaagttttttatcctggtccagggcacactccagataacgtagtggtttggctacctgaaaatagagttttgttcggtggttgttttgttaaaccgtacggtcttggtaatttgggtgacgcaaatttagaagcttggccaaagtccgccaaaatattaatgtctaaatatggtaaagcaaagttggttgtttcaggtcatagtgaaactgggaacgcatcactcttgaaacttacttgggagcaggctgttaaagggctaaaagaaagtaaaaaaccatcactgccaagtaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3326,Drugs,MEG_3326|Drugs|betalactams|Class_B_betalactamases|IMP,1062509492|WP_069280710.1|NG_051513|1|1|blaIMP-62|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-62 NG_051513:1-741,0
,atggctctggcactcgttggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctaagtggtactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcaatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagctttatgaatatgatcactacacgcacctggttttgcagcgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggagcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5911,Drugs,MEG_5911|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1049330924|WP_065825699.1|NG_051322|1|1|qnrB78|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB78 NG_051322:1-645,3
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagaggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgagcttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4642,Drugs,MEG_4642|Drugs|betalactams|Class_D_betalactamases|OXA,1391852918|WP_109545103.1|NG_057537|1|1|blaOXA-590|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-590 NG_057537:1-774,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagcctgcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5544,Drugs,MEG_5544|Drugs|betalactams|Class_C_betalactamases|PDC,1028110204|WP_063864574.1|NG_049893|1|1|blaPDC-21a|blaPDC|class_C_beta-lactamase_PDC-21a NG_049893:1-1194,0
,TTGTATCTTATGTCTAACATTCAAAACATGTCCCTGGAGGACATCATGGGAGAGCGCTTTGGTCGCTACTCCAAGTACATTATTCAAGACCGGGCTTTGCCAGATATTCGTGATGGGTTGAAGCCGGTTCAACGCCGTATTCTTTATTCTATGAATAAGGATAGCAATACTTTTGACAAGAGCTACCGTAAGTCGGCCAAGTCAGTCGGGAACATCATGGGGAATTTCCACCCACACGGGGATTCTTCTATCTATGATGCCATGGTTCGTATGTCACAGAACTGGAAAAATCGTGAGATTCTAGTTGAAATGCACGGTAATAACGGTTCTATGGACGGAGATCCTCCTGCGGCTATGCGTTATACTGAGGCACGTTTGTCTGAAATTGCAGGCTACCTTCTTCAGGATATCGAGAAAAAGACAGTTCCTTTTGCATGGAACTTTGACGATACGGAGAAAGAACCAACGGTCTTGCCAGCAGCCTTTCCAAACCTCTTGGTCAATGGTTCGACTGGGATTTCGGCTGGTTATGCCACAGACATTCCTCCCCATAATTTAGCTGAGGTCATAGATGCTGCAGTTTACATGATTGACCACCCAACTGCAAAGATTGATAAACTCATGGAATTCTTACCTGGACCAGACTTCCCTACAGGGGCTATTATTCAGGGTCGTGATGAAATCAAGAAAGCCTATGAGACTGGGAAAGGGCGCGTGGTTGTTCGTTCCAAGACTGAAATTGAAAAGCTAAAAGGTGGTAAGGAACAAATCGTTATTACTGAGATTCCTTATGAAATCAATAAGGCCAATCTAGTCAAGAAAATCGATGATGTTCGTGTTAATAACAAGGTAGCTGGGATTGCTGAGGTTCGTGATGAGTCTGACCGTGATGGTCTTCGTATCGCTATTGAACTTAAGAAAGACGCTAATACTGAGCTTGTTCTCAACTACTTATTTAAGTACACCGACCTACAAATCAACTACAACTTTAATATGGTGGCGATTGACAATTTCACACCTCGTCAGGTTGGGATTGTTCCAATCCTGTCTAGCTACATCGCTCACCGTCGAGAAGTGATTTTGGCGCGTTCACGCTTTGACAAAGAAAAGGCTGAGAAACGTCTCCGTATCGTCGAAGGTTTGATTCGTGTGATTTCGATTTTGGATGAAGTCATTGCTCTTATCCGTGCTTCTGAGAATAAGGCGGACGCCAAGGAAAACCTCAAAGTTAGCTATGATTTTACGGAAGAACAGGCTGAGGCTATCGTAACTTTGCAACTGTACCGTTTGACCAATACCGATGTGGTTGTCTTGCAGGAAGAAGAAGCAGAGCTTCGTGAGAAGATTGCTATGCTGGCGGCTATTATCGGTGATGAAAGGACTATGTACAATCTCATGAAGAAAGAACTTCGTGAGGTCAAGAAGAACTTTGCAACTCCTCGTTTGAGTTCTTTAGAAGACACTGCGAAAGCAATTGAGATTGATACAGCTAGTCTTATCGCTGAGGAAGATACCTACGTCAGCGTGACCAAGGCAGGTTACATCAAGCGTACCAGTCCACGTTCCTTTGCGGCTTCCACCTTGGAAGAAATTGGCAAGCGTGATGATGACCGTTTGATTTTTGTTCAATCTGCCAAGACAACCCAGCACCTCTTGATGTTCACAAGTCTTGGAAATGTCATCTACAGACCAATCCATGAGTTGGCAGATATTCGTTGGAAGGACATCGGAGAGCATCTGAGCCAAACCATCACAAACTTTGAAACGAATGAAGCAATCCTTTATGTGGAAGTACTGGATCAGTTTGACGATGCGACAACCTACTTTGCAGCGACTCGCCTTGGTCAAATCAAACGGGTAGAGCGAAAAGAATTCACTCCATGGCGGACCTATAGATCTAAGTCTGTCAAGTATGCTAAGCTCAAAGACGATACAGATCAGATTGTAGCAGTGGCTCCGATTAAACTAGATGATGTTGTCTTGGTTAGTCAAAATGGTTATGCCCTGCGTTTCAATATCGAAGAGGTTCCGGTTGTCGGTGCTAAGGCAGCAGGTGTCAAGGCTATGAATTTGAAAGAAGATGATGTCCTCCAATCTGGCTTTATCTGTAATACTTCGTCCTTCTACCTCTTGACCCAGCGTGGAAGCTTGAAACGTGTTTCCATTGAGGAAATTCTAGCAACCAGCCGTGCCAAACGAGGATTACAAGTCTTGCGTGAGTTGAAAAACAAACCGCATCGTGTCTTCTTGGCAGGAGCAGTTGCAGAGCAAGGATTTGTTGGCGATTTCTTCAGTACGGAAGTGGATGTGAACGACCAAACTCTGCTTGTCCAATCCAATAAAGGAACAATCTATGAAAGCCGATTGCAAGACTTGAACTTGTCAGAACGCACTAGCAATGGAAGCTTCATTTCTGACACGATTTCAGATGAAGAAGTTTTTGACGCTTATCTTCAGGAAGTAGTTACTGAAGATAAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5340,Drugs,MEG_5340|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|25307955|gb|AE007317.1|752241-754721 gi|116075884|gb|CP000410.1|759772-762252,3
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatgctggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatacgggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttggcgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcacctacttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2919,Drugs,MEG_2919|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,499585335|WP_011266118.1|NG_047870|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047870:101-1315,6
,ATGAAACTCTTTGCCCAGGGTACTTCACTGGACCTTAGCCATCCTCACGTAATGGGGATCCTCAACGTCACGCCTGATTCCTTTTCGGATGGTGGCACGCATAACTCGCTGATAGATGCGGTGAAACATGCGAATCTGATGATCAACGCTGGCGCGACGATCATTGACGTTGGTGGCGAGTCCACGCGCCCAGGGGCGGCGGAAGTTAGCGTTGAAGAAGAGTTGCAACGTGTTATTCCTGTGGTTGAGGCAATTGCTCAACGCTTCGAAGTCTGGATCTCAGTCGATACATCCAAACCAGAAGTCATCCGTGAGTCAGCGAAAGTTGGCGCTCACATTATTAATGATATCCGCTCCCTTTCCGAACCTGGCGCTCTGGAGGCGGCTGCAGAAACCGGTTTACCGGTTTGTCTGATGCATATGCAGGGAAATCCAAAAACCATGCAGGAAGCTCCGAAGTATGACGATGTCTTTGCAGAAGTGAATCGCTACTTTATTGAGCAAATAGCACGTTGCGAGCAGGCGGGTATCGCAAAAGAGAAATTGTTGCTCGACCCCGGATTCGGTTTCGGTAAAAATCTCTCCCATAACTATTCATTACTGGCGCGCCTGGCTGAATTTCACCATTTCAACCTGCCGCTGTTGGTGGGTATGTCACGAAAATCGATGATTGGGCAGCTGCTGAACGTGGGGCCGTCCGAGCGCCTGAGCGGTAGTCTGGCCTGTGCGGTCATTGCCGCAATGCAAGGCGCGCACATCATTCGTGTTCATGACGTCAAAGAAACCGTAGAAGCGATGCGGGTGGTGGAAGCCACTCTGTCTGCAAAGGAAAACAAACGCTATGAGTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2972,Drugs,MEG_2972|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|985000614|gb|CP014225.1|1522111-1521263 gi|958627747|gb|CP013253.1|98657-99505 gi|939732440|gb|CP011343.2|3299869-3299021 gi|939731527|gb|CP011342.2|3300614-3299766 gi|937526251|gb|CP012870.1|1316745-1317593 gi|937521852|gb|CP012869.1|1316745-1317593 gi|937517453|gb|CP012868.1|1316745-1317593 gi|932857508|emb|LN877770.1|4149235-4148387 gi|923416119|gb|CP011113.1|3281628-3280780 gi|899729770|gb|CP012127.1|3299356-3298508,8
,ATCTTATAAGTCTTATGAACATTCAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGTGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAATATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATTCAACAAGGCCAAATTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACTACAGAAGTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGAACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAATGAAGTGAAGCGTATTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAGTTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGTTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGAAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGCTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCAGTTCACTTCTTACCATTATGATCTGGGCCATTGCTATTTTAAAACTGATAATCTATC,beta-lactamase,antibiotic inactivation,betalactams,MEG_5238,Drugs,MEG_5238|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389165|gb|KJ135343.1|1-913,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgtttcagcaaggcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggctacggcaatgcggacgtctccggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatttcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaagctggtgaaccggcaattgccggtcaaggccgccgcctatgagctggcggacaacctcttcgaggtgggccaggccgatggctggcgcctgtatggcaagaccggcaccgggtcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccaactggtgtacgcccgcctgctgcaggacgagcgcgccacccagcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4546,Drugs,MEG_4546|Drugs|betalactams|Class_D_betalactamases|OXA,1625655404|WP_136512081.1|NG_064744|1|1|blaOXA-114w|blaOXA-114_like|class_D_beta-lactamase_OXA-114w NG_064744:1-828,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCACAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1387,Drugs,MEG_1387|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_102_MLQA01000023,0
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGAGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGACATTCTAGGAAATGAAAAACTCCTGCCTCATAAAACACGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCGCAGAGATTGCTGATACAGACCCTCTTTTGCATTTTGACATTGATACTGTTACACATGAGATTATGTTATCTTTTTTGGGAAAAGTACAGTTAGAAGTTATTTGTTCGCTATTAGAAGAAAAATATCATGTGGGCGTGGCTATGAAAGAGCCTTCGGTTATTTATCTGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAGGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTAATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7172,Drugs,MEG_7172|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/W/32/O)_2_FM164392 ,4
,atggacacaacgcaggtcacattgatacacaaaattctagctgcggcagatgagcgaaatccgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatactgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatagttgaaatgctcggcgggcgcgtcatggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattactcttactatgccgatgaagtaccaccagtggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatacgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_735,Drugs,MEG_735|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1105502078|WP_071846230.1|NG_052242|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052242:101-634,2
,atgaaagtttacacatcgagactgtttggattcacagtgaaaacaatatttctcacgcttctcacgcttgctggttgctcttctgctgaaacgcctgtcgtaaaaacggaaacgcccgcatctgcaatggatataaagttcgctgcactggaaaaacagtttggtgcgaggctcggcgtatatgcgatcgacaccgaaacagatttggcagttgcttatcgccaagatgaacaattcgcttttgcctctacgtacaaggctttagccgcaggtgcagtcttgcatcagaaaccattggaagagctcaacaaagtcatcacctacaccaaggacgacctcgttacttattcaccgatcacagaaaaacacgtagcgaccgggatgactcttcgcgaggttgcagacgccgcagttcgctatagcgacaacacagccggaaatctgttgttcaaagaattgggtggacctaaaggctttgaatcagctctgagacagattggtgatagtgttacgaaatccgaacgctatgagacggaattgaatgaggctaagccagaagatcttcgcgatacaagcacaccgaaagcacttgcaacgagcctccgagcctatacggtagggaatgcgctgtcgtctgacaagcagaagattcttatcgagtggctgcaaggcaacacgacgggagccaagctgattcgagcgggcgttcctaaagactggattgtcggagataagacgggagcagcaagctacggaacgcgaaacgatataggtatcatatggccaccgaataaaaagccgattgtcattgccgtgctgtctagcagagataagcaggacgctacttatgatgatgcgctcattgctgaagctaccaagattgttgttgacgcactgacggctgcaaaaccgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1200,Drugs,MEG_1200|Drugs|betalactams|Class_A_betalactamases|BBI,1199610393|WP_087344360.1|NG_063819|1|1|blaBBI|blaBBI|BBI_family_class_A_beta-lactamase NG_063819:1-915,0
,atggagaaaataatagacataactgtttttggctgcgagccagacgaaatggaggtttttcaaaagattacttatgagcttggcgttacagccacactcataaaagattctatatcagaaagcaatgctaaattagcagatggatgccggtgtgtaagcgtaagccataaagcggagctatcagaaccgattcttcttgcactaaaaaatgcaggggtaaagtatatcagtacccggagcattggctttaaccatattgatatacaggcggccgggttgctgggtatggttgttggcacagtagaatactcgccgggaagtgtggccgattataccgtcatgctgatgcttatgctgatgcgcggcacaaagtcgattctgcgtgaaacccagaggcagaattattgcctgaatgacctgcgcggaaaagaactgcgggatatgaccgtcggtgtgttaggaactgggcgaatcggacaggcagtcatggaacgcctgaagggattcggctgtaaggtattggcgtatgaccgaaatcaaaaagcaggagcggactatgtttcgtttcatgaactgctgaaaaaaagtgacattgttacactgcatattccgttggcagaagatacccgccatatgattggatgtgaagagctggaaatgatgaagcaggaggcgcttctgatcaatacaggacggggcgctttagtggataccgcagcattggtagaagcattaaaaggacagaaaatcggcggcgccgcactggatgttttagagggcgaagaaggtatcttttaccatgactgcactcaaagaacgatagaacatcctttcttgtctgtcctgcagggaatgccgaatgtcattgttacgccgcacacggcctatcacacggagcgggtgttggttgacacggttagaaataccattagaaattgtttgaattttgaaaggagtctgggaaatgtttaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7420,Drugs,MEG_7420|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,1028100567|WP_063856702.1|NG_048380|1|1|vanH-D|vanH-D|D-lactate_dehydrogenase_VanH-D NG_048380:101-1072,5
,ATGAATAGAATAAAAGTCGCAATCATCTTCGGCGGTTGCTCGGAGGAACATGATGTGTCGGTAAAATCCGCAATAGAAATTGCTGCGAACATTAATACTGAAAAATTCGATCCGCACTACATCGGAATTACAAAAAACGGCGTATGGAAGCTATGCAAGAAGCCATGTACGGAATGGGAAGCCGACAGTCTCCCCGCCATACTCTCCCCGGATAGGAAAACGCATGGGCTGCTTGTCATGAAAGAAAGCGAATACGAAACACGGCGTATTGATGTGGCTTTCCCGGTTTTGCATGGCAAATGCGGGGAGGATGGTGCGATACAGGGTCTGTTTGAATTGTCTGGTATCCCCTATGTAGGCTGCGATATTCAAAGCTCCGCAGCTTGCATGGACAAATCACTGGCCTACATTCTTACAAAAAATGCGGGCATCGCCGTTCCCGAATTTCAAATGATTGATAAAGGTGACAAGCCGGAGGCGGGTGCGCTTACCTACCCTGTCTTTGTGAAGCCGGCACGGTCAGGTTCGTCCTTTGGCGTAACCAAAGTAAACGGTACGGAAGAACTTAACGCTGCGATAGAAGCGGCAGGACAATATGATGGAAAAATCTTAATTGAGCAAGCGATTTCGGGCTGTGAGGTCGGGTGTGCGGTCATGGGGAACGAGGATGATTTGATTGTCGGCGAAGTGGATCAAATCCGGCTGAGCCACGGTATCTTCCGCATCCATCAGGAAAACGAGCCGGAAAAAGGCTCAGAAAATGCGATGATTACAGTTCCCGCAGACATTCCGGTCGAGGAACGAAATCGGGTGCAGGAAACGGCAAAGAAAGTATATCGGGTGCTTGGATGCAGAGGGCTTGCCCGTGTTGATCTTTTTTTGCAGGAGGATGGCGGCATCGTTCTAAATGAGGTCAATACCCTGCCTGGTTTTACATCGTACAGCCGCTACCCACGTATGGTGGCCGCCGCAGGAATCACGCTTCCTGCACTGATTGACAGCCTGATTACATTGGCGTTAAAGAGGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7353,Drugs,MEG_7353|Drugs|Glycopeptides|VanB-type_resistance_protein|VANB,(Gly)VanA-B:AF192329:28835-29863:1029,5
,AGGATGTATTGTGGTTATGCGTTATATTCGCCGGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAACTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATATGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6433,Drugs,MEG_6433|Drugs|betalactams|Class_A_betalactamases|SHV,gi|221149271|gb|EU418913.1|1-897,0
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatgctggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcaccttcttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2923,Drugs,MEG_2923|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,446136264|WP_000214119.1|NG_047869|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047869:101-1315,6
,ATGAAGAAGTGGGGGTTTTTATTTTTATTGTGCTTAGGTTTTGTCTTCATTAATAAAGCACTGTTTTTTCAGGAAAAAGTAGCAGTAGAAATTGAAAATTATGATCAAAATCCCAAAGATCATTTAGATAATAGAGGAACTTCGGAAAGTACCCAAACGAAAACGATTACAAATGAACAGATTTATCAAGGAAATCTGCTATTATTCAACAGTAAATATCCTGTTCGCCAAGAAAGTGTGAAGTCAGATATCGTCAATTTATCTAAACATAACGAATTGATAAATGGGTACGGGTTGCTTGATACGAATATTTATATGTCAAAAGGAATAGCACAAAAATTTTCAGAGATGGTCAATGATGCTTTAAAGGAAGGGGTTAGTCATTTTATTATTAATAGTGGCTATCGTGACTTTGATGAGCAAAGTGTGCTTTACCAAGAAATGGGGGCTGATTATGCCTTGCCAGCAGGTTATAGTGAACATAATTCAGGCTTATCACTTGATGTAGGATCAAGCTTAACGAAAATGGAGCGAGCACCTGAAGGAAAGTGGCTGAAAGAAAATGCTTGGAAATACGGCTTTATATTACGCTATCCAAAGGATAAGACTGATGTTACTGGAATTCAATATGAACCATGGCATATCCGTTATGTTGGTTTCCCTCACAGCGCGATTATGAAAGAAAAGAATTTCGCTCTAGAAGAATATATGGATTTTTTGAAGGAACAGAAGTCCATTACCACTACAATAGACCACCAAGTCTATAAAATTTTTTACTATCCTATCTCCCAAAATACAACGATCCATGTGCCTGCGAATGGCCAGTATGAAATTTCAGGCAACAATATGGATGGCGTGATTGTGACAGTGTATTCTGGTAAGCGAGACTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7594,Drugs,MEG_7594|Drugs|Glycopeptides|VanA-type_accessory_protein|VANYA,(Gly)VanY-Pt:AY926880.2|:5831-6721:891,5
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttaatacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtaccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagtgctaaaaaatacaccgattgatcaagttaacttacttcaactcgcgacgtatacaagtagcaacctcgctttacaatttccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccacttgatgccccagcatacggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaagggttctatcaattaggaaccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacattaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtgtttattcccaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcagttttaaatgcaataaaggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_533,Drugs,MEG_533|Drugs|betalactams|Class_C_betalactamases|ADC,1058243541|WP_068981611.1|NG_051443|1|1|blaADC-104|blaADC|class_C_beta-lactamase_ADC-104 NG_051443:1-1152,0
,atgtcgaaaaaattaaaatgcctagcgcttcttacgccattaattttgatccttccattgactgcttgtcagagttctagccaaaaaaaacagcaagtcgtgtcattaaatgagcaacagcgggtggcgaatttattccagcaggcgcaaacaataggggttttggtcatctatgatggcaaacaaattcaaacatacggcaatgcaacacgccgtgcagatcaacgttttatcccagcctcaacctttaaaatactgaatgcactgattggtatacagcatcataaaaccacgccaaatgaagtctttaaatgggatggtcaaaaacgtgcctttagcagttgggaaaaagatttaagtttagctgaagctatgcaggcatcggctgtacctgtctatcaggagctagcgcgacgcattggtctagaactcatgacccgtgaggtgaagcgtgttggctatggcaataaaaatattggaacccaagtcgataatttttggttggtcgggcctttgaaaattacacctgtagaagaagttcgatttgtctatgcattggccaagcaaaaactaccgtttgaccagtcaactcaacagcaagtgaaaggcatgttattggtggatgagcatcagggaaccaagatctatgccaagagcggttggggcatggacgttaccccgcaggttggatggtggacaggttggattgaacagccaaatggcaaaatcattgcattttcactgaatatgcaaatgagccaacctgagcatgcagatgcacgtaaagtgattgtttatcaagcattgcaagagctgggattgttagccaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4736,Drugs,MEG_4736|Drugs|betalactams|Class_D_betalactamases|OXA,514963024|WP_016651348.1|NG_062219|1|1|blaOXA-670|blaOXA-286_like|OXA-286_family_class_D_beta-lactamase_OXA-670 NG_062219:101-934,0
,ATGAAAAAATTTATACTTCCTATCTTCAGCATTTCTATTCTACTTTCTCTCAGTGCATGCTCATCTATTCAAACTAAATTTGAAGATACTTTTCATATTTCTAATCAGAAACATGAAAAAGCTATTAAAAGCTATTTTGATGAAGCTCAAACACAAGGTGTAATTATTATTAAGGAAGGTAAAAATATTAGCTCCTATGGTAATAACCTTGTACGAGCACATACAGAATATGTCCCTGCATCAACATTTAAGATGCTAAATGCTTTAATCGGACTAGAAAATCATAAAGCGACAACAAATGAGATTTTTAAATGGGATGGTAAAAAAAGATCTTATCCTATGTGGGAGAAAGATATGACTTTGGGTGAGGCCATGGCACTTTCAGCTGTTCCTGTATATCAAGATCTTGCGAGACGGATTGGCTTAAATCTCATGCAAAAAGAAGTTAAACGCGTTGGTTTTGGTAATATGAACATTGGAACACAAGTTGATAATTTCTGGTTGATTGGTCCTCTTAAGATTACACCAATACAAGAAGTGAATTTTGCCGATGATCTTGCGAATAATCGATTACCCTTTAAATTAGAAACTCAAGAAGAAGTAAAAAAGATGCTTCTGATTAAAGAAGTCAATGGTAGTAAAATTTATGCTAAAAGCGGATGGGGAATGGATGTAAGCCCACAAGTAGGTTGGTTAACAGGTTGGGTAGAAAAATCTAATGGAGAAAAAGTTTCCTTTTCTTTAAATATAGAAATGAAGCAAGGAATGTCTGGTTCTATTCGTAATGAGATTACTTATAAGTCGTTAGAGAATTTAGGGATTATATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5263,Drugs,MEG_5263|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-182_1_HM640278,0
,atgactctggcattagttggcgaaaaaattgacagaaatcgcttcaccggtgagaaagttgaaaatagtacattttttaactgcgatttttcaggtgccgacctgagcggcactgaatttatcggctgccagttctatgatcgcgaaagtcagaaagggtgcaattttagtcgcgcaatgctgaaagatgccattttcaaaagctgtgatttatcaatggcagatttccgcaacgtcactgccttgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggtgcaagctttatgaatatgatcaccacgcgcacctggttttgcagcgcatatatcactaatactaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgctggatggggactcaggtactgggtgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttaggtgacttagatattcggggtgttgatttacaaggcgttaagttagacagctaccgggcatcgttgctcatggagcggcttggcatcgctgtgattggttag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5882,Drugs,MEG_5882|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1391852862|WP_109545047.1|NG_057452|1|1|qnrB82|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB82 NG_057452:101-745,3
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcactataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctatttatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4697,Drugs,MEG_4697|Drugs|betalactams|Class_D_betalactamases|OXA,1559612990|WP_128268255.1|NG_063860|1|1|blaOXA-756|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-756 NG_063860:41-865,0
,atgttcaaacttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggcttcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7707,Drugs,MEG_7707|Drugs|betalactams|Class_B_betalactamases|VIM,1625655431|WP_136512108.1|NG_064785|1|1|blaVIM-63|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-63 NG_064785:1-801,0
,atgaaaacatttgccgcatatgtaattatcgcgtgtctttcgagtacggcattagctggttcaattacagaaaatatgtcttggaacaaagagttctctgccgaagccgtcaatggtgtcttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaatgacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaagcaatgggaaagagacttgaccttaagaggggcaatacaagtttcagctgttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcctatggcaaccagaatatcagtggtggcattgacaaattctggttggaaggccagcttagaatttccgcagttaatcaagtggagtttctagagtctctatatttaaataaattgtcagcatctaaagaaaaccagctaatagtaaaagaggctttggtaacggaggcggcacctgaatatctagtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttgggtgggttgagaaggagacagaggtttactttttcgcctttaacatggatatagacaacgaaagtaagttgccgctaagaaaatccattcccaccaaaatcatggaaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4423,Drugs,MEG_4423|Drugs|betalactams|Class_D_betalactamases|OXA,1509794534|WP_122630843.1|NG_062253|1|1|blaOXA-656|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-656 NG_062253:101-901,0
,atgaaaaaatcgttatctgcaacactgatttccgctctgctggcgttttccgccccggggttttctgccgctgataatgtcgcggcggtggtggacagcaccattaaaccgctgatggcacagcaggatattcccgggatggcggttgccgtctccgtaaagggtaagccctattatttcaattatggttttgccgatattcaggcaaaacagccggtcactgaaaatacactatttgagctcggatctgtaagtaaaactttcacaggtgtgctgggtgcggtttctgtggcgaaaaaagagatggcgctgaatgatccggcggcaaaataccagccggagctggctctgccgcagtggaaggggatcacattgctggatctggctacctataccgcaggcggactgccgttacaggtgccggatgcggtaaaaagccgtgcggatctgctgaatttctatcagcagtggcagccgtcccggaaaccgggcgatatgcgtctgtatgcaaacagcagtatcggcctgtttggtgctctgaccgcaaacgcggcggggatgccgtatgagcagttgctgactgcacggatcctggcaccgctggggttatctcacacctttattactgtgccggaaagtgcgcaaagccagtatgcgtacggttataaaaacaaaaaaccggtccgcgtgtcgccgggacagcttgatgcggaatcttacggcgtgaaatcctcctcaaaagatatgctgcgctgggcggaaatgaatatggagccgtcacgggccggtaatgcggatctggaaatggcaatgtatctcgcccagacccgctactataaaaccgccgcgattaaccaggggctgggctgggaaatgtatgactggccgcagcagaaagatatgatcattaacggtgtgaccaacgaggtcgcattgcagccgcatccggtaacagacaaccaggttcagccgtataaccgtgcttcctgggtgcataaaacgggcgcaacaactggtttcggcgcctatgtcgcctttattccggaaaaacaggtggcgattgtgattctggcgaataaaaactacccgaataccgaaagagtcaaagctgcacaggctattttgagtgcactggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2587,Drugs,MEG_2587|Drugs|betalactams|Class_C_betalactamases|DHA,1028104922|WP_063860108.1|NG_049069|1|1|blaDHA-23|blaDHA|class_C_beta-lactamase_DHA-23 NG_049069:1-1140,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggctacggcaatgcggacgtctcgggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaagctggtgaatcggcaattgccggtcaaggccgccgcctatgagctggcggacaacctcttcgaggtgggccaggccgatggctggcgcctgtatggcaagaccggcaccggttcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccggcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4542,Drugs,MEG_4542|Drugs|betalactams|Class_D_betalactamases|OXA,935615173|WP_054471662.1|NG_064735|1|1|blaOXA-114m|blaOXA-114_like|class_D_beta-lactamase_OXA-114m NG_064735:1-828,0
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAGTACGCCGTTTCTTTAGCCTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGATTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTATTTGTACACAGGAGAACTGGAAAACATCCGACAAGACACGTGGCTGTTGGATACGAAACATAAACAGAAAATCCAGCCGCTTTTTGAAGGAAACGGCTTTTGGCTAAGTGAAGAGCAACAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAACTACCTTATGTAGGCTGCGGTGTGGCGGCCTCCGCATTATGTATGAACAAATGGTTATTGCATCAAGCAGCAGAAGCGATTGGCGTACAAAGCGCTCCTACGATTCTCTTGACAAATCAAGACAACCAGCAAAGACAAATCGAAGCCTTTATCCAGACCCATGACTTTCCGGTTTTCTTTAAGCCTAATGAAGCTGGCTCCTCAAAAGGGATCACAAAAGTGACTTGTGTCGAAGAAATTGCTCCTGCCTTGAAGGAAGCCTTCGCTTATTGTTCAGCAGTGCTCTTACAAAAAAATATAGCTGGCGTTGAGATTGGTTGCGGTATCTTAGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCTATTTCATTAGTAGAAGGCTTTTTCGATTTTGAAGAAAAGTACCAGTTGATTAGCGCCAAGATCACCGTTCCTGCACCATTGCCTGAAACGATTGAAACCAAGGTCAAAGAACAAGCTCAGCTGCTCTATCACAGTCTTGGTCTTAAAGGACTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACTAGTCACTCCCGCTATCCTGCCATGATGGCAGCAATCGGCTTATCCTATCAAGAACTACTACAAAAACTGCTTGTCTTAGCAAAGGAGGAAGGCAAATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7368,Drugs,MEG_7368|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,gi|161779851|gb|EU151753.1|29-1081,5
,ATGAGCATCACTGCTACCATCAGGATTGGTCCTGATGAGATTCCGGCCATGCGGGCTGTGCTCGACCTGTTCGGCAGAGAGTTTGAGGACATGTCCGCCTACTCGGATCGCCAGCCGACAAATGATTACTTGGCCAAGCTTCTCCGCAGCGAGACGTTCATCGCGCTAGCCGCATTTGACCAAGGAACAGCAATAGGTGGGCTCGCTGCCTACGTTTTGCCCAAGTTCGAGCAAGCGCGTAGTGAGATCTACATTTATGACTTAGCAGTCGCATCCAGCTATCGACGGCAAGGAATCGCAACTTCCCTGATTAGCCACCTGAAGCGTGAGGCAATCAAGATTGGGGCATATGTGATCTATGTGCAAGCAGACTACGGAGACGACCCCGCGGTGGCTCTCTACACCAAGCTTGGTGTTCGGGAAGATGTCATGCACTTTGACATTGATCCAGGAACCGCCACCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_68,Drugs,MEG_68|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3-PRIME,(AGly)Aac3-If:AY884051:61-525:468,2
,atgaaaaaacggattaccccattttcccgatttgcatcaaaaggcctttccgcctgtagcgcaggcatgttgctggtgacggtggcacatgccgccaatacggcagcagcgccagccggcatggatgccatggtccaaaccgtgatgcaggcacaccagattccgggcatggccattgccatcatccagccaggaaagaccacttatcacaattatggtatcgcctcccgcgaaaccggccagccggtccgggaaaccaccctgtttgaaatcggctccctttccaaaccgtttactgcactggtcgcccagcgggctgaaaccgaaggccggattgacctgtctgcaccggccagccgctacgttaccgccctgcggggcagtgcattcgaccggatcaccctcaggcagctcggtacttatagtgcaggcgaattgccgctccagtttcctgacaatgtcaccaccccggcagacgtgctggcttattaccgccattggcaacctgtccatccggcaggtaccacccggctgtattccaatccgagcattggcctgatggggctggctgccagtcaggcaaccggagagtcctttgccggcctgctcgggacaacggtgctgcaacccctcggcatgaactcgacctatctgcaagtgcctccggaggcccgttcacgttatgccatgggttataccgccgccgggaaaccggtcagggtcagccccggtccgctggatgaggaaacctacggcgtcaagtccacaaccgcagacatggccggatttttattggcgcatatggaccctgcgcgcagcaaaggtgcattgcggtcggcattacagcaaacacgtgtaccggtttattgcgccggacagacccggcaaggactgggctgggaaagttatcaagactggaaaaacctcgacgtgctgctggcgggaaattcaaatcaaatggtgtttgaaccgcagccggtaaaagcctgtcttgccggcacctcgaatgagcccgacgtatgggtcaacaagacaggttctactgcgggattcggcgcttatgccgtattcctgcctgcccgacaggccggcattgtcatcctagccaaccgtaattacccgattgcagaccgtatccggctcgctcacggaattttgaccgcattgcactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3581,Drugs,MEG_3581|Drugs|betalactams|Class_A_betalactamases|LHK,1349894766|WP_104531869.1|NG_056487|1|1|blaLHK-6|blaLHK|class_C_beta-lactamase_LHK-6 NG_056487:1-1173,0
,ATTTTTAAACCGCTATTGACACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1415,Drugs,MEG_1415|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_85_NZ_FHDT01000016,0
,ttgagcgtttcgatcttacctgtgaaagaacaagacgctgccgactggctagcgctgcggaatcttctttggctcgcggatgatcacgcctcggagattgagcagtacttctctggtggacttgaggggcttgtagaagtgctcatcgcccgtgatgctaccggcgcggctgttgggcatgtcgaactctcgataagacatgacttggaagaactccaaggaatcaagaccggctacatcgaaggcctttatgtggccccaagccatcgatcaacagaccttgtgaggcgtttcttgcgtgagtccgagaagtgggccctagaacaagggtgcagcgcatttgcctcagacagaagtgatcgggtcatcacgcaccgcaagttcgcaggcagcgccgtctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_267,Drugs,MEG_267|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1031994773|WP_064190968.1|NG_048575|1|1|aac(6')-29a|aac(6')-29|aminoglycoside_N-acetyltransferase_AAC(6')-29a NG_048575:101-502,2
,ttgctgacccgaagaaccttcattgcctcggccgtgctggccggttggattcctgcccttgcacacgcccgcacggataagaaaactcgatggacgcgcgaaagtctcgcggcgttccaacaaggccttgcccaagtggaggccgccagccgcggacggctgggagtggccctgctggacgtgggcagtgggcaagccgccggctatcgcgccgacgaacgcttcctgatgctcagctccttcaagacgctgtccgcggcctacgtgctggcgcgggccgaccgtggcgaggaccagctgtcgcgccgcatcccgatcaccgacgccgatgtccgggagtattcgccggtcacgcggctgcatgtcgggccgcggggaatgacgctggccgaactctgtgaagcgacgatcaccaccagcgacaacgcggcggtcaacctcatgcacaagagctatggcggcccgcaagccctgacccgctacctgcgcagcctgggcgataccgtcacgcgccacgatcgctacgaacccgaattgaaccgcccgcacccgagcgaaccgcaggacaccaccaccccgcaggccatggcgcgcacgctggatacgctactgttcggcgacgcgctcaagccgcaatcgcggcagcaactgcaatcctggctgctggccaacacgacgggcggcaagcgcctgcgcgccggcatgccggcggattggaagatcggcgagaagacaggcacctattcgaaggtgggctgcaacgacgccggcttcgcgcaaccgcccggcgcggcgccgatcatcatcgcggcctatctggaaaccaccgcggtgccgatggaggagcgcgaccgctgcatcgccgaggtcggcaggctggtggcggcattgggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1184,Drugs,MEG_1184|Drugs|betalactams|Class_A_betalactamases|AXC,529016727|WP_020924773.1|NG_061617|1|1|blaAXC-1|blaAXC|carbapenem-hydrolyzing_class_A_beta-lactamase_AXC-1 NG_061617:101-997,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtgcttatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttgggaaagttgtagctttgtctatgaataaacctttcgaccaactcttagaaaaaactatttttccagatcttggcttaaaacatagctatgtaaatgttcctaaaactcagatgcaaaactatgcttttggctataaccaagaaaatcagccaattcgtgttaaccctggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaaagggcaattaatgaaacacatcagggtcactatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaatgttacaaactttactagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacgtatgtggtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcgtatacagttttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_598,Drugs,MEG_598|Drugs|betalactams|Class_C_betalactamases|ADC,490978796|WP_004840559.1|NG_064681|1|1|blaADC-123|blaADC|class_C_beta-lactamase_ADC-123 NG_064681:101-1252,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtggaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaataaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaaagttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4402,Drugs,MEG_4402|Drugs|betalactams|Class_D_betalactamases|OXA,1391852919|WP_109545104.1|NG_057538|1|1|blaOXA-604|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-604 NG_057538:1-762,0
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttgggcggtacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgtttccggactgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcatggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctgaggcaatggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaatgcccatgctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1603,Drugs,MEG_1603|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1028084256|WP_063843224.1|NG_047607|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_047607:101-733,6
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggttcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5679,Drugs,MEG_5679|Drugs|betalactams|Class_C_betalactamases|PDC,1209144261|WP_088245223.1|NG_055281|1|1|blaPDC-218|blaPDC|class_C_beta-lactamase_PDC-218 NG_055281:1-1194,0
,atgaagcgcctgatcctggccgccgctgcgtcgctgttggctctggcctcggcggcccacgccgacgacatgccggccaactggaccaagccgaccaagccctaccgtgtggtcggcaacatctattacgtcggcaccgagggcatctcgtcctggctgatcacgtcgtccgagggccatgtggtgctgcacggcgggccgaacgccgagacgggcaagctggtcgagcgcaacatcacggcgctgggcttccagcttgcggacctgaagatcctgatcaacacccacgcccactacgatcacgccggcggtctggcgcagttgaaggccgacaccggcgccaagctgtggatctcgcgcgacgacgccccggccatggcggcgggccaccacatcggcgacaatatctatggcccaacgccgatgccggccgccaagcccgacaggagcttcggcgaccagaccaagctgaagctgggcgagatcgccatggtcgcccacctgacgccgggccacaccattggctgcaccagctggaccacggccgtggtcgagaaggggcggccgctgaccgtcaccttcccgtgctcgctgtcggtggcaggcaatgtgctcgtgggcaacaagacccaccggaccatcgtcgccgactatcgcgccagcttcgccaagctgcgcgccattcctaccgacgtgatgctgcccgcgcacgaagagcaggggaacctgctggccaagcgccagaagcagctgcgcggtgatcccaacgcctttgtcgacccaggcgagcttgcccggttcgtcgacgcctccgaagccgccttcaacaaggagctcgcgcgccagcaggcggcggggcccaagccatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1634,Drugs,MEG_1634|Drugs|betalactams|Class_B_betalactamases|CAU,1028105810|WP_063860835.1|NG_049292|1|1|blaMBL1b|blaCAU/MBL1b|subclass_B3_metallo-beta-lactamase_MBL1b NG_049292:1-870,0
,CTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTGGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6888,Drugs,MEG_6888|Drugs|betalactams|Class_A_betalactamases|TEM,gi|21464495|gb|AY101764.1|1-1072,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTAGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2001,Drugs,MEG_2001|Drugs|betalactams|Class_C_betalactamases|CMY,blaCMY-142_1_KX881969,0
,atgaataaatattttacttactatgtgtttgcttctctttttctttctggttgtacggttcagcataacttaataaatgacgctcagagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaaacagataaaaaaattaatctgtatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttatcgcttgggaaaaagacatgacactaggagaagccatgaagctttccgcagtcccagtctatcaggaacttgcaagacgtattggtcttgatctcatgcaaaaagaagtagaacgtattgatttcggtaatactgaaattggacagcaggttgataatttctggttggtagggccattaaaggtcacgcctattcaagaggtagagtttgtttctcaattggcacatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgcttcttttagaagagagtaatggctacaaaatttttggaaagactggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcgcttttgcattaaatatggaaatgcggtcagaaatgccggcatctatacgtaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4516,Drugs,MEG_4516|Drugs|betalactams|Class_D_betalactamases|OXA,1625655423|WP_136512100.1|NG_064767|1|1|blaOXA-809|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-809 NG_064767:1-822,0
,ATGACCGACGCAACCATCCGCCACGACCACAAATTCGCCCTCGAAACCCTGCCCGTCAGCCTTGAAGACGAAATGCGCAAAAGCTATCTCGACTACGCCATGAGCGTCATTGTCGGGCGCGCGCTGCCGGACGTTCGCGACGGCCTAAAGCCGGTGCACCGGCGCGTACTGTACGCGATGCACGAGCTGAAAAATAACTGGAATGCCGCCTACAAAAAATCGGCGCGCATCGTCGGCGACGTCATCGGTAAATACCACCCCCACGGCGATTCCGCAGTTTACGACACCATCGTCCGTATGGCGCAAAATTTCGCTATGCGTTATGTGCTGATAGACGGACAGGGCAACTTCGGATCGGTGGACGGGCTTGCCGCCGCAGCCATGCGCTATACCGAAATCCGCATGGCGAAAATCTCACATGAAATGCTGGCAGACATTGAGGAAGAAACCGTTAATTTCGGCCCGAACTACGACGGTAGCGAACACGAGCCGCTTGTACTGCCGACCCGTTTCCCCACACTGCTCGTCAACGGCTCGTCCGGTATCGCCGTCGGTATGGCGACCAACATCCCGCCGCACAACCTCACCGACACCATCAACGCCTGTCTGCGTCTTTTGGACGAACCCAAAACCGAAATCGACGAACTGATCGACATTATCCAAGCCCCCGACTTCCCGACCGGGGCAACCATCTACGGCTTGGGCGGCGTGCGCGAAGGCTATAAAACAGGCCGCGGCCGCGTCGTTATACGCGGTAAGACCCATATCGAACCCATAGGCAAAAACGGCGAACGCGAAGCCATCGTTATCGACGAAATCCCCTATCAGGTCAACAAAGCCAAGTTGGTCGAGAAAATCGGCGATTTGGTTCGGGAAAAAACGCTGGAAGGCATTTCCGAGCTCCGCGACGAATCCGACAAATCCGGGATGCGCGTCGTTATCGAGCTGAAACGCAACGAAAATGCCGAAGTCGTCTTAAACCAACTCTACAAACTGACTCCGCTGCAAGACAGTTTCGGCATCAATATGGTTGTTTTGGTCGACGGACAACCGCGCCTGTTAAACCTGAAACAGATTCTCTCCGAATTCCTGCGCCACCGCCGCGAAGTCGTTACCCGACGTACGCTTTTCCGGCTGAAGAAGGCACGCCATGAAGGGCATATCGCCGAAGGCAAAGCCGTCGCACTGTCCAATATCGATGAAATCATCAAGCTCATCAAAGAATCGCCCAACGCGGCCGAGGCCAAAGAAAAACTGCTTGCGCGCCCTTGGCGCAGCAGCCTCGTTGAAGAAATGCTGACGCGTTCCGGTCTGGATTTGGAAATGATGCGTCCGGAAGGATTGGCTGCAAACATTGGTCTGAAAAAACAAGGTTATTACCTGAGCGAGATTCAGGCAGATGCTATTTTACGCATGAGCCTGCGAAACCTGACCGGCCTCGATCAGAAAGAAATTATCGAAAGCTACAAAAACCTGATGGGTAAAATCATCGACTTTGTGGATATCCTCTCCAAACCCGAACGCATTACCCAAATCATCCGTGACGAACTGGAAGAAATCAAAACCAACTATGGCGACGAACGCCGCAGCGAAATCAACCCGTTCGGCGGCGACATTGCCGATGAAGACCTGATTCCGCAACGCGAAATGGTCGTGACCCTGACCCACGGCGGCTATATAAAAACCCAGCCGACCACCGACTATCAGGCTCAGCGTCGCGGCGGGCGCGGCAAACAGGCGGCTGCCACCAAAGACGAAGACTTTATCGAAACCCTGTTTGTTGCCAACACGCATGACTATTTGATGTGTTTTACCAACCTCGGCAAGTGCCACTGGATTAAGGTTTACAAACTGCCCGAAGGCGGACGCAACAGCCGCGGCCGTCCGATTAACAACGTCATCCAGCTGGAAGAAGGCGAAAAAGTCAGCGCGATTCTGGCAGTACGCGAGTTTCCCGAAGACCAATACGTCTTCTTCGCCACCGCGCAGGGAATGGTGAAAAAAGTCCAACTTTCCGCCTTTAAAAACGTCCGCGCCCAAGGCATTAAAGCCATCGCACTCAAAGAAGGCGACTACCTCGTCGGCGCTGCGCAAACAGGCGGTGCGGACGACATTATGTTGTTCTCCAACTTGGGCAAAGCCATCCGCTTCAACGAATACTGGGAAAAATCCGGCAACGACGAAGCGGAAGATGCCGACATCGAAACCGAGATTTCAGACGACCTCGAAGACGAAACCGCCGACAACGAAAACACCCTGCCAAGCGGCAAAAACGGCGTGCGTCCGTCCGGTCGCGGCAGCGGCGGTTTGCGCGGTATGCGCCTGCCTGCCGACGGCAAAATCGTCAGCCTGATTACCTTCGCCCCTGAAACCGAAGAAAGCGGTTTGCAAGTTTTAACCGCCACCGCCAACGGATACGGAAAACGCACCCCGATTGCCGATTACAGCCGCAAAAACAAAGGCGGGCAAGGCAGTATTGCCATTAACACCGGCGAGCGCAACGGCGATTTGGTCGCCGCAACCTTGGTCGGCGAAACCGACGATTTGATGCTGATTACCAGCGGCGGCGTGCTTATCCGTACCAAAGTCGAACAAATCCGCGAAACCGGCCGCGCCGCAGCAGGCGTGAAACTGATTAACTTGGACGAAGGCGAAACCTTGGTATCGCTGGAACGTGTTGCCGAAGACGAATCCGAACTCTCCGGCGCTTCTGTAATTTCCAATGTAACCGAACCGGAAGCCGAGAACTGA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3177,Drugs,MEG_3177|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|AE004969.1|-|618438-621189|ARO:3003928|Neisseria gonorrhoeae gyrA conferring resistance to fluoroquinolones [Neisseria gonorrhoeae FA 1090] ,3
,TGGTCAAGTTATTAAGGGTGCAGGGCGGATGCCTTGGCACTAGGAGCCGATGAAGGACGTGATAAGCTGCGATAAGCTTCGGGGAGTTGCACGTAAACTTTGATCCGAAGATTTCCGAATGAGGAAACTCACTTAGAGTAATGTCTAAGTATCATTAAGTGAATACATAGCTTAATGAGGGGAACTCAGGGAACTGAAACATCTAAGTACCTGAAGGAAGAGAAAGAAATTCGATTCCGTAAGTAGCGGCGAGCGAACGCGGATTAGCCCAAACCAATAAAGTTTTCTTTATTGGGGTTGAGGACATACCACATATAAGAGGTCATTATAGACGAAGAAGTTTGGAAAAACTCATCATAGAAGGTAATAATCCTGTAGTCAAAATAATAATTCTTTAGGTATGATCCAGAGTACCACGGGACACGTGAAACCCTGTGGGAAGCAGGAGGGACCACCCTCCAAGGCTAAATACTACCTAGTGACCGATAGCGTATAGTACCGTGAGGGAAAGGTGAAAAGAACCCCGGGAGGGGAGTGAAATAGAACCTGAAACCCTGCACTTACAAGCTGTGGAAGCACATTTCTTGTGTGACCGCGTACTTTTTGTAGAACGGGCCAACGAGTTACGTTAAGTAGCAAGGTTAAGCACTTAAGGTGCGGAGCCGTAGCGAAAGCGAGTTTTAACTGAGCGTTCAGTTACTTGACGTAGACCCGAAACCGGGCGACCTACCCATGAGCAGGATGAAGCGAAAGTAAAATTTCGTGGAGGTCCGAACCCACGAGCGTTGAAAAGCTCGGGGATGACTTGTGGGTAGCGGTGAAATTCCAATCGAGCCCGGAGATAGCTGGTTCTCCCCGAAATAGCTTTAGGGCTAGCCTCAAGGTGAGAGATACGGAGGTAGAGCACTGAATGTCCTAGGGGGTATTGCACCTACCGAAGACTATCAAACTCCGAATGCCGTCATCTTATACTTGGGAGTCAGACTGTGGGTGATAAGATTCATAGTCGAAAGGGCAACAGCCCAGATCGTCAGCTAAGGTCCCTAAATGTAAGTTAAGTGGTAAAGGATGTGGGATTGCACAGACAACCAGGATGTTGGCTTAGAAGCAGCCACTCATTCAAAGAGTGCGTAATAGCTCACTGGTCGAGTGATCCTGCGCCGAAGATTTCCGGGGCTAAAACTTACTACCGAAGCTACGGCATCAGTAATGATGGGTAGGGGAGCTTCCCATACGGGTTGAAGCATGACCGTAAGGACATGTGGACAGTATGGGAGTGAGAATGTTGGCATGAGTAGCGAGATGTGGGTGAGAATCCCACAGGCCGTAAACCCAAGGTTTCCAGGGGAAGGTTCGTCCGCCCTGGGTTAGTCGGGACCTAAGCTGAGGCCGAAAGGCGTAGGTGATGGACAACAGGTTGATATTCCTGTACTACCGATAACCGTTTGAGAGAAGGGATGACACAGTAGGATAAGCTAAGCACACTGTTGGTTATGTGTGCCCAAGCATTGAGGCAGTCAAAGTAGGCAAATCCGCTTTGATAATGCTGGGATGTGATGGGGAGCGAAATTTAGTAGCGAAGTAGCTGATTTCACACTGTCAAGAAAAGTCTCTATCGAGGTTAAAGGTACCCGTACCGCAAACCGACACAGGTGGGTGAGGAGAGTATCCTAAGGCCAGCGAGAGAACTGTTGTTAAGGAACTCGGCAAAATGACCCCGTAACTTAGGGATAAGGGGTGCCACCATCAGGTGGCCGCAGAGAATAGGCCCAAGCGACTGTTTACCAAAAACATAGGTTTCTGCTAAGTCGCAAGACGATGTATAGGAGCTGACGCCTGCCCGGTGCTGGAAGGTTAAGGGGATCTGTTAGAGCAATCGAAGCAGTGAACTTAAGCCCCAGTAAACGGCGGCCGTAACTATAACGGTCCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCCGCACGAAAGGCGTAACGATTTGGGCACTGTCTCAACAACAGACTCGGTGAAATTGTAATTCCGGTGAAGATGCCGGATACCTGCGACAGGACGGAAAGACCCCATGGAGCTTTACTGTAGCTTGACATTGGGTCTTGGTACTACATGTACAGGATAGGTGGGAGGCTTTGAAACCAGGACGCCAGTTTTGGCGGAGCCATCCTTGGGATACCACCCTTGTAGTACTGGGACTCTAACCATAGGCCATGAATCTGGTCTTGGGACACTGTCAGGTGGGCAGTTTGACTGGGGCGGTCGCCTCCCAAAAGGTAACGGAGGCGCTCAAAGGTTCTCTCAGTACGGTCGGAAATCGTACGTAGAGTGTAAAGGCAAAAGAGAGCTTGATTGCAAGACATACAGGTCGAGCAAGGATGAAAATCGGACTTAGTGATCCGGTGGTTCTGCGTGGAAGGGCCATCGCTCAACGGATAAAAGCTACCCTGGGGATAACAGGCTTATCTCCCCCAAGAGTCCACATCGACGGGGAGGTTTGGCACCTCGATGTCGGCTCATCACATCCTGGGGCTGTAGTAGGTCCCAAGGGTTGGGCTGTTCGCCCATTAAAGTGGTACGCGAGCTGGGTTCAGAACGTCGTGAGACAGTTCGGTCCCTATCCGTCGCAGGCGTAGGAAATTTGAGAAGACCTGTCCTTAGTACGAGAGGACCGGGATGGACGTACCTCTGGTGTACCAGTTGTCCTGCCAAGGGCATGGCTGGGTAGCTATGTACGGAATGGATAAGCGCTGAAAGCATCTAAGCGCGAAGCCAACTTCAAGATAAGATTTCCCACCGCAAGGGTAAGACCCCAGAAAGACTATCTGGTTGATAGGTCGAAGGTGTAAGTGCAGCAATGTATTTAGCTTATCGATACTAATAGGTCGAGGACTTGACCAA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3988,Drugs,MEG_3988|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NR_076234.1|+|0-2900|ARO:3004654|Clostridioides difficile 23S rRNA with mutation conferring resistance to erythromycin and clindamycin [Clostridioides difficile] ,7
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgtgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcagttttgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgctttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccacggagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagccagcgtattgtcaaacaagccatgctgaccgaagccaatggcgactatattattcgggctaaaactggatacgatactaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggaaaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4616,Drugs,MEG_4616|Drugs|betalactams|Class_D_betalactamases|OXA,1625655407|WP_136512084.1|NG_064749|1|1|blaOXA-788|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-788 NG_064749:1-786,0
,atgattatcagtgagtttgatcgtgagaatattgtcttgcgagatcagcttgcagatcttttaagattgacttggcctgatgagtatgggacagagccgatgaaagaagtcgaacagttgatggctccagaacggattgctgtatcggcgattgaaggggaggaattggtcggttttgttggagcgatccctcaatatggcaaaacagggtgggagttacatcctttggtagtagcaagcgcgcatcgcaaacaacaaatcgggacacgattggtttcctacctggaaaaagaagtcgcttcatatggtggcctggtcatctatctagggacagatgatgttgaaggacaaaccaatttagttgcaacggatttatttgaagatacctttgcaaagttacaagaaatcaaaaatatcaatcatcatccctatacattttatgagaaacttggctatcagatcatcggtgtgatcccagatgcgaatgggtggaaccagcctgatatttggttagcaaaacgagtggccaaaagagagccaacggaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_173,Drugs,MEG_173|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,927053167|WP_053766315.1|NG_052207|1|1|aacA-ENT2|aacA-ENT2|aminoglycoside_6'-N-acetyltransferase NG_052207:101-649,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgataagcctggtaaatattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagactcaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgcttaagtttattcatgccaatctgaacccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaagggttctatcaattagaaaccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcgtatgcagttttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_554,Drugs,MEG_554|Drugs|betalactams|Class_C_betalactamases|ADC,1058243572|WP_068981614.1|NG_051446|1|1|blaADC-107|blaADC|class_C_beta-lactamase_ADC-107 NG_051446:1-1152,0
,atgcaatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtagtatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtgttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_513,Drugs,MEG_513|Drugs|betalactams|Class_C_betalactamases|ADC,1058243708|WP_068981624.1|NG_051457|1|1|blaADC-93|blaADC|class_C_beta-lactamase_ADC-93 NG_051457:1-1152,0
,GTGGGGCTTTGTAGGTATGGGGCTCATAATTGCTGCCTTTTTGCTCGCCCGATCCCCATCGTGGAAGTCGCTGCGGAGGCCGACGCCATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6616,Drugs,MEG_6616|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|984881271|gb|CP014215.1|2292290-2291364 gi|984881271|gb|CP014215.1|2305054-2304128 gi|970698242|gb|KT988020.1|22548-23474 gi|970698221|gb|KT988019.1|7360-8286 gi|970698093|gb|KT988018.1|115034-115960 gi|974752094|gb|KT164809.1|6041-5115 gi|974751547|gb|KU130294.1|238739-237813 gi|974751547|gb|KU130294.1|233386-234001 gi|974751143|gb|KU238092.1|13115-12189 gi|975048878|gb|CP013962.1|2821810-2822736 gi|974255378|gb|CP008857.1|6671196-6672122 gi|974022331|gb|CP013924.1|1441443-1442369 gi|974022331|gb|CP013924.1|2757492-2756566,8
,atgaagaaattatttgttttatgcatttttttgtttttaagtattactgcctcaggtgaggttttgcctgatttgaaaattgagaagcttgaagagggtgtttatcttcatacatcttttgaagaggttagcggttggggtgttgttactaaacatggtttggtagttcttgtaaataatgacgcctatctaattgacactccatttacaaataaagatactgaaaaattagttgcttggtttgtagggcgcggctttacaataaagggaagtgtttcctcacattttcatagcgacagtacgggtggaatagagtggcttaattctcaatctattcccacgtatgcatctgagttaacaaatgaacttctgaaaaagaacggtaaggtgcaagctacaaattcatttagcggggttagttattggctagttaaaaataaaattgaaattttttatcccggcccaggacatactcaagataacgtagtggtttggctacctgaaaacaaaattttattcggtggttgttttgttaaaccggacggtcttggtaatttggatgacgcaaatttaaaagcttggccaaagtccgcaaaaatattaatgtctaaatatggtaaagcaaagttagttgtttcaagtcatagtgaaattgggaacgcatcactcttgaaacttacttgggagcaggctgttaaagggctaaaagaaagtaaaaaaccattactgccaagtaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3316,Drugs,MEG_3316|Drugs|betalactams|Class_B_betalactamases|IMP,1102724729|WP_071593225.1|NG_052049|1|1|blaIMP-63|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-63 NG_052049:1-741,0
,ATGGAAAATGGTTTTTTGTTTTTAGATGAAATGTTGCATTGCGTCCGTTGGGATGCCAAGTACGCCACATGGGATAACTTCACAGGAAAACCGGTGGATGGGTATGAGGTGAATCGCATCATCGGCACAAAGGCCGTGGCGTTTGCTCTGCGCGAGGCACAAATCCATGCGGCACGCCTTGGCTATGGCTTGCTTTTATGGGATGGATATCGGCCAAAATCTGCGGTGGACTGTTTCCTGCGTTGGGCGGCGCAGCCGGAGGACAACCTCACAAAAGAAAAATATTACCCCAATATTGAGCGAGCCGAGTTGATTACAAAGGGCTATGTGGCCTCACAATCCAGCCATAGCCGTGGAAGCACAATTGATCTTACGCTCTACCACTTGGATACAGGGGAACTTGTTTCAATGGGAAGCAACTTCGATTTTATGGACGAACGGTCGCACCATACAGCAAAAGGGATAGGGAATGCAGAGGCACAAAATCGAAGATGCTTGCGTAAAATCATGGAAAGCAGCGGATTTCAGTCCTATCGCTTTGAATGGTGGCACTATAAGTTGATTGATGAGCCATACCCCGATACCTATTTTAATTTTGCCGTTTCATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7562,Drugs,MEG_7562|Drugs|Glycopeptides|VanB-type_resistance_protein|VANXB,gi|695199646|ref|NG_035288.1|29869-30477,5
,ATGAGAAACGAGGAAGTCATTAGTATGTGGCAACGGATGAAATGGGGTCTGTGTGTGCTGGCGGCACTCAGCGGTTCTGCGATGGCCGCACCGCTGACGGCGCAATACGTGTCGACTATCGCGACGCAGGAAGAACAGCGTCTTCATGCCCGGATTGGCATTGCGGTACTTGATACGGCGACCAACAGTATCACCCATTATCGGGGAGAAGAACGGTTCCCGTTAAACAGTACGCACAAGCCGCTGTTATGCGCAGCGTTATTACGCGAAGTCGACAGGAAGGCGCTGGCGCTTTCTGCTTCAACGCAGTTTGAATCCTCGCAGCTGGTGGAGTATTCGCCGATTACTGAAAAACATGTGGCGCCAGACGCCATGAGCTGGGCGCAATTGTGCAGCGCGGCGGTAAGCTACAGCGATAACACGGCCGCCAATCTCATCGCCAGGAAGCTCAACGGGCCGCAGGCCGTCACGCAGTTTTTGCGTGATTCGGGGGATACAATAACCCGCCTCGATCGCTATGAGCCTGAACTGAACAGCGCCATTCCCGGCGATGAACGCGACTCCACGACGCCTGTCGCGATAGCGCAGACGCTCAATACGCTACTGCTGGGGAACGTGTTGCAGCCATCCTCAAGAGAGCAGCTTATGCAGTGGATGCGGGACGACAAAGTGGCTGACGGTCTGCTGCGTTCGGTCTTGCCGGATGGCTGGAAAATCGCGGATAAAACCGGGGCGGGCGACAACGGCTCGCGTTCTATTGTCAGCGTTGTCTGGCCGACATCACAAAAACCTCTGCTCGTGGTTATCTATATTACACAAACTCCGGCGACAATGGCGCAGCGTGACGCCGCGATTGTCCGCATCGGGGAGTCGCTGTTTTCAACACTCGCAGTCTATGATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3660,Drugs,MEG_3660|Drugs|betalactams|Class_A_betalactamases|MAL,gi|38601955|emb|AJ609506.1|1-903,0
,atggctctggcactcgttggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaaatttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaattccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagctttatgaatatgatcaccacgcgcacctggttttgtagcgcatatatcacgaataccaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcggatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagctggacaactaccaggcgtcgttgctcatggagcggcttggcatcgcggtgattggttag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5891,Drugs,MEG_5891|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,836573978|WP_047731800.1|NG_050491|1|1|qnrB3|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB3 NG_050491:37-681,3
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgatgacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2203,Drugs,MEG_2203|Drugs|betalactams|Class_A_betalactamases|CTX,1209144249|WP_088245211.1|NG_055268|1|1|blaCTX-M-127|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-127 NG_055268:1-876,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcagcatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggataccccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6212,Drugs,MEG_6212|Drugs|betalactams|Class_A_betalactamases|SHV,1037232573|WP_064733493.1|NG_062279|1|1|blaSHV-207|blaSHV|class_A_beta-lactamase_SHV-207 NG_062279:1-861,0
,ATGGAAAAAAACAGAAAAAAACAAATCGTAGTTTTGAGTATAGCTTTAGTTTGCATTTTCATCTTGGTATTTTCATTGTTCCATAAATCAGCGACAAAAGATAGCGCAAATCCTCCTTTAACAAATGTTTTGACTGATAGCATTTCTCAAATTGTCTCAGCTTGTCCTGGCGAAATTGGTGTGGCGGTTATTGTTAATAACAGAGATACGGTTAAGGTCAATAATAAGAGTGTTTATCCTATGATGAGTGTGTTTAAGGTTCATCAGGCATTAGCTCTTTGTAATGACTTTGACAATAAAGGAATTTCACTTGATACCTTAGTAAATATAAATAGGGATAAACTTGACCCAAAGACTTGGAGTCCTATGCTGAAAGATTATTCAGGGCCAGTCATATCATTGACAGTGAGAGATTTGCTGCGTTATACTCTTACTCAGAGTGACAACAATGCAAGCAACCTTATGTTTAAGGATATGGTTAATGTCGCTCAAACAGATAGTTTTATAGCCACACTCATTCCTCGTTCAAGTTTTCAGATAGCTTATACGGAAGAGGAAATGTCGGCTGACCATAACAAGGCTTACTCTAACTATACATCTCCTCTTGGTGCTGCAATGTTGATGAATCGTTTGTTTACTGAAGGTCTTATCGATGATGAGAAACAAAGTTTCATTAAGAATACGTTAAAAGAATGCAAAACAGGTGTAGATAGGATAGCAGCTCCACTTCTTGATAAAGAAGGGGTTGTTATAGCGCATAAGACAGGTTCAGGTTATGTTAATGAAAATGGTGTTCTTGCAGCTCACAATGATGTTGCCTATATATGTCTGCCTAATAATATCAGTTATACCTTAGCGGTATTTGTTAAGGATTTCAAGGGAAATGAATCACAAGCGTCACAATATGTTGCGCATATATCAGCTGTAGTATATTCTTTATTAATGCAAACTTCAGTAAAATCTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1698,Drugs,MEG_1698|Drugs|betalactams|Class_A_betalactamases|CFX,gi|4566898|gb|AF118110.1|AF118110|1037-72 gi|209570233|emb|AM940013.1|1-921,0
,atgcgttctaccctgctcgccttcgccctggccgtggccctcccgatcgcgcacgccagtggcgccgagacaccactgccgcagctgcgggcctacaccgtggacgcctcgtggctgcagccgatggcaccgctgcagattgccgaccacacctggcagatcggcacgcaggacctgaccgccctgctggtgcagaccgctgacggcgcggtactgctcgacggcggcatgccacagatggccggccacctcatcagcaacatgaaggtgcgcggcgtggcgccgcaggacctgcggctgatcctgctcagccacgcgcacgccgaccatgccgggccggtggcggagctgaagcgccgtacgggcgccaaagtagcggccaacgccgaatcggcggtgctgctggcgcgcggtggcagcgacgatctgcacttcggcgatggcatcacctacccgcctgccagtgcagaccgcatcgtcatggatggcgaaatgatcacggtgggcggcatcgcgttcactgcgcacttcatgccggggcacaccccgggcagcaccgcgtggacctggaccgatacccgcgagggcaagccggtgcgcatcgcctacgccgacagcctgagtgcaccgggctaccagctgcagggcaacccccgttatccgcacctgatcgaggattacaggcacagcttagcgacggtgcgggcgctgccctgcgacgtgttgctgacaccgcatccgggtgccagcaactgggactacgctgccggcagcaaggccagcgccaaggcactgacctgcaaggcctacgcggatgcggccgaacagaagttcgacgcacagctggccaaggaaacggccggggcccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3525,Drugs,MEG_3525|Drugs|betalactams|Class_B_betalactamases|L1,1028083708|WP_063842676.1|NG_047503|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047503:1-873,0
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttgggcggtacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgtttccggaccgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcatggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctgtggcgggggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaatgcccatgctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1599,Drugs,MEG_1599|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1105502160|WP_071846311.1|NG_052381|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_052381:101-733,6
,ATGAAAAGTGATTTTGTTTTTGTGGACGAGTTGATATCGGGAATACGTTGGGATGCTAAATACGCCACCTGGGATAATTTTACCGGCAAACCGGTGGACGGCTATGCCGCCAATCGAATTGTCGGCACGAGAGCGTTGTGCGAAGCCCTGGAAAAAGCACGGGAAAACGCCGCATCCTTGGGCTTTGGCTTGCTTCTTTGGGATGGTTACCGCCCTCAATGCGCCGTAGATTGCTTTCTGCGCTGGTCTAAACAGCCGGAAGATGGTCGGACGAAACAAAAACACTATCCGAATATTGACCGCTCCGAGATCATCGAAAAAGGATATGTGGCTGCCAAGTCGGGCCACAGCCGGGGCGGCGCCATTGATTTAACCCTTTATCATTTAGCTTCCGGAACCCTTGTGCCCATGGGGGGCGATTTTGATTTGATGGATTCAGTCTCCCATCATGGCGCACATGGAATCAGCCAAGCCGAAGCGAGAAACCGTCAATATCTTTGCTCGATCATGGAGGCCAGCGGCTTTATTTCCTACGCTTGCGAGTGGTGGCATTACACCCTGAAACACGAACCTTATCCCAATACTTACTTTGATTTTCTCATTGCCTAGTTGAGTATCAAGCGTGATGACGAGAACTGTGAGGTGCTTTTGACAATGGAAATGACAGTACGCGAAATCGTTGCCGCCTGCGGCGGAAAATTACTCTGCGGGGACCCGGATACGATGGTGACCTCGGTGGTGACCGACAGCCGGAAAGTGACCGACGGTTCCCTGTTTGTCCCCCTCAAAGGCGAAAAGGCGGACGCCCACACCTTTCTGCACGCCGCATTCGCCTCGGGTGCAGCCGCGGCACTGACCCAGGAGCATACGCGGATGGAGGCGGAAGAAGCCTGGATCGCGGTGGATTCGACTCAGCTGGCGCTCCAGCACATTGCCGCCGCCTATCGGCAGAGATTTTCCATCCCTGTGGTTGGGATCACAGGGAGCGCCGGGAAGACGACGACGAAAGAAATGACCGCGCTGGCACTTTCCGCAGGATACAAGGTGATGAAGACGGGAGGAAACCATAACAGCCAGATCGGACTGCCCCTGATGATGTTTCAGTTTTCCAGGGAACACGAAGCGGCGGTGGTGGAGATGGGGATAAGCGATTTCGGCGAAATGGCGCGCCTGGCTCAGGTCGCCGAGCCGAAGTACGCCGTCATGACCAACCTCGGCATTACTCACATCGGCCAGCTCAAAACCCAGGAGAACATCCTGCGGGAGAAGCTGCACATCACGGACCGGTTCACTCAGGGTTCCGTTCTGTTTTTAAACGGGGACGATCCAATGCTGGCCGGACTCCGCGGCAAGACAGGGTATGAGGCCGTCTTTTACGGCACAGCGCCCTGGTGCGATTTCCGCGCAGAGGGGATTACGGTTCAAGGGGAAACCACCGCTTTCCGCTGCCTTGCTCCGGGGAGAGAGAGCGTGGAGGTGATCCTGCCGGTACTGGGAATGCACCATGTTCTGGATGCCCTGGCCGCCCTGGCCGTGGCGGAGCGGCTGGGCGTGCCCCTGGACCGGGCCGCCGCCGCGCTGGGGGATTACCGCCCCCTGGCCATGCGCCAGCAGATATACCATGTCAACGAGGTCGCTGTCATTGATGATTCTTACAACTCCAGTCCCGGCGCGGCCAAAAGCAGCCTGAGTGTCCTTGCGGGGTTCCGGGCCGGCCGCAGAGTAGCCGTGCTGGCGGATATGCTCGAACTGGGGGAGTATTCCCGGCAGGCCCATTTTGAAGTCGGTGTCTGCGCCGCGGAAAGCGGAGTGGATATTTTACTGACCGTCGGTCCGGAGGCGAAAGCCGTGGCCGAGGGTGCCCGCTCCGTCCGGTCCGGGATCGACTGCCGCGTTTTTGACCATAACCGTCAGGCCGCGGCGGAGTTGAAATCCTTTCTGTCTCCCGGTGACGCAGTTCTGGTCAAAGGCTCCCGCGGTATGCATACGGACGAAATCGTCCGCGCCCTGCTGCAGTTTCCCGCTTCGGTAGGGACAGTCCGGCCGGCCCAATAATCCCCGCCTGAAAAATATGAAAGAAAACCCGGCTTATAATGGAGTGTTTTTAAAATGTTAAACGTTGACAAGATAAGTGAAGAAACCTATTATGCGTTCATTTCTCAAGCGGATCTAGGCAATTTTATGCAGTATCCTTCCTGGGCCAAGGTCAAAACTGAGTGGACCAGCGATTTATTGGGGTGGTTCACCCCGGACAATAAATTGGCAGGGTGTGGTTTGATCTTATACCGGAAAATGCCCTGCCTTAACCGGTACCTGGCGTATTGTCCCCGCGGTCCCCTTATTGACTGGCAGAGCCCCAACCTCAGGGAATGGTTCGAACCTCTTGTGGCTTATTTGAGAAGCAAGCAGGTTTTCAGTATCAAGATCGATCCTCCGGTGGTCCAGGCAAAATGGTCTGCCCCCACCATTAAAACGTTTTTAGGGCAAGCCCGTGAACAGGGCAGCAAAGGGAAAGTTTTGCGCGATTTGCCGCCGGACGAAGACTACACAACGGTCCAACAAGTGCAGCAGCAATTACGGCAAATGGGTTGGCGGAAGCAGCGGGGGGATACGGGTTTCGCTGCGACCCAGCCCCAATATGTTTACCGCCTGCCCTTAGAGGGGCGCAGCCTGGAGGAGGTCTTCGCCGGTTTTCATACCAACTGGAGGCGCAATGTTAAAAAGGCCGAGCGTTTGGGCGTCAAGGTCCGGGTCGGGACCGAACAGGATTTACCGGCTTTTTATGAGCTGCTGAAGGTAACTTCAGAACGGGATCACTTCAAGGTGCGCAGTTTCTCCTACTTTTCCAATCTGTACCGGTCCTTAAAGGCTGAAGCGGCAGACCGTATTGCTCTTTATCTGGCGGAAGATGAAGAGGAATTATTGGCTGCTACCTTAGCCGTCCATTCCAACGCCCACTCATGGTATCTTTACGGGGCCAGCAGCAATGTAAAACGGGAGAAGGCCCCGAATCATGCTATCCAGTGGCGGATGATTCAAGATGCTTATCAGCTTAAGGCCTACACCTATGATTTTAGAGGCATCAGCCCTACCCTGGATGAATCTGACCCCCTGTTTGGGTTGTTGAGATTTAAATTGGGCTTTGGAGGCGAGGCTTGTGAAATGATCAGTGCTTGGGACTACCCCCTGCAGCCTTTATTATACCGGGCTTTCCAGCTGTACTTAAAACGGCGGTAGGGTGGGCCATATTCCTGAAAGGGGTCTCGACATGAAAAGAAAAAGATTGACTCAGTTGTTCCCATTCCTGCTGCCGGTCCGCAGGACCCAACGGAAATTATTCTTCTATACCGAGATGTACTTTGACCGGAACCACTATGCCAAAGCAAAGGCTCCGGAGTTTTTGCCTTTTTGCGTCTATGAAACCAAGTCGAAGCTTCTCAATGAAAATACCGGCATGGATATGAGATACCAGGAGAACAAGGTGTTTAATCTGCGCCTTGCCGCGGAAACTGTCAATGGCCTATTGATCCGCCCTGGTGAAACATTTTCATTTTGGCAGCGGGTGAGATATGCCGAGAAAAATGAGCGGTACAAGGACGGTTTGTGCGTGGTCAATGATGAATTGATTACGGTTCCGGGAGGCGGTTTGTGTCATCTCAGCAATTTGCTGTTCTGGCTGTTTCTGCATATGCCCCTTACGATTGTCGAACGGCATGCTCATGAGATTAAGGATTTTCCTTCGCCGGATGAGGATGAACCGGATGGTGTGGACGCCACAATCCACGAAGGGTGGTTGGATTTAAAGGTCAAAAACAATACCAATCTTACCTTCCAAATTGAAATAGCCATCGATGAGCCTTACATCTATGGCCGTATTTTTATGGATCAAGCCAAAAGGTATAGTTACGAGGTCGTTAATCGGGATAAGAGCTTTTTTAAAAAGGAGGGAAAAACCTTTGAGCGGGTTTCGGTTTGCCGGCAGGTGATCGACAACGAATCCAAACAGGTTGTTTCCGAAAAACTGCTTTATACGGATGTATTTGAAATCGGGTATGTGCTTCCGGAAGGAACGGCTATCGCAGACGAGAAGGCGTGATGGAAAGCGCTAAGCCGGCGGTGCAGTCTTAGATGCTCGCAGGAGAGGGTCTGCCCCCCCCCCATGGCACAGAACACGCCCTGAGGGATACTGTTTTGAAAAGACTATGATTGCCTGAAATATGAAAGGAGAAAACAGCATGGATCGGTTGAAAATCGCAATTATTTTCGGAGGCTGTTCCGAAGAACATCCCGTCTCCGTTAAATCGGCTGGGGAGGTTGCCAAAAACCTGGATCTCGATAAGTATGAACCCTTCTATATCGGGATTACGAAAAATGGGGTTTGGCAGCTTTGCCGCTACCCTGAGGCCAATTGGGAAAACGGCATTTGCCCTTCGGTTATCCTGTCACCGGACAGAAGCCTCCAGGGATTGCTTGTTCTGGAGCAGGGACAATATAAAACGATTCCTTTGGATCTGGTGTTTCCCGTTCTGCATGGTAAATTTGGCGAGGATGGGGCGGTGCAAGGTTTGTTGGAGCTCTCCGGCATCCCCTATGTGGGCTGCGATATCCCCAGTTCGGCCTTGTGCATGGACAAATCCCTTGCTTATATCGTCGCCGGAAACGCAGGAATTGCCACGCCAAAGTTCCGGACGGTCACGGCGAAAGAGGCCATTGATGCCGAACGGCTTGCTTATCCCGTTTATGTCAAGCCGGCCCGTTCGGGTTCATCCTTCGGCGTCACTAAAGTATGCCGCCAAGAAGAATTGCTGAGTGCGGTGGCAATCGCCAGCCAGTATGACTCGAAGGTGCTGATTGAAGAGGCTGTCATCGGCACTGAGGTAGGGTGTGCAATATTTGGCAACGATCTGGATTTAATGGCCGGGGAGGTCGATCAGATTCGCCTGTCTCACGGCTTTTTCAGAATCCATCAGGAGAATGAGCCGGAAAAGGGTTCCGAAAACTCAACCCTAATCGTTCCCGCCGACATTTCGCCGCAGGCGCGTTCGCGGGTTCAGGAGACGGCAAAAGCCATCTATCGCGCTTTGGGATGCAAGGGACTGGCACGGGTGGATATGTTCCTGAAGGAAGATGGAGAAGTAATCCTGAACGAGGTGAATACTTTGCCCGGTATGACCTCGTACAGCCGTTTTCCGAGGATGATGGCGGCCGCAGGCTTGCCCTTTGCCGAAGTGATCGACCGGCTTGTCTCGTTGGCCTTGCAAGGAAAAACAGGAGCCTTATCCCAACACTTACTTTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7572,Drugs,MEG_7572|Drugs|Glycopeptides|VanM-type_resistance_protein|VANXM,vanXmurFvanKWI_2_AP008230,5
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaatgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgtccactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_802,Drugs,MEG_802|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502189|WP_071846339.1|NG_052434|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052434:49-840,2
,atgaaaaatacattattaaaattaggggtatgtgttagtttactaggaataactccatttgttagtacaatttcttctgtacaagcagaacgaacggtagagcataaagtaataaaaaatgagacaggaactatttcaatttctcagttaaacaaaaatgtttgggttcatacggagttaggttattttaacggagaagcagttccttcgaacggtttaatccttaatacttctaaaggattagtacttgtcgattcttcttgggatgataagttaacgaaggaattaatagacatggcagaaaagaaatttaagaaccgcgtaacggatgttattattacacatgcacacgctgatcggattggtggaataaaaacgttgaaagaaagaggcattaaaacgcatagtacaacgttaactgcggaactagcaaagaaaaatggatatgaagaaccacttggagacttacaagcaattacgaaattgaagtttggaaatatgaaagtagaaacgttttatccagggaaaggacatacagaagataatatcgtcgtatggttaccacaatacaacatgttagttggaggctgtttagtgaagtctgcgtccgcgaaagatttaggaaatattactgatgcttatgtaaatgaatggtctacatcgattgagaatgtgctgaagcgatatgaaaatataaattttgtagtacctggtcatggagaagtaggggacaaaggattacttttacatacattggatttgttaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1205,Drugs,MEG_1205|Drugs|betalactams|Class_B_betalactamases|BCII,446721914|WP_000799227.1|NG_047222|1|1|BcII|BcII|BcII_family_subclass_B1_metallo-beta-lactamase NG_047222:101-871,0
,atgagtaacgcagtacccgccgagatttcggtacagctatcactggctctcaacgccatcgagcgtcatctggaatcaacgttgctggccgcgcatttgtacggctctgcactggacggtggcctgaagccatacagtgatattgatttgctggttactgtggctgcacggctcgatgagactgtccgacaagccctggtcgtagatctcttggaaatttctgcctcccctggccaaagtgaagctctccgcgccttggaagttaccatcgtcgtgcatggtgatgttgtcccttggcgttatccggccagacgggaactgcaattcggggagtggcagcgtaaggacattcttgcgggcatcttcgagcccgccacaaccgatgttgatctggctattctgctaactaaagtaaggcagcatagccttgcattggcaggttcggccgcagaggatttctttaacccagttccggaaggcgatctattcaaggcattgagcgacactctgaaactatggaattcgcagccggattgggaaggcgatgagcggaatgtagtgcttaccttgtctcgcatttggtacagcgcagcaaccggcaagatcgcaccgaaggatatcgttgccaactgggcaatggagcgtctgccagatcaacataagcccgtactgcttgaagcccggcaggcttatcttggacaaggagaagattgcttggcctcacgcgcggatcagttggcggcgttcgttcacttcgtgaaacatgaagccactaaattgcttagtgccatgccagtgatgtctaacaattcattcaagccgacgccgcttcgcggcgcggcttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_813,Drugs,MEG_813|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502146|WP_071846298.1|NG_052356|1|1|aadA6|aadA6|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA6 NG_052356:101-946,2
,atgtggcgagaagttaaacagcatatgagtaataaatttataaaaagggtagttaaaatgaaatattggaaaatattaagcttggtgttttgcacatttgcttttgcagttaattgcaaagcacacgcaggagtgaagcagattgagacaaagtacaatgttaaaattggcgtttatgcaattgacaccaataatggtaacagcttttcttatcgtcaggatgagcgctttccatttcaaagcactgttaagatggtagttgcagctgctgctttaaaaaatattgaagctgatgagagaataaaaatttcttcagatgatattgtgttttggagtcctatcgttcgcctgaatttagatagaggttacatgacgataaaggagcttgcagaagcagcaatgagttatagtgataatgctgcaactaatattctgattacaaggcttggaggaactaaaagcattaatgaatttgcaaaatcaataggaaacgcatcgttttatttagaaaatttagagcctaatttaaactcagatccaaataacattcatgatagctctactcccaaagatatggcccaaagtgttcaaaaactattgatagaaaataatgttttaagtcaagaaaatcagcatatattaaaaacttggatgatgaacaatactacaggttacaaaaaaatcagatatggattgcctctaggttggagcgctgcagaaaaaacaggtggaggctctggtacttctcatgatataggaattgtatggtcgcctgcatgtaagccaatagtactagcaatttatacattttcaaataaaaaagataatgcgcagcaggctgataaagcgattgctgaaacgactaaatttattcttgatgaattttctaagaaaaacatatgtttctcagcaacggattttaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3656,Drugs,MEG_3656|Drugs|betalactams|Class_A_betalactamases|M1,1028083756|WP_063842724.1|NG_047526|1|1|blaM-1|blaM-1|class_A_beta-lactamase NG_047526:1-927,0
,ATGAAAATAATGTTAGAGGGACTTCATATAAAACATTATGTTCAAGATCGTTTATTGTTGAACATAAATCGCCTAAAGATTTATCAGAATGATCGTATTGGTTTAGTTGGTAAAAATGGAAATGGAAAAACAACGTTACTTCACATATTATATAAAAAAATTGTGCCTGAAGAAGGTATTGTAAAACAATTTTCACATTGTGAACTTATTCCTCAATTGAAGCTCATAGAATCAACTAAAAGTGGTGGTGAAGTAACACGAAACTATATTCGGCAAGCGCTTGATAAAAATCCAGAACTGCTATTAGCAGATGAACCAACAACTAACTTAGATAATAACTATATAGAAAAATTAGAACAGGATTTAAAAAATTGGCATGGAGCATTTATTATAGTTTCACATGATCGCGCTTTTTTAGATAACTTATGTACTACTATATGGGAAATTGACGAGGGGAGAATAACTGAATATAAGGGGAATTATAGTAACTATGTTGAACAAAAAGAATTAGAAAGACATCGAGAAGAATTAGAATATGAAAAATATGAAAAAGAAAAGAAACGATTGGAAAAAGCTATAAATATAAAAGAACAGAAAGCTCAACGAGCAACTAAAAAACCGAAAAACTTAAGTTCATCTGAAGGCAAAATAAAAGGAACAAAGCCATACTTTGCAAGTAAGCAAAAGAAGTTACGAAAAACTGTAAAATCTCTAGAAACCAGACTAGAAAAACTTGAAAGGGTCGAAAAGAGAAACGAACTTCCTCCACTTAAAATGGATTTAGTGAACTTAGAAAGTGTAAAAAATAGAACTATAATACGTGGTGAAGATGTCTCGGGTACAATTGAAGGACGGGTATTGTGGAAAGCAAAAAGTTTTAGTATTCGCGGAGGAGACAAGATGGCAATTATCGGATCTAATGGTACAGGAAAGACAACGTTTATTAAAAAAATTGTGCATGGAAATCCTGGTATTTCATTATCGCCATCTGTCAAAATCGGTTATTTTAGCCAAAAAATAGATACATTAGAATTAGATAAGAGCATTTTAGAAAATGTTCAATCTTCTTCACAACAAAATGAAACTCTTATTCGAACTATTCTAGCTAGAATGCATTTTTTTAGAGATGATGTTTATAAACCAATAAGTGTCTTAAGTGGTGGAGAGCGAGTTAAAGTAGCACTAACTAAAGTATTCTTAAGTGAAGTTAATACGTTGGTACTAGATGAACCAACAAACTTTCTTGATATGGAAGCTATAGAGGCGTTTGAATCTTTGTTAAAGGAATATAATGGCAGTATAATTTTTGTATCTCACGATCGTAAATTTATCGAAAAAGTAGCCACTCGAATAATGACAATTGATAATAAAGAAATAAAAATATTTGATGGCACATATGAACAATTTAAACAAGCTGAAAAGCCAACAAGGAATATTAAAGAAGATAAAAAACTTTTACTTGAGACAAAAATTACAGAAGTACTCAGTCGATTGAGTATTGAACCTTCGGAAGAATTAGAACAAGAGTTTCAAAACTTAATAAATGAAAAAAGAAATTTAGATAAATAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_7686,Drugs,MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA,vga(A)LC_4_JQ312423,1
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagtttcccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccaaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5477,Drugs,MEG_5477|Drugs|betalactams|Class_C_betalactamases|PDC,1304472399|WP_100931731.1|NG_056055|1|1|blaPDC-221|blaPDC|class_C_beta-lactamase_PDC-221 NG_056055:1-1194,0
,ATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCTGCCCTTCTGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCTCGGTATCATTGAAGCACTGGGGCCAGATGGTAAGCCCTCTCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6690,Drugs,MEG_6690|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-144:DQ256080:215-1075:861,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcaaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgcgctcgcgagggcgacggagcgtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_5458,Drugs,MEG_5458|Drugs|betalactams|Class_C_betalactamases|PDC,730240874|WP_033945151.1|NG_049929|1|1|blaPDC-55|blaPDC|class_C_beta-lactamase_PDC-55 NG_049929:1-1215,0
,atgaaaaaatttatacttcctatcttcagcatttctactctactttctctcagtgcatgctcatctattcaaaataaatttgaaaatacttctgatatttctgatcagcaacatgaaaaagccattaaaagctattttgatgaagctcaaacacaaggtgtaatcattattaaagagggaaagaatattagaatctatggtaataacctggtacgagcacatacagaatatgtccctgcgtcaacatttaagatgctaaatgccttaattggattagaaaatcataaagctacaacaactgagattttcaaatgggatggtaaaaaaagatcttatcctatgtgggaaaaagatatgactttaggtgatgccatggcactttcagcagttcctgtatatcaagaacttgcaagacggactggcttagatctaatgcaaaaagaagttaaacgggttggttttggtaatatgaacatcgggacacaagttaataacttctggttagttggccccctcaagattacaccaatacaagaggctaattttgccgatgatcttgcgaataatcgattaccctttaaattagaaactcaagaagaagtaaaaaaaatgcttctgattaaagaagtcaatggtagtaaaatttatgcgaaaagtggatggggaatggatgtgacccctcaagtaggttggttaacaggttgggtagaaaaatctaatggcgaaaaagttcccttttctctaaacctagaaatgaagcaaggaatgtctggttctattcgtaatgaaattacttataaatcattagaaaatttagggattatataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4668,Drugs,MEG_4668|Drugs|betalactams|Class_D_betalactamases|OXA,1028109709|WP_063864112.1|NG_049775|1|1|blaOXA-499|blaOXA-143_like|OXA-143_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-499 NG_049775:1-828,0
,ACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATAAGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAACCGGTAAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6921,Drugs,MEG_6921|Drugs|betalactams|Class_A_betalactamases|TEM,gi|46370396|gb|AY589495.1|1-1042,0
,GAGTTTGAGATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGTCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGCGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAAACTGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_2372,Drugs,MEG_2372|Drugs|betalactams|Class_A_betalactamases|CTX,gi|126013667|gb|EF418608.1|1-890,0
,atgaaaaagctatttctgctacttggattgttagcctgttcgagtgcaacgtacgccgccaaacttaatgaagacatctccgcgattgaagagcatatttcgggtcgaatcggtgtgtctgtctgggatactcaaaccgatgaacattgggactatagaggcgacgagcgcttcccgatgatgagcacattcaaaacgcttgcatgtgcaacgatgcttagtgacatggataatgaaaagctcgataaaaacgccactgccaaagtagaagagcgcaatatggtggtttggtcaccagtaatggatcgtatggcaggtcaaacaacgcgttttgaacatgcttgtgaagccgcaatgcttatgagcgacaattccgcagcccacattgttttgcgtagcatttggggggtccacgcggggggcacttcgttcttgcgttctatcggtgataaagcaacgcgccttgaccgttttgaaccaagactgaacgaggcgaacccgggcgacaagcgagacaccacaacacctaatgccatggtaaatacgctgcatacgttgttagaaggtgatgcgctatcctacgaatcacgcattcaattaaaaatctggatgcaggataacaaagtctctgattctttgatgcgctctgtgttaccaaagggttggtcgattgccgatcgttctggcgcaggtggctttggatcacgcggtatcacagcaatgatctggaaagagaatcataaaccggtctacatcagcatttacattactgaaaccgatttatccttgcaggcgcgcgatcaggttatcgctcaagtgagccagttaatactggatgaagtacaatactatttagcgctcgctaaatactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7695,Drugs,MEG_7695|Drugs|betalactams|Class_A_betalactamases|VHW,1028110909|WP_063865165.1|NG_050335|1|1|blaVHW-1|blaVHW|carbenicillin-hydrolyzing_class_A_beta-lactamase_VHW-1 NG_050335:101-973,0
,atgatgaaaaaatcgttatgctccgctctgctcgtgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1806,Drugs,MEG_1806|Drugs|betalactams|Class_C_betalactamases|CMY,695262068|WP_032489027.1|NG_049266|1|1|blaLAT-3|blaLAT|CMY-2_family_cephalosporin-hydrolyzing_class_C_beta-lactamase_LAT-3 NG_049266:1-1146,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcttcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5593,Drugs,MEG_5593|Drugs|betalactams|Class_C_betalactamases|PDC,1034011082|WP_064484000.1|NG_050791|1|1|blaPDC-135|blaPDC|class_C_beta-lactamase_PDC-135 NG_050791:1-1194,0
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtcggcatgttcttttaataccgtacaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaaatgaaggtgttttagttataaaacgtgggcaaacagaggaaatctatggcaatgatcttaaaagatcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttgtttcctgattgggaaaaggacatgactctaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaagaatgtgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacggaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaacctcaaggaaaaattgtagcgttctcactcaatttagaaatgaaaaaaggcatacctagttctattcgaaaagaaattgcttataagggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4558,Drugs,MEG_4558|Drugs|betalactams|Class_D_betalactamases|OXA,1028109711|WP_063864114.1|NG_049781|1|1|blaOXA-503|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-503 NG_049781:1-822,0
,atgatcgaagcgtgtcactccgtcgaatgccctggctggctgcaacttcgttttctcctctggccgcaagatagcgccgacgaacaccttgctgaaatggcaatcttcgtggctgagccaaatcggttcgcgcagttcatcgcttacgacgaagcgaacaaaccactaggcttcgttgaggctgcgctccgatctgactacgtaaacggaaccaattcgtccccagtagcgtttcttgaaggggtctatgtcttaccggaagcacggcgtcgcggcatcgctcatgccttggtcggtgcagtcgagatatgggctcgtaatcgggcctgtaccgagttcgcatccgatgcatcaactgacaacccggaaagccatagatttcaccagtcacttgggttcaaagaaaccgagcgtgtcgtgtacttcaggaagatgcttgcgccagaatga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_93,Drugs,MEG_93|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1185244969|WP_085334908.1|NG_055007|1|1|aac(6')-Id|aac(6')-Id|aminoglycoside_N-acetyltransferase_AAC(6')-Id NG_055007:101-550,2
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgcatcctaatatgcgtgtaatgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaatcagaagatttcagaattgctccttgtaccctgtttatcatggaagcgcaaaaagcaacatagggattgagcagcttatagaagtgattacgaataaattttattcatcaacatacagaaagaagtctgaactttgcggaattgtcttcaaaattgaatattcggaagaaagacaacgtcttgcatatgtacgcctttatggcggaatcctgcatttgcgggattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaattgataaggcttattccggggaaattgttattttgcaaaatgagtttttgaagctaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatccgctccctctgctgcaaacaactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctacaatattatgtggattctacgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctattgcaagaaaagtatcatgtggaggtaaaaataaaaaagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagtgccaccgaatcccttctgggcttccattggtctttctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaagggatacgatatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagttttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcaccacaagaatatctttcacgagcatataacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggagaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7122,Drugs,MEG_7122|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,752377262|WP_041160408.1|NG_048238|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048238:101-2020,4
,ATGAACGAGAAAAATATAAAACACAGTCAAAACTTTATTACTTCAAAACATAATATAGATAAAATAATGACAAATATAAGATTAAATGAACATGATAATATCTTTGAAATCGGCTCAGGAAAAGGGCATTTTACCCTTGAATTAGTACAGAGGTGTAATTTCGTAACTGCCATTGAAATAGACCATAAATTATGCAAAACTACAGAAAATAAACTTGTTGATCACGATAATTTCCAAGTTTTAAACAAGGATATATTGCAGTTTAAATTTCCTAAAAACCAATCCTATAAAATATTTGGTAATATACGTTATAACATAAGTACAGATATAATACGCAAAATTGTTTTTGATAGTATAGCTGATGAGATTTATTTAATCGTGGAATACGGGTTTGCTAAAAGATTATTAAATACAAAACGCTCATTGGCATTATTTTTAATGGCAGAAGTTGATATTTCTATATTAAGTATGGTTCCAAGAGAATATTTTCATCCTAAACCTAAAGTGAATAGCTCACTTATCAGATTAAATAGAAAAAAATCAAGAATATCACACAAAGATAAACAGAAGTATAATTATTTCGTTATGAAATGGGTTAACAAAGAATACAAGAAAATATTTACAAAAAATCAATTTAACAATTCCTTAAAACATGCAGGAATTGACGATTTAAACAATATTAGCTTTGAACAATTCTTATCTCTTTTCAATAGCTATAAATTATTTAATAAGTAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2820,Drugs,MEG_2820|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,gi|695198047|ref|NG_034889.1|524-1258 gi|353127779|gb|JF968533.1|150-197,7
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGACATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCATTTAGATATGAGATAGAATTAAATTACTATTCGCCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1366,Drugs,MEG_1366|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_88_FKTX01000011,0
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttgggcggtacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgtttccggaccgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcatggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctggggcaatggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcagtgcccatgctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1615,Drugs,MEG_1615|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1028084259|WP_063843227.1|NG_047610|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_047610:101-733,6
,ATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGATAGGTTAATGACATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGGTGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAGATAGACAGATCGCTGAGATAGGTGGCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6869,Drugs,MEG_6869|Drugs|betalactams|Class_A_betalactamases|TEM,gi|114386383|gb|DQ834729.1|1-1066,0
,ATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGAAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACTTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCGATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTTCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGTAATCTGACGCTGGGTAAAGCATTGGGTGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAACGGTTTGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2422,Drugs,MEG_2422|Drugs|betalactams|Class_A_betalactamases|CTX,gi|695213670|ref|NG_036643.1|2087-2962 gi|695213667|ref|NG_036642.1|1115-1990 gi|16304817|emb|AJ416342.1|515-1390 gi|16304811|emb|AJ416340.1|595-1470 gi|933686806|gb|KT779550.1|2454-1581 gi|848613079|gb|KR494248.1|85037-84164 gi|822874760|gb|KM052220.1|32297-33170 gi|756791690|gb|KM377240.1|86734-87607 gi|756791559|gb|KM377239.1|98932-99805 gi|756791433|gb|KM377238.1|92102-91229,0
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaatgaaacccagagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaagcagataaaaaaattaatctgtatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttaccggttgggaaaaagacatgacactaggagaagccatgaagctttccgcagtcccagtctatcaggaacttgcgcgacgtatcggtcttgatctcatgcaaaaagaagtaaaacgtattggtttcggtaatgctgaaattggacagcaggttgataatttctggttggtagggccattaaaggttacgcctattcaagaggtagagtttgtttctcaattggcgcatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgcttcttttagaagagagtaatggctacaaaatttttggaaagaccggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcgcttttgcattaaatatggaaatgcggtcagaaatgcctgcatctatacgtaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4722,Drugs,MEG_4722|Drugs|betalactams|Class_D_betalactamases|OXA,736663066|WP_034670108.1|NG_064776|1|1|blaOXA-818|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-818 NG_064776:1-822,0
,ATGATGACAAAATCCCTAAGCTGTGCCCTGCTGCTCAGCGTCGCCAGCTCTGCATTCGCCGCACCGATGTCCGAAAAACAGCTGGCTGAGGTGGTGGAACGTACCGTTACGCCGCTGATGAACGCGCAGGCCATTCCGGGTATGGCGGTGGCGGTAATTTATCAGGGTCAGCCACACTACTTTACCTTCGGTAAAGCCGATGTTGCGGCGAACAAACCCGTCACCCCGCAAACCCTGTTTGAGCTGGGCTCTATAAGTAAAACCTTCACCGGCGTACTGGGCGGCGATGCCATTGCCCGGGGTGAAATAGCGCTGGGCGATCCGGTAGCAAAATACTGGCCTGAGCTCACGGGCAAGCAGTGGCAGGGCATTCGCATGCTGGATCTGGCAACCTACACCGCAGGCGGTCTGCCGTTACAGGTGCCGGATGAGGTCACGGATACCGCCTCTCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCGGGTACCACGCGTCTTTACGCTAACGCCAGCATCGGTCTTTTTGGTGCGCTGGCGGTTAAACCTTCCGGCATGAGCTATGAGCAGGCCATGACGACGCGGGTCTTTAAACCCCTCAAGCTGGACCATACCTGGATTAACGTCCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGATACCGTGAGGGTAAAGCGGTCCACGTTTCGCCAGGGATGCTGGACGCGGAAGCCTATGGCGTAAAAACTAACGTGAAGGATATGGCGAGCTGGCTGATAGCCAACATGAAGCCGGATTCTCTTCAGGCTCCCTCACTCAAGCAAGGCATTGCTCTGGCGCAGTCTCGCTACTGGCGCGTGGGGGCCATGTATCAGGGGTTGGGCTGGGAGATGCTCAACTGGCCGGTCGATGCCAAAACCGTCGTCGGAGGCAGTGATAACAAGGTGGCGCTGGCACCATTGCCCGTGGCAGAAGTGAATCCACCCGCGCCGCCGGTTAAGGCCTCCTGGGTCCATAAAACAGGCTCGACGGGTGGGTTTGGCAGCTACGTGGCATTTATTCCTGAAAAGCAGCTCGGCATTGTGATGCTGGCGAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCGTATCCTCGACGCGCTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3959,Drugs,MEG_3959|Drugs|betalactams|Class_C_betalactamases|MIR,gb|FJ237367|+|0-1146|ARO:3002173|MIR-8 [Klebsiella pneumoniae] ,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaaacacacgcatcgaacacgcttgtgaagctgccatgttgatgagcgacaacaccgccgcgaacttagtgttaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgctctattggcgacaaaacaacgcgacttgaccgattggagcctcgtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattcgctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1503,Drugs,MEG_1503|Drugs|betalactams|Class_A_betalactamases|CARB,646742063|WP_025577435.1|NG_050604|1|1|blaCARB-48|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-48 NG_050604:101-952,0
,atgaaaaaaatcgccattatttttggaggcaattcaccggaatacaccgtttctttagcctcagcaactagcgcaatcgaagcactccaatcatctccctatgactatgacctctctttgatcgggatcgccccagatgctatggattggtacttgtatacaggagaactggaaaacatccgacaagacacgtggttgttggatacgaaacataaacagaaaatccagccgctattcgaaggaaacggcttttggctaagtgaagagcagcaaacgttggtacctgatgttttatttcccattatgcatggcaaatatggggaagatggcagtatccaaggattgtttgaattgatgaagctgccttatgtaggttgcggggtggcaggttctgccttatgtatgaacaaatggctgctgcatcaagctgcagcagccattggcgtacaaagtgctcctacgattctcttgacaaatcaagccaaccagcaagaacaaatcgaagcttttatccagacccatggctttccagttttctttaagcctaatgaagcgggctcctcaaaagggatcactaaagtcacctgcgttgaagaaatcgcttctgccttaaaagaagcctttacttattgttccgcagtgctcctacaaaaaaatattgtcggtgttgagatcggttgcggtattttgggcaacgactctttgactgtcggtgcttgtgacgccatttcattagtagacggctttttcgattttgaagaaaagtaccagctgatcagcgccaaaatcaccgtccctgcgccattgcctgaaacgattgaaaccaaggtcaaagaacaagctcagctgctctatcgtagtcttggtcttaaaggtcttgctcgcatcgacttttttgtcacggatcaaggagaactatacttgaatgaaatcaatactatgccgggctttacgagtcactcccgctatcctgccatgatggcagcggtcggcttatcctatcaagaactactacaaaaactgcttgtcttagcaaaggaggaagtcaaatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7356,Drugs,MEG_7356|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,1028100546|WP_063856681.1|NG_048353|1|1|vanC2/3|vanC2/3|D-alanine--D-serine_ligase_VanC2/3 NG_048353:29-1081,5
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcgatcaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacttcaacccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_587,Drugs,MEG_587|Drugs|betalactams|Class_C_betalactamases|ADC,447133970|WP_001211226.1|NG_051494|1|1|blaADC-57|blaADC|class_C_beta-lactamase_ADC-57 NG_051494:1-1152,0
,ATGACCAACTACTTTGATAGCCCCTTCAAAGGCAAGCTGCTTTCTGAGCAAGTGAAGAACCCCAATATCAAAGTTGGGCGGTACAGCTATTACTCTGGCTACTATCATGGGCACTCATTCGATGACTGCGCACGGTATCTGTTTCCGGACCGTGATGACGTTGATAAGTTGATCATCGGTAGTTTCTGCTCTATCGGGAGTGGGGCTTCCTTTATCATGGCTGGCAATCAGGGGCATCGGTACGACTGGGCATCATCTTTCCCGTTCTTTTATATGCAGGAAGAACCTGCATTCTCAAGCGCACTCGATGCCTTCCAAAAAGCAGGTAATACTGTCATTGGCAATGACGTTTGGATCGGCTCTGAGGCAATGGTCATGCCCGGAATCAAGATCGGGCACGGTGCGGTGATAGGCAGCCGCTCGTTGGTGACAAAAGATGTGGGGCACTGTTGCAAAGTTAGCGATGAGGCAGCCTTTTGTCTTATTCAAAGGCCTTACATTTCAAAAACTCTGCTTACCAGGCGCATTTCGCCCAGGGGATCACCATAA,chloramphenicol acetyltransferase (CAT),antibiotic inactivation,Phenicol,MEG_1620,Drugs,MEG_1620|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB,(Phe)CatB4:EU935739:59054-59602:549,6
,atgttaaaagttattagtagtttattggtctacatgaccgcgtctgtcatggctgtcgcaagtccgttagcccattccggggagccgagtggtgagtatccgacagtcaacgaaattccggtcggagaggtccgactttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcggtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgaaaagcaaattggacttcccgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggcagaggggaacgagattcccacgcattctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagagctcttctatcctggtgctgcgcattcgaccgacaatctggttgtatacgtcccgtcagcgaacgtgctatacggtggttgtgccgttcgtgagttgtcaagcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccgttgagcggattcaaaaacactacccggaagcagaggtcgtcattcccgggcacggtctaccgggcggtctagacttgctccagcacacagcgaacgttgtcaaagcacacaaaaatcgctcagtcgccgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7701,Drugs,MEG_7701|Drugs|betalactams|Class_B_betalactamases|VIM,1226997330|WP_094009807.1|NG_055489|1|1|blaVIM-52|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-52 NG_055489:1-801,0
,TGACGGGCCCGGACACCTTTTTGCTTTTAATTACGGAACTGATTTCATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTGAC,beta-lactamase,antibiotic inactivation,betalactams,MEG_1980,Drugs,MEG_1980|Drugs|betalactams|Class_C_betalactamases|CMY,gi|53854915|gb|AY743434.1|1-1203,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcttccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaatggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgagaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacgcgtatcgaacacgcttgtgaagccgccatgttgatgagcgacaacaccgccgcaaacttagtgctaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgctctattggcgacaaagcaacgcgacttgaccgattggagccccgtttgaacgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctaccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatttggaaagacaactacaagccggtttacatcagtatttacgtcacagatactgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1517,Drugs,MEG_1517|Drugs|betalactams|Class_A_betalactamases|CARB,647047270|WP_025632811.1|NG_048724|1|1|blaCARB-21|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-21 NG_048724:101-952,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcgacctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5639,Drugs,MEG_5639|Drugs|betalactams|Class_C_betalactamases|PDC,1300152706|WP_100831609.1|NG_056400|1|1|blaPDC-245|blaPDC|class_C_beta-lactamase_PDC-245 NG_056400:1-1194,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttagacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4400,Drugs,MEG_4400|Drugs|betalactams|Class_D_betalactamases|OXA,488879085|WP_002791310.1|NG_049769|1|1|blaOXA-489|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-489 NG_049769:101-874,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacaaagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_790,Drugs,MEG_790|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502104|WP_071846256.1|NG_052287|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052287:101-892,2
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaccggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacagttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1829,Drugs,MEG_1829|Drugs|betalactams|Class_C_betalactamases|CMY,1132963064|WP_075985684.1|NG_052649|1|1|blaCMY-145|blaCMY|class_C_beta-lactamase_CMY-145 NG_052649:1-1146,0
,atgactacaaccaacgagatcagggtcgcggaggtagcggacgcgggggtcgtcgcaaagctattgcgcgatttcaacacagagtttgataccccggttcccgaaggccttgaggagcggtttgcgcagatcatcgcacacgacgacgccttcgttctcctcgccggcgatattggtttcgcctacgtcaccctgcgcccgagcccgtattacgacgggccggtggcgatgctcgacgagctctacgtcgcacctgcccaccgcaatcgcggggtcggcacggcgctgctgcagcgggtcttcgaggagatccgcaagcacagcgccggcgaattacaaatcaacgtcgacgaggtagacaccgatgcgcgccgcttttacgaacgccacggcctgaccaacatcgagcaaggctcccgcatgctgctctacatccgggagctttag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_42,Drugs,MEG_42|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,805306315|WP_046095284.1|NG_050595|1|1|aac(3)-XI|aac(3)-XI|aminoglycoside_N-acetyltransferase_AAC(3)-XI NG_050595:101-547,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggcgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5664,Drugs,MEG_5664|Drugs|betalactams|Class_C_betalactamases|PDC,1343491243|WP_104009859.1|NG_056422|1|1|blaPDC-230|blaPDC|class_C_beta-lactamase_PDC-230 NG_056422:1-1194,0
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttgggcggtacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgtttccggaccgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcatggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctgaggcaatggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaacgcccatgctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1613,Drugs,MEG_1613|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1028084258|WP_063843226.1|NG_047609|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_047609:101-733,6
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATAGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6688,Drugs,MEG_6688|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-129:AY452662:184-1044:861,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatgataatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4390,Drugs,MEG_4390|Drugs|betalactams|Class_D_betalactamases|OXA,1391852905|WP_109545090.1|NG_057524|1|1|blaOXA-586|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-586 NG_057524:1-774,0
,TTAATTTTCTTTTTTATTAAACATATGGCGTACTTTATCTATTCGATTATTTGGTCTGCGTGATTGAATAACTGGTTCACAAGTAGCAATTTGATAATCTTTTAATTCTGTCAAAAAAACTGCTTGCCCATTTGTATATAGAGTTAAAGTATTACGATATTCATTAATACAACGTGCAGGAATATGTCCTGTAAAAATAACTTCATCATTTTTTGATTGACTTGTTTCAATTATTGCACAATGTTTTTGTGCATCATTATATGCACGAGAAAAGTATTCCTGTGGTGTAAAAAGTATAAACGAAAGATATGGCTCTAATAATTGCGTTCCCGCTTTTTTCAATGTTTGTTCAAGTACAATTGGGGCAAGAAAGCGAAAATCCGAGGGAGTACTAACAGGGCTATAATAAACACCATATTCAAAACATATTTTACAATCTGTCACTTTCCAACCATACAATCCTTGCTCCAGTCCATAATTAATACCTTCTCTTACTGCATTTTGGAAACTTTGATTTAAATAACCGAGTGAAACTTTGCTTTCGTACTGTATTCCACTGCCAATTGGAAGTGGAGTTATTGATAATCCAATTGATGCCCAAAATGGATTTGGTGGTACTTCAATATGAATAGTATAATCTGCCTTTTGTAATGGCTTTTCCAAATAAATTACGGTTGGATCTTCGATTCTTATGTTTATGTGATATTTTTCAATCAACAGAGAACAGATAACTTCTAACTGCACTGTTCCTAAAAAAGAAATGATGATTTCATGTGTTATCGTATCAACATAATAACGTAAAAGAGGATCAGTATCTGCAATTTCTGTAAGAGCATCCAATAATTTTTCTCTCTCTTCTATTTTTATCGGTTCAATTCTTGTTCGTAGTATTGGTGCAGTATTGTCATTCCATACATTGCATGGCAAAATCTTTTCATTTCCTATAATATCGTTCAATCTTAATGTATTGTTAGGTATAATAAAAATATCTCCAGAACAAACTATTTTTGTCTGTATCATTTCCCCATTTGAAGGAATATATATTTCTGTAAGTTTCACTTTCTTTTTTTCTGGCAATATAATTGTATCTCGTAAGTGTAATGTTCCACTGTAAAGACGCAAATAAACTAATCTTTGCTTATGGTCTGTATATTCAATTTTAAAAACTCTTCCACATAGTTCTGAACCATTCTCATTCATTTCAGAACAAAAAAGATTTGAAATAGCTTCAATGAGTTGTTGAGTCCCTATATTATTTCTAGCACTTCCATGGTATATAGGAAACAACGAACCTTTTTTAACACACCTATATTCTTCATACGTTAATTCCTGTATAGTCAATTTTTCTCCTGCAATATATTTTTTTAAAAGTTTATCATTTCTGGAAATTACAGGATCCCAATCATCTAAATCAATAATATTTTTAATTGATATTTCTGGAGTTAATGTTACATTTTGCATAACAATAATATCATTTGAAAGTTTTTCTTTGATATTTTGATAAATATTATTTAAGTTAATTCCATCCTGATCTATTTTATTTATAAAAATAATTGTTGGTATATTCATTTTTTGAAGTGCATGGAATAGTATTCGAGTTTGTGCTTGTACACCATCTTTAGCAGAAATTACTAAAATAGCTCCATCAAGAACAGATAAGGAACGATACACTTCTGTTATAAAATCTGTATGTCCAGGAGTATCTACAATATTGATTTTGTAGTCATTCCAATTAAAAGAAGTAACTGCTGCCTGAATTGTGATTCCACGCTGACGTTCTAAAAACATAGTATCTGTCCTTGTTGTTCCCTTATCTACACTGCCTAATTCTAAAATCGCTCCACTTGTATAAAGTAGACTTTCCGTTAAGGTCGTCTTTCCTGCATCTACATGAGCAAGAATACCAATGTTGATTATTTTCAT,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_6998,Drugs,MEG_6998|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TET44,tet(44)_1_NZ_ABDU01000081,4
,GCTGCTGATCGTGGGTCTCGACGCCATGGGACTCGGCCTCATCATGCCGGTCCTTCCGGCGCTTCTGCGCGAGCTTGTGCCGGCGGAGCAGGTCGCTGGTCACTATGGTGCTTTGCTGTCACTCTATGCGTTGATGCAGGTCATCTTCGCGCCCGTGCTTGGACAGTTTTCAGATGCTTACGGTCGGCGTCCGGTGCTTCTGGCTTCTCTTGCGGGGGCCGCAGTCGATTACACGATTATGGCATCAGCGCCGGTCTTATGGGTTCTCTATATCGGCCGAATCGTTTCCGGCGTCACGGGAGCAACCGGAGCCGTAGCAGCCTCAACCATTGCCGATTCGACGGGGGAAGGTTCTCGCGCACGCTGGTTCGGCTACATGGGGGCCTGTTATGGAGCAGGCATGATTGCCGGGCCAGCACTTTGTGGCATGCTCGGTGGTATTTCTGCCCATGCTCCGTTTATCGCTGCTGCCCTTCTCAACGGCTTCGCGTTCCTGCTTGCCTACATTTTTCTCAAGGAGACTCATCACAGCCATGGCGGGACCCGAAAGCCGGTTCGCATCAAACCATTCGTTCTGTTCCGGCTGGATGATACATTGCGCGGGCTAGGTGCGCTTTTCGCAGTTTTCTTCATTATTCAACTGATCGGCCAAGTGCCTGCAGCCCTATGGGTCATCTATGGCGAGGACCGTTTTCAGTGGGACACCACGACTGTTGGTTTGTCGCTCGCGGCATTTGGAGCAACACACGCGATCTTCCAAGCGTTTGTTACCGGTCCGCTTTCAAGCCGGCTTGGAGAGCGGCGCACGCTACTCTTTGGCATGGCTGCGGATGCGACTGGCTTCATTCTTCTGGCTTTTGCCACGCAGGGATGGATGGTGTTCCCGATTTTGTTGCTGCTTGCCGCCGGAGGTGTTGGCATGCCGGCCTTGCAGGCAATGCTTTCAAATAATGTCAGCGGTAACAAGCAAGGAGCTTTACAGGGAACGCTTACAAGCCTCACCAATTTAAGTTCTATCGCAGGACCGCTTGGCTTCACGGCACTCTATTCTGCCACCGCCGGAGCATGGAACGGTTGGGTTTGGATTGTCGGCGCGATCCTCTATTTAATATGTCTGCCAATACTACGCAGACCATTCGCA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7079,Drugs,MEG_7079|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETG,gi|15027120|emb|AJ276217.1|1-1140,4
,AAGGTCAAAATCAAACGGCCTTTAGTATATCTCGGCTAAAGCCATTGCTGACTGTACACCTGATACCTATATAACGGCTTGTCTAGCCGCGGCCTTAGAGAGCACTCATCTTGAGTTTAGCTTCCTACTTAGATGCTTTCAGCAGTTATCTATCCATGCGTAGCTACCCAGCGTTTCCCATTGGAATGAGAACTGGTACACAATTGGCATGTCCTTTCAGGTCCTCTCGTACTATGAAAGGCTACTCTCAATGCTCTAACGCCTACACCGGATATGGACCAAACTGTCTCACGCATGAAATTTTAAAGCCGAATAAAACTTGCGGTCTTTAAAACTAACCCCTTTACTTTCGTAAAGGCATGGACTATGTCTTCATCCTGCTACTGTTAATGGCAGGAGTCGGCGTATTATACTTTCCCACTCTCGAGAAAATATCCTATAAATCGAGCAACAATAAATAAATTGTATGTAAACATTCTTTTAGAGATTGGCTAAATTTATAAAGTCTCTACGGGGACGATTTCTTTTTTTCACTTAAACTGTCTAGCACAGCACGAACGGTTTCAGAAGTTGTTTTACGCGTCTTCGAATCATTCAGAGCTGCAATTTGATCCACCCATGTACAAACTTCTAAGAATTTGTCCGGGGATTCTTTTGCTGACGGAAGCCGCCAAATAATTTTTAAAACTAAATTTGCTTGTTTTTGTTTTAGTTTTAGAAAAGGTTGTAGTTGTGTTAAAAAATTATGCAAAGGCTTGATTTCGCTTAGAATATAATCCGAAACGCTACCCCTATCTCTTACATAACCAACCCCAATTTCATCCACTAATTTGTCTAAAAACCAACGTCTCTGTGTCTTTTGCGTGACTTGGAACGCGAGTGATAGCTGATGCTTAAATTTATAAGACTGATTAGGCTTAATTTGAGCGATTATGCTACCGTCACCGTCTACAAACCCTGCTAAGTAGAGTAAGAACTCTTTATTATATTTTGTATTCATAAGATGTTTTATTTAATTTATTGAATTATTAAACCAAAAAGAAATGGTCTTCCCTCGGCGTTGCCATCTATTGCCCACGAATGTGGTTTATGCGACAGTTTGTACTTAAAACAATAGGAAGGTTTCACCGATATAAGCCGATACTTTGCTTACATTACTGCAAGCACACGCAGTGTTATTTACGTTTTGAACCCAGCTCACGTACCACTTTAATGGGCGAACAGCCCAACCCTTCGGACCTACTACAGACCGAGGATGTGATGAGCCGACATCGAGGTGCCAAACCTTCCCGTCGATGTGAACTCTTGGGGAAGATCAGCCTGTTATCCCTAGAGTAACTTTTATCCGTTGAGCGACGGCCCTTCCACGCGGCACCGTCGGATCACTAAGGCCGGCTTTCGCCCCTGCTCGACTTGTAGGTCTTGCAGTCAAGCTCCCTTTTGCCTTTACACTCAATGTCTGATTTCCGTCCAGACTGAGGGAACCTTTGCACGCCTCCGTTACCTTTTAGGAGGCATTCGCCCCAAATAAACTGCCCACCTGAAACTGTCAAGGGTCCTGATTCAAGGATCCCCATTAGGATTCTAGCTCTTCCAGAGTGGTCTCTCAATGACGGCTCTAATTACCCCGGAAGGTAATCTTCATAGCCTCCCACCTAGGCTGCGCAAGAAAAGCCCAAACCCAATTCCAAGATACAGTCAAGCTTCATAGGGTCTTTCTGTCCAGGTGTAGGTAGTCCGCATCTTCACGGGACAAGTCTATTTCACCGAGCCTCTCTCCGAGACAGCGCCCAGATCGTTACGCCTTTCGTGCAGGTCGAAACTTACTCGACAATGAATTTCGCTACCTTAGGATCGTTATAGTTACGACCGCCGTTCACCGGGGCTTCGGTCGTCAGCTTTTTTCTTACGAAATAACCAACTTCCTTAACCTTCCGGCACTGGGCAGGCGTCAGCCCCCATATATTGTCTTACGACTTTGCGGAGACCTGTGTTTTTGGTAAACAGTCGCCTGGGCCTGGTCACTGCGACCCACCTTGTTACGGATGGGTGCCCCTTCTTCCGAAGTTACGGGGCCAGTTTGCCGAGTTCCTTAGAGAGAGTTCTCTCGCGCCCCTTGGTATTCTCTACCAACCTACCTGTGTCGGTTTCAGGTACAGGTCATTAAATTATAAAGATGTATGAGCTTTTCTTGGAAGTATGACATCACTAGCTACTCGACGGCGAACCATCAAATAGGGATCACGTCTCCACTCAAGATAGCTTTTTTTCTATCTCTCAACGTCTAAACGCTTCCACTGCAATCCAAAAACAGTTCTAGCTTAGCCTCCTTCGTCCCTCAGATCATAATTTAACTCGTACAGGAATATTAACCTGTTTTCCATCGACGACGCCGTTTGGCCTAGTCTTAGGTCCTGACTAACCCCCCATGGACGAACCTAGTGGAGGAACCCTTAGGTTTTCGGGGCATTGGATTCTCACCAATGTTTTCGTTACTCAAGCCGACATTCTCACTTCCGCTTCGTCCATCCCCACTTACGTGAAAACTTCACCCGAGAGCGGAACGCTCCCCTACCTATAATTTATATAATAAATTATATCACAGCTTCGGCAGGTCACTTAGTCCCGGCCATTATCGGCGCAAGAACGCTTTACCAGTGAGCTATTACGCACTCTTTGAAGGGTGGCTGCTTCTAAGCAAACCTCCTGGTTGTTTCAGCATTCTCACATCCTTTTCCACTTAGTGACCATTTAGGGGCCTTAGCTGGTGATCTGGGCTGTTTCCCTCTTGACAATGAAGCTTATCCCCCACTGTCTCACTGGTTTACGGAAGACATGTCTTGTATTCTGAGTTTGCCACGACTTGGTACCGCTTTCGCAGCCCGCATCGAAACAGTAGCTTTACCCCAAGACAGTTCATCGTTACCGCTGCGCCTCAACGCATTTCGGGGAGATCCAGCTAGCTCCGAGTTCGATTGGAATTTCTCCCCTATTCACAGCTCATCCGCCGATTTTTCAACATCGGTCGGTTCGGACCTCCACTTGGTGTTACCCAAGCTTCATCCTGGCCATGAATAGATCACCCGGGTTCGGGTCCATAAGAAGTGACCATTTGCGCCCTATTCAGACTCGCTTTCGCTTGGGCTCCGGATTTTACTCCTTAACCCAGCCACTCCCTATAAGTCGCCGGCTCATTCTTCAACAGGCACGCGGTCACAAGCATTCTTGCTCCCACTGCTTGTCAGCATACGGTTTCATGTTCTATTTCACTCCCCAACAGGGGTTCTTTTCACCTTTCCCTCGTGGTACTATTTCGCTATCGGTCACTCAGGAGTATTTAGCCTTACGAGGTGGTCCTCGCTGATTCACACGGGATTTCACGTGCCCCATGCTACTCGGGATT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3981,Drugs,MEG_3981|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NC_005353.1|-|148590-151993|ARO:3004132|Chlamydomonas reinhardtii 23S rRNA with mutation conferring resistance to Erythromycin [Chlamydomonas reinhardtii] ,7
,atgaaaggaccaataataatgactagagaagaaagaatgaagattgttcatgaaattaaggaacgaatattggataaatatggggatgatgttaaggcaattggtgtttatggctctcttggtcgtcagactgatgggccctattcggatattgagatgatgtgtgttctgtcaacagagggagtagagttcagctatgaatggacaaccggtgagtggaaggcggaagtgaatttttatagcgaagagattctactagattatgcatctcgggtggaaccggattggccgcttacacatggtcgatttttctctattttgccgatttatgatccaggtggatactttgagaaagtgtaccaaactgctaaatcggtagaagcccaaaagttccacgatgcgatctgtgcccttatcgtagaagagctgtttgaatatgcaggcaaatggcgtaatattcgtgtgcaaggaccgacaacatttctaccatccttgactgtacaggtggcaatggcaggtgccatgttgattggtctgcatcatcgcatctgttatacgacgagcgcttcggtcttaactgaagcagttaagcaaccagatcttcctccaggttatgtccaactgtgccagctcgtaatgtctggtcaactttccgaccctgagaaacttctggaatcgctagagaatttctggaatggggttcaggagtgggcggaacgacacggatatatagtggatgtgtcaaaacgcataccattttga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_976,Drugs,MEG_976|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT4-PRIME,1028081078|WP_063840461.1|NG_047376|1|1|ant(4')-Ia|ant(4')-Ia|aminoglycoside_O-nucleotidyltransferase_ANT(4')-Ia NG_047376:1-762,2
,atgtcactgtatcgccatctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3462,Drugs,MEG_3462|Drugs|betalactams|Class_A_betalactamases|KPC,1188444897|WP_085562399.1|NG_054685|1|1|blaKPC-30|blaKPC|inhibitor-resistant_carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-30 NG_054685:1-882,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACTCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCAGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1999,Drugs,MEG_1999|Drugs|betalactams|Class_C_betalactamases|CMY,gi|846280687|gb|KR091911.1|139124-137979 gi|514883893|gb|JX442976.1|90905-92050 gi|269799027|gb|FJ855437.1|1772-2917,0
,ATGCTAAATTTAACCGTTTGTCAGGCACAGTCAAATCCAACAGACTACGCCTGTCTGACGGGCCCGGACATCCCCTTGACTCGCTATTACGGAAGATTACTGATGATGAAAAAATCTCTTTGCTGCGCCCTGCTGCTCGGCATCTCTTGCTCTGCTCTCGCCGCGCCAGTGTCAGAAAAACAGCTGGCGGAGGTGGTCGCGAATACGATTACCCCGCTGATGAAAGCCCAGTCGATTCCAGGCATGGCGGTGGCCGTTATTTATCAGGGTAAACCGCACTATTATACGTTTGGCAAAGCCGATATCGCGGCCAGCAAACCCGTTACGCCTCAGACTCTGTTCGAGCTGGGTTCTATAAGTAAAACCTTCACCGGGGTTTTAGGAGGGGATGCCATTGCTCGCGGTGAAATTTCGCTGGACGATCCGGTGACCAGATACTGGCCACAGCTGACGGGCAAGCAGTGGCAGGGGATTCGTATGCTGGATCTCGCAACCTACACCGCTGGCGGCCTGCCGCTACAGGTACCGGATGAGGTCACGGATAATGCCGCCCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCTGGCACAACGCGTCTTTACGCCAACGCCAGTATCGGTCTTTTTGGCGCGCTGGCGGTCAAACCTTCCGGCATGGGCTATGAGCAGGCCATGACGACGCGGGTCCTTAAGCCGCTCAAGCTGGACCATACCTGGATTAACGTTCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGCTATCGTGACGGTAAAGCGGTGCGCGTTTCGCCGGGAATGCTGGATGCACAAGCCTATGGCGTGAAAACCAACGTGCAGGATATGGCGAACTGGGTCATGGCAAACATGGCGCCGGAGAACGTTGCTGATGCCTCACTTAAGCAGGGCATCTCGCTGGCGCAGTCGCGCTACTGGCGTATCGGGTCAATGTATCAGGGTCTGGGCTGGGAGATGCTCAACTGGCCCGTGGAGGCCAACACGGTGATCGACGGCAGCGACAGTAAGGTGGCGCTGGCACCGCTGCCCGTGGCAGAAGTGAATCCACCGGCTCCCCCGGTCAAAGCGTCCTGGGTCCATAAAACGGGCTCTACTGGCGGGTTTGGCAGCTACGTGGCCTTTATTCCTGAAAAGCAGATCGGTATTGTGATGCTCGCGAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCATATCCTCGACGCGCTACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_489,Drugs,MEG_489|Drugs|betalactams|Class_C_betalactamases|ACT,gi|591542927|gb|KJ207207.1|378-1625 gi|666667507|gb|KJ949089.1|1-1146,0
,GTGGACATCGAGGTCGAACGGGGCCGGGTGCTCGGGCTGCTGGGTCACAACGGGGCCGGCAAGACGACCTTGGTGAACATCCTTGCCACGGTCTCCCCGGCGTCCGCGGGCACGGTGACCGTCGCCGGTTTCGACGTCGCGACGCAGGGCGCCGAGATCCGCGCGCGCATCGGGGTGACCGGCCAGTTCGCGTCGGTGGACGAGTACCTGAGCGGATTCCGCAACCTCGTCCTGATCGGCCGCCTCCTCGGGGCGGGACGGCGTGAGGCGGCGGCCCGGGCCACCGAGCTCCTGGAGCTGTTCGAGCTGACCGGGGCGGCCCACCAGCCCTCCCGCACCTACTCGGGCGGGATGCGCCGACGGCTCGACCTCGCCGCCAGCCTGGTCGGCCGGCCGGACGTGCTGTTCCTCGACGAGCCGACGACCGGGCTGGACCCGGCGACCCGGATCGCCCTGTGGGAGACGGTGGAGAAGCTGGTGGCGGGCGGCACGACCGTCCTGCTGACCACCCAGTACCTGGACGAGGCGGACCGGCTGGCCGACTGGATCACCGTCCTGTCGAAGGGCCGGGTGGTGGCCTCGGACACCACCGACCGGCTCAAGGCCGACCTGGGCCACCGGTCGGTGCGGGTGGTCCTTCCGCCCGCCGCCGACCTGACGGCCGCCGCCGCCGCGCTCACCGCCGGCGGGTTCCGTCCGCGGTCCGACGCCGGGGAGCACGCGCTGACCACGCCCGTGGACACCTCGGCCGGTATCGCGGGCGTCATCCGCGCGCTGGACACCGTCGGAACGCAGGCCGTCGAGCTGACCGTCAAGGAGCCGTCCCTGGACGACGTCTACCTGGCGCTCACCCATCCCTCACCCGCCGCCGACGCGGCCTGA,ATP-binding cassette (ABC) antibiotic efflux pump,antibiotic efflux,Multi-drug_resistance,MEG_2670,Drugs,MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA,gi|917646380|gb|CP012382.1|6061034-6060153 gi|159232381|emb|AM709783.1|1007-1888,1
,ATGGTTAATAAACTTTCAGCATATAAAACTTATTTATTATTTTCAGCTATTGCAGCAATGTGTTTTTCGTTAGTAGCTACAGTTATGGTAGTGTATCACATTGAAATAGTTCATTTAAATCCACTTCAACTTATACTTGTTGGAACTACTTTGGAATTAGCATGCTTTATATTTGAAATTCCTACAGGTATAGTTGCAGATGTGTATAGTCGTAAACTATCTATTGTTATTGGGGGAGTTTTAACAGGAGTGGGATTTATTTTAGAAGGTTCTATTTCTAGTTTTGTTTTCGTACTTGTAGCACAGATTGTATGGGGATTAGGGTCTACTTTTATCAGTGGCTCGCTTGAAGCTTGGATTGCGGAAGAAGAGAAGAATAAAGATTTAGATGAAATTTATATAAAGGGAGCACAAGCAGGGCAGATAGGAGCATTTATTGGAATAGTACTAAGCACTGTAATAGCTAATTTCTCTGTAAGGCTTCCTATTATAGTTAGTGGAGTTTTATTTATAATTCTTGCATTATTTTTATGGTTATATATGCCAGAAAATAATTTTAAACCATCTGCTCCTGGGGATTTAAATACATTCAAAAAGATGGTATATACATTTAAATCTGGTCTTAAAATTGTAAAAAGTAAATCTATAATTATGATTTTACTTGCAGTAACTTTATTTTATGGATTATCAAGTGAAGGTTATGATAGACTTTCTAATGCGCATTTTTTACAAGATACTACACTTCCTAAGCTTGGAAACCTTAGTTCAGTGACTTGGTTTGGAATTTTTGGAATTTTAGGAATGATATTGAGCTTCATAGTAATGCATTTTATGGCAAAGAATCTTAAGAATGAGGATAATAGGAAAAATGGAAAACTATTATTATGTATAAATATACTTTATATATCGTCTATGTTGATATTTGCTCTTACAAAAAACTTTAGTTTAATGTTAATAGCTTATTTGGCAACAAATACCTTTAGAATTATAAATGAACCTATATTCAGTGCGTGGTTAAATGGGCATATAGATGATAACTCTAGAGCTACTGTACTTTCTATAAATGGACAAATGAATTCCTTAGGTCAAATTTTAGGTGGACCAATTATAGGAATCATAGCTACAAATATTTCAGTAAGTATTGGTATAGCATGTACTTCGTTATTAGTAACACCGGTATTAGTGTTATATATTGTTGCTATGATAATTGATAAAAAGGTGGATGATAGAGTTGGAGGTATTGATTATGAAGAAAATAATTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7027,Drugs,MEG_7027|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,gi|16904629|dbj|AB054980.1|1-1263,4
,ATGATGAAAGGTTGGATAAAGTGCACATTGGCCGGGGCCGTGGTGCTGATGGCGAGTTTCTGGGGTGGCAGCGTGCGGGCGGCGGGGATCTCCCTCAAGCAGGTAAGCGGCCCGGTTTATGTTGTTGAAGATAACTACTACGTAAAGGAAAACTCCATGGTCTATTTCGGGGCCAAGGGGGTGACTGTGGTGGGGGCGACCTGGACGCCGGATACCGCCCGCGAGCTGCACAAGCTGATCAAACGGGTCAGCAGCAAGCCGGTGCTGGAGGTGATCAACACCAACTACCACACCGATCGGGCGGGCGGTAACGCCTACTGGAAGTCCATCGGGGCCAAGGTGGTGGCGACGCGCCAGACCTGGGATCTGATGAAGAGCGATTGGGCCGAGATTGTCGCCTTTACCCGCAAGGGGCTGCCGGAGTATCCGGATCTGCCGCTGGTGCTGCCCAACGTGGTGCACGATGGTGACTTCACGCTGCAAGAGGGCAAGGTGCGCGCCTTCTTCGCGGGCCCGGCCCACACGCCAGACGGCATCTTTGTCTACTTCCCCGACGAGCAGGTGCTCTATGGCAACTGCATCCTCAAGGAGAAGCTGGGCAACCTGAGCTTTGCCAATGTGAAGGCCTATCCGCAGACCATCGAACGGCTCAAAGCGATGAAGCTGCCGATCAAGACGGTGGTCGGCGGCCACGACTCCCCGCTGCACGGCCCCGAGCTGATTGATCACTACGAAGCGCTGATCAAGGCAAGCCCTCATTCATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2098,Drugs,MEG_2098|Drugs|betalactams|Class_B_betalactamases|CPHA,(Bla)cphA:AY261378:1-765:765,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6475,Drugs,MEG_6475|Drugs|betalactams|Class_A_betalactamases|SHV,gi|695214134|ref|NG_036739.1|1-861 gi|77702553|gb|DQ219477.1|1-861 gi|695198780|ref|NG_035078.1|451-1311,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTTACAGCCTCATTCTCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACAGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTACTCCTGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAACGTTACCGATATGGCCCGTTGGATTCAGGTCAACATGGATGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAAGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCACCCCGGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTGACGATGAGGCCCAGGATATTGGGCCTCCTTTCTTTCTCTTTTTTTCCTGTTGTCATCTACACTTAACAAAAATACAGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1997,Drugs,MEG_1997|Drugs|betalactams|Class_C_betalactamases|CMY,gi|753186447|gb|KM983294.1|1051-2279,0
,atggaaaatggttttttgtttttagatgaaatgttgcatggcgtccgttgggatgccaagtacgccacatgggataacttcacaggaaaaccggtggatgggtatgaggtgaatcgcatcatcggcacaaaggccgtggcgtttgctctgcgcgaggcacaaatccatgcggcacgccttggctatggcttgcttttatgggatggatatcggccaaaatctgcggtggactgtttcctgcgttgggcggcgcagccggaggacaacctcacaaaagaaaaatattaccccaatattgagcgagccgagttgattacaaagggctatgtggcctcacaatccagccatagccgtggaagcacaattgatcttacgctctaccacttggatacaggggaacttgtttcaatgggaagcaacttcgattttatggacgaacggtcgcaccatacagcaaaagggatagggaatgcagaggcacaaaatcgaagatgcttgcgtaaaatcatggaaagcagcggatttcagtcctatcgctttgaatggtggcactataagttgattgatgagccataccccgatacctattttaattttgccgtttcataa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7558,Drugs,MEG_7558|Drugs|Glycopeptides|VanB-type_resistance_protein|VANXB,1028100636|WP_063856771.1|NG_048484|1|1|vanX-B|vanX-B|D-Ala-D-Ala_dipeptidase_VanX-B NG_048484:101-709,5
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGGCATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATTGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1421,Drugs,MEG_1421|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_56_NZ_JUMU01000089,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccagcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5654,Drugs,MEG_5654|Drugs|betalactams|Class_C_betalactamases|PDC,1393270451|WP_109791196.1|NG_057594|1|1|blaPDC-262|blaPDC|class_C_beta-lactamase_PDC-262 NG_057594:1-1194,0
,atgagaaattttgttatactgtttttcatgttcatttgcttgggcttgaatgctcaggtagtaaaagaacctgaaaatatgcccaaagaatggaaccagacttatgaacccttcagaattgcaggtaatttatattacgtaggaacctatgatttggcttcttaccttattgtgacagacaaaggcaatattctcattaatacaggaacggcagaatcgcttccaataataaaagcaaatatccaaaagctcgggtttaattataaagacattaagatcttgctgcttactcaggctcactacgaccatacaggtgcattacaagatcttaaaacagaaaccgctgcaaaattctatgccgataaagaagatgctgatgtcctgagaacaggggggaagtccgattatgaaatgggaaaatatggtgtgacatttaaacctgttactccggataaaacattgaaagatcaggataaaataaaactgggaaatacaatcctgactttgcttcatcatcccggacatacaaaaggttcctgtagttttatttttgaaacaaaagacgagaagagaaaatatagagttttgatagctaatatgccctccgttattgttgataagaaattttctgaagttaccgcatatccaaatattcagtccgattatgcatatactttcaaagcaatgaagaatctagattttgacctttgggtggcatcacatgcaagtcagttcgatctgcatgaaaaacgtaaagaaggagatccgtacaatccgcaattgtttatggataagcaaagctatttccaaaaccttaatgatttggaaaaaagctatctcaacaaaataaaaaaagattcccaagataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3146,Drugs,MEG_3146|Drugs|betalactams|Class_B_betalactamases|GOB,895951660|WP_049037557.1|NG_050654|1|1|blaGOB-5|blaGOB|subclass_B3_metallo-beta-lactamase_GOB-5 NG_050654:101-973,0
,GTGTCATCCGCAAATCCGGGCCCGGCGGGCACGGCGGACCAGGCAGGCGGGGCGTTCACGCATCGGCAGATCCTGACGGCCABGTCGGGACTGCTGCTGGCCGTGTTCCTCGCGGCCCTGGACCAGACGGTCATCGCCACCGCGATGCGCACCATCGCGGACGACCTCCACGGCCAGACCGAGCAGGCATGGGCGACGACGGGCTACCTCATCGCCTCCGTCCTGGCGATGCCGTTCTACGGCAAGCTGTCCGACATCTACGGGCGCAAGCCCATGTACCTGATCTCCATCGTGGTGTTCATCGGCGGCTCGGTGCTGTGCGGCACGGCCGGCTCGATGTGGGAGCTGGCCCTCTTCCGGGCCGTCCAGGGACTGGGCGGCGGCGGGCTGATGTCCCTGCCCACCGCGGTGGTCGCCGACCTCGCCCCGGTGCGCGAGCGCGGCCGCTACTTCGCCTTCCTCCAGATGGCGTGGGTGGTCGCCAGCGTCGCGGGCCCGCTGGCGGGCGGCTTCTTCGCGGAGGCGGGCCAGGTCTTCGGCATCGACGGCTGGCGCTGGGTGTTCCTGCTCAACGTACCGCTGGGCCTGCTGGCCCTGGTCACCGTGCGCAAGGCCCTGAACCTGCCGCACGAACGGCGCGAGCACCGCATGGACGTACTGGGCGCGGCGGCGCTGGCGCTGTTCCTGGTGCCCCTGCTGATCGTCGCCGAACAGGGCCGGACCTGGGGCTGGGGCTCGCCGGCCGCCCTCGCCCTCTTCGCGCTCGGCGCGGCCGGGCTGGCGGTCTTCATCCCCGTCGAGCTGCGGCGCGGCGACGAGGCCATCCTGCCGCTGGGGCTCTTCCGGCGCGGCAGCATCGCGCTGTGCTCCGCGGTCAACTTCACCATCGGCGTCGGCATCTTCGGCACGGTCACCACCCTGCCGCTGTTCCTCCAGATGGTGCAGGGGCGGACCCCGACCCAGGCCGGACTGGTGGTCATCCCGTTCATGCTGGGCACCATCGCCTCGCAGATGGTCTCCGGCAAGCTCATCGCGTCCTCGGGCCGGTTCAAGAAACTGGCGATCGTGGGCCTGGGCTCGATGGCCGGGGCGCTGCTGGCCATGGCCACCACCGGCGCGACGACCCCGATGTGGGGCATCGTCCTGATCGTCCTCTGGCTCGGCGTCGGCATCGGCCTGTCCCAGACCGTCATCACCTCGCCCATGCAGAACTCGGCCCCCAAGAGCCAGCTCGGCGTGGCGAACGGCGCCTCCGGCCTGTGCCGGCAGATCGGCGGCTCCACCGGCATCGCGGTTCTGTTCTCCGTGATGTTCGCGGTGGCGCTCGGCCGCCTCGCCGACCTGCTGCACACCCCGCGCTACGAGCGCCTCCTGACGGACCCGGCGATCACCGGCGACCCCGCCAACCACCGCTTCCTTGACATGGCCGAGTCCGGGCAGGGCGCGGGGATCAACCTTGACGACACGTCCCTGCTGAACGGCATCGACGCCCGGCTGATGCAGCCGGTGACGGATTCCTTCGCCCACGGCTTCCACATCATGTTCCTCGCCGGCGGCGTGGTGCTGCTGGCCGGGTTCGTCATGACCTGGTTCCTGCGCGAACTCCAGGAGGAGACCGCGCCGGAGGAGGAGCGGCCGGCCGAGAGCGGCGCCGGGGCGAAGAACGGGCCGCTGCCCGCGTCGGACGCCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_4380,Drugs,MEG_4380|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|OTRB,(Tet)OtrB:AF079900:40-1733:1692,4
,ATGATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAGATTCTCTACCGTGCCGATGAACGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAAGAAGAGCGACCTGGTTAACTACAATCCCATTGCTGAGAAACACGTTAACGGCACTATGACGCTGGCTGAGCTTGGCGCAGCGGCGCTGCAGTATAGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGGCCCGATAAAGTGACGGCGTTTGCTCGCTCGTTGGGTGATGAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATACCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAAGCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTCTGCCGAAATCATGGGTAGTGGGCGATAAAACCGGCAGCGGAGATTATGGCACCACCAACGATATCGCGATTATCTGGCCGGAAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGCCGTCGGGATGTTCTGGCTGCGGCGGCGAAAATCGTAACCCACAGTTTCTGATGCAATAAATGGAGCGAGGTATCGCTCCATTTACGTTAAAAATGTGCTCCTGAACTTCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2413,Drugs,MEG_2413|Drugs|betalactams|Class_A_betalactamases|CTX,gi|675278059|gb|KJ911021.1|110-1044 gi|675278057|gb|KJ911020.1|112-1046,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactgacgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacagttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1795,Drugs,MEG_1795|Drugs|betalactams|Class_C_betalactamases|CMY,1188444893|WP_085562395.1|NG_054681|1|1|blaCMY-148|blaCMY|class_C_beta-lactamase_CMY-148 NG_054681:1-1146,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1439,Drugs,MEG_1439|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_58_NZ_JUUA01000057,0
,ATGACGCCATTACTGTATAAAAAAACAGGTACAAATATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGCTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTACGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTTGGCATTGAAATTCGCCACTGTCGTGCGCAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACTCGCACCTGGTTTTGTAGTGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGCTGGAAAAGTGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGTTGCTCATGGAACGTCTTGGCATCGCGGTGATTGGTTA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_5969,Drugs,MEG_5969|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gb|JQ349152|+|0-680|ARO:3002760|QnrB45 [Escherichia coli] ,3
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGGGCCCTATCTCAATAATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6628,Drugs,MEG_6628|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|24021288|gb|AF542061.1|2088-2903,8
,atgaataaacccgctgtcatcgcgctggtgattacactgctggacgcgatgggaattggtctgatcatgccggtattaccgtcactgctgcgggaatatctcccggaagcggatgtggcaaaccattacggcattctgctggcgctgtatgcggtgatgcaggtctgttttgctccgctgctgggcagatggtcagataagctggggcgcagaccggtgctgctgttatccctggcgggtgccgcgtttgattacacactgctggcactgtccaatgtgctgtggatgttgtatctcgggcggattatctccgggatcactggtgccaccggcgcggttgcggcttcggtagtggcggacagcacggcggtcagcgagcgtaccgcctggttcggccgtctcggtgcggcctttggtgccgggctgattgccgggccggctatcggcggactgkcgggggatatctcaccgcatctgccgtttgtcattgcggcaatactgaatgcctgcacctttctgatggtcttttttatctttaaaccggcggtacagacagaagaaaaaccggcggagcagaaacaagaaagcgcaggtatcagctttatcacactgcttaaacctctggcgctgttgctgtttgtcttttttaccgcgcagcttatcgggcagatcccggccactgtctgggtattgtttacggagagccgctttgcctgggacagcgcggcggtcggtttttcactggcgggactcggggcgatgcatgcactgtttcaggcggtggttgccggggcgctggcaaaacggctgagtgagaaaaccattattttcgccggatttattgccgatgccaccgcgtttttactgatgtctgctatcacttccggatggatggtgtatccggtcctgatcctgctggcaggcggcggaattgcactgcctgcattgcagggcattatctctgccggggcatcggcggcaaatcagggaaaactacagggtgtgctggtcagcctgaccaatctgaccggcgtggcgggcccgctgctgtttgcttttattttcagtcagacacagcagagtgcggacggtacggtgtggctgattggcacggcactgtacggtctgctgctggcaatctgtctgctgatcagaaaaccggcaccggtggcggccacctgctga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7061,Drugs,MEG_7061|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETC,1028099802|WP_063856074.1|NG_048184|1|1|tet(D)|tet(D)|tetracycline_efflux_MFS_transporter_Tet(D) NG_048184:101-1285,4
,atgcgcgataccaaattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccagcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggatccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5623,Drugs,MEG_5623|Drugs|betalactams|Class_C_betalactamases|PDC,730263800|WP_033962599.1|NG_049946|1|1|blaPDC-70|blaPDC|class_C_beta-lactamase_PDC-70 NG_049946:1-1194,0
,atgagtattaaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgagctggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttaagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgactgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaacccgccttgatagttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgacgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtggatctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6672,Drugs,MEG_6672|Drugs|betalactams|Class_A_betalactamases|TEM,1028110630|WP_063864908.1|NG_050254|1|1|blaTEM-224|blaTEM|class_A_beta-lactamase_TEM-224 NG_050254:1-861,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgcaggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggctacggcaatgcagacgtctcgggcgagcccggcaagcataacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaggctggtgaatcggcaattgccggtcaaggccgccgcctatgagcttgccgaaaacctcttcgaggcgggccaggccgatggctggcgcctgtatggcaagaccggcaccgggtcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccagcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4540,Drugs,MEG_4540|Drugs|betalactams|Class_D_betalactamases|OXA,1625655403|WP_136512080.1|NG_064743|1|1|blaOXA-114v|blaOXA-114_like|class_D_beta-lactamase_OXA-114v NG_064743:1-828,0
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaatgaaaccccgagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaaacagataaaaaaattaatctatatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttaccgcttgggaaaaagacatgacactaggagaagccatgaagctttctgcagtcccagtctatcaggaacttgcgcgacgtatcggtcttgatctcatgcaaaaagaagtaaaacgtattggtttcggtaatgctgaaattggacagcaggttgataatttctggttggtaggaccattaaaggttacgcctattcaagaggtagagtttgtttcccaattagcacatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgctacttctagaagagaataatggctacaagatttttggaaagactggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcgcttttgcattaaatatggaaatgcggtcagaaatgccggcatctatacgtaatgaattattgatgaaatcattaaaacagctaaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4723,Drugs,MEG_4723|Drugs|betalactams|Class_D_betalactamases|OXA,1625655424|WP_136512101.1|NG_064768|1|1|blaOXA-810|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-810 NG_064768:1-822,0
,atgactactaaacttccagaatcgatagcagaccaattatccgatacgctattaattttagaaaaccatcttggtgaaactattcaggcggttcatctgtttggttctgcagttgatggcggtttaaaaccatttagtgatatagacctgttgatcactgtgagtactcctttaggcgaatcaactagggtggcattgatgtccgacctgctgttggtatcagcttttccaggcaccgatgctaagcgccgtgcacttgaggtgactatattggcacaaaaagacgtggtgccgtggcgatatccggcgagacggcaaatgcaatttggtgaatggttgcgtcacgatatcaatgcaggtatttttgagccggcaatgacggaccacgacctagctatcttgttgacgaaggtgaggctgcatagcctagctttgtatggtccaacagctcaagagtttttcgatgagattcctgctattgatgtgcaacgttcactgctggaaacgttggcgctctggactacagaggcagattgggagggagatgaaagaaacatagttcttgccttagtacgtatttggtacactgcgatgaccggagatattgcgtctaaggatgccgctgctgattgggctcttcagcgtctgcccagcgagaacaagcacatcgttattgccgcaagagatgggtatcttggactgggaacagtcgatctggcagcctatccacaagagcgggcggaacttctgaactacatccggtctagcgtgacgacgaagctgcaatag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_871,Drugs,MEG_871|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1236170439|WP_094963248.1|NG_059333|1|1|aadA31|aadA31|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA31 NG_059333:101-889,2
,atgtccgccacgctccacgacaccgcagcggatcgtcggaaggccacccgccgcgaatggatcggcctggccgtggtcgccctgccgtgcctggtctacgccatggacctcacggtgctgaacctggcgctgccggtgctcagccgtgaactgcagccctccagcgcccagcttctctggatcctggacatctacggcttcttcgtcgccggcttcctgatcaccatgggcacgctgggcgaccgcatcggccggcgccggctgttgttgatcggcgcggcgttattcgcattcgcctcggtgctcgcggcgctggccgataccgccgcgctgttgatcgcggcgcgcgccttgctcggcctggccggcgccaccatcgcgccgtccaccatggcgctgatccgcaacatgttccacgacccgcgccagcgccagttcgccatcggcgtgtggatcgccgcgttttcgctgggcagcgcgatcggtccgctggtcggcggcgtgttgctggagttcttccactggggcgccgtgttctggctcaacgtgccgatgatgctgctgacgctggcgctcggccctcgcttcctgcccgagtatcgtgatccggacgcggggcacctggacctggccagcgtgctgctgtcgctggcggcggtgctgctgacgatctacgggctcaagcagttggccgagcatggagcgggcctcgcctcgatggctgcgctgctggccgggctggcggtcggggcgctgttcctgcgccgccagggccacatcgcctacccgctgctggacctgcggctgttcgcgcacgcgccgttccgcgcggcgctggcggcgtatgcgctggccgcgctggccatgttcggcgtctacatcttcatgacgcagtacctgcagctcgtgctggggctgtcgccgctgcaggccgggctggccacgctgccctggtccctgtgcttcgtcatcggttcgctgttgtcgccgcagctcgcggcgcgctggccggcggcgcgcatcctcgtcgtgggcctgtcggcagcggcgttcggcttcgccgtgctggggctggggcagggcctgtggtggctggtgccggccacgatcgtcatgggcctgggcctggcgccggtgttcaccatcggcaacgagatcatcatcaccagcgcgccgtccgagcgcgcgggcgcggcctcggccttgtcggagacggtgtccgaattcagcggcgcgctgggcatcgcgctgttcggcagcgtcggcctggtggtctaccggcaggcgctgaccagcgcggcgctgcccggcctgccggccgatgcgctgcaggcggccggtgcctcgctcgggggcgccgtgcacctggccgacaccctgccggcgtggcagggcgcggccttgctggcggccgcacgcgcgggcttcaccgatgcgctgcaggccacggcctgggccggcgcggtgctggtgctggtggccgctggactggtggcgcgcctgctgcgcaagcgcccagcgctcgcatctggttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Fluoroquinolones,MEG_5858,Drugs,MEG_5858|Drugs|Fluoroquinolones|Quinolone_active_efflux|QEPA,1423450404|WP_112021705.1|NG_062255|1|1|qepA9|qepA|fluoroquinolone_efflux_MFS_transporter_QepA9 NG_062255:101-1636,3
,ATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGAAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACTTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCGATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTTCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGACGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGTAATCTGACGCTGGGTAAAGCATTGGGTGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAACGGTTTGTAATAGCGGAAACGGAATGGGGAAACTCATTCCGTTTTTGTTTATCGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_2370,Drugs,MEG_2370|Drugs|betalactams|Class_A_betalactamases|CTX,gi|124263631|gb|EF210159.1|1-921,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAAAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTCAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACACATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGATGGTGTTTCAAAAGACTGTAAGGTGGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1450,Drugs,MEG_1450|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_22_JCHI01000035,0
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattgtaatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttaaaagagctaaacaagccttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagctataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgataccttttggctcgataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcgcaaaattctttacctttttccaaaaaaagtcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattattaaataagtatttagctaatttttccaacaataataggattaaaagcttttactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4583,Drugs,MEG_4583|Drugs|betalactams|Class_D_betalactamases|OXA,1391852891|WP_109545076.1|NG_057492|1|1|blaOXA-620|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-620 NG_057492:1-774,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagtttcccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5479,Drugs,MEG_5479|Drugs|betalactams|Class_C_betalactamases|PDC,1343491244|WP_104009860.1|NG_056423|1|1|blaPDC-231|blaPDC|class_C_beta-lactamase_PDC-231 NG_056423:1-1185,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaaatgggatggggaaaaaaggctattcccagaatgggaaaagaacatgaccctaggtgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatataggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4472,Drugs,MEG_4472|Drugs|betalactams|Class_D_betalactamases|OXA,1509794578|WP_122630887.1|NG_062307|1|1|blaOXA-685|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-685 NG_062307:40-864,0
,TTATTTCCTCCCGTTAAATAATAGATAACTATTAAAAATAGACAATACTTGCTCATAAGTAACGGTACTTAAATTGTTTACTTTGGCGTGTTTCATTGCTTGATGAAACTGATTTTTAGTAAACAGTTGACGATATTCTCGATTGACCCATTTTGAAACAAAGTACGTATATAGCTTCCAATATTTATCTGGAACATCTGTGGTATGGCGGGTAAGTTTTATTAAGACACTGTTTACTTTTGGTTTAGGATGAAAGCATTCCGCTGGCAGCTTAAGCAATTGCTGAATCGAGACTTGAGTGTGCAAGAGCAACCCTAGTGTTCGGTGAATATCCAAGGTACGCTTGTAGAATCCTTCTTCAACAATCAGATAGATGTCAGACGCATGGCTTTCAAAAACCACTTTTTTAATAATTTGTGTGCTTAAATGGTAAGGAATATTCCCAACAATTTTATACCTCTGTTTGTTAGGGAATTGAAACTGTAGAATATCTTGGTGAATTAAAGTGACACGAATGTTCAGTTTTAATTTTTCTGACGATAAGTTGAATAGATGACTGTCTAATTCAATAGACGTTACCTGTTTACTTATTTTAGCCAGTTTCGTCGTTAAATGCCCTTTACCTGTTCCAATTTCGTAAACGGTATCGGTTTCTTTTAAATTCAATTGTTTTATTATTTGGTTGAGTACCTTTTCATTCGTTAAAAAGTTTTGAGAATATTTTATATTTTTGTTCATGTAATCACTCCTGAAGTGATACAT,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2801,Drugs,MEG_2801|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,gi|13549398|gb|AY028776.1|4167-4928 gi|38707181|gb|AY357120.1|9307-8546 gi|23986282|gb|AY126342.1|1390-629 gi|496500|emb|X66468.1|8144-8905 gi|3127116|gb|AF061336.1|4167-4928 gi|1277132|gb|U50977.1|CVU50977|936-181,7
,atgaagacaaaatctctttgctgcgccctgctgctcagcacctcctgctctgttctcgccgcaccgatgtcagagaaacagctgtctgacgtggtggaacgtaccgttacccccctgatgaaggcgcaagccattccgggcatggcggtggcggtgatttatcagggtcatccgcactactttaccttcggaaaggccgatgttgcggcgaacaaacctgtcaccccgcaaaccctgtttgagctgggctctataagtaaaaccttcaccggcgtattaggtggcgatgcgattgcgcgcggagaaatatcgctgggcgaccccgtgacaaagtactggcccgagctaacaggcaagcagtggcagggtattcgcatgttagatctggcgacctacaccgcgggtggcctgccgctacaggtgccggatgaggtcacggataacgcctccctgctgcgtttctatcaagactggcaaccgcagtggaaaccaggcacaacgcgtctttatgcgaacgccagcatcgggctttttggcgccctcgcggttaaaccctccggtatgagctttgaacaggccatgacgaagcgggtcttcaagccgctcaaactggaccatacatggattgacgttccgaaagaagacgaggcgcattacgcctggggataccgtgatggtaaaacggtccacgtttcaccgggaatgttggatgccgaagcgtatggtgtcaaaaccaacgtccaggatatggcgagctgggtgaaggccaacatgaaccctgccgcccttccggattcaacgttgaaacagggtattgccttggcacagtctcgctactggcgcgtgggtgccatgtatcagggtctgggctgggagatgctcaactggccggtagaagccaaaaccgtcgtggagggcagcgataacaaggtggctcttgcaccgttaccggtggcagaagtgaaccctccagctccgccagtaaaagcatcatgggtacataaaacaggctcgacgggtggattcggcagctatgtcgcatttattcctgagaaggaactcggcattgttatgctggcgaacaagagctatccgaacccggcgcgcgtggaagcggcataccgtattctgagcgctctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_418,Drugs,MEG_418|Drugs|betalactams|Class_C_betalactamases|ACT,915613457|WP_050861789.1|NG_061403|1|1|blaACT-64|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-64 NG_061403:1-1146,0
,ATGAAAACAGTATTTATCCTTATCTCCATGCTTTTCCCTGTCGCAGTTATGGCACAGAAAAGCGTAAAAATATCCGATGATATCAGTATCACCCAACTCTCGGACAAAGTGTACACTTATGTATCCCTCGCCGAAATCGAAGGATGGGGTATGGTACCTTCCAACGGAATGATTGTTATCAACAACCATCAGGCAGCGTTGCTGGACACACCGATCAATGACGCACAAACGGAAACGCTGGTCAACTGGGTAGCGGACTCTTTGCATGCCAAAGTCACCACGTTTATCCCGAACCACTGGCACGGCGATTGTATTGGCGGACTGGGTTACCTGCAAAAGAAAGGTGTCCAATCATATGCAAACCAGATGACGATAGACCTCGCCAAGGAAAAAGGGTTGCCCGTACCGGAACATGGATTCACCGATTCACTGACCGTCAGCTTGGACGGCATGCCTCTCCAATGTTATTATTTAGGAGGCGGACATGCGACCGACAATATCGTGGTTTGGCTGCCGACAGAGAATATCCTTTTTGGCGGATGTATGCTTAAAGACAACCAGGCGACAAGCATCGGCAACATCTCGGACGCGGACGTGACGGCATGGCCGAAAACTCTCGATAAGGTAAAAGCCAAGTTCCCCTCGGCCCGCTACGTCGTGCCCGGACATGGCGACTATGGCGGAACCGAACTGATAGAGCATACCAAGCAGATCGTGAACCAATATATAGAAAGCACTTCAAAGCCATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1672,Drugs,MEG_1672|Drugs|betalactams|Class_B_betalactamases|CFIA,(Bla)cfiA2:AB087226:1-750:750,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgataagcctggtaaatattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcggccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagactcaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctcaatccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacaaattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacgtatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcagttttaaatgcaataaaggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_555,Drugs,MEG_555|Drugs|betalactams|Class_C_betalactamases|ADC,491251500|WP_005109685.1|NG_064679|1|1|blaADC-121|blaADC|class_C_beta-lactamase_ADC-121 NG_064679:101-1252,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacggggctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_884,Drugs,MEG_884|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502076|WP_071846228.1|NG_052239|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052239:101-892,2
,atgactaaaagagctcttttctttgctattagtaccatatttttgtcagcatgttctttcaatacagtacaacagcaccaaatacacactatttctactcataaaaattcagaagaaattaaatcactgtttgatcaggcacagaccacgggagttttagtgattaagcgtgggcaaaccgaagaaatttatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcaccataaagcgacgacaactgaaatgttcaaatgggatggacaaaagcgtttgtttcctgattgggaaaaagatatgactctgggtgaggcgatgaaagcttctgctattcctgtctatcaagaactagctcgacgaattggccttgatcttatgtccaaagaagtcaaacgtattggtttcggtaatgccgatattggttcaaaagtagataatttttggcttgtcggtccactcaaaattacgcctcagcaggaagtacagtttgcttatgaattagcccataaaactcttccctttagcaaaaatgtacaagaacaagttcaatctatggtgctcgtagaagaaaaaaacgggcgtaaaatttacgctaaaagcggttggggatgggatgtggatcctcaagtgggctggttaacaggctgggtcgttcaaccacaaggtgaaattgtggcattctcgctcaatttagaaatgaaaaaaggaacacctagttctattcgaaaagaaattgcttataaaggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4572,Drugs,MEG_4572|Drugs|betalactams|Class_D_betalactamases|OXA,1625655416|WP_136512093.1|NG_064760|1|1|blaOXA-802|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-802 NG_064760:1-822,0
,atgcaatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtgttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaaccgtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_509,Drugs,MEG_509|Drugs|betalactams|Class_C_betalactamases|ADC,1061158353|WP_069174569.1|NG_051493|1|1|blaADC-29|blaADC|class_C_extended-spectrum_beta-lactamase_ADC-29 NG_051493:101-1252,0
,GTGAAACCCAACATACCCCTGATCGTAATTCTGAGCACTGTCGCGCTCGACGCTGTCGGCATCGGCCTGATTATGCCGGTGCTGCCGGGCCTCCTGCGCGATCTGGTTCACTCGAACGACGTCACCGCCCACTATGGCATTCTGCTGGCGCTGTATGCGTTGGTGCAATTTGCCTGCGCACCTGTGCTGGGCGCGCTGTCGGATCGTTTCGGGCGGCGGCCAATCTTGCTCGTCTCGCTGGCCGGCGCCACTGTCGACTACGCCATCATGGCGACAGCGCCTTTCCTTTGGGTTCTCTATATCGGGCGGATCGTGGCCGGCATCACCGGGGCGACTGGGGCGGTAGCCGGCGCTTATATTGCCGATATCACTGATGGCGATGAGCGCGCGCGGCACTTCGGCTTCATGAGCGCCTGTTTCGGGTTCGGGATGGTCGCGGGACCTGTGCTCGGTGGGCTGATGGGCGGTTTCTCCCCCCACGCTCCGTTCTTCGCCGCGGCAGCCTTGAACGGCCTCAATTTCCTGACGGGCTGTTTCCTTTTGCCGGAGTCGCACAAAGGCGAACGCCGGCCGTTACGCCGGGAGGCTCTCAACCCGCTCAGCTTCGTTCGGTGGGCCCGGGGCATGACCGTCGTCGCCGCCCTGATGGCGGTCTTCTTCATCATGCAACTTGTCGGACAGGTGCCGGCCGCGCTTTGGGTCATTTTCGGCGAGGATCGCTTTCACTGGGACGCGACCACGATCGGCATTTCGCTTGCCGCATTTGGCATTCTGCATTCACTCGCCCAGGCAATGATCACCGGCCCTGTAGCCGCCCGGCTCGGCGAAAGGCGGGCACTCATGCTCGGAATGATTGCCGACGGCACAGGCTACATCCTGCTTGCCTTCGCGACACGGGGATGGATGGCGTTCCCGATCATGGTCCTGCTTGCTTCGGGTGGCATCGGAATGCCGGCGCTGCAAGCAATGTTGTCCAGGCAGGTGGATGAGGAACGCCAGGGGCAGCTGCAAGGCTCACTGGCGGCGCTCACCAGCCTGACCTCGATCGTCGGACCCCTCCTCTTCACGGCGATCTATGCGGCTTCTATAACAACGTGGAACGGGTGGGCATGGATTGCAGGCGCTGCCCTCTACTTGCTCTGCCTGCCGGCGCTGCGTCGCGGGCTTTGGAGCGGCGCAGGGCAACGAGCCGATCGCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7029,Drugs,MEG_7029|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,gi|2343035|gb|U75324.1|CVU75324|610-1809 gi|2576384|gb|U82001.1|EVU82001|3792-4991 gi|42508|emb|X00006.1|1328-2527,4
,ATGGGTAGGCTGAAAATCGGAATTCTGTTCGGCGGGCTTTCCGAAGAACATCCTATCTCCATCAAATCTGCGCGTGAGGTCCAGAAGCACCTCGACCTCGAGAAGTACGAGCCGTACTACATCGGGATCACCCAGAGCGGTTCCTGGATGCTGTGCGACGGCCCCGCCGAGGACTGGGAGAACGGCGACGTCCGCCCGGCCGTCCTGTCGCCGGACCGCGGTGTGCACGGCCTGCTCGTCCTGGACGAGGGCAAGTACGAGACGATCGCCCTCGACGTGGTGCTGCCGGTGCTGCACGGCAAGTTCGGCGAAGACGGCGCGATGCAGGGCCTGCTGGAGATCTCCGGCATCCCCTACGTCGGCTGCGACCTCCCGAGCTCGGTCATGTGCATCGACAAGTCGCTCACCTATTCGGTCGTCCGCGGCGCGGGGATCGCGACGCCGACCTTCCACATCGTCACGCCGGACAACGACGTCGACCCGGACGCGCTGAACTACCCGGTCTTCGTGAAGCCCGCCCGCTCCGGCTCGTCGTTCGGCGTCAGCAAGGTCTCCTCGAAGGAAGAGCTGCCCGCCGCGCTGGCGGAGGCGCGCCAGTACGACGCGAAGATCCTGATCGAAGAGGCCGTTATCGGCAGTGAGATCGGCTGCTCGATCCTCGGCGACGGCGAGGACCTGTTCGCGGGTGAGGTCGACCGGGTCGCGCTGACCCACGGCTTCTTCAAGATCCACCAGGAGAAGAGCCCCGAGACCGGTTCCGAGAACTCGAGCTTCATCGTCCCCGCCGACATCCCGGACGCCTCGCGTGACCTGGTCCAGGAGACGGCCAAGGTCATCTACCGTGCGCTGGGCTGCAGCGGGCTCGCGCGCGTGGACCTGTTCCTCAAGGAGGACGGCAGTGTCGTGCTCAACGAGGTCAACACCCTGCCCGGCCTGACCTCGTACAGCCGTTACCCGCGGATGATGAACGCCGCCGGCCTCTCGCTCGGCGACGTGATCGACCGCCTGGTGAAGCTGACGCTGGCGGGCGTGACGAATGAGGGATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7336,Drugs,MEG_7336|Drugs|Glycopeptides|VanA-type_resistance_protein|VANA,(Gly)VanA-Ao2:HQ679900:1034-2080:1047,5
,atgatgaaaaaatcgttatactgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcccggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1787,Drugs,MEG_1787|Drugs|betalactams|Class_C_betalactamases|CMY,1028104446|WP_063859814.1|NG_048806|1|1|blaCMY-138|blaCMY|class_C_beta-lactamase_CMY-138 NG_048806:1-1146,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccgggcattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5561,Drugs,MEG_5561|Drugs|betalactams|Class_C_betalactamases|PDC,1408841635|WP_111672908.1|NG_060566|1|1|blaPDC-301|blaPDC|class_C_beta-lactamase_PDC-301 NG_060566:1-1194,0
,ATCTTATAAGTCTTATGAACATTAAAACACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGTACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTCAAGTGGGACGGGCAAAAAAGGCTATTCCCAAAATGGGAAAAGGACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATAAAGTGCAATCCATGTTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTGGGTTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGAAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGCTTAGAACAATTAGGTATTTTATAGCCCAGTTCACTTTTACCATTTTGATCTGGGCCATTGCTATTTTAAAAACTGATAATCTATCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_5241,Drugs,MEG_5241|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389171|gb|KJ135346.1|1-901,0
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagttaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgatgaattattggaaaagtatatcgcaggagaaccaatcagccggaaaaaacttgcgcgggaggaacagcagcgggttcaagacgcctccctgttcccagtctatcatggcagcgccaaaaatggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggggcgccgccctatgcggcagcgttttcaaggttgagtacaccgattgcggccagcggcgtgtctatctacggttatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatcagggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggaccaaacccggctccctcgtaaaaggtggcgcgaggaccccctccccatgctgcggacgacgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgttgcgaagtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaaccctccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccataggactgtctgttacaccactctcgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcggggacgcagctgctggaaccttatctctccttcatcctctatgcgccccaggaatacctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggcccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcggagcgtatgccttacagagctgaaaggatatcaggccgctgtcggtcagccggtcatccagccccgccgtccaaacagccgcctggacaaggtgcgccatatgtttcagaaggtaatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7219,Drugs,MEG_7219|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,503844534|WP_014078528.1|NG_048283|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048283:101-2020,4
,atgttgaaaaaaataaaaataagcttgattcttgctcttgggcttaccagtttgcaggcatttggacaggagaatcctgatgtcaaaattgaaaagctaaaagataatctgtatgtatacacaacctacaatacatttaacgggactaaatatgccgcaaatgcagtatatctggtaactgataagggtgttgtggttatagactgtccgtggggagaagacaaatttaaaagctttacggacgagatttataaaaaacacggaaagaaagttattatgaatattgcaacacattctcatgatgatcgtgccggaggtcttgaatattttggtaaaataggtgcaaaaacttattctactaaaatgacagattctattttagcaaaagagaataagccaagagcacaatatacttttgacaataataaatctttcaaagtaggaaaatccgagtttcaggtttactatcccggaaaagggcacacagcagataatgtggtggtatggtttccaaaagaaaaagtattggttggaggttgtattataaaaagtgctgattcaaaggacctggggtatattggagaagcatatgtaaacgactggacgcagtctgtacacaatattcaacaaaagttttccggtgctcagtacgttgttgcagggcatgatgattggaaagatcaaagatcaatacaacatacactagacttaatcaatgaatatcaacaaaaacaaaaggcttcaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1251,Drugs,MEG_1251|Drugs|betalactams|Class_B_betalactamases|BLAB,658535175|WP_029729112.1|NG_048691|1|1|blaB-1|blaB|subclass_B1_metallo-beta-lactamase_BlaB-1 NG_048691:101-850,0
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataagacaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4500,Drugs,MEG_4500|Drugs|betalactams|Class_D_betalactamases|OXA,691082280|WP_032018141.1|NG_062345|1|1|blaOXA-717|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-717 NG_062345:13-837,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggacctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5656,Drugs,MEG_5656|Drugs|betalactams|Class_C_betalactamases|PDC,1035157547|WP_064511512.1|NG_050835|1|1|blaPDC-162|blaPDC|class_C_beta-lactamase_PDC-162 NG_050835:1-1194,0
,AAATGGTAAAAGTGAACTGGGCTATAAACTAACTCTATAAAATACCTAATTGTTCTAAGCTTTTATAAGTAATCTCTTTTCGAACAGAGCTAGGTATTCCTTTTTTCATTTCTAAGTTAAGGGAGAACGCTACAATATTCCCTTGAGGCTGAACAACCCATCCAGTTAACCAGCCTACTTGTGGGTTTACATCCCATCCCCAACCACTTTTTGCGTATATTTTATTTCCATTCTTTTCTTCTATGAATAGCATGGATTGCACTTCATCTTGGACTTTTTGGCTAAATGGAAGCGTTTTATTAGCTAGCTTGTAAGCAAATTGTGCCTCTTGCTGAGGAGTAATTTTTAAAGGACCCACTAGCCAAAAATTATCGACTTGGGTACCGATATCTGCATTGCCATAACCAACACGCTTCACTTCATTAGACATGAGTTCAAGTCCAATACGACGAGCTAAATCTTGATAAACCGGAATAGCGGAAGCTTTCATAGCATCGCCTAGGGTCATGTTCTTTTCCCATTCTGGGAATAGCCTTTTTTGCCCGTCCCACTTAAATACTTCTGTAGTGGTTGCCTTATGGTGCTCAAGGCCGATCAAAGCATTAAGCATTTTGAAGGTCGAAGCAGGTACATACTCGGTCGAAGCACGAGCAAGATCATTACCATAGCTTTGTTGAGTTTGGCCTTGTTGGATAACTAAAACACCCGTAGTGTGTGCTTCGTTAAATAAATTTTTAATTTTCTCTGCTTTTTCATCAGATTTTGAAGCACTGTGATTTGGATTAGCAGACACTATATAAGGTGAGCAGGCTGAAATAAAAATAGCGCTTGTTATAAGTAAGAGTGCTTTAATCTTCATAAGACTTATAAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5227,Drugs,MEG_5227|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389143|gb|KF986254.1|1-871,0
,atggctctggcactcgtcggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgataatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatctatccatggcggattttcgcaatgccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagttttatgaatatgatcactactcgcacctggttttgtagtgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggggacttagatattcggggcgttgatttacagggcgttaagttggacaactaccaggcatcgttgctcacggaacgtcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5887,Drugs,MEG_5887|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111579|WP_063865791.1|NG_050474|1|1|qnrB14|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB14 NG_050474:37-681,3
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCATTCTCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACTGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAAAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAGGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCACATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1928,Drugs,MEG_1928|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KF564648|+|0-1146|ARO:3002120|CMY-108 [Escherichia coli] ,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtccgcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_796,Drugs,MEG_796|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502101|WP_071846253.1|NG_052279|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052279:101-892,2
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAAAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGAAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGATGGTGTTTCAAAAGACTGTAAGGTGGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1446,Drugs,MEG_1446|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_66_CSGM01000014,0
,GTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGACGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6608,Drugs,MEG_6608|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|72536051|gb|DQ143913.1|3703-4533,8
,ATGTTGAAAAAAATAAAAATAAGCTTGATTCTTGCTCTTGGGCTTACCAGTTTGCAGGCATTTGGACAGGAGAATCCTGATGTCAAAATTGAAAAGCTAAAAGATAATCTGTATGTATACACAACCTACAATACATTTAACGGGACTAAATATGCCGCAAATGCAGTATATCTGGTAACTGATAAGGGTGTTGTGGTTATAGACTGTCCGTGGGGAGAAGACAAATTTAAAAGCTTTACGGACGAGATTTATAAAAAACACGGAAAGAAAGTTATTATGAATATTGCAACACATTCTCATGATGATCGTGCCGGAGGTCTTGAATATTTTGGTAAAATAGGTGCAAAAACTTATTCTACTAAAATGACAGATTCTATTTTAGCAAAAGAGAATAAGCCAAGAGCACAATATACTTTTGACAATAATAAATCTTTCAAAGTAGGAAAATCCGAGTTTCAGGTTTACTATCCCGGAAAAGGGCACACAGCAGATAATGTGGTGGTATGGTTTCCAAAAGAAAAAGTATTGGTTGGAGGTTGTATTATAAAAAGTGCTGATTCAAAGGACCTGGGGTATATTGGAGAAGCATATGTAAACGACTGGACGCAGTCTGTACACAATATTCAACAAAAGTTTTCCGGTGCTCAGTACGTTGTTGCAGGGCATGATGATTGGAAAGATCAAAGATCAATACAACATACACTAGACTTAATCAATGAATATCAGCAAAAACAAAAGGCTTCAAATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1253,Drugs,MEG_1253|Drugs|betalactams|Class_B_betalactamases|BLAB,(Bla)B-1:AF189298:1-750:750,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCATTCTCCACGTTTGCCGCCGCCAAAACAGAACCACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAATCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTAAAGTTCCGCAAAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGTATTCTTGAAAAGCTGCAATAACTAACGATGAGGCCCAGGATATTGGGCCTCCTTTCTTTCTCTTTTTTTCCTGTTGTCATCTACACTTAACAAAAATACAGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1966,Drugs,MEG_1966|Drugs|betalactams|Class_C_betalactamases|CMY,gi|388564851|gb|JQ733577.1|1027-2255,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccacttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4644,Drugs,MEG_4644|Drugs|betalactams|Class_D_betalactamases|OXA,640576121|WP_025006557.1|NG_057516|1|1|blaOXA-580|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-580 NG_057516:1-774,0
,atgtttcaaattcgcagctttctggttggtatcagtgcattcgtcatggccgtacttggatcagcagcatattccgcacagcctggcggtgaatatccgacagtagatgacataccggtaggggaagttcggctgtacaagattggcgatggcgtttggtcgcatatcgcaactcagaaactcggtgacacggtgtactcgtctaatggacttatcgtccgcgatgctgatgagttgcttcttattgatacagcgtggggggcgaagaacacggtagcccttctcgcggagattgaaaagcaaattggacttccagtaacgcgctcaatttctacgcacttccatgacgatcgagtcggtggagttgatgtcctccgggcggctggagtggcaacgtacacctcacccttgacacgccagctggccgaagcggcgggaaacgaggtgcctgcgcactctctaaaagcgctctcctctagtggagatgtggtgcgcttcggtcccgtagaggttttctatcctggtgctgcgcattcgggcgacaatcttgtggtatacgtgccggccgtgcgcgtactgtttggtggctgtgcagttcatgaggcgtcacgcgaatccgcgggttatgttgccgatgccaatttggcagaatggcctgctaccattaaacgaattcaacagcggtatccggaagcagaggtcgtcatccccggccacggtctaccgggcggtctggaattgctccaacacacaactaacgttgtcaaaacgcacaaagtacgcccggtggccgagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7720,Drugs,MEG_7720|Drugs|betalactams|Class_B_betalactamases|VIM,1511261583|WP_123002103.1|NG_062359|1|1|blaVIM-61|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-61 NG_062359:1-798,0
,ATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTATTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCATGTCGGCAGAATGCTTAATGAATTACAACAGTACTGCAATGAGTGGCAGGGCGGGGCGTAA,rRNA with mutation conferring antibiotic resistance,antibiotic inactivation,Phenicol,MEG_1592,Drugs,MEG_1592|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,gi|825088700|gb|KP975077.1|46940-46281 gi|723228927|gb|CP009857.1|4541-3882 gi|723224425|gb|CP009852.1|32471-33130 gi|640855748|gb|CP007733.1|62273-62932 gi|150958513|gb|CP000650.1|66898-66239 gi|38259307|emb|BX664015.1|101974-101315,6
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgtgcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4703,Drugs,MEG_4703|Drugs|betalactams|Class_D_betalactamases|OXA,1073722255|WP_070064535.1|NG_051751|1|1|blaOXA-536|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-536 NG_051751:1-825,0
,ATGACAAAACGTAAATTGCGCAATAACTGGATTATTGTTACCACGATGATTACGTTTGTCACGATATTTTTGTTTTGTTTAATTATTATTTTTTTCTTGAAAGATACACTGCATAATAGTGAGCTTGATGATGCAGAACGAAGCTCAAGCGATATTAATAATTTATTTCATTCTAAGCCTGTTAAAGATATATCTGCATTAGACTTGAATGCATCTTTAGGTAATTTTCAAGAGATAATTATTTATGATGAGCATAATAATAAATTATTTGAGACATCGAATGATAACACAGTGAGAGTTGAACCAGGTTATGAACACCGTTATTTTGACCGCGTAATAAAAAAACGCTATAAAGGCATTGAATATTTAATTATTAAAGAACCAATTACAACGCAAGATTTCAAAGGGTATAGCTTGTTAATTCATTCACTAGAAAATTATGATAACATCGTAAAATCATTGTATATCATTGCGCTGGCATTTGGAGTGATTGCAACAATTATAACTGCCACAATCAGTTATGTATTTTCAACACAAATTACTAAACCGCTTGTCAGTTTATCAAATAAAATGATTGAGATTCGACGAGATGGTTTTCAAAATAAATTGCAATTAAATACAAATTATGAAGAAATAGATAATTTAGCAAATACGTTTAATGAGATGATGAGCCAAATTGAAGAATCATTTAATCAACAAAGACAATTTGTTGAAGATGCGTCACATGAATTACGAACACCATTACAAATTATTCAAGGTCATTTAAATTTGATTCAGCGATGGGGAAAAAAAGACCCAGCAGTATTAGAAGAATCGTTAAATATTTCTATTGAAGAAATGAATCGTATCATAAAATTAGTCGAAGAATTACTTGAATTGACTAAAGGAGATGTAAATGACATTTCTTCTGAAGCGCAGACCGTGCATATTAATGATGAAATTCGCTCGCGAATACACTCATTAAAACAATTGCATCCTGATTATCAATTTGATACGGATCTGACATCTAAAAATCTAGAAATTAAAATGAAACCTCATCAATTCGAACAATTATTTTTAATCTTTATTGATAATGCAATCAAATATGATGTGAAGAATAAGAAAATTAAAGTTAAGACAAGGTTAAAAAATAAGCAAAAAATAATTGAAATTACAGATCATGGAATTGGTATTCCAGAGGAAGATCAAGATTTCATTTTTGATCGCTTTTATCGAGTGGATAAATCTCGTTCAAGAAGTCAAGGCGGTAATGGACTCGGATTATCTATTGCTCAAAAAATCATTCAATTAAACGGAGGATCGATTAAAATTAAAAGTGAAATTAATAAAGGAACAACGTTTAAAATCATATTTTAA,subunit of efflux pump conferring antibiotic resistance,antibiotic efflux,Multi-drug_resistance,MEG_1119,Drugs,MEG_1119|Drugs|Multi-drug_resistance|MDR_regulator|ARLS,gi|984671414|emb|LT009690.1|1468485-1467130 gi|974697948|dbj|AP017320.1|1455544-1454189 gi|927048389|gb|CP010890.1|1429829-1428474 gi|925190036|gb|CP012593.1|1428157-1426802 gi|827443540|gb|CP011528.1|1390990-1389635 gi|595636499|gb|CP007454.1|2466984-2468339 gi|408436493|emb|HE579073.1|1401884-1400529 gi|408434508|emb|HE579071.1|1401835-1400480 gi|408432519|emb|HE579069.1|1402061-1400706 gi|408430526|emb|HE579067.1|1402020-1400665,1
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGAGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGCAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1963,Drugs,MEG_1963|Drugs|betalactams|Class_C_betalactamases|CMY,gi|388564835|gb|JQ733573.1|1028-2255,0
,atgcgattcaaaaaaatttcttacttaattctaccttctctttttatttttaatacctcaatttatgcaggtaacacatcaaaagaacaagatatcaaaaaggttgttgatcagaactttaaaccattattagaaaaatatgatgttcctggtatggcggttggtgtcatccaaaacaataaaaagtacgaaatgtattatggcctacaatcggttcaagataaaaaatccgtaaatagcaatacgatttttgagctaggttcagtcagtaaattatttactgcgacggcaggtggatatgccaaaacgaaaggaaaaatctcttttgaagacaccccaggaaaatactggaaagagttaaaaaatacaccgattgaccgagtgaacctacttcaacttgcaacctatacgagtggcaaccttggcttacagtttccagatgaagttcaaacagaccaacaagttttaacctttttcaaagactggaaacctaaaaaccaaattggtgaatatagacaatattcaaacccaagtattggcctatttggaaaagttgtaggcttatcgatgaaccagccttttagtcaggttttagaaaagacaatttttccgtctcttcacttaaaacatagctatgtgaatgttcctaaaactcagatgcaaaactatgcatttggctataaccaagaaaatcagccgattcgtgtgaccccaggcccactagatgcgcctgcctacggcgttaaatctacattaccagacatgcttagctttattgatgccaatctaaatccacaaaaatatccagcagatattcgacgcgcaattgatgagactcataaaggtttttatcaagtaggtacgatgtatcaggcgcttggttgggaagagttttcttatccagctcctttacaaactttattagacagtaattctgaacaaatcgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcaatcaagatgttccataaaacaggttcaactaacggatttggaacttatgtcgtgtttattcccaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaagcggcttatgctgtactaaacgcgattaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_517,Drugs,MEG_517|Drugs|betalactams|Class_C_betalactamases|ADC,491180749|WP_005039111.1|NG_064685|1|1|blaADC-129|blaADC|class_C_beta-lactamase_ADC-129 NG_064685:101-1252,0
,atgaatgtcatcctgaaccgtcgaacgtttttattggctagcgctgtggtgtctgcgtcttattcgctaggtacgctggctggcgctaatcgggatgatgcttcctttcaagatcggctggctaagttggagcagaagctgaacggacggcttggggtatgcgccatcgataccgcagatggagcacagttgggctatcgcgccaatgagcggtttgccatgaacagcacgttcaaggtcatgctcgcttcagcgtttctcgcccgaagccaagacgaaccggggctcctcgaagagcggctcacgtacacccgggccgatctggtcacatactctcccgtgacggaaaagcacgtttccactgggatgaccgttgccgaattgtgcgccgcaggtattcagtacagtgataacaccgcggccaatgtgctcatgaaaaagctggggggccctgaagcggtcaccgcatttgcccgctcgataggcgatacgcattttcgcctcgatcgatgggaaaccgagctcaattcggctattccgggagatcctcgtgatacgagtacccctcaggccatggcaatgagtctgcaacgtctggcattgagtgacatgctggctgcggataaacagcatcagttgcaggcgtggttgaaaggcaataccacgggtggcaagcgtatccgggccggagtaccggctggctggcaggtaggcgataagacaggtacgggtgattacggctcggccaacgacgtggctatcctctggccgcctcgccgtgcacccgttgtgctggctctctattccgctcttgaaagccagcaggcggaagctcgcaatgacgtactggccgatgcggcgcgcattgtggctgaatgggtgacaggctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3654,Drugs,MEG_3654|Drugs|betalactams|Class_A_betalactamases|LUT,1028105807|WP_063860832.1|NG_049289|1|1|blaLUT-6|blaLUT|class_A_beta-lactamase_LUT-6 NG_049289:1-891,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagacagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5509,Drugs,MEG_5509|Drugs|betalactams|Class_C_betalactamases|PDC,959918488|WP_058180135.1|NG_050983|1|1|blaPDC-171|blaPDC|class_C_beta-lactamase_PDC-171 NG_050983:1-1194,0
,GATAATGTAATAGAAATTGGATCAGGAAAAGGTCATTTTACCAAAGAACTTGTCAAAATGAGTCGGTGGGTGGATTCTATAGAAATTGATGAGGACTTGTGTCAAGTCACCCAAAAAGTCGTGAAGCCTTTTCAGAATATAAAAGTTATCCATACGGATATTCTGAAATTTAACTTCCCCAAAAACAAAGACTATAAAATATTTGGTAATATCCCCTTTAACATCAGTACTGATATTGTCAAAAAAATTGCTTTTGAAAGCAATTCGAAATATAGTTACCTTATTGTGGAGAATGGTTTTGCAAAAAGATTACAAAATACGAAACGAGCTTTAGGTTTGCTATTGATGGTGGAATTGGACATAAGAGTTCTCAAAAAAGTGCCACGAGCATATTTTCACCCTAAACCGAATGTAGACTCTGTATTGATTGTTCTTGAACGACATCAACCATTGATTTTAAAGAAGGACTACAAAGAGTATCAATCTTTTGTTTATAAGTGGGTAAACCGTGAATATCGCGTTCTTTTTACTAAAAACCAATTCCGACAGGCTTTGAAGCATGCAAATGTCACTAATATTAATAAACTATCGAAG,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2786,Drugs,MEG_2786|Drugs|MLS|23S_rRNA_methyltransferases|ERMA,gi|164653710|gb|EU348757.1|1-594,7
,AAAAATGATTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGTATTCATGTTGTTGTTATTTCGTCTCTTACAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGTACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGTTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGAAACTCATTCCGTTTTTGTTTATCGCCTTAGACGCAAAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2397,Drugs,MEG_2397|Drugs|betalactams|Class_A_betalactamases|CTX,gi|452107691|gb|KC351754.1|1-1090,0
,ATGATGAAAGGTTGGATGAAGTGTGGATTGGCCGGCGCCGTGGTGCTGATGGCGAGTTTCTGGGGTGGCAGCGTGCGGGCGGCGGGGATGTCGCTGACGCAGGTGAGCGGCCCTGTGTATGTGGTAGAGGACAACTACTACGTGCAGGAAAATTCCATGGTCTATTTCGGGGCCAAGGGCGTGACTGTGGTGGGGGCGACCTGGACGCCGGACACCGCCCGCGAGCTGCACAAGCTGATCAAACGGGTCAGCCGCAAGCCGGTGCTGGAGGTGATCAACACCAACTACCACACCGACCGGGCTGGCGGTAACGCCTACTGGAAGTCCATCGGTGCCAAGGTGGTGTCGACCCGCCAGACCCGGGATCTGATGAAGAGCGACTGGGCCGAGATTGTTGCCTTTACCCGCAAGGGGCTGCCGGAGTACCCGGATCTGCCGCTGGTGCTGCCCAACGTGGTGCACGATGGCGACTTCACGCTGCAAGAGGGCAAGGTGCGCGCCTTCTACGCGGGCCCGGCCCATACGCCGGACGGCATCTTTGTCTACTTCCCCGACGAGCAGGTGCTCTATGGCAACTGCATTCTCAAGGAGAAGCTGGGCAACCTGAGCTTTGCCGATGTGAAGGCCTATCCACAGACGCTTGAGCGGCTGAAAGCGATGAAGCTGCCGATCAAGACGGTGATCGGCGGTCACGACTCACCGCTGCACGGCCCCGAGCTGATTGATCACTACGAAGCGCTGATCAAGGCCGCACCCCAGTCATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2107,Drugs,MEG_2107|Drugs|betalactams|Class_B_betalactamases|CPHA,gb|X57102|+|147-912|ARO:3003103|cphA7 [Aeromonas hydrophila] ,0
,atgcgatttaaaaaaatttcttgtttacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgggacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgataagcctggtaaatattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaagttgttgctttgtctatgaataaacctttcgatcaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaggaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaatctgaacccacaaaaatattcggcagatattcaacgtgcaattaatgaaacacatcagggtcgctatcaaataaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgttgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_622,Drugs,MEG_622|Drugs|betalactams|Class_C_betalactamases|ADC,1028102035|WP_063857812.1|NG_048673|1|1|blaADC-63|blaADC|class_C_beta-lactamase_ADC-63 NG_048673:1-1152,0
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgtgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatttaatcaccgcgatgaaatattcggttgtgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctgcacgccttcgattatggcaatgaggacatttcgggcaatttagatactttttggcttgatggtggcattcgaatttcggccactgagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagccagcgtattgtcaaacaagccatgctgaccgaagccaatggcgactatattattcgggctaaaacgggatactcgactagaatcgaacctaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggagaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4618,Drugs,MEG_4618|Drugs|betalactams|Class_D_betalactamases|OXA,1226997326|WP_094009803.1|NG_055475|1|1|blaOXA-514|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-514 NG_055475:1-798,0
,gtgagcggctgcgctgccacgatccgccaggccacaccggccgatgccgctgcatggtcgcagctgcgcgtgggcctgtggcccgacgccgatgatccactggaggagctggcgcagtcgctggccgatccggaaggtgcggtgttcctggcgtgcgcggctgatggtgaggcggtcggtttcgccgaggtacgcctgcgccacgaccatgtgaacggcaccggttcctcgccggtcgggttcctggaaggctggtatgtaacgccgcagtggcagggccgcgctgtcggccgtgccctgctggcggaagtgcaggcgtggacgcgggacgcgggctgcagcgagctggcctcggacagccgcctggaggacgtagaggcgcacgcggcacaccgcgcctgtggctttgaagagaccgagcgggtggtctatttccgcatgccgctggacgcggccacgcgggggtag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_256,Drugs,MEG_256|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,924513936|WP_053518652.1|NG_052204|1|1|aac(6')_Steno|aac(6')_Steno|aminoglycoside_6'-N-acetyltransferase NG_052204:101-568,2
,atgacccttaatccccaggtcgaggcgctgctcggcttcttcgcgcagatgccgccggtcgactacgccacgatcacgccggaagccctgcgcgagatgaacaagccgatgcagatgggcccgccgccagccgttgccgaagtgcgcgacctgacgatggacctgcccggccgttccatcgcggcgcgtctctacctacccgagggcccgggcgagacaccgccgctggtgttgttctaccacggcggcggctgggttatcggatcgatcgaatcccacgacgccacggcgcgggcgatcgcggcggcaagcggggcggcggtgctttcagtcgaataccggcttgcgcccgagaccaagttcccggggccgctggatgattgctacgacgccctggtctgggcggcaggccatgcggccgagcttggcatcgacgccgcgcgccttgccgtggccggcgacagcgcggggggcaaccttgccgccgcagtcgccatccgcgcgcgggacgaaggcgggccgaagcttgcccaccagctgctgatctatccggtgaccgacgccgacttcgccaacgggtcctataccgaaaacgccgagggctatttcctgaccacgcagatgatgcagtggttctggacgcaatatgtcgacgaccacggcgatccgcacccccacgcggcggtccttcgccatgataaccttgccggcctgcctccggcaacggtgctggtcgcgcagtatgatcccttgcgtgacgagggccttgcctatgccgaggcgctgaaggcggcaggcgtgccggtggagaccgaactggcacccggcatgatccacggcttcttctcgatgttcgaggccgtgcccgacgcgatgccctatgtcgaacgcgccggggcgcggctcaaggcggccttcgccgcctga,rRNA with mutation conferring antibiotic resistance,antibiotic inactivation,Phenicol,MEG_2864,Drugs,MEG_2864|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD,500246546|WP_011906899.1|NG_050583|1|1|estDL136|estDL136|chloramphenicol_hydrolase NG_050583:101-1027,6
,atgatgactcagagcattcgccgctcaatgttaacggtgatggcgacgctacccctgctatttagcagcgcaacgctgcatgcgcaggcttccagcgtgcaacagcagctggaagccctggagaaaagttcgggaggtcggcttggcgttgcgctgattaacaccgccgataattcgcagattctctaccgtgccgatgaacgttttgcgatgtgcagtaccagtaaggtgatggcggccgcggcggtgcttaaacagagcgagagcgataagcacctgctaaatcagcgcgttgaaatcaagaagagcgacctggttaactacaatcccattgcggagaaacacgttaacggcacgatgacgctggctgagcttggcgcagcggcgctgcagtatagcgacaatactgccatgaataagctgattgcccatctgggtggtcccgataaagtgacggcgtttgctcgctcgttgggtgatgagaccttccgtctggacagaaccgagcccacgctcaataccgccattccaggcgacccgcgtgataccaccacgccgctcgcgatggcgcagaccctgaaaaatctgacgctgggtaaagcgctggcggaaactcagcgggcacagttggtgacgtggcttaagggcaatactaccggtagcgcgagcattcgggcgggtctgccgaaatcatgggtagtgggcgataaaaccggcagcggagattatggcaccaccaacgatatcgcggttatctggccggaaaaccacgcaccgctggttctggtgacctactttacccaaccggagcagaaggcggaaagccgtcgggatattctggctgcggcggcgaaaatcgtaacccacggtttctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_2170,Drugs,MEG_2170|Drugs|betalactams|Class_A_betalactamases|CTX,923060884|WP_053444694.1|NG_048950|1|1|blaCTX-M-165|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-165 NG_048950:1-876,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctcattctccacgtttgccgccgccaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatcagcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttacagataaagccgcattactgcgtttttatcaaaactggcagccgcaatggactccgggcgctaagcgtctttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacagttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgttactcctggacaacttgacgccgaagcctatggcgtgaaatccaacgttaccgatatggcccgttggattcaggtcaacatggacgccagccgcgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagtgacagcaaagtggcattggcagcgcttcacaccgttgaggtaaacccgcccgccccggcagtgaaagcctcatgggtgcataaaacgggatccactggtggatttggcagctacgttgccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1809,Drugs,MEG_1809|Drugs|betalactams|Class_C_betalactamases|CMY,1028104374|WP_063859763.1|NG_048794|1|1|blaCMY-124|blaCMY|class_C_beta-lactamase_CMY-124 NG_048794:1-1146,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAACGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1943,Drugs,MEG_1943|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KP862819.1|+|0-1146|ARO:3003653|CMY-133 [Escherichia coli] ,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGAGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGAAAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1863,Drugs,MEG_1863|Drugs|betalactams|Class_C_betalactamases|CMY,gb|DQ139328|+|160-1306|ARO:3002032|CMY-21 [Escherichia coli] ,0
,atgaatattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaagaccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaagcaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattacgcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccctttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagtctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4530,Drugs,MEG_4530|Drugs|betalactams|Class_D_betalactamases|OXA,1509794545|WP_122630854.1|NG_062267|1|1|blaOXA-735|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-735 NG_062267:1-825,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACTGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCCCGCAGCACCGACGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAAAGATGCCGGTCGGTAATGATGGTGGTGAACCGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6453,Drugs,MEG_6453|Drugs|betalactams|Class_A_betalactamases|SHV,gi|32442314|gb|AY259119.1|117-1092,0
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACATTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGATAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGTACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1965,Drugs,MEG_1965|Drugs|betalactams|Class_C_betalactamases|CMY,gi|388564847|gb|JQ733576.1|1028-2255,0
,TCAGATCAACTGCAAACTACTGAGCACGGCACGAACGATACGGGCGCGCTTGGGCGCATCGGCATCGTCCTTCAGATCGATGTTCAACGCTACGCTCGTGATGTTGCCGTCGCGCTCAATCCAGCCCACCCACCAGCCGATGTCCGGCTTCTTGTCGACGAACCAGCCCGTCTTGCCATGCAACACGTAATCAGGATTGGCCTCGACAATCGAAATCTGACGCACGATGTCTTGCGAGCGTGCAGAGAACGGTAACGTCCCTCGCGCGAGACGTTGCAGGAAATCGACCTGCTCGCGTGCCGAGATCTGCAAGCTGTCGTCGACCCAGTAGGCGTCTGCGGCACGACCGATAGTGTGGTTCCCATACCCGGCCTCATTGAGTTTGCTCTGTGCAAACTGACGCGCAATCTTGTGCGAGACCACCTGATAGCACGGCAAACACGACACGCGAAACGCCGTGCGCAGATCCATCGCCGCGTTCCAGTACTTCCCGCGTCGCGGCTTGCCGTCCCAGGGAATGATCTCGCGTTCGTTATCGAGGGCGCCCGACTCGAGCGCCAGCAGGCTGTTGAAGATCTTGTACGTCGATGCAGGCGACATCCGCCGCTCGGCGCGCGCCGTGTCGAACGCCTGATACGTTTGCGTGCGTCCGTCGAGCACCACGATCGTTCCCTTAACACCTTCCGCATCGAAGAACTTGCCCCAATCGGCACGCTCCTTCATGTGCACCGCAGCGGCCTTAGTCCCCGCGGCCCCGCCCGCCGCTTCCGTCGCATGCGCCGGAACGGCGAACACCATGGGAGACACGACCGCGAGCGCAACCCGCAGCCCGAAGACACCACGCCGCCAGCGAGAAATTATCTTTTTCAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_4865,Drugs,MEG_4865|Drugs|betalactams|Class_D_betalactamases|OXA,gb|CEWL01000009.1|+|23801-24671|ARO:3001458|OXA-153 [Pandoraea apista] ,0
,atgaacaaaaatataaaatattctcaaaactttttaacgagtgaaaaagtactcaaccaaataataaaacaattgaatttaaaagaaaccgataccgtttacgaaattggaacaggtaaagggcatttaacgacgaaactggctaaaataagtaaacaggtaacgtctattgaattagacagtcatctattcaacttatcgtcagaaaaattaaaactgaatactcgtgtcactttaattcaccaagatattctacagtttcaattccctaacaaacagaggtataaaattgttgggaatattccttaccatttaagcacaaaaattattaaaaaagtggtttttgaaagccgtgcgtctgacatctatctgattgttgaagaaggattctacaagcgtaccttggatattcaccgaacactagggttgctcttgcacactcaagtctcgattcagcaattgcttaagctgccagcggaatgctttcatcctaaaccaaaagtaaacagtgtcttaataaaacttacccgccataccacagatgttccagataaatattggaagctatataagtactttgtttcaaaatgggtcaatcgagaatatcgtcaactgtttactaaaaatcagttttatcaagcaatgaaacacgccaaagtaaacaatttaagtaccattacttatgagcaagtattgtctatttttaatagttatctattatttaacgggaggaaaataattctatga,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2791,Drugs,MEG_2791|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,1028086476|WP_063844850.1|NG_047842|1|1|erm(B)|erm(B)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B) NG_047842:101-847,7
,atgaaaatcatgcctgtaagcgagcctttcttggccgactggctgcaattaagacgattactctggcctgatcatgaagacgcgcatttactggaaatgcggcagttactcgaacaaccacatactttgcaattattaagctataacgatcagcagcaagcaattgccatgctggaagcctcgattcgatatgaatatgtaaatggcacacaaacttcaccggtggcttttctggaaggtatttatgtgttgccagagtatcgacgttcaggtgttgctagcgcgttggtacagcaggtagaacactgggccaagcagtttgcatgtagcgaatttgcttcagatgctgcgctggataatacgatcagtcatgccatgcatcgcgcgctgggctttcaggaaaccgagcgtgtggtttattttaagaaaaacatcagttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_71,Drugs,MEG_71|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491430451|WP_005288246.1|NG_052528|1|1|aacA-ACI5|aacA-ACI5|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052528:101-541,2
,ATGCAGGAAAAAATAGATATTACGGTTTTTGGGTGTGAGCGGGATGAAGCGGCGGTATTCCGTAAACTTTCATCTGAGTATGGCGTCACAGTTTCGCTCATCGAAGATGTCGTATCAGAGCACAATGCAAAATTAGCGGACGGATGCCAGTGTGTCAGCGTAAGCCATAAGGCGGAGCTGTCGGAGCAGCTTCTCCTTGCGCTGAAACACGCAGGAGTGAAATACATCAGTACCCGGAGCATTGGATTCAACCATATTGATATACAGGCTGCAGGTCAGTTGGGTATGGCTGTTGGCACAGTGGCATACTCACCGGGAAGCGTGGCCGATTATACCGTCATGCTGATGCTCATGCTGCTGCGCGGCACAAAGTCGGTTCTACGAGGAACCCAGAAGCAGAATTATTGTCTGAATGACTGCCGTGGAAAAGAACTGCAGGATTTGACGGTTGGCGTCCTGGGAACCGGACGAATCGGACAGGCAGTCATGGAACGCCTGGAGGGAATCGGCTGCAAGGTGTTGGCCTATGACCGAACTCACAAAGCCGGAGCAAATTATGTTTCGTTTTGTGAATTATTGAAGAGCAGCGACATTGTTACGCTGCATGTGCCTCTGGCAGAGGATACCCGCCATATGATTGGGCGCGAGCAGCTAGAGATGATGAAGAGGGAGGCACTTCTGATCAACACGGCACGGGGGGCTTTAGTGGATACGGCTGCACTGGTTGCTGCGCTGAAAGAACAAAAAATCGGCGGAGCCGCCTTAGATGTCCTGGAAGGGGAAGAAGGCATCTTTTACCATGAATGCACACAAAAAACGATAGGGCATCCTTACCTCTCCGTTTTGCAGAAAATGCCCAATGTCATTGTTACGCCGCATACGGCCTATCATACGGATCGGGTACTGGTCGATACCGTGAGCAATACCATCCGAAATTGTCTGAATTTTGAAAGGAGTCTTGGAAATGTATAAGCTTAAAATTGCAGTCCTGTTTGGAGGCTGCTCAGAGGAACATGATGTTTCAGTGAAATCTGCGATGGAGGTTGCAGCAAATATAAACAAGGAAAAATACCAGCCGTTTTATATTGGAATCACAAAATCCGGCGCATGGAAACTATGCGATAAGCCCTGCCGGGACTGGGAGAACTATGCGGGATACCCGGCTGTGATTTCTCCGGACAGAAGGATCCATGGCCTGCTGATACAAAAGGACGGCGGATATGAGAGCCAGCCTGTAGACGTGGTGCTTCCGATGATTCATGGAAAATTTGGCGAGGACGGAACCATACAGGGTCTGCTTGAGCTGTCCGGCATTCCTTATGTGGGATGCGACATTCAAAGTTCTGTAATCTGTATGGATAAGTCGCTCGCTTATATGGTTGTGAAAAATGCGGGAATTGAGGTACCTGGGTTTCGAGTTCTACAAAAGGGGGACAGCCTGGAAGCAGAGACGCTCTCGTATCCGGTCTTTGTAAAGCCTGCCCGTTCCGGCTCCTCTTTTGGCGTGAATAAGGTATGCCGGGCAGAGGAACTGCAGGCAGCGGTCACAGAGGCGGGTAAGTATGACAGCAAAATATTGGTTGAGGAGGCCGTTTCCGGGAGTGAGGTAGGATGTGCCATACTGGGAAACGGAAACGATCTCATCACCGGCGAGGTCGATCAGATTGAATTGAAACACGGGTTTTTTAAGATCCATCAGGAAGCACAGCCGGAAAAGGGGTCTGAAAATGCTGTGATTAGAGTTCCAGCCGCCCTGCCGGATGAAGTTAGGGAGCAGATTCAGGAAACGGCGAAGAAGATTTACCGGGTACTTGGCTGCAGAGGTCTGGCCCGCATTGATTTGTTTTTACGGGAGGATGGAAGCATTGTCCTGAATGAAGTGAACACCATGCCCGGATTTACTTCCTATAGCCGTTATCCACGCATGATGACAGCAGCAGGGTTTACGCTTTCTGAAATATTGGACCGCTTGATTGGACTTTCACTTAGGAGGTAACCATCATGGAAAAGAACTTTGTCTTTTTGGATGAAATGCTGCCGGGCATCCGGTGGGATGCCAAATATGCCACATGGGACAATTTCACCGGGAAACCGGTAGACGGATACGAGGTAAACCGCATTGTGGGAACGAAAGAGCTTGGTGCCGCTTTACGTAAGGCACAGAAGGCGGCGGAGAAACTGGGATACGGTCTGCTCTTATGGGACGGCTACCGTCCCCAGTGTGCAGTGGACTGCTTTTTGACTTGGGCTTCCCTGCCGGAGAACAATCTGACGAAAAAGCGTTACTACCCAAATATCAAAAGGAACGAGATGATCACGAAAGGGTATGTGGCTTCTCAGTCCAGCCACAGTCGCGGGAGCGCGATTGATCTCACGATTTTTCGTTTGGACACGGGTATGCTTGTGCCAATGGGCGGAGATTTCGACTTTATGGATGTACGGTCGCATCATGCCGCCAGTGGTCTGAGCGAAGAGGAGGCCGGAAACCGTGAGCGCCTGCGTGATATCATGGAGCGCAGCGGATTTGAAGCCTACCGATATGAATGGTGGCATTATGTCTTGGCAGACGAGCCATACCCGGATACATATTTTGATTTTTGCATTGCCTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7432,Drugs,MEG_7432|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,VanHDX_4_AY082011,5
,atggttaaaaaatcactgcgcctgttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2209,Drugs,MEG_2209|Drugs|betalactams|Class_A_betalactamases|CTX,1228078875|WP_094166899.1|NG_062241|1|1|blaCTX-M-224|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-224 NG_062241:101-976,0
,TTGTCCAAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTAGATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAAAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGGTGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4306,Drugs,MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_15_KX620942 ,1
,gtgaaacccaacagacccctgatcgtaattctgagcactgtcgcgctcgacgctgtcggcatcggcctgattatgccggtgctgccgggcctcctgcgcgatctggttcactcgaacgacgtcaccgcccactatggcattctgctggcgctgtatgcgttggtgcaatttgcctgcgcacctgtgctgggcgcgctgtcggatcgtttcgggcggcggccaatcttgctcgtctcgctggccggcgccactgtcgactacgccatcatggcgacagtgcctttcctttgggttctctatatcgggcggatcgtggccggcatcaccggggcgactggggcggtagccggcgcttatattgccgatatcactgatggcgatgagcgcgcgcggcacttcggcttcatgagcgcctgtttcgggttcgggatggtcgcgggacctgtgctcggtgggctgatgggcggtttctccccccacgctccgttcttcgccgcggcagccttgaacggcctcaatttcctgacgggctgtttccttttgccggagtcgcacaaaggcgaacgccggccgttacgccgggaggctctcaacccgctcgcttcgttccggtgggcccggggcatgaccgtcgtcgccgccctgatggcggtcttcttcatcatgcaacttgtcggacaggtgccggccgcgctttgggtcattttcggcgaggatcgctttcactgggacgcgaccacgatcggcatttcgcttgccgcatttggcattctgcattcactcgcccaggcaatgatcaccgcccctgtagccgcccggctcggcgaaaggcgggcactcatgctcggaatgattgccgacggcacaggctacatcctgcttgccttcgcgacacggggatggatggcgttcccgatcatggtcctgcttgcttcgggtggcatcggaatgccggcgctgcaagcaatgttgtccaggcaggtggatgaggaacgtcaggggcagctgcaaggctcactggcggcgctcaccagcctgacctcgatcgtcggacccctcctcttcacggcgatctatgcggcttctataacaacgtggaacgggtgggcatggattgcaggcgctgccctctacttgctctgcctgccggcgctgcgtcgcgggctttggagcggcgcagggcaacgagccgatcgctga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7020,Drugs,MEG_7020|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,501574697|WP_012579085.1|NG_048159|1|1|tet(A)|tet(A)|tetracycline_efflux_MFS_transporter_Tet(A) NG_048159:101-1300,4
,atgtccgcaagcaaaacacccgttaccttgcgccttatgaccgagcgcgacctaccgatgctgcacgagtggttgaaccggccgcacattgtcgagtggtggggcggagaagaggcacgcccgactcttcacgaagtgctggaacactacctaccgagggttttggcagaagaatccgtcacaccgtacatcgcgatgttgggcgacgaacccatcggctacgctcagtcatacgtcgcactcggaagcggtgatggatggtgggaagatgaaactgaccctggcgtacgaggaatagaccaattcctggcaaaccaaacacagttgaacaagggcctgggaacaaagctcgtccaggcactcgttgaacggctgttctcggaccctaccgtgacgaagatccaaaccgacccggcgccaaacaatcatcgagctatccgctgctacgagaaagctggctttgttcagcaaaacgtcatcaccacaccagacggcccagccgtctacatggttcaaaccaggcaggccttcgagcgtgtgcgcagtgctgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_204,Drugs,MEG_204|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502061|WP_071846213.1|NG_052208|1|1|aacA32|aacA32|aminoglycoside_6'-N-acetyltransferase NG_052208:101-655,2
,ATGGCTGAATTACCTCAATCAAGAATAAATGAACGAAATATTACCAGTGAAATGCGTGAATCATTTTTAGATTATGCGATGAGTGTTATCGTTGCTCGTGCATTGCCAGATGTTCGTGACGGTTTAAAACCAGTACATCGTCGTATACTATATGGATTAAATGAACAAGGTATGACACCGGATAAATCATATAAAAAATCAGCACGTATCGTTGGTGACGTAATGGGTAAATATCACCCTCATGGTGACTCATCTATTTATGAAGCAATGGTACGTATGGCTCAAGATTTCAGTTATCGTTATCCGCTTGTTGATGGCCAAGGTAACTTTGGTTCAATGGATGGAGATGGCGCAGCAGCAATGCGTTATACTGAAGCGCGTATGACTAAAATCACACTTGAACTGTTACGTGATATTAATAAAGATACAATAGATTTTATCGATAACTATGATGGTAATGAAAGAGAGCCGTCAGTCTTACCTGCTCGATTCCCTAACTTGTTAGCCAATGGTGCATCAGGTATCGCGGTAGGTATGGCAACGAATATTCCACCACATAACTTAACAGAATTAATCAATGGTGTACTTAGCTTAAGTAAGAACCCTGATATTTCAATTGCTGAGTTAATGGAGGATATTGAAGGTCCTGATTTCCCTACTGCTGGACTTATTTTAGGTAAGAGTGGTATTAGACGTGCATATGAAACAGGTCGTGGTTCAATTCAAATGCGTTCTCGTGCAGTTATTGAAGAACGTGGAGGCGGACGTCAACGTATTGTTGTCACTGAAATTCCTTTCCAAGTGAATAAGGCTCGTATGATTGAAAAAATTGCAGAACTCGTTCGTGACAAGAAAATTGACGGTATCACTGATTTACGTGATGAAACAAGTTTACGTACTGGTGTGCGTGTCGTTATTGATGTGCGTAAGGATGCAAATGCTAGTGTCATTTTAAATAACTTATACAAACAAACGCCACTTCAAACATCATTTGGTGTGAATATGATTGCACTTGTAAATGGTAGACCGAAGCTTATTAATTTAAAAGAAGCGTTGGTACATTATTTAGAGCATCAAAAGACAGTTGTTAGAAGACGTACGCAATACAACTTACGTAAAGCTAAAGATCGTGCCCACATTTTAGAAGGATTACGTATCGCACTTGACCATATCGATGAAATTATTTCAACGATTCGTGAGTCAGATACAGATAAAGTTGCAATGGAAAGCTTGCAACAACGCTTCAAACTTTCTGAAAAACAAGCTCAAGCTATTTTAGACATGCGTTTAAGACGTCTAACAGGTTTAGAGAGAGACAAAATTGAAGCTGAATATAATGAGTTATTAAATTATATTAGTGAATTAGAAGCAATCTTAGCTGATGAAGAAGTGTTATTACAGTTAGTTAGAGATGAATTGACTGAAATTAGAGATCGTTTCGGTGATGATCGTCGTACAGAAATTCAATTAGGTGGATTTGAAGACTTAGAGGACGAAGACTTAATTCCAGAAGAACAAATAGTAATTACACTAAGCCATAATAACTACATTAAACGTTTGCCGGTATCTACATATCGTGCTCAAAACCGTGGTGGTCGTGGTGTTCAAGGTATGAATACATTGGAAGAAGATTTTGTCAGTCAATTGGTAACTTTAAGTACACATGACCATGTATTGTTCTTTACTAACAAAGGTCGTGTATACAAACTTAAAGGTTATGAAGTGCCTGAGTTATCAAGACAGTCTAAAGGTATTCCTGTAGTGAATGCTATTGAACTTGAAAATGATGAAGTCATTAGTACAATGATTGCTGTTAAAGACCTTGAAAGTGAAGACAACTTCTTAGTGTTTGCAACTAAACGTGGTGTCGTTAAACGTTCAGCATTAAGTAACTTCTCAAGAATAAATAGAAATGGTAAGATTGCGATTTCGTTCAGAGAAGATGATGAGTTAATTGCAGTTCGCTTAACAAGTGGTCAAGAAGATATCTTGATTGGTACATCACATGCATCATTAATTCGATTCCCTGAATCAACATTACGTCCTTTAGGCCGTACAGCAACGGGTGTGAAAGGTATTACACTTCGTGAAGGTGACGAAGTTGTAGGGCTTGATGTAGCTCATGCAAACAGTGTTGATGAAGTATTAGTAGTTACTGAAAATGGTTATGGTAAACGTACGCCAGTTAATGACTATCGTTTATCAAATCGTGGTGGTAAAGGTATTAAAACAGCTACGATTACTGAGCGTAATGGTAATGTTGTATGTATCACTACAGTAACTGGTGAAGAAGATTTAATGATTGTTACTAATGCAGGTGTCATTATTCGACTAGATGTTGCAGATATTTCTCAAAATGGTCGTGCAGCACAAGGTGTTCGCTTAATTCGCTTAGGTGATGATCAATTTGTTTCAACGGTTGCTAAAGTAAAAGAAGATGCAGAAGATGAAACGAATGAAGATGAGCAATCTACTTCAACTGTATCTGAAGATGGTACTGAACAACAACGTGAAGCGGTTGTAAATGATGAAACACCAGGAAATGCAATTCATACTGAAGTGATTGATTCAGAAGAAAATGATGAAGATGGACGTATTGAAGTAAGACAAGATTTCATGGATCGTGTTGAAGAAGATATACAACAATCATCAGATGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3207,Drugs,MEG_3207|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|49243355|emb|BX571857.1|7005-9668 gi|47118312|dbj|BA000033.2|7005-9668,3
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgctttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgagctggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttaagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaacccgccttgatagttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtggatctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacatgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6667,Drugs,MEG_6667|Drugs|betalactams|Class_A_betalactamases|TEM,1331531443|WP_102607453.1|NG_056168|1|1|blaTEM-9|blaTEM|class_A_extended-spectrum_beta-lactamase_TEM-9 NG_056168:1-861,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGTTCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGAGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1871,Drugs,MEG_1871|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EF685371|+|0-1143|ARO:3002040|CMY-29 [Escherichia coli] ,0
,atggttaaaaaatcactgcgtcagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggaagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgtggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgacttggttaactataatccgattgcggaaaagcacgtcgatgggacgatgtcactgactgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgatttctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcgtaatctgacgctgggtaaagcattgggtgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccaacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2210,Drugs,MEG_2210|Drugs|betalactams|Class_A_betalactamases|CTX,1028104763|WP_063860009.1|NG_048960|1|1|blaCTX-M-175|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-175 NG_048960:1-876,0
,TTCTTAGACGTCAGGTGGCACTTTAGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTTCTAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6913,Drugs,MEG_6913|Drugs|betalactams|Class_A_betalactamases|TEM,gi|393718030|gb|JX042489.1|1-1002,0
,atgtcctccagcgaatccaaagtcacgttgcgcctcatgaccgagcacgacctgccaatgctccacgactggctaaaccggcctcacatcgttgaatggtggggcggtgaggatgagcgccctactctcgacgaagtactcgagcactacctgccacgagtaatggcggaggaatcagtaactccatacattgccatgctgggcgatgaaccgatcggctacgcacagtcttacgtcgcactcgggagcggtgatggatggtgggaagacgagaccgacgcaggggtacgaggaattgaccaatctctagccaatccagcgcagttgagcaagggcctgggaacactcctggtccgaacgctcgttgaaaccttgttcgcggatccggccgtcacgaagatccaaaccgatccgtctccaaacaactaccgcgcaatccgctgctacgagaaggcagggtttgcacagcagggcgtcatcaccacgcctgacgggccggcggtctacatggttcaaacacggcaagcgttcgagcgcgcgcgcggtgctgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_208,Drugs,MEG_208|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502184|WP_071846334.1|NG_052423|1|1|aac(6')-set_A|aac(6')-set_A|aminoglycoside_6'-N-acetyltransferase NG_052423:101-655,2
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCCGGCCACATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCGAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATGCATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCAGGAAAAACTTGCGCGGGAGGAACAGCGGCGGGTTCAAGAAGCCTCCCTGTTTCCGGTCTATCATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGACTGTTCCAACCGATTGGGGAACAGGGGAGCGCCACCCTATGCGGCAGCGTTTTCAAGGTTGAGTACACCGATTGCGGCCAGCGGCGTGTCTATCTGCGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGCGAAATTGTTATCCTTCCCAGCGACAGCGTGAGGTTAAACGATGTATTAGGGGATCAAACCCGGCTCCCTCGTAAAAGGTGGCGCGAGGCCCCCCTCCCCATGCTGCGGACGACGATTGCGCCGAAAACGGCAGCGCAAAGAGAACGGCTGCTGGACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGCTGCGAAGTGGATTCCATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTCGTTTCCGCTTTGCTGTCGGAAAAATACAAGATTGAAACAGTGGTAAAGGAACCCACCGTCATTTATATGGAGCGGCCGCTCAAAGCAGCCAGCCACACCATCCATATCGAGGTGCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAGGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTTATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCAACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7175,Drugs,MEG_7175|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/W/O)-1_1_AY196921 ,4
,atgagttataacattattaacattgctgattctgaaaagaacaaggaagacgctgcacgaattctatattctgcatttcgcggaaagggaaaagatgcttggcctacattagattcagctcgtgaagaaatagcagagtgcatagcaagtcctaatatttgcttaggcataaccttagatgatcgcttagtagggtggggcggacttcgtcccatgtatgaaaccacatgggaattgcatcccttagtaatagatcctgattatcaaggtaatggattaggaagactgctcctatcaaagattgagagcactgcaaccacaaatagaataattggaataatgcttggaacagatgatgagacattgagtacaagtctttcaatgactgatatagatgagtctaatattttccaagagataaataatataattaatataaagaatcatccatttgaattttataaaaaatgcgggtacatcattgtcggtatagtacctaacgcaaatgggtatagaaaacctgacatttggatgtggaagaatctagaaaagaaaagtggctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_136,Drugs,MEG_136|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,638917972|WP_024437351.1|NG_052295|1|1|aacA43|aacA43|AAC(6')-Ia_family_aminoglycoside_6'-N-acetyltransferase_AacA43 NG_052295:101-664,2
,atgaataaatttgcgatcacagcattaacgatcaccgcccttgatgcgatggggatcgggttgatcatgccagtcttaccagccttactccgtgaatatgtctccatagaacacttggcaaatcattacggcatcttgttggctttatatgccatcatgcaggtattttttgccccgctacttggtagatggtctgataaattcggccgcagacccatcttgttgatctcccttgcaggggcagcgctggactacactttgttggctttatccagttcactatggatgctgtatttaggccgcctagcctcagggatcactggtgcaacaggtgcggtagccgcttctgttattgccgaccatacacagccacaacaacgtaccaagtggtttggtcgtttaggggctgcgtttggcgtgggtttaatcgccggccctgcgattggcggctttgctgggcagttatctcctcacttgccttttgtgattgcggcggtcttaaatgcatgctcttttgtggtgatttgggttatttttaaagatcaacgtaaggctgtcatacaggatgctcaacatggagatcaaccgtcgccaattccctttatgcaaataataaaaccaatcatccagctgcttttcgtcttttttatggcacagctcattgggcagatccctgccactacttgggtgttatttaccgaaggccgctttcagtgggatagcatgcaggttgggctgtctttagctggcttaggcgttatgcatgccctcttccaagcctttgttgctggcgccattgccaaaaaattcaatgaaaaggtcactatcattgtcggctttgccctagatggaagcgcatttattattttgtcattactggcagaaggttggttgatttaccctacattaatcttactcgccggtggcagtatcgcgttacccgcattgcaaagtttgatgtcagctcaagtcaaccaagctaaccaaggaaagctccaaggggttttagtcagtttaaccaatgccacaggggtcattggcccattattatttagtgttatttttggccaaacactgacgatgtgggatggctgggtatgggtgattggcgcgataatgtatgttttcttgatcgtatttattttatcgttttatagaagcagcagaccgacaattaaacagcagaccgacaattaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic target protection,Tetracyclines,MEG_7010,Drugs,MEG_7010|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TET57,1304472397|WP_100931729.1|NG_056039|1|1|tet(57)|tet(57)|tetracycline_efflux_MFS_transporter_Tet(57) NG_056039:1-1197,4
,ATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTTACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACATGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_345,Drugs,MEG_345|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|374282195|gb|JN596279.1|3804-4322 gi|208436671|gb|EU886978.1|86-604 gi|66269634|gb|AY920928.1|5101-5619,2
,ATTCGGGCCAAGCAGGGAGACAATGCCGCGCGCACCCCGCTCGCCAGCTCCGGTCTTATCGGCGATAAACCAGCCCGCCGGCAGCACGGAGCGGATCAACGGTCCGGCGACCCGATCGTCCACCATCCACTGCAGCAGCTGCCGTTGCGAACGGGCGCTCAGACGCTGGCTGGTCAGCAGCTTGCGCAGGGTCGCGGCCATGCTGGCCGGGGTAGTGGTGTCGCGGGCGTCGCCGGGAAGCGCCTCATTCAGTTCCGTTTCCCAGCGGTCAAGGCGGGTGACGTTGTCGCCGATCTGGCGCAAAAAGGCAGTCAATCCTGCGGGGCCGCCGACGGTGGCCAGCAGCAGATTGGCGGCGCTGTTATCGCTCATGGTAATGGCGGCGGCGCAGAGTTCGCCGACCGTCATGCCGTCGGCAAGGTGTTTTTCGCTGACCGGCGAGTAGTCCACCAGATCCTGCTGGCGATAGTGGATCTTTCGCTCCAGCTGTTCGTCACCGGCATCCACCCGCGCCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6447,Drugs,MEG_6447|Drugs|betalactams|Class_A_betalactamases|SHV,gi|264665731|gb|GQ290211.1|1-515,0
,ATGAGTGAACAAAACACACCACAAGTTCGTGAAATAAATATCAGTCAGGAAATGCGTACGTCCTTCTTGGATTATGCAATGAGCGTTATCGTGTCCCGTGCTCTTCCGGATGTTCGTGACGGTTTAAAACCGGTTCATAGACGGATTTTGTATGCAATGAATGATTTAGGCATGACAAGTGACAAGCCTTATAAAAAATCCGCGCGTATCGTTGGAGAAGTTATCGGGAAATACCACCCGCACGGTGATTCAGCGGTATATGAATCCATGGTCAGAATGGCTCAGGATTTCAACTACCGTTATATGCTCGTTGACGGTCACGGAAACTTCGGTTCTGTTGACGGAGACTCAGCGGCGGCCATGCGTTATACAGAAGCACGAATGTCTAAAATCTCAATGGAGATTCTTCGCGACATCACAAAAGACACAATCGATTACCAGGATAACTATGACGGGTCAGAAAGAGAACCTGTCGTTATGCCTTCAAGGTTCCCGAATCTGCTCGTGAACGGTGCTGCCGGCATTGCGGTAGGTATGGCAACAAACATTCCTCCGCACCAGCTGGGAGAAATCATTGACGGTGTACTTGCTGTTAGTGAGAATCCGGACATTACAATTCCAGAGCTTATGGAAGTCATTCCAGGGCCTGATTTCCCGACCGCGGGTCAAATCTTGGGACGCAGCGGTATCCGGAAAGCATACGAATCAGGCCGAGGCTCTATCACGATCCGGGCAAAAGCTGAGATCGAACAAACATCTTCGGGTAAAGAAAGAATTATCGTTACAGAGTTACCTTACCAAGTAAATAAGGCGAAATTAATTGAGAAAATTGCTGATCTCGTAAGGGACAAAAAGATAGAGGGTATCACAGATCTGCGTGATGAGTCAGATCGTACAGGTATGAGAATTGTCATTGAAATCAGACGCGATGCCAATGCGAATGTTATCTTAAACAATCTGTACAAACAAACTGCTCTACAAACATCTTTTGGCATCAACCTGCTTGCGCTTGTTGATGGCCAGCCGAAAGTTTTAACTCTTAAGCAATGCCTGGAGCATTACCTTGACCATCAAAAAGTTGTCATTAGACGCCGTACTGCTTATGAATTGCGTAAAGCAGAAGCGAGAGCTCATATCTTGGAAGGATTGAGAGTTGCACTGGATCATCTCGATGCAGTTATCTCCCTTATCCGTAATTCTCAAACGGCTGAAATTGCGAGAACAGGTTTAATTGAACAATTCTCACTGACAGAGAAGCAAGCACAAGCGATCCTTGACATGAGGCTCCAGCGTTTAACGGGACTGGAACGTGAAAAGATCGAAGAAGAATACCAGTCTCTTGTTAAATTAATTGCAGAGCTAAAAGACATCTTGGCAAATGAATATAAAGTGCTTGAGATCATTCGTGAAGAACTCACGGAAATCAAAGAGCGTTTTAACGATGAAAGACGTACTGAGATCGTCACTTCTGGACTGGAGACAATTGAAGATGAAGATCTCATCGAGAGAGAAAATATCGTAGTTACTCTGACGCACAACGGATACGTCAAACGTCTTCCTGCATCAACTTACCGCAGTCAAAAACGGGGCGGAAAAGGTGTACAAGGTATGGGAACAAACGAAGATGATTTCGTTGAACATTTGATCTCTACGTCAACTCATGACACGATTCTCTTCTTCTCGAACAAGGGGAAAGTGTATCGTGCAAAAGGGTATGAAATCCCTGAATACGGCAGAACGGCAAAAGGAATCCCGATTATTAACCTGCTGGAGGTAGAAAAGGGTGAGTGGATCAACGCGATTATTCCAGTCACGGAATTCAATGCGGAGCTTTACCTCTTCTTCACTACAAAGCATGGGGTTTCAAAACGAACATCGCTATCTCAATTCGCTAATATCCGCAACAATGGTCTAATTGCTCTGAGTCTTCGTGAAGATGATGAACTGATGGGTGTACGTCTGACTGACGGCACAAAACAAATCATCATTGGAACGAAAAACGGTTTACTGATTCGTTTCCCTGAAACAGATGTCCGAGAGATGGGAAGAACTGCGGCGGGCGTAAAAGGCATCACCCTGACGGATGACGACGTTGTTGTCGGCATGGAGATTTTAGAGGAAGAATCACACGTCCTTATCGTAACTGAAAAAGGGTACGGAAAACGAACTCCTGCTGAAGAGTACAGAACCCAAAGCCGGGGCGGAAAAGGACTCAAAACAGCGAAAATCACCGAGAACAACGGCCAACTAGTAGCAGTGAAAGCTACTAAAGGTGAAGAGGATCTAATGATTATTACAGCTAGCGGCGTACTCATCAGAATGGACATCAATGATATCTCCATCACCGGACGTGTCACTCAAGGTGTGCGTCTCATCAGAATGGCAGAAGAAGAGCATGTTGCTACAGTAGCTTTAGTTGAGAAAAACGAAGAAGATGAGAATGAAGAAGAACAAGAAGAAGTGTGA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3235,Drugs,MEG_3235|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|983204966|gb|CP014166.1|6993-9458 gi|846133629|gb|CP011882.1|959577-962042 gi|807072327|gb|CP011115.1|6993-9458 gi|749183975|gb|CP010314.1|6994-9459 gi|728887195|gb|CP010053.1|6993-9458 gi|728882887|gb|CP010052.1|6994-9459 gi|724425628|emb|LN680001.1|6994-9459 gi|723796434|emb|LN649259.1|6994-9459 gi|670919138|gb|CP005997.1|6994-9459 gi|649013680|gb|CP008698.1|6994-9459,3
,GTGAGTGAAATAATTCAAGATTTATCACTTGAAGATGTTTTAGGTGATCGCTTTGGAAGATATAGTAAATATATTATTCAAGAGCGTGCATTGCCAGATGTTCGTGATGGTTTAAAACCAGTACAACGTCGTATTTTATATGCAATGTATTCAAGTGGTAATACACACGATAAAAATTTCCGTAAAAGTGCGAAAACAGTCGGTGATGTTATTGGTCAATATCATCCACATGGAGACTACTCAGTGTACGAAGCAATGGTCCGTTTAAGTCAAGACTGGAAGTTACGACATGTCTTAATAGAAATGCATGGTAATAATGGTAGTATCGATAATGATCCGCCAGCGGCAATGCGTTACACTGAAGCTAAGTTAAGCTTACTAGCTGAAGAGTTATTACGTGATATTAATAAAGAGACAGTTTCTTTCATTCCAAACTATGATGATACGACACTCGAACCAATGGTATTGCCATCAAGATTTCCTAACTTACTAGTGAATGGTTCTACAGGTATATCTGCAGGTTACGCGACAGATATACCACCACATAATTTAGCTGAAGTGATTCAAGCAACACTTAAATATATTGATAATCCGGATATTACAGTCAATCAATTAATGAAATATATTAAAGGTCCTGATTTTCCAACTGGTGGTATTATTCAAGGTATTGATGGTATTAAAAAAGCTTATGAATCAGGTAAAGGTAGAATTATAGTTCGTTCTAAAGTTGAAGAAGAAACTTTACGCAATGGACGTAAACAGTTAATTATTACTGAAATTCCATATGAAGTGAACAAAAGTAGCTTAGTAAAACGTATCGATGAATTACGTGCTGACAAAAAAGTCGATGGTATCGTTGAAGTACGTGATGAAACTGATAGAACTGGTTTACGAATAGCAATTGAATTGAAAAAAGATGTGAACAGTGAATCAATCAAAAATTATCTTTATAAAAACTCTGATTTACAGATTTCATATAATTTCAACATGGTCGCTATTAGTGATGGTCGTCCAAAATTGATGGGTATTCGTCAAATTATAGATAGTTATTTGAATCACCAAATTGAGGTTGTTGCAAATAGAACGAAGTTTGAATTAGATAATGCAGAAAAACGTATGCATATCGTTGAAGGTTTGATTAAAGCGTTGTCAATTTTAGATAAAGTAATCGAATTGATTCGTAGCTCTAAAAACAAGCGTGACGCTAAAGAAAACCTTATCGAAGTATACGAGTTCACAGAAGAACAGGCTGAAGCAATTGTAATGTTACAGTTATATCGTTTAACAAATACTGACATAGTTGCGCTTGAAGGTGAACATAAAGAACTTGAAGCATTAATCAAACAATTACGTCATATTCTTGATAACCATGATGCATTATTGAATGTCATAAAAGAAGAATTGAATGAAATTAAAAAGAAATTCAAATCTGAACGACTGTCTTTAATTGAAGCAGAAATTGAAGAAATTAAAATTGACAAAGAAGTTATGGTGCCTAGTGAAGAAGTTATTTTAAGTATGACACGTCATGGATATATTAAACGTACTTCTATTCGTAGCTTTAATGCTAGCGGTGTTGAAGATATTGGTTTAAAAGATGGTGACAGTTTACTTAAACATCAAGAAGTAAATACGCAAGATACCGTACTAGTATTTACAAATAAAGGTCGTTATCTATTTATACCGGTTCATAAATTAGCAGATATTCGTTGGAAAGAATTGGGACAACATGTATCACAAATAGTTCCTATCGAAGAAGATGAAGTGGTTATTAATGTCTTTAATGAAAAGGACTTTAATACAGATGCATTTTATGTTTTTGCGACTCAAAATGGCATGATTAAGAAAAGTACAGTGCCTCTATTTAAAACAACGCGTTTTAATAAACCTTTAATTGCTACTAAAGTTAAAGAAAATGATGATTTGATTAGTGTTATGCGCTTTGAAAAAGATCAATTAATTACCGTCATTACTAATAAAGGTATGTCATTAACGTATAATACAAGTGAACTATCAGATACCGGATTAAGGGCAGCTGGTGTTAAATCAATAAATCTTAAAGCTGAAGATTTCGTTGTTATGACAGAAGGTGTTTCTGAAAATGATACTATATTGATGGCCACACAACGCGGCTCGTTAAAACGTATTAGTTTTAAAATCTTACAAGTTGCTAAAAGAGCACAACGTGGAATAACTTTATTAAAAGAATTAAAGAAAAATCCACATCGTATTGTAGCTGCACATGTAGTGACAGGTGAACATAGTCAATATACATTATATTCAAAATCAAATGAAGAACATGGTTTAATTAATGATATTCATAAATCTGAACAATATACAAATGGCTCATTCATTGTAGATACAGATGATTTTGGTGAAGTAATAGACATGTATATTAGCTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5355,Drugs,MEG_5355|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|899750970|gb|CP012120.1|2433921-2431519 gi|743649775|gb|CP010300.1|1374164-1376566 gi|743624649|gb|CP010299.1|1374164-1376566 gi|743618732|gb|CP010298.1|1374163-1376565 gi|743615870|gb|CP010297.1|1374164-1376566 gi|743612995|gb|CP010296.1|1374164-1376566 gi|743602172|gb|CP010295.1|1374164-1376566 gi|584463070|gb|CP007176.1|1393883-1396285 gi|87125858|gb|CP000255.1|1374167-1376569,3
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcaaatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtgggttggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4487,Drugs,MEG_4487|Drugs|betalactams|Class_D_betalactamases|OXA,1559612983|WP_128268248.1|NG_063853|1|1|blaOXA-749|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-749 NG_063853:30-854,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacacggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcggcattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggccacccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_886,Drugs,MEG_886|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502221|WP_071846371.1|NG_052501|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052501:101-892,2
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCCTCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAAACCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGATATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACGGATAAAACCGCATTACTGCACTTTTATCAAAACTGGCAGCCGCAATGGGCTCCGGGCGCTAAGAGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAGCCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAAAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGATGCCGAAGCCTATGGCGTGAAATCCAACGTTACCGATATGGCACGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCGGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1845,Drugs,MEG_1845|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AB300358|+|0-1146|ARO:3002037|CMY-26 [Klebsiella oxytoca] ,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTACCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6687,Drugs,MEG_6687|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-128:AY359287:186-1046:861,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgacgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcctagcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5437,Drugs,MEG_5437|Drugs|betalactams|Class_C_betalactamases|PDC,1393270461|WP_109791206.1|NG_057605|1|1|blaPDC-274|blaPDC|class_C_beta-lactamase_PDC-274 NG_057605:1-1194,0
,ttgtttagtttatataaaaaatttaaaggtttgttttatagcgttttattttggctttgtattctttcattttttagtgtattaaatgaaatggttttaaatgtttctttacctgatattgcaaatcattttaatactactcctggaattacaaactgggtaaacactgcatatatgttaactttttcgataggaacagcagtatatggaaaattatctgattatataaatataaaaaaattgttaattattggtattagtttgagctgtcttggttcattgattgcttttattggtcacaatcacttttttattttgatttttggtaggttagtacaaggagtaggatctgctgcattcccttcactgattatggtggttgtagctagaaatattacaagaaaaaaacaaggcaaagcctttggttttataggatcaattgtagctttaggtgaagggttaggtccttcaatagggggaataatagcacattatattcattggtcttacctacttatacttcctatgattacaatagtaactataccttttcttattaaagtaatggtacctggtaaatcaacaaaaaatacattagatatcgtaggtattgttttaatgtctataagtattatatgttttatgttatttacgacaaattataattggacttttttaatactcttcacaatcttttttgtgatttttattaaacatatttcaagagtttctaacccttttattaatcctaaactagggaaaaacattccgtttatgcttggtttgttttctggtgggctaatattttctatagtagctggttttatatcaatggtgccttatatgatgaaaactatttatcatgtaaatgtagcgacaataggtaatagtgttatttttcctggaaccatgagtgttattgtttttggttattttggtggttttttagtggatagaaaaggatcattatttgtttttattttaggatcattgtctatctctataagttttttaactattgcattttttgttgagtttagtatgtggttgactacttttatgtttatatttgttatgggcggattatcttttactaaaacagttatatcaaaaatagtatcaagtagtctttctgaagaagaagttgcttctggaatgagtttgctaaatttcacaagttttttatcagagggaacaggtatagcaattgtaggaggtttattgtcactacaattgattaatcgtaaactagttctggaatttataaattattcttctggagtgtatagtaatattcttgtagccatggctatccttattattttatgttgtcttttgacgattattgtatttaaacgttctaaaaagcagtttgaatag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7089,Drugs,MEG_7089|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETK,446414429|WP_000492284.1|NG_055987|1|1|tet(K)|tet(K)|tetracycline_efflux_MFS_transporter_Tet(K) NG_055987:36-1415,4
,atgaaaattttatcggtatctgagccgttattggcagattggttaagattaagaattttactttggccaaatactgaagacgcacatttgatagaaatgcgtcagctacttgcagaaaaacaaactttgcaattaatggcatactctaataatcaagcagtcgccatgcttgaagcttctattcgacatgaatatgtgaacggaaccgaaacttcgcctgttgcttatttagagggaatttatgtttgttccgaatttcgccgtctgggagttgccacgaatttgatccgacaagcagagcaatgggcaactcagtttgcttgtactgagtttgcttcagacacagccgttgataatctagttggtcaagccatgcataaggctttgggatttcaagaaaccgaacgtgtgatttacttttctaaaaaaataaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_72,Drugs,MEG_72|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491204525|WP_005062866.1|NG_052397|1|1|aac(6')_Acine|aac(6')_Acine|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052397:101-538,2
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGATGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6479,Drugs,MEG_6479|Drugs|betalactams|Class_A_betalactamases|SHV,gi|719628246|gb|CP009461.1|2389630-2390490 gi|562889802|gb|KF585135.1|48-908 gi|124053910|gb|EF035561.1|1-861 gi|46452171|gb|AY528717.1|575-1435,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgactttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgtccactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_793,Drugs,MEG_793|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,695262349|WP_032489308.1|NG_052227|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052227:101-892,2
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaataaaacccagagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaagcagataaaaaaattaatctatatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttaccgcttgggaaaaagacatgacactaggagaagccatgaagctttccgcagtcccagtctatcaggaacttgcgcgacgtatcggtcttgatctcatgcaaaaagaagtaaaacgtattggtttcggtaatgctgaaattggacagcaggttgataatttctggttggtagggccattaaaggttacgcctattcaagaggtagagtttgtttctcaattggcgcatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgcttcttttagaagagagtaatggctacaaaatttttggaaagaccggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcacttttgcattaaatatggaaatgcggtcagaaatgcctgcatctatacgtaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4517,Drugs,MEG_4517|Drugs|betalactams|Class_D_betalactamases|OXA,1188444919|WP_085562421.1|NG_054712|1|1|blaOXA-565|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-565 NG_054712:1-822,0
,atgaaaacagtatttatccttatctccatgcttttccctgtcgcagttatggcacagaaaagcgtaaaaatatctgatgatatcagtatcacccaactctcggataaagtgtacacttatgtatccctcgccgaaatcgaaggatggggcatggtaccttccaacggaataattgttatcaacaaccatcgggcagcgttgctggacacaccaatcaatgacgcacaaacggaaacgctggtcaactgggtggcagactctttgcatgccaaagtcaccacgtttatcccgaaccactggcacggcgattgtattggcggactgggttacctgcaaaagaaaggtgtccaatcatacgcaaaccagatgacgatagacctcgccaaggaaaaaggattgcccgtaccggaacatggattcaccgattcactgaccgtcagtctggacggcacgcctctccaatgttattatttaggaggcggacatgcgaccgacaatatcgtggtttggctgccgacagagaatatcctttttggcggatgtatgcttaaagacaaccaaacgacaagcatcggcaacatctcggacgcggacgtgacggcatggccgaaaactctcgataaggtaaaagccaagttcccctcggcccgctacgtcgtgcccggacatggcgactatggcggaaccgaactgatagagcataccaagcagatcgtgaaccaatatatagaaagcacctcaaagccatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1664,Drugs,MEG_1664|Drugs|betalactams|Class_B_betalactamases|CFIA,1188444888|WP_085562390.1|NG_054675|1|1|cfiA21|cfiA|subclass_B1_metallo-beta-lactamase_CfiA21 NG_054675:1-750,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAATTAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1443,Drugs,MEG_1443|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_101_LTLP01000099,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaaatatttaagtgggacgggcaaaaaaggctgttcccagaatgggaaaaggacatgcccctaggtgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4477,Drugs,MEG_4477|Drugs|betalactams|Class_D_betalactamases|OXA,1559612991|WP_128268256.1|NG_063861|1|1|blaOXA-757|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-757 NG_063861:41-865,0
,atgactctggcattagttggcgaaaaaattgacagaaatcgcttcaccagtgagaaagttgaaaatagtacattttttaactgcgatttttcaggtgccgacctgagcggcactgaatttatcggctgccagttctatgatcgcgaaagtcagaaaggatgcaattttagtcgcgcaatgctgaaagatgccattttcaaaagctgtgatttatcaatggcagatttccgcaacgtcagcgcattgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggtgcaagctttatgaatatgatcaccacacgcacctggttttgcagcgcatatatcactaataccaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctatgggaaaaccgctggatggggactcaggtactgggtgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttaggtgacttagatattcggggtgttgatttacaaggcgttaagttagacaactaccaggcatcgttgctcatggagcggcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5880,Drugs,MEG_5880|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111999|WP_063866199.1|NG_050522|1|1|qnrB59|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB59 NG_050522:37-681,3
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGCACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1336,Drugs,MEG_1336|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_118_NC_004461,0
,atgatgacaaaaactctttgctgcgccctgctgctcagcacctcctgctcagcgctggctggaccgctgtcagaaaaacagctggctgaagtggtggaacaaaccgttacgccgttaatgaaagcgcaggccattccgggtatggcggtggcggtgatttatgagggtcagccgcactactttacctttggcaaagccgatgtcgcaaagaacaaacccgttaccccacagaccctgttcgagctgggatctataagtaaaaccttcaccggcgtattgggtggcgatgccgttgctcgcggtgaaatatcgctgggcgaccctgtgacaaagtactggcccgcgctgacaggcaagcagtggcaggggatccgcatgctggatctggccacctataccgcaggaggtctgccgctacaggtaccggatgatgtcacggataatgcctctctgctgcgcttttatcaaaactggcagccgcagtggaagccgggtaccacgcgtctttacgccaacgccagcatcggtctttttggcgcgctggcggtgcagccttccggcatgagctatgagcaggccataacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggataccgtgacggtaaagcggtgcacgtttcgccgggcatgctcgacgcagaagcttatggcgtgaaaaccaacgtgcaggatatggcaagctgggtgatggtcaacatgaagccggaagcccttcaggatacgtcgctcgggcaaggtatcaccctggcgcagtctcgctactggcgcgtgggggcgatgtaccagggcttaggctgggaaatgcttaactggccggtcgatgccaaaaccgtggttgacggtagcgacaataaggtggcgctggcgccgctgcctgcgagggaggtgaatcccccagcgccgccggttaaggcatcctgggtccataaaacaggctctaccggcgggtttggcagctacgtagcatttattccggagaaaaatctcggcatcgtgatgctggcgaataaaagctatccaaaccctgcgcgggtggaggcggcgtaccgcattctcgacgcattgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_441,Drugs,MEG_441|Drugs|betalactams|Class_C_betalactamases|ACT,695712152|WP_032644152.1|NG_055522|1|1|blaACT-53|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-53 NG_055522:1-1146,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3469,Drugs,MEG_3469|Drugs|betalactams|Class_A_betalactamases|KPC,1391852859|WP_109545044.1|NG_057447|1|1|blaKPC-34|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-34 NG_057447:1-906,0
,atgtcgaaaattgaactaaaacaactatcttttgcctatgataatcaagaagcgttgctttttgatcaggcaaatatcacgatggataccaattggaaattaggattgattggccgcaatggccgtgggaaaacaaccttattaagattgttacaaaagcagttggattaccaaggagagattcttcatcaagtcgatttcgtctattttccacaaacagttgcagaagaacaacagctcacttattatgtcttacaagaggtgacttcttttgaacagtggaaattagaacgagaattaacgcttttaaacgttgatcctgaagttttatggcgtcccttttcttctttatcaggcggcgaaaagacgaaagttttattaggtcttctttttattgaagaaaatgcctttcctttaattgacgagccaacaaatcacttagatctagctggcagacaacaagtggctgaatatttgaagaaaaagaaacacgggtttattttagtcagccacgatcgggcatttgttgatgaagtggttgatcatattttggcgattgaaaaaagtcaattgacgctgtatcaagggaatttttctatttatgaagagcaaaaaaaattaagagatgcttttgaactagcagaaaatgaaaaaatcaaaaaagaagtcaatcgcttgaaagaaaccgctcgtaaaaaagcggaatggtcgatgaaccgtgaaggtgataagtacggcaacgctaaggaaaaagggagcggggcgatttttgatacaggagccattggtgcccgggcagcgcgcgtaatgaagcgctcgaaacatattcaacaacgcgccgaaacacaattagcagaaaaagaaaaactattaaaagatcttgagtatattgattctttgtcaatggattatcagccaacgcatcacaaaacattattgacggtggaagagcttcgtctaggctacgagaaaaattggctgtttgcgccaatttctttttcaataaacgcgggagaaattgtcggaataacaggaaaaaatggctcaggaaaatcgagcttgattcagtatttattggataatttttctggggattcagaaggcgaagccactttggctcaccaattaaccatttcttatgtgcgccaagattatgaagacaatcaaggaactttatccgaatttgcagagaaaaatcagttagattacacccaatttttaaataacttacgaaaacttgggatggagcgtgccgttttcactaatcgaattgaacaaatgagtatggggcaacggaaaaaagtcgaagtagccaaatcattgtctcaatcagcagagctttatatttgggatgaaccccttaattacttggatgtgtttaatcatcaacaattagaagcgctaatcttatctgtgaagcctgcaatgctagtgattgagcatgatgcgcatttcatgaagaaaataacggataaaaaaattgtcttgaaatcataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3642,Drugs,MEG_3642|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|LSA,488317802|WP_002387187.1|NG_047930|1|1|lsa(A)|lsa(A)|ABC-F_type_ribosomal_protection_protein_Lsa(A) NG_047930:101-1597,7
,ATGAACGAGAAAAATATAAAACACAGTCAAAACTTTATTACTTCAAAACATAATATAGATAAAATAATGACAAATATAAGATTAAATGAACATGATAATATCTTTGAAATCGGCTCAGGAAAAGGGCATTTTACCCTTGAATTAGTACAGAGGTGTAATTTCGTAACTGCCATTGAAATAGACCATAAATTATGCAAAACTACAGAAAATAAACTTGTTGATCACGATAATTTCCAAGTTTTAAACAAGGATATATTGCAGTTTAAATTTCCTAAAAACCAATCCTATAAAATATTTGGTAATATACCTTATAACATAAGTACGGATATAATACGCAAAATTGTTTTTGATAGTATAGCTGATGAGATTTATTTAATCGTGGAATACGGGTTTGCTAAAAGATTATTAAATACAAAACGCTCATTGGCATTATTTTTAATGGCAGAAGTTGATATTTCTATATTAAGTATGGTTCCAAGAGAATATTTTCATCCTAAACCTAAAGTGAATAGCTCACTTATCAGATTAAATAGAAAAAAATCAAGAATATCACACAAAGATAAACAGAAGTATAATTATTTCGTTATGAAATGGGTTAACAAAGAATACAAGAAAATATTTACAAAAAATCAATTTAACAATTCCTTAAAACATGCAGGAATTGACGATTTAAACAATATTAGCTTTGAACAATTCTTATCTCTTTTCAATAGCTATAAATTATTTAATAAGTAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2822,Drugs,MEG_2822|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,gi|961570267|gb|CP013617.1|2092-1358 gi|929861441|gb|CP010404.1|1680-2414 gi|757805033|dbj|AB982226.1|1683-2417 gi|757805030|dbj|AB982225.1|1392-2126 gi|700659238|gb|KF831357.1|2152-1418 gi|658131571|emb|HG380317.1|136-870 gi|537392238|gb|CP003981.1|84-818 gi|695224142|ref|NG_041022.1|5598-4864 gi|452753789|emb|HF569094.1|40393-39659 gi|407031691|gb|JX644443.1|2087-1353,7
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccagacacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5689,Drugs,MEG_5689|Drugs|betalactams|Class_C_betalactamases|PDC,1028110192|WP_063864562.1|NG_049872|1|1|blaPDC-105|blaPDC|class_C_beta-lactamase_PDC-105 NG_049872:1-1194,0
,AAGGCGTTTTGACAGACTATTCATGTTGTTGTTAATTCGTCTCTTCCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGACGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACTTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGACGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGGGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAACGGTTTGTAATAGCGGAAACGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_2381,Drugs,MEG_2381|Drugs|betalactams|Class_A_betalactamases|CTX,gi|19852069|gb|AF488377.1|1-950,0
,TTGCGATTAAATCAGATCACAAACGAAGCCTTTTTCTATCTATTTCAATTGGTTGTAGCTAAAGATCCTGTACATGAATGCCAATTTCATTCACCACGAGAATAACCATATGCAACAACGACGTGCGTTCGCGCTACTGACGCTGGGTAGCCTGCTGCTAGCCCCTTGTACTTATGCCCGCGGGGAGGCTCCGCTGACCGCCGCTGTGGACGGCATTATCCAGCCGATGCTCAAGGAGTATCGGATCCCGGGGATGGCGGTCGCCGTGCTGAAAGATGGCAAGGCCCACTATTTCAACTATGGGGTTGCCAACCGCGAGAGTGGTCAGCGCGTCAGCGAGCAGACCCTGTTCGAGATTGGCTCGGTCAGCAAGACCCTGACCGCGACCCTCGGTGCCTATGCTGCGGTCAAGGGGGGCTTTGAGCTGGATGACAAGGTGAGCCAGCACGCCCCCTGGCTCAAAGGTTCCGCCTTTGATGGTGTGACCATGGCCGAGCTTGCCACCTACAGTGCGGGTGGTTTGCCGCTGCAGTTCCCCGATGAGGTGGATTCGAATGACAAGATGCGCACTTACTATCGGCACTGGTCACCGGTTTATCCGGCGGGGACCCATCGCCAGTATTCCAACCCCAGCATAGGCCTGTTTGGTCACCTGGCCGCAAATAGTCTGGGCCAGCCATTTGAGCAACTGATGAGCCAGACCCTGCTGCCCAAGCTGGGTTTGCACCACACCTATATTCAGGTGCCGGAGTCGGCCATAGCGAACTATGCCTACGGCTATTCGAAGGAAGATAAGCCCGTCCGGGTCACTCCGGGCGTGCTGGCGGCCGAGGCTTACGGGATCAAGACCGGCTCGGCGGATCTGCTGAAGTTTACCGAGGCCAACATGGGGTATCAGGGAGATGCCGCGCTAAAAACGCGGATCGCGCTGACCCATACCGGTTTCTACTCGGTGGGAGACATGACTCAGGGGCTGGGTTGGGAGAGCTACGCCTATCCGTTGACCGAGCAGGCGCTGCTGGCGGGCAACTCCCCGGCGGTGAGCTTCCAGGCCAATCCGGTTACGCGCTTTGCGGTGCCCAAAGCGATGGGCGAGCAGCGGCTCTATAACAAGACGGGCTCGACTGGCGGCTTTGGCGCCTATGTGGCGTTCGTGCCCGCCAGAGGGATCGCCATCGTCATGCTGGCCAATCGCAACTATCCCATCGAGGCCAGGGTGAAGGCGGCTCACGCCATCCTGAGTCAGTTGGCCGAGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3046,Drugs,MEG_3046|Drugs|betalactams|Class_C_betalactamases|FOX,gi|453214|emb|X77455.1|592-1849,0
,ATCGATGGTAAAGGTTGGCAAAAAGATAAATCTTGGGGTGGTTACAACGTTACAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCAGATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAAGATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTACGGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCACCTCACTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCCACAAGTCGTAAATAAAACACATAAAGAAGATATTTATAGATCTTATGCAAACTTAATTGGCAAATCCGGTACTGCAGAACTCAAAATGAAACAAGGAGAAACTGGCAGACAAATTGGGTGGTTTATATCATATGATAAAGATAATCCAAACATGATGATGGCTATTAATGTTAAAGATGTACAAGATAAAGGAATGGCTAGCTACAATGCCAAAATCTCAGGTAAAGTGTATGATGAGCTATATGAGAACGGTAATAAAAAATACGATATAGATGAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3781,Drugs,MEG_3781|Drugs|betalactams|Penicillin_binding_protein|MECA,gi|695199814|ref|NG_035309.1|1-729 gi|938149449|gb|KR936061.1|2008-2267,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcttggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgccgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5644,Drugs,MEG_5644|Drugs|betalactams|Class_C_betalactamases|PDC,1209144256|WP_088245218.1|NG_055275|1|1|blaPDC-220|blaPDC|class_C_beta-lactamase_PDC-220 NG_055275:1-1194,0
,GCCACCCTGCCACTGGCGGTAGACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGCTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTGTCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGCACTGAATGAGGCGCTTCCCGGCGACGCGCGCGACACCACCACCCCGGCCAGCATGGCCGCCACGCTGCGCAAACTACTGACCGCGCAGCATCTGAGCGCCCGTTCGCAACAGCAACTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGCCGGGCTGGTTTATCGCCGACAAAACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAACCGGAGCGCATTGTGGTGCTCTATCTGCGGGATACCCCGGCGAGTATGGCCGAGCGTAATCAACATATCGCCGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3551,Drugs,MEG_3551|Drugs|betalactams|Class_A_betalactamases|LEN,gb|AJ635403|+|0-789|ARO:3002463|LEN-13 [Klebsiella pneumoniae] ,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggcagcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctagcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcggattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6197,Drugs,MEG_6197|Drugs|betalactams|Class_A_betalactamases|SHV,1028110280|WP_063864650.1|NG_050039|1|1|blaSHV-163|blaSHV|class_A_beta-lactamase_SHV-163 NG_050039:1-861,0
,GCCACCCTGCCACTGGCGGTATACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGCTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTGTCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGCACTGAATGAGGCGCTTCCCGGCGACGCGCGCGACACCACCACCCCGGCCAGCATGGCCGCCACGCTGCGCAAACTACTGACCGCGCAGCATCTGAGCGCCCGTTCGCAACAGCAACTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGGCGGGCTGGTTTATCGCCGACAAAACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAACCGGAGCGCATTGTGGTGATCTATCTGCGGGATACCCCGGCGAGTATGGCCGAGCGTAATCAACATATCGCCGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3552,Drugs,MEG_3552|Drugs|betalactams|Class_A_betalactamases|LEN,gb|AJ635406|+|0-789|ARO:3002462|LEN-12 [Klebsiella pneumoniae] ,0
,TTCGCTATTTTTTTAATAATTGCAAATATTATCTACAGCAGCGCCAGTGCATCAACAGATATCTCTACTGTTGCATCTCCATTATTTGAAGGAACTGAAGGTTGTTTTTTACTTTACGATGCATCCACAAACGCTGAAATTGCTCAATTCAATAAAGCAAAGTGTGCAACGCAAATGGCACCAGATTCAACTTTCAAGATCGCATTATCACTTATGGCATTTGATGCGGAAATAATAGATCAGAAAACCATATTCAAATGGGATAAAACCCCCAAAGGAATGGAGATCTGGAACAGCAATCATACACCAAAGACGTGGATGCAATTTTCTGTTGTTTGGGTTTCGCAAGAAATAACCCAAAAAATTGGATTAAATAAAATCAAGAATTATCTCAAAGATTTTGATTATGGAAATCAAGACTTCTCTGGAGATAAAGAAAGAAACAACGGATTAACAGAAGCATGGCTCGAAAGTAGCTTAAAAATTTCACCAGAAGAACAAATTCAATTCCTGCGTAAAATTATTAATCACAATCTCCCAGTTAAAAACTCAGCCATAGAAAACACCATAGAGAACATGTATCTACAAGATCTGGATAATAGTACAAAACTGTATGGGAAAACTGGTGCAGGATTCACAGCAAATAGAACCTTACAAAACGGATGGTTTGAAGGGTTTATTATAAGCAAATCAGGACATAAATATG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5146,Drugs,MEG_5146|Drugs|betalactams|Class_D_betalactamases|OXA,gb|KR780479.1|-|0-706|ARO:3001452|OXA-140 [Klebsiella pneumoniae subsp. pneumoniae] Partial,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATTAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6952,Drugs,MEG_6952|Drugs|betalactams|Class_A_betalactamases|TEM,blaTEM-32_1_CXLQ01000061,0
,atgttcaaaacgacgctctgcaccttattaattaccgcctcttgctccacatttgccgcccctcaacaaatcaacgatattgtgcatcgcacaattaccccgcttatagagcaacaaaagatccccggtatggcggtggcggtaatttatcagggtaaaccttattactttacctggggctatgcggacatcgccaaaaagcagcccgtcacacagcaaacgttgtttgagttaggttcggtcagcaaaacatttacgggcgtgcttggtggcgacgctattgctcgaggggaaatcaagttaagcgatcccacaacaaaatactggcctgaacttaccgctaaacagtggaatgggatcacactattacatctcgcaacctacaccgctggcggcctgccattgcaggtgccggatgaggtgaaatcctcaagcgacttgctgcgcttctatcaaaactggcagcctgcatgggctccaggaacacaacgtctgtatgccaactccagtatcggtttgttcggcgcactggctgtgaagccgtctggtttgagttttgagcaggcgatgaaaactcgtgtcttccagccactcaaactcaatcatacgtggattaatgtaccgtccgcagaagaaaagaactacgcctggggatatcgcgaaggtaaggcagtacatgtttcgccaggggcgttagatgctgaagcttatggtgtgaagtcgaccattgaagatatggcccgctgggtgcaaagcaatttaaaaccatttgatatcaatgagaaaacacttcaacaagggatacaactggcacaatctcgctactggcaaaccggcgatatgtatcagggtctgggctgggaaatgctggactggccgctaaatcctgacatcatcattaacggcagtgacaataaaattgcactggcagcacgccccgtaaaaccgattacgcccccaactcctgcagtacgcgcatcatgggtacataaaacgggggcgaccggcggatttggtagctatgtcgcgtttattccagaaaaagagctgggtatcgtgatgctggctaacaaaaactatcccaatccagcgagattcgccgccgcctggcagattctcaacgctctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1277,Drugs,MEG_1277|Drugs|betalactams|Class_C_betalactamases|BLAEC,1028105078|WP_063860263.1|NG_049084|1|1|blaEC-19|blaEC|class_C_extended-spectrum_beta-lactamase_EC-19 NG_049084:101-1234,0
,AGATAGTAAATTTTATAGATTTAAATCAACATCTATAACTGTATAATTCGTTTTCTCAACTCATTACAACACTCCGTTAGTAATGAAGCTCATTCTATACAATGACAGTTAATAGGTAAAGTTATGTCAAACAAAGTAAATTTTAAAACGGCTTCATTTTTGTTTAGTGTTTGTTTAGCTTTGTCGGCATTTAATGCTCATGCTAACAAAAGTGATGCTGCGGCAAAACAAATAAAAAAATTAGAGGAAGACTTTGATGGGAGGATTGGCGTCTTTGCAATAGATACAGGATCGGGTAATACATTTGGGTATAGATCAGATGAGCGGTTCCCTTTATGCAGTTCATTTAAAGGTTTTTTGGCGGCTGCTGTTTTAGAGAGGGTGCAACAAAAAAAACTAGATATCAACCAAAAGGTTAAATATGAGAGTAGGGATCTAGAATATTATTCACCTATTACAACAAAATATAAAGGCTCAGGTATGACATTAGGTGATATGGCTTCTGCTGCATTGCAATATAGCGACAATGGGGCAACAAATATAATTATGGAACGATTTCTTGGCGGTCCTGAGGGGATGACTAAATTTATGCGTTCTATTGGAGATAATGAGTTTAGGTTAGATCGCTGGGAACTGGAACTTAACACTGCAATCCCAGGAGATAAACGTGACACTTCAACGCCAAAAGCTGTTGCAAATAGTTTGAATAAACTAGCTTTGGGGAATGTTCTCAATGCTAAAGTGAAAGCGATTTATCAAAATTGGTTAAAAGGTAATACAACTGGTGATGCTCGAATTCGTGCTAGTGTTCCTGCTGATTGGGTTGTAGGTGACAAAACTGGGAGCTGTGGGGCATATGGTACTGCGAATGATTATGCCGTCATTTGGCCTAAAAATAGAGCACCATTAATTGTCTCTATATATACAACACGAAAATCGAAAGATGATAAGCACAGTGATAAAACTATTGCGGAAGCATCACGTATTGCAATTCAGGCAATTGATTAATATTGTCTTATAAATACCAAAAATTTCACGTCTCTTGTTTAAAGAGGCGTGCTTTAATATTTTCTTAGAGTCCAATACATGAGAGTTTTAATTTCGTTTTTTTTCCTTATTTTTTCTATTAGCGTTAGAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1318,Drugs,MEG_1318|Drugs|betalactams|Class_A_betalactamases|BLASME,gi|46403068|gb|AY584237.1|1-1138 gi|510203|emb|Z30237.1|218-1,0
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCCGGCCACATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCGAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATGCATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCAGGAAAAACTTGCGCGGGAGGAACAGCGGCGGGTTCAAGAAGCCTCCCTGTTTCCGGTCTATCATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGACTGTTCCAACCGATTGGGGAACAGGGGAGCGCCACCCTATGCGGCAGCGTTTTCAAGGTTGAGTACACCGATTGCGGCCAGCGGCGTGTCTATCTGCGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGCGAAATTGTTATCCTTCCCAGCGACAGCGTGAGGTTAAACGATGTATTAGGGGATCAAACCCGGCTCCCTCGTAAAAGGTGGCGCGAGGCCCCCCTCCCCATGCTGCGGACGACGATTGCGCCGAAAACGGCAGCGCAAAGAGAACGGCTGCTGGACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGCTGCGAAGTGGATTCCATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTCGTTTCCGCTTTGCTGTCGGAAAAATACAAGATTGAAACAGTGGTAAAGGAACCCACCGTCATTTATATGGAGCGGCCGCTCAAAGCAGCCAGCCACACCATCCATATCGAGGTGCCGCCCAACCCGTTTTGGGCATCTATCGGACTGTCTGTTACACCACTCCCGCTTGGCTCCGGCGTACAATACGAGAGCCGGGTTTCGCTGGGATACTTGAACCAGAGTTTTCAAAACGCTGTCAGGGATGGTATCCGTTACGGGCTGGAGCAGGGCTTGTTCGGCTGGAACGTAACGGACTGTAAGATTTGCTTTGAATACGGGCTTTATTACAGTCCAGTCAGCACGCCGGCGGACTTCCGCTCATTGGCCCCGATTGTATTGGAACAGGCATTGAAGGAATCGGGGACGCAGCTGCTGGAACCTTATCTCTCCTTCACCCTCTATGCGCCCCAGGAATACCTTTCCAGGGCTTATCATGATGCACCGAAATACTGTGCCACCATCGAAACGGCCCAGGTAAAAAAGGATGAAGTTGTCTTTACTGGCGAGATTCCCGCCCGCTGTATACAGGCATACCGTACTGATCTGGCCTTTTACACCAACGGGCAGAGCGTATGCCTTACAGAGCTAAAAGGGTATCAGGCCGCTGTCGGCCAGCCGGTCATCCAGCCCCGCCGTCCAAACAACCGCCTGGACAAGGTGCGCCATATGTTTCAGAAGGTAATGTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7176,Drugs,MEG_7176|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/W)-1_1_AY485126 ,4
,ATGTTGAAAAGTTCGTGGCGTAAAACCGCCCTGATGGCCGCCGCCGCCGTTCCGCTGCTGCTGGCGAGCGGTTCATTATGGGCCAGTGCCGATGCTATCCAGCAAAAGCTGGCTGATTTAGAAAAACGTTCCGGCGGTCGGCTGGGCGTAGCGCTGATTAACACGGCAGATGATTCGCAAACCCTCTATCGCGGCGATGAACGTTTTGCCATGTGCAGCACCGGTAAAGTGATGGCCGCCGCCGCGGTGTTAAAACAGAGCGAAAGCAATCCAGAGGTGGTGAATAAAAGGCTGGAGATTAAAAAATCGGATTTAGTGGTCTGGAGCCCGATCACCGAAAAACATCTGCAAAGCGGAATGACCCTGGCGGAACTCAGCGCGGCGGCGCTGCAGTACAGCGACAATACCGCGATGAATAAGATGATTAGCTACCTTGGCGGACCGGAAAAGGTGACCGCATTCGCCCAGAGTATCGGGGATGTCACTTTTCGTCTCGATCGTACGGAGCCGGCGCTGAACAGCGCGATTCCCGGCGATAAGCGCGATACCACCACCCCGTTGGCGATGGCCGAAAGCCTGCGCAAGCTGACGCTGGGCAATGCGCTGGGCGAACAGCAGCGCGCCCAGTTAGTGACGTGGCTAAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCAGGCCTGCCCGCAAGCTGGGCGGTCGGGGATAAAACCGGCGCCGGAGATTACGGCACCACCAACGATATTGCGGTGATCTGGCCGGAAAATCATGCCCCGCTGGTGCTGGTGACCTATTTTACCCAGCCGCAGCAGGATGCGAAAAGCCGCAAAGAGGTGTTAGCCGCGGCGGCAAAAATCGTCACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5320,Drugs,MEG_5320|Drugs|betalactams|Class_A_betalactamases|OXY,gi|662706586|gb|CP008841.1|2548225-2547350 gi|660567586|gb|CP008788.1|1536015-1535140 gi|341705|gb|M27459.1|KPNLACMASB|86-961 gi|219920904|emb|FM178414.1|1-825,0
,atgatgaaaaaatccctttgctgcgccctgctgctcggcatctcttgctctgctctcgccacgccagtgtcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaaccgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccggcgttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagcatcggtctttttggtgcgctggtggtcaaaccttctggcatgccctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgtgccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggtatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaacgttgctgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcgagggcagcgacagtaaggtagcgctggcgccgttgcccgtggtagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggctctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaatacaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgaggcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_426,Drugs,MEG_426|Drugs|betalactams|Class_C_betalactamases|ACT,505385353|WP_015572455.1|NG_050706|1|1|blaACT-43|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-43 NG_050706:1-1146,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaagacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2167,Drugs,MEG_2167|Drugs|betalactams|Class_A_betalactamases|CTX,1028104791|WP_063860036.1|NG_048966|1|1|blaCTX-M-182|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-182 NG_048966:1-876,0
,atgaacattaaagcacccttacttataacaagcgctatttttattccagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatatatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttaagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattccccgaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtgggttggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4435,Drugs,MEG_4435|Drugs|betalactams|Class_D_betalactamases|OXA,1559613006|WP_128268271.1|NG_063876|1|1|blaOXA-772|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-772 NG_063876:43-867,0
,ATGAGTAAAAAAGATATTGCACCTCAACGTCTGACACGTGAAATAGTCCTGCGTACCGCATTGGATATGTTGAATGAAGAAGGCATAGATTCAATAACCACACGCAAGCTAGCTCAACGATTGGGTATTAAATCTCCAACTCTATATTGGCATTTCAAGAATAAATCCTTGTTAATGGAAGCAATGGCGGAAACCATTATAAATGAACACCATTTAGTTTCTTTACCCATCGATGGGATGACATGGCAAGATTGGTTGCTCGCTAATTCTGTAAGCTTTCGTCGAGCACTACTAGCTTACCGTGATGGTGCTCGTCTACATGCAAGAACTAGCCCCAGTCAAGGACATTTCAACACGATTGAGGCCCAAGTTGCGCTGTTATCTCATGCTGGGTTTTCTCCTGTTGAAGCAGTTGCATTACTTATGACATTAGGAAGGTTTATTGTTGGGTGGGTCCTTGAGGAGCAGCAAGAAGAAATAAGATCAGACCCACCATTCGAAGCCGATCCAACTATATATCCACTCATGCTCCAAGGAGTGAATACCTTACAAAATATGAATGCGGATGACATTTTTGAAAATGGGATTCGTATGGTGATTATCGGTGCTGAAAGACAACTTGATATTAAAATGCAAACTTAA,tetR,antibiotic target alteration,Tetracyclines,MEG_7195,Drugs,MEG_7195|Drugs|Tetracyclines|Tetracycline_transcriptional_repressor|TETR,gi|924867386|gb|KT346360.1|3167-3808 gi|695211247|ref|NG_036045.1|683-42,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagctccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5649,Drugs,MEG_5649|Drugs|betalactams|Class_C_betalactamases|PDC,1393270453|WP_109791198.1|NG_057596|1|1|blaPDC-264|blaPDC|class_C_beta-lactamase_PDC-264 NG_057596:1-1194,0
,TCAGATCAGCTTCAGGTCCTTCAGCACCGACTTCACGATGCGTGCCCGTTTCGGGGCGTCCGCCTCCGACAGCATGTCGATGTTGATCGCGACGCTGGCGATGTTGCCGTCGCGCTCGATCCACCCTACCCACCAGCCGATATCGGGCTTCTTGTCGACGAACCAGCCCGTCTTGCCGTGAAGCACATAGTCCGGCGTGGCTTCGACGATCGACATCTGGCGCACGATGTCCTGCGAGCGCGCAGAGAACGGCAACGTGCCACGCGCGAGACGCTGCAGGAAGTCCACCTGCTCACGCGCCGAAATCTGCAGACTGTCGTCGACCCAATAGGCGTCCGGCGCGCCGCCAATGGTGCGGTTGCCATACCCGACCTCGTTCAGCTTCGCCTGCGCGTACCGGCGCCCGATCTTGTGCGAGACGACCTGATAGCAGGGCAGGCATGACACGCGAAACGCGGTCCTCAGGTCCATCGCCGCGTTCCAGTTCTTGATGCGTCGCGGCTTGCCATCCCAGGGAATGATCGCGCGTTCGTTGTCCAGCGCCCCGGAGTCGAGCGCCAGCAGGCTGTTGAATATCTTGTAAGTCGACGCCGGCGACATGCGCTTCTCGGCACGTGCGGCGTCGTAGGCCTGATAGGTTTGCGTGCGTGCGTCGAGCACCACGATCGTGCCCTTCACGCCCTCCGCGGTGAACAGCTTGCCCCAGTCGGCGCGCTCGGTGATGCGCCCCGGCGCGGCTTTCGGCACGTCGGCCGCATAGGCCGCAGGGGTGGCGGCGAGCGTTGCGGGCAAGACGACCGCGCCGACCAGCCGCCGCCACAGGCCGGCACGCCACCGGCGAGAAATTATCGTATTCAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5173,Drugs,MEG_5173|Drugs|betalactams|Class_D_betalactamases|OXA,gb|UGSG01000001.1|+|1909222-1910080|ARO:3001450|OXA-135 [Pandoraea pnomenusa] ,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagctccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaagacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagagcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5621,Drugs,MEG_5621|Drugs|betalactams|Class_C_betalactamases|PDC,1509794574|WP_122630883.1|NG_062303|1|1|blaPDC-316|blaPDC|class_C_beta-lactamase_PDC-316 NG_062303:1-1194,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATACCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTACGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1376,Drugs,MEG_1376|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_124_NC_013944,0
,ATGCACCTTGAACGGTCGATCGAGACGTCGGCGAATATTCTCATCAGCTGCCCAAAGCAGCTGGGTGGTCTCCTGCGTAGGCAGGCCATAACTCCAACTCGATGGATCTGCCGAATCGCGCTCCCACCCGGTGACCCACTCCACCGCGACCGAGATATGCACCAGCCGCTCGCCCACAGGCTCGATCCAGGTGCGATACTCCTCCACTTCCTCGTCGCTCACGAGCACATCGAAATCGATATCGCTCCACGCACTCGCCTCGCCCCGGGCATAGCTTCCCTTCAGCAAAATCGCGACCGCATGGGGATACGCTTCTCGCAGACGATCGATCCAGTAGGTAATGGTGAGGTGCATGCAAAACTCTTCAGAATGCGGACGTTGATCGTCCTGCGACTATGCCACCATTGTGGTGTTGATGGAGGCAACATGCCAGAACGAACACTCACACTTCGAGAACTCAACCGCACCCATTTGCAGCGACAACACCTGCCGAAGCTT,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_985,Drugs,MEG_985|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT4-PRIME,gi|151026|gb|M98270.1|PSEANT4IIA|498-1,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacggggcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5667,Drugs,MEG_5667|Drugs|betalactams|Class_C_betalactamases|PDC,1393270457|WP_109791202.1|NG_057600|1|1|blaPDC-268|blaPDC|class_C_beta-lactamase_PDC-268 NG_057600:1-1194,0
,TCGGCCCTCACTCAAGGATGTATTGTGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCAGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6422,Drugs,MEG_6422|Drugs|betalactams|Class_A_betalactamases|SHV,gi|160948450|emb|AM176553.2|1-891,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtgcgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctgaagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5674,Drugs,MEG_5674|Drugs|betalactams|Class_C_betalactamases|PDC,1408841612|WP_111672885.1|NG_060540|1|1|blaPDC-295|blaPDC|class_C_beta-lactamase_PDC-295 NG_060540:1-1194,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_772,Drugs,MEG_772|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,499425585|WP_011113049.1|NG_052317|1|1|aadA25|aadA25|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA25 NG_052317:101-892,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5642,Drugs,MEG_5642|Drugs|betalactams|Class_C_betalactamases|PDC,1040476863|WP_065102306.1|NG_050946|1|1|blaPDC-166|blaPDC|class_C_beta-lactamase_PDC-166 NG_050946:1-1188,0
,GTGGCAAAGCAAAAGTTCAAAATCACCAACTGGCCCACCTACAATAAAGCCCTCATCAACCGTGGCTCCATAACTTTCTGGCTGGATGATGAAGCTATTCAGGCCTGGTATGAGTCAGCAACACCTTCTTCACGAGGCAGACCTCAGCGCTATTCTGACCTTGCCATCACGACTGTGCTGGTCATTAAACGCGTATTCAGGCTGACCCTGCGCGCTGCGCAGGGCTTTATTGATTCCATTTTTTCTCTGATGAACGTTCCGCTACGCTGCCCGGATTACAGCTGTGTCAGCAGGCGGGCAAAGTCGGTTAATATCAGTTTCAAAACGCCCACCCGGGGTGAAATCGCACACCTGGTAATTGATTCCACCGGGCTGAAGGTCTTCGGTGAAGGCGAGTGGAAAGTCAAAAAGCATGGCCAGGAACGCCGTCGTATATGGCGTAAGCTGCATCTGGCAGTTGACAGTAAAACACATGAAATCATCTGCGCTGACCTGTCGCTGAACAACGTTACGGACTCAGAGGCCTTCCCGGGTTTTATCCGGCAAACCCACCGGAAAATCAGGTCAGCCGCCGAAGATGGAGCTTACGATACCCGGCTCTGTCACGATGAACTGCGGCGTAAGAAAATCAGCGCGCTTATCCCGCCCCGAAAAGGTGCGGGTTACTGGCCCGGTGAATATGCAGACCGTAACCGTGCAGTGGCTAATCAGCGAATGACCGGGAGTAATGCGCGGTGGAAATGGACAACAGATTACAACCGTCGCTCGATAGCGGAAACGGCGATGTACCGGGTAAAACAGCTGTTCGGGGGTTCACTGACGCTGCGTGACTACGATGGTCAGGTTGCGGAGGCTATGGCCCTGGTACGAGCGCTGAACAAAATGACGAAAGCAGGTATGCCTGAAAGCGTGCGTATTGCCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2378,Drugs,MEG_2378|Drugs|betalactams|Class_A_betalactamases|CTX,gi|16506517|gb|AY033516.1|3791-4714 gi|695208600|ref|NG_035613.1|1712-2635 gi|961666360|gb|KT185451.1|96494-96265 gi|817046807|gb|KP893385.1|135986-135757,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgcggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5585,Drugs,MEG_5585|Drugs|betalactams|Class_C_betalactamases|PDC,1408841610|WP_111672883.1|NG_060537|1|1|blaPDC-275|blaPDC|class_C_beta-lactamase_PDC-275 NG_060537:1-1194,0
,GTGGCACGACGTGCCCGCGTTGACGCCGAGCTGGTCCGGCGGGGCCTGGCGCGATCACGTCAACAGGCCGCGGAGTTGATCGGCGCCGGCAAGGTGCGCATCGACGGGCTGCCGGCGGTCAAGCCGGCCACCGCCGTGTCCGACACCACCGCGCTGACCGTGGTGACCGACAGTGAACGCGCCTGGGTATCGCGCGGAGCGCACAAACTAGTCGGTGCGCTGGAGGCGTTCGCGATCGCGGTGGCGGGCCGGCGCTGTCTGGACGCGGGCGCATCGACCGGTGGGTTCACCGAAGTACTGCTGGACCGTGGTGCCGCCCACGTGGTGGCCGCCGATGTCGGATACGGCCAGCTGGCGTGGTCGCTGCGCAACGATCCTCGGGTGGTGGTCCTCGAGCGGACCAACGCACGTGGCCTCACACCGGAGGCGATCGGCGGTCGCGTCGACCTGGTAGTGGCCGACCTGTCGTTCATCTCGTTGGCTACCGTGTTGCCCGCGCTGGTTGGATGCGCTTCGCGCGACGCCGATATCGTTCCACTGGTGAAGCCGCAGTTTGAGGTGGGGAAAGGTCAGGTCGGCCCCGGTGGGGTGGTCCATGACCCGCAGTTGCGTGCGCGGTCGGTGCTCGCGGTCGCGCGGCGGGCACAGGAGCTGGGCTGGCACAGCGTCGGCGTCAAGGCCAGCCCGCTGCCGGGCCCATCGGGCAATGTCGAGTACTTCCTGTGGTTGCGCACGCAGACCGACCGGGCATTGTCGGCCAAGGGATTGGAGGATGCGGTGCACCGTGCGATTAGCGAGGGCCCGTAG,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,Aminoglycosides,MEG_7258,Drugs,MEG_7258|Drugs|Aminoglycosides|Aminoglycoside-resistant_arabinosyltransferase|TLYA,gb|AE000516|+|1908741-1909548|ARO:3003445|Mycobacterium tuberculosis tlyA mutations conferring resistance to aminoglycosides [Mycobacterium tuberculosis CDC1551] ,2
,atgatgaaaaaatcgttatgctgcgctctgctgcttacagcctcattctccacgtttgccgccgccaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatcagcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttacagataaagccgcattactgcgtttttatcaaaactggcagccgcaatggactccgggcgctaagcgtctttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacagttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgttactcctggacaacttgacgccgaagcctatggcgtgaaatccaacgttaccgatatggcccgttggattcaggtcaacatggatgccagccgcgttcaggagaaaacgctccagcaaggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggtagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccaccccggcagtgaaagcctcatgggtgcataaaacgggatccactggtggatttggcagctacgttgccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1833,Drugs,MEG_1833|Drugs|betalactams|Class_C_betalactamases|CMY,1028104242|WP_063859654.1|NG_048776|1|1|blaCMY-106|blaCMY|class_C_beta-lactamase_CMY-106 NG_048776:101-1246,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaatggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4484,Drugs,MEG_4484|Drugs|betalactams|Class_D_betalactamases|OXA,1559612995|WP_128268260.1|NG_063865|1|1|blaOXA-761|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-761 NG_063865:15-839,0
,ATGAAAACAGTTTTTATCCTTATCTCCATGCTTTTCCCTGTCGCAGTTATGGCACAGAAAAGCGTAAAAATATCCGATGACATCAGTATCACCCAACTCTCGGACAAAGTGTACACTTATGTATCCCTCGCCGAAATCGAAGGATGGGGCATGGTACCTTCCAACGGGATGATTGTTATCAACAACCACCAGGCAGCGTTGCTGGACACACCGATCAATGACGCACAAACGGAAACGCTGGTCAACTGGGTGACAGACTCTTTGCATGCCAAAGTCACCACGTTTATCCCGAACCACTGGCACGGCGATTGTATTGGCGGACTGGGTTACCTGCAAAAGAAAGGTGTCCAATCATACGCGAACCAGATGACGATAGACCTCGCCAAGGAAAAAGGGTTGCCCGTACCGGAACATGGATTCACCGATTCACTGACCGTCAGCTTGGACGGCATGCCTCTCCAATGCTATTATTTAGGAGGCGGGCATGCGACCGACAATATCGTGGTTTGGCTGCCGACAGAGAATATCCTTTTTGGCGGATGTATGCTTAAAGACAACCAGGCGACAAGCATCGGCAATATCTCGGACGCGGACGTGACGGCATGGCCGAAAACTCTCGATAAGGTAAAAGCCAAGTTCCCCTCGGCCCGCTACGTCGTGCCCGGACATGGCGACTATGGCGGAACCGAACTGATAGAGCATACCAAGCAGATCGTGAACCAATATATAGAAAGCACCTCAAAGCCATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1670,Drugs,MEG_1670|Drugs|betalactams|Class_B_betalactamases|CFIA,(Bla)cfiA14:FM200789:162-911:750,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaataccccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagtgctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_607,Drugs,MEG_607|Drugs|betalactams|Class_C_betalactamases|ADC,447133983|WP_001211239.1|NG_056107|1|1|blaADC-165|blaADC|class_C_beta-lactamase_ADC-165 NG_056107:1-1152,0
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgtgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcagttgtgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgctttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccacggagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagccagcgtattgtcaaacaagccatgctgaccgaggcgaatgctgattatattattcgggcgaaaaccggttattcaggcagaattgagccgaaattcggttggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggagaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4615,Drugs,MEG_4615|Drugs|betalactams|Class_D_betalactamases|OXA,1102724731|WP_071593227.1|NG_052051|1|1|blaOXA-538|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-538 NG_052051:24-821,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgaaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcaacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_557,Drugs,MEG_557|Drugs|betalactams|Class_C_betalactamases|ADC,1440786781|WP_114699269.1|NG_061393|1|1|blaADC-177|blaADC|class_C_beta-lactamase_ADC-177 NG_061393:1-1152,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGAAAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAACCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCTCGTAGCACCTCGCAGGCGTGCCGGCCGATATGACTGGCGGCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6491,Drugs,MEG_6491|Drugs|betalactams|Class_A_betalactamases|SHV,gi|815976342|gb|CP011313.1|2734371-2735303 gi|164449661|gb|EU342351.1|173-1105,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcctggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5676,Drugs,MEG_5676|Drugs|betalactams|Class_C_betalactamases|PDC,730663159|WP_034066397.1|NG_049944|1|1|blaPDC-69|blaPDC|class_C_beta-lactamase_PDC-69 NG_049944:1-1194,0
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggctagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_857,Drugs,MEG_857|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502046|WP_071846198.1|NG_052156|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052156:101-892,2
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTAGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6638,Drugs,MEG_6638|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|954171462|gb|KT151662.1|76901-77716 gi|954171374|gb|KT151661.1|76901-77716 gi|954171188|gb|KT151659.1|76865-77680 gi|954171094|gb|KT151658.1|76873-77688 gi|954171002|gb|KT151657.1|76901-77716 gi|954170914|gb|KT151656.1|76901-77716 gi|954170819|gb|KT151655.1|76901-77716 gi|954170731|gb|KT151654.1|76901-77716 gi|787519209|gb|KJ817377.1|2902-2087 gi|787519087|gb|KJ817376.1|78428-79243,8
,CTATAGGGCAACCAGGCTGTCCTTGCCGGCGCTTGTAACACAGACGATGGCATCAAATGCCTCGCTCAATTTCGTTTCTACAGAGGCGCTTTGAGACCGCATTCGCTTTGCTTCCATGGGGGCATCTGTCAATGTCAGACATGAATTCTCCGTACCACAGGCGTCGATGACATACTGTTCCATACTATCCTCACGGATTGCATCGGCAGGCGTGGTCACAACAGAGAATCCAAGAGGACTTTTTGGCGATGGGAAATGCATTTCCGGCACGGTGGGTCCAAGATGGGTGAATGCAATCGCACGGTAATTCACCCTCTCTGCGAGGTGCTGCCCCATGGGAACAGCCGTAAGCTCGCCTGAAAAGGAGACTGGAGTTTTTTGTAGATGATTGTTGTGCGCCAGCAGAATTATCTTCACATCCGGATTCGCTCGAACCATTCCATCTACTACGCCCGCCATATACGAGTCACGTACGGAAGTATCTCCCTCAAGAGAGGTACCATCGAAGAAAGTTTTCATTATACGCAAGGTTTCCAACGTATACTCTATCGACTCTATTCGATCAGAGGCTTTTCGGAACAAATCGCTGTTGACGTGTTTTTTCAGGACGGGGGCAAGCGACGCCAAGCGGAGCTTCAATCTGGTTACCCCTGAGATAGCTTTCTCCTGCCGAGCCGTTTCTAGCTCCCCCCATTTTGCCGATGAAATAACCGCCGACTGGCCATCAATGGACGCCAACAAGTGAGTCAACATATCAACGTGCGGTTTCATGAGGTGATCGATGAGCTGGATAATTTCGGCCAATTGCGCTAGGTCGTCCCTTGGGTTCAGGGTGTTGGGTAAGGCGATTCCGACTAACTGCAGTTTTCTTCCTGATTCGCGGAGATATGATTTCAGCCAGATCAGCACTGAGCCATACACAGAAAAGGTCAGGGTATCCGAAAATCGCTCAAGTTCATGAGCACCGGCTGTTGAGTTGAGCCATTCAGATAACCGGGATGCCTGAATCGCCCCACATTTCCAAACCAATCGCAT,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_2748,Drugs,MEG_2748|Drugs|MLS|Macrolide_esterases|EREA,gb|M11277.1|-|246-1281|ARO:3000361|EreA [Plasmid pIP1100] ,7
,ATGACGACATCTGCGCCTGAGGACCGTATCGACCAGGTCGAGCAGGCCATCACCAAGAGCCGGCGCTACCAGACGGTGGCCCCGGCCACCGTGCGGCGCCTGGCCCGGGCTGCCCTCGTCGCCGCGCGGGGCGACGTGCCGGACGCGGTGAAGCGCACCAAGCGCGGGCTGCATGAGATCTACGGGGCCTTCCTGCCGCCCAGCCCGCCCAACTACGCAGCGTTGCTGCGGCAGCTCGACTCCGCTGTGGACGCCGGTGACGACGAGGCGGTCCGGGCGGCTCTGCGCCGCGCGATGTCAGTGCATGTGTCCACTCGTGAGCGATTGCCGCACCTGGCGGAGTTCTACCAGGAGATCTTCCGTCACGTGCCCCAGCCCAACACGCTGCGTGACCTCGCCTGTGGCCTCAATCCGCTGGCCGCTCCCTGGATGGGCCTGTCGGACCAGACCGTCTACGTCGCCTCCGACATCGACGCCCGGCTGATCGGCTTCGTGGACGCCGCCCTGACGAGGCTGGGCGTCGCGCACCGTACGAGCGTGGTCGACCTCCTCGAGGACCGCCTTGACGAGCCGACCGACGTCACGCTATTGCTGAAGACGCTGCCCTGTCTGGAGACTCAGCGACGAGGCTCCGGCTGGGAAGTGATTGACATTGTCAACTCGCCGATTATCGTGGTAACCTTCCCGACCAAGTCTCTCGGTCAGCGATCGAAGGGGATGTTTCAGAACTATTCACAAAGTTTTGAGTCCCAGGCCAGAGAACGGTCGTGCCGAATTCAGCGACTGGAGATCGGCAACGAGCTGATTTACGTCATTCAGAAATAG,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_3173,Drugs,MEG_3173|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|GRM,grmA_1_M55520 ,2
,CTAAGTTCTTAAGGGCGCATGGTGAATGCCTTGGCACTAGAAGCCGAAGAAGGACGTAGGAGGCTGCGATAAGCCTCGGGGAGCTGCCAACCGAGCTTTGATCCGAGGATCTCCGAATGGGGAAACCCAGCACGAGTGATGTCGTGTTACCCACTGCTGAATATATAGGCTTTGGGAGGAAACGCGGGGAAGTGAAACATCTCAGTACCCGTAGGAAGAGAAAACAACCGTGATTCCGTGAGTAGTGGCGAGCGAAAGCGGAAGATGGCTAAACCGCATGCATGTGATACCTGGTAGGGGTTGTGTGTGCGGGGTTGTGGGAGTTGTACTTGCCGGTTCTACCAGGCCGGCGGACAGTAAAAAAGTGTCGTGATTAGCGGAAGTGGTCTGGGACGGCCCGCCGCAGACGGTGAGAGTCCGGTACGCGAAAATCCGACACCTGTCTCGTACTTCATCCCGAGTAGCAGCGGGCTCGTGGAATCTGCTGTGAATCTGCCGGGACCACCCGGTAAGCCTAAATACTCTCTAGTGACCGATAGCGGATTAGTACCGTGAGGGAATGGTGAAAAGTACCCCGGGAGGGGAGTGAAATAGTACCTGAAACCATGTGCCTACAATCCGTCAAAGCCTCCTCGTGGGGTGATGGCGTGCCTTTTGAAGAATGAGCCTGCGAGTCAGGGACACGTCGCGAGGTTAACCCGTGTGGGGTAGCCGTAGCGAAAGCGAGTCTGAATAGGGCGCCCATAGTGGCGTGTTCTGGACCCGAAGCGGAGTGATCTACCCATGGCCAGGGTGAAGCGGCGGTAAGACGCCGTGGAGGCCCGAACCCACTTAGGTTGAAGACTGAGGGGATGAGCTGTGGGTAGGGGTGAAAGGCCAATCAAACTCCGTGATAGCTGGTTCTCCCCGAAATGCATTTAGGTGCAGCGTCGCGTGTTTCTTGTTGGAGGTAGAGCTACTGGATGGCCGATGGGCCCTACTAGGTTACTGACGTCAGCCAAACTCCGAATGCCAATAAGTTAGAGCGCGGCAGTGAGACGGCGGGGGAGAAGCTCCGTACGTCGAGAGGGAAACAGCCCAGATCGCCGGCTAAGGCCCCTAAGCGTGTACTAAGTGGAAAAGGATGTGCAGTCGCGAAGACAACCAGGAGGTTGGCTTAGAAGCAGCCACCCTTGAAAGAGTGCGTAATAGCTCACTGGTCAAGTGATTGTGCGCCGACAATGTAGCGGGGCTCAAGTACACCGCCGAAGCCGCGGCATTCATGCAATACATTCCCTTCGGGGCAGTGGCATGGATGGGTAGGGGAGCGTCCTGCACCCAGCGAAGCTGCGAAGTAATTCAGCAGTGGAGGGTGCGGGAGTGAGAATGCAGGCATGAGTAGCGACAGGCAAGTGAGAAACTTGCCCGCCGAATGACCAAGGGTTCCTGGGCCAGGCTAGTCCTCCCAGGGTAAGTCGGGACCTAAGGCGAGGCCGACAGGCGTAGTCGATGGACAACGGGTTGATATTCCCGTACCCGTGTGTGCGCGCCCATGATGAATCATCGGTACTAACCACCCAAAAGGTTCTAGATCAATCTCTTCGGAGTGCGACGTGAACCCGCTGCGTGGGACCTTCGGTGGTAGTAGTCAAGCGATGGGGTGACGCAGGAAGGTAGCTGTACCGGTTAGTGGTTATACCGGAGCAAGCCCGTAGGACGACATCTAGGCAAATCCGGATGTCATACGTCTGAGAGGTGACGCATAGCCGATTGAGGCGAATTCAGTGATCCTATGCTGCCAAGAAAAGCCTCTAGTGAGTTCACACACGGCCCGTACCCCAAACCAACACAGGTGGTCAGGTAGAGAATACTAAGGCGTACGAGATAACTATGGTTAAGGAACTCGGCAAAATACCCCCGTAACTTCGGGAGAAGGGGGACCTCGCTTGGTGACCGGACTTGCTCCGTGAGCTGAACGAGGTCGCAGAGACCAGTGAGAAGCGACTGTTTACTAAAAACACAGGTCCGTGCGAAGTCGCAAGACGATGTATACGGACTGACGCCTGCCCGGTGCTGGAAGGTTAAGAGGACCCGTTAACCCTTGGGTGAAGCGGAGAATTTAAGCCCCAGTAAACGGCGGTGGTAACTATAACCATCCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCTGCACGAATGGCGTAACGACTTCTCAACTGTCTCAACCATAGACTCGGCGAAATTGCACTACGAGTAAAGATGCTCGTTACGCGCGGCAGGACGAAAAGACCCCGGGACCTTCACTATAGCTTGGTATTGGCGTTTGGTTCGGTTTGTGTAGGATAGGTGGGAGACTGTGAAGCAGGCACGCCAGTGTTTGTGGAGTCATCGTTGAAATACCACTCTGATCGTATTGAACCTCTAACCTCGGACCGTATATCCGGTCCAGGGACAGTGCCTGGTGGGTAGTTTAACTGGGGCGGTTGCCTCCCAAAATGTAACGGAGGCGCCCAAAGGTTCCCTCAACCTGGACGGCAATCAGGTGTTGAGTGCAAGTGCACAAGGGAGCTTGACTGCGAGACCTACAAGTCAAGCAGGGACGAAAGTCGGGACTAGTGATCCGGCACCTCTGAGTGGAAGGGGTGTCGCTCAACGGATAAAAGGTACCCCGGGGATAACAGGCTGATCTTCCCCAAGAGTCCATATCGACGGGATGGTTTGGCACCTCGATGTCGGCTCGTCGCATCCTGGGGCTGGAGCAGGTCCCAAGGGTTGGGCTGTTCGCCCATTAAAGCGGCACGCGAGCTGGGTTTAGAACGTCGTGAGACAGTTCGGTCTCTATCCGCCGCGCGCGTCAGAAACTTGAGGAAACCTGTCCCTAGTACGAGAGGACCGGGACGGACGAACCTCTGGTGTACCAGTTGTTCCACCAGGAGCACGGCTGGATAGCTACGTTCGGACAGGATAACCGCTGAAAGCATCTAAGCGGGAAACCTATTCCAAGACCAGGTTTCTTACCCTTTTAGAGGGATAAGGTCACCCACAGACTATGGGTTCAATAGGCCAGACCTGCAAGCGTAGTAATACGTTCAGGGAACTGGCACTAATCGACCGAAAACTTACTAAT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3982,Drugs,MEG_3982|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NC_010397.1|+|1464207-1467319|ARO:3004163|Mycobaccterium abscessus 23S rRNA with mutation conferring resistance to clarithromycin [Mycobacteroides abscessus] ,7
,ATGGATTCCTTCGCCAAGGAGACGCTTCCGGTATCGCTGGAAGAAGAGATGCGCCGTAGCTATCTTGATTACGCGATGAGCGTGATCGTGGGGCGCGCGCTGCCAGACGTGCGTGACGGTCTCAAGCCTGTGCATCGCCGCGTGCTGTACGCGATGCACGAACTGAACAACGATTGGAACCGTGCCTATAAGAAGTCCGCGCGTATCGTCGGGGACGTCATCGGTAAGTACCACCCGCACGGCGACCAGTCGGTATACGACACCATCGTCCGCATGGCGCAGGACTTCTCCATGCGCTACATGCTGGTCGACGGCCAGGGCAACTTCGGCTCCATCGACGGCGACAACGCCGCGGCGATGCGCTACACCGAAATCCGCCTGGCCAAGATCGCGCACGAGTTGCTGGCCGATATCGACCAGGAAACGGTCGACTTCGGGCCCAACTACGACGGCAGCGAACAGGAGCCCCTGCTGCTGCCTTCGCGCCTGCCCAACCTGCTGGTCAACGGCAGCTCGGGTATCGCCGTGGGCATGGCCACCAACATTCCCCCGCACAACCTGCAGGAAGTGGTCGACGGCTGCCTGTATTGCCTGCGCAATCCGGAATGCTCGATCGACGAGCTGATCGAACTGATCCCGGCGCCGGACTTTCCCACGGGCGGGGTGATCTACGGCATCACGGGCGTTCGCGAGGGGTACCGCACCGGGCGCGGCCGCGTCATCATGCGCGCCAAGACCCACTTCGAGGACATGGAGAAGGGCAACCGCCAGGCCATCGTGGTCGACGCGATTCCCTACCAGGTCAACAAGAAGACCCTGCAGGAGCGCATCGCCGAGCTGGTCAACGACAAGAAGATCGAGGGCATTTCGGACATCCGCGACGAGTCGGACAAGGACGGCATGCGCCTGGTCATCGAGCTCAAGCGCGGCGAAGTGCCCGAGGTGGTGCTGAACAACCTGTACAAGAATACGCAGCTGCAGGACACCTTCGGCATGAACCTGGTGGCGCTGGTCGACGGCCAGCCGCGCCTGCTGAACCTCAAGCAGCTGATCGAGTACTTCCTGCAGCATCGCCGCGAAGTGGTGACGCGCCGCACCGTGTTCCAGCTGCGCAAGGCGCGCGAACGCGGCCACGTGCTGGAAGGCCTGGCGGTGGCGCTGGCCAACATCGACGACTTCATCGCCATCATCAAGGCGGCGCCCACCCCGCCGGTGGCGCGCCAGGAATTGATGGCGCGTTCCTGGGATTCGTCGCTGGTGCGTGAAATGCTGGCCCGCGTCGACGGCGACGCCGCCGGCGGCGTCGCGGCGTTCCGCCCCGACGACCTGGCGCCCGAGTACGGCCTGCAGGGCGATGGCAACTACCGGCTGAGCGAGACCCAGGCGCAGGAAATCCTCAACATGCGCCTGCAACGCCTGACCGGCCTGGAGCAGGACAAGATCATCGGCGAGTACAAGGACGTGATGGCCACCATCGCCGACCTGCTCGACATCCTGGCCCGTCCGGATCGCATCACCACGATCATCAGCGAAGAGCTGCAGGCCATCAAGGCCGAGTTCTCGACCTCGGCCAAGGATACGCGCCGCGCCGAAATCGAAGTCAACGCCACCGAGCTGGATACCGAAGACCTGATCACGCCGATGGACATGGTGGTCACCCTGTCGCATGGCGGATACATCAAGAGCCAGCCGCTGTCCGAGTACCGTTCGCAAAAGCGCGGCGGACGCGGCAAGCAGGCTACCGCCATGAAGGAGAACGACTGGGTCGACCAGCTGTTCATCGCCAATACGCACGACTACCTGCTGTGCTTCTCCAACCGGGGCCGGGTGTACTGGCTGAAGGTGTGGGAGGTGCCGCAGGGCACGCGCAACTCGCGCGGCAAGCCCATCGTCAACATGTTCCCGCTGGCCGACGGCGAGAAGGTGACCGTGGTGCTGCCGGTCAAGGAATTCAGCGAAGACCACTACGTCTTCATGGCGACGTCGCGCGGCACGGTCAAGAAGACCCCGCTGTCCGACTTCTCGAACCCGCGCAAGGCCGGCATCATCGCCGTCGACCTGGATGACGGCGATTACCTGATCGGCGCAGACCTGACCGACGGCAAGCACGATGTGATGTTGTTCTCCGACGCCGGCAAGGCGGTGCGCTTCGACGAGAACGACGTGCGTCCGATGGGCCGCAATGCGCGCGGCGTGCGCGGCATGATGCTCGAAGAGGGCCAGACCGTCATCGCGCTGCTGGTGGCCGGCGACGAGACCCAGAGCGTGCTGACCGCCACCGAGAACGGCTACGGCAAGCGCACCCCGATCACCGAGTACACCCGCCATGGCCGCGGCACCAAGGGCATGATCGCCATCCAGACCAGCTCGCGCAACGGCCGCGTGGTCGGCGCCGTGCTGGTGATGCCGTCCGACGAGATCATGCTGATCACCACCGGCGGCGTGCTGGTGCGCACCCGCGTGGCCGAGATCCGCGAGATGGGTCGCGCCACGCAGGGCGTCACGCTGATCAGCGTCGATGACGGCAGCAGCCTGTCCGGCGTGCGGCGCGTGGTCGAAAGCGATGCCGACGCCGATGACGAGGATGGCGGCGAAGAGGGCGGCGAAGAGGGCGGCGACCAAGGCGGCGACGATACCGGCGCCCAGGGCAAGGATTCTGAACCGACTGAACCTACGGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3231,Drugs,MEG_3231|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|973420427|gb|CP010966.1|963451-966132 gi|973416827|gb|CP010965.1|3093143-3090462 gi|937412521|gb|CP011401.1|3086413-3083732 gi|937409066|gb|CP011400.1|679881-682562 gi|937404317|gb|CP011448.1|964495-967176 gi|937400854|gb|CP011447.1|964504-967185 gi|937393878|gb|CP011446.1|963451-966132 gi|937390412|gb|CP011445.1|962402-965083 gi|937386949|gb|CP011444.1|963453-966134 gi|937383491|gb|CP011443.1|3092107-3089426,3
,ATGGAAAGAAAAGGGATTTTCATTAAGGTTTTTTCCTATACGATCATTGTCCTGCTACTGCTTGTCGGTGTAACAGCAACACTGTTTGCACAGCAATTTGTGTCTTATTTCAGAGTGATGGAATTACAGCAAACAGTAAAATCCTATCAGCCATTGGTGGAACTGATTCAGAATAGCGATAGGCTTGATATTCAAGAGGTGGCAGGGCTGTTTCACTACAATAACCAATCCTTTGAGTTTTATATTGAAGATAAAGAGGGAAGCGTACTCTATGCCACACCAAATGCCAATACATCAAATAGTTTTAGACCCGACTTTCTTTATGTGGTACATAGAGATGATAATATTTCGATTGTTGCTCAAAGCAAGGCAGGTGTGGGATTGCTTTATCAAGGGCTGACAATTCGGGGAATTGTTATGATTGCGATAATGGTTGTATTCAGCCTTTTATGCGCGTATATCTTTGCGCGGCAAATGACAACGCCGATCAAAGCCTTAGCGGACAGTGCGAATAAAATGGCAAACCTGAAAGATGTACCGCCGCCGCTGGAGCGAAAGGATGAGCTTGGCGCACTGGCTCATGATATGCATTCCATGTATGTCAGGCTGAAAGAAACCATCGCAAGGCTGGAGGATGAAATCGCAAGGGAACATGAGTTGGAGGAAACACAGCGATATTTCTTTGCGGCAGCTTCTCATGAGCTAAAAACGCCCATCGCGGCTACAAGCGTTCTGTTGGAGGGAATGCTTGAAAATATCGGTGACTACAAAGATCATTCTAAGTATCTGCGCGAATGCATCAAAATGATGGATAGGCAGGGCAAAATCATTTCCGAAATACTGGAGCTTGTCAGCCTGAATGATGGGAGAATCGTACCCATAGCTGAACCGTTGGACATAGGGCGCACGGTTGCCGAGTTGCTGCCCGATTTTCAAACCTTGGCAGAGGCAAACAACCAGCGGTTCGTCACAGATATTCCAGCCGGACAAATTGTCCTGTCCGATCCGAGGCTGCTCCAAAAGGCACTATCCAATGTCATATTGAATGCAGTTCAGAACACGCCGCAGGGAGGCGAGGTACGGATATGGAGTGAGCCTGGTGCTGAAAAATGCCGCCTTTTTGTTTTGAACATGGGCGTTCACATTGATGATACTGCGCTTCCAAGGCTGTTCACCCCATTCTATCGCATTGATCAGGCGCGAAGCAGAAAAAGTGGGCGAAGTGGTTTAGGACTTGCCATCGTACAAAAAACGCTGGATGCCATGAGCCTCCAGTATGCGCTGGAAAACACCTCGGATGGCGTTTTGTTCTGGCTGGATTTACCGCTCACATCAACATTGTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7495,Drugs,MEG_7495|Drugs|Glycopeptides|VanB-type_regulator|VANSB,gi|695199646|ref|NG_035288.1|24709-26052,5
,atgcaattcacaaagattgatataaataattggacacgaaaagagtatttcgaccactattttgacaatacgccctgcacatatagtatgacggtaaaactcgatatttctaagttgaaaaaggatggaaaaaaattatatccgactctcttatatggggttacaacaatcctcaatcgacacgaagagttcaggacggcattagataaaaacggacaggtaggtgttttttcagaaatgctgccttgctacacaatctttcataaggaaactgaaaccttttcgagtatttggactgagtttacagcagactatactgagtttcttcagaactatcaaaaggatatagacgcttatggtgaacgaaagggaatgttcgcaaagcctaatcctccggaaaacactttccctgtttctatgataccgtggacaagctttgaaggctttaacttaaatctaaaaaaaggatatgactatctactgccgatatttacgtttgggaagtattatgaggatggcggaaaatactatattcccttatcgattcaagtgcatcatgccgtttgtgatggctttcatgtttgccgttttttggatgaattacaagacttgctgaataaataa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1576,Drugs,MEG_1576|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,760091946|WP_043774378.1|NG_055993|1|1|catA13|catA13|type_A-13_chloramphenicol_O-acetyltransferase NG_055993:101-724,6
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcacgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5491,Drugs,MEG_5491|Drugs|betalactams|Class_C_betalactamases|PDC,1201190452|WP_087587972.1|NG_054993|1|1|blaPDC-208|blaPDC|class_C_beta-lactamase_PDC-208 NG_054993:1-1194,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4478,Drugs,MEG_4478|Drugs|betalactams|Class_D_betalactamases|OXA,1188444912|WP_085562414.1|NG_054704|1|1|blaOXA-560|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-560 NG_054704:1-825,0
,atgatcgtcaactgcgaccacgacaacctcgacgcctggctggcgctacgcgcggcgctgtggcccacttgtccgttggaagagcaccgcgcggagatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgccacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttacaccgtcgaacgcgcccgccgccagggctgggcggcgcgtttgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgacatcgccaatctggactcccagcgcctgcatgccgcgctgggctttgccgaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_96,Drugs,MEG_96|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,545149714|WP_021505085.1|NG_052297|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052297:101-541,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccaatggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatccccctgaagcgcctgcaggccggcaactcgacgccgatggcactgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5465,Drugs,MEG_5465|Drugs|betalactams|Class_C_betalactamases|PDC,1201190442|WP_087587962.1|NG_054980|1|1|blaPDC-194|blaPDC|class_C_beta-lactamase_PDC-194 NG_054980:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgatgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctaccactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5443,Drugs,MEG_5443|Drugs|betalactams|Class_C_betalactamases|PDC,1408841637|WP_111672910.1|NG_060568|1|1|blaPDC-303|blaPDC|class_C_beta-lactamase_PDC-303 NG_060568:1-1194,0
,atgaaaaagatccgccttattataatctctttactggctggaatgtgtactccagcattatctacaccagtcaatgttactgatacaatacaaagcacagaagaccatatcaaaggtcgggttggttttactgaaatagactttttatccgggaaggttctgagtagtcatcgccgtgaagaacgttttcctatgatgagcacattcaaagttttgttatgtggagcaatattagtacgtgttgataaagggcttgaacaacttgaacgccgaattacctataataagcatgacctggacgactattctccactaaccagtcagcacattgcagatggaatgacggtttctgagttatgcaatgctgccattaccaccagtgataacactgctgcaaatttattgctatcaactattggcgggccggagggattaactcattttctgcgtagcactggtgatagttatacaaggcttgatcgacacgaacccagccttaatgaggcgaagcctggcgatgagcgtgataccaccactccggcagcgatggctcaaacgctacaaaaattgttaaacggaagtgtacttacagaaaaatctcgaaaaaaattaataagctggatgcaggaagataaagtcggcgggcctctgttccgctctgtactgccagctggctggatgatagcggataaaacaggagcaggtgatcacggatctcggggcatcgttgcactgttgggccccggaggcaagccatctcgtatagtagtcctgtatattacaaatactcattcatctatgaatgaactcaacgagcatattgcagggatcggagattcagtaattaagaactggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3536,Drugs,MEG_3536|Drugs|betalactams|Class_A_betalactamases|LAP,690403011|WP_031942394.1|NG_049263|1|1|blaLAP-1|blaLAP|class_A_beta-lactamase_LAP-1 NG_049263:1-858,0
,atgactctggcattagttggcgaaaaaattgacagaaacagattcactggtgcgaaagttgaaaatagcacatttttcaactgtgatttttcgggtgccgacctcagcggcactgagtttattggctgtcagttctatgatcgagagagccagaaagggtgtaattttagtcgcgctatcctgaaagatgccattttcaaaagttgtgatctctccatggcggatttcaggaatgtgagcgcgctgggaatcgaaattcgccactgccgcgcacaaggttcagattttcgcggcgcaagctttatgaatatgattaccacacgcacctggttttgtagcgcctatatcaccaataccaacttaagctacgccaacttttcaaaagtcgtactggaaaagtgcgagctgtgggaaaaccgttggatgggtactcaggtactgggggcgacgttcagtggttcagatctttccggcggtgagttttcgtcgttcgactggcgggccgcaaactttacgcactgtgatttgaccaattcagaactgggcgatctcgatgtccggggtgttgatttgcaaggcgtcaaactggacagctaccaggcatcgttgatcctggaacgtcttggcatcgctgtcattggttaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5878,Drugs,MEG_5878|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,740855668|WP_038640920.1|NG_050472|1|1|qnrB12|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB12 NG_050472:101-745,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacctacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcagtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtkccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5523,Drugs,MEG_5523|Drugs|betalactams|Class_C_betalactamases|PDC,1393270448|WP_109791193.1|NG_057591|1|1|blaPDC-259|blaPDC|class_C_beta-lactamase_PDC-259 NG_057591:1-1194,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGTAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGGATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCTCGTAGCACCTCGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAGAGATGCCGGTCGGTAATGATGGTGGTGAACCGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6427,Drugs,MEG_6427|Drugs|betalactams|Class_A_betalactamases|SHV,gi|195954365|gb|EU979559.1|57-1032 gi|25989459|gb|AY079099.1|149-1124,0
,atgaaaaaattatttgttttatgtgtattcttgctttgtaacattgctactgcagaagattctttgcctgatttaaaaattgataagcttgaagaaggagtttatgttcatacttcgtttgaagaagttaaaggttggaatgtagtcacaaaacacggtctggtggttcttgtaaaaaatgacgcctatctgattgatactccaattactgttaaagatactgaaaaattagtcaattggttggttgagcgtggctataaaatcaaaggcagtatttcaacacatttccatgatgatagttcagctggaatagaatggcttaattctcaatctattcccacgtatgcatcgagattaacaaatgaacttcgtaaaaaaggcggcaagccgcaagctactaactcttttgatggcgttagttattcactcattaaaaacaagattgaagttttttatccaggcccagggcacactcaagataacgtagtagtttggttacctgaaaagaaaattttattcggtggttgttttgttaaaccggacggtcttggatatttgggggacgcaaatttagaggcttggccaaagtccgctaaaatattaatgtctaaatatgctaaggcaaaactggtcgtttcaagtcacagtgaaattggggatacatcactcttgaaacgtacatgggaacaagctgttaaagggctaaatgaaagtaaaaagccataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3315,Drugs,MEG_3315|Drugs|betalactams|Class_B_betalactamases|IMP,1625655392|WP_136512069.1|NG_064725|1|1|blaIMP-46|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-46 NG_064725:1-726,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctactcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgatgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatcgccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacagggtcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctggcgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5504,Drugs,MEG_5504|Drugs|betalactams|Class_C_betalactamases|PDC,1040941178|WP_065159032.1|NG_050982|1|1|blaPDC-170|blaPDC|class_C_beta-lactamase_PDC-170 NG_050982:1-1194,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCAGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1840,Drugs,MEG_1840|Drugs|betalactams|Class_C_betalactamases|CMY,(Bla)CMY-4:AF420597:1-1146:1146,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGTTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1998,Drugs,MEG_1998|Drugs|betalactams|Class_C_betalactamases|CMY,gi|828983113|gb|CP011657.1|2365948-2367175 gi|828940051|gb|CP011612.1|3646139-3644912 gi|347364916|gb|HM569226.2|1040-2267,0
,atgaaaaagataaaaattgttccacttattttaatagttgtagttgtcgggtttggtatatatttttatgcttcaaaagataaagaaattaataatactattgatgcaattgaagataaaaatttcaaacaagtttataaagatagcagttatatttctaaaagcgataatggtgaagtagaaatgactgaacgtccgataaaaatatataatagtttaggcgttaaagatataaacattcaggatcgtaaaataaaaaaagtatctaaaaataaaaaacgagtagatgctcaatataaaattaaaacaaactacggtaacattgatcgcaacgttcaatttaattttgttaaagaagatggtatgtggaagttagattgggatcatagcgtcattattccaggaatgcagaaagaccaaagcatacatattgaaaatttaaaatcagaacgtggtaaaattttagaccgaaacaatgtggaattggccaatacaggaacagcatatgagataggcatcgttccaaagaatgtatctaaaaaagattataaagcaatcgctaaagaactaagtatttctgaagactatatcaaacaacaaatggatcaaaattgggtacaagatgataccttcgttccacttaaaaccgttaaaaaaatggatgaatatttaagtgatttcgcaaaaaaatttcatcttacaactaatgaaacagaaagtcgtaactatcctctaggaaaagcgacttcacatctattaggttatgttggtcccattaactctgaagaattaaaacaaaaagaatataaaggctataaagatgatgcagttattggtaaaaagggactcgaaaaactttacgataaaaagctccaacatgaagatggctatcgtgtcacaatcgttgacgataatagcaatacaatcgcacatacattaatagagaaaaagaaaaaagatggcaaagatattcaactaactattgatgctaaagttcaaaagagtatttataacaacatgaaaaatgattatggctcaggtactgctatccaccctcaaacaggtgaattattagcacttgtaagcacaccttcatatgacgtctatccatttatgtatggcatgagtaacgaagaatataataaattaaccgaagataaaaaagaacctctgctcaacaagttccagattacaacttcaccaggttcaactcaaaaaatattaacagcaatgattgggttaaataacaaaacattagacgataaaacaagttataaaatcgatggtaaaggttggcaaaaagataaatcttggggtggttacaacgttacaagatatgaagtggtaaatggtaatatcgacttaaaacaagcaatagaatcatcagataacattttctttgctagagtagcactcgaattaggcagtaagaaatttgaaaaaggcataaaaaaactaggtgttggtgaagatataccaagtgattatccattttataatgctcaaatttcaaacaaaaatttagataatgaaatattattagctgattcaggttacggacaaggtgaaatactgattaacccagtacagatcctttcaatctatagcgcattagaaaataatggcaatattaacgcacctcacttattaaaagacacgaaaaacaaagtttggaagaaaaatattatttccaaagaaaatatcaatctattaactgatggtatgcaacaagtcgtaaataaaacacataaagaagatatttatagatcttatgcaaacttaattggcaaatccggtactgcagaactcaaaatgaaacaaggagaaactggcagacaaattgggtggtttatatcatatgataaagataatccaaacatgatgatggctattaatgttaaagatgtacaagataaaggaatggctagctacaatgccaaaatctcaggtaaagtgtatgatgagctatatgagaacggtaataaaaaatacgatatagatgaataa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3773,Drugs,MEG_3773|Drugs|betalactams|Penicillin_binding_protein|MECA,1028095729|WP_063852617.1|NG_047940|1|1|mecA|mecA|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA NG_047940:1-2007,0
,ATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTTACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGTTGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_363,Drugs,MEG_363|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|974319461|gb|CP008865.1|2545894-2545376 gi|971339514|gb|CP006662.2|83260-82742 gi|943457735|gb|KT818627.1|74820-74302 gi|943457735|gb|KT818627.1|136411-135893 gi|902625474|gb|CP011993.1|2651-2133 gi|902625122|gb|CP011990.1|137150-137668 gi|902618983|gb|CP011988.1|3506-2988 gi|902618894|gb|CP011987.1|7246-6728 gi|800908878|gb|KP345882.1|47652-48170 gi|760459974|gb|KJ958927.1|14264-13746 gi|760459883|gb|KJ958926.1|9176-8658,2
,atgaaaaaaatcatcttgtttttatggattttaaattttgcctttggacaagataaaatattagaagatttttttaaagattataatacaagtgggatttttataatctttgatggaaaaaattatgcaagtaatgattttcaaagagctaaacaagccttttctcctgcttcaacttttaaaatttttaatgctttaattgcgcttgataatggtgtagttaaagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattagcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgataccttttggctggataattctttgcaaatttctgcaaaaaatcaagctgatttactttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaacttcttctttttaaagaaaataaaatacaaaaaatttatgccaaaacaggttttaatgataatataaatttagcttggattgttggattcgtaaagactaaaaacaaaattttatcttttgctttaaatgttgatataaagcacgttaaaaatattaaaataagagaagaattgctagaaaaatatctagcaatcataacaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4666,Drugs,MEG_4666|Drugs|betalactams|Class_D_betalactamases|OXA,1391852892|WP_109545077.1|NG_057494|1|1|blaOXA-636|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-636 NG_057494:1-750,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcaccgcgctgtggccgtccggctcgcctgaagagcaccgcgcggaaatgcgcgagatactggcttcgccgcaccataccgtgtttatggcgcgggggctggacggcgctttcgttgcctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgccgaacgcgcccgccgccagggctgggccgcgcgcctgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggagcgagtagtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_156,Drugs,MEG_156|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,751567893|WP_041036791.1|NG_052449|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052449:101-541,2
,atggaaaaatcaaagcaattatataatcaagtgaacttctcacatcaggacttgcaagaacatatctttagcaattgtacttttatacattgtaattttacgcgctcaaaccttcgagatacacagttcattaactgtactttcatagagcagggggcactggaagggtgcgatttttcttatgctgatcttcgagatgcttcatttaaaaactgtcagctttcaatgtcccattttaagggggcaaattgctttggtattgaactgagagattgtgatcttaaaggagcaaattttagccaagttagttttgtaaatcaggtttcgaataaaatgtacttttgctctgcatacataacaggttgtaacttatcctatgccaattttgagcagcagcttattgaaaaatgtgacctgttcgaaaatagatggattggtgcaaatcttcgaggcgcttcatttaaagagtcagatttaagtcgtggcgttttttcggaagattgctgggaacagtttagagtacaaggttgtgatttaagtcattcagagctttatggtttagatcctcgaaagattgatctaacaggtgtaaaaatatgctcgtggcaacaggagcagttactggagcaattaggggtaatcattgttcctgactaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_6033,Drugs,MEG_6033|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRVC,516432985|WP_017822040.1|NG_062256|1|1|qnrVC10|qnrVC|quinolone_resistance_pentapeptide_repeat_protein_QnrVC10 NG_062256:1-657,3
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgcaggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgggccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_856,Drugs,MEG_856|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502082|WP_071846234.1|NG_052246|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052246:101-892,2
,ACGTCAGGTGGCACTTTTCGGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCCTAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGCGAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTGCGCCCTTCCGGCTGGCTGGTTAATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAAGTACC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6935,Drugs,MEG_6935|Drugs|betalactams|Class_A_betalactamases|TEM,gi|695198329|ref|NG_034953.1|1-1001,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATACTAAAGAGTTAAATAATTTAGAAAAAAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAAATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTACAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1334,Drugs,MEG_1334|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_51_NZ_JVWO01000108,0
,ATGATGAAAAAATCGTTATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGGTGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAATCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCTCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1885,Drugs,MEG_1885|Drugs|betalactams|Class_C_betalactamases|CMY,gb|HE819404|+|0-1146|ARO:3002103|CMY-90 [Citrobacter freundii] ,0
,ATGAGGGATGATTTCGTCTTCGTCGACGAGGTCGTCTCCGGAATCCGCTGGGACGCCAAGTACGCCACGTGGGACAACTTCACCGGCAAGCCGGTGGACGGCTACCTGGTGAACCGCGTCGTCGGAACACGTGCGTTCTGCGCGGCGCTGGAAAAGGCGCGGGACAAGGCCGCGGAACTCGGCTTCGGGCTGCTTCTCTGGGACGTGTACCGCCCGCAGCGCGCGGTGGACCGCTTCATGCGCTGGGCGGAAGAGCCCGAAGACGGCCGGAAGAAGGCCAGGCACTACCCGAACATCGAGCGGCCCCAGATGTTCGAACAGGGCTACGTGGCCACCAAGTCCGGGCACAGCCGGGGCAGCACGGTGGACCTGACGCTCTACCGCCTGGACACCGGTGAGCTCGCCGACATGGGCGGTGACCACGACCTGATGGACGTCGTCTCGCACCACGGTGCCGACGGGGTGCCGGAAGAGGCCGCGAAGAACCGCGCGCACCTGTGCGCGATCATGGAAGGTTCCGGCTTCAGCTCCTACGAGTGCGAGTGGTGGCACTACAACCTGAAGGACGAGCCTTACCCGGACACTTATTTGGATTTTCCCATCGAGTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7551,Drugs,MEG_7551|Drugs|Glycopeptides|VanA-type_resistance_protein|VANXA,(Gly)VanX-Ao1:AF060799:2604-3212:609,5
,TAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGCTGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAGATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6873,Drugs,MEG_6873|Drugs|betalactams|Class_A_betalactamases|TEM,gi|145975406|gb|EF534736.1|1-1074 gi|961666360|gb|KT185451.1|87739-87690,0
,gtgtcatttctcacttccgctcgtggctcgttggccacggtcctcatcacggctagcctcgacgccgccggcatgggcctggtgatgccgattcttcccgcactgctacacgaggcaggggtcaccgctgatgcggttccgctgaacgtcggagtgctgatcgcgctctacgcggtaatgcagttcatctttgcccccgtactgggaacgctgtcggaccgattcggccgccgccgggtgctgcttgtttccctggccggtgcgaccgtggactatctcgtgctcgccacgacgtccgctctgtcggtgttctatatcgcccgcgcagtggctgggataaccggagcgaccaatgcggtcaccgccaccgtgatcgccgacatcacgccaccccaccagcgcgccaagcgtttcggtttactcagtgcctgctatggcggcggaatgatcgcggggccagccatgggtggactgttcggtgccatctcgccacatctgccgtttttgctcgctgctcttctctcagcgagcaatctggcactcacctttatcctgttacgcgagacccgtcctgattcccctgcgcgctctgcgtcgctcgctcagcatcgtggtcgccccggcctcagcgcggtgcctgggattaccttcctattagtcgcattcggccttgttcaattcattgggcaggctccaggtgcgacctgggtgctgtttactgaacaccgcctcgactggagtcccgtcgaagttggaatctccctgtccgttttcgggatcgtacaggttctcgtgcaggccctccttactggccgcatcgtggagtggatcggtgaggcaaaaacagtcatcatcgggtgtgttaccgacgccttgggtctcgtaggcctggcgattgtcactgacgcattttccatggcgcctatcttggcggcactcgggatcggtggcatcggcctccccgctctgcaaacccttctctcccagcgcgtcgatgaacagcaccaagggcgcctccagggtgtgctcgccaggatcaacagcatcacatcgatcttcggaccggtcgctttcacaacgatcttcgcgctcacttacatcaacgccgacggcttcctctggctctgcgccgcagcactctacgtgccctgcgtgattctcatcatgcgtggtacagcagcgtccccgaagttcggctcttgggcgagcggcgactcgatgtga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6972,Drugs,MEG_6972|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET33,1391852853|WP_109545038.1|NG_048128|1|1|tet(33)|tet(33)|tetracycline_efflux_MFS_transporter_Tet(33) NG_048128:101-1324,4
,atgaaaattctgattttgctgcctttactgagttgtttgggcctgacagcgtgtagcctgcccgtttcatcttccccatctcaaagcactttgactcaatccacccaagctattgccagcttatttgatcaggcacaaagctctggcgttctagtgattcagcgtggtcaacagttacagatctatggcaatgatttaagccgagcaaataccgaatatgttcctgcctcaacctttaaaatagtgaatgccctgattggcttgcagcatggcaaagccacagccaatgaaatctttaaatgggatggcaagaaacgcagttttgccgcctgggaaaaagatatgacgctcggcgaggccatgcaagcttctgcggtaccggtctaccaggaactggcacgtcgtatcggtctggaattgatgcagcaggaagtgcaacgcatccggttcggcaatcagcagattgggcagcaggtcgataacttctggctgatcgggcctctaaaaattagcccgaaacaggaagtcgaatttgtctctgctcttgctcgaggagagctcccctttgatcctcaagtccagcagcaagttaaagccatgttacttttacaggaacggcaagcttatcgcctgtatgccaaatccggttggggcatggctgtagaaccgcaagttggctggctcaccgggtgggtcgaaatccctcagggggaaatcgtggcattttccctgaatatgcaaatgcaaaccaatatgaatccagccattcgccttgaaattctacagcaggctctgggcgaattagggctttacccaaaagcggagcagcaaagcaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4679,Drugs,MEG_4679|Drugs|betalactams|Class_D_betalactamases|OXA,1693892939|WP_140423316.1|NG_065434|1|1|blaOXA-648|blaOXA-134_like|OXA-134_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-648 NG_065434:1-840,0
,atgagtattcaacattttcgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagttctcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6670,Drugs,MEG_6670|Drugs|betalactams|Class_A_betalactamases|TEM,942450625|WP_055314508.1|NG_051939|1|1|blaTEM-213|blaTEM|class_A_beta-lactamase_TEM-213 NG_051939:101-961,0
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGACATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCGCCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1326,Drugs,MEG_1326|Drugs|betalactams|Class_A_betalactamases|BLAZ,gi|761646437|gb|CP010952.1|1848078-1848923 gi|304388018|gb|CP002146.1|21099-21944 gi|302334329|gb|CP002115.1|10150-10995 gi|260177101|gb|GQ900475.1|36842-37687 gi|260066169|gb|GQ900467.1|1253-408 gi|260066127|gb|GQ900425.1|17716-18561 gi|260066126|gb|GQ900424.1|8986-9831 gi|260066115|gb|GQ900413.1|8652-7807 gi|260066099|gb|GQ900397.1|16121-15276 gi|260066094|gb|GQ900392.1|17915-17070,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagagctgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaatctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcacagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtaggtgataagaccggcagcggcgactacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgatctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2183,Drugs,MEG_2183|Drugs|betalactams|Class_A_betalactamases|CTX,1394972209|WP_110092882.1|NG_059336|1|1|blaCTX-M-219|blaCTX-M|inhibitor-resistant_class_A_extended-spectrum_beta-lactamase_CTX-M-219 NG_059336:101-976,0
,TAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTAAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6908,Drugs,MEG_6908|Drugs|betalactams|Class_A_betalactamases|TEM,gi|342219561|gb|JN211012.1|1-1074,0
,ATTTTTTCTCTTGCCACTTTCGCGCATGCGCAAGAAGGCACGCTAGAACGTTCTGACTGGAGGAAGTTTTTCAGCGAATTTCAAGCCAAAGGCACGATAGTTGTGGCAGACGAACGCCAAGCGGATCGTGCCATGTTGGTTTTTGATCCTGTGCGATCGAAGAAACGCTACTCGCCTGCATCGACATTCAAGATACCTCATACACTTTTTGCACTTGATGCAGGCGCTGTTCGTGATGAGTTCCAGATTTTTCGATGGGACGGCGTTAACAGGGGCTTTGCAGGCCACAATCAAGACCAAGATTTGCGATCAGCAATGCGGAATTCTACTGTTTGGGTGTATGAGCTATTTGCAAAGGAAATTGGTGATGACAAAGCTCGGCGCTATTTGAAGAAAATCGACTATGGCAACGCCTATCCTTCGACAAGTAATGGCGATTACTGGATAGAAGGCAGCCTTGCAATCTCGGCGCAGGAGCAAATTGCATTTCTCAGGAAGCTCTATCGTAACGAGCTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGATCTCATGATTGTGGAAGCCGGTCGCAACTGGATACTGCGTGCAAAGACGGGCTGGGAAGGCCGTATGGGTTGGTGGGTAGGATGGGTTGAGTGGCCGACTGGCTCCGTATTCTTCGCACTGAATATTGATACGCCAAACAGAATGGATGATCTTTTCAAGAGGGAGGCAATCGTGCGGGCAATCCTTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_5277,Drugs,MEG_5277|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-36_1_AF300985 ,0
,atgaacaaaaatataaaatattctcaaaactttttaacgagtgaaaaagtactcaaccaaataataaaacaattgaatttaaaagaaaccgataccgtttacgaaattggaacaggtaaagggcatttaacgacgaaactggctaaaataagtaaacaggtaacgtctattgaattagacagtcatctattcaacttatcgtcagaaaaattaaaactgaatactcgtgtcactttaattcaccaagatattctacagtttcaattccctaacaaacagaggtataaaattgttgggaatattccttaccatttaagcacacaaattattaaaaaagtggtttttgaaagccgtgcgtctgacatctatctgattgttgaagaaggattctacaagcgtaccttggatattcaccgaacactagggttgctcttgcacactcaagtctcgattcagcaattgcttaagctgccagcggaatgctttcatcctaaaccaaaagtaaacagtgtcttaataaaacttacccgccataccacagatgttccagataaatattggaagctatataagtactttgtttcaaaatgggtcaatcgagaatatcgtcaactgtttactaaaaatcagtttcatcaagcaatgaaacacgccaaagtaaacaatttaagtaccattacttatgagcaagtattgtctatttttaatagttatctattatttaacgggaggaaacaactccctatattttag,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2792,Drugs,MEG_2792|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,499327877|WP_011018369.1|NG_056191|1|1|erm(B)|erm(B)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B) NG_056191:101-853,7
,ATGCTAAATTTAACCGTTTGTCAGCCACAGTCAAATCCAACAGACTGGGTATGTCTGACGGGCCCGGACACTCCCTTGACTCGCTATTACGGAAGATAACTGATGATGAAAAAATCCCTGTGCTGCGCCCTGCTGCTCAGCACCTCCTGCGCTGCATTAGCCGCACCTCTGTCAGAAACACAGCTGGCGAAGGTCGTGGAACGTACCGTTACGCCCCTGATGAAAGCGCAGTCTATTCCGGGTATGGCGGTCGCCGTGATCTATCAGGGCCAGCCGCACTACTTCACCTTCGGCAAGGCCGATGTCGCCGCGAACACACCCGTCACTGCACAAACGCTGTTTGAGCTGGGCTCAATCAGCAAAACCTTCACCGGCGTTCTGGGTGGCGATGCTATTGCTCGCGGTGAAATTTCGCTGGGCGATCCGGTGACCAAATACTGGCCTGAACTGACCGGCAAACAGTGGCAGGGCGTTCGCATGCTGGACCTGGCAACCTATACTGCCGGTGGCCTGCCGTTACAGGTGCCCGATGAGGTTACCGATAATGCCTCGCTGCTGCGTTTTTACCAGTCCTGGCAACCACAGTGGGCGCCAGGCACCACGCGTCTTTATGCGAATGCCAGCATCGGTCTGTTTGGGGCTCTGGCAGTGAAACCTTCTGGCATGCGCTTTGAGCAGGCGATGACGGAGCGGGTCCTGAAGCCGCTTAACCTGAACCATACGTGGATTAACGTTCCGAAGGCAGAAGAACAGCATTACGCCTGGGGTTATCGTGACGGTAAAGCGGTTCACGTTTCGCCGGGCATGCTCGATGCCGAAGCATATGGCGTGAAAACCAACGTGAAGGATATGGCGAGCTGGGTGGTGGCTAACATGGCCCCCGATGGGGTACAGGATGCCTCACTGAAGCAGGGCATGGTGCTTGCACAGTCTCGCTACTGGCGCACAGGCTCGATGTACCAGGGCCTGGGCTGGGAGATGCTCAACTGGCCGGTAGAAGCCAAAACCGTGGTGGAGGGCAGCGACAACAAGGTAGCGCTTGCACCGTTGCCCGTGGCAGAAGTGAACCCTCCGGCTCCACCGGTAAAAGCGTCATGGGTACATAAAACAGGCTCGACGGGCGGATTTGGCAGCTACGTGGCATTTATCCCTGAGAAGGAACTCGGCATCGTTATGCTGGCGAACAAGAGCTACCCGAACCCGGCACGCGTGGAAGCGGCATACCGTATTCTGAGCGCTCTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_486,Drugs,MEG_486|Drugs|betalactams|Class_C_betalactamases|ACT,gi|407731534|gb|JX440355.1|650-1897,0
,ATGAAACTCTTCGCTCAGGGCGCCACGCTCGATCTCACTCATCCGCATGTTATGGGGATCCTGAACGTAACGCCGGATTCGTTCTCCGACGGCGGCGCGCATAACACGCTGATTGAGGCGGTGAAACATGCGAATTTAATGGTGAATGCCGGGGCGACAATTATTGATGTGGGGGGGGAATCAACGCGACCAGGCGCGGCGGAAGTGAGCGTGGAAGAAGAGCTGGATCGCGTTATTCCGGTACTGGAAGCAATCGCGCAACGTTTTGAAGTGTGGATTTCTGTGGATACCTCTAAACCCGAGGTGATCCGTGAAGCGGCAAGGGCGGGCGCGCATATTATCAATGATGTCCGTTCGCTCTCCGAGCCCGGCGCGTTGGAAGCGGCAGCGGAAACCGGCTTGCCGGTCAGTCTTATGCACATGCAGGGCAACCCCAAAACCATGCAGGAGGCGCCGAAATATGACGATGTCTTTGCCGAGGTGAATCGCTACTTTATTGAGCAAATAGCACGTTGTGAGAAGGCCGGCATCGCAAAAGAGAAATTGTTGCTCGACCCCGGATTCGGTTTCGGTAAAAATCTCTCTCACAATTATACCTTACTGGCGCGACTGGGTGAGTTTCATCATTTTAACCTGCCGCTGCTGGTGGGCATGTCACGTAAAACGATGGTTGGTCAGTTACTTAACGTGGGACCATCAGACCGTCTGAACGGCAGCCTTGCGTGCGCGGTAATTGCCGCGATGCAGGGCGCGCAGATCATTCGCGTCCATGACGTCAAAGAAACCGTAGAGGCGATGCGGGTGGTGGAAGCCACTCTGTCTGCAAAGGGAAACAAACGCTATGAGTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2948,Drugs,MEG_2948|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|563346448|gb|CP006876.1|3347417-3346569 gi|197211055|gb|CP001138.1|3381795-3380947,8
,atgatcgtcaactgcgaccacgacaacctcgccgcctggctggcgctgcgcaccgcgctgtggccctccagctcgcctgaagatcaccgcgcggaaatgcgcgagatactggcttcaccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcaccggtggcgtttttggaagggatttataccgtcgagcgcgcgcgccgccagggctgggccgcgcgcttaatcgcacaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgacatcgccaatcttgactcccagcgcctgcatgcggcgctgggctttgccgaaacggagcgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_147,Drugs,MEG_147|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502183|WP_071846333.1|NG_052419|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052419:101-541,2
,TTTTATAAGTCTTATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGTGCTTCAAAATCTGATGACAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCATCAAGGTCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCAGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAATGGGATGGGGAAAAAAGGCTATTCCCAGAATGGGAAAAGAACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATAGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAAACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGCTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCAGTTCACTTTTACCATTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5245,Drugs,MEG_5245|Drugs|betalactams|Class_D_betalactamases|OXA,gi|751813257|gb|KM979377.1|1-872,0
,ATGAAAACAGTATTTATCCTTATCTCCATGCTTTTCCCTGTCGCAGTTATGGCACAGAAAAGCGTAAAAATATCCGATGATATCAGTATCACCCAACTCTCGGACAAAGTGTACACTTATGTATCCCTCGCCGAAATCGAAGGATGGGGTATGGTACCTTCCAACGGAATGATTGTTATCAACAACCATCAGGCAGCGTTGCTGGACACACCGATCAATGACGCACAAACGGAAACGCTGGTCAACTGGGTAGCGGACTCTTTGCATGCTAAAGTCACCACGTTTATCCCGAACCACTGGCACGGCGATTGTATTGGCGGACTGGGTTACCTGCAAAAGAAAGGTGTCCAATCATACGCAAACCAGATGACGATAGACCTCGCCAAGGAAAAAGGATTGCCCGTACCGGAACATGGATTCACCGATTCACTGACCGTCAGTCTGGACGGCATGCCTCTCCAATGTTATTATTTAGGAGGCGGACATGCGACCGACAATATCGTGGTTTGGCTGCCGACAGAGAATATCCTTTTTGGCGGATGTATGCTTAAAGACAACCAGGCGACAAGCATCGGCAACATCTCGGACGCGGACGTGACGGCATGGCCGAAAACTCTCGATAAGGTAAAAGCCAAGTTCCCCTCGGCCCGCTACGTCGTGCCCGGACATGGCGACTATGGCGGAACCGAACTGATAGAGCATACCAAGCAGATCGTGAACCAATATATAGAAAGCACCTCAAAGCCATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1673,Drugs,MEG_1673|Drugs|betalactams|Class_B_betalactamases|CFIA,(Bla)cfiA3:AB087228:1-750:750,0
,ATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTATTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCAGCGTCAGCGAGCAGACCCTGTTCGATATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGTCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCATTTGCCCAGTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGGGTCAACCCTGGCATGCTGGCGGACGAGGCCTACGGCATCAAGACCAGCTCGGCGGATCTGCTCGCCTTCGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACAAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGAGCCTCGAAGCCAATCCGACGGCGGCTCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTATCCCATCCCGGCCAGGGTGAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1843,Drugs,MEG_1843|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AB194410|+|0-1149|ARO:3002030|CMY-19 [Klebsiella pneumoniae] ,0
,ATGCTAAATTTAACCGTTTGTCAGGCACAGTCAAATCCAACAGACTACGCCTGTCTGATGGGCCCGGACACCCCCTTGACTCGCTATTACGGAAGATTACTGATGATGAAAAAATCCCTTTGCTGCGCCCTGCTGCTGGGCCTCTCTTGCTCTGCTCTCGCCGCGCCAGTATCAGAAAAACAGCTGGCGGAGGTGGTCGCGAATACGGTTACCCCGCTGATGAAAGCCCAGTCTGTTCCAGGCATGGCGGTGGCCGTTATTTATCAGGGAAAATCGCACTATTACACGTTTGGCAAGGCCGATATCGCGGCGAATAAACCCGTTACGCCTCAGACCCTGTTCGAGCTGGGTTCTATAAGTAAAACCTTCACCGGCGTTTTAGGTGGGGATGCCATTGCTCGCGGTGAAATTTCGCTGGACGATCCGGTGACCAGATACTGGCCACAGCTGACAGGCAAGCAGTGGCAGGGTATTCGTATGCTGGATCTCGCCACCTACACCGCTGGCGGCCTGCCGCTACAGGTACCGGATGAGGTCACGGATAACGCCTCCCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCTGGCACAACGCGTCTTTACGCCAACGCCAGCATCGGTCTTTTTGGCGCGCTGGCGGTCAAACCTTCTGGCATGCCCTATGAGCAGGCCATGACGACGCGGGTCCTTAAGCCGCTCAAGCTGGACCATACCTGGATTAACGTTCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGCTATCGTGACGGTAAAGCGGTGCGCGTTTCGCCGGGAATGCTGGATGCACAAGCCTATGGCGTGAAAACCAACGTGCAGGATATGGCGAACTGGGTCATGGCAAACATGGCGCCGGAGAAGGTTGCCGATGCCTCACTTAAGCAGGGCATCGCGCTGGCGCAGTCGCGCTACTGGCGTATCGGGTCAATGTATCAGGGTCTGGGCTGGGAGATGCTCAACTGGCCCGTGGAGGCCAACACGGTGGTCGAAGGCAGCGACAGTAAGGTAGCGCTGGCGCCATTACCCGTGGCAGAAGTGAATCCACCGGCTCCCCCGGTCAAAGCGTCCTGGGTCCATAAAACGGGTTCTACTGGCGGATTTGGCAGCTACGTGGCCTTTATTCCTGAAAAGCAGATCGGTATTGTGATGCTCGCGAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCATATCCTCAAGGCGCTTCAGTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_490,Drugs,MEG_490|Drugs|betalactams|Class_C_betalactamases|ACT,gi|591542941|gb|KJ207208.1|438-1684,0
,atgataatcagtgaatttgaccgtaataatccagtattgaaagatcagctttctgatttactgagactgacttggccggaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacgaatcgcggtagcagcggtagaccaagatgagttagtaggatttattggtgcaatccctcaatacggtatcacaggttggaaattgcatccattagttgtagaaagctcccgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagaggaggaatcacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaaacggacctgtatgagcatacatttgataaagtggcttccatccagaaccttcgtgaacatccgtatgaattctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaaatggctgggacaaaccggatatttggatggcaaaaacgattattcctcgaccagattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_141,Drugs,MEG_141|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,488256966|WP_002328174.1|NG_052260|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052260:101-649,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccgaccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5627,Drugs,MEG_5627|Drugs|betalactams|Class_C_betalactamases|PDC,1028110199|WP_063864569.1|NG_049881|1|1|blaPDC-113|blaPDC|class_C_beta-lactamase_PDC-113 NG_049881:1-1194,0
,atggaattgcccaatattatgcacccggtcgcgaagctgagcaccgcattagccgctgcattgatgctgagcgggtgcatgcccggtgaaatccgcccgacgattggccagcaaatggaaactggcgaccaacggtttggcgatctggttttccgccagctcgcaccgaatgtctggcagcacacttcctatctcgacatgccgggtttcggggcagtcgcttccaacggtttgatcgtcagggatggcggccgcgtgctggtggtcgataccgcctggaccaatgaccagaccgcccagatcctcaactggatcaagcaggagatcaacctgccggtcgcgctggcggtggtgactcacgcgcatcaggacaagatgggcggtatggacgcgctgcatgcggcggggattgcgacttatgccaatgcgttgtcgaaccagcttgccccgcaagaggggatggttgcggcgcaacacagcctgactttcgccgccaatggctgggtcgaaccagcaaccgcgcccaactttggcccgctcaaggtattttaccccggccccggccacaccagtgacaatatcaccgttgggatcgacggcaccgacatcgcttttggtggctgcctgatcaaggacagcaaggccaagtcgctcggcaatctcggtgatgccgacactgagcactacgccgcgtcagtgcgcgcgtttggtgcggcgttccccaaggccagcatgatcgtgatgagccattccgcccccgatagccgcgccgcaatcactcatacggcccgcatggccgacaagctgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4135,Drugs,MEG_4135|Drugs|betalactams|Class_B_betalactamases|NDM,1511261582|WP_123002102.1|NG_062358|1|1|blaNDM-27|blaNDM|subclass_B1_metallo-beta-lactamase_NDM-27 NG_062358:1-813,0
,atgaaaaagaactttgcctttttagatgaaatgattcccggaatccgatgggatgctaaatatgccacatgggacaatttcaccgggaaaccggtagacggatacatggtaaaccgtgttatgggaacgaaggagctgggagttgctttgcgtaaggctcagaagatggcggagaaactgggatatggtttgctcttatgggacggctatcgcccccagtgcgcagtggattgttttctgaattgggcttcccaaccggaagacaatctgacgaaaaagcgttactatccaaatatcaaaaggaatgagatggttgcgaaggggtatgtggcctcacaatccagccacagccgtggaagtacggttgaccttacaatttttcatttgaatagcggtatgcttgttcctatgggtggagattttgactttatggatgaacggtcacaccatgccgcaagcggtctgagcgaagaagaatcaaaaaaccggcagtgcttgcgttatatcatggagagtagcggatttgaagcctatcgttatgaatggtggcattacgtcttggcggacgagccatacccggatacatattttgatttttgcattgcctag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7564,Drugs,MEG_7564|Drugs|Glycopeptides|VanD-type_resistance_protein|VANXD,655082058|WP_028530136.1|NG_048492|1|1|vanX-D|vanX-D|D-Ala-D-Ala_dipeptidase_VanX-D NG_048492:101-709,5
,ATGATTATAGAATTAAATAAAAATAGTTTCCCAGAAGAGTTCAATAAGATAGAAGTACATGAGGGTAGTGTGAATATATTTATGAATAAAAATAGTATTACCCCTTTAAAAATTTTTAATGTGCTAGCTCCTGCGGCCAATATAATAAAGCAAGAAATACTGGCTTTAGGTGGAGATTGTGCTGTAAATAAATATTGTATAAATTGCAAAGTGGAAACTTCAGATATAATTTTATTAGGAACCAAAAGACAGTACAAAAAATTATTGCAAAAGCTTAAATGCATGACTTTTTTTAGAATAGAAGAAATAGTAGGGGAATTAGAAAATTATATTAACAATCATAAAAAAATTAAAACGGTTTTAAGAGATGGAAGAGAAATAAACTATGAGAATTTAAAGGTTATGGGAATTATAAATTGTACTCCAGATTCTTTTTATGAGGGCTCTAGAAAAAATTCTATAGAAGAAGCTTTAAAAACTGCAGAAAAGATGTTAAAAGAAGGGGCAGAAATTTTAGATATAGGTGGAGAATCCACAAGACCAGGTTCTGACCCAGTAGATGAAGAGGAAGAAATAAAAAGAGTAGTTCCTGTTATAAGAGAGATAAAGAATAAATTTAAGGATGTCATAATTTCCATAGATACTTATAGAGCAAATACGGCAAAGGCTGCCATAGAGGCAGGTGCAGACATAGTAAATGATATAAGTGCTATGAAGTATGATGAAAATATGGTGAAAGTAGTTAAAGAATACAATATACCTGTAATACTTATGCATGTAAAAGGAAAACCAAAGGATATGCAAATAGATCCAGTTTATGAGAATTTAATGAAAGAAATTCATCTTTATTTTAATGAGAGAATAGAGTACTGCAAATCTCATGGCATAACAGAGGATAAAATAATATTAGATCCAGGCATAGGTTTTGGAAAAACTGTAGAGCATAATCTAAAAATAATGAACAGATTAGAAGAATTGAAAAGCTTTAATCTTCCAGTACTTTTAGCAGCCTCAAGAAAAGCCACAATAGGAAAAGTTTTAGGAAACTTATCTACAGAAGAAAGATTAGAAGGAACTATAGCTTTATCCTGTTTAGCTGTAAATTCAGGACTTCAAATGGTGAGAGTACACGATGTTAAAGAAAATGTAAGAGCCATAAGAATGTTAGAGGCAGTAAGAAAAATATAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2940,Drugs,MEG_2940|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|226840737|gb|CP001581.1|1031347-1032534,8
,ATGAAACTACAGAACTCTTTTCGCGACTATACGGCAGAGTCCGCGCTGTTTGTGCGCCGGGCGCTGGTCGCCTTTTTGGGGATTTTGCTGCTGACCGGCGTGCTTATCGCCAACCTGTATAATCTGCAAATTGTTCGCTTTACCGACTACCAGACCCGCTCTAATGAAAACCGCATTAAGCTGGTGCCTATCGCGCCCAGCCGCGGCATTATCTACGATCGTAACGGTATCCCTCTGGCCCTCAACCGCACTATCTACCAGATAGAAATGATGCCGGAGAAAGTCGATAACGTGCAGCAAACGCTGGACGCTTTGCGCAGCGTGGTAGATCTGACCGATGACGATATTGCTGCATTCCGAAAAGAGCGCGCACGTTCACACCGTTTCACCTCTATTCCGGTGAAAACTAACCTGACCGAAGTACAAGTAGCTCGCTTTGCCGTCAATCAGTACCGTTTTCCGGGTGTCGAAGTTAAAGGCTATAAACGTCGTTACTATCCTTACGGTTCGGCGTTGACCCACGTCATCGGCTATGTGTCGAAAATCAACGATAAAGACGTCGAACGCCTGAATAATGACGGCAAACTGGCCAACTATGCGGCAACGCATGATATCGGTAAGCTGGGCATTGAGCGTTACTATGAAGATGTGCTGCACGGTCAGACCGGTTATGAAGAGGTTGAAGTTAACAACCGTGGGCGTGTTATTCGCCAGTTAAAAGAAGTACCACCGCAAGCCGGACACGATATTTACCTGACGCTGGATCTCAAACTCCAGCAATATATTGAAACGCTGCTGGCGGGTAGCCGCGCAGCTGTGGTAGTCACCGATCCGCGTACAGGTGGGGTGCTGGCGCTGGTTTCCACGCCTAGTTATGACCCAAACTTGTTTGTTGACGGTATCTCCAGCAAAGATTATTCCGCCTTGTTGAACGATCCGAATACACCGCTGGTGAACCGCGCCACACAGGGGGTTTATCCTCCCGCGTCTACAGTTAAACCCTATGTGGCGGTTTCGGCATTGAGCGCCGGGGTGATCACGCGCAATACGACGCTGTTTGACCCAGGCTGGTGGCAACTGCCAGGTTCGGAAAAACGTTATCGTGACTGGAAAAAATGGGGCCACGGGCGTCTGAATGTCACAAGATCGCTGGAAGAATCTGCGGATACCTTCTTCTATCAGGTGGCCTACGATATGGGGATCGATCGCCTCTCCGAATGGATGGGTAAATTCGGTTATGGTCATTACACCGGTATCGACCTGGCGGAAGAACGTTCCGGCAACATGCCTACCCGCGAATGGAAACAGAAACGCTTTAAAAAACCGTGGTATCAGGGTGACACCATTCCGGTTGGTATCGGTCAGGGTTACTGGACAGCGACCCCAATCCAGATGAGTAAGGCACTGATGATCCTGATTAATGACGGTATCGTGAAGGTTCCTCATTTGCTGATGAGCACCGCCGAAGACGGCAAACAGGTGCCATGGGTACAGCCGCATGAACCGCCCGTCGGCGATATTCATTCCGGTTACTGGGAGCTGGCGAAAGACGGTATGTACGGTGTTGCTAACCGCCCTAACGGTACGGCGCATAAATACTTTGCTAGCGCACCGTACAAAATTGCGGCGAAATCCGGTACCGCTCAGGTCTTCGGTCTGAAAGCGAACGAAACCTATAATGCGCACAAAATTGCCGAGCGTTTACGTGACCACAAACTGATGACCGCCTTTGCGCCATACAACAATCCGCAAGTGGCTGTCGCCATGATTCTGGAGAACGGTGGTGCGGGTCCGGCGGTTGGTACACTGATGCGCCAGATCCTCGACCACATTATGCTGGGTGATAACAACACCGATCTGCCTGCGGAAAATCCAGCGGTTGCCGCAGCGGAGGACCATTAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_5400,Drugs,MEG_5400|Drugs|betalactams|Penicillin_binding_protein|PBP2,(Bla)Penicillin_Binding_Protein_Ecoli:CP002291:664439-666340:1902,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCGCCCTGCCGCTGGTGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCGTGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCTCGTAGCACCTCGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6443,Drugs,MEG_6443|Drugs|betalactams|Class_A_betalactamases|SHV,gi|257359514|gb|GQ428198.1|48-986,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattcaggtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttgggggtgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4463,Drugs,MEG_4463|Drugs|betalactams|Class_D_betalactamases|OXA,1693892946|WP_140423323.1|NG_065441|1|1|blaOXA-831|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-831 NG_065441:1-825,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATTCTAACGCAAGGCCTGTTTCGCCGGCCGATGAGATCAGACGTATTGGGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCAACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6599,Drugs,MEG_6599|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|695209922|ref|NG_035908.1|2653-3492,8
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctgatcgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5631,Drugs,MEG_5631|Drugs|betalactams|Class_C_betalactamases|PDC,1035157538|WP_064511503.1|NG_050826|1|1|blaPDC-153|blaPDC|class_C_beta-lactamase_PDC-153 NG_050826:1-1194,0
,GCCGTCTAGTTCTGCTGTCTTGTCTCTCATGGCCGCTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTCGAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACTGTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCTGCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTACGGCAAAAATGCGCTGGTTCCGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATGACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTGTTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGATACCACGTTCCGTCTGGACCGCTGGGAGCTGGAGCTGAACTCCGCCATCCCAGGCGATGCGCGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCTGCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGCAACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACCTGCGGAGCGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCTATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGTACAGCGAGGCCGTCATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGGGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_3487,Drugs,MEG_3487|Drugs|betalactams|Class_A_betalactamases|KPC,(Bla)KPC-9:FJ624872:1-854:854,0
,atgagcaactctatacacaccggaatcgcaaggcaactttcacaggcacgcgatgtaattaaacgccacttggcatcaacgctgaaagccatacacttgtatggttctgcaattgatggtggcctcaaaccatatagcgacattgatctgctggttaccttagatgcacgcttggatgaagctaccagacgccccctgatgctcgatttcttgaatatctcggcaccaccgcgcgaaagctcagtactccggccgctagaggtaaccgttgttgcatgcaacgaagtagtgccttggcgttatccggcacgacgagaactgcagttcggggagtggctgcgggaggatattcttgaaggtgtcttcgagccagccgtctcggacaccgaccttgcaattctaataacgaaagctaggcaacgcagcatcgctttagtaggcccagtggctcaagaagtcttcatgccagtgccagagcatgactttctccaggtgctttccgatacccttaagctgtggaatgttcatgaggattgggaaaatgaggagcggaacatcgtgctcacgttagctcggatctggtatagcactgaaactggaggaatcgtccctaaggatgtggctgccgaatgggttttagggcgcttgccagctgagcataagtcaatactggttgaggcgcggcaagcctatcttgggctttgcaaggatagtcttgctttgcgtgcagatgagacttcggcgttcattggctatgcaaagtctgcggtcactgatttgctcgaaaagcgaaaatctcaaacttcgtatattcgcgatggcgccaagaacgtctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_872,Drugs,MEG_872|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502177|WP_071846328.1|NG_052412|1|1|aadA9|aadA9|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA9 NG_052412:101-937,2
,atggctctggcactcgttggcgaaaaaattgacagaaaccgcttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgcttggcattgaaattcgccactgtcgtgcgcaaggcgcagatttccgcggcgcaagctttatgaatatgatcactactcgcacctggttttgcagcgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgttggaaaaatgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctttccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtaacttagatattcggggcgttgatttacaaggcgttaagttggacaactaccaggcatcgctgctcatggaacgtcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5909,Drugs,MEG_5909|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111988|WP_063866188.1|NG_050520|1|1|qnrB57|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB57 NG_050520:37-681,3
,ATGAGGGTAGCGGTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGTTGGTTACTGTGGCCGTAAAGCTTGATGAAACGACGCGGCGAGCATTGCTCAATGACCTTATGGAGGCTTCGGCTTTCCCTGGCGAGAGCGAGACGCTCCGCGCTATAGAAGTCACCCTTGTCGTGCATGACGACATCATCCCGTGGCGTTATCCGGCTAAGCGCGAGCTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCATGATCGACATTGATCTAGCTATCCTGCTTACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCGGCAGCGGAGGAATTCTTTGACCCGGTTCCTGAACAGGATCTATTCGAGGCGCTGAGGGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCCGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAATAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATAAAACGCCTACCTGCCCAGTATCAGCCCGTCTTACTTGAAGCTAAGCAAGCTTATCTGGGACAAAAAGAAGATCACTTGGCCTCACGCGCAGATCACTTGGAAGAATTTATTCGCTTTGTGAAAGGCGAGATCATCAAGTCAGTTGGTAAATGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_966,Drugs,MEG_966|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|973585379|gb|KP054476.2|51842-52633 gi|971338783|gb|CP006659.2|2297685-2298476 gi|966344239|gb|KT291741.1|92-883 gi|957657109|dbj|LC099465.1|45-836 gi|953007066|gb|CP013143.1|6-797 gi|937637492|gb|KT334335.1|96763-95972 gi|928083869|gb|CP012682.1|73669-72878 gi|923091304|gb|KP942843.1|120-911 gi|918400318|dbj|AP014939.1|110915-111706 gi|908266278|gb|CP012170.1|134703-133912,2
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTTGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTGACGATGAGGCCCAGGATATTGGGCCTCCTTTCTTTCTCTTTTTTTCCTGTTGTCATCTACACTTAACAAAAATACAGCAACCAAAATCCCATGCGGGCCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_1974,Drugs,MEG_1974|Drugs|betalactams|Class_C_betalactamases|CMY,gi|42357702|gb|AY513266.1|165-1413,0
,ATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTACTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCGGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGCCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCGTTTGCCCCCTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGTGTCAACCCTGGCATGCTGGCGGACGAGGCCTATGGCATCAAGACCAGCTCGGCGGATCTGCTGCGTTTTGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACCAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGAGCCTCGAAGCCAATCCGACGGCGGCGCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTACCCCATCGAGGCGCGCATCAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1853,Drugs,MEG_1853|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AF357599|+|253-1402|ARO:3002022|CMY-11 [Escherichia coli] ,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAAATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1388,Drugs,MEG_1388|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_76_FFOR01000002,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtaccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgatcaagttaacttacttcaactcgcgacgtatacaagtggcaacctcgctttacaatttccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagctaaccccggcccacttgatgccccagcatacggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaccccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtcggcaccatgtatcaggcacttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagagactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccagcggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_591,Drugs,MEG_591|Drugs|betalactams|Class_C_betalactamases|ADC,1693892928|WP_140423305.1|NG_065420|1|1|blaADC-195|blaADC|class_C_beta-lactamase_ADC-195 NG_065420:1-1152,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgtggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagactcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2208,Drugs,MEG_2208|Drugs|betalactams|Class_A_betalactamases|CTX,1028104779|WP_063860025.1|NG_048963|1|1|blaCTX-M-179|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-179 NG_048963:1-876,0
,CGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGGCCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6870,Drugs,MEG_6870|Drugs|betalactams|Class_A_betalactamases|TEM,gi|13272527|gb|AF332513.1|AF332513|1-964,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcgtcgaaagaggacggtcgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcaaggcagccgcttcgacggcatcagcctgctcgacctcgcgacctacaccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgagcggatcatggagcagcgcctgttcccggccctgggcctcgaacagactcacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctccgggtcggccccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgactggaccggcagtgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatcgccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacagggtcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctggcgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5662,Drugs,MEG_5662|Drugs|betalactams|Class_C_betalactamases|PDC,1034011069|WP_064483998.1|NG_050789|1|1|blaPDC-133|blaPDC|class_C_beta-lactamase_PDC-133 NG_050789:1-1194,0
,CAAGTCTTATGAACATTCAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGTCTGCTAATCCAAATCACAGTGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGGATGGTAAAAAAAGGTTATTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCCATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAGCTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAGTTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAAACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCATGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCGGTTCACTTTTTACCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5257,Drugs,MEG_5257|Drugs|betalactams|Class_D_betalactamases|OXA,gi|94960150|gb|DQ519088.1|1-865 gi|742999896|gb|CP010397.1|2075049-2075912,0
,TTGTCCGAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGATATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGATTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGATGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAACTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATTATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4311,Drugs,MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_18_ALMH01000001 ,1
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcacgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccagcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5492,Drugs,MEG_5492|Drugs|betalactams|Class_C_betalactamases|PDC,959839687|WP_058128316.1|NG_055483|1|1|blaPDC-119|blaPDC|class_C_beta-lactamase_PDC-119 NG_055483:1-1194,0
,atgaagaagaatcaaggaatcgagcaattccgggtgattttggcgatgatggtggtggcgatccactgtctgcctcttcaccgcttatggcctgacggtgatatcctgatcacgttgacgctcttcagaattgccgtccccttcttttttatgatcagcggatattacgtgttcagcgacttagccacccaaaacagctatcctgccagacagcgtgtctggcagtttattaaaaagcagctgcaagtctacctcatagccacactgctctttttgccgcttgcttggtacagcggcatgcttgggttgaacatgccgctgggcacctttatccaaacattgttggtcactggcattctttaccatctttggtattttcctgcgatcattaccggcagtctactagtgatgggcctcttgacacggctttctttcaagcaggtgtttttcattgctgtcggtttgtatgtggttggtttaggtggggacagttggtctggcctggctgcacaaacacccattacgccactctattcactgatttttcaactattggatggaactcgcaacggcattttctttgctcctttgtttttgatcttaggggtactagcctctcaggggtaccagccaggaagatttgccaagaaaccagcttctccccatcgctatagttatctgctgatcagtctgatttgcttgcttttggaaagttaccttttgcatcactttaccacgccgaaacatgacagcatgtatgtttttttgcccttcgtcctgttgtttttatttccgatcatccagcaatggcaagcacccataatctggaaacaagcgggtcgactgtccctttggctctatttgctccatccttataccattgcagtgacccattttcttagtcaaaagctacccttgctgcaaaacaatctgatcaatttcttggtggtcttaggactgaccattggggtggtgcatggtctctttgctttgcaaaagctgttcccgttttcgaaaaaaacgccgcttcacttgcagcgagcagccaaagaattttccgcccccgctttgttgcacaacttgcaggaaatcaagcgattgatcccagcaacaacaaaagtgatggcggtggttaaagcggatgcttatggttgtgatgcgaagacggttgccggtaccctagaaagagccggcgtcgatttctttgccgttgctacccttgaagaagccattgaattacggcgagcaggcatcaaaagtcgcttactgattttagggtacacttctgcccaacatgccaaagagatgaaacattattccttgattcaaaccatcgttagtgaggcccatgggcatgctttagcccaaacaagcataccgatcgaatgccatttagcagtagatactggtatgcaccgcttaggcgttgcacctgatcttgaggcagttactggactttacgccttgccatctctcaagatcacacgcattttttcccatctaggctcttcagatcagctggatacggcaagtatcttgcggacacaagcccaaatcacttgttttgatgatctgttggctggcttatccgctagaaatatcgtctatggactgacacatctgcaaagcagctacggaatattgaattacccagagaaacactatgattatgtacgtccaggtattcttctaactggttcattgagcgtcccgaacgaaccaacgaagcagaagataaacgtacaaccgattttgacactcaaagccttactggtagacaaaaaaacagttgccgctggtgaagcgatcggctatggattaggcactatttttgatcgaccagccacgatcgggatcgttagcatcggctactgcgacggggttccacgtgccctatcaaaccaagggttccaactttcttatcaaggtgctttactcccgcagattgggttggtttgtatggatatgctcttgatcgatttaacggactatccagaactggcggtcgaaagttcgctcgaagtaatcagcgattggacgactaccgctgatcaagcacaaaccattaccaatgaattgatcagccgcctaggttcccgcatcacctctagttcaaagtag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7524,Drugs,MEG_7524|Drugs|Glycopeptides|VanC-type_resistance_protein|VANTC,1028100623|WP_063856758.1|NG_048462|1|1|vanTc2|vanTc2|membrane-bound_serine_racemase_VanT NG_048462:101-2221,5
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAATACACCGTTTCTTTAGCCTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGATTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACATACACAGAAAATCCAGCCACTTTTTGAAGGAAACGGCTTTTGGATAAGTGAAGCGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGTAAATACGGGGAAGATGGCAGTATCCAAGGAATGTTTGAATTGATGAAGCTGCCTTATGTAGGCTGTGGGGTGGCAGCCTCTGCCTTATGTATGAACAAATGGTTATTGCATCAAGCAGCAGCAGCGATTGGCGTACAAAGCGCTCCTACGATTCTCTTGACAAATCAAGCCAACCAGCAAAGACAAATCGAAGCCTTTATCCAGACCCATGGCTTTCCAGTTTTCTTTAAGCCTAATGAAGCGGGCTCCTCAAAAGGGATCACAAAAGTAACTTGTGTTGAAGAAATCGCTCCTGCCTTGAAGGAAGCCTTCGCTTATTGTTCCGCAGTGCTCTTACAAAAAAATATCGCTGGCGTTGAGATTGGTTGCGGTATCTTAGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCTATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGTTGATCAGCGCCAAAATCACCGTTCCTGCGCCATTGCCTGAAACGATTGAAACCAAAGTCAAAGAACAAGCTCAGCTGCTCTATCACAGTCTTGGTCTTAAAGGACTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGCTTATCCTATCAAGAATTACTACAAAAACTGCTTGTCTTAGCAAAGGAGGAAGGCAAATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7367,Drugs,MEG_7367|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,(Gly)VanC4:EU151752:29-1081:1053,5
,atggaatttaaattacaagaattaaatcttactaaccaagatacaggaccatatggtataaccgtttcagataaggggaaagtttggattacacaacataaagcaaatatgataagttgcatcaatttagatggaaaaattacagagtacccactaccgacaccagatgcaaaagtcatgtgtttaactatatcctcagatggggaagtttggtttactgagaatgcagcaaacaaaatagggaggattacaaaaaaagggattattaaggaatatacattgcctaacccagattcagcaccctacggtattacagaaggaccaaatggagatatatggtttacagaaatgaatggcaaccgtattggacgtattacggacgacggtaaaattcgtgaatacgagctgcctaataaaggatcttacccttcttttatcactttgggttctgataatgccctgtggttcacagaaaatcaaaataatgctattggtagaattacagaaagtggggatattacagagtttaaaattcctacacctgcatcaggaccagttggtattacaaaggggaacgacgatgctttatggtttgtggaaattatcggtaataagatagggcgaataactcctctgggggaaattaccgaattcaaaattccaacgccaaacgctcgacctcatgcaattactgctggagcaggaattgatttatggtttactgaatggggggctaataaaataggaaggctgacaagcaataatataattgaggaatacccaattcaaatcaaaagtggtgaaccacatggcatttgtttcgatggtgaaacaatttggtttgcaatggagtgtgacaagataggcaaattaactctcattaaggataatatggagtga,streptogramin inactivation enzyme,antibiotic inactivation,MLS,MEG_7691,Drugs,MEG_7691|Drugs|MLS|Streptogramin_B_ester_bond_cleavage|VGBA,1028100804|WP_063856939.1|NG_048562|1|1|vgb(A)|vgb(A)|streptogramin_B_lyase_Vgb(A) NG_048562:101-1000,7
,atgaatattataaatttaggaattcttgctcacattgatgcaggaaaaacttccgtaaccgagaatctgctgtttgccagtggagcaacggaaaagtgcggccgtgtggataatggtgacaccataacagactctatggatatagagaaacgtagaggaattactgttcgggcttctacgacatctattatctggaatggagtgaaatgcaatatcattgacactccgggacacatggattttattgcggaagtggagcggacattcaaaatgcttgatggagcagtcctcatcttatccgcaaaggaaggcatacaagcgcaaacaaagttgctgttcaatactttacaaaaactgcaaatcccgacaattatatttatcaataaaattgaccgtgacggtgtgaatttagagcgtttgtatctggatataaaaacaaatctgtctcaagatgtcctgtttatgcaaactgttgtcgatggattggtttatccgatttgctcccaaacatatataaaggaagaatacaaagaatttgtatgcaaccatgacgacaatatattagaacgatatttggcggatagcgaaatttcaccggctgattattggaatacgataatcgatcttgtggcaaaagccaaagtctatccggtactacatggatcagcaatgttcaatatcggtatcaatgagttgttggacgccatctcttcttttatacttcctccagaatcagtctcaaacagactttcagcttatctctataagatagagcatgaccccaaaggacataaaagaagttttctaaaaataattgacggaagtctgagacttcgagacattgtaagaatcaacgattcggaaaaattcatcaagattaaaaatctaaagactatttatcagggcagagagataaatgttgatgaagtgggggccaatgatatcgcgattgtagaagatatggaagattttcgaatcggagattatttaggtactaaaccttgtttgattcaagggttatctcatcagcatcccgctctcaaatcctccgtccggccagacaggtccgaagagagaagcaaggtgatatccgctctgaatacattgtggattgaagacccgtctttgtccttttccataaactcatatagtgatgaattggaaatctcgttatatggtttgacacaaaaggaaatcatacagacattgctggaagaacgattttccgtaaaggtccattttgatgagatcaagactatctacaaagaacgacctgtaaaaaaggtcaataagattattcagatcgaagtgccacccaacccttactgggccacaatagggctgacgcttgaacccttgccgttagggacagggttgcaaatcgaaagtgacatctcctatggttatctgaaccattcttttcaaaatgccgtttttgaagggattcgtatgtcttgccaatctggtttacatggatgggaagtgactgatctgaaagtaacttttactcaagccgagtattatagcccggtaagtacacctgctgatttcagacagctgaccccttatgtcttcaggctggccttgcaacagtcaggtgtggacattctcgaaccgatgctctattttgagttgcagataccccaagcggcaagttccaaagctattacagatttgcaaaaaatgatgtctgagattgaagacatcagttgcaataatgagtggtgtcatattaaagggaaagttccattaaatacaagtaaagactacgcctcagaagtaagttcatacactaagggcttaggcgtttttatggtcaagccatgcgggtatcaaataacaaaaggcgattattctgataatatccgcatgaacgaaaaagataaacttttattcatgttccaaaaatcaatgtcatcaaaataa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7180,Drugs,MEG_7180|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETQ,488624287|WP_002560998.1|NG_048269|1|1|tet(Q)|tet(Q)|tetracycline_resistance_ribosomal_protection_protein_Tet(Q) NG_048269:101-2026,4
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcaccgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_785,Drugs,MEG_785|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502083|WP_071846235.1|NG_052247|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052247:101-892,2
,ATGCAACAACGGCGTGCGTTCGCGCTACTGACGCTGGGTAGCCTGCTGTTAGCCCCTTGTACTTATGCCAGCGGGGAGGCTCCGTTGACCGCCGCTGTGGACGGCATTATCCAGCCGATGCTCAAGGCGTATCGGATCCCGGGGATGGCGGTCGCCGTACTGAAAGATGGCAAAGCCCACTATTTCAACTATGGGGTTGCCAACCGGGAGAGTGGCCAGCGCGTCAGCGAGCAGACCCTGTTCGAGATTGGCTCGGTCAGCAAGACCCTGACTGCGACCCTCGGTGCCTATGCCGCGGTCAAGGGGGGCTTTGAGCTGGATGACAAGGTGAGCCAGCACGCCCCCTGGCTCAAAGGTTCCGCCTTGGATGGTGTGACCATGGCCGAGCTTGCCACCTACAGTGCGGGTGGTTTGCCGCTGCAGTTCCCCGATGAGGTGGATTCGAATGACAAGATGCGCACTTACTATCGGAGCTGGTCACCGGTTTATCCGGCGGGGACCCATCGCCAGTATTCCAACCCCAGCATCGGCCTGTTTGGTCACCTGGCCGCAAATAGTCTGGGCCAGCCATTTGAGCAACTGATGAGCCAGACCCTGCTGCCCAAGCTGGGTTTGCACCACACCTATATCCAGGTACCGGAGTCGGCTATGGTGAACTATGCCTACGGCTATTCGAAGGAAGATAAGCCCGTCCGGGTCACTCCGGGCGTGCTGGCAGCCGAGGCTTACGGGATCAAGACCGGCTCGGCGGATCTGCTGAAGTTTGCCGAGGCAAACATGGGGTATCAGGGAGATGCCGCGGTAAAAAGCGCGATCGCGCTCACCCACACCGGTTTCTACTCGGTGGGAGACATGACCCAGGGACTGGGCTGGGAGAGTTACGCCTATCCGGTGACCGAGCAGACATTGCTGGCGGGTAACGCACCGGCGGTGAGCTTCCAGGCCAATCCGGTTACGCGCTTTGCGGTGCCCAAGGCGATGGGCGAGCAGCGGCTCTATAACAAGACGGGCTCGACTGGCGGCTTTGGCGCCTATGTGGCGTTCGTGCCCGCCAGAGGGATCGCCATCGTCATGCTGGCCAATCGCAACTATCCCATCGAGGCCAGGGTGAAGGCGGCTCACGCCATCCTGAGTCAGTTGGCCGAGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3033,Drugs,MEG_3033|Drugs|betalactams|Class_C_betalactamases|FOX,(Bla)FOX-6:AY034848:52-1200:1149,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgacgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgtccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5436,Drugs,MEG_5436|Drugs|betalactams|Class_C_betalactamases|PDC,1121341902|WP_073647245.1|NG_055276|1|1|blaPDC-213|blaPDC|class_C_beta-lactamase_PDC-213 NG_055276:1-1194,0
,atgaaaacatttgccgcatatgtaattatcgcgtgtctttcgagtacggcattagctggttcaattacagaaaatacgtcttggaacaaagagttctctgccgaagccgtcaatggtgtcttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaatgacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaagcaatgggaaagagacttgaccttaagaggggcaatacaagtttcagctgttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcctatggcaaccagaatatcagtggtggcattgacaaattctggttggaaagccagcttagaatttccgcagttaatcaagtggagtttctagagtctctatatttaaataaattgtcagcatctaaagaaaaccagctaatagtaaaagaggctttggtaacggaggcggcacctgaatatctagtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttgggtgggttgagaaggagacagaggtttactttttcgcctttaacatggatatagacaacgaaagtaagttgccgctaagaaaatccattcccaccaaaatcatggaaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4420,Drugs,MEG_4420|Drugs|betalactams|Class_D_betalactamases|OXA,1625655426|WP_136512103.1|NG_064780|1|1|blaOXA-823|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-823 NG_064780:1-801,0
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattataatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttaaaagagctaaaaaagctttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagacacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaatgctctcaagtgcctgcttttaaagaattggcaagaaacataggacttaaaactatgcaagaaagcttaaataaactttcttatggaaatacaaaaatttcaaaaatcgataccttttggctagataattctttacaaatttctgcaaaaaatcaagctgatttactttttaaactttcgcaaaattctttacctttttctaaaaaaaatcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagattaaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattattaaataagtatttagctaattttttcaacaataataggattaaaagcttttactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4576,Drugs,MEG_4576|Drugs|betalactams|Class_D_betalactamases|OXA,1391852927|WP_109545112.1|NG_057548|1|1|blaOXA-622|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-622 NG_057548:1-774,0
,atggtgacggtgttcggcattctgaatctcaccgaggactccttcttcgatgagagccggcggctagaccccgccggcgctgtcaccgcggcgatcgaaatgctgcgagtcggatcagacgtcgtggatgtcggaccggccgccagccatccggacgcgaggcctgtatcgccggccgatgagatcagacgtattgcgccgctcttagacgccctgtccgatcagatgcaccgtgtttcaatcgacagcttccaaccggaaacccagcgctatgcgctcaagcgcggcgtgggctacctgaacgatatccaaggatttcctgaccctgcgctctatcccgatattgctgaggcggactgcaggctggtggttatgcactcagcgcagcgggatggcatcgccacccgcaccggtcaccttcgactcgaagacgcgctcgacgagattgtgcggttcttcgaggcgcgggtttccgccttgcgacggagcggggtcgctgccgaccggctcatcctcgatccggggatgggatttttcttgagccccgcaccggaaacatcgctgcacgtgctgtcgaaccttcaaaagctgaagtcggcgttggggcttccgctattggtctcggtgtcgcggaaatccttcttgggcgccaccgttggccttcctgtaaaggatctgggtccagcgagccttgcggcggaacttcacgcgatcggcaatggcgctgactacgtccgcacccacgcgcctggagatctgcgaagcgcaatcaccttctcggaaaccctcgcgaaatttcgcagtcgcgacgccagagaccgagggttagatcatgcctag,beta-lactamase,antibiotic target replacement,Sulfonamides,MEG_6584,Drugs,MEG_6584|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,1028098606|WP_063855103.1|NG_048099|1|1|sul1|sul1|sulfonamide-resistant_dihydropteroate_synthase_Sul1 NG_048099:101-940,8
,ATGAATAGAATAAAAGTCGCAATCATCTTCGGCGGTTGCTCGGAGGAACATGATGTGTCGGTAAAATCCGCAATAGAAATTGCTGCGAACATTGATACGGAAAAATTCGATCCGCACTACATCGGAATTACAAAAAACGGTGTATGGAAGCTATGCAAGAAGCCATGTACGGAATGGGAAGCCGACAGTCTCCCCGCCATACTCTCCCCGGATAGGAAAACGCATGGGCTGCTTGTCATGAAAGAAAGCGAATACGAAACACGGCGTATTGATGTGGCTTTCCCGGTTTTGCATGGCAAATGCGGGGAGGATGGTGCGATACAGGGGCTGTTTGTATTGTCTGGTATCCCCTATGTGGGCTGTGATATTCAAAGCTCCGCAGCTTGCATGGACAAATCACTGGCCTACATTCTTACAAAAAATGCGGGCATCGCCGTTCCCGAATTTCAAATTATTGATAAAGGTGACAAGCCGGAGGCGGGTGCGCTTACCTACCCTGTCTTTGTGAAGCCGGCACGGTCAGGTTCGTCCTTTGGCGTAACCAAAGTAAACGGTACGGAAGAACTTAACGCTGCGATAGAAGCGGCAGGACAATATGATGGAAAAATCTTAATTGAGCAAGCGATTTCGGGCTGTGAGGTCGGGTGTGCGGTCATGGGGAACGAGGATGATTTGATTGTCGGCGAAGTGGATCAAATCCGGCTGAGCCACGGTATCTTCCGCATCCATCAGGAAAACGAGCCGGAAAAAGGCTCAGAAAATGCGATGATTACAGTTCCCGCAGACATTCCGGTCGAGGAACGAAATCGGGTGCAGGAAACGGCAAAGAAAGTATATCGGGTGCTTGGATGCAGAGGGCTTGCCCGTGTTGATCTTTTTTTGCAGGAGGATGGCGGCATCGTTCTAAATGAGGTCAATACCATGCCCGGTTTTACATCGTACAGCCGCTACCCACGTATGGTGGCCGCCGCAGGAATCACGCTTCCTGCACTGATTGACAGCCTGATTACATTGGCGTTAAAGAGGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7354,Drugs,MEG_7354|Drugs|Glycopeptides|VanB-type_resistance_protein|VANB,(Gly)VanB:AY655711:1-1029:1029,5
,atgttctctcgttggtcgaaacctttcgtgcttgccgccacggtgtgcgccatggcgatgagcgccgccactgcccacgccgagctcatcgtgcgcaacgatctcaagcgcgtgttcgacgaggccggcgtctccggcaccttcgtgctgatggatatcagcgccgaccgcacctacgtcgttgacccggcccgcgccgcgcggcgtatccatccggcctcaactttcaagatcccgaacagcctcatcgccttcgacacgggcgcagtgcgtgacgatcatgaagtgctgccatacggcggcaagccgcagccctacaagcagtgggagcacgacatggcgctgcccgaggcgatccgcctgtcggccgtgccgatctaccaggaagtggcgcgccgcgtcggccttgagcgcatgcaggcgtatgtcgatgcgttcgactatggcaatcgccagcttggcagcgtgatcgaccagttctggctgcgcggtccgctcgaaatctcggcgtttgaagaggcgcgcttcaccagccgcatggcgctcaagcagctgccggtgaagccgcgcacgtgggacatggtccatcgcatgctgctgatcgagcagcaaggcgatgccgcgctgtacgccaagaccggcgtcgccacggaataccagccggagatcggctggtgggtcggttgggtcgagcgtgccgggcgcgtctatgcctttgcgctgaacatcgacatgccgcgcgagggcgacatggccaagcgcattccgctgggcaagcagttgatgcaggcgctggaggtgtggccggcaccctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4739,Drugs,MEG_4739|Drugs|betalactams|Class_D_betalactamases|OXA,1331531453|WP_102607463.1|NG_056180|1|1|blaOXA-571|blaOXA-60_like|OXA-60_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-571 NG_056180:1-816,0
,ATGATGAAAAAATCGTTATGCTCCGCTCTGCTCGTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2000,Drugs,MEG_2000|Drugs|betalactams|Class_C_betalactamases|CMY,blaCMY-2b_1_U77414,0
,ATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGAAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2383,Drugs,MEG_2383|Drugs|betalactams|Class_A_betalactamases|CTX,gi|225579715|gb|FJ815277.1|1-876,0
,atgaataaacccgctgtcatcgcgctggtgattacactgctggacgcgatgggaattggtctgatcatgccggtattaccgtcactgctgcgggaatatctcccggaagcggatgtggcaaaccattacggcattctgctggcgctgtatgcggtgatgcaggtctgttttgctccgctgctgggcagatggtcagataagctggggcgcagaccggtgctgctgttatccctggcgggtgccgcgtttgattacacactgctggcactgtccaatgtgctgtggatgttgtatctcgggcggattatctccgggatcactggtgccaccggcgcggttgcggcttcggtagtggcggacagcacggcggtcagcgagcgtaccgcctggttcggccgtctcggtgcggcctttggtgccgggctgattgccgggccggctatcggcggactggcgggggatatctcaccgcatctgccgtttgtcattgcggcaatactgaatgcctgcacctttctgatggtcttttttatctttaaaccggcggtacagacagaagaaaaaccggcggagcagaaacaagaaagcgcaggtatcagctttatcacactgcttaaacctctggcgctgttgctgtttgtcttttttaccgcgcagcttatcgggcagatcccggccactgtctgggtattgtttacggagagccgctttgcctgggacagcgcggcggtcggtttttcactggcgggactcggggcgattcatgcactgtttcaggcggtggttgccggggcgctggcaaaacggctgagtgagaaaaccattattttcgccggatttattgccgatgccaccgcgtttttactgatgtctgctatcacttccggatggatggtgtatccggtcctgatcctgctggcaggcggcggaattgcactgcctgcattgcagggcattatctctgccggggcatcggcggcaaatcagggaaaactacagggtgtgctggtcagcctgaccaatctgaccggcgtggcgggcccgctgctgtttgcttttattttcagtcagacacagcagagtgcggacggtacggtgtggctgattggcacggcactgtacggtctgctgctggcaatctgtctgctgatcagaaaaccggcaccggtggcggccacctgctga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7060,Drugs,MEG_7060|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETC,1028099803|WP_063856075.1|NG_048185|1|1|tet(D)|tet(D)|tetracycline_efflux_MFS_transporter_Tet(D) NG_048185:1-1185,4
,AAATTGAAGAGTTTGATCATGGCTCAGATTGAACGCTGGCGGCAGGCCTAACACATGCAAGTCGAACGGTAACAGGAAACAGCTTGCTGTTTCGCTGACGAGTGGCGGACGGGTGAGTAATGTCTGGGAAACTGCCTGATGGAGGGGGATAACTACTGGAAACGGTAGCTAATACCGCATAACGTCGCAAGACCAAAGAGGGGGACCTTCGGGCCTCTTGCCATCAGATGTGCCCAGATGGGATTAGCTAGTAGGTGGGGTAACGGCTCACCTAGGCGACGATCCCTAGCTGGTCTGAGAGGATGACCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCCATGCCGCGTGTATGAAGAAGGCCTTCGGGTTGTAAAGTACTTTCAGCGGGGAGGAAGGGAGTAAAGTTAATACCTTTGCTCATTGACGTTACCCGCAGAAGAAGCACCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAGGGTGCAAGCGTTAATCGGAATTACTGGGCGTAAAGCGCACGCAGGCGGTTTGTTAAGTCAGATGTGAAATCCCCGGGCTCAACCTGGGAACTGCATCTGATACTGGCAAGCTTGAGTCTCGTAGAGGGGGGTAGAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGTCGACTTGGAGGTTGTGCCCTTGAGGCGTGGCTTCCGGAGCTAACGCGTTAAGTCGACCGCCTGGGGAGTACGGCCGCAAGGTTAAAACTCAAATGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGATGCAACGCGAAGAACCTTACCTGGTCTTGACATCCACGGAAGTTTTCAGAGATGAGAATGTGCCTTCGGGAACCGTGAGACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTTGTGAAATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATCCTTTGTTGCCAGCGGTCCGGCCGGGAACTCAAAGGAGACTGCCAGTGATAAACTGGAGGAAGGTGGGGATGACGTCAAGTCATCATGGCCCTTACGACCAGGGCTACACACGTGCTACAATGGCGCATACAAAGAGAAGCGACCTCGCGAGAGCAAGCGGACCTCATAAAGTGCGTCGTAGTCCGGATTGGAGTCTGCAACTCGACTCCATGAAGTCGGAATCGCTAGTAATCGTGGATCAGAATGCCACGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGGGAGTGGGTTGCAAAAGAAGTAGGTAGCTTAACCTTCGGGAGGGCGCTTACCACTTTGTGATTCATGACTGGGGTGAAGTCGTAACAAGGTAACCGTAGGGGAACCTGCGGTTGGATCACCTCCTTA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_6146,Drugs,MEG_6146|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|RRSC,gb|U00096|+|3941808-3943349|ARO:3003333|Escherichia coli 16S rRNA mutation in the rrsC gene conferring resistance to kasugamicin [Escherichia coli K-12] ,2
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcaacgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgataaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_889,Drugs,MEG_889|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502038|WP_071846190.1|NG_052144|1|1|aadA15|aadA15|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA15 NG_052144:101-892,2
,TGGATTGCGGAGGAAGAGAAGAATAAAGATTTAGATGAAATTTATATAAAGGGAGCACAAGCAGGGCAGATAGGAGCATTTATTGGAATAGTACTAAGCACTGTAATAGCTAATTTCTCTGTAAGGCTTCCTATTATAGTTAGTGGAGTTTTATTTATAATTCTTGCATTATTTTTATGGTTATATATGCCAGAAAATAATTTTAAACCATCTGCTCCTGGGGATTTAAATACATTCAAAAAGATGGTATATACATTTAAATCTGGTCTTAAAATTGTAAAAAGTAAATCTATAATTATGATTTTACTTGCAGTAACTTTATTTTATGGATTATCAAGCGAAGGTTATGATAGACTTTCTAATGCACATTTTTTACAAGATACTACACTTCCTAAGCTTGGAAACCTTAGTTCAGTGACTTGGTTTGGAATTTTTGGAATTTTAGGAATGATATTGAGCTTCATAGTAATGCATTTTATGGCAAAGAATCTTAAGAATGAGGATAATAGGAAAAATGGAAAACTATTATTATGTATAAATATACTTTATATATCGTCTATGTTGATATTTGCTCTTACAAAAAACTTTAGTTTAATGTTAATAGCTTATTTGGCAACAAATACCTTTAGAATTATAAATGAACCTATATTCAGTGCGTGGTTAAATGGGCATATA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7030,Drugs,MEG_7030|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,gi|327195628|gb|HQ399624.1|1-675,4
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacatcttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtgggcgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagtatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6201,Drugs,MEG_6201|Drugs|betalactams|Class_A_betalactamases|SHV,1028110275|WP_063864645.1|NG_050034|1|1|blaSHV-159|blaSHV|class_A_beta-lactamase_SHV-159 NG_050034:1-861,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcttggccgtagccatcagcctgaaaggaaaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5584,Drugs,MEG_5584|Drugs|betalactams|Class_C_betalactamases|PDC,730235634|WP_033940628.1|NG_049940|1|1|blaPDC-65|blaPDC|class_C_beta-lactamase_PDC-65 NG_049940:1-1194,0
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaatgaaacccagagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaagcagataaaaaaattaatctgtatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttaccggttgggaaaaagacatgacactaggagaagccatgaagctttccgcagtcccagtctatcaggaacttgcgcgacgtatcggtcttgatctcatgcaaaaagaagtaaaacgtattggtttcggtaatgctgaaattggacagcaggttgataatttctggttggtagggccattaaaggttacgcctattcaagaggtagagtttgtttctcaattggcgcatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgcttcttttagaagagagtaatggctacaaaatttttggaaagaccggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcacttttgcattaaatatggaaatgcggtcagaaatgcctgcatctatacttaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4523,Drugs,MEG_4523|Drugs|betalactams|Class_D_betalactamases|OXA,1625655422|WP_136512099.1|NG_064766|1|1|blaOXA-808|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-808 NG_064766:1-822,0
,TTGTCCGAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGATTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGGTGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4312,Drugs,MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_12_KX620936 ,1
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcctgaataacaaagcagagcgcattgtggtgatttatctgcgggataccccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6223,Drugs,MEG_6223|Drugs|betalactams|Class_A_betalactamases|SHV,490245401|WP_004143591.1|NG_062278|1|1|blaSHV-206|blaSHV|class_A_beta-lactamase_SHV-206 NG_062278:1-861,0
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGTTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCAAGGGGCTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2418,Drugs,MEG_2418|Drugs|betalactams|Class_A_betalactamases|CTX,gi|695208600|ref|NG_035613.1|757-1632,0
,ATGTTGAAAAAAATAAAAATAAGCTTGATTCTTGCTCTTGGGCTTACCAGTTTGCAGGCATTTGGACAGGAGAATCCTGATGTCAAAATTGAAAAGCTAAAAGATAATCTGTATGTATACACAACCTACAATACATTTAACGGGACTAAATATGCCGCAAATGCAGTATATCTGGTAACTGATAAGGGTGTTGTGGTTATAGACTGTCCGTGGGGAGAAGACAAATTTAAAAGCTTTACGGACGAGATTTATAAAAAACACGGAAAGAAAGTTATTATTAATATTGCAACACATTCTCATGATGATCGTGCCGGAGGTCTTGAATATTTTGGTAAAATAGGTGCAAAAACTTATTCTACTAAAATGACAGATTCTATTTTAGCAAAAGAGAATAAGCCAAGAGCACAATATACTTTTGACAATAATAAATCTTTCAAAGTAGGAAAATCCGAGTTTCAGGTTTACTATCCCGGAAAAGGGCACACAGCAGATAATGTGGTGGTATGGTTTCCAAAAGAAAAAGTATTGGTTGGAGGTTGTATTATAAAAAGTGCTGATTCAAAGGACCTGGGATATATTGGAGAAGCATATGTAAATGACTGGACGCAGTCTGTACACAATATTCAACAAAAGTTTTCTGGTGCTCAGTACGTTGTTGCAGGTCATGATGACTGGAAGGATCAAACATCAATACAGCATACATTGGATTTAATCAGTGAATATCAACAAAAACAAAAGGCTTCAAATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1269,Drugs,MEG_1269|Drugs|betalactams|Class_B_betalactamases|BLAB,gi|9587061|gb|AF189301.1|AF189301|1-750,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGCCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1878,Drugs,MEG_1878|Drugs|betalactams|Class_C_betalactamases|CMY,gb|FJ360626|+|0-1146|ARO:3002054|CMY-43 [Escherichia coli] ,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctactggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctagcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggataccccggcgagcatggtcgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6214,Drugs,MEG_6214|Drugs|betalactams|Class_A_betalactamases|SHV,1028110269|WP_063864639.1|NG_050028|1|1|blaSHV-153|blaSHV|class_A_beta-lactamase_SHV-153 NG_050028:1-861,0
,atgcgcctttgcctgacgacctttgccctgactgccacacttgcctttgatgtgactgccgccgacgcaccgctgccgcagctgcaggcctacaccgtggacgcctcgtggctgcagccgatggcaccgctgcagattgccgaccgcacctggcagatcggcaccgaggacctgaccgcgctgctggtgcagaccgccgacggtgcggtactgctcgacggcggcatgccgcagatggccggtcacctgctggacaacatgaaggcacgcggggtggcagcacaggatctacggctgatcctgctcagccacgcacacgccgaccatgccgggccagtggcggagctgaagcgccgtaccggcgccagcgtagcggccaacgccgaatcggccgtgctgctggcgcgcggtggcagcaacgacctgcactttggcgacagcatcacctttccgccggccagcgccgaccgcatcatcatggatggcgaagaggtcaccgtaggcggcatcgcgttcaccgcgcacttcatgccggggcacaccccaggcagcaccgcctggacctggaccgatacccgcgatggccagccggtgcgcatcgcctacgccgacagcctgagtgcgccgggctaccagctgcagggcaacgcccgttatccccgcctggtcgaggactaccggcgcagcttcgctacggtgcgcggcctgccctgcgacctgctgctgacgccgcatccgggcgccagcaactggaactatgccgccggtgcagaggccggagccaacgccctgacctgcaaggcctacgcggatgcggccgagaagaagttcgacgcacagctggccaaggaaacagccacggcacgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3522,Drugs,MEG_3522|Drugs|betalactams|Class_B_betalactamases|L1,1028083722|WP_063842690.1|NG_047508|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047508:1-870,0
,ttgttcacggctggtcggatctgcgccgccctgatcgttctggtggctttgatctcagcagcaccgaccgcatcggctgatccctccgcagcagttgcgcgtgcgttcgcgccactgctggatcagtacgatgtgccgggcatggccgtggccgtcacggttgacgggcgccagcacttctatgagttcggcgtcgtgtcgaagcagacgcaggcaccggtcaccagggacactctgttcgaaatcggctcggtgagcaagacattcaccgcgactctggccgggtacgccgcgacgcggggcgtactcaacctcgatgaccacccgggccggtatctacctgcgctggccggcacaccgatcgaccgcgccgagcttcggaatctcggcacctacaccgccggtggcctcccactgcagttccctgagtccgtcaccgacgacgaacagatgatcgcgtatttccagcagttccaaccagtcaccgctccaggcaaaatccggcagtactcgaatcccagtgtcggcctgttgggccacatctcggcgcgggccctgggcgggcagttcaccgacctgatgcagtcgcagatcctgactggtctcggattgcgcagaagtttcgtcgatgtgacggacgaggccatggacttctatgcgtggggttacgacaagaagaaccatccggtgcgggtgaacccgggagtgttcgacgccgaggcctacggagtcaaatcgacaaccgcggacatgattcgcttcatcgaacacaacatcgacccgggcgcactggagcccacacttcgtgaggctgtgaagagcactcaagtcggctattacaaggtgggcccgatggtgcaagacctgggctgggagcagtacccgtacccggtagcgctggaccagttattggcaggcaactcaggcgaaatggcgatgagcccgcaggccgcgacagccatcgccccgccgtcggtgggctcggcattgttcaacaagacgggatccaccgacggcttcggcgcgtatgcggcctttgtgccggaacggcgcatcggcatcgtgatgctggcgaacaagaacttcccgatccccgcgcgcgtcaccgcagcacacacggtgcttgacgctctggacgcctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1273,Drugs,MEG_1273|Drugs|betalactams|Class_C_betalactamases|BLAE,500048725|WP_011729443.1|NG_047493|1|1|blaE|blaE|class_C_beta-lactamase NG_047493:101-1243,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataaggtattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatataaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4660,Drugs,MEG_4660|Drugs|betalactams|Class_D_betalactamases|OXA,919271848|WP_052800105.1|NG_057520|1|1|blaOXA-597|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-597 NG_057520:1-774,0
,atgcgccccctcctcttcagtgcccttctcctgctttccgggcatacccaggccagcgaatggaacgacagccaggccgtggacaagctattcggcgcggccggggtgaaaggcaccttcgtcctctacgatgtgcagcggcagcgctatgtcggccatgaccgggagcgcgcggaaacccgcttcgttcccgcttccacctacaaggtggcgaacagcctgatcggcttatccacaggggcggttagatccgccgacgaggttcttccctatggcggcaagccccagcgcttcaaggcctgggagcacgacatgagcctgcgcgaggcgatcaaggcatcgaacgtaccggtctaccaggaactggcgcggcgcatcggcctggagcggatgcgcgccaatgtctcgcgcctgggttacggcaacgcggaaatcggccaggttgtggataacttctggttggtgggaccgctgaagatcagcgcgatggaacagacccactttctgctccgactggcgcagggagaattgccattccccgccccggtgcagtccaccgtgcgcgccatgaccctgctggaaagcggcccgggctgggagctgcacggcaagaccggctggtgcttcgactgcacgccggaactcggctggtgggtgggctgggtgaagcgcaacgagcggctctacggcttcgccctgaacatcgacatgcccggcggcgaggccgacatcggcaagcgcgtcgaactgggcaaggccagtctcaaggctctcgggatactgccctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4605,Drugs,MEG_4605|Drugs|betalactams|Class_D_betalactamases|OXA,489209583|WP_003118452.1|NG_049773|1|1|blaOXA-494|blaOXA-50_like|OXA-50_family_oxacillin-hydrolyzing_class_D_beta-lactamase_OXA-494 NG_049773:101-889,0
,gtgcgtaccctgaccaccctcggccttgccctgctgctggcccaacccgccgtggccgcccaggccgtcctgccgcaactgcagccctacaccgccccggccgcctggctgaccccggtggcaccgctgcgcatcgccgacaacacctggcacatcggcaccgccagcatcaccgcgctgctggtgaagacgccggaaggcgccgtgctgctggacggcggcatgccccaggtggccgaccacctgctggccaacatgcgcgagctgggtgtggcgccgggcgacctcaagctgatcctgcacagccacgcccacatcgatcacgtgggcccgctggccgccatcaagaaggccaccggcgcgcaactggtgagcaacgccgaatcggccgtgctgctgcagcgcggcgacagccaggacatccacttcggcgacgacatggtcttcgccccggtgcaggtggaccgcctggtgcaggacggcgaaaccgtggagctgggcggcatgaccttcaccgcccacttcacccccgggcacacccccggcagcctgagctggacctggaccgaccgccgcgacggcaagcccctgcgcatcgcctatagcgacagcctgagcgcccccggctacagcctgtggatgaacccgcgcttcccgaagatcgccgaggccttccgcagcggcttcgccgccgtccgcgccctgccctgcgacctgctgatcaccccccacgccgaggctagcggctgggactacaccaacgccgaacaccccaacccgtcacccatgagctgcaaggcctacgccgacaaggccgaggccgccttcgacgcgcaactgaagaagcagcgcggcggctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5805,Drugs,MEG_5805|Drugs|betalactams|Class_B_betalactamases|POM,764517322|WP_044403015.1|NG_049974|1|1|blaPOM-1|blaPOM|subclass_B3_metallo-beta-lactamase_POM-1 NG_049974:101-961,0
,TTATTCATCTATATCGTATTTTTTATTACCGTTCTCATATAGCTCATCATACACTTTACCTGAGATTTTGGCATTGTAGCTAGCCATTCCTTTATCTTGTACATCTTTAACATTAATAGCCATCATCATGTTTGGATTATCTTTATCATATGATATAAACCACCCAATTTGTCTGCCAGTTTCTCCTTGTTTCATTTTGAGTTCTGCAGTACCGGATTTGCCAATTAAGTTTGCATAAGATCTATAAATATCTTCTTTATGTGTTTTATTTACGACTTGTTGCATACCATCAGTTAATAGATTGATATTTTCTTTGGAAATAATATTTTTCTTCCAAACTTTGTTTTTCGTGTCTTTTAATAAGTGAGGTGCGTTAATATTGCCATTATTTTCTAATGCGCTATAGATTGAAAGGATCTGTACTGGGTTAATCAGTATTTCACCTTGTCCGTAACCTGAATCAGCTAATAATATTTCATTATCTAAATTTTTGTTTGAAATTTGAGCATTATAAAATGGATAATCACTTGGTATATCTTCACCAACACCTAGTTTTTTCATGCCTTTTTCAAATTTCTTACTGCCTAATTCGAGTGCTACTCTAGCAAAGAAAATGTTATCTGATGATTCTATTGCTTGTTTTAAGTCGATATTACCATTTACCACTTCATATCTTGTAACGTTGTAACCACCCCAAGATTTATCTTTTTGCCAACCTTTACCATCGATTTTATAACTTGTTTTATCGTCTAATGTTTTGTTATTTAACCCAATCATTGCTGTTAATATTTTTTGAGTTGAACCTGGTGAAGTTGTAATCTGGAACTTGTTGAGCAGAGGTTCTTTTTTATCTTCGGTTAATTTATTATATTCTTCGTTACTCATGCCATACATAAATGGATAGACGTCATATGAAGGTGTGCTTACAAGTGCTAATAATTCACCTGTTTGAGGGTGGATAGCAGTACCTGAGCCATAATCATTTTTCATGTTGTTATAAATACTCTTTTGAACTTTAGCATCAATAGTTAGTTGAATATCTTTGCCATCTTTTTTCTTTTTCTCTATTAATGTATGTGCGATTGTATTGCTATTATCGTCAACGATTGTGACACGATAGCCATCTTCATGTTGGAGCTTTTTATCGTAAAGTTTTTCGAGTCCCTTTTTACCAATAACTGCATCATCTTTATAGCCTTTATATTCTTTTTGTTTTAATTCTTCAGAGTTAATGGGACCAACATAACCTAATAGATGTGAAGTCGCTTTTCCTAGAGGATAGTTACGACTTTCTGTTTCATTAGTTGTAAGATGAAATTTTTTTGCGAAATCACTTAAATATTCATCCATTTTTTTAACGGTTTTAAGTGGAACGAAGGTATCATCTTGTACCCAATTTTGATCCATTTGTTGTTTGATATAGTCTTCAGAAATACTTAGTTCTTTAGCGATTGCTTTATAATCTTTTTTAGATACATTCTTTGGAACGATGCCTATCTCATATGCTGTTCCTGTATTGGCCAATTCCACATTGTTTCGGTCTAAAATTTTACCACGTTCTGATTTTAAATTTTCAATATGTATGCTTTGGTCTTTCTGCATTCCTGGAATAATGACGCTATGATCCCAATCTAACTTCCACATACCATCTTCTTTAACAAAATTAAATTGAACGTTGCGATCAATGTTACCGTAGTTTGTTTTAATTTTATATTGAGCATCTACTCGTTTTTTATTTTTAGATACTTTTTTTATTTTACGATCCTGAATGTTTATATCTTTAACGCCTAAACTATTATATATTTTTATCGGACGTTCAGTCATTTCTACTTCACCATTATCGCTTTTAGAAATATAACTGCTATCTTTATAAACTTGTTTGAAATTTTTATCTTCAATTGCATCAATAGTATTATTAATTTCTTTATCTTTTGAAGCATAAAAATATATACCAAACCCGACAACTACAACTATTAAAATAAGTGGAACAATTTTTATCTTTTTCATCAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3785,Drugs,MEG_3785|Drugs|betalactams|Penicillin_binding_protein|MECA,gi|985566378|dbj|LC068959.1|23781-25790 gi|985563902|dbj|AB721404.1|36931-38940 gi|984671414|emb|LT009690.1|41288-43297 gi|974697948|dbj|AP017320.1|44031-46040 gi|941146344|gb|CP007676.1|39577-41586 gi|941142962|gb|CP007672.1|39745-41754 gi|941139768|gb|CP007657.1|39744-41753 gi|937132516|gb|KT316803.1|4363-6372 gi|908230075|gb|CP009676.1|44285-46294 gi|899756207|gb|CP012119.1|1886676-1884667,0
,ATGAGTTATGGAGATTCCCGTGAGAAAATCCTTTCGGCAGCTACCCGGCTTTTTCAGCTGCAAGGGTATTACGGCACGGGGCTGAACCAGATTATAAAGGAAAGCGGCGCGCCTAAAGGCTCTCTTTACTACCACTTTCCCGGGGGTAAAGAACAGCTTGCGATCGAAGCCGTGAATGAGATGAAGGAGTATATCCGTCAGAAAATCGCGGACTGCATGGAAGCCTGCACCGATCCAGCGGAAGGCATTCAAGCCTTTTTGAAGGAGCTCTCCTGCCAGTTTTCATGTACGGAAGACATTGAAGGCTTGCCTGTGGGCTTGCTAGCGGCTGAGACGTCATTGAAAAGCGAACCGTTGCGCGAAGCCTGTCATGAAGCCTACAAAGAATGGGCCTCTGTGTATGAGGAAAAACTGCGGCAGACTGGCTGCAGCGAGAGCCGTGCAAAAGAAGCCAGCACTGTGGTTAACGCGATGATTGAAGGCGGCATCCTTTTATCTTTGACGGCAAAAAACAGTACGCCGCTCCTTCATATCTCCAGCTGCATTCCTGACCTGCTGAAGAGATAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7197,Drugs,MEG_7197|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_regulator|TETRM,gi|983204966|gb|CP014166.1|290695-290129 gi|807072327|gb|CP011115.1|290696-290130 gi|749183975|gb|CP010314.1|290698-290132 gi|728887195|gb|CP010053.1|290708-290142 gi|728882887|gb|CP010052.1|290705-290139 gi|724425628|emb|LN680001.1|290684-290118 gi|723796434|emb|LN649259.1|290684-290118 gi|649013680|gb|CP008698.1|290706-290140 gi|649009321|gb|CP007800.1|290706-290140 gi|558566549|gb|CP006881.1|290703-290137,4
,GCATTGATGCTGAGCGGGTGCATGCCCGGTGAAATCCGCCCGACGATTGGCCAGCAAATGGAAACTGGCGACCAACGGTTTGGCGATCTGGTTTTCCGCCAGCTCGCACCGAATGTCTGGCAGCACACTTCCTATCTCGACATGCCGGGTTTCGGGGCAGTCGCTTCCAACGGTTTGATCGTCAGGGATGGCGGCCGCGTGCTGGTGGTCGATACCGCCTGGACCGATGACCAGACCGCCCAGATCCTCAACTGGATCAAGCAGGAGATCAACCTGCCGGTCGCGCTGGCGGTGGTGACTCACGCGCATCAGGACAAGATGGGCGGTATGGACGCGCTGCATGCGGCGGGGATTGCGACTTATGCCAATGCGTTGTCGAACCAGCTTGCCCCGCAAGAGGGGATGGTTGCGGCGCAACACAGCCTGACTTTCGCCGCCAATGGCTGGGTCGAACCAGCAACCGCGCCCAACTTTGGCCCGCTCAAGGTATTTTACCCCGGCCCCGGCCACACCAGTGACAATATCACCGTTGGGATCGACGGCACCGACATCGCTTTTGGTGGCTGCCTGATCAAGGACAGCAAGGCCAAGTCGCTCGGCAATCTCGGTGATGCCGACACTGAGCACTACGCCGCGTCAGCGCGCGCGTTTGGTGCGGCGTTCCCCAAGGCCAGCATGATCGTGATGAGCCATTCCGCCCCCGATAGCCGCGCCGCAATCACTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_4159,Drugs,MEG_4159|Drugs|betalactams|Class_B_betalactamases|NDM,gi|974752094|gb|KT164809.1|1368-2091 gi|974752068|gb|KT164808.1|8391-9114 gi|974570295|emb|LN997846.1|3255921-3255198 gi|971825756|dbj|LC107774.1|58-781 gi|971497891|gb|CP012901.1|4095962-4096685 gi|971497742|gb|CP012903.1|22231-22954 gi|971497538|gb|CP012902.1|62438-63161 gi|969535508|gb|KT364224.1|58-781 gi|969535508|gb|KT364224.1|3296-4019 gi|963776569|gb|KU162940.1|58-781 gi|963776554|gb|KT365396.1|58-781,0
,GCCACCCTGCCACTGGTGGTATACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGCCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGCTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTGTCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCTTTTCTGCGCCAGATCGGTGACAACGTCACCCATCTTGACCGCTGGGAAACGGCACTGAATGAGGCGCTTCCCGGCGACGCGCGCGACACCACCACCCCGGCCAGCATGGCCGCCACGCTGCGCAAACTACTGACCGCGCAGCATCTGAGCGCCCGTTCGCAACAGCAACTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGCCGGGCTGGTTTATCGCCGACAAAACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAACCGGAGCGCATTGTGGTGATCTATCTGCGGGATACCCCGGCGAGTATGGCCGAGCGCAATCAACATATCGCCGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3554,Drugs,MEG_3554|Drugs|betalactams|Class_A_betalactamases|LEN,gb|AJ635424|+|0-789|ARO:3002458|LEN-8 [Klebsiella pneumoniae] ,0
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttaagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatagttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6660,Drugs,MEG_6660|Drugs|betalactams|Class_A_betalactamases|TEM,823106696|WP_047028173.1|NG_050256|1|1|blaTEM-26|blaTEM|class_A_extended-spectrum_beta-lactamase_TEM-26 NG_050256:101-961,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctatgcgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagtgcgttcggctacggcaatgcggacgtctcgggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaagctggtgaatcggcaattgccggtcaaggccgccgcttatgagctggccgacaacctcttcgaggtgggccaggccgatggctggcgcctgtatggcaaaaccggcaccgggtcgcccggcagcaacggcgtctacacggcggccaatgcctacggttggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccggtccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4724,Drugs,MEG_4724|Drugs|betalactams|Class_D_betalactamases|OXA,1625655400|WP_136512077.1|NG_064740|1|1|blaOXA-114s|blaOXA-114_like|class_D_beta-lactamase_OXA-114s NG_064740:1-828,0
,atgtttttttttaaaaaaagtgcaagtacatttatttttttgctctgtcttccattgaactcatttgcctctcaggaaagtaatggtgttgagcaaatgagggaattggaaacttcttttggggggcggataggtgtttatattttaaacacaaaaaatgggaaagaattttcctacagacaagatgagagatttcctttatgtagttcatttaaggcgttccttgctgcatccgtattaaaaagaactcaggataaatctgtttctcttgatgatatgatggaatattctggacgtgttatggaaaagcattctcctgtatcagaaaaataccgcgaaacaggagcaagcgtgcagactttggccaaggcagcaattcagtatagtgacaatggagcttctaatctattaatggaaagatacataggaggtcctgagggtttgactgcatttatgcggtcaacgggagacactgacttcaggcttgatcgttgggaattagaattaaactcagctattccaggcgatgaacgtgatacttccactccaaaagcagtggctatgagtcttaataatattgcttttggttcagtactcgatgctaaaaataaatccttgctacaggattggcttaaaggcaacactactggtaatgcgcgaattagagctgctgttccagataagtgggttgttggcgataaaacaggcacctgtggtttttatggtacagccaatgatattgctattttatggccagatgccaattcacctgcagttatggctgtctacacaacacgtcctaatcaaaacgacaaacatgacgaaacagttataaaaaatgctgcaaaaatagctataaatgcagtgtatgggagtactaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3056,Drugs,MEG_3056|Drugs|betalactams|Class_A_betalactamases|FRI,1553321449|WP_127728991.1|NG_063840|1|1|blaFRI-6|blaFRI|carbapenem-hydrolyzing_class_A_beta-lactamase_FRI-6 NG_063840:1-885,0
,atgagcaacgcagtgcccgccgagatttcggtacagctatcacaggcactcaacgtcatcgagcatcatctgggatcgacgttgctggccgtgcatttgtacggctctgcactcgacggtggcctgaagccatgcagtgatattgatttgctggttactgtgactgcacagctcgatgagactgtgcggcaggctctgttcgtagatttcctggaagtttccgcttctcccggccaaagtgaagctctccgtgccttggaagttaccatcgtcgtgtacggcgatgttgttccttggcgttatccagccagacgggaactgcaattcggggagtggcagcgcaaggacattcttgcgggcatcttcgagcccgcgacaaccgatgttgatctggctattctgctaactaaagcaaggcaacacagccttgccttggcaggttcggccgcggaagatttcttcaacccagtcccggaaagcgatctattcaaagcactggccgacaccttgaaactatggaactcacaaccggattgggcaggcgacgagcggaatgtagtgcttaccttgtctcgcatttggtacagcgcagcaaccggcaagatcgcgccgaaggatgtagctgccaactgggtaatggaacgcctgcccgtccaacatcagcccgtgctgcttgaagcccagcaggcttaccttggacaagggatggattgcttggcctcacgcgctgatcagttgactgcgttcatttactttgtgaagcacgaagccgccagtctgctcggctccacgccaatgatgtctaacagttcattcaacatgtccgcgagcaccccccccataactcttcgcctcatgaccgagcgcgacctgccgatgctccatgattggctcaaccggccgcacatcgttgagtggtggggtggtgacgaagagcgaccgactcttgatgaagtgctggaacactacctgcccagagcgatggcggaagagtccgtaacaccgtacatcgcaatgctgggcgaggaaccgatcggctatgctcagtcgtacgtcgcgctcggaagcggtgatggctggtgggaagatgaaactgatccaggagtgcgaggaatagaccagtttctggctgacccgacacagttgaacaaaggcctaggaacaaggcttgtccgcgctctcgttgaactactgttctcggaccccaccgtgacgaagattcagaccgacccgactccgaacaaccatcgagccatacgctgctatgagaaggcaggattcgtgcgggagaagatcatcaccacgcctgacgggccggcggtttacatggttcaaacacgacaagccttcgagagaaagcgcggtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_762,Drugs,MEG_762|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1080153693|WP_070342373.1|NG_051910|1|2|ant(3'')-I|ant(3'')-I|bifunctional_aminoglycoside_nucleotidyltransferase_ANT(3'')-Ia/aminoglycoside_N-acetyltransferase_AAC(6')-IIa NG_051910:101-1474,2
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtgcgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggctacggcaatgcggacgtctcgggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaagctggtgaatcggcaattgccggtcaaggccgccgcctatgagcttgccgaaaacctcttcgaggtgggccaggccgatggctggcgcctgtatggcaaaaccggcaccgggtcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccggcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4547,Drugs,MEG_4547|Drugs|betalactams|Class_D_betalactamases|OXA,924466515|WP_053498400.1|NG_064730|1|1|blaOXA-114h|blaOXA-114_like|class_D_beta-lactamase_OXA-114h NG_064730:1-828,0
,TTGGAAAAACGCCAAGAAGTTCAAGAATTAACCCTTGAAGAAGTAATGGGCGATCGTTTTGGAAGATATTCCAAATACATCATTCAAGAACGGGCCCTACCAGATATTCGAGATGGGCTAAAACCAGTACAACGCCGCATTCTCTTTTCAATGAATAAAGACGGCAATACCTTTGATAAAGGCTTTCGTAAATCAGCAAAATCTGTCGGAAACATTATGGGGAATTATCATCCCCATGGCGACAGCAGTATTTATGAAGCGATGGTGCGTCTAAGTCAAGACTGGAAATTACGGGAAGTACTAATTGAAATGCACGGAAACAACGGAAGTATGGATGGCGACCCACCAGCGGCGATGCGTTATACAGAAGCTCGTTTATCACAGTTAAGTGGTGAGTTGTTAAAAGATATCGACAAAAATACCGTCGATTTCGTCTGGAATTTTGACGATACAGAAAAAGAACCCACTGTTTTACCAGCCAAATATCCTAATTTATTGGTAAACGGCTCAACGGGGATTTCAGCAGGCTATGCAACAGAAATTCCTACGCATAATTTAGCGGAAATCATTGATGGAACTGTGTATTTAATTGATCATCCTAATGCAAGTTTAGAGAAATTAATGGAATACATTCCAGGACCAGATTTCCCAACAGGTGGGATTCTACAAGGAAAAGCAGAAATTAAAAAAGCCTACGAAACCGGCCGTGGTAAAGTAATTTTACGTGCGAAGACAAAGATTGAGCCTTTAAAAGGCGGCAAACAACAAATTGTCATTTCTGAAATTCCTTATGAAGTCAACAAAGCAACGCTAGTGAAGAAGATGGATGAAATCCGTTTAAATAAAAAAGTAGACGGCATTGCCGAAGTTCGTGACGAAAGTGACAGAACTGGCTTGCAAATTGTTGTTGAACTAAAAAAAGATGTCAATGCAGAAGGTATTTTAAATTATCTATTTAAAAACACTGAATTGCAAATCAATTACAACTTTAACATGGTAGCCATCGACAACATGACCCCGCAACAAGTGGGCCTAAAACGGATTTTAGAAAGTTACATTACGCATCGCAAATCAGTTATCATTAACCGTTGTCAATTTGAGTTGGACAAAGCTCGCAAACGTGAGCACATTGTTGCTGGTTTAATTAAAGCATTGTCTATCTTAGATAAAGTGATTGCAACAATCCGTGGCAGTAAAGATAAAAAAGATGCGAAGAAGAACTTAGTATCCGACTATGCGTTTACTGAAGAACAAGCTGAAGCAATCGTTACTTTACAGCTATACCGTTTAACCAATACGGATATTACTGATTTACAAGAAGAAGCGAAAACTTTAGAACAACAAATTGCTGAGTTATTGAACATTTTAAACAATGAAAAAGAACTATTCTCAGTCATGAAAAAAGAACTTCGCGAAGTTAAAAAGCAATATGGCAATCCGCGCTTAACTCAAATTGAAGAGGAAATCCAAGAAATCAAGATTGAAACAGCCGTGTTAGTTGCGCAGGAAGACGTGGTCGTAACCGTGACGCACGAAGGCTATATCAAGCGGAGTAGTATTCGTTCTTATACAGCATCAAAACCAGAAGAAATCGGCATGAAAGAAGGCGACTTTTTATTATATGCTGGCGAAGTCAATACATTAGATCATCTTTTACTAGTAACAAATAAAGGGAATATGATCTATCGCCCCGTCCATGAGTTGCCAGATTTACGCTGGAAAGAAATTGGCGAACATATTTCTCAAACCATTTTAAATCTTGCTATCGATGAATCGATTATTGCTGTATATCCTTATAAAGAGTTAAGTCCGACAAAAACCTTTGTTTTCATTACAAAAGCTGGCATGATTAAACAAACCAAAATGGCTGATTTTGAGCCTTGGCGCACTTATAAGAGCCGCCCGACATCTTGTATGAAATTAAAATCAGACCAAGATGAAATTACCAATGTTTATTTAACAAATGATCAAGACTTATTGGATGTTTTCCTCGTTAGCAATCGCGGTTTTGGCTTACGTTATCCATTATATGAAGTACCAGTCGTGGGTAGTAAAGCGGCTGGAGTTAAATCAATGAACCTCAAAGAAGACGATTATGTCGTTAATGGTTTACTGGTTCATTCTGAAGGGGATACACCGATTGTCATCGTTACCCAACGTGGCGGTGTTAAACGCATGTTAGCCCAAGAATTAACACAATTAGGACGAGCAAAACGTGGACTAATGGTCTTGCGGGAATTGAAGAAAAATCCACATCGTGTTGTCTTTATGTCTGAAAGTACCGATTTAGATTTATTAGTTACTACGCAAAAGGGCACACAAGAAGTTATTCAGTCGAAAAACTATCCAATCAGTGAACGAACATCCAACGGTTCCTTTGTCATCGATGAACAAAAAGATGGCCAAGTAATGGAAGTCCACGAGATGCATTCTGCAGTGATTGAAGAAGAACAAACAAACTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5341,Drugs,MEG_5341|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|29350190|gb|AE016830.1|1573667-1571205 gi|15982569|dbj|AB059406.1|2403-4865,3
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTAGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1866,Drugs,MEG_1866|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EF394370|+|0-1146|ARO:3002045|CMY-34 [Citrobacter freundii] ,0
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGACATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGAAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCGCCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1363,Drugs,MEG_1363|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_104_FQHI01000006,0
,TTGTTGCTCAGGCACTTATAAATAATGTTAAACTATAGTGTTGCGGAATTAAGGCATCATATAAAAGAATAAAATGAAAACAGTATTTATCCTTATCTCCATGCTTTTCCCTGTCGCAGTTATGGCACAGAAAAGCGTAAAAATATCCGATGACATCAGTATCACCCAACTCTCGGACAAAGTGTACACTTATGTATCCCTCGCCGAAATCGAAGGATGGGGTATGGTACCTTCCAACGGGATGATTGTTATCAACAACCACCAGGCAGCGTTGCTGGACACACCGATCAATGACGCACAAACGGAAATGCTGGTCAACTGGGTGACAGACTCTTTGCATGCCAAAGTCACCACGTTTATCCCGAACCACTGGCACGGCGATTGTATTGGCGGACTGGGTTACCTGCAAAGGAAAGGTGTCCAATCATACGCGAACCAGATGACGATAGACCTCGCCAAGGAAAAAGGGTTGCCCGTACCGGAACATGGATTCACCGATTCACTGACCGTCAGCTTGGACGGCATGCCTCTCCAATGTTATTATTTAGGAGGCGGACATGCGACCGACAATATCGTGGTTTGGCTGCCGACAGAGAATATCCTTTTTGGCGGATGTATGCTTAAAGACAACCAGGCGACAAGCATCGGCAACATCTCGGACGCGGACGTGACGGCATGGCCGAAAACTCTCGATAAGGTAAAAGCCAAGTTCCCCTCGGCCCGTTACGTCGTGCCCGGACATGGCGACTATGGCGGAACCGAACTGATAGAGCATACCAAGCAGATCGTGAACCAATATATAGAAAGCACTTCAAAGCCATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1678,Drugs,MEG_1678|Drugs|betalactams|Class_B_betalactamases|CFIA,gi|143933|gb|M34831.1|BNRCFIA|460-1282 gi|143931|gb|M63556.1|BNRCCRA|18-840,0
,atgaaaaactactttaacagccctttcaaaggggaacttctttctgagcaagtgaaaaatccaaatatcagagtaggccggtatagctattactctggctactatcacgggcactcatttgatgaatgcgcgcgatacttgtttccagatcgtgatgacgttgataaattgatcattggcagcttttgttctataggaagcggggcttccttcatcatggctggcaatcaggggcatcggcatgactgggcatcatccttccccttcttctatatgcaagaggagcctgctttctcaagtgcactcgacgccttccaaagagcaggtgataccgtcattggcaatgatgtctggataggctcggaggcaatgattatgcctggcatcaaaattggagacggtgccgtgataggtagtcgctcgttggtgacaaaagatgtagagccttatgcactcatcgggggaaatcccgcaaagcaaattaagaagcgcttctccgatgaggaaatctcattgctcatggagatggagtggtggaactggccactagataaaattaagacaacaatgcctctgctgtgctcgtcaaatatttttggtctgcataagtattggcgcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1608,Drugs,MEG_1608|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1028084262|WP_063843230.1|NG_047617|1|1|catB8|catB8|type_B-3_chloramphenicol_O-acetyltransferase_CatB8 NG_047617:101-733,6
,atgaaaaagttatttttgttggctgggctaatggtttgctcaaccctaagttacgcgtcccaactgaatgaggacatttctctcctcgagcaacaaacctcaagcagaattggggtgtcagtttgggatacccaagcagacgagcgttgggattaccgtggcgatgaacgcttcccactcatgagcacattcaaaaccctagcttgtgccaaaatgttaagtgatatggacagcggtaagctaagtaaaaatgcgaccgcaaaagtcgatgagcgcagtatcgttgtatggtctccagtgatggataagctcgcaggccaaaacacacgcatagagcacgcgtgtgaagccgctatgttaatgagtgataataccgcagccaacttagtattaaatgaaattggcggccctaaggccgtaacaatgtttctgcgaacaattggagataaagcaacgcgcctagacagaatagaacctcgcttgaacgaagccacaccaggcgacagccgcgacacaactacacctaacgccatactaaacactcttcgaactttggtcgaaggcgaaacgttgtcttatgagtctcgtgtacaattaaaaatctggatgcaggacaacaaagtttcagactcgttaatgcgttctgtattaccaacaggttggtctattgcagaccgttctggtgcgggaggtcatggttcgcgtggcattaacgcgattatatggaaggaaaatcatcgacctgtttacattagtatttatgtcacagaaaccgagctctcacttcaagctagggaccaactcgttgcgcagataagtcagttgattttacaaaagtacaaagacaattaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1497,Drugs,MEG_1497|Drugs|betalactams|Class_A_betalactamases|CARB,491517789|WP_005375420.1|NG_048745|1|1|blaCARB-42|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-42 NG_048745:1-852,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATAAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCCCGCAGCACCTCGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAAAGATGCCGGTCGGTAATGATGGTGGTGAACCGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6462,Drugs,MEG_6462|Drugs|betalactams|Class_A_betalactamases|SHV,gi|46452173|gb|AY528718.1|414-1389,0
,atgcgtcaatatcgactcgcccttctgccattgttagccgccctggcgctccccggttgggcgcatgaagccacggtgacgacggttaaacaagccgaaagccagctgcagggccgggtcggctacgccgaactggatttagcttccggccaactgctgtccggctatcgcgctggcgaacgcttcccgatgatgagcacctttaaagtgctgctctgcggcgcagtcttgtcgcgcgtcgataccggtgaagaacagctcgatcgccgtatccattaccggcagcaggatctggtggaatactcgccggtgacggagaagcatcttgccgatgggctcaccgtgggcgaactgtgcgcggccgccattaccctgagcgataatacggcggcaaacctgctgttgaccactctcggcggcccgcaggggctgaccacgttcctgcgccacagcggcgaccagacttcgcgactcgaccggtgggaaacggaactcaatgaagcgcggccgggcgatgtgcgtgatacgacgactccggaagcgatggccaggacactgcgaaatctgttgaccggccgcgtgctttcccccgcctcgcagcagcagttgcaacgctggatggtagaggacaaagttgcggggccgctgttgcgctctgcgctgccggcgggctggtttattgccgataagaccggagccggcaatcgcggctcgcgcggaatcatcgccgctctcggtccggacggtaaagccgcgcgcatcgtggtgatttatttaaccgcaaccccggcctcaatggatgagcgcaataaacagattgcggccatcggtgaaacgctggtcaggcactggtccaaagacgataaaagaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4370,Drugs,MEG_4370|Drugs|betalactams|Class_A_betalactamases|ORN,1028105951|WP_063860932.1|NG_049387|1|1|blaORN-2|blaORN|class_A_beta-lactamase_ORN-2 NG_049387:101-976,0
,ATGGGTGTCTTAAATGTTACCTCGGACTCATTTTATGATGGTGGCAAGTATCTGTCTGTTGATAGAGCCTGTGATCAGGCTTTAAAATTAATTGCATGTGGAGCTGATCTCATTGATATAGGTGGGGAATCAACCAAACCTGGTGCGCCGCCAGTCCCTTTAGATGTTGAACTATCAAGAGTTCTTCCCGTAATCAAACAACTTCGTGCCCTCGCAGATGTGTGTATTTCTATTGATACTAATAAGCCTGAAGTGATGGAAGCGGCAATCGATGCTGGTGCGAATGTTATAAATGATGTTTATGCTTTAAGAAGGGATGGTGCTTTGAATGTTGCTGCGCAGTTAGATGTTCCTGTTTGTTTAATGCACATGAAAGGAGAGCCTCGAACTATGCAAGAAAATCCTTCTTACCCAGAAGGAATAATGAAGGAATTACAGCATTTTTTTGAAGAGCGCATCGATAAATGCCAGAAAGCCGGGCTGAATAAGAATAAATTAATTCTTGACCCTGGCTTTGGTTTTGGAAAGCGCATTAAAGATAACCTAAAATTAATTTATCATCTGAACGAATTGCGTTCTTTTGGATTGCCAATTCTTTTGGGCGTTTCACGCAAAAGCACAATTGGTGCTGTATTGAATAATGAAGTTGAGCAACGTTTGATTGGAAGTATTACGCTAGGAATATATGCTGCTCTTAAAGGCACTGCAATTATCAGGACACATGATGTGGATGAAACGAATCAAGCATTAACTATGATTAATGCAATTTATCAAGCTGCTAAAGAAATCAGTTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2947,Drugs,MEG_2947|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|53752796|emb|CR628337.1|3094181-3093387,8
,atgatgacaaaatccctaagctgtgccctgctgctcagcgtcgccagcgctgcattcgccgcaccgatgtccgaaaaacagctggctgaggtggtggaacgtaccgttacgccgctgatgaacgcgcaggccattccgggtatggcggtggcggtaatttatcagggtcagccacactactttaccttcggtaaagccgatgttgcggcgaacaaacccgtcaccccgcaaaccctgtttgagctgggctctataagtaaaaccttcaccggcgtactgggcggcgatgccattgcccggggtgaaatagcgctgggcgatccggtagcaaaatactggcctgagctcacgggcaagcagtggcagggcattcgcatgctggatctggcaacctataccgcaggcggtctgccgttacaggtgccggatgaggtcacggataccgcctctctgctgcgcttttatcaaaactggcagccgcagtggaagccgggtaccacgcgtctttacgctaacgccagcatcggtctttttggtgcgctggcggttaaaccttccggcatgagctatgagcaggccatgacgacgcgggtctttaaacccctcaagctggaccatacctggattaacgtcccgaaagcggaagaggcgcattacgcctggggataccgtgagggtaaagcggtccacgtttcgccagggatgctggacgcggaagcctatggcgtaaaaactaacgtgaaggatatggcgagctggctgatagccaacatgaagccggattctcttcaggctccctcactcaagcaaggcattgctctggcgcagtctcgctactggcgcgtgggggctatgtatcaggggctgggctgggagatgctcaactggccggtcgatgccaaaaccgtcgtcggaggcagtgataacaaggtggcgctggcaccattgcccgtggcagaagtgaatccacccgcgccgccggtcaaagcctcctgggtccataaaacaggctcgacgggcgggtttggcagctacgtggcatttattcctgaaaagcagctcggcattgtgatgctggcgaataaaagctatccgaacccggcacgcgttgaggcggcataccgtatcctcgacgcgctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3952,Drugs,MEG_3952|Drugs|betalactams|Class_C_betalactamases|MIR,779962325|WP_045409557.1|NG_049308|1|1|blaMIR-7|blaMIR|cephalosporin-hydrolyzing_class_C_beta-lactamase_MIR-7 NG_049308:101-1246,0
,atgaatccctatctacagttagttagcaaagagtttccattagaaaaaaaccaagagccgccccacctcgtccttgctgcttttagtgaagaagaagtttacttgcagcctgaagcagccaaacaatgggaacgcctcgtcaaagccttaaaacttgaaaacgagatctgcttattagacggctatcgaaccgaaaagcagcaacggcatttatgggaatattccttaaaagaaaatggattagcctatacgaaacaatttgtggcgttgcccggctgcagcgagcatcagttaggcttagcgatcgatgttggtttaaaaggccagcaaggtgatttgatctgcccacggtttcgtgacagcgcagcggcggatttatttacacaggaaatgatgaactacggatttattttacgctatcccgcagacaaacaggagattacagggattggctatgaaccatggcattttcgttatgtcggtctacctcatagtcaaatcatcgccagtcaacagtggacattggaagaatactatcaatatcttgaacaaaccgcgaggcagttcgcatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7577,Drugs,MEG_7577|Drugs|Glycopeptides|VanC-type_resistance_protein|VANXYC,495652781|WP_008377360.1|NG_048510|1|1|vanXY-c4|vanXY-c4|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C NG_048510:101-673,5
,atgcgcgataccagattcccctgcctgtacggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccaaggcctgggctgggaagcctacgactggccgatctccctgaggcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5617,Drugs,MEG_5617|Drugs|betalactams|Class_C_betalactamases|PDC,1201190454|WP_087587974.1|NG_054995|1|1|blaPDC-210|blaPDC|class_C_beta-lactamase_PDC-210 NG_054995:1-1194,0
,gtgcgctcaaaaaactttagttggcggtactcccttgccgccacggtgttgttgttatcaccgttcgatttgctggcatcactcggcatggacatgtacttgccggcagtgccttttatgccaaacgcgcttggcacgacagcgagcacagttcagcttacgctggcaacgtacttggtcatgatcggtgccggtcagctcttgtttggaccgctatcggaccgactggggcgccgccccgttctactgggaggtggcctcgcctacgttgtggcgtcaatgggcctcgcttttacgtcattggctgaagtctttctggggcttcggattcttcaggcttgtggtgcctcggcgtgccttgtttccacgtttgcaacagtacgtgacatttacgcaggtcgcgaggaaagtaacgtcatttacggcatactcggatccatgctggccatggtcccggcggtaggcccattgctcggagcgctcgtcgacatgtggcttgggtggcgggctatctttgcgtttctaggtttgggcatgatcgctgcatctgcagcagcgtggcgattctggccagaaacccgggtgcaacgagttacgggcttgcaatggtcgcagctgctactccccgttaagtgcctgaacttctggttgtacacgttgtgttacgccgctggaatgggtagcttcttcgtctttttctccattgcgcccggactaataatgggcaggcaaggtgtgtctcagcttggcttcagcctgctgtttgccacagtggcaattgccatggtgttacggctcgttttatgggcgttgatacccaagtggggcagcccaagtgtcttgcgaatgggaatgggatgcctgatagctggagcagtattgcttgccatcaccgaaatatgggcttcgcagtccgtgttaggctttattgctccgatgtggctagtgggtattggtgtcgccacagcggtatctgtggcacccaatggcgctcttcaaggattcgaccatgttgctggaacggtcacggcagtttacttctgcttgggcggtgtactgctaggaagcatcggaacgttgatcatttcgctgttgccgcgcaacacggcttggccggttgtcgtgtactgtttgacccttgcaacagtcgtgctcggtctgtcttgtgtttcccgagcgaagggctctcgcggccagggggagcatgatgtggtcgcgctacaaagtgcggaaagtacgtcaaatcccaatcgttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1758,Drugs,MEG_1758|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,1028084279|WP_063843247.1|NG_047651|1|1|cmlA4|cmlA4|chloramphenicol_efflux_MFS_transporter_CmlA4 NG_047651:101-1357,6
,atggaaaaaaacagaaaaaaacaaatcgtagttttgagtatagctttagtttgcattttcatcttggtattttcattgttccataaatcagcgacaaaagatagcgcaaatcctcctttaacaaatgttttgactgatagcatttctcaaattgtctcagcttgtcctggcgaaattggtgtggcggttattgttaataacagagatacggttaaggtcaataataagagtgtttatcctatgatgagtgtgtttaaggttcatcaggcattagctctttgtaatgactttgacaataaaggaatttcacttgataccttagtaaatataaatagggataaacttgacccaaagacttggagtcctatgctgaaagattattcagggccagtcatatcattgacagtgagagatttgctgcgttatactcttactcagagtgacaacaatgcaagcaaccttatgtttaaggatatggttaatgtcgctcaaacagatagttttatagccacactcattcctcgttcaagttttcagatagcttatacggaagaggaaatgtcggctgaccataacaaggcttactctaactatacatctcctcttggtgctgcaatggtgatgaatcgtttgtttactgaaggtcttatcgatgatgagaaacaaagtttcattaagaatacgttaaaagaatgcaaaacaggtgtagataggatagcagctccacttcttgataaagaaggggttgttatagcgcataagacaggttcaggttatgttaatgaaaatggtgttcttgcagctcacaatgatgttgcctatatatgtctgcctaataatatcagttataccttagcggtatttgttaaggatttcaagggaaatgaatcacaagcgtcacaatatgttgcgcatatatcagctgtagtatattctttattaatgcaaacttcagtaaaatcttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1689,Drugs,MEG_1689|Drugs|betalactams|Class_A_betalactamases|CFX,1028084271|WP_063843239.1|NG_047636|1|1|cfxA_gen|cfxA_gen|CfxA_family_class_A_broad-spectrum_beta-lactamase NG_047636:1-966,0
,atgcctgatttaattcagttagaatatctacaagaaaaattacagcaacttttagcggaatcattatttgcaatttatctttatggttcagctgttgacggtggtttagggccagaaagtgatcttgatgtactggtcgtggtcactcaaccattaacttctgctttacgtgagcagcttgcacaagaattactaaaaatttcacagcctgttggggaattacaaaggccattagaagttactattttattaaaagatgagattcagtctggaatttatcctttaagttatgaaatacaatttggtgaatggctgcgtgaagagcttaaagaaggtggaacattgagctcaaagaaagacccagatattagtatattgcttagaaaagcgagatctcatcatacagttttatttgggccagctttaaaccaatgggcacctgaaatttctgatcaagaactatggcaagcaatgtctgacacttatcccgaaattgtagcgcattgggatgaggatgcagatgaaagaaaccagattttagctttgtgccggatctattttagtttagtgatgaaggatattgcttcaaaagacaatgctgcacgatgggttatgtctcagcttcctgatgagcagaaattcgtattgcagcgacttatacaggaatatagaggggaaatcggcaaacaaaattggcaagaggagcattatgctttgcagcctattgtcaattttttgagttcaaaaattgaagagcagtttgagcagaaaagaaatctgatcacataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_826,Drugs,MEG_826|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,503974121|WP_014208115.1|NG_054649|1|1|ant(3'')-IIa|ant(3'')-IIa|aminoglycoside_nucleotidyltransferase_ANT(3'')-IIa NG_054649:101-889,2
,ATGTCCGCCACGCTCCACGACACCGCAGCGGATCGTCGGAAGGCCACCCGCCGCGAATGGATCGGCCTGGCCGTGGTCGCCCTGCCGTGCCTGGTCTACGCCATGGACCTCACGGTGCTGAACCTGGCGCTGCCGGTGCTCAGCCGTGAACTGCAGCCCTCCAGCGCCCAGCTTCTCTGGATCCTGGACATCTACGGCTTCTTCGTCGCCGGCTTCCTGATCACCATGGGCACGCTGGGCGACCGCATCGGCCGGCGCCGGCTGTTGTTGATCGGCGCGGCGTTCTTCGCATTCGCCTCGGTGCTCGCGGCGCTGGCCGATACCGCCGCGCTGTTGATCGCGGCGCGCGCCTTGCTCGGCCTGGCCGGCGCCACCATCGCGCCGTCCACCATGGCGCTGGTCCGCAACATGTTCCACGACCCGCGCCAGCGCCAGTTCGCCATCGGCGTGTGGATCGCCGCGTTTTCGCTGGGCAGCGCGATCGGTCCGCTGGTCGGCGGCGTGTTGCTGGAGTTCTTCCACTGGGGCGCCGTGTTCTGGCTCAACGTGCCGGTGATGCTGCTGACGCTGGCGCTCGGCCCTCGCTTCCTGCCCGAGTATCGTGATCCGGACGCGGGGCACCTGGACCTGGCCAGCGTGCTGCTGTCGCTGGCGGCGGTGCTGCTGACGATCTACGGGCTCAAGCAGTTGGCCGAGCATGGAGCGGGCCTCGCCTCGATGGCTGCGCTGCTGGCCGGGCTGGCGGTCGGGGCGCTGTTCCTGCGCCGCCAGGGCCACATCGCCTACCCGCTGCTGGACCTGCGGCTGTTCGCGCACGCGCCGTTCCGCGCGGCGCTGGCGGCGTATGCGCTGGCCGCGCTGGCCATGTTCGGCGTCTACATCTTCATGACGCAGTACCTGCAGCTCGTGCTGGGGCTGTCGCCGCTGCAGGCCGGGCTGGCCACGCTGCCCTGGTCCCTGTGCTTCGTCATCGGTTCGCTGTTGTCGCCGCAGCTCGCGGCGCGCTGGCCGGCGGCGCGCATCCTCGTCGTGGGCCTGTCGGCAGCGGCGTTCGGCTTCGCCGTGCTGGGGCTGGGGCAGGGCCTGTGGTGGCTGGTGCCGGCCACGATCGTCATGGGCCTGGGCCTGGCGCCGGTGTTCACCATCGGCAACGAGATCATCATCACCAGCGCGCCGTCCGAGCGCGCGGGCGCGGCCTCGGCCTTGTCGGAGACGGTGTCCGAATTCAGCGGCGCGCTGGGCATCGCGCTGTTCGGCAGCGTCGGCCTGGTGGTCTACCGGCAGGCGCTGACCAGCGCGGCGCTGCCCGGCCTGCCGGCCGATGCGCTGCAGGCGGCCGGTGCCTCGCTCGGGGGCGCCGTGCACCTGGCCGACACCCTGCCGGCGTGGCAGGGCGCGGCCTTGCTGGCGGCCGCACGCGCGGGCTTCACCGATGCGCTGCAGGCCACGGCCTGGGCCGGCGCGGTGCTGGTGCTGGTGGCCGCTGGGCTGGTGGCGCGCCTGCTGCGCAAGCGCCCAGCGCTCGCATCTGGTTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Fluoroquinolones,MEG_5864,Drugs,MEG_5864|Drugs|Fluoroquinolones|Quinolone_active_efflux|QEPA,(Flq)QepA:AB263754:7052-8587:1536,3
,atgaatattaaacctgcatcagaagcttcactcaaagattggttagaattaagaaataaattgtggagtgattctgaatcttctcatttacaagagatgcatcaattattaaccgaaaaatatgccctacaattattggcctattctgagcaccaagctattgcgatgttagaagcctcaattcggtttgaatatgtgaatgggactgagacttctcctgtgggttttttggaaggtatttacgtacttcctgaacagcgtcgctcgggcgttgcaaccatgcttattcgacaggccgaagtgtgggcaaaacaattttcttgcactgaatttgcatctgatgctgcattggacaatgtaattagtcatgctatgcatcgttcattaggttttcaagaaactgaaaaaatcgtttattttagtaaaaaaatagattaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_116,Drugs,MEG_116|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491232938|WP_005091170.1|NG_052398|1|1|aacA-ACI1|aacA-ACI1|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052398:101-538,2
,gtgcgctcaaaaaactttagttggcggtactcccttgccgccacggtgttgttgttatcaccgttcgatttgctggcatcactcggcatggacatgtacttgccggcagtgccttttatgccaaacgcgcttggcacgacagcgagcacagttcagcttacgctgacaacgtacttggtcatgatcggtgccggtcagctcttgtttggaccgctatcggaccgactggggcgccgccccgttctactgggaggtggcctcgcctacgttgtggcgtcaatgggcctcgcttttacgtcattggctgaagtctttctggggcttcggattcttcaggcttgtggtgcctcggcgtgccttgtttccacgtttgcaacagtacgtgacatttacgcaggtcgcgaggaaagtaacgtcatttacggcatactcggatccatgctggccatggtcccggcggtaggcccattgctcggagcgctcgtcgacatgtggcttgggtggcgggctatctttgcgtttctaggtttgggcatgatcgctgcatctgcagcagcgtggcgattctggccagaaacccgggtgcaacgagttacgggcttgcaatggtcgcagctgctactccccgttaagtgcctgaacttctggttgtacacgttgtgttacgccgctggaatgggtagcttcttcgtctttttctccattgcgcccggactaataatgggcaggcaaggtgtgtctcagcttggcttcagcctgctgttcgccacagtggcaattgccatggtgtttacggctcgttttatggggcgtgtgatacccaagtggggcagcccaagtgtcttgcgaatgggaatgggatgcctgatagctggagcagtattgcttgccatcaccgaaatatgggcttcgcagtccgtgttaggctttattgctccgatgtggctagtgggtattggtgtcgccacagcggtatctgtggcacccaatggcgctcttcaaggattcgaccatgttgctggaacggtcacggcagtttacttctgcttgggcggtgtactgctaggaagcatcggaacgttgatcatttcgctgttgccgcgcaacacggcttggccggttgtcgtgtactgtttgacccttgcaacagtcgtgctcggtctgtcttgtgtttcccgagcggagggctctcgcggccagggggagcatgatgtggtcgcgctacaaagtgcggaaagtacgtcaaatcccaatcgttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1757,Drugs,MEG_1757|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,757619045|WP_042862943.1|NG_047649|1|1|cmlA10|cmlA|chloramphenicol_efflux_MFS_transporter_CmlA10 NG_047649:1-1260,6
,atgtttaaacttactctcgcattactaagttcggttatcggctttaatgcagcagcagagcctgtagttaaaccgcttcaatttgaagaaatcacgaataatgtgtttttagttaaatcgtatcgtgaatttaaaaacttacagagcccaaagaaacctattttggtcgatgctaattctttagtgtatgttgatggaaaggatgcgtatttgattgatacgccatggaatgcgtcgaacatgcctcagttgatgacgtggattgaaaacagaggattaacattaaagaaaacggtcttttctcattttcatgaagatcaaactggtggtttagaatacctgcaagaacatcactttgagacttacgcgtctgcattaacgaacaaatttttgaaaggtgataacaagaaagcgacgaatcatcaattttcaggtgataattttgtgttgttagaaaataagattgaagttttctatccgggaggaggccatactaaagacaatgcggtggtatggttaccaaaagaaaaagtattacttggcggttgtttaatgcgagcaaatgaggtgaatacgattgggtggactggtgatgccgatatgaaagcatgggcggggtctgctcaaaaagtcttaacgaaataccctcaagcaaattttgttgttcctggacacgggaacgttggtgaagggacgagtattattagtcatactgtcgatattaccggaaaaatttag,beta-lactamase,antibiotic inactivation,betalactams,MEG_720,Drugs,MEG_720|Drugs|betalactams|Class_B_betalactamases|ALI,648244138|WP_026025287.1|NG_057427|1|1|blaALI-1|blaALI|subclass_B1_metallo-beta-lactamase_ALI-1 NG_057427:101-838,0
,gtgaaacccaacagacccctgatcgtaattctgagcactgtcgcgctcgacgctgtcggcatcggcctgattatgccggtgctgccgggcctcctgcgcgatctggttcactcgaacgacgtcaccgcccactatggcattctgctggcgctgtatgcgttggtgcaatttgcctgcgcacctgtgctgggcgcgctgtcggatcgtttcgggcggcggccaatcttgctcgtctcgctggccggcgccactgtcgactacgccatcatggcgacagcgcctttcctttgggttctctatatcgggcggatcgtggccggcatcaccggggcgactggggcggtagccggcgcttatattgccgatatcactgatggcgatgagcgcgcgcggcacttcggcttcatgagcgcctgtttcgggttcgggatggtcgcgggacctgtgctcggtgggctgatgggcggtttctccccccacgctccgttcttcgccgcggcagccttgaacggcctcaatttcctgacgggctgtttccttttgccggagtcgcacaaaggcgaacgccggccgttacgccgggaggctctcaacccgctcgcttcgttccggtgggcccggggcatgaccgtcgtcgccgccctgatggcggtcttcttcatcatgcaacttgtcggacaggtgccggccgcgctttgggtcattttcggcgaggatcgctttcactgggacgcgaccacgatcggcatttcgcttgccgcatttggcattctgcattcactcgcccaggcaatgatcaccggccctgtagccgcccggctcggcgaaaggcgggcactcatgctcggaatgattgccgacggcacaggctacatcctgcttgccttcgcgacacggggatggatggcgttcccgatcatggtcctgcttgcttcgggtggcatcggaatgccggcgctgcaaacaatgttgtccaggcaggtggatgaggaacgtcaggggcagctgcaaggctcactggcggcgctcaccagcctgacctcgatcgtcggacccctcctcttcacggcgatctatgcggcttctataacaacgtggaacgggtgggcatggattgcaggcgctgccctctacttgctctgcctgccggcgctgcgtcgcgggctttggagcggcgcagggcaacgagccgatcgctga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7018,Drugs,MEG_7018|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,487900204|WP_001973670.1|NG_048156|1|1|tet(A)|tet(A)|tetracycline_efflux_MFS_transporter_Tet(A) NG_048156:101-1300,4
,ATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGTGCTTCAAAATCTGATGACAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCATCAAGGTCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACTTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGAACGGGCAAAAAAGGCTGTTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAATGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5274,Drugs,MEG_5274|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-208_1_KF305665,0
,GTGAGTGAAATAATTCAAGATTTATCACTTGAAGATGTTTTAGGTGATCGCTTTGGAAGATATAGTAAATATATTATTCAAGAGCGTGCATTGCCAGATGTTCGTGATGGTTTAAAACCAGTACAACGTCGTATTTTATATGCAATGTATTCAAGTGGTAATACACACGATAAAAATTTCCGTAAAAGTGCGAAAACAGTCGGTGATGTTATTGGTCAATATCATCCACATGGAGACTTCTCAGTGTACGAAGCAATGGTCCGTTTAAGTCAAGACTGGAAGTTACGACATGTCTTAATAGAAATGCATGGTAATAATGGTAGTATCGATAATGATCCACCAGCGGCAATGCGTTACACTGAAGCTAAGTTAAGCTTACTAGCTGAAGAGTTATTACGTGATATTAATAAAGAGACAGTTTCCTTCATTTCAAACTATGATGATACGACGCTCGAACCAATGGTATTGCCATCAAGATTTCCTAACTTACTAGTGAATGGTTCTACAGGTATATCTGCAGGTTACGCGACAGATATACCACCACATAATTTAGCTGAAGTGATTCAAGCAACACTTAAATATATTGATAATCCGGATATTACAGTCAATCAATTAATGAAATATATTAAAGGTCCTGATTTTCCAACTGGCGGTATTATTCAAGGTATTGATGGTATTAAAAAAGCTTATGAATCAGGTAAAGGTAGAATTATAGTTCGTTCTAAAGTTGAAGAAGAAACTTTACGCAATGGACGTAAACAGTTAATTATTACTGAAATTCCATATGAAGTGAACAAAAGTAGCTTAGTAAAACGTATCGATGAATTACGTGCTGACAAAAAAGTCGATGGTATCGTTGAAGTACGTGATGAAACTGATAGAACTGGTTTACGAATAGCAATTGAATTGAAAAAAGATGTGAACAGTGAATCAATCAAAAATTATCTTTATAAAAACTCTGATTTACAGATTTCATATAATTTCAACATGGTCGCTATTAGTGATGGTCGTCCAAAATTGATGGGTATTCGTCAAATTATAGATAGTTATTTAAATCATCAAATTGAGGTTGTTGCAAATAGAACGAAGTTTGAATTAGATAATGCTGAAAAACGCATGCATATCGTTGAAGGTTTGATTAAAGCGTTGTCAATTTTAGATAAAGTAATCGAATTGATTCGTAGCTCTAAAAACAAGCGTGACGCTAAAGAAAACCTTATCGAAGTATACGAGTTCACAGAAGAACAGGCTGAAGCAATTGTAATGTTACAGTTATATCGTTTAACAAACACTGACATAGTTGCGCTTGAAGGTGAACATAAAGAACTTGAAGCATTAATCAAACAATTACGTCATATTCTTGATAACCATGATGCATTATTGAATGTCATCAAAGAAGAATTGAATGAAATTAAAAAGAAATTCAAATCTGAACGACTGTCTTTAATTGAAGCAGAAATTGAAGAAATTAAAATTGACAAAGAAGTTATGGTGCCTAGTGAAGAAGTTATTTTAAGTATGACACGTCATGGATATATTAAACGTACTTCTATTCGTAGCTATAATGCTAGCGGTGTTGAAGATATTGGTTTAAAAGATGGTGACAGTTTACTTAAACATCAAGAAGTAAATACGCAAGATACCGTACTAGTATTTACAAATAAAGGTCGTTATCTATTTATACCGGTTCATAAATTAGCAGATATTCGTTGGAAAGAATTGGGGCAACATGTATCACAAATAGTTCCTATCGAAGAAGATGAAGTGGTTATTAATGTCTTTAATGAAAAGGACTTTAATACAGATGCATTTTATGTTTTTGCGACTCAAAATGGCATGATTAAGAAAAGTACAGTGCCTCTATTTAAAACAACGCGTTTTAATAAACCTTTAATTGCTACTAAAGTTAAAGAAAATGATGATTTGATTAGTGTTATGCGCTTTGAAAAAGATCAATTAATTACCATCATTACAAATAAAGGTATGTCTTTAACTTATAATACAAGTGAACTATCAGATACCGGATTAAGGGCAGCTGGTGTTAAATCAATAAATCTTAAAGCAGAAGATTTCGTTGTTATGACAGAAGGTGTTTCTGAAAATGATACTATATTGATGGCCACACAACGCGGCTCGTTAAAACGTATTAGTTTTAAAATCTTACAAGTTGCTAAAAGAGCACAACGTGGAATAACTTTATTAAAAGAATTAAAGAAAAATCCACATCGTATAGTAGCTGCACATGTAGTGACAGGTGAACATAGTCAATATACATTATATTCAAAATCAAACGAAGAACATGGTTTAATTAATGATATTCATAAATCTGAACAATATACAAATGGCTCATTCATTGTAGATACCGATGATTTTGGTGAAGTAATAGACATGTATATTAGCTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5329,Drugs,MEG_5329|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gb|BX571856.1|+|1419759-1422162|ARO:3003312|Staphylococcus aureus parC conferring resistance to fluoroquinolone [Staphylococcus aureus subsp. aureus MRSA252] ,3
,atgaacaaaaatataaaatattctcaaaactttttaacgagtgaaaaagtactcaaccaaataataaaacaattgaatttaaaagaaaccgataccgtttacgaaattggaacaggtaaagggcatttaacgacgaaactggctaaaataagtaaacaggtaacgtctattgaattagacagtcatctattcaacttatcgtcagaaaaattaaaactgaatactcgtgtcactttaattcaccaagatattctacagtttcaattccctaacaaacagaggtataaaattgttgggaatattccttaccatttaagcacacaaattattaaaaaagtggtttttgaaagccgtgcgtctgacatctatctgattgttgaagaaggattctacaagcgtaccttggatattcaccgaacactagggttgctcttgcacactcaagtctcgattcagcaattgcttaagctgccagcggaatgctttcatcctaaaccaaaagtaaacagtgtcttaataaaacttacccgccataccacagatgttccagataaatattggaagctatatacgtactttgtttcaaaatgggtcaatcgagaatatcgtcaactgtttactaaaaatcagtttcatcaagcaatgaaacacgccaaagtaaacaatttaagtaccattacttatgagcaagtattgtctatttttaatagttatctattatttaacgggaggaaataa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2793,Drugs,MEG_2793|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,446961539|WP_001038795.1|NG_047798|1|1|erm(B)|erm(B)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B) NG_047798:101-838,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccacccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5578,Drugs,MEG_5578|Drugs|betalactams|Class_C_betalactamases|PDC,685889027|WP_031630420.1|NG_049947|1|1|blaPDC-71|blaPDC|class_C_beta-lactamase_PDC-71 NG_049947:1-1194,0
,ATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCACTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_356,Drugs,MEG_356|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|930190865|emb|LN555650.1|261056-260559 gi|930189590|emb|HG530658.1|196764-196267 gi|873463574|gb|KR106190.1|15766-15269 gi|730042884|gb|KJ571202.1|4611-5108 gi|825088700|gb|KP975077.1|106374-105877 gi|821392896|gb|KP873171.1|21030-20533 gi|768032361|gb|KM975294.1|1561-2058 gi|742797756|emb|LK054503.1|13297-13794 gi|636632016|gb|KJ579055.1|207-704 gi|635661965|gb|KJ547703.1|1055-1552,2
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgattgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgacgcccgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6675,Drugs,MEG_6675|Drugs|betalactams|Class_A_betalactamases|TEM,1463920489|WP_116786831.1|NG_061611|1|1|blaTEM-236|blaTEM|class_A_extended-spectrum_beta-lactamase_TEM-236 NG_061611:1-861,0
,atgaaattattgtttgcggcgctatttgtcgtgatgttctgcggactcgctcgggctagcgattcgctgccggaactgcggatcgagaagatcgccgagggcgtttatctgcatacatctttccagcaagtgcaaggctatggccttgtcgatgcgaacggtctggtggtgctggacggacagggcgcctacatcatcgacacgccctggtcggagcgcgacacagcggcgctggtggcctggttgcaggagcgcaactatcaggtcaaggccagtgtttcgacgcactttcatgacgaccgcacggcggggatcgagtatctgaacgctatctcggtaccgacctatgcctcggcacggaccaatgcgttgctgaagcagaacggcaaggcgctggcgaccgagacattcgacgatgcgcctttatggctgctcgagggcaaggtcgaggtcttctatcccggtgctgggcatagcgtggataacctcgtcgtgtggttgccggagcagaagctgctgaacggcgggtgtttcgttcgggctgcggcggccggcacgctgggtaacaccgccgatgcggtcgtcagcgagtgggccgcttcggcagaaaggctgcagcgtcgatatcccgatgcgcagctcgtcattccgggtcatggtgtgccgggagatgtttccttgctcgaacacacgcgaaaacttgccttggcggcaactgcgaaagattga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5812,Drugs,MEG_5812|Drugs|betalactams|Class_B_betalactamases|PST,763060735|WP_043942497.1|NG_057439|1|1|blaPST-1|blaPST|subclass_B1_metallo-beta-lactamase_PST-1 NG_057439:101-829,0
,ATGTCCGCGAGCACCCCCCCCATAACTCTTCGCCTCATGACCGAGCGCGACCTGCCGATGCTCCATGACTGGCTCAACCGGCCGCACATCGTTGAGTGGTGGGGTGGCGACGAAGAGCGACCGACTCTTGATGAAGTGCTGGAACACTACCTGCCCAGAGCGATGGCGGAAGAGTCCGTAACACCGTACATCGCAATGCTGGGCGAGGAACCGATCGGCTATGCTCAGTCGTACGTCGCGCTCGGAAGCGGTGATGGCTGGTGGGAAGATGAAACTGATCCAGGAGTGCGAGGAATAGACCAGTCTCTGGCTGACCCGACACAGTTGAACAAAGGCCTAGGAACAAGGCTTGTCCGCGCTCTCGTTGAACTACTGTTCTCGGACCCCACCGTGACGAAGATTCAGACCGACCCGACTCCGAACAACCATCGAGCCATACGCTGCTATGAGAAGGCAGGATTCGTGCGGGAGAAGATCATCACCACGCCTGACGGGCCGGCGGTTTACATGGTTCAAACACGACAAGCCTTCGAGAGAAAGCGCGGTGTTGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_273,Drugs,MEG_273|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,(AGly)Aac6-IIa:M29695:707-1261:555,2
,atgaacattaaagccctcttccttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttgggtggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattgcttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4511,Drugs,MEG_4511|Drugs|betalactams|Class_D_betalactamases|OXA,1028106566|WP_063861490.1|NG_049493|1|1|blaOXA-197|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-197 NG_049493:1-825,0
,ATGAGCGATAAAATACTTGTTGTGGACGATGAACATGAAATTGCCGATTTGGTTGAGCTATACTTGAAAAACGAGAATTATACGGTTTTCAAATACTATACCGCCAAAGAAGCGTTGGAATGTATAGACAAGACCGATCTTGACCTTGCCATATTGGACATCATGCTTCCCGGCGCAAGCGGCCTCGCTATCTGCCAAAAGATAAGGGACAAGCACACCTATCCAATTATCATGCTGACCGCGAAAGATACGGAGGTAGATAAAATTACAGGGCTAACAATCGGCGCGGACGATTATATAACGAAGTCCTTTCGCCCGCTGGAGTTAATTGCGAGGGTCAAGGCGCAGTTGCGCCGATACAAAAAATACAGTGGAGTAGCGGAGCAGAACGAAAATGTTATCGTCCACTCCGGCCTTGTCATTAATATAAACACGCATGAGTGTTTTCTGAACGAGAAGCAGTTATCACTCACTCCCACCGAGTTTTCAATCCTGCGCATCCTCTGTGAAAACAAGGGGAATGTGGTTAGCTCCGAGCAGTTATTTCATGAGATATGGGGCGACGAATATTTCAGCAAGAGCAACAACACCATCACCGTGCATATCCGGCATCTGCGCGAAAAAATGAACGACACCATTGATAATCCGAAGTATATAAAAACGGTATGGGGGGTTGGCTATAAAATTGAAAAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7459,Drugs,MEG_7459|Drugs|Glycopeptides|VanA-type_regulator|VANRA,gi|66731632|gb|DQ018710.1|3048-3743,5
,atgccattagagattaaacaaatcactgagaacgagttgtcgcaaatggaagcgctgtcagctgtttttggtgaagtattttcagataaagaaacttacaccgagaacaagccaagtgccgactacgtgcggtcacttctcagcagtgattatttcattgcacttgcggcattggatgaaagcaaggtcataggaggattagcggcatacgaactcaaaaaattcgagcaagaacgcagtgaaatttacatttatgacctcgcagttattgctgcacaccgtcgaaaaggtgttgcaatagcgctaattgaaaggctgaaaataattgccgcggagcgaggtgcctacgtgatatatgtccaagctgacaccgggccagaggataagccggctatcgaactgtattcaaaacttggagtgcaggaagaggttctgcattttgatattgaggtaaaaggaaatcacggcgtcacataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_22,Drugs,MEG_22|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,499787584|WP_011468318.1|NG_048571|1|1|aac(3)-Ig|aac(3)-I|aminoglycoside_N-acetyltransferase_AAC(3)-Ig NG_048571:101-577,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggataccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5463,Drugs,MEG_5463|Drugs|betalactams|Class_C_betalactamases|PDC,1201190432|WP_087587952.1|NG_054967|1|1|blaPDC-181|blaPDC|class_C_beta-lactamase_PDC-181 NG_054967:1-1194,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCATTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6601,Drugs,MEG_6601|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|695211314|ref|NG_036058.1|3503-4342,8
,ttgagtatagatttaagtaacaaaaaaattccgaaagaagcaattcaagcattaaaaactatagcggaactacttgataatatgttaattggggtgtatttgtatggttcggcagtaatgggtggtttacgtatgaatagcgatgtagatattttggtaataacaaatcaaagtttatctgaaaaaactcgaaggaatcttacaaataggttaatgcttatatctgggaaaataggaaacataaaagatatgaggcctcttgaagttacggtcataaatcaaaaggatattgtcccttggcatttcccccccaaatatgaatttatgtatggcgagtggctaagagagcagtttgaaaagggagaaattcctgagtcgacttatgatccggatttagcaatacttttagcacaactaagaaaaaatagtattaaccttttgggaccaaaggcaacagaagtaattgagcctgtgccaatgacagatattcgaaaagcaattaaagaatcgttgcccgggttgatagctagcattaacggtgacgaacgcaatgtgattttaactttagccagaatgtggctgacagcatctactggtgaaattcgctcaaaagatctggcagctgaatgggcgatacctcaattacccgatgagcatgctactttactcaacaaagcgagagaggcttatttaggagagtgtgttgacaagtgggaaggaatggaatctgaggtggctgaactcgttaatcatatgaaaaagtctatagagtcttcccttaatatccaattaccttttcgaatagtttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1004,Drugs,MEG_1004|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT9,488223301|WP_002294509.1|NG_048075|1|1|spw|spw|ANT(9)_family_aminoglycoside_nucleotidyltransferase_Spw NG_048075:101-910,2
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGGTGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTCGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAGATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6930,Drugs,MEG_6930|Drugs|betalactams|Class_A_betalactamases|TEM,gi|6176543|gb|AF190693.1|AF190693|1-1103,0
,ATGTCACTGTATCGCCGTCTAGTTCTGCTGTCTTGTCTCTCATGGCCGCTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTCGAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACTGTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCTGCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTACGGCAAAAATGCGCTGGTTCCGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATGACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTGTTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGATACCACGTTCCGTCTGGACCGCTGGGAGCTGGAGCTGAACTCCGCCATCCCAGGCGATGCGCGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCTGCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGCAACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACCTGCGGAGTGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCTATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGTACAGCGAGGCCGTCATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGGGCGTCAACGGGCAGTAAGGCTCTGAAAATCATCTATTGGCCCACCACCGCCGCCCTTGCGGGCGGCATGGATTACCAACCACTGTCACATTTAGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3509,Drugs,MEG_3509|Drugs|betalactams|Class_A_betalactamases|KPC,gi|908777676|gb|KT148595.1|14544-13585 gi|940785863|gb|KT362706.1|18921-19880 gi|940785863|gb|KT362706.1|33197-32238 gi|933686953|gb|KT378598.1|7208-8167 gi|933686943|gb|KT378597.1|7208-8167 gi|933686933|gb|KT378596.1|7110-8069 gi|910286593|gb|CP012163.1|7361-6402 gi|910286593|gb|CP012163.1|60160-59201 gi|902611595|gb|CP011978.1|61933-60974 gi|828971628|gb|CP011646.1|38232-37273 gi|828971542|gb|CP011645.1|61971-61012 gi|828921939|gb|CP011589.1|20801-21760,0
,ATGATGACAAAATCCCTAAGCTGTGCCCTGCTGCTCAGCGTCGCCAGCGCTGCATTCGCCGCACCGATGTTCGAAAAACAGCTGGCTGAGGTGGTGGAACGTACCGTTACGCCGCTGATGAACGCGCAGGCCATTCCGGGTATGGCGGTGGCGGTAATTTATCAGGGTCAGCCACACTACTTTACCTTCGGTAAAGCCGATGTTGCGGCGAACAAACCCGTCACCCCGCAAACCCTGTTTGAGCTGGGCTCTATAAGTAAAACCTTCACCGGCGTACTGGGCGGCGATGCCATTGCCCGGGGTGAAATAGCGCTGGGCGATCCGGTAGCAAAATACTGGCCTGAGCTCACGGGCAAGCAGTGGCAGGGCATTCGCATGCTGGATCTGGCAACCTATACCGCAGGCGGTCTGCCGTTACAGGTGCCGGATGAGGTCACGGATACCGCCTCTCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCGGGCACCACGCGTCTTTACGCTAACGCCAGCATCGGTCTTTTTGGTGCGCTGGCGGTCAAACCTTCCGGCATGAGCTATGAGCAGGCCATGACGACGCGGGTCTTTAAACCCCTCAAGCTGGACCATACCTGGATTAACGTCCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGATACCGTGAGGGTAAAGCGGTCCACGTTTCGCCAGGGATGCTGGACGCGGAAGCCTATGGCGTAAAAACTAACGTGAAGGATATGGCGAGCTGGCTGATAGCCAACATGAAGCCGGATTCTCTTCACGCTCCCTCACTCAAGCAAGGCATTGCTCTGGCGCAGTCTCGCTACTGGCGCGTGGGTGCTATGTATCAGGGGTTAGGCTGGGAGATGCTCAACTGGCCGGTCGATGCCAAAACCGTCGTCGGAGGCAGTGATAACAAGGTGGCGCTGGCACCATTGCCCGTGGCAGAAGTGAATCCACCCGCGCCGCCGGTCAAAGCCTCCTGGGTCCATAAAACAGGCTCGACGGGCGGGTTTGGCAGCTACGTGGCATTTATTCCTGAAAAGCAGCTAGGCATTGTGATGCTGGCGAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCGTATCCTCGACGCGCTGCAGTAAAACATTGCCGGGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3974,Drugs,MEG_3974|Drugs|betalactams|Class_C_betalactamases|MIR,gi|695212938|ref|NG_036521.1|30-1188,0
,ATGGATCAAAAAAACAACAACCTCTTTCAAAAGGCAATTGAAGAAGTCTTTGCAGTTAGCTTTAGTAAGTATGCTAAATACATCATCCAAGATAGAGCTTTACCTGATCTAAGAGATGGGTTAAAACCAGTACAAAGACGGATCTTATATGGGATGTTTCAAATGGGCTTAAAACCCACCACTCCCTATAAAAAATCAGCCCGTGCTGTTGGGGAGATCATGGGGAAATACCACCCCCATGGTGATAGTTCCATTTATGATGCAATTATCAGAATGTCCCAAAGCTGAAAGAACAACTGAACAACTGTTTCTATCCATGGTAACAATGGTTCAGTGGATGGGGATAATGCTGCAGCAATGCGTTACACAGAAACCCGCTTAAGCTTGTATGGATTTGAACTATTAAAAGACATTGATAAAAAGTTAGTTAGTTTTATCAATAACTTTGATGATAGTGAAAAAGAACCAACGGTTTTACCAACCTTACTGCCTAACCTCTTTATCAATGGTGCGAGTGGGATAGCTGCTGGATATGCAACTAATATTGCTCCCCATAACACTAATGAACTATTAGATAGTCTTTGCTTGCGAATAGACCAACCTAATTGTGAACTTAAACAAATTTTAAAAATTGTTAAAGGTCCTGATTTTCCAACAGGGGGTAATGTTTATTTTGAAAAGAGTTTAAGTGATATTTATCAAGCAGGCAAAGGTAAATTTATTATCCAAGCTAAGTATGAAGTTAACAAGAACTTAAACCAGATTGAAATTACCCAAATCCCTTATGAAACACTGAAAGCTAACATTGTCAAACAAATTGAAGAGATTATCTTTGACAATAAACTATCTGCTATTGAAAGTGTCATTGATAGTTCAGATCGCAACGGCATTAGGATCATTATTAAACACAAGGACTTTTTGCCTGCTGAGAAGATCATGGCCTTTTTGTTTAAACACACCCAACTCCAAGTGAACTTTAACCTTAATAACACCGTGATTGCTAACCGCTTTCCCATCCAAATTGGTTTACTAAGTTACCTCGATCATTTTTTAAAGTTTTGTCATGAACTAATTATTAATAAAGCTAAGTATGAACTTGAGCTTGCAAGCAAGCGCTTGGAAATTATTTTAGGACTAATTAAAGCGATTAGTATCATTGATAAAATCATCAAATTAATTAGATCAGCAGTTGACAAAAGTGATGCAAGAGAAAAGTTAATTGATAACTTTAAATTTACTTTTAACCAAGCAGAGGCAATTGTTAGTTTGCGACTTTACCAACTAACTAACACTGATATTTTTGAACTTAACCAAGAACAAAATGAACTTGAAAAAACTGTGATTAGTTCAGAGCAACTAATTGCTAGTGAAAAAGCAAGAAACAAACTCCTAAAAAAACAGTTTGAAGGTTATAAAAAGCAGTTTCACCAGCAACGAAGGTCACAAATATGTGGCTTTATTAACCAAAAAAAGGTGGAGGAAAGTGAGCTAATTGAAAACAAAACTTATGGGGTTTTAATCACTAAAGCTGGTAACTACCATAAGTTTGAATCTAACCAACTATTAAAAAGCACCACTGATTTTAAAAGTGAGAGTGACACAATTATCTTTGCACAAACTATTGCTAATACCGACCAAATTTTTATTGTCACTTCACTAGGTAACATTATTAATATCCCTGTTTATAAATTAGCTTTCAATTCCAAAAATAAACTAGCAAGTTTAGTTAGTAAAAAACCAATCCTTTTGGAGTATGAAACGATTGTTTTTGTTGGAACAATGAACAGTGTAAACCAACCAATCCTTGTTTTAACTTCCAAACTAGGAATGGTTAAACGGATTGATTTAACCAAACTTAACATTAAGCCACTTAAAGCTACTTTGTGTATCTCACTCCGTGATAAAGACCATTTAGTAAGTGCATTTTTACAACAAGATGATAAACTGATCTGTTTAGTGTCTGATCACAACTATTACACTGTTTTTCACACCAATGAGATCCCATTAATTAGTAGTAAGGGGATGGGAGTGAAGGGGATGAAGTTAAAACTAGAGGATCAAATTAAGTTTGTTGTTGCTTTTGAAGCTAATGAACCGTTAGTGATGATATGTAGTGATGGTAGTGTCATTAACTTAAAACAAACTGAACTAGTTGTAGTTAGCAGGATGGCAACTGCAAAAAAACTGCCTGTTAAGAAAGCAATTAACTATTGTTTTAGTGATGCAACTAACACCCAGTTAATTAATTTTCAGGGTAAGAACGGTAGTAAATTAATTACAACTAGTGAACTGAACCAGATGAGTAAAACTGCAATTAGTCAAACCAGGTTTAACAAACTTAATTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5331,Drugs,MEG_5331|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gb|L43967.2|+|242223-244569|ARO:3004630|Mycoplasma Genitalium ParC mutations confers resistance to Moxifloxacin [Mycoplasma genitalium G37] ,3
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtcggcatgttcttttaataccgtacaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaatagaggaagtctatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaaacgtttatttcctgattgggaaaaggacatgactctaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaaaaatgtgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacgaaaaatttatgccaaaagtggttggggatgggatgttgacccacaagttggttggtttacaggctgggtagttcaacctcagggagaaattatagctttctcacttaatttagaaatgaagaaaggcatacctagttctattcgaaaagaaattgcttataaaggattagagcagctaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4566,Drugs,MEG_4566|Drugs|betalactams|Class_D_betalactamases|OXA,1057241290|WP_068611377.1|NG_051483|1|1|blaOXA-533|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-533 NG_051483:1-822,0
,atgaaaaagaactttgcctttttagatgaaatgattcccgggatccgatgggatgccaaatatgccacatgggacaatttcaccgggaaaccggtagacggatacatggtaaaccgtgttatgggaacgaaggagttgggagttgctttgcgtaaggctcagaagatggcggagaaactgggatatggtttgctcttatgggacggctatcgcccccagtgcgcagtgaattgttttctgaattgggcttcccaaccggaagacaatctgacgaaaaagcgttactatccaaatatcaaaaggaacgagatggtcaccaaagggtatgtggcttcccagtccagccacagccgcggaagtgcagttgaccttacgattttccgtttggatacggggatgcttgtgccaatgggcggagatttcgacttcatggatgtgcggtcacatcatgccgcaagcggtctgagcgaagaggaatcaaaaaaccggcagtgcttgcgttatatcatggaaagcagcggatttgaagcctatcgctatgaatggtggcattacgtcttggcggacgagccatacccggatacatactttgatttttgcattgcctag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7567,Drugs,MEG_7567|Drugs|Glycopeptides|VanD-type_resistance_protein|VANXD,1028100641|WP_063856776.1|NG_048493|1|1|vanX-D|vanX-D|D-Ala-D-Ala_dipeptidase_VanX-D NG_048493:101-709,5
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcagccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4458,Drugs,MEG_4458|Drugs|betalactams|Class_D_betalactamases|OXA,1509794555|WP_122630864.1|NG_062277|1|1|blaOXA-680|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-680 NG_062277:12-836,0
,TTAAGCAAATGTTAGCGGTAATTTAACCAGATAGGAGTACAGACATATGAAAATCGTAAAAAGGATATTATTAGTATTGTTAAGTTTATTTTTTACAATTGTGTATTCAAATGCTCAAGCTGACAACTTAACTTTGAAAATTGAGAATGTTTTAAAGGCAAAAAATGCCAGAATAGGAGTAGCAATATTCAACAGCAATGAGAAGGATACTTTGAAGATTAATAACGACTTCCATTTCCCGATGCAAAGCGTTATGAAATTTCCGATTGCTTTAGCCGTTTTGTCTGAGATAGATAAAGGGAATCTTTCTTTTGAACAAAAAATAGAGATTACCCCTCAAGACCTTTTGCCTAAAACGTGGAGTCCGATTAAAGAGGAATTCCCTAATGGAACAACTTTGACGATTGAACAAATACTAAATTATACAGTATCAGAGAGCGACAATATTGGTTGTGATATTTTGCTAAAATTAATCGGAGGAACTGATTCTGTTCAAAAATTCTTGAATGCTAATCATTTCACTGATATTTCAATCAAAGCAAACGAAGAACAAATGCACAAGGATTGGAATACCCAATATCAAAATTGGGCAACCCCAACAGCGATGAACAAACTGTTAATAGATACTTATAATAATAAGAACCAATTACTTTCTAAAAAAAGTTATGATTTTATTTGGAAAATTATGAGAGAAACAACAACAGGAAGTAACCGATTAAAAGGACAATTACCAAAGAATACAATTGTTGCTCATAAAACAGGGACTTCCGGAATAAATAATGGAATTGCAGCAGCCACTAATGATGTTGGGGTAATTACTTTACCGAATGGACAATTAATTTTTATAAGCGTATTTGTTGCAGAGTCCAAAGAAACTTCGGAAATTAATGAAAAGATTATTTCAGACATTGCAAAAATAACGTGGAATTACTATTTGAATAAATAAAAAACTACCGCTAACACTGGCTCATAGGCAATGGCGGGTTGAAGTGCAATTTGCAAAGTCGGTAGCCCGCCCGAGCGTTTTCTCGGTTTGACAGGAAAGGCTCACGCAAACCGCCACTGCCCATAGCCCAAACCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_7666,Drugs,MEG_7666|Drugs|betalactams|Class_A_betalactamases|VEB,gi|17999556|gb|AY027870.1|1-1081,0
,atgcggtgtaacaagaatgttttatctgtggttctgttgggcgcgctgagcctctcggcgggcaacgccttcggtcaagtatcacaagccgatgtcgatgccgtcatccgccccctgatgagcaaatataagataccgggaatggccgtggccctctcggtggatggccaacacaccttttacaactacggcgtggcctccaaggcgacaggccaggctgtcacccccaccacgctctttgagatcggctccctgagcaagaccttcaccgccactctggccagctatgcccagggccagggcaaattgcagtggagcgaccaggccagccactatctccccagcctcaaggggagcgccttcgatcgggtcacactgctcaatctggccacccacacctcgggcatgcccctcttcgtccccgatgaagtgaccaaccaggagcagctgatggcctggtaccaggcttggcagccgacagcccccataggcagccagcgggtctactccaacctggggatcggcatgctggggttgatcacggcacagagcttacagaaacccttcagtgaggcgatggagcaggatctgctcgcaccactgggcatgaaacactcctgggtcaaggtgccggaaaaccagatggccgagtatgcccagggctacaacaaactggatgagccggtgcgcgtcacgccgggccctccggatgcagaagcctatggtttgaagtccagcagtgccgacctgctgcgctggctcgatctcaacatggccatcacgcccccgtcgcccgcttggcagcaggccataacggagacccacaaagggtattaccagaccggggagtttacccaagccctgatatgggagtactacccctggcccacgaccaaagaaacgttgctggcgggcaacagcagcgagcggatcatgaagggcctgggcgccaagcccctcaccccaccccaagcagggccagagcaggcctggtataacaagaccggctccaccaacggcttctccacctatgccgtgtttatcccggggcaaaaaaccgcactcatactgctggccaacaaatggtatccgaacgatgcccgtatcgaagcggcatatgagctggtacaacgactgaaaaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_5324,Drugs,MEG_5324|Drugs|betalactams|Class_C_betalactamases|PAC,730609818|WP_034051940.1|NG_052627|1|1|blaPAC-1|blaPAC|class_C_beta-lactamase_PAC-1 NG_052627:101-1246,0
,atgaaaactcttattttgttgcctttacttagttgcttgagcctgacagcctgtagcttgcctgtttcaaattcgtcctctcaaatcacttcaactcaatctattcaaaccattgccaaattatttgatcaggcacaaagctctggcgttttagtaattcaacggggcccacatctacaggtctatggcaatgatttgagtcgtgcacataccgaatatattcctgcttcaacctttaaaatgctcaatgccctgattggcctgcaacatggtaaagccacgaccaatgaaatctttaaatgggatggcaagaagcgcagttttgcagcctgggaaaaagacctgaccctagccgaggccatgcaagcttctgctgtacccgtctatcaggaactggcacgtcgcattggtctggaactaatgcaacaggaagtgcaacgcattcgatttggtaatcagcagattggtcagcatatcgacaacttctggttagtcggacctttgaaaatcaccccggaacaagaagtcgaatttgcctctgcgcttgctcaagagcaacttgcctttgatcctcaagtccagcaacaagtcaaagccatgttactgttacaggagcgacaagcttatcgactatatgccaaatctggttggggtatggatgtggagccgcaagtcggctggctcaccggctggatcgaaacacctcaggacgaaatcgtggcattttcactgaatatgcagatgcaaagtaatatggatccggcgatccgtcttaaaattttgcagcaggccttggccgaattagggctttatccgaaagctgaagggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4424,Drugs,MEG_4424|Drugs|betalactams|Class_D_betalactamases|OXA,1073722256|WP_070064536.1|NG_051752|1|1|blaOXA-537|blaOXA-134_like|OXA-134_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-537 NG_051752:1-831,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgtcgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcatcgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6234,Drugs,MEG_6234|Drugs|betalactams|Class_A_betalactamases|SHV,1509794563|WP_122630872.1|NG_062289|1|1|blaSHV-217|blaSHV|class_A_beta-lactamase_SHV-217 NG_062289:1-861,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1332,Drugs,MEG_1332|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_46_CP010944,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggcagacgatgaacgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctaggcaggcttatcttggacaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_890,Drugs,MEG_890|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502035|WP_071846187.1|NG_052136|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052136:101-889,2
,GTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGTTGGTTACTGTGGCCGTAAAGCTTGATGAAACGACGCGGCGAGCATTGCTCAATGACCTTATGGAGGCTTCGGCTTTCCCTGGCGAGAGCGAGACGCTCCGCGCTATAGAAGTCACCCTTGTCGTGCATGACGACATCATCCCGTGGCGTTATCCGGCTAAGCGCGAGCTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCATGATCGACATTGGTCTAGCTATCCTGCTTACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCGGCAGCGGAGGAATTCTTTGACCCGGTTCCTGAACAGGATCTGTTCGAGGCGCTGAGGGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCCGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAATAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATAAAACGCCTACCTGCCCAGTATCAGCCCGTCTTACTTGAAGCTAAGCAAGCTTATCTGGGACAAAAAGAAGATCACTTGGCCTCACGCGCAGATCACTTGGAAGAATTTATTCGCTTTGTGAAAGGCGAGATCATCAAGTCAGTTGGTAAATGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_960,Drugs,MEG_960|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|695208190|ref|NG_035493.1|1942-2721,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccgagaaattaaaaaactggtagatcaaaactttaaacccttattagataaatatgatgtgccgggtatggccgtgggcattattcagaataataaaaaatatgaaacgtattacggtcttcaatctgttcaagataaaaaagccgtaagtagcagtaccatttttgaactaggttctgtcagtaaattatttaccgcaactgcaggtggatatgccaaaacaaaaggaacaatctcttttgatgacgcacctggcaaatattggaaagaactaaaaaatacaccgattgatcaagttaacttacttcaactcgcaacgtatacaagcggcaaccttgccttgcaatttccagatgaagtaaaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaactcaatcggtgaatatagacaatattcaaatccaagtattggcctatttggaaaagttgttgcattgtctatgaataaacctttcgaccaactcttagaaaaaacaatttttccagatcttggcttaaaacatagctatgtaaatgtaccgaagacccagatgcaaaactatgcttttggctataatcaagaaaatcagccaattcgtgttatccctggtccgttagatgcacctgcgtacggcgtcaaatcgacactacccgatatgcttaagtttattaatgccaacctcaacccacagaaatatccgaaagatattcaacgtgcaattaatgaaacacatcaaggtttctatcaagtcggcaccatgtatcaggcacttggttgggaagaattttcttatccagcgcctttacaaactttattagacagtaattcagaacaaattgtgatgaagcctaataaagtgactgccatttcaaaagaaccttcagttaagatgttccacaaaactggttcaaccaatggtttcggaacttatgtcgtgtttattcctaaagaaaatattggcttagtcatgttgaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcggtgttaaatgcaataaaaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_604,Drugs,MEG_604|Drugs|betalactams|Class_C_betalactamases|ADC,1016519580|WP_063099318.1|NG_064706|1|1|blaADC-151|blaADC|class_C_beta-lactamase_ADC-151 NG_064706:101-1252,0
,atgaattttaccagaattgatctgaacacctggaaccgcagagaacattttgctctttatcgtcagcagataaaatgcggattcagcctgaccacaaaactcgatattacagctttgcgtaccgcactggcggaaacggattataaattttatccggtgatgatttatctgatctcccgggttgttaatcagtttccggagttccggatggcaatgaaagataatgcactgatttactgggatcagaccgatcctgtatttactgtttttcataaagagactgaaacattttctgcgctcttctgccgttattgtccggatatcagtgaatttatggcgggctataatgcggtgatggcagaatatcagcataatactgcattgttcccgcagggagcgttaccagagaaccacctgaatatatcatcattaccctgggtgagttttgacggatttaacctgaatatcaccggtaatgatgattattttgctccggtgtttactatggcgaagtttcagcaggaagataaccgcgtattattacctgtttctgtacaggtacatcatgccgtttgtgatggctttcatgcagccaggtttattaatacacttcagatgatgtgtgataacatactgaaataa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1566,Drugs,MEG_1566|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,500075340|WP_011751353.1|NG_047594|1|1|catA2|catA2|type_A-2_chloramphenicol_O-acetyltransferase_CatII NG_047594:101-742,6
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgcccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_869,Drugs,MEG_869|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1693892904|WP_140423281.1|NG_065408|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_065408:101-892,2
,atggaaaaaaacagaaaaaaacaaatcgtagttttgagtatagctttagtttgcattttcatcttggtattttcattgttccataaatcagcgacaaaagatagcgcaaatcctcctttaacaaatgttttgactgatagcatttctcaaattgtctcagcttgtcctggcgaaattggtgtggcggttattgttaataacagagatacggttaaggtcaataataagagtgtttatcctatgatgagtgtgtttaaggttcatcaggcattagctctttgtaatgactttgacaataaaggaatttcacttgataccttagtaaatataaatagggataaacttgacccaaagacttggagtcctatgctgaaagattattcagggccagtcatatcattgacagtgagagatttgctgcgttatactcttactcagagtgacaacaatgcaagcaaccttatgtttaaggatatggttaatgtcgctcaaacagatagttttatagccacactcattcctcgttcaagttttcagatagcttatacggaagaggaaatgtcggctgaccataacaaggcttactctaactatacatctcctcttggtgctgcaatgttgatgaatcgtttgtttactgaaggtcttatcgatgatgagaaacaaagtttcattaagaatacgtttaaagaatgcaaaacaggtgtagataggatagcagctccacttcttgataaagaaggggttgttatagcgcataagacaggttcaggtgatgttaatgaaaatggtgttcttgcagctcacaatgatgttgcctatatatgtctgcctaataatatcagttataccttagcggtatttgttaaggatttcaagggaaatgaatcacaagcgtcacaatatgttgcgcatatatcagctgtagtatattctttattaatgcaaacttcagtaaaatcttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1690,Drugs,MEG_1690|Drugs|betalactams|Class_A_betalactamases|CFX,1028084272|WP_063843240.1|NG_047637|1|1|cfxA_gen|cfxA_gen|CfxA_family_class_A_broad-spectrum_beta-lactamase NG_047637:1-966,0
,ATGACTTTACTAAAATATAAAAAAATTACAATAATTGGTGCCGGGCCTGTTGGATTAACAATGGCGAGATTGTTACAGCAAAACGGCGTGGACATTACAGTTTACGAGAGAGACAAAGACCAAGATGCAAGGATTTTTGGTGGGACACTTGATCTGCACAGGGATTCGGGACAGGAAGCAATGAAAAGAGCGGGATTGTTACAAACTTATTATGACTTAGCTTTACCAATGGGTGTAAATATTGTTGATGAAAAGGGCAATATTTTAACCACAAAAAATGTAAGGCCCGAAAATCGTTTTGACAATCCTGAAATAAACAGAAATGACTTAAGGACTATCCTATTAAATAGTTTACAAAATGATACCGTCATTTGGGATAGAAAACTTGTTACCCTTGAACCTGATAAGGAGAAGTGGATACTAACTTTTGGGGATAAATCGAGTGAAACAGCAGATCTGGTTATTATTGCCAATGGTGGAATGTCTAAAGTAAGAAAATTTGTTACCGACACGGAAGTTGAAGAAACAGGTACTTTCAATATACAAGCCGATATTCATCAACCAGAGGTGAACTGTCCTGGATTTTTTCAGCTATGCAATGGAAACCGGCTAATGGCTGCTCATCAAGGTAATTTATTATTTGCGAATCCTAATAATAATGGTGCATTGCATTTTGGAATAAGTTTTAAAACACCTGATGAATGGAAAAGCAAAACGCAGGTAGATTTTCAAGACAGAAATAGTGTCGTTGATTTTCTCCTGAAAAAATTTTCCGATTGGGACGAACGCTACAAAGAACTGATTCGTTTGACATCATCTTTTGTAGGGTTAGCGACACGAATATTTCCCTTAGATAAGTCTTGGAAAAGTAAGCGTCCATTACCCATAACGATGATTGGAGATGCTGCTCATTTGATGCCTCCTTTTGCAGGACAAGGCGTAAACAGCGGGTTGATGGATGCCTTGATATTGTCGGATAATCTGACCAATGGGAAATTTAACAGCATTGAAGAGGCTATTGAAAATTATGAACAGCAAATGTTTGCTTATGGAAGAGAAGCACAGACAGAATCAATAATAAACGAAACGGAAATGTTCAGCCTCGACTTTTCGTTCCAAAAACTAATGAATCTATAA,tetracycline inactivation enzyme,antibiotic inactivation,Tetracyclines,MEG_7244,Drugs,MEG_7244|Drugs|Tetracyclines|Tetracycline_inactivation_enzymes|TETX,gi|31980335|dbj|AB097942.1|1-1137,4
,atgcgatttaaaaaaatttcttgtttacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgttgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_619,Drugs,MEG_619|Drugs|betalactams|Class_C_betalactamases|ADC,1028102037|WP_063857814.1|NG_048675|1|1|blaADC-67|blaADC|class_C_beta-lactamase_ADC-67 NG_048675:1-1152,0
,ATGAATAAATCAATTATTATTATACTGCTGATCACCGTATTAGATGCCATTGGTATCGGGCTTATCATGCCAGTACTCCCTACTCTATTAAATGAATTTGTCAGTGAAAATTCACTGGCAACCCATTACGGTGTGCTATTAGCGCTCTATGCTACCATGCAGGTTATTTTTGCTCCTATTCTAGGACGACTGTCTGATAAATACGGCAGAAAACCCATCTTGCTGTTTTCCCTTTTAGGCGCGGCACTCGACTATCTTTTAATGGCATTCTCAACCACACTTTGGATGCTCTATATTGGGCGCATCATTGCGGGGATCACAGGCGCAACAGGTGCCGTATGTGCATCAGCGATGAGTGATGTGACTCCCGCTAAAAATCGAACTCGCTATTTTGGTTTCTTAGGTGGTGCTTTTGGTGTTGGCCTTATTATCGGCCCAATGCTAGGGGGATTATTAGGTGATATCAGTGCTCATATGCCATTTATTTTTGCCGCTATTTCACACTCGATATTATTAATACTCTCTTTGCTCTTTTTCCGAGAAACACAAAAAAGAGAAGCGCTTGTTGCCAATAGGACACCTGAAAACCAAACTGCCTCAAATACAGTCACTGTTTTTTTTAAGAAAAGCCTCTACTTTTGGTTAGCAACCTATTTTATTATCCAGCTTATCGGGCAAATTCCTGCCACCATCTGGGTGCTGTTTACACAATATCGTTTTGATTGGAACACAACTTCTATCGGTATGTCTTTGGCGGTTCTGGGTGTATTACATATTTTCTTTCAGGCGATTGTCGCTGGGAAATTGGCACAAAAATGGGGCGAAAAAACCACCATTATGATCAGTATGTCTATTGATATGATGGGCTGTTTATTATTAGCGTGGATAGGCCACGTTTGGGTCATCTTACCAGCATTAATTTGCTTAGCGGCAGGAGGTATGGGGCAACCCGCATTACAAGGTTATTTATCAAAATCTGTCGATGATAATGCGCAAGGGAAATTACAAGGTACTCTGGTGAGCCTAACCAATATTACCGGGATCATTGGTCCCCTTTTATTTGCCTTTATTTATAGTTATAGCGTCGCTTATTGGGATGGTCTGTTATGGCTGATGGGGGCAATACTTTATGCTATGTTGCTTATTACCGCTTATTTTCACCAAAGAAAAACCACACCTTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7084,Drugs,MEG_7084|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETH,gi|483933409|emb|HF953351.1|10914-12095 gi|695213701|ref|NG_036651.1|4740-5921 gi|785798809|gb|CP011099.1|1616310-1617488 gi|785795794|gb|CP011098.1|1616287-1617465 gi|678222343|gb|KJ909292.1|5117-6295 gi|575439963|gb|CP006942.1|974729-973551 gi|511255433|gb|KC734562.1|4318-5496 gi|511255399|gb|KC734561.1|3612-2434 gi|511255369|gb|KC734560.1|4418-5596 gi|481063295|gb|CP005383.1|2178983-2180161,4
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_854,Drugs,MEG_854|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,582042001|WP_024131607.1|NG_052538|1|1|aadA25|aadA25|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA25 NG_052538:101-892,2
,TTGATTTATAAAAATTACAACTGTAATATCGGAGGGTTTATTTTGAAAAGGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCTCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1410,Drugs,MEG_1410|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_80_KU607855,0
,atgacgtggagaacgaccagaacacttttacagcctcaaaatctggacttcaatgagtttgagattcttacttccgtaattgagggcgcccgaattgtcggcattggcgagggcgctcattttgtcgcggagttttcactggctagagcaagtcttatccgctatttggtcgaaaggcatgattttaatgcgattggtttggaatgtggggcgattcaggcatcccggttatctgaatggctcaactcaacagccggtgctcatgaacttgagcgattttcggataccctgaccttttctgtgtatggctcagtgctgatctggctgaaatcatatctccgcgaatcaggaagaaaactgcagttagtcggaatcgacttacccaacaccctgaacccaagggacgacctagcgcaattggccgaaattatccagctcatcgatcacctcatgaaaccgcacgttgatatgctgactcacttgttggcgtccattgatggccagtcggcggttatttcatcggcaaaatggggggagctagaaacggctcggcaggagaaagctatctcaggggtaaccagattgaagctccgcttggcgtcgcttgcccctgtactgaaaaaacacgtcaacagcgatttgttccgaaaagcctctgatcgaatagagtcgatagagtatacgttggaaaccttgcgtatgatgaaaactttcttcgatggtacctctcttgagggagatacttccgtacgtgactcgtatatggcgggcgtagtagatggaatggttcgagcgaatccggatgtgaagataattctgctggcgcacaacaatcatttacaaaaaaccccagtctccttttcaggcgagcttacggctgttcccatggggcagcacctcgcagagagggtgaattaccgtgcgattgcattcacccatcttggacccaccgtgccggaaatgcatttcccatcgcccgacagtcctcttggattctctgttgtgaccacgcctgccgatgcaatccgtgaggatagtatggaacagtatgtcatcgacgcctgtggtacggagaattcatgtctgacattgacagatgcccccatggaagcaaagcgaatgcggtctcaaagcgcctctgtaaaaacgaaattgagcgaggcatttgatgccatcgtctgtgttccaagcgccggcaaggacagcctagttgccctatag,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_2745,Drugs,MEG_2745|Drugs|MLS|Macrolide_esterases|EREA,1028086016|WP_063844485.1|NG_047766|1|1|ere(A)|ere(A)|EreA_family_erythromycin_esterase NG_047766:101-1321,7
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGACGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6248,Drugs,MEG_6248|Drugs|betalactams|Class_A_betalactamases|SHV,(Bla)SHV-45:HQ877612:1-715:715,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccattgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5666,Drugs,MEG_5666|Drugs|betalactams|Class_C_betalactamases|PDC,1343491245|WP_104009861.1|NG_056424|1|1|blaPDC-232|blaPDC|class_C_beta-lactamase_PDC-232 NG_056424:1-1194,0
,ATGGAAAAAAACAGAAAAAAACAAATCGTAGTTTTGAGTATAGCTTTAGTTTGCATTTTCATCTTGGTATTTTCATTGTTCCATAAATCAGCGACAAAAGATAGCGCAAATCCTCCTTTAACAAATGTTTTGACTGATAGCATTTCTCAAATTGTCTCAGCTTGTCCTGGCGAAATTGGTGTGGCGGTTATTGTTAATAACAGAGATACGGTTAAGGTCAATAATAAGAGTGTTTATCCTATGATGAGTGTGTTTAAGGTTCATCAGGCATTAGCTCTTTGTAATGACTTTGACAATAAAGGAATTTCACTTGATACCTTAGTAAATATAAATAGGGATAAACTTGACCCAAAGACTTGGAGTCCTATGCTGAAAGATTATTCAGGGCCAGTCATATCATTGACAGTGAGAGATTTGCTGCGTTATACTCTTACTCAGAGTGACAACAATGCAAGCAACCTTATGTTTAAGGATATGGTTAATGTCGCTCAAACAGATAGTTTTATAGCCACACTCATTCCTCGTTCAAGTTTTCAGATAGCTTATACGGAAGAGGAAATGTCGGCTGACCATAACAAGGCTTACTCTAACTATACATCTCCTCTTGGTGCTGCAATGTTGATGAATCGTTTGTTTACTGAAGGTCTTATCGATGATGAGAAACAAAGTTTCATTAAGAATACGTTAAAAGAATGCAAAACAGGTGTAGATAGGATAGCAGCTCCACTTCTTGATAAAGAAGGGGTTGTTATAGCGCATAAGACAGGTTCAGGTAATGTTAATGAAAATGGTGTTCTTGCAGCTCACAATGATGTTGCCTATATATGTCTGCCTAATAATATCAGTTATACCTTAGCGGTATTTGTTAAGGATTTCAAGGGAAATGAATCACAAGCGTCACAATATGTTGCGCATATATCAGCTGTAGTATATTCTTTATTAATGCAAACTTCAGTAAAATCTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1693,Drugs,MEG_1693|Drugs|betalactams|Class_A_betalactamases|CFX,gb|AY769933|+|0-966|ARO:3003005|CfxA4 [Bacteroides fragilis] ,0
,TCACACGAATTGAATGTTCAGGGGATTAGGATGATGAGAAAAAGCGTAAGGCGGGCGATGTTAATGACGACAGCCTGTGTTTCGCTGCTGTTGGCCAGTGTGCCGCTGTGTGCCCAGGCGAACGATGTTCAACAAAAGCTCGCGGCGCTGGAGAAAAGCAGCGGGGGACGACTGGGTGTGGCGTTGATTAACACCGCCGATAACACGCAGACGCTCTACCGCGCCGACGAGCGTTTTGCCATGTGCAGCACCAGTAAAGTGATGGCGGTAGCGGCGGTGCTTAAGCAAAGTGAAACGCAAAAGGGCTTGTTGAGTCAGCGGGTTGAAATTAAGCCCTCAGACTTGATTAACTACAACCCCATTGCGGAAAAACACGTCAATGGCACGATGACATTCGGGGAGTTGAGCGCGGCGGCGCTACAGTACAGCGATAATACTGCCATGAATAAGCTGATTGCCCATCTCGGGGGGCCGGATAAAGTGACGGCATTTGCCCGTACGATTGGCGATGACACGTTCCGGCTCGATCGTACCGAGCCGACGCTCAACACCGCGATCCCCGGCGACCCGCGCGATACCACCACGCCGTTAGCGATGGCGCAGGCTCTGCGCAATCTGACGTTGGGCAATGCCCTGGGTGACACTCAGCGTGCGCAGCTGGTGATGTGGCTGAAAGGCAACACCACCGGCGCTGCCAGCATTCAGGCAGGGCTACCCACATCGTGGGTTGTCGGGGATAAAACCGGCAGCGGCGATTATGGTACGACGAATGATATCGCGGTTATTTGGCCGGAAGGTCGCGCGCCGCTCGTTCTGGTGACTTACTTCACCCAGTCGGAGCCGAAGGCAGAGAGCCGTCGTGACGTGCTCGCTGCTGCCGCCAGAATTGTCACCGACGGTTATTAATACTCACCATGTGGAGTGAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2387,Drugs,MEG_2387|Drugs|betalactams|Class_A_betalactamases|CTX,gi|238801079|gb|FJ971899.1|1-926,0
,atggcgctgcgcaaatccctgtcgctggcggcgctgaccgcctgtctcgtcgtgaccctgccgctgtcggccgcgcccaagaagaaggcgccggccaagaaggccgaagaggtgccgaccctgccgacattgatgccgcccgcaccacgctatctggtgccgcaatccgcgctcacctccgtccgcaatcccaaggagatcgaggaggaaacgggcgggcgcatgggcatcgcgctggtcgatcgcgagggcgcgctgatcctgggcttcaaccgcgatgatcgctttgccatgtgctcgaccttcaaggcgccgctggccgccgccgtgctgatcggcgcccagggcggcaagttcgggctggagggggagataccattcaccaaggacgatattctcgattatgcgccggtggtgaagaagaacaagaagcgcggccgcatgtcgatggccgaactggccgaggcggcggtcgaagtgagcgacaacagcgccgccaacctgttgctgccgatgctgggcgggccggaggggctgacctccttcattcgtgcccatggcgacaagatcacgcggctcgaccgtatcgaacccgagctgaacgagaatgtcgccggcgatccccgcgacacgaccagtccggcggcgatggccgggctgatgggacggttgctgttccgcgatatgcaggcggccgatgccgacaggctgcgcggctggctcaatgccagcaccaccggcgacaaaaggatcaaggcgggcctgcccgaaggctggacgtcgggcagcaagaccggcagctgcggcaccgcctataatgacgtcgcactggtgaagtcgccggcgggcgaggaatatatattggccatctatctcgaccggccgaccgtggacgacaagaaggccgaggcggcgatcgccgaggccgcccattcggcgctggaattcgtcagcaaggcgcagaagagcgggctggactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1311,Drugs,MEG_1311|Drugs|betalactams|Class_A_betalactamases|BLASGM,490318208|WP_004207704.1|NG_049988|1|1|blaSGM-6|blaSGM|class_A_beta-lactamase_SGM-6 NG_049988:101-1081,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccgcggcccactcgatgccgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_573,Drugs,MEG_573|Drugs|betalactams|Class_C_betalactamases|ADC,447133964|WP_001211220.1|NG_056059|1|1|blaADC-33|blaADC|cefepime-hydrolyzing_class_C_extended-spectrum_beta-lactamase_ADC-33 NG_056059:1-1155,0
,TTAAAATTCCTTCATTACACTCTTGGCGGTTTCACTTATCAACTTATCATTTGGCTTATCACTTTTATTGTCTTTATTCGTAAAAATGACTAAAACAATAGGTTCAGATTGGCCCTTAGGATAAACAAAAGCAACATCATTTCTAGAAGCATATGTTATTGCTTGACCACTTTTATCAGCAACCTTACAGTCTTTTGAAACACCGTCTTTAATTAAAGTATCTCCGCTTTTATTATTTAACATTAAATCAAGTAAGAATTTTTTGTTTTCTTTGCTTAATTTTCCATTTGCGATAAGTTTATTTAAAGTCTTACCGAAAGCAGCAGGTGTTGAAGTATCTTTTTTGCTCTTTGGTGAATAGTAATTTAATTCTATCTCATATCTAACTGGATTTGTTACTTTATCTCCTAGTTCTTTTAGACGTTGTTTAACTTTTTTGATTCCACCAATTTCTTTTATAATTTTATTGTTTGCTGTATTATCACTATATGCCATTGAAGCCTCAATAAGTTCTTTTAAAGTGATATCTTTTCCTACATATTTTTCTAAAATAGGAGAATAAGCAACTATATCATCTTTGTTAATATGTATTTTTTTATTTAACTTATTATAAGGTACTTGTTCTAACAAAATAGCACTATTTATCGCTTTTGAAGTCGAAGCATAGGCAAATCTCTTATCTGAATTAAATTTTACTTCCTTACCACTTTTAGTATCTAAAGCATAAACACCAATATGAGCATTATATTTTTTTTCTAAATCATTTAACTCTTTGGCATGTGAACTGTTTGAATTACATGCACTTAAAACTAAAGCAATTGCAATTAAAAATATTAACTTTTTCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1330,Drugs,MEG_1330|Drugs|betalactams|Class_A_betalactamases|BLAZ,gi|941149152|gb|CP007679.1|21373-20528 gi|929861413|gb|CP010403.1|4334-3489 gi|841332193|emb|LN866850.1|16106-16951 gi|748807120|gb|CP010526.1|1459959-1459114 gi|443426804|gb|CP003673.1|417-1262 gi|260066083|gb|GQ900381.1|30227-31072 gi|35186899|gb|AY373761.1|16916-16071 gi|695200772|ref|NG_036177.1|2064-2909 gi|57635977|gb|CP000028.1|1699-2544 gi|341312|gb|M25257.1|STALACBAF|984-139,0
,atgtccgccacgctccacgacaccgcagcggatcgtcggaaggccacccgccgcgaatggatcggcctggccgtggtcgccctgccgtgcctggtctacgccatggacctcacggtgctgaacctggcgctgccggtgctcagccgtgaactgcagccctccagcgcccagcttctctggatcctggacatctacggcttcttcgtcgccggcttcctgatcaccatgggcacgctgggcgaccgcatcggccggcgccggctgttgttgatcggcgcggcgttcttcgcattcgcctcggtgctcgcggcgctggccgataccgccgcgctgttgatcgcggcgcgcgccttgctcggcctggccggcgccaccatcgcgccgtccaccatggcgctggtccgcaacatgttccacgacccgcgccagcgccagttcgccatcggcgtgtggatcgccgcgttttcgctgggcagcgcgatcggtccgctggtcggcggcgtgttgctggagttcttccactggggcgccgtgttctggctcaacgtgccggtgatgctgctgacgctggcgctcggccctcgcttcctgcccgagtatcgtgatccggacgcggggcacctggacctggccagcgtgctgctgtcgctggcggcggtgctgctgacgatctacgggctcaagcagttggccgagcatggagcgggcctcgcctcgatggctgcgctgctggccgggctggcggtcggggcgctgttcctgcgccgccagggccacatcgcctacccgctgctggacctgcggctgttcgcgcacgcgccgttccgcgcggcgctggcggcgtatgcgctggccgcgctggccatgttcggcgtctacatcttcatgacgcagtacctgcagctcgtgctggggctgtcgccgctgcaggccgggctggccacgctgccctggtccctgtgcttcgtcatcggttcgctgttgtcgccgcagctcgcggcgcgctggccggcggcgcgcatcctcgtcgtgggcctgtcggcagcggcgttcggcttcgccgtgctggggctggggcagggcctgtggtggctggtgccggccacgatcgtcatgggcctgggcctggcgccggtgttcaccatcggcaacgagatcatcatcaccagcgcgccgtccgagcgcgcgggcgcggcctcggccttgtcggagacggtgtccgaattcagcggcgcgctgggcatcgcgctgttcggcagcgtcggcctggtggtctaccggcaggcgctgaccagcgcggcgctgcccggcctgccggccgatgcgctgcaggcggccggtgcctcgctcgggggcgccgtgcacctggccgacaccctgccggcgtggcagggcgcggccttgctggcggccgcacgcgcgggcttcaccgatgcgctgcaggccacggcctgggccggcgcggtgctggtgctggtggccgctgggctggtggcgcgcctgctgcgcaagcgcccaacgctcgcatctggttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Fluoroquinolones,MEG_5861,Drugs,MEG_5861|Drugs|Fluoroquinolones|Quinolone_active_efflux|QEPA,1028098233|WP_063854778.1|NG_048052|1|1|qepA5|qepA|fluoroquinolone_efflux_MFS_transporter_QepA5 NG_048052:101-1636,3
,atgaaaattattaatattggagttttagctcatgttgatgcgggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatacgtctgggaaattattggaagcattagaactcgaacaagaggaaagcataagatttcataattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgaatatacaaaaaaaagacaacgtcttgcatatatacgcctttatagtggagtactacatttacgagattcggttagagtatcagaaaaagaaaaaataaaagttacagaaatgtatacttcaataaatggtgaattatgtaagattgatagagcttattctggagaaattgttattttgcaaaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7109,Drugs,MEG_7109|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028099868|WP_063856115.1|NG_048222|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048222:26-1945,4
,ATGGCCGACGAGAACACCCCCGTCACCCCCGAAGAGGGCGGCGAACTCGTGATGCGTGTCGAGCCCGTCGGGCTTGAGACGGAGATGCAGCGCTCGTACCTGGACTACGCGATGTCCGTCATCGTGTCCCGTGCGCTGCCCGACGTCCGGGACGGTCTCAAGCCCGTCCACCGCCGTGTGCTGTACGCGATGTACGACGGCGGCTACCGCCCCGAGCGCGGCTTCTACAAGTGCGCCCGTGTCGTCGGCGACGTCATGGGCAACTACCACCCGCACGGCGACTCCTCCATCTACGACGCCCTGGTGCGCCTCGCCCAGCCGTGGTCGATGCGGATGCCGCTGGTGGACTCCAACGGCAACTTCGGCTCCCCGGGCAACGACCCCGCGGCGGCCATGCGCTACACCGAGTGCAAGATGGCGCCGCTGTCGATGGAGATGGTCCGGGACATCGACGAGGAGACCGTCGACTTCACGGACAACTACGACGGCCGCTCCCAGGAGCCGACCGTCCTGCCGGCCCGCTTCCCGAACCTGCTGATCAACGGCTCGGCCGGTATCGCGGTCGGCATGGCCACCAACATCCCGCCGCACAACCTGCGCGAGGTCGCGGCCGGCGCCCAGTGGTACCTGGAGAACCCCGAGGTCTCCCACGAGGAGCTGCTGGACGCGCTCATGGAGCGCATCAAGGGCCCCGACTTCCCGACCGGCGCCCTGGTGGTGGGCCGCAAGGGCATCGAGGAGGCGTACCGCACCGGCCGCGGCTCCATCACGATGCGCGCGGTGGTCGAGGTCGAGGAGATCCAGGGCCGCCAGTGCCTGGTGGTCACCGAGCTGCCGTACCAGGTGAACCCGGACAACCTGGCGCAGAAGATCGCCGACCTGGTGAAGGACGGCAAGATCGGCGGCATCGCGGACGTCCGCGACGAGACCAGCTCGCGCACCGGCCAGCGCCTGGTGATCGTCCTGAAGCGGGACGCGGTCGCCAAGGTCGTGCTGAACAACCTGTACAAGCACACGGACCTCCAGACGAACTTCGGCGCCAACATGCTGGCGCTGGTCGACGGCGTGCCGCGCACCCTGTCCCTGGACGCGTTCATCCGCCACTGGGTGACGCACCAGATCGAGGTCATCGTCCGCCGGACCCGGTTCCGGCTGCGCAAGGCCGAGGAGCGCGCCCACATCCTGCGCGGTCTGCTGAAGGCCCTCGACGCCATCGACGAGGTCATCGCGCTGATCCGGCGCAGTGAGACCGTCGAGATCGCGCGCAGCGGCCTGATGGGCCTCCTGGAGATCGACGAGATCCAGGCGAACGCCATCCTTGAGATGCAGCTGCGCCGGCTGGCGGCCCTGGAGCGGCAGAAGATCGTCCAGGAGCACGACGAACTCCAGGCGAAGATCAACGAGTACAACGAGATCCTCGCCTCGCCGGTGCGCCAGCGCGGGATCGTCAGCGAGGAGCTGGCCGCGATCGTCGAGAAGTACGGCGACGACCGCCAGACCAAGCTGATCCCGTACGAGGGCGACATGTCCATCGAGGACCTGATCGCCGAGGAGGACATCGTCGTCACCGTCACGCGCGGCGGCTACGTCAAGCGGACGAAGACGGACGACTACCGGGCGCAGAAGCGCGGCGGCAAGGGCGTGCGCGGCACGAAGCTGAAGGAAGACGACATCGTCGACCACTTCTTCGTCTCCACCACGCACCACTGGCTGCTGTTCTTCACCAACAAGGGCCGGGTGTACCGGGCGAAGGCGTACGAGCTGCCCGAGGCCGGCCGGGACGCGCGCGGCCAGCACGTGGCGAACCTGCTCGCCTTCCAGCCGGACGAGGCGATCGCCGAGATCCTGGCGATCCGTGACTACGAGGCGGCGCCGTACCTGGTGCTGGCCACCAAGTCGGGCTTGGTCAAGAAGACGCCACTGAAGGATTACGATTCGCCTCGCTCCGGCGGTGTCATCGCCATCAACCTGCGGGAACGCGAGGACGGTTCGGACGACGAGCTGATCGGCGCCGAGCTGGTCTCGGCGGACGACGATCTGCTGCTGATCAGCAAGAAGGCGCAGTCGATCCGGTTCACCGCCTCGGACGAGTCCCTGCGCCCGATGGGCCGCGCCACCTCCGGCGTCAAGGGGATGAGTTTCCGGGAGGGCGACGAGCTTCTCTCGATGAATGTGGTGCGACCCGGTACGTTCGTGTTCACTGCCACCGACGGTGGGTACGCGAAGCGGACCGCCGTCGACGAGTACCGCGTCCAGGGCCGCGGCGGCCTCGGCATCAAGGCCGCCAAGATCGTGGAGGACCGTGGTTCGCTCGTCGGCGCGCTGATCGTCGAGGAGAACGACGAAATCCTCGCGATCACCCTCTCCGGCGGTGTGATTCGCACGCGAGTCAGCGAGGTCAGGGAGACGGGCCGTGACACCATGGGCGTCCAACTGATCAATCTGGGCAAGCGCGATGCCGTGGTCGGTATCGCACGTAACGCCGAAGCGGGGCGCGAGGCGGAGGAAGTCGACGGCGACGTGGCCGTGGACGAGACCGCCGAGGGTGCCGCGATCACCGGCACGGACGAGGGTGAGGCACCCTCGGCCGAGTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3206,Drugs,MEG_3206|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|451789617|gb|CP003720.1|5647670-5650264 gi|374096398|gb|CP003275.1|5953965-5956559,3
,atgggcatcattcgcacatgtaggctcggccctgaccaagtcaaatccatgcgggctgctcttgatcttttcggtcgtgagttcggagacgtagccacctactcccaacatcagccggactccgattacctcgggaacttgctccgtagtaagacattcatcgcgcttgctgccttcgaccaagaagcggttgttggcgctctcgcggcttacgttctgcccaagtttgagcaggcgcgtagtgagatctatatctatgatctcgcagtctccggcgagcaccggaggcagggcattgccaccgcgctcatcaatcccctcaagcatgaggccaacgcgcttggtgcttatgtgatctacgtgcaagcagattacggtgacgatcccgcagtggctctctatacaaagttgggcatacgggaagaagtgatgcactttgatatcgacccaagtaccgccacctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_30,Drugs,MEG_30|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,1028080874|WP_063840257.1|NG_047236|1|1|aac(3)-I|aac(3)-I|AAC(3)-I_family_aminoglycoside_3-N-acetyltransferase NG_047236:101-565,2
,atggctctggcactcgttggcgaaaaaattaacagaaaccgcttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgcttggcattgaaattcgccactgtcgtgcgcaaggcgcagattttcgcggcgcaagttttatgaatatgatcactactcgcacctggttttgcagtgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgttggatgggggcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggcgcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcggtgattggttag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5888,Drugs,MEG_5888|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111702|WP_063865914.1|NG_050481|1|1|qnrB20|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB20 NG_050481:37-681,3
,ATGAAACCGGTTGGAACGGAGGAATACTGCTTGAGAAGTGAACATGAAATGATGAGTACCATTATCAATTTCGCTAAAAATGATGATAGAATACGACTGGCAACTTTGGAAGGGTCACGTACAAACAAAAATATTCCCGTTGATACATTCCGGGATTATGACATCTCTTACTTTGTAACAGATATTGAATCTTTCAAAGAGACTGACCAATGGCTTGAATTTTTTGGGAATCGGCTTATGATGCAAAAACCCGAAGATATGGAGCTTTTTCCGTCAGAGCTAGGTAACTGGTTTTCATATATAATTCTTTTTGAGGATGGTAATAAGTTAGACTTAACACTTATTCCAATTAACGAAGTGGGGGATTATTTTACCAAGAACGACGGTTTAGTTGAGGTCCTGCTTGATAAGGATACTCTAATCAATAATGAAGTGATCGCAGACGATCGTCAATATTGGATTAAAAAGCCGACCGCAAGAGCATTTGATGATTGTTGTAATGAGTTCTGGATGGTTTCAACGTACGTAGTAAAAGGACTAGCCAGAAAAGAAATACTCTTTGCGATTGACCATTTAAACGAGATTGGAAGACCTAATCTATTAAGAATGATGGCTTGGCAAATCGGGTCTGAACACGGATATACTTTTAGCGTAGGGAAGAACTATAAATTTATTAATCGTTACCTTCCTAATGAAGATTGGGAAAAGCTCCTATCAACCTATTCTGAGAATGGGTATCAGGAAATGTGGCAGTCGTTATTAACTTGTTATGAGTTATTTAGAAAATACTCAAAAGCTGTGTCAGAAAGTCTCGGCTATACGTATCCAGATTATGACGAAGCTATTACTAAGTATACGGAAAATATTTACTCCTCATTAGTAATTTAG,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_993,Drugs,MEG_993|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,(AGly)AadK-Pm:CP002869:c4442322-4441435:888,2
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggaaaaaaaacacgcccgacacttgctgacgtacaggaacagtatttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_217,Drugs,MEG_217|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502178|WP_071846329.1|NG_052414|1|1|aac(6')-Ib'|aac(6')-Ib'|aminoglycoside_N-acetyltransferase_AAC(6')-Ib' NG_052414:101-655,2
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaaatgggatggggaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatataggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4717,Drugs,MEG_4717|Drugs|betalactams|Class_D_betalactamases|OXA,1509794613|WP_122630922.1|NG_062342|1|1|blaOXA-714|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-714 NG_062342:22-846,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCCCTTTATCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCTGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTAAAGTTCCGCAAAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGGCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCAATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1846,Drugs,MEG_1846|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AB372224|+|0-1146|ARO:3002050|CMY-39 [Citrobacter freundii] ,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggtctcgcgcgcagatcagttggaagaatttgtccactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_799,Drugs,MEG_799|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502192|WP_071846342.1|NG_052439|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052439:101-892,2
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGTTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6621,Drugs,MEG_6621|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|118197419|gb|EF090911.1|141-956 gi|66840802|emb|AJ830714.1|146-961,8
,atgaaaacatttgccgcatatgtaattatcgcgtgtctttcgagtacggcattagctggttcaattacagaaaatatgtcttggaacaaagagttctctgccgaagccgtcaatggtgtcttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaatgacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaagcaatgggaaagagacttgaccttaagaggggcaatacaagtttcagctcttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcctatggcaaccagaatatcagtggtggcattgacaaattctggttggaaggccagcttagaatttccgcagttaatcaagtggagtttctagagtctctatatttaaataaattgtcagcatctaaagaaaaccagctaatagtaaaagaggctttggtaacggaggcggcacctgaatatctagtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttgggtgggttgagaaggagacagaggtttactttttcgcctttaacatggatatagacaacgaaagtaagttgccgctaagaaaatccattcccaccaaaatcatggaaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4676,Drugs,MEG_4676|Drugs|betalactams|Class_D_betalactamases|OXA,1509794533|WP_122630842.1|NG_062252|1|1|blaOXA-655|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-655 NG_062252:101-901,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggctcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6218,Drugs,MEG_6218|Drugs|betalactams|Class_A_betalactamases|SHV,1509794569|WP_122630878.1|NG_062298|1|1|blaSHV-226|blaSHV|class_A_beta-lactamase_SHV-226 NG_062298:1-861,0
,gtgaaaaagtttattttagtgatgttattatttatgttctcgattatttcttttggtaatgaaaatcaatttatgaaagagatttttgaaagaaaaggtttaaacggaacttttgttgtttatgatttaaaaaatgataaaattgattattataatttggatagagctaatgagagattttatcctgcttcatcatttaaaatttttaatactttgataggattagaaaatgggatagtaaaaaatgttgatgaaatgttttattattatgatggttctaaagtttttcttgattcatgggcaaaagattcgaatttaagatatgcaataaaggtatctcaagttccagcttataaaaagcttgcaagagaattgggaaaagaaagaatgcaagaaggattaaataaattaaattatggaaataaggaaataggtagtgagattgataagttttggttagaaggtccattaaaaataagtgcaatggaacaagttaaattattaaatctattatcacaatcaaaacttccttttaaattagaaaatcaagaacaagtaaaagatattacgattttagagaaaaaagatgattttattttacatggaaaaactgggtgggctactgataatatagttgttcctattggttggtttgtaggttggatagaaacttctgataatatatattcatttgctattaatttagatatttctgatagtaaatttttacctaaacgtgaagaaattgtaagagaatatttcaaaaatataaatgttataaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4741,Drugs,MEG_4741|Drugs|betalactams|Class_D_betalactamases|OXA,696257482|WP_032835180.1|NG_050724|1|1|blaOXA-85|blaOXA-85_like|oxacillin-hydrolyzing_class_D_beta-lactamase_OXA-85 NG_050724:101-886,0
,gtgaccactcggatgatcatcctcaacggcggttccagcgcggggaagtccggcatcgtacggtgcctccagtccgtccttcccgagccctggctggccttcggcgtcgactccctcatcgaggcgatgcccctgaagatgcagagcgccgaaggcggcatcgagttcgacgccgacggcggggtgagcatcgggcccgagttccgcgcccttgagggcgcctgggccgagggcgtcgtcgcgatggcccgcgcgggcgcccggatcatcatcgacgacgtcttcctcggcggtgccgccgcccaggagcgctggcggagcttcgtcggggacctggacgtgctctgggtcggcgtccggtgcgacggcgccgtcgccgagggccgggagaccgcgcgcggcgaccgcgtcgcgggcatggcggcgaagcaggcgtacgtcgtgcacgagggcgtggagtacgacgtggaggtcgacaccacgcacaaggagtcgatcgagtgcgcctgggcgatcgccgcccacgtcgtcccgtag,antibiotic molecule,antibiotic inactivation,Phenicol,MEG_2114,Drugs,MEG_2114|Drugs|Phenicol|Chloramphenicol_phosphotransferase|CPT,1028085756|WP_063844287.1|NG_047672|1|1|cpt|cpt|chloramphenicol_phosphotransferase_CPT NG_047672:101-637,6
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggacggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_222,Drugs,MEG_222|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502182|WP_071846332.1|NG_052418|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052418:101-655,2
,atgatcgtcaactgcgaccacgacaacctcgacgcctggctggcgctgcgctcggcgctgtggcccacttgtccgttggaagagcaccgcgcggagatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgttttcgttggctttgccgaggtcgcgctgcgccacgattacgtcaacggctgcgagtcgtcgccggtggcgtttctggaagggatctataccgtcgaacacgcccgccgccagggctgggccgcgcgattgatcgcacaggtgcaggaatgggccaagcagcaaggctgcagcgagctggcgtcggataccgacatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggaacgggtggtgttttaccgtaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_146,Drugs,MEG_146|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,896246624|WP_049241494.1|NG_052196|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052196:101-541,2
,TTGTAAGTGTCTAAGGGCGCATGGTGGATGCCTTGGCATCGAGAGCCGATGAAGGACGTGGGAGGCTGCGATAAGCCTCGGGGAGCTGTCAACCGAGCGTGGATCCGAGGATTTCCGAATGGGGAAACCCAGCACGAGTGATGTCGTGTTACCCGCATCTGAATATATAGGGTGCGGGAGGGAACGCGGGGAAGTGAAACATCTCAGTACCCGTAGGAGAAGAAAACAAAAGTGATTCCGTAAGTAGTGGCGAGCGAACGCGGAACATGGCTAAACCGCACGCATGGGTAACCGGGTAGGGGTTGTGTGTGCGGGGTTGTGGGATCGATACGTCTCAGCTCTACCCGGCTGAGGGGCAGTCAGAAAGTGTCGTGGTTAACGGAAGTGGCCTGGGATGGTCTGCCGTAGACGGTGAGAGCCCGGTACGTGAAAACCCGGCACCTGCCTTGTATCAATTCCCGAGTAGCAGCGGGCCCGTGGAATCTGCTGTGAATCTGCCGGGACCACCCGGTAAGCCTAAATACTCCTCGATGACCGATAGCGGAATAGTACCGTGAGGGAATGGTGAAAAGTACCCCGGGAGGGGAGTGAAAGAGTACCTGAAACCGTGTGCCTACAATCCGTCAGAGCCCTTTCGTGGGGTGATGGCGTGCCTTTTGAAGAATGAGCCTGCGAGTCAGGGACATGTCGCGAGGTTAACCCGTGCGGGGTAGCCGCAGCGAAAGCGAGTCTGAATAGGGCGTATCGCGCGCGAGCGTGTGTAGTGGCGTGTTCTGGACCCGAAGCGGAGTGATCTACCCATGGCCAGGGTGAAGCGCGGGTAAGACCGCGTGGAGGCCCGAACCCACTTAGGTTGAAGACTGAGGGGATGAGCTGTGGGTAGGGGTGAAAGGCCAATCAAACTCCGTGATAGCTGGTTCTCCCCGAAATGCATTTAGGTGCAGCGTTGCGTGTTTCACCACGGAGGTAGAGCTACTGGATGGCCGATGGGCCCCACTAGGTTACTGACGTCAGCCAAACTCCGAATGCCGTGGTGTATAGCGTGGCAGTGAGACGGCGGGGGATAAGCTCCGTACGTCGAAAGGGAAACAGCCCAGATCGCCGGCTAAGGCCCCAAAGCGTGTGCTAAGTGGGAAAGGATGTGCAGTCGCAGAGACAACCAGGAGGTTGGCTTAGAAGCAGCCACCCTTGAAAGAGTGCGTAATAGCTCACTGGTCAAGTGATTGTGCGCCGATAATGTAGCGGGGCTCAAGCACACCGCCGAAGCCGCGACAACCGCAAGGTTGGGTAGGGGAGCGTCCCTCATTCAGCGAAGCTGCCGGGTGACCGGTGGTGGAGGATGGGGGAGTGAGAATGCAGGCATGAGTAGCGATAAGGCAAGTGAGAACCTTGCCCGCCGAAAGACCAAGGGTTCCTGGGCCAGGCCAGTCCGCCCAGGGTGAGTCGGGACCTAAGGCGAGGCCGACAGGCGTAGTCGATGGACAACGGGTTGATATTCCCGTACCCGTGTGTGGGCGCCCGTGATGAATCAGCGGTACTAACCACCCAAAACCGGATCGATCACTCCCCTTCGGGGGCGTGGAGGTCTGGGGCTGCGTGGAGCCTTCGCTGGTAGTAGTCAAGCGATGGGGTGACGCAGGAAGGCAGCCGTACCAGTCAGTGGTAATACTGGGGCAAGCCAGTAGGGAGAGCGATAGGCAAATCCGTCGCTCACAAATCCTGAGAGGTGACGCATAGCCGATTGAGGCGAATTCGGTGATCCTCTGCTGCCAAGAAAAGCCTCTAGCGAGCACACACACGGCCCGTACCCCAAACCGACACAGGTGGTCAGGTAGAGAATACCAAGGCGTACGAGATAACTATGGTTAAGGAACTCGGCAAAATGCCCCCGTAACTTCGGGAGAAGGGGGACCGGAATACCGTGAACACCCTTGCGGTGGGAGCGGGATTCGGTCGCAGAAACCAGTGAGAAGCGACTGTTTACTAAAAACACAGGTCCGTGCGAAGTCGCAAGACGATGTATACGGACTGACGCCTGCCCGGTGCTGGAAGGTTAAGAGGACCCGTTAACCCGCAAGGGTGAAGCGGAGAATTTAAGCCCCAGTAAACGGCGGTGGTAACTATAACCATCCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCTGCACGAATGGCGTAACGACTTCTCAACTGTCTCAACCATAGACTCGGCGAAATTGCACTACGAGTAAAGATGCTCGTTACGCGCGGCAGGACGAAAAGACCCCGGGACCTTCACTACAACTTGGTATTGGTGTTCGGTACGGTTTGTGTAGGATAGGTGGGAGACTGTGAAACCTCAACGCCAGTTGGGGTGGAGTCGTTGTTGAAATACCACTCTGATCGTATTGGACACCTAACGTCGAACCCTGAATCGGGTTCACGGACAGTGCCTGGCGGGTAGTTTAACTGGGGCGGTTGCCTCCTAAAATGTAACGGAGGCGCCCAAAGGTTCCCTCAACCTGGACGGCAATCAGGTGGCGAGTGTAAGTGCACAAGGGAGCTTGACTGCGAGACCTACAAGTCAAGCAGGGACGAAAGTCGGGACTAGTGATCCGGCACCTCTGAGTGGAAGGGGTGTCGCTCAACGGATAAAAGGTACCCCGGGGATAACAGGCTGATCTTCCCCAAGAGTCCATATCGACGGGATGGTTTGGCACCTCGATGTCGGCTCGTCGCATCCTGGGGCTGGAGCAGGTCCCAAGGGTTGGGCTGTTCGCCCATTAAAGCGGCACGCGAGCTGGGTTTAGAACGTCGTGAGACAGTTCGGTCTCTATCCGCCGCGCGCGTCAGAAGCTTGAGGAAACCTGTCCCTAGTACGAGAGGACCGGGACGGACGAACCTCTAGTGCACCAGTTGTCCCACCAGGGGCACCGCTGGATAGCTACGTTCGGACAGGATAACCGCTGAAAGCATCTAAGCGGGAAACCTTCTCCAAGATCAGGCTTCTCACCCACTTGGTGGGATAAGGCCCCCCGCAGAACACGGGTTCGATAGGCCAGACCTGGAAGCTCAGTAATGAGTGAAGGGAACTGGCACTAACCGGCCGAAAACTTACCAACACAAATAATCG,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3993,Drugs,MEG_3993|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NZ_CP019883.1|+|5018387-5021505|ARO:3004168|Mycobacterium kansasii 23S rRNA with mutation conferring resistance to clarithromycin [Mycobacterium kansasii] ,7
,AGGTAAGGAGGTGATCCAACCGCAGGTTCCCCTACGGTTACCTTGTTACGACTTCACCCCAGTCATGAATCACAAAGTGGTAAGCGCCCTCCCGAAGGTTAAGCTACCTACTTCTTTTGCAACCCACTCCCATGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGTGGCATTCTGATCCACGATTACTAGCGATTCCGACTTCATGGAGTCGAGTTGCAGACTCCAATCCGGACTACGACGCACTTTATGAGGTCCGCTTGCTCTCGCGAGGTCGCTTCTCTTTGTATGCGCCATTGTAGCACGTGTGTAGCCCTGGTCGTAAGGGCCATGATGACTTGACGTCATCCCCACCTTCCTCCAGTTTATCACTGGCAGTCTCCTTTGAGTTCCCGACCTAATCGCTGGCAACAAAGGATAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATTTCACAACACGAGCTGACGACAGCCATGCAGCACCTGTCTCACAGTTCCCGAAGGCACCAATCCATCTCTGGAAAGTTCTGTGGATGTCAAGACCAGGTAAGGTTCTTCGCGTTGCATCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCATTTGAGTTTTAACCTTGCGGCCGTACTCCCCAGGCGGTCTACTTAACGCGTTAGCTCCGGAAGCCACGCCTCAAGGGCACAACCTCCAAGTAGACATCGTTTACGGCGTGGACTACCAGGGTATCTAATCCTGTTTGCTCCCCACGCTTTCGCACCTGAGCGTCAGTCTTTGTCCAGGGGGCCGCCTTCGCCACCGGTATTCCTCCAGATCTCTACGCATTTCACCGCTACACCTGGAATTCTACCCCCCTCTACAAGACTCAAGCCTGCCAGTTTCGAATGCAGTTCCCAGGTTGAGCCCGGGGATTTCACATCCGACTTGACAGACCGCCTGCGTGCGCTTTACGCCCAGTAATTCCGATTAACGCTTGCACCCTCCGTATTACCGCGGCTGCTGGCACGGAGTTAGCCGGTGCTTCTTCTGCGGGTAACGTCAATTGCTGCGGTTATTAACCACAACACCTTCCTCCCCGCTGAAAGTACTTTACAACCCGAAGGCCTTCTTCATACACGCGGCATGGCTGCATCAGGCTTGCGCCCATTGTGCAATATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGACCGTGTCTCAGTTCCAGTGTGGCTGGTCATCCTCTCAGACCAGCTAGGGATCGTCGCCTTGGTGAGCCGTTACCTCACCAACAAGCTAATCCCATCTGGGCACATCTGATGGCAAGAGGCCCGAAGGTCCCCCTCTTTGGTCTTGCGACGTTATGCGGTATTAGCCACCGTTTCCAGTAGTTATCCCCCTCCATCAGGCAGTTTCCCAGACATTACTCACCCGTCCGCCACTCGTCAGCGAAGCAGCAAGCTGCTTCCTGTTACCGTTCGACTTGCATGTGTTAGGCCTGCCGCCAGCGTTCAATCTGAGCCATGATCAAACTCTTCAATT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_2,Drugs,MEG_2|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|AE006468|+|3570463-3572006|ARO:3003512|Salmonella enterica serovar Typhimurium 16S rRNA mutation in the rrsD gene conferring resistance to spectinomycin [Salmonella enterica subsp. salamae] ,2
,atgggcatcattcgcacatgtaggctcggccctgaccaagtcaaatccatgagggctgctcttgatcttttcggtcgtgagttcggagacgtagccacctactcccaacatcagccggactccgattacctcgggaacttgctccgtagtaagacattcatcgcgcttgctgccttcgaccaagaagcggttgttggcgctctcgcggcttacgttctgccaaagtttgagcaggcgcgtagtgagatctatatctatgatctcgcagtctccggcgagcaccggaggcaaggcattgccaccgcgctcatcaatctcctcaagcatgaggccaacgcgcttggtgcttatgtgatctacgtgcaagcagattacggtgacgatcccgcagtggctctctatacaaagttgggcatacgggaagaagtgatgcactttgatatcgacccaagtaccgccacctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_25,Drugs,MEG_25|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,488018085|WP_002089484.1|NG_047234|1|1|aac(3)-I|aac(3)-I|AAC(3)-I_family_aminoglycoside_3-N-acetyltransferase NG_047234:101-565,2
,atggaacaatatacaattaaatttaaccaaatcaatcataaattgacagatttacgatcacttaacatcggtcatctttacgcttaccaatttgaaaaaatagcacttattgggggtaatggtactggcaaaaccacattactaaatatgattgctcaaaaaacaaaaccagaatctggaacagttgaaacggttggcgaaattcaatattttgaacagcttaacatggatgtggaaaatgattttaacacgttagacggtagtttaatgagtgaactccatatacctatgcatacaaccgacagtatgagtggtggtgaaaaagcaaaatataaattagctaatgtcatatcaaattatagtccgatattacttttagatgaacctacaaatcacttggataaaattggtaaagattatctgaaaaatattttaaaatattactatggtactttaattatagtaagtcatgatagagcacttatagaccaaattgctgacacaatttgggatatacaagaagatggcacaataagagtgtttaaaggtaattacacacagtatcaaaatcaatatgaacaagaacagttagaacaacaacgtcaatatgaacagtatataagtgaaaaacaaagattgtcccaagccagtaaagctaaacgaaatcaagcgcaacaaatggcacaagcatcatcaaaacaaaaaaacaaaagtatagcaccagatcgtttaagtgcatcaaaacaaaaaggcacggttgagaaggctgctcaaaaacaagctaagcatattgaaaaaagaatggaacatttggaagaagttgaaaaaccacaaagttatcatgaattcaatttcccacaaaataaaatttatgatatccataataattatccaatcattgcacaaaatctaacattggttaaaggaagtcaaaaactgctaacacaagtacgattccaaataccatatggcaaaaatatagcgctcgtaggtgcaaatggtgtaggtaagacaactttacttgaagctatttaccaccaaatagagggaattgattgttctcctaaagtgcaaatggcatactatcgtcaacttgcttatgaagacatgcgtgacgtttcattattgcaatatttaatggatgaaacggattcatcagaatcattcagtagagctattttaaataacttgggtttaaatgaagcacttgatcgttcttgtaatgttttgagtggtggggaaagaacgaaattatcgttagcagtattattttcaacgaaagcgaatatgttaattttggatgaaccaactaattttttagatattaaaacattagaagcattagaaatgtttatgaataaatatcctggaatcattttgtttacatcacatgatacaaggtttgttaaacatgtatcagataaaaaatgggaattaacaggacaatctcttcatgatataacttaa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_4066,Drugs,MEG_4066|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|MSRA,446361019|WP_000438874.1|NG_055998|1|1|msr(A)|msr(A)|ABC-F_type_ribosomal_protection_protein_Msr(A) NG_055998:101-1567,7
,ATGAGTTCGTCGGACCACATCCACGTCCCGGACGGCCTGGCCGAGTCGTACAGCAGAAGCGGTGGCGAGGAAGGGCGCGCCTGGATCGCCGGACTTCCCGCTCTCGTCGCGCGATGCGTCGACCGCTGGGAGCTGAAGAGGGACGGCGGCGTCCGCTCCGGTGAGGCCTCCCTCGTGGTGCCGGTGCTGCGTGCTGACGGCACCCGGGCGGCGCTCAAACTCCAGATGCCCCGGGAAGAGACGACGGCCGCGCTGATCGGCCTGCGAGCCTGGGGCGGGGACGGCATGGTGCGGCTGCTCGACCACGACGAGGAGAGCAGCACGATGCTGCTGGAACGCCTGGACGGTTCGCGGACGCTGGCGTCGGTCGAGGACGACGACGAGGCCATGGGCGTCCTCGCCGGGCTGCTGAACCGGCTGCACTCCGTTCCGGCACCTCCGGGGCTGCGGGGTCTGGGAGAGATCGCCGGCGCCATGGTGGAGGAAGTTCCCTCCGCTGTCGACTCGTTGGCGGATCCGGAGGACCGTAGCCGGTTGCGCGGCTGGGCGTCGGCCGTGGCCGAGCTGGTGGGCGAGCCCGGTGACCGCGTCCTGCACTGGGACCTGCACTACGAGAACGTGCTGGCCGCCGAGCGCGAACCGTGGCTGGCCATCGACCCCGAGCCGCTGGTCGGCGACCCGGGGTTCGACCTGTGGCCGGCCCTGGACACCGGTTGGGAGCGGATCGAGGCCACCGGTGACGCGCGGCGGGTGGTCCGGCGGCGCTTCGACCTGCTGACGGAAGCGCTGGAGCTGGACCGCGGGAGGGCGGCCGGGTGGACCCTGGCCCGGCTCCTGCAGAACACCCTGTGGGACATCGAGGACGGGCTGACGGCGATCGCCCCCTCCCAGATCGCCGTGGCCGAAGCGCTGGCGAAGCCCTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1088,Drugs,MEG_1088|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH6,(AGly)Aph6-Ia:AY971801:1-924:924,2
,atgaacaaaaaaaatataaaagacagtcaaaactttattacttcgaaacgtaatgtagataaaataatgacaaatataagcttaaatgaacatgataatatctttgaaattggctcaggaaaagggcattttacccttgaattagtacaaaggtgtaatttcgtaactgctattgaaatagaccataaattatgcaagactacagaaaataaacttgttaatcacgataattttcaagttttaaacaaggatatattgcagtttaaatttcctaaaaaccaatcctataaaatatttggtagtataccttacaacataagtacggatataatacgcaaagttgtttttgaaagtatagctgatgagagttatttaatcgtggaatacgggtttgctaaaaggttattgaatacaaagcgctcattggcgttacttttaatggcagaagttgatatttctatattaagtatggttccaagagaatattttcatcctaaacctaaagtgaatagctcgcttatcagattaaatagaaaaaaatcaagaatatcgtacaaagataaacagaagtataattatttcgttatgaaatgggttaacaaagaatacaagaaaatatttacaaagaatcaatttaacaaatccttaaaacatgcgggaattgacgatttaaacaatattagctttgagcaattcttgtctcttttcaatagctataaattatttaataagtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2808,Drugs,MEG_2808|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,503924496|WP_014158490.1|NG_047814|1|1|erm(C)|erm(C)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(C) NG_047814:101-835,7
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagaatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_565,Drugs,MEG_565|Drugs|betalactams|Class_C_betalactamases|ADC,691020409|WP_031980335.1|NG_056060|1|1|blaADC-162|blaADC|class_C_beta-lactamase_ADC-162 NG_056060:1-1152,0
,atgacttttaatattatcaaattagaaaattgggatagaaaagaatattttgaacactattttaaccagcaaactacgtatagcattactaaagaaattgatattactttgtttaaagatatgataaaaaagaaaggatatgaaatttatccttctttgatttatgcaattatggaagttgtaaataaaaataaagtgtttagaacaggaattaatagtgagaataaattaggttattgggataagttaaatcctttgtatacagtttttaataagcaaactgaaaaatttactaacatttggactgaatctgataacaacttcacttctttttataataattataaaaatgacttgcttgaatataaagataaagaagaaatgtttcctaaaaaaccgatacctgaaaacaccataccgatttcaatgattccttggattgattttagttcatttaatttaaacattggtaacaatagcaactttttattgcctattattacgataggtaaattttatagtgagaataataaaatttatataccagttgctttgcagcttcatcatgctgtatgtgatggttaccatgcttcattatttatgaatgaatttcaagatataattcataaggtagatgattggatttag,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1572,Drugs,MEG_1572|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,488420144|WP_002489529.1|NG_047566|1|1|catA7|catA7|type_A-7_chloramphenicol_O-acetyltransferase NG_047566:101-748,6
,atgaggagaagcgagggtgacgacgaaccacgcactctcccgcctcgggcccgggaccgggtgtacaccgcggtcacgcgggtgctcgccgtgctcctgctgcccgtggcgttcgtccgtcagcccggccgcgcccgcgagctggcctgcggctgggcgttgaggatgcgattcccggcagaggacctcaccgggctcaccgacggcgccagggcggcgttcaccgcggcgcgggccgaggcgctgtggcgtcacggccagctcgtcggtctcacttccggataccgcgatccccgggtccagcagcggatgttcgaggaggaggtgcgccgctcagggtccgtggccgccgcacggatgttcgtggcgccgccggccgagtccaaccacgtcaagggcatggcgctggacgtacgcccgcacgagggcgcgcgctggctggaggcgcacggcgcccgctacgacctctaccgcatctacgacaacgagtggtggcacttcgaacaccgcccggagtgcggtggcacgccaccacggcggctaccccacccaggcgcggcctgggcgagccggaacgggggccgggtctag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7593,Drugs,MEG_7593|Drugs|Glycopeptides|VanA-type_accessory_protein|VANYA,1028100690|WP_063856825.1|NG_048515|1|1|vanY-32487235|vanY-32487235|VanY-like_protein NG_048515:101-691,5
,GATTCACTATAGGGAAATGCAACAACGACGTGCGTTCGCGCTACTGACGCTGGGTAGCCTGCTGCTAGCCCCTTGTACTTATGCCAGCGGGGAGGCCCCGCTGACCGCCACTGTGGACGGCATTATCCAGCCGATGCTCAAGGAGTATCGGATCCCGGGGATAGCGGTCGCCGTACTGAAAGATGGCAAGGCCCACTATTTCAACTATGGGGTTGCCAACCGCGAGAGTGGCCAGCGCGTCAGCGAGCAGACCCTGTTCGAGATTGGCTCGGTCAGCAAGACCCTGACCGCGACCCTCGGTGCCTATGCTGCGGTCAAGGGGGGCTTTGTGCTGGATGACAAGGTGAGCCAGCACGCCCCCTGGCTCAAAGGTTCCGCCTTGGATGGTGTGACCATGGCCGAGCTTGCCACCTACAGTGCGGGTGGTTTGCCGCTGCAGTTCCCCGATAAGGTGGATTCGAATGACAAGATGCAAACTTACTATCGGAGCTGGTCACCGGTTTATCCGGCAGGGACTCATCGCCAGTATTCCAACCCCAGCATAGGCCTGTTTGGTCACCTGGCCGCAAATAGTCTGGGCCAGCCATTTGAGCAACTGATGAGCCAGACCCTGCTGCCCAAGCTGGGTTTGCACCACACCTATATCCAGGTGCCGGAGTCGGCCATGGCGAACTATGCCTACGGCTATTCGAAGGAAGATAAGCCCATCCGGGTCACTCCGGGCGTGCTGGCGGCCGAGGCTTACGGGATCAAGACCGGCTCGGCGGATCTGCTGAAGTTTGCCGAGGCAAACATGGGGTATCAGGGAGATGCCCTGGTAAAAAGCGCAATCGCGCTGACCCACACCGGTTTCTACTCGGTGGGGGAAATGACCCAGGGGCTGGGCTGGGAGAGTTACGACTATCCCGTCACCGAGCAGGTGCTGCTGGCGGGCAACTCCCCGGCGGTGAGCTTCCAGGCCAATCCGGTTACGCGCTTTGCGGTGCCCAAAGCGATGGGCGAGCAGCGGCTCTATAACAAGACGGGCTCGACTGGCGGCTTTGGCGCCTATGTGGCGTTCGTGCCCGCCAGAGGGATCGCCATCGTCATGCTGGCCAATCGCAACTATCCCATCGAGGCCAGGGTGAAGGCGGCTCACGCCATCCTGAGTCAGTTGGCCGAGTGATTTCCCTTTAGTGAGGGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3044,Drugs,MEG_3044|Drugs|betalactams|Class_C_betalactamases|FOX,gi|1841437|emb|Y11068.1|1-1183 gi|927028715|dbj|LC072710.1|606-1755,0
,ATGAACGGCGGAAGCAGGTTGAAGAATTGGGTTGTTCGGGCATTTTTTGCCTCCTATATGTACGCATTATTCAAAATCATCGTGCTCAAGTTTGGCCCGACAGACGTCGAGTTTCTATGGGTACGGCTAATGCGAAACTCGACCAACCCGGAATGTATTGCCGCCCGGCTGCATGCCGGCAATCTGATCCCTTTGAAGGAAATTTCCAGGGCGAGTGATTCGATGTCGGGGCACAGCCTTTTGAACTTGTTGGGGAATGTTGGGATCTTCGTCCCTTTAGGCATTTTCCTCGGTGTTCTGGCGAAATCCGGCAAACTGACGTTGGCAGGGTCGTTTTGGAGCTCCTTGGGCGTAAGTCTCGTGTTAGAATGCACACAAGTTTTATTTTCGATCGGAACATTCGACGTCGACGACCTCATTTTGAATTCCATCGGAGGCTCAATCGGTTTTGTCGTTTATGCGCTGTGCGCGCTAGGCTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7617,Drugs,MEG_7617|Drugs|Glycopeptides|VanA-type_accessory_protein|VANZA,(Gly)VanZ-Pa:DQ018711:7169-7648:480,5
,ATGAATCCCTATCTACAGTTAGTTAGCAAAGAATTTCCGTTAGAAAAAAACCAAGAGCCGCCTCATTTAGTCCTTGCTGCCTTCAGTGAAGACGAGGTTTACTTGCAACCAGAAGCAGCCAAACAATGGAAACGGCTAGTCAAAGCTTTAAAGCTTGAAGACGAGATCTGCTTATTAGATGGCTACCGAACCGAAAAGCAGCAACGGTATTTATGGGAATATTCCTTGAAAGAAAATGGGCTAGCCTATACGAAACAATTTGTGGCATTGCCCGGGTGCAGTGAACATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAAGGCAGCCAGGATGATTTGATCTGCCCACGATTTCGTGACAGCGCAGCCGCTGATTTATTTACCCAGGAAATGATGAACTATGGGTTTATTTTACGCTATCCCGCGGACAAACAGGAAATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTGCCCCATAGTCAAATCATCGCCAGCCAACAGTGGACCTTGGAAGAATACCATCAATACCTTGAACAAACGGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7579,Drugs,MEG_7579|Drugs|Glycopeptides|VanC-type_resistance_protein|VANXYC,(Gly)VanXYc3:AY033764:1075-1647:573,5
,ATGAAAATAATGTTAGAGGGACTTCATATAAAACATTATGTTCAAGATCGTTTATTGTTGAACATAAATCGCCTAAATATTTATCAGAATGATCGTATTGGTTTAATTGGTAAAAATGGAAGTGGAAAAACAACGTTACTTCACATATTATATAAAAAAATTGTGCCTGAAGAAGGTATTGTAAAACAATTTTCACATTGTGAACTTATTCCTCAATTGAAGCTCATAGAATCAACTAAAAGTGGTGGTGAAGTAACACGAAACTATATTCGGCAAGCGCTTGATAAAAATCCAGAACTGCTATTAGCAGATGAACCAACAACTAACTTAGATAATAACTATATAGAAAAATTAGAACAGGATTTAAAAAATTGGCATGGAGCATTTATTATAGTTTCACATGATCGCGCTTTTTTAGATAACTTGTGTACTACTATATGGGAAATTGACGAGGGGAGAATAACTGAATATAAGGGGAATTATAGTAACTATGTTGAACAAAAAGAATTAGAAAGACATCGAGAAGAATTAGAATATGAAAAATATGAAAAAGAAAAGAAACGATTGGAAAAAGCTATAAATATAAAAGAACAGAAAGCTCAACGAGCAACTAAAAAACCGAAAAACTTAAGTTTATCTGAAGGCAAAATAACAGGAGCAAAGCCATACTTTGCAGGTAAGCAAAAGAAGTTACGAAAAACTGTAAAATCTCTAGAAACCAGACTAGAAAAACTTGAAAGCGTCGAAAAGAGAAACGAACTTCCTCCACTTAAAATGGATTTAGTGAACTTAGAAAGTGTAAAAAATAGAACTATAATACGTGGTGAAGATGTCTCGGGTACAATTGAAGGACGGGTATTGTGGAAAGCAAAAAGTTTTAGTATTCGCGGAGGAGACAAGATGGCAATTATCGGATCTAATGGTACAGGAAAGACAACGTTTATTAAAAAAATTGTGCATGGGAATCCTGGTATTTCATTATCGCCATCTGTCAAAATCGGTTATTTTAGCCAAAAAATAGATACATTAGAATTAGATAAGAGTATTTTAGAAAACGTTCAATCTTCTTCACAACAAAATGAAACTCTTATTCGAACTATTCTAGCTAGAATGCATTTTTTTAGAGATGATGTTTATAAACCAATAAGTGTTTTAAGTGGTGGAGAGCGAGTTAAAGTAGCACTAACTAAAGTATTCTTAAGTGAAGTTAATACGTTGGTATTAGATGAACCAACAAACTTTCTTGATATGGAAGCTATAGAGGCGTTTGAATCTTTGTTAAAGGAATATAATGGCAGTATAATCTTTGTATCTCACGATCGTAAATTTATCGAAAAAGTAGCCACTCGAATAATGACAATTGATAATAAAGAAATAAAAATATTTGATGGCACATATGAACAATTTAAACAAGCTGAAAAGCCAACAAGGAATATTAAAGAAGATAAAAAACTTTTACTTGAGACAAAAATTACAGAAGTACTCAGTCGATTGAGTATTGAACCTTCGGAAGAATTAGAACAAGAGTTTCAAAACTTAATAAATGAAAAAAGAAATTTAGATAAATAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_7685,Drugs,MEG_7685|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA,gi|695214537|ref|NG_036833.1|48-1616 gi|641688293|emb|HG799495.1|70852-70880,1
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaaaggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5673,Drugs,MEG_5673|Drugs|betalactams|Class_C_betalactamases|PDC,1408841631|WP_111672904.1|NG_060562|1|1|blaPDC-292|blaPDC|class_C_beta-lactamase_PDC-292 NG_060562:1-1173,0
,atggtgacggtgttcggcattctgaatctcaccgaggactccttcttcgatgagagccggcggctagaccccgccggcgctgtcaccgcggcgatcgaaatgctgcgagtcggatcagacgtcgtggatgtcggaccggccgccagccatccggacgcgaggcctgtatcgccggccgatgagatcagacgtattgcgccgctcttagacgccctgtccgatcagatgcaccgtgtttcaatcgacagcttccaaccggaaacccagcgctatgcgctcaagcgcggcgtgggctacctgaacgatatccaaggatttcctgaccctgcgctctatcccgatattgctgaggcggactgcaggctggtggttatgcactcagcgcagcgggatggcatcgccacccgcaccggtcaccttcgacccgaagacgcgctcgacgagattgtgcggttcttcgaggcgcgggtttccgccttgcgacggagcggggtcgctgccgaccggctcatcctcgatccggggttgggatttttcttgagccccgcaccggaaacatcgctgcacgtgctgtcgaaccttcaaaagctgaagtcggcgttggggcttccgctattggtctcggtgtcgcggaaatccttcttgggcgccaccgttggccttcctgtaaaggatctgggtccagcgagccttgcggcggaacttcacgcgatcggcaatggcgctgactacgtccgcacccacgcgcctggagatctgcgaagcgcaatcaccttctcggaaaccctcgcgaaatttcgcagtcgcgacgccagagaccgagggttagatcatgcctag,beta-lactamase,antibiotic target replacement,Sulfonamides,MEG_6581,Drugs,MEG_6581|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,970318156|WP_058685609.1|NG_048101|1|1|sul1|sul1|sulfonamide-resistant_dihydropteroate_synthase_Sul1 NG_048101:101-940,8
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgcatcctaatatgcgtgtaatgaactttaccgaatctgaacaatgggatatggtaatagaaggaaatgattaccttttggagaaatatacgtctgggaaattattggaagcattagaactcgaacaagaggaaagcataagatttcataattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacgactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctgcgatattatgtggattctgcgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgcccaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaagggatacgctatggttgcgaacaaggattatatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7123,Drugs,MEG_7123|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100184|WP_063856397.1|NG_048237|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048237:101-2020,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5672,Drugs,MEG_5672|Drugs|betalactams|Class_C_betalactamases|PDC,1408841632|WP_111672905.1|NG_060563|1|1|blaPDC-293|blaPDC|class_C_beta-lactamase_PDC-293 NG_060563:1-1185,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTAAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6684,Drugs,MEG_6684|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-10:U09188:198-1005:858,0
,atgttcaaaacgacgctctgcgccttattaattaccgcctcttgctccacatttgctgcccctcaacaaatcaacgatattgtgcatcgcacaattaccccgcttatagagcaacaaaagatccccggtatggcggtggcggtaatttatcagggtaaaccttattactttacctggggctatgcggacatcgccaaaaagcagcccgtcacacagcaaacgttgtttgagttaggttcggtcagcaaaacatttacgggcgtgcttggtggcgacgctattgctcgaggggaaatcaagttaagcgatcccgcaacaaaatactggcctgaacttaccgctaaacagtggaatgggatcacactattacatcttgcgacctacaccgctggcggcctgccattgcaggtgccggatgaagtgaaatcctcaagcgacttgctgcgcttctatcaaaactggcagcctgcatgggctccaggaacacaacgtctgtatgccaactccagtatcggtttgttcggcgcactggctgtgaagccgtctggtttgagttttgagcaggcgatgcaaactcgtgtcttccagccactcaaactcaaccatacgtggattaatgtacctcccccagaagaaaagaattacgcctggggatatcgcgaaggtaaggcagtgcatgtttcgccaggggcgttagatgctgaagcttatggtgtgaagtcgaccattgaagatatggcccgctgggtacgaagcaatatgaatccccgtgatatcaacgacaaaacacttcagcaagggatacaactggcacaatctcgctactggcaaaccggcgatatgtatcagggcctgggctgggaaatgctggactggccggtaaatcctgacagcatcattaacggcaatggcaataaaattgcactggcagcacaccctgtaaaagcgattacgcccccaactcctgcagtacgcgcatcatgggtacataaaacaggggcaaccggcggatttggtagctatgtcgcgtttattccagaaaaagagctgggtatagtgatgctggctaacaaaaactatcccaatccagcgagagtcgccgccgcctggcagattctcaacgctctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1280,Drugs,MEG_1280|Drugs|betalactams|Class_C_betalactamases|BLAEC,1028105042|WP_063860228.1|NG_049079|1|1|blaEC-13|blaEC|class_C_extended-spectrum_beta-lactamase_EC-13 NG_049079:101-1234,0
,ttgaaaaaaatacttttactttttagtcttttttactcttttgctttggcaaatgataaattaaaagatttttttaaagactacaatacaagcggagtttttataacttttgatggaaaacattatgcaagtaataattttaaaagagctaaagaacctttttctcctgcttcgacttttaaaatttttaatgctttaattgcgcttgataatggtatagttaaagatacaaaggaaattttttatcattataagggtgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcctatggaaatgcaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgatggtataaatttggcttggattgtcggatttatagagagtaaaaacaaaattttatcttttgccttaaatgttgatataaagaatattaaaaatcttaaaataagagaagaattgctagaaaaatatatttattctttaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4630,Drugs,MEG_4630|Drugs|betalactams|Class_D_betalactamases|OXA,1391852895|WP_109545080.1|NG_057497|1|1|blaOXA-626|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-626 NG_057497:1-747,0
,ATGATTAAGAAAAGAATAGCAATCATTTTTGGAGGAAATTCAACGGAATACGAGGTGTCCTTGCAGTCGGCATCTGCCGTTTTTGAGAATATCAACACTAAAAAGTTTGACATTGTTCCTATTGGAATTACCAGAAATGGCGACTGGTATCATTACACAGGCAAAAAAGAAAAGATTGCAAATAATACTTGGTTTGAGGATAACGAAAACCTGTATTCTGTTGCGGTATCGCAAAACCGTTCTGTAAAAGGCTTTATAGAATTTAAGGAAGAAAAATTCTACATCATCAAGGTTGACTTGATATTTCCTGTATTGCACGGCAAGAACGGCGAGGACGGTACTTTGCAGGGATTATTTGAATTAGCAGGAATACCTGTTGTTGGGTGTGATACACTCTCGTCTGCTCTTTGTATGGACAAAGATAAGGCACATAAACTTGTTAGCCTTGCGGGTATCTCTGTTCCAAAATCAGTAACTTTTAAATTCTCTGGCAAAAAGGCAGCCTTGAAAAAAATTGAAAAGGAGTTAAGCTATCCATTATTTGTGAAGCCTGTCCGTGCAGGCTCGTCATTTGGAATAACAAAAGTAACTAAACAGCAGGAACTTGAAAACGCTATACAATTAGCGTTTGAACACGATGCGGAAGTCATTGTTGAAGAAACCATAAACGGCTTTGAGGTTGGTTGTGCGGTACTTGGTATAGATGAACTGATTGTCGGCAGAGTTGATGAAATCGAACTGTCAAGCGGCTTTTTTGATTATACAGAGAAATATACACTTAAATCTTCAAAGATATATATGCCTGCAAGGATTGATGCCGAAGCAGAAAAACGGATACAAGAAACGGCTGTAACCATATATAAAGCTCTGGGCTGTTCGGGTTTTTCCAGAGTGGATATGTTTTATACACCGTCTGGCGAAATTGTATTTAATGAGGTAAACACAATACCAGGCTTTACCTCGCACAGTCGCTATCCAAATATGATGAAAGGCATTGGTCTATCGTTCGCCCAAATGTTGGATAAGCTGATAGGTCTGTATGTGGAATGATGAAAACGATTGAGCTTGAAAAGGAAGAAATTTATTGTGGAAATTTGCTGCTCGTCAACAAAAATTATCCGCTACGAGATAACAATGTAAAGGGTTTAGTTCCTGCTGATGTACGCTTTCCAAATATTCTTATGAAGCGTGATGTGGCAAATGTTTTGCAGCTTATTTTTGAAAAAATCTCGGCAGGTAACTCTATCGTTCCTGTAAGCGGTTATCGCTCATTAGAAGAACAGACAGCCATATATGACGGCTCTCTCAAAGATAATGGAGAGGATTTTACAAGAAAATATGTTGCCCTGCCAAATCATAGCGAACATCAGACAGGACTTGCTATTGATTTGGGATTGAACGAAAAAGAAATAGATTTTATCCGTCCCGATTTCCCCTATGTCGGTATCTGTAATGAGTTTAGAAAAGCAGCCCCAGACTATGGATTTATCGAACGCTATGCAAAGGACAAAGAAGAAATCACGGGAATTTCACACGAGCCGTGGCATTTTCGATATGTAGGATACCCACACTCAAAAATTATGCAGGAAAATGGTTTTTCACTTGAAGAATACACACAATTTATAAAAGCCTATCTGGAAGATAAAAAATATCTTTTTGAGCAGGCTCACAGAGCTGAGATTGAAATATATTATGTTCCTGCAAAAGACGACAAAACGCTGATAAAAATACCAGAAAATTGTGTTTATCAGATTTCTGGTAATAACATAGACGGTTTTGTTGTGACCATATGGAGGAAAACAGATGACTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7396,Drugs,MEG_7396|Drugs|Glycopeptides|VanG-type_resistance_protein|VANG,VanG2XY_1_FJ872410,5
,ATGCTAAATTTAACCGTTTGTCAGGCACAGTCAAATCCAACAGACTACGCCTGTCTGACGGGCCCGGACATCCCCTTGACTCGCTATTACGGAAGATTACTGATGATGAAAAAATCCCTTTGCTGCGCCCTGCTGCTCGGCATCTCTTGCTCTGCTCTCGCCGCGCCAGTGTCAGAAAAACAGCTGGCGGAGGTGGTCGCGAATACGGTTACCCCGCTGATGAAAGCCCAGTCTGTTCCAGGCATGGCGGTGGCCGTTATTTATCAGGGAAAACCGCACTATTACACGTTTGGCAAGGCCGATATCGCGGCGAATAAACCCGTTACGCCTCAGACCCTGTTCGAGCTGGGTTCTATAAGTAAAACCTTCACCGGCGTTTTAGGTGGGGATGCCATTGCTCGCGGTGAAATTTCGCTGGACGATCCGGTGACCAGATACTGGCCAGAGCTGACGGGCAAGCAGTGGCAGGGTATTCGTATGCTGGATCTCGCCACCTACACCGCTGGCGGCCTGCCGCTACAGGTACCGGATGAGGTCACGGATAACGCCTCCCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCTGGCACAACGCGTCTTTACGCCAACGCCAGCATCGGTCTTTTTGGTGCGCTGGCGGTCAAACCTTCTGGCATGCCCTATGAGCAGGCCATGACGACGCGGGTCCTTAAGCCGCTCAAGCTGGACCATACCTGGATTAACGTGCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGCTATCGTGACGGTAAAGCGGTGCGCGTTTCGCCGGGTATGCTGGATGCACAAGCCTATGGCGTGAAAACCAACGTGCAGGATATGGCGAACTGGGTCATGGCAAACATGGCGCCGGAGAACGTTGCTGATGCCTCACTTAAGCAGGGCATCGCGCTGGCGCAGTCGCGCTACTGGCGTATCGGGTCAATGTATCAGGGTCTGGGCTGGGAGATGCTCAACTGGCCCGTGGAGGCCAACACGGTGGTCGAGGGCAGCGACAGTAAGGTAGCGCTGGCGCCGTTGCCCGTGGTAGAAGTGAATCCACCGGCTCCCCCGGTCAAAGCGTCCTGGGTCCATAAAACGGGCTCTACTGGCGGGTTTGGCAGCTACGTGGCCTTTATTCCTGAAAAGCAGATCGGTATTGTGATGCTCGCGAATACAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCATATCCTCGAGGCGCTACAGTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_491,Drugs,MEG_491|Drugs|betalactams|Class_C_betalactamases|ACT,gi|591542958|gb|KJ207209.1|353-1599,0
,ATGACGCAAACTTATAACGCTGATGCCATTGAGGTACTCACCGGGCTTGAGCCGGTTCGCCGCCGTCCGGGGATGTATACCGATACCACTCGCCCTAACCATTTGGGGCAAGAAGTCATTGATAACAGTGTGGATGAAGCACTGGCGGGTCACGCAAAACGCGTGGACGTTATTTTACATGCTGACCAGTCGTTAGAAGTTATTGACGATGGGCGCGGGATGCCGGTGGATATTCACCCGGAAGAGGGTGTACCGGCGGTTGAACTGATTCTTTGCCGTCTGCATGCAGGCGGTAAATTCTCTAACAAAAATTACCAGTTCTCTGGCGGCCTGCATGGCGTGGGGATTTCGGTGGTTAACGCCCTGTCGAAGCGCGTAGAAGTTAACGTGCGCCGCGATGGTCAGGTTTATAACATCGCCTTTGAAAATGGCGAAAAGGTGCAGGATTTACAGGTTGTCGGCACTTGCGGTAAACGCAATACTGGTACCAGTGTGCACTTCTGGCCGGATGAAACCTTCTTTGACAGCCCGCGATTTTCTGTTTCACGCCTGACGCATGTGCTGAAAGCCAAAGCGGTATTGTGCCCTGGCGTTGAGATCACTTTTAAAGATGAGATCAACAATACCGAACAACGCTGGTGCTATCAGGACGGTCTGAATGATTACCTGGCGGAAGCGGTAAATGGTCTGCCGACGCTGCCGGAAAAACCGTTTATCGGTAATTTCGCTGGTGATACTGAAGCTGTGGACTGGGCGCTACTGTGGCTGCCGGAAGGCGGTGAACTGCTGACCGAAAGCTACGTCAACCTTATCCCAACGATGCAGGGCGGTACCCATGTTAATGGTCTGCGTCAGGGCCTGTTGGACGCGATGCGTGAGTTCTGTGAATACCGCAATATTCTGCCGCGCGGTGTAAAGCTGTCGGCGGAAGATATCTGGGATCGCTGCGCCTATGTGCTGTCAGTAAAAATGCAGGATCCGCAGTTTGCCGGGCAGACGAAAGAGCGTCTCTCTTCGCGTCAATGCGCGGCATTCGTTTCTGGCGTGGTGAAAGATGCCTTTATCCTGTGGCTGAACCAGAACGTTCAGGCGGCTGAACTGCTGGCGGAGATGGCGATTTCCAGCGCCCAGCGCCGTATGCGTGCGGCCAAAAAAGTGGTGCGTAAAAAGCTGACCAGCGGCCCGGCGTTGCCTGGCAAACTGGCTGATTGTACCGCGCAGGACCTTAACCGTACCGAGCTGTTCCTTGTGGAAGGTGACTCCGCAGGCGGATCTGCCAAGCAGGCGCGCGATCGCGAATATCAGGCGATCATGCCACTGAAAGGTAAGATCCTTAACACCTGGGAAGTCTCTTCCGACGAAGTGCTGGCTTCGCAGGAAGTGCACGATATTTCGGTAGCGATCGGTATCGATCCTGACAGCGACGATCTGAGCCAGCTTCGTTATGGCAAAATCTGTATCCTCGCGGATGCGGACTCTGATGGTCTGCACATTGCCACGCTGCTCTGCGCTTTGTTCGTAAAACATTTCCGCGCGTTGGTGAAACACGGTCACGTTTACGTCGCACTGCCACCGCTCTACCGTATTGATCTCGGGAAAGAGGTTTATTACGCGCTGACGGAAGAAGAGAAAGAGGGCGTACTTGAGCAATTAAAACGCAAGAAAGGCAAGCCGAACGTCCAGCGTTTTAAAGGTCTGGGGGAAATGAACCCGATGCAATTGCGCGAAACCACGCTTGATCCGAACACTCGCCGTCTGGTGCAGTTGACTATCGATGATGAAGACGATCAGCGTACTGACGCGATGATGGATATGCTGCTGGCGAAGAAACGCTCGGAAGATCGCCGCAACTGGTTGCAAGAGAAAGGCGACATGGCGGAGATTGAGGTTTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5394,Drugs,MEG_5394|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PAREF,gb|AP009048.1|-|3172159-3174052|ARO:3003316|Escherichia coli parE conferring resistance to fluoroquinolones [Escherichia coli str. K-12 substr. W3110] ,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagcccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5634,Drugs,MEG_5634|Drugs|betalactams|Class_C_betalactamases|PDC,1034011109|WP_064484003.1|NG_050794|1|1|blaPDC-138|blaPDC|class_C_beta-lactamase_PDC-138 NG_050794:1-1194,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgcatcgaacacgcttgtgaggccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtgacgttatttttgcgatctattggcgacaaagcaacgcgacttgaccgattggaacccggtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattcgctcatgcgctctgttctaccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccagtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcagctgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1506,Drugs,MEG_1506|Drugs|betalactams|Class_A_betalactamases|CARB,658971525|WP_029815111.1|NG_048738|1|1|blaCARB-34|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-34 NG_048738:1-852,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGGCATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATTGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1350,Drugs,MEG_1350|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_44_NZ_JWJJ01000015,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5670,Drugs,MEG_5670|Drugs|betalactams|Class_C_betalactamases|PDC,553783586|WP_023115067.1|NG_049897|1|1|blaPDC-24|blaPDC|class_C_beta-lactamase_PDC-24 NG_049897:1-1194,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6437,Drugs,MEG_6437|Drugs|betalactams|Class_A_betalactamases|SHV,gi|256862161|gb|GQ389703.1|1-861 gi|77702543|gb|DQ219472.1|1-861,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacatcttgccgacggcatgacggtcggcgaactctgtgtcgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcatcgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6229,Drugs,MEG_6229|Drugs|betalactams|Class_A_betalactamases|SHV,1509794560|WP_122630869.1|NG_062286|1|1|blaSHV-214|blaSHV|class_A_beta-lactamase_SHV-214 NG_062286:1-861,0
,ATGAATGTTGAATATTCTAAAATAAAGAAAGCAGTACCTATTTTATTATTCTTATTTGTATTCAGTTTGGTTATAGACAACTCATTCAAATTGATTTCTGTAGCCATTGCTGATGACTTAAACATTTCAGTAACGACAGTAAGTTGGCAAGCGACATTAGCCGGTTTAGTAATTGGTATTGGCGCTGTAGTATACGCTTCATTATCTGATGCCATTAGTATACGCACACTATTTATTTATGGCGTGATATTAATCATTATCGGATCAATTATTGGTTACATTTTCCAACATCAATTCGCATTACTTTTAGTTGGACGTATTATTCAAACTGCAGGTTTAGCTGCTGCAGAGACATTATATGTGATATATGTTGCAAAGTATCTTTCTAAAGAGGACCAGAAGACTTACCTTGGCTTAAGTACGAGCAGTTATTCCTTGTCATTAGTTATCGGTACATTATCAGGTGGATTTATTTCTACGTATTTACACTGGACAAATATGTTTTTAATTGCATTAATCGTAGTATTTACGTTGCCATTCCTATTTAAATTATTACCAAAAGAAAATAATACAAATAAAGCTCATTTAGATTTTGTTGGCTTAATTCTAGTGGCAACTATCGCTACAACAGTTATGCTGTTTATTACGAACTTTAATTGGATATATATGATTGGTGCCTTAATTGCGATTATCGTTTTTGCGCTATATATTAAAAATGCGAAACGTCCATTAGTAAACAAATCATTTTTCCAAAATAAACGTTATGCTTCATTTTTATTTATAGTATTTGTAATGTATGCCATCCAATTGGGTTATATTTTTACGTTCCCATTCATAATGGAACAAATTTATCATCTTCAGCTAGACACAACATCACTGCTATTAGTACCGGGTTATATTGTAGCAGTCATCGTTGGTGCACTAAGTGGTAAAATCGGCGAATATCTTAATTCAAAACAAGCGATTATCACAGCAATTATTTTAATCGCACTGAGCTTGATTTTACCTGCATTTGCAGTAGGTAATCACATTTCAATCTTCGTCATTTCTATGATATTCTTTGCAGGTAGCTTTGCTTTAATGTATGCACCTTTACTTAACGAAGCCATTAAAACAATAGATCTTAATATGACAGGTGTGGCTATTGGTTTTTATAATTTAATTATTAATGTGGCGGTATCTGTAGGTATTGCGATTGCTGCGGCTTTAATCGATTTTAAAGCATTAAATTTCCCAGGCAATGATGCATTAAGTTCACATTTCGGTATTATTTTAATTATTTTAGGTTTAATGAGTATTGTCGGATTAGTTTTATTCGTCATCTTAAATCGTTGGACACAATCTGAAAAATAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6986,Drugs,MEG_6986|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET38,gi|657154530|gb|CP007447.1|133410-134762 gi|554590848|gb|CP006838.1|160631-161983 gi|532126991|gb|CP002388.1|99787-101139 gi|329312723|gb|CP002643.1|127481-128833 gi|302749911|gb|CP002120.1|130541-131893 gi|269939526|emb|FN433596.1|162179-163531,4
,TAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATAAGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGGCAGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6907,Drugs,MEG_6907|Drugs|betalactams|Class_A_betalactamases|TEM,gi|3282027|emb|Y17583.1|1-1071,0
,atgactaaaaaagctcttttctttgccattggtacgatgtttttatcggcatgttcttttaatacggtagaacagcatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaatagaggaagtctatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttatttcccgattgggaaaaagacatgacattaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttaatcttatgtctaaagaggtaaaacgtattggtttcggtaatgctgatattggttcaaaagtagataatttttggcttgttggcccacttaaaattacaccacaacaagaagcgcagtttgcttacaaattagcccacaaaactcttccctttagcaaaaatatgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacggaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaaccacaaggagaaattatagctttctcacttaatttagaaatgaaaaaaggcatacctagctctattcgaaaagaaattgcttataagggattggaacaactcggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4555,Drugs,MEG_4555|Drugs|betalactams|Class_D_betalactamases|OXA,1509794615|WP_122630924.1|NG_062347|1|1|blaOXA-778|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-778 NG_062347:1-822,0
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattgcaatacaagtggagtttttataacttttgatggaaaacattatgcaagtaatgattttaaaagagctaaacaagccttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaggcttaaataaactttcttatggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcgcaaaattctttacctttttccaaaaaaagtcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattgctagaaaaatatctagcaatcataacaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4580,Drugs,MEG_4580|Drugs|betalactams|Class_D_betalactamases|OXA,928800934|WP_053872444.1|NG_057504|1|1|blaOXA-639|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-639 NG_057504:1-750,0
,ATGGTATACCTAGCCAAAGAAGTCTTACCAGTCAACATAGAAGACGAATTGAAGCAATCCTATTTGGATTATGCGATGAGTGTCATTGTAGGCCGAGCATTGCCTGATGTACGTGATGGTTTAAAACCGGTGCATAGGCGAGTTCTTTTTGCGATGAGCGAGTTGGGTAATGATTGGAATAAACCTTATAAAAAATCTGCTCGTGTAGTAGGGGATGTCATCGGTAAATACCATCCTCACGGGGATACAGCTGTTTATGACACTATTGTCCGTATGGCCCAACCTTTTTCCATGCGCTACCTTTTAATCGATGGACAGGGTAATTTTGGCTCTGTAGATGGAGATGCTCCAGCTGCTATGCGTTACACTGAAGTAAGAATGTCCAAAGTGGCACATGCTTTACTGGCTGACTTGGATAAGGAAACCGTTGATTTTAGTCCTAACTATGATGAAACAGAATTTGCTCCAGTGGTATTGCCATCGAGAATTCCCAATTTGCTAGTTAATGGCTCTTCCGGTATTGCGGTAGGGATGGCTACTAATATTCCACCACATAATCTTACTGAAGTAATCAATGCATGTATTGCCTTAGTGGATGAACCTGACACGAGTCTTGAAGATTTAATGGAAATTATTCCTGGCCCTGATTTTCCTACAGCAGCAATTATTAATGGTCGTGCTGGAATTATTGAAGGTTATCGTACTGGAAAAGGGCGGGTTGTTATCAGGGCACGCACAGAAATTGAAACGGATGAAAATTCAGGCCGTCAGTCAATTATTATTCAGGAATTACCTTATCAGGTGAATAAAGCGCGTTTGATCGAGCGTATCGCTGAATTGGTAAGGGACAAGAAAATCGAGGGAATTTCCGGCTTGAGGGATGAGTCAGACAAGCAGGGAATGAGAGTAGTCATTGAATTAAAACGCAATGAAGTAGCAGATGTGGTATTGAATAACCTGTTCGCTCATACTCAAATGCAAAATGTATTCGGGATTAATATGGTTGCCCTGGTAGATGGCCAACCGCGTACTTTGAATTTGAAGCAAATACTGGAATATTTTATAAAACATCGAAGAGAGGTTGTTACCAGGCGCACAATATTTGAGTTGAAAAAAGCCAGAAATCGAGCCCATTTATTGGAGGGCTTGGGAATCGCCTTAGCTAATATCGATGAAATGATCGCGTTAATTAAGCAATCTCCTACTCCTCAAGACGCAAAAAATGCTTTATTAAGCAAAATATGGCAACCTGGCTTGGTAAAGGCTATGTTGGAAAAGGCTGGCTCAAACGCGTCAAGGCCTGATGATTTAACTGAAGAGTATGGTTTGCATGAGAACGGATATAAATTATCTGAAGCACAGGCACAAGCAATACTTGAATTAAGATTACATAGGCTAACAGCTCTTGAACAAGATAAAATAATTAACGAATTTGAAGAGCTATTGAATTTAATTAAAGAATTGCTTGATATATTGGCTTCACCTGAAAGACTTATGCAAGTTATTCGTGATGAATTGATAGAGATTAAATCCCAATTTGGTGATGAGAGACGAACGGAAATAACAGCCTCACAAGAAGATTTGACTATTGAAGATTTGATTACCGAAGAAGACGTTGTGGTCACTTTATCTCATCAAGGTTATGTAAAATATCAGCCCATTACAGCCTATCAGGCTCAGCGCCGAGGTGGCAAAGGCAAATCAGCAACTCATGTCAAGGATGAGGATTTTGTTGAGCGTTTGGTTATTGCGAGTACTCATGACACCTTATTATGTTTCTCCAATCATGGCAAATTATATTGGCTAAAAGCGTATCAATTGCCTCAAGCAAGCCGCACTTCGAGAGGAAGGCCTATAATTAATATTCTTCCTTTGGCAGAAGGTGAAGAGATTAATGCTATGCTCCCTGTTCGTGAGTATAAAGACGGCAGCTATGTGTTTATGGCAACCAAGAAGGGAACAGTTAAAAAAGTACCTTTAAACGCATTTAGCAGGCCGCGTTCCAATGGTATTATTGCTGTGGACCTGGAAGAAGATGACAGTCTCGTTGGAGTCGATATTACTGATGGTGCTCGCGATATTATGTTGTTTACCGATGCAGGCAAAGTAATCCGCTTTGATGAAAGTAAAGTGCGACCTATGGGACGCACGGCTCGAGGAGTTCGCGGAATTAGGGTAGAAAAGGATCAAGCCGTTAAATCCCTTGTGGTAGTCGACCCAAGTGGAGGTACCATTTTGACGGCAACTGAAAACGGCTACGGCAAGAGAACTCATATTGATGAATACCGAGTGTCAGGAAGGGGGGGGCAAGGCGTTATTTCCATTCAGGTTACTGAACGAAATGGTAAAGTGGTCCGCTCCCTACAGGTTACAGATAATGACGAAGCCATGTTAATTACAGATAAAGGAACTTTGGTTCGTTTTAAAGTTAATGAATTATCTGTGATAGGCAGAAATACACAAGGAGTTCGCCTGATTAATGTCAGTTCTGGTGAGACAGTTGTTGGAATGCAAAAAATTGTAGATCTTGGAGAAGAGTTAGAAGAATCAGAAGATTCATCCCTTAATGCTGATGACAACAGTGATGAATAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3202,Drugs,MEG_3202|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|295647398|gb|CP001828.1|1627815-1630406 gi|225791049|gb|CP000675.2|1629288-1631879,3
,atgagcaagttatctgtattctttatatttttgttttgcagcattgctaccgcagcagagtctttgccagatttaaaaattgaaaagcttgatgaaggcgtttatgttcatacttcgtttgaagaagttaacgggtggggcgtttttcctaaacatggtttggtggttcttgtaaatgctgaggcttacctaattgacactccatttacggctaaagatactgaaaagttagtcacttggtttgtggagcgtggctataaaataaaaggcagcatttcctctcattttcatagcgacagcacgggcggaatagagtggcttaattctcgatctatccccacgtatgcatctgaattaacaaatgaactgcttaaaaaagacggtaaggttcaagccacaaattcatttagcggagttaactattggctagttaaaaataaaattgaagttttttatccaggcccgggacacactccagataacgtagtggtttggttgcctgaaaggaaaatattattcggtggttgttttattaaaccgtacggtttaggcaatttgggtgacgcaaatatagaagcttggccaaagtccgccaaattattaaagtccaaatatggtaaggcaaaactggttgttccaggtcacagtgaagttggagacgcatcactcttgaaacttacattagagcaggcggttaaagggttaaacgaaagtaaaaaaccatcaaaaccaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3335,Drugs,MEG_3335|Drugs|betalactams|Class_B_betalactamases|IMP,1440786794|WP_114699282.1|NG_061411|1|1|blaIMP-78|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-78 NG_061411:1-741,0
,ATGGACAGAAAAAGATTGACACAGCGTTTCCCGTTCCTGCTTCCAATGAGACGGGCGCAGAGAAAAATGTGCTTTTATGCGGGAATGAGATTTGACGGCTGTCGCTATGCGCAGACGATAGGGGAAAAATCGCTTTCCCATTTGCTCTTTGAAACGGATTGCGCATTATACAACCACAATACCGGATTTGACATGATATACCAGGAAAACAAGGTGTTCAACTTAAAGCTGGCAGCAAAGACCTTAAACGGCTTATTGATAAGACCGGGGGAAACCTTTTCTTTCTGGTGGCTGGTACGCCATGCGGCCTATAAAGACGGCCTTACGGTGACCAATGGTAAACTCACCACCATGTCGGGCGGCGGTATGTGCCAGATGAGCAATTTACTATTTTGGATGTTCCTGCATACGCCATTGACAATTATCCAGCGCAGAGGTCACGAAGTAAAGGAGTTTCCAGAGCCAAACAGTGACGAGATTAAAGGGGTGGATGCAACCATTTCAGAGGGCTGGATTGATTTAAAAGTGCGAAACGATACCGACTGCACCTACCAAATATGGGTGACCTTAGATGATGAGAAAATCATCGGTCAGGTGTCCGCCGACAAAGAGCCCCAAGCATTATACAAAATTACAAATGGCAGTATCCAGTATGTCCGTGAAAGTGGCGGGATTTATGAATATGCCCAGGTTAAACGGATGCAAGTTGCCTTAGGTACCGGGGAAATAATAGATTGCAAGCTGCTTTATACAAACAAATGCAAAATCTGTTATCCCCTCCCGGAAAGTGTGGATATTCAGGAGGAGAACCAATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7541,Drugs,MEG_7541|Drugs|Glycopeptides|VanB-type_accessory_protein|VANWB,gi|577698901|gb|KF823969.1|3335-4150,5
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2376,Drugs,MEG_2376|Drugs|betalactams|Class_A_betalactamases|CTX,gi|16304814|emb|AJ416341.1|557-1432 gi|971520884|gb|CP008697.1|325072-324199 gi|971520884|gb|CP008697.1|497623-496750 gi|937637793|gb|KT868530.1|64770-63897 gi|873464024|gb|KR259130.1|1551-2424 gi|940516921|dbj|LC091534.1|1244-2117 gi|926473678|gb|CP012627.1|2210-1337 gi|918462945|gb|KP987215.1|32694-31821 gi|808208566|gb|CP009233.1|70343-71216 gi|675439089|dbj|AB915400.1|4574-5447 gi|675439084|dbj|AB915399.1|2909-3782,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgccattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_771,Drugs,MEG_771|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,695269895|WP_032491964.1|NG_052487|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052487:101-892,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatcagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgttgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_569,Drugs,MEG_569|Drugs|betalactams|Class_C_betalactamases|ADC,1625655385|WP_136512062.1|NG_064718|1|1|blaADC-65|blaADC|class_C_beta-lactamase_ADC-65 NG_064718:1-1158,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatcgcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcatttggttataaccaagaaaatcagccgattcgagttaaccccggcccactcggtgcccctgcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaaccgtttcggaacatatgtagtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctggatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_584,Drugs,MEG_584|Drugs|betalactams|Class_C_betalactamases|ADC,1625655379|WP_136512056.1|NG_064710|1|1|blaADC-187|blaADC|class_C_beta-lactamase_ADC-187 NG_064710:1-1152,0
,ATGGAAAAATATACAATTAAATTTAACCAAATCAATCATAAGCTGACAGATTTTCGATCCCTTAATATTGAAAATCTTTATGCTTATCAATTTGAAAAAATAGCACTTATTGGAGGTAATGGTACTGGCAAAACCACATTACTGAATATGATTGCTCAAAAAACAAAACCAGAATCTGGAACGGTTGAAACGGATGGCGAAATTCAATATTTTGAACAGCTTAACATGGATGTGGAAAATGATTTTAACACGTTAGACGGTAGTTTAATGAGTGAACTCCATATACCTATGCATACAACCGACAGTATGAGTGGTGGTGAAAAAGCAAAATATAAATTAGCTAATGTCATATCAAATTATAGTCCGATATTACTTTTAGATGAACCTACAAATCACTTGGATAAAATTGGTAAAGATTATCTGAATAATATTTTAAAATATTACTATGGTACTTTAATTATAGTAAGTCATGATAGAGCACTTATAGACCAAATTGCTGACACAATTTGGGATATACAAGAAGATGGCACAATAAGAGTGTTTAAAGGTAATTACACACAGTATCAAAATCAATATGAACAAGAACAGTTAGAACAACAACGTCAATATGAACAGTATATAAGTGAAAAACAAAGATTGTCCCAAGCCAGTAAAGCTAAACGAAATCAAGCGCAACAAATGGCACAAGCATCATCAAAACAAAAAAATAAAAGTATAGCACCAGATCGTTTAAGTGCATCAAAACAAAAAGGCACGGTTGAGAAGGCTGCTCAAAAACAAGCTAAGCATATTGAAAAAAGAATGGAACATTTGGAAGAAGTTGAAAAACCACAAAGTTATCATGAATTCAATTTTCCACAAAATAAAATTTATGATATCCATAATAATTATCCAATCATTGCACAAAATCTAACATTGGTTAAAGGAAGTCAAAAACTGCTAACACAAGTACGATTCCAAATACCATATGGCAAAAATATAGCGCTCGTAGGTGCAAATGGTGTAGGTAAGACAACTTTACTTGAAGCTATTTATCACCAAATAGAGGGAATTGATTGTTCTCCTAAAGTGCAAATGGCATACTATCGTCAACTTGCTTATGAAGACATGCGTGACGTTTCATTATTGCAATATTTAATGGATGAAACGGATTCATCAGAATCATTCAGTAGAGCTATTTTAAATAACTTGGGTTTAAATGAAGCACTTGAGCGTTCTTGTAATGTTTTGAGTGGTGGGGAAAGAACGAAATTATCGTTAGCAGTATTATTTTCAACGAAAGCGAATATGTTAATTTTGGATGAACCAACTAATTTTTTAGATATTAAAACATTAGAAGCATTAGAAATGTTTATGAATAAATATCCTGGAATCATTTTGTTTACATCACACGATACAAGGTTTGTTAAACATGTATCAGATAAAAAATGGGAATTAACAGGACAATCTATTCATGATATAACTTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_4070,Drugs,MEG_4070|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|MSRA,gi|57207863|dbj|AB092817.1|5638-7104 gi|57157628|dbj|AB179623.1|23402-21936 gi|3892641|dbj|AB013298.1|487-1953,7
,atgcgttatattcgcctgagtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgataggaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagttgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6205,Drugs,MEG_6205|Drugs|betalactams|Class_A_betalactamases|SHV,1509794566|WP_122630875.1|NG_062293|1|1|blaSHV-221|blaSHV|class_A_beta-lactamase_SHV-221 NG_062293:1-861,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCCTCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAACTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGACCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAAAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAACCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGTTGGATTCAGGTCAACATGGATGCCAGCCGCGTTCAGGAGAAAATGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGTGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGCTGAGGTAAACCCGCCCGCCCCGGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1941,Drugs,MEG_1941|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KM087845|+|0-1146|ARO:3002130|CMY-119 [Citrobacter freundii] ,0
,GCCGCACTCACCCCCATGGAGTTTTGATGTTCAAACTTTTGAGTAAGTTATTGGTCTATTTGACCGCGTCTATCATGGCTATTGCGAGTCCGCTCGCTTTTTCCGTAGATTCTAGCGGTGAGTATCCGACAGTCAGCGAAATTCCGGTCGGGGAGGTCCGGCTTTACCAGATTGCCGATGGTGTTTGGTCGCATATCGCAACGCGGTCGTTTGATGGCGCAGTCTACCCGTCCAATGGTCTCATTGTCCGTGATGGTGATGAGTTGCTTTTGATTGATACAGCGTGGGGTGCGAAAAACACAGCGGCACTTCTCGCGGAGATTGAGAAGCAAATTGGACTTCCTGTAACGCGTGCAGTCTCCACGCACTTTCATGACGACCGCGTCGGCGGCGTTGATGTCCTTCGGGCGGCTGGGGTGGCAACGTACGCATCACCGTCGACACGCCGGCTAGCGAACGAGATTCCCACGCACTCTCTAGAAGGACTCTCATCGAGCGGGGACGCAGTGCGCTTCGGTCCAGTAGAACTCTTCTATCCTGGTGCTGCGCATTCGACCGACAACTTAGTTGTGTACGTCCCGTCTGCGAGTGTGCTCTATGGTGGTTGTGCGATTTATGAGTTGTCACGCACGTCTGCGGGGAACGTGGCCGATGCCGATCTGGCTGAATGGCCCACCTCCATTGAGCGGATTCAACAACACTACCCGGAAGCACAGTTCGTCATTCCGGGGCACGGCCTGCCGGGCGGTCTAGACTTGCTCAAGCACACAACGAATGTTGTAAAAGCGCACACAAATCGCTCAGTCGTTGAGTAGCAGGCAGATGCGGCATAACATGAAGTTGCAGCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_7762,Drugs,MEG_7762|Drugs|betalactams|Class_B_betalactamases|VIM,gi|157310266|emb|AM778091.1|1-848,0
,GTGAATACATCCTATTCACAATCGAATTTACGACACAACCAAATTTTAATTTGGCTTTGCATTTTATCTTTTTTTAGCGTATTAAATGAAATGGTTTTGAACGTCTCATTACCTGATATTGCAAATGATTTTAATAAACCACCTGCGAGTACAAACTGGGTGAACACAGCCTTTATGTTAACCTTTTCCATTGGAACAGCTGTATATGGAAAGCTATCTGATCAATTAGGCATCAAAAGGTTACTCCTATTTGGAATTATAATAAATTGTTTCGGGTCGTTAATTGGGTTTGTTGGCCATTCTTTCTTTTCCTTACTTATTATGGCTCGTTTTATTCAAGGGGCTGGTGCAGCTGCATTTCCAGCACTCGTAATGGTTGTAGTTGCGCGCTATATTCCAAAGGAAAATAGGGGTAAAGCATTTGGTCTTATTGGATCGATAGTAGCCATGGGAGAAGGAGTCGGTCCAGCGATTGGTGGAATGATAGCCCATTATATTCATTGGTCCTATCTTCTACTCATTCCTATGATAACAATTATCACTGTTCCGTTTCTTATGAAATTATTAAAGAAAGAAGTAAGGATAAAAGGTCATTTTGATATCAAAGGAATTATACTAATGTCTGTAGGCATTGTATTTTTTATGTTGTTTACAACATCATATAGCATTTCTTTTCTTATCGTTAGCGTGCTGTCATTCCTGATATTTGTAAAACATATCAGGAAAGTAACAGATCCTTTTGTTGATCCCGGATTAGGGAAAAATATACCTTTTATGATTGGAGTTCTTTGTGGGGGAATTATATTTGGAACAGTAGCAGGGTTTGTCTCTATGGTTCCTTATATGATGAAAGATGTTCACCAGCTAAGTACTGCCGAAATCGGAAGTGTAATTATTTTCCCTGGAACAATGAGTGTCATTATTTTCGGCTACATTGGTGGGATACTTGTTGATAGAAGAGGTCCTTTATACGTGTTAAACATCGGAGTTACATTTCTTTCTGTTAGCTTTTTAACTGCTTCCTTTCTTTTAGAAACAACATCATGGTTCATGACAATTATAATCGTATTTGTTTTAGGTGGGCTTTCGTTCACCAAAACAGTTATATCAACAATTGTTTCAAGTAGCTTGAAACAGCAGGAAGCTGGTGCTGGAATGAGTTTGCTTAACTTTACCAGCTTTTTATCAGAGGGAACAGGTATTGCAATTGTAGGTGGTTTATTATCCATACCCTTACTTGATCAAAGGTTGTTACCTATGGAAGTTGATCAGTCAACTTATCTGTATAGTAATTTGTTATTACTTTTTTCAGGAATCATTGTCATTAGTTGGCTGGTTACCTTGAATGTATATAAACATTCTCAAAGGGATTTCTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7097,Drugs,MEG_7097|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETL,gi|19743627|gb|AY081910.1|21-1397 gi|748448277|gb|KP036966.1|6930-8305 gi|251817111|emb|FM252032.1|1066305-1067680,4
,gtgagcgacctggagcagcggggcgaacgggtcctgctgcgctccaccgtccccgccgacacccccgtcctcgacgcgatcgtccgcgaaagcgaggtcgcccggtggtggccgccgcccgaggcgtacgccgccatgctcgccgtcgtcgtggaaggcgaggtgatcggcgcgatccagttcagcgaggagagcgacccggagttccgccacgccggcatcgacctcttcctgtcggcccggtggcacgggcagggcctgggccccgacgccgtacgcaccctggcccgctggctgatcgccgagcgcggccaccaccgcctggtcatcgacccggccgccgccaacacgcacgccatccgcagctaccgcaaggtcggcttcgccccggtcgggatcatgcgcgcctactggcgcaaccaccgcaccggcgcgtgggaggacggcctgctcatggacctgctggcggccgaactgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_249,Drugs,MEG_249|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,664161234|WP_030695745.1|NG_054655|1|1|aacA-STR-13|aacA-STR-13|aminoglycoside_6'-N-acetyltransferase NG_054655:101-583,2
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtcggcatgttcttttaataccgtacaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaatagaggaaatctatggcaatgatcttaaaagatcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcacaaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttatttcccgattgggaaaaagacatgacattaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattagtttcggtaatgctgatattggttcaacagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaaaaatatgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacgaaaaatttatgccaaaagtggttggggatgggatgttgacccacaagttggttggtttacaggctgggtagttcaaccacaaggagaaattgtagcgttctcacttaatttagaaatgaagaaaggcatacctagttctattcgaaaagaaattacttataaaggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4564,Drugs,MEG_4564|Drugs|betalactams|Class_D_betalactamases|OXA,503972570|WP_014206564.1|NG_057487|1|1|blaOXA-642|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-642 NG_057487:1-822,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgttaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaaagttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4398,Drugs,MEG_4398|Drugs|betalactams|Class_D_betalactamases|OXA,919306557|WP_052803794.1|NG_057521|1|1|blaOXA-601|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-601 NG_057521:1-762,0
,atgagtaacgcagtacccgccgagatttcggtacagctatcactggctctcaacgccatcgagcgtcatctggaatcaacgttgctggccgtgcatttgtacggctctgcactggacggtggcctgaagccatacagtgatattgatttgctggttactgtggctgcacggctcgatgagactgtccgacaagccctggtcgtagatctcttggaaatttctgcctcccctggccaaagtgaagctctccgcgccttggaagttaccatcgtcgtgcatggtgatgttgtcccttggcgttatccggccagacgggaactgcaattcggggagtggcagcgtaaggacattcttgcgggcatcttcgagcccgccacaaccgatgttgatctggctattctgctaactaaagtaaggcagcgtagccttgcattggcaggttcggccgcaggggatttctttaacccagttccggaaggcgatctattcaaggcattgagcgacactctgaaactatggaattcgcagccggattgggaaggcgatgagcggaatgtagtgcttaccttgtctcgcatttggtacagcgcagcaaccggcaagatcgcaccgaaggatatcgttgccaactgggcaatggagcgtctgccagatcaacataagcccgtactgcttgaagcccggcaggcttatcttggacaaggagaagattgcttggcctcacgcgcggatcagttggcggcgttcgttcacttcgtgaaacatgaagccactaaattgcttagtgccatgccagtgatgtctaacaattcattcaagccgacgccgcttcgcggcgcggcttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_819,Drugs,MEG_819|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1028081071|WP_063840454.1|NG_047361|1|1|aadA6|aadA6|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA6 NG_047361:91-936,2
,TTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACATGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6686,Drugs,MEG_6686|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-110:AY130283:1-785:785,0
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAGCCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCGGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTCGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAGTCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCAGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATTTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATATATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_2398,Drugs,MEG_2398|Drugs|betalactams|Class_A_betalactamases|CTX,gi|47087855|gb|AY571969.1|10-888 gi|11321257|gb|AF305837.1|AF305837|1-879 gi|116257450|gb|DQ821704.2|1784-2659 gi|695211887|ref|NG_036283.1|1705-2580 gi|31096325|gb|AY293073.1|1-876,0
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_865,Drugs,MEG_865|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502214|WP_071846364.1|NG_052490|1|1|aadA3|aadA3|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA3 NG_052490:101-892,2
,ATGAATAGAATAAAAGTTGCAATACTGTTTGGGGGTTGCTCAGAGGAGCATGACGTATCGTTAAAATCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGTGTATGGAAAATGTGCGAAAAACCTTGCGCGGAATGGGAAAACGACAATTGCTATTCAGCTGTACTCTCGCCGGATAAAAAAATGCACGGATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCATGGCAAGTCAGGTGAAGATGGATCCATACAAGGTCTGTTTGAATTGTCCGGTATCCCTTTTGTAGGCTGCGATATTCAAAGCTCAGCAATTTGTATGGACAAATCGTTGACATACATCGTTGCGAAAAATGCTGGGATAGCTACTCCCGCCTTTTGGGTTATTAATAAAGATGATAGGCCGGTGGCAGCTACGTTTACCTATCCTGTTTTTGTTAAGCCGGCGCGTTCAGGCTCATCCTTCGGTGTGAAAAAAGTCAATAGCGCGGACGAATTGGACTACGCAATTGAATCGGCAAGACAATATGACAGCAAAATCTTAATTGAGCAGGCTGTTTCGGGCTGTGAGGTCGGTTGTGCGGTATTGGGAAACAGTGCCGCGTTAGTTGTTGGCGAGGTGGACCAAATCAGGCTGCAGTACGGAATCTTTCGTATTCATCAGGAAGTCGAGCCGGAAAAAGGCTCTGAAAACGCAGTTATAACCGTTCCCGCAGACCTTTCAGCAGAGGAGCGAGGACGGATACAGGAAACGGCAAAAAAAATATATAAAGCGCTCGGCTGTAGAGGTCTAGCCCGTGTGGATATGTTTTTACAAGATAACGGCCGCATTGTACTGAACGAAGTCAATACTCTGCCCGGTTTCACGTCATACAGTCGTTATCCCCGTATGATGGCCGCTGCAGGTATTGCACTTCCCGAACTGATTGACCGCTTGATCGTATTAGCGTTAAAGGGGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7339,Drugs,MEG_7339|Drugs|Glycopeptides|VanA-type_resistance_protein|VANA,gi|227069718|gb|FJ866609.1|4723-5754,5
,ATGGTTAATAAACTTTCAGCATATAAAACTTATTTATTATTTTCAGCTATTGCAGCAATGTGTTTTTCGTTAGTAGCTACAGTTATGGTAGTGTATCACATTGAAATAGTTCATTTAAATCCACTTCAACTTATACTTGTTGGAACTACTTTGGAATTAGCATGCTTTATATTTGAAATTCCTACAGGTATAGTTGCAGATGTGTATAGTCGTAAACTATCTATTGTTATTGGGGGAGTTTTAACAGGAGTGGGATTTATTTTAGAAGGTTCTATTTCTAGTTTTGTTTTCGTACTTGTAGCACAGATTGTATGGGGATTAGGGTCTACTTTTATCAGTGGCTCGCTTGAAGCTTGGATTGCAGAAGAAGAGAAGAATAAAGATTTAGATGAAATTTATATAAAGGGAGCACAAGCAGGGCAGATAGGAGCATTTATTGGAATAGTACTAAGCACTGTAATAGCTAATTTCTCTGTAAGGCTTCCTATTATAGTTAGTGGAGTTTTATTTATAATTCTTGCATTATTTTTATGGTTATATATGCCAGAAAATAATTTTAAACCATCTGCTCCTGGGGATTTAAATACATTCAAAAAGATGGTATATACATTTAAATCTGGTCTTAAAATTGTAAAAAGTAAATCTATAATTATGATTTTACTTGCAGTAACTTTATTTTATGGATTATCAAGTGAAGGTTATGATAGACTTTCTAATGCACATTTTTTACAAGATACTACACTTCCTAAGCTTGGAAACCTTAGTTCAGTGACTTGGTTTGGAATTTTTGGAATTTTAGGAATGATATTGAGCTTCATAGTAATGCATTTTATGGCAAAGAATCTTAAGAATGAGGATAATAGGAAAAATGGAAAACTATTATTATGTATAAATATACTTTATATATCGTCTATGTTGATATTTGCTCTTACAAAAAACTTTAGTTTAATGTTAATAGCTTATTTGGCAACAAATACCTTTAGAATTATAAATGAACCTATATTCAGTGCGTGGTTAAATGGGCATATAGATGATAACTCTAGAGCTACTGTACTTTCTATAAATGGACAAATGAATTCCTTAGGTCAAATTTTAGGTGGACCAATTATAGGAATCATAGCTACAAATATTTCAGTAAGTATTGGTATAGCATGTACTTCGTTATTAGTAACACCGGTATTAGTGTTATATATTGTTGCTATGATAATTGATAAAAAGGTGGATGATAGAGTTGGAGGTATTGATTATGAAGAAAATAATTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7031,Drugs,MEG_7031|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,gi|932127861|gb|CP009558.1|11043-12305 gi|349590089|gb|JN689220.1|40052-41314 gi|1845539|dbj|AB001076.1|329-1591 gi|32815048|gb|AY304475.1|1-663,4
,atggcaatccgaatcttcgcgatacttttctccattttttctcttgccactttcgcgcatgcgcaagaaggcacgctagaacgttctgactggaggaagtttttcagcgaatttcaagccaaaggcacgatagttgtggcagacgaacgccaagcggatcgtgccatgttggtttttgatcctgtgcgatcgaagaaacgctactcgcctgcatcgacattcaagatacctcatacactttttgcacttgatgcaggcgctgttcgtgatgagttccagatttttcgatgggacggcgttaacaggggctttgcaggccacaatcaagaccaagatttgcgatcagcaatgcggaattctactgtttgggtgtatgagctatttgcaaaggaaattggtgatgacaaagctcggcgctatttgaagaaaatcgactatggctacgccgatccttcgacaagtaatggcgattactggatagaaggcagccttgcaatctcggcgcaggagcaaattgcatttctcaggaagctctatcgtaacgagctgccctttcgggtagaacatcagcgcttggtcaaggatctcatgattgtggaagccggtcgcaactggatactgcgtgcaaagacgggctgggaaggccgtatgggttggtgggtaggatgggttgagtggccgactggctccgtattcttcgcactgaatattgatacgccaaacagaatggatgatcttttcaagagggaggcaatcgtgcgggcaatccttcgctctattgaagcgttaccgcccaacccggcagtcaactcggacgctgcgcgataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4627,Drugs,MEG_4627|Drugs|betalactams|Class_D_betalactamases|OXA,1105502234|WP_071846384.1|NG_052519|1|1|blaOXA-541|blaOXA-2_like|OXA-2_family_class_D_beta-lactamase_OXA-541 NG_052519:101-928,0
,atggaaaaatacaacaattggaaacgaaaattttatgcaatatgggcagggcaagcagtatcattaatcactagtgccatcctgcaaatggcgattattttttaccttacagaaaaaacaggatctgcgatggtcttgtctatggcttcattagtaggttttttaccctatgcgattttgggacctgccattggtgtgctagtggatcgtcatgataggaagaagataatgattggtgccgatttaattatcgcagcagctggtgcagtgcttgctattgttgcattctgtatggagctacctgtctggatgattatgatagtattgtttatccgtagcattggaacagcttttcataccccagcactcaatgcggttacaccacttttagtaccagaagaacagctaacgaaatgcgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcagttgcagtactcttatactccgtttgggatttaaatgctattattgccatcgacgtattgggtgctgtgattgcatctattacggtagcaattgtacgtatacctaagctgggtaatcaagtgcaaagtttagaaccaaatttcataagagagatgaaagaaggagttgtggttctgagacaaaacaaaggattgtttgccttattactcttaggaacactatatactatgccaatcaatgcactatttcctttaataagcatggaacactttaatggaacgcctgtgcatatttctattacggaaatttcctttgcatttgggatgctagcaggaggcttattattaggaagattagggggcttcgaaaagcatgtattactaataacaagttcattttttataatggggaccagtttagccgtttcgggaatacttcctccaaatggatttgtaatatttgtagtttgctgtgcaataatggggctttcggtgccattttatagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttgaccggaagtatcatgtcacttgctatgccaattgggttaattctttctggattctttgctgataaaatcggtgtaaatcattggtttttactatcaggtattttaattattggcattgctatagtttgccaaatgataactgaggttagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3807,Drugs,MEG_3807|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028097008|WP_063853705.1|NG_047974|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047974:1-1209,7
,atgagggtagcggtgaccatcgaaatttcgaaccgactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaggtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagccgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_897,Drugs,MEG_897|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502187|WP_071846337.1|NG_052430|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052430:101-892,2
,atggacgtacgtcaacacaaggctagtttttttagcgtagtaattacttttttatgtctcacgctatcattaaatgctaatgcaacagactcagtacttgaagcggttaccaatgctgaaactgaattaggcgctagaattggtctagctgcgcatgatttggaaacgggaaaacgttgggaacataaatctaatgaacgttttcctctaagtagtacctttaaaacacttgcctgtgcaaacgttcttcaaagagttgatctaggtaaagaaagaattgatagagttgtgagattctctgaaagcaatctcgttacatactcacctgtaacagaaaaacatgtgggtaaaaaagggatgtcgctcgcagagctgtgtcaggccacattatcaaccagtgataattcagctgccaattttattctacaagcgattgggggacctaaggctctaacgaaatttttgcgttccattggcgacgatactacgcgccttgatcgctgggaaacagaacttaacgaagcggtgcctggagataagcgagacacgacaacaccaattgcaatggtaacgacacttgaaaagttactaattgacgaaacactatctatcaaatctcgtcaacaactagaatcttggcttaaaggtaatgaggttggcgatgcattgtttcgtaaaggcgttccaagtgactggatagtagcagatagaacaggcgctggtggttatgggtcgcgtgctattactgcggtgatgtggcctccaaatcgcaagcctatcgtagccgctctatacattacagagacagacgcctcgtttgaagaaagaaatgctgtcattgcaaaaattggtgagcaaatagcgaagacagtattaatggagaatagccgtaactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_6151,Drugs,MEG_6151|Drugs|betalactams|Class_A_betalactamases|RTG,1559612968|WP_128268233.1|NG_063836|1|1|blaCARB-50|blaRTG|RTG_family_carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-50 NG_063836:1-897,0
,AGGTTAAGTTAATAAGGGCGCACGGTGGATGCCTTGGCACTAGGAGCCGACGAAGGACGTGACAAACGACGATATACCTTGGGTAGCTGTAAGTAAGCGATGATCCAGGGATTTCCGAATGGGGGAACCCAACAGGTAATACCTGTTACCCACATCTGTTAAGGATGTGAGGAGGAAGACGCAGTGAACTGAAACATCTAAGTAGCTGCAGGAAGAGAAAGCAAAAGCGATTGCCTTAGTAGCGGCGAGCGAAACGGCAGAAGGGCAAACCGAAGAGTTTACTCTTCGGGGTTGTAGGACTGCAATGTGGACTCAAAGATTATAGAAGAATGATTTGGGAAGATCAGCCAAAGAGAGTAATAGCCTCGTATTTAAAATAGTCTTTGTACCTAGCAGTATCCTGAGTACGGCGGGACACGTGAAATCCCGTCGGAATCTGGGAGGACCATCTCCCAACCCTAAATACTCCCTAGTGACCGATAGTGAACCAGTACCGTGAGGGAAAGGTGAAAAGCACCCCGGGAGGGGAGTGAAATAGAACCTGAAACCGTGTGCCTACAACAAGTTCGAGCCCGTTAATGGGTGAGAGCGTGCCTTTTGTAGAATGAACCGGCGAGTTACGTTATGATGCGAGGTTAAGTTGAAGAGACGGAGCCGTAGGGAAACCGAGTCTGAACAGGGCGAATTAGTATCATGACGTAGACCCGAAACCATGTGACCTACCCATGAGCAGGTTGAAGGTGCGGTAAGACGCACTGGAGGACCGAACCAGGGCACGTTGAAAAGTGCTTGGATGACTTGTGGGTAGCGGAGAAATTCCAAACGAACTTGGAGATAGCTGGTTCTCTCCGAAATAGCTTTAGGGCTAGCGTCGACATTAGAGATTCTTGGAGGTAGAGCACTGTTTGGGTGAGGGGTCCATCCCGGATTACCAATCTCAGATAAACTCCGAATGCCAATGAATTATGGTCGGCAGTCAGACTGCGAGTGCTAAGATCCGTAGTCGAAAGGGAAACAGCCCAGACCACCAGCTAAGGTCCCAAAATAATTGTTAAGTGGAAAAGGATGTGGGGTTGCACAGACAACTAGGATGTTAGCTTAGAAGCAGCTATTCATTCAAAGAGTGCGTAATAGCTCACTAGTCGAGTGACCCTGCGCCGAAAATGTACCGGGGCTAAAACAATTTACCGAAGCTGTGGATACCTTTATAGGTATGGTAGGAGAGCGTTCTATGTGTGATGAAGGTATACCGTGAGGAGTGCTGGAACGCATAGAAGTGAGAATGCCGGTATGAGTAGCGAAAGACAGGTGAGAATCCTGTCCACCGTAAGACTAAGGTTTCCAGGGGAAGGCTCGTCCGCCCTGGGTTAGTCGGGACCTAAGGAGAGACCGAAAGGTGTATCCGATGGACAACAGGTTGATATTCCTGTACTAGAGTATGTAGTGATGGAGGGACGCAGTAGGCTAACTAAAGCAGACGATTGGAAGAGTCTGTCTAAGCAGTGAGGTGTGAATTGAGTCAAATGCTTAATTCTATAACATTGAGCTGTGATGGGGAGCGAAGTTTAGTAGCGAAGTTAGTGACGTCACACTGCCAAGAAAAGCTTCTAGCGTTTAAACATACTCTACCCGTACCGCAAACCGACACAGGTAGTCGAGGCGAGTAGCCTCAGGTGAGCGAGAGAACTCTCGTTAAGGAACTCGGCAAAATGACCCCGTAACTTCGGGAGAAGGGGTGCTGACTTTAGGTCAGCCGCAGTGAATAGGCCCAAGCAACTGTTTATCAAAAACACAGCTCTCTGCTAAATCGTAAGATGATGTATAGGGGGTGACGCCTGCCCGGTGCTGGAAGGTTAAGAGGAGTGCTTAGCGTAAGCGAAGGTATGAATTGAAGCCCCAGTAAACGGCGGCCGTAACTATAACGGTCCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCCGCACGAAAGGCGTAATGATTTGGGCACTGTCTCAACGAGAGACTCGGTGAAATTTTAGTACCTGTGAAGATGCAGGTTACCCGCGACAGGACGGAAAGACCCCATGGAGCTTTACTGCAGTTTGATATTGAGTGTCTGTACCACATGTACAGGATAGGTAGGAGTCTAAGAGATCGGGACGCCAGTTTCGAAGGAGACGCTGTTGGGATACTACCCTTGTGTTATGGCCACTCTAACCCAGATAGGTGATCCCTATCGGAGACAGTGTCTGACGGGCAGTTTGACTGGGGCGGTCGCCTCCTAAAAGGTAACGGAGGCGCCCAAAGGTTCCCTCAGAATGGTTGGAAATCATTCGCAGAGTATAAAGGTATAAGGGAGCTTGACTGCGAGAGCTACAACTCGAGCAGGGACGAAAGTCGGGCTTAGTGATCCGGTGGTTCCGTATGGAAGGGCCATCGCTCAACGGATAAAAGCTACCCTGGGGATAACAGGCTTATCTCCCCCAAGAGTTCACATCGACGGGGAGGTTTGGCACCTCGATGTCGGCTCGTCGCATCCTGGGGCTGTAGTCGGTCCCAAGGGTTGGGCTGTTCGCCCATTAAAGCGGCACGCGAGCTGGGTTCAGAACGTCGTGAGACAGTTCGGTCCCTATCCGTCGCGGGCGTAGGAAATTTGAGAGGATCTGCTCCTAGTACGAGAGGACCAGAGTGGACTTACCGCTGGTGTACCAGTTGTCTTGCCAAAGGCATCGCTGGGTAGCTATGTAGGGAAGGGATAAACGCTGAAAGCATCTAAGTGTGAAACCCACCTCAAGATGAGATTTCCCATGATTATATATCAGTAAGAGCCCTGAGAGATGATCAGGTAGATAGGTTAGAAGTGGAAGTGTGGCGACACATGTAGCGGACTAATACTAATAGCTCGAGGACTTATCCAAA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3992,Drugs,MEG_3992|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NZ_CP018138.1|-|1692408-1695312|ARO:3004170|Streptococcus pneumoniae 23S rRNA with mutation conferring resistance to macrolide antibiotics [Streptococcus pneumoniae] ,7
,atgaacattaaagcactcttccttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttgggtggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatctagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagagaagaatggaaacaaaatgtacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4495,Drugs,MEG_4495|Drugs|betalactams|Class_D_betalactamases|OXA,1028106558|WP_063861482.1|NG_049491|1|1|blaOXA-195|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-195 NG_049491:1-825,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtccccgcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5533,Drugs,MEG_5533|Drugs|betalactams|Class_C_betalactamases|PDC,749551020|WP_040184286.1|NG_051744|1|1|blaPDC-74|blaPDC|class_C_beta-lactamase_PDC-74 NG_051744:101-1294,0
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttgggcggtacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgcttccggaccgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcatggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaagaagaacctgcattctcaaacgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctgaggcaatggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaatgcccatgctgtgctcgtctaatattgttggcctgcacaagtactggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1611,Drugs,MEG_1611|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1105502225|WP_071846375.1|NG_052507|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_052507:101-733,6
,atgcaaaataaaaaaatagcagttatttttggaggcaattcaacagagtacgaggtgtcattgcaatcggcatccgctgtttttgaaaatatcaataccaataaatttgacataattccaataggaattacaagaagtggtgaatggtatcactatacgggagaaaaggagaaaatcctaaacaatacttggtttgaagatagcaaaaatctatgccctgttgtcgtttcccaaaatcgttccgttaaaggctttttagaaattgcttcagacaaataccgtattataaaagttgatttggtattccccgtattgcatggcaaaaacggcgaaaatgggactttgcagggcatatttgaattggcaggaatacctgttgttggctgcgatacactctcatcagctctttgtatggataaggacagggcacataaactcgttagccttgcgggtatatctgttcctaaatcggtaacattcaaacgctttaacgaagaagcagcgatgaaagagattgaagcgaatttaacttatccgctgtttattaaacctgttcgtgcaggctcttcctttggaataacaaaagtaattgaaaagcaagagcttgatgctgccatagagttggcatttgaacacgatacagaagtcatcgttgaagaaacaataaacggctttgaagtcggttgtgccgtacttggcatagatgagctcattgttggcagagttgatgaaatcgaactgtcaagcggcttttttgattatacagagaaatatacgcttaaatcttcaaagatatatatgcctgcaaggattgatgccgaagcagaaaaacggatacaagaagcggctgtaaccatatataaagctctgggctgttcgggtttttccagagtggatatgttttatacaccgtctggcgaaattgtatttaatgaggtaaacacaataccaggctttacctcgcacagtcgctatccaaatatgatgaaaggcattggtctatcgttctcccaaatgttggataagctgataggtctgtatgtggaatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7394,Drugs,MEG_7394|Drugs|Glycopeptides|VanG-type_resistance_protein|VANG,1028100560|WP_063856695.1|NG_048368|1|1|vanG|vanG|D-alanine--D-serine_ligase_VanG NG_048368:101-1150,5
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaaatatttaagtgggacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggtgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcctaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4685,Drugs,MEG_4685|Drugs|betalactams|Class_D_betalactamases|OXA,1509794589|WP_122630898.1|NG_062318|1|1|blaOXA-696|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-696 NG_062318:13-837,0
,atgtgttgcatggaactgcacggagagaaagtcgtccttcgtccggtggaggacagcgagacggagacgctcgaccgcatcgtcagggaacccgaggtcgctgcgtggtggtcgcccccgaacgactaccggaacaccttcgccgtcttcctcgacgacgagatcatcggcgccgtgcagttcaccgaggagagcgaccccgagtaccggcacgccgggatcgacgtcttcctcaccgcccgccgcaccggcgccggactcggcaccgacaccgtgcgcaccctcgcccgctggctcctcgacgaccgcgggcaccaccgcctcaccatcgaccccgcggcggagaacgcaccggcgatcgccagctaccggaaggtcgggttccagccggtcggcgtgctgcgcaggtactggcgcgaccaccagacgggcgagtggcgcgacgggctgctcatggacctgctcgccgacgaactcgcctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_210,Drugs,MEG_210|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,648636680|WP_026328431.1|NG_052533|1|1|aacA-STR-10|aacA-STR-10|aminoglycoside_6'-N-acetyltransferase NG_052533:101-583,2
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6432,Drugs,MEG_6432|Drugs|betalactams|Class_A_betalactamases|SHV,gi|2113862|emb|X98100.1|74-934,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgcagacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcagcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcacttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagttgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6213,Drugs,MEG_6213|Drugs|betalactams|Class_A_betalactamases|SHV,1468279796|WP_117241614.1|NG_062295|1|1|blaSHV-223|blaSHV|class_A_beta-lactamase_SHV-223 NG_062295:1-861,0
,AGCTACTAAGAGCGAATGGTGGATGCCTTGACTGGTAAAGGCGATGAAGGACGTACTAGACTGCGATAAGCTACGGGGAGCTGTCAAGAAGCTTTGATCCGTAGATTTCCGAATGGGGCAACCCAATGTATAGAGATATACATTACCTATATAGGAGCGAACGAGGGGAATTGAAACATCTTAGTACCCTCAGGAAAAGAAATCAATAGAGATTGCGTCAGTAGCGGCGAGCGAAAGCGCAAGAGGGCAAACCCAGTGCTTGCACTGGGGGTTGTAGGACTGCAATGTGCAAGAGCTGAGTTTAGCAGAACATTCTGGAAAGTATAGCCATAGAGGGTGATAGTCCCGTATGCGAAAAACAAAGCTTAGCTAGCAGTATCCTGAGTAGGGCGGGACACGAGGAATCCTGTCTGAATCCGGGTCGACCACGATCCAACCCTAAATACTAATACCAGATCGATAGTGCACAAGTACCGTGAGGGAAAGGTGAAAAGAACTGAGGTGATCAGAGTGAAATAGAACCTGAAACCATTTGCTTACAATCATTCAGAGCACTATGTAGCAATACAGTGTGATGGACTGCCTTTTGCATAATGAGCCTGCGAGTTGTGGTGTCTGGCAAGGTTAAGCAAACGCGAAGCCGTAGCGAAAGCGAGTCTGAATAGGGCGCTTAGTCAGATGCTGCAGACCCGAAACGAAGTGATCTATCCATGAGCAAGTTGAAGCTAGTGTAAGAACTAGTGGAGGACTGAACCCATAGGCGTTGAAAAGCCCCGGGATGACTTGTGGATAGGGGTGAAAGGCCAATCAAACTTCGTGATAGCTGGTTCTCTCCGAAATATATTTAGGTATAGCGTTGTGTCGTAATATAAGGGGGTAGAGCACTGAATGGGCTAGGGCATACACCAATGTACCAAACCCTATCAAACTCCGAATACCTTATATGTAATCACAGCAGTCAGGCGGCGAGTGATAAAATCCGTCGTCAAGAGGGAAACAACCCAGACTACCAGCTAAGGTCCCTAAATCTTACTTAAGTGGAAAACGATGTGAAGTTACTTAAACAACCAGGAGGTTGGCTTAGAAGCAGCCATCCTTTAAAGAAAGCGTAATAGCTCACTGGTCTAGTGATTTTGCGCGGAAAATATAACGGGGCTAAAGTAAGTACCGAAGCTGTAGACTTAGTTTACTAAGTGGTAGGAGAGCGTTCTATTTGCGTCGAAGGTATACCGGTAAGGAGTGCTGGAGCGAATAGAAGTGAGCATGCAGGCATGAGTAGCGATAATTAATGTGAGAATCATTAACGCCGTAAACCCAAGGTTTCCTACGCGATGCTCGTCATCGTAGGGTTAGTCGGGTCCTAAGTCGAGTCCGAAAGGGGTAGACGATGGCAAATTGGTTAATATTCCAATACCAACATTAGTGTGCGATGGAAGGACGCTTAGGGCTAAGGGGGCTAGCGGATGGAAGTGCTAGTCTAAGGTCGTAGGAGGTTATACAGGCAAATCCGTATAACAATACTCCGAGAACTGAAAGGCTTTTTGAAGTCTTCGGATGGATAGAAGAACCCCTGATGCCGTCGAGCCAAGAAAAGTTTCTAAGTTTAGCTAATGTTGCCCGTACCGTAAACCGACACAGGTGGGTGGGATGAGTATTCTAAGGCGCGTGGAAGAACTCTCTTTAAGGAACTCTGCAAAATAGCACCGTATCTTCGGTATAAGGTGTGGTTAGCTTTGTATTAGGATTTACTCTGAAAGCAAGGAAACTTACAACAAAGAGTCCCTCCCGACTGTTTACCAAAAACACAGCACTCTGCTAACTCGTAAGAGGATGTATAGGGTGTGACGCCTGCCCGGTGCTCGAAGGTTAATTGATGGGGTTAGCATTAGCGAAGCTCTTGATCGAAGCCCGAGTAAACGGCGGCCGTAACTATAACGGTCCTAAGGTAGCGAAATTCCTTGTCGGTTAAATACCGACCTGCATGAATGGCGTAACGAGATGGGAGCTGTCTCAAAGAGGGATCCAGTGAAATTGTAGTGGAGGTGAAAATTCCTCCTACCCGCGGCAAGACGGAAAGACCCCGTGGACCTTTACTACAGCTTGACACTGCTACTTGGATAAGAATGTGCAGGATAGGTGGGAGGCTTTGAGTATATGACGCCAGTTGTATATGAGCCATTGTTGAGATACCACTCTTTCTTATTTGGGTAGCTAACCAGCTTGAGTTATCCTCAAGTGGGACAATGTCTGGTGGGTAGTTTGACTGGGGCGGTCGCCTCCCAAATAATAACGGAGGCTTACAAAGGTTGGCTCAGAACGGTTGGAAATCGTTCGTAGAGTATAAAGGTATAAGCCAGCTTAACTGCAAGACATACAAGTCAAGCAGAGACGAAAGTCGGTCTTAGTGATCCGGTGGTTCTGTGTGGAAGGGCCATCGCTCAAAGGATAAAAGGTACCCCGGGGATAACAGGCTGATCTCCCCCAAGAGCTCACATCGACGGGGAGGTTTGGCACCTCGATGTCGGCTCATCGCATCCTGGGGCTGGAGCAGGTCCCAAGGGTATGGCTGTTCGCCATTTAAAGCGGTACGCGAGCTGGGTTCAGAACGTCGTGAGACAGTTCGGTCCCTATCTGCCGTGGGCGTAAGAAGATTGAAGAGATTTGACCCTAGTACGAGAGGACCGGGTTGAACAAACCACTGGTGTAGCTGTTGTTCTGCCAAGAGCATCGCAGCGTAGCTAAGTTTGGAAAGGATAAACGCTGAAAGCATCTAAGCGTGAAGCCAACTCTAAGATGAATCTTCTCTAAGCTCTCTAGAAGACTACTAGTTTGATAGGCTGGGTGTGTAATGGATGAAAGTCCTTTAGCTGACCAGTACTAATAGAGCGTTTGGCTTATCTTTAATAAAGCAT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3987,Drugs,MEG_3987|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NR_076226.1|+|0-2912|ARO:3004546|Campylobacter jejuni 23S rRNA with mutation conferring resistance to erythromycin [Campylobacter jejuni subsp. jejuni] ,7
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6695,Drugs,MEG_6695|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-29:AJ277416:1-861:861,0
,atgcgtcaatatcgattcgcccttctgccattgttagccgccctggcgctccccggttgggcgcatgaagccacggtgacgacggttaaacaagccgaaagccagctgcagggccgggtcggctacgccgaactggatttagcttccggccaactgctgtccggctatcgcgctggcgaacgcttcccgatgatgagcacctttaaagtgctgctctgcggcgcagtcttgtcgcgcgtcgataccggtgaagaacagctcgatcgccgtatccattaccggcagcaggatctggtggaatactcgccggtgacggagaagcatcttgccgatgggctcaccgtgggcgaactgtgcgcggccgccattaccctgagcgataatacggcggcaaacctgctgttgaccactctcggcggcccgcaggggctgaccacgttcctgcgccacagcggcgaccagacttcgcgactcgaccggtgggaaacggaactcaatgaagcgcggccgggcgatgtgcgtgatacgacgactccggaagcgatggccaggacactgcgaaatctgttgaccggccgcgtgctttcccccgcctcgcagcagcagttgcaacgctggatggtagaggacaaagttgcggggccgctgttgcgctctgcgctgccggcgggctggtttattgccgataagaccggagccggcaatcgcggctcgcgcggaatcatcgccgctctcggtccggacggtaaagccgcgcgcatcgtggtgatttatttaaccgcaaccccggcctcaatggatgagcgcaataaacagattgcggccatcggtgaaacgctggtcaggcactggtccaaagacgataaaagaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4373,Drugs,MEG_4373|Drugs|betalactams|Class_A_betalactamases|ORN,491000675|WP_004862397.1|NG_049386|1|1|blaORN-1|blaORN|class_A_broad-spectrum_beta-lactamase_ORN-1 NG_049386:101-976,0
,ATGAGGGAAGTGGTGATCGCCGAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCACACAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCCCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_964,Drugs,MEG_964|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|950648732|gb|KT959107.1|9026-9817 gi|950648725|gb|KT959106.1|9026-9817 gi|950648717|gb|KT959105.1|9026-9817 gi|950648709|gb|KT959104.1|9026-9817 gi|950648702|gb|KT959103.1|9026-9817 gi|409729032|gb|JX141473.1|107723-108514 gi|695226212|ref|NG_041455.1|8795-9586 gi|260677483|gb|GQ388247.1|11237-12028 gi|169147133|emb|CU459141.1|3656860-3656069 gi|145321079|gb|EF522838.1|4137-4928,2
,atgcgatttaaaaaaatttcttgtttacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcggtgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccgatttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_620,Drugs,MEG_620|Drugs|betalactams|Class_C_betalactamases|ADC,1625655376|WP_136512053.1|NG_064670|1|1|blaADC-110|blaADC|class_C_beta-lactamase_ADC-110 NG_064670:1-1152,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGTACTTTTAAAGTTCTGATATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6899,Drugs,MEG_6899|Drugs|betalactams|Class_A_betalactamases|TEM,gi|270311271|gb|GU188444.1|1-861,0
,ATGTTGAAAAGTTCGTGGCGTAAAACCGCCCTGATGGCCGCCGCCGCCGTTCCGCTGCTGCTGGCGAGCGGTTCATTATGGGCCAGTGCCGATGCTATCCAGCAAAAGCTGGCTGATTTAGAAAAACGTTCCGGCGGTCGGCTGGGCGTAGCGCTGATTAACACGGCAGATGATTCGCAAACCCTCTATCGCGGCGATGAACGTTTTGCCATGTGCAGCACCGGTAAAGTGATGGCCGCCGCCGCGGTGTTAAAACAGAGCGAAAGCAATCCAGAGGTGGTGAATAAAAGGCTGGAGATTAAAAAATCGGATTTAGTGGTCTGGAGCCCGATCACCGAAAAACATCTGCAAAGCGGAATGACCCTGGCGGAACTCAGCGCGGCGGCGCTGCAGTACAGCGACAATACCGCGATGAATAAGATGATTAGCTACCTTGGCGGACCGGAAAAGGTGACCGCATTCGCCCAGAGTATCGGGGATGTCACTTTTCGTCTCGATCGTACGGAGCCGGCGCTGAACAGCGCGATTCCCGGCGATAAGCGCGATACCACCACCCCGTTGGCGATGGCCGAAAGCCTGCGCAAGCTGACGCTGGGCAATGCGCTGGGCGAACAGCAGCGCGCCCAGTTAGTAACGTGGCTAAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCAGGCCTGCCCGCAAGCTGGGTGGTCGGGGATAAAACCGGCGGCGGAGATTACGGCACCACCAACGATATCGCGGTGATCTGGCCGGAAAATCATGCCCCGCTGGTGCTGGTGACCTATTTTACCCAGCCGCAGCAGGATGCGAAAAGCCGCAAAGAGGTGTTAGCCGCGGCGGCAAAAATCGTCACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5285,Drugs,MEG_5285|Drugs|betalactams|Class_A_betalactamases|OXY,(Bla)OXY1-5:AY077483:181-1056:876,0
,ATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCATGTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAA,chloramphenicol acetyltransferase (CAT),antibiotic inactivation,Phenicol,MEG_1584,Drugs,MEG_1584|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,gb|KF030445.1|+|23979-24639|ARO:3004459|Shigella flexneri chloramphenicol acetyltransferase [Escherichia phage 1720a-02] ,6
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6863,Drugs,MEG_6863|Drugs|betalactams|Class_A_betalactamases|TEM,AAB59737.1 J01749.1:4153-3293,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcaccgcgctgtggccctccagctcgcctgaagatcaccgcgcggaaatgcgcgagatactggcttcaccgcaccactccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgtcgagggcgcccgccgccagggctgggccgcgcgcttaatcgcacaggtgcaggagtgggcgaagcagcaggggtgcagcgagctggcgtcggataccgacatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggagctggtggtgttttaccgcaaaacgctggtctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_155,Drugs,MEG_155|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,851965761|WP_048234935.1|NG_052472|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052472:101-541,2
,atgatggaatatcaaaacaataatggaaactatgacaaaaggaatcgtagaaaagccaaaaaaagaaaattgcttttttacagggctgcatgtgtcacactttgtttgctcattgtttctgtaatctttggagttgtgcattttttaggggagagtaaagatcccggccttttatccaaagaaaacacaaaaacagacaagaactattcgtggcttaccgacgatcagaatgaggcagtaccctcagttccagagccagccatatccgaccaggctaacaaaatttcggtaaatatcgcggcagcaaacgccattgtaatgaataaagacacaaatgaggtattgtaccagaaaaaaagcacagccaaaattgcgccggccagcactgctaagatgattatggctttgacagcacttgactattgttccccggaggatgaaatgaaagtaggtgcggagattgaaatgattcaaagcgattcgtcaaccgcatggcttatgaagggtgatacactgactgtcagacagctcctgattgcccttatgcttccatccggtaatgatgcggcctatacccttgcagtcaatactggaaagaagattgcaggagataaaagcctgacccatcagcaagcgattgaagtattcatggataaggtaaatgaaaaagccgtgaaccttggcgccacaaactcgaaatttgtagctccggatggatatgatgccgaaggccagtatactacagcttacgaccttgctatcattgcaaaagcatgtttggacaatcctatcatttcggagattgtagcgagttattcatcctatgaaaaatggccaaacggaagagaggtcacttacagcaattccaatgagcttctcgatccgaacagtccctattaccgtccggaggttatcggtttgaaaacaggaaccagcagccttggcggcgcatgtattgtttctgcagcggtgattgacggagaaacctatatctgtgtagttatgggctctacaaaggaaagcaggtttcaggacagtgttgatattttagataaaatcaaagcccagtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7600,Drugs,MEG_7600|Drugs|Glycopeptides|VanD-type_accessory_protein|VANYD,909655056|WP_049898469.1|NG_048524|1|1|vanY-D|vanY-D|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D NG_048524:101-1171,5
,ATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGTCTGCTAATCCAAATCACAGTGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCGCTACAGAAGTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGAACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAATGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGTTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5275,Drugs,MEG_5275|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-410_1_KJ584919,0
,atgatgacccagagcattcgccgcagcatgctgaccgtgatggcgaccctgccgctgctgtttagcagcgcgaccctgcatgcgcaggcgaacagcgtgcagcagcagctggaagcgctggaaaaaagcagcggcggccgcctgggcgtggcgctgattaacaccgcggataacagccagattctgtatcgcgcggatgaacgctttgcgatgtgcagcaccagcaaagtgatggcggcggcggcggtgctgaaacagagcgaaagcgataaacatctgctgaaccagcgcgtggaaattaaaaaaagcgatctggtgaactataacccgattgcggaaaaacatgtgaacggcaccatgaccctggcggaactgggcgcggcggcgctgcagtatagcgataacaccgcgatgaacaaactgattgcgcatctgggcggcccggataaagtgaccgcgtttgcgcgcagcctgggcgatgaaacctttcgcctggatcgcaccgaaaccaccctgaacaccgcgattccgggcgatccgcgcgataccaccaccccgctggcgatggcgcagaccctgaaaaacctgaccctgggcaaagcgctggcggaaacccagcgcgcgcagctggtgacctggctgaaaggcaacaccaccggcagcgcgagcattcgcgcgggcctgccgaaaagctgggtggtgggcgataaaaccggcagcggcgattatggcaccaccaacgatattgcggtgatttggccggaaaaccatgcgccgctggtgctggtgacctattttacccagccggaacagaaagcggaaagccgccgcgatattctggcggcggcggcgaaaattgtgacccatggcttttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2145,Drugs,MEG_2145|Drugs|betalactams|Class_A_betalactamases|CTX,1028104887|WP_063860073.1|NG_049026|1|1|blaCTX-M-74|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-74 NG_049026:1-876,0
,atgcgcgataccagatttccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggctctgggcgcaggcgcttgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5701,Drugs,MEG_5701|Drugs|betalactams|Class_C_betalactamases|PDC,553783192|WP_023114693.1|NG_049885|1|1|blaPDC-15|blaPDC|class_C_beta-lactamase_PDC-15 NG_049885:1-1194,0
,atgcgatttaacaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaacctttattagataaatatgatgtgccgggtatggccgtgggcgttattcagaataataaaaaatatgaaacgtattatggtcttcaatctgttcaagataaaaaagccgtaagtagcagtaccatttttgaactaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcaacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaagttgttgctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccgggccttggcttaaaacatagctatgtaaatgtaccgaagaaccagatgcaaaactatgcttttggctataatcaagaaaatcagccaattcgtgttaaccctggtccgctagatgctccagcatacggcgtcaaatcgacactacccgatatgcttaagtttattaatgccaacctaaatccacaaaaatatccagcagatattcaacgtgcaattaatgaaacacatcaaggtttctatcaagtcggcatcatgtatcaagcattaggttgggaagaattttcttatccagcgcctttacaaactttattagacagtaattcagaacaaattgtgatgaagcctaataaagtgactgccatttcaaaagaaccttcagttaagatgttccacaaaactggttcaaccaatggtttcggaacttatgtcgtgttcattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgccgtgttaaatggaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_628,Drugs,MEG_628|Drugs|betalactams|Class_C_betalactamases|ADC,491209743|WP_005068074.1|NG_064688|1|1|blaADC-132|blaADC|class_C_beta-lactamase_ADC-132 NG_064688:101-1252,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatttattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgtctggtaaatattggaaagtgctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaatccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttaagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_597,Drugs,MEG_597|Drugs|betalactams|Class_C_betalactamases|ADC,1315549098|WP_101244938.1|NG_056110|1|1|blaADC-168|blaADC|class_C_beta-lactamase_ADC-168 NG_056110:1-1152,0
,GTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGTTGGTTACTGTGGCCGTAAAGCTTGATGAAACGACGCGGCGAGCATTGCTCAATGACCTTATGGAGGCTTCGGCTTTCCCTGGCGAGAGCGAGACGCTCCGCGCTATAGAAGTCACCCTTGTCGTGCATGACGACATCATCCCGTGGCGTTATCCGGCTAAGCGCGAGCTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCATGATCGACATTGATCTAGCTATCCTGCTTACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCGGCAGCGGAGGAATTCTTTGACCCGGTTCCTGAACAGGATCTATTCGAGGCGCTGAGGGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCCGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAATAACCGGCAAAATCGCGCCGAAGGGTGTCGCTGCCGACTGGGCAATAAAACGCCTACCTGCCCAGTATCAGCCCGTCTTACTTGAAGCTAAGCAAGCTTATCTGGGACAAAAAGAAGATCACTTGGCCTCACGCGCAGATCACTTGGAAGAATTTATTCGCTTTGTGAAAGGCGAGATCATCAAGTCAGTTGGTAAATGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_974,Drugs,MEG_974|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,aadA2b_1_D43625,2
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGCGTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6624,Drugs,MEG_6624|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|16605601|emb|AJ289135.1|3990-4805,8
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcacggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5599,Drugs,MEG_5599|Drugs|betalactams|Class_C_betalactamases|PDC,896289153|WP_049272244.1|NG_051496|1|1|blaPDC-172|blaPDC|class_C_beta-lactamase_PDC-172 NG_051496:1-1194,0
,atgatcgtcatctgcgaccacggcaacctcgacgcctggctggcgctgcgcaccgcgctgtggccgtccggctcgcctgaagagcaccgcgcggaaatgcgcgagatactggcttcgccgcaccataccgcgtttatggcgcgggggctggacggcactttcgttgcctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccaccgaacgcgcccgccgccagggctgggccgcgcgcctgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggagcgagtagtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_169,Drugs,MEG_169|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,746536919|WP_039569351.1|NG_052427|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052427:101-541,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagagcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5502,Drugs,MEG_5502|Drugs|betalactams|Class_C_betalactamases|PDC,1201190437|WP_087587957.1|NG_054973|1|1|blaPDC-187|blaPDC|class_C_beta-lactamase_PDC-187 NG_054973:1-1194,0
,atgaatattaaaactatcttattggtaacaagcactcttcttatttctgcctgctcaccttatatagtgacagcaaatccaaataatagtgctttaaaagcagatgaaaaagcgcagaaaattaaagacatctttgaagaagcacatacaactggtgttttagttattcaacaaggtcaaacacaacaaagctatggtaacgatcttactcgagcttcaacagagtatgtaccggcttcaacatttaaaatgcttaatgctttaatcggccttgagcaccataaggtaaccacaacagaaatattcaaatgggataaaaaaaagcgactctttcctgaatgggaaagggatatgacgctaggcgatgctatgaaggcttctgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctgctgaggtaaaacgagtaaattatggtaatactaatattggcacccaagtcgataatttttggcttgtcggccctttaaagattacgcctcaacaagaagcacaatttgcctataggttagctaacaaaacccttccatttagtcaaaatgtacaagaacaagttcaatccatgcttttcatagaagaaaaaaatggaaataaaatatacgcaaaaagtggttggggatgggatatagacccacaggtgggttggttaactggctgggtggtccaacctaaagggaatattgtagcgttctcgctcaatttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttacaaaagcttagaaaaattaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4527,Drugs,MEG_4527|Drugs|betalactams|Class_D_betalactamases|OXA,1058244086|WP_068981642.1|NG_051477|1|1|blaOXA-527|blaOXA|class_D_beta-lactamase_OXA-527 NG_051477:1-825,0
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgattgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataagacaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4509,Drugs,MEG_4509|Drugs|betalactams|Class_D_betalactamases|OXA,1509794580|WP_122630889.1|NG_062309|1|1|blaOXA-687|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-687 NG_062309:14-838,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTCCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6595,Drugs,MEG_6595|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|45332239|gb|AY524415.2|9740-10579,8
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctggccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacatcttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagtatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6203,Drugs,MEG_6203|Drugs|betalactams|Class_A_betalactamases|SHV,1028110274|WP_063864644.1|NG_050033|1|1|blaSHV-158|blaSHV|class_A_beta-lactamase_SHV-158 NG_050033:1-861,0
,ATGTCGAATTCTTATGACTCCTCCAGTATCAAAGTCCTGAAAGGGCTGGATGCGGTGCGTAAGCGCCCGGGTATGTATATCGGCGACACGGATGACGGCACCGGTCTGCACCACATGGTATTCGAGGTGGTAGATAACGCTATCGACGAAGCGCTCGCAGGTCACTGTAAAGATATCGTCGTGACTATTCACGCCGATAACTCCGTGTCCGTAACGGATGATGGCCGTGGCATTCCGACCGGGATTCACCCGGAAGAAGGCGTCTCGGCGGCGGAAGTGATCATGACCGTTCTGCACGCGGGCGGTAAATTTGACGATAACTCCTATAAAGTCTCCGGCGGTCTGCACGGCGTGGGCGTCTCGGTAGTCAACGCTCTGTCGCAAAAACTGGAACTGGTTATCCAGCGAGATGGCAAAATTCACCGTCAGATCTACGAGCACGGCGTGCCGCAGGCACCCCTGGCCGTCACTGGCGATACCGATAAAACCGGCACGATGGTACGTTTCTGGCCGAGCCACGAAACCTTCACCAACGTCACTGAATTTGAATATGAGATCCTGGCGAAACGCCTGCGTGAACTGTCATTCCTGAACTCAGGCGTCTCCATCCGCCTGCGCGACAAGCGCGATGGCAAAGAAGATCATTTCCACTACGAAGGCGGCATCAAGGCGTTTGTTGAATATCTGAACAAGAATAAAACGCCGATCCACCCGAATATCTTCTATTTCTCCACCGAAAAAGACGGTATCGGCGTGGAAGTAGCGCTGCAGTGGAACGATGGTTTCCAGGAAAACATCTACTGCTTTACCAACAACATTCCGCAGCGCGACGGCGGTACTCACCTTGCAGGCTTCCGTGCGGCGATGACCCGTACGCTGAACGCCTACATGGACAAAGAAGGCTACAGCAAAAAAGCCAAAGTCAGCGCCACCGGCGACGATGCCCGTGAAGGTCTGATTGCGGTGGTTTCCGTAAAAGTACCGGATCCGAAATTCTCCTCACAGACCAAAGATAAGCTGGTCTCTTCCGAGGTGAAATCGGCGGTAGAACAGCAGATGAACGAACTGCTGAGCGAATACCTGCTGGAAAACCCATCTGACGCGAAAATCGTCGTCGGCAAAATTATCGACGCCGCGCGTGCGCGTGAAGCGGCGCGTCGCGCCCGTGAAATGACCCGTCGTAAAGGCGCGCTCGATTTAGCCGGTCTGCCGGGCAAACTGGCGGACTGTCAGGAACGCGACCCGGCGCTGTCCGAACTGTACCTGGTGGAAGGGGACTCCGCGGGCGGCTCTGCGAAGCAGGGGCGTAACCGCAAGAACCAGGCGATTCTGCCGCTGAAAGGTAAAATCCTTAACGTCGAGAAAGCGCGCTTCGACAAGATGCTTTCCTCCCAGGAAGTGGCGACGCTGATCACCGCGCTGGGCTGCGGTATCGGTCGCGACGAGTACAACCCGGACAAGCTGCGCTATCACAGCATCATCATCATGACCGATGCGGACGTCGACGGCTCGCACATCCGTACGCTGCTGTTGACCTTCTTCTATCGTCAGATGCCGGAAATTGTCGAGCGTGGCCACGTCTACATTGCGCAGCCGCCGCTGTACAAAGTGAAGAAAGGTAAGCAGGAACAGTACATTAAAGACGACGAAGCGATGGATCAGTACCAGATTTCCATCGCGCTTGACGGTGCGACTCTGCACGCGAACGCTCATGCGCCGGCGCTATCCGGCGAAGCGTTAGAAAAACTGGTCTCTGAATATAACGCCACGCAGAAAATGATTGGTCGTATGGAGCGTCGCTTCCCGAAAGCGCTGCTCAAAGAGCTGGTGTATCAGCCAACTCTGACCGAAGCCGATCTTTCTGATGAGCAGACTGTAACGCGCTGGGTGAATGCGCTGATTACCGAGCTGAACGAGAAAGAGCAGCACGGCAGTCAGTGGAAGTTCGATGTTCATACTAATACGGAACAGAATCTGTTCGAGCCGATCGTTCGCGTGCGTACGCATGGCGTGGATACCGATTATCCGTTGGATCACGAGTTTGTGACCGGCGCGGAATATCGTCGTATCTGCACGCTGGGCGAGAAGCTGCGTGGTCTGATTGAAGAGGACGCGTTTATCGAACGCGGCGAGCGTCGCCAGCCGGTAACCAGCTTCGAGCAGGCGCTGGAGTGGCTGGTGAAAGAATCACGTCGCGGTCTGGCTATCCAGCGTTATAAAGGTCTGGGTGAAATGAACCCGGATCAGCTGTGGGAAACCACCATGGACCCGGAAAGCCGCCGTATGCTGCGCGTGACCGTCAAAGATGCAATTGCTGCCGACCAGCTGTTCACTACGCTGATGGGTGATGCCGTTGAGCCGCGTCGTGCCTTTATCGAGGAGAACGCCCTGAAAGCAGCGAATATCGATATTTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3238,Drugs,MEG_3238|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRB,gb|AE006468.2|-|4038867-4041282|ARO:3003307|Salmonella serovars gyrB conferring resistance to fluoroquinolone [Salmonella enterica subsp. enterica serovar Typhimurium str. LT2] ,3
,atgatgaaaaaatctctttgctgcgccctgctgctcggcatctcttgctctgctctcgccgcgccagtgtcagaaaaacagctggcggaggtggtcgcgaatacgattaccccgctgatgaaagcccagtcgattccaggcatggcggtggccgttatttatcagggtaaaccgcactattacacgtttggcaaagccgatatcgcggccagcaaacccgttacgcctcagactctgttcgagctgggttctataagtaaaaccttcaccggggttttaggaggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctaacgggcaagcagtggcaggggattcgtatgctggatctcgcaacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataatgccgccctgctgcacttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagtatcggtctttttggcgcgctggcggtcaaaccttccggcatgggctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggaatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaaggttgctgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtgatcgagggcagcgacagtaaggtggcgctggcaccgcttcccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggctctactggcgggtttggcagttacgtggcctttattcctgaaaagcagttcggtattgtgatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgacgcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_435,Drugs,MEG_435|Drugs|betalactams|Class_C_betalactamases|ACT,695666453|WP_032625176.1|NG_064666|1|1|blaACT-66|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-66 NG_064666:1-1146,0
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaggcagtatcattaatcactagtgccatcctgcaaatggcgattattttttaccttacagaaaaaacaggatctgcgatggtcttgtctatggcttcactagtaggttttttaccctatgcggtctttggaccagccattggtgtattagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctggggcagtgcttgctattgttgcattgtatatggagttacctatctggatggttatggtagtattgtttatccgtagcattggaacagcttttcataccccggctctcaatgcggttacgccacttttagtaccagaagagcagcttacgaaatgtgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcggttgcagcattgttatattctgtttgggaattaaatgctattattgccatcgatgtattgggtgctatgattgcgtctattacggtagcaattgtacgtattcctaagctaggcgatcaagtgcaaagcttgaaaccaaatttcataagagaaatgaaagaaggaatggctgtactacggcaaaataaaggattatttgctttattactcgttggaacattatatatgtttgtttatatgcccataaatgcattatatcctttaatcactatggaatattttaatggtacaccgatgcatatttctattacggagattgcttatgcctctggtatgttgatagggggtctattattagggttatttgggaattaccaaaagcgaatcttattaataacggcatcaatttttatgatggggataagcttaaccatttcaggattacttcctcaaagtggatttttcatatttgtagtctgctgtgcaataatggggctttcggtgccattctatagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttgaccggaagtatcatgtcacttgctatgccaattgggttaattctttctggattcattgctgatagaatcggtgtaaatcattggtttttactatcaggtattttaattatttgtattgcaatagtttgcccaatgataactgagattagaaaattagatttaaaacaaaattcatag,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3817,Drugs,MEG_3817|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,501051336|WP_012102963.1|NG_047970|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047970:101-1327,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcaccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacgacatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacctacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5626,Drugs,MEG_5626|Drugs|betalactams|Class_C_betalactamases|PDC,1035157534|WP_064511499.1|NG_050821|1|1|blaPDC-148|blaPDC|class_C_beta-lactamase_PDC-148 NG_050821:1-1194,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCAAATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTACAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTATTCCAAAAGACTATAAAGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1375,Drugs,MEG_1375|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_116_NC_013348,0
,atgttcaagcatctgattttattagcgtctataaccgcgccgctaacccaggccgttgcggcggacccgctctccgtcgccgccgacaagctggccaaactggaacgcgactttggcggcagcatcggcgtctacgccatcgacaccggctccggcgccaccgtggccaaccgtcccaacgaacgttttcccctgtgcagctctttcaaaggctttctggcggcgggagtgctggcgcaaagccaagacaaacccggcctgctggacaaacgcatccgctacagcaagacggctctgcctaattggtccccgattaccaccaaacaccaggcaagcggcatgaccgtggccgagctcaacgccgcctccgtgcaatacagcgacaacggcgcggccaatctgctgctcaaggaaatcaacggccccgccgcgctgaccgccttcatgcgctccatcggcgacgcccgcttccgcctggatcgtctggagccggaactgaactccgccatccccggcgacccgcgcgacacctccacgcccaaagcggtggcggaaagcgcacaaaaactggcgctgggcaaggcgctgccggaaccgcaacgccaacggctggcggactggctgaagggcaacaccaccggcaacgccagaatccgcgccgcggtgccggccggctgggaagtgggggacaaaaccggcacttgcggcgtctacggcaccgccaacgacttcgcggtgatctggccgcccaagcgcgcgcccatcgtgctggcggtctacaccaagcacgccaagaaagaagccaagcacagcgacgaagtgatcgccgccgccgcgcgggcggcgctggaagcctttaacgtgaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2129,Drugs,MEG_2129|Drugs|betalactams|Class_A_betalactamases|CRH,1391852866|WP_109545051.1|NG_057457|1|1|blaCRH-3|blaCRH|carbapenem-hydrolyzing_class_A_beta-lactamase_CRH-3 NG_057457:1-873,0
,atgaacgagaaaaatataaaacacagtcaaaactttattacttcaaaacataatatagataaaataatgacaaatataagattaaatgaacatgataatatctttgaaatcggctcaggaaaagggcattttacccttgaattagtacagaggtgtaatttcgtaactgccattgaaatagaccataaattatgcaaaactacagaaaataaacttgttgatcacgataatttccaagttttaaacaaggatatattgcagtttaaatttcctaaaaaccaatcctataaaatatttggtaatataccttataacataagtacggatataatacgcaaaattgtttttgatagtatagctgatgagatttatttaatcgtggaatacgggtttgctaaaagattattaaatacaaaacgctcattggcattatttttaatggcagaagttgatatttctatattaagtatggttccaagagaatattttcatcctaaacctagagtgaatagctcacttatcagattaaatagaaaaaaatcaagaatatcacacaaagataaacagaagtataattatttcgttatgaaatgggttaacaaagaatacaagaaaatatttacaaaaaatcaatttaacaattccttaaaacatgcaggaattgacgatttaaacaatattagctttgaacaattcttatctcttttcaatagctataaattatttaataagtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2815,Drugs,MEG_2815|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,1028086394|WP_063844768.1|NG_047808|1|1|erm(C)|erm(C)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(C) NG_047808:101-835,7
,ATGAACAAAAATATAAAATATTCTCAAAACTTTTTAACGAGTGAAAAAGTACTCAACCAAATAATAAAACAATTGAATTTAAAAGAAACCGATACCGTTTACGAAATTGGAACAGGTAAAGGGCATTTAACGACGAAACTGGCTAAAATAAGTAAACAGGTAACGTCTATTGAATTAGACAGTCATCTATTCAACTTATCGTCAGAAAAATTAAAACTGAATACTCGTGTCACTTTAATTCACCAAGATATTCTACAGTTTCAATTCCCTAACAAACAGAGGTATAAAATTGTTGGGAATATTCCTTACCATTTAAGCACACAAATTATTAAAAAAGTGGTTTTTGAAAGCCGTGCGTCTGACATCTATCTGATTGTTGAAGAAGGATTCTACAAGCGTACCTTGGATATTCACCGAACACTAGGGTTGCTCTTGCACACTCAAGTCTCGATTCAGCAATTGCTTAAGCTGCCAGCGGAATGCTTTCATCCTAAACCAAAAGTAAACAGTGTCTTAATAAAACTTACCCGCCATACCACAGATGTTCCAGATAAATATTGGAAGCTATATACGTACTTTGTTTCAAAATGGGTCAATCGAGAATATCGTCAACTGTTTACTAAAAATCAGTTTCATCAAGCAATGAAACACGCCAAAGTAAACAATTTAAGTACCATTACTTATGAGCAAGTATTGTCTATTTTTAATAGTTATCTATTATTTAACGGGAGGAAACAACTCCCTATATTTTAG,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2806,Drugs,MEG_2806|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,erm(B)_26_AF080450 ,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagttatgggctggcgtcgaaagaggacggtcgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcaaggcagccgcttcgacggcatcagcctgctcgacctcgcgacctacaccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgagcggatcatggagcagcgcctgttcccggccctgggcctcgaacagactcacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctccgggtcggccccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgactggaccggcagtgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatcgccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacagggtcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctggcgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5555,Drugs,MEG_5555|Drugs|betalactams|Class_C_betalactamases|PDC,1040476868|WP_065102311.1|NG_050947|1|1|blaPDC-167|blaPDC|class_C_beta-lactamase_PDC-167 NG_050947:1-1194,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCCCTTTCTCCACGTTTGCCGCAGCCAAAACAGAACAACAGATTGCCGATACCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGGCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGGTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAAACTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTAACGATGAGGCCCAGGATATTGGGCCTCCTTTCTTTCTCTTTTTTTCCTGTTGTCATCTACACTTAACAAAAATACAGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1960,Drugs,MEG_1960|Drugs|betalactams|Class_C_betalactamases|CMY,gi|387861048|gb|JQ711184.1|1027-2255 gi|858970176|gb|KM985464.1|1-1146,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacatcgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtagctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgcttaagtttattcatgccaatctgaacccacagaaatatccgacagatattcaacgtgcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcagttttaaatgcaataaaggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_548,Drugs,MEG_548|Drugs|betalactams|Class_C_betalactamases|ADC,447133976|WP_001211232.1|NG_048663|1|1|blaADC-52|blaADC|class_C_extended-spectrum_beta-lactamase_ADC-52 NG_048663:1-1152,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccaatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcagccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5608,Drugs,MEG_5608|Drugs|betalactams|Class_C_betalactamases|PDC,1035157529|WP_064511494.1|NG_050816|1|1|blaPDC-143|blaPDC|class_C_beta-lactamase_PDC-143 NG_050816:1-1194,0
,atgatgaaaaaatctctttgctgcgccctgctgctcggcatctcttgctctgctctcgccgcgccagtgtcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgaaagcccagtcgattccaggcatggcggtggccgttatttatcagggtaaaccgcactattacacgtttggcaaagccgatatcgcggccagcaaacccgttacgcctcagactctgttcgagctgggttctataagtaaaaccttcaccggggttttaggaggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcaggggattcgtatgctggatctcgcaacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataatgccgccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagtatcggtctttttggcgcgctggcggtcaaaccttccggcatgggctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggaatactggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaaggttgctgatgcctcacttaagcagggcatctcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtgatcgagggcagcgacagtaaggtggcgctggcaccgctgcccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggctctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgacgcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_436,Drugs,MEG_436|Drugs|betalactams|Class_C_betalactamases|ACT,1028101949|WP_063857782.1|NG_048626|1|1|blaACT-39|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-39 NG_048626:1-1146,0
,atgttgaaaaggataaaaggattattggttctggccttaggttttacagggctacaggtttttgggcagcaaaatcctgatattaaaattgaaaaattaaaagataatttatacgtctatacaacctataataccttcaaagggactaaatatgcagctaatgcggtatatatggtaactgataaaggagtagtggtgatagactctccatggggagaagataaatttaaaagttttacagacgagatttataaaaagcatggaaagaaagtcatcatgaacattgctactcactctcatgatgatagagccggaggtcttgagtattttggtaaattaggtgcaaaaacttattccactaaaatgacagattctatcttagcaaaagagaataagccaagagcaaagtacacttttgataataataaatcctttaaagtaggaaagactgaatttcaggtctattatccgggaaaaggtcatacagcagataatgtggtggtatggttccctaaagacaaagtattagtaggaggctgcattgtaaaaagcggtgattcgaaagaccttgggtacattggagaagcttatgtaaatgactggacacagtccatacacaacattcagcagaaatttcccgatgttcagtatgtcgttgcaggccacgatgactggaaagatcaaacatcaatacaacatacactggatttaatcagtgattaccaacaaaaacaaaaggcttcaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1252,Drugs,MEG_1252|Drugs|betalactams|Class_B_betalactamases|BLAB,1693892929|WP_140423306.1|NG_065421|1|1|blaB-15|blaB|subclass_B1_metallo-beta-lactamase_BlaB-15 NG_065421:1-750,0
,ATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTGTACGTAGAACTCGAAGGCAATTTAAGTATGAAAGAAAAGGTAGTTGTTGATAAAGCGATTTCACTCTATACCGAATCATTCGGCGACCCGGCCCATGAACCCATTATTCTGATCATGGGGGCAATGTCGTCTGCGGTGTGGTGGCCTGATGAGTTTTGTTCCCAACTTGCCAAAATGGGTCGCTATGTGATCCGGTACGACCACCGTGATACCGGGAAATCAACAAGCTATGAGCCAGGTCAGGCTCCATATTCCGTTGAAGAATTAGCAGATGATGTGGTTCGCGTCATTGATGGTTATGGTCTGGAAGCTGCTCATTTAGTCGGCATGTCTTTGGGGGGATTTCTTTCCCAGCTTGTAGCTCTCAAGTATCCGAAACGTGTGAAGAGCTTGACGCTGATTGCTTCAGAACGGCTTGCAGATGCAGATCCGGATATGCCCGCTTTTGATCCTGCCATCATTGAGTATCACCAACGGGCGGAATCGCTGGATTGGTCTGATAGAGATGCTGTCGTCGCGTATCAGGTCGGAGCGTGGCGAATCAACTCAGGTACTGCGCATGCTTTTGACGCTGAGAAGATACAAAACATCGCTGAGTTAAATTTTGATCGCACTCCGAATATCCTGACAACATTCAACCACACTACTTTAGGTGGTGGCGAGAGATGGCTCGGGAGATTAAATGAGATAGCTGTACCAACTTTGATCATTCACGGCACGGAGGATCCTGTACTTCCTTATGTGCATGGGTTGGCACTGAAAGATGCGATTCGTGGTTCAAAAATGCTGACACTCGAAGGCACGGGACATGAGTTGCATCATGAAGACTGGCCGAGGATTATCCAGGCGATTAAGGGGCAAACGTCATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5255,Drugs,MEG_5255|Drugs|betalactams|Class_D_betalactamases|OXA,gi|937637492|gb|KT334335.1|98451-97525 gi|937637492|gb|KT334335.1|86339-86284 gi|928083869|gb|CP012682.1|75357-74431 gi|928083869|gb|CP012682.1|17933-17878 gi|828971497|gb|CP011644.1|25497-26423 gi|743008998|gb|CP010362.1|66711-65785 gi|742999823|gb|CP010396.1|9184-8258 gi|660582341|gb|CP008800.1|52403-53329 gi|587656709|gb|KF921569.1|531-1457 gi|587656699|gb|KF921568.1|531-1457 gi|587656689|gb|KF921567.1|531-1457 gi|587656679|gb|KF921566.1|531-1457,0
,ATGCCTGCCAAGCTTCGTGCGCGGCGCGAGTTGAACTGTGGCCAGTATGTTCTGCCACTGGGGGAGCGTACGCTAGTCATGGGAATTTTGAATGTGACACCTGATTCTTTCTCGGATGGCGGCCGTTATGTCAATGTGGAGGCAGCACTCGCACAAGCGCGTGCAATGGTTGAGGCTGGAGCTGACCTGATTGATATCGGTGGAGAATCGACACGTCCGGGGTCGGAAGCAGTCGATGAGGCGACGGAGCTGGACAGAGTGCTGCCAGTCATTCGGATGCTTTCGCAGGAATTGTCTGTTCCGCTGTCCATTGACACGTACAAAGCGGCGGTTGCAGAACGGGCTATTCTGGAGGGGGCACATATCATCAATGATGTATGGGGAGCGAAGCGTGACCCGCGGATGGCAGAGGTAGCTGCTCGTCTCGATGTGCCCATTATCCTGATGCACAACCGCGAAGACACGGACTATCACGACTTTTTCCCAAACTATATCAAAGACCTGCGTGAGTCCGTACAGATCGCCTTGCAGGCAGGGGTAAAGCAGGAGAGAATCATCCTCGATCCGGGGATCGGGTTTGTAAGGACTGTCGAGCAAAATCTCGAAACAATGCGCAGGCTGGATGATCTGGTAGGGCTGGGCTATCCTGTTCTACTTGCTACTTCACGCAAGCGGATGATCGGTCATGTTCTCGACTTGCCTGTAGATGAGCGTGTCGAAGGTACGGCAGCGACAGTTGCTCTCGGGGCGGCAAAAGGCTGTCATATGGTACGGGTGCATGATGTCAAAGAAATGAAGCGCGTTACGAAGATGATGGACGCGATGCTAAAAGGGGGCATTTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2939,Drugs,MEG_2939|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|226092535|dbj|AP008955.1|186149-186991,8
,atgaaaaagctatttctgctacttggattgttagcctgttcgagtgcaacgtacgccgcaaacttaatgaaaacatctccgcgattgaagaagcatatttcgggtcgaatcggtgtgtctgtctgggatactcaaaccgatgaacattgggactatagaggcgacgagcgcttcccgatgatgagcacattcaaaacgcttgcatgtgcaacgatgcttagtgacatggataatgaaaagctcgataaaaacgccactgccaaagtagaagagcgcaatatggtggtttggtcaccagtaatggatcgtatggcaagtcaaacaacgcgtattgaacatgcttgtgaagccgcaatgctgatgagcgacaataccgcagccaacattgttttgcgtagcattgggggtccacgcggtgtcactacgttcttgcgttctatcggtgataaagcaacgcgccttgaccgttttgaaccaagactgaacgaggcgaacccgggcgacaagcgagacaccacaacacctaatgccatggtaaatacgctgcatacgttgttagaaggtgatgcgctatcctacgaatcacgcattcaattaaaaatctggatgcaggataacaaagtctctgattctttgatgcgctctgtgttaccaaagggttggtcgattgccgatcgttctggcgcaggtggctttggatcacgcggtatcacagcaatgatctggaaagagaatcataaaccggtctacatcagcatttacattactgaaaccgatttatccttgcaggcgcgcgatcaggttatcgctcaagtgagccagttaatactggatgagtacaatactatttag,antibiotic molecule,antibiotic inactivation,betalactams,MEG_7807,Drugs,MEG_7807|Drugs|betalactams|Class_A_betalactamases|WHH,1028110907|WP_063865164.1|NG_050334|1|1|blaVHH-1|blaVHH|carbenicillin-hydrolyzing_class_A_beta-lactamase_VHH-1 NG_050334:101-952,0
,CTACTTTTTCTCCCTCAATAGCTTTAGGGTATGGTCTAGAGATTCCCTGTTTCCCCAGGCAGCGTGTCCGGTAATAACAATTTTGGTATCAGGATATTTCTGTTTTAACTTTTCGATGCTTTTTGGCCATGCGGCTAAATCGGATTCTCCAATATAGCCCAAATCATTGGCTTCGATGCTTTTAATCAGGCAGCCACCGAATAAAACTTTGTCTTTTGGAAACCAAACTACCAGATTATCCTTTGTATGCCCCTTGCCGGCATAGTAGGTGTTTATTTTATATTGTCCCACTGTAAAAGTAGTGTCGTTGGTAAAGGTGTAGGCTGCGCGTGGCTCTTTATTAGTTTTCAGAATTTCGTCGGTTAATTTATTGGTATAGGTTTTTATGCCCTTACTTTTAAAGAACGCTAAACCGCCTGCGCGGTCGCCATGCGAATGTGTGGCAATGGCCAGCACTACTTTTTGGTGATGTTTGGTCTGAATAGAGTCTAAAAAGGGCTGGAACTGCGTAGCATCCCAAGGGGCATCGATTACTACAACACCTTTATTGGTAACCAGGTAAACCGCATTTGCATCTGTTAAAGCGCCTTTGTAGGTATTGTATGTGGTGTAAACATAAAGATCGCCAGTTAAATGTTTGATTTTTATTTTTGGATTTTGCGCGAAAGAGGCAAAGGCAGATAAACAAAGTAAAAAGGAAAGAAGATAACGCAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5750,Drugs,MEG_5750|Drugs|betalactams|Class_B_betalactamases|PEDO,gb|KP109679|+|2260-2974|ARO:3003715|PEDO-3 [Pedobacter sp. Stok-3] ,0
,ATGCGCTTCATTCACGCACTATTACTGGCAGGGATCGCTCACTCTGCATATGCGTCGGAAAAATTAACCTTCAAGACCGATCTTGAGAAGCTAGAGCGCGAAAAAGCAGCTCAGATCGGTGTTGCGATCGTCGATCCCCAAGGAGAGATCGTCGCGGGCCACCGAATGGCGCAGCGTTTTGCAATGTGCTCAACGTTCAAGTTTCCGCTAGCCGCGCTGGTCTTTGAAAGAATTGACTCAGGCACCGAGCGGGGGGATCGAAAACTTTCATATGGGCCGGACATGATCGTCGAATGGTCTCCTGCCACGGAGCGGTTTCTAGCATCGGGACACATGACGGTTCTCGAGGCAGCGCAAGCTGCGGTGCAGCTTAGCGACAATGGGGCTACTAACCTCTTACTGAGAGAAATTGGCGGACCTGCTGCAATGACGCAGTATTTTCGTAAAATTGGCGACTCTGTGAGTCGGCTAGACCGGAAAGAGCCGGAGATGGGCGACAACACACCTGGCGACCTCAGAGATACAACTACGCCTATTGCTATGGCACGTACTGTGGCTAAAGTCCTCTATGGCGGCGCACTGACGTCCACCTCGACCCACACCATTGAGAGGTGGCTGATCGGAAACCAAACGGGAGACGCGACACTACGAGCGGGTTTTCCTAAAGATTGGGTTGTTGGAGAGAAAACTGGTACCTGCGCCAACGGGGGCCGGAACGACATTGGTTTTTTTAAAGCCCAGGAGAGAGATTACGCTGTAGCGGTGTATACAACGGCCCCGAAACTATCGGCCGTAGAACGTGACGAATTAGTTGCCTCTGTCGGTCAAGTTATTACACAACTCATCCTGAGCACGGACAAATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3102,Drugs,MEG_3102|Drugs|betalactams|Class_A_betalactamases|GES,(Bla)GES-1:HM370522:1-864:864;(Bla)GES-7:HQ170511:644-1507:864,0
,atgcgccactctctttttgccccgatcctcctgctcgccctgttcgccctgcccgcctgggcgcatgaggcgacggtaaaccaggtcaaagccgctgagcgccagctcgaggccagagtaggctacgcggagctggatttagccagcggacggctgctggcaagctatcgccccgacgagcgtttcccgatgatgagcacctttaaagtgccgctctgcgcggcggtactggcgcgcgtggatgccggagaggagaagctcgatcgccgcgtccgctaccgtcagcaggatctggttgaatactccccggtgaccgaaaagcacctcgccgacggcatgacggtagccgagctgtgcgctgcggcaatcacccttagcgataacaccgccgctaatctgctgctggcgagcgtcggcggcccgcaggggttgaccgccttcctgcgccgcagcggagaccagacttcgcgcctcgaccgctgggagaccgagcttaacgaggccctgcccggcgacgcgcgtgataccaccacgccgcaggcgatggccaaaaccttgcgcaatctgctcaccggcagcgtgctttccgccgcatcgcgacagcagctgcgcagctggatggttgacgataaggttgccggcccgctgctgcgctcggcgctgccgcacggctggtttatcgctgacaaaaccggcgcgggcaaccgcgggtcgcgcggtattatcgccgccctcggcccggacgggcagcccgcgcgcatcgtaattatttatttaaccggcaccgaggcctcaatggatgagcggaaccggcagattgccgagattggtgagacgctggttaagcactggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6954,Drugs,MEG_6954|Drugs|betalactams|Class_A_betalactamases|TER,1028110870|WP_063865146.1|NG_050310|1|1|blaTER-2|blaTER|class_A_beta-lactamase_TER-2 NG_050310:101-955,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccaaccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6215,Drugs,MEG_6215|Drugs|betalactams|Class_A_betalactamases|SHV,1044690748|WP_065419573.1|NG_051169|1|1|blaSHV-194|blaSHV|class_A_beta-lactamase_SHV-194 NG_051169:1-861,0
,atgcgttatgttcgcctgtgccttttctccctgattgccgccctgccactggcggtattcgccagccctccgccgcttgagcaagttacacgcagcgaaagtcagctggcgggccgcgtgggctatgttgaaatggatctggccagcggccgcacgctggccgcctggcgcgccagtgagcgctttccgctgatgagcacctttaaagtgctgctctgcggcgcggtgctggcccgggtggatgccggagacgaacagctggatcggcggatccgctaccgccagcaggatctggtggactactccccggtcagcgaaaaacaccttgccgacgggatgaccgttggcgaactctgcgccgccgccatcaccatgagcgacaacagcgccggcaatctgctgttgaagagcgttggcggccccgcgggattgaccgcttttctgcgccagatcggtgacaacgtcacccgccttgaccgctgggaaacggagctcaatgaagcgcttcccggcgacgtgcgcgacaccaccaccccagccagcatggccgccaccctgcgcaagctgctaaccagccacgcgctgagcgcccgttcgcagcagcagctgctgcagtggatggtggacgaccaggtggccggcccgctgatccgcgccgtgctgccggcgggctggtttatcgccgataaaaccggggccggcgagcggggctcacgcggcattgtcgccctcctcggcccgaacggcaaagcggagcgcatcgtggtgatctatctgcgggatacgccggcgaccatggccgagcgtaaccagcagatcgccagaataggcgcggcgctgatcgagcactggcagcgctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4237,Drugs,MEG_4237|Drugs|betalactams|Class_A_betalactamases|OKP,556282799|WP_023289605.1|NG_049361|1|1|blaOKP-A-17|blaOKP-A|class_A_broad-spectrum_beta-lactamase_OKP-A-17 NG_049361:101-961,0
,ATGAATAGAATAAAAGTCGCAATCATCTTCGGCGGTTGCTCGGAGGAACATGATGTGTCGGTAAAATCCGCAATAGAAATTGCTGCGAACATTGATACGGAAAAATTCGATCCGCACTACATCGGAATTACAAAAAACGGTGTATGGAAGCTATGCAAGAAGCCATGTACGGAATGGGAAGCCGACAGTCTCCCCGCCATACTCTCCCCGGATAGGAAAACGCATGGGCTGCTTGTCATGAAAGAAAGCGAATACGAAACACGGCGTATTGATGTGGCTTTCCCGGTTTTGCATGGCAAATGCGGGGAGGATGGTGCGATACAGGGGCTGTTTGTATTGTCTGGTATCCCCTATGTGGGCTGTGATATTCAAAGCTCCGCAGCTTGCATGGACAAATCACTGGCCTACATTCTTACAAAAAATGCGGGCATCGCCGTTCCCGAATTTCAAATGATTGATAAAGGTGACAAGCCGGAGGCGGGTGCGCTTACCTACCCTGTCTTTGTGAAGCCGGCACGGTCAGGTTCGTCCTTTGGCCTAACCAAAGTAAACGGTACGGAAGAACTTAACGCTGCGATAGAAGCGGCAGGACAATATGATGGAAAAATCTTAATTGAGCAAGCGATTTCGGGCTGTGAGGTCGGGTGTGCGGTCATGGGGAACGAGGATGATTTGATTGTCGGCGAAGTGGATCAAATCCGGCTGAGCCACGGTATCTTCCGCATCCATCAGGAAAACGAGCCGGAAAAAGGCTCAGAAAATGCGATGATTACAGTTCCCGCAGACATTCCGGTCGAGGAACGAAATCGGGTGCAGGAAACGGCAAAGAAAGTATATCGGGTGCTTGGATGCAGAGGGCTTGCCCGTGTTGATCTTTTTTTGCAGGAGGATGGCGGCATCGTTCTAAATGAGGTCAATACCCTGCCCGGTTTTACATCGTACAGCCGCTACCCACGTATGATGGCCGCCGCAGGAATCACGCTTCCTGCACTGATTGACAGCCTGATTACATTGGCGTTAAAGAGGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7355,Drugs,MEG_7355|Drugs|Glycopeptides|VanB-type_resistance_protein|VANB,gi|11878534|gb|AF310956.2|AF310956|5259-6287 gi|1763666|gb|U81452.1|EFU81452|150-1178,5
,atgaagaaattatttgttttatgtgtatgcttcctttgtagcattactgccgcaggagcggctttgcctgatttaaaaatcgagaagcttgaagaaggtgtttatgttcatacatcgttcgaagaagttaacggttggggtgttgtttctaaacacggattggtggttcttgtaaacactgacgcctatctgattgacactccatttactgctacagatactgaaaagttagtcaattggtttgtggagcgcggctataaaatcaaaggcactatttcctcacatttccatagcgacagcacagggggaatagagtggcttaattctcaatctattcccacgtatgcatctgaattaacaaatgaacttcttaaaaaagacggtaaggtgcaagctaaacactcatttagcggagttagttattggctagtcaaaaataaaattgaagttttttatcctggcccaggccacactcaagataacgtagtggtttggttacctgaaaataaaattttattcggtggttgctttgttaaacctcacggtcttggtaatttgggtgacgcaaatttagaagcttggccaaagtccgccaaaatattaatgtctaaatatggtaaagcaaaacttgttgtttcaagtcatagtgaaactgggggcgcatcactattgaaacgtacatgggaacaggctcttaaagggcttaaagaaagtaaaaagccatcaccgccaagtaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3327,Drugs,MEG_3327|Drugs|betalactams|Class_B_betalactamases|IMP,1625655391|WP_136512068.1|NG_064724|1|1|blaIMP-39|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-39 NG_064724:1-741,0
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTGGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6929,Drugs,MEG_6929|Drugs|betalactams|Class_A_betalactamases|TEM,gi|6176541|gb|AF190692.1|AF190692|1-1103,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAACCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAGGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6590,Drugs,MEG_6590|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|224814349|gb|FJ715937.1|7428-8267,8
,atgatgaaaacgattgagcttgaaaaggaagaaatttattgtggaaatttgctgctcgtcaacaaaaattatccgctacgagataacaatgtaaagggtttagttcctgctgatgtacgctttccaaatattcttatgaagcgtgatgtggcaaatgttttgcagcttatttttgaaaaaatctcggcaggtaactctatcgttcctgtaagcggttatcgctcattagaagaacagacagccatatatgacggctctctcaaagataatggagaggattttacaagaaaatatgttgccctgccaaatcatagcgaacatcagacaggacttgctattgatttgggattgaacgaaaaagaaatagattttatccgtcccgatttcccctatgtcggtatctgtaatgagtttagaaaagcagccccagactatggatttatcgaacgctatgcaaaggacaaagaagaaatcacgggaatttcacacgagccgtggcattttcgatatgtaggatacccacactcaaaaattatgcaggaaaatggtttttcacttgaagaatacacacaatttataaaagcctatctggaagataaaaaatatctttttgagcaggctcacagagctgagattgaaatatattatgttcctgcaaaagacgacaaaacgctgataaaaataccagaaaattgtgtttatcagatttctggtaataacatagacggttttgttgtgaccatatggaggaaaacagatgactaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7588,Drugs,MEG_7588|Drugs|Glycopeptides|VanG-type_resistance_protein|VANXYG,1028100648|WP_063856783.1|NG_048502|1|1|vanXY-G2|vanXY-G2|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-G2 NG_048502:101-865,5
,atgtcacttaatgtaaaaccaagtaaaatagccatcttgtttatctcttgtttattttcaatatcatttttctcacaggccaatacaaagggtatcgatgagattaaaaaccttgaaacagatttcaatggtagagttggtgtctacgctttagacactggctcaggtaaatcattttcgtacaaagcaaatgaacgatttccattatgtagttctttcaaaggctttttagctgctgctgtattaaaaggctctcaagataatcaactcaatcttaatcagatcgtgaattacaatacaagaagtttagagttccattcacccatcacaactaaatataaagataatggaatgtcattaggtgatatggctgctgccgctttacaatatagcgacaatggtgctactaatattattcttgaacgttatatcggtggtcctgagggtatgactaaattcatgcggtcgattggagatgaagattttagactcgatcgttgggagttagatctaaacacagctattccaggcgatgaacgtgacacatctacgcctgcagcagtagctaagagcctgaaaactcttgctctgggtaacatacttagtgagcgtgaaaaggaaacctatcagacatggttaaagggtaacacaaccggtgcagcgcgtattcgtgctagcgtaccaagcgattgggtagttggcgataaaactggtagttgcggagcatacggtactgcaaatgattatgcggtagtctggccaaagaaccgggctcctcttataatttctgtatacacaacaaaaaacgaaaaagaagccaagcatgaggataaagtaatcgcagaagcttcaagaatcgcaattgataaccttaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3304,Drugs,MEG_3304|Drugs|betalactams|Class_A_betalactamases|IMI,1277753419|WP_100086555.1|NG_055819|1|1|blaIMI-17|blaIMI|carbapenem-hydrolyzing_class_A_beta-lactamase_IMI-17 NG_055819:1-879,0
,GCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATTCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6307,Drugs,MEG_6307|Drugs|betalactams|Class_A_betalactamases|SHV,gb|AY150585|+|0-285|ARO:3001097|SHV-39 [Klebsiella pneumoniae] ,0
,ATGGAAAGAAAAGGGATTTTCATTAAGGTTTTTTCCTATACGATCATTGTCCTGCTACTGCTTGTCGGTGTAACAGCAACACTGTTTGCACAGCAATTTGTGTCTTATTTCAGAGTGATGGAATTACAGCAAACAGTAAAATCCTATCAGCCATTGGTGGAACTGATTCAGAATAGCGATAGGCTTGATATTCAAGAGGTGGCAGGGCTGTTTCACTACAATAACCAATCCTTTGAGTTTTATATTGAAGATAAAGAGGGAAGCGTACTCTATGCCACACCAAATGCCAATACATCAAATAGTTTTAGACCCGACTTTCTTTATGTGGTACATAGAGATGATAATATTTCGATTGTTGCTCAAAGCAAGGCAGGTGTGGGATTGCTTTATCAAGGGCTGACAATTCGGGGAATTGTTATGATTGCGATAATGGTTGTATTCAGCCTTTTATGCGCGTATATCTTTGCGCGGCAAATGACAACGCCGATCAAAGCCTTAGCGGACAGTGCGAATAAAATGGCAAACCTGAAAGATGTACCGCCGCCGCTGGAGCGAAAGGATGAGCTTGGCGCACTGGCTCATGATATGCATTCCATGTATGTCAGGCTGAAAGAAACCATCGCAAGGCTGGAGGATGAAATCGCAAGGCTGGAGGATGAAATCGCAAGGGAACATGAGTTGGAGGAAACACAGCGATATTTCTTTGCGGCAGCTTCTCATGAGCTAAAAACGCCCATCGCGGCTACAAGCGTTCTGTTGGAGGGAATGCTTGAAAATATCGGTGACTACAAAGATCATTCTAAGTATCTGCGCGAATGCATCAAAATGATGGATAGGCAGGGCAAAATCATTTCCGAAATACTGGAGCTTGTCAGCCTGAATGATGGGAGAATCGTACCCATAGCTGAACCGTTGGACATAGGGCGCACGGTTGCCGAGTTGCTGCCCGATTTTCAAACCTTGGCAGAGGCAAACAACCAGCGGTTCGTCACAGATATTCCAGCCGGGCAAATTGTCCTGTCCGATCCGAGGCTGCTCCAAAAGGCACTATCCAATGTCATATTGAATGCAGTTCAGAACACGCCGCAGGGAGGCGAGGTACGGATATGGAGTGAGCCTGGTGCTGAAAAATGCCGCCTTTTTGTTTTGAACATGGGCGTTCACATTGATGATACTGCGCTTCCAAGGCTGTTCACCCCATTCTATCGCATTGATCAGGCGCGAAGCAGAAAAAGTGGGCGAAGCGGTTTAGGACTTGCCATCGTACAAAAAACGCTGGATGCCATGAGCCTCCAGTATGCGCTGGAAAACACCTCGGATGGCGTTTTGTTCTGGCTGGATTTACCGCTCACATCAACATTGTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7494,Drugs,MEG_7494|Drugs|Glycopeptides|VanB-type_regulator|VANSB,gi|577698901|gb|KF823969.1|976-2340,5
,atgaatacgtcttattcacaatcaaatttacgacacaaccaaattttaatttggctttgcgttctatctttttttagcgtattaaatgaaatggttttgaacgtctcattacctgatattgcaaatgattttaataaatcaccggcgagtacaaactgggtgaacacagcctttatgttaaccttttctattggaacagctctatatggaaagctatctgatcagctaggcattaaaaggttactcctatttgggattataataaattgcttcggatcggtaattgcgtttgttggacattctttttttcccatacttattctggctcgatttattcaaggagctggtgcagctgcatttccagcactcgtgatggttgtagttgcgcgctatattccaaaggaaaataggggtaaagcgtttggtcttattggctccatagtagctatgggagaaggtatcggtccagctattggtggaatgatagctcattttatccattggtcttatcttctgctcattccaatgatgacaattatcactgttccgttccttattaaattgttgaaaaaagaagtaaggataaaaggtcattttgatattgtaggaattatactaatgtcagtgggcattgtattttttatgctgtttacaacatcttataacatttcttttctgatcatcagtattctgtcattcctgatatttgtaaaacatattaggaaagtaacagaaccttttgttgaacctgcactggggaaaaatatttcttttataattggtgtcctttgtggaggacttatatttggtacagtagcagggtttatctctatggttccttacatgatgaaagatgtatatcaactaagtactgctgcaattggcagtgtgattattttccctggagcaatgagcgttattatcttcggttacattggtggattacttgttgatagaaaaggtccattgtacgtgttaaccattggagttacatttctttccgttagctttttaattgctgccttttttttagaagtaacaccatggttactgacaattatattagtttttgtttttggtgggctgtcattcaccaaaacagttatatctacaattgtttcaagtagtttgaaacaaaaggaagctggtgccggaatgagtttgcttaattttaccagttttttatcagagggaatgggtattgcaattgttggtggtttattatctgtacgcttactgaatcagaagttgctacctatggaccttgatcaatccacttatttgtatagtaatatgctattcctttttacaggagtcgttgttactagttggctgatcaccttgaatgtatataaacgaagacaaattcaatttaaaagttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7092,Drugs,MEG_7092|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETL,501247083|WP_012290101.1|NG_048208|1|1|tet(L)|tet(L)|tetracycline_efflux_MFS_transporter_Tet(L) NG_048208:101-1483,4
,atgaatgttgaatattctaaaataaagaaagcagtacctattttattattcttatttgtattcagtttggttatagacaactcatttaaattgatttctgtagccattgctgatgacttaaacatttctgtaacgacagtaagttggcaagcgacattagccggtttagtaattggtattggcgctgtagtatacgcttcattatctgatgccattagtatacgcacactatttatttatggcgtgatattaatcattatcggatcaattattggttacattttccaacatcaattcgcattacttttagttggacgtattattcaaactgccggtttagccgctgcagagacattatatgtgatatatgttgcaaagtatctttctaaagaggaccagaagacttaccttggcttaagtacgagcagttattccttgtcattagttatcggtacattatcaggtggatttatttctacgtatttacactggacaaatatgtttttaattgcattaatcgtagtatttacgttgccattcctatttaaattattaccaaaagaaaataatacgaataaagctcatttagattttgttggcttaattctagtggcaactattgctacaacagtcatgctgtttattacgaactttaattggttatatatgattggtgccttaattgcgattatcgtttttgcgctatatattaaaaatgcgcaacgtccattagtaaataaatcatttttccaaaataaacgttatgcttcatttttatttatagtatttgtaatgtatgctatccaattgggttatatttttacgttcccattcataatggagcaaatttatcatctgcaactagacacaacatcactgttattagtaccgggttatatagtagcagtcatcgttggtgcactaagtggtaaaatcggcgaatatctgaattcaaaacaagcgattatcacagcaattattttaatcgcactgagcttgattttacctgcatttgcagtaggtaatcacatttcaatcttcgtcatttctatgatattctttgcaggtagctttgctttaatgtatgcacctttacttaacgaagccattaaaacaatagatcttaatatgacaggtgtggctattggtttttataatttaattattaatgtggcggtatctgtaggtattgcgattgctgcggctctaatcgattttaaagcattaaatttcccaggcaatgatgcattaagttcacatttcggtattattttaattattttaggtttaatgagtattgtcggattagttttattcgtcagcttaaatcgttggacacaatctgaaaaataa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6983,Drugs,MEG_6983|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET38,447023038|WP_001100294.1|NG_055984|1|1|tet(38)|tet(38)|tetracycline_efflux_MFS_transporter_Tet(38) NG_055984:101-1453,4
,atgtttagaattaaagttgcagttctgtttgggggctgttcagaggaacataatgtttcgataaaatctgcgatggagattgccgcaaacatagatacaaaaaaatatcagccttattatattggaatcacaaaatccggcgtttggaaaatgtgtgaaaaaccttgtttggagtgggaacaatatgcgggggatccggttgttttttcgccggacagaagtacgcatggtctgctgatacaaaaagacaaagggtatgaaatccagcctgtggatgtggtgtttccgatgattcatggcaagtttggggaggatggctccatacaaggcttgcttgaattgtcaggcattccgtatgtgggatgcgatattcaaagctccgtgatctgcatggataaggcgcttgcatataccgttgtgaaaaatgcgggtatcactgtgcctgggttccggatccttcaggagggggatcgcctggaaacggaggatttcgtatatcccgtttttgtaaagcctgcccgttccggctcatcctttggcgtaaacaaggtatgcaaggcagaagaactgcaggcagcaatcgaagaagcaagaaaatatgacagcaagattttgattgaagaggccgttaccgggagtgaggtaggctgcgccatactgggaaacggaaatgatctcatggctggcgaggtggatcagattgagctgagacacggcttttttaagattcatcaggaagcacagccggagaagggatctgaaaatgcagtcatccgagttccagccgccttaccggatgaggtaagagaacagattcaggaaacggcaatgaagatttaccggatacttggctgcagaggattggcccgcattgacctgtttttgcgggaggacggttgcattgtgctgaatgaagtgaataccatgccaggttttacttcctacagccgctatccccgcatgatgacagcagccggttttacgctttctgaaatactggatcgcttgattgaactttcacttaggaggtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7386,Drugs,MEG_7386|Drugs|Glycopeptides|VanD-type_resistance_protein|VAND,1028100555|WP_063856690.1|NG_048359|1|1|vanD|vanD|D-alanine--(R)-lactate_ligase_VanD NG_048359:101-1132,5
,AGGATAAAAAAATGACATGGAGAACGACCAGAACACTTTTACAGCCTCAAAAGCTGGAGTTCAATGAGTTTGAGATTCTTAATCCCGTAGTTGAGGGCGCCCGAATTGTCGGCATTGGCGAGGGTGCTCACTTTGTCGCGGAGTTCTCACTGGCTAGAGCTAGTCTTATTCGCTATTTTGTCGAGAGGCATGATTTTAATGCGATTGGTTTGGAATGTGGGGCGATTCAGGCATCCCGGCTATCTGAATGGCTCAACTCAACAGCCGGTGCTCATGAACTTGAGCGATTTTCGGATACCCTGACCTTTTCTTTGTATGGCTCAGTGCTGATTTGGGTTAAATCATATCTACGCGAATCAGGAAGAAAACTGCAGTTAGTCGGAATCGATTTACCCAACACCTTGAATCCAAGGGACGACCTAGCGCAATTGGCCGAAATTATCCAGGTCATCGACCACCTCATGAAACCCCACGTTGATGCGCTGACTCAGTTGTTGACGTCCATTGATGGCCAGTCGGCGGTTATTTCATCGGCAAAATGGGGGGAGTTGGAAACGGCTCAGCAGGAGAAAGCTATCTCAGGGGTAACCAGATTGAAGCTCCGTTTGGCGTCGCTTGCCCCTGTCCTGAAAAATCACGTCAACAGCGATTTTTTCCGAAAAGCCTCTGATCGAATAGAGTCGATAGAGTATACGTTGGAAACCTTGCGTGTAATGAAAGCTTTCTTCGATGGTACCTCTCTTGAGGGAGATACTTCCGTACGTGACTCGTATATGGCGGGCGTGGTGGATGGAATGGTTCGAGCGAATCCGGATGTAAGGATAATTCTGCTGGCGCACAACAATCATTTACAAAAAACTCCAGTTTCCTTTTCAGGCGAGCTTACGGCTGTTCCCATGGGACAGCATCTCGCAGAGAGGGAGGAGGGGGATTACCGTGCGATTGCATTCACCCATCTTGGACTCACCGTGCCGGAAATGCATTTCCCATCGCCCGACAGTCCTCTTGGATTCTCTGTTGTGACCACGCCTGCCGATGCAATCCGTGAGGATAGTGTGGAACAGTATGTCATCGATGCCTGTGGTAAGGAGGATTCATGCCTGACATTGACAGATGACCCCATGGAAGCAAAGCGAATGCGGTCCCAAAGCGCCTCTGTAGAAACGAATTTGAGCGAGGCATTTGATGCCATCGTCTGCGTTCCCAGCGCCGGCAAGGACAGCCTGGTTGCCCTATAG,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_2751,Drugs,MEG_2751|Drugs|MLS|Macrolide_esterases|EREA,gi|636631868|gb|KJ546444.1|710-1947 gi|636631799|gb|KJ543550.1|710-1947 gi|404515556|gb|JX297812.1|629-1866 gi|221047974|gb|FJ591050.1|689-1926 gi|156186306|gb|EU085376.1|671-1908 gi|56182558|gb|AY827837.1|705-1942 gi|66863972|dbj|AB188269.1|730-1967 gi|695198806|ref|NG_035084.1|126-1363 gi|659224503|gb|KJ668707.1|2796-4023 gi|659224503|gb|KJ668707.1|907-1105 gi|954629879|gb|CP013215.1|276726-275684 gi|954629879|gb|CP013215.1|280845-280647,7
,TGATCTGGCCACCTTCCGTAAGCAATATCTGGAACAACCAGCATCGACTGGTTTGGAGTTTTAATGAGTCACCCACAACTTGAGCTAATAGTCGCTGTGGATTCTAAGTTGGGATTCGGGAAAGGCGGCAAGATTCCATGGAAATGCAAAGAAGACATGGCGCGATTTACGCGGATTTCTAAAGAGATCCGCGTGTGCGTTATAGGGAAACACACGTATACTGACATGCGTGACATGCAGTTAGAAAAGGATGGCGCCGAGGAGCGAATCAAGGAGAAAGGAATTCTCCCCGAACGCGAATCGTTCGTGATCTCCTCGACGTTAAAACAAGAAGATGTCATAGGCGCTACTGTCGTTCCTGATCTTCGTGCTGTGATCAACCTGTATGAGAATACCGATCAACGCATTGCTGTCATTGGTGGGGAGAAGTTGTACATTCAAGCTCTTTCATCAGCAACGAAACTGCACATGACCATAATTCCAAGAGAGTTCGACTGTGATCGATTTATTCCTGTTGATCCGATCCAGAACAATTTTCACATTGATTCCAGTGCCAGCGAGACTGTGGAGGCAACCGTTGATGAGACTCAAGAGCGCATTCACTTTGCTACTTACGTGCGTAACAATCAGTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6602,Drugs,MEG_6602|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|695211993|ref|NG_036308.1|13265-13897 gi|695208285|ref|NG_035514.1|6941-7573 gi|89330179|emb|AM234698.1|11797-12429,8
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacaggtgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2165,Drugs,MEG_2165|Drugs|betalactams|Class_A_betalactamases|CTX,1188444898|WP_085562400.1|NG_054686|1|1|blaCTX-M-197|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-197 NG_054686:1-876,0
,atgtcacttaatgtaaaaccaagcagaatagccatcttgtttagctcttgtttagtttcaatatcatttttctcacaggccaatacaaagggcatcgatgatattaaaaaccttgaaacagatttcaatggtagaattggtgtctacgctttagacactggctcaggtaaatcattttcgtacaaagcaaatgaacgatttccattatgtagttctttcaaaggttttttagctgctgctgtattaaaacgctctcaagataatcaactcagtcttaatcagatcgtgaattacaatacaagaagtttagagttccattcacccatcacaactaaatataaagataatggaatgtcattaggtgatatggctgctgccgctttacaatatagtgacaatggtgctactaatattattcttgaacgttatatcggtggtcctgagggtatgactaaattcatgcggtcgattggagatgaagattttagactcgatcgttgggagttagatctaaacacagctattccaggcgatgaacgtgacacatctacacctgcagcagtagctaagagcctgaaaaccattgctctgggtaacatacttagtgagcgtgaaaaggaaacatatcagacatggttaaagggtaacacaaccggtgcagcgcgtattcgtgctagcgtaccaagcgattgggtagttggcgataaaactggtagttgcggagcatacggtactgcaaatgattatgcggtagtctggccaaagaaccgggctcctcttataatttctgtatacactacgaaatacgaaaaagaagccaagcatgaggataaagtaatcgcagaagcttcaagaatcgcaattgataaccttaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3303,Drugs,MEG_3303|Drugs|betalactams|Class_A_betalactamases|IMI,1625655390|WP_136512067.1|NG_064723|1|1|blaIMI-18|blaIMI|carbapenem-hydrolyzing_class_A_beta-lactamase_IMI-18 NG_064723:1-879,0
,atgaaaacagtatttatccttatctccatgcttttccctgtcgcagttatggcacagaaaagcgtaaaaatatccgatgatatcagtatcacccaactctcggacaaagtgtacacttatgtatccctcgccgaaatcgaaggatggggcatggtaccttccaacggaataattgttatcaacaaccatcgggcagcgttgctggacacaccgatcaatgacgcacaaacggaaacgctggtcaactgggtgacagactctttgcatgccaaagtcaccacgtttatcccgaaccactggcacggcgattgtattggcggactgggttacctgcaaaagaaaggtgtccaatcatacgcaaaccagatgacgatagacctcgccaaggaaaaaggattgcccgtaccggaacatggattcaccgattcactgaccgtcagtctggacggcatgcctctccaatgttattatttaggaggcggacatgcgaccgacaatatcgtggtttggctgccgacagagaatatcctttttggcggatgtatgcttaaagacaaccaaacgacaagcatcggcaacatctcggacgcggacgtgacggcatggccgaaaactctcgataaggtaaaagccaagttcccctcggcccgctacgtcgtgcccggacatggcgactatggcggaaccgaactgatagagcataccaagcagatcgtgaaccaatatatagaaagcacctcaaagccatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1661,Drugs,MEG_1661|Drugs|betalactams|Class_B_betalactamases|CFIA,1188444885|WP_085562387.1|NG_054670|1|1|cfiA24|cfiA|subclass_B1_metallo-beta-lactamase_CfiA24 NG_054670:1-750,0
,atgagccatattcaacgggaaacgtcttgctcgaggccgcgattaaattccaacctggatgctgatttatatgggtatagatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccaatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggcatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccccgggaaaacagcattccaggtattagaagaatatcctgattcaggtgaaaataatgttgatgcgctggcagtgttcctgcgccggttgcattcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataacggtttggttgatgctagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataagcttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgagttttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctga,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1028,Drugs,MEG_1028|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,1028082416|WP_063841683.1|NG_047429|1|1|aph(3')-Ia|aph(3')-Ia|aminoglycoside_O-phosphotransferase_APH(3')-Ia NG_047429:101-916,2
,atgacaaaaaagaaattgcccgttcgttttacgggtcagcactttactattgataaagtgctaataaaagatgcaataagacaagcaaatataagtaatcaggatacggttttagatattggggcaggcaaggggtttcttactgttcatttattaaaaatcgccaacaatgttgttgctattgaaaacgacacagctttggttgaacatttacgaaaattattttctgatgcccgaaatgttcaagttgtcggttgtgattttaggaattttgcagttccgaaatttcctttcaaagtggtgtcaaatattccttatggcattacttccgatattttcaaaatcctgatgtttgagagtcttggaaattttctgggaggttccattgtccttcaattagaacctacacaaaagttattttcgaggaagctttacaatccatataccgttttctatcatactttttttgatttgaaacttgtctatgaggtaggtcctgaaagtttcttgccaccgccaactgtcaaatcagccctgttaaacattaaaagaaaacacttattttttgattttaagtttaaagccaaatacttagcatttatttcctgtctgttagagaaacctgatttatctgtaaaaacagctttaaagtcgattttcaggaaaagtcaggtcaggtcaatttcggaaaaattcggtttaaaccttaatgctcaaattgtttgtttgtctccaagtcaatggttaaactgttttttggaaatgctggaagttgtccctgaaaaatttcatccttcgtag,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2829,Drugs,MEG_2829|Drugs|MLS|23S_rRNA_methyltransferases|ERMF,488758799|WP_002682030.1|NG_047825|1|1|erm(F)|erm(F)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(F) NG_047825:101-901,7
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagcaactggtaaaatcgcgccgaaggatgtcgctgccaactgggcaatggaacatctacctgcccagcatcagtctgtcttgcttgaagctagacaggcttatcttgggcaagaggaagatcgctcggtcttgcgcgcagataagttggaagaatttattcacttcatgaaaagcgagatcaccaaggtgctcggcaatgatgtctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_775,Drugs,MEG_775|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502174|WP_071846325.1|NG_052408|1|1|aadA8|aadA8|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA8 NG_052408:101-898,2
,ATGACCTACAGCGAACCAGCGCGATCAGCTGCCCCCCGCACCGGATCGCCGGCGTCCGCCTCCTCCTCGGCCGTCTTGGCGAGGGGAATCACGATTTATGGTTGCGGATCGGACGAGGCCGCCTTGTTCCGGGAGATGGCTCCTCGTTTCGGCGTAATGCCGAACATTGTGGACGAGCCGGTATCCGAGGCGAATATCGGGCTGGTCTCCGGAAATCGATGCATCAGTATCGGTCACAAGACCAAGGTCACGAATTCCATTCTTCTCGCCCTCGCCGAAGCGGGCGTGGAATACATCTCCACCAGGAGCATCGGCTTCAACCACATCGATGTGGAATACGCGGCGAGCGTCGGTATCACCGTGGGCAATGTCGCCTACTCGCCCGACAGCGTCGCCGACTTCACGCTGATGCTGATGCTGATGGCGGTGCGCGACGCCAAGTCCATCATCCGCCGCACCGAGGTGCACGACTACCGGCTGAACGAGGTGCGCGGGAAAGAGCTGCGCGATCTGACCGTCGGAGTGGTCGGAACAGGGCGGATCGGGGTCGCGGTGCTGGACCGGCTGCGTGGTTTCGGCTGCCGGGTGCTGGCCTACGACACGCTGCTGACCGCCTCGGCCGATTACGTTCCGCTCGACGAATTGCTCCAGCAGAGCGACATCGTGACGCTCCATGTGCCGCTCAACAACGATACCTATCATCTTCTCGACCGGAAGAACATCGAGCGGATGAAGGACGGCGCGTACATCATCAACACCGGACGTGGCCCGCTCATCGAAACCGAAGCCCTCATTTCGGCACTGGAAGACGGCAAACTGGGCGGAGCGGCATTGGACGTCGTCGAAGGAGAGGAAGGCATCTTCTACGCCGACTGCCGGAACAAGCCGCTCGAGAGCGAAACGTTGCTGCGGCTGGAAAAGCTGCCGAACGTGCTCATCAGTCCGCATACCGCCTATTACACGGACCACGCACTGAGTGACACTGTTGAAAACTCCATCATCAATTGTCTCCAATTCCGAAAGCGGGAAGTAGTATGGGTAGGCTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7400,Drugs,MEG_7400|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,(Gly)VanH-Ao1:AF060799:534-1580:1047,5
,ATGGCTGCTTGTCAAAGTTTAAGCCAACAAAAGCAACAGCTCACGACAGAAAAAAATGATCAGCAGCAGATCTCAAGTTTATTCCAGAGCGCTCAAACCAGTGGTGTTTTGGTGATTTATGACGGCAAGAAAATTCAAAGCTATGGCAATGCGCTTGATCGTGCAGAGCAGCGTTATATTCCCGCCTCAACCTTTAAAATGTTGAATGCTTTGATCGGGATACAACATCATAAGACTGCACCAAATGAAGTGTTTAAATGGGATGGAAAAAAGCGAGCATTTAGTAGCTGGGAAAAAGATTTAACCTTAGCTGAAGCGATGCAGGCATCGGCGGTACCCGTTTATCAAGAGTTGGCAAGACGGATTGGTTTAGAACTGATGACCCGTGAAGTGAAGCGTGTAGGTTATGGTAATAAAAATATTGGGACGCAAGTGGATAATTTCTGGTTAGTTGGTCCCTTAAAAATCACTCCCGTAGAGGAAGTTCGCTTTGCCTATGCATTAGCAAAACAGAAATTACCCTTTGATCAGCCGACACAGCAACAAGTCAAAGCGATGTTATTGGTGGATCAGATCCAGGATACCAAAATCTATGCCAAAAGCGGTTGGGGAATGGATGTCAGCCCGCAAGTGGGTTGGTGGACGGGGTGGATTGAACAGCCAAATGGTAAGGTCATTGCATTCTCATTGAATATGCAAATGAGCCAGCCTGAACATGCAGATGCACGTAAAGCGATTGTGTATCAAGCCTTGCAACAGTTGGGATTGTTAGCCACTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4837,Drugs,MEG_4837|Drugs|betalactams|Class_D_betalactamases|OXA,gb|ASQH01000019.1|+|55729-56509|ARO:3001741|OXA-286 [Acinetobacter gyllenbergii MTCC 11365] ,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgattttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1826,Drugs,MEG_1826|Drugs|betalactams|Class_C_betalactamases|CMY,1028104430|WP_063859802.1|NG_048804|1|1|blaCMY-134|blaCMY|class_C_beta-lactamase_CMY-134 NG_048804:11-1156,0
,atgagcaagttatctgtattctttatatttttgttttgtagcattgctaccgcagcagagtctttaccagatttaaaaattgaaaagcttgatgaaggcgtttatgttcatacttcgtttgaagaagttaacgggtggggcgttgttcctaaacatggtttggtggttcttgtaaatgctgaggcttatctaattgacactccatttacggctaaagatactgaaaagttagtcacttggtttgtggagcgtggctataaaataaaaggcagtatttcctctcattttcatagcgacagcacgggcggaatagagtggcttaattctcgatctatccccacgtatgcatctgaattaacaaatgaactgcttaaaaaagacggcaaggttcaagctacaaattcatttagcggagttaactattggctagttaaaaataaaattgaagttttttatccaggcccgggacacactccagataacgtagtggtttggctgcctgaaaggaaaatattattcggtggttgttttattaaaccgtacggtttaggcaatttgggtgacgcaaatatagaagcttggccaaagtccgccaaattattaaagtccaaatatggtaaggcaaaactggttgttccaagtcacagtgaagttggagacgcatcactcttgaaacttacaatagagcaggcggttaaagggttaaacgaaagtaaaaaaccatcaaaaccaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3338,Drugs,MEG_3338|Drugs|betalactams|Class_B_betalactamases|IMP,1331531449|WP_102607459.1|NG_056176|1|1|blaIMP-70|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-70 NG_056176:1-741,0
,ATGATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCAGATTAACACCGCCGATAATTCGCAGATTCTCTACGTGGCCGATGAGCGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAGAGCAAGCGACCTGGTTAACTACAATCCCATTGCGGAGAAACACGTTAACGGCACGATGACGCTGGCTGAGCTTGGCGCAGGCGCCCTGCAGTATAGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGGCCCGATAAAGTGACGGCGTTTGCTCGCTCGTTGGGTGATGAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATAGCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAAGCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTATGCCGAAATCATGGGGAGTGGGCGATAAAACCGGCAGCGGAGATTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGAAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGCCGTCGGGATATTCTGGCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGATGCAATAAATGGAGCGAGGTATCGCTCCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2415,Drugs,MEG_2415|Drugs|betalactams|Class_A_betalactamases|CTX,gi|695198069|ref|NG_034895.1|1-905,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGTACTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1864,Drugs,MEG_1864|Drugs|betalactams|Class_C_betalactamases|CMY,gb|DQ256079|+|0-1146|ARO:3002033|CMY-22 [Escherichia coli] ,0
,atgactctggcattagttggcgaaaaaattgacagaaaccgcttcaccggtgagaaagttgaaaatagtacattttttaactgcgatttttcaggtgccgacctgagcggcactgaatttatcggctgccagttctatgatcgcgaaagtcagaaagggtgcaattttagtcgcgcaatgctgaaagatgccattttcaaaagctgtgatttatcaatggcagatttccgcaacgtcagcgcattgggcattgaaattcgccactgccgcgcacaaggcgcagattttcgcggtgcaagctttatgaatatgatcaccacgcgtacctggttttgcagcgcatatatcactaataccaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctatgggaaaaccgctggatggggactcaggtactgggtgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcaggaaacttcacacattgcgatctgaccaattcggagttaggtgacttagatattcggggtgttgatttacaaggcgttaagttagacagctaccaggcatcgttgctcatggagcggcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5879,Drugs,MEG_5879|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111984|WP_063866184.1|NG_050519|1|1|qnrB56|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB56 NG_050519:37-681,3
,ATGCTCCTCTTGATTCTGATCCCTTTAACTGTTCGCTTTGTAGCAGGATTGAGGGTTTGGTACGGCTATGAACCCATTTATCAAATATTACGGCTTTTTGCTGATTATTGGCTCGTCTGTCTAGCCATCGGTGCCTTGCTGATCTGGGCAAGTACAACGATTTATTATATGAGTAAAGCCATCAGCTATTTGAATGAAACGATCCAAGCCACGAATCAATTGATTGCCGAACCCACGAAGCGAATCATTCTCTCCAGCAATCTGAACGATGTGCAAGAAGAAATGAACCAGTTACGGGAAAAAAATCTCCAAGATCAACGAGCAGCCAAAGAAGCAGAGCAGCGGAAAAATGATTTGATCGTCTATCTCGCACATGATTTACGCACACCTTTGACCAGTGTGATCGGCTACTTGACGCTGTTAGAAGAGGAACCTCAGCTTTCTACCGAACTACGGGCACGCTATACCAAGATCGCCTTGCAAAAAGCCCAGCGGCTAGAATTATTGATCAGCGAGTTTTTCGAAATCACCCGTTTTAATCTTACAACGATCGCCTTACAGACCGAAACCACGGATCTTAGCTTAATGCTGGAACAGTTGACGTTCGAATTTTTACCGCTGTTAGAAGAAAAGAACCTTCATTGGCAACTGCAGCTACAGAAAAAAGTCTTTGCGACCGTTGATACGGAGAAAATGGAACGCGTTTTTGATAACTTGATCCGCAATGCCATCAACTATAGTTATACCGATTCCCCCTTGCATTTAGCCATCAGTGCCTCTGATGATATCTTGATTCGATTGACCAATCATGGGAAAACGATCCCTGCTGAAAAAATTGGCTTGATTTTTGAGCCTTTTTATCGGATGGACGCTTCACGAGCGACTGCGACTGGTGGAACCGGTCTGGGGCTGCCGATCGCCAGAGAAATCGTTGAAGCATTAGGTGGAAAAATCTGGGCGGAAAGCCGTGACGAAACCATCGTCTTTTCGATTCGCCTACCAAAGGCAGCAATGGAAAAAAATGAACAGCGATCAAAGCCCCATCCATCTGAACCAACCGCTTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7503,Drugs,MEG_7503|Drugs|Glycopeptides|VanC-type_regulator|VANSC,gi|161779845|gb|EU151752.1|4600-5664,5
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5651,Drugs,MEG_5651|Drugs|betalactams|Class_C_betalactamases|PDC,730330442|WP_033987207.1|NG_049925|1|1|blaPDC-51|blaPDC|class_C_beta-lactamase_PDC-51 NG_049925:1-1194,0
,ATGGCTCTGGCACTCGTTGGCGATAAAATTGACAGAAACCGTTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATTCCAGTGCGCTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACTCGCACCTGGTTTTGCAGCGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGCTGGAAAAATGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTTTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGCTGGACAACTACCAGGCGTCGTTGCTCATGGAGCGACTTGGCATCGCGGTGATTGGTAGC,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6001,Drugs,MEG_6001|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,qnrB41_1_JN166690 ,3
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAGAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGAATCTCT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2437,Drugs,MEG_2437|Drugs|betalactams|Class_A_betalactamases|CTX,blaCTX-M-110_1_JF274242 ,0
,atgtcacttaatgtaaaaccaagtagaatagccatcttgtttagctcttgtttagtttcaatatcatttttctcacaggccaatacaaagggcatcgatgagattaaagaccttgaaacagatttcaatggtagaattggtgtctacgctttagacactggctcaggcaaatcattttcatacaaagcaaatgaacgatttccattatgtagttctttcaaaggttttttagctgctgctgtattaaaaggctctcaagataatcaactaaatcttaatcagatcgtaaattataatacaagaagtttagagttccattcacccatcacaactaaatataaagataatggaatgtcattaggtgatatggctgctgcagctttacaatatagcgacaatggtgctactaatattatccttgaacgatatatcggtggtcctgagggtatgactaaattcatgcggtcgattggagataaagattttagactcgatcgttgggagttagatctaaacacagctattcctggcgatgaacgtgacacatctacacctgcagcagtagctaagagcctgaaaacccttgcactgggtaacatactcaatgagcgtgaaaaggaaacctatcagacatggttaaagggtaacacaaccggtgcagcgcgtattcgtgctagcgtaccaagcgattgggtagttggcgataaaactggtagttgcggtgcatacggtacggcaaatgattatgcggtagtctggccaaagaaccgagctcctcttataatttctgtatacactacaaaaacgaaaaaagaagccaagcatgaggataaagtaatcgcagaagcttcaagaatcgcaattgataaccttaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3305,Drugs,MEG_3305|Drugs|betalactams|Class_A_betalactamases|IMI,1188444902|WP_085562404.1|NG_054694|1|1|blaIMI-15|blaIMI|carbapenem-hydrolyzing_class_A_beta-lactamase_IMI-15 NG_054694:1-879,0
,ttgaaaagtaaaaatattaaagtcaatcctgactttactcaagtgagaaataaaatttttatgagaacagctttaatggcatttatagccattattttcatatggattttatattcttttatattgtatggtaagttttctatctggatagtatcattctttgaaaatgcttttcgtatggaatataaagctgcattgaatttatatcagcagattttccgtaatagcatggagctcttcatgatactagctatggtgattgtgttttttataatattccgtgtttatttaaattggtttacaaaatattttagtgaaataaatcaaggtattgactctcttatcaaagaagatgttggagaagtggctttatctccagagttattggcaatagaaaagaaaataaactcaattaaacatatacttgaacaacgtaaatttgagacacaaatggcagaacaacgtaagaatgaacttattgtttatcttgcacatgatttaaaaacaccacttacatcagttatagggtatctgacactacttcgagatgaaagtcagatttctgaagaactgcgaaaaaaatatttatctatttcgttggataaggcagagcgtcttgaagatttaattaatgaattctttgaaattacaaggtttaatttatcaaatatatcacttgaatacagtacagtaagcttaactcgtatgcttgaacaactaacatatgagtttaaacctactttgatgagtaagaatttaaaatatacactgaatgttacaccaaatatgatgataaggtgtgatgttaataaaatgcaacgtgtatttgataacttattacgaaatgctgtttattatagttttgaagatactactattgaaataacagctgtacaggaggatgattatataaagcttaaatttataaatcatagtaatatgattccagaggaaaaacttgagcgtatttttgaacaattttacaggttggatacatctcgtaattcaaacagtggtagagctgggttgggacttgctatagctaaagaaatagtggagcttcataacgggacaataacagctcatagcgagaacaatataattacctttaaggttattattccgattgtaggaaatttgtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7498,Drugs,MEG_7498|Drugs|Glycopeptides|VanC-type_regulator|VANSC,500187918|WP_011861275.1|NG_061619|1|1|vanS-Cd|vanS-Cd|VanG-Cd-type_vancomycin_resistance_histidine_kinase_VanS NG_061619:101-1243,5
,GAGGGTAGCGGTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGTTGGTTACTGTGGCCGTAAAGCTTGATGAAACGACGCGGCGAGCATTGCTCAATGACCTTATGGAGGCTTCGGCTTTCCCTGGCGAGAGCGAGACGCTCCGCGCTATAGAAGTCACCCTTGTCGTGCATGACGACATCATCCCGTGGCGTTATCCGGCTAAGCGCGAGCTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCATGATCGACATTGATCTAGCTATCCTGCTTACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCGGCAGCGGAGGAATTCTTTGACCCGGTTCCTGAACAGGATCTATTCGAGGCGCTGAGGGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCCGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAATAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATAAAACGCCTACCTGCCCAGTATCAGCCCGTCTTACTTGAAGCTAAGCAAGCTTATCTGGGACAAAAAGAAGATCACTTGGCCTCACGCGCAGATCACTTGGAAGAATTTATTCGCTTTGTGAAAGGCGAGATCATCAAGTCAGTTGGTAAATGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_967,Drugs,MEG_967|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|973585379|gb|KP054476.2|51844-52633 gi|971338783|gb|CP006659.2|2297687-2298476 gi|966344239|gb|KT291741.1|94-883 gi|957657109|dbj|LC099465.1|47-836 gi|953007066|gb|CP013143.1|8-797 gi|937637492|gb|KT334335.1|96761-95972 gi|928083869|gb|CP012682.1|73667-72878 gi|923091304|gb|KP942843.1|122-911 gi|918400318|dbj|AP014939.1|110917-111706 gi|908266278|gb|CP012170.1|134701-133912,2
,atgaattatcaaattgtgaatattgcggaatgcagcaattaccagttagaagcagcaaatatactaacagaagcgttcaatgatcttggtaacaattcatggccagatatgacgagtgcaacaaaagaagtaaaacgatgtattgagagtccaaacctttgtttcggtctgctaataaataactccttagttggctggataggcttaaggccaatgtacaaggaaacgtgggaattgcatccattggttgtcagaccagattatcaaaataaaggtattggcaagatcctgcttaaggaattagaaaacagagctagagagcaaggtattattggaatcgctttaggaacagatgatgaatactatagaacaagtctctctttaataactataacagaagataatatatttgattcaataaaaaatattaaaaatattaataaacatccatatgagttttatcagaagaatggttattatattttgggaataattccaaatgccaatggtaaaaacaaaccagatatttggatgtggaaaagtttaatcaaagagtaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_120,Drugs,MEG_120|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,695263025|WP_032489895.1|NG_047275|1|1|aac(6')-Ia|aac(6')-Ia|aminoglycoside_6'-N-acetyltransferase_AAC(6')-Ia NG_047275:101-658,2
,atgataatcagtgaatttgaccgtaataatccagtattgaaagatcagctttctgatttactgagactgacttggccggaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacgaatcgcggtagcagcggtagaccaagatgagttagtaggatttattggtgcaatccctcaatacggtatcacaggttgggaattgcatccattagttgtagaaagctcccgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagagtaggaatcacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaaacggacctgtatgagcatacatttgataaagtggcttccatccagaaccttcgtgaacatccgtatgaattctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaaatggctgggacaaaccggatatttggatggcaaaaacgattattcctcgaccagattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_86,Drugs,MEG_86|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,498420626|WP_010728104.1|NG_052160|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052160:101-649,2
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctatggaaattataatcaaacagaaagtagagctgcaccctaatatgtgtgtgatgagctgtacggaacttgagcaatgggatgtggtaatagaaggaaatgatgaccttttagagaaatatatgtccggtaaatcattagaagcattagaactcgaacaagaggaaatcagaagatttcagaattgctccttgtaccctgtttatcatggaagcgcaaaaagcaacatagggattgagcagcttatagaagtgataacgaataaattttattcatcaacatacagaaagaagtctgaactttgcggaaatgtcttcaaaattgaatattcggaagaaagacaacgtcttgcatatgtacgcctttatggcggaatcctgcatttgcgggattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaattgataaggcttattccggggaaattgttattttgcaaaatgagtttttgaagctaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatccgctccctctgctgcaaacaactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctacaatattatgtggattctacgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctattgcaagaaaagtatcatgtggaggtaaaaataaaaaagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagtgccaccgaatcccttctgggcttccattggtctttctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaagggatacgatatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagttttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcaccacaagaatatctttcacgagcatataacgatgctcctaaatattgtgcgaacatcgtagacactcaactgaaaaataatgaggtcattcttagtggagaaattcctgctcggtgtattcaagaatatcgtaatgatttaactttctttacaaatggacgtagcgtttgtttaacagagttaaaagggtactatgttactactggtgaatctgtttgtcagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7120,Drugs,MEG_7120|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100183|WP_063856396.1|NG_048236|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048236:1-1920,4
,AATTCAATTTTATAAGTCTTATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGTTCACCTTATATAGTGACTGCTAATCCAAATCACAGCACTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGAACGGGCAAAAAAGGCTGTTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAATGAAGTGAAGCGTATTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAGTTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGTTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGAATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGAAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGCTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCAGTTCACTTCTTACCATTATGATCTGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5233,Drugs,MEG_5233|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389155|gb|KF986260.1|1-888,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTTGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTNGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATTGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATTTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6605,Drugs,MEG_6605|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|695212668|ref|NG_036469.1|7392-6553,8
,atgcgttattttcgcctgtgtattatctctctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgtaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgatgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagagaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6237,Drugs,MEG_6237|Drugs|betalactams|Class_A_betalactamases|SHV,1509794567|WP_122630876.1|NG_062294|1|1|blaSHV-222|blaSHV|class_A_beta-lactamase_SHV-222 NG_062294:1-861,0
,ATGAAAAAAAGTATTCAGCTTTTGATGATGTCAATGTTTTTAAGCCCATTGATCAATGCCCAGGTTAAAGATTTTGTAATTGAGCCGCCTGTTAAACCCAACCTGTATCTTTATAAAAGTTTCGGAGTTTTCGGGGGTAAAGAATATTCTGCCAATGCTGTATATCTTACCACTAAGAAAGGAGTTGTCTTATTTGATGTCCCATGGCAAAAGGAACAATATCAAACCCTTATGGACACCATACAAAAGCGTCATCACCTTCCTGTAATTGCTGTATTTGCCACCCACTCTCATGATGACAGAGCGGGTGATCTAAGCTTTTACAATCAAAAAGGAATTAAAACATATGCGACCGCCAAGACCAATGAACTGTTGAAAAAAGACGGAAAAGCAACCTCAACCGAAATTATAAAAACAGGAAAACCTTACAAAATTGGTGGTGAAGAATTTATGGTAGACTTTCTTGGAGAAGGACATACAGTTGATAATGTTGTTGTATGGTTCCCCAAATATAAAGTACTGGACGGAGGATGTCTTGTAAAAAGCAGGACAGCCACTGACCTGGGATATACCGGTGAAGCAAATGTAAAACAATGGCCGGAAACCATGCGAAAACTAAAAACGAAATATGCTCAGGCCACTCTGGTAATCCCGGGACACGACGAATGGAAAGGCGGTGGCCATGTACAGCATACTCTGGATCTTCTGGATAAGAATAAAAAGCCGGAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3404,Drugs,MEG_3404|Drugs|betalactams|Class_B_betalactamases|IND,(Bla)IND-2b:EF672681::1-732:732,0
,atgaatattatgccgatatctgaatcacaattatcagattggctagcattaagaagcttactctggcctgatcatgaagatgcgcatttattggaaatgcgccagctacttaaacaaaccgatactttacagttattggtgtattcggaaacgcaacttgcgatagcaatgttggaagcatcgatccgacatgaatatgtgaatggtacacaaacctcacccgtggcttttcttgaagggatttatgtattgcctgaatatcgacgttcaggcattgcgacccagttggttcagtgcgtagaggaatgggcgaaacaatttgcatgtacagagttcgcttcagatgcagcgcttgaaaatacgatcagtcatgcaatgcatcgggctttgggttttcatgaaactgaacgcgtggtgtactttaagaaaaatatcggctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_78,Drugs,MEG_78|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,507092197|WP_016162901.1|NG_052166|1|1|aacA-ACI6|aacA-ACI6|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052166:101-541,2
,ATGAAAAAATTTATACTTCCTATCTTCAGCATTTCTACTCTACTTTCTCTCAGTGCATGCTCATCTATTCAAAATAAATTTGAAAATACTTCTGATATTTCTGATCAGCAACATGAAAAAGCCATTAAAAGCTATTTTGATGAAGCTCAAACACAAGGTGTAATCATTATTAAAGAGGGAAAGAATATTAGAATCTATGGTAATAACCTGGTACGAGCACATACAGAATATGTCCCTGCGTCAACATTTAAGATGCTAAATGCCTTAATTGGATTAGAAAATCATAAAGCTACAACAACTGAGATTTTCAAATGGGATGGTAAAAAAAGATCTTATCCTATGTGGGAAAAAGATATGACTTTAGGTGATGCCATGGCACTTTCAGCAGTTCCTGTATATCAAGAACTTGCAAGACGGACTGGCTTAGATCTAATGCAAAAAGAAGTTAAACGGGTTGGTTTTGGTAATATGAACATCGGGACACAAGTTAATAACTTCTGGTTAGTTGGCCCCCTCAAGATTACACCAATACAAGAGGCTAATTTTGCCGATGATCTTGCGAATAATCGATTACCCTTTAAATTAGAAACTCAAGAAGAAGTAAAAAAAATGCTTCTGATTAAAGAAGTCAATGGTAGTAAAATTTATGCGAAAAGTGGATGGGGAATGGATGTGACCCCTCAAGTAGGTTGGTTAACAGGTTGGGTAGAAAAATCTAATGGCGAAAAAGTTCCCTTTTCTCTAAACCTAGAAATGAAGCAAGGAATGTCTGGTTCTATTCGTAATGAAATTACTTATAAATCATTAGAAAATTTAGGGATTATA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5265,Drugs,MEG_5265|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-499_1_KT964029,0
,ATGACCAGCCTTGCGCATCATGCGACAGAAAACCGCTCTGTAGCCGAATTTACTGAACAGGCTTACTTGAATTATGCTATGTACGTCATTATGGACCGTGCATTGCCGCATATCAGTGATGGCTTAAAGCCCGTACAGCGCCGTATTGTCTATGCTATGAGCGAGCTAGGCTTAAAAAGCAGTGGCAAGCCAAAAAAATCAGCGCGTACAGTGGGTGATGTACTTGGTAAATACCACCCACATGGTGACTCGGCATGTTATGAAGCCATGGTACTCATGGCTCAGCCATTTAGTTACCGCTATCCTTTAATCGAAGGTCAGGGGAACTGGGGTTCACCTGATGATCCTAAATCTTTTGCTGCAATGCGTTATACCGAAGCCAAGCTCTCAGCTTATAGTGAATTATTGCTGAGCGAATTAGGTCAGGGCACTAGCGAATGGCAAGATAACTTTGATGGTTCTTTAAAAGAACCGATCACTTTACCTGCACGTGTACCTAATATTCTTCTTAATGGTACAACAGGTATTGCTGTCGGGATGGCGACTGATATCCCGCCACATAATTTGCGTGAAGTTGTAAAAGGCACAATAGCTTTAATTCGTAATCCGCAAACCTCGGACGGAAAATTAGCTGAATATATTCCGGCTCCGGATTTACCAACCAAAGCTGAAATTATTACCCCGCCAGAAGAATTACTCAAAATCCAGACCACTGGTCGTGGTAGTTACCGTATGCGAGCGGTATATACCATTGAGAAAAATGAAATCGTAATTACTGAGCTGCCATATCAAGTCTCTGGTTCTAAGGTAATTACTCAAATTGCTGACCAAATGCAGGCGAAAAAGCTGCCATTAGTCGTTGATGTGCGTGATGAATCGGATCATGAAAACCCGACACGACTCGTGATTGTACTTCGCTCTAACCGTATTGATGCGGAAGCAGTGATGAGCCACTTATTTGCGACCACCGATTTAGAATCAAGTTATCGTGTCAATTTAAACATGATTGGCGAAGATGGCCGTCCTCAGGTGAAATCAATTCGTCGTATTTTGCTTGAATGGATCGAGATCCGTAAAAAAACGGTAACTCGTCGTTTACAGTACCATTTAAACCGTATTGAAAAGCGCCTGCATATTTTGGCAGGTCTTTTAATTGCTTATCTCGATATTGATACAGTCATTCGTATTATTCGTGAAGAAGACCAGCCTAAGCCAGTCTTGATGGAACACTTCAATATTGATGAGATACAGGCCGAAGCGATTTTAGAGCTTAAATTACGTCATTTGGCAAAGCTTGAAGAGATGGAAATTCGTCATGAACAAGATGAGCTTTCCGCGAAAGCTGCCATTATTCGTGAACAACTCGAAAATCCTGAATCTTTAAAAAATTTGATTATTGGCGAATTAAAAGAAGATGCGAAAAAGTTCGGTGATGAGCGCCGTTCTCCAATTGTTGCACGTGCTGAAGCGGTTCAAATTAAAGAACAGGATTTAATGCCAGCTGAAACGGTAACAGTCGTTTTGTCTGAAGCAGGCTGGGTTCGTGCGGCAAAAGGTGCGGATGTGGATGCTGAAAATCTGAACTACCGTGCTGGGGACCAATATTTAAGTCATGCTGTCGGGAAAACCAATCAGCGAGTTTACTTCCTTGATGAAACAGGGCGCAGCTATGCCTTGCCAATTAGTAACTTACCTTCAGCGAGAGGCTTGGGGGATCCATTAAGTTCTAAATTATCACCAGCAAGTGGCGTATCGTTTATTCAGGTTTATTTAGATGATGATGAGTCTGAATTGATTGCTGCAAGTTCGGCAGGTTATGGTTTTAAAACGCAAACCAAGCAATTAGATACCAATGCGAAAGCCGGTAAGACATTCTTAACGGTTCCGGATAAGGCAAAGGCTTTACCGCTCATTTCTGCCCAAAACATGACGCATTTGGCTGTACTGAGCTCAGCAGGGCGTTTGTTAATTTTAGATTTGGTAGAACTACCAAATTTAAATAAAGGTAAAGGTAATAAGTTGATACAACTTGAAGGCAAAGAGCAAATTTTATCCATGACAACCCTGAACTTAGATGAAATAATTCAGGTGGTTGCAGGTCAACAACATCTCAAATTAAAAGGTGATGATCTACAAAAATACATGGGTAAACGTGCTTCGAAAGGTCAGCTCTTACCACGTGGATATCAAAAAGCAAATAAACTGTTGATTCAGAGATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5336,Drugs,MEG_5336|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|183207914|gb|CP000863.1|240839-243058,3
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaagcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtaatgcttacgtggtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_837,Drugs,MEG_837|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1693892903|WP_140423280.1|NG_065407|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_065407:101-892,2
,atgcgatttaaaaaaatttcttgcttacttttatctcctctttttatttttaatacatcaatttatgcgggcaatacatcaaaagaacaagaaattaaaaaactggtagatcagaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagctgtaaatagcagtaccatttttgagctaggttcagttagtaaattatttaccgcaacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaaaaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcaacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaactcaatcggtgaatatagacaatattcaaatccaagcattggtttatttggaaaagttgtggcagtgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccagatcttggcttaaaacatagctatgtaaatgttcctaaaactcagatgcaaaactatgcttttggctataaccaagaaaatcagccaattcgtgttaaccctggtccactagatgctccagcatatggggttaaatcgacgctacccgatatgcttaagtttattaatgccaacctcaacccacagaaatatccgaaagatattcaacgtgcaattaatgaaacacatcaaggtttctaccaagtcggcacgatgtatcaggcacttggttgggaagaattttcttatccagcgcttttacaaactttattagacagtaattcagaacaaattgtgatgaagcctaataaagtgactgccatttcaaaagaaccttcagttaagatgttccacaaaactggttcaaccaatggtttcggaacttatgtcgtgttcattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcagtattgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_531,Drugs,MEG_531|Drugs|betalactams|Class_C_betalactamases|ADC,1625655384|WP_136512061.1|NG_064717|1|1|blaADC-24|blaADC|class_C_beta-lactamase_ADC-24 NG_064717:1-1152,0
,ATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCNAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAANGGTTTATNGAGAATATGTNTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCATGTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAA,rRNA with mutation conferring antibiotic resistance,antibiotic inactivation,Phenicol,MEG_1580,Drugs,MEG_1580|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,Phe|AF326777.3|gene18|Phenicol|Chloramphenicol_acetyltransferases|CATA,6
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaatctaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagatttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatgtgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttctctgttccctctttatcatggaagtgcaaaaagtaatatagggattgataaccttatagaagttattactaataaattttattcatcaacacatcgaggtccgtctgaactttgcggaaatgttttcaaaattgaatatacaaaaaaaagacaacgtcttgcatatatacgcctttatagtggagtactacatttacgagattcggttagagtatcagaaaaagaaaaaataaaagttacagaaatgtatacttcaataaatggtgaattatgtaagattgatagagcttattctggagaaattgttattttgcaaaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaagggatacgctatggttgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataatataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7108,Drugs,MEG_7108|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100202|WP_063856402.1|NG_048248|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048248:101-2020,4
,ATGAATACGCAAGCGCACGCCCCACATACCGATTCCAATACGCTGATGCTCGGCCGATACGCCGAACGCGCCTATCTCGAATACGCCATGAGCGTGGTCAAAGGCCGCGCGCTGCCTGAAGTTTCAGACGGCCAGAAGCCCGTGCAGCGGCGCATTTTGTTTGCCATGCGCGATATGGGTTTGACGGCGGGGGCGAAGCCGGTGAAATCGGCGCGCGTGGTCGGCGAGATTTTGGGTAAATACCACCCGCACGGCGACAGTTCCGCCTATGAGGCGATGGTGCGGATGGCGCAGGATTTTACCTTGCGCTATCCCTTAATCGACGGCATCGGCAACTTCGGCTCGCGCGACGGCGACGGGGCGGCGGCGATGCGTTACACCGAAGCGCGGCTGACGCCGATTGCGGAATTGCTGTTGTCCGAAATCAATCAGGGGACGGTGGATTTTGTGCCGAACTACGACGGCGCGTTTGACGAACCGCTGCACCTGCCCGCCCGCCTGCCTATGGTGTTGCTCAACGGCGCGTCAGGCATTGCGGTGGGCATGGCGACCGAGATTCCGCCGCACAATTTGAACGAAGTGACGCAGGCGGCGATTGCGTTGTTGAAAAAGCCGACGCTGGAAACCGCCGACCTGATGCAATATATTCCTGCCCCCGATTTTGCCGGCGGCGGTCAAATCATCACGCCGGCGGACGAATTGCGCCGGATTTATGAAACCGGCAAGGGCAGCGTGCGCGTGCGTGCGCGTTATGAAATCGAAAAATTGGCGCGCGGACAGTGGCGCGTCATCGTAACCGAGCTGCCGCCGAACGCCAATTCCGCCAAAATCCTTGCCGAAATCGAAGAGCAAACCAACCCGAAACCGAAAGCGGGTAAGAAACAGCTCAACCAAGACCAGCTCAATACCAAAAAGCTGATGCTGGATTTAATCGACCGCGTGCGCGACGAGTCCGACGGCGAACATCCCGTGCGACTGGTATTCGAGCCGAAATCCAGCCGCATCGATACCGATACCTTCATCAACACGCTGATGGCGCAAACTTCGCTGGAAGGCAATGTGTCGATGAACTTGGTGATGATGGGTTTGGACAACCGCCCCGCGCAGAAAAACCTGAAAACGATTTTGCAGGAATGGCTGGATTTCCGCACCGTAACCGTAACACGCCGTCTGAAATTCCGTTTGAACCAAGTGGAAAAACGGCTGCACATCCTCGAAGGCCGTCTGAAAGTCTTTCTGCACATCGACGAAGTGATTAAAGTCATCCGCGAATCAGACGACCCGAAAGCCGATTTGATGGCGGCGTTCGGGCTGACCGAAATCCAAGCCGAAGACATTTTGGAAATCCGCCTGCGCCAGTTGGCGCGTTTGGAGGGTTTCAAACTCGAAAAAGAATTGAACGAGTTGCGCGAGGAACAAGGCCGTCTGAACATCCTTTTGAGCGACGAAAACGAAAAACGCAAGCTGATTGTCAAAGAGATGCAGGCGGATATGAAACAATACGGCGACGCGCGACGCACGCTGGTGGAAGAGGCCGGACGCGCCGTGCTGACGCAGACCACCGCCGACGAACCCATCACGCTGATCCTGTCGGAAAAAGGCTGGATACGCAGCCGCGCCGGACACAATCTCGATTTGAGCCAAACCGCGTTCAAAGAAGGCGACTGCCTCAAACAAACCCTCGAAGGCAGAACGGTTTTACCCGTCGTCATCCTCGATTCATCGGGCAGAACCTACACGCTCGATGCCGCCGAAATCCCCGGAGGGCGCGGCGACGGCGTACCGGTTTCCTCCTTAATCGAGCTGCAAAACGGCGCGAAACCCGTTGCGATGTTGACAGGATTGCCGGAACAACATTATTTATTATCAAGCAGCAGCGGCTATGGCTTCATCACCAAGCTGGGCGATATGGTCGGGCGCGTGAAAGCGGGCAAAGTGGTGATGACCGCAGACAGCGGCGAAACCGTTTTGCCGCCGGTTGCCGTCTATGCCTCCTCGTTCATCAACCCCGACTGCAAAATCATTGCCGCCACCAGTCAAAACCGCGCCCTCGCCTTCCCCATCGGCGAATTGAAAATTATGGCGAAAGGCAAAGGGCTGCAAATCATCGGATTAAACGCCGGCGAATCGATGACGCATACCGCCGTTTCTTCCGAGCTGGAAATCCTGATTGAAAGCGAAGGCAGGCGCGGCGCGGCGCACAAAGACCGCATCCCCATCTCCCTGCTTGAGGCAAAACGCGGCAAAAAAGGCAGACTATTGCCCATATCGGGCAGCCTGAAACAGCTTTCTTCCCCTAAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5351,Drugs,MEG_5351|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|744797373|gb|CP006869.1|1925957-1923654 gi|325199235|gb|CP002420.1|666028-663725 gi|66731897|gb|AE002098.2|1665175-1667478,3
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtcggcatgttcttttaataccgtacaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaacagaggaaatctatggcaatgatcttaaaagatcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttgtttcctgattgggaaaaggacatgactctaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaagaatgtgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacagaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaacctcaaggagaaattgtagcgttctcactcaatttagaaatgaaaaaaggcatacctagttctattcgaaaagaaattgcttataagggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4561,Drugs,MEG_4561|Drugs|betalactams|Class_D_betalactamases|OXA,1188444916|WP_085562418.1|NG_054708|1|1|blaOXA-564|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-564 NG_054708:1-822,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTTTCCACCTTTGCCGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCGATTATCTACCAGGGAAAACCTTATTACTTTACCTGGGGTAAAGCTGATATCGCCAATAACCGTCCAGTCACTCAGCAAACGCTGTTTGAACTCGGCTCGGTCAGTAAAACGTTCAACGGCGTGCTGGGCGGCGATGCTATCGCTCGCGGCGAAATCAAGCTCAGCGATCCGGTCACGCAATACTGGCCTGAGCTGACGGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCGACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCCGACGACGTCACGGATAAAGCCGCCTTACTGCGTTTTTATCAAAACTGGCAGCCACAATGGGCACCGGGCGCTAAACGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCACTGGCGGTGAAACCTTCAGGCATGAGCTACGAAGAGGCGATGACCACCCGCGTCCTGCAGCCCTTAAAACTGGCGCATACATGGATTACGGTTCCACAGAGCGAACAAAAAGATTATGCATTGGGCTATCGCGAAGGAAAGCCTGTGCATGTATCCCCTGGCCAACTTGATGCCGAAGCCTATGGGGTAAAATCAAGCGTTGTCGATATGACCCGCTGGGTCCAGGCCAACATGGATGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGAATCAAGCTTGCGCAGTCACGTTACTGGCGTATTGGCGATATGTACCAGGGTCTGGGCTGGGAGATGCTGAACTGGCCGGTGAAAGCCGACTCAATAATTAACGGTAGCGACAGCAAAGTGGCGCTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCGCCTGCTGTGAAAGCATCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATTGTGATGCTGGCAAACAAGAGCTATCCAAACCCTGCTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1656,Drugs,MEG_1656|Drugs|betalactams|Class_C_betalactamases|CFE,gb|AB107899|+|1007-2153|ARO:3001856|CFE-1 [Escherichia coli] ,0
,GGAATCAACATCTCATGTCCGCCAACAATGCCGCAATAGTTCTACGAGTCATGGCCGAGAACGATCTGCCAATGCTCCATGCTTGGCTGAACCGCCCCCACATAGTCGAGTGGTGGGGCGGCGAGGATGAACGCCCAACTCTTGACGAAGTCTTAGAACACTATTCGCCCGAAGTTCTGGCAAAGCAAGCTGTAGTGCCTTACATCGCAATGCTAGATGACGAACCCATCGGCTACGCCCAATCCTACATCGCACTTGGAAGTGGCGATGGATGGTGGGAAGACGAAACTGATCCAGGGGTCCGCGGGATTGACCAGTCTTTGGCTAATCCATCACAGTTAAACAAGGGGTTGGGTACAAAGCTCGTACGCTCGCTCGTTGAACTCCTGTTTAGCGACCCGGCCGTAACGAAAATCCAAACCGATCCATCTCCTAGCAACCATCGCGCCATTCGCTGCTACGAGAAGGCCGGGTTCGTTCAAGAAAAAAACATCCTCACACCTGACGGCCCTGCGGTGTACATGGTCCAAACACGCCAGGCGTTCGAAAGCCTGCGCACTGTTCAAAGCTTCAAAATCAAGGGGAAGTGGTCATGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_362,Drugs,MEG_362|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|954629879|gb|CP013215.1|281635-281040 gi|948288909|gb|KR259328.1|131-726 gi|908266278|gb|CP012170.1|140073-140668 gi|828933802|gb|CP011601.1|168898-169493 gi|826570395|gb|KR262557.1|1614-2209 gi|758852100|gb|CP010893.1|30317-29722 gi|682122704|gb|KJ668596.1|1058-1653 gi|659224503|gb|KJ668707.1|117-712 gi|300245053|gb|HM173356.1|2085-2680 gi|226426103|gb|EU855788.1|275361-274766,2
,AAAAGGGCGAGTATGAAAAAATTATTTGTTTTATGTATCTTTTTGTTTTGTAGCATTACTGCCGCAGGAGAGTCTTTGCCTGATTTAAAAATTGAGAAGCTTGAAGACGGTGTTTATGTTCATACATCGTTTGAAGAAGTTAACGGTTGGGGTGTTGTTACTAAACACGGTTTGGTGTTTCTTGTAAACACAGACGCCTATCTGATTGACACTCCATTTGCTGCTAAAGACACTGAAAAGTTAGTAAATTGGTTTGTGGAGCGCGGTTATAAAATAAAAGGCAGTATTTCCTCACATTTTCATAGCGACAGCTCGGGTGGAATAGAATGGCTTAACTCTCAATCTATTCCCACGTATGCATCTGAATTAACAAACGAACTTCTTAAAAAGAACGGTAAGGTGCAAGCTAAAAACTCATTTAGCGGAGTTAGTTATTGGCTACTTAAAAATAAAATTGAAATTTTTTATCCGGGCCCTGGGCACACTCAAGATAACGTAGTGGTTTGGTTGCCTGAAAAGAAAATTTTATTTGGTGGGTGTTTTGTTAAACCGTACGGTCTTGGAAATCTCGATGATGCAAATGTTGAAGCGTGGCCACATTCTGCTGAAATATTAATGTCTAGGTATGGTAATGCAAAACTGGTTGTTCCAAGCCATAGTGACGTCGGAGATGCGTCGCTCTTGAAGCTTACATGGGAGCAGGCTGTTAAAGGGCTAAAAGAAAGTAAAAAACCATCACAGCCAAGTAACTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3392,Drugs,MEG_3392|Drugs|betalactams|Class_B_betalactamases|IMP,gi|37653301|emb|AJ584652.2|1032-1784,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5464,Drugs,MEG_5464|Drugs|betalactams|Class_C_betalactamases|PDC,553756795|WP_023089477.1|NG_055484|1|1|blaPDC-120|blaPDC|class_C_beta-lactamase_PDC-120 NG_055484:1-1194,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGGCATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1353,Drugs,MEG_1353|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_125_CP003194,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattaccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacaccgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2154,Drugs,MEG_2154|Drugs|betalactams|Class_A_betalactamases|CTX,1201190427|WP_087587947.1|NG_054961|1|1|blaCTX-M-199|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-199 NG_054961:1-876,0
,ATGAGCGTATCGGAAATCCGACCGATTGCCATTGAGGACGAACTCAAGCATTCATATTTAGATTACGCGATGAGTGTAATTGTATCTCGTGCATTGCCGGATGTGAGAGACGGTCTTAAACCTGTTCACCGTCGTGTGCTTTATGCCATGCACGAATTGGGCAATGACTATAACAAAGCCTACAAGAAATCTGCTCGTGTCGTTGGGGACGTAATCGGTAAATATCACCCGCATGGTGACTCAGCTGTTTATGAAACCATTGTTCGTATGGCTCAAGACTTTAGCTTACGTTATTTATTGGTTGATGGTCAGGGTAACTTCGGTTCGATCGATGGTGATAGCGCTGCGGCAATGCGTTATACCGAAGTCCGTATGACTAAGCTGGCACATGAGCTTCTTGCAGATTTAGAAAAAGACACAGTTGACTGGGAAGATAACTACGACGGTTCGGAACGTATCCCTGAAGTACTTCCGACACGTGTTCCAAACTTATTAATTAACGGTGCTGCTGGTATTGCTGTAGGTATGGCAACTAACATGGCACCACACAACATGACAGAAGTTGTGAATGCTTGTTTGGCTTATGCTGACAATCCGAATATCTCGATTGAAGGATTGATGGAATACATTACTGGTCCTGACTTCCCTACAGGCGGTATTATTTACGGTAAATCAGGTATTGTTGATGCCTACCGTACCGGTAAAGGTCGTTTACACATTCGTGGTAAATACCATTTCGAAGAAGATGAAAAGACAGGTCGTACAACCATCGTCTTTACTGAAATTCCATATCAAGTAAACAAAGCAAGAGTTATTGAACGTATTGCCGAGTTAGTAAAAGAGAAAAAGCTTGAAGGTATTTCAGAACTTCGTGATGAGTCTGATAAAGAAGGTATGCGTATTGCAATTGACTTGAAACGCGGTGAAAACGCAGAAGTCGTTGTAAATAACTTATTCTTAAATACCCAGCTTGAAAACTCATTCAGCATCAACATGGTTTGTCTAGACAATGGACAACCAAAATTGATGAATCTAAAAGATATTATTGCGGCATTTATTCGTCACCGCCAAGAAGTTGTGACACGCCGTACCATGTTCGAATTACGTAAAGCACGTGAACGTGGTCATATCTTGGAAGGCTTGACAGTTGCCTTAGCCAATATTGATGAAATTATTGAAACCATCAAAACTTCTGCAAACCCTGCTGAAGCGCGTGAGCGTTTACTTGCGGGTGAGTGGGCAGGTGGTGGCGTTGTTGCACTACTTGAAAAAGCTGGTGCAATTTCTGTTCGCCCAGATGAAATTGAAGGTGAAGATCCAAATCGTCCATTTGGTTTAAGTGATTCAATTTATCGTCTGTCACCAACACAAGTAGGCGCAATTTTAGAATTACGTTTACACCGTTTAACTGGTCTTGAACAAGACAAGTTACATGCGGAATATACTGAAATTTTAGGTCAAATTGCTGAACTTACTGCAATTTTAAATGACTTTAACTTGTTAATGGGTGTTATTCGCGAAGAGTTGGCACAAGTTTTACAACAATATGGCGATGCACGTCGTACCGAAATTGTTGAATCTCGTGTGGATTTCTGCCGTGAAGATTTAATTCCTGAAGAGCAAGTGGTATTAACGGTTTCGCAAACGGGTTATGCAAAAACTCAACCTCTTTCAGACTATCAGGCACAGCGCCGTGGTGGACGTGGTAAGTCTGCAACCTCAATGAAAGATGATGACTTTATTCAACATCTGATTGTGGCATCGAACCATGCGACCGTACTTTGCTTTACCAATGTGGGTAAAGTGTACCGTCTGAAAGTATTTGAAGTTCCTCAAGCATCACGTGGGGCAAAAGGCCGTCCAATCGTGAACTTGTTACCTCTAGATGCAACAGAAACCGTAACCGCAATCTTGCCGTTAACCGAGTTCCCGGAAAACCACTATGTGTTTATGGCGACAGCTTCTGGTACGGTTAAGCGTGTTGAGTTAGAGCAATTTGCAAACATTCGTTCAAATGGTCTACGTGCTATTGAACTTAATGAAGAAGATACTTTAATTGGTGTTGCGATTACTGATGGTAATCAGCAAATCATGTTGTTCTCTAACGAAGGTAAGGCAATTCGTTTTGCTGAAACTGACGTACGTGCAATGGGTCGTACAGCGAAAGGTGTACGCGGTATGCGCGTGAGTTTTGCAAGCAGCACCTTAAGTGAAGAAGATGCAGATGTTGAAAATGATGATTCAGATGATAATGATGATTCAACAGATTCAAGTCTAGTAAGTCGCATCGTATCGCTTGTTGTTGTACCTGAGACAGGCGAAGTACTGTGTGCGAGTGCCAACGGTTATGGTAAACGTACTCCAGTAAATGACTTCCCGACCAAGAAACGTGGTGGTAAGGGTGTTATTGCGATCAAGACAAGTGAACGTAACGGTGAGCTAGTTGGTGCAGTTTCTATTGATGAAACCAAAGAGTTATTATTAATTTCTGATGGTGGTACGCTTGTTCGTACGCGTGCTGCAGAAGTTGCAATGACAGGCCGTAATGCTCAAGGTGTTCGTCTGATCCGTTTAAGCGAAGAAGAAACGCTCGTTGGCGTAGTTTCAATTGAAGCTGTAGAAGACGAAGAAGAACTTCTTGAAGGTGAAGTAGATACGACTGAAACTGATAGCGAAGAAGCTGTATCTAATAATGAAGATACTTCTGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3183,Drugs,MEG_3183|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|CP010781.1|-|2990040-2992755|ARO:3003817|Acinetobacter baumannii gyrA conferring resistance to fluoroquinolones [Acinetobacter baumannii] ,3
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgcttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1819,Drugs,MEG_1819|Drugs|betalactams|Class_C_betalactamases|CMY,1028104531|WP_063859852.1|NG_048854|1|1|blaCMY-59|blaCMY|class_C_beta-lactamase_CMY-59 NG_048854:43-1188,0
,atggctctggcactcgttggcgaaaaaattgacagaaaccgcttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtacgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgcttggcattgaaattcgccactgtcgtgcgcaaggcgcagatttccgcggcgcaagctttatgaatatgatcactactcgcacctggttttgtagtgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcggtgattggttaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5906,Drugs,MEG_5906|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111902|WP_063866109.1|NG_050508|1|1|qnrB45|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB45 NG_050508:37-681,3
,atgactctggcattagttggcgaaaaaattgacagaaatcgcttcaccggtgagaaagttgaaaatagtacattttttaactgcgatttttcaggtgccgacctgagcggcactgaatttatcggctgccagttctatgatcgcgaaagtcagaaagggtgcaattttagtcgcgcaatgctgaaagatgccattttcaaaagctgtgatttatcaatggcagatttccgcaacgtcagtgccttgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggtgcaagctttatgaatatgatcaccacgcgcacctggttttgcagcgcatatatcactaatactaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgctggatggggactcaggtactgggtgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttaggtgacttagatattcggggtgttgatttacaaggcgttaagttagacagctaccgggcatcgttgctcatggagcggcttggtatcgctgtgattggttag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5896,Drugs,MEG_5896|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1391852861|WP_109545046.1|NG_057451|1|1|qnrB81|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB81 NG_057451:101-745,3
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctcaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcaatggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtagtgatttatctgcgggataccccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgctcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6202,Drugs,MEG_6202|Drugs|betalactams|Class_A_betalactamases|SHV,1028110296|WP_063864666.1|NG_050056|1|1|blaSHV-190|blaSHV|class_A_beta-lactamase_SHV-190 NG_050056:1-861,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacagggtctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_803,Drugs,MEG_803|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502188|WP_071846338.1|NG_052431|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052431:101-892,2
,atgatgaaaaaatccctttgctgcgccctgctgctgggcctctcttgctctgctctcgccgcgccagtgtcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaaccgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccggcgttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagcatcggtctttttggtgcgctggcggtcaaaccttctggcatgccctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggaatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaaggttgccgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcgaaggcagcgacagtaaggtagcgctggcgccgttacccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggttctactggcggatttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgaggcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_433,Drugs,MEG_433|Drugs|betalactams|Class_C_betalactamases|ACT,779806809|WP_045331818.1|NG_050704|1|1|blaACT-41|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-41 NG_050704:1-1146,0
,atgatgacccagagcattcgccgcagcatgctgaccgtgatggcgaccctgagcctgctgtttagcagcgcgaccctgcatgcgcaggcgaacagcgtgcagcagcagctggaagcgctggaaaaaagcagcggcggccgcctgggcgtggcgctgattaacaccgcggataacagccagattctgtatcgcgcggatgaacgctttgcgatgtgcagcaccagcaaagtgatggcggcggcggcggtgctgaaacagagcgaaagcgataaacatctgctgaaccagcgcgtggaaattaaaaaaagcgatctggtgaactataacccgattgcggaaaaacatgtgaacggcaccatgaccctggcggaactgggcgcggcggcgctgcagtatagcgataacaccgcgatgaacaaactgattgcgcatctgggcggcccggataaagtgaccgcgtttgcgcgcagcctgggcgatgaaacctttcgcctggatcgcaccgaaccgaccctgaacaccgcgattccgggcgatccgcgcgataccaccaccccgctggcgatggcgcagaccctgaaaaacctgaccctgggcaaagcgctggcggaaacccagcgcgcgcagctggtgacctggctgaaaggcaacaccaccggcagcgcgagcattcgcgcgggcctgccgaaaagctgggtggtgggcgataaaaccggcagcggcgattatggcaccaccaacgatattgcggtgatttggccggaaaaccatgcgccgctggtgctggtgacctattttacccagccggaacagaaagcggaaagccgccgcgatattctggcggcggcggcgaaaattgtgacccatggcttttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2144,Drugs,MEG_2144|Drugs|betalactams|Class_A_betalactamases|CTX,1028104888|WP_063860074.1|NG_049027|1|1|blaCTX-M-75|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-75 NG_049027:1-876,0
,atgaaaacatttgccgcatatgtaattatcgcgtgtctttcgagtacggcattagctggttcaattacagaaaatacgtcttggaacaaagagttctctgccgaagccgtcaatggtgtcttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaatgacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaagcaatgggaaagagacttgaccttaagaggggcaatacaagtttcagctgttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcctatggcaaccagaatatcagtggtggcattgacaaattctggttggaaggccagcttagaatttccgcagttaatcaagtggagtttctagagtctctatatttaaataaattgtcagcatctaaagaaaaccagctaatagtaaaagaggctttggtaacggaggcggcacctgaatatctagtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttggttgggttgagaagggaacagaggtttactttttcgcctttaacatggatatagacaacgaaaataagttgccgctaagaaaatccattcccaccaaaatcatggcaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4674,Drugs,MEG_4674|Drugs|betalactams|Class_D_betalactamases|OXA,1693892943|WP_140423320.1|NG_065438|1|1|blaOXA-827|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-827 NG_065438:1-801,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATCGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1919,Drugs,MEG_1919|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JX514368|+|271-1417|ARO:3002107|CMY-94 [Escherichia coli] ,0
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagtcagccacgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgttgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagattacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_868,Drugs,MEG_868|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502070|WP_071846222.1|NG_052232|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052232:71-862,2
,atgaaaaaacggattaccccattttcccgatttgcatcaaaaggcctttccgcctgtagcgcaggcatgttgctggtgacggtggcacatgccgccaatacggcagcagcaccagccggtgtggatgccatggtccaaaccgtgatgcaggcacaccagattccgggcatggccattgccatcatccagccaggaaagaccacttatcacaattatggtgtcgcctcccgcgaaaccggccagccggtccgggaaaccaccctgtttgaaatcggctccctttccaaaccgtttactgcactggtcgcccagcgggctgaaaccgaaggccggattgacctgtctgcaccggccagccgctacgttaccgccctgcggggcagtgcattcgaccggatcaccctcaggcagctcggtacttatagtgcaggcggattaccgctccagtttcctgacaatgtcactaccccggcagatgtactggcttattaccgccattggcaacctgtccatccggcaggtagcacccggctgtattccaatccgagcattggcctgatggggctggctgccagtcaggcaaccggagagtcctttgccggcctgctcgggacaacggtgctgcaacccctcggcatgaactcgacctatctgcaagtgcccccggaggcccgttcacgttatgccatgggttataccgccgccgggaaaccggtcagggtcaaccccggtccgctggatgaggaaacctacggcgtcaagtccacaaccgcagacatggccggatttttactggcgcatatggaccctgcgcgcagcaaaggtgcattgcggtcggcattacagcaaacacgtgtaccggtttattgtgccggacagacccggcaaggactgggctgggaaagttatcaagactggaaaaacctcgacgtgctgctggcgggaaattcaaatcaaatggtgtttgaaccgcagccggtaaaagcctgtcttgccggcaccatgaatgagcctgatgtgtgggtcaacaagaccggttctactgcgggattcggcgcttatgccgtattcctgcctgcccgacagaccggcattgtcatcctggccaaccgtaattacccgattgcagaccgtatccggctcgctcacgggattttgaccgcattgcactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3580,Drugs,MEG_3580|Drugs|betalactams|Class_A_betalactamases|LHK,1349894764|WP_104531867.1|NG_056485|1|1|blaLHK-4|blaLHK|class_C_beta-lactamase_LHK-4 NG_056485:1-1173,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCCTCGATGAGAGCCGGCGGCTAGACCCCTCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGTCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6603,Drugs,MEG_6603|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|695212518|ref|NG_036429.1|2846-3685,8
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcagcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatcagcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttacggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcagcggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1813,Drugs,MEG_1813|Drugs|betalactams|Class_C_betalactamases|CMY,1028104380|WP_063859768.1|NG_048795|1|1|blaCMY-125|blaCMY|class_C_beta-lactamase_CMY-125 NG_048795:1-1146,0
,ttgaaaaataaaaataaaaaaaacgactattccaaactagaacgaaaactctatatgtatattgtcgcgattgttgtggtagcagttatattcgtgttgtatattcgttcaatgatccgagggaagcttggggagtggatcgtacgttttttggaaaacgaatatggcttaaatcagctggacgcgatgaaattatatcattattccatacggaacaatatagaaatctttatttatgtggcgatcgccattagtattcttattctatgccgcgtcatgctttcaaaatttgcaaaatactttgacgagatcaataccggcattgatgtacttattcagaacgaagataaacaaattgagctttctgcggaaatggatgttatggaacacaagctcaacacattaaaacggactctggaaaagcgagagcaggatgcaaagctggccgaacaaagaaaaaatgatgttgttatgtacttggcgcatgatattaaaacgccccttacatccattatcggttatttgagcctgcttgacgaggcgccagacatgccggtagatcaaaaggcaaagtatgtgcatatcacgttggacaaagcgtatcgccttgaacaactaatcgacgagttttttgagattacacggtataacctccaaacgattactctcacaaaaacgcacatagacctatactatatgctggtgcagatgaccgatgaattttatccccagctttccgcacatggaaaacaggcgattatccacgcctccgtagatctgaccgtatccggtgacccagataaacttgcgagagtctttaacaacattttgaaaaacgccgctgcgtacagtgaggacaacagcatcattgacattaccgcgggcctatccgggaatatggtgtcaatcgtattcaagaacacaggaagcataccaaaagataagcttgctgccatatttgaaaagttctataggttggacaatgctcgttcttccgaaacaggcggcgcgggacttggattggcgatcgcaaaagaaatcattgtcctgcatggtgggcagatatatgcggaaagtaatgatcactacacgacatttacggtagagcttccagcctttccagacttggttgataaaagagattcctaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7486,Drugs,MEG_7486|Drugs|Glycopeptides|VanA-type_regulator|VANSA,1028100596|WP_063856731.1|NG_048427|1|1|vanS-A|vanS-A|VanA-type_vancomycin_resistance_histidine_kinase_VanS NG_048427:1-1149,5
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattacgcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccctttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4689,Drugs,MEG_4689|Drugs|betalactams|Class_D_betalactamases|OXA,1509794581|WP_122630890.1|NG_062310|1|1|blaOXA-688|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-688 NG_062310:32-856,0
,GGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTACCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGGATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6487,Drugs,MEG_6487|Drugs|betalactams|Class_A_betalactamases|SHV,gi|74422858|gb|DQ174308.1|1-865,0
,ATGAGGGAAGCGGTGATCGCCGAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCACACAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCGCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_961,Drugs,MEG_961|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|927928831|gb|KP754011.1|2104-2895 gi|331029077|gb|HQ386829.1|1547-2338 gi|695226656|ref|NG_041554.1|8007-8798 gi|374081727|emb|AM991328.2|685-1476 gi|317464132|gb|CP002446.1|3077511-3076720 gi|297787483|gb|GU585907.1|26909-26118 gi|695221349|ref|NG_039719.1|5499-6290 gi|207097977|gb|FJ042875.1|643-1434 gi|145284438|gb|EF527229.1|684-1475 gi|119698214|gb|EF051039.1|4097-4888,2
,TTCAAATATGTATCCGCTCATGATACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTAGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6896,Drugs,MEG_6896|Drugs|betalactams|Class_A_betalactamases|TEM,gi|25900616|emb|AJ437107.1|139-1069,0
,atgaaaacagtatttatccttatctccatgcttttccctgtcgcagttatggcacagaaaagcgtaaaaatatccgatgacatcagtatcacccaactctcggacaaagtgtacacttatgtatccctcgccgaaatcgaaggatggggtatggtaccttccaacgggatgattgttatcaacaaccaccaggcagcgttgctggacacaccgatcaatgacgcacaaacggaaatgctggtcaactgggtgacagactctttgcatgccaaagtcaccacgtttatcccgaaccactggcacggcgattgtattggcggactgggttacctgcaaaagaaaggtgtccgatcatacgcgaaccagatgacgatagacctcgccaaggaaaaaggattgcccgtaccggaacatggattcaccgattcactgaccgtcagcttggacggcatgcctctccaatgctattatttaggaggcgggcatgcgaccgacaatatcgtggtttggctgccgacagagaatatcctttttggcggatgtatgcttaaagacaaccaggcgacaagcatcggcaacatctcggacgcagacgtgacggcatggccgaaaactctcgataaggtaaaagccaagttcccctcggcccgctacgtcgtgcccggacatggcgactatggcggaaccgaactgatagagcataccaagcagatcgtgaaccaatatatagaaagcacctcaaagccatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1660,Drugs,MEG_1660|Drugs|betalactams|Class_B_betalactamases|CFIA,1188444881|WP_085562383.1|NG_054664|1|1|cfiA19|cfiA|subclass_B1_metallo-beta-lactamase_CfiA19 NG_054664:1-750,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgccgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5600,Drugs,MEG_5600|Drugs|betalactams|Class_C_betalactamases|PDC,1209144262|WP_088245224.1|NG_055282|1|1|blaPDC-219|blaPDC|class_C_beta-lactamase_PDC-219 NG_055282:1-1194,0
,GTTAACCCATTATGAACGTACGTAAACACAAGGCTAGTTTTTTTAGCGTAGTAATTACTTTTTTATGTCTCACGCTATCATTAAATGCTAATGCAACAGACTCAGTACTTGAAGCGGTTACCAATGCTGAAACTGAATTAGGCGCTAGAATTGGTCTAGCTGTGCATGATTTGGAAACGGGAAAACGTTGGGAACATAAATCTAATGAACGTTTTCCTCTAAGTAGTACCTTTAAAACACTTGCCTGTGCAAACGTTCTTCAAAGAGTTGATCTAGGTAAAGAAAGAATTGATAGAGTTGTGAGATTCTCTGAAAGCAATCTCGTTACATACTCACCTGTAACAGAAAAACATGTGGGTAAAAAAGGGATGTCGCTCGCAGAGCTGTGTCAGGCCACATTATCAACCAGTGATAATTCAGCTGCCAATTTTATTCTACAAGCGATTGGTGGACCTAAGGCTCTAACGAAATTTTTGCGTTCCATTGGCGACGATACTACGCGCCTTGATCGCTGGGAAACAGAACTTAACGAAGCGGTGCCTGGAGATAAGCGAGACACGACAACACCAATTGCAATGGTAACGACACTTGAAAAGTTACTAATTGACGAAACACTATCTATCAAATCTCGTCAACAACTAGAATCTTGGCTTAAAGGTAATGAGGTTGGCGATGCATTGTTTCGTAAAGGCGTTCCAAGTGACTGGATAGTAGCAGATAGAACAGGCGCTGGTGGTTATGGGTCGCGTGCTATTACTGCGGTGATGTGGCCTCCAAATCGCAAGCCTATCGTAGCCGCTCTATACATTACAGAGACAGACGCCTCGTTTGAAGAAAGAAATGCTGTCATTGCAAAAATTGGTGAGCAAATAGCGAAGACAGTATTAATGGAGAATAGCCGTAACTGATTTA,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1545,Drugs,MEG_1545|Drugs|betalactams|Class_A_betalactamases|CARB,gi|7381164|gb|AF135373.1|AF135373|1-912,0
,ATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTACTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCGGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGCCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCGTTTGCCCCCTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGTGTCAACCCTGGCATGCTGGCGGACGAGGCCTATGGCATCAAGACCAGCTCGGCGGATCTGCTGCGTTTTGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACCAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGATCCTCGAAGCCAATCCGACGGCGGCGCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTACCCCATCGAGGCGCGCATCAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1852,Drugs,MEG_1852|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AF357597|+|250-1399|ARO:3002021|CMY-10 [Klebsiella aerogenes] ,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1395,Drugs,MEG_1395|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_112_AKGL01000044,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagtttcccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaaggccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5476,Drugs,MEG_5476|Drugs|betalactams|Class_C_betalactamases|PDC,1343491223|WP_104009839.1|NG_056397|1|1|blaPDC-242|blaPDC|class_C_beta-lactamase_PDC-242 NG_056397:1-1194,0
,atgatgaaaaaatccctttgctgcgccctgctgctcggcatctcttgctctgctctcgccgcgccagtatcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaaccgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccggcgttttaggtggggatgccattgcgcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgagatcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagccaggcacaacgcgtctttacgccaatgccagcatcggtctttttggcgcgctggcggtcaaaccttccggcatgtcctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgtgccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggtatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaacgttgctgatgccacacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcggaggcagcgacagtaaggtagcgctggcgccgttgcccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggttctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgaggcgttacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_428,Drugs,MEG_428|Drugs|betalactams|Class_C_betalactamases|ACT,823297103|WP_047052637.1|NG_061414|1|1|blaACT-55|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-55 NG_061414:1-1146,0
,atggctctggcactcgttggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgaaagtagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccaatgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagttttatgaatatgatcactactcgcacctggttttgtagtgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagctggacaactaccaggcgtcgttgctcatggagcggcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5916,Drugs,MEG_5916|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111586|WP_063865798.1|NG_050475|1|1|qnrB15|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB15 NG_050475:37-681,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgatcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5466,Drugs,MEG_5466|Drugs|betalactams|Class_C_betalactamases|PDC,1408841623|WP_111672896.1|NG_060553|1|1|blaPDC-283|blaPDC|class_C_beta-lactamase_PDC-283 NG_060553:1-1194,0
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcagccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatatctagctctgttcgaaaagagattacttatagaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4498,Drugs,MEG_4498|Drugs|betalactams|Class_D_betalactamases|OXA,1559613011|WP_128268276.1|NG_063882|1|1|blaOXA-781|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-781 NG_063882:1-825,0
,ATGAAAATAATCAATATTGGAATTCTTGCCCATGTAGACGCTGGAAAGACGACCTTGACGGAGAGCCTGCTATATGCCAGCGGAGCCATTTCAGAACCGGGGAGCGTCGAAAAAGGGACAACGAGGACGGACACCATGTTTTTGGAGCGGCAGCGTGGGATTACCATTCAAGCGGCAGTCACTTCCTTCCAGTGGCACAGATGTAAAGTTAACATTGTGGATACGCCCGGCCACATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGTGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGACATTCTAGGAAATGAAAAACTCCTGCCTCATAAAACACGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCGCAGAGATTGCTGATACAGACCCTCTTTTGCATTTTGACATTGATACTGTTACACATGAGATTATGTTATCTTTTTTGGGAAAAGTACAGTTAGAAGTTATTTGTTCGCTATTAGAAGAAAAATATCATGTGGGCGTGGCTATGAAAGAGCCTTCGGTTATTTATCTGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAAGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTAATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTGA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7236,Drugs,MEG_7236|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,tet(W/32/O)_2_AM710602 ,4
,atgaaaaagataaaaattgttccacttattttaatagttgtagttgtcgggtttggtatatatttttatgcttcaaaagataaagaaattaataatactattgatgcaattgaagataaaaatttcaaacaagtttataaagatagcagttatatttctaaaagcgataatggtgaagtagaaatgactgaacgtccgataaaaatatataatagtttaggcgttaaagatataaacattcaggatcgtaaaataaaaaaagtatctaaaaataaaaaacgagtagatgctcaatataaaattaaaacaaactacggtaacattgatcgcaacgttcaatttaattttgttaaagaagatggtatgtggaagttagattgggatcatagcgtcattattccaggaatgcagaaagaccaaagcatacatattgaaaatttaaaatcagaacgtggtaaaattttagaccgaaacaatgtggaattggccaatacaggaacacatatgagattaggcatcgttccaaagaatgtatctaaaaaagattataaagcaatcgctaaagaactaagtatttctgaagactatatcaacaacaaatggatcaaaattgggtacaagatgataccttcgttccactttaaaaccgttaaaaaaatggatgaatatttaagtgatttcgcaaaaaaatttcatcttacaactaatgaaacagaaagtcgtaactatcctctagaaaaagcgacttcacatctattaggttatgttggtcccattaactctgaagaattaaaacaaaaagaatataaaggctataaagatgatgcagttattggtaaaaagggactcgaaaaactttacgataaaaagctccaacatgaagatggctatcgtgtcacaatcgttgacgataatagcaatacaatcgcacatacattaatagagaaaaagaaaaaagatggcaaagatattcaactaactattgatgctaaagttcaaaagagtatttataacaacatgaaaaatgattatggctcaggtactgctatccaccctcaaacaggtgaattattagcacttgtaagcacaccttcatatgacgtctatccatttatgtatggcatgagtaacgaagaatataataaattaaccgaagataaaaaagaacctctgctcaacaagttccagattacaacttcaccaggttcaactcaaaaaatattaacagcaatgattgggttaaataacaaaacattagacgataaaacaagttataaaatcgatggtaaaggttggcaaaaagataaatcttggggtggttacaacgttacaagatatgaagtggtaaatggtaatatcgacttaaaacaagcaatagaatcatcagataacattttctttgctagagtagcactcgaattaggcagtaagaaatttgaaaaaggcatgaaaaaactaggtgttggtgaagatataccaagtgattatccattttataatgctcaaatttcaaacaaaaatttagataatgaaatattattagctgattcaggttacggacaaggtgaaatactgattaacccagtacagatcctttcaatctatagcgcattagaaaataatggcaatattaacgcacctcacttattaaaagacacgaaaaacaaagtttggaagaaaaatattatttccaaagaaaatatcaatctattaaatgatggtatgcaacaagtcgtaaataaaacacataaagaagatatttatagatcttatgcaaacttaattggcaaatccggtactgcagaactcaaaatgaaacaaggagaaagtggcagacaaattgggtggtttatatcatatgataaagataatccaaacatgatgatggctattaatgttaaagatgtacaagataaaggaatggctagctacaatgccaaaatctcaggtaaagtgtatgatgagctatatgagaacggtaataaaaaatacgatatagatgaataa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3771,Drugs,MEG_3771|Drugs|betalactams|Penicillin_binding_protein|MECA,1028094339|WP_063851348.1|NG_047936|1|1|mecA|mecA|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA NG_047936:101-2107,0
,ATGGAAAATGGTTTTTTGTTTTTAGATGAAATGTTGCATGGCGTCCGTTGGGATGCCAAGTACGCCACATGGGATAACTTCACAGGAAAACCGGTGGATGGGTATGAGGTGAATCGCATCATCGGCACAAAGGCCGTGGCGTTTGCTCTGCGCGAGGCACAAATCCATGCGGCTGCGCTTGGCTATGGCTTGCTTTTATGGGATGGATATCGGCCAAGAACTGCGGTGGACTGCTTCCTGCGTTGGGCAGCGCAACCGGAGGACAATCTCACAAAAGAAAAATTTTACCCCAATATAGAGCGAGCCGAGTTGATTACAAAGGGTTATGTGGCCTCACAATCCAGCCATAGCCGTGGAAGCGCAATTGATCTTACGCTCTACCACCTGGATACAGGGGAACTTGTTTCAATGGGAAGTAACTTCGATTTTATGGACGAACGGTCGCATCATACAGCAAAAGGGATAGGGGATGCAGAGGCACAAAATCGAAGATGCTTGCGTAAAATCATGGAAAGCAGCGGATTTCAGTCTTATCGCTTTGAATGGTGGCACTATAAGTTGATTGATGAGCCATACCCCGATACCTATTTTAATTTTGCCGTTTCATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7561,Drugs,MEG_7561|Drugs|Glycopeptides|VanB-type_resistance_protein|VANXB,(Gly)VanX-B:AY655721:5891-6499:609,5
,atgctggtggagcaaggcagattggcaatacgtgcgttacagaaaagcgatgcgccggtgatgctgcactggctccaggatgaacgtgtgctggaattttacgaagggcgcgataaacgcttcgatctgcaaacggtcattgaagtttttatcgaagatcagggggaaaccacaccatgtctggtgttgctggatgataaaccgctgggctatgtgcagttctacccgctggatagcgaagataaacaggcattggaactaccggttgaggacgtgatctacgggctggatcagtttatcggcgaaccggatttctgggggctgggacttggcactgagcttgtctcgctggtgcgcgattatctcataacagacaaggccgcacagcgccttgttctcgacccgcaaagccgtaacttacgcgctattgcctgttatgaaaaatgcggctttgaaaaactctgcctcttgcctgcccatgaaatgcatgaagggcagctgcaggattgctggctaatgcagtattaccccgcgcgcagcagcctgattgcctcgtcacggccgaaaatatag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_184,Drugs,MEG_184|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,446882549|WP_000959805.1|NG_052083|1|1|aacA57-2|aacA57-2|aminoglycoside_N-acetyltransferase_AAC(6')-Ian NG_052083:101-673,2
,atggaattgcccaatattatgcacccggtcgcgaagctgagcaccgcattagccgctgcattgatgctgagcgggtgcatgcccggtgaaatccgcccgacgattggccagcaaatggaaactggcgaccaacggtttggcgatctggttttccgccagctcgcaccgaatgtctggcagcacacttcctatctcgacatgccgggtttcggggcagtcgcttccaacggtttgatcgtcagggatggcggccgcgtgctggtggtcgataccgcctggaccgatgaccagaccgcccagctcctcaactggatcaagcaggagatcaacctgccggtcgcgctggcggtggtgactcacgcgcatcaggacaagatgggcggtatggacgcgctgcatgcggcggggattgcgacttatgccaatgcgttgtcgaaccagcttgccccgcaagaggggatggttgcggcgcaacacagcctgactttcgccgccaatggctgggtcgaaccagcaaccgcgcccaactttggcccgctcaaggtattttaccccggccccggccacaccagtgacaatatcaccgttgggatcgacggcaccgacatcgcttttggtggctgcctgatcaaggacagcaaggccaagtcgctcggcaatctcggtgatgccgacactgagcactacgccgcgtcagcgcgcgcgtttggtgcggcgttccccaaggccagcatgatcgtgatgagccattccgcccccgatagccgcgccgcaatcactcatacggcccgcatggccgacaagctgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4140,Drugs,MEG_4140|Drugs|betalactams|Class_B_betalactamases|NDM,1408841639|WP_111672912.1|NG_060570|1|1|blaNDM-23|blaNDM|subclass_B1_metallo-beta-lactamase_NDM-23 NG_060570:1-813,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgccatgggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1815,Drugs,MEG_1815|Drugs|betalactams|Class_C_betalactamases|CMY,1509794527|WP_122630836.1|NG_062242|1|1|blaCMY-158|blaCMY|class_C_beta-lactamase_CMY-158 NG_062242:1-1146,0
,atgataatcagtgaatttgaccgtaataatccagtattgaaagatcagctttctgatttactgagactgacttggccggaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacgaatcgcggtagcagcggtagaccaagatgagttagtaggatttattggtgcaatccctcaatacggtatcacaggttgggaattgcatccattagttgtagaaagctcccgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagaggaggaatcacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaagcggacctgtatgagcatacatttgataaagtggcttccatccagaaccttcgtgaacatccgtatgaattctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaaatggctgggacaaaccggatatttggatggcaaaaacgattattcctcgaccaaattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_85,Drugs,MEG_85|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502203|WP_071846353.1|NG_052465|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052465:101-649,2
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgatcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6193,Drugs,MEG_6193|Drugs|betalactams|Class_A_betalactamases|SHV,1509794571|WP_122630880.1|NG_062300|1|1|blaSHV-228|blaSHV|class_A_beta-lactamase_SHV-228 NG_062300:1-861,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcgcgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggctacggcaatgcggacgtctcgggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaagctggtgaaccggcaattgccggtcaaggccgccgcttatgagcttgccgaaaacctcttcgaggcgggccaggccgatggctggcgcctgtatggcaaaaccggcaccgggtcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccggcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4545,Drugs,MEG_4545|Drugs|betalactams|Class_D_betalactamases|OXA,1625655399|WP_136512076.1|NG_064739|1|1|blaOXA-114r|blaOXA-114_like|class_D_beta-lactamase_OXA-114r NG_064739:1-828,0
,atgtccgccaacaatgccgcaatagttctacgagtcatgggcgagaacgatctgccaatgctccatgcttggctgaaccgcccccacatagtcgagtggtggggcggcgaggatgaacgcccaactcttgacgaagtcttagaacactattcgcccgaagttctggcaaagcaagctgtagtgccttacatcgcaatgctagatgacgaacccatcggctacgcccaatcctacatcgcacttggaagtggcgatggatggtgggaagacgaaactgatccaggggtccgcgggattgaccagtctttggctaatccatcacagttaaacaaggggttgggtacaaagctcgtacgctcgctcgttgaactcctgtttagcgacccggccgtaacgaaaatccaaaccgatccatctcctagcaaccatcgcgccattcgctgctacgagaaggccgggttcgttcaagaaaaaaacatcctcacacctgacggccctgcggtgtacatggtccaaacacgccaggcgttcgaaagcctgcgcactgttcaaagcttcaaaatcaaggggaagtggtcatga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_205,Drugs,MEG_205|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,779809410|WP_045332676.1|NG_052462|1|1|aac(6')-IIc|aac(6')-IIc|aminoglycoside_N-acetyltransferase_AAC(6')-IIc NG_052462:99-680,2
,GCGCCAATGTCAGATAAACAGCTGGCTGATGTGGTGAAACGTACCATTACGCCGTTGATGAAAGCCCAGACCATTCCCGGAATGGCGGTTGCGGTGATTTATCAGGGTCAGCCGCACTACTTTACCTTCGGCAATGCTGATGTCGCGGCAAACAAACCTGTCACCCCGCAAACCTTATTTGAGCTGGGTTCTATTAGTAAAACCTTCACCGGTGTTTTAGGTGGGGATGCCATTGCTCGCGGTGAGATTTCACTGACCGATCCGGCCACAAAATACTGGCCAGAATTGTCGGGCAAACAGTGGCAGGGTATTCGCATGCTCGATCTGGCGACCTATACCGCCGGTGGTCTGCCCCTGCAGGTACCGGACGAGGTTACGGATAGCGCCTCTCTGCTGCGCTTCTATCAAAACTGGCAGCCACAGTGGAAGCCGAGCACCACGCGCCTTTATGCGAATGCCAGCATCGGTCTTTTTGGTGCACTGGCGGTTAAACCGTCCGGCATGAGCTATGCGCAGGCAATGACGGAGCGGGTCTTTAAGCCGCTCAAACTGGGCCATACCTGGATTAACGTTCCGAAAACTGAAGAGGAGCATTACGCCTGGGGCTACCGCGACGGCAAACCGGTACACGTTTCGCCAGGCGCGCTGGACGCCGAAGCCTATGGCGTCAAAAGCAACGTGCAAGATATGGCGAGCTGGGTGATGGCAAATATAGCGCCGGAGCACGTTGCTGATGCGTCACTTAAGCAAGGGATCGCGCTGGCACAGTCTCGTTACTGGCGCATCGGCTCCATGTATCAGGGGCTGGGCTGGGAAATGCTCAACTGGCCGGTCGATGCCAAAACCGTTGTCGGCGGCAGTGATAACAACGTTGCGCTGGCACCGTTGCCTGCGAGAGAAGTGACTCCCCCGGTACCTCCGGTTAAGGCTTCATGGGTGCACAAAACGGGTTCAACTGGCGGATTTGGGGGCTATGTAGCTTTCATTCCGGAGAAAAATCTCGGTATCGTGAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_448,Drugs,MEG_448|Drugs|betalactams|Class_C_betalactamases|ACT,(Bla)ZEG-1:AY265891:1-1013:1013,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagagctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaagctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgattggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5528,Drugs,MEG_5528|Drugs|betalactams|Class_C_betalactamases|PDC,1408841617|WP_111672890.1|NG_060546|1|1|blaPDC-276|blaPDC|class_C_beta-lactamase_PDC-276 NG_060546:1-1194,0
,ATGTCGATACGAATTCTACTTGTCGAGGATGATGATCATATCTGTAATACAGTAAGGGCGTTTCTGGCTGAGGCAGGATATCAGGTGGATGCCTGCACAGATGGAAATGAGGCATACACCAAGTTTTACGAAAACACTTATCAACTGGTTATTCTTGATATTATGCTGCCCGGTATGAACGGGCATGAACTTTTGCGTGAATTTCGTGCGAAAAATGATACTCCCATTCTGATGATGACAGCCCTGTCGGATGACGAAAACCAAATCCGGGCGTTTGATGCAGAGGCAGACGACTATGTAACAAAGCCATTCAAGATGCAGATTTTACTAAAGCGGGTGGAAGCCCTGCTGCGGCGCAGCGGTGCGCTGGCAAAGGAAATCCGTGTCGGCAGGCTGACACTTCTGCCGGAGGATTTCACGGTACTTTGTGACGGTACAGAGCTGCCCCTGACACGAAAAGAATTTGAAATCCTTTTGCTGCTGGTGCAGAACAAAGGCAGAACCTTAACGCATGAAATCATTTTGTCACGTATATGGGGATATGACTTTGAGGGTGATGGCAGCACAGTCCACACTCATATCAAAAATTTGCGGGCCAAGCTGCCGGAAAATATCATCAAAACCATTCGCGGTGTAGGATACCGATTGGAGGAATCATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7462,Drugs,MEG_7462|Drugs|Glycopeptides|VanB-type_regulator|VANRB,(Gly)VanR-B:AY655721:69-728:660,5
,atgaatataaatgaatttccacaacaagtaaatcaagttatttcaatagcagaaaccatattacaaggtcaaatattggggatatatttatatggttcagcaacaatgaatgggctgcgtccagatagtgatatagatatactgataattactaaacaagaattgagtaattcaatcagagcagatctaacaaagcaattattgaaaatttctggctccgtaggctgtattgaaaaaagacctttagaggtaactattatcaatcaatctgatattgttccgttgcaatttccgccaaaatgtcagtatatgtatggtgaatggctaaggggagagatggaagcaggagaatatccgcaagcctgcaatgacccagatataatgattttattatggcaagcaagaaaaaatagcataactttgaagggggcggaaagcaaagagcttattcccgctatcccatttcacgaaattaaaaaagcaattcggttttctttacctggtttgatttccagctttaagggtgatgaaagaaatgtgttattaaccttatcacgaatgtggtttactttagtaacagaagaaatcacgacaaaagatgttgccgcaaaatgggtaattttaaaattgccggagagatttccccccctgctaacaacggcaaaggaagcttatttgggaaatttgtctgatgaatgggagacagtagaaaaggaagcgatggcacttgtagaatatatgaaaaaacaaattgaggaattacttagaacagagtag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1003,Drugs,MEG_1003|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT9,488642079|WP_002578722.1|NG_047322|1|1|aad9|aad9|ANT(9)_family_aminoglycoside_nucleotidyltransferase NG_047322:101-877,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaacgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccgcggcccactcgatgccgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_551,Drugs,MEG_551|Drugs|betalactams|Class_C_betalactamases|ADC,690991483|WP_031961878.1|NG_056163|1|1|blaADC-171|blaADC|class_C_beta-lactamase_ADC-171 NG_056163:101-1255,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggcgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5663,Drugs,MEG_5663|Drugs|betalactams|Class_C_betalactamases|PDC,1343491242|WP_104009858.1|NG_056421|1|1|blaPDC-229|blaPDC|class_C_beta-lactamase_PDC-229 NG_056421:1-1194,0
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagacctgtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_233,Drugs,MEG_233|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1040987976|WP_065187201.1|NG_052219|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052219:101-655,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccagcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5566,Drugs,MEG_5566|Drugs|betalactams|Class_C_betalactamases|PDC,1028110190|WP_063864560.1|NG_049868|1|1|blaPDC-101|blaPDC|class_C_beta-lactamase_PDC-101 NG_049868:1-1194,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1354,Drugs,MEG_1354|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_82_FGSJ01000003,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5581,Drugs,MEG_5581|Drugs|betalactams|Class_C_betalactamases|PDC,730540608|WP_034041053.1|NG_049918|1|1|blaPDC-45|blaPDC|class_C_beta-lactamase_PDC-45 NG_049918:1-1194,0
,ATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGTAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGGATGGTAAAAAAAGGTTATTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCCATGAAAGCTTCCGCTATTCGAGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAGCTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAGTTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAACAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAAACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGCTTAGAACAATTAGGTATTTTATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_4746,Drugs,MEG_4746|Drugs|betalactams|Class_D_betalactamases|OXA,(Bla)OXA-199:HQ637466:1233-2057:825,0
,atgtttaaaaaaacatttcgccaaactgctgcgatcgcagtttcattaatatctctattggcatccgccactctatgggctaacaccaataatacaattgaagcgcaattaagtgagcttgaaaaatacaatcaaggtcgtttaggagtggctttaatcaacacggaagataactcacaaataacataccgtggtgaagaacgttttgcgatggcaagtacaagtaaagttatggctgttgcggctgttttaaaagagagtgaaaaacaagcgggattattagataagaacattgcgattaaaaaatctgacttggttgcttacagtcctattacagaaaagcatttagtaacaggaatgtctttagctcaattaagtgcagccaccttgcaatatagtgataatacggcaatgaataaaattctagattatttaggaggaccttccagcgttactcaatttgcacgttcaattaatgatgtaacttatcgcctagatcgcaaagagcctgaattaaatacagccattcatggtgatcctcgtgataccacctctccaattgcgatggctaaaagccttcaagcattaacattaggtgacgcattaggtcaatctcaacgccaacaacttgttacttggttaaaaggtaatacaacaggtgatcacagtattaaagcgggtttaccaaaacactggattgttggcgataaaaccggtagtggtgattatggtacaactaacgatattgccgttatttggccagaaaaccatgcaccattaattttagtcgtttattttacacaacaagaaaaagatgcaaaataccgtaaagatattattgctaaagctactgaaattgtcacaaaagagtttgccaattcacctcaaacaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3282,Drugs,MEG_3282|Drugs|betalactams|Class_A_betalactamases|HUGA,1028094273|WP_063851311.1|NG_047910|1|1|hugA|hugA|class_A_beta-lactamase NG_047910:101-997,0
,GTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTTACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAAGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_350,Drugs,MEG_350|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|459978567|dbj|AB777500.1|1127-1681 gi|441482385|gb|JX982232.1|280-834,2
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggctgggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6217,Drugs,MEG_6217|Drugs|betalactams|Class_A_betalactamases|SHV,556493810|WP_023341517.1|NG_062283|1|1|blaSHV-211|blaSHV|class_A_beta-lactamase_SHV-211 NG_062283:1-861,0
,atgaacatcaacgatgccctcacctccatcctggcctcaaaaaaataccgcgccctttgcccggataccgtgcggcgcatcctgaccgaggaatgggggcggcataaatcccccaaacaggccgtagaggctgcacgcacccggctgcatggaatttgcggggcatatgtcaccccggaatcgctcaaggctgctgccgccgcgctttctgcgggcgatgtaaaaaaggcattgtcgctgcatgcctccaccaaggagcgactggccgagctggataccctgtacgattttatcttttcagccgaaactccccgccgcgtgctggatatcgcctgcggtcttaaccccttggcgctatacgagcgcggcattgcatccgtgtggggctgtgatatccaccagggattaggggatgtaatcaccccctttgctagggaaaaagattgggattttacctttgccctgcaggatgtgctgtgtgcgccgcccgccgaagccggcgacctggcgctgatttttaagcttttgcccctgctggagcgggagcaggccggttctgccatggcacttttacaatccctcaataccccgcgcatggctgtcagctttcccacgcgtagtttaggcgggcgtggaaaaggcatggaggcgaactacgccgcatggttcgagggcggcttgcccaccgagtttgaaattgaggataaaaagaccatcggaacagaacttatatatttgataaaaaagaatggataa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_6061,Drugs,MEG_6061|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|RMTB,695688995|WP_032634099.1|NG_051536|1|1|rmtB4|rmtB|16S_rRNA_(guanine(1405)-N(7))-methyltransferase_RmtB4 NG_051536:1-756,2
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaggcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcagacgaccatctcgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccgccagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_879,Drugs,MEG_879|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502079|WP_071846231.1|NG_052243|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052243:101-889,2
,CGATTGGCATTGGTTCCTTTTTAGAGATTTGTTTAAGATAAGATATAACTCATTGAGATGTGTCATAGTATTCGTCGTTAGAAAACAATTATTATGACATTATTTCAATGAGTTATCTATTTTTGTCGTGTACAGAGCTCTTTTTTATTTTCTATTGATCTGGTGTTTAAAATGAATAAATATTTTACTTGCTATGTGGTTGCTTCTCTTTTTCTTTCTGGTTGTACGGTTCAGCATAATTTAATAAATGAAACCCCGAGTCAGATTGTTCAAGGACATAATCAGGTGATTCATCAATACTTTGATGAAAAAAACACCTCAGGTGTGCTGGTTATTCAAACAGATAAAAAAATTAATCTATATGGTAATGCTCTAAGCCGCGCAAATACAGAATATGTGCCAGCCTCTACATTTAAAATGTTGAATGCCCTGATCGGATTGGAGAACCAGAAAACGGATATTAATGAAATATTTAAATGGAAGGGCGAGAAAAGGTCATTTACCGCTTGGGAAAAAGACATGACACTAGGAGAAGCCATGAAGCTTTCTGCAGTCCCAGTCTATCAGGAACTTGCGCGACGTATCGGTCTTGATCTCATGCAAAAAGAAGTAAAACGTATTGGTTTCGGTAATGCTGAAATTGGACAGCAGGTTGATAATTTCTGGTTGGTAGGACCATTAAAGGTTACGCCTATTCAAGAGGTAGAGTTTGTTTCCCAATTAGCACATACACAGCTTCCATTTAGTGAAAAAGTGCAGGCTAATGTAAAAAATATGCTTCTTTTAGAAGAGAGTAATGGCTACAAAATTTTTGGAAAGACTGGTTGGGCGGCAATGGATATAAAACCACAAGTGGGCTGGTTGACCGGCTGGGTTGAGCAGCCAGATGGAAAAATTGTCGCTTTTGCATTAAATATGGAAATGCGGTCAGAAATGCCGGCATCTATACGTAATGAATTATTGATGAAATCATTAAAACAGCTGAATATTATTTAAGAGCTGACAGAAACTCTAATTATG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5211,Drugs,MEG_5211|Drugs|betalactams|Class_D_betalactamases|OXA,gi|208431881|gb|FJ194494.1|1-1020,0
,ATGATTAAAAAGATTATTTCTGGAGCTTGCTTGGTTTTGCTGGCTGGGTGCGTGTTGGGTGTGAAGCCGGCGGGGAAAGAGACGGGGTTTATGATTGATTCTGGACGTTTTGCCGGGATGGATGGCTGCGCTATTGTTTTTGATGCGCGGATGGGAAAAATTGCGGGGGTTTATGGGGAGAAGCGGTGCAAGGAACGGGTTACGGCTTGTTCTACGTTCAAGGTGCCGCTGGCTTTGATGGCTTTTGATTCTGGGGTGCTGAGCGACGAGAGCACGGTGCTGAAGTGGGATGGAGTGCAGTGGCCGTTCGACTCCTGGAACCAGGACCAGACGGCGGCCTCGTGGCTGCGCAATTCGGTGGTGTGGTATTCGCAGCGGCTGACTCCAATGCTGGGCTTGGAAAAGATAAAGGCTTACCTAAAGGCTTTCGATTACGGGAATCAGGACTTTTCTTCCGGCCTGACCAGCGCTTGGCTTACCATCACCAAGAGCGATACGAATCCGGATAAGGGCAGTCTTAAAATCTCAGCCTACGAGGAACTGGAGTTCTTTAGACGGTTTTGGCGTGGCGCGCTCCCGGTGAGCGGGGCCGCGGTGGAGAAGACTAAAAAAATGATTTACCTGGAGACCTCTCCCGGCGGTTATGCGCTGCACGGCAAGACCGGCTCCGGCTATCTCGACGGATTGACCGGGGATTTCGGCTGGTTCGCCGGCCACGTAGAGGGCAAAGGCCGGGAGTATTTTGTTGTAACGGCCGTCACGCGGAATGGGAATGCCGCCGACGCACGCATCCCCGGCCTGGTGGCGAAGGAACTCGCCAAGAACATCCTTAAAGATAATTCGGTCTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6148,Drugs,MEG_6148|Drugs|betalactams|Class_A_betalactamases|RSA,gb|MG739504.1|+|0-852|ARO:3004445|RSA-2 [uncultured bacterium] ,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaataccccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagtgctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggtccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaacctcaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtatcataaaactggctcaaccaacggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_610,Drugs,MEG_610|Drugs|betalactams|Class_C_betalactamases|ADC,447133982|WP_001211238.1|NG_048650|1|1|blaADC-26|blaADC|class_C_extended-spectrum_beta-lactamase_ADC-26 NG_048650:1-1152,0
,ATGGCTGAATTACCTCAATCAAGAATAAATGAACGAAATATTACCAGTGAAATGCGTGAATCATTTTTAGATTATGCGATGAGTGTTATCGTTGCTCGTGCATTGCCAGATGTTCGTGACGGTTTAAAACCAGTACATCGTCGTATACTATATGGATTAAATGAACAAGGTATGACACCGGATAAATCATATAAAAAATCAGCACGTATCGTTGGTGACGTAATGGGTAAATATCACCCTCATGGTGACTTATCTATCTATGAAGCAATGGTACGTATGGCTCAAGATTTCAGTTATCGTTATCCGCTTGTTGATGGCCAAGGTAACTTTGGTTCAATGGATGGAGATGGCGCAGCAGCAATGCGTTATACTGAAGCACGTATGACTAAAATCACACTTGAACTGTTACGTGATATTAATAAAGATACAATAGATTTTATCGATAACTATGATGGTAATGAAAGAGAGCCGTCAGTCTTACCTGCTCGATTCCCTAACTTGTTAGCCAATGGTGCATCAGGTATCGCGGTAGGTATGGCAACGAATATTCCACCACATAACTTAACAGAATTGATCAATGGTGTACTTAGCTTAAGTAAGAATCCTGATATTTCAATTGCTGAGTTAATGGAAGATATTGAAGGTCCTGATTTCCCAACTGCTGGACTTATTTTAGGTAAGAGTGGTATTAGACGCGCATATGAAACAGGTCGTGGTTCAATTCAAATGCGTTCTCGTGCAGTTATTGAAGAACGTGGAGGCGGACGTCAACGTATTGTTGTCACTGAAATTCCTTTCCAAGTGAATAAGGCTCGTATGATTGAAAAAATTGCAGAGCTTGTTCGTGACAAGAAAATTGACGGTATTACTGATTTACGTGATGAAACAAGTTTACGTACTGGTGTGCGTGTCGTTATTGATGTGCGTAAGGATGCCAATGCTAGTGTCATTTTAAATAACTTATACAAACAAACACCTCTTCAAACATCATTTGGTGTGAATATGATTGCTCTAGTGAATGGTAGACCGAAGCTGATTAATTTAAAAGAAGCGTTAGTACATTATTTAGAGCATCAAAAGACAGTTGTTAGAAGACGTACGCAATACAACTTACGTAAAGCTAAAGATCGTGCCCACATTTTAGAAGGGTTACGTATTGCGTTAGATCATATCGATGAAATTATTTCAACGATTCGTGAATCAGAAACAGATAAAGTCGCAATGGAAAGTTTGCAACAACGCTTCAAACTTTCTGAAAAACAAGCTCAAGCTATTTTAGACATGCGTTTAAGACGTCTAACAGGTTTAGAGAGAGACAAAATTGAAGCTGAATATAATGAGTTATTAAATTATATTAGTGAATTAGAAGCAATCTTAGCTGATGAAGAAGTGTTATTACAGTTAGTTAGAGATGAATTGACTGAAATTAGAGATCGCTTCGGTGATGATCGTCGTACTGAAATTCAATTAGGTGGATTTGAAGACTTAGAGGACGAGGACTTAATTCCAGAAGAACAAATTGTAATTACTTTGAGCCATAATAACTATATTAAACGTTTGCCGGTATCTACATATCGTGCTCAAAACCGTGGTGGTCGTGGTGTTCAAGGTATGAATACATTGGAAGAAGATTTTGTCAGTCAATTGGTAACTTTAAGTACACATGACCATGTATTGTTCTTTACTAACAAAGGTCGTGTATACAAACTAAAAGGTTATGAAGTGCCTGAGTTATCAAGACAGTCTAAAGGTATTCCTGTAGTGAATGCTATTGAACTTGAAAATGATGAAATCATTAGTACAATGATTGCTGTTAAAGACCTTGAAAGTGAAGATAACTTCTTAGTGTTTGCAACTAAACGTGGTGTCGTTAAACGTTCAGCATTAAGTAACTTCTCAAGAATAAATAGAAATGGTAAGATTGCGATTTCGTTCAGAGAAGATGATGAGTTAATTGCAGTTCGCTTAACAAGTGGTCAAGAAGATATCTTGATTGGTACATCACATGCATCATTAATTCGATTCCCTGAATCAACATTACGTCCTTTAGGCCGTACAGCAACGGGTGTGAAAGGTATTACACTTCGTGAAGGTGACGAAGTTGTAGGGCTTGATGTAGCTCATGCAAACAGTGTTGATGAAGTATTAGTAGTTACTGAAAATGGTTATGGTAAACGTACGCCAGTTAATGACTATCGTTTATCAAATCGTGGTGGTAAAGGTATTAAAACAGCTACGATTACTGAGCGTAATGGTAATGTTGTATGTATCACTACAGTAACTGGTGAAGAAGATTTAATGATTGTTACTAATGCAGGTGTCATTATTCGACTAGATGTTGCAGATATTTCTCAAAATGGTCGTGCAGCACAAGGTGTTCGCTTAATTCGCTTAGGCGATGATCAATTTGTTTCAACGGTTGCTAAAGTAAAAGAGGATGCAGACGAAGAAAATGAAGATGAACAATCTACTGTATCTGAAGATGGTACTGAACAACAACGTGAAGCGGTTGTAAATGATGAAACACCAGGAAATGCAATTCATACTGAAGTGATTGATTCAGAAGTAAATGATGAAGATGGACGTATTGAAGTAAGACAAGATTTCATGGACCGTGTTGAAGAAGACATACAACAATCATCAGATGATGATGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3186,Drugs,MEG_3186|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|NC_002952|+|7004-9665|ARO:3003296|Staphylococcus aureus gyrA conferring resistance to fluoroquinolones [Staphylococcus aureus subsp. aureus MRSA252] ,3
,ATGGTCTTAGTAATGAAAGATATCGGCATTACCATTTATGGATCTGAGCAGGATGAGGCTGATGTGTTCCAGGAAATTTCATCTCGATTTGGCGTTACACCTACCATTGTAAGCTCTCCTATATCAGAAACCAACGTAATGTTAGCCCCTAAAAATAAGTGTATCAGCGTGGGGCACAAGTCTGAGATTCACAAATCTATCCTTATTGCATTGAAGGAATCCGGCGTCAAATATATCTCTACTCGAAGTATTGGTTACAATCATATAGATATGAAGGCAGCGGAAAAAATGGGTATTGCTGTCGAGAACGTCACTTATTCACCAGATAGTGTTGCCGATTATACATTGATGCTGATACTTATGGCAATACGCCATACGAAATCTACTTTGTGCTCTATGGAAAAACATGATTTCAGACTGAACAGCGTCCGTGGTAAAGTACTGCGTGACCTGACAGTAGGTGTACTGGGAACCGGTCATATAGGCAAAGCGGTTATTGAGCGACTACAGGGGTTTGGAGGTCACGTGTTGGCGTACGGCAACAACAAAGAGGCGACGGCAAATTATGTATCCTTCAATGAATTACTGCAAAAAAGTGACATTCTAACCATTCATGTACCCCTTAGCGATGACACATACCATATGATCGGTCACGAACAGATTAAAGCAATGAAACAGGGCGCCTTTCTTATTAATACTGCTCGAGGTGGACTTATAGATACCGAAGTTCTGGTTAAAGCACTGGAGGACGGAAAACTGGGGGGCGCCGCATTAGATGTATTAGAGGGAGAAGAAGGGCTTTTCTACTTTGATTGCACCCAAAAGCCAATTAACAATCAATTTTTGCTGAAACTTCAAAGGATGCCAAATGTGACAATCACACCGCATACGGCTTACTATAGCGAAAAAACGTTACGTGATACTGTTGAAAAAACAGTCAAGAACTGTTTGGAATTTGAGAGGAGAGAGACACATGAATAGATTGAAAATAGCCATCCTGTTTGGGGGTTGCTCAGAAGAGCATAATGTATCGGTAAAATCAGCGGCAGAGATTGCCAACAACATTGATATAGGAAAATATGAACCAATATACATCGGAATAACCCAATCTGGCGTTTGGAAAACATGCGAAAAACCATGTATAGATTGGGATAATGAACACTGTCGCTCGGCAGTACTTTCTCCGGATAAAAAAATGCATGGGTTGCTTATTATGCAAGATAAAGGATATCAAATACAGCGTATAGATGTAGTCTTTTCAGTGTTGCACGGAAAATCGGGTGAAGACGGCGCCATACAAGGATTATTTGAATTGTCTGGTATACCTTATGTAGGCTGTGATATTCAAAGTTCGGCGGTTTGTATGGACAAATCACTGGCATATATTATTGCGAAAAACGCTGGCATAGCTACTCCTGAATTTCAGGTCATTTATAAAGACGATAAGCCAGCGGCAGATTCGTTTACCTATCCCGTTTTTGTTAAGCCAGCACGTTCAGGTTCCTCCTATGGTGTGAATAAAGTTAATAGTGCGGATGAATTGGACTCCGCAATTGACTTGGCAAGACAATATGACAGCAAAATCCTAATTGAGCAGGGTGTTTTAGGTTATGAGGTCGGTTGTGCCGTATTGGGAAACAGTTTCGACTTGATTGTTGGTGAAGTGGATCAAATCAGACTGCAACACGGTATTTTTCGTATTCATCAGGAAGCCGAGCCGGAAAAAGGTTCTGAAAACGCAACTATAACCGTTCCCGCAGAACTATCGGCAGAGGAGCGAGAACGGATAAAAGAAGCGGCAAAAAATATATATAAGGCGCTCGGGTGTAGAGGTCTTTCTCGTGTTGATATGTTTTTACAAGATAACGGCCGCATTGTACTAAATGAAGTCAATACCATGCCTGGTTTCACGTCATACAGCCGTTATCCACGTATGATGGTCTCAGCAGGTATAACAATTCCCGAACTGATTGACCATCTGATTGTATTAGCTGTAAAGGAGTGATAGGCATGGAAAAAGGATTTACCTTTTTAGATGAAATATTAAACGATGTTCGTTGGGACGCTAAATATGCTACGTGGGACAACTTCACTGGAAAACCAATTGATGGATATGAAGTAAATCGAATTATAGGAACATATGAGTTAGCCGATGCGCTATTGAAGGTTCAAGAATTAGCTTTTAACCAAGGTTATGGATTGCTTTTATGGGACGGTTACCGTCCCCAACAAGCTGTAAATTGTTTTTTGCAATGGGCGGCACAGCCGGAAGATAATCGAACAAAGGCAAAATATTATCCCAATATTGACCGAACTGAGATGGTTTCAAAAGGATACGTGGCTTCAAAATCAAGTCATAGCCGCGGAAGTGCAATTGATCTTACACTTTATCGATTAGACACGGACGAACTTGTTCCGATGGGGAGCGGATTTGATTTTATGGATGAGCGCTCTCATCATGAGGCAAAAGGAATTACGAGCAATGAAGCGCAAAACCGTAGATTTTTGCGTTCCATTATGGAAAACAGTGGGTTTGAAGCGTATAGTTTCGAATGGTGGCACTATGTATTGATAAACGAACCTTATCCCTATAGCTGCTTTGATTTTCCTGTCAAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7433,Drugs,MEG_7433|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,VanHMX_1_FJ349556,5
,ATGTCAATCATGCGACTATTTACATTCATTTTAAGTATTTTTATCGTAGGAATGGTTGAAATGATGGTTGCAGGAATTATGAACTTGATGAGTCAGGACTTACATGTATCAGAAGCTGTCGTTGGTCAATTAGTGACAATGTACGCTTTAACATTTGCGATATGTGGACCTATTCTGGTTAAATTAACGAACCGTTTTTCATCAAGGCCTGTATTATTATGGACATTACTTATATTTATCATTGGTAATGGCATTATTGCTGTAGCGCCAAATTTTTCAATATTAGTAGTTGGTAGAATTATCTCATCTGCAGCAGCAGCACTAATTATCGTAAAAGTATTAGCTATTACAGCGATGTTATCAGCACCTAAAAATCGTGGCAAAATGATTGGACTTGTCTATACAGGGTTTAGTGGGGCCAATGTTTTTGGTGTACCAATTGGAACGGTTATCGGCGATTTAGTAGGTTGGCGCTATACATTTCTATTCTTAATTATTGTGAGTATTATTGTTGGCTTCTTGATGATGATCTATTTACCGAAGGATCAGGAAATACAACGAGGCCCTGTGAATCATGAGGCACCATCTCATGAAAATCATGTTACTTCGAAAATATTAAGACCTGCTGAAGTAGCAAAATATTTAATTATTACGTTTTTAGTATTGATTGCAAACTCAGTGACATTCGTCTTTATAAATCCACTTATTTTATCTAATGGTCATGATATGTCATTCGTTTCATTAGCACTTCTAGTAAATGGAATCGCTGGCGTTATTGGAACATCATTGGGTGGTATATTCTCCGATAAAATTACAAGTAAGCGTTGGTTAATGATTTCTGTTTCTATTTTTATCGTTATGATGTTACTTATGAATTTAATCTTACCTGGTTCAGGTCTATTGTTAGCAGGACTATTTATTTGGAATATCATGCAATGGAGTACTAATCCAGCAGTGCAAAGCGGTGTGATTCAACATGTTGAAGGCGACACAAGCCAAGTAATGAGTTGGAACATGTCTAGTTTAAACGCTGGTATTGGTGTTGGCGGCATTATTGGAGGCTTGGTCATGACACATGTTTCTGTTCAAGCTATCACATATACGAGTGCCATCATTGGCGCATTAGGATTAATCGTTGTTTTCACATTGAAAAATAATCATTATGCTAAAACATTTAAATCATCATAA,rRNA with mutation conferring antibiotic resistance,antibiotic efflux,Phenicol,MEG_2614,Drugs,MEG_2614|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|DHAP,(Phe)Dha1:BA000018:2517801-2518988:1188,6
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGACATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAATGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCGCCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1367,Drugs,MEG_1367|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_107_FQDM01000011,0
,ATGAATAGTTCGACAAAGATCGCATTGGTAATTACGTTACTCGATGCCATGGGGATTGGCCTTATCATGCCAGTCTTGCCAACGTTATTACGTGAACTTATTGCTTCGGAAGATATCGCTAACCACTTAGGCGTATTGCTTGCACTTTATGCGTTAATGCAGGTTATCTTTGCTCCTTGGCTTGGAAAAATGTCTGACCGATTTGGTCGGCGCCCAGTGCTGTTGTTGTCATTAATAGGCGCATCGCTGGATTACTTATTGCTGGCTTTTTCAAGTGCGCTTTGGATGCTGTATTTAGGCCGTTTGCTTTCAGGGATCACAGGAGCTACTGGGGCTGTCGCGGCATCGGTCATTGCCGATACCACCTCAGCTTCTCAACGCGTGAAGTGGTTCGGTTGGTTAGGGGCAAGTTTTGGGCTTGGTTTAATAGCGGGGCCTATTATTGGTGGTTTTGCAGGAGAGATTTCACCGCATAGTCCCTTTTTTATCGCTGCGTTGCTAAATATTGTCACTTTCCTTGTGGTTATGTTTTGGTTCCGTGAAACCAAAAATACACGTGATAATACAGATACCGAAGTAGGGGTTGAGACGCAATCGAATTCGGTATACATCACTTTATTTAAAACGATGCCCATTTTGTTGATTATTTATTTTTCAGCGCAATTGATAGGCCAAATTCCCGCAACGGTGTGGGTGCTATTTACCGAAAATCGTTTTGGATGGAATAGCATGATGGTTGGCTTTTCATTAGCGGGTCTTGGTCTTTTACACTCAGTATTCCAAGCCTTTGTGGCAGGAAGAATAGCCACTAAATGGGGCGAAAAAACGGCAGTACTGCTCGGATTTATTGCAGATAGTAGTGCATTTGCCTTTTTAGCGTTTATATCTGAAGGTTGGTTAGTTTTCCCTGTTTTAATTTTATTGGCTGGTGGTGGGATCGCTTTACCTGCATTACAGGGAGTGATGTCTATCCAAACAAAGAGTCATCAGCAAGGTGCTTTACAGGGATTATTGGTGAGCCTTAACAATGCAACCGGTGTTATTGGCCCATTACTGTTTGCTGTTATTTATAATCATTCACTACCAATTTGGGATGGCTGGATTTGGATTATTGGTTTAGCGTTTTACTGTATTATTATCCTGCTATCGATGACCTTCATGTTAACCCCTCAAGCTCAGGGGAGTAAACAGGAGACAAGTGCTTAG,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7047,Drugs,MEG_7047|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,(Tet)TetB:AB089594:1-1206:1206,4
,atgaagaaattatttgttttatgtgtatgcttcctttgtagcattactgccgcaggagcggctttgcctgatttaaaaatcgagaagcttgaagaaggtgtttatgttcatacatcgttcgaagaagttaacggttggggtgttttttctaaacacggtttggtggttcttgtaaacactgacgcctatctgattgacactccatttactgctacagatactgaaaagttagtcaattggtttgtggagcgcggctataaaatcaaaggcactatttcctcacatttccatagcgacagcacagggggaatagagtggcttaattctcaatctattcccacgtatgcatctgaattaacaaatgaacttcttaaaaaagacggtaaggtgcaagctaaaaactcatttagcggagttagttattggctagttaaaaataaaattgaagttttttatcccggcccggggcacactcaagataacgtagtggtttggttacctgaaaagaaaattttattcggtggttgttttgttaaaccggacggtcttggtaatttgggtgacgcaaatttagaagcttggccaaagtccgccaaaatattaatgtctaaatatggtaaagcaaaactggttgtttcaagtcatagtgaaattggggacgcatcactcttgaaacgtacatgggaacaggctgttaaagggctaaatgaaagtaaaaaaccatcacagccaagtaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3328,Drugs,MEG_3328|Drugs|betalactams|Class_B_betalactamases|IMP,1028105457|WP_063860582.1|NG_049187|1|1|blaIMP-23|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-23 NG_049187:1-741,0
,GTGCGTTCAACACCGCCGGCCTCAGCCGGTCGTTCAACACCGCCGGCGTTAGCCGGCCATTCAACACCGCCGGCGTTAGCCGGCCATTCAACGCTGTGCGGCCGTCCAGTCGCAGGTGATCGTGCGCTGATCATGGCGATCGTCAACCGCACCCCGGATTCGTTTTACGACAAGGGTGCGACTTTCAGCGACGCGGCTGCCAGAGACGCGGTCCACCGGGCCGTCGCCGACGGTGCCGACGTCATCGACGTCGGCGGTGTCAAAGCCGGCCCGGGTGAACGCGTCGACGTCGACACCGAGATCACGCGGCTGGTGCCGTTCATCGAATGGCTCCGCGGTGCTTACCCGGACCAGCTGATCAGTGTCGACACCTGGCGCGCGCAGGTGGCGAAGGCGGCCTGCGCGGCGGGGGCGGACCTGATCAACGACACCTGGGGTGGCGTCGACCCGGCCATGCCCGAGGTGGCCGCCGAGTTCGGCGCGGGCCTGGTGTGTGCGCACACCGGCGGCGCGCTGCCACGCACGCGACCCTTCCGGGTGAGCTACGGTACGACTACCCGCGGTGTGGTGGATGCTGTGATTAGCCAGGTCACAGCCGCCGCCGAGCGGGCCGTCGCGGCCGGGGTGGCCCGCGAGAAGGTGTTGATCGACCCGGCACACGACTTCGGCAAGAACACCTTCCATGGGCTGCTGCTATTGCGACACGTGGCCGATCTTGTTATGACCGGGTGGCCCGTGCTGATGGCTTTGAGCAACAAGGACGTTGTCGGGGAGACTCTGGGCGTGGATTTGACCGAACGGCTTGAGGGAACGCTGGCAGCCACCGCGTTGGCTGCGGCCGCCGGGGCGCGCATGTTTCGGGTGCATGAGGTCGCCGCCACCCGGCGGGTGCTGGAAATGGTGGCATCGATTCAGGGGGTCCGGCCGCCGACGCGCACGGTGAGAGGACTCGCATGA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2969,Drugs,MEG_2969|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|984994143|gb|CP010340.1|1359436-1360392 gi|984989958|gb|CP010339.1|1353309-1354265 gi|984985728|gb|CP010338.1|1354369-1355325 gi|984976917|gb|CP010336.1|1349886-1350842 gi|984959134|gb|CP010332.1|1352775-1353731 gi|984950177|gb|CP010330.1|1352479-1353435 gi|984945858|gb|CP010329.1|1351054-1352010 gi|971171538|gb|CP013741.1|1354097-1355053 gi|927989386|gb|CP011455.1|1349665-1350621 gi|923105817|gb|CP012506.1|1342305-1343261,8
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataagactttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4648,Drugs,MEG_4648|Drugs|betalactams|Class_D_betalactamases|OXA,1391852902|WP_109545087.1|NG_057509|1|1|blaOXA-608|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-608 NG_057509:1-774,0
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaagaacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggtcatatggattttttggcggaagtataccgttctttatccgttttagacggagcagtattattagtttctgcaaaggatggcatacaggcacagacccgtatactgtttcatgcactacagacaatgaagattccgacaatcttttttatcaataaaattgaccaagaggggattgatttgccaatggtatatcgagaaatgaaagcaaagctttcttcggaaattatagtgaagcaaaaggttgggcagcatccccatataaatgtaacggacaatgacgatatggaacagtgggatgcggtaattatgggaaacgatgaactattagagaaatatatgtcagggaaaccgtttaaaatgtcagaactggaacaggaagaaaacaggagattccaaaacggaacgttatttcccgtttatcacggaagcgctaaaaacaatctggggattcggcagcttatagaagtgattgccagtaaattttattcatcaacgcctgaaggtcaatctgaactatgcgggcaggtttttaagattgaatattcagagaaaaggcggcgttttgtttatgtgcgtatatatagcggaacattgcatttgagggatgttattagaatatctgaaaaagagaaaataaaaatcacagagatgtgtgttccgacaaacggtgaattatattcatccgatatagcctgctctggtgatattgtaattttaccaaatgatgttttgcagctaaacagtattttggggaacgaaatgctgttgccgcagagaaaatttattgaaaatcctctccctatgctccaaacaacgattgcagtaaagaaatctgaacagcgggaaatattgcttggggcacttacagaaatttcagatggcgaccctcttttaaaatattatgtggatactacaacgcatgagattatactttcttttttggggaaagtgcagatggaagtcatttgtgccatccttgaggaaaaatatcatgtggaggcagaaataaaagagcctactgttatatatatggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaatcaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7150,Drugs,MEG_7150|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,1028100270|WP_063856405.1|NG_048262|1|1|tet(O)|tet(O)|tetracycline_resistance_ribosomal_protection_protein_Tet(O) NG_048262:14-1933,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggtacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatcaccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5677,Drugs,MEG_5677|Drugs|betalactams|Class_C_betalactamases|PDC,959913202|WP_058176209.1|NG_049867|1|1|blaPDC-100|blaPDC|class_C_beta-lactamase_PDC-100 NG_049867:1-1194,0
,ATGAAAAAAGATAGAAAAGAAGAAATACAAGAAGTTACTGAAAACATTATTGAAAAAAATATGGCCGATATAATGTCTGATAGATTCGGACGTTATTCAAAATACATTATTCAACAAAGAGCAATTCCTGATGCTCGTGATGGACTAAAACCTGTTCAACGTCGGATTTTATATTCAATGTGAAATTTACATTTAAAAAATAGCGAGCCTTTTAAAAAATCAGCTAGAATCGTTGGGGATGTTATCGGACGTTATCACCCTCATGGAGATAGTTCAATATACGAGGCATTAGTCAGAATGGCTCAAGATTGAAAAAGCAATTTCCCATTAATTGAAATGCATGGTAATAAAGGTTCAATTGATGATGACCCTGCCGCTGCAATGCGTTACACTGAATCAAGACTTGAAAAAATTAGTGAACTGATGTTGAGAGATTTAGACAGAAAAGTTGTAAAAATGGCTCCAAACTTTGATGACTCTGAATACGAACCAATTGTTTTGCCGGCCTTATTTCCTAATTTATTAGTTAACGGTGCTAAAGGAATTGCTGCTGGTTTTGCTACAGAAATCCCACCACATAATCTAGGCGAAGTTATTGATGCAACAATTGCATTAATCAAAAATCCTACAATATCAATTGAAGAATTAAGTGAAATAGTTAAAGGCCCAGATTTCCCAACAGGAGCAATTATTAATGGTATAAATGAAATAAAAAAAGCTCTTTCAAGTGGGCAAGGTAGAATTACAATTTCTTCGAAATATCATTACGTTTATGATAAAAAAGATGAATCGAAAATTATTGGTATTGAAATAATTGAAATTCCTTTTGGGGTTGTTAAATCAAAATTAGTTGCCGACATTGATGCAATTGCAATAGATAAAAAAATTTCTGGTATTAAAGAAGTTTTGGACCAAACAGATAGAAATGGAATTTCAATATTTATTCAATTAGAAGATGGTGCAAATGCTGACGCAATAATTGCATACTTAATGAATAAAACCGAACTAAGCATCTCGTATAGTTATAACATGGTTGCAATTGACAATAACCGTCCAGTAATTTTGAATCTCTATAGTGCCTTAATTGCTTATTTAAGTCATTTAAAAGAAGTTAATATAAATGGTATTAATTATGATTTAAAGAAGTTTAAATTGAGACTAGAAATAGTTGAAGGGTTCATTAAAGTAGCCGAAATTTCTGATGAAGTTATACATTTGATTAAAGAAAGCGATAACTCAAAAAAAGGTGTTATCCTTGCATTGATGAATAAATTTAAATTTAGTGAATTGCAAGCAACAGCGATTGCTGAATTAAGATTGTATAAGCTTTCAAGAATGGATCAAATCGAATTTCAAGAAGAAAAGAAAAACCTTGAAATTCAAATTGAAAATTGCAATAAATTATTAAATGATAAATGAGAATTTAATCAATATTTAATAAAGCAATTGCTTGAAATAAAAAATCAATATTCAAAGCCAAGATTAACGGAAATTTCAGATCAAAAAATCGATAAAGAAATTGATCATAAATTATTGACAAAAAATGAAGATTTTTATTTATATATAACCAAAGATGGATATTATAAAAAAATAAGTTTAAAAGTTTATACTAGCAATGAATTAAACACATTCAAATTAAAAGAAGAAGATAATGTTTTCTATTTTGATAAAGTAAACTCATTATCAAAGATATTATTCTTTACAAATTTAGGGAATTATTTTATTATTGATTGCCATTTGTTTAAAGATTGCAATTGAAAAGATCTTGGTCAACATATTTCATCAATAGTAGCTCTAGAAAGCTCAGAAAAAATTATTAGAGTTATAGAAATTACGTCATTCAATAGTTATGCAAACTTTATTTTAATGTCAAAATTAGGATATGCCAAAAAAGTTAATTTAAGAGATTTTGAAAATAAATCTTCTCTTAAAACAAAAACTTGCATGTCGTTTAAGGATGATAATGATGAATTAATAGATGCCCAAATTTCTAATGATGAAAAAATGCTATTTATTTTACTAAATAATGGTATGTATCATTTAGTTTCAGAAAACGAACTAAAGGTTGGAATTTCTTTGAAAGCAAGAGGCATTAGACTTCTTTTAAACTTATATAAACATCCTCAACTTCAAGTAAGTGGTTTTATAACAGTTTCAAAATACAACAATATAATTTATTTAACGCAAGGTGGTTATATAAAATGTTGGGATACTAGCAAATTAGAATTGACCACACGCAATACTCCAAAAATGTTGTTTACGCCACTAAAAAATAATATTTTAGGTCTTCAATCACTTGCTGTTACATTGAGCAATTTAAAAATGTTATACACTGATAATAATGGTAATTTGGCAGAATATGATTGAAAATTTATATTAAAAGATAAGACTAAGGAAAGTAAACTTCTTAAATTAGATTATTCATTTACTAACCCTGGGTATTTTATTACGCCAATAAAAATTAATGAATTAATTGAAGCTGATGAAATAGAGCAGGAAAAAATAAGACAAGAATATCAAGGATATATTGATAAAAATATTGAATTGACCGCTGAACATGCTTTGATTAAAAAATCCTATGATCAAGATATTCAACATTTAAATAATGAAGAACAAGAAGAACTATTTCAAATATCTACAGAAGATATTGAATTACCAAATGTTTCAAATAATGTTAATGACAACCAAAAAGATAAAAAAAATATAGCAACAAAAGAAAGCGTTAGTCAGAAAATACAAGAAATTGAAAAAATAGATCTTGAAACAATAATGCAAAAAATTAAACAAATTAAGAAAAAATAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5330,Drugs,MEG_5330|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gb|CP011538.1|-|660262-663064|ARO:3003310|Mycoplasma hominis parC conferring resistance to fluoroquinolone [Mycoplasma hominis] ,3
,GTGAGCGATCTGATCCAAATCGAGGAAGAGCTCAAGAAGTCCTATCTGGAATATTCCTTGAGCGTCATCATAGGCCGCGCCATCCCCGATGTGCGCGACGGCCTCAAACCCGTGCACCGGCGCATTCTCTACGCCATGCACGATCTGTCCAACACCTACAACCGGCCCTACAAGAAATCCGCCCGCGTCGTCGGTGACGTCATCGGTAAATACCATCCCCACGGCGACCAATCCGTGTACGACGCCCTGGTCCGCATGGCCCAGGACTTCTCCATGCGCGACGCCATCGTGGATGGCCAGGGCAACTTCGGCTCCATCGACGGCGACGCCGCGGCGGCCATGCGATACACCGAAGTCCGCATGTCCCGCCTGGCCGGCGAGTTCTTGGCCGACATCGAAAAGGAAACCGTCGATTTTCGGCCCAACTACGACAACAGCCTGGAAGAGCCGGCCGTCCTGCCCACCAAGGTGCCCAATCTGCTTTTAAACGGCTCCTCGGGCATCGCCGTCGGCATGGCCACCAACATCCCGCCCCACAACCTGGGCGAGCTGTGCGACGGCCTGCTGCACCTGCTCGACACGCCCTCCTGCCCGGTCACCGACATCATCGGCCTGGTCAAGGGGCCGGACTTCCCCACCGGCGCGGCCATCTACGGCGGCAAGGGACTCACCGAAGCCTACACCACCGGACGCGGCACCATCAAAATCCGGGGCCGGGCCGAGGTCGAGGAACGCAAGAAAGATTATGTTTCCGTGGTCATCCGGGAAATCCCGTATGCGCTCAACAAGTCTTCCCTGGTGGAAAAGATCGCGGCGCTCATTAACGACGGCCGCATCGAGGGCGTGTCCGACCTGCGCGACGAGTCCGACCGCAAGGGCATCCGCATTGTCCTGGATCTCAAAAAGGGCGTCATCCCCGACATCGTCATCAACGCCCTGTACAAGTACACGCCGCTGGAAACCTCGTTCGGCATCAACATGCTTGTGGTTGCCGACAACCGGCCGGCGCTTTTAAACATCAAGCAGGTCCTGGAGCACTTCCTCACCCACCGCCGCGACGTCATCCTGCGCCGCACCCGGTTCGATCTGCGAAAGAGCGAGGAGCGCGCCCACATCCTCGAAGGCCTGCGCATCGCCCTGGACAACATCGACGAAGTGGTCTCCATCATCCGGGCCTCCAAAAACGCCGTCGAAGCCCGGGAACGGTTGATGGAGCGCTTCGGCCTGTCCGAGCGCCAGGCCCAGGCCATCCTGGACATGCGCCTTCAACGCCTGACCAACCTGGAGCGCCAAAAGCTCATCGACGAGTACAACGAGCTCATCAAGCTCATTGAATACCTGCGCTCGATCCTGGAAAACGACGAGGTGCTGCGCGGCGTCATCCGCGACGAAATCAAGGAAATCCAGGACCGTTACGCCACCCCGCGCAAGACTGAGATTCTGGAGGACCTTGAAGGCATCAACATCCTCGATCTCATCCCCGACGAGGACGTGGTCATCACCCTGTCGCGCCGGGGCTACATCAAGCGCACCAAAATCGATAATTACCAGCAACAAAAGCGCGGCGGCAAAGGCATCGCCGGGGTGGCCACGGCCGGCGACGACTTTGTCCAGTCGTTTTGCGCCACCACCAACCACCAGCAGTTGTTGCTTTTTACCAACCTCGGCCGCATGTTCATGCTGCCCGTGCACCAGATTCCCGAAGGCCAGCGCACGGCCAAGGGCGCGCACATCGCCAACCTGCTGCCCATGGACAAGGAAGAGTTCGTGGCCACGGCCCTGTCCATCCGCGAGTTCTCCGAGGAGCGCTATTTCCTGTTCGTGACCCGCAAGGGCATGGTCAAGCGCACCTGCACCGACCTCTACAAGAACTGCCGTTCCACGGGCATCATCGCCGTGGGGCTTAAGGAAAACGACGAACTCCTGACCGTCAAGGAGATCGACGACGAGACCGAAGTCTTGCTGGCCACCCAGCAGGGCCTGTCCAACCGCTTCCACATCAGCGGCGTGCGCCCCACCGGCCGGGGCGCGGCCGGCGTCAAGGGCATTGCCCTTAAGGGCAACGACCGTGTGGCCGCCGGCGTGGTCATCACCAGCGTCAGCCGCTCCGAGGTGCTCACTGTCTCAGCCAACGGCTACGGCAAGCGCACCTCCATCGAACACTACCCTATCCGCAACCGGGGCGGCTCCGGCGTCATCAACATGCGCGTGACGCCCAAGACCGGTCAGGTCATCGGCGCGGTCATGGTCGGCGACGACGACGAACTGCTGCTGTTAACCTCCGCCAACAAGATCATCCGCCTGTCCGTCTCCGGCATCTCGTCCGTGGGCCGGGCCACCCAGGGCGTCATGCTGGTGCGCATGGACGAAAACGATACCGTCATGGGCTTTGACCTGGTCGATCCGAGCGACCTCGACCGGTGCGCGCCCTCCGGCGAATAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3197,Drugs,MEG_3197|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|239794502|dbj|AP010904.1|5459-7900,3
,ATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGCTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTTGGCATTGAAATTCGCCACTGTCGTGCGCAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACTCGCACCTGGTTTTGCAGCGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAATGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTTGCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGCTGCTCATGGAACGTCTTGGCATCGCGGTAATTGGTTA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6006,Drugs,MEG_6006|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,qnrB43_1_JQ349151 ,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccagaacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccaaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5483,Drugs,MEG_5483|Drugs|betalactams|Class_C_betalactamases|PDC,730293167|WP_033974288.1|NG_049931|1|1|blaPDC-57|blaPDC|class_C_beta-lactamase_PDC-57 NG_049931:1-1194,0
,atgttacgcagcagggtgacggtgttcggcattctgaatctcaccgaggactccttcttcgatgagagccggcggctagaccccgccggcgctgtcaccgcggcgatcgaaatgctgcgagtcggatcagacgtcgtggatgtcggaccggccgccagccatccggacgcgaggcctgtatcgccggccgatgagatcagacgtattgcgccgctcttagacgccctgtccgatcagatgcaccgtgtttcaatcgacagcttccaaccggaaacccagcgctatgcgctcaagcgcggcgtgggctacctgaacgatatccaaggatttcctgaccctgcgctctatcccgatattgctgaggcggactgcaggctggtggttatgcactcagcgcagcgggatggcatcgccacccgcaccggtcaccttcgacccgaagacgcgctcgacgagattgtgcggttcttcgaggcgcgggtttccgccttgcgacggagcggggtcgctgccgaccggctcatcctcgatccggggatgggatttttcttgagccccgcaccggaaacatcgctgcacgtgctgtcgaaccttcaaaagctgaagtcggcgttggggcttccgctattggtctcggtgtcgcggaaatccttcttgggcgccaccgttggccttcctgtaaaggatctgggtccagcgagccttgcggcggaacttcacgcgatcggcaatggcgctgactacgtccgcacccacgcgcctggagatctgcgaagcgcaatcaccttctcggaaaccctcgcgaaatttcgcagtcgcaacgccagagaccgagggttagatcatgcctag,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6586,Drugs,MEG_6586|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,495205159|WP_007929940.1|NG_048087|1|1|sul1|sul1|sulfonamide-resistant_dihydropteroate_synthase_Sul1 NG_048087:101-952,8
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTACGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6632,Drugs,MEG_6632|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|66840767|emb|AJ830710.1|146-961,8
,atgaaaacatttgccgcatatgtaattatcgcgtgtctttcgagtacggcattagctggttcaattacagaaaatacgtcttggaacaaagagttctctgccgaagccgtcaatggtgtcttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaatgacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaagcaatgggaaagagacttgaccttaagaggggcaatacaagtttcagctgttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcctatggcaaacagaatatcagtggtggcattgacaaattctggttggaaggccagcttagaatttccgcagttaatcaagtggagtttctagagtctctatatttaaataaattgtcagcatctaaagaaaaccagctaatagtaaaagaggctttggtaacggaggcggcacctgaatatctagtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttgggtgggttgagaaggagacagaggtttactttttcgcctttaacatggatatagacaacgaaagtaagttgccgctaagaaaatccattcccaccaaaatcatggaaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4418,Drugs,MEG_4418|Drugs|betalactams|Class_D_betalactamases|OXA,1625655427|WP_136512104.1|NG_064781|1|1|blaOXA-824|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-824 NG_064781:1-801,0
,atgtttgctaaaaattcaaaggcatattctgtctacctgctgttccgatttgtctgttccctggcggtttctatgtccacagtgctttccatcgtgtaccacctggaggtggtgcagctggatgctttccagcttgtcctggtagggacggttctggagacctcctgctttctgttcgagatacccaccggtgtggtggcggatttgtatagccgtcggcgctcggtgctgattggaatgttcctctacggcctgggctttctgatggagggtgcgctaccgtggttcgcgccggttctgctggcccaggttgtctggggttgcggtgataccttcatcaccggcgctctggaggcgtggattgcctcggaggaagaggacaaacccatagacaaggtgttcctgcggggcagtcaaatggggcaaatcggcggcgttctgggcgtggtgctgggcacactgctgggaaacataaacctgcaaatgcctgtcatcttggggggcagtttgtgcttgttgttggggctggtgttggttcgcatcatgccagaaaccaacttctcccctgctattgaggaacggcagggcttgcttaaagactttgtctgcctgttcaagctcaacctgggctttgtgaaaggcgcacctgtgttgctggcgctcttagcaatcacactatgcgggggacttgccagtgaaggctttgaccggctctccaccgctcattttctggatgacacggtaatacccgttatcgggccgctgaacagcgtcacttggttcggtgttatcagtcttatcggcagcggcttaggtattctggcttctcagttgctcatcgcccgcatggagaaaaaagggactgtcagccgaaccagtgtggtcatgtccaccagcgccgggtatatcctgtgcctggttctcttcgcggtggggcggagcttttggttcatgttgttggtgttcctgctggcggggcttatgcgcaccatcaaggagcctgtgctggccgcctggatgaacgaccatgtggatgagaaaatgcgcgccacagtcttttccaccagcggacagctggactctttcgggcagatcatcggcgggcctattgtggggctggtagcccagcaggtgtccataccctgggggctggtctgtaccgctttcctgctgttgcccgcgctgttcttagtgccggtggcgggaaagaagcgggattga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic target protection,Tetracyclines,MEG_6991,Drugs,MEG_6991|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TET40,496540878|WP_009247026.1|NG_048141|1|1|tet(40)|tet(40)|tetracycline_efflux_MFS_transporter_Tet(40) NG_048141:101-1321,4
,ATGAAAACATTTGCCGCATATGTAATTACTGCGTGTCTTTCAAGTACGGCATTAGCTAGTTCAATTACAGAAAATACGTCTTGGAACAAAGAGTTCTCTGCCGAAGCCGTCAATGGTGTTTTCGTGCTTTGTAAAAGTAGCAGTAAATCCTGCGCTACCAATAACTTAGCTCGTGCATCAAAGGAATATCTTCCAGCATCAACATTTAAGATCCCCAGCGCAATTATCGGCCTAGAAACTGGTGTCATAAAGAATGAGCATCAGGTTTTCAAATGGGACGGAAAGCCAAGAGCCATGAAACAATGGGAAAGAGACTTGAGCTTAAGAGGGGCAATACAAGTTTCAGCGGTTCCCGTATTTCAACAAATCGCCAGAGAAGTTGGCGAAGTAAGAATGCAGAAATACCTTAAAAAATTTTCATATGGCAACCAGAATATCAGTGGTGGCATTGACAAATTCTGGTTGGAGGATCAGCTAAGAATTTCCGCAGTTAATCAAGTGGAGTTTCTAGAGTCTCTATTTTTAAATAAATTGTCAGCATCAAAAGAAAATCAGCTAATAGTAAAAGAGGCTTTGGTAACGGAGGCTGCGCCTGAATATCTTGTGCATTCAAAAACTGGTTTTTCTGGTGTGGGAACTGAGTCAAATCCTGGTGTCGCATGGTGGGTTGGTTGGGTTGAGAAGGGAACAGAGGTTTACTTTTTCGCCTTTAACATGGATATAGACAACGAAAATAAGTTGCCGCTAAGAAAATCCATTCCCACCAAAATCATGGCAAGTGAGGGCATCATTGGTGGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5223,Drugs,MEG_5223|Drugs|betalactams|Class_D_betalactamases|OXA,gi|4105144|gb|AF043558.1|AF043558|1-801,0
,TGTTAGCGGTAATTTAACCAGATAGGAGTACAGACATATGAAAATCGTAAAAAGGATATTATTAGTATTGTTAAGTTTATTTTTTACAGTTGAGTATTCAAATGCTCAAACTGACAACTTAACTTTGAAAATTGAGAATGTTTTAAAGGCAAAAAATGCCAGAATAGGAGTAGCAATATTCAACAGCAATGAGAAGGATACTTTGAAGATTAATAACGACTTCCATTTCCCGATGCAAAGCGTTATGAAATTTCCGATTGCTTTAGCCGTTTTGTCTGAGATAGATAAAGGGAATCTTTCTTTTGAACAAAAAATAGAGATTACCCCTCAAGACCTTTTGCCTAAAATGTGGAGTCCGATTAAAGAGGAATTCCCTAATGGAACAACTTTGACGATTGAACAAATACTAAATTATACAGTATCAGAGAGCGACAATATTGGTTGTGATATTTTGCTAAAATTAATCGGAGGAACTGATTCTGTTCAAAAATTCTTGAATGCTAATCATTTCACTGATATTTCAATCAAAGCAAACGAAGAACAAATGCACAAGGATTGGAATACCCAATATCAAAATTGGGCAACCCCAACAGCGATGAACAAACTGTTAATAGATACTTATAATAATAAGAACCAATTACTTTCTAAAAAAAGTTATGATTTTATTTGGAAAATTATGAGAGAAACAACAACAGGAAGTAACCGATTAAAAGGACAATTACCAAAGAATACAATTGTTGCTCATAAAACAGGGACTTCCGGAATAAATAATGGAATTGCAGCAGCCACTAATGATGTTGGGGTAATTACTTTACCGAATGGACAATTAATTTTTATAAGCGTATTTGTTGCAGAGTCCAAAGAAACTTCGGAAATTAATGAAAAGATTATTTCAGACATTGCAAAAATAACGTGGAATTACTATTTGAATAAATAAAAAACTACCGCTAACACTGGCTCATAGGCAATGGCGGGTTGAAGTGCAATTTGCAAAGTCGGTAGCCCGCCCGAGCGTTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_7665,Drugs,MEG_7665|Drugs|betalactams|Class_A_betalactamases|VEB,gi|126202236|gb|EF420108.1|1-1017,0
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaatgaaacccagagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaaacagataaaaaaattaatttgtatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttaccacttgggaaaaagacatgacactaggagaagccatgaagctttctgcagtcccagtctatcaggaacttgcaagacgtatcggtcttgatctcatgcaaaaagaagtagaacgtattgatttcggtaatgctgaaattggacagcaggttgacaatttctggttgataggcccattaaaggtcacgcctattcaagaggtagagtttgtttctcaattggcacatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgctacttctagaagagaataatggctacaagatttttggaaagactggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcgcttttgcattaaatatggaaatgcggtcagaaatgcctgcatctatacgtaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4520,Drugs,MEG_4520|Drugs|betalactams|Class_D_betalactamases|OXA,1125678991|WP_075040046.1|NG_064775|1|1|blaOXA-817|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-817 NG_064775:1-822,0
,TTGAATCGAACTAATATTTTTTTTGGTGAATCGCATTCTGACTGGTTGCCTGTCAGAGGCGGAGAATCTGGTGATTTTGTTTTTCGACGTGGTGACGGGCATGCCTTCGCGAAAATCGCACCTGCTTCCCGCCGCGGTGAGCTCGCTGGAGAGCGTGACCGCCTCATTTGGCTCAAAGGTCGAGGTGTGGCTTGCCCCGAGGTCATCAACTGGCAGGAGGAACAGGAGGGTGCATGCTTGGTGATAACGGCAATTCCGGGAGTACCGGCGGCTGATCTGTCTGGAGCGGATTTGCTCAAAGCGTGGCCGTCAATGGGGCAGCAACTTGGCGCTGTTCACAGCCTATCGGTTGATCAATGTCCGTTTGAGCGCAGGCTGTCGCGAATGTTCGGACGCGCCGTTGATGTGGTGTCCCGCAATGCCGTCAATCCCGACTTCTTACCGGACGAGGACAAGAGTACGCCGCAGCTCGATCTTTTGGCTCGTGTCGAACGAGAGCTACCGGTGCGGCTCGACCAAGAGCGCACCGATATGGTTGTTTGCCATGGTGATCCCTGCATGCCGAACTTCATGGTGGACCCTAAAACTCTTCAATGCACGGGTCTGATCGACCTTGGGCGGCTCGGAACAGCAGATCGCTATGCCGATTTGGCACTCATGATTGCTAACGCCGAAGAGAACTGGGCAGCGCCAGATGAAGCAGAGCGCGCCTTCGCTGTCCTATTCAATGTATTGGGGATCGAAGCCCCCGACCGCGAACGCCTTGCCTTCTATCTGCGATTGGACCCTCTGACTTGGGGTTGA,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1057,Drugs,MEG_1057|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,gi|981191958|emb|LN999997.1|2509425-2510228 gi|975007785|gb|CP010832.1|3628-2825 gi|954666075|gb|KT962845.1|18711-17908 gi|971497891|gb|CP012901.1|3691790-3692593 gi|971339514|gb|CP006662.2|54045-53242 gi|959153704|gb|CP012993.1|20977-21780 gi|959147947|gb|CP012988.1|72243-71440 gi|957647579|dbj|AP017302.1|121620-122423 gi|957647579|dbj|AP017302.1|419616-418813 gi|954171562|gb|KT151663.1|74577-75380 gi|954171278|gb|KT151660.1|74577-75380,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaggttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctacgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_576,Drugs,MEG_576|Drugs|betalactams|Class_C_betalactamases|ADC,1625655377|WP_136512054.1|NG_064671|1|1|blaADC-112|blaADC|class_C_beta-lactamase_ADC-112 NG_064671:1-1152,0
,atgaatgtcatcctgaaccgtcgaacgtttttattgactagcgctgtggtgtctgcgtcttattcgctaggtacgctggctggcgctaatcgggatgatgcttcctttcaagatcggctggctaagttggagcagcagctgaacggacggcttggagtatgcgccatcgataccgcaaatggagcacagttgggctatcgcgccaatgagcggtttgccatgaacagcacgttcaaggtcatgctcgcctcagcgtttctcgcccgaagccaagacgaaccggggctcctcgaagaacggctcacgtacacccgggccgatctggtcacatactctcccgtgacggaaaagcacgtttccactgggatgaccgttgccgaattgtgcgccgcaggcattcagtacagtgataacaccgcggccaatgtgctcatgaaaaagctggggggccctgaagcggtcaccgcatttgcccgttcgataggcgatacgcattttcgcctcgatcggtgggaaaccgaactcaattcggctattccgggagatcctcgtgatacgagtacccctcaggccatggcaatgagcctgcaacgtctggcattgggtgacatgctggctgcggataaacagcatcagttgcaggcgtggttgaaaggcaataccacaggtggcaagcgtatccgggccggggtaccggctggctggcaggtaggcgataagacaggtacgggtgattacggctcggccaacgacgtggctatcctctggccgcctcgccgtacacccgttgtgctggctctctattccgctcttgaaaaccagcaggcggaagcgcgcaatgacgtgctggccgatgcggcgcgcattgtggctgaatgggtgacaggctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3651,Drugs,MEG_3651|Drugs|betalactams|Class_A_betalactamases|LUT,1028105803|WP_063860828.1|NG_049285|1|1|blaLUT-2|blaLUT|class_A_beta-lactamase_LUT-2 NG_049285:1-891,0
,atgttcaaacttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgttttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7714,Drugs,MEG_7714|Drugs|betalactams|Class_B_betalactamases|VIM,1559613022|WP_128268287.1|NG_063896|1|1|blaVIM-62|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-62 NG_063896:1-801,0
,ATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGAAGACTGGGGGTGGCATTGATTAACACAGCGGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTCGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCAGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATTTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2218,Drugs,MEG_2218|Drugs|betalactams|Class_A_betalactamases|CTX,(Bla)CTX-M-133:AB185834:1-876:876,0
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGACGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2411,Drugs,MEG_2411|Drugs|betalactams|Class_A_betalactamases|CTX,gi|668347740|dbj|AB976606.1|145-1020 gi|125634071|gb|EF374096.1|1-876,0
,atgagcaagttatctgtattctttatatttttgttttgcagcattgctaccgcagcagagtctttgccagatttaaaaattgaaaagcttgatgaaggcgtttatgttcatacttcgtttgaagaagttaacgggtggggcgtttttcctaaacatggtttggtggttcttgtaaatgctgaggcttacctaattgacactccatttacggctaaagatactgaaaagttagtcacttggtttgtggagcgtggctataaaataaaaggcagcatttcctctcattttcatagcgacagcacgggcggaatagagtggcttaattctcgatctatccccacgtatgcatctgaattaacaaatgaactgcttaaaaaagacggtaaggttcaagccacaaattcatttagcggagttaactattggctagttaaaaataaaattgaagttttttatccaggcccgggacacactccagataacgtagtggtttggttgcctgaaaggaaaatattattcggtggttgttttattaaaccgtacggtttaggcaatttgggtgacgcaaatatagaagcttggccaaagtccgccaaatcattaaagtccaaatatggtaaggcaaaactggttgttccaagtcacagtgaagttggagacgcatcactcttgaaacttacattagagcaggcggttaaagggttaaacgaaagtaaaaaaccatcaaaaccaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3333,Drugs,MEG_3333|Drugs|betalactams|Class_B_betalactamases|IMP,1440786793|WP_114699281.1|NG_061410|1|1|blaIMP-77|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-77 NG_061410:1-741,0
,atgaataaaaaaataaaactaatttttattttaattttttcaataaatttatttgcaaatgatgtggaacttgaaaatttatttaaaaaataccaagttgaaggaactttagtattagagtctttaaatacaaaaaaagtagatatttataatgaaaagagagcaaatacatcattttctcctgcttcaacatttaaaataccaaatactttgatagctttaaatgaaggtgttgtaaacaaagattctataatagtttgggataaaaaagtaagagaatttgatgcttggaataaagaccaaactttacaatcagctttcaaaagttcatgtgtttggtgttataaagagttcgcttcaaaaattggagttgaaaaatatagtaagtatctaaaagagcttaattatggaaataaaacaataggcaaagatgtaactgatttttggttggatgagagtttgagaattacagcttttgaagagataagatttttaaaacaattacaagcaaacaatttagcttttaaacaagaagatataaatcttttaaaagagttgatgattgatgaaaaaagcgaaaattatgtagttagagcaaaaacaggttgggaaggaaaatatggttggtatgttggttatgttgaaacaaaaaatgatgtttggttttttgctttaaatatcgacacaaaaacaaaagaagatttagcaaaaagaaaagctttaactttagaagctttaaaaacaaaaggtattataaattga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4515,Drugs,MEG_4515|Drugs|betalactams|Class_D_betalactamases|OXA,526475188|WP_020848173.1|NG_049771|1|1|blaOXA-491|blaOXA|class_D_beta-lactamase_OXA-491 NG_049771:101-862,0
,atgaaaatattgttagaggctcttcgtataaaaccctatgttcaagatcgtttactgttgaacatagatcaattacagatttatcagaatgaccgaattgggttagttggtggaaatggcagtggaaaaacaacgttacttcacatattggatgaaaagctttttcctgaagaaggtactgtaactcagtattcacggtgcgaactcattccacaattgaaacatatggaaacaacaaaaagtggtggtgaagtaacacgaaaatatattcagcaagcacttgataaaaacccagaactgttactagcagatgaaccgacaactaaccttgatacaaattatatagaaaacttagagcgaaaattaaaggactggcatggagcatttatcatcgtttcacatgatcgtgctttcttagatactctttgtacgagtatatgggaaatcaaagacgggggtataaccgaatacaaagggaactatagtgactatattgagcagaaagaattagaaaatcgccaagagcaattagcacatgaaaaatatgaaaaagaaaagaaacagttagaagaggccataaagttaaaagaagagaaagctcaacgagctactaagaaaccgaaaaatataagttcatcggaagcaaggctaaaaggagcgaagccatacttcgcaaataaacagaagaagttacggaaaacggcaaaagctctagaaactagactggataagcttgaaaaggtagaaaaaacaaaagaactacccccacttaaaatggatttattgaattcagagacttttaaaaatcggattatactccgtgttgaagatgtttcgggtgtaattgaggaacgagtattgtggaaagcagctagtttttacgttcgaggaggagataagctggcaattatcggctctaacggtacgggcaagaccacctttattaaaaaaattgttcaggataagccaggtatttcattttcaccatctgttaaaattggttactttagccagaatctagacatattagagctcgacaagactattttagaaaacgtccaatcttcttcacggcaaaatgaaactcttattcgaaccattctagcgagaatgcattttttcagagatgatgttcataaaccagtaaatgtcttaagtgggggagagcgagttaaggtagcactaactaaagtgttcttaagtgatgttaatacgttagtattagatgaaccaacaaactttcttgatatggaggctatagaggcgtttgaatccttattagaggagtatgaaggaagcgtaatttttgtctcccatgatcgtaggtttatcgaaaaaatagctacccgaatcatgatgattgataataaagaaattaaaatatttgaaggaacatatgaccaatttaaagctaaacaagctagggaggaaacacgggatataaaagaggataaaaaacttttacttgaaacaaggattactgagatactcagtcgattgagtattgaaccttcggaggaattagaaaaagagttccaaaacctaattaacgagaaaagaaatttagataattga,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_7679,Drugs,MEG_7679|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA,1028100801|WP_063856936.1|NG_048553|1|1|vga(A)|vga(A)|ABC-F_type_ribosomal_protection_protein_Vga(A) NG_048553:101-1675,1
,ATGAAAAAATTAATCATCGCCATCGTGATTGTAATCATCGCTGTTGGTTCAGGCGTATTCTTTTATGCATCTAAAGATAAGAAAATAAACGAAACAATTGATGCCATTGAAGATAAAAACGTTAAGCAAGTCTTTAAAAATAGTACTTACCAATCTAAAAACGATAATGGTGAAGTAGAAATGACAGACCGCCCTATTAAGATTTATGACAGTCTCGGCGTCAAAGATATCAACATTAAAGATCGTGATATCAAAAAGGTTTCGAAAAACAAAAAGCAAGTCACAGCAAAGTATGAACTGCAAACGAATTACGGCAAAATTAATCATGACGTTAAATTAAACTTTATTAAAGAAGATAAAGATTGGAAATTGGATTGGAATCAAAGTGTCATTATTCCAGGCATGAAGAAAAATCAATCCATCAATATTGAACCATTGAAATCAGAACGTGGTAAGATTTTAGACCGAAACAATGTAGAGTTAGCCACTACAGGAACAGCACATGAAGTTGGTATTGTTCCTAATAATGTTTCCACAAGTGATTACAAAGCAATCGCTGAAAAGTTAGACCTTTCAGAATCGTATATTAAACAACAAACAGAACAGGATTGGGTTAAAGATGATACATTCGTCCCTCTCAAGACTGTTCAAGATATGAATCAAGATTTAAAGAATTTTGTTGAAAAGTATCATCTCACATCACAGGAAACAGAAAGTCGAGAGTATCCGTTTGAAGAAGCAACAACGCACTTACTTGGATACGTTGGCCCTATTAATTCAGAAGAATTGAAGCAAAAAGCATTTAAAGGTTATAAAAAGGATGCCATCGTTGGTAAAAAAGGTATCGAAAAACTATACGATAAAGAACTTCAAAATAAAGACGGATACCGTGTCACAATTATTGATGATCAAAATAAAGTGATAGATACATTAATCGAGAAAAAGAAAAAAGACGGTAAAGATATTAAATTAACCATTGATGCTAGAGTCCAAAAAAGTATTTATAACAACATGAAAGATGACTACGGTTCGGGGACTGCTATTCATCCAAAAACTGGTGAACTCTTAGCACTTGTCAGCACGCCATCTTATGATGTTTATCCATTTATGAATGGAATGAACGATGAAGATTATAAGAAATTAACTGAAGATGATAAAGAGCCACTCCTTAATAAGTTCCAAATTACGACATCACCGGGTTCGACTCAAAAAATATTAACAGCCATGATTGGCTTAAACAATAAGACATTAGACGGCAAAACAAGTTATAAAATTAATGGAAAAGGTTGGCAAAAAGATAAATCTTGGGGTGACTACAACGTTACAAGATATGAGGTCGTGAATGGCGATATTGACTTAAAACAAGCTATTGAATCATCAGATAATATCTTCTTTGCGAGAGTTGCACTTGAATTAGGCAGCAAAAAATTCGAAGAAGGAATGAAACGCCTTGGTGTTGGTGAAGATATCCCGAGTGATTATCCATTCTACAATGCACAAATTTCAAATAAGAACTTAGATAATGAAATATTGTTAGCTGACTCAGGTTATGGCCAAGGTGAAATATTAATCAATCCTGTTCAAATTCTTTCAATATACAGCGCATTAGAGAACAAAGGTAATGTGAATGCACCACATGTACTGAAAGATACGAAAAATAAAGTCTGGAAGAAGAACATCATTTCCCAGGAAAATATTAAGTTGTTAACAGACGGTATGCAACAAGTCGTTAACAAAACACATAGAGAAGATATTTATAGATCATATGCCAACTTAGTTGGTAAATCAGGTACAGCTGAACTCAAGATGAAACAAGGTGAGACAGGACAACAAATAGGTTGGTTCATTTCATATGATAAAAATAATCCAAATATGATGATGGCTATTAATGTGAAAGATGTACAAGATAAAGGCATGGCAAGTTACAATGCCAAAATATCTGGAAAAGTGTATGACGATTTATATGATAACGGTAAGAAAACATATCGTATTGATAAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3791,Drugs,MEG_3791|Drugs|betalactams|Penicillin_binding_protein|MECA,mecA1_3_Y13094,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGTTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1890,Drugs,MEG_1890|Drugs|betalactams|Class_C_betalactamases|CMY,gb|HM569226|+|1039-2185|ARO:3002059|CMY-48 [Citrobacter freundii] ,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCCCTTTCTCCACGTTTGACGCAGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCATGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAAAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGTGGCCTGGCACATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1954,Drugs,MEG_1954|Drugs|betalactams|Class_C_betalactamases|CMY,gi|301088270|gb|HM565135.1|1-1146,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccagtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2161,Drugs,MEG_2161|Drugs|betalactams|Class_A_betalactamases|CTX,1028104788|WP_063860034.1|NG_048964|1|1|blaCTX-M-180|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-180 NG_048964:1-876,0
,atgagaatagtgaatggaccaataataatgactagagaagaaagaatgaagattgttcatgaaattaaggaacgaatattggataaatatggggatgatgttaaggctattggtgtttatggctctcttggtcgtcagactgatgggccctattcggatattgagatgatgtgtgtcatgtcaacagaggaagcagagttcagccatgaatggacaaccggtgagtggaaggtggaagtgaattttgatagcgaagagattctactagattatgcatctcaggtggaatcagattggccgcttacacatggtcaatttttctctattttgccgatttatgattcaggtggatacttagagaaagtgtatcaaactgctaaatcggtagaagcccaaaagttccacgatgcgatttgtgcccttatcgtagaagagctgtttgaatatgcaggcaaatggcgtaatattcgtgtgcaaggaccgacaacatttctaccatccttgactgtacaggtagcaatggcaggtgccatgttgattggtctgcatcatcgcatctgttatacgacgagcgcttcggtcttaactgaagcagttaagcaatcagatcttccttcaggttatgaccatctgtgccagttcgtaatgtctggtcaactttccgactctgagaaacttctggaatcgctagagaatttctggaatgggattcaggagtggacagaacgacacggatatatagtggatgtgtcaaaacgcataccattttga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_978,Drugs,MEG_978|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT4-PRIME,695257003|WP_032488330.1|NG_056101|1|1|ant(4')-Ia|ant(4')-Ia|aminoglycoside_O-nucleotidyltransferase_ANT(4')-Ia NG_056101:101-871,2
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAAGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAACTGGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2402,Drugs,MEG_2402|Drugs|betalactams|Class_A_betalactamases|CTX,gi|56554762|gb|AY847143.1|83-963,0
,atgaaaataattaacttaggcattctgggtcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaagtataccgttctttatccgtattagacggagcagtattattagtttctgcaaaggatggcatacaggcacagacccgtatactgtttcatgcactacagataatgaagattccgacaatttttttcatcaataaaattgaccaagaggggattgatttgccaatggtatatcgggaaatgaaagcaaagctttcttcggaaattatagtgaagcaaaaggttgggcagcatccccatataaatgtaacggacaatgacgatatggaacagtgggatgcggtaattatgggaaacgatgaactattagagaaatatatgtcagggaaaccgtttaaaatgtcagaactggaacaggaagaaaacaggagattccaaaacggaacgttatttcccgtttatcacggaagcgctaaaaacaatctggggattcggcagcttatagaagtaattgccagtaaattttattcatcaacgcctgaaggtcaatctgaactatgcgggcaggtttttaagattgaatattcagagaaaaggcggcgttttgtttatgtgcgtatatatagcggaacattgcatttgagggatgttattagaatatctgaaaaagagaaaataaaaatcacagagatgtatgttccgacaaacggtgaattatattcatccgatacagcctgctctggtgatattgtaattttaccaaatgatgttttgcagctaaacagtattttggggaacgaaatactgttgccgcagagaaaatttattgaaaatcctctccctatgctccaaacaacgattgcagtaaagaaatctgaacagcgggaaatattgcttggggcacttacagaaatttcagatggcgaccctcttttaaaatattatgtggatactacaacgcatgagattatactttcttttttggggaatgtgcagatggaagtcatttgtgccatccttgaggaaaaatatcatgtggaggcagaaataaaagagcctactgttatatatatggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaatcaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7149,Drugs,MEG_7149|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,915495706|WP_050824634.1|NG_048258|1|1|tet(O)|tet(O)|tetracycline_resistance_ribosomal_protection_protein_Tet(O) NG_048258:1-1920,4
,atgcgttcgtttgccatatcgactgtgttggtgatgtcctcactgttagcgtcgtcaatcattgccgccccgacttttgcctcaaccgcggtgaagaaggagtggcaagaaacccgcagttgggatgccatttttactcagcatcaagctgaaccgcaacaagctaaactgcaaaaaactaagctccaacaaacctcgggcgtggtagcactatggaacgaaaacaagcaacagggatataccaacaatcttaaacgtgccaatcaaggttttttacctgcatcgacctttaaaatccctaacagtttgattgcgcttgatctcggtgtggtgaaggatgaacatcaagtgtttaagtgggatggtaaaagccgtgatattgccacttggaatcgtgaccacaacttgattaccgggatgaagtattcggtggtgccagtctatcaagagtttgcccgccaaattggtgaggcgcgaatgtcgaagatgatcgcctctttcgattatggtaatgaggatatctcgggtaacttagatagcttttggcttgatggtggtattcggatatcggccactgagcaaatcgatttcctgcgccgactttattacaacaaaatacacgcttcagagcgcagtcaacgcatcgttaagcaagccatgctcaccgaggcgaattctgattatattatccgcgcaaaaaccggttatgcggtcagagctgagccaagcattggctggtgggttggttggatagaactcgatgataatgtgtggttttttgcaatgaatatggatatccctgatgccgcaggtttgccattgcgccaagccattactaaagaagtattaaaactggaacacgtaattccttag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4626,Drugs,MEG_4626|Drugs|betalactams|Class_D_betalactamases|OXA,1201190419|WP_087587939.1|NG_054953|1|1|blaOXA-548|blaOXA-548_like|class_D_beta-lactamase_OXA-548 NG_054953:1-873,0
,CAATACTAAAACTTTAATTATTACCCTAAAAATTATGAAAAAAAGCATACAGTTTTTTATTGTTTCCCTATTATTAAGTCCGTTTGCTAATGCTCAGGTAAAGGATTTTGTAATAGAACCTCCTATCAGCAAGAACTTATATATTTATAAAACTTTTGGTGTATTCGGAGGAAAAGAATATTCTGCCAACGCTGTTTACCTTGTCACAAAAAAAGGAGTAGTCCTGTTTGATGTTCCCTGGGAAAAAGTTCAGTACCAAAGCTTGATGGATACCATAAAAAAACGTCATAATTTACCTGTAGTGGCAGTATTTGCTACCCATTCTCATGATGACAGAGCCGGAGATTTAAGCTTCTTCAACAAAAAAGGGATTAAGACCTATGCCACGGCAAAAACCAATGAGTTATTGAAAAAAGAAGGTAAAGCGGTGTCCAGCAATATTATAAATACAGGGAAAGCTTATCATATAGGCGGAGAAGAATTTGTGGTTGATTTTATTGGAGAAGGACATACCGTAGATAATGTAGTGGTATGGTTTCCAAAATATAAAGTTCTTGATGGCGGCTGCTTAGTAAAAAGTACTTCTGCAACAGATTTAGGATATATCAAGGAAGCAAACGTTGAACAATGGCCACAAACTATGAATACTTTAAAATCCAAATACTCTCAGGCAACCTTAATCATTCCGGGACATGACGAATGGAAAGGCGGCGGACATGTAGAACATACATTAGAGCTTTTGAATAAAAAATAATTCTATAACATTTCAATAAAAAATCCCGAATGAAAATTCGGGATTTATATT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3422,Drugs,MEG_3422|Drugs|betalactams|Class_B_betalactamases|IND,gi|270266461|gb|GU186045.1|1-805 gi|302357573|dbj|AB563173.1|827-856,0
,ATGACTCTGGCATTAGTTGGCGAAAAAATTGACAGAAATCGCTTCACCGGTGAGAAAGTTGAAAATAGTACATTTTTTAACTGCGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGCCAGTTCTATGATCGCGAAAGTCAAAAAGGATGCAATTTTAGTCGCGCAATGCTGAAAGATGCCATTTTCAAAAGCTGTGATTTATCAATGGCAGATTTCCGCAACGTCAGCGCATTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGTGCAAGCTTTATGAATATGATCACCACGCGCACCTGGTTTTGCAGCGCATATATCACTAATACCAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTATGGGAAAACCGCTGGATGGGGACTCAGGTACTGGGTGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTAGGTGACTTAGATATTCGGGGTGTTGATTTACAAGGCGTTAAGTTAGACAACTACCAGGCATCGTTGCTCATGGAGCGGCTTGGCATCGCTGTGATTGGTTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5996,Drugs,MEG_5996|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gi|695214163|ref|NG_036745.1|1-645,3
,atgatgaaaaaatccctttgctgcgccctgctgctcggcctctcttgctctgctctcgccgcgccagtatcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgatagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaatcgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccggcgttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagcatcggtctttttggtgcgctggcggtcaaaccttctggcatgccctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggaatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaaggttgccgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcgaaggcagcgacagtaaggtagcgctggcgccgttacccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggttctactggcggatttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgaggcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_429,Drugs,MEG_429|Drugs|betalactams|Class_C_betalactamases|ACT,779820744|WP_045337464.1|NG_050709|1|1|blaACT-46|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-46 NG_050709:1-1146,0
,atgaaaattattaatattggagttttagctcatgttgatgcgggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacagaggtacaacgaaaacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattgtttcatgcacttaggaaaataggtattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcaaaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7111,Drugs,MEG_7111|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100163|WP_063856393.1|NG_048229|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048229:4-1923,4
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattgtaatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttcaaagagctaaacaaaccttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttctatcattataagggtgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaggcttaaataaactttcttatggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcgcaaaattctttacctttttccaaaaaaagtcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattattaaataagtatttagctaatttttccaacaataataggattaaaagcttttactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4584,Drugs,MEG_4584|Drugs|betalactams|Class_D_betalactamases|OXA,1079831656|WP_070233680.1|NG_057546|1|1|blaOXA-614|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-614 NG_057546:1-774,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTACATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1331,Drugs,MEG_1331|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_54_NZ_JVRB01000003,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgtggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacaccgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2206,Drugs,MEG_2206|Drugs|betalactams|Class_A_betalactamases|CTX,1062509488|WP_069280706.1|NG_051509|1|1|blaCTX-M-190|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-190 NG_051509:101-976,0
,ATGGCTGAATTACCTCAATCAAGAATAAATGAACGAAATATTACCAGTGAAATGCGTGAATCATTTTTAGATTATGCGATGAGTGTTATCGTTGCTCGTGCATTGCCAGATGTTCGTGACGGTTTAAAACCAGTACATCGTCGTATACTATATGGATTAAATGAACAAGGTATGACACCGGATAAATCATATAAAAAATCAGCACGTATCGTTGGTGACGTAATGGGTAAATATCACCCTCATGGTGACTCATCTATTTATGAAGCAATGGTACGTATGGCTCAAGATTTCAGTTATCGTTATCCGCTTGTTGATGGCCAAGGTAACTTTGGTTCAATGGATGGAGATGGCGCAGCAGCAATGCGTTATACTGAAGCGCGTATGACTAAAATCACACTTGAACTGTTACGTGATATTAATAAAGATACAATAGATTTTATCGATAACTATGATGGTAATGAAAGAGAGCCGTCAGTCTTACCTGCTCGATTCCCTAACTTATTAGCCAATGGTGCATCAGGTATCGCGGTAGGTATGGCAACGAATATTCCACCACATAACTTAACAGAATTAATCAATGGTGTACTTAGCTTAAGTAAGAACCCTGATATTTCAATTGCTGAGTTAATGGAAGATATTGAAGGTCCTGATTTCCCAACTGCTGGACTTATTTTAGGTAAGAGTGGTATTAGACGCGCATATGAAACAGGTCGTGGTTCAATTCAAATGCGTTCTCGTGCAGTTATTGAAGAACGTGGAGGCCGACGTCAACGTATTGTTGTCACTGAAATTCCTTTCCAAGTGAATAAGGCTCGTATGATTGAAAAAATTGCAGAGCTCGTTCGTGACAAGAAAATTGACGGTATCACTGATTTACGTGATGAAACAAGTTTACGTACTGGTGTGCGTGTCGTTATTGATGTGCGTAAGGATGCAAATGCTAGTGTCATTTTAAATAACTTATACAAACAAACACCTCTTCAAACATCATTTGGTGTGAATATGATTGCACTTGTAAATGGTAGACCGAAGCTTATTAATTTAAAAGAAGCGTTGGTACATTATTTAGAGCATCAAAAGACAGTTGTTAGAAGACGTACGCAATATAACTTACGTAAAGCTAAAGATCGTGCCCACATTTTAGAAGGATTACGTATCGCACTTGACCATATCGATGAAATTATTTCAACGATTCGTGAGTCAGATACAGATAAAGTTGCAATGGAAAGCTTGCAACAACGCTTCAAACTTTCTGAAAAACAAGCTCAAGCTATTTTAGACATGCGTTTAAGACGTCTAACTGGTTTAGAGAGAGACAAAATTGAAGCTGAATATAATGAGTTATTAAATTATATTAGTGAATTAGAAGCAATCTTAGCTGATGAAGAAGTGTTATTACAGTTAGTTAGAGATGAATTGACTGAAATTAGAGATCGTTTCGGTGATGAGCGTCGTACAGAAATTCAATTAGGTGGATTTGAAGACTTAGAGGACGAAGACTTAATTCCAGAAGAACAAATAGTAATTACTTTGAGCCATAATAACTACATTAAACGTTTGCCGGTATCTACATATCGTGCTCAAAACCGTGGTGGTCGTGGTGTTCAAGGTATGAATACATTGGAAGAAGATTTTGTCAGTCAATTGGTAACTTTAAGTACACATGACCATGTATTGTTCTTTACTAACAAAGGTCGTGTATACAAACTAAAAGGTTATGAAGTGCCTGAGTTATCAAGACAGTCTAAAGGTATTCCTGTAGTGAATGCTATTGAACTTGAAAATGATGAAGTCATTAGTACAATGATTGCTGTTAAAGACCTTGAAAGTGAAGACAACTTCTTAGTGTTTGCAACTAAACGTGGTGTCGTTAAACGTTCAGCATTAAGTAACTTCTCAAGAATAAATAGAAATGGTAAGATTGCGATTTCGTTCAGAGAAGATGATGAGTTAATTGCAGTTCGCTTAACAAGTGGTCAAGAAGATATCTTGATTGGTACATCACATGCATCATTAATTCGATTCCCTGAATCAACATTACGTCCTTTAGGCCGTACAGCAACGGGTGTGAAAGGTATTACACTTCGTGAAGGTGACGAAGTTGTAGGGCTTGATGTAGCTCATGCAAACAGTGTTGATGAAGTATTAGTAGTTACTGAAAATGGTTATGGTAAACGTACGCCAGTTAATGACTATCGTTTATCAAATCGTGGTGGTAAAGGTATTAAAACAGCTACGATTACTGAGCGTAATGGTAATGTTGTATGTATCACTACAGTAACTGGTGAAGAAGATTTAATGATTGTTACTAATGCCGGTGTCATTATTCGACTAGATGTTGCAGATATTTCTCAAAATGGTCGTGCAGCACAAGGTGTTCGCTTAATTCGCTTAGGCGATGATCAATTTGTTTCAACGGTTGCTAAAGTAAAAGAGGATGCAGATGAAGTAAATGAAGATGAACAATCTACTGTATCTGAAGATGGTACTGAACAACAACGTGAAGCGGTTGTAAATGATGAAACACCAGGAAATGCAATTCATACTGAAGTGATTGATTCAGAAGAAAATGATGAAGATGGACGTATTGAAGTAAGACAAGATTTCATGGATCGTGTTGAAGAAGATATACAACAATCATCAGATGAAGATGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3221,Drugs,MEG_3221|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|82655308|emb|AJ938182.1|7005-9665,3
,ATGGGGCAGCAACTTGGCGCTGTTCACAGCCTATCGGTTGATCAATGTCCGTTTGAGCGCAGGCTGTCGCGAATGTTCGGACGCGCCGTTGATGTGGTGTCCCGCAATGCCGTCAATCCCGACTTCTTACCGGACGAGGACAAGAGTACGCCGCAGCTCGATCTTTTGGCTCGTGTCGAACGAGAGCTACCGGTGCGGCTCGACCAAGAGCGCACCGATATGGTTGTTTGCCATGGTGATCCCTGCATGCCGAACTTCATGGTGGACCCTAAAACTCTTCAATGCACGGGTCTGATCGACCTTGGGCGGCTCGGAACAGCAGATCGCTATGCCGATTTGGCACTCATGATTGCTAACGCCGAAGAGAACTGGGCAGCGCCAGATGAAGCAGAGCGCGCCTTCGCTGTCCTATTCAATGTATTGGGGATCGAAGCCCCCGACCGCGAACGCCTTGCCTTCTATCTGCGATTGGACCCTCTGACTTGGGGTTGA,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1058,Drugs,MEG_1058|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,gi|984686374|gb|HQ700358.2|19996-19505 gi|974751547|gb|KU130294.1|219297-218806 gi|974751143|gb|KU238092.1|9800-9309 gi|981191958|emb|LN999997.1|2509737-2510228 gi|975007785|gb|CP010832.1|3316-2825 gi|954666075|gb|KT962845.1|18399-17908 gi|971497891|gb|CP012901.1|3692102-3692593 gi|971493847|gb|CP010351.1|33767-34258 gi|971339514|gb|CP006662.2|53733-53242 gi|943457735|gb|KT818627.1|109435-108944,2
,ATGAAAAAGAACTTTGCCTTTTTAGATGAAATGATTCCCGGAATCCGATGGGATGCTAAATATGCCACATGGGACAATTTCACCGGGAAACCGGTAGACGGATACATGGTAAACCGTGTTATGGGAACGAAGGAGCTGGGAGTTGCTTTGCGTAAGGCTCAGAAGATGGCGGAGAAACTGGGATATGGTTTGCTCTTATGGGACGGCTATCGCCCCCAGTGCGCAGTGGATTGTTTTCTGAATTGGACTTCCCAACCGGAAGACAATCTGACGAAAAAGCGTTACTATCCAAATATCAAAAGGAATGAGATGGTTGCGAAGGGGTATGTGGCCTCAAAATCCAGCCACAGCCGTGGAAGTACGGTTGACCTTACAATTTTTCATTTGAATAGCGGTATGCTTGTTCCTATGGGTGGAGATTTTGACTATATGGATGAACGGTCACACCATACCGCAAGCGGTCTGAGCGAAGAAGAATCAAAAAACCGGCAGTGTTTGCGTTATATCATGGAGAGCAGCGGATTTGAAGCCTATCGTTATGAATGGTGGCATTACGTCTTGGTGGACGAGCCATACCCGGATACATATTTTGATTTTTGGATGGCCTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7568,Drugs,MEG_7568|Drugs|Glycopeptides|VanD-type_resistance_protein|VANXD,gi|40021670|gb|AY489045.1|5047-5655,5
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCACCCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6626,Drugs,MEG_6626|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|20386405|gb|AF497970.1|5780-6595 gi|12054883|emb|AJ249249.1|1614-2429 gi|695208244|ref|NG_035503.1|449-1264,8
,atgatgatgactaaatccctttgctgcgccctgctgctcagcacctcctgctcggtattggctaccccgatgtcagaaaaacagctggctgaggtggtggaacggaccgttacgccgctgatgaaagcgcaggccattccgggtatggcggtggcggtgatttatgagggtcagccgcactacttcaccttcggtaaagccgatgttgcggcgaacaaacctgtcactccacaaaccttgttcgaactgggttctataagtaaaaccttcaccggcgtactcggtggcgatgccattgctcgcggtgaaatatcgctgggcgatccggtgacaaaatactggcctgagctgacaggcaagcagtggcaggggatccgcatgctggatctggcaacctataccgcaggaggtttgccgttacaggtaccggatgaggtcacggataacgcctctctgttgcgcttttatcaaaactggcagccgcagtggaagccgggcaccacgcgtctttacgccaatgccagcattggtctttttggcgcgctggcggtcaaaccttccggcatgagctatgagcaggccataacgacgcgggtctttaagccgctcaagctggaccatacgtggattaacgttccgaaagcggaagaggcgcattacgcctggggataccgcgacggtaaagcggtacacgtttcgccaggaatgctggacgctgaagcctatggcgtaaaaaccaacgtgcaggatatggcaagctgggtgatggtcaacatgaagccggactcccttcaggataattcactcaggaaaggccttaccctggcgcagtctcgctactggggcgtgggggccatgtatcaggggttaggctgggaaatgcttaactggccggtcgatgccaaaaccgtggttgaaggtagcgacaataaggttgcactggcaccgctgcctgcgagagaagtgaatccaccagcgctcccggtcaacgcatcctgggtccataaaacaggctctaccggcgggtttggcagctacgtggcatttattcctgaaaagcagctcggtattgtgatgctggcaaataaaagctatccgaacccggcacgcgttgaggcggcataccgtattttgagcgcgctgtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_443,Drugs,MEG_443|Drugs|betalactams|Class_C_betalactamases|ACT,1625655374|WP_136512051.1|NG_064668|1|1|blaACT-68|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-68 NG_064668:1-1146,0
,ATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGCTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATTCCAGTGCGCTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACCACACGCACCTGGTTTTGTAGCGCATATATCACGAATACCAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTCTCAGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCGAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGCTGGACAACTACCAGGCGTCGTTGCTCATGGAGCGGCTTGGCATCGCGGTGATTGGTTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5994,Drugs,MEG_5994|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gi|341873880|gb|JN173051.1|37-681,3
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgataggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatggccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattgctcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4451,Drugs,MEG_4451|Drugs|betalactams|Class_D_betalactamases|OXA,1559613009|WP_128268274.1|NG_063879|1|1|blaOXA-775|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-775 NG_063879:14-838,0
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggaaggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccatatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_221,Drugs,MEG_221|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1104448619|WP_071766399.1|NG_052086|1|1|aac(6')-Ib-cr7|aac(6')-Ib-cr|fluoroquinolone-acetylating_aminoglycoside_6'-N-acetyltransferase_AAC(6')-Ib-cr7 NG_052086:101-655,2
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttgggcggtacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgtttccggaccgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcatggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctttgaggcaatggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaatgcccatgctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1600,Drugs,MEG_1600|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1105502197|WP_071846347.1|NG_052444|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_052444:101-733,6
,atgattacgaaatcgaacatcgcgcggattggcttgccgctggctttggccatggcgctgcccggctgcatccccggcgagatccgcccgtcgattggtgagcaggtggataagggtgaccagcgcttcggcgatctggtgttccgccagctggcgcccaatgtgtggcaacatacctcgttcatggatgtgccgggctttggcgcggtttcttccaacgggctgatcgtcaaggatggcgaacgggtgctgttggtcgataccgcctggaccgatgatcagaccagccagatcctcaactggattaagcaagagatcaatctgccggtggcgctggcggtggtcacccacgcgcatcaggacaagatgggcgggatgggcgcgctgcacgcggaggcaatccccacttacgccaatgccttgtcgaaccagcttgccccgcaagaggggatgacggcggcgcagcacagcctgaccttcgccgccaacggctgggtcgacccggcgaccgcgcccaatttcgggccgctcagggtgttctatcccggccccggccacaccagtgacaatatcaccgtcgggatcgatggcaccgacatcgcctttggcggctgcctgatcaaagacagcaaggccaagtcgctcggcaatctcggcgatgccgacaccgaacgctatgccgcctcggcgcgcgcatttggtgcggcttttccgaaggcgaacacgattgcgatgagccattccgcgcctgacagccgcgccgcgatcacccacaccgcgcggatggccgacaagctgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_709,Drugs,MEG_709|Drugs|betalactams|Class_B_betalactamases|AFM,1072331906|WP_069953510.1|NG_063835|1|1|blaAFM-1|blaAFM|subclass_B1_metallo-beta-lactamase_AFM-1 NG_063835:1-804,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1383,Drugs,MEG_1383|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_64_CSJB01000017,0
,atgcatacgcggaaggcaataacggaggcgcttcaaaaactcggagtccaaaccggtgacctcttgatggtgcatgcctcacttaaagcgattggtccggtcgaaggaggagcggagacggtcgttgccgcgttacgctccgcggttgggccgactggcactgtgatgggatacgcgtcgtgggaccgatcaccctacgaggagactctgaatggcgctcggctggatgacgaagcccgccgtacctggctgccgttcgatcccgcaacagccgggacttaccgtgggttcggcctgctgaatcaatttctggttcaagcccccggcgcgcggcgcagcgcgcaccccgatgcatcgatggtcgcggttggtccgctggctgaaacgctgacggagcctcacgaactcggtcacgccttgggggaaggatcgcccgtcgagcggttcgttcgccttggcgggaaggccctgctgttgggtgcgccgctaaactccgttaccgcattgcactacgccgaggcggttgccgatatccccaacaaacggtgggtgacgtatgagatgccgatgcttggaagagacggtgaagtcgcctggaaaacggcatcggattacgattcaaacggcattctcgattgctttgctatcgaaggaaagccggatgcggttgaaactatagcaaatgcttacgtgaagctcggtcgccatcgagaaggtgtcgtgggctttgctcagtgctacctgttcgacgcgcaggacatcgtgacgttcggcgtcacctatcttgagaagcatttcggaaccactccgatcgtgcctccgcacgaggccgtcgagccgtcttgcgagccttcaggttag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_21,Drugs,MEG_21|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,1028080882|WP_063840265.1|NG_047246|1|1|aac(3)-IIa|aac(3)-IIa|aminoglycoside_N-acetyltransferase_AAC(3)-IIa NG_047246:101-961,2
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagtgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcgaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccggagatgagcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacgggggccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3099,Drugs,MEG_3099|Drugs|betalactams|Class_A_betalactamases|GES,1028105367|WP_063860516.1|NG_049134|1|1|blaGES-30|blaGES|class_A_beta-lactamase_GES-30 NG_049134:1-864,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacggcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2204,Drugs,MEG_2204|Drugs|betalactams|Class_A_betalactamases|CTX,1058243967|WP_068981633.1|NG_051468|1|1|blaCTX-M-189|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-189 NG_051468:1-876,0
,atgaaaaataataatgtaacagaaaaagaattattttatattttagatttatttgaacacatgaaagtaacttattggttagatggtggctggggggtagatgtattaactggaaaacaacaaagagaacacagagatatagatatagattttgacgctcaacacactcaaaaagttatacaaaaattagaagatataggatacaaaatagaagttgattggatgccttcacgtatggaacttaagcatgaagaatatgggtatttagatattcatcctataaatctaaatgatgatggatcaattacccaagcaaacccagaaggtggtaattatgttttccaaaatgactggttttcagaaactaattacaaaggtcgaaaaataccatgtatttcaaaagaagctcaacttctttttcattctggttatgatttaacagaaaaagaccattttgatataaaaaatttaaaatcaataacataa,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3601,Drugs,MEG_3601|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUA,499964295|WP_011645013.1|NG_047918|1|1|lnu(A)|lnu(A)|lincosamide_nucleotidyltransferase_Lnu(A) NG_047918:101-586,7
,atgatgaaaaaatcccttttctgcgccctgctgctcggcatctcttgctctgctctcgccgcgccagtatcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaaccgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccggcgttttaggtggggatgccattgcgcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgagatcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagccaggcacaacgcgtctttacgccaatgccagcatcggtctttttggcgcgctgacggtcaaaccttccggcatgtcctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgtgccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggtatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaacgttgctgatgccacacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcggaggcagcgacagtaaggtagcgctggcgccgttgcccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggttctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgaggcgttacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_434,Drugs,MEG_434|Drugs|betalactams|Class_C_betalactamases|ACT,1423070191|WP_111976052.1|NG_061402|1|1|blaACT-60|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-60 NG_061402:1-1146,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctacttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattacgcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4474,Drugs,MEG_4474|Drugs|betalactams|Class_D_betalactamases|OXA,1188444906|WP_085562408.1|NG_054698|1|1|blaOXA-554|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-554 NG_054698:1-825,0
,ATGAAAAAAATTTATATTAGTGTGCTAGTTCTTTTACTAATTATGATTATAATAACTTGGTTATTCAAAGATGACGATATTGAGAAAACAATTAGTTCTATTGAAAAAGGAAACTATAACGAAGTATATAAAAATAGTTCAGAAAAATCTAAACTGGCATATGGAGAAGAAGAAATTGTAGATAGGAATAAAAAAATTTACAAAGATTTAAGTGTCAATAACTTAAAAATTACTAATCATGAAATTAAAAAAACTGGAAAAGATAAAAAGCAAGTTGATGTTAAATATAACATATATACAAAATATGGAACTATACGACGTAATACACAATTAAACTTTATTTATGAAGATAAGCATTGGAAATTAGATTGGAGACCAGACGTAATAGTACCTGGTTTGAAAAATGGACAGAAAATTAATATAGAAACATTAAAATCAGAGCGAGGCAAAATAAAAGATAGAAATGGTATAGAATTAGCTAAAACTGGAAATACATATGAAATCGGTATTGTCCCTAACAAAACACCCAAAGAAAAATATGATGATATTGCTCGTGACTTACAAATTGATACAAAAGCTATAACCAATAAAGTTAATCAAAAATGGGTTCAGCCAGATTCATTTGTACCAATTAAAAAGATAAATAAACAAGATGAATATATAGACAAATTAATTAAATCATACAATTTACAAATAAACACTATAAAAAGCCGTGTTTATCCATTGAACGAAGCAACAGTACACCTTTTAGGTTATGTGGGTCCAATTAATTCTGACGAGTTAAAAAGTAAGCAATTTAGAAACTATAGCAAAAATACTGTTATTGGAAAAAAAGGCTTAGAACGCCTCTATGATAAACAATTGCAAAACACTGATGGTTTTAAGGTATCCATTGCAAATACTTATGACAATAAACCTTTAGACACATTATTGGAGAAAAAGGCTGAAAACGGAAAAGATCTTCATTTAACTATAGATGCTAGAGTACAAGAAAGTATTTATAAACATATGAAAAATGACGATGGATCTGGTACAGCATTACAACCAAAAACTGGAGAAATTTTAGCTTTGGTAAGTACCCCATCGTACGATGTTTATCCATTCATGAATGGATTAAGCAATAATGACTACCGTAAATTAACTAACAATAAAAAAGAGCCTTTGCTCAACAAATTTCAAATCACTACATCACCAGGTTCAACCCAAAAAATATTAACATCTATTATAGCCTTAAAAGAAAATAAACTAGACAAAAATACTAATTTTGATATTTATGGTAAGGGTTGGCAAAAAGATGCATCATGGGGGAATTATAATATCACAAGATTTAAAGTAGTAGACGGCAATATCGATTTAAAGCAAGCAATAGAATCATCAGACAACATATTTTTTGCCCGCATTGCATTAGCATTAGGAGCCAAAAAATTTGAGCAAGGTATGCAAGATTTGGGAATCGGTGAAAATATCCCGAGTGATTATCCCTTTTATAAAGCACAAATCTCAAATAGTAATTTAAAAAATGAAATATTATTAGCAGATTCAGGATATGGCCAAGGCGAGATACTAGTAAACCCTATACAAATTTTATCAATATACAGTGCTTTAGAAAATAACGGAAATATACAAAATCCTCATGTTTTACGTAAAACAAAATCTCAAATATGGAAAAAAGATATTATACCTAAAAAAGACATAGATATATTAACTAATGGTATGGAACGTGTAGTTAATAAAACACATAGGGATGATATATACAAAAATTATGCCCGAATTATTGGTAAATCTGGCACAGCAGAATTAAAAATGAATCAAGGGGAAACTGGAAGACAAATAGGTTGGTTTGTTTCATATAATAAAAATAATCCTAATATGTTAATGGCGATTAATGTTAAAGACGTTCAAAATAAAGGGATGGCCAGCTATAATGCTACTATATCTGGAAAAGTTTATGATGATTTGTATGATAATGGAAAAACTCAATTTGATATAGATCAGTAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_5404,Drugs,MEG_5404|Drugs|betalactams|Penicillin_binding_protein|PBP2,gi|871340505|gb|KT192641.1|1-1998 gi|657406205|emb|LK024544.1|6531-4534 gi|452754752|emb|HF569116.1|3738-1741 gi|344176319|emb|FR821779.1|37678-35681 gi|375313938|gb|JN794592.1|1-313,0
,atgaagtttttatgggcattttcgcatttaataccatccgtggtttttgcaagtagttcaaagtttcagcaagttgaacaagacgttaaggcaattgaagtttctctttctgctcgtataggtgtttccgtttatgatactcaaaatggagaatattgggattacaatggcaatcagcgcttcccgttaacaagtacttttaaaacaatagcttgcgctaaattactatatgatgctgagcaaggaaaagttaatcccaatagtacagtcgagattaagaaagcagatcttgtgacctattcccctgtaatagaaaagcaagtagggcaggcaatcacactcgatgatgcgtgcttcgcaactatgactacaagtgataatactgcggcaaatatcatcctaagtgctgtaggtggccccaaaggcgttactgattttttaagacaaattggggacaaagagactcgtctagaccgtattgagcctgatttaaatgaaggtaagctcggtgatttgagggatacgacaactcctaaggcaatagccagtactttgaataaatttttatttggttccgcgctatctgaaatgaaccagaaaaaattagagtcttggatggtgaacaatcaagtcactggtaatttactacgttcagtattgccggcgggatggaacattgcggatcgctcaggtgctggcggatttggtgctcggagtattacagcagttgtgtggagtgagcatcaagccccaattattgtgagcatctatctagctcaaacacaggcttcaatggcagagcgaaatgatgcgattgttaaaattggtcattcaatttttgacgtttatacatcacagtcgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5811,Drugs,MEG_5811|Drugs|betalactams|Class_A_betalactamases|PSE,1105502208|WP_071846358.1|NG_052478|1|1|blaPSE|blaPSE|PSE_family_carbenicillin-hydrolyzing_class_A_beta-lactamase NG_052478:101-967,0
,ATGAAAAAATCGTTATCTGCAACACTGATTTCCGCTCTGCTGGCGTTTTCCGCCCCGGGGTTTTCTGCCGCTGATAATGTCGCGGCGGTGGTGGACAGCACCATTAAACCGCTGATGGCACAGCAGGATATTCCCGGGATGGCGGTTGCCGTCTCCGTAAAGGGTAAGCCCTATTATTTCAATTACGGTTTTGCCGATGTTCAGGCAAAACAGCCTGTCACTGAAAATACACTATTTGAGCTCGGATCTGTAAGTAAAACTTTCACAGGTGTGCTGGGTGCGGTTTCCGTGGCGAAAAAAGAGATGACGTTGAATGACCCGGCAGAAAAATACCAGCCGGAGCTGGCTCTGCCGCAGTGGAAGGGGATCACACTGCTGGATCTGGCTACCTACACCGCAGGCGGGCTGCCGTTACAGGTGCCGGATGCGGTGAAAAGCCGTGCGGATCTGCTGCATTTCTATCAGCAGTGGCAGCCGTCCCGGAAACCGGGCGATATGCGTCTGTATGCAAACAGCAGTATCGGCCTGTTTGGTGCTCTGACCGCCAACGCGGCGGGGATGCCGTATGAGCAGTTGCTGACTGCACGGATCCTGGCACCGCTGGGGTTATCTCACACCTTTATTACTGTGCCGGAAAGTGCGCAAAGCCAGTATGCGTACGGTTATAAAAACAAAAAACCGGTCCGCGTGTCGCCGGGACAGCTTGATGCGGAATCTTACGGTGTGAAATCCGCCTCAAAAGATATGCTGCGCTGGGCGGAAATGAATATGGAGCCGTCACGGGCCGGTAATGCGGATCTGGAAATGGCAATGTATCTCGCCCAGACCCGCTACTATAAAACCGCCGCGATTAATCAGGGTCTGGGCTGGGAAATGTACGACTGGCCGCAGCAGAAAGATATGATCATTAACGGCGTGACAAACGAGGTCGCATTGCAGCCGCACCCGGTAACAGACAACCAGGTTCAGCCGTATAACCGTGCTTCCTGGGTGCATAAAACGGGGGCAACAACGGGTTTCGGCGCCTATGTGGCCTTTATTCCGGAAAAACAGGTGGCGATTGTGATTCTGGCGAATAAAAACTACCCGAATACCGAAAGAGTCAAAGCCGCACAGGCTATTTTGAGTGCACTGGAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2593,Drugs,MEG_2593|Drugs|betalactams|Class_C_betalactamases|DHA,(Bla)MOR:Y10283:546-1685:1140,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggttgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4455,Drugs,MEG_4455|Drugs|betalactams|Class_D_betalactamases|OXA,1509794609|WP_122630918.1|NG_062338|1|1|blaOXA-710|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-710 NG_062338:22-846,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGGTGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAATCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCTCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1908,Drugs,MEG_1908|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JQ733575|+|1027-2173|ARO:3002091|CMY-78 [Citrobacter freundii] ,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgaaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_558,Drugs,MEG_558|Drugs|betalactams|Class_C_betalactamases|ADC,705415259|WP_033502167.1|NG_064698|1|1|blaADC-143|blaADC|class_C_beta-lactamase_ADC-143 NG_064698:101-1252,0
,TTGACAATCATACAAATTTAATATATACTACGCAAAAATATCAAGGATTATAAATGTCTAAAAAAAATTTTATATTAATATTTATTTTTGTTATTTTAACATCTTGTAAAAATACAGAAAAAATATCAAATGAAACTACATTAATAGATAATATATTTACTAATAGCAATGCTGAAGGAACATTAGTTATATATAATTTAAATGATGATAAATATATAATTCATAATAAAGAAAGAGCTGAACAAAGATTTTATCCAGCATCAACATTTAAAATATATAATAGTTTAATAGGCTTAAATGAAAAAGCAGTTAAAGATGTAGATGAAGTATTTTATAAATATAATGGCGAAAAAGTTTTTCTTGAATCTTGGGCTAAGGACTCTAATTTAAGATATGCAATTAAAAATTCGCAAGTACCGGCATATAAAGAATTAGCAAGAAGAATAGGTCTTAAAAAGATGAAAGAGAATATAGAAAAACTAGATTTTGGTAATAAAAGTATAGGTGATAGTGTAGATACTTTTTGGCTTGAAGGACCTTTGGAAATAAGTGCGATGGAGCAAATTAAATTATTAACTAAATTAGCTCAAAATGAATTACCGTATCCTATAGAAATACAAAAAGCTGTTTCTGATATTACTATACTAGAGCAAACTTACAATTATACGCTTCATGGAAAAACTGGATTAGCTGATTCTAAAAACATGACAACTGAGCCTATTGGTTGGTTCGTAGGCTGGCTTGAAGAAAATGATAATATATATGTCTTTGCTTTAAATATTGATAATATAAATTCAGATGACCTTGCAAAAAGGATAAATATAGTAAAAGAAAGTTTAAAAGCATTAAATTTATTAAAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5221,Drugs,MEG_5221|Drugs|betalactams|Class_D_betalactamases|OXA,gi|404429427|emb|HE793032.1|162237-161375 gi|158634583|gb|EU086834.1|36-898,0
,atgcaaaatcaagataaatttttaaaacaatttaaaaaattagcacttttagataaaaatatacgccttgttacacttgaaggctcaagggttaataaaaaagcgaagaaagataaatatcaagactatgatatttcattttttgtgccacttgataaaatgaaagattttttagggcttaatgaaaagcaaaattttaacgaatgtaaaaacttgccaaaatgtattttagagcttgaaaaatcttcatattttaaaaaaattttaatgcttcaaatgcctgaatgtatggagttttatccacctgatttgccacaaaattggataagttttttagtgctttttgaaagtggagtgaggcttgatttaaccattattcctttagaagatttgaaaaattactatgaatttgagcctttaagccaagcgcttttggataaaaatgggctttttacgcacactattccaaaagccccatttagcatcacacaccttagccaaagaagctttgatgatgtttgcaatgagttttattttctttatagttgcttaaaaaaagctcttttaagaaagcagtttattttgtcaaatcatttgctaaattctttgagaaaagcactttttgatttgcttagttttaaaattggcttaaattttggctttgaaatctggctgggaaaagaatacactaatattttagaatttttagaagaaaaagaagtaaaaatcatcttaaaatcttttaacaccgccacgctagaacacatcaaaaaagcaagaaaaaagcttgaaattttatttcataaaaatgctaaatttgtagcaaaaaagagtgattttaagctttttccttaccgaaaaaatgtgaaaaggtattgtaaaattttaggaaaattgtaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_990,Drugs,MEG_990|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,488873570|WP_002785795.1|NG_054665|1|1|aadE-Cc|aadE-Cc|aminoglycoside_6-adenylyltransferase_AadE-Cc NG_054665:101-1000,2
,GTAAATATTTTCTTACATTCTTGGCACAATATATTTTTCCATGATCGCTACGATTTCAATTTTTCAGCATGTTAGAGTGGTATTTAAGGTCACCAATATCATGAAGTTTAAAATGAAAGGTTTATTTTGTGTCATCCTCAGTAGTTTGGCATTTTCAGGTTGTGTTTATGATTCAAAACTACAACGCCCAGTCATATCAGAGCGAGAAACTGAGATTCCTTTATTATTTAATCAAGCACAGACTCAAGCTGTGTTTGTTACTTATGATGGGATTCATCTAAAAAGTTATGGTAATGATCTAAGCCGAGCAAAGACTGAATATATTCCTGCATCTACATTTAAGATGTTGAATGCTTTAATTGGCTTGCAAAATGGAAAAGCAACCAATACTGAAGTATTTCAGTGGAATGGTGAAAAGCGTGCTTTTTCAGCATGGGAAAAAGATATGACTTTGGCAGAAGCGATGCAGGCTTCAGCTGTTCCCGTATATCAAGAGCTTGCTCGACGTATTGGCTTGGAATTGATGCGTGAAGAAGTGAAGCGTGTAGGTTTTGGCAATGCGGAGATTGGTCAGCAAGTCGATAATTTTTGGTTGGTGGGTCCTTTAAAAATCTCCCCTGAACAAGAAGTTCAATTTGCCTATCAACTGGCGATGAAGCAATTACCTTTTGATCGAAATGTACAGCAACAAGTCAAAGATATGCTTTATATCGAGAGACGTGGTGACAGTAAACTGTATGCTAAAAGTGGTTGGGGAATGGATGTTGAACCTCAAGTGGGTTGGTATACGGGATGGGTTGAACAACCCAATGGCAAGGTGACTGCATTTGCGTTAAATATGAACATGCAAGCAGGTAATGATCCAGCTGAACGTAAACAATTAACCTTAAGTATTTTGGACAAATTGGGTCTATTTTTTTATTTAAGATAAATGCATGAGTTAAAAAAATGCCCAGTTTATTGGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5220,Drugs,MEG_5220|Drugs|betalactams|Class_D_betalactamases|OXA,gi|392295713|gb|JQ422054.1|1-966,0
,gtgcgcagctctgccatcattgccctgctgatcgtggggctcgacgccatgggtctcggcctcatcatgcccgtccttccgacgcttctgcgtgagcttgtgccagcagagcaggtcgccggtcactatggtgccttgctgtcgctctatgcattgatgcaggtcgtcttcgcacccgtgcttggacagctttcggattcttacggtcggcgtccggtgcttctggcttcccttgcgggagccgcagtcgattatgcgattatggcatcagcgccggtcttatgggtgctctatatcggccgactcgtctccggcatcacgggcgcaaccggagctgtagctgcctcaaccattgccgattcgacgggggaaggttctcgcgcacgctggttcggctacatgggggcctgttatggggcgggcatgattgccgggccagcacttggtggcatgctcggtggtatctctgctcatgccccatttatcgccgccgcccttctcaacgggttcgcgttcctgcttgcctgcattttcctcagggagacccgtcgcggtcatggcaagaccggaaagccggttcgtatccaaccatttgttctattccggctggacgatgtgttgcgtgggttgactgctcttttcgccgttttcttcattattcaactgatcggccaagtgcctgcggccctatgggttatatatggcgaggatcgttttcagtggaacaccgcgaccgttggtttgtcgctcgcggcgtttggggcaacacatgcgatcttccaagcgtttgttaccggcccgctttcaagccggcttggagagcggcgcacgctactgtttggcatggctgcggatgcgactggcttcgttcttctggcttttgccacgcagggatggatggtgttcccgattctgttgctgcttgccgccgggggtgttggcatgccggccttgcaagcaatgctctcaaacaatgtcagcagtaacaagcaaggggctttgcagggaacgctaacgagcctcaccaatctaagctctatcgcaggaccgcttggcttcacagcactctattctgccaccgccggagcatggaacggttgggtttggattgtcggcgcgatcctctatttaatatgtctgccaatactacgcagaccattcgcaacttcattgtga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7076,Drugs,MEG_7076|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETG,1028099805|WP_063856077.1|NG_048192|1|1|tet(G)|tet(G)|tetracycline_efflux_MFS_transporter_Tet(G) NG_048192:1-1176,4
,atgaacattaaagccctcttacttataacaagcactatttttatttcagcctgctcaccctatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcagccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccctttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4496,Drugs,MEG_4496|Drugs|betalactams|Class_D_betalactamases|OXA,1559612997|WP_128268262.1|NG_063867|1|1|blaOXA-763|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-763 NG_063867:14-838,0
,atgtcacttaatgtaaaaccaagtagaatagccatcttgtttagctcttgtttagtttcaatatcatttttctcacaggccaatacaaagggcatcgatgagattaaaaaccttgaaacagatttcaatggtagaattggtgtctacgctttagacactggctcaggtaaatcattttcatacaaagcaaatgaacgatttccattatgtagttctttcaaaggttttttagctgctgctgtattaaaaggctctcaagataatcaactaaatcttaatcagatcgtgaattacaatacaagaagtttagagttccattcacccatcacaactaaatataaagataatggaatgtcattaggtgatatggctgctgccgctttacaatatagcgacaatggtgctactaatattattcttgaacgatatatcggtggtcctgagggtatgactaaattcatgcggtcgattggagataaagattttagactcgatcgttgggagttagatctaaacacagctattcctggcgatgaacgtgacacatctacacctgcagcagtagctaagagcgtgaaaacccttgctctgggtaacatacttaatgagcgtgaaaaggaaacctatcagacatggttaaagggtaacacaaccggtgcagcacgtattcgtgctagcgtaccaagcgattgggtagttggcgataaaactggtagttgcggagcatacggtacggcaaatgattatgcggtagtctggccaaagaaccgagctcctcttataatttctgtatacactacaaaaaacgaaaaagaagccaagcatgacgataaagtaatcgcagaagcttcaagaatcgcaattgataaccttaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3297,Drugs,MEG_3297|Drugs|betalactams|Class_A_betalactamases|IMI,983404063|WP_060571602.1|NG_049171|1|1|blaIMI-9|blaIMI|carbapenem-hydrolyzing_class_A_beta-lactamase_IMI-9 NG_049171:101-979,0
,atgacatggagaacgaccagaacacttttacagcctcaaaagctggagttcaatgagtttgagattcttaatcccgtagttgagggcgcccgaattgtcggcattggcgagggtgctcactttgtcgcggagttctcactggctagagctagtcttattcgctattttgtcgagaggcatgattttaatgcgattggtttggaatgtggggcgattcaggcatcccggctatctgaatggctcaactcaacagccggtgctcatgaacttgagcgattttcggataccctgaccttttcttcgtatggctcagtgctgatttgggttaaatcatatctacgcgaatcaggaagaaaactgcagttagtcggaatcgatttacccaacaccttgaatccaagggacgacctagcgcaattggccgaaattatccaggtcatcgaccacctcatgaaaccccacgttgatgcgctgactcagttgttgacgtccattgatggccagtcggcggttatttcatcggcaaaatggggggagttggaaacggctcagcaggagaaagctatctcaggggtaaccagattgaagctccgtttggcgtcgcttgcccctgtcctgaaaaatcacgtcaacagcgattttttccgaaaagcctctgatcgaatagagtcgatagagtatacgttggaaaccttgcgtgtaatgaaagctttcttcgatggtacctctcttgagggagatacttccgtacgtgactcgtatatggcgggcgtggtggatggaatggttcgagcgaatccggatgtaaggataattctgctggcgcacaacaatcatttacaaaaaactccagtttccttttcaggcgagcttacggctgttcccatgggacagcatctcgcagagagggaggagggggattaccgtgcgattgcattcacccatcttggactcaccgtgccggaaatgcatttcccatcgcccgacagtcctcttggattctctgttgtgaccacgcctgccgatgcaatccgtgaggatagtgtggaacagtatgtcatcgatgcctgtggtaaggaggattcatgcctgacattgacagatgaccccatggaagcaaagcgaatgcggtcccaaagcgcctctgtagaaacgaatttgagcgaggcatttgatgccatcgtctgcgttcccagcgccggcaaggacagcctggttgccctatag,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_2743,Drugs,MEG_2743|Drugs|MLS|Macrolide_esterases|EREA,695263664|WP_032490534.1|NG_050404|1|1|ere(A2)|ere(A)|inactive_erythromycin_esterase_Ere(A2) NG_050404:67-1293,7
,ATGCGTTTTATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGAGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6249,Drugs,MEG_6249|Drugs|betalactams|Class_A_betalactamases|SHV,(Bla)SHV-55:HQ877613:1-715:715,0
,ATGAAGACAGTTGCGATTATCTTTGGCGGAGTTTCTTCTGAATATGAAGTTTCACTGAAATCTGCTGTAGCGATTATTAAAAATATGGAATCTATTGATTATAACGTAATGAAAATAGGGATCACCGAAGAAGGTCATTGGTATCTATTTGAAGGAACGACAGACAAAATAAAGAAAGATCGTTGGTTTTTAGATGAAAGCTGTGAAGAAATCGTAGTTGATTTCGCAAAAAAAAGCTTTGTATTGAAAAACAGTAAAAAAATAATCAAGCCTGATATTTTATTCCCAGTTTTACATGGAGGTTATGGTGAGAATGGTGCTATGCAGGGAGTATTTGAGTTATTAGATATTCCATATGTAGGTTGTGGTATCGGAGCTGCAGCAATCTCTATGAATAAAATAATGCTCCATCAATTTGCTGAAGCAATTGGTGTAAAAAGCACCCCTAGTATGATTATAGAAAAGGGACAAGACCTACAAAAAGTCGATGCGTTTGCGAAAATACATGGATTTCCTTTATATATTAAACCGAATGAGGCAGGCTCATCAAAAGGAATTAGCAAGGTAGAACGAAAAAGTGATTTATATAAAGCAATAGACGAAGCTTCAAAATATGATAGTCGTATTTTAATTCAAAAGGAAGTGAAAGGGGTAGAAATTGGTTGTGGTATTTTAGGAAATGAACAATTGGTCGTTGGAGAATGTGACCAAATCAGTCTTGTGGATGGCTTTTTCGATTATGAAGAGAAATACAATTTAGTAACAGCAGAAATTTTGTTACCAGCTAAACTATCAATAGACAAAAAAGAAGATATTCAGATGAAAGCAAAAAAACTATACAGACTATTAGGATGCAAAGGATTAGCGAGAATCGACTTTTTCTTAACTGATGACGGAGAAATTTTATTAAATGAAATCAATACAATGCCTGGTTTTACAGAGCATTCGAGATTTCCAATGATGATGAATGAGATTGGGATGGACTACAAAGAGATTATAGAAAACCTATTAGTATTGGCGGTGGAAAATCATGAAAAAAAATTATCTACGATTGATTAATGAAAACAATGAAATAAAAGACTCTGAGAGACCAAGTCACCTTGTTCAGGCTCCGTTTGCACAAACAAATATACTAGTTGATCCTATGGTAGCGATACAGCTAGAAAAACTAATAAAGACAACAGGTCTTGATAGCCAAATTATTACCATTGATGGCTATCGTTCAAAGGAGACACAGCAAGCACTTTGGGATGAGACGATTCAAGAAAAAGGGCTTGAATTTGCGCACAAATATGTGGCAAAGCCTGGATGTAGTGAACATGAAATTGGTTTAGCAGTGGATTTGGGGTTAGCTACGAAAGAAAATGATTTTATTCGCCCAAGTTTCACTGATAGTCCGATTGTTGATAAATTTTTAAAGCATATGACAGATTTCGGCTTTATCTTAAGATATCAAAAAGGAAAAGAATCTATTACCAATATAAACTATGAACCATGGCATTTCAGGTATGTAGGGACACCCCATAGTTCGATTATGGTACAGCAAAACTGGGTATTAGAAGAATACATTGAATTCATTGAGTCAATAAGAGGAACTGCTTATGAAGCATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7390,Drugs,MEG_7390|Drugs|Glycopeptides|VanE-type_resistance_protein|VANE,VanEXY_1_FJ872411,5
,ATGAGCCATATTCAACGGGAAACGTCTTGCTCGAGGCCGCGATTAAATTCCAACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCCGGGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAGCTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1079,Drugs,MEG_1079|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-PRIME,gi|974708445|gb|KT203761.1|4614-3799 gi|961454902|gb|KT991388.1|7213-8028 gi|937637492|gb|KT334335.1|88391-87576 gi|944397480|gb|CP013024.1|53217-54032 gi|939564300|gb|CP012956.1|42356-41541 gi|927351340|gb|KT207463.1|2413-1598 gi|922980777|gb|KP897158.1|1473-2288 gi|916354859|gb|KT339320.1|3886-4701 gi|916354855|gb|KT339319.1|4680-5495 gi|916354852|gb|KT339318.1|3814-4629,2
,ATGTCACTGTATCGCCGTCTAGTTCTGCTGTCTTGTCTCTCATGGCCGCTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTCGAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACTGTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCTGCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTACGGCAAAAATGCGCTGGTTCCGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATGACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTGTTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGATACCACGTTCCGTCTGGACCGCTGGGAGCTGGAGCTGAACTCCGCCATCCCAAGCGATGCGCGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCTGCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGCAACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACCTGCGGAGTGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCTATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGCACAGCGAGGCCGTCATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGGGCGTCAACGGGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3484,Drugs,MEG_3484|Drugs|betalactams|Class_A_betalactamases|KPC,(Bla)KPC-1:AF297554:131-1012:882,0
,ATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGGTGGCTCAATGAGCATCATTGCAACCGTCAAGATCGGCCCTGACGAAATTTCAGCCATGAGGGCTGTGCTCGATCTCTTCGGCAAAGAGTTTGAGGACATTCCAACCTACTCTGATCGCCAGCCGACCAATGAGTATCTTGCCAATCTTCTGCACAGCGAGACGTTCATCGCGCTCGCTGCTTTTGACCGCGGAACAGCAATAGGTGGGCTCGCAGCCTACGTTCTACCCAAGTTCGAGCAAGCGCGAAGCGAGATCTACATTTATGACTTGGCAGTCGCTTCCAGCCATCGAAGGCTAGGAGTCGCAACTGCCCTGATTAGCCACCTGAAGCGTGTGGCGGTTGAACTTGGCGCGTATGTAATCTATGTGCAAGCAGACTACGGTGACGATCCGGCAGTCGCTCTCTACACAAAGCTTGGAGTTCGGGAAGACGTCATGCACTTCGACATTGATCCATTGACC,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_70,Drugs,MEG_70|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3-PRIME,gi|18958399|gb|AF355189.1|1369-1890 gi|425862449|gb|JX566708.1|329-386 gi|317018024|gb|GU390404.1|273-330 gi|317018003|gb|GU390401.1|293-350 gi|429201046|gb|JX193301.1|3545-3601,2
,atgcgttatgttcgcctgtgtgttatctccctgttagccaccctgccactggtggtatacgccggtccacagccgcttgagcagattaaacaaagcgaaagccagctgccgggccgcgtggggatggtggaaatggatctggccagcggccgcacgctggccgcctggcgcgccgatgaacgctttcccatggtgagcacctttaaagtgctgctgtgcggcgcggtgctggcgcgggtggatgccgggctcgaacaactggatcggcggatccactaccgccagcaggatctggtggactactccccggtcagcgaaaaacaccttgtcgacgggatgacgatcggcgaactctgcgccgccgccatcaccctgagcgataacagcgctggcaatctgctgctggccaccgtcggcggccccgcgggattaactgcttttctgcgccagatcggtgacaacgtcacccatcttgaccgctgggaaacggcactgaatgaggcgcttcccggcgacgcgcgcgacaccaccaccccggccagcatggccgccacgctgcgcaaactactgaccgcgcagcatctgagcgcccgttcgcaacagcaactcctgcagtggatggtggacgatcgggttgccggcccgctgatccgcgccgtgctgccgccgggctggtttatcgccgacaaaaccggggctggcgaacggggtgcgcgcggcattgtcgccctgctcggcccggacggcaaaccggagcgcattgtggtgatctatctgcgggataccccggcgagtatggccgagcgtaatcaacatatcgccgggatcggcgcagcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3545,Drugs,MEG_3545|Drugs|betalactams|Class_A_betalactamases|LEN,765286263|WP_044614545.1|NG_050779|1|1|blaLEN-8|blaLEN|class_A_beta-lactamase_LEN-8 NG_050779:101-961,0
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatgtgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttctctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaagggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacgactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctgcgatattatgtggattctgcgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctgctgcaagaaaagtatcatgtggagatagaaataaaagagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagttccaccgaatcctttctgggcttccattggtctatctgtagcacagcttccattagggagcggagtgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaggggatacgctatggttgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagcacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7130,Drugs,MEG_7130|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100162|WP_063856392.1|NG_048228|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048228:101-2020,4
,atgagcatcattgcaaccgtcaagatcggccctgacgaaatttcagccatgagggctgtgctcgatctcttcggcaaagagtttgaggacattccaacctactctgatcgccagccgaccaatgagtatcttgccaatcttctgcacagcgagacgttcatcgcgctcgctgcttttgaccgcggaacagcaataggtgggctcgccgcctacgttctacccaagttcgagcaagcgcgaagcgagatctacatttatgacttggcagtcgcttccagccatcgaaggctaggagtcgcaactgccctgattagccacctgaagcgtgtggcggttgaacttggcgcgtatgtaatctatgtgcaagcagactacggtgacgatccggcagtcgctctctacacaaagcttggagttcgggaagacgtcatgcacttcgacattgatccaagaaccgccacctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_38,Drugs,MEG_38|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,498491671|WP_010792467.1|NG_047257|1|1|aac(3)-Ib|aac(3)-I|aminoglycoside_N-acetyltransferase_AAC(3)-Ib NG_047257:101-565,2
,ATGAGTGTAAATCATCAAAAAATTATTAATACACCTTTAGACAACATTGTTGGTGAAAGTTATGCAAAATATGCAAAATACATTATTCAAGATCGTGCTTTACCTGATATTCGTGATGGTTTAAAACCTGTTCAACGACGAATTTTATACGCAATGAGTGAATTAGGAATCTTTTATGATAAACCTTATAAAAAATCTGCACGTACAGTAGGAGAAGTAATTGGTAAATATCATCCACATGGAGATTCATCAATTTATGAAGCAATGGTGAGAATGAGTCAAGATTGAAAAAATAATCTATGTTTATTAGATATGCATGGTAATAAAGGTTCAATTGATGGTGATAATGCTGCTGCAATGCGTTATACAGAAGCTCGATTATCAAAAATTGCTAGTGTAATGTTAGCCAACTTAAAAAAAGATGTTGTTAAATTTAGTCCAAACTTTGATGATAGTGAAAAAGAGCCATCAATTTTACCATCTCTTTTTCCTAATTTGTTAATCAATGGAGCAACAGGAATTGCTTCTGGTTATGCAACAAATATTCCTCCTCATAACCCTAATGAAGTTTTTGATGCTTTAATTTATCGTATTGATCATCCAGATTGTAGTGTAGAAAAACTAATTGAAATCTGTCCTGCGCCAGATTTTCCCACAGGTGGGGAAATCCACGATTTAAATGGATGTGCTAATGCTCACAAAACTGGTGAAGGTAAATTTATAATTCGTGCTTGCATTGATTTTAAAATCAATGATAATAAGATTAATCAAATTATTATTAGTTCAATCCCTTATGAAACAAACAAGGCTTTAATCATTAAAGAAATTGAAGATATTATTTATAATAAAGAAGTTGCTGGATTAATCGAAGTTCGTGATGAATCTGATGCTAAGGGAATTAGTATAATTATTGATACTAAAAAAGATATTAATTTAGAAAATGTTAAAAACTATTTATATAAAAAAACCAACTTGGAAATCAGCTATAATACAAAATTTATTGCAATTGTTCACCGAACTCCTACACTTGTAAATCTATCTACATATTTAGATGCTCAAATTAATCATAGTTTAGATGTAATTAATAAAGTCGATTTATATGATCTAAACAAAATTTTGTTACGTATTGAAATTGTTGAAGGCTTAATTAAATGCGTTGATTTAATTGATGAAATTATTAAAATTATTCGTGCTAGTGAATCGCGTCAAGATGCAAAAAATACTTTAATTCAAGTTTTTAATTTTACAAATAATCAAGCTGAAGCGATTATTATGATGCGTTTACATAATTTGACACGTACTGATATATTTGATTTAAAAAATGAATGACAAACGCTACAAGACGAAGCTAAAACGCTACAAGAACGAATAAATTCACTTCAAGTTCGCAAAAATTATTTAAAACAAAAAATGATTGAATTTAAAAAAACTTTTGGTTTTGAACGCAAAACAAAATTATTTGATGAATTAGTAAAAGTTGAAATAAACGAAGATCAAATGATCGAAAAACAAAATTTGAATTTAGTAATAAGTCGTGATGGATACATTAAAACTGTTTCTAAAAAGTCATTTGAGTCATCTAAATATGATGAATTAGGATTAAAAACTAATGATATTCTTTTTTATCATAATATCATTAATTCTCATGATAAAATCCTAATCATTACATCAAAAGCTAAATTAATTAATTTAGTTGCTCATAAAATCACTTCTATGCGGTGAAAAGATGTTGGTGAACACTTAAATAATTATGTGAAATTTGATGCTAATGAAAAAGTTATAGCTGTTTATATATGGAACGAACAATTTAAAATTGATGAATATCAATTAGTTTTGGCTTCTAGATTAAATCTAATTAAAAGAATTGAATTAAGCGAGTTGGATATAAATAAAAATAGTAAACAAATTAGCATTATGAAATTAAATGATAATGATAATTTAATCAGTGCTAATTTAATCAAAAAAGGTCATAATCAATTTATTATTGCAATTTCTAAATTAGGATTAGCCCTGCTATTTTTAGTTCATGAAATTAATTGCTTAAATCGTTTAGCTAAAGGAATTAAAATTATGAAATTAAAACCAAATGATGAGGTTAGTGCTATTTTAATTACTCCTAATAATGGTTATAATGTTCAACTTTTTTTAGAACGGGGAAGTAAGTGTTTTAATATTAGTGAATTAAAATTATCAAAACGTGCGGCCACACCAACAAATTTATATCCAATAACAAAAAAAGTGCAAAATGTTTTAGCAGCTTTTTTAGTTGCTCATGAAAATGTTTTTTATCTTTTAGATCAACAACAAAAAATAAATCCATATTACTTATCAAACCCCAAACCAACAAAACTAGATACTAAAATTAGTATCTATGAAAACGATCAAATGATCACTGATGTAGTTAAAGATTGCTTTTTAAGTGATGAAGCAATTAGTGATTTTAAAAAAATTAATATGTACGCAAATGAATTTGATAATGAAATGCTAAAAATTAATAAAAATCACGATGATTCACAATTAGAATTAATTGATGAAGAGGAAGAAAAAAAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5328,Drugs,MEG_5328|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gb|AF222894.1|+|531446-533999|ARO:3003309|Ureaplasma urealyticum parC conferring resistance to fluoroquinolone [Ureaplasma parvum serovar 3 str. ATCC 700970] ,3
,atgatgacaaaatccctaagctgtgccctgctgctcagcgtcaccagctctgcattcgccgcaccgatgtccgaaaaacagctggctgaggtggtggaacgtaccgttacgccgctgatgaacgcgcaggccattccgggtatggcggtggcggtaatttatcagggtcagccacactactttaccttcggtaaagccgatgttgcggcgaacaaacccgtcaccccgcaaaccctgtttgagctgggctctataagtaaaaccttcaccggcgtactgggcggcgatgccattgcccggggtgaagtagcgctgggcgatccggtagcaaaatactggcctgagctcacgggcaagcagtggcagggcattcgcatgctggatctggcaacctataccgcaggcggtctgccgttacaggtgccggatgaggtcacggataccgcctctctgctgcgcttttatcaaaactggcagccgcagtggaagccgggcaccacgcgtctttacgctaacgccagcatcggtctttttggtgcgttggcggttaaaccttccggcatgagctatgagcaggccatgacgacgcgggtctttaaacccctcaagctggaccatacctggattaacgtcccgaaagcggaagaggcgcattacgcctggggataccgtgagggtaaagcggtccacgtttcgccagggatgctggacgcggaagcctatggcgtaaaaactaacgtgaaggatatggcgagctgggtgatagccaacatgaagccggattctcttcaggctccctcactcaagcaaggcattgctctggcgcagtctcgctactggcgcgtgggggctatgtatcaggggttaggctgggagatgctcaactggccggtcgatgccaaaaccgtcgtcggaggcagtgataacaaggtggcgctggcaccattgcccgtggcagaagtgaatccacccgcgccgccggttaaggcctcctgggtccataaaacaggctcgacgggtgggtttggcagctacgtggcatttattcctgaaaagcagctcggcattgtgatgctggcgaataaaagctatccgaacccggcacgcgttgaggcggcataccgtatcctcgacgcgctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3951,Drugs,MEG_3951|Drugs|betalactams|Class_C_betalactamases|MIR,1270501843|WP_099156057.1|NG_055671|1|1|blaMIR-22|blaMIR|cephalosporin-hydrolyzing_class_C_beta-lactamase_MIR-22 NG_055671:1-1146,0
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattataatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttaaaagagctaaaaaagctttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagacacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaatgctctcaagtgcctgcttttaaagaattggcaagaaacataggacttaaaactatgcaagaaagcttaaataaactttcttatggaaatacaaaaatttcaaaaatcgataccttttggctagataattctttacaaatttctgcaaaaaatcaagctgatttactttttaaactttcgcaaaattctttacctttttctaaaaaaaatcaagaagaagttaaaaaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagattaaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattattaaataagtatttagctaattttttcaacaataataggattaaaagcttttactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4575,Drugs,MEG_4575|Drugs|betalactams|Class_D_betalactamases|OXA,1209253190|WP_088303859.1|NG_057551|1|1|blaOXA-624|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-624 NG_057551:1-774,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggacctggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5661,Drugs,MEG_5661|Drugs|betalactams|Class_C_betalactamases|PDC,1393270445|WP_109791190.1|NG_057588|1|1|blaPDC-256|blaPDC|class_C_beta-lactamase_PDC-256 NG_057588:1-1194,0
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaagcagtatcattaatcactagtgccatcctgcaaatggcgattattttttaccttacagagaaaacaggatctgcgatggtcttgtctatggcttcactagtaggttttttaccctatgcggtctttggacctgcgattggtgtgctagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctggtgcagtgcttactattgttgcattgtatatggagctacctgtctggatagctatgatagtattgtttatccgtagcattggaacagcttttcataccccagcactcaatgcggttacgccacttttagtaccagaagaacagctgacgaaatgtgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcagttgcagcactcttatactccgtttgggatctaaatgctattattgccatcgatgtattgggtgctgtgattgcatctattacggtagcaattgtacgtattcctaagctgggtgatcgcgtgcaaagtttggacccaaatttcataagagaaatgaaagaaggaattgtcgttatgagacaaaacaaaggattgtttgccttattactcttaggaacactatatacttttgtttatatgccaattaatgcactatatcctttaatcagcatggaatattttaatggaacaccgatgcatatttctattaccgaaattgcttttgcctctggcatgctggcaggcggcttgatattaggaagattgggaagttacgaaaagcgtgtacctttaataacaggttcattttttatgatgggagctagtttagccattgcaggattacttcctccaagtggatttttcatatttgtagtctgctgtgcaataatggggctttcagttccattttacagcggtgtacaaacagcactttttcagcaaaaaatcaagcctgaatatttagggcgtgtattttccttcaccggtagtatcatgtcacttgcaatgccactagggttaatcctttccgggttctttgctgatagaatcggtgtaaatcattggtttttactatcaggtattttaattatttgcattgcaatagtttgcccgatgatgactgaggttagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3810,Drugs,MEG_3810|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028096985|WP_063853682.1|NG_047971|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047971:1-1218,7
,atgaactttaataaaattgatttatacaattggaagagaaaagagatatttaatcattatttgaaccaacaaacgacttttagtataaccacagaaattgatattagtgttttataccgaaacataaaacaagaaggatataaattttaccctgcatttatttccttagtgacaagggtgataaactcaaatacagcttttagaactggttaccataacgacggagaattaggttattgggataagttagagccactttatacaatttttgatggtgattctagaacatcctctggtattgggactcctgtaaagaatgactccaaagagttttatgaattatacctttctgatgttgaaaaatataatggttcggggaaattgtttcccaaaacacctatacctgaaaatgctttttctctttctattattccatggactctatttactgggtttaacttaaatatccataataatagtaattaccttctacccattataacggcaggaaaattcattaatataggtaattcaatatatttaccgctatctttacaggaacatcattctgttggtgatggttatcatgcaggactgtttatgaactctattcaggaattgtcagataggcctaatgactggcttttataa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1565,Drugs,MEG_1565|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,695263449|WP_032490319.1|NG_047576|1|1|catA9|catA9|type_A-9_chloramphenicol_O-acetyltransferase NG_047576:101-751,6
,GTGATCGCCGAAATTTCGACACAACTGTTAGAGGTGCTTAGTGTCATTGAGCGCCATCTGGAGCCGACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGAATGGCGGCCTGAAGCCATACAGCGATATTGATTTGCTGGTTACTGTGACTGTAAGGCTTAATGAAACAACGCGGCGAGCTTTGCTCAACGACCTTCTGGAGGTTTCGACTTTCCCCGGCGAGAGTGAGGCTCTCCGCGCTATAGAAGTCACCATTGTCGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGAGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTCCCTGAACAGGATCTATTCGAGGCACTAAATGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCTCGTATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTACCGGCCCAGTATCAGCCCGTCTTGCTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTTGCACGCTGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGAGCACCAAGGTAGTCGGCAAATGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_919,Drugs,MEG_919|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,(AGly)AadA24:HQ123586:88-768:781,2
,ATGAAAAAAATTTATATTAGTGTTCTAGTTCTTTTACTAATTATGATTATAATAACTTGGCTATTCAAAGATGACGATATTGAGAAAACAATTAGTTCTATTGAAAAAGGAAACTATAACGAAGTATATAAAAATAGTTCAGAAAAATCTAAACTGGCATATGGAGAAGAAATTATAGATAGGAATAAAAAAATTTACAAAGATTTAAGTGTCAATAACTTAAAAATTACTAATCATAAAATTAAAAAAACTGGAAAAGATAAAAAGCAGGTTGATGTTAAATATAACATATATACAAAATATGGAAATATACGACGTAATACACAATTAAACTTTATTTATGAAGATAAGCATTGGAAATTAGATTGGAGACCAGACGTAATAGTACCTGGTTTGAAAAATGGACAGAAAATTAATATAGAAACATTAAAATCAGAGCGAGGCAAAATAAAAGATAGAAATGGTATAGAATTAGCTAAAAATGGAAATACATATGAAATCGGTATTGTCCCTAACAAAACACCCGAAGAAAAATATGATGATATTGCTCGTGACTTACAAATTGATACAAAAGCTATAACCAATAAAGTTAATCAAAAATGGGTTCAGCCAGATTCATTTGTACCAATTAAAAAGATAAATAAACAAGATGAATCTATAGACAAATTAATTAAATCATACAATTTACAAATAAACACTATAAAAAGCCGTGTTTATCCATTGAACGAAGCAACAGTACACCTTTTAGGTTATGTGGGTCCAATTAATTCTGACGAGTTAAAAAGTAAGCAATTTAGAAACTATAGCAAAAATACTGTTATTGGAAAAAAGGGCTTAGAACGCCTCTATGATAAACAATTGCAAAACACTGATGGTTTTAAGGTATCCATTGCAAATACTTATGACAATAAACCTTTAGACACATTATTGGAGAAAAAGGCTGAAAACGGAAAAGATCTTCATTTAACTATAGATGCTAGAGTACAAGAAAGTATTTATAAACATATGAAAAATGACGATGGATCTGGTACAGCATTACAACCAAAAACTGGAGAAATTTTAGCTTTGGTAAGTACCCCATCGTACGATGTTTATCCATTCATGAATGGATTAAGCAATAATGACTACCGTAAATTAACTAACAATAAAAGAGAGCCTTTGCTCAACAAATTTCAAATCACTACATCACCAGGTTCAACCCAAAAAATATTAACATCTATTATAGCCTTAAAAGAAAATAAACTAGACAAAAATACTAATTTTGATATTTATGGTAAGAGTTGGCAAAAAGATGCATCATGGGGGAATTATAATATCACAAGATTTAAAGTAGTAAACGGCAATATCGATTTAAAGCAAGCAATAGAATCATCAGACAACATATTTTTTGCCCGCATTGCATTAGCATTAGGAGCCAAAAAATTTGAGCAAGGTATGCAAGATTTGGGAATCGGTGAAAATATCCCGAGTGATTATCCCTTTTATAAAGCACAAATCTCAAATAGTAATTTAAAAAATGAAATATTATTAGCAGATTCAGGATATGGCCAAGGCGAGATACTAGTAAACCCTATACAAATTTTATCAATATACAGTGCTTTAGAAAATAACGGAAATATACAAAATCCTCATGTTTTACGTAAAACAAAATCTCAAATATGGAAAAAAGATATTATACCTAAAAAAGACATAGATATATTAACTAATGGTATGGAACGTGTAGTTAATAAAACACATAGGGATGATATATACAAAAATTATGCCCGAATTATTGGTAAATCTGGCACAGCAGAATTAAAAATGAATCAAGGGGAAACTGGAAGACAAATAGGTTGGTTTGTTTCATATAATAAAAATAATCCTAATATGTTAATGGCGATTAATGTTAAAGACGTTCAAAATAAAGGGATGGCCAGCTATAATGCTACTATATCTGGAAAAGTTTATGATGATTTGTATGATAATGGAAAAACTCAATTTGATATAGATCAGTAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3799,Drugs,MEG_3799|Drugs|betalactams|Penicillin_binding_protein|MECC,mecC_3_KR732654,0
,TTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACATGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6756,Drugs,MEG_6756|Drugs|betalactams|Class_A_betalactamases|TEM,gb|AY130285|+|0-785|ARO:3000981|TEM-118 [Klebsiella oxytoca] ,0
,atgactaaaaaagctcttttctttgccattagtacgatgtttttgtcggcatgttcttttaataccgtacaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaatagaggaagtctatggcaatgatcctaaaagagcatcaaccgactatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttatttcccgattgggaaaaagacatgacattaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaagaatgtgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacggaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaacctcaaggagaaattgtagcgttctcactcaatttagaaatgaaaaaaggcatacctagttctattcgaaaagaaattgcttataagggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4552,Drugs,MEG_4552|Drugs|betalactams|Class_D_betalactamases|OXA,1058244073|WP_068981641.1|NG_051476|1|1|blaOXA-526|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-526 NG_051476:1-822,0
,atgaacgagaaaaatataaaacacagtcaaaactttattacttcaaaacataatatagataaaataatgacaaatataagattaaatgaacatgataatatctttgaaatcggctcaggaaaagggcattttacccttgaattagtacagaggtgtaatttcgtaactgccattgaaatagaccataaattatgcaaaactacagaaaataaacttgttgatcacgataatttccaagttttaaacaaggatatattgcagtttaaatttcctaaaaaccaatcctataaaatattcggtaatataccttataacataagtacggatataatacgcaaaattgtttttgatagtatagctgatgagatttatttaatcgtggaatacgggtttgctaaaagattattaaatacaaaacgctcattggcattatttttaatggcagaagttgatatttctatattaagtatggttccaagagaatattttcatcctaaacctaaagtgaatagctcacttatcagattaaatagaaaaaaatcaagaatatcacacaaagataaacagaagtataattatttcgttatgaaatgggttgacaaagaatacaagaaaatatttacaaaaaatcaatttaacaattccttaaaacatgcaggaattgacgatttaaacaatattagctttgaacaattcttatctcttttcaatagctataaattatttaataagtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2813,Drugs,MEG_2813|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,499601687|WP_011282421.1|NG_047815|1|1|erm(C)|erm(C)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(C) NG_047815:101-835,7
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcaccgcgctgtggccgtccggctcgcctgaagatcaccgcgcggaaatgcgcgagatactggcttcaccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgccgaacgcgcccgccgccagggctgggccgcgcgcctgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggagcgggtagtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_159,Drugs,MEG_159|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,896207031|WP_049212943.1|NG_052191|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052191:101-541,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaagaactatttttccagagcttggcttaaaatatagttatgtaaatgtgcctaaaactcagatacaaaactatgcatttggttataaccaagaaaatcagccgattcgagttaatcctggtccactcgatgcaccagcatacggcgttaaatctaccttacctgatatgcttaagtttattaatgccaacctaaacccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcgtatgcagttttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_574,Drugs,MEG_574|Drugs|betalactams|Class_C_betalactamases|ADC,487973913|WP_002046804.1|NG_056109|1|1|blaADC-167|blaADC|class_C_beta-lactamase_ADC-167 NG_056109:1-1152,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgatcacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2202,Drugs,MEG_2202|Drugs|betalactams|Class_A_betalactamases|CTX,1028104789|WP_063860035.1|NG_048965|1|1|blaCTX-M-181|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-181 NG_048965:1-876,0
,atggaaatcaaaaagttaagtagtgctaatattaacttatggatagcgctaagagagcagttatggccgcatcaccctgaaaatgcaaatagatctgatggcaaaaatattattctgtctgatgaattggcttcatttattgctgtagatgaggatgggctaggtattggtttcgctgatgcatccatacggaatgattatgtgaatggctgtattcatagccctgttgccttccttgaaggcatttttattgtcccaccctctcggcgtggtggtgttgccaaacagttagttgatgctgtgcaagcatgggggttagaaaaggggtgccaggaactggcgtctgatactgcattggacaacgttttatcacagcaagtccatgaagctttgggatttaaggaaactgaaagagtcgtttactaccgcaaagtctcacttcgctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_190,Drugs,MEG_190|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,902774993|WP_049646085.1|NG_052198|1|1|aac(6')_Yersi|aac(6')_Yersi|aminoglycoside_6'-N-acetyltransferase NG_052198:101-547,2
,atgaccactaccattagcttcgtcacgctgcgcctcatgaccgagcacgaccttccgatgctccatgactggctaaatcggcctcacatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_125,Drugs,MEG_125|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502185|WP_071846335.1|NG_052628|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052628:101-655,2
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcatcgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgagatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6222,Drugs,MEG_6222|Drugs|betalactams|Class_A_betalactamases|SHV,1062509496|WP_069280714.1|NG_051521|1|1|blaSHV-196|blaSHV|class_A_beta-lactamase_SHV-196 NG_051521:1-861,0
,atgcgatttaaaaaaatttcttgcttacttttacctcctctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatatagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagccttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaggaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatccaccttaccggatatgttgagttttatttatgccaaccttaacccacagaaatatccggcagatattcaacgtgcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccagcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacgtatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaacaaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgagtgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_526,Drugs,MEG_526|Drugs|betalactams|Class_C_betalactamases|ADC,638913583|WP_024436624.1|NG_055286|1|1|blaADC-156|blaADC|class_C_beta-lactamase_ADC-156 NG_055286:1-1152,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5536,Drugs,MEG_5536|Drugs|betalactams|Class_C_betalactamases|PDC,1201190436|WP_087587956.1|NG_054972|1|1|blaPDC-186|blaPDC|class_C_beta-lactamase_PDC-186 NG_054972:1-1188,0
,TTCCCCTAACATGAATTTGTAATGAAAAAATTTATACTTCCTATATTCAGCATTTCTATTCTAGTTTCTCTCAGTGCATGTTCATCTATTAAAACTAAATCTGAAGATAATTTTCATATTTCTTCTCAGCAACATGAAAAAGCTATTAAAAGCTATTTTGATGAAGCTCAAACACAGGGTGTAATTATTATTAAAGAGGGTAAAAATCTTAGCACCTATGGTAATGCTCTTGCACGAGCAAATAAAGAATATGTCCCTGCATCAACATTTAAGATGCTAAATGCTTTAATCGGGCTAGAAAATCATAAAGCAACAACAAATGAGATTTTCAAATGGGATGGTAAAAAAAGAACTTATCCTATGTGGGAGAAAGATATGACTTTAGGTGAGGCAATGGCATTGTCAGCAGTTCCAGTATATCAAGAGCTTGCAAGACGGACTGGCCTAGAGCTAATGCAGAAAGAAGTAAAGCGGGTTAATTTTGGAAATACAAATATTGGAACACAGGTCGATAATTTTTGGTTAGTTGGCCCCCTTAAAATTACACCAGTACAAGAAGTTAATTTTGCCGATGACCTTGCACATAACCGATTACCTTTTAAATTAGAAACTCAAGAAGAAGTTGAAAAAATGCTTCTAATTAAAGAAGTAAATGGTAGTAAGATTTATGCAAAAAGTGGATGGGGAATGGGTGTTACTCCACAGGTAGGTTGGTTGACTGGTTGGGTGGAGCAAGCTAATGGAAAAAAAATCCCCTTTTCGCTCAACTTAGAAATGAAAGAAGGAATGTCTGGTTCTATTCGTAATGAAATTACTTATAAGTTGCTAGAAAATCTTGGAATCATTTAATAATTTCTAAAATTAACATAATACCGCCTTATGCGAAATGCTTGAAATTTTCTTATAAGCATCAATAGTTTAGTCAAAGCCGTTCTAGAGTTCAGCGCACTAGAACGGCTTTTTCATGATTATTCACGTTCCACGCCTATTATTTGAGTAATGTTTCACAACTTTGATTAGTAC,beta-lactamase,antibiotic inactivation,betalactams,MEG_5202,Drugs,MEG_5202|Drugs|betalactams|Class_D_betalactamases|OXA,gi|11493691|gb|AF201826.1|AF201826|1-1023 gi|908777896|gb|KT022421.1|54-1,0
,atgcgctttattcacgcactattcctggcagggatcgctcactctgcatctgcgtcggaaaacttaaccttcaggaccgatcttgagaagctagagcgcgagaaagcagctgagatcggtgttgcgatcgtcgatccccaaggacagatcgtcgcgggccaccgaatcgagcagcgttttgcaatgtgctctacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcgtacgggcgggacatgatcgtcgaatggtctcctgccgcggagcggtttctcgcatcgggacatatgacggttctcgaggcagcgcaagcggcggtgcagctcagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccggagatgagcgacaacacacctggcgacctcagagatacaaccacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgcccacctcgacccacacaattgagaggtggctgatcggaaaccaaacgggagacgcgacattacgagcgggttttcctaaagattgggttattggagagaaaaccggcacctgcgccaacgggggccggaacgacattgggttttttaaagcccaggacagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgaacaacgtgacgaattagttgcctctgtcggtcaagttattacgcaactcatcctaagtacggacaagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3101,Drugs,MEG_3101|Drugs|betalactams|Class_A_betalactamases|GES,1609427440|WP_135350920.1|NG_065425|1|1|blaGES-41|blaGES|class_A_beta-lactamase_GES-41 NG_065425:1-864,0
,CTAAGCTGTGCCCTGCTGCTCAGCGTTGCCAGCGCTGCATTCGCCGCACCGATGTCCGAAAAACAGCTGGCTGAGGTGGTGGAACGCACCGTTACGCCGCTGATGAACGCGCAGGCCATTCCGGGTATGGCGGTGGCGGTGATTTATCAGGGTCAGCCGCACTACTTTACCTTCGGTAAAGCTGATGTTGCAGCGAACAAACCCGTCACCCCGCAAACCTTGTTCGAGCTGGGTTCGATAAGTAAAACCTTCACCGGCGTATTGGGTGGTGATGCGATTGCGCGCGGTGAAATAACGCTGGGCGATCCGGTGACCAAATACTGGCCTGAGCTCACGGGCAAGCAGTGGCAGGGCATTCGCATGCTGGATCTGGCAACCTACACCGCAGGCGGTCTGCCGTTGCAGGTGCCGGATGAGGTCACGGATACCGCCTCCCTGCTGCGCTTTTATCAAAACTGGCAGCCAAAGTGGAAGCCGGGCACCACGCGTCTTTACGCTAACACCAGCATCGGTCTTTTTGGCGCGCTGGCGGTCAAACCCTCCGGCATGAGCTATGAGCAGGCCATGACGACGCGGGTCTTTAAGCCGCTCAAGCTGGACCATACCTGGATTAACGTCCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGATACCGTGACGGTAAAGCGGTCCACGTTTCGCCAGGGATGCTGGACGCGGAAGCCTATGGCGTAAAAACCAACGTGCAGGATATGGCAAGCTGGGTGATGGTCAACATGATGCCGGACTCCCTTCAGGATTCCCCACTTAAGCACGGTATCGCCCTGGCACAGTCTCGCTACTGGCGCGTGGGAGCCATGTATCAAGGATTGGGCTGGGAAATGCTGAACTGGCCGGTCGACGCCCAAACGGTGGTCGGGGGCAGCGACAATAAGGTGGCGCTGGCGCCGTTGCCTGCAAGAGAAGTGAATCCACCGGCACCACCGGTTAAGGCCTCCTGGGTCCATAAAACGGGCTCTACCGGCGGATTTGGCAGCTACGTGGCATTTATTCCTGAAAAGCAGCTCGGCATTG,beta-lactamase,antibiotic inactivation,betalactams,MEG_447,Drugs,MEG_447|Drugs|betalactams|Class_C_betalactamases|ACT,(Bla)CMG:AY265892:1-1054:1054,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagctaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_564,Drugs,MEG_564|Drugs|betalactams|Class_C_betalactamases|ADC,447133959|WP_001211215.1|NG_064674|1|1|blaADC-115|blaADC|class_C_beta-lactamase_ADC-115 NG_064674:101-1252,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggacaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_794,Drugs,MEG_794|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502124|WP_071846276.1|NG_052322|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052322:101-892,2
,atgaaaaaaatcatcttgtttttatggattttaaattttgcctttggacaagataaaatattagaagatttttttaaagattataatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttcaaagagcaaaacaaaccttttctcctgcttcaacttttaaaatttttaatgctttaattgcgcttgataatggtgtaattaaagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgatactttttggctggataattctttgcaaatttctgcaaaaaatcaagctgatttactttttaaactttcacaaaattctttacccttttccaataaaagtcaagaagaagtcaaaaaacttcttctttttaaagaaaataaaatacaaaaaatttatgctaaaacaggttttaatgataatataaatttagcttggattgttggattcgtaaagactaaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagagaaaaattgctagaaaaatatatttattctttaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4664,Drugs,MEG_4664|Drugs|betalactams|Class_D_betalactamases|OXA,489026470|WP_002936877.1|NG_057493|1|1|blaOXA-623|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-623 NG_057493:1-747,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcacctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5647,Drugs,MEG_5647|Drugs|betalactams|Class_C_betalactamases|PDC,1408841627|WP_111672900.1|NG_060558|1|1|blaPDC-289|blaPDC|class_C_beta-lactamase_PDC-289 NG_060558:1-1194,0
,ATGATGAAAAAATCGTTATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATGGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGTTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAACGACCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTACACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGCAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1849,Drugs,MEG_1849|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AB699171|+|0-1143|ARO:3002100|CMY-87 [Klebsiella pneumoniae] ,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatgactag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4651,Drugs,MEG_4651|Drugs|betalactams|Class_D_betalactamases|OXA,919265210|WP_052798312.1|NG_057518|1|1|blaOXA-609|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-609 NG_057518:1-774,0
,ATGAGCGACCTTGCCAGAGAAATTACACCGGTCAACATTGAGGAAGAGTTAAAGAACTCCTATCTGGATTACGCGATGTCGGTTATTGTCGGCCGCGCGCTTCCGGATGTCCGAGATGGCCTCAAGCCGGTACACCGTCGCGTACTTTACGCCATGAACGTGTTGGGCAATGACTGGAATAAAGCCTACAAAAAATCCGCCCGTGTCGTTGGTGACGTAATCGGTAAATACCATCCCCACGGTGATTCCGCCGTTTACGATACCATTGTACGTATGGCTCAGCCGTTCTCGCTGCGTTATACGCTGGTGGATGGTCAGGGCAACTTCGGTTCTATCGACGGCGACTCCGCCGCGGCGATGCGTTATACGGAAATCCGTCTGGCGAAGATCGCCCATGAACTGATGGCCGACCTCGACAAAGAAACCGTTGATTTTGTAGACAACTATGACGGCACGGAAAAAATCCCTGACGTCATGCCGACCAAAATCCCGAACCTGCTGGTAAACGGTTCATCCGGTATCGCCGTCGGGATGGCGACGAACATTCCGCCGCATAACCTGACGGAAGTGATTAACGGCTGCCTCGCGTATATCGATGATGAAGATATCAGCATCGAAGGGCTGATGGAGCACATTCCTGGCCCGGATTTCCCGACGTCCGCCATTATCAACGGCCGTCGCGGCATTGAAGAGGCGTATCGCACCGGGCGCGGCAAAATCTACATTCGCGCGCGCGCGGAAGTGGAAGTCGATCCGAAAAACGGCCGCGAAACCATTATCGTGCACGAAATTCCGTATCAGGTGAACAAAGCGCGCCTGATCGAGAAAATCGCCGAGCTGGTGAAAGACAAACGCGTCGAAGGCATCAGCGCGCTGCGCGACGAGTCTGACAAAGACGGTATGCGCATCGTCATTGAGATCAAACGCGACGCCGTCGGCGAAGTGGTGCTCAATAATCTCTATTCCCAGACGCAGCTTCAGGTGTCTTTCGGTATCAACATGGTCGCGCTGCACCACGGTCAGCCGAAGATCATGGCGCTGAAAGAGATTCTGGCGGCGTTCGTTCGCCACCGTCGTGAAGTCGTGACCCGCCGCACCATCTTTGAACTGCGCAAAGCCCGCGAGCGTGCGCATATCTTAGAAGGTCTGGCGATTGCGCTGGCCAACATCGACCCGATTATTGAGCTGATTCGCCGCGCGCCGAACCCGTCCGAAGCGAAAGCGGGCCTCATCGCCCAGGCGTGGGAGCTGGGCACCGTTTCCGCGATGCTGGAGCGCGCCGGCGACGACGCCGCGCGTCCGGAATGGCTGGAGCCGGAGTTCGGTATTCGCGATGGCAAATACTGGCTGACCGAGCAGCAGGCACAGGCGATCCTCGATCTGCGTCTGCAGAAACTCACCGGCCTTGAGCATGAAAAACTGCTCGACGAGTATAAAGAGCTGCTGGAGCAGATCGCTGAGCTGCTGCATATCCTCGGCAGCGCCGACCGCCTGATGGAAGTAATCCGCGAAGAGCTGGAGCTGATCCGCGATCAGTTCGGCGATGAGCGCCGCACCGAAATCACCGCCAACAGCGCCGATATCAACATCGAAGATCTGATCAACCAGGAAGATGTGGTGGTCACCCTGTCTCACCAGGGCTATGTGAAGTATCAGCCGCTGACGGATTACGAAGCGCAGCGCCGCGGCGGTAAAGGCAAATCCGCCGCGCGTATTAAAGAAGAAGACTTTATCGACCGCCTGCTGGTGGCCAACACCCACGATACGATCCTCTGCTTCTCAAGCCGTGGACGTCTCTACTGGATGAAAGTCTACCAGTTGCCGGAAGCGAGCCGCGGCGCCCGCGGACGTCCTATCGTCAACCTGCTGCCGCTGGAAGCGAACGAGCGTATCACCGCGATTCTGCCGGTACGCGAGTATGAAGAAGGCGTTAACGTCTTTATGGCGACCGCGAGCGGCACCGTGAAGAAAACGGCGCTGACCGAGTTCAGCCGTCCGCGTACCGCCGGTATCATCGCGGTGAACCTGAACGAGGGCGATGAGCTGATCGGCGTCGACCTGACCGCAGGTAAAGACGAAGTGATGCTGTTCTCCGCGCAGGGCAAAGTGGTGCGCTTCAAAGAAGACGCGGTGCGTCCGATGGGTCGTACCGCCACTGGCGTGCGCGGTATTCGCCTCGGCGAGGGCGACAGCGTTGTGTCGCTTATCGTACCGCGCGGCGAAGGCGCTATCCTGACCGCCACCCAGAACGGTTACGGCAAGCGTACCGCGGTGGAAGAGTACCCGACCAAGTCGCGCGCGACGAAAGGGGTTATCTCCATCAAGGTGACCGATCGCAACGGGCCGGTCGTCGGCGCGGTGCAGGTCGATGACGCAGACCAGATCATGATGATCACCGATGCCGGCACCCTGGTGCGTACGCGCGTATCGGAAATCAGCGTGGTGGGCCGTAACACCCAGGGCGTTATCCTCATCCGCACCGCGGAAGATGAAAACGTGGTGGGTCTGCAACGTGTCGCCGAACCGGTAGATGACGAAGAGCTCGACTCTATCGACGGCAGCGTGGCGGAAGGCGACGATGAAATCGCGCCGGAAACCGACGTTGACGACGACGCGGCGGACGACGCCGACGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3205,Drugs,MEG_3205|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|323575285|emb|FN543093.2|3008219-3005583,3
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCTTTCTCCACGTTTGCCGCCGCCAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCAATTCCGGGCATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACTCAACAAACGCTGTTTGAACTCGGATCGGTCAGTAAAACGTTCAACGGCGTGCTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGCATTACTGGCCTGAACTGACTGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCGTTACTACGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGCGCCCTGGCGGTGAAACCCTCAGGCATGAGCTACGAAGAGGCGATGACCAAACGCGTCCTGCACCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGCCAACTTGATGCCGAAGCCTACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGCATCGAGCTTGCGCAGTCACGTTACTGGCGTGTTGGCGATATGTACCAGGGCCTGGGCTGGGAGATGCTGAACTGGCCGGTGAAAGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTGGCACTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAATAAGAGCTACCCAAACCCTGTTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1914,Drugs,MEG_1914|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JX440349|+|1026-2172|ARO:3002087|CMY-74 [Citrobacter braakii] ,0
,atgtctgcatacggacacggccgtcacgagcatggccaaaattttctcaccaaccacaagatcatcaactccatcatcgaccttgtgaaacaaacctccggccccatcattgagatcggaccaggaagcggtgccctcactcacccgatggcccacttggggagggcgataacggcagttgaagtggacgcaaaactagctgccaaaatcacacaagaaacctcctcggcggcggtcgaagtggtccatgatgatttccttaacttccggttacccgccactccctgcgtcattgtgggaaacattccctttcacctcaccactgccattcttcgaaagttgctgcatgcgccagcatggactgacgctgtactcctcatgcagtgggaagtcgctcgccgccgggccggggtaggcgcaagcacgatgatgacggctcagtggtccccatggttcacatttcacctgggttctcgggtaccaaggtctgctttccggccacagccaaacgttgacggggggatcttagtgatccgccgggtgggtgacccgaagattccgatagagcagcgcaaagcctttcaggcgatggtgcacaccgttttcactgcccggggacgcgggataggggaaattctccgaaggcagggttgttttcatcacgttcagaaacacaatcatggttgcgctcgcgaggaatcgaccccgcgaccctacctcccagattgcacaccaacgactggatcgatctcttccaggtga,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2855,Drugs,MEG_2855|Drugs|MLS|23S_rRNA_methyltransferases|ERMX,695257004|WP_032488331.1|NG_047847|1|1|erm(X)|erm(X)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(X) NG_047847:101-862,7
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaaggagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaagctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4470,Drugs,MEG_4470|Drugs|betalactams|Class_D_betalactamases|OXA,1559612974|WP_128268239.1|NG_063844|1|1|blaOXA-740|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-740 NG_063844:41-865,0
,ACAATAAGTTACTAAGGGCTTATGGTGGATGCCTTGGCACTAAAAGGCGATGAAGGACGTGTTAACCTGCGATAAGCTTCGGGGAGGTGGTAAAAACCTGAGATCCGGAGGTGTCCGAATGGAGCAATCTGGTAGCTTGCAAAAGTTACCATTAATTAATGAATTCATAGTTAATTAAAGCGATACGTGGTGAAGTGAAACATCTCAGTAACCACAGGAAAAGAAAACGAATGTGATTCCGTGTGTAGTGGCGAGCGAAAGCGGAACAGGCCAAACCTATCTGAGGATAGGGGTTGTAGGGCTTGCATTATGGAAGTTAAAAGGATAGAAGAAGCTGTTGGAAAGCAGCGCCAAAGAGGGTGATAGCCCCGTATTTGAAATCTTTTTAATACCTAGCAAGAAACCTGAGTAGCTCGAAAAACGTTATTTTGAGTGAATCTGCCCAGACCATTGGGTAAGCCTAAATACTAATTAGTGACCGATAGCGAAACAGTACCGTGAGGGAAAGGTGAAAAGAACCCAGAGATGGGAGTGAAATAGATTCTGAAACCATATGCCTACAACGTGTCAGAGCACATTAATGTGTGATGGCGTGCGTTTTGAAGTATGAGCCGGCGAGTTATGATAGCAAGCGTTAGTTAACCAGGAGATGGGGAGCTGTAGCGAAAGCGAGTTTTAAGAGAGCGTTTGTTTGTTATCATAGACCCGAAACGGGTTGAGCTAGTCATGAGCAGGTTGAAGGTTGAGTAACATTAACTGGAGGACCGAACCGACTCTCGTTGAAACGATAGCGGATGACTTGTGATTAGGGGTGAAATTCCAATCGAAATCCGTGATAGCTGGTTCTCGTCGAAATAGCTTTAAGGCTAGCGTAAGATCACAAATAAGTGGAGGTAAAGCTACTGAATGTATGATGGCGCCACCTAGGCGTACTGAATACAATTAAACTCTGAATGCCATTTATTTTATTCTTGCAGTCAGACAGTGGGGGATAAGCTTCATTGTCAAGAGGGGAAGAGCCCAGATCATTAAATAAGGTCCCCAAAATATACTAAGTGGAAAAGGATGTGAAAGTGCTAAAACAGCAAGGATGTTGGCTTAGAAGCAGCCATCGTTTAAAGAGTGCGTAACAGCTCACTTGTCGAGTGTTTTTGCGCCGAAGATGTAACGGGGCTAAGTATATTACCGAATTTATGGATAAGATATTTTTATCTTGTGGTAGACGAGCGTTGTATTGGAGTTGAAGTCAAAGCGTGAGCATTGGTGGATCCAATACAAGTGAGAATGCCGGCGTGAGTAACGCTTGGGAGTGAGAATCTCCCAAACCGATTGACTAAGGTTTCCTGGACCAGGGTCGTCCTTCCAGGGTTAGTCTGGACCTAAGCTGAGGCTGAAGAGCGTAGGCGATGGACAACAGGTTAATATTCCTGTACTTACAGTTAGACTGATGGAGTGACAAAGAAGGTTATCCACCCCCATTATTGGATTTGGGGATAAACCATAAGGTGGTACAATAGGCAAATCCGTTGTGCATAACACTGAGTGGTGATGTCGAGTGAACGAGTGATCAAGTAGCGAAGGTGGCAATTAATCATGCTTTCAAGAAAAGCTGCTAGGGCTAATTTAACTGTAACCAGTACCGAGAACGAACACACGTAGTCAAGGAGAGGATCCTAAGGTTAGCGAGTGAACTATAGCCAAGGAACTCTGCAAATTAACCCCGTAAGTTAGCGAGAAGGGGTGCTTATCTAAAAGTAAGCCGCAGTGAAGAACGAGGGGGGACTGTTTAACTAAAACACAACTCTATGCCAAACCGTAAGGTGATGTATATGGGGTGACACCTGCCCAGTGCTGGAAGGTTAAAGAAGGAGGTTAGCAATTTATTGCAAAGCTTTTAACTGAAGCCCCAGTGAACGGCGGCCGTAACTATAACGGTCCTAAGGTAGCGAAATTCCTAGTCGGGTAAATTCCGTCCCGCTTGAATGGTGTAACCATCTCTTGACTGTCTCGGCTATAGACTCGGTGAAATCCAGGTACGGGTGAAGACACCCGTTAGGCGCAACGGGACGGAAAGACCCCGTGAAGCTTTACTGTAGCTTAATATTGATCAAAACACCACCATGTAGAGAATAGGTAGGAGCAATTGATGCAAGTTCGCAAGGATTTGTTGATGTGAAATGTGGAATACTACCCTTGGTTATGTTTTGTTCTAATTGGTAACTGTGATCCAGTTTCAAGACAGTGTTAGGTGGGCAGTTTGACTGGGGCGGTCGCCTCCTAAAAGGTAACGGAGGCGCACAAAGGTACCTTCAGTACGGTTGGAAATCGTATTTAGAGTGTAATGGTATAAGGGTGCTTGACTGTGAGACTTACAGGTCGAACAGGTGAGAAATCAGGTCATAGTGATCCGGTGGTTCAGTATGGAATGGCCATCGCTCAACGGATAAAAGCTACTCCGGGGATAACAGGCTGATACTGCCCAAGAGTTCATATCGACGGCAGTGTTTGGCACCTCGATGTCGACTCATCTCATCCTCGAGCTGAAGCAGGTTCGAAGGGTTCGGCTGTTCGCCGATTAAAGAGATACGTGAGTTGGGTTCAAACCGTCGTGAGACAGGTTGGTCCCTATCTATTGTGCCCACAGGAAGATTGAAGAGCTTTGCTTCTAGTACGAGAGGACCGGAGCGAGGACACCGCTTATGCTCCAGTTGTAGCGCCAGCTGCACCGCTGGGT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Multi-drug_resistance,MEG_3740,Drugs,MEG_3740|Drugs|Multi-drug_resistance|MDR_23S_rRNA_mutation|MDR23S,gb|L43967.2|+|171727-174461|ARO:3004616|Mycoplasma genitalium 23S rRNA mutations confers resistance to fluoroquinolone and macrolide antibiotics [Mycoplasma genitalium G37] ,1
,atgcgcgataccggattcccctgcctgtgcggcatcgccgcctccacactgctgttcgccgccacctcggccattgccggcgaggccccggcggatcgcctgaagacactggtcgacgccgccgtacaaccggtgatgaaggccaatgatattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcttcgaaagaggacggtcgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgtgccagcctgcactggccggcgctgcaaggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaagaccaggcacagatccgcgactactaccgccagtggcagccgacctacacgccgggcagccagcgcctctactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggatcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccctctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcaatgccaacctgcatccggagcgcctggacaagccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggcgggcaactcgacgccgatggcgctgcaaccgcacaggatcgccagactgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccaggccgcgacctgggcctggtgatcctggccaaccgcaattatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5711,Drugs,MEG_5711|Drugs|betalactams|Class_C_betalactamases|PDC,950497593|WP_057388025.1|NG_054982|1|1|blaPDC-197|blaPDC|class_C_beta-lactamase_PDC-197 NG_054982:1-1194,0
,ATGGAATTGCCCAATATTATGCACCCGGTCGCGAAGCTGAGCACCGCATTAGCCGCTGCATTGATGCTGAGCGGGTGCATGCCCGGTGAAATCCGCCCGACGATTGGCCAGCAAATGGAAACTGGCGACCAACGGTTTGGCGATCTGGTTTTCCGCCAGCTCGCACCGAATGTCTGGCAGCACACTTCCTATCTCGACATGCCGGGTTTCGGGGCAGTCGCTTCCAACGGTTTGATCGTCAGGGATGGCGGCCGCGTGCTGGTGGTCGATACCGCCTGGACCGATGACCAGACCGCCCAGATCCTCAACTGGATCAAGCAGGAGATCAACCTGCCGGTCGCGCTGGCGGTGGTGACTCACGCGCATCAGGACAAGATGGGCGGTATGGACGCGCTGCATGCGGCGGGGATTGCGACTTATGCCAATGCGTTGTCGAACCAGCTTGCCCCGCAAAAGGGGATGGTTGCGGCGCAACACAGCCTGACTTTCGCCGCCAATGGCTGGGTCGAACCAGCAACCGCGCCCAACTTTGGCCCGCTCAAGGTATTTTACCCCGGCCCCGGCCACACCAGTGACAATATCACCGTTGGGATCGACGGCACCGACATCGCTTTTGGTGGCTGCCTGATCAAGGACAGCAAGGCCAAGTCGCTCGGCAATCTCGGTGATGCCGACACTGAGCACTACGCCGCGTCAGCGCGCGCGTTTGGTGCGGCGTTCCCCAAGGCCAGCATGATCGTGATGAGCCATTCCGCCCCCGATAGCCGCGCCGCAATCACTCATACGGCCCGCATGGCCGACAAGCTGCGCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4152,Drugs,MEG_4152|Drugs|betalactams|Class_B_betalactamases|NDM,gb|KC999080|+|379-1192|ARO:3002359|NDM-9 [Klebsiella pneumoniae subsp. pneumoniae] ,0
,atgaaaaaactatttgttttatgtatatttttgttttgtagcattactgccgcaggagcgtctttgcctgatttaaaaattgagaagcttgaagagggtgtttatgttcatacatcgtttgaagaagttaacggctggggtgttgtttctaaacacggtttggtggttcttgtaaatactgacgcctatctgattgacactccatttactgctaaagatactgaaaagttagtcaattggtttgtggagcgcggctataaaatcaaaggcagtatttcctcacatttccatagcgacagcacgggtggaatagagtggcttaattctcaatctattcccacgtatgcatctgtattaacaaatgaacttctcaaaaaagacggtaaggtgcaagctaaaaactcatttagcggagttagctattggctagttaaaaataaaattgaagttttttatccaggcccagggcacactcaagataacgtagtggtttggctacctaaaaataaaatcttatttggtggttgttttgttaaaccatatggtcttggtaatctagatgacgcaaatgttgaagcatggccacattcggctgaaaaattaatatctaagtatggtaatgcaaaactggttgttccaggccatagtgacataggagatgcgtcgctcttgaagcttacgtgggaacaggcggtaaaagggcttaatgaaagcaaaaaaagtaacactgttcattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3318,Drugs,MEG_3318|Drugs|betalactams|Class_B_betalactamases|IMP,1252412300|WP_096807443.1|NG_055584|1|1|blaIMP-68|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-68 NG_055584:1-738,0
,atgcgatttaaaaaaatttcttgcttacttttacctcctctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccgagaaattaaaaaactggtagatcaaaactttaaacctttattagataaatatgatgtgccgggtatggccgtgggcgttattcagaataataaaaaatatgaaacgtattatggtcttcaatctgttcaagataaaaaagccgtaagtagcagcaccatttttgaactaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatttcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcaacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaactcaatcggtgaatatagacaatattcaaatccaagcattggtttatttggaaaagttgtggcattgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccagatcttggcttaaaacatagctatgtaaatgttcctaaaactcagatgcaaaactatgcttttggctataaccaagaaaatcagccaattcgtgttaaccctggtccgctagatgctccagcatatggggttaaatcgacgctacccgatatgcttaagtttattaatgccaacctcaacacacagaaatatccgaaagatattcaacgtgcaattaatgaaacacatcagggtttctatcaagtcggcaccatgtatcaggcacttggttgggaagaattttcttatccagcgcctttacaaactttattagacagtaattcagaacaaattgtgatgaagcctaataaagtgactgccatttcaaaagaaccttcagttaagatgttccacaaaactggttcaaccaatggtttcggaacttatgtcgtgttcattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgccgtgttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_527,Drugs,MEG_527|Drugs|betalactams|Class_C_betalactamases|ADC,1028102018|WP_063857796.1|NG_048647|1|1|blaADC-22|blaADC|class_C_extended-spectrum_beta-lactamase_ADC-22 NG_048647:1-1152,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4489,Drugs,MEG_4489|Drugs|betalactams|Class_D_betalactamases|OXA,638870189|WP_024433915.1|NG_049397|1|1|blaOXA-104|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-104 NG_049397:101-925,0
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaagtataccgttctttatccgtattagacggagcagtattattagtttctgcaaaggatggcatacaggcacagacccgtatactgtttcatgcactacagataatgaagattccgacaatttttttcatcaataaaattgaccaagaggggattgatttgccaatggtatatcgggaaatgaaagcaaagctttcttcggaaattatagtgaagcaaaaggttgggcagcatccccatataaatgtaacggacaatgacgatatggaacagtgggatgcggtaattatgggaaacgatgaactattagagaaatatatgtcagggaaaccgtttaaaatgtcagaactggaacaggaagaaaacaggagattccaaaacggaacgttatttcccgtttatcacggaagcgctaaaaacaatctggggattcggcagcttatagaagtaattgccagtaaattttattcatcaacgcctgaaggtcaatctgaactatgcgggcaggtttttaagattgaatattcggaagaaagacaacgtcttgcatatgtacgcctttatggcggaatcctgcatttgcgggattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaattgataaggcttattccggggaaattgttattttgcaaaatgagtttttgaagctaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcctctccctatgctccaaacaactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctacaatattatgtggatactacaacgcatgagattatactttcttttttggggaatgtgcagatggaagtcatttgtgccatccttgaggaaaaatatcatgtggaggcagaaataaaagagcctactgttatatatatggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaatcaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttgtttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7155,Drugs,MEG_7155|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,488961139|WP_002872163.1|NG_048259|1|1|tet(O)|tet(O)|tetracycline_resistance_ribosomal_protection_protein_Tet(O) NG_048259:1-1920,4
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACATTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCGTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6589,Drugs,MEG_6589|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|21898660|gb|AY115475.1|5130-5969 gi|974751547|gb|KU130294.1|233473-234001 gi|982189197|gb|CP013993.1|5430539-5431065,8
,ATGGAAAAAAACAGAAAAAAACAAATCGTAGTTTTGAGTATAGCTTTAGTTTGCATTTTCATCTTGGTATTTTCATTGTTCCATAAATCAGCGACAAAAGATAGCGCAAATCCTCCTTTAACAAATGTTTTGACTGATAGCATTTCTCAAATTGTCTCAGCTTGTCCTGGCGAAATTGGTGTGGCGGTTATTGTTAATAACAGAGATACGGTTAAGGTCAATAATAAGAGTGTTTATCCTATGATGAGTGTGTTTAAGGTTCATCAGGCATTAGCTCTTTGTAATGACTTTGACAATAAAGGAATTTCACTTGATACCTTAGTAAATATAAATAGGGATAAACTTGACCCAAAGACTTGGAGTCCTATGCTGAAAGATTATTCAGGGCCAGTCATATCATTGACAGTGAGAGATTTGCTGCGTTATACTCTTACTCAGAGTGACAACAATGCAAGCAACCTTATGTTTAAGGATATGGTTAATGTCGCTCAAACAGATAGTTTTATAGCCACACTCATTCCTCGTTCAAGTTTTCAGATAGCTTATACGGAAGAGGAAATGTCGGCTGACCATAACAAGGCTTACTCTAACTATACATCTCCTCTTGGTGCTGCAATGTTGATGAATCGTTTGTTTACTGAAGGTCTTATCGATGATGAGAAACAAAGTTTCATTAAGAATACGTTAAAAGAATGCAAAACAGGTGTAGATAGGATAGCAGCTCCACTTCTTGATAAAGAAGGGGTTGTTATAGCGCATAAGACAGGTTCAGGTGATGTTAATGAAAATGGTGTTCTTGCAGCTCACAATGATGTTGCCTATATATGTCTGCCTAATAATATCAGTTATACCTTAGCGGTATTTGTTAAGGATTTCAAGGGAAATGAATCACAAGCGTCACAATATGTTGCGCATATATCAGCTGTAGTATATTCTTTATTAATGCAAACTTCAGTAAAATCTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1692,Drugs,MEG_1692|Drugs|betalactams|Class_A_betalactamases|CFX,gb|AF472622|+|52-1018|ARO:3003003|CfxA3 [Capnocytophaga ochracea] ,0
,ATGAATAAATCAATTATTATCATACTGCTTGTCACAGTATTAGATGCCATTGGTATTGGCCTTATCATGCCAGTACTACCAACACTATTAAACGAGTTTGTGAGCGAAAACAGACTCGCCAATCATTACGGTATATTATTAGCACTCTATGCGACGATGCAGGTGATCTTCGCACCTATTTTAGGAAAATTATCAGATAAATATGGCAGAAAACCTATTTTATTATTTTCGCTATTGGGTGCGGCATTAGATTACCTATTAATGGCTTGCTCTACCTCATTATGGATGCTCTACATTGGACGCATTATTGCGGGTATAACAGGAGCCACTGGTGCAGTATGCGCATCAGCAATGACTGATGTTACTCACCCTCATGAAAGAACACGCTATTTCGGTTTTTTGGGTGGTGCATTTGGTGTGGGTTTAATTATTGGCCCCATGTTAGGGGGATTACTGGGTGAGATCAGCGCCCATACGCCATTTATCTTTGCGGCTATTTCTCATTCGTTATTATTTATATTTTCATTACTTTGTTTCCAAGAAACTCAAACCACAAAAATATCGACTGAAATATCCGCATTAAATCAGGATACAGCACCTCACTCTGCCACTGGTTTTATTAAAAAGAGTCTCTGTTTTTGGCTTATTGCCTATTTTATTATTCAACTAATAGGGCAAATTCCGGCCACTATTTGGGTGCTATTCACACAAGTGCGTTTCGCTTGGCACACTACTGAAGTAGGTTTATCTCTTGCATTTCTTGGTGTATTACATATTTTTTTTCAAGCGGTTCTCGCAGGAAAACTGGCGCAAAAATGGGGAGAACGCAACACGGTTATCATTAGCATGTCTATTGATGCATTTGGTTGCTTATTATTAGCCTGGATAAGCCATGTTTGGGTTATGCTCCCCGCTTTAATCTGTTTAGCTGCGGGAGGAATGGGACAACCTGCTTTACAAGGATATTTATCAAAATCTGTTGATCATCATGTTCAAGGACAATTACAAGGAACGTTAGTAAGTCTAACGAATATAACTGGGATTGTCGGCCCGTTACTCTTCTCTTTTATTTATAGTTACAGCGTTGAATATTGGGATGGCTTATTGTGGTTTATTGGTGCAATGCTTTACAGTGGATTACTTGTAGCCAGTTATTTTAAACAGAAATCACCAATATTAAAAAAATTTCCCTCATAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7088,Drugs,MEG_7088|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETJ,tet(J)_1_ACLE01000065,4
,atgataaacacagtgcccgccgagatttcggtacagttatcacaggcactcaacgtcatcgagcatcatctgggatcgacgttgctggccatgcatttgtatggctctgcactcgacggtggcctgaagccatacagtgatattgatttgctggttactgtgaccgcacggctcgatgagagtgtgcggcaagctctgttcgtcgatctcttgggggtttccgttttccctggtcaaagcagagttctccgcgccttggaagttaccattgtcgtgcacagtgacatcgttccttggcgctatccggacagacgggaactgcaattcggggagtggcagcgcaaagacattcttgcgggcatcttcgagcctgcgacaaccgatgttgatctagccattctgctaacaaaagcaaggcaacatagccttgccttggccggttcggctggggaagatttcttcaacccagtcccggaaagcgatctattcaaggcactggccgacaccctgaaactatggaactcacagccggattggataggtgacgagcggaatgtagtgcttactttgtctcgtatttggtacagcgcagcaaccggcaagatcgcgccgaaggatgttgccgccaactgggtaatggagcgtttgccagttcaacatcagcccgtgctgcttgaagcccggcaggcttatcttggacaaggagaagattgcttggcttcgctcacggatcagttagaggcgtttgttcacttcgtgaagcatgaagccactaaactgcttggtgccacgccaatgatgtctaacaattcattcaagccgacgccgcttcgcggcgcggcttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_825,Drugs,MEG_825|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1080153679|WP_070342359.1|NG_051878|1|1|aadA10|aadA10|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA10 NG_051878:101-946,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctgggtgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5643,Drugs,MEG_5643|Drugs|betalactams|Class_C_betalactamases|PDC,1188444892|WP_085562394.1|NG_054680|1|1|blaPDC-178|blaPDC|class_C_beta-lactamase_PDC-178 NG_054680:1-1194,0
,atgaaaatattattagcattctttcttctttcaagtttgacttttatttcttgcaaagaatcatcctctaaccacaatcaggcaaatcaagaaaacaagaaggaaataatcaataaacctttaaccgacagcttgatagtctatcaaaccgaaaatctgataattaacaaactctcaaatcacatttatgaacatatttcctttttaaatacggacgattttggaaaagttgcctgcaatggaatgttagttttaaatgagaataaagtagttgtttttgatacaccaacagacgacaaaagttcgttagagttaataaattttgtaacgaatacattaaaaagtgaaattatagggctaattccaactcattttcacgatgattgtattggtggaataacggaatttgaaaaccataatattcaaacctatgtctctaaagaaactatagaattattaaaagataacggtcaagaattctctaatccaactaaagattttgacaatagtctcacattagatatcggaaacaagaaagtttatgcggaatattttggagaagggcacactaaagataatgttgtgggctatttcccagaagataacgcagtattcggtggatgcttgataaaggaaattgacgcgagtaaaggatatttaggagatgcaaatattaaagaatggtcaacaacagtagaaaaagtaaaactcaaatatcccaatgctaaaattgtaataccaggacacggaaaatggggtggaattgaattatttgactacacaataaaactatttgaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4105,Drugs,MEG_4105|Drugs|betalactams|Class_B_betalactamases|MYO,1173101458|WP_081048762.1|NG_059325|1|1|blaMYO-1|blaMYO|subclass_B1_metallo-beta-lactamase_MYO-1 NG_059325:101-901,0
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagtcaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgataaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgtgcgggaggaacagcggcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgccgccctatgcggcagcgttttcaaggtggagtatacagattgcggccagcggcgtgtctatctacggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggacccaacccggctccctcgtaaaaggtggcgtgaggaccccctccccatgctgcggacgtcgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgctgcgaggtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccataggactgtctgttacaccactctcgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcagggacgcaactgctggaaccttatctctccttcaccctctatgcgccccgggaatatctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggtccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcagagcgtatgccttacagaactgaaagggtatcaggccgctgtcggcaagccagtcatccagccccgccgtccaaacagccgcctggacaaggtgcgctatatgtttcagaagataatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7215,Drugs,MEG_7215|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100279|WP_063856414.1|NG_048282|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048282:73-1992,4
,ATGGCTGAATTACCTCAATCAAGAATAAATGAACGAAATATTACCAGTGAAATGCGTGAATCATTTTTAGATTATGCGATGAGTGTTATCGTTGCTCGTGCATTGCCAGATGTTCGTGACGGTTTAAAACCAGTACATCGTCGTATACTATATGGATTAAATGAACAAGGTATGACACCGGATAAATCATATAAAAAATCAGCACGTATCGTTGGTGACGTAATGGGTAAATATCACCCTCATGGTGACTCATCTATTTATGAAGCAATGGTACGTATGGCTCAAGATTTCAGTTATCGTTATCCGCTTGTTGATGGCCAAGGTAACTTTGGTTCAATGGATGGAGATGGCGCAGCAGCAATGCGTTATACTGAAGCGCGTATGACTAAAATCACACTTGAACTGTTACGTGATATTAATAAAGATACAATAGATTTTATCGATAACTATGATGGTAATGAAAGAGAGCCGTCAGTCTTACCTGCTCGATTCCCTAACTTATTAGCCAATGGTGCATCAGGTATCGCGGTAGGTATGGCAACGAATATTCCACCACATAACTTAACAGAATTAATCAATGGTGTACTTAGCTTAAGTAAGAACCCTGATATTTCAATTGCTGAGTTAATGGAGGATATTGAAGGTCCTGATTTCCCAACTGCTGGACTTATTTTAGGTAAGAGTGGTATTAGACGTGCATATGAAACAGGTCGTGGTTCAATTCAAATGCGTTCTCGTGCAGTTATTGAAGAACGTGGAGGCGGACGTCAACGTATTGTTGTCACTGAAATTCCTTTCCAAGTGAATAAGGCTCGTATGATTGAAAAAATTGCAGAGCTCGTTCGTGACAAGAAAATTGACGGTATCACTGATTTACGTGATGAAACAAGTTTACGTACTGGTGTGCGTGTCGTTATTGATGTGCGTAAGGATGCAAATGCTAGTGTCATTTTAAATAACTTATACAAACAAACACCTCTTCAAACATCATTTGGTGTGAATATGATTGCACTTGTAAATGGTAGACCGAAGCTTATTAATTTAAAAGAAGCGTTGGTACATTATTTAGAGCATCAAAAGACAGTTGTTAGAAGACGTACGCAATACAACTTACGTAAAGCTAAAGATCGTGCCCACATTTTAGAAGGATTACGTATCGCACTTGACCATATCGATGAAATTATTTCAACGATTCGTGAGTCAGATACAGATAAAGTTGCAATGGAAAGCTTGCAACAACGCTTCAAACTTTCTGAAAAACAAGCTCAAGCTATTTTAGACATGCGTTTAAGACGTCTAACAGGTTTAGAGAGAGACAAAATTGAAGCTGAATATAATGAGTTATTAAATTATATTAGTGAATTAGAAGCAATCTTAGCTGATGAAGAAGTGTTATTACAGTTAGTTAGAGATGAATTGACTGAAATTAGAGATCGTTTCGGTGATGATCGTCGTACAGAAATTCAATTAGGTGGATTTGAAGACTTAGAGGACGAAGACTTAATTCCAGAAGAACAAATAGTAATTACACTAAGCCATAATAACTACATTAAACGTTTGCCGGTATCTACATATCGTGCTCAAAACCGTGGTGGTCGTGGTGTTCAAGGTATGAATACATTGGAAGAAGATTTTGTCAGTCAATTGGTAACTTTAAGTACACATGACCATGTATTGTTCTTTACTAACAAAGGTCGTGTATACAAACTTAAAGGTTACGAAGTGCCTGAGTTATCAAGACAGTCTAAAGGTATTCCTGTAGTGAATGCTATTGAACTTGAAAATGATGAAGTCATTAGTACAATGATTGCTGTTAAAGACCTTGAAAGTGAAGACAACTTCTTAGTGTTTGCAACTAAACGTGGTGTCGTTAAACGTTCAGCATTAAGTAACTTCTCAAGAATAAATAGAAATGGTAAGATTGCGATTTCGTTCAGAGAAGATGATGAGTTAATTGCAGTTCGCTTAACAAGTGGTCAAGAAGATATCTTGATTGGTACATCACATGCATCATTAATTCGATTCCCTGAATCAACATTACGTCCTTTAGGCCGTACAGCAACGGGTGTGAAAGGTATTACACTTCGTGAAGGTGACGAAGTTGTAGGGCTTGATGTAGCTCATGCAAACAGTGTTGATGAAGTATTAGTAGTTACTGAAAATGGTTATGGTAAACGTACGCCAGTTAATGACTATCGCTTATCAAATCGTGGTGGTAAAGGTATTAAAACAGCTACGATTACTGAGCGTAATGGTAATGTTGTATGTATCACTACAGTAACTGGTGAAGAAGATTTAATGATTGTTACTAATGCAGGTGTCATTATTCGACTAGATGTTGCAGATATTTCTCAAAATGGTCGTGCAGCACAAGGTGTTCGCTTAATTCGCTTAGGTGATGATCAATTTGTTTCAACGGTTGCTAAAGTAAAAGAAGATGCAGAAGATGAAACGAATGAAGATGAGCAATCTACTTCAACTGTATCTGAAGATGGTACTGAACAACAACGTGAAGCGGTTGTAAATGATGAAACACCAGGAAATGCAATTCATACTGAAGTGATTGATTCAGAAGAAAATGATGAAGATGGACGTATTGAAGTAAGACAAGATTTCATGGATCGTGTTGAAGAAGATATACAACAATCATCAGATGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3222,Drugs,MEG_3222|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|827440804|gb|CP011526.1|7032-9695 gi|777226173|emb|LN831049.1|692495-689832 gi|374362062|gb|CP003033.1|7005-9668 gi|87201381|gb|CP000253.1|7005-9668 gi|540540|dbj|D10489.1|STAGYRABA|2152-4815,3
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtctccaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatgctggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcaccttcttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcatccaaagcctgatagtcagtatcgtcgggacattggcggtgacgctgttaaacggcgatacagcgtggcccgtgatttgttacgccacggcaatggcagtgctggtgtcgttggggctggcgctccttcgatcccgtgatgctgccaccgagaagtcgccagtcgtctag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2915,Drugs,MEG_2915|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,1028086745|WP_063845118.1|NG_047872|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047872:101-1315,6
,ATGAATAAATCAATTATTATTATACTGCTGATCACCGTATTAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGGTTAGGCCGCATGGACACAACGCAGGTCACATTGATACACAAAATTCTAGCTGCGGCAGATGAGCGAAATCTGCCGCTCTGGATCGGTGGGGGCTGGGCGATCGATGCACGGCTAGGGCGTGTAACACGCAAGCACGATGATATTGATCTGACGTTTCCCGGCGAGAGGCGCGGCGAGCTCGAGGCAATAGTTGAAATGCTCGGCGGGCGCGTCATGGAGGAGTTGGACTATGGATTCTTAGCGGAGATCGGGGATGAGTTACTTGACTGCGAACCTGCTTGGTGGGCAGACGAAGCGTATGAAATCGCGGAGGCTCCGCAGGGCTCGTGCCCAGAGGCGGCTGAGGGCGTCATCGCCGGGCGGCCAGTCCGTTGTAACAGCTGGGAGGCGATCATCTGGGATTACTTTTACTATGCCGATGAAGTACCACCAGTGGACTGGCCTACAAAGCACATAGAGTCCTACAGGCTCGCATGCACCTCACTCGGGGCGGAAAAGGTTGAGGTCTTGCGTGCCGCTTTCAGGTCGCGATATGCGGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_753,Drugs,MEG_753|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,gi|356596244|gb|CP003022.1|336102-336731 gi|356596244|gb|CP003022.1|343814-343856 gi|333975538|gb|JF769133.1|3706-4335 gi|667483963|gb|KJ439039.1|29208-29796 gi|667483878|gb|KJ411925.1|29208-29796 gi|667695446|gb|CP008733.1|12607-12019 gi|108741875|gb|DQ520939.1|17-605,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagcgagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgccgccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5573,Drugs,MEG_5573|Drugs|betalactams|Class_C_betalactamases|PDC,1209144254|WP_088245216.1|NG_055273|1|1|blaPDC-211|blaPDC|class_C_beta-lactamase_PDC-211 NG_055273:1-1194,0
,ATGACCAACCAGCCAGATCACATCCTCATCGTCGATGACGATCGCGACATCCGCAGCCTGCTCGCCGATTACCTGGAGAAGCAGGGCCTGCGCTGCACCACCGCGGCGGACGGCCGCGAGATGAAGGCGGCGCTGGAACGCCACCGTGTCGACCTGATCGTGCTCGACCTGATGCTGCCGGGCGAAGACGGCCTGACGCTGTGCCGCAACCTGCGCGCCGGCGGCAGCCACGCCAACACGCCGATCCTGATGCTGACCGCGCGCGGCGAGGACATGGACCGCATCATCGGTCTGGAGATGGGAGCCGACGACTACCTGCCCAAGCCCTTCGTGCCGCGCGAACTCTATGCCCGCGTACGCGCCATCCTGCGCCGCGCGCGCGCGTTGCCCCCCAACCTCGACACCCAGCCGCAGGCGCAGGCGCGCGAGCTGCGCTTCGCGCAGTGGCGGCTCGACACCGTCAACCGCCACCTCATCGATGCGCAGGGCACCGTGGTGCCGTTGTCGGGCGCCGAATACCGCATGCTCGGCGTGTTCCTCGCCCATCCGCAGCGCGTGCTGTCGCGCGATCAGTTGATGGAGCTGACCCAGGGCCGCGAAGCCGACGTGTTCGACCGCTCGATCGACCTGATGGTGAGCCGCCTGCGCCAGCGCCTGGGGGATAACGCGCGCGAACCCGCCATCATCAAGACCGTGCGCAACGAGGGCTATGTGCTCAGCGCCGAGGTCGTTGCCGGCGACGGGAGCCTGAGCCAGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,reduced permeability to antibiotic,betalactams,MEG_4290,Drugs,MEG_4290|Drugs|betalactams|Mutant_porin_proteins|OMPR,gi|119668705|emb|AM406670.1|3025977-3026735,0
,atgaagacaaaatccctttgctgtgccctgatgctcagcacctcctgctctgttctcgccgcgccgatgtcagagaaacagctgtctgacgtggtggaacgtaccgttacccccctgatgaaagcgcaagccattccgggcatggcggtagcggtgatttatcagggtcagccgcactactttaccttcggaaaggccgatgttgcggcgaacaaacctgtcaccccgcaaaccctgtttgagctgggctctataagtaaaaccttcaccggcgtattaggtggcgatgcgattgcgcgcggagaaatatcgctgggcgaccccgtgacaaagtactggcccgagctaacaggcaagcagtggcagggtattcgcatgttggatctggcgacctacaccgcgggtggcctgccgctacaggtgccggatgaggtcacggataacgcctccctgctgcgtttctatcaacactggcaaccgcagtggaaaccaggcacaacgcgtctttatgcgaacgccagcatcgggctttttggcgccctcgcggttaaaccctccggtatgagctttgaacaggccatgacgaagcgggtcttcaagccactcaaactggaccatacatggattaacgttccgaaagaagaagaggcgcattacgcctggggataccgtgacggtaaagcaacccacgtttcaccgggaatgctggatgccgaagcgtatggtgtcaaaaccaacgtccaggatatggcgagctgggtgaaggccaacatgaaccctgacgcccttccggattcaacgttgaaacagggtattgccctggcacagtctcgctactggcgcgtgggtgccatgtatcagggtctgggctgggagatgctcaactggccggtagaagccaaaaccgtcgtggagggcagcgataacaaggtggctcttgcaccgttaccggtggcagaagtgaaccctccagctccgccagtaaaagcatcatgggtacataaaacaggctcgacgggtggattcggcagctatgtcgcatttattcctgagaaggaactcggcattgttatgctggcgaacaagagctacccgaacccggcgcgcgtggaagcggcataccgtattctgagcgctctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_416,Drugs,MEG_416|Drugs|betalactams|Class_C_betalactamases|ACT,772624199|WP_045269678.1|NG_050714|1|1|blaACT-51|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-51 NG_050714:1-1146,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatccatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_791,Drugs,MEG_791|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502204|WP_071846354.1|NG_052473|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052473:101-892,2
,ATGATAAATAAGGAGCAGAATATAATGGATAATAGAAATTCTAAAAACTCACAGAACTTTATAACATCCCGAAAATATATCAATGATATATTAAAAGAAACAAGCATAGGCGCTGATGATAATATAATTGAAATTGGAACTGGAAAAGGACATTTTACAAAGCAATTATCTAATATTGCTAGATTTGTAACTGGCGTAGAAATTGATAAGTCTTTATATCGTAATTTAAAAAAGGATATTGAATTGTCCAATAATGTCGAATTAGTGAACAAAGATATATTGAAGTATCAGTTCCCTAAATGTAAAAAGTATAAGGTTTTTGGTAATATACCATACAATATAAGTACTGAAATAGTTAAAAAAATCTTATATGAGGGGAATGCTGAATATAATTACCTTATTGTAGAATATGGTTTTGCTAAACGAATTATGGATAAACGAAGAGCACTAGGTCTATTACTTTTGACTAAATTAGATGTTGAAATATTAAAAGTAATTCCCAACACTTATTTTCATCCTAAACCTAGAGTAGAATCGGCATTAATCTTATTAAAGCAGCACAAATCTTTAATCCAAAAAAGAGACGAAAAATTATATCAATTTTTTGTGTATAAATGGGTAAATAAAGAGTATAAACAATTATTTACAAAAAATCAGTTTAATAAGGCGTTAAAAAATGCTAAAGTAAAAAATATAAATGAAATGACAAATGAACAATTTATATCAATTTTTCATAGTTATAAATTGTTTAATTAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2769,Drugs,MEG_2769|Drugs|MLS|23S_rRNA_methyltransferases|ERM,gb|LN623525.1|+|13980-14736|ARO:3003971|erm(44) [Staphylococcus saprophyticus] ,7
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1874,Drugs,MEG_1874|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EU496816|+|0-1140|ARO:3002044|CMY-33 [Escherichia coli] ,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgcatcgaacacgcttgtgaagccgccatgttgatgagcgacaacaccgccgcgaacttagtgttaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgctctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcactcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacacagacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1504,Drugs,MEG_1504|Drugs|betalactams|Class_A_betalactamases|CARB,646531766|WP_025551322.1|NG_048741|1|1|blaCARB-38|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-38 NG_048741:1-852,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAGCCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1432,Drugs,MEG_1432|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_99_LTNH01000008,0
,ATGGTGAAAAGCCTTGAGGGAGTGACCGATATGTTAAGTAAAGCCAATCGTGCAAAGACAGCTATTTGCGGAATTATCAATGTAACCCCAGACTCCTTTTCGGACGGTGGTCAATTTTTTGCTCTTGAGCAGGCACTCCAGCAGGCTCGTAAATTGATAGCAGAAGGGGCTAGCATGCTAGATATCGGTGGAGAATCAACTCGGCCGGGAAGTAGCTATTATGTTGAGATAGAAGAGGAGATCCAGCGTGTTGTTCCAGTGATTAAAGCGATTCGCAAGGAAAGTGATGTCCTCATTTCTATTGATACTTGGAAAAGTCAGGTTGCAGAGGCTGCTTTGGCTGCTGGTGCCAATCTAGTCAATGATATCACTGGTCTCATGGGTGATGAAAAAATGGCCCATGTGATAGCTAAAGATGGAGCGAAAGTGGTCATTATGTTTAATCCTGTTATGGCTCGACCTCAGCATCCTAGCTCGCTCATATTCCCTCATTTTGGATTTAATCAAGCTTTTACAGAGGAAGAGTTAGCTGACTTTGAAACATTGCCAATCGAAGAGTTGATGGAGACTTTCTTTGAAAGAGCACTAGCGAGAGCAAATCAAGCTGGAATTGCACAAGAAAATATCCTGTTGGATCCAGGAATCGGCTTTGGGCTGACTAAGAAAGAAAATTTGCTTCTTTTACGAGACCTGGATAAACTACATCAGAAGGGCTATCCAATCTTTCTTGGAGTGTCGCGCAAGAGGTTTGTCATCAATATCCTTGAAGAAAATGGTTTTGAAGTCAATCCTGAGACAGAACTTGGTTTCCACAATCGGGACACAGCTTCGGCTCATGTAACCAGTATCGCTGCGAGACAGGGTGTGGAAGTGGTGCGCGTGCATGACGTAGCTAGTCACAGGATGGCAGTTGAAATTGCCTCCGCCATTCGTCTGGCTGATGAAGCGGAAAATCTAGATTTAAAACAATATAAATAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2957,Drugs,MEG_2957|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|909837468|gb|CP003357.2|339598-340575 gi|225726369|gb|CP000921.1|300601-301578,8
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggggagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4404,Drugs,MEG_4404|Drugs|betalactams|Class_D_betalactamases|OXA,1391852915|WP_109545100.1|NG_057534|1|1|blaOXA-612|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-612 NG_057534:1-774,0
,ATGAAAATTATTAATATTGGAGTTTTAGCTCATGTTGATGCAGGAAAAACTACCTTAACAGAAAGCTTATTATATAACAGTGGAGCGATTACAGAATTAGGAAGCGTGGACAAAGGTACAACGAGGACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACAGGAATAACCTCTTTTCAGTGGGAAAATACGAAGGTGAACATCATAGACACGCCAGGACATATGGATTTCTTAGCAGAAGTATATCGTTCATTATCAGTTTTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATGGCGTACAAGCACAAACTCGTATATTATTTCATGCACTTAGGAAAATGGGGATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCCGAAATTGTAATCAAACAGAAGGTAGAACTGTATCCTAATATGTGTGTGACGAACTTTACCGAATCTGAACAATGGGATACGGTAATAGAGGGAAACGATGACCTTTTAGAGAAATATATGTCCGGTAAATCATTAGAAGCATTGGAACTCGAACAAGAGGAAAGCATAAGATTTCATAATTGTTCCCTGTTCCCTGTTTATCACGGAAGTGCAAAAAACAATATAGGGATTGATAACCTTATAGAAGTGATTACGAATAAATTTTATTCATCAACACATCGAGGTCCGTCTGAACTTTGCGGAAATGTTTTCAAAATTGAATATACAAAAAAAAGACAACGTCTTGCATATATACGCCTTTATAGTGGAGTACTACATTTACGAGATTCGGTTAGAGTATCAGAAAAAGAAAAAATAAAAGTTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAGATTGATAGAGCTTATTCTGGAGAAATTGTTATTTTGCAAAATGAGTTTTTGAAGTTAAATAGTGTTCTTGGAGATACAAAACTATTGCCACAGAGAAAAAAGATTGAAAATCCGCACCCTCTACTACGAACAACTGTTGAACCGAGTAAACCTGAACAGAGAGAAATGTTGCTTGATGCCCTTTTGGAAATCTCAGATAGTGATCCGCTTCTACGATATTACGTGGATTCTACGACACATGAAATTATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGATTAGTGCACTGTTGCAAGAAAAGTATCATGTGGAGATAGAACTAAAAGAGCCTACAGTCATTTATATGGAGAGACCGTTAAAAAATGCAGAATATACCATTCACATCGAAGTGCCGCCAAATCCTTTCTGGGCTTCCATTGGTTTATCTGTATCACCGCTTCCGTTGGGAAGTGGAATGCAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCATTTCAAAATGCAGTTATGGAAGGGATACGCTATGGTTGCGAACAAGGATTATATGGTTGGAATGTGACGGATTGTAAAATCTGTTTTAAGTATGGCTTATACTATAGCCCTGTTAGTACCCCAGCAGATTTTCGGATGCTTGCTCCTATTGTATTGGAACAAGTCTTAAAAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAATTTATACGCCACAGGAATATCTTTCACGAGCATACAACGATGCTCCTAAATATTGTGCGAACATCGTAGACACTCAATTGAAAAATAATGAGGTCATTCTTAGTGGAGAAATCCCTGCTCGGTGTATTCAAGAATATCGTAGTGATTTAACTTTCTTTACAAATGGACGTAGTGTTTGTTTAACAGAGTTAAAAGGGTACCATGTTACTACCGGTGAACCTGTTTGCCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7140,Drugs,MEG_7140|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|404282|emb|X75073.1|228-2147,4
,ATGCTAAATTTAACCGTTTGTCAGGCACTGTCAAATCCAACAGACTACGCCTGTCTGACGGGCCCGGACATCCCCTTGACTCGCTATTACGGAAGATTACTGATGATGAAAAAATCCCTTTGCTGCGCCCTGCTGCTCGGCATCTCTTGCTCTGCTCTCGCCACGCCAGTGTCAGAAAAACAGCTGGCGGAGGTGGTCGCGAATACGGTTACCCCGCTGATGAAAGCCCAGTCTGTTCCAGGCATGGCGGTGGCCGTTATTTATCAGGGAAAACCGCACTATTACACGTTTGGCAAGGCCGATATCGCGGCGAATAAACCCGTTACGCCTCAGACCCTGTTCGAGCTGGGTTCTATAAGTAAAACCTTCACCGGCGTTTTAGGTGGGGATGCCATTGCTCGCGGTGAAATTTCGCTGGACGATCCGGTGACCAGATACTGGCCACAGCTGACGGGCAAGCAGTGGCAGGGTATTCGTATGCTGGATCTCGCCACCTACACCGCTGGCGGCCTGCCGCTACAGGTACCGGATGAGGTCACGGATAACGCCTCCCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCTGGCACAACGCGTCTTTACGCCAACGCCAGCATCGGTCTTTTTGGTGCGCTGGCGGTCAAACCTTCTGGCATGCCCTATGAGCAGGCCATGACGACGCGGGTCCTTAAGCCGCTCAAGCTGGACCATACCTGGATTAACGTGCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGCTATCGTGATGGTAAAGCGGTGCGTGTTTCGCCGGGTATGCTAGATGCACAAGCCTATGGCGTGAAAACCAACGTGCAGGATATGGCGAACTGGGTCATGGCAAACATGGCGCCGGAGAACGTTGCTGATGCCTCACTTAAGCAGGGCATCGCGCTGGCGCAGTCGCGCTACTGGCGTATCGGGTCAATGTATCAGGGTCTGGGCTGGGAGATGCTCAACTGGCCCGTGGAGGCCAACACGGTGGTCGAGGGCAGCGACAGTAAGGTAGCGCTGGCGCCGTTGCCCGTGGCAGAAGTGAATCCACCGGCTCCCCCGGTCAAAGCGTCCTGGGTCCATAAAACGGGCTCTACTGGCGGGTTTGGCAGCTACGTGGCCTTTATTCCTGAAAAGCAGATCGGTATTGTGATGCTCGCGAATACAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCATATCCTCGAGGCGCTACAGTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_492,Drugs,MEG_492|Drugs|betalactams|Class_C_betalactamases|ACT,gi|595583477|gb|KF992026.1|652-1898,0
,ATGCGTCAATATCGATTCGCCCTTCTCCCATTGTTAGCCGCCCTGGCGCTCCCCGGTTGGGCGCATCAAGCTACGGTGACGACGGTTAAACAAGCCGAAAGCCAGCTTCAGGGTCGGGTCGGCTACGCCGAACTGGATTTAGCTTCCGGGCAACTGCTGGCCGGCTATCGTTCTGACGAACGGTTCCCGATGATGAGCACTTTTAAAGTTCTGCTCTGCGGCGCAGTCTTGTCGCGTGTCGATGCCGGTGAAGAACAGCTCGATCGCCGTATCCATTACCGGCAGCAGGATCTGGTGGAATATTCGCCGGTGACGGAAAAGCATCTTACCGATGGGCTCACCGTGGGCGAACTGTGCGCTGCCGCCATTACCCTGAGCGATAATACGGCGGCAAACCTGCTGTTGACCACTCTCGGCGGCCCGCAGGGGCTGACCAGCTTCCTGCGCCACAGCGGCGACCAGACTTCGCGGCTTGACCGTTGGGAAACGGAACTCAATGAAGCGCGGCCGGGCGACGTGCGAGATACCACGACTCCGCAAGCGATGGCCAGGACACTGCGAAATCTGTTGACCGGTCGCGTGCTTTCCAGCGCCTCGCAGCAGCAGTTGCAACGCTGGATGGTAGAGGACAAAGTTGCGGGGCCGCTGTTGCGATCGGTGCTCCCGGCGGGCTGGTTTATTGCCGATAAGACCGGAGCCGGCAATCGCGGTTCGCGCGGGATCATCGCTGCTCTCGGTCCGGACGGTAAAGCTGCGCGCATCGTGGTGATTTATTTGACCGGGACCCCCGCCGCAATGGATGAACGCAATAAACAGATTGCGGCCATCGGCGCAACGCTGGTCACGCACTGGTCCGCAGACGAGAACAGACCCTAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_1296,Drugs,MEG_1296|Drugs|betalactams|Class_B_betalactamases|BLAPLA,blaPLA-4A_1_AY507664 ,0
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagtcaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgataaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgtgcgggaggaacagcggcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgccgccctatgcggcagcgttttcaaggtggagtatacagattgcggccagcggcgtgtctatctacggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggacccaacccggctccctcgtaaaaggtggcgtgaggaccccctccccatgctgcggacgacgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgttgcgaagtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaaccctccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccataggactgtctgttacaccactctcgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcggggacgcagctgctggaaccttatctctccttcatcctctatgcgccccaggaatacctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggcccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcggagcgtatgccttacagagctgaaaggatatcaggccgctgtcggtcagccggtcatccagccccgccgtccaaacagccgcctggacaaggtgcgccatatgtttcagaaggtaatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7213,Drugs,MEG_7213|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100288|WP_063856423.1|NG_048297|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048297:101-2020,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgctcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5619,Drugs,MEG_5619|Drugs|betalactams|Class_C_betalactamases|PDC,553776492|WP_023108311.1|NG_049895|1|1|blaPDC-22|blaPDC|class_C_beta-lactamase_PDC-22 NG_049895:1-1194,0
,atgaatgtcatcctgaaccgtcgaacgtttttattggctagcgctgtggtgtctgcgtcttattcgctaggtacgctggctggcgctaatcgggatgatgcttcctttcaagatcggctggctaagttggagcagaagctgaacggacggcttggagtatgcgccatcgataccgcaaatggagcacagctgggctatcgcgccaatgagcggtttgccatgaacagcacgttcaaggtcatgctcgcttcagcgtttctcgcccgaagccaagacgaaccggggctcctcgaagaacggctcatgtacacccgggccgatctggtcacatactctcccgtgacggaaaagcacgtttccactgggatgaccgttgccgaattgtgcgccgcaggcattcagtacagtgataacaccgcggccaatgtgctcatgaaaaagctggggggccctgaagcggtcaccgcatttgcccgttcgataggcgatacgcattttcgcctcgatcggtgggaaaccgaactcaattcggctattccgggagatcctcgtgatacgagtacccctcaggccatggcaatgagcctgcaacgtctggcattgggtgacatgctggctgcggataaacagcatcagttgcaggcgtggttgaaaggcaataccacaggtggcaagcgtatccgggccggggtaccggctggctggcaggtaggcgataagacaggtacgggtgattacggctcggccaacgacgtggctatcctctggccgcctcgccgtgcacccgttgtgctggctctctattccgctcttgaaaaccagcaggcggaagcgcgcaatgacgtgctggccgatgcggcgcgcattgtggctgaatgggtgacaggctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3653,Drugs,MEG_3653|Drugs|betalactams|Class_A_betalactamases|LUT,1028105804|WP_063860829.1|NG_049286|1|1|blaLUT-3|blaLUT|class_A_beta-lactamase_LUT-3 NG_049286:1-891,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggcggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaactatttttccagagcttggcttaaaatatagttatgtaaatgtgcctaaaactcagatacaaaactatgcatttggttataaccaagaaaatcagccgattcgagttaatcctggtccactcgatgcaccagcatacggcgttaaatctaccttacctgatatgcttaagtttattaatgccaacctaaacccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcgtatgcagttttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_552,Drugs,MEG_552|Drugs|betalactams|Class_C_betalactamases|ADC,447133965|WP_001211221.1|NG_051452|1|1|blaADC-88|blaADC|class_C_beta-lactamase_ADC-88 NG_051452:1-1152,0
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataagacaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgcttttccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4502,Drugs,MEG_4502|Drugs|betalactams|Class_D_betalactamases|OXA,1058244040|WP_068981638.1|NG_051473|1|1|blaOXA-523|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-523 NG_051473:1-825,0
,atgataaaaagttcgtggcgtaaaattgcaatgctagccgccgccgttccgctgctgctggcgagcggcgcactgtgggccagtaccgatgctatccatcagaagctgacagatctcgagaagcgttcaggcggcaggttgggcgtggcgctaatcaacacggcagataattctcaaatcttatatcgcggcgacgagcgttttgccatgtgcagcaccagtaaagtgatggccgccgccgcggtattaaaacagagcgaaagcaataaagaggtggtaaataaaaggctggagattaacgcagccgatttggtggtctggagtccgattaccgaaaaacatctccagagcggaatgacgctggctgagctaagcgcggcgacgctgcaatatagcgacaatacggcgatgaatctgatcatcggccaccttggcgggccggaaaaagtcaccgccttcgcccacagtatcggcgatgccacctttcgtctcgatcgtacggagcccacgctgaataccgccatcccgggcgatgagcgtgataccagcacgccgctggcgatggctgaaagcctacgcaagctgacgcttggcgatgcgctgggcgaacagcaacgcgcccagttagtcacctggctgaaaggcaataccaccggcgggcaaagcattcgcgcgggcctgcctgaaagctgggtggtcggcgataaaaccggcgccggagattacggcaccaccaatgatattgcggttatctggccggaagatcacgctccgctggtattagtcacctactttacccagccgcagcaggatgcgaaaaaccgcaaagaggtgttagccgcagcggcaaaaatcgtgaccgaagggctttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_5279,Drugs,MEG_5279|Drugs|betalactams|Class_A_betalactamases|OXY,1028110179|WP_063864549.1|NG_049850|1|1|blaOXY-2-13|blaOXY-2|class_A_extended-spectrum_beta-lactamase_OXY-2-13 NG_049850:1-873,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccgatttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaaaaatggaaataaaatatacgcaaaaagtggttggggatggaatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4454,Drugs,MEG_4454|Drugs|betalactams|Class_D_betalactamases|OXA,1509794583|WP_122630892.1|NG_062312|1|1|blaOXA-690|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-690 NG_062312:12-836,0
,ATGTCTAACATTCAAAACATGTCCCTGGAGGACATCATGGGAGAGCGCTTTGGTCGCTACTCCAAGTACATTATTCAAGACCGGGCTTTGCCAGATATTCGTGATGGGTTGAAGCCGGTTCAGCGCCGTATTCTTTATTCTATGAATAAGGATAGCAATACTTTTGACAAGAGCTACCGTAAGTCGGCCAAGTCAGTCGGGAACATCATGGGGAATTTCCACCCACACGGGGATTCTTCTATCTATGATGCCATGGTTCGTATGTCACAGAACTGGAAAAATCGTGAGATTCTAGTTGAAATGCACGGTAATAACGGTTCTATGGACGGAGATCCTCCTGCGGCTATGCGTTATACTGAGGCACGTTTGTCTGAAATTGCAGGCTACCTTCTTCAGGATATCGAGAAAAAGACAGTTCCTTTTGCATGGAACTTTGACGATACGGAGAAAGAACCAACGGTCTTGCCAGCAGCCTTTCCAAACCTCTTGGTCAATGGTTCGACTGGGATTTCGGCTGGTTATGCCACAGACATTCCTCCCCATAATTTAGCTGAGGTCATAGATGCTGCAGTTTACATGATTGACCACCCAACTGCAAAGATTGATAAACTCATGGAATTCTTGCCTGGACCAGACTTCCCTACAGGGGCTATTATTCAGGGTCGTGATGAAATCAAGAAAGCTTATGAGACTGGGAAAGGGCGCGTGGTTGTTCGTTCCAAGACTGAAATTGAAAAGCTAAAAGGTGGTAAGGAACAAATCGTTATTATTGAGATTCCTTATGAAATCAATAAGGCCAATCTAGTCAAGAAAATCGATGATGTTCGTGTTAATAACAAGGTAGCTGGGATTGCTGAGGTTCGTGATGAGTCTGACCGTGATGGTCTTCGTATCGCTATCGAACTTAAGAAAGACGCTAATACTGAGCTTGTTCTCAACTACTTATTTAAGTACACCGACCTACAAATCAACTACAACTTTAATATGGTGGCGATTGACAATTTCACACCTCGTCAGGTTGGGATTGTTCCAATCCTGTCTAGCTATATCGCTCACCGTCGAGAAGTGATTTTGGCGCGTTCACGCTTTGACAAAGAAAAGGCTGAGAAACGTCTCCATATCGTCGAAGGTTTGATTCGTGTGATTTCGATTTTGGATGAAGTCATTGCTCTTATCCGTGCTTCTGAGAATAAGGCGGACGCCAAGGAAAACCTCAAAGTTAGCTATGATTTTACGGAAGAACAGGCTGAGGCTATCGTAACTTTGCAACTGTACCGTTTGACCAATACCGATGTGGTTGTCTTGCAGGAAGAAGAAGCAGAGCTTCGTGAGAAGATTGCTATGCTGGCGGCTATTATCGGTGATGAAAGGACTATGTACAATCTCATGAAGAAAGAACTTCGTGAGGTCAAGAAGAAATTTGCAACTCCTCGTTTGAGTTCTTTAGAAGACACTGCGAAAGCAATTGAGATTGATACAGCTAGTCTTATCGCTGAGGAAGATACCTACGTCAGCGTGACCAAGGCAGGTTACATCAAGCGTACCAGTCCACGTTCCTTTGCGGCTTCCACCTTGGAAGAAATTGGCAAGCGTGATGATGACCGTTTGATTTTTGTTCAATCTGCCAAGACAACCCAGCACCTCTTGATGTTCACAAGTCTTGGAAATGTCATCTACAGACCAATCCATGAGTTGGCAGATATTCGTTGGAAGGACATCGGAGAGCATCTGAGCCAAACCATCACAAACTTTGAAACGAATGAAGAAATCCTTTATGTGGAAGTACTGGATCAGTTTGACGATGCGACAACCTACTTTGCAGTGACTCGCCTTGGTCAAATCAAACGGGTAGAGCGAAAAGAATTCACTCCATGGCGGACCTATAGATCTAAGTCTGTCAAGTATGCTAAGCTCAAAGACGATACAGATCAGATTGTAGCAGTGGCTCCGATTAAACTAGATGATGTTGTCTTGGTTAGTCAAAATGGTTATGCCCTGCGTTTCAATATCGAAGAGGTTCCGGTTGTCGGTGCTAAGGCAGCAGGTGTCAAGGCTATGAATTTGAAAGAAGATGATGTCCTCCAATCTGGCTTTATCTGTAATACTTCGTCCTTCTACCTCTTGACCCAGCGTGGAAGCTTGAAACGTGTTTCCATTGAGGAAATTCTAGCAACCAGCCGTGCCAAACGAGGATTACAAGTCTTGCGTGAGTTGAAAAACAAACCGCATCGTGTCTTCTTGGCAGGAGCAGTTGCAGAGCAAGGATTTGTTGGCGATTTCTTCAGTACGGAAGTGGATGTGAACGACCAAACTCTGCTTGTCCAATCCAATAAAGGAACAATCTATGAAAGCCGATTGCAAGACTTGAACTTGTCAGAACGCACTAGCAATGGAAGCTTCATTTCTGACACGATTTCAGATGAAGAAGTTTTTGACGCTTATCTTCAGGAAGTAGTTACTGAAGATAAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5327,Drugs,MEG_5327|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gb|AE005672|+|800699-803171|ARO:3003311|Streptococcus pneumoniae parC conferring resistance to fluoroquinolone [Streptococcus pneumoniae TIGR4] ,3
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctgttccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4700,Drugs,MEG_4700|Drugs|betalactams|Class_D_betalactamases|OXA,1393270471|WP_109791216.1|NG_057616|1|1|blaOXA-654|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-654 NG_057616:1-825,0
,atgtataggattaacgttgcggtcctgtttgggggctgctcagaagaacatactgtatcaataaagtctgcaatggagcttgcggcaaacattgatacggaaaaatatcagcctttttatatcgggatcacaaaatccggtgtttggaaattgtgtgaaaagccctgcctggattgggaacaatatgcaaaatatccggtcgtcttttcgccgggcagaaatacgcatggttttctgatacaaaaagaggatagatatgaaatccaacctgtagatgtagtgttccccatcattcatggaaaattcggagaagatggctcaatacaggggctgctcgaattatcgggtattccctatgttggctgtgatattcaaagctccgtgatttgcatggataaatcgcttgcttatactaccgtaaaaaatgcaggtattgaagtccctgattttcagattatccaggacggtgacagcccgaaaaccgagtgctttagctttcctctttttgtgaaacctgcacgctctggttcttcttttggagtaaataaagtagataaagcggaggatttatgcgctgccataaacgaagcaaggcaatatgacagaaaagtattgattgagcaggccgtttctggaagtgaggttggctgcgccgtattgggaaccggtacggacctaattgtcggagaggtcgatcagattagcctaaaacatggcttttttaagattcatcaggaagcacagcctgaaaaggggtctgaaaatgcaacgatcgaagtgccggctgatcttccggcaaaggtaagagagcggattcagaaaacagctaagaagatttatcaggtgctcggctgcagaggactggcccgtattgatttgtttttgcgggaggacgggcatattgtcctcaatgaagtgaataccatgcccggttttacttcgtatagccgctatccctgtatgatgactgcggcaggctttaccctttcggaactcattgatcgtttgattgaactggcgctcaggaggtag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7383,Drugs,MEG_7383|Drugs|Glycopeptides|VanD-type_resistance_protein|VAND,1028100558|WP_063856693.1|NG_048364|1|1|vanD|vanD|D-alanine--(R)-lactate_ligase_VanD NG_048364:101-1132,5
,ATGCGCGGTAAACACACTGTCATTCTGGGCGCGGCACTGTCGGCGCTTTTTGCCGGCGCGGCTGGCGCGCAGATGCTCGAATGCACGCTGGTCGCCGATGCCGCGAGCGGTCAGGAGCTTTACCGCAAGGGTGCCTGTGACAAGGCCTTCGCGCCAATGTCGACGTTCAAGGTGCCGTTGGCCGTCATGGGCTACGATGCTGGCATTCTTGTGGACGCGCATAATCCGCGCTGGGACTACAAGCCGGAATTCAATGGCTACAAATTCCAGCAGAAAACCACCGACCCTACGATCTGGGAAAAGGACTCGATCGTCTGGTATTCGCAGCAATTGACCCGCAAGATGGGGCAAAAACGCTTTGCCGCATACGTGGCCGGGTTCGGCTATGGCAATGGCGATATCTCCGGTGAGCCCGGTAAGAGCAACGGCCTGACGCATTCATGGCTGGGCTCCTCGCTGAAGATTTCKCCGGAAGGACAGGTGCGGTTCGTACGCGATCTGCTGTCGGCGAAACTGCCGGCTTCGAAAGACGCCCAGCAAATGACGGTTTCCATCCTGCCGCATTTCGCGGCCGGTGATTGGGCTGTGCAGGGCAAGACCGGCACCGGCTCGTTCATCGACGCCAGGGGTGCGAAGGCGCCGCTCGGATGGTTCATCGGCTGGGCGACGCACGAGGAACGCCGCGTCGTCTTCGCCCGCATGACTGCGGGCGGGAAGAAGGGCGAGCAACCCGCCGGACCGGCTGCCCGCGACGCCTTCCTCAAGGCATTGCCGGATCTCGCGAAAAGGTTCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4751,Drugs,MEG_4751|Drugs|betalactams|Class_D_betalactamases|OXA,(Bla)OXA-45:AM849110:2553-3347:795,0
,atgcagtactccattcgctcggttcgtgtttcggatacatctgattggttacgccttcgcaacctcctgtgggaaggggatgaccacgaaaccgagatcgcccagtttttcgccggagccctggccgagcccaacgaagtgctggtagcccatgaagatgcgggggccgttgttgggcatgtcgagttatccatccgcgaggatgtcgcagggctggaaggcatcagagcgggctatatcgaaggcctgtacatcgagcaggcccatcgctcgtccagcgtcgcgacgcagttactacagcactccgagcaatgggcccaaagtcagggatgccgggcgtttgcatcggatcgagaggatcgcctgatcatccataagtggttttctgtgggtccgctttctaacccttcattccagcggaccgccttcggcggccgctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_178,Drugs,MEG_178|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502103|WP_071846255.1|NG_052286|1|1|aacA34|aacA34|aminoglycoside_6'-N-acetyltransferase_AacA34 NG_052286:101-541,2
,ATGACCGACGCAACCATCCGCCACGACCACAAATTCGCCCTCGAAACCCTGCCGGTAAGCCTTGAAGACGAAATGCGCAAAAGCTATCTCGACTACGCCATGAGCGTCATTGTCGGGCGCGCGCTGCCGGACGTTCGCGACGGTCTCAAGCCGGTACACCGCCGCGTACTGTACGCGATGCACGAGCTGAAAAACAACTGGAATGCCGCCTACAAAAAATCGGCGCGCATTGTCGGCGACGTCATCGGTAAATACCACCCCCACGGCGATACCGCCGTATACGACACCATCGTCCGTATGGCGCAAAATTTCGCTATGCGTTATGTGCTGATAGACGGACAGGGCAACTTCGGATCGGTGGACGGGCTTGCCGCCGCAGCCATGCGCTACACCGAAATCCGCATGGCGAAAATTTCCCACGAAATGCTGGCAGACATTGAGGAAGAAACCGTCAATTTCGGCCCGAACTACGACGGTAGCGAACACGAGCCGCTTGTACTGCCGACCCGTTTCCCCACACTGCTCGTCAACGGCTCGTCCGGCATCGCCGTCGGCATGGCGACCAATATCCCGCCGCACAACCTTTCTGATACCGTCAATGCCTGCCTGCGCCTGCTCGATGCACCCGACACCGAAATCGACGAACTGATCGACATTATCCAAGCCCCCGACTTCCCGACCGGGGCAACCATCTACGGCTTGAGCGGCGTGCGCGAAGGCTATAAAACAGGCCGCGGCCGCGTCGTTATGCGCGGTAAGACCCATATCGAACCCATAGGCAGAAACGGCGAACGCGAAGCCATCGTTATCGACGAAATCCCCTATCAGGTCAACAAAGCCAAGCTGGTCGAGAAAATCGGCGATTTGGTTCGGGAAAAAACACTGGAAGGCATTTCCGAGCTCCGCGACGAATCCGACAAATCCGGTATGCGCGTCGTTATCGAGCTGAAACGCAACGAAAATGCCGAAGTCGTCTTAAACCAACTCTACAAACTGACTCCGCTGCAAGACAGTTTCGGCATCAATATGGTGGTTTTGGTCGACGGACAACCGCGCCTGTTGAACCTGAAACAGATTCTCTCCGAATTCCTGCGCCACCGCCGCGAAGTCGTTACCCGACGTACGCTTTTCCGGCTGAAGAAGGCACGCCATGAAGGGCATATTGCCGAAGGCAAAGCCGTCGCACTGTCCAATATCGATGAAATCATCAAGCTCATCAAAGAATCGCCCAACGCAGCCGAGGCCAAAGACAAACTGCTTGCGCGCCCTTGGCGCAGCAGCCTCGTTGAAGAAATGCTGACGCGTTCCGGTCTGGATTTGGAAATGATGCGTCCGGAAGGATTGGCTGCAAACATCGGCTTGAAAGAGCAAGGTTATTACCTGAGCGAGATTCAGGCAGATGCTATTTTACGCATGAGCCTGCGAAACCTGACCGGCCTCGATCAAGAAGAAATTGTCGAAAGCTACAAAAACCTGATGGGTAAAATCATCGACTTTGTGGATATCCTCTCCAAACCCGAACGCATTACCCAAATCATCCGCGACGAACTGGAAGAAATCAAAACCAACTATGGCGACGAACGCCGCAGCGAAATCAACCCGTTCGGCGGCGACATTGCCGATGAAGACCTGATTCCGCAACGCGAAATGGTCGTTACCCTGACACATGGCGGCTATATCAAAACCCAGCCGACCACCGACTATCAGGCGCAGCGTCGCGGCGGGCGCGGCAAACAGGCGGCTGCCACCAAAGACGAAGACTTTATCGAAACCCTGTTTGTTGCCAACACGCATGATTATTTGATGTGCTTTACCAATTTGGGCAAGTGTCATTGGATTAAGGTTTACAAACTGCCCGAAGGCGGACGCAACAGCCGCGGCCGTCCGATTAACAACGTCATCCAGTTGGAAGAAGGCGAAAAAGTCAGCGCGATTCTGGCAGTACGCGAGTTCCCCGAAGACCAATACGTCTTCTTCGCCACCGCGCAGGGAATGGTGAAAAAAGTCCAACTTTCCGCCTTTAAAAACGTCCGCGCCCAAGGCATTAAAGCCATCGCGCTCAAAGAAGGCGACTACCTCGTCGGCGCTGCGCAAACAGGCGGTGCGGACGACATCATGCTGTTCTCCAACTTAGGTAAAGCCATCCGCTTCAACGAATACTGGGAAAAATCCGGCAACGACGAAGCGGAAGATGCCGACATCGAAACCGAAATTTCAGACGGCATCGAAGATGAAACCGCCGACAGCGAAAACGCACTGCCGAGCGGCAAACACGGTGTTCGCCCGTCCGGTCGCGGCAGCGGCGGTTTGCGCGGTATGCGCCTGCCTGCCGACGGCAAAATCGTCAGCCTGATTACCTTCGCCCCTGAAACCGAAGAAAGCGGTTTGCAAGTTTTAACCGCCACCGCCAACGGATACGGAAAACGCACCCCGATTGCCGATTACAGCCGCAAAAACAAAGGCGGGCAAGGCAATATTGCCATTAACACTGGCGAGCGAAACGGCGATTTGGTCGCCGCAACCTTGGTCGGCGAAACCGACGATTTGATGCTGATTACCAGCGGCGGCGTACTTATCCGCACCAAAGTCGAACAAATCCGCGAAACCGGCCGCGCCGCAGCAGGCGTGAAACTGATTAACTTGGACGAAGGCGAAACCTTGGTATCGCTGGAACGTGTTGCCGAAGACGAATCCGAACTCTCCGACGCTTCTGTAATTTCCAATGTAACCGAACCGGAAGTCGAGAACTGA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3217,Drugs,MEG_3217|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|738778022|gb|KJ415226.1|1-2751 gi|744797373|gb|CP006869.1|9404-6654 gi|325199235|gb|CP002420.1|921641-918891 gi|66731897|gb|AE002098.2|1409972-1412722,3
,atggacgacagcacgttgcgccggaagtacccgcaccacgagtggcacgcagtgaacgaaggagactcgggcgccttcgtctaccagctcaccggcggccccgagccccagcccgagctctacgcgaagatcgccccccgcgcccccgagaactccgccttcgacctgtccggcgaggccgaccggctggagtggctccaccgccacgggatccccgtcccccgcgtcgtcgagcgcggtgccgacgacaccgccgcgtggctcgtcacggaggccgtccccggcgtcgcggcggccgaggagtggcccgagcaccagcggttcgccgtggtcgaggcgatggcggagctggcccgcgccctccacgagctgcccgtggaggactgccccttcgaccggcgcctcgacgcggcggtcgccgaggcccggcggaacgtcgccgagggcctggtggacctcgacgacctgcaggaggagcgggccgggtggaccggcgaccagctcctggcggagctcgaccgcacccgtcccgagaaggaggacctggtcgtctgccatggcgacctgtgccccaacaacgtcctgctcgaccccgggacctgccgggtcaccggcgtgatcgacgtcggccgcctcggggtcgccgaccgccacgccgacatcgccctggccgcccgcgagctggagatcgacgaggacccctggttcggccccgcctacgccgagcggttcctggagcggtacggcgcccaccgcgtcgacaaggagaagctggccttctaccagcttctcgacgagttcttctga,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1037,Drugs,MEG_1037|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,665529601|WP_031129630.1|NG_047451|1|1|aph(3')-Va|aph(3')-Va|aminoglycoside_O-phosphotransferase_APH(3')-Va NG_047451:101-907,2
,atgcgtaaaaaaatgcagaacacattgaagctgttatccgtgattacctgtctggcagcaactgcccaaggtgctctggctgctaatatcgatgagagcaaaattaaagacaccgttgatgacctgatccagccgctgatgcagaagaataatattcccggtatgtcggtcgcagtgaccgtcaacggtaaaaactacatttataactatgggttagcggcaaaacagcctcagcagccggttacggaaaatacgttatttgaagtgggttcgctgagtaaaacgtttgctgccaccttggcgtcctatgcgcaggtgagcggtaagctgtctttggatcaaagcgttagccattacgttccagagttgcgtggcagcagctttgaccacgttagcgtactcaatgtgggcacgcatacctcaggcctacagctatttatgccggaagatattaaaaataccacacagctgatggcttatctaaaagcatggaaacctgccgatgcggctggaacccatcgcgtttattccaatatcggtactggtttgctagggatgattgcggcgaaaagtctgggtgtgagctatgaagatgcgattgagaaaaccctccttcctcagttaggcatgcatcacagctacttgaaggttccggctgaccagatggaaaactatgcgtggggctacaacaagaaagatgagccagtgcacgtgaatatggagattttgggtaacgaagcttatggtatcaaaaccacttccagcgacttgttacgctacgtgcaagccaatatggggcagttaaagcttgatgctaatgccaagatgcaacaggctctgacagccacccacaccggctatttcaagtcgggtgagattactcaggatctgatgtgggagcagctgccatatccggtttctctgccgaatttgctcaccggtaacgatatggcgatgacgaaaagcgtggctacgccgattgttccgccgttaccgccacaggaaaatgtgtggattaataagaccggatcaactaacggcttcggtgcctatattgcgtttgttcctgctaagaagatggggatcgtgatgctggctaacaaaaactactcaatcgatcagcgagtgacggtggcgtataaaatcctgagctcgttggaagggaataagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_384,Drugs,MEG_384|Drugs|betalactams|Class_C_betalactamases|ACC,746123694|WP_039189232.1|NG_048589|1|1|blaACC-1a|blaACC|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACC-1a NG_048589:1-1173,0
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattgcaatacaagtggagtttttataacttttgatggaaaacattatgcaagtaatgattttaaaagagctaaacaagccttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatgatgtagttagagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaggcttaaataaactttcttatggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcgcaaaattctttacctttttccaaaaaaagtcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattgctagaaaaatatctagcaatcataacaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4579,Drugs,MEG_4579|Drugs|betalactams|Class_D_betalactamases|OXA,1391852924|WP_109545109.1|NG_057543|1|1|blaOXA-640|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-640 NG_057543:1-750,0
,ATGTCAGCCCTGGCCGCACCTGGCCTCAGCGCTATCCGTGACTCACTCCGGTGCCCGATCTGCGCCGGTCGCCTCGAACTGACACCGGGGGCACTGCGTTGTCGTCAGCGACACACCTTCAACATCGCTCGGCACGGCTACGTCAGCCTACTGTCTGGGACTAATGCGATCAGCGGGGATGATGCGCCGATGATCCAAGCTCGAGAACGTTTCCTCGCGACCGGCGCCTACGAGCCGATACGCCGGGCCGTCTCGACGATGGTGTCTCATACGATCCCTCGTGATGGCATAGTTCTCGATGTTGGCTGTGGTACCGGCTACTACCTCGCCGGTGCGCTCGACAAAGTGACCGGGGCTCGCGGCCTGGGGCTTGACTCCTCGGTGCGTGCGCTGCGGGTCGCTGCGCGCGTCCACGAGCGAGCAGCCGCAGCGAGCTGGGACGTGTTCCGCCCGTATCCGTTGGCCGACCAGTCGGTGGATGCTGTGCTGAACATGTTCGCTCCGCGCAACCCCGGCGAGTTTCACCGGGTCCTCCGCCCGAACGGCAGCCTGATCGTGGTGCGTCCGACGGTCGACCACCTGGCCGAGTTGCGCCGCGATGTGCCCGACTCGGTGACTATCGATGTTTCCAAGGAGCAACGCCTGCATGACGCCCTGGCACCGTTCTTCGAACAGGAGCGAGATCAACACGTCGGCTACATCGCAGAGATTGAACCGCAAACGGCTCGCGATCTGCTCGGAATGACGCCGAGTGCGCGGCACATCACCCCGGCAGAGGTCTCGGACGACGACCTGCCCGAGCGAGTCACCATATCCGTGCTTGTCAGCTCATACCGGCTACGGGAGACTTGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_4107,Drugs,MEG_4107|Drugs|MLS|23S_rRNA_methyltransferases|MYRA,gi|4583389|gb|AF121000.1|AF121000|10981-11832,7
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatccggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggtatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccttcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgaacactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6199,Drugs,MEG_6199|Drugs|betalactams|Class_A_betalactamases|SHV,1509794564|WP_122630873.1|NG_062290|1|1|blaSHV-218|blaSHV|class_A_beta-lactamase_SHV-218 NG_062290:1-861,0
,atgatgaaaaaatcgttatgctgcgcgttgctgctgacagcctctttctccacgtttgccgccgcaaaaacagaacaacagattgccgatatcgtaaaccgtaccatcacaccgctgatgcaagaacaggctattccgggtatggccgtagcaattatctaccagggaaaaccctattactttacctgggggaaagccgatatcgccaatgaccgccccgtcacccggcaaacgctgtttgagcttggatcggtaagtaagacgtttaacggtgtgctgggcggcgatgctatcgcccgtggtgaaattaagctcagcgatccggtcacccaatactggcccgaattaactggcaaacaatggcagggtatcagcctgctgcacctggccacctatacggcgggtggtctgccgcttcaggtacctgacgacgttacagataaagcggcattactgcgcttttatcaaaactggcagccgcaatgggtcccgggagctaaacgcctgtatgctaactccagtattggtctgtttggcgcactggcggtgaaaccttcaggaataggctatgaagaggcgatgaccaaacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccacagagcgaacaaaaggattatgcctggggttatcgcgaagggaagcccgtgcacgtatctccgggtcagcttgatgccgaagcctacggggtgaaatccagccttgtcgatatgactcgttgggttcaggccaacatggacgccagccaggtgcaggagaaaacgctccgacagggaattgaaattgcacaggctcgttactggcatattggcgacatgtaccagggattaggttgggagatgctgaactggccggtgaatgccgactcgataatcaacggtagcgacagtaaagtcgcgttagcggcgcttcccgtcgttgaggtcaatccgcccgcccctgcagtgaaagcctcatgggtgcacaaaaccggctccactggcggatttggcagctacgttgcgttcgttccggaaaaaaatctcggcatcgtgatgctggcaaacaaaagctacccaaaccctgctcgcgtcgaggccgcctggcgtattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1788,Drugs,MEG_1788|Drugs|betalactams|Class_C_betalactamases|CMY,1509794528|WP_122630837.1|NG_062243|1|1|blaCMY-159|blaCMY|class_C_beta-lactamase_CMY-159 NG_062243:1-1146,0
,atgtacaaatttttaagcagtattttactacttgcatctacgactttcgtattcgctcaatccaaacccttaaaggttgaaaaactacaggataacatctatgtttacattacgtatcaaatgtataacggtgtggaatattcgtccaatgccttatatatagtaacagatgagggagcgattctaatcgatacgccttgggataaagagcaaaatgaccctttagtagaacatatcagaaaacaacacaacaaagaggtaaaatgggtgattacgacacactttcatgaagatcgctcaggaggattggactatttcagaaaagcaggggctgaaacctatacttatgcattaacgaatgaaattctcaaaaacagaaatgaaccccaagcagaatttacttttggcaaggaaaaacatttcacttttggcaaagaagagatcgtagtttattttttaggagaagggcatagcaaggataatacagtagtatggtttccaaaagaaaaagttttatacggaggttgtttgattaaaagtgctgaagcaacagacattggttatattggagatggtaatactgatgcatggcctgcaacaatcaaagcagttaaaagcaagtttaaacaagcgaaaacagtaattccagggcatgataattggaatcaatccggtcatatcgagaatacagaacgcattttatcagcttacaatgcacaaaaagtaaaaaacaacaagcaaatataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4001,Drugs,MEG_4001|Drugs|betalactams|Class_B_betalactamases|MOC,985813815|WP_060874262.1|NG_051495|1|1|blaMOC-1|blaMOC|subclass_B1_metallo-beta-lactamase_MOC-1 NG_051495:1-747,0
,atgaacgagaaaaatataaaacacagtcaaaagtttattacttcaaaacataatatagataaaataatgacaaatataagattaaatgaacatgataatatctttgaaatcggctcaggaaaaggcgattttacccttgaattagtacagaggtgtaatttcgtaactgccattgaaatagaccataaattatgcaaaactacagaaaaaaaacttgttgatcacgataatttccaagttttaaacaaggatatattgcagtttaaatttcctaaaaaccaatcctataaaatatttggtaatataccttataacataagtacggatataatacgcaaaattgtttttgatagtatagctgatgagatttatttaatcgtggaatacgggtttgctaaaagattattaaatacaaaacgctcattggcattatttttaatggcagaagttgatatttctatattaagtatggttccaagagaatattttcatcctaaacctaaagtgaatagctcacttatcagattaaatagaaaaaaatcaagaatatcacacaaagataaacagaagtataattatttcgttatgaaatgggttaacaaagaatacaagaaaatatttacaaaaaatcaatttaacaattccttaaaacatgcaggaattgacgatttaaacaatattagctttgaacaattcttatctcttttcaatagctataaattatttaataagtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2817,Drugs,MEG_2817|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,695262052|WP_032489011.1|NG_047812|1|1|erm(C)|erm(C)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(C) NG_047812:101-835,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccactattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5510,Drugs,MEG_5510|Drugs|betalactams|Class_C_betalactamases|PDC,1028110211|WP_063864581.1|NG_049913|1|1|blaPDC-40|blaPDC|class_C_beta-lactamase_PDC-40 NG_049913:1-1194,0
,ATGACCGATCGTTCTGAGACGGAGCTCCCTCCCTCCGTCAATACCCAGCCCTTCGATAATACCAAGGTAAAACGCACCTCTTTCTCTATATTAGGTGCTATTAGCGTATCTCACTTACTTAACGATATGATCCAGTCGCTGATTCTGGCGATTTATCCGCTATTACAAGCCGAGTTTTCGCTGAGTTTTGCGCAGATTGGATTAATCACCCTCACTTATCAGCTTACCGCCTCATTATTACAGCCACTTATTGGTCTTTATACCGATAAGCATCCGCAGCCCTATTCACTGCCGATTGGCATGGGTTTCACCTTATCAGGTATCTTGCTGCTTGCGGTTGCCACGACTTTCCCAGGTGGTTTTACATGGCATGCGGCATTAGTCGGAACCGGTTCTTCGGTCTTCCACCCAGAATCCTCACGCGTAGCCGCTAGGCTACCGGTGGCCGCCACGGTATGGCTCAGTCTATTTTTGGGTGGGAGGCAATTTCGGCAGCGCCTTGGCCCACTATTAGCCGCGATCCTTATCGCACCTTACGGTAAAGGCAATGTAGGTTGGTTTTCACTCGCGGCACTGCTGGCTATTGTGGTGCTGTTGCAGGTCAGTAAATGGTATCAGCAACAACAAAGAGCAACCTATGGCAAAGTAGTAAAAGTCTCATCGGCCAAAATACTGCCTAAAAAGACGGTTATTAGCGCCCTAGCTATCTTAATGGTGCTGATATTCTCTAAATACTTCTACTTGACCAGTATTAGTAGCTATTACACCTTTTATTTGATGCATAAGTTTGGTGTTTCGGTACAAAATGCCCAAATACATTTATTTGTCTTCTTATTCGCAGTGGCCGCTGGCACCATCATTGGCGGCCCTCTTGGCGATAGGATAGGTCGAAAGTATGTTATTTGGGGGTCAATATTGGGCGTTGCGCCATTTACCCTTATTTTACCCTACGTTTCTCTGTATTGGACCGGGGTTTTAACCGTGATCATTGGCCTTATCCTTGCCTCTGCCTTCTCGGCAATACTGGTGTATGCGCAAGAGCTTATTCCGGGTAAAGTGGGCATGGTATCCGGTCTATTCTTCGGTTTTGCTTTCGGTATGGGGGGGTTAGGTGCGGCTGTACTAGGGTATGTTGCTGATTTAACCAGTATTGAACTGGTTTATCAAATATGCGCCTTCTTACCATTACTGGGGATAATTACGGTCTTCCTGCCCAATATAGAAGATAAGTAA,subunit of efflux pump conferring antibiotic resistance,antibiotic efflux,Multi-drug_resistance,MEG_6083,Drugs,MEG_6083|Drugs|Multi-drug_resistance|Multi-drug_MFS_efflux_pumps|ROSA,gi|1197638|gb|U46859.1|YEU46859|25527-24295,1
,ATGTACGTGATCATGGACCGTGCGTTGCCGTTTATTGGTGATGGTCTGAAACCTGTTCAGCGCCGCATTGTGTATGCGATGTCTGAACTGGGCCTGAATGCCAGCGCCAAATTTAAAAAATCGGCCCGTACCGTCGGTGACGTACTGGGTAAATACCATCCGCACGGCGATAGCGCCTGTTATGAAGCGATGGTCCTGATGGCGCAACCGTTCTCTTACCGTTATCCGCTGGTTGATGGTCAGGGGAACTGGGGCGCGCCGGACGATCCGAAATCGTTCGCGGCAATGCGTTACACCGAATCCCGGTTGTCGAAATATTCCGAGCTGCTATTGAGCGAGCTGGGGCAGGGGACGGCTGACTGGGTGCCAAACTTCGACGGCACTTTGCAGGAGCCGAAAATGCTACCTGCCCGTCTGCCAAACATTTTGCTTAACGGCACCACCGGTATTGCCGTCGGCATGGCGACCGATATTCCACCGCATAACCTGCGTGAAGTGGCTCAGGCGGCAATCGCATTAATCGACCAGCCGAAAACCACGCTCGATCAGCTGCTGGATATCGTGCAGGGGCCGGATTATCCGACTGAAGCGGAAATTATCACTTCGCGCGCCGAGATCCGTAAAATCTACGAGAACGGACGTGGTTCAGTGCGTATGCGCGCGGTGTGGAAGAAAGAAGATGGCGCGGTGGTTATCAGCGCATTGCCGCATCAGGTTTCAGGTGCGCGCGTACTGGAGCAAATTGCTGCGCAAATGCGCAACAAAAAGCTGCCGATGGTTGACGATCTGCGCGATGAATCTGACCACGAGAACCCGACCCGCCTGGTGATTGTGCCGCGTTCCAACCGCGTGGATATGGATCAGGTGATGAACCACCTCTTCGCTACCACCGATCTGGAAAAGAGCTATCGTATTAACCTTAATATGATCGGTCTGGATGGTCGTCCGGCGGTGAAAAACCTGCTGGAAATCCTCTCCGAATGGCTGGTGTTCCGCCGCGATACCGTGCGCCGCCGACTGAACTATCGTCTGGAGAAAGTCCTCAAGCGCCTGCATATCCTCGAAGGTTTGCTGGTGGCGTTTCTCAATATCGACGAAGTGATTGAGATCATTCGTAATGAAGATGAACCGAAACCGGCGCTGATGTCGCGGTTTGGCCTTACGGAAACCCAGGCGGAAGCGATCCTCGAACTGAAACTGCGTCATCTTGCCAAACTGGAAGAGATGAAGATTCGCGGTGAGCAGAGTGAACTGGAAAAAGAGCGCGACCAGTTGCAGGGCATTTTGGCTTCCGAGCGTAAAATGAATAACCTGCTGAAGAAAGAACTGCAGGCAGACGCGCAAGCCTACGGTGACGATCGTCGTTCGCCGTTGCAGGAACGCGAAGAAGCGAAAGCGATGAGCGAGCACGACATGCTGCCGTCTGAACCTGTCACCATTGTGCTGTCGCAGATGGGCTGGGTACGCAGCGCTAAAGGCCATGATATCGACGCGCCGGGCCTGAATTATAAAGCGGGTGATAGCTTCAAAGCGGCGGTGAAAGGTAAGAGCAACCAACCGGTAGTGTTTGTTGATTCCACCGGTCGTAGCTATGCCATTGACCCGATTACGCTGCCGTCGGCGCGTGGTCAGGGCGAGCCGCTCACCGGCAAATTAACGTTGCCGCCTGGGGCGACCGTTGACCATATGCTGATGGAAAGCGACGATCAGAAACTGCTGATGGCTTCCGATGCGGGTTACGGTTTCGTCTGCACCTTTAACGATCTGGTGGCGCGTAACCGTGCAGGTAAGGCTTTGATCACCTTACCGGAAAATGCCCATGTTATGCCGCCGGTGGTGATTGAAGATGCTTCCGATATGCTGCTGGCAATCACTCAGGCAGGCCGTATGTTGATGTTCCCGGTAAGTGATCTGCCGCAGCTGTCGAAGGGCAAAGGCAACAAGATTATCAACATTCCATCGGCAGAAGCCGCGCGTGGAGAAGATGGTCTGGCGCAATTGTACGTTCTGCCGCCGCAAAGCACGCTGACCATTCATGTTGGGAAACGCAAAATTAAACTGCGCCCGGAAGAGTTACAGAAAGTCACTGGCGAACGTGGACGCCGCGGTACGTTGATGCGCGGTTTGCAGCGTATCGATCGTGTTGAGATCGACTCTCCTCGCCGTGCCAGCAGCGGTGATAGCGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5363,Drugs,MEG_5363|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|985000614|gb|CP014225.1|1363107-1360915 gi|958627747|gb|CP013253.1|257424-259616 gi|939732440|gb|CP011343.2|3140979-3138787 gi|939731527|gb|CP011342.2|3141724-3139532 gi|937526251|gb|CP012870.1|1475749-1477941 gi|937521852|gb|CP012869.1|1475749-1477941 gi|937517453|gb|CP012868.1|1475749-1477941 gi|932857508|emb|LN877770.1|3990239-3988047 gi|923416119|gb|CP011113.1|3122625-3120433 gi|899729770|gb|CP012127.1|3140353-3138161,3
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggactgcttccagcgctacaccagcgcgttcggctacggcaatgcggacgtctccggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaaggtggtgaaccggcaattgccggtcaaggccgccgcctatgagctggcggacaacctcttcgaggtgggccaggccgatggctggcgcctgtatggcaagaccggcaccggttcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggctcgcaaggatggccgccaactggtgtacgcccgcctgctgcaggacgagcgcgccacccagcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4544,Drugs,MEG_4544|Drugs|betalactams|Class_D_betalactamases|OXA,1625655396|WP_136512073.1|NG_064733|1|1|blaOXA-114k|blaOXA-114_like|class_D_beta-lactamase_OXA-114k NG_064733:1-828,0
,atgaaaattattaatattggagttttagctcatgttgatgcgggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacagaggtacaacgaaaacggataatacgcttttagaacgtcagagaggaattacaattcagacggcgataacctcttttcagtggaaaaatactaagataaacatcatagacacgccaggacatatggattttttagcagaagtatatcgttcattatcagtattagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattgtttcatgcacttaggaaaataggtattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgcggaaattgtaatcaaacagaaggtagaactgcatcctaatatgcgtgtaatgaactttaccgaatctgaacaatgggatatggtaatagaaggaaatgattaccttttggagaaatatacgtctgggaaattattggaagcattagaactcgaacaagaggaaagcataagatttcataattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacggctgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctgcgatattatgtggattctgcgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctgctgcaagaaaagtatcatgtggagatagaaataaaagagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagttccaccgaatcctttctgggcttccattggtctatctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaacttcctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7113,Drugs,MEG_7113|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,504199711|WP_014386813.1|NG_048242|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048242:101-2020,4
,atgaaaggattttttagaataaagagcgtggtttgcggagtgtttttactgatgatttcagtcaatgcttttgctcagaaaagtgaactacgggaaaagcttcagcgtattgtcaatgcacattcagcgaccattggattctcgctgacagatctccggaatggagataccttaacggttaacggtacaaaacatttacccatgcaaagtgtctataaatttcatcttgcacttgccgttttagatcaggttgatcagggtaagttaaagctggatcagaaaataatggttaaaaaaagtgacttgttaccagatacctggagcccgttaagagataaatacccgaacggagaagttgaaattcctttgtcagaaattttaagttttacagtttcgcaaagtgataacaatggttgtgatatcctgttcaggttgattggcggccctgcaaaagtaaaccggtatattcatcatcttgggataaaagatgtagccattacagctactgaagaacaaatgcaccagaatgaccagatccagtttaccaattggactacccctcaggctgctacagagttactgggactgttttatgctaaaaaaatactttctccggcatcccatgaatttttatgtaaggtcatgaccgaaacgtctaccggagctgacaaaattaaaggtttattgcctgcaggtactttagccgcccataaaaccggtagctcaggcgctaataaatcagggctgacagcagcttccaatgatattggcattgtaactcttcctgacggaaaacattttgccgttgctgcattcgtgtctatgactaaagaagatgaaaaagcaactgacctgattattgcagagcttactaaagcgagctgggattacctgaccacagggaaaccataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3649,Drugs,MEG_3649|Drugs|betalactams|Class_A_betalactamases|LUS,754464290|WP_041881964.1|NG_055472|1|1|blaLUS-1|blaLUS|class_A_beta-lactamase_LUS-1 NG_055472:101-1012,0
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcgaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagcaggagatgagcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacgggggccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3092,Drugs,MEG_3092|Drugs|betalactams|Class_A_betalactamases|GES,1028105363|WP_063860512.1|NG_049130|1|1|blaGES-27|blaGES|class_A_beta-lactamase_GES-27 NG_049130:1-864,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtgcgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5592,Drugs,MEG_5592|Drugs|betalactams|Class_C_betalactamases|PDC,1035157537|WP_064511502.1|NG_050825|1|1|blaPDC-152|blaPDC|class_C_beta-lactamase_PDC-152 NG_050825:1-1194,0
,ATGGAGAAAATAATAGACATAACTGTTTTTGGCTGCGAGCCAGACGAAATGGAGGTTTTTCAAAAGATTTCTTATGAGCTTGGCGTTACGGCCACACTCATAAAAGATTCTATATCAGAAAGCAATGCTGGATTAGCTAATGGATGCCGGTGTGTAAGCGTAAGCCATAAAGCGGAGCTATCAGAACCGATTCTTCTTGCACTAAAAAATGCAGGGGTAAAATATATCAGTACCCGGAGCATTGGCTTTAACCATATTGATATACAGGCGGCTGGGTTACTGGGTATGGTTGTTGGTACAGTAGAATACTCGCCGGGAAGTGTGGCCGATTATACCGTCATGCTGATGCTTATGCTGATGCGCGGCACAAAGTCGATTCTGCGTGAAACCCAGAGGCAGAATTATTGCCTGAATGACCTGCGCGGAAAAGAACTGCGGGATATGACCGTGGGTGTGTTAGGAACTGGACGAATCGGACAGGCAGTCATGGAACGTCTGGAGGGATTCGGCTGTAAGGTATTGGCGTATGACCGAAATCAAAAAGCAGGAGCGGACTATGTTTCGTTTCATGAGCTGCTGAAAAAAAGTGACATTGTTACACTGCATATCCCGTTGGCGGAGGATACCCGCCATATGATTGGCTATGAAGAGCTGGAAATGATGAAGCAGGAGGCGCTTCTGATCAATACAGGGCGGGGCGCTTTAGTGGATACCGCAGCATTGGTAGAAGCATTAAAAGGACAGAAAATCGGCGGCGCCGCCCTGGATGTTTTAGAGGGCGAAGAAGGTATCTTTTATCATGACTGCACCCAAAGAAGGATAGAACATCCTTTCCTGTCGGTCCTGCAGGGAATGCCGAATGTCATTGTTACGCCGCACACAGCCTATCACACGGAACGGGTGTTGGTTGACACGGTCAGAAATACTATTAGAAATTGTTTGAACTTTGAAAGGAGTCTGGGAAATGTTTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7428,Drugs,MEG_7428|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,gi|5759260|gb|AF175293.1|AF175293|3115-4086,5
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaactctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactctccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6210,Drugs,MEG_6210|Drugs|betalactams|Class_A_betalactamases|SHV,1028110298|WP_063864668.1|NG_050058|1|1|blaSHV-193|blaSHV|class_A_beta-lactamase_SHV-193 NG_050058:1-861,0
,atgattatcagtgagtttgatcgtgataatttggttttacgtgaccaattagccgatcttttgagattgacttggccagatgaatacggtgaacagccgatgaaagaagtagagcgactgctggaagatgaaaggatcgccgtctctgcaatcgaaggagatgagctgattggttttgtcggtgcgattccacaatatggtcaaactggttgggaactgcatcccttagtcgtcgaaagtatgtaccgtaagcaacaagttggtacacgcctagtgagttatctagaaaaagagattgcctcacaaggcggaatcgttgtctatttaggaacggatgatgtggaaaggcaaacaagcttggcgattgaagaagacctgtttgaagatacctttgacaagcttgaaacgattcaaaacaggaaagatcatccttatgaattctatgagaaacttggctatcagatcgttggggtaattccggatgcgaatggctggaataagccagatatttggatggccaaacgaattgctagaaaacatggaagtgaatga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_174,Drugs,MEG_174|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,510802924|WP_016177698.1|NG_052168|1|1|aacA-ENT3|aacA-ENT3|aminoglycoside_6'-N-acetyltransferase NG_052168:101-652,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgaagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5505,Drugs,MEG_5505|Drugs|betalactams|Class_C_betalactamases|PDC,1079344457|WP_070142141.1|NG_052625|1|1|blaPDC-174|blaPDC|class_C_beta-lactamase_PDC-174 NG_052625:101-1294,0
,atgcgccatgcgacaatcctcaacctgtgcggcctcgccgcttccaccctgttcttcgcgacaacatcggccttcgccacggaggcgccggcggagcgcctgaaggctctggtggacgccgccgtgcaaccggtcatgaaggccaatgatatcccgggactggccgtcgccatcactctcaagggcgaaccgcattacttcagttatggggtggcctcgaaggaggacgcccgcaaggtgacccccgagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctacgccctggcccaggacaagatgcgcctcgacgaccgtgccagccggcactggcccgccctgcagggcagccgcttcgacggtatcagcctgctcgacctcggcacctacaccgctggcggcctgccgctacagttccccggtgcggtgcagaaggatccggcgcagatccgcgactattaccgccagtggcaaccgacctacgccccgggcagccaccgccagtactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccattcgagcgcagcatggaacggcagctgttcccggcgctcggcctggagcacacctttatccgggtgcccgccgcgcagcaggggctgtacgcccagggctacggcaaggacgaccgcccgctgcgggtcggacccggtccgctggacgccgaggcctacgggctgaagtccagcgttgcggacctgctgcgcttcgtcgaggccaacctgcaccccgagcgcctggagaagccctgggcgcaggccctcgacgccacccatcgcggctactacaaggtgggcgacatgacccagggcctgggttgggaagcctacgattggccgatcgacctgaggcgcctgcaggcgggcaactcggcgccgatggcgctgcaggcgcacaaggtcgccaggttgccggcgccgcaagccctggacggccagcgcctgctgaacaagaccggctccaccaacggtttcggcgcctacctggcgttcatcccgggacgcgacgtcggcctggtgatcctggccaatcgcaactaccccaatgccgagcgggtgaagatcgcttacgccatcctcagcggcctggaacagcaggccaaggtaccgctggtgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5582,Drugs,MEG_5582|Drugs|betalactams|Class_C_betalactamases|PDC,959911064|WP_058174497.1|NG_057582|1|1|blaPDC-250|blaPDC_var|class_C_beta-lactamase_PDC-250 NG_057582:1-1194,0
,ATGAGCGACCTTGCCAGAGAAATAACACCGGTCAACATCGAGGAAGAGCTGAAAAGCTCCTATCTGGATTATGCGATGTCCGTTATTGTCGGACGTGCGTTACCAGATGTCCGTGATGGACTGAAACCGGTGCACCGTCGCGTACTGTTTGCGATGAATGTACTGGGTAATGACTGGAATAAACCATACAAAAAATCGGCCCGTGTAGTCGGGGACGTTATCGGTAAATACCACCCGCATGGTGACAGCGCGGTCTACGACACTATCGTGCGTATGGCCCAGCCGTTCTCACTGCGCTATATGCTGGTGGATGGGCAGGGTAACTTCGGTTCCGTCGATGGTGACTCCGCCGCGGCGATGCGTTATACCGAAATCCGTATGTCTAAAATTGCTCACGAATTGTTAGCGGATTTAGAAAAAGATACCGTTGACTTCGTGCCTAACTATGATGGTACGGAACAAATTCCGGCTGTTATGCCGACCAGAATCCCTAACCTGCTGGTAAACGGTTCGTCGGGTATTGCGGTAGGGATGGCAACCAATATTCCGCCACATAATCTTTCTGAGGTTATTGATGGCTGTCTGGCTTATATAGAAGATGAAAACATCAGCATTGAAGGGCTGATGGAGTATATCCCTGGCCCAGACTTCCCAACAGCAGCCATTATTAATGGCCGCCGTGGTATTGAAGAGGCTTATCGTACTGGTCGCGGTAAGGTCTATATCCGCGCACGTGCTGAAGTCGAAGCGGATGCCAAAACGGGCCGTGAAACCATTATTGTTCATGAGATCCCGTATCAGGTGAACAAAGCACGGTTGATTGAGAAAATCGCCGAGCTGGTAAAAGAAAAACGTGTCGAAGGCATCAGCGCGTTACGCGATGAGTCTGATAAAGACGGCATGCGCATCGTGATTGAAATCAAACGTGATGCGGTCGGGGAAGTGGTGCTGAATAACCTCTACTCTCTGACACAATTGCAGGTGACTTTCGGTATCAATATGGTGGCCTTGTCTCAGGGGCAACCGAAGCTGCTTAACCTGAAAGACATTCTGGTTGCTTTTGTTCGTCACCGTCGTGAAGTGGTGACTCGCCGTACCATTTTTGAACTGCGTAAAGCACGTGATCGCGCCCATATCCTTGAAGCGTTGGCGATTGCACTGGCTAACATTGATCCGATTATCGAATTGATTCGCCGTGCATCGACCCCTGCGGAAGCAAAAGCCGGTTTGATTGCCAGTCCTTGGGAGTTAGGTAACGTTGCTTCCATGCTGGAACGTGCTGGTGATGACGCGGCCCGCCCTGAGTGGCTGGAAGCGGAATTTGGTATCCGTGACGGTAAATATTACCTTACCGAGCAACAGGCTCAGGCTATTTTGGATCTGCGTTTGCAGAAACTGACAGGTCTGGAGCATGAGAAACTGCTGGATGAGTATAAAGAGCTGCTCACCTTAATTGGCGAGCTGATCTTTATTCTAGAAAATCCGGATCGCCTGATGGAGGTTATCCGCGAAGAATTAGTGGCGATCAAAGAGCAATATAACGATCTTCGTCGCACTGAGATCACCGCGAATACCTCTGATATCAATATTGAAGACCTGATTAATCAAGAAGATGTGGTTGTGACGTTGTCCCATCAGGGCTACGTCAAATACCAGCCGTTGAGTGATTACGAAGCTCAGCGTCGTGGTGGTAAAGGTAAATCTGCTGCACGTATCAAAGAAGAAGACTTTATTGATCGCCTGCTCGTTGCCAATACCCACGATACCATCTTGTGCTTCTCCAGCCGTGGCCGTCTCTATTGGATGAAGGTCTATCAACTGCCGGAAGCCAGCCGTGGGGCTCGTGGCCGTCCCATCGTCAACTTGTTGCCGCTTGAGCCAAATGAGCGTATTACCGCCATTCTGCCTGTGCGCGAATATGAAGAAGGCTGTCATGTCTTTATGGCTACCGCCAGCGGTACTGTGAAGAAAACGGCATTGACGGAGTTCAGTCGCCCACGTAGCGCCGGTATTATCGCCGTTAATTTGAACGAAGGTGATGAGCTTATCGGTGTGGATCTGACGGATGGCAGCAATGAAGTTATGCTGTTCTCAGCATTGGGTAAAGTGGTTCGTTTCCCAGAAGGGCAGGTTCGCTCTATGGGCCGTACCGCAACCGGTGTCCGTGGGATCAACCTCAATGGCGATGATCGGGTTATTTCTCTGATCATTCCTCGTGGTGATGGTGAAATCCTGACCGTAACTGAAAACGGTTATGGTAAGCGTACTGCAGTGGCAGAATATCCAACCAAGTCCCGTGCGACTCAGGGGGTTATCTCCATTAAAGTCAGTGAGCGTAATGGTAAGGTTGTCGGTGCTGTTCAAGTTGCACCAACTGACCAAATCATGATGATCACTGATGCTGGCACACTGGTACGTACTCGCGTATCCGAAGTGAGTGTCGTAGGGCGTAATACCCAAGGTGTGACCCTGATCCGTACCGCAGAAGATGAACATGTTGTTGGTTTGCAACGTGTCGCTGAACCTGAAGAGGATGATGATATCCTTGATGGCGAATCATCAGAAGGTGAAGAGGGCAGCGAAGAAAACGCGGCACTAAATGCACCATCAGATGATGTTGCCGATGAAGACACTGATGCAGAAGACGACACTGATGTAGAAGACGACAACGCATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3224,Drugs,MEG_3224|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|908262105|gb|CP006794.1|2898194-2900869 gi|908258101|gb|CP006754.1|202827-200152 gi|908253871|gb|CP006751.1|343287-340612 gi|908249689|gb|CP006748.1|4286196-4288871 gi|908245216|gb|CP006806.1|3174228-3171553 gi|908241204|gb|CP006758.1|1677739-1680414 gi|908236972|gb|CP006762.1|1041404-1038729 gi|908221924|gb|CP006792.1|1880720-1878045 gi|908217725|gb|CP006783.1|222741-225416 gi|805411710|gb|CP009836.1|2776596-2779271,3
,ATGGATCCTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACATGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6685,Drugs,MEG_6685|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-102:AY029354:3-833:831,0
,atgatgacaaaatccctaagctgtgccctgctgctcagcgtcaccagcgctgcattcgccgcaccgatgtccgaaacacagctggctgaggtggtggaacgtaccgttacgccgctgatgaacgcgcaggccattccgggtatggcggtggcggtaatttatcagggtcagccacactactttaccttcggtaaagccgatgttgcggcgaacaaacccgtcaccccgcaaaccctgtttgagctgggctctataagtaaaaccttcaccggcgtactgggcggcgatgccattgcccggggtgaaatagcgctgggcgatccggtagcaaaatactggcctgagctcacgggcaagcagtggcagggcattcgcatgctggatctggcaacctataccgcaggcggtctgccgttacaggtgccggatgaggtcacggataccgcctctctgctgcgcttttatcaaaactggcagccgcagtggaagccgggcaccacgcgtctttacgctaacgccagcatcggtctttttggtgcgctggcggttaaaccttccggcatgagctatgagcaggccatgacgacgcgggtctttaaacccctcaagctggaccatacctggattaacgtcccgaaagcggaagaggcgcattacgcctggggataccgtgagggtaaagcggtccacgtttcgccagggatgctggacgcggaagcctatggcgtaaaaactaacgtgaaggatatggcgagctggctgatagccaacatgaagccggattctcttcaggctccctcactcaagcaaggcattgctctggcgcagtctcgctactggcgcgtgggggccatgtatcaggggttgggctgggagatgctcaactggccggtcgatgccaaaaccgtcgtcggaggcagtgataacaaggtggcgctggcaccattgcccgtggcagaagtgaatccacccgcgccgccggtcaaagcctcctgggtccataaaacaggctcgacgggcgggtttggcagctacgtggcatttattcctgaaaagcagctcggcattgtgatgctggcgaataaaagctatccgaacccggcacgcgttgaggcggcataccgtatcctcgacgcgctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3949,Drugs,MEG_3949|Drugs|betalactams|Class_C_betalactamases|MIR,765031466|WP_044597278.1|NG_050722|1|1|blaMIR-20|blaMIR|cephalosporin-hydrolyzing_class_C_beta-lactamase_MIR-20 NG_050722:1-1146,0
,gtgagaacacgtttatttcctttattaagtatatctatttcaatttttttaagtgcgtgctcctctccatttatcgaacctaaagacatcctgcctatttctactactgatcaaactcaacaagcgattggctcctattttgatgaagctcagacacagggtgttattgtcattaaggatgggcacaatattgatacttatggtaatgatttaacccgagccaatacattgtatgtacctgcatcaacttttaagatgttaaatgctttaattggtttggaaaacaataaagctacagtcgatgaagtttttaaatgggatgggaaaaagcgttcatattctatatgggaaaaagatatgaatttgggtgaagccatgaagttatcagcggttcctgtatatcaagaactcgcaaaacggataggcgtagatctaatgcaaaaagaagtaaaaagagtcaaatttggtaattcaaatattgggacaaaagttgatgacttttggttggtaggcccattaaagattactcctattcaagaagttgagtttgctgacaaacttgcccatcaagagctaccattcaaacagcaagtacaaaaacaagtccaagatatgctgttaataaaggaagtagagggtaacaaaatttatgcaaagagcgggtggggaatgaatgtcacccctcaagtaggctggttaacaggttgggtggaacaacctaacgggaaaaaaatagctttttcattgaacattgagatgaaaccaaacatgcctggttcagtccgtaatgaaatagctcttaaatcattaaaacgcttaggtattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4628,Drugs,MEG_4628|Drugs|betalactams|Class_D_betalactamases|OXA,1509879091|WP_122634439.1|NG_062355|1|1|blaOXA-679|blaOXA|OXA-667_family_class_D_beta-lactamase_OXA-679 NG_062355:1-831,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactcttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaagactacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5565,Drugs,MEG_5565|Drugs|betalactams|Class_C_betalactamases|PDC,1408841628|WP_111672901.1|NG_060559|1|1|blaPDC-290|blaPDC|class_C_beta-lactamase_PDC-290 NG_060559:1-1194,0
,ATGAATAAAAAAATAAAACTAATTTTTATTTTAATTTTTTCAATAAATTTATTCGCAAATGATGTTGAACTTGAAAATTTATTTAAAAAATACCAAGTTGAAGGAACTTTAGTATTAGAGTCTTTAAATACAAAAAAAGTAGATATTTATAATGAAAAGAGAGCAAATACATCGTTTTCTCCTGCTTCAACATTTAAAATACCAAATACTTTGATAGCTTTAAATGAAGGTGTTGTAAACAAAGATTCTATAATAGTTTGGGATAAAAAAGTAAGAGAATTTGATGCTTGGAATAAAGACCAAACTTTACAATCAGCTTTCAAAAGTTCATGTGTTTGGTGTTATAAAGAGTTCGCTTCAAAAATTGGAGTTGAAAAATATAAAAAGTATCTAAAAGAGCTTAATTATGGAAATAAAACAATAGGCAAAGATGTAACTGATTTTTGGTTGGATGAGAGTTTGAGAATTACAGCTTTTGAAGAGATAAGATTTTTAAAACAATTACAATCAAACAATTTAGCTTTTAAACAAGAAGATATAAATCTTTTAAAAGAGTTGATGATTGATGAAAAAAGCGAAAATTATGTAGTTAGAGCAAAAACAGGTTGGGAAGGAAAATATGGTTGGTATGTTGGTTATGTTGAAACAAAAAATGATGTTTGGTTTTTTGCTTTAAATATCGACACAAAAACAAAAGAAGATTTAGCAAAAAGAAAAGCTTTAACTTTAGAAGCTTTAAAAACAAAAGGTATTATAGATTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5269,Drugs,MEG_5269|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-490_1_KU721147,0
,GTGTCCACGTTTCATAAAGTTCTGATCAACACCATGATCTCCAACGTCACCACTGGATTTCTGTTCTTTGCCGTGGTGTTTTGGATGTATCTTTCCACTGGCAACGTCGCACTGACCGGCATCGTCAGTGGAATTTACATGGGTTTGATCGCCGTTTGTTCCATCTTTTTCGGAACCGTTGTTGATCACAATCGCAAGAAGTCCGTCATGCTGTTTTCCAGCGTCACCACACTCGTGTTTTATTGTCTCAGTGCCCTGGTGTGGGTGTTTTGGCTGGAGGAAGACGGCCTGAGCATCGGAAATACCGCCCTGTGGGTGTTCGTTTCTTTCATCCTCATCGGATCAATCGTGGAACACATGCGCAACATCGCACTGTCCACCGTGGTCACGCTGTTGGTTCCTGAAGCTGAACGCGACAAAGCAAACGGCCTGGTAGGAGCCGTGCAAGGTGTTGGATTTTTAGTCACCAGCGTCATTGCTGGTTCCGCCATCGGGTTCTTGGGCATGGAAATCACCCTGTGGATCTGCCTTGGGCTCTCACTTGTCGCGCTGCTGCACCTGCTGCCGATTCGCGTCGACGAACCGGAAATCATCACCCAAGAAGACGCACAGCCTACTGTTTCTGACGATTCAGTTCCCACACCTACCTCCGATTTGGCGATCGTGTCCAAAGGCATCGACCTAAAAGGATCAATGAAAATCATCCTGAGTGTTCCGGGACTGCTCGCGCTTGTGTTGTTTGCGTCCTTCAACAACCTCATCGGCGGCGTGTACTCCGCACTCATGGACCCTTACGGCCTGGAACTTTTCAGCCCACAGCTGTGGGGGCTACTGCTTGGACTCACCAGCCTCGGCTTCATCGTTGGTGGTGCTGTGATCTCCAAAACTGGCTTGGGCAAAAACCCTGTGCGCACCTTGCTGCTGGTTAATGTTGGTGTGGCTTTTGTTGGCATGTTATTTGCCATTCGCGAATGGTGGTGGCTCTACATCCTGGGCATTTTCATCTTCATGGCTATCACCCCAGCTGCCGAAGCCGCAGAACAAACCATCCTTCAACGAGTCGTCCCATTCCGCCAACAAGGCCGCGTATTTGGACTAGCCATGGCAGTGGAAATGGCAGCCAACCCGCTCTCCACAGTGATCGTGGCGATTTTGGCCGAAGCCTACCTCATTCCATGGATGGCTGGCCCCGGCGCGGACACCATCTGGGGCGTGATCCTCGGCGAGGGTAAAGCTCGCGGCATGGCACTGATGTTCCTCGCATCAGGTGCCATCATGTTGGTTGTCGTGCTGTTGGCATTCATGTCGAGGTCCTACCGGAAACTCAGCCAGTACTACGCCACCACCAGCCAAGACATTGCGGGAGCTGCTGAGAAGTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Multi-drug_resistance,MEG_1779,Drugs,MEG_1779|Drugs|Multi-drug_resistance|Multi-drug_MFS_efflux_pumps|CMR,cmr_1_U43535,1
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCATTCTCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCTGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGAAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGGCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACACTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1881,Drugs,MEG_1881|Drugs|betalactams|Class_C_betalactamases|CMY,gb|FN556186|+|0-1146|ARO:3002057|CMY-46 [Escherichia coli] ,0
,atgaagcactcttcgctacggcgttcactattattagccggtattaccctgcccttagtcaattttgcgctgccaacctgggccgctgcgattccgggatcattagacaagcaattggcagcacttgagcatagtgctaacggtcgtttaggcattgcgatgattaatagcggcgctggcaccaaaattttgtatcgcggagctcaacgtttcccattctgtagtacttttaagtttatgctggccgctgctgtattagatcaaagccagtctcagccaaatttactcaataagcatataaattaccatgagagtgacttgttatcttatgccccgatcacgcgtaaaaatctggcgtgtggcatgaccgtctccgagttatgtgctgccaccattcaatatagtgataacactgccgcgaatttattaattaaagagttgggtggtttagcggctgttaatcagtttgctcgcagtattggcgatcagatgttcagattagaccgctgggagcctgatttaaataccgcgctacctaatgacccacgtgataccaccactcctgcggctatggcagcgagtatgaataaattggtgctgggtgatgcattgcgccctgcccaacgaagtcaactcgctgcatggctgaaaggaaataccaccggggatgccacaattcgtgcgggtgcccctactgactggattgtgggtgacaaaacgggtagtggcgattacggaaccaccaatgatattgcggtactttggccgactaaaggcgcgccgattgttttagtcgtgtatttcacgcaacgcgaaaaagacgcgaagccacggcgcgatgtattggcctctgcgacccaaataattttgtcgcaaatatcctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1241,Drugs,MEG_1241|Drugs|betalactams|Class_A_betalactamases|BLAA,500140296|WP_011816299.1|NG_052043|1|1|blaA_Yent|blaA_Yent|class_A_beta-lactamase_BlaA NG_052043:101-985,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_797,Drugs,MEG_797|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,487837357|WP_001910823.1|NG_052318|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052318:89-880,2
,atgatgaaaaaatctctttgctgcgccctgctgctcggcatctcttgctctgctctcgccgcgccagtgtcagaaaaacagctggcggaggtggtcgcgaatacggttaccccgctgatgaaagcccagtcgattccaggcatggcggtggccgttatttatcagggtaaaccgcactattacacgtttggcaaagccgatatcgcggccagcaaacccgttacgcctcagactctgttcgagctgggttctataagtaaaaccttcaccggggttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcaggggattcgtatgctggatctcgcaacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataatgccgccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagtatcggtctttttggcgcgctggcggtcaaaccttccggcatgggctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggaatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggagaaggttgctgatgcctcacttaagcagggcatctcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtgatcgagggcagcgacagtaaggtggcgctggcaccgctgcccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggctctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcgacgcgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_437,Drugs,MEG_437|Drugs|betalactams|Class_C_betalactamases|ACT,772738945|WP_045309142.1|NG_050710|1|1|blaACT-47|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-47 NG_050710:1-1146,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccagggcaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgccgccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatcaccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcatacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5614,Drugs,MEG_5614|Drugs|betalactams|Class_C_betalactamases|PDC,1343491222|WP_104009838.1|NG_056396|1|1|blaPDC-241|blaPDC|class_C_beta-lactamase_PDC-241 NG_056396:1-1194,0
,atgaacattcaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcatgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttgggtggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4718,Drugs,MEG_4718|Drugs|betalactams|Class_D_betalactamases|OXA,1028106562|WP_063861486.1|NG_049492|1|1|blaOXA-196|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-196 NG_049492:1-825,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaatattatgcccggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1825,Drugs,MEG_1825|Drugs|betalactams|Class_C_betalactamases|CMY,1188444894|WP_085562396.1|NG_054682|1|1|blaCMY-149|blaCMY|class_C_beta-lactamase_CMY-149 NG_054682:1-1146,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgccggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5481,Drugs,MEG_5481|Drugs|betalactams|Class_C_betalactamases|PDC,1393270447|WP_109791192.1|NG_057590|1|1|blaPDC-258|blaPDC|class_C_beta-lactamase_PDC-258 NG_057590:1-1194,0
,atgaaaattctgatttttctgcctttactgagttgcttgagcctgacagcgtgtagcctgcccgtttcatcttccccatctcagatcacttcaactcaatctacccaaaccattgcccaattatttgatcaggcgcaaagctctggcgttttagggattcagcgtggtcaacagatacaggtctatggtaatgatttaagtcgtgcaaataccgaatatgttcctgcttctacttttaaaatgctcaatgccctgattggcctgcaacatggcaaagctacaaccaatgaaatttttaaatgggatggcaagaaacgcagtttttcagcttgggaaaaagacatgactctcggccaagccatgcaagcgtctgctgtacccgtttatcaggaactggcacgtcgtattggccttgaactgatgcaacaggaagtacaacgcatccaatttggtaatcagcagattggtcaacaggtcgataacttctggttggtaggccctttgaaagttactccaaaacaggaagtccaatttgtttctgtgttggcccgagagcaactggcctttgatcctcaagtccagcaacaagtcaaagccatgttatttttacaggagcggaaagcttatcgactatatgtcaaatccggttggggcatggatgtggaaccgcaagtcggctggctcaccggctgggttgaaacaccgcaggctgaaatcgtggcattttcactcaatatgcagatgcaaaatggtatagatccggcgatccgccttgaaattttgcagcaggctttgggcgaattagggctttacccaaaagtggggcagcaaagcaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4426,Drugs,MEG_4426|Drugs|betalactams|Class_D_betalactamases|OXA,1034009413|WP_064483990.1|NG_050781|1|1|blaOXA-496|blaOXA-134_like|OXA-134_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-496 NG_050781:1-840,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcgcctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgtcggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6231,Drugs,MEG_6231|Drugs|betalactams|Class_A_betalactamases|SHV,1028110262|WP_063864632.1|NG_050021|1|1|blaSHV-147|blaSHV|class_A_beta-lactamase_SHV-147 NG_050021:1-861,0
,TATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAACCGGTAAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6903,Drugs,MEG_6903|Drugs|betalactams|Class_A_betalactamases|TEM,gi|296953|emb|X65253.1|175-1044,0
,TAAGTCTTATGAACATTAAAGCACTCTTCCTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGGATGGTAAAAAAAGGCTATTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCCATGAAAGCTTCCGCTATTCCAGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAGCTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAGTTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCATTTCACTTTTTACCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5258,Drugs,MEG_5258|Drugs|betalactams|Class_D_betalactamases|OXA,gi|94960152|gb|DQ519089.1|1-865,0
,ATGAGGGTAGCGGTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCGCGCGCAGATCAGTTGGAAGAATTTGTCCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_962,Drugs,MEG_962|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|937354980|gb|KR296704.1|90-881 gi|619497957|gb|KJ170699.1|35929-35138 gi|221047985|gb|FJ591054.1|68-859,2
,atgataatcagtgaatttgaccgtaataatccagtattgaaagatcagctttctgatttactgagactgacttggccggaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacgaatcgcggtagcagcggtagaccaagatgagttagtaggatttattggtgcaatccctcaatacggtatcacaggttgggaattgcatccattaattgtagaaagctcccgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagaggaggaatcacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaaacggacctgtatgagcatacatttgataaagtggcttccatccagaaccttcgtgaacatccgtatgaattctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaaatggctgggacaaaccggatatttggatggcaaaaacgattattcctcgaccagattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_142,Drugs,MEG_142|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,498415023|WP_010723742.1|NG_052161|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052161:101-649,2
,ATGCATACGCGGAAGGCAATAACGGAGGCAATTCGAAAACTCGGAGTCCAAACCGGTGACCTGTTGATGGTGCATGCCTCACTTAAAGCGATTGGTCCGGTCGAAGGAGGAGCGGAGACGGTCGTTGCCGCGTTACGCTCCGCGGTTGGGCCGACTGGCACTGTGATGGGATACGCGTCGTGGGACCGATCACCCTACGAGGAGACTCTGAATGGCGCTCGGTTGGATGACAAAGCCCGCCGTACCTGGCCGCCGTTCGATCCCGCAACGGCCGGGACTTACCGTGGGTTCGGCCTGCTGAATCAATTTCTGGTTCAAGCCCCCGGCGCGCGGCGCAGCGCGCACCCCGATGCATCGATGGTCGCGGTTGGTCCGCTAGCTGAAACGCTGACGGAGCCTCACGAACTCGGTCACGCCTTGGGGGAAGGGTCGCCCGTCGAGCGGTTCGTCCGCCTTGGCGGGAAGGCCCTGCTGTTGGGTGCGCCGCTAAACTCCGTTACCGCATTGCACTACGCCGAGGCGGTTGCGGATATCCCCAACAAACGATGGGTGACGTATGAGATGCCGATGCTTGGAAGAAACGGTGAAGTCGCCTGGAAAACGGCATCAGAATACGATTCAAACGGCATTCTCGATTGCTTTGCTATCGAAGGAAAGCCGGATGCGGTCGAAACTATAGCAAATGCTTACGTGAAGCTCGGTCGCCATCGAGAAGGTGTCGTGGGCTTTGCTCAGTGCTACCTGTTCGACGCGCAGGACATCGTGACGTTCGGCGTCACCTATCTTGAGAAGCACTTCGGAGCCACTCCGATCGTGCCAGCACACGAAGCCGCCCAGCGCTCTTGCGAGCCTTCCGGTTAG,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_44,Drugs,MEG_44|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,(AGly)Aac3-IIa:X51534:91-951:861,2
,atgaatgaaaaaatcttagtggttgatgatgaaaaagaattggccgacttagttgaagtatatctgaaaaacgatggatataccgtttataaattttataatggcaaggatgcactaaagtgtattgaatccgtggaactggatttagccatattggatatcatgcttccggatgtagacgggtttcagatctgccagaaaatccgggaaaagttttacttccctgttatcatgctgacagcaaaagtggaggacggggataaaatcatgggactgtccgtggcggatgattatattacaaagccgtttaacccgctggaagtggttgcgagagtaaaggcgcagctgcggcagtacatgcggtacaagcagcccagcttaaagcaggaggctgaatgcacagaatacgatatcagagggatgacaatcagcaagagcagccataagtgtatcctgtttggaaaggagattcagctgacgccaacggagttttcgattctttggtatctgtgcgagcgtcagggtacggttgtttctacggaggaattatttgaggcagtatggggtgaacggttttttgacagcaataatactgtgatggcgcatatcgggcggctccgggagaaaatgaaggaaccgtcaagaaatccgaaatttataaaaactgtgtggggagtgggatataccattgaaaaatag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7476,Drugs,MEG_7476|Drugs|Glycopeptides|VanD-type_regulator|VANRD,552941447|WP_023042613.1|NG_048400|1|1|vanR-D|vanR-D|VanD-type_vancomycin_resistance_DNA-binding_response_regulator_VanR NG_048400:77-775,5
,atgagccatattcaacgggagacgtcttgctcgaggccgcgattaaattccaacctggatgctgatttatatgggtatagatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggcatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccccgggaaaacagcattccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagcgttcctgcgccggttgcattcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgtctcactcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataagcttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgaattttcaccttcattacagaaacggtttttttataaatatggcattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctga,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1030,Drugs,MEG_1030|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,499350473|WP_011039766.1|NG_047436|1|1|aph(3')-Ia|aph(3')-Ia|aminoglycoside_O-phosphotransferase_APH(3')-Ia NG_047436:101-916,2
,GTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTTACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTCGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_335,Drugs,MEG_335|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|11345443|gb|AY007784.1|20-574,2
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCGGTTATCTACCAGGGAAAACCCTATTATTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGTCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCACGCTGGCGGTGAAACCCTCCGGTATGAGCTACGAAGAGGCGATGACCAGACGCGTTCTGCAGCCATTAAAGCTGGCGCATACCTGGATTACGGTTCCACAGAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAACCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCACTGGGTACAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAACAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCCGATTCGATCATCAACGGCAGCGACAGCAAAGTAGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTACACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1877,Drugs,MEG_1877|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EU515251|+|0-1146|ARO:3002051|CMY-40 [Escherichia coli] ,0
,atgttccctcgctggtcaaagacctttgcgctggccctcacagcctatgcgttcgtgatgggtgccagtcaggcgcacgccgagctggtcgtgcgcgatgacctcaagcgcgtgttcgacgaagccggtgttaccggcaccttcgtgctgatggacatccgtggtgatcgcacctacgtggtggacccggcacgcgccgcgcggcgcatccaccctgcatcaaccttcaagattcccaacagcctgatcgccttcgatacgggtgccgtgcgtgacgaccaggaggtgattccatacggtggcaagccacagcccttcaaacagtgggagaaggacatggcattgcccgaggcgatccgcgtgtcgaacgtgccgatctaccaggaggttgcgcgccgtatcggccccgcgcgcatgcaggcctatgtggatgcctttgactacggcaaccgccagatcggcagcgtgattgaccagttttggctgcgtggtccattggaaatttccgcatttgaagaggcgcgcttcaccagccgccttgcgctcaagcaactgccggtgaagccgcgcacgtgggatctggttcaccgcatgctgctgatcgagaaacagggcgatgccgcgctgtacgccaagacgggggtcgctaccgagtatcagcccgagatcggctggtgggtgggctgggtcgagcgtgaggggaaggtgtacgcgttcgccctgaacatcgacatgccgcttgaggccgacatggccaagcgcattccgttaggaaaacggctgatgcaggcattggaagtgtggccaacaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4738,Drugs,MEG_4738|Drugs|betalactams|Class_D_betalactamases|OXA,1039445784|WP_064808881.1|NG_056182|1|1|blaOXA-573|blaOXA-60_like|OXA-60_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-573 NG_056182:1-816,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAGATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTATTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1378,Drugs,MEG_1378|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_109_AOAS01000022,0
,ATGCGCGATACCAGATTCCCCTGCCTGTGCGGCATCGCCGCTTCCACACTGCTGTTCGCCACCACCCCGGCCATTGCCGGCGAGGCCCCGGCGGATCGCCTGAAGGCACTGGTCGACGCCGCCGTACAACCGGTGATGAAGGCCAATGACATTCCGGGCCTGGCCGTAGCCATCAGCCTGAAAGGAGAACCGCATTACTTCAGCTATGGGCTGGCCTCGAAAGAGGACGGCCGCCGGGTGACGCCGGAGACCCTGTTCGAGATCGGCTCGGTGAGCAAGACCTTCACCGCCACCCTCGCCGGCTATGCCCTGACCCAGGACAAGATGCGCCTCGACGACCGCGCCAGCCAGCACTGGCCGGCACTGCAGGGCAGCCGCTTCGACGGCATCAGCCTGCTCGACCTCGCGACCTATACCGCCGGCGGCTTGCCGCTGCAGTTTCCCGACTCGGTGCAGAAGGACCAGGCACAGATCCGCGACTACTACCGCCAGTGGCAGCCGACCTACGCGCCGGGCAGCCAGCGCCTCTATTCCAACCCGAGCATCGGCCTGTTCGGCTATCTCGCCGCGCGCAGCCTGGGCCAGCCGTTCGAACGGCTCATGGAGCAGCAAGTGTTCCCGGCACTGGGCCTCGAACAGACCCACCTCGACGTGCCCGAGGCGGCGCTGGCGCAGTACGCCCAGGGCTACGGCAAGGACGACCGCCCGCTACGGGTCGGTCCCGGCCCGCTGGATGCCGAAGGCTACGGGGTGAAGACCAGCGCGGCCGACCTGCTGCGCTTCGTCGATGCCAACCTGCATCCGGAGCGCCTGGACAGGCCCTGGGCGCAGGCGCTCGATGCCACCCATCGCGGTTACTACAAGGTCGGCGACATGACCCAGGGCCTGGGCTGGGAAGCCTACGACTGGCCGATCTCCCTGAAGCGCCTGCAGGCCGGCAACTCGACGCCGATGGCGCTGCAACCGCACAGGATCGCCAGGCTGCCCGCGCCACAGGCGCTGGAGGGCCAGCGCCTGCTGAACAAGACCGGTTCCACCAACGGCTTCGGCGCCTACGTGGCGTTCGTCCCGGGCCGCGACCTGGGACTGGTGATCCTGGCCAACCGCAACTATCCCAATGCCGAGCGGGTGAAGATCGCCTACGCCATCCTCAGCGGCCTGGAGCAGCAGGGCAAGGTGCCGCTGAAGCGCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5746,Drugs,MEG_5746|Drugs|betalactams|Class_C_betalactamases|PDC,gi|20135565|gb|AY083595.1|45-1238,0
,ATGGACAGAAAAAGATTGACACAGCGTTTCCCGTTCCTGCTTCCAATGAGACGGGCGCAGAGAAAAATGTGCTTTTATGCGGGAATGAGATTTGACGGCTGTCGCTATGCGCAGACGATAGGGGAAAAATCGCTTTCCCATTTGCTCTTTGAAACGGATTGCGCATTATACAACCACAATACCGGATTTGACATGATATACCAGGAAAACAAGGTGTTCAACTTAAAGCTGGCAGCAAAGACCTTAAACGGCTTATTGATAAGACCGGGGGAAACCTTTTCTTTCTGGTGGCTGGTTCGCCATGCGGACAAAGATACCCCCTATAAAGACGGCCTTACGGTGGCCAATGGTAAGCTCACCACCATGTCGGGCGGCGGTATGTGCCAGATGAGCAATTTACTATTTTGGGTGTTCCTGCATACGCCATTGACAATTATCCAGCGCAGCGGTCACGTAGTAAAGGAGTTTCCAGAGCCAAACAGTGACGAGATCAAAGGGGTGGATGCAACCATCTCAGAGGGCTGGATTGATTTAAAAGTGCGAAACGATACCGACTGCACCTACCAAATATGGGTGACCCTAGATGATGAGAAAATCATCGGTCAGGTGTTCGCCGACAAACAGCCTCAAGCATTATACAAAATTGCAAACGGCAGTATTCAGTATGTCCGTGAAAGTGGCGGGATTTATGAATATGCCAAGGTTGAACGGATGCAAGTTGCCTTAGGTACCGGGGAAATAATAGATTGCAAGCTGCTTTATACAAACAAATGCAAAATCTGCTATCCCCTCCCGGAAAGTGTGGATATTCAGGAGGCGAACCAATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7542,Drugs,MEG_7542|Drugs|Glycopeptides|VanB-type_accessory_protein|VANWB,gi|695199646|ref|NG_035288.1|27047-27874,5
,AAGGCGTTTTGACAGACTATTCATGTTGTTGTTAATTCGTCTCTTCCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGAAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACTTGGTTAACTATAATCCGATTGCGGAAAAGCACGTCGATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTTCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGTAATCTGACGCTGGGTAAAGCATTGGGTGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAACGGTTTGTAATAGCGGAAACGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_2432,Drugs,MEG_2432|Drugs|betalactams|Class_A_betalactamases|CTX,gi|933686806|gb|KT779550.1|2516-1567 gi|848613079|gb|KR494248.1|85099-84150 gi|822874760|gb|KM052220.1|32235-33184 gi|756791690|gb|KM377240.1|86672-87621 gi|756791559|gb|KM377239.1|98870-99819 gi|756791433|gb|KM377238.1|92164-91215 gi|745795237|gb|CP007651.1|102652-101703 gi|700369833|gb|KJ563250.1|68054-67105 gi|695941297|gb|CP009580.1|9652-10601 gi|695941297|gb|CP009580.1|117303-116354 gi|681884821|gb|KM094197.1|81-1030,0
,ATGCAAAAAAGACTTATACATTTATCCATTATCTTCTTTCTGCTATGTCCTGCCCTGGTAGTTGCGCAGAACAGTCCTCTTGAAACTCAACTCAAGAAAGCCATAGAAGGGAAAAAAGCCGAAATAGGAATTGCAGTCATTATCGACGGGCAAGATACGATAACAGTCAATAATGATATTCATTATCCTATGATGAGTGTTTTCAAATTTCATCAGGCATTGGCATTGGCCGATTACATGCATCATCAAAAGCAACCTTTGGAAACCCGGTTATTGATTAAAAAGTCGGATTTAAAGCCGGACACCTATAGTCCGCTTCGAGAAACATACCCGCAGGGAGGAATCGAAATGAGCATTGCCGATCTACTGAAATATACGCTTCAGCAAAGTGACAATAATGCCTGCGATATTCTTTTTAATTATCAAGGTGGTCCGGATGCCGTGAATAAGTATCTTCATTCATTGGGAATTCGTGAATGTGCTGTCATCCATACAGAAAACGATATGCATGAGAATCTGGAGTTCTGTTACCAAAACTGGACTACTCCATTGGCAGCCGCCAAATTACTGGAAATATTTCGCAATGAAAACCTTTTTGACAAAGAATACAAGAATTTCATTTATCAAACAATGGTGGAATGTCAGACAGGACAAGACCGCCTGATTGCTCCACTGCTCGATAAAAAAGTAACAATGGGGCATAAAACCGGAACAGGCGACCGTAATGCGAAAGGACAACAGATCGGTTGCAATGACATCGGGTTTATTCTTCTTCCCGACGGACATGCCTATAGTATAGCCGTCTTCGTGAAAGATTCCGAAGCAGATAACAGAGAAAACAGTGAGATTATCGCAGAAATTTCGCGCATCGTTTACGAATACGTAACGCAACAGATAGATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1650,Drugs,MEG_1650|Drugs|betalactams|Class_A_betalactamases|CEPA,gi|307075856|emb|FR688022.1|1-903,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgacccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaccgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_845,Drugs,MEG_845|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502100|WP_071846252.1|NG_052278|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052278:101-892,2
,ATGGTATACCTAGCCAAAGAAGTCTTACCAGTCAACATAGAAGACGAATTGAAGCAATCCTATTTGGATTATGCGATGAGTGTCATTGTAGGCCGAGCATTGCCTGATGTACGTGATGGTTTAAAACCGGTGCATAGGCGAGTTCTTTTTGCGATGAGCGAGTTGGGTAATGATTGGAATAAACCTTATAAAAAATCTGCTCGTGTAGTAGGGGATGTCATCGGTAAATACCATCCTCATGGGGATACAGCTGTTTATGACACTATTGTTCGTATGGCTCAGCCCTTTTCCATGCGTTATATGCTGATTGATGGGCAGGGTAATTTTGGTTCTGTAGACGGAGATGCTCCAGCTGCCATGCGTTACACTGAAGTACGAATGTCCAAGGTGGCGCATGCTTTACTGGCTGATTTGGATAAGGAAACCGTTGATTTTAGTCCTAACTATGATGAAACAGAATTTGCTCCAGTGGTATTGCCATCGAGAATTCCCAATTTACTAGTTAATGGCTCTTCCGGTATTGCGGTAGGGATGGCTACTAATATTCCACCACATAATCTTACCGAAGTAATCAATGCATGTATTGCCTTAGTGGATGAACCTGACACGAGTCTTGAAGATTTAATGGAAATTATTCCTGGCCCTGATTTTCCTACAGCAGCAATTATTAATGGTCGTGCTGGAATTATTGAAGGTTATCGTACTGGAAAAGGGCGGGTTGTTATCAGGGCACGCACAGAAATTGAAACGGATGAAAGTTCAGGACGTCAGTCAATTATTATTCAGGAATTACCCTATCAGGTGAATAAAGCGCGTTTGATCGAGCGTATTGCTGAATTGGTAAGAGACAAGAAAATCGAAGGAATTTCCGGCTTGAGGGATGAGTCAGATAAGCAGGGAATGAGAGTAGTCATTGAGTTAAAACGCAATGAAGTAGCAGATGTGGTATTGAATAACCTGTTCGCTCATACTCAAATGCAAAATGTATTCGGGATTAATATGGTTGCCCTGGTGGATGGCCAACCGCGTACTTTGAATTTGAAGCAAATACTGGAATATTTTATAAAACATCGAAGAGAGGTTGTTACCAGACGCACAATATTTGAATTGAAAAAAGCCAGAAATCGAGCCCATTTATTGGAGGGCTTGGGAATCGCCTTGGCTAATATCGATGAAATGATCGCATTAATTAAGCAATCTTCTACTCCTCAAGACGCAAAAAGTGCTTTATTAAGCAAAATATGGCAACCTGGCTTGGTAAAGGCCATGTTGGAAAAGGCTGGCTCAAACGCGTCAAGGCCTGATGATTTAACTGAAGAGTATGGTTTGCATGAGAACGGATATAAATTATCTGAAGCGCAGGCACAAGCAATACTTGAATTAAGATTACATAGGCTAACAGCTCTTGAACAAGATAAAATAATTAATGAATTTGAAGAGCTATTGAATTTAATTAAAGAATTGCTTGACATATTGGCTTCACCTGAAAGACTTATGCAAGTTATTCGTGATGAATTGATAGAGATTAAATCCCAATTTGGTGATGAGAGGCGAACGGAAATAACAGCCTCACAAGAAGATTTGACTATTGAAGATTTGATTACCGAAGAAGACGTTGTGGTCACTTTATCTCATCAAGGTTATGTAAAATATCAGCCCATTACAGCCTATCAGGCTCAGCGCCGAGGTGGCAAAGGCAAATCGGCAACTCATGTCAAGGATGAGGATTTTGTTGAGCGTTTGGTTATTGCGAGTACTCATGACACCTTATTATGTTTCTCCAATCATGGCAAATTATATTGGCTAAAAGCATATCAATTGCCTCAAGCAAGCCGTGCTTCGAGAGGAAGGCCTATAATCAATATTCTTCCTTTGGCTGAAGGCGAAGAGATTAATGCTATGCTCCCTGTCCGTGAGTATAAAGACGGCAGCTATGTATTTATGGCAACCAAGAAGGGAACAGTTAAAAAAGTGCCTTTAAACGCATTTAGCAGGCCGCGTTCCAATGGTATTATTGCTGTGGACCTGGAAGAGGATGACAGTCTCGTTGGAGTGGATATTACTGATGGTGCTCGCGATATTATGTTGTTTACTGATGCAGGCAAAGTGATCCGCTTTGATGAAAGTAAAGTGCGACCTATGGGGCGCACGGCTCGAGGAGTTCGTGGAATTAGGGTAGAAAAGGATCAAGCCGTTAAATCTCTTGTGGTAGTCGATCCAAGTGGAGGCACCATTTTGACGGCAACTGAAAACGGCTACGGCAAGAGAACTCATATTGATGAATATCGAGTGTCAGGACGGGGCGGGCAAGGTGTTATTTCCATTCAGGTTACTGAACGAAATGGTAAAGTGGTCCGCTCCTTGCAGGTTACCGATAATGACGAAGCCATGTTAATTACAGATAAAGGGACTTTGGTTCGTTTTAAAGTCAATGAATTATCTGTGATAGGCCGAAATACACAAGGAGTTCGTCTGATTAATGTCAGTTCTGGTGAGGCAGTTGTTGGAATGCAAAAAATTGTAGATCTTGGAGAAGAATTAGAAGAGGCAGAAGACTCATCCCTTAATGCTGAAGACAGCAGTGATGAATAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3209,Drugs,MEG_3209|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|53752796|emb|CR628337.1|1525332-1527923,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgtcaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggtgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5641,Drugs,MEG_5641|Drugs|betalactams|Class_C_betalactamases|PDC,959840760|WP_058129018.1|NG_049871|1|1|blaPDC-104|blaPDC|class_C_beta-lactamase_PDC-104 NG_049871:1-1194,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAATAGTTCACATGCCAAAGAGTTAAATGATTTAGAGAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAGAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1356,Drugs,MEG_1356|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_96_LNDI01000019,0
,ATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGAAGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTTACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCATATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_276,Drugs,MEG_276|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,(AGly/Flqn)Aac6Ib-cr:EF636461:1124-1642:519,2
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAATCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCTCGAAGGGAAGCCTTTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCTGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1931,Drugs,MEG_1931|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KJ207202|+|548-1694|ARO:3002098|CMY-85 [Citrobacter freundii] ,0
,atgcaatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtgttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtagttcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_511,Drugs,MEG_511|Drugs|betalactams|Class_C_betalactamases|ADC,1058243715|WP_068981625.1|NG_051458|1|1|blaADC-94|blaADC|class_C_beta-lactamase_ADC-94 NG_051458:1-1152,0
,ATGAATCGAACTAATATTTTTTTTGGTGAATCGCATTCTGACTGGTTGCCTGTCAGAGGCGGAGAATCTGGTGATTTTGTTTTTCGACGTGGTGACGGGCATGCCTTCGCGAAAATCGCACCTGCTTCCCGCCGCGGTGAGCTCGCTGGAGAGCGTGACCGCCTCATTTGGCTCAAAGGTCGAGGTGTGGCTTGCCCCGAGGTGATCAACTGGCAGGAGGAACAGGAGGGTGCATGCTTGGTGATAACGGCAATTCCGGGAGTACCGGCGGCTGATCTGTCTGGAGCGGATTTGCTCAAAGCGTGGCCGTCAATGGGGCAGCAACTTGGCGCTGTTCACAGCCTATCGGTTGATCAATGTCCGTTTGAGCGCAGGCTGTCGCGAATGTTCGGACGCGCCGTTGATGTGGTGTCCCGCAATGCCGTCAATCCCGACTTCTTACCGGACGAGGACAAGAGTACGCCGCAGCTCGATCTTTTGGCTCGTGTCGAACGAGAGCTACCGGTGCGGCTCGACCAAGAGCGCACCGATATGGTTGTTTGCCATGGTGATCCCTGCATGCCGAACTTCATGGTGGACCCTAAAACTCTTCAATGCACGGGTCTGATCGACCTTGGGCGGCTCGGAACAGCAGATCGCTATGCCGATTTGGCACTCATGATTGCTAACGCCGAAGAGAACTGGGCAGCGCCAGATGAAGCAGAGCGCGCCTTCGCTGTCCTATTCAATGTATTGGGGATCGAAGCCCCCGACCGCGAACGCCTTGCCTTCTATCTGCGATTGGACCCTCTGACTTGGGGTTGA,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1053,Drugs,MEG_1053|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,gi|3220157|gb|AF024602.1|AF024602|2353-3156 gi|984686374|gb|HQ700358.2|20307-19505 gi|974751547|gb|KU130294.1|219608-218806 gi|971493847|gb|CP010351.1|33456-34258 gi|873464424|gb|KR014106.1|34318-35120 gi|954171462|gb|KT151662.1|77778-78580 gi|954171374|gb|KT151661.1|77778-78580 gi|954171188|gb|KT151659.1|77742-78544 gi|954171094|gb|KT151658.1|77750-78552 gi|954171002|gb|KT151657.1|77778-78580,2
,ATGAAAAAGATAAAAATTGTTCCACTTATTTTAATAGTTGTAGTTGTCGGGTTTGGTATATATTTTTATGCTTCAAAAGATAAAGAAATTAATAATACTATTGATGCAATTGAAGATAAAAATTTCAAACAAGTTTATAAAGATAGCAGTTATATTTCTAAAAGCGATAATGGTGAAGTAGAAATGACTGAACGTCCGATAAAAATATATAATAGTTTAGGCGTTAAAGATATAAACATTCAGGATCGTAAAATAAAAAAAGTATCTAAAAATAAAAAACGAGTAGATGCTCAATATAAAATTAAAACAAACTACGGTAACATTGATCGCAACGTTCAATTTAATTTTGTTAAAGAAGATGGTATGTGGAAGTTAGATTGGGATCATAGCGTCATTATTCCAGGAATGCAGAAAGACCAAAGCATACATATTGAAAATTTAAAATCAGAACGTGGTAAAATTTTAGACCGAAACAATGTGGAATTGGCCAATACAGGAACAGCATATGAGATAGGCATCGTTCCAAAGAATGTATCTAAAAAAGATTATAAAGCAATCGCTAAAGAACTAAGTATTTCTGAAGACTATATCAAACAACAAATGGATCAAAATTGGGTACAAGATGATACCTTCGTTCCACTTAAAACCGTTAAAAAAATGGATGAATATTTAAGTGATTTCGCAAAAAAATTTCATCTTACAACTAATGAAACAGAAAGTCGTAACTATCCTCTAGAAAAAGCGACTTCACATCTATTAGGTTATGTTGGTCCCATTAACTCTGAAGAATTAAAACAAAAAGAATATAAAGGCTATAAAGATGATGCAGTTATTGGTAAAAAGGGACTCGAAAAACTTTACGATAAAAAGCTCCAACATGAAGATGGCTATCGTGTCACAATCGTTGACGATAATAGCAATACAATCGCACATACATTAATAGAGAAAAAGAAAAAAGATGGCAAAGATATTCAACTAACTATTGATGCTAAAGTTCAAAAGAGTATTTATAACAACATGAAAAATGATTATGGCTCAGGTACTGCTATCCACCCTCAAACAGGTGAATTATTAGCACTTGTAAGCACACCTTCATATGACGTCTATCCATTTATGTATGGCATGAGTAACGAAGAATATAATAAATTAACCGAAGATAAAAAAGAACCTCTGCTCAACAAGTTCCAGATTACAACTTCACCAGGTTCAACTCAAAAAATATTAACAGCAATGATTGGGTTAAATAACAAAACATTAGACGATAAAACAAGTTATAAAATCGATGGTAAAGGTTGGCAAAAAGATAAATCTTGGGGTGGTTACAACGTTACAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCAGATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAAGATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTACGGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCACCTCACTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCAACAAGTCGTAAATAAAACACATAAAGAAGATATTTATAGATCTTATGCAAACTTAATTGGCAAATCCGGTACTGCAGAACTCAAAATGAAACAAGGAGAAACTGGCAGACAAATTGGGTGGTTTATATCATATGATAAAGATAATCCAAACATGATGATGGCTATTAATGTTAAAGATGTACAAGATAAAGGAATGGCTAGCTACAATGCCAAAATCTCAGGTAAAGTGTATGATGAGCTATATGAGAACGGTAATAAAAAATACGATATAGATGAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3782,Drugs,MEG_3782|Drugs|betalactams|Penicillin_binding_protein|MECA,gi|955659783|emb|LN864705.1|5925-3919 gi|938149445|gb|KR936059.1|1-2007 gi|696158524|gb|KM281804.1|8026-6020 gi|675300911|gb|CP007499.1|43087-41081 gi|647513781|dbj|AB478934.1|6981-4975 gi|636561279|gb|CP007659.1|41741-39735 gi|556502764|emb|HG515014.1|13896-11890 gi|549124399|emb|HE984157.2|6196-8202 gi|545582967|gb|CP003604.1|42403-40397 gi|452754715|emb|HF569115.1|25607-23601,0
,AGAATTTGATCTTGGTTCAGATTGAACGCTGGCGGCGTGGATGAGGCATGCAAGTCGAACGGAATAATGACTTCGGTTGTTATTTAGTGGCGGAAGGGTTAGTAATACATAGATAATCTGTCCTCAACTTGGGAATAACGGTTGGAAACGACCGCTAATACCGAATGTGGTATGTTTAGGCATCTAAAACATATTAAAGAAGGGGATCTTCGGACCTTTCGGTTGAGGGAGAGTCTATGGGATATCAGCTTGTTGGTGGGGTAATGGCCTACCAAGGCTTTGACGTCTAGGCGGATTGAGAGATTGACCGCCAACACTGGGACTGAGACACTGCCCAGACTTCTACGGAAGGCTGCAGTCGAGAATCTTTCGCAATGGACGAAAGTCTGACGAAGCGACGCCGCGTGTGTGATGAAGGCTCTAGGGTTGTAAAGCACTTTCGCTTGGGAATAAGAGAGATTGGCTAATATCCAATCGATTTGAGCGTACCAGGTAAAGAAGCACCGGCTAACTCCGTGCCAGCAGCTGCGGTAATACGGAGGGTGCTAGCGTTAATCGGATTTATTGGGCGTAAAGGGCGTGTAGGCGGAAAGGAAAGTTAGATGTTAAATCTTGGGGCTCAACCCCAAGCCAGCATCTAATACTATCTTTCTAGAGGGTAGATGGAGAAAAGGGAATTCCACGTGTAGCGGTGAAATGCGTAGATATGTGGAAGAACACCAGTGGCGAAGGCGCTTTTCTAATTTACACCTGACGCTAAGGCGCGAAAGCAAGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCTTGCCGTAAACGATGCATACTTGATGTGGATAGTCTCAACCCTATCCGTGTCGTAGCTAACGCGTTAAGTATGCCGCCTGAGGAGTACACTCGCAAGGGTGAAACTCAAAAGAATTGACGGGGGCCCGCACAAGCAGTGGAGCATGTGGTTTAATTCGATGCAACGCGAAGAACCTTACCTGGGCTTGACATGTATTTGACCGCGGCAGAAATGTCGTTTTCCGCAAGGACAGATACACAGGTGCTGCATGGCTGTCGTCAGCTCGTGCCGTGAGGTGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATCGTTAGTTGCCAACACTTAGGGTGGGAACTCTAACGAGACTGCCTGGGTTAACCAGGAGGAAGGCGAGGATGACGTCAAGTCAGCATGGCCCTTATGCCCAGGGCTACACACGTGCTACAATGGCCAGTACAGAAGGTAGCAATATCGTGAGATGGAGCAAATCCTCAAAGCTGGCCCCAGTTCGGATTGTAGTCTGCAACTCGACTACATGAAGTCGGAATTGCTAGTAATGGCGTGTCAGCTATAACGCCGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACATCATGGGAGTTGGTTTTGCCTTAAGTCGTTGACTCAACCTGCAAAGGAGAGAGGCGCCCAAGGTGAGGCTGATGACTGGGATGAAGTCGTAACAAG,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_1,Drugs,MEG_1|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|AB001778.1|+|0-1507|ARO:3003485|Chlamydophila psittaci 16S rRNA mutation conferring resistance to spectinomycin [Chlamydia psittaci 6BC] ,2
,atgaaaaagaactttgcctttttagatgaaatgattcccgggatccgatgggatgccaaatatgccacctgggacaatttcaccgggaaaccggtagacggatacatggtaaaccgtgttatgggaacgaaggagctgggagttgctttgcgtaaggctcagaagatggcggagaagctaggatatggtttgctcttatgggacggctatcgcccccagtgcgcagtgaattgttttctgaattgggcttcccaaccggaagacaatctgacgaaaaagcgttactatccaaatatcaaaaggaatgagatggttgcgaaggggtatgtggcctcacaatccagccacagccgtggaagtacggttgaccttacaatttttcatttgaatagcggtatgcttgttcctatgggtggagattttgactttatggatgaacggtcacaccatgccgcaagcggtctgagcgaagaagaatcaaaaaaccggcagtgcttgcgttatatcatggagagtagcggatttgaagcctatcgttatgaatggtggcattacgtcttggcggacgagccatacccggatacatattttgatttttgcattgcctag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7565,Drugs,MEG_7565|Drugs|Glycopeptides|VanD-type_resistance_protein|VANXD,552941804|WP_023042861.1|NG_048487|1|1|vanX-D|vanX-D|D-Ala-D-Ala_dipeptidase_VanX-D NG_048487:101-709,5
,atgaacattaaagcactcttacttataacaagcgctatttttagttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggccctttaaaaattacgcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccctttagccaaaaagtccaagaagaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4695,Drugs,MEG_4695|Drugs|betalactams|Class_D_betalactamases|OXA,1188444914|WP_085562416.1|NG_054706|1|1|blaOXA-562|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-562 NG_054706:1-825,0
,ATGAATGTCATTATAAAAGCTGTAGTTACTGCCTCGACGCTACTGATGGTATCTTTTAGTTCATTCGAAACCTCAGCGCAATCCCCACTGTTAAAAGGGCAAATTGAATCCATAGTCATTGGAAAAAAAGCCACTGTAGGCGTTGCAGTGTGGGGGCCTGACGATCTGGAACCTTTACTGATTAATCCTTTTGAAAAATTCCCAATGCAAAGTGTATTTAAATTGCATTTAGCTATGTTGGTACTGCATCAGGTTGATCAGGGAAAGTTGGATTTAAATCAGACCGTTATCGTAAACAGGGCTAAGGTTTTACAGAATACCTGGGCTCCGATAATGAAAGCGTATCAGGGAGACGAGTTTAGTGTTCCAGTGCAGCAACTGCTGCAATACTCGGTCTCGCACAGCGATAACGTGGCCTGTGATTTGTTATTTGAACTGGTTGGTGGACCAGCTGCTTTGCATGACTATATCCAGTCTATGGGTATAAAGGAGACCGCTGTGGTCGCAAATGAAGCGCAGATGCACGCCGATGATCAGGTGCAGTATCAAAACTGGACCTCGATGAAAGGTGCTGCAGAGATCCTGAAAAAGTTTGAGCAAAAAACACAGCTGTCTGAAACCTCGCAGGCTTTGTTATGGAAGTGGATGGTCGAAACCACCACAGGACCAGAGCGGTTAAAAGGTTTGTTACCAGCTGGTACTGTGGTCGCACATAAAACTGGTACTTCGGGTATCAAAGCCGGAAAAACTGCGGCCACTAATGATTTAGGTATCATTCTGTTGCCTGATGGACGGCCCTTGCTGGTTGCTGTTTTTGTGAAAGACTCAGCCGAGTCAAGCCGAACCAATGAAGCTATCATTGCGCAGGTTGCTCAGACTGCGTATCAATTTGAATTGAAAAAGCTTTCTGCCCTAAGCCCAAATTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5766,Drugs,MEG_5766|Drugs|betalactams|Class_A_betalactamases|PER,gb|FJ627180|+|0-926|ARO:3002367|PER-5 [Providencia rettgeri] ,0
,TTTTTATGATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCACGCGCAGACGAACAGCGTGCAGCAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAGATTCTCTACCGTGCCGATGAACGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAAGAAGAGCGACCTGGTTAACTACAATCCCATTGCGGAGAAACACGTTAACGGCACGATGACGCTGGCTGAGCTTGGCGCAGCGGCGCTGCAGTATAGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGGCCCGATAAAGTGACGGCGTTTGCTCGCTCGTTGGGTGATGAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATACCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAAGCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTCTGCCGAAATCATGGGGAGTGGGCGATAAAACCGGCAGCGGAGATTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGCAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGCCGTCGGGATGTTCTGGCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGATGCAATAAATGGAGCGAGGTATCGCTCCATTTACGTTAAAAATGTGCTCCTGAACTTCAGTCTTGTCTTGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_2396,Drugs,MEG_2396|Drugs|betalactams|Class_A_betalactamases|CTX,gi|397001530|gb|JX017309.1|6997-7948 gi|397001520|gb|JX017308.1|6998-7949 gi|397001506|gb|JX017307.1|11173-12124 gi|397001496|gb|JX017306.1|6220-7171 gi|10946250|gb|AF286192.1|981-1932 gi|2443464|gb|U95364.1|STU95364|1-952,0
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagataagttgggtgcacgagtgggttacatcgagctggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttaagtactcaccagtcacagaaaagcatcttacgaatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaacccgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccagtgagcgtggatctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtacctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6657,Drugs,MEG_6657|Drugs|betalactams|Class_A_betalactamases|TEM,1188444904|WP_085562406.1|NG_054696|1|1|blaTEM-227|blaTEM|class_A_beta-lactamase_TEM-227 NG_054696:1-861,0
,atgaggttcgaagaatgggtcaaagataagcatattccttncaaacngaatcaccctgatgataattacgatgattttaagccattaagaaanataattggagatacccgagttgtagcattaggtgaaaattctcatttcataaaagaattctttttgttacgacatacgcttttgcgtttttttatcgaagatctaggttttactacgtttgcttttgaatttggttttgctgagggtcaaatcatcaataactggatacatggacaaggaactgacgatgaaataggcagattcttaaaacacttctattatccagaagagctcaaaaccacatttctatggctaagggagtacaataaagcagcaaaagaaaaaatcacatttcttggcattgatatacccagaaatggaggttcatacttaccaaatatggagatagtgcatgacttttttagaacagcggataaagaagcactacacattatcgatgatgcatttaatattgcaaaaaagattgattacttctccacatcacaggcagccttaaatttacatgagctaacagattctgagaaatgccgtttaactagccaattagctcgagtaaaagttcgccttgaagctatggctccaattcacattgaaaaatatgggattgataaatatgagacaattctgcattatgccaacggtatgatatacttggactataacattcaagctatgtcgggctttatttcaggaggcggaatgcagggcgatatgggtgcaaaagacaaatacatggcagattctgtgctgtggcatttaaaaaacccacaaagtgagcagaaagtgatagtagtagcacataatgcacatattcaaaaaacacccattctgtatgatggatttctaagttgcctaccaatgggccaaagacttaaaaatgccattggtgatgattatatgtctttaggtattacttcttatagtgggcatactgcagccctctatccggaagttgatacaaaatatggttttcgagttgataacttccaactgcaggaaccaaatgaaggttctgtcgagaaagctatttctggttgtggagttactaattcttttgtcttttttagaaatattcctgaagatttacaatccatcccgaacatgattcgatttgantctatttacatgaaagcagaactcgagaaagctttcgatggaatatttcaaattgaaaagtcatctgtatctgaggtcgtttatgaataa,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_2752,Drugs,MEG_2752|Drugs|MLS|Macrolide_esterases|EREB,1028086017|WP_063844486.1|NG_047769|1|1|ere(B)|ere(B)|EreB_family_erythromycin_esterase NG_047769:101-1360,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcaaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctgggtgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgtcgatggcgctgcaaccgcacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5513,Drugs,MEG_5513|Drugs|betalactams|Class_C_betalactamases|PDC,1035157540|WP_064511505.1|NG_050828|1|1|blaPDC-155|blaPDC|class_C_beta-lactamase_PDC-155 NG_050828:1-1194,0
,AACAATGCGCTCATCGTCATCCTCGGCACCGTCACCCTGGATGCTGTAGGCATAGGCTTGGTTATGCCGGTACTGCCGGGCCTCTTGCGGGATATCGTCCATTCCGACAGCATCGCCAGTCACTATGGCGTGCTGCTAGCGCTATATGCGTTGATGCAATTTCTATGCGCACCCGTTCTCGGAGCACTGTCCGACCGCTTTGGCCGCCGCCCAGTCCTGCTCGCTTCGCTACTTGGAGCCACTATCGACTACGCGATCATGGCGACCACACCCGTCCTGTGGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGGCCTGTCGCTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAACGTTTCGGCGAGAAGCAGGCCATTATCGCCGGCATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTCCCCATTATGATTCTTCTCGCTTCCGGCGGCATCGGGATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGATCGCTCGCGGCTCTTACCAGCCTAACTTCGATCACTGGACCGCTGATCGTCACGGCGATTTATGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATGGATTGTAGGCGCCGCCCTATACCTTGTCTGCCTCC,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7066,Drugs,MEG_7066|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETC,gi|961454907|gb|KT991389.1|1310-173 gi|961454907|gb|KT991389.1|3654-3683 gi|627769342|gb|KF195927.1|6870-5733 gi|669174522|dbj|AB775653.1|67-1204 gi|507466429|dbj|AB777650.1|505-1642 gi|507466429|dbj|AB777650.1|2190-2283 gi|507466429|dbj|AB777650.1|2337-2280 gi|507466420|dbj|AB777647.1|2247-1110 gi|507466420|dbj|AB777647.1|562-469 gi|507466420|dbj|AB777647.1|415-472 gi|496543269|gb|KC820641.1|3911-5048 gi|496543253|gb|KC820640.1|3910-5047 gi|448967488|gb|KC562906.1|5372-6509 gi|358444205|gb|JN381160.1|95-1232 gi|346421642|gb|JN204911.1|1285-2422,4
,atggctctggcactcgttggcgaaaaaattgacagaaaccgcttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgcttggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagctttatgaatatgatcaccacgcgcacctggttttgtagcgcatatatcacgaatacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaagtgtgagctgtgggaaaaccgttggatgggtacccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggggttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5908,Drugs,MEG_5908|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111590|WP_063865802.1|NG_050476|1|1|qnrB16|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB16 NG_050476:37-681,3
,atgaatgtcatcctgaaccgccgaacgtttttattggctagcgctgtggtgtctgcgtcttattcgctaggtacgctggctggcgctaatcgggatgacgcttcctttcaagatcggctggctaagttggagcagaagctgaacggacggcttggggtatgcgccatcgataccgcaaatggagcacagttgggctatcgcgccaatgagcggtttgccatgaacagcacgttcaaggtcatgctcgcctcagcgtttctcgcccgaagccaagacgaaccggggctcctcgaagagcggctcacgtacacccgggccgatctggtcacatactctcccgtgacggaaaagcacgtttccactgggatgaccgttgccgaattgtgcgccgcaggcattcagtacagtgataacaccgcggccaatgtgctcatgaaaaagctggggggccctgaagcggtcaccgcatttgcccgttcgataggcgatacgcattttcgcctcgatcggtgggaaaccgaactcaattcggctattccgggagatcctcgtgatacgagtacccctcaggccatggcaatgagcctgcaacgtctggcattgggtgacatgctggctgcggataaacagcatcagttgcaggcgtggttgaaaggcaataccacaggtggcaagcgtatccgggccggggtaccggctggctggcaggtaggcgataagacaggtacaggtgattacggctcggccaacgacgtggctatcctctggccgcctcgccgtgcacccgttgtgctggctctctattccgctcttgaaagccagcaggcggaagcgcgcaatgacgtactggccgatgcggcgcgcattgtggctgaatgggtgacaggctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3650,Drugs,MEG_3650|Drugs|betalactams|Class_A_betalactamases|LUT,1028105805|WP_063860830.1|NG_049287|1|1|blaLUT-4|blaLUT|class_A_beta-lactamase_LUT-4 NG_049287:1-891,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcttggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacacccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccaaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5439,Drugs,MEG_5439|Drugs|betalactams|Class_C_betalactamases|PDC,1463920496|WP_116786838.1|NG_061625|1|1|blaPDC-306|blaPDC|class_C_beta-lactamase_PDC-306 NG_061625:1-1194,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagtatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6192,Drugs,MEG_6192|Drugs|betalactams|Class_A_betalactamases|SHV,1028110271|WP_063864641.1|NG_050030|1|1|blaSHV-155|blaSHV|class_A_beta-lactamase_SHV-155 NG_050030:1-861,0
,gtgtcagtcgaaatcatccatctcactggaaacgatgttgcgttgttgcagtcaataaatgccatgttcggcgaggcattcaacgaccaagatagttatgcccgcaacaagccgccatcaagctatcttcaaaaactgcttagcacttctagttttattgcgttggctgcggttgacgagcaaaaagtcattggcgctatcgccgcgtatgagttgcaaaaattcgagcagcaaagaagcgagatttatatctacgatctcgctgtagcggcaacccgccgcagagaaggcatagctacagctctaattaaaaaactcaaggctataggcgcagcgcgtggagcttatgtgatttacgtccaagctgataaaggcgtagaagaccaaccagccatagagctctataaaaaactaggaaccatcgaagacgtatttcatttcgacattgcggttgagcagagtaaaaatcatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_35,Drugs,MEG_35|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,489247580|WP_003155734.1|NG_052489|1|1|aac(3)-I|aac(3)-I|AAC(3)-I_family_aminoglycoside_3-N-acetyltransferase NG_052489:101-577,2
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcactgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5692,Drugs,MEG_5692|Drugs|betalactams|Class_C_betalactamases|PDC,1028110194|WP_063864564.1|NG_049874|1|1|blaPDC-107|blaPDC|class_C_beta-lactamase_PDC-107 NG_049874:1-1194,0
,atggaattgcccaatattatgcacccggtcgcgaagctgagcaccgcattagccgctgcattgatgctgagcgggtgcatgcccggtgaaatccgcccgacgattggccagcaaatggaaactggcgaccaacggtttggcgatctggttttccgccagctcgcaccgaatgtctggcagcacacttcctatctcgacatgccgggtttcggggcagtcgcttccaacggtttgatcgtcagggatggcggccgcgtgctggtggtcgataccgcctggaccgatgaccagaccgcccagatcctcaactggatcaagcaggagatcaacctgccggtcgcgctggcggtggtgactcacgcgcatcaggacaagatgggcggtatggacgcgctgcatgcggcggggattgcgacttatgccaatgcgttgtcgaaccagcttgccccgcaagaggggatggttgcggcgcaacacagcctgactttcgccgccaatggctgggtcgaaccagcaaccgcgcccaactttggcccgctcaaggtattttaccccggccccggccacaccagtgacaatatcaccgttgggatcgacggcaccgacatcgcttttggtggctgcctgatcaaggacagcaaggccaagtcgctcggcaatctcggtgatgccgacactgagcactacgccgcgtcagcgcgcgcgtttggtgcggcgttccccaaggccagcatgatcgtgatgagccattccgcccccgatagccgcgccgcaatcactcatacggcccgcatggtcgacaagctgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4138,Drugs,MEG_4138|Drugs|betalactams|Class_B_betalactamases|NDM,1625655395|WP_136512072.1|NG_064729|1|1|blaNDM-28|blaNDM|subclass_B1_metallo-beta-lactamase_NDM-28 NG_064729:1-813,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAATCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCTCGAAGGGAAGCCTTTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCTGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1982,Drugs,MEG_1982|Drugs|betalactams|Class_C_betalactamases|CMY,gi|591542826|gb|KJ207202.1|549-1776,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGTCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1930,Drugs,MEG_1930|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KJ155695|+|0-1146|ARO:3002122|CMY-111 [Serratia marcescens] ,0
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGTGAAATTGTTATCCTTCCCAGCGACAGCGTGAGGTTAAGCGATGTATTAGGGGACCCAACCCGGCTCCCTCGTAAAAGGTGGCGTGAGGACCCCCTCCCCATGCTGCGGACGTCGATTGCGCCGAAAACGGCAGCGCAAAGAGAACGGCTGCTGAACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGCTGCGAGGTGGATTCCATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTTGTTTCCGCTTTGCTGTCGGAAAAATACAAGCTTGAAACAGTGGTAAAGGAACCCACCGTCATTTATATGGAGCGGCCGCTCAAAGCAGCCAGCCACACCATCCATATCGAGGTGCCGCCCAACCCGTTTTGGGCATCCATCGGACTGTCTGTTACACCACTCCCGCTTGGCTCCGGTGTACAATACGAGAGCCGGGTTTCGCTGGGATACTTGAACCAGAGTTTTCAAAACGCTGTCAGGGATGGTATCCGTTACGGGCTGGAGCAGGGCTTGTTCGGCTGGAACGTAACGGACTGTAAGATTTGCTTTGAATACGGGCTTTATTACAGTCCGGTCAGCACGCCGGCGGACTTCCGCTCATTGGCCCCGATTGTATTGGAACAGGCATTGAAGGAATCAGGGACGCAACTGCTGGAACCTTATCTCTCCTTCACCCTCTATGCGCCCCGGGAATATCTTTCCAGGGCTTATCATGATGCACCGAAATACTGTGCCACCATCGAAACGGTCCAGGTAAAAAAGGATGAAGTTGTCTTTACTGGCGAGATTCCCGCCCGCTGTATACAGGCATACCGTACTGATCTGGCCTTTTACACCAACGGGCAGAGCGTATGCCTTACAGAACTGAAAGGGTATCAGGCCGCTGTCGGCAAGCCAGTCATCCAGCCCCGCCGTCCAAACAACCGCCTGGACAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7173,Drugs,MEG_7173|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/W)_1_AM889118 ,4
,ATGCTAAATTTAACCGTTTGTCAGCCACAGTCAAATCCAACAGACTGGGTATGTCTGACGGGCCCGGACACTCCCTTGACTCGCTATTACGGAAGATAACTGATGATGAAAAAATCCCTGTGCTGCGCCCTGCTGCTCAGCACCTCCTGCGCTGCATTAGCCGCACCTATGTCAGAAACACAGCTGGCGAAGGTCGTGGCACGTACCGTTACGCCCCTGATGAAAGCGCAGTCTATTCCGGGTATGGCGGTCGCCGTGATCTATCAGGGCCAGCCGCACTACTTCACCTTCGGCAAGGCCGATGTCGCAGCGAACACACCCGTCACTGCACAAACGCTGTTTGAGCTGGGCTCAATCAGCAAAACCTTCACCGGCGTTCTGGGTGGCGATGCTATTGCTCGCGGTGAAATTTCGCTGAGCGATCCGGTGACCAAATACTGGCCTGAGCTGACCGGCAAACAGTGGCAGGGCGTTCGCATGCTGGACCTGGCAACCTATACTGCCGGTGGCCTGCCGTTACAGGTGCCCGATGAGGTTACCGATAATGCCTCGCTGCTGCGTTTTTACCAGTCCTGGCAACCACAGTGGGCGCCAGGCACCACGCGTCTTTATGCGAATGCCAGCATCGGTCTGTTTGGGGCTCTGGCGGTGAAACCTTCTGGCATGCGCTTTGAGCAGGCGATGACAGAGCGGGTCCTGAAGCCGCTTAACCTGAACCATACGTGGATTAACGTTCCGAAGGCAGAAGAACAGCATTACGCCTGGGGTTATCGTGACGGTAAAGCGGTTCACGTTTCGCCGGGCATGCTCGATGCCGAAGCGTATGGCGTGAAAACCAACGTGAAGGATATGGCGAGCTGGGTAGTGGCTAACATGGCCCCCGATGGCGTACAGGATGCCTCACTGAAGCAGGGCATGGCGCTTGCACAGTCTCGCTACTGGCGCACAGGCTCGATGTACCAGGGCCTGGGCTGGGAGATGCTCAACTGGCCGGTAGAAGCCAAAACCGTGGTGGAGGGCAGCGACAACAAAGTAGCGCTTGCGCCGTTGCCCGTGGCAGAAGTGAACCCTCCTGCTCCACCGGTAAAAGCGTCATGGGTACATAAAACAGGCTCGACGGGCGGATTTGGCAGCTACGTGGCATTTATCCCTGAGAAGAAACTCGGCATTGTTATGCTGGCGAACAAGAGCTACCCGAACCCGGCGCGCGTGGAAGCGGCATACCGTATTCTGAGCGCTCTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_493,Drugs,MEG_493|Drugs|betalactams|Class_C_betalactamases|ACT,gi|595583481|gb|KF992027.1|599-1846,0
,atggctaagttattaataatgagcatagtaagcttttgttttatatttctattggtattattttttaggtacatattaaaacgctattttaattatatgttaaattataaagtttggtatctaactcttcttgcaggattaattcctttcattcctattaaattctctctttttaaatttaataatgtgaataatcaagcgcccacagttgaaagtaagtcacacgacttgaaccataacataaataccaccaaacctattcaagagttcgcaacagatatccataagtttaattgggattcaattgataatatctgcacagttatttggatagttttagttattattttaagttttaaatttttgaaagccttattatatcttaaatatttaaagaaacagtcactttatctaaacgaaaatgaaaaaaataaaatagatacgatacttttcaaccatcaatataaaaaaaatattgtgattcgaaaagcagagactattcaatctccaataactttttggtatgggaaatatattattttgattcctagttcatattttaaaagtgtaattgacaaaagactaaaatatataatattgcatgaatatgctcatgctaaaaatagagatactttacatttaattatctttaatatcttctctattattatgagttacaatccattagtacatattgtaaaaagaaagataattcatgacaatgaagtagaagccgatagatttgtccttaataatattaacaaaaatgaatttaaaacttatgcggaatctattatggactccgtattaaatgttccattttttaataaaaatatattaagccattcatttaatggtaaaaagtcattactcaaaagaagattaattaatataaaagaagccaatctgaaaaaacagtccaaattaattctaatttttatttgtatttttacttttttgctcatggtaattcaaagccagtttttgatggggcaatccataactgattataattataaaaagcccttacacaacgattaccaaattttagataaaagtaaaatttttggttcaaatagtggatctttcgtcatgtacagcatgaagaaagacaaatactatatttataacgaaaaagaaagtagaaaaaggtattctcctaattcaacttataaaatttatttagctatgtttggacttgaccgacatattataaatgatgaaaattcacgtatgtcatggaatcataagcattacccttttgatgcttggaataaggaacaagatttaaatacagcaatgcaaaattcagttaattggtacttcgaacgtattagcgatcaaataccaaagaactatactgcgactcaactcaagcaattaaattatggtaataaaaatttgggaagttataaaagctattggatggaagatagtttgaaaatatctaatcttgaacaagtaatagtttttaaaaatatgatggaacaaaataaccattttagtaaaaaagcaaagaatcaattatcttcttcattattgattaagaaaaatgaaaagtatgaactgtatgggaaaacaggtacaggtatagtaaacgggaagtataataatgggtggtttgtaggttacgtaattacaaatcatgataagtattattttgctacacatttatcagatggaaagccgtctgggaaaaatgctgaattaatcagtgaaaaaatattaaaagaaatgggtgttttaaatggccaataa,beta-lactamase,antibiotic target alteration,betalactams,MEG_1301,Drugs,MEG_1301|Drugs|betalactams|Penicillin_binding_protein_regulator|BLAR,1028083901|WP_063842869.1|NG_047536|1|1|blaR1|blaR1|beta-lactam_sensor/signal_transducer_BlaR1 NG_047536:101-1858,0
,CACATCGACGTGGAATACGCCGAGAGCATCGGCATCACCGTCGGTAACGTCGCCTACTCGCCGGACAGCGTCGCGGACTTCACGCTGATGCTGATGCTGATGGTGATACGCGACGCCAAATCCATCATCCGCCGCACGGAAGTCCATGACTACCGGCTGAACGCCGTACGCGGGAAAGAACTGCGCGACCTGACCGTCGGGGTGGTCGGAACAGGGCGCATCGGTGTCGCGGTCATGGACAGGTTGAAGGGCTTCGGCTGCCGGGTGCTGGCCTATGACACGATCCCCAACGCCTCCGCCGATTACGTCCCCCTCGACGATTTGCTGCAGCAGAGCGATATCGTGACACTTCACGTGCCACTCAACACGGACACGTATCACCTCCTCGATCGTCGGAACATCGAGGAGATGAAGGGTGGCGCGTACATCATCAACACCGGGCGCGGTCCACTCATCGAAACCGAGGCCCTCATCTCGGCCCTGGAAAGCGGAAACCTCGGCGGAGCGGCGCTGGACGTCCTCGAAGGAGAGGAAGGCATCTTCTACGCCGACTGCCGGGACAAGGCAATCGACGGCAACAAGCCGTTGCTGCGGCTGCAGGAGCTGTCGAACGTGATCATCAGTCCGCATACCGCCTATTACACGGACCACGCTCTGAGCGACACTGTTGAAAACTCCATCATCAATTGCCTCGAATTCGAAAGCGGGAAGTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7399,Drugs,MEG_7399|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,(Gly)VanH-Ac2:AY618461:1-714:714,5
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1327,Drugs,MEG_1327|Drugs|betalactams|Class_A_betalactamases|BLAZ,gi|899756175|gb|CP012118.1|11212-12057 gi|899750899|gb|CP012121.1|49703-48858 gi|584465780|gb|CP007177.1|8789-7944 gi|304384149|gb|CP002139.1|8558-7713 gi|304386437|gb|CP002143.1|8560-7715 gi|304384496|gb|CP002141.1|8557-7712 gi|304381946|gb|CP002135.1|8558-7713 gi|304381909|gb|CP002134.1|8558-7713 gi|304380339|gb|CP002132.1|8559-7714 gi|260066114|gb|GQ900412.1|13653-14498,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgattgagcgccgtctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagcgggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_833,Drugs,MEG_833|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502105|WP_071846257.1|NG_052296|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052296:101-889,2
,GGCATCCAAGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGAAAAGGATAAGTATGAAAAAATTATTTGTTTTATGTGTATTCTTCTTCTGCAACATTGCAGTTGCAGAAGAATCTTTGCCTGATTTAAAAATTGAGAAGCTTGAAGAAGGCGTTTATGTTCATACTTCGTTTGAAGAAGTTAAAGGTTGGAGTGTGGTCACTAAACACGGTTTGGTGGTTCTTGTGAAAAATGACGCCTATCTGATTGATACTCCAATTACTGCTAAAGATACTGAAAAATTAGTCAATTGGTTTGTTGAGCGGGGCTATAAAATCAAAGGCAGTATTTCAACACATTTCCATGGTGACAGTACGGCTGGAATAGAGTGGCTTAATTCTCAATCTATCCCCACATATGCTTCTGAATTAACAAATGAACTTCTTAAAAAAGACAATAAGGTACAAGCTAAACACTCTTTTAATGGGGTTAGTTATTCACTAATTAAAAACAAAATTGAAGTTTTTTATCCAGGCCCAGGGCACACTCAAGATAACGTAGTGGTTTGGTTACCTGAAAAGAAAATTTTATTCGGTGGTTGCTTTGTTAAACCGGACGGTCTTGGCTATTTGGGGGACGCAAATTTAGAAGCTTGGCCAAAGTCCGCTAAAATATTAATGTCTAAATATGGTAAAGCAAAACTAGTTGTGTCGAGTCATAGTGATATTGGAGATGTATCACTCTTGAAACGTACATGGGAGCAGGCTGTTAAAGGGCTGAATGAAAGTAAAAAATCATCACAGCCAAGCGACTAAATTTCTAACAAGGCGCTTCAGCACCGCGCACTTCGTGCGCTCGACAGTTCGTAAGCCGCTTTTTTGTGGTTTTGCTACGCAAAAGGTTTCCACAAAAAATCAACTTACAAACTGCGGCTGAGCTTAACGTTAGAAGGCCCAGGCTATGCAGTACTCCATTCGCTCGGTTCGTGTTTCGGATACATCTGATTGGTTACGCCTTCGCAATCTCCTGTGGGAAGGGGATGACCACGAAACCGAGATCGCCCAGTTTTTCGCCGGAGCCCTGGCCGAGCCCAACGAAGTGCTGGTAGCCCATGATGATGCGGGGGCCGTTGTTGGGCATGTCGAGTTATCCATCCGCGAGGATGTCGCAGGGCTGGAGGGCATCAGAGCGGGCTATATCGAAGGCCTGTACATCGAGGAGGCCCATCGCTCGTCCAGCGTCGCGACGCAGTTACTACGGCACTCCGAGCAATGGGCCCAAAGTCAGGGATGCCGGGCGTTTGCATCGGATCGAGAGGATCGCCTGATCATCCATAAGCGGTTTTCTGTGAGTCCGCTTTCTAACCCTTCATTCCAGCGGACCGCCTTCGGCGGCCGCTGAATTTGAACGTTAGATGCACTAAGCACATAATTGCTCACAGCCAAACTATCAGGTCAAGTCTGCTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3396,Drugs,MEG_3396|Drugs|betalactams|Class_B_betalactamases|IMP,gi|62736339|gb|AY553332.1|1-1505 gi|226426103|gb|EU855788.1|275470-275370 gi|226426103|gb|EU855788.1|139851-139925 gi|226426103|gb|EU855788.1|269337-269280 gi|226426103|gb|EU855788.1|139920-139967 gi|226425792|gb|EU855787.1|253232-253332 gi|226425792|gb|EU855787.1|139851-139925 gi|226425792|gb|EU855787.1|259365-259422 gi|226425792|gb|EU855787.1|139920-139967 gi|365269063|gb|JN624388.2|3938-3995 gi|239702135|emb|FN397627.1|1662-1718,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcgatcaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacttcaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcacctttacaaactttattagacagtaattcagaacaaattgtgatgaagcctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_546,Drugs,MEG_546|Drugs|betalactams|Class_C_betalactamases|ADC,949769351|WP_057093064.1|NG_056105|1|1|blaADC-163|blaADC|class_C_beta-lactamase_ADC-163 NG_056105:1-1152,0
,ATGAAAAAAATTTATATTAGTGTTCTAGTTCTTTTGCTAATTATGATTATAATAACTTGGTTATTCAGAGATAACGATATTGAGAAAACAATTAATTCTATTGAAAAAGGAAACTATAACAAAGTATATAAAAATAGTTCAGAAGCATCTAAACTGGCATATGGAGAAGAAGAAATTATAGATAGGAATAAAAAAATTTACAAAGATTTAAGTGTCAATAACTTAAAAATTACTAATCATAAAACTAAAAAAATCGGAAAAGATAAAAAGCAAGTTGATGTTAGATATAACATATATACAAAATATGGAAATATACGCCGTAATACACAATTAAACTTTATTTATGAAGAAAAGCATTGGAAATTAGATTGGGACCAGGGAGTAATAATACCTGGATTGAAAAATAGGCAAAAAATTAATATAGAAACATTAAAATCAGAACGAGGCAAAATAAAAGATAGAAATGGTATAGAGTTGGCTAAAACTGGAAATACATACGAAATCGGTATTGTCCCTAATAAAACACCCAAAAATAAGTATGACGATATTGCTCGTGGTTTACAAATTGATACAAAAGCTATAACCAATAAAGTTAATCAAAAATGGGTACAGCCAGATTCATTTGTACCAATTAAAAAGATAAATAAAAAAGACGAATCTATAGACAAATTAATTAAATCATACAATTTACAAATAAATACTGTAAAAAGTCGTGTTTATCCATTGAATGAAGCAACAGTACACCTTTTAGGTTATGTGGGCCCCATTAATTCTGACGAGTTAAAAAGTAAGCAATTTGGAAACTATAGCAAAAATACTGTTATTGGAAAAAGGGGATTAGAGCGCCTCTATGATAAACAATTGCAAAACACTGATGGTTTTAGGGTATCCATTGCTAATACTTACGATAATAAATCTTTAGACACATTATTGGAGAAAAAAGCTAAAAACGGAAAAGATCTTCATTTAACAATAGATGCTAGGGTACAAGAAAGTATTTATAATCATATGAAAAATGACTTTGGATCTGGTACAGCATTACAACCTAAAACTGGGGAAATTTTAGCTTTGGTAAGTACCCCTTCATATGATGTTTATCCATTCATTAATGGAATTAGCAATCATGATTATCATAAATTAACTAACAATAAAAAAGAGCCGTTACTCAATAAATTTCAAATCACTACATCACCGGGTTCAACCCAAAAAATATTAACGTCTATTATTGCCTTAAAAGAAAATAAACTAGACGACAATACTAATTTTGATATTTATGGTAAAGGATGGCAAAAAGATGTATCTTGGGGAGATTATAATATAACAAGATTTAAAGTGGTAGACGGTAAGATAGATTTAAAGCAAGCAATAGAATCATCAGACAACATATTTTTTGCACGTATTGCATTAGCTTTAGGAGCTAAAAAATTTGAGCAAGGTATGCAAGATTTAGGTGTTGGTGAAAATATCCCGAGCGATTACCCCTTTTATAAAGCACAAATTTCAAATAGTAATTTAAATAATGACATATTACTAGCAGATTCAGGATATGGCCAAGGCGAGATACTAGTAAATCCTATACAAATTTTGTCAATCTACAGTGCTTTAGAAAATAACGGGAATATACAAAATCCTCATGTTTTACGTGAAACAAAGTCTCAAATTTGGAAAAAGTCTATTATATCTAAAAAAGACATAGATATATTAACTAATGGTATGGAACGTGTAGTGACTAAAACACATAGAGATGATATCTACAAAAATTATGCCCGAATTATAGGTAAATCTGGCACAGCAGAATTAAAAATGAAACAAGGTGAAACCGGAAGACAAATAGGTTGGTTTGTTTCATATGATAAACATAACCCCAATATGCTAATGGCAATTAATGTTAAAGACGTTCAAAATAAAGGGATGGCTAGCTATAATGCTGCTATATCTGGAAAAGTTTATGATGATTTATATGATTATGGAAAAACTAAATTTGACATAGATGAGTAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3800,Drugs,MEG_3800|Drugs|betalactams|Penicillin_binding_protein|MECC,mecC2_1_KF955540,0
,atgtccgaaaccttgcaactcgaacagttaacaggatctttacagcagcttttgggtgaatccctatttgccatttatctgtatggttcagctgttgatggcgggctaggtccagaaagtgatctggatgttttggttgtggtgagtcaagctctgacactccagcaacgacagcaactggcagaaaccttattaaaaatttcgtatccaattggggcagcacagcgtgcacttgaagtcaccatcgtacttaaagcgcaaattctttcaggcagttatccactcagctacgaactacaatttggagaatggttacgggaggagttaaaccaaggtgctttgctccgcacacatacagaccctgatctgagtattttgctgaagaaagcacaagtgcatcatcgtagtttgttggggccaagtttgacacagtggtcaacggcaattcctgaacagcacctctggcaggcaatggcagacacctatccctcgattgtggaacattgggatgaggatgccgatgagcgtaatcaaattttggccttatgccgtatttattttagtttggtgacgagtgagattgtgcctaaagaccaggccgcacactgggtgatagctcagttaccgtcgcagcatcaacccattttgcagcgcatgatccaagaatataaaggtgagataggcaagcaaagctggcaacaacagcatcaggctttaggagctgttgttgacttcctgagttcaaaaattgatgaacaatttaagaagaagagtagcctgatcaaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_836,Drugs,MEG_836|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,490896642|WP_004758588.1|NG_054654|1|1|ant(3'')-IIc|ant(3'')-IIc|aminoglycoside_nucleotidyltransferase_ANT(3'')-IIc NG_054654:101-889,2
,ATCTTATAAGTCTTATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATAAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATAGGCTTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCTATGAAAGTTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCATTTCACTTTTTACCATTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5239,Drugs,MEG_5239|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389167|gb|KJ135344.1|1-874,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATGGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGTTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGACCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTACACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGCAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGTGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTCCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1961,Drugs,MEG_1961|Drugs|betalactams|Class_C_betalactamases|CMY,gi|387861052|gb|JQ711185.1|1028-2255,0
,ATGAATAACATCGGCATTACTGTTTATGGATGTGAGCAGGATGAGGCAGATGCATTCCATGCTCTTTCGCCTCGCTTTGGCGTTATGGCAACGATAATTAACGCCAACGTGTCGGAATCCAACGCCAAATCCGCGCCTTTCAATCAATGTATCAGTGTGGGACATAAATCAGAGATTTCCGCCTCTATTCTTCTTGCGCTGAAGAGAGCCGGTGTGAAATATATTTCTACCCGAAGCATCGGCTGCAATCATATAGATACAACTGCTGCTAAGAGAATGGGCATCACTGTCGACAATGTGGCGTACTCGCCGGATAGCGTTGCCGATTATACTATGATGCTAATTCTTATGGCAGTACGCAACGTAAAATCGATTGTGCGCTCTGTGGAAAAACATGATTTCAGGTTGGACAGCGACCGTGGCAAGGTACTCAGCGACATGACAGTTGGTGTGGTGGGAACGGGCCAGATAGGCAAAGCGGTTATTGAGCGGCTGCGAGGATTTGGATGTAAAGTGTTGGCTTATAGTCGCAGCCGAAGTATAGAGGTAAACTATGTACCGTTTGATGAGTTGCTGCAAAATAGCGATATCGTTACGCTTCATGTGCCGCTCAATACGGATACGCACTATATTATCAGCCACGAACAAATACAGAGAATGAAGCAAGGAGCATTTCTTATCAATACTGGGCGCGGTCCACTTGTAGATACCTATGAGTTGGTTAAAGCATTAGAAAACGGGAAACTGGGCGGTGCCGCATTGGATGTATTGGAAGGAGAGGAAGAGTTTTTCTACTCTGATTGCACCCAAAAACCAATTGATAATCAATTTTTACTTAAACTTCAAAGAATGCCTAACGTGATAATCACACCGCATACGGCCTATTATACCGAGCAAGCGTTGCGTGATACCGTTGAAAAAACCATTAAAAACTGTTTGGATTTTGAAAGGAGACAGGAGCATGAATAGAATAAAAGTTGCAATACTGTTTGGGGGTTGCTCAGAGGAGCATGACGTATCGGTAAAATCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGTGTATGGAAAATGTGCGAAAAACCTTGCGCGGAATGGGAAAACGACAATTGCTATTCAGCTGTACTCTCGCCGGATAAAAAAATGCACGGATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCATGGCAAGTCAGGTGAAGATGGATCCATACAAGGTCTGTTTGAATTGTCCGGTATCCCTTTTGTAGGCTGCGATATTCAAAGCTCAGCAATTTGTATGGACAAATCGTTGACATACATCGTTGCGAAAAATGCTGGGATAGCTACTCCCGCCTTTTGGGTTATTAATAAAGATGATAGGCCGGTGGCAGCTACGTTTACCTATCCTGTTTTTGTTAAGCCGGCGCGTTCAGGCTCATCCTTCGGTGTGAAAAAAGTCAATAGCGCGGACGAATTGGACTACGCAATTGAATCGGCAAGACAATATGACAGCAAAATCTTAATTGAGCAGGCTGTTTCGGGCTGTGAGGTCGGTTGTGCGGTATTGGGAAACAGTGCCGCGTTAGTTGTTGGCGAGGTGGACCAAATCAGGCTGCAGTACGGAATCTTTCGTATTCATCAGGAAGTCGAGCCGGAAAAAGGCTCTGAAAACGCAGTTATAACCGTTCCCGCAGACCTTTCAGCAGAGGAGCGAGGACGGATACAGGAAACGGCAAAAAAAATATATAAAGCGCTCGGCTGTAGAGGTCTAGCCCGTGTGGATATGTTTTTACAAGATAACGGCCGCATTGTACTGAACGAAGTCAATACTCTGCCCGGTTTCACGTCATACAGTCGTTATCCCCGTATGATGGCCGCTGCAGGTATTGCACTTCCCGAACTGATTGACCGCTTGATCGTATTAGCGTTAAAGGGGTGATAAGCATGGAAATAGGATTTACTTTTTTAGATGAAATAGTACACGGTGTTCGTTGGGACGCTAAATATGCCACTTGGGATAATTTCACCGGAAAACCGGTTGACGGTTATGAAGTAAATCGCATTGTAGGGACATACGAGTTGGCTGAATCGCTTTTGAAGGCAAAAGAACTGGCTGCTACCCAAGGGTACGGATTGCTTCTATGGGACGGTTACCGTCCTAAGCGTGCTGTAAACTGTTTTATGCAATGGGCTGCACAGCCGGAAAATAACCTGACAAAGGAAAGTTATTATCCCAATATTGACCGAACTGAGATGATTTCAAAAGGATACGTGGCTTCAAAATCAAGCCATAGCCGCGGCAGTGCCATTGATCTTACGCTTTATCGATTAGACACGGGTGAGCTTGTACCAATGGGGAGCCGATTTGATTTTATGGATGAACGCTCTCATCATGCGGCAAATGGAATATCATGCAATGAAGCGCAAAATCGCAGACGTTTGCGCTCCATCATGGAAAACAGTGGGTTTGAAGCATATAGCCTCGAATGGTGGCACTATGTATTAAGAGACGAACCATACCCCAATAGCTATTTTGATTTCCCCGTTAAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7410,Drugs,MEG_7410|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,VanHAX_2_M97297,5
,GAATTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACATGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6945,Drugs,MEG_6945|Drugs|betalactams|Class_A_betalactamases|TEM,gi|695224309|ref|NG_041046.1|1-1069,0
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcagccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccctttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4499,Drugs,MEG_4499|Drugs|betalactams|Class_D_betalactamases|OXA,1509794575|WP_122630884.1|NG_062304|1|1|blaOXA-682|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-682 NG_062304:14-838,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatacaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgggcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4386,Drugs,MEG_4386|Drugs|betalactams|Class_D_betalactamases|OXA,1391852909|WP_109545094.1|NG_057528|1|1|blaOXA-600|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-600 NG_057528:1-774,0
,CATCGACTCGGACTACGACCATTACCCCTGATAATGCTTCATAATATTAGAAAAAGGAGAAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCTTTTTGCCTTCCTGTTTTTGCTCACCCAAAAACGCTGGTGAAAGTAAAAGATGCTGAAAATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAAAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAGTGACGTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_6871,Drugs,MEG_6871|Drugs|betalactams|Class_A_betalactamases|TEM,gi|134154076|gb|EF468463.1|1-943,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATATAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1437,Drugs,MEG_1437|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_31_JIFU01000008,0
,CGGTGCAAATCAAACACACTGATTGCGTCTGACGGGCCCGGACACCTTTTTGCTTTTAATTACGGAACTGATTTCATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGGAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAACTGACGATGAGGCCCAGGATATTGGGCCTCCTTTCTTTCTCTTTTTTTCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_1989,Drugs,MEG_1989|Drugs|betalactams|Class_C_betalactamases|CMY,gi|641682562|emb|HG941718.1|4940329-4941599 gi|93277247|gb|DQ463751.1|1-1271 gi|90568484|gb|DQ438952.1|86-1356,0
,atgaaaattattaatataggtgttttagctcatgttgacgcaggaaaaactactttgacagaaagcttactatatactagtggagcgattgcggagtcaggaagcgtggatacaggcacaacaagaacggatactacatttttagaacgtcagcgaggaattacaattcagacagcagtaacctcttttcagtggaaagatattaaggtaaatatcatagatactccaggacatatggattttttagcagaagtatatcgctcgttatcagttttagatggggcaatcctactaatttctgcgagagatggagtacaagcacaaactcggatattatttcatgcactaaataaaatgggtattcccacaatcttttttatcaataagattgaccaaaatgggattgatttatcaacggtttatcaagatattaaagagaaactttctatggaaattataatcaaacagaaagtagagctgcaccctaatatgtgtgtgatgagctgtacggaacctgagcaatgggatgtggtaatagaaggaaatgattatcttttggagaaatatacacttgggaaatcattggagatattagaactcgaacaagaggaaatcagaagatttcagaattgctccttgtaccctgtttatcatggaagcgcaaaaagcaacatagggattgagcagcttatagaagtgataacgaataaattttattcatcaacatacagaaagaagtctgaactttgcggaaatgtcttcaaaattgaatattcggaagaaagacaacgtcttgcatatgtacgcctttatggcggaatcctgcatttgcgggattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaattgataaggcttattccggggaaattgttattttgcaaaatgagtttttgaagctaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatccgctccctctgctgcaaacaactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctacaatattatgtggattctacgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctattgcaagaaaagtatcatgtggaggtaaaaataaaaaagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagtgccaccgaatcccttctgggcttccattggtctttctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaagggatacgatatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagttttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcaccacaagaatatctttcacgagcatataacgatgctcctaaatattgtgcgaacatcgtagacactcaactgaaaaataatgaggtcattcttagtggagaaattcctgctcggtgtattcaagaatatcgtaatgatttaactttctttacaaatggacgtagcgtttgtttaacagagttaaaagggtactatgttactactggtgaatctgtttgtcagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7114,Drugs,MEG_7114|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,500187484|WP_011860841.1|NG_048243|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048243:101-2020,4
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtattcaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattgggcttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcaacaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatatctagctctgttcgaaaagagattacttatagaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4503,Drugs,MEG_4503|Drugs|betalactams|Class_D_betalactamases|OXA,1559612975|WP_128268240.1|NG_063845|1|1|blaOXA-741|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-741 NG_063845:40-864,0
,atgatcgtcaactgcgaccacgacaaccttgatgcctggctggcgctgcgctcggcgctgtggcccacctgcctgcgggaagaacaccgcgcagaaatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgagatcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttacaccgtcgaacgcgcccgccgccagggctgggccgcgcgcctgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgacatcgccaatctggactcccaacgcctgcatgcggcgctaggctttgccgaaacggaacgggtggtgttttaccgcaaaatgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_104,Drugs,MEG_104|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,817735110|WP_046687856.1|NG_052466|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052466:101-541,2
,ATGTTTAGAATTAAAGTTGCAGTTCTGTTTGGGGGCTGTTCAGAGGAACATAATGTTTCGATAAAATCTGCGATGGAGATTGCCGCAAACATAGATACAAAAAAGTATCAGCCTTATTATATTGGAATCACAAAATCCGGCGTTTGGAAAATGTGTGAAAAACCTTGTTTGGAGTGGGAACAATATGCGGGGGATCCGGTTGTTTTTTCACCGGACAGAAGTACGCATGGTCTGCTGATACAAAAAGACACTGGGTATGAAATCCAGCCTGTGGATGTGGGATTACCGATGATTCATGGCAAGTTTGGCGAGGATGGCTCCATACAAGGCTTGCTTGAATTGTCAGGCATTCCGTATGTGGGATGCGATATTCAAAGCTCCGTGACCTGCATGGATAAGGCGCTTGCATATACCGTTGTGAAAAATGCGGGTATCGCTGTGCCTGGGTTCCGGATCCTTCAGGAGGGGGATCGCCTGGAAACAGAGGATTTCGTATATCCCGTTTTTGTAAAGCCTGCCCGTTCCGGCTCATCCTTTGGCGTAAACAAGGTATGCAAGGCAGAAGAACTGCAGGCAGCAATCGAAGATGCAAGAAAATATGACAGCAAGATTTTGATTGAAGAGGCCGTTACCGGGAGTGAGGTAGGCTGCGCCATACTGGGAAACGGAAATGATCTCATGGCTGGCGAGGTGGATCAGATTGAGCTGAGACACGGCTTTTTTAAGATTCATCAGGAAGCACAGCCGGAGAAAGGATCTGAAAATGCAGTCATCCGAGTTCCAGCCGCCTTACCGGATGAGGTAATAGAACGGATTCAGAAAACAGCAATGAAGATTTACCGGATACTTGGCTGCAGAGGATTGGCCCGCATTGACCTGTTTTTGCGGGAGGACGGCTGCATTGTGTTGAATGAAGTGAATACCATGCCGGGTTTTACTTCCTACAGCCGTTATCCCCGCATGATGACAGCAGCCGGTTTTACGCTTACTGAAATACTGGATCGCTTGATTGAACTTTCACTTAGGAGGTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7389,Drugs,MEG_7389|Drugs|Glycopeptides|VanD-type_resistance_protein|VAND,gi|5759260|gb|AF175293.1|AF175293|4079-5110,5
,GGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6917,Drugs,MEG_6917|Drugs|betalactams|Class_A_betalactamases|TEM,gi|4557165|gb|AF104441.1|1-1054,0
,atgagccatattcaacgggaaacgtcttgctcgaggcagcgattaaattccaacctggatgctgatttatatgggtataaatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggaatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccccgggaaaacagcattccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagcgttcctgcgccggttgcattcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgatgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataagcttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataatcttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccattctatggaactgcctcggtgaattttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctga,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1023,Drugs,MEG_1023|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,445940475|WP_000018330.1|NG_047441|1|1|aph(3')-Ia|aph(3')-Ia|aminoglycoside_O-phosphotransferase_APH(3')-Ia NG_047441:101-916,2
,atgagggaagcggtgaccgccgaaatttcgactcaactatcagaggtgcttagcgtcatcgagcgccatctggagtcgacgttgctggccgtgcatttgtacggctccgcagtggatggcggcttgaagccatacagcgatattgatttgctggttactgtgaccgtaaggcttaatgaagcaacacggcaagctttgctcaatgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacatcgatctggctatcttgctaacgaaagcgagagaacatagcgtggctttggtaggtccggcggcggaggaactctttgatccagttcctgaacaagatctaatcaaggcgctgaatgaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagcaactggtaaaatcgcgccgaaggatgtcgctgccaactgggcaatggaacatctacctgcccagcatcagtctgtcttgcttgaagctagacaggcttatcttgggcaagaggaagatcgctcggtcttgcgcgcagataagttggaagaatttattcacttcatgaaaagcgagatcaccaaggtgctcggcaatgatgtctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_781,Drugs,MEG_781|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502117|WP_071846269.1|NG_052310|1|1|aadA13|aadA13|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA13 NG_052310:101-898,2
,ATGATGAAAAAATCGTTATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGAGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTACCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGTTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1936,Drugs,MEG_1936|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KM087837|+|0-1146|ARO:3002123|CMY-112 [Citrobacter freundii] ,0
,ATGATGAAAAAATCGTTATGCTCCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAACCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGGAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACTGTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAAAAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCTTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACGACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3537,Drugs,MEG_3537|Drugs|betalactams|Class_C_betalactamases|LAT,gb|X78117|+|141-1287|ARO:3001857|LAT-1 [Klebsiella pneumoniae] ,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattagtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1791,Drugs,MEG_1791|Drugs|betalactams|Class_C_betalactamases|CMY,1073722257|WP_070064537.1|NG_051753|1|1|blaCMY-142|blaCMY|class_C_beta-lactamase_CMY-142 NG_051753:1-1146,0
,atggacagaaaaagattgacacagcgtttcccgttcctgcttccaatgagacgggcgcagagaaaaatgtgcttttatgcgggaatgagatttgacggctgtcgctatgcgcagacgataggggaaaaatcgctttcccatttgctctttgaaacggattgcgcattatacaaccacaataccggatttgacatgatataccaggaaaacaaggtgttcaacttaaagctggcagcaaagaccttaaacggcttattgataagaccgggggaaaccttttctttctggtggctggtacgccatgcggacaaagataccccctataaagacggccttacggtgaccaatggtaaactcaccaccatgtcgggcggcggtatgtgccagatgagcaatttactattttggatgttcctgcatacgccatcgacaattatccagcgcagaggtcacgaagtaaaggagtttccagagccaaacagtgacgagattaaaggggtggatgcaaccatttcagagggctggattgatttaaaagtgcgaaacgataccgactgcacctaccaaatatgggtgaccttagatgatgagaaaatcatcggtcaggtgtccgccgacaaagagccccaagcattatacaaaattacaaatggcagtatccagtatgtccgtgaaagtggcgggatttatgaatatgcccaggttaaacggatgcaagttgccttaggtaccggggaaataatagattgcaagctgctttatacaaacaaatgcaaaatctgttatcccctcccggaaagtgtggatattcaggaggagaaccaatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7538,Drugs,MEG_7538|Drugs|Glycopeptides|VanB-type_accessory_protein|VANWB,1028100628|WP_063856763.1|NG_048469|1|1|vanW-B|vanW-B|glycopeptide_resistance_accessory_protein_VanW-B NG_048469:101-928,5
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACGGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGACATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCGCCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1371,Drugs,MEG_1371|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_47_NZ_JYGF01000020,0
,atgactaaaaaagctcttttctttgctattagtgccatatttttgtcagcatgttctttcaatacagtacaacagcaccaaatacacgctatttctactcataaaaattcagaagaaattaaatcactgtttgatcaggcacagaccacgggagttttagtgattaagcgtgggcaaaccgaagaaatttatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacatttaaaatgctaaatgctttaattggacttgaacatcataaagcaacgacaactgaaatgttcaaatgggatggacaaaagcgtttatttcctgattgggaaaaggatatgactctgggtgaggccatgaaagcttctgctattcctgtctatcaagaactagcgcgaagaattggccttgatcttatgtccaaagaggtcaagcgtattggtttcggtaatgctgatattggttcaaaagtagataatttttggcttgttggtccccttaaaattacacctcagcaagaaacccaatttgcttatgaattagcacataaaactcttccctttagcaaaaatgtacaagaacaagttcaatctatggtgttcgtagaagaaaaaaacggacgtaaaatttacgctaaaagcggttggggattggatatggatcctcaagttggctggttaacaggctgggtcgttcaaccacaaggagaaattgtggcattctcgctcaatttagaaatgaaaaaaggcatacctagttctatccgaaaagaaattgcttataagggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4571,Drugs,MEG_4571|Drugs|betalactams|Class_D_betalactamases|OXA,1625655415|WP_136512092.1|NG_064759|1|1|blaOXA-801|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-801 NG_064759:1-822,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAAAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCGAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGATGGTGTTTCAAAAGACTGTAAGGTGGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1343,Drugs,MEG_1343|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_24_JBLQ01000018,0
,TCGGCCCTCACTCAAGGATGTATTGTGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGCATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6419,Drugs,MEG_6419|Drugs|betalactams|Class_A_betalactamases|SHV,gi|160948440|emb|AM176550.2|1-891,0
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgtgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcagttgtgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgctttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccacggagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagccagcgtattgtcaaacaagccatgctgaccgaagccaatggtgactatattattcgggctaaaactggatactcgactaaacctaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggaaaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4613,Drugs,MEG_4613|Drugs|betalactams|Class_D_betalactamases|OXA,1188444882|WP_085562384.1|NG_054666|1|1|blaOXA-517|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-517 NG_054666:1-792,0
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAAGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTATCAGAAAACTGAAGGAACCTCCATTGAATCGAACTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6633,Drugs,MEG_6633|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|66840966|emb|AJ877041.1|146-997 gi|975007785|gb|CP010832.1|3652-3615 gi|954666075|gb|KT962845.1|18735-18698 gi|971339514|gb|CP006662.2|54069-54032 gi|943457735|gb|KT818627.1|109771-109734,8
,ATGAATAAATCAATTATTATTATACTGCTGATCACCGTATTAGATGCCATTGGTATCGGGCTTATCATGCCAGTACTCCCTACTCTATTAAATGAATTTGTCAGTGAAAATTCACTGGCAACCCATTACGGTGTGCTATTAGCGCTCTATGCTACCATGCAGGTTATTTTTGCTCCTATTCTAGGACGACTGTCTGATAAATACGGCAGAAAACCCATCTTGCTGTTTTCCCTTTTAGGCGCGGCACTCGACTATCTTTTAATGGCATTCTCAACCACACTTTGGATGCTCTATATTGGGCGCATCATTGCGGGGATCACAGGCGCAACAGGTGCCGTATGTGCATCAGCGATGAGTGATGTGACTCCCGCTAAAAATCGAACTCGCTATTTTGGTTTCTTAGGTGGTGCTTTTGGTGTTGGCCTTATTATCGGCCCAATGCTAGGGGGATTATTAGGTGATATCAGTGCTCATATGCCATTTATTTTTGCCGCTATTTCACACTCGATATTATTAATACTCTCTTTGCTCTTTTTCCGAGAAACACAAAAAAGAGAAGCGCTTGTTGCCAATAGGACACCTGAAAACCAAACTGCCTCAAATACAGTCACTGTTTTTTTTAAGAAAAGCCTCTACTTTTGGTTAGCAACCTATTTTATTATCCAGCTTATCGGGCAAATTCCTGCCACCATCTGGGTGCTGTTTACACAATATCGTTTTGATTGGAACACAACTTCTATCGGTATGTCTTTGGCGGTTCTGGGTGTATTACATATTTTCTTTCAGGCGATTGTCGCTGGGAAATTGGCACAAAAATGGGGCGAAAAAACCACCATTATGATCAGTATGTCTATTGATATGATGGGCTGTTTATTATTAGCGTGGATAGGCCACGTTTGGGTCATCTTACCAGCATTAATTTGCTTAGCGGCAGGAGGTATGGGGCAACCCGCATTACAAGGTTATTTATCAAAATCTGTCGATGATAATGCGCAAGGGAAATTACAAGGTACTCTGGTGAGCCTAACCAATATTACCGGGATCATTGGTCCCCTTTTATTTGCCTTTATTTATAGTTATAGCGTCGCTTATTGGGATGGTCTGTTATGGCTGATGGGGGCAATACTTTATGCTATGTTGCTTATTACCGCTTATTTTCACCAAAGAAAAAGCGATTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7086,Drugs,MEG_7086|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETH,gi|695211671|ref|NG_036104.1|1215-2393 gi|695199890|ref|NG_035330.1|986-2164 gi|38224931|gb|AY362554.1|3455-4633 gi|785798809|gb|CP011099.1|1616310-1617480 gi|785795794|gb|CP011098.1|1616287-1617457 gi|678222343|gb|KJ909292.1|5117-6287 gi|575439963|gb|CP006942.1|974729-973559 gi|511255433|gb|KC734562.1|4318-5488 gi|511255399|gb|KC734561.1|3612-2442 gi|511255369|gb|KC734560.1|4418-5588,4
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAATGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1436,Drugs,MEG_1436|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_95_MAJJ01000071,0
,TAAGTGTTTAAGGGCGCATGGTGGATGCCTTGGCATCGAGAGCCGATGAAGGACGTGGGAGGCTGCGATATGCCTCGGGGAGCTGTCAACCGAGCATTGATCCGAGGATTTCCGAATGGGGAAACCCAGCACGAGTGATGTCGTGTTACCCGCATCTGAATATATAGGGTGCGGGAGGGAACGCGGGGAAGTGAAACATCTCAGTACCCGTAGGAGAAGAAAACAATTGTGATTCCGTAAGTAGTGGCGAGCGAACGCGGAACAGGCTAAACCGCACGCATGTGATACCGGGTAGGGGTTGTGTGTGCGGGGTTGTGGGAGGATACATCTCAGCTCTACCTGGCTGAGGGGTAGTCAGAAAGTGTCGTGGTTAGCGGAAGTGGCCTGGGATGGTCTGCCGTAGACGGTGAGAGCCCGGTACGCGAAAACCCGTCACCTACCTTGTATCAATTCCCGAGTAGCAGCGGGCCCGTGGAATCTGCTGTGAATCTGCCGGGACCACCCGGTAAGCCTAAATACTTCTCGATGACCGATAGCGGATTAGTACCGTGAGGGAATGGTGAAAAGTACCCCGGGAGGGGAGTGAAATAGTACCTGAAACCGTGTGCCTACAATCCGTCAGAGCCTCCTTGTGGGGTGATGGCGTGCCTTTTGAAGAATGAGCCTGCGAGTCAGGGACACGTCGCGAGGTTAACCCGTGCGGGGTAGCCGCAGCGAAAGCGAGTCTGAATAGGGCGCATCCCCTTTGGGGTGTAGTGGCGTGTTCTGGACCCGAAGCGGAGTGATCTACCCATGGCCAGGGTGAAGCGCGGGTAAGACCGCGTGGAGGCCCGAACCCACTTAGGTTGAAGACTGAGGGGATGAGCTGTGGGTAGGGGTGAAAGGCCAATCAAACTCCGTGATAGCTGGTTCTCCCCGAAATGCATTTAGGTGCAGCGTTGCGTGGTTCACCACGGAGGTAGAGCTACTGGATGGCCGATGGGCCCTACTAGGTTACTGACGTCAGCCAAACTCCGAATGCCGTGGTGTAAAGCGTGGCAGTGAGACGGCGGGGGATAAGCTCCGTACGTCGAAAGGGAAACAGCCCAGATCGCCGGCTAAGGCCCCTAAGCGTGTGCTAAGTGGAAAAGGATGTGTAGTCGCAGAGACAACCAGGAGGTTGGCTTAGAAGCAGCCACCCTTGAAAGAGTGCGTAATAGCTCACTGGTCAAGTGATTATGCGCCGATAATGTAGCGGGGCTCAAGCACACCGCCGAAGCCGCGGCACATTCACGTTTACGTGGATGTGGGTAGGGGGAGCGTCCCTCATTCAGCGAAGCCTCCGGGTGACCGGTGGTGGAGGGTGGGGGAGTGAGAATGCAGGCATGAGTAGCGATAAGGCAAGTGAGAACCTTGCCCGCCGTAAGACCAAGGGTTCCTGGGCCAGGCCAGTCCGCCCAGGGTGAGTCGGGACCTAAGGCGAGGCCGACAGGCGTAGTCGATGGACAACGGGTTGATATTCCCGTACCCGTGTATGGGCGTCCCTGATGAATCAGCGGTACTAACCACCCAAAACCGGATCGACCATTCCCCTTCGGGGGCATGGAGTTTCGGGGCTGCGTGGGACCTTCGCTGGTAGTAGTCAAGCAATGGGGTGACGCAGGAAGGTAGCCGTACCAGTCAGTGGTAATACTGGGGCAAGCCTGTAGGGAGAGCGATAGGCAAATCCGTCGCTCATTAATCCTGAGAGGTGATGCATAGCCGATTGAGGTGAATTCGGTGATCCTCTGCTGCCAAGAAAAGCCTCTAGCGAGCACATACACGGCCCGTACCCCAAACCAACACAGGTGGTCAGGTAGAGAATACCAAGGCGTACGAGATAACTATGGTTAAGGAACTCGGCAAAATGCCCCCGTAACTTCGGGAGAAGGGGGGCCGGAATACCGTGAACACCCTTGCGGTGGGAGCGGGATCCGGCCGCAGAAACCAGTGGGTAGCGACTGTTTACTAAAAACACAGGTCCGTGCGAAGTCGCAAGACGATGTATACGGACTGACGCCTGCCCGGTGCTGGAAGGTTAAGAGGACCCGTTAACCGTAAGGTGAAGCGGAGAATTTAAGCCCCAGTAAACGGCGGTGGTAACTATAACCATCCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCTGCACGAATGGCGTAACGACTTCCCAACTGTCTCAACCATAGACTCGGCGAAATTGCACTACGAGTAAAGATGCTCGTTACGCGCGGCAGGACGAAAAGACCCCGGGACCTTCACTACAACTTGGTATTGGTGTTCGGTACGGTTTGTGTAGGATAGGTGGGAGACTGTGAAATACAGACGCCAGTTTGTATGGAGTCGTTGTTGAAATACCACTCTGATCGTATTGGACACCTAACGTCGAACCCTTATCGGGTTCACGGACAGTGCCTGGCGGGTAGTTTAACTGGGGCGGTTGCCTCCTAAAATGTAACGGAGGCGCCCAAAGGTTCCCTCAACCTGGACGGCAATCAGGTGACGAGTGTAAGTGCACAAGGGAGCTTGACTGCGAGACTTACAAGTCAAGCAGGGACGAAAGTCGGGACTAGTGATCCGGCACCCCCGAGTGGAAGGGGTGTCGCTCAACGGATAAAAGGTACCCCGGGGATAACAGGCTGATCTTCCCCAAGAGTCCATATCGACGGGATGGTTTGGCACCTCGATGTCGGCTCGTCGCATCCTGGGGCTGGAGCAGGTCCCAAGGGTTGGGCTGTTCGCCCATTAAAGCGGCACGCGAGCTGGGTTTAGAACGTCGTGAGACAGTTCGGTCTCTATCCGCCGCGCGCGTCAGAAACTTGAGGAAACCTGTCCCTAGTACGAGAGGACCGGGACGGACGAACCTCTGGTATACCAGTTGTTCCACCAGGAGCACGGCTGGATAGCCACGTTCGGACAGGATAACCGCTGAAAGCATCTAAGCGGGAAACCTTCTCCAAGATCAGGTTTCTCACCCTTTTAGAGGGATAAGGCCCCCCGCAGACCACGGGTTCGATAGGCTAGACCTGGAAGCTCAGCAATGAGTGCAGGGAACTGGCACTAACCGGCCGAAAACTTAC,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3985,Drugs,MEG_3985|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NR_076151.1|+|0-3103|ARO:3004166|Mycobacterium intracellulare 23S rRNA with mutation conferring resistance to clarithromycin [Mycobacterium intracellulare] ,7
,atgcgatttaaaaaaatttcttgtctacttttctccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttactgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccctggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttatttatgccaaccttaacccacagaaatatccggctgatattcaaagggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgagtgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_618,Drugs,MEG_618|Drugs|betalactams|Class_C_betalactamases|ADC,691117724|WP_032037870.1|NG_055788|1|1|blaADC-160|blaADC|class_C_beta-lactamase_ADC-160 NG_055788:1-1152,0
,atgaaaaaaagcattcaattttttattgtttccatgttgttgagcccttttgccaatgcacaggtaaaagattttgtaattgagccacctattaaatccaatctatatatttacaagacttttggagtattcggaggtaaagaatattctgccaatgcagcctatcttaagactaaaaaaggtgtaattctgtttgatgtaccctgggaaaaagtacagtatcaaagcctgatggataccatcaaaaaacgtcataacttaccggtaattgccgtatttgctacgcattcccatgatgaccgtgcaggagacttaagctttttcaataataaaggcattaagacgtatgctaccctgaaaaccaatgagtttctgaagaaagatggaaaagcaacatccacagagatcatccaaaccggaaaaccttatcacattggcggagaagaatttgtggtcgattttcttggtgaaggacatactgctgataatgtagtggtatggtttccaaaatataatgttttggatggcggatgtcttgtaaaaagtaattctgctactgacttaggatacattaaagaagccaatgtagaacaatggcccaagacgatgaataaattaaaaaccaaatattcaaaagccacattaattattcccgggcatgatgaatggaaagggggtggacatgttgaacacactttagagcttttgaacaaaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3400,Drugs,MEG_3400|Drugs|betalactams|Class_B_betalactamases|IND,919213656|WP_052769157.1|NG_054943|1|1|blaIND-16|blaIND|subclass_B1_metallo-beta-lactamase_IND-16 NG_054943:1-720,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcaacaggcctgcgccgagcgctacacgccagcctcgaccttcaaggtggccattgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggctacggcaatgcggacgtctcgggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaggctggtgaaccggcaattgccggtcaaggccgccgcctatgagcttgccgaaaacctcttcgaggtgggccaggccgatggctggcgcctgtttggcaagaccggcaccgggtcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccggcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4538,Drugs,MEG_4538|Drugs|betalactams|Class_D_betalactamases|OXA,1625655397|WP_136512074.1|NG_064736|1|1|blaOXA-114n|blaOXA-114_like|class_D_beta-lactamase_OXA-114n NG_064736:1-828,0
,atgcgtcaatatcgattcgcccttctgccattgttagccgccctggcgctccccggttgggcgcatgaagccacggtgacgacggttaaacaagccgaaagccagctgcagggccgggtcggctacgccgaactggatttagcttccggccaactgctgtccggctatcgcgctggcgaacgcttcccgatgatgagcacctttaaagtgctgctctgcggcgcagtcttgtcgcgcgtcgataccggtgaagaacagctcgatcgccgtatccattaccggcagcaggatctggtggaatactcgccggtgacggagaagcatcttgccgatgggctcaacgtgggcgaactgtgcgcggccgccattaccctgagcgataatacggcggcaaacctgctgttgaccactctcggcggcccgcaggggctgaccacgttcctgcgccacagcggcgaccagacttcgcgactcgaccggtgggaaacggaactcaatgaagcgcggccgggcgatgtgcgtgatacgacgactccggaagcgatggccaggacactgcgaaatctgttgaccggccgcgtgctttcccccgcctcgcagcagcagttgcaacgctggatggtagaggacaaagttgcggggccgctgttgcgctctgcgctgccggcgggctggtttattgccgataagaccggagccggcaatcgcggctcgcgcggaatcatcgccgctctcggtccggacggtaaagccgcgcgcatcgtggtgatttatttaaccgcaaccccggcctcaatggatgagcgcaataaacagattgcggccatcggtgaaacgctggtcaggcactggtccaaagacgataaaagaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4371,Drugs,MEG_4371|Drugs|betalactams|Class_A_betalactamases|ORN,1028105953|WP_063860934.1|NG_049389|1|1|blaORN-4|blaORN|class_A_beta-lactamase_ORN-4 NG_049389:101-976,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaataccccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagtgctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgatcaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatatagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_611,Drugs,MEG_611|Drugs|betalactams|Class_C_betalactamases|ADC,1028102030|WP_063857807.1|NG_048665|1|1|blaADC-54|blaADC|class_C_beta-lactamase_ADC-54 NG_048665:1-1152,0
,atgacaaagaaagaacacactacgattacagagttatttcaagttttggacttgttggaaagcctggacatgcagttttggttggatggaggctggggagtggatgtcttgtacggacagcaaacccgcttgcatagagatattgacattgattttgatgccaattatacagaccaactccttgatcttttgcaggagagaggatatcaaattgaaacaaattggttgcccacccgtgtggaactgtatagcaaagaattaggctatattgatatccatccttttgtcttgaatgcggacggcacttccaaacaagccgacttggatggaggctggtatgaatttcaaccggactattttggaacagcagtctttgaaggcagaagcatcccttgcatttctgcaaaagggcaacaagtattccattcgggctacgatttaagagagaaggatattcacgatttatctataattaaacaatgtataacaacaatgagcctaacaattagataa,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3606,Drugs,MEG_3606|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUA,490437755|WP_004308783.1|NG_047920|1|1|lnu(AN2)|lnu(AN2)|lincosamide_nucleotidyltransferase_Lnu(AN2) NG_047920:101-613,7
,atgcgccctctcctcttcagtgcccttctcctgctttccgggcatacccaggccagcgaatggaacgacagccaggccgtggacaagctattcggcgcggccggggtgaaaggcaccttcgtcctctacgatgtgcagcggcagtgctatgtcggccatgaccgggagcgcgcggaaacccgcttcgttcccgcttccacctacaaggtggcgaacagcctgatcggcttatccacaggggcggttagatccgccgacgaggttcttccctatggcggcaagccccagcgcttcaaggcctgggagcacgacatgagcctgcgcgaggcgatcaaggcatcgaacgtaccggtctaccaggaactggcgcggcgcatcggcctggagcggatgcgcgccaatgtctcgcgcctgggttacggcaacgcggaaatcggccaggttgtggataacttctggttggtgggaccgctgaagatcagcgcgatggaacagacccgctttctgctccgactggcgcagggagaattgccattccccgccccggtgcagtccaccgtgcgcgccatgaccctgctggaaagcggcccgggctgggagctgcacggcaagacaggctggtgcttcgactgcacgccggaactcggctggtgggtgggctgggtgaagcgcaacgagcggctctacggcttcgccctgaacatcgacatgcccggcggcgaggccgacatcggcaagcgcgtcgaactgggcaaggccagtctcaaggctctcgggatactgccctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4606,Drugs,MEG_4606|Drugs|betalactams|Class_D_betalactamases|OXA,489253968|WP_003161965.1|NG_050612|1|1|blaOXA-486|blaOXA-50_like|OXA-50_family_oxacillin-hydrolyzing_class_D_beta-lactamase_OXA-486 NG_050612:101-889,0
